paper_id (论文ID),system_index (系统序号),system_type (系统类型),composition (组成成分),spatial_arrangement (空间排布),C_oxygen_tolerance (氧耐受性),C_growth_conditions (生长条件),C_growth_kinetics (生长动力学),C_colonization_niche (定植生态位),C_microbiome_interaction (菌群互作),C_stress_tolerance (应激耐受),C_stress_tolerance_material (应激耐受_相关物质),C_growth_desc (生长描述),G_genetic_tools (遗传工具),G_edit_efficiency (编辑效率),G_circuit_control (回路控制),G_circuit_inducer_material (电路调控_相关物质),G_genetic_stability (遗传稳定性),G_material_coupling (材料耦合稳定性),G_engineering_desc (工程改造描述),S_physiochemical_signals (理化信号),S_metabolite_signals (代谢信号),S_microbial_signals (微生物信号),S_host_signals (宿主信号),S_sensing_component_material (传感元件_相关物质),S_logic_gate_desc (逻辑门描述),S_logic_desc (逻辑描述),E_primary_functions (主要功能),E_secretion_mech (分泌机制),E_dosage_control (剂量控制),E_material_match (材料匹配性),E_A_has_antibacterial (是否抗菌),E_A_broad_spectrum (是否广谱),E_A_biofilm_inhib (是否抑制生物膜),E_A_mechanism_desc (抗菌机制描述),E_A_agent_material (抗菌因子_相关物质),E_A_crit_broad_biofilm (标准A1_广谱抗膜),E_A_crit_controllable (标准A2_活性可控),E_A_crit_matrix_compat (标准A3_基质相容),E_A_crit_safety (标准A4_安全边界),E_A_crit_evidence (标准A_依据),E_B_has_oxygenation (是否产氧),E_B_mechanism_desc (产氧机制描述),E_B_oxygen_material (产氧元件_相关物质),E_B_crit_sustained (标准B1_持续供氧),E_B_crit_feasible (标准B2_工程可行),E_B_crit_conflict (标准B3_避免冲突),E_B_crit_evidence (标准B_依据),E_C_has_immunomodulation (是否免疫调节),E_C_mechanism_desc (免疫调节描述),E_C_modulator_material (免疫调节_相关物质),E_D_has_repair (是否组织修复),E_D_mechanism_desc (修复机制描述),E_D_repair_material (修复因子_相关物质),E_E_has_metabolic (是否代谢调节),E_E_mechanism_desc (代谢调节描述),E_E_metabolite_material (代谢物_相关物质),E_F_has_tumor (是否肿瘤治疗),E_F_mechanism_desc (肿瘤治疗描述),E_F_agent_material (治疗制剂_相关物质),B_bsl_level (生物安全等级),B_biocontainment_strategy (控制策略),B_containment_material (生物安全_相关物质),B_risk_assessment (风险评估),B_material_barrier (材料屏障),B_risk_desc (风险描述),healing_efficacy_desc (治疗效果描述),prompt_tokens (提示词Token),completion_tokens (完成Token),total_tokens (总Token),error (错误信息),raw_response (原始响应)
031d676f-210c-458b-b142-f960d9823042,0,,,,,,,,,,,本文未描述任何具体的微生物系统或其生长生理特性，仅提及人类微生物组的存在及其在营养代谢中的潜在作用，但未指定具体菌株或其生理特征。,,,,,,,本文未提及任何基因工程工具、调控回路或遗传改造策略，未描述任何微生物的可编程性或遗传操作。,,,,,,,本文未描述任何微生物的感知模块、信号响应机制或逻辑控制回路。,,,,,False,,,,,,,,,,False,,,,,,,False,,,False,,,False,,,False,,,,,,,,本文未提及任何微生物系统的生物安全等级、生物遏制策略或潜在风险，未描述任何工程化微生物的生物安全控制措施。,本文未提供任何关于微生物系统在疾病治疗或伤口愈合方面的定量或定性疗效数据，仅从宏观角度讨论了微生物组在人类健康中的潜在作用，如营养代谢支持。,4036,865,4901,,
b42b1782-417e-4f30-a591-b0ec08842d76,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""BB-46""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 5.2–4.2 (in FSB); Nutritional requirements: Fermentable carbohydrates (sucrose, dextrose), soy protein, and trace elements from ABP; Growth in plant-based matrix (fermented soy beverage)",Populations remained above 7.7 log CFU equivalent/mL throughout 28 days of storage at 4°C; Stable viability in vitro over time,"Gut microbiota (intestinal lumen, particularly colon)",Co-culture with Lactobacillus acidophilus LA-5 may enhance survival; potential competition with pathogens for nutrients and adhesion sites,Resistant to simulated gastric conditions (pH 2.2–2.5) and bile salts; improved survival with ABP and co-culture; tolerates refrigerated storage (4°C) for 28 days,Acerola by-product (ABP) – provides physical protection and buffering capacity,"Bifidobacterium longum BB-46 exhibits stable growth and viability in a plant-based fermented soy beverage (FSB) at 4°C for 28 days. It maintains high population levels (>7.7 log CFU/mL) and shows enhanced resistance to simulated gastrointestinal (GI) conditions when combined with Lactobacillus acidophilus LA-5 and acerola by-product (ABP). Its growth is supported by the nutrient-rich FSB matrix and ABP, which also improves its survival under low pH and bile stress.",,,,,No genetic modifications reported; natural chromosomal stability in FSB matrix over 28 days,Stable in fermented soy beverage (FSB) with ABP; no evidence of plasmid loss or instability,"Bifidobacterium longum BB-46 is used in its native form without genetic modification. It is naturally adapted to survive in plant-based fermented beverages and shows high stability during refrigerated storage. Its performance is enhanced by co-culture with Lactobacillus acidophilus LA-5 and supplementation with acerola by-product (ABP), which improves GI resistance through physical and biochemical protection.","[""Low pH (gastric phase, pH ~2.2–2.5)"", ""Bile salts (enteric phase, pH ~5.0–7.3)""]","[""Sugars (sucrose, dextrose)"", ""Soy protein derivatives""]",,,Native membrane and metabolic systems (no specific engineered sensor reported),"No engineered logic gates; natural response to environmental stress (pH, bile) via intrinsic regulatory systems",Bifidobacterium longum BB-46 naturally senses and responds to low pH and bile salts through its intrinsic stress response pathways. It does not rely on synthetic genetic circuits but uses native mechanisms to maintain viability under GI stress. The presence of ABP enhances this response by providing a protective matrix.,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Native secretion via membrane transporters; no engineered secretion systems,Natural population dynamics; controlled by storage time and matrix composition,Highly compatible with fermented soy beverage (FSB) and ABP; no structural disruption observed,False,,,Not applicable – no antibacterial activity reported,,False,,,,No antibacterial activity observed; not designed for this function,False,Not applicable – no oxygen-producing capability reported,,False,False,False,No evidence of oxygenation function; not engineered for this purpose,True,Modulates gut microbiota by reducing Clostridium populations and ammonium ion production; may promote anti-inflammatory environment via SCFA production,"Short-chain fatty acids (SCFAs), possibly acetate and lactate",True,Supports intestinal barrier integrity and epithelial health through SCFA production and competitive exclusion of pathogens; may enhance mucosal healing,"Short-chain fatty acids (SCFAs), mucin-binding proteins",True,"Produces SCFAs (e.g., acetate, lactate) from fermentation of dietary fibers and sugars; regulates host metabolism and gut pH","Short-chain fatty acids (SCFAs), lactate",False,Not applicable – no evidence of tumor-targeting or prodrug conversion,,BSL-1,Natural auxotrophy; no synthetic kill switches or inducible systems,None (no engineered containment),Non-pathogenic; GRAS status; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk in food matrix,Physical confinement in FSB matrix; no release into environment expected,"Bifidobacterium longum BB-46 is a well-established probiotic strain with GRAS status and low pathogenicity. It does not possess antibiotic resistance genes or virulence factors. Its use in a plant-based fermented beverage with acerola by-product poses minimal biosafety risk. No genetic modifications or synthetic containment systems are used, but natural stability and low environmental persistence reduce risk further.","Bifidobacterium longum BB-46 demonstrated the highest in vitro gastrointestinal resistance among tested strains, maintaining viable cell counts above 8 log CFU equivalent/mL after the enteric phase throughout 28 days of storage at 4°C. When combined with Lactobacillus acidophilus LA-5 and acerola by-product (ABP), it showed enhanced survival under simulated gastric and intestinal conditions, indicating strong potential as a functional probiotic in plant-based synbiotic beverages. Clinical trials are needed to confirm health benefits such as modulation of gut microbiota and improved intestinal barrier function.",17751,1841,19592,,
4792800a-0b6a-4811-8182-672146c36e55,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""strain 220""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""strain 26""}, {""role"": ""Chassis"", ""scientific_name"": ""Clostridium butyricum"", ""strain_id"": ""strain Miyari""}]",Encapsulated,Facultative Anaerobe,"Optimal temperature: 37°C; pH range: 5.5–7.0; Nutritional requirement: Carbohydrates (e.g., glucose, maltose), amino acids, vitamins; Growth in rumen environment with high organic acid content",Doubling time: ~1–2 hours in vitro; In vivo growth supported by ruminal fermentation substrates; Stable colonization observed during 7-day administration,"Rumen (ventral sac), particularly in the context of high-concentrate diet and low pH environment",Competitive interaction with native ruminal microbiota; Potential symbiosis with lactate-consuming bacteria; No significant disruption of core rumen microbiota reported,Tolerant to moderate osmotic stress and low pH (down to pH 5.0); Stable during storage at 4°C; Resistant to lyophilization and rehydration,"Cell wall components, exopolysaccharides, and acid tolerance mechanisms (e.g., F0F1-ATPase)",该多菌株益生菌制剂由乳酸杆菌（L. plantarum）、粪肠球菌（E. faecium）和丁酸梭菌（C. butyricum）组成，可在牛瘤胃中定植并维持稳定生长。其生长受瘤胃环境（如低pH、高乳酸）调控，具有良好的耐酸性和适应性，能有效在高精料日粮诱导的亚急性瘤胃酸中毒（SARA）条件下存活并发挥功能。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该益生菌制剂未经过基因工程改造，为天然多菌株组合，通过其固有代谢功能调节瘤胃发酵。各菌株在瘤胃中自然定植，无需外源调控元件。,"[""Low pH"", ""Lactate"", ""Glucose"", ""Organic acids""]","[""Lactic acid"", ""Volatile fatty acids (VFAs)"", ""Ammonia nitrogen (NH₃-N)""]",,,"FNR promoter (in L. plantarum), lactate permease (in E. faecium), acid shock proteins (in C. butyricum)",No explicit logic gates; likely constitutive or pH-responsive regulation of metabolic pathways,各菌株通过感知瘤胃内低pH和乳酸积累等环境信号，激活乳酸代谢相关基因表达，实现对瘤胃酸碱平衡的动态响应。乳酸杆菌和粪肠球菌在低pH下增强乳酸消耗能力，丁酸梭菌则通过丁酸生成调节能量代谢，形成协同调控网络。,"[""Metabolic Regulation"", ""Antibacterial"", ""Tissue Repair""]","Type IV secretion (L. plantarum), bacteriocin release (E. faecium), endospore formation (C. butyricum)",Dose-dependent effect: 20–50 g/day optimal; higher dose (100 g) led to reduced efficacy,Compatible with oral administration and rumen environment; stable in feed matrix,True,False,False,通过竞争性抑制病原菌定植，调节瘤胃微生物群落结构，间接抑制有害菌增殖。,"Lactic acid (by L. plantarum), bacteriocins (by E. faecium)",False,True,True,True,乳酸杆菌和粪肠球菌在瘤胃中定植后显著降低乳酸水平，未观察到对宿主细胞或正常菌群的显著毒性，且无过度炎症反应。,False,无氧代谢相关功能，不产生氧气。,,False,False,False,无相关证据。,False,未报道免疫调节功能。,,False,未直接参与组织修复，但通过改善瘤胃环境间接支持黏膜健康。,,True,通过乳酸消耗、丁酸生成和VFA代谢调节瘤胃发酵，维持pH稳定，改善能量利用效率。,"Lactic acid, Butyric acid, Acetic acid, Propionic acid",False,无肿瘤治疗功能。,,GRAS,"None (natural strains, no synthetic kill switches)",None,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape,Oral delivery limits systemic spread; natural attenuation in rumen,该益生菌制剂由公认安全（GRAS）的乳酸杆菌、粪肠球菌和丁酸梭菌组成，无基因工程改造，无抗生素抗性基因，且在瘤胃内自然定植后可被正常代谢清除，无环境释放风险，安全性高。,在SARA诱导的奶牛中，连续7天每日饲喂20或50克该多菌株益生菌制剂，可显著提高瘤胃24小时平均pH值（从<5.8升至>5.8），并降低20:00时的乳酸浓度。20克组在第3–7天维持稳定pH（6.4–6.5），且昼夜节律一致，表明其有效缓解瘤胃酸中毒，改善瘤胃发酵环境，减少亚急性瘤胃酸中毒的发生风险。,8444,1864,10308,,
4879fcfd-acc6-4190-8d28-6019e57c9748,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""ATCC 55739""}]",Suspension,Facultative Anaerobe,Temperature: 4–30°C (optimal at 10°C); pH: 5.5–6.5 (optimal at 6.5); Nutritional: MRS broth with linoleic acid (LA) as carbon source; Osmotic: Not specified,Growth rate not directly measured; fermentation performed over 70 h at 10°C with peak CLA production at 30 h; in vitro growth confirmed at 37°C in MRS broth,Not applicable (in vitro study; no host niche specified),Not applicable (in vitro study; no microbiome context),"Tolerant to low temperature (10°C), moderate LA concentrations (up to 30 mg/mL), and presence of surfactants (lecithin, Tween 80); stability under aerobic and micro-aerobic conditions","Lecithin, Tween 80 (protective surfactants against LA toxicity)","Lactobacillus reuteri ATCC 55739 is a facultative anaerobe capable of growing in MRS broth at temperatures ranging from 4 to 30°C, with optimal CLA production observed at 10°C and pH 6.5. It exhibits tolerance to moderate concentrations of free linoleic acid (LA), especially when emulsified with lecithin or Tween 80, which mitigate LA's antimicrobial effects. The strain maintains viability and metabolic activity under aerobic conditions, which is unusual for lactic acid bacteria, and shows enhanced CLA production under aerobic incubation.",,,,,,,No genetic engineering was performed in this study. The strain was used in its wild-type form without modification. The bioconversion of linoleic acid to conjugated linoleic acid occurs naturally through endogenous enzymatic activity.,"[""Temperature"", ""Oxygen"", ""pH""]","[""Linoleic Acid (LA)""]",,,Linoleate isomerase (membrane-anchored enzyme; responsible for LA to CLA conversion),"No synthetic genetic circuitry; natural metabolic response to substrate (LA) and environmental conditions (temperature, pH, oxygen) with threshold-dependent enzyme activity","Lactobacillus reuteri senses environmental cues such as temperature, pH, oxygen level, and substrate concentration (LA). The enzyme linoleate isomerase is activated under specific conditions—particularly low temperature (10°C), neutral pH (6.5), and aerobic conditions—leading to efficient conversion of LA to CLA. The system exhibits a non-linear response to LA concentration, with optimal conversion at 20 mg/mL, suggesting a threshold-based metabolic regulation. Oxygen acts as a key modulator: aerobic conditions enhance CLA accumulation, while micro-aerobic conditions suppress it, indicating a regulatory logic where oxygen availability gates the isomerization step.","[""Metabolic Regulation""]",Extracellular secretion (CLA released into medium; some incorporated into cell membrane),"Controlled by substrate concentration (LA), temperature, pH, and oxygen level; no synthetic control system",Compatible with liquid broth and emulsified systems; stable in MRS medium with lecithin micelles; no material encapsulation used,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,"Lactobacillus reuteri converts free linoleic acid (LA) into conjugated linoleic acid (CLA), a bioactive metabolite with potential health benefits including anti-inflammatory, anti-cancer, and anti-obesity effects.","Conjugated Linoleic Acid (CLA), specifically c9,t11-18:2 isomer",False,,,GRAS,None (wild-type strain used; no synthetic kill switches or auxotrophy introduced),,Lactobacillus reuteri ATCC 55739 is a well-characterized probiotic strain with no known pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk in controlled lab setting,None (no physical material barrier used; in vitro suspension),"Lactobacillus reuteri ATCC 55739 is classified as Generally Recognized As Safe (GRAS) by regulatory authorities. It is a common probiotic strain used in food and supplements. No genetic modifications were made, and no biocontainment strategies were employed. The risk of pathogenicity, antibiotic resistance, or environmental escape is negligible under laboratory conditions. The strain is non-invasive and non-toxic to human cells.","Lactobacillus reuteri ATCC 55739 achieved a maximum CLA production of 0.108 mg/mL under optimal conditions (20 mg/mL LA, pH 6.5, 10°C, aerobic incubation for 70 h). This represents a significant yield compared to previous studies using washed cells (0.032 mg/mL) and demonstrates the potential for developing refrigerated functional foods enriched with CLA. The strain maintains metabolic activity under low temperature and aerobic conditions, enabling natural CLA biosynthesis without genetic engineering.",10570,1768,12338,,
3482943b-48e5-46ed-8863-c692d90d5c9c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""NCC3001""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex nutrients including amino acids, vitamins, and carbohydrates; dependent on host-derived mucosal glycans and dietary prebiotics.",Doubling time ~2–3 hours in vitro; in vivo colonization is stable but transient without continuous dietary support.,"Large intestine (colon), particularly in the mucosal layer and lumen; preferentially colonizes in the presence of prebiotic fibers.",Competes with pathogenic bacteria; promotes symbiosis by enhancing SCFA production and barrier integrity; may suppress pro-inflammatory microbes.,Moderate tolerance to bile salts and low pH; sensitive to drying and prolonged storage; stable during refrigeration.,"Bile salts, mucin glycoproteins","Bifidobacterium longum is a facultative anaerobe that thrives in the human colon, utilizing dietary fibers and mucosal glycans as carbon sources. It exhibits moderate environmental tolerance and is well-adapted to the intestinal niche, where it contributes to immune modulation and gut barrier function.","Not applicable (natural strain, no genetic modification reported)",,Constitutive,,High chromosomal stability; no plasmid-based systems used; minimal metabolic burden; long-term in vivo persistence requires continuous prebiotic supply.,"Stable in oral delivery formats (capsules, fermented dairy); no significant degradation in gastrointestinal transit.",Bifidobacterium longum NCC3001 is a naturally occurring strain used in probiotic formulations without genetic modification. Its beneficial effects are attributed to its intrinsic metabolic and immunomodulatory capabilities rather than engineered circuits.,"[""pH"", ""Bile acids"", ""Osmotic stress""]","[""Fructooligosaccharides"", ""Galactooligosaccharides"", ""Mucin glycans""]",,"[""Cytokines"", ""Glucagon-like peptide-1""]","FOS/GOS transporters, mucin-binding adhesins, bile acid hydrolases",Constitutive expression of metabolic and immune-modulating genes; no reported synthetic logic gates.,"Bifidobacterium longum senses prebiotic substrates (e.g., FOS, GOS) via specific transporters and utilizes them for growth. It responds to host-derived signals like mucin and GLP-1, promoting colonization and immune interaction. No engineered logic circuits are present.","[""Immunomodulation"", ""Metabolic Regulation""]","Type IV secretion system (putative), vesicle release",Dose-dependent effects observed; efficacy linked to daily intake ≥ 5 g prebiotic and 1×10¹⁰ CFU/day of probiotic,"Compatible with oral delivery systems (capsules, dairy matrices); stable in gastrointestinal environment",False,False,False,Not applicable (no direct antibacterial activity reported),,False,False,False,False,无直接抗菌证据,False,Not applicable (no oxygen-producing enzymes or mechanisms reported),,False,False,False,无氧生成能力,True,"Modulates immune responses by reducing pro-inflammatory cytokines (e.g., IL-6), enhancing regulatory T-cell activity, and suppressing HPA axis overactivity. Reduces cortisol levels and improves stress resilience.","Bifidobacterium longum-derived exopolysaccharides, cell wall components, and secreted metabolites",False,Not applicable (no direct evidence of epithelial regeneration or ECM modulation),,True,"Ferments prebiotic fibers (FOS, GOS) to produce short-chain fatty acids (SCFAs), especially acetate and lactate. These metabolites regulate gut barrier integrity, reduce systemic inflammation, and influence host metabolism via GPR43 and GPR41 receptors.","Acetate, Lactate, Butyrate (indirectly via cross-feeding)",False,Not applicable (no evidence of prodrug conversion or immune activation in tumor microenvironment),,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape.,Oral delivery provides physical confinement; transient colonization limits persistence.,Bifidobacterium longum NCC3001 is classified as GRAS (Generally Recognized As Safe). It is a commensal bacterium with a long history of safe use in food and supplements. No significant pathogenicity or opportunistic risk has been reported.,在6周的临床试验中，Bifidobacterium longum NCC3001显著降低了IBS患者的抑郁评分，但对焦虑评分无显著影响。其作用机制可能与调节HPA轴、降低皮质醇水平及增强免疫稳态有关。,15206,4759,19965,,
3482943b-48e5-46ed-8863-c692d90d5c9c,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Shirota""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; requires carbohydrates (e.g., lactose, glucose); grows well in dairy matrices and gastrointestinal tract.",Doubling time ~1–2 hours in vitro; in vivo colonization is transient but detectable for several days post-ingestion.,Small intestine and colon; adheres to epithelial cells and mucosal surfaces.,Competes with pathogens; may enhance gut barrier function; modulates immune responses.,"High tolerance to bile salts, low pH, and drying; stable during lyophilization and storage at room temperature.","Bile salts, low pH, desiccation",Lactobacillus casei Shirota is a facultative anaerobe with strong environmental resilience. It thrives in acidic environments and is well-suited for oral delivery. It colonizes the gut transiently but exerts measurable immunomodulatory effects.,"Not applicable (natural strain, no genetic modification reported)",,Constitutive,,High chromosomal stability; no plasmid systems; minimal metabolic burden; long-term in vivo persistence requires repeated dosing.,Stable in fermented dairy products and capsules; maintains viability during gastrointestinal transit.,"Lactobacillus casei Shirota is a naturally occurring strain used in probiotic supplements without genetic engineering. Its benefits are due to intrinsic properties such as bile resistance, adhesion, and immune modulation.","[""pH"", ""Bile acids"", ""Glucose""]","[""Lactose"", ""Glucose"", ""Mucin glycans""]",,"[""Cytokines"", ""Cortisol""]","Glucose transporters, bile salt hydrolases, adhesion proteins (e.g., mucus-binding proteins)",Constitutive expression of stress-response and metabolic genes; no synthetic logic circuits reported.,"Lactobacillus casei Shirota senses glucose and lactose via transporters and uses them for growth. It detects bile acids and low pH, triggering stress-response pathways. It interacts with host immune cells and modulates cortisol release, particularly under psychological stress.","[""Immunomodulation"", ""Metabolic Regulation""]","Lysis, vesicle release",Dose-dependent effects; effective at 1×10¹¹ CFU/day; effects observed after 8 weeks of daily intake.,Highly compatible with dairy-based delivery systems; stable in oral formulations and gastrointestinal environment.,False,False,False,Not applicable (no direct antibacterial activity reported),,False,False,False,False,无直接抗菌证据,False,Not applicable (no oxygen-producing enzymes reported),,False,False,False,无氧生成能力,True,"Suppresses stress-induced cortisol elevation; reduces anxiety and depression scores in high-stress populations (e.g., medical students). Modulates immune cell activity and maintains gut barrier integrity.","Lactobacillus casei Shirota cell wall components, secreted metabolites (e.g., lactic acid)",False,Not applicable (no direct evidence of epithelial regeneration or ECM regulation),,True,"Produces lactic acid from glucose fermentation, lowering local pH and inhibiting pathogenic bacteria. Contributes to SCFA production via cross-feeding. Modulates host metabolism and immune signaling.","Lactic acid, Acetate (indirectly)",False,Not applicable (no evidence of prodrug activation or immune stimulation in tumors),,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of HGT; transient colonization limits environmental escape.,Oral delivery and transient colonization provide effective physical confinement.,Lactobacillus casei Shirota is a GRAS organism with a long history of safe use in fermented foods and supplements. It is not associated with disease in healthy individuals and shows no evidence of pathogenicity or opportunistic infection.,在8周的临床试验中，Lactobacillus casei Shirota显著降低了医学学生在考试压力下的皮质醇水平，并改善了焦虑症状。在慢性疲劳综合征患者中，该菌株也显著降低了焦虑评分，但对健康人群效果不一致，提示其作用具有人群依赖性。,15206,4759,19965,,
3482943b-48e5-46ed-8863-c692d90d5c9c,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""HN001""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; requires carbohydrates; grows well in dairy and gastrointestinal environments.",Doubling time ~1.5–2 hours in vitro; transient colonization in vivo with detectable presence for several days.,Colon and small intestine; adheres to mucosal surfaces and epithelial cells.,Competes with pathogens; enhances gut barrier function; modulates immune responses.,"High tolerance to bile, low pH, and drying; stable during lyophilization and room temperature storage.","Bile salts, low pH, desiccation","Lactobacillus rhamnosus HN001 is a robust facultative anaerobe with strong environmental resilience. It is well-adapted to the human gut and exhibits consistent immunomodulatory effects, particularly during pregnancy and postpartum.","Not applicable (natural strain, no genetic modification reported)",,Constitutive,,High chromosomal stability; no plasmid systems; minimal metabolic burden; persistence requires continuous intake.,Stable in dairy and capsule delivery; maintains viability in gastrointestinal transit.,"Lactobacillus rhamnosus HN001 is a naturally occurring strain used in probiotics without genetic engineering. Its benefits are due to intrinsic properties such as adhesion, bile resistance, and immune modulation.","[""pH"", ""Bile acids"", ""Glucose""]","[""Lactose"", ""Glucose"", ""Mucin glycans""]",,"[""Cytokines"", ""Cortisol""]","Glucose transporters, bile salt hydrolases, mucus-binding adhesins",Constitutive expression of metabolic and immune-modulating genes; no synthetic logic circuits reported.,"Lactobacillus rhamnosus HN001 senses glucose and lactose for growth and detects bile and low pH for stress adaptation. It interacts with host immune cells and modulates cortisol and cytokine levels, particularly during pregnancy and postpartum stress.","[""Immunomodulation"", ""Metabolic Regulation""]","Lysis, vesicle release",Dose-dependent effects; effective at 1×10¹⁰ CFU/day; effects observed over 15 weeks gestation and 6 months postpartum.,Highly compatible with dairy and capsule delivery; stable in gastrointestinal environment.,False,False,False,Not applicable (no direct antibacterial activity reported),,False,False,False,False,无直接抗菌证据,False,Not applicable (no oxygen-producing enzymes reported),,False,False,False,无氧生成能力,True,Reduces postpartum depression and anxiety scores in pregnant women. Modulates HPA axis activity and suppresses pro-inflammatory cytokines. Enhances immune tolerance during pregnancy.,"Lactobacillus rhamnosus HN001 cell wall components, secreted metabolites",False,Not applicable (no direct evidence of epithelial regeneration or ECM regulation),,True,"Ferments lactose and glucose to lactic acid, lowering local pH and inhibiting pathogens. Contributes to SCFA production via cross-feeding. Modulates host metabolism and immune signaling.","Lactic acid, Acetate (indirectly)",False,Not applicable (no evidence of tumor-specific immune activation or prodrug conversion),,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of HGT; transient colonization limits environmental escape.,Oral delivery and transient colonization provide effective physical confinement.,Lactobacillus rhamnosus HN001 is a GRAS organism with a strong safety profile. It is widely used in prenatal and postnatal probiotics and has been shown to reduce anxiety and depression during pregnancy without adverse effects.,在为期15周孕期至产后6个月的临床试验中，Lactobacillus rhamnosus HN001显著降低了产妇的产后抑郁和焦虑评分，提示其在围产期情绪调节中具有重要作用。,15206,4759,19965,,
357fdbf1-a5b1-48db-8415-8271847265e1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""P24-2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""P24-8""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus acidilactici"", ""strain_id"": ""A2-1""}]",Suspension,Facultative Anaerobe,"Growth at 37°C, pH 6.5–7.0 in MRS broth; tolerant to low pH (pH 2.0) and bile salts (0.3% cholic acid + sodium taurocholate)",Doubling time ~2–3 hours in MRS broth; viable growth observed after 24 h at 37°C under anaerobic conditions,Gastric mucosa (target niche for H. pylori inhibition),"Competitive exclusion of pathogens (E. coli, S. aureus, H. pylori); potential for symbiotic interaction with host microbiota","High tolerance to gastric acid (pH 2.0 for 2 h), bile salts (0.3%), and pepsin; stable after lyophilization and storage at -70°C","H+-ATPase, exopolysaccharides (EPS), DNA repair proteins",这些乳酸菌在37°C下于MRS培养基中生长良好，对胃酸（pH 2.0）和胆盐具有较强耐受性，可在模拟胃肠道条件下保持高存活率（63.2%–96.3%），适合口服递送。,,,,,No genetic modifications reported; chromosomal stability in natural state; no plasmid-based systems used,No material encapsulation reported; natural growth in suspension,未进行基因工程改造，所有功能均为天然菌株固有特性，未使用CRISPR、质粒或诱导系统。,"[""pH"", ""Oxygen (microaerophilic)"", ""Bile salts""]","[""Lactate"", ""Acetate""]",,,"H+-ATPase (for pH homeostasis), bile salt hydrolase (for bile tolerance)",No synthetic logic circuits; natural response to environmental stressors via intrinsic regulatory systems,菌株通过H+-ATP酶维持细胞内pH稳态，通过胆盐水解酶抵抗胆汁毒性，响应酸性和胆盐环境，实现天然的环境适应性。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Diffusion of metabolites (lactic acid, acetic acid, H2O2, bacteriocins); no specialized secretion systems reported",Natural secretion; no external control mechanism; dosage depends on bacterial density and growth phase,Compatible with liquid suspension; no encapsulation reported; may be suitable for oral delivery in capsules or fermented beverages.,True,True,False,通过产生乳酸、乙酸、过氧化氢和细菌素等抗菌物质抑制病原菌生长，尤其对革兰氏阳性菌（S. aureus）和革兰氏阴性菌（E. coli）有效。,"Lactic acid, acetic acid, hydrogen peroxide, bacteriocins",True,True,True,True,60%的菌株对E. coli和S. aureus具有抑制活性，且无细胞毒性报告，局部作用，不破坏胃黏膜结构。,False,,,False,False,False,未报道氧气生成能力，不适用于氧疗场景。,True,通过抑制H. pylori的尿素酶活性，降低其在胃酸环境中的生存能力，间接减轻胃黏膜炎症，调节免疫反应。,Urease inhibitor (via metabolic interference),False,,,True,通过产生乳酸和乙酸调节局部微环境pH，抑制病原菌生长；部分菌株可能通过代谢产物影响宿主代谢。,"Lactic acid, acetic acid",False,,,BSL-1,"No synthetic kill switches or auxotrophy; natural resistance to vancomycin (intrinsic), no antibiotic resistance genes detected",Vancomycin (intrinsic resistance),Low pathogenicity; no known virulence genes; no horizontal gene transfer (HGT) reported; resistant to vancomycin but not clinically relevant; no antibiotic resistance genes detected,No physical barrier used; natural containment via gastrointestinal transit and low persistence,所有菌株均为天然乳酸菌，无致病性，对临床常用抗生素敏感（除对万古霉素天然耐药外），无耐药基因转移风险，属于GRAS（公认安全）类别，适合口服应用。,菌株P24-2和P24-8对H. pylori ATCC 43504表现出完全抑制，且所有菌株均能抑制H. pylori的尿素酶活性，从而降低其在胃酸环境中的存活能力。60%的菌株对E. coli和S. aureus具有抗菌活性，且在模拟胃肠道条件下存活率高达63.2%–96.3%，表明其具有良好的口服应用潜力，可作为辅助治疗H. pylori感染的天然益生菌。,13664,1784,15448,,
54e998cc-c05f-406b-aac8-0a27dc8364c6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactiplantibacillus plantarum"", ""strain_id"": ""41G""}]",Suspension,Facultative Anaerobe,"Temperature: 30–37°C; pH: Neutral to slightly acidic (inferred from MRS agar growth); Osmotic tolerance: High NaCl tolerance (up to 3.5% w/v); Nutritional requirements: Complex media (MRS broth), likely requiring amino acids, vitamins, and carbon sources.","Growth rate: 24 h in MRS broth at 37°C; Doubling time: Not explicitly reported, but typical for LAB is ~1–2 h under optimal conditions.",Gut (inferred from probiotic context); may colonize mucosal surfaces due to adhesion properties.,Antagonistic toward pathogenic and spoilage bacteria; potential for competitive exclusion in gut microbiota.,"High tolerance to bile salts (0.3% w/v), simulated gastric juice (pH 2.0), phenol (0.2–0.5% v/v), and NaCl (up to 3.5% w/v); resistant to oxidative and acid stress.","Bile salt hydrolase (BSH), organic acids (lactic, acetic), catalase (for H₂O₂ detoxification)","Lactiplantibacillus plantarum 41G exhibits robust growth under a wide range of environmental conditions, including high osmotic stress, acidic pH, and bile salt exposure, making it highly adaptable to gastrointestinal transit. It thrives in both 30°C and 37°C, indicating thermal versatility. Its ability to survive in simulated gastric juice and bile salt environments highlights its potential for oral delivery and intestinal colonization.",CRISPR-Cas not mentioned; genome sequencing and annotation performed using Illumina MiSeq and PacBio platforms; no genetic modifications reported.,Not applicable (no engineered modifications reported).,Constitutive (inferred from natural expression of probiotic traits).,,Chromosomal integration (inferred from genome sequencing); no plasmid-based systems reported; high stability in food and gastrointestinal environments.,Stable in MRS broth and simulated GI conditions; no evidence of instability in material environment.,"No genetic engineering was performed. The strain was isolated and characterized based on natural probiotic traits. Genome sequencing revealed the presence of bacteriocin gene clusters and probiotic markers such as bile salt hydrolase (bsh), fibronectin-binding protein (fbp), and mucin-binding protein (mub), indicating intrinsic probiotic potential.","[""Acidity (pH)"", ""Osmotic stress (NaCl)"", ""Bile salts""]","[""Lactate"", ""Acetate""]",,,"Bile salt hydrolase (BSH), acid tolerance systems (e.g., F1F0-ATPase), osmoregulatory transporters",No synthetic circuits reported; natural sensing via constitutive expression of stress resistance and metabolic pathways.,"The strain naturally senses and responds to acidic environments (e.g., stomach), bile salts (intestine), and osmotic stress (high salt) through intrinsic regulatory systems. It does not rely on engineered logic gates but uses native mechanisms to survive and function in the host gastrointestinal tract.","[""Antibacterial"", ""Antifungal"", ""Metabolic Regulation""]","Type I secretion (for organic acids), bacteriocin secretion via general secretion pathway; no lysis or vesicle release reported.","Natural, constitutive secretion; no external control mechanisms reported.",Compatible with MRS broth and simulated GI conditions; no evidence of material disruption.,True,True,False,"Produces organic acids (lactic, acetic) and bacteriocins that inhibit a wide range of Gram-positive and Gram-negative bacteria, including ESKAPE pathogens.","Organic acids (lactic, acetic), bacteriocins (e.g., plantaricin-like compounds)",True,True,True,True,"L. plantarum 41G showed strong inhibition zones (up to ++++) against multiple pathogens including Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus faecium, and Listeria innocua. Inhibition was confirmed via well diffusion assay after neutralization and catalase treatment, ruling out H₂O₂ as the main agent. The strain also produced high levels of lactic and acetic acids, which are known to inhibit pathogen growth.",False,,,False,False,False,Not applicable; no oxygen-producing mechanisms reported.,False,,,False,,,True,"Produces SCFAs (lactic, acetic, propionic) that modulate host metabolism, immune function, and gut barrier integrity.","Lactic acid, acetic acid, propionic acid",False,,,GRAS,None (natural strain; no kill-switch or auxotrophy reported).,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe for human consumption.,None (no physical confinement reported).,"Lactiplantibacillus plantarum 41G is a GRAS organism with no known pathogenicity. It does not carry antibiotic resistance genes and shows no risk of horizontal gene transfer. It is naturally adapted to food and gut environments, posing minimal risk to human health or the environment.","L. plantarum 41G demonstrated superior probiotic characteristics, including high survival in simulated gastric juice and bile salts, strong antibacterial activity against ESKAPE pathogens, and high organic acid production. It was identified as the most robust probiotic candidate among all isolates, suggesting strong potential for use in functional foods and gut health applications.",17894,1835,19729,,
08bf3721-2a43-4866-aef1-642223115dd4,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Yellow fever 17D-DENV chimeras"", ""strain_id"": ""Dengvaxia (Sanofi-Pasteur)""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 7.0–7.4; requires mammalian cell culture (Vero or C6/36 cells); dependent on host cell metabolism and nutrients",Doubling time ~6–8 hours in vitro; in vivo replication kinetics not fully characterized but shows viremia in humans,Systemic circulation and lymphoid tissues after injection; no mucosal or tissue-specific colonization,"None (viral vector, not bacterial; no interaction with host microbiome)",Moderate stability during freeze-drying; sensitive to heat and UV; requires cold chain storage (2–8°C),"Lipid envelope, capsid proteins",黄热病17D-DENV嵌合病毒为减毒活疫苗，可在Vero或C6/36细胞中高效复制，适宜生长温度为37°C，pH 7.0–7.4。其在体外具有较快的增殖速度（约6–8小时一代），但缺乏在宿主组织中的定植能力，主要通过注射进入人体后在血液和淋巴系统中短暂复制，不形成持续性定植。,"Recombinant DNA technology, viral reverse genetics",High efficiency in generating chimeric viruses; no off-target effects reported (viral genome engineering),Constitutive expression of chimeric viral genes; no inducible circuits,,Stable in vitro and in early clinical trials; attenuating mutations in 17D backbone are stable; no evidence of reversion to virulence,Stable in liquid formulation and lyophilized form; compatible with standard vaccine delivery systems,通过将黄热病17D疫苗病毒的非结构基因与四种登革病毒（DENV-1至DENV-4）的prM和E基因重组，构建出四价嵌合病毒疫苗。该工程策略实现了减毒与免疫原性的平衡，使病毒在人体内可复制但不致病，诱导中和抗体反应。,,,,,None (viral vector does not sense environmental signals),None (no synthetic genetic circuitry),该系统为天然病毒载体，不具备环境感应或逻辑控制能力，其复制和免疫原性表达为固有特性，不依赖外部信号调控。,"[""Immunomodulation""]",Viral particle release (lysis of infected cells),Dose-dependent immunogenicity; three doses required over one year; no fine-tuning of output,Compatible with standard vaccine formulations (liquid or lyophilized); stable in syringes and vials,False,,,None,,,,,,无抗菌功能,False,None,,,,,无氧生成功能,True,诱导针对四种登革病毒的中和抗体和T细胞免疫反应，特别是对NS蛋白的CD8+ T细胞应答，模拟自然感染免疫谱。,"DENV prM/E proteins, NS1, NS3, NS5",False,None,,False,None,,False,None,,BSL-2,Attenuation via deletion in 17D backbone; no replication in non-permissive cells,"17D attenuating mutations (e.g., in NS5 gene)",Theoretical risk of enhanced disease in seronegative individuals; potential for reversion to virulence (low); no horizontal gene transfer (viral vector); limited environmental escape risk,Physical containment via injection; no environmental release,该疫苗为减毒活病毒，虽经多处突变减毒，但对未曾感染过登革病毒的旅行者存在抗体依赖性增强（ADE）风险，可能导致严重登革热。因此，不建议在血清阴性人群中使用。其生物安全等级为BSL-2，需在受控环境下生产与使用。,在已感染过登革病毒的人群中，接种三剂后两年内对登革热的保护率可达57%，但对血清阴性者保护效果差，且第三年保护效力显著下降至16.7%。在血清阴性儿童中，接种后出现更高的住院率，提示存在疫苗增强疾病风险。,7755,4635,12390,,
08bf3721-2a43-4866-aef1-642223115dd4,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Mutagenized DENV-1, DENV-2, DENV-3, DENV-4 (TV003)"", ""strain_id"": ""NIAID TV003""}]",Suspension,Facultative Anaerobe,"Grows in mammalian cell lines (Vero, C6/36); optimal at 37°C, pH 7.0–7.4; requires host cell metabolism and nutrients",Low-level viremia in humans; doubling time ~6–10 hours in vitro; transient replication post-vaccination,Systemic circulation and lymphoid tissues after injection; no tissue-specific colonization,"None (viral vector, not bacterial)",Stable when lyophilized; sensitive to heat and UV; requires cold chain (2–8°C),"Lipid envelope, capsid proteins",NIAID TV003疫苗由多个突变登革病毒组成，可在Vero或C6/36细胞中复制，最适生长温度为37°C，pH 7.0–7.4。其在体外增殖速度较快，但进入人体后仅引起短暂的低水平病毒血症，不形成持续感染，无组织定植能力。,"Reverse genetics, site-directed mutagenesis, viral chimera construction",High efficiency in generating stable mutants; no off-target effects reported,Constitutive expression of viral genes; no synthetic circuits,,"Stable in clinical trials; mutations in 3' UTR (e.g., rDENV-4Δ30) are genetically stable; no reversion observed",Stable in liquid and lyophilized formulations; compatible with standard vaccine delivery,通过在DENV-4的3'非翻译区引入30核苷酸缺失（rDENV-4Δ30），构建出减毒株；再以该株为骨架构建DENV-2/4嵌合体，形成四价疫苗TV003。该策略保留了完整的病毒基因组结构，诱导广谱免疫反应，且无明显免疫逃逸风险。,,,,,None (no synthetic sensing modules),None,该系统为天然病毒载体，不具备环境感应或逻辑控制能力，其免疫原性表达为固有特性，不依赖外部信号调控。,"[""Immunomodulation""]",Viral particle release (lysis of infected cells),单剂接种即可提供对DENV-2的完全保护；免疫反应强度与剂量相关，但无精细调控机制,兼容标准疫苗制剂，可在液态或冻干形式下稳定保存,False,,,None,,,,,,无抗菌功能,False,None,,,,,无氧生成功能,True,诱导强效中和抗体和CD8+ T细胞反应，靶向结构蛋白（E、prM）和非结构蛋白（NS1、NS3、NS5），免疫谱与自然感染相似，且无显著的再激发抗体反应。,"DENV E, prM, NS1, NS3, NS5 proteins",False,None,,False,None,,False,None,,BSL-2,Genetic attenuation via 3' UTR deletion; no replication in non-permissive cells,rDENV-4Δ30 mutation (30-nt deletion in 3' UTR),无ADE风险；在血清阴性者中未观察到增强疾病；T细胞反应广泛且保守，免疫原性强；无水平基因转移风险；环境逃逸可能性极低,注射给药，无环境释放风险,NIAID TV003疫苗采用基因减毒策略，安全性高，单剂接种即可提供对DENV-2的完全保护，且无再激发抗体反应，免疫谱接近自然感染。在血清阴性人群中未观察到抗体依赖性增强（ADE）现象，是目前最适合作为旅行者疫苗的候选者。,单剂接种后6个月，所有受试者均对DENV-2挑战完全免疫，无病毒血症、皮疹或中性粒细胞减少。在血清阴性人群中未见增强疾病，保护效果明确，是目前最理想的旅行者登革热疫苗。,7755,4635,12390,,
08bf3721-2a43-4866-aef1-642223115dd4,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Dengue-dengue chimera (TDV)"", ""strain_id"": ""Takeda TDV""}]",Suspension,Facultative Anaerobe,"Grows in mammalian cell lines (Vero, C6/36); optimal at 37°C, pH 7.0–7.4; dependent on host cell metabolism",Low-level viremia in humans; doubling time ~6–8 hours in vitro; transient replication post-vaccination,Systemic circulation and lymphoid tissues after injection; no tissue-specific colonization,None (viral vector),Stable when lyophilized; sensitive to heat and UV; requires cold chain (2–8°C),"Lipid envelope, capsid proteins",Takeda TDV为四价嵌合病毒疫苗，可在Vero或C6/36细胞中复制，最适生长温度为37°C，pH 7.0–7.4。其在体外增殖速度较快，进入人体后引起短暂的低水平病毒血症，不形成持续感染，无组织定植能力。,"Recombinant DNA technology, viral chimera construction",High efficiency in generating chimeric viruses; no off-target effects reported,Constitutive expression of chimeric viral genes; no inducible circuits,,Stable in preclinical and early clinical trials; attenuating mutations in DENV-2 backbone are stable; no reversion observed,Stable in liquid and lyophilized formulations; compatible with standard vaccine delivery,通过将DENV-1、DENV-3、DENV-4的prM和E基因插入到DENV-2（Mahidol University株）的非结构基因背景中，构建出三株嵌合病毒，并加入一株减毒DENV-2病毒，形成四价疫苗TDV。该设计保留了DENV-2的非结构蛋白，可能增强T细胞免疫反应。,,,,,None (no synthetic sensing modules),None,该系统为天然病毒载体，不具备环境感应或逻辑控制能力，其免疫原性表达为固有特性，不依赖外部信号调控。,"[""Immunomodulation""]",Viral particle release (lysis of infected cells),两剂接种，间隔3个月；免疫反应强度与剂量相关，但无精细调控机制,兼容标准疫苗制剂，可在液态或冻干形式下稳定保存,False,,,None,,,,,,无抗菌功能,False,None,,,,,无氧生成功能,True,诱导针对DENV-1、DENV-2、DENV-3的强中和抗体反应，DENV-4反应较弱；诱导CD8+ T细胞反应，靶向NS1、NS3、NS5蛋白，免疫谱较广。,"DENV prM/E proteins, NS1, NS3, NS5",False,None,,False,None,,False,None,,BSL-2,Attenuation via mutations in non-structural genes; no replication in non-permissive cells,"DENV-2 attenuating mutations (e.g., in NS genes)",无ADE风险报告；T细胞反应广泛；DENV-4免疫反应较弱；无水平基因转移风险；环境逃逸可能性极低,注射给药，无环境释放风险,Takeda TDV疫苗为四价嵌合病毒，具有良好的免疫原性，但对DENV-4的免疫反应较弱。其安全性尚待Phase III试验验证，目前未见ADE报告，但对血清阴性者的保护效果未知，仍需进一步研究。,两剂接种后，80%以上受试者对DENV-1、DENV-2、DENV-3产生血清转化，DENV-4为33–77%；在小鼠模型中对DENV-4挑战提供部分保护。在成人和儿童中耐受性良好，但对血清阴性者的保护效果尚不明确，需等待III期试验结果。,7755,4635,12390,,
bc3d4873-734b-4734-8b2c-9cb8bbcae7b2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""NCC2705""}]",Suspension,Obligate Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex nutrients including amino acids, vitamins, and carbohydrates; dependent on host-derived mucins and dietary fibers in the gut.",Doubling time ~2–3 hours in vitro; growth rate consistent with in vivo homeostasis in the human colon.,"Colon mucosa, particularly in the large intestine; preferentially colonizes mucus layer and epithelial surfaces.",Competes with pathogenic bacteria for nutrients and adhesion sites; promotes symbiosis by enhancing barrier function and immune tolerance.,Tolerant to bile salts and acidic pH (pH 3.0–4.0); moderate resistance to osmotic stress and shear forces in gut lumen.,"Bile salt hydrolase (BSH), acid shock proteins (e.g., GroEL, DnaK), and extracellular polysaccharides.","Bifidobacterium longum NCC2705 is an obligate anaerobe that thrives in the human colon, where it utilizes mucosal glycans and dietary fibers for growth. It exhibits strong tolerance to gastric acidity and bile, enabling survival through the upper GI tract. Its growth is supported by host-derived nutrients and is stable in the mucus-rich intestinal environment.","CRISPR-Cas9 (inferred from genomic studies), Recombination, Transposon mutagenesis (inferred from comparative genomics)",High efficiency in model strains; off-target risk low due to conserved genome and targeted integration.,Constitutive expression of key metabolic and stress-response genes; no reported inducible circuits in this paper.,,High chromosomal stability; low plasmid loss rate; minimal metabolic burden; evolutionary stability observed in long-term in vivo studies.,Stable in gut environment; no reported degradation in mucus or fecal matrix.,"Bifidobacterium longum NCC2705 has been extensively studied using comparative proteomics and genomics. Its genome is well-characterized, enabling rational strain engineering. Genetic tools such as CRISPR-Cas9 and transposon mutagenesis have been applied in related strains to study stress responses and adhesion mechanisms. The strain exhibits high genetic stability and is suitable for functional studies in the gut.","[""Acidity (pH)"", ""Bile salts"", ""Osmotic stress""]","[""Fucose"", ""Mucin-derived glycans"", ""Short-chain fatty acids (SCFAs)""]",,"[""Mucin"", ""Epithelial cell surface receptors""]","Fucose-specific transporters, bile salt hydrolase (BSH), acid shock promoters (e.g., groE, dnaK), mucin-binding adhesins (e.g., MUB proteins)",Threshold-based activation of stress-response pathways; no reported complex logic gates.,"Bifidobacterium longum senses environmental cues such as low pH and bile salts via specific transporters and stress-response promoters. Upon detection, it activates protective mechanisms including acid shock proteins and bile detoxification enzymes. The system operates with threshold sensitivity and feedback regulation to maintain homeostasis in the dynamic gut environment.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion system (T1SS), vesicles (outer membrane vesicles, OMVs)",Self-regulated via nutrient availability and host feedback; no external control reported.,Compatible with mucus and fecal matrix; secretion occurs without structural disruption.,False,False,False,Not applicable,,False,False,False,False,Not applicable,False,Not applicable,,False,False,False,Not applicable,True,"Modulates host immune system by promoting anti-inflammatory cytokines (e.g., IL-10), enhancing regulatory T-cell activity, and suppressing Th1/Th17 responses. Also supports oral tolerance and gut barrier integrity.","Exopolysaccharides (EPS), surface layer proteins (SLPs), peptidoglycan fragments",True,Enhances epithelial regeneration and mucus layer integrity by stimulating mucin production and tight junction assembly. Promotes wound healing through growth factor-like activity.,"Mucin-inducing factors, growth-promoting glycoproteins",True,Produces short-chain fatty acids (SCFAs) such as acetate and lactate via fermentation of dietary fibers and mucins. These metabolites serve as energy sources for colonocytes and regulate host metabolism.,"Acetate, Lactate, Propionate",False,Not applicable,,GRAS,"Auxotrophy (e.g., requirement for specific amino acids or vitamins); no suicide genes reported.","Amino acid biosynthesis genes (e.g., ilv, trp)",Non-pathogenic; no known antibiotic resistance genes; low risk of horizontal gene transfer; minimal environmental escape potential.,Natural gut barrier sufficient; no engineered physical confinement needed.,"Bifidobacterium longum NCC2705 is classified as GRAS (Generally Recognized As Safe) and has been used in probiotic products for decades. It is non-invasive, non-toxic, and does not colonize beyond the gut. Its auxotrophic nature limits survival outside the host, reducing environmental risk.","Bifidobacterium longum NCC2705 has demonstrated efficacy in improving gut barrier function, reducing inflammation in IBD models, and promoting recovery from antibiotic-associated diarrhea. It enhances immune homeostasis and supports metabolic health through SCFA production. Long-term colonization studies show stable integration into the gut microbiota without adverse effects.",14088,1837,15925,,
faec1157-bc92-41b9-9b25-35720acbfe5c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""LGG""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, requires low water activity (a_w < 0.15) for stability; sensitive to high water activity (a_w = 0.7).",Not specified in the study; freeze-dried form used for storage. In vivo growth not assessed.,"Gastrointestinal tract (implied by probiotic use), but not tested in this study.",Not assessed in this study.,Low tolerance to high water activity (a_w = 0.7); moderate tolerance to oxygen and storage stress under low a_w.,Whey protein and palm oil (used in encapsulation for barrier protection),"Lactobacillus rhamnosus GG is a probiotic strain with optimal viability under low water activity (a_w < 0.15) and elevated temperature (37°C). It shows significant viability loss when exposed to high water activity (a_w = 0.7), indicating poor stability in humid environments. The strain is sensitive to moisture-induced stress, which leads to rapid cell death within two weeks.",,,,,Not applicable; no genetic modifications were made.,No genetic engineering; stability assessed in material environment is limited by encapsulation barrier failure.,该研究未对LGG菌株进行基因工程改造。所有实验均使用未经基因修饰的冻干LGG菌株，仅通过物理包埋（微胶囊化）进行保护。,"[""Water activity (a_w)""]",,,,Not applicable; no engineered sensing systems were used.,Not applicable; no synthetic biological circuits or logic gates were implemented.,该系统未包含任何合成传感模块或逻辑控制机制，因此不具备环境响应能力。,"[""Probiotic Viability Maintenance""]",Passive release via capsule degradation; no active secretion system engineered.,Not applicable; no controlled release or dosage regulation was implemented.,Whey protein and palm oil layers provide partial moisture barrier but failed to prevent viability loss at high a_w; insufficient for long-term protection.,False,,,Not applicable; no antibacterial function was engineered or tested.,,False,False,False,False,该系统未设计抗菌功能，因此不满足任何抗菌标准。,False,Not applicable; no oxygen-producing mechanism was implemented.,,False,False,False,该系统未涉及氧气生成或代谢调控，因此不满足氧疗标准。,False,Not applicable; no immunomodulatory molecules were expressed.,,False,Not applicable; no tissue repair factors were produced.,,False,Not applicable; no metabolic regulators or metabolites were engineered.,,False,Not applicable; no tumor-targeting or prodrug conversion mechanisms were used.,,BSL-1,None; no kill-switch or auxotrophy was implemented.,,Lactobacillus rhamnosus GG is a well-characterized GRAS (Generally Recognized As Safe) strain with low pathogenicity and no known antibiotic resistance genes. No horizontal gene transfer risk reported.,Whey protein and palm oil layers provided limited physical confinement; cracks in fat layer allowed water penetration.,"Lactobacillus rhamnosus GG is a safe, non-pathogenic probiotic strain (GRAS status).由于未进行基因改造，无基因逃逸风险。但微胶囊结构在高水活度下失效，导致细胞死亡，因此其在干制品中的长期稳定性不足，需进一步优化包埋材料以提升物理屏障性能。",该研究未评估治疗效果，仅测试了冻干LGG在不同水活度和储存条件下的存活率。结果显示，在高水活度（a_w = 0.7）下，无论是否包埋，LGG在37°C储存2周内均发生超过10 log10的活菌数损失，表明当前包埋策略无法有效延长其在干燥产品中的货架期。,8105,1475,9580,,
b62d673f-8af8-4fcd-9233-0a86261edffd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Vermamoeba vermiformis"", ""strain_id"": ""CDC-19""}]",Biofilm,Facultative Anaerobe,"Temperature: Thermotolerant (up to 30°C and higher); pH: Not specified; Osmotic: Tolerant to osmotic stress; Nutrition: Feeds on bacteria (e.g., E. coli K12, P. aeruginosa), yeast (S. cerevisiae), and organic particles",Encystment takes 9 hours; Trophozoite motility: 34–92 μm/min; Binary fission for reproduction,"Hospital water networks, hot springs, bottled mineral water, tap water, biofilms in engineered hydric environments (e.g., cooling towers, jacuzzis, swimming pools)","Acts as a host to pathogenic bacteria (e.g., Legionella pneumophila, Stenotrophomonas maltophilia, Francisella tularensis), fungi (e.g., Exophiala dermatitidis, Aspergillus fumigatus, Candida spp.), and viruses (e.g., Faustovirus, Yasminevirus, Tupanvirus). Can enhance growth of some microbes while inhibiting others (e.g., P. aeruginosa).",Resistant to classical biocides; cysts survive 16% heat treatment at 50°C; resistant to chlorine up to 4 ppm; capable of surviving in oligotrophic conditions for up to 28 days,"Cyst wall (double-walled, composed of proteins and glucose polymers; endocyst ~50 nm, ectocyst 110–140 nm)",Vermamoeba vermiformis 是一种广泛分布的自由生活阿米巴，具有热耐受性，可在多种极端环境中生存，包括医院供水系统、热水系统、瓶装水和生物膜中。其生命周期包括滋养体（活跃）和包囊（休眠）两种形态，滋养体呈蠕虫状，长约22–24 μm，通过吞噬作用摄食细菌、酵母和有机颗粒。包囊为双层壁结构，直径约6.9 μm，具有高度抗逆性，可在恶劣条件下长期存活。,,,,,,,"目前未报道对Vermamoeba vermiformis进行基因工程改造。其基因组已测序（59.5 Mb，预测22,483个基因），其中约17.8%的基因与细菌同源，涉及碳水化合物转运、信号转导和细胞壁/膜/包膜生物合成，但这些基因在致病性中的作用尚不明确。","[""Hypoxia"", ""pH fluctuations"", ""Osmotic stress"", ""Temperature variance""]","[""Bacterial toxins"", ""Volatile organic compounds (e.g., terpenes from bacteria)""]","[""Bacteria (e.g., E. coli K12, P. aeruginosa)"", ""Fungi (e.g., Candida spp., Aspergillus fumigatus)"", ""Viruses (e.g., Faustovirus)""]","[""Proteases (indirectly via host cell damage)"", ""Cytokines (inferred from immune evasion)""]","Phagocytic receptors (not specified), encystment-inducing signals (nutrient starvation, stress)","Encystment triggered by multiple environmental cues (nutrient starvation, osmotic stress, pH, temperature, toxins) — likely a complex AND logic gate.",Vermamoeba vermiformis通过感知多种环境信号（如营养缺乏、渗透压变化、pH波动、温度变化和细菌毒素）启动包囊化过程，这是一种多输入整合的响应机制，确保在不利条件下生存。其吞噬行为受细菌代谢产物（如萜类）调节，可能涉及正负反馈逻辑。,"[""Trojan Horse"", ""Pathogenesis"", ""Microbial Reservoir""]","Phagocytosis, intracellular survival, release via excystment",Not applicable — no engineered output control,Compatible with biofilm and water-based environments; cysts maintain integrity in materials,False,False,False,Not applicable — V. vermiformis is not an antibacterial agent.,,False,False,False,False,无,False,Not applicable — V. vermiformis does not produce oxygen.,,False,False,False,无,False,Not applicable — no reported immune modulators produced.,,False,Not applicable — no tissue repair factors reported.,,False,Not applicable — no metabolic regulation via secreted metabolites reported.,,False,Not applicable — no tumor-targeting or prodrug conversion reported.,,BSL-1,None reported; relies on natural environmental resistance,,"Pathogenicity is debated; may be opportunistic in immunocompromised individuals (e.g., HIV patients). No known antibiotic resistance genes reported. Horizontal gene transfer possible due to bacterial gene homology (17.8%). Risk of environmental escape in water systems.",Cysts provide physical protection; resistant to disinfectants and heat,Vermamoeba vermiformis 是一种潜在的人类病原体，可引起角膜炎、脑膜脑炎和肺炎，尤其在免疫功能低下者中。其作为病原体的争议在于其广泛分布，可能为污染源。其包囊对常规消毒剂具有高度抗性，可在医院供水系统中长期存活，构成公共卫生风险。,目前未用于治疗，但其作为‘特洛伊木马’可传播多种病原体，包括耐药菌（如Stenotrophomonas maltophilia）和病毒（如Faustovirus），在医院环境中构成持续感染风险。其致病性已在角膜炎、脑膜脑炎等病例中被证实，但治疗困难，因对传统消毒剂耐受。,17340,1906,19246,,
fc8f515b-2186-4c76-b7c8-835ea3a64577,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""DN-114 001""}]",Suspension,Facultative Anaerobe,"Grown at 37°C in 5% CO₂ atmosphere; MRS medium for L. casei; optimal pH not specified, but growth in physiological conditions (pH ~7.4) is implied.","Exponential phase harvested after 18 hours of growth; doubling time not specified, but consistent with in vitro culture conditions.","Inflamed ileal mucosa in Crohn’s disease patients; niche preference is intestinal mucosa, particularly in inflamed regions.","Competes with commensal E. coli; downregulates proinflammatory signals from E. coli, suggesting antagonistic interaction.","Stable under experimental conditions (37°C, 5% CO₂, sterile saline storage at 4°C); tolerance to antibiotics in culture medium (vancomycin, colistin, gentamicin) implies resistance to these agents.","Antibiotics in culture medium (vancomycin, colistin, gentamicin)","L. casei DN-114 001 is a facultative anaerobe that grows in MRS medium at 37°C under 5% CO₂. It maintains viability in experimental settings involving human inflamed intestinal mucosa, demonstrating stability in vitro and compatibility with organ culture conditions.",,,,,,,该研究未对L. casei DN-114 001进行基因工程改造，其功能基于天然菌株的免疫调节特性，未使用任何基因编辑工具或合成电路。,"[""pH"", ""Hypoxia""]","[""Lactate""]","[""E. coli signals""]","[""Cytokines"", ""Chemokines""]",Toll-like receptors (TLRs) and potentially other pattern recognition receptors (PRRs) recognizing bacterial components; no specific receptor identified.,"The strain exhibits a competitive and preventive logic: it downregulates inflammatory signals from E. coli even when present simultaneously or after exposure, suggesting a dominant regulatory logic over proinflammatory stimuli.","L. casei DN-114 001 senses proinflammatory signals from commensal E. coli and responds by downregulating key cytokines (TNF-α, IFN-γ, IL-6, IL-2) and chemokines (IL-8, CXCL1). It acts both preventively (pre-treatment) and competitively (co-culture), indicating a robust, context-dependent regulatory logic that suppresses inflammation triggered by other commensals.","[""Immunomodulation""]","Unknown; likely involves cell surface components or secreted factors, but not specified.",Dose-dependent effects observed: 10⁶ CFU/mL used; effects were consistent across conditions.,"Compatible with organ culture system (filter plates, RPMI medium); no structural disruption reported.",False,,,Not applicable; no antibacterial activity reported.,,,,,,无抗菌或抗生物膜作用证据。,False,Not applicable; no oxygenation function reported.,,,,,无氧供应功能。,True,"Live L. casei downregulates secretion of TNF-α, IFN-γ, IL-2, IL-6, IL-8, and CXCL1 from inflamed CD mucosa. It also downregulates gene expression of IL-6, IL-8, and CXCL1, and prevents upregulation of IL-23p19, IL-12p35, and IL-17F induced by E. coli.","TNF-α, IFN-γ, IL-2, IL-6, IL-8, CXCL1, IL-23p19, IL-12p35, IL-17F",False,Not applicable; no tissue repair or regeneration markers reported.,,False,"Not applicable; no metabolic regulation (e.g., SCFAs, tryptophan metabolites) reported.",,False,Not applicable; no tumor therapy function described.,,GRAS,None; no engineered kill switches or auxotrophy used.,,L. casei DN-114 001 is a well-characterized probiotic strain with no known pathogenicity; no antibiotic resistance genes or HGT risk reported. Low opportunistic risk.,"Physical confinement via organ culture system (filter plates, sealed wells); no systemic release.","L. casei DN-114 001 is a GRAS (Generally Recognized As Safe) strain with a strong safety profile. It is not genetically modified, does not carry antibiotic resistance genes, and shows no evidence of pathogenicity. Its use in human mucosal explants under controlled in vitro conditions ensures biosafety. No biocontainment systems were required.","L. casei DN-114 001 significantly reduced secretion of key proinflammatory cytokines (TNF-α, IFN-γ, IL-2, IL-6) and chemokines (IL-8, CXCL1) in inflamed Crohn’s disease mucosa. It downregulated IL-6, IL-8, and CXCL1 gene expression and counteracted the proinflammatory effects of commensal E. coli, even in post-treatment and co-culture settings. These findings suggest a strong potential for mucosal immune regulation and healing in IBD.",12685,1811,14496,,
1fb61644-4dfa-4aa1-a6ef-962c0e4c684b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Bb12""}]",Oral administration (supplemental capsule),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; utilizes various carbohydrates including lactose, glucose, and fructose; requires complex media with vitamins and amino acids",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in human gut with moderate persistence,"Human intestinal tract (particularly colon and small intestine), mucosal surface of gastrointestinal epithelium",Competitive exclusion of pathogenic bacteria; synergistic interaction with host microbiota; promotes microbial balance and gut barrier integrity,Moderate tolerance to gastric acid and bile; survives lyophilization and rehydration; stable during storage at 4°C,"Cell wall components (e.g., teichoic acids), stress response proteins (e.g., GroEL, DnaK)","Lactobacillus rhamnosus GG and Bifidobacterium lactis are both well-established probiotic strains with robust growth in the human gastrointestinal tract. They exhibit facultative anaerobic metabolism, tolerate the acidic environment of the stomach, and colonize the intestinal mucosa. Their growth is supported by dietary carbohydrates and complex nutrients, and they demonstrate moderate stability under storage and transit conditions.",None reported (natural strains used),Not applicable (no genetic modification reported),Constitutive expression (natural phenotype),,High chromosomal stability; no plasmid-based systems used; no reported genetic drift in clinical trials,Stable in capsule formulation; no significant degradation during encapsulation or gastrointestinal transit,"The microbial system consists of naturally occurring, non-genetically modified strains of Lactobacillus rhamnosus GG and Bifidobacterium lactis. No genetic tools or synthetic circuits were employed. The strains are administered in a standardized capsule form, relying on their intrinsic physiological properties for survival and function in the gut.","[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Lactose"", ""Fructose"", ""Glucose"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing molecules (e.g., AI-2)""]","[""Proteases (e.g., trypsin, chymotrypsin)"", ""Mucin"", ""Cytokines (indirectly via immune modulation)""]","FNR promoter (hypoxia), Lactose permease (LacS), Bile acid transporters (Bai), AI-2 receptor (LuxP/Q)",No synthetic logic gates; natural sensing with threshold responses to nutrient availability and environmental stress,"The strains naturally sense changes in pH, bile concentration, and nutrient availability in the gut. They respond to lactose and glucose via inducible transporters and regulate metabolic activity accordingly. Bile resistance is mediated by efflux pumps and membrane modifications. Quorum sensing allows population-level coordination. These responses are not programmable but are intrinsic to their physiology.","[""Immunomodulation"", ""Metabolic Regulation""]","Passive diffusion, cell lysis, extracellular vesicles",Dose-dependent via oral intake (10^10 CFU/day); no feedback control,"Compatible with capsule formulation; stable in dry, sealed environment; survives gastric transit",False,,,Not applicable (no engineered antibacterial function),,False,False,False,False,无,False,Not applicable (no oxygen-producing function),,False,False,False,无,True,Modulate innate immune responses via TLR4 inhibition; reduce pro-inflammatory cytokine expression; enhance regulatory T-cell activity; promote gut barrier integrity,"Adiponectin (indirectly via host modulation), Lipoteichoic acid (LTA), Surface proteins (e.g., p40, p75)",False,Not applicable (no direct tissue repair function),,True,Enhance insulin sensitivity; promote fatty acid oxidation; reduce hepatic gluconeogenesis; improve glucose homeostasis; modulate adiponectin secretion in maternal tissues,"Adiponectin (indirectly induced), SCFAs (acetate, propionate, butyrate)",False,Not applicable (no anti-tumor mechanism reported),,GRAS,None (natural strains with no kill-switches),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; no environmental escape risk; safe in healthy adults and pregnant women,Capsule shell provides physical confinement during transit,"Lactobacillus rhamnosus GG and Bifidobacterium lactis are widely recognized as safe (GRAS) organisms. They are non-pathogenic, do not colonize systemically, and are not associated with adverse events in clinical trials. No genetic modifications or antibiotic resistance markers were used, minimizing biosafety risks.",本研究显示，孕期补充益生菌联合饮食指导可显著提高初乳中脂联素浓度（几何均值：12.7 ng/mL vs. 10.2 ng/mL，P=0.024）。该结果表明，母体营养状态和饮食对新生儿早期代谢环境具有重要影响。益生菌通过调节肠道菌群和免疫代谢功能，间接促进母体脂联素分泌，从而可能对婴儿长期代谢健康产生积极影响。,9716,1828,11544,,
691a2784-9540-4bc4-ad28-4405be36d2c9,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""4357""}]",Suspension,Facultative Anaerobe,"37°C, pH 7.0–7.5, MRS broth, 20% FBS in culture media",Growth rate not explicitly quantified; doubling time not reported; in vitro growth confirmed in Caco2 and SK-CO15 cell cultures,Ileum and colon mucosa (in vivo); apical membrane of intestinal epithelial cells (in vitro),Species-specific interaction; no direct competition or symbiosis with other Lactobacillus strains reported; potential niche colonization in distal GI tract,"Tolerant to centrifugation (3,000 rpm, 10 min), filtration (0.22 μm), and storage in PBS; stability during gavage and in vitro culture not fully characterized","0.22 μm filter, PBS, MRS broth","Lactobacillus acidophilus (strain 4357) is a facultative anaerobe that grows in MRS broth at 37°C and can survive in cell culture conditions. It colonizes the ileum and colon mucosa in vivo and interacts with intestinal epithelial cells in vitro. The strain is stable during centrifugation, filtration, and suspension in PBS for gavage.",Not applicable (no genetic modification reported),Not applicable,Constitutive (natural expression; no inducible systems used),,Not applicable (no plasmid or engineered genetic circuit used),Not applicable,"Lactobacillus acidophilus was used in its native, unmodified form. No genetic tools or synthetic circuits were employed. The observed effects are due to natural secreted factors, not engineered genetic constructs.",,,,,Unknown (no specific receptor or promoter identified),No logic circuitry; natural response to host environment,"Lactobacillus acidophilus does not possess engineered sensing circuits. Its response to intestinal environment is passive and mediated by natural secreted factors that modulate host NHE3 expression. No threshold, amplification, or noise suppression mechanisms were reported.","[""Tissue Repair"", ""Metabolic Regulation""]","Secreted soluble factors (e.g., metabolites, peptides) in culture supernatant",Dose-dependent effect (1:10 and 1:50 dilutions of CS effective; higher dilutions ineffective),Compatible with cell culture media and PBS; effective in in vitro and in vivo models,False,,,Not applicable,,False,False,False,False,无,False,Not applicable,,False,False,False,无,False,Not applicable,,True,"Upregulates NHE3 expression and function in intestinal epithelial cells, enhancing Na⁺/H⁺ exchange and promoting electroneutral NaCl absorption, which supports epithelial barrier integrity and fluid homeostasis.",NHE3 (SLC9A3),True,"Stimulates intestinal Na⁺ absorption via upregulation of NHE3, contributing to electrolyte and fluid homeostasis, which is critical in preventing diarrhea.",Na⁺ (via NHE3-mediated transport),False,Not applicable,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; non-pathogenic; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; environmental escape unlikely due to natural gut colonization,None (no physical confinement used in study),"Lactobacillus acidophilus strain 4357 is a well-established probiotic with GRAS status. It is non-pathogenic, does not carry antibiotic resistance genes, and is not known to cause infections. No biocontainment strategies were used, but its natural gut tropism limits environmental persistence.",口服Lactobacillus acidophilus显著上调小鼠回肠和结肠中NHE3的mRNA和蛋白表达，增强Na⁺/H⁺交换活性，促进肠道电解质吸收，可能通过增强NaCl吸收发挥抗腹泻作用。在体外，LA培养上清液可剂量依赖性地提升Caco2和SK-CO15细胞中NHE3的表达与功能，且该效应由转录机制介导。这些结果表明，LA通过分泌可溶性因子调控宿主肠道离子转运，具有潜在的治疗腹泻的临床价值。,13382,1564,14946,,
8c7cb2fb-ae49-4242-b4e4-f9eaadfe5df9,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium"", ""strain_id"": ""Not specified""}]",Suspension,Strict Anaerobe,"Anaerobic, Gram-positive, gastrointestinal tract environment (pH ~6.5–7.0, nutrient-rich, low oxygen)","Not explicitly mentioned; typical for Bifidobacterium: moderate growth rate, doubling time ~2–4 hours in vitro","Intestinal epithelium, particularly colon (apical surface of epithelial cells)",Commensal interaction; part of natural gut flora; potential for symbiosis with host and competition with pathogens,"Not explicitly mentioned; generally moderate tolerance to bile and low pH, but sensitive to oxygen and drying",Not specified,Bifidobacterium 是一种严格厌氧的革兰氏阳性细菌，属于肠道正常菌群，主要定植于结肠上皮细胞表面，通过分泌可溶性因子调节离子转运功能，具有良好的肠道环境适应性。,Not applicable,Not applicable,Not applicable,Not applicable,Not applicable,Not applicable,该研究未涉及基因工程改造，仅使用天然存在的 Bifidobacterium 菌株及其培养上清液进行功能研究。,"[""pH"", ""Osmotic stress (indirect via intestinal environment)""]","[""Bile acids"", ""Glucose (via host-derived nutrients)""]",,"[""Cytokines (indirect, via inflammation)"", ""Tissue degradation fragments (indirect)""]",Not specified; likely involves surface receptors or secreted factors interacting with host epithelial cells,Not applicable,Bifidobacterium 通过分泌可溶性因子感知宿主肠道微环境，并通过 ERK1/2 信号通路调控 DRA 基因表达，实现对离子平衡的响应性调节。,"[""Metabolic Regulation"", ""Tissue Repair""]",Culture supernatant (soluble factors),Not applicable,Not applicable,False,,,Not applicable,,False,False,False,False,未提及抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未涉及氧气生成或氧合功能。,False,Not applicable,,True,通过上调 DRA（Cl⁻/HCO₃⁻ 交换体）表达，增强肠道上皮细胞对氯离子的重吸收，从而恢复水和电解质平衡，促进肠道屏障功能修复。,SLC26A3 (DRA protein),True,通过分泌可溶性因子激活 ERK1/2 信号通路，上调 SLC26A3 基因表达，调节肠道离子代谢，改善腹泻相关的电解质紊乱。,Not specified; likely small molecules or peptides in culture supernatant,False,Not applicable,,BSL-1,Not applicable,,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no horizontal gene transfer risk in natural strains; safe for human consumption.,Not applicable,Bifidobacterium 属于公认安全（GRAS）菌种，广泛用于食品和益生菌制剂，无致病性，无抗生素抗性基因，环境逃逸风险极低，适合用于肠道疾病治疗。,Bifidobacterium 菌株及其培养上清液可显著增强 Caco-2 细胞中 DRA 基因的表达和 Cl⁻/HCO₃⁻ 交换活性，通过 ERK1/2 信号通路恢复肠道离子平衡，为治疗溃疡性结肠炎和感染性腹泻提供了潜在机制支持。,4702,1412,6114,,
10c51f7a-9cbe-41e0-b201-7c2c3553fe44,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Phaeobacter 27-4"", ""strain_id"": ""27-4""}]",Encapsulated,Facultative Anaerobe,"Temperature: 18–20 °C; pH: neutral (implied by marine conditions); Osmotic: Marine salinity; Nutrition: Marine Broth (MB), microalgae (Isochrysis galbana), organic matter (MB addition)",Doubling time not specified; maintained in biofilter for at least 10 days; released into seawater at 10^3–10^5 CFU/ml and persisted for up to 11 days,"Inert marine surfaces (ceramic biofilters), seawater, biofilm-forming in rearing tanks","Antagonizes Vibrionaceae (e.g., V. anguillarum); reduces total Vibrionaceae and bacterial carrying capacity; does not colonize larvae or rotifers",Survives in seawater for at least 11 days; stable under moderate aeration and light; tolerates organic matter (MB) and microalgae,Ceramic biofilter matrix,"Phaeobacter 27-4 is a marine, biofilm-forming bacterium that colonizes inert surfaces such as ceramic biofilters. It grows under turbot larval rearing conditions (18–20 °C, constant aeration, light) and maintains viability for over 10 days in the biofilter. It is released into seawater at detectable levels (10^3–10^5 CFU/ml) and persists for up to 11 days, contributing to pathogen control without colonizing the host.",Not specified (no genetic modification reported),Not applicable,Not applicable,Not applicable,High stability in biofilter matrix; no evidence of genetic drift or plasmid loss; maintained in biofilter for 10 days without external supplementation,High stability within ceramic biofilter; biofilm structure supports long-term viability and function,"The system uses the naturally occurring probiotic strain Phaeobacter 27-4 without genetic modification. It is immobilized on ceramic biofilters to enable sustained release into seawater, eliminating the need for repeated bioencapsulation. The biofilter acts as a stable, self-replenishing delivery system.","[""Organic matter (MB)"", ""Microalgae (Isochrysis galbana)"", ""Oxygen saturation (>90%)""]","[""Nutrient availability (organic matter)"", ""Microbial competition (Vibrionaceae presence)""]","[""Vibrio anguillarum (pathogen presence)""]","[""None reported""]",Not specified (likely native quorum sensing or nutrient-sensing systems),Not applicable (no engineered logic; function is constitutive antagonism),"The system operates via constitutive production of antagonistic compounds (e.g., TDA) in response to environmental cues such as nutrient availability and pathogen presence. No engineered logic gates are used; the response is passive and continuous.","[""Antibacterial"", ""Environmental Quality Improvement""]",Passive release from biofilm into seawater,"Sustained, continuous release from biofilter; no external control mechanism",High compatibility with ceramic biofilter; maintains structural integrity and function over 10 days,True,True,True,"Phaeobacter 27-4 produces tropodithietic acid (TDA), which kills and inhibits growth of Vibrio anguillarum and other Vibrionaceae. It also reduces total Vibrionaceae counts in seawater and biofilters.",Tropodithietic acid (TDA),True,True,True,True,TDA effectively reduced V. anguillarum to undetectable levels by 144 h; total Vibrionaceae were reduced below detection limit; no cytotoxicity or microbiome disruption reported; localized action in biofilter and seawater.,False,Not applicable,Not applicable,False,False,False,Not applicable,False,Not applicable,Not applicable,False,Not applicable,Not applicable,False,Not applicable,Not applicable,False,Not applicable,Not applicable,BSL-1,No genetic kill-switch or auxotrophy reported; natural inability to colonize host (larvae) acts as biological containment,None (natural non-colonization),Low pathogenicity; not known to colonize fish larvae; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; environmental escape unlikely due to non-colonization,Ceramic biofilter physically confines the strain; prevents uncontrolled release,"Phaeobacter 27-4 is a naturally occurring marine bacterium with low pathogenicity. It does not colonize turbot larvae or rotifers, limiting environmental spread. The ceramic biofilter provides physical containment, and the strain is not genetically modified, reducing biosafety risks. It is classified as GRAS (Generally Recognized As Safe) in aquaculture contexts.","The probiofilter significantly reduced larval mortality from 76% (infected, no probiofilter) to 35–40% (infected, with probiofilter), matching uninfected controls. It reduced V. anguillarum to undetectable levels by 144 h, decreased total Vibrionaceae, and improved seawater quality by reducing turbidity. The system provides sustained probiotic delivery for at least 10 days with a single application.",18212,1798,20010,,
d019d24c-ca14-493e-9958-ec5879c14419,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus johnsonii"", ""strain_id"": ""PV012, PV017, PV018, PV019, PV039""}]",Suspension,Aerotolerant,"37°C, anaerobic conditions, MRS broth; pH 7 for growth, acid and bile tolerance tested","Growth rate not quantified; viable after 4 h at pH 3, some strains survived pH 1 and 2","Intestinal epithelium (Caco-2 cells), gastrointestinal tract (stomach, small intestine, cecum, colon)","Antagonistic to pathogens (E. coli, S. aureus, P. aeruginosa, C. albicans); potential for competition with host microbiota","High acid tolerance (pH 1–3), bile resistance (up to 8% bovine bile), mercury resistance (IC50 up to 125 μmol/L), tolerance to osmotic and ionic stress","Mercuric reductase (merA) gene (in PV012), bile salt hydrolases, acid shock proteins",该研究从草原田鼠肠道中分离出与Lactobacillus johnsonii高度相似的30株乳酸杆菌。这些菌株表现出良好的耐酸性（在pH 1–3下孵育4小时后仍可存活），对胆汁（最高8%牛胆汁）具有抗性，且部分菌株对无机汞表现出显著抗性（IC50高达125 μmol/L）。它们在37°C、厌氧条件下可在MRS培养基中生长，且部分菌株（如PV012）表现出强黏附能力，适合在肠道环境中定植。,"16S rRNA gene sequencing, RAPD fingerprinting, PCR-based qPCR",Not applicable (no genetic modification reported),Not applicable (no synthetic circuits described),,High (clonal isolates maintained over multiple passages; RAPD confirmed genetic stability),Not applicable (no material encapsulation described),本研究未对菌株进行基因工程改造，仅通过16S rRNA测序和RAPD分析对分离菌株进行分类与鉴定。部分菌株（如PV012）的基因组中检测到潜在的merA基因，提示其具有汞解毒能力，但未进行功能验证或工程化改造。,"[""Acidity (pH 1–3)"", ""Bile (0.13–8%)"", ""Mercury (HgCl2)""]","[""Lactic acid (produced in vitro)"", ""Hydrogen peroxide (H2O2)""]",,,"FNR-like promoters (inferred), merA gene (for mercury), bile salt hydrolases","No synthetic logic gates reported; natural responses to environmental stressors (acid, bile, mercury) are likely constitutive",菌株对酸、胆汁和汞等环境压力表现出天然的应答能力，未见明确的逻辑门控机制。例如，PV012菌株在高汞浓度下表现出适应性，IC50值随时间延长而升高，提示可能存在诱导型抗性机制（如merA基因表达）。,"[""Antibacterial"", ""Antifungal"", ""Detoxification"", ""Adhesion""]","Secretion of lactic acid, H2O2, bacteriocins via general secretion pathways; no specific secretion system reported",Not applicable (no controlled release or dosage tuning described),Not applicable (no encapsulation or material matrix described),True,True,False,"通过分泌抗菌物质（如乳酸、过氧化氢、细菌素）抑制多种病原菌生长，包括革兰氏阳性菌（S. aureus）和革兰氏阴性菌（E. coli, P. aeruginosa）。","Lactic acid, H2O2, bacteriocins",True,True,,True,11株菌株的培养上清液在1/8稀释度下即可抑制多种细菌生长，且对真菌（C. albicans）也具有抑制作用，表明其具有广谱抗菌活性。未见细胞毒性或组织损伤报告，安全性良好。,False,,,False,False,False,未提及氧气生成或光依赖性氧合机制。,False,,,False,,,False,,,False,,,BSL-1,"Auxotrophy (inferred from natural gut origin), no suicide genes or inducible kill switches reported",None reported,Low pathogenicity; no antibiotic resistance genes reported (except neomycin resistance); no evidence of horizontal gene transfer; environmental escape unlikely due to host-adapted nature,None (no physical barrier or encapsulation used),所研究的乳酸杆菌为草原田鼠肠道来源，属于非致病性菌株，且未发现耐药基因或毒力因子。其在体外表现出良好的安全性，对宿主细胞无明显毒性，且在自然环境中难以长期存活，因此生物安全风险极低。,本研究未进行体内治疗实验，但筛选出的5株菌株（PV012、PV017、PV018、PV019、PV039）表现出强酸耐受、胆汁抗性、重金属（汞）抗性、广谱抗菌活性及对人肠上皮细胞（Caco-2）的强黏附能力，具备作为益生菌用于调节肠道-脑轴、改善社交行为障碍的潜力。,17234,1841,19075,,
8a09ba70-ac76-471a-928a-aa89f1183bb7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli Nissle 1917"", ""strain_id"": ""EcN""}]","Oral administration, transient gut colonization",Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, utilizes various carbon sources including glucose and lactose; no specific vitamin requirement reported","Rapid growth in vitro with doubling time ~20–30 min; detectable in stool at 6 months post-administration, indicating sustained colonization in early infancy","Intestinal lumen, particularly colon",Competes with pathogenic bacteria; reduces colonization by pathogenic species; may modulate host immune system via interaction with gut epithelium and immune cells,Tolerant to gastric acid and bile salts; survives passage through gastrointestinal tract; stable during oral administration,Outer membrane LPS and acid resistance systems,"EcN is a facultative anaerobe capable of rapid growth in the human gut, survives gastrointestinal transit, and establishes transient but persistent colonization in infants. It is well-tolerated and shows strong competitive exclusion of pathogens.",Not genetically modified in the cited study; naturally occurring strain used,Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems used; no evidence of horizontal gene transfer reported,Stable in oral formulation and gastrointestinal environment,EcN is used in its native form without genetic modification. Its therapeutic effect relies on natural immunomodulatory properties and competitive exclusion of pathogens.,"[""pH"", ""Osmotic stress"", ""Bile salts""]","[""Glucose"", ""Lactose""]",,"[""Toll-like receptor 4 (TLR4)"", ""Cytokines (IL-10, TNF-α, IL-2)""]","Outer membrane lipopolysaccharide (LPS), TLR4 receptor",No engineered logic; natural immune modulation via receptor-ligand interaction,"EcN senses host immune environment via TLR4 and modulates cytokine secretion (e.g., increases IL-10, decreases TNF-α and IL-2) through its LPS, leading to anti-inflammatory effects.","[""Immunomodulation"", ""Antibacterial""]",Natural secretion of LPS and other surface molecules; no engineered secretion systems,Dose-dependent effect; administered once daily for 5 days in newborns,Compatible with oral administration and gastrointestinal transit,True,True,False,Competitive exclusion of pathogenic bacteria through colonization resistance and direct inhibition via antimicrobial factors,"Colonization resistance, competitive exclusion",True,True,,True,EcN reduced pathogen colonization in newborns without causing adverse effects; no evidence of microbiome disruption or tissue damage.,False,,,False,False,False,,True,Modulates immune response by increasing anti-inflammatory IL-10 and decreasing pro-inflammatory TNF-α and IL-2 from T cells,"LPS (outer membrane), IL-10, TNF-α, IL-2",False,,,False,,,False,,,BSL-1,"None (naturally occurring strain, non-pathogenic)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape,Oral delivery with natural gut transit; no physical containment required,"EcN is a well-characterized, non-pathogenic strain with a long history of safe use in humans. It does not carry antibiotic resistance genes and is not associated with virulence factors. Its use in newborns has shown no safety concerns.","In a randomized trial, EcN administration to newborns reduced colonization by pathogenic bacteria and promoted immune education. It was detectable in 90% of infants at 6 months, suggesting effective early colonization and potential for long-term immune modulation.",9946,2857,12803,,
8a09ba70-ac76-471a-928a-aa89f1183bb7,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. infantis"", ""strain_id"": ""B. longum infantis""}]","Oral administration, intestinal colonization in breast-fed infants",Strict Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; requires specific carbon sources such as human milk oligosaccharides (HMOs); dependent on host milk for sustained colonization",Slow growth in vitro; colonizes effectively in breast-fed infants; abundance declines after weaning,"Intestinal mucosa, particularly in breast-fed infants",Symbiotic with host; promotes growth of other beneficial microbes; prevents colonization by pathogenic bacteria,Sensitive to oxygen and drying; stable in breast milk environment; survives gastrointestinal transit,"Mucin-binding proteins, HMO utilization systems","B. longum infantis is a strict anaerobe that thrives in the infant gut, especially in breast-fed infants. It depends on HMOs for growth and colonization, and its abundance is highest during breastfeeding.",Not genetically modified in the cited study; naturally occurring strain used,Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems used; stable in host environment,Stable in breast milk and intestinal environment,B. longum infantis is used in its native form. Its ability to utilize HMOs and colonize the infant gut is intrinsic and does not require genetic modification.,"[""pH"", ""Osmotic stress"", ""Bile salts""]","[""Human milk oligosaccharides (HMOs)"", ""Lactose""]",,"[""Mucin"", ""Immune cells (via cytokine feedback)""]","HMO-specific transporters and glycosidases, mucin-binding adhesins",No engineered logic; natural metabolic sensing via HMO utilization,"B. longum infantis senses HMOs in breast milk via specific transporters and enzymes, enabling selective growth and colonization. It also senses mucosal environment via adhesins.","[""Immunomodulation"", ""Antibacterial""]",Natural secretion of SCFAs and other metabolites; no engineered systems,Dose-dependent on HMO availability; administered orally,Compatible with oral delivery and breast milk environment,True,True,False,Prevents colonization by pathogenic bacteria through competitive exclusion and production of antimicrobial compounds,"Competitive exclusion, antimicrobial metabolites",True,True,,True,B. longum infantis effectively colonizes the infant gut and prevents pathogen colonization without causing adverse effects.,False,,,False,False,False,,True,Promotes immune tolerance and anti-inflammatory responses through modulation of T cell activity and cytokine balance,"HMO metabolites, SCFAs (acetate, lactate)",False,,,True,Metabolizes HMOs into short-chain fatty acids (SCFAs) that regulate host metabolism and immune function,"Acetate, lactate",False,,,BSL-1,"None (naturally occurring, non-pathogenic)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of HGT; no environmental escape risk,Oral delivery with natural gut transit; no physical containment required,B. longum infantis is a GRAS (Generally Recognized As Safe) organism with a long history of safe use in infants. It is naturally adapted to the infant gut and does not pose safety risks.,B. longum infantis effectively colonizes the intestinal tract in breast-fed infants and promotes immune education. It is associated with reduced risk of β cell autoimmunity and is a promising candidate for early-life microbiome modulation.,9946,2857,12803,,
a272df6a-25cf-4047-a4c5-c8cc189e01cc,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus uberis"", ""strain_id"": ""KJ2^m""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus oralis"", ""strain_id"": ""K3^ra""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus rattus"", ""strain_id"": ""JH145^m""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, neutral pH, requires carbohydrates (e.g., sucrose, glucose) as carbon sources; tolerates moderate osmotic stress; dependent on host-derived nutrients in oral environment",Doubling time ~60–90 minutes in vitro; in vivo colonization dynamics suggest stable persistence in oral cavity over 1-year period,"Oral cavity, particularly tooth surfaces and gingival crevices; preferentially colonizes enamel and early plaque biofilms","Competitive inhibition against cariogenic bacteria (e.g., Streptococcus mutans); co-aggregation with other commensals; potential for symbiotic interactions in oral microbiome","Tolerant to drying (in tablet form), moderate shear stress during chewing; stable during storage at room temperature for up to 12 months","Erythritol (sweetener), tablet matrix (protective encapsulation)",该微生物系统由三种唾液链球菌组成，均为兼性厌氧菌，可在口腔环境中定植并维持稳定生长。其生长依赖于宿主提供的碳源（如蔗糖、葡萄糖），在37°C、中性pH条件下表现出良好的增殖能力。在咀嚼片中封装后，具有良好的干燥和储存稳定性，可在室温下保存一年，适合长期口服使用。,,,,,No genetic modifications reported; natural strains used; chromosomal stability in oral environment; no plasmid-based systems,Stable in chewable tablet matrix; no evidence of degradation or loss of viability during encapsulation and storage,"该系统未进行基因工程改造，使用的是天然存在的三种唾液链球菌（S. uberis KJ2^m, S. oralis K3^ra, S. rattus JH145^m），通过口服补充方式定植于口腔，无需外源基因调控或合成回路。","[""pH"", ""Glucose"", ""Lactate""]","[""Sucrose"", ""Glucose"", ""Lactate""]",,,"Native metabolic sensors (e.g., PTS systems for glucose, lactate permeases, pH-responsive regulators)",No engineered logic gates; natural sensing via metabolic and environmental cues; threshold-based activation of competitive inhibition and bacteriocin production,三种菌株通过感知口腔中的糖类（如蔗糖、葡萄糖）和乳酸水平，以及局部pH变化，启动其定植和代谢活动。当环境中有足够碳源时，菌株优先利用糖类并产生过氧化氢等抗菌物质，抑制致龋菌生长。该过程为自然响应机制，无人工逻辑门控，但具有内在的阈值响应特性。,"[""Antibacterial"", ""Metabolic Regulation""]",Spontaneous secretion (via general secretion pathways); no engineered lysis or vesicle systems,"One tablet per day (1×10⁸ CFU total), controlled by patient compliance and tablet formulation",Highly compatible with chewable tablet matrix; encapsulation preserves viability and allows controlled release during chewing,True,False,True,通过竞争性抑制、共聚集及产生过氧化氢等抗菌物质，抑制致龋菌（如S. mutans）在牙面的定植与生物膜形成,"Hydrogen peroxide (H₂O₂), bacteriocins",False,True,True,True,在临床试验中，试验组儿童的龋齿进展（Δds）显著低于对照组（0.2 vs. 0.8，p<0.05），且未观察到不良反应，表明其抗菌作用具有可控性、局部性和安全性。,False,,,,,,,False,,,False,,,True,通过调节口腔微环境中的糖代谢，降低酸性环境形成，抑制牙釉质脱矿，促进口腔生态平衡,"Hydrogen peroxide (H₂O₂), organic acids (lactic, acetic)",False,,,GRAS,No genetic modifications; natural strains; no kill-switches or auxotrophy reported,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; low risk of environmental escape due to oral-only administration and natural clearance,Tablet matrix provides physical confinement; oral delivery limits systemic spread,该微生物系统由三种被广泛认为安全（GRAS）的唾液链球菌组成，未进行基因改造，无致病性或耐药基因，通过口服摄入后在口腔中定植并自然清除，无长期滞留风险。物理封装在咀嚼片中进一步增强了生物安全性。,在为期一年的随机对照试验中，试验组儿童的龋齿进展（Δds）显著低于对照组（0.2 vs. 0.8，p<0.05），预防分数达75%，绝对风险降低22%，需治疗人数约为5人。该结果表明，每日服用含三种唾液链球菌的益生菌咀嚼片可有效减少早期儿童龋齿的发生，尤其在抑制釉质早期脱矿方面效果显著。,7679,1832,9511,,
79606a00-110f-4bbe-8d30-57bc678440a3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus salivarius"", ""strain_id"": ""K12, M18, TOVE-R""}]","Suspension (oral cavity, biofilm-associated)",Facultative Anaerobe,"Optimal growth at 37°C, neutral to slightly alkaline pH (6.5–7.5), tolerates moderate osmotic stress; utilizes glucose and other carbohydrates as carbon sources; dependent on host-derived nutrients in vivo.",Rapid growth in vitro with doubling time ~30–45 min; in vivo colonization persistence observed for >2 weeks post-dosing.,"Oral cavity (tongue dorsum, salivary glands, gingival crevices), breast milk ducts, intestinal tract (via ingestion of saliva); preferentially colonizes epithelial surfaces and biofilm niches.","Competes with pathogenic streptococci (e.g., S. mutans, S. pyogenes); modulates host immune responses; promotes microbial homeostasis; symbiotic with host epithelium.","Tolerant to moderate pH fluctuations, bile salts (in intestinal transit), and desiccation; enhanced survival in fresh cultures vs. freeze-dried forms.",Surface fimbriae and fibrils (enhance adhesion and biofilm formation),"S. salivarius is a numerically dominant oral commensal that thrives in the human oral cavity, exhibiting strong adherence to epithelial surfaces and persistence over time. It is naturally adapted to the oral environment, with high tolerance to physiological stressors such as pH shifts and nutrient variability. Its ability to colonize and persist in the oral mucosa and even translocate to the intestinal tract via saliva ingestion makes it ideal for systemic probiotic effects.",Megaplasmid-based genetic systems (up to 240 kb); natural plasmid transfer observed; no reported CRISPR-Cas or recombinase systems used in current studies.,Not explicitly reported; natural megaplasmid-encoded traits suggest high stability and horizontal transfer potential.,Constitutive expression of bacteriocins and adhesins; no synthetic circuits described.,,High chromosomal and megaplasmid stability; no antibiotic resistance genes detected; low metabolic burden; long-term in vivo persistence indicates evolutionary stability.,"Surface structures (fimbriae/fibrils) remain functional in oral environment, supporting integration into biofilms.","S. salivarius naturally harbors large megaplasmids encoding bacteriocins, adhesins, and polyketide synthases. These traits are constitutively expressed and contribute to competitive exclusion of pathogens. No synthetic genetic circuits have been engineered; natural genetic architecture is leveraged for probiotic function.","[""pH"", ""Glucose"", ""Hypoxia""]","[""Lactate"", ""Bile Acids"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR-like regulators (hypoxia sensing), glucose transporters, and surface adhesins (e.g., antigen I/II family)","No synthetic logic gates reported; natural sensing integrates multiple signals (nutrient availability, pH, host factors) to regulate adhesion and bacteriocin production.","S. salivarius senses environmental cues such as glucose levels and pH to regulate metabolic activity and adhesion. It responds to host-derived signals like proteases and cytokines, suggesting innate ability to detect inflammation. Its natural regulatory networks allow dynamic adaptation to the oral microenvironment, enabling targeted colonization and antimicrobial activity.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion system (bacteriocins), surface adhesins, and extracellular vesicles",Dose-dependent persistence; efficacy linked to duration of colonization rather than controlled release mechanisms.,"Compatible with oral delivery forms (lozenges, rinses); maintains activity in saliva and biofilm matrices.",True,True,True,"Produces bacteriocins (e.g., BLIS K12, M18) that inhibit pathogenic streptococci (S. mutans, S. pyogenes), preventing colonization and biofilm formation.","Bacteriocins (BLIS K12, BLIS M18)",True,True,True,True,S. salivarius K12 and M18 strains significantly reduce S. mutans levels in children with dental caries; BLIS-producing strains correlate with lower acquisition of S. pyogenes. No significant cytotoxicity or microbiome disruption reported.,False,,,False,False,False,,True,Modulates host immune responses by attenuating pro-inflammatory cytokines and promoting homeostatic activity; reduces inflammation induced by pathogens.,"Bacteriocins, surface adhesins, and secreted immunomodulatory molecules",True,Promotes epithelial integrity and wound healing through strong adherence to host cells and stimulation of host cell repair pathways.,"Surface adhesins (e.g., antigen I/II), extracellular matrix-modulating factors",False,,,False,,,GRAS,"Auxotrophy (natural metabolic dependencies), lack of virulence genes, no antibiotic resistance markers","Megaplasmid-encoded traits (no resistance genes), natural host specificity","Low pathogenicity; rare opportunistic infections (endocarditis, meningitis) reported only in immunocompromised hosts; no evidence of horizontal gene transfer of virulence factors.",Oral delivery limits systemic spread; natural colonization is localized to mucosal surfaces.,"S. salivarius is considered safe with a long history of human exposure via breast milk and oral flora. It is closely related to S. thermophilus, a well-established GRAS organism. No antibiotic resistance genes or virulence factors have been detected in BLIS-producing strains. Its host-specificity and lack of systemic dissemination make it a low-risk probiotic candidate.","S. salivarius K12 and M18 strains significantly reduce salivary S. mutans levels in children with dental caries after 3-month treatment. Persistence of the strain correlates with clinical improvement. In halitosis patients, probiotic dosing reduces volatile sulfur compounds, especially with sustained colonization. In animal models, probiotic consortia delay subgingival recolonization by periodontal pathogens and reduce inflammation. Long-term persistence (>2 weeks) is critical for efficacy.",9519,1980,11499,,
7b44b4ce-e8b5-4b0a-bcf5-d8502b2e4b0e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, tolerant to bile salts and low pH (gastric conditions)",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in gut mucosa with moderate persistence,Intestinal mucosa (gut lumen and epithelial surface),Competitive exclusion of pathogenic bacteria; promotes symbiosis with commensal microbiota; modulates host immune tolerance,"Tolerant to drying, lyophilization, and moderate shear stress; stable during storage at 4°C for up to 12 months",Exopolysaccharides (EPS) and cell surface adhesins,该菌株为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下良好生长，对胃酸和胆盐具有较强耐受性，能定植于肠道黏膜表面，具有中等持久性，适用于口服制剂。,Plasmid-based expression system (pMG36e-derived vector),High efficiency (>90%) with low off-target risk; no chromosomal integration reported,Constitutive expression of immunomodulatory factors,,Plasmid stability maintained under selective pressure (antibiotic resistance marker); no significant metabolic burden observed,"Stable in gel-based delivery systems (e.g., alginate beads) without loss of viability",通过质粒系统实现免疫调节因子的组成型表达，未进行复杂逻辑调控，适用于肠道免疫调节应用。,"[""pH"", ""Bile Acids""]","[""Lactate"", ""Glucose""]",,"[""Proteases"", ""Cytokines""]","FNR promoter (responsive to hypoxia), Lactate dehydrogenase promoter (responsive to lactate)","No complex logic gates; simple constitutive expression with feedback from environmental cues (pH, bile)",该菌株通过FNR启动子感知肠道低氧环境，通过乳酸脱氢酶启动子响应局部代谢物变化，实现对肠道微环境的适应性响应，但无复杂逻辑控制。,"[""Immunomodulation"", ""Tissue Repair""]",Type IV secretion system (T4SS) and vesicle-mediated release,Constitutive output; dosage controlled by administration frequency and dose,Compatible with alginate and chitosan-based encapsulation matrices; maintains viability and function,False,,,,,,,,,,False,,,,,,,True,"Promotes differentiation of tolerogenic dendritic cells, enhances intestinal barrier integrity, reduces pro-inflammatory cytokines (e.g., IL-6, TNF-α), increases anti-inflammatory IL-10 and TGF-β.","TGF-β, IL-10, SCFAs (e.g., butyrate)",True,"Enhances intestinal mucosal barrier function by upregulating tight junction proteins (e.g., occludin, ZO-1), promotes epithelial cell proliferation and wound healing.","Occludin, ZO-1, EGF-like factors",True,"Produces short-chain fatty acids (SCFAs) such as butyrate and acetate, which regulate host metabolism, immune function, and gut homeostasis.","Butyrate, Acetate",False,,,GRAS,Auxotrophy (require exogenous amino acids for growth),Lysine auxotrophy,Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; potential risk in immunocompromised infants due to rare bacteremia,Physical confinement via enteric-coated capsules prevents premature release in stomach,该菌株被列为GRAS（公认安全），在健康人群中有良好安全性记录；但在早产儿、免疫缺陷患儿中需谨慎使用，存在极低概率的菌血症风险，建议在特殊人群中使用时加强监测。,在过敏性疾病患儿中，口服Lactobacillus rhamnosus GG可显著改善肠道屏障功能，促进耐受性树突状细胞分化，降低血清炎症因子水平，提高生活质量评分，但对已建立的过敏症状改善有限，主要适用于过敏性疾病的一级预防。,3235,1571,4806,,
ba0338b1-fe23-4c07-86f6-fa9d16e401c6,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus Lc705"", ""strain_id"": ""DSM 7061""}, {""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium freudenreichii subsp. shermanii Js"", ""strain_id"": ""DSM 7067""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve Bb99"", ""strain_id"": ""DSM 13692""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C (L. rhamnosus GG, L. rhamnosus Lc705, B. breve Bb99); 30°C (P. freudenreichii subsp. shermanii Js). pH: Neutral (6.9–7.3). Carbon source: Glucose (MRS broth). Anaerobic conditions required for B. breve Bb99 and P. freudenreichii subsp. shermanii Js.","Doubling time not specified. Growth rate: 18–20 h (L. rhamnosus GG, L. rhamnosus Lc705), 48 h (P. freudenreichii subsp. shermanii Js), 24 h (B. breve Bb99). In vitro growth only.",Gastrointestinal epithelium (Caco-2 cell line model).,Competitive inhibition of H. pylori adhesion. No direct evidence of symbiosis or competition with host microbiome.,Not evaluated in the study. Lyophilized storage used for H. pylori; probiotics stored at -80°C in glycerol.,,四种益生菌均为非致病性微生物，可在体外培养条件下生长。L. rhamnosus GG 和 L. rhamnosus Lc705 为兼性厌氧菌，可在有氧条件下生长；P. freudenreichii subsp. shermanii Js 和 B. breve Bb99 为专性厌氧菌，需在厌氧环境中培养。所有菌株均能在模拟胃肠道环境的培养基中增殖，且对 H. pylori 的黏附具有抑制作用。,,,,,,,该研究未对益生菌进行基因改造，所有功能均为天然菌株的固有特性，未使用任何遗传工具或合成电路。,"[""pH""]","[""Glucose""]",,"[""Cytokines (IL-8, IL-10)"", ""Eicosanoids (PGE2, LTB4)""]",Not specified. Likely involves surface receptors and signaling pathways in epithelial cells.,No engineered logic gates. Natural responses to H. pylori infection are strain-dependent and context-specific.,各菌株对 H. pylori 感染的响应具有特异性：L. rhamnosus GG、L. rhamnosus Lc705 和 P. freudenreichii subsp. shermanii Js 可抑制 IL-8 和 PGE2 的释放，而 B. breve Bb99 则促进 IL-8 和 LTB4 的释放。组合使用时，促炎效应占主导，表明天然信号响应之间存在复杂互作，无明确逻辑门控机制。,"[""Immunomodulation"", ""Barrier Function Modulation"", ""Anti-adhesion""]",Not specified. Likely passive secretion via cell lysis or membrane permeability.,"Dose-dependent effects observed (e.g., 10^7 to 10^9 CFU/ml). No controlled release or feedback system.",Suspension in culture medium; no encapsulation or material barrier described.,False,False,False,"None. The study focuses on anti-adhesion and immunomodulation, not direct antibacterial activity.",,False,False,False,False,无直接抗菌或抗生物膜证据。,False,None. No oxygen-producing enzymes or mechanisms reported.,,False,False,False,未涉及氧合功能。,True,"L. rhamnosus GG, L. rhamnosus Lc705, and P. freudenreichii subsp. shermanii Js inhibit H. pylori-induced IL-8 and PGE2 release. B. breve Bb99 enhances IL-8 and LTB4 release. Combination leads to increased proinflammatory mediators.","IL-8, IL-10, PGE2, LTB4",False,"No evidence of angiogenesis, epithelial regeneration, or ECM regulation.",,False,"No data on SCFAs, tryptophan metabolites, or neurotransmitter production.",,False,"No evidence of immune activation, prodrug conversion, or toxin activation.",,GRAS,None. No kill switches or auxotrophy used.,,"All strains are non-pathogenic, GRAS status. No antibiotic resistance genes or HGT data reported. Low risk of environmental escape.",None. No physical confinement used.,所有菌株均为公认安全（GRAS）的益生菌，无致病性或耐药基因报道，无基因工程改造，因此生物安全风险极低。但组合使用时可能引发促炎反应，需注意临床应用中的免疫平衡。,在体外Caco-2细胞模型中，四种益生菌组合可显著抑制H. pylori黏附，但对屏障功能具有双相作用：初期改善，后期加剧损伤。组合使用时，促炎因子（IL-8、PGE2、LTB4）水平升高，表明其免疫调节作用在组合中被抵消甚至逆转。因此，尽管单个菌株具有抗炎潜力，但组合使用可能适得其反，提示需个体化筛选与评估。,17923,1950,19873,,
f634b811-230c-401b-b3a6-07cbfc6e6e04,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""ATCC 39392""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerant to low pH (2.5–3.7) in fruit juices; requires lactose and other fermentable carbohydrates as carbon sources.",Doubling time ~1.5–2 hours in vitro; viability maintained during refrigerated storage (4°C) for up to 30 days.,Gastrointestinal tract (particularly small intestine); survives in acidic and bile-rich environments.,Competitive exclusion of pathogenic bacteria; potential symbiosis with host microbiota by enhancing microbial balance.,"Tolerant to osmotic stress, moderate heat (up to 50°C), and lyophilization; sensitive to high temperatures (>70°C) and prolonged drying.","Whey protein isolate (WPI), resistant starch (RS), alginate, chitosan","Lactobacillus acidophilus is a facultative anaerobe with strong acid tolerance and ability to ferment lactose and other sugars. It exhibits good viability under refrigerated storage and in low-pH environments such as fruit juices, making it suitable for use in functional foods. Its growth is supported by prebiotics like inulin and resistant starch, which enhance survival during encapsulation and storage.",Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,该系统未涉及基因工程改造，仅通过微胶囊化技术增强菌株的物理保护和稳定性。,"[""Low pH"", ""Osmotic stress"", ""Bile salts""]","[""Lactose"", ""Glucose"", ""Fructooligosaccharides (FOS)""]",,,Not mentioned,Not mentioned,该系统未涉及合成生物学中的感知与逻辑控制模块，仅依赖于天然生理适应性。,"[""Antibacterial"", ""Metabolic Regulation""]",Passive diffusion through microcapsule matrix; no active secretion systems reported.,Controlled by encapsulation density and release kinetics in gastrointestinal tract.,"High compatibility with alginate, chitosan, whey protein, and resistant starch matrices; maintains structural integrity during food processing and storage.",True,False,False,通过产生有机酸（如乳酸）降低局部pH，抑制病原菌生长；在面包和果汁中表现出对多种细菌的抑制作用。,Lactic acid,False,True,True,True,在面包和果汁中，微胶囊化L. acidophilus在烘焙和储存后仍保持较高存活率，且未报告对宿主细胞的显著毒性，表明其活性可控且局部作用安全。,False,未涉及氧气生成或耗氧调控机制。,Not mentioned,False,False,False,未提及氧气相关功能。,False,未提及免疫调节功能。,Not mentioned,False,未提及组织修复功能。,Not mentioned,True,通过发酵乳糖和可溶性碳水化合物产生短链脂肪酸（SCFAs），调节肠道代谢环境，改善宿主代谢健康。,Short-chain fatty acids (SCFAs),False,未提及肿瘤治疗功能。,Not mentioned,GRAS,Not applicable (no genetic kill switches or auxotrophy introduced).,Not mentioned,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe for human consumption.,"Microcapsule matrix (e.g., alginate, chitosan) provides physical confinement and limits environmental escape.","Lactobacillus acidophilus ATCC 39392 is a well-characterized, non-pathogenic strain classified as GRAS (Generally Recognized As Safe). It does not possess known virulence factors or antibiotic resistance genes. The microencapsulation system acts as a physical barrier, preventing unintended release into the environment. No synthetic genetic controls are used, minimizing biosafety risks.",在烘焙食品（如蛋糕、面包）中，微胶囊化L. acidophilus在烘焙后仍保持约10%的存活率，储存4周后存活率下降约3 log，显著优于游离细胞（下降8 log）。在果汁中，微胶囊化可显著提升其在低pH和酚类化合物环境下的存活率，尤其在WPI/RS复合基质中表现优异。该系统有效增强了益生菌在多种食品基质中的稳定性，支持其作为功能性食品载体的潜力。,13807,1591,15398,,
4161faaa-bc1b-444e-a043-02b858622cf9,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""KU200656""}]",Suspension,Facultative Anaerobe,Growth at 37°C in MRS broth; tolerant to pH 2.5 (gastric acid) and 0.3% oxgall (bile salts),Growth rate not explicitly quantified; cultured for 18 h at 37°C for experiments,"Intestinal epithelium (HT-29 cells), gastrointestinal tract","Co-aggregates with pathogens (S. aureus, L. monocytogenes, E. coli, S. Typhimurium); competes for adhesion sites","High tolerance to gastric acid (99.48% survival), bile salts (102.40% survival), and oxidative stress (via H₂O₂ production)","Hydrogen peroxide (H₂O₂), organic acids (lactic, acetic), biosurfactants",该菌株为从泡菜中分离的植物乳杆菌KU200656，具有良好的胃酸和胆盐耐受性，能在37°C下在MRS培养基中生长。其细胞表面疏水性高，能有效黏附于人结肠癌HT-29细胞，表现出良好的肠道定植潜力。,,,,,,,该研究未对菌株进行基因工程改造，所有功能均基于天然代谢产物和生理特性，未涉及外源基因插入或调控回路设计。,"[""pH"", ""Oxidative stress""]","[""Bile acids"", ""Glucose""]","[""Quorum sensing (AI-2)""]","[""Mucin binding sites"", ""Epithelial cell surface receptors""]","Cell surface hydrophobicity, adhesion proteins (e.g., Mubs, SLAPs), flagellar motility genes (fliA, flaA), icaA promoter",No engineered logic gates; natural sensing via surface receptors and gene expression regulation in response to pathogen presence and environmental cues.,该菌株通过细胞表面疏水性和黏附蛋白识别宿主细胞表面受体，通过感知病原体存在（如通过共聚集）和环境信号（如pH、胆汁酸）启动抗菌和抗生物膜反应。其调控机制依赖于天然基因表达调控网络，如通过抑制icaA、flaA、prfA等基因表达来抑制生物膜形成。,"[""Antibacterial"", ""Anti-biofilm""]","Cell-free supernatant (CFS), likely via passive diffusion or membrane leakage","Controlled by concentration of CFS (e.g., 1/2 MIC); activity is dose-dependent",Compatible with liquid suspension; no encapsulation or matrix described,True,True,True,通过细胞外分泌物（CFS）抑制多种食源性病原菌生长，包括S. aureus、L. monocytogenes、E. coli和S. Typhimurium。其机制包括产生有机酸、H₂O₂、生物表面活性剂等抗菌物质。,"Cell-free supernatant (CFS), hydrogen peroxide (H₂O₂), organic acids (lactic, acetic), biosurfactants",True,True,True,True,CFS在1/2 MIC浓度下即可显著抑制多种病原菌生长和生物膜形成，且未报告对宿主细胞的显著毒性，表明其活性可控且安全。,False,,,False,False,False,该菌株未被报道具有产氧能力，不涉及氧合功能。,False,,,False,,,False,,,False,,,GRAS,"None (natural strain, no engineered kill switches)",,"No β-glucuronidase production; sensitive to tetracycline, ampicillin, chloramphenicol, doxycycline; resistant to streptomycin, gentamicin, kanamycin, ciprofloxacin (intrinsic resistance); no antibiotic resistance gene transfer reported.",Not applicable (no physical material barrier used),该菌株为从泡菜中分离的天然植物乳杆菌，不产生致癌酶β-葡萄糖醛酸苷酶，且对多种抗生素敏感，具有GRAS（公认安全）潜力。其内在耐药性（如对氨基糖苷类）符合CLSI标准，无水平基因转移风险报告，安全性良好。,该菌株在体外表现出对多种食源性病原菌（金黄色葡萄球菌、单核细胞增生李斯特菌、大肠杆菌、沙门氏菌）的强抗菌和抗生物膜活性。其细胞外上清液（CFS）在1/2 MIC浓度下即可显著抑制生物膜形成，并下调icaA、flaA、prfA、fliA等关键生物膜相关基因的表达，表明其具有潜在的肠道健康促进和食源性疾病防控能力。,15001,1721,16722,,
efb55a66-4acc-4732-bd9c-d2d75ba6443c,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""L. rhamnosus, L. acidophilus, L. paracasei, L. plantarum""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""B. longum, B. breve, B. lactis, B. bifidum""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""S. thermophilus""}, {""role"": ""Helper"", ""scientific_name"": ""Enterococcus faecalis"", ""strain_id"": ""E. faecalis""}, {""role"": ""Helper"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""B. subtilis""}]",Suspension,Facultative Anaerobe,"Optimal temperature: 37°C; pH range: 5.5–7.0; Nutritional requirements: Carbohydrates (e.g., lactose, glucose), amino acids, vitamins; Osmotic tolerance: Moderate; Bile tolerance: Moderate (in vitro studies show survival in 0.1–0.3% bile)",Doubling time: ~1–2 hours in vitro; Growth rate consistent in vivo under intestinal conditions; In vivo homeostasis maintained in gut lumen,"Intestinal mucosa, particularly colon and ileum; Preferentially colonizes mucus layer and epithelial surface","Competitive exclusion of pathogenic bacteria; Symbiotic interaction with host immune system; Modulates microbiome composition by promoting beneficial taxa (e.g., SCFA producers)",Moderate tolerance to drying and lyophilization; Resistant to gastric acid (pH 2.0–3.0) for 2–3 hours; Tolerant to shear stress during encapsulation; Storage stability at 4°C for up to 6 months,"Cell wall components (e.g., peptidoglycan), exopolysaccharides (EPS), and acid tolerance response (ATR) proteins",这些益生菌株为兼性厌氧菌，可在37°C、pH 5.5–7.0的条件下生长，依赖碳水化合物、氨基酸和维生素。它们能耐受胃酸和中等胆汁浓度，可在肠道黏膜和上皮表面定植，具有良好的储存和加工稳定性，适合用于口服制剂。,"Plasmid-based expression systems (e.g., pTRKH2), CRISPR-Cas9 (in research strains), Recombination (for chromosomal integration)",High efficiency (>90%) in lab strains; Low off-target risk with optimized guide RNAs; No reported horizontal gene transfer in clinical formulations,"Constitutive expression of key genes; Inducible systems (e.g., lactose-inducible promoters) used in research","Lactose, IPTG (in experimental setups)",Plasmid stability: High (copy number 10–20); Loss rate <1% per generation; Chromosomal integration: Stable; Metabolic burden: Low; Evolutionary drift: Minimal in vivo; Long-term in vivo consistency: Confirmed in animal models,"Stable in gel-based delivery systems (e.g., alginate, chitosan); No significant degradation in encapsulated form",通过质粒或染色体整合方式构建工程菌株，实现关键基因的稳定表达。使用乳糖或IPTG诱导系统调控基因表达，确保在肠道环境中可控释放功能蛋白。工程菌株在封装材料中保持遗传稳定性，适合长期口服治疗。,"[""pH"", ""Glucose"", ""Lactate"", ""Osmotic stress""]","[""Bile acids"", ""Short-chain fatty acids (SCFAs)"", ""Choline"", ""Trimethylamine (TMA)""]","[""AHL (Acyl-Homoserine Lactone)"", ""AI-2 (Autoinducer-2)""]","[""Cytokines (TNF-α, IL-1β)"", ""Proteases (MMPs)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactose permease (lactose), Bile acid-responsive repressor (Bacillus), TMA-sensing receptor (E. coli)",AND gate: Requires both low pH and high lactate for activation; Thresholds: SCFA concentration >10 mM triggers response; Noise suppression: Feedback loops via quorum sensing; Dynamic range: 10–1000-fold change in signal,系统通过整合pH、乳酸和SCFA等信号，采用AND逻辑门实现精确响应。当肠道环境呈现酸性且乳酸积累时，启动功能基因表达。通过群体感应分子（AHL/AI-2）实现群体协调，抑制背景噪声，确保在病理性微环境中特异性激活。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type III Secretion System (in engineered strains), Vesicles (exosomes), Lysis (controlled release)","Dose-dependent response; Controlled by formulation (e.g., enteric-coated capsules); Duration of action: 24–72 hours post-administration","High compatibility with alginate, chitosan, and hydrogel matrices; Permeability allows sustained release of metabolites and proteins",True,True,True,通过分泌细菌素（如乳酸菌素）、有机酸（乳酸、乙酸）和过氧化氢抑制病原菌生长；破坏生物膜结构，防止其形成。,"Bacteriocins (e.g., Lactocin, Lactacin), Organic acids (lactic acid, acetic acid), Hydrogen peroxide",True,True,True,True,在动物模型中，VSL#3和L. rhamnosus显著降低肝酶水平和炎症因子，且未观察到宿主细胞毒性或肠道菌群严重失衡。,False,无氧生成机制。,,False,False,False,未提及氧生成能力，因此不满足氧疗条件。,True,通过调节Treg/Th17平衡、抑制NF-κB通路、降低TNF-α和IL-1β水平，减轻肝脏炎症。,"TGF-β, IL-10, Treg-inducing factors",True,促进肝细胞再生，增强肠道屏障功能，通过SCFAs（如丁酸）修复受损上皮。,"Butyrate, Epidermal growth factor (EGF), Mucin-2",True,调节胆汁酸代谢，促进SCFA生成，改善胰岛素敏感性，降低内毒素血症。,"Short-chain fatty acids (SCFAs), Bile acids (BA), Trimethylamine-N-oxide (TMAO)",False,,,GRAS,"Auxotrophy (e.g., leucine auxotrophy), Suicide genes (e.g., ccdB), Temperature-sensitive plasmids","Leucine, Heat shock (42°C)",Low pathogenicity; No known antibiotic resistance genes; No evidence of HGT in clinical trials; Low environmental escape risk due to poor survival outside host,Enteric coating prevents premature release; Gel matrix limits migration beyond gut lumen,该益生菌群为公认安全（GRAS）等级，无致病性，无耐药基因，且通过营养缺陷型和自杀基因实现生物遏制。封装材料有效防止其在肠道外扩散，安全性高。,在多项临床试验中，益生菌联合治疗显著降低ALT、AST、TG和TNF-α水平，改善肝脏脂肪变性和纤维化。在NAFLD患者中，12周治疗后肝脂肪含量下降20–30%，BMI和胰岛素抵抗指数显著改善。,15270,2343,17613,,
ad7eb3c4-1b86-4db8-bf90-7e355e99492b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus toyoi"", ""strain_id"": ""Toyocerin®""}]",Suspension,Facultative Anaerobe,"Temperature: 30–40°C; pH: 6.0–8.0; Osmotic: Moderate tolerance; Nutrition: Requires carbon sources (e.g., glucose), amino acids, vitamins, and minerals for growth.",Doubling time: ~2–3 hours in vitro; Growth rate: Rapid in nutrient-rich environments; In vivo homeostasis not explicitly reported.,"Intestinal lumen (non-colonizing), primarily transient in the gastrointestinal tract.",Competes with pathogenic bacteria for nutrients; does not establish long-term colonization; promotes beneficial microbial balance.,"High tolerance to gastric transit, heat, drying, and storage due to sporulation; stable during feed processing and transport.",Spores (Bacillus toyoi),"Bacillus toyoi é uma bactéria não-ácido-láctica que forma esporos, conferindo alta sobrevivência durante o trânsito gastrointestinal, processamento de rações e armazenamento. Cresce em condições aeróbicas e facultativamente anaeróbicas, com boa tolerância a variações de pH e osmolaridade. Não coloniza permanentemente o trato intestinal, atuando principalmente por competição nutricional com patógenos.",None (natural strain used; no genetic modification reported),Not applicable,Constitutive,,High (spore-forming nature ensures stability; no plasmid or integration reported),Stable in feed matrix; no degradation or loss of viability reported during storage or feeding.,"O Bacillus toyoi é utilizado como probiótico natural sem engenharia genética. Sua estabilidade é garantida pela formação de esporos, que protegem o micro-organismo durante o processamento da ração e o trânsito gastrointestinal. Não há necessidade de circuitos regulatórios, pois sua ação é constitutiva e baseada em competição nutricional.","[""pH"", ""Osmotic stress"", ""Nutrient availability""]","[""Glucose"", ""Amino acids"", ""Lactate""]","[""Quorum sensing (indirect via competition)""]",,"Nutrient transporters and sporulation regulators (e.g., Spo0A)",Constitutive expression; no complex logic or threshold control reported.,"O Bacillus toyoi não apresenta circuitos de sensores programáveis. Sua atividade é constitutiva, com expressão contínua de proteínas relacionadas à competição por nutrientes e à formação de esporos. Não há evidência de resposta a sinais ambientais específicos ou gate lógico.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion (via cell lysis or passive diffusion),Dose-dependent; controlled by feed concentration and administration schedule.,Highly compatible with feed matrix; stable during pelleting and storage.,True,True,False,"Compete with pathogenic bacteria (e.g., Salmonella, E. coli) for nutrients in the intestinal lumen, reducing their colonization and proliferation.",Nutrient competition (indirect mechanism),True,True,True,True,"O Bacillus toyoi reduz a carga de bactérias patogênicas no intestino por competição por nutrientes, sem causar danos significativos ao epitélio intestinal. Não há evidência de efeito tóxico ou desequilíbrio microbiótico.",False,,,False,False,False,Não aplicável; o sistema não possui função de oxigenação.,True,Modula o sistema imunológico por ativação de células imunes e produção de metabólitos que estimulam a resposta inflamatória controlada.,"Metabolites (e.g., organic acids, bacteriocins)",True,"Promove a saúde intestinal ao reduzir a inflamação e a produção de metabólitos tóxicos, favorecendo a regeneração do epitélio intestinal.","Organic acids (e.g., lactic, acetic), bacteriocins",False,,,False,,,BSL-1,Auxotrophy (nutrient-dependent growth; no environmental escape),"Nutrient availability (e.g., specific amino acids)",Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental persistence.,Feed matrix provides physical confinement; no release into environment.,"Bacillus toyoi é classificado como BSL-1 e GRAS (Generally Recognized As Safe). Não apresenta patogenicidade, resistência a antibióticos ou risco de transferência horizontal de genes. Sua dependência nutricional limita sua sobrevivência fora do trato gastrointestinal, garantindo segurança ambiental e de saúde pública.","O uso de Bacillus toyoi em combinação com prebiótico (simbiótico) promoveu os melhores resultados de ganho de peso (99,87 kg) e conversão alimentar (2,12 kg/kg) em suínos entre 28 e 142 dias de idade. A ração simbiótica foi mais eficiente que antibiótico, melhorando o desempenho animal sem comprometer as características de carcaça ou a morfometria intestinal. A ação é baseada em competição com patógenos, modulação imunológica e promoção da saúde intestinal.",14848,1827,16675,,
cd50ca18-7b82-48ad-b10b-0829b82d23b1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""Multiple species (e.g., L. plantarum WCFS1, L. reuteri, L. gasseri, L. acidophilus NCFM)""}]",Suspension,Facultative Anaerobe,Optimal growth at 37°C; pH tolerance in gastrointestinal tract (GIT); capable of surviving bile acids and intestinal environment; nutritional requirements include carbon sources such as glucose and lactose; dependent on host metabolites in gut niche,Growth rate and doubling time not explicitly quantified; in vitro growth supported under standard lab conditions; in vivo stability demonstrated by survival in intestinal tract,"Gastrointestinal tract (GIT), particularly intestinal mucosa and lumen; adapted for survival in harsh gut environment including bile, low pH, and competition with microbiome",Competitive with native gut microbiota; potential for symbiosis due to probiotic nature; minimal disruption to microbiome when engineered appropriately,"Tolerant to bile, low pH, osmotic stress, and temperature shifts; stable during lyophilization and rehydration; resistant to shear stress in industrial processing","Bile salt hydrolase (bsh), lipoteichoic acid (ltaS), S-layer proteins (slpX)","Lactobacillus species are facultative anaerobes with strong adaptation to the human gastrointestinal tract. They exhibit robust growth under physiological conditions, including bile tolerance and acid resistance, enabling survival in the gut. Their nutritional flexibility supports growth on various carbon sources, and they maintain viability during storage and processing, making them ideal for probiotic and therapeutic applications.","CRISPR-Cas9, Recombineering (ssDNA/dsDNA), Cre-loxP system, pORI vectors, suicide vectors, homologous recombination, conditional replication, upp-based counterselection, alr-based food-grade selection",High efficiency with recombineering (up to 19% in L. reuteri); CRISPR-Cas9 enhances low-efficiency recombineering; Cre-loxP enables marker-free gene replacement; off-target risk minimized by asymmetric lox sites (lox66/lox71) and low recombination between residual loxP and lox72,"Inducible (nisin, xylose, pH, temperature, lactose); constitutive (pSIP411); logic gates not explicitly described but implied via promoter regulation","Nisin (for pnisA), xylose (for pxyL), pH shift (for p170), temperature (for pL/φR), lactose (for placA), gRNA (for CRISPR-Cas9)",High chromosomal integration stability via Cre-loxP and pORI systems; plasmid stability improved with conditionally replicating vectors; low drift due to marker-free integration; long-term in vivo consistency demonstrated by survival in GIT; metabolic burden minimized by chromosomal integration,Stable in encapsulation and delivery systems; compatible with food-grade and therapeutic formulations; no reported degradation in matrix environments,"Advanced genetic tools enable precise, marker-free genome editing in Lactobacillus species. The pORI system allows site-specific integration using conditional replication. The Cre-loxP system enables efficient marker excision. Recombineering with ssDNA/dsDNA substrates allows high-throughput, selection-free editing. CRISPR-Cas9 enhances recombineering in low-efficiency strains. Inducible promoters (e.g., pSIP411, pnisA) provide tight control over gene expression. Food-grade selection (alr, upp) avoids antibiotic resistance markers, enhancing safety for human use.","[""pH"", ""Temperature"", ""Osmotic stress"", ""Hypoxia""]","[""Bile acids"", ""Lactose"", ""Glucose"", ""Xylose""]","[""Nisin (quorum-sensing molecule)""]","[""Proteases"", ""Cytokines (implied via immune modulation)""]","NisK/NisR two-component system (for nisin), pSIP promoters (sakacin A/P systems), FNR-like regulators (implied for hypoxia), pH-responsive promoters (p170)","Inducible systems act as AND gates (e.g., expression only when inducer present and promoter active); threshold control via promoter strength; noise suppression via tight regulation; no explicit logic circuits described beyond promoter control","Lactobacillus strains utilize inducible promoters that respond to specific environmental cues such as nisin, pH, temperature, or sugar availability. These systems function as conditional switches, enabling precise control over gene expression. The integration of CRISPR-Cas9 with recombineering allows for targeted editing only in cells that have incorporated the desired mutation, effectively creating a selection logic that eliminates wild-type cells. This enables high-fidelity genome editing with minimal off-target effects.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type IV secretion (e.g., pSIP vectors for extracellular delivery of nuclease A); general secretion via Sec pathway; potential for vesicle-mediated delivery","Tight control via inducible promoters (e.g., pSIP411, pnisA); expression can be turned on/off in response to environmental cues; dosage adjustable via inducer concentration",High compatibility with encapsulation and delivery matrices; stable during formulation; compatible with food-grade and pharmaceutical delivery systems,False,,,Not applicable; no direct antibacterial mechanism described in the paper.,,False,,,,无相关证据,False,Not applicable; no oxygen-producing enzymes or systems described.,,False,False,False,无相关证据,True,"Engineered strains secrete therapeutic proteins such as interleukin-10 (IL-10), which modulates immune responses to reduce inflammation in colitis and inflammatory bowel disease.",Interleukin-10 (IL-10),True,"Lactobacillus strains promote epithelial barrier integrity and mucosal healing through secretion of growth factors and modulation of immune signaling, supporting tissue regeneration in the gut.","Growth factors (implied), IL-10, mucosal repair signaling molecules",True,"Lactobacillus species metabolize bile acids and regulate host metabolism via production of short-chain fatty acids (SCFAs) and other metabolites, influencing glucose and lipid homeostasis.","Short-chain fatty acids (SCFAs), bile acid metabolites",False,Not applicable; no prodrug conversion or immune activation against tumors described.,,BSL-1,"Auxotrophy (alr-based selection), kill switches (via CRISPR-Cas9 targeting of essential genes), suicide vectors (pORI), conditional replication, upp-based counterselection","Alanine racemase (alr), uracil-phosphoribosyltransferase (upp), Cre recombinase, CRISPR-Cas9 (targeting essential genes)",Low pathogenicity; no known virulence factors; antibiotic resistance genes avoided via food-grade markers; low risk of horizontal gene transfer due to chromosomal integration; minimal environmental escape risk due to poor survival outside gut; no evidence of microbiome disruption in studies,Physical confinement via encapsulation and controlled release; limited colonization due to engineered auxotrophy and self-destruct mechanisms,"Lactobacillus strains are generally recognized as safe (GRAS) and have a long history of use in food and probiotics. Genetic modifications are designed to enhance safety: auxotrophy prevents uncontrolled growth; CRISPR-Cas9 systems can be used for kill switches; marker-free integration reduces HGT risk. The use of food-grade selection systems (alr, upp) avoids antibiotic resistance genes. Overall, the engineered strains are considered low-risk for human and environmental exposure.",工程化Lactobacillus菌株在小鼠模型中成功用于治疗结肠炎，通过分泌白细胞介素-10（IL-10）显著减轻肠道炎症。在人类临床试验中，IL-10分泌型L. lactis虽未显示显著疗效，但验证了微生物作为治疗性蛋白递送平台的可行性。这些菌株在肠道中存活并持续释放治疗蛋白，支持黏膜修复和免疫调节，为慢性肠道疾病治疗提供了潜在策略。,11586,2396,13982,,
0f0f41a7-5169-48fe-a316-09415672910c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""DSM 24730""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""DSM 24731""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""DSM 24732""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""DSM 24733""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""DSM 24734""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""DSM 24735""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""DSM 24736""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""DSM 24737""}]",Oral supplementation (Suspension),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, tolerant to bile salts and low pH (gastric conditions), utilizes various carbohydrates including lactose, glucose, and fructose",Doubling time ~1.5–2 hours in vitro; stable colonization observed in gut mucosa after oral administration,"Gut mucosa (intestinal lumen and epithelial surface), particularly in the colon",Competitive exclusion of pathogenic bacteria; synergistic interactions with host microbiota; no reported antagonism with commensals,"Tolerant to lyophilization, refrigeration, and short-term exposure to drying; resistant to gastric acid and bile salts during transit","Bile salts, gastric acid (HCl), and lyophilization buffer",该多菌株益生菌组合为兼性厌氧菌，可在37°C、pH 6.0–7.0条件下生长，对胃酸和胆盐具有较强耐受性，能有效定植于肠道黏膜，利用多种碳源进行代谢，具有良好的体外生长速率和体内定植能力。,"Not applicable (commercially available probiotic product, no genetic modification reported)",N/A,Constitutive (no inducible circuits reported),N/A,High chromosomal stability; no plasmids used; no evidence of genetic drift or loss in vivo over 6 months,Stable in oral formulation (sachets); maintains viability during storage and gastrointestinal transit,该益生菌产品为市售非基因工程制剂，未进行任何基因改造，其功能依赖于天然菌株的生理特性，具有良好的遗传稳定性，无需依赖外源性调控系统。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Lactose"", ""Fructose"", ""Galactose""]",,,"General metabolic sensors (e.g., PTS systems, sugar transporters); no specific engineered receptors reported",No engineered logic gates; natural metabolic regulation based on substrate availability,各菌株通过天然代谢感应系统感知肠道环境中的pH、胆汁酸、糖类等信号，根据底物浓度自动调节代谢活性，无外源性逻辑门控机制。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (e.g., for SCFAs), passive diffusion, and vesicle release",Dose-dependent effect via oral intake (2 sachets/day); no feedback control reported,Compatible with oral formulation (sachets); stable during gastrointestinal transit and intestinal release,False,False,False,N/A,N/A,False,False,False,False,未报告抗菌或抗生物膜功能。,False,N/A,N/A,False,False,False,未报告氧气生成功能。,True,"Modulates systemic and central nervous system immune activation by reducing monocyte activation and pro-inflammatory cytokine release; decreases CSF neopterin levels, a marker of CNS immune activation.","Neopterin (indirectly), IL-10, TGF-β, and other anti-inflammatory mediators produced by probiotic strains",True,"Improves gut barrier integrity, reduces microbial translocation, and may indirectly support blood-brain barrier restoration by reducing systemic inflammation.","Short-chain fatty acids (SCFAs), mucin-modulating factors, and extracellular matrix regulators",True,"Regulates tryptophan metabolism, enhances SCFA production (e.g., acetate, butyrate), and modulates host energy metabolism via microbial fermentation.","Short-chain fatty acids (SCFAs), tryptophan metabolites (e.g., indole derivatives)",False,N/A,N/A,GRAS,No genetic kill switches or auxotrophy; natural attenuation via lack of virulence factors,None,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; no environmental escape risk due to non-pathogenic nature and poor environmental survival,Oral delivery with natural gut transit; no physical confinement required,该多菌株益生菌组合为公认安全（GRAS）物质，无致病性、无抗生素抗性基因，不具有水平基因转移能力，且在环境中生存力弱，无逃逸风险，安全性高。,在为期6个月的高剂量多菌株益生菌补充后，干预组患者脑脊液中神经炎症标志物（新蝶呤）浓度显著下降（T0: 34.14 nmol/L vs. T6: 24.11 nmol/L，p=0.011），同时在多个神经认知测试中表现出显著改善，包括Rey-Osterrieth复杂图形测试的即时与延迟回忆、Rey听觉词语学习测试的即时与延迟回忆、时间与重量估计测试、音位性词语流畅性测试等，提示其对HIV感染者神经炎症和认知功能障碍具有显著改善作用。,14154,2036,16190,,
82463867-1211-4b01-8961-6d3421bac328,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LA-5""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""BB-12""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei subsp. paracasei"", ""strain_id"": ""L. paracasei""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""431""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""BC513""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, tolerance to bile and acid; requires complex nutrients including vitamins and amino acids.",Doubling time not specified; in vitro growth supported under standard laboratory conditions.,"Intestinal mucosa, particularly in the colon and small intestine.",Competitive exclusion of pathogenic bacteria; symbiotic interaction with host immune system and commensal microbiota.,"Tolerant to bile, acid, and moderate osmotic stress; stable during lyophilization and rehydration.","Bile salts, acid resistance proteins, and spore formation (in Bacillus coagulans)",该多菌株益生菌产品由五种菌株组成，包括Lactobacillus acidophilus LA-5、Bifidobacterium animalis subsp. lactis BB-12、Lactobacillus paracasei subsp. paracasei、L. casei 431和Bacillus coagulans BC513。这些菌株均具有良好的酸和胆汁耐受性，可在肠道环境中定植并维持稳定。其中，Bacillus coagulans以芽孢形式存在，具有较强的环境耐受性，可在干燥和储存条件下长期存活。整体生长生理特性表明其适合在人体肠道内定植并发挥免疫调节功能。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未涉及基因工程改造，所有菌株均为天然来源，未进行人工基因编辑或调控回路设计。其功能依赖于天然代谢通路和宿主-微生物互作机制。,"[""Acidity"", ""Bile""]","[""Short-chain fatty acids (SCFAs)"", ""Lactate""]","[""Quorum sensing (indirect via microbiota modulation)""]","[""Cytokines (IL-10, TNF-α)"", ""Proteases (indirect via mucosal barrier integrity)""]","Acid resistance promoters (e.g., FNR-like regulators), bile salt hydrolase (BSH) genes",No engineered logic gates; natural sensing via environmental adaptation and host feedback.,各菌株通过感知肠道内的酸性环境和胆汁成分实现定植适应，同时响应宿主免疫信号（如IL-10和TNF-α）进行动态调节。其行为由天然代谢与宿主免疫系统的双向反馈驱动，无人工逻辑控制。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Not specified,Not specified,Not specified,False,False,False,Not applicable,,False,False,False,False,未检测到抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未涉及氧气生成机制。,True,通过上调IL-10、IgA和调节TNF-α水平，增强抗炎反应，抑制过度免疫激活。,"IL-10, IgA, TNF-α",True,通过增加粪便IgA水平和促进短链脂肪酸（SCFA）产生菌（如Faecalibacterium spp.）的丰度，增强肠道屏障功能，减少腹痛。,"Faecalibacterium spp., SCFAs",True,通过促进SCFA（如丁酸）的产生，调节肠道代谢环境，改善神经-免疫-代谢轴功能。,Short-chain fatty acids (SCFAs),False,Not applicable,,GRAS,"None (natural strains, no kill switches)",None,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; low environmental escape risk.,"None (oral administration, no physical confinement)",所有菌株均为公认安全（GRAS）菌株，无致病性、无抗生素抗性基因，且未进行基因改造，因此生物安全风险极低。口服给药后在肠道内定植，无长期环境释放风险。,该多菌株益生菌产品显著降低了受试者的腹痛症状（p<0.05），并提高了粪便IgA水平和IL-10浓度，表明其具有增强肠道黏膜屏障功能和抗炎作用。同时，其可促进有益菌（如Faecalibacterium spp.）的增殖，抑制潜在致病菌（如Dialister spp.、Escherichia/Shigella）的生长，从而改善肠道微生态平衡，间接缓解与压力相关的肠道不适。,18691,1808,20499,,
20a9fe5e-29fa-4676-b57f-9ab9cd432a4f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,Temperature: 37°C; pH: neutral; Nutritional requirements: standard MRS medium; Growth in zebrafish gut environment,Colonization achieved at 1.55 × 10⁶ CFU/fish/day; stable in intestinal environment over 28 days,"Intestinal epithelium (small intestine and colon), particularly in the context of alcohol-induced gut barrier dysfunction",Modulates gut microbiota composition; promotes beneficial bacterial balance; enhances barrier integrity without significant disruption of native microbiome,Tolerant to freeze-drying (freeze-dried probiotic used); stable during storage and rehydration; resistant to gastric transit in zebrafish model,Freeze-dried formulation (Culturelle),"Lactobacillus rhamnosus GG is a facultative anaerobe capable of colonizing the zebrafish intestinal tract under experimental conditions. It thrives at 37°C in a neutral pH environment and demonstrates stability during freeze-drying and rehydration. The strain successfully colonized the gut at a dose of 1.55 × 10⁶ CFU/fish/day, persisting over a 28-day ethanol exposure period, indicating robust adaptation to the host intestinal environment.","None (native strain, no genetic modification reported)",,Constitutive (no inducible circuits described),,High (no genetic modifications; native strain used; stable colonization observed over 28 days),No genetic material used; strain is naturally stable in the intestinal environment,"Lactobacillus rhamnosus GG was used in its native, unmodified form. No genetic engineering tools such as CRISPR-Cas, plasmids, or inducible promoters were employed. The strain's natural ability to colonize the gut and exert beneficial effects was leveraged without any synthetic genetic circuits.","[""Ethanol"", ""pH (intestinal environment)""]","[""Lipopolysaccharide (LPS)"", ""Acetaldehyde (metabolite of ethanol)""]",,"[""Toll-like receptor 4 (TLR-4) activation"", ""Inflammasome components (NLRP3, ASC, caspase-1)""]","Native receptors (e.g., TLR-4, NLRP3 inflammasome complex); no engineered sensors reported",No synthetic logic gates; natural response to inflammatory and metabolic signals,"Lactobacillus rhamnosus GG does not possess engineered sensing circuits. Instead, it naturally responds to host-derived signals such as ethanol-induced gut barrier disruption and LPS translocation. Its activity is triggered by the presence of inflammatory mediators and microbial products, leading to modulation of immune responses and tight junction expression through endogenous pathways.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Passive secretion of metabolites and cell wall components; no engineered secretion systems reported,Dose-dependent colonization and effect (1.55 × 10⁶ CFU/fish/day effective); no dynamic control mechanisms,Compatible with oral administration and intestinal environment; freeze-dried formulation suitable for delivery,False,,,Not applicable (no antibacterial mechanism reported),,False,,,,Lactobacillus rhamnosus GG was not evaluated for antibacterial or biofilm inhibition activity in this study.,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,No evidence of oxygenation activity; not a feature of LGG.,True,"Reduces hepatic expression of pro-inflammatory cytokine IL-1β and modulates inflammasome activation (NLRP3, ASC, caspase-1). Also increases expression of anti-inflammatory IL-10.","IL-1β, IL-10, NLRP3 inflammasome components",True,"Enhances intestinal barrier integrity by upregulating tight junction proteins, particularly claudin-15a (cldn15a), and improving gut permeability markers.","Claudin-15a (cldn15a), JAM-1 (f11r)",True,"Reduces hepatic lipid accumulation (steatosis) in ethanol-exposed zebrafish, indicating modulation of lipid metabolism.",Hepatic triglycerides (lipid accumulation),False,Not applicable (no tumor model or prodrug conversion reported),,GRAS,"None (native strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe for human consumption (GRAS status),None (no physical material barrier used; oral delivery only),"Lactobacillus rhamnosus GG is a well-established probiotic strain with GRAS status. It is non-pathogenic, does not carry antibiotic resistance genes, and has been safely used in humans and animal models. No genetic modifications or biocontainment strategies were employed, but its natural safety profile supports low risk of environmental escape or adverse effects.","Lactobacillus rhamnosus GG supplementation significantly reduced hepatic lipid accumulation (steatosis) and decreased expression of pro-inflammatory IL-1β in zebrafish exposed to ethanol. It enhanced intestinal barrier function by upregulating tight junction protein claudin-15a (cldn15a), demonstrating protective effects against alcohol-induced liver injury through modulation of gut permeability and inflammasome activation.",11885,1817,13702,,
261f5e8d-77b0-4219-a9f4-aeb4f29823ca,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""UCC118""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates bile salts and gastric acidity; utilizes glucose and other carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; stable transit through gastrointestinal tract in vivo,"Human ileal-cecal region, gastrointestinal tract (GIT)",Modulates gut microflora; promotes symbiosis with host microbiome; competes with pathogenic bacteria,"Tolerant to bile, low pH, osmotic stress; survives lyophilization and rehydration; stable under moderate shear stress","Bile salts, gastric acid, lyophilization buffer","Lactobacillus salivarius UCC118 is a facultative anaerobe capable of surviving in the harsh conditions of the gastrointestinal tract, including low pH and bile exposure. It exhibits robust growth in vitro and demonstrates stable transit through the human gut, maintaining viability and colonization potential. Its ability to persist in the ileal-cecal region supports its role as a gut-resident probiotic.",Not specified,,Not specified,,No plasmid-based systems reported; chromosomal integration not described; no evidence of genetic drift or instability in vivo,No engineered material environment described; natural survival in GIT without synthetic encapsulation,"Lactobacillus salivarius UCC118 has not been genetically modified in the studies referenced. Its probiotic effects are attributed to native physiological traits rather than synthetic genetic circuits. No CRISPR, recombinase, or inducible promoter systems were used.","[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter, LasR receptor, AI-2 receptor (LuxP/Q)",No explicit logic gates reported; likely constitutive expression of immune-modulatory genes; threshold-based response to environmental cues,"Lactobacillus salivarius UCC118 senses changes in gut pH and bile concentration, which trigger adaptive responses. It detects microbial quorum-sensing molecules (AHL, AI-2) and host-derived signals such as proteases and cytokines, enabling it to modulate immune activity in a context-dependent manner. The sensing system appears to operate through native promoters and receptors without engineered logic circuits.","[""Immunomodulation"", ""Metabolic Regulation""]","Type IV secretion system (inferred from immune modulation), Vesicles",Natural colonization-dependent; no external dosage control; persistence limited to duration of intake,Compatible with oral delivery via fermented milk; no synthetic material encapsulation reported,False,,,,,,,,,,False,,,,,,,True,"Modulates immune system by reducing pro-inflammatory cytokines (e.g., TNF-α) and enhancing anti-inflammatory responses; promotes regulatory T-cell activity",Lactobacillus salivarius UCC118 (native strain),False,,,True,"Modulates gut microbiota composition; influences glucose metabolism and lipid profiles; however, no significant effect on fasting glucose in obese pregnancy was observed in clinical trial","Short-chain fatty acids (SCFAs), Lactate",False,,,GRAS,"None (natural strain, no synthetic kill-switches)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape,None (oral delivery without physical confinement),"Lactobacillus salivarius UCC118 is classified as Generally Recognized As Safe (GRAS). It has been used in multiple human and animal studies without adverse effects. No evidence of pathogenicity, antibiotic resistance, or horizontal gene transfer was reported. Its natural attenuation and lack of invasive traits make it a low-risk probiotic.","In a randomized controlled trial, Lactobacillus salivarius UCC118 did not reduce maternal fasting glucose levels in obese pregnancy, despite successful transit through the gastrointestinal tract and modulation of gut microflora. It demonstrated immunomodulatory and metabolic regulatory potential in vitro and in animal models, but failed to show significant metabolic benefits in human clinical settings. Its primary efficacy lies in immune system engagement and gut microbiota modulation rather than direct therapeutic healing.",3961,1584,5545,,
8669a2b2-19e2-42fe-9d36-74137c02d508,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli Nissle 1917"", ""strain_id"": ""EcN""}]",Suspension,Facultative Anaerobe,Temperature: 37°C; pH: not specified; Osmotic: not specified; Nutrition: not specified; Carbon source: not specified; Host metabolite dependency: not specified,Doubling time: not specified; In vivo vs in vitro: not specified,"Intestinal mucosa (jejunum, ileum, caecum, colon); Hypoxic conditions in gut lumen",Competes with established intestinal flora; Adheres to epithelial cells; Prevents adhesion/invasion of pathogenic bacteria; No significant alteration of intestinal barrier integrity; No major immune cell recruitment at low doses,Tolerates gastric transit (evidenced by persistence after oral administration); Tolerates storage in glycerol at -70°C; Tolerates lyophilization/rehydration (implied by use of frozen cultures); UV and drying tolerance: not specified,Glycerol (for cryopreservation),"EcN is a facultative anaerobe that can colonize the intestinal tract of conventionally reared piglets for at least 4 weeks after oral administration. It adheres strongly to porcine intestinal epithelial cells, prevents pathogen adhesion, and persists in the gut despite competition with resident microbiota. It survives gastrointestinal transit and maintains viability in the intestinal environment, indicating robust growth physiology in the porcine gut.","Multiplex PCR, GEI II-PCR, PFGE (XbaI), K5 phage spot test",Not applicable (no genetic modification reported),Not applicable (no synthetic circuits described),,High chromosomal stability (identical PFGE patterns in re-isolates); Plasmid pMUT1/pMUT2 present in original strain but not confirmed in all re-isolates; No evidence of plasmid loss or mutation in core genome; Long-term in vivo stability demonstrated over 33 days,Stable in intestinal environment; No disruption of gut structure; Compatible with mucosal colonization,"No genetic engineering was performed in this study. The strain was used in its native form. Identification and verification of colonization relied on molecular markers (multiplex PCR, GEI II-PCR, PFGE, K5 phage sensitivity) rather than synthetic genetic circuits.","[""Hypoxia"", ""pH""]","[""Lactate"", ""Glucose""]","[""Quorum sensing (indirectly via biofilm formation)""]","[""Proteases"", ""Cytokines""]","F1C fimbriae, ECP (E. coli common pilus), Iha (adherence-conferring molecule); Type 1 fimbriae",Not applicable (no synthetic logic circuits reported),"EcN uses natural adhesion systems (F1C fimbriae, ECP, Iha) to sense and respond to host epithelial surfaces. It forms biofilms on inert surfaces and intestinal mucosa, suggesting a threshold-based colonization mechanism. The strain avoids immune activation by lacking α-hemolysin and producing serum-sensitive LPS, indicating a stealth strategy.","[""Antibacterial"", ""Colonization"", ""Barrier Enhancement""]",Type I secretion (microcins H47 and M); Adhesion-mediated delivery via fimbriae,Not applicable (natural colonization; no controllable output),Compatible with intestinal mucosa; no structural disruption observed,True,True,True,"EcN secretes microcins H47 and M, which inhibit growth of other bacteria including E. coli and Salmonella. It also prevents adhesion and invasion of pathogenic bacteria by competitive exclusion and biofilm formation.",Microcins H47 and M,True,True,True,True,EcN inhibits growth of E. coli and Salmonella spp. via microcins; prevents pathogen adhesion/invasion; no significant inflammation or immune cell recruitment observed; low cytotoxicity; localized retention in gut.,False,,,False,False,False,Not applicable,False,,,True,EcN strengthens epithelial tight junctions in intestinal T84 cells and enhances barrier integrity. It adheres to intestinal epithelium and prevents pathogen invasion.,"F1C fimbriae, ECP, Iha (adhesion molecules)",False,,,False,,,BSL-1,None (no synthetic kill switches or auxotrophy reported),,"Non-pathogenic; lacks Shiga toxin, heat-labile/stable enterotoxins, cytotoxic necrotizing factor, and α-hemolysin; serum-sensitive due to rough LPS; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape",None (no physical confinement used),"EcN is a well-characterized probiotic strain with a strong safety profile. It lacks major virulence factors, is serum-sensitive, and does not produce recognized toxins. It does not persist in the environment due to rapid inactivation at room temperature. No evidence of pathogenicity or microbiome disruption in piglets. Classified as GRAS (Generally Recognized As Safe) in humans and calves.","EcN successfully colonized the intestine of conventionally reared piglets for at least 33 days after oral administration. It was detected in faeces and intestinal mucosal swabs up to 33 days post-treatment. Re-isolation from multiple intestinal sites (ileum, colon, caecum) confirmed persistent colonization. The strain maintained genetic stability (identical PFGE patterns) and phenotypic markers (rdar morphotype, K5 phage sensitivity) in re-isolates. No adverse effects on piglet health were observed. Results demonstrate strong colonization potential and long-term persistence in the porcine gut.",18015,1868,19883,,
01d7fc70-4a65-4fd7-ad74-61059e73e833,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""W13""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae var. boulardii"", ""strain_id"": ""ATCC MYA-796""}]",Suspension,Facultative Anaerobe,"Growth at 30°C on YPG agar; incubation at 37°C in YPG broth; pH 7.3 for washing; tolerance to simulated gastrointestinal conditions including pH 2.0 (gastric), pH 8.0 (intestinal), and presence of bile salts and enzymes.","Doubling time not specified; viable count maintained at ~7.7 log CFU/mL before GIT exposure, with gradual decline after intestinal passage (e.g., W13: 7.66 → 5.87 log CFU/mL after sequential conditions).","Human gastrointestinal tract (simulated transit through salivary, gastric, and intestinal environments); potential for intestinal colonization due to bile and pH tolerance.","No direct interaction data reported; however, S. cerevisiae var. boulardii is recognized as a probiotic yeast with potential symbiotic or competitive interactions with gut microbiota.","Tolerant to low pH (pH 2.0), bile salts, proteolytic enzymes (pepsin, pancreatin), and osmotic stress (simulated GI fluids); moderate stability during sequential GI passage.","Cell wall components (mannoproteins, β-glucans) likely contribute to structural integrity under GI stress.",该研究中使用的酿酒酵母（S. cerevisiae）和贝氏酵母（S. cerevisiae var. boulardii）在模拟人体胃肠道条件下表现出良好的生长适应性，可在37°C下生长，耐受胃酸（pH 2.0）和肠道环境（pH 8.0）中的胆汁盐与消化酶。尽管在肠道模拟条件下活菌数有所下降，但菌株仍保持较高存活率，尤其贝氏酵母表现出更强的耐受性。,,,,,,,本研究未涉及基因工程改造，所有酵母菌株均以天然状态使用，未进行任何遗传修饰或合成回路设计。,"[""pH"", ""Hypoxia""]","[""Bile Acids""]",,,"Cell wall macromolecules (mannoproteins, β-glucans) – responsible for OTA binding via electrostatic and hydrophobic interactions.",No engineered logic gates; natural binding behavior is passive and non-regulated.,酵母对赭曲霉毒素A的结合是基于细胞壁上带电荷的多糖（如甘露蛋白和β-葡聚糖）与毒素之间的非特异性物理吸附，无主动感知或逻辑调控机制。,"[""Metabolic Regulation""]","Passive binding to cell wall (non-secretory, non-lytic mechanism)",Not applicable – binding is passive and not dose-controllable via genetic circuits.,Compatible with suspension in PBS; stable under simulated GI conditions without structural disruption.,False,,,Not applicable – no antibacterial activity reported.,,False,False,False,False,无相关证据。,False,Not applicable – no oxygen production or consumption reported.,,False,False,False,无相关证据。,False,Not applicable – no immune-modulating molecules reported.,,False,Not applicable – no tissue repair functions reported.,,True,"Yeast cells bind ochratoxin A (OTA) via cell wall components, reducing its bioavailability in the gastrointestinal tract. This detoxification mechanism prevents systemic absorption and reduces toxicity.",Ochratoxin A (OTA),False,Not applicable – no anti-tumor activity reported.,,GRAS,None – no kill-switch or auxotrophy used.,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk in natural strains; environmental escape unlikely due to non-invasive nature.,None – no physical confinement used in the study.,酿酒酵母（S. cerevisiae）和贝氏酵母（S. cerevisiae var. boulardii）均被美国FDA列为GRAS（公认安全）微生物，且在欧盟QPS清单中被认定为安全。研究中使用的菌株未经过基因改造，无致病性或耐药基因，且在模拟胃肠道条件下仍保持一定存活率，表明其具有良好的生物安全性。,在模拟胃肠道条件下，S. cerevisiae W13和S. cerevisiae var. boulardii ATCC MYA-796对赭曲霉毒素A的去除率分别达到21%和30%，且在顺序模拟实验中去除率最高达44%。其中W13菌株表现出最强的稳定结合能力，释放率仅为18%，表明其结合复合物更稳定，具有良好的潜在应用前景。,9795,1697,11492,,
4375ee60-277c-4e3c-b4f3-ec4729115cce,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium"", ""strain_id"": ""Various strains (e.g., B. bifidum S17, B. breve UCC2003, B. adolescentis, B. longum subsp. longum)""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerant to bile salts and intestinal pH; utilizes mucins and complex carbohydrates as carbon sources",Moderate growth rate; doubling time ~2–3 hours in vitro; persistence in gut environment supported by adaptation to GIT conditions,Gastrointestinal tract (especially colon and mucus layer); preferentially adheres to intestinal epithelial cells and mucus,Competitive exclusion of pathogens; symbiotic with host immune system; no evidence of pathogenicity or disruption of native microbiota,"Tolerant to bile, low pH, osmotic stress, and intestinal transit; stable during lyophilization and storage","Bile salts, mucin degradation enzymes, stress-responsive promoters","Bifidobacteria are facultative anaerobes that thrive in the human gastrointestinal tract, particularly in the colon. They exhibit moderate growth rates and are highly adapted to intestinal conditions, including bile tolerance and acid resistance. Their ability to utilize mucins and complex carbohydrates supports long-term persistence in the gut. They are non-pathogenic and maintain stability during manufacturing and storage processes.",CRISPR-Cas systems not explicitly mentioned; genetic tools limited in most Bifidobacterium species; heterologous expression in Lactococcus lactis used for functional validation,Low to moderate; limited by lack of robust genetic tools in native species,Constitutive expression of adhesive genes; regulated by carbon source and GIT-related stress,"Carbon sources (e.g., starch, cellobiose, maltodextrin); bile salts",Chromosomal integration of pilus genes; stable in vivo; no significant drift reported; low metabolic burden,Genetic constructs remain stable in host tissue and mucus environments,"Genetic engineering of bifidobacteria is challenging due to limited tools. However, pilus genes (e.g., pil2, pil3 in B. bifidum) are naturally expressed in response to intestinal conditions. Heterologous expression in Lactococcus lactis confirmed functional adhesion, indicating potential for synthetic biology applications. Regulation is primarily environmental (carbon source, bile), not inducible via synthetic circuits.","[""Bile"", ""pH"", ""Osmotic stress"", ""Carbon source availability""]","[""Mucins"", ""Starch"", ""Cellobiose"", ""Maltodextrin""]",,"[""Intestinal epithelial cells (IECs)"", ""Extracellular matrix (ECM) proteins""]","Pilus gene promoters (e.g., regulated by carbon source); stress-responsive promoters (e.g., bile-induced); surface-exposed moonlighting proteins (e.g., enolase, transaldolase)","Threshold-based activation; expression increases in response to specific environmental cues (e.g., presence of mucins or IECs); no synthetic logic gates reported","Bifidobacteria sense intestinal conditions such as bile, low pH, and availability of complex carbohydrates. Pilus and moonlighting protein expression is upregulated in response to these signals, particularly in the presence of host cells or mucins. This adaptive response enables targeted adhesion and colonization. The system functions as a threshold-based sensor network rather than a programmable logic circuit.","[""Adhesion"", ""Immune Modulation"", ""Pathogen Exclusion""]","Surface-exposed proteins (pili, moonlighting proteins); no active secretion systems reported",Not applicable; activity is naturally regulated by environmental cues,Compatible with mucus and intestinal matrix; adhesion is enhanced in physiological environments,False,,,Not applicable; bifidobacteria are not engineered for direct antibacterial activity,,False,False,False,False,无,False,Not applicable; bifidobacteria are not used for oxygenation,,False,False,False,无,True,Modulates intestinal and systemic immune responses; enhances anti-tumor immunity and supports checkpoint-inhibition therapy,"Bifidobacterial surface proteins (e.g., pili, enolase, transaldolase) interacting with immune cells",False,Not applicable; no direct tissue repair functions reported,,False,Not applicable; no evidence of metabolic regulation via secreted metabolites,,True,Enhances anti-tumor immune responses and supports checkpoint-inhibition cancer therapy,"Bifidobacterial cell surface components (e.g., pili, moonlighting proteins) that stimulate immune activation",BSL-1,No genetic kill switches; relies on natural non-pathogenicity and auxotrophy,"Bile salts, mucin, carbon sources",No pathogenicity reported; no antibiotic resistance genes identified; low risk of horizontal gene transfer; no environmental escape documented,Mucus layer and intestinal epithelium act as natural physical barriers,Bifidobacteria are classified as GRAS (Generally Recognized As Safe) and have no known pathogenic potential. They are naturally adapted to the human gut and do not cause disease. Their use in probiotics is well-established. No engineered safety systems are required due to inherent safety profile.,"Bifidobacteria enhance immune responses, support anti-tumor therapy, and promote gut health. They adhere effectively to intestinal epithelial cells and mucus, enabling colonization and functional persistence. Their ability to modulate immunity and exclude pathogens contributes to improved outcomes in inflammatory bowel disease, irritable bowel syndrome, and cancer immunotherapy.",9292,1832,11124,,
0e718877-3d8c-450b-a55c-c699be774705,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""LMT1-48""}]",Suspension,Facultative Anaerobe,"Grows at 37°C, utilizes D-glucose, D-fructose, D-mannose, D-ribose, and N-acetylglucosamine as carbon sources; pH 3.95 in culture supernatant","Rapid growth observed in MRS broth; doubling time not explicitly reported, but growth confirmed within 24 h at 37°C","Intestinal tract (gut microbiota), particularly in the context of high-fat diet-induced obesity and pathogenic Enterobacter cloacae colonization","Inhibits growth of pathogenic Enterobacter cloacae; promotes gut microbiota diversity, increases abundance of Verrucomicrobia and Proteobacteria, potentially enriching Akkermansia muciniphila","Tolerant to low pH (pH 3.95 in supernatant), stable in vitro culture conditions; no data on UV, drying, or shear stress","Lactic acid (produced during fermentation, contributes to low pH environment)","Lactobacillus plantarum LMT1-48 is a rod-shaped, non-motile, facultative anaerobic bacterium that grows rapidly in the presence of glucose, fructose, mannose, ribose, and N-acetylglucosamine. It thrives in the intestinal environment under high-fat diet conditions and exhibits strong antimicrobial activity against Enterobacter cloacae. Its growth leads to acidification of the environment, which contributes to its inhibitory effects.",,,,,,,"Lactobacillus plantarum LMT1-48 was isolated from traditional Korean fermented foods (kimchi) and identified via 16S rRNA sequencing. No genetic modifications were performed; the strain functions naturally through its intrinsic metabolic and antimicrobial properties. No plasmids, CRISPR systems, or synthetic circuits were used.","[""pH""]","[""Glucose"", ""Fructose"", ""Mannose"", ""Ribose"", ""N-acetylglucosamine""]",,,"Lactic acid production (inferred from pH drop to 3.95), but no specific receptor or promoter identified",No engineered logic gates or threshold control reported; activity is constitutive and driven by nutrient availability and environmental pH,"Lactobacillus plantarum LMT1-48 senses available fermentable carbohydrates (glucose, fructose, etc.) and responds by metabolizing them, producing lactic acid and lowering the local pH. This creates an unfavorable environment for pathogenic Enterobacter cloacae. The response is not regulated by external inducers or complex logic; it is a direct metabolic consequence of nutrient utilization.","[""Antibacterial"", ""Metabolic Regulation"", ""Immunomodulation""]","Secretion of metabolites (e.g., SCFAs, lactic acid) via passive diffusion or membrane transport; no specific secretion system reported",Oral administration at 10^9 CFU/day; dosage is fixed and not dynamically controlled,Compatible with oral delivery; no encapsulation or material barrier described; functions in natural gut environment,True,False,False,"Inhibits growth of Enterobacter cloacae through production of antimicrobial metabolites (likely short-chain fatty acids and lactic acid), not solely due to low pH. Activity persists even when pH is controlled at 3.95, indicating additional mechanisms.","Short-chain fatty acids (SCFAs), lactic acid",False,True,True,True,"L. plantarum LMT1-48 significantly reduced E. cloacae CFU counts in coculture experiments even at controlled pH (3.95), indicating antimicrobial activity beyond acidification. No cytotoxicity or microbiome disruption reported. Activity is localized to the gut, consistent with safety.",False,,,False,False,False,,True,"Reduces serum leptin and total cholesterol levels, indicating modulation of adipokine signaling and lipid metabolism. May indirectly modulate immune responses by reducing inflammation via gut barrier protection and microbiota modulation.","Leptin, cholesterol, SCFAs (inferred)",False,,,True,"Regulates lipid and glucose metabolism by reducing body weight, abdominal fat volume, leptin, and total cholesterol levels. Increases gut microbiota diversity, potentially enhancing metabolic homeostasis.","Short-chain fatty acids (SCFAs), lactic acid",False,,,GRAS,"None (natural strain, no synthetic kill switches or auxotrophy reported)",,No pathogenicity or antibiotic resistance genes reported. L. plantarum is generally recognized as safe (GRAS). No horizontal gene transfer or environmental escape concerns mentioned.,None (oral delivery without physical confinement),"Lactobacillus plantarum LMT1-48 is a naturally occurring strain isolated from fermented foods and infant feces. It is classified as GRAS with no reported pathogenicity, antibiotic resistance, or risk of horizontal gene transfer. No biocontainment strategies were implemented, but its natural habitat and low virulence suggest minimal risk.","L. plantarum LMT1-48 administration significantly reduced body weight and abdominal fat volume in E. cloacae-induced HFD-fed mice. It lowered serum leptin and total cholesterol levels, increased gut microbiota diversity (especially Verrucomicrobia and Proteobacteria), and ameliorated obesity. These effects were associated with inhibition of pathogenic E. cloacae and modulation of metabolic and immune parameters.",10362,1825,12187,,
bea5e163-bbf0-4c03-bdac-6a8ca44c6973,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}]","Peroral consumption (systemic distribution via gastrointestinal tract, potential mucosal colonization)",Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerant to bile salts and low pH (gastric conditions), utilizes glucose and other carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization ability in gastrointestinal and upper respiratory mucosa demonstrated in prior studies,"Gastrointestinal tract and upper respiratory mucosa (nasopharynx), with potential transient colonization at mucosal surfaces","Competitive exclusion of pathogens, modulation of host immune response; no significant disruption of resident microbiota reported","Tolerant to drying, lyophilization, and moderate shear stress; stable during storage in juice formulation","Cell wall structure, exopolysaccharides, and stress-response genes (e.g., clp, groEL)","Lactobacillus rhamnosus GG is a facultative anaerobe capable of surviving gastric transit and colonizing the gastrointestinal and upper respiratory mucosa. It exhibits robust growth under physiological conditions, tolerates bile and low pH, and maintains viability during storage in food matrices. Its ability to transiently colonize mucosal surfaces supports its role in immune modulation.",,,,,,,"Lactobacillus rhamnosus GG was used in its native, unmodified form. No genetic modifications were introduced in this study. The strain was administered as live or heat-inactivated cells in juice, with no engineered circuits or synthetic biology components.","[""pH"", ""Bile acids"", ""Glucose""]","[""Lactate"", ""SCFAs""]",,"[""Proteases"", ""Cytokines""]","FNR-like regulators, two-component systems (e.g., LiaRS), and surface adhesins (e.g., pili, mucus-binding proteins)",No engineered logic gates; natural sensing via receptor-mediated pathways with threshold responses to environmental cues,"L. rhamnosus GG naturally senses host-derived signals such as pH changes, bile acids, and nutrient availability via membrane-bound receptors and transcriptional regulators. It responds to mucosal environments by upregulating adhesion and immune-modulating factors, but no synthetic logic circuits were implemented.","[""Immunomodulation""]","Type I secretion system (for pili and EPS), passive diffusion of metabolites",Dose-dependent immune modulation via daily oral intake (10^9 CFU/day); no controllable release mechanism,Compatible with juice formulation; stable during encapsulation and oral delivery; no adverse interaction with matrix,False,,,,,,,,,,False,,,,,,,True,"Modulates innate and adaptive immune responses by enhancing dendritic cell function, increasing IL-10 and TGF-β production, and reducing pro-inflammatory cytokines (e.g., IL-6, TNF-α). Promotes mucosal barrier integrity and IgA secretion.","Surface proteins (e.g., pili, p75), exopolysaccharides (EPS), and secreted metabolites (e.g., lactic acid, bacteriocins)",False,,,False,,,False,,,GRAS,"None (naturally occurring, non-pathogenic strain)",,"Non-pathogenic, no known virulence factors; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape concerns",Oral delivery with natural clearance; no physical confinement required,"Lactobacillus rhamnosus GG is a well-characterized, generally recognized as safe (GRAS) probiotic strain. It has been used in numerous clinical trials without serious adverse events. No genetic modifications were made, and it does not persist long-term in the host, minimizing risks of colonization or gene transfer.",本研究未发现口服L. rhamnosus GG对实验性鼻病毒（HRV）感染后鼻咽部病毒载量有显著影响。然而，病毒载量与临床症状总评分呈显著正相关（第2天相关系数0.61，p<0.001；第5天相关系数0.28，p=0.034）。提示病毒复制水平与症状严重程度密切相关。尽管未达到统计学差异，但活菌组和灭活菌组的病毒载量均低于安慰剂组，提示潜在的免疫调节作用可能减轻症状，但需更大样本量研究验证。,8978,1619,10597,,
acfd28c9-7e93-4633-8555-78146388a2e3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""MM1""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""MM4""}]",Suspension,Facultative Anaerobe,"Temperature: 28°C; pH: 7.0–7.5; Nutritional requirements: Complex media (nutrient broth, MRS agar); Tolerance: Resistant to artificial gastric and intestinal fluids",Growth rate: 24–48 h for 2–3 doublings in nutrient broth at 28°C; In vitro growth consistent with in vivo gut environment,Gut of juvenile Epinephelus coioides (autochthonous source),Potential for competitive colonization in host gut; minor components of total culturable bacterial load in gut (1.0 × 10⁴ to 3.8 × 10⁴ CFU/g),"Resistant to artificial gastric and intestinal fluids; Stable in diet storage at 4°C for up to 60 days (viability loss: 35.2% for L. lactis, 50.6% for E. faecium)","Cell wall structure, acid tolerance mechanisms","Lactococcus lactis MM1 and Enterococcus faecium MM4 are lactic acid bacteria isolated from the gut of juvenile grouper Epinephelus coioides. They grow well at 28°C in nutrient broth and are resistant to simulated gastric and intestinal conditions, indicating their potential to survive in the host gastrointestinal tract. Both strains are autochthonous to the host, enhancing their colonization ability. They maintain viability in feed for up to 60 days when stored at 4°C, though with gradual decline in concentration.",Not mentioned,null,Not mentioned,null,Not mentioned,Not mentioned,No genetic modifications were performed. The strains were used in their native form as probiotics without any engineered circuits or synthetic biology tools.,"[""pH"", ""Gastric fluid"", ""Intestinal fluid""]","[""Nutrients (in gut environment)""]","[""None reported""]","[""None reported""]","Cell wall and membrane components; acid tolerance systems (e.g., F0F1-ATPase); bile salt hydrolase activity (inferred from resistance)",Not applicable (no engineered logic),"No synthetic sensing circuits were implemented. Natural environmental sensing (e.g., pH, bile) enables survival in the host gut, but no specific engineered logic gates or thresholds were described.","[""Immunomodulation"", ""Digestive Enzyme Modulation""]",Not mentioned (likely passive secretion of metabolites or cell wall components),Dose: 1.0 × 10⁸ CFU/g diet; controlled via feed formulation; no dynamic control reported,Compatible with cold-pressed pellet diet; viability maintained in feed for 60 days,False,False,False,Not applicable (no direct antibacterial mechanism reported),null,False,False,False,False,No evidence of antibacterial activity in this study; strains were not tested for direct pathogen inhibition in vivo.,False,Not applicable (no oxygen-producing mechanism reported),null,False,False,False,No evidence of oxygenation function; no enzymatic or metabolic pathways for oxygen production described.,True,Modulates humoral immune responses: increases serum complement C3 and lysozyme activity in L. lactis-fed fish; decreases lysozyme in E. faecium-fed fish. No effect on phagocytic activity or SOD.,"Cell wall components (e.g., peptidoglycan, teichoic acids), secreted metabolites (e.g., organic acids, bacteriocins), or surface proteins",False,Not applicable (no evidence of tissue repair or regeneration effects),null,False,Not applicable (no metabolic modulation reported),null,False,Not applicable (no cancer-related function reported),null,BSL-1,None (natural strains used; no kill-switch or auxotrophy reported),null,Low pathogenicity; GRAS status for LAB; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; environmental escape unlikely due to autochthonous origin,Physical confinement via feed pellet and controlled aquaculture environment,Lactococcus lactis MM1 and Enterococcus faecium MM4 are native to the host gut and considered safe. No genetic modifications or antibiotic resistance genes were reported. They are not known pathogens and are used in aquaculture without containment. Their autochthonous origin reduces risk of ecological disruption.,"Dietary administration of L. lactis MM1 and E. faecium MM4 significantly improved feed conversion ratio (FCR) in juvenile grouper Epinephelus coioides over 60 days, despite slight reductions in feed intake and growth rate. Hepatopancreatic protease activity was significantly increased in both probiotic groups, suggesting enhanced protein digestion. Humoral immune parameters were modulated: serum lysozyme activity increased in L. lactis-fed fish and complement C3 levels increased in both groups. No significant effect on cellular immunity (phagocytosis, SOD). The study demonstrates potential for these strains to enhance feed utilization and modulate immune function in aquaculture.",14663,1780,16443,,
4ffbf882-090d-43a1-8ab2-663148e463f2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GR-1""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in MRS medium; optimal pH not explicitly stated, but adapted to vaginal niche (pH ~4.5–5.0); utilizes lactose, maltose, rhamnose, ribose as carbon sources",Growth rate not quantified; exhibits bi-phase growth curve on sorbitol; no growth on glycogen,Vaginal epithelium (especially in the urethra and vaginal mucosa); capable of temporary colonization in human vagina after oral intake,"Competes with uropathogens; does not induce strong pro-inflammatory cytokines (TNF, IL-8) in vaginal epithelial cells; lacks pili-mediated adhesion to intestinal mucus, reducing intestinal persistence but potentially facilitating ascension to vagina","High resistance to oxidative stress (H₂O₂); low survival in simulated gastric juice (pH 2.0); moderate tolerance to bile and lysozyme (not explicitly tested, but inferred from context)","Thioredoxin genes (GR1_00460, GR1_01468, GR1_01733) likely responsible for oxidative stress resistance","Lactobacillus rhamnosus GR-1 is a facultative anaerobe that grows optimally at 37°C and is adapted to the vaginal niche. It efficiently metabolizes lactose, maltose, rhamnose, and ribose—carbohydrates present in vaginal epithelium—while lacking the ability to utilize fucose or glycogen. It shows enhanced resistance to oxidative stress, which is critical in the vaginal environment, but poor survival under gastric acidity, limiting oral bioavailability. It can temporarily colonize the human vagina after oral administration, suggesting a unique niche adaptation for urogenital health.",CRISPR-Cas not used; genome sequenced using Illumina paired-end sequencing; annotation via GeneMark and Glimmer,Not applicable (no genetic modification reported),Constitutive expression of native genes; no inducible circuits described,,Chromosomal integration; no plasmids reported; stable in vaginal environment based on temporary colonization; no evidence of genetic drift or instability in vivo,No engineered material environment described; natural EPS production may support stability in mucosal matrices,"Lactobacillus rhamnosus GR-1 was not genetically modified in this study. Its genome was sequenced and compared to other strains to identify niche-specific adaptations. Key features include a unique exopolysaccharide (EPS) cluster for glucose-rich, rhamnose-lacking EPS synthesis and enhanced carbohydrate metabolism genes for lactose, maltose, rhamnose, and ribose utilization. No plasmid-based systems or synthetic circuits were used.","[""Oxidative stress (H₂O₂)"", ""pH (vaginal niche ~4.5–5.0)""]","[""Lactose"", ""Maltose"", ""Rhamnose"", ""Ribose"", ""Sorbitol""]",,"[""Epithelial cell surface (via lectin-like proteins)""]","Lectin-like protein 1 (Lrp1) mediates tissue-specific adherence to vaginal epithelium; thioredoxin genes (GR1_00460, GR1_01468, GR1_01733) involved in oxidative stress sensing/resistance","No synthetic logic gates; natural regulatory networks control gene expression in response to nutrient availability and stress (e.g., constitutive expression of EPS and sugar metabolism genes)","Lactobacillus rhamnosus GR-1 senses nutrient availability (lactose, maltose, rhamnose, ribose) and oxidative stress via intrinsic metabolic and redox-sensitive pathways. It uses lectin-like protein 1 to recognize host epithelial glycans, enabling targeted adhesion. The absence of pili suggests a lack of quorum-sensing or complex signal integration, relying instead on constitutive expression of niche-adapted genes.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Extracellular polysaccharide (EPS) secretion via EPS gene cluster; potential secretion via general secretory pathway; no evidence of lysis or vesicle-based delivery,Not controllable; natural expression of genes; dosage depends on colonization level and metabolic activity,EPS is glucose-rich and rhamnose-lacking; may be compatible with mucosal matrices; no evidence of material disruption or gas production,True,False,True,Disrupts urogenital biofilms via lectin-like protein 1; inhibits adhesion and growth of uropathogens such as E. coli and S. aureus; competes for epithelial binding sites,Lectin-like protein 1 (Lrp1),True,True,True,True,"L. rhamnosus GR-1 disrupts biofilms formed by uropathogens in vitro; does not induce strong pro-inflammatory responses (TNF, IL-8), indicating localized, non-damaging activity; maintains structural integrity in vaginal mucosa without causing tissue disruption.",False,,,False,False,False,No evidence of oxygen production or oxygenation mechanism in the study.,True,"Modulates host immune response by inducing IL-6 expression while not inducing TNF or IL-8 in vaginal epithelial cells, suggesting anti-inflammatory or immune-tolerogenic activity",Exopolysaccharide (EPS) and lectin-like protein 1 (Lrp1),True,Enhances host defenses by promoting epithelial integrity and reducing pathogen adhesion; may support mucosal barrier function via EPS and adhesion molecules,"Exopolysaccharide (EPS), Lectin-like protein 1 (Lrp1)",False,,,False,,,GRAS,Auxotrophy not reported; no kill-switches or synthetic containment systems; natural attenuation via poor gastric survival,,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape; low opportunistic risk,Physical confinement not used; natural colonization limited to mucosal surfaces,"Lactobacillus rhamnosus GR-1 is classified as GRAS (Generally Recognized As Safe). It is non-pathogenic, does not carry antibiotic resistance genes, and shows low risk of horizontal gene transfer. Its poor survival in gastric conditions limits systemic spread. It is naturally confined to mucosal surfaces and does not persist long-term in the gut or environment. No synthetic biocontainment systems are used.","L. rhamnosus GR-1 effectively colonizes the human vagina after oral administration and temporarily persists, reducing uropathogen adhesion and biofilm formation. It modulates immune responses by inducing IL-6 without triggering pro-inflammatory cytokines (TNF, IL-8), suggesting a role in restoring vaginal homeostasis. It is clinically effective in preventing recurrent urinary tract infections and may improve outcomes in bacterial vaginosis and aerobic vaginitis. Vaginal administration may be more effective than oral due to better survival and colonization.",18072,2157,20229,,
31a9fda1-0f58-4527-9422-ac62888a8acd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GR-1"", ""strain_id"": ""GR-1""}]",Suspension,Facultative Anaerobe,"37°C, pH range from initial juice pH (~3.4–3.9) to lower pH after fermentation due to lactic acid production; utilizes fructose as substrate; grows in fruit juices with or without inulin fiber",Achieved ≥10⁷ CFU/mL within 72 h of fermentation and maintained viability for 30 days of refrigerated storage; growth rate consistent with facultative heterofermentative metabolism,Gastrointestinal tract (specifically urogenital mucosa for UTI prevention); not designed for tissue colonization,No direct interaction with host microbiome described; potential to modulate gut microbiota via probiotic activity,Bile and acid resistant; survives passage through gastrointestinal tract; stable under refrigeration (4°C) for 30 days,"Bile salts, acidic environment (pH ~3.4–3.9), refrigeration","Lactobacillus rhamnosus GR-1 is a facultative anaerobe capable of surviving in acidic fruit juices, producing lactic acid during fermentation, and maintaining high viability (≥10⁷ CFU/mL) over 72 hours of fermentation and 30 days of refrigerated storage. It is bile and acid resistant, enabling gastrointestinal survival, and thrives in fructose-rich environments such as fruit juices.",,,,,,,该研究未对L. rhamnosus GR-1进行基因改造，其功能依赖于天然生理特性，未使用任何遗传工具或合成电路进行编程。,"[""Acidity (pH decrease due to lactic acid production)"", ""Fructose (substrate availability)""]","[""Fructose"", ""Lactic acid (end product)""]",,,"FNR promoter (implied by anaerobic growth), fructose utilization pathways",No engineered logic gates; natural metabolic regulation based on substrate availability and environmental pH,"L. rhamnosus GR-1 naturally senses fructose and low pH environments, triggering fermentation and acid production. Its growth is regulated by substrate availability and acid tolerance, without synthetic sensing circuits.","[""Metabolic Regulation""]",None (natural secretion of lactic acid; no engineered secretion systems),Natural; dependent on fermentation time and substrate availability,Compatible with fruit juice matrix; no structural disruption observed; inulin fiber does not interfere with microbial activity,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,"L. rhamnosus GR-1 ferments fructose in fruit juices to produce lactic acid, lowering pH and potentially modulating gut microbiota and host metabolism.",Lactic acid,False,,,GRAS,None (no kill-switch or auxotrophy used),,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk due to non-competitive nature in natural environments,None (no physical confinement beyond packaging),"L. rhamnosus GR-1 is a well-characterized probiotic strain with GRAS status. It is not pathogenic, does not carry antibiotic resistance genes, and is considered safe for human consumption. No biocontainment strategies were implemented, but its low environmental fitness reduces escape risk.",该研究未评估治疗功效，但结果显示L. rhamnosus GR-1在苹果汁、橙汁和葡萄汁中发酵72小时后，活菌数均达到或超过10⁷ CFU/mL，且在4°C冷藏30天后仍保持高活力。橙汁中菌株存活率最高，感官评价显示苹果汁（尤其是添加长链菊粉的样品）在风味和整体可接受性方面得分较高，表明其作为非乳基益生菌产品的潜力。,13419,1475,14894,,
99ef7c72-2ec0-4d31-8f86-2363746ba3ee,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, requires carbohydrates (e.g., lactose, glucose) as carbon sources; dependent on host-derived nutrients in gastrointestinal environment",Doubling time ~1–2 hours in vitro; in vivo colonization observed within 24–48 hours post-administration,"Gastrointestinal tract (small intestine and colon), particularly in mucosal layers and lumen",Symbiotic with host microbiota; competes with pathogenic bacteria for adhesion sites and nutrients; may enhance microbial balance,Moderate tolerance to gastric acid and bile; survives lyophilization and refrigerated storage; sensitive to high shear stress during processing,"Bile salts, gastric acid (HCl), lyophilization stabilizers (e.g., trehalose)",该研究中涉及的益生菌株（如嗜酸乳杆菌和双歧杆菌）为兼性厌氧菌，适宜在37°C、pH 5.5–6.5的肠道环境中生长，依赖乳糖、葡萄糖等碳源。在体外培养中，其倍增时间为1–2小时；在体内可于24–48小时内定植于肠道黏膜和肠腔，具有良好的黏膜定植能力。对胃酸和胆盐具有中等耐受性，可通过冻干技术长期保存，但对高剪切力较敏感。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未涉及对益生菌的基因工程改造，所有益生菌均为天然菌株，未进行基因编辑或合成回路设计。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter, Lactate receptor (LldR), Bile acid sensor (BacA)",Not specified,研究未描述益生菌的信号感应与逻辑处理机制，未涉及合成生物学回路设计。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I Secretion (e.g., for cytokines), Vesicles (exosomes)",Not specified,"Compatible with oral delivery (capsules, yogurt); stable in food matrices such as Yakult and Vaalia",False,,,Not specified,,False,False,False,False,未提及抗菌或抗生物膜功能。,False,Not specified,,False,False,False,未提及氧气生成功能。,True,通过调节肠道免疫反应，促进抗炎细胞因子（如IL-10）分泌，抑制促炎因子（如TNF-α、IL-6）释放，增强黏膜屏障功能。,"IL-10, TGF-β, Secretory IgA",True,促进肠上皮细胞增殖，增强黏膜屏障完整性，加速受损肠黏膜修复。,"Epidermal Growth Factor (EGF), Tissue Inhibitor of Metalloproteinases (TIMP)",True,通过发酵碳水化合物产生短链脂肪酸（SCFAs），调节肠道pH，抑制病原菌生长，调节宿主能量代谢。,"Acetate, Propionate, Butyrate",False,Not specified,,GRAS,"Auxotrophy (e.g., vitamin-dependent strains), Natural attenuation","Vitamin B12, Folic acid",Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; minimal environmental escape due to poor survival outside host,Oral delivery limits systemic spread; gastrointestinal transit limits persistence,嗜酸乳杆菌和双歧杆菌均为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，不易发生水平基因转移。其在体外环境中生存能力弱，难以在自然环境中长期定植，因此生态风险极低。,研究中，73%的家长表示若医生推荐，愿意为孩子使用益生菌。24名使用益生菌的儿童中，多数家长报告症状改善，包括腹泻、腹痛、消化不良等。益生菌被广泛认为对肠道健康有益，尤其在缓解功能性胃肠症状方面效果显著。,6123,1637,7760,,
1aab145a-0146-4e81-9e43-a090c5d53b06,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus crispatus"", ""strain_id"": ""LC""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""LR""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""BB""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis LMG S-28195"", ""strain_id"": ""BL""}]",Oral administration (gastrointestinal tract),Facultative Anaerobe,"Optimal growth in intestinal environment (pH ~6.5–7.0, anaerobic to microaerophilic), utilizes carbohydrates as carbon sources, dependent on host-derived nutrients","Not explicitly reported; assumed moderate growth rate typical of gut commensals in vivo, consistent with colonization during oral administration","Gastrointestinal lumen (upper and lower tracts), Peyer’s patches, lamina propria","Competitive inhibition of pathogenic bacteria, modulation of immune cells (DCs, T cells), promotion of regulatory T cell differentiation; symbiotic with host immune system","Tolerant to gastric acidity and bile salts (inferred from oral administration and survival in gut), stable during lyophilization and storage (implied by use in experimental models)","Bile salts, gastric acid (natural environmental stressors)",这些益生菌株为肠道共生菌，可在胃肠道中定植，利用碳水化合物作为碳源，在微需氧至厌氧环境中生长，对胃酸和胆盐具有耐受性，能够与宿主免疫系统相互作用并调节免疫稳态。,,,,,No genetic modification reported; natural strains used; chromosomal stability assumed in vivo,No engineered material environment; natural gut environment supports survival and function,未对菌株进行基因工程改造，使用的是天然存在的益生菌株，通过口服给药在肠道中定植并发挥免疫调节作用。,"[""pH"", ""Osmotic stress"", ""Bile acids""]","[""Glucose"", ""Lactate"", ""SCFAs""]","[""Quorum sensing (indirectly via microbiota interaction)""]","[""Cytokines (IL-10, TGF-β)"", ""Tissue degradation fragments (via immune cell signaling)""]","Pattern recognition receptors (PRRs) such as TLR2, TLR9; CD103+ dendritic cell receptors",No synthetic logic circuits; natural sensing via PRRs and immune cell crosstalk with threshold responses to microbial load and cytokine levels,菌株通过模式识别受体（如TLR2、TLR9）感知宿主和微生物信号，通过与树突状细胞和T细胞的相互作用，实现对免疫反应的阈值调控，促进调节性T细胞分化，维持免疫耐受。,"[""Immunomodulation""]","Secretion of cytokines (IL-10, TGF-β), modulation of immune cell signaling","Oral administration (2.5 × 10⁹ CFU/rat, 30 doses), timing-dependent (acute and chronic phases of EAMG)",No encapsulating material; natural gut environment supports function and delivery,False,False,False,,,False,False,False,False,,False,,,False,False,False,,True,通过诱导树突状细胞产生IL-10和TGF-β，促进FOXP3+调节性T细胞（Treg）分化，抑制Th17细胞反应，调节免疫平衡，减轻自身免疫损伤。,"IL-10, TGF-β, FOXP3",False,,,False,,,False,,,GRAS,Natural attenuation; no synthetic kill switches or auxotrophy reported,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to gut-specific colonization,Gut epithelial barrier and immune surveillance provide physical and biological containment,所用菌株为公认安全（GRAS）的益生菌，无致病性，不携带抗生素抗性基因，不会在环境中长期存活，通过肠道屏障和免疫系统实现自然生物安全控制。,在实验性自身免疫性重症肌无力（EAMG）大鼠模型中，口服给予乳酸杆菌（LC+LR）和双歧杆菌（BB+BL）可显著降低临床评分（第7–9周），减少抗AChR IgG抗体水平，提高肌肉AChR含量，同时上调Peyer’s patch和脾脏中FOXP3 mRNA表达，下调IFN-γ表达，表明其具有显著的免疫调节和疾病缓解作用。,10834,1699,12533,,
11552a56-dddb-4237-845a-75229dd395fd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""Nissle 1917 (EcN)""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5; tolerates moderate osmotic stress; utilizes glucose and other carbon sources; requires minimal vitamins and amino acids",Doubling time ~20–30 minutes in vitro; in vivo colonization stability observed in murine models,"Intestinal mucosa, particularly in the colon; competes with pathogens for binding sites",Competes with pathogens like Salmonella Typhimurium and Shigella flexneri; promotes balanced gut microbiota,"Tolerant to bile salts, moderate pH shifts, and transient oxygen exposure; stable during lyophilization and rehydration","Bile salt hydrolase (BSH), catalase, superoxide dismutase",该菌株为兼性厌氧菌，最适生长温度为37°C，pH范围6.5–7.5，可在肠道环境中稳定定植，对胆盐和pH波动具有较强耐受性，能利用多种碳源，营养需求低，具有良好的储存和运输稳定性。,"Plasmid-based expression systems, CRISPR-Cas9 (implied in functional studies)",High efficiency in gene knockout and overexpression; low off-target risk reported in model systems,"Constitutive and inducible (e.g., arabinose-inducible promoters) expression of effector genes","L-arabinose, IPTG (inferred from common use in E. coli systems)",High plasmid stability (copy number ~10–20); chromosomal integration possible; low metabolic burden; stable in vivo over 7 days,Genetic circuits remain functional in gel and suspension matrices; no significant degradation observed,通过质粒或染色体整合方式构建基因回路，实现对效应基因的可控表达，如抗粘附、抗侵袭因子的分泌，且在肠道环境中保持稳定表达。,"[""pH"", ""Oxygen tension"", ""Bile acids""]","[""Glucose"", ""Sialic acid"", ""Iron (via siderophores)""]","[""Quorum sensing molecules (AHL, AI-2)""]","[""Proteases (e.g., MMPs)"", ""Cytokines (e.g., IL-8)""]","FNR promoter (hypoxia), Bsh promoter (bile), Fur regulator (iron), LuxR-type receptors (QS)",AND gate: requires both low oxygen and high bile for full activation; threshold-based response to iron availability,该系统通过整合多种环境信号（如低氧、胆汁酸、铁离子浓度）实现逻辑门控，确保在病灶微环境中特异性激活抗病原体功能，避免在正常肠道中过度表达。,"[""Antiadhesive"", ""Antiinvasion"", ""Antivirulence"", ""Immunomodulation""]","Type I secretion system (T1SS), outer membrane vesicles (OMVs)","Tunable via inducible promoters (e.g., arabinose); dose-dependent effect observed in vivo",Compatible with hydrogel and oral delivery matrices; maintains viability and function,True,False,True,通过分泌抑制性因子干扰病原体粘附与侵袭，同时抑制QS系统，从而抑制生物膜形成,"Secreted protein (EcN factor), exopolysaccharides",True,True,True,True,在体外和动物模型中，EcN显著抑制沙门氏菌和志贺氏菌的粘附与侵袭，且不破坏宿主细胞，无明显毒性。,False,,,False,False,False,,True,调节宿主免疫反应，增强IgA分泌，促进Th1/Th2平衡，抑制过度炎症,"Secreted immunomodulatory proteins, SCFAs (acetate, propionate)",True,促进上皮屏障修复，增强紧密连接蛋白表达，加速黏膜再生,"MUC2 mucin, E-cadherin, β-catenin",True,通过产生短链脂肪酸（SCFAs）调节肠道代谢，维持pH平衡，抑制病原体生长,"Acetate, Propionate, Butyrate",False,,,GRAS,"Auxotrophy (e.g., for essential amino acids), kill-switch (e.g., arabinose-dependent expression)","L-arabinose, tryptophan auxotrophy",Non-pathogenic; no known virulence genes; no antibiotic resistance genes reported; low HGT risk; no environmental escape documented,Physical confinement in oral capsules or hydrogels prevents systemic dissemination,EcN为公认安全（GRAS）菌株，无致病性，无抗生素抗性基因，通过营养缺陷型和诱导型自杀系统实现生物安全控制，材料封装可有效防止环境释放。,在小鼠模型中，EcN显著减少沙门氏菌和志贺氏菌的肠道定植，降低炎症反应，促进黏膜修复，伤口愈合时间缩短30%以上。,15031,1745,16776,,
14e20cca-101f-44ec-b613-f0b898327175,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GR-1"", ""strain_id"": ""GR-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum RC-14"", ""strain_id"": ""RC-14""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates physiological pH range (4.5–5.0) and moderate osmotic stress; utilizes glucose and other carbohydrates as carbon sources; dependent on host-derived nutrients in vivo.",Doubling time ~60–90 min in vitro; in vivo colonization observed within days post-administration; stable persistence in vaginal niche over 2 months with sustained dosing.,"Vaginal epithelium, particularly in the lower genital tract; preferentially adheres to epithelial cells and competes with pathogens for adhesion sites.","Competitive exclusion of pathogenic anaerobes (e.g., Gardnerella vaginalis); promotes symbiosis with resident microbiota by restoring ecological balance; no significant disruption of commensal flora reported.",Resistant to gastric acidity and bile salts (oral route); tolerates lyophilization and rehydration; stable under refrigerated storage; moderate shear stress tolerance in encapsulated formulations.,"Cell wall components (e.g., teichoic acids), extracellular polysaccharides, and biofilm matrix proteins","Lactobacillus acidophilus, L. rhamnosus GR-1, and L. fermentum RC-14 are facultative anaerobes capable of thriving in the vaginal environment. They grow optimally at body temperature and pH levels typical of the healthy vagina. These strains exhibit strong resistance to gastrointestinal transit when administered orally, enabling them to ascend to the vaginal tract. They colonize the vaginal epithelium effectively, compete with pathogens for adhesion sites, and maintain a low pH through lactic acid production. Their stability under storage and encapsulation conditions supports their use in both oral and vaginal delivery systems.",Not specified,Not specified,Constitutive,,High chromosomal stability; no plasmid-based systems reported; minimal metabolic burden; long-term in vivo consistency observed over 2-month treatment periods.,Stable in both oral capsules and vaginal tablets; no significant degradation or loss of viability in carrier matrices.,"The microbial systems are not genetically modified in the reviewed studies. Their therapeutic effects rely on native physiological functions, including natural colonization ability, acid production, and antimicrobial substance secretion. No synthetic circuits or inducible systems were employed.","[""pH"", ""Hypoxia"", ""Lactate""]","[""Bile Acids"", ""Glucose"", ""Polyamines""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), Lactate permease (lactate sensing), Bile acid receptors (e.g., Bile acid-binding proteins)","No explicit logic gates reported; likely constitutive expression of effector functions with threshold-based response to environmental cues (e.g., pH drop triggers acid production).","The strains sense changes in the vaginal microenvironment such as pH elevation (indicative of BV), lactate levels, and presence of bile acids from intestinal ascension. They respond by upregulating lactic acid and hydrogen peroxide production. While no engineered logic circuits are present, their natural regulatory networks allow for adaptive responses to host and microbial signals, enabling effective niche colonization and pathogen inhibition.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I Secretion (lactic acid, H₂O₂), Bacteriocin release via membrane vesicles, Lysis (in some strains)",Dose-dependent; effective at ≥10⁸ CFU/day; sustained effect with 2-month regimen; no evidence of overproduction or toxicity.,"High compatibility with oral capsules, vaginal tablets, and yogurt carriers; maintains viability and function during encapsulation and release.",True,True,True,"Inhibit growth of Gardnerella vaginalis, Prevotella spp., and other BV-associated anaerobes via production of lactic acid, hydrogen peroxide, and bacteriocins; block pathogen adherence to epithelial cells.","Lactic acid, Hydrogen peroxide, Bacteriocins (e.g., lactocin, reuterin)",True,True,True,True,Multiple clinical trials show significant reduction in BV recurrence and Nugent score after 2-month oral or vaginal administration of ≥10⁸ CFU/day. No reported cytotoxicity or microbiome disruption; localized activity confirmed by vaginal colonization without systemic spread.,False,,,False,False,False,,True,"Modulate local immune responses by reducing pro-inflammatory cytokines (e.g., IL-6, TNF-α) and enhancing anti-inflammatory mediators; promote regulatory T-cell activity.","Lactic acid, Exopolysaccharides (EPS), Surface proteins (e.g., pili)",True,Enhance epithelial barrier integrity; promote mucosal healing through stimulation of epithelial cell proliferation and collagen synthesis; reduce inflammation-induced tissue damage.,"Lactic acid, Exopolysaccharides (EPS), Growth factors (e.g., TGF-β analogs)",False,,,False,,,BSL-1,Auxotrophy (no known auxotrophic markers reported; natural attenuation via lack of long-term colonization in non-target sites),,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape documented; GRAS status for L. acidophilus and L. rhamnosus GR-1.,Physical confinement via vaginal epithelium and mucus layer; oral delivery ensures limited systemic exposure.,"All strains used are well-characterized, non-pathogenic, and GRAS (Generally Recognized As Safe). No adverse effects reported in clinical trials. Natural inability to persist long-term in non-target environments reduces ecological risk. No genetic modifications increase biosafety concerns.","Oral or vaginal administration of ≥10⁸ CFU/day of L. acidophilus, L. rhamnosus GR-1, or L. fermentum RC-14 for 2 months significantly restored normal vaginal flora, reduced BV recurrence by up to 60%, and improved clinical and microbiological cure rates. Clinical trials reported 88% cure rates in probiotic groups versus 40% in placebo groups. Long-term prophylaxis (60 days) reduced recurrence by stabilizing the vaginal microbiota. No adverse effects were reported.",10100,2078,12178,,
b03e4a00-c320-44e9-81f4-6beb65b87803,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactiplantibacillus plantarum"", ""strain_id"": ""AWP4""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: neutral (MRS agar with CaCO3); Osmotic tolerance: 6.5% NaCl (positive), 18% NaCl (positive); Nutritional requirements: Carbon sources: glucose, fructose, lactose, maltose, sucrose, xylose, etc.; Growth at 15°C and 45°C (positive)",Growth rate: 48 h in MRS broth; Doubling time: not specified; In vitro growth consistent with in vivo conditions (simulated GI environment),Intestinal mucosa (inferred from adhesion and mucin binding assays),Competitive exclusion of pathogens (via adhesion inhibition and antibacterial activity); potential symbiosis with host microbiota,Resistant to simulated gastric juice (pH 2.0) and intestinal juice (pH 8.0); Tolerant to bile salts and oxidative stress (inferred from antioxidant activity); Stable at -80°C with 20% glycerol,"Bile salts, gastric acid (HCl), reactive oxygen species (ROS)",该菌株为乳酸杆菌属植物乳杆菌（Lactiplantibacillus plantarum），在37°C、厌氧条件下于MRS培养基中生长良好。对胃酸和胆盐具有较强耐受性，可在模拟胃肠环境中保持高存活率。具有良好的黏附能力，能与黏液结合并抑制病原菌在肠上皮细胞上的定植。,Not applicable (no genetic modification reported),Not applicable,Not applicable,Not applicable,"Not applicable (naturally occurring strain, no plasmid or integration reported)",Not applicable,该菌株未经过基因工程改造，为天然分离菌株，其功能由其固有代谢和生理特性决定。,"[""pH"", ""Bile salts"", ""Oxidative stress (ROS)""]","[""Glucose"", ""Fructose"", ""Lactose"", ""Maltose"", ""Sucrose""]",,"[""Mucin"", ""Intestinal epithelial cells""]","Cell surface hydrophobicity, mucin-binding proteins, adhesion receptors",Not applicable (no synthetic circuit reported),该菌株通过细胞表面特性（如疏水性、黏附蛋白）感知宿主肠道环境，响应pH、胆盐和黏液等信号，实现对肠道微环境的适应性定植。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Type I secretion (inferred from lactic acid and bacteriocin secretion),"Not applicable (natural strain, no controllable output)",Compatible with food matrices and simulated GI environment,True,True,False,分泌抗菌物质抑制多种病原菌生长，包括大肠杆菌、金黄色葡萄球菌、沙门氏菌和志贺氏菌。,"Bacteriocins or organic acids (e.g., lactic acid)",True,True,True,True,对四种指示病原菌均表现出抑制作用，抑制圈直径超过11.5 mm；在HT-29细胞上无细胞毒性；未提及生物膜抑制实验，但具有黏附抑制能力。,False,无相关报道,Not applicable,False,False,False,未检测到氧生成能力,True,通过抑制病原菌黏附和调节免疫反应，间接发挥免疫调节作用。,"Lactic acid, bacteriocins, surface adhesins",True,通过抑制病原菌黏附和促进肠道屏障功能，间接支持组织修复。,"Mucin-binding proteins, adhesion factors",True,可降解多种碳源，具有胆固醇同化能力，调节宿主代谢。,"Lactic acid, cholesterol",False,无相关报道,Not applicable,GRAS,"None (naturally occurring, no kill switch or auxotrophy reported)",Not applicable,Non-pathogenic; no hemolysis; low cytotoxicity; resistant to vancomycin and aminoglycosides (intrinsic resistance); no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned,None (no physical confinement reported),该菌株为天然分离的植物乳杆菌，无溶血性，对HT-29细胞无毒性，对多种抗生素敏感，且具有内在耐药性（如对万古霉素），符合GRAS标准，安全性良好。,该菌株在体外表现出优异的抗病原菌能力（抑制圈直径达19.44 mm）、强黏附能力（黏液结合率49.70%）、高抗氧化活性（DPPH清除率936.82 μmol/L）和胆固醇同化能力（49.72%），且对肠道上皮细胞无毒性，具备良好的潜在益生功能，可作为食品添加剂替代化学合成物。,19091,1718,20809,,
25bd6c5d-a4fd-40af-8193-1b0d39172c51,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Akkermansia muciniphila"", ""strain_id"": ""ATCC BAA-835""}]",Oral administration (gut colonization),Strict Anaerobe,"37°C, pH 6.5, in basal medium with 0.25% w/v mucin under strict anaerobic conditions",Not explicitly reported; cultured under standard anaerobic conditions,Intestinal mucosal layer (gut mucus),Enhances gut microbiota homeostasis; increases abundance of Allstipes and Lactobacillus; correlates positively with antitumor immune response,Resistant to pasteurization (heat-stable); maintains function after heat treatment,Amuc (outer membrane protein),"Akkermansia muciniphila is a strict anaerobe that thrives in the mucosal layer of the gut, utilizing mucin as a primary carbon source. It colonizes the intestinal epithelium and contributes to gut barrier integrity. The strain is stable under pasteurization, indicating robustness of its key functional components.","Not applicable (natural strain, no genetic modification reported)",,Constitutive (natural expression of Amuc),,High (naturally stable in gut environment; no evidence of plasmid loss or drift),Stable in oral delivery and gut environment,"The microbial system is a naturally occurring commensal strain without genetic modification. Its therapeutic function is driven by constitutive expression of the outer membrane protein Amuc, which is naturally produced and secreted by the bacterium.","[""pH"", ""Mucin availability""]","[""Mucin""]",,"[""Toll-like receptor 2 (TLR2)""]",Amuc (outer membrane protein of Akkermansia muciniphila),Constitutive activation of TLR2 signaling pathway; no reported inducible or logic-gated control,"The sensing mechanism is based on the constitutive presence of Amuc, which directly binds to and activates TLR2 on host immune cells. This interaction triggers downstream immune signaling without requiring external inducers or complex logic circuits.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Outer membrane protein secretion (Amuc is naturally expressed and released from the outer membrane),Oral administration at 1×10⁸ CFU every 3 days; dose-dependent effects observed,Compatible with oral delivery; stable in gastrointestinal environment,False,,,Not applicable (no direct antibacterial activity reported),,False,,,,No evidence of antibacterial activity; not a primary function,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,No evidence of oxygenation function,True,"Amuc activates TLR2 signaling, leading to dendritic cell maturation, increased CD8+ T cell infiltration, reduced Treg ratio, and enhanced IFN-γ and IL-2 production in tumor microenvironment.",Amuc (outer membrane protein of Akkermansia muciniphila),True,Protects intestinal barrier integrity by maintaining goblet cell numbers and mucus layer thickness; prevents IL-2-induced mucosal damage.,Amuc (via TLR2-mediated signaling),True,"Modulates gut microbiota composition (increases Allstipes and Lactobacillus), enhances mucin production, and supports metabolic homeostasis.","Mucin (host-derived), SCFAs (indirectly via microbiota modulation)",True,"Enhances antitumor immune surveillance by promoting CTL activation, reducing Tregs, and suppressing tumor-repopulating cells. Synergizes with IL-2 to improve tumor clearance.",Amuc (outer membrane protein),GRAS,Natural strain with no antibiotic resistance genes; no synthetic kill switches reported,,Low pathogenicity; no evidence of systemic invasion or HGT; no antibiotic resistance genes reported; safe in immunocompetent hosts,Oral delivery provides natural physical barrier; gut mucosa limits systemic spread,"Akkermansia muciniphila is a well-characterized commensal bacterium with GRAS status. It does not invade tissues, shows no toxicity in mice, and is not associated with disease in humans. Its effects are localized to the gut and mucosal immune system.","In colorectal cancer patient-derived tumor tissues, combination therapy with IL-2 and AKK significantly increased tumor cell apoptosis and enhanced antitumor immune responses. In mouse models, the combination therapy significantly reduced tumor volume and weight, prolonged survival, and improved immune microenvironment (increased CD8+/CD4+ ratio, reduced Tregs, increased IFN-γ and IL-2). AKK also protected intestinal barrier function during IL-2 treatment, preventing mucosal damage and maintaining microbiota homeostasis.",14074,1640,15714,,
b6cd030a-0e2e-4620-9b68-ac380caf7a4f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactiplantibacillus plantarum"", ""strain_id"": ""Various (e.g., WCFS1, ST28MS, ZDY 2013, LUHS135, IMC510, IMC513)""}]",Suspension,Facultative Anaerobe,"Mesophilic (optimal growth at 30–37°C), pH 5.0–7.0, tolerant to osmotic stress and bile salts; utilizes a wide range of carbohydrates including glucose, fructose, lactose, and pentoses.",Moderate growth rate; doubling time ~60–90 min in vitro; capable of sustained survival in GI tract despite transient colonization.,"Gastrointestinal tract (intestinal mucosa, lumen), particularly in the small intestine and colon; adheres to mucus layer and epithelial cells.",Competes with pathogens for nutrients and adhesion sites; modulates host microbiota composition; may synergize with commensal bacteria.,"High tolerance to acid (pH 1.5–3.0), bile salts, osmotic stress, and oxidative stress; survives lyophilization and rehydration.","OpuC osmoregulatory system, groES-groEL chaperones, hcrA-dnaK-dnaJ-GrpE operon, NADH oxidases, peroxidases, manganese transporters","Lactiplantibacillus plantarum is a versatile, mesophilic, facultative anaerobe with strong adaptation to the gastrointestinal environment. It exhibits excellent acid and bile tolerance, enabling survival through the stomach and upper intestine. Its ability to adhere to intestinal mucus and epithelial cells supports transient colonization and interaction with host tissues. It thrives on diverse carbon sources and maintains viability under stress conditions, making it well-suited for probiotic applications.","CRISPR-Cas9 (Class II Type II system), Recombination, Transposons (implied by genomic plasticity)",High efficiency in genome editing; low off-target risk due to well-characterized Cas9 systems; CRISPR-Cas system present in most strains.,"Constitutive expression of key genes (e.g., bsh, plnE/F); potential for inducible systems via promoter engineering (e.g., pH-responsive promoters).","pH-responsive promoters (e.g., FNR-like), native promoters of bsh or pln operons",High chromosomal stability; plasmid-free in many strains; low metabolic burden; evolutionarily stable due to niche adaptation.,Genetic circuits remain functional in food matrices and during GI transit; no reported instability in encapsulated or fermented environments.,"Lactiplantibacillus plantarum possesses a large, plastic genome with multiple gene clusters for stress resistance, carbohydrate utilization, and antimicrobial production. Its natural CRISPR-Cas system enables precise genome editing. Genes for bacteriocin (plantaricin) and bile salt hydrolase (BSH) production are often chromosomally integrated and stably expressed, allowing for predictable functional output without plasmid dependency.","[""Hypoxia"", ""Acidity (pH)"", ""Oxidative Stress (ROS/RNS)"", ""Lactate""]","[""Bile Acids"", ""Glucose"", ""Fructose"", ""Pentoses""]","[""Quorum Sensing (AHL, AI-2)"", ""Bacteriocin signals (e.g., Plantaricin A)""]","[""Mucin"", ""Tight Junction Proteins"", ""Cytokines (indirectly via immune modulation)""]","FNR promoter (hypoxia), Bsh promoter (bile acid sensing), PlnE/F promoters (bacteriocin regulation), Msa (mannose-specific adhesion receptor), CnaB (collagen-binding protein)",AND gate logic: bacteriocin production induced by both low pH and presence of target pathogen; threshold-based activation of stress response systems.,"Lactiplantibacillus plantarum senses environmental cues such as low pH and bile acids via specific promoters and receptors. It integrates signals from host mucus and microbial competition to activate adhesion, stress resistance, and antimicrobial pathways. Bacteriocin production is often triggered by a combination of pH drop and pathogen presence, ensuring targeted activity. The system exhibits noise suppression through redundant stress response pathways and threshold control.","[""Antibacterial"", ""Antigenotoxic"", ""Immunomodulation"", ""Metabolic Regulation""]","Type I Secretion (bacteriocins), Type IV Secretion (some EPS), Lysis (in some cases)","Constitutive expression; dosage controlled by strain-specific gene regulation and environmental cues (pH, nutrient availability).",Compatible with food matrices and GI environment; stable in fermented foods and during encapsulation.,True,True,True,"Produces bacteriocins (plantaricins), organic acids (lactic acid), hydrogen peroxide, and exopolysaccharides (EPS) that inhibit pathogen growth and disrupt biofilm formation.","Plantaricin C, Plantaricin W, Plantaricin ZJ5, Lactic acid, Hydrogen peroxide, Exopolysaccharides (EPS)",True,True,True,True,"Strains inhibit a broad range of Gram-positive and Gram-negative pathogens (e.g., S. aureus, E. coli, L. monocytogenes, P. aeruginosa). EPS and bacteriocins disrupt biofilm formation. No significant cytotoxicity reported; localized activity in GI tract.",False,Not applicable.,,False,False,False,No evidence of oxygen production or oxygenation function.,True,"Modulates immune responses via EPS-TLR2/NF-κB interaction, BSH-mediated bile acid metabolism, and cytokine regulation.","Exopolysaccharides (EPS), Bile Salt Hydrolase (BSH), TLR2 ligands",False,Not reported.,,True,"Modulates host lipid and glucose metabolism via bile acid deconjugation and secondary bile acid production (e.g., lithocholic acid).","Deconjugated bile acids (e.g., deoxycholic acid, lithocholic acid), Short-chain fatty acids (SCFAs)",False,Not reported.,,GRAS,"Auxotrophy (e.g., amino acid dependency), Natural attenuation (transient colonization), No antibiotic resistance genes reported in core strains.","Amino acid biosynthesis genes (e.g., leuA, hisD), Bile acid metabolism genes",Low pathogenicity; no virulence genes or toxin genes identified; no horizontal gene transfer risk in core strains; safe for human consumption.,Physical confinement in food matrix prevents environmental escape; transient colonization limits persistence.,"Lactiplantibacillus plantarum is classified as Generally Recognized as Safe (GRAS) by FDA and has Qualified Presumption of Safety (QPS) by EFSA. It has a long history of safe use in fermented foods. No evidence of pathogenicity, antibiotic resistance, or horizontal gene transfer. Its transient nature in the gut reduces ecological risk.","Lactiplantibacillus plantarum strains isolated from fermented foods demonstrate significant health benefits, including inhibition of foodborne and intestinal pathogens, reduction of genotoxicity from carcinogens (e.g., 4-NQO, aflatoxin B1), modulation of bile acid metabolism, and enhancement of gut barrier function. Clinical and preclinical studies confirm their ability to reduce inflammation, improve lipid profiles, and support immune homeostasis. These effects are strain-specific but consistently observed across multiple studies, supporting their potential as functional probiotics.",15310,2262,17572,,
1c961df6-e819-4578-b30a-07598e62e651,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""CNCM I-1572""}]",Suspension,Facultative Anaerobe,Anaerobic growth at 37°C; MRS broth or vk-MRS agar supplemented with vancomycin (1 μg/ml) and kanamycin (10 μg/ml); requires fructose as carbon source in formulation,24 h incubation at 37°C; viable counts observed up to 6.7 log₁₀ CFU/g feces; persistence in feces up to 5 days post-intake,"Intestinal tract (fecal environment), particularly in the colon",Modulates intestinal microbial ecosystems; no significant competition or disruption reported; compatible with host microbiome,Resistant to simulated gastric juice and bile salts (inferred from survival in GIT); stable at room temperature and 37°C for at least 48 h in feces; freeze-dried stability in drinkable vials,Exopolysaccharide (EPS) capsule (DG EPS) confers protection against antibiotics and environmental stresses,该菌株为专性厌氧菌，可在37°C下于MRS培养基中生长24小时。在含万古霉素和卡那霉素的选择性培养基（vk-MRS）上表现出独特的黏性丝状菌落形态，便于分离鉴定。在健康成人摄入后，该菌株可成功通过胃肠道并定植于肠道，最高存活浓度达6.7 log₁₀ CFU/g粪便，且在停用后仍可在粪便中检测到长达5天。其黏性多糖荚膜（DG EPS）赋予其对多种抗生素和环境压力的内在抗性，是其在胃肠道中存活的关键因素。,Strain-specific PCR with primers rtWELFf and rtWELFr targeting the glycosyl transferase gene welF,Not applicable (no genetic modification reported),Constitutive (no inducible circuit described),,No plasmid or integrative vector reported; chromosomal stability inferred from consistent recovery over time; no evidence of genetic drift or loss,Stable in drinkable vial formulation (10 ml fructose solution with preservatives); freeze-dried form maintains viability until end of shelf life,本研究未对L. paracasei DG进行基因工程改造。通过设计针对welF基因的特异性引物（rtWELFf/rtWELFr）进行菌落PCR验证，结合vk-MRS选择性培养基上的黏性丝状菌落表型，实现了对目标菌株的高特异性、高灵敏度的活菌定量。该方法无需基因编辑，仅依赖于天然存在的遗传和表型特征（如EPS荚膜）进行识别。,"[""pH (simulated gastric juice)"", ""Bile salts (in vivo)""]","[""Fructose (in formulation)""]",,,Exopolysaccharide (EPS) capsule (DG EPS) – intrinsic property enabling resistance to environmental stresses,No synthetic logic circuit; natural resistance to antibiotics and environmental stressors via EPS capsule,该菌株未构建人工感知系统。其在胃肠道中的存活能力主要依赖于天然的黏性多糖荚膜（DG EPS），该结构可物理屏障作用，减少抗生素和胆汁盐的渗透，从而实现对胃酸、胆盐等理化压力的非特异性响应。无明确的基因调控逻辑门，属于被动耐受机制。,"[""Immunomodulation"", ""Microbial Ecosystem Modulation""]",Not applicable (no engineered secretion system reported),One billion CFU per vial; daily intake; persistence in feces up to 5 days post-intake,Compatible with drinkable vial formulation (10 ml fructose solution with preservatives); stable in freeze-dried form,False,,,Not applicable (no antibacterial activity reported),,,,,,无,False,Not applicable (no oxygenation function reported),,,,,无,True,Modulates host immune response via its unique polysaccharide capsule (DG EPS); influences intestinal immune system in healthy adults,Exopolysaccharide (EPS) capsule (DG EPS),False,Not applicable (no tissue repair function reported),,False,Not applicable (no metabolic regulation function reported),,False,Not applicable (no tumor therapy function reported),,GRAS,No genetic containment strategy reported; natural resistance to antibiotics via EPS capsule (non-transferable),Exopolysaccharide (EPS) capsule (DG EPS),No antibiotic resistance genes detected in genome; no horizontal gene transfer risk; low pathogenicity; safe for healthy adults,Physical confinement via drinkable vial (DryCap technology); freeze-drying preserves viability and prevents escape,L. paracasei CNCM I-1572被归类为GRAS（公认安全）菌株，其基因组中未检测到抗生素抗性基因，其对卡那霉素等抗生素的抗性源于天然的黏性多糖荚膜（DG EPS），该特性非由可转移质粒或基因编码，因此无水平基因转移风险。在健康成人中使用未见不良事件，且通过口服摄入后可被有效回收，表明其具有良好的生物安全性。,在20名健康成人志愿者中，所有受试者在摄入后均成功在粪便中回收到活的L. paracasei DG菌株，最高存活浓度达6.7 log₁₀ CFU/g粪便，且在停用后仍可在粪便中检测到长达5天。该结果证实，以每瓶不少于10亿CFU的剂量通过口服饮料形式摄入，该菌株可有效通过胃肠道并定植于肠道，具有良好的肠道存活能力与定植潜力。,12438,1897,14335,,
7597f2ab-c2c7-401c-b10b-f438bb201d37,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis ssp. lactis"", ""strain_id"": ""Bb12 (ATCC 27536)""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in anaerobic conditions; tolerant to bile salts and low pH (gastric conditions); requires complex nutrients including amino acids, vitamins, and carbohydrates.",Doubling time ~2–3 hours in vitro; stable in food matrices over 9 months with minimal loss (0.45 log10 units after 9 months).,"Oral cavity, particularly in association with salivary pellicle and mucosal surfaces.",Competitive exclusion of oral pathogens; potential for symbiosis with resident microbiota by modulating pH and inhibiting pathogen adhesion.,"High tolerance to lyophilization, storage at room temperature, and mechanical shear during gum processing; stable in xylitol-containing gum matrix.","Xylitol, gum matrix (chewing gum mass, lecithin, glycerol)","Bifidobacterium animalis ssp. lactis Bb12 is a facultative anaerobe with strong environmental tolerance, capable of surviving in the oral cavity and maintaining viability in chewing gum for up to 9 months. It grows optimally under anaerobic conditions at 37°C and is resistant to bile and low pH, enabling it to persist in the gastrointestinal and oral environments. Its stability in the gum matrix ensures delivery to the oral mucosa.","Not applicable (natural strain, no genetic modification reported)",N/A,Constitutive,N/A,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift or loss in long-term storage.,High stability in xylitol-containing chewing gum matrix; no degradation or loss of viability during 9-month storage.,"The strain Bb12 is used in its native form without genetic modification. Its functionality relies on natural metabolic and ecological properties, including acid production and competitive exclusion of pathogens. No synthetic circuits or inducible systems are employed.","[""pH"", ""Osmotic stress (via xylitol)""]","[""Glucose"", ""Lactate""]",,"[""Proteases (salivary)"", ""Mucosal surface contact""]","General stress response systems (e.g., acid tolerance response, osmotic stress regulators); no specific engineered sensor reported.",Constitutive expression; no logic gates or threshold control observed.,The strain exhibits constitutive activity without environmental sensing or feedback regulation. Its presence in the oral cavity is sustained by physical retention in the gum matrix and natural adaptation to oral conditions.,"[""Immunomodulation"", ""Metabolic Regulation""]",Passive release from gum matrix upon chewing; no active secretion systems reported.,Controlled by chewing frequency (twice daily) and gum composition; dose delivered per 2 gums: ~2.87 × 10⁸ CFU.,High compatibility with xylitol-containing chewing gum; stable in matrix without structural disruption or excessive gas production.,False,,,N/A,,,,,,N/A,False,N/A,,,,,N/A,True,"Stimulates salivary IgA secretion, enhancing mucosal immunity and resistance to infection.",Secretory IgA (sIgA) induction via host immune signaling,False,N/A,,True,"Produces organic acids (e.g., lactic acid) that lower local pH, inhibiting cariogenic bacteria; contributes to oral pH homeostasis.",Lactic acid,False,N/A,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",N/A,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low opportunistic risk in healthy individuals.,Physical confinement via chewing gum matrix; limited systemic exposure.,"Bifidobacterium animalis ssp. lactis Bb12 is a well-characterized GRAS strain with a long history of safe use in food and supplements. It does not colonize permanently and is not associated with infections in immunocompetent individuals. No adverse effects were observed in the study except mild gastrointestinal gas, likely due to aerophagia.","Xylitol-containing chewing gum, with or without probiotics, significantly increased unstimulated salivary flow rate after 2 months of use, reduced dry mouth sensation, and elevated salivary IgA levels and pH. However, no additional benefit was observed from adding Bb12 compared to placebo. The probiotic strain demonstrated good stability in the gum matrix and transient presence in saliva, suggesting potential for mucosal immune modulation, but not significant clinical improvement in hyposalivation parameters.",8680,3382,12062,,
7597f2ab-c2c7-401c-b10b-f438bb201d37,1,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""LGG (ATCC 53103)""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""2C (DSM 14579)""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""46 (DSM 14583)""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerant to bile and low pH; requires carbohydrates (e.g., glucose, lactose) and amino acids.",Doubling time ~1–2 hours in vitro; moderate stability in gum matrix (decreased by 1.65 log10 units after 9 months).,"Oral cavity, particularly in association with mucosal surfaces and salivary pellicle.",Competitive inhibition of pathogens; potential synergistic interactions with B. longum strains in modulating immune responses.,Moderate tolerance to lyophilization and storage; reduced viability after 7.5 months in gum matrix.,"Xylitol, gum matrix (lecithin, glycerol)","Lactobacillus rhamnosus LGG is a facultative anaerobe with strong acid tolerance and bile resistance, enabling survival in the oral and gastrointestinal tracts. It is capable of transient colonization in the oral cavity. The B. longum strains 2C and 46 are also facultative anaerobes with similar environmental tolerance and are selected for gut barrier stabilization. The consortium is delivered via chewing gum and maintains viability for up to 4 months, after which stability declines.","Not applicable (natural strains, no genetic modification reported)",N/A,Constitutive,N/A,High chromosomal stability; no plasmid systems used; no evidence of drift in short-term use.,Moderate stability in xylitol-containing gum; viability declines after 7.5 months.,"The consortium is used in its native form without genetic engineering. Functional synergy arises from natural metabolic and ecological interactions between LGG and B. longum strains, particularly in immune modulation and pathogen inhibition.","[""pH"", ""Glucose"", ""Osmotic stress (xylitol)""]","[""Lactate"", ""Bile acids""]",,"[""Proteases (salivary)"", ""Mucosal surface contact""]","General stress response systems (e.g., acid tolerance, osmotic regulators); no engineered sensors reported.",Constitutive expression; no logic gates or feedback control observed.,The consortium functions via constitutive metabolic activity without environmental sensing. Its presence in the oral cavity is sustained by physical retention in the gum matrix and natural adaptation to oral conditions.,"[""Immunomodulation"", ""Metabolic Regulation""]",Passive release from gum matrix upon chewing; no active secretion systems reported.,Controlled by chewing frequency (twice daily); total dose per 2 gums: ~3.35 × 10⁸ CFU.,"Moderate compatibility with xylitol-containing gum; viability declines after 7.5 months, but sufficient for 3-month intervention.",False,,,N/A,,,,,,N/A,False,N/A,,,,,N/A,True,"Stimulates salivary IgA secretion and modulates mucosal immune responses, enhancing resistance to infection.",Secretory IgA (sIgA) induction via host immune signaling,False,N/A,,True,"Produces lactic acid and other organic acids that lower local pH, inhibiting cariogenic bacteria; contributes to oral pH balance.",Lactic acid,False,N/A,,GRAS,"None (natural strains, no kill-switch or auxotrophy reported)",N/A,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low opportunistic risk in healthy individuals.,Physical confinement via chewing gum matrix; limited systemic exposure.,"Lactobacillus rhamnosus LGG and B. longum 2C/46 are well-established GRAS strains with extensive safety records. The consortium showed transient presence in saliva (61.1% positive samples at 3 months), indicating oral colonization without persistent overgrowth. No adverse effects were reported except mild gastrointestinal gas, likely due to aerophagia.","The consortium of LGG, B. longum 2C, and B. longum 46 was transiently detectable in saliva (61.1% positive at 3 months), suggesting oral colonization. It contributed to increased salivary IgA and pH, and reduced dry mouth sensation, similar to placebo. However, no statistically significant improvement over placebo was observed in salivary flow rate, IgA, or pH. The probiotic effect was not superior to xylitol gum alone, but the strains demonstrated stability and biological activity in the oral environment.",8680,3382,12062,,
daf9c01e-687b-402a-b21d-9b5b53ab5b92,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Roseobacter sp. 27-4"", ""strain_id"": ""27-4""}]",Encapsulated,Facultative Anaerobe,"Growth at 20–23°C, marine environment, aerobic conditions, in marine broth (MB) with glucose and skimmed milk","Growth rate: 3 days for pre-culture, 2 days for main culture; doubling time not specified; in vitro growth confirmed, no in vivo growth rate data provided",Gastrointestinal lumen of turbot larvae; does not colonize intestinal epithelium,Antagonistic to Vibrio anguillarum; no evidence of symbiosis or competition with host microbiome; does not colonize gut epithelium,"Tolerant to moderate shear stress (rotifer enrichment), stable in seawater; no data on UV, drying, or lyophilization","Marine broth (MB), sterile seawater","Roseobacter strain 27-4 is a marine bacterium that grows aerobically in marine broth at 20–23°C. It does not colonize the intestinal epithelium of turbot larvae but persists in the gastrointestinal lumen. It is not pathogenic to larvae when delivered as live cells, but its culture supernatant is toxic due to nutrient-driven proliferation of opportunistic pathogens.",,,,,No genetic modifications reported; natural strain used; stability in marine environment and rotifers confirmed by repeated detection,Stable in marine broth and seawater; maintains viability during rotifer bioencapsulation,"No genetic engineering was performed. The strain was used in its natural form for probiotic testing. No plasmids, promoters, or synthetic circuits were introduced.",,,,,Not applicable (no engineered sensors reported),Not applicable (no synthetic logic circuits described),"No engineered sensing or logic systems were used. The strain's probiotic effect is attributed to natural antagonism, not responsive genetic circuits.","[""Antibacterial""]",Soluble factor secretion (sulphur-containing antibacterial compound),Requires repeated addition (every 48–72 h) to maintain effective levels; no controlled release or feedback system reported,Compatible with rotifer bioencapsulation and marine broth; stable in seawater and rearing tanks,True,False,False,Roseobacter 27-4 produces a soluble sulphur-containing antibacterial factor that inhibits Vibrio anguillarum in vitro under stagnant conditions. The effect is density-dependent and occurs at high cell densities.,Sulphur-containing antibacterial factor,False,True,True,True,"The strain is non-pathogenic to turbot larvae when delivered as live cells. Mortality was only observed with culture supernatant, which is due to secondary pathogen growth, not direct toxicity of Roseobacter. The antibacterial effect is localized and does not disrupt the rearing environment.",False,,,False,False,False,,False,,,False,,,False,,,False,,,BSL-1,"None (natural strain, no kill-switch or auxotrophy reported)",,Non-pathogenic to turbot larvae; no antibiotic resistance genes or HGT risk reported; low opportunistic risk; no environmental escape data,Physical confinement via rearing tanks and rotifer delivery system; no engineered barrier,"Roseobacter strain 27-4 is non-pathogenic and safe for use in turbot larval rearing. However, its culture supernatant promotes growth of opportunistic pathogens like Vibrionaceae, so careful handling is required. No genetic modifications or biosafety risks are associated with the strain as used.","In turbot larvae challenged with Vibrio anguillarum, the addition of Roseobacter 27-4 reduced accumulated mortality from 34% to 68% relative to control, effectively halving mortality. Survival was significantly improved (p < 0.05), and larvae showed no signs of tissue damage. The probiotic effect was sustained through repeated delivery via bioencapsulated rotifers.",16310,1485,17795,,
60687ac4-2bf5-407d-b4f1-75a0f3bc3372,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""W3110 (K12)""}, {""role"": ""Chassis"", ""scientific_name"": ""Staphylococcus albus"", ""strain_id"": ""Unknown""}]",Encapsulated in electrospun PVA nanofibres,Facultative Anaerobe,Growth at 37°C in LB medium (rich medium) or Vogel–Bonner minimal medium; E. coli requires glucose as carbon source; S. albus cannot grow in defined medium but grows well in LB.,E. coli reaches ~1–2 × 10⁹ cells/mL in batch culture; S. albus reaches ~8 × 10⁹ cells/mL in stationary phase.,Not specified – used in lab settings; potential for wound or tissue surface application via nanofibre mat.,Not specified – no interaction with host microbiome described.,"High tolerance to mechanical stress (resists >50,000×g); E. coli more sensitive to rapid dehydration during electrospinning; S. albus shows high viability post-encapsulation.",Glycerol (protects E. coli from dehydration during electrospinning),大肠杆菌（E. coli）为革兰氏阴性杆菌，可在LB培养基中37°C生长，密度可达1–2×10⁹ cells/mL；金黄色葡萄球菌（S. albus）为革兰氏阳性球菌，需在LB等富营养培养基中生长，密度可达8×10⁹ cells/mL。两者均具有较强的细胞壁结构，能耐受高机械应力，但大肠杆菌在快速脱水过程中易失活。,Not applicable – no genetic modifications reported.,Not applicable,Not applicable,Not applicable,Not applicable – no plasmids or engineered circuits used.,Not applicable,未进行基因工程改造，仅通过物理封装方式将细菌和病毒嵌入聚乙烯醇（PVA）纳米纤维中，无遗传调控或合成电路设计。,,,,,Not applicable,Not applicable,未设计任何感知或逻辑控制模块，系统为被动封装，无响应环境信号的能力。,"[""Antibacterial"", ""Viral Delivery""]",Passive release upon dissolution of PVA matrix,Not controllable – release depends on matrix degradation rate,High compatibility – PVA nanofibres provide stable encapsulation and allow gradual release upon hydration,True,False,False,通过物理封装维持细菌活性，但未主动释放抗菌物质；其主要功能为作为载体，而非直接杀菌。,Not applicable,False,False,True,True,细菌在纳米纤维中保持活性，且未破坏纤维结构，但未表现出主动抗菌或抗生物膜能力。,False,无氧生成机制。,Not applicable,False,False,False,未涉及氧气生成或代谢调控。,False,未表达免疫调节因子。,Not applicable,False,未分泌组织修复因子。,Not applicable,False,未调控代谢产物如SCFAs或色氨酸代谢物。,Not applicable,False,未用于肿瘤治疗。,Not applicable,BSL-1,Physical encapsulation in PVA nanofibres,Poly(vinyl alcohol) (PVA) matrix,E. coli K12 is non-pathogenic; S. albus is non-pathogenic; bacteriophages are host-specific and do not infect human cells. No antibiotic resistance genes or HGT risk reported.,Effective – PVA matrix prevents release of organisms until dissolution in aqueous environment,该系统使用非致病性大肠杆菌K12和金黄色葡萄球菌，且病毒仅感染细菌，无感染人类风险。物理封装提供有效屏障，防止生物体逃逸，符合BSL-1标准。,未评估伤口愈合效果；但纳米纤维可作为载体用于药物、基因或噬菌体递送，具有潜在治疗应用前景。,9810,1482,11292,,
1bf78a88-65f6-4181-a2a8-a73dbeaa0f09,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""CRL 431""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in MRS broth; pH not explicitly stated, but MRS is typically near neutral; nutritional requirements include carbohydrates, amino acids, and vitamins as part of MRS medium.",Growth rate not quantified; cells harvested after overnight incubation (12–16 h) at 37°C.,Small intestine lamina propria and intestinal lumen,Competes with enterobacteria; increases lactobacilli population; modulates microbiota balance by reducing enterobacteria in non-stressed mice.,Tolerant to lyophilization/rehydration (used in preparation); stable in 10% non-fat milk; viability maintained during daily suspension preparation.,Non-fat milk (vehicle for suspension),该乳酸杆菌在37°C下于MRS培养基中生长，为兼性厌氧菌，可定植于小肠固有层和肠腔，具有良好的稳定性，可在非脂肪牛奶中保持活力，用于口服给药。,,,,,,,该菌株未经过基因工程改造，为天然分离株，直接用于口服干预，无外源基因插入或调控回路设计。,,,,,,,该菌株未被工程化设计为响应特定信号，其免疫调节作用为天然生理功能，无明确的传感逻辑模块。,"[""Immunomodulation"", ""Microbiota Regulation""]",Natural secretion (no engineered delivery system),Oral administration at 1×10⁸ CFU/mL in drinking water daily; dose maintained via daily preparation.,Compatible with oral suspension in drinking water; no encapsulation or material barrier used.,False,,,,,,,,,,False,,,,,,,True,通过增加IgA+ B细胞、CD4+ T细胞、CD11b+巨噬细胞和CD11c+树突状细胞数量，提升肠道黏膜免疫应答；调节IFN-γ水平，恢复免疫稳态。,Lactobacillus casei CRL 431 (natural immunomodulatory activity),True,改善应激诱导的小肠绒毛缩短和隐窝深度减少，恢复肠道屏障结构，可能通过调节Bcl-2蛋白平衡细胞凋亡与增殖。,Lactobacillus casei CRL 431 (indirect via immune modulation),False,,,False,,,GRAS,"None (natural strain, no synthetic kill switches or auxotrophy)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape reported.,None (no physical confinement used),Lactobacillus casei CRL 431为公认安全（GRAS）菌株，来源于婴儿粪便，无致病性，未进行基因改造，无生物安全风险，适用于口服干预。,在应激小鼠模型中，L. casei CRL 431显著恢复了IgA+ B细胞、CD4+ T细胞和巨噬细胞数量，改善了肠道组织结构，降低了IFN-γ水平，增强了黏膜免疫，并调节了肠道菌群平衡，提示其在应激状态下具有显著的免疫调节和肠道保护作用。,13792,1372,15164,,
45fa2de5-0bf6-46a4-95d4-0e26134e38be,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""SP1""}]","Oral administration (sachet, dissolved in water)",Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerates moderate osmotic stress; requires carbohydrates (e.g., glucose, fructose) as carbon sources; no specific vitamin dependency reported","Doubling time ~1.5–2 hours in vitro; in vivo colonization ability in oral cavity is moderate, with transient persistence after ingestion","Oral cavity (gingival crevice, mucosal surfaces); transient colonization, not permanent engraftment","Competitive exclusion of periodontal pathogens (e.g., Porphyromonas gingivalis, Tannerella forsythia); may promote symbiosis with commensal oral microbiota by reducing inflammation",Tolerant to gastric acid (pH 2–3) and bile salts; stable during lyophilization and rehydration; resistant to moderate shear stress during oral ingestion,"Cell wall components (e.g., teichoic acids), acid tolerance response (ATR) genes","Lactobacillus rhamnosus SP1 is a facultative anaerobe capable of surviving in the oral environment, with moderate tolerance to acidic and osmotic stresses. It transiently colonizes the oral cavity after ingestion, where it exerts beneficial effects through competitive exclusion and immune modulation.",,,,,Chromosomal stability; no plasmid-based genetic modifications reported; no evidence of metabolic burden or drift in clinical use,No genetic modifications; stability in sachet formulation (lyophilized powder) is maintained during storage and reconstitution,Lactobacillus rhamnosus SP1 used in this study is a naturally occurring strain without genetic engineering. Its probiotic effects are attributed to intrinsic biological properties rather than synthetic circuits or engineered pathways.,"[""pH"", ""Glucose"", ""Osmotic stress""]","[""Lactate"", ""Bile acids""]",,"[""Proteases"", ""Cytokines (e.g., IL-1β, TNF-α)""]","FNR-like regulators (hypoxia sensing), lactate permeases, bile acid transporters, TLR2/4 signaling pathways","No engineered logic gates; natural sensing of environmental cues (e.g., low pH, lactate accumulation) triggers adaptive responses such as acid tolerance and biofilm formation","Lactobacillus rhamnosus SP1 naturally senses changes in oral environment such as pH drop due to bacterial metabolism, lactate accumulation, and bile exposure. It responds by activating acid tolerance mechanisms and modulating surface adhesins, enabling transient survival and interaction with host tissues.","[""Immunomodulation"", ""Antibacterial""]",Passive diffusion and cell lysis; no specialized secretion systems reported,One sachet daily (2 × 10⁷ CFU/day) for 3 months; dosage is fixed and not dynamically controllable,High compatibility with sachet formulation; stable during lyophilization and rehydration; no interference with gel or matrix structure,True,False,True,"Inhibits biofilm formation by periodontal pathogens through competitive exclusion and production of lactic acid, which lowers local pH and disrupts microbial community stability.",Lactic acid,False,True,True,True,Lactobacillus rhamnosus SP1 reduces pathogenic bacterial load and inhibits biofilm formation in periodontal pockets; no significant cytotoxicity or microbiome disruption observed in clinical trial.,False,,,False,False,False,,True,"Modulates host immune response by downregulating pro-inflammatory cytokines (e.g., IL-1β, TNF-α) and promoting anti-inflammatory mediators, thereby reducing gingival inflammation in periodontitis.","Cell wall components (e.g., peptidoglycan, lipoteichoic acid), secreted immunomodulatory proteins",False,,,False,,,False,,,GRAS,Auxotrophy (natural requirement for specific nutrients not available in host environment); no suicide genes or inducible kill switches,"Nutrient-dependent growth (e.g., specific amino acids, vitamins)",Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer observed; low risk of environmental escape due to transient colonization,Sachet packaging provides physical containment; oral ingestion limits environmental release,Lactobacillus rhamnosus SP1 is classified as GRAS (Generally Recognized As Safe) with decades of clinical use. No adverse events were reported in this trial or in prior studies. Its transient nature in the oral cavity and lack of genetic modifications minimize biosafety risks.,在为期1年的随访中，试验组（SRP + L. rhamnosus SP1）在牙周探诊深度（PPD）减少方面优于对照组（SRP + 安慰剂），尤其在PPD ≥ 6 mm的患者比例上显著降低，表明该益生菌可减少对牙周手术的需求。临床参数如CAL、BOP和PI均持续改善，且无不良反应，显示其在慢性牙周炎非手术治疗中的良好疗效和安全性。,7979,1751,9730,,
e0af4588-089e-4e47-b195-891358c4d984,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""C59""}]",Suspension,Facultative Anaerobe,"30°C in M17 broth with 0.5% glucose (GM17); pH tolerance not explicitly stated, but survives in gastrointestinal tract","Growth for 18 h at 30°C; in vivo survival limited to 6 h post-oral administration, no long-term colonization",Gastrointestinal tract (transient passage through intestines),No significant impact on resident flora; does not proliferate in intestines,Survives low pH and high bile concentration; heat-killed cells lose function,Capsular polysaccharide (implicated in immune evasion),该菌株为乳酸乳球菌（Lactococcus lactis）C59，属于乳酸菌，可在30°C下于含0.5%葡萄糖的M17培养基中生长18小时。该菌株具有耐酸和耐胆盐的能力，可在胃肠道中短暂存活，但无法在肠道内长期定植或增殖。其细胞表面具有荚膜多糖，可能有助于逃避巨噬细胞吞噬，从而在肠道中实现短暂免疫调节作用。,,,,,,,该研究未对Lactococcus lactis C59进行基因工程改造，所有功能均基于其天然生理特性。,"[""pH"", ""Bile""]",,,"[""Cytokines"", ""Antigen (OVA)""]",Capsular polysaccharide (putative immune recognition molecule),No engineered logic; natural immune modulation via antigen and cytokine feedback,该菌株通过其表面荚膜多糖与宿主免疫细胞相互作用，诱导免疫调节反应。在体外实验中，其可抑制抗CD3抗体刺激下T细胞的IL-4分泌，但不显著影响IFN-γ或IL-10。其作用机制依赖于活菌状态，表明其可能通过特定分子感知宿主免疫微环境并调节Th2反应。,"[""Immunomodulation""]",Passive release via cell lysis or natural secretion (not engineered),Dose-dependent suppression of IL-4 and IgE; effective at 70 μg dry weight/day,Compatible with oral suspension in saline; no encapsulation or material barrier used,False,,,,,,,,,,False,,,,,,,True,"Oral administration of live C59 significantly suppressed IL-4 production by splenocytes and CD4+ T cells, leading to reduced total IgE antibody levels in OVA-sensitized mice.",IL-4 (suppressed),False,,,False,,,False,,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Non-pathogenic; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; transient gut passage reduces environmental escape risk,None (oral administration without physical confinement),Lactococcus lactis C59为食品级安全菌株（GRAS），无致病性，不产生抗生素抗性基因，且在肠道中仅短暂存活，无法定植，因此环境逃逸风险极低。其功能依赖于活菌状态，热灭活后即失效，具有天然安全性。,口服活菌C59显著降低OVA致敏小鼠的总IgE抗体水平（P < 0.05），其机制为抑制脾细胞和CD4+ T细胞的IL-4分泌，从而调节Th1/Th2平衡。该效应在三个独立实验中均得到验证，但未显著影响特异性IgE、IgG1或IgG2a水平。菌株在口服后6小时内可检测到活菌，但24小时后即无法检出，表明其为短暂作用的免疫调节剂。,13431,1486,14917,,
2dc939af-25a7-4e3b-bf8a-857247d3baf2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""Not specified""}]",Oral suspension (capsule or drink),Facultative Anaerobe,"Optimal growth at 30–37°C, pH 5–7; tolerates gastric acidity and bile salts; utilizes glucose and other carbohydrates as carbon sources",Moderate growth rate in vitro; no in vivo growth kinetics reported in the paper,"Intestinal lumen, particularly in the context of disrupted microbiota (e.g., post-antibiotic or CDI setting)",Potential competitive exclusion of pathogens; may modulate host immune response; no evidence of stable colonization or symbiosis with resident microbiota,"Tolerant to gastric acid and bile; stable during storage in dry form; limited data on UV, shear, or lyophilization stability","Cell wall components (e.g., mannoproteins), intrinsic stress response pathways","Saccharomyces boulardii is a non-pathogenic yeast that can survive passage through the gastrointestinal tract, resist gastric acidity and bile, and transiently colonize the intestinal lumen. It is used orally for its purported ability to restore gut homeostasis after antibiotic disruption, particularly in the context of Clostridium difficile infection.","Not applicable (natural isolate, not genetically modified)",Not applicable,Constitutive (no engineered genetic circuits described),,"High (natural strain, no plasmid or integration; chromosomal stability assumed)",No engineered material coupling; natural yeast cells encapsulated in capsules or suspended in drinks,"Saccharomyces boulardii is used in its natural, unmodified form. No genetic modifications or synthetic circuits are described in the paper. Its therapeutic effect is attributed to natural biological properties rather than engineered functionality.","[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]",,"[""Proteases"", ""Cytokines""]","Cell surface mannoproteins, membrane transporters, and intrinsic metabolic sensors (e.g., glucose sensors)",No engineered logic gates; natural sensing via metabolic and environmental adaptation,"S. boulardii senses changes in intestinal pH and bile acid concentration, which are altered during antibiotic use and CDI. It responds by surviving in the hostile gut environment and potentially modulating immune responses. No synthetic logic or threshold control is involved.","[""Immunomodulation"", ""Antibacterial""]",Secretion via extracellular vesicles and constitutive release of soluble factors,"Dose-dependent; oral administration with fixed dosing (e.g., 1–2 g/day); no dynamic control","Compatible with oral delivery systems (capsules, drinks); stable in dry form but may degrade in liquid formulations over time",True,False,False,"Secretes protease inhibitors (e.g., chymotrypsin-like protease inhibitors) that neutralize C. difficile toxins A and B; may compete for adhesion sites and nutrients","Protease inhibitors (e.g., chymotrypsin-like inhibitors)",False,True,True,True,"S. boulardii was shown to reduce recurrence of CDI in small studies, likely through neutralization of toxins and competitive exclusion. However, no evidence of broad-spectrum activity against other pathogens or biofilm inhibition was reported.",False,,,False,False,False,No evidence of oxygenation function; not applicable,True,"Modulates host immune response by reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6) and enhancing anti-inflammatory responses; may stimulate IgA production","Cell wall mannoproteins, secreted immunomodulatory factors",False,,,False,,,False,,,BSL-1,"None (natural isolate, no kill-switch or auxotrophy)",,"Risk of fungemia in immunocompromised or critically ill patients; potential for environmental contamination in ICUs; no antibiotic resistance genes reported, but strain may be genetically similar to pathogenic S. cerevisiae",Oral delivery provides limited physical barrier; no encapsulation or engineered containment,"Although S. boulardii is generally considered safe, there are documented cases of fungemia, particularly in intensive care settings where it is prepared bedside. Its use in immunocompromised patients carries a risk of systemic infection. The lack of quality control in commercial products further increases safety concerns.","S. boulardii showed a borderline significant reduction in recurrence of Clostridium difficile infection in small, flawed studies, particularly in patients with recurrent CDI. However, the evidence is not robust, and meta-analyses have concluded that there is insufficient evidence to support its use for prevention or treatment of CDI. The effect is likely limited to specific subgroups and may not be generalizable.",6463,1638,8101,,
a92b3181-5799-49da-972d-ccf15dc6b70d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""35624""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex nutrients including amino acids, vitamins, and carbohydrates; dependent on host-derived metabolites in gut environment",Doubling time ~2–3 hours in vitro; in vivo homeostasis maintained through adaptation to intestinal niche; consistent with gut colonization dynamics,"Gut mucosa, particularly in the large intestine; preferentially colonizes in the context of a mixed microbiota",Competitive exclusion of pathogens; modulates resident microbiota by promoting bifidogenic effects; synergistic with other commensals like Lactobacillus species,Moderate tolerance to gastric acid and bile; stable during lyophilization and rehydration; resistant to shear stress in encapsulated delivery systems,"Capsule matrix (e.g., enteric-coated capsules) provides protection against gastric degradation","Bifidobacterium longum 35624 is a facultative anaerobe with optimal growth at 37°C and neutral pH. It thrives in the human gut environment, utilizing host-derived and dietary carbohydrates. It demonstrates strong colonization ability in the large intestine, where it modulates the gut microbiota and supports mucosal homeostasis. Its stability in encapsulated form ensures survival through the gastrointestinal tract.",Not explicitly mentioned; likely relies on natural genetic stability and strain-specific traits,Not applicable (no genetic modification reported),Constitutive (natural expression of beneficial traits),,High chromosomal stability; no plasmid-based systems reported; no evidence of drift or loss of function in human trials,Stable within encapsulated delivery systems; maintains functionality during storage and transit,"Bifidobacterium longum 35624 is used in its native form without genetic modification. Its therapeutic effects are attributed to intrinsic physiological properties, including anti-inflammatory cytokine induction and modulation of gut microbial communities. No synthetic circuits or inducible systems are employed.","[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""SCFAs"", ""Mucus polysaccharides"", ""Plant polysaccharides""]","[""Quorum sensing (indirect via community shifts)""]","[""Cytokines (e.g., IL-10)"", ""Tissue degradation fragments (mucosal integrity)""]","Carbohydrate utilization systems (e.g., glycoside hydrolases), mucin-binding adhesins, and surface receptors for host-derived metabolites","Adaptive response logic: nutrient availability triggers metabolic shifts (e.g., upregulation of plant polysaccharide degradation when dietary fiber is present; upregulation of mucus degradation when host glycans are available). Thresholds are set by metabolic feedback and community competition.","Bifidobacterium longum 35624 senses environmental cues such as pH, bile, and nutrient availability. It dynamically adjusts its metabolic activity—switching between plant polysaccharide and host mucin utilization based on substrate availability. This adaptive logic allows it to thrive in fluctuating gut conditions and maintain niche dominance. It also responds to host immune signals, such as cytokine levels, to modulate its anti-inflammatory output.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Natural secretion of metabolites and immunomodulatory factors; no engineered secretion systems reported,Dose-dependent efficacy; 10^8 CFU/day effective in human trials; higher doses (10^10) showed reduced efficacy due to incomplete release from delivery device,High compatibility with encapsulated delivery systems; maintains viability and function during storage and GI transit,False,False,False,Not applicable (no direct antibacterial mechanism reported),,False,False,False,False,无直接抗菌证据，不涉及生物膜抑制或广谱杀菌,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,无氧生成机制，不适用于缺氧环境干预,True,"Stimulates anti-inflammatory cytokine release (e.g., IL-10) in gut epithelial and immune cells; reduces proinflammatory cytokines (e.g., TNF-α, IL-6); enhances mucosal barrier function",Interleukin-10 (IL-10),True,Improves gut barrier integrity by enhancing tight junction function; reduces intestinal permeability; promotes epithelial regeneration and mucus layer restoration,"Mucin-associated proteins, tight junction regulators",True,"Modulates host metabolism by fermenting dietary fibers into SCFAs (e.g., acetate, lactate); influences glucose homeostasis and lipid metabolism; reduces systemic inflammation linked to metabolic syndrome",Short-chain fatty acids (SCFAs),False,Not applicable,,GRAS,Natural attenuation; no genetic kill switches or auxotrophy reported,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; minimal risk of environmental escape; well-established safety in human use,Enteric-coated capsules provide physical confinement and prevent premature release in stomach,"Bifidobacterium longum 35624 is classified as Generally Recognized as Safe (GRAS) and has been used in infant formulas and dietary supplements. It exhibits low virulence, no known antibiotic resistance genes, and no evidence of pathogenicity in immunocompetent individuals. Its use in clinical trials has shown no serious adverse events. Physical encapsulation further enhances safety by ensuring targeted delivery and containment.",在两项人类临床试验中，Bifidobacterium longum 35624（10^8 CFU/天）显著缓解了肠易激综合征（IBS）症状，改善了肠道屏障功能，并降低了炎症标志物水平。在小鼠模型中，该菌株可减少病原体负荷并调节免疫反应。其疗效具有菌株特异性，且在高剂量下因释放不完全而效果下降。,12758,8242,21000,,
a92b3181-5799-49da-972d-ccf15dc6b70d,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; requires glucose and amino acids; tolerant to bile and low pH",Doubling time ~1.5–2 hours in vitro; maintains viability in gut environment; consistent with rapid colonization and persistence,"Gut mucosa, particularly in the small intestine; adheres to epithelial cells via surface adhesins",Competitive exclusion of pathogens; species-specific modulation of immune responses; does not significantly alter global microbiota structure,High tolerance to gastric acid and bile; stable during lyophilization; resistant to shear stress in suspension,Surface adhesins and extracellular matrix components enhance survival,Lactobacillus rhamnosus GG is a facultative anaerobe that grows optimally at 37°C and slightly acidic pH. It exhibits strong adhesion to intestinal epithelial cells and survives harsh gastric conditions. It colonizes the small intestine and maintains persistence through competitive exclusion and immune modulation. Its resilience makes it suitable for oral delivery in suspension.,Not applicable (native strain used),Not applicable,Constitutive (natural expression of surface proteins and metabolites),,High chromosomal stability; no plasmid-based systems; no evidence of genetic drift in long-term studies,Stable in suspension formulations; maintains functionality during storage and delivery,"Lactobacillus rhamnosus GG is used in its native form. Its beneficial effects stem from natural surface adhesins, secreted metabolites, and immune-modulating proteins. No genetic modifications or synthetic circuits are involved.","[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""SCFAs"", ""Mucus glycans""]","[""Quorum sensing (indirect)""]","[""Cytokines (e.g., TNF-α, IFN-γ)"", ""Tight junction disruption signals""]","Surface adhesins (e.g., p40/p75), bile salt hydrolases, and cytokine receptors","Threshold-based response: upon sensing proinflammatory cytokines or barrier disruption, the strain upregulates anti-inflammatory and barrier-protective factors. Acts as a logical AND gate: requires both pathogen presence and host stress signals to activate protective response.","Lactobacillus rhamnosus GG senses changes in pH, bile, and nutrient availability. It detects host-derived inflammatory signals such as TNF-α and IFN-γ. When both microbial challenge and host stress are present, it activates protective mechanisms—reducing chemokine release and preventing NF-κB nuclear translocation. This logic ensures targeted, context-dependent immune modulation.","[""Immunomodulation"", ""Tissue Repair""]",Natural secretion of immunomodulatory proteins and metabolites; no engineered systems,Effective at 10^9 CFU/day; species-specific response; higher doses not necessarily more effective,Compatible with suspension delivery; maintains viability and function in liquid formulations,False,False,False,Not applicable (no direct antibacterial mechanism reported),,False,False,False,False,无直接抗菌作用，不涉及生物膜抑制,False,Not applicable,,False,False,False,无氧生成机制,True,Attenuates cytokine-induced epithelial dysfunction; reduces CXCL-8 and CCL-11 chemokine release; inhibits NF-κB translocation; promotes anti-inflammatory environment,"Interleukin-10 (IL-10), TGF-β",True,Preserves intestinal barrier integrity by preventing tight junction disruption; enhances epithelial cell resistance to pathogen and cytokine challenge,"Tight junction proteins (e.g., occludin, ZO-1)",False,Not applicable,,False,Not applicable,,GRAS,Natural attenuation; no genetic kill switches,,Low pathogenicity; no antibiotic resistance genes; no evidence of HGT; safe in healthy and immunocompromised populations; widely used in food and supplements,Suspension formulation provides minimal physical barrier; relies on natural colonization and clearance,"Lactobacillus rhamnosus GG is GRAS and has been extensively studied in humans. It is non-pathogenic, does not carry antibiotic resistance genes, and shows no evidence of horizontal gene transfer. It is safe for use in infants and adults. Its natural clearance from the gut ensures low long-term risk.",在体外模型中，Lactobacillus rhamnosus GG能有效保护肠道上皮屏障，防止由EHEC O157:H7或TNF-α引起的屏障破坏。其作用具有菌株特异性，其他乳酸杆菌菌株无此效果。在临床前研究中，该菌株显著减轻了炎症反应，改善了肠道屏障功能，具有潜在的治疗IBS和炎症性肠病的应用前景。,12758,8242,21000,,
a92b3181-5799-49da-972d-ccf15dc6b70d,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""transgenic IFN-β""}]",Encapsulated,Facultative Anaerobe,"Optimal at 37°C, pH 5.5–6.5; requires glucose and amino acids; bile-tolerant",Doubling time ~1.5–2 hours in vitro; stable in gut environment; consistent with colonization dynamics,Small intestine; adheres to epithelial cells; localized delivery to intestinal mucosa,No significant alteration of resident microbiota; may compete with pathogens,High tolerance to gastric acid and bile; stable during lyophilization; resistant to shear stress in encapsulated form,Enteric-coated capsules protect against gastric degradation,Lactobacillus acidophilus is a facultative anaerobe that grows optimally at 37°C and slightly acidic pH. It survives gastric transit due to bile and acid tolerance. It colonizes the small intestine and is used for localized delivery of recombinant proteins. Encapsulation enhances stability and targeted release.,CRISPR-Cas9 or plasmid-based expression system (implied by transgenic expression),High efficiency (constitutive expression confirmed); low off-target risk (no evidence reported),Constitutive (murine IFN-β expression under native promoter),,High plasmid stability; chromosomal integration not reported; metabolic burden may exist but not quantified; long-term in vivo consistency not fully evaluated,Stable in encapsulated delivery; maintains expression during storage and GI transit,"Lactobacillus acidophilus was genetically modified to constitutively express murine interferon-beta (IFN-β). The transgene is under a constitutive promoter, ensuring continuous secretion. This engineered strain was used to study localized immune modulation in colitis models. The system is stable in encapsulated form but may face challenges in long-term in vivo consistency.","[""pH"", ""Bile acids"", ""Glucose""]","[""SCFAs"", ""Mucus glycans""]","[""Quorum sensing (indirect)""]","[""Cytokines (e.g., TNF-α)"", ""Tissue damage signals""]",Surface receptors for host metabolites and immune signals; no engineered sensors,No synthetic logic; constitutive expression regardless of environmental cues,"The strain lacks engineered sensing modules. It constitutively secretes IFN-β without environmental feedback. This results in continuous immune stimulation, which may lead to unintended consequences such as exacerbation of inflammation.","[""Immunomodulation""]",Constitutive secretion via native secretion systems; no engineered delivery,Continuous secretion; no inducible control; dosage not adjustable post-administration,Encapsulated delivery ensures targeted release; compatible with intestinal environment,False,False,False,Not applicable,,False,False,False,False,无抗菌作用,False,Not applicable,,False,False,False,无氧生成机制,True,"Constitutive secretion of IFN-β leads to systemic and local immune activation; however, in colitis models, it exacerbated disease by increasing proinflammatory cytokines and pathogenic CD4+ T cells",Interferon-beta (IFN-β),False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,Kill switch not implemented; relies on natural clearance; no auxotrophy,,Low pathogenicity; no antibiotic resistance genes; risk of unintended immune activation; potential for prolonged IFN-β exposure; no evidence of HGT; escape risk low,Enteric-coated capsules provide physical confinement and delay release until intestinal environment,"Lactobacillus acidophilus is a BSL-1 organism. The transgenic strain expresses IFN-β constitutively, which led to unexpected exacerbation of colitis in animal models. This highlights the risk of uncontrolled immune activation. While the strain is naturally cleared, prolonged cytokine secretion poses safety concerns. No kill switches or auxotrophy are used, increasing risk of persistence. Physical encapsulation provides partial containment.",在DSS诱导的结肠炎小鼠模型中，表达IFN-β的Lactobacillus acidophilus导致更严重的体重下降、肠道增厚和炎症，增加了病理性CD4+ T细胞比例和炎症因子（如IL-6、TNF）水平。这表明局部IFN-β递送可能加重炎症，而非缓解。该结果 underscores基因工程菌株的潜在风险，尤其是缺乏调控机制时。,12758,8242,21000,,
a92b3181-5799-49da-972d-ccf15dc6b70d,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""420""}]",Encapsulated,Facultative Anaerobe,"Optimal at 37°C, pH 6.5–7.0; requires complex nutrients including amino acids, vitamins, and carbohydrates; dependent on host metabolites",Doubling time ~2–3 hours in vitro; maintains in vivo stability in high-fat diet models,Large intestine; adheres to mucosal surface; modulates gut barrier,Improves gut barrier function; reduces bacterial translocation; promotes beneficial microbial shifts,High tolerance to gastric acid and bile; stable during lyophilization; resistant to shear stress in encapsulated form,Capsule matrix enhances survival,"Bifidobacterium lactis 420 is a facultative anaerobe that thrives in the human gut. It is highly resistant to gastric conditions and colonizes the large intestine. It improves intestinal barrier integrity and reduces systemic inflammation, making it effective in metabolic syndrome models.",Not applicable (native strain used),Not applicable,Constitutive,,High chromosomal stability; no plasmid systems; no evidence of drift,Stable in encapsulated delivery; maintains function during storage,Bifidobacterium lactis 420 is used in its native form. Its therapeutic effects are due to natural barrier-enhancing and anti-inflammatory properties. No genetic modifications are involved.,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""SCFAs"", ""Mucus polysaccharides""]","[""Quorum sensing (indirect)""]","[""Cytokines (e.g., IL-1β)"", ""Barrier integrity signals""]","Carbohydrate utilization systems, mucin-binding proteins",Adaptive logic: responds to nutrient availability and host stress signals to modulate barrier and immune responses,"Bifidobacterium lactis 420 senses changes in gut environment, including pH, bile, and nutrient availability. It adjusts its metabolic activity to support barrier function and reduce inflammation. It responds to host cytokines and barrier disruption signals, promoting tissue repair and immune homeostasis.","[""Tissue Repair"", ""Metabolic Regulation""]",Natural secretion of metabolites and barrier-enhancing factors,Effective at 10^9 CFU/day; dose-dependent effects; no evidence of toxicity at tested doses,High compatibility with encapsulated delivery; maintains viability and function,False,False,False,Not applicable,,False,False,False,False,无抗菌作用,False,Not applicable,,False,False,False,无氧生成机制,True,Reduces systemic inflammation; lowers plasma LPS levels; improves glucose tolerance; modulates immune cell activity,Interleukin-1β (IL-1β),True,Enhances intestinal epithelial barrier function; reduces bacterial translocation to adipose tissue; restores gut integrity,"Tight junction proteins, mucosal repair factors",True,Improves glucose tolerance; reduces insulin resistance; lowers systemic inflammation; modulates lipid metabolism,Short-chain fatty acids (SCFAs),False,Not applicable,,GRAS,Natural clearance; no genetic kill switches,,Low pathogenicity; no antibiotic resistance genes; no HGT; safe in high-fat diet models; minimal risk of environmental escape,Enteric-coated capsules provide physical confinement,"Bifidobacterium lactis 420 is GRAS and has been used in dietary supplements. It is safe in animal models of metabolic syndrome and shows no adverse effects. It reduces inflammation and improves metabolic health. No genetic modifications or containment systems are used, but physical encapsulation enhances delivery safety.",在高脂饮食小鼠模型中，Bifidobacterium lactis 420显著改善了肠道屏障功能，减少了细菌易位至脂肪组织，降低了血浆LPS水平和炎症反应，同时改善了葡萄糖耐量。该菌株可作为治疗代谢综合征和肥胖相关炎症的新策略。,12758,8242,21000,,
a92b3181-5799-49da-972d-ccf15dc6b70d,4,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""R0052""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""R0175""}]",Suspension,Facultative Anaerobe,"Optimal at 37°C, pH 6.0–6.5; requires glucose and amino acids; bile-tolerant",Doubling time ~1.5–2 hours in vitro; maintains in vivo stability in rat models,Gut mucosa; adheres to intestinal epithelium; localized in small and large intestine,Synergistic with host microbiota; reduces proinflammatory cytokines; promotes gut homeostasis,High tolerance to gastric acid and bile; stable in suspension; resistant to shear stress,Surface adhesins and extracellular matrix components,"Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 are facultative anaerobes that thrive in the human gut. They survive gastric transit and colonize the intestinal mucosa. Their combined use enhances gut barrier integrity and reduces inflammation, particularly in post-MI models.",Not applicable (native strains used),Not applicable,Constitutive,,High chromosomal stability; no plasmid systems; no evidence of drift,Stable in suspension; maintains function during delivery,The two strains are used in their native form. Their therapeutic effects are due to intrinsic anti-inflammatory and barrier-protective properties. No genetic modifications are involved.,"[""pH"", ""Bile acids"", ""Glucose""]","[""SCFAs"", ""Mucus glycans""]","[""Quorum sensing (indirect)""]","[""Cytokines (e.g., IL-1β)"", ""Apoptosis signals""]","Surface receptors, carbohydrate utilization systems","Adaptive response: responds to host stress signals (e.g., post-MI inflammation) to modulate immune and neural responses",The strains sense changes in gut environment and host stress signals. They respond by reducing proinflammatory cytokines and apoptosis in the limbic system. This adaptive logic supports neurogastroenterological homeostasis and reduces post-MI depression.,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Natural secretion of metabolites and immunomodulatory factors,1 billion CFU/day; effective in behavioral and biochemical outcomes,Compatible with suspension delivery; maintains viability and function,False,False,False,Not applicable,,False,False,False,False,无抗菌作用,False,Not applicable,,False,False,False,无氧生成机制,True,Reduces IL-1β levels; attenuates depressive behavior; modulates immune response in post-MI state,Interleukin-1β (IL-1β),True,Restores intestinal barrier integrity; reduces apoptosis in limbic system; promotes neural recovery,"Neuroprotective factors, tight junction proteins",True,Modulates gut-brain axis; influences neurotransmitter balance; reduces systemic inflammation,Short-chain fatty acids (SCFAs),False,Not applicable,,GRAS,Natural clearance; no genetic kill switches,,Low pathogenicity; no antibiotic resistance genes; no HGT; safe in animal models; minimal environmental risk,Suspension formulation provides minimal physical barrier,"Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 are GRAS. They are safe in post-MI rat models and show no adverse effects. Their use reduces depression-like behavior and restores gut integrity. No genetic modifications are used, and natural clearance ensures low long-term risk.",在心肌梗死后大鼠模型中，Lactobacillus helveticus R0052与Bifidobacterium longum R0175联合使用显著改善了社交行为和强迫游泳测试表现，降低了血浆IL-1β水平，并恢复了肠道屏障完整性。该组合可有效干预心肌梗死后抑郁行为，提示肠道-大脑轴在心梗后反应中的关键作用。,12758,8242,21000,,
ffafef1f-4f6e-4917-babe-c907aa854922,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""HN001""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""420""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, requires complex media with carbohydrates (e.g., glucose, fructose) and amino acids; tolerant to bile salts and low pH (gastric conditions)",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in gut mucosa with stable persistence over 6 months postpartum,"Gut mucosa (intestinal lumen and epithelial surface), particularly in the distal small intestine and colon",Competitive exclusion of pathogenic bacteria; synergistic co-colonization with endogenous Bifidobacteria; minimal disruption to core microbiome,"Tolerant to lyophilization, room temperature storage for up to 12 months; resistant to shear stress during encapsulation; moderate UV sensitivity","Microcrystalline cellulose (in placebo), protective matrix in capsule form",该研究中使用的益生菌为Lactobacillus rhamnosus HN001和Bifidobacterium animalis subsp. lactis 420，均为兼性厌氧菌，可在人体肠道环境中定植并维持稳定。其生长最适温度为37°C，pH范围为5.5–6.5，依赖于碳水化合物和氨基酸等营养物质。在胃酸和胆汁环境中具有较强耐受性，可成功通过胃肠道到达结肠并定植，表现出良好的体内稳定性。,Plasmid-based expression system (not explicitly described); standard fermentation and lyophilization for production,Not applicable (no genetic modification reported),Constitutive expression (no inducible systems used),,High chromosomal stability; no plasmid-based systems used; no reported gene loss or drift during 6-month intervention,Stable in capsule matrix (microcrystalline cellulose and medium-chain fatty acids); no degradation during storage or GI transit,本研究中使用的益生菌未经过基因改造，其功能依赖于天然代谢途径。Lactobacillus rhamnosus HN001和Bifidobacterium animalis subsp. lactis 420通过口服摄入，在肠道中自然定植并持续表达其生理功能，无需外源调控系统。其遗传稳定性高，未使用质粒或可移动遗传元件，避免了基因水平转移风险。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Short-chain fatty acids (SCFAs)"", ""Tryptophan metabolites""]","[""Quorum sensing molecules (AHL, AI-2)""]","[""Cytokines (e.g., IL-6, TNF-α)"", ""Proteases (e.g., MMPs)""]","FNR promoter (hypoxia), Lactate receptor (LacR), Bile acid transporter (BaiCD), Tryptophan permease (TnaA)",AND gate: requires both low pH and bile presence for optimal colonization; threshold-based activation of immune modulation pathways,这些益生菌通过感知肠道内的pH值、胆汁酸、乳酸和葡萄糖等生理化学信号，结合宿主释放的细胞因子和蛋白酶，实现对微环境的响应。其定植机制采用AND逻辑门，需同时满足低pH和胆汁存在条件才启动定植程序。此外，对色氨酸代谢物和短链脂肪酸的感知可触发免疫调节通路，实现动态平衡。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]","Type IV secretion system (T4SS), Vesicles (exosomes)",Dose-dependent effect: 10^10 CFU/day; no feedback control system; duration-controlled via daily intake,High compatibility with oral capsule delivery system; stable in microcrystalline cellulose and medium-chain triglyceride matrix,False,,,,,,,,,,False,,,,,,,True,"Modulate systemic and mucosal immune responses by downregulating pro-inflammatory cytokines (IL-6, TNF-α) and upregulating anti-inflammatory IL-10; enhance regulatory T cell (Treg) activity.","IL-10, TGF-β, SCFAs (butyrate, acetate)",True,"Promote intestinal barrier integrity via upregulation of tight junction proteins (occludin, ZO-1); stimulate epithelial cell proliferation and mucus production.","Occludin, ZO-1, MUC2",True,Modulate host metabolism by fermenting dietary fibers into SCFAs; influence tryptophan metabolism toward kynurenine pathway and serotonin synthesis.,"Butyrate, Acetate, Serotonin, Kynurenine",False,,,GRAS,Auxotrophy (require exogenous nutrients not available in environment); no antibiotic resistance genes detected,"Lactose, Bile salts (required for growth)",Non-pathogenic; no evidence of virulence genes; no horizontal gene transfer observed; low opportunistic risk in healthy individuals,Capsule shell prevents environmental release; gastrointestinal transit limits systemic spread,Lactobacillus rhamnosus HN001和Bifidobacterium animalis subsp. lactis 420均为公认安全（GRAS）菌株，无致病性或毒力基因，不携带抗生素抗性基因，且依赖于特定营养物质（如乳糖、胆汁酸）生长，无法在自然环境中长期存活。胶囊封装有效防止其释放至环境，具有良好的生物安全性和可控性。,在妊娠期至产后12个月期间，联合使用鱼油和益生菌干预组的EPDS评分在妊娠晚期较早期妊娠上升1.11分，而仅使用鱼油的组别下降0.85分。在产后12个月时，鱼油+安慰剂组的EPDS评分显著低于益生菌+安慰剂组（p=0.039）。尽管干预效果较小，但表明该益生菌组合对改善孕期及产后抑郁症状具有潜在益处，尤其在长期随访中表现出一定优势。,16782,2053,18835,,
eb4593e2-1a4c-4e4d-bd29-11a924be6ff6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""19070-2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 12246""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, utilizes glucose and other carbohydrates as carbon sources; requires no special vitamins or amino acids beyond standard growth media.",Doubling time ~1.5–2 hours in vitro; stable in vivo colonization observed in human gut over 6-week treatment period.,"Small intestinal mucosa, particularly in the proximal small intestine; adheres to epithelial cells.",Competitive exclusion of pathogenic bacteria; no significant disruption of native microbiota reported; may promote symbiosis with commensal flora.,Resistant to gastric acid and bile salts; stable during lyophilization and rehydration; tolerates moderate osmotic stress.,"Cell wall components (e.g., teichoic acids), stress-response proteins (e.g., GroEL), and extracellular polysaccharides.",该研究中使用的Lactobacillus rhamnosus 19070-2和L. reuteri DSM 12246均为非致病性乳酸菌，可在人体肠道内定植并维持稳定生长。它们对胃酸和胆汁具有较强耐受性，适合口服给药。在体外和健康志愿者中已验证其黏附于肠黏膜的能力，且在6周治疗期间表现出良好的体内稳定性。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未对菌株进行基因改造，所有功能均依赖于天然菌株的生理特性，未使用任何基因工程手段。,"[""pH"", ""Glucose""]","[""Bile Acids"", ""Lactate""]",,"[""Proteases"", ""Cytokines""]","FNR-like regulators (for hypoxia), lactose permease (for glucose), bile salt hydrolases (for bile acids)",Not specified,该研究未涉及人工设计的传感逻辑电路，其响应机制基于天然菌株对肠道微环境的自然感知能力，如对pH变化、营养物质和胆汁酸的感应，但未明确描述具体逻辑门控机制。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type IV secretion system (putative), passive diffusion",Dose-dependent effect: 10^10 CFU twice daily; effects observed after 6 weeks of consistent administration.,Lyophilized powder formulation compatible with oral delivery; stable in suspension in water or preferred liquid.,False,,,Not applicable,,False,False,False,False,未使用抗菌机制，无相关证据。,False,Not applicable,,False,False,False,未涉及氧气生成机制，无相关证据。,True,通过刺激抗炎细胞因子（如IL-10）和增强分泌型IgA的产生，调节肠道黏膜免疫反应，减轻局部炎症。,"IL-10, Secretory IgA",True,通过促进肠上皮细胞增殖和黏液分泌，增强肠屏障功能，修复受损的黏膜屏障。,"Mucin, Epithelial growth factors",True,通过调节短链脂肪酸（SCFAs）的产生和肠道代谢环境，改善肠道微生态平衡。,Short-chain fatty acids (SCFAs),False,Not applicable,,GRAS,None (natural strains with no known pathogenicity),None,No pathogenicity reported; no antibiotic resistance genes detected; no horizontal gene transfer observed; low risk of environmental escape due to poor survival outside host.,Oral administration with natural gut transit; no engineered containment required.,Lactobacillus rhamnosus 19070-2和L. reuteri DSM 12246均为公认安全（GRAS）菌株，已在健康志愿者中验证其安全性和黏附能力。未发现致病性、抗生素抗性基因或水平基因转移风险，且在体外和体内均表现出良好的生物安全性。,在41名中重度特应性皮炎儿童中，6周益生菌治疗显著降低了胃肠道症状发生率（从39%降至10%，P=0.002），并显著改善了小肠通透性（乳果糖/甘露醇比值从0.110降至0.073，P=0.001）。同时，乳果糖排泄量减少50%（P=0.02），表明肠屏障功能得到修复。临床严重程度评分（SCORAD）与小肠通透性呈正相关（r=0.61，P=0.02），提示益生菌通过增强肠屏障功能，间接缓解了特应性皮炎症状。,7597,1736,9333,,
6648a6c5-03ba-44a5-a92f-5d10a3829f71,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Carnobacterium divergens"", ""strain_id"": ""V41""}, {""role"": ""Chassis"", ""scientific_name"": ""Psychrobacter sp."", ""strain_id"": ""GP12""}, {""role"": ""Chassis"", ""scientific_name"": ""Pseudomonas sp."", ""strain_id"": ""GP21""}, {""role"": ""Chassis"", ""scientific_name"": ""Shewanella sp."", ""strain_id"": ""GS11""}, {""role"": ""Chassis"", ""scientific_name"": ""Photobacterium sp."", ""strain_id"": ""GP31""}, {""role"": ""Chassis"", ""scientific_name"": ""Vibrio sp."", ""strain_id"": ""GV11""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus sp."", ""strain_id"": ""Enterococcus sp.""}, {""role"": ""Chassis"", ""scientific_name"": ""Arthrobacter sp."", ""strain_id"": ""Arthrobacter sp.""}, {""role"": ""Chassis"", ""scientific_name"": ""Phaeobacter gallaeciensis"", ""strain_id"": ""BS107 (DSM17395)""}]",Encapsulated,Facultative Anaerobe,"Temperature: 13–20°C; pH: neutral to slightly alkaline; osmotic tolerance: moderate; nutrition: diverse carbon sources including proteins, carbohydrates, and lipids; dependent on host-derived nutrients in gut environment",Doubling time: 2–4 hours in vitro; growth rate consistent in vivo under aquaculture conditions; stable colonization in larval gut,"Intestinal tract, pyloric caeca, hindgut chamber, mucus layer of gut epithelium","Competitive exclusion of pathogens (e.g., Vibrio anguillarum, Aeromonas salmonicida); modulation of gut microbiota composition; synergistic with host immune system","Tolerant to osmotic stress, moderate shear stress, and cold temperatures; stable during lyophilization and rehydration; survives harsh GI tract conditions","Siderophores, biofilm matrix, extracellular enzymes",这些微生物均为从大西洋鳕鱼肠道或其养殖环境中分离的革兰氏阴性或阳性菌，具有良好的冷适应性，可在13–20°C的低温条件下生长。它们在养殖水体和鱼肠道中表现出稳定的定植能力，能耐受消化道的酸碱变化和渗透压波动，部分菌株（如Psychrobacter sp. GP12）还能在低铁环境中形成生物膜，增强环境适应性。,None reported,Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems reported; no evidence of genetic drift in in vivo studies,Stable in encapsulated formulations and rearing water; no reported degradation in material environment,目前未报道对这些微生物进行基因工程改造。所有功能均依赖于天然代谢途径和固有基因表达，未使用CRISPR、重组酶或转座子等工具进行编辑。其功能表达为天然构成型，无需诱导剂控制。,"[""Temperature"", ""pH"", ""Salt concentration"", ""Iron concentration""]","[""Siderophores"", ""Lactate"", ""Glucose"", ""Amino acids""]","[""Quorum sensing (indirect via biofilm formation)"", ""Pathogen-specific molecules (e.g., Vibrio surface antigens)""]","[""Mucus layer"", ""Intestinal epithelial cells"", ""Immune cells (head kidney leukocytes)""]","FNR-like promoters (temperature/pH sensing), iron-sensing regulators (Fur), biofilm adhesion proteins (e.g., LapA, LapB)","Threshold-dependent response; no complex logic gates reported; response modulated by environmental cues (e.g., temperature, iron) and bacterial density (biofilm formation)",这些微生物通过感知温度、pH、盐度和铁浓度等环境信号调节其拮抗活性和生物膜形成。例如，Shewanella sp. GS11在20°C时抑制活性更强，而Photobacterium sp. GP31在高温下活性下降。铁浓度影响生物膜形成，表明其具有环境适应性调控机制。未见复杂逻辑门（如AND/OR）的报道，主要为单一信号响应。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Type I Secretion (e.g., for enzymes), Lysis (for extracellular metabolites), Vesicles (potential, not confirmed)",Dose-dependent response; controlled by administration frequency and concentration in rearing water or feed,Compatible with encapsulation in feed or water; stable in gel-like or suspension formulations; no structural collapse observed,True,True,True,通过产生抗菌代谢物（如TDA、细菌素、铁载体）、竞争黏附位点、抑制病原菌生长和生物膜形成来发挥抗菌作用。,"Tropodithietic acid (TDA), bacteriocins, siderophores, extracellular enzymes",True,True,True,True,多株菌（如C. divergens V41、Phaeobacter gallaeciensis、GP12）在体外和体内均有效抑制V. anguillarum和A. salmonicida；生物膜形成能力增强定植稳定性；未见对宿主细胞显著毒性或微生物群落过度扰动。,False,,,False,False,False,未报道任何产氧机制或光依赖性氧生成系统。,True,通过激活头肾白细胞中的免疫相关基因（如bpi/lbp、lyz、il1β、il8）和抗氧化防御基因，增强先天免疫反应，即使热灭活后仍保持活性。,"Heat-inactivated bacterial cells, extracellular signaling molecules",False,,,True,通过分泌蛋白酶、淀粉酶、纤维素酶、几丁质酶等酶类，促进宿主消化，释放必需氨基酸，调节肠道酶活性，改善营养吸收。,"Protease, amylase, cellulase, chitinase, siderophores",False,,,BSL-1,"Auxotrophy (iron-dependent growth), temperature sensitivity (optimal at 13–20°C), no known virulence genes","Iron limitation, low temperature",Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low environmental escape risk due to cold-adapted nature and poor competitiveness in wild environments,Physical confinement in aquaculture tanks; limited survival outside controlled rearing systems,所有候选菌株均为从鳕鱼肠道或养殖水体中分离的非致病性菌株，无已知毒力因子或耐药基因。其生长依赖于低温和特定营养（如铁），在自然环境中难以长期存活，因此生态风险极低。,在鳕鱼幼鱼阶段，使用C. divergens V41、Psychrobacter sp. GP12、Phaeobacter gallaeciensis等菌株可显著提高存活率（提升10%以上），降低肠道Vibrio菌群数量，促进生长性能和消化酶活性。热灭活菌株仍具免疫调节功能，表明其应用安全性高，具有可持续替代抗生素的潜力。,15407,2255,17662,,
fa9b24af-37a8-47d3-b37b-6178b9bf750f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""03""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""2412""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""ACD1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus bulgaricus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": """"}]",Encapsulated,Facultative Anaerobe,"Growth at 37°C, pH 3.75–4.20 (in yogurt), in MRS broth or 12% reconstituted skim milk with 1% glucose and 1% yeast extract",Doubling time not specified; viable counts maintained at 1.6 × 10⁹/g at day 0 and 2.5 × 10⁷/g at day 30 during storage at 5°C,Gastric environment (targeted for H. pylori eradication),No antagonistic activity observed among the lactic acid bacteria strains in the product; no mention of competition with host microbiome,High stability during refrigerated storage (5°C) for up to 40 days; viable cells maintained at 1.9 × 10⁷/g after 40 days,Refrigerated storage (5°C),该微生物系统由多种乳酸菌组成，包括L. casei 03、L. acidophilus 2412、L. acidophilus ACD1以及商业发酵剂（L. bulgaricus、S. thermophilus和L. acidophilus）。这些菌株在37°C下于MRS培养基或添加葡萄糖和酵母提取物的脱脂牛奶中生长良好，pH值可降至3.75–4.20。在5°C冷藏条件下，其活菌数在40天内保持稳定，表明具有良好的储存稳定性。,,,,,No genetic modifications reported; all strains used were naturally occurring and not engineered for stability or expression,No evidence of genetic engineering; stability in yogurt matrix is attributed to natural resilience of the strains,该系统未进行任何基因工程改造，所有菌株均为天然存在的乳酸菌，通过传统发酵工艺制备成酸奶产品，未引入外源基因或调控元件。,"[""pH""]","[""Glucose"", ""Yeast extract""]",,,pH-responsive growth environment (inferred from acid production),No engineered logic gates or sensors; natural metabolic responses to environmental pH and nutrients,该系统未设计任何人工感知模块，其功能依赖于乳酸菌在低pH环境下的自然生长和代谢活动，通过酸化环境间接抑制H. pylori，无主动感知或逻辑控制机制。,"[""Antibacterial""]","Spontaneous secretion of organic acids, hydrogen peroxide, antimicrobial peptides","Not controllable; dosage depends on consumption volume (175 ml, three times daily)",High compatibility with yogurt matrix; no structural disruption reported,True,False,False,通过产生有机酸、过氧化氢、抗菌肽等物质抑制H. pylori生长，整体发酵乳的抑制效果强于活菌或上清液,"Organic acids, hydrogen peroxide, antimicrobial peptides, milk peptides",False,False,True,True,在体外实验中，该酸奶对H. pylori的抑制效果与阿莫西林MIC相当，且在40天内保持活性，表明其在基质中具有良好的兼容性和安全性。,False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,None,,No pathogenicity reported; no antibiotic resistance genes mentioned; no horizontal gene transfer risk noted; low risk of environmental escape due to lack of persistence in human gut,Physical confinement in yogurt container; no engineered containment,该系统由多种公认安全（GRAS）的乳酸菌组成，未进行基因改造，无致病性或耐药基因，且在人体内无法长期定植，因此生物安全风险极低。,在27名H. pylori阳性受试者中，仅1人（约3.7%）在30天酸奶摄入后实现H. pylori根除，其余26人尿素呼气试验仍为阳性，表明该酸奶产品在体内无法有效根除H. pylori感染。,7372,1674,9046,,
e1177ea7-cf33-4f72-88cf-ef0adbd2844d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""MG242""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in MRS broth (anaerobic), pH 7.4; tolerant to pH 3–4 and bile salts (0.1–0.4%)",Growth to 10⁸ CFU/mL in 18 h; doubling time not specified,Vaginal mucosa (target niche for VVC biocontrol),Competes with Candida albicans and other pathogens; may support healthy vaginal microbiota,"Resistant to pepsin (pH 3–4), pancreatin (pH 7–8), bile salts (up to 0.4%), and heat (enhanced by skim milk in freeze-drying)",Skim milk (protectant during freeze-drying),"Lactobacillus salivarius MG242 is a facultative anaerobe that grows optimally at 37°C in MRS broth under anaerobic conditions. It exhibits strong resistance to acidic environments (pH 3–4) and bile salts, indicating potential survival in the gastrointestinal tract. It shows high cell hydrophobicity and autoaggregation, which support mucosal adhesion and colonization in the vaginal niche. The strain maintains viability under thermal stress when immobilized in skim milk, enhancing shelf-life stability.",,,,,,,该研究未对L. salivarius MG242进行基因工程改造，其抗真菌活性为天然表型，未涉及人工调控电路或遗传修饰。,"[""pH"", ""Bile Salts""]",,,,Not specified (natural sensing of pH and bile salts via cell envelope and membrane transporters),Not applicable (no engineered logic circuits described),该菌株未经过工程化设计，其对pH和胆盐的响应为天然生理行为，无复杂逻辑处理机制。,"[""Antibacterial"", ""Antifungal""]",Unknown (likely passive diffusion or cell lysis),"Not applicable (natural secretion, no controllable output)",Compatible with freeze-dried powder and skim milk matrix; stable in encapsulated form,True,False,False,通过分泌抑制性物质（如有机酸）抑制C. albicans生长，导致真菌细胞萎缩，显著降低其存活率。,"Organic acids (lactic acid, acetic acid) and unknown inhibitory substances",False,True,True,True,在共培养中对C. albicans的抑制率达到99.99±0.01%，且未观察到对宿主细胞的毒性，表明活性可控且局部作用。,False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,None (no kill-switch or auxotrophy described),,"Low pathogenicity; resistant to some antibiotics (e.g., gentamicin, kanamycin), but sensitive to ampicillin and tetracycline; no horizontal gene transfer or environmental escape reported.",Freeze-dried powder with skim milk provides physical confinement and stability,"L. salivarius MG242 is classified as GRAS (Generally Recognized As Safe) and has been isolated from human vagina. It shows no significant pathogenicity and is sensitive to common antibiotics. No genetic modifications or antibiotic resistance genes were reported. The use of skim milk as a protective matrix enhances stability and reduces risk of premature release. No biocontainment systems were implemented, but the natural low virulence and niche specificity reduce escape risk.",在体外共培养中，L. salivarius MG242对C. albicans的抑制率达到99.99±0.01%，显著抑制其生长并导致细胞萎缩。加速储存试验表明，冻干后在10%脱脂乳中保存，其半衰期延长至8.31个月，且在40–60°C下热稳定性显著提升，表明其具有良好的制剂稳定性和潜在的临床应用前景。,10448,1510,11958,,
30b1210e-5a31-4655-81bf-a6ca7f022ae5,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Yarrowia lipolytica"", ""strain_id"": ""Scotan S.A, Poland""}, {""role"": ""Helper"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Bacillus licheniformis"", ""strain_id"": ""1.6 × 10⁹ CFU/g""}, {""role"": ""Helper"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""1.6 × 10⁹ CFU/g""}]",Encapsulated (in feed matrix),Facultative Anaerobe,"Grows on lipid substrates (e.g., glycerol), uses wheat, soybean meal, triticale, rapeseed cake, potato protein as carbon/nutrient sources; optimal growth in poultry gut environment",Rapid growth on lipid substrates; no specific doubling time reported; in vivo stability confirmed via gut colonization and immune modulation,"Intestinal tract (small intestine), gut lumen","Competitive exclusion of pathogenic bacteria (E. coli, coliforms); synergistic with Bacillus spp. (probiotic); reduces fungal overgrowth; modulates host microbiota balance","Tolerant to feed processing and gastrointestinal transit; no data on UV, drying, or shear stress; stability in feed matrix confirmed","Feed matrix (wheat, soybean meal, etc.)","Yarrowia lipolytica is a facultative anaerobe capable of rapid growth on lipid substrates such as glycerol, commonly found in biofuel byproducts. It thrives in the poultry gut environment when fed in compound feeds, demonstrating strong colonization ability in the small intestine. It is stable in feed formulations and maintains viability during gastrointestinal transit, contributing to sustained modulation of gut microbiota and host immunity.",Not applicable (no genetic modification reported),Not applicable,Constitutive (natural expression of cell wall components),None,High (no plasmids or engineered circuits; chromosomal stability in natural form),Stable in feed matrix; no evidence of degradation or loss of function during feed processing or gut transit,"No genetic engineering was performed. The microbial system relies on natural physiological properties of Yarrowia lipolytica and Bacillus spp. for functionality. The yeast's beneficial effects are attributed to endogenous cell wall components (e.g., β-glucans), not engineered circuits.","[""pH (lowered by probiotic fermentation)"", ""Nutrient availability (lipids, carbohydrates)""]","[""Lactate (produced by Bacillus probiotics)"", ""Organic acids (e.g., lactic acid from probiotic fermentation)""]","[""Quorum sensing (indirect via probiotic-Bacillus interactions)""]","[""Intestinal epithelium (adhesion sites)"", ""Immune cell signals (indirect via immune modulation)""]",β-glucans (cell wall components of Yarrowia lipolytica),"No engineered logic; natural immune stimulation via pattern recognition (e.g., β-glucan recognition by Dectin-1 receptors)","Yarrowia lipolytica does not possess engineered sensing circuits. Its immune-modulating effects are triggered by natural recognition of β-glucans in the host immune system, particularly by macrophages and dendritic cells, leading to activation of innate immunity without requiring external inducers or complex logic gates.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Cell wall components (β-glucans) released naturally during growth and lysis,Dose-dependent via feed concentration (3% in feed); no external control mechanism,Highly compatible with feed matrix; stable during processing and gut transit,True,True,False,"Reduces total microorganisms, coliforms, and E. coli; inhibits pathogenic colonization via competitive exclusion and immune stimulation",β-glucans (cell wall components),True,True,True,True,"Yarrowia lipolytica significantly reduced coliforms (P < 0.001) and E. coli (P = 0.032) in the small intestine. No pathogenic bacteria (Salmonella, Proteus, Pseudomonas) were detected. The effect was synergistic with probiotics, indicating controlled, localized activity without systemic disruption.",False,Not applicable,None,False,False,False,No evidence of oxygen production or hypoxia alleviation; not a feature of this system.,True,"Stimulates phagocytic activity, increases NBT value, lysozyme content, and IgY/IgM levels; reduces H:L ratio, indicating enhanced adaptive immunity",β-glucans (Yarrowia lipolytica cell wall),True,"Promotes erythropoiesis (increased Hb, RBC, Ht), suggesting improved oxygen-carrying capacity and tissue oxygenation; supports mucosal integrity via microbiota balance","Hemoglobin, erythrocytes, iron-copper-zinc (nutrient cofactors)",False,Not applicable,None,False,Not applicable,None,BSL-1,Natural attenuation (no engineered kill switches); auxotrophy not reported,None,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape unlikely due to feed-based delivery,Feed matrix provides physical confinement; no release into environment,"Yarrowia lipolytica is a GRAS (Generally Recognized As Safe) organism with no known pathogenicity. It is not an opportunistic pathogen and does not carry antibiotic resistance genes. Its use in feed ensures physical containment. The system poses minimal risk to human health, animal health, or the environment.","Yarrowia lipolytica significantly improved gut microbiota by reducing coliforms (P < 0.001), E. coli (P = 0.032), and fungi (P < 0.001). It enhanced immunity by increasing phagocytic activity (%pc, P = 0.021), NBT value (P = 0.013), lysozyme (P = 0.013), and erythropoiesis (Hb ↑ P = 0.049, RBC ↑ P = 0.027, Ht ↑ P < 0.001). The combined use with Bacillus probiotics showed synergistic effects, further reducing pathogens and enhancing immune markers. The system is effective in promoting gut health and systemic immunity in turkeys.",17793,2047,19840,,
4c727823-ddd8-464c-8478-2b81c5901e58,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""P1 (5-strain mixture)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""P1 (5-strain mixture)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus cellobiosus"", ""strain_id"": ""P1 (5-strain mixture)""}, {""role"": ""Chassis"", ""scientific_name"": ""Kluyvera ascorbata"", ""strain_id"": ""P1 (5-strain mixture)""}, {""role"": ""Chassis"", ""scientific_name"": ""Klebsiella travesanii"", ""strain_id"": ""P1 (5-strain mixture)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""P2 (single strain)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus cellobiosus"", ""strain_id"": ""P2 (single strain)""}]",Suspension (administered in drinking water),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, requires carbon sources such as glucose and amino acids; lactic acid bacteria are mesophilic and grow in low pH environments (pH 4.5–6.0).",Doubling time ~20–30 min for E. coli; ~60–90 min for Lactobacillus spp.; in vivo growth supported by gut environment and nutrient availability.,Gastrointestinal tract of turkeys (intestinal lumen and mucosal surface); competes for adhesion sites and nutrients.,Competitive exclusion of Salmonella by occupying binding sites and consuming nutrients; may modulate host immune response and support epithelial barrier function.,Moderate tolerance to osmotic stress and moderate pH shifts; sensitive to high temperatures (>45°C) and drying; stabilized with skim milk during administration.,Skim milk (stabilizer in drinking water),该系统中的微生物为多种肠道共生菌，包括大肠杆菌、克鲁维酵母菌属、克雷伯菌属及乳酸杆菌。它们均为兼性厌氧菌，适宜在37°C、中性至微酸性环境中生长，依赖于宿主肠道中的碳源和氨基酸。在鸡舍环境中通过饮水投喂，可在肠道内定植并竞争性抑制沙门氏菌的定植。,,,,,No genetic modifications reported; natural strains used; plasmid stability not assessed; chromosomal integration not performed.,Stability maintained in skim milk-containing water; no evidence of degradation in delivery medium.,未对菌株进行基因改造，所有菌株均为天然分离的非致病性菌株，通过竞争性排斥机制抑制沙门氏菌，未使用任何合成生物学工具。,"[""pH"", ""Nutrient availability""]","[""Glucose"", ""Lactate""]",,,"Natural metabolic sensors (e.g., lactose permease, glucose transporters, pH-responsive regulators)",No engineered logic gates; natural physiological responses to nutrient and pH changes.,菌株通过感知肠道内的pH值和营养物质（如葡萄糖、乳酸）变化，调节自身代谢与生长，实现对环境的适应性响应，但无人工设计的逻辑门控系统。,"[""Antibacterial""]","Natural secretion (e.g., organic acids, bacteriocins, metabolic byproducts)",Controlled by administration dose (1×10⁶–1×10⁸ CFU/mL) and duration (3 days via vaccine medicator),Compatible with drinking water delivery system; stabilized by skim milk; no structural disruption observed.,True,True,False,通过竞争性排斥机制，占据肠道黏膜受体位点，消耗营养资源，抑制沙门氏菌定植与增殖。,Competitive exclusion (natural colonization competition),True,True,True,True,在商业肉鸡舍中，P1和P2联合有机酸处理后，沙门氏菌阳性拖拭样本减少87.5%和75%，且无明显组织损伤或微生物群落失衡报告。,False,,,False,False,False,,False,,,False,,,False,,,False,,,BSL-1,Non-pathogenic strains; no antibiotic resistance genes reported; no kill-switches or auxotrophy used.,,All strains are non-pathogenic and previously isolated from healthy poultry; no evidence of horizontal gene transfer or environmental escape; low opportunistic risk.,Physical delivery via water lines; no encapsulation or barrier system used.,所有菌株均为非致病性肠道共生菌，已在多项研究中证明安全，未发现毒力基因或抗生素抗性基因，且在鸡舍环境中无逃逸风险，属于低风险生物制剂。,在实验1中，P1单独使用可使沙门氏菌阳性拖拭样本减少90%；在实验2中，有机酸预处理后使用P1或P2，沙门氏菌减少率分别达87.5%和75%，表明该益生菌组合可有效降低鸡舍环境中的沙门氏菌负荷，减少屠宰场交叉污染风险。,6106,1817,7923,,
9c4a7ae8-5a07-467b-999b-e5360587436a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 17938""}]",Oral suspension (drops),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric acidity; survives transit through upper GI tract",Survives intestinal transit; transient colonization in infants; no long-term persistence after discontinuation,"Gut lumen, particularly in breastfed infants; may colonize mucosal surface in neonates",Competes with pathogenic bacteria for nutrients and binding sites; may modulate host immune tolerance,"Tolerates gastric acid, bile salts, and lyophilization; stable during storage and rehydration","Cell wall structure and acid tolerance genes (e.g., *dlt* operon)",该菌株为兼性厌氧菌，可在37°C、pH 6.0–7.0条件下生长，能耐受胃酸和胆汁，成功通过上消化道并定植于肠道。在婴儿中可短暂定植，但停用后通常无法长期维持。,Not specified (natural strain used),Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems reported,Stable in oral drops and formula matrices,该菌株为天然分离株，未经过基因工程改造，其功能依赖于天然代谢与免疫调节机制。,"[""pH"", ""Bile acids""]","[""Lactate"", ""Glucose""]",,"[""Proteases"", ""Cytokines""]","Lactate permease and pH-sensing regulators (e.g., *gad* system)",No engineered logic; natural response to environmental cues,该菌株通过感知肠道pH、胆汁酸、乳酸和葡萄糖等信号，调节自身代谢与黏附行为，响应宿主炎症因子（如IL-8、TNF-α）变化，实现免疫调节。,"[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]",Constitutive secretion of reuterin and immunomodulatory molecules,Dose-dependent effect; 10⁸ CFUs/day in drops; efficacy observed at consistent daily dosing,Compatible with oral drops and formula; stable in liquid matrix,True,False,False,Competes with pathogens for binding sites and nutrients; produces reuterin (antimicrobial compound) in vitro,Reuterin,False,True,True,True,在婴儿中使用安全，未见显著毒性或微生物群落紊乱；在口服滴剂中保持活性。,False,,,False,False,False,无相关证据,True,"Downregulates pro-inflammatory cytokines (IL-8, IL-1β, TNF-α); upregulates anti-inflammatory IL-10; modulates mucosal immune response","IL-10, IL-8, TNF-α",True,Improves mucosal healing in pediatric UC; reduces endoscopic and histologic scores; enhances epithelial barrier function,"Mucin, tight junction proteins (ZO-1, occludin)",False,,,False,,,GRAS,Auxotrophy (natural strain with no antibiotic resistance genes in DSM 17938),Tetracycline and lincomycin resistance genes absent in DSM 17938,Low pathogenicity; no reported cases of sepsis; no horizontal gene transfer risk in this strain,Oral delivery limits systemic exposure; physical barrier of GI mucosa,该菌株为GRAS级，无耐药基因，安全性良好。在健康儿童中耐受性佳，仅偶见胃肠不适。在高危人群（如早产儿、免疫缺陷者）中需谨慎使用。,在母乳喂养婴儿中，每日10⁸ CFU的L. reuteri DSM 17938可显著减少哭闹时间（平均减少42–50分钟/天），改善功能性胃肠疾病症状。在儿童溃疡性结肠炎中，直肠给药可显著降低Mayo评分，改善黏膜愈合。,15510,7379,22889,,
9c4a7ae8-5a07-467b-999b-e5360587436a,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}]","Oral suspension (capsules, powder, or formula)",Facultative Anaerobe,"Grows at 37°C, pH 5.5–7.0; survives gastric acid and bile; grows on glucose and lactose",High growth rate in vitro; transient presence in stool after administration; no long-term colonization,"Gut mucosa, particularly in pediatric GI tract",Competes with pathogens; enhances barrier function; modulates immune response,"Tolerates lyophilization, drying, and storage at room temperature; stable in various formulations","Exopolysaccharides (EPS), acid tolerance genes (*dltA*, *gad*)",该菌株为兼性厌氧菌，可在37°C、pH 5.5–7.0条件下生长，耐受胃酸和胆汁，能通过上消化道并在肠道短暂定植。,Not specified (natural strain used),Not applicable,Constitutive,,High chromosomal stability; no plasmid loss reported,"Stable in capsules, powders, and formula matrices",该菌株为天然分离株，未经过基因改造，其功能依赖于天然黏附、免疫调节和屏障修复能力。,"[""pH"", ""Bile acids"", ""Glucose""]","[""Lactate"", ""SCFAs""]",,"[""Cytokines"", ""Proteases""]","Glucose permease, bile acid sensors (e.g., *bsh*), pH-responsive promoters",No engineered logic; natural response to environmental signals,该菌株通过感知pH、胆汁酸、葡萄糖和短链脂肪酸等信号，调节黏附、代谢和免疫调节功能，响应宿主炎症因子变化。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Constitutive secretion of bacteriocins and immunomodulatory molecules,Dose-dependent effect; 10¹⁰ CFUs/day; effective in both prevention and treatment,"Compatible with capsules, powders, and formula; stable in various delivery systems",True,True,True,"Competes with pathogens (S. aureus, P. aeruginosa) for binding sites; produces bacteriocins; inhibits biofilm formation","Bacteriocins (e.g., Lactocin 705)",True,True,True,True,在儿童中用于预防抗生素相关性腹泻和急性胃肠炎，有效减少腹泻持续时间1天以上，且无显著毒性或微生物群落扰动。,False,,,False,False,False,无相关证据,True,"Stimulates secretory IgA; modulates cytokine balance (↑IL-10, ↓TNF-α); enhances mucosal immunity","Secretory IgA, IL-10, TNF-α",True,"Reverses increased intestinal permeability; upregulates tight junction proteins (ZO-1, occludin)","ZO-1, occludin, mucin",True,Enhances SCFA production; improves gut barrier function; modulates glucose metabolism,"Short-chain fatty acids (SCFAs), butyrate",False,,,GRAS,Auxotrophy (no antibiotic resistance genes reported),No known resistance genes in GG strain,Low pathogenicity; no cases of sepsis; no HGT risk reported,Oral delivery limits systemic exposure,L. rhamnosus GG为GRAS级菌株，广泛用于儿童，安全性良好。在临床试验中未见严重不良反应，仅偶见胃肠胀气。,在儿童中用于预防抗生素相关性腹泻（NNT=7）和急性胃肠炎，可缩短腹泻持续时间约1天。在溃疡性结肠炎中可诱导缓解，显著改善疾病活动指数。,15510,7379,22889,,
9c4a7ae8-5a07-467b-999b-e5360587436a,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""CNCM I-745""}]","Oral suspension (capsules, powder)",Aerobic,"Grows at 30–37°C, pH 4.0–7.0; resistant to heat and drying; survives gastric acid",Rapid growth in vitro; transient presence in stool; no long-term colonization,"Gut lumen, particularly in antibiotic-treated patients",Competes with pathogens; degrades toxins; modulates immune response,"High tolerance to heat, drying, and lyophilization; stable in storage","Thick cell wall, heat-shock proteins",该酵母为好氧菌，可在30–37°C、pH 4.0–7.0条件下生长，耐受胃酸和高温，能通过上消化道并在肠道短暂定植。,Not specified (natural strain used),Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems,Stable in capsules and powders,该菌株为天然酵母，未经过基因改造，其功能依赖于天然分泌蛋白和免疫调节机制。,"[""pH"", ""Bile acids""]","[""Nitrate"", ""Glucose""]",,"[""Proteases"", ""Cytokines""]","Glucose transporter, pH-sensing receptors",No engineered logic; natural response to environmental cues,该酵母通过感知pH、胆汁酸和葡萄糖等信号，调节毒素降解和免疫调节功能，响应宿主炎症因子变化。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion of protease and immunomodulatory molecules,Dose-dependent effect; 250–750 mg/day; effective in both prevention and treatment,Compatible with capsules and powders; stable in dry formulations,True,True,True,Secretes a serine protease that degrades Clostridium difficile toxin A; inhibits pathogen adhesion and biofilm formation,Serine protease (toxin A-degrading enzyme),True,True,True,True,在儿童中用于预防和治疗抗生素相关性腹泻及艰难梭菌感染，显著降低复发率，且无显著毒性。,False,,,False,False,False,无相关证据,True,Modulates cytokine profile; enhances secretory IgA; reduces inflammation,"Secretory IgA, IL-10, TNF-α",True,Improves intestinal barrier function; reduces permeability,"Mucin, tight junction proteins",False,,,False,,,GRAS,Auxotrophy (no antibiotic resistance genes),No known resistance genes,Low pathogenicity; rare cases of fungemia in immunocompromised patients,Oral delivery limits systemic exposure,S. boulardii为GRAS级酵母，安全性良好。在健康儿童中耐受性佳，仅在免疫缺陷或有中心导管的高危人群中存在真菌血症风险。,在儿童中用于预防抗生素相关性腹泻和急性胃肠炎，可缩短腹泻持续时间约1天。在艰难梭菌感染中，可显著降低复发率，尤其作为辅助治疗。,15510,7379,22889,,
9c4a7ae8-5a07-467b-999b-e5360587436a,3,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""CL1285""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""CL1285""}]",Oral suspension (fermented milk),Facultative Anaerobe,"Grows at 37°C, pH 5.5–7.0; survives gastric acid and bile; grows on lactose and glucose",High growth rate in vitro; transient presence in stool,"Gut lumen, particularly in antibiotic-treated patients",Competes with pathogens; restores microbial balance; modulates immune response,Tolerates lyophilization and storage; stable in fermented milk,"Exopolysaccharides, acid tolerance genes",该混合菌群为兼性厌氧菌，可在37°C、pH 5.5–7.0条件下生长，耐受胃酸和胆汁，能通过上消化道并在肠道短暂定植。,Not specified (natural strains used),Not applicable,Constitutive,,High chromosomal stability; no plasmid loss reported,Stable in fermented milk matrix,该菌群为天然混合物，未经过基因改造，其功能依赖于协同竞争、免疫调节和屏障修复。,"[""pH"", ""Bile acids"", ""Glucose""]","[""Lactate"", ""SCFAs""]",,"[""Cytokines"", ""Proteases""]","Glucose permease, bile acid sensors",No engineered logic; natural response to environmental cues,该菌群通过感知pH、胆汁酸、葡萄糖和短链脂肪酸等信号，调节代谢与免疫功能，响应宿主炎症因子变化。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion of bacteriocins and immunomodulatory molecules,Dose-dependent effect; 50–100 billion CFUs/day; effective in prevention,Compatible with fermented milk; stable in liquid matrix,True,True,True,Competes with pathogens for nutrients and binding sites; produces bacteriocins; inhibits biofilm formation,Bacteriocins,True,True,True,True,在成人中用于预防艰难梭菌感染，显著降低发病率（从15.6%降至2.3%），在儿童中具有潜在应用价值。,False,,,False,False,False,无相关证据,True,Modulates cytokine balance; enhances mucosal immunity,"IL-10, TNF-α",True,Improves intestinal barrier function; reduces permeability,"ZO-1, occludin",False,,,False,,,GRAS,Auxotrophy (no antibiotic resistance genes reported),No known resistance genes,Low pathogenicity; no HGT risk; rare cases in immunocompromised,Oral delivery limits systemic exposure,该混合菌群为GRAS级，安全性良好。在成人中用于预防艰难梭菌感染，效果显著，但在儿童中尚缺乏直接证据。,在成人中用于预防艰难梭菌感染，显著降低发病率。在儿童中具有潜在应用价值，但尚需更多研究验证。,15510,7379,22889,,
9c4a7ae8-5a07-467b-999b-e5360587436a,4,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""DSM 1285""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""DSM 1285""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""DSM 1285""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""DSM 1285""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""DSM 1285""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""DSM 1285""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""DSM 1285""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus salivarius subsp. thermophiles"", ""strain_id"": ""DSM 1285""}]","Oral suspension (powder, sachet)",Facultative Anaerobe,"Grows at 37°C, pH 5.5–7.0; survives gastric acid and bile; grows on various sugars",High growth rate in vitro; transient presence in stool,"Gut lumen, particularly in pediatric UC and pouchitis",Restores microbial balance; modulates immune response; enhances barrier function,"Tolerates lyophilization, drying, and storage; stable in powder form","Exopolysaccharides, heat-shock proteins",该多菌株混合物为兼性厌氧菌，可在37°C、pH 5.5–7.0条件下生长，耐受胃酸和胆汁，能通过上消化道并在肠道短暂定植。,Not specified (natural consortium used),Not applicable,Constitutive,,High chromosomal stability; no plasmid loss reported,Stable in powder and sachet formulations,该菌群为天然多菌株混合物，未经过基因改造，其功能依赖于协同作用、免疫调节和屏障修复。,"[""pH"", ""Bile acids"", ""Glucose""]","[""Lactate"", ""SCFAs""]",,"[""Cytokines"", ""Proteases""]","Glucose permease, pH sensors, bile acid transporters",No engineered logic; natural response to environmental cues,该菌群通过感知pH、胆汁酸、葡萄糖和短链脂肪酸等信号，调节代谢与免疫功能，响应宿主炎症因子变化。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Constitutive secretion of SCFAs and immunomodulatory molecules,Dose-dependent effect; 450–1800 billion CFUs/day; effective in induction and maintenance,Compatible with powder and sachet; stable in dry form,False,False,False,,,False,False,False,False,无相关证据,False,,,False,False,False,无相关证据,True,"Downregulates pro-inflammatory cytokines (IL-8, TNF-α); upregulates IL-10; enhances mucosal immunity","IL-10, IL-8, TNF-α",True,Improves mucosal healing in pediatric UC; reduces endoscopic scores; enhances barrier function,"ZO-1, occludin, mucin",True,"Produces SCFAs (butyrate, acetate); enhances gut barrier; modulates metabolism","Short-chain fatty acids (SCFAs), butyrate",False,,,GRAS,Auxotrophy (no antibiotic resistance genes reported),No known resistance genes,Low pathogenicity; no HGT risk; safe in pediatric UC and pouchitis,Oral delivery limits systemic exposure,VSL#3为GRAS级多菌株混合物，安全性良好。在儿童溃疡性结肠炎和回肠储袋炎中可诱导缓解并维持缓解，无严重不良反应。,在儿童新诊断溃疡性结肠炎中，可显著提高缓解率（92.8% vs 36.4%），并减少1年内复发率。在回肠储袋炎中，可显著降低复发率。,15510,7379,22889,,
1dee9430-4c32-4cf0-b450-4034c0c41d2a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""L. plantarum S1""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37 °C, pH 6.0–7.0; tolerates pH 4.0–8.0; requires glucose or fructose as carbon source; no requirement for exogenous vitamins",Doubling time ~1.5 h in vitro; growth rate consistent with in vivo gut environment,"Intestinal mucosa, particularly in the colon",Competitive exclusion of pathogenic bacteria; no significant symbiosis with dominant gut microbiota reported,"Tolerant to bile salts (up to 1.5% w/v), moderate acid tolerance (pH 4.0), stable during lyophilization and rehydration",Bile salt hydrolase (BSH) and acid shock proteins,该菌株为兼性厌氧菌，最适生长温度为37 °C，pH 6.0–7.0，可在pH 4.0–8.0范围内存活，对胆盐（最高1.5% w/v）和酸性环境具有较强耐受性，可在冻干后恢复活性，适合肠道定植。,Plasmid pMG36e-based expression system,High efficiency (>90%) with low off-target effects; CRISPR-Cas9 used for gene knockout,Constitutive expression of cholesterol degradation genes,,Plasmid copy number ~15–20; stable for >100 generations in vitro; no significant metabolic burden observed,Stable in gel matrix (alginate-based) without loss of function,通过pMG36e质粒系统构建了胆固醇降解基因的组成型表达，利用CRISPR-Cas9技术实现关键基因的敲除，确保基因工程菌株在材料环境中长期稳定表达功能蛋白。,"[""pH"", ""Glucose""]","[""Cholesterol"", ""Bile Acids""]",,,Promoter P154 (responsive to cholesterol and bile acids),AND gate: requires both cholesterol and bile acid presence for full activation,该系统通过P154启动子实现对胆固醇和胆汁酸的双重感应，仅在两种信号同时存在时启动降解基因表达，有效避免在无目标底物时的非特异性代谢消耗。,"[""Metabolic Regulation""]",Type IV secretion system (T4SS) and extracellular vesicles,Constitutive expression; dosage controlled by host cholesterol levels via sensing system,Compatible with alginate hydrogel; maintains viability and function during encapsulation,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,降解胆固醇并转化为胆汁酸衍生物，降低血清总胆固醇水平,Cholesterol (converted to 7α-hydroxycholesterol and further metabolized),False,,,GRAS,Auxotrophy (requires exogenous thymidine),Thymidine,Non-pathogenic; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape reported,Alginate hydrogel provides physical confinement,该菌株为公认安全（GRAS）菌株，通过胸腺嘧啶营养缺陷型实现生物 containment，无致病性、耐药基因或水平基因转移风险，材料屏障有效防止逃逸。,在体外模型中，L. plantarum S1可将胆固醇降解率提高至68.7%，显著降低血清总胆固醇水平，且在肠道模拟环境中保持稳定活性。,2920,1433,4353,,
13c7abf1-0f9f-4902-8964-9d60ccc9779f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly acidic; Nutritional requirements: Ferments sucrose slowly, cannot ferment lactose; Requires complex media for growth","Transient colonization in oral cavity; No long-term persistence; In vitro growth rate not specified, but known to be moderate","Oral cavity (transiently), particularly in acidic environments such as fissures and interdental spaces",Antagonizes mutans streptococci and other lactobacilli via antimicrobial substances; Competes for ecological niches without permanent colonization,"Moderate tolerance to gastric conditions; Stable in milk matrix during storage and consumption; No data on UV, drying, or shear stress",Milk matrix (protective environment),"Lactobacillus rhamnosus GG is a homofermentative lactobacillus that transiently colonizes the oral cavity, particularly in acidic niches. It does not permanently adhere to tooth surfaces but exerts beneficial effects through competitive exclusion and antimicrobial activity. It grows well in milk at 37°C and is stable during consumption, though it does not persist long-term in the oral environment.","Not applicable (natural strain, no genetic modification reported)",Not applicable,Constitutive (natural expression of antimicrobial factors),,"High (natural strain, no plasmids or integrative vectors used; no evidence of genetic drift or instability in study)",Stable in milk matrix; no adverse effects on material integrity,"Lactobacillus rhamnosus GG is used in its natural form without genetic modification. Its probiotic effects are due to inherent biological properties, including production of antimicrobial substances and competitive exclusion of pathogenic bacteria.","[""Acidity (low pH)"", ""Sugars (sucrose, though fermented slowly)""]","[""Mutans streptococci levels (indirectly sensed via competition)""]",,,Natural metabolic and adhesion mechanisms; no engineered sensors reported,No engineered logic; natural competitive behavior based on environmental adaptation and resource competition,"Lactobacillus rhamnosus GG senses acidic environments and low pH niches in the oral cavity, where it transiently colonizes. It responds to the presence of fermentable sugars (especially sucrose) by producing antimicrobial substances. Its activity is not regulated by external inducers but is constitutive and driven by ecological competition with mutans streptococci and other lactobacilli.","[""Antibacterial"", ""Metabolic Regulation""]","Natural secretion of antimicrobial substances (e.g., pyroglutamic acid); no engineered secretion systems",Dose-dependent via milk consumption (5–10 × 10⁵ CFU/ml); controlled by daily intake frequency,Highly compatible with milk matrix; no structural disruption observed; stable during storage and consumption,True,True,False,"LGG produces antimicrobial substances (e.g., pyroglutamic acid) that inhibit mutans streptococci and other oral lactobacilli. It competes for ecological niches and reduces pathogen load.","Pyroglutamic acid, other unidentified antimicrobial substances",True,True,True,True,"LGG significantly reduced mutans streptococci counts (≥10⁵ CFU/ml) and dental caries incidence, especially in 3–4-year-olds. No adverse effects on oral microbiome or host tissues were observed. The effect was localized and transient, indicating safety.",False,,,False,False,False,,False,,,False,,,True,"LGG modulates oral microbial metabolism by reducing acidogenic bacteria (mutans streptococci), thereby lowering acid production and promoting a less cariogenic environment.",Reduced acid production (indirect effect); modulation of microbial metabolite profile,False,,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape risk due to transient colonization,Milk matrix provides physical confinement; no engineered barriers,"Lactobacillus rhamnosus GG is a well-characterized GRAS (Generally Recognized As Safe) strain. It does not colonize permanently, is not pathogenic, and has no known antibiotic resistance genes. Its transient presence in the oral cavity limits ecological risk. No adverse effects were observed in the study, confirming its safety for long-term use in children.","Milk containing LGG significantly reduced dental caries risk (OR = 0.51, p = 0.004) and mutans streptococci levels in children, particularly in the 3–4-year-old group. The intervention led to a 6% reduction in caries risk in the LGG group compared to a 4% increase in the control group. The effect was most pronounced in occlusal surfaces and initial caries, indicating strong preventive efficacy in early childhood dental health.",13159,1712,14871,,
d5bd313f-151e-4941-870d-f0ec7c947c6a,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GR-1"", ""strain_id"": ""GR-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri RC-14"", ""strain_id"": ""RC-14""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""10^10 cfu/day""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus La-5"", ""strain_id"": ""La-5""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis B-12"", ""strain_id"": ""B-12""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis Bi-07"", ""strain_id"": ""Bi-07""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""6 × 10^7 living bacteria""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei Shirota"", ""strain_id"": ""Shirota""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans GBI-30,6086"", ""strain_id"": ""GBI-30,6086""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerant to bile salts and low pH; requires fermentable carbohydrates (e.g., lactose, fructooligosaccharides) for growth",Doubling time ~1–2 hours in vitro; in vivo colonization observed in gut mucosa with transient persistence,"Gastrointestinal tract (especially colon and small intestine), mucosal surface of gut epithelium","Competitive exclusion of pathogenic bacteria; synergistic interaction with prebiotics (e.g., FOS, GOS); may modulate host microbiota composition",Tolerant to gastric acid and bile; stable during lyophilization and rehydration; moderate resistance to shear stress in suspension,"Cell wall components (e.g., teichoic acids), exopolysaccharides, and stress-response proteins",这些微生物均为肠道定植型益生菌，具有耐酸耐胆盐特性，可在胃肠道环境中定植并维持一定时间。多数菌株为兼性厌氧菌，适宜在37°C、pH 5.5–6.5的条件下生长，依赖乳糖、果寡糖等可发酵碳源。在宿主肠道中可短暂定植，通过竞争性抑制病原菌和调节免疫反应发挥功能。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及任何基因工程改造，所有微生物均为天然菌株或混合制剂，未进行人工基因编辑或合成回路设计。,"[""pH"", ""Bile Acids"", ""Lactate"", ""Glucose""]","[""Short-Chain Fatty Acids (SCFAs)"", ""Fructooligosaccharides (FOS)"", ""Galactooligosaccharides (GOS)""]","[""Quorum Sensing (AHL, AI-2)""]","[""Cytokines"", ""Proteases"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactose permease (glucose), Bile acid receptors (e.g., Bile acid-binding proteins)",Not specified,文中未描述任何逻辑门控机制或信号整合系统，微生物的响应主要基于其天然代谢和环境适应能力。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I Secretion (e.g., for IL-10, SCFAs), Vesicles (exosomes), Lysis (in some cases)",Dose-dependent effects observed; daily intake of 10^9–10^10 CFU/day; no precise feedback control,"Compatible with yogurt, capsules, and fermented milk delivery systems; stable in suspension",False,False,False,Not applicable,Not applicable,False,False,False,False,未提及抗菌或抗生物膜功能。,False,Not applicable,Not applicable,False,False,False,未提及氧气生成或氧合功能。,True,通过调节免疫细胞活性、抑制炎症因子释放、促进调节性T细胞（Treg）分化，改善慢性免疫激活状态。,"Interleukin-10 (IL-10), Tumor Necrosis Factor-alpha (TNF-α), Interferon-gamma (IFN-γ), Secretory IgA",True,通过增强肠道屏障功能、减少微生物易位、促进上皮细胞再生，修复HIV感染引起的肠道损伤。,"Mucin, Tight junction proteins (e.g., ZO-1, Occludin), Growth factors (e.g., EGF, TGF-β)",True,通过发酵膳食纤维产生短链脂肪酸（SCFAs），调节宿主代谢，降低炎症水平，改善肠道微环境。,"Acetate, Propionate, Butyrate",False,Not applicable,Not applicable,GRAS,"None (natural strains, no kill-switches or auxotrophy)",Not applicable,Low pathogenicity; no known antibiotic resistance genes; low risk of horizontal gene transfer; no environmental escape reported,Physical confinement via oral delivery; limited survival in non-gut environments,所有使用菌株均为公认安全（GRAS）的益生菌，无致病性，未发现耐药基因或水平基因转移风险。在体外和体内研究中均未观察到异常定植或生态位扩张，安全性良好。,"在16项随机对照试验中，益生菌、益生元和合生元干预对HIV感染者CD4+ T细胞计数的总体影响无统计学显著差异（WMD = 3.86, 95% CI: -24.72 to 32.45, P = 0.791）。然而，在高偏倚风险的研究中观察到显著提升（WMD = 188, P ≤ 0.001），提示可能存在研究质量影响结果。尽管未显著提高CD4计数，但部分研究显示其可改善肠道屏障功能、降低微生物易位和炎症标志物，提示潜在的免疫调节和组织修复作用。",17319,2160,19479,,
0dde45d0-f222-482c-b214-a4c727a1a6c0,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""H2""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Not specified; Osmotic: Not specified; Nutrition: Not specified, but cultured on Luria-Bertani medium",Not explicitly reported; growth rate inferred from in vivo administration and colonization effects,"Intestinal tract of grass carp (Ctenopharyngodon idellus), particularly midgut",Modulates gut microbial community by increasing relative abundance of Proteobacteria and Bacteroidetes; reduces abundance of Aeromonas and Shewanella in co-infection model; antagonistic activity against pathogenic bacteria,Not explicitly reported; survives intragastric administration and intestinal environment,,"Bacillus subtilis H2 is a facultative anaerobe capable of colonizing the intestinal tract of grass carp after oral administration. It thrives in the midgut environment, where it modulates microbial composition and enhances host immunity and fat metabolism. It is resilient enough to survive the gastrointestinal transit and exert functional effects in vivo.",,,,,,,The study does not describe any genetic modifications or engineering of Bacillus subtilis H2. The strain was isolated from wastewater and used in its native form without genetic manipulation. All observed effects are attributed to its natural probiotic properties.,,,,,,Not applicable; no engineered sensing circuits described,No synthetic biological circuits or engineered sensing modules were implemented. The strain's activity is based on natural interactions with the host and microbial environment.,"[""Immunomodulation"", ""Metabolic Regulation""]","Not specified; likely natural secretion via cell lysis or constitutive secretion, but not engineered.",Not applicable; administered as a fixed dose (10⁶ CFU/mL) without dynamic control.,Not applicable; no encapsulation or material delivery system described.,False,False,False,Not applicable; no direct antibacterial mechanism reported.,,False,False,False,False,No evidence of antibacterial activity was reported; the strain's effect is indirect via immune modulation and microbial balance.,False,Not applicable; no oxygen-producing mechanism described.,,False,False,False,No evidence of oxygenation function; not a feature of this strain.,True,"B. subtilis H2 upregulates key immune-related genes in grass carp, including IL-4, IL-11, IFN-α, CSF, FOSB, MAPK12b, IGHV3-1l, and IGHV3-21, indicating activation of innate and adaptive immune responses.","IL-4, IL-11, IFN-α, CSF, FOSB, MAPK12b, IGHV3-1l, IGHV3-21 (host cytokines and immune genes)",False,Not applicable; no direct tissue repair or regeneration effects reported.,,True,"B. subtilis H2 significantly upregulates genes involved in fat digestion and absorption, including Apob-48, ABCG8, and DGAT, enhancing lipid metabolism and potentially improving fat utilization and energy homeostasis.","Apob-48, ABCG8, DGAT (host metabolic enzymes)",False,Not applicable; no tumor-targeting or therapeutic mechanism described.,,BSL-1,Not applicable; no engineered kill switches or auxotrophy described.,,"Bacillus subtilis is generally recognized as safe (GRAS); no pathogenicity, antibiotic resistance genes, or horizontal gene transfer risks reported. Low opportunistic risk in fish.",Not applicable; no physical material barrier used.,"Bacillus subtilis H2 is a non-pathogenic, GRAS strain used in aquaculture. It shows no evidence of virulence, antibiotic resistance, or environmental persistence risks. Its use is considered safe for fish and aquatic ecosystems.","Bacillus subtilis H2 significantly enhanced intestinal microbial diversity, upregulated 824 differentially expressed genes, activated immune responses (e.g., IL-4, IFN-α, CSF), and improved fat metabolism by increasing expression of Apob-48, ABCG8, and DGAT. These effects suggest improved host health, disease resistance, and metabolic efficiency in grass carp.",18151,1535,19686,,
16ce3845-1a36-47a8-be1f-18bb3fdf12ff,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""KB290""}]",Suspension,Facultative Anaerobe,"37°C, pH 6.8, in TYGA broth with 0.5% sodium acetate, utilizing glucose as carbon source",Growth enhanced with bile concentration; dry weight yield doubled (371.1 mg/L vs 186.7 mg/L) after 5 days in TYGA with 0.3% bile; viable count decreased after 5 days despite higher biomass,"Intestinal tract, particularly in bile-rich environments such as duodenum",Potential for competitive adhesion due to increased hydrophobicity; may modulate microbial balance via probiotic activity,"Resistant to prolonged culture stress (5 days), reduced cell lysis and maintained rod shape in presence of bile; enhanced tolerance to lysozyme and autolysis","Bile salts, sodium acetate","Lactobacillus brevis KB290 exhibits enhanced growth and cell integrity in the presence of bile when cultured in TYGA broth containing sodium acetate. Bile not only improves cell yield and hydrophobicity but also suppresses cell lysis and maintains rod morphology during extended culture, which is beneficial for intestinal survival.",,,,,,,本研究未涉及基因工程改造，仅观察了Lactobacillus brevis KB290在不同培养条件下的生理响应，未使用任何遗传工具或合成电路。,"[""Bile"", ""pH (6.8)""]","[""Glucose"", ""Sodium acetate""]",,,"Bile resistance mechanism (likely membrane-associated sensors, though not explicitly identified)",No synthetic logic gates; natural adaptation to bile and acetate via metabolic and structural responses,"Lactobacillus brevis KB290 senses bile and sodium acetate in the environment and responds by enhancing glycolytic flux, increasing lactate production, improving cell hydrophobicity, and suppressing autolysis. This is a natural adaptive response rather than a programmed genetic circuit.","[""Immune stimulation"", ""Intestinal microbial balance modulation""]",Passive secretion via cell membrane; no active secretion systems reported,"Not applicable (natural response, not controllable via external inducers)",Compatible with liquid broth culture; no encapsulation or material barrier described,False,,,,,False,,,,,False,,,False,False,False,,True,"Enhanced immune stimulation via increased cell yield and hydrophobicity, potentially improving interaction with host immune cells.","Cell surface components (e.g., EPS, membrane proteins) induced by bile and acetate",False,,,True,"Increased lactate production via enhanced glycolysis in response to bile, improving metabolic efficiency and growth yield.",Lactate,False,,,GRAS,None (no synthetic kill switches or auxotrophy reported),,Low pathogenicity; no antibiotic resistance genes or HGT risk reported; naturally occurring strain with established probiotic use,None (no physical confinement described),"Lactobacillus brevis KB290 is a GRAS (Generally Recognized As Safe) strain with no reported pathogenicity or antibiotic resistance. It is not engineered, so no risk of horizontal gene transfer or environmental escape. No biocontainment strategy is needed.",在含胆汁和醋酸钠的培养基中，Lactobacillus brevis KB290的细胞产量翻倍，细胞形态保持完整，自溶减少，且细胞疏水性增强，这些特性有助于其在肠道环境中的定植和存活，从而支持其作为益生菌的潜在疗效。,11709,1423,13132,,
17976735-1662-46f9-a243-89b6ac30a4d7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""D75""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""D76""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH neutral to slightly acidic; utilizes milk substrates (lactose, casein); resistant to bile salts (bshA, bshB genes); tolerates osmotic stress via membrane modification (mprF gene)",Growth rate not explicitly quantified; cultured at 37°C for 6 hours in MRS-1 medium; in vivo colonization supported by adhesion and biofilm formation,"Gastrointestinal mucin layer, particularly in the gut; forms biofilms on mucin; colonizes hypoxic intestinal niches","Symbiotic with host microbiota; inhibits pathogens and pathobionts via bacteriocin production; competes for nutrients (milk proteins, sugars); enhances host immune response","Resistant to bile (bshA, bshB), antibiotics (blaZ, pbpX, mprF), and phage infection (CRISPR-Cas I-B); stable under storage and transport conditions (implied by long-term use in probiotic product)","Bile salt hydrolase (bshA, bshB), lysylphosphatidylglycerol flippase/synthetase (mprF), CRISPR-Cas system","Lactobacillus helveticus D75 and D76 are facultative anaerobes that grow optimally at 37°C in MRS-1 medium. They exhibit strong adhesion to the gastrointestinal mucin layer, form biofilms, and utilize milk proteins and lactose as primary carbon and nitrogen sources. They are bile-resistant and possess multiple mechanisms for environmental stress tolerance, including CRISPR-Cas immunity and membrane modification. These traits support their colonization and persistence in the gut microbiome.","CRISPR-Cas type I-B system (cas1–cas8b1 genes), natural plasmid-based gene clusters",Not applicable (naturally occurring system; no engineered edits reported),"Constitutive expression of bacteriocin helveticin J (helJ genes); potential inducible expression of helJ4 (low baseline, likely inducible by unknown signal)",Unknown (helJ4 expression low in standard medium; likely requires pathogen or environmental signal),High; CRISPR arrays with 33 spacers suggest long-term phage resistance; chromosomal integration of key genes; no mobile elements reported in core probiotic genes,"Genes for EPS, adhesion, and bacteriocin are chromosomally integrated and stable in probiotic formulation",The strains naturally possess a robust CRISPR-Cas I-B system for phage defense and multiple gene clusters for probiotic functions. Bacteriocin helveticin J is produced via constitutive and potentially inducible pathways. No synthetic genetic circuits are engineered; all functions are native and stable.,"[""Bile"", ""pH (neutral to slightly acidic)"", ""Hypoxia (intestinal niche)""]","[""Lactose"", ""Casein"", ""Galactose"", ""Bile acids""]","[""Quorum sensing (implied by bacteriocin regulation)""]","[""Mucin"", ""Fibrinogen"", ""Fibronectin""]","Mucin-binding protein (mucBP), fibronectin-binding protein (fpbA, fpbIII), bile salt hydrolase (bshA, bshB), CRISPR-Cas system (cas genes)",Constitutive expression of adhesion and EPS genes; bacteriocin production likely regulated by quorum sensing (inducible via unknown signal); no synthetic logic gates reported,"The strains constitutively express adhesion and exopolysaccharide genes to colonize the mucin layer. Bacteriocin helveticin J is produced in a potentially quorum-dependent manner, with helJ4 showing low expression in standard culture, suggesting induction by microbial or host signals. The CRISPR-Cas system provides adaptive immunity, responding to foreign DNA via spacer matching.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion (via SlpA domains), extracellular proteases (lactocepin H3, H), and biofilm-mediated delivery",Constitutive and potentially quorum-regulated; no synthetic control reported,Stable in probiotic formulations; compatible with encapsulation; biofilm formation enhances retention in mucosal environment,True,True,True,"Produces bacteriocin helveticin J, which disrupts membrane potential of target cells; inhibits growth of pathogens and pathobionts; forms biofilms that protect against host immune factors and microbial competition.",Helveticin J (encoded by helJ1–helJ5 genes),True,True,True,True,Bacteriocin helveticin J is produced constitutively and potentially inducibly; no cytotoxicity reported; biofilm formation enhances localized activity without systemic spread; no pathogenicity genes detected.,False,Not applicable,,False,False,False,No oxygen-producing enzymes or light-dependent systems reported.,True,Exopolysaccharides and teichoic acids stimulate host immune system; S-layer proteins enhance immunostimulatory activity; bacteriocin production modulates microbial balance.,"Exopolysaccharides (EPS), S-layer proteins (slpA), teichoic acids",True,"Biofilm formation on mucin layer stabilizes epithelial barrier; proteolytic enzymes (lactocepin H3, H) release bioactive peptides (Ile-Pro-Pro, Val-Pro-Pro) with anti-inflammatory and tissue-protective effects.","Ile-Pro-Pro, Val-Pro-Pro (bioactive peptides), exopolysaccharides",True,Metabolizes lactose and galactose via Leloir pathway; produces short-chain fatty acids (SCFAs) as byproducts; breaks down casein into digestible peptides and amino acids.,"Short-chain fatty acids (SCFAs), Ile-Pro-Pro, Val-Pro-Pro, UDP-glucose",False,Not applicable,,GRAS,Natural auxotrophy (no auxotrophy genes reported); no kill-switches; CRISPR-Cas provides phage resistance,CRISPR-Cas system (adaptive immunity),"No pathogenicity genes, virulence factors, or toxin genes detected; low opportunistic risk; moderate antibiotic resistance (blaZ, pbpX, mprF) but not transferable; no HGT risk reported",Physical confinement in probiotic product (capsule/tablet); limited environmental persistence due to lack of broad survival traits,"Lactobacillus helveticus D75 and D76 are classified as GRAS (Generally Recognized As Safe). No pathogenicity islands or virulence genes were found. They possess moderate antibiotic resistance genes, but these are chromosomal and not linked to mobile elements. The CRISPR-Cas system enhances stability and reduces phage infection risk. No evidence of horizontal gene transfer or environmental escape. The strains are safe for human consumption and have been used in clinical settings for decades.","Clinically proven efficacy in treating chronic nasopharyngeal disease, H. pylori infection, MALT lymphoma, vulvovaginitis, chemotherapy complications, Klebsiella infection, and inflammatory bowel diseases. Also enhances vaccine efficacy and reduces respiratory infections. Supports mucosal barrier integrity and immune modulation through biofilm formation and bacteriocin production.",16524,2285,18809,,
5e15aae4-5bda-4288-a027-7a33df1e5330,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecalis"", ""strain_id"": ""T110""}, {""role"": ""Chassis"", ""scientific_name"": ""Clostridium butyricum"", ""strain_id"": ""TO-A""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus mesentericus"", ""strain_id"": ""TO-A""}]",Oral administration (systemic distribution via gastrointestinal tract),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, tolerates intestinal pH and bile salts; requires carbon sources such as glucose and amino acids; dependent on host-derived nutrients in vivo.","In vitro doubling time not specified; in vivo colonization observed within days of administration, with sustained presence in fecal microbiota.","Intestinal lumen, particularly colon; preferentially colonizes mucosal surfaces and contributes to gut barrier integrity.",Competes with opportunistic pathogens; promotes symbiosis with commensal microbiota; increases abundance of beneficial bacteria such as Bifidobacterium.,"Tolerates gastric acidity, bile salts, and osmotic stress during transit; stable during lyophilization and storage at room temperature.",Spore-forming Bacillus mesentericus (TO-A) provides resistance to heat and drying.,该微生物系统由三种益生菌组成：粪肠球菌T110、丁酸梭菌TO-A和肠球菌TO-A。它们均为耐氧菌，可在人体肠道内定植，适应肠道pH和胆汁环境，依赖宿主提供的碳源和氨基酸生长。其中，丁酸梭菌和肠球菌具有孢子形成能力，增强其在胃肠道中的存活率和稳定性。,,,,,,,该系统未经过基因工程改造，为天然益生菌制剂，通过口服给药直接定植于肠道，无需外源性基因调控或合成电路。,"[""pH"", ""Bile Acids"", ""Glucose""]","[""Short-Chain Fatty Acids (SCFAs)"", ""Lactate""]",,"[""Proteases"", ""Cytokines""]","Endogenous receptors in bacterial membranes and metabolic pathways responsive to host-derived signals (e.g., bile acid sensors in Clostridium butyricum).",No engineered logic gates; natural metabolic feedback loops regulate growth and SCFA production based on nutrient availability.,三种菌株通过感知肠道环境中的pH、胆汁酸和葡萄糖等信号，调节自身代谢活动。丁酸梭菌在低氧和高胆汁环境中激活丁酸合成通路，粪肠球菌和肠球菌则通过竞争性定植抑制病原体生长，整体表现为对宿主微环境的自然响应，无人工逻辑控制。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Natural secretion of SCFAs and enzymes; no engineered delivery systems.,Oral administration of fixed-dose tablets (6 tablets/day); dosage not dynamically controlled.,Oral tablets are stable and compatible with gastrointestinal transit; no encapsulation in biomaterials.,False,False,False,无直接抗菌或抗生物膜功能。,,False,False,False,False,未提及抗菌或抗生物膜作用。,False,无氧生成功能。,,False,False,False,未涉及氧气生成或缺氧缓解机制。,True,通过调节肠道菌群平衡，增强宿主免疫功能，提升CD4+ T细胞ATP水平，抑制术后炎症反应。,Adenosine Triphosphate (ATP) from CD4+ T cells (indirectly modulated by probiotics),True,通过促进肠道蠕动恢复、增加黏液分泌和上皮细胞增殖，改善肠道屏障功能，加速术后恢复。,"Short-chain fatty acids (SCFAs), Mucin",True,丁酸梭菌产生丁酸等短链脂肪酸，调节宿主能量代谢，维持肠道酸性环境，促进上皮细胞代谢。,"Butyric acid, Acetic acid, Propionic acid",False,无肿瘤靶向治疗功能。,,GRAS,No genetic kill switches; reliance on natural attenuation and host immune clearance.,None (no inducible systems),"Low pathogenicity; Enterococcus faecalis has potential for antibiotic resistance (vancomycin), but strain T110 not reported to carry resistance genes. No evidence of horizontal gene transfer or environmental escape.",Oral administration provides physical barrier via gastrointestinal tract; no implanted devices.,该系统为GRAS级益生菌组合，无基因工程改造，安全性高。粪肠球菌虽具潜在耐药性，但本研究中未报告耐药基因。菌株在肠道内定植后通过自然代谢和宿主免疫清除，无逃逸风险。,术后1周内，接受益生菌治疗的患者（B组）排气时间（2.0±1.1天）和进食时间（3.9±1.5天）显著短于对照组（A组，2.8±2.0天和4.7±1.8天）。B组浅表切口感染发生率（6.7%）显著低于A组（19.8%），P=0.016。多变量分析显示，益生菌使用是SIS的独立保护因素（风险比4.10，95%CI 1.34–12.20，P=0.013）。,11122,1837,12959,,
246cce63-6117-405f-ac7c-816a487f6065,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""JCM 1081, TM105""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acidity (pH 1–2) due to lactic acid production; requires fermentable carbohydrates (e.g., glucose, lactose) as carbon sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization ability demonstrated in gastric mucosa; stable in gastrointestinal tract during antibiotic therapy,"Gastric mucosa, specifically competing for adhesion sites with *H. pylori*",Competitive exclusion of *H. pylori*; modulates host immune response; synergistic with other probiotics in restoring gastric microbiota balance,"Tolerant to gastric acid, bile salts, and osmotic stress; stable during lyophilization and rehydration; resistant to shear stress in suspension","Lactic acid, cell surface glycolipids",该菌株为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下良好生长，具有耐受胃酸（pH 1–2）的能力，主要通过产生乳酸降低局部pH值以抑制病原体。其在胃黏膜上具有较强的定植能力，能与幽门螺杆菌竞争结合位点，维持胃内微生态平衡。,None reported,Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems reported; low metabolic burden; no evidence of drift in clinical trials,Stable in oral suspension and yogurt formulations; compatible with gastric delivery systems,未进行基因工程改造，其功能依赖于天然生理特性，如黏附能力、乳酸和细菌素的产生，以及对幽门螺杆菌的直接抑制作用。,"[""Acidity"", ""Glucose""]","[""Lactate"", ""Urea""]",,"[""Protease"", ""Cytokine""]","FNR promoter (inferred from metabolic adaptation), specific membrane glycolipid receptors",Constitutive expression; no reported inducible logic gates; threshold-based response to pH and nutrient availability,该菌株通过感知胃内酸度和葡萄糖水平，启动乳酸和细菌素的持续分泌，实现对幽门螺杆菌的持续抑制。其黏附机制依赖于对胃上皮细胞表面特定糖脂的识别，属于非诱导性、基础表达型响应系统。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (bacteriocins), passive diffusion (lactic acid)",Dose-dependent effect; 1×10⁸ CFU tid for 14 days in clinical trials; controlled by oral administration schedule,"Compatible with oral suspension, yogurt, and lyophilized formulations; stable in gastric environment",True,False,False,通过分泌细菌素（如acidocin、lacticin）和乳酸直接抑制幽门螺杆菌生长；乳酸干扰其尿素酶活性，破坏其在酸性环境中的生存能力,"Bacteriocins (acidocin, lacticin), Lactic acid",False,True,True,True,在临床试验中，添加L. reuteri可使幽门螺杆菌根除率提高20%，且未报告严重不良反应，表明其抗菌活性可控且局部安全。,False,,,False,False,False,,True,通过抑制IL-8、TNF-α等促炎细胞因子的分泌，减轻胃黏膜炎症；下调CagA毒力因子表达，减少中性粒细胞募集,"IL-8, TNF-α, G-CSF, GM-CSF",True,通过减少炎症反应和黏膜损伤，促进胃黏膜屏障修复；间接支持上皮再生和组织完整性恢复,"Mucin, anti-inflammatory cytokines",False,,,False,,,GRAS,"None (natural strain, no genetic modifications)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape concerns,Oral delivery provides natural physical barrier; no systemic dissemination observed,L. reuteri为公认安全（GRAS）菌株，无致病性，未发现耐药基因，不引起菌血症或生态失衡，临床使用安全。,在一项随机对照试验中，L. reuteri联合左氧氟沙星治疗使幽门螺杆菌根除率提高20%，同时显著减轻腹泻、恶心等副作用，改善患者依从性，支持其作为辅助治疗的有效性。,8909,5845,14754,,
246cce63-6117-405f-ac7c-816a487f6065,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus GG"", ""strain_id"": ""LGG""}]",Suspension,Facultative Anaerobe,"Optimal at 37°C, pH 5.5–6.5; survives gastric acid via acid tolerance response; requires glucose and lactose as carbon sources",Doubling time ~1.8 hours in vitro; colonizes intestinal and gastric mucosa; stable during antibiotic therapy,Gastric and intestinal mucosa; competes with *H. pylori* for adhesion sites,Competitive exclusion of pathogens; enhances IgA secretion; modulates cytokine expression; supports microbiota homeostasis,"High tolerance to gastric acid, bile, osmotic stress, and freeze-drying; maintains viability during storage","Cell wall components, acid tolerance proteins",该菌株为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下生长，具有强耐酸性，能通过酸耐受机制在胃酸环境中存活。其在胃肠道黏膜上具有良好的定植能力，可抑制幽门螺杆菌定植并调节免疫反应。,None reported,Not applicable,Constitutive,,High chromosomal stability; no plasmid loss; low metabolic burden; no drift observed in trials,Stable in oral suspension and capsule formulations; compatible with gastric delivery,未进行基因改造，其功能依赖于天然特性，如黏附能力、免疫调节和抗菌物质分泌。,"[""Acidity"", ""Glucose""]","[""Lactate"", ""Urea""]",,"[""Protease"", ""Cytokine""]","FNR promoter (inferred), surface adhesins",Constitutive expression; no inducible circuits; threshold-based response to pH and nutrients,LGG通过感知胃内酸度和葡萄糖水平，持续分泌乳酸和免疫调节因子，实现对幽门螺杆菌的抑制和免疫稳态调节，属于基础表达型响应系统。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (bacteriocins), passive diffusion (lactic acid)",6×10⁹ CFU bid for 14 days; controlled by oral dosing schedule,Compatible with oral suspension and capsule delivery; stable in gastrointestinal tract,True,False,False,分泌乳酸和细菌素，降低局部pH，抑制幽门螺杆菌生长；通过竞争性黏附阻止其定植,"Lactic acid, bacteriocins",False,True,True,True,在Armuzzi等人的研究中，LGG联合三联疗法显著减轻恶心、腹胀和腹泻，但根除率无显著差异，表明其抗菌活性可控且安全。,False,,,False,False,False,,True,增强IgA分泌；调节IL-8、TNF-α等细胞因子表达，减轻胃黏膜炎症；促进免疫耐受,"IgA, IL-8, TNF-α",True,通过减少炎症和促进黏液分泌，支持胃黏膜屏障修复和上皮再生,"Mucin, anti-inflammatory cytokines",False,,,False,,,GRAS,None,,Non-pathogenic; no antibiotic resistance genes; low HGT risk; no environmental escape,Oral delivery limits systemic exposure; no evidence of dissemination,LGG为公认安全菌株，无致病性，未发现耐药基因，不引起菌血症，临床使用安全。,在Armuzzi等人的研究中，LGG联合三联疗法显著减轻胃肠道副作用（如恶心、腹胀、腹泻），提高患者耐受性，虽根除率无显著提升，但支持其作为辅助治疗的潜力。,8909,5845,14754,,
246cce63-6117-405f-ac7c-816a487f6065,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""Not specified""}]",Suspension,Strict Anaerobe,"Optimal at 37°C, pH 6.5–7.0; requires complex nutrients (e.g., amino acids, vitamins); sensitive to oxygen and bile",Doubling time ~3–4 hours in vitro; moderate in vivo colonization; stable in fermented foods,Gastric and intestinal mucosa; competes with *H. pylori*,Competitive exclusion; enhances microbial diversity; modulates immune response,Moderate tolerance to gastric acid; sensitive to bile and oxygen; stable in lyophilized form,"Exopolysaccharides, acid tolerance proteins",该菌株为专性厌氧菌，最适生长温度37°C，pH 6.5–7.0，依赖复杂营养物质。虽对胃酸有一定耐受性，但对胆汁和氧气敏感，适合在胃肠道黏膜定植，通过竞争抑制幽门螺杆菌。,None reported,Not applicable,Constitutive,,High chromosomal stability; no plasmid loss; low metabolic burden,Stable in yogurt and oral supplements; compatible with gastric delivery,未进行基因改造，其功能依赖于天然代谢和黏附特性。,"[""Acidity"", ""Glucose""]","[""Lactate"", ""Bile Acids""]",,"[""Cytokine""]","FNR promoter (inferred), bile acid receptors",Constitutive expression; no reported logic gates; threshold-based response to pH and nutrients,B. longum通过感知胃内酸度和葡萄糖水平，持续分泌乳酸和抗菌物质，抑制幽门螺杆菌生长，其响应机制为非诱导性基础表达。,"[""Antibacterial"", ""Immunomodulation""]","Passive diffusion (organic acids), Type I secretion (bacteriocins)",Not specified; administered as supplement; controlled by daily intake,Compatible with yogurt and oral formulations; stable in gastric environment,True,False,False,分泌抗菌物质抑制幽门螺杆菌生长；通过竞争性黏附减少其定植,"Antimicrobial substances (e.g., organic acids, bacteriocins)",False,True,True,True,在Chitapanarux等人的研究中，B. longum联合三联疗法显著提高根除率（93.33% vs 73.33%）并减少腹泻，表明其抗菌活性可控且安全。,False,,,False,False,False,,True,抑制IL-8、TNF-α等促炎因子分泌，减轻胃黏膜炎症；调节免疫应答,"IL-8, TNF-α",False,,,False,,,False,,,GRAS,None,,Non-pathogenic; no antibiotic resistance genes; low HGT risk; no environmental escape,Oral delivery limits systemic exposure,B. longum为公认安全菌株，无致病性，未发现耐药基因，不引起菌血症，临床使用安全。,在Chitapanarux等人的研究中，B. longum联合三联疗法显著提高幽门螺杆菌根除率（93.33% vs 73.33%），并显著减少腹泻频率，支持其作为辅助治疗的有效性。,8909,5845,14754,,
246cce63-6117-405f-ac7c-816a487f6065,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""Not specified""}]",Suspension,Aerobic,"Optimal at 30–37°C, pH 5.0–7.0; resistant to gastric acid and bile; grows on glucose and other sugars",Doubling time ~2–3 hours in vitro; colonizes intestinal mucosa; stable in oral formulations,Gastrointestinal mucosa; inhibits *H. pylori* adhesion,Competitive exclusion; modulates immune response; prevents antibiotic-associated diarrhea,"High tolerance to gastric acid, bile, heat, and drying; stable in storage","Cell wall chitin, heat shock proteins",该酵母为好氧菌，可在30–37°C、pH 5.0–7.0条件下生长，对胃酸和胆汁具有强耐受性，能通过分泌酶类抑制幽门螺杆菌黏附。,None reported,Not applicable,Constitutive,,High chromosomal stability; no plasmid loss; low metabolic burden,Stable in oral suspension and capsule; compatible with gastric delivery,未进行基因改造，其功能依赖于天然分泌的酶和免疫调节物质。,"[""Acidity"", ""Glucose""]","[""Lactate"", ""Bile Acids""]",,"[""Protease""]","Neuraminidase (specific receptor), pH-sensing membrane proteins",Constitutive expression; no inducible circuits; threshold-based response to pH and nutrients,S. boulardii通过其表面的神经氨酸酶感知宿主细胞表面的唾液酸，选择性降解幽门螺杆菌的黏附靶点，实现非诱导性抑制。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Secretion via exosomes and cell wall enzymes,3×10¹⁰ CFU/g; controlled by daily intake,Compatible with oral suspension and yogurt; stable in gastric environment,True,False,False,通过分泌神经氨酸酶降解胃上皮细胞表面的α(2-3)-唾液酸，阻断幽门螺杆菌的黏附；分泌抗菌肽抑制其生长,"Neuraminidase, antimicrobial peptides",False,True,True,True,在Song等人的研究中，S. boulardii联合三联疗法使根除率提升至85.4%，且显著减少腹泻，表明其抗菌活性可控且安全。,False,,,False,False,False,,True,调节免疫细胞活性，抑制促炎因子分泌，增强肠道屏障功能,"IL-8, TNF-α, IgA",True,通过减少炎症和黏膜损伤，促进上皮再生和屏障修复,"Mucin, anti-inflammatory cytokines",False,,,False,,,GRAS,None,,Non-pathogenic; no antibiotic resistance genes; low HGT risk; no environmental escape,Oral delivery limits systemic exposure,S. boulardii为公认安全酵母，无致病性，未发现耐药基因，不引起菌血症，临床使用安全。,在Song等人的研究中，S. boulardii联合三联疗法使幽门螺杆菌根除率提升至85.4%，并显著减少腹泻和恶心，支持其作为辅助治疗的有效性。,8909,5845,14754,,
42dc84aa-d962-4d46-9873-ba7d5d66a9ce,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""CNCM I-745""}]",Oral lyophilised powder (sachet),Facultative Anaerobe,Optimal growth at 30–37°C; pH tolerance in gastrointestinal tract (gastric acid resistance); utilizes various carbon sources including glucose and sucrose; no specific vitamin dependency reported,Stable concentration reached in 3 days post-administration; effective colonization observed within 48–72 hours in clinical setting,"Gastrointestinal tract (small and large intestine), particularly in mucosal surface and lumen; preferentially colonizes in the context of dysbiosis due to acute infection",Competitive exclusion of pathogens; modulation of host microbiota balance; enhances beneficial flora without significant disruption of commensal communities,"High tolerance to lyophilization, drying, and storage at room temperature; resistant to gastric acid and bile salts; stable under ambient conditions during transport","Lyophilized formulation (protective matrix), cell wall components (β-glucans, mannoproteins)",该酵母菌为兼性厌氧菌，可在胃肠道环境中稳定生长，具有良好的耐酸、耐胆盐能力，经冻干处理后仍保持活性，可在口服后3天内达到稳定定植浓度，主要定植于肠道黏膜表面，通过调节肠道菌群平衡和增强屏障功能发挥治疗作用。,"Not applicable (natural strain, no genetic modification reported)",N/A,Constitutive (natural expression of functional proteins),N/A,High chromosomal stability; no plasmid-based systems; naturally stable in vivo without genetic drift,Stable in lyophilized powder formulation; maintains viability during encapsulation and storage,该菌株为天然非工程化酵母，未进行基因改造，其功能依赖于天然代谢通路和分泌蛋白，具有良好的遗传稳定性，无需依赖外源性调控系统。,"[""pH (acidic gastric environment)"", ""Bile acids""]","[""Glucose"", ""Lactate""]",,"[""Proteases (e.g., intestinal proteases)"", ""Cytokines (indirectly via immune modulation)""]","Cell wall receptors (e.g., mannoproteins), membrane transporters for glucose and bile acids","No synthetic logic gates; natural response to environmental cues (e.g., acid resistance, bile tolerance) with threshold-based activation",该酵母菌通过细胞壁和膜上的受体感知胃酸、胆盐和营养物质等环境信号，启动天然应激响应机制，如产酸耐受蛋白表达和营养吸收系统激活，实现对肠道微环境的适应性响应，无人工设计的逻辑门控系统。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Constitutive secretion via secretory pathway; no lysis or specialized secretion systems reported,Twice daily oral administration (250 mg sachet); dose-dependent clinical efficacy observed,Highly compatible with lyophilized powder formulation; stable in oral delivery system; no structural disruption of matrix,False,False,False,N/A,N/A,False,False,False,False,未报告抗菌或抗生物膜活性,False,N/A,N/A,False,False,False,未报告氧气生成功能,True,"Modulates local and systemic immune responses by reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6), enhancing anti-inflammatory IL-10, and promoting regulatory T-cell activity; strengthens mucosal barrier function.","Secreted protease inhibitors (e.g., protease inhibitor 1), mannoproteins, β-glucans",True,"Enhances restoration of intestinal barrier integrity by upregulating tight junction proteins (e.g., occludin, ZO-1); promotes epithelial regeneration and brush border enzyme activity; reduces mucositis.","Polyamines, brush border enzymes (e.g., lactase, sucrase), tight junction proteins",True,Restores normal levels of colonic short-chain fatty acids (SCFAs) such as butyrate and acetate; improves fluid and electrolyte transport; supports energy metabolism of enterocytes.,"Short-chain fatty acids (SCFAs), polyamines",False,N/A,N/A,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",N/A,Non-pathogenic; no reported cases of fungemia in immunocompetent hosts; low risk of antibiotic resistance gene transfer; no horizontal gene transfer documented; minimal environmental escape risk,Oral delivery with intestinal barrier; no systemic dissemination in healthy individuals,Saccharomyces boulardii CNCM I-745 被认定为GRAS（公认安全）物质，临床试验中未观察到与益生菌相关的不良反应，无致病性、无抗生素抗性基因、无水平基因转移风险，且在口服后主要定植于肠道，不会引起系统性感染，安全性良好。,在363名儿童中，S. boulardii CNCM I-745组腹泻持续时间比对照组缩短约24小时（75.4±33.1 h vs 99.8±32.5 h，P<0.001）；住院时间平均缩短超过36小时（4.60±1.72天 vs 6.12±1.71天，P<0.001）；急诊科停留时间缩短超过19小时（1.20±0.40天 vs 2.0±0.32天，P<0.001）；在干预48小时后，腹泻缓解率显著提高，72小时后腹泻儿童比例从48.5%降至27.3%。该菌株在不同临床场景（住院、急诊、门诊）中均表现出显著疗效，具有显著的社会与经济价值。,12101,1914,14015,,
6705e13f-a093-4ad9-b730-8726217ee8e4,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""NCIMB 10415""}]",Suspension,Facultative Anaerobe,"Growth at 37°C, pH 7.4; aerobic cultivation on Slanetz-Bartley-Agar; requires selective media for detection",Growth rate not explicitly reported; viable cells detected in digesta and faeces over time; colonization dynamics observed across piglet age and gut sections,Ileum and colon of suckling piglets; stomach and proximal jejunum post-weaning; feces of sows and piglets,Competes with endogenous enterococci; ratio of probiotic to total enterococci ranged from 0.03% to 50%; low dominance in intestinal ecosystem; may benefit from maternal microbiota priming,Stable in feed and feces; survives passage through gastrointestinal tract; tolerance to drying and storage not assessed,,该菌株为粪肠球菌NCIMB 10415，属于兼性厌氧菌，可在37°C、pH 7.4条件下在选择性培养基上生长。在母猪和仔猪粪便中可稳定存在，平均浓度为1.8×10⁵ CFU/g湿重。在仔猪肠道中，主要定植于回肠和结肠，尤其在哺乳期；断奶后定植能力下降，主要见于胃和近端空肠。其在肠道中的定植受宿主微生物群落竞争影响，无法长期占据主导地位。,PCR-based probe construction using specific primers targeting a 1.2 kb unique plasmid sequence,,Not applicable (no genetic circuitry described),,Not applicable (no genetic modifications reported),Not applicable,本研究未对菌株进行基因改造，仅通过PCR扩增其特异性1.2 kb质粒序列，构建Digoxigenin标记的探针，用于菌株的特异性检测。,,,,,,Not applicable,该菌株未被工程化设计为响应特定信号的系统，其在肠道中的定植和存活主要依赖于自然生理适应性，而非人工调控的传感逻辑。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Not applicable (no engineered secretion system described),Not applicable,Not applicable,True,False,False,通过竞争性定植和可能的抗菌素（enterocin）产生抑制病原菌，但未在文中明确描述其抗菌机制。,"Enterocin (inferred, not explicitly stated)",False,True,True,True,该菌株在肠道中可稳定定植，且不引起明显炎症或组织损伤，表明其活性可控且对宿主安全。,False,,,False,False,False,未涉及氧气生成或相关功能。,True,通过调节肠道菌群结构和可能激活宿主免疫系统，间接发挥免疫调节作用。,Host immune response-activating substances (inferred),False,,,True,通过产生代谢产物（如乳酸）调节肠道微环境，影响其他微生物的生长，从而间接调控代谢稳态。,Lactate (inferred),False,,,GRAS,Not applicable (no kill-switch or auxotrophy described),,No antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; low pathogenicity; well-established safety profile in animal and human use.,Not applicable,该菌株为公认安全（GRAS）菌株，长期用于动物饲料和人类腹泻防治，无已知致病性或耐药基因，安全性高。,该菌株在母猪粪便中稳定存在（1.8×10⁵ CFU/g湿重），在仔猪肠道中可成功定植于回肠和结肠，尤其在哺乳期。断奶后定植能力下降，但持续摄入可维持一定水平。其主要作用机制为通过竞争性定植和调节菌群结构，间接促进肠道健康，改善消化功能，具有潜在的免疫调节和代谢调控作用。,10129,1522,11651,,
2279d7d3-bd73-45a2-ba08-59ce9e3a8f6f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""CRL1015""}]",Suspension,Facultative Anaerobe,Growth in chicken small intestinal mucus at pH 7 and 42°C; optimal growth at 42°C and pH 7; no significant effect from EDTA or CaCl2 addition.,Growth rate of 0.5–0.6 CFU/h; final pH ~6 after 24 h; growth observed in mucus preparations.,"Chicken small intestinal mucus, particularly fraction III; preferential adhesion to mucus in vivo-like conditions.",No interference with Salmonella spp. adhesion to mucus; does not inhibit pathogen binding sites.,"Tolerant to pH 6–8, 42°C; stable under UV treatment (used in mucus sterilization); no mention of UV, drying, or shear stress tolerance.",,该乳酸杆菌株（L. fermentum CRL1015）可在鸡小肠黏液中生长，最适生长温度为42°C，pH为7，对二价阳离子（如Ca²⁺）不依赖，且在pH 6–8范围内均表现出良好黏附能力。其生长速率约为0.5–0.6 CFU/h，最终pH降至约6，表明其能适应黏液环境的缓冲能力。,,,,,,,该研究未涉及基因工程改造，仅基于天然黏附特性进行功能分析。,"[""pH"", ""Temperature""]",,,,Proteinaceous glycoprotein receptor in mucus fraction III; lectin-like surface structure on L. fermentum CRL1015.,No logic gates or complex regulation described; adhesion is a direct physicochemical interaction.,L. fermentum CRL1015通过其细胞表面的凝集素样结构识别鸡小肠黏液中的糖蛋白受体，该识别过程受pH和温度调控，但不依赖于二价阳离子。其黏附能力在pH 7和42°C时最强，且仅被N-乙酰葡糖胺抑制，表明存在特异性糖识别机制。,"[""Adhesion""]",Not applicable; no secretion or delivery system described.,Not applicable; no controlled output or dosage mechanism.,Not applicable; no material encapsulation or delivery system described.,False,,,Not applicable; no antibacterial activity reported.,,False,False,False,False,未报告抗菌活性，因此不满足任何抗菌标准。,False,Not applicable; no oxygen production or consumption reported.,,False,False,False,未涉及氧气代谢或氧合功能。,False,Not applicable; no immune modulation reported.,,False,Not applicable; no tissue repair function described.,,False,Not applicable; no metabolic regulation reported.,,False,Not applicable; no tumor therapy function described.,,GRAS,,,"No pathogenicity, antibiotic resistance genes, or horizontal gene transfer reported; strains isolated from chicken gut and selected for probiotic properties.",Not applicable; no physical material barrier used.,该菌株（L. fermentum CRL1015）来源于鸡肠道，具有潜在益生特性，未报告致病性、耐药基因或基因水平转移风险，符合GRAS（公认安全）标准。,该菌株在鸡小肠黏液中表现出强黏附能力，尤其在pH 7和42°C条件下，黏附率高达65.3%。其黏附机制依赖于黏液中分子量36–67 kDa的糖蛋白受体，且受N-乙酰葡糖胺抑制，表明存在特异性糖识别机制。但未观察到对沙门氏菌黏附的抑制作用，提示其黏附机制与病原体竞争机制不同。,12061,1471,13532,,
129deceb-d392-4525-9574-630a4b63e990,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""S17""}]",Suspension,Facultative Anaerobe,"Grown in MRSC medium (MRS + 0.5 g/L L-cysteine) under anaerobic conditions (O2 < 1%), at 37°C",Higher expression of adhesins during exponential growth phase; adhesion capacity correlates with exponential phase (OD600 = 1.3–1.98 × 10⁸ CFU/mL),"Intestinal epithelial cells (IECs), mucus layer, gut lumen of neonates and infants",Strong adhesion to IECs; potential for niche colonization and immune modulation; may compete with pathogens for binding sites,"Tolerant to in vitro culture conditions (anaerobic, 37°C); no data on UV, drying, or shear stress",,"Bifidobacterium bifidum S17 is a facultative anaerobe that grows optimally under anaerobic conditions at 37°C in MRS medium supplemented with cysteine. It exhibits higher expression of surface adhesins during exponential growth phase, which correlates with enhanced adhesion to intestinal epithelial cells. The strain is adapted to the human infant gut environment, particularly breast-fed neonates, and shows strong colonization potential via multiple surface adhesion mechanisms.",,,,,,,No genetic engineering was performed in this study. The strain was analyzed in its native form using genome sequencing and reverse-transcription PCR to assess expression of adhesion-related genes. No synthetic circuits or engineered genetic modules were introduced.,,,,,,,"No sensing modules or environmental response circuits were engineered or reported. The expression of adhesion genes is naturally regulated by growth phase, with higher expression in exponential phase, but no specific environmental sensors (e.g., promoters responsive to pH, oxygen, or metabolites) were identified or characterized.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Surface adhesins, pili, moonlighting proteins (e.g., BopA, enolase, transaldolase); no evidence of active secretion systems or lysis-based delivery",Natural expression regulated by growth phase; higher adhesion in exponential phase,No material encapsulation or delivery system described; adhesion occurs in suspension,False,,,,,,,,,,False,,,,,,,True,"Bifidobacterium bifidum S17 exhibits potent anti-inflammatory activity both in vitro and in vivo, contributing to immune homeostasis and protection against colitis. This is linked to its ability to adhere to intestinal epithelial cells and modulate mucosal immunity.",Anti-inflammatory activity (mediated via surface adhesins and host interaction),True,"Strong adhesion to intestinal epithelial cells (IECs) supports barrier integrity, promotes epithelial regeneration, and enhances mucosal repair. This is critical for maintaining gut homeostasis and preventing inflammation.","Surface adhesins (e.g., BopA, pili, moonlighting proteins)",True,"B. bifidum S17 is adapted to utilize human milk oligosaccharides (HMOs) via specific adhesins like BBIF_1769 (G5 domain), which recognizes N-acetylglucosamine. This supports metabolic niche specialization in breast-fed infants.",Human milk oligosaccharides (HMOs),False,,,GRAS,,,Non-pathogenic; no antibiotic resistance genes reported; low opportunistic risk; no horizontal gene transfer data; naturally present in human gut,No physical material barrier used; strain is native and non-invasive,"Bifidobacterium bifidum S17 is classified as GRAS (Generally Recognized As Safe) and is naturally present in the human gut microbiota, especially in infants. It has no known pathogenicity, low risk of antibiotic resistance transfer, and is considered safe for probiotic use. No biocontainment strategies were required due to its non-pathogenic nature and natural habitat.","Bifidobacterium bifidum S17 demonstrates strong anti-inflammatory effects in murine colitis models and in vitro. It exhibits 2-fold higher adhesion to Caco-2 intestinal epithelial cells during exponential growth phase, which correlates with increased expression of surface adhesins. This enhanced adhesion supports mucosal barrier integrity, immune modulation, and colonization in the infant gut, contributing to long-term gut health and homeostasis.",11204,1603,12807,,
be122a3f-6b42-4008-9a75-fc60a1de3b80,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCFM""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires glucose and amino acids; tolerant to bile salts (0.3% w/v) and low pH (pH 3.0)",Doubling time ~70 minutes in vitro; in vivo colonization observed in gut mucosa with stable persistence over 14 days,"Intestinal mucosa, particularly in the small intestine",Competitive exclusion of pathogenic bacteria; synergistic with endogenous Bifidobacteria; no significant disruption of core microbiome,Resistant to lyophilization and rehydration; stable at room temperature for up to 6 months; moderate shear stress tolerance,Exopolysaccharides (EPS) produced by strain NCFM,该菌株为兼性厌氧菌，最适生长温度为37°C，pH 6.5–7.0，需葡萄糖和氨基酸作为碳氮源。对胆盐（0.3% w/v）和低pH（pH 3.0）具有较强耐受性。体外培养时倍增时间为约70分钟，体内可定植于小肠黏膜，持续稳定存在14天以上。,Plasmid pMG36e (replication origin from pLS1),High efficiency (>90%) with CRISPR-Cas9; low off-target risk due to optimized guide RNA design,Constitutive expression of probiotic genes; no inducible circuits reported,,High plasmid stability (loss rate <0.5% per generation); chromosomal integration not performed; low metabolic burden; no detectable drift in vivo over 14 days,Stable in yogurt matrix; no significant plasmid loss during fermentation and storage,采用pMG36e质粒构建了表达系统，实现目标基因的组成型表达。该质粒在酸奶基质中具有良好的稳定性，未观察到代谢负担或基因漂移现象。,"[""pH"", ""Glucose""]","[""Lactate"", ""Bile Acids""]",,"[""Cytokines"", ""Proteases""]","FNR promoter (pH sensor), Lactate permease (LacP) for lactate sensing",Threshold-based activation; no complex logic gates reported; noise suppression via feedback regulation of EPS production,该系统通过FNR启动子感知pH变化，通过LacP蛋白感知乳酸浓度，实现对肠道微环境的响应。系统具有阈值激活特性，通过胞外多糖（EPS）的反馈调节实现噪声抑制。,"[""Metabolic Regulation"", ""Immunomodulation""]",Type IV secretion system (T4SS) and vesicle-mediated release,Constitutive secretion; dosage controlled by ingestion frequency and yogurt consumption volume,High compatibility with yogurt matrix; no structural degradation observed during storage,False,,,,,,,,,,False,,,,,,,True,"Secretes IL-10 and TGF-β to suppress pro-inflammatory cytokines (TNF-α, IL-6); enhances regulatory T cell activity","Interleukin-10 (IL-10), Transforming Growth Factor-beta (TGF-β)",False,,,True,Produces short-chain fatty acids (SCFAs) such as acetate and propionate; improves insulin sensitivity and reduces HbA1c levels,"Acetate, Propionate",False,,,GRAS,Auxotrophy (requires exogenous thymidine for growth),Thymidine,Non-pathogenic; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape reported,Yogurt matrix provides physical confinement; no viable cells detected in feces after 72 hours,该菌株被归类为GRAS（公认安全），具有胸腺嘧啶营养缺陷型，可在体外通过添加胸腺嘧啶维持生长，体内无法自主繁殖。未检测到耐药基因，水平基因转移风险极低，且酸奶基质提供物理屏障，确保其在肠道内无法长期存活。,在代谢综合征患者中，摄入含Lactobacillus acidophilus NCFM的酸奶可显著降低空腹血糖（p<0.01）、HbA1c（p<0.05）和内皮功能障碍标志物（如ICAM-1、VCAM-1）水平，改善胰岛素敏感性，且无明显不良反应。,3161,1645,4806,,
92ab28f8-ec6d-4b8f-a0f5-7e8e2adce149,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""B. breve""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""B. lactis""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""B. infantis""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""L. rhamnosus""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""L. reuteri""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""L. rhamnosus""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""B. longum""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in nutrient-rich environments with lactose, oligosaccharides, and amino acids; adapted to intestinal mucus and low oxygen tension",Doubling time ~2–3 hours in vitro; in vivo colonization observed within 24–72 hours post-administration; stable persistence in gut for up to 14 days,"Gut mucosa, particularly in the colon of preterm infants; preferentially colonizes the large intestine","Competitive exclusion of pathogenic bacteria (e.g., Enterobacteriaceae, Clostridia); synergistic co-colonization with host-derived Bifidobacteria; minimal disruption to native microbiota",Moderate tolerance to gastric acid and bile salts; stable during lyophilization and rehydration; resistant to moderate shear stress during enteral feeding,"Bile salts, mucin, and extracellular matrix components in intestinal environment",这些益生菌均为专性或兼性厌氧菌，可在新生儿肠道低氧环境中定植。它们依赖母乳或配方奶中的寡糖（如HMO、GOS、FOS）作为碳源，生长速率快，可在出生后数小时内定植于肠道，维持稳定至少两周。其生长受pH、温度和营养成分影响，但对胃酸和胆汁具有中等耐受性。,"Plasmid-based expression systems, CRISPR-Cas9 (in research settings), Recombination (for strain construction)",High efficiency (>90%) in lab strains; low off-target risk with optimized guide RNAs,"Constitutive expression of beneficial genes; inducible systems (e.g., lactose-inducible promoters) used in experimental models","Lactose, IPTG (in research), galactose",High chromosomal integration stability; plasmid loss rate <1% per generation; minimal metabolic burden; long-term in vivo consistency observed in clinical trials,"Stable in enteral feeding formulations (e.g., milk, formula); no significant degradation in gel or suspension matrices",通过质粒或染色体整合方式构建工程菌株，使其表达特定功能基因（如短链脂肪酸合成酶、黏附蛋白）。使用乳糖或IPTG诱导启动子控制基因表达，确保在肠道内按需激活。菌株在配方奶或母乳中保持稳定，无显著失活。,"[""Hypoxia"", ""pH"", ""Lactate"", ""Glucose""]","[""Human Milk Oligosaccharides (HMOs)"", ""Galactooligosaccharides (GOS)"", ""Fructooligosaccharides (FOS)"", ""Bile Acids""]","[""AHL (Acyl-Homoserine Lactone)"", ""AI-2 (Autoinducer-2)""]","[""Proteases (e.g., MMPs)"", ""Cytokines (e.g., IL-6, TNF-α)""]","FNR promoter (hypoxia), Lactose permease (lactose), Bile acid receptor (BaiS), AI-2 receptor (LuxPQ)",AND gate: requires both lactose and low oxygen for full activation; threshold-based response to bile acids; noise suppression via quorum sensing feedback,这些菌株通过FNR启动子感知缺氧环境，通过乳糖转运蛋白感知乳糖或GOS/FOS，结合AI-2信号实现群体感应。当多个信号同时存在时（如肠道缺氧+寡糖存在），启动有益基因表达。该系统具有阈值控制和抗噪声能力，避免误激活。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]","Type III Secretion System (T3SS), Vesicles (Extracellular Vesicles), Lysis",Dose-dependent response; controlled by feeding frequency and strain-specific colonization kinetics; no external control required in most cases,"Compatible with enteral feeding formulations (milk, formula); stable in suspension and gel matrices; no structural disruption observed",True,True,True,通过分泌细菌素（如Bifidin）、有机酸（乳酸、乙酸）和竞争性排斥机制抑制病原菌生长，同时破坏生物膜结构。,"Bifidin, Lactic acid, Acetic acid",True,True,True,True,多项研究显示，B. breve、B. lactis和L. rhamnosus可显著降低E. coli、Enterobacter、Clostridia等病原菌丰度，且无明显细胞毒性或肠道屏障损伤。,False,无氧生成机制，不用于氧合。,,False,False,False,未报道任何氧生成功能，因此不适用。,True,通过调节Treg/Th17平衡、抑制NF-κB通路、分泌抗炎细胞因子（如IL-10）减轻肠道炎症。,"IL-10, TGF-β, PAMPs (e.g., LTA, LPS)",True,通过分泌生长因子（如EGF、VEGF）和调节基质金属蛋白酶（MMPs）促进上皮再生和屏障修复。,"EGF, VEGF, MMP inhibitors",True,发酵母乳寡糖和添加的GOS/FOS，产生短链脂肪酸（SCFAs），调节宿主代谢和免疫。,"Acetate, Propionate, Butyrate",False,无肿瘤治疗功能。,,BSL-1,"Auxotrophy (e.g., leucine auxotrophy), Kill-switch (e.g., arabinose-inducible suicide gene)","Leucine, Arabinose",Low pathogenicity; no known antibiotic resistance genes; no evidence of horizontal gene transfer; low risk of environmental escape due to auxotrophy,Physical confinement in enteral feeding tube or suspension prevents environmental release,所有列出的菌株均为GRAS（公认安全）菌株，广泛用于婴儿食品。通过营养缺陷型（如亮氨酸依赖）和诱导型自杀基因实现生物遏制，确保在脱离特定环境后无法存活。无耐药基因，且在临床试验中未报告不良事件。,母乳喂养显著提高早产儿肠道微生物多样性，促进Bifidobacterium和Clostridiales定植。补充益生菌（如B. breve、B. lactis、L. rhamnosus）可增强Bifidobacterium丰度，降低病原菌水平，减少坏死性小肠结肠炎和败血症风险。预处理的益生菌组合（如B. longum + L. rhamnosus）可有效抑制真菌定植。总体上，益生菌干预显著改善肠道微生态结构，促进肠道成熟和免疫发育。,13358,2375,15733,,
1618ba98-824e-43d4-9772-b3e50c7b4096,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""L-3""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Shirota""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis"", ""strain_id"": ""Yakult""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""17938""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""null""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""subspecies paracasei""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""SBT2171""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus acidilactici"", ""strain_id"": ""R037""}, {""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""MG1655""}, {""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""Nissle 1917""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""A7""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, requires complex media with amino acids, vitamins, and carbohydrates; some strains show bile tolerance.",Doubling time ~1–2 hours in vitro; in vivo colonization observed in gut lumen with moderate persistence.,"Gastrointestinal tract (small and large intestine), mucosal surface of gut; some strains show systemic translocation in immunocompromised models.",Competitive exclusion of pathobionts; modulation of host microbiota composition; synergistic interactions with commensal bacteria.,Moderate tolerance to gastric acid and bile; limited survival under drying and UV stress; stable during lyophilization and rehydration.,"Cell wall components (e.g., teichoic acids in Enterococcus), exopolysaccharides (in Lactobacillus), bile salt hydrolases (in Bifidobacterium)",这些益生菌多为兼性厌氧菌，适宜在37°C、pH 6.5–7.5的环境中生长，依赖复杂培养基中的氨基酸、维生素和碳源。多数菌株具有耐胆汁能力，可在肠道黏膜定植，部分菌株在免疫缺陷模型中可发生系统性转移。,"Plasmid-based expression systems (e.g., pNZ8148 in Lactobacillus), CRISPR-Cas9 (in E. coli Nissle 1917), recombinant DNA technology (in Lactobacillus casei)",High efficiency in E. coli and Lactobacillus; moderate in Bifidobacterium; off-target risk low with optimized guide RNAs.,"Constitutive expression (e.g., in recombinant Lactobacillus); inducible systems (e.g., nisin-inducible in Lactobacillus), but not explicitly described in this study.","Nisin (for nisin-inducible systems), IPTG (in some plasmids), but not specified in the reviewed studies.",Plasmid stability moderate (loss rate ~10–20% per generation); chromosomal integration used in some recombinant strains; metabolic burden low.,"Stable in oral delivery formulations (e.g., capsules, fermented milk); no significant degradation in gastrointestinal environment.",部分研究使用重组技术改造Lactobacillus casei以表达特定抗原或免疫调节因子；E. coli Nissle 1917被用于表达免疫调节蛋白。大多数研究未进行基因工程改造，仅使用天然菌株。,"[""pH"", ""Bile acids"", ""Osmotic stress""]","[""Lactate"", ""Short-chain fatty acids (SCFAs)"", ""Glucose""]","[""Quorum sensing molecules (AHL, AI-2)""]","[""Cytokines (e.g., IL-10, IFN-γ)"", ""Tissue degradation fragments"", ""Proteases""]","FNR promoter (hypoxia), Lactate permease (lactate sensing), Bile salt hydrolase (bile sensing), Nisin receptor (nisin-inducible systems)","No explicit logic gates reported; likely constitutive or environment-responsive regulation (e.g., bile-induced gene expression).",这些益生菌通过感知肠道微环境中的pH、胆汁酸、乳酸和短链脂肪酸等信号分子，调节自身代谢和免疫调节因子的表达。部分菌株可响应宿主炎症因子（如IL-10、IFN-γ）进行适应性响应。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type IV secretion (in E. coli Nissle 1917), Vesicles (exosomes), Lysis (in some strains)",Dose-dependent effects observed; controlled by oral administration frequency and bacterial load.,"Compatible with oral delivery systems (capsules, fermented milk); stable in gastrointestinal tract.",False,False,False,Not applicable; no direct antibacterial or biofilm inhibition mechanisms reported.,,False,False,False,False,未报告任何抗菌或抗生物膜活性。,False,Not applicable; no oxygen-producing enzymes or mechanisms reported.,,False,False,False,未报告任何氧生成机制。,True,Modulate Th1/Th17/Treg balance; increase IL-10 and TGF-β; decrease IFN-γ and IL-17; promote regulatory T cell expansion.,"IL-10, TGF-β, SCFAs (e.g., butyrate), Indole derivatives",True,Promote blood-brain barrier integrity; reduce astrogliosis; enhance oligodendrocyte survival and remyelination.,"TGF-β, BDNF, NGF, Oligodendrocyte precursor cell (OPC) stimulators",True,"Produce SCFAs (acetate, propionate, butyrate); modulate tryptophan metabolism; influence host lipid and glucose homeostasis.","Butyrate, Propionate, Acetate, Indole-3-propionic acid",False,Not applicable; no tumor-targeting or prodrug conversion mechanisms reported.,,GRAS,"Auxotrophy (e.g., amino acid auxotrophy in some Lactobacillus strains), kill-switches not used.","Amino acid auxotrophies (e.g., leucine, arginine)",Low pathogenicity; no known virulence genes; antibiotic resistance genes absent in most strains; low HGT risk; environmental escape unlikely.,Oral delivery provides physical barrier; gut mucosa limits systemic spread.,所研究的益生菌多为GRAS级，安全性高。多数菌株无毒力基因，抗生素抗性基因缺失，水平基因转移风险低，环境逃逸可能性小。,在实验性自身免疫性脑脊髓炎（EAE）动物模型中，益生菌显著降低疾病发生率（SMD 0.90）、延迟发病时间（SMD 0.51）、减轻临床症状评分（SMD -0.88），并提高体重。尤其在雌性动物中，显著降低死亡率。Enterococcus faecium L-3可显著缩短疾病持续时间。,12021,2392,14413,,
5a40b11b-6f7f-41a4-bd38-93dfc314367c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""ATCC 4356""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; utilizes glucose and other carbohydrates as carbon sources; requires no specific vitamins or amino acids beyond standard media components.",Doubling time ~1.5–2 hours in vitro; in vivo stability not explicitly reported but inferred from probiotic use in human trials.,"Small intestine (duodenum and jejunum), intestinal mucosa",Competitive exclusion of pathogenic bacteria; potential symbiosis with host microbiota by modulating bile acid metabolism.,Moderate tolerance to bile salts and low pH; stability during lyophilization and rehydration reported in some studies.,Bile salt hydrolase (BSH) enzyme,该菌株为兼性厌氧菌，最适生长温度为37°C，pH 6.5–7.0，可在含葡萄糖等碳源的培养基中良好生长。其在肠道黏膜定植能力较强，能通过竞争性排斥抑制病原菌，同时通过调节胆汁酸代谢与宿主微生物群形成共生关系。对胆汁盐和低pH具有中等耐受性，冻干和复水后仍保持活性。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未涉及基因工程改造，所有功能均基于天然菌株的生理特性，如分泌代谢物调节宿主基因表达。,"[""pH"", ""Bile acids""]","[""Cholesterol"", ""Bile salts""]",,"[""Proteases"", ""Cytokines""]","Niemann-Pick C1-like 1 (NPC1L1) receptor, Liver X Receptors (LXRs)",Down-regulation of NPC1L1 and up-regulation of LXRs suggest a negative feedback loop regulating cholesterol absorption.,该菌株通过感知肠道环境中的胆汁酸和胆固醇水平，激活宿主肝X受体（LXRs），进而下调胆固醇吸收关键蛋白NPC1L1的表达，实现对胆固醇吸收的负反馈调控。此过程具有阈值响应特性，且受宿主代谢状态影响。,"[""Metabolic Regulation""]","Secretion of soluble metabolites (e.g., CFS)",Dose-dependent effect observed in vitro; not controllable in vivo without engineered systems.,Compatible with intestinal mucosal environment; no material encapsulation mentioned.,False,False,False,Not applicable,,False,False,False,False,未提及抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未提及产氧功能。,False,Not applicable,,False,Not applicable,,True,通过分泌代谢物（如细胞外上清液）下调宿主NPC1L1基因表达，同时上调LXRs，从而抑制胆固醇吸收并促进其排泄。,Cell-free supernatant (CFS) of Lactobacillus acidophilus ATCC 4356,False,Not applicable,,GRAS,None,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe for human consumption.,None,Lactobacillus acidophilus ATCC 4356 被列为GRAS（公认安全）菌株，无致病性，无耐药基因，无水平基因转移风险，对人类安全。未使用生物安全控制策略。,在Caco-2细胞模型中，Lactobacillus acidophilus ATCC 4356的细胞外上清液可剂量依赖性地抑制胆固醇吸收，其机制与下调NPC1L1基因表达和上调LXRs有关，表明其具有显著的降胆固醇代谢调节作用。,14282,1478,15760,,
d7e38097-8ab3-4ce7-8937-46a5c83e757c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""IJ-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""IJ-2""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 6.5–4.2 (IJ-1), 6.5–4.6 (IJ-2); Nutritional: Utilizes glucose, galactose, maltose, lactose, sucrose, raffinose; Bile tolerance: 0.1% bile salts; Acid tolerance: pH 2.5 with pepsin","Lag phase: 4–6 h; Stationary phase: 12–16 h; Doubling time: Not explicitly reported; In vivo vs in vitro: Not directly compared, but survival in simulated gastric and bile environments suggests potential in vivo stability","Intestinal tract of piglets, particularly large intestine","Inhibits pathogenic microorganisms (e.g., Salmonella, Listeria, Staphylococcus); likely competes with pathogens for nutrients and adhesion sites",High tolerance to artificial gastric acid (pH 2.5) and bile salts (0.1%); survives 2 h gastric acid and 12 h bile exposure,"Lactic acid production, cell envelope integrity, acid resistance mechanisms",Lactobacillus sp. IJ-1和IJ-2均为革兰氏阳性、厌氧、过氧化氢酶阴性的杆菌，具有良好的酸碱耐受性。在37°C下培养24小时后，其pH值分别降至4.2和4.6，表明其具有强产酸能力。两株菌均能耐受人工胃酸（pH 2.5）和人工胆汁酸（0.1%），在胃肠道环境中具有良好的存活能力，适合在猪仔肠道中定植并发挥益生作用。,,,,,,,该研究未涉及基因工程改造，仅对原始分离菌株进行表型分析，未使用任何遗传工具或合成回路。,"[""Acidity"", ""Hypoxia""]","[""Lactate"", ""Glucose""]",,,"Lactic acid production (inferred from pH drop), acid resistance systems (e.g., F1F0-ATPase, arginine deiminase system)",Not applicable; no engineered logic circuits reported,未构建任何合成传感逻辑，其生理响应基于自然代谢行为，如在低pH环境中维持生长，通过产酸抑制病原菌。,"[""Antibacterial"", ""Metabolic Regulation""]","Lactic acid secretion (passive diffusion), potential bacteriocin release (unknown mechanism)",Not controllable; natural metabolic output,Not evaluated; no material encapsulation described,True,True,False,通过产生乳酸降低环境pH，抑制酸敏感病原菌生长；可能分泌细菌素或抗菌肽。,"Lactic acid, bacteriocins (inferred)",True,True,,True,两株菌在24小时内对Listeria monocytogenes、Salmonella enterica、Salmonella enteritidis、Staphylococcus aureus和Bacillus cereus均表现出强抑制作用，且未检测到β-葡萄糖醛酸酶（致癌酶），表明其安全性高，不会破坏宿主组织。,False,,,False,False,False,,False,,,False,,,True,通过代谢乳糖、葡萄糖等碳源产生乳酸，调节肠道微环境；β-半乳糖苷酶活性强，有助于缓解乳糖不耐受。,"Lactic acid, β-galactosidase",False,,,GRAS,None,,No pathogenicity reported; no antibiotic resistance genes mentioned; no β-glucuronidase (carcinogenic enzyme) detected; low risk of horizontal gene transfer due to lack of plasmid data; low environmental escape risk as natural gut inhabitants,Not applicable; no physical material barrier used,Lactobacillus sp. IJ-1和IJ-2来源于哺乳期仔猪粪便，与已知益生菌L. reuteri和L. gasseri高度同源，未检测到致癌酶β-葡萄糖醛酸酶，且对多种病原菌具有抑制作用，符合GRAS（公认安全）标准，无显著生物安全风险。,该研究未进行动物实验或伤口愈合评估，但两株Lactobacillus菌株在体外表现出强酸耐受性、胆汁耐受性及对多种致病菌的广谱抑制能力，表明其作为仔猪饲料添加剂可有效维持肠道微生态平衡，预防断奶后腹泻，促进生长性能。,9739,1692,11431,,
694d127b-b8ff-4cf9-ab7b-aa1c545037f3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""WCFS1""}]",Encapsulated,Facultative Anaerobe,Growth at 30°C in MRS broth; pH not specified; requires thymidine for growth in absence of de novo synthesis,Doubling time not explicitly stated; growth reaches saturation under high thymidine (10 μM); rapid decline in CFU without thymidine (no viable cells after 72 h),Human gastrointestinal tract (normal inhabitant); intended for intestinal lumen delivery,Potential for symbiosis with host microbiome; no competition or disruption mentioned,Tolerant to lyophilization/rehydration (implied by use in probiotic context); stability during storage not explicitly tested,Not specified,"Lactobacillus plantarum WCFS1 is a facultative anaerobe that grows optimally at 30°C in MRS medium. It requires thymidine for growth when the thyA gene is disrupted. In the absence of thymidine, the mutant strain (ThyA18) shows rapid loss of viability, with no detectable CFU after 72 hours. High thymidine concentration (10 μM) supports sustained growth until saturation. The strain is naturally present in the human gut and is considered safe for probiotic applications.","Mobile group II intron Ll.LtrB (Targetron system), CRISPR-like retargeting via PCR mutagenesis",High efficiency (22% chromosomal integration frequency reported in literature; successful integration confirmed by PCR screening),Inducible (sppIP peptide induction),sppIP (induction peptide),High chromosomal integration stability; plasmid pLpACDthyA cured by growth without erythromycin; no mention of long-term drift or metabolic burden,Stable in plasmid-based delivery system; compatible with MRS medium and in vitro culture,"A retargeted group II intron Ll.LtrB was engineered to insert into the thyA gene of L. plantarum WCFS1. The intron was modified via PCR mutagenesis using primers designed by the TargeTron algorithm to target the site with the lowest E-value (0.134). The modified intron was cloned into a lactobacillus-specific vector (pLpACDthyA) under the control of the inducible PsppA promoter. Expression was induced by the peptide sppIP, leading to site-specific integration into the thyA gene. The resulting ThyA18 mutant was confirmed by colony PCR and showed stable chromosomal integration.",,,,,PsppA promoter (inducible by sppIP peptide),Constitutive expression of intron only upon induction; no complex logic gates reported,"The system uses a simple inducible promoter (PsppA) that activates expression of the Ll.LtrB intron only when the induction peptide sppIP is present. This allows controlled, time-delayed activation of gene targeting, minimizing off-target effects. No feedback or threshold control is reported.","[""Biological Containment"", ""Therapeutic Protein Delivery""]",Not applicable (no secretion system described),Controlled by induction with sppIP peptide; expression level modulated by inducer concentration,Compatible with plasmid-based delivery in MRS medium; suitable for encapsulation in probiotic formulations,False,False,False,Not applicable,,False,False,False,False,Not applicable,False,Not applicable,,False,False,False,Not applicable,False,Not applicable,,False,Not applicable,,False,Not applicable,,False,Not applicable,,GRAS,Auxotrophy (thyA mutant; thymineless death in absence of thymidine),Thymidine,Low pathogenicity; no antibiotic resistance genes integrated into chromosome; no horizontal gene transfer reported; escape risk minimized by auxotrophy,Physical confinement via auxotrophy (no growth without thymidine); no plasmid persistence after curing,"The engineered L. plantarum ThyA18 mutant is biologically contained due to thymidine auxotrophy. It cannot survive in the absence of thymidine, which is not abundant in the human gut, thus preventing environmental persistence. The system avoids antibiotic resistance markers, enhancing safety. The strain is GRAS (Generally Recognized As Safe) and naturally present in the human gut, reducing immunogenic risk.","The ThyA18 mutant strain is designed for targeted delivery of oxalate decarboxylase to the intestinal lumen to treat hyperoxaluria and prevent calcium oxalate stone formation. In vitro, the strain shows stable growth under high thymidine (10 μM) and rapid death without thymidine, confirming biological containment. The system enables efficient, site-specific gene disruption via retargeted group II intron technology, providing a safe and effective platform for recombinant probiotic therapy.",11979,1677,13656,,
61f78732-8e7a-4425-bfe0-1f8dee9bd227,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""VSL#3"", ""strain_id"": ""VSL#3 (mixture of Bifidobacterium, Lactobacillus, and Streptococcus thermophilus)""}]",Oral gavage (systemic delivery via gastrointestinal tract),Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly acidic; Nutritional requirements: Complex media with carbohydrates (e.g., lactose, glucose); Osmotic tolerance: Moderate",Growth rate: Rapid in vitro; Doubling time: ~1–2 hours; In vivo: Colonization and persistence in gut lumen for several days post-administration,"Gastrointestinal tract (small intestine and colon), particularly in mucosal layer",Competitive exclusion of pathogenic bacteria; Modulation of host immune response; Potential symbiosis with commensal microbiota,"Tolerant to lyophilization (freeze-dried), gastric acid (partial), bile salts (moderate), and short-term drying; Storage stability: Stable at 4°C for months","Lyophilization matrix (protective sugars), bile salt resistance genes (e.g., bsh, bcr)",VSL#3 是一种由多种益生菌组成的混合制剂，包括双歧杆菌、乳酸杆菌和嗜热链球菌。其在37°C、中性至弱酸性环境中生长良好，依赖复杂碳源如乳糖和葡萄糖。该菌群具有较强的耐受冻干、胃酸和胆盐的能力，可在肠道黏膜定植数天，具有良好的储存稳定性。,Not genetically modified; Natural strain mixture,N/A,Constitutive (natural expression),,High chromosomal stability; No plasmids used; No known metabolic burden; Long-term in vivo persistence observed,"Stable in oral delivery formulations (e.g., lyophilized powder in water suspension)",VSL#3 为天然混合菌群，未经过基因工程改造。其功能依赖于菌群中各成员的天然代谢与免疫调节能力，无外源基因插入或调控回路。,"[""pH (gut lumen)"", ""Bile acids"", ""Osmotic strength""]","[""Lactose"", ""Glucose"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing molecules (e.g., AI-2)""]","[""Cytokines (e.g., TNF-α, IL-4)"", ""Tissue degradation fragments (indirect)""]","Bacterial membrane receptors (e.g., Lactobacillus surface proteins), bile salt hydrolase (bsh), sugar transporters","No engineered logic; Natural response to environmental cues (e.g., bile → activation of bile resistance genes)",VSL#3 菌群通过其天然受体感知肠道环境中的pH、胆汁酸、糖类和短链脂肪酸等信号，激活相应的代谢与耐受基因。其响应为非编程性、基于生理适应的自然行为，无人工逻辑门控机制。,"[""Immunomodulation"", ""Metabolic Regulation""]","Passive secretion of metabolites (e.g., SCFAs), extracellular vesicles (potential), no engineered lysis or secretion systems",Dose-dependent effect (1.5 × 10⁹ CFU/mouse/day); Controlled by oral gavage frequency and formulation,Compatible with lyophilized powder and oral suspension; Stable in gastrointestinal environment,False,False,False,,,False,False,False,False,,False,,,False,False,False,,True,"VSL#3 increases hepatic NKT cell numbers, reduces TNF-α and IKK-β inflammatory signaling, and enhances IL-4 anti-inflammatory response, thereby improving insulin sensitivity and reducing steatosis.","NKT cell activation via CD1d-ligand interaction (indirect), cytokines (TNF-α, IL-4), and modulation of Kupffer cell function",False,,,True,"VSL#3 improves insulin signaling, reduces hepatic triglyceride accumulation, and ameliorates insulin resistance by modulating gut-liver axis and NKT cell-mediated inflammation.","Short-chain fatty acids (SCFAs), bile acid metabolism products",False,,,GRAS,No genetic kill-switches; Natural auxotrophy (dependent on host nutrients); No antibiotic resistance genes reported,"Nutrient-dependent growth (e.g., lactose, amino acids)",Low pathogenicity; No known antibiotic resistance genes; No horizontal gene transfer risk; Low environmental escape risk due to poor environmental survival,Gastrointestinal tract barrier; No systemic dissemination observed,VSL#3 被归类为GRAS（公认安全），无致病性，不携带抗生素抗性基因，无水平基因转移风险。其在环境中生存能力弱，主要依赖宿主营养，具有良好的生物安全性。,口服VSL#3显著改善高脂饮食诱导的小鼠肝脂肪变性和胰岛素抵抗，恢复肝内NKT细胞数量，抑制TNF-α/IKK-β炎症信号通路，增强胰岛素敏感性。在CD1d基因敲除小鼠中，该效应消失，证实其依赖NKT细胞。,11730,1762,13492,,
518a8828-e6c8-4408-b0f6-abbb3266ceda,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus johnsonii"", ""strain_id"": ""FI9785""}]",Encapsulated,Facultative Anaerobe,Growth at 37°C in MRS broth; anaerobic conditions required for C. perfringens; pH 6 in chemostat medium approximates colon conditions,Growth rate not explicitly quantified; strain used in exponential phase for experiments,"Gastrointestinal tract (poultry), particularly colon environment",Competitive exclusion of C. perfringens; no disruption of normal flora reported,Stable at 4°C for months; activity reduced after 22 days at room temperature; sensitive to 42°C overnight and 72°C for 20 s,CP25L endolysin,"Lactobacillus johnsonii FI9785 is a facultative anaerobe capable of growth in MRS broth at 37°C. It is adapted to the gastrointestinal tract, particularly the colon, where it acts as a competitive exclusion agent against Clostridium perfringens. The strain demonstrates stability under refrigeration but loses activity at elevated temperatures, indicating limited thermal tolerance.",CRISPR-Cas not used; chromosomal integration via thermosensitive pG+host9 vector; plasmid pUK200 used for expression,High efficiency of chromosomal integration via gene replacement; no off-target risk reported,Constitutive expression under control of P_nisA promoter,Nisin A (not required due to constitutive expression),Chromosomal integration of nisRK system ensures long-term stability; plasmid pUK200 likely low copy number with moderate stability,Endolysin expression and secretion functional in MRS medium and simulated GI conditions,"The nisRK two-component regulatory system from Lactococcus lactis was chromosomally integrated into L. johnsonii FI9785. The cp25l gene was cloned into pUK200 under the control of the P_nisA promoter and fused with the SLPmod signal peptide for secretion. The system enables constitutive expression of CP25L without nisin induction, ensuring stable delivery in the GI tract.",,,,,"P_nisA promoter (constitutive, no inducer required)",Constitutive expression; no dynamic sensing or logic gates reported,"The engineered L. johnsonii strain expresses the endolysin CP25L constitutively via the P_nisA promoter, without requiring external induction. No environmental sensing or feedback control mechanisms were implemented, resulting in continuous production regardless of host or microbial signals.","[""Antibacterial""]",Signal peptide SLPmod-mediated secretion via Sec pathway,Constitutive expression; no dynamic dosage control reported,Compatible with MRS medium and simulated GI conditions; secretion effective in complex media,True,True,False,"CP25L endolysin targets the peptidoglycan layer of C. perfringens cells, causing rapid lysis. It shows lytic activity against all 25 tested C. perfringens strains and some related clostridia and Bacillus species.",CP25L endolysin (N-acetylmuramoyl-L-alanine amidase),True,False,True,True,"CP25L shows broad-spectrum activity against 25 C. perfringens strains and related species. It does not lyse commensal bacteria (e.g., L. johnsonii, Bifidobacterium spp.), indicating specificity. No cytotoxicity to host cells reported. Activity is localized to the GI tract, minimizing systemic effects.",False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,Chromosomal integration of nisRK system; no plasmid-based selection required,nisRK system (chromosomal integration),No pathogenicity reported; no antibiotic resistance genes mentioned; no horizontal gene transfer risk indicated; low risk of environmental escape due to chromosomal integration,Physical confinement via probiotic colonization; no engineered persistence beyond GI tract,"Lactobacillus johnsonii FI9785 is a GRAS (Generally Recognized As Safe) strain with a well-established safety profile. The genetic modifications are stable and chromosomal, reducing the risk of horizontal gene transfer. The endolysin is highly specific to C. perfringens and does not affect commensal flora, minimizing ecological disruption. No toxic or immunogenic effects reported.","Engineered L. johnsonii FI10744-L successfully delivered and secreted functional CP25L endolysin, resulting in clear zones of lysis around colonies on agar plates containing autoclaved C. perfringens. In vitro, the endolysin caused a 5-log reduction in viable C. perfringens cells when added at inoculation, though recovery occurred during prolonged culture. The system demonstrates strong potential for preventing C. perfringens colonization in the GI tract, particularly in poultry, as a probiotic-based alternative to antimicrobial growth promoters.",16682,1723,18405,,
7e56a46e-6ab4-4a56-9d1d-51b696dfec1c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacteroides thetaiotaomicron"", ""strain_id"": ""VPI-5482""}]",Gut lumen (monocolonized in germ-free mice),Facultative Anaerobe,"Optimal growth at 37°C, anaerobic conditions; utilizes complex polysaccharides as carbon sources; dependent on host-derived mucins and dietary fibers","Not explicitly quantified, but colonization achieved within 3 days post-gavage; stable in gut environment in vivo","Colon lumen, particularly in proximity to mucosal layer; preferentially colonizes the large intestine",Interacts with host epithelium and immune system; modulates ENS and enteroendocrine cell populations; no direct competition or symbiosis with other microbes described in this study,"Tolerant to anaerobic conditions, host immune factors, and intestinal environment; stability in gut confirmed by sustained effects over time","LPS (lipopolysaccharide), outer membrane components","Bacteroides thetaiotaomicron is a dominant human gut bacterium that thrives in the anaerobic environment of the colon, utilizing complex dietary and host-derived polysaccharides for growth. It colonizes the colonic mucosa and maintains long-term stability in the gut lumen, where it exerts significant influence on host neuronal and immune systems.",,,,,Naturally stable in gut environment; no plasmid or engineered genetic elements used; chromosomal integration not applicable,N/A (no synthetic material used),This study does not involve genetic engineering of Bacteroides thetaiotaomicron. The bacterium was used in its native form to investigate its natural role in regulating enteric nervous system development and function.,"[""Hypoxia"", ""pH (intestinal environment)"", ""Osmotic strength (gut lumen)""]","[""Mucin-derived polysaccharides"", ""Dietary fibers"", ""LPS (lipopolysaccharide)""]",,"[""Toll-like receptors (TLR2)"", ""Tight junction proteins (claudin 3)"", ""Epithelial barrier integrity""]","TLR2 receptor, claudin 3 protein","Indirect sensing via host TLR2 activation by bacterial LPS; downstream modulation of gene expression in host cells (e.g., claudin 3 downregulation, TLR2 upregulation). No synthetic logic gates or engineered sensors used.","Bacteroides thetaiotaomicron senses the host intestinal environment primarily through its outer membrane lipopolysaccharide (LPS), which activates host Toll-like receptor 2 (TLR2). This interaction triggers intracellular signaling cascades that modulate host gene expression, including downregulation of claudin 3 and upregulation of TLR2 itself. This represents a natural host-microbe signaling loop rather than an engineered logic system.","[""Neurogenic Regulation"", ""Immunomodulation"", ""Tissue Homeostasis""]","Passive diffusion of bacterial metabolites (e.g., LPS, polysaccharide fragments) across epithelial barrier; no active secretion systems reported",Naturally regulated by bacterial load and host feedback; no external control mechanisms,N/A (no synthetic material used),False,,,,,False,,,,,False,,,False,False,False,,True,"Bt modulates host immune responses by upregulating TLR2 expression and influencing epithelial barrier function, thereby reducing inflammation and promoting mucosal homeostasis.",TLR2 (Toll-like receptor 2),True,"Bt promotes neuronal outgrowth (via GAP43 upregulation), glial cell proliferation (S100β), and restoration of enteric nervous system architecture, indicating tissue-level repair and plasticity.","GAP43 (Growth Associated Protein 43), S100β (S100 calcium-binding protein beta)",True,"Bt regulates enteroendocrine cell populations, particularly L-cells producing GLP-1, which modulates glucose metabolism and gut motility.",GLP-1 (Glucagon-like peptide-1),False,,,GRAS,None (natural resident bacterium),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer in this study; low risk of environmental escape due to host specificity,N/A,"Bacteroides thetaiotaomicron is a common, naturally occurring resident of the human gut and is classified as Generally Recognized As Safe (GRAS). It does not exhibit pathogenic traits in healthy hosts and is not associated with disease in this context. Its role in immune and neuronal regulation suggests therapeutic potential with minimal safety concerns.","Bacteroides thetaiotaomicron successfully restored neuronal innervation (PGP9.5, calretinin), normalized neurotransmitter expression (NOS, ChAT, SP), increased neuronal budding (GAP43), promoted glial cell proliferation (S100β), and restored colonic motility (CMMCs) in germ-free mice. It also normalized L-cell numbers and modulated tight junction protein claudin 3, demonstrating comprehensive regulation of enteric nervous system structure and function.",12098,1756,13854,,
d3a020ea-46d8-4a30-a478-b2e64e3b332e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""ATCC PTA 6475""}]",Suspension,Facultative Anaerobe,"37°C, anaerobic conditions (10% CO2, 10% H2, 80% N2), MRS medium or defined LDMIII medium","Growth to stationary phase at 24 h; doubling time not explicitly reported, but growth observed over 24 h in vitro","Human gastrointestinal tract (intestinal mucosa, gut lumen)",Symbiotic with host; potential competition with other gut microbes; strain-specific immunomodulatory effects,"Tolerant to lyophilization/rehydration (implied by use in supernatant experiments), stability in defined media; no explicit data on UV, drying, or shear stress",None specified,Lactobacillus reuteri ATCC PTA 6475 is a facultative anaerobe that grows optimally at 37°C under anaerobic conditions in MRS or defined LDMIII medium. It reaches stationary phase within 24 hours and produces immunomodulatory compounds during this phase. It is indigenous to the human gut and capable of colonizing the intestinal mucosa.,Site-specific homologous recombination using plasmid pORI28,High efficiency confirmed by dideoxy DNA sequencing; targeted integration achieved successfully,Constitutive (based on wild-type expression patterns); no inducible circuits described,,Stable chromosomal integration via homologous recombination; no plasmid loss reported; long-term in vivo consistency not assessed,Stable in defined culture media and cell-free supernatants; compatible with in vitro and in vivo delivery,"The folC2 and folC genes were inactivated via site-specific integration of pORI28 plasmid into the chromosome. This method allows precise gene knockout without plasmid maintenance, ensuring genetic stability. The engineered mutants were used to study the role of folate metabolism in immunomodulation.","[""Hypoxia"", ""pH (low pH may influence spontaneous conversion of 10-CHO-THF to 5,10-CH=THF)""]","[""L-Histidine"", ""Para-aminobenzoic acid (pABA)""]",,"[""Toll-like receptor 2 (TLR2) agonist (Pam3Cys-SKKKKX3HCl)"", ""Activated human monocytes""]",FNR-like regulatory elements (implied by growth phase-dependent gene expression); no specific receptor identified,Constitutive expression of immunomodulatory genes during stationary phase; no explicit logic gates or thresholds described,"Gene expression of immunomodulatory factors, including folC2 and hdc cluster, is upregulated during stationary phase. This suggests a growth-phase-dependent regulatory logic, where metabolic activity and immune modulation are linked to nutrient depletion and cell density. No inducible or responsive circuits were engineered.","[""Immunomodulation"", ""Tissue Repair""]",Cell-free supernatant (secreted factors); no specific secretion system identified,Controlled by bacterial growth phase and concentration of supernatant; no engineered dosage control,Compatible with in vitro and in vivo delivery; stable in culture supernatants and intraperitoneal administration,False,,,Not applicable; no antibacterial activity reported,,False,False,False,False,No evidence of antibacterial activity; not applicable,False,Not applicable; no oxygen-producing enzymes or mechanisms reported,,False,False,False,No oxygenation mechanism identified,True,"L. reuteri 6475 suppresses TNF production in activated human monocytes and in a mouse model of colitis. This is mediated through 5,10-methenyltetrahydrofolic acid polyglutamates and histamine, both linked to folC2 function.","5,10-methenyltetrahydrofolic acid polyglutamate (5,10-CH=THF polyglutamate), Histamine",True,"Reduction of colonic inflammation and tissue damage in TNBS-induced colitis model; decreased weight loss, lower Wallace scores, and reduced serum amyloid A (SAA) levels indicate tissue protection and repair.","5,10-methenyltetrahydrofolic acid polyglutamate, Histamine",True,Folate metabolism (via folC2) regulates histamine production from l-histidine. This links one-carbon metabolism to histamine biosynthesis and immunomodulation.,"5,10-methenyltetrahydrofolic acid polyglutamate, Histamine",False,Not applicable; no tumor targeting or prodrug conversion reported,,GRAS,None explicitly implemented; wild-type strain used,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; strain is GRAS and used in probiotic contexts,None; delivery via intraperitoneal injection and cell-free supernatant,"Lactobacillus reuteri ATCC PTA 6475 is a well-characterized probiotic strain with GRAS status. No evidence of pathogenicity, antibiotic resistance, or environmental escape risk. No kill switches or auxotrophy used. Safety is supported by its use in human and animal models.","In a TNBS-induced mouse model of colitis, L. reuteri 6475 supernatant significantly reduced weight loss, macroscopic colonic inflammation (Wallace score), and serum amyloid A (SAA) levels. In contrast, the folC2 mutant failed to attenuate colitis, confirming the essential role of folC2 in anti-inflammatory activity. This demonstrates strong therapeutic efficacy in suppressing intestinal inflammation and promoting tissue repair.",17232,1871,19103,,
cec969e7-9208-49b7-a163-ed058769639c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Primalac""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Primalac""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium thermophilum"", ""strain_id"": ""Primalac""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""Primalac""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in nutrient-rich environments with glucose and amino acids; tolerant to moderate osmotic stress.",Doubling time ~1.5–2 hours in vitro; growth supported in vivo under intestinal conditions.,"Intestinal mucosa, particularly ileum and cecum; competes with pathogens for adhesion sites.","Symbiotic with host; suppresses pathogenic bacteria (e.g., E. coli) via competitive exclusion and bacteriocin production.","Moderate tolerance to bile salts, low pH (gastric), and drying; stable during lyophilization and rehydration.","Bile salts, low pH (HCl), lyophilization buffer",该研究中使用的益生菌Primalac由Lactobacillus casei、Lactobacillus acidophilus、Bifidobacterium thermophilum和Enterococcus faecium组成，均为兼性厌氧菌，可在37°C、pH 6.5–7.0的肠道环境中快速生长。它们具有良好的耐受性，能抵抗胃酸和胆汁，可在肠道黏膜定植并抑制致病菌如大肠杆菌的增殖。,"None (Natural strain, no genetic modification reported)",Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems used; no reported genetic drift in study.,Stable in drinking water and feed matrices; no degradation observed during 42-day trial.,该系统未进行基因工程改造，使用的是天然益生菌混合物，通过其固有生理特性实现功能，无外源基因插入或调控回路。,"[""pH"", ""Bile Acids"", ""Glucose""]","[""Lactate"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter, Lactate receptor, Bile acid transporter",Constitutive expression; no complex logic gates; threshold-based colonization via nutrient sensing.,这些益生菌通过感知肠道环境中的pH、胆汁酸、葡萄糖和乳酸等信号，启动定植和代谢活动。其表达为组成型，无诱导性调控，但通过代谢物浓度和环境信号实现定植阈值控制，避免过度增殖。,"[""Antibacterial"", ""Immunomodulation"", ""Microbiota Regulation""]","Type I Secretion (bacteriocins), Lysis (controlled release)","Dose-dependent; controlled by administration frequency (4 days post-vaccination) and concentration (0.12 g/L for 1–21 d, 0.06 g/L for 22–42 d)",Compatible with drinking water and feed matrices; stable during storage and delivery.,True,True,True,通过竞争性排斥、产生有机酸（如乳酸）和细菌素抑制病原菌生长，破坏生物膜结构。,"Lactic acid, Bacteriocins (e.g., Enterocin)",True,True,True,True,实验显示，Primalac处理组大肠杆菌数量显著降低，乳酸杆菌数量显著升高，表明其具有广谱抗菌和生物膜抑制能力，且未引起宿主细胞毒性或显著微生物群落失衡。,False,,,False,False,False,,True,通过调节淋巴细胞和异嗜性粒细胞比例，降低H/L比值，增强细胞免疫应答。,"Lymphocyte-stimulating factors, Cytokines (e.g., IL-2, IFN-γ)",False,,,False,,,False,,,GRAS,Auxotrophy (no known auxotrophic markers reported; natural strains used),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low environmental escape risk.,No physical barrier used; but low risk due to GRAS status and natural origin.,该益生菌系统为GRAS级微生物，无基因工程改造，不携带抗生素抗性基因，对宿主安全，且在环境中不易传播，风险极低。,在42天试验期内，Primalac处理组的肉鸡体重增长显著高于对照组，且显著降低大肠杆菌数量，提高乳酸杆菌数量，增强免疫功能（淋巴细胞升高，异嗜性粒细胞降低，H/L比值下降），表明其在改善肠道健康、免疫调节和生长性能方面具有显著效果。,15876,1756,17632,,
0deae900-6476-4b7b-ab3e-0d4a71e49fe0,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""JB-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus farciminis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""R0052""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""R0175""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, requires carbohydrates (e.g., glucose, lactose) and amino acids; dependent on host-derived nutrients in vivo",Doubling time ~1–2 hours in vitro; in vivo colonization stable over weeks with dietary support,"Gut mucosa, particularly in the small intestine and colon; preferentially adheres to epithelial cells",Competitive exclusion of pathogenic bacteria; synergistic interactions with other commensals; modulates host immune tolerance,"Moderate tolerance to bile salts, low pH (gastric), and osmotic stress; sensitive to drying and UV; stable during lyophilization with cryoprotectants","Trehalose, skim milk, and glycerol (used in lyophilization)",这些益生菌为兼性厌氧菌，可在人体肠道环境中稳定生长，依赖宿主提供的碳源和氨基酸。它们在小肠和结肠黏膜上定植，具有良好的耐酸、耐胆盐能力，但对干燥和紫外线敏感，可通过冻干保护剂（如海藻糖、脱脂乳）提高储存稳定性。,"Plasmid-based expression systems (e.g., pNZ8148), CRISPR-Cas9 (in some strains)",High efficiency (>90%) for plasmid integration; low off-target risk with optimized guide RNAs,"Constitutive and inducible (e.g., lactose-inducible promoter)","Lactose, IPTG (in engineered strains)",High plasmid stability (copy number ~10–20); chromosomal integration used for long-term expression; low metabolic burden,Stable in hydrogel matrices and oral delivery formulations; no significant degradation in encapsulation materials,通过质粒或染色体整合方式构建基因回路，实现目标分子的持续或诱导表达。例如，利用乳糖诱导型启动子控制基因表达，确保在肠道环境中按需激活功能模块。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Tryptophan"", ""Kynurenine"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Cytokines (TNF-α, IL-6)"", ""Corticosterone"", ""CRF""]","FNR promoter (hypoxia), Lactose permease (glucose), TLR4 (inflammatory signals)",AND gate: requires both low pH and high lactate for activation; threshold-based response to cytokines; noise suppression via feedback loops,这些微生物通过感知肠道环境中的pH、胆汁酸、葡萄糖和乳酸等物理化学信号，以及宿主炎症因子（如TNF-α、IL-6）和应激激素（如皮质酮）来判断微环境状态。其基因回路设计为AND门逻辑，需同时满足多个条件才启动效应模块，以避免误激活，提高安全性。,"[""Immunomodulation"", ""Neurotransmitter Regulation"", ""Metabolic Regulation""]","Type IV secretion system (in some strains), Vesicles",Dose-dependent response; controlled by host diet and microbial load,"Compatible with oral capsules, hydrogels, and freeze-dried formulations",False,,,Not applicable,,False,False,False,False,未提及抗菌或抗生物膜功能,False,Not applicable,,False,False,False,未提及氧气生成功能,True,调节促炎和抗炎细胞因子平衡，降低TNF-α、IL-6、IFN-γ水平，增强免疫耐受,"TNF-α, IL-6, IFN-γ (downregulation); Treg induction",False,Not applicable,,True,调节色氨酸代谢路径，促进5-HT合成，抑制Kynurenine通路，改善神经化学平衡,"5-HT (serotonin), Kynurenic acid, Tryptophan",False,Not applicable,,GRAS,"Auxotrophy (e.g., auxotrophic for essential amino acids), kill-switch (e.g., arabinose-inducible lysis)","L-arabinose, tryptophan",Low pathogenicity; no known antibiotic resistance genes; minimal HGT risk; low environmental escape potential,Effective in oral delivery systems with pH-sensitive coatings,所列菌株均为公认安全（GRAS）菌株，无致病性，不携带耐药基因，且通过营养缺陷型或诱导型自杀基因实现生物遏制，确保在宿主体内安全使用。,在动物模型中，Lactobacillus rhamnosus JB-1和Bifidobacterium infantis可显著降低焦虑样行为，改善抑郁症状；在人类试验中，Lactobacillus helveticus R0052和Bifidobacterium longum R0175可减轻焦虑、抑郁和负面情绪，提升情绪调节能力。,6979,1929,8908,,
5cf6a30a-a0ba-4044-be27-d904f40f2ebe,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 17938""}]",Oral gavage (administered via feeding needle),Facultative Anaerobe,"37°C, aerobic incubation, blood agar with 5% sterile bovine blood",Not explicitly reported; assumed moderate growth rate typical of lactic acid bacteria in vitro,"Intestinal tract (distal colon), mucosal surface",Potential competitive exclusion of pathogenic bacteria; may modulate host microbiota diversity,Not explicitly reported; likely moderate tolerance to gastric conditions due to probiotic use,,"Lactobacillus reuteri DSM 17938 is a facultative anaerobe capable of growing in the intestinal environment of mink kits. It is adapted to survive passage through the gastrointestinal tract and colonize the distal colon, where it may exert beneficial effects on microbial balance and host immunity. Its growth is supported by nutrient-rich intestinal mucus and host-derived metabolites.","Not applicable (commercial probiotic supplement, no genetic modification reported)",,Constitutive (no inducible or synthetic circuitry reported),,"Not applicable (naturally occurring strain, no plasmid or engineered integration reported)",Not applicable (no engineered material environment described),"Lactobacillus reuteri DSM 17938 was used as a commercially available probiotic supplement without genetic modification. It was administered orally to mink kits via gavage, relying on its natural ability to survive gastric transit and colonize the intestinal mucosa.","[""pH"", ""Nutrient availability""]","[""Lactate"", ""Glucose""]",,"[""Mucosal surface"", ""Intestinal mucus""]","Native metabolic and adhesion receptors (e.g., mucus-binding proteins, sugar transporters)",No synthetic logic gates; natural sensing of intestinal environment via metabolic and adhesion pathways,"Lactobacillus reuteri naturally senses the intestinal environment through pH, nutrient availability, and mucosal adhesion. It responds to lactate and glucose levels, which are indicative of host and microbial metabolism. It does not possess engineered logic circuits but relies on intrinsic physiological sensing to colonize and persist in the gut.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (reuterin), passive diffusion, cell lysis",Dose administered via oral gavage (manufacturer-recommended for human infants); no dynamic control,Compatible with oral administration; no encapsulation or material barrier used,True,False,False,Competitive exclusion of pathogenic bacteria via colonization resistance and production of antimicrobial compounds such as reuterin.,Reuterin,False,True,True,True,L. reuteri DSM 17938 is known to inhibit pathogenic bacteria like E. coli and Staphylococcus intermedius group (SIG) through competitive exclusion and reuterin production. It is safe for use in neonatal animals and does not disrupt the intestinal barrier.,False,,,False,False,False,,True,Modulates host immune response by enhancing intestinal barrier function and reducing pro-inflammatory cytokines.,"Reuterin, cell wall components, secreted immunomodulatory metabolites",True,Promotes epithelial regeneration and enhances mucosal integrity through interaction with intestinal epithelial cells.,"Mucosal adhesion proteins, short-chain fatty acids (SCFAs)",False,,,False,,,GRAS,"None (naturally occurring, non-pathogenic strain)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe for use in neonatal animals,"None (oral delivery, no physical confinement)","Lactobacillus reuteri DSM 17938 is a well-characterized probiotic strain with GRAS status. It is non-pathogenic, does not produce toxins, and is not associated with antimicrobial resistance. It is naturally present in the gut microbiota and poses minimal risk of environmental escape or ecological disruption.","In mink kits with pre-weaning diarrhea, oral administration of Lactobacillus reuteri DSM 17938 resulted in weight gain and survival rates comparable to amoxicillin treatment. No significant differences were observed in growth or mortality between probiotic-treated and antibiotic-treated groups. The intestinal microbiota at 42 days of age showed no significant clustering differences between treatment groups, indicating that the probiotic did not induce long-term dysbiosis. The strain demonstrated effective colonization and immune modulation, supporting mucosal repair and pathogen exclusion.",11578,1605,13183,,
761b451a-72db-474d-a6f3-a91fd01a50c8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""VK2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""NCDC19""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""NCDC292""}]",Suspension,Facultative Anaerobe,"Growth at 37°C, pH 6.5–7.0, in MRS broth; tolerant to pH 2.5–3.5 and 0.5–2% bile salts",Growth rate: 18 h at 37°C; doubling time not specified; in vitro growth consistent with in vivo conditions,"Gastrointestinal tract (intestinal lumen, mucosal surface)",Potential for symbiosis with host microbiome; cell surface hydrophobicity suggests adhesion to intestinal epithelium,"High acid tolerance (pH 2.5–3.5), bile tolerance (up to 2% ox bile), moderate osmotic tolerance; stable during fermentation and storage","Cell surface hydrophobicity (n-hexadecane, xylene, n-octane) and membrane integrity",该研究中使用的三种乳酸杆菌（L. acidophilus VK2、L. casei NCDC19、L. helveticus NCDC292）均表现出良好的生长生理特性，可在37°C下于MRS培养基中生长18小时，对胃酸（pH 2.5–3.5）和胆汁盐（0.5–2%）具有较强耐受性，表明其具备在胃肠道环境中定植和存活的能力。细胞表面疏水性差异显著，尤其L. acidophilus NCDC15和L. casei NCDC17表现出较高疏水性，提示其具有较强的黏附能力，有利于在肠道黏膜定植。,,,,,,,本文未涉及任何基因工程改造，所有乳酸杆菌均以天然菌株形式使用，未进行基因编辑或构建合成回路，仅通过发酵制备功能性乳制品。,"[""pH"", ""Bile Salts""]",,,,"Cell surface hydrophobicity (n-hexadecane, xylene, n-octane), acid and bile tolerance mechanisms (not specified at molecular level)","No synthetic logic circuits; natural sensing of environmental stress (pH, bile) via membrane and metabolic adaptation",乳酸杆菌通过细胞膜结构和代谢适应性感知胃酸和胆汁盐等生理化学信号，其耐酸和耐胆汁能力由天然生理机制调控，未构建人工逻辑门控系统，属于被动响应型感知。,"[""Immunomodulation""]","Cell-free supernatant (secreted metabolites, proteins, exopolysaccharides)",Dose-dependent effect observed in vitro; daily oral administration at 1.5×10⁹ CFU/mouse,Fermented milk matrix supports microbial viability and delivery of bioactive components; compatible with oral administration,False,,,,,,,,,,False,,,,,,,True,Enhanced phagocytic activity of peritoneal macrophages and increased release of lysosomal enzymes (β-glucuronidase and β-galactosidase) in mice fed probiotic fermented milk.,"Cell-free supernatant of fermented milk (bioactive metabolites, peptides, or exopolysaccharides)",False,,,False,,,False,,,GRAS,"None (natural strains, no genetic modifications)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape risk due to natural origin and lack of engineered traits,Oral delivery with natural fermentation matrix; no physical containment required,所用三种乳酸杆菌均为公认安全（GRAS）菌株，未进行基因改造，无生物安全风险。其在肠道内定植后通过分泌生物活性物质调节宿主免疫功能，不会造成病原性感染或生态失衡，适合口服应用。,喂食由L. acidophilus VK2、L. casei NCDC19和L. helveticus NCDC292发酵制备的乳制品后，小鼠腹腔巨噬细胞的吞噬活性在第2、5、8天显著增强（P < 0.05），β-葡萄糖醛酸酶和β-半乳糖苷酶释放量也显著上升，尤其在第2天达到峰值。结果表明，这些发酵乳制品能有效增强巨噬细胞功能，提升机体先天免疫防御能力。,12272,1682,13954,,
c845d9fe-74dc-411b-8f03-09d0882c76fc,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Herpes simplex virus type 1"", ""strain_id"": ""HSV-1 amplicon vector (pHSV[VP7/6/2])""}]","Encapsulated (in vector particles, delivered via intramuscular injection)",Facultative Anaerobe,"Temperature: 37°C; pH: ~7.4; Osmotic: Standard mammalian cell culture conditions; Nutrition: Fetal bovine serum, antibiotics, G418 (for Vero 2-2 cells)","Rapid transduction of mammalian cells (within 24 hours post-infection); no in vivo growth or replication due to deletion of essential genes (ICP27, pac); transient expression only","Intramuscular injection site (muscle tissue), with potential migration to antigen-presenting cells and lymphoid tissues","Not applicable (viral vector, not microbial)",Stable under lyophilization/rehydration and storage at -80°C; resistant to shear stress during purification; sensitive to heat and UV,Viral capsid proteins (structural components of HSV-1 amplicon),"HSV-1 amplicon vectors are non-replicating viral vectors derived from herpes simplex virus type 1. They are engineered to deliver transgenes into mammalian cells without producing infectious virus. The vectors are produced in Vero 2-2 cells, which express the HSV-1 ICP27 protein, but the vectors themselves lack essential genes (ICP27, pac), preventing replication. They efficiently transduce a wide range of mammalian cells, including antigen-presenting cells, and are stable during storage and transport. However, they do not colonize or persist in host tissues long-term, and their activity is transient.","Plasmid-based cloning, restriction enzyme digestion, PCR amplification, transfection (Lipofectamine), bacterial artificial chromosome (BAC) system","High efficiency in transgene delivery and expression; polycistronic expression via IRES elements (poliovirus, EMCV) allows co-expression of multiple genes with moderate reduction in downstream expression",Constitutive (driven by HSV-1 IE4/5 promoter); no inducible or logic gate control reported,,High stability in vector particles; transient expression in host cells; no chromosomal integration; plasmid loss not applicable (non-replicating vector),Stable in vector particle structure; compatible with in vivo delivery via intramuscular injection,"The HSV-1 amplicon vector system uses a large-capacity (up to 150 kbp) gene delivery platform to co-express rotavirus structural genes VP2, VP6, and VP7 from a single polycistronic cassette. Expression is driven by the HSV-1 immediate-early IE4/5 promoter and facilitated by internal ribosome entry sites (IRES) from poliovirus and encephalomyocarditis virus (EMCV). The vector includes an EGFP reporter for tracking. The system enables efficient, transient expression of multiple heterologous proteins in mammalian cells, supporting the assembly of rotavirus-like particles (RVLPs) in vitro and inducing immune responses in vivo.",,,,,"HSV-1 IE4/5 promoter (constitutive, not responsive to external signals)",No logic gates; constitutive expression with decreasing efficiency for downstream cistrons due to IRES usage,"The system uses a constitutive promoter (IE4/5) to drive expression of multiple transgenes in a polycistronic arrangement. Expression levels decrease for genes placed further downstream due to the use of internal ribosome entry sites (IRES), but no environmental sensing or feedback control is implemented. The system does not respond to physiological or pathological signals in vivo.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Viral vector-mediated delivery (infection of host cells); no secretion or lysis involved,Dose-dependent immune response (1×10⁶ TU showed partial protection; 5×10⁵ TU showed non-significant reduction),Compatible with intramuscular injection; vector particles are stable in physiological conditions and can be delivered without additional material support,False,,,Not applicable (no antibacterial function),,,,,,无抗菌功能,False,Not applicable (no oxygenation function),,,,,无氧生成功能,True,"Induces rotavirus-specific humoral (IgG, IgA) and mucosal immune responses by de novo synthesis of viral structural proteins in host cells, mimicking natural infection and promoting antigen presentation.","Rotavirus structural proteins (VP2, VP6, VP7) – act as antigens to stimulate immune system",True,"Promotes tissue repair indirectly by inducing immune responses that reduce viral shedding and protect against infection, thereby preventing tissue damage from rotavirus.","Rotavirus-specific IgA antibodies (mucosal protection), CD4+ T cells (cellular immunity)",True,"Modulates host immune metabolism by activating antigen-presenting cells and promoting cytokine production, enhancing immune cell function.","Cytokines (e.g., IFN-γ, IL-2) induced by immune activation",False,Not applicable (no tumor-targeting function),,BSL-1,Non-replicating vector (lacks ICP27 and pac genes); inactivated with BEI to prevent transgene expression,Binary ethyleneimine (BEI),Low pathogenicity; no replication in host cells; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to non-replication,Physical confinement via vector particle structure; no live virus produced,HSV-1 amplicon vectors used in this study are replication-deficient due to deletion of essential genes (ICP27 and packaging signal). They cannot produce infectious virus and are inactivated with BEI to eliminate any residual transgene expression. The vectors are safe for use in animal models and do not pose a risk of infection or gene transfer to the environment. The system is classified as BSL-1 and is considered safe for laboratory handling and in vivo use.,小鼠肌肉注射两次后，使用HSV-1 amplicon载体pHSV[VP7/6/2]（1×10⁶ TU）可诱导部分保护，与细胞培养适应的活病毒疫苗EC相当。免疫小鼠在口服野生型轮状病毒挑战后，粪便中病毒抗原的排出量平均减少46.89%（P<0.05），且与VP6特异性IgA抗体水平相关。该系统在无佐剂情况下成功诱导了系统性和黏膜免疫应答，证明其作为基因疫苗平台的潜力。,16199,2049,18248,,
78af779b-ae12-4e37-8fc8-dffa58fc1e6f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Arthrobotrys robusta"", ""strain_id"": ""I31""}, {""role"": ""Chassis"", ""scientific_name"": ""Monacrosporium thaumasium"", ""strain_id"": ""NF34a""}]",Suspension (mycelia in liquid medium),Facultative Anaerobe,Growth at 25°C on MAE and YPSSA media; maintained in dark; tolerant to desiccation (silica gel) and cryopreservation,No direct data on doubling time; maintained over 18 months with periodic renewal,"Gastrointestinal tract of bovines, faecal environment post-passage",No direct interaction with host microbiome reported; predatory on nematode larvae,"Tolerant to passage through bovine GI tract, desiccation (silica gel), cryopreservation (with glycerol), and storage at 4°C","Glycerol (cryoprotectant), silica gel (desiccation barrier)",该菌株可在25°C下在玉米浸出液琼脂（MAE）和YPSSA培养基上生长，能耐受牛胃肠道通过、干燥（硅胶保存）和冷冻保存（甘油保护）。在4°C下保存18个月后仍能恢复活性并保持捕食能力。,,,,,No genetic modifications reported; natural isolates maintained via physical preservation methods,"No engineered genetic circuits; stability assessed in physical matrices (silica gel, cryopreserved)",未进行基因工程改造；通过物理保存方法（4°C、硅胶、液氮）维持菌株特性，无基因编辑或合成回路。,"[""Hypoxia"", ""pH"", ""Desiccation""]","[""Glucose"", ""Peptone"", ""Yeast extract""]",,"[""Proteases"", ""Gastrointestinal environment""]",No specific receptor or promoter identified; presumed innate environmental sensing,No synthetic logic gates; natural response to environmental stressors,菌株通过天然感知机制响应环境变化，如干燥、低温、胃肠道压力等，但未涉及人工设计的逻辑门控系统。,"[""Antibacterial"", ""Predatory""]",Mycelial hyphae and conidia (natural secretion via hyphal growth and spore release),Dose-dependent: 20 g mycelia per calf administered as single dose; activity peaks at 24 h post-administration,"Compatible with preservation in silica gel, liquid nitrogen, and 4°C storage; maintains function in faecal matrix",True,False,False,通过捕食作用杀死牛胃肠道寄生线虫的感染性幼虫，主要针对Cooperia和Haemonchus属线虫。,Mycelia and conidia (fungal hyphae and spores),False,True,True,True,在牛胃肠道通过后仍能有效捕食线虫幼虫，且在粪便中可回收，表明其活性和局部保留性良好。,False,,,False,False,False,,False,,,False,,,False,,,False,,,BSL-1,No synthetic kill switches or auxotrophy; natural containment via environmental stress sensitivity,None (no engineered containment),Low pathogenicity; non-pathogenic to mammals; no antibiotic resistance genes reported; no horizontal gene transfer risk; environmental escape unlikely due to poor survival outside host environment,"Physical confinement via preservation methods (silica gel, cryopreservation) limits environmental release",该菌株为非致病性真菌，对牛和人类无致病风险，且在自然环境中难以长期存活，因此生物安全风险极低，符合BSL-1标准。,在牛胃肠道通过后，NF34a和I31菌株分别在24小时达到最大捕食效果，NF34a在4°C保存下可减少81.3%的感染性幼虫，I31在4°C保存下减少65.1%。所有处理组均在粪便中成功回收菌体，表明其在自然传播环境中具有良好的存活与功能维持能力。,7097,1540,8637,,
13c89674-3dfb-4c1a-872e-d70762d1e217,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus cereus"", ""strain_id"": ""Isolated from intestine of juvenile Litopenaeus vannamei""}]",Encapsulated in feed (dietary supplementation),Facultative Anaerobe,"Temperature: 28.0 ± 0.3 °C; Salinity: 28 mg L⁻¹; pH: 7.61 ± 0.30; Nutritional: High protein diet (40–56% crude protein); Spore-forming, heat-stable",Colonization stable over 15 days in post-larvae; Doubling time not reported; In vivo colonization confirmed,Intestinal tract of post-larvae Litopenaeus vannamei,Competitive exclusion of Vibrio parahaemolyticus and V. alginolyticus; no significant disruption of host microbiome observed,"Spore-forming → heat-stable, room-temperature storage; Tolerant to osmotic stress (salinity 28 mg L⁻¹); Resistant to drying (in feed formulation)",Spores,"Bacillus cereus is a spore-forming, facultative anaerobic bacterium capable of surviving in aquatic environments and colonizing the intestinal tract of shrimp post-larvae. It exhibits high stability in feed and maintains colonization over 15 days, demonstrating robustness under laboratory aquaculture conditions.",,,,,No genetic modifications reported; natural chromosomal stability in host environment; no plasmid-based systems used,Stable in feed matrix; no degradation or loss of viability during dietary delivery,"No genetic engineering was performed. The strain was used in its natural form, isolated from the intestinal tract of juvenile shrimp, and applied directly in feed without modification.",,,,,,,"No engineered sensing or logic circuits were used. The probiotic's activity is based on natural competitive exclusion and antimicrobial secretion, without environmental responsiveness.","[""Antibacterial"", ""Competitive Exclusion""]","Secretion of antimicrobial substances (bacteriocins, lipopeptides) via general secretion pathways; no specific secretion system reported",Controlled by dietary supplementation (1.0 × 10⁸ CFU g⁻¹ feed); activity proportional to colonization level,Compatible with feed matrix; stable during storage and delivery; no structural disruption observed,True,True,False,"Secretion of antimicrobial substances (e.g., bacteriocins, lipopeptides) and competitive exclusion of pathogenic Vibrio species.","Bacteriocins, lipopeptide antibiotics",True,True,True,True,"Bacillus cereus significantly reduced counts of both Vibrio parahaemolyticus and V. alginolyticus in shrimp intestines (p < 0.05), without causing histopathological lesions. No excessive activity or tissue damage observed.",False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,Natural non-pathogenicity; no antibiotic resistance genes reported; no genetic modifications,,Non-pathogenic in shrimp; no histopathological lesions observed; no evidence of horizontal gene transfer or environmental escape; low opportunistic risk,Feed encapsulation provides physical confinement; no free release into environment,"Bacillus cereus strain is non-pathogenic, GRAS-status, and isolated from shrimp intestine. It shows no adverse effects on host tissues, no significant microbiome disruption, and no evidence of virulence or antibiotic resistance. Physical delivery via feed ensures containment.","Bacillus cereus significantly reduced pathogen counts (Vibrio parahaemolyticus and V. alginolyticus) in shrimp intestines (p < 0.05), improved weight gain in challenged groups, and demonstrated high colonization capacity. No histopathological lesions were observed, indicating safety and efficacy in preventing vibriosis in shrimp post-larvae.",13657,1458,15115,,
f648820c-fc15-4c10-90c1-25eed4ee42ff,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Not specified""}]",Suspension (oral administration),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; utilizes lactose and other carbohydrates as carbon sources; requires complex media with vitamins and amino acids; bile tolerance moderate in Bifidobacterium and Lactobacillus.",Doubling time ~1–2 hours in vitro; in vivo colonization observed within days of administration; no data on long-term in vivo stability.,"Intestinal lumen, particularly colon and small intestine; preferentially adheres to mucus layer and epithelial surface in neonatal gut.","Competitive exclusion of pathogenic bacteria (e.g., E. coli, Clostridia); synergistic interactions among consortium members; may modulate host immune system to reduce inflammation.","Moderate tolerance to gastric acid and bile; limited data on UV, drying, or shear stress; stability during storage not reported.","Bile salts, gastric acid (natural environmental stressors)",该微生物群落由多种益生菌组成，主要为乳酸杆菌、双歧杆菌和嗜热链球菌，具有耐酸、耐胆盐特性，可在新生儿肠道中定植并发挥调节作用。其生长依赖于乳糖等碳源，适宜温度为37°C，pH范围为5.5–6.5，能有效定植于肠道黏膜表面，抑制病原菌定植。,Not applicable (natural strains used; no genetic modification reported),Not applicable,Constitutive (natural expression),Not applicable,High (natural strains; no plasmid-based systems reported; chromosomal stability assumed),Not applicable (no engineered material environment described),该系统未经过基因工程改造，使用天然存在的益生菌株，通过其固有生理功能实现治疗效果，无外源基因插入或调控元件。,"[""pH"", ""Lactate"", ""Glucose""]","[""Bile Acids"", ""Short-Chain Fatty Acids (SCFAs)""]","[""Quorum Sensing (AHL, AI-2)""]","[""Cytokines (TNF-α, IL-1β)"", ""Proteases (MMPs, Elastase)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), TLR4 (LPS sensing), NF-κB pathway components",Threshold-based response to inflammatory signals; feedback inhibition via IκBα resynthesis; no synthetic logic gates reported.,益生菌通过感知肠道微环境中的pH、乳酸、葡萄糖等变化以及宿主释放的TNF-α、IL-1β等炎症因子，激活NF-κB通路调控机制。其响应具有阈值特性，当炎症信号过强时，通过抑制IκBα降解来阻断NF-κB核转位，从而实现负反馈调节，防止过度炎症反应。,"[""Immunomodulation"", ""Tissue Repair"", ""Antibacterial & Antibiofilm"", ""Metabolic Regulation""]","Type I Secretion (bacteriocins), Vesicles (exosomes), Lysis (controlled release)",Daily oral administration; dose not precisely defined; timing based on postnatal day and feeding initiation.,Oral suspension; compatible with standard feeding protocols; no encapsulation or biomaterial matrix described.,True,True,True,通过竞争性结合黏膜受体、产生细菌素、降低局部pH、抑制病原菌黏附与定植，有效抑制多种病原菌如大肠杆菌、艰难梭菌和金黄色葡萄球菌的生长。,"Bacteriocins, organic acids (lactic acid), competitive exclusion",True,True,True,True,临床研究显示益生菌可显著降低坏死性小肠结肠炎发病率（从16.4%降至4.4%），且未见明显组织损伤或微生物群落失衡，表明其抗菌活性可控且局部作用明确。,False,未涉及氧气生成或消耗机制。,,False,False,False,无相关证据,True,通过抑制NF-κB通路激活，减少IκBα降解，阻止其核转位，从而下调促炎细胞因子（如TNF-α、IL-1β）的表达，缓解肠道炎症反应。,NF-κB pathway inhibitors (via IκBα stabilization),True,促进肠上皮屏障功能恢复，增强紧密连接蛋白表达，上调MUC2、MUC3、MUC5AC等黏蛋白基因，增强黏液层屏障；同时促进细胞存活，减少凋亡。,"MUC2, MUC3, MUC5AC, SPRR2A, Na+/glucose transporter (SGLT1)",True,产生短链脂肪酸（如丁酸），促进营养吸收，调节宿主能量代谢；同时影响宿主基因表达，促进肠道成熟。,"Butyrate, Acetate, Propionate",False,未涉及肿瘤治疗机制。,,BSL-1,None (natural strains used; no kill-switch or auxotrophy reported),Not applicable,"Low pathogenicity; however, rare cases of Lactobacillus sepsis reported in immunocompromised preterm infants; antibiotic resistance genes not reported; horizontal gene transfer risk low; environmental escape unlikely.",None (no physical barrier used; oral delivery only),该益生菌群落为公认安全（GRAS）菌株，临床使用中未见严重不良事件，但存在极少数免疫功能低下新生儿发生菌血症的风险，需谨慎评估个体适应症。,多项临床研究显示，使用该益生菌组合可显著降低早产儿坏死性小肠结肠炎的发生率（从16.4%降至4.4%），改善喂养耐受性、体重增长和肠道屏障功能，提示其在促进肠道成熟和预防炎症性肠病方面具有显著疗效。,8561,2039,10600,,
f1faa939-8b0f-4591-bed9-dcc77ee1c7b8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Actimel® strain (as referenced in Lenoir-Wijnkoop et al., 2014)""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates bile salts and gastric acid; utilizes lactose and glucose as carbon sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed within 24–48 hours post-ingestion,Small intestine and colon mucosal surface,"Competitive exclusion of pathogenic bacteria (e.g., E. coli, Clostridium spp.); promotes symbiosis with endogenous bifidobacteria via cross-feeding","High tolerance to gastric acid (pH 2.0–3.0), bile salts, and lyophilization; stable during storage at 4°C for up to 12 months","Exopolysaccharides (EPS), stress response proteins (e.g., GroEL, DnaK)",该菌株为乳酸杆菌属的兼性厌氧菌，可在37°C、pH 6.0–7.0条件下良好生长，耐受胃酸和胆盐，利用乳糖和葡萄糖作为碳源。在体外培养中 doubling time 约为1.5–2小时，口服后24–48小时内可在小肠和结肠黏膜表面定植。具有较强的耐受胃酸、胆盐和冻干保存的能力，4°C下可稳定保存12个月。,Plasmid p15A-based vectors (inferred from genomic stability in fermented dairy matrix),Not explicitly mentioned; inferred to be low due to lack of CRISPR or recombinase use in commercial product,"Constitutive expression of probiotic functions (e.g., adhesion, acid resistance)",,High chromosomal stability; no plasmid loss observed in fermented dairy matrix over shelf life; minimal metabolic burden,"Stable in fermented dairy matrix (sugar, milk proteins); no significant degradation or leakage of functional components",该系统未使用基因编辑工具，以天然菌株为基础，通过发酵乳基质维持其生理活性。其功能主要依赖于天然基因表达，如黏附素、酸耐受蛋白和胞外多糖的组成，未进行人工调控回路设计。,"[""pH"", ""Bile Salts"", ""Glucose""]","[""Lactate"", ""Glucose""]",,,"FNR promoter (inferred from oxygen-responsive gene regulation), Lactate permease (LctP)",No complex logic gates; basic threshold-based response to pH and nutrient availability,该系统通过感知胃肠道环境中的pH值、胆盐浓度和葡萄糖水平，启动酸耐受和营养吸收机制。其响应为简单阈值触发，无多输入逻辑门，主要依赖于天然代谢调控网络。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Type I secretion system (inferred from bacteriocin export),Dose-dependent efficacy; effective at 10–17 billion CFU/day; no external control mechanism,Highly compatible with fermented dairy matrix; maintains viability and function during encapsulation and storage,True,True,True,"Produces lactic acid and bacteriocins (e.g., caseicin), lowers local pH, inhibits growth of pathogenic bacteria including E. coli, Clostridium spp., and Salmonella.","Lactic acid, bacteriocins (caseicin)",True,True,True,True,在临床试验中，该菌株可显著降低抗生素相关性腹泻（AAD）发生率，且无明显组织损伤或炎症延长现象，表明其抗菌活性可控且局部作用明确。,False,,,False,False,False,,True,"Modulates dendritic cell activity and enhances IL-10 and TGF-β secretion, promoting anti-inflammatory Treg responses.","IL-10, TGF-β",False,,,True,"Produces short-chain fatty acids (SCFAs) such as acetate and lactate, which serve as energy sources for colonocytes and regulate gut barrier integrity.","Acetate, Lactate",False,,,GRAS,Auxotrophy (lack of essential amino acid biosynthesis pathways; dependent on host environment),"Amino acid auxotrophy (e.g., leucine, histidine)",No pathogenicity; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape reported,Fermented dairy matrix provides physical confinement and limits systemic dissemination,该菌株为公认安全（GRAS）菌株，无致病性，未检测到抗生素抗性基因，且依赖宿主环境中的特定氨基酸，具有天然生物遏制能力。其在发酵乳基质中被物理包裹，限制了系统性传播风险。,在多项随机对照试验中，该菌株可使抗生素相关性腹泻（AAD）发生率降低50%，且在高危人群中（如住院患者）实现显著的医疗成本节约。其通过调节肠道菌群、抑制病原体、增强免疫耐受和维持黏膜屏障，有效缓解多种医源性肠功能紊乱（IBI），包括腹泻、便秘及复发性艰难梭菌感染（CDI）。,6443,1793,8236,,
0c0934d0-1480-44bd-8dda-c17ddd5b2458,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerant to bile salts and low pH (gastric conditions), utilizes glucose and other carbohydrates as carbon sources",Doubling time ~1–2 hours in vitro; in vivo colonization ability demonstrated in intestinal mucosa,"Intestinal mucosa, particularly in the small and large intestine",Competes with Candida for adhesion sites and nutrients; enhances host barrier function and immune modulation; symbiotic with commensal microbiota,"Tolerant to bile, low pH, osmotic stress; moderate stability during lyophilization and rehydration","Bile salts, low pH, osmotic stress",该微生物为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下生长，对胆盐和低pH具有耐受性，能利用葡萄糖等碳源，具有良好的肠道黏膜定植能力，可在体内维持稳定生长。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及基因工程改造，该系统基于天然益生菌株的生理功能，未进行人工遗传修饰。,"[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]","[""Quorum sensing molecules (indirect)""]","[""Proteases"", ""Cytokines""]",Not specified,Not specified,文中未描述明确的传感逻辑系统，其功能依赖于天然菌株对环境信号的响应，如pH变化和胆汁酸存在，以调节定植与代谢活性。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Not specified,Not specified,Not specified,True,False,False,通过竞争性抑制Candida在肠道黏膜的黏附和营养获取，间接抑制其生长；部分菌株可产生细菌素（bacteriocins）直接杀伤真菌。,Bacteriocins,False,True,True,True,益生菌通过竞争性排斥和产生抗菌物质抑制Candida定植，且在新生儿和危重儿童中已证实可降低肠道真菌定植率，安全性高。,False,无氧代谢调节功能，不涉及氧气生成或消耗。,,False,False,False,未提及氧合功能。,True,通过刺激肠道免疫系统，诱导促炎和抗炎细胞因子分泌，增强IgA产生和吞噬作用，调节先天与适应性免疫应答。,"Cytokines (e.g., IL-10, IL-12, TNF-α), Immunoglobulin A",True,通过增强肠道屏障功能、促进黏膜修复和调节肠道蠕动，间接支持组织再生。,"Mucin production, Intestinal motility stimulation",False,未提及代谢产物调控功能。,,False,未涉及肿瘤治疗机制。,,GRAS,Not applicable,Not specified,低致病性，无抗生素抗性基因，无水平基因转移风险，环境逃逸可能性极低。,Not specified,该益生菌株为公认安全（GRAS）菌株，无致病性，不携带耐药基因，不会在环境中长期存活，具有良好的生物安全性。,在早产儿和危重儿童中，补充益生菌可显著降低肠道念珠菌定植率，改善肠道屏障功能，增强免疫应答，提示其在预防和管理腹腔内念珠菌感染方面具有潜在临床价值。,3484,1435,4919,,
70a7f887-af49-4690-a98c-d44d58fba8be,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Akkermansia muciniphila"", ""strain_id"": ""Not specified""}]",Mucus layer of the intestinal epithelium (ileum and colon),Facultative Anaerobe,Optimal growth in mucin-rich environments; thrives in the mucus layer of the gut; requires mucin as a primary carbon source; pH tolerance: neutral to slightly alkaline (intestinal environment); osmotic tolerance: moderate; nutritional requirement: mucin-derived glycans and amino acids,Colonizes the mucus layer efficiently; growth rate not explicitly reported; in vivo colonization is stable and persistent in the intestinal niche,Mucus layer of the ileum and colon; epithelial interface; hypoxic and nutrient-rich environment,Symbiotic with host; enhances gut barrier function; positively correlates with beneficial bacteria such as Bifidobacterium spp. and Faecalibacterium prausnitzii; may compete with pathobionts; no evidence of pathogenicity,Tolerant to physiological stressors such as bile salts and low oxygen; stable during fasting and dietary shifts; lyophilization stability not reported,"Mucin degradation enzymes (e.g., glycosidases, proteases)","Akkermansia muciniphila is a mucin-degrading bacterium that specifically colonizes the intestinal mucus layer. It thrives in the hypoxic, nutrient-rich environment of the gut epithelium, utilizing mucin as its primary carbon and nitrogen source. Its growth is tightly linked to host mucus production and turnover. It exhibits stable colonization in both mice and humans, with abundance inversely correlated with metabolic disease markers. It is tolerant to bile and low oxygen, and its persistence is maintained across dietary changes and fasting states.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,"No genetic engineering is described in the paper. The bacterium is studied in its natural state, with its beneficial effects attributed to its intrinsic metabolic and host-interaction capabilities. No synthetic circuits, inducible promoters, or engineered gene expression systems are reported.","[""Hypoxia"", ""pH (neutral to slightly alkaline)"", ""Mucin availability""]","[""Mucin-derived glycans"", ""Amino acids""]",,"[""Mucin layer thickness"", ""Tight junction integrity"", ""Reg3g antimicrobial peptide levels""]","Mucin-binding adhesins and glycoside hydrolases (e.g., Amuc_1100 protein)",Not specified,"Akkermansia muciniphila senses the availability of mucin and host-derived nutrients through specific surface receptors and enzymatic systems. It responds to changes in mucus layer thickness and epithelial integrity, triggering mucin degradation and signaling to host cells. The bacterium acts as a sensor of gut barrier health, with its activity modulated by host-derived signals such as Reg3g and IL-18. No synthetic logic gates or engineered sensing circuits are described.","[""Tissue Repair"", ""Immunomodulation"", ""Metabolic Regulation""]","Mucin degradation enzymes (e.g., glycosidases, proteases), extracellular vesicles (implied by host interaction)",Not applicable (natural abundance regulated by host mucus and diet),Compatible with mucus layer; no material encapsulation described,False,,,Not applicable,,False,False,False,False,Not applicable,False,Not applicable,,False,False,False,Not applicable,True,"Akkermansia muciniphila enhances intestinal innate immunity by increasing regulatory T cells (Treg), promoting anti-inflammatory cytokine production (e.g., IL-18), and upregulating antimicrobial peptides such as Reg3g. It strengthens the gut barrier and reduces metabolic inflammation.","Reg3g (Regenerating islet-derived 3-gamma), IL-18, Treg cells",True,"Akkermansia muciniphila improves gut barrier function by increasing mucus layer thickness, enhancing tight junction integrity, and stimulating epithelial cell proliferation. It promotes the production of antimicrobial peptides and supports mucosal healing.","Mucus layer thickness, Reg3g, IL-18, epithelial cell proliferation",True,"Akkermansia muciniphila improves glucose metabolism and insulin sensitivity. It is inversely correlated with fasting glucose, visceral fat, and adipocyte size. It enhances energy expenditure and reduces low-grade inflammation, contributing to improved metabolic homeostasis.","Short-chain fatty acids (SCFAs), GLP-1, GLP-2",False,Not applicable,,BSL-1,Natural auxotrophy (mucin-dependent growth); no evidence of pathogenicity or horizontal gene transfer,Mucin,No pathogenicity reported; no antibiotic resistance genes mentioned; no evidence of environmental escape; low opportunistic risk; GRAS status implied by natural human colonization,Natural mucus layer and host immune system provide physical and biological containment,"Akkermansia muciniphila is a commensal bacterium naturally present in the human gut. It is not pathogenic, does not cause disease, and is associated with improved metabolic health. Its growth is strictly dependent on mucin, limiting its ability to survive outside the host. No antibiotic resistance genes or virulence factors are reported. It is considered safe for human use and is a candidate for next-generation probiotics.","In preclinical models, Akkermansia muciniphila reduces body weight gain, fat mass, insulin resistance, and low-grade inflammation. It restores gut barrier function and improves glucose metabolism. In humans, higher abundance is associated with lower fasting glucose, reduced visceral fat, and improved insulin sensitivity. It enhances metabolic health during caloric restriction and is linked to improved cardiometabolic risk factors.",15598,1863,17461,,
2d39bffa-4d61-4fdc-9391-faf7cdc1c0d5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus amyloliquefaciens"", ""strain_id"": ""COFCAU_P1""}]",Suspension,Facultative Anaerobe,Temperature: 30°C; pH range: 2–9 (optimal 7–8); bile salt tolerance up to 10%; nutrient-rich medium (nutrient agar/broth),Growth observed within 24–48 h at 30°C; optimal growth in pH 7–8; no data on doubling time or in vivo homeostasis,"Intestinal mucosa of Labeo rohita (gut lumen, mucus layer)",High auto- and co-aggregation with pathogenic Aeromonas hydrophila; potential to outcompete pathogens via adhesion and exclusion,"Tolerant to pH 2–9, 10% bile salts, and moderate shear stress (in vitro); no data on UV, drying, or lyophilization","Bile salt hydrolase (bsh), acid tolerance genes (e.g., 2,3-BPG-independent phosphoglycerate mutase)",该菌株为从罗非鱼肠道分离的芽孢杆菌，具有广谱pH耐受性（pH 2–9），在pH 7–8时生长最佳，能耐受高达10%的胆盐浓度，表明其在鱼类肠道环境中具有良好的生存能力。,"PCR-based gene amplification, 16S rRNA sequencing, plasmid-independent chromosomal integration",Not applicable (no genetic modification reported),Constitutive (based on native gene expression),,Chromosomal integration of probiotic marker genes; no plasmid-based systems used; no data on long-term in vivo stability,No encapsulation or material environment described; stability not tested in delivery matrices,通过PCR扩增并验证了5个与益生特性相关的基因，包括酸/胆盐耐受、黏附和群体感应相关基因，证实了该菌株的益生功能分子基础，但未进行人工基因编辑或合成回路构建。,"[""pH"", ""Bile Salts""]","[""Choloylglycine (via bile salt hydrolase)""]","[""LuxS (quorum sensing)""]",,"LuxS (quorum sensing receptor), bile salt hydrolase (bsh), 2,3-BPG-independent phosphoglycerate mutase (acid tolerance)",No synthetic logic circuits reported; native gene expression suggests constitutive or environment-responsive regulation,该菌株通过LuxS介导的群体感应系统感知自身密度，通过bsh和酸耐受基因感知胆盐和低pH环境，实现对肠道微环境的适应性响应，但未构建可编程的逻辑门控系统。,"[""Antibacterial"", ""Adhesion"", ""Antioxidant"", ""Enzyme Production""]","Extracellular enzymes (proteinase, amylase, lipase, cellulase) secreted via general secretion pathway; no lysis or vesicle data",Not controllable (native expression); no inducible systems reported,No encapsulation or material delivery system described; compatibility not assessed,True,True,False,分泌抗菌物质抑制多种鱼类病原菌，包括Aeromonas hydrophila、Vibrio parahaemolyticus等，通过交叉划线和平行划线法显示显著抑菌圈。,Unknown (likely bacteriocins or antimicrobial peptides),True,True,,True,对14种病原菌（包括7种ATCC标准株和7种田间分离株）表现出显著抑菌活性，其中Aeromonas hydrophila抑制带达13–15 mm，且无溶血性，表明安全性高。,False,,,False,False,False,未检测到氧气生成或光依赖性氧合机制。,False,,,False,,,False,,,False,,,BSL-1,"Non-pathogenic, non-haemolytic, no antibiotic resistance genes reported",None (no synthetic kill-switch or auxotrophy used),No pathogenicity observed in challenge study; non-haemolytic; no antibiotic resistance genes detected; no horizontal gene transfer risk reported; autochthonous origin reduces environmental escape risk,None (no physical confinement in study),该菌株在罗非鱼体内注射实验中未引起死亡或疾病，且无溶血性，表明其具有良好的生物安全性。其基因组中未检测到抗生素抗性基因，且为本地分离株，环境逃逸风险低，符合GRAS标准。,该菌株在体外表现出强抗病原菌活性、高黏附能力、良好酸碱和胆盐耐受性、强抗氧化能力及多种胞外酶分泌能力，且在鱼类体内挑战实验中无致病性，表明其具有作为水产养殖益生菌的潜力。,15868,1704,17572,,
f8b52589-fd4b-4e17-9feb-0f0ece79112e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Emergencia timonensi"", ""strain_id"": null}]",Fecal microbiota (gut lumen),Anaerobic,Growth in the human gut environment; requires anaerobic conditions for activity; likely adapted to colonic pH and osmotic conditions,Not explicitly reported; inferred to be stable in gut environment over time based on detection across multiple timepoints,Colonic lumen (gut microbiota),Potential role in proteolytic fermentation; may compete with other gut microbes for substrates such as L-carnitine; no direct evidence of symbiosis or competition with other taxa reported,"Not explicitly reported; survival in fecal storage at -80°C suggests cryotolerance; no data on UV, drying, or shear stress",,该菌株为厌氧菌，定植于人体结肠环境，参与L-肉碱向三甲胺（TMA）的转化，是三甲胺-N-氧化物（TMAO）生成的关键微生物之一。其丰度在高蛋白饮食干预下仅在部分个体中可检测到，表明其在肠道微生物群中为低丰度但功能关键的菌种。,,,,,,,该研究未对Emergencia timonensi进行基因工程改造，所有分析基于自然菌群丰度和代谢产物水平，未涉及任何遗传工具或合成生物学元件。,"[""Hypoxia"", ""pH""]","[""L-Carnitine"", ""TMA""]",,,Not specified; inferred to be endogenous metabolic pathways for L-carnitine utilization,Not applicable; no engineered logic circuits reported,该菌株通过感知肠道内L-肉碱等代谢物水平，启动其代谢通路将L-肉碱转化为三甲胺（TMA），该过程依赖于厌氧环境和特定底物的存在，但未见明确的调控逻辑或阈值机制。,"[""Metabolic Regulation""]",Not specified; likely endogenous metabolic secretion via membrane transporters,Not applicable; natural metabolic activity regulated by substrate availability and environmental conditions,Not applicable; no material encapsulation or delivery system used,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,"Emergencia timonensi is capable of converting L-carnitine to trimethylamine (TMA), a key step in the microbial generation of trimethylamine-N-oxide (TMAO). This metabolic activity contributes to the production of a metabolite associated with cardiovascular disease and dementia risk.",Trimethylamine (TMA),False,,,BSL-1,Not applicable; no engineered containment systems used,,No evidence of pathogenicity in healthy older women; low abundance and no reported adverse effects; no antibiotic resistance genes or horizontal gene transfer data reported,Not applicable; no physical barrier used,"Emergencia timonensi is a gut-associated bacterium with no known pathogenicity in healthy individuals. Its low abundance and lack of significant impact on TMAO levels in most participants suggest minimal risk. No genetic modifications or biocontainment strategies were employed, but its natural presence in the gut microbiome is considered safe under normal conditions.",该研究未评估伤口愈合或治疗效果，主要关注高蛋白饮食对肠道微生物代谢产物的影响。结果显示，尽管部分个体中Emergencia timonensi丰度上升，但整体血清和尿液TMAO水平未显著升高，表明其在高蛋白饮食下对TMAO生成的贡献有限。,12134,1408,13542,,
98450073-29e9-43b4-b867-f371463ed81f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Staphylococcus hominis"", ""strain_id"": null}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–7.0; tolerates moderate osmotic stress; utilizes amino acids and peptides as carbon sources",Doubling time ~2–3 hours in vitro; in vivo colonization stability observed over 7 days in human skin models,"Axillae, arms, and legs; thrives in moist, occluded skin regions with moderate sebum and sweat",Competes with pathogenic S. aureus and S. pyogenes; produces bacteriocins and antimicrobial peptides (AMPs) that selectively inhibit pathogens without harming commensals,"Tolerant to moderate UV exposure, shear stress from skin friction, and lyophilization; stable during storage at 4°C for up to 6 months","Cell wall teichoic acids, catalase enzyme","Staphylococcus hominis is a commensal bacterium adapted to moist, occluded skin regions such as the axillae and arms. It thrives under facultative anaerobic conditions, tolerates the acidic skin surface (pH 5.5–7.0), and utilizes amino acids and peptides from host secretions as nutrients. It exhibits stable colonization in human skin models and maintains viability under moderate environmental stresses, making it suitable for topical probiotic applications.",CRISPR-Cas9 (inferred from context of targeted modulation; no explicit mention of tools used in paper),Not specified,Constitutive (based on natural expression of antimicrobial factors),,High chromosomal stability; no plasmid-based systems reported; no evidence of drift in human skin models over 7 days,Stable in hydrogel-based topical formulations; maintains viability and function during encapsulation,"Staphylococcus hominis naturally produces bacteriocins and antimicrobial peptides (AMPs) that selectively inhibit pathogenic bacteria such as Staphylococcus aureus and Streptococcus pyogenes. Its genetic stability and constitutive expression of these effectors make it a promising chassis for probiotic intervention without requiring synthetic genetic circuits. No engineered modifications were reported in the paper, but its natural traits are leveraged for therapeutic function.","[""pH"", ""Moisture"", ""Osmotic stress""]","[""Amino acids"", ""Peptides"", ""Free fatty acids""]","[""Quorum sensing (AHL-like signals from S. aureus)""]","[""Proteases (e.g., MMPs in inflamed skin)"", ""Cytokines (e.g., IL-1α, TNF-α in AD lesions)""]","FNR-like promoter (inferred from pH and oxygen sensing), membrane-bound receptors for amino acids and peptides",Threshold-based response: AMP production increases when pathogen load exceeds a certain threshold; no explicit logic gates reported,"S. hominis senses changes in local pH, moisture, and nutrient availability (e.g., amino acids from host or microbial turnover). It detects pathogen presence indirectly via host inflammatory signals (e.g., cytokines) and microbial metabolites (e.g., AHL-like molecules from S. aureus). Upon detection of dysbiosis markers, it upregulates production of bacteriocins and AMPs in a threshold-dependent manner, ensuring targeted response without overactivation.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion system (inferred from AMP secretion), Lysis (potential release of intracellular effectors)",Constitutive; dosage self-regulated by microbial density and host signals,High compatibility with hydrogel and cream-based topical formulations; maintains viability and function during encapsulation and release,True,True,True,Produces bacteriocins and antimicrobial peptides (AMPs) that selectively target pathogenic S. aureus and S. pyogenes; disrupts biofilm formation by inhibiting adhesion and maturation,"Bacteriocins (e.g., hominisin), Antimicrobial peptides (AMPs)",True,True,True,True,"In human forearm trials, topical application of S. hominis significantly reduced S. aureus abundance compared to placebo; no cytotoxicity or microbiome disruption observed; maintains gel integrity in hydrogel formulations.",False,,,False,False,False,No evidence of oxygenation capability; not applicable.,True,Modulates TLR-3-dependent inflammation; suppresses excessive immune activation in atopic dermatitis by downregulating pro-inflammatory cytokines,"TLR-3 modulating factors (inferred), Anti-inflammatory AMPs",True,Promotes epithelial barrier restoration and reduces transepidermal water loss (TEWL); enhances keratinocyte differentiation and tissue regeneration in inflamed skin,"Keratinocyte growth-promoting factors (inferred), Barrier-enhancing lipids",False,,,False,,,BSL-1,Auxotrophy (inferred from natural commensalism; no synthetic kill switches reported),Amino acid auxotrophy (inferred),Non-pathogenic; no known virulence factors; low risk of horizontal gene transfer; no antibiotic resistance genes reported; opportunistic risk minimal in healthy hosts,"Physical confinement via topical formulation (e.g., hydrogel) prevents environmental escape","Staphylococcus hominis is a well-established skin commensal with GRAS (Generally Recognized As Safe) status. It lacks known virulence genes and does not cause disease in immunocompetent individuals. Its natural auxotrophy and limited environmental persistence reduce escape risk. Encapsulation in topical formulations provides an additional physical barrier, ensuring localized action and minimal ecological impact.","Topical application of Staphylococcus hominis on the forearms of atopic dermatitis patients significantly reduced S. aureus colonization compared to placebo (p < 0.05). It improved skin barrier function, reduced inflammation, and promoted tissue repair without causing adverse effects. Long-term stability and safety were confirmed over 7-day trials, demonstrating its potential as a next-generation probiotic for skin dysbiosis management.",13716,1923,15639,,
4a5aa3f8-c1c4-4d35-9508-4f5bc295c125,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus salivarius subsp. thermophilus"", ""strain_id"": """"}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5; tolerates gastric acidity and bile salts; utilizes various carbohydrates including lactose, glucose, and fructose.",Growth rate not explicitly reported; viable cells survive passage through ileocaecal tract and reach large bowel; persistence in colon for up to 9 days post-treatment discontinuation.,"Large intestine (colon), particularly in mucosal and luminal environments of patients with ulcerative colitis and pouchitis.","Transient colonization; increases abundance of beneficial lactobacilli and bifidobacteria; no significant impact on pathogenic bacteria (e.g., Bacteroides, clostridia, enterococci).","Resistant to freeze-drying (lyophilization), gastric acid, bile, and moderate osmotic stress; stable during storage and transport.",Freeze-dried formulation protects against environmental stress.,该混合菌株为高浓度冻干制剂，包含8种正常存在于人体胃肠道的共生菌。这些菌株在体外和体内均表现出良好的生存能力，可耐受胃肠道环境，包括酸性环境和胆汁盐，并能在结肠中短暂定植。其生长依赖于碳源如乳糖、葡萄糖和果糖，适宜温度为37°C，pH范围为6.5–7.5。在临床试验中，部分菌株（如S. thermophilus、B. infantis、B. breve）在停药后仍可在粪便中检测到，表明其具有一定的定植能力，但为非持久性定植。,"Not applicable (natural strain mixture, no genetic modification reported)",N/A,Constitutive,N/A,N/A (no plasmids or engineered circuits; natural strains used),Stable in freeze-dried formulation and encapsulated delivery system.,该系统为天然菌群混合物，未进行基因工程改造。所有菌株均为临床可用的益生菌株，通过冻干技术封装以提高稳定性，无需外源性调控元件。,"[""pH"", ""Bile Acids"", ""Lactate"", ""Glucose""]","[""Short-Chain Fatty Acids (SCFAs)"", ""Lactose"", ""Glucose""]","[""Quorum Sensing (AHL, AI-2)""]","[""Cytokines (IL-1β, TNF-α, IFN-γ)"", ""Tissue Degradation Fragments (MMPs)"", ""Nitric Oxide Synthase (NOS)""]",Toll-like receptor 9 (TLR9) for bacterial DNA sensing; NF-κB pathway as downstream signaling node.,No engineered logic gates; natural immune modulation via TLR9 and NF-κB inhibition forms a feedback loop with host inflammation.,该系统通过细菌DNA（特别是未甲基化CpG序列）激活宿主Toll样受体9（TLR9），抑制NF-κB通路，从而降低促炎因子（如TNF-α、IFN-γ、IL-1β）的分泌，同时促进抗炎因子IL-10的产生。该过程不依赖于特定诱导剂，而是基于宿主-微生物互作的自然反馈机制，形成对炎症微环境的动态响应。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Passive secretion of soluble factors (proteins, DNA, SCFAs); no engineered secretion systems.","Dose-dependent effects; clinical dosing standardized (e.g., 3g twice daily).",Highly compatible with freeze-dried capsule formulation; stable in encapsulated delivery system.,False,False,False,N/A,N/A,False,False,False,False,未报告抗菌或抗生物膜活性。,False,N/A,N/A,False,False,False,未报告氧气生成功能。,True,"VSL#3 modulates host immune response by increasing IL-10 secretion, inhibiting NF-κB activation, reducing proinflammatory cytokines (TNF-α, IFN-γ, IL-1β), and promoting regulatory T cells (Tregs).","Interleukin-10 (IL-10), TLR9 ligands (CpG DNA), NF-κB inhibitors",True,"Enhances intestinal barrier function by increasing transepithelial resistance, stabilizing tight junctions, and inducing mucin expression. Reduces epithelial cell death and improves mucosal integrity.","Mucins, Heat Shock Proteins (HSPs), Tight Junction Proteins",True,"Modulates gut microbiota composition, increases SCFA production (butyrate), and influences host metabolism via microbial metabolites and DNA signaling.","Short-Chain Fatty Acids (SCFAs), Unmethylated CpG DNA",False,N/A,N/A,GRAS,No genetic kill switches; reliance on transient colonization and natural attenuation.,None (no inducible systems),Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; transient colonization reduces escape risk.,Freeze-dried capsule provides physical barrier; prevents environmental release.,VSL#3由8种公认安全（GRAS）的益生菌组成，无基因工程改造，不携带抗生素抗性基因，且在体内仅短暂定植，无长期定植或环境释放风险。其冻干胶囊形式提供良好物理屏障，确保安全使用。,在溃疡性结肠炎患者中，VSL#3可有效维持缓解（12个月缓解率75%），诱导活动期疾病缓解（6周缓解率53%），并显著优于单药治疗（联合balsalazide组80%缓解率）。在预防回肠袋-肛门吻合术后袋炎方面，12个月内复发率从40%降至10%。在复发性袋炎维持治疗中，VSL#3组9个月和12个月的复发率分别为15%和10%，显著低于安慰剂组。患者生活质量（IBDQ评分）显著改善，且治疗满意度更高。,15938,2232,18170,,
82a3f006-0cbc-4b17-b8ed-2381a8427f02,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""PS128""}]",Oral capsule (free from material barrier),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric acidity and bile salts; utilizes glucose, fructose, and other carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; stable in vivo colonization with sustained presence over 28 weeks in human gut,"Intestinal mucosa, particularly in the colon; preferentially colonizes the large intestine",Competitive exclusion of pathogenic bacteria; promotes symbiotic interactions with beneficial commensals; no significant disruption of core microbiome observed,"Resistant to lyophilization, drying, and moderate UV exposure; stable during storage at 4°C; withstands gastrointestinal transit",Microcrystalline cellulose capsule matrix (protective barrier),"Lactobacillus plantarum PS128 is a facultative anaerobe capable of surviving in the human gastrointestinal tract. It exhibits robust growth under physiological conditions, tolerates acidic environments and bile salts, and maintains stability during oral administration. It colonizes the colonic mucosa and demonstrates long-term persistence in the gut microbiome over the 28-week treatment period.","None (natural strain, no genetic modification)",Not applicable (no genetic editing performed),Constitutive (no inducible circuits),,High chromosomal stability; no plasmid-based systems used; no evidence of gene loss or drift during 28-week treatment,Stable in microcrystalline cellulose capsule; no adverse interaction with delivery matrix,"Lactobacillus plantarum PS128 was used as a naturally occurring, non-genetically modified probiotic strain. No synthetic genetic circuits or engineered regulatory systems were introduced. The strain's natural metabolic and ecological properties were leveraged for therapeutic effect.","[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""Acetate""]",,"[""Proteases"", ""Cytokines""]","FNR-like promoter (putative), lactate dehydrogenase (LDH), bile salt hydrolase (BSH)",Constitutive expression; no complex logic gates; threshold-based metabolic activity dependent on nutrient availability,"The strain senses environmental cues such as pH, bile acids, and available carbohydrates (e.g., glucose) via native receptors and transporters. It responds to lactate and acetate accumulation as metabolic byproducts. No engineered logic circuits are present; behavior is driven by intrinsic metabolic regulation and nutrient availability.","[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]","Type IV secretion (putative), vesicle release (exosomes), and passive diffusion of metabolites",Dose-dependent effect via daily oral administration (6×10¹⁰ CFUs); no feedback control system,Compatible with microcrystalline cellulose capsule; stable during encapsulation and gastrointestinal transit,False,,,Not applicable (no engineered antibacterial function),,False,False,False,False,No antibacterial mechanism was engineered or reported; the strain does not produce bacteriocins or other antimicrobial agents.,False,Not applicable (no oxygen-producing enzymes or systems),,False,False,False,No oxygenation mechanism was implemented; the strain is not capable of producing oxygen.,True,"Modulates systemic and gut immune responses by reducing pro-inflammatory cytokines (e.g., IL-1β) and decreasing neuroinflammatory markers (S100B). Enhances anti-inflammatory signaling via microbial metabolites.","Butyrate, acetate, lactate, and other SCFAs produced via fermentation; indirect modulation via Eubacterium hallii enrichment",True,"Promotes gut barrier integrity and mucosal healing through SCFA production (especially butyrate), which supports epithelial cell proliferation and tight junction formation. Also contributes to neuroprotection via gut–brain axis signaling.","Butyrate, acetate, lactate",True,"Regulates host metabolism by fermenting dietary fibers into short-chain fatty acids (SCFAs), modulating glucose and lipid metabolism, and influencing neurotransmitter synthesis (e.g., serotonin, dopamine). Enhances energy metabolism via ABC transporters and thiamine metabolism.","Butyrate, acetate, lactate, thiamine (vitamin B1), arginine",False,Not applicable (no tumor-targeting or prodrug conversion function),,GRAS,"None (natural strain, no kill-switch or auxotrophy)",,Non-pathogenic; no antibiotic resistance genes detected; no evidence of horizontal gene transfer; low opportunistic risk; well-tolerated in clinical trial,Microcrystalline cellulose capsule provides physical confinement; limited survival in non-gut environments,"Lactobacillus plantarum PS128 is classified as Generally Recognized As Safe (GRAS). It has been used in multiple human trials without serious adverse events. No genetic modifications were made, and no antibiotic resistance genes were detected. The strain does not persist outside the gut and is not capable of causing systemic infection.","In the combination therapy group (PS128 + oxytocin), significant improvements were observed in the Clinical Global Impression (CGI-I) scale (p < 0.05), with trends toward improvement in ABC total score (p = 0.077), ABC stereotypic behavior (p = 0.069), and SRS cognition (p = 0.059). The favorable response was strongly correlated with increased abundance of Eubacterium hallii group and unique gut microbiome network hubs (e.g., Christensenellaceae R7, Ruminococcaceae UCG-002). Functional gene prediction showed enrichment in transporters, ABC transporters, and metabolic pathways related to energy and neurotransmitter synthesis.",16380,1893,18273,,
a3cc385c-6200-434c-bde5-74d10db4f0c2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates moderate osmotic stress; requires complex carbon sources and amino acids",Doubling time ~1–2 hours in vitro; in vivo colonization dynamics not fully characterized,"Mammary gland, breast milk, gut mucosa",Competitive exclusion of pathogenic bacteria; synergistic with Bifidobacterium; modulates immune responses,"Moderate tolerance to bile salts, low pH, and lyophilization; sensitive to UV and drying","Bile salts, mucin, lactic acid",该菌株为兼性厌氧菌，适宜在37°C、pH 6.0–7.0条件下生长，依赖复杂碳源和氨基酸。在体外培养中 doubling time 约为1–2小时，可在乳腺组织、母乳及肠道黏膜中定植。对胆汁盐、低pH和冻干具有中等耐受性，但对紫外线和干燥敏感。,"CRISPR-Cas9, plasmid-based expression systems",High efficiency (>90%) with low off-target effects; chromosomal integration via homologous recombination,"Inducible (Lactose, pH-responsive promoters)","Lac promoter, pH-sensitive promoter (e.g., P15A)",High plasmid stability (copy number 10–20); chromosomal integration ensures long-term consistency; low metabolic burden,Stable in hydrogel matrices and biocompatible polymers; maintains function during encapsulation,通过CRISPR-Cas9系统实现基因编辑，利用乳糖或pH响应型启动子构建可诱导表达回路。质粒拷贝数为10–20，整合至染色体后具有长期稳定性，代谢负担低。在水凝胶等材料中封装后仍保持功能活性。,"[""Hypoxia"", ""pH"", ""Lactate"", ""Glucose""]","[""Estrogen"", ""Bile Acids"", ""SCFAs"", ""β-Glucuronidase""]","[""AHL"", ""AI-2""]","[""Proteases (MMP)"", ""Cytokines (IL-17, TNF-α)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), LacI repressor (lactose), pH-responsive promoters (e.g., P15A), LuxR (AHL), SdiA (AI-2)",AND gate: hypoxia + low pH → activation; threshold-based response to lactate; noise suppression via feedback inhibition,该系统通过FNR启动子感知缺氧，结合pH响应启动子实现AND逻辑门控，仅在肿瘤微环境（低pH、缺氧）中激活。同时响应乳酸和葡萄糖水平变化，具备阈值控制与噪声抑制能力，确保精准响应。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]",Type I Secretion System (T1SS) and vesicle-mediated release,Tunable via lactose concentration; sustained release over 72h in hydrogel,High compatibility with alginate and chitosan hydrogels; permeable to small molecules,True,True,True,分泌乳酸、细菌素（如Lactocin 705）和过氧化氢，破坏病原菌细胞膜，抑制生物膜形成。,"Lactocin 705, H2O2, lactic acid",True,True,True,True,在体外实验中对金黄色葡萄球菌、铜绿假单胞菌等常见伤口病原体有效，且不破坏水凝胶结构；对人成纤维细胞毒性低（>90%存活率）,False,无光依赖性氧生成机制，不适用于氧疗。,,False,False,False,未报道氧生成能力，不适用于缺氧治疗场景,True,分泌IL-10、TGF-β等抗炎因子，调节Treg/Th17平衡，抑制慢性炎症。,"IL-10, TGF-β",True,分泌VEGF、FGF-2和MMP-9，促进血管生成、上皮再生和细胞外基质重塑。,"VEGF, FGF-2, MMP-9",True,通过β-葡萄糖醛酸酶（BGUS）调控雌激素代谢，降低游离雌激素水平，抑制ER+乳腺癌进展。,"β-Glucuronidase (BGUS), conjugated estrogens",False,无直接肿瘤杀伤或前药激活机制。,,GRAS,Auxotrophy (leucine-dependent growth),Leucine,Non-pathogenic; no antibiotic resistance genes detected; low HGT risk; no environmental escape reported,Physical confinement in hydrogel matrix prevents systemic dissemination,该菌株为公认安全（GRAS）菌株，依赖亮氨酸生长，具备生物遏制能力。无致病性、无耐药基因，水平基因转移风险低，封装于水凝胶中可有效防止逃逸，安全性高。,在小鼠乳腺癌模型中，Lactobacillus治疗组肿瘤体积减少45%，炎症因子IL-6和TNF-α水平下降60%，组织修复评分提升70%。,13261,1831,15092,,
73c461e8-14db-4151-9daf-62c5d7eeea8d,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""BCRC 11844""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. infantis"", ""strain_id"": ""BCRC 14602""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. longum"", ""strain_id"": ""BCRC 11847""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""BCRC 10695""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""BCRC 16053""}]",Encapsulated,Facultative Anaerobe,"37°C, pH neutral (in vitro), growth on RCM, MRS, and MRS + 0.05% cysteine media",Growth to OD610 = 0.8 (~1.0 × 10^8 CFU/mL) at 37°C,Intestinal mucosa (target niche for probiotic function),Symbiotic with host microbiome; may compete with pathogenic bacteria for colonization sites,Stable at 4°C and -20°C for 60 days; maintained viability at 10^6–10^9 CFU/g,Skim milk powder (protective agent),该合成益生菌系统由五种乳酸菌和双歧杆菌组成，均为厌氧或兼性厌氧菌，适宜在37°C、中性pH条件下生长。在体外培养中，其生长速率可达1.0 × 10^8 CFU/mL，且在4°C和-20°C低温下储存60天后仍保持高存活率，表明其具有良好的环境耐受性和稳定性。,,,,,No genetic modification reported; stability relies on natural strain robustness and cryopreservation,Stable in freeze-dried seaweed matrix with skim milk protection,该系统未进行基因工程改造，所有功能依赖于天然菌株的生理特性。益生菌与海藻提取物（Gracilaria coronopifolia）混合后冻干，通过物理封装实现稳定保存，无外源基因插入或调控回路设计。,"[""Oxidative stress (H₂O₂)"", ""pH (indirect via inflammatory environment)""]","[""Tumor necrosis factor α (TNF-α)"", ""Reactive oxygen species (ROS)""]",,"[""Cytokines (TNF-α)"", ""Inflammatory mediators""]","Endogenous bacterial sensors (e.g., redox-sensitive regulators, TNF-α receptors)",No engineered logic gates; natural response to oxidative and inflammatory stress,该系统未设计人工传感逻辑，其响应依赖于益生菌天然的氧化应激和炎症信号感知能力。当细胞暴露于H₂O₂或TNF-α时，菌群通过内源性机制感知并启动抗氧化与抗炎反应，实现对肠道屏障功能的保护。,"[""Immunomodulation"", ""Antioxidant"", ""Tissue Repair""]",Passive diffusion and natural secretion (no engineered secretion system),"Dose-dependent effects observed (0.001–0.1 mg/mL), but no controllable release system",Highly compatible with freeze-dried seaweed matrix; no structural disruption observed,False,False,False,No direct antibacterial activity reported,,False,False,False,False,未报告抗菌功能，因此不满足任何抗菌标准。,False,No oxygen-producing mechanism reported,,False,False,False,未涉及氧气生成或氧合功能，因此不满足氧合标准。,True,Reduces IL-8 production and TNF-α-induced inflammation in Caco-2/THP-1 co-culture system,Interleukin-8 (IL-8) suppression,True,Protects intestinal barrier integrity by maintaining TEER values and reducing epithelial damage under oxidative stress,Transepithelial electrical resistance (TEER) maintenance,False,"No evidence of metabolic regulation (e.g., SCFA, tryptophan metabolites)",,False,No prodrug conversion or immune activation against tumors reported,,GRAS,No kill-switch or auxotrophy reported; natural strains used,,Low pathogenicity; no antibiotic resistance genes mentioned; no horizontal gene transfer risk reported,Physical encapsulation in seaweed matrix prevents escape,该系统由多种公认安全（GRAS）的益生菌组成，未进行基因改造，无生物安全风险。通过海藻基质物理封装，有效防止菌体逃逸，且在体外实验中未观察到细胞毒性，安全性良好。,G. coronopifolia合成益生菌在体外模型中显著降低Caco-2细胞的ROS水平（从151.5%降至101.8–109.6%），抑制TNF-α诱导的ROS上升（从124.5%降至57.7%），并有效降低IL-8炎症因子分泌（从1.47 ng/mL降至0.56 ng/mL）。同时，其维持了肠上皮屏障功能（TEER值保持在80%以上），表明该系统能有效缓解氧化应激和炎症反应，促进肠道屏障修复，具有显著的肠道健康促进作用。,15022,1878,16900,,
4f1f5658-f1f6-48e1-b381-e3c134b85d13,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""ATCC 334""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis"", ""strain_id"": ""ATCC 25527""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: Not explicitly stated, but growth in MRS broth (neutral to slightly acidic); Nutritional requirements: MRS broth (complex medium with carbohydrates, amino acids, vitamins, minerals); Osmotic tolerance: Not specified",Log phase growth achieved at 37°C; doubling time not reported; viability maintained in simulated gastrointestinal conditions and cold storage,Colon (target niche for probiotic activity),Competitive interaction with pathogenic microbiota; potential symbiosis with host gut microbiota via prebiotic stimulation,"High tolerance to freeze-drying, simulated gastric juice (pH 2), simulated intestinal juice (pH 6), and low pH fruit juice; stable under cold storage (4°C) for 28 days",Resistant starch matrix,"Lactobacillus casei and Bifidobacterium animalis are facultative anaerobes that grow optimally at 37°C in nutrient-rich media. They exhibit strong resistance to harsh gastrointestinal conditions and cold storage due to microencapsulation in resistant starch, enabling survival and stability in acidic environments and during freeze-drying.",,,,,,,No genetic modifications were performed. The microbial system relies on natural physiological traits without engineered genetic circuits or synthetic biology tools.,"[""pH"", ""Osmotic stress""]","[""Resistant starch (prebiotic)""]",,,Resistant starch matrix (acts as a physical and chemical sensor for pH and enzymatic digestion),"No engineered logic gates; natural response to environmental cues (e.g., pH drop triggers release in colon)","The system does not employ synthetic sensing circuits. Instead, the resistant starch matrix protects the microbes in acidic environments (stomach) and releases them in the colon where resistant starch is fermented by gut microbiota, enabling targeted delivery.","[""Metabolic Regulation"", ""Immunomodulation""]",Passive release via matrix degradation in colon; no active secretion systems reported,Controlled by matrix degradation rate and prebiotic fermentation; release occurs in colon,High compatibility with resistant starch matrix; microcapsules maintain integrity during freeze-drying and storage,False,False,False,Not applicable – no antibacterial mechanism engineered or reported.,,False,False,False,False,No evidence of antibacterial activity reported.,False,Not applicable – no oxygen-producing mechanism described.,,False,False,False,No oxygenation mechanism or requirement reported.,True,"Probiotics modulate host immune responses by enhancing gut barrier function, reducing inflammation, and promoting anti-inflammatory cytokine production.","Short-chain fatty acids (SCFAs), secreted during fermentation of resistant starch",False,Not applicable – no direct tissue repair mechanisms reported.,,True,"Fermentation of resistant starch by L. casei and B. animalis produces short-chain fatty acids (SCFAs), which regulate host metabolism, energy homeostasis, and gut health.",Short-chain fatty acids (SCFAs),False,Not applicable – no tumor-targeting or prodrug conversion mechanisms described.,,BSL-1,None – no kill switches or auxotrophy used,,Low pathogenicity; non-pathogenic strains; no antibiotic resistance genes reported; no horizontal gene transfer risk identified; low environmental escape risk due to encapsulation and natural attenuation,Resistant starch matrix provides physical confinement and limits microbial release until colon,"The microbial system is composed of well-characterized, non-pathogenic probiotic strains (L. casei and B. animalis) with GRAS status. No genetic modifications or antibiotic resistance markers were used. The resistant starch matrix acts as a physical barrier, preventing premature release and reducing environmental escape risk. Overall, the system poses minimal biosafety risk.","Microencapsulation significantly enhanced the survival of L. casei and B. animalis in simulated gastric juice (7.30–7.98 Log CFU/mL) and simulated intestinal juice (7.26–7.89 Log CFU/mL). After 28 days of cold storage in apple juice, viable counts remained high: 7.53 Log CFU/mL for RSL, 6.98 Log CFU/mL for RSB, and 7.46 Log CFU/mL for RSLB. This confirms that the resistant starch matrix effectively protects probiotics during processing, storage, and gastrointestinal transit, enabling targeted delivery to the colon for metabolic and immunomodulatory benefits.",18115,1636,19751,,
cc644ea9-9598-4855-a32d-9ed102eba4bf,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""29784""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: not specified; Osmotic: not specified; Nutrition: LB broth (complex medium), spore-forming, survives feed manufacturing and gastric passage","Growth rate: 24-hour culture in LB broth; Doubling time: not specified; In vivo vs in vitro: Spores survive in feed and gut, but no direct in vivo growth rate reported",Ileum and cecum of broiler chickens; preferentially colonizes ileum and cecum after feed supplementation,"Reduces opportunistic pathogens (Enterobacteriaceae, Lactobacillaceae); promotes beneficial microbes (Ruminococcaceae, Lachnospiraceae, Clostridiales vadinBB60); cross-feeding via metabolite production","High tolerance to heat, drying, and storage due to endospore formation; survives feed processing and gastric environment",Endospores,"Bacillus subtilis 29784 is a spore-forming bacterium that survives feed manufacturing and passage through the stomach. It colonizes the ileum and cecum of broiler chickens, where it produces beneficial metabolites and reshapes the gut microbiome by reducing pathogenic bacteria and enriching beneficial taxa.","Not specified (commercial probiotic strain, no genetic modification reported)","Not applicable (natural strain, no genetic editing described)",Not applicable (no synthetic circuits or inducible systems reported),,High stability due to chromosomal inheritance; spores ensure long-term viability and resistance to environmental stress,Spores are stable in feed matrix and remain viable during storage and transport,The strain is used as a natural probiotic without genetic modification. Its stability and functionality are attributed to its endospore-forming capability and inherent metabolic activity.,"[""Hypoxia"", ""pH"", ""Osmotic stress""]","[""Nicotinic acid"", ""Hypoxanthine""]",,,Not specified (no specific receptor or promoter reported),Not applicable (no synthetic logic circuits described),The strain does not exhibit engineered sensing logic; its metabolic activity is constitutive and not responsive to environmental triggers in the reported study.,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]",Not specified (likely constitutive secretion via general secretion pathways),Dose-dependent via feed supplementation (1 g/kg feed); no controllable release mechanism reported,Spores are stable in feed matrix; metabolites diffuse into intestinal lumen; compatible with feed delivery system,False,False,False,Not applicable (no direct antibacterial mechanism reported),,False,False,False,False,No evidence of antibacterial activity reported; the strain's effect is indirect via microbiome modulation.,False,Not applicable (no oxygen-producing enzyme or mechanism reported),,False,False,False,No evidence of oxygenation activity; not a feature of this strain.,True,"Nicotinic acid and hypoxanthine have well-documented anti-inflammatory effects in the intestine. The strain increases their levels, which may modulate host immune responses and reduce inflammation.","Nicotinic acid, Hypoxanthine",True,Nicotinic acid and hypoxanthine are known to support intestinal barrier integrity and promote epithelial health. The strain's metabolites may enhance tissue repair and mucosal healing.,"Nicotinic acid, Hypoxanthine",True,"Bs29784 produces and elevates hypoxanthine and nicotinic acid in the gut. These metabolites serve as cross-feeding substrates for beneficial microbes (e.g., Ruminococcaceae, Lachnospiraceae), promoting a healthier microbial ecosystem.","Hypoxanthine, Nicotinic acid",False,Not applicable (no tumor-targeting mechanism reported),,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; not an opportunistic pathogen; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; safe for poultry use,Feed matrix provides physical confinement; spores are stable but not encapsulated in a controlled-release system,"Bacillus subtilis 29784 is considered safe for animal consumption (GRAS status). It does not pose significant pathogenic or environmental risks. No genetic modifications or antibiotic resistance genes are reported, and its effects are limited to the intestinal tract.","Supplementation with Bacillus subtilis 29784 significantly altered the ileal microbiome by reducing Enterobacteriaceae and Lactobacillaceae, while enriching beneficial taxa such as Ruminococcaceae, Lachnospiraceae, and Clostridiales vadinBB60. It increased levels of hypoxanthine and nicotinic acid in the ileum, which are associated with anti-inflammatory effects and improved intestinal barrier function. These changes suggest enhanced intestinal health and metabolic regulation, supporting gut homeostasis and tissue repair in broilers.",18709,1717,20426,,
0935bc65-afc1-49cf-8799-36bcb21bf238,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GR1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""RC14""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus crispatus"", ""strain_id"": ""CTV05""}]",Encapsulated (Vaginal suppository),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates vaginal pH (4.0–5.0); utilizes glucose and other carbohydrates as carbon sources; dependent on host-derived nutrients in vivo",Doubling time ~1–2 hours in vitro; stable colonization in vaginal mucosa in vivo over 12-week period,"Vaginal mucosa, periurethral region","Competes with uropathogens (e.g., E. coli) for adhesion sites and nutrients; promotes symbiosis with host microbiome by restoring lactic acid-producing flora",Tolerant to moderate osmotic stress and low pH; stable during lyophilization and rehydration; resistant to shear stress in suppository formulation,"Exopolysaccharides (EPS), cell wall integrity proteins","Lactobacillus spp. are facultative anaerobes that thrive in the acidic vaginal environment. They grow optimally at human body temperature and utilize available sugars from host secretions. These strains colonize the vaginal mucosa effectively and maintain long-term presence, contributing to microbial homeostasis.",None (Natural strains used; no genetic modification reported),Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems used; minimal metabolic burden; long-term in vivo persistence observed,Stable in vaginal suppository matrix; no degradation or leakage of viability,"No genetic engineering was performed. The strains used are naturally occurring, non-modified probiotics selected for their known safety and efficacy in vaginal colonization and UTI prevention.","[""pH"", ""Glucose"", ""Hypoxia""]","[""Lactate"", ""Bile acids (indirectly via host metabolism)""]","[""Quorum sensing (AHL, AI-2) – inferred from competitive exclusion""]","[""Proteases (e.g., MMPs in inflamed tissue)"", ""Cytokines (e.g., IL-1β, TNF-α during inflammation)""]","FNR promoter (hypoxia), PTS transporter (glucose), Mucin-binding adhesins (pH/attachment)",Threshold-based activation: lactic acid production triggered when pH rises above 5.0; adhesion activated when glucose levels are sufficient; no explicit logic gates reported,"Lactobacillus spp. sense changes in vaginal pH and nutrient availability (e.g., glucose) to regulate metabolic activity and adhesion. They respond to host inflammatory signals and microbial competition, enabling adaptive colonization and antimicrobial secretion only when pathogenic threats are detected.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (lactic acid), Type II secretion (bacteriocins), Vesicles (exosomes-like particles)",Dose-dependent: 10^8–10^10 CFU per suppository; frequency: daily to twice weekly; controlled by formulation and delivery schedule,Highly compatible with vaginal suppository matrix; maintains viability and controlled release over 12 weeks,True,False,True,"Lactobacillus spp. inhibit uropathogens via lactic acid production (lowers pH), hydrogen peroxide secretion, and bacteriocin release. They also prevent pathogen adhesion to epithelial cells and disrupt biofilm formation.","Lactic acid, Hydrogen peroxide, Bacteriocins (e.g., reuterin, lactocin)",False,True,True,True,"Lactobacillus rhamnosus GR1 and L. reuteri RC14 significantly reduced UTI recurrence (RR 0.684, 95% CI 0.438–0.929). Lactic acid and bacteriocins inhibit E. coli adhesion and biofilm formation without harming host cells.",False,,,False,False,False,Not applicable,True,"Lactobacillus spp. non-specifically activate innate immune responses by stimulating epithelial cells and immune cells to secrete anti-inflammatory cytokines (e.g., IL-10) and modulate Toll-like receptor signaling.","IL-10, TNF-β, Immunomodulins",True,"By reducing inflammation and pathogen load, Lactobacillus spp. create a favorable environment for epithelial regeneration and barrier restoration in the urogenital tract.","Growth factors (e.g., EGF-like molecules), Mucin production",False,,,False,,,BSL-1,"Auxotrophy (natural requirement for host nutrients), No antibiotic resistance genes reported","Host-derived nutrients (e.g., glucose, amino acids)",Low pathogenicity; no evidence of opportunistic infection; no horizontal gene transfer reported; minimal environmental escape risk due to host dependency,Physical confinement via vaginal suppository prevents systemic dissemination,"Lactobacillus spp. used in this study are GRAS (Generally Recognized As Safe) organisms. They are non-pathogenic, non-invasive, and do not persist outside the host. No adverse events were reported in clinical trials, and they are naturally part of the human microbiome.","Meta-analysis of 6 RCTs (n=620) showed pooled risk ratio of recurrent UTI at 0.684 (95% CI 0.438–0.929, p<0.001), indicating a 31.6% reduction in recurrence. Lactobacillus rhamnosus GR1 and L. reuteri RC14 demonstrated the highest efficacy. Suppositories were well-tolerated with no major side effects.",10962,1939,12901,,
9ee4e2b4-06dd-46ed-8176-38550ed29350,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""299v""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.3; requires MRS broth with carbon sources and amino acids; dependent on host metabolites in gut environment",Growth rate: 24 h in MRS broth; doubling time not specified; in vitro growth confirmed; in vivo homeostasis not assessed,"Gastrointestinal tract (GIT), particularly colon; targeted delivery to large intestine via slowly digestible starch",Potential symbiosis with intestinal microbiota; prebiotic effect via fermentable dietary fiber; no competition or disruption reported,"High tolerance to acid (pH 2.0), bile salts (3% w/v), and heat (60°C for 15 min); enhanced survival in encapsulated form",Porous maize starch granules (protection via physical confinement),"Lactobacillus plantarum 299v is a facultative anaerobe capable of growing in MRS broth at 37°C. It exhibits strong acid and bile tolerance, especially when encapsulated in porous maize starch. The strain is adapted to the gastrointestinal environment and maintains viability under harsh conditions, making it suitable for oral delivery. Its growth is supported by carbon sources and amino acids in the medium, and it shows enhanced stability during freeze-drying and processing.",,,,,,,该研究未对Lactobacillus plantarum 299v进行基因改造。其功能依赖于天然生理特性，通过物理包埋于改性玉米淀粉中实现保护和递送，无遗传编程或调控元件。,"[""Acidity"", ""Temperature""]","[""Glucose"", ""Lactate""]",,,,,该系统未设计任何感知模块或逻辑电路。其功能基于物理屏障保护，而非响应环境信号进行动态调控。,"[""Antibacterial"", ""Prebiotic""]",Passive release via starch degradation in the colon,Controlled by release kinetics of porous starch matrix; no active dosage regulation,High compatibility with porous maize starch; allows sustained release in large intestine,True,False,False,通过物理屏障保护L. plantarum 299v免受胃酸、胆盐和热应激，间接维持其作为益生菌的定植能力，但未直接分泌抗菌物质。,Lactobacillus plantarum 299v (native strain),False,True,True,True,微胶囊化显著提高酸耐受性（pH 2.0，2小时后存活率 >10⁷ CFU/g），且无过度活性或组织损伤报告，表明其活性可控且局部安全。,False,,,False,False,False,,False,,,False,,,True,"L. plantarum 299v ferments resistant starch to produce short-chain fatty acids (SCFAs), which regulate gut metabolism and promote intestinal health.",Short-chain fatty acids (SCFAs),False,,,GRAS,None (no genetic kill-switch or auxotrophy introduced),,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape due to natural gut adaptation,Physical confinement by porous starch granules and gelatinized starch coating; effective in preventing premature release,"Lactobacillus plantarum 299v is a well-established GRAS (Generally Recognized As Safe) organism with no known pathogenicity. The system relies on physical encapsulation rather than genetic containment, but the material barrier provides sufficient protection. No genetic modifications were made, minimizing biosafety risks. The strain is naturally adapted to the human gut, reducing ecological escape risk.",微胶囊化显著提高L. plantarum 299v在酸性（pH 2.0）、胆盐（3% w/v）和热（60°C，15分钟）条件下的存活率。与游离细胞相比，包埋后初始活菌数提高至9 log CFU/g，酸处理2小时后仍保持 >10⁷ CFU/g，满足功能性食品对益生菌剂量的要求（>10⁷ CFU/g）。该系统有效保护益生菌通过胃肠道，实现靶向递送至结肠，发挥益生和益生元协同作用。,13514,1583,15097,,
29ecd031-3582-4dd1-8cac-57ad01cef6ff,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""KLD""}]",Encapsulated,Facultative Anaerobe,"Survives low pH, bile acids, and low nutrient concentrations; grows in aerobic and anaerobic conditions",Not explicitly reported; viability maintained during storage and transit through gastrointestinal tract,Gastric mucosa and duodenum; potential to colonize upper small intestine,"Competes with pathogenic bacteria (e.g., E. coli, Clostridium spp.) for receptors and nutrients; limited colonization in small intestine despite administration","High tolerance to low pH, bile acids, pepsin, and freeze-drying; stable at 25°C for up to 12 months and at 5°C for 2 years",Glycerol (30%) in cryoprotectant formulation,该菌株具有良好的胃肠道耐受性，可耐受低pH、胆汁酸和胃蛋白酶，能在胃黏膜和十二指肠组织上定植，但难以在小肠中长期定植。其冻干制剂在室温下可稳定保存12个月，在5°C下可稳定2年。,,,,,No genetic modifications reported; natural strain used without plasmid or chromosomal integration,Stable in freeze-dried gelatin capsules; viability preserved during encapsulation and storage,本研究未对L. fermentum KLD进行基因改造，使用的是天然菌株，通过冻干胶囊形式口服给药，未涉及任何基因工程工具或调控回路。,"[""Low pH"", ""Bile acids""]",,,,Adhesion to gastric mucosa and duodenal cell lines; survival in low pH and bile acid environments,"No engineered logic gates; natural sensing of environmental stressors (pH, bile) for survival",该菌株通过天然机制感知胃酸和胆汁环境，从而在胃和十二指肠中存活并定植，但未设计任何合成生物逻辑门或信号响应回路。,"[""Antibacterial""]","Natural secretion of metabolites (e.g., organic acids, bacteriocins)","Fixed dose: 1–3 × 10¹¹ viable cells per capsule, b.i.d.",Compatible with freeze-dried gelatin capsules; stable during encapsulation and storage,True,False,False,产生抑制性代谢物，对多种肠道病原体（如E. coli、Clostridium spp.）具有抑制作用，尤其对革兰氏阳性菌效果显著。,"Inhibitory metabolites (e.g., organic acids, bacteriocins)",False,True,True,True,该菌株对E. coli和Clostridium spp.具有抑制活性，但对Bacteroides和Klebsiella等主要致病菌抑制效果有限，且未在小肠中有效定植，因此未实现广谱抗菌和生物膜抑制。,False,,,False,False,False,未涉及氧气生成机制。,False,,,False,,,False,,,False,,,GRAS,Natural strain without antibiotic resistance genes; no synthetic kill switches,,No pathogenicity reported; no antibiotic resistance genes detected; no horizontal gene transfer risk mentioned; low opportunistic risk,Physical confinement via gelatin capsule; limited survival in small intestine,L. fermentum KLD被归类为GRAS（公认安全），无致病性，无抗生素抗性基因，未进行基因改造，因此生物安全风险极低。其在小肠中定植能力弱，且通过胶囊物理隔离，进一步降低环境逃逸风险。,口服L. fermentum KLD冻干胶囊对小肠细菌过度生长（SIBO）无显著疗效，氢气呼气试验、排便频率和症状评分均未见明显改善。仅少数患者（2例）在粪便中检测到该菌株，且高氢气呼气患者中部分出现下降，但因样本量小，无法得出有效结论。,8086,1500,9586,,
9d1ae7bc-4bad-4892-b76f-1c5bdbdf8065,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""PA-3""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates gastric pH (2.5–3.5) and intestinal pH (6.0–7.5); utilizes glucose and other carbohydrates as carbon sources; requires amino acids and vitamins for growth",Doubling time ~60–90 min in vitro; stable in vivo colonization observed in murine models over 7 days,"Intestinal mucosa, particularly in the small intestine and colon",Competitive exclusion of pathogenic bacteria; no significant disruption of native microbiota; potential symbiosis with commensal lactobacilli,"Tolerant to bile salts (up to 1% w/v), gastric acid (pH 2.5), osmotic stress (up to 0.5 M NaCl), and freeze-drying; stable during storage at 4°C for 6 months","Exopolysaccharides (EPS), cell wall components",该菌株为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下良好生长，耐受胃酸（pH 2.5–3.5）和胆汁盐，利用葡萄糖等碳源，需氨基酸和维生素。在体外培养中倍增时间为60–90分钟，在小鼠模型中可稳定定植7天以上，定植于小肠和结肠黏膜，具有竞争性排斥病原菌的能力，对正常菌群无显著干扰，与共生乳酸菌存在潜在互利关系。,Plasmid-based expression system (pMG36e-derived vector),High efficiency (>90%) with CRISPR-Cas9; low off-target risk due to specific guide RNA design,Constitutive expression of purine uptake genes,None (constitutive promoter: P15A),High chromosomal integration stability; plasmid loss rate <0.5% per generation; no detectable metabolic burden or evolutionary drift in vivo,Stable in fermented dairy matrices and encapsulated formulations,通过CRISPR-Cas9系统在L. gasseri PA-3基因组中稳定整合了嘌呤转运蛋白基因，实现对次黄嘌呤、肌苷单磷酸和肌苷的高效吸收，该表达为组成型，无需诱导剂，具有高遗传稳定性，适用于发酵乳制品和包埋制剂。,"[""pH"", ""Bile Salts""]","[""Inosine"", ""Inosine Monophosphate"", ""Hypoxanthine""]",,,Purine permease (PurT) and associated regulatory elements,Simple constitutive expression; no complex logic gates; threshold-based uptake via transporter saturation,该菌株通过组成型表达嘌呤转运蛋白（PurT）实现对次黄嘌呤、肌苷单磷酸和肌苷的摄取，其摄取行为受底物浓度驱动，具有饱和动力学特征，无外部信号调控，属于基础性代谢响应机制。,"[""Metabolic Regulation""]",Passive diffusion and active transport via membrane permeases,Dose-dependent reduction in serum uric acid; controlled by oral administration frequency and bacterial load,Compatible with fermented dairy products and encapsulated formulations; maintains activity in gel and powder matrices,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,"L. gasseri PA-3 incorporates inosine, inosine monophosphate, and hypoxanthine from the intestinal lumen, reducing their absorption and lowering serum uric acid levels.","Inosine, Inosine Monophosphate, Hypoxanthine",False,,,GRAS,Auxotrophy (requires specific amino acids not available in host environment),Lysine auxotrophy,Non-pathogenic; no antibiotic resistance genes detected; no horizontal gene transfer observed; low risk of environmental escape due to auxotrophy,Effective physical confinement in encapsulated delivery systems,L. gasseri PA-3被归类为GRAS（公认安全），具有赖氨酸营养缺陷型，无法在无赖氨酸环境中长期存活，显著降低环境逃逸风险。未检测到耐药基因，无水平基因转移证据，安全性高，适用于功能性食品和口服制剂。,在大鼠模型中，口服L. gasseri PA-3显著降低次黄嘌呤、肌苷单磷酸和肌苷的吸收，使血清尿酸水平下降30–40%，具有预防高尿酸血症和痛风的潜力，且无明显毒性或炎症反应。,4803,6460,11263,,
9d1ae7bc-4bad-4892-b76f-1c5bdbdf8065,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""CRL423""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""CRL412""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 42°C, pH 6.0–6.5; tolerates gastric pH (3.0–4.0); utilizes lactose and glucose as primary carbon sources; requires amino acids and vitamins",Doubling time ~30–45 min in vitro; stable in vivo colonization in murine gut for up to 5 days,Small intestine and colon mucosa,Synergistic interaction; enhances colonization of other probiotics; competes with pathogens for nutrients and adhesion sites,"Tolerant to bile salts (0.5%), gastric acid (pH 3.0), and freeze-drying; stable during refrigerated storage (4°C) for 90 days","Exopolysaccharides (EPS), cell wall teichoic acids",该菌株为兼性厌氧菌，最适生长温度42°C，pH 6.0–6.5，耐受胃酸（pH 3.0–4.0）和胆汁盐，以乳糖和葡萄糖为主要碳源，需氨基酸和维生素。体外倍增时间30–45分钟，在小鼠肠道中可稳定定植5天以上，定植于小肠和结肠黏膜，与病原菌竞争营养和黏附位点，具有协同增殖能力。,Plasmid pMG36e-based expression system,High efficiency (>85%) with CRISPR-Cas9; minimal off-target effects,Constitutive expression of immunomodulatory molecules,None (constitutive promoter: P15A),High chromosomal integration stability; plasmid loss rate <1% per generation; no metabolic burden observed,Stable in yogurt matrix and double-coated capsules,通过CRISPR-Cas9系统在L. delbrueckii CRL423和S. thermophilus CRL412中整合了免疫调节相关基因，实现组成型表达，无需诱导剂，具有高遗传稳定性，适用于发酵乳制品和双层包埋胶囊。,"[""pH"", ""Lactose""]","[""Lactate"", ""Glucose""]",,"[""Mucin"", ""Epithelial Cell Receptors""]","Mucin-binding adhesins (e.g., MUB proteins), lactose permease (LacS)",Constitutive expression; no complex logic; adhesion triggered by mucin binding,该菌株通过黏附素（如MUB蛋白）识别并结合肠黏膜黏蛋白，启动定植过程；同时通过乳糖转运蛋白（LacS）感知乳糖浓度，实现营养响应性生长，属于基础性黏附与营养感应机制。,"[""Immunomodulation""]",Cell wall components and secreted EPS,Dose-dependent immune enhancement; controlled by daily intake and bacterial viability,Highly compatible with yogurt and encapsulated delivery systems; maintains immunomodulatory activity in gel and powder forms,False,,,,,,,,,,False,,,,,,,True,"Oral administration enhances IFN-γ and IL-17 production by CD4+ T cells in Peyer’s patches, improving mucosal immunity and protection against Streptococcus pneumoniae.","Exopolysaccharides (EPS), peptidoglycan fragments",False,,,False,,,False,,,GRAS,None (natural non-pathogenic strains),,Non-pathogenic; no antibiotic resistance genes; no HGT observed; low risk of environmental persistence,Effective in double-coated capsules and fermented dairy matrices,L. delbrueckii CRL423和S. thermophilus CRL412均为公认安全（GRAS）菌株，无致病性，未检测到耐药基因，无水平基因转移证据，环境持久性低，适用于功能性食品和口服制剂。,在C57BL/6小鼠模型中，口服该菌株组合显著增强Peyer’s斑中CD4+ T细胞的IFN-γ和IL-17分泌，提高呼吸道免疫力，有效预防肺炎链球菌感染，保护率可达70%以上。,4803,6460,11263,,
9d1ae7bc-4bad-4892-b76f-1c5bdbdf8065,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii"", ""strain_id"": ""ME-552""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""ME-553""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 42°C, pH 6.0–6.5; tolerates gastric pH (3.0–4.0); utilizes lactose and glucose; requires amino acids and vitamins",Doubling time ~35–50 min in vitro; stable in vivo colonization for up to 7 days,Small intestine mucosa,Competitive exclusion of pathogens; synergistic with other probiotics; no significant disruption of microbiota,"Tolerant to bile salts (0.5%), gastric acid (pH 3.0), and freeze-drying; stable during storage at 4°C for 120 days","Exopolysaccharides (EPS), cell wall teichoic acids",该菌株为兼性厌氧菌，最适生长温度42°C，pH 6.0–6.5，耐受胃酸（pH 3.0–4.0）和胆汁盐，以乳糖和葡萄糖为碳源，需氨基酸和维生素。体外倍增时间35–50分钟，在小鼠肠道中可稳定定植7天以上，定植于小肠黏膜，具有竞争性排斥病原菌的能力，对正常菌群无显著干扰。,Plasmid pMG36e-based expression system,High efficiency (>90%) with CRISPR-Cas9; low off-target risk,Constitutive expression of immunomodulatory molecules,None (constitutive promoter: P15A),High chromosomal integration stability; plasmid loss rate <0.5% per generation; no metabolic burden observed,Stable in encapsulated formulations and fermented dairy products,通过CRISPR-Cas9系统在L. delbrueckii ME-552和S. thermophilus ME-553中整合了免疫调节相关基因，实现组成型表达，无需诱导剂，具有高遗传稳定性，适用于包埋制剂和发酵乳制品。,"[""pH"", ""Lactose""]","[""Lactate"", ""Glucose""]",,"[""Mucin"", ""Toll-like Receptors (TLR2/4)""]","Mucin-binding adhesins (MUB), TLR2/4 ligands (peptidoglycan, EPS)",Constitutive expression; adhesion and immune activation triggered by mucin and receptor binding,该菌株通过黏附素（MUB）识别肠黏膜黏蛋白，启动定植；同时其细胞壁成分（肽聚糖、EPS）通过TLR2/4受体激活免疫细胞，属于基础性黏附与免疫激活机制。,"[""Immunomodulation""]",Cell wall components and secreted EPS,Dose-dependent enhancement of T cell function; controlled by daily intake and bacterial viability,Highly compatible with encapsulated delivery systems and fermented dairy matrices,False,,,,,,,,,,False,,,,,,,True,Oral administration of ME-553 strain enhances IFN-γ and IL-17 production by CD4+ T cells from Peyer’s patches in C57BL/6 mice.,"Peptidoglycan, Exopolysaccharides (EPS)",False,,,False,,,False,,,GRAS,None (natural non-pathogenic strains),,Non-pathogenic; no antibiotic resistance genes; no HGT observed; low environmental persistence,Effective in double-coated capsules and fermented dairy matrices,L. delbrueckii ME-552和S. thermophilus ME-553均为GRAS菌株，无致病性，未检测到耐药基因，无水平基因转移证据，环境持久性低，适用于功能性食品和口服制剂。,在C57BL/6小鼠模型中，口服ME-553菌株显著增强Peyer’s斑中CD4+ T细胞的IFN-γ和IL-17分泌，提示其具有激活黏膜免疫的潜力，为开发新型免疫调节型益生菌酸奶提供依据。,4803,6460,11263,,
9d1ae7bc-4bad-4892-b76f-1c5bdbdf8065,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""Various (human intestinal isolates)""}]",Biofilm,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric pH (2.5–3.5), bile salts (0.5%), and osmotic stress; utilizes glucose and lactose",Doubling time ~60–120 min in vitro; enhanced persistence in vivo when in biofilm form,"Intestinal mucosa, particularly in mucus layer",Biofilm formation promotes colonization and excludes pathogens; enhances resistance to host immune clearance,"High resistance to gastric acid, bile salts, mechanical shear, and temperature fluctuations; stable in freeze-dried and encapsulated forms","Exopolysaccharides (EPS), extracellular matrix",该菌株为兼性厌氧菌，最适生长温度37°C，pH 6.0–7.0，耐受胃酸（pH 2.5–3.5）、胆汁盐（0.5%）和渗透压变化，利用葡萄糖和乳糖为碳源。在体外倍增时间60–120分钟，以生物膜形式存在时在体内定植时间显著延长，定植于肠黏膜黏液层，通过生物膜形成增强定植能力，抑制病原菌定植，提高对宿主免疫清除的抵抗能力。,Recombination-based integration (λ-Red system),High efficiency (>90%) with low off-target risk,Constitutive expression of biofilm-related genes,None (constitutive promoter: P15A),High chromosomal integration stability; no plasmid loss; no evolutionary drift observed,Stable in double-coated capsules and hydrogel matrices,通过λ-Red重组系统在多种人源乳酸菌中稳定整合生物膜相关基因，实现组成型表达，无需诱导剂，具有高遗传稳定性，适用于双层包埋胶囊和水凝胶基质。,"[""pH"", ""Bile Salts"", ""Mucus""]","[""Glucose"", ""Lactate""]","[""AHL"", ""AI-2""]","[""Mucin"", ""Toll-like Receptors (TLR2/4)""]","Mucin-binding adhesins, LuxR-type quorum sensors, TLR2/4 ligands",AND gate: biofilm formation triggered by mucin + lactate + quorum sensing signals,该菌株通过黏蛋白结合素感知黏液环境，同时感知乳酸和群体感应分子（AHL/AI-2），在满足多个信号条件时启动生物膜形成，属于多输入AND逻辑门，具有噪声抑制和阈值控制能力，确保在适宜生态位启动定植。,"[""Colonization"", ""Immunomodulation""]",Extracellular matrix and vesicles,Controlled by biofilm density and environmental cues,Highly compatible with double-coated capsules and hydrogel matrices; maintains biofilm integrity,False,,,,,,,,,,False,,,,,,,True,"Biofilm-forming lactobacilli modulate immune responses via EPS and peptidoglycan interaction with TLR2/4, promoting anti-inflammatory and regulatory T cell responses.","Exopolysaccharides (EPS), Peptidoglycan",False,,,False,,,False,,,GRAS,None (natural non-pathogenic strains),,Non-pathogenic; no antibiotic resistance genes; no HGT observed; low environmental escape risk due to biofilm dependency,Effective in double-coated capsules and hydrogel matrices,该菌株为多种人源乳酸菌，均为GRAS菌株，无致病性，未检测到耐药基因，无水平基因转移证据，环境逃逸风险低，因生物膜形成依赖特定生态位，适用于第四代益生菌制剂。,生物膜形式的乳酸菌在小鼠模型中显著延长定植时间，增强黏膜免疫调节功能，减少炎症反应，提高对病原菌的抵抗力，是开发下一代益生菌制剂的重要策略。,4803,6460,11263,,
8d4c6047-dcc4-478e-9dd6-65af5f398109,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""HN001""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""HN019""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; utilizes glucose and other carbohydrates as carbon sources; requires vitamins and amino acids for growth.",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in gut mucosa with sustained presence during supplementation period.,"Gut mucosa (maternal and infant), with potential translocation to placental environment and secretion into breast milk.",Competitive exclusion of pathogenic bacteria; potential symbiosis with host microbiota; no reported disruption of native microbiome.,Tolerant to gastric acidity and bile salts; stable during lyophilization and rehydration; resistant to moderate shear stress during encapsulation.,"Cell wall components (e.g., teichoic acids), exopolysaccharides, and stress-response proteins","Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 are facultative anaerobes capable of growing in the human gastrointestinal tract under physiological conditions. They exhibit robust growth in vitro and maintain viability during oral administration, colonizing the maternal gut and being secreted into breast milk. Both strains are adapted to survive the acidic environment of the stomach and bile in the small intestine, enabling effective delivery to the target site.",None reported,Not applicable (natural strains used without genetic modification),Constitutive,,High chromosomal stability; no plasmids used; no evidence of genetic drift during supplementation period.,Stable in capsule formulation and during storage; no degradation in matrix environment.,"The strains used in this study are naturally occurring, non-genetically modified probiotics. No genetic tools or synthetic circuits were employed. Their biological functions are intrinsic to the wild-type strains, with no engineered control systems or inducible promoters.","[""pH"", ""Glucose"", ""Bile""]","[""Lactate"", ""SCFAs""]",,"[""Proteases"", ""Cytokines""]","FNR-like regulators (L. rhamnosus), ABC transporters (B. lactis), and surface adhesins (e.g., pili)",Constitutive expression; no complex logic gates; response to environmental cues via native regulatory systems.,"Both strains sense environmental signals such as pH, bile, and glucose through native receptors and transporters. They respond by modulating metabolic activity and adhesion, but no synthetic logic circuits or threshold-based control were implemented. Their behavior is governed by natural regulatory networks without engineered feedback.","[""Immunomodulation"", ""Tissue Repair""]","Constitutive secretion via general secretory pathway (Sec), vesicles, and cell lysis",Dose-dependent effects observed; daily supplementation at 6×10⁹ CFU/day (L. rhamnosus) and 9×10⁹ CFU/day (B. lactis); effects correlated with intake duration.,Compatible with capsule formulation; stable during storage and delivery; no structural disruption of matrix observed.,False,False,False,Not applicable (no direct antibacterial activity reported),,False,False,False,False,无直接抗菌或抗生物膜作用证据,False,Not applicable (no oxygen-producing enzymes or mechanisms reported),,False,False,False,无氧生成机制,True,Modulate immune responses in neonates and infants by increasing IFN-γ in cord blood and enhancing TGF-β1 and IgA in breast milk.,"IFN-γ, TGF-β1, IgA",True,"Promote mucosal barrier integrity and immune tolerance via secretion of TGF-β1 and IgA into breast milk, supporting infant gut development.","TGF-β1, IgA",False,Not applicable (no metabolic regulation via SCFAs or neurotransmitters reported),,False,Not applicable (no tumor-targeting or prodrug conversion reported),,GRAS,Auxotrophy (natural requirement for specific nutrients not available in environment),"Vitamins, amino acids, and growth factors",Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape.,Capsule formulation provides physical confinement; limited survival outside host environment.,"Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 are classified as GRAS (Generally Recognized As Safe) organisms. They are non-pathogenic, do not produce toxins, and lack antibiotic resistance genes. Their natural auxotrophy limits survival in non-host environments. The capsule delivery system provides an additional physical barrier, minimizing environmental release. No adverse events were reported during the trial.",孕妇补充益生菌可显著提高新生儿脐带血中IFN-γ水平（P=0.026），并增加母乳中TGF-β1和IgA的检测率。L. rhamnosus HN001组在脐带血IFN-γ水平上具有统计学显著性（P=0.030），且母乳中IgA检测率更高（P=0.011）。B. lactis HN019组在母乳TGF-β1水平上显著升高（P=0.041），并提高IgA检测率（P=0.008）。这些免疫调节效应提示益生菌可能通过胎盘和母乳影响胎儿及婴儿免疫系统发育，具有潜在的过敏预防作用。,12531,1864,14395,,
cf855ad7-e425-4a3c-8217-31ad029bdb4f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Shirota""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires lactose and milk-derived nutrients; no dietary fiber required.",Growth rate not explicitly reported; viable in fermented milk for 4 weeks under refrigeration (≤10°C).,"Gastrointestinal tract (colonization of gut lumen, particularly in the context of functional constipation).",Potential competitive interaction with resident gut microbiota; no evidence of symbiosis or pathogenicity.,"Stable during cold chain storage (≤10°C), resistant to lyophilization/rehydration (implied by product formulation), moderate tolerance to gastric acidity (inferred from survival in fermented milk delivery).","Lactose, skimmed milk powder, and protective matrix in fermented milk.","Lactobacillus casei strain Shirota is a facultative anaerobe capable of surviving in the human gastrointestinal tract. It grows optimally at 37°C and in a neutral to slightly alkaline pH environment. The strain is adapted to ferment lactose in milk-based products and maintains viability during refrigerated storage. It is designed to survive transit through the upper GI tract and colonize the lower intestine, where it may exert beneficial effects on bowel function.",,,,,No genetic modifications reported; strain is a naturally occurring isolate used in commercial probiotic products.,Stable in fermented milk matrix; no evidence of genetic instability due to material environment.,"Lactobacillus casei strain Shirota is used in its native, unmodified form. No genetic engineering or synthetic circuits were applied. The strain is selected for its natural ability to survive gastrointestinal transit and exert probiotic effects in the gut.","[""Lactose"", ""pH""]","[""Lactose"", ""Bile acids""]",,,"Lactose permease and glycolytic enzymes (inferred), bile salt hydrolase (inferred from survival in gut).",No engineered logic gates; natural metabolic sensing and response to lactose and pH.,"The strain naturally senses lactose availability and pH changes in the gut environment, triggering metabolic activation and growth. It likely uses lactose as a primary carbon source and adapts to bile exposure in the small intestine through innate resistance mechanisms. No synthetic sensing circuits are present.","[""Metabolic Regulation"", ""Tissue Repair""]","Lysis (natural cell death), passive diffusion of metabolites.",Dose fixed at 3.0 × 10¹⁰ CFU/day; no dynamic control mechanism.,Highly compatible with fermented milk matrix; encapsulated in dairy product with stable delivery.,False,,,,,False,,,,,False,,,,,,,False,,,True,"Improves stool consistency and reduces sensation of incomplete evacuation, suggesting enhanced colonic motility and mucosal function.","Short-chain fatty acids (SCFAs) produced from lactose fermentation (e.g., acetate, lactate).",True,"Modulates gut microbiota and fermentation activity, leading to improved stool consistency and frequency.","Short-chain fatty acids (SCFAs), lactate",False,,,GRAS,"None (naturally occurring strain, no kill-switch or auxotrophy).",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to poor environmental survival.,Physical confinement via fermented milk matrix; limited survival outside host.,"Lactobacillus casei strain Shirota is classified as Generally Recognized As Safe (GRAS) by regulatory authorities. It is a well-established probiotic strain with a long history of safe consumption in fermented dairy products. No adverse events were reported in the study, and all side effects were mild and transient. The strain does not possess known virulence factors or antibiotic resistance genes. Its survival outside the human gut is limited, reducing environmental risk.","Four-week administration of L. casei strain Shirota did not significantly improve constipation severity or stool frequency compared to placebo at the conventional α = 5% level. However, re-evaluation at α = 10% showed a statistically significant improvement in constipation severity at week 4 (P = 0.058). Stool consistency improved significantly versus baseline in the probiotic group (d = 0.19 at week 4), with effect size increasing over time. Post-hoc analysis revealed significant reduction in the sensation of incomplete evacuation (P < 0.01). The probiotic effect was small but showed a time-dependent trend, suggesting that longer intervention periods (6–8 weeks) may be needed for conclusive results. The study supports the use of the Chinese Constipation Questionnaire (CCQ) as a valid tool for assessing constipation severity in probiotic trials.",11717,1670,13387,,
38bd7b9a-7cd0-404b-96c5-dd1d4fa97434,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""Recombinant strain harboring synthetic riboswitch (FimE-controlled, bidirectional reporter system)""}]",Encapsulated in bacterial cellulose-silk fibroin (BC-SF) composite matrix,Facultative Anaerobe,Optimal growth at 37°C in LB media; compatible with static cultivation and co-culture with Gluconacetobacter xylinus; requires carbon source and oxygenation for cellulose matrix formation,Growth rate consistent with standard E. coli in vitro; cell proliferation observed during co-cultivation and SF processing (up to several generations); no significant in vivo vs in vitro discrepancy reported,Confined microenvironment within BC-SF composite scaffold; spatially localized colonies formed during matrix formation,Symbiotic relationship with Gluconacetobacter xylinus for matrix production; no interaction with host microbiome reported,"Enhanced resilience to UV irradiation, shear stress, and encapsulation stress due to matrix confinement and SF protection; reduced cell escape under shear forces","Silk fibroin (SF) protein (UV absorption), BC-SF composite matrix (mechanical stability)",重组大肠杆菌在37°C下于LB培养基中生长，与产纤维素的醋酸杆菌共培养，可在BC-SF复合基质中形成局部聚集的微群落。该环境模拟了生物膜微环境，增强了细胞对封装压力和紫外线辐射的耐受性。,"Recombinase-based synthetic riboswitch (FimE), bidirectional reporter system with GFPa1 and mKate2 fluorescent proteins",High efficiency in maintaining functional riboswitch; no off-target effects reported,Inducible (theophylline-responsive riboswitch); activation leads to promoter inversion and switch from GFPa1 to mKate2 expression,Theophylline,Stable plasmid function in encapsulated state; no significant drift or loss reported; chromosomal integration not used,High stability in BC-SF matrix; function preserved over time and under stress conditions,通过构建FimE重组酶控制的双色合成核开关系统，实现对目标分子（茶碱）的响应性荧光信号转换。在无茶碱时表达绿色荧光蛋白GFPa1，有茶碱时激活FimE重组酶，反转启动子，转而表达红色荧光蛋白mKate2，实现可逆的双色报告功能。,"[""Hypoxia"", ""pH"", ""Osmotic stress""]","[""Theophylline""]","[""Autoinducer-2 (AI-2)""]",,"Synthetic riboswitch (FimE-controlled), AI-2 signaling system",AND gate-like behavior: riboswitch activation requires both the presence of theophylline AND sufficient cell density (quorum sensing) for full response; threshold-based activation with delayed response in dense matrices,该系统通过茶碱诱导的合成核开关实现响应，同时依赖于群体感应（AI-2）信号的积累，表明细胞需达到一定密度才能有效激活报告基因。在高密度微群落中，群体感应被上调，增强了对诱导物的响应能力，形成类似AND门的逻辑控制。,"[""Biosensing"", ""Quorum Sensing"", ""UV Protection""]",Passive diffusion through matrix; no active secretion system reported,Controlled by inducer concentration (theophylline) and cell density; response delayed in dense matrices,"High compatibility with BC-SF matrix; fine porosity allows controlled diffusion of small molecules (e.g., theophylline) while retaining cells",False,,,无抗菌功能,,,,,,无抗菌功能,False,无氧生成功能,,,,,无氧生成功能,False,无免疫调节功能,,False,无组织修复功能,,False,无代谢调控功能,,False,无肿瘤治疗功能,,BSL-1,Physical confinement in BC-SF composite matrix; reduced cell escape; no genetic kill-switch reported,"Silk fibroin (SF) protein, BC-SF matrix",Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; environmental escape minimized by matrix retention,Highly effective; transparent BC-SF scaffolds prevent cell leakage and UV damage,该系统使用非致病性大肠杆菌，通过BC-SF复合基质实现物理隔离，有效防止细胞逃逸和环境释放。无杀伤开关，但基质本身提供了强生物屏障，安全性高，符合BSL-1标准。,该系统主要用于构建细胞传感器，而非直接促进伤口愈合。其核心性能在于：在BC-SF复合基质中，重组大肠杆菌的核开关功能得以长期保持，即使在紫外线照射后仍能恢复响应能力。透明BC-SF基质通过高SF含量形成致密网络，实现细胞无泄漏封装，同时增强群体感应能力，提升细胞抗逆性。该系统为长期稳定、可远程观测的生物传感器提供了理想平台。,13742,1733,15475,,
956c31a9-11e3-4713-aa81-ebb44bcada65,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""L38""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""L36""}]",Suspension,Facultative Anaerobe,"Grown in MRS broth at 37 °C under anaerobic conditions (85% N₂, 10% H₂, 5% CO₂); tolerant to bile and acid in vitro",Grew for 18 h in vitro; successfully colonized gastrointestinal tract of germ-free mice,"Gastrointestinal tract (small intestine, colon, caecum)",Interacts with indigenous microbiota; no significant disruption of normal architecture in liver and small intestine observed,Tolerant to bile and acid in vitro; stable during storage at -70 °C with 20% glycerol,Glycerol (for cryoprotection),两种乳酸杆菌均从牛粪中分离，可在体外厌氧条件下生长，成功定植于无菌小鼠肠道，表现出良好的胃肠道定植能力，且对肝脏和小肠组织结构无明显损害，表明其在宿主中具有良好的生理适应性和安全性。,,,,,No genetic modifications reported; natural strains used,No engineered genetic circuits; stability in suspension form,未对两种乳酸杆菌进行基因工程改造，使用的是天然分离菌株，未引入外源基因或调控回路，因此不具备可编程性。,"[""Acidity"", ""Bile""]","[""LPS (Lipopolysaccharide)""]",,"[""Cytokines (IL-6, IL-10, IL-12b, IFN-γ, TNF-α)""]",Not specified (likely native receptors for LPS and environmental cues),No synthetic logic circuits; natural immune modulation via cytokine feedback,两种菌株通过感知宿主肠道环境中的病原体相关分子模式（如LPS）和炎症因子，调节宿主免疫细胞的反应，形成天然的免疫调节回路，但未涉及人工设计的逻辑门控机制。,"[""Immunomodulation""]",Not specified (likely passive secretion or cell lysis),Daily gavage administration; no controlled release or dosage tuning,Suspension in saline; compatible with oral delivery but not encapsulated in a functional material,False,,,No direct antibacterial activity reported; no significant reduction in Salmonella translocation or colonization,,False,,,,未观察到对沙门氏菌感染的保护作用，未显著减少肝脾中沙门氏菌的转移，表明其不具备有效的抗菌或抗生物膜功能。,False,No oxygen production or oxygenation mechanism reported,,False,False,False,未提及任何与氧生成相关的机制，因此不具有氧合功能。,True,"Modulates cytokine expression (IL-5, IL-10, IL-12b, IFN-γ, IL-17a, TGF-β1, TNF-α) in intestinal mucosa; reduces IgA production in response to infection","Cytokines (IL-10, IL-12b, IFN-γ, IL-17a, TGF-β1)",False,No evidence of tissue repair or regeneration activity,,False,"No reported metabolic regulation or metabolite production (e.g., SCFAs)",,False,No tumor-targeting or prodrug conversion activity reported,,GRAS,No genetic kill switches or auxotrophy reported,,No pathogenicity observed; no adverse effects on liver/spleen; no antibiotic resistance genes mentioned; low risk of horizontal gene transfer,No physical material barrier used; administered as free suspension,两种菌株在小鼠模型中未引起组织损伤或炎症，未导致肝脾肿大或结构破坏，且在无菌小鼠中成功定植，表明其具有良好的安全性，符合GRAS标准，无明显生物安全风险。,两种乳酸杆菌在沙门氏菌感染小鼠模型中未提供保护作用，未减少肝脾中沙门氏菌的转移，未改善组织病理学评分，但L38菌株表现出显著的抗炎作用，如在结肠中上调IL-10表达，提示其在炎症性肠病模型中具有潜在应用价值。,13827,1599,15426,,
238e8c91-bbe2-41fd-8a21-1645fee65c44,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Weissella kimchii"", ""strain_id"": ""PL9023""}]",Suspension,Facultative Anaerobe,Growth at 37°C in MRS broth; pH range 4.4–7.2; utilizes carbohydrates as carbon sources; no requirement for complex vitamins or amino acids mentioned.,Growth rate not quantified; incubated for 48–72 h in anaerobic conditions for hydrogen peroxide production; no in vivo growth data provided.,"Vaginal epithelial surface, particularly in acidic environments (pH 4.4–6.0)","Competes with pathogens (C. albicans, E. coli, S. aureus, S. agalactiae) for adherence sites; coaggregates with C. albicans; no evidence of symbiosis with other vaginal microbes.","High hydrophobicity (RH 95.77% in hexadecane); resistant to heat (10 min boiling), proteinase K, and periodate treatment; stable under varying pH (4.4–7.2); no data on UV, drying, or shear stress.",Glycoproteins (surface adhesion factors),"Weissella kimchii PL9023 is a facultative anaerobe that grows optimally at 37°C and pH 4.4–7.2, with strong adherence to vaginal epithelial cells under acidic conditions. It exhibits high surface hydrophobicity and stability against proteolytic and oxidative treatments, suggesting robustness in the vaginal environment.",,,,,,,No genetic engineering was performed. The strain was isolated and characterized based on natural phenotypic traits without synthetic circuitry or genetic modifications.,"[""pH"", ""Hypoxia""]",,,,Glycoproteins (surface adhesion factors),No engineered logic gates; natural sensing via pH-dependent adhesion and coaggregation.,"Weissella kimchii PL9023 senses environmental pH through its surface glycoproteins, enhancing adhesion at lower pH (4.4–6.0), which is typical of the vaginal tract. It also detects the presence of Candida albicans via coaggregation, enabling targeted interference without specific inducible circuits.","[""Antibacterial"", ""Interference"", ""Immunomodulation""]",Passive secretion (diffusion of hydrogen peroxide and bacteriocin-like substances),Not controllable; activity depends on natural growth and metabolic output.,Compatible with vaginal mucosal environment; no data on encapsulation or gel matrix compatibility.,True,True,False,"Inhibits growth and adherence of C. albicans, E. coli, S. aureus, and S. agalactiae via hydrogen peroxide and bacteriocin-like substances.","Hydrogen peroxide, bacteriocin-like substances",True,True,True,True,"Demonstrated inhibition of multiple vaginal pathogens (C. albicans, E. coli, S. aureus, S. agalactiae) without cytotoxicity; no harmful metabolites produced; localized action in vaginal environment.",False,,,False,False,False,No evidence of oxygen production or oxygenation mechanism.,True,"Reduces pathogen colonization and adhesion, indirectly modulating immune response by preventing infection and inflammation.","Hydrogen peroxide, bacteriocin-like substances",False,,,False,,,False,,,GRAS,"None (natural strain, no engineered kill switches)",,"No production of harmful metabolites (ammonia, indole, gelatinase, β-glucuronidase, nitroreductase); non-pathogenic; no antibiotic resistance genes reported.",None (no physical confinement used in study),"Weissella kimchii PL9023 is a GRAS (Generally Recognized As Safe) strain isolated from a healthy woman. It does not produce virulence factors or harmful enzymes, and shows no pathogenicity. It is considered safe for local vaginal application.","Weissella kimchii PL9023 significantly reduced adherence of multiple vaginal pathogens (C. albicans, E. coli, S. aureus, S. agalactiae) to vaginal epithelial cells at pH 4.4–7.2, particularly under acidic conditions. It coaggregates with C. albicans and inhibits its binding, suggesting strong potential for preventing recurrent vaginal infections. No cytotoxicity or harmful metabolites were detected, supporting its use as a safe probiotic for vaginal health.",8273,1599,9872,,
c59536e8-62fa-4d8c-88a3-4cc937277afd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Rift Valley fever virus"", ""strain_id"": ""rMP12-C13type""}]",Suspension,Facultative Anaerobe,Temperature: 37°C (in vitro); pH: physiological; Nutritional requirements: host cell machinery (no defined media); Osmotic tolerance: moderate (in vivo host environment),"Rapid replication in mammalian cells; doubling time ~4–6 hours in vitro; in vivo: transient viremia in MP-12, absent in rMP12-C13type","Systemic infection (lymph nodes, liver, spleen); local replication at inoculation site","None (viral system, not microbial)","Moderate stability in freeze-dried form; sensitive to UV, heat, and drying; stable during short-term storage at 4°C","Lipid envelope, capsid proteins",该病毒为负链RNA病毒，可在哺乳动物细胞中快速复制，具有较强的体外增殖能力。rMP12-C13type因NSs基因缺失而显著减毒，不引起血症，但保留了良好的免疫原性。在小鼠模型中，其生长动力学与亲本MP-12相似，但无系统性扩散，安全性更高。,Reverse genetics,High (precise gene replacement via reverse genetics); Off-target risk: low (targeted insertion of truncated NSs or foreign genes),Constitutive (viral gene expression driven by native promoters),,High (stable genome due to reverse genetics engineering; no plasmid-based system; integration not required); Metabolic burden: low; Evolutionary stability: high (NSs truncation prevents reversion to virulence),No material encapsulation; viral particles are naturally released,通过反向遗传学技术，将MP-12病毒的NSs基因替换为C13型69%的框内截短序列，构建rMP12-C13type。该改造使病毒在S、M、L三个基因段均减毒，同时引入了DIVA标记（抗NSs IgG阴性），便于区分感染与疫苗接种。此外，还构建了rMP12-mPKRN167，将NSs替换为小鼠蛋白激酶的显性负性形式，以增强免疫原性。,"[""Temperature"", ""pH"", ""Host cell machinery availability""]",,,"[""Type I interferon response"", ""Dendritic cell activation""]","NSs protein (functional domain), IFN-β promoter (for immune evasion sensing)",Constitutive expression; no complex logic gates; immune evasion via NSs degradation of host transcription machinery,病毒通过NSs蛋白主动抑制宿主先天免疫反应，特别是干扰素β基因的启动子活性，从而逃避免疫识别。在rMP12-C13type中，NSs功能缺失，导致病毒蛋白在引流淋巴结中积累，增强抗原呈递，但不引发系统性免疫抑制。,"[""Immunomodulation"", ""Tumor Therapy""]",Viral particle release (natural budding),Single-dose vaccination; immune response strength controlled by viral load and host immunity,No material encapsulation; natural viral release,False,,,,,,,,,,False,,,,,,,True,通过缺失NSs基因，解除对宿主转录和干扰素通路的抑制，增强树突状细胞抗原呈递，促进T细胞和B细胞活化，诱导高滴度中和抗体。,"NSs protein (loss-of-function), Type I interferon (IFN-α/β)",False,,,False,,,True,通过将NSs基因替换为显性负性小鼠蛋白激酶（mPKRN167），增强病毒在引流淋巴结中的蛋白积累，激活更强的抗病毒免疫应答，实现对野生型RVFV的100%保护，具有潜在的抗病毒治疗和免疫治疗功能。,mPKRN167 (dominant-negative mouse protein kinase),BSL-2,Genetic attenuation via NSs truncation; no functional NSs protein prevents reversion to virulence; DIVA marker allows differentiation between vaccinated and infected animals,NSs gene (truncated),"Low pathogenicity in immune-competent hosts; no viremia in rMP12-C13type; no horizontal transmission risk in mosquitoes (due to lack of NSm in some variants); no antibiotic resistance genes; no HGT risk (RNA virus, no integration)",None (viral particles not encapsulated in material),rMP12-C13type因NSs基因缺失而显著减毒，不引起血症，且无法在免疫健全宿主中复制，安全性高。其缺乏NSs功能，无法抑制干扰素，因此不会导致严重免疫逃逸。该病毒在非免疫宿主中仍可能复制，但无致病性。在蚊媒传播方面，由于NSm缺失或功能异常，传播能力降低，风险可控。整体为低风险生物制剂，适用于BSL-2实验室操作。,在小鼠模型中，rMP12-C13type可诱导高水平中和抗体，与亲本MP-12相当；rMP12-mPKRN167在单剂量接种后对野生型RVFV攻击提供100%保护。该疫苗无血症，安全性显著优于MP-12，且具备DIVA标记功能，适用于兽用和人用疫苗开发。,5733,1832,7565,,
ac4b7ad1-6f26-456b-a314-b4ec4f8565cf,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""AGO11 (IL-10 expressing), AGO13 (TFF1 expressing)""}]",Oral administration (mucosal delivery),Facultative Anaerobe,"Optimal growth at 30–37°C, pH 6.0–7.0, tolerant to moderate osmotic stress; grows on lactose and other carbohydrates; no strict nutritional auxotrophy reported",Moderate growth rate in vitro; short survival time in gastrointestinal tract (GIT) in vivo,"Gastrointestinal tract (GIT), particularly mucosal surfaces",Minimal competition with native microbiota; no significant disruption reported; lacks strong immune-modulatory properties compared to lactobacilli,Moderate tolerance to gastric acid and bile; sensitive to shear stress and drying; lyophilization possible with stabilization agents,None explicitly mentioned,"Lactococcus lactis is a facultative anaerobe with moderate growth kinetics in vitro, but exhibits short survival in the gastrointestinal tract. It colonizes mucosal surfaces after oral administration and is used as a delivery vehicle due to its food-grade status and safety profile.","Plasmid-based expression systems (e.g., pNZ8148, pMG36e), constitutive promoters (e.g., P32, P110)",High efficiency in transformation and stable plasmid maintenance; low off-target risk due to lack of chromosomal integration,"Constitutive expression of therapeutic molecules (IL-10, TFF1)",None (constitutive expression),Plasmid stability in vitro; moderate stability in vivo due to lack of selective pressure; low metabolic burden reported,Stable in oral formulations and mucosal environments; compatible with encapsulation in enteric-coated tablets,"Genetically modified Lactococcus lactis strains (AGO11 and AGO13) were engineered to constitutively express human interleukin-10 (IL-10) and trefoil factor 1 (TFF1), respectively, using plasmid-based systems. These strains are designed for mucosal delivery to treat inflammatory bowel disease and oral mucositis.","[""pH"", ""Osmotic stress""]","[""Lactose"", ""Glucose""]",,"[""Proteases"", ""Cytokines""]",None explicitly mentioned; relies on constitutive promoters rather than environmental sensing,No logic gates; constitutive expression without feedback control,The system operates via constitutive expression of therapeutic proteins without environmental sensing or feedback regulation. No dynamic control or threshold-based activation is implemented.,"[""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion via Sec pathway,Fixed output based on constitutive expression; no dynamic dosage adjustment,Compatible with oral delivery systems and enteric-coated formulations; stable in gel or tablet matrices,False,,,None,,False,False,False,False,Not applicable,False,None,,False,False,False,Not applicable,True,Local delivery of anti-inflammatory cytokine IL-10 to modulate mucosal immune responses and reduce intestinal inflammation in IBD.,Interleukin-10 (IL-10),True,"Delivery of trefoil factor 1 (TFF1), a protein that promotes epithelial restitution and mucosal healing in oral mucositis.",Trefoil Factor 1 (TFF1),False,None,,False,None,,BSL-1,"Auxotrophy (e.g., uracil auxotrophy), suicide genes (e.g., ccdB), and plasmid loss under non-selective conditions","Uracil auxotrophy, ccdB toxin-antitoxin system",Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer in vivo; low environmental escape risk due to poor survival in gut,Enteric coating prevents release in upper GI; physical confinement in capsule limits environmental exposure,"Lactococcus lactis is a GRAS organism with a long history of safe use in food fermentation. The genetically modified strains (AGO11, AGO13) have been tested in phase I and II clinical trials, showing good safety and tolerability. Biocontainment strategies such as auxotrophy and suicide genes prevent persistence in the environment. No significant adverse events were reported in human trials.","Phase I trial confirmed safety and feasibility of IL-10 delivery via GM L. lactis in humans. Phase IIa trial showed positive efficacy of AGO13 (TFF1-expressing strain) in treating oral mucositis in 25 patients compared to placebo. However, no statistically significant improvement in mucosal healing was observed in Crohn’s disease patients in the IL-10 trial, suggesting the need for improved expression systems or combination therapies.",7248,4861,12109,,
ac4b7ad1-6f26-456b-a314-b4ec4f8565cf,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""BL23""}]",Oral administration (mucosal delivery),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerant to bile and gastric acid; utilizes glucose, lactose, and other carbohydrates; requires vitamins and amino acids for optimal growth",Moderate growth rate in vitro; persists longer in GIT than L. lactis; doubling time ~1.5–2 hours,"Gastrointestinal tract (GIT), particularly colon and mucosal surfaces",Competes with pathogens; promotes homeostasis; synergistic with native microbiota; immune-modulatory interactions,"High tolerance to bile, acid, and osmotic stress; stable during lyophilization and rehydration; resistant to shear stress","Bile salts, acid shock proteins, stress response regulators","Lactobacillus casei BL23 is a facultative anaerobe with strong persistence in the gastrointestinal tract. It exhibits high tolerance to gastric acid and bile, enabling effective delivery to the colon. It is naturally adapted to the human gut environment and supports mucosal homeostasis.","Plasmid-based systems (e.g., pSIP series), CRISPR-Cas9 for chromosomal integration, recombinase systems",High transformation efficiency; chromosomal integration improves stability; low off-target risk with CRISPR-Cas9,"Constitutive and inducible (e.g., lactose-inducible promoter) expression","Lactose, IPTG (for synthetic promoters)",High chromosomal integration stability; low plasmid loss rate; minimal metabolic burden; evolutionarily stable in vivo,Stable in encapsulated formulations and hydrogels; compatible with biodegradable matrices,"Lactobacillus casei BL23 has been genetically modified to express therapeutic proteins such as superoxide dismutase (SOD), manganese-dependent catalase, and elafin. Expression is driven by constitutive or inducible promoters, with chromosomal integration enhancing long-term stability.","[""Hypoxia"", ""pH"", ""ROS""]","[""Lactose"", ""Glucose""]","[""AHL (in some engineered variants)""]","[""Proteases (e.g., MMPs)"", ""Cytokines""]","FNR promoter (hypoxia), lactose-inducible promoter (LacI), ROS-responsive promoters",AND gate: expression only under hypoxia and presence of lactose; threshold-based activation for ROS,"Engineered L. casei BL23 can sense hypoxia, lactose, and ROS via specific promoters. A logic AND gate ensures expression only in inflamed, hypoxic gut environments with available nutrients. This enables targeted delivery of therapeutic molecules to diseased sites.","[""Antioxidant"", ""Immunomodulation"", ""Tissue Repair""]",Sec-dependent secretion; some strains use lysis for release,"Inducible expression allows dosage control via nutrient availability (e.g., lactose)","Compatible with oral capsules, hydrogels, and biofilm matrices; maintains activity in encapsulated form",False,,,None,,False,False,False,False,Not applicable,False,None,,False,False,False,Not applicable,True,"Expression of SOD and catalase reduces oxidative stress; elafin inhibits proteases involved in inflammation, promoting mucosal healing.",Elafin,True,"Elafin inhibits proteases (e.g., elastase, MMPs), accelerates mucosal healing, and restores barrier integrity in colitis models.",Elafin,False,None,,False,None,,BSL-1,"Auxotrophy (e.g., uracil), suicide genes (ccdB), and chromosomal integration","Uracil auxotrophy, ccdB toxin-antitoxin system",Low pathogenicity; no antibiotic resistance genes; no evidence of HGT; low environmental escape risk due to poor survival outside gut,Encapsulation prevents premature release; physical confinement limits environmental exposure,Lactobacillus casei BL23 is a GRAS strain with a long history of safe use. Engineered variants show no adverse effects in preclinical models. Biocontainment via auxotrophy and suicide genes ensures limited persistence. No clinical safety concerns reported in animal studies.,GM L. casei BL23 expressing SOD or catalase reduced intestinal inflammation and oxidative stress in murine colitis models. Elafin-expressing strain prevented inflammation and accelerated mucosal healing in multiple colitis models. These results suggest strong potential for treating IBD and other inflammatory conditions.,7248,4861,12109,,
ac4b7ad1-6f26-456b-a314-b4ec4f8565cf,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""Not specified""}]",Oral administration (mucosal delivery),Strict Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; requires complex media with amino acids, vitamins, and carbohydrates; highly sensitive to oxygen",Slow growth rate in vitro; long-term persistence in GIT; doubling time ~3–4 hours,"Hypoxic regions of the colon, tumor hypoxia, mucosal surfaces",Symbiotic with host microbiota; competes with pathogens; enhances gut barrier function,Moderate tolerance to bile and acid; sensitive to drying and UV; stable in lyophilized form with cryoprotectants,"Cryoprotectants (e.g., trehalose), bile salt hydrolases","Bifidobacterium longum is a strict anaerobe with slow growth in vitro but excellent persistence in the human gut. It preferentially colonizes hypoxic niches such as the colon and tumor microenvironment, making it ideal for targeted delivery.","Plasmid-based systems (e.g., pBb1), chromosomal integration via homologous recombination, CRISPR-Cas9",Moderate transformation efficiency; high stability with chromosomal integration; low off-target risk,"Constitutive and inducible (e.g., lactose-inducible promoter)","Lactose, galactose",High chromosomal integration stability; low plasmid loss; minimal metabolic burden; evolutionarily stable in vivo,Stable in oral formulations and hydrogels; compatible with biodegradable matrices,"Bifidobacterium longum has been engineered to express therapeutic molecules such as IL-10 and α-melanocyte-stimulating hormone (α-MSH). Expression is driven by constitutive or inducible promoters, with chromosomal integration ensuring long-term stability.","[""Hypoxia"", ""pH"", ""ROS""]","[""Lactose"", ""Galactose"", ""Bile acids""]","[""AHL""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), lactose-inducible promoter (LacI), ROS-responsive promoters",AND gate: expression only under hypoxia and presence of lactose; threshold-based activation for ROS,"Bifidobacterium longum senses hypoxia, lactose, and ROS via specific promoters. An AND gate ensures expression only in inflamed, hypoxic gut or tumor environments with available nutrients, enabling precise targeting of therapeutic molecules.","[""Immunomodulation"", ""Tissue Repair""]",Sec-dependent secretion; some strains use lysis for release,"Inducible expression via nutrient availability (e.g., lactose)",Compatible with oral capsules and hydrogels; maintains activity in encapsulated form,False,,,None,,False,False,False,False,Not applicable,False,None,,False,False,False,Not applicable,True,Expression of IL-10 and α-MSH reduces inflammation and promotes mucosal healing in colitis models.,"Interleukin-10 (IL-10), α-melanocyte-stimulating hormone (α-MSH)",True,α-MSH promotes anti-inflammatory responses and tissue regeneration in colitis models.,α-melanocyte-stimulating hormone (α-MSH),False,None,,False,None,,BSL-1,"Auxotrophy (e.g., uracil), suicide genes (ccdB), chromosomal integration","Uracil auxotrophy, ccdB toxin-antitoxin system",Low pathogenicity; no antibiotic resistance genes; no evidence of HGT; low environmental escape risk due to poor survival outside gut,Encapsulation prevents premature release; physical confinement limits environmental exposure,Bifidobacterium longum is a GRAS organism with a long history of safe use. Engineered strains show no adverse effects in preclinical models. Biocontainment via auxotrophy and suicide genes ensures limited persistence. No clinical safety concerns reported.,"Oral administration of GM B. longum expressing IL-10 or α-MSH effectively treated colitis in murine models. α-MSH-expressing strain showed significant anti-inflammatory and tissue-repair effects, suggesting strong potential for treating IBD and other inflammatory diseases.",7248,4861,12109,,
1144a7b1-ab26-4525-b89e-abc11e2240ae,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""ŁOCK 0860, ŁOCK 1091, ŁOCK 1092, ŁOCK 1094, ŁOCK 1087""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 5.5 (in vitro); Growth medium: MRS broth, nutrient broth; Bile salts: 1–2% (w/v); Acidic environment: pH 2.0–3.0",High survival rate in acidic conditions (>88% after 4 h); High resistance to bile salts (≤10% reduction in population after 4 h),"Gastrointestinal tract of monogastric animals (swine, poultry); Adheres to intestinal epithelium","Competitive exclusion of pathogens via adhesion, co-aggregation, and antimicrobial metabolite production","High resistance to acidic pH (pH 2.0–3.0), bile salts (1–2% w/v), and moderate tolerance to drying and storage (cryobanked at -22°C)","Cell wall components, exopolysaccharides, and metabolic adaptation to low pH and bile",该研究中评估的Lactobacillus菌株在37°C下于MRS或营养肉汤中生长良好，具有优异的耐酸性和耐胆盐能力，能在pH 2.0–3.0和1–2%胆盐环境中保持超过88%的存活率，表明其在胃肠道环境中的强适应性。,,,,,,,文中未提及任何基因工程改造，所有特性均为天然菌株的固有属性，未进行人工遗传修饰。,"[""Acidity (pH 2.0–3.0)"", ""Bile salts""]",,,,Cell surface receptors and membrane transporters responsive to low pH and bile salts,No engineered logic gates; natural physiological responses to environmental stressors,菌株通过细胞膜和表面受体感知酸性环境和胆盐，启动应激反应机制，如质子泵、膜稳定蛋白和代谢重编程，以维持细胞完整性。,"[""Antibacterial"", ""Adhesion"", ""Competitive Exclusion""]","Passive diffusion of metabolites (e.g., lactic acid, bacteriocins) through cell membrane","Natural, uncontrolled secretion; dependent on growth phase and environmental conditions",Compatible with feed matrices; no encapsulation or delivery system described,True,True,False,通过产生抑制性代谢物、竞争结合位点和营养，抑制多种病原菌生长，包括沙门氏菌、李斯特菌、弯曲杆菌等。,"Lactic acid, bacteriocins, organic acids, hydrogen peroxide",True,True,True,True,所有菌株对沙门氏菌、李斯特菌和弯曲杆菌均表现出强或中等拮抗活性，且无β-溶血性，表明其安全且具有广谱抗菌能力。,False,,,False,False,False,未检测到氧生成能力，无相关机制。,False,,,False,,,False,,,False,,,GRAS,"None (natural strains, no synthetic kill switches)",,"No β-hemolysis, no mucin degradation, low cytotoxicity to Caco-2 cells, moderate antibiotic resistance; no evidence of horizontal gene transfer or pathogenicity",None (no physical confinement described),所研究的Lactobacillus菌株未表现出β-溶血性、黏液降解能力或对Caco-2细胞的显著细胞毒性，且在抗生素耐药性测试中仅对部分抗生素表现出中等敏感性，整体安全性良好，符合GRAS标准。,所有菌株均表现出对沙门氏菌、李斯特菌和弯曲杆菌的强拮抗活性，且在酸性环境和胆盐中具有高存活率，能有效黏附于Caco-2细胞并抑制病原体附着（最高达62.58%），表明其在替代抗生素饲料添加剂方面具有显著潜力。,19313,1532,20845,,
b504c50e-ba7c-4193-85b3-e993e5b3ae35,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Arthrospira platensis"", ""strain_id"": ""Templer, Zhongshan, China""}]",Encapsulated,Facultative Anaerobe,"Temperature: 22 ± 1°C; pH: not specified; Osmotic: not specified; Nutrition: complex organic matter in aqueous suspension; Carbon source: photosynthetic (light-dependent), but in gut environment likely utilizes undigested polysaccharides and other components from spirulina",Not directly measured in vivo; in vitro growth is rapid under optimal light and nutrient conditions; in vivo stability in gut not quantified,"Distal large intestine (cecum and colon), where undigested spirulina components transit and interact with resident microbiota","Modulates composition of colonic microbiota by promoting beneficial genera (e.g., Barnesiella, Bacteroides, Clostridium XIVa) and suppressing others (e.g., Flavonifractor); potential prebiotic-like interaction without engineered symbiosis","Tolerant to gastric transit (acidic environment), bile exposure, and intestinal exudate; stability during oral gavage and storage in suspension; lyophilization not tested","Cell wall components of Arthrospira platensis (e.g., glycoproteins, peptidoglycan-like structures) likely contribute to resistance",螺旋藻（Arthrospira platensis）为一种蓝绿藻，可在水体中通过光合作用快速生长。在本研究中，其以口服悬液形式给予小鼠，经胃肠道传输至结肠，其未被完全消化的成分在结肠内与微生物群落相互作用，表现出对特定菌属的调节作用。,,,,,,,本研究未对螺旋藻进行基因改造，其作用机制基于天然成分（如多糖、多酚、不饱和脂肪酸）对肠道微生物群的非靶向调节，属于天然营养干预，无遗传工程干预。,"[""pH"", ""Osmotic stress"", ""Bile acids""]","[""Polysaccharides"", ""Polyphenols"", ""Fatty acids""]",,,"Cell wall and membrane components of Arthrospira platensis; potential recognition by host immune receptors (e.g., TLRs) and microbial metabolite sensors",No engineered logic; natural response to environmental cues via passive diffusion and receptor binding,螺旋藻作为天然营养物质，其在肠道中的作用不依赖于基因回路或逻辑门控，而是通过其细胞壁和代谢产物与肠道环境及微生物群落发生被动相互作用，响应pH、胆汁酸、渗透压等物理化学信号，以及自身释放的多糖、多酚等代谢物信号。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Passive release of undigested components (polysaccharides, polyphenols, fatty acids) during transit through the GI tract",Dose-dependent modulation (1.5 g/kg vs 3.0 g/kg); effects observed in a graded manner,Oral suspension is compatible with gastrointestinal transit and cecal colonization; no encapsulation material used,False,False,False,Not applicable,,False,False,False,False,未检测到抗菌或抗生物膜活性。,False,Not applicable,,False,False,False,未涉及氧气生成或氧合机制。,True,螺旋藻通过调节肠道菌群结构，间接增强宿主免疫功能，表现为抗氧化酶SOD活性升高，炎症标志物MDA下降，提示抗炎和免疫调节作用。,"SOD (Superoxide Dismutase), MDA (Malondialdehyde)",True,通过调节肠道菌群，促进代谢稳态，改善氧化应激和脂质代谢，间接支持肠道屏障修复与组织稳态维持。,"Leptin, Bacteroides, Barnesiella",True,螺旋藻显著调节肠道菌群，促进Bacteroides和Barnesiella等菌属增殖，降低Flavonifractor丰度，从而改善脂质代谢（TC、TG下降）和氧化应激（MDA下降，SOD上升），并提升食欲激素Leptin水平。,"Leptin, SCFAs (inferred), Bacteroides-derived metabolites",False,Not applicable,,GRAS,"None (natural organism, no genetic modification)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; no environmental escape risk due to non-replicative nature in gut; no engineered persistence,Gastrointestinal tract acts as natural physical barrier; no synthetic material barrier used,螺旋藻为公认安全（GRAS）的食品补充剂，未经过基因改造，无生物安全风险。其在肠道内不增殖，主要通过未消化成分发挥预生物作用，无致病性、耐药基因或水平基因转移风险，环境逃逸可能性极低。,口服螺旋藻在健康小鼠中表现出剂量依赖性调节结肠微生物群的能力，高剂量（3.0 g/kg）显著增加Bacteroides和Barnesiella丰度，降低Flavonifractor丰度，同时显著降低血清MDA（氧化应激标志物）和TC/TG（脂质水平），并提高Leptin水平，提示其在改善代谢健康、减轻氧化应激和调节食欲方面具有潜在治疗价值。,12447,1802,14249,,
e2a862c3-8f2c-4c58-948f-e1bc7661a991,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 36–37°C, pH 5.5–6.5; bile and acid tolerant; utilizes glucose and other carbohydrates as carbon sources",Growth rate not explicitly reported; in vitro doubling time estimated at ~1–2 hours under optimal conditions; consistent with in vivo gut colonization dynamics,"Gut mucosa, particularly in the small intestine and colon",Competes with pathogenic Enterobacteriaceae for adhesion sites and nutrients; may modulate host immune responses and stabilize gut microbiota,"Tolerant to bile acids, low pH, and moderate osmotic stress; stable during lyophilization and rehydration; resistant to shear stress in suspension","Bile salt hydrolase (BSH), acid shock proteins, and extracellular polysaccharides","Lactobacillus rhamnosus GG is a bile- and acid-resistant probiotic strain capable of surviving gastrointestinal transit and colonizing the human gut. It exhibits facultative anaerobic growth, thrives in the intestinal environment, and maintains stability under various stress conditions encountered during travel and storage.","None (natural strain, no genetic modification reported)",Not applicable,Constitutive,,High chromosomal stability; no plasmids reported; no evidence of genetic drift or loss in vivo,Stable in tablet formulation (Dicoflor®); maintains viability during storage and in gastrointestinal environment,"Lactobacillus rhamnosus GG was used in its native, unmodified form. No genetic circuits, inducible promoters, or engineered regulatory systems were employed. The strain relies on its intrinsic physiological traits for function.","[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]",,,"Bile salt hydrolase (BSH), acid-responsive promoters (e.g., P1, P2), and surface adhesins (e.g., p40, p75)",No synthetic logic gates; natural sensing via receptor-mediated adhesion and metabolic adaptation,"Lactobacillus rhamnosus GG senses the intestinal environment through pH and bile acid gradients, triggering adaptive responses such as adhesion, acid resistance, and bile tolerance. These responses are constitutive and not regulated by synthetic logic circuits.","[""Antibacterial"", ""Immunomodulation""]",Constitutive secretion of metabolites and surface proteins; no engineered secretion systems,Dose-dependent effect via oral intake (6 billion CFU twice daily); controlled by administration schedule,Compatible with tablet formulation (Dicoflor®); stable during encapsulation and gastrointestinal transit,True,False,False,"Competitive exclusion of pathogenic Enterobacteriaceae by binding to intestinal epithelial cells and producing bacteriocins (e.g., lactocin 705), which inhibit growth of Gram-negative bacteria.","Bacteriocins (e.g., lactocin 705), organic acids (lactic acid), and surface adhesins",False,True,True,True,"LGG demonstrated competitive exclusion of ESBL-producing Enterobacteriaceae in the gut; however, no significant reduction in colonization rates was observed in the trial. The effect was limited to niche competition and not sufficient to prevent colonization under high exposure conditions.",False,,,False,False,False,No oxygenation mechanism was engineered or present in LGG.,True,"Modulates host immune responses by enhancing mucosal barrier function, promoting anti-inflammatory cytokine production (e.g., IL-10), and reducing pro-inflammatory responses (e.g., TNF-α).","Exopolysaccharides (EPS), surface proteins (p40, p75), and secreted immunomodulatory metabolites",False,,,False,,,False,,,GRAS,"None (natural strain, no kill-switch or auxotrophy)",,Non-pathogenic; no known virulence factors; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape,Physical barrier provided by tablet matrix and gastrointestinal mucosa,"Lactobacillus rhamnosus GG is classified as Generally Recognized As Safe (GRAS) by the FDA and EFSA. It has a long history of safe use in humans, with no reported adverse events in the study. No genetic modifications or biocontainment systems were used, but its natural low pathogenicity and inability to persist long-term in non-host environments mitigate risks.","LGG did not significantly reduce colonization with ESBL-producing Enterobacteriaceae in travelers to India. Despite its known protective effects against traveler’s diarrhea and gut dysbiosis, the high environmental exposure during travel led to >90% colonization rates in both groups. The strain demonstrated competitive exclusion potential in vitro and in vivo, but this was insufficient to prevent colonization under high-pathogen load conditions. No significant improvement in long-term clearance or immune modulation was observed in the trial.",12660,1697,14357,,
eca5c058-86ce-404a-91d2-2ac3e966bb4e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""R0011""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""R0052""}]","Encapsulated (in maternal milk, transferred to pups)",Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires lactose and other fermentable carbohydrates; dependent on host-derived nutrients in gastrointestinal tract",Moderate growth rate in vitro; transient colonization in host gut without long-term persistence; stable in maternal milk during delivery to pups,Gastrointestinal tract (transient colonization in infant gut via maternal milk),Commensal interaction; no evidence of competitive exclusion or symbiosis with resident microbiota; may modulate immune tolerance,Tolerant to gastric acidity and bile salts; stable during lyophilization and rehydration; survives in drinking water for 2 days,Lactobacillus rhamnosus R0011 (resistant to low pH and bile),该系统由Lactobacillus rhamnosus R0011和L. helveticus R0052组成，为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，依赖乳糖等可发酵碳源。在母体乳汁中稳定存在，通过哺乳传递至幼崽，实现短暂定植于幼崽肠道，不长期存活，但能有效传递至宿主并发挥功能。,"Not applicable (natural strain, no genetic modification reported)",N/A,Constitutive (no inducible circuits reported),N/A,High (no plasmid-based systems; chromosomal stability in natural strains; no evidence of genetic drift or loss in vivo),Stable in maternal milk and during oral delivery to pups; no degradation in liquid formulation,该系统未经过基因工程改造，使用天然菌株L. rhamnosus R0011和L. helveticus R0052，通过母体饮水摄入后定植于幼崽肠道，无需人工调控电路或诱导剂，具有天然的遗传稳定性，可在母乳中保持活性并传递至幼崽。,"[""pH (gastric acidity)"", ""Bile salts""]","[""Lactose"", ""Glucose""]",,"[""Cytokines (pro-inflammatory)"", ""Corticotropin-releasing hormone (CRH)""]","FNR promoter (hypoxia sensor), bile salt hydrolase (bile sensing), lactose permease (nutrient sensing)",Constitutive expression; no reported logic gates or threshold control; response driven by environmental availability of nutrients and host signals,该系统依赖于环境中的pH、胆盐和可发酵碳源（如乳糖）进行定植和代谢，通过天然受体（如乳糖转运蛋白、胆盐水解酶）感知宿主微环境，无复杂逻辑门控机制，表现为持续性定植与代谢活动，响应宿主炎症状态（如CRH和促炎因子）调节免疫功能。,"[""Immunomodulation"", ""Metabolic Regulation""]","Passive secretion (natural metabolic byproducts), no engineered secretion systems reported",Dose-dependent via maternal intake; controlled by concentration in drinking water (10^9 CFU/mL),Highly compatible with maternal milk and oral delivery; stable in liquid formulation without structural disruption,False,,,N/A,N/A,False,False,False,False,未涉及抗菌或抗生物膜功能,False,N/A,N/A,False,False,False,未涉及氧气生成功能,True,通过下调促炎细胞因子（如IL-6、TNF-α）和恢复肠道屏障功能，调节免疫稳态，缓解母体分离诱导的炎症反应。,"Pro-inflammatory cytokines (IL-6, TNF-α), tight junction proteins (occludin, ZO-1)",False,N/A,N/A,True,调节色氨酸代谢，影响血清素合成，从而调控情绪相关神经递质水平，改善应激诱导的情绪失调。,"Serotonin (5-HT), Tryptophan metabolites (kynurenine pathway)",False,N/A,N/A,GRAS,Auxotrophy (nutrient-dependent growth; no long-term persistence in host),"Lactose, glucose (required for growth)",Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer observed; minimal environmental escape risk due to transient colonization,Physical confinement via maternal milk delivery; no free-living environmental release,该系统为GRAS级益生菌，无致病性，不携带抗生素抗性基因，依赖宿主营养（如乳糖）生长，无法在无宿主环境中长期存活，具有天然生物安全屏障，通过母乳传递实现靶向递送，风险极低。,在母体分离（MS）幼鼠模型中，经Lacidofil处理的幼鼠表现出与正常饲养幼鼠一致的婴儿期遗忘现象和对恐惧消退的抗复发能力，显著逆转了早期生活压力导致的情绪学习轨迹异常，恢复了正常发育进程，且效果不依赖于母体焦虑或母性行为的改变，表明该益生菌制剂在非侵入性干预早期应激相关情绪障碍方面具有显著疗效。,11938,1818,13756,,
47e6305e-14bb-4d0a-bbff-8c2b2dc64d42,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""ATCC PTA 6475""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in MRS or LDM3 medium; pH not explicitly stated, but typical for lactobacilli (pH 5.5–6.5); requires erythromycin for plasmid maintenance in vitro",Growth rate not quantified; cultured to OD600 of 3.5–3.7 in LDM3 medium; no in vivo growth rate reported,"Gut lumen, particularly small intestine (jejunum); demonstrated colonization and systemic delivery in mouse model",Probiotic strain with native ability to ameliorate obesity; interacts with host immune system via IL-22 signaling; no direct competition/symbiosis with other microbes reported,"Tolerant to lyophilization/rehydration (used in animal experiments); stable at -80°C; no data on UV, shear, or osmotic stress",Glycerol (15% vol/vol) used in wash buffer for cryoprotection,"Lactobacillus reuteri ATCC PTA 6475 is a facultative anaerobe capable of growing in standard laboratory media (MRS, LDM3) at 37°C. It exhibits probiotic properties, including weight gain reduction and fat pad reduction in obese mice. The strain thrives in the gut environment and maintains genetic stability due to low mutation rate. It is used as a chassis for oral delivery of recombinant IL-22.","CRISPR-Cas9 (implied by high-throughput genome editing tools available), Ligase Cycling Reaction (LCR), Phusion Hot Start polymerase, electrotransformation",High efficiency; successful cloning confirmed by colony PCR and DNA sequencing; plasmid integration confirmed in transformants,Constitutive expression from high-copy plasmid pJP028; no inducible system reported,,High chromosomal stability due to low mutation rate; plasmid stability maintained with erythromycin selection; no data on long-term in vivo stability or metabolic burden,Stable in LDM3 medium and in suspension for oral gavage; no evidence of degradation during storage or delivery,"Lactobacillus reuteri ATCC PTA 6475 was engineered to secrete murine interleukin-22 (mIL-22) using a high-copy plasmid (pJP028). The mIL-22 gene was codon-optimized and fused to a native L. reuteri signal peptide for secretion. The construct was assembled via ligase cycling reaction and transformed into electrocompetent L. reuteri. The resulting strain (VPL3461) was validated by ELISA and Western blot, showing secretion of mIL-22, though with incomplete signal peptide cleavage.",,,,,,No sensing or logic circuitry reported; expression is constitutive,该系统未设计任何环境感应模块或逻辑门控机制，mIL-22的表达为组成型，由高拷贝质粒pJP028驱动，不依赖于外部信号或内部调控网络。,"[""Immunomodulation"", ""Tissue Repair""]",Signal peptide-mediated secretion via native bacterial secretion machinery; partial cleavage observed (81.7% unprocessed fusion protein),Constitutive expression; dosage controlled by bacterial load (10^9 CFU/mouse) and plasmid copy number; no dynamic or tunable control reported,Compatible with oral delivery in liquid suspension; stable in LDM3 medium; no evidence of matrix disruption,False,,,,,,,,,,False,,,,,,,True,"Recombinant L. reuteri secretes biologically active murine IL-22, which activates the STAT3 signaling pathway in host tissues, leading to reduced inflammation and improved metabolic regulation.",Interleukin-22 (IL-22),True,"IL-22 upregulates reg3β and reg3γ genes in the jejunum, which promote epithelial regeneration, reduce apoptosis, and enhance barrier function. It also contributes to hepatoprotection and tissue repair in the liver.","Reg3β, Reg3γ",True,"IL-22 regulates lipid metabolism in liver and adipose tissues by downregulating lipogenic genes and upregulating antiapoptotic genes, thereby reducing hepatic steatosis and improving metabolic homeostasis.",Interleukin-22 (IL-22),False,,,GRAS,No explicit biocontainment strategy reported; reliance on natural attenuation and low pathogenicity,,L. reuteri ATCC PTA 6475 is a well-characterized probiotic with no known pathogenicity; low risk of horizontal gene transfer; no antibiotic resistance genes reported; no evidence of environmental escape in study,Oral delivery via gavage; physical confinement limited to gastrointestinal tract; no engineered physical barrier,该系统使用的是公认安全（GRAS）的Lactobacillus reuteri ATCC PTA 6475菌株，具有低致病性、低抗生素抗性风险和低水平基因水平转移潜力。尽管未使用人工生物遏制策略，但其天然的肠道定植特性和低环境适应性降低了逃逸风险。未来临床应用需建立更严格的生物和环境遏制机制。,在高脂饮食诱导的肥胖小鼠模型中，表达IL-22的工程化L. reuteri显著降低了肝脏重量（较对照组减少20.7%，P<0.001）和肝三酰甘油水平（较对照组减少11.4倍，P<0.001），且优于野生型L. reuteri。同时，该治疗显著上调了空肠中reg3β和reg3γ基因的表达（分别增加2.6倍和2.9倍，P<0.05），表明其具有显著的免疫调节和组织修复能力。,11834,1951,13785,,
39d80d61-8177-4726-abfd-0d66bac4d447,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""Unique IS2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""UBLR58""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""UBBLA70""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""UBLP40""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""UBBr01""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""UBBI01""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, requires glucose and amino acids; tolerant to bile salts and gastric acidity",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed after 28-day supplementation,"Gut lumen, particularly colon and ileum; preferentially colonizes mucosal surfaces under stress conditions",Competitive exclusion of pathogenic bacteria; synergistic interactions with host microbiota; no significant disruption of native microbiome reported,"Resistant to lyophilization, storage at room temperature for 12 months, and gastric transit; tolerates osmotic stress and moderate shear forces","Spore formation (Bacillus coagulans), exopolysaccharides (Lactobacillus, Bifidobacterium)",该多菌株益生菌制剂由六种不同菌株组成，均为耐胃酸和胆汁的兼性厌氧菌，可在肠道环境中定植并维持稳定生长。其中，Bacillus coagulans 以孢子形式存在，具有良好的耐受性和稳定性；Lactobacillus 和 Bifidobacterium 菌株在肠道中可利用碳水化合物和氨基酸进行代谢，支持其在宿主肠道中的持久定植。,,,,,No genetic modification reported; natural strains used; chromosomal stability confirmed in vivo over 28 days,Stable in capsule matrix; no degradation or loss of viability during encapsulation and storage,本研究中使用的益生菌菌株均为天然分离株，未经过基因工程改造。其功能依赖于天然代谢通路，如GABA和短链脂肪酸的合成，无需外源调控回路。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Glutamate"", ""Lactate"", ""Short-Chain Fatty Acids (SCFAs)""]",,"[""Cortisol"", ""Cytokines (indirectly via inflammation)""]","FNR promoter (hypoxia), GABA transporter (glutamate sensing), bile salt hydrolase (bile acid sensing)",No engineered logic gates; natural sensing via metabolic feedback and quorum-like responses,各菌株通过感知肠道微环境中的pH、葡萄糖、胆汁酸和代谢物（如谷氨酸）进行响应，调控自身代谢活动。例如，Lactobacillus 和 Bifidobacterium 菌株通过感知谷氨酸水平启动GABA合成通路，而Bacillus coagulans则在低氧和高胆汁环境中激活孢子萌发机制。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Passive diffusion, extracellular vesicles",Dose-dependent effect; 2 billion CFU per strain (2×/day) for 28 days; no feedback control,High compatibility with capsule matrix; stable release in gastrointestinal tract,False,False,False,,,False,False,False,False,,False,,,False,False,False,,True,通过调节肠道屏障功能、抑制促炎因子（如IL-6、TNF-α）和促进抗炎因子（如IL-10）释放，减轻系统性炎症反应。,"Short-chain fatty acids (SCFAs), GABA, IL-10",True,通过产生丁酸等短链脂肪酸，促进肠上皮细胞增殖和紧密连接蛋白表达，增强肠道屏障完整性，间接支持组织修复。,"Butyrate, Acetate, Propionate",True,通过代谢谷氨酸生成GABA，调节中枢神经系统功能；同时产生丁酸、乙酸和丙酸，调节宿主能量代谢和免疫稳态。,"Gamma-aminobutyric acid (GABA), Butyrate, Acetate, Propionate",False,,,GRAS,No genetic kill switches; natural attenuation via lack of long-term colonization,Glutamine (auxotrophy not confirmed),No pathogenicity reported; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape observed,Capsule matrix prevents release into environment; gastrointestinal transit limits survival outside host,该多菌株益生菌制剂被归类为GRAS（公认安全），所有菌株均为人体正常菌群成员，无致病性记录。在临床试验中未报告不良事件，且无抗生素抗性基因或水平基因转移风险。胶囊封装提供了物理屏障，防止菌株在体外扩散。,在为期28天的双盲安慰剂对照试验中，服用多菌株益生菌的受试者在PSS、DASS、STAI评分及血清皮质醇水平上均显著下降（P<0.001）。PSS评分从24.44降至15.00，DASS从20.83降至12.72，STAI从48.58降至39.78，皮质醇从23.29 μg/dL降至13.27 μg/dL，表明该制剂能有效缓解考试压力相关的心理和生理应激反应。,8801,1984,10785,,
0f3f0993-0d13-4bdf-838c-f54a64c22373,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": """"}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 4.5–6.0; utilizes glucose and other carbohydrates as carbon sources; dependent on host-derived nutrients in vaginal environment",Doubling time ~60–90 min in vitro; stable colonization observed in vivo after probiotic administration,"Vaginal mucosa, particularly in the lower vaginal fornix and epithelial surface",Competitive exclusion of Candida albicans; synergistic stabilization of vaginal microbiota; inhibition of pathogen adhesion via surface colonization,Moderate tolerance to osmotic stress and pH fluctuations; stable during lyophilization and rehydration; resistant to vaginal exudate shear forces,"Exopolysaccharides (EPS), cell surface adhesins",该微生物群落为阴道定植型乳酸菌复合体，具有耐受阴道微环境（如酸性pH、有限营养）的能力，可在治疗后快速定植并恢复阴道微生态平衡。,None (natural strains used; no genetic modification reported),Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems; no reported genetic drift in clinical use,Stable in vaginal gel formulation; maintains viability during encapsulation and release,该系统未经过基因工程改造，直接使用天然乳酸菌株，通过其固有生理特性实现功能，无需外源调控元件。,"[""pH"", ""Glucose"", ""Lactate""]","[""Bile acids"", ""SCFAs""]",,,"Lactate dehydrogenase (LDH), pH-responsive promoters (e.g., P1 promoter in L. rhamnosus)",Constitutive expression; no complex logic gates; threshold-based metabolic activity in response to local pH and nutrient availability,乳酸菌通过感知阴道环境中的乳酸、葡萄糖和pH变化，自动启动代谢活动，维持酸性微环境，抑制病原体生长，无需外部诱导信号。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion system (for bacteriocins), Vesicles (exosomes-like), Passive diffusion","Self-regulated by environmental cues (pH, nutrients); no external dosage control",High compatibility with vaginal gel matrix; maintains viability and release kinetics,True,False,True,通过产生乳酸、细菌素（如乳酸菌素）和 biosurfactants 抑制C. albicans的生长和生物膜形成，竞争性阻断其在阴道上皮的黏附。,"Lactic acid, Bacteriocins (e.g., Lactacin B), Biosurfactants",False,True,True,True,乳酸菌在阴道环境中持续产生乳酸，维持pH<4.5，有效抑制C. albicans生长，且无明显细胞毒性，局部使用安全。,False,,,False,False,False,,True,通过调节NF-κB通路，抑制过度炎症反应，同时诱导IL-1α和IL-1β表达，增强黏膜免疫屏障功能。,"Lactobacillus-derived exopolysaccharides (EPS), Lipoteichoic acid (LTA)",True,通过分泌细胞因子和调节黏膜屏障功能，促进上皮再生和组织修复，改善阴道组织炎症损伤。,"Epidermal growth factor (EGF)-like molecules, Mucin-like glycoproteins",False,,,False,,,GRAS,Auxotrophy (nutrient-dependent survival); no antibiotic resistance genes detected,"Glucose, amino acids (required for growth)",Low pathogenicity; no known virulence factors; no horizontal gene transfer reported; minimal risk of environmental escape,Vaginal mucosal barrier and local retention; no systemic dissemination observed,该乳酸菌复合体为公认安全（GRAS）菌株，无致病性、无抗生素抗性基因，依赖宿主营养生长，具有天然生物安全屏障，临床使用中未见不良反应。,联合使用抗真菌药物与阴道乳酸菌制剂后，临床症状缓解率从第一组的79.7%降至第二组的31.1%，微生物学治愈率从93.7%提升至95.2%，显著降低复发风险，有效恢复阴道微生态平衡。,10780,1695,12475,,
6cccd031-3f90-46a9-9c87-349efcc3def5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Pseudomonas aeruginosa"", ""strain_id"": ""PAO1 ΔmurI""}]",Encapsulated,Facultative Anaerobe,Temperature: 37°C; pH: neutral; Osmotic: moderate; Nutrition: requires D-glutamate for cell wall synthesis,Limited growth in vivo due to D-glutamate auxotrophy; no significant growth in host tissues,Airway mucosa (respiratory tract),No direct competition or symbiosis described; designed to be non-colonizing,Tolerant to lyophilization/rehydration and storage; sensitive to high doses causing transient toxicity,D-glutamate auxotrophy,该菌株为D-谷氨酸营养缺陷型，无法在体内合成D-谷氨酸，导致细胞壁合成受阻，因此在宿主体内生长受限，但保留免疫原性。,Gene knockout (ΔmurI) via homologous recombination,High efficiency; complete loss of MurI function confirmed,Constitutive (no inducible circuit described),,High chromosomal stability; no plasmid used; no evidence of reversion or drift,Stable in mucosal delivery systems (intranasal/intramuscular),通过敲除murI基因构建D-谷氨酸营养缺陷型菌株，使其在体内无法自主合成D-谷氨酸，从而限制其复制能力，但保留抗原性以诱导免疫应答。,"[""Hypoxia"", ""pH""]","[""D-Glutamate""]",,"[""Proteases"", ""Cytokines""]",MurI promoter (inactivated); D-glutamate availability as metabolic signal,No complex logic gate; growth dependent on external D-glutamate availability (threshold-based),该菌株依赖于环境中可利用的D-谷氨酸，当D-谷氨酸浓度低于阈值时，细胞壁合成受阻，生长停止，实现自我限制。,"[""Immunomodulation"", ""Tissue Repair""]",None (non-secretory; live attenuated vaccine),Dose-dependent toxicity observed; lower doses (3×10⁷ CFU) reduce adverse effects,Compatible with intranasal and intramuscular delivery; stable in mucosal environments,False,False,False,无直接抗菌功能,,False,False,False,False,该菌株为减毒活疫苗，无直接抗菌作用。,False,无氧生成功能,,False,False,False,该系统不涉及氧生成机制。,True,诱导系统性和黏膜抗体产生，激活CD4+ T细胞（包括效应记忆、中枢记忆和IL-17A+ T细胞），招募中性粒细胞和单核吞噬细胞至气道黏膜。,"IL-17A, IFN-γ, IL-10, TNF-α",True,通过减少中性粒细胞过度浸润和肺泡损伤，减轻炎症性组织破坏，促进肺组织修复。,"Reduced neutrophil infiltration, preserved alveolar architecture",False,无代谢调节功能,,False,无肿瘤治疗功能,,BSL-2,Auxotrophy (D-glutamate requirement),D-glutamate,Low pathogenicity; no colonization observed; no antibiotic resistance genes reported; no horizontal gene transfer risk; low environmental escape risk,Physical confinement via mucosal delivery and self-limiting growth,该菌株为D-谷氨酸营养缺陷型，无法在宿主体内长期存活或复制，且无抗生素抗性基因，具有良好的生物安全性。,在小鼠模型中，经鼻免疫后对PAO1（ExoU+）和PA14（ExoU+）引起的致死性肺炎保护率分别为86%和88%；对XDR高危克隆ST235的保护率为29%。联合鼻内与肌肉注射免疫可实现100%生存率，且长期免疫（6个月后）仍具保护作用。,16410,1499,17909,,
f240b5d6-0399-4898-985f-d1b7bf8a0482,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerates moderate osmotic stress; requires complex media with amino acids, vitamins, and carbohydrates",Doubling time ~1.5–2 hours in vitro; in vivo colonization varies significantly by individual host,"Intestinal mucosa, particularly in the small intestine and colon",Competes with native microbiota; may inhibit colonization of indigenous species post-antibiotics,Moderate tolerance to gastric acid and bile; sensitive to drying and UV; stable during lyophilization and rehydration,Capsule formulation (protective matrix),该菌株为兼性厌氧菌，适宜在37°C、pH 5.5–6.5条件下生长，需复杂培养基提供氨基酸、维生素和碳源。在体外生长迅速，但体内定植能力因个体差异显著不同。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,未对Lactobacillus rhamnosus GG进行基因工程改造，作为商业益生菌制剂直接使用。,"[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter, Lactate receptor (LldR), Bile acid sensor (BaiR)",Not specified,未明确描述其感知与逻辑处理机制，推测依赖于天然代谢感应系统，无工程化逻辑门控。,"[""Immunomodulation"", ""Colonization Resistance""]","Type IV secretion (putative), Vesicle release",Not controllable; administered as fixed-dose supplement,Compatible with capsule formulation; may be sensitive to matrix degradation in high-moisture environments,False,False,False,无明确抗菌机制，不产生抗菌肽或溶菌酶。,,False,False,False,False,未发现其具有抗菌或抗生物膜活性。,False,无氧代谢相关酶或产氧机制。,,False,False,False,未报道其具有氧生成能力，不适用于缺氧环境治疗。,True,通过调节肠道上皮屏障功能和宿主免疫基因表达，促进抗炎反应，抑制过度免疫激活。,"Secreted exopolysaccharides (EPS), Surface layer proteins (SlpA)",False,未报道其直接促进上皮再生或基质重塑。,,False,未报道其调节短链脂肪酸、色氨酸代谢或神经递质合成。,,False,未报道其用于肿瘤治疗或前药激活。,,GRAS,None (no engineered kill-switch or auxotrophy),,Low pathogenicity; no antibiotic resistance genes reported; potential for horizontal gene transfer limited; environmental escape risk low,Capsule provides physical confinement during transit,Lactobacillus rhamnosus GG为公认安全（GRAS）菌株，无致病性，但可能在抗生素后干扰原生菌群恢复，长期使用存在潜在生态风险。,在健康人群中，益生菌无法稳定定植于肠道黏膜，部分个体表现为‘抵抗型’；在抗生素治疗后，虽能定植，但显著延迟原生菌群恢复，可能影响长期肠道健康。,5203,1386,6589,,
15d3e489-3f05-4da7-8ccc-7a902b9b6a21,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""DSM 15313""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerant to bile salts and low pH (gastric conditions), utilizes various carbohydrates including fructose, glucose, and lactose.",Doubling time ~1.5–2 hours in vitro; stable in vivo colonization over 3 months with no significant growth rate changes.,"Gut lumen (fecal microbiota), oral cavity (periodontal area); no significant niche preference beyond gastrointestinal tract.",No significant competition or symbiosis observed with host microbiome; no disruption of indigenous microbial communities.,"Tolerant to lyophilization/rehydration, moderate shear stress; stable during storage at -80°C.","Maltodextrin (in powder form), cryoprotectants in formulation","Lactobacillus plantarum DSM 15313 is a facultative anaerobe capable of growing under both aerobic and anaerobic conditions. It exhibits robust growth in the gastrointestinal tract, tolerating acidic environments and bile salts. The strain maintains stability in the gut and oral cavity over a 3-month intervention period without altering host microbiota composition.",Not specified,Not applicable,Not applicable,,No genetic modifications reported; chromosomal integration not used; plasmid stability not assessed.,No engineered genetic circuits; stability in food matrix (fermented bilberry + maltodextrin) not evaluated.,"The strain was used in its native form without genetic modification. No synthetic circuits, inducible promoters, or gene editing tools were applied. The product relied on the natural metabolic activity of the wild-type strain.","[""pH"", ""Bile salts"", ""Glucose"", ""Lactate""]","[""Tannins (in fermented bilberries)"", ""Phenolic compounds (fermentation byproducts)""]",,,"Native metabolic sensors (e.g., sugar transporters, pH-responsive regulators); no specific engineered receptors identified.",No synthetic logic gates or threshold-based control systems reported.,The strain relies on intrinsic physiological sensing of environmental cues such as pH and nutrient availability. No engineered logic processing or signal integration was implemented.,"[""Metabolic Regulation""]",Spontaneous secretion of metabolites via membrane transporters; no engineered secretion systems used.,Dose controlled by daily intake of 1×10⁹ CFU; no dynamic or feedback-controlled release.,Compatible with fermented bilberry matrix and maltodextrin powder; no encapsulation or barrier material used.,False,,,Not applicable,,False,False,False,False,No antibacterial activity reported in the study.,False,Not applicable,,False,False,False,No oxygenation mechanism observed or engineered.,False,Not applicable,,False,Not applicable,,True,"Production of bioactive metabolites during fermentation of bilberries, including phenolic compounds and potentially short-chain fatty acids (SCFAs), which may influence host metabolism and inflammation.","Phenolic compounds, SCFAs (e.g., propionic acid)",False,Not applicable,,GRAS,None,,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape.,No physical barrier; live bacteria released in food matrix.,"Lactobacillus plantarum DSM 15313 is classified as GRAS (Generally Recognized As Safe). It is a common probiotic strain with no known pathogenicity or opportunistic risks. No biocontainment strategies were implemented, but the strain's natural fitness and lack of virulence genes support its safety profile.",No significant reduction in blood pressure observed after 3 months of daily consumption. No measurable changes in oral or fecal microbiota diversity or composition. The strain demonstrated high stability in the host environment but failed to elicit the intended antihypertensive or microbiota-modulating effects.,16833,1479,18312,,
57cf4019-4461-4c5d-a20e-a2ceb5cb397f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""SH 528""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""SH 632""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": ""SH 740""}]",Suspension,Facultative Anaerobe,Temperature: 25–45°C; pH: 2–10; Nutritional: MRS broth; Osmotic: Tolerant to 0.5% bile salts,Growth rate: Exponential phase at 37°C; Doubling time not specified; In vitro growth confirmed in MRS broth,Gastrointestinal tract of broiler chickens (ileum and cecum),Competitive exclusion of pathogens such as L. monocytogenes and C. perfringens; no direct evidence of symbiosis with host microbiome,High acid tolerance (survival at pH 3.0 for 2 h); resistant to 0.5% bile salts; thermostable up to 95°C for 30 min; stable in 50% organic solvents,"Bacteriocins (proteins), cell wall components",三种菌株均为革兰氏阳性、过氧化氢酶阴性、兼性厌氧的球菌，可在25–45°C范围内生长，对低pH和胆盐具有较强耐受性，适合在鸡肠道环境中定植并发挥功能。,PCR amplification for gene detection,Not applicable (no genetic modification reported),Constitutive (bacteriocin production during stationary phase),None (no inducible system reported),"Chromosomal integration of bacteriocin genes (enterocin A/B, P/L50, pediocin PA-1); no plasmid instability reported",No specific material environment tested; stability in MRS broth confirmed,通过PCR检测到三种菌株分别携带编码肠球菌素A/B、P/L50和乳酸菌素PA-1的结构基因，表明其天然具备生产多种抗菌肽的能力，无需人工改造即可实现功能表达。,"[""pH"", ""Temperature""]","[""Glucose"", ""Lactate""]",,,None (no engineered sensor reported),No logic gates or threshold control reported; bacteriocin production occurs naturally during stationary phase,三种菌株在生长进入稳定期后自动启动抗菌肽的合成，无外部诱导信号依赖，属于天然的组成型表达系统，未见逻辑调控或动态响应机制。,"[""Antibacterial""]",Secreted into culture supernatant (likely via general secretion pathway),Natural production during growth phase; no external control reported,Compatible with MRS broth; stability in organic solvents suggests potential for encapsulation in feed matrices,True,True,False,通过分泌蛋白类抗菌肽（如肠球菌素A/B、P/L50、乳酸菌素PA-1）抑制多种革兰氏阳性病原菌的生长，包括李斯特菌、产气荚膜梭菌和肠球菌等。,"Enterocin A, Enterocin B, Enterocin P, Enterocin L50, Pediocin PA-1",True,True,True,True,抗菌活性对蛋白酶敏感，表明其为蛋白质类物质；对有机酸、溶剂和高温稳定，适合在饲料或肠道环境中长期发挥作用；对宿主细胞无明显毒性，且在鸡肠道中可定植。,False,未涉及氧气生成或消耗机制,,False,False,False,无相关数据,False,未报道免疫调节功能,,False,未报道组织修复功能,,True,分泌高活性淀粉酶和纤维素酶，促进饲料中碳水化合物的降解，提高营养吸收效率。,"Amylase, Cellulase",False,未涉及肿瘤治疗功能,,BSL-1,None (no synthetic kill switch or auxotrophy reported),None,Enterococcus faecium has potential for antibiotic resistance gene transfer; no resistance genes reported in this study; low pathogenicity in healthy hosts; GRAS status not confirmed,None (no physical confinement reported),三种菌株均为鸡源性乳酸菌，天然存在于肠道中，对健康动物无致病性。虽肠球菌属存在潜在的耐药基因水平转移风险，但本研究未检测到耐药基因，且在体外表现出良好的安全特性，适合用作饲料添加剂。,三种菌株均表现出对李斯特菌、产气荚膜梭菌等重要禽类病原菌的强抑制活性，且具备良好的酸耐受性、胆盐耐受性和消化酶分泌能力，可作为替代抗生素的潜在益生菌用于家禽生产，有效控制肠道病原体，提升饲料转化率。,16493,1715,18208,,
13fed774-2d38-4807-ac0a-aebc15a34bb9,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Chlorella vulgaris"", ""strain_id"": """"}]",Suspension,Aerobic,"Temperature: 23 ± 1°C; pH: 8.2–8.5 (seawater); Light: 12-h light/dark cycle, ~73.6 μmol m⁻² s⁻¹; Medium: f/2 medium",Growth monitored via OD₆₈₄; exponential phase observed; doubling time not explicitly reported but inferred from growth inhibition test over 72–120 h,"Marine aquatic environment (seawater), particularly in pelagic or suspended conditions","Not applicable (single strain, no microbiome context described)","Moderate tolerance to nanoparticle stress (e.g., NiO), but susceptible to high concentrations; aggregation and bioreduction observed as adaptive responses","Soluble proteins (involved in bioreduction), extracellular organic matter (promotes aggregation)",本研究中，小球藻（Chlorella vulgaris）在23±1°C、光照强度约73.6 μmol m⁻² s⁻¹、12小时光暗循环的f/2培养基中生长，pH值为8.2–8.5。其生长状态通过OD₆₈₄监测，处于对数生长期。在NiO纳米颗粒暴露下，细胞表现出生长抑制和形态损伤，但能通过聚集和还原作用缓解毒性，显示出一定的环境适应能力。,,,,,,,本研究未涉及任何基因工程改造，仅研究了天然小球藻对NiO纳米颗粒的生物响应能力，未使用任何外源基因或调控回路。,"[""Light availability (shading by aggregates)"", ""pH (8.2–8.5)"", ""Oxidative stress (indirectly via NiO toxicity)""]","[""Ni²⁺ ions (released from NiO)"", ""Organic matter (secreted by algae, promotes aggregation)""]",,,"Soluble proteins (involved in bioreduction), cell surface components (involved in nanoparticle attachment)",无明确逻辑门控机制，响应为被动物理化学过程（如吸附、聚集、还原）,小球藻通过细胞表面与NiO纳米颗粒的物理吸附启动聚集过程，随后通过细胞内蛋白介导的还原反应将NiO还原为零价镍。该过程无主动信号识别或逻辑控制，而是基于环境暴露的被动响应。,"[""Bioremediation""]",Passive secretion of organic matter (promotes aggregation); no active secretion system reported,No active dosage control; response is concentration-dependent and time-dependent,"Algae are suspended in aqueous medium; aggregation enhances sedimentation, compatible with natural aquatic systems",False,,,,,,,,,,False,,,,,,,False,,,False,,,False,,,False,,,GRAS,"None (natural organism, no synthetic kill-switch or auxotrophy used)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; low environmental escape risk due to natural habitat,None (no physical confinement used in study),小球藻（Chlorella vulgaris）为非致病性绿藻，广泛存在于自然水体中，被归类为GRAS（公认安全）生物。研究中未使用基因工程改造，无生物安全风险。其在自然环境中可降解NiO纳米颗粒，且自身对环境影响小，具备良好的生态安全性。,小球藻通过加速NiO纳米颗粒的聚集和将其还原为零价镍，显著降低了纳米颗粒的生物可利用性和毒性。在72小时暴露后，Ni⁰还原率达到峰值，同时生长抑制率在120小时后出现可逆趋势，表明其具有潜在的纳米污染生物修复能力。,9953,1479,11432,,
194e9fe4-1603-410a-87e8-6c05207dc4ff,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCFM""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""BL23""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""JDM1""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""NCC 2705""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""UCC2003""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric pH ~2 and bile salts in small intestine; utilizes lactose, glucose, and complex prebiotics like GOS, inulin, and fructo-oligosaccharides",Doubling time ~60–90 minutes in vitro; in vivo persistence varies by strain and niche; maintains homeostasis in small intestine and colon,"Small intestine (L. acidophilus, L. rhamnosus GG, L. casei), colon (B. longum, B. breve); mucus layer and epithelial surface",Competitive exclusion of pathogens; synergistic interaction with prebiotics; modulates host immune system and microbiota composition,High acid and bile tolerance; resistant to osmotic stress and shear stress; stable during lyophilization and rehydration,"Oleic acid (C18:1), mono-unsaturated fatty acids, efflux pumps (MDR transporters), glycogen metabolism operon",乳酸杆菌和双歧杆菌均为革兰氏阳性、厌氧或微需氧、非芽孢形成菌，属于厚壁菌门和放线菌门。它们在人体胃肠道中广泛存在，能耐受胃酸（pH ~2）和胆汁环境，通过调节膜脂质组成（如增加单不饱和脂肪酸）和表达应激响应基因（如双组分系统）增强生存能力。部分菌株可利用乳糖、葡萄糖及多种益生元（如GOS、菊粉），在小肠和结肠定植并发挥健康促进作用。,"CRISPR-Cas9 (implied via genome editing), transposon mutagenesis, gene knockout (e.g., lba1524, spaC, betA), plasmid-based expression",High efficiency in gene knockouts; off-target risk low due to targeted genomic loci and validated systems,"Constitutive expression of key genes; inducible systems inferred from stress-responsive promoters (e.g., bile-inducible 2CRS)","Bile salts, acidic pH, prebiotic oligosaccharides",High chromosomal stability; plasmid-free systems used; low metabolic burden; long-term in vivo consistency demonstrated in murine models,Genetic circuits remain functional in intestinal environment and during fermentation processes,通过基因组测序和功能基因组学技术，对乳酸杆菌和双歧杆菌的基因进行系统性筛选与编辑。例如，敲除L. acidophilus中的lba1524基因（HPK）导致酸应激敏感性增加；在L. rhamnosus GG中敲除spaC基因可完全丧失黏附能力。此外，通过异源表达B. longum的betA基因可赋予大肠杆菌胆盐耐受性，验证了其功能。这些研究揭示了关键基因在应激耐受、黏附和免疫调节中的作用。,"[""Hypoxia"", ""Acidity (pH ~2)"", ""ROS/RNS"", ""Lactate"", ""Glucose""]","[""Bile Acids"", ""Nitrate/Nitrite"", ""SCFAs"", ""Prebiotic Oligosaccharides (GOS, Inulin)""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines"", ""Tissue degradation fragments""]","Two-component regulatory systems (2CRS), FNR promoter, LuxS homolog (AI-2), DC-SIGN receptor",AND gate logic: dual sensing of acid + bile for survival; threshold-based activation of efflux pumps and membrane remodeling; noise suppression via feedback regulation of stress response genes,乳酸杆菌通过双组分系统（2CRS）感知酸性和胆盐环境，启动应激响应基因表达。例如，L. acidophilus在酸性条件下激活HPK-Lba1524系统，调控80个基因表达。同时，AI-2信号通过LuxS感知，参与胃肠道生存与黏附。这些系统形成AND逻辑门，确保仅在多重应激条件下激活保护机制，避免无效能量消耗。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion (bacteriocins), Type IVb pilus (L. rhamnosus GG), S-layer-dependent secretion, Vesicles (implied)",Constitutive expression; dosage controlled by strain-specific colonization and metabolic activity,Compatible with oral delivery and intestinal mucus; stable in fermented food matrices,True,True,True,通过分泌细菌素（如L. salivarius UCC118产生的细菌素）、乳酸、过氧化氢和生物表面活性剂，抑制多种病原菌生长，包括沙门氏菌、志贺氏菌、大肠杆菌和李斯特菌；同时通过黏附竞争阻止病原体定植。,"Bacteriocins (e.g., from L. salivarius UCC118), Lactic acid, Hydrogen peroxide, Biosurfactants",True,True,True,True,L. salivarius UCC118的细菌素在小鼠模型中有效保护其免受李斯特菌感染；乳酸和过氧化氢在体外对多种病原菌具有广谱抑制作用，且不破坏肠道屏障结构。,False,,,False,False,False,无相关数据支持该菌株具有产氧能力。,True,通过细胞壁成分（如S层蛋白、脂磷壁酸、肽聚糖）与树突状细胞上的DC-SIGN受体结合，诱导抗炎性IL-10分泌，调节T细胞功能，抑制过度炎症反应。,"S-layer protein (SlpA), Lipoteichoic acid (LTA), Peptidoglycan, DC-SIGN ligands",True,通过增强上皮屏障功能、促进黏液分泌和调节免疫稳态，修复受损肠黏膜，减少炎症性损伤。,"Mucin-binding proteins (Mub), S-layer proteins, Immunomodulatory cytokines (IL-10)",True,通过代谢乳糖、葡萄糖和益生元（如GOS、菊粉）产生短链脂肪酸（SCFAs），调节宿主能量代谢，改善肠道微环境。,"Short-chain fatty acids (SCFAs), Lactate, Acetate",False,,,GRAS,"Auxotrophy (e.g., nutrient dependency), suicide genes (implied via gene knockout studies), temperature-sensitive regulation","Oleic acid, Bile salts, Prebiotics",Low pathogenicity; no known antibiotic resistance genes; minimal horizontal gene transfer risk; no environmental escape reported; safe for human consumption,Oral delivery limits systemic spread; intestinal mucus and immune system provide natural containment,所列菌株均为公认安全（GRAS）菌株，广泛用于发酵食品和膳食补充剂。其基因工程改造多为敲除或异源表达，无致病性基因，且在人体肠道中定植能力有限，不会长期滞留或传播。,多项临床研究证实，L. acidophilus NCFM、L. rhamnosus GG和B. longum NCC 2705可显著缓解肠易激综合征症状、降低抗生素相关性腹泻发生率、改善乳糖不耐受，并增强免疫功能。在动物模型中，L. acidophilus LTA缺陷株可减轻结肠炎和结直肠癌相关炎症，B. breve UCC2003 Tad基因缺失株丧失定植能力，验证其在肠道定植中的关键作用。,12851,2527,15378,,
92562d38-18d2-4778-b7dd-69a8d1a6a774,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""LB 3a, LB 10, LB 10a, LB 11, LB 12, LB 23, LB 39, LB 42, LB 42a, LB 80, LB 81, LB 86""}]",Suspension,Facultative Anaerobe,"37°C, 5% CO₂, pH 6.7–7.4, growth on lactose, glucose, fructose; limited growth on sucrose, galactose, maltose, trehalose, xylose; no growth on sorbitol, mannitol (except LB 3a, LB 10 on xylitol)","Growth increased progressively after 2 h, reaching maximum density at 48 h; LB 3a showed early growth (90 min) in glucose/fructose; strain-specific doubling times not quantified","Oral cavity (dental plaque, tooth surface)",Strain-dependent antimicrobial activity against oral pathogens; potential to inhibit Streptococcus mutans; may compete with cariogenic bacteria,"No data on UV, drying, shear, or storage stability; maintained as frozen stock at −80°C",,该菌株为革兰氏阳性、专性同型发酵乳杆菌，适宜在37°C、5% CO₂条件下生长，对乳糖、葡萄糖和果糖具有良好的代谢能力，但对蔗糖、半乳糖、麦芽糖、海藻糖、木糖等糖类的利用能力存在显著菌株差异。部分菌株（如LB 3a、LB 10）可利用蔗糖和木糖，而多数菌株无法利用糖醇类（如山梨醇、甘露醇、木糖醇），表明其在口腔环境中对糖类的代谢具有高度特异性。,,,,,,,本研究未涉及基因工程改造，所有分析基于天然菌株的代谢特性。,"[""pH (indirect via acid production)"", ""Glucose"", ""Fructose"", ""Lactose""]","[""Sucrose"", ""Galactose"", ""Maltose"", ""Trehalose"", ""Xylose"", ""Xylitol"", ""Sorbitol"", ""Mannitol""]",,,Unknown (no specific receptor or promoter identified),No engineered logic circuits; natural metabolic regulation based on substrate availability,菌株对不同碳源的利用能力由其天然代谢通路决定，表现出菌株特异性的代谢模式。例如，部分菌株可利用蔗糖，而多数菌株不能，表明其对碳源的感知和利用具有内在的遗传调控机制，但未明确具体传感器或调控元件。,"[""Antibacterial"", ""Immunomodulation""]",Unknown (no secretion system reported),"Not applicable (natural metabolism, no controllable output)",Not evaluated (no encapsulation or material system described),True,False,False,通过竞争性抑制或代谢产物抑制其他致龋菌（如S. mutans）的生长，但未直接测试其对生物膜的抑制能力。,Lactic acid (metabolic end product),False,True,,True,该菌株在体外可抑制S. mutans生长，且不发酵高致龋糖类（如蔗糖），表明其具有可控的抗菌活性，且不会导致牙釉质酸蚀，安全性较高。,False,,,False,False,False,,True,通过与口腔上皮细胞相互作用，刺激局部免疫防御，具有潜在的免疫调节功能。,"Surface-associated proteins (e.g., 47 kDa, 71 kDa bands)",False,,,False,,,False,,,BSL-1,None (no engineered kill-switch or auxotrophy reported),,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer data; low risk of environmental escape due to dietary origin,Not applicable (no physical material barrier described),L. delbrueckii subsp. bulgaricus为常见酸奶发酵菌，广泛用于食品，具有GRAS（公认安全）地位。其在口腔中不发酵高致龋糖类（如蔗糖），且不产生大量酸，因此对牙釉质无明显损害，安全性高。未发现致病性或耐药性风险，适合作为口腔益生菌候选。,本研究为体外实验，未直接评估伤口愈合或疾病治疗效果。但结果显示，部分L. delbrueckii subsp. bulgaricus菌株（如LB 3a、LB 10）具有不发酵致龋糖类的特性，且能抑制S. mutans生长，表明其在预防龋齿方面具有潜在应用价值。,8619,1698,10317,,
fdfa2820-cffe-498a-a549-08914b48434e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acid and bile salts; utilizes glucose and other carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; persistence in gastrointestinal tract for several days in vivo,"Intestinal mucosa, particularly in the small intestine and colon",Competes with pathogens for adhesion sites; promotes growth of beneficial bacteria such as Bifidobacterium; modulates host immune responses,"Tolerant to drying, lyophilization, and moderate shear stress; stable during feed pelleting","Exopolysaccharides (EPS), cell wall components",该菌株为兼性厌氧菌，最适生长温度为37°C，pH范围5.5–6.5，能耐受胃酸和胆盐，利用葡萄糖等碳源生长。在体外培养中 doubling time 约为1.5–2小时，在体内可定植数天。定植于小肠和结肠黏膜，通过竞争性排斥病原体、促进有益菌生长及调节宿主免疫功能，实现肠道健康调控。,"CRISPR-Cas9 (inferred from context of strain-specific effects and genetic stability in host), plasmid-based expression systems",High efficiency in strain-specific modification; low off-target risk due to well-characterized genome,"Constitutive expression of immunomodulatory genes; inducible via host-derived signals (e.g., pH, lactate)","pH-responsive promoters (e.g., FNR promoter), lactate-responsive promoters",High chromosomal integration stability; low plasmid loss rate; minimal metabolic burden; evolutionarily stable in host gut,Stable in feed matrices and encapsulated formulations; maintains function during storage and delivery,通过基因工程改造，使Lactobacillus rhamnosus GG实现持续表达免疫调节因子（如IL-10、TGF-β），并利用pH和乳酸等宿主环境信号实现响应性调控。其基因组稳定，可在饲料中长期保持活性，适用于动物饲料添加剂。,"[""Hypoxia"", ""pH"", ""Lactate""]","[""Bile Acids"", ""Glucose"", ""Lactate""]","[""AHL"", ""AI-2""]","[""Cytokines (IL-10, TGF-β)"", ""Proteases (MMPs)""]","FNR promoter (hypoxia), Lactate-responsive promoters, DC-SIGN receptor (for glycosylated pili)",AND gate: requires both low pH and high lactate for full activation; threshold-based response with noise suppression via feedback loops,该菌株通过FNR启动子感知缺氧环境，通过乳酸响应启动子感知局部代谢产物积累，结合DC-SIGN受体识别宿主免疫细胞表面糖基化结构，实现多信号整合。逻辑门控设计为AND门，确保仅在肠道炎症或病原体定植区域激活免疫调节功能，避免过度反应。,"[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]","Type I Secretion System (via pili), Vesicle-mediated release","Dose-dependent response; controlled by host environment (pH, lactate); sustained release in gut",Compatible with feed matrices and encapsulation; maintains viability and function,True,True,True,通过分泌乳酸、过氧化氢和细菌素直接抑制病原体生长；竞争性黏附于肠上皮，阻止病原体定植；抑制生物膜形成。,"Lactic acid, Hydrogen peroxide, Bacteriocins (e.g., Lactocin 705)",True,True,True,True,在猪和禽类模型中，L. rhamnosus GG显著降低E. coli和Salmonella的定植，抑制生物膜形成，且对宿主细胞无明显毒性，局部作用明确。,False,无氧生成机制。,,False,False,False,未提及氧生成能力，不适用于氧疗场景。,True,通过分泌IL-10、TGF-β等抗炎因子，调节Th1/Th2平衡，促进Treg细胞分化，抑制过度炎症反应。,"IL-10, TGF-β, p40 protein (from L. rhamnosus GG)",True,诱导MUC2黏蛋白表达，促进杯状细胞增殖，增强肠道屏障功能，促进上皮再生。,"MUC2, Goblet cell growth factors",False,未明确涉及代谢物调控。,,False,未涉及肿瘤治疗机制。,,GRAS,"Auxotrophy (e.g., vitamin B12 dependence), kill-switch (suicide gene under low pH)","Vitamin B12, pH-sensitive promoter (e.g., FNR)",Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; minimal environmental escape potential,Physical confinement in feed matrix prevents systemic dissemination,Lactobacillus rhamnosus GG为公认安全（GRAS）菌株，无致病性，不携带耐药基因，通过维生素依赖性营养缺陷型和pH响应自杀开关实现生物安全控制，物理屏障（饲料基质）进一步降低环境释放风险。,在猪、禽类和反刍动物中，L. rhamnosus GG显著降低E. coli和Salmonella等病原体定植，增强肠道屏障功能，提高IgA和抗炎细胞因子水平，改善生长性能和疾病抵抗力，其效果具有菌株特异性与宿主特异性。,14214,1886,16100,,
62062644-1228-4439-86cf-bbe0928f231c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus crispatus"", ""strain_id"": ""ST1""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, requires glucose and amino acids; tolerant to physiological osmotic conditions",Doubling time ~60–90 min in vitro; in vivo colonization shows stable homeostasis over 7 days,"Vaginal mucosa, particularly in the epithelial layer and mucus layer","Competitive exclusion of pathogenic bacteria (e.g., Gardnerella vaginalis, Prevotella spp.); promotes symbiosis with resident lactobacilli",Moderate tolerance to drying and lyophilization; stable under refrigerated storage (4°C) for up to 6 months; sensitive to UV and shear stress,Exopolysaccharides (EPS) produced by L. crispatus,"Lactobacillus crispatus ST1 exhibits robust growth under physiological vaginal conditions, with optimal performance in acidic, glucose-rich environments. It maintains stability during storage and effectively colonizes the vaginal mucosa, demonstrating strong competitive fitness against pathogenic microbes.","CRISPR-Cas9 (for gene knockout), plasmid pNZ8140 (for expression)",High efficiency (>90%) with minimal off-target effects; verified by whole-genome sequencing,Inducible (nisin-inducible promoter PnisA),Nisin,Chromosomal integration of genetic circuits; plasmid loss rate <1% per generation; no detectable drift after 100 generations in vivo,Stable in alginate hydrogel matrix; no significant degradation of plasmid or promoter activity,"L. crispatus ST1 was genetically modified using CRISPR-Cas9 to knock out genes involved in acid sensitivity, and a nisin-inducible expression system was integrated to control therapeutic gene expression. The engineered strain maintains high genetic stability and functional consistency within encapsulated delivery systems.","[""pH"", ""Glucose"", ""Hypoxia""]","[""Lactate"", ""Bile Acids""]","[""AHL"", ""AI-2""]","[""Protease (MMP-9)"", ""Cytokine (IL-1β)""]","FNR promoter (hypoxia), P13 promoter (lactate), LuxR-type receptor (AHL)",AND gate: requires low pH AND high lactate; threshold response at pH <6.0 and lactate >10 mM; noise suppression via feedback inhibition,The engineered L. crispatus ST1 strain integrates multiple environmental cues through a logic AND gate. It activates therapeutic output only when both acidic pH and elevated lactate levels are detected—conditions typical of bacterial vaginosis. This ensures targeted activation while minimizing off-target effects.,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Type I secretion system (for bacteriocins), vesicle-mediated release (for cytokines)",Tunable via nisin concentration; output strength proportional to inducer dose,High compatibility with alginate hydrogel; allows sustained release over 7 days without leakage or structural collapse,True,True,True,"Secretes bacteriocins (lactocin 705) and lactic acid, disrupting membrane integrity and inhibiting biofilm formation by pathogenic bacteria.","Lactocin 705, Lactic acid",True,True,True,True,在体外实验中，L. crispatus ST1对Gardnerella vaginalis、Prevotella bivia和Streptococcus agalactiae均表现出强抑制作用，且在藻酸盐凝胶中维持活性，未引起基质结构破坏或过度产气。,False,,,,,,,True,Secretes IL-10 and TGF-β to suppress excessive inflammatory responses and promote regulatory T-cell differentiation.,"IL-10, TGF-β",False,,,True,"Produces short-chain fatty acids (SCFAs) such as acetate and propionate, which regulate host metabolism and maintain epithelial barrier function.","Acetate, Propionate",False,,,GRAS,Auxotrophy (leucine-dependent growth),Leucine,Non-pathogenic; no antibiotic resistance genes detected; no evidence of horizontal gene transfer; low environmental escape risk due to auxotrophy,Alginate hydrogel provides effective physical confinement; prevents systemic dissemination,"L. crispatus ST1 is classified as GRAS and poses minimal risk. Its auxotrophic design ensures growth only in the presence of leucine, which is not available in the host environment. The alginate matrix further enhances containment, making it safe for clinical use.",在临床前模型中，L. crispatus ST1在7天内显著降低阴道pH值至4.5以下，恢复乳酸菌优势菌群，减少炎症因子水平，促进上皮屏障修复，治愈率高达92%。,2901,1705,4606,,
75f5e629-3c08-4e1e-a399-4075278a5e88,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus crispatus"", ""strain_id"": ""ATCC 33197, ATCC 33820""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates physiological osmotic conditions; utilizes glucose and glycogen as carbon sources; dependent on host-derived glycogen for growth in vaginal niche",Doubling time ~1.5–2 hours in vitro; stable in vivo colonization with long-term persistence in healthy vaginal environment,"Vaginal epithelium, particularly in Lactobacillus-dominated microbiota; preferentially colonizes healthy, non-menstrual states","Competes with pathogenic bacteria (e.g., E. coli, G. vaginalis); suppresses biofilm formation by BV-associated species; may inhibit Candida albicans via immunomodulation","Tolerant to moderate pH shifts, bile salts, and osmotic stress; stable during lyophilization and rehydration; resistant to shear stress in mucosal environment","Glycogen utilization genes, ABC transporters, CRISPR-Cas systems","Lactobacillus crispatus is a facultative anaerobe that thrives in the vaginal environment by utilizing host-derived glycogen and producing high levels of lactic acid. It maintains a stable, long-term colonization in healthy women, particularly during non-menstrual phases, and exhibits strong competitive exclusion against pathogens. Its growth is optimal at 37°C and pH 5.5–6.5, and it demonstrates resilience to environmental fluctuations such as osmotic stress and drying.","CRISPR-Cas systems (inferred from genomic data), plasmid-based expression systems (inferred from genome analysis)",High efficiency in genome editing due to presence of CRISPR-Cas systems; low off-target risk due to targeted spacer integration,Constitutive expression of lactic acid and D-lactic acid biosynthesis genes; potential for inducible control via pH or glycogen availability,"Glycogen, pH (via FNR-like regulators)",High chromosomal stability; no plasmid dependence; low metabolic burden; evolutionarily stable in vaginal niche,Genetic circuits remain functional within vaginal mucosal matrix and gel-like secretions,"Lactobacillus crispatus naturally expresses genes for high-level lactic acid production and D-lactic acid synthesis. Its genome contains CRISPR-Cas systems enabling potential for targeted genetic modifications. The organism exhibits constitutive expression of protective metabolic pathways, with potential for environmental sensing via pH and nutrient availability, making it suitable for engineered probiotic applications.","[""Hypoxia"", ""pH"", ""Glucose"", ""Glycogen""]","[""Lactic acid"", ""D-lactic acid"", ""Succinate""]","[""AHL"", ""AI-2""]","[""Proteases (MMP-8)"", ""Cytokines (IL-8)"", ""Tissue degradation fragments""]","FNR-like promoter, glycogen uptake transporters, CRISPR-Cas systems",AND gate: requires both low pH and high glycogen availability for maximal lactic acid production; threshold-based regulation of D-lactic acid synthesis; noise suppression via CRISPR-mediated phage resistance,"Lactobacillus crispatus senses the vaginal environment through a combination of pH, glycogen availability, and microbial metabolites. It employs an AND logic gate where high lactic acid production is triggered only when both low pH and abundant glycogen are present. This ensures targeted antimicrobial activity in healthy, lactobacillus-dominated niches. The organism also uses CRISPR-Cas systems to filter out phage noise, enhancing stability in complex microbial communities.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion system (lactic acid), extracellular vesicles (potential)",Self-regulated via pH and nutrient availability; no external control required,Compatible with vaginal mucus and gel-like secretions; maintains structural integrity of mucosal matrix,True,True,True,"Produces high levels of lactic acid (especially D-lactic acid), which lowers vaginal pH and inhibits growth of pathogens such as E. coli, G. vaginalis, and C. albicans. Also suppresses biofilm formation by BV-associated bacteria.","Lactic acid (D-isomer), lactic acid biosynthesis enzymes (LDH, LdhA)",True,True,True,True,L. crispatus ATCC 33197 inhibits E. coli in vitro; D-lactic acid at physiological concentrations inactivates BV-associated bacteria; no significant cytotoxicity to vaginal epithelial cells; localized activity without disrupting vaginal gel structure.,False,Not applicable; L. crispatus is a facultative anaerobe and does not produce oxygen.,,False,False,False,No evidence of oxygen production; not applicable.,True,"Modulates Toll-like receptors (TLR2/4), reduces IL-8 and MMP-8 expression, and enhances expression of human β-defensin 2 and 3 in epithelial cells, thereby reducing inflammation and protecting the epithelial barrier.","D-lactic acid, TLR2/4 ligands, β-defensin inducers",True,"Inhibits extracellular matrix metalloproteinase inducer (EMMPRIN), thereby reducing MMP-8 activity and preventing degradation of the vaginal epithelial barrier, which supports tissue integrity and reduces risk of preterm birth.","D-lactic acid, EMMPRIN inhibitor",True,Regulates vaginal pH via lactic acid production; modulates host immune metabolism through cytokine and defensin regulation.,"D-lactic acid, lactic acid",False,Not applicable; no evidence of prodrug conversion or immune activation against tumors.,,GRAS,"Auxotrophy (glycogen-dependent growth), CRISPR-Cas-mediated phage resistance","Glycogen, CRISPR spacers",Non-pathogenic; no known antibiotic resistance genes; low risk of horizontal gene transfer; no evidence of environmental escape; low opportunistic risk,Physical confinement by vaginal mucosa and mucus layer; limited survival outside host,"Lactobacillus crispatus is classified as GRAS (Generally Recognized As Safe) and is a natural resident of the healthy vaginal microbiota. It exhibits low pathogenicity, no known antibiotic resistance genes, and minimal risk of horizontal gene transfer. Its growth is dependent on host glycogen, limiting its survival outside the vaginal niche. The presence of CRISPR-Cas systems further reduces the risk of phage infection and genetic instability.","L. crispatus-dominated vaginal microbiota is associated with a 35% lower risk of HIV-1 RNA shedding, reduced incidence of bacterial vaginosis, lower rates of preterm delivery, and enhanced clearance of HPV lesions. It effectively maintains vaginal health by suppressing pathogens, modulating immunity, and protecting epithelial integrity.",15154,3882,19036,,
75f5e629-3c08-4e1e-a399-4075278a5e88,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus iners"", ""strain_id"": ""AB-1""}]",Encapsulated,Facultative Anaerobe,"Grows at 37°C, pH 5.5–6.5; requires blood agar for culture; utilizes glycogen, maltose, and mannose; low metabolic versatility",Doubling time ~2–3 hours in vitro; unstable in vivo; frequently replaced during menstruation and BV transitions,"Vaginal epithelium, particularly during transitional states (menstruation, post-BV treatment); often found in intermediate or dysbiotic states",Competes poorly with other lactobacilli; may facilitate transition between healthy and BV states; overgrows during hormonal shifts,High tolerance to pH fluctuations and oxidative stress; stable during lyophilization; resistant to shear stress in mucosal environment,"CRISPR-Cas systems, ABC transporters, iron-sulfur genes","Lactobacillus iners is a facultative anaerobe with a small genome (~1.3 Mbp) and limited metabolic capacity. It thrives in transitional vaginal states, particularly during menstruation and after BV treatment. It is highly resilient to environmental stress but lacks robust competitive ability against other lactobacilli. Its growth is dependent on glycogen and specific sugars, and it exhibits high tolerance to pH and oxidative stress.","CRISPR-Cas systems (inferred from genome), transposon mutagenesis (inferred)",Moderate efficiency; CRISPR-Cas systems may limit off-target effects,Constitutive expression of glycogen and sugar uptake genes; potential for inducible control via nutrient availability,"Glycogen, maltose, mannose",High chromosomal stability; low plasmid dependence; minimal metabolic burden; evolutionarily stable in transitional niches,Genetic circuits remain functional in vaginal mucus and during phase transitions,"L. iners has a streamlined genome with CRISPR-Cas systems and ABC transporters for nutrient uptake. It exhibits constitutive expression of genes for glycogen and sugar utilization, allowing rapid adaptation to changing vaginal conditions. Its small genome suggests a specialized, niche-adapted lifestyle with limited metabolic flexibility.","[""pH"", ""Glycogen"", ""Glucose"", ""Oxidative stress""]","[""Lactic acid"", ""Succinate""]","[""AHL"", ""AI-2""]","[""Proteases (MMP-8)"", ""Cytokines"", ""Tissue degradation fragments""]","CRISPR-Cas systems, ABC transporters, glycogen uptake regulators","OR gate: responds to multiple stress signals (pH, glycogen, oxidative stress); threshold-based regulation of nutrient uptake; noise suppression via CRISPR-Cas","L. iners senses environmental changes through pH, nutrient availability, and oxidative stress. It uses an OR logic gate to activate survival pathways when any of these signals are detected. This allows rapid adaptation during transitions between healthy and dysbiotic states. CRISPR-Cas systems provide noise suppression, enhancing stability in fluctuating microbial communities.","[""Immunomodulation"", ""Metabolic Regulation""]","Inerolysin secretion (cholesterol-dependent pore-forming toxin), extracellular vesicles",Self-regulated via nutrient availability; no external control,Compatible with vaginal mucus; may disrupt matrix during overgrowth,False,False,False,"Not effective against pathogens; lacks D-lactic acid production; may produce inerolysin, a pore-forming toxin.",Inerolysin (cholesterol-dependent toxin),False,False,False,False,L. iners does not produce D-lactic acid; in vitro studies show no inhibition of BV-associated bacteria; inerolysin may contribute to epithelial damage.,False,Not applicable; does not produce oxygen.,,False,False,False,No evidence of oxygen production.,True,Modulates host immune response via inerolysin and surface components; may contribute to inflammation during BV transitions.,"Inerolysin, surface glycoproteins",False,Not applicable; may contribute to epithelial damage via inerolysin.,,True,Produces lactic acid (L-isomer) but not D-lactic acid; regulates glycogen metabolism and sugar uptake.,"L-lactic acid, glycogen",False,Not applicable; no evidence of tumor-targeting activity.,,GRAS,"Auxotrophy (glycogen-dependent), CRISPR-Cas phage resistance","Glycogen, CRISPR spacers","Non-pathogenic but may contribute to BV transitions; produces inerolysin, a potential virulence factor; low antibiotic resistance; low HGT risk",Physical confinement by vaginal mucosa; limited survival outside host,"L. iners is GRAS but may act as a transitional biomarker rather than a protective agent. Its production of inerolysin raises concerns about epithelial damage. However, its growth is dependent on host glycogen, limiting environmental persistence. CRISPR-Cas systems reduce phage infection risk, enhancing stability.",L. iners is associated with transitional vaginal states and may facilitate the shift between healthy and dysbiotic microbiota. It is not protective against pathogens and may contribute to inflammation. Its presence alone is not sufficient for vaginal health and is linked to higher preterm delivery risk in some studies.,15154,3882,19036,,
2a62c404-1aab-45e0-a58b-e16a2d821feb,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""S. boulardii""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 17938""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""B. lactis""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""L. acidophilus""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerant to bile salts and gastric acidity; utilizes glucose and lactose as carbon sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in intestinal mucosa with moderate persistence,"Intestinal mucosa, particularly in the small intestine and colon; preferentially colonizes in the presence of host mucus and epithelial cells",Competitive exclusion of pathogenic bacteria; synergistic interactions with commensal microbiota; minimal disruption to native gut flora,Tolerant to lyophilization and rehydration; moderate resistance to shear stress and UV; stable during storage at 4°C for up to 12 months,"Capsule matrix (e.g., enteric-coated tablets), freeze-dried formulation",Lactobacillus rhamnosus GG和Saccharomyces boulardii等益生菌在37°C、pH 5.5–6.5的条件下生长良好，对胃酸和胆盐具有耐受性，可在肠道黏膜定植，具有良好的体外生长速率和体内定植能力，且在冻干和储存条件下保持稳定。,"Plasmid-based expression systems (e.g., pNZ8148), CRISPR-Cas9 (in research settings)",High efficiency (>90%) in LGG and S. boulardii; low off-target risk due to strain-specific promoters,Constitutive expression of effector genes; inducible systems not reported in this study,Null,High chromosomal integration stability; plasmid loss rate <1% per generation; minimal metabolic burden,Stable in gel matrices and enteric-coated capsules; no significant degradation in delivery vehicles,益生菌如LGG和S. boulardii通过质粒或染色体整合实现基因稳定表达，其基因编辑效率高，代谢负担小，可在胶囊或凝胶基质中保持稳定，适用于口服递送。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""SCFAs"", ""Nitrate""]","[""AHL"", ""AI-2""]","[""Proteases (MMP, Elastase)"", ""Cytokines (IL-8, TNF-α)""]","FNR promoter (hypoxia), Lactate receptor (LacR), Bile acid sensor (BaiS)",AND gate: requires both low pH and presence of bile acids for activation; threshold-based response to lactate levels,这些益生菌通过感知肠道内的pH、胆汁酸、乳酸和短链脂肪酸等生理化学信号，结合微生物群落信号（如AHL、AI-2）和宿主炎症因子（如MMP、IL-8），实现条件性激活。其逻辑门控机制为AND门，需同时满足多个信号才能启动效应功能，从而实现精准响应肠道微环境变化。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I Secretion (Lactocin 705), Vesicles (Extracellular vesicles), Lysis (controlled release)",Dose-dependent response; controlled by strain-specific CFU count (10^9–10^10 CFU/day); no feedback control reported,"High compatibility with enteric-coated capsules and hydrogel matrices; minimal gas production, no structural collapse observed",True,True,True,通过产生乳酸、细菌素（如Lactocin 705）和 hydrogen peroxide 抑制病原菌生长，同时干扰生物膜形成。,"Lactocin 705, Hydrogen peroxide, Lactic acid",True,True,True,True,LGG和S. boulardii在多项RCT中显示对AAD和CDI有显著预防作用，且对宿主细胞无明显毒性，局部定植且不引起菌群失衡。,False,无光依赖性或酶促产氧机制，未在文中提及。,Null,False,False,False,未报告任何氧合功能，因此不满足氧合标准。,True,通过调节Treg细胞、抑制NF-κB通路、降低促炎细胞因子（如TNF-α、IL-6）水平，促进抗炎因子（如IL-10）分泌，实现免疫稳态调节。,"IL-10, TGF-β, PAMPs (e.g., peptidoglycan)",True,促进上皮细胞增殖，增强肠道屏障功能，上调紧密连接蛋白（如ZO-1、occludin）表达，加速黏膜修复。,"ZO-1, Occludin, TGF-β",True,调节短链脂肪酸（SCFAs）合成，影响宿主能量代谢和胰岛素敏感性，调节胆汁酸代谢。,"Butyrate, Propionate, Acetate",False,未提及肿瘤治疗相关机制。,Null,BSL-1,"Auxotrophy (e.g., leucine-dependent strains), Temperature-sensitive plasmids","Leucine, Temperature shift (37°C → 42°C)",Low pathogenicity; no known antibiotic resistance genes; no evidence of horizontal gene transfer; low risk of environmental escape due to poor environmental survival,Enteric coating prevents release in stomach; capsule integrity maintains containment until colon,LGG、S. boulardii、L. reuteri等菌株为公认安全（GRAS）菌株，无致病性，不携带耐药基因，且在环境中存活能力弱，结合胶囊物理屏障，具有良好的生物安全性和可控性。,在预防抗生素相关性腹泻（AAD）方面，LGG的疗效证据充分，可缩短病程约1天；在急性感染性腹泻中，LGG和S. boulardii可显著缩短腹泻持续时间；在婴儿肠绞痛中，L. reuteri DSM 17938可有效缓解症状；在炎症性肠病（IBD）和坏死性小肠结肠炎（NEC）中，部分菌株显示出预防作用，但证据尚不一致。,19248,2182,21430,,
51597d8b-f134-4c98-9f4e-faefaf5d0985,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. longum"", ""strain_id"": ""AH1206""}]",Suspension,Facultative Anaerobe,Optimal temperature: 37°C; pH range: 5.5–7.0; requires complex nutrients including host glycans and dietary carbohydrates; dependent on mucus and milk oligosaccharides for colonization.,"Moderate growth rate; doubling time not specified; stable persistence in vivo for at least 6 months in permissive hosts, unlike most probiotics with short-term in vivo activity.","Human gut mucosa, particularly in individuals with low baseline abundance of B. longum and lacking functional carbohydrate utilization genes.",Competes with resident microbiota for resources; engraftment facilitated in hosts with low abundance of related species; may benefit from 'empty niche' conditions and reduced competition.,"Tolerant to gastrointestinal transit (acid, bile); stable during freeze-drying and storage; resistant to shear stress in formulation.",Genes for acid resistance and adherence to intestinal epithelium,该菌株为人类肠道核心微生物群成员，具有与宿主共同进化的特征，能有效克服胃肠道环境中的栖息地过滤，具备在肠道黏膜定植的能力。其生长依赖于宿主来源的糖类（如黏液和母乳寡糖），在资源竞争较弱或宿主微生物群被扰动的条件下可实现长期定植。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及对B. longum subsp. longum AH1206进行基因工程改造。其成功定植主要归因于其天然的生态适应性，而非人工遗传修饰。,"[""pH"", ""Bile Acids"", ""Hypoxia""]","[""Milk Oligosaccharides"", ""Carbohydrates"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Glycans"", ""Epithelial Adhesion Sites"", ""Defensins""]","FNR promoter, Lactate receptor, Glycan-binding proteins","Threshold-based activation; likely involves AND logic between nutrient availability and host-derived signals (e.g., glycans + low competition).",该菌株通过感知宿主提供的糖类（如母乳寡糖）和黏膜表面的黏附位点，结合低竞争环境（如缺乏同源物种）来启动定植。其响应机制具有阈值特性，仅在资源可用且竞争压力较低时激活代谢活动，体现‘限制相似性’与‘空缺生态位’的生态逻辑。,"[""Colonization"", ""Metabolic Regulation"", ""Immunomodulation""]","Type IV secretion system (putative), Vesicles",Not specified,Compatible with oral delivery and gastrointestinal transit; stable in capsule formulations.,False,False,False,Not applicable,,False,False,False,False,未提及抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未提及产氧功能。,True,Modulates host immune responses through interaction with epithelial cells and immune cells; may reduce inflammation via SCFA production and regulation of Treg activity.,"Short-chain fatty acids (SCFAs), IL-10, TGF-β",True,Promotes epithelial barrier integrity and mucosal healing by enhancing mucus production and tight junction formation.,"Mucin, ZO-1, Occludin",True,"Regulates host metabolism by fermenting dietary and host-derived carbohydrates into beneficial metabolites such as SCFAs (acetate, lactate, propionate).","Short-chain fatty acids (SCFAs), Lactate",False,Not applicable,,GRAS,"Auxotrophy (nutrient dependency), Natural attenuation","Milk oligosaccharides, Host glycans",Low pathogenicity; no known antibiotic resistance genes; minimal horizontal gene transfer risk; low environmental escape potential due to host specificity.,Capsule formulation provides physical confinement during transit.,B. longum subsp. longum AH1206为人类肠道共生菌，具有GRAS（公认安全）地位。其定植依赖于宿主特异性营养物质，不具备在环境中的独立生存能力，因此生态风险极低。无已知致病性或抗生素抗性基因，且在非宿主环境中无法长期存活，安全性高。,在部分受试者中实现长达6个月的稳定定植，显著改善肠道屏障功能，调节免疫反应，并通过代谢产物（如SCFAs）促进宿主健康。其长期定植能力远优于大多数商业益生菌，体现了生态适应性在微生物疗法中的关键作用。,14714,1659,16373,,
974ad55b-d254-4105-8c17-1566b4fbf01f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium freudenreichii"", ""strain_id"": ""DSM 20271""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, anaerobic conditions; requires lactate or glucose as carbon source; tolerates pH 5.0–2.0 and 0.1% bile salts; grows in YEL, BM, MCHC, and DMEM media.",Growth rate: 0.04–0.11 h⁻¹; doubling time ~6–10 h; biomass production up to 1.67 g L⁻¹ in DMEM; adapted strain shows increased growth rate in DMEM and MCHC.,"Simulated human colon environment (MCHC medium), mimicking gut lumen; potential for intestinal colonization and survival in colorectal tumor microenvironment.",Competes with host microbiota for nutrients; enhanced SCFA production in CRC-conditioned medium suggests metabolic crosstalk with cancer cells.,"Resists simulated digestive stress (pH 2.0–5.0, bile salts); adapted strain shows improved survival and growth under stress; stable in freeze-dried form.","Bile salts, low pH (HCl), and lyophilization stability",该菌株为厌氧生长的革兰氏阳性菌，最适生长温度为37°C，可在多种培养基中生长，包括YEL、BM、MCHC和DMEM。其在模拟消化道应激（pH 2.0–5.0，0.1%胆盐）后表现出更强的生长适应性，尤其在DMEM和MCHC中。该菌株能有效利用乳酸和葡萄糖作为碳源，具有良好的肠道定植潜力。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未对菌株进行基因工程改造，仅使用野生型P. freudenreichii DSM 20271及其经模拟消化应激适应后的菌株，未涉及CRISPR、质粒或诱导系统等遗传工具。,"[""Hypoxia"", ""pH"", ""Lactate""]","[""Lactate"", ""Glucose""]",,,"Lactate utilization via metabolic pathways (e.g., lactate dehydrogenase); pH sensing likely via general stress response systems",No engineered logic gates; natural metabolic response to lactate and pH changes.,P. freudenreichii自然感知癌细胞代谢产物乳酸，并将其作为优选碳源，从而增强其生长和短链脂肪酸（SCFA）的产生。该响应为非编程性代谢适应，无明确逻辑门控机制。,"[""Metabolic Regulation"", ""Tumor Therapy""]",Passive diffusion of SCFAs through bacterial cell membrane,Controlled by bacterial growth and metabolic activity; SCFA concentration depends on carbon source availability and culture conditions.,"Compatible with liquid culture media (BM, DMEM, MCHC); no encapsulation or material barrier described.",False,False,False,Not applicable,Not applicable,False,False,False,False,未评估抗菌或抗生物膜功能。,False,Not applicable,Not applicable,False,False,False,未涉及氧气生成机制。,False,Not applicable,Not applicable,False,Not applicable,Not applicable,True,P. freudenreichii通过代谢乳酸产生短链脂肪酸（SCFA），包括乙酸和丙酸，这些代谢物可调节癌细胞代谢并诱导其凋亡。,"Acetate, Propionate",True,P. freudenreichii产生的SCFA（乙酸和丙酸）可抑制结直肠癌细胞增殖，诱导细胞周期阻滞（G2/M期）和亚G1期积累，从而促进癌细胞死亡。,"Acetate, Propionate",GRAS,Not applicable,Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; environmental escape unlikely due to non-pathogenic nature.,Not applicable,P. freudenreichii为公认安全（GRAS）菌株，广泛用于奶酪生产，无致病性记录，无抗生素抗性基因，不具有环境逃逸风险，安全性高。,在DMEM发酵液中，P. freudenreichii产生的乙酸（0.79 g/L）和丙酸（2.6 g/L）可使RKO结直肠癌细胞增殖抑制约21%；在BM发酵液中抑制率可达53%。细胞周期分析显示，SCFA处理导致癌细胞在G2/M期阻滞和亚G1期积累，表明其具有显著的抗肿瘤效应。此外，癌细胞分泌的乳酸可显著增强该菌株的SCFA产量，提示其在肿瘤微环境中具有自我强化的治疗潜力。,18482,1688,20170,,
7099918f-dd1a-49f3-a75b-1f1ce302af4a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus LA-5"", ""strain_id"": ""LA-5""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis BB-12"", ""strain_id"": ""BB-12""}, {""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium jensenii 702"", ""strain_id"": ""702""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 4.0–6.0; tolerates pH 2.0–4.0 in vitro; requires anaerobic conditions for optimal growth (P. jensenii 702 at 30°C)",Doubling time not specified; viable counts maintained at 10^5–10^6 cfu/g after adhesion assay; growth in vitro under anaerobic conditions,Intestinal epithelium (Caco-2 cell line); preferred adhesion in fruit yogurt matrix,"Competes with starter cultures (S. thermophilus, L. delbrueckii subsp. bulgaricus) in yogurt; no evidence of symbiosis or pathogenic interaction","Moderate tolerance to acid (pH 2.0–4.0), bile (0.3%), and freezing (-20°C for 24 weeks); enhanced survival in ice cream matrix","Fat content (10%), cocoa powder, stabilizers (guar gum, xanthan gum), buffering capacity of food matrix",三种益生菌在不同载体食品中均表现出良好的生长生理特性，尤其在冰激凌中对胃酸和胆汁的耐受性显著增强。L. acidophilus LA-5 和 B. animalis subsp. lactis BB-12 在冰激凌中表现出更高的存活率，而 P. jensenii 702 在冰激凌中也表现出优于酸奶的耐受性。所有菌株在-20°C冷冻24周后仍保持活性，表明其在冷冻条件下具有良好的稳定性。,,,,,,,本文未涉及基因工程改造，所有益生菌均为天然菌株，未进行遗传修饰。,"[""pH"", ""Bile salts"", ""Hypoxia""]","[""Lactate"", ""Glucose""]",,,No specific sensor identified; intrinsic resistance to low pH and bile salts,No engineered logic gates; natural physiological responses to environmental stress,益生菌通过其天然耐酸性和耐胆汁能力响应胃肠道环境变化，未设计人工逻辑控制回路。,"[""Gastrointestinal Tolerance"", ""Adhesion""]",Passive release via food matrix; no engineered secretion system,Not applicable; no controlled release or dosage modulation,Good compatibility with ice cream and yogurt matrices; physical protection from gastric and intestinal environments,False,False,False,无抗菌或抗生物膜功能描述,,False,False,False,False,未提及抗菌功能,False,无氧生成功能描述,,False,False,False,未提及氧生成功能,False,无免疫调节功能描述,,False,无组织修复功能描述,,False,无代谢调控功能描述,,False,无肿瘤治疗功能描述,,GRAS,No engineered biocontainment; natural non-pathogenic strains,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk identified; no environmental escape risk due to food matrix encapsulation,Physical barrier provided by food matrix (ice cream/yogurt) limits environmental release,三种益生菌均为公认安全（GRAS）菌株，无致病性，无抗生素抗性基因，未进行基因改造，且被食品基质包裹，降低了环境逃逸风险。,在体外模拟胃肠道环境中，冰激凌作为载体显著提高了L. acidophilus LA-5、B. animalis subsp. lactis BB-12和P. jensenii 702对酸和胆汁的耐受性。水果酸奶在体外黏附实验中表现出最佳的黏附能力，所有菌株在黏附后仍保持10^5–10^6 cfu/g的活菌数。冷冻24周后，冰激凌中的益生菌仍保持良好活性和黏附能力，表明其在长期储存下功能稳定。,16447,1608,18055,,
5a88c1b5-60b3-43af-9380-1bf7e8f8b9b9,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""L. salivarius ssp. salivarius UCC118""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium"", ""strain_id"": ""B. longum BB536""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""Genetically engineered for IL-10 production""}, {""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium acidipropionici"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Butyrivibrio fibrisolvens"", ""strain_id"": ""MDT-1""}, {""role"": ""Helper"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""TH-4""}, {""role"": ""Helper"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""299V""}, {""role"": ""Helper"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""DR20""}, {""role"": ""Helper"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""A1""}, {""role"": ""Helper"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Shirota""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""913""}, {""role"": ""Helper"", ""scientific_name"": ""Lactobacillus bulgaricus"", ""strain_id"": ""291""}, {""role"": ""Helper"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""Not specified""}]","Oral ingestion, colon-targeted delivery",Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric acidity and bile salts; utilizes carbohydrates (e.g., lactose, fructose) as carbon sources; dependent on host-derived nutrients in gut environment",Doubling time ~1–2 hours in vitro; in vivo colonization observed in murine models with sustained presence over days; consistent with intestinal homeostasis,"Colon mucosa, particularly in the distal colon; preferentially colonizes mucus layer and epithelial surface; competes with pathogenic flora","Competitive exclusion of pathogenic bacteria (e.g., coliforms); synergistic co-colonization with other beneficial strains; enhances microbial balance without disrupting core microbiota","Tolerant to bile salts, low pH (gastric), osmotic stress; moderate resistance to drying and lyophilization; stable during storage at 4°C","Cell wall components (e.g., peptidoglycan), exopolysaccharides, stress-response proteins",多种乳酸菌和双歧杆菌为兼性厌氧菌，可在人体肠道环境中稳定生长。它们能耐受胃酸和胆汁，利用碳水化合物作为主要能源，在结肠黏膜表面定植，通过竞争排斥抑制有害菌群，维持肠道微生态平衡。,Plasmid-based expression systems; CRISPR-Cas not mentioned; recombinant DNA technology used for IL-10 and TGF-β delivery,High efficiency in Lactococcus lactis and E. coli strains; no off-target effects reported in cited studies,"Constitutive expression of therapeutic genes (e.g., IL-10, TGF-β); no inducible systems described",,Plasmid stability in Lactococcus lactis; chromosomal integration not confirmed; low metabolic burden; long-term in vivo consistency demonstrated in murine models,Genetic constructs remain stable during oral delivery and intestinal transit; no degradation in gut environment reported,通过基因工程技术改造乳酸乳球菌，使其持续表达抗炎细胞因子IL-10；同时利用非致病性大肠杆菌作为载体，递送TGF-β基因至结肠黏膜，以抑制肿瘤生长。这些工程菌株在动物模型中表现出良好的稳定性与治疗效果。,"[""pH"", ""Hypoxia"", ""Lactate"", ""Glucose""]","[""Short Chain Fatty Acids (SCFAs)"", ""Bile Acids"", ""Nitrate/Nitrite"", ""Lactose"", ""Fructose""]","[""Quorum Sensing (AHL)"", ""AI-2""]","[""Proteases (e.g., MMPs)"", ""Cytokines (e.g., IL-10, TNF-α)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactose permease (glucose), Bile acid receptors (e.g., Bile acid-inducible promoters), Quorum sensing receptors (e.g., LasR, LuxR)","AND gate logic observed in some synbiotic combinations (e.g., prebiotic + probiotic required for full effect); threshold-based activation of immune response; noise suppression via feedback loops in cytokine regulation",微生物系统通过感知肠道环境中的pH、乳酸、短链脂肪酸及胆汁酸等信号，结合自身代谢产物与宿主免疫因子，实现对炎症和肿瘤微环境的响应。在合成益生菌中，需同时存在益生菌与益生元才能激活免疫调节通路，体现AND逻辑门特性。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair"", ""Tumor Therapy""]",Type IV secretion system (in engineered Lactococcus lactis); extracellular release of cytokines and SCFAs; lysis of cells for payload release,Dose-dependent effects observed in animal models; oral administration allows natural dosage regulation via gut transit time and microbial load,Compatible with oral delivery systems; stable in gastrointestinal tract; no interference with intestinal matrix structure,True,True,True,通过产生有机酸（如乳酸）、细菌素及竞争性排斥机制，抑制多种肠道致病菌（如大肠杆菌、沙门氏菌）的生长，并干扰生物膜形成。,"Lactic acid, bacteriocins, competitive exclusion",True,True,True,True,多项动物实验显示，乳酸菌和双歧杆菌可显著减少粪便中腐败菌数量，同时抑制生物膜形成，且对宿主细胞无明显毒性，表明其具有良好的安全边界。,False,,,,,,,True,通过分泌IL-10、TGF-β等抗炎因子，调节T细胞功能，增强NK细胞活性，抑制过度免疫反应，减轻肠道炎症。,"Interleukin-10 (IL-10), Transforming Growth Factor-beta (TGF-β), Peptidoglycan",True,通过促进上皮细胞再生、增强紧密连接蛋白表达、修复肠屏障功能，改善肠道通透性，防止癌变启动。,"Tight junction proteins (e.g., occludin, ZO-1), Mucin-2",True,通过发酵碳水化合物产生短链脂肪酸（如丁酸、丙酸、乙酸），调节宿主能量代谢，抑制癌细胞增殖，诱导凋亡。,"Butyrate, Propionate, Acetate",True,通过诱导癌细胞凋亡、抑制肿瘤增殖、增强免疫监视功能，实现抗肿瘤作用。丁酸菌株可显著减少异常隐窝灶（ACF）数量。,"Butyrate, Peptidoglycan, IL-10, TGF-β",BSL-1,"Auxotrophy (e.g., nutrient-dependent growth); suicide genes not used; no antibiotic resistance markers reported","Nutrient-dependent growth (e.g., specific amino acids, sugars)",Low pathogenicity; non-invasive; no known antibiotic resistance genes; no evidence of horizontal gene transfer in studies; low risk of environmental escape,Gastrointestinal tract acts as natural physical barrier; no systemic dissemination reported,所涉及的菌株均为公认安全（GRAS）菌株，无致病性记录，且在动物实验中未发现长期定植或传播风险，整体生物安全等级为BSL-1，适合用于人体干预。,在多种动物模型中，益生菌、益生元及合生元组合显著减少异常隐窝灶（ACF）数量，抑制肿瘤发生；增强NK细胞活性，促进细胞凋亡，改善肠道屏障功能，降低结直肠癌发生风险。在高脂饮食模型中，益生菌与益生元联用效果更显著，提示其在高危人群中的潜在应用价值。,8478,2636,11114,,
1306c049-9928-4f54-8caa-f8ba8d85ac4b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""HAC01, ZJUFT17, MTCC5690, KLDS 1.0344""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus sakei"", ""strain_id"": ""OK67, PK16""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""CECT 8145, MKK4, 01""}, {""role"": ""Chassis"", ""scientific_name"": ""Akkermansia muciniphila"", ""strain_id"": ""Lactobacillus paracasei TD062""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Ll2, BFE5264""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Lactobacillus casei Q14""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""BC30""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""SBT2055""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LA1/K8, NX2-6""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus coryniformis subsp. torquens"", ""strain_id"": ""T3""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""subsp. paracasei G15, M5, X12, TD062""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus amyloliquefaciens"", ""strain_id"": ""CCFM419, CBSYD1""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""None""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates bile salts and gastric acidity; utilizes various carbohydrates including lactose, glucose, and fructose.",Doubling time ~1–2 hours in vitro; growth rate consistent with in vivo gut environment.,"Intestinal mucosa, particularly in the colon and ileum; adheres to mucus layer and epithelial cells.",Competes with pathobionts for nutrients and adhesion sites; promotes growth of beneficial bacteria such as Bifidobacterium and Lactobacillus; suppresses LPS-producing bacteria.,"Tolerant to bile, low pH, osmotic stress, and moderate shear stress; stable during lyophilization and rehydration.","Exopolysaccharides (EPS), cell wall components, and stress-response proteins (e.g., HSPs)",上述微生物多为乳酸菌或双歧杆菌，属于兼性厌氧菌，可在肠道环境中稳定生长。它们能耐受胃酸和胆汁，定植于肠道黏膜，利用多种碳源进行代谢，具有良好的环境适应性和稳定性，适合用于功能性食品和肠道健康干预。,"CRISPR-Cas9 (inferred from modern strain engineering), plasmid-based expression systems (e.g., pNZ8048), transposon mutagenesis",High efficiency (>90%) in Lactobacillus and Bifidobacterium; low off-target risk with optimized guide RNAs.,"Constitutive expression of metabolic genes; inducible promoters (e.g., nisin-inducible PnisA) used in some engineered strains.","Nisin, IPTG, or natural metabolites (e.g., lactose, glucose)",High chromosomal integration stability; plasmid loss rate <1% per generation; metabolic burden minimal; long-term in vivo stability demonstrated in murine models.,"Genetic circuits remain functional in encapsulated matrices (e.g., alginate beads, hydrogels) and during freeze-drying.",通过CRISPR-Cas9等工具对乳酸菌和双歧杆菌进行基因编辑，构建稳定表达特定代谢酶或信号分子的工程菌株。利用诱导型或组成型启动子调控目标基因表达，确保在肠道环境中持续发挥功能。基因整合稳定，适合长期应用。,"[""pH"", ""Bile acids"", ""Osmotic stress"", ""Glucose"", ""Lactate""]","[""Short-chain fatty acids (SCFAs)"", ""Lipopolysaccharide (LPS)"", ""Free fatty acids (FFAs)"", ""Cholesterol"", ""Bile acids""]","[""Quorum sensing molecules (AHL, AI-2)"", ""Bacteriocins""]","[""Cytokines (TNF-α, IL-6, IL-1β)"", ""Toll-like receptor ligands (TLR4 agonists)"", ""Proteases (MMPs, elastase)""]","FNR promoter (hypoxia), Lactose permease (glucose), Bile salt hydrolase (BSH) promoter, TLR4-binding motifs",AND gate: requires both low pH and high bile to activate colonization genes; threshold-based response to LPS levels; noise suppression via feedback loops.,这些微生物通过感知肠道内的pH、胆汁酸、游离脂肪酸和炎症因子等信号，启动相应的调控通路。例如，低pH和高胆汁环境可激活定植相关基因；LPS水平升高时，通过NF-κB通路触发免疫调节反应。系统具备阈值感应和噪声过滤能力，确保在病理性信号下精准响应。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair"", ""Antibacterial""]","Type I secretion system (bacteriocins), lysis (for cell-free extracts), vesicles (exosomes)","Dose-dependent effects observed; controlled by microbial load and delivery vehicle (e.g., capsules, hydrogels)","Compatible with alginate, chitosan, and gelatin-based matrices; permeable to nutrients and signaling molecules",True,True,True,通过分泌细菌素、有机酸和 bacteriocins 抑制病原菌生长，破坏生物膜结构，减少肠道定植能力。,"Bacteriocins, lactic acid, hydrogen peroxide",True,True,True,True,多项研究显示，Lactobacillus和Bifidobacterium能有效抑制S. aureus、P. aeruginosa等常见病原体，并减少生物膜形成，且对宿主细胞无显著毒性，局部定植安全。,False,,,False,False,False,无相关数据支持该系统具备氧生成能力。,True,通过调节Treg/Th17平衡、抑制NF-κB通路、降低M1巨噬细胞比例、促进IL-10分泌，缓解慢性低度炎症。,"IL-10, TGF-β, SCFAs (butyrate), exopolysaccharides",True,"促进肠道屏障修复，上调紧密连接蛋白（Occludin, ZO-1）表达，增强黏液分泌，改善肠通透性。","Tight junction proteins (Occludin, ZO-1), mucin-2, growth factors (EGF, TGF-β)",True,调节脂质、葡萄糖和胆固醇代谢，通过激活AMPK、PPAR-α、SIRT1等通路促进脂肪酸氧化，抑制脂质合成，改善胰岛素敏感性。,"Short-chain fatty acids (SCFAs), GABA, exopolysaccharides",False,,,GRAS,"Auxotrophy (e.g., amino acid auxotrophy), kill-switch (e.g., arabinose-inducible lysis gene)","Amino acid auxotrophs, arabinose, IPTG",Low pathogenicity; no known antibiotic resistance genes; no evidence of horizontal gene transfer; low environmental escape risk due to poor survival outside gut.,"Physical confinement via encapsulation (e.g., enteric-coated capsules) prevents systemic dissemination.",所有列出的微生物均为公认安全（GRAS）菌株，无致病性记录。通过营养缺陷型或自杀基因实现生物遏制，确保在非肠道环境中无法长期存活。封装技术进一步增强安全性，防止意外释放。,在高脂饮食诱导的肥胖小鼠模型中，多种乳酸菌和双歧杆菌显著降低体脂、改善胰岛素抵抗、调节肠道菌群结构、减轻炎症反应。例如，L. plantarum HAC01和L. sakei OK67可分别降低脂肪组织重量30%以上，提升胰岛素敏感性；A. muciniphila可减少脂肪质量并改善血脂异常。此外，热灭活菌和细胞外成分（如EPS、SCFAs）也表现出显著代谢调节作用，提示其在功能性食品开发中的巨大潜力。,15712,2732,18444,,
220642b2-eb4d-4740-945a-7c570919c1b3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus pentosus"", ""strain_id"": ""GMNL-77""}]",Oral administration (gastrointestinal tract),Facultative Anaerobe,Growth in gastrointestinal tract; resistant to bile and stomach acid; fermentative metabolism on carbohydrates,Not specified in the text,Gastrointestinal tract (intestine),Modulates gut microbiota composition; may compete with pathogenic bacteria,"Resistant to bile, stomach acid, and several antibiotics; stable under environmental stress during fermentation","Bile salts, gastric acid, antibiotics","Lactobacillus pentosus GMNL-77 is a lactic acid bacterium that colonizes the gastrointestinal tract and exhibits resistance to harsh gastric conditions. It is used in food fermentation and maintains viability under stress, enabling effective delivery to the gut.",,,,,,,No genetic engineering was performed. The strain functions naturally through its intrinsic immunomodulatory properties without synthetic circuitry.,"[""Acidity (gastric pH)"", ""Bile""]","[""Glucose"", ""Lactate""]",,"[""Cytokines (IL-6, TNF-α)"", ""Immune cell infiltration""]","Intestinal dendritic cell receptors, T-cell surface receptors",No synthetic logic gates; natural immune sensing via pattern recognition receptors (PRRs) and cytokine feedback,"The strain senses host immune signals (e.g., elevated TNF-α, IL-6) and inflammatory microenvironment via innate immune receptors. It modulates T-cell differentiation through dendritic cell interaction, functioning as a natural feedback system to suppress excessive inflammation.","[""Immunomodulation""]",Natural secretion of immunomodulatory metabolites and cell surface molecules,Dose-dependent effect via oral administration (1×10¹⁰ CFU/day); no synthetic control system,Compatible with oral delivery; stable in gastrointestinal environment,False,,,,,,,,,,False,,,,,,,True,"Reduces production of pro-inflammatory cytokines (IL-23, IL-17A/F, IL-22, IL-6, TNF-α) and inhibits pathogenic Th17 cell activity; promotes Treg cell differentiation.","IL-23/IL-17A axis cytokines, Treg cells",False,,,False,,,False,,,GRAS,Natural attenuation; no synthetic kill switches,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe in healthy individuals,Gastrointestinal barrier limits systemic spread,Lactobacillus pentosus GMNL-77 is considered safe (GRAS status) with no reported adverse events in clinical studies. It is naturally present in fermented foods and does not pose significant risk of infection or environmental escape.,"Oral administration of L. pentosus GMNL-77 significantly suppressed skin inflammation in imiquimod-induced psoriasis mouse models, reducing erythematous scaling, epidermal hyperplasia, and infiltration of immune cells. It decreased pro-inflammatory cytokines (IL-23, IL-17A/F, IL-22, IL-6, TNF-α) and reduced pathogenic CD4+ T-cell populations in spleen, indicating effective immunomodulation and amelioration of psoriatic lesions.",11276,5129,16405,,
220642b2-eb4d-4740-945a-7c570919c1b3,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus sakei"", ""strain_id"": ""proBio65""}]",Topical application (ethanol extract SEL001),Facultative Anaerobe,"Resistant to bile, stomach acid, and antibiotics; grows in meat fermentation environments",Not specified,Skin surface (after topical application),Competes with pathogenic microbes on skin; may modulate local immune response,"Resistant to bile, gastric acid, and multiple antibiotics; stable in ethanol extract","Bile salts, gastric acid, ethanol","Lactobacillus sakei proBio65 is a robust strain resistant to harsh conditions, used in meat fermentation. When applied topically as ethanol extract SEL001, it maintains stability and exerts anti-inflammatory effects on skin.",,,,,,,No genetic modification; natural bioactive compounds in extract mediate effects.,"[""pH (skin surface)"", ""Lactate""]","[""Bile acids (indirectly via skin barrier disruption)"", ""SCFAs (potential cross-talk)""]",,"[""Cytokines (IL-17A, IL-23, IL-19)"", ""Inflammatory cell infiltration""]","Skin dendritic cells, keratinocytes, TLRs",Natural immune sensing; no synthetic logic gates,"The extract senses inflammatory signals from psoriatic skin (e.g., elevated IL-17A, IL-23) via skin immune cells. It triggers anti-inflammatory responses through modulation of cytokine expression and immune cell activity, functioning as a natural feedback system.","[""Immunomodulation""]",Topical delivery of ethanol extract (SEL001) containing bioactive compounds,Dose-dependent effect; topical application with defined extract concentration,Compatible with topical formulation; stable in ethanol extract; does not disrupt skin barrier,False,,,,,,,,,,False,,,,,,,True,"Downregulates expression of psoriasis-related cytokines (IL-19, IL-17A, IL-23); reduces epidermal hyperplasia and dermal collagen loss; protects against histopathological damage in mouse skin.","IL-19, IL-17A, IL-23",False,,,False,,,False,,,GRAS,No synthetic containment; natural attenuation,,Low pathogenicity; no antibiotic resistance genes reported; safe in topical use; no evidence of systemic spread,Topical application limits systemic exposure,"Lactobacillus sakei proBio65 is considered safe (GRAS) and used in food fermentation. Topical application of its extract (SEL001) showed no adverse effects in animal models, with no risk of infection or environmental escape.","Topical application of SEL001 (ethanol extract of L. sakei proBio65) significantly protected mouse ear and dorsal skin from imiquimod-induced psoriasis-like inflammation. It reduced epidermal hyperplasia, dermal collagen loss, and inflammatory cell infiltration. Gene expression of IL-19, IL-17A, and IL-23 was downregulated, indicating effective immunomodulation and tissue protection.",11276,5129,16405,,
220642b2-eb4d-4740-945a-7c570919c1b3,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""35,264""}]",Oral administration (gastrointestinal tract),Strict Anaerobe,Grows in gastrointestinal tract; requires anaerobic conditions; utilizes oligosaccharides and complex carbohydrates,Not specified,Large intestine (colon),Competes with pathogenic bacteria; promotes gut barrier integrity; modulates immune system,Stable in freeze-dried form; survives gastrointestinal transit,"Lyophilization, gastric acid","Bifidobacterium infantis 35,264 is a strict anaerobe that colonizes the colon. It survives oral administration due to resistance to gastric acid and bile, and exerts immunomodulatory effects via gut microbiota interaction.",,,,,,,No genetic engineering; natural immunomodulatory function via metabolic and signaling pathways.,"[""pH (intestinal)"", ""Osmotic strength""]","[""Glucose"", ""Oligosaccharides"", ""SCFAs""]",,"[""Cytokines (IL-6, TNF-α)"", ""Systemic inflammation markers""]","Gut epithelial receptors, dendritic cells, TLRs",Natural immune sensing; no synthetic logic,"The strain senses host inflammatory signals (e.g., elevated IL-6, TNF-α) and nutrient availability in the gut. It modulates immune responses via dendritic cell interaction, promoting Treg differentiation and suppressing Th17 activity, acting as a natural homeostatic regulator.","[""Immunomodulation""]","Natural secretion of immunomodulatory metabolites (e.g., SCFAs)",Dose-dependent effect via oral intake (1×10¹⁰ CFU/day); no synthetic control,Compatible with oral delivery; stable in freeze-dried form,False,,,,,,,,,,False,,,,,,,True,"Reduces systemic levels of IL-6, TNF-α, and C-reactive protein (CRP); modulates T-cell responses; promotes anti-inflammatory environment.","IL-6, TNF-α, CRP",False,,,False,,,False,,,GRAS,Natural attenuation; no synthetic kill switches,,Low pathogenicity; no antibiotic resistance genes; safe in healthy individuals; no evidence of HGT or environmental escape,Gastrointestinal barrier limits systemic spread,"Bifidobacterium infantis 35,264 is classified as GRAS and widely used in probiotics. Clinical trials showed no adverse effects, with significant reduction in systemic inflammation markers, indicating high safety and low risk.","Oral supplementation of B. infantis 35,264 for 6–8 weeks significantly reduced plasma levels of IL-6, TNF-α, and C-reactive protein (CRP) in patients with mild to moderate psoriasis. This systemic immunomodulation correlated with clinical improvement in skin lesions, demonstrating effective amelioration of psoriatic inflammation.",11276,5129,16405,,
220642b2-eb4d-4740-945a-7c570919c1b3,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus sporogenes"", ""strain_id"": null}]",Oral administration (gastrointestinal tract),Facultative Anaerobe,Grows in gastrointestinal tract; resistant to gastric acid and bile,Not specified,Gastrointestinal tract,Modulates gut microbiota; may compete with pathogens,Resistant to gastric acid and bile; stable in oral formulations,"Gastric acid, bile salts",Lactobacillus sporogenes is a facultative anaerobe that survives gastrointestinal transit and colonizes the gut. It exerts beneficial effects through immune modulation and microbiota balance.,,,,,,,No genetic engineering; natural probiotic activity.,"[""pH (gastric)"", ""Bile""]","[""Glucose"", ""Lactate""]",,"[""Cytokines (IL-6, TNF-α)"", ""Systemic inflammation""]","Gut immune cells, epithelial receptors",Natural immune sensing; no synthetic logic,"The strain senses inflammatory signals in the gut and modulates immune responses via dendritic cell and T-cell interaction, promoting anti-inflammatory pathways.","[""Immunomodulation""]",Natural secretion of immunomodulatory factors,Oral administration; dose not specified; continuous for 6 months,Compatible with oral delivery; stable in gastrointestinal environment,False,,,,,,,,,,False,,,,,,,True,Ameliorated pustular psoriasis in a clinical case study; reduced fever and lesion progression; improved general condition after 15 days of treatment.,"IL-6, TNF-α (systemic markers)",False,,,False,,,False,,,GRAS,Natural attenuation,,Low pathogenicity; no reported adverse events; safe in clinical use,Gastrointestinal barrier limits systemic spread,"Lactobacillus sporogenes is considered safe (GRAS) and used in clinical settings. A single case study showed significant improvement in pustular psoriasis without adverse effects, indicating low risk.","In a clinical case study, oral treatment with L. sporogenes led to rapid reduction in fever and lesion progression within 15 days. After 6 months, plaque psoriasis significantly improved, with no new lesions and enhanced general health, demonstrating therapeutic potential in refractory psoriasis.",11276,5129,16405,,
245b63ba-8d07-4a6b-b895-25dd1da0174c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""GPI-1(S)""}]",Suspension,Facultative Anaerobe,"37°C, pH 5.5–7.0, MRS broth with 0.3% ox-bile, microaerobic environment",Growth rate not explicitly quantified; exponential phase reached within 24 h at 37°C,"Human gut (adult origin), intestinal lumen",Potential for symbiosis with host microbiome; no competitive or antagonistic interactions reported,"Tolerant to bile salts (0.3% ox-bile), acid stress (pH 4.38–4.93 in fermented curd), moderate osmotic tolerance","Bile salt hydrolase (BSH), acid tolerance mechanisms",该菌株为从成人肠道分离的乳酸杆菌，可在37°C、微需氧条件下在MRS培养基中生长，对胆盐和酸性环境具有较强耐受性，能有效降低胆固醇并产生高活性β-和α-半乳糖苷酶，具有良好的肠道定植潜力。,,,,,,,该研究未对L. salivarius GPI-1(S)进行基因工程改造，其功能基于天然代谢能力，未涉及可编程遗传回路或外源基因插入。,"[""Acidity (pH)"", ""Bile salts""]","[""Cholesterol"", ""Lactose"", ""Oligosaccharides (raffinose, stachyose)""]",,,"Bile salt hydrolase (BSH), lactose permease, α-galactosidase promoter",无明确逻辑门控机制，响应环境信号（如pH、胆盐）进行酶表达调控,该菌株通过感知环境pH和胆盐浓度等生理化学信号，调控β-和α-半乳糖苷酶及胆盐水解酶的表达，实现对乳糖和寡糖的降解，但未涉及复杂逻辑控制。,"[""Metabolic Regulation"", ""Cholesterol Removal""]",Extracellular enzyme secretion (likely via general secretory pathway),Natural expression level; no external control mechanism reported,Compatible with fermented dairy matrices (curd); stable in MRS broth and fermented milk,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,通过分泌α-半乳糖苷酶和β-半乳糖苷酶，降解植物性食物中的抗营养寡糖（如棉子糖、水苏糖）和乳糖，改善消化吸收，减少胀气。,"α-Galactosidase, β-Galactosidase",False,,,GRAS,"None (natural strain, no engineered kill switches)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape,Physical confinement in fermented food matrix,L. salivarius GPI-1(S)为天然分离菌株，属于公认安全（GRAS）菌种，无致病性、无抗生素抗性基因，未进行基因改造，安全性高，适合用于食品和益生菌产品。,在体外实验中，L. salivarius GPI-1(S)表现出比标准菌株LGG和L. plantarum ATCC 8014更高的β-半乳糖苷酶（438.04 Miller units）和α-半乳糖苷酶活性（12.939 U/mg蛋白），胆固醇去除率达45.35%（直接培养）和44.84%（发酵乳），且pH值低（4.92），表明其具有优异的代谢调节和降脂功能，是潜在的益生菌候选菌株。,18566,4321,22887,,
245b63ba-8d07-4a6b-b895-25dd1da0174c,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""GPI-3""}]",Suspension,Facultative Anaerobe,"37°C, pH 5.5–7.0, MRS broth with 0.3% ox-bile, microaerobic environment",Growth rate not explicitly quantified; exponential phase reached within 24 h at 37°C,"Human gut (adult origin), intestinal lumen",Potential for symbiosis with host microbiome; no competitive or antagonistic interactions reported,"Tolerant to bile salts (0.3% ox-bile), acid stress (pH 4.38–4.93 in fermented curd), moderate osmotic tolerance","Bile salt hydrolase (BSH), acid tolerance mechanisms",该菌株为从成人肠道分离的乳酸杆菌，可在37°C、微需氧条件下在MRS培养基中生长，对胆盐和酸性环境具有较强耐受性，能有效降低胆固醇并产生高活性β-半乳糖苷酶，具有良好的肠道定植潜力。,,,,,,,该研究未对L. fermentum GPI-3进行基因工程改造，其功能基于天然代谢能力，未涉及可编程遗传回路或外源基因插入。,"[""Acidity (pH)"", ""Bile salts""]","[""Cholesterol"", ""Lactose"", ""Oligosaccharides (raffinose, stachyose)""]",,,"Bile salt hydrolase (BSH), lactose permease, α-galactosidase promoter",无明确逻辑门控机制，响应环境信号（如pH、胆盐）进行酶表达调控,该菌株通过感知环境pH和胆盐浓度等生理化学信号，调控β-和α-半乳糖苷酶及胆盐水解酶的表达，实现对乳糖和寡糖的降解，但未涉及复杂逻辑控制。,"[""Metabolic Regulation"", ""Cholesterol Removal""]",Extracellular enzyme secretion (likely via general secretory pathway),Natural expression level; no external control mechanism reported,Compatible with fermented dairy matrices (curd); stable in MRS broth and fermented milk,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,通过分泌β-半乳糖苷酶降解乳糖，改善乳糖不耐受；同时分泌α-半乳糖苷酶降解植物性寡糖，减少胀气。,"β-Galactosidase, α-Galactosidase",False,,,GRAS,"None (natural strain, no engineered kill switches)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape,Physical confinement in fermented food matrix,L. fermentum GPI-3为天然分离菌株，属于公认安全（GRAS）菌种，无致病性、无抗生素抗性基因，未进行基因改造，安全性高，适合用于食品和益生菌产品。,在体外实验中，L. fermentum GPI-3表现出比标准菌株LGG和L. plantarum ATCC 8014更高的β-半乳糖苷酶活性（444.62 Miller units），胆固醇去除率达40.59%（直接培养），是具有优异代谢调节功能的潜在益生菌候选菌株。,18566,4321,22887,,
245b63ba-8d07-4a6b-b895-25dd1da0174c,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""SCB""}]",Suspension,Facultative Anaerobe,"37°C, pH 5.5–7.0, MRS broth with 0.3% ox-bile, microaerobic environment",Growth rate not explicitly quantified; exponential phase reached within 24 h at 37°C,"Human gut (child origin), intestinal lumen",Potential for symbiosis with host microbiome; no competitive or antagonistic interactions reported,"Tolerant to bile salts (0.3% ox-bile), acid stress (pH 4.38 in fermented curd), moderate osmotic tolerance","Bile salt hydrolase (BSH), acid tolerance mechanisms",该菌株为从儿童肠道分离的乳酸杆菌，可在37°C、微需氧条件下在MRS培养基中生长，对胆盐和酸性环境具有极强耐受性，pH可低至4.38，能高效降低胆固醇，是极具潜力的益生菌候选菌株。,,,,,,,该研究未对L. rhamnosus SCB进行基因工程改造，其功能基于天然代谢能力，未涉及可编程遗传回路或外源基因插入。,"[""Acidity (pH)"", ""Bile salts""]","[""Cholesterol"", ""Lactose"", ""Oligosaccharides (raffinose, stachyose)""]",,,"Bile salt hydrolase (BSH), lactose permease, α-galactosidase promoter",无明确逻辑门控机制，响应环境信号（如pH、胆盐）进行酶表达调控,该菌株通过感知环境pH和胆盐浓度等生理化学信号，调控β-和α-半乳糖苷酶及胆盐水解酶的表达，实现对乳糖和寡糖的降解，但未涉及复杂逻辑控制。,"[""Metabolic Regulation"", ""Cholesterol Removal""]",Extracellular enzyme secretion (likely via general secretory pathway),Natural expression level; no external control mechanism reported,Compatible with fermented dairy matrices (curd); stable in MRS broth and fermented milk,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,通过分泌β-半乳糖苷酶降解乳糖，改善乳糖不耐受；同时分泌α-半乳糖苷酶降解植物性寡糖，减少胀气。,"β-Galactosidase, α-Galactosidase",False,,,GRAS,"None (natural strain, no engineered kill switches)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape,Physical confinement in fermented food matrix,L. rhamnosus SCB为天然分离菌株，属于公认安全（GRAS）菌种，无致病性、无抗生素抗性基因，未进行基因改造，安全性高，尤其在酸性环境下表现出极强的胆固醇降低能力，是极具潜力的益生菌候选菌株。,在体外实验中，L. rhamnosus SCB表现出最高的胆固醇去除率（78.76%直接培养，76.50%发酵乳），pH低至4.38，且β-半乳糖苷酶活性较高，是目前报道中胆固醇清除能力最强的菌株之一，具有极高的应用潜力。,18566,4321,22887,,
a4f08351-d823-445b-8a0c-802330041925,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""ATCC 55730, DSM 17938""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, requires lactose and other fermentable carbohydrates; dependent on host-derived nutrients in the gut environment","Doubling time ~1.5–2 hours in vitro; in vivo colonization observed within 7 days post-administration, with sustained presence over 21–28 days","Small intestine and colon, particularly in the mucosal layer of the gut; preferentially colonizes the intestinal epithelium of breastfed infants","Competes with pathogenic coliforms (e.g., E. coli); modulates gut microbiota by reducing coliform abundance and restoring Lactobacillus distribution; may promote symbiosis with host immune system",Tolerant to gastric acidity (pH 2.0–3.0) and bile salts; stable during lyophilization and rehydration; resistant to moderate osmotic stress,"Cell wall components (e.g., teichoic acids), extracellular polysaccharides, and stress-response proteins","Lactobacillus reuteri is a facultative anaerobe that thrives in the human intestinal tract, particularly in breastfed infants. It exhibits robust growth under physiological conditions, colonizes the gut mucosa, and maintains stability during transit through the gastrointestinal tract. Its ability to survive gastric acid and bile enables effective delivery to the small intestine, where it exerts beneficial effects on gut microbiota and immune modulation.",Not specified (no genetic modification reported),Not applicable (wild-type strain used),Constitutive (no inducible circuits reported),,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift or loss in clinical trials,Stable in oral suspension formulation; maintains viability during storage and delivery,"The Lactobacillus reuteri strains used in this study are wild-type, non-genetically modified organisms. No synthetic genetic circuits or engineered regulatory systems were employed. The probiotic effect is attributed to natural physiological properties of the strain, including colonization ability and antimicrobial activity.","[""pH"", ""Lactose"", ""Bile acids""]","[""Lactose"", ""Short-chain fatty acids (SCFAs)""]","[""Coliform-derived metabolites (e.g., LPS, indole)""]","[""Mucosal cytokines (e.g., IL-10, TGF-β)"", ""Intestinal epithelial integrity markers""]","FNR-like regulators, lactose permease (LacS), bile acid receptors (e.g., Bile acid-binding proteins)",No synthetic logic gates; natural sensing via nutrient availability and host-microbe interaction thresholds,"Lactobacillus reuteri senses environmental cues such as lactose availability and bile acid concentration in the gut. It responds to changes in pH and host-derived signals to modulate its metabolic activity and colonization behavior. The response is threshold-based, with activation of beneficial functions (e.g., antimicrobial production) when pathogenic bacteria are detected or when host immune signals indicate dysbiosis.","[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Constitutive secretion of reuterin and immunomodulatory molecules via membrane transporters; no lysis or vesicle release reported,Fixed daily dose (10^6 CFU/day); controlled by oral administration schedule; effect is time-dependent and cumulative over 7–21 days,Compatible with oral suspension formulation; stable in liquid medium; no interference with delivery vehicle,True,True,True,"L. reuteri produces reuterin (3-hydroxypropionaldehyde), a broad-spectrum antimicrobial compound that inhibits growth of pathogenic coliforms (e.g., E. coli) and prevents biofilm formation in the gut.",Reuterin (3-hydroxypropionaldehyde),True,True,True,True,Reuterin production is naturally regulated and does not cause significant tissue damage; clinical trials showed no adverse effects; localized action in the gut with minimal systemic exposure.,False,,,False,False,False,No oxygenation mechanism reported; not applicable.,True,"L. reuteri modulates host immune responses by promoting anti-inflammatory cytokine production (e.g., IL-10) and enhancing regulatory T-cell activity, thereby reducing gut inflammation associated with colic.","IL-10, TGF-β, and bacterial surface molecules (e.g., peptidoglycan fragments)",False,,,True,"L. reuteri influences gut metabolism by producing SCFAs (e.g., acetate, lactate) and modulating fatty acid profiles, which may improve intestinal barrier function and reduce inflammation.","Acetate, Lactate, Short-chain fatty acids (SCFAs)",False,,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,"Low pathogenicity; no evidence of virulence genes; however, ATCC 55730 strain carries tetracycline and lincomycin resistance genes (potential HGT risk); replaced by DSM 17938 in later trials to mitigate risk",Oral delivery with natural gut transit; no physical barrier required; limited systemic exposure,"Lactobacillus reuteri strains ATCC 55730 and DSM 17938 are generally recognized as safe (GRAS). While ATCC 55730 carries antibiotic resistance genes, these were not expressed in clinical settings and were replaced in subsequent studies. No adverse events were reported in trials. The risk of horizontal gene transfer is low due to natural gut confinement and lack of conjugative plasmids. Overall, the safety profile is favorable for use in infants.","Probiotic supplementation with L. reuteri significantly reduced daily crying time by an average of 56.03 minutes (95% CI: -59.92 to -52.15) within 7 days, with maximal effect at 21 days. Treatment success rate (reduction in crying time >50%) was achieved in 94% of infants (RR: 0.06; NNT: 2). The effect was progressive and sustained over 28 days, with no short-term safety concerns reported.",11270,2005,13275,,
ea7744a6-d5e5-47df-b72b-fe8aaa8f3256,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""Not specified""}]",Oral gavage suspension,Facultative Anaerobe,Growth on Sabouraud dextrose agar; optimal growth at 37°C; tolerance to pH and osmotic conditions typical of gastrointestinal tract,Not explicitly reported; assumed to grow under standard laboratory conditions (in vitro) with typical yeast doubling time (~90–120 min). In vivo homeostasis not directly assessed.,"Intestinal lumen (small intestine, ileum)",Competes with pathogenic bacteria for adhesion sites; may modulate host immune response without significant disruption of indigenous microbiota.,"Tolerant to heat (autoclaved at 121°C for 15 min), lyophilization (used in commercial preparation), and gastrointestinal stresses (acid, bile, osmotic).","Cell wall components (e.g., mannoproteins, β-glucans)","Saccharomyces boulardii is a non-pathogenic yeast that can survive in the gastrointestinal tract, withstand heat and lyophilization, and maintain viability under physiological conditions. It colonizes the intestinal lumen and exerts protective effects via structural components rather than metabolic activity.",,,,,,,"No genetic engineering was performed. The yeast was used in its natural form, either viable or heat-killed, without modification.","[""Hypoxia"", ""pH"", ""Osmotic stress""]","[""Bile acids"", ""Lactate"", ""Glucose""]","[""Quorum sensing molecules (indirectly via competition)""]","[""Proteases"", ""Cytokines (IL-10, IFN-γ)""]","Cell wall components (e.g., mannoproteins, β-glucans), which may interact with host pattern recognition receptors (e.g., TLRs, Dectin-1)",No engineered logic gates; natural sensing via receptor-ligand interactions with host and microbial signals.,"Saccharomyces boulardii senses the intestinal environment through structural components of its cell wall that interact with host immune receptors. It responds to changes in pH, bile, osmolarity, and microbial load, triggering immune modulation and barrier protection without requiring metabolic activity.","[""Immunomodulation"", ""Tissue Repair"", ""Barrier Protection""]",Passive release of cell wall components; no active secretion systems reported.,Dose-dependent effects observed (10^9 CFU/mL); controlled via gavage administration.,Compatible with oral delivery; stable in suspension and withstands gastrointestinal transit.,False,,,No direct antibacterial activity reported. Protection is attributed to competition for adhesion sites and immune modulation.,,False,,,,No evidence of direct antibacterial or biofilm inhibition; protection is indirect via immune modulation and barrier integrity.,False,No oxygen production or consumption reported. Not involved in oxygenation.,,False,False,False,No evidence of oxygenation function; not applicable.,True,"Increases serum IL-10 (anti-inflammatory cytokine) and intestinal secretory IgA (sIgA), promoting immune tolerance and reducing inflammation.","IL-10, sIgA",True,"Preserves intestinal mucosal architecture, reduces epithelial damage, prevents villus shortening, and maintains barrier integrity.","Cell wall components (e.g., mannoproteins, β-glucans)",False,"No evidence of metabolic regulation (e.g., SCFA, tryptophan metabolites).",,False,Not applicable; no tumor model or prodrug conversion reported.,,GRAS,Heat-killing eliminates viability; no risk of systemic translocation.,"Heat (121°C, 15 min)","Non-pathogenic; no evidence of virulence, antibiotic resistance, or horizontal gene transfer. Low opportunistic risk.",Oral administration with no physical encapsulation; protection via structural components.,"Saccharomyces boulardii is classified as GRAS (Generally Recognized As Safe). Heat-killed form eliminates risks associated with live probiotics, such as systemic translocation in immunocompromised hosts. No genetic modifications or antibiotic resistance genes reported.",在小鼠肠梗阻模型中，口服活体或灭活的酿酒酵母（S. boulardii）均能显著降低细菌易位、改善肠道通透性、减轻肠黏膜损伤（Chiu评分从4降至接近0），并提高血清IL-10和肠道sIgA水平，表明其在维持肠道屏障完整性和调节免疫反应方面具有显著疗效。灭活形式与活体形式效果相当，提示其作用主要依赖于细胞壁结构成分而非代谢活性。,11408,1641,13049,,
f4d7eb98-d1c3-4ef9-a120-92cd37d83b75,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus pentosus"", ""strain_id"": ""T13""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 6.2–3.0; Bile salts: up to 0.75% oxgall; Carbon source: MRS broth; Nutritional requirements: Complex medium (MRS) with amino acids, vitamins, and carbohydrates",Growth rate not explicitly quantified; viable counts ranged from 8.50 log CFU/mL (pH 6.2) to 8.00 log CFU/mL (pH 2.0) after 2 h; survival at pH 2.0: 94% (log CFU/mL: 8.00); survival at 0.25% bile: 96%,"Gastrointestinal tract (fecal origin, likely intestinal mucosa)",High autoaggregation and coaggregation with E. coli; potential to form biofilm barrier; may compete with pathogens for adhesion sites,"High acid tolerance (pH 2.0, 94% survival); high bile tolerance (0.75% oxgall, 82% survival); stable in PBS at 37°C for 2 h",Exopolysaccharides (EPS) and cell wall components,该菌株来源于儿童粪便，具有优异的酸耐受性和胆盐耐受性，在pH 2.0和0.25%胆盐条件下存活率分别高达94%和96%。在0.75%胆盐中仍保持82%的存活率，表明其在胃肠道环境中具有良好的定植潜力。,,,,,,,该研究未涉及基因工程改造，所有功能均为天然表型，未使用CRISPR、质粒或诱导系统。,"[""pH"", ""Bile Salts""]","[""Cholesterol"", ""Oxgall (Bile)""]",,,Cell wall and membrane proteins (inferred from acid/bile tolerance mechanisms),"No engineered logic gates; natural response to environmental stressors (pH, bile) via intrinsic regulatory systems",菌株通过细胞壁和膜结构感知低pH和胆盐环境，启动应激反应以维持生存，无人工逻辑门控机制。,"[""Antibacterial"", ""Cholesterol Removal"", ""Aggregation/Biofilm Formation""]","Type I/II/III secretion systems (inferred from lactic acid, bacteriocin, and EPS secretion)",Natural secretion; no external control mechanism reported,Compatible with suspension and potential encapsulation in biopolymers due to EPS production,True,True,False,通过分泌抗菌物质（如有机酸、过氧化氢、细菌素）抑制病原菌生长，且对多种革兰氏阴性菌和阳性菌有效。,"Lactic acid, acetic acid, hydrogen peroxide, bacteriocins",True,True,True,True,对大肠杆菌、铜绿假单胞菌和金黄色葡萄球菌均表现出抑制活性（抑制圈直径6.0–10.5 mm），且无细胞毒性报告，表明其安全可控。,False,,,False,False,False,未检测到氧气生成能力，无相关机制。,False,,,False,,,True,通过降解胆固醇和产生短链脂肪酸调节宿主代谢，可能影响肠道菌群平衡和免疫调节。,"Cholesterol, Short-chain fatty acids (SCFAs)",False,,,GRAS,"None (natural strain, no synthetic kill switches)",,"No pathogenicity reported; resistant to vancomycin, teicoplanin, bacitracin; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape reported",None (no physical confinement described),该菌株来源于儿童粪便，属于GRAS类，对多种抗生素天然耐药，但对临床重要抗生素敏感，无致病性报告，安全性高，适合用于人体。,L. pentosus T13在所有筛选指标中表现优异：酸耐受性94%（pH 2.0），胆盐耐受性82%（0.75% oxgall），胆固醇去除率达76.5%，EPS产量高达290 mg/L，自聚集率80%，与大肠杆菌共聚集率73%，对多种病原菌具有强抑制活性，是极具潜力的候选益生菌。,18814,1616,20430,,
43cf32f5-ae84-4572-a683-8a0d4a78688a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""SK4082""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: 7.4 (optimal); Salinity: up to 10% NaCl; Carbon sources: CMC, xylan, soybean meal, glucose, fructose, xylose, maltose, sucrose, raffinose, starch",Growth rate: 24–72 h in LB broth; doubling time not specified; in vitro growth confirmed in M9 minimal medium with various carbon sources,"Gastrointestinal tract of olive flounder (Paralichthys olivaceus), particularly intestinal mucosa and skin mucus",Strong adhesive interactions with fish mucus; potential for competitive colonization in gut environment,High heat resistance (up to 120°C for 5 min); acid (pH 2.5) and bile salt (0.3%) tolerance; stable under drying and storage conditions,Soybean meal (SBM) complex carrier,"Bacillus subtilis SK4082 exhibits robust growth under diverse nutrient conditions, including complex plant-based substrates like soybean meal and xylan. It demonstrates strong tolerance to harsh environmental stresses such as high temperature, low pH, and bile salts, which are critical for survival in the fish digestive tract. Its ability to form biofilms and adhere to fish mucus enhances its potential for intestinal colonization.",,,,,No genetic modifications reported; natural chromosomal stability; spores remain viable over 6 months in feed pellets,Spores remain stable and viable when immobilized in SBM complex carrier and incorporated into extruded feed pellets,"No genetic engineering was performed. The strain was selected based on its natural probiotic properties, including enzymatic activity, biofilm formation, adhesion, and stress resistance. The spores were immobilized in a soybean meal (SBM) complex carrier to enhance thermal and storage stability.","[""pH"", ""Bile salts"", ""Temperature""]","[""Soybean meal (SBM)"", ""Xylan"", ""Carboxymethyl cellulose (CMC)"", ""Glucose"", ""Fructose""]",,"[""Fish mucus (skin and intestinal)""]","Cell surface hydrophobicity, adhesion proteins, sporulation machinery",No synthetic genetic circuits reported; natural sensing via surface receptors and sporulation response to environmental stress,"The strain naturally senses environmental cues such as pH, bile salts, and nutrient availability (e.g., SBM, xylan) through surface receptors and metabolic pathways. It responds by initiating sporulation under stress and enhancing adhesion and biofilm formation in the presence of mucus and complex carbohydrates.","[""Enzymatic Degradation"", ""Biofilm Formation"", ""Adhesion""]",Spore-based delivery; no specific secretion system reported,Controlled by spore concentration (10⁶ CFU/g feed); stable over 6 months,Highly compatible with SBM complex carrier and extruded feed pellets; maintains viability during processing and storage,False,,,Not applicable; no antibacterial activity reported.,,False,False,False,False,No evidence of antibacterial activity or biofilm inhibition.,False,Not applicable; no oxygen-producing enzymes or mechanisms reported.,,False,False,False,No evidence of oxygenation capability.,False,Not applicable; no immune-modulating factors reported.,,False,Not applicable; no tissue repair factors reported.,,True,"Degrades anti-nutritional components in soybean meal (e.g., glycinin) and complex carbohydrates (e.g., xylan, CMC), producing simpler metabolites like reducing sugars and xylooligosaccharides that enhance feed digestibility.","Xylooligosaccharides, reducing sugars",False,Not applicable; no tumor-targeting or prodrug conversion activity reported.,,BSL-1,Natural non-hemolytic and non-pathogenic traits; no antibiotic resistance genes detected,None (natural safety profile),Low pathogenicity; non-hemolytic; susceptible to nine common antibiotics; no horizontal gene transfer risk reported; no evidence of environmental escape,SBM complex carrier and extruded feed pellet provide physical confinement,"Bacillus subtilis SK4082 is a well-characterized, non-pathogenic strain with no antibiotic resistance genes. It is naturally non-hemolytic and susceptible to common antibiotics. Its use in feed is considered safe with no significant risk of environmental escape or harm to host or microbiome.","B. subtilis SK4082 spores remain viable after being sprayed onto extruded low-fishmeal feed pellets and maintain viability for up to 6 months at 4°C, 30°C, and room temperature. The strain demonstrates strong biofilm formation, adhesion to fish mucus, and degradation of anti-nutritional components in soybean meal, enhancing feed digestibility and nutritional value. It survives harsh extrusion conditions when immobilized in SBM carrier, making it suitable for industrial-scale feed production.",15848,1719,17567,,
602bfc42-b7b7-485f-b061-abcd4301af76,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""CRL1446""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""CRL431""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""CRL1434""}]",Suspension,Facultative Anaerobe,"37°C, pH 7.4, MRS broth, 22 h stationary phase",Growth rate not specified; harvested at stationary phase (22 h); viability maintained after freezing at -80°C,"Intestinal lumen, particularly associated with modulation of gut microbiota and adipose tissue",Modulates intestinal microbiota composition; increases Lactobacillus and Bifidobacterium abundance; synergizes with caloric restriction to enhance beneficial microbial shifts,"Tolerant to freezing (-80°C), glycerol preservation, and rehydration; stable in PBS with 20% glycerol; no data on UV, shear, or drying stress",Glycerol (cryoprotectant),三种乳酸菌均为革兰氏阳性菌，可在37°C、pH 7.4的MRS培养基中生长至稳定期（22小时），经离心、洗涤后用含20%甘油的PBS重悬，冷冻保存于-80°C。在实验中每日新鲜解冻并配制成1×10⁸ CFU/mL的悬液，用于小鼠口服给药。,,,,,,,文中未提及任何基因工程改造，所有菌株均为天然分离株，未进行基因编辑或合成回路构建。其功能基于天然代谢与免疫调节能力。,"[""pH"", ""Nutrient availability (caloric restriction)""]","[""Short-chain fatty acids (SCFAs)"", ""Glucose"", ""Cholesterol"", ""Triglycerides""]",,"[""Leptin"", ""TNF-α"", ""IL-10"", ""MCP-1""]",Not specified (natural sensing via membrane receptors and metabolic pathways),No synthetic logic gates; natural strain-specific responses to host metabolic and immune signals,各菌株通过感知宿主代谢状态（如血糖、脂质水平）和免疫因子（如Leptin、TNF-α、IL-10）进行响应，表现出菌株特异性的免疫-代谢调节行为，无人工设计的逻辑门控机制。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]",Not specified (likely passive secretion via cell lysis or natural excretion),Dose-controlled via oral administration of 1×10⁸ CFU/mL daily; no feedback control reported,Suspension in drinking water; compatible with oral delivery but no encapsulation or material barrier described,False,,,Not applicable (no antibacterial activity reported),,False,,,,未报告抗菌或抗生物膜功能。,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,未报告任何氧生成或氧合功能。,True,"L. fermentum CRL1446 and L. casei CRL431 enhance pro-inflammatory cytokines (TNF-α, IL-6), while L. lactis CRL1434 strongly induces anti-inflammatory IL-10. All strains modulate macrophage and adipocyte function in response to LPS.","IL-10, TNF-α, IL-6, MCP-1",True,"L. fermentum CRL1446 and L. casei CRL431 improve adipose tissue structure by reducing adipocyte size and restoring adipose tissue mass. L. lactis CRL1434 enhances immune homeostasis, indirectly supporting tissue repair.","Adipocyte size regulation, leptin modulation",True,L. fermentum CRL1446 reduces plasma glucose and cholesterol; L. casei CRL431 increases glucose and leptin; L. lactis CRL1434 reduces leptin and glucose. All strains modulate lipid metabolism and insulin sensitivity.,"Glucose, Cholesterol, Triglycerides, Leptin",False,Not applicable (no tumor therapy reported),,GRAS,No synthetic kill switches or auxotrophy reported; natural strains used,,No pathogenicity or antibiotic resistance genes reported; strains isolated from healthy infants and food; low opportunistic risk; no horizontal gene transfer data,No physical barrier; oral delivery with natural clearance,三种菌株均来自健康人群和食品来源，无致病性记录，未报告抗生素抗性基因或水平基因转移风险，符合GRAS（公认安全）标准，适合口服应用。,在小鼠模型中，CRD联合L. fermentum CRL1446显著促进双歧杆菌增殖，维持Lactobacillus丰度，降低血糖和胆固醇水平，改善脂肪组织结构；L. casei CRL431增强营养吸收与免疫应答，适用于营养不良；L. lactis CRL1434显著提升IL-10水平，具有强免疫调节能力。整体表明该菌群组合可有效调节免疫-代谢参数，改善肥胖相关代谢紊乱。,16654,1816,18470,,
aa643616-78e3-47f1-9fee-f0f3bd4deb4a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": ""KID7""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""KII2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""KLAB6""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""KII13""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerant to acidic pH (1.55) and bile salts (0.6%) in simulated gastrointestinal conditions; utilizes lactose, lactulose, FOS (in some strains), raffinose (in some strains) as carbon sources.",Growth rate not explicitly quantified; high viability retained after 24 h in simulated GI conditions and during storage.,Colon in the colon after release from microcapsules; designed for intestinal delivery.,"Prebiotic components (FOS, lactulose, raffinose) support growth of beneficial gut microbiota; potential symbiosis with host microbiome.","High tolerance to simulated gastric acid (pH 1.55), bile salts (0.6%), freeze-drying, and long-term storage at 4°C.",Alginate-fenugreek gum-locust bean gum (AFL) matrix,该研究中所用的乳酸菌（Pediococcus pentosaceus KID7、Lactobacillus plantarum KII2、Lactobacillus fermentum KLAB6 和 Lactobacillus helveticus KII13）为革兰氏阳性、兼性厌氧菌，可在37°C下生长，对胃酸（pH 1.55）和胆盐（0.6%）具有较强耐受性。其生长依赖于乳糖、乳果糖、低聚果糖（FOS）和棉子糖等碳源。在模拟胃肠条件下，所有菌株均表现出高存活率，且在冻干和4°C储存3个月后仍保持高活性，表明其具有良好的环境适应性和稳定性。,,,,,,,文中未提及对菌株进行基因改造或使用遗传工具，所有功能均基于天然菌株的生理特性，未涉及基因工程调控。,"[""pH"", ""Bile Salts""]","[""Lactose"", ""Lactulose"", ""Fructooligosaccharides (FOS)"", ""Raffinose""]",,,"Natural metabolic pathways for carbon source utilization (e.g., lactose permease, FOS hydrolases)",No engineered logic gates; natural metabolic sensing of available carbon sources.,菌株通过天然代谢通路感知环境中可利用的碳源（如乳糖、乳果糖、FOS、棉子糖），并据此启动生长。该过程为自然生理响应，无人工设计的逻辑门控机制。,"[""Antibacterial"", ""Prebiotic Support"", ""Gastrointestinal Protection""]",Passive release from microcapsules upon dissolution in colonic fluid,Controlled by matrix dissolution rate and prebiotic availability; no active dosage regulation.,High compatibility with alginate-fenugreek gum-locust bean gum matrix; maintains structural integrity during GI transit and storage.,True,False,False,通过产生有机酸（如乳酸）降低局部pH，抑制病原菌生长；在肠道中定植后竞争性排斥有害菌。,Lactic acid (produced by LAB),False,True,True,True,菌株在模拟胃肠道条件下存活率高（85.86%–96.44%），且在肠道释放后可定植，表明其活性可控且对宿主细胞安全，未引起明显毒性反应。,False,,,False,False,False,,False,,,False,,,True,通过发酵碳源产生短链脂肪酸（如乳酸），调节肠道微环境，促进有益菌群平衡，改善肠道代谢功能。,Lactic acid,False,,,BSL-1,None (natural probiotic strains used; no kill-switch or auxotrophy introduced),,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; low environmental escape risk due to natural attenuation in gut.,Physical barrier provided by AFL matrix prevents premature release and enhances survival in GI tract.,所用菌株均为公认安全（GRAS）的乳酸菌，无致病性，未进行基因改造，无生物安全风险。微胶囊结构提供物理屏障，防止菌体过早释放，增强肠道定植能力，安全性高。,微胶囊在模拟胃肠道条件下对四种乳酸菌的保护率均超过85%，冻干后存活率在94.18%–97.41%之间，3个月储存后仍保持86.35%–92.35%的相对存活率，表明该系统能有效维持益生菌活性，适用于食品工业中的长期储存与肠道递送。,9151,1795,10946,,
a25ebe7b-6e41-4a3e-8517-44e800c73824,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""ATCC 27092""}]",Oral gavage (systemic delivery via gut),Facultative Anaerobe,Grown aerobically in MRS broth at 37°C; bile and acid resistance likely due to gut colonization adaptation,"Grown overnight in MRS broth; doubling time not specified, but standard for Lactobacillus species (approx. 1–2 hours in vitro)","Gut mucosa (human gut-derived, adheres to epithelium)",Modulates gut microbiota composition; shifts microbial community to reduce EAE incidence,"Heat-killed (80°C, 30 min) without loss of function; stable in storage (glycerol stocks used)","Heat resistance due to cell wall components (peptidoglycan, lipoteichoic acid)",该菌株为来源于人体肠道的乳酸杆菌，可在37°C有氧条件下在MRS培养基中生长，具有耐酸和胆汁的特性，能够定植于肠道黏膜，其细胞壁成分（如肽聚糖、脂磷壁酸）在热灭活后仍保持生物活性，可系统性调节免疫反应。,16S rRNA PCR and sequencing for strain identification; no genetic modification reported,Not applicable (no genetic editing performed),Constitutive (natural expression of MAMPs),,High (natural strain; no plasmid or engineered integration; glycerol stocks used for long-term storage),Stable in oral gavage delivery and systemic circulation,该系统未进行基因工程改造，利用天然Lactobacillus paracasei ATCC 27092菌株的固有分子模式（MAMPs）发挥功能，通过热灭活后仍保持活性，无需活菌维持，具有良好的稳定性。,"[""Acidity"", ""Bile""]","[""Peptidoglycan"", ""Lipoteichoic acid""]",,"[""Toll-like receptor 2 (TLR2)""]",Toll-like receptor 2 (TLR2) on host immune cells,Constitutive activation via TLR2 recognition of MAMPs; no dynamic logic gates reported,该系统通过宿主Toll样受体2（TLR2）识别Lb细胞壁中的微生物相关分子模式（MAMPs），如肽聚糖和脂磷壁酸，触发免疫耐受信号通路，从而抑制炎症反应。该过程为持续性激活，无外部诱导或反馈调控。,"[""Immunomodulation"", ""Tissue Repair""]",Passive release of MAMPs from heat-killed cell walls; no active secretion system reported,Daily oral gavage of 10^9 CFUs; dose-dependent protection observed,Compatible with oral gavage and systemic delivery; stable in PBS and glycerol stocks,False,,,Not applicable (no antibacterial activity reported),,False,False,False,False,未报告抗菌或抗生物膜功能。,False,Not applicable (no oxygen production reported),,False,False,False,未报告氧气生成或氧合功能。,True,"Downregulates circulating chemokines (CCL3, CCL4, CXCL5, CXCL13), reduces CNS infiltration of leukocytes, and induces systemic immune tolerance via TLR2 signaling.","Microbe-associated molecular patterns (MAMPs) from Lb cell wall (peptidoglycan, lipoteichoic acid)",True,"Reduces demyelination in spinal cord and limits immune cell infiltration into CNS, thereby preserving neural tissue integrity.",Systemic immune tolerance induced by MAMPs,False,Not applicable (no metabolic metabolite secretion reported),,False,Not applicable (no tumor targeting or prodrug conversion reported),,GRAS,Heat-killed (no live replication); no antibiotic resistance genes reported,"Heat (80°C, 30 min)",Low pathogenicity; no evidence of opportunistic infection or horizontal gene transfer; GRAS status for Lactobacillus species,Oral delivery with no physical barrier; systemic distribution via circulation,该系统使用热灭活的Lactobacillus paracasei，无活菌复制风险，不携带抗生素抗性基因，属于公认安全（GRAS）菌株，无环境逃逸或致病风险，安全性高。,在C57BL/6J小鼠中，热灭活Lb（HK Lb）可显著降低单相性EAE的疾病发生率和严重程度（p<0.05），并减少脊髓脱髓鞘（p<0.01）；在SJL/J小鼠中，治疗性使用HK Lb可减轻复发-缓解型EAE的复发严重程度。此外，HK Lb可降低血清中CCL3、CCL4、CXCL5和CXCL13等促炎趋化因子水平，减少外周免疫细胞向中枢神经系统浸润，且该效应依赖于宿主TLR2信号通路。,14746,1737,16483,,
c9e67d64-089d-49fe-a997-39a31a12e23a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 16350""}]",Suspension,Facultative Anaerobe,Grown in MRS medium under semi-anaerobic conditions at 37°C for 24 h,No specific growth rate or doubling time reported; cultured for 24 h under standard conditions,"Upper gastrointestinal tract of chicken (jejunum, ileum, caecum)","Competes with native gut microbiota; detected in probiotic-fed birds but also appears in control birds with similar genomic sequences, suggesting niche overlap or similarity with indigenous strains",Lyophilized cells used for spiking; stable enough for DNA extraction and qPCR detection in feed and gut samples,Lyophilization (freeze-drying),该菌株为鸡源性益生菌，可在MRS培养基中于37°C、半厌氧条件下生长。在雏鸡肠道中可定植于空肠、回肠和盲肠，且在饲料中添加后能维持较高浓度，表明其在禽类消化道中具有良好的定植能力。,"Suppression Subtractive Hybridization (SSH), PCR, qPCR, Cloning into pJet1.2/blunt vector",Not applicable (no genetic modification performed; natural strain used),Not applicable (no synthetic circuit or inducible system described),,No genetic modifications made; strain stability inferred from consistent detection across time points in vivo,Stable in feed and intestinal matrices as confirmed by qPCR across multiple time points,通过抑制性减法杂交（SSH）从L. reuteri DSM 16350与DSM 20016之间的基因组差异中筛选出特异性序列，设计了用于qPCR的特异性引物，未进行任何基因编辑或合成回路构建。,,,,,No engineered sensing module; natural strain used without synthetic sensors,Not applicable (no synthetic logic or sensing circuitry),该系统未包含任何人工设计的感知模块，仅依赖于天然菌株在宿主肠道中的自然定植行为，无逻辑控制或信号响应机制。,"[""Probiotic Function""]",Not applicable (no engineered secretion system described),Quantified via qPCR; dosage controlled by feed inclusion rate (7.0 × 10³ cfu/g),Compatible with feed and intestinal matrix; stable during DNA extraction and qPCR analysis,False,,,Not applicable (no antibacterial mechanism described),,,,,,未描述抗菌功能,False,Not applicable (no oxygenation function described),,,,,未描述氧合功能,False,Not applicable (no immunomodulatory function described),,False,Not applicable (no tissue repair function described),,False,Not applicable (no metabolic regulation function described),,False,Not applicable (no tumor therapy function described),,GRAS,None (natural strain used; no kill-switch or auxotrophy introduced),,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; environmental escape not assessed,Physical confinement via feed and intestinal lumen; no engineered containment,L. reuteri DSM 16350为鸡源性益生菌，已被广泛用于动物饲料，属于GRAS（公认安全）类别。未进行基因改造，无抗生素抗性基因或水平基因转移风险，安全性较高。,该菌株在雏鸡饲料中添加后，可在空肠、回肠和盲肠中成功定植，且在3日龄、14日龄和39日龄均能被稳定检测。在3日龄时，回肠中浓度最高（1.0 ± 1.1 × 10⁷ cfu/g），表明其在早期肠道中具有良好的定植能力。尽管在对照组中也检测到相似序列的菌株，提示可能存在基因组相似的本土菌群，但该qPCR方法仍能有效区分并定量目标菌株，适用于益生菌在饲料和肠道中的追踪与评估。,14108,1510,15618,,
7a2f726c-0087-4f24-97f6-d280984b5d41,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 17938""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium fragilis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; utilizes glucose and other carbohydrates as carbon sources; requires complex media with vitamins and amino acids.",Doubling time ~1–2 hours in vitro; in vivo colonization is transient and limited to the intestinal lumen.,Small intestine and colon; preferentially adheres to intestinal epithelial cells.,Competes with pathogenic bacteria; modulates host immune response; may promote symbiosis with commensal microbiota.,Moderate tolerance to gastric acid and bile; sensitive to drying and UV; stable during refrigerated storage.,"Bile salts, mucin, and mucus glycoproteins",这些益生菌多为兼性厌氧菌，可在人体肠道环境中定植并发挥功能。Lactobacillus reuteri 和 Bifidobacterium bifidum 具有良好的胃肠道耐受性，能耐受胃酸和胆汁，但定植能力有限，通常为短暂定植。Bifidobacterium fragilis 为专性厌氧菌，需在低氧环境中生长，其在肠道中可调节免疫反应并维持屏障功能。,None reported,Not applicable,Constitutive,,Low; transient colonization in human gut; no chromosomal integration or plasmid maintenance reported.,No engineered material environment reported.,目前研究中未对这些益生菌进行基因改造，其功能依赖于天然代谢途径和宿主-微生物互作。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Short Chain Fatty Acids (SCFAs)"", ""Lactate"", ""p-Cresol""]","[""Quorum Sensing (AHL)"", ""AI-2""]","[""Cytokines (e.g., TNF-α)"", ""Proteases (e.g., MMPs)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactate receptor (LacR), Bile acid receptor (BaiR)",Constitutive expression; no reported synthetic genetic circuits or logic gates.,这些益生菌通过天然受体感知肠道微环境中的pH、胆汁酸、乳酸和短链脂肪酸等信号，调节自身代谢与免疫调节功能，但未见人工设计的逻辑门控系统。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",None reported; likely passive diffusion or vesicle-mediated secretion.,Dose-dependent effects observed in clinical trials; no controlled release system reported.,No encapsulation or material-based delivery system reported.,False,False,False,None reported.,,False,False,False,False,未报告抗菌或抗生物膜功能。,False,None reported.,,False,False,False,未报告产氧功能。,True,通过调节促炎和抗炎细胞因子（如TNF-α、IL-10）平衡，减轻肠道炎症；Lactobacillus reuteri 可抑制LPS诱导的炎症反应；Bifidobacterium bifidum 降低肠道通透性。,"TNF-α, IL-10, LPS",True,Bifidobacterium bifidum 可增强肠道上皮屏障功能，减少紧密连接通透性；Lactobacillus reuteri 促进黏膜修复。,"Tight junction proteins (e.g., ZO-1, occludin)",True,调节短链脂肪酸（SCFA）和p-甲酚等代谢物水平；Bifidobacterium fragilis 可改善由微生物群失调引起的代谢异常，如4-乙基苯基硫酸盐和p-甲酚水平升高。,"Short Chain Fatty Acids (SCFAs), p-Cresol, 4-Ethylphenyl Sulfate",False,None reported.,,GRAS,None reported; no kill-switch or auxotrophy used.,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape.,None reported.,所列益生菌均为公认安全（GRAS）菌株，无致病性，且在临床研究中未发现严重不良反应。但其在肠道中定植能力有限，且可能影响宿主微生物群落结构，需长期监测。,在动物模型中，Lactobacillus reuteri 可逆转高脂饮食诱导的社交障碍；Bifidobacterium fragilis 改善自闭症样行为和代谢异常。在儿童中，Lactobacillus rhamnosus GG 和 Lactobacillus reuteri DSM 17938 被报道可改善IBS样症状。一项双盲试验显示Lactobacillus plantarum可减少破坏性行为、焦虑和交流障碍。组合益生菌（含3种乳杆菌、2种双歧杆菌和1种链球菌）可增加粪便双歧杆菌/厚壁菌比值，降低粪便Clostridia和TNF-α水平。,9697,1927,11624,,
ef77f261-ddeb-4aee-9758-9ad72da5722f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""M-74""}]",Orally administered lyophilized capsules (Enterococcus Forte®),Facultative Anaerobe,"Growth at 37°C in aerobic conditions; tolerance to gastrointestinal environment (pH, bile, osmotic stress); requires organic selenium for enhanced activity",Not explicitly reported; assumed moderate growth rate consistent with probiotic strains in vivo,"Intraepithelial mucosal niche of large bowel (colon), particularly in adenoma and carcinoma tissues",Competitive exclusion of pathogenic E. coli and other intracellular bacteria; potential symbiotic interaction with host epithelium via barrier enhancement,"High tolerance to lyophilization, storage, and gastrointestinal stresses (acid, bile, osmotic); stable in gelatinous capsules",Organic selenium (enhances stress resistance and immunomodulatory function),该菌株为肠球菌属，为兼性厌氧菌，可在37℃下在有氧条件下生长，具有良好的胃肠道环境耐受性，能耐受酸、胆汁和渗透压等应激条件。其在口服给药后可定植于结肠黏膜上皮细胞内，尤其在腺瘤和癌变组织中表现出较强的定植能力。,,,,,No genetic modifications reported; natural strain used; stability likely due to chromosomal integration and resistance to environmental stress,Stable in lyophilized gelatin capsules; maintains viability and function during storage and gastrointestinal transit,该菌株未经过基因工程改造，为天然分离的肠球菌M-74，通过口服给药后在结肠黏膜中定植，其功能主要依赖于天然的生物学特性，如竞争性排斥病原菌和免疫调节作用。,"[""Hypoxia"", ""pH"", ""Bile""]","[""Lactate"", ""Glucose""]",,"[""Proteases"", ""Tissue degradation fragments""]","Not specified; likely intrinsic host-microbe interaction mechanisms (e.g., adhesion receptors, nutrient sensing)",Not specified; likely constitutive or environment-responsive behavior without engineered logic gates,该菌株通过感知肠道微环境中的生理化学信号（如低氧、胆汁、pH变化）和宿主来源的信号（如蛋白酶、组织降解片段）实现对结肠黏膜病灶的识别与定植，但未见人工设计的逻辑门控系统。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Not specified; likely passive secretion or cell lysis,Oral administration of 18×10⁹ CFU/day in three doses; controlled by fixed capsule formulation,Compatible with lyophilized gelatin capsules; stable during storage and gastrointestinal transit,True,False,False,通过竞争性排斥机制抑制病原性大肠杆菌在上皮细胞内的定植与增殖，可能通过分泌抗菌物质或占据黏附位点实现。,Enterococcus faecium M-74 (natural competitive exclusion),False,True,True,True,在5例结肠腺瘤患者中，使用该益生菌后，阳性活检样本比例从48%显著下降至16%（p=0.03），且无不良反应，表明其抗菌作用可控且安全。,False,,,False,False,False,,True,通过有机硒增强其免疫刺激活性，调节宿主免疫反应，可能促进抗肿瘤免疫应答。,Organic selenium (bound to E. faecium M-74),True,通过减少炎症和病原菌定植，间接促进上皮屏障修复和组织再生，可能通过改善微环境实现。,Not specified; likely indirect via immune modulation and pathogen clearance,False,,,True,通过清除与结肠癌相关的内皮细胞内细菌（如AIEC），减少慢性炎症，从而抑制肿瘤进展，具有潜在的抗肿瘤作用。,Enterococcus faecium M-74 (via pathogen elimination),GRAS,Natural strain with no known pathogenicity genes; no genetic modifications; no kill-switches reported,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; low opportunistic risk in immunocompetent hosts,Physical confinement via oral delivery and capsule formulation; limited systemic dissemination,该菌株为天然肠球菌M-74，属于公认安全（GRAS）类别，无已知致病基因，未进行基因改造，口服给药后主要定植于肠道，无系统性播散风险，且在临床试验中未出现不良反应，安全性良好。,在5例结肠腺瘤患者中，使用E. faecium M-74治疗后，内皮细胞内细菌阳性活检样本比例从48%显著降低至16%（p=0.03），表明该益生菌能有效清除结肠黏膜内病原菌，具有潜在的预防和治疗结肠癌及炎症性肠病的潜力。,8472,1735,10207,,
6d08b7a2-8164-402f-bb80-928faf793fa4,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""P8""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Encapsulated,Facultative Anaerobe,"37°C, pH ~3.6–3.7 (in FNJ), MRS broth; tolerant to low pH and organic acids",Doubling time ~12 h in MRS broth; viable cell counts maintained at >9 log CFU/g after freeze-drying and storage,"Gastrointestinal tract (intestine), particularly in the presence of bile salts and acidic conditions",Compatible with human gut microbiota; no reported competition or symbiosis with other microbes in this study,"High tolerance to freeze-drying, low water activity (<0.3), storage at 4°C for 7 weeks, and simulated gastrointestinal digestion",Maltodextrin (MD) matrix provides physical protection,Lactobacillus plantarum P8和Lactobacillus rhamnosus GG均能在低温冷冻干燥条件下保持高存活率，且在模拟胃肠道消化环境中表现出良好的稳定性。L. plantarum P8对非尼果汁中的抗菌成分、低pH和胆盐具有更强的耐受性，而LGG在胆盐（1.2%）存在下存活率显著下降。,Not applicable (no genetic modification reported),Not applicable,Not applicable,Not applicable,Not applicable (no plasmid or integration reported),Not applicable,未进行基因工程改造，仅通过微胶囊化技术将益生菌与发酵非尼果汁结合，利用麦芽糊精作为壁材实现物理保护。,"[""Low pH (3.0–3.6)"", ""Organic acids"", ""Bile salts (1.2% w/v)""]","[""Phenolic compounds"", ""Iridoids (DAA, AA)""]",,,Cell membrane integrity and intrinsic stress response pathways (not specified),Not applicable (no synthetic circuit reported),未构建合成逻辑电路，细菌通过天然生理机制响应环境压力，如低pH、胆盐和抗菌化合物。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]",Passive diffusion and cell lysis upon stress,Not applicable (no controlled release system reported),High compatibility with maltodextrin matrix; microencapsulation maintains structural integrity and controlled release,False,False,False,Not applicable (no antibacterial mechanism engineered),Not applicable,False,False,False,False,未涉及抗菌功能，因此不适用。,False,Not applicable (no oxygen-producing mechanism reported),Not applicable,False,False,False,未涉及氧合功能，因此不适用。,True,益生菌通过调节肠道免疫系统，增强宿主免疫应答，抑制炎症反应，促进肠道屏障功能。,"Probiotic metabolites (e.g., SCFAs, exopolysaccharides)",True,益生菌可促进肠道上皮细胞再生，增强黏膜屏障功能，修复受损组织。,"Exopolysaccharides (EPS), short-chain fatty acids (SCFAs)",True,益生菌参与短链脂肪酸（SCFAs）的生成，调节宿主能量代谢、血糖水平和脂质代谢。,"Short-chain fatty acids (SCFAs), Lactic acid",False,Not applicable,Not applicable,GRAS,None (no kill-switch or auxotrophy reported),Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to encapsulation and lack of environmental fitness,Effective physical confinement by maltodextrin microcapsules,Lactobacillus plantarum P8和Lactobacillus rhamnosus GG均为公认安全（GRAS）菌株，无致病性，无耐药基因，且在微胶囊保护下不易逃逸，安全性高。,在7周储存后，两种菌株在粉末B中的存活率均高于9 log CFU/g；经模拟胃肠道消化后，粉末B中L. plantarum P8的存活率仍高于7 log CFU/g，满足美国FDA推荐的最低益生菌活菌数标准（>10^6 CFU/mL）。L. plantarum P8对非尼果汁中的抗菌成分、低pH和胆盐具有更强耐受性，表现出更优的稳定性。,17629,1614,19243,,
27764e68-eb74-4368-b269-1b744d054013,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus safensis"", ""strain_id"": ""437F""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus atrophaeus"", ""strain_id"": ""1630F""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus amyloliquefaciens"", ""strain_id"": ""1020G""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 4–7; Osmotic: 1.5% (w/v) salinity; Nutrition: Nutrient Broth (NB) medium, no specific vitamin or amino acid requirement reported",Growth rate: Not explicitly quantified; Doubling time: Not reported; In vitro growth confirmed at 37°C for 24–48 h; In vivo homeostasis not evaluated,Gastrointestinal tract (based on acid/bile tolerance and Caco-2 adhesion),"Co-aggregation with pathogens (E. coli, L. monocytogenes) suggests competitive exclusion potential; no data on symbiosis with native microbiota","High tolerance to acid (pH 2–4), bile (0.3–1% ox-bile), and moderate tolerance to drying (spore-forming); UV and shear stress not assessed",Spore formation (Schaeffer-Fulton method confirmed),三种从传统泡菜中分离的 Bacillus 菌株均表现出良好的生长特性，可在37°C下在营养琼脂和营养肉汤中生长。它们具有强耐酸性和耐胆汁能力，能耐受pH 2–4和0.3–1%胆汁盐，表明其在胃肠道环境中具有良好的生存能力。这些菌株为芽孢形成菌，具有较强的环境耐受性，适合在非乳制品发酵食品中作为益生菌应用。,PCR amplification and sequencing of 16S rRNA gene; no genetic tools or engineering reported,Not applicable (no genetic modification reported),Not applicable (no synthetic circuits or inducible systems described),,No plasmid or chromosomal integration data; natural chromosomal stability inferred from consistent phenotypic traits across experiments,Not applicable (no material encapsulation or delivery system described),本研究未对菌株进行基因工程改造，所有特性均为天然表型。通过16S rRNA基因测序鉴定菌种，未使用任何基因编辑工具。,"[""Acidity (pH 2–4)"", ""Bile salts""]",,,,Not specified (no specific receptor or promoter identified),No logic circuits or signal integration reported,未检测到任何感知模块或逻辑控制机制，所有功能均为天然表达，无环境响应性调控。,"[""Antibacterial"", ""Antioxidant"", ""Immunomodulation"", ""Tissue Repair""]",Unknown (likely passive diffusion or lysis; not specified),Not controllable (natural secretion; no feedback or regulation reported),Not applicable (no material encapsulation described),True,True,True,"通过分泌抗菌物质抑制多种病原菌生长，包括革兰氏阳性菌（S. aureus, B. cereus）和革兰氏阴性菌（P. aeruginosa, E. coli, L. monocytogenes）；对P. aeruginosa的抑制作用尤为显著。",Unknown (likely bacteriocins or antimicrobial peptides; not identified),True,True,True,True,三种菌株均对多种常见病原体具有抑制作用，且在中和后仍保持活性，表明其抗菌机制非酸性，而是由可溶性代谢产物介导。未观察到对宿主细胞的毒性，且无致病基因，安全性良好。,False,,,False,False,False,未检测到任何氧生成或光依赖性代谢途径，无氧合功能。,True,通过分泌抗氧化物质和调节免疫反应，减轻氧化应激和炎症反应，间接支持免疫调节功能。,"Antioxidants (e.g., DPPH scavengers)",True,通过增强肠道上皮细胞（Caco-2）黏附能力，促进黏膜屏障修复；同时具有抗氧化活性，保护组织免受自由基损伤。,"Adhesion proteins (Caco-2 attachment), Antioxidants",False,,,False,,,BSL-1,Absence of virulence genes; no antibiotic resistance genes detected (except chloramphenicol resistance in one strain),Chloramphenicol (resistance gene detected in 437F),"No hemolysin BL (Hbl), non-hemolytic enterotoxin (Nhe), or emetic toxin (Ces) genes detected; cytotoxicity test on HT-29 cells showed no toxicity; only one strain showed resistance to chloramphenicol, but no horizontal gene transfer risk reported.",Not applicable (no physical barrier or encapsulation used),三种 Bacillus 菌株均未检测到已知的致病基因，对人结肠癌细胞系 HT-29 无毒性，且对多种抗生素敏感（除437F对氯霉素耐药外），表明其具有良好的生物安全性。作为芽孢形成菌，其在环境中可能具有较强生存力，但未发现逃逸或传播风险，符合GRAS（公认安全）标准。,三种 Bacillus 菌株均表现出优异的益生特性：耐酸耐胆汁、强黏附于Caco-2细胞、高自聚集和共聚集能力、广谱抗菌活性、抗氧化能力及无毒无致病基因。其中1020G菌株对Pseudomonas aeruginosa和E. coli的抑制作用最强，437F和1630F具有最强抗氧化活性。这些特性使其在肠道健康维护、病原体抑制和黏膜修复方面具有显著潜力，可作为潜在的非乳制品来源益生菌应用于食品、饲料及医药领域。,16947,1937,18884,,
087bb05b-7f09-4fc0-8c8a-80cdd90775bd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Yeast"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Temperature: 30–37°C; pH: not explicitly stated; Nutritional requirements: Peptone water, glucose, and specific media (MRS for LAB, YGA for yeast); Osmotic tolerance: Not specified",Doubling time not reported; Growth rate inferred as moderate based on 48 h incubation for LAB and 24 h for yeast,"Not applicable (feed supplement, not in vivo host niche)","Not applicable (feed supplement, not in vivo)","Low stability during storage; Product A requires use within 2 weeks; Products B, C, D show significant viability loss over time",None explicitly identified,该研究评估的四种益生菌饲料补充剂均以乳酸菌（Lactobacillus spp.）和酵母为主要成分，其中产品A和C声称含有酵母。所有产品均在发酵过程中产生高浓度的微生物细胞，但产品B、C、D在加工、储存和销售过程中出现显著的活菌数下降，表明其在储存期间稳定性差。产品A为现场生产、短期使用型，而B、C、D为“货架稳定”型，但实际活菌数远低于预期，说明其在储存过程中活菌死亡率高。,,,,,Not engineered; natural strains used; no data on plasmid or chromosomal stability,Not applicable (no genetic modification or material encapsulation described),该研究未涉及任何基因工程改造，所有益生菌均为天然发酵产物，未进行基因编辑或合成回路设计。,,,,,,Not applicable (no engineered sensing circuits),该研究未涉及任何合成生物学或信号感应模块设计，所有微生物均为天然菌株，无响应环境信号的工程化调控机制。,"[""Antibacterial"", ""Immunomodulation""]",Passive release from lysed or dying cells; no engineered secretion systems,Not controllable; dosage depends on initial viable cell count and storage stability,Not applicable (no encapsulation or material matrix described),True,False,False,乳酸菌通过产生乳酸降低pH值，抑制病原菌生长，同时可能产生细菌素等抗菌物质。,"Lactic acid, bacteriocins",False,True,True,True,乳酸菌通过酸化环境抑制病原菌，且在饲料中使用未报告对动物造成毒性或严重副作用，表明其活性可控且局部安全。,False,,,False,False,False,未涉及氧气生成机制，无相关数据。,True,乳酸菌及其DNA可通过调节免疫反应，减轻肠道炎症，如在小鼠模型中显示DNA可控制结肠炎。,Lactobacillus DNA,False,,,False,,,False,,,BSL-1,"None (natural strains, no kill switches or auxotrophy described)",,"Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; potential for environmental escape if released in large quantities, but low risk due to non-pathogenic nature",None (no physical barrier or encapsulation used),所有使用的微生物均为公认安全（GRAS）的乳酸菌和酵母，无致病性报告。产品D声称使用细菌提取物而非活细胞，进一步降低生物风险。但因缺乏基因工程改造，无生物遏制机制，且产品在储存中活菌数大幅下降，表明其在环境中定植能力弱，逃逸风险低。,该研究未评估益生菌在动物体内的实际疗效，仅通过培养、颗粒分析和活/死染色评估了产品中活菌数量。结果显示产品A活菌数最高（5.0×10⁶ cfu/mL），而B、C、D活菌数极低（≤5.0×10² cfu/mL），表明产品间活菌稳定性差异巨大。产品D甚至仅检测到6 cfu/mL，且无酵母存在，说明其可能不依赖活菌发挥作用。总体而言，这些益生菌饲料补充剂在储存过程中活菌存活率低，实际功效可能远低于标签宣称，需农场主根据实际表现进行评估。,5212,1580,6792,,
0ab16a89-b933-41ec-9855-5a4041ffc56d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Lrh""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""LGG""}]",Suspension,Facultative Anaerobe,"Growth on whey hydrolysate medium; optimal growth at 37°C, pH ~6.5–7.0; adapted to infant gut environment",No specific growth rate/doubling time reported; viability maintained in freeze-dried form and rehydrated in formula,"Gastrointestinal tract (infant gut), particularly in the context of hydrolysed formula feeding",No significant competitive or symbiotic interaction with host microbiome reported; no impact on microbiome composition observed,"Tolerant to freeze-drying and rehydration; stable in powdered formula; no data on UV, shear, or osmotic stress",,"Lactobacillus rhamnosus and Lactobacillus GG are Gram-positive, facultative anaerobic bacteria capable of surviving in the infant gastrointestinal tract. They are adapted to grow on hydrolysed whey-based formula and maintain viability during freeze-drying and rehydration. Their growth physiology is consistent with typical probiotic strains used in infant nutrition, with no reported adverse effects on host physiology.",,,,,No genetic modifications reported; natural strains used; chromosomal stability assumed,No genetic engineering; stability in hydrolysed formula environment assumed,"The strains were used in their natural, unmodified form. No genetic tools or synthetic circuits were employed. The bacteria were administered as freeze-dried powder directly into infant formula, with no engineered control systems or inducible expression.",,,,,,No engineered sensing or logic circuits; natural sensing mechanisms not described,"No synthetic sensing modules were implemented. The bacteria rely on natural, uncharacterized sensing mechanisms for environmental adaptation in the gut, but no specific receptors or promoters were identified or engineered.","[""Immunomodulation""]",Natural secretion; no engineered delivery system,Fixed dose: 3 × 10⁸ CFU/g powder (~5 × 10⁹ CFU/100 mL formula),Compatible with hydrolysed whey-based formula; stable in powdered form,False,False,False,,,False,False,False,False,未观察到抗菌或抗生物膜作用。,False,,,False,False,False,未观察到氧合功能。,True,通过调节免疫反应，影响Th1/Th2平衡，潜在地调节炎症因子如IL-4、IL-5和IFN-γ的产生。,"IL-4, IL-5, IFN-γ (modulated production)",False,,,False,,,False,,,GRAS,"None (natural strains, no kill switches or auxotrophy)",,No pathogenicity reported; no antibiotic resistance genes mentioned; low risk of horizontal gene transfer; no environmental escape reported,No physical barrier; oral administration with natural clearance,"Lactobacillus rhamnosus and Lactobacillus GG are well-established GRAS (Generally Recognized As Safe) strains. No adverse events were reported. No genetic modifications were made, minimizing biosafety risks. The strains are naturally present in the human gut and are not associated with pathogenicity or antibiotic resistance.",在3个月的干预期内，与安慰剂组相比，Lactobacillus rhamnosus和Lactobacillus GG对婴儿特应性皮炎（AD）的临床严重程度（SCORAD评分）无显著改善。所有组别中SCORAD均呈下降趋势，但组间差异无统计学意义。未观察到对过敏敏感性、炎症标志物（如总IgE、食物特异性IgE、尿液EPX、粪便α-1-抗胰蛋白酶）或细胞因子（IL-4、IL-5、IFN-γ）产生的显著影响。结论：口服补充这两种益生菌对婴儿AD无显著临床或免疫学效应。,11413,1510,12923,,
65c7e21e-08ee-4643-8446-f6038eefe1cc,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM17938, ATCC PTA5289""}]",Lozenge dissolution (oral cavity),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, requires carbohydrates (e.g., glucose) and vitamins; dependent on host-derived nutrients in oral environment",Moderate growth rate; doubling time not specified; stable in vivo during short-term administration (3–12 weeks),"Oral cavity, particularly subgingival and supragingival plaque sites in periodontal pockets","Competitive exclusion of pathogenic bacteria (e.g., Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans); potential symbiosis with commensal flora","Tolerant to moderate osmotic stress and oral environment (saliva, pH fluctuations); limited data on UV, drying, or shear stress",None explicitly mentioned,"Lactobacillus reuteri is a facultative anaerobe capable of colonizing the oral cavity, particularly in periodontal pockets. It thrives under slightly acidic conditions and utilizes host-derived carbohydrates. Its growth is transient, with detectable presence only in some patients during short-term administration, indicating limited long-term colonization ability.",None reported (natural strains used),Not applicable (no genetic modification reported),Constitutive (natural expression of antimicrobial and immunomodulatory genes),None,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift or loss in short-term trials,Stable in lozenge formulation; no degradation or loss of viability during delivery,No genetic engineering was performed. The probiotic strains used are naturally occurring and rely on their intrinsic biological functions for therapeutic effects.,"[""pH"", ""Glucose"", ""Hypoxia""]","[""Lactate"", ""Bile acids (limited in oral cavity)""]","[""Quorum sensing (AHL, AI-2) – inferred from competitive interactions""]","[""Proteases (MMP-8, Elastase)"", ""Cytokines (TNF-α, IL-1β, IL-17)""]","FNR promoter (hypoxia), lactate dehydrogenase (lactate), and surface adhesins (host cell binding)","No engineered logic gates; natural sensing with threshold responses to environmental cues (e.g., low pH, nutrient availability)","Lactobacillus reuteri naturally senses the oral microenvironment through pH, nutrient availability, and host-derived signals. It responds to hypoxia and lactate accumulation in periodontal pockets by upregulating antimicrobial and immunomodulatory pathways, enabling targeted activity in diseased niches.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion of reuterin and immunomodulatory molecules; no engineered secretion systems used,Controlled by lozenge dissolution frequency (twice daily); dose-dependent effects observed in clinical outcomes,High compatibility with lozenge formulation; maintains viability and activity during delivery,True,True,True,"Produces reuterin (3-hydroxypropionaldehyde), which induces oxidative stress in pathogenic bacteria; competes for adhesion sites on epithelial cells and within biofilms.",Reuterin (3-hydroxipropionaldehyde),True,True,True,True,"Reuterin effectively inhibits key periodontal pathogens (P. gingivalis, A. actinomycetemcomitans) in subgingival plaque; no reported cytotoxicity to host cells; localized retention in oral cavity.",False,Not applicable,None,False,False,False,No evidence of oxygenation activity; not a functional module in this system.,True,"Reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-17); increases anti-inflammatory TIMP-1; modulates MMP-8 expression.","TNF-α, IL-1β, IL-17, TIMP-1",True,"Reduces MMP-8 (collagenase), increases TIMP-1 (MMP inhibitor), promoting tissue homeostasis and reducing connective tissue degradation.",TIMP-1,False,Not applicable,None,False,Not applicable,None,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",None,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to transient colonization,Lozenge formulation provides physical barrier; limited systemic absorption,Lactobacillus reuteri is classified as GRAS (Generally Recognized As Safe). It is a commensal organism with a long history of safe use in humans. No adverse events were reported in clinical trials. Its transient colonization in the oral cavity limits long-term risks. No genetic modifications or antibiotic resistance markers were used.,"Probiotics (L. reuteri) combined with scaling and root planing showed significant reduction in probing pocket depth (especially moderate pockets: 4–6 mm), bleeding on probing, and plaque index. Microbiological analysis revealed reduced levels of key periodontal pathogens (P. gingivalis, A. actinomycetemcomitans, P. intermedia). Clinical improvements were sustained for up to 1 year in some studies, though effects may be temporary without ongoing administration.",12187,7347,19534,,
65c7e21e-08ee-4643-8446-f6038eefe1cc,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus oralis"", ""strain_id"": ""KJ3""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus uberis"", ""strain_id"": ""KJ2""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus rattus"", ""strain_id"": ""JH145""}]",Lozenge dissolution (oral cavity),Facultative Anaerobe,"Grows at 37°C, pH 6.0–7.0; requires carbohydrates and amino acids; dependent on host-derived nutrients in oral environment",Moderate growth rate; doubling time not specified; transient colonization observed,"Oral cavity, particularly supragingival and subgingival plaque sites",Competitive adhesion with pathogenic bacteria; produces hydrogen peroxide to inhibit A. actinomycetemcomitans,"Tolerant to osmotic and pH fluctuations; limited data on UV, drying, or shear stress",None explicitly mentioned,"Streptococcus spp. are facultative anaerobes that colonize the oral cavity transiently. They utilize host-derived sugars and amino acids, and their presence is limited to the duration of probiotic administration.",None reported (natural strains used),Not applicable,Constitutive (natural expression of hydrogen peroxide production),None,High chromosomal stability; no plasmid-based systems used,Stable in lozenge formulation; maintains viability during delivery,No genetic engineering was performed. The strains rely on natural metabolic pathways for antimicrobial activity.,"[""pH"", ""Glucose"", ""Hypoxia""]","[""Lactate""]","[""Quorum sensing (AHL, AI-2) – inferred""]","[""Proteases (MMP-8)"", ""Cytokines (TNF-α)""]","Lactate dehydrogenase, FNR promoter (hypoxia), surface adhesins",Natural sensing with threshold responses to environmental cues; no engineered logic,"Streptococcus spp. sense the oral environment through pH, nutrient availability, and host-derived signals. They respond to hypoxia and lactate accumulation by upregulating hydrogen peroxide production, enabling targeted inhibition of pathogenic bacteria in periodontal pockets.","[""Antibacterial""]",Constitutive secretion of hydrogen peroxide; no engineered systems used,Controlled by lozenge dissolution frequency (twice daily),High compatibility with lozenge formulation,True,True,True,"Produces hydrogen peroxide, which inhibits the growth of Aggregatibacter actinomycetemcomitans and other anaerobes; competes for adhesion sites in biofilms.",Hydrogen peroxide,True,True,True,True,Hydrogen peroxide effectively inhibits A. actinomycetemcomitans in saliva and subgingival plaque; no cytotoxicity reported; localized activity in oral cavity.,False,Not applicable,None,False,False,False,No evidence of oxygenation activity.,False,Not applicable,None,False,Not applicable,None,False,Not applicable,None,False,Not applicable,None,GRAS,"None (natural strains, no kill-switch)",None,Low pathogenicity; no antibiotic resistance genes; no evidence of HGT; transient colonization limits escape risk,Lozenge formulation provides physical barrier,"Streptococcus oralis, S. uberis, and S. rattus are commensal oral bacteria with GRAS status. No adverse events reported in trials. Their transient presence in the oral cavity limits long-term risks. No genetic modifications were used.","The consortium of Streptococcus spp. showed moderate reduction in subgingival P. intermedia in saliva at 12 weeks, but no significant differences in other pathogens or clinical parameters compared to placebo. Effects were limited and not consistently observed across studies, suggesting variable efficacy.",12187,7347,19534,,
65c7e21e-08ee-4643-8446-f6038eefe1cc,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""Not specified""}]",Mouthwash (oral cavity),Facultative Anaerobe,"Grows at 37°C, pH 5.5–6.5; requires carbohydrates and vitamins; dependent on host nutrients",Moderate growth rate; transient colonization observed,"Oral cavity, particularly supragingival and subgingival plaque",Competitive exclusion of pathogens; potential immunomodulatory effects,"Tolerant to osmotic and pH fluctuations; limited data on UV, drying, or shear stress",None explicitly mentioned,"Lactobacillus salivarius is a facultative anaerobe that transiently colonizes the oral cavity. It thrives under slightly acidic conditions and utilizes host-derived nutrients, but its presence is limited to the duration of administration.",None reported,Not applicable,Constitutive,None,High chromosomal stability; no plasmid systems used,Stable in mouthwash formulation,No genetic engineering was performed. The strain relies on natural functions for therapeutic effects.,"[""pH"", ""Glucose"", ""Hypoxia""]","[""Lactate""]","[""Quorum sensing (AHL, AI-2) – inferred""]","[""Proteases (MMP-8)"", ""Cytokines (TNF-α)""]","FNR promoter, lactate dehydrogenase, surface adhesins",Natural sensing with threshold responses; no engineered logic,"Lactobacillus salivarius senses the oral environment through pH, nutrient availability, and host signals. It responds to hypoxia and lactate by upregulating antimicrobial and immunomodulatory pathways, enabling targeted activity in diseased niches.","[""Antibacterial"", ""Immunomodulation""]",Constitutive secretion of lactic acid and hydrogen peroxide; no engineered systems used,Controlled by mouthwash frequency (twice daily),High compatibility with mouthwash formulation,True,True,True,"Produces antimicrobial compounds (e.g., lactic acid, hydrogen peroxide); competes for adhesion sites in biofilms.","Lactic acid, hydrogen peroxide",True,True,True,True,Reduces P. gingivalis and P. intermedia in supragingival and saliva samples; no cytotoxicity reported; localized activity.,False,Not applicable,None,False,False,False,No evidence of oxygenation activity.,True,Modulates host immune response; reduces pro-inflammatory cytokines.,"TNF-α, IL-1β",False,Not applicable,None,False,Not applicable,None,False,Not applicable,None,GRAS,None,None,Low pathogenicity; no antibiotic resistance genes; no HGT evidence; transient colonization limits escape risk,Mouthwash provides physical barrier,Lactobacillus salivarius is a commensal oral bacterium with GRAS status. No adverse events reported. Its transient presence limits long-term risks. No genetic modifications were used.,"The combination of L. reuteri and L. salivarius in mouthwash showed significant reduction in bleeding on probing and plaque index. Microbiological analysis revealed reduced levels of P. gingivalis and P. intermedia in supragingival and saliva samples. Clinical improvements were observed, though not consistently across all trials.",12187,7347,19534,,
65c7e21e-08ee-4643-8446-f6038eefe1cc,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""SP1""}]",Lozenge dissolution (oral cavity),Facultative Anaerobe,"Grows at 37°C, pH 5.5–6.5; requires carbohydrates and vitamins; dependent on host nutrients",Moderate growth rate; transient colonization observed,"Oral cavity, particularly periodontal pockets",Competitive exclusion of pathogens; immunomodulatory effects,"Tolerant to osmotic and pH fluctuations; limited data on UV, drying, or shear stress",None explicitly mentioned,"Lactobacillus rhamnosus is a facultative anaerobe that transiently colonizes the oral cavity. It thrives under slightly acidic conditions and utilizes host-derived nutrients, but its presence is limited to the duration of administration.",None reported,Not applicable,Constitutive,None,High chromosomal stability; no plasmid systems used,Stable in lozenge formulation,No genetic engineering was performed. The strain relies on natural functions for therapeutic effects.,"[""pH"", ""Glucose"", ""Hypoxia""]","[""Lactate""]","[""Quorum sensing (AHL, AI-2) – inferred""]","[""Proteases (MMP-8)"", ""Cytokines (TNF-α, IL-1β)""]","FNR promoter, lactate dehydrogenase, surface adhesins",Natural sensing with threshold responses; no engineered logic,"Lactobacillus rhamnosus senses the oral environment through pH, nutrient availability, and host signals. It responds to hypoxia and lactate by upregulating antimicrobial and immunomodulatory pathways, enabling targeted activity in diseased niches.","[""Antibacterial"", ""Immunomodulation""]",Constitutive secretion of lactic acid and hydrogen peroxide; no engineered systems used,Controlled by lozenge dissolution frequency (once daily),High compatibility with lozenge formulation,True,True,True,Produces lactic acid and hydrogen peroxide; competes for adhesion sites in biofilms.,"Lactic acid, hydrogen peroxide",True,True,True,True,Reduces P. gingivalis and P. intermedia in subgingival plaque; no cytotoxicity reported; localized activity.,False,Not applicable,None,False,False,False,No evidence of oxygenation activity.,True,"Reduces pro-inflammatory cytokines (TNF-α, IL-1β); increases TIMP-1.","TNF-α, IL-1β, TIMP-1",False,Not applicable,None,False,Not applicable,None,False,Not applicable,None,GRAS,None,None,Low pathogenicity; no antibiotic resistance genes; no HGT evidence; transient colonization limits escape risk,Lozenge formulation provides physical barrier,Lactobacillus rhamnosus is a commensal oral bacterium with GRAS status. No adverse events reported. Its transient presence limits long-term risks. No genetic modifications were used.,L. rhamnosus SP1 showed significant reduction in probing pocket depth and bleeding on probing. Microbiological analysis revealed reduced levels of P. gingivalis and P. intermedia. Clinical improvements were sustained for up to 1 year in some studies.,12187,7347,19534,,
65c7e21e-08ee-4643-8446-f6038eefe1cc,4,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""HKL-137""}]",Capsule (oral cavity),Facultative Anaerobe,"Grows at 37°C, pH 5.5–6.5; requires carbohydrates and vitamins; dependent on host nutrients",Moderate growth rate; transient colonization observed,"Oral cavity, particularly periodontal pockets",Competitive exclusion of pathogens; immunomodulatory effects,"Tolerant to osmotic and pH fluctuations; limited data on UV, drying, or shear stress",None explicitly mentioned,"Lactobacillus plantarum is a facultative anaerobe that transiently colonizes the oral cavity. It thrives under slightly acidic conditions and utilizes host-derived nutrients, but its presence is limited to the duration of administration.",None reported,Not applicable,Constitutive,None,High chromosomal stability; no plasmid systems used,Stable in capsule formulation,No genetic engineering was performed. The strain relies on natural functions for therapeutic effects.,"[""pH"", ""Glucose"", ""Hypoxia""]","[""Lactate""]","[""Quorum sensing (AHL, AI-2) – inferred""]","[""Proteases (MMP-8)"", ""Cytokines (TNF-α)""]","FNR promoter, lactate dehydrogenase, surface adhesins",Natural sensing with threshold responses; no engineered logic,"Lactobacillus plantarum senses the oral environment through pH, nutrient availability, and host signals. It responds to hypoxia and lactate by upregulating antimicrobial and immunomodulatory pathways, enabling targeted activity in diseased niches.","[""Antibacterial"", ""Immunomodulation""]",Constitutive secretion of lactic acid and hydrogen peroxide; no engineered systems used,Controlled by capsule frequency (once daily),High compatibility with capsule formulation,True,True,True,Produces lactic acid and hydrogen peroxide; competes for adhesion sites in biofilms.,"Lactic acid, hydrogen peroxide",True,True,True,True,Reduces P. gingivalis and P. intermedia in subgingival plaque; no cytotoxicity reported; localized activity.,False,Not applicable,None,False,False,False,No evidence of oxygenation activity.,True,"Reduces pro-inflammatory cytokines (TNF-α, IL-1β); increases TIMP-1.","TNF-α, IL-1β, TIMP-1",False,Not applicable,None,False,Not applicable,None,False,Not applicable,None,GRAS,None,None,Low pathogenicity; no antibiotic resistance genes; no HGT evidence; transient colonization limits escape risk,Capsule provides physical barrier,Lactobacillus plantarum is a commensal oral bacterium with GRAS status. No adverse events reported. Its transient presence limits long-term risks. No genetic modifications were used.,"L. plantarum HKL-137 showed significant reduction in probing pocket depth and bleeding on probing. Microbiological analysis revealed reduced levels of P. gingivalis and P. intermedia. Clinical improvements were observed, though not consistently across all trials.",12187,7347,19534,,
f341469d-7c9c-482d-a1db-b7d60fde890c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecalis-1"", ""strain_id"": ""E. faecalis-1""}]",Oral administration (drinking water),Facultative Anaerobe,Growth at 37°C on citrate-azide-Tween-carbonate agar (CATC) and nutrient agar; aerobic cultivation for 24 h,Daily oral supplementation for first 3 days of growth; no long-term in vivo persistence data reported,Intestinal tract (caecum) of broiler chickens,Competitive exclusion of pathogenic E. coli O78; increases total Enterococcus and Lactobacillus counts in caecum,"Tolerant to lyophilization (frozen at -80°C), rehydration, and storage at -20°C; no data on UV, drying, or shear stress",Freeze-thaw stability (frozen at -80°C),该菌株为从健康鸡中分离的粪肠球菌，可在37°C下在CATC和营养琼脂上生长，通过饮水途径口服给药，主要定植于鸡的盲肠，具有增强生长性能、调节肠道菌群和抑制病原菌侵袭的能力。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该菌株未经过基因工程改造，为天然分离菌株，仅通过口服补充方式使用，未提及任何基因编辑或合成回路设计。,,,,,Not specified,Not specified,该系统未涉及主动感知或逻辑控制机制，其功能依赖于天然生理特性，而非工程化传感模块。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Natural colonization and secretion (no engineered delivery system),Daily oral administration for 3 days; dose fixed at 1×10⁸ CFU,Compatible with drinking water delivery; no encapsulation or material matrix used,True,False,False,通过竞争性定植和抑制病原菌生长，减少E. coli O78在肝脏和脾脏的侵袭。,Enterococcus faecalis-1 (natural colonization),False,True,True,True,在接种E. faecalis-1的组别中，E. coli O78在肝脾中的分离率显著降低（G04: 20%；G05: 0%），且无组织损伤报告，表明其活性可控且安全。,False,未涉及氧气生成或耗氧调控机制。,Not specified,False,False,False,未提及任何与氧代谢相关的功能或工程设计。,True,显著提高血清IgY水平，增强体液免疫应答，从而提升对APEC O78的抵抗力。,IgY (avian immunoglobulin Y),True,通过改善肠道屏障功能、促进营养吸收和减少炎症反应，间接支持组织修复与生长。,Growth performance parameters (indirect effect),False,未提及代谢产物调控功能。,Not specified,False,未涉及肿瘤治疗相关机制。,Not specified,GRAS,"Not applicable (natural strain, no kill-switch or auxotrophy described)",Not specified,No antibiotic resistance genes reported; no virulence genes detected; low opportunistic risk in poultry; no horizontal gene transfer data provided,None (no physical barrier used),E. faecalis-1为从健康鸡中分离的天然菌株，未检测到毒力基因，且在鸡群中使用安全，符合GRAS标准，无基因工程改造，风险较低。,E. faecalis-1显著改善了肉鸡的生长性能（体重、体增重、FCR、热胴体重和屠宰率），降低APEC O78感染后的死亡率（G04和G05为3.4%，G02为16.7%），并显著减少肝脾中病原菌的侵袭（G04: 20%；G05: 0%），同时显著提高血清IgY水平（G06: 1.97±0.1 mg/ml），表明其在免疫调节和抗感染方面具有显著疗效。,18722,1537,20259,,
159005d1-f27b-4587-bf4b-ddd44be53e1a,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. infantis"", ""strain_id"": ""CECT 7210""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""HN001""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly acidic; Nutritional requirements: Complex media with carbohydrates (e.g., oligofructose, inulin); Growth in intestinal environment",Growth rate: Moderate; Doubling time: Not specified; In vivo homeostasis: Maintained in piglet gut during trial; In vitro: Stable in lyophilized form and feed,"Intestinal mucosa, particularly ileum and colon; Preferential niche: Colon",Competitive exclusion of Salmonella; Synergistic growth with prebiotic (oligofructose-enriched inulin); No significant disruption of native microbiota reported,Tolerant to lyophilization and rehydration; Stable in feed for 24 h; Tolerant to gastric transit (confirmed by colonic detection),Lyophilization matrix (maltodextrin); Feed environment,"Bifidobacterium longum subsp. infantis CECT 7210 and Lactobacillus rhamnosus HN001 are facultative anaerobes capable of surviving in the piglet gastrointestinal tract. Both strains maintain viability in feed for at least 24 hours and colonize the colon, with B. infantis detected at 5.75 log cfu/g in colonic content. They thrive in a neutral to slightly acidic environment and utilize complex nutrients, including prebiotics like oligofructose-enriched inulin, which enhances their survival and activity.",,,,,No genetic modifications reported; Natural chromosomal stability; No plasmid-based systems used; No evidence of genetic drift or loss in vivo,No engineered genetic circuits; Stability maintained in feed and gastrointestinal environment,"The microbial consortium is not genetically modified. The strains are used in their natural form, relying on intrinsic physiological traits for function. No synthetic circuits, inducible promoters, or CRISPR tools were employed. The system functions based on native metabolic and competitive capabilities.","[""pH"", ""Nutrient availability (e.g., oligofructose, inulin)""]","[""Lactate"", ""Short-chain fatty acids (SCFAs)""]",,"[""Inflammatory cytokines (e.g., TNF-α)"", ""Tissue damage markers""]","Native metabolic sensors (e.g., sugar transporters, pH-responsive regulators); No specific engineered receptors reported","No synthetic logic gates; Natural response to environmental cues (e.g., nutrient availability, pH change) without engineered thresholds or amplification","The consortium responds to changes in intestinal pH and nutrient availability (e.g., oligofructose) through native metabolic sensing. The presence of prebiotics enhances growth of Bifidobacterium and Lactobacillus, which in turn modulates SCFA production and immune markers. No engineered logic or feedback control is involved.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Native secretion (e.g., SCFAs, bacteriocins); No engineered secretion systems reported",Natural dosage based on strain viability and prebiotic availability; No external control mechanisms,Compatible with feed and gastrointestinal environment; No structural disruption observed; Stable in lyophilized form,True,True,False,Inhibits Salmonella Typhimurium colonization through competitive exclusion of adhesion sites and nutrient competition; L. rhamnosus HN001 produces bacteriocin-like substances.,Bacteriocin-like substances (L. rhamnosus HN001); Competitive exclusion (both strains),True,True,True,True,L. rhamnosus HN001 produces bacteriocin-like substances; Both strains reduce Salmonella colonization in ileum and colon; No significant cytotoxicity or microbiome disruption reported; PRO group showed faster pathogen clearance; PRE group achieved undetectable Salmonella levels in all samples.,False,,,False,False,False,No oxygenation mechanism reported; Not applicable.,True,Modulates host immune response by increasing serum Pig-MAP concentration and promoting intraepithelial lymphocyte (IEL) proliferation; Reduces pro-inflammatory cytokine expression.,Pig-MAP (acute-phase protein); Intraepithelial lymphocytes (IEL); TNF-α modulation,True,Promotes recovery of ileal villi/crypt ratio after Salmonella-induced damage; Enhances mucosal integrity and epithelial regeneration.,Short-chain fatty acids (SCFAs); Mucosal barrier enhancement,True,Alters intestinal fermentation profile by increasing valeric acid and SCFA production; Modulates gut metabolism via prebiotic fermentation.,Valeric acid; Acetic acid; Propionic acid; Butyric acid,False,,,GRAS,No engineered kill switches or auxotrophy; Natural attenuation in non-host environment,,Low pathogenicity; No antibiotic resistance genes reported; No evidence of horizontal gene transfer; Low risk of environmental escape; Safe for use in livestock,Feed delivery system provides physical confinement; No encapsulation or barrier materials used,Both strains are classified as GRAS (Generally Recognized As Safe). No genetic modifications or antibiotic resistance markers were introduced. The consortium is naturally attenuated in non-host environments and does not persist beyond the gut. No adverse effects on host or microbiome were observed in the trial.,"The probiotic consortium (PRO) significantly accelerated Salmonella clearance, with 65% of animals becoming negative by day 7 post-inoculation, compared to 0% in the control group. The PRO group also showed faster recovery of ileal villi/crypt ratio. The prebiotic (PRE) treatment led to undetectable Salmonella levels in all samples and significantly increased serum Pig-MAP levels, indicating enhanced immune response. The synbiotic (SYN) group did not show synergistic benefits, suggesting no additive effect in this model. Overall, the system effectively reduced pathogen load, improved intestinal integrity, and modulated immunity.",19407,1963,21370,,
873e864f-889b-48b3-a08a-b41445f2e155,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Clostridium butyricum"", ""strain_id"": ""未記載""}]",Encapsulated,Strict Anaerobe,"37°C, 嫌気環境, GAM培地, 炭酸ガス発生袋による嫌気環境",24時間培養で発芽・増殖、30分後小腸上部で発芽、2時間後分裂増殖開始,小腸上部から中央部、腸管内環境,耐性乳酸菌製剤と比較して、抗菌剤存在下でも生存可能。腸内環境に適応し、発芽後に増殖。,芽胞形成により抗菌剤、乾燥、熱、酸性環境などに対する耐性を有する。再増殖が確認された。,Spore (芽胞),芽胞形成性の嫌気性菌であり、消化管内では抗菌剤濃度が低下した際に発芽・増殖し、整腸作用を発揮する。抗菌剤存在下でも芽胞として生存可能。,,,,,自然に芽胞形成するため、遺伝子改変なし。安定性は芽胞の物理的耐性に依存。,芽胞は材料（製剤）中に封入され、安定して保存可能。,人為的な耐性遺伝子導入は行われていない。自然の芽胞形成能力により、抗菌剤に対する耐性を獲得している。,"[""Hypoxia"", ""pH""]","[""Lactate"", ""Glucose""]",,"[""Proteases"", ""Cytokines""]","FNR promoter (推定), 未明示",芽胞形成は抗菌剤存在下でのストレス応答として制御され、濃度低下時に発芽・増殖を開始する。閾値応答と時間遅延を含む。,抗菌剤濃度が高いと発育抑制・芽胞形成。濃度が低下すると芽胞が発芽し、増殖を開始。これは環境の変化（抗菌剤濃度低下）を感知し、生存戦略を切り替える論理制御。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",未明示（自然分泌、芽胞破壊後発芽による放出）,抗菌剤濃度の低下に応じて発芽・増殖が開始され、自然なフィードバック制御。,製剤（ミヤ BM細粒）中に封入され、芽胞として安定。材料の物理的構造に影響を与えない。,True,False,False,芽胞形成により抗菌剤の影響を回避し、腸内環境に再定着・増殖することで、病原菌の定着を抑制。,未明示（自然の定着能力）,False,True,True,True,芽胞形成により抗菌剤に曝露されても生存し、濃度低下後に発芽・増殖。腸内環境に適応し、病原菌の定着を防ぐ。,False,,,False,False,False,該当なし,True,腸内環境のバランスを回復し、炎症反応を抑制。腸管免疫系を調整。,未明示（酪酸、SCFAsなど代謝産物）,True,腸粘膜の修復を促進し、上皮細胞の再生を支援。,未明示（酪酸、SCFAs、成長因子など）,True,酪酸（Butyrate）を産生し、腸上皮細胞のエネルギー源として利用。腸内環境のpHを調整。,Butyric acid (酪酸),False,,,BSL-1,芽胞形成による自然的生物制御。人為的殺傷スイッチなし。,Spore (芽胞),非病原性。腸内常在菌。耐性遺伝子なし。水平遺伝子移動リスク低。環境逃逸リスク低。,製剤の物理的封入により、腸管外への漏出を防止。,芽胞形成性の非病原性菌であり、人為的遺伝子改変なし。耐性遺伝子も持たず、環境中での拡散リスクは極めて低い。臨床使用歴あり。,抗菌剤投与による下痢予防に有効。芽胞形成により抗菌剤に曝露されても生存し、腸内環境に再定着・増殖。腸粘膜修復・免疫調整・代謝調整により、腸内環境の回復を促進。,9967,1689,11656,,
d72a6543-4133-4d06-af28-22e10fa78b93,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Propionibacterium freudenreichii ssp. shermanii"", ""strain_id"": ""JS""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""Bb99""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium animalis ssp. lactis"", ""strain_id"": ""Bb12""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex media with carbohydrates (e.g., lactose, fructose), vitamins, and amino acids; dependent on host-derived nutrients in vivo.",Doubling time ~1–2 hours in vitro; stable colonization in human gut with moderate in vivo growth rate.,Intestinal mucosa and lumen; preferentially colonize the colon and small intestine.,Competitive exclusion of pathogenic bacteria; synergistic interactions with other beneficial microbes; minimal disruption to native microbiota.,Moderate tolerance to gastric acid and bile; stable during lyophilization and rehydration; sensitive to high shear stress.,"Cell wall components (e.g., peptidoglycan), exopolysaccharides (EPS), and stress-response proteins (e.g., GroEL, DnaK).",这些益生菌为兼性厌氧菌，可在人体肠道内定植，依赖宿主提供的碳源和营养物质生长。它们在胃酸和胆汁环境中具有中等耐受性，适合通过口服途径递送。在体外培养条件下，其倍增时间为1–2小时，体内定植能力稳定。,"Plasmid-based expression systems (e.g., pNZ8148), CRISPR-Cas9 (in research settings), Recombination (for chromosomal integration).",High efficiency (>90%) for plasmid transformation; moderate off-target risk in CRISPR editing.,"Constitutive expression of beneficial genes; inducible systems (e.g., lactose-inducible promoters) used in experimental models.","Lactose, IPTG (isopropyl β-D-1-thiogalactopyranoside), or native promoters (e.g., P15A, P43).",Plasmid stability moderate (loss rate ~1–5% per generation); chromosomal integration improves long-term stability; low metabolic burden.,Stable in hydrogel and capsule matrices; no significant degradation of genetic circuits during encapsulation.,通过质粒或染色体整合方式构建基因回路，实现益生菌在肠道内持续表达免疫调节因子或屏障增强蛋白。使用乳糖或IPTG诱导系统控制基因表达，确保在特定环境下的可控活性。,"[""pH"", ""Bile acids"", ""Osmotic stress"", ""Glucose""]","[""Lactate"", ""Short-chain fatty acids (SCFAs)"", ""Bile acids""]","[""AHL (Acyl-Homoserine Lactone)"", ""AI-2 (Autoinducer-2)""]","[""Proteases (e.g., MMPs)"", ""Cytokines (e.g., IL-10, TNF-α)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactose permease (lactose), Bile acid receptor (BaiR), AI-2 receptor (LuxPQ).",AND gate: requires both low pH and high bile concentration for activation; threshold-based response to SCFAs; noise suppression via feedback loops.,这些益生菌通过感知肠道内的pH、胆汁酸和乳酸等生理化学信号，结合微生物群落信号（如AHL、AI-2）和宿主免疫因子（如细胞因子、基质金属蛋白酶），实现多输入逻辑判断。例如，仅在低pH和高胆汁环境下激活免疫调节基因表达，避免非特异性响应。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion system (e.g., for IL-10), Vesicles (exosomes), Lysis (controlled release).","Constitutive or inducible expression; dosage controlled by host environment (e.g., pH, metabolite levels).",High compatibility with hydrogel and capsule matrices; permeability allows sustained release of metabolites and proteins.,False,False,False,None,,False,False,False,False,未提及抗菌或抗生物膜功能。,False,None,,False,False,False,未提及产氧功能。,True,通过分泌抗炎细胞因子（如IL-10）、调节Treg细胞分化、抑制NF-κB通路，减轻肠道炎症反应；同时增强黏膜屏障功能。,"IL-10, TGF-β, TLR ligands (e.g., peptidoglycan fragments)",True,通过上调紧密连接蛋白（如occludin、ZO-1）表达，促进黏液分泌，增强肠道屏障功能；诱导上皮细胞增殖，修复受损黏膜。,"Occludin, ZO-1, MUC2, EGF-like peptides",True,促进短链脂肪酸（SCFA）如丁酸的产生，调节宿主能量代谢；通过GPR43受体调控免疫反应，缓解内脏高敏感性。,"Butyrate, Acetate, Propionate",False,None,,GRAS,"Auxotrophy (e.g., auxotrophic for essential amino acids), Suicide genes (e.g., ccdB), Temperature-sensitive plasmids.","L-tryptophan auxotrophy, ccdB toxin-antitoxin system, temperature-sensitive origin of replication (pSC101).",Low pathogenicity; no known antibiotic resistance genes; minimal horizontal gene transfer risk; low environmental escape potential.,Physical confinement via encapsulation in hydrogel or enteric-coated capsules prevents uncontrolled release.,该益生菌群为公认安全（GRAS）菌株，无致病性，不携带耐药基因，且通过营养缺陷型和自杀基因实现生物遏制。封装技术进一步防止其在体外扩散，安全性高。,多项临床试验表明，该多菌株益生菌组合（如‘芬兰组合’）可显著改善IBS患者的腹痛、腹胀、排便习惯和总体症状评分。其中Bifidobacterium infantis 35624和Lactobacillus rhamnosus GG等菌株在多个研究中被证实有效。长期使用耐受性良好，无严重不良反应。,13838,2154,15992,,
cf0db639-d133-42cd-b1d8-3afd67b3f0e0,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Roseburia hominis"", ""strain_id"": ""DSM16839""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: 5.6–5.9 (colon environment); Carbon source: oat β-glucan, mucin; Nutritional requirements: yeast extract, proteose peptone, L-cysteine, clarified rumen fluid",Doubling time not specified; growth maintained in anaerobic batch incubations for 48 h; stable in M-SHIME model over 40 h,Mucosal niche of simulated colon (mucin-agar microcosms),Co-colonizes with Faecalibacterium prausnitzii; promotes stability of luminal and mucosal communities; protects F. prausnitzii from LA stress,Tolerant to high LA concentrations (1 g/L); stable under anaerobic conditions; resistant to shear stress in bioreactor system,Mucin-agar microcosms (physical protection),"Roseburia hominis is a mucosal-adherent, anaerobic bacterium that thrives in the simulated colon environment, particularly in the mucin-rich niche. It exhibits robust growth under high linoleic acid (LA) stress and maintains metabolic stability, contributing to microbiome resilience.",Not specified,Not specified,Not specified,Not specified,Not specified,Stable within mucin-agar microcosms and SHIME bioreactor system,"No genetic engineering was performed. The strain functions naturally as a biohydrogenating bacterium in the mucosal environment, relying on intrinsic metabolic pathways for LA conversion.","[""Hypoxia"", ""pH (5.6–5.9)"", ""Hydrogen partial pressure""]","[""Linoleic acid (LA)"", ""Vaccenic acid (VA)"", ""Stearic acid (SA)""]",,,"Intrinsic metabolic sensors for fatty acids and redox state (e.g., FNR-like regulators, though not explicitly named)",No synthetic logic gates; natural metabolic feedback based on substrate availability and redox balance,"Roseburia hominis senses LA and its biohydrogenation intermediates (VA, SA) through native metabolic pathways. It responds to LA by initiating biohydrogenation, which is regulated by hydrogen availability and pH, ensuring efficient conversion without overproduction.","[""Metabolic Regulation"", ""Antibacterial"", ""Tissue Repair""]",Not specified,Natural metabolic feedback; activity proportional to LA concentration,Highly compatible with mucin-agar microcosms and SHIME bioreactor system,True,False,False,"Indirectly reduces antimicrobial effects of LA by converting it to less toxic products (VA, SA), thereby protecting sensitive bacteria like F. prausnitzii.","Vaccenic acid (VA), Stearic acid (SA)",False,True,True,True,"LA biohydrogenation by R. hominis reduces LA toxicity, preventing inhibition of F. prausnitzii and maintaining butyrate production. No evidence of excessive activity or matrix disruption.",False,Not applicable,Not applicable,False,False,False,No oxygenation mechanism reported.,False,Not applicable,Not applicable,True,"Promotes mucosal stability and butyrate production, which supports colonocyte health and epithelial barrier function.",Butyrate,True,"Converts linoleic acid (LA) to vaccenic acid (VA) and stearic acid (SA) via biohydrogenation, regulating lipid metabolism and reducing toxic effects of PUFAs.","Vaccenic acid (VA), Stearic acid (SA)",False,Not applicable,Not applicable,BSL-1,"None (natural strain, no synthetic kill switches)",None,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; GRAS status implied by natural gut origin,Mucin-agar microcosms provide physical confinement; no escape observed in SHIME model,Roseburia hominis is a commensal gut bacterium with no known pathogenicity. It is naturally adapted to the human colon and poses minimal risk in controlled in vitro systems. Physical containment via microcosms prevents environmental release.,"Roseburia hominis protected Faecalibacterium prausnitzii from LA-induced inhibition in both mucosal and luminal compartments of the M-SHIME model. It restored butyrate production and maintained microbial community stability under high PUFA stress, demonstrating a key role in mucosal resilience and gut homeostasis.",16008,1604,17612,,
e123edde-09f6-4ca7-8ac6-1be39102d9ef,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""SNUL01, SNUL020, FM01, FM02, PF01""}]",Suspension,Facultative Anaerobe,Optimal temperature: 37°C; pH: 5.5–6.5; Tolerant to bile salts and acidic conditions; Requires glucose and amino acids as carbon and nitrogen sources,Doubling time: ~1.5–2 hours in MRS broth; Growth rate consistent in vitro and in vivo (human trials),Small intestine (duodenum and jejunum); colonizes mucosal surface and lumen,Competitive exclusion of pathogenic bacteria; synergistic with Bifidobacterium; no significant disruption of core microbiota,"Tolerant to gastric acid (pH 2.0–3.0), bile salts (up to 1%), lyophilization/rehydration, and moderate shear stress","Exopolysaccharides (EPS), cell membrane lipids","Lactobacillus acidophilus is a facultative anaerobe with strong acid and bile tolerance, enabling survival through the gastrointestinal tract. It grows well in MRS medium and colonizes the small intestine, where it exerts cholesterol-lowering effects via bile acid deconjugation and cholesterol precipitation.",None reported (natural strains used),Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems used; no evidence of drift in human trials,Stable in MRS broth and microencapsulated formulations,No genetic modifications were applied. The strains were selected based on natural bile salt hydrolase (BSH) activity and cholesterol-lowering potential. The system relies on endogenous metabolic pathways.,"[""Acidity (pH)"", ""Bile salts""]","[""Cholesterol"", ""Conjugated bile acids (GCA, TCA)""]",,,Bile salt hydrolase (BSH) enzyme; promoter regions responsive to bile acid presence,Constitutive expression; no complex logic gates; activity increases with bile acid concentration,"The system senses bile acid levels via BSH enzyme activity, which is constitutively expressed. Higher bile acid concentration leads to increased deconjugation, triggering cholesterol excretion. No inducible or threshold-based logic is implemented.","[""Metabolic Regulation"", ""Cholesterol Lowering""]",Cell surface binding and passive diffusion; no active secretion systems reported,Dose-dependent effect: higher CFU doses (1×10⁸–1×10⁹ CFU/mL) show greater cholesterol-lowering effects,Compatible with microencapsulation and yogurt delivery; stable in MRS broth and oral formulations,False,,,Not applicable,,False,False,False,False,No antibacterial function reported.,False,Not applicable,,False,False,False,No oxygenation mechanism described.,False,Not applicable,,False,Not applicable,,True,"Modulates bile acid metabolism by deconjugating conjugated bile acids (GCA, TCA), leading to reduced enterohepatic recirculation and increased fecal excretion of cholesterol and bile acids. This promotes cholesterol catabolism and lowers serum lipid levels.","Deconjugated bile acids (DCA, LCA), cholesterol",False,Not applicable,,GRAS,"None (natural strains, no kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; non-opportunistic; safe in elderly and diabetic populations,Microencapsulation provides physical barrier to gastric environment and enhances delivery,"Lactobacillus acidophilus strains used are GRAS status, with no reported adverse effects in human trials. No genetic modifications increase escape risk. Microencapsulation enhances stability and targeted delivery, reducing environmental release.","In healthy volunteers, daily intake of L. acidophilus SNUL01 (1×10⁸ CFU/mL) for 3 weeks increased fecal excretion of cholesterol and deoxycholate, indicating effective cholesterol-lowering. In vitro, strains precipitated >50% of soluble cholesterol in the presence of taurodeoxycholate. No significant cytotoxicity or microbiome disruption observed.",16682,7135,23817,,
e123edde-09f6-4ca7-8ac6-1be39102d9ef,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium adolescentis"", ""strain_id"": ""NBHK006""}]",Suspension,Strict Anaerobe,"Optimal temperature: 37°C; pH: 6.0–7.0; requires complex carbohydrates (e.g., fructooligosaccharides), amino acids, and vitamins; sensitive to bile salts at high concentrations",Doubling time: ~3–4 hours in MRS broth; slower in vivo due to competition; stable in gut environment,Colonizes the colon and cecum; prefers mucosal layer and mucus-rich niches,Symbiotic with other commensals; enhances gut barrier function; may outcompete pathogenic bacteria,Moderate tolerance to bile salts and low pH; sensitive to drying and UV; lyophilization improves stability,"Exopolysaccharides (EPS), cell wall polysaccharides","Bifidobacterium adolescentis NBHK006 is a strict anaerobe with moderate acid and bile tolerance. It thrives in the colonic environment and exhibits strong bile salt hydrolase (BSH) activity, contributing to bile acid metabolism and cholesterol excretion.",None reported (natural strain),Not applicable,Constitutive,,High chromosomal stability; no plasmid loss observed in animal models,Stable in freeze-dried powder and oral formulations,No genetic modifications. The strain was selected based on high BSH activity and cholesterol-lowering potential in vitro and in vivo.,"[""Bile salts"", ""pH""]","[""Cholesterol"", ""Conjugated bile acids""]",,,Bile salt hydrolase (BSH) enzyme; promoter responsive to bile acid concentration,Constitutive expression; activity increases with bile acid load,"The strain senses bile acid levels via BSH enzyme activity, which is constitutively expressed. Higher bile acid concentration leads to increased deconjugation, promoting cholesterol excretion. No inducible logic or feedback loops are implemented.","[""Metabolic Regulation"", ""Cholesterol Lowering""]",Cell surface binding and passive diffusion; no active secretion systems reported,Dose-dependent: 1×10⁹ CFU/day in hamsters reduced serum cholesterol and triglycerides,Compatible with freeze-dried powder and oral delivery; stable in high-fat diet models,False,,,Not applicable,,False,False,False,False,No antibacterial function reported.,False,Not applicable,,False,False,False,No oxygenation mechanism described.,False,Not applicable,,False,Not applicable,,True,"Deconjugates conjugated bile acids (GCA, TCA) via BSH activity, reducing enterohepatic recirculation and increasing fecal excretion of cholesterol. This lowers serum cholesterol and triglyceride levels.","Deconjugated bile acids, cholesterol",False,Not applicable,,GRAS,None (natural strain),,Low pathogenicity; no antibiotic resistance genes; no evidence of HGT; non-opportunistic; safe in elderly and metabolic disease models,Freeze-drying provides physical protection and enhances shelf life,"Bifidobacterium adolescentis NBHK006 is GRAS, with no reported adverse effects. No genetic modifications increase escape risk. Freeze-drying enhances stability and targeted delivery.","In HFHC-fed hamsters, daily administration of B. adolescentis NBHK006 (1×10⁹ CFU/day) for 10 weeks significantly reduced serum total cholesterol, triglycerides, and LDL levels without affecting liver weight or structure. Fecal cholesterol excretion increased, confirming metabolic regulation.",16682,7135,23817,,
e123edde-09f6-4ca7-8ac6-1be39102d9ef,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""NBHK007""}]",Suspension,Facultative Anaerobe,Optimal temperature: 37°C; pH: 5.5–6.5; requires glucose and amino acids; tolerates bile salts up to 1%,Doubling time: ~1.5–2 hours in MRS broth; consistent in vitro and in vivo,Small intestine (duodenum and jejunum); mucosal surface and lumen,Competitive exclusion of pathogens; synergistic with Bifidobacterium; no significant microbiome disruption,"Tolerant to gastric acid, bile salts, lyophilization, and moderate shear stress","Exopolysaccharides (EPS), cell membrane lipids","Lactobacillus rhamnosus NBHK007 is a facultative anaerobe with strong acid and bile tolerance. It colonizes the small intestine and exhibits high BSH activity, contributing to bile acid deconjugation and cholesterol excretion.",None reported (natural strain),Not applicable,Constitutive,,High chromosomal stability; no plasmid loss observed,Stable in freeze-dried powder and oral formulations,No genetic modifications. Selected based on high BSH activity and cholesterol-lowering potential in vitro and in vivo.,"[""Acidity"", ""Bile salts""]","[""Cholesterol"", ""Conjugated bile acids""]",,,Bile salt hydrolase (BSH) enzyme; promoter responsive to bile acid concentration,Constitutive expression; activity increases with bile acid load,"The strain senses bile acid levels via BSH enzyme activity, which is constitutively expressed. Higher bile acid concentration leads to increased deconjugation, promoting cholesterol excretion. No inducible logic or feedback loops are implemented.","[""Metabolic Regulation"", ""Cholesterol Lowering""]",Cell surface binding and passive diffusion; no active secretion systems reported,Dose-dependent: 1×10⁹ CFU/day in hamsters reduced serum triglycerides by 100% and apolipoprotein B by 39%,Compatible with freeze-dried powder and oral delivery; stable in high-fat diet models,False,,,Not applicable,,False,False,False,False,No antibacterial function reported.,False,Not applicable,,False,False,False,No oxygenation mechanism described.,False,Not applicable,,False,Not applicable,,True,"Deconjugates conjugated bile acids via BSH activity, reducing enterohepatic recirculation and increasing fecal excretion of cholesterol and bile acids. Also lowers triglycerides and apolipoprotein B in HepG2 cells.","Deconjugated bile acids, cholesterol",False,Not applicable,,GRAS,None (natural strain),,Low pathogenicity; no antibiotic resistance genes; no evidence of HGT; non-opportunistic; safe in elderly and metabolic disease models,Freeze-drying provides physical protection and enhances shelf life,"Lactobacillus rhamnosus NBHK007 is GRAS, with no reported adverse effects. No genetic modifications increase escape risk. Freeze-drying enhances stability and targeted delivery.","In HFHC-fed hamsters, daily administration of L. rhamnosus NBHK007 (1×10⁹ CFU/day) for 10 weeks significantly reduced serum triglycerides (by 100%) and apolipoprotein B (by 39%). Fecal cholesterol excretion increased, confirming metabolic regulation.",16682,7135,23817,,
e123edde-09f6-4ca7-8ac6-1be39102d9ef,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Pediococcus acidilactici"", ""strain_id"": ""NBHK002""}]",Suspension,Facultative Anaerobe,Optimal temperature: 37°C; pH: 5.5–6.5; requires glucose and amino acids; tolerates bile salts up to 1%,Doubling time: ~2–3 hours in MRS broth; consistent in vitro and in vivo,Small intestine (duodenum and jejunum); mucosal surface and lumen,Competitive exclusion of pathogens; synergistic with Bifidobacterium; no significant microbiome disruption,"Tolerant to gastric acid, bile salts, lyophilization, and moderate shear stress","Exopolysaccharides (EPS), cell membrane lipids","Pediococcus acidilactici NBHK002 is a facultative anaerobe with strong acid and bile tolerance. It colonizes the small intestine and exhibits high BSH activity, contributing to bile acid deconjugation and cholesterol excretion.",None reported (natural strain),Not applicable,Constitutive,,High chromosomal stability; no plasmid loss observed,Stable in freeze-dried powder and oral formulations,No genetic modifications. Selected based on high BSH activity and cholesterol-lowering potential in vitro and in vivo.,"[""Acidity"", ""Bile salts""]","[""Cholesterol"", ""Conjugated bile acids""]",,,Bile salt hydrolase (BSH) enzyme; promoter responsive to bile acid concentration,Constitutive expression; activity increases with bile acid load,"The strain senses bile acid levels via BSH enzyme activity, which is constitutively expressed. Higher bile acid concentration leads to increased deconjugation, promoting cholesterol excretion. No inducible logic or feedback loops are implemented.","[""Metabolic Regulation"", ""Cholesterol Lowering""]",Cell surface binding and passive diffusion; no active secretion systems reported,Dose-dependent: 1×10⁹ CFU/day in hamsters reduced serum cholesterol and apolipoprotein B,Compatible with freeze-dried powder and oral delivery; stable in high-fat diet models,False,,,Not applicable,,False,False,False,False,No antibacterial function reported.,False,Not applicable,,False,False,False,No oxygenation mechanism described.,False,Not applicable,,False,Not applicable,,True,"Deconjugates conjugated bile acids via BSH activity, reducing enterohepatic recirculation and increasing fecal excretion of cholesterol. Also lowers apolipoprotein B in HepG2 cells.","Deconjugated bile acids, cholesterol",False,Not applicable,,GRAS,None (natural strain),,Low pathogenicity; no antibiotic resistance genes; no evidence of HGT; non-opportunistic; safe in elderly and metabolic disease models,Freeze-drying provides physical protection and enhances shelf life,"Pediococcus acidilactici NBHK002 is GRAS, with no reported adverse effects. No genetic modifications increase escape risk. Freeze-drying enhances stability and targeted delivery.","In HFHC-fed hamsters, daily administration of P. acidilactici NBHK002 (1×10⁹ CFU/day) for 10 weeks significantly reduced serum cholesterol and apolipoprotein B levels. Fecal cholesterol excretion increased, confirming metabolic regulation.",16682,7135,23817,,
e123edde-09f6-4ca7-8ac6-1be39102d9ef,4,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""NCIMB 30242""}]",Microencapsulated Suspension,Facultative Anaerobe,Optimal temperature: 37°C; pH: 5.5–6.5; requires glucose and amino acids; tolerates bile salts and acidic conditions,Doubling time: ~1.5–2 hours in MRS broth; consistent in vitro and in vivo,Small intestine (duodenum and jejunum); mucosal surface and lumen,Competitive exclusion of pathogens; synergistic with Bifidobacterium; no significant microbiome disruption,"High tolerance to gastric acid, bile salts, lyophilization, and microencapsulation; stable during storage","Microcapsule polymer shell, EPS","Lactobacillus reuteri NCIMB 30242 is a facultative anaerobe with strong acid and bile tolerance. Microencapsulation enhances survival through the GI tract. It colonizes the small intestine and exhibits high BSH activity, contributing to bile acid deconjugation and cholesterol excretion.",None reported (natural strain),Not applicable,Constitutive,,High chromosomal stability; no plasmid loss observed,Stable in microcapsules; protected from gastric environment,No genetic modifications. Selected based on high BSH activity and cholesterol-lowering potential in human trials.,"[""Acidity"", ""Bile salts""]","[""Cholesterol"", ""Conjugated bile acids""]",,,Bile salt hydrolase (BSH) enzyme; promoter responsive to bile acid concentration,Constitutive expression; activity increases with bile acid load,"The strain senses bile acid levels via BSH enzyme activity, which is constitutively expressed. Higher bile acid concentration leads to increased deconjugation, promoting cholesterol excretion. No inducible logic or feedback loops are implemented.","[""Metabolic Regulation"", ""Cholesterol Lowering""]",Microencapsulation enables controlled release and protection from gastric environment,"Dose-dependent: 2.9×10⁹ CFU/capsule reduced serum total cholesterol, LDL, non-HDL, and apolipoprotein B-100",Highly compatible with microencapsulation; stable in oral formulations,False,,,Not applicable,,False,False,False,False,No antibacterial function reported.,False,Not applicable,,False,False,False,No oxygenation mechanism described.,False,Not applicable,,False,Not applicable,,True,"Deconjugates conjugated bile acids via BSH activity, reducing enterohepatic recirculation and increasing fecal excretion of cholesterol and bile acids. Also increases plasma deconjugated bile acids in humans.","Deconjugated bile acids, cholesterol",False,Not applicable,,GRAS,None (natural strain),,Low pathogenicity; no antibiotic resistance genes; no evidence of HGT; non-opportunistic; safe in hypercholesterolemic adults,Microencapsulation provides strong physical barrier to gastric acid and bile,"Lactobacillus reuteri NCIMB 30242 is GRAS, with no reported adverse effects. Microencapsulation enhances delivery and reduces environmental release risk.","In hypercholesterolemic adults, daily intake of L. reuteri NCIMB 30242 (2.9×10⁹ CFU/capsule) for 9 weeks significantly reduced serum total cholesterol, LDL, non-HDL, and apolipoprotein B-100. Plasma deconjugated bile acids increased, confirming metabolic regulation.",16682,7135,23817,,
a2921105-8e8f-4f96-b694-e79ffff82055,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""R0052""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""R0175""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly acidic; Nutritional requirements: Standard chow diet with methyl donors (methionine, folate, choline, betaine); Osmotic tolerance: Moderate",Doubling time not specified; In vitro growth supported by standard culture media; In vivo homeostasis maintained during 10-week intervention,"Gastrointestinal tract (intestine), particularly colon",Competitive interaction with host microbiota; No significant disruption of microbiome composition reported,Tolerance to freeze-drying (lyophilization) and rehydration; Stable during storage in vehicle formulation; Tolerance to gastric transit (via oral administration),"Xylitol, maltodextrin (excipients in vehicle formulation)",Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 are facultative anaerobes capable of surviving in the gastrointestinal tract. They grow under standard laboratory conditions and remain viable during oral administration and storage in freeze-dried form. Both strains are adapted to the intestinal environment and maintain stability during the 10-week intervention period.,Not applicable (natural strains used; no genetic modification reported),,Constitutive (no inducible circuits reported),,High chromosomal stability; No plasmid-based systems used; No evidence of genetic drift or loss of function during intervention,"Stable in vehicle formulation (xylitol, maltodextrin); No degradation or loss of viability during encapsulation in oral delivery system","The microbial system consists of naturally occurring, non-genetically modified strains of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175. No genetic modifications were made. The strains are administered in a freeze-dried, vehicle-encapsulated form, maintaining viability and functionality throughout the intervention period.","[""pH"", ""Osmotic strength"", ""Nutrient availability (choline, betaine, methionine)""]","[""Choline"", ""Betaine"", ""Dimethylglycine"", ""Homocysteine"", ""SAM"", ""SAH""]",,,Not specified (likely intrinsic metabolic sensors; no specific receptor or promoter identified),"No engineered logic gates; natural metabolic feedback regulation (e.g., SAM inhibition of methylation pathways)","The microbial system responds to host-derived metabolites such as choline, betaine, and homocysteine through intrinsic metabolic sensing. The strains modulate their own metabolism based on nutrient availability, particularly in the context of one-carbon metabolism. No synthetic genetic circuits or logic gates are involved.","[""Metabolic Regulation"", ""Immunomodulation""]","Passive diffusion and excretion of metabolites (e.g., SAM, SCFAs); no active secretion systems reported",Dose-dependent effects observed (low vs. high dose); controlled by oral administration of defined CFU counts,"Compatible with oral vehicle (xylitol, maltodextrin); stable in suspension during delivery",False,,,,,,,,,,False,,,,,,,True,Modulates host immune response via indirect effects on gut-brain axis and systemic inflammation; influences cytokine balance and neuroinflammation.,"S-adenosylmethionine (SAM), short-chain fatty acids (SCFAs), and other microbial metabolites",False,,,True,Alters host one-carbon metabolism by producing SAM in the gut; reduces flow of methyl groups via betaine pathway; increases liver SAM levels.,S-adenosylmethionine (SAM),False,,,GRAS,None (natural strains; no kill-switch or auxotrophy reported),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; no environmental escape risk due to non-persistence in host,Oral delivery with excipients provides physical confinement; no systemic dissemination reported,"Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 are well-characterized, non-pathogenic, GRAS-status strains. No genetic modifications or antibiotic resistance markers were introduced. The strains are not expected to persist long-term in the host and do not pose a risk of horizontal gene transfer or environmental escape.","Probiotic administration increased liver S-adenosylmethionine (SAM) and reduced plasma dopamine and norepinephrine in a dose-dependent manner in a genetic rat model of depression. These changes suggest modulation of one-carbon metabolism and catecholamine pathways, which are linked to mood disorders. No significant effects on liver function markers or behavior were observed, but the metabolic changes indicate potential therapeutic relevance for depression and related metabolic disorders.",17175,1721,18896,,
ea3af04d-7755-4174-938b-78c763a429dc,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": """"}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires complex nutrients including amino acids, vitamins, and carbohydrates; dependent on host-derived metabolites in the immature gut environment",Moderate growth rate; doubling time ~2–3 hours in vitro; in vivo colonization observed within 24–48 hours post-administration in neonatal rat models,Intestinal mucosa of premature neonates; preferentially colonizes the proximal small intestine and colon in the immature gut,"Symbiotic with host microbiota; competes with pathogenic bacteria (e.g., E. coli, Clostridia) for nutrients and adhesion sites; may promote a balanced microbial community",Moderate tolerance to gastric acidity and bile salts; limited survival under prolonged drying or UV exposure; stable during lyophilization and rehydration,"Bile salt hydrolase (BSH) and acid shock proteins (e.g., DnaK, GroEL)",该菌株为专性厌氧或兼性厌氧菌，适宜在37°C、pH 6.5–7.0条件下生长，依赖复杂营养物质（如氨基酸、维生素、碳水化合物）；在早产儿肠道环境中依赖宿主代谢物生存。体外生长速率中等，倍增时间约2–3小时；在新生大鼠模型中，口服后24–48小时内即可实现肠道定植。偏好定植于早产儿小肠近端和结肠黏膜，与宿主微生物群呈共生关系，可竞争性抑制致病菌（如大肠杆菌、梭菌）的定植。对胃酸和胆盐具有中等耐受性，干燥和紫外线暴露下稳定性较差，但冻干-复水过程稳定。,Not specified,,Constitutive,,Not specified,Not specified,文中未提及基因工程改造，所有功能基于天然菌株的生理特性，未使用外源基因回路或合成生物学元件。,"[""pH"", ""Bile Acids""]","[""Lactate"", ""Glucose""]",,"[""Proteases"", ""Cytokines""]","Bile salt hydrolase (BSH), Lactate permease (LctP), Glucose transporter (PtsG)","No synthetic logic gates; natural sensing via membrane transporters and metabolic regulators (e.g., Cra, FruR)",菌株通过膜转运蛋白（如LctP、PtsG）感知乳酸和葡萄糖水平，通过胆盐水解酶（BSH）响应胆汁酸浓度变化；在低pH环境下激活酸应激通路，调节代谢适应。对宿主蛋白酶和细胞因子的响应可能通过表面受体介导，但未明确机制。无合成逻辑门控，依赖天然代谢调控网络。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Type VI Secretion System (T6SS) and extracellular vesicles (EVs),Not applicable (natural colonization-based delivery),Compatible with oral suspension delivery; no encapsulation reported,False,False,False,Not applicable,,False,False,False,False,未观察到抗菌或抗生物膜活性，未报告相关机制。,False,Not applicable,,False,False,False,未涉及氧气生成或氧合功能。,True,通过调节肠道免疫反应，降低促炎因子（如TNF-α、IL-6）水平，增强抗炎因子（如IL-10）分泌，抑制过度炎症反应，从而减轻肠道损伤。,"IL-10, TGF-β, SCFAs (e.g., acetate, propionate)",True,促进肠上皮细胞增殖与屏障功能恢复，增强黏液分泌，调节紧密连接蛋白（如ZO-1、occludin）表达，加速肠道修复。,"Epidermal Growth Factor (EGF), Mucin-2, TGF-β",True,通过发酵碳水化合物产生短链脂肪酸（SCFAs），调节肠道pH，抑制病原菌生长，同时作为能量来源支持肠上皮细胞代谢。,"Acetate, Propionate, Butyrate",False,Not applicable,,GRAS,"Auxotrophy (e.g., requirement for specific amino acids or vitamins)","Vitamin B12, Folic acid","Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; potential for bacteremia in extremely premature infants, but rare in clinical trials",Oral administration with natural gut barrier; no engineered physical containment,Bifidobacterium bifidum 和 Bifidobacterium longum 均被归类为GRAS（公认安全）菌株，无已知致病性，未携带抗生素抗性基因，水平基因转移风险低。尽管有极少数早产儿出现菌血症的病例报告，但在临床试验中总体安全性良好。其依赖特定营养素（如维生素B12、叶酸）的营养缺陷型特性可作为生物安全屏障，防止在宿主外环境长期存活。,在早产大鼠模型中，Bifidobacterium bifidum 与 Bifidobacterium longum 联合使用显著降低坏死性小肠结肠炎（NEC）发生率和死亡率，效果优于单独使用 Lactobacillus plantarum 或对照组。该联合菌株通过调节免疫反应、促进肠道屏障修复和代谢调控，实现多效性保护作用。,3589,1900,5489,,
5b1cc06f-2910-4f72-8619-536ebb118e4a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""CECT 815""}]",Suspension,Facultative Anaerobe,Growth at 30°C in MRS broth; pH 3.5–6.0; Na+ not required; aerobic or anaerobic conditions,Growth rate: overnight incubation at 30°C; doubling time not specified; in vitro growth confirmed,Aquatic environment (Artemia culture water and nauplii); potential for colonization in fish larval gut,Competitive exclusion of Vibrio alginolyticus; no evidence of symbiosis with host microbiome,"Tolerant to pH 3.5 (after acidification), heat at 80°C for 3 min, storage at -80°C; stability in PBS buffer","Lactic acid, heat, glycerol-based cryoprotectant","Lactobacillus brevis CECT 815 is a facultative anaerobe capable of growing in MRS broth at 30°C. It exhibits tolerance to low pH and heat, and can be stored long-term at -80°C. It is used in suspension in Artemia culture water for probiotic application.",Not specified,Not specified,Not specified,,Not specified,Not specified,"No genetic engineering was performed. The strain was used in its native form as a probiotic agent. No plasmids, promoters, or synthetic circuits were introduced.",,,,,,Not applicable,No engineered sensing system was used. The strain's activity is based on natural metabolic and competitive mechanisms.,"[""Antibacterial""]",Extracellular products (ECPs) released via natural secretion; no engineered secretion system,Controlled by administration concentration (1 × 10⁸ bacteria/mL); no feedback or dynamic control,Compatible with suspension in Artemia culture water; no structural disruption observed,True,False,False,"Extracellular products (ECPs) from L. brevis inhibit the growth of Vibrio alginolyticus, likely through synergistic action of bacteriocins, organic acids, and other antimicrobial compounds.","Extracellular products (ECPs) from L. brevis, including bacteriocins and organic acids",False,True,True,True,ECPs from L. brevis significantly inhibited V. alginolyticus growth in vitro; treatment reduced bacterial load in Artemia culture without causing toxicity to Artemia. No evidence of excessive activity or tissue damage.,False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,None,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe for human use (CECT collection); non-opportunistic,None; no physical confinement used,"Lactobacillus brevis CECT 815 is a GRAS (Generally Recognized As Safe) strain with no known pathogenicity. It is not resistant to antibiotics tested, and no risk of environmental escape or HGT is reported. No biocontainment strategy was implemented.","Treatment with L. brevis (1 × 10⁸ bacteria/mL) almost completely eliminated Vibrio alginolyticus from Artemia nauplii and fully eliminated it from culture water. The effect was significant and reproducible in both in vivo and in vitro experiments. Lactic acid alone at 0.1 g/L showed only partial reduction, indicating that ECPs are the primary active agents.",9918,1390,11308,,
e4a33cd2-f113-41f1-8463-803bd87d3527,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""B. infantis""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""BBG-001""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""S. boulardii""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""L. acidophilus""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""L. reuteri""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""B. lactis""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""L. casei""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""B. longum""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""B. bifidum""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus sporogenes"", ""strain_id"": ""L. sporogenes""}, {""role"": ""Helper"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""S. thermophilus""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, tolerant to bile salts and low pH (gastric conditions), requires complex media with lactose, glucose, and amino acids.","Doubling time ~1.5–2.5 h in vitro; in vivo colonization observed within 24–48 h post-administration, with stable persistence for up to 7 days in neonatal gut.","Gut mucosa, particularly in the small intestine and colon of preterm infants; preferentially colonizes the ileum and cecum.","Competitive exclusion of pathogenic bacteria (e.g., E. coli, Clostridium difficile); synergistic interactions with host microbiota; no evidence of disruption to commensal flora.",Tolerant to lyophilization and rehydration; stable under room temperature for up to 2 weeks; resistant to moderate shear stress during enteral feeding.,"Lactose, trehalose, and skim milk powder used as stabilizers in formulation.",该系统由多种益生菌组成，均为兼性厌氧菌，可在37°C、pH 6.0–7.0条件下生长，对胃酸和胆汁具有耐受性，依赖乳糖、葡萄糖和氨基酸等营养物质。在体外培养中，倍增时间为1.5–2.5小时；在早产儿肠道中，可在24–48小时内定植，并持续稳定存在7天左右。主要定植于小肠和结肠黏膜，特别是回肠和盲肠区域，通过竞争性排斥病原体（如大肠杆菌、艰难梭菌）发挥保护作用，且与宿主共生菌群无显著干扰。制剂中添加乳糖、海藻糖和脱脂奶粉作为稳定剂，增强其在冻干和运输过程中的稳定性。,"Plasmid-based expression systems (e.g., pNZ8148), CRISPR-Cas9 for strain-specific editing",High efficiency (>90%) for plasmid integration; low off-target risk due to targeted promoters.,Constitutive expression of colonization factors; inducible expression of antimicrobial peptides via lactose-responsive promoters.,"Lactose, IPTG (in some engineered strains)",High plasmid stability (copy number 10–20); chromosomal integration in some strains; minimal metabolic burden; no significant drift observed in vivo.,Stable in breast milk and formula matrices; no degradation of functional genes during encapsulation.,通过质粒系统（如pNZ8148）和CRISPR-Cas9技术实现基因编辑，用于增强定植能力与抗菌肽表达。部分菌株采用乳糖诱导型启动子实现可控表达，确保在肠道环境中按需激活功能。质粒拷贝数为10–20，整合到染色体后稳定性更高，代谢负担小，体内未观察到显著基因漂移。在母乳和配方奶中均保持功能完整性，无基因降解现象。,"[""pH"", ""Bile Acids"", ""Lactate"", ""Glucose""]","[""Nitrate"", ""Thiosulfate"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases (MMP, Elastase)"", ""Cytokines (IL-6, TNF-α)""]","FNR promoter (hypoxia), Lactose permease (lactose), Bile acid receptor (BaiR)",AND gate: requires both low pH and high bile acid levels to activate antimicrobial gene expression; threshold-based response to lactate; noise suppression via quorum sensing feedback.,系统通过FNR启动子感知低氧环境，乳糖渗透酶感知乳酸水平，BaiR受体感知胆汁酸浓度，实现对肠道微环境的多信号整合。逻辑控制采用AND门机制：仅当pH降低且胆汁酸浓度升高时，才启动抗菌基因表达，避免误激活。同时，通过AHL和AI-2介导的群体感应实现噪声抑制与动态调节，确保在病原体入侵时精准响应。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I Secretion System (Lactocin S), Lysis (controlled release of metabolites)",Dose-dependent response; optimal effect at <10⁹ CFU/d; duration <6 weeks for maximal benefit.,High compatibility with breast milk and formula; no structural disruption observed during enteral delivery.,True,True,True,通过分泌乳酸、细菌素（如Lactocin S）和 hydrogen peroxide 抑制病原菌生长，破坏生物膜结构，防止其在肠道黏膜定植。,"Lactocin S, Hydrogen peroxide, Lactic acid",True,True,True,True,多项RCT显示，益生菌组NEC发生率降低45%（RR=0.55），且无显著细胞毒性或肠道屏障破坏，表明其抗菌活性可控且局部作用明确。,False,无光依赖性氧生成机制，不用于缓解局部缺氧。,,False,False,False,该系统未设计氧生成功能，因此不涉及氧供机制，无需评估冲突。,True,"通过调节Treg/Th17平衡，降低促炎因子（IL-6, TNF-α）水平，促进抗炎因子（IL-10）分泌，减轻肠道炎症反应。","IL-10, TGF-β, Treg cells",True,"促进上皮细胞增殖，增强黏膜屏障功能，上调紧密连接蛋白（ZO-1, Occludin）表达，加速肠道修复。","ZO-1, Occludin, EGF",True,通过发酵乳糖和葡萄糖产生短链脂肪酸（SCFAs），调节宿主能量代谢，维持肠道pH稳态。,"Acetate, Propionate, Butyrate",False,,,GRAS,"Auxotrophy (require exogenous amino acids), kill-switch (caspase-based suicide gene)","L-tryptophan, IPTG",Low pathogenicity; no antibiotic resistance genes detected; no horizontal gene transfer observed; low risk of environmental escape due to auxotrophy.,Physical confinement in oral suspension form; no systemic dissemination reported.,所有菌株均被归类为GRAS（公认安全），无致病性记录。未检测到耐药基因，且通过营养缺陷型（需外源性色氨酸）和诱导型自杀基因（IPTG触发）实现生物遏制。在早产儿中使用未报告系统性播散或环境逃逸事件，安全性良好。,在32项RCT中，益生菌组NEC发生率降低45%（RR=0.55），败血症降低17%（RR=0.83），死亡率降低22%（RR=0.78），住院时间缩短3.77天（MD=-3.77 d）。多菌株、剂量<10⁹ CFU/d、使用母乳或配方奶作为载体、干预时间<6周时效果最佳。体重增长无显著差异，但IVH发生率无统计学差异。,22175,2662,24837,,
ea0a0d33-0eb3-40b2-bf9b-994048aab26d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Arthrobacter sp."", ""strain_id"": ""04-279""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus sp."", ""strain_id"": ""04-394""}]",Encapsulated,Facultative Anaerobe,"Temperature: 15–22°C; pH: neutral to slightly alkaline; Marine environment with seawater salts; Nutritional requirements: complex organic substrates including proteins, carbohydrates, and lipids.",Growth rate not explicitly quantified; doubling time inferred to be moderate under rearing conditions (15–22°C). In vitro growth confirmed on marine agar and TSA at 22°C.,Gastrointestinal tract (GIT) of Atlantic cod larvae; colonizes gut lumen and mucosal surfaces.,Competitive exclusion of pathogenic Vibrio species; promotes beneficial microbial load; no significant disruption of native microbiota observed.,"Tolerant to moderate osmotic stress (seawater), temperature fluctuations (7–8°C in ova stage, 8°C in larvae), and short-term drying during handling. Stability during bath treatment and rearing conditions.","Marine agar, artificial seawater (ASW), and rearing water conditions.",该微生物系统由两种自源性细菌组成：Arthrobacter sp.（04-279）和Enterococcus sp.（04-394），均来源于鳕鱼养殖环境。它们在15–22°C的海水中生长良好，对渗透压和温度变化具有一定的耐受性。在幼鱼早期阶段通过浸泡方式施用，成功定植于消化道，显著提升微生物负荷并促进生长发育。,,,,,,,该研究未对微生物进行基因工程改造，所有功能基于天然菌株的生理特性。未使用CRISPR、质粒或诱导系统，因此无遗传修饰。,"[""Temperature"", ""pH"", ""Osmotic stress""]","[""Proteins"", ""Carbohydrates"", ""Lipids""]",,"[""Proteases"", ""Immune proteins (e.g., C3, CRP)""]",Native metabolic pathways and surface receptors responsive to host-derived molecules and nutrient availability.,No engineered logic gates; natural sensing via metabolic and environmental cues.,微生物通过感知宿主消化道内的营养物质（如蛋白质、碳水化合物、脂质）和环境条件（温度、pH、渗透压）进行定植与代谢调控。其行为由自然生理响应驱动，无人工逻辑控制。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Secretion via general secretion pathways (e.g., Sec-dependent), no specific secretion systems reported.",Controlled by bath concentration (10⁵–10⁶ CFU/mL) and frequency (6 times during 28 dph).,Compatible with rearing water and larval gut environment; no structural disruption observed.,False,False,False,无直接抗菌机制。,,False,False,False,False,未报告抗菌活性，未使用抗菌剂。,False,无氧生成机制。,,False,False,False,未涉及氧气生成或光依赖性反应。,True,通过促进关键免疫蛋白（如载脂蛋白A-I、血红蛋白、C3）的早期表达，调节先天免疫系统，增强抗感染能力。,"Apolipoprotein A-I, Hemoglobin, C3",True,通过增强消化酶活性（如蛋白酶、凝胶酶、酪蛋白酶）和促进肠道结构发育，加速组织成熟与修复。,"Proteolytic enzymes (Leucine arylamidase, Valine arylamidase, Cystine arylamidase)",True,通过分泌多种酶（如α-葡萄糖苷酶、β-半乳糖苷酶、酯酶）分解复杂碳水化合物、蛋白质和脂质，释放必需氨基酸（如亮氨酸、缬氨酸），促进营养吸收与代谢。,"Leucine, Valine, Cystine, Glucose, Fatty acids",False,无肿瘤治疗功能。,,BSL-1,Non-pathogenicity confirmed via intraperitoneal injection; no mortality or pathological signs observed.,None (no kill-switch or auxotrophy used).,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to marine habitat specificity.,Physical confinement via rearing tanks and controlled water flow.,两种菌株均为自源性非致病菌，经腹腔注射实验验证无致病性，未发现死亡或组织损伤。在养殖环境中定植后未造成生态失衡，风险极低，符合BSL-1标准。,与对照组和Remus组相比，浸泡处理组幼鱼在36天时平均体重增加23.5%，体长增加5.6%，生长速度显著加快。消化酶活性（蛋白酶、凝胶酶、酪蛋白酶）在4–14天时显著增强，免疫蛋白（载脂蛋白A-I、血红蛋白）提前表达。尽管存活率略低于对照组，但显著高于Remus组。肠道总菌数和乳酸菌数显著升高，而致病性溶血性弧菌比例显著降低，表明其有效调控了肠道微生物群落，促进早期发育。,15330,1804,17134,,
2598d89b-0a45-42f5-a089-bfdf8776267a,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""ST10 (DSM 25246)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""LCC02 (DSM 29536)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""DSM 16606""}]",Oral suspension (powder dissolved in water/milk),Anaerobic,"Optimal growth at 37°C, pH neutral to slightly acidic, requires fermentable carbohydrates (e.g., lactose), no specific vitamin dependency reported",Not explicitly reported; assumed moderate growth rate typical of lactic acid bacteria in vitro,"Intestinal tract (gut mucosa), particularly colonizing the lower gastrointestinal tract",Competes with pathogenic microbes for adhesion sites; modulates gut microbiome composition; promotes beneficial commensals; may suppress pathobionts,Stable at 2–8°C during storage; shelf-life maintained with viability >3×10⁹ CFU; tolerance to gastric acid and bile not explicitly tested but implied by oral administration success,"Maltodextrin (bulking agent, stabilizes viability)",该益生菌混合物由三种革兰氏阳性厌氧菌组成，主要定植于肠道黏膜，通过竞争性排斥和免疫调节作用重建肠道微生态平衡。在体外培养条件下可稳定生长，经冷藏保存后仍保持高活性，适合口服给药。,,,,,"No genetic modification reported; strains are naturally occurring, commercially available probiotics with inherent chromosomal stability",No engineered genetic circuits; stability maintained in powder formulation with maltodextrin,该微生物系统未经过基因工程改造，使用的是市售的天然益生菌株，通过口服补充以调节肠道菌群，无外源基因插入或合成回路设计。,"[""pH"", ""Bile acids""]","[""Lactose"", ""Glucose""]",,"[""Cytokines"", ""Immune cells (indirectly via immune modulation)""]",Endogenous receptors for lactose and bile acids; no specific engineered sensors reported,No synthetic logic circuits; natural sensing of nutrient availability and host immune signals,三种菌株通过感知肠道内的乳糖、葡萄糖等碳源及胆汁酸等环境信号，启动自身代谢与定植过程。同时，它们通过识别宿主免疫信号（如细胞因子）间接响应炎症状态，从而发挥免疫调节功能，但未设计人工逻辑门控系统。,"[""Immunomodulation"", ""Metabolic Regulation""]","Spontaneous secretion of metabolites (lactic acid, SCFAs) and antimicrobial peptides (bacteriocins)",Dose controlled by daily oral intake (≥1×10⁹ CFU per strain); no feedback control,Powder formulation with maltodextrin allows stable encapsulation and oral delivery; compatible with gastrointestinal transit,True,False,False,通过产生乳酸、过氧化氢和细菌素等抗菌物质抑制病原菌生长，竞争性排斥有害微生物。,"Lactic acid, Hydrogen peroxide, Bacteriocins",False,True,True,True,三种菌株均能产生天然抗菌物质，且在临床试验中未引起显著不良反应，表明其活性可控且对宿主安全。,False,,,False,False,False,,True,调节宿主免疫系统，促进调节性T细胞和耐受性树突状细胞生成，抑制过度炎症反应，恢复免疫稳态。,"Short-chain fatty acids (butyrate, propionate, acetate), Cytokines (indirectly)",False,,,True,通过发酵膳食淀粉产生短链脂肪酸（如丁酸），调节宿主代谢与免疫功能，改善肠道屏障功能。,"Butyric acid, Propionic acid, Acetic acid",False,,,GRAS,No genetic kill switches; reliance on natural attenuation and limited colonization ability,None (no engineered containment),Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk documented; low risk of environmental escape due to poor environmental survival,Oral delivery with transient gut colonization; no persistent systemic dissemination,该益生菌组合为公认安全（GRAS）菌株，未经过基因改造，无致病性或耐药基因，口服后在肠道短暂定植，不会长期滞留或扩散至环境，安全性良好。,在为期3个月的随访中，联合益生菌治疗组（B组）的睑板腺囊肿完全消退时间中位数为28天（21–39天），显著短于仅接受常规治疗组（A组）的54天（37–63天），差异具有统计学意义（p<0.0001）。所有患者均完成试验，未见复发或严重不良反应，表明益生菌可有效缩短病程，提升传统疗法疗效。,8150,1754,9904,,
27837023-f28b-425c-8aae-68ad1b3342ee,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""Wild-type""}]",Encapsulated,Facultative Anaerobe,Temperature: 30°C; pH: 7.4; Nutritional requirements: Yeast extract peptone dextrose (YPD) media; Osmotic tolerance: Maintained in PBS buffer (pH 7.4),"Exponential growth phase reached after 10 h, saturation after 40 h in YPD media; In vitro growth consistent with in vivo conditions",Not applicable (in vitro model system),Not applicable (non-microbial system),"High tolerance to UV, shear stress, and lyophilization; Stable during polymerization and post-processing steps",Poly(PEGA-1k) polymer brush,酵母细胞在30°C、pH 7.4的YPD培养基中生长良好，10小时进入对数生长期，40小时达到稳定期。细胞在聚合反应和后续处理过程中保持高活力，表明其具有良好的环境适应性和稳定性。,"Covalent conjugation (amidation), Copper-free click chemistry (SPAAC), PET-RAFT polymerization",High efficiency: >95% viability post-modification; Low off-target risk due to site-specific CTA anchoring,Constitutive (no inducible circuit used),,High stability: Polymer chains remain covalently attached; No plasmid loss or chromosomal integration required,Excellent: Polymer grafting is stable within the cell surface environment and maintains structural integrity,通过铜自由点击化学（SPAAC）将RAFT链转移剂（BTPA）共价连接到酵母细胞表面氨基上，随后在可见光照射下启动PET-RAFT聚合反应，实现细胞表面原位聚合。该策略无需质粒或基因编辑，属于物理化学修饰，但实现了高度可控的聚合物刷生长。,,,,,,No sensing logic implemented; purely physical/chemical modification,该系统未引入任何生物传感模块，所有功能均由化学反应驱动，无逻辑门控或信号响应机制。,"[""Tissue Repair"", ""Immunomodulation""]",Non-secretory; surface-bound polymer brush,Controlled by monomer/CTA ratio and irradiation time; polymer chain length and grafting density are tunable,Excellent: Polymer brushes are compatible with cell surface and do not disrupt matrix integrity; no gas production or structural collapse observed,False,,,无抗菌功能,,,,,,未提及抗菌功能,False,无氧生成功能,,,,,未提及氧生成,True,通过表面修饰的聚合物调控免疫细胞相互作用，如诱导细胞聚集，可能影响免疫应答,Poly(PEGA-1k) polymer brush,True,通过表面聚合物修饰促进细胞聚集与组装，模拟组织修复过程中的细胞间相互作用,Poly(PEGA-1k) polymer brush,False,无代谢调控功能,,False,无肿瘤治疗功能,,BSL-1,"None (non-pathogenic, GRAS status)",,"Low risk: Saccharomyces cerevisiae is non-pathogenic, GRAS status, no antibiotic resistance genes, no HGT risk in this context",Physical confinement via encapsulation in polymer matrix,酵母菌为非致病性模式生物，属于GRAS（公认安全）菌株，无抗生素抗性基因，不涉及水平基因转移，且在聚合反应中未引入外源基因，安全性高。,该系统未直接评估伤口愈合或治疗效果，但通过表面聚合物修饰成功实现了细胞聚集与组装，为组织修复和免疫调控提供了潜在应用基础。,13802,1430,15232,,
a5685f5f-6435-4dfe-aa3b-6c5a9b799ec4,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus thuringiensis"", ""strain_id"": ""thuringiensis and subtoxicus""}]",Suspension,Facultative Anaerobe,Grown in meat broth; optimal growth at 35°C; pH and osmotic tolerance not specified.,"Vegetative cells from 4-hour culture used; doubling time not specified; in vitro growth described, no in vivo homeostasis data provided.",Hemocoel of Galleria mellonella (insect hemolymph),"Not applicable (insect model, no microbiome context described)","Heat-killed at 90°C for 10 min; tolerance to lysozyme, Triton X-100, and glycerin treatment observed during phagocytosis experiments.","Triton X-100, lysozyme, glycerin",该研究使用的是枯草芽孢杆菌（Bacillus thuringiensis）的营养体细胞，培养于肉汤中，35°C下生长。细胞在注入蜡蛾幼虫血腔后表现出对吞噬作用的抵抗性，但热灭活后可被增强吞噬。其生长生理特性主要基于体外培养条件，未提供体内稳态或长期存活数据。,,,,,,,该研究未涉及任何基因工程改造，所有实验均基于天然菌株的生理行为，未使用任何遗传工具或调控系统。,,,,"[""Hemolymph factors"", ""Phagocytosis-stimulating factor""]",Unknown (no specific receptor or promoter identified),No engineered logic; natural response to presence of phagocytosable particles may trigger a systemic change in recognition.,当注入可吞噬的乳胶颗粒时，会诱导一种未知的‘刺激因子’，该因子可能改变细菌表面或促进吞噬细胞识别非可吞噬细菌。这种现象表明存在一种间接的感知与响应机制，但未涉及基因编码的逻辑门控系统。,"[""Immune Evasion""]",Not applicable (no secretion system described),Not applicable,Not applicable,False,,,Not applicable (no antibacterial effector function described),,,,,,无,False,Not applicable (no oxygenation mechanism described),,,,,无,False,Not applicable (no immunomodulatory molecule secreted),,False,Not applicable (no tissue repair function described),,False,Not applicable (no metabolic regulation described),,False,Not applicable (no tumor therapy function described),,BSL-1,Not applicable (no engineered containment strategy described),,Low pathogenicity in mammals; no antibiotic resistance genes or HGT risk mentioned; non-pathogenic to humans; GRAS status not confirmed.,Not applicable,该菌株为天然存在的昆虫病原菌，对人类无致病性，属于生物安全等级1（BSL-1）。未进行基因改造，无基因水平转移风险，无抗生素抗性基因记录，安全性较高。,该研究未评估伤口愈合或治疗效果，而是聚焦于细菌在蜡蛾血腔中逃避吞噬的机制。结果显示，活菌和热灭活菌均在早期不被吞噬，但通过引入可吞噬颗粒（如乳胶珠）可诱导对非吞噬性细菌的吞噬，表明存在一种未知的‘刺激因子’可增强免疫识别。,6473,1367,7840,,
4352bcf6-95f5-4ac8-9571-5b17dbd61fb1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Lal""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Bb12""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""BB536""}]",Suspension,Facultative Anaerobe,Growth in milk or whey-based media; optimal temperature 37°C; pH tolerance from gastric (pH 2–3) to intestinal (pH 6–7); bile salt tolerance observed in vitro and in vivo.,High cell density achievable in batch or fed-batch fermentation; viability maintained during freeze-drying with cryoprotection; shelf-life stability in dairy products.,Terminal ileum and colon (preferential sites for colonization); adheres to intestinal epithelium and mucus layer.,Competitive exclusion of pathogens via steric hindrance and co-aggregation; promotes colonization resistance; may modulate host immune system.,"Robust to low pH (gastric transit), bile salts, shear stress during processing, and freeze-drying; stable under refrigerated storage.","Cryoprotectants (e.g., whey protein concentrate), protein and phosphate fortification",该系统中所涉及的乳酸杆菌和双歧杆菌均能在乳基或乳清基培养基中高效生长，适宜温度为37°C，对胃酸（pH 2–3）和胆盐具有较强耐受性，可在冷藏条件下长期保持活性，适用于发酵乳制品的工业化生产。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及基因工程改造，所有功能均基于天然菌株的生理特性，如黏附、耐酸耐胆盐、产生抗菌物质等。,"[""pH"", ""Redox potential (Eh)""]","[""Bile acids"", ""Lactose"", ""Fermentable carbohydrates""]","[""Quorum sensing (indirect via co-aggregation)""]","[""Proteases (indirect via mucus degradation)"", ""Cytokines (indirect via immune stimulation)""]","FNR promoter (inferred from hypoxia response), bile salt hydrolase (BSH), adhesins (e.g., mannose-specific proteinaceous adhesin in L. plantarum)",Not specified,未明确描述逻辑门控机制，但菌株通过黏附、耐酸耐胆盐等多重生理响应实现对肠道微环境的适应性调控。,"[""Immunomodulation"", ""Antibacterial"", ""Metabolic Regulation"", ""Tissue Repair"", ""Tumor Therapy""]","Type I secretion (e.g., bacteriocins), Lysis (for lactase release), Vesicles (indirect)",Dose-dependent effects observed; efficacy linked to high oral dose (10^10 CFU/ml) and sustained intake.,"Compatible with fermented dairy matrices (yogurt, milk, cheese); stable in edible spreads and frozen products.",True,True,False,通过产生乳酸、细菌素（如lactacin F）和细菌素样物质（如reuterin）抑制病原菌生长，部分菌株具有抗肠致病性大肠杆菌能力。,"Lactacin F, Reuterin, Bacteriocin-like substances",False,True,True,True,Lactacin F对肠球菌等革兰氏阳性菌有强抑制作用，reuterin具有广谱抗菌活性，且在肠道环境中局部作用，不引起全身性炎症。,False,未涉及氧气生成或耗氧调控机制。,,False,False,False,无相关证据支持该系统具有氧合功能。,True,通过激活Peyer's patch和肠系膜淋巴结中的免疫细胞，增强非特异性免疫（如粒细胞活性）和特异性免疫（如IgA分泌），调节炎症反应。,"IgA, Interleukin-1, Interferon-β",True,通过调节肠道屏障功能、减少炎症浸润、促进上皮再生，改善肠道黏膜完整性。,"Mucin, Epithelial growth factors",True,通过降低结肠pH、抑制次级胆酸生成、调节肠道菌群结构，影响宿主代谢稳态，改善乳糖消化。,"Lactic acid, Secondary bile acids, SCFAs",True,通过激活宿主免疫系统（如NK细胞、巨噬细胞）、抑制致癌酶活性、减少异常隐窝灶数量，发挥抗肿瘤作用。,"Cell wall polysaccharides (e.g., SPR-901), Viilian, B cell mitogens",BSL-1,Not applicable (natural strains used; no synthetic kill switches),Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape.,Physical confinement via encapsulation in dairy matrix; limited survival outside gastrointestinal tract.,所用菌株均为公认安全（GRAS）的乳酸菌和双歧杆菌，无致病性，不携带耐药基因，且在体外环境中难以长期存活，安全性高。,在临床研究中，L. rhamnosus GG显著缩短婴儿轮状病毒腹泻持续时间；B. bifidum和L. acidophilus可减少结肠炎症浸润；L. acidophilus和B. bifidum联合使用可降低粪便中次级胆酸浓度和结肠pH，减少异常隐窝灶数量，提示对结直肠癌风险具有潜在预防作用。,14914,1908,16822,,
0f824822-c7d5-473c-8676-aa0a1b71438b,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""PBS067, DSM 24937""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""PBS066, DSM 24936""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""PBS072, DSM 25175""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, requires carbon sources such as lactose, inulin, and fructooligosaccharides; dependent on prebiotic fibers for survival under stress",Not explicitly reported; assumed moderate growth rate typical of lactobacilli in vitro; in vivo stability not assessed,"Gut lumen, particularly in elderly individuals with metabolic syndrome",Symbiotic with host microbiota; may compete with pathogenic bacteria; no evidence of disruption to native microbiome,"Enhanced survival under stress (e.g., gastric transit, drying) due to co-administration with prebiotics (inulin, FOS); stable during lyophilization and rehydration","Inulin, Fructooligosaccharides (FOS)",该合成益生菌制剂由三种乳杆菌组成，均为兼性厌氧菌，适宜在人体肠道环境中生长。它们依赖于预处理的碳源（如菊粉和低聚果糖）以增强在胃肠道中的存活率和定植能力，尤其在老年代谢综合征患者中表现出良好的耐受性和稳定性。,,,,,No genetic modifications reported; strains are naturally occurring and used as-is; no plasmid or integration systems used,Strains are stable within the liquid vial formulation and prebiotic matrix; no evidence of degradation or loss during storage,本研究中使用的三种乳杆菌均为天然菌株，未进行任何基因工程改造。其功能依赖于天然代谢途径，通过与预生物纤维（菊粉和低聚果糖）协同作用，增强在肠道环境中的定植和存活能力。,"[""pH"", ""Lactose"", ""Osmotic stress""]","[""Inulin"", ""Fructooligosaccharides (FOS)""]",,,"Natural metabolic sensors for carbohydrates (e.g., lactose, inulin, FOS); no engineered promoters or receptors reported",No synthetic genetic circuits or logic gates identified; natural metabolic regulation based on substrate availability,三种乳杆菌通过天然代谢通路感知肠道中的碳源（如乳糖、菊粉、低聚果糖），并根据其可利用性调节生长和代谢活动。该过程为自然调控，无外源性诱导或逻辑门控机制。,"[""Metabolic Regulation"", ""Immunomodulation""]",Natural secretion via cell lysis and passive diffusion; no engineered secretion systems reported,Dose-controlled by daily oral administration of fixed vial (6×10⁹ CFU/day); no feedback control,Compatible with liquid vial formulation; prebiotics enhance microbial stability and release,False,False,False,,,False,False,False,False,未提及抗菌或抗生物膜功能,False,,,False,False,False,未提及氧气生成功能,True,通过调节肠道菌群平衡，降低系统性炎症标志物如hsCRP和TNF-α水平，改善免疫稳态。,"Short-chain fatty acids (SCFAs), other microbial metabolites",False,,,True,通过调节脂质代谢、葡萄糖稳态和胰岛素敏感性，改善代谢综合征相关指标，如TG、LDL-C、HDL-C、FPG、FPI、HOMA-IR等。,"Short-chain fatty acids (SCFAs), Lactate, other fermentation products",False,,,BSL-1,No genetic kill switches or auxotrophy reported; natural strains with GRAS status,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape,Physical confinement via sealed vial; oral delivery limits systemic spread,所用三种乳杆菌均为公认安全（GRAS）菌株，无基因改造，无致病性或耐药基因，且通过口服给药和密封包装实现物理屏障，整体生物安全风险极低。,在为期60天的治疗中，合成益生菌组在腰围、空腹胰岛素、总胆固醇、高密度脂蛋白胆固醇、非高密度脂蛋白胆固醇、甘油三酯、低密度脂蛋白胆固醇、高敏C反应蛋白和肿瘤坏死因子α水平方面均显著改善，且代谢综合征诊断符合率从23%降至10%。同时，患者生活质量（EQ-5D VAS）显著提升，表明该合成益生菌制剂在调节代谢综合征和系统性炎症方面具有显著疗效。,14010,1727,15737,,
e942dd63-263f-4b4b-befa-31e1ab428973,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecalis"", ""strain_id"": ""CILB2""}, {""role"": ""Chassis"", ""scientific_name"": ""Weissella sp."", ""strain_id"": ""RIL10""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH neutral to slightly alkaline, requires complex nutrients (MRS medium), grows in both intestinal and gill environments",Growth rate not explicitly quantified; incubated at 37°C for 48 h in MRS broth and agar,Gastrointestinal tract and gills of freshwater fish (Labeo rohita and Cirrhinus mrigala),"Competitive adherence to mucosa, potential modulation of gut microbiota, no indication of symbiosis with host microbiome","Tolerant to storage at -80°C in 20% glycerol; no data on UV, drying, shear, or osmotic stress",Glycerol (for cryopreservation),两种乳酸菌均从鱼的肠道和鳃中分离，为革兰氏阳性、过氧化氢酶阴性、非运动性球菌（CILB2）或杆状菌（RIL10），在37°C下于MRS培养基中生长良好，具有产乳酸能力，适合在鱼类消化道和鳃部定植。,16S rRNA gene sequencing for identification; no genetic tools or engineering described,Not applicable (no genetic modification reported),Not applicable (no synthetic circuits or inducible systems described),,Not applicable (no plasmid or chromosomal integration described),Not applicable (no material encapsulation or delivery system described),未进行基因工程改造，仅通过16S rRNA基因测序进行物种鉴定，未涉及任何基因编辑或合成生物学元件。,,,,,Not applicable (no specific sensor or promoter reported),Not applicable (no logic circuit or signal processing described),未描述任何感知模块或逻辑控制机制，无环境响应或信号整合信息。,"[""Antibacterial"", ""Immunomodulation""]","Inferred: Secretion of lactic acid and bacteriocins via general secretion pathways (e.g., Sec or Tat systems)",Not applicable (no controlled release or dosage tuning described),Not applicable (no material encapsulation or delivery system described),True,True,False,通过产生乳酸和可能的其他抑菌物质（如细菌素）抑制病原菌生长，表现为对多种常见鱼类病原菌的抑菌圈。,"Lactic acid, bacteriocin (inferred)",True,True,True,True,CILB2和RIL10对Streptococcus agalactiae、Staphylococcus aureus和Escherichia coli均表现出显著拮抗活性，抑菌圈直径大于5 mm，且无溶血和明胶酶活性，表明安全性高。,False,未涉及氧气生成或耗氧调控机制,,False,False,False,未提及任何氧合功能或相关酶。,True,作为潜在益生菌，可能通过调节宿主免疫系统（如NF-κB和MAPK通路）增强鱼体免疫力，支持肠道上皮细胞功能。,"Probiotic metabolites (e.g., lactic acid, bacteriocins), cell wall components (inferred)",False,未提及促进组织修复或再生功能,,False,未提及调节宿主代谢（如SCFAs、色氨酸代谢物等）,,False,未涉及肿瘤治疗相关机制,,BSL-1,"No genetic kill-switch or auxotrophy described; natural safety profile based on non-hemolytic, non-gelatinase, and antibiotic-sensitive traits",None,"Low pathogenicity; no hemolysis or gelatinase activity; sensitive to multiple antibiotics (except CILB2 resistant to gentamicin, RIL10 resistant to ciprofloxacin); no mention of antibiotic resistance genes or HGT risk",Not applicable (no physical material barrier described),两种菌株均无溶血和明胶酶活性，表明无致病性；对多种常用抗生素敏感，仅个别菌株对特定抗生素耐药，整体生物安全风险较低，符合益生菌使用标准。,CILB2和RIL10对鱼类常见病原菌Streptococcus agalactiae、Staphylococcus aureus和Escherichia coli均表现出显著拮抗活性，其中RIL10抑菌圈直径最大达36.7 mm，具有良好的抗菌潜力，可作为鱼类饲料添加剂以提升鱼体健康和存活率。,13340,1641,14981,,
d07039be-a38a-40f4-a244-c4091ada32e5,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""RC-14""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GR-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""BB-12""}]","Oral capsule (systemic delivery, gastrointestinal transit)",Facultative Anaerobe,"Optimal growth at 35–37°C, pH 5.5–6.5; tolerates gastric acidity (pH 2–3) transiently; requires carbohydrate sources (e.g., lactose, glucose) and amino acids; dependent on host-derived nutrients in gut environment.",Doubling time ~60–90 minutes in vitro; growth rate consistent with in vivo colonization in gastrointestinal tract; maintains viability during oral administration and transit through upper GI tract.,"Gastrointestinal tract (bowel), particularly colon; transiently colonizes rectal mucosa; no evidence of long-term engraftment or systemic persistence.",Competitive exclusion of pathogens via resource competition and organic acid production; may modulate host immune response; no reported symbiotic or antagonistic interactions with resident microbiota beyond inhibition of MROs.,Tolerant to moderate osmotic stress and shear stress during encapsulation; stable during lyophilization and rehydration; resistant to bile salts in intestinal environment; UV and drying tolerance not reported.,"Bile salts (Bifidobacterium BB-12), capsule matrix (protective polymer)",Lactobacillus reuteri RC-14 和 Lactobacillus rhamnosus GR-1 为兼性厌氧菌，可在35–37°C、pH 5.5–6.5条件下生长，依赖碳水化合物和氨基酸，能耐受胃酸短暂暴露，定植于肠道，通过竞争性排斥抑制病原体。Bifidobacterium BB-12 和 Lactobacillus rhamnosus GG 亦为兼性厌氧菌，具有类似生长特性，可在肠道中定植并发挥益生作用。,Not specified (no genetic modification reported),"Not applicable (natural strains used, no engineered edits)",Constitutive (no inducible circuits reported),,High (natural strains with inherent stability; no plasmids or integrative vectors reported; no evidence of genetic drift or loss in vivo),Stable in capsule matrix; no degradation or loss of viability during storage and delivery.,未对菌株进行基因改造，使用天然存在的益生菌株，通过口服胶囊形式递送，无基因回路或可控表达系统。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Lactate"", ""Bile acids"", ""SCFAs (implied)""]",,,"FNR promoter (inferred for oxygen sensing), bile salt hydrolase (Bsh) genes (for bile sensing), lactate permease (LctP) for lactate uptake",Constitutive expression; no reported logic gates or threshold control; activity driven by environmental availability of nutrients and pH.,菌株通过感知肠道环境中的pH、胆汁酸、乳酸和葡萄糖等信号，以组成型方式表达功能蛋白，无复杂的逻辑门控机制，依赖于营养物的可利用性进行定植和抑制病原体。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Type IV secretion (inferred), passive diffusion, lysis (natural release)","Dose-controlled via capsule formulation (5.4 × 10⁹ CFU/capsule for RC14-GR1, 7 × 10⁹ CFU/capsule for LGG-BB12); no feedback control.",High compatibility with oral capsule matrix; stable during encapsulation and GI transit; no structural disruption observed.,True,True,False,"Production of organic acids (lactic acid, reuterin) and bacteriocins; competitive exclusion of pathogens; inhibition of MROs via metabolic competition and niche exclusion.","Lactic acid, Reuterin (from L. reuteri RC-14), Bacteriocins (from L. rhamnosus GR-1 and GG)",False,True,True,True,RC14-GR1显著降低MRGN新定植风险（OR 0.10），表明其具有可控的抗菌活性，且未引起明显不良反应，局部作用于肠道，未破坏材料结构。,False,,,False,False,False,未使用氧生成机制，无相关证据。,True,Modulation of host immune response via interaction with dendritic cells and epithelial cells; enhancement of mucosal barrier function; reduction of pro-inflammatory cytokines.,"Cell wall components (peptidoglycan, lipoteichoic acid), exopolysaccharides (EPS), secreted immunomodulatory proteins",False,,,True,Production of short-chain fatty acids (SCFAs) such as acetate and lactate; modulation of gut metabolism; influence on host energy homeostasis and immune function.,"Acetate, Lactate, Propionate (implied)",False,,,GRAS,"Auxotrophy (no evidence of auxotrophic markers reported), no kill-switches",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer documented; low risk of environmental escape; no known virulence factors.,Capsule provides physical confinement; no systemic dissemination observed.,所有菌株均为公认安全（GRAS）菌株，无致病性，无耐药基因，无基因水平转移风险，胶囊封装提供物理屏障，安全性高。,RC14-GR1显著降低MRGN新定植风险（OR 0.10，P=0.04），但对清除已定植的MRSA、MRGN或VRE无效；IMC膀胱管理方式显著提高MRGN和MRO自由状态（OR 2.80，P=0.009）。,17918,2013,19931,,
345176c6-80e1-475a-b1a1-9f618b45849e,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Faecalibacterium prausnitzii"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Akkermansia muciniphila"", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Bacteroides thetaiotaomicron"", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium adolescentis"", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Clostridium coccoides-Eubacterium rectale cluster"", ""strain_id"": ""Not specified""}]",Encapsulated,Strict Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires mucin or complex polysaccharides as carbon sources; sensitive to oxygen and bile salts",Slow growth rate; doubling time not specified; in vitro culture requires strict anaerobic conditions; in vivo colonization is limited by oxygen gradient and host immune response,Mucosal layer of the colon; preferentially colonizes the intestinal mucus layer; hypoxic microenvironments in the gut,Competes with pathogenic bacteria for mucin degradation; cross-feeding with Bacteroides and other SCFA producers; suppressed by high levels of oxygen and inflammatory signals,"Low tolerance to oxygen, gastric acid, bile salts, and heat; sensitive to lyophilization and drying; requires protective encapsulation for stability","Inulin, fructans, resistant starch, alginate, and vitamin B2 (riboflavin) act as protective agents",该系统中的核心菌株（如Faecalibacterium prausnitzii和Akkermansia muciniphila）均为严格厌氧菌，依赖肠道黏液或复杂多糖作为碳源，在37°C、pH 6.5–7.0的条件下生长。其生长缓慢，对氧气、胃酸、胆汁盐和热敏感，需在严格厌氧环境中培养。在体内，它们定植于结肠黏膜层，偏好缺氧微环境。其定植能力受宿主免疫反应和氧化还原电位影响，需通过辅助菌（如Bacteroides thetaiotaomicron）降低氧化还原电位以促进定植。,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,该系统未涉及基因工程改造，所有功能依赖于天然代谢途径和菌群间互作。,"[""Hypoxia"", ""pH"", ""ROS/RNS""]","[""Mucin"", ""Butyrate"", ""Acetate"", ""Lactate""]","[""AHL"", ""AI-2""]","[""Protease"", ""Cytokine"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), riboflavin (vitamin B2) as redox shuttle, mucin-binding adhesins",AND gate: requires both mucin presence and low oxygen for optimal growth; threshold-based activation of butyrate production in response to lactate/acetate levels,系统通过感知肠道缺氧环境（FNR启动子响应）和黏液基质（黏附蛋白识别）协同激活定植与代谢。同时，通过感知乳酸和乙酸浓度，调控丁酸生成，实现代谢互作。维生素B2作为电子穿梭体，使F. prausnitzii在微氧环境中维持氧化还原平衡，体现了一种天然的抗氧逻辑机制。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type IV secretion system (inferred from cross-feeding), extracellular release of SCFAs","Self-regulated by substrate availability (e.g., mucin, lactate); no external control mechanism described","High compatibility with alginate, inulin, and resistant starch matrices; encapsulation enhances survival and controlled release",True,True,True,通过产生丁酸和抑制病原菌竞争性定植，间接抑制多种肠道病原体生长；同时通过调节黏液屏障减少病原菌附着。,Butyrate,True,True,True,True,丁酸具有广谱抗菌活性，可抑制多种致病菌；通过增强黏液屏障减少生物膜形成；在体内未观察到显著毒性或菌群失衡。,False,无直接产氧机制，但通过丁酸代谢消耗氧气，间接改善局部缺氧环境。,Not applicable,False,False,False,无光依赖或非光依赖产氧机制，不适用于氧疗场景。,True,丁酸抑制NF-κB通路，减少促炎细胞因子（如TNF-α、IL-6）释放，促进Treg细胞分化，调节免疫稳态。,Butyrate,True,丁酸促进肠上皮细胞增殖，增强紧密连接蛋白（如ZO-1、occludin）表达，修复受损肠屏障。,Butyrate,True,通过产生短链脂肪酸（SCFAs）调节宿主能量代谢，改善胰岛素敏感性，降低肥胖相关代谢紊乱。,Short-chain fatty acids (SCFAs),False,未涉及肿瘤治疗功能。,Not applicable,BSL-1,"Auxotrophy (e.g., vitamin B2 dependency), oxygen sensitivity",Vitamin B2 (riboflavin),Low pathogenicity; F. prausnitzii and A. muciniphila are commensals; potential risk in immunocompromised hosts; no antibiotic resistance genes reported,Alginate and inulin encapsulation provides physical confinement and protects against premature release,该系统为天然共生菌群，无致病性，属于BSL-1等级。其对氧气极度敏感，可作为天然生物遏制机制。维生素B2依赖性进一步限制其在非营养环境中存活。封装材料（如海藻酸钠、菊粉）提供物理屏障，防止逃逸。总体风险极低。,在动物模型中，该系统可显著改善代谢综合征、炎症性肠病和肠道屏障损伤。通过增加Akkermansia和Faecalibacterium丰度，降低F/B比值，提升丁酸水平，促进黏液修复和免疫调节，实现肠道微生态重建和功能恢复。,16658,2044,18702,,
9b11580c-1845-438e-b658-4db2921fa8c2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""Bb-12""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""Bifidobacterium infantis""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 17938""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""S. boulardii""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acidity; thrives in nutrient-rich, low-oxygen intestinal environment; requires prebiotics (e.g., oligosaccharides) for optimal colonization",Doubling time ~1–2 hours in vitro; stable in vivo colonization in infant gut over weeks; consistent with in vivo homeostasis,"Intestinal mucosa, particularly in the colon; preferentially colonizes breastfed infants; binds to mucus layer and enterocytes",Competitive exclusion of pathogenic bacteria; enhances colonization resistance; synergizes with native flora; promotes growth of beneficial bacteria via SCFA production,"Tolerant to gastric acid, bile salts, and moderate osmotic stress; stable during lyophilization and storage at 4°C; resistant to drying and rehydration","Mucin-binding adhesins, acid-resistant cell wall components, bile salt hydrolases",这些益生菌均为人源性，可在婴儿肠道中定植并增殖，具有良好的耐酸性、耐胆盐性和在低氧环境下的生长能力。它们主要定植于结肠黏膜表面，通过竞争性排斥、产生有机酸和调节免疫等方式维持肠道微生态平衡。,None reported,Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems reported; minimal metabolic burden; long-term in vivo persistence observed,Stable in food matrices and infant formulas; no significant degradation in delivery vehicles,未进行基因工程改造，其功能依赖于天然菌株的生理特性，如黏附能力、有机酸分泌和免疫调节活性。,"[""pH"", ""Hypoxia"", ""Bile Acids""]","[""Lactose"", ""Oligosaccharides"", ""Short-Chain Fatty Acids (SCFAs)""]","[""AHL"", ""AI-2""]","[""Secretory IgA"", ""Cytokines (e.g., IL-4, IFN-γ)"", ""Mucin""]","FNR promoter (hypoxia), Bile salt hydrolase (bile), Mucin-binding adhesins (mucosal attachment)",Constitutive expression; threshold-based response to nutrient availability; feedback inhibition via SCFA accumulation,这些菌株通过感知肠道环境中的pH、胆汁酸和低氧条件启动定植过程；通过识别乳糖、寡糖等营养物质激活代谢通路；同时响应宿主免疫信号（如sIgA）和黏蛋白表达，实现对肠道微环境的动态适应。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Constitutive secretion of organic acids, bacteriocins, and immunomodulatory molecules; no lysis or vesicle-mediated delivery reported",Dose-dependent effects; efficacy observed at 10^9–10^10 CFU/day; no external control mechanisms,"Compatible with infant formulas, breast milk, and oral suspensions; stable in encapsulated and lyophilized forms",True,True,True,通过产生乳酸、乙酸等有机酸降低局部pH，抑制病原菌生长；分泌细菌素（bacteriocins）直接杀伤有害菌；竞争性排斥病原体定植。,"Lactic acid, Acetic acid, Bacteriocins",True,True,True,True,LGG和B. breve在临床试验中显著减少腹泻持续时间，且无明显组织损伤；LGG在新生儿中预防NEC有效，提示其抗菌与生物膜抑制能力安全可控。,False,,,False,False,False,,True,调节Th1/Th2平衡，降低IL-4、IL-5等Th2型细胞因子，增加IFN-γ等Th1型因子；增强sIgA分泌，促进免疫耐受；抑制Treg细胞功能异常。,"Interleukin-4 (IL-4), Interferon-gamma (IFN-γ), Secretory IgA",True,通过上调黏蛋白基因表达，促进黏膜屏障修复；增强肠道通透性调节，减少炎症损伤；促进上皮再生。,"Mucin genes (MUC2), Epithelial growth factors",True,发酵碳水化合物产生短链脂肪酸（SCFAs），如乙酸、丙酸、丁酸，具有抗炎作用并提供能量；调节肠道pH，抑制有害菌生长。,"Short-chain fatty acids (SCFAs), Lactic acid",False,,,GRAS,Auxotrophy (nutrient-dependent growth); no antibiotic resistance genes reported,"Lactose, Oligosaccharides",Low pathogenicity; no evidence of HGT; opportunistic infections rare; D-lactate production may cause neurological symptoms in susceptible infants,Oral delivery limits systemic spread; gastrointestinal barrier prevents escape,LGG和B. infantis等菌株被广泛用于婴儿，安全性良好。尽管有极少数LGG相关败血症报告，但均发生在有中心静脉导管的住院患儿中，提示与宿主免疫状态相关。D-乳酸可能在代谢缺陷儿童中引起酸中毒，需注意。,LGG显著缩短急性病毒性腹泻持续时间，降低住院率；预防抗生素相关性腹泻和新生儿坏死性小肠结肠炎（NEC）；在过敏性湿疹患儿中改善临床评分并调节免疫标志物。在有家族过敏史的婴儿中，LGG可降低2岁和4岁时湿疹发生率。,7811,2042,9853,,
d82aec11-b6e6-4dc5-b1e2-b97b5ad9e611,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus pumilus"", ""strain_id"": ""SG43""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus megaterium"", ""strain_id"": ""SG183""}]",Encapsulated,Strict Aerobe,Optimal growth at 25–30°C; growth on PGYE and DSM media; efficient sporulation on solid and liquid media.,Vegetative cells grow to high densities (1.5–1.76 × 10⁹ cfu/ml); spores are stable and germinate in GI tract.,"Gastrointestinal tract (colon), particularly in the large intestine; transient colonization without permanent establishment.",Allochthonous organism; does not permanently colonize; may support beneficial commensals like Faecalibacterium prausnitzii.,High heat stability (resists 95°C for 15 min); resistant to simulated gastric fluid (pH 3–4); spores of SG183 resistant to pH 2; resistant to simulated intestinal fluid (SIF).,Sporulenes (heptaprenyl lipids) in spores; squalene-hopene cyclase enzyme.,"Bacillus pumilus SG43 and Bacillus megaterium SG183 are strict aerobes that grow efficiently at 25–30°C on various media, form spores readily, and exhibit high resistance to heat and gastrointestinal stresses. Spores survive passage through the stomach and are shed in feces within 18 days, indicating transient colonization of the GI tract without permanent establishment.",Genome sequencing via Illumina mate-paired sequencing; no genetic modification reported.,Not applicable (no engineered modifications reported).,Constitutive expression of carotenoid and riboflavin biosynthesis pathways.,Not applicable (no inducible circuits reported).,High chromosomal stability; no plasmids reported; intrinsic resistance genes present but not linked to horizontal gene transfer risk.,Spores maintain stability in encapsulated formulations and during storage.,No genetic engineering was performed. The strains naturally produce high levels of riboflavin and C30 carotenoids via constitutive biosynthetic pathways. Genome analysis confirmed the presence of complete carotenoid and riboflavin biosynthesis operons without evidence of plasmid-based or engineered genetic elements.,"[""Hypoxia"", ""pH"", ""Oxidative stress (H₂O₂)""]","[""Carotenoids"", ""Riboflavin""]",,,Squalene-hopene cyclase (spore-specific enzyme); carotenoid biosynthesis operon (regulated by growth phase and light in SG183).,Constitutive expression; no synthetic logic circuits. Pigment production is inversely correlated with sporulation (alternative developmental response).,"Pigment production and sporulation are mutually exclusive developmental pathways in Bacillus pumilus SG43. Sporulation in DSM medium suppresses pigment production, while growth in BTC medium favors pigment accumulation. Light induces pigment production in SG183 but not in SG43. This suggests a natural regulatory logic where environmental cues (light, medium composition) modulate metabolic output via developmental trade-offs.","[""Antioxidant"", ""Metabolic Regulation"", ""Tissue Repair""]",Spore-mediated delivery; riboflavin excreted into medium; carotenoids embedded in cell wall and spore membrane.,Dose-dependent increase in Faecalibacterium prausnitzii levels with daily administration of spores.,Spores are stable in encapsulated formulations and resist GI degradation; suitable for oral delivery.,False,,,Not applicable (no antibacterial effector reported).,,False,False,False,False,No evidence of antibacterial activity reported.,False,Not applicable (no oxygen-producing enzyme reported).,,False,False,False,No oxygenation mechanism identified.,False,Not applicable (no cytokine or immune modulator reported).,,True,"Promotes growth of Faecalibacterium prausnitzii, a butyrate-producing bacterium associated with improved gut barrier function and mucosal healing.",Faecalibacterium prausnitzii (indirectly stimulated via antioxidant delivery),True,"Delivers riboflavin and carotenoids, which act as antioxidants and redox modulators, lowering intestinal redox potential to support anaerobic commensals.","Riboflavin (Vitamin B2), C30 Carotenoids",False,Not applicable (no tumor-targeting or prodrug conversion mechanism reported).,,GRAS,No synthetic kill switches; reliance on transient colonization and natural clearance.,Sporulenes (spore-specific lipids); intrinsic resistance genes.,"No pathogenicity genes; no enterotoxin genes (e.g., hbl, nhe); no transposons with antibiotic resistance; intrinsic resistance to antibiotics via efflux pumps; no evidence of horizontal gene transfer risk.",Spores are physically confined and shed within 18 days; no permanent colonization.,"Both strains are non-pathogenic, lack virulence genes, and do not persist in the gut. They are resistant to gastric and intestinal fluids, but their transient nature and lack of colonization reduce long-term ecological risk. No evidence of genotoxicity or acute toxicity in mice. GRAS status is supported by absence of toxigenic activity and antibiotic resistance genes.","Daily administration of Bacillus pumilus SG43 spores significantly increased Faecalibacterium prausnitzii levels in mouse colon (p = 0.04), suggesting potential for improving gut barrier function and reducing inflammation in inflammatory bowel disease. Spores were more effective than vegetative cells, likely due to enhanced survival and delivery of antioxidants (riboflavin and sporulenes) to the large intestine.",16492,1876,18368,,
ca7cf5ba-a08a-4dd5-952c-43c7bbe5dfb6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""DSM 10663 NCIMB 10415""}]",Oral supplementation (gel and liquid additive),Facultative Anaerobe,"Growth in gastrointestinal tract; tolerates pH and osmotic conditions of gut; utilizes sugars (sucrose, glucose, lactose) as carbon sources",No specific growth rate or doubling time reported; survives gastrointestinal passage and likely colonizes gut,"Intestinal tract (gut mucosa, particularly in suckling piglets)",Competes with pathogenic E. coli; may stimulate growth of other lactic acid bacteria (LAB) such as lactobacilli,Tolerates storage at 4°C; survives gastrointestinal transit; stable in gel and liquid formulations,"Peanut oil, sucrose, glucose, lactose (formulation components)",该菌株为肠球菌属，属于革兰氏阳性球菌，为兼性厌氧菌，可在猪小肠环境中存活并定植。其生长依赖于糖类（如蔗糖、葡萄糖、乳糖）作为碳源，能耐受胃肠道的酸性环境和渗透压变化，具有良好的稳定性，可在口服制剂中保持活性。,,,,,,,该研究未对 Enterococcus faecium DSM 10663 NCIMB 10415 进行基因工程改造，仅作为天然存在的益生菌株使用，未引入外源基因或调控回路。,"[""pH"", ""Osmotic stress""]","[""Glucose"", ""Sucrose"", ""Lactose""]",,,No specific sensor identified; likely relies on native metabolic sensing of nutrients and environmental conditions,No engineered logic gates; natural metabolic responses to nutrient availability,该菌株通过感知肠道中的糖类（如葡萄糖、蔗糖、乳糖）和pH等环境信号，启动自身代谢活动，但未设计任何人工逻辑控制回路，其响应为自然生理行为。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Natural secretion of metabolic products (e.g., lactic acid); no engineered secretion system",Controlled by defined daily administration (gel and liquid additive); dosage adjusted based on age and health status,Compatible with gel (peanut oil-based) and liquid (sugar-based) formulations; stable in both matrices,True,False,False,通过与携带I型菌毛的致病性大肠杆菌协同作用，抑制其定植；可能通过竞争性排斥或代谢产物抑制病原菌生长。,Lactic acid (metabolic end product),False,True,True,True,该菌株可显著降低仔猪腹泻发生率（14.8% vs 40.0%），且无明显细胞毒性或微生物群落紊乱，表明其抗菌作用具有可控性和安全性。,False,,,False,False,False,,True,可能通过刺激宿主免疫系统，增强肠道屏障功能，调节免疫应答，从而减少腹泻发生。,"Lactic acid, bacterial cell wall components (e.g., peptidoglycan)",False,,,True,通过产生短链脂肪酸（如乳酸）调节肠道代谢环境，促进营养吸收，维持肠道稳态。,Lactic acid,False,,,GRAS,"None (natural strain, no engineered kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer documented; low risk of environmental escape due to gut-restricted colonization,Physical confinement via oral delivery and gut retention; no systemic dissemination reported,Enterococcus faecium DSM 10663 NCIMB 10415 被广泛用作动物饲料添加剂，具有GRAS（公认安全）地位。其为天然益生菌，无基因工程改造，不携带已知的抗生素抗性基因，且在肠道内定植，不易逃逸至环境，安全性高。,口服补充该菌株从出生至断奶可显著降低仔猪腹泻发生率（14.8% vs 40.0%），并提高日增重17 g/天（p < 0.05），表明其在改善仔猪健康和生产性能方面具有显著效果。,9794,1572,11366,,
9bf44bf4-aabd-47f9-850f-f6a316eeb0d8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces"", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in media containing carbohydrates (e.g., lactose, glucose), with tolerance to bile salts and low pH (gastric conditions)",Doubling time ~60–90 minutes in vitro; in vivo colonization is transient but sufficient for health benefit,"Intestinal lumen, mucosal surface, vaginal tract, skin surface",Symbiotic with host microbiota; competes with pathogenic bacteria for nutrients and adhesion sites,"Tolerant to drying, lyophilization, moderate UV exposure, and shear stress during processing","Exopolysaccharides (EPS), biofilm formation, spore formation (in Bacillus)",这些微生物多为革兰氏阳性菌，属于乳酸菌或双歧杆菌等传统益生菌，具有在人体肠道等环境中定植并维持生理平衡的能力。它们在37°C、中性至弱碱性pH条件下生长良好，能耐受胃酸和胆汁，适合口服给药。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及对益生菌进行基因改造。传统益生菌基于长期使用历史，其安全性已通过GRAS或QPS认证，无需基因工程干预。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""SCFAs"", ""Lactate"", ""Glucose""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines"", ""Tissue degradation fragments""]","FNR promoter, LasR receptor, LuxI/LuxR system (inferred from context)",Not specified,文中未描述具体的逻辑门控机制，但指出益生菌可通过感知宿主微环境信号（如pH、代谢物）调节自身行为，实现与宿主的动态互作。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]","Type I–VI secretion systems, vesicles, lysis (inferred)",Not specified,Not specified,False,,,Not applicable,,False,False,False,False,未提及抗菌或抗生物膜功能,False,Not applicable,,False,False,False,未提及产氧功能,True,通过调节宿主免疫系统，增强黏膜屏障功能，抑制过度炎症反应，促进免疫耐受。,"Cytokines (e.g., IL-10, TGF-β), SCFAs (e.g., butyrate)",True,通过分泌生长因子和调节肠道上皮细胞增殖，促进肠黏膜修复和屏障功能恢复。,"Epidermal Growth Factor (EGF), TGF-β, SCFAs",True,通过发酵碳水化合物产生短链脂肪酸（SCFAs），调节宿主能量代谢、血糖稳态和脂质代谢。,"Short-Chain Fatty Acids (SCFAs), e.g., acetate, propionate, butyrate",False,Not applicable,,BSL-1,"Auxotrophy, GRAS/QPS status","Nutrient-dependent growth (e.g., specific amino acids, vitamins)",Low pathogenicity; no known antibiotic resistance genes; low risk of horizontal gene transfer; limited environmental escape due to host-restricted growth,Not applicable,传统益生菌如乳酸杆菌、双歧杆菌等已被广泛使用，具有GRAS或QPS认证，安全性高。其在人体内定植能力有限，不易在环境中长期存活，风险较低。,这些益生菌通过调节肠道菌群、增强免疫功能、促进黏膜修复和代谢平衡，在多种疾病模型中显示出改善肠道健康、缓解炎症性肠病和代谢综合征的潜力。,6509,1627,8136,,
24ada457-68b1-4047-8445-0d230bca71af,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""Symbioflor®2, Genotype G1⁺ (G1/2, G6/7, G8)""}]",Suspension (in gut lumen),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, tolerates moderate osmotic stress; utilizes glucose and other carbon sources; no specific vitamin dependency reported","High initial growth post-ingestion; sustained colonization for up to 30 weeks (mean: 18.7 weeks, median: 25.7 weeks); in vivo persistence exceeds in vitro expectations","Human intestinal lumen, particularly in the colon; capable of competing with host E. coli and establishing long-term presence",Competes with host E. coli strains; may create niche for commensal E. coli recovery post-antibiotics; no significant disruption of overall microbiota reported,"Tolerates gastric transit (acidic environment), bile salts, and moderate osmotic stress; survives lyophilization and storage in product; stable during intestinal transit","Natural E. coli cell envelope, bile resistance genes (inferred)",该研究中使用的益生菌大肠杆菌（Symbioflor®2）在单次高剂量摄入后，可在人体肠道内长期定植，持续时间长达30周。其生长生理特性包括在37°C、中性pH条件下快速增殖，能耐受胃肠道环境中的酸性和胆盐压力，且在宿主肠道微生物群中具有较强的竞争力，可长期占据生态位。,Not specified (natural genotypes used; no genetic modification reported),Not applicable (no engineered modifications),Not applicable (no synthetic circuits described),,High chromosomal stability; genotype G1⁺ persisted for months without evidence of plasmid loss or integration; no genetic drift reported,Stable in oral formulation (lyophilized powder); maintains viability during storage and gastrointestinal transit,本研究未对大肠杆菌进行基因工程改造，所用菌株为天然存在的益生菌型大肠杆菌（Symbioflor®2），其长期定植能力源于其固有的生态适应性，而非人工设计的遗传回路。,"[""pH"", ""Bile acids"", ""Osmotic stress""]","[""Glucose"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing (inferred from competition dynamics)""]","[""Proteases (inferred from gut environment)"", ""Cytokines (indirectly via immune modulation)""]","Inferred: FNR promoter (hypoxia), Bile acid transporters, Glucose uptake systems (e.g., ptsG), and quorum sensing receptors (e.g., LuxS/AI-2)",Competition-based logic: persistence depends on niche establishment and competitive exclusion; threshold-like behavior in dominance shift (G1⁺ overtakes others after initial phase),该系统通过感知肠道环境中的pH、胆汁酸和渗透压等物理化学信号，以及葡萄糖等代谢物，实现对肠道生态位的适应。其逻辑机制表现为：初期多种基因型共存，随后通过竞争性排斥，G1⁺型菌株在数天后逐渐占据主导地位，表现出类似‘AND门’逻辑——需同时满足环境适应与竞争能力才能长期定植。,"[""Colonisation"", ""Microbiome Modulation""]",Passive secretion (natural metabolic activity); no engineered secretion systems reported,Not controllable (single high-dose intake; no feedback regulation),Compatible with oral formulation (lyophilized powder); stable during GI transit,False,False,False,Not applicable (no engineered antibacterial function),,False,False,False,False,无相关证据,False,Not applicable (no oxygen-producing function),,False,False,False,无相关证据,True,Indirect immunomodulation via niche occupation and competition with pathogenic strains; may stimulate immune surveillance; self-reported improvement in immune defense by volunteers,"Inferred: Microbial-associated molecular patterns (MAMPs), e.g., LPS, flagellin, and secreted metabolites",False,Not applicable (no direct tissue repair function),,True,Modulates gut environment via production of SCFAs and competition for nutrients; may influence host metabolism through microbial community shifts,"Short-chain fatty acids (SCFAs), e.g., acetate, propionate",False,Not applicable (no tumor-targeting function),,GRAS,Natural auxotrophy (inferred); no suicide genes or kill switches reported,"Inferred: Nutrient dependency (e.g., for specific amino acids or vitamins)",Low pathogenicity; no severe side effects observed; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape reported,Oral formulation provides physical barrier; natural clearance via feces,该益生菌大肠杆菌菌株为长期使用的GRAS级产品，未发现严重不良反应。其在人体肠道内长期定植但未引起炎症或菌群失衡，且在抗生素治疗后可被清除，表明其具有良好的生物安全性。无基因工程改造，无耐药基因，无致病性，属于低风险生物制剂。,该研究未直接评估伤口愈合或疾病治疗效果，但结果显示，单次高剂量摄入后，益生菌大肠杆菌在5名志愿者中均实现长期定植（最长30周，平均18.7周），其中G1⁺型菌株为唯一持续存在的基因型。该菌株在肠道中表现出强竞争力，可替代宿主菌株并促进其恢复，提示其在调节肠道微生态、增强免疫防御方面具有显著潜力。,11589,1866,13455,,
21725db6-7268-43de-bdde-007ef0f33ec7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Chryseobacterium sp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Pseudomonas sp. 1"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Pseudomonas sp. 2"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Stenotrophomonas sp."", ""strain_id"": ""Not specified""}]","Encapsulated (on skin surface, applied as probiotic treatment)",Facultative Anaerobe,"Optimal growth at room temperature (22–25°C), neutral to slightly alkaline pH, moderate osmotic tolerance; dependent on host skin environment (moist, nutrient-rich surface)",Not explicitly reported; inferred to grow in vitro under standard lab conditions; no in vivo doubling time data available,"Cutaneous surface of amphibian skin (epidermis), particularly in moist, microaerophilic environments","Competitive with resident microbiota; failed to persist in A. zeteki skin, suggesting strong competition from native microbial community",Not explicitly reported; assumed moderate tolerance to environmental fluctuations due to amphibian skin habitat,,这些细菌均为从巴拿马蛙类皮肤中分离的革兰氏阴性菌，具有在体外抑制蛙壶菌（Bd）的能力。它们在实验中被应用于金蛙皮肤表面，但未能在体内长期定植，表明其在宿主皮肤微环境中的适应性有限。,,,,,,,文中未提及对这些细菌进行基因改造。所有实验均使用原始分离株作为益生菌候选，未进行任何遗传修饰或合成生物学设计。,"[""Hypoxia"", ""pH"", ""Moisture""]","[""Bd zoospores"", ""Host skin metabolites""]",,"[""Skin peptides"", ""Immune factors""]",Not specified (no engineered sensors reported),Not applicable (no synthetic circuits described),这些细菌未被设计为具有响应性逻辑电路。其功能依赖于天然代谢产物的产生，而非环境信号触发的基因调控。,"[""Antibacterial""]",Unknown (likely passive secretion via outer membrane or lysis; no specific secretion system reported),Not controllable (no engineered regulation of output; activity depends on natural growth and metabolite production),Poor (failed to persist in skin environment; no evidence of stable encapsulation or sustained release),True,False,False,通过产生抗真菌代谢物抑制蛙壶菌（Batrachochytrium dendrobatidis）的生长，该机制在体外实验中被证实有效。,"Antifungal metabolites (e.g., indole derivatives, phenazines, or other unknown compounds)",False,False,False,False,体外实验显示这些细菌能有效抑制蛙壶菌，但体内应用后未能定植，因此无法评估其在生物膜或组织中的实际抗菌效果。,False,,,False,False,False,无相关数据支持该功能。,False,,,False,,,False,,,False,,,BSL-1,None (no kill-switches or auxotrophy reported),,Low pathogenicity; no reports of virulence in amphibians or humans; no antibiotic resistance genes reported; potential for horizontal gene transfer not assessed; environmental escape risk low due to lack of persistence.,None (no physical barrier used in experiment; probiotics applied directly to skin),这些细菌均为从野生蛙类皮肤中分离的非致病性菌株，未见致病报道，且在体外实验中表现出良好的安全性。但由于其在宿主皮肤上无法定植，因此实际生态风险较低。,实验结果显示，尽管体外具有强抗蛙壶菌活性，但四种候选益生菌在金蛙皮肤上均未能长期定植。约30%的感染个体成功清除了病原体，但这一结果与益生菌处理无关，而是与初始皮肤微生物群落结构密切相关。这表明宿主皮肤微生物群落的天然组成比外源性益生菌更关键，提示未来应优先筛选与宿主共存且能稳定定植的本土菌株用于益生菌开发。,11914,1577,13491,,
42bbc73b-394f-4ffa-995f-4d31c0cf60e6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus licheniformis"", ""strain_id"": ""MTCC""}]",Encapsulated,Facultative Anaerobe,"Temperature: 38°C; pH: 7.2 (PBS); Nutritional requirements: Complex medium (Tryptic soya broth), supplemented with carbon sources and amino acids from basal diet (casein, gelatin, dextrin, starch).",Growth rate: Not explicitly quantified; doubling time inferred from 48 h incubation at 38°C. In vivo growth supported by gut environment of M. rosenbergii.,Gastrointestinal tract (gut microbiota of Macrobrachium rosenbergii),"Competitive exclusion of pathogenic bacteria (Aeromonas spp., Pseudomonas spp.); symbiotic relationship with host via immune modulation.","Moderate tolerance to storage at 4°C (viability dropped to 35.25% after 30 days); resistant to drying during feed pelletization (45°C, 1–2 h); stable under autoclaving (121°C, 15 psi, 25 min).","Spore formation (endospore) confers resistance to heat, drying, and chemical stress.","Bacillus licheniformis is a Gram-positive, endospore-forming bacterium capable of surviving in the aquatic environment and colonizing the gut of giant freshwater prawns. It grows optimally at 38°C and is stable in feed formulations, with viability maintained for up to 30 days at 4°C, though with gradual decline. It successfully colonizes the gastrointestinal tract, where it outcompetes pathogenic bacteria and enhances host growth and immunity.",,,,,No genetic modifications reported; natural chromosomal stability in host environment. Spore formation ensures long-term survival and persistence.,Stable in feed matrix (pellets) and during storage; viability maintained in encapsulated form.,"No genetic engineering was performed. The strain was used in its native form as a probiotic. Its functionality relies on natural traits such as spore formation, enzyme secretion, and competitive exclusion.","[""pH"", ""Temperature""]","[""Glucose"", ""Amino acids"", ""Carbon sources (e.g., dextrin, starch)""]",,,"Endospore formation regulated by environmental cues (e.g., nutrient depletion, temperature); no specific receptor or promoter reported.",No synthetic logic circuits; natural response to nutrient availability and environmental stress.,"Bacillus licheniformis senses nutrient availability and environmental stress (e.g., temperature, pH) through intrinsic regulatory systems. Upon nutrient depletion, it enters sporulation phase, ensuring survival. It colonizes the gut by sensing host-derived nutrients and outcompeting pathogens via metabolic competition.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I–VI secretion systems (inferred from genus), lysis (spore germination), extracellular enzyme secretion",Dose-dependent response observed; highest effects at 1.0 × 10⁹ cfu/g feed; no synthetic control systems.,Compatible with feed pellet matrix; stable during autoclaving and drying; encapsulated in feed for delivery.,True,True,True,"Secretes bacteriocins (e.g., polymyxin, bacitracin, gramicidin) and extracellular enzymes that degrade biofilms and slime layers, enhancing antibiotic penetration. Competes with pathogens for nutrients and space.","Bacteriocins (polymyxin, bacitracin, gramicidin), extracellular enzymes (proteases, amylases)",True,True,True,True,Significant reduction in pathogenic Aeromonas spp. and Pseudomonas spp. in gut; inhibition of biofilm formation via enzyme secretion; no reported cytotoxicity or microbiome disruption; localized action in gut.,False,,,False,False,False,No evidence of oxygen production or oxygenation function.,True,"Enhances cellular and humoral immunity via cell wall components (β-glucan, lipopolysaccharide) and competitive exclusion of pathogens. Stimulates haemocyte proliferation, phenol oxidase (PO), and superoxide dismutase (SOD) activity.","β-glucan, lipopolysaccharide (LPS), cell wall components",True,Promotes tissue integrity by reducing pathogen load and inflammation. Indirectly supports tissue repair by enhancing immune function and reducing infection burden.,"Immune mediators (PO, SOD), reduced pathogen-induced tissue damage",False,,,False,,,GRAS,Natural auxotrophy (no synthetic kill switches); spore formation limits overgrowth.,Spore formation (endospore) acts as natural containment.,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape documented.,Feed pellet encapsulation provides physical confinement.,"Bacillus licheniformis is classified as GRAS (Generally Recognized As Safe). It is non-pathogenic, does not produce toxins, and lacks antibiotic resistance genes. Its spore-forming nature limits uncontrolled proliferation. Encapsulation in feed ensures localized delivery and reduces environmental release risk.","Dietary supplementation of Bacillus licheniformis at 1.0 × 10⁹ cfu/g feed significantly improved growth (112.25% weight gain), reduced feed conversion ratio (2.14), enhanced immune parameters (highest THC, PO, SOD, and antibacterial activity), and reduced cumulative mortality by 50% after Vibrio alginolyticus challenge. It successfully colonized the gut, suppressed pathogenic bacteria (Aeromonas, Pseudomonas), and provided dose-dependent protection, indicating strong therapeutic efficacy in prawn health management.",17480,1861,19341,,
2dd9bf53-d5d8-4e0d-b3d4-7ca1a401c400,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""0103, 0123, 0140, 0147, 0157, 0611, 0612, 1002""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates pH 3.0 for up to 24 hours; survives 2% bile salt; grows in MRS broth with up to 6% NaCl",Doubling time not reported; viable counts maintained at >4 log CFU/ml after 24 h at pH 3.0; growth rate reduced at 2% bile salt but not abolished,Gastrointestinal tract (small intestine and colon); potential for intestinal mucosal adhesion,Competitive exclusion of pathogens via antibacterial metabolites; auto-aggregation may enhance colonization and biofilm formation,Tolerant to 60°C for 10 min (up to 86.6% viability); resistant to 6% NaCl; survives 24 h at pH 3.0; tolerates 2% bile salt,"Heat shock proteins (HSPs), membrane integrity, acid tolerance systems (e.g., H+-ATPase)",该研究中分离的植物乳杆菌（Lactobacillus plantarum）具有良好的酸耐受性、胆盐耐受性、热稳定性和高盐耐受性，能够在模拟胃肠道环境中存活，具备作为益生菌候选菌株的生理基础。,,,,,,,本文未涉及基因工程改造，所有菌株均为天然分离菌株，未进行人工遗传修饰。,"[""pH"", ""Bile Salts"", ""Osmotic Pressure""]","[""Lactate"", ""Glucose""]",,,"H+-ATPase, membrane transporters, acid tolerance systems (e.g., F1F0-ATPase)",No engineered logic gates; natural sensing via pH homeostasis and osmotic regulation systems,植物乳杆菌通过H+-ATP酶系统维持细胞内pH稳定，响应外部酸性环境；通过膜转运蛋白调节渗透压，实现对胃肠道恶劣环境的自然适应。,"[""Antibacterial"", ""Immunomodulation""]","Type I secretion (e.g., bacteriocins), passive diffusion of organic acids, hydrogen peroxide",Not controllable; natural secretion based on growth phase and environmental conditions,Compatible with food matrices; no data on encapsulation or gel compatibility,True,True,False,分泌有机酸、过氧化氢、细菌素等抗菌物质，抑制常见食源性病原菌生长,"Organic acids (lactic, acetic), hydrogen peroxide, bacteriocins",True,True,True,True,多数植物乳杆菌对李斯特菌、沙门氏菌、金黄色葡萄球菌等具有显著抑制作用，抑制圈直径达8–17 mm，且未提及对宿主细胞毒性，表明其具有可控且安全的抗菌活性。,False,,,False,False,False,无相关数据支持该菌株具有产氧能力。,True,通过调节宿主免疫反应，增强肠道屏障功能，抑制炎症因子释放,"Cell surface proteins, exopolysaccharides (EPS), secreted metabolites",False,,,False,,,False,,,GRAS,"None (natural strain, no engineered kill switches)",,No antibiotic resistance genes reported; low pathogenicity; no evidence of horizontal gene transfer; safe for human consumption,None (no physical confinement described),植物乳杆菌为公认安全（GRAS）菌种，未发现耐药基因或致病性特征，无基因工程改造，无逃逸风险，适合用于食品和功能性产品。,该研究评估了植物乳杆菌在模拟胃肠道环境中的存活能力、耐酸耐胆盐能力、热稳定性和抗菌活性，结果显示多个菌株（如0147、0611、0612）在pH 3.0下24小时后仍保持>4 log CFU/ml，且对李斯特菌等病原菌具有强抑制作用，表明其具有良好的益生潜力，可作为功能性食品的候选菌株。,21330,1585,22915,,
3ac778cc-2f5a-4ba9-8738-71733784882a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""AQAHBS001""}]",Encapsulated,Facultative Anaerobe,Temperature: 25–37°C; pH: 5.5–9.0; Tolerant to high osmotic stress and extreme pH; Grows on alternative non-expensive ingredients including soybean meal and complex carbohydrates,Growth rate: Rapid; Doubling time: ~20–30 min in optimal conditions; In vitro growth consistent with in vivo colonization ability,"Gut lumen of Litopenaeus vannamei, particularly in the intestine and hepatopancreas","Competes with opportunistic pathogens (e.g., Vibrio spp.) for colonization sites; promotes beneficial bacteria (e.g., Pseudoalteromonas); suppresses pathogenic microbial groups","High tolerance to heat, pH extremes, osmotic stress, and drying; Spores survive feed processing and storage; Resistant to UV and shear stress during formulation","Spore coat proteins (e.g., CotA, SASP)","Bacillus subtilis AQAHBS001 is a robust, spore-forming bacterium with strong environmental resilience. It thrives in variable aquatic conditions typical of shrimp ponds and can germinate in the shrimp gut to exert beneficial effects. Its ability to grow on low-cost, non-expensive feed ingredients like soybean meal and complex carbohydrates makes it ideal for sustainable aquaculture applications.","Plasmid-based expression systems (implied), CRISPR-Cas not mentioned",Not specified,Constitutive (implied from natural enzyme production),,High chromosomal stability; no plasmid loss reported; low metabolic burden; long-term in vivo consistency observed,Spores remain stable in feed matrix; germination triggered by gut conditions,"Bacillus subtilis AQAHBS001 is naturally engineered through selection for high enzyme production (e.g., carbohydrases, proteases) and antimicrobial peptide synthesis. It is used in its wild-type form without genetic modification, relying on native gene expression for functional performance in feed.","[""pH"", ""Temperature"", ""Osmotic stress""]","[""Soybean meal components"", ""Complex carbohydrates (starch, non-starch polysaccharides)"", ""Protein degradation products""]","[""Quorum sensing molecules (AHL, AI-2) – inferred from competition""]","[""Proteases (e.g., trypsin inhibitors in soy)"", ""Immune factors (e.g., lysozyme, anti-LPS factors)""]","FNR-like regulators, Spo0A, and other sporulation/growth regulators; specific receptors for nutrient uptake (e.g., ABC transporters)",Constitutive expression with threshold-based activation upon nutrient availability; no explicit logic gates reported,"The strain senses nutrient availability (e.g., complex carbohydrates, proteins) in the shrimp gut and activates metabolic pathways accordingly. Spore germination is triggered by specific gut conditions (pH, nutrients), enabling timely activation of beneficial functions without external induction.","[""Antibacterial"", ""Gut Microbiota Modulation"", ""Feed Intake Improvement""]",Secretion via Sec pathway and general secretion system (Type I/II); no lysis or vesicle release reported,Dose-dependent effects observed; higher probiotic concentration leads to greater pathogen suppression and immune enhancement,High compatibility with feed matrix; spores remain stable during feed processing and encapsulation; no structural degradation of feed observed,True,True,False,"Produces antimicrobial peptides (AMPs) that inhibit pathogenic bacteria such as Vibrio parahaemolyticus, Vibrio alginolyticus, and Vibrio harveyi; competes for colonization sites in the gut","Antimicrobial peptides (AMPs), e.g., subtilin, bacilysin",True,True,True,True,Bacillus subtilis AQAHBS001 significantly reduced Vibrio spp. levels in hepatopancreas and intestine; no adverse effects on host cells reported; localized action in gut; no disruption of feed matrix structure,False,,,False,False,False,,True,"Enhances immune response by upregulating phagocytic activity, prophenoloxidase, lysozyme, and anti-lipopolysaccharide factor (ALF) genes; increases intestinal wall thickness","Immune-stimulating metabolites and surface molecules (e.g., lipoteichoic acid, peptidoglycan fragments)",True,Improves intestinal wall thickness and gut integrity; supports epithelial regeneration and barrier function,"Extracellular matrix components, mucus-stimulating factors",True,"Enhances digestion of complex carbohydrates (starch, non-starch polysaccharides) and proteins (soybean meal) via overproduction of carbohydrases and proteases; improves nutrient assimilation","Glucose, amino acids, short-chain fatty acids (SCFAs) – inferred from improved digestion",False,,,GRAS,"Auxotrophy (implied from natural strain use), no kill-switches reported","Nutrient-dependent growth (e.g., specific amino acids, vitamins)",Low pathogenicity; no known toxin production in this strain; no antibiotic resistance genes reported; low risk of horizontal gene transfer; environmental escape unlikely due to competitive disadvantage outside host,Physical confinement via feed encapsulation; spores remain dormant until gut conditions trigger germination,"Bacillus subtilis AQAHBS001 is classified as GRAS by FDA. It has a long history of safe use in animal feed and human probiotics. No evidence of virulence or toxin production in this strain. Its dependence on gut-specific conditions limits environmental persistence, reducing ecological risk.","Bacillus subtilis AQAHBS001 significantly improved feed conversion ratio, weight gain, survival rate, and immune parameters in Litopenaeus vannamei. It effectively reduced Vibrio spp. colonization in gut and hepatopancreas, enhanced intestinal integrity, and enabled full replacement of fishmeal with soybean meal and complex carbohydrates in aquafeeds, demonstrating high efficacy in sustainable shrimp aquaculture.",9476,6514,15990,,
3ac778cc-2f5a-4ba9-8738-71733784882a,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""ATCC 7050""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37–45°C; pH: 5.0–8.5; Tolerant to bile salts and gastric conditions; Grows on soybean meal, starch, and non-starch polysaccharides",Growth rate: Moderate; Doubling time: ~30–40 min; In vitro growth consistent with in vivo performance,Intestinal tract of Litopenaeus vannamei; preferentially colonizes gut mucosa,"Suppresses opportunistic pathogens (Vibrio, Tenacibaculum, Photobacterium); downregulates Muricauda, Kangiella, Shewanella; promotes Pseudoalteromonas","High spore stability under heat, drying, and storage; Resistant to bile and low pH; Tolerant to osmotic and shear stress","Spore coat proteins, SASP, and heat-shock proteins","Bacillus coagulans ATCC 7050 is a thermotolerant, spore-forming bacterium with strong resilience to feed processing and gastrointestinal conditions. It effectively colonizes the shrimp gut and modulates microbial balance, making it suitable for functional feed applications.",Not genetically modified; wild-type strain used,,Constitutive,,High chromosomal stability; no plasmid loss; low metabolic burden; consistent in vivo performance,Spores remain viable in feed matrix; germination triggered by gut conditions,"Bacillus coagulans ATCC 7050 is used in its native form without genetic modification. Its beneficial effects stem from natural enzyme production and antimicrobial activity, with no synthetic circuits or inducible systems.","[""pH"", ""Temperature"", ""Osmotic stress""]","[""Soybean meal"", ""Starch"", ""Non-starch polysaccharides""]","[""Quorum sensing molecules (AHL, AI-2) – inferred""]","[""Bile acids"", ""Proteases""]","Spo0A, SigH, and other sporulation regulators; nutrient-specific transporters",Constitutive expression with nutrient-dependent activation; no complex logic gates reported,"The strain senses nutrient availability (e.g., complex carbohydrates, proteins) and environmental cues (pH, temperature) in the shrimp gut, triggering germination and metabolic activation. Its response is tuned to gut-specific conditions, ensuring targeted activity.","[""Antibacterial"", ""Gut Microbiota Modulation"", ""Feed Intake Improvement""]",Secretion via Sec pathway; no lysis or vesicle release reported,"Dose-dependent improvement in growth, immune response, and pathogen suppression",Excellent compatibility with feed matrix; spores stable during processing; no adverse effects on feed structure,True,True,False,"Inhibits Vibrio, Tenacibaculum, Photobacterium, and other opportunistic pathogens; suppresses pathogen colonization through competitive exclusion and antimicrobial compound production","Antimicrobial peptides (AMPs), organic acids (e.g., lactic acid)",True,True,True,True,Bacillus coagulans ATCC 7050 reduced pathogen levels in gut and pond water; improved food conversion ratio; no cytotoxicity reported; localized action; no feed matrix disruption,False,,,False,False,False,,True,"Enhances immune responses including enzyme activity (lysozyme, protease), phagocytosis, and immune gene expression","Peptidoglycan, lipoteichoic acid, and secreted immunomodulatory metabolites",True,Improves intestinal microbiota balance and gut integrity; supports epithelial regeneration,"Mucus-stimulating factors, extracellular matrix components",True,"Overproduces carbohydrases (e.g., alpha-galactosidase, cellulase, pectinase) and proteases to degrade complex carbohydrates and proteins in soybean meal and grains","Glucose, amino acids, SCFAs",False,,,GRAS,"Auxotrophy (implied), no kill-switches","Nutrient-dependent growth (e.g., specific carbon sources)",Low pathogenicity; no known toxin production; no antibiotic resistance genes; low HGT risk; environmental escape unlikely due to competitive disadvantage,Feed encapsulation prevents environmental release; spores remain dormant until gut conditions trigger germination,Bacillus coagulans ATCC 7050 is GRAS and widely used in animal and human probiotics. It has a strong safety profile with no reported adverse effects in shrimp or consumers. Its dependence on gut-specific conditions limits environmental persistence.,"Bacillus coagulans ATCC 7050 significantly improved growth, food conversion ratio, immune response, and gut microbiota balance in Litopenaeus vannamei. It effectively suppressed pathogenic bacteria, enhanced digestion of vegetable ingredients, and enabled sustainable aquafeed formulations with high levels of non-digestible carbohydrates, demonstrating strong performance in shrimp aquaculture.",9476,6514,15990,,
3ac778cc-2f5a-4ba9-8738-71733784882a,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus cereus"", ""strain_id"": ""Not specified""}]",Encapsulated,Facultative Anaerobe,Temperature: 25–40°C; pH: 5.0–9.0; Tolerant to high osmotic and thermal stress; Grows on complex substrates including soy and starch,Growth rate: Rapid; Doubling time: ~25–35 min; In vitro growth consistent with in vivo colonization,Gut lumen of Litopenaeus vannamei post-larvae,Competes with Vibrio parahaemolyticus and Vibrio alginolyticus; prevents pathogen establishment,"High spore stability under heat, drying, and storage; Resistant to bile and low pH; Tolerant to shear stress","Spore coat proteins, SASP, and heat-shock proteins","Bacillus cereus is a spore-forming, facultative anaerobe with strong environmental resilience. It colonizes the shrimp gut and inhibits pathogen proliferation through competition and antimicrobial activity, though its use requires careful safety evaluation.",Not genetically modified; wild-type strain used,,Constitutive,,High chromosomal stability; no plasmid loss; consistent in vivo performance,Spores stable in feed; germination triggered by gut conditions,"Bacillus cereus is used in its native form. Its probiotic function relies on natural antimicrobial peptide production and competitive exclusion, without synthetic genetic circuits.","[""pH"", ""Temperature"", ""Osmotic stress""]","[""Soybean meal"", ""Starch"", ""Protein degradation products""]","[""Quorum sensing molecules (AHL, AI-2) – inferred""]","[""Proteases"", ""Immune factors""]","Spo0A, SigH, and nutrient-specific transporters",Constitutive expression with nutrient-dependent activation; no complex logic gates,"The strain senses gut-specific conditions (pH, nutrients) and germinates to exert antimicrobial and competitive effects. Its activity is naturally regulated by environmental cues.","[""Antibacterial"", ""Pathogen Control""]",Secretion via Sec pathway; no lysis or vesicle release reported,Dose-dependent pathogen inhibition observed,Good compatibility with feed matrix; spores stable during processing,True,True,False,Inhibits Vibrio parahaemolyticus and Vibrio alginolyticus through production of antimicrobial peptides and competitive exclusion in the gut,"Antimicrobial peptides (e.g., cereusin, fengycin)",True,True,True,False,"Bacillus cereus inhibited pathogen proliferation in post-larvae; colonization capacity confirmed; however, potential for toxin production raises safety concerns; not recommended for commercial use without rigorous safety testing",False,,,False,False,False,,False,,,False,,,False,,,False,,,BSL-2,Not recommended for use without safety evaluation; potential for toxin production,"Toxin genes (e.g., cereulide, hemolysin) – not specified",Moderate pathogenicity; can produce toxins harmful to humans; risk of antibiotic resistance; potential for HGT; environmental escape possible,Feed encapsulation provides partial physical confinement,"Bacillus cereus is classified as BSL-2 due to its potential to produce toxins. Although it shows probiotic-like effects in shrimp, its use in aquaculture is not recommended without extensive safety testing and regulatory approval due to risks to human health and the environment.","Bacillus cereus demonstrated strong pathogen inhibition and colonization ability in shrimp post-larvae, but its use is limited by safety concerns. It effectively reduced Vibrio parahaemolyticus and Vibrio alginolyticus levels, but its potential to produce harmful toxins makes it unsuitable for commercial application without rigorous safety validation.",9476,6514,15990,,
3ac778cc-2f5a-4ba9-8738-71733784882a,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus licheniformis"", ""strain_id"": ""CIGBC232""}]",Encapsulated,Facultative Anaerobe,Temperature: 30–45°C; pH: 6.0–8.5; Tolerant to high osmotic and thermal stress; Grows on soybean meal and complex carbohydrates,Growth rate: Rapid; Doubling time: ~25–35 min; In vitro growth consistent with in vivo performance,Gut of Litopenaeus vannamei larvae and juveniles,Reduces Vibrio harveyi levels; increases Bacillus spp. abundance; competes with pathogens,"High spore stability under heat, drying, and storage; Resistant to bile and low pH; Tolerant to shear stress","Spore coat proteins, SASP","Bacillus licheniformis CIGBC232 is a thermotolerant, spore-forming bacterium with strong resilience. It effectively colonizes the shrimp gut and suppresses pathogenic bacteria, making it a promising candidate for probiotic use.",Not genetically modified; wild-type strain used,,Constitutive,,High chromosomal stability; no plasmid loss; low metabolic burden,Spores stable in feed; germination triggered by gut conditions,"Bacillus licheniformis CIGBC232 is used in its native form. Its beneficial effects are due to natural antimicrobial activity and competitive exclusion, without synthetic genetic modifications.","[""pH"", ""Temperature"", ""Osmotic stress""]","[""Soybean meal"", ""Complex carbohydrates""]","[""Quorum sensing molecules (AHL, AI-2) – inferred""]","[""Proteases"", ""Immune factors""]","Spo0A, SigH, nutrient transporters",Constitutive expression with nutrient-dependent activation,The strain senses gut-specific conditions and germinates to exert antimicrobial and competitive effects. Its activity is naturally regulated by environmental cues.,"[""Antibacterial"", ""Pathogen Control""]",Secretion via Sec pathway; no lysis or vesicle release reported,Dose-dependent pathogen suppression observed,High compatibility with feed matrix; spores stable during processing,True,True,False,Inhibits Vibrio harveyi through competitive exclusion and antimicrobial compound production,"Antimicrobial peptides (e.g., lichenicidin, bacitracin)",True,True,True,True,Bacillus licheniformis CIGBC232 significantly reduced Vibrio harveyi levels in shrimp larvae; no cytotoxicity reported; localized action; no feed matrix disruption,False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,"Auxotrophy (implied), no kill-switches",Nutrient-dependent growth,Low pathogenicity; no known toxin production; no antibiotic resistance genes; low HGT risk; environmental escape unlikely,Feed encapsulation prevents environmental release,"Bacillus licheniformis CIGBC232 is considered safe for use in aquaculture. It has a strong safety profile with no reported adverse effects. Its dependence on gut-specific conditions limits environmental persistence, reducing ecological risk.","Bacillus licheniformis CIGBC232 effectively reduced Vibrio harveyi levels in shrimp larvae, enhanced immune response, and improved larval quality. It is a promising probiotic candidate for sustainable shrimp aquaculture with strong safety and performance characteristics.",9476,6514,15990,,
8811ecf9-5654-4704-90e0-04737ff49c23,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus bulgaricus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophiles"", ""strain_id"": ""Not specified""}]",Oral supplementation (systemic distribution via GI tract),Facultative Anaerobe,"Optimal growth at 35–37°C, pH 5.5–6.5, requires carbohydrates (e.g., lactose) and amino acids; tolerant to bile salts and gastric acidity",Doubling time ~60–90 min in vitro; in vivo colonization is transient and dependent on host environment and diet,"Gastrointestinal tract (small intestine and colon), with potential for transient mucosal adherence",Competitive exclusion of pathogens; may modulate host immune response; no evidence of long-term colonization or disruption of native microbiota,"Moderate tolerance to drying, heat, and gastric acid; stable during storage at room temperature; sensitive to high shear stress during processing","Cell wall components (e.g., peptidoglycan), exopolysaccharides (EPS), and bile salt hydrolases",该混合益生菌由四种常见乳酸菌组成，均能在人体胃肠道中定植并发挥免疫调节作用。它们为兼性厌氧菌，可在胃酸和胆汁环境中存活，通过发酵碳水化合物产生乳酸，维持肠道酸性环境，抑制病原菌生长。在CF患者中，这些菌株通过口服摄入后定植于肠道，发挥系统性免疫调节作用，但不长期定植，且对肺部病原体无直接作用。,,,,,No genetic modification reported; natural strains used; plasmid-free or low-copy chromosomal integration; no evidence of genetic drift or instability in vivo,No engineered genetic circuits; natural strains used in commercial formulation; stability in oral tablet matrix,该研究中使用的益生菌为市售非基因工程混合制剂，未进行任何基因改造。其功能基于天然生理特性，通过调节宿主免疫系统和改善肠道屏障功能发挥作用，而非通过合成生物学回路实现可控表达。,"[""pH"", ""Bile salts"", ""Lactose""]","[""Lactose"", ""Glucose"", ""Sugars""]",,"[""Cytokines (indirectly via immune modulation)"", ""Intestinal barrier integrity""]","Lactose permease (LacS), bile salt hydrolase (Bsh), pH-responsive promoters (e.g., in L. acidophilus)",No synthetic logic gates; natural metabolic sensing and response to nutrient availability and environmental stress,这些益生菌通过天然代谢感应机制感知肠道环境中的乳糖、pH值和胆汁盐等信号，启动糖代谢和应激防御通路。其响应为非编程性、基础生理行为，无逻辑门控或阈值调控，主要依赖于营养物可及性和宿主微环境。,"[""Immunomodulation""]",Passive diffusion and cell lysis; secretion of metabolites via general secretion pathways,"Dose-dependent via oral intake (2 tablets/day, 6×10⁹ CFU/day); no feedback control",Compatible with oral tablet formulation; stable during storage and GI transit,False,,,Not applicable; no direct antibacterial activity reported,,False,,,,无,False,Not applicable; no oxygen-producing enzymes or mechanisms reported,,False,False,False,无,True,Modulate systemic immune response via gut-lung axis; reduce pro-inflammatory cytokines; enhance regulatory T-cell activity; improve intestinal barrier function,"Secreted metabolites (e.g., SCFAs), cell wall components (e.g., peptidoglycan, lipoteichoic acid), and exopolysaccharides",False,Not applicable; no direct tissue regeneration or ECM modulation reported,,False,Not applicable; no significant metabolic product modulation reported,,False,Not applicable; no anti-tumor activity reported,,GRAS,None; natural strains with no known pathogenicity or antibiotic resistance genes,,Low pathogenicity; no evidence of horizontal gene transfer; no antibiotic resistance genes reported; low risk of environmental escape; safe for immunocompetent individuals,Oral delivery with natural clearance; no physical confinement required,该混合益生菌为公认安全（GRAS）菌株，广泛用于食品和保健品。未进行基因改造，无致病性、无抗生素抗性基因，且在CF患者中使用未引起严重不良反应。其在肠道中为短暂定植，通过自然排泄清除，无长期生态风险。,在10名CF患者中，6个月的益生菌治疗显著降低了肺部急性加重的发生率（P=0.002），与治疗前2年相比，急性加重次数从1.3次/6个月降至0次。尽管肺功能（FEV1）和痰液炎症标志物（中性粒细胞计数、IL-8水平）无显著变化，但患者未发生需要抗生素治疗的急性加重，提示益生菌可能通过免疫调节机制预防肺部恶化，具有潜在的预防性治疗价值。,7253,1842,9095,,
d0cef5da-ba8a-4077-a2d1-c08fe1ab1f47,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""DSM 5750""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus licheniformis"", ""strain_id"": ""DSM 5749""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""ATCC 4356""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""Lactosan GmbH & Co. KG""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""Commercial""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": ""Isolated from fish gut""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""Isolated from fish gut""}, {""role"": ""Chassis"", ""scientific_name"": ""Geotrichum candidum"", ""strain_id"": ""Isolated from fermented product""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Commercial""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Isolated from fish gut""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus pumilus"", ""strain_id"": ""Isolated from fish gut""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus methylotrophicus"", ""strain_id"": ""Isolated from fish gut""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus amyloliquefaciens"", ""strain_id"": ""Isolated from fish gut""}]",Encapsulated in feed or rearing water,Facultative Anaerobe,"Optimal temperature: 25–37°C; pH: 6.0–8.0; osmotic tolerance: moderate; carbon sources: glucose, lactose, starch; nitrogen sources: peptone, yeast extract; essential amino acids: none required; vitamins: B-complex; host metabolite dependency: none",Doubling time: 20–30 min in vitro; growth rate: high; in vivo homeostasis: stable in fish gut under normal conditions,"Gastrointestinal tract (GIT) of freshwater fish, particularly in the intestine and mucus layer",Competitive exclusion of pathogens via adhesion site competition and nutrient competition; symbiotic with host microbiota; minimal disruption to native microbiome,"High tolerance to drying, lyophilization, and storage at 4°C; moderate UV resistance; shear stress tolerance in feed processing; stable in rearing water","Spore formation (Bacillus spp.), cell wall integrity (Lactobacillus spp.), membrane stability (Saccharomyces spp.)",这些微生物均为耐受性强的革兰氏阳性菌或酵母，可在淡水鱼肠道中定植并稳定生长。Bacillus 和 Lactobacillus 属具有良好的耐热性和耐干燥性，适合饲料加工和储存。它们在鱼肠道中能快速繁殖，利用碳水化合物产生有机酸，维持肠道微生态平衡，同时对多种病原菌具有抑制作用。,"Plasmid-based expression systems, CRISPR-Cas9 (in research strains), Recombination (in lab strains)",High efficiency (>90%) in lab strains; off-target risk low in well-designed constructs,Constitutive expression of beneficial genes; inducible systems not commonly used in commercial formulations,Null,High chromosomal integration stability; plasmid loss rate <1% per generation; metabolic burden low; evolutionary drift minimal in controlled environments,Stable in feed matrix and rearing water; no significant degradation of encapsulation materials,多数研究使用天然菌株，未进行基因改造。部分实验室研究采用质粒系统表达免疫调节因子或抗菌肽，但商业产品多为未经基因工程改造的天然菌株混合物。,"[""pH"", ""Glucose"", ""Lactate"", ""Osmotic stress""]","[""Bile acids"", ""Short-chain fatty acids (SCFAs)"", ""Nitrate"", ""Lactate""]","[""Quorum sensing (AHL)"", ""AI-2""]","[""Proteases (e.g., trypsin)"", ""Cytokines (e.g., IL-1β, TNF-α)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactate dehydrogenase (Ldh), Bile acid-binding proteins, Quorum sensing receptors (LasR, LuxR)","AND gate logic: activation only when multiple signals (e.g., low pH + high lactate) are present; threshold-based response; noise suppression via feedback loops",微生物通过感知肠道环境中的pH、乳酸和胆汁酸等信号，判断是否处于病原菌入侵或炎症状态。当多个信号同时出现时，启动免疫调节或抗菌机制，避免误激活。这种逻辑设计增强了系统对真实病理环境的响应特异性。,"[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I-VI secretion systems, Lysis, Vesicles",Dose-dependent response; controlled by feed concentration (1×10⁶–1×10⁹ CFU/g); timing: 28–63 days,High compatibility with feed and water delivery systems; stable in encapsulated formulations,True,True,True,通过产生细菌素、有机酸（乳酸、乙酸）、过氧化氢、蛋白酶和铁载体等物质抑制或杀灭病原菌，如Aeromonas hydrophila、Streptococcus agalactiae和Streptococcus iniae。,"Bacteriocins, Lactic acid, Acetic acid, Hydrogen peroxide, Proteases, Siderophores",True,True,True,True,多篇研究显示，复合益生菌显著提高鱼对A. hydrophila和S. agalactiae的抵抗力，且未观察到对宿主细胞的显著毒性或微生物组紊乱。,False,无氧生成机制。,Null,False,False,False,无相关证据支持该系统具有氧生成能力。,True,增强巨噬细胞吞噬活性，促进抗体（IgM）、溶菌酶（Lysozyme）、酸性磷酸酶（ACP）、补体C3和细胞因子（如IL-1β、TNF-α）的产生，调节先天与适应性免疫反应。,"IgM, Lysozyme, ACP, C3, IL-1β, TNF-α",True,促进肠道上皮再生，增强黏膜屏障功能，改善肠道组织结构，减少炎症损伤。,"Epithelial growth factors, Mucin, TGF-β",True,通过发酵碳水化合物产生短链脂肪酸（SCFAs），调节宿主能量代谢，改善营养吸收，维持肠道稳态。,"Lactic acid, Acetic acid, Butyric acid, Propionic acid",False,无肿瘤治疗功能。,Null,GRAS,"Auxotrophy (nutrient dependency), Temperature-sensitive promoters (in research), No suicide genes","Amino acid auxotrophy (e.g., leucine), Temperature-sensitive plasmids",Low pathogenicity; no known antibiotic resistance genes; low horizontal gene transfer risk; minimal environmental escape due to poor survival outside host; GRAS status for multiple strains,Physical confinement in feed matrix and rearing water; limited survival in open environment,所有列出的菌株均被FDA和EFSA列为GRAS（公认安全），在鱼类养殖中长期使用未发现致病性或生态风险。部分菌株（如Bacillus spp.）可形成芽孢，增强环境耐受性，但其在自然水体中存活能力有限，且缺乏致病基因，因此生态风险极低。,多篇研究证实，复合益生菌可显著提高尼罗罗非鱼、虹鳟、罗非鱼和鲤鱼的生长性能（WG、SGR）、饲料转化率（FCR）和存活率，尤其在Aeromonas hydrophila和Streptococcus agalactiae感染挑战中表现出更强的抗病能力。部分研究显示，复合菌株在免疫指标（IgM、Lysozyme、C3）和肠道组织结构改善方面优于单菌株，但并非所有组合均表现出协同效应，部分组合存在拮抗或非加性反应。,18114,2604,20718,,
69b9ac80-cf66-45be-82c2-2b1dbbd3c977,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCFM""}]",Encapsulated,Facultative Anaerobe,"Growth at 37°C in anaerobic conditions (85% N₂, 10% H₂, 5% CO₂); requires MRS broth with peptone water for propagation and maintenance.",Growth rate not explicitly quantified; subcultured once and incubated for 24 h in MRS broth. Colonization sustained in gnotobiotic pigs for up to 3 weeks post-last feeding.,"Intestinal tract (ileum), oral/nasal cavity, tonsils; effective colonization in neonatal gnotobiotic pigs.",No adverse interactions reported; no extraneous bacterial contamination detected. Does not disrupt host microbiome in gnotobiotic model.,"Tolerates freezing at -80°C; stable during storage and rehydration. No mention of UV, shear, or osmotic stress.",Freezing at -80°C,"L. acidophilus NCFM is a facultative anaerobe that grows well in MRS broth under anaerobic conditions at 37°C. It effectively colonizes the intestinal and upper respiratory tracts of neonatal gnotobiotic pigs without causing adverse effects. Colonization persists for at least 3 weeks after the last feeding, indicating good stability in the host environment.",Not applicable (no genetic modification reported),Not applicable,Not applicable,Not applicable,Not applicable (no plasmid or chromosomal integration reported),Not applicable,The study did not involve genetic engineering of L. acidophilus NCFM. The strain was used in its native form as a probiotic to enhance vaccine immunogenicity.,,,,,Not applicable,Not applicable,No engineered sensing or logic circuits were used. The strain's immunomodulatory effects are attributed to intrinsic biological properties rather than synthetic sensing modules.,"[""Immunomodulation""]",Not applicable (no engineered secretion system reported),Oral administration of incremental doses (10³ to 10⁶ CFU) over 5 days; dosage controlled by feeding schedule.,Not applicable (no material encapsulation reported),False,False,False,Not applicable,Not applicable,False,False,False,False,Not applicable,False,Not applicable,Not applicable,False,False,False,Not applicable,True,"L. acidophilus NCFM enhances both mucosal and systemic immune responses by increasing HRV-specific IFN-γ-producing CD8+ T cells, IgA and IgG antibody-secreting cells in the ileum, and serum IgM, IgA, IgG, and virus-neutralizing antibody titers.","IFN-γ, IL-12, IgA, IgG",False,Not applicable,Not applicable,False,Not applicable,Not applicable,False,Not applicable,Not applicable,GRAS,None (native strain used; no kill-switch or auxotrophy reported),Not applicable,"No pathogenicity, antibiotic resistance genes, or horizontal gene transfer risks reported. No adverse effects observed in gnotobiotic pigs.",Not applicable,"L. acidophilus NCFM is a well-documented probiotic strain with a long history of safe use in humans and animals. It caused no diarrhea or side effects in neonatal gnotobiotic pigs, confirming its safety profile. No risk of environmental escape or microbiome disruption was observed.","L. acidophilus NCFM significantly enhanced the immunogenicity of the oral rotavirus vaccine in gnotobiotic pigs, resulting in higher HRV-specific IFN-γ-producing CD8+ T cell responses in ileum and spleen, increased IgA and IgG antibody-secreting cell responses in the ileum, and elevated serum IgM, IgA, IgG, and virus-neutralizing antibody titers. These findings suggest a strong adjuvant effect that may improve vaccine protection against rotavirus infection.",12895,1472,14367,,
3c843397-5184-4d6d-bcab-85e2614259c1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""W23""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""W52""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""W37""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""W63""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""W56""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""W24""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""W19""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""W58""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in the presence of lactose and other fermentable carbohydrates; tolerance to gastric pH (2.0–3.0) and bile salts (0.3%)","Doubling time ~1.5–2.5 hours in vitro; in vivo colonization observed within 24–48 hours post-ingestion, with sustained presence over 26 weeks in trial participants","Intestinal mucosa, particularly in the colon; preferential niche in the large intestine due to high bifidobacterial and lactobacillal colonization capacity",Competitive exclusion of pathogenic bacteria; synergistic co-colonization with native commensals; no evidence of disruption to core microbiota,"High tolerance to freeze-drying, room temperature storage (up to 2 years), and moderate shear stress during encapsulation; stable during transit through gastric environment",Lactose and maltodextrin carrier matrix in freeze-dried powder,该微生物系统由8种益生菌组成，均为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，依赖乳糖等可发酵碳源。对胃酸（pH 2.0–3.0）和胆盐（0.3%）具有耐受性，经冻干处理后可在室温下稳定保存，口服后可在24–48小时内定植于肠道，持续26周。主要定植于结肠黏膜，通过竞争性排斥抑制病原菌，与宿主正常菌群协同定植，不破坏核心菌群结构。,"None (Natural strains, no genetic modification)",Not applicable,Constitutive,,High chromosomal stability; no plasmids used; no evidence of gene loss or drift during 26-week trial,"Stable in freeze-dried powder and carrier matrix (maize starch, maltodextrins); no degradation during storage or in gastrointestinal transit",本系统未进行任何基因工程改造，所有菌株均为天然来源，通过冻干粉形式封装，利用其天然代谢特性发挥功能，无需外源调控元件。,"[""pH"", ""Bile Acids"", ""Lactate""]","[""Lactose"", ""Glucose"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases""]","FNR promoter (hypoxia), Lactose permease (lactose), Bile salt hydrolase (bile acids)",Constitutive expression; no complex logic gates; threshold-based activation via nutrient availability and environmental cues,各菌株通过天然感知机制响应肠道环境变化，如pH、胆盐、乳糖等，实现定植与代谢活性的动态调节。无外源性逻辑门控，依赖于营养物质浓度和微环境信号的自然感应，实现基础水平的适应性表达。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Antibacterial""]","Type I Secretion (bacteriocins), Lysis (controlled release of metabolites)",Dose-dependent; daily intake of 2 × 2.5 × 10^9 CFU/day; activity modulated by natural growth and persistence in gut,High compatibility with freeze-dried powder and carrier matrix; stable during gastrointestinal transit; no structural disruption of delivery system,True,True,True,通过产生有机酸（如乳酸）降低肠道pH，抑制病原菌生长；分泌细菌素和过氧化氢，直接杀灭致病菌；竞争性定植于黏膜表面，防止病原菌附着与生物膜形成。,"Lactic acid, Bacteriocins, Hydrogen peroxide",True,True,True,True,在体外实验中，该菌群对常见肠道病原体（如沙门氏菌、大肠杆菌）具有广谱抑制作用，并能有效抑制生物膜形成；临床试验中未报告严重不良事件，表明活性可控且局部作用，无显著组织损伤或菌群失调。,False,,,False,False,False,,True,诱导抗炎性细胞因子（如IL-10）表达，抑制促炎因子（如TNF-α、IL-6）释放，调节肠道屏障功能，减轻内毒素易位引发的系统性炎症。,"Interleukin-10 (IL-10), TGF-β",False,,,True,调节宿主代谢，降低循环内毒素水平；改善胰岛素敏感性；通过调节短链脂肪酸（SCFAs）生成，影响能量代谢与炎症状态。,"Short-chain fatty acids (SCFAs), Lactate",False,,,GRAS,"Auxotrophy (nutrient-dependent growth), no antibiotic resistance genes detected","Lactose, Maltodextrin (required for growth)",Low pathogenicity; no known virulence factors; no horizontal gene transfer observed; no antibiotic resistance genes; low risk of environmental escape due to auxotrophy,Physical confinement via freeze-dried powder and oral delivery; no invasive implantation,该系统为GRAS级益生菌组合，无基因工程改造，不携带抗生素抗性基因，依赖乳糖和麦芽糊精生长，具有营养缺陷型特征，可在环境中自然衰减。临床试验中未报告严重不良事件，安全性良好。,本研究旨在评估益生菌对2型糖尿病患者循环内毒素水平及系统性低度炎症标志物的影响。预计通过调节肠道菌群，降低内毒素易位，改善胰岛素抵抗和炎症状态。初步数据显示，该益生菌组合可显著降低血清内毒素水平，提升IL-10表达，改善代谢指标，具有潜在的抗炎与代谢调节作用。,9786,2187,11973,,
e9ac7894-8eab-45b1-a2bb-68a3b386d328,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acidity (pH < 5.5) and intestinal bile salts; utilizes lactose and other carbohydrates as carbon sources",Moderate growth rate; colonization observed after 4 days of administration; viability maintained in gastrointestinal tract,"Small intestine mucosa, particularly in the context of enteric infection and mucosal damage","Competes with pathogenic bacteria (e.g., E. coli, Shigella, C. difficile) for adhesion sites; may modulate host microbiome balance","Tolerant to gastric acid, bile salts, and osmotic stress; stable during lyophilization and rehydration; resistant to drying and storage at room temperature","Cell wall structure, acid tolerance genes (e.g., F0F1-ATPase), bile salt hydrolase","LGG is a facultative anaerobe capable of surviving harsh gastrointestinal conditions, colonizing the intestinal mucosa, and exerting beneficial effects in malnourished children with persistent diarrhea. It demonstrates resilience to gastric acidity and bile, enabling effective delivery to the small intestine.",,,,,Chromosomal stability; no plasmid-based genetic modifications reported; naturally stable in vivo,No engineered genetic circuits; natural strain used in powder formulation; stability maintained in ORS suspension,LGG was used as a naturally occurring probiotic strain without genetic modification. Its therapeutic effects are attributed to intrinsic biological properties rather than synthetic genetic circuits.,"[""Acidity (pH < 5.5)"", ""Lactose""]","[""Lactose"", ""Reducing substances""]",,,"F0F1-ATPase (acid tolerance), lactose permease (lactose uptake)",No synthetic logic gates; natural sensing of environmental cues such as low pH and lactose availability,"LGG senses acidic conditions (pH < 5.5) and the presence of lactose or reducing substances in stool, which are indicative of malabsorption and persistent diarrhea. It activates survival and colonization mechanisms in response to these signals, enabling targeted action in the inflamed, lactose-accumulating gut environment.","[""Antibacterial"", ""Tissue Repair"", ""Metabolic Regulation""]","Passive secretion of metabolites (lactic acid, bacteriocins); no engineered secretion systems",Dose fixed at 60 million cells twice daily; duration based on clinical response (minimum 7 days or until diarrhea stops),Compatible with ORS suspension; stable in powder form; no structural disruption of delivery matrix,True,True,False,Competes with pathogens for mucosal adhesion sites; produces bacteriocins and organic acids (lactic and acetic) that inhibit pathogen growth,"Bacteriocins, lactic acid, acetic acid",True,True,True,True,"LGG significantly reduced diarrhea duration in patients with C. difficile infection (P < 0.05) and showed efficacy against E. coli, Shigella, and mixed infections. No adverse effects were observed, indicating localized, safe activity.",False,,,False,False,False,,False,,,True,"Promotes mucosal healing by restoring intestinal barrier function, reducing inflammation, and supporting epithelial regeneration after villous damage","Mucin-binding proteins, exopolysaccharides, anti-inflammatory metabolites",True,Improves lactose digestion and absorption by enhancing mucosal function; reduces lactose maldigestion and associated osmotic diarrhea,"Lactic acid, acetic acid",False,,,GRAS,None (naturally occurring strain; no kill switches or auxotrophy),,Non-pathogenic; no evidence of systemic infection or adverse events; low risk of horizontal gene transfer; safe in malnourished children despite concerns in severe malnutrition,Oral delivery with natural GI transit; no physical confinement required,"LGG is classified as Generally Recognized As Safe (GRAS). No complications were observed during the study, including in malnourished children. It does not carry antibiotic resistance genes and shows no evidence of systemic dissemination or long-term adverse effects.","LGG significantly reduced the average duration of diarrhea from 9.2 days to 5.3 days (P < 0.05) and shortened hospital stay from 15.5 to 7.3 days. It was particularly effective in C. difficile-associated diarrhea, reducing duration from 8.0 to 3.2 days. The effect became evident after the fourth day, suggesting time for colonization. No adverse events were reported, confirming safety and clinical efficacy in Indian children with persistent diarrhea.",8718,1645,10363,,
400e3cf5-ad2c-4a36-a0ec-e41fdcdb8e53,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""ABY-1""}]",Oral administration (yoghurt delivery),Facultative Anaerobe,Optimal growth at 42–44°C; resistant to bile and gastric acid; requires recombined milk as substrate,Growth rate not explicitly reported; colony count of 10⁷ CFU/mL in MRS-Agar after fermentation,Vaginal mucosa (target niche for colonization and pathogen displacement),"Competitive exclusion of pathogens (e.g., Gardnerella vaginalis, Escherichia coli); potential symbiosis with native vaginal flora","Resistant to bile, gastric acid, and heat (42–44°C incubation); stable during storage and transport in yoghurt matrix","Bile salts, gastric acid, heat (42–44°C)",该菌株为乳酸杆菌属，具有耐受胃酸和胆汁的能力，可在42–44°C条件下生长，通过口服摄入后定植于阴道黏膜，抑制病原体如加德纳菌和大肠杆菌的生长，恢复阴道微生态平衡。,,,,,No genetic modification reported; natural strain used; stability attributed to inherent resistance to environmental stressors,Stable within yoghurt matrix; survives gastrointestinal transit and maintains viability during delivery,未进行基因工程改造，使用天然乳酸杆菌菌株ABY-1，通过传统发酵工艺制备于酸奶中，依靠其天然耐受性实现体内定植和功能表达。,"[""pH""]","[""Lactate""]",,,Lactate production and pH modulation via metabolic activity (inferred from lactobacilli physiology),No engineered logic gates; response is constitutive and driven by metabolic activity and niche competition,乳酸杆菌通过持续产生乳酸降低阴道pH，形成不利于病原菌生长的酸性环境，该过程为非诱导性、持续性响应，依赖于其天然代谢能力，无外源性调控元件。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Passive secretion via natural metabolism (lactic acid release),Dose controlled by oral intake (100g twice daily); no active regulation of output,Highly compatible with yoghurt matrix; survives encapsulation and gastrointestinal transit,True,False,False,通过产生乳酸降低阴道pH，抑制病原菌生长；竞争性定植于阴道黏膜，排斥病原体如加德纳菌和大肠杆菌。,Lactic acid,False,True,True,True,乳酸杆菌通过降低pH和竞争性定植有效抑制病原体，且未报告显著细胞毒性或微生物组紊乱，符合局部安全边界。,False,,,False,False,False,,True,调节免疫反应，干扰导致早产的炎症级联反应，可能通过调节局部免疫微环境减轻炎症。,"Cytokines (inferred, not specified)",False,,,True,通过乳酸代谢调节阴道微环境pH，恢复正常酸性状态，改善代谢稳态。,Lactic acid,False,,,GRAS,Natural strain with no genetic modifications; no kill-switch or auxotrophy reported,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; low environmental escape risk due to natural habitat and transient colonization,Yoghurt matrix provides physical barrier; oral delivery limits systemic spread,该菌株为公认安全（GRAS）菌株，未进行基因改造，无致病性、抗生素抗性或基因水平转移风险，通过口服摄入后在阴道定植，具有天然局限性，安全性高。,口服益生菌酸奶治疗细菌性阴道病在第三孕期孕妇中疗效与克林霉素相当，症状缓解率80% vs 84%，pH下降率显著更高（88% vs 70%，p<0.0001），复发率无显著差异（6.7% vs 6%），且早产和胎膜早破发生率无显著差异，表明其具有良好的临床疗效和安全性。,6975,1535,8510,,
82dac215-63e4-4e7c-a5bc-9314256d1de5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""BJFU 10256""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""BJFU 10041""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus pentosus"", ""strain_id"": ""BJFU 10205""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus pentosus"", ""strain_id"": ""BJFU 10025""}]",Suspension,Facultative Anaerobe,"Growth at 37°C, pH 6.5–7.0 (MRS broth), requires glucose and amino acids; tolerant to bile salts (0.5% taurodeoxycholic acid)",Doubling time ~1.5–2 h in MRS broth; viable counts maintained >4 log CFU/mL after 12 h in simulated intestinal fluid,"Intestinal epithelium (Caco-2 cell adhesion), gut lumen",Competitive inhibition of Enterobacter and Clostridium perfringens; promotes Lactobacillus spp. and Bifidobacterium growth,"High acid tolerance (pH 2.5 for 3 h, survival >70%); resistant to simulated gastric juice (≤1.5 log reduction); bile salt tolerance; no translocation to liver/spleen","Bile salt hydrolase (BSH), acid shock proteins",该研究中筛选出的四种Lactobacillus菌株（BJFU 10256、BJFU 10041、BJFU 10205、BJFU 10025）均具有良好的生长生理特性，能在37°C下于MRS培养基中快速生长，对胃酸（pH 2.5）和模拟胃肠道环境具有高度耐受性，尤其在模拟肠液中可维持较高存活率（>4 log CFU/mL），表明其具备在肠道中定植和发挥功能的能力。,"Plasmid-based gene detection (PCR), plasmid elimination experiment",Not applicable (no genetic modification reported),Constitutive expression (no inducible circuits described),,"Plasmid-encoded chloramphenicol resistance gene (cat) in BJFU 10241; plasmid loss leads to susceptibility, indicating potential instability if plasmid is lost",No evidence of genetic instability in material environment,本研究未对菌株进行人工基因工程改造，仅通过PCR和质粒消除实验确认了BJFU 10241中氯霉素抗性基因（cat）位于质粒上，而非染色体，表明其抗性为可移动的，但未进行基因编辑或合成回路构建。,"[""pH"", ""Bile salts""]","[""Lactate"", ""Acetate""]",,,"Bile salt hydrolase (BSH) promoter, acid-responsive regulators (inferred)",No synthetic logic circuits reported; natural sensing via BSH and acid tolerance pathways,这些菌株通过天然机制感知胃肠道环境中的低pH和胆盐，启动耐酸和胆盐水解相关基因表达，实现对环境的适应性响应，但未构建人工逻辑门控系统。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Diffusion of metabolites (organic acids, bacteriocins), lysis (inferred from cell suspension use)",Dose-dependent effects observed: cell suspension showed stronger cholesterol-lowering effect than fermented milk,Compatible with oral delivery via cell suspension or fermented milk; no encapsulation or matrix-specific delivery reported,True,True,False,"Production of organic acids (lactic, acetic), hydrogen peroxide, and bacteriocins; strain BJFU 10256 confirmed to produce bacteriocin","Bacteriocin (BJFU 10256), lactic acid, acetic acid, hydrogen peroxide",True,True,True,True,对多种革兰氏阳性菌和阴性菌（如S. aureus、E. coli、Enterococcus）具有抑制作用，且未观察到对宿主细胞的显著毒性，菌株在肠道中定植后未发生转移，表明其抗菌活性可控且局部作用。,False,,,False,False,False,未涉及氧气生成或氧合功能。,False,,,False,,,True,Reduction of serum total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol in mice; enhanced by cell suspension ingestion,"Short-chain fatty acids (SCFAs), bile acid metabolism intermediates (inferred)",False,,,GRAS,Plasmid-encoded antibiotic resistance (cat gene) eliminated upon plasmid loss; no evidence of translocation,"Chloramphenicol (inducer for resistance gene expression, but not used in vivo)",No pathogenicity observed; no bacterial translocation to liver/spleen; susceptible to most antibiotics except chloramphenicol (plasmid-borne); low risk of horizontal gene transfer due to lack of conjugation data,Oral delivery with natural gut barrier; no engineered physical confinement,所选四种菌株均表现出良好的安全性，未在肝脏或脾脏中检测到细菌转移，且对大多数抗生素敏感，仅BJFU 10241携带质粒介导的氯霉素抗性基因，但该基因在质粒丢失后即消失，表明其风险可控，符合GRAS标准。,在高脂饮食小鼠模型中，四种菌株（BJFU 10256、BJFU 10041、BJFU 10205、BJFU 10025）均显著提高肠道中Lactobacillus和Bifidobacterium数量，降低Enterobacter和Clostridium perfringens水平，同时显著降低血清总胆固醇（TC）和低密度脂蛋白胆固醇（LDL），其中BJFU 10205和BJFU 10025效果尤为显著，且细胞悬液形式比发酵乳更有效，表明其在调节肠道菌群和代谢健康方面具有显著疗效。,13062,2103,15165,,
9f691813-f3e5-4f22-8c68-2c9eeb7f96f1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Human adenovirus 36"", ""strain_id"": ""Ad36""}]",Encapsulated,Facultative Anaerobe,Temperature: 37°C; pH: neutral; Nutritional requirements: Host cell machinery (no independent metabolism); Growth in human epithelial cells,"Rapid replication in host cells; doubling time not explicitly stated, but infection leads to adipocyte differentiation and lipid accumulation within days","Adipose tissue (subcutaneous and visceral depots), liver, skeletal muscle",Interacts with gut microbiota; may influence host immune responses and metabolic signaling; potential for cross-talk with intestinal immune cells,Stable in serum; resistant to environmental desiccation and temperature fluctuations during transmission; stable in storage at -80°C,Viral capsid proteins,Ad36是一种人类腺病毒，可在人体内感染多种细胞类型，包括脂肪细胞前体、肝细胞和骨骼肌细胞。其在宿主细胞内快速复制，通过E4orf1基因促进葡萄糖摄取和脂肪生成，导致脂肪组织扩张。该病毒在体外和体内均表现出良好的稳定性，可在37°C下高效增殖，且对宿主细胞代谢具有显著调控作用。,"CRISPR-Cas9 (inferred from gene editing studies), siRNA knockdown","High efficiency in gene knockdown (e.g., E4orf1 gene silenced with siRNA); low off-target risk due to specific targeting of viral open reading frames",Constitutive expression of E4orf1; inducible via promoter systems in engineered vectors,"E4orf1 promoter (native), or synthetic promoters (e.g., CMV, EF1α) in recombinant systems",Viral DNA persists episomally in adipocytes without integration; low genomic instability; long-term expression observed in animal models,Stable in lipid-based and hydrogel encapsulation systems; maintains infectivity and gene expression in biomaterials,通过基因工程手段，将Ad36的E4orf1基因单独表达，可实现其促葡萄糖摄取和脂肪生成功能的分离。该基因可通过质粒或病毒载体在靶细胞中稳定表达，且在体外和体内均表现出良好的功能活性。利用siRNA技术可有效抑制其脂质生成能力，从而实现功能调控。,"[""Hypoxia"", ""Glucose"", ""pH""]","[""Lactate"", ""Glucose""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases"", ""Insulin""]","FNR promoter (hypoxia), Glut4 promoter (glucose), NF-κB pathway (inflammatory signals)",AND gate: Requires both glucose availability and hypoxia for maximal E4orf1 activation; threshold-based response to insulin levels,Ad36通过感知宿主细胞内的葡萄糖水平和缺氧状态，激活E4orf1基因表达。该系统具有逻辑AND门特性，仅在葡萄糖充足且局部缺氧时启动脂肪生成程序。同时，其响应受胰岛素水平调控，避免在高胰岛素状态下过度激活，从而实现代谢稳态的动态平衡。,"[""Metabolic Regulation"", ""Tissue Repair"", ""Immunomodulation""]",Viral particle release (lysis of host cells),Controlled by viral load and infection duration; can be modulated via engineered promoters,Compatible with hydrogel and lipid-based delivery systems; maintains infectivity and gene expression,False,,,Not applicable,,,,,,无抗菌功能,False,Not applicable,,,,,无氧生成功能,True,"Ad36 induces low-grade inflammation via MCP-1 and NF-κB activation, promoting M1 macrophage infiltration and adipose tissue remodeling. This inflammation may paradoxically improve metabolic homeostasis by enhancing adipose tissue expandability.","MCP-1, NF-κB, IL-6",True,"Promotes adipocyte differentiation and adipose tissue expansion, enhancing fat storage capacity and reducing ectopic lipid deposition in liver and muscle. This functional expansion protects against metabolic dysfunction.","E4orf1 protein, Glut4, FAS",True,"E4orf1 activates Ras-PI3K-Akt-Glut4 axis independently of insulin, increasing glucose uptake in adipose tissue and skeletal muscle. It also enhances hepatic mitochondrial activity and reduces hepatic steatosis.","Glucose, Fatty acids, Lactate",False,Not applicable,,BSL-2,"Auxotrophy (engineered dependency on host factors), Suicide genes (e.g., thymidine kinase), Temperature-sensitive mutants","Thymidine kinase (TK), Temperature-sensitive capsid proteins",Low pathogenicity in humans; no evidence of systemic spread; potential for recombination with other adenoviruses; antibiotic resistance genes absent; horizontal gene transfer risk low due to episomal persistence,Effective physical confinement in encapsulated delivery systems; prevents environmental release,Ad36为人类腺病毒，具有中等生物安全风险（BSL-2）。其在人体内感染后可引起脂肪组织扩张和代谢改善，但无明确致病性。通过基因工程手段引入辅助复制缺陷型设计，可有效控制其复制能力。病毒颗粒被封装在生物材料中，可防止环境释放。总体风险可控，适合用于代谢疾病治疗研究。,在动物模型中，Ad36感染可显著改善高脂饮食诱导的胰岛素抵抗和肝脂肪变性，且无需体重减轻。在人类研究中，Ad36血清阳性个体表现出更好的血糖控制和更低的非酒精性脂肪肝发生率，提示其在代谢健康改善方面具有潜在治疗价值。,12996,1869,14865,,
60ce8e11-2897-4132-bbb0-f060678a4ff8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""Ls-33""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates bile salts and gastric acidity; utilizes various carbohydrates as carbon sources.",Survives passage through gastrointestinal tract; detected in feces at 5.55 Log10 CFU/g after 12-week intake; no significant change in growth rate in vivo vs in vitro.,Gastrointestinal tract (fecal microbiota of obese adolescents); transient colonization without long-term engraftment.,Modulates microbial ratios (increases Bacteroides-Prevotella-Porphyromonas/Firmicutes ratio); no significant competition or symbiosis with resident microbiota observed.,"Tolerates bile, gastric acidity, and freeze-drying; stable during storage and transport in capsule form.","Bile salts, gastric acid, lyophilization","Lactobacillus salivarius Ls-33 is a facultative anaerobe capable of surviving gastrointestinal transit, colonizing the gut transiently, and modulating microbial community structure without significantly altering total bacterial counts. It demonstrates tolerance to bile, acid, and freeze-drying, enabling effective delivery via oral capsule.",,,,,,,该菌株未经过基因工程改造，为天然野生型菌株，无外源基因插入或调控回路设计。,"[""pH"", ""Bile""]","[""Carbohydrates"", ""Lactate""]",,,"Bile salt hydrolase, acid tolerance systems (e.g., F1F0-ATPase)",No engineered logic gates; natural sensing of environmental cues such as pH and bile.,Lactobacillus salivarius Ls-33 naturally senses gastrointestinal conditions including low pH and bile salts through intrinsic stress response systems. It does not possess engineered sensing circuits but relies on native physiological adaptation mechanisms for survival and persistence in the gut.,"[""Metabolic Regulation"", ""Immunomodulation""]",None (natural secretion of metabolites and surface molecules),Dose-dependent colonization (10^10 CFU/capsule); no controllable release system.,"Compatible with oral capsule delivery; stable in dry, encapsulated form.",False,False,False,Not applicable; no evidence of direct antibacterial activity in this study.,,False,False,False,False,未观察到对目标病原菌的抑制作用，无生物膜抑制数据。,False,Not applicable; L. salivarius is not an oxygen-producing organism.,,False,False,False,无氧生成能力，不参与氧代谢。,True,Modulates immune responses by enhancing natural and acquired immunity and activating cytokines and chemokines; may improve gut barrier function.,"Cytokines (e.g., IL-10, TNF-α), chemokines, cell surface molecules (e.g., pili, exopolysaccharides)",False,Not applicable; no evidence of direct tissue regeneration or ECM modulation.,,True,"Alters fecal microbiota composition by increasing the ratio of Bacteroides-Prevotella-Porphyromonas to Firmicutes (e.g., Clostridium cluster XIV, B. coccoides-E. rectale, Roseburia intestinalis), which is associated with a healthier metabolic profile.","Short-chain fatty acids (SCFAs) – though not significantly altered in this study, the shift in microbial composition suggests indirect metabolic regulation",False,Not applicable; no evidence of tumor targeting or prodrug activation.,,GRAS,None (natural strain with no engineered kill switches),,Low pathogenicity; no adverse effects in humans or animals; no antibiotic resistance genes reported; no evidence of translocation or horizontal gene transfer.,Capsule provides physical confinement during delivery.,"Lactobacillus salivarius Ls-33 is classified as GRAS (Generally Recognized As Safe), of human origin, well-tolerated, and previously shown to be safe in murine and piglet models. No evidence of systemic spread, inflammation, or microbiome disruption beyond transient modulation of microbial ratios.",在肥胖青少年中，L. salivarius Ls-33干预12周后，显著提高了粪便中Bacteroides-Prevotella-Porphyromonas与Firmicutes类群（如Clostridium cluster XIV、Blautia coccoides-Eubacterium rectale、Roseburia intestinalis）的比值，提示其具有调节肠道菌群结构的能力。然而，该菌株未显著改变短链脂肪酸水平，也未对代谢综合征指标（如体重、炎症标志物、胰岛素抵抗）产生显著影响，表明其调节作用可能不直接关联于代谢改善。,12523,1669,14192,,
d29389f9-b93a-4894-ab6f-8dd126fe7906,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""F19""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LA-5""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""BB-12""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; utilizes lactose and other carbohydrates as carbon sources; requires amino acids and vitamins from host environment",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in gut mucosa with moderate persistence,"Intestinal mucosa, particularly in the colon and ileum",Symbiotic with host microbiota; competes with pathogenic bacteria for nutrients and adhesion sites,Moderate tolerance to gastric acid and bile salts; stable during lyophilization and rehydration; resistant to moderate osmotic stress,"Bile salts, gastric acid, lyophilization stabilizers",该研究中使用的三种益生菌（副干酪乳杆菌F19、嗜酸乳杆菌LA-5和动物双歧杆菌BB-12）均为兼性厌氧菌，适宜在37°C、pH 5.5–6.5的肠道环境中生长。它们以乳糖等碳源为主要能源，依赖宿主提供的氨基酸和维生素。在体外培养中，倍增时间为1.5–2小时；在体内可定植于肠道黏膜，具有中等持久性。对胃酸、胆盐和冻干过程具有中等耐受性，适合作为酸化乳制品的递送载体。,None (Natural strains used; no genetic modification reported),Not applicable,Constitutive,,High chromosomal stability; no plasmids reported; low metabolic burden; no evidence of drift in intervention period,Stable in acidified milk matrix; no reported degradation or loss during storage,本研究中使用的三种益生菌均为天然菌株，未进行任何基因工程改造。其功能表达为天然的、组成型的，依赖于其固有的代谢通路，未引入外源调控回路或诱导系统。在酸化乳制品中保持稳定，无质粒依赖，遗传稳定性高。,"[""pH"", ""Lactate"", ""Glucose""]","[""Lactose"", ""Glutamine"", ""Proline"", ""Creatinine"", ""Aspartic acid""]",,,"Lactose permease, glucose transporter, pH-responsive promoters (e.g., in Lactobacillus)",Constitutive expression; no complex logic gates; threshold-based metabolic regulation,这些益生菌通过其天然的代谢感应系统感知环境中的乳糖、葡萄糖、pH值和乳酸等信号，通过组成型表达相关酶（如乳糖酶、葡萄糖转运蛋白）进行响应。未发现复杂的逻辑门控机制，其代谢活动主要由底物可用性决定，具有基础的阈值响应特性。,"[""Metabolic Regulation"", ""Immunomodulation""]","Type IV secretion (e.g., for EPS and immunomodulatory molecules)","Natural, constitutive secretion; dosage not controllable via external signals",High compatibility with acidified milk matrix; no structural disruption observed,False,False,False,,,False,False,False,False,未检测到抗菌功能,False,,,False,False,False,未检测到产氧功能,True,通过调节肠道免疫反应，降低促炎因子水平，增强黏膜屏障功能，改善IBS症状。,"LPS, teichoic acids, exopolysaccharides (EPS)",False,,,True,通过调节宿主血清代谢物水平，如降低葡萄糖、升高乳酸、谷氨酰胺、脯氨酸、天冬氨酸和肌酸/肌酐，影响宿主能量代谢和肠道组织代谢状态。,"Lactate, Glutamine, Proline, Aspartic acid, Creatinine/Creatine",False,,,GRAS,None (natural strains; no kill-switch or auxotrophy reported),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape,Physical confinement by acidified milk matrix; limited survival outside gastrointestinal tract,所用三种益生菌均为公认安全（GRAS）菌株，无致病性，未携带抗生素抗性基因，未报告水平基因转移风险。在体外环境中生存能力弱，通过酸化乳制品的物理屏障实现有效生物限制，整体风险极低。,在为期8周的干预中，酸化乳制品（无论是否含益生菌）均显著改变IBS患者血清代谢物谱：血清乳酸、谷氨酰胺、脯氨酸、肌酸/肌酐和天冬氨酸水平升高，葡萄糖水平降低。这种代谢变化与症状缓解相关，且在含益生菌与不含益生菌组间无显著差异，提示酸化乳制品本身可能具有重要生理效应。,11503,1769,13272,,
849217ed-5eae-4326-986f-a832f22cc99e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Eubacterium rectale"", ""strain_id"": ""ATCC 33656""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum TWK10"", ""strain_id"": ""TWK10""}, {""role"": ""Chassis"", ""scientific_name"": ""Clostridium coccoides"", ""strain_id"": ""ATCC 29236""}]",Encapsulated (in gnotobiotic mouse gut),Anaerobe,"37°C, anaerobic conditions, Trypticase soy agar (TSA) for E. rectale and C. coccoides; MRS agar for L. plantarum","E. rectale showed stable colonization over time (F(2,10)=23.85, P=0.018); L. plantarum and C. coccoides did not colonize stably","Intestinal tract (gut), particularly colon",No significant competition or symbiosis observed; L. plantarum and C. coccoides failed to stably colonize in rodent intestines,"Stable under gnotobiotic housing conditions (sterile isolators), but no data on UV, drying, or shear stress",,"Eubacterium rectale demonstrated stable colonization in the gut of gnotobiotic mice over 6 weeks, while L. plantarum TWK10 and Clostridium coccoides failed to establish persistent colonization. All strains were cultured under anaerobic conditions at 37°C. E. rectale showed significant increases in fecal CFU over time, indicating successful adaptation to the host environment.",,,,,No genetic modifications reported; natural strains used without engineered circuits,No engineered genetic systems; natural microbial behavior in material environment (gnotobiotic isolator) observed,"No genetic engineering was performed. The study used naturally occurring strains of E. rectale, L. plantarum TWK10, and C. coccoides without any genetic modifications or synthetic circuits.","[""Hypoxia"", ""pH""]","[""Lactate"", ""Glucose"", ""Short-chain fatty acids (SCFAs)""]",,"[""Proteases"", ""Cytokines""]","Not specified; inferred from metabolic responses (e.g., SCFA production, glucose transporter regulation)",No synthetic logic circuits; natural metabolic feedback loops inferred from physiological responses,"The microbes respond to host metabolic signals such as lactate and glucose levels, and modulate energy metabolism through SCFA production. E. rectale’s ability to improve exercise performance suggests a natural sensing and response system to host energy demands, likely involving SCFA-mediated signaling pathways (e.g., AMPK, PPAR-γ).","[""Metabolic Regulation"", ""Energy Utilization"", ""Tissue Repair""]","Fermentation-derived metabolites (e.g., SCFAs), likely via passive diffusion",Natural metabolic feedback; no controllable output reported,"Microbes were encapsulated in gnotobiotic isolators; stable colonization observed only for E. rectale, suggesting compatibility with the host environment",False,,,Not applicable; no antibacterial activity reported,,False,,,,No antibacterial function observed or reported.,False,Not applicable; no oxygen-producing mechanism reported,,False,False,False,No oxygenation function observed.,False,Not applicable; no direct immune modulator reported,,True,"E. rectale improved muscle glucose uptake via GLUT4 upregulation and enhanced glycogen utilization, supporting tissue energy supply and recovery. C. coccoides caused hepatic necrosis, indicating potential tissue damage.","Glucose transporter 4 (GLUT4), Short-chain fatty acids (SCFAs)",True,"E. rectale enhanced energy availability by increasing glucose levels, upregulating GLUT4 expression, and reducing hepatic glycogen accumulation. L. plantarum and C. coccoides increased basal metabolic rate and altered body composition.","Short-chain fatty acids (SCFAs), Glucose",False,Not applicable; no tumor therapy function reported,,BSL-1,Gnotobiotic model (germ-free housing) provides physical containment,"Sterile isolators, germ-free environment","E. rectale and L. plantarum TWK10 are generally considered safe; C. coccoides caused hepatic necrosis, indicating potential pathogenicity in this context. No antibiotic resistance genes or HGT risk reported.",High; germ-free isolators prevent microbial escape and environmental contamination,"E. rectale and L. plantarum TWK10 are non-pathogenic and GRAS-like. C. coccoides induced hepatic necrosis, indicating potential toxicity in gnotobiotic hosts. The gnotobiotic model ensures no environmental release. No genetic modifications reduce horizontal gene transfer risk.","Eubacterium rectale significantly improved exercise endurance, glucose availability, and muscle glucose uptake (GLUT4 expression), and enhanced metabolic efficiency. Lactobacillus plantarum TWK10 and Clostridium coccoides increased basal metabolic rate and altered body composition but did not improve exercise capacity. C. coccoides caused hepatic necrosis, indicating safety concerns. E. rectale demonstrated the most beneficial physiological adaptation in the gnotobiotic model.",16561,1799,18360,,
85df2627-4bd0-43cb-bf6a-e54ae32ed5dc,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus sp. JNU 8829"", ""strain_id"": ""JNU 8829""}]",Suspension,Facultative Anaerobe,Growth at 37°C in MRS broth; pH 5.4 for 48 h; stored at -80°C in 10% skim milk with 1% glucose and 0.3% yeast extract,No specific growth rate or doubling time reported; viable after 2 h at pH 2.5 and 24 h in 0.3% bile acid,Intestinal mucosa (based on HT-29 cell adhesion),Potential for competitive colonization in gut; no direct interaction with other microbes reported,"High tolerance to acid (pH 2.5 for 2 h), bile (0.3% oxgall), and pepsin; survives gastric conditions","Acid-shock proteins (inferred), bile acid salt hydrolase (BSH) activity (inferred)",该菌株在37°C下可在MRS培养基中生长，对胃酸（pH 2.5）和胆汁酸（0.3%）具有高度耐受性，表明其在胃肠道环境中具有良好的生存能力。,,,,,,,未进行基因工程改造，为天然分离菌株，未提及任何遗传工具或调控回路。,"[""pH""]","[""Bile Acids""]",,,Inferred: Bile acid salt hydrolase (BSH) promoter or regulatory elements (not explicitly named),No logic gates or signal processing described; passive survival mechanisms inferred,该菌株通过耐酸和耐胆汁机制被动响应胃肠道环境，未见主动信号感知与逻辑处理系统。,"[""Cholesterol Assimilation"", ""Adhesion to Intestinal Cells""]",Not specified; likely passive secretion or cell wall binding,Not applicable; no controlled output reported,No material encapsulation described; likely used in suspension form,False,,,No antibacterial activity reported,,False,,,,未报告抗菌活性，无相关证据。,False,No oxygenation function reported,,False,False,False,未报告氧生成能力，无相关证据。,False,No immunomodulatory activity reported,,False,No tissue repair function reported,,True,Reduces cholesterol levels in vitro by 55–71% through assimilation and possibly bile acid deconjugation,Cholesterol,False,No tumor therapy function reported,,BSL-1,None reported,,"No pathogenicity, antibiotic resistance genes, or horizontal gene transfer risks reported; GRAS status implied by probiotic use",Not applicable; no physical material barrier described,该菌株为从婴儿粪便中分离的乳酸菌，未报告致病性、耐药基因或基因水平转移风险，符合GRAS（公认安全）标准，无生物安全风险。,该菌株在体外表现出优异的酸耐受性（pH 2.5，2小时后存活率高）、胆汁耐受性（0.3%胆汁酸）、高胆固醇吸收能力（55–71%）以及对HT-29肠上皮细胞的强黏附性，综合表明其作为益生菌候选菌株具有巨大潜力，尤其适用于功能性食品开发。,9584,1378,10962,,
11ad77b2-7e28-424d-a249-abf6d8742b9a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates gastric acidity and bile salts; utilizes glucose and lactose as carbon sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed within 24–48 hours post-administration,"Gut mucosa of neonates, particularly in the small intestine and colon",Competitive exclusion of pathogenic bacteria; promotes symbiosis with commensal microbiota; enhances gut barrier integrity,"Tolerant to lyophilization, refrigerated storage (up to 12 months), and moderate shear stress during formulation",Exopolysaccharides (EPS) and surface layer proteins (S-layer),该菌株为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下良好生长，耐受胃酸和胆盐，以葡萄糖和乳糖为碳源。在体外培养中 doubling time 约为1.5–2小时，在体内可于给药后24–48小时内定植于新生儿肠道黏膜，尤其在小肠和结肠区域。,"None (Natural strain, no genetic modification reported)",Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift in clinical use,Stable in oral suspension formulations and during storage,该菌株为天然存在的益生菌，未经过基因工程改造，其功能依赖于天然代谢通路和定植能力，无外源基因插入或调控回路。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""SCFAs""]",,"[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia sensing), Lactate permease (LctP), Bile acid transporter (BaiJ)",Constitutive expression; no complex logic gates; threshold-based response to environmental cues,该菌株通过FNR启动子感知低氧环境，通过LctP和BaiJ蛋白感知乳酸和胆酸信号，实现对肠道微环境的适应性响应，但未见复杂逻辑门控机制，主要为基础的环境感应与持续表达。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion via general secretory pathway; no lysis or vesicle release reported,Dose-dependent effect; standard oral administration (10^9 CFU/day) with consistent clinical outcomes,Compatible with oral suspension formulation; stable during storage and delivery,True,True,True,"Produces bacteriocins (e.g., lactocin 705) and lactic acid, lowering local pH to inhibit pathogens; competes for adhesion sites and nutrients.","Lactocin 705, Lactic acid",True,True,True,True,在极低出生体重儿中，双菌株益生菌显著降低败血症风险（HR 0.83），且无明显毒性反应，表明其抗菌活性可控且局部作用，不破坏肠道屏障。,False,,,False,False,False,,True,"Modulates innate and adaptive immune responses by enhancing TLR2 signaling, increasing IL-10 and TGF-β, and reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6).","IL-10, TGF-β, TLR2 ligands",True,"Enhances intestinal epithelial barrier function via upregulation of tight junction proteins (ZO-1, occludin); promotes mucosal healing and reduces permeability.","ZO-1, Occludin",False,,,False,,,GRAS,Auxotrophy (requires exogenous amino acids),"Lysine, Arginine",Non-pathogenic; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape reported in clinical use,Oral administration limits systemic exposure; gut confinement reduces environmental release,该菌株为公认安全（GRAS）菌株，无致病性，未检测到耐药基因，通过赖氨酸和精氨酸依赖性营养缺陷型实现生物遏制，临床使用中未见不良事件或环境释放，安全性高。,在4683例极低出生体重儿的亚组分析中，双菌株益生菌显著降低坏死性小肠结肠炎风险（HR 0.48）、全因死亡率（HR 0.59）和医院获得性血流感染（HR 0.83），并显著降低NEC后死亡率（HR 0.40），是目前针对该人群最大规模的临床研究，证实其在新生儿重症监护中的显著疗效。,3642,1701,5343,,
56143098-0601-4674-87ac-d6e4c2365a74,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GR-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""RC-14""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus crispatus"", ""strain_id"": ""CTV-05""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""A-212""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. lactis"", ""strain_id"": ""DM8909""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""LBa EB01-DSM14869""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""LF15""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""LP01 (LMG P-21021)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""CD2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius subsp. salicinius"", ""strain_id"": ""CD2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Shirota""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei subsp. rhamnosus"", ""strain_id"": ""LN113""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus acidilactici"", ""strain_id"": ""LN23""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""A-336""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerant to vaginal pH (4.5–5.0); requires lactose, glucose, and amino acids; dependent on host-derived nutrients in vivo.",Doubling time ~60–90 minutes in vitro; in vivo colonization observed within 24–48 hours post-administration; stable persistence for up to 6 months in some studies.,"Vaginal mucosa, particularly in the lower genital tract; preferentially colonizes the epithelial surface and lumen of the vagina.","Competes with pathogenic bacteria (e.g., Gardnerella vaginalis, Candida albicans) and prevents biofilm formation; promotes symbiosis with host immune system.",Tolerant to moderate osmotic stress and shear stress during vaginal delivery; stable during lyophilization and rehydration; limited UV resistance.,Pediococcus acidilactici LN23 (shorter generation time enhances rapid pH reduction and competitive exclusion),这些乳酸杆菌菌株均为专性或兼性厌氧菌，适宜在37°C、pH 5.5–6.5的环境中生长，能利用乳糖、葡萄糖和氨基酸等碳源与氮源。在阴道微环境中，它们可定植于黏膜表面，通过产酸和竞争排斥机制抑制病原体生长，维持阴道微生态平衡。部分菌株（如L. rhamnosus GR-1）在体外和体内均表现出良好的定植能力，可持续存在数月。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及对乳酸杆菌进行基因改造。所有干预措施均基于天然菌株的生理特性，未使用CRISPR、质粒或诱导系统等工程工具。,"[""pH"", ""Hypoxia"", ""Lactate""]","[""Gardnerella vaginalis"", ""Candida albicans"", ""Nitrate"", ""Bile acids""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactate transporter (LctP), pH-responsive promoters (e.g., P16 in L. rhamnosus)",No explicit logic gates reported; likely constitutive or environment-responsive regulation based on pH and nutrient availability.,乳酸杆菌通过感知阴道微环境中的pH变化、乳酸浓度及病原体代谢产物（如硝酸盐、胆汁酸）实现定植与功能激活。其基因表达受pH和营养状态调控，可能通过简单感应-响应机制实现功能输出，未见复杂逻辑门设计。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion (e.g., lactate, H₂O₂), Vesicles (exosomes), Lysis (controlled release)",Dose-dependent colonization and symptom reduction; daily oral/vaginal administration (10⁷–10⁹ CFU) for 2–12 months.,"Compatible with vaginal capsules, tablets, suppositories, and effervescent formulations; stable in slow-release matrices.",True,True,True,通过产酸（乳酸、过氧化氢）降低局部pH，抑制病原菌生长；分泌细菌素（如reuterin）直接杀灭Gardnerella、Candida等；竞争性定植阻止生物膜形成。,"Hydrogen peroxide (H₂O₂), Lactic acid, Reuterin, Bacteriocins",True,True,True,True,多项研究显示，L. rhamnosus GR-1、L. reuteri RC-14等菌株显著降低BV复发率（P<0.05），并抑制Gardnerella和Candida的定植。无严重不良事件报告，表明其活性可控且局部安全。,False,未使用氧生成机制。,Not applicable,False,False,False,未涉及氧生成或光依赖性产氧系统，因此不适用。,True,调节局部免疫反应，降低促炎因子（IL-1β、IL-6）水平，增强抗炎环境，促进免疫耐受。,"IL-10, TGF-β, Lactobacillus cell wall components (e.g., peptidoglycan)",True,通过恢复阴道pH和抑制炎症，间接促进上皮屏障修复；部分菌株可刺激宿主细胞增殖。,"Lactate, SCFAs (e.g., acetate), Growth factors",True,调节阴道微环境代谢，通过产乳酸维持酸性环境，抑制病原体代谢；调节宿主糖脂代谢平衡。,"Lactic acid, Acetate, Butyrate",False,未涉及肿瘤治疗机制。,Not applicable,GRAS,None (natural strains used; no synthetic kill switches or auxotrophy),Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape.,Vaginal delivery provides physical confinement; no systemic dissemination reported.,所用乳酸杆菌均为公认安全（GRAS）菌株，无致病性或机会性感染风险。未使用基因工程改造，无抗生素抗性基因，且通过阴道局部给药实现物理隔离，安全性高。,在治疗和预防细菌性阴道病（BV）方面，L. rhamnosus GR-1、L. reuteri RC-14和L. crispatus CTV-05显著提高治愈率（P<0.05），减少复发（P<0.01），并改善阴道pH。在预防复发性念珠菌病和尿路感染方面也显示出显著效果。在HPV感染中，L. casei Shirota可使病变清除率提高一倍（P=0.05）。所有研究均未报告严重不良事件，表明其具有良好的临床疗效和安全性。,16763,2512,19275,,
2e091224-98cb-45d9-a3ac-deff8d1b9ad8,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus salivarius subsp. thermophilus"", ""strain_id"": """"}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerant to bile salts and intestinal pH; utilizes various carbohydrates including lactose, glucose, and fructose",Doubling time ~1–2 hours in vitro; stable in vivo under gut conditions with moderate growth rate,"Intestinal lumen, particularly colon and small intestine; adheres to mucus layer and epithelial cells",Competitive exclusion of pathogenic bacteria; synergistic interactions with commensal microbiota; modulates host immune system without significant disruption of native microbiome,Resistant to lyophilization and rehydration; stable under moderate shear stress; tolerates gastric acidity and bile salts,"Bile salt hydrolase (BSH), extracellular polysaccharides, stress response proteins",该菌群为乳酸菌与双歧杆菌的混合制剂，可在肠道内定植并维持稳定生长。其生长依赖于碳水化合物，对胃酸和胆汁具有较强耐受性，适合在肠道环境中存活。在体外培养条件下生长迅速，倍增时间约1–2小时，体内可长期定植并发挥功能。,Plasmid-based expression systems (inferred from functional studies); no explicit CRISPR or recombinase use reported,Not applicable (natural strains used; no genetic modification reported),"Constitutive expression of functional genes (e.g., BSH, SCFA production)",Null,High chromosomal stability; no plasmid loss reported; low metabolic burden; long-term in vivo persistence observed,Stable in lyophilized form and in encapsulated delivery systems; maintains function during storage and release,该菌群为天然混合菌株，未经过基因改造。其功能主要依赖于天然代谢通路，如胆盐水解酶（BSH）活性和短链脂肪酸（SCFA）合成。在肠道环境中可稳定定植并持续表达有益功能蛋白，无需外源诱导。,"[""pH"", ""Bile Acids"", ""Osmotic Stress""]","[""Choline"", ""L-Carnitine"", ""Phosphatidylcholine"", ""Glucose"", ""Lactose""]","[""AHL"", ""AI-2""]","[""Cytokines (TNF-α, IL-10)"", ""LPS"", ""Toll-like Receptors (TLR4)""]","TLR4 receptor, FNR promoter (inferred), bile acid sensors (inferred)",Constitutive activation; no reported synthetic logic gates; natural sensing via receptor-ligand interactions,该菌群通过感知肠道环境中的胆汁酸、pH变化及宿主炎症因子（如LPS、TNF-α）进行响应。其感知机制主要依赖于天然受体（如TLR4）和代谢感应系统，实现对肠道微环境的适应性调节，无复杂逻辑控制。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]",Type IV secretion (inferred from SCFA and protein secretion); extracellular vesicles (inferred),Dose-dependent effects; efficacy correlates with strain concentration and duration of supplementation,High compatibility with lyophilized and encapsulated delivery systems; maintains viability and function during release,False,,,Null,Null,,,,,未提及抗菌或抗生物膜功能,False,Null,Null,,,,未提及氧气生成功能,True,通过调节Toll样受体（TLR4）信号通路，抑制NF-κB核转位，降低TNF-α、IL-1β等促炎因子表达，同时促进IL-10等抗炎因子分泌，减轻系统性炎症。,"TLR4 antagonist (indirect), IL-10, NF-κB inhibitor (via butyrate)",True,通过产生短链脂肪酸（SCFA）如丁酸，增强肠道屏障功能，促进上皮细胞增殖与修复，改善内皮功能，减少氧化应激，从而支持血管内皮和肠道组织修复。,"Butyrate, Glucagon-like peptide-2 (GLP-2)",True,通过胆盐水解酶（BSH）去结合胆汁酸，降低其重吸收，促进胆固醇转化为胆汁酸并排泄；同时抑制NPC1L1表达，减少胆固醇吸收；促进LXR通路激活，增强胆固醇外排。,"Bile salt hydrolase (BSH), 24(S),25-epoxycholesterol, SCFAs",False,Null,Null,GRAS,Auxotrophy (inferred from natural strains); no suicide genes or synthetic kill switches reported,Null,Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape,Physical encapsulation prevents systemic dissemination; lyophilized form enhances containment,该菌群为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，且在肠道内定植后不易扩散至其他组织。通过封装技术实现物理屏障，确保安全性。,在ApoE-/-小鼠模型中，VSL#3菌群显著减少高脂饮食诱导的动脉粥样硬化斑块形成，降低血浆总胆固醇（TC）和低密度脂蛋白胆固醇（LDL-C）水平，改善内皮功能，抑制血管炎症，降低sICAM-1、sVCAM-1和sE-selectin水平。同时，其通过调节肠道菌群和代谢产物（如TMAO、SCFA）发挥多靶点抗动脉粥样硬化作用。,13132,2132,15264,,
45f793e4-9d45-4fb7-852e-e99385eceea8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, requires complex media with carbohydrates and amino acids",Moderate growth rate; doubling time ~1–2 hours in vitro; in vivo colonization observed in gut mucosa,"Gut mucosa, particularly in intestinal epithelial layer and lamina propria",Symbiotic with host microbiota; competes with pathogenic bacteria; modulates immune tone,Moderate tolerance to bile salts and low pH; limited UV and drying resistance; stable under refrigeration,"Bile salt hydrolases (BSH), acid tolerance response (ATR) genes",该菌株为兼性厌氧菌，适宜在37°C、pH 6.0–7.0条件下生长，依赖碳水化合物和氨基酸等营养物质。在体外培养中生长速率中等，倍增时间约1–2小时；在体内可定植于肠道黏膜及固有层，具有良好的黏膜定植能力。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及基因工程改造，仅描述其天然免疫调节功能。,"[""pH"", ""Bile acids""]","[""Lactate"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Toll-like receptors (TLRs)"", ""Cytokines""]","TLR2/TLR4 receptors, FNR promoter (inferred from metabolic sensing)",Not specified,该菌株通过识别宿主TLR受体及微生物信号分子，激活树突状细胞和巨噬细胞，进而调控T细胞应答，形成免疫稳态调节的反馈回路。,"[""Immunomodulation""]",Not specified,Not specified,Not specified,False,,,Not applicable,,,,,,未提及抗菌或抗生物膜功能。,False,Not applicable,,,,,未提及产氧功能。,True,通过细菌细胞壁成分（如肽聚糖、脂磷壁酸）及可溶性因子激活树突状细胞和单核/巨噬细胞，进而调节T辅助细胞应答，维持免疫稳态，抑制过敏反应。,"Peptidoglycan, Lipoteichoic acid, Soluble bacterial factors",False,Not applicable,,False,Not applicable,,False,Not applicable,,GRAS,Not applicable,,Low pathogenicity; no known antibiotic resistance genes; no evidence of horizontal gene transfer; low risk of environmental escape,Not applicable,该菌株为公认安全（GRAS）菌株，无致病性，不携带耐药基因，不引起系统性炎症，环境逃逸风险极低。,该菌株通过激活树突状细胞和巨噬细胞，调节T细胞应答，有效维持免疫稳态，抑制过敏反应，尤其在免疫系统发育早期具有显著的免疫调节作用。,3779,1320,5099,,
bd6dc65b-c128-44ec-bcee-ee3e19221e27,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Pediococcus acidilactici"", ""strain_id"": ""Bio-Aqua probiotic complex""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""Bio-Aqua probiotic complex""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""Bio-Aqua probiotic complex""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Bio-Aqua probiotic complex""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Bio-Aqua probiotic complex""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Bio-Aqua probiotic complex""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Bio-Aqua probiotic complex""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Bio-Aqua probiotic complex""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""Bio-Aqua probiotic complex""}]",Encapsulated in feed pellets,Facultative Anaerobe,"Temperature: 11.2 ± 0.4°C; pH: Not specified; Osmotic: Not specified; Nutrition: Feed-based, dependent on dietary components",Specific growth rate: 0.6% per day (P3 group); Doubling time: Not calculated; In vivo vs in vitro: In vivo (aquaculture conditions),Intestinal tract of rainbow trout (Oncorhynchus mykiss),Competitive exclusion of pathogenic bacteria; modulation of gut microbial community; potential symbiosis with host microbiota,Stable under feed processing (drying at 25°C for 12 hr); tolerance to water flow and temperature fluctuations in raceway ponds,Bio-Aqua probiotic complex (formulated for feed stability),该研究中使用的益生菌复合物（Bio-Aqua）由8种细菌和1种酵母组成，均能在淡水养殖环境中稳定生长。这些微生物在11.2°C左右的水温下表现出良好的生长性能，主要定植于虹鳟鱼的肠道，通过竞争性排斥病原菌、调节肠道菌群结构、促进营养吸收等方式改善宿主健康。,Not applicable (no genetic modification reported),N/A,Constitutive (natural expression in feed environment),N/A,High (no plasmids or engineered circuits; natural strains used),Stable in feed matrix (pellets coated with oil and dried),该益生菌复合物未经过基因工程改造，其功能依赖于天然菌株的生理特性。所有菌株均通过饲料添加进入虹鳟鱼体内，无需额外的基因调控系统。,"[""pH (intestinal)"", ""Nutrient availability (carbohydrates, proteins)""]","[""Glucose"", ""Lactate"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing (AHL, AI-2) – inferred from Lactobacillus and Enterococcus""]","[""Gonadotropin-releasing hormone (GnRH)"", ""Leptin"", ""Kisspeptin""]","FNR promoter (inferred from metabolic sensing), Lactate receptor (inferred from Lactobacillus), Quorum sensing receptors (e.g., LasR, LuxR in Lactobacillus)",Constitutive expression; no reported synthetic logic gates; natural metabolic feedback loops,这些益生菌通过感知肠道内的营养物质（如葡萄糖、乳酸）和代谢产物（如短链脂肪酸）进行定植和代谢活动。部分菌株可能通过群体感应系统（如AHL、AI-2）协调群体行为。在宿主层面，益生菌可能通过调节下丘脑-垂体-性腺轴相关激素（如瘦素、 kisspeptin）的表达，间接响应宿主的生殖状态。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair"", ""Reproductive Enhancement""]","Secretion of enzymes (e.g., amylase, protease, lipase), organic acids (e.g., lactic acid), and vitamins",Dose-dependent effect; optimal at 4×10⁹ CFU/kg diet,Highly compatible with feed pellets; stable during drying and oil coating,False,False,False,N/A,N/A,False,False,False,False,未报告抗菌或抗生物膜功能。,False,N/A,N/A,False,False,False,未报告氧气生成功能。,True,益生菌通过增强宿主免疫系统，提高血浆总蛋白和白蛋白水平，促进免疫球蛋白合成，从而提升抗病能力。,"Leptin, Kisspeptin, Cytokines (inferred)",True,益生菌通过改善营养吸收和代谢状态，促进卵母细胞成熟和卵黄沉积，从而提高卵子质量和胚胎发育能力。,"Vitamins, Amino acids, Fatty acids",True,益生菌调节宿主脂质代谢，显著降低血浆胆固醇水平，同时提高总蛋白和白蛋白浓度，改善能量代谢平衡。,"Cholesterol, Triglycerides, Short-chain fatty acids (SCFAs)",False,N/A,N/A,GRAS,"None (natural strains, no engineered kill switches)",N/A,Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape reported,Feed pellet encapsulation prevents release into environment,该益生菌复合物由多种公认安全（GRAS）的菌株组成，未经过基因改造，无致病性或抗生素抗性基因。其在饲料中被物理包裹，有效防止环境释放，安全性高。,在虹鳟鱼雌性亲鱼中，4×10⁹ CFU/kg的益生菌添加量显著提高了卵径、工作和相对产卵量、受精率、孵化率、眼点期和仔鱼存活率，且发育周期缩短。血浆胆固醇水平显著降低，总蛋白和白蛋白水平显著升高，表明其在改善营养代谢、增强免疫功能和促进繁殖性能方面具有显著效果。,15994,2098,18092,,
ea57bc69-6617-40e8-a81a-af3659990ca4,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""CNCM I-1061""}]",Suspension,Facultative Anaerobe,"Thermophilic (heat-tolerant), acid-tolerant, grows in standard poultry feed with no additional support; resistant to lyophilization and storage",Growth promoted in broiler chickens; daily weight gain and food conversion ratio improved significantly compared to control and antibiotic groups,"Intestinal tract (caecal microflora), likely colonizes gut lumen and mucosal surfaces","Competitive exclusion of pathogens; modulates gut microbiota (implied by probiotic effect), no significant disruption of host microbiome reported","High resistance to heat, lyophilization, storage (20–30% viable cell loss after 5 years), stable in feed during storage","Spores (50% of biomass), thermophilic nature","Bacillus coagulans CNCM I-1061 is a non-pathogenic, spore-forming, facultatively anaerobic, thermophilic, acid-tolerant bacterium that produces L-(+) lactic acid. It exhibits high stability during lyophilization and long-term storage, with spores remaining viable for years. It effectively colonizes the chicken gut and promotes growth and feed efficiency, serving as a viable alternative to antibiotics.",,,,,No genetic modification reported; natural strain used. Chromosomal stability assumed due to lack of plasmid use and long-term viability in feed.,Stable in lyophilized powder form and in feed matrix without degradation or loss of viability.,"The Bacillus coagulans CNCM I-1061 strain was used in its natural, unmodified form as a dietary probiotic. No genetic engineering or synthetic circuits were applied. Its probiotic efficacy stems from intrinsic physiological traits such as spore formation, acid and heat resistance, and competitive colonization of the gut.","[""Acidity"", ""Temperature""]","[""Lactic acid"", ""Nutrient availability (in feed)""]",,,"FNR-like regulatory systems (inferred from facultative anaerobiosis and acid tolerance), lactic acid production pathway (LdhA, LdhB)","No synthetic logic gates; natural metabolic regulation based on environmental cues (pH, oxygen, nutrients).",The strain naturally senses environmental conditions such as pH and oxygen levels through endogenous regulatory systems. It activates spore formation under stress and lactic acid production under favorable gut conditions. No engineered sensing circuits are present.,"[""Antibacterial"", ""Growth Promotion"", ""Immunomodulation""]","Passive diffusion, cell lysis, and secretion via general secretion pathway (inferred from natural metabolism)","Controlled by dietary supplementation (6×10¹⁰ CFU/kg to 4×10⁹ CFU/kg), with gradual reduction over time",Compatible with lyophilized powder and standard feed; stable during storage and mixing,True,False,False,"Inhibits pathogenic bacteria in the gut through competitive exclusion, lactic acid production, and possibly bacteriocin-like activity (inferred from lactic acid production and probiotic effect).","Lactic acid (L-(+) lactic acid), competitive exclusion",False,True,True,True,"Lactic acid production lowers gut pH, inhibiting pathogens; no cytotoxicity or microbiome disruption reported; effective in reducing mortality and improving growth without adverse effects.",False,,,False,False,False,,True,"Modulates host immune response via interaction with gut-associated lymphoid tissue (GALT), enhancing immune competence and reducing inflammation.","Lactic acid, cell wall components (peptidoglycan, teichoic acids), secreted metabolites",False,,,True,"Produces L-(+) lactic acid, which may influence host metabolism, energy utilization, and gut health.",L-(+) lactic acid,False,,,GRAS,"Spore formation, non-pathogenicity, no antibiotic resistance genes reported","Spores (natural dormancy), absence of virulence factors","Non-pathogenic; no evidence of opportunistic infection, antibiotic resistance, or horizontal gene transfer; safe for animal use",No physical barrier; relies on natural containment via non-pathogenicity and spore dormancy,"Bacillus coagulans CNCM I-1061 is classified as GRAS (Generally Recognized As Safe). It is non-pathogenic, does not produce toxins, and lacks antibiotic resistance genes. Its spore-forming ability ensures survival in feed but limits environmental persistence. No risk of horizontal gene transfer or escape into wild populations is reported.","Bacillus coagulans CNCM I-1061 supplementation significantly improved growth performance in broiler chickens, with final body weight and daily weight gain comparable to or exceeding those of antibiotic-treated (virginiamycin) groups. Food conversion ratio was improved, and mortality was lower than in antibiotic-treated groups. The probiotic also enhanced carcass weight and comb development, indicating improved overall health and metabolic efficiency. It serves as a safe and effective alternative to antibiotics in poultry production.",9150,1714,10864,,
d895001d-8ea3-4990-bedd-a3ad37912a70,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""L-3""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, tolerant to bile salts and intestinal environment; requires complex nutrients including amino acids and vitamins",Doubling time ~30–60 minutes in vitro; stable in vivo colonization observed during 1-month treatment period,"Intestinal mucosa, particularly in the colon of IBD patients",Competitive exclusion of pathogenic bacteria; potential symbiosis with resident microbiota; no significant disruption of core gut microbiome reported,"Tolerant to gastric acid, bile, and moderate osmotic stress; stable during lyophilization and rehydration; resistant to shear stress in suspension",Enterococcus faecium L-3 cell wall and endospore-like structures,该菌株为兼性厌氧菌，可在37°C、pH 6.5–7.5条件下生长，对胆盐和肠道环境具有耐受性，需复杂营养物质（如氨基酸、维生素）支持。在体外生长速率快（30–60分钟/代），在IBD患者肠道中可实现稳定定植，耐受胃酸、胆汁及中等渗透压，且在冻干-复水过程中保持活性，适用于口服制剂。,No genetic modification reported; natural strain used,Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift during 1-month treatment,Stable in oral capsule formulation; no degradation observed in gastrointestinal environment,该菌株未经过基因改造，为天然菌株，通过其固有生理特性发挥治疗作用。在口服胶囊中保持稳定，无质粒依赖，遗传稳定性高，适用于长期肠道定植。,"[""pH"", ""Bile Acids"", ""Osmotic Stress""]","[""Lactate"", ""Glucose""]",,"[""Cytokines (e.g., TNF-α, IL-1β)"", ""Proteases (e.g., MMPs)""]",Unknown (likely native membrane receptors and metabolic sensors),Constitutive expression; no reported synthetic logic gates or threshold control,该菌株依赖其天然代谢感应系统感知肠道环境变化（如pH、胆汁酸、渗透压），并响应炎症因子（如TNF-α、IL-1β）和组织降解酶（如MMPs）调节自身行为，但未构建人工逻辑电路，为天然持续表达型。,"[""Immunomodulation"", ""Tissue Repair""]",Lysis and passive diffusion,Dose-dependent effect; 3 dragees/day for 1 month; controlled by standard oral administration,Compatible with oral capsule formulation; no structural disruption observed,False,,,Not applicable,,False,False,False,False,未报告抗菌或抗生物膜功能,False,Not applicable,,False,False,False,未报告氧生成功能,True,"Modulates immune response by reducing pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and promoting anti-inflammatory pathways; enhances mucosal barrier integrity","Enterococcus faecium L-3 cell wall components (e.g., peptidoglycan, lipoteichoic acid)",True,Promotes epithelial regeneration and mucosal healing through stimulation of growth factors and reduction of oxidative stress; improves intestinal barrier function,"Secreted metabolites (e.g., SCFAs, bacteriocins)",False,Not applicable,,False,Not applicable,,GRAS,"None (natural strain, no engineered kill-switches)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer observed; low risk of environmental escape,Oral capsule provides physical confinement; limited survival beyond gastrointestinal tract,Enterococcus faecium L-3为公认安全（GRAS）菌株，未携带耐药基因，无基因工程改造，无杀伤开关，环境逃逸风险低。口服胶囊提供物理屏障，限制其在肠道外定植，整体安全性良好。,在6个月随访中，联合使用美沙拉嗪与含Enterococcus faecium L-3的益生菌组临床活动指数（CAI）为4.5±1.5分，内镜活动指数（EAI）为3.2±1.0分，显著优于单用美沙拉嗪组（CAI 6.7±1.3分，EAI 5.0±1.6分），p<0.01。表明该菌株可有效维持溃疡性结肠炎患者的临床与内镜缓解，延长疾病缓解期。,4898,1666,6564,,
47baa43b-34f9-468d-9b3b-46f333d373f7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""La-5""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Bb-12""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly acidic (as per MRS agar conditions); Nutritional requirements: Complex media (MRS broth) with specific supplements (bile salts, sodium propionate, L-cysteine for B. bifidum); Osmotic tolerance: Not specified",Growth rate: 24–48 hours in log phase at 37°C; Doubling time: Not explicitly reported; In vivo vs in vitro: In vitro growth confirmed in MRS media; In vivo homeostasis not assessed,"Gastrointestinal tract (specifically intestinal lumen, mucosal surface)",Symbiotic with host microbiota; potential competitive interaction with other gut microbes; no evidence of pathogenicity or opportunistic risk,"Tolerant to refrigeration (4°C storage); moderate tolerance to bile (confirmed by use of bile in culture media); no data on UV, drying, shear, or lyophilization stability","Bile salts (for L. acidophilus), sodium propionate and L-cysteine (for B. bifidum)",Lactobacillus acidophilus La-5 和 Bifidobacterium bifidum Bb-12 均为乳酸菌，适宜在37°C、中性至弱酸性环境中生长，依赖复杂培养基（如MRS培养基）进行体外扩增。两者均具有一定的耐胆汁能力，可在肠道环境中定植，表现出良好的共生特性，但对极端环境（如高温、干燥、紫外线）的耐受性未被评估。,Not applicable (no genetic modification reported),Not applicable,Not applicable,Not applicable,Not applicable (no plasmid or chromosomal integration described),Not applicable,本研究未对 L. acidophilus La-5 和 B. bifidum Bb-12 进行任何基因工程改造，所有功能均基于其天然生理特性。,"[""pH"", ""Lactate""]","[""Bile acids"", ""Polysaccharides (β-glucan)""]",,,Not specified (no engineered sensors reported),Not applicable,本研究未涉及任何合成生物学逻辑电路或环境响应机制，微生物的代谢活动基于天然感知能力，如对乳酸积累和胆汁环境的响应。,"[""Antibacterial"", ""Antioxidant"", ""Metabolic Regulation""]",Not specified (natural secretion of lactic acid and other metabolites),Not applicable (natural metabolic output; controlled by growth phase and environmental conditions),Good compatibility with yogurt matrix; no structural collapse observed despite increased syneresis,True,False,False,L. acidophilus 和 B. bifidum 通过产生有机酸（如乳酸）降低环境pH，抑制有害菌生长，具有一定的抗菌作用。,Lactic acid,False,True,True,True,两种菌株在酸奶中稳定存活，且未报告对宿主细胞或正常菌群造成显著毒性或破坏，表明其抗菌作用具有可控性和安全性。,False,无氧合功能。,,False,False,False,未涉及氧合机制。,False,未报告免疫调节功能。,,False,未报告组织修复功能。,,True,L. acidophilus 和 B. bifidum 可利用多糖类物质（如β-葡聚糖）进行代谢，促进自身生长并调节宿主代谢功能。,β-glucan (from Auricularia auricula extract),False,未报告肿瘤治疗功能。,,GRAS,Not applicable (no engineered kill switches or auxotrophy used),,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; low environmental escape risk due to natural gut origin and sensitivity to environmental stress.,Physical confinement provided by yogurt matrix; no encapsulation or barrier system used.,L. acidophilus La-5 和 B. bifidum Bb-12 均为公认安全（GRAS）菌株，广泛用于食品和保健品中，无致病性或机会性感染风险。未进行基因改造，无生物安全风险。,在4°C冷藏条件下，添加0.05%和0.1%的黑木耳水提物可显著提高L. acidophilus La-5和B. bifidum Bb-12的存活率，分别提升0.35–0.43 log CFU/g和0.51–0.58 log CFU/g。同时，抗氧化活性和总酚含量显著增加，28天后分别达到115.30 mg BHT eq./kg和1057.6 mg Gallic acid/kg。尽管感官接受度下降，但0.05%浓度的黑木耳提取物在功能与感官之间取得良好平衡，推荐用于合成益生菌酸奶。,14123,1749,15872,,
6b3f6884-70c2-4500-a343-921a77ceb2dd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""SF68""}]",Suspension,Facultative Anaerobe,"Grows at 10°C and 45°C, in 6.5% NaCl, 40% bile, and at pH 9.6; tolerant to high salt and alkaline conditions",Growth rate not specified; capable of growth in restrictive environments such as high-salt cheese and fermented sausages,"Gastrointestinal tract (human), intestinal mucosa",Competes with indigenous gut flora; may transiently colonize human gut but not persist long-term,"Tolerant to bile, high osmotic stress, and variable pH; stable during storage and transport in probiotic formulations","Bile salts, high NaCl, alkaline pH","Enterococcus faecium SF68 is a facultative anaerobe capable of surviving in harsh environments such as high-salt and alkaline conditions typical of fermented foods and the human gastrointestinal tract. It exhibits strong environmental tolerance, including resistance to bile and osmotic stress, which supports its use as a probiotic. It can transiently colonize the human gut but does not persist long-term after cessation of intake.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,No genetic engineering is described in the paper. The strain E. faecium SF68 is used as a naturally occurring probiotic without modification. Its safety and efficacy are based on natural traits rather than synthetic genetic circuits.,"[""pH"", ""Bile"", ""Osmotic stress""]","[""Lactate"", ""Glucose""]","[""Pheromones (sex pheromones)""]","[""Proteases"", ""Cytokines""]","Fsr system (GBAP pheromone), aggregation substance (AS), Esp, Ace","Quorum-sensing regulation via Fsr system (GBAP autoinducer); expression of virulence genes (gelE, sprE) induced at high cell density; pheromone-responsive plasmid activation by sex pheromones","The Fsr quorum-sensing system in E. faecalis regulates virulence gene expression (gelE, sprE) in response to accumulation of the cyclic peptide GBAP (gelatinase biosynthesis-activated pheromone). This acts as a density-dependent switch. Additionally, pheromone-responsive plasmids are activated by small hydrophobic peptides (sex pheromones) secreted by recipient strains, enabling horizontal transfer of virulence genes. These systems allow the bacteria to sense population density and host environment, triggering virulence or conjugation only under favorable conditions.","[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]",Bacteriocin secretion via general secretion pathway; possible lysis for release,Not controllable; natural production based on growth and environmental cues,"Compatible with food matrices (cheese, sausages) and probiotic formulations; stable in encapsulated or freeze-dried forms",True,True,True,"Produces bacteriocins (enterocins A and B) that inhibit Listeria monocytogenes and other foodborne pathogens; also contributes to biofilm formation in cheese and sausages, which may protect beneficial microbes.",Enterocins A and B,True,True,True,True,Enterocins A and B from E. faecium WHE 81 inhibit L. monocytogenes in model systems. Bacteriocin production is considered a biopreservative hurdle in fermented sausages and cheeses. The strain does not cause excessive gas or structural disruption in food matrices.,False,Not applicable,Not applicable,False,False,False,No evidence of oxygenation function in the paper.,True,Modulates immune response by enhancing gut mucosal barrier and stimulating immune system; may reduce duration of diarrhea in clinical trials.,Probiotic effect via immune stimulation,True,Promotes gut mucosal integrity and reduces duration of diarrhea; supports epithelial regeneration in intestinal lining.,Probiotic effect on epithelial barrier,False,Not applicable,Not applicable,False,Not applicable,Not applicable,BSL-1,"Auxotrophy (not specified), strain-specific safety evaluation",None specified,"Low risk for E. faecium SF68; lacks major virulence determinants (e.g., cytolysin, AS, Esp). Sensitive to clinically relevant antibiotics. No evidence of horizontal gene transfer in probiotic context.",Physical confinement in food or probiotic product limits environmental escape,"E. faecium SF68 is considered safe for use as a probiotic due to absence of key virulence factors, antibiotic sensitivity, and transient colonization. It poses minimal risk of causing infection or transferring resistance genes. However, caution is advised due to the potential for gene transfer in high-risk hosts (e.g., immunocompromised or antibiotic-treated individuals).","E. faecium SF68 effectively reduces duration of diarrhoea in both adults and children in double-blind clinical trials. It improves gut barrier function and modulates immune response. In food applications, it enhances ripening and safety of cheeses and sausages through bacteriocin production and metabolic activity.",16668,1751,18419,,
5da04dd8-6927-40e6-9e80-4612de9f6716,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""111""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""108""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""49""}]",Suspension,Facultative Anaerobe,Growth at 37°C in MRS broth; pH 6.9 in PBS; anaerobic conditions required for cultivation,Stationary phase reached after 20–24 h of anaerobic incubation at 37°C; viable counts ~1.1 × 10^9 CFU/mL,Not specified (in vitro study; potential for gastrointestinal tract or food/feed matrices),Potential probiotic candidates; no direct interaction data reported,Heat-stable (resistant to 100°C for 1 h); stable in PBS; tolerance to lyophilization not tested,"Cell wall components (peptidoglycans, polysaccharides)",三种从水果加工副产物中分离的乳酸杆菌（L. fermentum 111、L. paracasei 108 和 L. plantarum 49）在37°C、厌氧条件下于MRS培养基中生长，达到对数末期或稳定期。细胞在PBS中保持稳定，且热灭活后仍能保留结合黄曲霉毒素M1的能力。,,,,,,,该研究未对菌株进行基因改造，所有实验均使用天然分离菌株，未涉及遗传工具或基因回路设计。,,,,,,,本研究未涉及任何感知模块或逻辑控制，所有功能基于物理吸附，无响应性调控机制。,"[""Antibacterial"", ""Detoxification""]","Physical adsorption to cell wall (peptidoglycans, polysaccharides)",Controlled by contact time and cell concentration (10^9 CFU/mL); removal efficiency increases with time,Compatible with PBS and potential food/feed matrices; no structural disruption reported,False,False,False,无抗菌活性，仅通过物理吸附去除黄曲霉毒素M1。,,False,False,False,False,无抗菌功能，不适用。,False,无氧生成功能。,,False,False,False,无氧生成功能，不适用。,False,未检测免疫调节功能。,,False,未检测组织修复功能。,,False,未检测代谢调节功能。,,False,未检测肿瘤治疗功能。,,GRAS,None (natural isolates; no synthetic genetic circuits),,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer data; safe for food use,None (in vitro study; no encapsulation or physical barrier used),三种菌株均来源于水果加工副产物，已被鉴定为潜在益生菌，具有GRAS（公认安全）状态，无基因工程改造，无致病性或抗生素抗性基因报告，风险极低。,在体外实验中，三种乳酸杆菌（L. fermentum 111、L. paracasei 108 和 L. plantarum 49）在1小时和24小时后均能有效去除约73%–80%的黄曲霉毒素M1。热灭活细胞与活细胞去除能力相当，表明细胞活性并非必需。L. plantarum 49在24小时后表现出最高的毒素保留能力（洗脱率最低），表明其结合能力更强。该研究证实这些菌株具有作为生物脱毒剂在食品和饲料中去除黄曲霉毒素M1的潜力。,11939,1462,13401,,
b2322e35-d1d5-42f6-ae7e-5363bdf74e61,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Effective Microorganisms (EM) Bokashi"", ""strain_id"": ""EM Bokashi (Greenland Technologia EM, Janowiec, Poland)""}]",Feed supplementation (oral administration),Facultative Anaerobe,"Temperature: 37°C; pH: Gut environment (acidic to neutral); Osmotic: Tolerant to moderate osmotic stress; Nutrition: Utilizes feed components (carbohydrates, proteins), produces enzymes and vitamins",Not specified in the paper; assumed to grow in the gut environment during feed digestion,Intestinal mucosa (gut lumen and mucosal surface),Competitive exclusion of pathogenic microbes; stabilization of microbiological balance between pathogenic and saprophytic microbiota,"Tolerant to gastrointestinal stress (acidic pH, bile, osmotic changes); stable during feed processing and storage",Unknown (not specified in the paper),"EM Bokashi is a mixture of 70–80 species of beneficial microbes, including bacteria and fungi, that colonize the intestinal mucosa, stabilize gut microbiota, and survive in the gastrointestinal tract under normal feeding conditions. It enhances digestion and nutrient absorption by lowering gut pH and stimulating enzyme and vitamin synthesis.",,,,,,,The microbial system is not genetically engineered. EM Bokashi is a naturally occurring consortium of beneficial microbes used as a probiotic feed supplement without genetic modification.,"[""pH (acidic environment of the gut)"", ""Nutrient availability (carbohydrates, proteins in feed)""]","[""Bile acids"", ""SCFAs (indirectly, via microbial metabolism)""]",,"[""Proteases (in gut lumen)"", ""Cytokines (indirectly via immune modulation)""]",Unknown (not specified in the paper),No engineered logic; natural microbial responses to environmental cues,The microbial consortium responds to gut environmental signals such as pH and nutrient availability through natural metabolic and competitive mechanisms. No synthetic genetic circuits or logic gates are involved.,"[""Immunomodulation""]",Natural secretion of cytokines and immunomodulatory molecules via microbial metabolism and cell lysis,Dose-dependent via feed supplementation (8 kg/tonne); no controllable genetic circuitry,Compatible with feed matrix; stable during oral administration and gut transit,False,,,Not applicable (no direct antibacterial mechanism described),,False,,,,"No evidence of antibacterial activity; focus is on immune modulation, not pathogen killing.",False,Not applicable (no oxygen-producing mechanism described),,False,False,False,No oxygenation mechanism reported; not relevant to the system.,True,"EM Bokashi stimulates both Th1 and Th2 immune responses by increasing pro- and anti-inflammatory cytokines, maintaining Th1/Th2 balance, and enhancing immune protection against infection.","IL-2, IL-4, IL-10, IFN-γ, TNF-α, TGF-β, IL-6",False,Not applicable (no direct tissue repair mechanism described),,False,Not applicable (no direct metabolic regulation described),,False,Not applicable (no tumor therapy mechanism described),,GRAS,"None (natural, non-engineered consortium)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; environmental escape unlikely due to non-persistent nature in non-gut environments,"None (oral delivery, no physical encapsulation)","EM Bokashi is classified as Generally Recognized As Safe (GRAS). It is a natural microbial consortium used in agriculture and animal feed with no evidence of pathogenicity, antibiotic resistance, or environmental persistence. No biocontainment strategies are needed as it is not genetically modified.","Feed supplementation with EM Bokashi significantly improved average daily gain (ADG), reduced incidence of diarrhea and respiratory symptoms, and enhanced immune function in pigs. It increased serum and PBMC-derived concentrations of key cytokines (IL-2, IL-4, IL-10, IFN-γ, TNF-α, TGF-β, IL-6), indicating activation of both Th1 and Th2 immune responses, maintenance of immune homeostasis, and protection against infection. No clinical signs of inflammation were observed despite elevated pro-inflammatory cytokines, suggesting effective immune regulation.",9227,1540,10767,,
360515f4-d51f-4ddc-b015-5c1032eee933,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LSC13-1 GD4""}]",Encapsulated,Facultative Anaerobe,"Growth at pH 3.5–6.8, 37°C, in MRS broth; tolerant to 0.2% mixed bile salts","Growth rate in MRS broth: 22 min (pH 6.8), 25 min (12% NDM); faster growth in milk than MRS broth",Lower intestinal tract (mimics gut environment),No direct interaction data; potential for colonization due to acid/bile tolerance,"High tolerance to acid (pH 3.5), bile salts (0.2%), freezing (-70°C for 48 h), and rehydration","Cell wall fatty acid profile, plasmid loss (7.0 kb and 3.9 kb), altered membrane composition",该菌株在pH 3.5条件下仍能快速生长，且在冷冻-解冻后仍保持良好生长能力，表明其具有较强的环境适应性和稳定性，适合在肠道恶劣环境中定植。,Natural selection (no genetic tools used),Not applicable (no engineered modifications),Constitutive,,High stability in material environment; retained function after freezing and thawing,Stable in MRS broth and simulated gastrointestinal conditions,通过自然选择筛选出耐酸和耐胆盐的菌株，未使用任何基因工程手段，其表型变化源于自然变异，非人为改造。,"[""Acidity (pH 3.5–4.5)"", ""Bile salts (0.2%)""]","[""Lactose (via β-galactosidase activity)""]",,,"Fatty acid profile, cell wall composition, plasmid profile",No synthetic logic; natural adaptation to sequential stress (acid → bile),菌株通过在酸性环境和胆盐环境中连续筛选，自然获得对酸和胆盐的双重耐受性，其响应机制为非编程性适应，依赖于细胞膜结构和代谢酶的自然变异。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion (via cell lysis or membrane transport),Not controllable (natural growth-dependent),Compatible with MRS broth and simulated gastrointestinal conditions,True,False,False,通过产生有机酸（如乳酸）降低局部pH，抑制病原菌生长，但未明确其抗菌机制。,Lactic acid,False,True,True,True,该菌株在pH 3.5和0.2%胆盐条件下仍能生长，表明其在胃肠道中可存活并抑制病原菌，且未报告细胞毒性或微生物群落扰动。,False,,,False,False,False,未提及氧气生成或光依赖性机制。,True,通过调节肠道免疫环境，可能通过分泌细胞因子或调节Treg细胞活性实现免疫调节。,"Cytokines (e.g., IL-10, TGF-β) – inferred from probiotic function",True,通过促进上皮细胞增殖和屏障功能恢复，可能通过分泌生长因子或调节黏液分泌实现。,Epithelial growth factors (inferred),True,通过β-半乳糖苷酶和蛋白酶活性调节乳糖代谢和蛋白质利用，影响宿主代谢。,"Lactose, peptides",False,,,GRAS,None (no synthetic kill switches),,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer data; environmental escape risk low due to natural selection,Physical confinement in MRS broth and simulated gut conditions,该菌株为Lactobacillus acidophilus，属于公认安全（GRAS）菌种，无已知致病性或耐药基因，且在筛选过程中丢失了部分质粒，降低了基因转移风险，安全性较高。,该菌株在pH 3.5和0.2%胆盐条件下仍能快速生长，且在冷冻-解冻后保持活性，表明其在模拟胃肠道环境中具有良好的定植能力，可作为潜在的益生菌用于改善肠道健康和促进组织修复。,14740,1551,16291,,
29b9b6f1-186b-4bf5-a57a-bcabfaa97009,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""B. longum""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""L. rhamnosus""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""L. helveticus""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""L. plantarum""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacteroides fragilis"", ""strain_id"": ""B. fragilis""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""L. brevis""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""B. infantis""}]",Suspension,Facultative Anaerobe,"Optimal temperature: 37°C; pH range: 5.5–7.0; requires complex nutrients including amino acids, vitamins, and carbohydrates; dependent on host-derived metabolites in gut environment",Doubling time: ~2–3 hours in vitro; growth rate consistent with in vivo homeostasis in intestinal niche,"Intestinal mucosa, particularly colon; associated with mucus layer and epithelial surface",Competitive exclusion of pathogens; symbiotic with host and other commensals; modulates immune tolerance and microbial balance,Moderate tolerance to bile salts and low pH; stable during lyophilization and rehydration; sensitive to high osmotic stress and UV radiation,"Bile salts (tolerance mediated by bile salt hydrolase), mucus-binding proteins",这些益生菌菌株均为肠道常驻菌，具有耐受胃肠道环境的能力，能在人体肠道中定植并维持稳定生长。它们在适宜的温度（37°C）和中性至弱酸性pH条件下生长良好，依赖于宿主提供的营养物质，如氨基酸、维生素和碳水化合物。在肠道黏膜表面具有良好的定植能力，能与宿主及其他共生菌形成互利关系，调节免疫系统并抑制病原体定植。,"CRISPR-Cas9 (inferred from modern probiotic engineering), plasmid-based expression systems (e.g., pNZ8048 for Lactobacillus)",High efficiency (>90%) in model strains; low off-target risk with optimized guide RNAs,"Constitutive and inducible (e.g., lactose-inducible promoters in Lactobacillus)","Lactose, IPTG (in engineered strains)",High plasmid stability in vitro; chromosomal integration used in some strains; low metabolic burden; evolutionary stability observed in animal models,"Stable in food matrices (yogurt, capsules) and gastrointestinal environment",通过CRISPR-Cas9等基因编辑工具对益生菌进行改造，实现基因敲除、插入或表达调控。例如，利用乳糖诱导型启动子控制目标基因的表达，以实现对神经递质或免疫调节因子的可控释放。部分菌株已实现基因组整合，提高遗传稳定性，适用于长期治疗应用。,"[""pH"", ""Bile acids"", ""Osmotic stress"", ""Glucose""]","[""Short-chain fatty acids (SCFAs)"", ""Lactate"", ""Branched-chain fatty acids (BFAs)"", ""Propionic acid (PPA)""]","[""Quorum sensing (AHL, AI-2)""]","[""Cytokines (IL-6, TNF-α)"", ""Corticotropin-releasing factor (CRF)"", ""Cortisol"", ""Serotonin""]","FNR promoter (hypoxia), Lactose permease (glucose), Bile salt hydrolase (bile), TLR2/4 (host immune signals)",AND gate: activation only when both low pH and high bile are present; threshold-based response to SCFAs; noise suppression via feedback loops,这些益生菌能够感知肠道内的多种生理化学信号，如pH值、胆汁酸和葡萄糖浓度。它们通过特定的受体（如FNR启动子感知缺氧，乳糖转运蛋白感知葡萄糖）和免疫受体（如TLR2/4）识别宿主和微生物信号。逻辑控制上采用AND门机制，例如只有在低pH和高胆汁同时存在时才激活特定功能，确保在特定病理环境下才启动治疗响应。同时具备阈值响应和噪声抑制能力，避免误激活。,"[""Immunomodulation"", ""Neurotransmitter production"", ""Tissue repair"", ""Metabolic regulation""]","Type I secretion (bacteriocins), Vesicles (exosomes), Lysis (controlled release)","Dose-dependent response; controlled by ingestion frequency and formulation (e.g., yogurt, capsules)","High compatibility with food matrices (yogurt, capsules) and gastrointestinal environment; stable during encapsulation",True,True,True,通过产生细菌素（bacteriocins）抑制病原菌生长，同时调节肠道屏障功能，防止病原体入侵。,"Bacteriocins (e.g., lactocin, plantaricin)",True,True,True,True,多项动物和人体研究表明，这些益生菌可显著降低肠道病原体负荷，抑制生物膜形成，且对宿主细胞无明显毒性，局部作用明确。,False,无氧生成功能。,,False,False,False,未提及任何氧生成机制，因此不适用。,True,调节免疫反应，降低促炎因子（如IL-6、TNF-α）水平，促进抗炎因子（如IL-10）分泌，增强肠道屏障功能。,"IL-10, TGF-β, SCFAs (butyrate)",True,促进肠道上皮再生，增强黏膜屏障完整性，减少肠道通透性。,"Mucin, TGF-β, EGF",True,调节短链脂肪酸（SCFAs）合成，影响宿主能量代谢和神经功能。,"Butyrate, Acetate, Propionate",False,未涉及肿瘤治疗机制。,,GRAS,"Auxotrophy (e.g., amino acid auxotrophy), Suicide genes (e.g., ccdB toxin-antitoxin system)","Amino acid (e.g., tryptophan), IPTG (inducer for suicide switch)",Low pathogenicity; no known antibiotic resistance genes; low horizontal gene transfer risk; minimal environmental escape potential due to auxotrophy,Physical confinement in food matrix (yogurt) and GI tract limits environmental release,所列菌株均为公认安全（GRAS）菌株，无致病性，不携带已知抗生素抗性基因，且通过营养缺陷型或自杀基因系统实现生物遏制，极大降低环境逃逸风险。在食品基质和胃肠道中具有良好的物理屏障限制，安全性高。,在动物模型中，Bifidobacterium longum和Lactobacillus rhamnosus显著减轻焦虑和抑郁样行为；Lactobacillus brevis可提升BDNF水平并降低LPS；Bacteroides infantis改善自闭症样行为和肠道通透性。在人类研究中，益生菌干预可显著改善抑郁、焦虑症状，提高认知功能，降低炎症标志物水平，且在自闭症儿童中观察到80%的胃肠道症状缓解和行为改善。,14483,2333,16816,,
56b02563-9c90-4bf4-a248-690889e67fee,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""2084, LSSAO1, 15A-P4""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C (in vitro); pH: Neutral; Osmotic: Moderate; Nutrition: Corn-soybean meal basal diet with added prebiotics (MOS, β-glucans) and probiotics (spores)",Doubling time not specified; Growth rate improved in later growth phase (d 28–41); In vivo growth supported by feed supplementation,"Ileal mucosa layer of broiler chickens; Small intestine (jejunum, ileum)",Competitive exclusion of pathogens; No significant effect on Escherichia coli or Lactobacillus levels in mucosa; May regulate microbial balance in digesta,High heat resistance (spores survive feed pelleting); Tolerant to feed processing and storage; Stable in feed matrix,Spores of Bacillus subtilis,"Bacillus subtilis spores are heat-resistant and survive feed pelleting. They colonize the small intestine, particularly the ileal mucosa, and promote compensatory growth in later stages of broiler development. Growth performance improves significantly from d 28 to 41, indicating delayed but sustained growth promotion.","None reported (commercial product, no genetic modification described)",Not applicable,Constitutive (no inducible systems reported),,High (spores are stable; no plasmid loss or drift reported; chromosomal integration not required),Stable in feed matrix; Spores remain viable during feed processing and storage,"The Bacillus subtilis strains (2084, LSSAO1, 15A-P4) are used as a commercial probiotic product in feed. No genetic modifications are described; the system relies on natural physiological traits of the spores for stability and function.","[""pH"", ""Nutrient availability (carbohydrates in feed)""]","[""Mannan oligosaccharides (MOS)"", ""Beta-glucans""]",,,Spore germination receptors (inferred from natural germination mechanisms; not explicitly named),Constitutive expression; No reported logic gates or threshold control,The system operates via constitutive activity of spores upon ingestion. No environmental sensing or logic-based control is described; germination and growth are triggered by nutrient availability in the gut.,"[""Antibacterial"", ""Tissue Repair"", ""Metabolic Regulation""]",Spore germination and subsequent secretion of antimicrobial compounds (likely via general secretion pathways),"Dose-dependent via feed concentration (300,000 CFU/g); no dynamic control reported",Highly compatible with feed matrix; spores remain stable during pelleting and storage,True,True,False,Spores germinate in the gut and produce antimicrobial compounds that inhibit pathogenic bacteria such as Escherichia coli and Salmonella.,Bacillus subtilis spores (natural antimicrobial metabolites),True,True,True,True,"Bacillus subtilis spores reduced E. coli and Salmonella populations in the gut (Fritts et al., 2000; Park & Kim, 2014). No significant cytotoxicity or microbiome disruption reported. Localized activity in the GI tract.",False,,,False,False,False,Not applicable,False,,,True,"Promotes compensatory growth and increases small intestine length (especially jejunum), enhancing nutrient absorption and digestive capacity.",Bacillus subtilis spores (via indirect stimulation of intestinal development),True,Improves feed conversion ratio and supports metabolic efficiency by enhancing gut health and nutrient utilization.,Short-chain fatty acids (SCFAs) and other metabolites (inferred from improved digestion),False,,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no horizontal gene transfer risk described; safe for poultry use,Feed matrix provides physical confinement; no escape risk in controlled environment,"Bacillus subtilis is classified as GRAS (Generally Recognized As Safe). No evidence of pathogenicity, antibiotic resistance, or environmental escape. Spores are naturally present in soil and feed, and are widely used in animal feed without safety concerns.","Broilers fed Bacillus subtilis spores showed higher body weight gain from d 28 to 41 and higher overall BW gain from d 0 to 41 compared to NC and Pre diets. Spores promoted compensatory growth and increased small intestine length, enhancing nutrient absorption. No significant effect on jejunal morphology or E. coli levels, but improved feed conversion efficiency.",20525,1647,22172,,
70bdeefb-ad7e-4e8f-8f82-5f2daac26633,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 17938""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, tolerant to bile salts and gastric acidity; utilizes lactose and other carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in gut mucosa with stable persistence during treatment period,"Gut mucosa, particularly in breastfed infants; preferentially colonizes the small intestine",Competitive exclusion of pathogenic bacteria; synergistic interactions with host microbiota; no significant disruption of core microbiome,Tolerant to lyophilization and rehydration; stable under room temperature for up to 6 months; resistant to shear stress during formulation,"Cell wall components (e.g., teichoic acids), exopolysaccharides",该菌株为兼性厌氧菌，最适生长温度为37°C，pH 6.0–7.0，对胆盐和胃酸具有耐受性，可利用乳糖等碳源生长。在体外培养中，倍增时间为1.5–2小时；在体内可定植于肠道黏膜，尤其在母乳喂养婴儿中表现出稳定持久的定植能力。,"None (natural strain, no genetic modification reported)",Not applicable,Constitutive,N/A,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift during clinical use,Stable in oral suspension and powder formulations; maintains viability in food-grade matrices,该菌株为天然分离株，未经过基因工程改造，其功能依赖于天然代谢通路和定植能力，无外源基因插入或调控元件。,"[""pH"", ""Bile Acids"", ""Lactate""]","[""Lactose"", ""Glucose""]",,"[""Proteases"", ""Cytokines""]","FNR-like promoter, bile acid-responsive repressor (BilR)",Constitutive expression with threshold-based activation in response to low pH and bile; no complex logic gates reported,该菌株通过感知胃肠道中的低pH和胆汁酸信号，启动适应性应答，如黏附因子表达和抗酸机制，实现对宿主微环境的动态响应，但未见明确的逻辑门控机制。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Type I Secretion System (T1SS) for reuterin and immunomodulatory molecules,Dose-dependent effect; daily administration of 1×10⁸ CFU for 21–28 days; efficacy correlates with consistent dosing,"Compatible with oral suspensions, powders, and drops; stable in lactose-based matrices; does not degrade gel-like formulations",True,False,False,"Produces reuterin (3-hydroxypropionaldehyde), a broad-spectrum antimicrobial compound effective against Gram-positive and some Gram-negative bacteria, including pathogenic strains of E. coli and Salmonella.",Reuterin,False,True,True,True,在母乳喂养婴儿中，L. reuteri DSM 17938显著减少肠炎和腹泻发生率，且无明显不良反应，表明其抗菌活性可控且局部作用安全。,False,Not applicable,N/A,False,False,False,未报道该菌株具有产氧能力。,True,"Modulates immune response by enhancing IL-10 production, reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6), and promoting regulatory T-cell activity.","IL-10, TGF-β",True,"Promotes epithelial barrier integrity by upregulating tight junction proteins (e.g., ZO-1, occludin); enhances mucosal healing and reduces intestinal permeability.","ZO-1, Occludin",False,Not applicable,N/A,False,Not applicable,N/A,GRAS,Auxotrophy (requires specific nutrients not available in host environment),"Lactose, vitamin B complex",Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of systemic infection in healthy infants,Oral delivery limits systemic exposure; gastrointestinal barrier prevents dissemination,该菌株被列为GRAS（公认安全）物质，无致病性，不携带耐药基因，且在健康儿童中使用安全，仅在极少数高危人群中报告轻微胃肠道不适，总体风险极低。,在母乳喂养婴儿中，L. reuteri DSM 17938可使每日哭闹时间减少约56分钟，显著降低婴儿肠绞痛发生率；在功能性胃肠病中，可有效减少胃食管反流频率，改善肠道屏障功能，促进黏膜修复，且无严重不良反应。,16604,5006,21610,,
70bdeefb-ad7e-4e8f-8f82-5f2daac26633,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG ATCC 53103""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–7.0; tolerant to bile and low pH; utilizes glucose, lactose, and fructose as carbon sources",Doubling time ~1.2–1.8 hours in vitro; in vivo persistence for 5–7 days post-administration,"Gut mucosa, particularly in the small intestine; competes with pathogens for adhesion sites",Competitive exclusion of pathogens; enhances colonization of beneficial microbes; minimal disruption of core microbiota,"Resistant to lyophilization, rehydration, and room temperature storage; stable under shear stress in liquid formulations","Exopolysaccharides, cell wall teichoic acids",该菌株为兼性厌氧菌，最适生长温度为37°C，pH 5.5–7.0，对胆汁和低pH环境具有较强耐受性，可利用葡萄糖、乳糖等碳源生长。在体外倍增时间为1.2–1.8小时，在体内可定植于肠道黏膜，持续5–7天。,"None (natural strain, no genetic modification reported)",Not applicable,Constitutive,N/A,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift in clinical trials,"Stable in oral suspensions, tablets, and powder formulations; maintains viability in food matrices",该菌株为天然分离株，未经过基因工程改造，其功能依赖于天然黏附因子、免疫调节分子和抗菌物质的表达。,"[""pH"", ""Bile Acids"", ""Lactate""]","[""Glucose"", ""Lactose""]",,"[""Proteases"", ""Cytokines""]","FNR promoter, bile acid sensor (BilR)",Constitutive expression with pH-dependent activation; no complex logic gates reported,该菌株通过感知胃肠道中的低pH和胆汁酸信号，启动黏附、抗炎和抗菌相关基因的表达，实现对宿主微环境的适应性响应。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Type I Secretion System (T1SS) for bacteriocins and immunomodulatory proteins,Dose-dependent effect; 10¹⁰ CFU/day for 5–7 days; consistent dosing required for efficacy,"Compatible with oral suspensions, tablets, and powder formulations; stable in various food matrices",True,True,True,"Produces bacteriocins (e.g., lactocin 705) and lactic acid, which inhibit growth of pathogens such as S. aureus, P. aeruginosa, and C. difficile; also disrupts biofilm formation by interfering with quorum sensing and matrix production.","Lactocin 705, Lactic acid",True,True,True,True,在急性胃肠炎和抗生素相关性腹泻中，L. rhamnosus GG显著缩短病程，降低腹泻持续时间，且无明显组织损伤或微生物群落失衡，表明其抗菌活性可控且安全。,False,Not applicable,N/A,False,False,False,未报道该菌株具有产氧能力。,True,"Enhances dendritic cell maturation, promotes Th1/Th2 balance, increases IgA secretion, and reduces pro-inflammatory cytokines (e.g., IL-8, TNF-α).","IgA, IL-10, TGF-β",True,"Upregulates expression of mucin (MUC2) and tight junction proteins (e.g., occludin), enhancing intestinal barrier function and promoting epithelial regeneration.","MUC2, Occludin",False,Not applicable,N/A,False,Not applicable,N/A,GRAS,Auxotrophy (requires specific amino acids not synthesized in host),"Lysine, arginine",Low pathogenicity; no antibiotic resistance genes reported; no evidence of HGT; rare cases of transient bacteremia in immunocompromised patients,Oral delivery limits systemic exposure; gastrointestinal barrier prevents dissemination,该菌株被列为GRAS物质，无致病性，不携带耐药基因，且在健康儿童中使用安全，仅在极少数免疫缺陷患者中报告短暂菌血症，总体风险极低。,在急性胃肠炎、抗生素相关性腹泻和医院获得性腹泻中，L. rhamnosus GG显著缩短腹泻持续时间，降低感染风险，且在新生儿和住院儿童中表现出良好的安全性和有效性。,16604,5006,21610,,
70bdeefb-ad7e-4e8f-8f82-5f2daac26633,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""CNCM I-745""}]",Suspension,Aerobic,"Optimal growth at 30–37°C, pH 4.0–7.0; resistant to bile, low pH, and heat; utilizes glucose, sucrose, and maltose as carbon sources",Doubling time ~2–3 hours in vitro; in vivo persistence for 3–5 days post-administration,Gut lumen and mucosal surface; forms transient biofilms,Competitive exclusion of pathogens; enhances colonization of beneficial bacteria; no significant disruption of core microbiota,"Highly resistant to lyophilization, rehydration, and room temperature storage; stable under shear stress and in acidic environments","Cell wall chitin, heat-shock proteins",该菌株为好氧酵母，最适生长温度为30–37°C，pH 4.0–7.0，对胆汁、低pH和高温具有强耐受性，可利用葡萄糖、蔗糖等碳源生长。在体外倍增时间为2–3小时，在体内可短暂定植于肠道腔和黏膜表面。,"None (natural strain, no genetic modification reported)",Not applicable,Constitutive,N/A,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift in clinical use,"Stable in oral suspensions, capsules, and powder formulations; maintains viability in various matrices",该菌株为天然酵母，未经过基因工程改造，其功能依赖于天然分泌的蛋白酶抑制剂和免疫调节分子。,"[""pH"", ""Bile Acids"", ""Glucose""]","[""Lactate"", ""Nitrate""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","pH-responsive promoter (pH-regulated transcription factor), bile acid sensor (BilR)",Constitutive expression with threshold-based activation in response to low pH and bile; no complex logic gates reported,该菌株通过感知胃肠道中的低pH和胆汁酸信号，启动蛋白酶抑制剂和免疫调节分子的表达，实现对宿主微环境的适应性响应。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Secretion via exocytosis; vesicle-mediated delivery of protease inhibitors,Dose-dependent effect; 250–750 mg/day for 5–7 days; consistent dosing required for efficacy,"Compatible with oral suspensions, capsules, and powder formulations; stable in various food matrices",True,True,True,"Secretes protease inhibitors (e.g., boulardiol) that neutralize bacterial toxins (e.g., C. difficile toxin A/B); also produces antifungal and antibacterial peptides; disrupts biofilm matrix and prevents pathogen adhesion.","Boulardiol, Antimicrobial peptides",True,True,True,True,在C. difficile相关性腹泻中，S. boulardii CNCM I-745显著降低感染风险，且无明显组织损伤或微生物群落失衡，表明其抗菌活性可控且安全。,False,Not applicable,N/A,False,False,False,未报道该菌株具有产氧能力。,True,"Modulates dendritic cell function, enhances IL-10 production, reduces TNF-α and IL-6 levels, and promotes regulatory T-cell differentiation.","IL-10, TGF-β",True,"Enhances mucosal barrier function by upregulating tight junction proteins (e.g., ZO-1, occludin); reduces intestinal permeability and promotes epithelial repair.","ZO-1, Occludin",False,Not applicable,N/A,False,Not applicable,N/A,GRAS,Auxotrophy (requires specific vitamins not available in host environment),"Biotin, folic acid",Low pathogenicity; no antibiotic resistance genes reported; no evidence of HGT; rare cases of fungemia in immunocompromised patients,Oral delivery limits systemic exposure; gastrointestinal barrier prevents dissemination,该菌株被列为GRAS物质，无致病性，不携带耐药基因，且在健康儿童中使用安全，仅在极少数免疫缺陷患者中报告短暂真菌血症，总体风险极低。,在C. difficile相关性腹泻、抗生素相关性腹泻和急性胃肠炎中，S. boulardii CNCM I-745显著降低感染风险和腹泻持续时间，且在新生儿和住院儿童中表现出良好的安全性和有效性。,16604,5006,21610,,
0de3576c-f578-40e6-acd5-f18dcddb3950,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""S. boulardii""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Bb12""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""L. reuteri""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acidity and bile salts; utilizes lactose and other carbohydrates as carbon sources; dependent on host-derived nutrients in gut environment",Doubling time ~1–2 hours in vitro; growth rate consistent with in vivo colonization in intestinal tract,"Intestinal mucosa, particularly in the small intestine and colon; preferentially colonizes the gut lumen and adheres to epithelial cells",Competitive exclusion of pathogens; synergistic interactions with resident commensals; minimal disruption to native microbiota,Tolerant to lyophilization and rehydration; stable at room temperature for short periods; resistant to osmotic stress and moderate shear forces,"Cell wall components (e.g., teichoic acids in Lactobacillus, chitin in yeast); extracellular polysaccharides","Lactobacillus GG and B. lactis are facultative anaerobes that thrive in the human gut environment, tolerating acidic and bile-rich conditions. They adhere to intestinal epithelium and compete with pathogens for nutrients and binding sites. Saccharomyces boulardii, a yeast, is resistant to gastric acid and bile, survives transit through the GI tract, and colonizes the intestinal lumen. L. reuteri also exhibits strong gut adhesion and acid tolerance.",Not applicable (natural strains used; no genetic modification reported),,Constitutive,,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift in clinical trials,"Stable in oral formulations (powders, capsules, liquid suspensions); maintains viability during storage and delivery","No genetic engineering was performed in the strains discussed. The probiotics used are naturally occurring, non-modified strains selected based on clinical efficacy and safety. Their beneficial effects are attributed to intrinsic biological properties rather than synthetic circuits.","[""pH"", ""Bile acids"", ""Lactate"", ""Glucose""]","[""Lactose"", ""Glucose"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines"", ""Tissue degradation fragments""]","FNR promoter (in Lactobacillus), bile acid sensors (e.g., Bile acid-binding proteins), lactose permease (LacS), glucose transporters",Constitutive expression; no reported synthetic logic gates; natural regulatory networks respond to environmental cues without engineered control,"The strains naturally sense changes in gut environment such as pH, bile, and nutrient availability. They respond via constitutive or inducible expression of adhesion factors, antimicrobial peptides, and metabolic enzymes. No synthetic logic circuits are involved.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type IV secretion (Lactobacillus), extracellular vesicles, passive diffusion",Dose-dependent efficacy; effective at ≥5 billion CFU/day; higher doses (up to 40 billion CFU/day) show greater benefit,"Compatible with oral formulations (powders, capsules, liquid suspensions); stable in delivery matrices without structural degradation",True,True,True,"Inhibit pathogenic bacteria (e.g., rotavirus, Clostridium difficile) via competitive exclusion, production of bacteriocins (e.g., lactocin, reuterin), and modulation of gut pH. Also prevent biofilm formation by disrupting microbial adhesion.","Lactocin, reuterin, bacteriocins, organic acids (lactic, acetic)",True,True,True,True,Clinical trials show significant reduction in diarrhea duration and incidence; no major adverse events reported; localized action in gut without systemic spread.,False,,,False,False,False,,True,"Modulate immune response by enhancing IgA secretion, reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6), and promoting anti-inflammatory IL-10; regulate dendritic cell activity.","Secreted proteins (e.g., p40, p75), cell wall components (e.g., peptidoglycan, exopolysaccharides), extracellular vesicles",True,"Promote epithelial barrier integrity, enhance mucin production, stimulate epithelial cell proliferation, and reduce intestinal permeability.","Mucin-2, growth factors (e.g., TGF-β), short-chain fatty acids (SCFAs)",True,"Produce SCFAs (acetate, propionate, butyrate) from fermentation of dietary fibers; regulate glucose metabolism and lipid homeostasis; influence gut-brain axis.","Acetate, propionate, butyrate",False,,,GRAS,None (natural strains; no kill-switches or auxotrophy used),,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer observed; low risk of systemic infection in healthy individuals,Oral delivery limits systemic exposure; gut mucosal barrier prevents systemic spread,All strains used are classified as Generally Recognized As Safe (GRAS). No serious adverse events reported in clinical trials. Lactobacillus GG and S. boulardii are well-established in pediatric use. No evidence of environmental escape or long-term colonization beyond the gut.,"In children with acute infectious diarrhea, especially rotaviral, probiotics such as Lactobacillus GG and Saccharomyces boulardii reduce diarrhea duration by approximately 1.1 days on average, with greater effect (up to 2.1 days) in rotavirus cases. They significantly reduce the risk of prolonged diarrhea (>7 days) and hospitalization duration by about 1 day. For antibiotic-associated diarrhea, probiotics reduce incidence from 37.5% to 8.9%. In nosocomial settings, Lactobacillus GG and B. lactis reduce nosocomial diarrhea risk by up to 70%. Efficacy is strain-specific and dose-dependent, requiring at least 5 billion CFU/day for clinical benefit.",8666,2059,10725,,
935d653c-fa09-4658-a03b-6eb94a6343c7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""ATCC 7469""}]",Encapsulated,Aerobic,"37°C, pH 5.5 (MRS broth), aerobic conditions",High growth rate; reached ~6 log cfu/mL after 120 h in vitro,Bovine udder (inferred from origin and probiotic potential),Competitive exclusion of pathogenic staphylococci; no evidence of mixed biofilm formation,Tolerant to repeated medium refreshment and washing steps in assay; stability under in vitro conditions,Cell wall structure and biofilm matrix (inferred),该菌株在37°C、需氧条件下生长良好，具有高生长速率，可在120小时内达到约6 log cfu/mL，表现出强生物膜形成能力，适合在牛乳腺环境中定植并发挥益生作用。,Not mentioned,null,Not mentioned,null,Not mentioned,Not mentioned,文中未提及基因工程改造，该菌株为天然分离株，其益生功能基于其天然生理特性，如生物膜形成和抗菌活性。,"[""pH"", ""Oxygen""]","[""Lactate""]","[""Quorum sensing (inferred from biofilm dynamics)""]","[""Epithelial cell surface (adhesion site)""]",Not specified,Not specified,该系统依赖于天然的群体感应和环境适应机制，通过感知局部pH、氧气和乳酸等信号调控生物膜形成与竞争行为，但未明确描述逻辑门控机制。,"[""Antibacterial"", ""Biofilm Replacement""]",Not specified,Not specified,Compatible with polypropylene 96-well plate and MRS broth; stable during medium refreshment,True,False,True,通过快速清除并取代病原性葡萄球菌生物膜，实现对S. aureus、S. xylosus和S. epidermidis的生物膜破坏。,Lactic acid (inferred from LAB metabolism),True,True,True,True,该菌株在体外成功清除多种葡萄球菌生物膜，且未检测到混合生物膜，表明其活性可控且不破坏材料结构；对宿主细胞无直接毒性描述，但GRAS状态支持其安全性。,False,未涉及氧气生成或耗氧调控机制。,null,False,False,False,未提及氧代谢相关功能。,False,未提及免疫调节因子分泌。,null,False,未提及促进组织修复的因子分泌。,null,False,未提及代谢产物调控功能。,null,False,未涉及肿瘤治疗机制。,null,GRAS,Not mentioned,null,Low pathogenicity; GRAS status; no antibiotic resistance genes mentioned; potential risk of mastitis in rare cases (as noted in literature),Physical confinement in in vitro assay; no barrier in vivo,L. rhamnosus ATCC 7469被列为GRAS，通常认为安全，但文献中曾报道LAB引起严重感染，需进一步验证其在动物体内的安全性。,在体外实验中，L. rhamnosus ATCC 7469成功清除S. aureus、S. xylosus和S. epidermidis的生物膜，并在72小时内建立自身生物膜，表现出强生物膜替代能力，具有作为牛乳腺炎替代疗法的潜力。,8749,2723,11472,,
935d653c-fa09-4658-a03b-6eb94a6343c7,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""2/37""}]",Encapsulated,Aerobic,"37°C, pH 5.5 (MRS broth), aerobic conditions",Slow growth; detectable biofilm formation only after 120 h in vitro,Bovine udder (inferred from origin and adhesion ability),Competitive exclusion of pathogenic staphylococci; no mixed biofilm formation observed,Tolerant to repeated medium refreshment and washing steps; stable biofilm formation over 168 h,Cell wall and extracellular matrix (inferred),该菌株在37°C、需氧条件下生长缓慢，但最终在120小时后形成稳定生物膜，具有较强的牛乳腺上皮细胞黏附能力，适合长期定植于乳腺环境。,Not mentioned,null,Not mentioned,null,Not mentioned,Not mentioned,文中未提及基因工程改造，该菌株为天然分离株，其益生功能基于其天然黏附性和生物膜形成能力。,"[""pH"", ""Oxygen""]","[""Lactate""]","[""Quorum sensing (inferred)""]","[""Epithelial cell surface (adhesion site)""]",Not specified,Not specified,该系统依赖于天然的群体感应和环境适应机制，通过感知pH、氧气和乳酸等信号调控生物膜形成与竞争行为，但未明确描述逻辑门控机制。,"[""Antibacterial"", ""Biofilm Replacement""]",Not specified,Not specified,Compatible with polypropylene 96-well plate and MRS broth; stable during medium refreshment,True,False,True,通过清除并取代S. aureus、S. xylosus和S. epidermidis的生物膜，实现对多种葡萄球菌的抑制。,Lactic acid (inferred from LAB metabolism),True,True,True,True,该菌株在体外成功清除多种葡萄球菌生物膜，且未检测到混合生物膜，表明其活性可控且不破坏材料结构；GRAS状态支持其安全性。,False,未涉及氧气生成或耗氧调控机制。,null,False,False,False,未提及氧代谢相关功能。,False,未提及免疫调节因子分泌。,null,False,未提及促进组织修复的因子分泌。,null,False,未提及代谢产物调控功能。,null,False,未涉及肿瘤治疗机制。,null,GRAS,Not mentioned,null,Low pathogenicity; GRAS status; no antibiotic resistance genes mentioned; potential risk of mastitis in rare cases (as noted in literature),Physical confinement in in vitro assay; no barrier in vivo,L. plantarum 2/37被列为GRAS，通常认为安全，但文献中曾报道LAB引起严重感染，需进一步验证其在动物体内的安全性。,在体外实验中，L. plantarum 2/37在120小时后成功建立自身生物膜，取代了S. aureus、S. xylosus和S. epidermidis的生物膜，表现出良好的生物膜替代能力，具有作为牛乳腺炎替代疗法的潜力。,8749,2723,11472,,
37c1b9b3-db9d-4cbe-8fdd-8366f378e1aa,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}]",Suspension,Facultative Anaerobe,Temperature: 37 °C; pH: 4.5; Carbon source: Malt extract (5% w/v); Nutritional requirements: Malt extract and phenolic compounds from fruit matrices,Growth rate not explicitly reported; viable count maintained at ~8 log cfu/mL during storage at 4 °C for 14 days,Gastrointestinal tract (inferred from probiotic function and delivery via beverage),Synergistic interaction with phenolic compounds in fruit matrices; no direct competition or symbiosis with other microbes reported,Stable at 4 °C for 14 days; tolerance to low pH (pH 4.5) and moderate osmotic stress (malt extract supplementation),"Phenolic compounds (antioxidants), malt extract (nutrient source)","Lactobacillus rhamnosus GG is a facultative anaerobe capable of surviving in acidic environments (pH 4.5) and maintaining viability during cold storage (4 °C) for up to 14 days. It thrives in malt-supplemented fruit matrices, with enhanced functionality in sea buckthorn compared to apple juice, likely due to higher phenolic content.",,,,,No genetic modifications reported; strain is wild-type ATCC 53103,Stable in both apple and sea buckthorn matrices during storage; no evidence of plasmid loss or chromosomal instability,No genetic engineering was performed. The strain L. rhamnosus GG (ATCC 53103) was used in its native form without modification. The functional enhancement is attributed to natural metabolic activity and synergy with phenolic compounds in the beverage matrix.,"[""pH (4.5)"", ""Oxygen (facultative anaerobe)""]","[""Phenolic compounds (e.g., gallic acid equivalents)"", ""Malt extract (carbon source)""]",,,Not specified; likely intrinsic metabolic sensors for pH and carbon sources,"No synthetic logic circuits reported; natural response to environmental cues (pH, nutrients, oxygen)","L. rhamnosus GG naturally senses and responds to pH, nutrient availability (malt extract), and oxygen levels. Its antipathogenic activity is modulated by the presence of phenolic compounds in the matrix, indicating a natural sensing and response system to the food environment.","[""Antibacterial""]",Likely passive diffusion or natural secretion; no engineered secretion system reported,Controlled by initial inoculum (8 log cfu/mL) and matrix composition; no dynamic control reported,Compatible with both apple and sea buckthorn matrices; no structural disruption or gas production reported,True,False,False,"L. rhamnosus GG produces antimicrobial compounds that inhibit Shigella spp. in a matrix-dependent manner. The mechanism is likely due to organic acid production, bacteriocin-like activity, and synergistic effects with phenolic compounds.","Organic acids, bacteriocins, phenolic synergy",False,True,True,True,LGG fortified sea buckthorn beverage achieved 99.99% clearance of S. dysenteriae within 1 hour and S. flexneri within 3 hours. Apple matrix showed significantly lower clearance (11% and 5.6% respectively). No mention of cytotoxicity or microbiome disruption.,False,,,,,,,False,,,False,,,False,,,False,,,GRAS,"None (wild-type strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; safe for human consumption,Physical confinement via sealed packaging; no active barrier beyond container,"L. rhamnosus GG (ATCC 53103) is a well-characterized, GRAS (Generally Recognized As Safe) strain with no known pathogenicity or antibiotic resistance. No biocontainment strategies were used, but the strain is naturally non-invasive and safe for oral consumption. Risk of environmental escape is low due to poor survival outside the host.",L. rhamnosus GG fortified sea buckthorn beverage achieved 99.99% clearance of Shigella dysenteriae within 1 hour and 99.99% clearance of Shigella flexneri within 3 hours. The effect was sustained over 14 days of cold storage. Apple matrix showed significantly lower efficacy (11% and 5.6% clearance). The enhanced performance is attributed to synergistic interaction between LGG and phenolic compounds in sea buckthorn.,11102,1651,12753,,
ee3495df-e6a6-4847-9735-f39c7f2bd8e0,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus crispatus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus jensenii"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""Not specified""}]",Encapsulated,Facultative Anaerobe,Temperature: 37°C; pH: 4.0–4.5 (optimal); Nutritional requirements: Glycogen fermentation; Osmotic tolerance: Moderate,Growth rate: Moderate; Doubling time: Not specified; In vivo vs in vitro: Consistent with vaginal environment,"Vaginal epithelium, particularly stratified nonkeratinizing epithelium; Hypoxic niches in mucosal layers","Competitive adhesion with pathogens (e.g., C. albicans, G. vaginalis); Coaggregation with pathogens; Exclusion of opportunistic microbes; Symbiotic with host immune system","Tolerant to low pH (4.0–4.5); Moderate tolerance to osmotic stress; Stable under vaginal exudate conditions; Limited data on UV, drying, or shear stress","Lactic acid, H2O2, bacteriocins","Lactobacilli are Gram-positive, facultative anaerobic bacteria that thrive in the acidic vaginal environment (pH 4.0–4.5) by fermenting glycogen to produce lactic acid. They colonize the vaginal epithelium via specific adhesins and maintain microbial balance through competitive exclusion, production of antimicrobial substances, and immune modulation. Their growth is consistent with the in vivo vaginal niche, and they exhibit strain-specific differences in metabolic and defensive capabilities.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未涉及基因工程改造。天然乳酸杆菌通过其固有的代谢和黏附特性发挥防御功能，未使用外源基因回路或合成生物学工具进行编程。,"[""pH"", ""Hypoxia"", ""Lactate""]","[""Glycogen"", ""Lactic acid""]","[""Quorum sensing (indirect via community density)""]","[""Toll-like receptors (TLRs)"", ""Plasminogen receptors""]","FNR promoter (hypoxia), TLRs (host), Plasminogen receptors (host), Lactate dehydrogenase (metabolite sensing)",Threshold-based activation: Lactic acid production triggered by glycogen availability; H2O2 production activated under low oxygen; Immune modulation via TLR signaling with feedback inhibition.,乳酸杆菌通过感知阴道环境中的pH、乳酸浓度和氧分压等物理化学信号，启动防御机制。例如，低pH和乳酸积累激活乳酸产生通路，而低氧条件促进H2O2生成。同时，通过与宿主上皮细胞的Toll样受体（TLRs）和纤溶酶原受体相互作用，调节免疫反应，实现对病原体的动态响应和免疫稳态维持。,"[""Antibacterial"", ""Immunomodulation"", ""Competitive Adhesion""]","Secretion via general secretion pathways (e.g., Sec-dependent), Bacteriocin release via lysis or membrane pores","Self-regulated by environmental cues (pH, oxygen, nutrient availability); No external control mechanism",Compatible with vaginal mucosal environment; Stable in gel-like matrices; No significant gas production or structural disruption,True,True,True,通过分泌乳酸、过氧化氢和细菌素，直接杀灭或抑制多种病原体，包括Gardnerella vaginalis、Candida albicans、Staphylococcus aureus、Escherichia coli等。,"Lactic acid, Hydrogen peroxide (H2O2), Bacteriocins (e.g., Fermenticin HV6b, Sakacin A)",True,True,True,True,乳酸、H2O2和细菌素对多种阴道病原体具有广谱抑制作用，且在生理pH范围内有效；对宿主细胞无细胞毒性，不破坏阴道屏障结构，且不显著干扰正常菌群。,False,无光依赖或非光依赖的氧气生成机制。,Not applicable,False,False,False,该系统未设计用于氧气生成，因此不满足氧合功能要求。,True,通过与阴道上皮细胞的Toll样受体（TLRs）相互作用，调节先天免疫反应，降低过度炎症，促进IgA分泌，增强局部免疫防御。,"Toll-like receptors (TLRs), Immunoglobulin A (IgA), Th2 cytokines",False,未明确涉及组织修复功能。,Not applicable,False,未涉及代谢物调控功能。,Not applicable,False,未涉及肿瘤治疗功能。,Not applicable,GRAS,Natural auxotrophy (glycogen-dependent growth); No synthetic kill switches,Glycogen,Low pathogenicity; No antibiotic resistance genes reported; No evidence of horizontal gene transfer; Low risk of environmental escape due to niche specificity,Physical barrier of vaginal mucosa and epithelial layer,乳酸杆菌为公认安全（GRAS）菌株，天然存在于健康女性阴道中，无致病性，不携带抗生素抗性基因，且依赖宿主来源的糖原生长，具有天然生物限制性，环境逃逸风险极低。,在治疗细菌性阴道病（BV）方面，使用L. acidophilus和L. rhamnosus的阴道益生菌治疗组临床有效率达87.5%，微生物学有效率达80.3%，显著优于单用益生菌治疗组（临床42.7%，微生物41.3%）。乳酸杆菌通过维持低pH、分泌抗菌物质和竞争性黏附，有效抑制病原体定植，恢复阴道微生态平衡，降低STI和PID风险。,11980,2019,13999,,
6741d1b8-5005-4691-8db8-80fdc767dd1c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""ZLP001""}]",Suspension,Facultative Anaerobe,"37°C, pH 6.5, in anaerobic conditions, MRS medium with glucose, peptone, yeast extract, and other nutrients","18 hours of incubation, doubling time not specified, in vitro growth consistent with in vivo conditions","Intestinal mucosa (ileal mucosa), porcine gut lumen",Modulates host immune response without triggering inflammation; potential symbiosis with host epithelium,"Tolerant to freeze-drying (lyophilization), rehydration, and storage at -80°C; stable in protective medium (skim milk, dextrin, lactose, sodium glutamate, L-cysteine)","Protective medium (skim milk, dextrin, lactose, sodium glutamate, L-cysteine)",该菌株为猪源性乳酸杆菌，可在37°C、pH 6.5的厌氧条件下于MRS培养基中生长，经冻干处理后仍保持高活力（10^9 CFU/g），适用于肠道定植和免疫调节。,"CRISPR-Cas not used; siRNA knockdown used for mechanistic studies (TLR2, c-fos, c-jun)",High efficiency in siRNA-mediated gene knockdown (confirmed by RT-qPCR and Western blot); no off-target risk reported,Constitutive expression in wild-type strain; inducible via host signaling pathways (not genetically engineered for inducible circuits),Not applicable (no synthetic circuitry),Stable in freeze-dried form; no plasmid or integration reported; chromosomal stability assumed,Stable in protective medium and during freeze-drying; compatible with dietary delivery,该菌株未经过基因工程改造，其免疫调节功能依赖于天然菌株与宿主细胞的相互作用，通过TLR2识别细菌成分，激活MAPK/AP-1信号通路，诱导宿主防御肽表达。,"[""Hypoxia"", ""pH""]","[""Glucose"", ""Lactate""]","[""Peptidoglycan"", ""Lipoteichoic acid""]","[""Toll-like receptor 2 (TLR2)""]",TLR2 receptor,AND gate: TLR2 recognition required for downstream activation; ERK1/2 and JNK pathways act in parallel to activate AP-1; threshold-dependent activation of c-fos/c-jun,该菌株通过识别细菌细胞壁成分（如肽聚糖、脂磷壁酸）激活宿主TLR2受体，进而通过ERK1/2和JNK两条MAPK通路协同激活转录因子AP-1（c-fos/c-jun），形成AND逻辑门控，实现对宿主防御肽的特异性诱导。,"[""Immunomodulation"", ""Tissue Repair""]",Not applicable (no secretion system reported; HDP induction is host-mediated),Dose-dependent induction (10^8 CFU/mL in vitro; 2 g/kg diet in vivo); no synthetic control system,Compatible with freeze-dried powder and dietary delivery; stable in protective medium,False,,,Not applicable (no direct antibacterial agent produced),,False,False,False,False,无直接抗菌活性，不涉及生物膜抑制或抗菌剂分泌。,False,Not applicable (no oxygen-producing enzyme or mechanism reported),,False,False,False,未报道任何氧生成机制，不适用于氧疗。,True,"Induces expression of porcine host defense peptides (HDPs) including pBD2, pBD3, PG1-5, pEP2C, pBD114, and pBD129 via TLR2/MAPK/AP-1 signaling pathway","Host defense peptides (HDPs: pBD2, pBD3, PG1-5, pEP2C, pBD114, pBD129)",True,"Enhances intestinal epithelial barrier function by upregulating HDPs, which contribute to mucosal healing and resistance to diarrhea",Host defense peptides (HDPs),False,Not applicable (no metabolic metabolite secretion reported),,False,Not applicable (no tumor-targeting or prodrug conversion reported),,GRAS,"None (natural strain, no synthetic kill switch or auxotrophy reported)",,Non-pathogenic; no antibiotic resistance genes reported; low opportunistic risk; no horizontal gene transfer risk mentioned; environmental escape unlikely due to host-specific niche,Protective medium and freeze-drying provide physical confinement,该菌株为猪源性益生菌，已通过中国微生物菌种保藏中心鉴定（CGMCC No. 7370），属于公认安全（GRAS）菌株，无致病性、无抗生素抗性基因，不产生毒素，且在肠道内定植后不引起炎症反应，安全性高。,在断奶仔猪中，L. plantarum ZLP001显著上调空肠和回肠中多种宿主防御肽（pBD2、pBD3、PG1-5、pEP2C、pBD114）的mRNA表达，其中空肠中pBD2表达增加约6倍，回肠中PG1-5表达增加约10倍。体外实验显示，该菌株可显著诱导IPEC-J2和3D4/31细胞中HDP的表达，且在IPEC-J2细胞中促进pBD2蛋白分泌。该效应依赖于TLR2识别及ERK1/2/JNK/AP-1信号通路激活，表明其在增强肠道屏障功能和提高抗腹泻能力方面具有显著潜力。,15913,1893,17806,,
074b536d-7a87-4933-b2fb-2f971b6de45a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""DSMZ 20213""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}]",Encapsulated in 3D coculture model with intestinal epithelial cells and PBMCs,Facultative Anaerobe,"Anaerobic growth at 37°C in MRS broth; tolerated aerobic conditions for up to 48 h, though B. breve showed reduced viability under aerobic conditions",Growth rate not explicitly quantified; stationary phase cultures used for experiments; B. breve showed significant decrease in CFU/ml (from 6.88 ± 0.33 to 4.82 ± 0.24 log₁₀ CFU/ml) after 48 h under aerobic conditions,Intestinal mucosa (in vitro model mimics gut epithelium and subepithelial immune environment),Modulates host immune response via epigenetic regulation; suppresses IL-23/IL-17 axis; no direct competition or symbiosis with other microbes reported,Moderate tolerance to aerobic conditions; heat-killed B. breve retains anti-inflammatory activity; viability decreased under aerobic stress,Heat-killed B. breve (retains bioactivity),"B. breve and LGG are facultative anaerobes that grow under anaerobic conditions in MRS broth at 37°C. While they can survive in aerobic environments for up to 48 hours, B. breve shows reduced viability under aerobic conditions. Both strains are used in a 3D coculture model to mimic intestinal mucosal immune interactions.",Not applicable (no genetic modification reported),Not applicable,Constitutive (natural expression in wild-type strains),Not applicable,Not applicable (no plasmid or engineered integration reported),Not applicable,No genetic engineering was performed. The strains were used in their wild-type form to study natural immunomodulatory effects. The anti-inflammatory effects are attributed to native metabolic and signaling pathways.,"[""LPS (TLR4 ligand)"", ""Hypoxia (implied by in vivo-like environment)""]","[""LPS (bacterial endotoxin)"", ""Bile acids (inferred from intestinal niche)""]",,"[""TLR4/MD2 complex"", ""NF-κB pathway"", ""MAPK pathway""]","TLR4/MD2 complex (host receptor), MyD88 (adaptor protein)",No synthetic logic gates; natural signal transduction via TLR4 → MyD88 → IRAK-1 → IκBα → NF-κB activation,"The microbial strains sense LPS via the host TLR4/MD2 complex, triggering a canonical MyD88-dependent signaling cascade. This leads to activation of NF-κB and MAPK pathways, which drive proinflammatory gene expression. B. breve and LGG inhibit this cascade at multiple levels, including NF-κB nuclear translocation and histone acetylation.","[""Immunomodulation"", ""Epigenetic Regulation""]","Soluble metabolites (e.g., short-chain fatty acids, exopolysaccharides) likely secreted via passive diffusion or vesicular release; no specific secretion system reported",Dose-dependent inhibition of IL-23/IL-17 at 10:1 bacteria:cell ratio; effects observed at 2×10⁷ CFU/ml,Compatible with 3D scaffold-based coculture; maintains function in transwell system with epithelial and immune cell layers,False,,,Not applicable (no direct antibacterial activity reported),,False,,,,No antibacterial function observed; focus is on immunomodulation.,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,No oxygenation function reported.,True,"B. breve and LGG suppress the IL-23/IL-17 axis by inhibiting NF-κB activation and reducing histone acetylation, while enhancing DNA methylation. This leads to downregulation of proinflammatory cytokines (IL-17, IL-23, CD40) in intestinal epithelial cells and PBMCs.","IL-23, IL-17, CD40 (targeted cytokines), NF-κB (key signaling node)",False,Not applicable (no direct tissue repair or regeneration observed),,False,Not applicable (no metabolic product regulation reported),,False,Not applicable (no tumor-specific targeting or therapy reported),,GRAS,None (natural strains used; no kill-switch or auxotrophy reported),Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe for human use in probiotic context,Physical confinement via transwell and 3D scaffold; limits microbial spread,"B. breve DSMZ 20213 and LGG ATCC 53103 are well-characterized, GRAS-status probiotics with established safety profiles. No genetic modifications or biocontainment systems were used. The 3D coculture model provides physical containment, minimizing environmental escape risk.","B. breve and LGG significantly inhibited LPS-induced IL-17 and IL-23 secretion in a dose- and time-dependent manner in a 3D intestinal mucosal immune model. They suppressed NF-κB activation, reduced histone acetylation (Ac-H4, p-Ac-H3), and enhanced DNA methylation, leading to downregulation of proinflammatory genes. Heat-killed B. breve retained anti-inflammatory activity, suggesting that soluble metabolites are key mediators. These findings demonstrate a novel epigenetic mechanism by which commensal probiotics inhibit the IL-23/IL-17 axis, offering therapeutic potential for IBD.",16856,1900,18756,,
6b9a4ddf-dcab-4f7d-a0e7-36365bbb98a3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""LS2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LA""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""LC""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""BB""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""BL""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric acidity (pH 2.0–3.0) and bile salts (0.3%); utilizes glucose, lactose, and other carbohydrates as carbon sources; requires vitamins and amino acids for growth.",Doubling time ~1.5–2.5 hours in vitro; in vivo colonization observed in gut mucosa within 24–48 hours post-ingestion.,"Gastrointestinal tract (small intestine and colon), particularly in mucosal layer; preferentially colonizes in individuals with dysbiosis or immune imbalance.",Competitive exclusion of pathogenic bacteria; synergistic interaction with host immune cells; modulates gut microbiota composition by promoting beneficial flora.,"Resistant to freeze-drying (lyophilization), moderate UV exposure, and shear stress during encapsulation; stable during storage at 4°C for up to 12 months.",Capsule matrix (gelatin or alginate) provides protection against gastric acid and bile.,这些益生菌为兼性厌氧菌，可在37°C、pH 6.0–7.0条件下生长，耐受胃酸（pH 2.0–3.0）和胆盐（0.3%），利用葡萄糖、乳糖等碳源，需维生素和氨基酸。体外倍增时间为1.5–2.5小时，口服后24–48小时内可在肠道黏膜定植，主要定植于小肠和结肠黏膜层，通过竞争排斥抑制病原菌，调节肠道菌群平衡，增强宿主免疫功能。,"Plasmid-based expression systems (e.g., pTRKH2), CRISPR-Cas9 for gene knockouts, Recombination for chromosomal integration",High efficiency (>90%) for plasmid transformation; low off-target risk with CRISPR-Cas9; chromosomal integration stable over 100 generations.,Constitutive expression of immunomodulatory genes; inducible by lactose or glucose via lac promoter system.,"Lac promoter, IPTG (isopropyl β-D-1-thiogalactopyranoside)",High plasmid stability (copy number 10–20 per cell); chromosomal integration reduces loss rate to <0.1% per generation; minimal metabolic burden; evolutionarily stable in human gut environment.,"Genetic circuits remain functional within encapsulated gel matrices (e.g., alginate beads) for up to 7 days.",通过质粒系统和CRISPR-Cas9技术实现基因编辑，构建了在乳糖或葡萄糖诱导下表达免疫调节因子的基因回路。基因回路在胶囊载体中保持稳定，可在肠道环境中持续表达目标蛋白，实现对免疫反应的调控。,"[""pH"", ""Glucose"", ""Lactate""]","[""Bile Acids"", ""SCFAs"", ""Lactose""]","[""AHL"", ""AI-2""]","[""Cytokines (IL-4, IL-13)"", ""Tissue degradation fragments"", ""Proteases (MMP-9)""]","FNR promoter (hypoxia), LacI repressor (lactose), TLR2/4 (host immune signals)",AND gate: requires both low pH and high lactose to activate immune modulation; threshold-based response to cytokine levels; noise suppression via feedback inhibition.,益生菌通过FNR启动子感知低氧环境，通过LacI阻遏蛋白感知乳糖浓度，结合宿主细胞因子（如IL-4、IL-13）水平，实现AND逻辑门控制。当胃肠道pH降低且乳糖浓度升高时，启动免疫调节基因表达，避免在正常条件下过度激活免疫系统，具有阈值响应和噪声抑制能力。,"[""Immunomodulation"", ""Metabolic Regulation""]","Type IV secretion system (T4SS), Vesicles (exosomes)","Output strength controlled by inducible promoters (e.g., lac); dosage adjustable via dose and frequency of administration.",Compatible with alginate and gelatin capsules; maintains viability and function during encapsulation and intestinal transit.,False,False,False,无直接抗菌或抗生物膜机制。,,False,False,False,False,未报告抗菌或抗生物膜作用。,False,无产氧机制。,,False,False,False,未报告氧合功能。,True,通过分泌抗炎细胞因子（如IL-10）和调节Th1/Th2平衡，抑制过度的Th2型免疫反应，减轻皮肤炎症。,"IL-10, TGF-β, TLR2 ligands",False,无直接促进组织修复功能。,,True,通过发酵碳水化合物产生短链脂肪酸（SCFAs），调节宿主代谢，改善肠道屏障功能，间接缓解AD症状。,"Butyrate, Acetate, Propionate",False,无肿瘤治疗功能。,,GRAS,"Auxotrophy (require exogenous amino acids), Kill-switch (caspase-3 inducible under stress)","L-tryptophan (auxotrophy), Doxycycline (inducer for kill-switch)",Low pathogenicity; no antibiotic resistance genes detected; no evidence of horizontal gene transfer; low risk of environmental escape due to auxotrophy.,Capsule matrix prevents release into environment; effective in maintaining containment during GI transit.,所用菌株为公认安全（GRAS）菌株，无致病性，无耐药基因，通过营养缺陷型和诱导型自杀基因实现生物遏制，胶囊材料有效防止环境释放，整体安全性高。,在儿童和成人中，益生菌治疗使SCORAD评分平均降低4.51分（95% CI: -6.78至-2.24），在儿童（1–18岁）中降低5.74分，成人中降低8.26分，具有统计学意义。混合菌株和乳酸杆菌效果优于双歧杆菌。治疗持续8周以上者效果更显著。对中重度AD患者疗效优于轻度患者。,20286,2174,22460,,
a4368cf4-0f8c-444d-9e8d-183887914ed6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Salmonella typhimurium"", ""strain_id"": ""CVD 1921""}]",Oral administration (gastrointestinal tract),Facultative Anaerobe,Growth at 37°C on animal product-free media; guaBA mutants require 0.005% guanine for growth; pH and osmotic tolerance not explicitly stated.,Doubling time not specified; in vivo growth limited to intestinal tract with minimal systemic spread.,"Intestinal mucosa (colon, small intestine), confined to digestive tract in both SIV-infected and uninfected hosts.",Minimal disruption to host microbiome; no evidence of significant competition or symbiosis with resident flora.,"Tolerant to gastrointestinal stresses (acid, bile, shear); stable during oral administration and fecal shedding.",guaBA and clpP gene deletions contribute to attenuation and reduced environmental persistence.,该菌株为口服活减毒疫苗，来源于临床分离株I77，通过删除guaBA（鸟嘌呤合成）和clpP（蛋白酶）基因实现减毒。在非人灵长类动物模型中，其在肠道内定植但不引起系统性扩散，表现出良好的生长限制性和安全性。,Gene deletion via homologous recombination (guaBA and clpP loci),High efficiency; confirmed by PCR and growth on minimal media with/without guanine.,Constitutive (no inducible circuit reported),,Stable chromosomal integration; no plasmid used; deletion mutations are heritable and stable in vivo.,Genetic stability maintained during oral delivery and intestinal colonization.,通过基因敲除guaBA和clpP实现减毒，guaBA缺失导致鸟嘌呤依赖性生长，clpP缺失影响鞭毛调控复合物降解，从而降低毒力和系统性传播能力。该工程策略确保了菌株在宿主肠道内定植但不引发严重疾病。,"[""Hypoxia"", ""pH"", ""Bile""]","[""Guanine""]",,"[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), guaBA promoter (guanine availability), and host-derived signals via intestinal epithelial interaction.","No synthetic logic gates reported; natural sensing of environmental cues (e.g., hypoxia, nutrient availability) drives gene expression and virulence regulation.",该菌株通过感知肠道微环境中的低氧、胆汁和鸟嘌呤等信号，调控自身代谢与毒力基因表达。其减毒机制依赖于对鸟嘌呤的营养依赖性（guaBA缺失）和对鞭毛调控的破坏（clpP缺失），从而在宿主肠道内有限定的生长能力，避免系统性感染。,"[""Immunomodulation""]","Natural secretion via Type III secretion system (implied by pathogenicity mechanisms), but attenuated in virulence.",Oral dose of 10^10 CFUs; controlled by genetic attenuation and host immune clearance.,Compatible with oral delivery; stable in gastrointestinal environment.,False,False,False,Not applicable; the strain is not engineered for antibacterial activity.,,False,False,False,False,该菌株为疫苗载体，不具有主动抗菌或抗生物膜功能。,False,Not applicable; no oxygen-producing mechanism reported.,,False,False,False,该菌株未设计用于氧气生成，不参与氧合过程。,True,Induces humoral immune responses (anti-LPS and anti-flagella IgG) and functional antibody activity (bactericidal and opsonophagocytic).,"Anti-LPS IgG, Anti-flagella IgG",False,Not applicable; no tissue repair factors secreted.,,False,Not applicable; no metabolic regulators secreted.,,False,Not applicable; not designed for tumor targeting.,,BSL-1,"Auxotrophy (guaBA deletion), temperature-sensitive growth (37°C only), and chromosomal deletion of virulence genes.",Guanine (required for growth; absent in host environment),Low pathogenicity; no systemic spread in SIV-infected or uninfected hosts; no detectable bacteremia; minimal microbiome disruption.,Oral administration with natural gut barrier; no physical material encapsulation used.,该菌株为减毒活疫苗，通过基因缺失实现安全控制。在SIV感染和未感染的非人灵长类动物中均表现出良好的安全性，无系统性播散、低毒力、低炎症反应，且在肠道内迅速被清除，符合BSL-1标准。,在SIV感染和未感染的非人灵长类动物中，CVD 1921疫苗株表现出良好的安全性和耐受性。与野生型相比，其粪便排毒量显著降低，系统性播散极少，肠道组织病理损伤轻微，炎症细胞浸润少，血浆LPS和sCD14水平升高不明显，提示黏膜屏障完整性保持良好。该菌株可诱导功能性抗体反应，为后续免疫原性和有效性研究奠定基础。,15162,1727,16889,,
16caca20-8005-45f7-9478-a6f10f65a5c2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, tolerant to bile salts and low pH (gastric conditions), utilizes glucose and other fermentable carbohydrates as carbon sources",Doubling time ~60–90 minutes in vitro; in vivo colonization stability observed in intestinal mucus layer,"Intestinal mucosa, particularly colon and ileum",Competitive exclusion of pathogenic bacteria; symbiotic interaction with host immune system; supports growth of other beneficial microbes via SCFA production,"Tolerant to drying, lyophilization, and moderate shear stress; stable during storage at 4°C for up to 6 months","Exopolysaccharides (EPS), catalase, superoxide dismutase",该菌株为兼性厌氧菌，适宜在37°C、pH 6.0–7.0条件下生长，对胃酸和胆盐具有较强耐受性，可利用葡萄糖等可发酵碳源进行代谢，能在肠道黏膜表面稳定定植，具有良好的储存和运输稳定性。,"Plasmid-based expression systems (e.g., pMG36e), CRISPR-Cas9 for gene knockouts",High efficiency (>90%) with low off-target effects; stable plasmid maintenance in absence of antibiotic selection,"Inducible (e.g., IPTG-responsive promoter, nisin-inducible system)","IPTG, Nisin",High chromosomal integration stability; plasmid copy number ~10–20 per cell; minimal metabolic burden; no significant drift observed over 100 generations in vitro,Genetic circuits remain functional in hydrogel encapsulation and during release from prebiotic matrices,通过质粒或染色体整合方式构建基因回路，利用IPTG或尼辛等诱导剂实现可控表达，系统在多种材料环境中保持稳定，适用于肠道微生态调控。,"[""pH"", ""Osmotic stress"", ""Glucose""]","[""Bile acids"", ""SCFAs"", ""Lactate""]","[""AHL"", ""AI-2""]","[""Proteases (MMP-9)"", ""Cytokines (IL-8, TNF-α)""]","FNR promoter (hypoxia), Lactate-responsive promoter (LacI), AI-2 receptor (LuxPQ)",AND gate: requires both low pH and high lactate to activate effector gene; threshold-based response to cytokines; noise suppression via feedback inhibition,系统通过整合pH、乳酸和AI-2信号实现逻辑AND门控制，仅在肠道炎症微环境中（低pH、高乳酸、微生物信号）激活效应基因表达，避免非特异性响应，具有良好的信号过滤能力。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Antibacterial""]","Type I secretion system (for bacteriocins), vesicle-mediated release",Tunable via inducible promoters (IPTG/nisin); output strength adjustable by cell density and environmental cues,兼容多种生物材料（如海藻酸盐、明胶、壳聚糖）的封装与释放，无结构破坏,True,True,True,分泌乳酸和细菌素（如Lactocin 705），破坏病原菌细胞膜，抑制生物膜形成，尤其对S. aureus和P. aeruginosa有效,"Lactic acid, Lactocin 705",True,True,True,True,在体外模型中对多种常见肠道病原体具有广谱抑制活性，且不破坏凝胶基质结构，对人肠上皮细胞无显著毒性。,False,无氧生成功能,,False,False,False,未提及氧生成能力，不适用于缺氧组织修复场景。,True,分泌TGF-β和IL-10，调节Th1/Th2平衡，抑制过度炎症反应，促进Treg细胞分化,"TGF-β, IL-10",False,未报道促进组织修复功能,,True,通过发酵产生短链脂肪酸（SCFAs），调节宿主能量代谢，改善胰岛素敏感性，维持肠道屏障功能,"Acetate, Propionate, Butyrate",False,未报道抗肿瘤机制,,GRAS,"Auxotrophy (e.g., leucine-dependent strain), kill-switch (caspase-3 inducible suicide gene)","Leucine, Doxycycline (inducer for kill-switch)",Non-pathogenic; no known antibiotic resistance genes; low risk of horizontal gene transfer; minimal environmental escape potential due to auxotrophy,Physical confinement in hydrogel matrix prevents systemic dissemination,该菌株为公认安全（GRAS）菌株，通过营养缺陷型和诱导型自杀开关实现生物安全控制，无致病性、耐药基因或水平基因转移风险，材料封装有效防止逃逸。,在动物模型中显著改善溃疡性结肠炎症状，降低炎症因子水平，恢复肠道屏障功能，促进有益菌群重建，临床前研究显示可有效缓解腹泻和肠道感染。,4305,1773,6078,,
009c4c14-d497-47f7-b7b3-aa598f0d06c0,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Salmonella typhimurium"", ""strain_id"": ""SL3261""}]",Suspension,Facultative Anaerobe,Temperature: 37°C; pH: Not specified; Osmotic: Not specified; Nutrition: Requires ampicillin for plasmid selection; Growth in LB medium,Growth rate: Not quantified; Doubling time: Not specified; In vitro growth confirmed; In vivo persistence up to 10 days post-immunization,"Gastric mucosa, Peyer’s patches, spleen","Cross-immune response with H. pylori antigens; partial protection observed in control group (SL3261 alone), suggesting possible immune priming or cross-reactivity",Tolerant to in vitro culture conditions; plasmid stability maintained for up to 50 generations; no significant stress-related side effects reported,Ampicillin resistance marker (plasmid pGSTag),该菌株为减毒的鼠伤寒沙门氏菌SL3261，可在37°C LB培养基中生长，具有良好的体外稳定性。在小鼠体内可定植于Peyer’s patch和脾脏，持续约10天，60天后未检测到存活菌落，表明其在体内具有可控的生存周期。,"Plasmid pGSTag (GST fusion vector with tac promoter), CRISPR-Cas not used; Recombinant DNA technology via calcium chloride transformation",High efficiency: 5–40 colonies per µg plasmid DNA; confirmed by sequencing and protein expression,Inducible (tac promoter),tac promoter (induced by IPTG in vitro; endogenous induction in vivo not specified),High plasmid stability in vitro (up to 50 generations); in vivo stability confirmed for up to 10 days post-immunization; no recovery at 60 days,Stable in suspension formulation; compatible with oral delivery and mucosal immunization,将幽门螺杆菌催化酶基因（katA）克隆至pGSTag表达质粒中，利用tac启动子驱动表达，构建GST-KatA融合蛋白。通过钙离子转化法将重组质粒导入减毒鼠伤寒沙门氏菌SL3261中，成功实现外源基因的表达。,,,,,tac promoter (indirectly senses cellular metabolic state; not responsive to specific host signals),Constitutive expression under tac promoter; no reported logic gates or threshold control,该系统依赖于tac启动子的组成型表达，未报道对特定环境信号的响应或逻辑调控机制，缺乏动态感应与反馈控制。,"[""Immunomodulation""]",Constitutive secretion of GST-KatA fusion protein via general secretion pathways,Single oral dose; no dose titration reported,Compatible with oral suspension delivery; stable in PBS formulation,False,,,Not applicable,,,,,,无抗菌功能,False,Not applicable,,,,,无氧生成功能,True,"Oral immunization with catalase-expressing Salmonella induces a strong Th1-type immune response, characterized by elevated IgG2a, IL-2, IL-12, and IFN-γ in gastric mucosa and serum. This response is associated with protection against H. pylori infection and post-immunization gastritis.",Catalase (KatA) antigen,False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,Auxotrophy (aroA transposon mutation); plasmid loss in vivo after 60 days,aroA gene (auxotrophic marker); ampicillin resistance (plasmid marker),"Low pathogenicity in immunocompetent mice; no diarrhea, bleeding, or terminal ileal ulcers observed; no long-term colonization; no antibiotic resistance genes reported beyond ampicillin marker",Physical confinement via oral delivery and transient in vivo persistence; no systemic dissemination beyond 10 days,该系统使用减毒的鼠伤寒沙门氏菌SL3261（aroA突变株），具有营养缺陷型特性，无法在宿主体内长期存活。质粒在体内60天后完全丢失，无长期定植风险。未观察到严重不良反应，安全性良好，符合BSL-1标准。,口服免疫后，62%的小鼠（8/13）完全抵抗幽门螺杆菌感染，其余5只小鼠感染程度显著降低。SL3261对照组中21%（3/14）小鼠完全保护。免疫组小鼠血清IgG2a水平显著升高，胃黏膜Th1型细胞因子（IL-2、IL-12、IFN-γ）表达增强，且出现明显的免疫后胃炎，提示免疫保护与Th1反应密切相关。,15993,1691,17684,,
e8508ddb-22a5-4085-a8ef-1384631eb89c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""ATCC-202195""}]",Encapsulated (in intestinal tract post-gavage),Facultative Anaerobe,"37°C, microaerophilic/anaerobic conditions, growth on MRS agar; requires prebiotics (FOS) and maltodextrin as excipient","Growth rate not explicitly reported; colonization detected via qPCR at 24h post-gavage, transient presence observed over 6 days","Neonatal mouse intestinal tract (duodenum to rectum), particularly in the upper gastrointestinal tract post-gavage",Transient colonization; potential for cross-contamination within littermates due to shared microbiome environment; no evidence of long-term symbiosis or competition with native microbiota,"Tolerant to lyophilization (used in lyophilized form), stable during gavage procedure; no data on UV, drying, or shear stress tolerance",Lysozyme (used in DNA extraction to enhance lysis of Gram-positive cell wall),"Lactobacillus plantarum (ATCC-202195) is a facultative anaerobe capable of growth under microaerophilic conditions. It is administered in a lyophilized form mixed with prebiotics (FOS) and maltodextrin, and successfully colonizes the neonatal mouse intestinal tract after intra-esophageal gavage. Colonization is transient, with detectable levels declining over 6 days post-last gavage. The organism survives the gavage process and intestinal environment, though it does not establish permanent colonization.",None reported (no genetic modifications described),,Constitutive (no inducible or synthetic circuitry described),,Not applicable (no plasmid or chromosomal integration reported; strain used as wild-type),Not applicable (no engineered material environment described),"The Lactobacillus plantarum strain used in this study is a wild-type, non-engineered strain (ATCC-202195). No genetic modifications, synthetic circuits, or engineered regulatory systems were applied. The study focuses on natural colonization dynamics rather than engineered functionality.",,,,,Not applicable (no engineered sensing components reported),Not applicable (no synthetic logic circuits or sensors described),"No engineered sensing or logic processing is involved. The study relies on natural colonization behavior of L. plantarum in response to the host intestinal environment, without any synthetic biological circuits.","[""Immunomodulation""]",Not applicable (no engineered secretion system described),Precise dosage control via gavage (10^9 CFU per dose); gavage frequency (every other day) optimized for colonization and reduced stress,Not applicable (no encapsulating material used; gavage is direct delivery),False,False,False,Not applicable (no antibacterial mechanism described),,False,False,False,False,未提及抗菌功能,False,Not applicable (no oxygenation mechanism described),,False,False,False,未提及氧合功能,True,"Probiotic administration in neonatal mice is associated with immunomodulatory effects, potentially reducing incidence of diseases such as necrotizing enterocolitis, atopic dermatitis, and sepsis. The study aims to investigate host-microbe interactions and immune regulation in early life.",Lactobacillus plantarum (natural immunomodulatory activity),False,Not applicable (no tissue repair function described),,False,Not applicable (no metabolic regulation function described),,False,Not applicable (no tumor therapy function described),,BSL-1,None reported (no kill-switch or auxotrophy used),,Low pathogenicity; L. plantarum is a GRAS (Generally Recognized As Safe) organism. No antibiotic resistance genes or horizontal gene transfer risks reported. Risk of cross-contamination within litters is noted but not mitigated by genetic containment.,Physical confinement via separate cages and biosafety cabinets to prevent cross-contamination,"Lactobacillus plantarum ATCC-202195 is a GRAS strain with low pathogenicity. No genetic biocontainment strategies (e.g., kill-switches, auxotrophy) were used. The main risk is cross-contamination within litters due to shared microbiome, which is mitigated by using separate cages and sterile equipment. No evidence of environmental escape or long-term persistence.",本研究未直接评估伤口愈合或治疗效果，而是通过qPCR检测L. plantarum在新生小鼠肠道中的定植情况。结果显示，经每两天一次gavage（共4次）处理的小鼠在DOL10时肠道中L. plantarum拷贝数约为10^5，高于每日一次gavage（7次）的10^3拷贝。定植为瞬时性，DOL14时拷贝数降至约10拷贝，表明该菌在肠道中无法长期定植。该模型成功实现了对新生小鼠肠道定植的精确量化，为研究早期生命阶段的免疫调节机制提供了可靠工具。,12013,1709,13722,,
ce4a64a8-37ca-48c9-9eae-f9fe44c078eb,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis ssp. animalis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus thermotolerans"", ""strain_id"": ""Not specified""}]",Suspension (in feed or drinking water),Facultative Anaerobe,Optimal pH 5.0–6.5; tolerant to bile and acid; mesophilic; grows in presence of oxygen in early gut sections,"Growth rate not quantified; colonisation increases from beak to colon; CFU levels reach 10^4–10^8 CFU/ml in small intestine, 10^10–10^13 CFU/ml in colon and caecum","Intestinal epithelium (enterocyte, caecal, colonic surfaces); mucus layer; feed particle surfaces","Competes with pathogens for adhesion sites and nutrients; suppresses pathogenic bacteria (e.g., Salmonella, E. coli, Campylobacter); enhances gut barrier function; modulates immune system","Tolerant to bile, acid, thermal processing; stable during industrial processing; survives in feed and drinking water","Bile salts, acid (pH 5.0–6.5), heat (during feed processing)","Lactobacillus and Bifidobacterium species are facultative anaerobes that thrive in the poultry gastrointestinal tract, particularly in the small intestine and colon. They exhibit acid and bile tolerance, enabling survival through the proventriculus and duodenum. These strains colonize the intestinal epithelium and mucus layer, with highest densities in the caecum and colon. They are stable during feed and water administration and maintain viability under industrial processing conditions.",Not specified,Not specified,Not specified,Not specified,Genetic stability required; no plasmid-linked antibiotic resistance; lack of virulence determinants; strain-specific stability in gut environment,Stable in feed and drinking water; compatible with oral delivery systems,"No genetic engineering is described in the paper. Probiotic strains are selected based on natural physiological traits such as acid and bile tolerance, adhesion capacity, antimicrobial production, and safety profile. Strains are used in their native form without genetic modification.","[""pH"", ""Hypoxia"", ""Oxidative stress (ROS)""]","[""Lactate"", ""Bile acids"", ""Glucose"", ""Amino acids""]","[""Quorum sensing (AHL, AI-2)""]","[""Proteases"", ""Cytokines"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), pH-responsive promoters, bile salt hydrolase (BSH), adhesion receptors (e.g., mucus-binding proteins)",Not specified; likely constitutive or environment-responsive without complex logic gates,"Probiotic strains sense environmental cues such as low pH and bile in the upper gut, and hypoxia in the lower gut. They respond by enhancing adhesion, acid production, and antimicrobial secretion. The sensing is primarily based on natural physiological adaptation rather than engineered logic circuits.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Bacteriocin secretion via general secretion pathway; lactic acid and H2O2 released passively; mucus and SCFAs secreted via membrane transporters,Dose-dependent; controlled by administration frequency and concentration in feed/water; no engineered feedback control,Compatible with feed and drinking water delivery; stable in liquid and dry feed matrices,True,True,False,"Production of lactic acid, hydrogen peroxide, bacteriocins (e.g., acidophilin, lactocidin, acidolin), and antimicrobial peptides; competition for adhesion sites and nutrients; inhibition of pathogen colonization","Lactic acid, hydrogen peroxide, bacteriocins (acidophilin, lactocidin, acidolin, lactolin, nisin, diplococcin), antimicrobial peptides",True,True,True,True,"Probiotics inhibit a broad range of pathogens including Salmonella, E. coli, Campylobacter, Clostridium, and Listeria. They reduce pathogen colonization through competitive exclusion and antimicrobial production. No evidence of excessive tissue damage or microbiome disruption; localized action in gut.",False,Not applicable,Not applicable,False,False,False,Not applicable,True,Stimulates immune system via enhancement of innate immunity; upregulates MUC2 gene expression; increases goblet cell number; enhances phagocytic activity; increases CD4+ and CD25+ T lymphocytes and NK cell activity; modulates toll-like receptor signaling,"MUC2 mucin, cytokines (e.g., IL-10, TNF-α), TLR ligands, NK cell activators",True,"Enhances intestinal barrier function by increasing mucus production (MUC2), stabilizing tight junctions (ZO-1, occludin), restoring cytoskeleton architecture, and promoting epithelial cell survival","MUC2 mucin, ZO-1, occludin, actin, cytoskeletal proteins",True,"Ferments carbohydrates and proteins to produce short-chain fatty acids (SCFAs: acetate, lactate, succinate), which are absorbed and used as energy sources; reduces toxic metabolites (ammonia, phenols, amines); enhances nutrient absorption and digestion","Acetate, lactate, succinate, SCFAs, ATP",False,Not applicable,Not applicable,GRAS,No engineered kill switches; relies on natural attenuation and elimination after supplementation stops,"None (natural strains, no auxotrophy or inducible systems)",Low pathogenicity; no virulence determinants; no plasmid-linked antibiotic resistance; low risk of horizontal gene transfer; non-opportunistic; safe for poultry and human consumption,Physical barrier provided by intestinal mucosa and host immune system; no engineered physical confinement,"All listed probiotic strains are considered safe for poultry and humans. They are non-pathogenic, lack virulence genes, and do not carry antibiotic resistance genes on plasmids. They are naturally eliminated from the gut after supplementation ends, minimizing environmental escape risk. No engineered biocontainment is used, but natural attenuation ensures safety.","Probiotics improve feed conversion, enhance growth performance, reduce colonization of enteric pathogens (e.g., Salmonella, E. coli), strengthen intestinal barrier function, increase mucus production, stimulate immune responses, and promote nutrient absorption. They are effective as prophylactic agents in poultry production systems without antibiotic use.",9355,2203,11558,,
d10ac173-e7ae-4737-89ae-d25a508cc5eb,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}]",Suspension,Facultative Anaerobe,"pH 3.20 ± 0.03, 4°C storage, 37°C culture in DMEM with 10% FBS, 5% CO2",Live bacteria maintained at 5.9 × 10⁷ to 6.3 × 10⁷ CFU/mL after 6–12 h incubation; increased to 5.2 × 10⁸ CFU/mL after 24 h in blueberry juice,"Gut lumen, intestinal mucosa","Modulates gut microbiota, improves intestinal barrier function, reduces endotoxemia",Stable at 4°C for 24 h; survives in acidic blueberry juice (pH 3.2); tolerance to lyophilization/rehydration not explicitly reported,Blueberry juice (pH 3.2) and refrigeration (4°C),该益生菌混合物在酸性蓝莓汁中具有良好的存活能力，可在4°C下稳定保存24小时，其活菌数在6–12小时内维持在5.9×10⁷至6.3×10⁷ CFU/mL，24小时后增至5.2×10⁸ CFU/mL，表明其在模拟肠道环境和储存条件下具有较强的生理适应性。,Not applicable (no genetic modification reported),Not applicable,Constitutive,Null,No plasmid or chromosomal integration reported; stability inferred from consistent CFU counts over 24 h,Stable in blueberry juice matrix; no structural disruption reported,该系统未进行基因工程改造，益生菌以天然菌株形式使用，通过其固有代谢功能发挥治疗作用，未涉及人工调控回路或基因编辑。,"[""pH"", ""Hypoxia""]","[""Free Fatty Acids (Oleic Acid:Palmitic Acid = 2:1)"", ""Lipopolysaccharide (LPS)""]","[""Quorum Sensing (indirect via microbiota modulation)""]","[""Cytokines (IL-22)"", ""Proteases (indirect via inflammation)""]",Not specified (natural sensing via membrane receptors and metabolic pathways),Not applicable (no synthetic logic circuits reported),该系统未构建人工感知逻辑，其功能依赖于益生菌对肠道微环境（如pH、脂肪酸、LPS）的自然响应，通过调节免疫和代谢通路实现治疗效果。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]",Not specified (likely via natural secretion or cell lysis),Dose-dependent effect observed: 10⁸ CFU/mL used in vivo; effects diminished when IL-22 was silenced,Compatible with blueberry juice matrix; no adverse effects on gel or suspension structure reported,False,,,Not applicable,Null,False,False,False,False,未涉及抗菌或抗生物膜功能。,False,Not applicable,Null,False,False,False,未涉及氧气生成或氧合功能。,True,益生菌通过调节肠道菌群，减少内毒素血症，激活IL-22信号通路，抑制炎症反应，促进抗炎因子表达。,Interleukin-22 (IL-22),True,通过激活JAK1/STAT3信号通路，抑制BAX介导的肝细胞凋亡，促进肝细胞存活与修复，减轻脂肪变性和炎症损伤。,JAK1/STAT3/BAX signaling pathway,True,蓝莓中的多酚类物质（如花青素）与益生菌协同作用，降低肝细胞内甘油三酯和胆固醇积累，改善脂质代谢紊乱。,"Anthocyanins (e.g., cyanidin-3-glucoside)",False,Not applicable,Null,GRAS,Auxotrophy (inferred from natural probiotic strains),Not specified,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer evidence; low risk of environmental escape due to gut-restricted colonization,Physical confinement via oral gavage and intestinal retention,该益生菌混合物为公认安全（GRAS）菌株，无致病性，不携带耐药基因，且在肠道内定植，不易逃逸至环境，具有良好的生物安全性。,在体外和体内模型中，蓝莓-益生菌联合治疗显著减少肝细胞脂滴积累，降低血清ALT、AST、TG、TC、LDL水平，提高HDL水平，改善肝组织病理学改变（HE和ORO染色），降低NAS评分。IL-22基因沉默后，上述治疗效果被显著削弱，表明其疗效依赖于IL-22介导的JAK1/STAT3/BAX信号通路。,11803,1776,13579,,
3cad76e3-e26c-4c7f-a1d2-c54c59c718bf,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG (ATCC 53103)""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates gastric acidity and bile salts; utilizes lactose, glucose, and other carbohydrates as carbon sources; requires vitamins and amino acids from host or diet.",Doubling time ~1.5–2 hours in vitro; growth rate consistent with in vivo colonization in gut; no significant growth inhibition observed in vivo.,"Gut mucosa, particularly in the small intestine and colon; preferentially colonizes the intestinal epithelium in infants with family history of allergy.",Competes with pathogenic bacteria; may promote symbiosis with commensal microbiota; no evidence of disruption of native microbiome.,"Tolerant to lyophilization, refrigeration, and moderate shear stress; stable during storage and transport; resistant to drying and UV exposure.","Cell wall components (e.g., teichoic acids), intracellular antioxidants (e.g., superoxide dismutase), and biofilm-like matrix formation.",该菌株为兼性厌氧菌，适宜在37°C、pH 6.5–7.0条件下生长，能耐受胃酸和胆盐，利用乳糖、葡萄糖等碳源，依赖宿主或饮食中的维生素和氨基酸。在体外生长速率稳定，Doubling time约1.5–2小时，体内定植能力良好，无显著生长抑制现象。,Plasmid-based expression systems (not explicitly described); no CRISPR or recombinase tools used.,Not applicable; no genetic modifications reported.,Constitutive expression of probiotic functions; no inducible circuits described.,,High chromosomal stability; no plasmid-based constructs reported; no evidence of gene loss or drift in long-term in vivo studies.,Stable in oral suspension and infant formula; no degradation observed during encapsulation or delivery.,该菌株未经过基因改造，其功能依赖于天然代谢通路。在母体孕期和婴儿出生后6个月内口服给药，通过自然定植发挥免疫调节作用，无外源基因插入或表达系统。,"[""pH"", ""Glucose"", ""Lactate""]","[""Bile Acids"", ""SCFAs"", ""Lactose""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases""]","FNR promoter (hypoxia), Lactose permease (glucose), Bile acid receptors (e.g., Bile acid-binding proteins), Quorum sensing receptors (e.g., LasR, LuxR homologs)",No complex logic gates reported; likely simple constitutive activation based on nutrient availability and host environment.,该菌株通过感知肠道环境中的pH、乳酸、葡萄糖、胆汁酸等信号，结合自身代谢需求，实现对定植和免疫调节功能的自然调控。未见人工设计的逻辑门控系统。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Type IV secretion system (putative); vesicle-mediated delivery of immunomodulatory molecules.,Dose-dependent effect; administered at fixed dose (perinatal supplementation); no feedback control reported.,Compatible with oral suspension and infant formula; stable during encapsulation and gastrointestinal transit.,False,,,Not applicable; no direct antibacterial activity reported.,,False,False,False,False,无相关证据,False,Not applicable; no oxygen-producing enzymes or mechanisms reported.,,False,False,False,无相关证据,True,"Modulates immune response by reducing IgE production, suppressing Th2 cytokines (IL-4, IL-13), increasing mucosal IgA, and promoting regulatory T cell activity.","Retinol (vitamin A), Calcium (Ca), Zinc (Zn), Lactobacillus GG surface proteins (e.g., p40, p75)",True,"Enhances intestinal barrier integrity, promotes epithelial regeneration, and supports mucosal healing via modulation of cytokine profiles and tight junction proteins.","Retinol, TGF-β, IL-10, Mucin-2",True,"Regulates host metabolism by influencing vitamin A, calcium, and zinc homeostasis; modulates arachidonic acid cascade and prostaglandin E2 production.","Retinol, Calcium, Zinc, Prostaglandin E2",False,Not applicable; no anti-tumor activity reported.,,GRAS,Auxotrophy (nutrient dependency); no suicide genes or kill switches reported.,"Vitamin A, Calcium, Zinc (essential nutrients required for survival)",Non-pathogenic; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape reported.,Oral delivery limits systemic spread; gut confinement reduces environmental release.,Lactobacillus GG为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，无水平基因转移风险。其在肠道内定植，通过营养依赖性实现生物安全控制，口服给药方式有效防止环境释放。,在出生至48个月的随访中，孕期和婴儿期补充Lactobacillus GG可显著降低特应性皮炎（AE）的发生风险（OR=0.31，P=0.013）。同时，增加维生素A、钙和锌的摄入可进一步降低AE风险。补充组儿童在48个月时身高和体重-身高比无显著差异，表明其生长发育正常，安全性良好。,17146,1850,18996,,
16a637d4-39f4-401e-9318-0dd19e35ec76,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""UFMG 905""}]",Oral gavage suspension,Facultative Anaerobe,"Grown in YPD broth (yeast extract 1%, peptone 2%, dextrose 2%) at 37°C for 24 h; optimal growth temperature 37°C, pH neutral; nutritional requirements include carbon (dextrose), nitrogen (peptone), and vitamins/minerals from yeast extract.",Growth rate not explicitly quantified; cultured for 24 h at 37°C with agitation (150 rpm); viable cells used for treatment.,"Gastrointestinal tract (colonization or survival in germ-free and conventional mice); intestinal mucosa, particularly ileum.","Competes with pathogenic bacteria (e.g., E. coli, Salmonella) for adhesion sites; may bind mannose residues on bacterial surfaces, reducing bacterial translocation.",Heat-killed form stable at 121°C for 15 min; viable cells survive in simulated intestinal environment; tolerance to gastric pH not explicitly tested but inferred from oral administration success.,"Heat-inactivation at 121°C for 15 min (for non-viable form); yeast cell wall components (e.g., mannoproteins) may confer structural stability.",该酵母菌株在37°C下于YPD培养基中生长良好，可定植或在无菌及常规小鼠肠道中存活。其生长依赖于碳源（葡萄糖）、氮源（蛋白胨）和维生素/矿物质（来自酵母提取物），为兼性厌氧菌，适应肠道环境。,,,,,,,该研究未对Saccharomyces cerevisiae UFMG 905进行基因工程改造，仅使用天然菌株进行口服治疗。,,,,,,,该研究未报道任何基因回路或传感模块，未涉及环境响应或逻辑控制机制。,"[""Immunomodulation"", ""Gut Barrier Integrity Preservation""]","Passive release of cell wall components and secreted factors (e.g., polyamines); no engineered secretion system reported.",Oral gavage of 10^9 CFU/mL for 10 days; dosage not dynamically controlled.,Oral suspension compatible with gastrointestinal delivery; no encapsulation or material matrix used.,False,False,False,无直接抗菌作用，但通过竞争性结合或免疫调节间接减少细菌粘附与转移。,,False,False,False,False,该酵母无直接抗菌活性，但通过抑制细菌粘附和减少细菌易位发挥保护作用。,False,未涉及氧气生成或代谢调节。,,False,False,False,未报道任何氧合机制或相关酶。,True,显著上调IL-10水平，增强抗炎反应；对IFN-γ无显著影响，提示免疫调节偏向抗炎。,IL-10,True,显著减轻肠道组织损伤，保护肠绒毛结构，减少黏膜侵蚀和水肿，维持上皮完整性。,Intestinal mucosal integrity (structural preservation),False,未报道代谢产物调节功能。,,False,未涉及肿瘤治疗机制。,,GRAS,"None (natural strain, no genetic modifications).",,"Non-pathogenic; no reported virulence, antibiotic resistance genes, or horizontal gene transfer risk. GRAS status implied.",None (oral administration without physical confinement).,该酵母菌株为非致病性，未进行基因改造，无生物安全风险。其作为益生菌已广泛用于动物模型，符合GRAS标准。,在小鼠肠梗阻模型中，无论活菌还是灭活菌，均显著降低细菌易位（BT）和肠道通透性，保护肠黏膜结构，减轻组织损伤。活菌可显著提升sIgA水平，而灭活菌在免疫调节（IL-10上调）和屏障保护方面同样有效。,11578,1485,13063,,
1ae78b62-6d9d-484a-bab2-4e2a35488b15,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacteroides spp."", ""strain_id"": ""Not specified""}]",Not specified,Strict Anaerobe,Anaerobic conditions; optimal pH and osmotic strength typical of intestinal environment; dependent on host-derived nutrients such as mucin and complex carbohydrates,"Long-term colonization possible after single administration; growth rate not explicitly stated, but high persistence suggests stable in vivo homeostasis","Intestinal tract, particularly colon; mucosal surface and lumen; vertical transmission from mother to offspring",Highly host-adapted; capable of stable colonization without competition from environmental strains; may outcompete less adapted species in the gut niche,Low tolerance to air exposure; rapidly loses viability upon aerobic exposure; moderate tolerance to bile and pH fluctuations due to intestinal adaptation,None (no specific stress resistance genes mentioned),"Bacteroides spp. are strict anaerobes with no adaptation to aerobic environments. They are vertically transmitted from mother to offspring and efficiently colonize the intestinal tract after a single dose. Their ecological strategy relies on host adaptation and high colonization capacity rather than environmental persistence. They thrive in the anaerobic, nutrient-rich gut environment and are not dependent on external environmental supply.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,"The paper does not describe any genetic engineering of Bacteroides spp. for probiotic use. The focus is on natural ecological traits rather than synthetic modifications. No synthetic circuits, inducible promoters, or genetic tools are mentioned.","[""Hypoxia"", ""pH""]","[""Mucin"", ""Complex Carbohydrates"", ""SCFAs""]","[""Quorum sensing (indirectly implied via colonization dynamics)""]","[""Proteases (e.g., from host mucus degradation)"", ""Cytokines (inflammatory signals during dysbiosis)""]",Not specified (no specific receptor or promoter identified),Not specified,The paper does not describe engineered sensing logic. Natural sensing is inferred from ecological adaptation: Bacteroides sense host-derived nutrients and anaerobic conditions to initiate colonization and metabolic activity. No synthetic logic gates or thresholds are described.,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]",Not specified,Single-dose administration sufficient for long-term colonization; no need for repeated dosing,Not specified,False,,,Not applicable,,False,False,False,False,Not applicable,False,Not applicable,,False,False,False,Not applicable,True,Modulates host immune response through interaction with gut epithelium and immune cells; may promote anti-inflammatory environment and tolerance,Not specified (likely via surface polysaccharides or secreted metabolites),True,Promotes epithelial barrier integrity and mucosal healing through production of short-chain fatty acids (SCFAs) and modulation of host cell signaling,"SCFAs (e.g., acetate, propionate, butyrate)",True,"Metabolizes complex dietary and host-derived carbohydrates (e.g., mucin) into SCFAs, which regulate host metabolism, energy homeostasis, and gut health",Short-chain fatty acids (SCFAs),False,Not applicable,,BSL-1,None (natural host-adapted strains; no engineered kill switches or auxotrophy described),Not specified,Low pathogenicity; no antibiotic resistance genes mentioned; vertical transmission suggests host-specificity; low risk of horizontal gene transfer due to host adaptation,Not specified,"Bacteroides spp. are core members of the human and animal gut microbiota, selected over millions of years for host compatibility. They are not opportunistic pathogens and do not require engineered containment. Their natural ecology ensures safety, and they are unlikely to cause harm even if introduced into a new host. No evidence of virulence or antibiotic resistance genes is reported.","Bacteroides spp. efficiently colonize the intestinal tract after a single dose, particularly in young animals or post-dysbiosis recovery. They contribute to metabolic regulation, immunomodulation, and tissue repair, supporting gut homeostasis and resilience. Their long-term persistence after one administration makes them highly effective for restoring gut microbiota balance without repeated dosing.",9593,1528,11121,,
14aa4a87-83df-4e04-aa51-bb378dc2a1d2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Staphylococcus epidermidis"", ""strain_id"": ""Coagulase-negative Staphylococci (CoNS) strains from healthy human skin""}]",Encapsulated (on skin surface),Facultative Anaerobe,"Optimal growth at 37°C, neutral to slightly alkaline pH (pH 7.0–7.5), moderate osmotic tolerance, utilizes glucose and amino acids as carbon sources","Moderate growth rate, doubling time ~2–3 hours in vitro; consistent colonization ability in vivo on human skin","Healthy human skin surface, particularly in non-atopic individuals",Competitive exclusion of pathogenic S. aureus; promotes immune homeostasis via anti-inflammatory signaling; symbiotic with epithelial barrier,"Tolerant to mild UV exposure, moderate shear stress, and desiccation; stable during lyophilization and rehydration",Cell wall teichoic acids and biofilm matrix components,该菌株为健康人体皮肤表面常见的凝固酶阴性葡萄球菌（CoNS），在正常皮肤微环境中具有良好的定植能力，可在37℃、中性至弱碱性pH条件下生长，利用葡萄糖和氨基酸作为碳源，具有中等生长速率，可在体外稳定维持，且对干燥、轻微紫外线和剪切力具有较强耐受性，适合在皮肤表面长期定植。,Not specified,,Constitutive,,High chromosomal stability; no plasmid-based systems reported; low metabolic burden; no evidence of drift in clinical settings,Stable in skin surface microenvironment without structural disruption,该系统未使用基因工程改造，天然存在的CoNS菌株通过其固有代谢和分泌功能发挥保护作用，无需外源调控元件，具有良好的体内稳定性。,"[""pH"", ""Osmotic stress""]","[""Glucose"", ""Amino acids""]","[""S. aureus presence (indirect via competition)""]","[""Th2 cytokines (IL-4, IL-13)"", ""Antimicrobial peptides (defensins)""]","FNR-like regulatory systems (inferred), quorum sensing receptors (e.g., Agr system homologs)",Threshold-based competition logic: suppresses S. aureus only when CoNS reaches sufficient density; no explicit AND/OR gates reported,该系统通过感知局部微生物密度和宿主免疫状态（如Th2细胞因子水平）进行响应，当CoNS菌群达到一定丰度时，启动对金黄色葡萄球菌的抑制机制，体现为密度依赖性竞争调控，具有天然的阈值响应能力，可有效避免过度激活。,"[""Antibacterial"", ""Immunomodulation""]",Type I secretion system (for AMPs),Density-dependent; self-regulated by population size and environmental cues,High compatibility with skin surface microenvironment; does not disrupt epithelial integrity or cause gel collapse,True,False,True,Produces antimicrobial peptides (AMPs) such as epidermin and lantibiotics that inhibit S. aureus survival and biofilm formation,"Epidermin, lantibiotics",False,True,True,True,在健康皮肤中，CoNS菌株可有效抑制金黄色葡萄球菌定植和生物膜形成，且不引起明显炎症反应，表明其活性可控且局部安全。,False,,,,,,,True,"Modulates immune responses by suppressing Th2-mediated inflammation, enhancing Treg cell activity, and reducing IL-4/IL-13 signaling","Anti-inflammatory cytokines (e.g., IL-10), Treg-inducing factors",False,,,False,,,False,,,BSL-1,Natural auxotrophy (no artificial kill switches),"Nutrient-dependent growth (e.g., specific amino acids)",Non-pathogenic; low opportunistic risk; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; minimal environmental escape potential,Skin epithelial barrier provides effective physical confinement,该菌株为健康人体皮肤正常菌群成员，无致病性记录，不携带抗生素抗性基因，不引起机会性感染，且依赖特定营养物质生长，具有天然生物安全屏障，适合用于皮肤微生态修复。,临床试验显示，应用有益CoNS菌株可显著减少特应性皮炎患者皮肤中金黄色葡萄球菌的定植，降低皮肤炎症水平，改善临床症状，提示其在调节皮肤微生态和缓解过敏性疾病方面具有显著疗效。,4301,1609,5910,,
bcc4f5fa-7b55-4dda-a567-89a6b2c2e649,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Megavirus chilensis"", ""strain_id"": ""Not specified""}]","Environmental (Seawater, filtered particulate matter)",Facultative Anaerobe,"Marine environment, temperature range not specified, pH neutral (oceanic), osmotic tolerance to seawater salinity, carbon source likely organic matter from host cell lysis",Not specified (viral replication cycle inferred from host infection dynamics),"Marine surface photic zone, associated with microalgae (e.g., Phaeocystis globosa, Chrysochromulina ericina) and microflagellate grazers","Parasitic on eukaryotic unicellular protists; potential for virophage co-infection (e.g., Sputnik-like virophages); no evidence of symbiosis or competition with bacterial microbiome","Tolerance to marine environmental stresses (UV, salinity, temperature fluctuations); stable in filtered seawater samples stored at -80°C","DNA repair proteins (e.g., MutS), capsid structure",该系统为海洋巨病毒，主要感染微藻和原生动物，其生长依赖于宿主细胞，通过裂解宿主释放子代病毒颗粒。在海洋环境中，其稳定性高，可在过滤后的颗粒物中长期保存，适应海水的盐度、pH和温度波动。,"PCR-based amplification, degenerate primers, pyrosequencing","Not applicable (natural viral genome, no genetic modification)",Constitutive (viral gene expression during infection cycle),Not applicable,High (viral genome stable in environmental samples; MutS8 clade conserved across isolates),Compatible with environmental DNA extraction and PCR amplification from filters,本研究未对病毒进行基因工程改造，而是基于MutS8基因开发特异性PCR引物，用于检测和系统发育分析海洋中的巨病毒。通过设计混合反向引物和简并正向引物，实现对多种巨病毒的扩增，具有良好的特异性和稳定性。,"[""Hypoxia"", ""pH"", ""ROS""]","[""Lactate"", ""Glucose"", ""Bile acids""]","[""AHL"", ""AI-2""]","[""Protease"", ""Cytokine"", ""Tissue degradation fragments""]","MutS protein (domain V, ABC ATPase motif)",Not applicable (no synthetic circuit; natural viral infection cycle driven by host cell entry and replication),该系统无人工逻辑控制模块，其感染行为由宿主细胞的生理状态和病毒基因组的自然表达程序驱动。MutS蛋白作为DNA错配修复酶，可能在病毒基因组复制过程中感知复制错误，但未见明确的信号感应与逻辑处理机制。,"[""Antibacterial"", ""Tissue Repair"", ""Metabolic Regulation""]",Lysis (host cell rupture),Not controllable (natural infection cycle),Compatible with environmental DNA extraction and PCR amplification from 0.2 μm filters,True,True,False,通过裂解宿主细胞（如微藻）释放子代病毒颗粒，实现对宿主种群的清除，具有广谱抗原生生物活性。,Viral capsid and lytic enzymes,True,False,False,False,该病毒通过裂解微藻宿主实现清除，对多种微藻具有感染能力，但未评估其对非目标生物或生物膜的影响，且无可控性设计。,False,无氧生成机制。,Not applicable,False,False,False,该系统不涉及氧气生成或代谢调节功能。,False,未检测到免疫调节因子分泌。,Not applicable,False,无组织修复因子分泌。,Not applicable,False,未检测到代谢物调节功能。,Not applicable,False,无肿瘤治疗相关机制。,Not applicable,BSL-1,Natural attenuation in marine environment; no engineered kill switches,Not applicable,Low pathogenicity to humans; opportunistic pathogen of Acanthamoeba; no known antibiotic resistance genes; horizontal gene transfer potential via transduction; environmental escape likely but limited by host specificity,Physical confinement via filtration (0.2 μm) and storage at -80°C,该系统为天然海洋巨病毒，对人类无致病性，主要感染微藻和原生动物，不具有广泛传播能力。其基因组稳定，无抗生素抗性基因，但可通过转导介导基因水平转移。在实验中通过过滤和低温保存实现物理隔离，风险较低。,该研究未评估治疗效果，而是开发了基于MutS8基因的分子诊断工具，用于检测和分析海洋中巨病毒的多样性与分布。在缅因州海岸水样中成功扩增出550 bp的MutS8片段，揭示了多个新发现的病毒类群，表明该标记在揭示巨病毒生态分布方面具有潜力。,10074,1687,11761,,
3436c9f6-218e-42cd-a200-a88c5fc7348b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""NCC2705, MG1, UCC2003""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerant to bile acids and low pH; utilizes various carbohydrates including lactose, fructose, and raffinose; dependent on host-derived nutrients in vivo",Doubling time ~2–3 hours in vitro; in vivo colonization stable over time with sustained presence in intestinal and tumor niches,"Gastrointestinal tract (especially colon), hypoxic tumor core after systemic translocation",Symbiotic with host microbiota; competes with pathogens like Gram-negative bacteria; no significant disruption of native microbiome reported,Moderate tolerance to osmotic stress and bile; limited UV and drying resistance; lyophilization stability reported for some strains,"Bile acids, raffinose, osmotic agents","Bifidobacterium longum is a facultative anaerobe that thrives in the human gut and can translocate from the gastrointestinal tract to solid tumors. It grows optimally at 37°C and pH 6.5–7.0, utilizing various carbohydrates. It exhibits tolerance to bile and low pH, enabling survival in the intestinal environment. Its ability to colonize hypoxic tumor regions after oral administration makes it a promising chassis for targeted delivery. It maintains stability in vivo and shows minimal disruption to the host microbiome.","Electroporation, CRISPR-Cas (implied), plasmid-based transformation, suicide vectors, in vitro methylation of plasmids",Low to moderate; transformation efficiencies typically 10²–10⁴ CFU/μg DNA; improved to ~10⁷ CFU/μg in B. breve UCC2003 via methylation of plasmids in E. coli expressing B. breve methyltransferases,"Constitutive (P_hup, P_gap, P_amy, P_16S), inducible (P_raf, bile-inducible, arabinose-inducible P_BAD), logic gates not reported","Raffinose, bile acids, arabinose, iron (inferred from microarray study)","Plasmid stability varies; pTB6, pMB1, pMG1, pBC1 replicons show stable maintenance; chromosomal integration possible but inefficient; metabolic burden observed; long-term in vivo consistency not fully established",Stable in gel-like matrices and encapsulated delivery systems; no evidence of degradation or loss of function in material environment,"Genetic engineering of Bifidobacterium longum relies on electroporation and shuttle vectors derived from native plasmids (e.g., pTB6, pMB1, pMG1, pBC1). Promoters such as P_hup and P_gap are used for constitutive expression, while bile- and raffinose-inducible systems allow controlled expression. Methylation of plasmids in E. coli expressing host-specific methyltransferases significantly improves transformation efficiency. Despite progress, transformation remains inefficient in most strains, limiting targeted mutagenesis. Non-antibiotic selection markers (e.g., levansucrase) are being explored to overcome safety and regulatory concerns.","[""Hypoxia"", ""pH"", ""Osmotic Stress"", ""Glucose"", ""Raffinose""]","[""Bile Acids"", ""Raffinose"", ""Iron""]",,"[""Proteases"", ""Cytokines""]","P_raf (α-galactosidase promoter), bile-inducible promoter (P_bile), P_BAD (araC-P_BAD system), P_16S rRNA promoter",AND gate implied: bile + raffinose induction; threshold-based repression by glucose; no reported noise suppression or dynamic range tuning,"Bifidobacterium longum can sense environmental cues such as bile acids and raffinose via specific promoters (e.g., bile-inducible and P_raf). The P_raf promoter is induced by raffinose and repressed by glucose, enabling a form of metabolic logic. The arabinose-inducible P_BAD system allows external control, though its use is limited to strains capable of arabinose metabolism. These systems provide basic on/off control, but advanced logic circuits (e.g., AND/OR gates) have not been implemented. Sensing is coupled with material permeability through diffusion of small molecules like bile and sugars.","[""Tumor Therapy"", ""Immunomodulation"", ""Metabolic Regulation""]","Type I secretion (Sec pathway), lysis, surface display (limited)","Controlled by promoter strength and inducible systems (e.g., bile, raffinose); dosage not precisely tunable in vivo",Compatible with encapsulation in hydrogels and oral delivery matrices; secretion via Sec pathway allows release into surrounding environment,False,False,False,Not applicable; no direct antibacterial activity reported,,False,False,False,False,无直接抗菌或抗生物膜功能,False,Not applicable; no oxygen-producing enzymes reported,,False,False,False,无氧生成机制,True,"Expression of human interleukin 10 (IL-10), TNF-related apoptosis-inducing ligand (TRAIL), and endostatin modulates immune responses, promoting anti-inflammatory and anti-tumor immunity","Human interleukin 10 (IL-10), TRAIL, endostatin",False,Not applicable; no direct tissue repair factors reported,,True,"Production of SCFAs (e.g., acetate, lactate) and modulation of host metabolism via secreted enzymes (e.g., cholesterol oxidase) influence host metabolic homeostasis","Acetate, lactate, cholesterol oxidase",True,"Selective colonization of solid tumors; delivery of prodrug-converting enzymes (e.g., cytosine deaminase), tumor antigens, and therapeutic proteins (e.g., endostatin, TRAIL) for localized cancer therapy","Cytosine deaminase, endostatin, TRAIL, tumor antigens",GRAS,"Auxotrophy (implied), suicide vectors (used in mutagenesis), non-antibiotic selection markers (levansucrase, glucosamine synthase)","Levansucrase, glucosamine synthase, suicide vectors",Non-pathogenic; no known virulence factors; low risk of horizontal gene transfer; antibiotic resistance genes avoided via non-antibiotic markers; no environmental escape reported,Physical confinement via encapsulation prevents systemic spread; oral delivery limits exposure,"Bifidobacterium longum is classified as GRAS and has a long history of safe use in infant formulas and probiotics. It lacks lipopolysaccharides and does not cause disease. Genetic modifications use non-antibiotic selection markers to avoid resistance gene transfer. Encapsulation provides physical containment. No evidence of pathogenicity or environmental escape. Overall, biosafety risk is very low.","B. longum UCC2003 successfully colonized tumors after oral administration, achieving levels comparable to intravenous delivery. Recombinant strains expressing IL-10, TRAIL, and endostatin showed anti-tumor effects in animal models. Oral delivery of engineered strains enabled systemic targeting without severe side effects. However, protein expression levels remain low, limiting therapeutic potency. Further optimization of promoters and copy number is needed to enhance efficacy.",14018,2234,16252,,
a3d149b4-9eee-4069-a5ad-a86bebf07755,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""DB104, WB700, DB403, 168""}]",Encapsulated,Facultative Anaerobe,"Temperature: 25–37°C; pH: 6.0–8.0; Nutritional requirements: Complex medium with carbon sources (e.g., glucose, peptone), nitrogen, minerals; Osmotic tolerance: Moderate; Bile tolerance: Not specified",Doubling time: ~20–30 min in rich medium; In vitro growth well-characterized; In vivo stability not reported,"Gut lumen, mucosal surfaces (probiotic niche); Not specified for therapeutic delivery",Probiotic interaction; No significant competition or pathogenicity reported; Compatible with host microbiota,"High resistance to heat (up to 80°C), UV, drying, organic solvents, extreme pH; Stable during storage and rehydration","Spore coat proteins (e.g., CotG, CotA), cortex, exosporium","Bacillus subtilis is a Gram-positive, facultative anaerobic bacterium with a robust sporulation capability. It grows rapidly in rich media, forms highly stable endospores under nutrient stress, and exhibits excellent resistance to environmental stresses. Its spores are non-pathogenic, GRAS-status, and suitable for oral delivery. The spore structure provides intrinsic stability and protection for immobilized enzymes.","CRISPR-Cas9 (implied via plasmid-based engineering), Recombination (homologous double-crossover), Plasmid transformation (pHS, pDHAFB, pCotG-LacZ)","High efficiency in spore coat protein fusion; Successful expression in multiple strains (DB104, WB700, DB403); Low off-target risk due to targeted integration",Constitutive (CotG promoter-driven expression); No inducible systems reported,None (constitutive expression under CotG promoter),High chromosomal integration stability; Plasmid pHS is high-copy number but stable in sporulation; No significant drift reported; Long-term in vivo consistency not assessed,High stability within spore matrix; Enzyme remains functional after encapsulation and re-use,"Genetic engineering involves fusing target enzymes (e.g., β-galactosidase, chitinase, nitrilase) to spore coat proteins like CotG via recombinant plasmids. The CotG promoter drives constitutive expression during sporulation, resulting in in situ enzyme display on the spore surface. This method ensures high retention and stability of the enzyme without leakage.","[""Hypoxia"", ""pH"", ""Temperature""]","[""Glucose"", ""Lactose""]",,,"CotG promoter (responsive to sporulation signals), Spore coat proteins (CotG, CotB, CotC)",Constitutive expression; No complex logic gates reported; Thresholds not defined; No noise suppression mechanisms described,"The system relies on constitutive expression of the enzyme during sporulation, driven by the CotG promoter. No environmental sensing or dynamic regulation is involved. The enzyme is displayed on the spore surface as a result of developmental programming, not external stimuli.","[""Enzyme Stabilization"", ""Therapeutic Delivery""]",In situ surface display during sporulation; No lysis or secretion systems used,Controlled by spore concentration and enzyme expression level; No dynamic feedback or tunable output,High compatibility with spore matrix; Enzymes remain stable and active within the spore coat; No structural disruption observed,False,,,Not applicable,,,,,,Not applicable,False,Not applicable,,,,,Not applicable,False,Not applicable,,False,Not applicable,,False,Not applicable,,False,Not applicable,,GRAS,Auxotrophy (implied by sporulation requirement); No kill-switch reported,Spore formation (nutrient starvation-induced),Low pathogenicity; No antibiotic resistance genes reported; No horizontal gene transfer risk in non-pathogenic strains; Environmental escape unlikely due to poor survival outside host,Spore coat and exosporium provide physical confinement; Resistant to gastric degradation,Bacillus subtilis spores are widely recognized as safe (GRAS) and non-pathogenic. They are used in probiotics and food applications. The system does not involve pathogenic strains or antibiotic resistance genes. Spore formation acts as a natural containment mechanism. The physical barrier of the spore coat protects the enzyme and limits unintended release.,"Spore-immobilized enzymes show enhanced thermal and pH stability, reusability (up to 10 cycles), and resistance to organic solvents. For example, spore-displayed β-galactosidase retained >45% activity after 2 hours at 40°C, while free enzyme was inactivated. Nitrilase retained >60% activity at 85°C for 60 min. These properties enable efficient enzyme delivery and sustained catalytic activity in harsh environments, making them ideal for therapeutic and industrial applications.",14656,1737,16393,,
a7572538-2378-473e-940e-43d3fcf50eff,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""Bb1""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""St10""}]",Encapsulated,Facultative Anaerobe,"Growth at 37–39°C, pH 6.10, in reconstituted skim milk with yeast extract and glucose (Bb1); in 10% reconstituted skim milk with sodium glycerophosphate (St10)",Not explicitly reported; cultures incubated for 16–24 h prior to drying,Human intestine (implied by probiotic use),Typical probiotic strains; no direct interaction data reported,Moderate tolerance to drying stress; survival decreases with increasing air temperature during drying,None explicitly identified,"Bifidobacterium infantis and Streptococcus thermophilus are probiotic bacteria commonly used in dairy products. They grow under controlled conditions (37–39°C, pH 6.10) in milk-based media. Their viability is significantly reduced during drying, especially at high air temperatures (≥90°C), indicating sensitivity to thermal and dehydration stress.",,,,,,,"No genetic engineering was performed. The study focused on the inactivation kinetics of naturally occurring probiotic strains during drying, without any synthetic genetic circuits or modifications.","[""Temperature"", ""Water content""]",,,,None explicitly identified,None,"No sensing or logic modules were engineered. The study analyzed natural responses of bacteria to drying-induced stress (temperature and water content changes), not engineered signal processing.","[""None""]",None,None,Encapsulated in milk droplets; survival depends on drying conditions,False,,,Not applicable,,,,,,Not applicable,False,Not applicable,,,,,Not applicable,False,Not applicable,,False,Not applicable,,False,Not applicable,,False,Not applicable,,GRAS,None,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned,Physical confinement via milk droplet encapsulation,"Bifidobacterium infantis and Streptococcus thermophilus are generally recognized as safe (GRAS) probiotics. No genetic modifications were made, and no biocontainment strategies were employed. The primary risk is loss of viability during drying, not biological hazard.","The study did not evaluate therapeutic or healing outcomes. It focused on inactivation kinetics during drying, showing that survival of both strains decreases significantly with increasing air temperature, with near-complete inactivation at 110°C after 180 seconds.",9695,1226,10921,,
484b61e4-d6d4-4b0e-b5ef-58bda4682130,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""IMV B-7280""}]",Suspension,Facultative Anaerobe,"37°C, aerobic and anaerobic conditions, MRS agar medium, growth in vitro",Doubling time not specified; growth observed within 24–48 h in vitro,Gut mucosa (intestinal lumen),"Competitive exclusion of pathogenic Gram-positive cocci (staphylococci, streptococci), suppression of fungi; promotes beneficial Lactobacillus and Bifidobacterium spp.",Lyophilized form stable; viability confirmed post-thaw; tolerance to gastric conditions not explicitly stated,Cell wall components (implied by survival in gut environment),该菌株为乳杆菌属，可在37°C下在MRS培养基上生长，属于兼性厌氧菌，能定植于小鼠肠道，具有良好的耐受性，可在体外稳定保存。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未对L. casei IMV B-7280进行基因改造，其功能基于天然代谢特性，未使用任何遗传工具进行工程化设计。,"[""pH"", ""Bile acids""]","[""Cholesterol"", ""Bile acid conjugates""]",,,Bile salt hydrolase (BSH) enzyme (inferred from cholesterol-lowering mechanism),Not specified,该菌株通过感知胆汁酸和胆固醇水平，激活其代谢通路，实现对胆固醇的降解与结合，但未描述明确的逻辑门控机制。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]",Not specified,Oral administration at 1×10⁶ cells per animal daily for 7 days,Suspension in PBS; compatible with oral delivery,False,False,False,Not applicable,Not applicable,False,False,False,False,未涉及抗菌或抗生物膜功能。,False,Not applicable,Not applicable,False,False,False,未涉及氧气生成功能。,True,调节免疫反应，诱导多种细胞因子，改善肠道免疫稳态，减少炎症反应。,Cytokines (inferred from immune-modulatory properties),True,恢复肥胖小鼠肝脏组织结构，减轻肝细胞脂肪变性和坏死，促进肝组织修复。,Hepatocyte regeneration factors (inferred from histological recovery),True,通过胆盐水解酶（BSH）降解胆汁酸，直接结合胆固醇，调节胆固醇代谢，降低血清总胆固醇和游离胆固醇水平。,"Bile salt hydrolase (BSH), Cholesterol",False,Not applicable,Not applicable,GRAS,Not applicable,Not applicable,No pathogenicity reported; no antibiotic resistance genes mentioned; low risk of horizontal gene transfer; no environmental escape reported,Oral delivery with natural gut colonization; no physical barrier used,L. casei IMV B-7280为公认安全（GRAS）菌株，无致病性，无耐药基因，无基因水平转移风险，适合用于代谢疾病干预。,L. casei IMV B-7280显著降低肥胖小鼠体重、血清胆固醇水平，改善肝脏形态，恢复肝组织结构，促进肠道有益菌群（Lactobacillus和Bifidobacterium）增殖，抑制有害菌和真菌，具有显著的代谢调节和组织修复作用。,18663,2908,21571,,
484b61e4-d6d4-4b0e-b5ef-58bda4682130,1,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis"", ""strain_id"": ""VKB""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis"", ""strain_id"": ""VKL""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""IMV B-7280""}]",Suspension,Facultative Anaerobe,"37°C, anaerobic conditions for Bifidobacterium, aerobic for Lactobacillus; MRS and bifidum agar media",Growth observed within 24–48 h in vitro; no doubling time reported,Gut mucosa (intestinal lumen),"Synergistic colonization; enhances Lactobacillus and Bifidobacterium populations; suppresses staphylococci, streptococci, and fungi",Lyophilized form stable; viability confirmed post-thaw; tolerance to gastrointestinal transit not explicitly stated,Cell wall components (implied by gut survival),该混合菌群由B. animalis VKB、B. animalis VKL和L. casei IMV B-7280组成，均为兼性厌氧菌，可在37°C下在相应培养基上生长，具有良好的肠道定植能力，能协同调节肠道微生态。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该菌群未经过基因改造，其功能基于天然菌株的协同作用，未使用任何遗传工具。,"[""pH"", ""Bile acids""]","[""Cholesterol"", ""Bile acid conjugates""]",,,Bile salt hydrolase (BSH) enzyme (inferred from cholesterol-lowering mechanism),Not specified,混合菌群通过感知胆汁酸和胆固醇水平，协同激活代谢通路，实现胆固醇的降解与结合，但未描述明确的逻辑门控机制。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]",Not specified,Oral administration at 1×10⁶ cells per animal daily for 7 days,Suspension in PBS; compatible with oral delivery,False,False,False,Not applicable,Not applicable,False,False,False,False,未涉及抗菌或抗生物膜功能。,False,Not applicable,Not applicable,False,False,False,未涉及氧气生成功能。,True,通过调节免疫反应，诱导细胞因子，改善肠道免疫稳态，减少炎症反应。,Cytokines (inferred from immune-modulatory properties),True,有效恢复肥胖小鼠肝脏组织结构，显著减轻肝细胞脂肪变性和坏死，促进肝组织修复。,Hepatocyte regeneration factors (inferred from histological recovery),True,通过胆盐水解酶（BSH）降解胆汁酸，直接结合胆固醇，调节胆固醇代谢，显著降低血清总胆固醇和游离胆固醇水平。,"Bile salt hydrolase (BSH), Cholesterol",False,Not applicable,Not applicable,GRAS,Not applicable,Not applicable,无致病性报告；无抗生素耐药基因；低水平基因转移风险；无环境逃逸报告,口服给药，自然肠道定植；无物理屏障,该混合菌群由公认安全（GRAS）菌株组成，无致病性，无耐药基因，无基因水平转移风险，适合用于代谢疾病干预。,B. animalis VKL/B. animalis VKB/L. casei IMV B-7280混合菌群显著降低肥胖小鼠体重、血清胆固醇水平，有效恢复肝脏组织结构，减轻肝细胞脂肪变性和坏死，促进肠道有益菌群（Lactobacillus和Bifidobacterium）增殖，抑制有害菌和真菌，具有显著的代谢调节和组织修复作用。,18663,2908,21571,,
848228ec-5907-424f-b622-84caef98ffaa,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium"", ""strain_id"": ""Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium breve""}]",Oral gavage (systemic delivery to gut),Facultative Anaerobe,Anaerobic environment; grows in gut lumen; requires complex nutrients including carbohydrates and amino acids,Not explicitly quantified; established colonization after oral gavage with 1×10⁹ cfu/mouse; persistence in gut microbiota post-administration,"Intestinal lumen, particularly mucosal surface of colon; associated with gut immune homeostasis",Competes with pathogenic bacteria; restores dysbiotic microbiota after vancomycin treatment; may modulate host immune response via cross-talk with immune cells,Lyophilized form stable; survives gastric transit and intestinal environment; tolerance to bile and low pH not explicitly stated but implied by probiotic use,Lyophilization (freeze-drying) for storage stability,Bifidobacterium 是一种革兰氏阳性、专性厌氧的益生菌，主要定植于肠道黏膜表面，通过调节宿主免疫系统来缓解免疫病理损伤。其在口服给药后可有效定植并维持一定水平，尤其在抗生素诱导的菌群失调后表现出显著的恢复能力。,,,,,,,该研究未对Bifidobacterium进行基因改造，其功能依赖于天然菌株的生理特性，通过口服给药实现定植与免疫调节作用，无外源基因插入或合成回路设计。,"[""Hypoxia"", ""pH""]","[""Short-chain fatty acids (SCFAs)"", ""Bile acids""]",,"[""Cytokines (e.g., IL-6, KC, CSF3)"", ""Tissue degradation fragments""]","Not specified; likely endogenous receptors for SCFAs (e.g., GPR41/GPR43) and bile acid sensors",No synthetic logic gates; natural sensing of metabolic and inflammatory signals with threshold-dependent immune modulation,Bifidobacterium通过感知肠道微环境中的短链脂肪酸（SCFAs）和胆汁酸等代谢物，以及宿主释放的炎症因子（如IL-6、KC、CSF3），激活免疫调节通路。其响应具有阈值特性，仅在免疫失衡状态下发挥调节作用，避免过度激活。,"[""Immunomodulation""]","Passive secretion of metabolites (e.g., SCFAs); no engineered secretion system",Oral gavage at 300 μL containing 1×10⁹ cfu/mouse; dosage not dynamically controlled,Compatible with oral delivery; survives gastrointestinal transit; no encapsulation material used,False,,,,,,,,,,False,,,,,,,True,"Bifidobacterium ameliorates intestinal immunopathology by enhancing regulatory T cell (Treg) function, particularly in the context of CTLA-4 blockade. It does not increase Treg cell numbers but enhances their metabolic fitness and suppressive capacity.",Regulatory T cells (Treg) - functional enhancement via metabolic reprogramming,False,,,False,,,False,,,GRAS,None (natural probiotic strain; no synthetic kill switches or auxotrophy),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe for human use in clinical settings,None (oral delivery without physical barrier),Bifidobacterium 属于公认安全（GRAS）菌株，广泛用于益生菌制剂，无致病性、无耐药基因，且在动物实验中未观察到系统性感染或生态位入侵，安全性高。,在抗CTLA-4抗体联合DSS诱导的结肠炎模型中，Bifidobacterium治疗显著减轻体重下降（从75%恢复至95%初始体重），降低组织病理评分，减少炎症细胞浸润和血清炎症因子（KC、IL-6、CSF3）水平。更重要的是，该治疗不影响抗肿瘤免疫应答，B16F10黑色素瘤生长速率与对照组无显著差异，表明其可有效缓解免疫病理损伤而不削弱抗肿瘤疗效。,9685,1590,11275,,
5a0c1ce6-f9d9-4731-af38-c1143c81cd4a,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates moderate osmotic stress; requires fermentable carbohydrates and amino acids for growth",Doubling time ~1–2 hours in vitro; in vivo colonization observed in gut mucosa with stable persistence over weeks,"Intestinal mucosa, particularly colon and ileum; preferentially colonizes mucus layer and epithelial surfaces",Competitive exclusion of pathogenic bacteria; synergistic interaction with host immune system; supports SCFA-producing commensals,Moderate tolerance to gastric acid and bile; stable during lyophilization and rehydration; resistant to shear stress in suspension,"Cell wall components (e.g., peptidoglycan), exopolysaccharides (EPS), and intracellular antioxidants","Lactobacillus and Bifidobacterium strains are facultative anaerobes that thrive in the human gut environment, utilizing dietary fibers and host-derived glycans. They exhibit robust growth under physiological conditions and maintain stability in the intestinal mucosa, contributing to gut barrier integrity and immune modulation.","Plasmid-based expression systems (e.g., pSMB1), CRISPR-Cas9 for gene knockouts",High efficiency (>90%) in Lactobacillus; low off-target risk due to minimal genome plasticity,"Constitutive expression of beneficial enzymes; inducible promoters (e.g., lactose-inducible) used in experimental models","Lactose, xylose, or IPTG (in engineered strains)",High plasmid stability (copy number 1–5); chromosomal integration used for long-term expression; minimal metabolic burden; stable in vivo over 4–6 weeks,"Genetic circuits remain functional in encapsulated formulations (e.g., alginate beads) and fermented dairy matrices","Genetic modifications include deletion of urease and tryptophanase genes to reduce uremic toxin production, and insertion of genes for SCFA biosynthesis (e.g., butyrate kinase). These strains are engineered to enhance colonization and metabolic activity in the CKD gut environment.","[""pH"", ""Glucose"", ""Lactate""]","[""Urea"", ""Indoxyl sulfate (IS)"", ""p-Cresyl sulfate (PCS)""]","[""AHL"", ""AI-2""]","[""Proteases (e.g., MMP-9)"", ""Cytokines (e.g., IL-6, TNF-α)""]","FNR promoter (hypoxia), Lactose permease (glucose), Tryptophanase promoter (tryptophan/IS), Quorum-sensing receptors (LasR, LuxR)",AND gate: requires both low pH and high lactate for activation; threshold-based response to urea; noise suppression via feedback inhibition,"The microbial consortium senses multiple environmental cues: low pH and high lactate indicate inflamed or dysbiotic gut; urea and IS levels signal CKD progression. An AND gate ensures activation only when multiple disease markers are present, minimizing off-target activity. Feedback loops regulate enzyme expression to prevent overproduction and maintain homeostasis.","[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Type IV secretion system (T4SS), vesicles (outer membrane vesicles), lysis",Tunable via inducible promoters; output strength modulated by nutrient availability and host signals,"Compatible with alginate, chitosan, and fermented dairy matrices; permeability allows SCFA and cytokine diffusion",True,True,True,"Production of bacteriocins (e.g., lactocin, bifidocin) and organic acids (lactic, acetic) that inhibit pathogenic bacteria and disrupt biofilm matrix","Bacteriocins (lactocin, bifidocin), lactic acid, acetic acid",True,True,True,True,"In vitro studies show inhibition of S. aureus, P. aeruginosa, and E. coli; no significant cytotoxicity to human intestinal cells; no disruption of gel matrix in encapsulated formulations",False,Not applicable,Not applicable,False,False,False,No oxygen-producing mechanism reported; not applicable,True,"Secretion of IL-10 and TGF-β; downregulation of NF-κB and MAPK pathways; inhibition of pro-inflammatory cytokines (TNF-α, IL-6)","Interleukin-10 (IL-10), Transforming growth factor-beta (TGF-β)",True,"Stimulation of epithelial cell proliferation and migration; enhancement of tight junction proteins (occludin, claudin-1); promotion of collagen synthesis and angiogenesis","Epidermal growth factor (EGF), Vascular endothelial growth factor (VEGF), Tissue inhibitor of metalloproteinases (TIMP-1)",True,"Production of short-chain fatty acids (SCFAs: acetate, propionate, butyrate); reduction of uremic toxins (IS, PCS) via metabolic degradation; modulation of tryptophan and phenylalanine metabolism","Butyrate, Propionate, Acetate, Indole-3-acetic acid (IAA)",False,Not applicable,Not applicable,GRAS,"Auxotrophy (e.g., leucine auxotrophy), kill-switch (caspase-3 inducible under high urea)","Leucine, IPTG",Low pathogenicity; no known antibiotic resistance genes; no evidence of horizontal gene transfer; low environmental escape risk due to auxotrophy,Physical confinement in encapsulated beads or dairy matrix prevents systemic dissemination,The microbial consortium is composed of GRAS strains with well-documented safety profiles. Genetic modifications include auxotrophy and kill-switches to prevent persistence in non-target environments. No evidence of virulence or antibiotic resistance. Physical encapsulation ensures localized delivery and containment.,"Clinical trials show significant reduction in plasma IS (28%), PCS (14%), and inflammatory markers (IL-6, TNF-α). In experimental models, improved gut barrier function, reduced fibrosis, and delayed GFR decline. In CKD patients, enhanced nutritional status and reduced oxidative stress. Long-term use associated with improved quality of life and reduced hospitalization for sepsis.",15917,2064,17981,,
4a5e5716-b1fa-45ff-b6c0-b143b1eecc1e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LA-5""}]",Suspension,Facultative Anaerobe,"Microaerophilic conditions (5% CO2, 37°C) in MRS broth; grows in early stationary phase at OD495 = 2.0 × 10^8 CFU/mL",Growth rate not explicitly quantified; cultivated to early stationary phase for experiments,"Subgingival biofilm environment (oral mucosa, gingival epithelium)",Competes with Porphyromonas gingivalis for adhesion sites; may alter local microbiome balance,"Tolerant to host glycan-rich, low-oxygen subgingival environment; stability in vitro under standard culture conditions",None specified,"L. acidophilus LA-5 is a facultative anaerobe that grows under microaerophilic conditions and can survive in the oxygen-poor, glycan-rich subgingival niche. It maintains viability during co-infection with P. gingivalis and exhibits enhanced adhesion in the presence of the pathogen.",None specified,Not applicable (no genetic modification reported),Constitutive (no inducible systems reported),None,Not applicable (no plasmid or chromosomal integration reported),Not applicable (no material encapsulation described),"No genetic engineering was performed. The strain functions naturally through its intrinsic properties such as adhesion, immune modulation, and competition with pathogens.","[""Hypoxia"", ""pH (indirect via metabolic acid production)""]","[""Host glycan-rich environment"", ""Bile acids (indirect, oral cavity)""]","[""Quorum sensing (indirect via pathogen presence)""]","[""Proteases (P. gingivalis gingipains may alter host surface receptors)"", ""Cytokines (TNF-α, IL-1β, CXCL8)""]","Surface layer (S-layer) proteins, peptidoglycan, lipoteichoic acid","No synthetic logic gates; natural sensing via receptor-ligand interactions (e.g., TLR2/4 modulation)","L. acidophilus LA-5 senses the host microenvironment through surface molecules like S-layer proteins and peptidoglycan, which interact with host pattern recognition receptors (TLRs). It responds to pathogen presence by modulating TLR4 expression and cytokine production, indicating a natural feedback loop in immune regulation.","[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]",None (no secretion system reported; effects mediated via surface molecules and metabolites),Not applicable (no controlled release or dosing system described),Not applicable (no material encapsulation or delivery system used),True,False,False,Reduces adhesion and invasion of P. gingivalis by competing for epithelial receptors and potentially altering pathogen fitness via metabolic byproducts.,None (direct antibacterial activity not reported; effect is indirect via competition and immune modulation),False,True,True,True,"L. acidophilus LA-5 significantly reduced P. gingivalis adhesion and invasion in co-culture with OBA-9 cells, without causing cytotoxicity. It also enhanced host cell viability and did not disrupt the epithelial barrier.",False,Not applicable,None,False,False,False,No evidence of oxygenation function.,True,"Downregulates TLR4 expression and reduces synthesis of pro-inflammatory cytokines (TNF-α, IL-1β) while increasing CXCL8 secretion, promoting neutrophil recruitment and resolving inflammation.","S-layer-associated proteins, peptidoglycan, lipoteichoic acid",True,"Promotes epithelial cell viability and proliferation; enhances CXCL8 secretion, which supports cell migration and tissue regeneration.","CXCL8 (chemokine), S-layer proteins",False,Not applicable,None,False,Not applicable,None,BSL-1,"None (natural strain, no synthetic kill switches or auxotrophy reported)",None,Low pathogenicity; GRAS status; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape.,None (no physical barrier used),"L. acidophilus LA-5 is a well-characterized, non-pathogenic, GRAS (Generally Recognized As Safe) strain with low risk of adverse effects. It does not possess known virulence factors or antibiotic resistance genes. No synthetic containment systems were used.","L. acidophilus LA-5 co-infection with P. gingivalis significantly prevented loss of OBA-9 cell viability, reduced pathogen adhesion and invasion, downregulated TLR4 expression, decreased TNF-α and IL-1β levels, and increased CXCL8 secretion. These effects indicate strong immunomodulatory and protective activity in the context of periodontal epithelial defense, suggesting potential for therapeutic use in periodontitis.",15469,1678,17147,,
a37c72a3-6b82-4d0e-8acc-487a6fb32da1,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""BC1031""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""DSMZ 32550""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""BR101""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LA1063""}]",Suspension,Facultative Anaerobe,"Anaerobic conditions (MRS broth, anaerobic jar with gas pack), 37°C, pH ~6.5–7.0, with L-cysteine and mineral oil for liquid cultures",Growth rate not explicitly quantified; doubling time not reported; in vitro growth confirmed under anaerobic conditions,"Human intestinal epithelium (Caco-2 cell model), gut mucosal surface",Competitive exclusion of VRE; potential synergistic interactions among strains; no direct evidence of symbiosis with host microbiota,"Stable under lyophilization (used in commercial products); tolerance to storage and rehydration not explicitly tested; no data on UV, shear, or osmotic stress",,该四菌株混合物在厌氧条件下于MRS培养基中生长良好，适用于模拟人类肠道环境。Bacillus coagulans 和 Lactobacillus 属菌株均具有良好的体外生长能力，可在肠道模拟环境中抑制VRE的增殖。,,,,,,,本研究未对菌株进行基因工程改造，所有功能均依赖于天然代谢与生理特性，未使用CRISPR、质粒或诱导系统。,"[""Hypoxia"", ""pH""]","[""Lactate"", ""Glucose""]","[""Quorum sensing (FsrABC-like system)""]","[""Proteases"", ""Tissue degradation fragments""]",FsrABC quorum-sensing system (homologous to Staphylococcus aureus AgrABC),Coordinated downregulation of multiple virulence genes; potential AND-like logic via quorum-sensing inhibition,四菌株混合物通过抑制VRE的FsrABC群体感应系统，协同下调多种黏附相关基因的表达，表现出对宿主环境信号的响应与逻辑调控能力。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I/II secretion (bacteriocins), pilus-mediated competition, extracellular vesicles (inferred)",Dose-dependent inhibition observed; efficacy increases with combination ratio,Compatible with suspension in DMEM/MRS; no encapsulation reported,True,False,False,通过竞争性抑制、直接黏附竞争和群体感应干扰，降低VRE在肠道上皮细胞的定植能力。,"Bacteriocins, fengycins (from Bacillus coagulans), pilus-mediated competition (LGG)",False,True,True,True,该混合物显著减少VRE在体外共培养中的数量，并抑制其在Caco-2细胞上的黏附，且未观察到对宿主细胞的显著毒性。,False,,,False,False,False,,True,Lactobacillus酸化环境，诱导宿主产生抗菌肽LL-37，增强肠道屏障功能。,Human LL-37 (antimicrobial peptide),True,通过减少病原体黏附和炎症反应，间接促进肠道上皮修复。,"Mucus layer stabilization, epithelial barrier enhancement",True,Lactobacillus产生短链脂肪酸（SCFAs），调节肠道微生态平衡，抑制病原体生长。,Short-chain fatty acids (SCFAs),False,,,GRAS,"None (natural strains, no synthetic kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; no environmental escape risk in controlled setting,None (no physical confinement used in study),四株菌均为公认安全（GRAS）菌株，未进行基因改造，无致病性或耐药基因风险，适合用于人体肠道定植干预。,该四菌株混合物在体外显著抑制VRE的增殖，减少其在Caco-2细胞上的黏附，并下调9个黏附相关基因的表达，表明其具有良好的肠道定植抑制与黏膜修复潜力，已进入临床试验阶段（NCT03822819）。,14968,1654,16622,,
8edf293c-e637-4f21-a057-b3298ec4bf35,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lacticaseibacillus casei"", ""strain_id"": ""AMBR2""}]",Encapsulated,Facultative Anaerobe,"Temperature: 34°C (nasopharynx), pH: 6.3–7.0; Nutritional requirements: general LAB growth media; Tolerance to moderate oxygen levels and ROS",Doubling time not specified; Temporal colonization observed in healthy volunteers after nasal administration,Nasopharynx and anterior nares; adheres to human respiratory epithelium,"Competes with pathobionts such as S. aureus, H. influenzae, M. catarrhalis; potential for niche exclusion","Tolerates mucociliary clearance; stable during nasal spray delivery; no data on UV, drying, or lyophilization",Haeme- and manganese-dependent catalase (gene identified),该菌株为鼻咽部健康个体中分离的Lacticaseibacillus casei AMBR2，具有良好的黏附能力，可在鼻腔内短暂定植。其生长环境为34°C、pH 6.3–7.0，对氧气和活性氧具有耐受性，能适应上呼吸道的生理条件。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,未提及基因工程改造，但该菌株通过表达secA2/secY2基因簇编码的菌毛实现对上呼吸道上皮的强黏附，是其适应性关键因素。,"[""Oxygen"", ""pH"", ""Reactive Oxygen Species (ROS)""]","[""Lactate"", ""Glucose""]","[""Quorum sensing (indirectly implied via competition)""]","[""Proteases"", ""Cytokines (inferred from immunomodulation)""]","Haeme- and manganese-dependent catalase (for ROS sensing), secA2/secY2 gene cluster (for adhesion regulation)",Not specified,未明确描述逻辑门控机制，但其黏附和抗氧化能力可视为对环境信号的响应，实现定植与生存的动态调控。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Not specified,Not specified,Nasal spray formulation allows encapsulation and delivery; compatible with mucosal application,True,True,False,通过竞争性排斥抑制S. aureus、H. influenzae和M. catarrhalis的黏附与生长,Bacteriocins or competitive exclusion (not specified),True,True,True,True,在体外实验中，L. casei AMBR2可显著抑制S. aureus、H. influenzae和M. catarrhalis的黏附，且在健康志愿者中安全定植，无明显毒性。,False,未提及产氧机制,Not specified,False,False,False,未提及氧合功能，因此不满足氧合标准。,True,通过与宿主模式识别受体（PRRs）相互作用，调节免疫反应，减轻炎症,Microbial-associated molecular patterns (MAMPs),True,恢复慢性鼻窦炎患者气道上皮屏障功能，增强紧密连接蛋白表达,Bacterial lysate or secreted factors (not specified),False,未提及代谢调节功能,Not specified,False,未提及肿瘤治疗功能,Not specified,BSL-1,Not specified,Not specified,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; GRAS status implied by long-term use in food,Nasal spray provides physical confinement; transient colonization limits environmental escape,Lacticaseibacillus casei AMBR2来源于健康鼻咽部，具有良好的安全性记录。其为传统乳酸菌，长期用于食品，无致病性报道，且在健康志愿者中仅短暂定植，风险较低。,在健康志愿者中，L. casei AMBR2可通过鼻喷雾实现短暂定植，恢复气道上皮屏障功能，抑制病原体黏附，具有潜在的治疗慢性鼻窦炎和过敏性鼻炎的前景。临床研究正在推进中。,11380,4128,15508,,
8edf293c-e637-4f21-a057-b3298ec4bf35,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Dolosigranulum pigrum"", ""strain_id"": ""Not specified""}]",Encapsulated,Facultative Anaerobe,Temperature: ~34°C; pH: 6.3–7.0; High abundance in healthy URT (up to 50%); Nutritional requirements not specified,Not specified; high relative abundance in healthy individuals suggests robust growth,Anterior nares and nasopharynx; dominant in healthy URT,Competes with pathobionts; associated with lower incidence of URT infections and bronchiolitis,Not specified,Not specified,Dolosigranulum pigrum在健康上呼吸道中丰度高，可达50%，是健康标志菌群。其在健康个体中占主导地位，与减少上呼吸道感染和支气管炎相关，表明其具有良好的环境适应能力。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,未提及基因工程改造，但其在健康人群中高丰度和稳定性表明其具有天然适应性。,"[""Oxygen"", ""pH"", ""Reactive Oxygen Species (ROS)""]","[""Lactate"", ""Glucose""]","[""Quorum sensing (inferred)""]","[""Proteases"", ""Cytokines (inferred)""]",Not specified,Not specified,未明确描述传感逻辑，但其在健康状态下高丰度且在疾病中减少，表明其对环境信号具有响应能力。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Not specified,Not specified,Nasal spray formulation suitable for encapsulation and mucosal delivery,True,True,False,对S. aureus具有抗菌作用，可能通过竞争或分泌抑制物质实现,Unknown (possibly bacteriocins or metabolic inhibition),True,True,True,True,在健康个体中丰度高，疾病中减少；对S. aureus有抑制作用，且无致病性报道，表明其具有可控且安全的抗菌活性。,False,未提及产氧机制,Not specified,False,False,False,未提及氧合功能，因此不满足氧合标准。,True,通过调节宿主免疫反应，减轻炎症，维持黏膜稳态,Microbial-associated molecular patterns (MAMPs),True,与健康状态相关，可能通过增强屏障功能和免疫调节促进组织修复,Secreted metabolites or surface components (not specified),False,未提及代谢调节功能,Not specified,False,未提及肿瘤治疗功能,Not specified,BSL-1,Not specified,Not specified,Low pathogenicity; no antibiotic resistance genes reported; GRAS status implied by natural presence in healthy humans,Nasal spray provides physical confinement; transient colonization limits escape,Dolosigranulum pigrum是健康上呼吸道的常见菌群，与低感染率相关，无致病性报道，安全性高，适合作为下一代鼻腔益生菌。,Dolosigranulum pigrum在健康个体中丰度高，疾病中显著减少，提示其在维持上呼吸道健康和预防感染中具有重要作用。其作为鼻腔益生菌具有巨大潜力，但尚需临床验证。,11380,4128,15508,,
8edf293c-e637-4f21-a057-b3298ec4bf35,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""W136""}]",Encapsulated,Facultative Anaerobe,Temperature: ~34°C; pH: 6.3–7.0; Nutritional requirements: standard LAB media; detected in healthy URT,Not specified; well-tolerated in clinical use,Nasopharynx and nasal cavity; detected in healthy individuals,Competes with pathogens; potential for niche exclusion,Tolerates nasal irrigation; stable in formulation,Not specified,Lactococcus lactis W136来源于健康人群鼻腔，可在鼻腔内定植，耐受鼻腔冲洗，具有良好的耐受性和安全性。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,未提及基因工程改造，但其在临床试验中表现出良好的耐受性和定植能力。,"[""Oxygen"", ""pH"", ""Reactive Oxygen Species (ROS)""]","[""Lactate"", ""Glucose""]","[""Quorum sensing (inferred)""]","[""Proteases"", ""Cytokines (inferred)""]",Not specified,Not specified,未明确描述传感逻辑，但其在健康人群中存在且在临床试验中安全使用，表明其对环境信号具有适应性。,"[""Immunomodulation"", ""Tissue Repair""]",Not specified,Not specified,Intranasal irrigation formulation compatible with mucosal delivery,False,False,False,未明确抗菌机制,Not specified,False,False,False,False,未报告抗菌活性，但临床试验中未观察到不良反应。,False,未提及产氧机制,Not specified,False,False,False,未提及氧合功能，因此不满足氧合标准。,True,通过调节免疫反应，减轻炎症，改善症状,Microbial-associated molecular patterns (MAMPs),True,改善鼻腔黏膜屏障功能，缓解炎症，促进组织修复,Secreted factors or lysate (not specified),False,未提及代谢调节功能,Not specified,False,未提及肿瘤治疗功能,Not specified,BSL-1,Not specified,Not specified,Low pathogenicity; no antibiotic resistance genes reported; GRAS status implied by food use,Intranasal irrigation provides physical confinement; transient exposure limits escape,Lactococcus lactis W136在健康人群中存在，用于鼻腔冲洗，耐受性良好，无严重不良反应，安全性高。,在慢性鼻窦炎患者中，L. lactis W136鼻腔冲洗治疗2周后，SNOT-22评分显著下降，症状和生活质量明显改善，表明其在缓解上呼吸道炎症方面具有临床潜力。,11380,4128,15508,,
cda841d9-2787-463f-85fe-3f65e1f517d4,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus curvatus"", ""strain_id"": ""HY7601""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""KY1032""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; utilizes fructose, glucose, and various organic acids as carbon sources; requires vitamins and amino acids for growth.","Doubling time ~1.5–2 hours in vitro; in vivo stability not explicitly reported, but sustained colonization observed in gut over 3-week treatment.","Gut lumen, particularly colon and small intestine; preferentially colonizes mucosal surfaces in high-fructose environment.",Modulates gut microbiota composition; may compete with pathogenic bacteria; no evidence of symbiosis with host microbiome.,"Tolerant to gastric acid (pH 2.0–3.0), bile salts (0.3% bile), and freeze-drying; stable during lyophilization and rehydration.",Lactose (used as stabilizer in freeze-dried formulation),该双菌株为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，利用果糖、葡萄糖等碳源，需维生素和氨基酸。在体外培养中倍增时间为1.5–2小时，口服后可在肠道内稳定定植，耐受胃酸和胆盐，冻干后仍保持活性。,"Not applicable (natural strains, no genetic modification reported)",N/A,Constitutive,N/A,High chromosomal stability; no plasmids reported; no evidence of genetic drift or loss in vivo.,Stable in freeze-dried formulation with lactose; no degradation during storage.,该系统未经过基因工程改造，为天然分离的益生菌株，通过其固有代谢功能发挥治疗作用，无外源基因插入或调控元件。,"[""Fructose"", ""pH""]","[""Glucose"", ""Triglycerides"", ""Cholesterol""]",,,"Fructose transporter (FruA), glucose permease (PtsG), and pH-responsive regulators (e.g., PhoP/PhoR in L. plantarum)",Constitutive expression; no reported logic gates or threshold control; activity driven by substrate availability.,菌株通过感知肠道内果糖、葡萄糖等代谢物浓度变化，启动其代谢调控功能，无复杂逻辑门控机制，表现为持续性响应。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (e.g., SCFAs, exopolysaccharides); passive diffusion of metabolites",Dose-dependent effect: high dose (10¹⁰ cfu/d) more effective than low dose (10⁹ cfu/d); no external control mechanism.,Compatible with freeze-dried formulation; stable in lactose matrix; suitable for oral delivery.,False,False,False,N/A,N/A,False,False,False,False,未报告抗菌或抗生物膜活性。,False,N/A,N/A,False,False,False,未报告产氧功能。,True,Reduces systemic inflammation and oxidative stress; downregulates pro-inflammatory cytokines and enhances antioxidant enzyme activity.,"Lactobacillus-derived metabolites (e.g., SCFAs, exopolysaccharides)",True,Improves hepatic lipid metabolism and reduces liver steatosis; promotes β-oxidation and suppresses lipogenesis.,"PPARα, CPT2, CYP7A1 (host gene upregulation via microbial signaling)",True,"Modulates hepatic lipid metabolism by upregulating β-oxidation genes (PPARα, CPT2) and downregulating lipogenesis genes (SREBP1, FAS, SCD1).","Short-chain fatty acids (SCFAs), bile acids",False,N/A,N/A,GRAS,"None (natural strains, no kill-switch or auxotrophy reported)",N/A,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape.,Physical barrier provided by freeze-dried capsule; limited survival in non-gut environments.,该双菌株为公认安全（GRAS）菌株，来源于韩国泡菜，无致病性、无耐药基因，未进行基因改造，无生物安全风险，口服后在肠道定植，不易在环境或宿主外长期存活。,高剂量（10¹⁰ cfu/d）益生菌显著降低高果糖饮食诱导大鼠的血浆葡萄糖、胰岛素、甘油三酯和氧化应激水平，改善胰岛素抵抗（HOMA-IR下降34%），并显著减少肝重和肝胆固醇含量（下降27%）。高剂量处理还显著上调肝脏β-氧化相关基因（PPARα、CPT2）表达，下调脂质合成相关基因（SREBP1、FAS、SCD1）表达，表明其在调节代谢综合征核心特征方面具有显著疗效。,11400,1766,13166,,
32b0b04b-bc2c-450e-b207-bdf4156ecd5d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""ATCC PTA 6475""}]",Oral gavage (systemic distribution via gut lumen),Anaerobic,"Optimal growth at 37°C, pH 6.5–7.0, requires complex nutrients including carbohydrates and amino acids; dependent on host-derived metabolites in gut environment",Not explicitly quantified; assumed moderate growth rate typical of Lactobacillus spp. in vivo (colonization established within 24–48 h post-administration),"Gut lumen, particularly intestinal mucosa and lamina propria; preferentially colonizes mucosal surfaces in the colon",Competes with pathogenic bacteria; modulates gut microbiota composition by reducing ILC3-promoting microbes; enhances beneficial microbial balance,"Tolerant to gastric acidity (due to lactic acid production), bile salts, and osmotic stress; stable during oral administration and transit through GI tract","Lactic acid, hydrogen peroxide, and cell wall components (e.g., teichoic acids) contribute to acid and oxidative stress resistance","Lactobacillus reuteri is a Gram-positive, rod-shaped, anaerobic bacterium that naturally resides in the gastrointestinal tract. It thrives in the gut environment by utilizing host-derived nutrients and maintaining a stable colonization in the intestinal mucosa. It exhibits strong tolerance to gastric and intestinal stresses, enabling effective delivery and persistence after oral administration.","Not applicable (natural strain, no genetic modification reported)",N/A,Constitutive (natural expression of immunomodulatory factors),N/A,High chromosomal stability; no plasmids or foreign DNA introduced; natural strain maintains identity in vivo,Stable in physiological gut environment; no material-based genetic instability observed,"L. reuteri used in this study is a naturally occurring probiotic strain (ATCC PTA 6475) without any genetic engineering. Its immunomodulatory effects are attributed to native metabolic and signaling pathways, including production of tryptophan metabolites and modulation of host immune cells.","[""pH (acidic environment of stomach)"", ""Bile acids (intestinal environment)""]","[""Tryptophan (precursor for AhR ligands)"", ""SCFAs (indirectly via microbiome modulation)""]","[""Quorum sensing molecules (inferred from community dynamics)""]","[""Cytokines (IL-23, IL-17, IFN-γ)"", ""Tissue damage fragments (from DSS-induced epithelial injury)""]",Aryl hydrocarbon receptor (AhR) ligands derived from tryptophan catabolism; potential involvement of surface receptors for bile acids and cytokines,Constitutive activity with feedback modulation via host immune signals; no synthetic logic gates; natural sensing of microbial and host-derived cues to regulate immune output,"L. reuteri senses the gut microenvironment through intrinsic receptors for bile acids and pH, and detects host immune signals such as IL-23 and IL-17. It responds by producing immunomodulatory metabolites (e.g., tryptophan derivatives) that activate AhR in host cells, leading to suppression of ILC3 activation. This represents a natural feedback loop where microbial presence modulates immune cell behavior in response to inflammation.","[""Immunomodulation""]",Secretion of tryptophan metabolites via passive diffusion and membrane transport; no specialized secretion systems reported,Oral gavage at fixed dose (1×10⁹ CFU/mouse); dosage is not dynamically controlled but effective at standard administration,Compatible with oral delivery; stable in gastrointestinal environment; no material encapsulation used,False,False,False,Not applicable (no direct antibacterial activity reported in this study),N/A,False,False,False,False,No evidence of antibacterial or biofilm inhibition activity in this study.,False,Not applicable (no oxygen-producing mechanism reported),N/A,False,False,False,No evidence of oxygenation function or related enzymatic activity.,True,"L. reuteri suppresses group 3 innate lymphoid cells (ILC3s) by producing tryptophan metabolites that act as ligands for the aryl hydrocarbon receptor (AhR), leading to reduced IL-23 and IL-17 production and decreased intestinal inflammation.",Tryptophan catabolites (AhR ligands),False,Not directly involved in tissue repair; indirect benefit via reduced inflammation and ILC3 suppression.,N/A,False,"No direct evidence of metabolic regulation (e.g., SCFA, neurotransmitter production) reported.",N/A,False,No direct tumor-killing or prodrug conversion activity reported.,N/A,GRAS,None (natural probiotic strain with no engineered kill switches),N/A,"Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; non-invasive, non-colonizing beyond gut; no environmental escape risk",None (no physical confinement used; relies on natural gut barrier),"L. reuteri ATCC PTA 6475 is a well-characterized, GRAS (Generally Recognized As Safe) probiotic strain. It is non-pathogenic, non-invasive, and does not persist long-term in the gut. No genetic modifications or antibiotic resistance markers were introduced, minimizing biosafety risks. Its natural attenuation and limited colonization reduce the risk of unintended ecological impact.","Oral administration of L. reuteri (1×10⁹ CFU/mouse) completely abrogated ICB-associated colitis in mice, as evidenced by normalized body weight, improved survival (from 20% to 100%), reduced histological damage, decreased serum levels of pro-inflammatory cytokines (TNF-α, IL-6, IFN-γ, KC), and significant reduction in intestinal ILC3 infiltration. Importantly, this protective effect was achieved without compromising the antitumor efficacy of ICB immunotherapy against B16 melanoma.",15390,1912,17302,,
f61a4eba-45a1-4f23-a8b8-e2d4596e6c45,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""Not specified""}]",Encapsulated in alginate hydrogel,Facultative Anaerobe,"Optimal growth at 37°C, pH 7.0–7.5; requires carbon sources (e.g., glucose), amino acids, vitamins; compatible with Ca²⁺-mediated gelation",Growth rate not explicitly stated; viable for up to nine days post-printing in alginate gel,Not applicable (in vitro engineered system),Not applicable,Moderate tolerance to shear stress during extrusion; sensitive to high temperatures (>65°C),Alginate hydrogel provides mechanical protection,大肠杆菌（Escherichia coli）为兼性厌氧菌，最适生长温度为37°C，pH 7.0–7.5，可在含碳源、氨基酸和维生素的培养基中生长。在海藻酸钠水凝胶中可维持活性长达九天，适用于3D打印环境。,"Chemical induction (rhamnose, IPTG), plasmid-based expression",High efficiency in protein expression upon induction; no off-target risk mentioned,"Inducible (rhamnose, IPTG, AHL); spatially controlled via multi-ink printing","Rhamnose, IPTG, Acylated homoserine lactone (AHL)","Plasmid-based expression; stability not explicitly quantified, but functional for at least nine days in gel",Stable within alginate and Flink hydrogels; no significant degradation observed,通过化学诱导剂（如鼠李糖、IPTG、AHL）调控基因表达，实现空间分层的多功能蛋白表达。利用质粒系统在大肠杆菌中实现CsgA和TasA等蛋白的可控表达，支持3D打印生物膜和逻辑门功能。,"[""pH"", ""Osmotic stress""]","[""Rhamnose"", ""IPTG"", ""AHL""]","[""Acylated homoserine lactone (AHL)""]",,"Rhamnose promoter, IPTG promoter, AHL receptor (LuxR-type)",AND gate logic demonstrated in multi-ink wearable sensors; response to multiple inducers simultaneously,通过多通道打印实现对多种化学信号（鼠李糖、IPTG、AHL）的响应，构建了可编程的逻辑门系统。在柔性可穿戴传感器中，当检测到任一信号时，可触发绿色荧光输出，实现多输入-单输出的逻辑控制。,"[""Antibacterial"", ""Protein Secretion"", ""Biosensing""]",Secretion via outer membrane vesicles and periplasmic release,Controlled by inducer concentration and spatial patterning,"High compatibility with alginate, agarose, Flink, and Pluronic F127-DA hydrogels",False,False,False,Not applicable,,False,False,False,False,未涉及抗菌功能,False,Not applicable,,False,False,False,未涉及氧生成功能,False,Not applicable,,False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,Physical confinement in hydrogel matrix; no kill-switch or auxotrophy reported,"Hydrogel matrix (alginate, agarose, Flink)",Low pathogenicity; no antibiotic resistance genes mentioned; minimal risk of horizontal gene transfer in controlled environment,Effective physical barrier via hydrogel encapsulation; prevents cell escape,大肠杆菌为公认安全（GRAS）菌株，无致病性，且通过水凝胶物理封装有效防止细胞泄漏，生物安全风险较低。,未直接评估伤口愈合效果，但3D打印的工程菌可在水凝胶中长期存活并表达目标蛋白，具备用于生物材料制造和可穿戴传感器的潜力。,7953,4270,12223,,
f61a4eba-45a1-4f23-a8b8-e2d4596e6c45,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""Not specified""}]",Encapsulated in agarose hydrogel as spores,Facultative Anaerobe,Spores stable at high temperatures (up to 65°C); germinate upon nutrient and oxygen availability; pH 6.0–8.0,Spores remain dormant during printing; germination occurs post-printing; no doubling time reported,Hypoxic wound environment (model wound patch),Competitive with S. aureus; produces antibiotics to inhibit pathogen,"High tolerance to heat, drying, UV, and desiccation; stable during long-term storage","Spore coat proteins, agarose matrix",枯草芽孢杆菌（Bacillus subtilis）为兼性厌氧菌，其孢子可耐受高达65°C的高温，可在干燥、紫外线和极端环境中长期存活。在3D打印后，孢子在营养和氧气存在下可萌发，用于响应病原体并释放抗生素。,"Spore-based expression system; inducible promoters (e.g., for antibiotic production)",High efficiency in spore germination and gene expression post-activation; no off-target risk reported,Inducible (quorum sensing of S. aureus); self-activated upon pathogen detection,"Staphylococcus aureus quorum sensing molecules (e.g., AIP)",High stability due to spore dormancy; chromosomal integration likely; minimal metabolic burden,Stable in agarose hydrogel; spores remain viable after rehydration,利用枯草芽孢杆菌孢子的高稳定性，将其封装于高温熔融的琼脂糖水凝胶中进行3D打印。孢子在打印后可萌发，并通过感知金黄色葡萄球菌的群体感应信号，启动抗生素（如lysostaphin和thiocillin）的表达，实现靶向抗菌功能。,"[""Oxygen"", ""Nutrient availability""]","[""AIP (Autoinducing Peptide)""]","[""AIP (from S. aureus)""]",,"AIP receptor (e.g., ComP/ComA system)",AND gate: requires both germination (oxygen/nutrients) AND pathogen signal (AIP) to activate antibiotic production,枯草芽孢杆菌孢子在萌发后，需同时感知氧气和金黄色葡萄球菌的AIP信号，才能启动抗生素合成基因表达，形成双重安全逻辑门，避免误激活。,"[""Antibacterial"", ""Biosensing"", ""Self-Healing""]",Lysis of vegetative cells; secretion via Sec pathway,Controlled by pathogen signal and germination rate,High compatibility with agarose hydrogel; stable during printing and rehydration,True,False,False,"Spores germinate in wound model, sense S. aureus via AIP, and produce lysostaphin and thiocillin to selectively kill S. aureus","Lysostaphin, Thiocillin",False,True,True,True,选择性杀灭金黄色葡萄球菌，不伤害自身菌株；在3D打印结构中保持活性，无结构破坏；无明显细胞毒性，局部作用明确。,False,Not applicable,,False,False,False,未涉及氧生成功能,False,Not applicable,,False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,Physical confinement in agarose hydrogel; spore dormancy acts as natural containment,"Agarose hydrogel, spore coat",Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape due to dormancy,Highly effective physical barrier via agarose matrix and spore dormancy,枯草芽孢杆菌为GRAS菌株，孢子形态赋予其极强的环境耐受性，且在水凝胶中被物理封闭，无逃逸风险，生物安全等级为BSL-1。,在模拟伤口模型中，3D打印的枯草芽孢杆菌孢子可成功萌发并响应金黄色葡萄球菌信号，选择性释放抗生素，有效抑制病原体，具备潜在的伤口感染防控能力。,7953,4270,12223,,
f61a4eba-45a1-4f23-a8b8-e2d4596e6c45,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Acetobacter xylinum"", ""strain_id"": ""Not specified""}]",Encapsulated in Flink bio-ink,Aerobic,"Requires high oxygen tension; grows at 30°C, pH 5.0–6.0; produces bacterial cellulose at air–water interface",Growth rate not specified; cellulose production sustained over time,Air–water interface (simulated skin graft surface),Not applicable,Moderate tolerance to shear stress; sensitive to high temperatures,Flink hydrogel matrix,醋酸杆菌（Acetobacter xylinum）为好氧菌，最适生长温度为30°C，pH 5.0–6.0，可在空气-水界面持续合成细菌纤维素，适用于3D打印个性化皮肤移植物。,Wildtype strain used; no genetic modification reported,Not applicable,Constitutive (natural cellulose production),None,High stability due to wildtype nature; no plasmid loss risk,Stable in Flink hydrogel; supports long-term cellulose production,利用野生型醋酸杆菌在Flink水凝胶中3D打印细菌纤维素，模拟个性化皮肤移植物。无需基因改造，依赖其天然的纤维素合成能力。,"[""Oxygen"", ""pH""]",,,,"Oxygen sensor (e.g., cytochrome oxidase), pH-sensitive regulators",Constitutive expression; no complex logic,野生型醋酸杆菌在氧气和适宜pH条件下持续表达纤维素合成酶，无外部调控，属于基础型表达系统。,"[""Tissue Repair"", ""Biomaterial Production""]",Extracellular secretion of cellulose via membrane transporters,Controlled by oxygen availability and growth duration,Excellent compatibility with Flink hydrogel; supports high-fidelity printing and structural integrity,False,False,False,Not applicable,,False,False,False,False,未涉及抗菌功能,False,Not applicable,,False,False,False,未涉及氧生成功能,False,Not applicable,,True,"Produces bacterial cellulose, a biocompatible, high-tensile-strength material suitable for wound healing and tissue engineering",Bacterial cellulose,False,Not applicable,,False,Not applicable,,BSL-1,Physical confinement in Flink hydrogel; no genetic modification,Flink hydrogel,Non-pathogenic; no antibiotic resistance genes; low risk of environmental escape,Effective physical barrier via hydrogel encapsulation,醋酸杆菌为公认安全菌株，无基因改造，通过Flink水凝胶物理封装，无逃逸风险，生物安全等级为BSL-1。,成功在3D打印的娃娃面部模型上生成细菌纤维素，模拟个性化皮肤移植物，具备高水保留率、高抗拉强度和生物相容性，适用于伤口愈合和组织工程。,7953,4270,12223,,
6170f38e-e881-4ca3-a240-e1892ef9803a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Acid-tolerant, grows in milk, meat, fruits, vegetables, cereal grains; optimal growth at 30–37°C, pH 5.0–6.5; requires fermentable carbohydrates",Doubling time ~60–90 min in vitro; viability maintained under gastrointestinal transit conditions,"Intestinal tract, vaginal and oral mucosal surfaces of humans and animals",Competitive exclusion of pathogens; symbiotic with host microbiota; may modulate immune responses,"Resistant to bile acids, low pH (gastric), osmotic stress; moderate tolerance to drying and shear stress","Cell wall components (e.g., S-layer proteins), acid tolerance systems (e.g., F1F0-ATPase)",Lactobacillus 是革兰氏阳性、耐酸、兼性厌氧的发酵型细菌，属于厚壁菌门。它们广泛存在于食品相关环境（如牛奶、肉类、水果、蔬菜、谷物）中，常作为发酵食品的启动菌。自然定植于人和动物的肠道、阴道和口腔黏膜表面，具有良好的胃肠道存活能力，能耐受低pH和胆汁环境，是重要的益生菌候选菌属。,"PCR, 16S/23S-5S rRNA sequencing, qPCR, MLST, WGS",Not applicable (no genetic engineering described),Not applicable (no synthetic circuits described),,Not applicable (no engineered plasmids or integration described),Not applicable,该文未描述对Lactobacillus进行基因工程改造，仅聚焦于其分类鉴定方法。,"[""Acidity (pH)"", ""Hypoxia (indirectly via fermentation)""]","[""Lactate"", ""Glucose"", ""Bile acids""]","[""Quorum sensing (AHL, AI-2)""]","[""Proteases (e.g., MMPs)"", ""Cytokines""]","FNR promoter (hypoxia), F1F0-ATPase (acid tolerance), S-layer proteins (surface recognition)",Not applicable (no synthetic logic circuits described),文中未描述人工设计的信号感知与逻辑处理系统，仅提及天然生理响应机制。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Antibacterial""]",Type I/II secretion systems (inferred from Gram-positive cell wall structure),"Not applicable (natural secretion, no controllable output described)","Compatible with food matrices (yogurt, fermented vegetables); stable in encapsulated forms",True,False,False,通过产生有机酸（如乳酸）降低局部pH，抑制病原菌生长；部分菌株产生细菌素（bacteriocins）直接杀伤病原体。,"Lactic acid, Bacteriocins",False,True,True,True,通过降低pH和产生细菌素抑制病原菌，如沙门氏菌和大肠杆菌，且在肠道中局部作用，不显著破坏正常菌群。,False,,,False,False,False,未提及氧气生成能力。,True,通过细胞壁成分（如肽聚糖、脂磷壁酸）和DNA序列（如TTTCGTTT）激活免疫细胞，调节免疫应答，增强黏膜屏障功能。,"Peptidoglycan, Lipoteichoic acid, Genomic DNA (TTTCGTTT motif)",False,,,True,调节宿主代谢功能，如降低胆固醇、改善乳糖耐受性、调节肠道菌群代谢活动。,"Short-chain fatty acids (SCFAs), Lactate",False,,,GRAS,None (natural probiotic strains used),,"Non-pathogenic, no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape concerns",Physical confinement not required; natural colonization limited to mucosal surfaces,Lactobacillus 属菌株被广泛认为是安全的（GRAS），无致病性，不携带抗生素抗性基因，且在自然环境中定植能力有限，不会造成生态风险。,在临床试验中，含有足够活菌数的强化酸奶可有效改善肠道健康，缩短轮状病毒性腹泻、抗生素相关性腹泻及克罗恩病的病程。部分菌株（如L. rhamnosus GG、L. casei Shirota）已被证实可降低腹泻持续时间与发作频率，增强免疫功能，改善过敏症状。,14513,1623,16136,,
ec25bdd3-9e1a-4176-a049-d321a02c9273,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, requires complex nutrients including amino acids and vitamins; dependent on host-derived metabolites in gut environment",Doubling time ~1.5–2 hours in vitro; in vivo homeostasis maintained through adaptation to intestinal niche,"Intestinal mucosa, particularly in the small intestine and colon",Symbiotic with host microbiome; competes with pathogenic bacteria for adhesion sites and nutrients,Moderate tolerance to bile salts and low pH (gastric conditions); stable under lyophilization and rehydration; sensitive to high shear stress,Bile salts (tolerance mediated by bile salt hydrolase activity),该菌株为兼性厌氧菌，适宜在37°C、pH 6.0–7.0条件下生长，依赖复杂营养物质（如氨基酸、维生素）及宿主代谢物，在肠道黏膜中定植，具有与肠道微生物群共生并竞争性抑制病原菌的能力。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未涉及对Lactobacillus gasseri的基因工程改造，仅基于其天然代谢功能进行营养基因组学分析。,"[""pH"", ""Bile acids""]","[""Omega-3 fatty acids"", ""Omega-6 fatty acids"", ""Free fatty acids""]",,"[""Cytokines"", ""Tissue degradation fragments""]",Not specified,Not specified,文中未描述明确的信号感应逻辑或基因调控回路，仅通过基因表达谱分析推断其对ω-3/ω-6脂肪酸的响应。,"[""Metabolic Regulation""]",Not specified,Not specified,Not specified,False,,,Not applicable,,,,,,未提及抗菌或抗生物膜功能,False,Not applicable,,,,,未提及氧气生成功能,False,Not applicable,,False,Not applicable,,True,通过调节与脂质代谢相关的基因（如FADS1、FADS2、PPARα、PPARγ、ADIPOQ、LPL等）影响宿主的脂肪酸代谢和炎症反应，从而参与心血管疾病风险调控。,"Omega-3 fatty acids, Omega-6 fatty acids",False,Not applicable,,GRAS,Not specified,,低致病性，无抗生素抗性基因，无水平基因转移风险，环境逃逸可能性极低,Not specified,Lactobacillus gasseri为公认安全（GRAS）菌株，常用于益生菌产品，无已知致病性，不携带抗生素抗性基因，且在自然环境中难以长期存活，安全性高。,该研究未评估治疗效果，而是通过微阵列分析揭示Lactobacillus gasseri与ω-3/ω-6脂肪酸摄入对心血管疾病相关基因网络（如FADS1、PPARγ、ADIPOQ等）的调控作用，提示其在代谢调节和疾病预防中的潜在价值。,3369,1341,4710,,
c8eb964a-ea4c-4392-b0e4-0ce96111a6a5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. infantis"", ""strain_id"": ""RO033""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""RO071""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""RO052""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in the presence of lactose and other carbohydrates; adapted to the human gastrointestinal tract.","Growth rate consistent with in vitro conditions; no significant differences in growth parameters (weight, height, head circumference) observed between probiotic and placebo groups in vivo.","Gut mucosa, particularly in the colon; preferential colonization in the infant gut environment.",Competitive exclusion of pathogenic bacteria via nutrient competition and adhesion site occupation; no significant disruption of the native microbiome observed.,Tolerant to freeze-drying and rehydration; stable during storage at room temperature; resistant to gastric acidity and bile salts.,"Potato starch (excipient), freeze-drying process",三种益生菌均在健康婴儿肠道中表现出良好的生长适应性，无生长抑制现象。在体外培养条件下生长良好，且在口服后能稳定定植于婴儿肠道，未引起生长迟缓或代谢紊乱。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未对菌株进行基因工程改造，所有菌株均为天然野生型，未引入外源基因或质粒。,"[""pH"", ""Lactose"", ""Bile acids""]","[""Lactate"", ""Glucose""]",,,Not specified,Not specified,未涉及合成生物学逻辑电路设计，菌株依赖其天然代谢感应机制响应肠道微环境变化。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Spontaneous secretion of organic acids and immunomodulatory molecules,Dose-dependent effect via daily intake of 3×10⁹ CFU; no evidence of overactivity or toxicity.,Compatible with powder formulation and oral delivery; stable in excipient (potato starch).,True,False,False,通过产生乳酸、乙酸等有机酸降低肠道pH，抑制病原菌生长；竞争营养和黏附位点。,"Lactic acid, Acetic acid",False,True,True,True,三种菌株均未引起腹泻、发热或严重不良事件，且粪便性状与安慰剂组无差异，表明其抗菌作用可控且安全。,False,Not applicable,Not applicable,False,False,False,未涉及氧气生成机制。,True,调节免疫反应，增强Th1/Th2平衡，促进抗炎因子分泌，降低过敏风险。,"Cytokines (e.g., IL-10, TGF-β)",True,促进肠道屏障功能恢复，增强黏膜完整性，改善肠道通透性。,"Mucin, Tight junction proteins",False,Not applicable,Not applicable,False,Not applicable,Not applicable,GRAS,None (natural strains with no engineered kill switches),Not applicable,No pathogenicity reported; no antibiotic resistance genes detected; no horizontal gene transfer observed; low risk of systemic infection in healthy infants.,Oral administration with natural gut barrier; no physical confinement required.,三种菌株均为公认安全（GRAS）菌株，已在婴幼儿中多次使用，未报告严重不良事件或菌血症。在健康婴儿中使用安全且耐受性良好。,在8周干预期内，所有益生菌组与安慰剂组在体重、身高、头围增长方面无显著差异，且不良事件、粪便性状、D-乳酸尿排泄水平均等效，表明其在婴儿中具有良好的安全性和耐受性，可作为安全的肠道定植菌株。,18451,1521,19972,,
4f87f07f-360b-4fce-9a7f-8dbeaa2cd6b5,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Cecal microflora"", ""strain_id"": ""In vivo passaged through broilers and layers""}]","Encapsulated (in cecal contents, in vivo)",Facultative Anaerobe,"37°C, anaerobic conditions, pH 5.5–6.5, lactose-supplemented diet (5% w/w)",Growth rate not explicitly stated; maintained via in vivo passage over 2 years with consistent colonization ability,"Cecal lumen of broilers and layers, particularly in lactose-fed birds",Competitive exclusion of Salmonella; complex microbial interactions within cecal community; likely symbiotic with host gut environment,Stable through repeated in vivo passage; resistant to storage stress via continuous host maintenance; tolerance to dietary lactose and cecal pH shifts,"Lactose (dietary), cecal environment (anaerobic, pH-buffered)",该微生物群落通过在产蛋鸡和肉鸡体内连续传代维持活性超过2年，能够在37°C、厌氧条件下在鸡盲肠内定植，并通过代谢乳糖产生大量丙酸，显著降低盲肠pH，从而抑制沙门氏菌定植。其生长依赖于宿主提供的营养环境和乳糖补充，表现出良好的体内稳定性。,,,,,High stability due to continuous in vivo passage; no genetic modifications reported; natural community maintained over time,Stable within the cecal environment; no evidence of material-based instability,未进行基因工程改造，通过在肉鸡和蛋鸡体内连续传代维持活性微生物群落，确保其竞争性排斥能力的长期一致性。,"[""Hypoxia"", ""pH"", ""Lactose""]","[""Lactose"", ""Propionic acid""]",,,"Lactose utilization pathways (e.g., lactose permease, β-galactosidase); pH-sensing mechanisms in anaerobic gut bacteria",No explicit logic gates; likely constitutive metabolic activity in response to lactose availability and pH changes,微生物群落通过感知乳糖的存在和盲肠pH变化，启动代谢活动，产生大量未解离丙酸，从而抑制沙门氏菌生长。该响应为非诱导性、持续性代谢行为，依赖于宿主环境中的底物供给。,"[""Antibacterial"", ""Metabolic Regulation""]","Passive diffusion of metabolites (e.g., propionic acid) from microbial cells",Controlled by host diet (lactose supplementation) and microbial population dynamics,High compatibility with cecal environment; no artificial material used; natural encapsulation in gut lumen,True,True,False,通过产生大量未解离丙酸，显著降低盲肠pH，造成酸性环境，抑制沙门氏菌定植和增殖。,Undissociated propionic acid,True,True,True,True,"在乳糖喂养条件下，无论是否为乳糖发酵型沙门氏菌，均能实现10,000倍的沙门氏菌减少，且未见对宿主细胞造成明显毒性，表明其具有局部作用和安全性。",False,,,,,,,False,,,False,,,True,通过乳糖发酵产生大量丙酸，调节盲肠内环境，影响宿主代谢和微生物群落平衡。,Propionic acid,False,,,GRAS,Natural attenuation via host environment; no synthetic kill switches or auxotrophy reported,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape unlikely due to host dependency,Physical confinement within host gastrointestinal tract; no external material barrier,该微生物群落为鸡盲肠正常菌群，无已知致病性，不携带抗生素抗性基因，依赖宿主环境生存，无法在体外长期存活，因此生物安全风险极低，属于GRAS（公认安全）类别。,"在鸡盲肠中，无论在沙门氏菌感染前或感染后3天内给予，均能将沙门氏菌数量减少10,000倍。乳糖补充显著增强效果，使未解离丙酸浓度从2.4 μmol/g提升至12–16.8 μmol/g，同时盲肠pH显著下降，有效抑制病原菌定植。该系统在体内连续传代超过2年仍保持稳定效能。",10268,1585,11853,,
08310a91-a516-446e-ab9c-9c52af25375f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""NRRL B-4495""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NRRL B-442""}]",Encapsulated,Facultative Anaerobe,Growth at 37°C in MRS broth; optimal pH ~7.2; tolerance to low pH (3.0) and 0.3% Oxgall bile salt,Growth rate: ~13 h to early stationary phase in MRS broth; doubling time not explicitly reported,Intestinal tract (inferred from probiotic function and acid/bile tolerance),Potential symbiosis with host gut microbiota; no competition data reported,"High tolerance to acid (pH 3.0), bile (0.3% Oxgall), and thermal stress during spray drying; stable under refrigerated storage","Maltodextrin (protective matrix), raspberry juice (natural antioxidants, ascorbic acid)",乳酸杆菌在37°C下于MRS培养基中生长，对酸性环境（pH 3.0）和胆盐（0.3% Oxgall）具有较强耐受性。喷雾干燥后仍保持良好的酸碱和胆盐耐受能力，表明其在胃肠道环境中具有良好的生存潜力。,,,,,No genetic modifications reported; natural strains used; stability maintained via encapsulation and low-temperature storage,Encapsulation in raspberry powder with maltodextrin enhances survival and stability during storage,未对乳酸杆菌进行基因工程改造，仅通过喷雾干燥技术将菌株包埋于覆盆子粉中，利用天然成分（如麦芽糊精和覆盆子汁）作为保护基质，以提高其在储存过程中的稳定性。,"[""pH"", ""Bile Salts""]",,,,"FNR promoter (inferred from acid tolerance), bile salt hydrolase (inferred from bile tolerance)",No synthetic logic circuits reported; natural sensing mechanisms present,乳酸杆菌通过细胞膜H+-ATP酶等天然机制感知酸性环境，通过代谢胆盐为氨基酸和类固醇衍生物来抵抗胆盐的破坏作用，但其具体调控通路尚未明确。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Passive diffusion and cell lysis (inferred from natural secretion and survival in matrix),Controlled by encapsulation and storage conditions; release depends on matrix degradation,High compatibility with raspberry powder and maltodextrin matrix; maintains structural integrity and controlled release,True,False,False,通过产生有机酸降低局部pH，抑制病原菌生长；同时通过竞争性定植和分泌抗菌物质（如乳酸）发挥抗菌作用。,Lactic acid,False,True,True,True,乳酸杆菌在pH 3.0下仍能生长，表明其在胃酸环境中具有生存能力；对多种抗生素敏感性变化未影响其基本抗菌功能，且在包埋后仍保持活性。,False,,,False,False,False,未涉及氧气生成或氧合功能。,True,通过调节宿主免疫反应，增强肠道屏障功能，促进抗炎因子分泌，抑制过度免疫应答。,"Cytokines (e.g., IL-10, TGF-β) – inferred from probiotic function",False,,,True,通过调节短链脂肪酸（SCFAs）等代谢产物的生成，影响宿主能量代谢、肠道菌群平衡及神经内分泌功能。,Short-chain fatty acids (SCFAs),False,,,GRAS,None (natural strains used; no synthetic kill switches),,Low pathogenicity; no antibiotic resistance genes reported; potential for horizontal gene transfer not assessed; no evidence of environmental escape,Physical barrier provided by encapsulation in raspberry powder matrix,所用菌株为公认安全（GRAS）的乳酸杆菌，无致病性，未进行基因改造，无合成生物安全控制措施。其包埋形式提供了物理屏障，降低了环境释放风险。,在30天储存期内，冷藏条件下CFU/g保留率高达98%（R10样本），表明该包埋系统能有效维持乳酸杆菌的存活率和功能活性，具有良好的货架期稳定性，适用于非乳基益生菌产品的开发。,12629,1603,14232,,
7084e8c0-62da-4a6a-a6d7-fd6cc42f62b5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCFM""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, neutral to slightly acidic pH (6.0–7.0), requires complex media with carbohydrates (e.g., glucose) and amino acids; tolerant to bile salts and low pH (gastric conditions)",Doubling time ~60–90 minutes in vitro; in vivo colonization stability in intestinal environment with moderate growth rate under host-microbiome competition,"Intestinal mucosa, particularly in the small intestine and colon; binds to mucus layer via surface proteins","Competitive exclusion of pathogens (e.g., C. difficile) through niche occupation and resource competition; potential symbiosis with host immune system via secreted factors","Moderate tolerance to bile, low pH, osmotic stress; limited UV and drying resistance; stable during lyophilization and rehydration","Bile salts, mucin-binding proteins (e.g., GAPDH, enolase)","Lactobacillus acidophilus NCFM is a facultative anaerobe that thrives in the human gut environment. It grows optimally at 37°C and neutral to slightly acidic pH, utilizing carbohydrates and amino acids from the host diet. It exhibits strong tolerance to bile and low gastric pH, enabling survival through the upper GI tract. Its ability to adhere to intestinal mucus via surface proteins supports long-term colonization and competitive exclusion of pathogens.",Not explicitly mentioned,,"Not applicable (natural strain, no synthetic circuits reported)",,Chromosomal integration likely; no plasmid-based systems reported; low metabolic burden due to natural adaptation to gut environment,No engineered material environment described; natural surface proteins function in host mucosal matrix,"The strain is a naturally occurring probiotic with no reported genetic modifications. Its functional properties arise from native surface and secreted proteins, including moonlighting enzymes, which are expressed under natural regulatory control.","[""pH"", ""Osmotic stress"", ""Hypoxia""]","[""Glucose"", ""Bile acids"", ""Lactate""]","[""Quorum sensing (AI-2)"", ""Pathogen-specific molecules (indirect)""]","[""Mucin"", ""Fibronectin"", ""Collagen"", ""Plasminogen""]","GAPDH, enolase, pyruvate kinase, surface adhesins",No synthetic logic gates; natural sensing via protein-ligand binding with threshold-dependent adhesion and secretion; potential feedback via nutrient availability and host matrix contact,"Lactobacillus acidophilus NCFM senses environmental cues such as pH, bile, and host mucosal components (e.g., mucin, fibronectin) through surface-exposed moonlighting proteins. These proteins act as receptors that trigger adhesion and secretion responses. The binding of GAPDH to mucin or plasminogen initiates colonization and immune modulation. The system operates with threshold sensitivity and may exhibit feedback regulation based on nutrient availability and host tissue contact, enabling adaptive colonization without synthetic circuitry.","[""Colonization"", ""Immunomodulation"", ""Pathogen Exclusion""]",Non-canonical secretion (likely involving moonlighting protein translocation without signal peptides); potential involvement of outer membrane vesicles or membrane blebbing,"Natural regulation via environmental cues (pH, nutrient, host matrix); no synthetic dosage control",High compatibility with intestinal mucus and extracellular matrix; surface proteins remain functional in mucosal environment without structural disruption,False,,,No direct antibacterial or biofilm inhibition activity reported; relies on competitive exclusion and niche occupation,,False,,,,无直接抗菌活性，不满足抗菌模块标准,False,No oxygen-producing or oxygen-consuming metabolic activity reported; not involved in hypoxia alleviation,,False,,,无氧代谢功能，不满足氧合模块标准,True,"Surface proteins (e.g., GAPDH, enolase) bind host immune components such as plasminogen and fibronectin, modulating immune cell activity and promoting anti-inflammatory responses. Secreted proteins may regulate cytokine production and immune tolerance.","GAPDH, enolase, pyruvate kinase",True,"Surface adhesion to intestinal mucin and extracellular matrix components (e.g., fibronectin, collagen) supports epithelial barrier integrity and may promote tissue repair by stabilizing the mucosal layer and preventing pathogen invasion.","GAPDH, enolase, fibronectin-binding proteins",True,"Secreted and surface-localized metabolic enzymes (e.g., GAPDH, enolase) may influence host metabolism by modulating local nutrient availability and signaling pathways. These proteins may also affect host cell energy metabolism via interaction with host receptors.","GAPDH, enolase, pyruvate kinase",False,No reported anti-tumor or prodrug conversion activity,,GRAS,"Natural auxotrophy (e.g., vitamin dependency); no synthetic kill switches reported","Vitamin B12, folic acid",Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; minimal environmental escape risk due to gut-specific adaptation,Natural mucosal colonization limits systemic spread; no engineered physical barrier,"Lactobacillus acidophilus NCFM is classified as Generally Recognized As Safe (GRAS) by the FDA. It is a well-established probiotic with a long history of safe use in humans. It does not possess known virulence factors or antibiotic resistance genes. Its natural auxotrophy and gut-specific niche reduce the risk of environmental persistence or unintended spread. No synthetic biocontainment systems are used, but its ecological constraints provide inherent safety.",通过表面蛋白（如GAPDH、烯醇酶）与宿主黏液和细胞外基质结合，增强肠道屏障功能，抑制病原体定植，调节免疫反应，从而改善肠道稳态。在炎症性肠病和艰难梭菌感染模型中，该菌株表现出良好的定植能力和免疫调节效果，有助于恢复肠道微生态平衡。,4466,1937,6403,,
15b48a9e-603d-4701-b214-3009c65df608,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""CBG-C11""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""CBG-C10""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""CBG-C2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""CBG-C15""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""CBG-C21""}]",Suspension,Facultative Anaerobe,Grown in MRS medium at 37°C for 15 h; requires linoleic acid (0.5 mg/mL); optimal pH and osmotic conditions not specified,Growth rate not quantified; doubling time not reported; in vitro growth confirmed; in vivo stability not assessed,Gut lumen; potential for intestinal mucosal adherence and colonization,Competitive exclusion of pathogenic bacteria; potential for symbiotic interaction with host microbiota; no evidence of disruption to native microbiome,"Tolerant to lyophilization and rehydration; stable in freezing conservative (10% creaming powder, 10% dextran, 5% sorbitol); stability under storage not quantified","Dextran, sorbitol, creaming powder",该混合菌群由五株益生菌组成，包括三种双歧杆菌（B. longum、B. lactis、B. breve）和两种乳杆菌（L. reuteri、L. plantarum），均在MRS培养基中37°C培养15小时。菌株经离心收集后，与含10%脱脂奶粉、10%右旋糖酐和5%山梨醇的冷冻保护剂混合，进行冻干处理，用于动物实验。菌株在体外具有良好的生长能力，冻干后仍保持较高活力，适用于口服给药。,,,,,No genetic modifications reported; natural strains used; chromosomal stability assumed; no plasmid-based systems used,Stable in lyophilized formulation with dextran and sorbitol; no reported degradation in delivery matrix,该微生物系统为天然未改造的益生菌混合物，未使用任何基因编辑工具或合成生物学元件。所有菌株均为野生型，通过冻干技术封装以提高稳定性，适用于口服递送。,"[""pH"", ""Bile acids""]","[""Cholesterol"", ""Bile salts""]",,,Bile salt hydrolase (BSH) activity; cholesterol removal assay,No synthetic logic circuits reported; natural sensing via BSH and cholesterol-binding mechanisms,该系统通过天然的胆盐水解酶（BSH）活性和胆固醇去除能力感知肠道环境中的胆汁酸和胆固醇水平，从而启动降脂机制。未使用人工调控回路，依赖于菌株的自然代谢响应能力。,"[""Metabolic Regulation"", ""Tissue Repair""]",Natural secretion via cell lysis or passive diffusion; no engineered secretion systems reported,"Dose-dependent effects observed (low, medium, high doses); controlled by oral gavage administration",Compatible with lyophilized formulation; stable in freeze-dried powder; suitable for oral delivery,False,,,Not applicable,,,,,,未涉及抗菌功能,False,Not applicable,,,,,未涉及氧合功能,False,Not applicable,,True,通过减少肝脏脂质沉积和改善肝功能指标（ALT、AST）来缓解非酒精性脂肪肝（NAFLD）损伤，促进肝组织修复。,Hepatic lipid metabolism regulation,True,通过抑制SREBP1、FAS和ACC等关键蛋白的表达，降低肝脏胆固醇和脂肪酸合成，从而调节脂质代谢。,"SREBP1, FAS, ACC",False,Not applicable,,GRAS,No genetic kill switches or auxotrophy reported; natural strains used,,No pathogenicity reported; no antibiotic resistance genes mentioned; low risk of horizontal gene transfer; no environmental escape data,Physical barrier provided by freeze-dried capsule; oral delivery limits systemic spread,该益生菌混合物由五种公认安全（GRAS）的菌株组成，未进行基因改造，无致病性或耐药基因报道，通过口服给药实现物理隔离，风险极低。,在高胆固醇饮食诱导的高胆固醇血症大鼠模型中，该益生菌混合物显著降低血清总胆固醇（TC）、甘油三酯（TG）和低密度脂蛋白（LDL）水平，同时升高高密度脂蛋白（HDL）水平。肝脏组织学分析显示，混合物显著减轻肝脂肪变性，降低肝组织中TC和TG含量。Western blot结果显示，SREBP1、FAS和ACC等胆固醇合成相关蛋白表达下调。高剂量组效果最显著，与辛伐他汀治疗组相当，表明该混合菌群具有显著的降脂和肝保护作用。,13497,1792,15289,,
a13115c9-9fd8-4598-9309-c9148d3fc982,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus sp."", ""strain_id"": ""Be2, B10, B18""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactic acid bacteria (LAB)"", ""strain_id"": ""Lta2, Lta6, Lta8, Lta10""}]",Encapsulated (in feed or water),Facultative Anaerobe,Temperature: 30–37°C; pH: 7.95–8.10; Aerobic or facultative conditions; Nutritional requirements: Trypticase soy broth (TS) or MRS broth,"Log phase: Be2 and B10 (~117 h), B18 (~68 h), LAB strains (~42 h); Growth in feed at 4°C for 14 days with gradual decline in viability",Aquatic environment and fish gut (tilapia culture system),Competitive exclusion of pathogenic Vibrio; potential modulation of gut microbiota through metabolic byproducts,"Bacilli: Spore-forming, heat-resistant; LAB: Sensitive to high temperatures, viable at 4°C for 14 days","Spores (Bacillus), Refrigeration (4°C) for LAB","Bacillus strains are facultative anaerobes that grow under aerobic conditions and form spores, enhancing survival in aquatic environments. Lactic acid bacteria (LAB) are Gram-positive cocci that grow in chains or pairs, thrive in anaerobic conditions but tolerate oxygen. Both groups exhibit growth under suboptimal temperature (19.9–24.8°C) and high-density culture conditions, with Bacillus showing higher growth rates than LAB. LAB viability in feed stored at 4°C declined gradually over 14 days, indicating moderate stability.",,,,,"No genetic modifications reported; natural strains used. Bacillus spores provide inherent stability; LAB viability in feed decreased over time, indicating limited stability.",LAB viability maintained in feed with Dry Oil (adhesive) at 4°C for 14 days; Bacilli added directly to water without encapsulation.,"No genetic engineering was performed. The selected Bacillus and LAB strains were used in their natural form. Bacillus strains were added to water, while LAB were sprayed onto feed as a probiotic supplement. No plasmids, promoters, or synthetic circuits were used.",,,,,,,"No sensing modules or genetic circuits were engineered. The strains were selected based on phenotypic traits (haemolysis, enzyme activity, antagonism) rather than responsive genetic systems.","[""Growth Promotion"", ""Immune Stimulation"", ""Environmental Improvement""]","Passive secretion (natural metabolic products, enzymes, organic acids)",Controlled by feed concentration (5×10⁴ CFU/g) and water addition (1×10³ CFU/mL) every 15 days,LAB compatible with feed encapsulation using Dry Oil; Bacilli compatible with water addition without structural disruption,True,False,False,"Bacillus strain B18 showed inhibitory activity against Vibrio (6 mm halo), suggesting antibacterial potential via bacteriocins or other secreted factors.",Bacteriocin-like compounds (from B18 strain),False,True,True,True,"Only one strain (B18) showed inhibition against Vibrio; no evidence of broad-spectrum activity or biofilm inhibition. Activity was localized and not excessive, with no reported cytotoxicity. Strains were non-haemolytic (γ-haemolysis), indicating safety.",False,,,False,False,False,No oxygenation mechanism was reported. No evidence of oxygen-producing enzymes or light-dependent systems.,True,"Probiotic bacteria may enhance host immune response by competitive exclusion of pathogens and modulation of gut microbiota, indirectly improving disease resistance.","Bacterial cell wall components, metabolic byproducts (e.g., organic acids)",False,,,True,"LAB produce lactic and acetic acids, which may lower gut pH and improve nutrient digestion and absorption. Bacillus may produce enzymes that aid in feed breakdown.","Lactic acid, acetic acid, enzymes (e.g., naphthol-AS-BI-phosphohydrolase, α-glucosidase)",False,,,BSL-1,Natural non-pathogenic strains; no genetic kill switches or auxotrophy used,,"No pathogenicity reported; all strains were non-haemolytic (γ-haemolysis), no antibiotic resistance genes mentioned. Low risk of horizontal gene transfer. No environmental escape reported.",Physical confinement in indoor tanks; no open release,All selected strains are non-haemolytic and non-pathogenic. Bacillus spores are naturally stable and do not pose high risk. LAB are GRAS (Generally Recognized As Safe) in aquaculture. No genetic modifications or antibiotic resistance genes were used. Risk of environmental escape is low due to controlled indoor culture.,"Fish fed with LAB or a mixture of LAB and Bacillus showed significantly higher growth performance (final weight: 15.82 g and 14.96 g, respectively) compared to control (9.87 g) after 134 days. Specific growth rate (SGR) was significantly improved in all bacterial treatments (3.51% day⁻¹ for LAB, 3.47% day⁻¹ for mixture). Survival rates were similar across treatments (90.8–93.2%), indicating no adverse effects. The results suggest that these probiotic strains effectively promote growth and maintain health under high-density and suboptimal temperature conditions.",12621,1822,14443,,
afe8de7a-449b-4380-930f-4250eaf3ef89,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""BT01""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""BA05""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""BP07""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""BP06""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""BD08""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""BB02""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""BL03""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""BI04""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerant to bile salts and low pH; utilizes lactose, glucose, and various carbohydrates; dependent on host-derived nutrients in gut environment",Growth rate not explicitly quantified; in vitro doubling time estimated to be ~60–90 min based on typical LAB kinetics; consistent with in vivo colonization potential,"Intestinal mucosa, particularly in the small intestine and colon; preferentially colonizes mucus layer and adheres to epithelial cells",Competitive exclusion of pathogens via adhesion competition; potential for symbiotic interactions with host immune system; no evidence of pathogenicity or disruption of native microbiota,"Tolerant to bile salts, low pH, osmotic stress, and moderate shear stress; stable during lyophilization and rehydration; storage stability not explicitly tested but typical for probiotics","Bile salts, low pH, osmotic stress",该多物种益生菌产品VSL#3中的8种菌株均为乳酸菌和双歧杆菌，具有良好的肠道适应性。它们在37°C、pH 6.5–7.0条件下生长良好，能耐受胆汁和低pH环境，利用乳糖、葡萄糖等多种碳源，依赖宿主提供的营养物质在肠道中定植。这些菌株在体外表现出良好的生长动力学，预计倍增时间为60–90分钟，具备在体内持续定植的能力。,"CRISPR-Cas systems (3 loci in S. thermophilus BT01), Restriction-Modification (R/M) systems, plasmid-based genes (e.g., lacF, transporters)",Not applicable; no genetic engineering reported in the study,Constitutive expression of surface adhesins and pili; no inducible circuits described,,"High chromosomal stability; plasmids present in S. thermophilus BT01 and L. helveticus BD08 (3.3 kb and 4.5 kb, respectively); plasmid copy number not quantified; no evidence of gene loss or drift",Plasmid stability confirmed in genomic context; no material-specific engineering reported,该研究未对菌株进行人工基因改造，但通过基因组分析发现其天然具备多种防御系统（如CRISPR-Cas和R/M系统）和表面结构基因（如pili、S层蛋白），这些天然基因元件赋予其在肠道环境中的稳定性和功能活性。,"[""pH"", ""Bile acids"", ""Lactate"", ""Glucose""]","[""Lactose"", ""Glucose"", ""Fructose"", ""Amino acids""]","[""Quorum sensing (indirect via pili expression)""]","[""Mucus (via mucus-binding pili)"", ""Intestinal epithelium (via LPXTG proteins)""]","FNR-like regulators (inferred), LPXTG motifs, Tad pilus gene clusters, sortase-dependent pilus systems","No synthetic logic gates; natural expression of adhesion and colonization genes is likely constitutive or modulated by environmental cues (e.g., nutrient availability, host contact)",这些菌株通过天然基因表达系统感知肠道环境中的pH、胆汁酸、乳糖、葡萄糖等信号，通过LPXTG蛋白、Tad pili和sortase依赖性菌毛等结构实现与宿主黏膜的特异性结合。其表达机制为组成型或环境响应型，无明确的逻辑门控设计，但具有良好的环境适应性和定植能力。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","LPXTG-dependent surface display, sortase-mediated pilus assembly, extracellular secretion via SecA2-SecY2 system",Not applicable; natural expression levels; no controllable output reported,Compatible with oral delivery; no encapsulation or material-specific delivery system described,False,False,False,Not applicable; no direct antibacterial effector molecules reported,,False,False,False,False,未报告任何抗菌活性或生物膜抑制功能,False,Not applicable; no oxygen-producing enzymes or systems identified,,False,False,False,未发现任何产氧机制,True,"Surface proteins (LPXTG, S-layer, pili) interact with dendritic cells and immune receptors (e.g., DC-SIGN), modulating cytokine production and immune tolerance; Tad pili and sortase-dependent pili enhance host immune signaling","Tad pili (B. breve BB02), sortase-dependent pili (B. animalis subsp. lactis BL03/BI04), LPXTG proteins (L. paracasei BP07, L. plantarum BP06), S-layer proteins (L. helveticus BD08, L. paracasei BP07)",True,Tight adherence pili (Tad) and mucus-binding pili promote intestinal barrier integrity; glycosylated surface proteins may enhance epithelial cell development and mucosal healing,"Tad pili (B. breve BB02), mucus-binding pili (L. paracasei BP07), glycosylated LPXTG proteins (L. plantarum BP06)",True,Urease activity in S. thermophilus BT01 modulates nitrogen availability; lactose and carbohydrate metabolism influence gut microbial ecology and SCFA production; potential for SCFA production via fermentation,"Urease (S. thermophilus BT01), lactose transporters (L. helveticus BD08), carbohydrate transporters (L. helveticus BD08, L. paracasei BP07)",False,Not applicable; no evidence of tumor-targeting or prodrug conversion,,GRAS,Natural auxotrophy (no synthetic kill switches); no antibiotic resistance genes transferred; resistance genes located near transposons but not transferable,"Transposon-associated tetW, aminoglycoside resistance genes",No virulence genes identified; resistance genes are non-transferable; no pathogenicity observed; low opportunistic risk; no horizontal gene transfer detected,Oral administration; no physical barrier required; natural gut confinement,该多物种益生菌产品VSL#3中的菌株均被归类为GRAS（公认安全），无致病性基因，抗生素抗性基因位于转座子附近但未发现可转移性。所有菌株对多种抗生素敏感，符合EFSA安全标准。无合成杀伤开关或人工生物遏制系统，但其天然基因组稳定性高，生态适应性强，无环境逃逸风险。,临床试验显示VSL#3可显著改善溃疡性结肠炎、回肠袋炎、非酒精性脂肪肝病及肥胖相关炎症状态。其机制可能与增强肠道屏障功能、调节免疫反应、改善代谢稳态有关。基因组分析证实其具备多种益生功能基因，支持其在治疗胃肠道疾病中的有效性。,16301,2448,18749,,
c0e5fe58-3be7-4bfa-b4c4-90c622c05349,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Biobac®1""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Biobac®1""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""Biobac®1""}]",Suspension,Facultative Anaerobe,"Growth at 37°C, pH 6.5–7.0, utilizes lactose and other carbohydrates as carbon sources; requires complex nutrients including vitamins and amino acids.",Growth rate not explicitly reported; likely moderate doubling time in vitro under optimal conditions; in vivo colonization supported by gut environment.,"Intestinal tract of calves, particularly the small intestine and colon, where they establish in the mucosal layer.",Competitive exclusion of pathogens such as Cryptosporidium parvum and rotavirus; potential for symbiotic interaction with host microbiota by enhancing microbial balance.,Tolerant to moderate osmotic stress and gastric acidity; stability during storage and rehydration in milk-based diets.,Cell wall components and exopolysaccharides (EPS) contributing to acid and bile resistance.,"As probiotic strains, Lactobacillus acidophilus, Bifidobacterium bifidum, and Enterococcus faecium are well-adapted to the bovine neonatal gut environment. They thrive in the intestinal tract under physiological conditions, utilizing lactose from milk as a primary carbon source. These organisms are facultative anaerobes, allowing them to survive in both oxygen-rich and low-oxygen environments of the gut. They exhibit moderate tolerance to bile and gastric acidity, enabling survival through the stomach. Their ability to colonize the intestinal mucosa and compete with pathogens supports their role in maintaining gut health.","Not applicable (commercial probiotic formulation, no genetic modification reported)",Not applicable,Constitutive (natural expression of beneficial traits),,High (natural strains with stable genomic architecture; no plasmid-based systems reported),Stable in milk-based delivery system; no significant degradation or loss of viability during storage and administration.,"The microbial system consists of naturally occurring, non-genetically modified probiotic strains. No synthetic genetic circuits or inducible systems are employed. The beneficial effects are attributed to the inherent physiological properties of the strains, including competitive exclusion, production of organic acids, and immune modulation. The strains are delivered in a commercial formulation (Biobac®1) and remain stable in milk without genetic engineering.","[""pH"", ""Lactose"", ""Bile""]","[""Lactose"", ""Glucose""]",,,"Lactose permease and acid-sensing regulators (e.g., FNR-like systems in L. acidophilus; bile salt hydrolases in E. faecium)",Constitutive expression; no complex logic gates; response is triggered by nutrient availability and environmental conditions.,"The probiotic strains sense lactose and glucose in the milk diet, which serve as primary carbon sources. They detect changes in pH and bile salts in the gastrointestinal tract, triggering adaptive responses such as acid tolerance and bile resistance. These sensing mechanisms are intrinsic and not regulated by synthetic circuits. The response is primarily constitutive, with expression of beneficial functions (e.g., acid production, adhesion) activated upon colonization and nutrient availability.","[""Antibacterial"", ""Immunomodulation""]","Type I secretion (lactic acid), passive diffusion (bacteriocins), and cell lysis (release of immunomodulatory molecules)",Dose-dependent; administered at 2 g/day in milk and 4 g in gel pre-colostro; no feedback control reported,Highly compatible with milk-based delivery; stable in liquid and gel forms; no structural disruption of feed matrix,True,True,False,"Inhibition of pathogenic microorganisms such as Cryptosporidium parvum and rotavirus through competitive exclusion, production of organic acids (lactic acid), and lowering of intestinal pH.","Lactic acid, bacteriocins (e.g., enterocin from E. faecium), and competitive adhesion to intestinal mucosa",True,True,True,True,"Probiotic supplementation reduced diarrhea duration in calves fed antibiotic-free milk (P < 0.05). No adverse effects on growth or feed intake were observed. The mechanism involves competitive exclusion and acid production, which are localized and do not disrupt gut structure.",False,,,False,False,False,Not applicable; no oxygenation mechanism reported.,True,"Stimulation of the host immune system through interaction with intestinal epithelial cells and immune cells, enhancing local and systemic immune responses.","Exopolysaccharides (EPS), cell wall components (peptidoglycan), and secreted cytokines (e.g., IL-10, TGF-β)",False,,,False,,,False,,,GRAS,No genetic containment; natural strains with low pathogenicity,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape.,Physical confinement via milk delivery system; no engineered barriers,"The probiotic strains Lactobacillus acidophilus, Bifidobacterium bifidum, and Enterococcus faecium are classified as Generally Recognized as Safe (GRAS). They are non-pathogenic, do not carry known antibiotic resistance genes, and are not associated with virulence factors. Their use in calves is considered safe, with no reported adverse effects. The delivery system (milk) provides physical containment, and the strains are naturally limited to the gastrointestinal tract.","A adição de probiótico reduziu significativamente o número de dias com diarréia em bezerras alimentadas com leite sem resíduo de antimicrobianos (P < 0,05), sem afetar o consumo de concentrado, água ou ganho de peso. O efeito foi mais evidente no grupo L, sugerindo que a presença de antimicrobianos no leite (LTM) pode interferir na eficácia do probiótico. A redução na duração da diarréia está associada à ação antibacteriana e imunomoduladora dos probióticos, que promovem equilíbrio microbiano e proteção intestinal.",11752,2008,13760,,
cbaebdda-3703-45b0-9835-2afad871eafb,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""IP5""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 4.0–4.5, in MRS medium with glucose and oxalate; tolerant to 20 mM sodium oxalate",Doubling time not specified; growth observed over 72 h in MRS-ox medium with viable counts reaching ~7.75 log cfu/mL,"Intestinal tract (gut lumen), particularly colon where oxalate absorption occurs",Potential to compete with pathogenic bacteria; may modulate gut microbiota via EPS and oxalate degradation,"High resistance to low pH (57% survival at pH 2.0 for 120 min), high bile salt tolerance (103% survival at 0.3% bile), stable in glycerol at -80°C","Exopolysaccharide (EPS) production, acid-adaptive mechanisms",该菌株为兼性厌氧菌，最适生长温度为37°C，在MRS培养基中可耐受20 mM钠草酸盐。在pH 2.0条件下120分钟存活率为57%，在0.3%胆盐中存活率为103%，表明其具有良好的胃肠道耐受性。在含草酸盐的培养基中仍能正常生长，表明其对草酸盐具有较强耐受性。,,,,,,,该研究未涉及基因工程改造，所有功能均为天然菌株固有特性，未使用外源质粒或诱导系统。,"[""pH"", ""Oxalate""]","[""Sodium Oxalate""]",,,"Oxalate utilization enzymes (e.g., oxalate decarboxylase or formyl-CoA transferase), pH-responsive regulators",No synthetic logic gates; natural induction of oxalate degradation enzymes upon exposure to oxalate,菌株在接触草酸盐后可诱导表达草酸盐降解酶，实现对草酸盐的响应性降解，属于天然的代谢感应机制，无人工逻辑门控。,"[""Metabolic Regulation""]",Passive diffusion / cell lysis (natural secretion of enzymes),Natural expression level; no controllable output mechanism described,Compatible with suspension in liquid media; EPS may enhance stability in gastrointestinal environment,False,False,False,,,False,False,False,False,未提及抗菌或抗生物膜功能。,False,,,False,False,False,未提及产氧功能。,False,,,False,,,True,通过降解草酸盐降低肠道草酸盐浓度，从而减少草酸钙结石形成风险，调节宿主草酸代谢。,Oxalate (降解产物：CO2 + formate),False,,,GRAS,"None (natural strain, no synthetic kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; non-pathogenic in human gut,None (no physical confinement described),L. fermentum IP5为食品级安全菌株，无致病性，无抗生素抗性基因，未进行基因改造，无逃逸风险，属于GRAS级别，安全性高。,该菌株在含20 mM草酸盐的培养基中仍能保持高存活率（97%以上），并在10 mM和20 mM草酸盐条件下分别降解36.29%和28.79%的草酸盐，表明其在预防草酸钙结石方面具有显著潜力。,20589,4266,24855,,
cbaebdda-3703-45b0-9835-2afad871eafb,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""YG7""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 4.0–4.5, in MRS medium with glucose and oxalate; tolerant to 20 mM sodium oxalate",Doubling time not specified; growth observed over 72 h in MRS-ox medium with viable counts reaching ~8.28 log cfu/mL,"Intestinal tract (gut lumen), particularly colon where oxalate absorption occurs",Potential to compete with pathogenic bacteria; may modulate gut microbiota via EPS and oxalate degradation,"High resistance to low pH (49% survival at pH 2.0 for 120 min), high bile salt tolerance (98% survival at 0.3% bile), stable in glycerol at -80°C","Exopolysaccharide (EPS) production, acid-adaptive mechanisms",该菌株为兼性厌氧菌，最适生长温度为37°C，在MRS培养基中可耐受20 mM钠草酸盐。在pH 2.0条件下120分钟存活率为49%，在0.3%胆盐中存活率为98%，表明其具有良好的胃肠道耐受性。在含草酸盐的培养基中仍能正常生长，表明其对草酸盐具有较强耐受性。,,,,,,,该研究未涉及基因工程改造，所有功能均为天然菌株固有特性，未使用外源质粒或诱导系统。,"[""pH"", ""Oxalate""]","[""Sodium Oxalate""]",,,"Oxalate utilization enzymes (e.g., oxalate decarboxylase or formyl-CoA transferase), pH-responsive regulators",No synthetic logic gates; natural induction of oxalate degradation enzymes upon exposure to oxalate,菌株在接触草酸盐后可诱导表达草酸盐降解酶，实现对草酸盐的响应性降解，属于天然的代谢感应机制，无人工逻辑门控。,"[""Metabolic Regulation""]",Passive diffusion / cell lysis (natural secretion of enzymes),Natural expression level; no controllable output mechanism described,Compatible with suspension in liquid media; EPS may enhance stability in gastrointestinal environment,False,False,False,,,False,False,False,False,未提及抗菌或抗生物膜功能。,False,,,False,False,False,未提及产氧功能。,False,,,False,,,True,通过降解草酸盐降低肠道草酸盐浓度，从而减少草酸钙结石形成风险，调节宿主草酸代谢。,Oxalate (降解产物：CO2 + formate),False,,,GRAS,"None (natural strain, no synthetic kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; non-pathogenic in human gut,None (no physical confinement described),L. brevis YG7为食品级安全菌株，无致病性，无抗生素抗性基因，未进行基因改造，无逃逸风险，属于GRAS级别，安全性高。,该菌株在含20 mM草酸盐的培养基中仍能保持高存活率（97%以上），并在10 mM和20 mM草酸盐条件下表现出良好的降解活性，未受草酸盐抑制，表明其在预防草酸钙结石方面具有显著潜力。,20589,4266,24855,,
cbaebdda-3703-45b0-9835-2afad871eafb,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""MP1""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 4.0–4.5, in MRS medium with glucose and oxalate; tolerant to 20 mM sodium oxalate",Doubling time not specified; growth observed over 72 h in MRS-ox medium with viable counts reaching ~7.88 log cfu/mL,"Intestinal tract (gut lumen), particularly colon where oxalate absorption occurs",Potential to compete with pathogenic bacteria; may modulate gut microbiota via EPS and oxalate degradation,"High resistance to low pH (43% survival at pH 2.0 for 120 min), high bile salt tolerance (97% survival at 0.3% bile), stable in glycerol at -80°C","Exopolysaccharide (EPS) production, acid-adaptive mechanisms",该菌株为兼性厌氧菌，最适生长温度为37°C，在MRS培养基中可耐受20 mM钠草酸盐。在pH 2.0条件下120分钟存活率为43%，在0.3%胆盐中存活率为97%，表明其具有良好的胃肠道耐受性。在含草酸盐的培养基中仍能正常生长，表明其对草酸盐具有较强耐受性。,,,,,,,该研究未涉及基因工程改造，所有功能均为天然菌株固有特性，未使用外源质粒或诱导系统。,"[""pH"", ""Oxalate""]","[""Sodium Oxalate""]",,,"Oxalate utilization enzymes (e.g., oxalate decarboxylase or formyl-CoA transferase), pH-responsive regulators",No synthetic logic gates; natural induction of oxalate degradation enzymes upon exposure to oxalate,菌株在接触草酸盐后可诱导表达草酸盐降解酶，实现对草酸盐的响应性降解，属于天然的代谢感应机制，无人工逻辑门控。,"[""Metabolic Regulation""]",Passive diffusion / cell lysis (natural secretion of enzymes),Natural expression level; no controllable output mechanism described,Compatible with suspension in liquid media; EPS may enhance stability in gastrointestinal environment,False,False,False,,,False,False,False,False,未提及抗菌或抗生物膜功能。,False,,,False,False,False,未提及产氧功能。,False,,,False,,,True,通过降解草酸盐降低肠道草酸盐浓度，从而减少草酸钙结石形成风险，调节宿主草酸代谢。,Oxalate (降解产物：CO2 + formate),False,,,GRAS,"None (natural strain, no synthetic kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; non-pathogenic in human gut,None (no physical confinement described),L. rhamnosus MP1为食品级安全菌株，无致病性，无抗生素抗性基因，未进行基因改造，无逃逸风险，属于GRAS级别，安全性高。,该菌株在含20 mM草酸盐的培养基中仍能保持高存活率（97%以上），并在10 mM和20 mM草酸盐条件下表现出良好的降解活性，未受草酸盐抑制，表明其在预防草酸钙结石方面具有显著潜力。,20589,4266,24855,,
16e4c555-1a41-4ba8-9e51-ba0f95e2b7a5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Serratia marcescens"", ""strain_id"": ""Wild-type""}]",Encapsulated (on surface of polystyrene microbeads),Facultative Anaerobe,"Optimal growth at 30–37 °C, neutral pH, moderate osmotic strength; adheres to both hydrophobic and hydrophilic surfaces","High motility speed (up to ~15 μm/s in unpatterned beads); doubling time not specified, but high adhesion strength suggests robust in vitro growth",Surface-attached in aqueous environments; not colonizing host tissues,"Not applicable (non-host-associated, used in vitro)",High adhesion strength to diverse surfaces; tolerance to shear and environmental fluctuations in lab conditions,Flagella and surface adhesins,Serratia marcescens 是一种具有鞭毛的化能异养细菌，可在多种表面（包括疏水和亲水表面）上高效附着，表现出高运动速度和强粘附力，适合在体外微环境中的生物驱动应用。,"Not applicable (wild-type strain used, no genetic modification reported)",,Constitutive (natural motility behavior),,Not applicable (no plasmid or engineered genetic circuit),Stable attachment to polystyrene microbeads via surface modification,该系统未进行基因工程改造，直接使用野生型 Serratia marcescens 细菌，通过等离子体表面图案化技术将其定向附着于聚苯乙烯微珠表面，以实现可控的生物驱动性能。,"[""Hypoxia"", ""pH"", ""Osmotic strength""]","[""Glucose"", ""Lactate""]",,,Flagellar motor and chemotaxis system (inherent in wild-type S. marcescens),No synthetic logic; natural run-and-tumble behavior follows stochastic decision-making based on chemotactic gradients,Serratia marcescens 具有天然的趋化性系统，通过随机的“运行-翻滚”模式响应环境中的化学梯度，实现非定向但高效的运动。该系统未引入人工逻辑门控机制。,"[""Propulsion""]",Flagellar propulsion (mechanical actuation via flagella),Controlled by number and spatial configuration of attached bacteria,High compatibility with polystyrene microbeads; stable under fluid shear and during motion,False,,,Not applicable (no antibacterial function),,False,False,False,False,无抗菌功能，不适用,False,Not applicable (no oxygen production or consumption reported),,False,False,False,无氧生成功能，不适用,False,Not applicable (no immune-modulating molecules secreted),,False,Not applicable (no tissue repair factors produced),,False,Not applicable (no metabolic regulation observed),,False,Not applicable (no tumor-targeting or prodrug conversion function),,BSL-1,"None (wild-type, non-pathogenic in standard lab conditions)",,Low pathogenicity; not known to cause human disease; no antibiotic resistance genes reported; low risk of horizontal gene transfer in lab setting,Physical confinement by microbead encapsulation and lab containment,Serratia marcescens 为 BSL-1 级生物，无已知致病性，未在本研究中进行基因改造，无抗生素抗性基因，且通过微珠物理封装实现生物隔离，风险极低。,本研究聚焦于细菌驱动微珠的运动性能，未涉及伤口愈合或治疗效果。实验表明，通过等离子体图案化技术将细菌限制在微珠表面的一半区域，可使推进速度从 14.8 ± 1.1 μm/s 提升至 28.2 ± 10.5 μm/s，提升近一倍，验证了细菌配置对集体推进力的关键影响。,7718,1475,9193,,
1a388a62-be38-4c93-8814-52ea8964126e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis ssp. lactis"", ""strain_id"": ""BB-12""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 3.09 (acidic), requires anaerobic conditions for cultivation",Growth rate not explicitly reported; maintained viability during storage at 4°C with recovery of sub-lethally injured cells,Gut microbiota (implied by probiotic function),Potential symbiosis with host gut microbiota; no competition with other microbes reported,"Moderate tolerance to heat (spray drying at 130°C inlet), low moisture, and storage at 25°C; better survival with inulin encapsulation",Inulin (as thermoprotector and stabilizer),该菌株为乳酸杆菌亚种，适宜在37°C、pH 3.09的酸性环境中生长，需厌氧条件培养。在喷雾干燥过程中表现出一定热稳定性，尤其在使用菊粉作为包埋剂时，细胞存活率显著提高。在4°C冷藏条件下，细胞活力持续维持在6 log CFU/g以上，且有恢复性增长，表明其在低温下具有良好的生理稳定性。,Not applicable (no genetic modification reported),Null,Constitutive,Null,Null (no plasmid or chromosomal integration reported),Null,该系统未进行基因工程改造，仅通过物理包埋技术（喷雾干燥）实现微胶囊化，利用麦芽糊精和/或菊粉作为壁材，以保护菌体在加工和储存过程中的活性。,"[""pH"", ""Temperature""]","[""Organic Acids (Citric Acid)"", ""Sugars (Low molecular weight)""]",,,Null,Null,该系统未设计任何感知模块或逻辑控制回路，仅依赖于物理包埋以响应环境变化（如pH、温度），无主动感知或调控机制。,"[""Metabolic Regulation""]",Passive release via microcapsule degradation,Controlled by encapsulation matrix and release kinetics,Good compatibility with maltodextrin and inulin matrices; inulin provides slower release,False,False,False,Null,Null,False,False,False,False,未提及抗菌功能,False,Null,Null,False,False,False,未提及氧合功能,False,Null,Null,False,Null,Null,True,通过调节肠道菌群平衡，促进有益菌定植，改善肠道微生态，可能通过产生短链脂肪酸（SCFAs）等代谢产物发挥调节作用。,Short-Chain Fatty Acids (SCFAs),False,Null,Null,GRAS,Null,Null,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; safe for human consumption,Physical barrier provided by microcapsule matrix (maltodextrin/inulin),Bifidobacterium animalis ssp. lactis BB-12为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，且通过微胶囊物理屏障实现环境隔离，风险极低。,该产品为功能性非乳基益生菌饮料，经30天储存后，在4°C条件下，BB-12菌株存活量保持在6 log CFU/g以上，符合益生菌产品标准；在25°C下，使用菊粉包埋的样品（PFI）仍能维持高于6 log CFU/g的存活率，表明其在常温下具有良好的稳定性。菊粉包埋显著提升菌体在干燥和储存过程中的存活率，同时改善了粉末的物理稳定性（低吸湿性、低结块倾向）。,15632,1451,17083,,
1ab4ec72-2064-4c6a-8cbe-ebb09bc56dbe,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires carbohydrates (e.g., lactose, fructose) as carbon sources; dependent on host-derived nutrients in gut environment",Doubling time ~1–2 hours in vitro; in vivo colonization observed within 24–48 hours post-administration,"Intestinal lumen, particularly colon and ileum; preferentially adheres to mucus layer in gut epithelium",Competitive exclusion of pathogenic bacteria; synergistic interactions with resident commensals; may enhance microbial diversity,Moderate tolerance to gastric acid and bile salts; stable during lyophilization and rehydration; sensitive to high shear stress and UV radiation,"Bile salts, mucin, and protective encapsulation materials (e.g., alginate, chitosan)",该系统以乳酸杆菌和双歧杆菌为底盘菌株，属于兼性厌氧菌，适宜在37°C、pH 6.5–7.0的肠道环境中生长。其生长依赖于碳水化合物（如乳糖、果糖）作为碳源，在体外培养中倍增时间为1–2小时，体内定植可在24–48小时内实现。主要定植于肠道黏膜层，通过竞争性排斥病原菌并促进菌群多样性，发挥有益作用。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未涉及基因工程改造，所有菌株均为天然存在的益生菌，未进行人工基因编辑或合成回路构建。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""Short-Chain Fatty Acids (SCFAs)""]","[""Quorum Sensing (AI-2)""]","[""Cytokines (e.g., IL-6, TNF-α)"", ""Mucin""]","FNR promoter, Lactate receptor (LctP), AI-2 receptor (LuxPQ)",Not specified,该系统依赖于天然代谢感应机制，如乳酸感知、pH变化响应及AI-2信号分子感知，通过调控代谢通量和黏附能力实现对肠道微环境的适应性响应，但未构建人工逻辑门控系统。,"[""Metabolic Regulation"", ""Immunomodulation""]","Type IV secretion system (natural), Vesicles (exosomes)",Dose-dependent effects observed; efficacy varies with dosage and duration of supplementation,"Compatible with oral delivery systems (e.g., capsules, tablets); stable in gastrointestinal tract",False,,,Not applicable,,,,,,未涉及抗菌功能,False,Not applicable,,,,,未涉及氧合功能,True,通过调节肠道免疫反应，降低促炎因子（如IL-6、TNF-α）水平，增强抗炎因子（如IL-10）分泌，改善肠道屏障功能，减轻慢性低度炎症状态。,"IL-10, TGF-β, SCFAs (e.g., butyrate)",False,Not applicable,,True,通过产生短链脂肪酸（SCFAs）如丁酸、乙酸和丙酸，调节宿主能量代谢，改善胰岛素敏感性，降低空腹血糖和糖化血红蛋白水平。,"Butyrate, Acetate, Propionate",False,Not applicable,,GRAS,Natural attenuation; no genetic modifications or kill switches,None,Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape,Gastrointestinal tract acts as natural barrier; limited systemic translocation,该系统使用的是公认安全（GRAS）的益生菌株，无基因改造，不携带抗生素抗性基因，无生物安全风险。其在肠道内定植后通过自然衰减机制清除，不会造成环境释放或长期定植，安全性高。,本研究旨在系统评价益生菌、益生元和合生元在糖尿病前期患者中的疗效。结果显示，补充益生菌可显著降低糖化血红蛋白（HbA1c）和空腹血糖水平，改善胰岛素抵抗指数和胰岛素敏感性，同时降低炎症标志物水平，具有良好的代谢调节和免疫调节作用。,5994,1643,7637,,
e4612f54-693b-4a3e-832c-ddfebd8289ee,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacteriophage"", ""strain_id"": ""N/A""}]",Suspension,N/A,N/A,N/A,N/A,N/A,N/A,N/A,噬菌体是感染细菌的病毒，不依赖宿主细胞以外的营养生长，其生命周期包括吸附、注入、复制、组装和裂解等阶段。在体外可通过宿主细菌培养扩增，对温度、pH等环境因素敏感，需冷藏保存以维持活性。,N/A,N/A,N/A,N/A,N/A,N/A,噬菌体天然具有高度特异性，无需人工基因编辑即可靶向特定细菌。部分研究尝试通过基因工程改造噬菌体，增强其宿主范围或引入报告基因，但文中未提及具体工程化手段。,"[""N/A""]","[""N/A""]","[""N/A""]","[""N/A""]",N/A,N/A,噬菌体通过其尾部结构识别宿主细菌表面的特异性受体，实现精准靶向，该过程为天然的‘门控’机制，无需复杂逻辑电路。,"[""Antibacterial""]",Lysis,N/A,N/A,True,False,False,噬菌体通过吸附宿主细菌并注入其基因组，利用宿主细胞的复制机制进行自我复制，最终导致细菌裂解死亡。该过程具有高度特异性，仅针对特定细菌株。,Bacteriophage (lytic type),False,True,True,True,噬菌体仅感染特定细菌，不破坏人体细胞或正常菌群，且在临床案例中成功治疗了伤寒和霍乱，表明其具有良好的安全性与局部作用边界。,False,N/A,N/A,False,False,False,N/A,False,N/A,N/A,False,N/A,N/A,False,N/A,N/A,False,N/A,N/A,BSL-1,N/A,N/A,噬菌体具有高度宿主特异性，不会感染真核细胞或非目标细菌，因此无致病性风险。但存在潜在的基因水平转移风险，如温和噬菌体携带毒力基因，可能引发细菌致病性增强。,N/A,噬菌体作为天然病毒，仅感染特定细菌，对人体无直接毒性，且在历史上已有成功治疗案例。但需注意避免使用温和噬菌体或未纯化的制剂，以防基因转移或杂质引发不良反应。,在历史案例中，噬菌体成功治愈了患伤寒的母亲，且在霍乱、细菌性痢疾等感染中显示出显著疗效。在动物模型和体外实验中，噬菌体可有效清除特定病原菌，具有良好的治疗潜力。,5908,1251,7159,,
59f16d7b-4428-4c4e-b0e2-105403dec3cd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Aeromonas sobria"", ""strain_id"": ""A3-51""}]",Oral administration via feed with sodium alginate encapsulation,Facultative Anaerobe,Growth at 22°C on TNA with 1% NaCl; optimal growth in tryptone soya broth (TNB) supplemented with 1% NaCl,Growth rate not explicitly quantified; cultured for 24 h at 22°C for experiments,Gut of rainbow trout (Oncorhynchus mykiss),Competitive inhibition of Vibrio harveyi; cross-reactivity with V. harveyi antigens suggests potential for immune modulation without disrupting native microbiota,Tolerant to storage in sodium alginate and calcium chloride solidification; stability during oral delivery confirmed by in vivo efficacy,Sodium alginate and CaCl₂ for encapsulation,"A3-51 is a facultative anaerobe capable of growing at 22°C in standard marine broth (TNA/TNB) with 1% NaCl. It is orally administered to rainbow trout via feed encapsulated in sodium alginate, indicating tolerance to gastrointestinal conditions and stability during processing and delivery.",,,Constitutive (natural expression),,No genetic modifications reported; natural strain used; stability inferred from consistent immune response over 6 weeks of feeding,Stable in sodium alginate matrix; maintains viability and immunogenicity during encapsulation and oral delivery,"No genetic engineering was performed. A3-51 was used as a naturally occurring probiotic strain with inherent immunogenic properties. Its ability to induce cross-reactive antibodies against Vibrio harveyi is due to native surface antigens, not engineered circuits.",,,,,Native outer membrane proteins (OMPs) and extracellular products (ECPs) of A3-51,No synthetic logic gates; immune response triggered by antigen recognition via natural immune system,"A3-51 does not possess engineered sensing circuits. Immune activation occurs through natural recognition of conserved outer membrane proteins (e.g., ~93 kDa band) by the host immune system, leading to antibody production and cross-reactivity with V. harveyi.","[""Immunomodulation"", ""Tissue Repair""]",Natural secretion of OMPs and ECPs; no engineered secretion systems used,Oral administration of 50 μg antigen per fish per week for 6 weeks; dose controlled by feed formulation,Highly compatible with sodium alginate encapsulation; stable during solidification with CaCl₂; maintains viability and immunogenicity,False,,,Not applicable; no direct antibacterial mechanism reported,,False,,,,"No evidence of direct antibacterial activity; protection is immune-mediated, not due to bacteriocin production or direct killing.",False,Not applicable; no oxygen-producing enzymes or mechanisms reported,,False,False,False,No evidence of oxygenation function; not involved in hypoxia alleviation.,True,Induces production of cross-reactive antibodies against Vibrio harveyi via recognition of conserved outer membrane proteins (OMPs) and extracellular products (ECPs). Enhances lysozyme activity and systemic immune response.,Outer membrane proteins (OMPs) and extracellular products (ECPs) of A3-51 (specifically a ~93 kDa protein),True,"Promotes tissue healing by enhancing innate immune responses, including increased lysozyme activity and macrophage function, which support tissue integrity and pathogen clearance.","Lysozyme, macrophage respiratory burst, and bacteriocidal activity",False,Not applicable; no evidence of metabolic product secretion affecting host metabolism,,False,Not applicable; no tumor-targeting or prodrug conversion mechanisms reported,,GRAS,Natural strain with no genetic modifications; no kill-switches or auxotrophy reported,,Low pathogenicity; isolated from rainbow trout; no antibiotic resistance genes or HGT risk reported; non-opportunistic in fish hosts,Sodium alginate and CaCl₂ encapsulation provides physical barrier to environmental release,"A3-51 is a naturally occurring, non-pathogenic strain isolated from rainbow trout. It is considered safe for use in aquaculture with no evidence of virulence, antibiotic resistance, or horizontal gene transfer. Encapsulation further reduces environmental escape risk.","Fish fed with A3-51 showed 70% relative percentage survival (RPS) against Vibrio harveyi infection, comparable to intraperitoneal vaccination (80% RPS). The probiotic induced strong cross-reactive antibody titres (ELISA limit dilution >12,800) and increased lysozyme activity, indicating effective immune stimulation and protection.",17779,1639,19418,,
cfdd5ca1-615a-4e86-bed2-f00c57ea083f,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""Y20""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus murinus"", ""strain_id"": ""Y74""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""HT47""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""HT119""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""HT121""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium adolescentis"", ""strain_id"": ""ATCC15703""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""ATCC15697""}]",Suspension,Facultative Anaerobe,Grown in MRS medium under anaerobic conditions; acid-tolerant (pH 2.0) and bile salt-tolerant (0.3% bovine bile salt),"Not explicitly reported; assumed to grow in vitro under standard conditions (37°C, anaerobic), but no in vivo doubling time or growth rate provided","Gut lumen, particularly after antibiotic-induced dysbiosis; transient colonization without long-term persistence","Modulates gut microbiota by increasing Firmicutes and Bacteroidetes, decreasing Proteobacteria and Verrucomicrobia; promotes beneficial taxa (e.g., Butyricicoccus, Ruminococcus) and suppresses C. difficile-associated taxa (e.g., Akkermansia, Bacteroides)",Tolerant to low pH (pH 2.0) and bile salts (0.3% bovine bile salt); stability during oral administration and storage in PBS not detailed,Bovine bile salt (0.3%) and low pH (2.0),该益生菌群由五株乳杆菌和两株双歧杆菌组成，均具有耐酸和耐胆盐特性，可在肠道环境中存活并发挥功能。尽管其在肠道中无法长期定植，但可通过代谢产物调节肠道菌群结构和胆汁酸谱，从而抑制艰难梭菌的定植。,,,,,No genetic modifications reported; natural strains used without plasmid or chromosomal integration,No engineered genetic circuits; stability in suspension form not assessed,该益生菌群为天然菌株混合物，未进行基因工程改造。其功能依赖于各菌株的天然代谢能力，如产生短链脂肪酸、调节胆汁酸代谢等，而非人工设计的基因回路。,"[""pH"", ""Bile Salts""]","[""Primary Bile Acids"", ""Secondary Bile Acids"", ""Short-Chain Fatty Acids""]",,,Natural metabolic adaptation to bile acids and low pH; no specific receptor or promoter identified,No synthetic logic gates; natural physiological responses to environmental cues,各菌株通过天然耐酸性和耐胆盐能力感知肠道环境，响应低pH和胆盐浓度，从而在抗生素破坏后的肠道中存活并发挥调节作用。其功能不依赖于人工设计的传感逻辑，而是基于自然生理适应性。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Antibacterial""]","Natural secretion of metabolites (e.g., SCFAs, bile acid-modifying enzymes)",Dose-dependent effect observed (9-day oral gavage at 4×10⁸ CFU/mL); no feedback control system,Compatible with oral suspension delivery; no encapsulation or material barrier mentioned,True,False,False,通过调节肠道菌群结构和胆汁酸代谢，间接抑制艰难梭菌定植，而非直接分泌抗菌物质,None (indirect mechanism),False,True,True,True,该菌群通过降低初级胆汁酸、升高次级胆汁酸水平，抑制艰难梭菌生长；同时增加有益菌群（如Butyricicoccus、Ruminococcus），减少炎症反应，表明其作用具有可控性和安全性。,False,,,False,False,False,,True,降低结肠组织中IL-12和Reg3-β的mRNA表达水平，减轻炎症反应,"IL-12, Reg3-β",False,,,True,显著降低初级胆汁酸（如TCA、TUDCA）水平，升高次级胆汁酸（如DCA、LCA）水平，同时调节短链脂肪酸（如丁酸）水平,"Primary Bile Acids, Secondary Bile Acids, Butyric Acid",False,,,BSL-1,No engineered kill switches or auxotrophy; natural strains used,None,"No antibiotic resistance genes reported; strains are well-characterized (ATCC strains); potential risk from wild marmot-derived strains (L. murinus Y74, L. plantarum HT47, HT121) requires further safety evaluation","None (oral suspension, no physical confinement)",该益生菌群由标准菌株和野生来源菌株组成，整体为BSL-1级别。虽无基因工程改造，但来自西藏野生旱獭的三株乳杆菌需进一步评估其安全性。菌群在肠道中为瞬时定植，无长期滞留风险，且未见明显致病性或耐药性报道。,在小鼠模型中，口服给予该益生菌群9天后，艰难梭菌在粪便中的拷贝数显著降低（第10天时从7.53±0.20降至5.77±0.62，P<0.001）；结肠组织炎症评分显著下降，IL-12和Reg3-β mRNA表达水平降低，表明其具有良好的抗感染和抗炎效果。,16171,1979,18150,,
99474bfa-516b-426e-9738-936c654b02e4,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""Recombinant strain expressing E. coli appA phytase""}]","Encapsulated (in feed, gut environment)",Facultative Anaerobe,Growth at 30°C in M17 broth with erythromycin; pH and osmotic tolerance not specified,Growth rate not quantified; cultured at 30°C for 24–48 h prior to use,"Gastrointestinal tract of broiler chickens (intestine, particularly jejunum)",Co-administered with Lactobacillus salivarius; may compete or synergize with native gut microbiota,Tolerant to lyophilization and storage at 4°C; cryoprotected with 6% skimmed milk and 12% sucrose,6% skimmed milk and 12% sucrose (cryoprotectant),该重组乳酸乳球菌在30°C下于M17培养基中培养，通过电穿孔法导入大肠杆菌appA基因，具有表达植酸酶的能力。其在鸡肠道环境中可稳定存活并发挥功能，具有良好的耐受性，适用于饲料添加。,Electro-transformation of E. coli appA phytase gene into L. lactis,High efficiency (successful expression of phytase in gut environment); no off-target risk mentioned,Constitutive (gene expression not regulated by inducer),,Stable in gut environment; no mention of plasmid loss or drift; maintained via erythromycin selection in vitro,Stable in feed matrix and gut environment; cryoprotected for storage,通过电穿孔将大肠杆菌appA植酸酶基因导入乳酸乳球菌，构建重组菌株，使其在鸡肠道中持续表达植酸酶，从而提高植酸磷的降解效率。,,,,,,No sensing logic; constitutive expression of phytase,该系统为组成型表达，不依赖于任何环境信号，植酸酶在肠道中持续释放，无需外部调控。,"[""Metabolic Regulation""]",Constitutive secretion (no specific secretion system mentioned),Not controllable; constitutive expression in gut environment,Compatible with feed matrix and intestinal environment; stable after lyophilization,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,通过表达植酸酶降解饲料中的植酸磷，提高磷、钙、镁、铁等矿物质的生物利用度，促进营养吸收和骨骼发育。,Phytase (appA gene product from E. coli),False,,,BSL-1,Auxotrophy (erythromycin-dependent growth in vitro; not specified in vivo),Erythromycin,Low pathogenicity; non-pathogenic strain; no antibiotic resistance genes mentioned; no horizontal gene transfer risk reported,Physical confinement via feed delivery; no engineered containment in gut,该重组乳酸乳球菌为非致病性菌株，使用抗生素（红霉素）进行体外筛选，体内无选择压力，安全性高，符合GRAS标准。,在磷缺乏日粮中，重组乳酸乳球菌显著提高了肉鸡的体重、日增重、饲料转化率、植酸磷的表观消化率、磷和钙的保留率，以及胫骨的长度和强度，效果与商业植酸酶（Hostazym®）相当。同时，与L. salivarius联用可显著改善空肠绒毛高度和表面积，促进肠道健康。,16831,1424,18255,,
824e4c3a-1cf6-4f4b-a8e5-9bf8b6cb5d5d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus durans"", ""strain_id"": ""DB-1aa""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""DB-b2-15b""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Cu2-PM7""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""Cu3-PM8""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""IB-pM15""}]",Suspension,Facultative Anaerobe,"Temperature: 30–40 °C; pH: 4–9; NaCl: up to 2%; Carbon sources: glucose, fructose, sucrose, mannose, lactose, maltose, xylose, trehalose, raffinose, cellobiose, inulin, sodium gluconate, salicin, dulcitol, mannitol, adonitol, arabinose, sorbitol, erythritol, α-methyl-d-glucoside, rhamnose, melezitose, α-methyl-d-mannoside, xylitol, ONPG, esculin",Growth rate: Not explicitly quantified; Doubling time: Not reported; In vitro growth confirmed in MRS medium at 37 °C; In vivo homeostasis not assessed,Gastrointestinal tract (implied by probiotic evaluation in Caco-2 cells and simulated GI conditions),"Co-aggregation with pathogens (S. aureus, E. coli, L. monocytogenes, P. aeruginosa, etc.) suggests competitive exclusion potential; no direct evidence of symbiosis with host microbiota","Acid tolerance (pH 2–3), bile resistance (up to 1.5% ox-bile), survival under simulated gastric (pH 2.5) and intestinal (pH 8.0) conditions; tolerance to osmotic stress (2% NaCl); no data on UV, drying, or shear stress","Bile salts (ox-bile), low pH (HCl), simulated gastric juice (pepsin, NaCl, NaHCO3)",这些乳酸菌分离自发酵食品，具有良好的酸耐受性和胆汁耐受性，能在模拟胃肠道环境中存活，表明其具备作为益生菌在肠道定植的生理基础。,"RAPD-PCR, 16S rDNA sequencing",Not applicable (no genetic modification reported),Constitutive (no inducible systems described),,Not assessed (no plasmid or chromosomal integration data reported),Not assessed (no encapsulation or material environment described),通过16S rDNA测序和RAPD-PCR进行物种鉴定，未进行任何基因工程改造，系统为天然分离菌株。,"[""Acidity"", ""Bile""]","[""Glucose"", ""Fructose"", ""Sucrose"", ""Mannose"", ""Lactose"", ""Maltose"", ""Xylose"", ""Trehalose"", ""Raffinose"", ""Cellobiose"", ""Inulin"", ""Sodium gluconate"", ""Salicin"", ""Dulcitol"", ""Mannitol"", ""Adonitol"", ""Arabinose"", ""Sorbitol"", ""Erythritol"", ""α-methyl-d-glucoside"", ""Rhamnose"", ""Melezitose"", ""α-methyl-d-mannoside"", ""Xylitol"", ""ONPG"", ""Esculin""]",,,Not specified (no specific receptor or promoter identified),No logic circuits described; response is likely constitutive based on growth and survival assays,未检测到特定的信号感应模块或逻辑门控机制，所有功能基于天然生理特性，无工程化调控。,"[""Antibacterial"", ""Antioxidant"", ""Adhesion""]",Cell-free supernatant (CFS) secretion; likely via passive diffusion or general secretion systems,Not controllable (natural production; no inducible or tunable systems),Not assessed (no material encapsulation or delivery system described),True,True,False,通过产生抗菌化合物（AMC）抑制多种食源性病原菌，包括M. luteus、S. aureus、E. coli、P. aeruginosa、K. pneumoniae、S. typhimurium、S. flexneri、L. monocytogenes、B. subtilis等。,"Antimicrobial compounds (AMC), likely bacteriocins (e.g., lantibiotics)",True,,,,在琼脂孔扩散实验中对多种常见食源性病原体表现出抑菌圈，证明其广谱抗菌活性。,False,,,False,False,False,未检测到氧气生成或相关酶活性。,False,,,False,,,False,,,False,,,GRAS,None (no kill-switch or auxotrophy reported),,"Non-hemolytic, non-gelatinase, non-lecithinase, non-biogenic amine-producing; antibiotic susceptibility tested (no resistance to vancomycin, gentamycin, etc. reported); low pathogenicity risk; no horizontal gene transfer data",Not applicable (no physical material barrier described),所选菌株均无溶血、蛋白酶、磷脂酶活性，不产生生物胺，且对多种抗生素敏感，符合GRAS标准，安全性较高。,所选菌株在模拟胃肠道条件下具有良好的存活率，表现出强酸耐受性、胆汁耐受性及对多种病原菌的抑制能力，且能有效黏附于Caco-2细胞，具备作为功能性食品益生菌的潜力。,18272,1974,20246,,
444c4b5b-fa43-41bb-99a1-67d9605be529,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acidity; utilizes lactose and other carbohydrates as carbon sources; dependent on host-derived nutrients in gut environment","Doubling time ~60–90 minutes in vitro; in vivo colonization observed within 24–48 hours post-ingestion, with transient persistence in gut lumen",Small intestine and colon (mucosal surface and lumen); preferentially colonizes mucosal layer of intestinal tract,"Competes with pathogenic bacteria (e.g., *Clostridium*, *Salmonella*) for nutrients and adhesion sites; promotes symbiosis with resident microbiota by enhancing SCFA production and barrier integrity",Moderate tolerance to bile salts and low pH; limited survival under drying and UV stress; stable during refrigerated storage (4°C) for up to 6 months,"Bile salt hydrolase (BSH), acid tolerance response (ATR) genes",乳酸杆菌和双歧杆菌为兼性厌氧菌，可在37℃、pH 5.5–6.5条件下生长，耐受胃酸和胆汁，利用乳糖等碳源，在肠道中可定植于黏膜表面，通过竞争性排斥病原菌并促进有益菌群平衡，维持肠道微生态稳态。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,目前文献未提及对乳酸杆菌或双歧杆菌进行基因工程改造，其功能主要依赖天然代谢特性，如产酸、黏附、抑制病原菌等。,"[""pH"", ""Lactate"", ""Glucose""]","[""Inulin-type fructans"", ""Bile acids""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), Lactate-responsive promoters, Bile acid sensors (e.g., BshR)",Not specified,未明确描述其信号感知逻辑，但天然具备对环境pH、乳酸、胆汁酸等变化的响应能力，可能通过代谢调控网络实现阈值感应与动态适应。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Antibacterial & Antibiofilm""]","Type I secretion system (for bacteriocins), Vesicles (exosomes-like), Lysis (natural release)",Not applicable (natural colonization and transient presence; dosage not externally controllable),Compatible with fermented dairy and plant-based matrices; stable in yogurt and capsule forms,True,False,True,通过产生乳酸、细菌素（如acidolin）和 biosurfactants 抑制病原菌生长，同时干扰生物膜形成，增强肠道屏障功能。,"Lactic acid, Bacteriocins (e.g., acidolin), Biosurfactants",False,True,True,True,乳酸杆菌和双歧杆菌在体外对沙门氏菌、大肠杆菌等病原菌具有抑制作用，且能减少生物膜形成，同时对宿主细胞无明显毒性，定植后可被自然清除。,False,Not applicable,,False,False,False,未涉及氧气生成机制，无相关证据。,True,通过调节树突状细胞和T细胞反应，促进抗炎性细胞因子（如IL-10）分泌，抑制促炎因子（如TNF-α、IL-6），增强黏膜免疫屏障。,"IL-10, TGF-β, Secreted exopolysaccharides (EPS)",False,Not applicable,,True,通过发酵可溶性纤维（如菊粉）产生短链脂肪酸（SCFAs），如乙酸、丙酸和丁酸，调节宿主能量代谢、血糖稳态和脂质合成。,"Short-chain fatty acids (SCFAs): Acetate, Propionate, Butyrate",False,Not applicable,,GRAS,"Natural attenuation (transient colonization, no long-term persistence)",None (no synthetic kill-switches or auxotrophy used),Low pathogenicity; no known antibiotic resistance genes reported; minimal horizontal gene transfer risk; no environmental escape due to poor survival outside host,"Physical confinement in food matrix (e.g., yogurt, capsules) limits environmental release",乳酸杆菌和双歧杆菌被广泛认定为GRAS（公认安全）菌株，天然存在于人体肠道，无致病性，不携带耐药基因，定植后可自然清除，安全性高，适合作为功能性食品成分。,在多项人体研究中，乳酸杆菌和双歧杆菌可缓解乳糖不耐受症状，改善腹泻（尤其是抗生素相关性腹泻），增强免疫功能，降低粪便中致癌酶活性，提示其在调节肠道健康和预防慢性疾病方面具有潜在疗效。,3785,1748,5533,,
be63b53e-bbdf-4fc4-9227-d87f5eb2d1d1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Adeno-associated virus serotype 2"", ""strain_id"": ""AAV2""}]",Encapsulated,,"Temperature: 37°C; pH: physiological (not explicitly stated); Nutritional requirements: None (viral vector, not a living organism); Host cell dependency: Human colonic cell lines (COLO 205, MIP-101, SW620), HeLa cells","Not applicable (viral vector, not a replicating organism)",Inflamed colon mucosa and submucosa (in vivo); Colonic epithelial cells (in vitro),,Stable under storage and handling conditions (implied by use in experiments); Tolerance to freeze-thaw cycles (implied by cryosectioning in vivo),None (non-living vector),"AAV2 is a non-replicating viral vector that relies on host cells for gene expression. It shows poor transduction efficiency in free form for colonic cell lines and inflamed colon tissue, but its delivery is significantly enhanced when conjugated to microbeads with lectin. It does not grow or replicate independently.",Biotinylation with sulfo-NHS-LC-biotin; Conjugation via avidin-biotin interaction,High efficiency (>95% binding of AAV2 to microbeads); No off-target risk (non-genetic modification),Constitutive (CMV promoter drives lacZ expression),None (constitutive expression),High stability in microbead conjugates; No plasmid or chromosomal integration (viral vector does not integrate unless engineered),High stability in microbead matrix; Conjugation maintains functional integrity,"AAV2 was biotinylated on its surface using sulfo-NHS-LC-biotin, then conjugated to avidin-coated fluorescent microbeads. Lectin (Con A) was co-attached to the microbead surface to enhance cell binding. This engineered system enables targeted delivery and efficient transduction of poorly permissive colonic cells and inflamed colon tissue.",,,,,Concanavalin A (Con A) – binds α-D-mannosyl moieties on host cell surface carbohydrates,No logic gates; simple binding mechanism based on lectin-carbohydrate interaction,"The system relies on the non-specific, high-affinity binding of Con A to α-D-mannosyl residues abundantly present on the surface of colonic epithelial cells. This binding facilitates stable association of the AAV2-microbead conjugates with target cells, enabling efficient transduction. No dynamic regulation or signal processing occurs.","[""Gene Delivery""]",Viral transduction (AAV2-mediated gene delivery),Controlled by number of AAV2 particles per microbead and total dose administered,High compatibility with microbead encapsulation; microbeads provide physical protection and enhance retention in inflamed tissue,False,,,None,,,,,,Not applicable,False,None,,,,,Not applicable,False,None,,False,None,,False,None,,False,None,,BSL-1,None (non-replicating viral vector; no autonomous replication),None,Low pathogenicity; no known human disease association; no antibiotic resistance genes; no horizontal gene transfer (non-integrating in this study); low environmental escape risk,Microbeads provide physical confinement and reduce systemic spread,"AAV2 is a non-pathogenic, non-replicating viral vector with a strong safety profile. It does not integrate into the host genome in this study, minimizing mutagenesis risk. The microbead conjugation enhances localized delivery and reduces systemic exposure, further improving safety.","In the mouse colitis model, AAV2-microbead conjugates bearing Con A achieved efficient transduction of the inflamed colon, primarily in the mucosal layer, crypts, and submucosal layer. Transduction was significantly enhanced (up to 30-fold in COLO 205 cells) compared to free AAV2 or conjugates without lectin. This system enables sustained transgene expression in target tissues, making it highly effective for long-term gene therapy strategies in inflammatory bowel disease.",15027,1532,16559,,
2f018fb0-81d5-4fa1-b3e5-6f62429c1d40,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""IL-10 secreting strain""}]",Suspension,Facultative Anaerobe,"Optimal growth at 30–37°C, pH 6.0–7.0, requires lactose or glucose as carbon source; no specific bile or osmotic tolerance mentioned",Growth rate not specified; used in oral administration for in vivo studies,Intestinal lumen (colonic mucosa),No direct competition or symbiosis described; designed to coexist with native microbiota,Not explicitly mentioned; assumed moderate stability under gastrointestinal conditions,,"Lactococcus lactis is a facultative anaerobe, commonly used in probiotic applications, capable of surviving in the intestinal environment and colonizing the gut mucosa after oral administration. It is metabolically versatile, utilizing lactose and glucose as primary carbon sources, and maintains viability under physiological pH and temperature conditions.",Plasmid-based gene expression (IL-10 expression vector),High efficiency in recombinant protein expression; no off-target risk reported,Constitutive (IL-10 expression under strong promoter),,Stable plasmid maintenance in vivo; no significant drift reported in mouse models,Compatible with oral delivery and intestinal environment,"Lactococcus lactis was genetically modified to constitutively express human interleukin-10 (IL-10) via a plasmid vector. This engineered strain was used in mouse models of colitis to deliver anti-inflammatory cytokines directly to the intestinal mucosa, demonstrating significant attenuation of inflammation.",,,,,,No complex logic; constitutive expression without environmental sensing,"The engineered Lactococcus lactis strain does not incorporate environmental sensing or dynamic regulation. It constitutively secretes IL-10 regardless of local conditions, relying on passive delivery to inflamed tissues.","[""Immunomodulation""]",Constitutive secretion via general secretion pathway,Not controllable; constitutive expression leads to sustained IL-10 release,Compatible with oral delivery and intestinal mucosal environment,False,False,False,Not applicable,,False,False,False,False,无,False,Not applicable,,False,False,False,无,True,"Engineered L. lactis secretes human IL-10, which suppresses pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and promotes regulatory T cell activity, thereby reducing mucosal inflammation in colitis models.",Interleukin-10 (IL-10),False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,No specific kill-switch or auxotrophy reported; relies on natural attenuation,,"Low pathogenicity; non-pathogenic, GRAS status; no antibiotic resistance genes reported; minimal risk of horizontal gene transfer",Oral delivery limits systemic spread; intestinal confinement reduces environmental escape risk,"Lactococcus lactis is a well-established GRAS organism with no known pathogenicity. It is not capable of causing disease in humans and is naturally cleared from the gut. No biocontainment systems were used, but its inherent biological safety and transient colonization make it a low-risk therapeutic agent.",在DSS诱导的结肠炎小鼠模型中，口服工程化L. lactis（分泌IL-10）可使结肠炎症状减轻约50%，显著降低TNF-α、IL-6、IL-1β等促炎因子水平，改善肠道屏障功能，促进黏膜修复。,13249,4229,17478,,
2f018fb0-81d5-4fa1-b3e5-6f62429c1d40,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""pBDMSH or PEP-1-hMnSOD vector""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex nutrients including sugars and amino acids; bile tolerance not explicitly stated",Growth rate not specified; survives in intestinal environment post-oral administration,Colon lumen and mucosal surface,Competes with pathobionts; may promote symbiosis by enhancing anti-inflammatory environment,Moderate tolerance to gastric acidity and bile; lyophilization stability not mentioned,"Bile salts, gastric acid (inferred from probiotic use)",Bifidobacterium longum is a facultative anaerobe commonly found in the human gut. It thrives in the colon under neutral to slightly acidic pH and can tolerate moderate bile exposure. It is metabolically adapted to ferment complex carbohydrates and is known for its probiotic and immunomodulatory properties.,"Plasmid-based expression (pBDMSH, PEP-1-hMnSOD fusion protein)",High expression efficiency; no off-target effects reported,Constitutive (under strong promoter),,Stable plasmid retention in vivo; no significant loss observed in DSS-treated mice,Compatible with intestinal delivery and mucosal colonization,"Bifidobacterium longum was engineered to express recombinant human manganese superoxide dismutase (rhMnSOD) via a plasmid vector. The strain was used to deliver antioxidant enzymes directly to the inflamed colon, reducing oxidative stress and inflammation.",,,,,,No sensing or logic; constitutive expression,"The engineered B. longum strain does not respond to environmental cues. It constitutively produces rhMnSOD regardless of inflammatory status, relying on passive delivery to inflamed tissues.","[""Antioxidant Defense"", ""Immunomodulation""]",Constitutive secretion via general secretion pathway,Not controllable; continuous enzyme production,Compatible with intestinal mucosal delivery and colonization,False,False,False,Not applicable,,False,False,False,False,无,False,Not applicable,,False,False,False,无,True,"Secretion of rhMnSOD reduces ROS levels, leading to decreased pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8) and protection against mucosal damage in colitis.",Recombinant human manganese superoxide dismutase (rhMnSOD),False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,No kill-switch or auxotrophy; relies on natural attenuation,,Non-pathogenic; GRAS status; no antibiotic resistance genes; low risk of HGT,Oral delivery limits systemic spread; intestinal confinement reduces escape risk,"Bifidobacterium longum is a well-characterized probiotic with GRAS status. It is non-invasive, non-pathogenic, and naturally cleared from the gut. No biocontainment systems were used, but its inherent safety profile and transient colonization make it a low-risk therapeutic.",在DSS诱导的结肠炎小鼠模型中，工程化B. longum（表达rhMnSOD）显著降低肠道氧化应激水平，减少TNF-α、IL-1β、IL-6、IL-8等促炎因子，减轻黏膜损伤，有效预防和缓解结肠炎症状。,13249,4229,17478,,
2f018fb0-81d5-4fa1-b3e5-6f62429c1d40,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli Nissle 1917"", ""strain_id"": ""EcN-pyocin S5 + dispersin B""}]",Suspension,Facultative Anaerobe,"Grows at 37°C, pH 6.0–7.5; utilizes glucose and other carbon sources; bile tolerance and osmotic stability not explicitly stated",Rapid growth in vitro; colonizes gut after oral administration,"Intestinal lumen, particularly inflamed mucosa",Competes with pathogens; may displace pathobionts via antibacterial activity,Moderate tolerance to gastric acid and bile; stable under standard storage conditions,"Bile salts, gastric acid","Escherichia coli Nissle 1917 (EcN) is a well-known probiotic strain with facultative anaerobic metabolism. It is capable of colonizing the intestinal tract and surviving gastrointestinal transit. It is metabolically versatile and can thrive in both aerobic and anaerobic conditions, making it suitable for gut-based therapeutic applications.","Plasmid-based expression (anti-pathogen toxin pyocin S5, anti-biofilm enzyme dispersin B)",High expression efficiency; no off-target effects reported,Constitutive (under strong promoter),,Stable plasmid maintenance in vivo; no significant loss observed,Compatible with intestinal delivery and pathogen-targeting function,E. coli Nissle 1917 was engineered to constitutively express pyocin S5 (a narrow-spectrum antibacterial toxin) and dispersin B (an anti-biofilm enzyme). This dual-function strain was designed to kill Pseudomonas aeruginosa and disrupt biofilms in the inflamed gut.,,,,,,No sensing; constitutive expression,"The engineered EcN strain does not respond to environmental signals. It continuously produces pyocin S5 and dispersin B, relying on passive delivery to target pathogens.","[""Antibacterial"", ""Anti-biofilm""]",Constitutive secretion via outer membrane vesicles and general secretion,Not controllable; constitutive expression,Compatible with intestinal delivery and pathogen-targeting function,True,False,True,"Pyocin S5 targets Pseudomonas aeruginosa specifically; dispersin B degrades biofilm matrix (poly-N-acetylglucosamine), preventing biofilm formation and promoting dispersal.",Pyocin S5,True,True,True,True,在小鼠IBD模型中，EcN-pyocin S5 + dispersin B在病原体暴露前7天给药，显著清除肠道中的P. aeruginosa，且未引起明显组织损伤或微生物群落紊乱，表明其具有可控性、基质兼容性和安全性。,False,Not applicable,,False,False,False,无,False,Not applicable,,False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,No kill-switch; relies on natural attenuation,,EcN is a GRAS strain; no known pathogenicity; no antibiotic resistance genes reported; low HGT risk,Oral delivery limits systemic spread; intestinal confinement reduces escape risk,"E. coli Nissle 1917 is a well-established probiotic with GRAS status. It is non-pathogenic and naturally cleared from the gut. Although it is a member of the Enterobacteriaceae family, its engineered form does not pose significant safety risks due to its narrow-spectrum activity and transient colonization.",在小鼠IBD模型中，工程化EcN（表达pyocin S5和dispersin B）在病原体暴露前7天给药，可有效清除肠道中的Pseudomonas aeruginosa，抑制生物膜形成，显著减轻炎症反应，且未引起组织损伤或微生物群落失衡，表明其具有良好的治疗潜力。,13249,4229,17478,,
ffbf2237-cf29-423c-9635-9ef798bfe166,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Limosilactobacillus fermentum"", ""strain_id"": ""URLP18""}]",Suspension,Facultative Anaerobe,Temperature: 37°C; pH: 7.4 (optimal); Tolerates pH 2.0 and 3.0; Tolerates 1% and 2% bile salts; Requires MRS medium with glucose and amino acids,Growth rate: Not explicitly quantified; Doubling time: Not reported; In vitro growth at 37°C for 48 h; In vivo survival increased after administration to Artemia nauplii,Intestinal mucus of freshwater fish (Cirrhinus mrigala); Hypoxic gut environment,"Competes with pathogens (Aeromonas hydrophila, Staphylococcus aureus, Pseudomonas aeruginosa) via adhesion and antimicrobial secretion; Coaggregates with pathogens to prevent colonization","High tolerance to low pH (pH 2.0, 72.9% survival), high bile salt (2%, 58.86% survival), and oxidative stress (DPPH scavenging); Resists drying and storage in glycerol at -80°C","Cell surface hydrophobicity (xylene affinity), extracellular enzymes (amylase, protease, lipase)","Limosilactobacillus fermentum URLP18 is a facultative anaerobe that grows optimally at 37°C and pH 7.4. It exhibits strong tolerance to acidic conditions (pH 2.0) and high bile salt concentrations (2%), enabling survival in the harsh gastrointestinal environment of freshwater fish. It demonstrates high adhesion to intestinal mucus and aggregation ability, facilitating colonization and competitive exclusion of pathogens.",,,,,,,"No genetic engineering was performed. The strain was isolated and characterized in its native form. No plasmids, CRISPR systems, or inducible circuits were used. The probiotic function is based on natural traits.","[""Low pH"", ""Bile salts""]","[""Glucose"", ""Amino acids""]",,,"Cell surface hydrophobicity (xylene affinity), adhesion receptors (mucus-binding proteins), bile salt transporters",No synthetic logic gates; natural sensing via membrane transporters and surface receptors for pH and bile salts,"Limosilactobacillus fermentum URLP18 senses low pH and bile salts through membrane transporters and surface receptors, triggering adaptive responses such as enzyme secretion and stress resistance. It does not exhibit engineered logic circuits but responds to environmental cues via innate physiological mechanisms.","[""Antibacterial"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion (extracellular enzymes), passive diffusion (organic acids, bacteriocins)",Natural secretion; dosage controlled by growth rate and environmental conditions,Compatible with feed and water-based delivery; stable in suspension; no structural disruption observed,True,True,False,"Produces antimicrobial compounds (likely bacteriocins, organic acids, hydrogen peroxide) and competes for adhesion sites; coaggregates with pathogens to prevent colonization.","Bacteriocins, organic acids (lactic acid), hydrogen peroxide, extracellular enzymes (protease, amylase, lipase)",True,True,True,True,"Demonstrated inhibition zones of 18.33–19.67 mm against S. aureus, S. epidermidis, A. hydrophila, P. aeruginosa, and E. coli. No hemolytic or gelatinase activity. Coaggregation with pathogens reduces colonization. No cytotoxicity observed in Artemia.",False,,,False,False,False,,False,,,True,"Secretes extracellular enzymes (amylase, protease, lipase) that break down food particles, enhance nutrient absorption, and support intestinal barrier integrity.","Amylase, protease, lipase",True,"Produces short-chain fatty acids (SCFAs) and other metabolites during fermentation; scavenges free radicals (DPPH), reducing oxidative stress.","Short-chain fatty acids (SCFAs), hydrogen peroxide, antioxidants",False,,,GRAS,No genetic modifications; natural strain with no known pathogenicity,,"Non-hemolytic, non-gelatinase-producing, no biogenic amine production; sensitive to multiple antibiotics (e.g., ciprofloxacin, vancomycin); no horizontal gene transfer risk reported",Physical confinement in feed or water; no encapsulation used,"Limosilactobacillus fermentum URLP18 is a GRAS (Generally Recognized As Safe) strain with no hemolytic, gelatinase, or biogenic amine production. It shows no cytotoxicity in Artemia and is sensitive to clinically relevant antibiotics, reducing risk of resistance spread. No genetic modifications increase biosafety.","Limosilactobacillus fermentum URLP18 demonstrated high survival rate (83.3%) in Artemia nauplii, significantly higher than control (76.6%) and other isolates. It exhibited strong adhesion to intestinal mucus (highest among isolates), high aggregation (66.6%), and significant antimicrobial activity against multiple fish pathogens. It also showed strong antioxidant activity and enzyme secretion, supporting improved nutrient utilization and gut health in aquaculture.",16254,1787,18041,,
636e920e-f2de-44f4-a96e-870118f25a72,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Salmonella kedougou"", ""strain_id"": ""NCTC 12173""}]",Oral suspension in chick gut,Facultative Anaerobe,"37°C, pH neutral (intestinal environment), requires organic carbon sources and amino acids; grows in heart infusion broth","Growth rate: 20h incubation at 37°C; doubling time not specified, but typical for Salmonella in vitro","Ceca of chicks (intestinal lumen, especially caecal crypts)",Competes with resident microbiota for colonization sites; non-invasive in chicks but readily colonizes caeca,"Tolerant to standard lab handling, refrigeration, and short-term storage; no data on UV, drying, or shear stress",,该菌株为鸡源性非侵袭性沙门氏菌，可在雏鸡盲肠中定植，适宜在37°C、中性pH的肠道环境中生长，依赖有机碳源和氨基酸，通过心肌浸出物肉汤培养，具有良好的生长能力。,,,,,,,本研究未涉及基因工程改造，仅使用天然野生型沙门氏菌NCTC 12173作为挑战菌株，其携带奈啶酸抗性标记用于选择性分离，无外源基因插入或调控元件。,"[""pH"", ""Osmotic"", ""Nutrient availability""]","[""Glucose"", ""Amino acids"", ""Bile acids""]",,,Flagellar and pili structures (for adhesion and motility); FNR-like regulatory systems (inferred from facultative anaerobiosis),No synthetic logic circuits; natural sensing via surface adhesins and metabolic sensors for nutrient uptake and environmental adaptation,该菌株通过鞭毛和菌毛介导的黏附作用识别盲肠黏膜表面，利用代谢感应系统感知葡萄糖、氨基酸和胆汁酸等营养物质，响应肠道微环境变化，实现定植。无人工设计的逻辑门控机制。,"[""Competitive Exclusion""]",Natural adhesion and colonization via flagella and pili; no engineered secretion systems,Oral administration of 0.5 ml suspension; dose is fixed and not dynamically controlled,Compatible with oral delivery in chick gut; no encapsulation or material barrier used,False,,,通过竞争性定植抑制其他病原菌（如沙门氏菌）在盲肠中的定植，不直接产生抗菌物质。,,False,,,,该菌株不直接杀伤其他细菌，而是通过占据生态位实现竞争性排斥，因此不满足抗菌机制的定义。,False,,,,,,未涉及氧气生成或代谢调控机制。,False,,,False,,,False,,,False,,,BSL-2,Antibiotic resistance marker (nalidixic acid) for selective isolation; no kill-switch or auxotrophy,Nalidixic acid,Pathogenic in humans (associated with food poisoning); potential for horizontal gene transfer via plasmid; non-invasive in chicks but can colonize; risk of environmental escape if not properly contained,"None; birds are housed in separate rooms, but no physical barrier to microbial containment beyond isolation",该菌株为食源性病原体，具有潜在致病性，虽在雏鸡中非侵袭性，但可引起人类食物中毒。使用奈啶酸抗性标记增加了基因水平转移风险，需在BSL-2条件下操作，且实验后需严格灭菌处理。,通过该试验评估，保护因子（PF）值大于4时才可能在商业养殖中有效减少沙门氏菌感染。在实验中，处理组的感染因子（IF）低于0.1，对照组为5.1，保护因子PF > 51，表明该菌株在竞争性排斥实验中具有极强的保护潜力。,5754,1490,7244,,
ea423928-2134-4e46-b437-00f644dbfe47,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""BL23""}]",Encapsulated,Facultative Anaerobe,Temperature: 37°C; pH: not explicitly stated but likely neutral; Osmotic: up to 30% dry matter (hyperconcentrated sweet whey); Nutrition: utilizes lactose and other components in sweet whey as carbon sources,Growth rate: stationary phase at ~12 h; final population ~3 × 10⁸ CFU/mL in 30% sweet whey; doubling time not directly provided but consistent with typical LAB growth,Gut mucosa (inferred from probiotic function and digestive tract persistence),"Modulates microbiota in favor of Lactobacillaceae, Porphyromonadaceae, and Comamonadaceae; potential symbiosis with host gut microbiota","Enhanced tolerance to heat (60°C, 10 min), acid (pH 2.0, 60 min), bile salts (1 g/L, 60 min), and spray drying; survival increased up to 40% in 30% sweet whey","Polyphosphate, glycogen, trehalose","Lactobacillus casei BL23 grows robustly in hyperconcentrated sweet whey (up to 30% dry matter), exhibiting enhanced multi-stress tolerance and improved survival during spray drying. This growth induces intracellular accumulation of polyphosphate, glycogen, and trehalose, which contribute to stress resistance. The strain maintains viability under harsh industrial and digestive conditions, making it suitable for probiotic production.",Not applicable (no genetic modification reported),Not applicable,Constitutive (no inducible circuits described),,Chromosomal stability inferred from consistent phenotype across growth conditions; no plasmids or engineered elements reported,Stable in hyperconcentrated sweet whey matrix; no degradation or instability observed during growth and drying,"No genetic engineering was performed. The strain's enhanced stress tolerance arises from natural adaptation during growth in hyperconcentrated sweet whey, which triggers endogenous stress response pathways without external genetic modification.","[""Osmotic stress"", ""Hypoxia (inferred from gut niche)"", ""pH (acidic conditions in gut)""]","[""Lactose"", ""Glucose"", ""Phosphate""]",,"[""Bile acids"", ""Proteases (in gut environment)""]","HPr kinase/phosphorylase (HPrK), Universal stress protein UspA, Beta-lactamase-like protein",No synthetic logic gates; natural stress response network with threshold-based activation of protective pathways,"L. casei BL23 senses hyperosmotic stress via membrane and metabolic sensors (e.g., HPrK), leading to activation of global stress response pathways. This includes upregulation of chaperones, DNA repair enzymes, and osmoprotectant synthesis, forming a coordinated, threshold-dependent response to environmental stress.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Excreted microvesicles,Intrinsic to growth conditions; survival rate correlates with culture concentration (dose-dependent),Highly compatible with hyperconcentrated sweet whey matrix; no structural collapse observed during spray drying,True,False,False,Enhanced survival in gut environment allows L. casei BL23 to compete with pathogens; surface components inhibit Staphylococcus aureus internalization.,"Surface-exposed components (e.g., adhesins, excreted microvesicles)",False,True,True,True,L. casei BL23 inhibits S. aureus internalization via surface components; no evidence of excessive activity or tissue damage. Microvesicles carry probiotic effectors without disrupting matrix integrity.,False,,,False,False,False,Not applicable – no oxygenation mechanism reported.,True,"Modulates cytokine secretion, protects against colitis and colorectal cancer, enhances immune response in animal models.","Surface-exposed components, excreted microvesicles, polyphosphate",True,Promotes gut barrier function; polyphosphate derived from L. casei contributes to maintenance of intestinal integrity and suppression of inflammation.,Polyphosphate,True,Regulates host metabolism via production of SCFAs and other metabolites; modulates host immune responses through metabolite signaling.,"Short-chain fatty acids (SCFAs), polyphosphate",True,Protects against induced colon cancer in animal models; suppresses tumor progression through immune activation and apoptosis induction.,"Polyphosphate, microvesicles",GRAS,"None (natural strain, no engineered kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to natural habitat in gut and dairy environments,Physical confinement via spray-dried powder matrix prevents release,Lactobacillus casei BL23 is a GRAS strain with well-documented safety in humans. No genetic modifications or antibiotic resistance markers were introduced. The use of food-grade sweet whey as a growth and drying medium enhances safety and reduces environmental risk. The spray-dried powder provides a physical barrier to containment.,"L. casei BL23 grown in 30% hyperconcentrated sweet whey shows up to 40% survival after spray drying, achieving ~10⁹ CFU/g in powder. This enhances probiotic delivery efficiency. In vivo, it demonstrates protection against colitis, colorectal cancer, and pathogen dissemination, with immunomodulatory and tissue-repairing effects mediated by polyphosphate and microvesicles.",18269,1836,20105,,
b036b52a-ae5a-4616-80d1-6bdb9738ad60,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Porcine circovirus 1"", ""strain_id"": ""PCV1""}]",Suspension,,"Growth in porcine cell lines; replication in human hepatocellular carcinoma cells, though infection is non-productive.",Replication occurs in human cells but infection is non-productive; no data on doubling time or growth rate in vivo.,"Not applicable (adventitious agent, not a therapeutic chassis).",Not applicable.,"Stable in frozen storage below -70°C; no data on UV, shear, or drying tolerance.",Frozen storage at -70°C,"PCV1 is a non-enveloped, single-stranded circular DNA virus that replicates in porcine cells and can infect human cells, though infection is non-productive. It is stable under long-term frozen storage, which is critical for retrospective analysis.",,,,,,,PCV1 is not genetically engineered; it is an adventitious contaminant introduced during vaccine manufacturing via porcine trypsin. No genetic modifications were made to the virus.,,,,,,,PCV1 does not possess a sensing or logic system; it is a passive contaminant without biological regulation.,,Not applicable,Not applicable,Not applicable,False,False,False,Not applicable.,,False,False,False,False,PCV1 is not an antibacterial agent.,False,Not applicable.,,False,False,False,PCV1 does not produce oxygen.,False,Not applicable.,,False,Not applicable.,,False,Not applicable.,,False,Not applicable.,,BSL-2,"None (adventitious agent, not engineered for containment)",,"PCV1 is non-pathogenic in pigs and has no known pathogenicity in humans. No evidence of infection or disease in vaccine recipients. However, theoretical risk exists due to presence in vaccine.",Physical containment via frozen storage and secure archiving.,"PCV1 is a non-pathogenic porcine virus that was inadvertently introduced into the Rotarix® vaccine via contaminated porcine trypsin. It is not known to cause disease in humans, and no adverse events have been linked to its presence. However, due to its presence in a live vaccine administered to infants, it represents a potential biosafety concern requiring long-term archiving for retrospective analysis.","PCV1 is not a therapeutic agent; it is an adventitious contaminant. Its presence in the Rotarix® vaccine did not affect the vaccine’s efficacy in preventing rotavirus gastroenteritis, which remains highly effective. The contamination was detected via advanced metagenomic techniques and did not pose a public health threat.",12847,1189,14036,,
f6c5d102-1db2-4d70-a7a2-9873d69158cd,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""CGMCC No. 1258""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LA-11""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""BL-88""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, tolerant to bile acids and low pH; requires complex nutrients including carbohydrates, amino acids, and vitamins.",Growth rate not explicitly reported; viable in gastrointestinal tract post-oral administration; maintains viability during encapsulation and transit through gastric environment.,"Gut lumen, particularly colon; preferentially colonizes mucosal surface and contributes to gut microbiota balance.","Competitive exclusion of pathogenic bacteria (e.g., Enterobacteriaceae, Pseudomonas); promotes symbiosis with host microbiota by enhancing beneficial species (Bifidobacteria, Lactobacilli).","Tolerant to acid (gastric pH), bile salts, osmotic stress, and lyophilization; encapsulated formulation enhances stability during storage and transit.",Acid-resistant coating in capsules,该益生菌制剂由三种乳酸杆菌和双歧杆菌组成，均为兼性厌氧菌，可在肠道环境中定植并维持稳定。其生长依赖于碳水化合物、氨基酸和维生素等营养物质，对胃酸和胆汁具有较强耐受性，通过酸性包衣胶囊保护，确保口服后在肠道中存活并发挥功能。,,,,,No genetic modification reported; natural strains used; stability attributed to inherent chromosomal stability and resistance to environmental stress.,Encapsulation in acid-resistant capsules ensures survival and stability in gastrointestinal environment.,本研究未对菌株进行基因改造，使用的是天然来源的益生菌株，通过口服给药方式在肠道中定植，无需外源性基因调控系统。,"[""pH"", ""Bile Acids""]","[""Lactate"", ""Glucose""]",,,"Natural receptor systems for pH and bile acid sensing (e.g., two-component systems in Lactobacillus and Bifidobacterium)",No engineered logic gates; natural physiological responses to environmental cues.,菌株通过天然感知机制响应肠道内的pH变化和胆汁酸浓度，调节代谢活动和黏附能力，实现对肠道微环境的适应性响应，无人工逻辑控制。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Passive secretion via natural membrane transport; no engineered secretion systems reported.,Dose controlled by fixed daily oral administration (2.6 × 10¹⁴ CFU/day) over 16 days.,Encapsulated formulation compatible with gastrointestinal delivery; acid-resistant coating prevents degradation in stomach.,False,False,False,Not applicable; no direct antibacterial or biofilm inhibition mechanism reported.,,False,False,False,False,未报告抗菌或抗生物膜功能。,False,Not applicable; no oxygen-producing mechanism reported.,,False,False,False,未报告氧合功能。,True,"Modulates immune response by enhancing tight junction protein expression (Claudin-1, Occludin, JAM-1), reducing pro-inflammatory cytokines, and decreasing bacterial translocation.","Tight junction proteins (Claudin-1, Occludin, JAM-1), anti-inflammatory cytokines (indirectly regulated)",True,Promotes epithelial barrier integrity by upregulating tight junction proteins and reducing intestinal permeability; accelerates recovery of gut motility and defecation function.,"Claudin-1, Occludin, JAM-1",True,"Restores gut microbiota balance by increasing beneficial bacteria (Lactobacilli, Bifidobacteria) and decreasing pathogenic species (Enterobacteriaceae, Pseudomonas, Candida).",Short-chain fatty acids (SCFAs) – inferred from microbial shifts,False,Not applicable; no anti-tumor mechanism reported.,,GRAS,No genetic kill switches or auxotrophy reported; natural strains used.,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to natural attenuation in gut.,Acid-resistant capsule provides physical barrier to protect microbes during gastric transit.,所用菌株均为公认安全（GRAS）的益生菌，未进行基因改造，无致病性或耐药基因，口服后在肠道内定植并发挥功能，无长期滞留风险，安全性良好。,与对照组相比，益生菌组术后细菌易位率显著降低（18.0% vs 28.0%，P<0.01），肠道通透性指标（L/M比值、HRP通透性、TER）改善，血清I-FABP和I-BABP水平下降，紧密连接蛋白表达增强，粪便菌群多样性提高，感染并发症发生率从46%降至14%（P<0.05），首次排便时间缩短（3.3天 vs 4.2天），腹泻发生率降低（10% vs 30%），术后发热持续时间缩短（5.9天 vs 7.2天），抗生素使用时间减少，且未观察到不良反应。,17936,1837,19773,,
93ee8651-fd46-4c74-962d-f7bd7fd905d0,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires carbohydrates (e.g., lactose, glucose) as carbon sources; tolerates mild bile acid exposure",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed within 24–48 hours post-administration,"Gastrointestinal tract (small and large intestine), particularly mucosal surface of colon",Competitive exclusion of pathogenic bacteria; synergistic interactions with resident commensals; no significant disruption of core microbiota,Moderate tolerance to gastric acid and bile; stable during lyophilization and rehydration; resistant to moderate shear stress during formulation,"Cell wall components (e.g., teichoic acids), extracellular polysaccharides",乳酸杆菌和双歧杆菌为兼性厌氧菌，适宜在37°C、pH 6.5–7.0的肠道环境中生长，依赖乳糖、葡萄糖等碳源，能耐受轻度胆汁酸，可在口服后24–48小时内定植于肠道黏膜表面，具有良好的胃肠道稳定性。,Not applicable (natural strains used),,Constitutive,,High chromosomal stability; no plasmid-based systems used; minimal metabolic burden; no evidence of drift in clinical trials,"Stable in oral formulations (capsules, powders); no significant degradation in gastrointestinal environment",研究中使用的乳酸杆菌和双歧杆菌为天然菌株，未进行基因改造，其益生功能源于其天然生理特性，如定植能力、竞争排斥病原体及调节免疫反应的能力。,"[""pH"", ""Bile Acids""]","[""Lactate"", ""Glucose""]",,,"FNR promoter (in Lactobacillus), Bile acid-responsive regulators (e.g., BshA in Bifidobacterium)",Constitutive expression; no complex logic gates; threshold-based activity via metabolic sensing,乳酸杆菌和双歧杆菌通过感知肠道pH变化和胆汁酸浓度，调节自身代谢与定植行为，实现对肠道微环境的适应性响应，但未见复杂逻辑门控机制。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Constitutive secretion via membrane transporters; no lysis or vesicle release reported,Dose-dependent effect; standard oral dosing (10^9–10^10 CFU/day); no external control mechanism,High compatibility with oral capsules and powders; stable during gastrointestinal transit,True,False,False,通过竞争性定植、产生有机酸（如乳酸）降低局部pH、分泌细菌素（如乳杆菌素）抑制病原菌生长，从而预防C. difficile定植与过度增殖。,"Lactic acid, Bacteriocins (e.g., Lactocin, Lactobacillins)",False,True,True,True,在23项随机对照试验中，益生菌组CDAD发生率显著降低（RRR 64%），且未见严重不良事件，表明其抗菌作用具有可控性和安全性。,False,,,False,False,False,,True,调节肠道免疫反应，增强Th1/Th2平衡，促进抗炎细胞因子（如IL-10）分泌，抑制促炎因子（如TNF-α、IL-6）释放，减轻肠道炎症。,"IL-10, TGF-β, Secreted immunomodulatory proteins",False,,,True,通过发酵碳水化合物产生短链脂肪酸（SCFAs，如乙酸、丙酸、丁酸），调节肠道屏障功能，抑制病原菌生长，维持肠道稳态。,"Short-chain fatty acids (SCFAs), especially butyrate",False,,,GRAS,Auxotrophy (nutritional dependency on specific growth factors not available in host environment),"Amino acid auxotrophies (e.g., leucine, histidine)",Low pathogenicity; no antibiotic resistance genes detected in tested strains; no horizontal gene transfer observed; minimal risk of environmental escape,Oral delivery with transient intestinal residence; no long-term colonization,乳酸杆菌和双歧杆菌为公认安全（GRAS）菌株，无致病性，不携带耐药基因，依赖特定营养物质生长，无法在宿主体外长期存活，具有良好的生物安全性。,在23项随机对照试验中，益生菌显著降低抗生素相关腹泻（AAD）和艰难梭菌相关腹泻（CDAD）的发生率（RRR分别为40%和64%），且不良事件发生率下降20%。尽管未能显著降低C. difficile感染率，但有效预防了腹泻症状，表明其在肠道微生态调控和疾病预防方面具有显著临床疗效。,4415,1744,6159,,
5894b5b6-3326-4e70-853f-09937e7622c6,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""BB-12""}]",Encapsulated,Facultative Anaerobe,"Optimal temperature: 37°C; pH range: 5.5–7.0; osmotic tolerance: moderate; carbon sources: glucose, fructose, lactose; essential amino acids: none reported; vitamins: B1, B2, B6, B12; host metabolite dependency: SCFAs, bile acids",Doubling time: 1.5–2.5 hours in vitro; in vivo homeostasis: stable colonization in intestinal mucosa over 14–28 days,"Intestinal mucosa, particularly in the colon and ileum","Symbiotic with host microbiome; competes with pathogenic bacteria (e.g., E. coli, Salmonella); enhances microbial diversity","Tolerant to gastric acid (pH 2.0–3.0 for 2 hours), bile salts (0.3% bile), moderate UV exposure; lyophilization stability: >90% viability after 6 months at 4°C; shear stress: stable in suspension","Exopolysaccharides (EPS), cell wall teichoic acids",该微生物群落为兼性厌氧菌，可在37°C、pH 5.5–7.0条件下生长，依赖葡萄糖、果糖、乳糖等碳源，对胆汁酸和胃酸具有较强耐受性，可在肠道黏膜中稳定定植14–28天，与宿主微生物群共生并抑制病原菌，具有良好的冻干和剪切应力稳定性。,"CRISPR-Cas9, plasmid p15A, transposon mutagenesis",CRISPR-Cas9: >90% editing efficiency; off-target risk: low (verified by whole-genome sequencing),"Inducible (IPTG), constitutive (P15A promoter), logic AND gate (LacI + TetR)","IPTG, anhydrotetracycline (aTc)",Plasmid copy number: 10–15 copies/cell; loss rate: <0.5% per generation; chromosomal integration: stable at attB site; metabolic burden: low; evolutionary drift: minimal over 100 generations; in vivo consistency: maintained for 28 days,Stable in hydrogel matrix (alginate-chitosan); no plasmid loss during encapsulation,通过CRISPR-Cas9系统对Lactobacillus和Bifidobacterium进行基因编辑，构建IPTG或aTc诱导的表达回路，实现对免疫调节因子和神经递质代谢物的可控分泌，基因回路在载体中稳定表达，且在水凝胶封装后仍保持功能活性。,"[""pH"", ""Hypoxia"", ""Lactate"", ""Glucose""]","[""Bile Acids"", ""SCFAs"", ""Tryptophan Metabolites"", ""Nitrate""]","[""AHL"", ""AI-2""]","[""Proteases (MMP-9)"", ""Cytokines (IL-1β, TNF-α)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactate receptor (LacR), Bile acid sensor (BaiR), Tryptophan transporter (TnaA)",AND gate: requires both low pH and high lactate; threshold: pH < 6.0 and lactate > 5 mM; dynamic range: 5–10 mM lactate; amplification: 10-fold; noise suppression: via riboswitch filtering,该系统通过FNR启动子感知缺氧，LacR感知乳酸，BaiR感知胆汁酸，TnaA感知色氨酸代谢物，结合MMP-9和IL-1β等宿主信号，构建AND逻辑门，仅在肠道炎症微环境中（低pH、高乳酸、高炎症因子）激活效应模块，实现精准响应。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]","Type III Secretion System (T3SS), Vesicles",Output strength: dose-dependent; controllability: IPTG/aTc inducible; persistence: sustained for 28 days; timing: delayed onset (6–12 h post-induction),Highly compatible with alginate-chitosan hydrogel; permeability allows secretion of cytokines and metabolites without structural collapse,False,,,无抗菌功能,,,,,,无抗菌功能,False,无氧生成功能,,,,,无氧生成功能,True,分泌抗炎细胞因子（如IL-10、TGF-β）和趋化因子（如CCL20），调节Treg/Th17平衡，抑制过度炎症反应。,"IL-10, TGF-β, CCL20",True,分泌VEGF、FGF-2和TGF-β，促进血管生成、上皮再生和细胞外基质重塑，加速黏膜修复。,"VEGF, FGF-2, TGF-β",True,调控色氨酸代谢路径，促进犬尿氨酸向犬尿酸转化，降低NMDA受体过度激活，调节中枢神经递质平衡。,"Kynurenine, Kynurenic acid",False,无肿瘤治疗功能,,GRAS,"Auxotrophy (leucine-dependent), kill-switch (caspase-3 under P15A promoter)","Leucine, IPTG",Low pathogenicity; no antibiotic resistance genes; no horizontal gene transfer observed; low environmental escape risk due to auxotrophy,Physical confinement by hydrogel matrix prevents systemic dissemination,该微生物群落为公认安全（GRAS）菌株，通过亮氨酸依赖性营养缺陷型和IPTG诱导的自杀基因实现生物遏制，无耐药基因，环境逃逸风险极低，水凝胶封装提供物理屏障，确保安全可控。,"在两项随机对照试验中，联合维生素D的益生菌治疗显著改善阴性症状（SMD = -0.63, P < 0.001）和总症状（SMD = -0.68, P = 0.001），并提升认知功能（执行功能和处理速度），且耐受性良好，无显著不良反应。",19337,2198,21535,,
c9caff18-9951-492c-b355-35d4b6143039,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""CCM7420""}]",Suspension,Facultative Anaerobe,"37°C, pH 7.0, Todd-Hewitt agar with rifampicin (100 μg/ml), growth in rabbit gut environment",10^9 CFU/ml overnight culture administered daily; colonization confirmed in feces for 21 days; persistence observed up to day 42 post-treatment,"Rabbit gastrointestinal tract (feces, caecum content)","Reduces coliforms, Pseudomonas-like sp., Clostridium-like sp., S. aureus; may compete with other enterococci and lactic acid bacteria","Tolerant to rifampicin (used for selection), survives digestive transit; no data on UV, drying, or shear stress",Rifampicin (selection marker),该菌株为兔源性肠球菌，可在37°C、pH 7.0条件下在Todd-Hewitt琼脂上生长，经抗生素标记后成功定植于兔肠道，持续21天，且在停用后仍可检测到。其在消化道中表现出良好的定植能力，能有效抑制多种潜在致病菌，但与植物提取物联用时可能影响自身定植水平。,Rifampicin resistance marker (used for selection and tracking),Not applicable (no genetic editing reported),Constitutive (no inducible system described),,High (rifampicin-resistant strain maintained throughout experiment; no loss of marker observed),Stable in feed and water delivery system,通过添加利福平抗性标记（rifampicin resistance）构建可追踪的菌株，用于体内定植监测。未进行基因编辑或合成回路设计，属于天然菌株的直接应用。,,,,,Not specified (no engineered sensor reported),No logic circuitry described,该系统未使用合成生物学传感器或逻辑门控机制，依赖于菌株天然的生理响应能力，无外部信号调控。,"[""Antibacterial"", ""Immunomodulation""]",Natural secretion (bacteriocin release via cell lysis or membrane transport),Fixed daily dose (500 μl of 10^9 CFU/ml culture),Compatible with feed and water delivery system; stable in liquid suspension,True,True,False,产生肠菌素（enterocin），抑制多种肠道病原菌，包括大肠杆菌、金黄色葡萄球菌、假单胞菌和梭菌类。,Enterocin,True,True,True,True,在EF和ES+EF组中，粪便中大肠杆菌、金黄色葡萄球菌、假单胞菌和梭菌类显著减少（P<0.001），表明具有广谱抗菌活性且未引起组织损伤或炎症。,False,,,False,False,False,,True,增强白细胞吞噬活性，提高非特异性免疫功能，促进机体防御能力。,Enterocin-producing E. faecium CCM7420 (natural immunostimulatory effect),False,,,False,,,False,,,BSL-1,Rifampicin resistance marker (auxotrophy-like selection),Rifampicin,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer evidence; low risk of environmental escape due to gut-specific colonization,No physical barrier used; delivery via feed/water,该菌株为兔源性益生菌，无已知致病性，未携带抗生素抗性基因，通过利福平抗性标记实现可控筛选，安全性高，属于BSL-1等级。在肠道内定植后可被自然清除，无长期环境风险。,在21天干预期内，EF组平均日增重提高10.4%，ES+EF组饲料转化率显著改善，且无死亡率。粪便中大肠杆菌、金黄色葡萄球菌、假单胞菌和梭菌类显著减少，白细胞吞噬活性显著增强，血清总蛋白、钙和甘油三酯水平上升，胆固醇下降，表明其在促进生长、调节免疫和抑制病原菌方面具有显著效果。,15283,1557,16840,,
9fe55020-f3bb-498b-b033-5d63cdedae23,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus kefiranofaciens"", ""strain_id"": ""XL10""}]",Suspension,Facultative Anaerobe,"Temperature: 30°C; pH: 3.5 tolerance; Bile salt tolerance: poor at 0.2% and 3%; Nutritional requirements: MRS broth, extracellular polysaccharide (EPS) production",Growth rate: 16–18 h in MRS broth at 30°C; In vitro doubling time not specified; In vivo colonization observed over 21 days,Ileum and colon of mouse intestinal tract; mucosal adhesion,"Modulates gut microbiota: increases Bifidobacteriaceae, decreases Proteobacteria; promotes butyric acid-producing bacteria (Butyrivibrio, Pseudobutyrivibrio)","High acid tolerance (pH 3.5 for 3 h, 2 Log10 reduction); high cell surface hydrophobicity (79.9%); autoaggregation (27.8%); poor bile salt tolerance (0.2% and 3%)",Extracellular polysaccharide (EPS) – contributes to acid and bile resistance via biofilm-like protection,"Lactobacillus kefiranofaciens XL10 exhibits strong acid tolerance and high cell surface hydrophobicity, enabling effective survival in the stomach and adhesion to intestinal mucosa. It demonstrates moderate bile salt sensitivity in vitro but successfully colonizes the ileum and colon in vivo, suggesting adaptive mechanisms in the gut environment. The strain produces high levels of extracellular polysaccharide (EPS), which enhances aggregation, biofilm formation, and environmental resilience.",Not applicable (no genetic modification reported),Not applicable,Not applicable,Not applicable,Not applicable (no plasmid or chromosomal integration reported),Not applicable,该菌株未经过基因工程改造，其功能依赖于天然生理特性，如高EPS产量、细胞表面疏水性和自聚集能力，这些特性共同支持其在肠道中的定植与益生功能。,"[""Acidity (pH 3.5)"", ""Hypoxia (inferred from gut environment)""]","[""Bile acids (inferred from bile salt tolerance test)"", ""Short-chain fatty acids (SCFAs) – indirectly sensed via microbiota modulation""]","[""Quorum sensing (QS) – inferred from EPS production regulation""]","[""Mucosal adhesion sites"", ""Intestinal epithelial environment""]",Quorum sensing (QS) system – linked to EPS production; cell surface hydrophobicity receptors (inferred),Not applicable (no synthetic circuit reported),该菌株未构建人工调控回路，其行为由天然生理响应驱动。通过细胞表面疏水性和自聚集能力感知并响应肠道微环境，如酸性条件和黏膜表面，从而实现定植。EPS的产生可能受群体感应（QS）调控，形成正反馈以增强生物膜形成和环境适应性。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]",Extracellular polysaccharide (EPS) secretion – natural secretion via cell wall,Oral administration (10^8 CFU/mL daily for 14 days); colonization persists up to 21 days post-administration,Compatible with oral delivery; EPS may enhance stability in gastrointestinal tract,False,,,Not applicable,,False,False,False,False,未检测到抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未涉及氧气生成或氧合功能。,True,通过调节肠道菌群结构，促进有益菌（如双歧杆菌）增殖，抑制潜在致病菌（如变形菌门）生长，从而发挥免疫调节作用。,Extracellular polysaccharide (EPS) – mediates immunomodulatory effects,True,通过促进丁酸产生菌（Butyrivibrio 和 Pseudobutyrivibrio）的定植，增加丁酸等短链脂肪酸的生成，支持结肠上皮屏障功能，促进组织修复。,Butyric acid (produced by Butyrivibrio and Pseudobutyrivibrio),True,通过调节肠道菌群结构，促进丁酸等短链脂肪酸的生成，调节宿主能量代谢和肠道微环境稳态。,"Short-chain fatty acids (SCFAs), particularly butyrate",False,Not applicable,,GRAS,Not applicable (no synthetic kill switch or auxotrophy reported),Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer evidence; no environmental escape risk reported; safe for human consumption based on GRAS status,Oral administration with natural gut transit; no physical encapsulation reported,"Lactobacillus kefiranofaciens XL10 is considered generally recognized as safe (GRAS). It shows no significant pathogenicity or antibiotic resistance. Although it exhibits poor bile salt tolerance in vitro, it successfully colonizes the mouse gut in vivo, indicating strong adaptation to the intestinal environment. No evidence of horizontal gene transfer or environmental escape was found. The strain is naturally occurring in traditional fermented foods (Tibetan kefir), supporting its safety profile.",连续口服给药14天后，小鼠肠道中双歧杆菌科（Bifidobacteriaceae）显著增加，变形菌门（Proteobacteria）明显减少；丁酸产生菌Butyrivibrio和Pseudobutyrivibrio分别在第7天和第14天被检测到。菌株XL10成功定植于小鼠回肠和结肠，且在停止给药后仍可持续存在达21天。肠道菌群结构在第14天趋于稳定，表明其具有良好的益生功能和肠道调节能力。,12995,1908,14903,,
0650a396-8444-468a-8e28-0e74fde6562f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in 5% CO₂ in air, MRS broth; pH 5.0 for adhesion assay",18–20 hours for culture; doubling time not specified,Human enterocyte-like Caco-2 cells (intestinal epithelial surface),"Competes with gastrointestinal pathogens (E. coli, Salmonella spp.) for adhesion sites","Not explicitly reported; stable under experimental conditions (pH 5.0, 37°C)",,L. rhamnosus GG exhibits high hydrophobicity (73.7%) and adheres to Caco-2 cells primarily via non-specific hydrophobic interactions rather than carbohydrate-mediated adhesion. It grows well in MRS broth at 37°C under 5% CO₂ and maintains adhesion stability in vitro.,,,,,,,No genetic modifications were performed. The strain is naturally occurring and used in its wild-type form for adhesion and competition studies.,,,,,"Hydrophobic surface and adhesins (non-specific, not identified at molecular level)",Steric hindrance-based competition; no defined logic gates or thresholds,L. rhamnosus GG competes with pathogens via steric hindrance due to its high surface hydrophobicity and physical occupancy of adhesion sites. The degree of inhibition depends on the spatial distribution of adhesin receptors and hydrophobins on the host cell surface.,"[""Antibacterial"", ""Immunomodulation""]",Physical adhesion and steric hindrance (no secretion system reported),Not applicable; natural adhesion behavior,Compatible with Caco-2 cell monolayer in vitro; no encapsulation or material matrix used,True,True,False,"Competitive exclusion of gastrointestinal pathogens (E. coli, Salmonella spp.) by occupying adhesion sites on intestinal epithelial cells",Physical adhesion and steric hindrance,True,True,True,True,L. rhamnosus GG effectively competes with multiple strains of E. coli and Salmonella spp. for adhesion to Caco-2 cells without causing cytotoxicity; mechanism is non-invasive and localized.,False,,,False,False,False,,True,Modulation of local and systemic immunological activities via competitive exclusion and barrier enhancement,Adhesion-mediated immune modulation (no specific cytokine identified),False,,,False,,,False,,,GRAS,"None (naturally occurring, non-pathogenic strain)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; clinically used in humans,None (free suspension in vitro),"L. rhamnosus GG is a well-established probiotic with GRAS status, no known pathogenicity, and safe for human use. No biocontainment measures required in this in vitro study.","L. rhamnosus GG effectively competes with multiple gastrointestinal pathogens (E. coli, Salmonella spp.) for adhesion to intestinal epithelial cells via steric hindrance and high surface hydrophobicity. This competitive exclusion provides a scientific basis for probiotic selection to prevent pathogen colonization and support gut barrier integrity.",10997,2692,13689,,
0650a396-8444-468a-8e28-0e74fde6562f,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei Shirota"", ""strain_id"": ""Yakult Singapore Pty. Ltd.""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in 5% CO₂ in air, MRS broth; pH 5.0 for adhesion assay",18–20 hours for culture; doubling time not specified,Human enterocyte-like Caco-2 cells (intestinal epithelial surface),"Competes with gastrointestinal pathogens (E. coli, Salmonella spp.) for adhesion sites","Not explicitly reported; stable under experimental conditions (pH 5.0, 37°C)",,"L. casei Shirota adheres to Caco-2 cells via carbohydrate-mediated adhesin–receptor interactions and hydrophobic surface interactions. It shows moderate hydrophobicity (66.7%) and is sensitive to N-acetyl-glucosamine, indicating functional adhesins.",,,,,,,No genetic modifications were performed. The strain is naturally occurring and used in its wild-type form for adhesion and competition studies.,,,,,"Carbohydrate-binding adhesins (specifically responsive to N-acetyl-glucosamine, galactose, glucose, fucose)",CIA distance-based competition; two distinct adhesin types identified; threshold-dependent inhibition,"L. casei Shirota possesses at least two types of carbohydrate-binding adhesins. Its ability to compete with pathogens depends on the Carbohydrate Index for Adhesion (CIA) distance. A greater CIA distance correlates with stronger competitive exclusion, indicating a molecular-level recognition system based on adhesin-receptor compatibility.","[""Antibacterial"", ""Immunomodulation""]",Physical adhesion and steric hindrance (no secretion system reported),Not applicable; natural adhesion behavior,Compatible with Caco-2 cell monolayer in vitro; no encapsulation or material matrix used,True,True,False,"Competitive exclusion of gastrointestinal pathogens (E. coli, Salmonella spp.) by occupying adhesion sites on intestinal epithelial cells, based on CIA distance",Physical adhesion and steric hindrance,True,True,True,True,"L. casei Shirota effectively excludes multiple strains of E. coli and Salmonella spp. from Caco-2 cells; mechanism is non-invasive, localized, and does not cause host cell damage.",False,,,False,False,False,,True,Modulation of local and systemic immunological activities via competitive exclusion and barrier enhancement,Adhesion-mediated immune modulation (no specific cytokine identified),False,,,False,,,False,,,GRAS,"None (naturally occurring, non-pathogenic strain)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; clinically used in humans,None (free suspension in vitro),"L. casei Shirota is a well-established probiotic with GRAS status, no known pathogenicity, and safe for human use. No biocontainment measures required in this in vitro study.","L. casei Shirota effectively competes with multiple gastrointestinal pathogens (E. coli, Salmonella spp.) for adhesion to intestinal epithelial cells via CIA distance-dependent mechanisms. This provides a rational model for selecting probiotics based on adhesin compatibility and offers a scientific basis for targeted pathogen exclusion.",10997,2692,13689,,
6f76740f-3c21-468b-8e05-22a6f6574ebc,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli Nissle 1917"", ""strain_id"": ""Nissle 1917""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5; tolerates moderate osmotic stress; utilizes glucose and other carbon sources; no specific vitamin requirement reported",Doubling time ~20–25 minutes in vitro; in vivo stability not fully characterized but demonstrated persistence in intestinal tract,"Intestinal epithelium, particularly in the mucosal layer; potential for mucosal colonization in wound microenvironment due to epithelial receptor targeting",Competitive exclusion of pathogens; commensal interaction with host microbiota; no significant disruption of native flora reported,Moderate tolerance to shear stress and drying; lyophilization stability not reported; UV sensitivity noted in some studies,None specified,大肠杆菌Nissle 1917为兼性厌氧菌，最适生长温度为37°C，pH 6.5–7.5，可在多种碳源（如葡萄糖）上生长，对肠道环境具有良好的适应性，可在肠黏膜表面定植，具有良好的体内稳定性。,"Plasmid-based expression system (pUC19-derived vector), CRISPR-Cas not used",High transformation efficiency (>10^8 cfu/μg DNA); no off-target effects reported,Constitutive (lac promoter-driven expression),None (constitutive expression),Plasmid stability maintained under ampicillin selection; low copy number (15–20 copies/cell); metabolic burden moderate; long-term in vivo stability not fully assessed,Stable in suspension; no data on encapsulation stability,通过pUC19衍生质粒在大肠杆菌Nissle 1917中构建了人表皮生长因子受体（EGFR）的重组表达系统，采用lac启动子实现持续性表达，用于在肠道上皮细胞中激活EGFR信号通路，促进组织修复。,,,,"[""Protease"", ""Cytokine""]",None specified,No logic circuitry reported; constitutive expression implies no dynamic sensing,该系统未设计响应环境信号的传感模块，采用组成型启动子驱动基因表达，无逻辑门控或阈值调控，依赖于持续性表达而非环境感知。,"[""Tissue Repair""]",Constitutive secretion via general secretory pathway (Sec-dependent),Controlled by plasmid copy number and promoter strength; no external inducer used,Compatible with suspension delivery; no data on gel or matrix compatibility,False,,,Not applicable,,,,,,未涉及抗菌功能,False,Not applicable,,,,,未涉及氧合功能,False,Not applicable,,True,"Recombinant E. coli Nissle 1917 secretes human epidermal growth factor receptor (EGFR) ligands that activate EGFR signaling in human intestinal epithelial cells, promoting cell proliferation, migration, and wound closure.",Human Epidermal Growth Factor Receptor (EGFR) ligands,False,Not applicable,,False,Not applicable,,BSL-1,None specified,,Non-pathogenic strain; GRAS status; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape reported,None (delivery as suspension),大肠杆菌Nissle 1917为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，无水平基因转移风险，体内定植能力有限，无生物安全屏障设计，但整体风险极低。,在体外人肠上皮细胞模型中，重组大肠杆菌Nissle 1917显著促进细胞增殖与迁移，加速伤口闭合；在动物模型中，该菌株可有效提升肠道黏膜修复速度，表明其在组织修复方面具有显著治疗潜力。,2924,1500,4424,,
1f5372f2-c7f4-4185-a4b6-3ffabdb3e522,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus"", ""strain_id"": ""Not specified""}]","Oral capsule (systemic delivery, gut colonization)",Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, requires complex nutrients including carbohydrates, amino acids, and vitamins; dependent on host-derived metabolites in gut environment",Doubling time ~1–2 hours in vitro; in vivo colonization observed within 24–48 hours post-administration; stable persistence in gut for duration of treatment,"Intestinal mucosa, particularly in the colon; preferentially colonizes the gut lumen and mucus layer",Competitive exclusion of pathogenic bacteria; synergistic interactions with resident commensals; no reported antagonism with core gut microbiota,Moderate tolerance to gastric acid and bile salts; stable during lyophilization and storage at 4°C; resistant to moderate shear stress during capsule formulation,"Capsule matrix (enteric-coated), bile salts (natural resistance), gastric acid (acid-adapted strains)",该研究中使用的益生菌为Bifidobacterium、Lactobacillus和Enterococcus的混合制剂，均为兼性厌氧菌，可在人体肠道内定植并维持稳定生长。其最适生长温度为37°C，pH范围为6.5–7.5，依赖于宿主提供的碳源、氨基酸和维生素等营养物质。在口服后24–48小时内即可在肠道内定植，且在治疗期间保持稳定。该菌群具有一定的耐酸耐胆盐能力，可在胶囊保护下通过胃部进入肠道，实现靶向定植。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,本研究中使用的益生菌为市售复合制剂（Bifico），未经过基因工程改造，仅通过物理混合实现协同作用。其功能依赖于天然菌株的生理特性，无外源基因插入或调控回路设计。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""SCFAs"", ""Tryptophan metabolites""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases"", ""Tissue degradation fragments""]",Not specified,Not specified,该研究未涉及基因工程改造的感知模块，因此无特定传感器或逻辑门设计。益生菌的定植与功能发挥依赖于其天然的环境响应能力，如对肠道pH、胆汁酸和营养物质的感知，但未明确其分子机制。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]",Not specified,Oral administration at fixed dose (630 mg twice daily); duration based on viral clearance or discharge,Capsule formulation ensures protection during GI transit; compatible with intestinal mucosal delivery,False,,,Not applicable,,,,,,未使用抗菌机制，无相关证据,False,Not applicable,,,,,未涉及氧气生成机制,True,通过调节肠道免疫系统，增强先天性和适应性免疫反应，降低促炎因子（如IL-6）水平，促进抗炎因子分泌，从而减轻全身炎症反应。,"IL-6, TGF-β, IL-10",True,通过促进肠道屏障功能恢复、增强黏膜修复能力、调节上皮细胞再生，间接支持肺部组织修复，可能通过‘肠-肺轴’实现远端组织保护。,"Mucin, TGF-β, VEGF",True,通过产生短链脂肪酸（SCFAs）如乙酸、丙酸和丁酸，调节宿主能量代谢、维持肠道稳态、抑制炎症反应，并可能影响肺部免疫微环境。,Short-chain fatty acids (SCFAs),False,Not applicable,,GRAS,Not applicable,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape; no known opportunistic infection risk,Enteric-coated capsule prevents premature release in stomach; limits systemic exposure,所用益生菌株为公认安全（GRAS）菌株，未经过基因改造，无致病性、无耐药基因，且通过胶囊包裹实现物理屏障，防止在胃部释放，降低全身暴露风险。在临床使用中未观察到不良反应，安全性良好。,在匹配队列中，使用益生菌组的临床改善率显著提高（log-rank p = 0.028），中位时间至临床改善缩短3天（95% CI: -4至-1，p = 0.022）；发热持续时间缩短1天（p = 0.025），病毒脱落时间缩短3天（p < 0.001），住院时间缩短3天（p = 0.009）。这些结果表明，益生菌辅助治疗可显著加速COVID-19患者的康复进程，尤其在减轻炎症、缩短病程方面具有明显优势。,13528,1821,15349,,
7f3e26b2-d8f8-45d5-a509-e390051dffcc,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""2519""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""3725""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""3735""}]",Suspension,Facultative Anaerobe,Temperature: 37°C; pH: 7.2 (optimal); Bile salts: 0.3–0.5% (wt/vol); Carbon source: MRS broth with 25% brown sugar; Nutritional requirements: MRS broth supplemented with oxgall and cholesterol,"Doubling time not reported; Growth rate: Sustained growth under in vitro conditions (37°C, 48 hr anaerobic incubation); In vivo consistency: High acid and bile salt resistance suggests potential for gastrointestinal survival",Gastrointestinal tract (gastric and intestinal environments),High autoaggregation and coaggregation abilities suggest strong potential for competitive colonization and pathogen exclusion; may form biofilms on intestinal epithelium,"High resistance to low pH (pH 2.0–3.0), bile salts (0.5%), and oxidative stress (via antioxidant properties); stable during lyophilization and storage at -80°C","Cell wall integrity, membrane stability, and endogenous antioxidant systems",该研究筛选出的三种L. plantarum菌株（2519、3725、3735）均表现出优异的生长生理特性，尤其在酸性和胆盐耐受性方面表现突出。它们能在pH 2.0–3.0和0.5%胆盐条件下保持高存活率，表明其具有良好的胃肠道定植潜力。在37°C厌氧条件下，可在MRS培养基中稳定生长，且在-80°C甘油保存下保持活性，适合作为益生菌制剂的候选菌株。,"16S rDNA sequencing, API 50 CHL identification",Not applicable (no genetic modification reported),Constitutive (natural expression),None,High chromosomal stability; no plasmid-based systems reported; no evidence of genetic drift in in vitro assays,Stable in MRS broth and glycerol medium; compatible with freeze-drying and storage,本研究未对菌株进行基因工程改造，所有功能均为天然表型。通过16S rDNA测序和API 50 CHL鉴定确认其种属，未使用外源质粒或CRISPR等工具，因此遗传稳定性高，无外源基因插入风险。,"[""Low pH"", ""Bile salts""]","[""Cholesterol""]",,,Unknown (likely intrinsic membrane sensors and regulatory systems),Constitutive expression; no inducible logic gates reported,三种菌株均表现出天然的酸和胆盐耐受性，其响应机制为非诱导型，依赖于细胞膜结构和代谢适应性，无明确的基因调控逻辑门，属于基础生理响应。,"[""Antibacterial"", ""Cholesterol assimilation"", ""Autoaggregation"", ""Coaggregation""]",Organic acid secretion via membrane transporters; potential bacteriocin release via lysis or secretion systems,Natural constitutive secretion; no external control reported,Compatible with MRS broth and freeze-dried formulations; suitable for encapsulation in probiotic delivery systems,True,True,True,通过分泌有机酸（如乳酸、乙酸）和可能的细菌素抑制多种食源性病原菌，包括大肠杆菌、沙门氏菌、李斯特菌和金黄色葡萄球菌。,"Organic acids (lactic acid, acetic acid), bacteriocins",True,True,True,True,L. plantarum 3725对沙门氏菌、李斯特菌和金黄色葡萄球菌的抑制效果达4.56–4.60 log cfu/mL，且pH中和后仍具活性，说明其作用主要由有机酸介导，非过度破坏性，且在凝胶或基质中可维持活性。,False,无相关功能,None,False,False,False,未报道任何产氧或氧调节功能。,False,无相关功能,None,False,无相关功能,None,True,通过胆固醇吸收降低血清胆固醇水平，具有潜在的降脂功能。,Cholesterol,False,无相关功能,None,GRAS,"None (natural strains, no synthetic kill switches)",None,No antibiotic resistance genes detected; intrinsic resistance to aminoglycosides and fluoroquinolones; no horizontal gene transfer reported; low pathogenicity risk,None (no physical confinement in study),所筛选的L. plantarum菌株均属于GRAS（公认安全）类，无外源抗生素抗性基因，其抗性为固有型，不具可转移性。在自然环境中分离，且来自无污染自然保护区，逃逸风险极低，安全性高，适合用于食品和益生菌制剂。,L. plantarum 2519、3725和3735在酸耐受性、胆盐耐受性、自聚集性、共聚集性及胆固醇吸收方面均优于或相当于参考菌株LGG。其中，L. plantarum 2519自聚集率达94.62%，L. plantarum 3725胆固醇吸收率达47.83%，对多种食源性病原菌抑制效果达4.6 log cfu/mL，表明其具有优异的益生功能潜力，可作为功能性食品或益生菌制剂的优选菌株。,20376,1902,22278,,
8c63ff92-328f-444b-87b7-0cddbeb8f849,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCFM""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates bile salts (0.3% w/v) and gastric acidity (pH 2.5–3.0) for 2 hours",Doubling time ~1.5 hours in vitro; in vivo colonization observed within 24 hours post-consumption,"Large intestine (colon), particularly mucosal surface of the distal colon",Competitive exclusion of pathogenic Enterobacteriaceae; synergistic with resident Bifidobacterium spp. in SCFA production,Resistant to lyophilization and rehydration; stable during 6-month storage at 4°C; moderate shear tolerance in liquid formulation,Exopolysaccharides (EPS) produced by L. acidophilus NCFM,该菌株为兼性厌氧菌，适宜在37°C、pH 6.5–7.0条件下生长，能耐受胃酸（pH 2.5–3.0）和胆盐（0.3% w/v），在体外培养中 doubling time 约为1.5小时，口服后24小时内可在肠道黏膜定植，主要定植于结肠远端黏膜表面。,"Plasmid pSIP409 (lactococcal origin), CRISPR-Cas9 for gene knockout",High efficiency (>90%) for targeted gene disruption; low off-target effects reported,Constitutive expression of EPS and lactase genes,,Chromosomal integration of key genes; plasmid loss rate <0.5% per generation; no significant metabolic burden observed,Stable in fermented milk matrix; no degradation of plasmid or gene expression during storage,通过CRISPR-Cas9技术对L. acidophilus NCFM进行基因编辑，实现关键代谢基因（如乳糖酶和胞外多糖合成基因）的稳定表达，采用pSIP409质粒系统实现基因的高效整合与表达，确保在发酵乳基质中长期稳定。,"[""pH"", ""Bile Acids""]","[""Lactose"", ""Glucose""]",,"[""Mucin"", ""Proteases""]",Lactose permease (LacS) and bile acid receptor (BilP),Threshold-based activation: expression of EPS and lactase genes triggered when lactose >0.5% and pH >5.5,该系统通过乳糖转运蛋白（LacS）和胆盐受体（BilP）感知肠道环境中的乳糖和胆盐浓度，当乳糖浓度超过0.5%且pH高于5.5时，启动胞外多糖和乳糖酶的表达，实现对肠道微环境的响应性调控。,"[""Metabolic Regulation"", ""Tissue Repair""]",Type I Secretion System (T1SS) for EPS export,Dose-dependent effect; 10^9 CFU/day shown to improve bowel habits in elderly,High compatibility with fermented milk matrix; EPS secretion does not disrupt gel structure,False,,,,,,,,,,False,,,,,,,False,,,True,Enhances mucosal barrier integrity via increased mucus production and tight junction protein expression,Exopolysaccharides (EPS),True,"Produces short-chain fatty acids (SCFAs) such as acetate and lactate, modulating colonic pH and promoting healthy bowel movements","Acetate, Lactate",False,,,GRAS,Auxotrophy for thymidine (thymidine-requiring mutant),Thymidine,Non-pathogenic; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape reported,Fermented milk matrix provides physical confinement and limits systemic dissemination,该菌株为GRAS级微生物，经基因改造后为胸腺嘧啶营养缺陷型，可在无胸腺嘧啶环境中被选择性清除，具有良好的生物安全性和环境可控性。,在养老院老年人群中，每日摄入含10^9 CFU的L. acidophilus NCFM发酵乳，连续4周后，Bristol粪便量表评分从3.2提升至4.8，显著改善便秘症状，且无明显不良反应。,2866,1615,4481,,
9086d833-0d44-452f-a6a6-de6649ef197a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Clostridium butyricum"", ""strain_id"": ""DSSJ""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""KJT""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus licheniformis"", ""strain_id"": ""DB""}]",Suspension,Facultative Anaerobe,"Growth at 37°C, pH tolerance not explicitly stated, requires CO2 (5%) for Lactobacillus plantarum; general tolerance to intestinal environment","Average daily weight gain of 0.39 Jin (Clostridium butyricum), 0.3 Jin (Lactobacillus plantarum), 0.47 Jin (Bacillus licheniformis); in vivo growth supported by intestinal colonization","Intestinal tract (gastrointestinal tract of chickens), particularly in the terminal ileum and digestive tract","Competitive exclusion of pathogenic bacteria (e.g., E. coli, Salmonella); promotes balance of intestinal flora; supports anaerobic environment via oxygen consumption (Bacillus)",Survival in simulated gastrointestinal environment (as tested for strain Y5); tolerance to bile and pH (implied by probiotic criteria),"Bile salt hydrolase (Bsh), acid protease, neutral protease","Clostridium butyricum, Lactobacillus plantarum, and Bacillus licheniformis are capable of surviving in the gastrointestinal tract, colonizing the intestinal mucosa, and promoting growth and digestibility in chickens. They exhibit strong adaptation to the intestinal environment, with Clostridium butyricum showing the highest weight gain. These strains are resilient to digestive stresses and contribute to maintaining intestinal homeostasis.",,,,,,,"No genetic engineering was performed in this study. The probiotics were used in their native form, relying on natural enzyme production and metabolic activity for function. No synthetic circuits, inducible promoters, or genetic modifications were reported.","[""pH"", ""Oxygen""]","[""Bile acids"", ""Lactose"", ""Starch"", ""Proteins""]",,,"Bile salt hydrolase (Bsh), acid protease, neutral protease, β-amylase",No synthetic logic circuits reported; natural metabolic responses to substrate availability and environmental conditions.,"The probiotics naturally sense and respond to the presence of substrates such as starch, proteins, and bile acids in the gut. Their enzyme production is constitutive and substrate-dependent, with activity increasing in response to nutrient availability. No engineered sensing logic or threshold control was implemented.","[""Digestive Enzyme Production"", ""Nutrient Digestibility Enhancement"", ""Pathogen Inhibition""]","Constitutive secretion of enzymes via natural secretion systems (e.g., Sec pathway)",Natural enzyme activity regulated by substrate availability and environmental conditions; no external control mechanism,Compatible with feed and intestinal environment; no encapsulation or material barrier reported,True,True,False,"Lactic acid production lowers intestinal pH, inhibiting growth of pathogens like E. coli and Salmonella. Bacillus consumes oxygen, creating anaerobic conditions favorable to beneficial bacteria and unfavorable to aerobes.","Lactic acid, oxygen consumption",True,True,True,True,Lactic acid production reduces pH and inhibits pathogenic bacteria; oxygen consumption by Bacillus prevents growth of aerobic pathogens. No cytotoxicity or microbiome disruption reported.,False,,,False,False,False,,False,,,False,,,True,"Production of digestive enzymes (e.g., β-amylase, proteases) enhances nutrient breakdown and absorption, improving metabolic efficiency and energy utilization.","Reducing sugars, amino acids, fatty acids",False,,,GRAS,None (natural strains used without kill switches or auxotrophy),,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; safe for use in feed,None (no physical confinement or encapsulation used),All strains used are recognized as safe (GRAS) for animal feed. No genetic modifications or biocontainment strategies were employed. The strains are naturally occurring and well-characterized probiotics with no known pathogenicity or antibiotic resistance. They are unlikely to escape or cause harm in the environment.,"Clostridium butyricum showed the highest weight gain (1.16 Jin over 15 days), followed by Bacillus licheniformis (2.42 Jin) and Lactobacillus plantarum (1.81 Jin). Apparent digestibility of dry matter, crude protein, and organic compounds improved significantly (e.g., dry matter digestibility increased from 67.8% to 78.3%). β-amylase at 30–40 U/g maximized reducing sugar yield. Overall, probiotics significantly enhanced growth and nutrient digestibility in chickens.",10793,1698,12491,,
25943934-ca2a-4fb5-bb3f-0dd59456e161,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""ATCC 11842""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires lactose and other fermentable carbohydrates; grows in milk-based media (MRS broth).","Doubling time ~1.5–2 hours in vitro; in vivo stability not explicitly reported, but survives gastrointestinal transit.","Gastrointestinal tract (small intestine, colon); adheres to intestinal epithelium.",Competitive exclusion of pathogens; modulates host microbiome via immune signaling; no direct evidence of symbiosis with other strains.,"Tolerant to gastric acidity (pH 2–3), bile salts, osmotic stress; survives lyophilization and rehydration.","Cell wall components (e.g., teichoic acids), stress response proteins (e.g., chaperones), and acid tolerance systems.",乳酸菌（LAB）为兼性厌氧菌，适宜在37°C、pH 6.5–7.0的环境中生长，依赖乳糖等可发酵碳源。在体外培养中，其倍增时间为1.5–2小时。在体内可耐受胃酸（pH 2–3）和胆盐，具有良好的胃肠道定植能力，能通过胃肠道屏障并定植于小肠和结肠黏膜，表现出较强的环境适应性和稳定性。,Not specified (no genetic modification reported),"Not applicable (natural strains used, no editing described)",Constitutive (no inducible circuits reported),,High chromosomal stability; no plasmids reported; no evidence of genetic drift in study.,No engineered material environment; natural strains used in food matrix.,研究中使用的是天然存在的乳酸菌株，未进行任何基因工程改造。L. rhamnosus GG 和 L. delbrueckii subsp. bulgaricus 均为传统发酵菌种，其免疫调节功能源于天然代谢产物和细胞成分，无需外源基因调控。,"[""pH"", ""Lactate""]","[""Lactose"", ""Glucose""]",,"[""Proteases"", ""Cytokines""]","Cell wall components (e.g., peptidoglycan, lipoteichoic acid), surface receptors (e.g., TLR2, TLR9), and secreted metabolites (e.g., SCFAs).",No engineered logic gates; natural sensing via pattern recognition receptors (PRRs) with threshold-dependent activation.,乳酸菌通过其细胞壁成分（如肽聚糖、脂磷壁酸）与宿主免疫细胞表面的Toll样受体（TLR2、TLR9）结合，触发免疫信号通路。该过程具有阈值响应特性，仅在达到一定菌量或特定代谢产物浓度时激活免疫反应。同时，肠道上皮细胞可通过分泌细胞因子调节免疫反应强度，实现对免疫应答的负反馈调控。,"[""Immunomodulation""]","Cell wall components and secreted metabolites (e.g., SCFAs); no specific secretion systems reported.",Dose-dependent immune stimulation; effects observed at 100–200 g/day in vivo.,Compatible with fermented milk matrix; survives encapsulation in dairy products without structural disruption.,False,,,,,,,,,,False,,,,,,,True,通过激活树突状细胞（DC）和调节T细胞反应，促进Th1型免疫应答，增强自然杀伤细胞（NK）活性和巨噬细胞吞噬功能，调节促炎与抗炎细胞因子平衡。,"Peptidoglycan, lipoteichoic acid, SCFAs (e.g., acetate, propionate), and secreted cytokines (e.g., IL-12, IFN-γ, IL-10)",False,,,False,,,False,,,GRAS,"None (natural strains, no kill-switches or auxotrophy reported)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape concerns.,Physical barrier provided by gastrointestinal mucosa and food matrix.,L. rhamnosus GG 和 L. delbrueckii subsp. bulgaricus 均为公认安全（GRAS）菌株，广泛用于食品发酵，无致病性记录，不携带已知抗生素抗性基因，且在正常条件下不会在环境中长期存活，安全性高。,在健康女性中，每日摄入含乳酸菌的发酵乳制品（包括传统酸奶和益生菌产品）可显著增强免疫功能，表现为自然杀伤细胞活性提高、T细胞活化标志物CD69表达上升、促炎细胞因子（IFN-γ、IL-1β、TNF-α）分泌增加，且在停用后仍维持一定免疫增强效应。体外实验显示，L. rhamnosus GG 更强地诱导树突状细胞成熟，而 L. delbrueckii 则更显著促进促炎因子分泌。两种菌株均能通过肠道上皮屏障影响系统性免疫，但其效应依赖于直接接触，表明其免疫调节作用具有局部性和条件依赖性。,8827,1845,10672,,
60a56303-0e93-4405-bb84-d9e79bba79c0,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""NFBC 338""}]",Encapsulated,Facultative Anaerobe,Anaerobic growth at 37°C on MRS medium with 10 μg/ml chloramphenicol; resistant to gastrointestinal transit stresses,Growth in stationary phase; cultured to stationary phase before use; no specific doubling time reported,"Intestinal lumen, particularly in the context of high-fat diet-induced metabolic dysfunction",No significant alteration in caecal microbiome composition observed; suggests minimal competition or disruption of resident microbiota,Resistant to gastric transit; stable after lyophilization and storage at 4°C; tolerant to freeze-thaw cycles,Trehalose (used in lyophilization buffer),该工程菌株为Lactobacillus paracasei NFBC 338，属于兼性厌氧菌，可在37°C厌氧条件下于MRS培养基中生长。该菌株具有良好的胃肠道耐受性，能耐受胃酸和胆汁环境，且在冻干后仍保持活性，适合口服递送。,"Plasmid pNZ44, CRISPR-Cas not used; overlap extension PCR (OE-PCR), restriction enzyme digestion, T4 DNA ligase, electroporation",High efficiency confirmed by DNA sequencing and MALDI-TOF MS; successful transformation and stable plasmid maintenance,Constitutive expression via pNZ44 promoter; no inducible system reported,,Stable plasmid maintenance with chloramphenicol selection; no evidence of plasmid loss in vivo; chromosomal integration not performed,Stable in lyophilized form with trehalose; suitable for encapsulation and oral delivery,通过重叠延伸PCR构建KGLP-1基因，并利用乳酸菌素（pediocin）信号肽序列实现分泌。将KGLP-1基因与pediocin信号肽融合后克隆至pNZ44质粒中，通过电穿孔法转化至Lactobacillus paracasei NFBC 338中，实现DPP-4抗性GLP-1类似物的持续分泌。,,,,,,No sensing or logic circuitry reported; constitutive expression only,该系统未设计任何环境感应模块，GLP-1类似物的表达为组成型，不受宿主或环境信号调控，仅依赖于质粒的持续表达。,"[""Metabolic Regulation"", ""Immunomodulation""]","Leader peptide-mediated secretion via pediocin export system (pedB, pedC, pedD membrane proteins)",Controlled by oral administration of 10^9 CFU/day; expression is constitutive and not tunable in this study,Compatible with lyophilization and oral delivery; stable in trehalose matrix; no structural disruption reported,False,,,,,,,,,,False,,,,,,,True,"Secreted KGLP-1 analogue modulates immune responses via GLP-1 receptor signaling; reduces pro-inflammatory cytokines (IL-6, TNF-α) and promotes anti-inflammatory IL-10.",KGLP-1 (DPP-4-resistant GLP-1 analogue),False,,,True,"KGLP-1 secretion improves glucose metabolism, insulin sensitivity, and lipid/cholesterol metabolism by activating intestinal and pancreatic GLP-1 receptors, reducing chylomicron production and lowering triglycerides, LDL-C, and TRL-C.",KGLP-1 (long-acting GLP-1 analogue),False,,,GRAS,Auxotrophy not used; no kill-switch reported; reliance on chloramphenicol selection in vitro,Chloramphenicol (antibiotic selection marker),No pathogenicity reported; non-pathogenic probiotic strain; no antibiotic resistance genes beyond chloramphenicol; low risk of horizontal gene transfer; no evidence of environmental escape in study,Lyophilized formulation provides physical confinement; oral delivery limits systemic spread,该菌株为公认安全（GRAS）的Lactobacillus paracasei NFBC 338，无致病性，不携带已知抗生素抗性基因（除氯霉素外），且在动物实验中未引起微生物组显著变化，表明其具有良好的生物安全性。,在高脂饮食诱导的肥胖大鼠中，短期干预（3周）显著降低血清LDL-C（19%）、甘油三酯（20%）和TRL-C；在小鼠中，长期干预（12周）显著改善葡萄糖耐量、胰岛素敏感性、胰岛素分泌及胆固醇代谢，降低总胆固醇和餐后胆固醇水平。此外，该菌株独立于GLP-1分泌，可显著减少脂肪组织积累并调节氨基酸、生物胺和磷脂代谢，提示其具有多重代谢调节功能。,16343,1701,18044,,
121b583b-a627-4f63-a4cb-afe5df0567cf,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacteroides thetaiotaomicron"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Akkermansia muciniphila"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Faecalibacterium prausnitzii"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Coprococcus eutactus"", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Lactobacillus paracasei CNCM I-3689"", ""strain_id"": ""CNCM I-3689""}, {""role"": ""Helper"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""Not specified""}, {""role"": ""Prey"", ""scientific_name"": ""Clostridioides difficile"", ""strain_id"": ""Not specified""}]",Biofilm,Facultative Anaerobe,"Optimal temperature: 37°C; pH: 6.5–7.5; Nutritional requirements: Non-digestible carbohydrates (NDCs), host-derived glycans (e.g., mucin), amino acids, vitamins; Osmotic tolerance: Moderate; Bile tolerance: High (due to bile acid metabolism)",Doubling time: ~1.5–2 hours in vitro; In vivo homeostasis: Stable over weeks to months; Growth rate consistent between in vitro and in vivo conditions,"Colon mucosa, mucus layer, hypoxic regions of the large intestine","Mutualism with host (mucin degradation, SCFA production); Cross-feeding with Bifidobacterium and other fermenters; Antagonism against pathogens via bacteriocin production (E. coli), SCFA-mediated inhibition; Biofilm formation enhances persistence and resistance to stress","High tolerance to bile acids, osmotic stress, and low pH; Moderate tolerance to shear stress; Stable during lyophilization and rehydration; UV sensitivity not reported","Bile acid resistance genes (e.g., bile salt hydrolases), mucus-binding adhesins, biofilm matrix components",该微生物群落以拟杆菌属（Bacteroides thetaiotaomicron）和阿克曼氏菌（Akkermansia muciniphila）为底盘，具有在肠道黏液层中定植并利用宿主黏蛋白和非消化性碳水化合物的能力。其生长依赖于低氧环境，能通过代谢灵活性适应营养变化，表现出高度的生态稳定性。在抗生素扰动后，该群落可通过交叉喂养和生物膜形成维持功能冗余，促进肠道生态系统的恢复。,"CRISPR-Cas9 (inferred from context of strain-specific modulation), Recombination (inferred from probiotic strain engineering)",High efficiency in model strains; Off-target risk not reported,Constitutive expression of key metabolic genes; Inducible systems not reported,Not applicable,High chromosomal stability; Plasmid stability not reported; Metabolic burden low; Evolutionary stability supported by niche specialization; Long-term in vivo consistency observed in murine models,Stable in mucus and biofilm matrices; Compatible with encapsulation in prebiotic fibers,通过补充特定益生菌（如Lactobacillus paracasei CNCM I-3689）和非消化性碳水化合物（NDCs），调控肠道微生物群落结构。利用拟杆菌属和阿克曼氏菌的代谢灵活性，促进黏蛋白降解与短链脂肪酸（SCFA）生成，恢复肠道屏障功能。通过交叉喂养机制增强群落稳定性，实现功能冗余。,"[""Hypoxia"", ""pH"", ""ROS"", ""Lactate""]","[""Bile Acids"", ""SCFAs"", ""Glucose"", ""Mucin""]","[""AHL"", ""AI-2""]","[""Protease"", ""Cytokines"", ""Mucin""]","FNR promoter (hypoxia), Bile acid receptor (BacA), Quorum sensing receptors (LasR, LuxR homologs), Mucin-binding adhesins",AND gate: Hypoxia + Mucin presence → Biofilm formation; Thresholds: SCFA levels regulate metabolic switching; Noise suppression via feedback inhibition of metabolic pathways,该群落通过多重信号感知机制实现动态调控：在低氧和黏蛋白存在条件下，启动生物膜形成；通过短链脂肪酸（SCFA）浓度反馈调节代谢路径，避免过度发酵；利用群体感应分子（AHL/AI-2）协调群落行为，实现协同代谢与竞争抑制。逻辑控制确保在健康状态下维持稳态，在扰动后快速响应并恢复功能。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type VI secretion system (T6SS), Vesicles, Lysis",Output strength regulated by substrate availability (NDCs); Controllability via dietary modulation; Persistence linked to biofilm formation,High compatibility with mucus layer and prebiotic matrices; Permeable to gel-like environments; No structural disruption observed,True,True,True,通过产生抗菌素（如大肠杆菌的微菌素）和短链脂肪酸（SCFAs）抑制病原体生长，同时通过生物膜形成增强定植能力，防止病原体入侵。,"Microcins (E. coli), Short-chain fatty acids (SCFAs)",True,True,True,True,研究显示，补充Lactobacillus paracasei CNCM I-3689可减少万古霉素耐药肠球菌，恢复对艰难梭菌的定植抗性；SCFAs可抑制多种病原体生长，且在生理浓度下无细胞毒性。,False,无光依赖或非光依赖的氧气生成机制。,Not applicable,False,False,False,未提及氧气生成功能，因此不适用。,True,通过调节免疫细胞活性，降低促炎因子（如TNF-α、IL-6）水平，促进抗炎因子（如IL-10）分泌，维持肠道免疫稳态。,"Interleukin-10 (IL-10), TGF-β",True,通过产生短链脂肪酸（SCFAs）促进上皮细胞增殖，增强肠道屏障功能，修复受损黏膜。,"Butyrate, Acetate",True,通过代谢碳水化合物产生短链脂肪酸（SCFAs），调节宿主能量代谢，改善胰岛素敏感性，抑制炎症。,"Butyrate, Acetate, Propionate",False,未涉及肿瘤治疗机制。,Not applicable,BSL-1,"Auxotrophy (e.g., dependence on mucin or NDCs), Kill-switch (inferred from ecological niche restriction)","Mucin, Non-digestible carbohydrates (NDCs)",Low pathogenicity; No known antibiotic resistance genes reported; Low horizontal gene transfer risk due to niche specificity; Environmental escape unlikely due to host dependency,Mucus layer and intestinal epithelium act as effective physical barriers,该微生物群落为人体肠道共生菌，无致病性，依赖宿主提供的黏蛋白和非消化性碳水化合物生存，具有天然的生物安全屏障。在正常条件下不会在环境中长期存活，且缺乏抗生素抗性基因，因此风险极低。,在抗生素扰动后，该群落可通过恢复微生物多样性、增强功能冗余和促进短链脂肪酸（SCFA）生成，显著改善肠道屏障功能，减少炎症反应。动物模型显示，补充Lactobacillus paracasei CNCM I-3689可加速Bacteroidetes恢复，降低万古霉素耐药肠球菌水平，提高对艰难梭菌的定植抗性。长期摄入富含非消化性碳水化合物的饮食可维持群落稳定性，预防代谢性疾病发生。,12128,2448,14576,,
294642b6-c372-4e57-80d7-69d170840533,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""CP2305s""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""CPA305C""}]",Suspension,Facultative Anaerobe,"Growth at 37°C, pH 6.5–7.0, in MRS medium; requires complex nutrients including peptides, amino acids, vitamins, and carbohydrates.",Doubling time not specified; growth observed in vitro under standard laboratory conditions.,Ileal mucosa (target site of study); likely transient colonization in the small intestine.,No direct interaction data reported; strain-specific immune modulation suggests potential for niche-specific host-microbe crosstalk.,Not explicitly reported; viability maintained during oral administration and in vivo passage.,,"Lactobacillus gasseri CP2305s and Lactobacillus plantarum CPA305C are facultative anaerobes capable of growing in standard MRS medium under aerobic or microaerophilic conditions. They are adapted to the gastrointestinal environment and survive oral administration in mice. Their growth is supported by complex nutrients including peptides, amino acids, vitamins, and carbohydrates. Both strains are transient colonizers in the ileum, with no evidence of long-term persistence.",,,,,,,"No genetic modifications were performed. The strains were used in their native form for probiotic supplementation. No plasmids, CRISPR systems, or synthetic circuits were employed. The study focused on natural host-microbe interactions without engineered genetic circuits.","[""pH"", ""Hypoxia""]","[""Lactate"", ""Glucose""]",,"[""Toll-like receptor 2 (TLR2)"", ""Cytokines (IL-12, IL-10)""]",TLR2 receptor; IL-12/IL-10 signaling pathways,No synthetic logic gates; natural immune sensing via TLR2 and cytokine feedback loops.,"The microbial strains are sensed by host immune cells via TLR2, which is expressed at higher levels in suckling mice. This leads to differential activation of downstream signaling (e.g., NF-κB), resulting in strain-specific cytokine production (IL-12 by L. gasseri, IL-10 by L. plantarum). The host’s developmental stage determines the sensitivity and response magnitude, indicating a developmental-stage-dependent logic in immune recognition.","[""Immunomodulation""]","Passive secretion of immunomodulatory molecules (e.g., cytokines, cell wall components); no engineered secretion systems used.",Dose controlled by oral administration of 10⁶ CFU/g body weight; no dynamic control mechanisms.,Strains were administered in suspension via oral gavage; no encapsulation or material-based delivery system used.,False,,,,,,,,,,False,,,,,,,True,"L. gasseri CP2305s strongly induces IL-12, promoting Th1-type immune responses; L. plantarum CPA305C induces IL-10, promoting anti-inflammatory and regulatory responses. Both strains modulate host immune signaling pathways in an age-dependent manner.","Interleukin-12 (IL-12), Interleukin-10 (IL-10)",False,,,False,,,False,,,BSL-1,None; no kill switches or auxotrophy used.,,No antibiotic resistance genes reported; both strains are GRAS (Generally Recognized As Safe) for human consumption. Low pathogenicity; no evidence of horizontal gene transfer or environmental escape in this study.,None; no physical barrier used for containment.,"Lactobacillus gasseri CP2305s and Lactobacillus plantarum CPA305C are well-characterized probiotic strains with established safety profiles. They are classified as BSL-1 and GRAS. No genetic modifications were made, eliminating risks of horizontal gene transfer or uncontrolled proliferation. The study used standard oral administration without engineered containment, but the natural attenuation and transient colonization reduce ecological risk.","The study did not assess wound healing or therapeutic outcomes. Instead, it demonstrated that the same probiotic strains elicit completely different gene expression profiles in the ileal mucosa of suckling versus adult mice, indicating age-specific immunomodulatory effects. This suggests that probiotic efficacy is developmentally regulated, with implications for personalized probiotic use across age groups.",8622,1621,10243,,
e1a5b8ff-2175-442f-9ba6-055b5cce82b5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""Isolated from intestine of Cirrhinus mrigala""}]",Encapsulated in feed pellets,Facultative Anaerobe,"Temperature: 35°C; pH: not specified; Osmotic: not specified; Nutrition: complex diet (fish meal, wheat flour, soybean meal, groundnut oil cake); Carbon source: organic substrates in feed",Growth rate: 24 h incubation at 35°C; Doubling time: not specified; In vivo vs in vitro: viable in feed and intestinal tract of fish,"Intestinal tract of livebearing ornamental fish (Poecilia reticulata, Poecilia sphenops, Xiphophorus helleri, Xiphophorus maculatus)","Colonizes gut, enhances beneficial microbial activity; no mention of competition or symbiosis with native microbiota","High tolerance to drying (lyophilization), heat (spore formation), storage at 4°C; survives passage through gastrointestinal tract",Endospores (Bacillus subtilis spores),"Bacillus subtilis is a spore-forming, facultative anaerobic bacterium capable of surviving in feed during storage and colonizing the intestinal tract of ornamental fish. It grows optimally at 35°C and maintains viability in feed for up to 90 days at 4°C, attributed to its endospore-forming ability.",,,,,No genetic modification; natural strain used; chromosomal stability assumed due to lack of plasmid use,Stable in feed matrix; maintains viability during storage and digestion,"The Bacillus subtilis strain used in this study is a naturally occurring, non-genetically modified probiotic isolated from the intestine of Cirrhinus mrigala. It was not genetically engineered; its probiotic function relies on natural metabolic and colonization properties.",,,,,,,No engineered sensing or logic circuits; natural environmental sensing via metabolic adaptation to gut conditions.,"[""Reproductive Performance Enhancement"", ""Nutrient Synthesis"", ""Immune Support""]",Natural secretion of enzymes and vitamins via cell lysis and extracellular release,Controlled by dietary concentration (5×10⁵ to 5×10⁸ cells/g feed); no feedback control,High compatibility with feed matrix; stable in pelletized feed and during storage,False,False,False,Not applicable; no antibacterial mechanism reported in this study.,,False,False,False,False,无抗菌功能相关证据,False,Not applicable; no oxygen-producing mechanism reported.,,False,False,False,无氧生成相关证据,False,Not applicable; no direct immune modulator reported.,,False,Not applicable; no tissue repair factor reported.,,True,"Bacillus subtilis synthesizes B-group vitamins (e.g., thiamine, vitamin B12), essential fatty acids, and digestive enzymes (amylase, protease, lipase), which enhance nutrient assimilation and support reproductive physiology.","Thiamine (Vitamin B1), Vitamin B12, Essential fatty acids (e.g., arachidonic acid, DHA, EPA), Amylase, Protease, Lipase",False,Not applicable; no tumor-targeting or prodrug conversion function.,,GRAS,None; natural strain used without genetic modification,,Non-pathogenic; confirmed via immersion challenge assay on fish fingerlings; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk due to non-replication outside host,Feed pellet matrix provides physical confinement,"Bacillus subtilis strain is non-pathogenic, GRAS-status, and confirmed safe in fish challenge tests. It does not carry antibiotic resistance genes and is not genetically modified. Its spore-forming ability ensures survival in feed but limits environmental persistence. Physical confinement in feed pellets prevents uncontrolled release.",在所有四种观赏性卵胎生鱼类（Poecilia reticulata、Poecilia sphenops、Xiphophorus helleri、Xiphophorus maculatus）中，添加Bacillus subtilis的饲料显著提高了雌鱼的生殖性能，包括卵腺体指数（GSI）、产卵量、仔鱼存活率、仔鱼平均体重和体长，同时显著降低了死鱼和畸形鱼的数量。最高效果出现在T3组（5×10⁶ cells/g饲料），表明10⁶–10⁸ cells/g的剂量足以显著提升繁殖性能，更高剂量未带来额外益处。,19496,1602,21098,,
c3b9bcdc-8b31-44e5-b9bf-efa3f06cff3e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium SF68"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus acidilacticii"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": """"}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric acidity (pH 2–3) and intestinal bile; utilizes glucose, lactose, and other carbohydrates as carbon sources; requires no specific vitamins beyond those in standard media",Doubling time ~60–90 min in vitro; in vivo colonization observed within 24–48 hours post-ingestion; stable in gastrointestinal tract for 3–7 days,Small intestine and colon; preferentially colonizes mucosal surfaces and lumen of gastrointestinal tract,"Competitive exclusion of pathogenic bacteria (e.g., E. coli, Clostridium perfringens); synergistic interaction with prebiotics (e.g., inulin, FOS); promotes growth of indigenous beneficial microbiota","Moderate tolerance to drying, heat (up to 50°C for short periods), and shear stress; enhanced stability via microencapsulation; survives lyophilization and rehydration","Microencapsulation matrix (e.g., alginate, chitosan)",这些益生菌为兼性厌氧菌，可在37°C、pH 6.0–7.0条件下良好生长，耐受胃酸和胆汁环境，利用葡萄糖、乳糖等碳源，无需额外维生素。在体外倍增时间为60–90分钟，口服后24–48小时内可在肠道定植，持续3–7天。主要定植于小肠和结肠黏膜表面及肠腔，通过竞争排斥作用抑制大肠杆菌、产气荚膜梭菌等病原体，并与益生元协同促进内源性有益菌群生长。,None reported,Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems reported; minimal metabolic burden; no evidence of drift in vivo,Stable in microencapsulated formulations; no significant degradation in delivery matrix,文中未提及对益生菌进行基因改造。所有功能均依赖于天然菌株的生理特性，如定植能力、代谢产物分泌及与宿主和微生物群的相互作用。,"[""pH"", ""Glucose"", ""Lactate""]","[""Short-chain fatty acids (SCFAs)"", ""Bile acids""]","[""Quorum sensing (AHL, AI-2)""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), Lactate receptor (LacR), Bile acid transporter (BaiS)",Threshold-based activation; low-level sensing of pH and lactate; no reported complex logic gates,这些益生菌通过感知肠道pH变化、乳酸浓度及胆汁酸水平来调节自身代谢与定植行为。例如，低pH和高乳酸环境可激活乳酸代谢相关基因，而胆汁酸则诱导耐受性基因表达。整体为简单阈值响应机制，无复杂逻辑门控，但具备一定的环境适应性筛选能力。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion (e.g., bacteriocins), Vesicles (exosomes), Lysis (controlled release)",Dose-dependent effects; efficacy linked to daily intake of 10^8–10^10 CFU; no reported overstimulation or toxicity,Compatible with microencapsulation; maintains viability and function in feed matrices,True,True,False,通过分泌有机酸（如乳酸）、细菌素（如乳杆菌素）和竞争性排斥机制抑制病原菌生长，尤其对大肠杆菌、产气荚膜梭菌等具有显著抑制作用。,"Lactic acid, Bacteriocins (e.g., Lactocin, Enterocin)",True,True,True,True,在猪、牛、羊、犬、猫等动物中，摄入益生菌后大肠杆菌和产气荚膜梭菌数量显著减少，腹泻发生率下降，且未观察到对正常菌群造成显著破坏。,False,,,False,False,False,,True,通过调节肠道免疫屏障功能，促进IgA、IgM分泌，增加CD4+ T细胞和成熟B细胞比例，增强特异性免疫应答，同时抑制过度炎症反应。,"IgA, IgM, CD4+ T cells, B cells (CD21+/MHC-II+)",True,通过改善肠道上皮细胞形态（如增加绒毛高度、隐窝深度），促进营养吸收，修复受损肠黏膜，间接支持组织再生。,"Short-chain fatty acids (SCFAs), Epithelial growth factors",True,通过发酵碳水化合物产生短链脂肪酸（乙酸、丙酸、丁酸），降低肠道pH，促进矿物质吸收，调节葡萄糖代谢和胰岛素敏感性。,"Acetate, Propionate, Butyrate",False,,,BSL-1,"Auxotrophy (e.g., vitamin-dependent strains), Natural attenuation","Vitamin B12, Folic acid",Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape; GRAS status for several strains,Microencapsulation provides physical confinement and protects against degradation,所列益生菌均为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，不引起水平基因转移，且在环境中难以长期存活。微胶囊化技术进一步增强了其物理屏障作用，防止逃逸。,在猪、牛、羊、犬、猫等动物中，益生菌补充显著改善了繁殖性能、早期生长速率、免疫功能和肠道健康。具体表现为：断奶仔猪增重提高、腹泻率下降；奶牛产奶量增加、乳脂和乳蛋白含量上升；羔羊和幼犬死亡率降低；幼猫腹泻治疗率从60%降至10%。益生元与益生菌联用可协同增强肠道屏障功能和免疫应答。,5534,2104,7638,,
f55115c2-ec23-4826-8929-a5670b262c7d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""11741""}]",Biofilm,Facultative Anaerobe,Growth at 37°C in MRS broth; pH not specified; nutrient-rich environment supported by IMDM in assays,Growth rate not quantified; biofilm formation observed over 6–24 hours; no effect of fluorophores on viability,"Intestinal lumen, particularly relevant to microbiota-gut-brain axis",Potential for interkingdom communication via biogenic amine uptake; may influence host signaling and microbial interactions,"Tolerant to temperature shifts (37°C vs 25°C); no data on UV, drying, or shear stress",,该菌株在37°C下于MRS培养基中生长良好，可形成生物膜，对荧光探针无毒性，表明其在肠道环境中具有良好的生理稳定性。,,,,,,,研究未涉及基因工程改造，仅通过荧光探针检测天然存在的转运蛋白功能，未对基因进行编辑或调控。,"[""Hypoxia"", ""pH"", ""Temperature""]","[""Norepinephrine"", ""Serotonin"", ""Fluoxetine"", ""Nitrite""]",,"[""Biogenic Amines"", ""Neurotransmitters""]",PMAT-like and OCT-like transporters (putative homologs of SLC29A4 and SLC22 family),"Competitive inhibition observed; uptake inhibited by natural substrates (NE, SER) and inhibitors (fluoxetine, decynium-22), suggesting substrate-specific, regulated uptake with threshold sensitivity",该菌株通过PMAT和OCT样转运蛋白识别并摄取生物胺类物质，其摄取过程受自然底物和药物的竞争性抑制，表现出类似受体-配体的特异性识别与调控逻辑，具有阈值响应和信号过滤能力。,"[""Metabolic Regulation"", ""Interkingdom Communication""]",Passive uptake via membrane transporters (no secretion system reported),Not applicable; uptake is passive and regulated by substrate concentration and competition,Compatible with biofilm formation in microplate assays; no data on encapsulation or material integration,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,通过PMAT和OCT样转运蛋白摄取生物胺（如去甲肾上腺素、5-羟色胺），调节肠道内神经活性物质浓度，参与微生物-宿主代谢互作。,"Norepinephrine, Serotonin, Fluoxetine",False,,,GRAS,None reported; no kill-switch or auxotrophy used,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer data; environmental escape risk not assessed,Biofilm formation may provide physical confinement in host environment,Lactobacillus salivarius为公认安全（GRAS）菌株，无已知致病性，未进行基因改造，无生物安全风险，但其在肠道中摄取神经活性物质的能力可能影响宿主生理，需进一步评估长期安全性。,该研究未评估伤口愈合或治疗效果，但发现L. salivarius可通过PMAT和OCT样转运蛋白摄取生物胺，提示其在调节肠道-脑轴功能中具有潜在益生作用，可能改善应激相关肠道通透性和行为异常。,11515,1398,12913,,
08de6726-974c-4305-90a0-b503ce6e95e9,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Candidatus Arthromitus"", ""strain_id"": ""SFB (Segmented Filamentous Bacteria)""}]","Orally administered spores, colonizing distal ileum",Facultative Anaerobe,"Optimal growth at 37°C, pH neutral to slightly alkaline; tolerant to intestinal pH and bile; requires host-derived nutrients for growth",Spore-forming bacteria exhibit dormancy during transit; germinate in the distal ileum post-inoculation; colonization observed as early as 3 dpi with full establishment by 7 dpi,"Distal ileum epithelium, specifically adhering to intestinal villi; also detected in ceca",Promotes early immune maturation; enhances SFB colonization; no evidence of pathogenicity or inflammation; may outcompete pathogens via niche occupation,"High tolerance to chloroform, low pH, bile, and desiccation due to spore formation; stable during storage at -80°C",Spore coat (protective protein layer),该系统以肠道中分离的孢子形式口服给药，主要由分节丝状菌（SFB）构成。SFB为兼性厌氧菌，其孢子在胃肠道环境中具有极强的稳定性，可在氯仿处理后存活并定植于鸡的远端回肠。孢子在3天内即可在部分鸡只中检测到，7天后全部定植，表明其具有良好的定植能力。SFB定植于回肠上皮，不引起炎症，且能促进免疫系统早期成熟。,,,,,,,该系统未经过基因工程改造，天然存在的分节丝状菌（SFB）通过口服给药实现定植，其功能由宿主-微生物互作自然调控，无需人工基因回路。,"[""Hypoxia"", ""pH"", ""Bile""]","[""Propionate"", ""Glucose""]","[""Quorum sensing (indirect via community structure)""]","[""Proteases"", ""Cytokines (IL-17, TNF-α)""]","FNR promoter (hypoxia sensor), TLRs (pattern recognition), mTOR pathway (nutrient sensing)","AND gate: requires both hypoxia and nutrient availability (e.g., propionate) for full immune activation; threshold-based activation of TH17 differentiation",分节丝状菌（SFB）通过感知肠道微环境中的低氧、胆汁酸和短链脂肪酸（如丙酸）等信号，激活宿主免疫通路。其定植触发Toll样受体（TLR）和mTOR信号通路，形成“AND”逻辑：仅当低氧与丙酸存在时，TH17细胞分化路径被显著激活。该系统具有动态范围调节能力，能根据信号强度调整免疫响应强度，实现噪声抑制。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Host-derived secretion (e.g., HDPs, IgA)",Self-regulated by host immune feedback; no external control needed,Spores are stable in oral delivery; no material encapsulation used,True,True,False,通过诱导宿主产生抗菌肽（HDPs）如gallinacins，增强对多种沙门氏菌的体外杀伤能力，尤其在7和14天时显著增强。,Host-defense peptides (HDPs),True,True,True,True,在7和14天时，SPORE组小肠刮片对多种沙门氏菌（包括高毒力株）的杀伤能力显著高于对照组，且不依赖IgA，表明其为可控、安全的抗菌机制。,False,,,False,False,False,未检测到氧生成相关机制，因此不适用。,True,激活先天免疫（TLR、JAK-STAT、NK细胞）和适应性免疫（T/B细胞受体、TH17分化），上调PI3K/Akt、mTOR、胰岛素信号通路，促进免疫系统成熟。,"IL-17, TNF-α, IFN-γ, TLR ligands",True,通过激活Wnt信号通路和AMPK通路，促进肠上皮干细胞分化为肠细胞，增强肠道屏障功能，降低肠道通透性。,"Wnt ligands, Akt, AMPK",True,通过激活mTOR、HIF-1α、胰岛素和AMPK信号通路，调控宿主肠道代谢状态，从分解代谢向合成代谢转变，促进细胞增殖与屏障修复。,"Propionate, ATP, AMP",False,,,BSL-1,Natural attenuation via host immune system; no synthetic kill switches,None,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape due to host-restricted niche,None (natural colonization without engineered containment),该系统为天然肠道共生菌（SFB），无致病性，不携带抗生素抗性基因，且仅在鸡的远端回肠定植，不会在环境中长期存活，风险极低，符合BSL-1标准。,口服给药后，SPORE组鸡只在3天时即表现出显著降低的肠道通透性（P<0.01），7天和14天时对多种沙门氏菌的体外杀伤能力显著增强，且伴随TH17免疫通路激活和肠道屏障功能改善。尽管体重增长略低于对照组，但这是免疫系统早期激活的代谢代价，整体表明该系统能有效促进肠道免疫成熟与屏障修复。,16872,1862,18734,,
12161368-a35f-460c-abcc-8ab7ad4ecf8a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus MCCB101"", ""strain_id"": ""MCCB101""}]",Suspension,Facultative Anaerobe,"Temperature: 24–27°C, pH: 7.5–8, Salinity: 15–18%, Nutritional requirements: Standard shrimp feed with probiotic supplementation (10³ cells/animal/day)",Growth rate not explicitly reported; maintained in aquaculture system for 14 days with stable water parameters,Intestine and gills (primary sites of AMP upregulation),"Competitive exclusion of pathogens (e.g., WSV), immunostimulation of host immune system","Tolerant to standard aquaculture conditions (aeration, water quality); no data on UV, drying, or lyophilization",,"Bacillus MCCB101 is a gram-positive, facultative anaerobic bacterium capable of growth in marine aquaculture environments with optimal temperature (24–27°C), pH (7.5–8), and salinity (15–18%). It colonizes the intestinal and gill tissues of Penaeus monodon, where it induces strong upregulation of antimicrobial peptides. The strain is administered via feed and survives in the gut environment for at least 14 days, supporting sustained immune stimulation.",,,,,,,"Bacillus MCCB101 was not genetically modified in this study. Its immunostimulatory effects are attributed to natural probiotic properties, including the ability to upregulate host antimicrobial peptide (AMP) genes without genetic engineering.",,,,,,,"No engineered sensing modules were used. Bacillus MCCB101 naturally interacts with the host immune system through recognition of pathogen-associated molecular patterns (PAMPs), triggering innate immune responses via host pattern recognition receptors. This interaction leads to the upregulation of AMP genes in a non-engineered, natural signaling cascade.","[""Antibacterial"", ""Immunomodulation"", ""Antiviral""]",Host-derived secretion (AMPs produced by shrimp haemocytes and tissues),Dose-dependent effect: 10³ cells/animal/day administered via feed; higher survival rate observed with Bacillus MCCB101 compared to combination or Micrococcus,Compatible with feed-based delivery; no encapsulation or material barrier used,True,False,False,"Bacillus MCCB101 enhances host production of antimicrobial peptides (AMPs) such as ALF, crustins, and penaeidins, which exhibit broad-spectrum activity against bacteria and viruses. The upregulation of these AMPs leads to reduced WSV infection and improved survival.","Antimicrobial peptides (ALF, crustins, penaeidins)",False,True,True,True,"Bacillus MCCB101 administration significantly upregulated AMP genes in shrimp tissues (gills, intestine) and reduced WSV gene expression. No evidence of tissue damage or microbiome disruption was reported. The effect is localized to the host immune system, with no indication of excessive or uncontrolled activity.",False,,,False,False,False,,True,"Bacillus MCCB101 acts as an immunostimulant by upregulating the expression of key antimicrobial peptides (AMPs) in shrimp haemocytes, gills, and intestine. This enhances the host's innate immune response against both bacterial and viral pathogens.","Antimicrobial peptides (ALF, crustins, penaeidins)",False,,,False,,,False,,,BSL-1,Natural attenuation; no kill-switch or auxotrophy used,,"Low pathogenicity; Bacillus MCCB101 is a non-pathogenic, gram-positive bacterium used in aquaculture. No antibiotic resistance genes or horizontal gene transfer risks reported. No evidence of environmental escape or host microbiome disruption.",None (administered via feed; no physical confinement),"Bacillus MCCB101 is classified as BSL-1 with GRAS (Generally Recognized As Safe) status in aquaculture. It is non-pathogenic, does not carry antibiotic resistance genes, and is naturally cleared from the system. No engineered safety mechanisms were used, but its natural attenuation and low virulence ensure minimal risk.","Bacillus MCCB101 administration resulted in a 73% survival rate in WSV-challenged shrimp, significantly higher than control (30%), Micrococcus (56%), and combination (40%). It induced strong upregulation of antimicrobial peptides (ALF, penaeidins) in gills and intestine, reduced WSV gene expression, and enhanced host immune defense without causing tissue damage or microbiome disruption.",11933,1638,13571,,
db1d1135-fa5d-4493-9a12-28b087d8b4da,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paraplantarum"", ""strain_id"": ""a3""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus mundtii"", ""strain_id"": ""s6""}]",Encapsulated,Facultative Anaerobe,"Temperature: 30°C; pH: 6.0–6.5 (MRS medium); Nutritional: MRS broth (polypeptone, yeast extract, glucose, etc.)",Doubling time not specified; growth observed in vitro at 30°C for 24–48 h; persistence in gut over 3 weeks,Gut of abalone Haliotis gigantea,"Competitive exclusion of pathogens (Listonella anguillarum, Vibrio harveyi, V. carchariae); no mention of symbiosis with native microbiota","High resistance to bile salts (≥90% survival), gastric juice (pH 1.5–2.0), and freezing (-30°C storage stability)","Bile salt tolerance (bile salt resistance genes), gastric juice tolerance (acid-resistant cell envelope components)","Lactobacillus paraplantarum a3 and Enterococcus mundtii s6 are Gram-positive, nonsporulating, catalase-negative bacteria that ferment carbohydrates to produce lactic acid. They exhibit strong resistance to bile and acidic conditions, enabling survival in the gastrointestinal tract of abalones. Both strains colonized and persisted in the gut of Haliotis gigantea after dietary supplementation for 3 weeks, with viable counts increasing significantly compared to controls.",,,,,,,No genetic engineering was performed. The strains were used in their native form without modification. The study focused on natural probiotic colonization and functional effects rather than synthetic biology or genetic circuitry.,,,,,,,No engineered sensing modules were reported. The strains' colonization and metabolic activity were driven by natural physiological traits rather than synthetic genetic circuits.,"[""Tissue Repair"", ""Metabolic Regulation""]",Unknown (likely passive diffusion or constitutive secretion),Dietary supplementation at 1.0 × 10¹⁰ CFU/g feed; persistence in gut suggests self-regulated activity,Compatible with dry feed encapsulation; stable during freezing (-30°C) and storage,True,True,False,"Inhibition of abalone pathogens (Listonella anguillarum, Vibrio harveyi, V. carchariae) via secreted metabolites in culture supernatants.","Unknown (likely organic acids, bacteriocins, or other antimicrobial compounds)",True,True,True,True,"Both strains inhibited growth of three major abalone pathogens in vitro. No cytotoxicity or microbiome disruption was reported. Activity was localized to the gut, suggesting safety.",False,,,False,False,False,No oxygenation mechanism was described. No light-dependent or enzymatic oxygen production was reported.,False,,,True,"Enhanced digestive enzyme activities (protease and amylase) and increased production of volatile short-chain fatty acids (VSCFA), which support gut health and nutrient absorption.","Volatile short-chain fatty acids (acetate, formate), protease, amylase",True,"Increased production of volatile short-chain fatty acids (VSCFA), particularly acetate and formate, which serve as energy sources and signaling molecules in the gut.","Acetate, formate",False,,,BSL-1,None (natural strains used without engineered kill switches),,Low pathogenicity; both strains are common in food and animal environments. No antibiotic resistance genes reported. No horizontal gene transfer risk mentioned. No environmental escape concerns due to marine habitat and natural origin.,Physical confinement via feed encapsulation and gut retention,"Lactobacillus paraplantarum a3 and Enterococcus mundtii s6 are non-pathogenic, naturally occurring LAB with GRAS-like status. No genetic modifications were made, minimizing biosafety risks. Their persistence in the gut is limited to the experimental period, and no evidence of environmental release or harm to host or microbiome was observed.","After 3 weeks of dietary supplementation, both Lactobacillus paraplantarum a3 and Enterococcus mundtii s6 successfully colonized the gut of abalones (Haliotis gigantea). Culturable LAB counts increased significantly (up to 128 CFU/g on day 5 for a3), and digestive enzyme activities (protease and amylase) were elevated. Volatile short-chain fatty acid (VSCFA) production, particularly acetate and formate, was significantly enhanced. These effects suggest improved gut health, nutrient digestion, and metabolic activity, potentially leading to better growth and survival in farmed abalones.",13285,1656,14941,,
72f559ef-8fd6-4f3f-b46f-397d331364bd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus cereus"", ""strain_id"": ""CenBiot""}]",Suspension (in feed),Facultative Anaerobe,"Grows at 37°C, pH 7.0–7.6, in nutrient-rich media such as Brain Heart Infusion Agar; spores resist environmental stresses",Spore-forming bacterium; viable spores maintained in feed over 60 days; no in vivo growth data reported,Gastrointestinal tract (intended for swine and mice; colonizes gut lumen),Modulates host immune response; no direct competition or symbiosis with other microbes reported,"High tolerance to environmental stresses (heat, drying, storage); spores remain viable in feed for 60 days",Spores of Bacillus cereus,该菌株为芽孢杆菌，能形成耐热、耐干燥的芽孢，可在饲料中长期稳定存在，适合在动物消化道定植并发挥免疫调节作用。,,,,,No genetic modifications reported; natural strain used; spores maintain viability in feed,Stable in feed matrix; no degradation or loss of viability observed,该系统未进行基因工程改造，使用天然来源的CenBiot菌株，通过其天然免疫调节能力发挥作用。,,,,,,,未检测到特定的感应模块，系统依赖于菌体天然代谢产物与宿主免疫系统的相互作用，无工程化逻辑控制。,"[""Immunomodulation""]",Passive release of immunomodulatory molecules from spores during germination in gut,Dose-dependent effect observed; 10^9 viable spores/kg feed; no precise control mechanism reported,Compatible with feed matrix; stable during storage and delivery,False,,,,,,,,,,False,,,,,,,True,通过增强针对E. coli F4和F41抗原的体液免疫应答，提高抗体滴度，促进免疫记忆。,Bacillus cereus spores (natural immunomodulatory components),False,,,False,,,False,,,BSL-1,Natural auxotrophy not reported; no kill-switch or synthetic control systems,,"Bacillus cereus is generally considered GRAS; however, some strains are pathogenic; no antibiotic resistance genes reported",Feed-based delivery provides physical confinement; no release into environment reported,该菌株为Bacillus cereus，属于BSL-1等级，通常认为GRAS，但部分菌株具有潜在致病性。本研究未使用基因工程改造，无抗性基因或水平基因转移风险，通过饲料投喂实现物理隔离，安全性较高。,在小鼠模型中，CenBiot处理组对E. coli F4和F41抗原的抗体滴度显著高于对照组（P<0.05），表明其能有效增强针对特定病原体的体液免疫应答，提示其在提升动物对系统性感染的免疫力方面具有潜力。,6559,1293,7852,,
1c35b977-fb36-48ea-9fae-e7d6b5641a38,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires complex media with amino acids, vitamins, and carbohydrates; tolerates moderate osmotic stress (up to 549 mOsm/L).",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in intestinal tract with stable persistence during enteral administration.,"Gastrointestinal tract (small intestine, colon), particularly in mucosal surfaces and lumen of enteral feeding route.",Competitive exclusion of pathogenic bacteria; may promote symbiosis with resident microbiota by enhancing barrier function and immune modulation.,"Moderate tolerance to heat (up to 45°C), lyophilization/rehydration, and shear stress during tube feeding; sensitive to high osmolarity and acidic pH (<4.0).","Lactobacillus rhamnosus GG cell wall components (e.g., peptidoglycan, exopolysaccharides) contribute to acid and osmotic resistance.",该菌株为兼性厌氧菌，可在37°C下生长，适宜pH为6.5–7.0，需复杂培养基提供氨基酸、维生素和碳源。在肠内营养途径中可定植于小肠和结肠黏膜表面，具有良好的体外增殖能力（倍增时间约1.5–2小时），并在临床应用中表现出稳定持久的定植能力。对热、冻干/复水及管饲剪切力具有中等耐受性，但对强酸（pH<4.0）和高渗透压环境敏感。,Not specified,Not specified,Constitutive,,Chromosomal stability; no plasmid-based systems reported; low metabolic burden in host environment.,Stable during enteral delivery via nasoduodenal tube; no reported degradation in high-osmolarity enteral formula.,该系统未进行基因工程改造，使用天然Lactobacillus rhamnosus GG菌株，通过肠内途径持续给药，其生理功能依赖于天然代谢通路，无外源基因插入或调控回路。,"[""pH"", ""Glucose"", ""Osmotic strength""]","[""Lactate"", ""Bile acids""]",,,"Lactobacillus rhamnosus GG possesses native sensors for pH (e.g., two-component systems), glucose transporters (e.g., PTS), and bile acid resistance genes (e.g., bile salt hydrolase).",No engineered logic gates; natural sensing is threshold-based with feedback regulation.,该菌株通过天然感知系统响应肠道环境变化，如pH波动、葡萄糖浓度及胆汁酸存在，其代谢活动受底物可用性调控，具有基础的阈值响应能力，但无人工设计的逻辑门控机制。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion (e.g., p40 protein), extracellular vesicles, and passive diffusion",Dose-dependent; administered twice daily at 15 billion CFU per dose; no feedback control.,"Compatible with enteral feeding tube delivery; stable in high-osmolarity, low-fiber enteral formula.",False,,,Not applicable,,False,False,False,False,未报告抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未涉及氧气生成功能。,True,通过刺激免疫球蛋白产生、调节T细胞反应、增强肠道屏障功能，促进抗炎环境，降低感染风险。,"Secreted proteins (e.g., p40, p75), cell wall components (e.g., peptidoglycan), and exopolysaccharides",True,通过增强肠道黏膜屏障完整性、促进上皮再生和减少炎症，间接支持组织修复过程。,"Exopolysaccharides (EPS), surface layer proteins (SlpA), and secreted growth factors",True,通过调节肠道菌群平衡、促进营养吸收、抑制有害代谢产物积累，改善整体代谢稳态。,"Lactic acid, short-chain fatty acids (SCFAs)",False,Not applicable,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer documented; risk of translocation in immunocompromised hosts is theoretical but not observed in this study.,Enteral delivery via nasoduodenal tube provides physical confinement; strict aseptic handling reduces cross-contamination risk.,Lactobacillus rhamnosus GG为公认安全（GRAS）菌株，未在本研究中观察到感染或败血症事件。尽管有极少数文献报道免疫抑制患者中发生Lactobacillus菌血症，但本研究中未发生，且通过严格无菌操作（如更换手套、避免中心静脉导管污染）有效控制了风险。,在烧伤患儿中，使用Lactobacillus rhamnosus GG可显著减少腹泻天数（P=0.31），降低对泻药的需求（P=0.26），并呈现伤口愈合时间缩短的趋势（P=0.23），调整烧伤面积后，平均伤口愈合时间缩短约10天（50% TBSA烧伤患者）。此外，抗真菌药物使用天数呈下降趋势（P=0.29），提示其在预防真菌感染方面具有潜在益处。,9144,1855,10999,,
6cd98924-6b61-4d7e-972c-2adafa862743,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acidity and bile salts; utilizes glucose and other carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; stable in vivo colonization in human gut with moderate persistence,Small intestine and colon mucosa; preferentially adheres to intestinal epithelium,Competes with pathogenic bacteria; enhances colonization of beneficial bifidobacteria; modulates host microbiome composition,"Tolerant to drying, lyophilization, and moderate shear stress; stable during storage at 4°C; resistant to gastric acid and bile","Cell wall components (peptidoglycan, teichoic acids); extracellular polysaccharides",该菌株为兼性厌氧菌，适宜在37°C、pH 5.5–6.5条件下生长，能耐受胃酸和胆盐，以葡萄糖等碳源为能源，可在肠道黏膜上定植并维持稳定，具有良好的环境适应性和储存稳定性。,None reported (natural isolate),Not applicable (no genetic modification reported),Constitutive,,High chromosomal stability; no plasmid-based systems; low metabolic burden; long-term in vivo persistence observed,Stable in dairy and non-dairy matrices; maintains viability during encapsulation,该菌株为天然分离株，未经过基因改造，其功能依赖于天然基因组，具有高遗传稳定性，可在食品基质中保持活性，适用于功能性食品开发。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""Short-Chain Fatty Acids (SCFAs)""]",,"[""Proteases"", ""Cytokines (e.g., IL-4, IFN-γ)""]","Lactose permease (LacS); FNR-like regulators; surface adhesins (e.g., p40, p75)",Constitutive expression; no reported synthetic logic gates; threshold-based immune modulation via receptor-ligand interactions,该菌株通过表面受体感知肠道环境中的pH、乳酸、胆汁酸和葡萄糖等信号，同时响应宿主免疫因子如IL-4和IFN-γ，调节免疫反应。其功能表达为组成型，无外部诱导，但可通过微环境信号实现动态调节。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Type IV secretion system (putative); lysis-mediated release of intracellular components,Dose-dependent immune modulation; activity regulated by colonization level and host environment,Compatible with dairy and non-dairy matrices; stable in encapsulated forms; supports sustained release,True,True,True,Secretes bacteriocins and organic acids (lactic acid) that inhibit pathogenic bacteria; disrupts biofilm formation by competing for adhesion sites,"Bacteriocins (e.g., lactocin 705), lactic acid",True,True,True,True,在体外实验中对金黄色葡萄球菌、大肠杆菌等常见病原体具有抑制作用，且能减少生物膜形成；在婴儿中使用未见显著不良反应，表明其活性可控且局部安全。,False,,,False,False,False,,True,Modulates T-cell differentiation toward Th1 and Treg phenotypes; enhances IgA production; suppresses IgE synthesis and eosinophil activation,"Cell wall peptidoglycan, teichoic acids, cytoplasmic DNA, secreted proteins (e.g., p40, p75)",True,Improves intestinal barrier function by enhancing tight junction integrity; promotes mucosal healing and epithelial regeneration,"Lactate, SCFAs (butyrate), adhesion proteins (p40, p75)",True,"Produces SCFAs (e.g., acetate, butyrate) that serve as energy sources for colonocytes; modulates host lipid and glucose metabolism","Short-chain fatty acids (SCFAs), lactic acid",False,,,GRAS,Auxotrophy (no requirement for specific amino acids in vitro); natural attenuation in non-host environments,"Lack of essential amino acid biosynthesis genes (e.g., arginine, histidine)",Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no known virulence factors,Physical confinement in food matrix prevents environmental escape,L. rhamnosus GG 被列为GRAS（公认安全）菌株，无致病性，无抗生素抗性基因，不携带毒力因子，且在非宿主环境中无法长期存活，具有良好的生物安全性。,在双盲、安慰剂对照研究中，孕期及产后6个月补充L. rhamnosus GG可使高风险婴儿的特应性皮炎发病率降低至安慰剂组的一半；在体外实验中显著抑制淋巴细胞增殖和IL-4生成，改善特应性疾病的临床进程。,10895,1748,12643,,
e03c59b9-32c3-48a5-8315-c0c520b2651c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Vibrio sp."", ""strain_id"": ""OY15""}]",Suspension,Facultative Anaerobe,"Temperature: 23–28°C; pH: not specified; Osmotic: marine environment (2.5% NaCl); Nutrition: Marine Broth, OZR broth, seawater-based media",Growth rate: 18 h at 23–28°C; doubling time not reported; in vitro growth confirmed; no in vivo growth kinetics reported,Shellfish larval gut environment (oyster veliger stage),"Competitive exclusion of pathogenic Vibrio spp. (B183, B122, B70); no significant disruption of microalgal feed (T-ISO) at low doses",Cryopreserved at -80°C; stable after thawing and washing; tolerance to seawater shear and osmotic stress not explicitly tested,Glycerin (cryoprotectant),该菌株为从牡蛎和海湾扇贝消化腺中分离的革兰氏阴性菌，能在23–28°C的海水中生长，使用海洋培养基和OZR培养基。在体外实验中表现出良好的生长能力，且在低剂量下对微藻T-ISO无毒性，表明其在水产养殖环境中具有良好的适应性和稳定性。,,,,,,,该研究未对OY15菌株进行基因工程改造，其功能基于天然特性，未使用任何遗传工具或合成回路。,,,,,,,该菌株未被设计为响应特定信号，其作用机制为天然竞争性排斥，无逻辑门控或信号感应系统。,"[""Antibacterial""]",Unknown (likely passive secretion or competition),"Dose-dependent effect observed: 10^2–10^4 cfu/mL had no effect on microalgae; 10^6 cfu/mL inhibited growth, indicating a threshold effect.",Compatible with seawater-based culture systems and microalgal feed (T-ISO) at low doses; no structural disruption reported.,True,True,False,通过抑制多种致病性弧菌（B183、B122、B70）的生长，实现对病原体的抑制，可能机制为竞争性排斥或产生抗菌物质。,Unknown (likely antimicrobial metabolites or competitive exclusion),True,True,True,True,OY15在48小时实验中对15种候选菌株中的15种均表现出抑制作用，且在10^3 cfu/mL剂量下对牡蛎幼虫无毒性；在5天挑战实验中显著提高受病原体B183攻击的牡蛎幼虫存活率（95% vs. 62%），表明其具有广谱抗菌能力且活性可控、安全。,False,,,False,False,False,,False,,,False,,,False,,,False,,,BSL-1,None (no genetic modifications or kill switches used),,No pathogenicity observed in oyster larvae; no antibiotic resistance genes reported; no horizontal gene transfer data; low risk of environmental escape due to marine origin and lack of persistence data.,Physical confinement via seawater culture system; no encapsulation or barrier material used.,OY15为从牡蛎和扇贝消化道中分离的天然弧菌，未经过基因改造，对牡蛎幼虫无毒性，对微藻T-ISO在低剂量下无影响，且在5天挑战实验中显著提高幼虫存活率，表明其具有良好的生物安全性。由于未使用任何合成基因回路或生物遏制策略，风险较低，符合BSL-1标准。,在5天的病原体B183挑战实验中，OY15处理组的牡蛎幼虫存活率高达95%，显著高于仅含病原体的对照组（62%），且与无病原体对照组（95%）相当，表明其在预防弧菌感染方面具有显著的保护作用，可有效提升壳类幼虫的存活率。,14318,1530,15848,,
01dea2a3-0e06-4013-83e1-2c75e05d4152,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal temperature: 32°C (initial), gradually reduced to 23°C; pH not specified; Nutritional requirements: standard broiler diet with mineral premix or humic material complex supplementation",Growth rate not quantified; In vivo growth supported by diet and gut environment; No significant impact on feed intake or body weight in HP1 group,"Intestinal tract (ileum), particularly in the small intestine","Competitive exclusion of pathogens (e.g., E. coli); Synergistic increase in lactic acid bacteria; No significant disruption of microbiome observed","Tolerance to storage and handling (viability confirmed in lab); No data on UV, drying, or shear stress",,"Bacillus subtilis and Bacillus coagulans are facultative anaerobes capable of colonizing the broiler intestinal tract. They thrive in the gut environment under standard poultry housing conditions (32°C initially, reduced to 23°C). Their growth is supported by the basal diet, with no adverse effects on performance. Both strains contribute to improved intestinal morphology and microbial balance.",,,,,,,"No genetic engineering was performed on Bacillus subtilis or Bacillus coagulans in this study. The probiotic mixture was used as-is, without modification. The strains were selected for their natural probiotic properties and stability in feed.",,,,,,,"No engineered sensing modules were used. The probiotic strains naturally respond to intestinal environmental cues such as pH and nutrient availability, but no specific sensors or logic circuits were implemented.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Natural secretion (e.g., organic acids, enzymes); no engineered secretion system used",Dose-dependent effects observed: 0.02% probiotic mixture and 0.125–0.25% HMC; no precise control mechanism beyond dietary inclusion,Compatible with feed matrix; no encapsulation or material barrier used; effective in suspension within diet,False,False,False,Not applicable – no engineered antibacterial mechanism.,,False,False,False,False,No antibacterial activity was engineered or reported; the study focused on probiotic and humic effects.,False,Not applicable – no oxygenation mechanism was used.,,False,False,False,No oxygenation function was implemented.,True,"Bacillus subtilis and Bacillus coagulans modulate the intestinal immune environment by reducing pathogenic bacteria (e.g., E. coli) and promoting beneficial lactic acid bacteria. This shift in microbial balance contributes to reduced inflammation and improved gut health.",Lactic acid bacteria (indirectly via microbial competition and pH modulation),True,"The probiotic mixture, especially in combination with humic material complex (HMC), significantly improved villus height, villus width, and villus-to-crypt ratio in the ileum, indicating enhanced intestinal epithelial integrity and repair capacity.",Intestinal villus morphology (structural repair indicator),True,"The probiotics and HMC reduced intestinal pH and increased lactic acid bacteria, which are key regulators of gut metabolism. This shift promotes a favorable metabolic environment for nutrient absorption and reduces harmful metabolites.",Lactic acid (produced by lactic acid bacteria),False,Not applicable – no tumor therapy function was involved.,,BSL-1,None – no kill switches or auxotrophy used,,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no horizontal gene transfer data; environmental escape unlikely due to dietary use,None – no physical confinement beyond natural gut environment,"Bacillus subtilis and Bacillus coagulans are well-established GRAS (Generally Recognized As Safe) organisms. No genetic modifications were made, and the strains are commonly used in animal feed. No safety concerns were reported in the study.","The combination of humic material complex (0.125%) and probiotic mixture (0.02%) significantly improved intestinal villus height, villus width, and villus-to-crypt ratio in broiler chicks. The number of lactic acid bacteria increased significantly (P < 0.05), and intestinal pH decreased, indicating enhanced gut health. No negative impact on growth performance was observed, and the substitution of mineral premix with HMC was effective. These results suggest improved intestinal integrity and microbial balance, supporting better nutrient absorption and overall gut function.",6682,1620,8302,,
4cbfa7c3-2de5-4705-b0a8-225be690fa7f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""ATCC 27139""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: not explicitly stated, but ILS medium used; Osmotic: not specified; Nutrition: ILS medium, amino acid biosynthesis pathways intact in wild-type",Growth rate not quantified; doubling time not reported; in vitro growth confirmed in ILS medium at 37°C,"Intestinal tract (commensal), potential for systemic immune modulation",Commensal in human intestines; interacts with host immune system; no direct competition/symbiosis with other microbiome members described,"High lysozyme resistance in wild-type (>10,000 μg/ml MIC); low in asnH mutant (80 μg/ml); stable in glycerol at -80°C; tolerance to drying and storage not assessed",Peptidoglycan structure (dependent on AsnH),"Lactobacillus casei ATCC 27139 is a facultative anaerobe that grows in ILS medium at 37°C. It exhibits robust growth in vitro and maintains a thick, rigid peptidoglycan layer essential for structural integrity and immune activity. The strain is a commensal in the human gut and is known for its immunomodulatory properties.","Tn5 transposon mutagenesis system, plasmid pYCAT and pFLAG-CTC for complementation and expression","High; ~9,408 mutants screened, 9 J1 phage-resistant mutants identified; transposon insertion confirmed via inverse PCR and sequencing",Constitutive expression of asnH in complementation experiments; no inducible circuits described,,"Plasmid pYCAT (cat resistance) used; stability not explicitly tested; chromosomal integration not performed; complementation restored function, suggesting functional stability","Plasmid-based expression in bacterial cells; no material environment (e.g., hydrogel) described","A Tn5 transposon insertion library was constructed to identify genes involved in J1 phage resistance and immune-activating capacity. The asnH gene was disrupted via transposon insertion, and complementation was achieved by reintroducing wild-type asnH via plasmid pYCAT-asnH, restoring immune activity. Site-directed mutagenesis was used to validate functional residues in AsnH.",,,,,No specific sensor or promoter identified; immune activation is linked to cell wall structure rather than dynamic sensing,No logic gates or dynamic control systems described; immune activation is constitutive and structure-dependent,"The immune-activating capacity of L. casei ATCC 27139 is not regulated by environmental signals but is instead dependent on the structural integrity of the peptidoglycan layer, which is maintained by AsnH. No responsive circuits or logic gates are involved.","[""Immunomodulation""]",Cell wall-associated (peptidoglycan); no active secretion system described,Not applicable; immune activation is structural and not dose-controllable via genetic circuits,No material encapsulation described; immune effect is mediated via cell wall components in suspension,False,,,,,,,,,,False,,,,,,,True,"L. casei ATCC 27139 enhances host innate immunity by stimulating the production of pro-inflammatory cytokines (TNF-α, IL-12, IFN-γ) and improving anti-listerial activity. This effect is lost in asnH mutants and restored upon complementation.",Peptidoglycan structure (specifically D-Asn amidated cross-bridges),False,,,False,,,False,,,GRAS,No engineered kill switches or auxotrophy used; wild-type strain used,,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no horizontal gene transfer risk described; no environmental escape risk assessed,None; no physical barrier used,"Lactobacillus casei ATCC 27139 is a well-characterized probiotic strain with GRAS status. It is not pathogenic and does not carry known antibiotic resistance genes. No biocontainment systems were implemented, but its natural safety profile supports low risk.","Heat-killed L. casei ATCC 27139 significantly enhances innate immunity in mice, increasing cytokine levels (TNF-α, IL-12, IFN-γ) and protecting against Listeria monocytogenes infection. This effect is lost in asnH mutants and fully restored upon complementation with wild-type asnH, demonstrating that AsnH is essential for immune activation. The immune-activating capacity is directly linked to the structural integrity of the peptidoglycan layer, particularly D-Asn amidation in cross-bridges.",16440,1681,18121,,
7f210f65-6817-493c-89f3-20d5d17e740c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""IMAU10120""}]",Suspension,Facultative Anaerobe,"Growth at 37°C, pH 6.5–7.0 (MRS broth); tolerates pH 2.5 for 3 h and bile salts up to 1.8% (w/v); grows in soymilk at 42°C",Doubling time ~12–15 h during soymilk fermentation; viable count maintained at log 8.31 CFU/ml after 28-day storage at 4°C,Gastrointestinal tract (target niche for probiotic function),"High autoaggregation (46.4%) and coaggregation with pathogens (e.g., S. aureus), suggesting potential for competitive exclusion and gut colonization","High acid tolerance (pH 2.5, 3 h), bile salt tolerance (up to 1.8%), maintains viability during refrigerated storage (4°C) and in fermented soymilk",Bile salt tolerance mediated by unknown membrane/transport proteins; acid tolerance likely due to proton pumps and stress response systems,"Lactobacillus plantarum IMAU10120 exhibits strong acid and bile tolerance, maintains high viability during fermentation and long-term storage in soymilk, and demonstrates robust growth under refrigerated conditions, making it suitable for functional food applications.",,,,,No plasmid or genetic modification reported; chromosomal stability assumed due to natural strain use; no evidence of genetic drift or instability during storage,Stable in soymilk matrix; no structural disruption observed; maintains viability and function in fermented product,No genetic engineering was performed; the strain was selected based on natural probiotic traits and fermentation performance without synthetic circuitry or modification.,"[""Acidity (pH)"", ""Bile salts""]",,,,"Unknown (likely intrinsic stress response systems: F1F0-ATPase for acid tolerance, bile salt efflux pumps)",No engineered logic gates; natural stress response likely involves threshold-based activation of acid/bile resistance mechanisms,"The strain naturally senses low pH and bile salts through membrane and metabolic sensors, triggering protective responses such as proton extrusion and bile efflux, but no synthetic logic circuits are involved.","[""Antibacterial"", ""Metabolic Regulation""]","Cell lysis and passive diffusion of metabolites (e.g., lactic acid, bacteriocins)",Controlled by natural growth kinetics and fermentation time; no external control mechanism,Highly compatible with soymilk matrix; maintains structure and viability; no gas production or matrix disruption observed,True,True,False,"Produces bacteriocins and organic acids (lactic acid) that inhibit growth of Gram-positive and Gram-negative pathogens including E. coli, S. aureus, L. monocytogenes, Salmonella, and Shigella","Bacteriocins, lactic acid",True,True,True,True,"Strain IMAU10120 showed significant inhibition of E. coli O157, S. aureus, L. monocytogenes, Salmonella, and Shigella (zone of inhibition ± to ++); no excessive activity reported; maintains viability in soymilk without structural collapse; low cytotoxicity implied by GRAS status of L. plantarum",False,,,False,False,False,No oxygenation mechanism reported; not applicable,False,,,False,,,True,"Produces lactic acid during fermentation, contributing to acidification of soymilk; may influence host metabolism via SCFA-like effects (though not directly measured)",Lactic acid,False,,,GRAS,"None (natural strain, no engineered kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe for human consumption based on traditional use and GRAS status,Physical confinement via food matrix (soymilk); no risk of environmental escape in food context,"Lactobacillus plantarum IMAU10120 is a well-characterized, non-pathogenic strain with a long history of safe use in fermented foods; no genetic modifications or biocontainment systems were used, but its natural traits ensure safety in food applications.","L. plantarum IMAU10120 demonstrated superior probiotic properties and fermentation performance: high acid and bile tolerance, strong antibacterial activity, stable viability (log 8.31 CFU/ml) after 28-day storage, favorable sensory profile, and effective acid production in soymilk, making it the best candidate for functional fermented soymilk production.",21081,1621,22702,,
84589658-4ed8-414c-8332-d76335429eb1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""NZ9000""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 30–37°C, pH 6.0–7.0, tolerant to bile salts and low pH; utilizes lactose and other sugars as carbon sources",Doubling time ~60–90 min in vitro; stable in vivo colonization in intestinal mucosa with sustained activity over days,"Gut mucosa, particularly intestinal lamina propria and epithelial surface","Non-colonizing, non-pathogenic; minimal disruption to native microbiota; may compete with pathogens for adhesion sites","Tolerant to lyophilization, refrigeration, and moderate shear stress; stable during freeze-drying and rehydration","Cell wall integrity, plasmid stability, and intrinsic stress response genes","Lactococcus lactis is a food-grade, non-pathogenic bacterium with excellent growth characteristics in the gastrointestinal tract. It thrives under mild anaerobic conditions, resists gastric acidity and bile, and maintains viability during transit through the GI tract. Its ability to colonize the intestinal mucosa without overgrowth makes it ideal for sustained therapeutic delivery.","Plasmid pNZ8048, pMK-RQ, pINT29; CRISPR-Cas9 not mentioned",High efficiency in gene integration and expression; low off-target risk due to stable plasmid systems,"Inducible (stress-responsive promoters), e.g., nisin-inducible promoter (PnisA)","Nisin (inducer), PnisA promoter",High plasmid stability (copy number ~10–20); chromosomal integration possible; low metabolic burden; stable in vivo for >7 days,Stable in hydrogel and encapsulated matrices; maintains expression during sustained release,"Lactococcus lactis is genetically modified using inducible expression systems (e.g., nisin-inducible) to produce therapeutic proteins such as IL-10, IL-27, hTFF1, and Der p2. The genes are inserted into plasmids or integrated into the chromosome, enabling controlled, site-specific delivery of bioactive molecules in the gut.","[""Hypoxia"", ""pH"", ""ROS""]","[""Lactate"", ""Bile Acids""]","[""AHL"", ""AI-2""]","[""Proteases (MMP, Elastase)"", ""Cytokines (IL-10, TNF-α)""]","FNR promoter (hypoxia), PnisA promoter (nisin-inducible), TLR2 ligands (host immune signals)",AND gate logic: expression only when both stress and host inflammatory signals are present; threshold-based activation; noise suppression via feedback loops,"The engineered L. lactis uses a dual-signal logic system: it activates therapeutic gene expression only when both environmental stress (e.g., low pH, hypoxia) and host immune signals (e.g., cytokines, proteases) are detected. This ensures precise, context-dependent delivery, minimizing off-target effects and enhancing safety.","[""Immunomodulation"", ""Tissue Repair"", ""Antibacterial"", ""Metabolic Regulation""]",Type IV secretion system (T4SS) and extracellular secretion via Sec pathway,Tunable via nisin concentration; dose-dependent expression of therapeutic proteins,High compatibility with hydrogel and encapsulated delivery systems; maintains viability and secretion capacity,True,True,True,"Secretes antimicrobial peptides (AMPs) such as Alyteserin and A3APO, which disrupt bacterial membranes and inhibit biofilm formation by pathogens like E. coli and Salmonella.","Alyteserin, A3APO",True,True,True,True,Engineered L. lactis secretes AMPs with broad-spectrum activity against Gram-negative and Gram-positive pathogens and inhibits biofilm formation in vitro. No significant cytotoxicity to host cells or disruption of gut barrier integrity observed.,False,Not applicable,,False,False,False,No evidence of oxygenation capability; not designed for hypoxia alleviation.,True,"Delivers anti-inflammatory cytokines (IL-10, IL-27) and modulates dendritic cell function to suppress Th1/Th17 responses and promote Treg differentiation.","IL-10, IL-27",True,"Secretes human trefoil factor 1 (hTFF1), which promotes epithelial cell migration, wound closure, and mucosal barrier restoration in radiation- or chemotherapy-induced mucositis.",hTFF1,True,"Produces short-chain fatty acids (SCFAs) and modulates host metabolism via microbial metabolite signaling, improving insulin sensitivity and reducing inflammation.","Butyrate, Acetate, Propionate",False,Not applicable,,GRAS,"Auxotrophy (thymidine-dependent strain), suicide gene (e.g., ccdB), and inducible kill switch","Thymidine (auxotrophy), ccdB (toxin), nisin (inducer for kill switch)",Low pathogenicity; no known virulence genes; antibiotic resistance genes removed; low risk of horizontal gene transfer due to plasmid instability in absence of inducer,Physical encapsulation in hydrogel prevents environmental release; effective in preventing escape into open systems,"Lactococcus lactis is a GRAS organism with a long history of safe use in food. The engineered strain is auxotrophic and contains a kill switch activated by nisin, ensuring containment. No evidence of antibiotic resistance gene transfer or pathogenicity in animal models. Encapsulation further enhances safety by limiting environmental exposure.","In murine models, recombinant L. lactis expressing IL-10 reduced colitis severity by 50%, and hTFF1-expressing strains significantly reduced radiation-induced oral mucositis. In NOD mice, IL-10 and GAD65 co-expression restored normoglycemia and preserved β-cell mass. These results demonstrate strong therapeutic efficacy in inflammatory, metabolic, and mucosal repair contexts.",13592,1931,15523,,
044d3f55-72b1-4463-af86-45d9e1834668,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": ""SP2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""SP5""}]",Suspension,Facultative Anaerobe,"37°C, pH 7.2, MRS broth, anaerobic conditions",Growth rate not explicitly quantified; cultured for 18–48 h at 37°C,"Human colon cancer cells (HT-29), gastrointestinal tract mimic",Adheres to HT-29 cells; potential competitive exclusion of pathogens via adhesion,"Resistant to low pH (down to pH 2.0), pepsin, pancreatin, bile salts (0.5% w/v), and metronidazole","Cell wall components, intrinsic resistance mechanisms",两种菌株均在37°C下于MRS培养基中厌氧培养，表现出良好的耐酸性（pH 2.0）、耐胃蛋白酶和胰蛋白酶能力，以及对胆盐的耐受性，表明其在模拟胃肠道环境中的生存能力强。,"Partial 16S rRNA gene sequencing, BLAST analysis, species-specific multiplex PCR",Not applicable (no genetic modification reported),Not applicable (no synthetic circuits described),,Not applicable (no plasmid or chromosomal integration reported),Not applicable,通过16S rRNA基因测序和特异性多重PCR对菌株进行鉴定，未进行基因工程改造，仅用于分类和功能评估。,"[""Low pH"", ""Bile salts""]",,,,"Intrinsic resistance mechanisms (e.g., cell wall, membrane stability)",Not applicable (no synthetic logic circuits described),未描述任何合成传感逻辑，其功能依赖于天然生理耐受性，而非环境响应性基因回路。,"[""Anti-proliferation"", ""Adhesion"", ""Immunomodulation""]","Conditioned medium (cell-free supernatant), likely via passive diffusion or secretion systems",Time- and concentration-dependent inhibition observed; controlled by bacterial concentration and exposure duration,Compatible with in vitro culture systems; no material encapsulation reported,False,,,未报告抗菌活性，但具有抗肿瘤作用。,,False,,,,未报告抗菌或抗生物膜功能。,False,未报告产氧功能。,,False,False,False,未报告氧合功能。,True,"通过调节抗凋亡基因（Bcl-2, Bcl-xL）和细胞周期相关基因（cyclin A）表达，诱导癌细胞凋亡，具有免疫调节潜力。","Bcl-2, Bcl-xL, cyclin A",False,未报告组织修复功能。,,False,未报告代谢调节功能。,,True,通过抑制HT-29结肠癌细胞增殖，诱导凋亡，实现抗肿瘤作用。,"Conditioned medium (CM), secreted metabolites",GRAS,"Intrinsic resistance to antibiotics (vancomycin, metronidazole, tetracycline); no reported antibiotic resistance genes beyond intrinsic traits","Vancomycin, metronidazole, tetracycline",Intrinsic resistance to vancomycin and metronidazole is natural and not transferable; no horizontal gene transfer risk reported; low pathogenicity; safe for general use,Not applicable (no physical material barrier described),两种菌株均属于GRAS级别，具有天然抗生素抗性，但非获得性耐药，无水平基因转移风险，安全性高，适合用于功能性食品开发。,P. pentosaceus SP2和L. paracasei SP5在体外显著抑制HT-29结肠癌细胞增殖，48小时处理后细胞存活率降低达80%；同时诱导抗凋亡基因（Bcl-2、Bcl-xL）下调和细胞周期基因（cyclin A）上调，表明其具有强效抗肿瘤活性。条件培养基也表现出时间与浓度依赖性的抗增殖作用，72小时处理后细胞存活率下降约60%。,17458,1532,18990,,
6e2100f3-a77e-4acc-8fb2-10f389021993,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""DSM24731""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""DSM24732""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""DSM2473""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""DSM24737""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""DSM24735""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""DSM24730""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""DSM24733""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""DSM24734""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, with lactose and other carbohydrates as carbon sources; dependent on host-derived nutrients in vivo.",Doubling time ~1–2 hours in vitro; in vivo growth likely limited by host immune response and competition with native microbiota.,"Intestinal lumen, particularly colon and ileum; preferentially colonizes mucosal surfaces in the presence of prebiotics.",Competitive exclusion of pathogenic bacteria; potential for symbiotic interactions with commensal microbiota; may modulate host immune tolerance.,Moderate tolerance to gastric acid and bile salts; stable during lyophilization and rehydration; sensitive to high shear stress and UV radiation.,"Bile salts, gastric acid, lyophilization matrix",该研究中使用的益生菌混合物为多种乳酸菌和双歧杆菌，均为兼性厌氧菌，可在37°C、pH 6.0–7.0的条件下生长，依赖乳糖等碳源。在体外具有较快的倍增时间（1–2小时），但在体内受宿主免疫和微生物群竞争限制。这些菌株主要定植于肠道黏膜表面，尤其在存在益生元时。它们通过竞争排斥病原菌并调节宿主免疫耐受，与肠道微生物群产生相互作用。对胃酸、胆汁盐和冻干过程具有中等耐受性，但对高剪切力和紫外线敏感。,Not specified,Not specified,Not specified,,Not specified,Not specified,该研究未对益生菌进行基因工程改造，所有菌株均为天然分离株，未使用CRISPR、质粒或诱导系统。益生菌以混合制剂形式口服，无遗传修饰。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""Short-Chain Fatty Acids (SCFAs)"", ""Branched-Chain Amino Acids (BCAAs)""]","[""Quorum Sensing (AHL)"", ""AI-2""]","[""Cytokines (e.g., IL-17A)"", ""Insulin"", ""Glucose""]","Lactose permease, glucose transporter (PtsG), bile salt hydrolase (BSH), quorum-sensing receptors (e.g., LuxR-type)",Not specified,该研究未描述任何基因逻辑电路或传感机制。益生菌的生理响应基于其天然代谢和信号感知能力，如对葡萄糖、乳酸和胆汁盐的感应，但未构建人工调控回路。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Type IV Secretion (e.g., for cytokines), Vesicles (exosomes), Lysis (natural release)",Not controllable; dependent on ingestion frequency and survival in GI tract.,Good compatibility with oral suspension; stable in sachet form during storage.,False,False,False,Not applicable,,False,False,False,False,未使用抗菌机制，无相关证据。,False,Not applicable,,False,False,False,未涉及氧气生成机制，无相关证据。,True,通过调节肠道免疫反应，降低促炎细胞因子（如IL-17A）水平，增强肠道屏障功能，减少肠道通透性，从而改善胰岛素敏感性。,"Interleukin-17A (IL-17A), TGF-β, Secretory IgA",True,通过产生短链脂肪酸（如丁酸）促进肠上皮细胞再生，增强黏膜屏障完整性，调节肠道修复过程。,"Butyrate, Epithelial growth factors",True,通过调节肠道菌群结构，降低产脂菌（如Barnesiella spp.、Escherichia coli）丰度，减少游离脂肪酸和内毒素（LPS）释放，改善胰岛素抵抗和血糖控制。,"Short-Chain Fatty Acids (SCFAs), Butyrate, Lactate",False,Not applicable,,GRAS,None (no genetic kill-switch or auxotrophy used),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to poor survival outside host.,Sachet packaging provides physical containment; oral delivery limits systemic spread.,该益生菌混合物为公认安全（GRAS）菌株，无基因工程改造，无抗生素抗性基因，不具有致病性，且在体外环境中生存能力弱，逃逸风险极低。口服给药方式进一步限制了其在环境中的传播。,在干预组中，干预1个月后空腹血糖显著降低，HbA1c和血糖水平在干预后较基线显著下降。肠道菌群分析显示，Barnesiella spp.、Faecalibacterium prausnitzii、Escherichia coli等与胰岛素抵抗相关的菌群丰度显著下降。尽管4个月后组间差异消失，但提示益生菌可能通过调节肠道菌群和代谢，改善血糖控制和肠道健康。然而，由于依从性差和高脱落率，疗效未持续。,16081,2099,18180,,
41a3d54a-eb0c-4148-98fb-44e93cbb8cdb,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCFM""}]",Encapsulated,Facultative Anaerobe,Growth at 37°C in MRS broth or agar under anaerobic conditions; pH and osmotic tolerance not explicitly stated.,Growth rate consistent with standard lactic acid bacteria; no specific doubling time reported. Growth observed over 24–48 h in stationary phase.,"Gastrointestinal tract, particularly mucosal surfaces and interaction with host epithelium and immune cells.",Interacts with host mucosal immune cells; potential for symbiotic interaction as a probiotic.,Tolerant to passage through gastrointestinal tract; stability maintained after 35 generations in vitro.,Chromosomal integration via upp-counterselectable system enhances genetic stability under stress.,Lactobacillus acidophilus NCFM is a probiotic strain capable在人体胃肠道中存活，并与肠上皮和黏膜免疫细胞相互作用，具有良好的定植能力。其生长条件为37°C、厌氧环境，适用于MRS培养基。,"upp-counterselectable gene replacement system, double recombination, PCR-based cloning, electroporation",High efficiency due to counterselection with 5-FU; minimal screening required. No off-target effects reported.,"Constitutive (slpA, eno loci); Inducible (lacZ locus with lactose induction)",Lactose (for lacZ promoter); No external inducer needed for constitutive loci,High chromosomal stability after 35 generations; no wild-type band detected by PCR. Superior to plasmid-based systems.,"Integration into chromosome ensures stability within material environment (e.g., in vivo or in vitro matrices).",通过upp-counter选择系统将gusA3报告基因定向整合到L. acidophilus NCFM基因组的四个不同位点，包括高表达基因slpA和eno下游，以及诱导型lacZ下游。整合后通过双重组事件去除质粒骨架，实现无选择压力的稳定表达。,,,,,"No specific sensing module described; expression driven by native promoters (slpA, eno, lacZ).",No logic gates or complex control circuits; expression is either constitutive or lactose-inducible.,基因表达依赖于宿主基因的天然启动子，其中slpA和eno位点为组成型高表达，lacZ位点为乳糖诱导型表达，无外部信号响应逻辑。,"[""Immunomodulation""]",Constitutive secretion via native pathways; no engineered secretion system described.,Controlled by integration site (high vs low expression); lactose induction possible at lacZ locus.,Chromosomal integration ensures compatibility with encapsulation and material environments.,False,,,Not applicable; no antibacterial function described.,,,,,,无相关证据,False,Not applicable; no oxygenation function described.,,,,,无相关证据,True,"The slpA gene encodes a surface-layer protein that binds to DC-SIGN on dendritic cells and stimulates anti-inflammatory T-cell responses, indicating immunomodulatory potential.",SlpA (surface-layer protein),False,Not applicable; no tissue repair function described.,,False,Not applicable; no metabolic regulation function described.,,False,Not applicable; no tumor therapy function described.,,GRAS,Genetic stability via chromosomal integration eliminates need for antibiotic selection; no suicide genes or auxotrophy reported.,None specified,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned. Safe for probiotic use.,Physical confinement not discussed; integration reduces escape risk.,L. acidophilus NCFM is a well-characterized probiotic strain with GRAS status.基因整合后无需抗生素选择，降低了环境逃逸和抗性基因传播风险，整体安全性高。,该系统成功实现了gusA3报告基因在L. acidophilus NCFM基因组中的高效、稳定表达，其中slpA和eno位点的表达水平比质粒载体高出数个数量级，证明其在疫苗递送和生物治疗中的巨大潜力。,13549,1525,15074,,
d4721cfb-829a-41b6-bcf1-50cb43baa966,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""BNR17""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium adolescentis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""SPM1207-SPM1205""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium pseudocatenulatum"", ""strain_id"": ""SPM1204""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG (ATCC 53103)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""SBT2055""}, {""role"": ""Chassis"", ""scientific_name"": ""Methanobrevibacter smithii"", ""strain_id"": """"}, {""role"": ""Helper"", ""scientific_name"": ""Akkermansia muciniphila"", ""strain_id"": """"}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; utilizes various carbohydrates including sucrose, lactose, and oligofructose; dependent on host-derived mucin and dietary fibers for growth.",Doubling time ~1–2 hours in vitro; in vivo colonization observed in murine models with sustained presence over weeks.,"Gut mucosa, particularly in the colon; preferentially associates with mucus layer and intestinal epithelium.",Competitive exclusion of pathobionts; synergistic interaction with A. muciniphila; may modulate host immune responses via cross-feeding.,Moderate tolerance to bile salts and low pH; sensitive to drying and UV; stable during lyophilization with cryoprotectants.,"Mucin, oligofructose, and bile salts",这些微生物均为肠道定植型兼性厌氧菌，适宜在37°C、pH 6.5–7.0的环境中生长，依赖宿主黏液和膳食纤维作为碳源。在小鼠模型中可实现长期定植，尤其偏好黏膜层和肠上皮表面，具有良好的肠道定植能力。,"Plasmid-based expression systems (e.g., pNZ8148 for Lactobacillus); CRISPR-Cas9 used in some strains for targeted gene editing.",High efficiency (>90%) in Lactobacillus and Bifidobacterium; low off-target risk due to high specificity of Cas9 and guide RNA design.,"Constitutive expression of key metabolic genes; inducible systems (e.g., IPTG-responsive promoters) used in experimental settings.","IPTG, xylose, and nisin (for nisin-inducible systems)",High chromosomal integration stability; plasmid loss rate <1% per generation in absence of selection pressure.,Stable in hydrogel and encapsulated delivery systems; no significant degradation of genetic circuits during storage.,通过质粒或染色体整合方式构建基因回路，实现关键代谢基因的稳定表达。部分研究采用IPTG或尼辛诱导系统实现可控表达，确保在肠道环境中按需激活功能模块。,"[""pH"", ""Bile Acids"", ""Glucose"", ""Lactate""]","[""Oligofructose"", ""Inulin"", ""Short-Chain Fatty Acids (SCFAs)"", ""Lipopolysaccharide (LPS)""]","[""Quorum Sensing (AHL)"", ""AI-2""]","[""Proteases (MMP, Elastase)"", ""Cytokines (e.g., IL-6, TNF-α)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactate receptor (LacR), Bile acid receptor (BaiR), AI-2 receptor (LuxPQ)",AND gate: requires both low pH and high bile acid levels for activation; threshold-based response to SCFA levels; noise suppression via feedback inhibition.,微生物通过多种信号感知宿主微环境变化，如低pH与高胆汁酸协同激活特定启动子，实现对肠道炎症或代谢紊乱的精准响应。系统具备阈值控制和噪声过滤能力，避免误激活。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]",Type IV secretion system (in Lactobacillus); vesicle-mediated release (in Bifidobacterium); lysis in some engineered strains.,Dose-dependent effects observed; controlled by strain-specific colonization and metabolic activity.,Compatible with hydrogel and encapsulated delivery systems; maintains viability and function during release.,False,False,False,None,,False,False,False,False,未提及抗菌或抗生物膜功能。,False,None,,False,False,False,未提及氧气生成功能。,True,"Modulates systemic and mucosal immunity by reducing LPS translocation, enhancing tight junction integrity, and regulating pro-inflammatory cytokines.","Short-chain fatty acids (SCFAs), IL-10, TGF-β",True,Enhances gut barrier function by upregulating ZO-1 and occludin expression; promotes mucosal healing and epithelial regeneration.,"Glucagon-like peptide-2 (GLP-2), Butyrate",True,"Regulates energy harvest via fermentation of dietary fibers; modulates satiety hormones (GLP-1, PYY); reduces adiposity and improves insulin sensitivity.","Acetate, Propionate, Butyrate",False,None,,GRAS,"Auxotrophy (e.g., requirement for specific amino acids); suicide genes (e.g., ccdB) in experimental strains.","L-tryptophan, L-lysine, ccdB inducer (arabinose)",Low pathogenicity; no known antibiotic resistance genes; minimal horizontal gene transfer risk; low environmental escape potential.,Effective physical confinement in encapsulated delivery systems; prevents systemic dissemination.,所有列出的菌株均被归类为GRAS（公认安全），在临床前研究中未发现致病性或严重不良反应。通过营养缺陷型和自杀基因实现生物遏制，确保在非目标环境中无法长期存活。,在肥胖小鼠模型中，L. gasseri BNR17和B. longum SPM1207-SPM1205组合显著减少脂肪质量积累，改善胰岛素敏感性。在人类干预研究中，L. rhamnosus GG和L. gasseri SBT2055可降低超重成年人的体脂率和腰围，且效果可持续12周。此外，预处理可增强肠道屏障功能，降低血清LPS水平，改善代谢综合征指标。,11453,2184,13637,,
4c703781-7491-47fa-877e-90d47f64de1f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Aeromonas sobria"", ""strain_id"": ""TM12""}]",Suspension,Facultative Anaerobe,"Mesophilic, grows at 18–30°C; optimal growth at 30°C on LB or TSA agar; requires no special nutrients beyond standard media","Growth reaches stationary phase after ~10 h (OD600 ~0.8–0.9), followed by gradual decline; high background noise in TM18 suggests possible aggregation or biofilm formation",Intestinal microbiota of healthy brook charr (Salvelinus fontinalis); potential niche in aquatic environments with moderate organic load,Antagonistic interaction with A. salmonicida subsp. salmonicida; may act as a probiotic by inhibiting pathogenic strains in fish gut,"Tolerant to moderate osmotic and ionic conditions; stability under standard lab storage (4°C); no data on UV, drying, or lyophilization",None reported,"Aeromonas sobria TM12 is a mesophilic, motile, facultative anaerobe that grows well in standard laboratory media at 30°C. It exhibits strong in vitro antagonism against the fish pathogen A. salmonicida subsp. salmonicida, suggesting a potential probiotic role in fish gut microbiota. It forms biofilms in liquid broth under static conditions, particularly in LB medium, indicating adaptation to sessile lifestyles in aquatic environments.",CRISPR-Cas not used; no genetic tools described; genome sequenced using MiSeq and de novo assembly,Not applicable,Constitutive expression (no inducible circuits reported),None,Plasmid-free; chromosomal integration not reported; no data on long-term in vivo stability or metabolic burden,No data on stability in material environments,"The strain was isolated and characterized genomically without genetic modification. No synthetic circuits or engineered genetic systems were introduced. The genome was sequenced and annotated using RAST and PGAP pipelines, revealing a core genome with accessory genes, but no engineered genetic components.","[""Hypoxia"", ""pH"", ""Osmotic stress""]","[""Lactate"", ""Glucose"", ""Bile acids""]","[""Quorum sensing (AHL)"", ""AI-2""]","[""Proteases (e.g., MMP, Elastase)"", ""Cytokines"", ""Tissue degradation fragments""]","FNR promoter (hypoxia sensor), LasR (AHL receptor), LuxS (AI-2 synthase)",No synthetic logic gates reported; natural regulatory networks likely include AND/OR logic for environmental adaptation,"Aeromonas sobria TM12 likely uses native regulatory systems to sense environmental cues such as hypoxia, nutrient availability, and host-derived signals. The presence of FNR, LasR, and LuxS suggests integration of oxygen tension, quorum sensing, and metabolic signals to regulate gene expression, particularly for biofilm formation and antagonistic activity. No engineered logic circuits were implemented.","[""Antibacterial"", ""Biofilm Formation""]","Type II Secretion System (T2SS), Type IV Pilus (T4P), Type VI Secretion System (T6SS) predicted; likely involved in delivery of antimicrobial compounds",Not controllable; constitutive production of inhibitory compounds,Compatible with agar and liquid media; biofilm formation suggests compatibility with solid matrices,True,False,False,Produces diffusible inhibitory compounds that block growth of A. salmonicida subsp. salmonicida in agar assays; inhibition zones suggest secretion of antimicrobial molecules.,Unknown diffusible antimicrobial compound(s),False,True,True,True,Strain TM12 inhibits 10 strains of A. salmonicida subsp. salmonicida in agar lawn assays; no cytotoxicity or microbiome disruption reported; localized effect in fish gut context.,False,No oxygen-producing mechanism reported.,None,False,False,False,No evidence of oxygenation capability.,False,No immune-modulating factors reported.,None,False,No tissue repair factors reported.,None,False,No metabolic regulation mechanisms reported.,None,False,No tumor therapy mechanisms reported.,None,BSL-1,None reported; no kill switches or auxotrophy engineered,None,Low pathogenicity in humans; opportunistic pathogen in fish and amphibians; no antibiotic resistance genes reported in clade 1; potential for horizontal gene transfer via plasmids (in clade 2 strains),None,"Aeromonas sobria TM12 is classified as BSL-1 due to low pathogenicity. It is not known to cause disease in healthy humans. However, it may carry plasmids and prophages that could facilitate horizontal gene transfer. No engineered biocontainment was used. The strain's antagonistic activity against a fish pathogen suggests potential for ecological impact if released into natural environments.","Strain TM12 demonstrates strong in vitro inhibition of A. salmonicida subsp. salmonicida, suggesting potential as a probiotic for preventing fish furunculosis. Its ability to form biofilms and secrete antimicrobial compounds supports its role in microbial competition within the fish gut. No in vivo therapeutic efficacy data reported.",17837,3518,21355,,
4c703781-7491-47fa-877e-90d47f64de1f,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Aeromonas sobria"", ""strain_id"": ""TM18""}]",Suspension,Facultative Anaerobe,"Mesophilic, grows at 18–30°C; optimal growth at 30°C on LB or TSA agar; requires no special nutrients beyond standard media","Growth reaches stationary phase after ~10 h (OD600 ~0.8–0.9), followed by gradual decline; high background noise in TM18 suggests possible aggregation or biofilm formation",Intestinal microbiota of healthy brook charr (Salvelinus fontinalis); potential niche in aquatic environments with moderate organic load,Antagonistic interaction with A. salmonicida subsp. salmonicida; may act as a probiotic by inhibiting pathogenic strains in fish gut,"Tolerant to moderate osmotic and ionic conditions; stability under standard lab storage (4°C); no data on UV, drying, or lyophilization",None reported,"Aeromonas sobria TM18 is a mesophilic, motile, facultative anaerobe that grows well in standard laboratory media at 30°C. It exhibits strong in vitro antagonism against the fish pathogen A. salmonicida subsp. salmonicida, with larger inhibition zones than TM12. It forms biofilms in liquid broth under static conditions, particularly in LB medium, indicating adaptation to sessile lifestyles in aquatic environments.",CRISPR-Cas not used; no genetic tools described; genome sequenced using MiSeq and de novo assembly,Not applicable,Constitutive expression (no inducible circuits reported),None,Plasmid-bearing (3 plasmids); chromosomal integration not reported; no data on long-term in vivo stability or metabolic burden,No data on stability in material environments,"The strain was isolated and characterized genomically without genetic modification. No synthetic circuits or engineered genetic systems were introduced. The genome was sequenced and annotated using RAST and PGAP pipelines, revealing a core genome with accessory genes, but no engineered genetic components.","[""Hypoxia"", ""pH"", ""Osmotic stress""]","[""Lactate"", ""Glucose"", ""Bile acids""]","[""Quorum sensing (AHL)"", ""AI-2""]","[""Proteases (e.g., MMP, Elastase)"", ""Cytokines"", ""Tissue degradation fragments""]","FNR promoter (hypoxia sensor), LasR (AHL receptor), LuxS (AI-2 synthase)",No synthetic logic gates reported; natural regulatory networks likely include AND/OR logic for environmental adaptation,"Aeromonas sobria TM18 likely uses native regulatory systems to sense environmental cues such as hypoxia, nutrient availability, and host-derived signals. The presence of FNR, LasR, and LuxS suggests integration of oxygen tension, quorum sensing, and metabolic signals to regulate gene expression, particularly for biofilm formation and antagonistic activity. No engineered logic circuits were implemented.","[""Antibacterial"", ""Biofilm Formation""]","Type II Secretion System (T2SS), Type IV Pilus (T4P), Type VI Secretion System (T6SS) predicted; likely involved in delivery of antimicrobial compounds",Not controllable; constitutive production of inhibitory compounds,Compatible with agar and liquid media; biofilm formation suggests compatibility with solid matrices,True,False,False,Produces diffusible inhibitory compounds that block growth of A. salmonicida subsp. salmonicida in agar assays; inhibition zones suggest secretion of antimicrobial molecules.,Unknown diffusible antimicrobial compound(s),False,True,True,True,Strain TM18 inhibits 10 strains of A. salmonicida subsp. salmonicida in agar lawn assays; no cytotoxicity or microbiome disruption reported; localized effect in fish gut context.,False,No oxygen-producing mechanism reported.,None,False,False,False,No evidence of oxygenation capability.,False,No immune-modulating factors reported.,None,False,No tissue repair factors reported.,None,False,No metabolic regulation mechanisms reported.,None,False,No tumor therapy mechanisms reported.,None,BSL-1,None reported; no kill switches or auxotrophy engineered,None,"Low pathogenicity in humans; opportunistic pathogen in fish and amphibians; carries plasmids (pTM18-1, pTM18-2, pTM18-3); potential for horizontal gene transfer via plasmids",None,"Aeromonas sobria TM18 is classified as BSL-1 due to low pathogenicity. It is not known to cause disease in healthy humans. However, it carries three plasmids, including a ColE1-like replicon, which may facilitate horizontal gene transfer. No engineered biocontainment was used. The strain's strong antagonistic activity against a fish pathogen suggests potential for ecological impact if released into natural environments.","Strain TM18 demonstrates strong in vitro inhibition of A. salmonicida subsp. salmonicida, with larger inhibition zones than TM12. Its ability to form biofilms and secrete antimicrobial compounds supports its role in microbial competition within the fish gut. No in vivo therapeutic efficacy data reported.",17837,3518,21355,,
4f33545c-a06e-4472-b786-9c52bd3e589c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium adolesentis"", ""strain_id"": ""BBMN23""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, neutral to slightly acidic pH (pH 6.5–7.0), moderate osmotic tolerance; utilizes complex carbohydrates as primary carbon sources",Doubling time ~2–3 hours in vitro; consistent growth kinetics observed in simulated gut conditions,"Adult human gut, particularly mucosal surface and intestinal lumen",Positive immunomodulatory interactions; enhances macrophage activity and intestinal function; likely competes with pathogenic bacteria via nutrient competition and niche exclusion,Moderate tolerance to bile salts and low pH (gastric conditions); stable during lyophilization and rehydration; resistant to shear stress in suspension,Glutamate decarboxylase (BBMN23_1411) and γ-aminobutyrate antiporter (BBMN23_1412) for acid resistance,Bifidobacterium adolesentis BBMN23 是一种从百岁老人粪便中分离的益生菌，具有良好的肠道定植能力。其生长最适温度为37°C，pH 6.5–7.0，能有效利用复杂碳水化合物，对胆盐和酸性环境具有较强耐受性，适合在肠道环境中长期存活。,"None (natural strain, no reported genetic modifications)",,Constitutive,,High chromosomal stability; no plasmids reported; natural genome is stable in vivo and in vitro,No engineered material coupling; natural strain compatible with standard probiotic delivery matrices,该菌株为天然分离菌株，未经过人工基因改造，其基因组完整且稳定，具备天然的益生特性，无需外源遗传工具即可实现功能表达。,"[""pH"", ""Hypoxia""]","[""Glucose"", ""Complex Carbohydrates""]",,"[""Bile Acids"", ""Mucin""]",Glutamate decarboxylase (BBMN23_1411) and γ-aminobutyrate antiporter (BBMN23_1412) for acid sensing; pilus-associated adhesins for mucosal recognition,Constitutive expression; no reported synthetic logic circuits; natural sensing via metabolic and adhesion pathways,BBMN23通过其表面菌毛和黏附蛋白感知肠道黏液和胆汁酸，同时利用葡萄糖和复杂碳水化合物作为信号分子调节代谢活性，其酸耐受系统（GAD系统）在低pH环境下自动激活，实现自我保护。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",None (natural secretion via general secretory pathway; no engineered delivery systems),Natural expression levels; no controllable output mechanism reported,Compatible with oral and encapsulated delivery systems; stable in gel and powder matrices,False,,,,,,,,,,False,,,,,,,True,"Enhances macrophage activity by increasing NO, IL-6, and TNF-α secretion; positively regulates immune function in mice","Nitric Oxide (NO), Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-α)",True,Improves intestinal barrier function and enhances intestinal motility; promotes mucosal healing via immune modulation,"Mucin-binding pili, SCFAs (indirectly via fermentation)",True,Produces γ-aminobutyric acid (GABA) via glutamate decarboxylase system; regulates gut-brain axis and neurotransmitter balance,γ-Aminobutyric Acid (GABA),False,,,BSL-1,"None (natural strain, no synthetic kill switches or auxotrophy reported)",,Non-pathogenic; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no evidence of environmental escape,Physical confinement via encapsulation or oral delivery limits environmental release,Bifidobacterium adolesentis BBMN23为天然益生菌，属于GRAS（公认安全）类别，无致病性，无抗生素抗性基因，不携带毒力因子，且在肠道内定植后不易扩散至环境，安全性高。,该菌株可显著增强巨噬细胞活性，促进小鼠肠道功能恢复，改善免疫调节能力，其产生的γ-氨基丁酸（GABA）有助于维持肠道稳态和神经调节，是潜在的肠道健康调节剂。,4388,1625,6013,,
c26c4c61-a915-4677-b571-805125b4bf2a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""Infloran ® strain (Desma Healthcare SpA, Torino, Italy)""}]",Encapsulated (in probiotic capsule),Facultative Anaerobe,"Optimal growth at 37°C, pH neutral to slightly alkaline, requires complex nutrients including amino acids, vitamins, and carbohydrates (e.g., glucose, fructose, maltose). Growth supported by intestinal mucus and host-derived metabolites.","Not explicitly reported; inferred to grow in vitro under standard conditions (37°C, 6 days incubation). In vivo growth likely limited by host immune response and gut environment.","Gut mucosa (intestinal lumen and mucosal surface), particularly in preterm infants with immature gut microbiota.",Competitive exclusion of pathogenic bacteria; potential symbiosis with host immune system and other commensals. May disrupt microbial balance in vulnerable neonates.,"Tolerant to lyophilization (freeze-dried in capsule), stable during storage at room temperature. Sensitive to gastric acid and bile in vivo, but protected by capsule delivery.",Capsule matrix (protective barrier against gastric acid and bile),Bifidobacterium longum 是一种专性或兼性厌氧的革兰氏阳性杆菌，适宜在37°C、中性至弱碱性环境中生长，依赖复杂的营养物质（如氨基酸、维生素和碳水化合物）。在早产儿肠道中，其定植能力受限于宿主免疫系统和肠道微环境，但可通过口服胶囊形式在肠道内定植，发挥益生作用。,,,,,No genetic modifications reported. Strain is a naturally occurring isolate used in probiotic formulation. Stability in capsule and during storage is ensured by lyophilization.,Stable within the capsule matrix; no evidence of genetic instability during encapsulation or in vivo delivery.,该菌株未经过基因工程改造，作为天然益生菌株直接用于口服制剂。其遗传稳定性由冻干工艺和胶囊保护层维持，无外源基因插入或表达系统。,"[""Hypoxia"", ""pH""]","[""Glucose"", ""Fructose"", ""Maltose"", ""Saccharose""]",,"[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia sensor), sugar transporters and metabolic regulators (glucose/fructose sensing)",No engineered logic gates reported. Natural metabolic regulation via substrate availability and oxygen tension.,Bifidobacterium longum 通过感知肠道内的低氧环境（FNR调控）和可发酵碳源（如葡萄糖、果糖）的浓度，调控其代谢活性。在缺氧和碳源充足条件下启动生长与定植程序，但未见人工设计的逻辑门控系统。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Passive diffusion and vesicle release (natural secretion); no engineered secretion systems reported.,"Controlled by oral dosing regimen (once daily, 2 weeks duration); no feedback-controlled release.",Compatible with capsule matrix; protected during transit through GI tract. No evidence of material disruption.,False,,,,,,,,,,False,,,,,,,True,"Modulates host immune system by enhancing gut barrier function, reducing pro-inflammatory cytokines, and promoting regulatory T-cell responses.","Bifidobacterial cell wall components (e.g., peptidoglycan, exopolysaccharides), secreted metabolites",True,Promotes epithelial regeneration and mucosal barrier integrity through stimulation of mucus production and tight junction protein expression.,"Exopolysaccharides (EPS), short-chain fatty acids (SCFAs)",True,"Produces SCFAs (e.g., acetate, lactate) from fermentation of dietary carbohydrates, which regulate host metabolism, energy homeostasis, and gut pH.","Acetate, Lactate, Succinate",False,,,BSL-1,No genetic kill switches or auxotrophy reported. Natural strain with low pathogenicity.,,"Low pathogenicity in healthy adults; however, in VLBW infants with immature immune systems and intestinal barriers, risk of bacteremia increases. No antibiotic resistance genes reported. Horizontal gene transfer risk low. Environmental escape unlikely due to non-persistence.","Capsule provides physical barrier against gastric acid and bile, but not sufficient to prevent translocation in compromised neonates.",尽管Bifidobacterium longum通常被视为安全的益生菌（GRAS），但在极低出生体重早产儿中，其可能引起菌血症，尤其在肠道屏障不成熟或存在炎症/坏死性小肠结肠炎的情况下。本研究三例病例均在使用Infloran®后出现B. longum菌血症，提示其在脆弱人群中存在潜在风险，需谨慎使用。,在三例早产儿中，B. longum 菌血症与坏死性小肠结肠炎（NEC）相关，其中一例需手术治疗。尽管益生菌在预防NEC方面有潜在益处，但本研究揭示其在极低出生体重婴儿中可能导致菌血症，提示其在该人群中的治疗效益需权衡安全性。,6276,1773,8049,,
e98dc03f-12ab-49cf-9957-15e8e9013c2d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""HN019""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires rich media; sensitive to oxygen and bile",Moderate growth rate; doubling time ~2–3 hours in vitro; in vivo colonization is transient (1–2 weeks post-consumption),"Gastrointestinal tract (colon), particularly in the large intestine",Symbiotic with host microbiota; no significant competition reported; may support beneficial microbial balance,"Moderate tolerance to low pH and bile; sensitive to high temperature (>30°C), drying, and oxygen; requires cryoprotectants for stability","Cryoprotectants (e.g., trehalose, inulin)","Bifidobacterium lactis HN019 is a facultative anaerobe with moderate growth kinetics, capable of surviving in the human gastrointestinal tract for up to two weeks. It thrives in neutral to slightly alkaline conditions and requires rich growth media. It exhibits sensitivity to oxygen and high temperatures, necessitating cryoprotectants and low-temperature storage for industrial stability.",Not specified,Not specified,Not specified,,High genetic stability; no mention of plasmid loss or drift; strain maintains identity and functionality over production cycles,"Stable in dry powder, capsule, and tablet matrices; stability enhanced by micro-encapsulation and low water activity",The strain is not genetically modified. Its functionality is based on natural physiological traits. Stability is maintained through formulation and process optimization rather than genetic engineering.,"[""pH"", ""Oxygen""]","[""Lactate"", ""Bile acids""]",,,"FNR promoter (inferred from oxygen sensitivity); bile acid resistance genes (e.g., bile salt hydrolase)",No engineered logic gates; natural sensing of pH and oxygen gradients in GI tract,"Bifidobacterium lactis HN019 naturally senses environmental changes such as low pH in the stomach and oxygen levels in the gut. It activates survival mechanisms in response to bile acids and acidic conditions, enabling transit through the gastrointestinal tract. No synthetic genetic circuits are used.","[""Immunomodulation"", ""Metabolic Regulation""]",Passive diffusion and cell lysis,"Controlled by product formulation (e.g., CFU per dose); typically 10^9 CFU/dose","High compatibility with dry powder, capsule, tablet, and confectionary matrices; micro-encapsulation enhances protection and delivery",False,,,Not applicable,,False,False,False,False,无相关证据,False,Not applicable,,False,False,False,无相关证据,True,Modulates host immune system by enhancing immune cell activity and cytokine production; supports mucosal barrier function,"Exopolysaccharides (EPS), cell wall components",False,Not applicable,,True,Produces short-chain fatty acids (SCFAs) such as acetate and lactate; regulates gut metabolism and energy homeostasis,"Acetate, Lactate",False,Not applicable,,GRAS,Auxotrophy (inferred from growth requirements); no antibiotic resistance genes,"Nutrient-dependent growth (e.g., specific carbon sources)",Non-pathogenic; no transmissible antibiotic resistance genes; low risk of translocation; transient colonization; safe for general population,Effective physical barrier via encapsulation and low water activity packaging,"Bifidobacterium lactis HN019 is classified as GRAS and has a long history of safe use. It does not persist in the gut beyond 1–2 weeks, minimizing long-term risks. No evidence of pathogenicity or horizontal gene transfer. Safety is further enhanced by encapsulation and low-moisture packaging.","Bifidobacterium lactis HN019 demonstrates improved gut health, immune modulation, and metabolic regulation in human studies. It maintains viability in various food matrices, including chocolate (12 months), capsules/tablets (12–24 months), and dairy products (weeks to months). Its stability is enhanced by cryoprotectants and micro-encapsulation, ensuring effective delivery to the gastrointestinal tract.",6290,1538,7828,,
2af1d343-2a6a-4a2c-a7b6-7288fd378994,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecalis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus mesenteroides"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus bulgaricus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""Not specified""}]",Oral administration (gastrointestinal tract),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates bile acids and intestinal pH; utilizes glucose and other carbohydrates as carbon sources; dependent on host-derived nutrients in gut environment",Doubling time ~1–2 hours in vitro; maintains homeostasis in human gut microbiome; consistent in vivo colonization post-administration,"Intestinal lumen and mucosal surface, particularly in colon and ileum; preferentially colonizes mucosal layer of colorectal surgery patients","Competes with pathogenic bacteria (e.g., Pseudomonas aeruginosa); promotes symbiosis with resident microbiota; enhances microbial diversity and stability","Tolerant to gastric acid, bile salts, and moderate osmotic stress; stable during lyophilization and storage at 4°C; resistant to shear stress during oral delivery","Cell wall components (e.g., peptidoglycan), exopolysaccharides, and stress-response proteins",这些益生菌多为兼性厌氧菌，可在人体肠道内定植并维持生长，对胃酸、胆汁等环境具有较强耐受性，能利用肠道内碳源进行代谢，通过竞争排斥和免疫调节机制抑制病原菌定植，从而在结直肠术后患者中发挥保护作用。,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,该研究未涉及基因工程改造，所有益生菌均为天然菌株或商业制剂，未进行人工基因编辑或合成回路设计。,"[""pH"", ""Bile acids"", ""Glucose"", ""Hypoxia""]","[""Short-chain fatty acids (SCFAs)"", ""Lactate"", ""Nitrate""]","[""Quorum sensing molecules (AHL, AI-2)""]","[""Proteases (e.g., MMPs)"", ""Cytokines (e.g., TNF-α, IL-10)""]","FNR promoter (hypoxia), Bile acid receptors (e.g., Bile acid-binding proteins), Glucose transporters, Quorum sensing receptors (e.g., LasR, LuxR)",Not mentioned,文中未描述任何基因逻辑门或信号处理机制，所有功能均基于天然菌株的生理响应，无工程化传感系统。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I-VI secretion systems, Vesicles, Lysis (natural release)",Dose-dependent effects; optimal dose range 10^8–10^11 CFU/day; timing: preoperative 3–15 days,Oral capsules or powders compatible with gastrointestinal transit; stable in enteric-coated formulations; no interference with gel or matrix structure,True,True,True,通过竞争性排斥、产生有机酸（如乳酸）、分泌细菌素（bacteriocins）和增强黏膜屏障功能，抑制多种病原菌（如大肠杆菌、金黄色葡萄球菌、铜绿假单胞菌）的定植与生物膜形成。,"Lactic acid, Bacteriocins (e.g., plantaricin), Organic acids",True,True,True,True,多中心随机对照试验显示，多菌株益生菌组合显著降低术后感染率（OR=0.30），包括手术部位感染和非手术部位感染，且无明显细胞毒性或菌血症风险。,False,未涉及氧气生成或耗氧调控机制。,,False,False,False,无相关证据支持该系统具有氧合功能。,True,调节肠道免疫反应，抑制过度炎症（如下调TNF-α、IL-6），同时促进抗炎因子（如IL-10）分泌，增强黏膜屏障功能，改善术后免疫失衡。,"IL-10, TNF-α, TGF-β",True,通过促进黏膜屏障修复、上调紧密连接蛋白（如ZO-1、occludin）表达、加速肠道上皮再生，改善术后肠道通透性，减少细菌易位。,"Tight junction proteins (ZO-1, occludin), Growth factors (e.g., EGF)",True,通过发酵膳食纤维产生短链脂肪酸（SCFAs，如乙酸、丙酸、丁酸），调节肠道pH，抑制病原菌生长，同时作为能量来源支持结肠上皮细胞代谢，具有抗炎和抗癌潜力。,"Short-chain fatty acids (SCFAs), Butyrate",False,未涉及肿瘤靶向治疗或前药激活机制。,,GRAS,"Auxotrophy (nutrient dependency), No antibiotic resistance genes reported","Nutrient-limited environment (e.g., absence of specific amino acids or vitamins)",Low pathogenicity; no reported cases of bacteremia/fungemia in included trials; no horizontal gene transfer observed; low environmental escape risk due to poor survival outside host,Gastrointestinal tract acts as natural physical barrier; oral delivery limits systemic spread,所有使用的益生菌均为公认安全（GRAS）菌株，未发现致病性或耐药基因，临床试验中未报告严重不良事件，且在肠道内定植后难以在体外长期存活，安全性较高。,多菌株益生菌组合显著降低结直肠术后总感染率（OR=0.30）、手术部位感染（OR=0.48）和非手术部位感染（OR=0.36），并改善肠道屏障功能，减少细菌易位，促进黏膜修复，具有良好的临床疗效。,13767,2310,16077,,
b45cc6eb-c625-4ce9-90ca-16d5e06453f8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acidity and bile salts; utilizes glucose and other carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; stable in vivo colonization in infant gut with transient persistence,"Intestinal mucosa, particularly in the small intestine and colon of infants",Competes with pathogens for nutrients and binding sites; promotes symbiosis with host microbiota; no significant disruption of native microbiome observed,"Tolerant to drying, lyophilization, and moderate shear stress; stable during storage at 4°C; resistant to bile and low pH","Bile salts, gastric acid (HCl), lyophilization matrix",该菌株为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下良好生长，耐受胃酸和胆盐，以葡萄糖等碳源为能源，在婴儿肠道黏膜（小肠和结肠）中可短暂定植，具有较强的环境适应性和稳定性。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未涉及基因工程改造，L. rhamnosus GG作为天然存在的益生菌株直接使用，未进行任何遗传修饰。,"[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases""]","FNR promoter, Lactate receptor, Bile acid sensor",Not specified,未明确描述其感知与逻辑处理机制，但基于其在肠道环境中的定植能力，推测其具备对pH、胆盐、乳酸等环境信号的响应能力，可能通过调控基因表达实现适应性调节。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type IV secretion system, Vesicles",Dose-dependent effects observed; optimal dose range 1×10¹⁰ to 2×10¹² CFU/day; no evidence of overactivity at high doses,Compatible with oral delivery; stable in infant formula and suspension formulations,True,True,True,通过分泌乳酸、过氧化氢及细菌素（如Lactocin 705）抑制多种病原菌生长，包括S. aureus和P. aeruginosa，并有效抑制生物膜形成。,"Lactic acid, Hydrogen peroxide, Bacteriocins (e.g., Lactocin 705)",True,True,True,True,在多项临床试验中，L. rhamnosus GG在婴儿中使用安全，未见显著细胞毒性或微生物群落紊乱，且在高剂量（高达2×10¹² CFU/天）下仍保持良好耐受性。,False,未涉及氧气生成或消耗机制。,Not applicable,False,False,False,未报告任何与氧合相关的功能或机制。,True,通过调节Toll样受体（TLR）信号通路，增强抗原呈递细胞功能，促进Th1/Th2平衡，降低IgE水平，减轻过敏反应。,"Cytokines (IL-10, TGF-β), TLR ligands",True,促进肠道上皮屏障功能恢复，增强黏液分泌，诱导紧密连接蛋白表达，加速黏膜修复。,"Mucin, Tight junction proteins (e.g., ZO-1, Occludin)",True,发酵碳水化合物产生短链脂肪酸（SCFAs），如乙酸、丙酸和丁酸，调节肠道pH，抑制病原菌生长，调节宿主代谢。,"Short-chain fatty acids (SCFAs): Acetate, Propionate, Butyrate",False,未涉及肿瘤治疗功能。,Not applicable,GRAS,"Auxotrophy (e.g., requirement for specific amino acids), no known virulence genes","Amino acid auxotrophy (e.g., arginine, histidine)",No documented cases of bacteraemia or fungemia; low opportunistic risk; no antibiotic resistance genes reported; no horizontal gene transfer observed; low environmental escape risk,Oral administration provides natural physical barrier; no engineered containment required,L. rhamnosus GG被广泛认定为GRAS（公认安全），在婴儿中长期使用（长达2年）未见重大安全问题。尽管有极少数报告称可能与特定配方奶粉联合使用时引起轻微不良反应，但均未证实与菌株本身直接相关。,在早产儿中显著降低坏死性小肠结肠炎（NEC）发生率；在腹泻婴儿中缩短病程并减少排便频率；在特应性皮炎婴儿中改善皮肤症状，降低过敏反应风险。长期随访（10年）未发现生长发育异常或肥胖风险增加。,13781,1730,15511,,
5e762a1c-2707-4049-8c0b-7ae70e57dd6f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""CAU 7856""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""CAU 6728""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus acidilactici"", ""strain_id"": ""CAU 9567, 9967, 9896""}]",Suspension (in culture supernatant),Facultative Anaerobe,"37°C, 5% CO₂, pH not explicitly stated; grows on modified MRS media",Growth rate not quantified; culture broth showed peak antimicrobial activity on day 4,Gastrointestinal tract and potentially urogenital tract in infants,Competitive exclusion of uropathogens; potential for colonization in healthy infants,"Not explicitly reported; isolated from feces, suggesting tolerance to intestinal environment",,该研究中分离的乳酸菌（LAB）为革兰氏阳性、兼性厌氧菌，可在37°C、5% CO₂条件下在改良MRS培养基上生长。其中Lactobacillus brevis、Enterococcus faecium和Pediococcus acidilactici均来源于健康婴儿粪便，具有良好的体外抗菌活性，表明其在体内定植潜力较强。,,,,,,,本研究未涉及基因工程改造，所有菌株均为天然分离株，未进行人工遗传修饰。,,,,,,,本研究未涉及合成生物学或信号感应模块的设计，未描述任何感应逻辑或调控回路。,"[""Antibacterial""]","Secretion of antimicrobial metabolites (lactic acid, hydrogen peroxide, bacteriocins)",Not controllable; activity increases over time (peak at day 4 of culture),"Not evaluated; used in agar diffusion assay, but no encapsulation or material integration described",True,True,False,通过分泌抗菌物质（如乳酸、过氧化氢、细菌素等）抑制尿路致病菌生长，包括多种E. coli、Staphylococcus saprophyticus、Proteus vulgaris、Enterobacter cloacae、Pseudomonas aeruginosa和Bacillus anthracis。,"Lactic acid, Hydrogen peroxide, Bacteriocin-like compounds",True,False,False,False,三种LAB菌株对9种E. coli及6种其他尿路致病菌均表现出显著抗菌活性，尤其对Bacillus anthracis和Pseudomonas aeruginosa效果强，表明具有广谱抗菌能力。但未评估生物膜抑制、剂量控制、基质兼容性及细胞毒性。,False,,,False,False,False,,False,,,False,,,False,,,False,,,BSL-1,"None (natural isolates, no engineered kill switches)",,"Enterococcus faecium has potential for antibiotic resistance gene transfer and systemic infection (e.g., endocarditis, septicemia). Other LAB are generally considered safe but may pose risks in immunocompromised hosts.",None; no physical barrier or encapsulation used in this study,Lactobacillus brevis、Enterococcus faecium和Pediococcus acidilactici均为健康婴儿粪便中分离的天然菌株，属于GRAS（公认安全）类别，但Enterococcus faecium存在耐药基因水平转移风险，且已有文献报道其可引起心内膜炎、败血症等系统性感染，需警惕在免疫缺陷患儿中使用。,本研究为体外实验，未评估实际伤口愈合或临床疗效。但结果显示三种LAB菌株对多种尿路致病菌具有显著抑制作用，尤其在第4天培养上清中抗菌活性最强，提示其作为潜在益生菌用于儿童尿路感染预防和治疗具有前景。,9428,1504,10932,,
d12d4a4a-11ca-424f-9133-0295ecb13176,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""MF405176.1""}]",Suspension,Facultative Anaerobe,Temperature: 30–42°C; pH: 3–7; NaCl: up to 12%; bile: up to 2.0% (w/v); phenol: up to 0.4% (v/v); gastric juice: pH 1.5,Growth rate: 37°C; doubling time not specified; in vitro growth confirmed under simulated gastric conditions,"Gastrointestinal tract (colon, intestinal mucus)",Competitive exclusion of pathogens; potential symbiosis with host microbiota,"Tolerates acid (pH 1.5), bile (up to 2.0%), high salt (12%), phenol (0.4%), and simulated gastric juice; stable at 30–42°C","Cell wall components, membrane integrity, stress response proteins",该菌株为乳酸杆菌，能在30–42°C、pH 3–7条件下生长，耐受高达12% NaCl、2.0%胆汁、0.4%苯酚及pH 1.5的模拟胃液，具备良好的胃肠道环境适应能力。,16S rRNA sequencing for identification; no genetic tools used for engineering,Not applicable (no genetic modification reported),Constitutive (no inducible circuits reported),,Chromosomal stability confirmed via 16S rRNA sequencing; no plasmid-based systems used,No engineered material environment reported,未进行基因工程改造，仅通过16S rRNA测序进行物种鉴定，无基因编辑或调控回路设计。,"[""pH"", ""Bile"", ""Salt"", ""Phenol""]","[""Glucose"", ""Fructose"", ""Maltose"", ""Lactose"", ""Galactose"", ""Sucrose"", ""Dextrose""]",,,"General stress response systems (e.g., acid tolerance response, bile resistance regulators)",No logic gates reported; constitutive expression of stress resistance genes,该菌株通过非特异性应激响应系统感知酸、胆汁、盐和苯酚等环境变化，无明确逻辑门控机制，表现为基础性耐受能力。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion system (likely), extracellular release via lysis",Not controllable (natural secretion),Compatible with food-grade matrices; no encapsulation reported,True,True,False,分泌抗菌物质（如有机酸、细菌素）抑制多种病原菌生长，包括耐药菌株,"Organic acids (lactic acid), bacteriocins",True,True,True,True,对多种敏感及多重耐药病原体（如大肠杆菌、金黄色葡萄球菌、肺炎克雷伯菌）均表现出强抑制活性，且无细胞毒性，局部作用明确。,False,无氧生成机制,,False,False,False,未检测到氧生成能力，不适用于氧疗场景。,True,通过调节免疫细胞活性，增强抗炎反应，促进免疫稳态,"Cell surface proteins, exopolysaccharides (EPS), secreted metabolites",True,促进上皮细胞黏附与增殖，增强肠道屏障功能，支持组织再生,"Exopolysaccharides (EPS), cell surface adhesins",False,未检测到代谢调节功能,,False,无肿瘤治疗相关机制,,GRAS,None (no kill-switch or auxotrophy reported),,"No hemolysis, DNAse, or gelatinase activity; susceptible to antibiotics; no virulence genes detected",None (free suspension in vitro),该菌株无溶血、DNA酶或明胶酶活性，对多种抗生素敏感，未检测到致病基因，符合GRAS标准，安全性良好。,该菌株在体外表现出强抗病原菌活性，对HT-29和HTC-116结肠癌细胞具有显著抑制作用（IC50最低），且具有高细胞黏附性，支持其在肠道修复与免疫调节中的潜在应用。,19504,7782,27286,,
d12d4a4a-11ca-424f-9133-0295ecb13176,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""MF033346.1""}]",Suspension,Facultative Anaerobe,Temperature: 30–42°C; pH: 3–7; NaCl: up to 12%; bile: up to 2.0% (w/v); phenol: up to 0.4% (v/v); gastric juice: pH 1.5,Growth rate: 37°C; doubling time not specified; in vitro growth confirmed under simulated gastric conditions,"Gastrointestinal tract (colon, intestinal mucus)",Competitive exclusion of pathogens; potential symbiosis with host microbiota,"Tolerates acid (pH 1.5), bile (up to 2.0%), high salt (12%), phenol (0.4%), and simulated gastric juice; stable at 30–42°C","Cell wall components, membrane integrity, stress response proteins",该菌株为发酵乳杆菌，能在30–42°C、pH 3–7条件下生长，耐受高达12% NaCl、2.0%胆汁、0.4%苯酚及pH 1.5的模拟胃液，具备良好的胃肠道环境适应能力。,16S rRNA sequencing for identification; no genetic tools used for engineering,Not applicable (no genetic modification reported),Constitutive (no inducible circuits reported),,Chromosomal stability confirmed via 16S rRNA sequencing; no plasmid-based systems used,No engineered material environment reported,未进行基因工程改造，仅通过16S rRNA测序进行物种鉴定，无基因编辑或调控回路设计。,"[""pH"", ""Bile"", ""Salt"", ""Phenol""]","[""Glucose"", ""Fructose"", ""Maltose"", ""Lactose"", ""Galactose"", ""Sucrose"", ""Dextrose""]",,,"General stress response systems (e.g., acid tolerance response, bile resistance regulators)",No logic gates reported; constitutive expression of stress resistance genes,该菌株通过非特异性应激响应系统感知酸、胆汁、盐和苯酚等环境变化，无明确逻辑门控机制，表现为基础性耐受能力。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion system (likely), extracellular release via lysis",Not controllable (natural secretion),Compatible with food-grade matrices; no encapsulation reported,True,True,False,分泌抗菌物质（如有机酸、细菌素）抑制多种病原菌生长，包括耐药菌株,"Organic acids (lactic acid), bacteriocins",True,True,True,True,对多种敏感及多重耐药病原体（如大肠杆菌、金黄色葡萄球菌、肺炎克雷伯菌）均表现出强抑制活性，且无细胞毒性，局部作用明确。,False,无氧生成机制,,False,False,False,未检测到氧生成能力，不适用于氧疗场景。,True,通过调节免疫细胞活性，增强抗炎反应，促进免疫稳态,"Cell surface proteins, exopolysaccharides (EPS), secreted metabolites",True,促进上皮细胞黏附与增殖，增强肠道屏障功能，支持组织再生,"Exopolysaccharides (EPS), cell surface adhesins",False,未检测到代谢调节功能,,False,无肿瘤治疗相关机制,,GRAS,None (no kill-switch or auxotrophy reported),,"No hemolysis, DNAse, or gelatinase activity; susceptible to antibiotics; no virulence genes detected",None (free suspension in vitro),该菌株无溶血、DNA酶或明胶酶活性，对多种抗生素敏感，未检测到致病基因，符合GRAS标准，安全性良好。,该菌株在体外表现出强抗病原菌活性，对HT-29和HTC-116结肠癌细胞具有显著抑制作用，且具有高细胞黏附性，支持其在肠道修复与免疫调节中的潜在应用。,19504,7782,27286,,
d12d4a4a-11ca-424f-9133-0295ecb13176,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis subsp. lactis"", ""strain_id"": ""MF480428.1""}]",Suspension,Facultative Anaerobe,Temperature: 30–42°C; pH: 3–7; NaCl: up to 12%; bile: up to 2.0% (w/v); phenol: up to 0.4% (v/v); gastric juice: pH 1.5,Growth rate: 37°C; doubling time not specified; in vitro growth confirmed under simulated gastric conditions,"Gastrointestinal tract (colon, intestinal mucus)",Competitive exclusion of pathogens; potential symbiosis with host microbiota,"Tolerates acid (pH 1.5), bile (up to 2.0%), high salt (12%), phenol (0.4%), and simulated gastric juice; stable at 30–42°C","Cell wall components, membrane integrity, stress response proteins",该菌株为乳酸乳球菌，能在30–42°C、pH 3–7条件下生长，耐受高达12% NaCl、2.0%胆汁、0.4%苯酚及pH 1.5的模拟胃液，具备良好的胃肠道环境适应能力。,16S rRNA sequencing for identification; no genetic tools used for engineering,Not applicable (no genetic modification reported),Constitutive (no inducible circuits reported),,Chromosomal stability confirmed via 16S rRNA sequencing; no plasmid-based systems used,No engineered material environment reported,未进行基因工程改造，仅通过16S rRNA测序进行物种鉴定，无基因编辑或调控回路设计。,"[""pH"", ""Bile"", ""Salt"", ""Phenol""]","[""Glucose"", ""Fructose"", ""Maltose"", ""Lactose"", ""Galactose"", ""Sucrose"", ""Dextrose""]",,,"General stress response systems (e.g., acid tolerance response, bile resistance regulators)",No logic gates reported; constitutive expression of stress resistance genes,该菌株通过非特异性应激响应系统感知酸、胆汁、盐和苯酚等环境变化，无明确逻辑门控机制，表现为基础性耐受能力。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion system (likely), extracellular release via lysis",Not controllable (natural secretion),Compatible with food-grade matrices; no encapsulation reported,True,True,False,分泌抗菌物质（如有机酸、细菌素）抑制多种病原菌生长，包括耐药菌株,"Organic acids (lactic acid), bacteriocins",True,True,True,True,对多种敏感及多重耐药病原体（如大肠杆菌、金黄色葡萄球菌、肺炎克雷伯菌）均表现出强抑制活性，且无细胞毒性，局部作用明确。,False,无氧生成机制,,False,False,False,未检测到氧生成能力，不适用于氧疗场景。,True,通过调节免疫细胞活性，增强抗炎反应，促进免疫稳态,"Cell surface proteins, exopolysaccharides (EPS), secreted metabolites",True,促进上皮细胞黏附与增殖，增强肠道屏障功能，支持组织再生,"Exopolysaccharides (EPS), cell surface adhesins",False,未检测到代谢调节功能,,False,无肿瘤治疗相关机制,,GRAS,None (no kill-switch or auxotrophy reported),,"No hemolysis, DNAse, or gelatinase activity; susceptible to antibiotics; no virulence genes detected",None (free suspension in vitro),该菌株无溶血、DNA酶或明胶酶活性，对多种抗生素敏感，未检测到致病基因，符合GRAS标准，安全性良好。,该菌株在体外表现出强抗病原菌活性，对HT-29和HTC-116结肠癌细胞具有显著抑制作用，且具有高细胞黏附性，支持其在肠道修复与免疫调节中的潜在应用。,19504,7782,27286,,
d12d4a4a-11ca-424f-9133-0295ecb13176,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""MF480431.1""}]",Suspension,Facultative Anaerobe,Temperature: 30–42°C; pH: 3–7; NaCl: up to 12%; bile: up to 2.0% (w/v); phenol: up to 0.4% (v/v); gastric juice: pH 1.5,Growth rate: 37°C; doubling time not specified; in vitro growth confirmed under simulated gastric conditions,"Gastrointestinal tract (colon, intestinal mucus)",Competitive exclusion of pathogens; potential symbiosis with host microbiota,"Tolerates acid (pH 1.5), bile (up to 2.0%), high salt (12%), phenol (0.4%), and simulated gastric juice; stable at 30–42°C","Cell wall components, membrane integrity, stress response proteins",该菌株为粪肠球菌，能在30–42°C、pH 3–7条件下生长，耐受高达12% NaCl、2.0%胆汁、0.4%苯酚及pH 1.5的模拟胃液，具备良好的胃肠道环境适应能力。,16S rRNA sequencing for identification; no genetic tools used for engineering,Not applicable (no genetic modification reported),Constitutive (no inducible circuits reported),,Chromosomal stability confirmed via 16S rRNA sequencing; no plasmid-based systems used,No engineered material environment reported,未进行基因工程改造，仅通过16S rRNA测序进行物种鉴定，无基因编辑或调控回路设计。,"[""pH"", ""Bile"", ""Salt"", ""Phenol""]","[""Glucose"", ""Fructose"", ""Maltose"", ""Lactose"", ""Galactose"", ""Sucrose"", ""Dextrose""]",,,"General stress response systems (e.g., acid tolerance response, bile resistance regulators)",No logic gates reported; constitutive expression of stress resistance genes,该菌株通过非特异性应激响应系统感知酸、胆汁、盐和苯酚等环境变化，无明确逻辑门控机制，表现为基础性耐受能力。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion system (likely), extracellular release via lysis",Not controllable (natural secretion),Compatible with food-grade matrices; no encapsulation reported,True,True,False,分泌抗菌物质（如有机酸、细菌素）抑制多种病原菌生长，包括耐药菌株,"Organic acids (lactic acid), bacteriocins",True,True,True,True,对多种敏感及多重耐药病原体（如大肠杆菌、金黄色葡萄球菌、肺炎克雷伯菌）均表现出强抑制活性，且无细胞毒性，局部作用明确。,False,无氧生成机制,,False,False,False,未检测到氧生成能力，不适用于氧疗场景。,True,通过调节免疫细胞活性，增强抗炎反应，促进免疫稳态,"Cell surface proteins, exopolysaccharides (EPS), secreted metabolites",True,促进上皮细胞黏附与增殖，增强肠道屏障功能，支持组织再生,"Exopolysaccharides (EPS), cell surface adhesins",False,未检测到代谢调节功能,,False,无肿瘤治疗相关机制,,GRAS,None (no kill-switch or auxotrophy reported),,"No hemolysis, DNAse, or gelatinase activity; susceptible to antibiotics; no virulence genes detected",None (free suspension in vitro),该菌株无溶血、DNA酶或明胶酶活性，对多种抗生素敏感，未检测到致病基因，符合GRAS标准，安全性良好。,该菌株在体外表现出强抗病原菌活性，对HT-29和HTC-116结肠癌细胞具有显著抑制作用，且具有高细胞黏附性，支持其在肠道修复与免疫调节中的潜在应用。,19504,7782,27286,,
d12d4a4a-11ca-424f-9133-0295ecb13176,4,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Pediococcus acidilactici"", ""strain_id"": ""MF480434.1""}]",Suspension,Facultative Anaerobe,Temperature: 30–42°C; pH: 3–7; NaCl: up to 12%; bile: up to 2.0% (w/v); phenol: up to 0.4% (v/v); gastric juice: pH 1.5,Growth rate: 37°C; doubling time not specified; in vitro growth confirmed under simulated gastric conditions,"Gastrointestinal tract (colon, intestinal mucus)",Competitive exclusion of pathogens; potential symbiosis with host microbiota,"Tolerates acid (pH 1.5), bile (up to 2.0%), high salt (12%), phenol (0.4%), and simulated gastric juice; stable at 30–42°C","Cell wall components, membrane integrity, stress response proteins",该菌株为酸乳球菌，能在30–42°C、pH 3–7条件下生长，耐受高达12% NaCl、2.0%胆汁、0.4%苯酚及pH 1.5的模拟胃液，具备良好的胃肠道环境适应能力。,16S rRNA sequencing for identification; no genetic tools used for engineering,Not applicable (no genetic modification reported),Constitutive (no inducible circuits reported),,Chromosomal stability confirmed via 16S rRNA sequencing; no plasmid-based systems used,No engineered material environment reported,未进行基因工程改造，仅通过16S rRNA测序进行物种鉴定，无基因编辑或调控回路设计。,"[""pH"", ""Bile"", ""Salt"", ""Phenol""]","[""Glucose"", ""Fructose"", ""Maltose"", ""Lactose"", ""Galactose"", ""Sucrose"", ""Dextrose""]",,,"General stress response systems (e.g., acid tolerance response, bile resistance regulators)",No logic gates reported; constitutive expression of stress resistance genes,该菌株通过非特异性应激响应系统感知酸、胆汁、盐和苯酚等环境变化，无明确逻辑门控机制，表现为基础性耐受能力。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion system (likely), extracellular release via lysis",Not controllable (natural secretion),Compatible with food-grade matrices; no encapsulation reported,True,True,False,分泌抗菌物质（如有机酸、细菌素）抑制多种病原菌生长，包括耐药菌株,"Organic acids (lactic acid), bacteriocins",True,True,True,True,对多种敏感及多重耐药病原体（如大肠杆菌、金黄色葡萄球菌、肺炎克雷伯菌）均表现出强抑制活性，且无细胞毒性，局部作用明确。,False,无氧生成机制,,False,False,False,未检测到氧生成能力，不适用于氧疗场景。,True,通过调节免疫细胞活性，增强抗炎反应，促进免疫稳态,"Cell surface proteins, exopolysaccharides (EPS), secreted metabolites",True,促进上皮细胞黏附与增殖，增强肠道屏障功能，支持组织再生,"Exopolysaccharides (EPS), cell surface adhesins",False,未检测到代谢调节功能,,False,无肿瘤治疗相关机制,,GRAS,None (no kill-switch or auxotrophy reported),,"No hemolysis, DNAse, or gelatinase activity; susceptible to antibiotics; no virulence genes detected",None (free suspension in vitro),该菌株无溶血、DNA酶或明胶酶活性，对多种抗生素敏感，未检测到致病基因，符合GRAS标准，安全性良好。,该菌株在体外表现出强抗病原菌活性，对HT-29和HTC-116结肠癌细胞具有显著抑制作用，且具有高细胞黏附性，支持其在肠道修复与免疫调节中的潜在应用。,19504,7782,27286,,
5b2883a0-7be2-48f4-8049-50852df8eb66,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": """"}]",Suspension,Facultative Anaerobe,"Temperature: 37°C (inferred from poultry gut environment); pH: Neutral to slightly acidic (typical for chicken small intestine); Osmotic: Tolerant to intestinal osmolarity; Nutrition: Requires carbohydrates (e.g., glucose, lactose) and amino acids; dependent on host-derived nutrients in gut lumen.",Growth rate not explicitly reported; assumed moderate in vivo growth consistent with intestinal colonization over 14 days.,"Small intestine (ileum, jejunum, duodenum); preferentially colonizes distal small intestine (ileum) for Lactobacillus; duodenum for Bifidobacterium.",Competitive interaction with native microbiota; enhances mucin synthesis and secretion; may inhibit pathogen adhesion via mucin layer modulation.,"Tolerant to gastrointestinal transit (acidic pH, bile); stability during lyophilization/rehydration (implied by probiotic formulation); resistant to shear stress in intestinal lumen.","Cell wall components (e.g., peptidoglycan), exopolysaccharides (EPS), and metabolic adaptation to bile salts.",该益生菌混合物由多种革兰氏阳性菌组成，包括乳酸杆菌和双歧杆菌，可在鸡小肠中定植，尤其在回肠中显著增加乳酸杆菌比例。其生长依赖于肠道环境中的碳源和氨基酸，具有耐酸、耐胆盐能力，可在肠道中维持稳定定植，影响黏液动态。,Not applicable (no genetic modification reported),null,Constitutive,null,High (natural strains; no plasmid-based systems reported; chromosomal stability in gut environment),Stable in dietary matrix (feed supplement); no evidence of instability in intestinal environment.,该系统为天然益生菌混合物，未进行基因工程改造。其功能依赖于天然菌株的生理特性，如黏液结合能力、黏液合成刺激作用和竞争性排斥病原体。,"[""pH"", ""Bile Acids"", ""Glucose""]","[""Lactate"", ""SCFAs"", ""Mucin""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","Mucin-binding proteins (e.g., MUB in Lactobacillus), bile salt hydrolases, sugar transporters, and surface adhesins.","No engineered logic gates; natural sensing via receptor-ligand interactions (e.g., mucin binding triggers gene expression).",这些菌株通过表面受体感知肠道环境中的黏液、胆汁酸、葡萄糖和乳酸等信号，激活黏液合成相关基因表达。例如，Lactobacillus在接触黏液后可诱导黏液蛋白基因表达，形成正反馈调节。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I/II secretion systems (inferred from mucin-binding and mucin-modulating activity); extracellular vesicles (possible, not reported)",Natural dosage control via colonization density and environmental feedback; no external control mechanism.,Compatible with feed matrix; stable during oral administration and intestinal transit.,False,False,False,null,null,False,False,False,False,无抗菌或抗生物膜功能的证据。,False,null,null,False,False,False,无产氧功能的证据。,True,益生菌通过刺激黏液合成和分泌，增强肠道屏障功能，间接调节免疫反应；可能通过调节炎症因子表达影响局部免疫环境。,"Mucin glycoproteins, prostaglandins (e.g., PGE2), and bacterial cell wall components (e.g., peptidoglycan)",True,通过增加黏液分泌和改善肠道上皮结构（如增大杯状细胞“杯”面积、增加绒毛表面积）促进黏膜修复和屏障完整性。,"Mucin glycoproteins, growth factors (indirectly via epithelial stimulation)",True,通过调节黏液代谢动态（合成、分泌、降解）影响营养吸收和肠道微环境稳态；可能通过代谢产物（如SCFAs）调节宿主代谢。,"Short-chain fatty acids (SCFAs), Mucin glycoproteins",False,null,null,GRAS,Auxotrophy (implied by natural attenuation in gut); no kill-switch or synthetic control reported.,"Nutrient-dependent growth (e.g., specific carbon sources not available in environment)",Low pathogenicity; no antibiotic resistance genes reported; minimal horizontal gene transfer risk; low environmental escape potential due to poor environmental survival.,Physical confinement via intestinal mucosal barrier and host immune system.,该益生菌混合物为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，且在环境中的存活能力弱，因此生物安全风险极低。,在14天内，益生菌补充显著增加了回肠中乳酸杆菌的比例，提高了空肠和回肠的杯状细胞密度和黏液糖蛋白水平，增强了黏液屏障功能，改善了肠道上皮结构，促进黏膜修复，从而提升肠道健康和营养吸收能力。,14594,1878,16472,,
ea617e8f-3e88-4d04-976a-8c96bea2286c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""P8""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerates gastric acid (pH 2.0–3.0), bile salts (0.3–1.0%), and intestinal fluid; requires fermentable carbohydrates (e.g., glucose, fructose) as carbon sources.",Doubling time ~1.5–2 hours in vitro; stable colonization in human gut with detectable fecal persistence up to 17 weeks post-administration cessation.,"Gastrointestinal tract (small and large intestine), particularly in the mucosal layer of the colon; preferentially colonizes in the presence of dietary fermentable fibers.","Competes with opportunistic pathogens (e.g., Shigella, Escherichia, Enterobacter); promotes growth of beneficial gut microbiota (e.g., Lactobacillus spp.).","High tolerance to gastric acid, bile, osmotic stress, and temperature fluctuations (up to 45°C); stable during lyophilization and rehydration; resistant to UV and shear stress during processing.","Bile salt hydrolase (BSH), acid shock proteins (e.g., GroEL, DnaK), and extracellular polysaccharides (EPS) contribute to environmental resilience.","Lactobacillus plantarum P8 is a facultative anaerobe with strong gastrointestinal resilience, capable of surviving harsh gastric conditions and colonizing the human gut for extended periods. It thrives under physiological conditions of the human intestine, utilizing fermentable carbohydrates as energy sources. Its ability to persist in fecal samples for up to 17 weeks after cessation of intake indicates robust colonization and stability in the host environment.",Not specified (no genetic modification reported),Not applicable (wild-type strain used),Constitutive expression (no inducible systems reported),,"High chromosomal stability; no plasmid-based systems used; genomic analysis shows neutral evolution (19 SNPs in core genome) and reductive evolution (loss of 1–3 plasmids in ~42% of isolates), indicating adaptation to gut environment without instability.",Stable in maltodextrin-based powder formulation; no degradation observed during storage at <30°C.,"Lactobacillus plantarum P8 was used in its native, unmodified form. No genetic engineering or synthetic circuits were applied. The strain was selected based on its intrinsic resilience and health-promoting properties, with no artificial modifications to its genome.","[""pH"", ""Glucose"", ""Bile""]","[""Short-chain fatty acids (SCFAs)"", ""Lactate""]",,"[""Cytokines (IFN-γ, TNF-α)"", ""Cortisol""]","Putative two-component systems (TCS) and membrane transporters responsive to pH and bile; potential SCFA receptors (e.g., GPR41/GPR43 analogs); cytokine-binding domains in surface proteins (inferred from immunomodulatory effects).",No synthetic logic gates reported; natural sensing likely involves threshold-based activation of stress response and immune modulation pathways.,"L. plantarum P8 senses environmental cues such as low pH and bile salts via membrane sensors, triggering acid and bile resistance mechanisms. It detects host-derived metabolites like SCFAs and lactate, which may modulate its metabolic activity. The strain also responds to systemic immune signals (e.g., IFN-γ, TNF-α), suggesting cross-talk with host immune cells. These inputs likely integrate through constitutive regulatory networks to modulate immune and metabolic outputs.","[""Immunomodulation"", ""Metabolic Regulation"", ""Cognition Enhancement""]","Type IV secretion system (inferred from surface protein secretion), vesicle-mediated release (exosomes), and passive diffusion of metabolites.",Daily oral administration of 10 log CFU/day; effects observed after 4 weeks and sustained over 12 weeks; no evidence of over-activation or toxicity.,Compatible with maltodextrin-based powder formulation; stable during encapsulation and storage; no adverse interaction with excipients.,False,False,False,Not applicable (no direct antibacterial activity reported),,False,False,False,False,No evidence of antibacterial or biofilm inhibition activity was reported in the study.,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,"No oxygenation mechanism or related enzyme (e.g., catalase, superoxide dismutase) was reported as a primary function.",True,"Reduces pro-inflammatory cytokines (IFN-γ, TNF-α) and modulates immune cell activity; enhances secretory IgA levels; promotes anti-inflammatory environment in gut and systemic circulation.","Short-chain fatty acids (SCFAs), extracellular polysaccharides (EPS), surface proteins (e.g., pili, adhesins), and secreted metabolites that interact with host immune receptors (e.g., TLRs, GPCRs).",False,Not applicable (no direct tissue repair or angiogenesis activity reported),,True,"Increases fecal levels of short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate; modulates host glucose and lipid metabolism via gut microbiota-mediated signaling.","Acetate, Propionate, Butyrate",False,Not applicable (no anti-tumor or prodrug conversion activity reported),,GRAS,Auxotrophy (inferred from genomic stability and lack of antibiotic resistance genes); no suicide genes or inducible kill switches reported.,None (no engineered containment systems used),No pathogenicity or virulence genes detected; no antibiotic resistance genes (ARGs) identified; low risk of horizontal gene transfer (HGT); no evidence of environmental escape or persistence beyond gut.,Physical barrier provided by oral delivery and intestinal mucus layer; no systemic dissemination reported.,"L. plantarum P8 is classified as Generally Recognized As Safe (GRAS). It has been isolated from traditional fermented foods, shows no virulence factors, and exhibits genomic stability with neutral evolution. No adverse events were reported in the clinical trial. The strain is not genetically modified, reducing biosafety concerns. Its natural auxotrophy and limited survival outside the gut further reduce ecological risk.","L. plantarum P8 significantly reduced perceived stress (mean difference: 2.94, p = 0.048), anxiety (mean difference: 2.82, p = 0.031), and total DASS-42 scores (mean difference: 8.04, p = 0.041) after 12 weeks. It enhanced memory and cognition, particularly social emotional cognition (p = 0.002) and verbal learning (p = 0.044). Pro-inflammatory cytokines IFN-γ and TNF-α were significantly reduced (p < 0.001), and fecal SCFA levels increased. These effects were more pronounced in women, suggesting sex-specific modulation of gut-brain axis.",20452,2145,22597,,
95e8bd4a-d03b-4402-9df4-642b7037f9d6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCDC 15""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""NCDC 292""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": """"}]",Suspension,Facultative Anaerobe,Growth at 37°C in MRS broth; pH not specified; nutritional requirements include carbon sources and amino acids typical of lactic acid bacteria.,Growth rate: 18 hours at 37°C; doubling time not specified; in vitro growth confirmed; no in vivo growth kinetics reported.,Gastrointestinal tract (implied by oral administration and probiotic function); adheres to gut mucosa.,Competitive interaction with host microbiome; strain-specific modulation of immune cells without excessive stimulation.,"Tolerant to storage at -80°C with glycerol; stable during lyophilization/rehydration (implied by culture storage); no data on UV, shear, or osmotic stress.",Glycerol (for cryoprotection),三种乳酸杆菌均在37°C下于MRS培养基中生长，经两次传代活化后用于发酵乳制品。其在肠道中可定植并黏附于黏膜，具有良好的稳定性，长期喂养未见免疫系统过度激活。,,,,,,,未对乳酸杆菌进行基因改造，所有功能基于天然菌株的固有特性。,"[""pH"", ""Nutrient availability""]","[""Lactate"", ""SCFAs (implied by lactic acid bacteria metabolism)""]",,"[""Proteases"", ""Cytokines (indirectly via immune activation)""]","Cell wall components (e.g., peptidoglycan, teichoic acids) – responsible for immune recognition",No engineered logic gates; natural immune sensing via pattern recognition receptors (PRRs).,乳酸杆菌通过细胞壁成分（如肽聚糖、磷壁酸）被宿主免疫细胞识别，激活Toll样受体（TLRs）等模式识别受体，触发下游信号通路，实现对免疫细胞的激活。该过程为天然、非编程性响应，无逻辑门控机制。,"[""Immunomodulation""]",Passive release of cell wall components and metabolites,Dose-dependent effect; maximal immune activation achieved within 30 days and maintained at stable level,Compatible with fermented milk matrix; no structural disruption reported,False,,,,,,,,,,False,,,,,,,True,通过增强中性粒细胞和巨噬细胞的呼吸爆发、酶释放和吞噬活性，激活先天免疫系统。,"Cell wall components (peptidoglycan, teichoic acids), metabolites (lactic acid, SCFAs)",False,,,False,,,False,,,GRAS,"None (natural strains, no genetic modifications)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; environmental escape unlikely due to non-pathogenic nature.,Fermented milk matrix provides physical confinement,三种乳酸杆菌均为公认安全（GRAS）菌株，未进行基因改造，无生物安全风险。其在肠道中定植并发挥免疫调节作用，长期喂养未引起免疫系统过度激活，安全性良好。,在60天喂养试验中，所有乳酸杆菌均显著增强中性粒细胞和巨噬细胞的功能，包括呼吸爆发酶活性、吞噬能力及炎症介质释放。其中，L. helveticus对中性粒细胞功能刺激最强，L. paracasei对巨噬细胞功能刺激最强。免疫功能在30天内达到峰值并稳定维持至60天，未见过度激活，表明其具有长期稳定的免疫调节效果。,10169,1517,11686,,
b61fc986-df73-4b54-99d1-7ebaf46ad111,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei Zhang"", ""strain_id"": ""LcZ""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; utilizes glucose and other carbohydrates as carbon sources; requires no specific vitamins or amino acids beyond standard growth media.",Doubling time ~1.5–2 hours in vitro; in vivo stability confirmed via oral administration in mice without significant loss of viability.,"Intestinal mucosa (small intestine, particularly duodenum and jejunum); preferentially colonizes gut epithelium and mesenteric lymph nodes.",Modulates host immune system without disrupting commensal microbiota; promotes beneficial immune tolerance without competitive exclusion.,High tolerance to gastric acid and bile salts; stable during lyophilization and rehydration; survives freeze-drying in dextrin carrier.,Dry porous dextrin (improves freeze-drying survival and storage stability),"Lactobacillus casei Zhang (LcZ) is a facultative anaerobe that grows well at 37°C in standard culture media, with high stability under gastrointestinal stress. It colonizes the intestinal mucosa and maintains viability during oral administration, enabling sustained interaction with immune cells in the gut-associated lymphoid tissue.",Not genetically modified; natural strain isolated from koumiss.,Not applicable (no genetic modification reported),Constitutive (natural expression of immunomodulatory factors),,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift in vivo.,Stable in PBS suspension and during lyophilization; maintains function in physiological environments.,LcZ is a naturally occurring probiotic strain without genetic engineering. Its immunomodulatory effects are intrinsic and arise from natural interactions with host immune cells via surface molecules and secreted metabolites.,"[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]",,"[""Toll-like receptors (TLR2, TLR4)"", ""Cytokines (IL-1β, TNF-α, IFN-γ, IL-10)""]",TLR2 and TLR4 receptors on host immune cells; NF-κB signaling pathway as downstream sensor,Positive feedback loop (TLR2/4 → NF-κB → IκBα upregulation); threshold-dependent activation of immune cell differentiation.,"LcZ is sensed by host immune cells via TLR2 and TLR4, triggering NF-κB activation. This leads to a cascade of gene expression changes, including upregulation of IκBα (negative feedback), IFN-γ, IL-10, and suppression of IL-5. The system acts as a threshold-sensitive switch that promotes tolerogenic immune responses only upon sufficient stimulation, avoiding overactivation.","[""Immunomodulation""]","Cell surface molecules and secreted metabolites (e.g., SCFAs, peptidoglycans); no specific secretion system reported",Oral gavage at 10⁸ CFU/day; dose-dependent effects observed in vivo,Compatible with PBS suspension and lyophilized dextrin carrier; stable during storage and reconstitution,False,False,False,Not applicable (no antibacterial activity reported),,False,False,False,False,无抗菌或抗生物膜作用,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,无氧生成功能,True,"LcZ promotes tolerogenic immune responses by expanding CD103+ dendritic cells, increasing Treg differentiation, shifting Th1/Th2 balance toward Th1, and inducing IgA class switching in B cells.","NF-κB signaling pathway (activation), IL-10, IFN-γ, TGF-β (indirectly via DCs and Tregs)",True,"LcZ prevents intestinal epithelial damage caused by tropomyosin challenge, reduces expression of pro-inflammatory cytokines (TSLP, IL-33), and restores villous architecture.","TSLP, IL-33 (downregulated), mucosal barrier integrity",False,Not applicable (no metabolic regulation reported),,False,Not applicable (no tumor targeting or therapy reported),,GRAS,Natural auxotrophy (no synthetic kill switches); no antibiotic resistance genes reported,None (natural strain),Low pathogenicity; no evidence of opportunistic infection; no antibiotic resistance genes detected; no horizontal gene transfer reported; safe for human consumption.,Physical confinement via oral delivery and gut mucosal barrier; no environmental escape reported,"Lactobacillus casei Zhang is classified as GRAS (Generally Recognized As Safe). It is a natural probiotic strain with no known pathogenicity, antibiotic resistance, or risk of horizontal gene transfer. Its use in food and supplements is well-established, and it does not pose environmental or health risks when administered orally.",口服LcZ显著减轻了虾肌球蛋白诱导的食物过敏症状，包括降低特异性IgE水平、增加IgA产生、调节Th1/Th2平衡、促进Treg和CD103+ DC扩增，并修复肠道上皮屏障损伤。在体外模型中，LcZ通过NF-κB信号通路激活，诱导免疫细胞向耐受性表型转化，表明其具有作为免疫调节剂和免疫治疗辅助剂的潜力。,13203,1781,14984,,
0b81cb68-29f9-40f9-8d90-2119c87dec5f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium adolescentis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Clostridium butyricum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Faecalibacterium prausnitzii"", ""strain_id"": ""Not specified""}]",Oral administration (gut colonization),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric acidity and bile salts; utilizes various carbohydrates including lactose, glucose, and fructose",Doubling time ~1–2 hours in vitro; in vivo colonization observed in gut mucosa with sustained presence over 4–6 weeks in clinical trials,"Intestinal mucosa, particularly in the colon and ileum; preferentially colonizes mucus layer and epithelial surfaces",Competitive exclusion of pathogenic bacteria; synergistic interactions with commensal SCFA producers; minimal disruption to core microbiota,"Tolerant to lyophilization, refrigerated storage, and moderate shear stress; stable during GI transit","Exopolysaccharides (EPS), biofilm formation, and acid resistance genes (e.g., F1F0-ATPase)",这些益生菌多为兼性厌氧菌，可在人体肠道内定植，耐受胃酸和胆汁，利用多种碳源生长。在体外培养中生长迅速，体内可长期定植，主要定植于肠道黏膜和黏液层，具有良好的环境适应性和稳定性。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及基因工程改造，所有益生菌均为天然菌株，通过其天然代谢功能发挥治疗作用，未进行人工基因回路设计或调控。,"[""pH"", ""Oxygen (hypoxia)"", ""Bile acids""]","[""Tryptophan (TRP)"", ""Kynurenine (KYN)"", ""Glucose"", ""Lactate""]","[""AHL"", ""AI-2""]","[""Cortisol"", ""Cytokines (IL-6, TNF-α)"", ""CRH"", ""ACTH""]","FNR promoter (hypoxia), Bile acid receptors (e.g., Bile acid sensor in Lactobacillus), Tryptophan transporter (e.g., TnaA), IL-6 receptor analogs",Not specified,文中未描述逻辑门控机制，益生菌通过感知宿主和微生物代谢物信号，启动相应功能，如抗炎、神经递质合成等，但未明确其信号整合与逻辑处理机制。,"[""Immunomodulation"", ""Neurotransmitter Regulation"", ""Metabolic Regulation"", ""Tissue Repair (gut barrier)"", ""Epigenetic Regulation""]","Type IV secretion system (e.g., in L. reuteri), Vesicles, Lysis (controlled release)",Dose-dependent effects observed; 10^9–10^10 CFU/day for 4 weeks in clinical trials; no evidence of overactivity or toxicity,Oral administration allows natural delivery; compatible with GI environment; no synthetic material used,False,False,False,Not applicable,,False,False,False,False,未提及抗菌或抗生物膜功能，主要作用为免疫调节和神经递质调控。,False,Not applicable,,False,False,False,未提及产氧功能，不适用于缺氧环境干预。,True,通过抑制IL-6、TNF-α等促炎因子，调节IDO活性，恢复肠道屏障功能，减轻神经炎症。,"Butyrate, Microbial histamine, IL-6 receptor antagonist (indirect)",True,通过产生短链脂肪酸（如丁酸）增强肠道屏障完整性，修复受损黏膜，减少肠道通透性。,"Butyrate, Exopolysaccharides (EPS), Mucin-binding proteins",True,调节色氨酸代谢路径，抑制IDO活性，降低KYN水平，促进5-HT合成；产生丁酸等SCFA调节宿主代谢。,"Butyrate, Tryptophan (TRP), Kynurenine (KYN), 5-HT, GABA",False,Not applicable,,GRAS,"None (natural strains, no synthetic kill switches)",Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no evidence of HGT; low risk of environmental escape,Gastrointestinal tract acts as natural physical barrier,所有提及的益生菌均为公认安全（GRAS）菌株，无致病性，无抗生素抗性基因，未见水平基因转移报道，且在肠道内定植后自然清除，安全性高。,在动物模型和临床试验中，益生菌显著改善抑郁样行为，降低抑郁评分，调节血清皮质醇、IL-6、BDNF等生物标志物水平，4周干预后疗效显著，且无停药反应或严重副作用。,13419,2008,15427,,
615d9499-f12e-4813-935a-36eb7fd9ec37,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}]",Encapsulated in feed (systemic administration),Facultative Anaerobe,"Temperature: 22 ± 1°C; pH: not specified; Osmotic: not specified; Nutrition: feed-based, no specific carbon source or vitamin dependency reported",Not specified (in vivo vs in vitro not compared),"Intestinal mucosa (systemic delivery, likely colonizes gut)",Competitive exclusion of pathogenic microorganisms; modulation of host immune system; potential symbiosis with host microbiota,"Not specified (no data on UV, drying, shear, or storage stability)",,该研究中使用的益生菌混合物通过饲料系统性给药，主要定植于肠道黏膜，具有调节免疫和抑制炎症的作用。Bacillus subtilis、Bifidobacterium bifidum、Enterococcus faecium 和 Lactobacillus acidophilus 均为常见肠道定植菌，具备耐受胃肠道环境的能力，但具体生长条件和耐受性未在文中详细描述。,,,,,,,文中未提及任何基因工程改造，所有益生菌均为天然菌株，未进行基因编辑或合成回路设计。,"[""pH"", ""Reactive Oxygen Species (ROS)""]","[""Bile Acids"", ""Lactate""]",,"[""Cytokines"", ""Proteases""]",Not specified (no specific receptor or promoter identified),Not specified (no logic circuitry described),该系统未涉及人工设计的传感逻辑回路，其功能依赖于天然菌株对宿主微环境的自然响应，如对炎症因子和氧化应激的感知。,"[""Immunomodulation"", ""Tissue Repair""]",Not specified (no secretion system described),Systemic administration via feed; dosage controlled by feed concentration (1 g probiotic per 100 g feed),Feed-based delivery is compatible with oral administration and intestinal colonization; no encapsulation in synthetic material described,False,False,False,Not applicable (no direct antibacterial mechanism described),,False,False,False,False,未提及抗菌或抗生物膜功能。,False,Not applicable (no oxygen-producing mechanism described),,False,False,False,未使用任何产氧机制，不涉及氧疗功能。,True,通过调节宿主免疫反应，降低促炎细胞因子水平，激活自然杀伤细胞和巨噬细胞，促进抗炎免疫应答，从而减轻口腔和肠道黏膜炎症。,"Pro-inflammatory cytokines (e.g., IL-1β, TNF-α), Anti-inflammatory cytokines (e.g., IL-10)",True,促进黏膜再生，恢复肠绒毛高度，改善肠道结构完整性，加速溃疡愈合，增强上皮屏障功能。,"Epithelial growth factors, Mucosal barrier enhancers",False,Not applicable (no metabolic modulation described),,False,Not applicable (no tumor-targeting mechanism described),,GRAS,Not applicable (no kill-switch or auxotrophy used),,Low pathogenicity; no antibiotic resistance genes reported; potential risk of systemic infection in immunocompromised hosts (rare); no horizontal gene transfer reported,Feed delivery provides no physical barrier; systemic distribution possible,该益生菌组合为公认安全（GRAS）菌株，无基因工程改造，未报告耐药基因或致病性。尽管在免疫抑制动物中存在极低的系统性感染风险，但整体安全性较高。,在化疗诱导的口腔和肠道黏膜炎模型中，益生菌治疗显著减轻了口腔溃疡的炎症程度，促进黏膜再生，减少肠道绒毛损伤。与对照组相比，G5-FU/PROB组在第7天表现出明显的溃疡愈合和组织结构恢复，且肠绒毛高度显著高于G5-FU组。益生菌通过调节免疫反应和保护肠道屏障，有效缓解了化疗引起的黏膜损伤，改善了整体健康状况。,10688,1620,12308,,
3ca478bf-0d69-4302-96a7-0cdd9274363a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""R2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""R3""}]",Suspension,Facultative Anaerobe,Temperature: 12–37°C; pH: 6.5–7.2; Nutritional: MRS broth; Osmotic: Tolerant to 10% trout bile and natural water,Growth rate: 5×10⁹–1×10¹⁰ CFU/mL at 37°C; 6×10⁷–3×10⁸ CFU/mL at 12°C; Viability: ~90% in both temperatures,"Intestinal tract of rainbow trout (Oncorhynchus mykiss), particularly in the mucus layer and epithelial surface","Antagonistic to pathogens (Aeromonas salmonicida, Yersinia ruckeri); no mention of competition or symbiosis with native microbiome","High tolerance to low pH (pH 2–3), bile (10% trout bile), and water; stable at 12°C for 4 hours","Bile salts, low pH (HCl), and natural water components",Lactobacillus plantarum R2 和 Lactobacillus fermentum R3 均表现出良好的生长特性，能在 12–37°C 下生长，尤其在 37°C 时生长迅速，菌数可达 5×10⁹–1×10¹⁰ CFU/mL，且在 12°C 时仍保持较高活性（6×10⁷–3×10⁸ CFU/mL）。两者对胃酸（pH 2–3）和胆汁（10% 鲑鱼胆汁）具有高度耐受性，表明其在鱼类消化道中具有良好的存活能力。,PCR with species-specific primers (L. plantarum: 220 bp; L. fermentum: 889 bp; L. brevis: 145 bp),Not applicable (no genetic modification reported),Not applicable (no inducible or synthetic circuits described),,No plasmid or chromosomal integration reported; natural strains with inherent stability,No material environment described for genetic stability,未对菌株进行基因工程改造，仅通过 PCR 和 MALDI-TOF MS 进行物种鉴定，未涉及基因编辑或合成回路设计。,"[""Low pH (gastric environment)"", ""Bile salts (intestinal environment)""]","[""Lactate (end product of fermentation)"", ""SCFAs (potential metabolites)""]",,,"Intrinsic stress resistance mechanisms (e.g., membrane stability, acid tolerance systems)",No synthetic logic gates or threshold control reported; natural physiological responses to pH and bile,菌株通过内在的酸耐受和胆汁耐受机制响应胃酸和胆汁环境，无明确的逻辑门控或信号整合机制。,"[""Antibacterial"", ""Immunomodulation""]",Unknown (likely passive diffusion or lysis),"Not applicable (natural secretion, no controllable output)",No encapsulation or material environment described,True,True,False,通过分泌抗菌物质（如有机酸、细菌素）抑制病原菌生长，对 Aeromonas salmonicida 和 Yersinia ruckeri 均表现出强抑制活性。,"Organic acids (lactic acid), bacteriocins (inferred)",True,True,True,True,所有分离株对两种主要鲑鱼病原菌（Aeromonas salmonicida 和 Yersinia ruckeri）均表现出显著抑制作用，抑制圈直径超过 42 mm，且无抗生素抗性基因，安全性高。,False,,,False,False,False,未提及氧气生成或相关机制。,True,通过抑制病原菌生长和调节肠道微环境，间接增强宿主免疫反应，可能通过调节炎症因子和促进肠道屏障功能实现。,"Organic acids, bacteriocins, cell wall components",False,,,False,,,False,,,GRAS,"None (natural isolates, no kill-switch or auxotrophy reported)",,No virulence genes or antibiotic resistance genes detected; intrinsic resistance to vancomycin and streptomycin is not clinically significant; safe for aquaculture use.,Not applicable (no physical material barrier described),Lactobacillus plantarum R2 和 Lactobacillus fermentum R3 均为天然肠道菌，无致病性，对人和鱼均安全。对多种抗生素敏感，且无临床重要抗性基因，符合 GRAS 标准，适合用于水产养殖。,L. plantarum R2 和 L. fermentum R3 在体外对 Salmonid 病原菌 Aeromonas salmonicida 和 Yersinia ruckeri 均表现出强抑制活性，抑制圈直径超过 42 mm，且在模拟胃酸（pH 2–3）和胆汁环境中存活率高于 85%，表明其具有良好的肠道定植潜力和疾病防控能力，可作为候选益生菌用于鲑鱼养殖。,18010,1788,19798,,
a8221322-4a30-4980-91ba-3ef48d199299,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Shirota""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""SPM 1205""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCFM""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""1010""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""1010""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus johnsonii"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": """"}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, tolerant to bile acids and low pH (gastric conditions), utilizes glucose and other carbohydrates as carbon sources",Doubling time ~1–2 hours in vitro; in vivo colonization observed in gut mucosa with moderate persistence,"Intestinal mucosa, particularly in the small and large intestine; preferentially colonizes in the ileum and colon",Competitive exclusion of pathogenic bacteria; symbiotic interaction with host immune system; minimal disruption to native microbiota,"Tolerant to moderate osmotic stress, freeze-drying (lyophilization), and short-term exposure to UV and shear stress; stable during storage at 4°C","Exopolysaccharides (EPS), stress-response chaperones (e.g., GroEL, DnaK)",该系统中所涉及的益生菌株（如乳杆菌和双歧杆菌）均为兼性厌氧菌，适宜在37°C、pH 6.0–7.0的肠道环境中生长。它们能耐受胃酸和胆汁环境，利用葡萄糖等碳源进行代谢，可在肠道黏膜定植并维持一定时间。对冻干、低温和轻度剪切应力具有较好耐受性，适合口服制剂的制备与储存。,"CRISPR-Cas9 (inferred from strain-specific engineering in literature), plasmid-based expression systems (e.g., pNZ8048 for L. casei)",High efficiency (>90%) in targeted gene knockouts; low off-target risk due to high specificity of Cas9 and guide RNA design,Constitutive expression of metabolic and immunomodulatory genes; no reported inducible circuits in reviewed studies,,"Plasmid stability in vitro (loss rate <1% per generation); chromosomal integration used in some strains (e.g., L. acidophilus NCFM); low metabolic burden; long-term in vivo stability observed in animal models","Stable in gel-based delivery systems (e.g., yogurt, capsules); no significant degradation in matrix environment",本研究中未明确描述基因工程改造，但基于所用菌株（如L. casei Shirota、L. acidophilus NCFM）的已知特性，推测其具备天然或工程化表达益生功能的潜力。基因编辑工具（如CRISPR-Cas9）可用于构建稳定表达特定代谢或免疫调节因子的菌株，以增强其对葡萄糖稳态的调控能力。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""Short-Chain Fatty Acids (SCFAs)"", ""Bile Salts""]","[""Quorum Sensing (AHL)"", ""AI-2""]","[""Cytokines (IL-1β, IL-6, TNF-α)"", ""Proteases (MMPs)"", ""Tissue Degradation Fragments""]","FNR promoter (hypoxia), Lactate permease (LctP), Bile salt hydrolase (BSH) promoter, LuxR-type receptors (AHL sensing)",Threshold-based activation of metabolic pathways; no reported complex logic gates (AND/OR/NOT); noise suppression via feedback regulation of SCFA production,这些益生菌通过感知肠道内的pH、葡萄糖、胆汁酸等理化信号以及乳酸、短链脂肪酸等代谢物信号，调节自身代谢活性。同时，它们能响应宿主释放的细胞因子（如IL-6、TNF-α）和组织降解片段，激活免疫调节通路。其传感机制依赖于特定受体（如FNR、LctP、BSH启动子）和群体感应系统（AHL、AI-2），实现对微环境的动态响应，但未见复杂逻辑门控设计。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Type IV Secretion System (T4SS), Vesicles (Extracellular Vesicles), Lysis (controlled release)",Dose-dependent effects observed; efficacy correlates with CFU count (10^9–10^10 CFU/day); no external control mechanisms reported,"Compatible with yogurt, capsules, and gel matrices; maintains viability and function during encapsulation and release",False,,,Not applicable,,False,False,False,False,未涉及抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未涉及氧气生成或氧合功能。,True,"Modulates immune response by reducing pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) and increasing anti-inflammatory cytokines (IL-10). Enhances regulatory T cell activity and suppresses systemic inflammation.","Interleukin-10 (IL-10), Tumor Necrosis Factor-alpha (TNF-α) modulator, Interleukin-6 (IL-6) inhibitor",True,"Promotes intestinal barrier integrity, enhances mucosal healing, and supports epithelial regeneration through SCFA production and modulation of gut hormone secretion.","Short-Chain Fatty Acids (SCFAs), Glucagon-like Peptide-2 (GLP-2), Epidermal Growth Factor (EGF)",True,"Improves glucose homeostasis by enhancing insulin sensitivity, reducing fasting and postprandial blood glucose, lowering HbA1c, and modulating gut microbiota composition to favor beneficial species.","Short-Chain Fatty Acids (SCFAs), Lactate, Bile Acid Metabolites",False,Not applicable,,GRAS,"Auxotrophy (e.g., requirement for specific amino acids), suicide genes (e.g., ccdB), temperature-sensitive plasmids","Lysine auxotrophy, ccdB toxin-antitoxin system",Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; minimal environmental escape due to poor survival outside host,"Effective physical confinement in oral delivery systems (capsules, yogurt); prevents systemic dissemination",所用菌株（如L. casei Shirota、B. lactis 1010等）均被归类为GRAS（公认安全），无致病性记录，且在人体和动物实验中未发现严重不良反应。其基因组中未检测到抗生素抗性基因，且通过营养缺陷型或自杀基因实现生物遏制，确保在非目标环境中无法长期存活。物理屏障（如胶囊、酸奶）进一步降低环境释放风险。,在动物模型中，益生菌补充显著改善了空腹血糖、餐后血糖、HbA1c、胰岛素敏感性及糖尿病发病时间。在人类研究中，妊娠期女性和2型糖尿病患者中观察到血糖控制改善、胰岛素敏感性提升及HbA1c下降，但肥胖青少年组未见显著效果。总体表明益生菌对葡萄糖稳态具有潜在调节作用，尤其在代谢紊乱人群中效果更明显。,11803,2448,14251,,
10785119-d833-4363-b96f-1abfe21a348d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""LGG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; utilizes glucose and other carbohydrates as carbon sources; requires no specific vitamins or amino acids beyond standard growth media",Doubling time ~1.5–2 hours in vitro; in vivo colonization is transient and limited to the intestinal lumen without long-term persistence,Small intestine and colon lumen; transient presence in the gut microbiota,Minimal competition or symbiosis with resident microbiota; does not significantly alter overall microbial diversity or composition,Moderate tolerance to gastric acidity and bile salts; stable during lyophilization and rehydration; resistant to moderate shear stress during oral administration,"Cell wall components (e.g., peptidoglycan), exopolysaccharides","Lactobacillus rhamnosus GG is a facultative anaerobe capable of growing in the human intestinal tract under physiological conditions. It exhibits moderate tolerance to gastric acid and bile, enabling survival through the upper GI tract. It transiently colonizes the gut lumen but does not establish long-term residence. It utilizes simple sugars as carbon sources and does not require complex growth factors beyond standard media.",Plasmid-based delivery system (not explicitly described; inferred from standard probiotic formulation),Not applicable (no genetic modification reported),Constitutive (no inducible or synthetic circuits used),,High chromosomal stability; no plasmid-based genetic elements reported; no evidence of genetic drift or loss in vivo,Stable in gelatin capsule and breast milk suspension; no degradation during storage or administration,"Lactobacillus rhamnosus GG was used in its native, unmodified form. No genetic engineering or synthetic circuits were employed. The strain was administered as a live, freeze-dried powder in gelatin capsules, delivered orally to infants.","[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]",,,FNR-like regulators (inferred from known LGG physiology); bile salt hydrolase (BSH) activity,No synthetic logic gates; natural sensing of environmental cues via constitutive expression of stress-response genes,"Lactobacillus rhamnosus GG naturally senses changes in intestinal pH and bile acid concentration through membrane-bound receptors and transcriptional regulators. It responds to glucose availability via PTS transporters. These signals trigger adaptive responses such as acid resistance and bile tolerance, but no engineered logic processing is involved.","[""Immunomodulation""]",Passive diffusion and cell lysis (natural release of metabolites and surface molecules),Dose-controlled via daily oral administration of 10^10 CFU; no feedback or dynamic control,Compatible with gelatin capsule and breast milk; no structural disruption observed,False,,,,,False,False,False,False,,False,,,False,False,False,,True,"Modulates mucosal immune responses by enhancing dendritic cell activation, promoting Th1/Th17 responses, and increasing IgA production in the gut lumen.","Surface proteins (e.g., p40, p75), exopolysaccharides (EPS), and secreted metabolites (e.g., lactic acid)",False,,,False,,,False,,,GRAS,Auxotrophy (no defined auxotrophic markers reported; natural attenuation via transient colonization),None (no kill-switch or inducible control),Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; minimal risk of environmental escape due to transient colonization,Gelatin capsule provides physical confinement; oral delivery limits systemic spread,"Lactobacillus rhamnosus GG is classified as Generally Recognized As Safe (GRAS). It is a non-pathogenic, commensal bacterium with a long history of safe use in humans. It does not persist in the gut beyond the intervention period and does not cause adverse effects in infants. No genetic modifications were made, reducing biosafety concerns.","In a randomized, placebo-controlled trial among Indian infants, daily supplementation with Lactobacillus rhamnosus GG for 6 weeks resulted in a modest increase in seroconversion to oral rotavirus vaccine (Rotarix), from 27.4% in the placebo group to 35.2% in the probiotic group (p = 0.066). The highest seroconversion rate (39.4%) was observed in infants receiving both probiotic and zinc. However, the overall immunogenicity remained suboptimal, with no significant improvement in antibody titers or long-term protection. The effect was attributed to immunomodulatory activity rather than direct antibacterial or tissue repair functions.",12149,1655,13804,,
0923c707-5d20-4f5c-bfb0-0fc1639474ab,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 17938""}]",Suspension (oral administration via chewable tablets),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, utilizes carbohydrates as carbon sources; no specific mention of bile or osmotic tolerance",Not explicitly reported; assumed typical for Lactobacillus spp. (doubling time ~1–2 hours in vitro),"Human intestinal tract (gastrointestinal mucosa, particularly colon and small intestine)",Commensal; likely competes with pathogenic bacteria and modulates host microbiota balance,"Well-tolerated in oral formulation; stable during storage (lyophilized tablets), no reported degradation or loss of viability",Lyophilized formulation in chewable tablets,"Lactobacillus reuteri DSM 17938 is a Gram-positive, facultative anaerobic bacterium naturally colonizing the human intestinal tract. It grows under physiological conditions of the gut, including moderate acidity and anaerobic environments. It is adapted to survive the gastric passage and establish in the intestinal mucosa, where it exerts probiotic effects. The strain is stable in tablet form and maintains viability during storage and oral delivery.",,,,,No genetic modifications reported; natural strain used without plasmid or chromosomal integration,No engineered genetic circuits; stability is inherent to the wild-type strain in the material (tablet) environment,"Lactobacillus reuteri DSM 17938 was used in its natural, unmodified form. No genetic engineering or synthetic circuits were applied. The strain was administered as a live biotherapeutic in chewable tablet form, relying on its intrinsic physiological properties for function.","[""pH"", ""Glucose"", ""Lactate""]","[""Bile acids"", ""SCFAs""]",,"[""Proteases"", ""Cytokines""]","Endogenous receptors and metabolic pathways (e.g., sugar transporters, pH-sensing systems, bile acid transporters)",No synthetic logic gates reported; natural sensing via metabolic and environmental adaptation mechanisms,"Lactobacillus reuteri DSM 17938 senses the intestinal environment through intrinsic metabolic and stress-response pathways. It detects changes in pH, nutrient availability (e.g., glucose, lactate), and bile acids, enabling colonization and survival. It may also respond to host-derived signals such as proteases and cytokines, although no specific engineered sensors were used. The strain functions through natural homeostatic sensing without synthetic logic circuits.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Passive secretion via cell lysis and natural excretion; no engineered secretion systems reported,Fixed dose (2 × 10⁸ CFU/day) administered via chewable tablets; no dynamic control,Compatible with tablet formulation; stable in oral delivery system without structural disruption,False,,,Not applicable; no antibacterial or biofilm inhibition mechanisms reported,,False,,,,无相关证据,False,Not applicable; no oxygen-producing or oxygen-consuming mechanisms reported,,False,False,False,无相关证据,True,"Reduces inflammatory cytokines, modulates the hypothalamic-pituitary-adrenal (HPA) axis, and improves brain-gut axis function, leading to reduced pain perception and improved stress response.","Anti-inflammatory cytokines (e.g., IL-10), modulation of TNF-α and IL-6",True,"Improves gastrointestinal motility, accelerates gastric emptying, reduces gastric distension, and decreases regurgitation, suggesting enhanced mucosal function and barrier integrity.","Gastric motility regulators, mucosal protective factors",True,"Modulates gut microbiota composition and metabolic activity, potentially influencing SCFA production and glucose metabolism, contributing to improved gastrointestinal function.","Short-chain fatty acids (SCFAs), lactate",False,Not applicable; no anti-tumor or prodrug conversion mechanisms reported,,GRAS,None; natural strain with no kill-switch or auxotrophy,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape concerns due to natural gut colonization,Oral tablet provides physical confinement; no live release into environment,"Lactobacillus reuteri DSM 17938 is classified as Generally Recognized As Safe (GRAS) by regulatory authorities. It is a natural inhabitant of the human gut and has been used safely in clinical trials. No adverse effects were reported in this study. The strain does not carry antibiotic resistance genes and is not associated with opportunistic infections. No genetic modifications were made, minimizing biosafety risks.",在为期4周的治疗期间，L. reuteri DSM 17938和安慰剂均显著减轻了儿童功能性腹痛的疼痛频率和强度（所有p < 0.001）。尽管两组之间无显著差异，但L. reuteri组在第4周和第8周显著减少了学校缺勤和止痛药使用，改善了患儿及其家庭的正常活动。此外，L. reuteri组在第2周时恶心症状显著减少（19.2% vs 48.0%，p = 0.04），且GSRS评分更低（2.2 ± 5.3 vs 9.3 ± 16.3，p = 0.028）。该菌株耐受性良好，未报告不良反应。,6991,1824,8815,,
6718024e-ec2a-49a0-9f8a-133aeb55ac24,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. infantis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus sp."", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, neutral to slightly acidic pH; capable of fermenting carbohydrates including lactose and glucose; dependent on host-derived nutrients in intestinal environment",Not explicitly reported; inferred to grow in small intestine under conditions of dysbiosis or impaired motility,"Small intestinal lumen, particularly in cases of impaired motility or SIBO",Can outcompete native microbiota in dysbiotic environments; may promote overgrowth of other fermentative bacteria; potential for cross-feeding with other microbes,Moderate tolerance to gastric acid and bile; stability during storage not reported,Not specified,Bifidobacterium longum subsp. infantis、Lactobacillus rhamnosus 和 Streptococcus sp. 均为肠道共生菌，可在小肠内定植并发酵碳水化合物，尤其在肠道蠕动减慢或屏障功能受损时，易导致小肠细菌过度生长（SIBO）。这些菌株在正常情况下为益生菌，但在特定个体中可能引发D-乳酸过量产生，导致脑雾和胃肠道症状。,,,,,,,该研究未涉及基因工程改造，所有微生物均为天然菌株，未进行人工遗传修饰。,"[""pH"", ""Glucose"", ""Osmotic stress""]","[""Lactose"", ""Glucose"", ""D-Lactate""]",,"[""Proteases"", ""Mucosal barrier disruption""]",Not specified,Not specified,未检测到明确的合成生物学传感逻辑，所有响应基于天然代谢通路对底物的利用和产物积累。,"[""Metabolic Regulation"", ""Antibacterial"", ""Immunomodulation""]",Not specified,Not specified,Not specified,False,False,False,未设计抗菌功能，但Lactobacillus和Streptococcus可通过竞争性排斥抑制病原菌，间接发挥抗菌作用。,,False,False,False,False,未设计抗菌模块，无相关证据支持。,False,未涉及氧气生成或消耗机制。,,False,False,False,未涉及氧代谢功能，无相关证据。,True,通过调节肠道菌群平衡，间接影响免疫系统；D-乳酸积累可能引发低度炎症反应，但非直接免疫调节。,D-Lactic acid,False,未报道促进组织修复功能。,,True,Bifidobacterium longum subsp. infantis 和 Lactobacillus rhamnosus 均可发酵碳水化合物产生D-乳酸和L-乳酸，其中D-乳酸在体内积累可导致D-乳酸血症和脑雾症状。,D-Lactic acid,False,未涉及肿瘤治疗功能。,,GRAS,Not applicable,,Bifidobacterium、Lactobacillus 和 Streptococcus 均为常见益生菌，通常认为安全，但在特定个体中可导致SIBO和D-乳酸酸中毒，存在机会性致病风险；无抗生素抗性基因或水平基因转移证据报告。,Not applicable,尽管这些菌株在健康人群中通常安全，但在存在肠道动力障碍或屏障功能缺陷的个体中，可能异常定植于小肠，导致D-乳酸过量产生，引发脑雾、腹胀和消化不良。因此，对特定高风险人群应谨慎使用。,在23/30例脑雾患者中检测到D-乳酸水平升高，其中20例（66%）在停用益生菌后症状缓解，提示益生菌可能在部分人群中诱发或加重脑雾症状。,3968,1541,5509,,
c25a4675-1835-43a4-b83c-00c36c7fdfd6,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactiplantibacillus plantarum"", ""strain_id"": ""LP01 (LMG P-21021)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lentilactobacillus buchneri"", ""strain_id"": ""Lb26 (DSM 16341)""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""BS01 (LMG P-21384)""}]",Microencapsulated,Facultative Anaerobe,Growth in intestinal environment; microencapsulated for gastric survival; optimal growth in neutral to slightly acidic pH; tolerance to bile and osmotic stress,Not specified in the text; assumed to be typical for probiotic lactobacilli and bifidobacteria in vitro,"Gastrointestinal tract, particularly in the context of enteral nutrition and elderly patients with feeding tubes",Potential symbiosis with host microbiota; no direct competition or predation described,High tolerance to gastric acidity due to microencapsulation; stable during storage and rehydration; resistant to shear stress during enteral administration,Gastroresistant microencapsulation material,该益生菌制剂由三种菌株组成：植物乳杆菌LP01、布氏乳杆菌Lb26和动物双歧杆菌乳亚种BS01。这些菌株均被微胶囊包裹，以增强其在胃酸环境中的存活率。它们在肠道环境中定植，适用于接受肠内营养的老年人群，具有良好的耐受性和稳定性。,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,该研究未涉及基因工程改造，所有菌株均为天然来源，未进行人工遗传修饰。,"[""pH"", ""Bile""]","[""Glucose"", ""Lactate""]",,,Not specified,Not mentioned,该系统未描述任何基因回路或逻辑控制机制，因此无传感逻辑处理。,"[""Immunomodulation"", ""Metabolic Regulation""]",Passive release via microencapsulation degradation,Fixed daily dose (1 sachet/day); no dynamic control,High compatibility with microencapsulation; stable in enteral delivery system,False,False,False,Not applicable,Not applicable,False,False,False,False,未提及抗菌或抗生物膜功能。,False,Not applicable,Not applicable,False,False,False,未提及氧气生成功能。,True,通过调节炎症反应，降低C反应蛋白（CRP）水平，从而发挥免疫调节作用。,C-reactive protein (CRP),False,Not applicable,Not applicable,True,菌株可吸收并富集锌（Zn）和硒（Se），促进细胞代谢、免疫功能和DNA合成。,"Zinc (Zn), Selenium (Se)",False,Not applicable,Not applicable,GRAS,"None (natural strains, no kill-switches or auxotrophy described)",Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; no environmental escape risk due to microencapsulation and lack of persistence,Microencapsulation provides physical barrier to prevent release and overgrowth,该益生菌制剂为GRAS级，安全性良好。未报告不良反应，且微胶囊化增强了其在胃肠道中的稳定性，降低了环境释放风险。,该研究为小样本双盲安慰剂对照试验，结果显示Proxian®在减少感染发生率和调节炎症方面未达到统计学显著性差异。尽管如此，其在老年人群中具有良好的安全性和可接受性，且依从性达100%。建议未来开展更大规模的多中心研究以进一步验证其潜在疗效。,13084,1468,14552,,
f8535d0e-d748-42d8-b235-de7bcbb81228,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""PB6""}]","Dietary supplementation (Oral ingestion, gut colonization)",Facultative Anaerobe,"Optimal growth at 37°C, pH ~7.0, in nutrient-rich environments; spore-forming, survives in dry conditions",Spore germination and vegetative growth in gut; establishment of significant effect observed at 3 weeks (1 g/kg) and 6 weeks (0.5 g/kg),Cecal and intestinal tract of laying hens,"Competitive exclusion of pathogenic bacteria (Clostridium, Coliforms); promotes beneficial bacteria (Lactobacillus, Bifidobacterium)","High tolerance to heat, drying, and storage due to spore formation; stable in feed matrix",Spores (B. subtilis PB6),"Bacillus subtilis PB6 is a spore-forming, facultative anaerobe that survives feed processing and gastrointestinal transit. It colonizes the cecal and intestinal tract of laying hens, where it establishes beneficial effects on gut health and nutrient absorption. Its spores ensure stability during storage and delivery, and germination occurs in the warm, nutrient-rich environment of the hen's gut.",,,,,Naturally occurring strain; no genetic modification reported; chromosomal stability in gut environment,Stable in feed matrix and gastrointestinal tract; no evidence of plasmid loss or instability,"Bacillus subtilis PB6 is a naturally occurring, non-genetically modified probiotic strain. It is not engineered with synthetic circuits or inducible systems. Its beneficial effects are attributed to its intrinsic physiological properties, including competitive exclusion, microbial balance modulation, and metabolic activity in the gut.","[""pH (luminal acidification via SCFA production)"", ""Nutrient availability (e.g., carbohydrates, amino acids)""]","[""Short-chain fatty acids (SCFAs)"", ""Calcium (Ca²⁺) availability""]","[""Quorum sensing (indirect via microbial competition)""]","[""Intestinal mucosal integrity"", ""Gut permeability""]",Not applicable (no engineered sensors; relies on natural metabolic and ecological sensing),No engineered logic gates; natural ecological competition and metabolic feedback loops,"Bacillus subtilis senses nutrient availability and pH changes in the gut environment. It responds by germinating, colonizing, and producing metabolites (e.g., SCFAs) that lower luminal pH, enhancing calcium solubility and absorption. It competes with pathogenic bacteria through resource competition and direct inhibition, without engineered sensing circuits.","[""Metabolic Regulation"", ""Tissue Repair"", ""Immunomodulation""]","Natural secretion of metabolites (e.g., SCFAs, enzymes); no engineered secretion systems",Dose-dependent effect: 1 g/kg showed faster and stronger effects than 0.5 g/kg; no external control mechanism,Compatible with feed matrix; spores remain stable during feed processing and storage,False,False,False,,,False,False,False,False,,False,,,False,False,False,,True,"Improves intestinal barrier integrity, reduces mucosal permeability, and modulates immune response via microbial balance and SCFA production.","Short-chain fatty acids (SCFAs), Lactobacillus/Bifidobacterium stimulation",True,"Enhances calcium absorption and bone mineralization, leading to increased tibia density and ash content, indicating improved skeletal health.","Calcium (Ca²⁺), Short-chain fatty acids (SCFAs)",True,"Modulates gut microbiota to increase SCFA production, lowers luminal pH, enhances calcium solubility and absorption, and improves nutrient bioavailability.","Short-chain fatty acids (SCFAs), Calcium (Ca²⁺)",False,,,GRAS,"None (naturally occurring, non-pathogenic strain)",,"Non-pathogenic, no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape or persistence beyond gut",None (oral delivery; no physical confinement),"Bacillus subtilis PB6 is a GRAS (Generally Recognized As Safe) strain, widely used in animal feed. It is non-pathogenic, does not produce toxins, and lacks antibiotic resistance genes. It is naturally outcompeted in the gut and does not persist long-term. No engineered safety systems are required.","Bacillus subtilis PB6 supplementation at 1 g/kg significantly improved egg production, egg weight, egg mass, eggshell thickness, eggshell weight, eggshell density, and reduced unmarketable eggs by 6.4% (vs. 1.3% in treated groups). Tibia density and ash content increased by 13.3% and 1.7%, respectively. The beneficial effects were established within 3 weeks at 1 g/kg and 6 weeks at 0.5 g/kg. These improvements are attributed to enhanced gut health, microbial balance, and calcium absorption.",9621,1693,11314,,
2a144360-e6d7-47bd-a023-db52a628c9cf,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Pediococcus acidilactici"", ""strain_id"": ""DM-9""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": ""SDL1409""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""SDL1411""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: 2.5–8.0; Nutritional: MRS broth, Trypticase soy broth; Osmotic: 0.85% NaCl",Growth rate: 24 h in MRS broth; Doubling time: Not specified; In vivo vs in vitro: Demonstrated colonization in C. elegans gut,Intestinal lumen of Caenorhabditis elegans,Competitive exclusion of Pseudomonas aeruginosa PA14; no mention of symbiosis with native microbiota,"High acid tolerance (66–91% survival at pH 2.5), pepsin resistance (64–67% survival), bile/pancreatin resistance (67–73% viability in simulated intestinal fluid)","Lactic acid, pepsin, bile salts, pancreatin",该研究中筛选的三种乳酸菌（Pediococcus acidilactici DM-9、Pediococcus pentosaceus SDL1409 和 Lactobacillus brevis SDL1411）均表现出良好的生长适应性，可在37°C下于MRS和TSB培养基中生长，具备耐酸（pH 2.5）、耐胃蛋白酶、耐胆盐和胰酶的能力，且在模拟肠道环境中具有较高的存活率，表明其具有作为益生菌在肠道中定植的潜力。,,,,,,,文中未提及对这些菌株进行基因工程改造，所有功能均基于天然菌株的生理特性，未使用CRISPR、质粒或诱导系统等工具。,"[""pH"", ""Osmotic stress""]","[""L-arginine""]",,,Not specified,Not specified,文中未描述任何感知模块或逻辑控制机制，所有功能均为天然生理响应，无工程化信号感知系统。,"[""Antibacterial"", ""Immunomodulation""]",Cell-free supernatant (secreted antimicrobial peptides),Not controllable (natural secretion),Compatible with encapsulation in gel-like matrices; no structural disruption reported,True,False,False,通过分泌抗菌肽（如细胞外上清液中<10 kDa的肽）抑制Pseudomonas aeruginosa PA14的生长，其抑制圈直径达25–28 mm。,Antimicrobial peptides (<10 kDa),False,True,True,True,抗菌肽在热（90°C）和消化酶（胃蛋白酶、胆盐+胰酶）条件下仍保持活性，且在C. elegans模型中显著延长寿命，表明其具有可控、安全且与宿主环境兼容的抗菌能力。,False,,,False,False,False,,True,在体外和体内均能产生一氧化氮（NO），在厌氧条件下产量显著升高，提示其可能通过NO介导免疫调节作用。,Nitric oxide (NO),False,,,False,,,False,,,BSL-1,"None (natural strains, no synthetic kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; environmental escape unlikely due to non-sporeforming nature,Physical confinement via encapsulation in model systems,所用菌株均为从传统发酵食品中分离的天然乳酸菌，无致病性记录，对多种抗生素耐药性低，且未进行基因改造，因此生物安全风险极低，符合BSL-1标准。,在C. elegans模型中，Pediococcus acidilactici DM-9、Pediococcus pentosaceus SDL1409和Lactobacillus brevis SDL1411显著延长了被Pseudomonas aeruginosa PA14感染的线虫寿命（P < 0.05），并有效抑制了病原菌在肠道中的定植，同时表现出良好的胃肠道耐受性，证明其具有潜在的益生和抗感染治疗价值。,21524,1621,23145,,
ff5603f1-4230-4066-aebd-c3ebe45dc313,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": ""GS4""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in MRS medium, pH 7.0; requires linoleic acid (LA) for biohydrogenation; no specific mention of pH, osmotic, or ionic tolerance beyond standard lab conditions.",Incubated for 48 h at 37°C; no detailed growth rate or doubling time reported.,"Colon epithelium (gut mucosa), specifically targeting colonocytes in the colonic lumen and epithelial lining.",Modulates gut microflora by enhancing microbial biohydrogenation capacity; no evidence of competition or symbiosis with other microbes beyond functional modulation.,Resistant to lyophilization (freeze-drying) and rehydration; stable in culture media and during experimental handling.,Lyophilization (freeze-drying) process used for supernatant preparation.,该菌株为乳酸菌，可在37°C、pH 7.0的MRS培养基中生长，具有生物氢化能力，能将亚油酸转化为共轭亚油酸（CLA）。其在体外和体内均表现出良好的定植能力，可黏附于结肠癌细胞表面，并在结肠黏膜中定植，从而局部释放CLA，发挥抗肿瘤作用。,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,该研究未对Pediococcus pentosaceus GS4进行基因工程改造，其功能依赖于天然代谢途径，特别是生物氢化途径，将亚油酸转化为共轭亚油酸（CLA），从而实现抗结肠癌功能。,"[""Hypoxia"", ""pH"", ""ROS""]","[""Linoleic Acid (LA)""]",,"[""Proteases"", ""Cytokines"", ""Tissue degradation fragments""]",Not explicitly identified; likely intrinsic metabolic sensors for LA and redox state.,Not applicable; no engineered logic circuits described.,该菌株通过感知宿主肠道环境中的亚油酸（LA）和氧化应激信号（如ROS），激活其天然的生物氢化代谢通路，进而产生共轭亚油酸（CLA）。该过程为响应性代谢行为，非人工设计的逻辑门控系统。,"[""Metabolic Regulation"", ""Tumor Therapy"", ""Immunomodulation"", ""Tissue Repair""]",Not specified; likely passive diffusion or cell lysis.,Not applicable; natural metabolic output without engineered control.,Compatible with oral administration and gut environment; no encapsulation or material barrier described.,False,False,False,Not applicable; no antibacterial activity reported.,,False,False,False,False,未报告抗菌或抗生物膜活性。,False,Not applicable; no oxygen production or oxygenation mechanism reported.,,False,False,False,未涉及氧气生成或氧合功能。,True,通过抑制NF-κB和p-Akt信号通路，减轻炎症反应，调节免疫应答，降低促炎因子水平。,"NF-κB, p-Akt",True,通过诱导结肠细胞凋亡、修复DNA损伤、增强线粒体膜电位稳定性和促进细胞周期调控，实现组织修复与再生。,"p53, p21, Bax, Bcl-2, cleaved PARP",True,通过生物氢化作用将亚油酸（LA）转化为共轭亚油酸（CLA），调节宿主代谢，抑制肿瘤生长。,Conjugated Linoleic Acid (CLA),True,通过诱导结肠癌细胞凋亡、抑制NF-κB和p-Akt通路、促进DNA断裂和caspase-3活化，实现肿瘤抑制。,Conjugated Linoleic Acid (CLA),GRAS,Not applicable; no kill-switch or auxotrophy reported.,Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe in animal models.,Not applicable; no physical barrier used.,Pediococcus pentosaceus GS4被归类为GRAS（公认安全），在动物实验中未观察到毒性或炎症反应，具有良好的生物安全性。其天然代谢功能不涉及基因工程改造，无逃逸风险。,在AOM诱导的结肠癌小鼠模型中，GS4显著降低疾病活动指数（DAI），减轻结肠组织炎症和肿瘤样病变，减少氧化应激，诱导结肠细胞凋亡，促进DNA断裂和caspase-3活化，提高Bax/Bcl-2比值，抑制NF-κB和p-Akt表达，同时增强肠道微生物群的生物氢化能力，表明其在结肠癌预防和治疗中具有显著疗效。,16295,1675,17970,,
1c6cf006-4ef7-4f11-9ef4-ab714b98ee8a,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCFM""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""Lpc-37""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""Bl-04""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""Bi-07""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""HN019""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires complex media with carbohydrates (e.g., lactose, glucose), vitamins, and amino acids; tolerates bile salts and gastric acidity.",Growth rate not explicitly reported; in vitro doubling time estimated at ~1–2 hours under optimal conditions; in vivo colonization observed in human gut with transient persistence.,"Large intestine (colon), particularly in the mucosal layer and lumen; preferentially colonizes the distal colon in constipated individuals.",Competitive exclusion of pathogenic bacteria; synergistic interactions with host microbiota; no significant disruption of native microbiome observed.,"Tolerant to refrigeration (2–8°C), lyophilization, and moderate osmotic stress; sensitive to high temperatures (>45°C) and drying without protection.","Microcrystalline cellulose (used as placebo carrier, provides physical protection in formulation)",该益生菌混合物由五株乳杆菌和双歧杆菌组成，均为兼性厌氧菌，可在37°C、pH 6.5–7.0的条件下生长，依赖于碳水化合物、维生素和氨基酸等营养物质。它们能耐受胃酸和胆盐，可在肠道内定植，尤其在结肠远端，具有良好的耐受性和短期定植能力。,"Not applicable (natural strains, no genetic modification reported)",Not applicable,Constitutive,Null,High chromosomal stability; no plasmids used; no evidence of genetic drift or loss in human gut over 2 weeks.,Stable in microcrystalline cellulose matrix; no degradation or loss of viability during storage and delivery.,该系统未经过基因工程改造，所有菌株均为天然存在的商业益生菌株，通过传统发酵和冻干工艺制备，无外源基因插入或调控回路。,"[""pH"", ""Bile Acids"", ""Lactate""]","[""Glucose"", ""Lactose"", ""Fructose""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), Lactate permease (lactate sensing), Bile acid receptors (e.g., Bile acid-binding proteins)",Constitutive expression; no reported synthetic logic gates; natural sensing with threshold-based response to environmental cues.,各菌株通过天然受体感知肠道环境中的pH、胆汁酸、乳酸、葡萄糖等信号，实现对宿主微环境的适应性响应。例如，乳酸杆菌通过乳酸转运蛋白感知乳酸浓度变化，双歧杆菌通过胆汁酸受体感知胆汁环境，从而调节代谢活性。无合成逻辑门控机制。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Type IV Secretion System (T4SS), Vesicles (Extracellular vesicles)",Fixed daily dose (10^10 CFU/day); no dynamic dosage adjustment; controlled by formulation and administration schedule.,Compatible with microcrystalline cellulose matrix; maintains viability during encapsulation and gastrointestinal transit.,False,False,False,Null,Null,False,False,False,False,未观察到抗菌或抗生物膜作用。,False,Null,Null,False,False,False,未报告氧气生成功能。,True,调节肠道免疫反应，降低促炎因子水平，增强黏膜屏障功能，通过调节Treg细胞活性和抑制NF-κB通路实现抗炎作用。,"Cytokines (e.g., IL-10, TGF-β), TLR ligands",True,促进肠道上皮细胞再生，增强黏膜屏障完整性，调节细胞外基质合成，改善肠道通透性。,"Mucin-2, EGF-like peptides, TGF-β",True,调节短链脂肪酸（SCFAs）生成，促进结肠内乙酸、丙酸和丁酸的合成，改善肠道微生态平衡，调节宿主能量代谢。,"Short-chain fatty acids (SCFAs), Acetate, Propionate, Butyrate",False,Null,Null,GRAS,"Auxotrophy (nutrient-dependent growth), no antibiotic resistance genes detected","Lack of essential amino acids (e.g., arginine, lysine) in gut environment",Low pathogenicity; no known virulence factors; no horizontal gene transfer observed; no antibiotic resistance genes detected; low risk of environmental escape.,Microcrystalline cellulose matrix provides physical confinement and limits survival outside gut.,该益生菌混合物为公认安全（GRAS）级别，所有菌株均为商业化益生菌，无致病性、无抗生素抗性基因，且在肠道中依赖特定营养物质生长，具有天然生物遏制机制。物理屏障（微晶纤维素）进一步降低环境释放风险。,在为期两周的双盲随机安慰剂对照试验中，该益生菌混合物未在主要终点（腹胀严重程度）上显示出显著疗效。然而，事后分析显示，与安慰剂组相比，试验组在第7天和第14天的排气（flatulence）症状显著减轻（ITT：P=0.0313和P=0.0116；PP：P=0.0253和P=0.0102），且所有消化症状的平均视觉模拟评分（AUC）也显著改善。此外，对粪便样本的qPCR分析显示，71.7%的试验组参与者在干预后可检测到目标菌株，表明其在肠道中具有良好的定植能力。总体而言，该混合物安全耐受，对改善功能性便秘患者的排气症状具有潜在益处。,12388,2086,14474,,
d9a2dce7-d38b-4d03-9d80-b538633a2e03,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Bb-12""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""CCRC 14634""}]",Suspension,Facultative Anaerobe,Grown in MRS medium supplemented with 0.05% cysteine-HCl at 37°C under anaerobic conditions,"24 hours of growth at 37°C, cell density adjusted to 1×10⁸–1×10⁹ cells/ml",Human gastrointestinal tract (intestine),Competitive interaction with other intestinal microbiota; potential symbiosis through antimutagenic activity,"Tolerant to heat (up to 100°C for 20 min), centrifugation, and storage in PBS at 4°C for up to 24 hours","Cell wall components (peptidoglycan, polysaccharides)","Bifidobacterium lactis Bb-12 and B. longum CCRC 14634 are anaerobically grown in MRS medium with cysteine supplementation at 37°C for 24 hours. They exhibit high viability and stability in suspension, with cell density maintained at 1×10⁸–1×10⁹ cells/ml. These strains are well-adapted to the human gut environment and show robust growth under physiological conditions.",,,,,,,"No genetic engineering was performed in this study. The antimutagenic activity is intrinsic to the wild-type strains, primarily mediated by cell wall components and metabolic interactions.","[""pH"", ""Temperature""]","[""Benzo[a]pyrene (B[a]P)"", ""B[a]P metabolites"", ""S9 mix (P450-mediated metabolites)""]",,,"Cell wall components (peptidoglycan, polysaccharides)","Time-dependent response: antimutagenic activity increases with preincubation time (0–40 min), indicating a cumulative interaction mechanism without explicit logic gates.","The antimutagenic effect is not controlled by a genetic circuit but arises from physical and chemical interactions. The longer the preincubation time between bifidobacterial cells and B[a]P or its metabolites, the greater the inhibition of mutagenicity, suggesting a passive, time-dependent binding and inactivation process.","[""Antimutagenic""]",Passive binding via cell wall; no active secretion or lysis observed,Controlled by cell concentration and preincubation time,Compatible with PBS and agar-based assay matrices; no encapsulation or material barrier used,False,,,"Not applicable. The study focuses on antimutagenic activity, not antibacterial or biofilm inhibition.",,False,,,,Not applicable,False,Not applicable. No oxygenation mechanism was investigated.,,False,False,False,Not applicable,False,Not applicable. No immune modulation was studied.,,False,Not applicable. No tissue repair function was evaluated.,,False,Not applicable. No metabolic regulation was investigated.,,False,Not applicable. No tumor therapy mechanism was studied.,,GRAS,None (natural strains with no engineered kill switches),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe for human consumption as probiotics,None (no physical confinement used),"Bifidobacterium lactis Bb-12 and B. longum CCRC 14634 are well-established probiotic strains with GRAS status. They are non-pathogenic, non-invasive, and do not pose significant risk to human health. No genetic modifications were made, and no biocontainment systems were employed.","B. lactis Bb-12 and B. longum CCRC 14634 exhibited the highest antimutagenic activity against benzo[a]pyrene (B[a]P), with inhibition rates of up to 91.1% and 89.6% respectively, depending on preincubation time. The mechanism involves desmutagenic activity through chemical complex formation between cell walls and B[a]P or its metabolites, leading to inactivation of mutagenic compounds. This suggests strong potential for chemoprevention of carcinogenesis in the gastrointestinal tract.",15861,1586,17447,,
15da6eee-4a72-488a-bbc3-e1d240b34407,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""IB-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""IB-2""}]",Suspension,Facultative Anaerobe,"37°C, pH 6.5, MRS medium, heterofermentative (IB-1), homofermentative (IB-2)",Growth rate: steady increase up to 54 h; Doubling time not explicitly reported; In vitro growth consistent with industrial fermentation conditions,Gastrointestinal tract (inferred from probiotic evaluation),"Antagonistic to pathogens (E. coli, B. cereus, L. monocytogenes); potential for competitive exclusion in gut microbiome","High tolerance to bile salts (2%), acidic pH (down to pH 1.0), moderate resistance to lactic acid accumulation","Bile salt hydrolase (BSH), H⁺-ATPase",两种菌株均能在37°C下于MRS培养基中良好生长，具有耐受高浓度胆盐（2%）和低pH（最低至pH 1.0）的能力。L. plantarum (IB-1)在酸性环境下的存活率优于L. lactis (IB-2)，尤其在pH 3.0时4小时后仍保持88.13%存活率。两者在54小时内均能积累较高生物量（IB-1: 0.65 g/L；IB-2: 0.58 g/L）并产生大量乳酸（IB-1: 181.93 mM；IB-2: 154.44 mM），表明其在工业发酵中具有良好的生长和代谢能力。,16S rRNA sequencing for identification; no genetic tools used for engineering,Not applicable (no genetic modification reported),Constitutive (inferred from natural expression),,No plasmid or chromosomal integration reported; natural strains likely stable in vitro,No material environment described for genetic stability,未对菌株进行基因工程改造，仅通过16S rRNA测序和生化特征鉴定其种属。所有功能均为天然表达，未使用外源调控元件或合成电路。,"[""pH"", ""Lactic acid""]","[""Lactose"", ""Maltose"", ""Sucrose"", ""Galactose""]",,,"H⁺-ATPase (for acid tolerance), Bile salt hydrolase (BSH) (for bile tolerance)",No synthetic logic gates reported; natural sensing via metabolic and stress response pathways,菌株通过H⁺-ATPase感知酸性环境并调节质子泵以维持胞内pH稳态；通过胆盐水解酶（BSH）感知并降解胆盐，降低其毒性。这些机制为天然的、非编程的生理响应，无明确逻辑门控结构。,"[""Antibacterial"", ""Metabolic Regulation"", ""Tissue Repair (indirect via probiotic function)""]","Constitutive secretion (natural release of metabolites, enzymes, and antimicrobial compounds)","Natural, uncontrolled secretion; dependent on growth phase and environmental conditions",No encapsulation or material environment described; suitable for liquid fermentation and probiotic delivery,True,True,False,分泌抗菌物质（如有机酸、细菌素）抑制病原菌生长，对E. coli、B. cereus、L. monocytogenes均表现出显著抑菌圈（IB-1对E. coli和B. cereus为+++，IB-2对三者均有效）,"Organic acids (lactic acid), bacteriocins (inferred)",True,True,True,True,两种菌株均对多种常见食源性病原菌（E. coli、B. cereus、L. monocytogenes）具有强抑制作用，且在体外实验中未观察到对宿主细胞的直接毒性，符合安全边界要求。,False,,,False,False,False,未涉及氧气生成或氧合功能。,False,,,False,,,True,产生维生素B12和β-半乳糖苷酶，调节宿主代谢，改善乳糖消化与维生素合成,"Vitamin B12, β-galactosidase",False,,,GRAS,"None (natural strains, no synthetic kill switches or auxotrophy reported)",,Non-pathogenic; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; low environmental escape risk due to natural origin and lack of engineered persistence,Not applicable (no physical material barrier described),L. plantarum 和 L. lactis 均为公认安全（GRAS）菌种，广泛用于食品发酵。未报告致病性、抗生素抗性基因或水平基因转移风险。无基因工程改造，因此无生物安全风险。,在体外实验中，IB-1和IB-2均表现出优异的耐酸性（pH 3.0下存活率>88%）、耐胆盐性（2%胆盐下存活率>58%），并能高效生产乳酸（>150 mM）、维生素B12（约8 μg/mL）和β-半乳糖苷酶（0.5 U/mL）。对多种食源性病原菌具有强抑制作用，具备作为益生菌和工业生产菌株的潜力。,12201,1833,14034,,
c7c31e8f-cd66-4879-a81d-d7b44f08a854,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus bulgaricus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly acidic; Nutritional requirements: Carbohydrates (e.g., lactose), amino acids, vitamins; Growth in gastrointestinal tract environment",Doubling time not specified; In vitro growth consistent with in vivo colonization ability,"Gastrointestinal tract (gut mucosa, intestinal lumen)",Symbiotic with host microbiota; Competes with pathogenic bacteria; Modulates gut microbial balance,Tolerant to gastric acid and bile; Stable during lyophilization and rehydration; Resistant to moderate osmotic stress,"Cell wall components, exopolysaccharides, stress-response proteins",该研究中使用的益生菌为双歧杆菌、嗜热链球菌和保加利亚乳杆菌，均为常见的肠道定植型益生菌，具有耐酸耐胆盐特性，可在胃肠道环境中稳定生长并定植于肠黏膜，发挥调节免疫和代谢的作用。,Not applicable (no genetic modification reported),Not applicable,Constitutive,Not applicable,High chromosomal stability; No plasmid-based systems used; No evidence of genetic drift or loss in vivo,Stable in blueberry juice matrix; No reported instability due to encapsulation or delivery,研究中未对益生菌进行基因工程改造，其功能依赖于天然代谢活性和定植能力，通过调节宿主SIRT1通路发挥抗肝细胞凋亡作用。,"[""Acidity (gastric pH)"", ""Bile acids""]","[""Lactose"", ""Glucose"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing (AI-2, AHL)""]","[""Cytokines (indirectly via immune modulation)"", ""Tissue degradation fragments (via gut-liver axis)""]","Bile acid transporters, acid tolerance systems (e.g., F1F0-ATPase), sugar transporters, quorum sensing receptors (e.g., LuxR-type)",Constitutive expression; No reported synthetic logic circuits; Sensing is passive and responsive to environmental cues,益生菌通过其天然的代谢感应系统感知肠道环境中的酸碱度、胆汁酸、乳糖和葡萄糖等信号，启动定植和代谢活动，但未构建人工调控逻辑电路。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Type IV secretion system (putative), Vesicles (exosomes), Lysis (natural release)",Dose-dependent effect; Controlled by oral administration frequency and concentration,Compatible with blueberry juice matrix; No structural disruption observed,False,False,False,Not applicable,Not applicable,False,False,False,False,未涉及抗菌或抗生物膜功能。,False,Not applicable,Not applicable,False,False,False,未涉及氧气生成或氧合功能。,True,益生菌通过调节肠道免疫稳态，抑制促炎因子释放，增强抗炎反应，间接减轻肝脏炎症和氧化应激。,"Cytokines (e.g., IL-10, TGF-β), SCFAs (butyrate, acetate)",True,通过激活SIRT1通路，抑制肝细胞凋亡，促进肝细胞再生，改善肝组织结构损伤。,"SIRT1, FOXO1, Bcl-2",True,益生菌与蓝莓汁协同调节宿主代谢，通过上调SIRT1表达，改善脂质代谢，降低甘油三酯和胆固醇水平，减少肝脂肪变性。,"Short-chain fatty acids (SCFAs), Tryptophan metabolites",False,Not applicable,Not applicable,GRAS,Auxotrophy (natural limitation in host environment),"Nutrient dependency (e.g., lactose, vitamins)",Low pathogenicity; No antibiotic resistance genes reported; No evidence of horizontal gene transfer; Low risk of environmental escape,Blueberry juice matrix provides partial physical confinement,所用益生菌为公认安全（GRAS）菌株，无致病性，不携带耐药基因，且在宿主肠道内依赖特定营养物质生长，不易在环境中长期存活，安全性高。,蓝莓汁与益生菌联合使用显著减轻酒精性脂肪肝小鼠的肝细胞损伤、脂质沉积和细胞凋亡，通过上调SIRT1表达，抑制FOXO1、FasL、caspase-3、BAX等凋亡相关因子，改善肝功能指标（ALT、AST、TG、HDL-C、LDL-C、SOD、GSH、MDA），具有显著的协同保护作用。,14481,1729,16210,,
9b9cdf74-d9c9-4333-8068-f96832ec1a75,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": null}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": null}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus spp."", ""strain_id"": null}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": null}]",Suspension,Facultative Anaerobe,Optimal temperature: 37–40°C; pH range: 5.0–7.0; Tolerant to bile salts and low gastric pH; Requires fermentable carbohydrates and amino acids for growth,Doubling time: 20–60 min in vitro; Growth rate maintained in vivo under intestinal conditions; Stable colonization observed in piglet gut post-weaning,"Small intestine (jejunum and ileum), large intestine (caecum and colon); Preferentially colonizes mucosal surfaces and crypts",Competes with pathogenic ETEC and coliforms for nutrients and adhesion sites; Synergistic with prebiotics to enhance beneficial microbiota; No significant disruption of native microbiome observed,Tolerant to moderate osmotic stress and shear stress; Stable during lyophilization and rehydration; Resistant to bile salts and low pH (pH 2.5–3.5) in stomach,"Bile salt hydrolase (BSH), acid tolerance response (ATR) genes, exopolysaccharides (EPS)",乳酸杆菌、双歧杆菌、肠球菌和酵母菌等益生菌在断奶猪肠道中具有良好的生长适应性，能耐受胃酸和胆盐环境，可在小肠和大肠黏膜表面定植，通过竞争排斥抑制致病性大肠杆菌（ETEC）的增殖，维持肠道微生态平衡。,"Plasmid-based expression systems, CRISPR-Cas9 (in research settings), Recombination (for gene insertion)",High efficiency (>90%) in Lactobacillus and Bifidobacterium; Low off-target risk with optimized CRISPR systems,"Constitutive expression of beneficial genes; Inducible systems using lactose or sugar promoters (e.g., P_lac, P_araBAD)","Lactose, arabinose, glucose",High plasmid stability in Lactobacillus (copy number: 1–5); Chromosomal integration reduces loss rate; Metabolic burden minimal; Long-term in vivo stability observed over 7–14 days,"Stable in feed matrices (pellets, powders); No significant degradation in encapsulated forms; Compatible with prebiotic carriers",通过质粒或染色体整合方式构建工程化益生菌，使其持续表达抗菌肽、黏附抑制因子或免疫调节蛋白。利用乳糖或阿拉伯糖诱导型启动子实现可控表达，确保在肠道中按需激活功能，避免过度代谢负担。,"[""Low pH (gastric)"", ""Bile salts"", ""Lactate"", ""Glucose"", ""Oxygen (hypoxia)""]","[""Lactose (from milk)"", ""Fermentable carbohydrates"", ""Short-chain fatty acids (SCFAs)"", ""Ammonia"", ""Bile acids""]","[""AHL (Acyl-Homoserine Lactone)"", ""AI-2 (Autoinducer-2)""]","[""Proteases (e.g., trypsin)"", ""Cytokines (e.g., IL-1β, TNF-α)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactose permease (LacY), Bile salt hydrolase (BSH), LuxI/LuxR (quorum sensing)",AND gate: Requires both low pH and presence of lactose for activation; Threshold-based response to SCFAs; Noise suppression via feedback inhibition,益生菌通过感知胃酸、胆盐、乳糖和低氧环境等多重生理信号，结合微生物群落密度（AI-2）和宿主炎症因子（如IL-1β），实现逻辑判断。仅在肠道病原体活跃或屏障受损时启动抗菌或免疫调节功能，避免非必要激活。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type IV secretion system (Lactobacillus), Vesicle release (Extracellular vesicles), Lysis (controlled release)",Dose-dependent response; Controlled by feed concentration (10^6–10^9 CFU/g); No evidence of over-activation or persistence beyond 14 days,"Compatible with feed matrices (pellets, powders); Stable in prebiotic carriers; Permeable to intestinal mucus layer",True,True,True,分泌乳酸、细菌素（如乳酸菌素）、过氧化氢等物质，直接杀灭或抑制ETEC、沙门氏菌等病原菌；竞争性抑制病原菌黏附于肠上皮细胞；破坏生物膜结构。,"Lactic acid, bacteriocins (e.g., lactocin), hydrogen peroxide, exopolysaccharides (EPS)",True,True,True,True,在断奶猪模型中，添加乳酸杆菌和双歧杆菌可显著降低大肠杆菌数量（P<0.05），减少腹泻发生率，且对宿主细胞无明显毒性，粪便中未检测到微生物群落紊乱。,False,,,,,,,True,调节肠道免疫反应，降低促炎因子（IL-1β、TNF-α）水平，促进抗炎因子（IL-10）分泌；增强T细胞和B细胞活性，提升黏膜免疫屏障。,"IL-10, TGF-β, peptidoglycan fragments, exopolysaccharides (EPS)",True,促进肠上皮细胞增殖与修复，增加绒毛高度，减少隐窝深度；分泌生长因子（如EGF）和细胞外基质成分，加速黏膜屏障重建。,"Epidermal Growth Factor (EGF), TGF-β, mucin (MUC2)",True,产生短链脂肪酸（SCFAs，如乙酸、丙酸、丁酸），调节肠道pH，抑制病原菌生长；促进宿主能量代谢，改善营养吸收。,"Butyrate, acetate, propionate",False,,,GRAS,"Auxotrophy (e.g., leucine-dependent strains), Suicide genes (e.g., ccdB), Temperature-sensitive plasmids","Leucine, heat shock (42°C)",Low pathogenicity; No known antibiotic resistance genes; No horizontal gene transfer reported; Low environmental escape risk due to poor survival outside host,Feed matrix acts as physical barrier; No release into environment during normal use,所用益生菌株（如乳酸杆菌、双歧杆菌、肠球菌和酵母）均为公认安全（GRAS）菌种，无致病性，不携带耐药基因，且在体外环境中难以长期存活。通过营养缺陷型和自杀基因实现生物安全控制，确保其在断奶猪肠道中发挥功能后迅速失活。,在断奶猪模型中，添加益生菌可显著降低腹泻发生率（减少40–60%），提高日增重（ADG）10–15%，改善饲料转化率（FCR）8–12%，并促进肠道绒毛高度增加（+20%），隐窝深度减少（-15%），有效替代抗生素生长促进剂。,16581,2329,18910,,
0c71bc6f-f3bc-4627-94bc-5a11aa83964b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""CGMCC 9951""}]",Suspension,Facultative Anaerobe,"Temperature: 30–45°C; pH: 6.8–7.2; NaCl tolerance: up to 5% w/v; Carbon sources: glucose, lactose, maltose, sucrose, trehalose, starch, cellulose",Growth rate: 37°C for 48 h in TSB; Spore formation confirmed; No in vivo growth data reported,"Intestinal mucus (jejunum, ileum, transverse colon, sigmoid colon)",Competitive adhesion to intestinal mucus; No direct evidence of symbiosis or competition with other gut microbes,"High resistance to acid (pH 2.0 for 2 h, 90.1% survival), bile salt (0.9% w/v for 4 h, 20% reduction in viability), heat (80°C for 30 min), and desiccation (spore-forming ability)","Spore coat proteins, endospore structure",该菌株为芽孢形成菌，能在30–45°C范围内生长，耐受pH 2.0的强酸环境（2小时存活率90.1%）和0.9% w/v胆盐（4小时存活率仅下降20%），具有良好的胃肠道环境适应能力。其芽孢结构赋予其对热、干燥和消化道环境的强耐受性，是理想的口服益生菌候选菌株。,,,,,,,该研究未涉及基因工程改造，菌株为天然分离株，未进行任何遗传修饰。,"[""pH"", ""Bile Salt""]",,,,Spore formation system (pH and bile resistance mechanisms),No engineered logic gates reported; natural sensing via spore germination and stress response pathways,菌株通过芽孢结构感知胃肠道环境中的低pH和胆盐，启动芽孢萌发和生长程序，实现对胃肠道环境的自然响应。未见人工设计的逻辑门控系统。,"[""Antibacterial"", ""Adhesion"", ""Enzymatic Digestion""]",Unknown (likely passive diffusion or cell lysis),"Not applicable (natural strain, no controllable output)",Not applicable (no material encapsulation described),True,True,False,分泌抗菌物质抑制多种病原菌生长，包括大肠杆菌O8、金黄色葡萄球菌、沙门氏菌、链球菌、李斯特菌和巴氏杆菌。,Unknown secreted antimicrobial compounds (likely bacteriocins or organic acids),True,True,True,True,对6种主要病原菌均表现出广谱抗菌活性，且在动物毒性试验中未见致病性，表明其活性可控且安全。,False,,,False,False,False,未报道氧气生成功能。,False,,,False,,,True,分泌淀粉酶、蛋白酶和纤维素酶，促进宿主对碳水化合物、蛋白质和纤维素的消化吸收。,"Amylase, Protease, Cellulase",False,,,GRAS,"None (natural strain, no kill switch or auxotrophy reported)",,No pathogenicity; no toxin production (confirmed by rabbit ileal loop assay); no antibiotic resistance genes detected; no horizontal gene transfer risk reported; low opportunistic risk,None (no physical barrier described),该菌株经兔肠袢实验、急性与亚慢性毒性试验均未显示毒性，且对15种常用兽用抗生素均敏感，无耐药基因，不产生肠毒素或呕吐毒素，符合GRAS标准，安全性高。,该菌株在猪肠道黏液上表现出强于B. subtilis JT143和L. acidophilus LY24的黏附能力（分别为44.5%、48.9%、42.6%和37.6%），在pH 2.0下存活率达90.1%，在0.9%胆盐中存活率仅下降20%，且对多种病原菌具有广谱抗菌活性，具备优良的益生菌特性，是极具潜力的商业化益生菌候选菌株。,19171,1570,20741,,
16a279c6-d67b-4d82-93fa-b712e22ecc86,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""Not specified""}]",Encapsulated,Facultative Anaerobe,"Temperature: ~37°C, pH: physiological (~7.0), osmotic strength: moderate; requires carbon sources (e.g., glucose), amino acids, vitamins","Doubling time ~20–30 min in vitro; in vivo homeostasis not explicitly reported, but viability maintained for >1 month in silica gel",Not applicable (in vitro system; no host colonization),Not applicable (no host microbiome context),"Moderate tolerance to shear stress (protected by silica), UV and drying (improved by glycerol), lyophilization/rehydration (successful with cryo-SEM validation)","Glycerol, organically modified silanes (e.g., N-(3-triethoxysilylpropyl) gluconamide)",大肠杆菌在37°C、pH 7.0的条件下生长良好，需碳源、氨基酸和维生素。在硅胶基质中，其代谢活性可维持一个月以上，且在添加甘油或QS分子后，存活率接近100%。,CRISPR-Cas not mentioned; likely plasmid-based systems (implied by recombinant protein production and reporter genes),Not specified,"Inducible (e.g., reporter gene activation by chemical inducers); quorum sensing (QS) molecules used for metabolic modulation","Acylated homoserine lactones (AHLs), chemical inducers (e.g., for reporter genes)",High stability due to physical confinement in silica matrix; no cell division possible in pure silica gel; plasmid loss minimized by encapsulation,High genetic stability within silica environment; no evidence of plasmid leakage or drift,通过溶胶-凝胶法将大肠杆菌封装在硅基质中，利用QS分子（如酰基高丝氨酸内酯）维持细胞处于静止状态，增强其抗应激能力。报告基因系统可长期保持响应性，适用于生物传感器应用。,"[""Hypoxia"", ""pH"", ""ROS/RNS""]","[""Glucose"", ""Lactate""]","[""Quorum Sensing (AHL)""]","[""Proteases"", ""Cytokines""]","Quorum sensing receptors (e.g., LasR, LuxR homologs), reporter gene promoters (e.g., lacZ, GFP promoters)",AND gate implied: activity only when both environmental stress and chemical inducer present; threshold control via QS modulation,细胞通过群体感应分子感知自身密度，结合外部化学诱导物（如诱导剂）触发报告基因表达，形成逻辑AND门控。该系统可实现对环境应激的高灵敏度响应，同时抑制非特异性背景信号。,"[""Biosensors"", ""Bioreactors"", ""Metabolic Regulation""]",Diffusion through porous silica matrix,Controlled by matrix porosity and nutrient diffusion; output strength modulated by cell density and environmental conditions,High compatibility with porous silica matrix; nutrient and product diffusion maintained via controlled pore size,False,,,Not applicable,,,,,,无抗菌功能,False,Not applicable,,,,,无氧生成功能,False,Not applicable,,False,Not applicable,,True,通过代谢调控维持细胞长期活性，支持持续的生物转化与产物合成，如乙醇、酚类降解物、重组蛋白等。,"Ethanol, phenol, recombinant proteins",False,Not applicable,,BSL-1,Physical confinement via silica matrix; no cell division possible in pure silica gel,"Silica gel, glycerol, organically modified silanes",Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; minimal environmental escape risk due to immobilization,Highly effective physical barrier; prevents cell leakage and proliferation,大肠杆菌被完全封装在硅基质中，无法分裂或逃逸，且无致病性基因，属于低风险生物安全等级（BSL-1），材料屏障有效防止细胞扩散。,该系统主要用于生物传感器和连续生物反应器，可长期维持细胞活性（>1个月），实现对污染物（如苯酚）的降解、重组蛋白的生产及化学诱导物的检测，适用于环境修复与生物制造。,13849,4292,18141,,
16a279c6-d67b-4d82-93fa-b712e22ecc86,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Synechococcus sp. PCC 6301"", ""strain_id"": ""PCC 6301""}]",Encapsulated,Oxygenic Photosynthetic (Aerobic),"Temperature: ~30°C, pH: neutral to slightly alkaline, osmotic strength: moderate; requires CO2, light, nitrogen, trace metals",Doubling time ~6–8 hours in vitro; photosynthetic activity preserved for 12 weeks in silica gel,Not applicable (in vitro system; no host colonization),Not applicable,"High tolerance to light, UV, osmotic stress; stable under prolonged light exposure; resistant to drying (via silica protection)","Silica matrix, glycerol (in some protocols)",蓝藻Synechococcus sp. PCC 6301在30°C、中性pH条件下生长良好，依赖光能和CO2进行光合作用。在硅胶基质中，其光合色素（叶绿素a、藻蓝蛋白）和细胞壁结构得以完整保存，活性维持12周以上。,Not specified,Not specified,Constitutive (photosynthetic apparatus naturally active); no inducible circuits reported,,High stability due to physical confinement; no cell division in pure silica gel; no evidence of genetic drift,High stability in silica environment; no plasmid loss reported,通过溶胶-凝胶法将蓝藻PCC 6301封装在多孔透明硅基质中，利用其天然光合系统实现持续的CO2固定与氧气生成，无需外源基因改造。,"[""Hypoxia"", ""Light Intensity"", ""pH"", ""ROS/RNS""]","[""CO2"", ""Glucose""]",,,"Photosynthetic apparatus (PSI/PSII), light-harvesting complexes",Constitutive activation; no complex logic gates reported,蓝藻的光合作用系统为天然的光响应装置，无需外部调控即可在光照下持续激活，具有自维持特性，适用于长期光生物反应器。,"[""Photosynthesis"", ""Bioreactors"", ""Metabolic Regulation""]",Diffusion through porous silica matrix,Controlled by light intensity and duration; output strength proportional to illumination,"Excellent compatibility with porous silica matrix; transparent to visible light, allows efficient light penetration",False,,,Not applicable,,,,,,无抗菌功能,True,通过光合作用持续释放氧气，维持局部氧环境，适用于缺氧环境修复。,Photosynthetic apparatus (PSII),True,True,True,在12周内持续释放氧气，且不促进病原菌生长，与抗菌模块兼容。,False,Not applicable,,False,Not applicable,,True,通过光合作用固定CO2，合成多糖类代谢产物（如鼠李糖、半乳糖）。,"Polysaccharides (rhamnose, galactose), O2",False,Not applicable,,BSL-1,Physical confinement via silica matrix; no cell division possible in pure silica gel,"Silica gel, glycerol",Low pathogenicity; no antibiotic resistance genes; no evidence of HGT; minimal escape risk,Highly effective physical barrier; prevents cell leakage and proliferation,蓝藻被完全封装在硅基质中，无法分裂或逃逸，且无致病性，属于低风险生物安全等级（BSL-1），材料屏障有效防止细胞扩散。,该系统可实现长达12周的持续光合作用，稳定释放氧气并固定CO2，适用于环境修复、生物燃料生产及人工光合反应器，具有长期稳定性与高生物活性。,13849,4292,18141,,
16a279c6-d67b-4d82-93fa-b712e22ecc86,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Thylakoids"", ""strain_id"": ""Not applicable (organelle)""}]",Encapsulated,Oxygenic Photosynthetic (Aerobic),"Temperature: ~25°C, pH: neutral, light: visible (400–700 nm), requires water and CO2","Not applicable (organelle, not replicating); photochemical activity preserved for >1 month",Not applicable,Not applicable,High tolerance to light and oxidative stress due to silica protection; stable under prolonged illumination,"Fumed silica, ion-exchanged sodium silicate, quaternary SiO4 units",类囊体膜在25°C、中性pH和光照条件下保持光化学活性，封装后可维持超过一个月，且无细胞分裂能力。,"Not applicable (organelle, no genome)",,Constitutive (natural photosynthetic activity),,High stability due to physical confinement and matrix rigidity,High stability in silica environment; no degradation observed,通过溶胶-凝胶法将类囊体封装在三维硅基质中，利用硅纳米颗粒与离子交换硅酸盐构建低收缩、高稳定性的基质，保护光合膜结构。,"[""Light Intensity"", ""pH"", ""ROS/RNS""]","[""Water"", ""CO2""]",,,"Photosynthetic reaction centers (PSII, PSI), light-harvesting complexes",Constitutive activation; no logic gates,类囊体的光合作用系统为天然光响应装置，无需外部调控即可在光照下持续激活，具有自维持特性。,"[""Photosynthesis"", ""Bioreactors"", ""Oxygenation""]",Diffusion through porous silica matrix,Controlled by light intensity and duration; output strength proportional to illumination,"Excellent compatibility with porous silica matrix; transparent to visible light, allows efficient light penetration",False,,,Not applicable,,,,,,无抗菌功能,True,通过光合作用在光照下持续释放氧气，适用于缺氧环境修复。,Photosystem II (PSII),True,True,True,在1个月内持续产氧，且不促进病原菌生长，与抗菌模块兼容。,False,Not applicable,,False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,Physical confinement via silica matrix; no replication possible,"Silica gel, fumed silica",No pathogenicity; no antibiotic resistance genes; no HGT; no escape risk,Highly effective physical barrier; prevents leakage,类囊体为无生命结构，无法复制，被完全封装在硅基质中，无生物安全风险，属于BSL-1等级。,该系统可实现超过一个月的持续光合作用，稳定产氧，适用于人工光合反应器、生物燃料生产及缺氧环境修复，具有高稳定性和长期活性。,13849,4292,18141,,
3c022c75-8ec0-4b6e-b1c6-4f2bf707d8e2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""99""}, {""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium freudenreichii ssp. shermanii JS"", ""strain_id"": ""JS""}, {""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli Nissle 1917"", ""strain_id"": ""1917""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCC 2628, NCC 2766, NCC 2767""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""CECT 7347""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium pseudocatenulatum"", ""strain_id"": ""JCM 7041""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei Shirota"", ""strain_id"": ""LcS""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric acidity (pH 2–3) and bile salts; utilizes various carbohydrates including lactose, glucose, and fructose.",Doubling time ~1–2 hours in vitro; in vivo colonization observed in intestinal mucosa with sustained persistence in gut lumen.,"Intestinal mucosa, particularly Peyer's patches and lamina propria; preferentially adheres to intestinal epithelial cells.",Competitive exclusion of pathogens; synergistic interactions with commensal microbiota; minimal disruption to native microbiome.,"Tolerant to gastric acid, bile salts, osmotic stress, and moderate heat; stable during lyophilization and rehydration.","Cell wall components (e.g., teichoic acids), exopolysaccharides, and stress-response proteins (e.g., chaperones)",上述菌株均为乳酸菌或大肠杆菌，具有良好的胃肠道耐受性，可在肠道黏膜定植并维持稳定生长。它们能耐受胃酸和胆汁，利用多种碳源，适宜在37°C、pH 6–7条件下生长，部分菌株在体外具有快速增殖能力，且在体内可长期定植于肠道黏膜，尤其在派伊尔集合淋巴结等免疫相关区域。,,,,,,,文中未提及对这些菌株进行基因工程改造，所有功能均基于天然菌株的固有特性。,"[""pH"", ""Osmotic stress"", ""Bile acids""]","[""Lactate"", ""Glucose"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines"", ""Tissue degradation fragments""]","Toll-like receptors (TLRs), particularly TLR2, TLR4, TLR5, TLR7, TLR8, and TLR9; NOD-like receptors (NLRs); C-type lectin receptors (CLRs)",No explicit logic gates; sensing is based on pattern recognition with threshold-dependent activation of downstream signaling pathways.,这些益生菌通过识别病原体相关分子模式（PAMPs）如脂多糖（LPS）、肽聚糖、鞭毛蛋白和核酸，由Toll样受体（TLRs）等模式识别受体（PRRs）感知，触发MyD88依赖性信号通路，从而激活抗原呈递细胞（APCs）。该过程具有阈值响应特性，且可通过细胞内信号级联放大，实现对免疫反应的精细调控。,"[""Immunomodulation""]","Soluble factors (e.g., metabolites, proteins, DNA, cell wall components) released via lysis or passive diffusion",Strain-specific and dose-dependent; natural secretion without external control,Compatible with intestinal mucus and epithelial barrier; no evidence of structural disruption,False,,,,,,,,,,False,,,,,,,True,益生菌通过激活树突状细胞（DCs）、巨噬细胞和单核细胞，诱导其成熟并分泌特定细胞因子，从而调节辅助性T细胞（Th1/Th2/Treg/Th17）分化，促进免疫稳态。例如，LGG可诱导IL-10生成，缓解过敏性炎症；Bb-12可增强黏膜和全身免疫应答。,"IL-10, IL-12, IFN-γ, TGF-β, IL-4, IL-6, IL-13, MUC-3, ZO-1",False,,,False,,,False,,,GRAS,"None (natural strains, no engineered kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape unlikely due to poor environmental survival.,Intestinal epithelium and mucus layer act as physical barrier,所有列出的菌株均被美国FDA列为GRAS（公认安全）物质，无致病性记录，不携带抗生素抗性基因，且在自然环境中生存能力弱，不易逃逸。其免疫调节功能基于天然代谢产物和细胞成分，无基因工程改造，安全性高。,在动物模型和临床试验中，LGG可缓解婴儿牛奶蛋白过敏和特应性皮炎的肠道炎症；Bb-12可增强流感疫苗后的黏膜和全身免疫应答；B. breve和B. longum可改善食物过敏和肠病患者的肠道屏障功能与免疫平衡；EcN与抗生素联用可促进肠道损伤修复。这些菌株通过激活抗原呈递细胞（APCs）并调节Th1/Th2/Treg/Th17平衡，实现对肠道和全身免疫系统的有效调控。,8203,2024,10227,,
5a84d485-6b60-4759-9d63-58ef90456ac2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""DDS-1""}]",Suspension,Facultative Anaerobe,"Grown on MRS-C agar under anaerobic conditions at 37 °C; tolerates pH 3.0–7.0, bile salts, and pancreatic enzymes.",Survived simulated digestion with >75% initial CFU retained after 240 min; doubling time not specified.,Human colonic mucosa (HT-29 and LS174T cells),No significant competition or disruption observed; potential for symbiosis via immunomodulation.,"High resistance to gastric acid (pH 3.0), bile salts (0.3%), pancreatic enzymes, and simulated digestion; lyophilized form stable.",Bile salt hydrolase (BSH) activity (inferred from survival data),该菌株为人类来源的乳酸杆菌，具有良好的胃肠道耐受性，能在模拟消化环境中保持高存活率（10⁷–10⁸ CFU/mL），在胃酸和胆汁条件下表现出优异的稳定性，适合在肠道黏膜定植。,,,,,,,该研究未涉及基因工程改造，所有功能基于天然菌株的生理特性。,"[""pH"", ""Bile Salts"", ""Pancreatic Enzymes""]",,,,"Inferred: Surface adhesion proteins and stress response systems (e.g., BSH, pH homeostasis mechanisms)",No engineered logic gates; natural sensing via surface receptors and metabolic adaptation.,该菌株通过表面黏附蛋白感知宿主细胞表面，通过pH调节系统和胆盐水解酶（BSH）响应胃酸和胆汁环境，实现对消化道恶劣条件的自然适应，无人工逻辑控制。,"[""Immunomodulation""]","Passive secretion (natural metabolites, cytokines)","Not applicable (natural strain, no controllable output)",Compatible with cell culture and in vitro models; no encapsulation reported.,False,False,False,未检测到抗菌或抗生物膜活性。,,False,False,False,False,未报告抗菌或抗生物膜功能。,False,未检测到氧气生成或氧合功能。,,False,False,False,未报告氧合功能。,True,显著下调促炎因子IL-8和TNF-α，上调抗炎因子IL-10，尤其在后处理条件下效果突出。,"IL-10 (anti-inflammatory), TNF-α (pro-inflammatory), IL-8 (pro-inflammatory)",False,未检测到促进组织修复的功能。,,False,未检测到代谢调节功能。,,False,未检测到肿瘤治疗功能。,,GRAS,"None (natural strain, no synthetic kill switches)",,No pathogenicity reported; no antibiotic resistance genes mentioned; low risk of horizontal gene transfer; human origin reduces escape risk.,None (no physical confinement used in study),该菌株为人类来源，长期用于食品和膳食补充剂，具有GRAS（公认安全）地位，无已知致病性或抗生素抗性基因，临床研究显示安全有效，无生物安全风险。,在体外模拟消化模型中，DDS-1菌株表现出最高的存活率（10⁷–10⁸ CFU/mL），对HT-29和LS174T细胞具有最强的黏附能力（87–93%），并显著下调IL-8和TNF-α，上调IL-10，尤其在LPS刺激后的后处理条件下效果最显著，综合表现优于其他来源的菌株。,13212,1423,14635,,
fe4cbade-3fe2-4c7f-b3d5-f00303f860b5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus salivarius"", ""strain_id"": ""K12""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""L10""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""B94""}]","Oral administration, transient gut colonization",Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, requires complex nutrients including amino acids, vitamins, and carbohydrates; intestinal environment with bile tolerance and moderate osmotic strength.","Doubling time not reported; in vitro growth supported by standard media; in vivo colonization transient, not long-term stable.","Oral cavity (S. salivarius K12), intestinal lumen (L. acidophilus L10, B. lactis B94); transient presence in gut after oral intake.",Potential for competition with native gut microbiota; no evidence of symbiosis or significant disruption; stable indigenous microbiota observed post-treatment.,"Tolerant to gastric acidity (transient), bile salts, moderate osmotic stress; lyophilization stability not reported; no data on UV or shear stress.","Bile salts, gastric acid (natural environmental stressors)",该多菌株益生菌制剂由三种不同来源的细菌组成：口腔来源的唾液链球菌K12、肠道来源的嗜酸乳杆菌L10和乳双歧杆菌B94。它们在人体内主要定植于口腔和肠道，具有一定的耐酸性和耐胆盐能力，可在短期口服后在粪便中检测到，但未实现长期稳定定植。,,,,,No genetic modifications reported; natural strains used; plasmid stability not applicable; chromosomal integration not performed.,No engineered genetic circuits; no data on stability within material environment.,该研究中使用的益生菌为天然菌株，未进行任何基因工程改造。其功能基于天然代谢活性，如参与磺胺水杨酸（SSZ）的偶氮还原，但未通过基因编辑手段增强或调控该功能。,"[""pH"", ""Bile Acids""]","[""Sulfasalazine (SSZ)"", ""Sulfapyridine (SP)""]",,,"16S rRNA gene (used for detection, not sensing); no specific engineered sensor reported.",No synthetic genetic circuits or logic gates reported; natural metabolic responses only.,该系统未设计任何合成传感逻辑模块，其在肠道中的行为基于自然生理响应，如对胃酸、胆汁和底物（如SSZ）的耐受性，但无主动信号识别与处理机制。,"[""Metabolic Regulation""]",Natural secretion of azoreductase enzymes; no engineered secretion systems reported.,Dose fixed at 1.8×10⁹ CFU/day; no controllable output reported.,Oral powder formulation; compatible with gastrointestinal transit; no encapsulation material described.,False,,,Not applicable; no antibacterial function reported.,,False,,,,未检测到抗菌活性。,False,Not applicable; no oxygen-producing function reported.,,False,False,False,未检测到氧生成功能。,False,Not applicable; no immunomodulatory cytokine or checkpoint molecule reported.,,False,Not applicable; no tissue repair factors reported.,,True,通过肠道菌群的偶氮还原酶活性，将磺胺水杨酸（SSZ）分解为磺胺吡啶（SP）和5-氨基水杨酸（5-ASA），从而调节药物代谢。,"Sulfapyridine (SP), 5-Aminosalicylic acid (5-ASA)",False,Not applicable; no tumor-targeting or prodrug activation function reported.,,GRAS,No kill switches or auxotrophy; natural strains with no known pathogenicity.,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk identified; no environmental escape risk due to transient colonization.,No physical barrier; oral administration with natural clearance.,该益生菌制剂为公认安全（GRAS）菌株，未进行基因改造，无致病性或耐药基因，短期口服后在粪便中可检测到，但未长期定植，无显著生物安全风险。,本研究为初步探索性试验，未评估治疗效果。结果显示短期口服该益生菌制剂对类风湿关节炎患者磺胺水杨酸（SSZ）的代谢无显著影响，且未引起严重不良反应，仅少数患者出现轻度胃肠道不适。,8491,1655,10146,,
1e35bbf6-cc23-4f5e-9ff1-a605394924ff,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""ATCC 314""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""NCIMB 5221""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: 6.8 (in AIJ); Nutritional requirements: MRS broth, glucose, yeast extract, pancreatin, oxgall, starch, potassium phosphate","Doubling time not explicitly stated; in SIF, co-culture showed higher viability (2.5×10⁷ cfu/mL for L. acidophilus, 8.3×10⁷ cfu/mL for L. fermentum) at 8 h compared to pure cultures",Intestinal tract (colon and terminal ileum),Synergistic growth and enhanced antioxidant activity in co-culture; no direct competition observed,High resistance to simulated intestinal fluids (SIF and AIJ); maintained viability in bile (oxgall) and proteolytic environment (pancreatin),"Bile salts (oxgall), proteases (pancreatin)",该共生体在模拟肠液中表现出优异的生存能力，尤其在共培养条件下，L. fermentum 和 L. acidophilus 的存活率显著高于单独培养。其生长依赖于 MRS 培养基中的碳源（葡萄糖、淀粉）和氮源（酵母提取物），并能耐受胆汁和胰酶环境，表明其具有良好的肠道定植潜力。,Not applicable (no genetic modification reported),Not applicable,Not applicable,Not applicable,Not applicable,Not applicable,该系统未进行基因工程改造，其功能依赖于天然代谢产物的协同作用，未涉及可编程调控或基因编辑。,"[""pH"", ""Bile acids"", ""Proteases""]","[""Glucose"", ""Starch""]",,,"Not explicitly identified; likely intrinsic bacterial sensors for pH, bile, and proteases",Not applicable (no synthetic circuitry described),系统未设计逻辑门控机制，其响应基于天然生理适应性，而非人工调控的传感逻辑。,"[""Tumor Therapy"", ""Metabolic Regulation"", ""Immunomodulation""]",Cell-free extracts (secreted metabolites via passive diffusion or lysis),Dose-dependent: 1×10¹⁰ cfu/day administered orally; effects observed at this dose in vivo,Compatible with oral administration and intestinal environment; no encapsulation material specified,False,False,False,Not applicable (no antibacterial activity reported),Not applicable,False,False,False,False,未报告抗菌活性，因此不满足任何抗菌标准。,False,Not applicable (no oxygen-producing mechanism described),Not applicable,False,False,False,未涉及氧气生成或氧合功能，因此不满足氧合标准。,True,"Modulates immune markers such as Ki-67, β-catenin, E-cadherin, and cleaved caspase-3, indicating regulation of proliferation and apoptosis pathways.","Cell-free metabolites (proteins, small molecules) secreted by L. fermentum and L. acidophilus",False,Not applicable (no direct tissue repair or ECM regulation reported),Not applicable,True,Enhances total antioxidant capacity (TAC) and modulates metabolic pathways related to cancer cell proliferation and apoptosis.,"Antioxidant compounds (e.g., ferulic acid, other small molecules) produced by L. fermentum NCIMB 5221",True,"Inhibits intestinal tumor formation via downregulation of β-catenin and Ki-67, and induction of apoptosis in cancer cells.","Secreted bioactive metabolites (proteins, peptides, organic acids) from co-culture",GRAS,None (natural strains used; no kill-switch or auxotrophy reported),Not applicable,Low pathogenicity; no antibiotic resistance genes or HGT risk reported; non-opportunistic; safe for oral use,Oral delivery with natural gut barrier; no engineered physical containment,L. acidophilus ATCC 314 和 L. fermentum NCIMB 5221 均为公认安全（GRAS）菌株，无致病性或耐药基因，未进行基因改造，因此生物安全风险极低，适合口服生物治疗应用。,在 ApcMin/+ 小鼠模型中，La-Lf 共生体显著减少肠道肿瘤数量（1.7倍，P=0.016），降低 Ki-67 和 β-catenin 表达水平（P=0.008 和 P=0.041），并诱导癌细胞凋亡（P<0.001），表明其在抑制结直肠癌发生方面具有显著疗效。,18403,1697,20100,,
b93a5cb8-bad0-478d-b9d7-98ef50b97f8b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus johnsonii"", ""strain_id"": ""La1""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 6.5–7.0 (optimal); Nutritional requirements: Lactose, amino acids, vitamins; Tolerance to bile: 0.1% bile acid; Tolerance to gastric juice: pH 2.0",Doubling time: ~1.5–2 h in vitro; In vivo: transient colonization with rapid turnover (4 days post-administration),"Human intestinal epithelium (Caco-2, HT-29 cells); Mucus layer; Colon",Competitive exclusion of pathogenic bacteria; Indirect promotion of Bifidobacterium and Lactobacillus; No significant disruption of native microbiota,High resistance to simulated gastric juice (pH 2.0) and bile acid; Survives 30 min gastric + 60 min bile exposure (>40% survival); Tolerant to lyophilization and rehydration (implied by product use),"Lipoteichoic acid (LTA), cell wall components","Lactobacillus johnsonii La1 is a facultative anaerobe capable of surviving harsh gastrointestinal conditions, adhering to intestinal epithelial cells, and transiently colonizing the human gut. It thrives at 37°C and neutral to slightly acidic pH, with high tolerance to bile and gastric acid. It exhibits strong adhesion to Caco-2 and HT-29 cells, enabling effective interaction with the intestinal mucosa. After ingestion, it persists in the gut for up to 4 days before being shed with epithelial turnover, indicating transient but effective colonization.",RAPD-PCR for strain identification; No genetic modification reported,Not applicable (no engineered modifications),"Constitutive (natural expression of adhesion, acid production, antimicrobial substances)",None (natural regulation),Chromosomal stability; No plasmid-based systems; No evidence of genetic drift or instability in vivo,Stable in fermented milk matrix; No degradation during storage or transit,"Lactobacillus johnsonii La1 is a naturally occurring probiotic strain with no reported genetic modifications. Its beneficial functions are driven by native genes encoding adhesion molecules (e.g., lipoteichoic acid), acid production (lactic acid), and antimicrobial substances. The strain is identified in feces using strain-specific RAPD-PCR, confirming its viability and persistence in the gut without engineered circuits.","[""pH"", ""Bile acids"", ""Gastric juice (low pH)""]","[""Lactose"", ""Glucose"", ""Lactic acid""]",,,"Lipoteichoic acid (LTA), gangliotri- and gangliotetra-osylceramides (asialo-GM1) on Caco-2 cells",No synthetic logic gates; natural sensing via receptor-ligand interaction (LTA–asialo-GM1) for adhesion; pH-dependent metabolic activity,"Lactobacillus johnsonii La1 senses environmental cues such as low pH and bile acids via its cell wall components. It adheres to intestinal epithelial cells through specific receptor-ligand interactions between its lipoteichoic acid and host gangliosides (asialo-GM1). This adhesion is a key step in colonization and is enhanced under physiological conditions. The strain also senses lactose and glucose in the gut, triggering lactic acid production. No synthetic logic circuits are involved; all responses are naturally regulated.","[""Antibacterial"", ""Metabolic Regulation"", ""Tissue Repair"", ""Immunomodulation""]","Secretion via general secretion pathways (e.g., Sec-dependent); no specific secretion systems reported",Dose-dependent effects: 1×10⁹ CFU/day; effects observed within 3–4 days of ingestion,Highly compatible with fermented milk matrix; stable during storage and transit; no structural disruption observed,True,True,False,"Secretes non-bacteriocin antimicrobial substances effective against Salmonella typhimurium, Listeria monocytogenes, Pseudomonas aeruginosa, and other pathogens.",Non-bacteriocin antimicrobial substances,True,True,True,True,"The strain produces broad-spectrum antimicrobial substances that inhibit pathogens without harming beneficial bacteria like Bifidobacterium and Lactobacillus. It reduces lecithinase-positive Clostridium, a harmful bacterium associated with carcinogenic enzymes. No cytotoxicity or microbiome disruption reported.",False,Not applicable,None,False,False,False,No evidence of oxygen production or oxygenation activity.,True,"Activates natural killer cells, enhances IgA synthesis, modulates cytokine production, and induces strain-specific immune signals via interaction with intestinal epithelial cells.","Lipoteichoic acid (LTA), secreted immunomodulatory factors",True,"Promotes intestinal peristalsis and defecation frequency via SCFA production (e.g., butyric acid), which serves as an energy source for colonocytes and enhances motility.","Short-chain fatty acids (SCFAs), particularly butyric acid",True,"Produces lactic acid and other SCFAs, lowers fecal pH, and modulates gut metabolism. Promotes growth of beneficial bacteria by creating a favorable acidic environment.","Lactic acid, acetic acid, propionic acid, butyric acid, valeric acid",False,Not applicable,None,GRAS,Transient colonization; no long-term persistence; disappears within 4 days after cessation,Intestinal epithelial turnover (3–4 days),Non-pathogenic; no antibiotic resistance genes reported; no horizontal gene transfer risk; safe for human consumption (Shu et al. 1999); no environmental escape risk due to transient nature,Fermented milk matrix provides physical and chemical protection; no engineered containment needed,"Lactobacillus johnsonii La1 is classified as GRAS (Generally Recognized As Safe). It does not persist in the gut beyond 4 days, eliminating long-term colonization risks. It shows no pathogenicity, antibiotic resistance, or potential for horizontal gene transfer. Its transient nature ensures safety, and it is naturally adapted to the human gut environment.","Ingestion of fermented milk containing L. johnsonii La1 significantly increased fecal Bifidobacterium (from 11.0% to 18.0%) and Lactobacillus (from 10⁵·³ to 10⁷·¹ CFU/g), reduced lecithinase-positive Clostridium (from 55% to 14%), increased fecal lactic acid (from 0.031 to 0.208 mg/g), lowered fecal pH (from 7.66 to 7.17), and improved defecation frequency in constipated subjects (from 3.8 to 5.7 times/week). The strain was detected in all subjects during the test period and disappeared within 4 days after cessation, confirming transient colonization and safety. These changes indicate significant improvement in intestinal microflora, metabolic environment, and bowel function.",17415,2175,19590,,
a84229dc-633f-4a3f-9e0f-09d18ee04eea,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""FM-B11""}]",Suspension (in drinking water),Facultative Anaerobe,Optimal growth in the avian gastrointestinal tract; tolerant to pH and bile in the gut; utilizes available carbohydrates in poultry feed,"Rapid colonization and growth in the gut within 3 days of administration; no specific doubling time reported, but effective within short-term treatment window","Intestinal tract (gastrointestinal tract) of turkeys, particularly in the ceca and small intestine",Competitive exclusion of pathogenic bacteria; promotes dominance of beneficial microbiota; no significant disruption of native microbiome reported,Tolerant to storage and transport in commercial formulation; stable in drinking water for 3 days; resistant to gastric acidity and bile salts,Cell wall components and metabolic adaptations of Lactobacillus spp.,该乳酸杆菌菌株为兼性厌氧菌，可在家禽肠道内快速定植并生长，对胃酸和胆汁具有较强耐受性，能有效利用饲料中的碳源，在3天内完成初步定植，适用于商业化饮水给药方式。,,,,,No genetic modifications reported; strain is a naturally occurring commercial probiotic culture with inherent stability in the gut environment,Stable in drinking water formulation; no reported degradation or loss of viability during 3-day administration,该菌株为未经基因改造的天然商业益生菌，通过自然定植和竞争性排斥机制发挥作用，未使用任何基因编辑工具或合成生物学元件。,"[""pH"", ""Bile""]","[""Carbohydrates"", ""Lactate""]",,,Unknown (natural sensing mechanisms of Lactobacillus spp. in gut environment),No engineered logic gates; relies on natural metabolic and colonization responses,该菌株通过感知肠道内的pH变化和胆汁环境，以及利用可发酵碳水化合物，实现自然定植与生长，无人工设计的逻辑控制回路。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Passive diffusion and cell lysis (natural release of metabolites),Controlled by administration schedule (3 days at placement and move-out); dose fixed at 10^6 CFU/mL in drinking water,Compatible with drinking water delivery system; stable in liquid formulation for 3 days,True,False,False,"Competitive exclusion of pathogenic bacteria via colonization resistance and production of organic acids (e.g., lactic acid) that lower gut pH",Lactic acid,False,True,True,True,通过竞争性定植和产酸降低肠道pH，有效抑制病原菌生长，未报告对宿主细胞或正常菌群造成显著毒性或破坏。,False,,,False,False,False,,True,Modulates host immune response by enhancing mucosal immunity and reducing systemic inflammation through interaction with gut-associated lymphoid tissue (GALT),"Cell wall components (e.g., peptidoglycan, teichoic acids), secreted metabolites",True,Promotes intestinal epithelial integrity and barrier function by stimulating mucus production and tight junction protein expression,"Mucus, tight junction proteins (e.g., occludin, claudin)",False,,,False,,,GRAS,"None (naturally occurring, non-pathogenic strain)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape concerns due to lack of persistence outside host,None (no physical confinement used; delivered via drinking water),FM-B11为经批准的GRAS（公认安全）菌株，无致病性、无耐药基因，不具环境持久性，通过饮水给药后在宿主体内自然清除，安全性高。,在118个商业肉用火鸡群中，使用FM-B11益生菌显著提高了市场体重（增加190克）和平均日增重（增加1.63克），降低了每公斤活禽的生产成本（从59.90美分降至58.37美分）。对历史表现中等和较差的农场效果尤为显著，而表现优异的农场未见明显改善，表明其主要在健康状况较差的群体中发挥调节作用。,5771,1557,7328,,
5ccb6218-fa12-4363-9613-274456924fe0,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus salivarius"", ""strain_id"": ""K12""}]",Suspension (oral lozenge delivery),Facultative Anaerobe,"Optimal growth at 37°C, pH 7.0–7.5; utilizes glucose, fructose, lactose, maltose, trehalose, raffinose, inulin, and other carbohydrates; no hemolytic activity on human or sheep blood agar; grows on MitisSalivarius agar.",No specific doubling time reported; stable growth in vitro over 15 years of storage and repeated subculturing.,"Oral cavity (pioneer colonizer of infants, mucosal surfaces of healthy individuals)",No significant disruption of oral microbiota; does not inhibit commensal streptococci or other major oral taxa; may displace pathogenic strains via bacteriocin production.,"Stable after 15-year storage at -70°C, repeated in vitro propagation, and commercial freeze-drying; no loss of metabolic or genetic stability.",Lyophilization (freeze-drying) process preserves viability and phenotype.,该菌株为口腔黏膜的定植先锋菌，可在37℃、pH 7.0–7.5条件下生长，利用多种碳源（如葡萄糖、果糖、乳糖、麦芽糖等），无溶血活性，可在MitisSalivarius培养基上生长。其代谢和遗传特性在长期保存、反复传代及商业化冻干后保持稳定，表明其在体外环境中具有良好的生理稳定性。,,,,,No plasmid-based systems used; chromosomal stability confirmed over 15 years of storage and repeated subculturing; no detectable genetic drift.,Stable in freeze-dried lozenge formulation; maintains phenotype during storage and rehydration.,该菌株未经过人工基因改造，其功能特性（如产生类细菌素）为天然固有属性，未引入外源质粒或基因编辑工具，遗传稳定性高。,,,,,,,该菌株未报道具有人工设计的感应模块，其功能响应依赖于天然代谢和定植行为，无明确的逻辑控制或信号感应机制。,"[""Antibacterial""]",Bacteriocin secretion (likely via general secretion pathway or lantibiotic-specific export),Natural expression of bacteriocins; dosage controlled by colonization level and host environment.,Compatible with freeze-dried lozenge formulation; maintains viability and function upon rehydration.,True,True,False,通过产生类细菌素（lantibiotic bacteriocins）抑制病原菌，特别是对化脓性链球菌（S. pyogenes）和引起口臭的细菌具有显著抑制作用。,Lantibiotic bacteriocins (BLIS K12),True,True,True,True,该菌株对S. pyogenes和多种口臭相关菌株具有广谱抑制活性；在人体试验中未引起不良反应，且在口腔内局部定植，未造成微生物群落失衡，表明其活性可控且安全。,False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,"None (naturally occurring, non-pathogenic strain)",,"No virulence genes detected (sagA, scpA, smez-2, speB, emm); no hemolytic activity; intrinsic resistance to gentamicin and ofloxacin is low and common in wild-type S. salivarius; no horizontal gene transfer risk reported; no pathogenicity in healthy humans.",Physical barrier provided by oral mucosa and natural clearance mechanisms.,该菌株为天然存在于健康人唾液中的非致病性菌株，未检测到已知的毒力基因，无溶血活性，对多种抗生素敏感，且在人体试验中未引起任何不良反应。其遗传和代谢特性稳定，长期储存和反复传代后无变异，表明其具有极低的生物安全风险，符合GRAS（公认安全）标准。,在为期3天的口服试验中，14名受试者均未出现不良症状；S. salivarius K12在口腔内成功定植，且在停药后1个月仍可在部分个体中检测到具有K12样抑菌活性的菌株，表明其具有良好的定植能力和持续的抗菌效果。,9104,1585,10689,,
bbe5393c-b14d-41b9-8a67-cf2bb364d40f,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis subsp. lactis"", ""strain_id"": ""Ll2""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus sp. SJ-10"", ""strain_id"": ""BSJ-10""}, {""role"": ""Helper"", ""scientific_name"": ""Bacillus clausii"", ""strain_id"": ""BC""}, {""role"": ""Helper"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""FGL0001""}]",Encapsulated,Facultative Anaerobe,"Temperature: 25–30°C; pH: 6.5–7.5; Carbon sources: Glucose, FOS, inulin, MOS, BGO; Nutritional requirements: Amino acids, vitamins, minerals","Doubling time: ~20–30 min in vitro; Growth rate: High in vitro; In vivo homeostasis: Moderate, dependent on host gut environment",Intestinal mucosa of olive flounder (Paralichthys olivaceus); Gut lumen and mucus layer,"Competitive exclusion of pathogens (e.g., Vibrio spp., Streptococcus spp.); Symbiotic interaction with host immune system; Modulates gut microbiota composition","Tolerance to gastric pH (pH 2–3), bile salts, osmotic stress; Stable during feed storage (up to 6 months); Resistant to lyophilization and rehydration","Peptidoglycan (Bacillus spp.), Teichoic acid (Lactococcus spp.), Exopolysaccharides (Bacillus clausii)",该微生物系统由多种革兰氏阳性菌组成，包括乳酸乳球菌（Lactococcus lactis subsp. lactis Ll2）、芽孢杆菌（Bacillus sp. SJ-10）和乳酸杆菌（Lactobacillus plantarum FGL0001）。这些菌株在25–30°C、pH 6.5–7.5的条件下生长良好，可利用葡萄糖、果寡糖（FOS）、菊粉、甘露寡糖（MOS）和β-葡聚糖寡糖（BGO）作为碳源。它们在鱼类肠道中定植，通过竞争排斥病原体并调节宿主免疫系统，实现共生关系。对胃酸、胆汁、渗透压和冻干/复水等环境压力具有较强耐受性，适合在饲料中长期储存和应用。,"CRISPR-Cas9 (for antigen cloning), Recombinant plasmid transformation (e.g., pUC19-based vectors)",High efficiency (>90%) for antigen integration; Low off-target risk due to targeted integration into chromosomal loci,"Constitutive (e.g., P15A promoter), Inducible (e.g., IPTG-inducible in Ll2 for antigen expression)","IPTG (Isopropyl β-D-1-thiogalactopyranoside), P15A promoter",High plasmid stability (copy number: 10–20); Chromosomal integration confirmed; Low metabolic burden; Evolutionary stability observed over 30-day feeding trials,"Stable in feed matrix (pellets, gel); No significant degradation during encapsulation or storage",通过CRISPR-Cas9技术将病原体抗原（如S. iniae的SiMA蛋白、E. tarda的OmpA和FlgD蛋白）整合至Lactococcus lactis BFE920（LLB）和L. plantarum FGL0001的基因组中，构建口服疫苗。使用P15A启动子实现抗原的组成型表达，IPTG可诱导表达。系统在饲料中稳定存在，无显著代谢负担，长期喂养后仍保持功能活性。,"[""pH"", ""Osmotic stress"", ""Bile acids""]","[""Glucose"", ""FOS"", ""MOS"", ""BGO""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines (TNF-α, IL-1β, IL-6)""]","FNR promoter (hypoxia), Lactose permease (lactose), P15A promoter (constitutive), TLR2/4 (host pattern recognition)",AND gate: Requires both prebiotic (BGO) and probiotic (Ll2/BSJ-10) presence for optimal growth; Threshold: BGO concentration >0.1% triggers immune gene expression; Noise suppression via quorum sensing (AHL/AI-2) feedback,系统通过感知肠道中的预生物（如BGO）和宿主免疫信号（如TNF-α、IL-1β）实现逻辑控制。当预生物浓度超过0.1%且宿主炎症信号存在时，激活免疫调节基因表达。通过AHL和AI-2介导的群体感应实现信号放大与噪声抑制，确保在病原体入侵时精准响应，避免过度免疫反应。,"[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]","Type III Secretion (Ll2), Lysis (BSJ-10), Vesicles (Extracellular vesicles)",Dose-dependent response; Controlled by feed concentration (1×10⁶–1×10⁸ CFU/g); Persistence: Up to 30 days in gut,High compatibility with feed pellets and encapsulation matrices; No structural disruption observed,True,True,True,分泌乳酸、过氧化氢、细菌素（如Nisin Z）和抗菌肽（AMPs），破坏病原体细胞膜；抑制生物膜形成；通过竞争性定植阻止病原体附着。,"Nisin Z, Lactic acid, Hydrogen peroxide, Bacteriocins",True,True,True,True,在体外实验中，Ll2和BSJ-10对S. iniae、E. tarda、Vibrio spp.等常见病原体具有广谱抑制作用；在饲料中添加后，显著降低生物膜形成；无明显组织损伤或微生物群落失衡，表明局部作用且安全。,False,,,,,,,True,通过MAMPs（如肽聚糖、脂磷壁酸）激活DCs和TLRs，诱导TNF-α、IL-1β、IL-6、IFN-γ等促炎因子转录；同时调节Treg相关基因（FOXP3、IL-10、TGF-β）实现免疫平衡。,"TNF-α, IL-1β, IL-6, IFN-γ, FOXP3, IL-10, TGF-β",True,促进肠道上皮细胞增殖；增强黏膜屏障功能；上调紧密连接蛋白（claudin）表达，降低肠道通透性；促进伤口愈合。,"Claudin, Growth factors (e.g., EGF), Mucin",True,发酵预生物产生短链脂肪酸（SCFAs，如乙酸、丙酸、丁酸），通过GPR41/43受体调节宿主代谢与免疫。,"Acetic acid, Propionic acid, Butyric acid",False,,,GRAS,"Auxotrophy (e.g., amino acid auxotrophy), Temperature-sensitive kill switch (e.g., ccdB toxin under 37°C)","Amino acid auxotrophy (e.g., leucine), ccdB toxin system",Low pathogenicity; No known virulence genes; No antibiotic resistance genes detected; No horizontal gene transfer observed; Low environmental escape risk due to poor survival outside host,Feed pellet encapsulation prevents environmental release; No free-floating cells in water,该系统由多种GRAS级微生物组成，无致病性基因或抗生素抗性基因。通过氨基酸营养缺陷型和温度敏感性自杀基因实现生物遏制，确保在非宿主环境中无法存活。饲料包埋进一步防止环境释放，整体风险极低。,在8–16周的喂养试验中，合成益生菌组（如Ll2 + BGO、BSJ-10 + BGO）显著提高体重增长（WG）15–38%，饲料利用率（FUP）提升20%以上，血清溶菌酶（LZs）和呼吸爆发（RB）活性显著增强。对链球菌病（Streptococcosis）和爱德华氏菌病（Edwardsiellosis）的挑战试验中，存活率提高至65.7%（对照组仅5.7%），免疫基因（TNF-α、IL-6、IFN-γ）表达上调，肠道屏障功能改善，表明其在促进鱼类生长、增强免疫力和疾病抵抗方面具有显著疗效。,17628,2606,20234,,
c421efff-711d-4b7e-b5df-6c4e4ab3e613,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""ATCC PTA 5289 & DSM 17938""}]",Lozenge (Oral administration),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerant to bile salts and gastric acidity; requires carbohydrates (e.g., glucose) and amino acids for growth.",Doubling time ~60–90 minutes in vitro; stable in oral environment with moderate in vivo persistence.,"Oral cavity, particularly gingival crevices and mucosal surfaces; preferentially colonizes sites with low oxygen tension and moderate inflammation.",Competitive exclusion of periodontopathogens via production of reuterin and lactic acid; no significant disruption of commensal microbiota observed.,"Tolerant to drying, moderate temperature fluctuations, and short-term exposure to shear stress; stable during lyophilization and rehydration.","Reuterin (antimicrobial compound), exopolysaccharides (EPS)",该菌株为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下生长，对胃酸和胆盐具有耐受性，依赖葡萄糖等碳源及氨基酸生长。在口腔环境中可定植于牙龈沟和黏膜表面，尤其偏好低氧和轻度炎症环境，具有良好的稳定性和耐受性。,"None (Natural strain, no genetic modification reported)",Not applicable,Constitutive (No inducible circuits reported),,High chromosomal stability; no plasmids used; no reported genetic drift in clinical setting.,Stable in lozenge matrix; no significant degradation or loss of viability during storage and dissolution.,该系统未进行基因工程改造，使用天然双菌株L. reuteri ATCC PTA 5289与DSM 17938，通过口服洛津递送，无需外源调控元件，具有天然遗传稳定性。,"[""pH"", ""Lactate"", ""Oxygen (Hypoxia)""]","[""Glucose"", ""Bile acids""]","[""Quorum sensing molecules (e.g., AI-2)""]","[""Proteases (e.g., MMP-8)"", ""Cytokines (e.g., IL-1β, TNF-α)""]","FNR-like promoter (hypoxia sensing), Lactate permease (lactate sensing), Bile acid transporter (bile sensing)",Constitutive expression; no complex logic gates; threshold-based response to environmental cues.,该系统依赖于天然代谢感应机制，通过pH、乳酸、氧浓度等环境信号触发基因表达，无人工逻辑门控，但具有阈值响应能力，可在炎症微环境中实现动态适应。,"[""Immunomodulation"", ""Tissue Repair""]","Constitutive secretion via general secretory pathway (Sec), no lysis or vesicle release reported.",Dose-controlled via lozenge consumption (2×/day); activity proportional to colonization level.,Highly compatible with lozenge matrix; maintains viability and function during dissolution and oral exposure.,False,False,False,No direct antibacterial activity observed against periodontopathogens.,,False,False,False,False,未观察到对牙周致病菌的抑制作用，无生物膜抑制证据。,False,No oxygen-producing mechanism reported.,,False,False,False,未发现该菌株具有产氧能力，不参与局部氧合。,True,"Reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-8, MMP-8) and increases anti-inflammatory markers (TIMP-1).","Reuterin, Lactic acid, Exopolysaccharides (EPS)",True,Promotes periodontal tissue regeneration by reducing inflammation and enhancing epithelial barrier function.,"Reuterin, Lactic acid, IL-10",False,No evidence of metabolic regulation via SCFAs or tryptophan metabolites.,,False,No anti-tumor activity reported.,,GRAS,"None (Natural strain, no kill-switch or auxotrophy reported)",,"Non-pathogenic, no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk.",Lozenge matrix provides physical confinement; limited systemic absorption.,该菌株为公认安全（GRAS）菌株，无致病性、无耐药基因，不依赖人工生物遏制策略，通过口服洛津递送实现物理隔离，安全性高。,在24周时，益生菌洛津组的探诊深度（PPD）显著低于对照组（2.64±0.33 mm vs 2.92±0.42 mm），尤其在中度（4–6 mm）和深部（≥7 mm）袋中差异更显著。益生菌组有67%的深袋从≥4 mm改善至≤3 mm，且需要手术的位点比例显著降低（45% vs 8%），表明其在促进牙周组织愈合和减少手术需求方面具有显著临床疗效。,18558,1753,20311,,
8bcfa292-f3aa-43ba-bd19-b2ffab8e3b27,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus kefiranofaciens"", ""strain_id"": ""M""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus kefiri"", ""strain_id"": ""K""}]",Oral administration (gastrointestinal tract),Facultative Anaerobe,Growth at 30–37°C in MRS broth; optimal growth at 37°C; pH tolerance not explicitly stated; requires lactose or other fermentable carbohydrates as carbon source.,Doubling time not reported; cultured for 24 hours in MRS broth to reach ~10^9 CFU/mL.,"Intestinal lumen, particularly in the context of gut microbiota modulation and enteroendocrine cell interaction.","Modulates intestinal microbiota by increasing Lactobacillus and Bifidobacterium, decreasing Clostridium perfringens; promotes symbiotic balance.",Stable during freezing at -20°C with 20% glycerol; survives oral administration and gastrointestinal transit.,Glycerol (cryoprotectant),两种乳酸菌均为兼性厌氧菌，可在30–37°C下生长，以MRS培养基为营养来源，经冷冻保存后仍保持活性，适用于口服给药。,16S rDNA sequencing for identification; no genetic modification reported.,Not applicable (no genetic engineering performed).,Constitutive (no inducible circuits reported).,,No plasmid or chromosomal integration reported; natural strains used without engineered stability markers.,No engineered material coupling; natural strains used in oral delivery.,未对菌株进行基因改造，仅通过16S rDNA测序鉴定其种属，利用其天然功能进行筛选和应用。,"[""pH"", ""Glucose"", ""Osmotic stress (via gut environment)""]","[""Short-chain fatty acids (SCFAs)"", ""Lactose (carbon source)""]","[""Peptidoglycan (from Gram-positive bacteria)"", ""Lipoteichoic acid""]","[""Toll-like receptor 2 (TLR2)"", ""Cytokines (IL-1β, TNF-α, IL-6)""]","TLR2 receptor (host), peptidoglycan/lipoteichoic acid recognition (bacterial surface components)",No synthetic logic circuits; natural sensing via TLR2 and metabolic feedback.,菌株通过识别宿主TLR2受体及自身细胞壁成分（如肽聚糖、脂磷壁酸）感知宿主免疫状态，进而调节GLP-1分泌，但该过程不依赖TLR2信号通路。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]",Passive secretion via natural metabolic pathways; no engineered secretion systems reported.,Oral administration at 1×10^8 CFU/day; dose-dependent effects observed in vivo.,Compatible with oral delivery; survives gastrointestinal transit and colonizes gut.,False,,,Not applicable (no antibacterial function reported).,,False,,,,无相关证据,False,Not applicable (no oxygen-producing function reported).,,False,False,False,无相关证据,True,"Inhibits proinflammatory cytokines (TNF-α, IL-1β, IL-6, IL-2) and enhances anti-inflammatory IL-10 in pancreas, spleen, and kidney.","IL-10 (anti-inflammatory cytokine), TNF-α, IL-1β, IL-6 (proinflammatory cytokines)",True,"Reduces β-cell destruction in pancreatic islets, restores islet morphology, and increases β-cell area ratio.","Glucagon-like peptide-1 (GLP-1), insulin (indirectly via β-cell protection)",True,"Enhances GLP-1 secretion, improves glucose homeostasis, reduces fasting blood glucose, and improves glucose tolerance.","Glucagon-like peptide-1 (GLP-1), butyrate (slightly increased)",False,Not applicable (no tumor therapy function reported).,,GRAS,None (natural strains used; no kill-switch or auxotrophy reported).,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned.,Oral administration with natural gut colonization; no physical barrier used.,两种菌株均为食品级安全菌株，未发现致病性、耐药基因或环境逃逸风险，适用于口服益生菌应用。,在STZ诱导的T1D小鼠模型中，口服Lb. kefiranofaciens M和Lb. kefiri K可显著降低空腹血糖水平，改善葡萄糖耐量，减少β细胞破坏，提高胰岛中β细胞比例，并调节免疫反应，抑制促炎因子、促进抗炎因子IL-10的表达，从而延缓T1D进展。,18342,1707,20049,,
3aca48b4-ea22-478b-bfc2-e6f9d4d6ec52,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG (ATCC 53103)""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates mild acidity and bile salts; utilizes lactose and other carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; consistent growth in human intestinal environment in vivo,"Gastrointestinal tract (small intestine and colon), particularly in mucosal layer of infants with atopic dermatitis",Competitive exclusion of pathogenic bacteria; synergistic interaction with host immune system; no significant disruption of native microbiota,Tolerant to lyophilization and rehydration; stable during storage at 4°C; moderate resistance to gastric acid and bile,"Cell wall components (e.g., teichoic acids), extracellular polysaccharides",该菌株为兼性厌氧菌，最适生长温度为37°C，pH 6.5–7.0，可在婴儿肠道黏膜层定植，耐受胃酸和胆盐，具有良好的体外与体内生长一致性，适用于口服制剂。,"Not specified (natural strain, no genetic modification reported)",,Constitutive,,High chromosomal stability; no plasmid-based systems used; no reported metabolic burden or drift in clinical trials,Stable in extensively hydrolyzed formula matrix; no adverse interaction with food components,该菌株为天然分离株，未进行基因改造，其功能依赖于天然代谢与免疫调节能力，遗传稳定性高，适用于食品与临床制剂。,"[""pH"", ""Bile Acids""]","[""Lactose"", ""Glucose""]",,"[""Cytokines"", ""Immune Cell Signals""]","FNR-like regulators, bile acid transporters, sugar permeases",Constitutive expression with feedback modulation via host immune signals; threshold-based immune modulation,该菌株通过感知肠道pH变化和胆汁酸浓度，调节自身代谢与黏附能力；同时响应宿主免疫信号（如细胞因子），实现动态免疫调节，具有阈值响应与负反馈机制。,"[""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion via general secretory pathway; cell wall-associated proteins,Dose-dependent immune modulation; clinical dosing at 10^9–10^10 CFU/day; no evidence of overactivity,High compatibility with extensively hydrolyzed formula; no structural disruption or gas production,False,,,,,,,,,,False,,,,,,,True,"Modulates Th1/Th2 balance, reduces pro-inflammatory cytokines (IL-4, IL-5, IL-13), increases anti-inflammatory IL-10 and TGF-β; enhances regulatory T cell activity","Lactobacillus GG cell wall components, secreted metabolites (e.g., lactic acid, exopolysaccharides)",True,"Promotes intestinal barrier integrity by upregulating tight junction proteins (occludin, ZO-1); enhances mucosal healing and epithelial regeneration","Exopolysaccharides (EPS), surface layer proteins (SlpA)",False,,,False,,,GRAS,"Auxotrophy (no requirement for specific amino acids in vivo), natural attenuation","Lack of essential amino acid biosynthesis genes (e.g., histidine, arginine)",Non-pathogenic; no antibiotic resistance genes detected; no horizontal gene transfer observed; low opportunistic risk in healthy infants,No physical barrier required; natural attenuation in gut environment,"Lactobacillus GG (ATCC 53103) is classified as GRAS, with extensive clinical history in infants and adults. It exhibits low pathogenicity, no antibiotic resistance, and no evidence of environmental escape or HGT. Its auxotrophic nature limits survival outside host environment.",在芬兰的随机双盲对照试验中，接受含Lactobacillus GG的水解配方奶的特应性皮炎伴牛奶过敏婴儿，临床症状显著减轻，肠道和系统性过敏炎症标志物显著降低。在另一项针对牛奶过敏成人的随机双盲交叉研究中也观察到类似效果。,3392,1568,4960,,
057a8118-ee6b-4dad-aecb-c0866228d303,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus bulgaricus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus indicus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus thermophilus"", ""strain_id"": ""Not specified""}]",Oral supplementation (capsule/tablet form),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; utilizes glucose, lactose, and other carbohydrates; requires complex media with vitamins and amino acids",Doubling time ~1–2 hours in vitro; in vivo colonization observed in gut mucosa with transient persistence,"Intestinal mucosa (small and large intestine), particularly in the ileum and colon",Competitive exclusion of pathogenic bacteria; synergistic interactions with host microbiota; may enhance SCFA production,Moderate tolerance to gastric acid and bile salts; stable during lyophilization and storage at 4°C; limited resistance to UV and shear stress,"Bile salts, mucin, and prebiotic fibers (e.g., inulin) enhance survival",这些益生菌多为兼性厌氧菌，适宜在37°C、pH 6.0–7.0的肠道环境中生长，依赖葡萄糖、乳糖等碳源，需复杂培养基提供维生素和氨基酸。在体内可定植于小肠和结肠黏膜，具有短暂定植能力，通过竞争排斥抑制病原菌，促进短链脂肪酸生成，改善肠道微生态平衡。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及任何基因工程改造，所有菌株均为天然存在的益生菌，未进行人工基因编辑或合成回路设计。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""SCFAs"", ""Inulin""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter, Lactate receptor, Bile acid transporter",Not specified,文中未描述任何基因回路或逻辑门控机制，所有功能基于天然菌株的生理响应，无工程化信号整合系统。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Type IV secretion system, Vesicles",Oral administration with fixed dose; no dynamic control,Encapsulated in capsules or tablets; compatible with gastrointestinal transit,False,False,False,Not applicable,Not applicable,False,False,False,False,未涉及抗菌或抗生物膜功能。,False,Not applicable,Not applicable,False,False,False,未涉及氧气生成或氧合功能。,True,通过调节肠道免疫反应，降低促炎因子（如CRP）水平，改善系统性炎症状态。,"C-reactive protein (CRP), IL-10, TGF-β",True,通过增强肠道屏障功能，减少内毒素易位，促进黏膜修复，间接支持组织再生。,"Mucin, tight junction proteins",True,通过产生短链脂肪酸（SCFAs）调节宿主能量代谢，改善胰岛素敏感性，降低血糖和胰岛素水平。,"Short-chain fatty acids (SCFAs), Acetate, Propionate, Butyrate",False,Not applicable,Not applicable,GRAS,None,Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape,Capsule shell provides physical barrier during transit,所有使用菌株均属于公认安全（GRAS）类别，无致病性记录，未发现抗生素抗性基因，且在临床试验中未报告不良事件，安全性良好。,在多中心随机对照试验的系统评价中，益生菌和合生元补充显著降低多囊卵巢综合征女性的空腹血糖（-2.52 mg/dL）、胰岛素（-2.27 μIU/mL）、胰岛素抵抗指数（-0.69）、C反应蛋白（-1.69 Hedges’）和总睾酮（-0.12 ng/mL），提示其在改善糖代谢、炎症和激素水平方面具有显著疗效。,9357,1924,11281,,
926e8a0d-5101-4624-b822-2b542a1ea984,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus salivarius subsp. thermophilus"", ""strain_id"": """"}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral; Osmotic: Moderate; Nutrition: Complex media with glucose, amino acids, vitamins",Growth rate: Not specified; Doubling time: Not specified; In vivo vs In vitro: Not directly compared,"Nasal mucosa (prophylactic delivery), gastrointestinal tract (natural habitat)",Modulates immune response without significant competition or symbiosis described; potential for immune tolerance induction,Freeze-dried stability; sonication-resistant; tolerance to PBS and freezing/thawing cycles,Lyophilization and sonication protocols,"VSL#3 is a freeze-dried mixture of 8 Gram-positive bacterial species, including Lactobacillus and Bifidobacterium strains, which are normal components of the human gastrointestinal microflora. The consortium is stable in suspension and can be reconstituted in PBS for in vitro and in vivo use. It exhibits robust survival under freeze-thaw and sonication conditions, indicating high physical stability. The bacteria are facultative anaerobes, capable of growth under both aerobic and anaerobic conditions, and are adapted to the human gut environment. The consortium is used in a prophylactic intranasal delivery model to avoid colonization, suggesting limited mucosal persistence.","Not applicable (natural mixture, no genetic modification reported)",Not applicable,Not applicable,Not applicable,Not applicable (no plasmid or chromosomal integration described),Not applicable,"VSL#3 is a naturally occurring, non-genetically modified consortium of 8 bacterial species. No genetic tools or engineering strategies were used in this study. The mixture is used in its native form, either live or sonicated, without any modification. The immunomodulatory effects are attributed to the collective activity of the native bacterial components and their secreted or structural molecules.","[""pH"", ""Osmotic stress""]","[""Glucose"", ""Amino acids""]",,"[""Cytokines (IL-10, IFN-γ)"", ""Immune cell receptors (DCs, T cells)""]","Unknown (natural bacterial surface molecules, PAMPs such as peptidoglycan, lipoteichoic acid, and bacterial DNA)",No engineered logic gates; natural immune recognition via pattern recognition receptors (PRRs) such as TLRs and NLRs,"The consortium functions through innate immune recognition via pathogen-associated molecular patterns (PAMPs) on bacterial surfaces. These are detected by pattern recognition receptors (PRRs) on dendritic cells and macrophages, triggering downstream signaling cascades (e.g., NF-κB, STAT pathways). The response is not programmable but is a natural, conserved immune activation mechanism. The outcome is a shift toward a Treg/Th0 profile, characterized by increased IL-10 and IFN-γ, without inducing a strong Th1 response. This suggests a balanced, context-dependent immune modulation rather than a synthetic logic circuit.","[""Immunomodulation""]",Passive release of PAMPs and soluble factors upon lysis (sonication); natural secretion of immunomodulatory molecules,Dose-dependent effects observed at 10^7 bacteria; optimal dose selected for IL-10 induction,Compatible with PBS suspension and intranasal delivery; sonicated preparation maintains immunomodulatory activity,False,False,False,Not applicable,,False,False,False,False,Not applicable,False,Not applicable,,False,False,False,Not applicable,True,"Induces maturation of dendritic cells and shifts immune responses from Th2 to Treg/Th0 profile by increasing IL-10 and IFN-γ production. Suppresses allergen-induced IL-5 and IL-13, reduces IgG1, and enhances regulatory T cell activity.","Bacterial PAMPs (e.g., peptidoglycan, lipoteichoic acid, DNA), IL-10, IFN-γ",False,Not applicable,,False,Not applicable,,False,Not applicable,,GRAS,"None (natural mixture, no kill-switch or auxotrophy reported)",None,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; low risk of environmental escape due to non-colonizing delivery route,Physical confinement via intranasal delivery and sonication prevents live colonization,"VSL#3 is a well-established, non-pathogenic probiotic mixture composed of 8 species naturally found in the human gut. It is classified as GRAS (Generally Recognized As Safe). The study used a sonicated (inactivated) preparation to prevent nasal colonization, minimizing risks of persistence or unintended ecological impact. No genetic modifications or antibiotic resistance genes were involved. The delivery route (intranasal) and inactivation method (sonication) provide effective physical containment. Overall, the risk profile is very low.","In vivo prophylactic intranasal treatment with sonicated VSL#3 significantly reduced allergen-specific IgG1 levels and markedly suppressed IL-13 and IL-4 mRNA expression in lung tissue, while increasing IL-10 expression. This indicates effective modulation of Th2-biased allergic responses at the local (lung) level without inducing a Th1 response. The immunomodulatory effect was observed both in vitro and in vivo, with the sonicated preparation retaining full activity, suggesting that live bacteria are not required for efficacy. The results support the potential of VSL#3 as a safe and effective prophylactic agent for allergic diseases.",15660,2066,17726,,
a2262ad3-82b4-4a09-9fbc-b703820985c9,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG (ATCC 55103)""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Bb12""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""W23""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""W52""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""W58""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""BGN4""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""AD011""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""LP+""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""ATCC BAA-999""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""ST11+""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""AD031""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, tolerant to bile salts and low pH (gastric conditions), requires complex media with carbohydrates (e.g., lactose, glucose) and amino acids",Doubling time ~1–2 hours in vitro; in vivo colonization observed in intestinal tract with moderate persistence,"Intestinal mucosa, particularly in the small intestine and colon",Competitive exclusion of pathogenic bacteria; potential symbiosis with host microbiota through SCFA production and immune modulation,Moderate tolerance to drying and storage; sensitive to high UV and shear stress; lyophilization improves stability,"Trehalose, skim milk, and glycerol in lyophilization matrix",这些益生菌株均为兼性厌氧菌，适宜在37°C、pH 6.0–7.0的环境中生长，对胃酸和胆盐具有一定的耐受性，依赖于乳糖、葡萄糖等碳源及氨基酸等营养物质。在肠道黏膜上定植，具有中等持久性，可通过竞争排斥抑制病原菌，与宿主微生物群产生协同作用。,Not specified,null,null,null,null,null,文中未提及任何基因工程改造，所有菌株均为天然分离或商业来源的益生菌，未进行人工遗传修饰。,"[""pH"", ""Bile Acids"", ""Glucose""]","[""Lactate"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter, Lactate receptor, Bile acid sensor (Bacillus-type), Quorum sensing receptors (LasR, LuxR homologs)",No explicit logic gates described; likely constitutive or environment-responsive regulation based on nutrient availability and host signals,这些菌株通过感知肠道内的pH、胆汁酸、乳酸和短链脂肪酸等代谢物，以及宿主蛋白酶和细胞因子等信号分子，调节自身代谢与免疫调节功能。部分菌株可能通过群体感应系统感知微生物密度，但未明确描述逻辑门控机制。,"[""Immunomodulation"", ""Metabolic Regulation""]","Type I secretion (e.g., for cytokines), Vesicles (exosomes), Lysis (in some strains)",Not controllable; dosage depends on administration schedule and viability,"Compatible with oral formulations (capsules, powders); not encapsulated in biomaterials in this context",False,False,False,null,null,False,False,False,False,未提及抗菌或抗生物膜功能。,False,null,null,False,False,False,未提及产氧功能。,True,通过调节Th1/Th2平衡、诱导Treg细胞分化、抑制促炎细胞因子（如IL-4、IL-5、IL-13）释放，增强肠道屏障功能，从而预防过敏性皮炎。,"IL-10, TGF-β, Treg-inducing factors",False,null,null,True,通过发酵碳水化合物产生短链脂肪酸（如乙酸、丙酸、丁酸），调节宿主能量代谢、肠道屏障功能和免疫稳态。,"Short-chain fatty acids (SCFAs), especially butyrate",False,null,null,GRAS,None,null,Low pathogenicity; no antibiotic resistance genes reported in major strains; low risk of horizontal gene transfer; no evidence of environmental escape,Oral administration provides natural barrier; no physical confinement used,所有菌株均为公认安全（GRAS）级别，无致病性，未发现耐药基因，水平基因转移风险极低。由于为口服给药，具有天然屏障，安全性较高。,在高风险婴儿中，益生菌混合物可显著降低湿疹发生风险（相对风险RR=0.54，95%CI: 0.43–0.68），主要归因于免疫调节和代谢调控作用，但因菌株异质性强，结果存在显著异质性，尚不足以支持广泛推荐。,4621,1953,6574,,
80a8af89-07d5-4672-85ab-be82e63e2a36,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in whey medium, pH 4.8–5.8; optimal growth at pH 5.8; adapted to stable low pH conditions.",Specific growth rate reduced by ~30% at pH 4.8 compared to pH 5.8; mid-exponential and late exponential phases analyzed at 4h/12h (pH 5.8) and 4h/14h (pH 4.8).,"Gastrointestinal tract (GIT), particularly ileum and colon; transient colonization ability.",Transient colonization of host GIT; potential modulation of host immune response; no direct competition or symbiosis with other microbiota described.,Tolerates acid stress (pH 4.8–5.8); maintains viability under industrial and gastrointestinal pH conditions; moderate tolerance to osmotic and ionic stress via industrial whey medium.,"F0F1-ATP synthase (for pH homeostasis), phosphoketolase (xfp), Clp proteases (ClpP, ClpX, ClpE), and surface antigen LGG_02016.","Lactobacillus rhamnosus GG is a facultative anaerobe capable of surviving in acidic environments, including industrial fermentation (pH ~4.5–5.8) and the human gastrointestinal tract (pH 2–7). It exhibits reduced growth rate under low pH (pH 4.8) but maintains viability through adaptive proteomic and metabolic responses. Growth is optimized at pH 5.8, with significant physiological adaptation observed at pH 4.8.",Not applicable (no genetic modification reported in this study),,Not applicable,,Not applicable (no engineered plasmids or integration reported),Not applicable,No genetic engineering was performed in this study. The strain was used in its native form for proteomic and transcriptomic analysis under controlled bioreactor conditions.,"[""pH (4.8 vs 5.8)"", ""Hypoxia (implied by anaerobic growth)"", ""Lactate (end-product of fermentation)""]","[""Pyruvate"", ""Glucose (via glycolytic flux)"", ""Nucleotides (pyrimidine/purine biosynthesis intermediates)""]","[""Autoinducer-2 (AI-2) via LuxS""]","[""None reported""]","F0F1-ATP synthase (pH sensing), LuxS (AI-2 production), Clp proteases (stress sensing), and phosphorylation of glycolytic enzymes (e.g., GapA, Pyk, TpiA) as regulatory sensors.",No synthetic logic circuits; natural regulatory logic inferred from differential expression and phosphorylation patterns: upregulation of ATPase and stress proteins under low pH; downregulation of nucleotide and protein synthesis pathways.,"L. rhamnosus GG senses pH via membrane potential and proton influx, triggering a cascade of responses including upregulation of F0F1-ATP synthase to maintain intracellular pH, modulation of glycolytic flux via phosphorylation of enzymes like pyruvate kinase and glyceraldehyde-3-phosphate dehydrogenase, and suppression of nucleotide and protein synthesis under acid stress. The phosphorylation of central metabolic enzymes acts as a post-translational regulatory switch to redirect metabolic flux.","[""Acid Stress Response"", ""Metabolic Regulation"", ""Protein Homeostasis""]",Not applicable (no engineered secretion system reported),Not applicable,Not applicable,False,,,Not applicable (no antibacterial function engineered or reported),,False,False,False,False,No antibacterial activity reported or engineered.,False,Not applicable (no oxygenation mechanism reported),,False,False,False,No oxygenation function observed or engineered.,False,Not applicable (no immunomodulatory effect directly measured in this study),,False,Not applicable (no tissue repair function reported),,True,"L. rhamnosus GG modulates pyruvate metabolism and central carbon metabolism in response to pH. At low pH, glycolytic enzymes (e.g., pyruvate kinase, GAPDH) are phosphorylated, altering flux. Nucleotide biosynthesis (pyrimidine/purine) is downregulated, while ATP synthase and stress proteins are upregulated.","Pyruvate, lactate, ATP, nucleotides (UTP, CTP, GTP, ATP), and phosphorylated glycolytic intermediates",False,Not applicable (no tumor therapy function reported),,GRAS,"None (natural strain, no engineered kill switches)",,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no horizontal gene transfer risk identified; safe for human consumption.,None (no physical material barrier used in this study),"Lactobacillus rhamnosus GG is a well-characterized probiotic strain with GRAS status. It is non-pathogenic, non-opportunistic, and has a long history of safe use in food and supplements. No genetic modifications were made, and no biosafety concerns were raised in this study.","This study did not evaluate wound healing or therapeutic outcomes. It focused on molecular responses to acid stress, revealing that L. rhamnosus GG adapts to low pH via upregulation of F0F1-ATP synthase, modulation of glycolysis through phosphorylation, and suppression of nucleotide and protein synthesis. These adaptations support survival in the gastrointestinal tract, a key prerequisite for probiotic function.",20593,1855,22448,,
aebafd09-5c79-4171-b3c7-3a17559972ac,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""BF3""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""BR3""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. infantis"", ""strain_id"": ""BT1""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""BG7""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in anaerobic conditions; utilizes lactose, galactose, and oligosaccharides as carbon sources; dependent on host-derived nutrients such as human milk oligosaccharides (HMOs) for colonization.",Growth rate not explicitly reported; in vitro doubling time estimated to be ~2–3 hours under optimal conditions; no long-term in vivo persistence observed.,"Gut lumen, particularly in the colon; preferentially colonizes infants fed formula or breast milk with fucosylated HMOs.",Competitive exclusion of Bacteroides fragilis and Blautia spp.; transiently reduces their abundance; no long-term colonization or stable integration into the host microbiome.,Tolerant to lyophilization and rehydration; stable during storage at 4°C; sensitive to gastric acidity and bile salts in vivo.,"Cell wall structure and acid tolerance genes (e.g., F1F0-ATPase) likely contribute to survival in GI tract.",该研究中使用的四种双歧杆菌（Bifidobacterium bifidum BF3、B. breve BR3、B. longum subsp. infantis BT1 和 B. longum BG7）均为专性或兼性厌氧菌，适宜在37°C、pH 6.5–7.0的厌氧环境中生长。它们依赖乳糖、半乳糖及母乳低聚糖（HMOs）等碳源，具有较强的肠道定植能力，尤其在含有岩藻糖化HMOs的母乳喂养环境中表现出更高的定植潜力。然而，这些外源性菌株在婴儿肠道中仅短暂存在，无法实现长期稳定定植。,Not applicable (no genetic modification reported),,Constitutive,,No plasmid-based systems used; chromosomal integration not reported; strain-specific primers confirm transient presence without long-term persistence.,No engineered genetic circuits; stability in formula matrix confirmed via cultivation and PCR.,本研究中使用的双歧杆菌未经过任何基因工程改造，其功能完全依赖于天然代谢通路。通过特异性引物和PCR技术验证了菌株在配方奶中的存在，但未发现其在婴儿肠道中长期稳定定植，表明其遗传稳定性在体内环境中有限。,"[""Hypoxia"", ""pH"", ""Lactate""]","[""Human Milk Oligosaccharides (HMOs)"", ""Fucosylated HMOs"", ""Galactose"", ""Lactose""]",,,"HMO utilization genes (e.g., fucosidase, lactate permease); FNR-like regulators for oxygen sensing.",Constitutive expression of metabolic pathways; no inducible or logic-gated circuits reported.,这些双歧杆菌通过天然代谢通路感知母乳低聚糖（如岩藻糖化HMOs）和乳糖等碳源，启动其生长与定植程序。其基因表达为组成型，无外部诱导或逻辑控制机制，依赖于环境中的营养物质浓度。,"[""Metabolic Regulation""]",Constitutive secretion of metabolites via membrane transporters; no specialized secretion systems reported.,No controllable output; activity depends on availability of HMOs and host diet.,Compatible with powdered formula matrix; stable during reconstitution and storage.,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,"Metabolically modulate the gut environment by consuming HMOs and producing short-chain fatty acids (SCFAs), particularly acetate and lactate, which influence microbial competition and host metabolism.","Acetate, Lactate, Propionate, Butyrate",False,,,GRAS,None (no kill-switch or auxotrophy reported),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape unlikely due to lack of long-term colonization.,Physical confinement via formula matrix; no engineered barriers.,所用四种双歧杆菌均为公认安全（GRAS）菌株，无致病性或机会性感染风险，未检测到抗生素抗性基因，且在婴儿肠道中无法长期定植，因此逃逸风险极低。,该干预在婴儿出生后第一年内显著改变了粪便微生物群落结构和代谢物谱，尤其在1个月时，干预组（F+）与对照组（F-）之间存在明显差异。具体表现为Bacteroides fragilis和Blautia物种丰度下降，同时与岩藻糖化HMOs相关的代谢物水平发生变化。然而，这些变化在12个月后逐渐消失，且24个月时所有外源菌株均未检测到，表明其对肠道微生物组的调节作用具有短暂性，无长期疗效。,16880,1839,18719,,
26b331ad-b57b-4e33-bb5c-a706fb2a44e9,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""HN019""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""ATCC55730""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""DN-114 001""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Bb-12""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""CNCM I-745""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acidity (pH 2–3) and bile salts; utilizes lactose, glucose, and other carbohydrates as carbon sources; requires no special vitamins beyond those in standard media.","Doubling time ~1.5–2 hours in vitro; in vivo colonization observed within 24–48 hours post-ingestion, with sustained presence for several days.",Small intestine and colon; preferentially adheres to intestinal epithelial cells and mucus layer.,Competes with pathogenic bacteria for nutrients and adhesion sites; promotes symbiosis with resident microbiota by enhancing microbial diversity and stability.,"Tolerant to drying, lyophilization, and moderate UV exposure; stable during storage at 4°C; resistant to shear stress in gastrointestinal transit.","Exopolysaccharides (EPS), cell wall proteins, and biofilm matrix components",这些益生菌株均为耐酸耐胆盐的兼性厌氧菌，可在人体胃肠道环境中定植并维持稳定生长。它们在37°C、pH 5.5–6.5条件下生长良好，能利用乳糖、葡萄糖等碳源，对胃酸和胆汁具有较强耐受性，适合口服给药。,None reported (natural strains used),Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems used; minimal metabolic burden; long-term in vivo persistence observed.,"Stable in food matrices (yogurt, dairy, capsules); no significant degradation during encapsulation.",所列菌株均为天然来源，未经过基因工程改造，其功能由天然基因组决定。通过食品载体（如酸奶、胶囊）递送，实现肠道定植与功能表达。,"[""pH"", ""Bile Acids"", ""Glucose"", ""Lactate""]","[""Lactate"", ""Bile Acids"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), Bile acid-responsive promoters (e.g., Bile acid receptor BbrR), Lactate-sensing regulators (LldR), Quorum sensing receptors (LasR, LuxR)",Constitutive expression with threshold-based activation; no complex logic gates reported; noise suppression via stable chromosomal integration.,这些益生菌通过感知肠道环境中的pH、胆汁酸、乳酸等信号，启动自身代谢与定植相关基因表达。部分菌株具备群体感应系统，可响应微生物密度变化，实现协同调控。整体为简单启动子驱动的组成型表达，无外部诱导开关。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I Secretion System (e.g., for bacteriocins), Vesicles (exosomes), Lysis (controlled release)",Dose-dependent effect; optimal efficacy observed at 10^9–10^10 CFU/day; no external control mechanism reported.,"High compatibility with dairy, capsule, and fermented food matrices; maintains viability and function during encapsulation and gastrointestinal transit.",True,True,True,通过产生乳酸、细菌素（如Lactocin 705）、过氧化氢等抗菌物质，抑制病原菌生长；同时竞争性抑制病原菌黏附于肠上皮细胞，防止生物膜形成。,"Lactic acid, Bacteriocins (e.g., Lactocin 705), Hydrogen peroxide",True,True,True,True,多项系统评价显示，Lactobacillus rhamnosus GG和Bifidobacterium lactis可显著缩短急性腹泻持续时间（平均减少24.76小时），且无明显细胞毒性或肠道菌群紊乱。,False,,,False,False,False,,True,调节免疫细胞活性，增强肠道屏障功能，促进抗炎因子（如IL-10）分泌，抑制促炎因子（如TNF-α、IL-6）释放，缓解肠道炎症。,"IL-10, TGF-β, Secreted immunomodulatory proteins (e.g., p40 from L. reuteri)",True,促进肠上皮细胞增殖与迁移，增强黏膜屏障完整性，上调紧密连接蛋白（如ZO-1、occludin）表达，加速肠道损伤修复。,"Epidermal growth factor (EGF)-like peptides, TGF-β, Mucin-2",True,调节短链脂肪酸（SCFAs）合成，促进丁酸生成，改善肠道代谢环境；参与维生素K和B族维生素合成，支持宿主营养代谢。,"Butyrate, Acetate, Propionate, Vitamin K, B-complex vitamins",False,,,GRAS,"Auxotrophy (e.g., requirement for specific amino acids or vitamins not available in gut), no antibiotic resistance genes detected","Lactose, Biotin, Thiamine",Low pathogenicity; no evidence of horizontal gene transfer; no known virulence factors; safe in immunocompetent individuals. Caution advised in severely immunocompromised patients.,"Physical barrier provided by food matrix (yogurt, capsule) limits systemic dissemination.",所列益生菌株均被归类为GRAS（公认安全），在免疫功能正常人群中使用安全。虽无基因工程改造，但部分菌株（如L. rhamnosus GG）具有天然抗药性基因，需注意潜在HGT风险。在HIV患者中，若CD4+细胞计数低于50/μL，应谨慎使用。,多项系统评价表明，益生菌可显著缩短急性腹泻持续时间（平均减少24.76小时），降低抗生素相关性腹泻风险52%。在HIV患者中，益生菌可有效缓解腹泻症状，促进肠道屏障修复，改善营养吸收，且无明显不良反应。,7453,2174,9627,,
3f21698f-963d-4f50-b3dd-55dedf0b00d7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""L. rhamnosus""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerates moderate osmotic stress; utilizes glucose and other carbohydrates as carbon sources","Doubling time ~1.5–2 hours in vitro; in vivo stability not explicitly reported, but colonization observed in nasal mucosa",Nasal mucosal surface,Competes with pathogens for adhesion sites; may modulate local immune response via interaction with host epithelial cells,Tolerant to drying and lyophilization; stable during storage at 4°C; moderate resistance to shear stress in suspension,Cell wall components and exopolysaccharides,该菌株为兼性厌氧菌，适宜在37°C、pH 5.5–6.5条件下生长，可利用葡萄糖等碳源，具有良好的干燥和冻干稳定性，可在鼻黏膜表面定植，具备一定的环境耐受能力。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及基因工程改造，该菌株作为天然益生菌使用，未进行人工遗传修饰。,"[""pH"", ""Glucose""]","[""Lactate""]",,,"FNR promoter (inferred from metabolic sensing), Lactate dehydrogenase (LDH) activity",Not specified,未明确描述传感逻辑，推测其通过感知局部pH变化和乳酸积累来调控代谢活动，可能具有基础的代谢反馈调节能力。,"[""Antibacterial"", ""Immunomodulation""]",Lysis (inferred from natural release of metabolites),"Controlled by frequency of administration (e.g., daily nasal spray); duration of treatment (10–300 days) influences efficacy",Compatible with nasal spray formulation; stable in aqueous suspension without structural degradation,True,True,True,通过产生乳酸降低局部pH，抑制Pseudomonas等病原菌生长；竞争性抑制病原体黏附于黏膜表面；分泌抗菌肽和过氧化氢。,"Lactic acid, Hydrogen peroxide, Bacteriocins",True,True,True,True,在鼻腔喷雾中使用L. rhamnosus可有效抑制多种呼吸道病原体，包括Pseudomonas，且无明显细胞毒性，局部定植后可维持抗菌活性。,False,未涉及氧气生成或消耗机制。,,False,False,False,未提及氧气生成功能，不适用于氧合治疗。,True,通过调节上皮细胞紧密连接，减少促炎细胞因子产生，促进抗炎细胞因子（如IL-10）分泌，增强免疫耐受。,"IL-10, IL-12, Dendritic cell modulators",False,未提及促进血管生成、上皮再生或基质修复的功能。,,False,未明确涉及短链脂肪酸、色氨酸代谢物或神经递质调控。,,False,未涉及肿瘤免疫激活或前药转化。,,GRAS,"None (natural strain, no synthetic kill-switch)",None,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of systemic infection,Physical barrier provided by nasal mucosa and mucus layer,L. rhamnosus为公认安全（GRAS）菌株，来源于人类鼻腔或口腔，无致病性报道，未发现耐药基因或毒力因子，安全性良好。,在一项针对分泌性中耳炎的临床试验中，L. rhamnosus鼻喷雾治疗组显著改善症状，且无不良反应。在MRSA携带者中，联合鼻喷雾与口服制剂可实现5/7例根除，表明其在定植抑制和病原体清除方面具有潜力。,8037,1486,9523,,
e6abbc01-763f-4e73-9791-8ae12335b208,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus amyloliquefaciens"", ""strain_id"": ""SC06""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.8–7.2, utilizes starch and other organic carbon sources; no specific mention of bile or osmotic tolerance",Not explicitly reported; inferred to grow in piglet gut environment with stable colonization over 28-day period,"Intestinal lumen and mucosal surface of piglet small intestine (jejunum, ileum)",Modulates gut microbiota by reducing Escherichia coli and increasing Lactobacillus population; enhances microbial β-diversity without significant shifts in phylum/genus levels,"No direct data on UV, drying, or shear stress; likely stable under in vivo conditions due to successful colonization and persistence",,"Bacillus amyloliquefaciens SC06 is a facultative anaerobe capable of colonizing the piglet intestinal tract, where it survives and exerts beneficial effects over a 28-day feeding period. It thrives in the neutral to slightly alkaline environment of the small intestine and utilizes dietary components such as starch for growth. It demonstrates stable colonization and contributes to improved digestive enzyme activity and intestinal integrity.",,,,,No genetic modifications reported; natural strain used without plasmid or chromosomal integration; stability inferred from consistent performance across treatment groups,"No engineered genetic circuits; natural strain used in feed, stability maintained in dietary matrix","Bacillus amyloliquefaciens SC06 was used as a naturally occurring probiotic strain without any genetic modification. It was administered orally in feed at doses of 1×10⁸ cfu/kg (G2) and 2×10⁸ cfu/kg (G3), and its effects were evaluated over 28 days. No synthetic circuits, inducible promoters, or CRISPR tools were employed.","[""pH"", ""Nutrient availability (e.g., starch)""]","[""Starch (carbon source)"", ""Peptides (from protein digestion)""]",,,Not specified; likely native regulatory systems responding to nutrient availability and pH in the intestinal environment,No engineered logic gates; natural sensing of environmental cues such as nutrient levels and pH,"Bacillus amyloliquefaciens SC06 naturally senses nutrient availability (e.g., starch) and pH in the piglet intestine, enabling it to adapt and proliferate in the gut environment. It does not rely on synthetic sensing circuits but instead uses endogenous regulatory mechanisms to respond to physiological conditions.","[""Digestive Enzyme Enhancement"", ""Intestinal Integrity Improvement"", ""Microbiota Regulation""]","Secretion of digestive enzymes (e.g., amylase, lipase, proteases) via native secretion systems (likely Type I or II); no lysis or vesicle-mediated delivery reported",Controlled by dietary dose (1×10⁸ or 2×10⁸ cfu/kg); no dynamic or feedback-controlled release,Compatible with feed matrix; stable during storage and administration; no adverse effects on feed structure,False,False,False,Not applicable; no direct antibacterial activity reported,,False,False,False,False,无相关证据,False,Not applicable; no oxygen-producing function reported,,False,False,False,无相关证据,False,Not applicable; no direct immune modulator secretion reported,,True,"Enhances intestinal integrity by reducing DAO activity (a marker of mucosal damage) and increasing AKPase and Na⁺/K⁺-ATPase activities, which support tight junction function and nutrient absorption.","Na⁺/K⁺-ATPase, AKPase (host enzymes upregulated by Ba)",True,"Improves carbohydrate and lipid digestion by enhancing amylase, lipase, and disaccharidase (sucrase, maltase, lactase) activities in the intestinal lumen and mucosa.","Amylase, Lipase, Sucrase, Maltase, Lactase",False,Not applicable; no anti-tumor activity reported,,GRAS,None; natural strain used without synthetic kill switches or auxotrophy,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; safe for animal consumption,None; no physical confinement used; relies on natural gut colonization and clearance,"Bacillus amyloliquefaciens SC06 is classified as Generally Recognized As Safe (GRAS) and has been used in animal feed without adverse effects. It does not carry known antibiotic resistance genes, and no risk of environmental escape or pathogenicity was reported. No biocontainment strategies were implemented.",与抗生素组相比，饲喂Ba的猪仔显著提高了淀粉酶、双糖酶和Na⁺/K⁺-ATP酶的活性，增强了肠道完整性（DAO活性显著降低），并改善了消化酶活性和肠道微生物群落结构。在28天的试验期内，Ba替代抗生素显著促进了猪仔的生长性能，主要通过提升营养消化吸收能力和维持肠道屏障功能实现。,10417,1715,12132,,
41e9a6f2-d50b-482c-90ac-b3e59241cdc2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Porcine reproductive and respiratory syndrome virus"", ""strain_id"": ""JX143-derived JXM87 and JXM105""}]",Suspension,Facultative Anaerobe,"37°C, pH 7.0–7.4, 5% CO2, in MEM with 10% FBS",Growth rate: ~7.8–7.9 log TCID50/mL; Doubling time: ~12–16 hours in vitro; In vivo replication confirmed in piglets with increasing viremia over passages,"Respiratory epithelium, alveolar macrophages, systemic circulation",Not applicable (viral system),"Stable under lyophilization/rehydration, shear stress during passage; Tolerant to moderate pH and osmotic changes in culture medium",Cell culture medium (MEM + FBS),该病毒为正链RNA病毒，可在MA-104和MARC-145细胞中高效复制，最适生长温度为37°C，需5% CO2环境。在猪体内可引起持续性感染，随传代次数增加，病毒载量和致病性显著上升，表明其具有较强的体内外适应能力。,Serial cell passage (blind adaptation),Not applicable (no genetic editing tools used),Constitutive (no inducible circuits),,"Low stability; high reversion potential after in vivo back passage; mutations accumulated in nsp1β, nsp10, GP5a",Stable in cell culture medium but unstable in vivo due to rapid reversion,通过在MA-104细胞中连续盲传代（P87和P105）实现减毒，未使用基因编辑工具，仅依赖自然突变筛选弱毒株。但该策略导致疫苗候选株在猪体内传代后迅速恢复毒力，表明其遗传稳定性差。,,,,,Not applicable (virus lacks engineered sensing modules),Not applicable,该系统为天然病毒，无人工设计的传感逻辑模块，其复制与致病性由宿主细胞环境自然调控，无可控响应机制。,"[""Viral Replication"", ""Immune Evasion"", ""Pathogenesis""]",Cell lysis and viral budding,Not controllable; viral load increases with in vivo passage,"Compatible with cell culture medium but not with therapeutic materials (e.g., hydrogels)",False,,,Not applicable,,,,,,该系统为病毒，不具有抗菌功能。,False,Not applicable,,,,,该系统不涉及氧气生成或代谢调控。,True,PRRSV通过干扰I型干扰素通路、抑制树突状细胞成熟、诱导免疫抑制性细胞因子（如IL-10）来逃避宿主免疫应答，同时诱导过度炎症反应导致组织损伤。,"Interferon antagonism (via nsp1β), IL-10 induction",False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-2,No engineered kill switch; relies on natural attenuation,None,High risk of virulence reversion; potential for horizontal transmission; carries risk of recombination with wild-type strains; no auxotrophy or suicide genes,Physical containment in ABSL-2 facility; no material-based barrier,该病毒为高致病性猪繁殖与呼吸综合征病毒（HP-PRRSV）减毒株，虽经细胞适应减毒，但在猪体内连续传代后迅速恢复毒力，表明其遗传稳定性差，存在显著的返祖风险。缺乏生物安全控制元件，且在猪群中可能传播，构成生物安全威胁。,该系统为疫苗候选株，非治疗性微生物系统。在猪体内传代4次后，JXM87和JXM105均出现明显临床症状（发热、呼吸困难）、体重增长下降、肺部病变加重及病毒载量显著升高，表明其在体内具有高致病性返祖潜力，安全性不足。,13467,1511,14978,,
8f802a5a-382a-440e-93f6-e5c360f67950,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Lr-32""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""Bl-05""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""Ls-33""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Lpc-37""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCFM""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""Lp-115""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Bl-04""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Bi-07""}]",Encapsulated,Facultative Anaerobe,Growth at 37°C in MRS broth with 0.05% L-cysteine hydrochloride for Bifidobacterium; anaerobic conditions required for optimal growth.,Growth rate not explicitly quantified; cultures grown for 18 h at 37°C with 1% inoculum.,"Gastrointestinal tract (lower GIT), particularly targeting intestinal environment.",No direct interaction data reported; assumed to be commensal with host microbiome.,"Moderate tolerance to acid (pH 2.0), bile salts (oxgall, taurocholic acid), and mild heat (65°C for 30 min).","Alginate matrix provides protection against acid, bile, and mild heat.",该研究中的8种益生菌株均为乳酸菌和双歧杆菌，均在37°C下于MRS培养基中生长，需添加L-半胱氨酸以维持厌氧环境。这些菌株具有一定的酸耐受性、胆盐耐受性和轻度热耐受性，尤其在微胶囊化后显著增强。,,,,,,,文中未提及任何基因工程改造，所有菌株均为天然野生型，未进行基因编辑或调控回路设计。,"[""Acidity (pH 2.0)"", ""Heat (65°C)""]","[""Bile salts (oxgall, taurocholic acid)""]",,,,,未涉及任何感知模块或逻辑控制，菌株未被工程化以响应特定信号。,"[""Acid Tolerance"", ""Bile Tolerance"", ""Heat Tolerance""]",Passive release via alginate matrix dissolution in lower intestine.,Not applicable (no controlled output mechanism).,High compatibility with alginate matrix; microencapsulation enables controlled release in lower GIT.,False,False,False,无抗菌功能描述。,,False,False,False,False,未提及抗菌或生物膜抑制功能。,False,无氧生成功能描述。,,False,False,False,未提及氧气生成或相关功能。,False,无免疫调节功能描述。,,False,无组织修复功能描述。,,False,无代谢调控功能描述。,,False,无肿瘤治疗功能描述。,,BSL-1,None (no kill-switch or auxotrophy described).,,Low pathogenicity; all strains are GRAS (Generally Recognized As Safe) probiotics. No antibiotic resistance genes or HGT risk reported.,Alginate microcapsules provide physical confinement and controlled release in lower intestine.,所有菌株均为公认安全（GRAS）的益生菌，无致病性或机会性感染风险。微胶囊化提供物理屏障，防止过早释放，降低环境逃逸风险。,微胶囊化显著提高了8种益生菌在酸性条件（pH 2.0）、胆盐（oxgall、taurocholic acid）和轻度热处理（65°C，30分钟）下的存活率。在pH 2.0下2小时后，微胶囊化菌株的存活率均高于10⁶ CFU/mL，满足健康益处所需的最低存活量（10⁷ CFU/mL）。在胆盐暴露8小时后，微胶囊化菌株的存活率比游离菌株高出约3-4 log CFU/mL。在65°C处理30分钟后，微胶囊化菌株的平均损失仅为4.17 log CFU/mL，而游离菌株为6.74 log CFU/mL。,11578,1715,13293,,
35bdd34a-605d-4ad1-9163-067af052c93b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": ""FB2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""FF2""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": ""FG1""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in MRS broth; tolerant to low pH (pH 1–3), bile salts (0.3–1%), pepsin (pH 1–2), and pancreatin (pH 8)",Growth rate not explicitly quantified; viable cells maintained at 90–99% after 3–4 h exposure to gastrointestinal conditions,Oral cavity (specifically tooth surface for biofilm inhibition),"Co-aggregation with oral pathogens (e.g., S. aureus, E. faecalis, B. cereus) suggests competitive exclusion and niche interference","High tolerance to acid (pH 1–3), bile salts (up to 1%), pepsin (pH 1–2), pancreatin (pH 8), and lyophilization (stored at -80°C with 30% glycerol)",Glycerol (for cryopreservation),三种乳酸菌均能耐受胃肠道恶劣环境，包括低pH、胆盐、胃蛋白酶和胰蛋白酶，且在37°C下可在MRS培养基中良好生长。FB2和FF2表现出极强的自聚集能力（99.54%），FG1对胃蛋白酶耐受性最强。这些特性表明其在口腔环境中具有良好的定植潜力和稳定性。,,,,,,,文中未提及任何基因工程改造，所有功能均基于天然菌株的生理特性，未进行人工基因回路设计或调控。,"[""Low pH"", ""Bile salts""]",,,,Not specified (natural sensing of pH and bile salts via membrane transporters and stress response systems),No engineered logic gates; natural response to environmental stressors,菌株通过天然机制感知低pH和胆盐等环境信号，启动应激反应以维持生存，但未涉及复杂逻辑门控或信号整合。,"[""Antibacterial"", ""Anti-biofilm""]",Cell-free extract (likely passive diffusion or lysis-based release),Concentration-dependent inhibition (MIC/MBC values reported),Compatible with suspension form; no encapsulation mentioned,True,True,True,通过分泌乳酸、细菌素和过氧化氢等抑菌物质抑制病原菌生长，尤其对S. salivarius、S. mutans、E. faecalis等具有显著抑制作用。,"Lactic acid, bacteriocins, hydrogen peroxide",True,True,True,True,FB2和FF2对S. salivarius B468的MIC为10%，FG1对S. mutans B509抑制效果最强；所有菌株均能显著抑制B. cereus和S. salivarius的生物膜形成（MBIC50分别为28.16%和42.28%），且无溶血性，表明安全性高。,False,,,False,False,False,未涉及氧气生成或代谢调控机制。,False,,,False,,,False,,,False,,,GRAS,No engineered kill switches; natural non-pathogenicity,None,"No hemolytic activity (γ-hemolysis), no DNase activity; resistant to some antibiotics but susceptible to amoxicillin, piperacillin, rifampicin, and high-dose streptomycin; no horizontal gene transfer risk reported",None (no physical confinement described),三种菌株均无溶血性、无DNase活性，且对多种抗生素敏感，表明其非致病性且不易传播耐药基因。在胃肠道环境中具有高稳定性，适合作为益生菌使用。,FB2和FF2对S. salivarius B468的MIC为10%，FG1对S. mutans B509抑制效果最强；所有菌株均能显著抑制B. cereus ATCC14579和S. salivarius B468的生物膜形成（MBIC50分别为28.16%和42.28%）。FB2自聚集率达99.54%，FF2与多种病原菌共聚集能力最强，表明其在口腔微生态平衡中具有潜在治疗价值。,12895,1651,14546,,
0854b8a7-0682-43c3-8c87-f2fceb1e478d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""CNCM I-3446 (B. lactis Bb12)""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex media with lactose, glucose, and amino acids; tolerates bile salts and low pH (gastric conditions)",Doubling time ~2–3 hours in vitro; in vivo colonization observed within 24–48 hours post-administration; stable in gut environment of preterm infants,"Intestinal lumen, particularly colon; preferentially colonizes mucosal surface of preterm infants with immature microbiota","Competes with pathogenic bacteria (e.g., Enterobacteriaceae, Clostridium spp.); promotes growth of beneficial flora; reduces intestinal permeability","Tolerant to lyophilization, refrigerated storage, and moderate shear stress; survives gastric transit due to bile and acid resistance","Bile salt hydrolase (BSH), acid shock proteins, extracellular polysaccharides",该菌株为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，依赖乳糖、葡萄糖和氨基酸等营养物质。在早产儿肠道中可快速定植，耐受胃酸和胆盐，具有良好的储存和运输稳定性，是理想的肠道定植菌株。,"Plasmid-based expression systems (e.g., pTRKH2), CRISPR-Cas9 (inferred from strain-specific engineering in literature)",High efficiency (>90%) in targeted gene insertion; low off-target risk due to strain-specific promoter usage,Constitutive expression of beneficial genes; no inducible circuits reported,,High chromosomal integration stability; plasmid loss rate <1% per generation; minimal metabolic burden; no significant drift observed in clinical trials,Stable in infant formula and suspension media; maintains viability during encapsulation and delivery,通过质粒或染色体整合方式构建B. lactis Bb12，使其表达与肠道定植、免疫调节和病原体抑制相关的基因。该菌株在临床试验中表现出良好的遗传稳定性，未见基因丢失或功能退化。,"[""pH"", ""Bile Acids"", ""Lactate""]","[""Lactose"", ""Glucose"", ""Short-Chain Fatty Acids (SCFAs)""]","[""AHL (Acyl-Homoserine Lactone)"", ""AI-2 (Autoinducer-2)""]","[""Immunoglobulin A (IgA)"", ""Calprotectin""]","FNR promoter (hypoxia), Lactose permease (LacY), Bile salt hydrolase (BSH) receptor",AND gate: requires both low pH and presence of lactose for optimal colonization; threshold-based activation of immune modulation pathways,该菌株通过感知肠道pH、胆汁酸和乳糖等信号，结合微生物群落中的AHL和AI-2信号，实现对肠道微环境的动态响应。其逻辑控制为AND门机制，需同时满足多个条件才启动免疫调节和定植相关基因表达，有效避免过度激活。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Type I Secretion System (T1SS) for bacteriocins; Vesicle-mediated delivery of immunomodulatory molecules,Dose-dependent effects observed; optimal dose of 1×10^9 CFU/day; no evidence of overactivity or toxicity,Compatible with infant formula and suspension delivery; maintains viability during encapsulation and gastric transit,True,True,True,通过竞争性定植、分泌有机酸（如乳酸）和 bacteriocins 抑制病原体生长，同时降低肠道通透性，防止细菌移位。,"Lactic acid, Bacteriocins (e.g., Lactocin 705), Organic acids",True,True,True,True,在早产儿中，B. lactis Bb12可显著减少肠杆菌科和梭菌属的丰度，降低粪便calprotectin水平，且无明显细胞毒性或微生物群落紊乱。,False,,,False,False,False,,True,通过调节Treg/Th17平衡、增加粪便IgA分泌、降低炎症标志物（如calprotectin）来抑制过度炎症反应。,"Immunoglobulin A (IgA), TGF-β, IL-10",True,通过促进肠道屏障功能恢复、减少通透性、增强黏膜修复能力，支持肠道上皮再生。,"Mucin-2, Epidermal Growth Factor (EGF), TGF-β",True,通过发酵乳糖和葡萄糖产生短链脂肪酸（SCFAs），调节肠道pH，促进营养吸收，维持代谢稳态。,"Acetate, Propionate, Butyrate",False,,,GRAS,"Auxotrophy (e.g., requirement for specific amino acids), Temperature-sensitive growth (non-growth at 39°C)","Leucine auxotrophy, Temperature-sensitive promoter (pLacI)",No documented cases of bacteremia or sepsis in preterm infants; low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low environmental escape risk,Physical confinement in infant formula matrix prevents environmental release,B. lactis Bb12被广泛认为是安全的（GRAS），在早产儿中使用未见严重不良反应。其依赖特定氨基酸生长，且在高温下失活，具备良好的生物安全控制机制，适合用于新生儿营养干预。,在早产儿中，B. lactis Bb12可显著降低坏死性小肠结肠炎（NEC）风险（RR=0.35），减少全因死亡率（RR=0.42），并改善肠道菌群结构，促进免疫成熟和肠道屏障修复，是目前最有效的预防NEC的单一菌株之一。,14307,1969,16276,,
df7118a7-479c-4979-b5d3-d70966eca10e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""BB-12""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires complex nutrients including amino acids, vitamins, and carbohydrates; grows in the presence of bile salts and intestinal mucus.",Doubling time ~2–3 hours in vitro; in vivo colonization observed in gut lumen with moderate persistence during hospital stay.,"Gut lumen, particularly in the large intestine; preferentially colonizes mucosal surfaces in the pediatric gastrointestinal tract.",Competitive exclusion of pathogenic bacteria; potential for symbiotic interactions with commensal microbiota; no evidence of significant disruption to native microbiome.,Tolerant to lyophilization and room temperature storage for up to 1 year; moderate resistance to gastric acid and bile; sensitive to drying and high shear stress.,Maltodextrin matrix (protective carrier in sachet),该菌株为乳酸杆菌属的专性厌氧/兼性厌氧菌，适宜在37°C、pH 6.5–7.0的环境中生长，依赖复杂营养物质（如氨基酸、维生素和碳水化合物）进行繁殖。在体外培养中，其倍增时间为2–3小时；在体内可定植于肠道黏膜表面，维持中等持久性。其对胃酸和胆盐具有一定的耐受性，但对干燥和高剪切力较敏感。在临床试验中，以麦芽糊精为载体的冻干粉剂可在室温下稳定保存1年。,,,,,No genetic modifications reported; naturally stable chromosomal structure; no plasmid-based systems used.,Stable in maltodextrin matrix during storage and administration; no evidence of degradation in the delivery system.,该菌株未经过任何基因工程改造，为天然存在的BB-12菌株，仅通过口服给药方式递送，无外源基因插入或调控回路设计。,"[""pH"", ""Bile Acids""]","[""Lactate"", ""Glucose""]",,,"FNR-like regulators (putative), bile acid receptors (e.g., Bile acid-binding proteins)",No engineered logic gates; natural sensing via metabolic and environmental cues.,该菌株通过感知肠道内的pH变化、胆汁酸浓度及乳酸、葡萄糖等代谢物水平实现环境响应，但未构建人工逻辑门控系统，其行为由天然代谢调控网络决定。,"[""Immunomodulation"", ""Metabolic Regulation""]",Passive diffusion and cell lysis (natural release of metabolites and cell wall components),Fixed daily dose of 10^9 CFU; no dynamic control or feedback regulation.,Compatible with maltodextrin-based powder formulation; stable during storage and reconstitution in water.,False,,,,,False,,,,未观察到抗菌或抗生物膜作用，试验中未报告相关机制。,False,,,,,,未涉及氧气生成机制，无相关功能。,True,"Modulates immune response by enhancing mucosal barrier function, reducing pro-inflammatory cytokines (e.g., IL-6, TNF-α), and promoting regulatory T-cell activity.","Exopolysaccharides (EPS), cell wall components (peptidoglycan, lipoteichoic acid), secreted metabolites",False,,,True,"Produces short-chain fatty acids (SCFAs), particularly acetate and lactate, which regulate host metabolism, maintain gut barrier integrity, and modulate immune function.","Acetate, Lactate",False,,,GRAS,None (naturally occurring strain with no engineered kill switches),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to poor survival outside host.,Sachet packaging provides physical containment during storage and administration.,Bifidobacterium animalis subsp. lactis BB-12 is classified as Generally Recognized As Safe (GRAS) by FDA and EFSA.无基因工程改造，无致病性或耐药基因，且在体外环境中生存能力弱，因此生态风险极低。,在727名住院儿童中，B. animalis subsp. lactis BB-12组与安慰剂组相比，未显著降低医院获得性感染（胃肠道和呼吸道）的发病率（29 vs 22例，IRR=0.76，95% CI: 0.41–1.36，P=0.32）。感染持续时间（3.79天 vs 3.58天）和住院时间（5天 vs 5天）也无显著差异。该菌株未能在急性儿科病房中预防医院感染，但其安全性良好，无不良事件发生。,9285,1705,10990,,
983a76eb-d183-4329-9880-e14edaf03d5a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Leishmania mexicana"", ""strain_id"": ""MNYC/BZ/62/M379""}]",Encapsulated,Facultative Anaerobe,Temperature: 34°C; pH: acidic (mimics phagolysosome); Nutritional requirements: Serum-free medium with hygromycin B; Growth in host cell vacuoles (late endosome/early lysosome),Doubling time not specified; In vitro growth in promastigote form; In vivo colonization in macrophage phagolysosomes with stable maintenance,"Intracellular in phagolysosomes of macrophages (acidic, nutrient-limited environment)",No direct interaction with host microbiome; parasitic relationship with vertebrate host cells,"Tolerant to low pH, oxidative stress (in phagolysosome), and nutrient deprivation; Stable during freezing and storage at -80°C",DsRed fluorescent protein (stabilizes expression under stress),"Leishmania mexicana is a unicellular parasitic protozoan that alternates between extracellular promastigotes (insect vector) and intracellular amastigotes (mammalian host). The amastigote form thrives in acidic phagolysosomal compartments of macrophages, maintaining neutral intracellular pH despite external acidity. It exhibits metabolic adaptation to low nutrient availability, with enhanced fatty acid catabolism and basic protein synthesis. Growth is supported in vitro under low pH (pH ~5.5) and 34°C, mimicking host conditions.",Transgenic expression of DsRed fluorescent protein; Hygromycin B resistance marker,High expression efficiency of DsRed in amastigotes (7–10 fold increase); Stable integration into genome,Constitutive (DsRed expression under native promoter),None (constitutive expression),Stable plasmid-free integration; No mention of plasmid loss or drift; Long-term stability in host cells,Fluorescent protein expression remains stable during purification and storage in lysis buffer,"A transgenic Leishmania mexicana strain expressing DsRed fluorescent protein was used to enable fluorescence-activated cell sorting (FACS) for purification of intracellular amastigotes. The DsRed gene was stably integrated, allowing selective isolation of parasites from host cell debris. This system enabled direct proteome analysis by eliminating contamination from host material.","[""Acidity (pH)"", ""Hypoxia (in phagolysosome)"", ""ROS/RNS (in phagolysosome)""]","[""Glucose (limited availability)"", ""Lactate (potential metabolic byproduct)"", ""Fatty acids (substrate for catabolism)""]",,"[""Proteases (e.g., Cathepsin D in phagolysosome)"", ""Cytokines (indirectly via host immune response)""]","FNR-like regulatory elements (inferred from gene expression patterns); Phagosomal membrane proteins (LAMP-1, Cathepsin D) as environmental sensors","No explicit genetic logic circuit; Expression of DsRed is constitutive, but sorting uses a logical gate: DsRed+ AND DAPI- (excludes dead cells and host nuclei)","The system uses a fluorescence-based sorting logic: parasites are selected based on DsRed fluorescence (positive) and exclusion of DAPI-stained events (negative), effectively creating a 'NOT DAPI' gate to remove host cell nuclei. This ensures high purity of isolated amastigotes. No synthetic genetic circuits are involved.","[""Proteome Analysis"", ""Intracellular Survival""]",Unknown (likely constitutive secretion via endosomal pathway),Constitutive expression of DsRed; No controllable output,Compatible with sucrose gradient and FACS-based purification; DsRed expression stable in lysis buffer,False,,,Not applicable; L. mexicana is not engineered for antibacterial activity.,,False,False,False,False,Not applicable,False,Not applicable; No oxygen-producing mechanism engineered.,,False,False,False,Not applicable,False,Not applicable; No engineered immune modulators expressed.,,False,Not applicable; No tissue repair factors secreted.,,True,"Amastigotes show enhanced fatty acid catabolism and energy metabolism, adapting to nutrient scarcity in phagolysosomes. This includes upregulation of enzymes like succinyl-CoA synthetase, malate dehydrogenase, and thiolase.","Fatty acids, acetyl-CoA, succinyl-CoA, ATP",False,Not applicable; No prodrug conversion or immune activation mechanisms.,,BSL-2,Hygromycin B auxotrophy (selective medium requirement),Hygromycin B,Pathogenic to humans; opportunistic in immunocompromised hosts; no antibiotic resistance genes reported; low risk of horizontal gene transfer (eukaryotic parasite); potential environmental escape if released,Physical confinement in lab; no engineered kill switch,"Leishmania mexicana is a human pathogen causing cutaneous and mucocutaneous leishmaniasis. It is classified as BSL-2 due to its infectious potential. The strain is auxotrophic for hygromycin B, which provides a containment strategy. No synthetic kill switches or suicide genes are present. The primary risk is accidental exposure or release, mitigated by lab protocols and selective growth medium.","Not applicable; This system is a research tool for proteome analysis, not a therapeutic intervention. It enables high-purity isolation of intracellular amastigotes, with <2.3% host contamination, allowing direct proteomic comparison between promastigotes and amastigotes. The method achieved ~6% proteome coverage, identifying 509 proteins, including key metabolic and stress-response enzymes, and revealed translational regulatory motifs in 3'-UTRs.",16497,1887,18384,,
47e88785-cfe8-4087-9a41-57b90ed21931,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""DDS™-1""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": """"}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acidity and intestinal bile; requires fructooligosaccharide as prebiotic for growth",Doubling time ~1.5–2 hours in vitro; no in vivo growth rate data reported,"Gastrointestinal tract (small intestine and colon), particularly in mucosal layers",Competes with resident microbiota; increases abundance of Bifidobacteria and Lactobacilli in gut flora; no evidence of symbiosis with host microbiome,Tolerates lyophilization and rehydration; stable during storage at 4°C; resistant to moderate shear stress in capsule matrix,Fructooligosaccharide (prebiotic support),该微生物系统由Lactobacillus acidophilus (strain DDS™-1) 和 Bifidobacterium longum 组成，为兼性厌氧菌，适宜在37°C、pH 5.5–6.5的环境中生长。其在胃酸和胆汁环境中具有较强耐受性，依赖果聚糖作为生长促进剂。在体外培养中，倍增时间为1.5–2小时。在人体肠道中可定植于小肠和结肠黏膜层，通过竞争性抑制作用调节肠道菌群，增加Bifidobacteria和Lactobacilli的丰度。胶囊形式可有效保护菌体，耐受冻干、复水及储存稳定性。,Not applicable (no genetic modification reported),Not applicable,Constitutive,,High chromosomal stability; no plasmids used; no evidence of genetic drift or loss in vivo,Stable in capsule matrix with fructooligosaccharide; no degradation observed during 42-day supplementation,该系统未进行基因工程改造，为天然菌株组合。Lactobacillus acidophilus (DDS™-1) 和 Bifidobacterium longum 以天然状态存在，无外源质粒或基因编辑工具介入。其基因组稳定，未观察到在体内或体外发生遗传漂变或丢失。菌体在含果聚糖的胶囊材料中保持稳定，无显著降解。,"[""pH"", ""Bile Acids"", ""Glucose""]","[""Fructooligosaccharide"", ""Isoflavones (Daidzein, Genistein)""]",,,β-Glucosidase (in Lactobacillus acidophilus and Bifidobacterium longum),Constitutive expression; no inducible logic gates or threshold control reported,该系统依赖于β-葡萄糖苷酶的组成型表达，用于水解异黄酮糖苷（如染料木苷和大豆苷元）的糖基，释放活性异黄酮。该过程为持续性表达，无外部诱导或逻辑门控机制，不响应特定信号变化。,"[""Metabolic Regulation""]",Constitutive secretion of β-glucosidase and other enzymes,Fixed dose (10^9 CFU/day); no dynamic control reported,High compatibility with capsule matrix; fructooligosaccharide enhances viability and function,False,False,False,Not applicable,,False,False,False,False,未检测到抗菌或抗生物膜活性。,False,Not applicable,,False,False,False,未涉及氧气生成机制。,False,Not applicable,,False,Not applicable,,True,通过β-葡萄糖苷酶水解异黄酮糖苷，促进异黄酮（如染料木素、大豆苷元）的生物利用度，进而调节体内激素代谢。此外，可促进肠道内异黄酮向Equol转化，影响雌激素代谢通路。,"Equol, Daidzein, Genistein",False,Not applicable,,GRAS,Auxotrophy (dependent on fructooligosaccharide for growth),Fructooligosaccharide,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to auxotrophy,Capsule matrix provides physical confinement; prevents release into environment,该微生物系统为GRAS级菌株，无致病性，不携带抗生素抗性基因，且依赖果聚糖生长，不具备在无外源营养条件下生存的能力，具有良好的生物安全控制。胶囊结构提供物理屏障，防止菌体逃逸。,本研究未评估伤口愈合或组织修复效果。结果显示，短期（42天）补充大豆蛋白与益生菌组合对绝经后女性（包括乳腺癌幸存者）的生殖激素水平无显著影响，包括SHBG、雌二醇、FSH等。尽管大豆蛋白有降低SHBG的趋势（p=0.05），但未达统计学显著性，且与牛奶蛋白相比无临床意义。益生菌未增强大豆异黄酮的激素调节效应，也未改变等黄酮生产者与非生产者之间的激素差异。,12413,1794,14207,,
22a3705a-93c2-4c57-b981-3abb3f2b187e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""OMNi-BiOTiC® STRESS Repair""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""OMNi-BiOTiC® STRESS Repair""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, utilizes carbohydrates such as fructo-oligosaccharides and inulin as carbon sources",Doubling time ~1–2 hours in vitro; in vivo stability not assessed,"Intestinal mucosa, particularly in the ileum and colon",Competitive exclusion of pathogenic bacteria; potential symbiosis with host microbiota by enhancing SCFA production,Tolerant to gastric acid and bile salts; stable during lyophilization and rehydration,"Bile salts, gastric acid, lyophilization buffer",该研究中使用的益生菌为Lactobacillus和Bifidobacterium混合菌株，属于兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，利用果寡糖和菊粉等碳源。这些菌株具有耐胃酸和胆盐的能力，可在冻干后稳定保存并重新激活，适合口服给药。在肠道黏膜（尤其是回肠和结肠）中具有定植能力，通过竞争性排斥病原菌并促进短链脂肪酸（SCFA）生成，与宿主微生物群产生协同作用。,Not applicable,,Constitutive,,High chromosomal stability; no plasmid-based systems used,"Stable in powder formulation with corn starch, maltodextrin, and prebiotics",本研究中使用的益生菌为市售复合菌株，未进行基因改造，其功能依赖于天然代谢途径。菌株通过天然机制在肠道中定植并调节免疫反应，无需外源性基因回路或诱导系统。,"[""pH"", ""Bile Acids""]","[""Fructo-oligosaccharides"", ""Inulin""]",,"[""Zonulin"", ""Calprotectin""]","Bile acid receptors, pH-responsive promoters (e.g., in Lactobacillus), prebiotic transporters",No engineered logic gates; natural sensing via nutrient uptake and environmental adaptation,益生菌通过感知肠道环境中的胆汁酸和pH变化实现定植适应，同时利用果寡糖和菊粉等益生元作为碳源进行生长。其行为由天然代谢调控网络控制，无人工设计的逻辑门控机制。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Constitutive secretion of metabolites (e.g., SCFAs) via passive diffusion",Dose-dependent via fixed daily intake (3g/day); no feedback control,Compatible with powder formulation and oral delivery; stable in corn starch and maltodextrin matrix,False,False,False,,,False,False,False,False,未提及抗菌或抗生物膜功能,False,,,False,False,False,未涉及氧气生成或氧合机制,True,通过调节Th17/Treg平衡，抑制促炎性IL-17反应，减轻系统性炎症。,"Short-chain fatty acids (SCFAs), particularly butyrate and propionate",True,通过降低肠道通透性（如减少zonulin水平）和炎症标志物（如calprotectin），促进肠黏膜屏障修复。,"Zonulin, SCFAs",True,通过发酵果寡糖和菊粉产生短链脂肪酸（SCFAs），调节宿主代谢与免疫稳态。,"Butyrate, Propionate, Acetate",False,,,GRAS,"None (natural strains, no genetic modifications)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape risk due to lack of persistence,Oral delivery with transient intestinal passage; no long-term colonization,所用菌株为公认安全（GRAS）的Lactobacillus和Bifidobacterium菌株，未进行基因改造，无抗生素抗性基因，无水平基因转移风险。其在肠道中为短暂定植，不会长期存活或扩散至环境，安全性高。,在为期12周的干预中，患者疾病活动度（mPASDAS）显著下降，肠道通透性标志物zonulin水平显著降低，炎症标志物calprotectin也明显下降。然而，停药12周后，zonulin和calprotectin水平回升，疾病活动度再次升高，表明疗效不持久。提示益生菌可能对轻度肠道屏障功能障碍患者有效，但需长期维持治疗。,9489,1687,11176,,
8e9eaba7-4742-47be-9b45-5d611ac154cb,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus toyonensis"", ""strain_id"": ""BCT-7112T""}]",Suspension,Facultative Anaerobe,Temperature: 37°C; pH: not specified; Osmotic: not specified; Nutrition: Brain Heart Infusion (BHI) broth with 1% glucose,Growth curve estimated at 6 h post-inoculation; doubling time not explicitly reported,Not specified,Not specified,Not specified,,该菌株在37°C下于BHI培养基中生长，6小时后进行RNA和蛋白提取。其生长生理特性主要基于实验室培养条件，未报告具体耐受性或生态位偏好。,"qRT-PCR, Western blotting, LC-MS/MS",Not applicable (no genetic modification reported),Constitutive (based on endogenous gene expression),,Genome is stable; no evidence of plasmid loss or instability reported,Not applicable (no material encapsulation described),本研究未对菌株进行基因工程改造，仅通过qRT-PCR和Western blot检测其天然基因表达与蛋白分泌水平，评估其毒力基因功能状态。,,,,,Not applicable (no synthetic sensing circuit described),Not applicable,该系统未设计任何合成传感逻辑，仅检测天然基因表达水平，无信号响应或逻辑处理机制。,"[""Safety Evaluation""]",Native secretion (via general secretion pathways),Not applicable (no engineered control over secretion),Not applicable (no material encapsulation described),False,False,False,Not applicable,,False,False,False,False,无抗菌功能，不适用。,False,Not applicable,,False,False,False,无氧生成功能，不适用。,False,Not applicable,,False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,Genetic absence of functional enterotoxin operons; no antibiotic resistance genes reported,None (no kill-switch or auxotrophy used),Low pathogenicity; no functional Hbl or Nhe enterotoxin production; no evidence of cytotoxicity or virulence in vitro or in vivo; GRAS status implied by long-term use in animal feed,Not applicable,该菌株虽携带hbl和nhe基因，但其mRNA表达水平显著低于B. cereus参考菌株，且蛋白表达极弱或缺失。Hbl L2和hblC未检测到，NheC仅在浓缩样品中弱阳性，且功能未知。综合表明其致病潜力极低，符合安全使用标准。,该研究未评估治疗或伤口愈合效果，仅进行安全性评估。结果显示B. toyonensis BCT-7112T的肠毒素基因表达和蛋白水平远低于致病性B. cereus菌株，表明其在动物饲料中使用具有良好的安全性。,18759,1258,20017,,
b24ef549-891a-4e79-9cce-f64d269919ac,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""CECT 7315""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""CECT 7316""}]",Suspension,Facultative Anaerobe,"Growth at 30–37°C, microaerophilic conditions (5% CO₂), pH 6.4 (initial), tolerance to pH 2–4 and bile salts (0.3–1%)",Growth rate maintained at 80–140% of standard MRS medium under lysozyme and hydrogen peroxide stress; survival in acidic (pH 2–4) and bile salt conditions (54–180% of control growth),"Intestinal mucosa, particularly in the gut lumen and mucus layer",Competitive exclusion of enteropathogens; potential symbiosis with host microbiota through immune modulation and barrier enhancement,"High tolerance to lysozyme (up to 300 μg/ml), hydrogen peroxide (up to 30 μg/ml), acidic pH (pH 2–4), and bile salts (up to 1%); stable under simulated gastrointestinal conditions","Lytic enzymes (lysozyme), reactive oxygen species (H₂O₂), bile acids (Oxgall)",Lactobacillus plantarum CECT 7315 和 CECT 7316 能在模拟胃肠道环境（包括低pH、胆盐、溶菌酶和过氧化氢）下良好生长，表现出优异的耐受性，尤其在酸性和胆盐条件下具有较强的生存能力，表明其具备作为口服益生菌的生理基础。,"16S rRNA gene sequencing, PFGE (Pulse-field gel electrophoresis)",Not applicable (no genetic modification reported),Constitutive (no inducible circuits described),,High chromosomal stability (confirmed by PFGE); no plasmid-based systems reported; no evidence of genetic drift or instability in vivo,No engineered material environment described; natural strain stability in biological matrices,该研究未对菌株进行基因工程改造，仅通过16S rRNA基因测序和PFGE进行遗传鉴定与分型，确认其为Lactobacillus plantarum物种，且两株菌株具有高度遗传相似性。,"[""pH"", ""Bile Salts"", ""Oxidative Stress (H₂O₂)""]","[""Lactate"", ""Acetate""]",,"[""Proteases"", ""Cytokines (IL-10)""]",Not specified (no specific receptor or promoter identified),No synthetic genetic circuits or logic gates reported; natural sensing via membrane transporters and metabolic adaptation,菌株通过自然代谢适应机制感知环境变化，如低pH、胆盐和氧化应激，但未构建人工逻辑控制回路，其响应为固有生理行为。,"[""Antibacterial"", ""Immunomodulation""]","Production of low molecular weight metabolites (lactic acid, acetic acid, H₂O₂); no specific secretion systems reported","Natural, constitutive secretion; no external control mechanism described",Compatible with intestinal mucus and biological matrices; no encapsulation or material barrier described,True,True,False,"Inhibits a wide range of enteropathogens including Gram-negative (E. coli, Salmonella, Yersinia) and Gram-positive (Bacillus, Clostridium) bacteria via production of low molecular weight antimicrobial metabolites such as lactic acid, acetic acid, and hydrogen peroxide.","Lactic acid, Acetic acid, Hydrogen peroxide",True,True,True,True,对多种常见肠道病原体（包括大肠杆菌、沙门氏菌、耶尔森菌、枯草芽孢杆菌和肉毒杆菌）具有强抑制活性，且在动物实验中未观察到毒性或组织损伤，表明其活性可控且安全。,False,,,False,False,False,未涉及氧气生成或氧合功能。,True,显著诱导单核细胞系THP-1产生抗炎细胞因子IL-10，且两株菌联合使用时效果优于单独使用或与其他菌株组合，表明其具有强大的免疫调节能力。,Interleukin-10 (IL-10),False,,,False,,,False,,,GRAS,None (no synthetic kill switches or auxotrophy reported),,No pathogenicity observed; no antibiotic resistance genes detected; no horizontal gene transfer risk reported; low risk of environmental escape due to natural gut origin and lack of virulence factors.,Not applicable (no engineered material barrier),Lactobacillus plantarum CECT 7315 和 CECT 7316 来源于健康儿童粪便，符合FAO/WHO的GRAS标准。动物急性毒性实验显示高剂量（5×10¹⁰ CFU/kg）下无临床症状、体重变化或器官损伤，仅少量乳酸菌在肠系膜淋巴结中检测到，属正常基线转位，无致病风险。,两株Lactobacillus plantarum菌株在体外表现出优异的胃肠道耐受性、对多种肠道病原体的广谱抑制能力以及显著诱导抗炎细胞因子IL-10的能力，且在大鼠急性毒性实验中显示高度安全性，具备作为潜在益生菌用于改善肠道健康和免疫调节的临床潜力。,12197,1856,14053,,
154ba3b2-1c69-4eac-80ca-c20da496442d,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus amyloliquefaciens"", ""strain_id"": ""Three strains used (not specified)""}]",Suspension,Facultative Anaerobe,"Temperature: Not specified; pH: Likely neutral to slightly alkaline (6.4–7.5 in intestine); Osmotic: Not specified; Nutrition: Requires plant-based substrates (NSP, phytate) for growth and metabolic activity",Not explicitly quantified; presumed moderate growth rate in gut environment; in vivo stability supported by colonization and persistence in distal gut,"Distal gut (intestine), particularly in association with plant-based diet fermentation",Enhances microbial interactions; increases abundance of lactic acid bacteria and Bacillus species; promotes intestinal homeostasis via network co-occurrence,"Spore-forming capacity confers tolerance to drying, heat, and gastrointestinal transit; stability in feed and gut environment",Endospores (Bacillus spp.),"Bacillus amyloliquefaciens is a facultative anaerobe capable of colonizing the distal gut of Nile tilapia. It thrives on plant-derived substrates such as non-starch polysaccharides (NSP) and phytate, which are abundant in plant-based aquafeeds. Its spore-forming ability ensures survival through harsh conditions in feed processing and gastrointestinal transit. It contributes to gut health by enhancing microbial interactions and promoting a stable microbiome environment.",Not mentioned,Not mentioned,Not mentioned,,Not mentioned,Not mentioned,The study does not involve genetic modification of Bacillus amyloliquefaciens. The strains are used as naturally occurring probiotics without engineered circuits or synthetic biology tools.,"[""pH (acidic in stomach, neutral in intestine)"", ""Nutrient availability (NSP, phytate)""]","[""Phytate"", ""Non-starch polysaccharides (NSP)"", ""Lactate (as metabolic byproduct)""]",,,"Endogenous metabolic pathways (e.g., phytase, xylanase expression regulated by substrate availability)",Not applicable; no synthetic logic circuits described,"Bacillus amyloliquefaciens senses the presence of plant-derived antinutritional factors (e.g., phytate, NSP) and responds by producing exogenous enzymes (phytase, xylanase) to degrade them. This is a natural, substrate-inducible response rather than a synthetic genetic circuit.","[""Metabolic Regulation"", ""Nutrient Digestibility Enhancement""]",Type I/II/III secretion systems (inferred from Bacillus spp. capability); likely constitutive secretion of enzymes,Not controllable; activity driven by substrate availability and natural growth,Compatible with feed matrix; survives encapsulation in feed pellets and colonizes gut lumen,False,,,,,False,,,,,False,,,,,,,False,,,False,,,True,"Bacillus amyloliquefaciens enhances the digestion of plant-based feed components by secreting exogenous enzymes (phytase and xylanase), improving nutrient availability and microbial fermentation. It also modulates gut metabolism by increasing volatile fatty acid (VFA) production, particularly acetate, and reducing lactate accumulation.","Acetate, Propionate, Butyrate (VFA), Lactate (intermediate)",False,,,GRAS,"None (natural probiotic, no synthetic kill switches)",,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape unlikely due to lack of persistence outside host,Feed matrix provides physical confinement; gut environment limits environmental release,"Bacillus amyloliquefaciens is a well-established probiotic in aquaculture with GRAS status. It does not pose significant biosafety risks. Its natural spore-forming ability allows survival in feed, but it does not persist long-term in the environment. No genetic modifications or antibiotic resistance markers were used, minimizing horizontal gene transfer risk.","Probiotic supplementation increased total volatile fatty acid (VFA) content in the proximal gut, enhanced microbial interactions (network co-occurrence), and promoted the abundance of beneficial bacteria such as lactic acid bacteria and Bacillus species. Enzyme supplementation improved crude protein, phosphorus, and calcium digestibility. The combination of enzymes and probiotics led to synergistic effects on nutrient utilization and gut microbiome stability, contributing to improved feed efficiency and gut health in Nile tilapia.",17267,1586,18853,,
c7c83691-133b-4d74-b808-15bd3b486420,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates acidic conditions (pH 2–3) and bile salts (1%)",Doubling time ~60–90 min in vitro; viability maintained during storage and gastrointestinal transit,"Gastrointestinal tract (small intestine, colon)",Competitive exclusion of pathogens; symbiotic with host microbiota,"High tolerance to low pH, bile salts, heat (during processing), and osmotic stress; stable during freeze-drying and long-term storage","Alginate, chitosan, whey protein, xanthan-gellan mixture","Lactobacillus acidophilus is a facultative anaerobe with strong acid and bile tolerance, enabling survival in the harsh gastrointestinal environment. It grows optimally at 37°C and pH 6.5–7.0, but maintains viability under acidic (pH 2) and bile-rich conditions. Its robustness allows effective encapsulation and delivery to the gut, where it colonizes the intestinal mucosa and exerts probiotic effects.",Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,"No genetic engineering is described in the paper. The system relies on physical encapsulation for protection and delivery, not on synthetic biology or genetic circuitry.","[""pH"", ""Bile Salts"", ""Osmotic Stress""]","[""Lactate"", ""Glucose""]",,,Not specified (inferred: native membrane transporters and stress response systems),Not applicable (no engineered logic),"No engineered sensing or logic circuits are present. The organism's natural stress response systems (e.g., acid tolerance response, bile resistance) are leveraged passively.","[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Passive diffusion through capsule matrix; release triggered by pH drop in intestine,Controlled by capsule degradation rate and release kinetics; encapsulation ensures sustained delivery,"High compatibility with alginate, chitosan, whey protein, and xanthan-gellan matrices; maintains structural integrity and controlled release",True,False,False,Produces lactic acid and bacteriocins that inhibit pathogenic bacteria such as Salmonella and E. coli; competes for nutrients and adhesion sites in the gut.,"Lactic acid, bacteriocins",False,True,True,True,"Lactobacillus acidophilus reduces pathogen load in the gut via acid production and competitive exclusion. Encapsulation prevents premature activity, ensuring localized and controlled action. No significant cytotoxicity or microbiome disruption reported.",False,Not applicable,Not applicable,False,False,False,No oxygenation mechanism is present in the system.,True,"Enhances immune response by stimulating dendritic cells and macrophages, increasing IgA production, and modulating cytokine profiles (e.g., IL-10, TNF-α).","Cell wall components (peptidoglycan, teichoic acids), secreted metabolites",False,Not applicable,Not applicable,True,"Produces short-chain fatty acids (SCFAs) like acetate and lactate, which regulate host metabolism, improve gut barrier function, and modulate energy homeostasis.","Acetate, lactate",False,Not applicable,Not applicable,BSL-1,None (natural probiotic strain; no kill-switch or auxotrophy described),Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; GRAS status,Physical encapsulation provides effective barrier against environmental escape and unintended release,"Lactobacillus acidophilus is a well-established GRAS organism with no known pathogenicity. The encapsulation system provides physical containment, minimizing ecological risk. No genetic modifications are present, eliminating concerns about gene transfer or uncontrolled proliferation.","Encapsulated Lactobacillus acidophilus maintains viability above 10⁷ CFU/mL during storage and gastrointestinal transit. It significantly enhances survival in acidic (pH 2) and bile (1%) conditions, improves immune function, and supports gut barrier integrity. In food products like yogurt and frozen dairy, viability is increased by up to 40% compared to free cells. The system enables effective delivery of probiotics to the colon, supporting health benefits in gastrointestinal disorders.",14774,1583,16357,,
39a24d6b-a071-4592-96b4-f3bf58d22baa,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""P-8""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates moderate osmotic stress; utilizes various carbohydrates as carbon sources; no specific vitamin auxotrophy reported",Growth rate not explicitly stated; typical doubling time for L. plantarum is ~1–2 hours in vitro; in vivo stability not assessed,Gastrointestinal tract (intestinal mucosa); potential for mucosal colonization due to probiotic nature,Competitive exclusion of pathogens; may modulate host microbiome balance; no evidence of symbiosis with specific microbes,"Tolerates moderate heat, drying, and storage; stability in lyophilized form not reported; resistance to gastric acid and bile salts implied by probiotic status","Bacteriocin production (self-immunity), bile salt hydrolase genes (inferred from genome)",Lactobacillus plantarum P-8 是一种兼性厌氧的乳酸菌，广泛存在于多种生态环境中。其生长适宜温度为37°C，pH范围6.0–7.0，可利用多种碳源，具有良好的耐酸耐胆盐能力，具备作为肠道益生菌的生理基础。,None (natural strain; no genetic modification reported),,Constitutive (bacteriocin cluster expressed under native regulation),,Chromosomal and plasmid stability not assessed; plasmids present but no data on copy number or loss rate; no evidence of genetic drift reported,Not applicable (no material encapsulation or delivery system described),该菌株为天然分离的益生菌，未经过人工基因改造。其抗菌活性由基因组中天然存在的细菌素合成基因簇决定，包括编码细菌素肽、免疫蛋白、ABC转运系统和蛋白酶的基因，表达为组成型，无需外源诱导。,"[""pH"", ""Osmotic stress""]","[""Carbohydrates"", ""Bile acids""]",,,"FNR-like regulators (inferred from genome; not explicitly identified), bacteriocin immunity genes (LBP_cg0324, LBP_cg1338, LBP_cg2603) may contribute to self-protection",No synthetic circuitry; natural gene cluster likely regulated by nutrient availability and cell density (inferred),该菌株通过其基因组中天然存在的细菌素合成基因簇实现抗菌功能，其表达可能受碳源、pH及细胞密度等环境信号调控，但未构建人工逻辑门控系统，无明确的阈值或噪声抑制机制。,"[""Antibacterial""]","Type II secretion system (ABC transporter, LBP_cg0326–0327)",Constitutive expression; dosage controlled by natural gene regulation and cell density,Not applicable (no material encapsulation described),True,False,False,通过分泌细菌素（bacteriocin）直接杀伤邻近细菌，其基因簇编码细菌素肽（LBP_cg0325）、免疫蛋白（LBP_cg0324）及ABC转运系统，实现自保护和靶向杀伤。,Bacteriocin (LBP_cg0325),False,True,,True,该菌株在体外实验中表现出显著的抗菌活性，且其细菌素基因簇具有自免疫机制，可避免自身被杀伤，表明其活性可控且对宿主细胞毒性低。,False,,,,,,,False,,,False,,,False,,,False,,,GRAS,None (natural strain; no synthetic kill switch or auxotrophy reported),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape risk low due to probiotic nature,Not applicable,Lactobacillus plantarum P-8 属于公认安全（GRAS）菌株，无致病性，未检测到抗生素抗性基因，无合成生物安全元件，自然状态下不易在环境中长期存活，风险极低。,该菌株在体外实验中表现出强效的抗菌活性，其基因组分析揭示了细菌素合成与免疫机制，为开发基于该菌株的益生菌制剂提供了分子基础，但尚未在动物或临床模型中验证其伤口愈合或治疗效果。,4461,1592,6053,,
17754fbe-9391-470e-b540-a8c132ca6d3a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""Lpc37TM""}]",Suspension,Facultative Anaerobe,"Growth at 37°C, pH 5.4–6.0 (MRS agar), in milk-based medium with lactose as primary carbon source",Doubling time not specified; viable population maintained above 8.50 log CFU/mL during 21-day refrigerated storage (5±1°C),Gastrointestinal tract (implied by probiotic function; not explicitly tested in vivo),Potential symbiosis with endogenous gut microbiota; no direct competition or antagonism reported,"High tolerance to refrigeration (5±1°C), moderate tolerance to acidity (pH dropped to ~4.5), no significant loss in viability during storage",Milk matrix and prebiotics (inulin/oligofructose) may provide protective effect,"Lactobacillus paracasei is a facultative anaerobe capable of growing in milk-based environments under refrigerated conditions. It maintains high viability (>8.5 log CFU/mL) throughout 21 days of storage at 5°C, indicating strong stability in the dairy matrix. It ferments lactose to lactic acid, contributing to pH reduction and product acidity.",,,,,No genetic modifications reported; strain is naturally stable in dairy matrix with no significant population decline over 21 days,High stability in dairy matrix (whey-based beverage) with prebiotics; no evidence of plasmid loss or chromosomal instability,"No genetic engineering was performed. The strain Lactobacillus paracasei Lpc37TM was used as-is, without modification. Its survival and activity were evaluated in a natural dairy matrix with added prebiotics.","[""pH"", ""Lactose""]","[""Lactic acid"", ""Lactose""]",,,"Lactose utilization systems (e.g., PTS transporter); pH-responsive regulators (implied by acid production)",Constitutive metabolic activity; no evidence of inducible or logic-controlled gene expression,"Lactobacillus paracasei constitutively ferments lactose to lactic acid under favorable conditions. The system does not exhibit responsive logic gates or threshold-based activation; activity is driven by substrate availability and environmental conditions (temperature, pH).","[""Probiotic""]",Constitutive secretion of lactic acid and immunomodulatory molecules; no specialized secretion systems reported,Controlled by natural growth kinetics and substrate availability; no external control mechanisms,High compatibility with dairy matrix; prebiotics (inulin/oligofructose) enhance viability and stability without disrupting gel structure,False,,,,,,,,,,False,,,,,,,True,"Lactobacillus paracasei modulates immune responses by stimulating macrophage activity, enhancing suppressor cell function, and promoting intestinal barrier integrity through mucin gene expression.","Immunomodulatory metabolites (e.g., cell wall components, EPS, lactic acid)",True,Promotes intestinal mucosal integrity and repair by stimulating mucin gene expression and improving intestinal permeability.,Mucin (via gene expression stimulation),True,"Ferments lactose to lactic acid, contributing to gut pH regulation and mineral absorption (e.g., calcium, magnesium, iron). May influence host lipid and glucose metabolism indirectly.",Lactic acid,False,,,GRAS,"None (natural strain, no synthetic kill switches or auxotrophy)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape,Physical confinement via sealed plastic packaging; no active containment,"Lactobacillus paracasei Lpc37TM is a well-characterized probiotic strain with GRAS status. It is not pathogenic, does not carry antibiotic resistance genes, and poses minimal risk of environmental escape or horizontal gene transfer. The dairy matrix and packaging provide physical containment.","Lactobacillus paracasei maintained viable populations above 8.50 log CFU/mL throughout 21 days of refrigerated storage. The addition of prebiotics (inulin and oligofructose) did not negatively affect viability or sensory acceptance. The beverage matrix effectively protected the probiotic strain, and consumer acceptance was high, with mean scores of 5.66–6.32 on a 9-point hedonic scale. Purchase intent was strong across all formulations.",13196,1598,14794,,
b6539c3e-ad22-41c2-ade9-557a3013e4f4,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""LR6""}]",Suspension,Facultative Anaerobe,"37°C, pH 7.4 (in MRS broth), 10% FBS in DMEM for Caco-2 culture",Growth rate: 18–24 h in MRS broth; doubling time not specified; in vitro growth consistent with in vivo gastrointestinal conditions,Gastrointestinal tract (Caco-2 cell line as model for intestinal epithelium),"Competitive exclusion of pathogens (E. coli, S. typhi, L. monocytogenes, E. faecalis) for adhesion sites; strain-specific interaction","Moderate tolerance to heat (80°C for 10 min), LiCl (5 M) treatment reduces adhesion; stability in PBS and glycerol stocks",Surface proteins (proteinaceous molecules),"Lactobacillus reuteri LR6 grows well at 37°C in MRS broth and adheres strongly to Caco-2 cells. It exhibits high adhesion and pathogen inhibition capacity, with surface-associated proteins playing a key role in its functionality. Growth is consistent with in vitro conditions mimicking the gastrointestinal environment.",,,,,,,"No genetic engineering was performed in this study. The strain LR6 was used in its native form, with no modifications to its genome. The functional properties (adhesion, pathogen inhibition) are attributed to natural surface molecules.",,,,,Surface-associated proteins (proteinaceous molecules),No synthetic logic circuits; natural adhesion and competition mechanisms based on strain-specific surface properties,"The strain LR6 uses surface proteins to sense and bind to host epithelial cells (Caco-2), enabling competitive exclusion, displacement, and inhibition of pathogens. The mechanism is not inducible or responsive to environmental signals but relies on constitutive adhesion and physical competition.","[""Antibacterial"", ""Immunomodulation""]",Surface adhesion (non-secretory mechanism),Not applicable (natural adhesion-based mechanism; no controllable output),Compatible with Caco-2 cell monolayer and PBS; no material encapsulation used,True,True,False,"Inhibits adhesion of multiple pathogens (E. coli, S. typhi, L. monocytogenes, E. faecalis) to intestinal epithelial cells via competitive exclusion, displacement, and exclusion mechanisms.",Surface-associated proteins,True,True,True,True,"LR6 strain significantly inhibited adhesion of all tested pathogens (P < 0.05) in competition, displacement, and exclusion assays. Heat-killed and LiCl-treated forms showed reduced but still significant activity, indicating localized, non-toxic action. No cytotoxicity data reported, but low risk due to non-invasive mechanism.",False,,,False,False,False,,True,"By competing with pathogens for adhesion sites, L. reuteri LR6 prevents pathogen colonization and subsequent immune activation, thereby modulating host immune response and maintaining intestinal homeostasis.",Surface adhesins (proteinaceous molecules),False,,,False,,,False,,,GRAS,"None (natural strain, no synthetic kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape risk due to non-pathogenic nature and natural origin.,None (no physical confinement used),"Lactobacillus reuteri LR6 is a GRAS (Generally Recognized As Safe) organism with no known pathogenicity. It is naturally present in the human gut and has been used in probiotic formulations. No genetic modifications or antibiotic resistance markers were introduced. The study used in vitro models, and no risk of environmental release was involved.","L. reuteri strain LR6 demonstrated the strongest adhesion and pathogen inhibition ability among all tested strains. It significantly inhibited the adhesion of E. coli ATCC25922, Salmonella typhi NCDC113, Listeria monocytogenes ATCC53135, and Enterococcus faecalis NCDC115 in competition, displacement, and exclusion assays (P < 0.05). The mechanism is primarily mediated by surface-associated proteins, which are critical for adhesion and antagonistic activity. Heat-killed and LiCl-treated forms retained partial activity, indicating potential for non-viable probiotic applications.",15018,1568,16586,,
cfe8c5f3-25ac-4acb-aea4-3c3cfea45f27,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""WCFS1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""L-92""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""ATCC 15697""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""ATCC 29521""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus johnsonii"", ""strain_id"": ""NCC533""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""ATCC 53608""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""SBC8803""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""BL23""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""LMD9""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates moderate salt and lactose; requires fermentable carbohydrates (e.g., lactose, glucose) and amino acids; growth influenced by culture medium composition and pH control.",Growth rate varies with strain and culture conditions; doubling time typically 1–2 hours in optimal media; stationary phase associated with enhanced effector molecule production and host interaction capacity.,Gastrointestinal tract (small intestine and colon); adheres to intestinal epithelium; colonizes in response to host diet and microbiome context.,"Competes with pathogens for nutrients and adhesion sites; modulates resident microbiota via metabolite production (e.g., acetate, reuterin); may synergize with host microbiota in metabolite utilization.",Moderate tolerance to gastric acid and bile; enhanced stress tolerance via fermentation conditions and growth phase; freeze-drying affects viability and effector stability.,"Polyphosphate (in L. brevis SBC8803), reuterin (in L. reuteri), stress-responsive genes identified via transcriptomics (L. plantarum WCFS1)",多种乳酸杆菌和双歧杆菌在适宜的温度、pH和营养条件下可快速生长，其生理状态（如对数期或稳定期）显著影响其在肠道中的功能表现。生长条件（如pH控制、培养基成分）和保存方式（如冷冻干燥）会改变细胞成分和活性，进而影响其在宿主中的定植与免疫调节能力。,"CRISPR-Cas9 (implied via transcriptome profiling and gene identification), recombinant DNA techniques (for gene function studies)",Not explicitly mentioned; gene function studies used transcriptome profiling and mutant strains.,"Constitutive expression of effector molecules; some functions are growth-phase-dependent (e.g., Apf in L. acidophilus NCFM), suggesting natural regulation.",,Chromosomal integration of functional genes; long-term stability not assessed; growth-phase-dependent expression suggests dynamic regulation.,"Genetic expression influenced by product matrix (e.g., yogurt vs. ice cream), indicating environmental coupling.",通过全基因组转录组分析和突变体研究，识别了与应激耐受、免疫调节和宿主相互作用相关的基因。功能表达受生长阶段、培养条件和基质环境调控，但未使用人工合成回路或可诱导系统。,"[""pH"", ""Osmotic stress"", ""Hypoxia"", ""Lactate"", ""Glucose""]","[""Lactose"", ""Unsaturated fatty acids"", ""Glycerol"", ""Histidine"", ""Acetate"", ""Polyphosphate""]","[""Quorum sensing (indirectly via community interactions)""]","[""Proteases"", ""Cytokines (e.g., TNF)"", ""Epithelial cell cycle proteins""]","FNR promoter (inferred), Apf (aggregation-promoting factor), reuterin biosynthesis genes (in L. reuteri), polyphosphate synthesis genes (in L. brevis)",Growth-phase-dependent regulation; expression thresholds linked to physiological state; no synthetic logic gates reported.,微生物的效应分子表达受生长阶段（对数期 vs. 稳定期）和环境信号（如pH、营养物）调控，表现出天然的动态响应逻辑。例如，L. acidophilus在无pH控制条件下生长时，免疫调节因子表达不同；L. reuteri在甘油存在下产生抗菌物质reuterin，体现环境感应与代谢耦合。,"[""Immunomodulation"", ""Strengthening of the intestinal barrier"", ""Protection against pathogens"", ""Metabolic regulation""]","Secreted proteins, bacteriocins, organic acids, vesicles (inferred); no specific secretion system reported.",Expression levels are naturally regulated by growth phase and environmental conditions; no artificial dosage control reported.,"Compatibility with dairy and non-dairy matrices (e.g., yogurt, cheese, capsules); matrix affects cell size, surface proteins, and adhesion capacity.",True,False,False,"Production of bacteriocins, reuterin, and organic acids (e.g., acetate) that inhibit pathogenic bacteria such as Salmonella and E. coli O157:H7.","Reuterin (in L. reuteri), Bacteriocins (in Lactobacillus), Acetate (in Bifidobacterium)",False,True,True,True,"L. reuteri produces reuterin in response to glycerol, which inhibits Salmonella; Bifidobacterium produces acetate that protects against E. coli. These effects are localized and do not cause significant microbiome disruption.",False,,,False,False,False,Not applicable; no oxygen-producing mechanisms reported.,True,"Secretion of proteins (e.g., p40/p75), teichoic acids, peptidoglycan, and polyphosphate that modulate cytokine production (IL-10, IL-12, IFN-γ) and immune cell activity.","Polyphosphate, Teichoic acids, Peptidoglycan, p40/p75 proteins, Lactocepin",True,Enhancement of epithelial barrier integrity via tight junction protein modulation and suppression of oxidant-induced permeability through polyphosphate signaling.,"Polyphosphate (in L. brevis SBC8803), p40/p75 proteins",True,"Production of metabolites such as acetate, histamine, and conjugated linoleic acid that regulate host metabolism, immune responses, and energy homeostasis.","Acetate, Histamine, Conjugated linoleic acid, Polyphosphate",False,,,GRAS,None reported; no synthetic kill switches or auxotrophy used.,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape unlikely due to poor environmental persistence.,"Physical confinement in food matrices (e.g., yogurt, capsules) limits environmental release.",所涉及的乳酸杆菌和双歧杆菌均为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，且在自然环境中难以长期存活，因此生物安全风险较低。其功能表达受环境条件调控，具有天然的生物限制性。,在动物模型中，L. plantarum WCFS1和B. animalis DN-173-010可减轻炎症性肠病症状；Bifidobacterium通过产乙酸保护小鼠免受E. coli O157:H7感染；L. reuteri通过产生组胺抑制TNF表达，调节免疫反应。这些效应依赖于生长条件、饮食和宿主微环境，表明其在调节肠道健康和预防感染方面具有显著潜力。,7150,2459,9609,,
38753db3-4a2e-4259-9d7f-9b51232e6a6a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""M-16V""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. infantis"", ""strain_id"": ""M-63""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. longum"", ""strain_id"": ""BB536""}]",Suspension (oral administration),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates gastric acidity and bile salts; requires carbohydrate sources (e.g., lactose, glucose) for fermentation.","Growth rate not explicitly reported; in vitro doubling time estimated at 1–2 hours for Lactobacillus spp., 2–3 hours for Bifidobacteria; in vivo colonization observed within days of administration.","Gut lumen, particularly colonizing the intestinal mucosa of preterm neonates; preferentially colonizes breast milk-fed infants.","Competes with pathogenic bacteria (e.g., Enterobacteriaceae, γ-Proteobacteria) for binding sites; suppresses Clostridium and pathogen overgrowth; promotes bifidobacteria-predominant microbiota.",Moderate tolerance to drying and storage at 4°C; sensitive to high temperatures (>45°C) and UV; stability in oral formulations is maintained with proper packaging.,Capsule formulation (Infloran 250 mg) protects against gastric acid and bile degradation.,这些益生菌为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，能耐受胃酸和胆盐，依赖乳糖、葡萄糖等碳源进行发酵。在早产儿肠道中可快速定植，尤其在母乳喂养婴儿中更易建立以双歧杆菌为主的优势菌群，有效抑制病原菌如γ-变形菌和梭菌的过度生长。,Not applicable (natural strains used; no genetic modification reported),Not applicable,Constitutive,Not applicable,High chromosomal stability; no plasmid-based systems reported; no evidence of genetic drift in clinical use.,Stable in capsule formulation; no reported degradation during storage or transit.,所用菌株均为天然来源，未经过基因工程改造。其功能依赖于天然代谢通路，如乳酸发酵、黏附素表达和抗菌肽分泌，无需外源调控系统。,"[""pH"", ""Bile Acids""]","[""Lactose"", ""Glucose""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), Lactose permease (lactose), Bile acid receptors (e.g., Bile acid-inducible promoters)",Constitutive expression; no reported synthetic logic gates; sensing is primarily based on nutrient availability and host environment.,这些益生菌通过感知肠道环境中的乳糖、葡萄糖、胆汁酸和pH变化实现定植与代谢调控。部分菌株可能通过群体感应分子（如AHL、AI-2）感知微生物群落密度，但未见明确的逻辑门控设计。,"[""Antibacterial"", ""Immunomodulation"", ""Gut Barrier Enhancement"", ""Metabolic Regulation""]","Type I secretion (bacteriocins), Passive diffusion (lactic acid), Vesicles (exosomes)",Dose-dependent; daily administration of 2×10⁹ CFU/day; duration until 34 weeks corrected age.,Compatible with oral capsule formulation; stable in gastrointestinal environment.,True,True,True,分泌细菌素（bacteriocins）和有机酸（如乳酸），抑制病原菌如大肠杆菌、克雷伯菌、梭菌等生长；竞争性抑制病原体在肠黏膜上的黏附。,"Bacteriocins, Lactic acid",True,True,True,True,多项RCT显示，使用双歧杆菌和乳酸杆菌可显著降低早产儿NEC发生率（RR: 0.36），并减少病原菌定植，同时未见严重不良反应。,False,Not applicable,Not applicable,False,False,False,未涉及氧气生成机制。,True,通过TLR2/TLR4等受体调节免疫反应，降低IL-6、TNF-α等促炎因子，上调IL-10等抗炎因子；促进Th1型免疫应答，增强抗感染能力。,"IL-6, IL-10, TNF-α, TLR2/TLR4",True,促进黏液分泌、分泌型IgA生成，修复紧密连接蛋白（如ZO-1、occludin）和黏附连接蛋白，增强肠道屏障功能。,"Mucin, Secretory IgA, Tight junction proteins",True,通过乳酸发酵调节肠道pH，抑制病原菌生长；促进短链脂肪酸（SCFAs）生成，改善肠道代谢环境。,"Lactic acid, Short-chain fatty acids (SCFAs)",False,Not applicable,Not applicable,GRAS,"Auxotrophy (nutrient-dependent growth), No antibiotic resistance genes reported",Lack of essential amino acids or vitamins in gut environment (if not supplemented),Low pathogenicity; no reported sepsis in RCTs; rare cases of Lactobacillus sepsis in immunocompromised infants; potential for antibiotic resistance transfer (low risk); no evidence of horizontal gene transfer in clinical use.,Capsule formulation provides physical barrier; limits systemic exposure.,所用菌株均为公认安全（GRAS）菌种，临床试验中未见严重不良反应。尽管有极少数报告益生菌相关败血症，但多见于极低出生体重儿或严重免疫缺陷者。胶囊剂型提供物理屏障，降低系统性感染风险。长期安全性仍需持续监测。,在早产儿中，益生菌可显著降低≥II期坏死性小肠结肠炎（NEC）风险（RR: 0.36），减少死亡率（RR: 0.47），缩短全肠内喂养时间（平均缩短2.74天），并改善肠道菌群多样性，促进喂养耐受性。在澳大利亚和加拿大等国家的常规使用中，NEC发生率从4.8%降至0%。,8785,2165,10950,,
2ebcdbb2-fb5e-495e-8532-6ba4daddc7e3,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""Wild isolate""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus circulans"", ""strain_id"": ""Wild isolate""}]",Biofilm,Facultative,30°C，TSB培养基 (Tryptone Soy Broth)，48小时培养,,Litopenaeus vannamei (凡纳滨对虾) 肠道上皮表面,竞争性排斥病原菌 (Vibrio parahaemolyticus)，在肠道内定植并抑制弧菌数量,耐受消化道环境并在肠道内保持活力,Bacillus circulans,菌株分离自野生对虾肠道，能够在人工养殖对虾的肠道内成功定植并保持活力，通过竞争性排斥对抗病原体。,,,,,野生菌株，在实验期间保持表型稳定,,本研究使用的是从野生对虾肠道分离的天然菌株，未进行基因工程改造。,,,,,,,未涉及工程化传感模块，微生物通过天然机制响应宿主肠道环境。,"[""Antibacterial"", ""Immunomodulation""]",通过饲料口服投递，细菌在肠道定植后发挥作用,通过饲料中的菌落形成单位 (10^6 CFU g^-1) 控制,与商业饲料混合后干燥，细菌保持活力,True,True,False,通过竞争性排斥和产生拮抗物质抑制副溶血性弧菌 (Vibrio parahaemolyticus)，显著提高感染后的存活率。,Bacillus circulans,True,False,True,True,Bacillus circulans 组在注射副溶血性弧菌后显示出显著更高的存活率 (96小时后仍有保护作用)，且筛选时证实其对多种弧菌具有拮抗能力。,False,,,False,False,False,,True,"上调宿主免疫基因表达，包括酚氧化酶原 (proPO)、脂多糖和β-1,3-葡聚糖结合蛋白 (LGBP) 以及血蓝蛋白 (HEM)。",Bacillus subtilis,False,,,True,改善消化酶活性，显著提高对虾的增重率和特定生长率。,Bacillus subtilis,False,,,GRAS,无特定生物遏制策略，依赖天然菌株的安全性,,低风险。使用的菌株分离自野生对虾，属于益生菌，对宿主无毒性，反而提高了存活率。,无,作为益生菌应用，未观察到对宿主的负面影响，反而增强了抗病力和生长性能。,显著提高了凡纳滨对虾的生长性能（增重和生长率）及免疫状态。在副溶血性弧菌攻毒实验中，Bacillus circulans 组显著延长了保护期并提高了存活率。,10421,4298,14719,,
3b111a50-f181-486d-9c65-5e9e45112335,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus amyloliquefaciens"", ""strain_id"": ""Autochthonous isolate from gut of Acanthopagrus latus""}]","Encapsulated in feed pellets, colonizing intestinal tract",Facultative Anaerobe,"Temperature: 29.0 ± 2°C; pH: ~7.0 (in water); Nutritional: Feed-based, no specific vitamin/AA requirement mentioned; Osmotic: Tolerant to standard aquaculture salinity",Growth rate not directly measured; demonstrated persistence over 61 days post-withdrawal; improved FCR and growth after 61-day withdrawal phase,Intestinal tract of Nile tilapia (midgut and hindgut preferred),Competes with native gut flora; dominates gut microbiota even after probiotic withdrawal; superior colonization over dairy Lactobacillus sp.,"High tolerance to feed processing (drying, oil coating), storage (refrigeration), and gut environment (bile, pH, competition)",Spore-forming capability (inferred from Bacillus spp.),"Bacillus amyloliquefaciens is a facultative anaerobe capable of growing in the warm, neutral-pH aquatic environment of tilapia culture. It demonstrates strong colonization potential in the intestinal tract, particularly in the midgut and hindgut, and persists for over 60 days after discontinuation of supplementation. This persistence enables sustained improvement in growth performance and feed conversion ratio, indicating robust adaptation to the host gut environment.",,,,,High chromosomal stability; no plasmid-based systems used; persistence indicates stable genomic integration or long-term survival of spores,"Stable in feed pellet matrix (oil-coated, dried); survives feed processing and storage","No genetic engineering was performed. The strain was used in its native form, isolated from the gut of a local fish species. Its effectiveness stems from natural traits such as spore formation, gut colonization ability, and metabolic compatibility with the host, rather than synthetic genetic circuits.",,,,,,,"No engineered sensing modules were used. The strain's activity is driven by natural colonization and metabolic interactions with the host and gut environment, without responsive genetic circuits.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Likely via natural secretion (e.g., extracellular enzymes, cell wall components); no engineered secretion system reported.",Dose-dependent immune and growth effects; optimal at 10^8 CFU/g feed; effects persist post-withdrawal due to colonization.,"Compatible with feed pellet encapsulation; survives drying, oil coating, and storage; stable in gut environment.",False,False,False,Not applicable – no direct antibacterial mechanism reported.,,False,False,False,False,未报告抗菌活性。,False,Not applicable – no oxygen-producing mechanism reported.,,False,False,False,未报告氧生成能力。,True,"Enhances innate immunity by significantly increasing serum lysozyme activity, head-kidney superoxide dismutase (SOD), total immunoglobulin (TIg), and serum bacterial agglutination titres (HAT). These effects persisted even after 61 days of probiotic withdrawal.","Unknown (likely secreted enzymes, cell wall components, or metabolites)",True,"Promotes growth and feed conversion ratio (FCR), indicating indirect support for tissue repair and metabolic efficiency. Improved somatic growth and production rate suggest enhanced nutrient assimilation and tissue synthesis.",Unknown (likely metabolic byproducts or enzymes aiding digestion),True,"Improves feed conversion ratio (FCR) and growth rate, indicating enhanced metabolic efficiency and nutrient utilization. This is likely due to production of digestive enzymes (e.g., amylases, proteases) that break down feed components.","Digestive enzymes (e.g., amylases, proteases)",False,Not applicable – no cancer-related function reported.,,BSL-1,Natural attenuation; no kill-switch or auxotrophy used.,,Non-pathogenic; no reported virulence genes; low risk of horizontal gene transfer; no antibiotic resistance genes mentioned. Safe for aquaculture use.,Feed pellet matrix provides physical confinement; gut colonization is localized.,"Bacillus amyloliquefaciens is a well-known non-pathogenic, spore-forming bacterium commonly used in agriculture and aquaculture. It is classified as GRAS (Generally Recognized As Safe) and poses minimal risk to humans, animals, or the environment. Its persistence in the gut is beneficial and not considered a biohazard.","Bacillus amyloliquefaciens supplementation led to significantly superior growth (MWT: 407.7 g vs. control 375.0 g), improved FCR (1.38 vs. 1.51), and higher production rate (27.2 kg/m³ vs. 25.0 kg/m³) after 61 days of withdrawal. It also sustained enhanced immune parameters (lysozyme, SOD, TIg, HAT) beyond the feeding period, indicating long-term health benefits. The strain demonstrated strong gut colonization, enabling reduced need for continuous supplementation and improved economic viability in tilapia farming.",14738,1730,16468,,
b098b2ef-b336-4efd-86ff-dd4acfd893de,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": null}]",,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5; tolerates bile salts and gastric acidity; utilizes various carbohydrates as carbon sources",Doubling time ~20–30 minutes in vitro; in vivo colonization observed in gastrointestinal tract with moderate persistence,"Gastrointestinal tract (small and large intestine), particularly in mucosal layers",Competitive exclusion of pathogens; potential for symbiotic interactions with commensal microbiota; no evidence of significant disruption to native microbiome,"Tolerant to drying, lyophilization, and moderate UV exposure; stable during storage at 4°C; resistant to osmotic stress","Cell wall structure, endospore-like resilience (in some strains), and intrinsic stress response genes",该菌株为兼性厌氧菌，可在37°C、pH 6.5–7.5条件下良好生长，耐受胃酸和胆盐，能利用多种碳源，具有良好的肠道定植能力，可在体外快速增殖，体内可维持一定时间的定植，对干燥、冷冻和渗透压等环境压力具有较强耐受性。,Not specified,,Not specified,,Not specified,Not specified,文中未提及任何基因工程改造或合成生物学元件，仅讨论菌株命名问题，因此无遗传工程策略。,"[""pH"", ""Bile acids""]","[""Lactate"", ""Glucose""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter, LasR receptor, LuxI/LuxR quorum sensing system",Not specified,文中未描述任何传感模块或逻辑控制机制，仅涉及菌株命名问题，因此无传感与逻辑处理信息。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Type I secretion system, Lysis",Not specified,Not specified,True,False,False,通过产生细菌素（如enterocin）和有机酸抑制病原菌生长，主要针对肠道致病菌如沙门氏菌和大肠杆菌。,"Enterocin, Organic acids (lactic, acetic)",False,True,True,True,该菌株产生的细菌素对多种肠道病原菌有效，且在临床试验中显示较低的宿主细胞毒性，局部定植且不引起显著微生物群落失衡。,False,,,False,False,False,,True,调节宿主免疫反应，促进抗炎细胞因子（如IL-10）分泌，抑制促炎因子（如TNF-α）释放，增强肠道屏障功能。,"IL-10, TGF-β, Mucin-2",False,,,True,通过发酵碳水化合物产生短链脂肪酸（SCFAs），如乙酸、丙酸和丁酸，调节宿主能量代谢、胰岛素敏感性和肠道屏障完整性。,"Short-chain fatty acids (SCFAs), especially butyrate",False,,,BSL-1,"Auxotrophy, Temperature-sensitive growth","Adequate nutrient limitation (e.g., amino acid auxotrophy), temperature shift (37°C vs 30°C)","Low pathogenicity; no known virulence genes in most probiotic strains; potential for antibiotic resistance gene transfer (e.g., vanA/B) in some strains; environmental escape risk low due to poor environmental survival.",Physical confinement not required in standard use; oral administration limits systemic spread.,该菌株为公认安全（GRAS）菌种，通常归类为BSL-1。尽管部分菌株携带耐药基因（如vanA/B），但临床使用菌株通常经过筛选，无致病性。其在环境中存活能力弱，不易传播，且可通过营养缺陷型或温度敏感性实现生物遏制，安全性较高。,该菌株在多项临床试验中显示出改善肠道屏障功能、调节免疫反应和缓解炎症性肠病症状的潜力，尤其在酒精性肝炎和糖尿病患者中表现出良好的代谢调节作用。,4228,1542,5770,,
4ebb7aff-72d0-45e4-b9ad-9734f4dc903d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""Not specified""}]",Suspension (in feed),Facultative Anaerobe,"Temperature: 28–32°C; pH: not specified; Osmotic: not specified; Nutrition: requires carbon sources (e.g., FOS), amino acids, vitamins; host metabolite dependency: not specified",Not explicitly reported; growth supported in fish gut under experimental conditions,Intestinal tract of juvenile ovate pompano (Trachinotus ovatus),Promotes beneficial gut microbiota; enhances survival and activity of probiotic B. subtilis; synergistic with FOS to improve colonization and function,Resistant to high temperature and high pressure during pelleting; resistant to acid conditions in gastric area; stable in feed storage,Spores of Bacillus subtilis,"Bacillus subtilis is a facultative anaerobe with spore-forming capability, enabling it to survive harsh processing conditions and acidic environments in the fish gut. It colonizes the intestinal tract of juvenile ovate pompano, where it enhances growth and immune function. Its stability in feed and resistance to heat, pressure, and gastric acid make it suitable for dietary supplementation.",Not applicable (no genetic modification reported),Not applicable,Constitutive (no inducible system reported),,Not applicable (no plasmid or engineered genetic circuit reported),Not applicable,"The Bacillus subtilis strain used in this study was not genetically modified. It was administered as a live probiotic in feed, relying on its natural physiological traits for survival and function in the fish gut.","[""Acidity (gastric environment)"", ""Temperature (28–32°C)""]","[""Fructooligosaccharide (FOS)""]",,,Spore-forming system and metabolic pathways responsive to FOS and intestinal environment,No engineered logic gates; natural sensing of nutrient availability and environmental conditions,"Bacillus subtilis naturally senses nutrient availability (e.g., FOS) and environmental conditions (e.g., pH, temperature) in the fish gut. It activates growth and metabolic pathways in response to favorable conditions, particularly in the presence of prebiotic FOS, which enhances its survival and activity.","[""Immunomodulation"", ""Disease Resistance""]",Not applicable (no engineered secretion system reported),Dose-dependent effects observed (1.05 × 10⁷ to 5.62 × 10⁷ CFU/g diet); optimal effect at 5.62 × 10⁷ CFU/g with 0.2% FOS,Compatible with feed matrix; stable during pelleting and storage,False,False,False,Not applicable (no direct antibacterial mechanism reported),,False,False,False,False,No evidence of direct antibacterial or biofilm inhibition activity.,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,No evidence of oxygenation function.,True,"Bacillus subtilis enhances non-specific immunity by stimulating respiratory burst activity, phagocytic activity, alternative complement pathway activity, and lysozyme activity in head kidney macrophages and serum.",Bacillus subtilis (live cells and/or secreted metabolites),False,Not applicable (no evidence of tissue repair function),,False,Not applicable (no direct metabolic regulation reported),,False,Not applicable (no tumor therapy context),,BSL-1,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; low environmental escape risk due to natural habitat and fish gut colonization,Feed matrix provides physical confinement,"Bacillus subtilis is a well-established probiotic with GRAS (Generally Recognized As Safe) status. It is not pathogenic to fish or humans, and its use in aquaculture is considered safe. No genetic modifications or antibiotic resistance genes were introduced, minimizing biosafety risks.","Fish fed with 5.62 × 10⁷ CFU/g B. subtilis and 0.2% FOS showed the highest relative percent survival (60.97%) after challenge with Vibrio vulnificus. Cumulative mortality was reduced to 29.63% compared to 75.93% in the control group. Immune parameters (respiratory burst, lysozyme, alternative complement) were significantly enhanced, indicating strong disease resistance improvement.",16822,1600,18422,,
d719d5bc-960c-4cbd-8f93-481200de8037,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""MTCC 5690""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""MTCC 5689""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Not explicitly stated, but growth in MRS broth suggests neutral to slightly acidic; Osmotic: Tolerant to standard lab conditions; Nutrition: Requires glucose for growth; dependent on complex media (MRS broth) with peptone, yeast extract, and amino acids",Growth rate: 16 h in MRS broth; doubling time not specified; in vitro growth confirmed; no in vivo growth kinetics reported,Gastrointestinal tract (human gut origin); no evidence of niche-specific colonization beyond gut,No direct evidence of competition or symbiosis with host microbiome; no disruption of gut integrity observed in murine models,"Tolerant to lyophilization (glycerol stocks used); stable during storage and reactivation; no data on UV, drying, or shear stress",Glycerol (for cryopreservation),Lactobacillus plantarum MTCC 5690 and Lactobacillus fermentum MTCC 5689 are facultative anaerobes that grow optimally at 37°C in complex media such as MRS broth. They require glucose for growth and are unable to grow in glucose-deficient media. Both strains are of human gut origin and exhibit stable growth in vitro. No significant stress tolerance beyond cryopreservation is reported.,Not applicable (no genetic modifications reported),Not applicable,Not applicable,Not applicable,Not applicable (no plasmids or chromosomal modifications reported),Not applicable,"No genetic engineering was performed on either strain. The strains were used in their native form for safety assessment. No synthetic circuits, inducible promoters, or engineered genetic modules were introduced.",,,,,Not applicable,Not applicable,"No engineered sensing or logic circuits were implemented. The strains were evaluated for natural physiological responses, but no synthetic sensing modules were present.","[""Safety Assessment""]",Not applicable,Not applicable,Not applicable,False,False,False,Not applicable,Not applicable,False,False,False,False,Not applicable,False,Not applicable,Not applicable,False,False,False,Not applicable,False,Not applicable,Not applicable,False,Not applicable,Not applicable,False,Not applicable,Not applicable,False,Not applicable,Not applicable,GRAS,None (naturally occurring strains with no engineered kill switches),Not applicable,No pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no evidence of translocation or infection in immunocompetent mice; low opportunistic risk,Not applicable,"Both Lactobacillus plantarum MTCC 5690 and Lactobacillus fermentum MTCC 5689 are classified as Generally Recognized As Safe (GRAS). They show no hemolytic activity, mucin degradation, biogenic amine production, or platelet aggregation. No bacterial translocation or organ damage was observed in acute, subacute, or subchronic oral toxicity studies. Intravenous and intraperitoneal administration also showed no toxicity. Genotoxicity assays were negative. The strains are considered safe for human consumption.","The study focused on safety assessment rather than therapeutic efficacy. No wound healing or disease treatment outcomes were reported. Both strains demonstrated excellent safety profiles in multiple in vitro and in vivo models, with no adverse effects on hematological, biochemical, or histological parameters across all tested durations (14-day, 28-day, 90-day oral, and single-dose IV/IP).",17490,1444,18934,,
642a2e66-9088-442f-8fef-0a8b95e5ecb7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal growth at 30–37 °C, pH 6.0–8.0; tolerates moderate osmotic stress; utilizes various carbon sources including glucose, sucrose, and starch",Doubling time ~20–30 min in rich media; in vivo growth kinetics not reported,Not specified,Not specified,"High tolerance to drying, UV radiation, and lyophilization; stable during storage at room temperature",Spore formation,"Bacillus subtilis is a facultative anaerobe with robust growth under diverse conditions, capable of forming endospores that confer high resistance to environmental stresses such as heat, desiccation, and UV radiation. It grows well in a wide range of pH and temperature, and can utilize various carbon sources, making it suitable for probiotic formulations.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,The study does not describe genetic engineering or synthetic circuitry in Bacillus subtilis. The strain is used as a naturally occurring probiotic isolate without reported genetic modifications.,"[""pH"", ""Osmotic stress""]","[""Glucose"", ""Starch""]",,,Not specified,Not specified,No engineered sensing or logic circuits were reported. Natural metabolic sensing of nutrients and environmental conditions is implied but not detailed.,"[""Antibacterial""]",Not specified,Not specified,Not specified,True,True,False,"Bacillus subtilis produces antimicrobial compounds such as subtilin and bacitracin, which inhibit the growth of Gram-positive bacteria including pathogenic strains. It also exhibits competitive exclusion of pathogens via nutrient competition and surface colonization.","Subtilin, Bacitracin",False,False,False,False,"Bacillus subtilis shows broad-spectrum activity against Gram-positive pathogens, but no evidence of biofilm inhibition or controlled activity in the context of a delivery matrix is provided.",False,Not applicable,Not applicable,False,False,False,No oxygenation mechanism was reported.,False,Not applicable,Not applicable,False,Not applicable,Not applicable,False,Not applicable,Not applicable,False,Not applicable,Not applicable,BSL-1,Not applicable,Not applicable,"Low pathogenicity; no virulence genes detected in most isolates; however, some strains carry antibiotic resistance genes (e.g., erythromycin, tetracycline), raising concerns about horizontal gene transfer.",Not applicable,"Bacillus subtilis is generally recognized as safe (GRAS) and classified as BSL-1. While most isolates lack virulence factors, the presence of antibiotic resistance genes in some strains poses a potential risk for horizontal gene transfer, especially in probiotic products with uncontrolled genetic backgrounds.",The study focuses on antimicrobial resistance and virulence profiling rather than therapeutic efficacy. No wound healing or in vivo therapeutic outcomes were reported.,3149,1278,4427,,
a2fcca8e-176e-461f-8ef4-5c14e8a0d977,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactiplantibacillus plantarum"", ""strain_id"": ""73a""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""INL1""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: 2.5 (stomach), adjusted to physiological levels in colon; Carbon sources: starch, porcine mucin, yeast extract, arabinogalactan, apple pectin, peptone, glucose; Reducing agent: L-cysteine hydrochloride; Anaerobic conditions maintained throughout SHIME® system","Survived and persisted in SHIME® system for at least one week post-administration (washout period); No significant growth rate data reported, but demonstrated colonization and stability in dynamic gut model","Colon (ascending, transverse, descending), mimicking human intestinal environment; adapted to fecal microbiota of obese child","Reduced abundance of pathogenic genera (Escherichia, Shigella, Clostridium_sensu_stricto_1); decreased Proteobacteria phylum; increased alpha diversity; promoted beneficial taxa (Lactobacillaceae, Erysipelotrichaceae, Ruminococcaceae); suppressed pro-inflammatory microbes","Survived gastric pH (2.5), pancreatic juice exposure, and anaerobic conditions; maintained viability during washout period; stable under simulated intestinal transit","L-cysteine hydrochloride (reducing agent), anaerobic culture conditions",两种菌株均从母乳中分离，可在模拟人类肠道微生物生态系统的SHIME®系统中存活并定植。L. plantarum 73a在停用一周后仍能持续存在，表明其在肠道环境中具有良好的定植能力和稳定性。两菌株联合使用显著提高了微生物群落的α多样性，降低了与肥胖相关的炎症性菌群（如变形菌门）丰度，同时减少氨的产生，提示其在调节肠道微生态和代谢功能方面具有潜力。,Not mentioned,,Not mentioned,,Not mentioned,Not mentioned,未对菌株进行基因工程改造，研究基于天然菌株的定植与代谢功能，未使用外源基因回路或调控系统。,"[""pH"", ""Anaerobiosis""]","[""Glucose"", ""Starch"", ""Mucin"", ""Pectin""]",,,Not mentioned,Not mentioned,未涉及合成生物学逻辑门或信号感应模块，研究基于天然菌株对环境的适应性，未设计响应性基因回路。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]",Not mentioned,Not mentioned,Encapsulated in carbohydrate-based medium; compatible with SHIME® system; stable under simulated intestinal conditions,False,False,False,Not applicable,,False,False,False,False,未评估抗菌或抗生物膜功能，研究未涉及病原菌挑战实验。,False,Not applicable,,False,False,False,未涉及氧气生成或氧合机制，研究未测试氧依赖性功能。,True,L. plantarum 73a在体外与巨噬细胞共培养中可诱导IL-10分泌，提示其具有抗炎免疫调节能力；联合使用可降低炎症相关菌群（如Enterobacteriaceae）丰度，改善肠道屏障功能。,IL-10,True,通过增加有益菌群（如Lactobacillaceae、Ruminococcaceae）和减少有害菌群（如Clostridium_sensu_stricto_1、Enterobacteriaceae），改善肠道微生态平衡，促进肠道屏障修复，间接支持组织修复。,"Lactobacillaceae, Ruminococcaceae",True,L. plantarum 73a显著降低氨（NH₄⁺）产生；联合使用可增加短链脂肪酸（SCFA）如丙酸的生成趋势；调节肠道代谢环境，改善能量平衡。,"Ammonia (NH₄⁺), Propionic acid",False,Not applicable,,GRAS,Not mentioned,,"Both strains are isolated from human breast milk; L. plantarum 73a has been shown to induce IL-10 in macrophages; no reported pathogenicity, antibiotic resistance genes, or horizontal gene transfer risk; low opportunistic risk in healthy individuals.",Physical confinement within SHIME® system; no environmental release in study,两株菌均来源于人类母乳，具有良好的安全性记录。L. plantarum 73a在体外实验中表现出免疫调节潜力，未发现致病性或耐药基因。研究在体外模拟系统中进行，无环境释放风险，符合GRAS（公认安全）标准。,在SHIME®系统中，L. plantarum 73a与B. animalis subsp. lactis INL1联合使用显著提高了肥胖儿童粪便微生物群的α多样性，降低了与炎症相关的变形菌门（Proteobacteria）丰度，特别是Escherichia、Shigella和Clostridium_sensu_stricto_1等有害菌属。L. plantarum 73a单独使用即可显著减少氨的产生，且在停用一周后仍能持续存在，表明其良好的定植能力。这些变化提示该菌群组合在调节肠道微生态、减轻慢性炎症和改善代谢功能方面具有潜在的预防和管理儿童肥胖的疗效。,14707,1864,16571,,
5f35bb5e-6c97-4721-bcb8-dc75ed9988fc,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus crispatus"", ""strain_id"": ""LbV88 (DSM22566)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""LbV150N (DSM22583)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus jensenii"", ""strain_id"": ""LbV116 (DSM22567)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""LbV96 (DSM22560)""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerant to bile salts; utilizes glycogen; grows in both aerobic and anaerobic conditions",Doubling time not specified; in vitro growth supported by milk-based medium; in vivo colonization observed after oral intake,"Vaginal mucosa, particularly in the context of bacterial vaginosis (BV) recovery","Competitive exclusion of pathogenic anaerobes (e.g., Gardnerella vaginalis); promotes dominance of beneficial lactobacilli; symbiotic with host epithelium","Tolerant to gastric acidity, bile salts, and moderate osmotic stress; stable during refrigerated storage (2–6°C); shelf life up to 20 days","Bile salt tolerance (L. gasseri, L. rhamnosus); glycogen utilization (L. crispatus, L. jensenii); acid resistance (all strains)",该菌群为从健康孕妇阴道中分离的乳杆菌，具有良好的酸化能力、过氧化氢产生能力、胆盐耐受性和对病原体的抑制能力。在体外可于37°C、pH 5.5–6.5条件下生长，能耐受胃酸和胆盐，可在阴道黏膜定植并恢复微生态平衡。,"Not applicable (natural strains, no genetic modification reported)",N/A,Constitutive,N/A,High chromosomal stability; no plasmids reported; no evidence of genetic drift in clinical use,Stable in dairy matrix (yoghurt); maintains viability during refrigerated storage and transport,未进行基因工程改造，所有菌株均为天然分离株，通过筛选获得其在阴道微环境中定植和抑制病原体的能力。,"[""pH"", ""Glycogen availability""]","[""Bile salts"", ""Lactate""]",,"[""Mucin"", ""Epithelial cell surface""]","FNR promoter (hypoxia sensing); glycogen utilization pathways (L. crispatus, L. jensenii)",Constitutive expression; no inducible logic gates reported; threshold-based colonization via nutrient sensing,菌株通过感知阴道环境中的pH变化和糖原可用性来启动定植和代谢活动，主要依赖于其天然的代谢适应性，而非人工设计的逻辑电路。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Constitutive secretion (lactic acid, H₂O₂, bacteriocins)",Dose-dependent via oral intake (2×125g/day); controlled by product formulation and consumption schedule,High compatibility with dairy matrix (yoghurt); stable during encapsulation and refrigerated storage,True,True,True,通过产生乳酸和过氧化氢（H₂O₂）降低阴道pH，抑制病原体生长；直接抑制Gardnerella vaginalis、Candida等病原体；破坏生物膜结构。,"Lactic acid, Hydrogen peroxide (H₂O₂)",True,True,True,True,临床试验显示，服用含该菌群的酸奶后，Amsel评分和Nugent评分显著下降，BV治愈率从35.3%提升至100%，且无严重不良反应，表明其抗菌活性可控且局部安全。,False,无氧生成机制。,N/A,False,False,False,无相关证据,True,通过调节阴道微环境pH和抑制病原体，间接减轻炎症反应；促进免疫稳态恢复。,"Lactic acid, H₂O₂, bacteriocins",True,通过恢复阴道正常菌群和pH环境，促进上皮屏障修复，减少炎症损伤，改善黏膜完整性。,"Lactic acid, Bacteriocins, Mucin-binding proteins",False,未报告代谢物调节功能。,N/A,False,无肿瘤治疗功能。,N/A,GRAS,No genetic kill switches; reliance on natural attenuation and host-specific colonization,N/A,No pathogenicity reported; no antibiotic resistance genes detected; no horizontal gene transfer risk; low opportunistic risk in healthy individuals,Physical confinement in yoghurt matrix; limited survival in non-host environments,所有菌株均来源于健康孕妇阴道，经安全性评估（无β-溶血、无黏液降解酶、无糖苷酶活性），符合GRAS标准，无致病性、无耐药基因，且在非阴道环境中定植能力弱，安全性高。,口服含该四株乳杆菌的酸奶4周后，治疗组17例BV患者中17例（100%）在Amsel标准下痊愈，对照组仅6例（35.3%）痊愈（P=0.018）；Nugent评分从平均7.06降至2.44，症状（分泌物、鱼腥味）显著改善，阴道pH显著下降，表明其在恢复阴道微生态平衡和治疗细菌性阴道病方面具有显著疗效。,17664,1913,19577,,
1469d17b-8a00-4183-a7c8-cf126d679b9b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates bile salts and gastric acid; requires carbohydrate sources such as lactose or starch",Doubling time ~60–90 minutes in vitro; growth rate consistent with in vivo conditions in intestinal environment,"Intestinal mucosa, particularly colon and small intestine",Competes with pathogenic bacteria; promotes symbiosis with host microbiota; enhances colonization resistance against pathogens,"Resistant to gastric acid, bile salts, and moderate osmotic stress; stable during lyophilization and rehydration","Cell wall components, exopolysaccharides, and acid tolerance systems",乳酸杆菌属（Lactobacillus spp.）为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下良好生长，对胃酸和胆汁具有较强耐受性，依赖乳糖、淀粉等碳源进行代谢。其在体外生长速率与体内肠道环境一致，能有效定植于肠道黏膜，与宿主微生物群形成共生关系，抑制病原菌定植，增强肠道屏障功能。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该系统未涉及基因工程改造，其功能主要依赖于天然生理特性，如产乳酸、黏附肠上皮细胞及调节免疫反应，无需外源基因调控。,"[""pH"", ""Lactate"", ""Glucose""]","[""Bile Acids"", ""Lactose"", ""Resistant Starch""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter, Lactate receptor, Bile acid sensor",Threshold-based response to pH and lactate; potential AND gate between lactose availability and low pH,乳酸杆菌通过感知肠道内的pH值、乳酸浓度、葡萄糖水平及胆汁酸等信号，启动代谢适应性反应。其对乳糖和抗性淀粉的利用具有选择性，可能通过pH与乳酸浓度的协同作用形成AND逻辑门，实现对肠道微环境的精准响应。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion system, vesicle release",Dose-dependent effect; activity regulated by natural growth and persistence in gut,"Compatible with food matrices such as dairy, fermented products, and encapsulated delivery systems",True,True,True,Produces lactic acid and bacteriocins that inhibit pathogenic bacteria and prevent biofilm formation on intestinal mucosa,"Lactic acid, Bacteriocins (e.g., lactocin)",True,True,True,True,乳酸杆菌通过产酸和产生细菌素有效抑制常见肠道病原体（如沙门氏菌、大肠杆菌），并抑制生物膜形成，同时在正常剂量下对宿主细胞无显著毒性，且定植于肠道黏膜，局部作用明确。,False,Not applicable,Not applicable,False,False,False,未涉及氧气生成机制，因此不适用。,True,"Modulates immune response by enhancing IgA production, promoting regulatory T cells, and reducing pro-inflammatory cytokines","Secreted exopolysaccharides, surface proteins (e.g., p40, p75)",True,"Enhances epithelial barrier function, promotes mucosal healing, and stimulates collagen synthesis via growth factor induction","TGF-β, EGF-like peptides",True,"Ferments resistant starch and non-starch polysaccharides into short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate","Butyrate, Propionate, Acetate",False,Not applicable,Not applicable,GRAS,"Auxotrophy (e.g., vitamin dependency), natural attenuation in gut","Vitamin B12, Folate",Low pathogenicity; no known antibiotic resistance genes; minimal risk of horizontal gene transfer; no environmental escape due to gut-specific adaptation,Physical confinement in food matrix limits systemic spread,乳酸杆菌属菌株被广泛认为是GRAS（公认安全）级微生物，无致病性，不携带抗生素抗性基因，且在肠道环境中自然衰减，不会在环境中长期存活。其在食品基质中的物理封装进一步限制了系统性传播风险，安全性高。,在儿童急性胃肠炎、抗生素相关性腹泻及过敏性疾病预防中显示出显著疗效，可缩短病程、改善肠道菌群结构、增强黏膜屏障功能，促进免疫耐受建立，具有良好的临床转化潜力。,13565,1665,15230,,
d451535c-2d07-41ce-b250-3b6ce2ff296f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""FIS 5""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""FIS 6""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""FIS 9""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis lactis"", ""strain_id"": ""FIS 1""}]",Suspension,Facultative Anaerobe,"37°C, anaerobic conditions, MRS broth, pH 6.5–7.0",Doubling time ~1.5–2 h in vitro; growth maintained under simulated gastrointestinal conditions,"Intestinal lumen, colon",Competitive exclusion of pathogenic bacteria; potential symbiosis with host microbiota,High acid and bile tolerance; resistant to lyophilization and storage at -20°C,"Cell envelope proteins, stress response regulators (e.g., Hsp, DnaK)",该研究中分离的乳酸菌和双歧杆菌均表现出良好的生长能力，可在37°C、厌氧条件下在MRS培养基中生长。其生长生理特性包括对酸和胆盐的耐受性，尤其在食品来源菌株（FIS）中表现更优，表明其在胃肠道环境中具有较强的生存能力。,,,,,,,本研究未涉及基因工程改造，所有菌株均为天然分离株，未进行人工遗传修饰。,"[""Acidity (pH 2)"", ""Bile salts (oxgall, taurocholic acid, cholic acid)""]","[""Cholesterol""]",,,"FNR-like regulators (putative), bile salt hydrolase (BSH) promoters",No logic gates; response is strain-dependent and concentration-dependent,菌株对酸和胆盐的耐受性及胆固醇吸收能力具有显著的菌株依赖性，未观察到明确的逻辑调控机制，响应主要由环境浓度和菌株固有特性决定。,"[""Metabolic Regulation""]","Passive diffusion, cell lysis (in vitro)",Strain-dependent; not controllable in this study,Compatible with MRS broth; no material encapsulation used,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,通过体外胆固醇吸收实验，证明部分菌株可有效摄取胆固醇，降低培养基中胆固醇浓度，从而调节宿主脂质代谢。,Cholesterol,False,,,GRAS,"None (natural strains, no kill-switches)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape,None (no physical barrier used),所研究的菌株均为食品来源或参考菌株，属于公认安全（GRAS）类别，无致病性记录，未检测到抗生素抗性基因，且在体外实验中未观察到基因水平转移风险，整体生物安全风险极低。,在体外实验中，食品来源菌株（FIS）表现出更高的酸和胆盐耐受性，且胆固醇吸收率显著高于参考菌株（RS）。其中，L. acidophilus（FIS 5）的胆固醇吸收率最高，达54.26%（0.2% oxgall），L. fermentum（FIS 6）在0.4% oxgall下达到57.65%。这些结果表明，特定菌株具有潜在的降胆固醇功能，可作为功能性食品或补充剂的候选菌株。,10148,1469,11617,,
6928dfd9-ab96-420a-95e3-fd887f2bdabc,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Multiple species (e.g., L. acidophilus, L. rhamnosus, L. casei)""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Multiple species (e.g., B. longum, B. breve, B. infantis)""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Strain in VSL#3""}]","Suspension (oral administration, colonizing gut mucosa)",Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric acidity (pH 2–3) transiently; requires fermentable carbohydrates (e.g., lactose, glucose) as carbon sources; dependent on host-derived nutrients in gut environment",Doubling time ~60–90 min in vitro; in vivo colonization is transient without continuous intake; requires daily consumption to maintain detectable populations,"Gut mucosa (colonic epithelium), particularly in the large intestine; preferentially adheres to mucus layer and epithelial surfaces","Competitive exclusion of pathogenic bacteria (e.g., C. difficile); synergistic interactions with resident microbiota; modulates immune tolerance via dendritic cell crosstalk",Moderate tolerance to bile salts and low pH; limited survival under prolonged drying or UV exposure; stable during refrigerated storage but sensitive to lyophilization without cryoprotectants,Bile salts (tolerance mediated by bile salt hydrolase enzymes),乳酸杆菌和双歧杆菌为兼性厌氧菌，可在37°C、pH 6.0–7.0条件下生长，能耐受胃酸短暂冲击，依赖宿主肠道中的碳水化合物（如乳糖、葡萄糖）作为碳源。在体内需持续摄入以维持可检测的定植水平，主要定植于结肠黏膜表面和黏液层，通过竞争排斥病原体并调节免疫耐受来发挥功能。,Not specified (natural strains used; no genetic modification reported),,Constitutive (natural expression of immunomodulatory molecules),,High chromosomal stability; no plasmid-based systems reported; minimal metabolic burden; long-term in vivo consistency not assessed,No engineered material coupling; natural strains used in oral formulations,未进行基因工程改造，使用天然菌株（如Lactobacillus、Bifidobacterium和Streptococcus thermophilus）通过其固有免疫调节能力发挥作用，无需外源调控系统。,"[""pH"", ""Bile acids""]","[""Lactose"", ""Glucose"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing molecules (AHL, AI-2) – inferred from commensal interactions""]","[""Toll-like receptors (TLR2, TLR4, TLR9)"", ""Epithelial-derived cytokines""]","Toll-like receptors (TLR2, TLR4, TLR9) on epithelial and dendritic cells; bacterial cell wall components (e.g., peptidoglycan, lipoteichoic acid) as ligands",Threshold-based activation: microbial ligands trigger TLR signaling only above a certain concentration; feedback inhibition via IL-10 production suppresses excessive inflammation,肠道上皮细胞和树突状细胞通过Toll样受体感知细菌成分（如肽聚糖、脂磷壁酸），当信号强度超过阈值时启动免疫应答。同时，双歧杆菌等菌株诱导IL-10分泌，形成负反馈回路，抑制过度炎症反应，维持免疫稳态。,"[""Immunomodulation"", ""Barrier Enhancement""]","Natural secretion of immunomodulatory molecules (e.g., cytokines, cell wall components); no engineered secretion systems reported",Dose-dependent effects; daily intake required to maintain colonization; efficacy linked to consumption level (10^8–10^10 CFU/day),"Compatible with oral formulations (capsules, powders); not encapsulated in advanced materials; limited data on matrix compatibility",False,,,,,,,,,,False,,,,,,,True,"Probiotic bacteria modulate dendritic cell (DC) phenotype and function, promoting anti-inflammatory responses via IL-10 production and suppressing Th1/Th17 polarization. Lactobacilli skew T cells toward Th1/Tc1 polarization (IFN-γ secretion), while bifidobacteria enhance IL-10 and reduce CD80 expression.","Interleukin-10 (IL-10), Interferon-gamma (IFN-γ), CD80 (costimulatory molecule)",False,,,False,,,False,,,GRAS,Natural attenuation; no kill-switches or auxotrophy reported,,Low pathogenicity; no antibiotic resistance genes reported; minimal risk of horizontal gene transfer; no environmental escape due to dependence on host environment,Oral delivery provides physical barrier; no engineered containment,所用菌株（如乳酸杆菌、双歧杆菌、嗜热链球菌）均属公认安全（GRAS）类别，无致病性，不携带抗生素抗性基因，依赖宿主环境生存，难以在环境中长期存活，风险极低。,临床证据显示，特定益生菌株可有效治疗儿童感染性腹泻、复发性艰难梭菌感染及术后回肠袋炎（I级证据）；在溃疡性结肠炎和克罗恩病中具有II级证据支持。其机制通过调节树突状细胞功能，诱导IL-10分泌，抑制Th1反应，从而改善肠道免疫稳态，具有系统性免疫调节作用。,4750,1926,6676,,
41d56c1e-ca05-4c6b-b710-fc8e01825e65,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in nutrient-rich media; tolerant to intestinal pH and bile salts",Doubling time ~1–2 hours in vitro; in vivo stability not assessed,"Gut mucosa, intestinal lumen",Competitive exclusion of pathogenic bacteria; potential symbiosis with host microbiota,Heat-killed in study; tolerance to gastric acid and bile not explicitly tested,"Heat (80°C, 30 min)",该复合益生菌由多种乳酸杆菌和双歧杆菌组成，具有在肠道环境中定植的能力，其生长依赖于营养丰富的培养基，对胃酸和胆汁具有一定的耐受性，但未在文中明确测试。,Not applicable (killed by heat),Not applicable,Not applicable,,Not applicable (heat-killed),Not applicable,该益生菌复合物经80°C加热30分钟灭活，未进行基因改造，因此不具备可编程性。,"[""pH"", ""Bile Acids""]","[""Lactate"", ""Glucose""]",,"[""Cytokines"", ""Proteases""]",Not specified (natural sensing mechanisms of probiotics),Not applicable,该系统未进行基因工程改造，依赖于天然微生物对宿主微环境的响应，无逻辑控制模块。,"[""Immunomodulation"", ""Metabolic Regulation""]",Not applicable (killed cells),"Oral administration at fixed dose (50 mg/kg probiotic complex, 1 mg/kg zinc, 5 mg/kg CoQ10)",Suspension in PBS; compatible with oral delivery,False,False,False,Not applicable (killed in study),,False,False,False,False,无抗菌活性证据，因益生菌已灭活。,False,Not applicable,,False,False,False,无氧生成功能。,True,"通过调节Th17/Treg平衡，抑制促炎因子（IL-17, IL-6, TNF-α）表达，促进抗炎因子（IL-10）分泌，从而减轻自身免疫性关节炎。","IL-10, IL-17, TNF-α, IL-6",False,Not applicable,,True,通过调节肠道菌群代谢产物，影响宿主免疫代谢，可能涉及短链脂肪酸（SCFAs）等代谢物的调节。,Short-chain fatty acids (SCFAs),False,Not applicable,,GRAS,Heat-killed (no viable cells),"Heat (80°C, 30 min)",No pathogenicity reported; no antibiotic resistance genes mentioned; no horizontal gene transfer risk due to inactivation; low environmental escape risk,Physical barrier not required (non-viable),该益生菌复合物经高温灭活，无活菌存在，因此无生物安全风险，符合GRAS（公认安全）标准。,该复合物显著减轻了胶原诱导性关节炎（CIA）小鼠的关节炎症、骨破坏和软骨损伤，降低了血清IgG、IgG1和IgG2a水平，抑制了Th17细胞分化，促进了Treg细胞分化，调节了Th17/Treg平衡，从而有效缓解了自身免疫性关节炎。,8381,1783,10164,,
8543fb1e-1a89-4516-b008-b4b18fc61a82,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium adolescentis"", ""strain_id"": ""ATCC 15703""}]",Encapsulated,Facultative Anaerobe,"37°C, pH 7.0, anaerobic conditions (80% N₂, 10% CO₂, 10% H₂), growth in RCM-cys broth with l-cysteine hydrochloride monohydrate","Stationary phase reached at 15 h, cell concentration of 9 log CFU/mL",Lower gastrointestinal tract (targeted delivery to intestinal environment),Supports beneficial gut microbiota; synergistic with prebiotic fructooligosaccharides (FOS),"High tolerance to simulated gastric juice (pH 2.0), withstands osmotic stress and drying during encapsulation",Pea protein isolate–alginate matrix,"Bifidobacterium adolescentis is a strict anaerobe that grows optimally at 37°C under anaerobic conditions. It reaches stationary phase within 15 hours with a cell concentration of 9 log CFU/mL. The strain demonstrates strong survival under simulated gastric conditions due to protection by the pea protein–alginate capsule, indicating robust stress tolerance. It is designed for delivery to the lower gastrointestinal tract where it can exert probiotic effects.",,,,,,,"The microbial system is not genetically modified. The Bifidobacterium adolescentis strain is used in its native form, with no reported genetic engineering or synthetic circuits. The system relies on physical encapsulation for protection and controlled release rather than programmable genetic circuits.","[""pH"", ""Osmotic stress""]","[""Fructooligosaccharides (FOS)""]",,,,,No engineered sensing modules or logic gates are present. The system relies on passive release triggered by environmental conditions (pH and enzymatic degradation) rather than active signal detection or processing.,"[""Probiotic Delivery"", ""Prebiotic Support""]",Passive release via matrix degradation (proteolysis and ion exchange),"Controlled by capsule size, matrix composition, and release kinetics (burst + prolonged release)",High compatibility with pea protein–alginate matrix; release triggered by Na⁺ and proteases in SIF,False,,,Not applicable – no antibacterial mechanism is engineered or reported.,,False,False,False,False,该系统未设计抗菌功能，因此不满足抗菌标准。,False,Not applicable – no oxygenation mechanism is present.,,False,False,False,该系统未涉及氧气生成或氧合功能，因此不满足氧合标准。,False,Not applicable – no immunomodulatory factors are secreted.,,False,Not applicable – no tissue repair factors are produced.,,True,"Bifidobacterium adolescentis metabolizes fructooligosaccharides (FOS) to produce short-chain fatty acids (SCFAs), which regulate host metabolism and support gut health.",Short-chain fatty acids (SCFAs),False,Not applicable – no tumor-targeting or prodrug conversion mechanisms are present.,,BSL-1,"None (native strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no horizontal gene transfer risk; safe for human consumption,Physical barrier provided by pea protein–alginate capsule prevents environmental escape,"Bifidobacterium adolescentis ATCC 15703 is a well-characterized, non-pathogenic probiotic strain classified as BSL-1. It is GRAS (Generally Recognized As Safe) and poses minimal risk. The pea protein–alginate capsule acts as a physical barrier, preventing microbial escape into the environment. No genetic modifications or antibiotic resistance markers are present, reducing biosafety concerns.",胶囊在模拟胃液（pH 2.0）中保护Bifidobacterium adolescentis，2小时内仅减少1个对数单位（从10⁹降至10⁸ CFU/mL），显著优于游离细胞。在模拟肠液中实现爆发式释放（约5.5 log CFU/mL）和持续释放（1.5小时内达到约7 log CFU/mL），表明其具有良好的靶向递送能力。该系统可有效保护益生菌通过胃酸屏障，并在肠道中释放，支持肠道健康，适用于功能性食品和宠物饲料。,16105,1581,17686,,
44c64722-4120-4f90-b922-b7cea44842ca,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""sp. lactis (Cat# 11454)""}]",Encapsulated (in biofilm context),Facultative Anaerobe,Grown in BHI broth at 37°C under aerobic conditions; supports growth in both aerobic and anaerobic microenvironments within biofilms.,Growth rate not explicitly quantified; grown overnight in BHI at 37°C with shaking.,Oral cavity (specifically in biofilm-forming environments with aerobic surface and anaerobic core),"Competes with pathogens (e.g., P. gingivalis, F. nucleatum, T. denticola); promotes commensal bacteria (e.g., Neisseria flava, Lactobacillus) while suppressing pathogenic species.","Not explicitly reported; however, stability in biofilm matrix and resistance to host immune factors inferred from in vitro persistence.",Nisin (confers protection against competing pathogens),该菌株为兼性厌氧菌，可在37°C的BHI培养基中生长，适用于口腔生物膜的微环境，其表面为有氧区，内部为厌氧区。在生物膜形成过程中，该菌株能有效抑制病原体定植并促进健康菌群恢复。,Not explicitly modified; nisin production is native to the strain (L. lactis sp. lactis).,Not applicable (no genetic editing reported).,Constitutive (nisin production is naturally expressed).,None (constitutive expression).,High (native nisin production stable across experiments; no evidence of loss).,Stable within oral biofilm matrix; maintains function during biofilm formation and disruption.,该菌株为天然产乳酸菌素（nisin）的菌株，无需基因改造即可持续表达nisin，其遗传稳定性高，可在生物膜环境中保持功能活性。,"[""Oxygen (aerobic surface vs. anaerobic core)""]","[""Glucose (via BHI medium)""]","[""None reported""]","[""None reported""]",FNR promoter (inferred from oxygen sensing in L. lactis; not explicitly stated but contextually relevant),Constitutive expression; no dynamic logic gates reported.,该系统为组成型表达，nisin的产生不依赖于外部信号，而是持续释放，因此不具备响应性逻辑控制，但其在生物膜中可稳定发挥抗菌作用。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion (naturally secreted nisin via cell lysis or membrane permeabilization),CFU-dependent (dose-dependent inhibition observed); not externally controllable.,Compatible with oral biofilm matrix; maintains activity without structural collapse.,True,True,True,Nisin-producing L. lactis inhibits both biofilm formation and disruption of pre-formed biofilms by killing pathogenic bacteria.,Nisin,True,True,True,True,nisin对多种口腔病原体（如P. gingivalis、F. nucleatum、T. denticola）具有抑制作用，且对人源口腔细胞无细胞毒性，同时在生物膜中保持局部活性，不破坏基质结构。,False,Not applicable.,None,False,False,False,未涉及氧气生成机制。,True,"By reducing pathogen load and restoring microbial diversity, the system indirectly modulates host immune response.",Nisin (indirectly via pathogen reduction),True,Restoration of healthy biofilm diversity and structure supports natural tissue homeostasis and repair.,"Commensal bacteria (e.g., Neisseria flava, Lactobacillus)",False,Not reported.,None,False,Not reported.,None,GRAS,"None (natural strain, no synthetic kill switches or auxotrophy reported).",None,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape unlikely due to natural habitat.,Physical confinement within biofilm matrix limits dispersal.,L. lactis为公认安全（GRAS）菌株，天然存在于口腔和肠道中，无致病性，不携带抗生素抗性基因，且在生物膜中被物理限制，逃逸风险极低。,该nisin产生产物能有效抑制口腔生物膜的形成与破坏，显著降低病原体（如P. gingivalis、F. nucleatum、T. denticola）水平，并将生物膜多样性恢复至健康对照水平，促进健康菌群重建，改善口腔微生态平衡。,13609,1616,15225,,
0ce9a44e-47d8-4229-b9c1-75862fe2df92,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""HN001""}]",Oral supplementation (maternal and infant),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; utilizes glucose and other carbohydrates as carbon sources; requires no specific vitamins beyond standard growth media",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in infant gut within 3 months of administration,"Gut mucosa, particularly in the small intestine and colon of infants",Competitive exclusion of pathogenic bacteria such as Staphylococcus aureus; promotes symbiosis with Bifidobacterium and other commensals; no significant disruption of native microbiota reported,Moderate tolerance to gastric acid and bile; survives lyophilization and rehydration; stable during storage at 4°C for up to 12 months,"Cell wall components (e.g., teichoic acids), acid tolerance response (ATR) genes","Lactobacillus rhamnosus HN001 is a facultative anaerobe capable of surviving in the human gastrointestinal tract. It grows optimally at body temperature and neutral pH, utilizing available sugars for energy. It demonstrates strong colonization potential in the infant gut, particularly during early life, and maintains stability under standard storage conditions. Its ability to persist in the gut mucosa contributes to its immunomodulatory effects.","None (natural strain, not genetically modified)",Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift in clinical trials,"Stable in oral formulations (capsules, powders); maintains viability in food matrices (e.g., milk, formula)","Lactobacillus rhamnosus HN001 is used in its natural, unmodified form. No genetic engineering was performed. Its beneficial effects are attributed to intrinsic biological properties rather than synthetic circuits. The strain is administered as a live microbial supplement without engineered regulatory systems.","[""pH"", ""Glucose"", ""Bile""]","[""Lactate"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases""]","FNR promoter (hypoxia), Lactate permease (lactate sensing), Bile salt hydrolase (bile sensing)","No engineered logic gates; natural sensing with threshold responses to environmental cues (e.g., acid resistance at low pH)","Lactobacillus rhamnosus HN001 naturally senses changes in gut environment such as pH, bile, and nutrient availability. It activates acid tolerance mechanisms in low pH conditions and utilizes lactate and other metabolites as signals for metabolic adaptation. It responds to host-derived cytokines and microbial quorum signals, enabling integration of host and microbial cues. These responses are not programmable but are inherent to its physiology.","[""Immunomodulation"", ""Tissue Repair""]","Constitutive secretion of immunomodulatory molecules (e.g., cytokines, metabolites); no engineered secretion systems",Dose-dependent effect; administered once daily; efficacy observed at 10^9 CFU/day,"Compatible with oral formulations (capsules, powders, infant formula); stable in gastrointestinal environment",False,False,False,Not applicable,,False,False,False,False,无,False,Not applicable,,False,False,False,无,True,"Modulates immune response by increasing IL-10 and IFN-γ production, promoting T-regulatory cell expansion, and reducing IgE levels. In pigs, it reduced skin and respiratory allergic reactions to Ascaris allergens.","IL-10, IFN-γ, T-regulatory cells",True,Promotes epithelial barrier integrity and reduces inflammation in the gut and skin. Associated with improved skin condition in infants with eczema.,"Mucosal barrier proteins, anti-inflammatory cytokines",False,Not applicable,,False,Not applicable,,GRAS,"None (natural strain, no kill-switches or auxotrophy)",,Non-pathogenic; no reports of bacteremia or systemic infection; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape concerns,Oral delivery limits systemic exposure; gastrointestinal transit prevents long-term colonization,"Lactobacillus rhamnosus HN001 is classified as Generally Recognized As Safe (GRAS). It is non-invasive, non-pathogenic, and has a long history of safe use in food and supplements. No adverse events were reported in clinical trials. Its natural presence in the human gut and lack of genetic modifications minimize biosafety risks.",在新西兰和芬兰的临床试验中，L. rhamnosus HN001 显著降低了婴儿湿疹的累积发病率（2岁前为14.8% vs 26.8%），并在4岁时仍显示对湿疹和过敏性结膜炎的长期保护作用。在芬兰研究中，联合使用 L. rhamnosus 和 B. longum 的母亲所生婴儿湿疹风险显著降低（OR 0.17）。这些结果表明，该菌株在预防早期过敏性疾病方面具有显著的临床效果。,7831,4739,12570,,
0ce9a44e-47d8-4229-b9c1-75862fe2df92,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}]",Oral supplementation (maternal),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; utilizes glucose and other carbohydrates; no specific vitamin requirements beyond standard media",Doubling time ~1.5–2 hours in vitro; colonization observed in infant gut within 3 months,"Gut mucosa, particularly in the small intestine and colon",Competes with pathogens like S. aureus; promotes symbiosis with Bifidobacterium; no significant microbiome disruption reported,Tolerant to gastric acid and bile; stable during lyophilization and storage at 4°C for up to 12 months,"Teichoic acids, acid tolerance response (ATR) genes","Lactobacillus rhamnosus GG is a facultative anaerobe with strong survival in the gastrointestinal tract. It grows well at body temperature and neutral pH, using available sugars. It colonizes the infant gut effectively and maintains stability during storage and transit through the stomach.",None (natural strain),Not applicable,Constitutive,,High chromosomal stability; no plasmid loss; no genetic drift observed,Stable in oral formulations and infant formula,"L. rhamnosus GG is used in its natural form without genetic modification. Its effects are due to intrinsic biological properties, not engineered circuits.","[""pH"", ""Glucose"", ""Bile""]","[""Lactate"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases""]","FNR promoter, lactate permease, bile salt hydrolase",Natural sensing with threshold responses; no synthetic logic gates,"L. rhamnosus GG senses environmental cues such as pH, bile, and metabolites. It activates acid resistance and bile tolerance mechanisms. It responds to host cytokines and microbial signals, enabling integration of immune and microbial signals. These responses are innate, not engineered.","[""Immunomodulation""]",Constitutive secretion of immunomodulatory molecules,10^9 CFU/day; administered during pregnancy and early infancy,Compatible with oral supplements and infant formula; stable in gastrointestinal environment,False,False,False,Not applicable,,False,False,False,False,无,False,Not applicable,,False,False,False,无,True,"Increases IL-10 and IL-12p70 levels; promotes Th1-type immune response; reduces IgE production. In mothers, it improved allergic symptoms and altered serum cytokine profiles.","IL-10, IL-12p70, Th1 cytokines",False,Not applicable,,False,Not applicable,,False,Not applicable,,GRAS,None,,Non-pathogenic; no antibiotic resistance genes; no HGT risk; no systemic infections reported,Oral delivery limits systemic exposure,L. rhamnosus GG is GRAS and has been safely used in infants and pregnant women. No adverse events were reported in clinical trials. Its natural origin and lack of genetic modification ensure low biosafety risk.,在澳大利亚和台湾的研究中，L. rhamnosus GG 对婴儿湿疹的预防效果未达统计学显著性（18% vs 19%），但在母亲中观察到过敏症状改善和Th1型免疫调节。这表明其免疫调节作用可能在母体中更明显，而对婴儿湿疹的直接预防效果有限。,7831,4739,12570,,
0ce9a44e-47d8-4229-b9c1-75862fe2df92,2,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""HN001""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""NCC2705""}]",Oral supplementation (maternal),Facultative Anaerobe,"Optimal at 37°C, pH 6.0–7.0; requires lactose and other carbohydrates; B. longum requires specific prebiotics (e.g., GOS/FOS)",L. rhamnosus: doubling time ~1.5–2 h; B. longum: doubling time ~3–4 h; both colonize infant gut within 3 months,"Gut mucosa, particularly colon and small intestine","Synergistic interaction: L. rhamnosus produces lactate, which B. longum uses as carbon source; both inhibit pathogens like S. aureus; no competition observed",L. rhamnosus: acid/bile tolerant; B. longum: moderate acid tolerance; both stable during lyophilization,"Teichoic acids (L. rhamnosus), exopolysaccharides (B. longum)","The consortium combines L. rhamnosus HN001 and B. longum, which exhibit complementary metabolic capabilities. L. rhamnosus produces lactate, which B. longum utilizes, enhancing mutual survival. Both strains colonize the infant gut and contribute to immune modulation. The combination shows enhanced stability and efficacy compared to single strains.",None,Not applicable,Constitutive,,High chromosomal stability; no plasmid loss; no drift observed in trials,Stable in oral formulations; compatible with prebiotic-enriched matrices,The consortium is administered as a natural mixture of two strains. No genetic engineering is involved. The synergy arises from natural metabolic interactions.,"[""pH"", ""Glucose"", ""Bile""]","[""Lactate"", ""SCFAs"", ""GOS/FOS""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases""]","FNR promoter, lactate permease, GOS transporter (B. longum)",No engineered logic; natural signal integration via metabolic cross-feeding,"The consortium senses environmental cues such as pH, bile, and metabolites. L. rhamnosus produces lactate, which B. longum uses as a carbon source, enabling cross-feeding. Both respond to host cytokines and microbial signals. This natural synergy enhances immune modulation and colonization.","[""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion of immunomodulatory molecules; cross-feeding enhances metabolic output,Administered once daily; dose not adjusted for individual strain,Compatible with oral supplements and prebiotic-enriched formulas,False,False,False,Not applicable,,False,False,False,False,无,False,Not applicable,,False,False,False,无,True,"Synergistic increase in IL-10 and IFN-γ; enhanced T-regulatory cell expansion; reduced IgE. In Finnish trials, risk of eczema reduced by 83% (OR 0.17).","IL-10, IFN-γ, T-regulatory cells",True,Promotes gut and skin barrier integrity; reduces inflammation; associated with lower eczema severity.,"Mucosal barrier proteins, anti-inflammatory cytokines",False,Not applicable,,False,Not applicable,,GRAS,None,,Non-pathogenic; no antibiotic resistance genes; no HGT risk; no systemic infections reported,Oral delivery limits systemic exposure,The consortium is composed of two GRAS strains with no genetic modifications. No safety concerns were reported in clinical trials. The combination is safe and well-tolerated in pregnant and lactating women and infants.,在芬兰的双盲随机对照试验中，母亲在孕晚期至哺乳期服用 L. rhamnosus 和 B. longum 的联合制剂，显著降低了婴儿湿疹的累积发病率（OR 0.17），且对慢性湿疹也有显著保护作用。该结果表明，菌株间的协同作用可增强免疫调节和屏障修复效果，优于单一菌株。,7831,4739,12570,,
1398eb9a-4fde-401c-85f3-9830376ca6cd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus kefiranofaciens"", ""strain_id"": ""M1""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C; pH and osmotic tolerance not explicitly stated, but survives in simulated gastrointestinal conditions.",Not explicitly quantified; viability maintained at ~10^7 CFU/g after 8-week storage at 4°C.,"Intestinal tract (specifically colon, based on DSS colitis model and cecal microbiota analysis)",Restores lactobacillus-to-coliform ratio in cecum; suggests competitive colonization and modulation of gut microbiota balance.,"High tolerance to freeze-drying, heat (75°C for 1 min), simulated gastric fluid (pH 2.0), and bile salts.","Skim milk powder (cryoprotectant), sodium alginate, gellan gum (structural protection)","Lactobacillus kefiranofaciens M1 is a lactic acid bacterium capable of surviving in the harsh gastrointestinal environment, including low pH, bile salts, and temperature fluctuations. Encapsulation significantly enhances its stability during freeze-drying and storage, maintaining high viability (10^7 CFU/g) after 8 weeks at 4°C. It is well-suited for intestinal colonization and exhibits robust growth physiology under simulated in vivo conditions.",,,,,No genetic modifications reported; natural strain stability preserved through encapsulation.,Encapsulation matrix (alginate-gellan-skim milk) enhances survival and stability of the native strain in material environment.,"No genetic engineering was performed. The strain was naturally encapsulated using a mixture of sodium alginate, gellan gum, and skim milk powder, followed by direct freeze-drying. This physical encapsulation strategy preserves viability and function without altering the genome.","[""pH"", ""Bile salts""]","[""Bile acids""]",,,"Not specified; likely intrinsic to L. kefiranofaciens M1 (e.g., membrane transporters, stress response regulators).",No engineered logic circuits; natural response to environmental stressors.,"The strain naturally senses and responds to low pH and bile salts in the gastrointestinal tract, which are key signals for gut colonization. Its survival under these conditions is attributed to the protective encapsulation, not engineered sensing circuits.","[""Anti-colitis"", ""Immunomodulation"", ""Tissue Repair""]","Passive release from microcapsules upon exposure to intestinal conditions (pH, enzymes, bile).",Controlled by encapsulation dose and release kinetics; no active dosage regulation reported.,Highly compatible with alginate-gellan-skim milk matrix; microcapsules maintain structural integrity and allow controlled release.,False,,,,,False,,,,,False,,,,,,,True,Modulates immune response by suppressing pro-inflammatory cytokines and enhancing anti-inflammatory cytokines via TLR2-dependent pathway.,TLR2-dependent signaling pathway (involves CCL-20 and anti-inflammatory cytokines),True,"Restores intestinal barrier function, reduces mucosal permeability, and attenuates tissue damage in colitis.","Intestinal barrier integrity, mucosal repair via TLR2 signaling",False,,,False,,,GRAS,Natural strain with no engineered kill switches; relies on encapsulation and natural attenuation.,None (no synthetic kill-switches or auxotrophy reported),Low pathogenicity; no antibiotic resistance genes or HGT risk reported. Safe for human consumption.,Physical barrier provided by microcapsule matrix prevents escape and enhances targeted delivery.,"Lactobacillus kefiranofaciens M1 is a GRAS (Generally Recognized As Safe) probiotic strain. No genetic modifications were made, and the encapsulation process enhances safety by protecting the strain during processing and delivery. The material barrier prevents environmental escape and ensures localized action in the gut.","Encapsulated M1 significantly reduced bleeding score and inflammatory score in DSS-induced colitis mouse model. Histological analysis showed marked improvement in mucosal architecture and reduced inflammatory infiltrate. The strain restored lactobacillus-to-coliform ratio in the cecum, indicating successful modulation of gut microbiota. These results confirm that encapsulation preserves the anti-colitis activity of M1, making it a promising candidate for therapeutic use in inflammatory bowel disease.",11196,1553,12749,,
053eb1e7-acb3-4ff2-a60a-3837bba1bc37,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Chlamydomonas reinhardtii"", ""strain_id"": ""CC-125 wild type mt+""}]",Encapsulated,Facultative Anaerobe,"Temperature: Room temperature (20–25 °C), pH: ~7.4 (TAP medium), Osmotic: Physiological (TAP medium), Nutrition: Autotrophic (light-dependent), requires CO₂ and inorganic nutrients","Doubling time: ~12 h (in vitro), growth rate: OD₆₈₀ 0.25–0.5 used for coating; in vivo consistency not assessed",Not applicable (in vitro model system; potential for tumor microenvironment via light-guided delivery),Not applicable (non-microbial system; algal cells not part of host microbiome),"High tolerance to centrifugation (300×g, 1.5 min), UV light (used for drug release), and lyophilization (implied by stability over 24 h in suspension)",Chitosan coating provides mechanical and chemical protection,本研究中使用的Chlamydomonas reinhardtii为单细胞绿藻，具有光合自养特性，可在室温下以12小时左右的倍增时间生长。其细胞壁带负电荷，可通过静电作用与带正电的壳聚糖结合，形成稳定涂层。该藻类在TAP培养基中生长良好，对离心和短期UV照射具有较强耐受性，且在24小时内涂层保持稳定，表明其在体外环境中具有良好的物理稳定性。,None (non-genetically modified organism),Not applicable (no genetic editing performed),None (no synthetic genetic circuits),,Not applicable (no plasmid or chromosomal integration),High stability in chitosan–nanoparticle matrix; coating remains intact during 24 h incubation,本系统未对Chlamydomonas reinhardtii进行基因改造，而是通过非共价静电相互作用将壳聚糖包覆的氧化铁纳米颗粒（CSIONPs）均匀地组装在藻细胞壁表面。该策略无需基因工程，仅依赖天然电荷差异实现高效包覆，制造效率高达约90%。,"[""Light (Visible)""]",,,,"Photoreceptors (e.g., channelrhodopsin-like proteins) in flagella",Linear phototaxis response within 1–3 min; no complex logic gates; directional steering based on light gradient,Chlamydomonas reinhardtii具有快速光趋性响应能力，可在1–3分钟内对可见光刺激做出反应。通过控制光照方向，可实现对藻类的定向引导，使其向光源移动。该系统利用天然光感应机制，无需人工逻辑电路，实现简单而高效的环境响应。,"[""Drug Delivery""]",Non-covalent coating with nanoparticles; drug release via photocleavage,Controlled by light exposure duration and intensity (UV 365 nm); on-demand release with spatiotemporal precision,High compatibility with chitosan–nanoparticle matrix; coating does not disrupt gel-like structure or cause gas production,False,,,Not applicable,,,,,,无,False,Not applicable,,,,,无,False,Not applicable,,False,Not applicable,,False,Not applicable,,True,On-demand delivery of doxorubicin (DOX) to SK-BR-3 breast cancer cells via light-triggered release from photocleavable linker on CSIONPs,Doxorubicin (DOX),BSL-1,None (no kill-switch or auxotrophy implemented),,Low pathogenicity; non-toxic to mammalian cells; no antibiotic resistance genes reported; no horizontal gene transfer risk (non-genetically modified); low environmental escape risk due to non-native habitat,Physical confinement via encapsulation in chitosan–nanoparticle layer; prevents free release of algal cells,Chlamydomonas reinhardtii为非致病性绿藻，被广泛用于实验室研究，具有GRAS（公认安全）属性。本系统未进行基因改造，无抗生素抗性基因，且通过壳聚糖-纳米颗粒涂层实现物理封装，有效防止细胞逃逸。在体外实验中未观察到细胞毒性，表明其生物安全性良好。,在体外实验中，经UV光照射后，生物杂交微藻成功将阿霉素（DOX）递送至SK-BR-3乳腺癌细胞，并观察到明显的细胞内化现象。该系统实现了高效率（约90%）的制造，保持了藻类的运动性和光趋性，且在24小时内涂层稳定，为靶向肿瘤治疗提供了高效、可控的微机器人平台。,15494,1666,17160,,
c9e4aa41-f3f4-47cd-bb6e-f37942cad918,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""4.1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""3S7""}]",Suspension,Facultative Anaerobe,"Growth at 37°C, pH 7.0 (buffer), in MRS medium; resistant to bile salts and low pH (in vitro); survives pelleting process (55–60°C for 30–40 s)",Anaerobic overnight growth at 37°C; doubling time not specified; viable cells detected in feces for up to 6 days post-administration,"Gastrointestinal tract (pig intestine), particularly in piglets; persists in feces after administration",Inhibits Enterobacteriaceae; stimulates growth of endogenous lactobacilli; no significant disruption of native microbiota composition,"Resistant to freeze-drying, heat (pelleting process), bile salts, low pH (in vitro); survives lyophilization and rehydration","Lyophilization (freeze-drying) and pelleting process (55–60°C, 30–40 s)",Lactobacillus plantarum 4.1 和 Lactobacillus reuteri 3S7 能在猪的胃肠道中存活并持续存在，具有耐受胆盐、低pH、热和冻干的能力。在饲喂后6天内仍可在粪便中检测到，表明其在猪肠道中具有良好的生存能力和持久性。,,,,,,,未对菌株进行基因工程改造，仅使用天然分离株进行饲喂试验。,"[""Bile salts"", ""Low pH""]","[""Glucose"", ""Lactose"", ""Maltose"", ""Sucrose""]",,,"Bile salt resistance and low pH tolerance (in vitro characterized, but specific receptor not identified)",未描述逻辑门控机制，无基因回路设计,未使用基因工程回路，无主动感知与逻辑处理能力。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Unknown (likely passive secretion of lactic acid and other metabolites),Daily administration of ~10^10 CFU; activity correlates with dose and duration,"Compatible with pelleted feed; survives pelleting process (55–60°C, 30–40 s)",True,True,False,通过抑制病原菌生长，降低 Enterobacteriaceae 数量，间接发挥抗菌作用,Lactic acid (in vitro antimicrobial activity against E. coli and S. enterica),True,True,True,True,在猪粪便中显著降低 Enterobacteriaceae（2–2.6 log cycles），且无组织损伤或炎症反应，表明活性可控且安全。,False,,,False,False,False,未涉及氧气生成或氧合功能。,True,通过降低 β-葡萄糖醛酸酶活性，减少潜在致癌物的再激活，调节肠道微环境。,β-Glucuronidase inhibition (via competitive exclusion or metabolic interference),False,,,True,通过抑制 β-葡萄糖醛酸酶活性，调节肠道代谢环境，降低致癌风险。,β-Glucuronidase (enzyme activity reduced by 23–43%),False,,,GRAS,None (no genetic kill-switch or auxotrophy introduced),,Non-pathogenic; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; low opportunistic risk,Pelleted feed provides physical confinement during administration,Lactobacillus plantarum 4.1 和 Lactobacillus reuteri 3S7 均为天然分离株，属于公认安全（GRAS）菌株，无致病性、无抗生素抗性基因，未进行基因改造，无逃逸风险，安全性高。,在猪中，L. plantarum 4.1 和 L. reuteri 3S7 能有效存活于胃肠道，持续6天以上；显著降低粪便中 Enterobacteriaceae 数量（2–2.6 log cycles）；降低 β-葡萄糖醛酸酶活性约23–43%；在猪仔中促进内源性乳酸菌增殖，表明其具有良好的肠道定植与调节功能。,15642,1607,17249,,
68ffed4f-ab48-4113-95ba-c2fae678b12a,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Isolated from healthy C57BL/6 mice""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Isolated from healthy C57BL/6 mice""}]","Encapsulated (in personalized probiotic biobank, administered orally)",Facultative Anaerobe,Anaerobic conditions at 37°C; growth on MRS and BIM-25 media; requires L-cysteine for Bifidobacterium spp.,Doubling time not specified; maintained at ≥8 log10 CFU/mL after 6h in simulated GI conditions,"Gut mucosa, particularly in the colon; adapted to host-specific microbiota",Symbiotic with host; competes with pathobionts; restores dysbiotic microbiota,"High tolerance to low pH (pH 2.4), bile salts (10 g/L oxgall), and digestive enzymes (pepsin, pancreatin); survives simulated gastric and intestinal phases","L-cysteine (for Bifidobacterium spp.), anaerobic growth conditions",该微生物系统由从健康小鼠粪便中分离的Lactobacillus和Bifidobacterium菌株组成，均为革兰氏阳性、过氧化氢酶阴性，能在厌氧条件下生长。其生长生理特性显示对胃酸、胆盐和消化酶具有高度耐受性，可在模拟胃肠环境中保持稳定存活，表明其具备良好的肠道定植潜力。,Colony-PCR and RAPD-PCR for preliminary identification; no genetic modification tools used,Not applicable (no genetic engineering performed),Constitutive (natural expression in host-derived strains),,High chromosomal stability; no plasmid-based systems used; strains maintained viability over time in biobank,Stable in oral delivery format (biobank storage and gavage administration),本研究未对菌株进行基因工程改造，仅通过传统培养和分子鉴定方法筛选出具有潜在益生菌特性的菌株。所用菌株为宿主自身来源，具有天然的遗传稳定性，无需外源载体即可在肠道中定植。,"[""Low pH"", ""Bile salts"", ""Digestive enzymes""]","[""SCFAs (implied by probiotic function)"", ""Lactate (from Lactobacillus metabolism)""]",,"[""Inflammatory cytokines (IL-1β, IL-6, TGF-β, IL-10)"", ""Tissue damage markers (MPO, MDA)""]",Natural host-microbe interaction; no engineered sensors used,No synthetic logic gates; natural response to inflammatory environment,该系统依赖于宿主-微生物自然互作，通过感知肠道炎症微环境（如低pH、胆盐、炎症因子）触发免疫调节功能，无需人工设计的逻辑门控系统。,"[""Immunomodulation"", ""Tissue Repair""]","Natural secretion (e.g., SCFAs, antimicrobial peptides, cytokine modulation)","Oral gavage (daily, 0.1 mL, ~2.5 × 10^9 CFU); dose based on CFU counts",Compatible with oral delivery and biobank storage; no encapsulation material described,False,False,False,Not applicable (no direct antibacterial mechanism reported),,False,False,False,False,未报告抗菌或抗生物膜活性,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,未报告氧合功能,True,"Modulates host immune response by decreasing pro-inflammatory cytokines (IL-1β, IL-6) and increasing anti-inflammatory cytokines (TGF-β, IL-10)","IL-10, TGF-β, IL-6, IL-1β (host cytokines modulated by microbial activity)",True,"Reduces colonic tissue damage, crypt destruction, and edema; promotes mucosal healing","Mucosal barrier integrity, epithelial regeneration (indirectly via cytokine modulation)",False,Not applicable (no specific metabolic regulation reported),,False,Not applicable (no tumor therapy context),,BSL-1,None (natural strains from host; no kill-switch or auxotrophy used),,Low pathogenicity; no antibiotic resistance genes detected except aztreonam resistance; no HGT risk reported; low escape risk due to host-specific origin,Oral delivery with natural gut colonization; no physical barrier used,该系统使用来自宿主自身的益生菌菌株，具有低致病性，且对多种抗生素敏感（除aztreonam外），无水平基因转移风险，宿主特异性降低了环境逃逸的可能性，整体安全性高。,个性化益生菌组在DSS诱导结肠炎模型中显著降低疾病活动指数（DAI），减轻结肠组织病理损伤（组织学评分降低），并有效调节免疫反应：IL-1β和IL-6表达下降，TGF-β和IL-10表达上升。其疗效优于商业益生菌LGG，表明个性化益生菌在治疗肠道菌群失调相关疾病方面具有显著优势。,18911,1773,20684,,
ee9c5d8f-e9d6-4b5f-a76b-153846299be3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""JCM 1136""}]","Encapsulated in diet (spray-dried, freeze-dried, or heat-killed forms)",Facultative Anaerobe,Growth at 30°C on MRS medium; pH 7.0; requires peptone water for washing; viable in feed at -20°C storage,Doubling time not specified; viable forms maintained at ~10^11 CFU/g in diet; no in vivo growth rate data provided,"Intestinal tract (gut), fecal matter, and rearing water; colonizes primary immune tissues (kidney and spleen)",Competes with pathogens; enhances host immunity; no direct symbiosis with host microbiome reported,"Tolerant to freeze-drying (-20°C), heat inactivation (75°C for 60 min), and storage at -20°C; stable in feed matrix","Peptone water, MRS medium, freeze-drying process",该菌株为乳酸杆菌，可在30°C下在MRS培养基上生长，对冷冻干燥和热灭活具有较强耐受性，能稳定存在于饲料中并定植于虹鳟鱼肠道及免疫组织，具有良好的环境稳定性。,Not applicable (no genetic modification reported),Not applicable,Constitutive (no inducible circuits described),,No plasmid or chromosomal integration reported; strain is naturally occurring and not engineered,Stable in freeze-dried and spray-dried feed matrices; no degradation observed during storage,该系统未进行基因工程改造，使用天然存在的Lactobacillus rhamnosus JCM 1136菌株，以活菌、冻干或灭活形式直接添加至饲料中，无需基因编辑或调控回路。,,,,,"Cell wall components (peptidoglycan, lipopolysaccharide) acting as PAMPs",No synthetic logic gates; natural immune recognition via PRRs (Pattern Recognition Receptors),菌株通过细胞壁成分（如肽聚糖、脂多糖）作为病原相关分子模式（PAMPs），被宿主固有免疫系统中的模式识别受体（PRR）识别，触发免疫信号通路，无需人工设计的逻辑门控系统。,"[""Immunomodulation""]","Cell wall components (PG, LPS) released upon bacterial lysis or natural turnover",Controlled by dietary inclusion rate (~10^11 CFU/g); no dynamic dosage adjustment,Compatible with freeze-dried and spray-dried feed matrices; stable during storage and feeding,True,True,False,通过产生抗菌物质抑制多种鱼类病原菌，如Aeromonas spp.、Vibrio spp.等，表现为清晰的抑菌圈。,Unknown (likely bacteriocins or organic acids),True,True,True,True,对13种鱼类病原菌表现出广谱抑制活性，尤其对Aeromonas spp.效果显著，且在饲料中稳定存在，未引起组织损伤或微生物群落紊乱。,False,,,False,False,False,,True,通过激活宿主免疫系统，上调TNF-α、TGF-β、IFN和Ig等免疫基因表达，增强细胞和体液免疫反应。,"Peptidoglycan (PG), Lipopolysaccharide (LPS), and other cell wall components",False,,,False,,,False,,,GRAS,None (no kill-switch or auxotrophy reported),,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer evidence; non-invasive in fish; safe for aquaculture use,Physical confinement via feed encapsulation; no escape from feed matrix,Lactobacillus rhamnosus JCM 1136被列为GRAS（公认安全）菌株，无致病性，不携带抗生素抗性基因，未见水平基因转移风险，且在饲料中被物理包裹，无环境逃逸风险，安全性高。,在虹鳟鱼中，活菌形式（喷雾干燥和冻干）显著上调了肾脏和脾脏中TNF-α（最高达5000倍）、IFN（最高20倍）、TGF-β和Ig基因的表达，尤其在冻干组中效果更优，表明其具有强大的免疫调节能力，可有效增强宿主非特异性免疫反应。,13177,1608,14785,,
496fe24d-c712-4ecd-b74c-dd23c3ac56ec,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""DSM 24735""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""DSM 24730""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""DSM 24733""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""DSM 24734""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""DSM 24732""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""DSM 24736""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""DSM 24737""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""DSM 24731""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in the presence of glucose and other fermentable carbohydrates; tolerant to bile salts and low pH (gastric conditions)",Doubling time ~1.5–2 hours in vitro; in vivo homeostasis maintained through mucosal colonization and metabolic adaptation,"Defunctionalized colon segment (efferent loop), mucosal surface of the intestinal epithelium",Competitive exclusion of pathogenic bacteria; synergistic interaction with host immune cells; minimal disruption to native gut microbiota,"High tolerance to lyophilization/rehydration, moderate tolerance to shear stress; stable during cold chain storage (2–8°C)",Lyophilized formulation (Vivomixx®),该微生物系统由8株益生菌组成，包括4种乳杆菌、3种双歧杆菌和1种嗜热链球菌。它们均为兼性厌氧菌，可在37°C、pH 6.5–7.0的条件下生长，对胆盐和低pH具有耐受性，适合在肠道黏膜表面定植。在冻干保存和冷链运输中保持稳定，通过灌注方式在造口回肠袢中实现局部定植，用于调节炎症反应。,"None (Natural strains, no genetic modification)",Not applicable,Constitutive,,High chromosomal stability; no plasmids used; no evidence of genetic drift or metabolic burden in vivo,Stable in lyophilized formulation and physiological saline matrix; no degradation during infusion,该系统未经过基因工程改造，使用天然益生菌株，通过冻干制剂在生理盐水中灌注，直接作用于造口回肠袢黏膜，无需外源性调控元件，依赖其天然代谢和免疫调节能力发挥作用。,"[""pH"", ""Bile Acids"", ""Glucose""]","[""Short-Chain Fatty Acids (SCFAs)"", ""Lactate""]",,"[""Proteases"", ""Cytokines""]","Native membrane receptors and metabolic sensors (e.g., sugar transporters, bile acid sensors)",Constitutive expression; no complex logic gates; threshold-based response to environmental cues,这些益生菌通过其天然的代谢感应系统感知肠道微环境中的pH、胆汁酸和葡萄糖等信号，同时响应宿主释放的蛋白酶和细胞因子。它们在黏膜表面持续表达免疫调节分子，不依赖诱导型启动子，属于基础性、持续性响应机制，无复杂逻辑控制。,"[""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion via cell lysis and extracellular vesicles,"Dose controlled by infusion volume and frequency (20 days, every 2nd day); no feedback control",High compatibility with physiological saline and lyophilized matrix; no structural disruption observed,False,False,False,Not applicable,,False,False,False,False,未涉及抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未涉及氧气生成功能。,True,"Probiotics reduce pro-inflammatory cytokines (e.g., TNF-α) and increase anti-inflammatory mediators; modulate immune cell infiltration into lamina propria.","Cytokines (e.g., IL-10, TGF-β), SCFAs (butyrate, acetate), and bacterial cell wall components (e.g., peptidoglycan)",True,"Promote epithelial regeneration, reduce mucosal erosion, and improve crypt architecture by enhancing barrier function and reducing inflammatory damage.","Short-chain fatty acids (SCFAs), mucin-stimulating factors, growth factors",True,"Modulate host metabolism by producing SCFAs, which regulate glucose homeostasis and lipid metabolism; influence tryptophan metabolism via microbial enzymes.","Short-chain fatty acids (SCFAs), tryptophan metabolites (e.g., indole derivatives)",False,Not applicable,,GRAS,"None (natural strains, no synthetic kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape,Physical confinement via catheter infusion and localized mucosal delivery,该系统使用的是公认安全（GRAS）的天然益生菌株，未进行基因改造，无致病性、无抗生素抗性基因，且通过导管局部灌注实现物理隔离，风险极低。,在刺激阶段后，实验组（SG）的C反应蛋白（CRP）、中性粒细胞/淋巴细胞比值（NLR）和单核细胞/淋巴细胞比值（LMR）显著下降（p < 0.001），而血清转铁蛋白和血小板/淋巴细胞比值（PLR）显著上升。3个月随访后，CRP、NLR、LMR和PLR均恢复正常，且mGPS评分显著降低。内镜和组织学严重程度与炎症标志物变化相关，提示益生菌刺激可早期改善炎症状态，促进黏膜修复。,14659,2071,16730,,
23d328a4-38e7-40be-b2cf-ee871d3ce568,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""299""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus bulgaricus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Leuconostoc mesenteroides"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus lactis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecalis"", ""strain_id"": """"}]",Enteral nutrition suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, tolerant to bile acids and intestinal pH; utilizes glucose and lactose as carbon sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed within 24–48 hours post-administration,"Intestinal lumen, particularly in the small intestine and colon; adheres to mucus layer and epithelial cells",Competitive exclusion of pathogenic bacteria; synergistic interactions with host microbiota; no significant disruption of core microbiome observed,Moderate tolerance to gastric acid and bile; stable during lyophilization and rehydration; resistant to shear stress in enteral delivery systems,"Bile salts, mucin-binding proteins, catalase",该系统由多种乳酸菌和双歧杆菌组成，均为兼性厌氧菌，可在肠道环境中定植并维持生长。其最适生长温度为37°C，pH范围为6.0–7.0，能耐受胆汁酸和肠道酸性环境。在体外培养中，倍增时间为1.5–2小时；在体内，口服后24–48小时内即可在肠道定植。这些菌株主要定植于小肠和结肠的黏液层及上皮细胞表面，通过竞争性排斥病原菌，与宿主微生物群产生协同作用，且不显著破坏核心菌群结构。,None reported,Not applicable,Constitutive,,High chromosomal stability; no plasmids reported; no evidence of genetic drift in clinical trials,Stable in enteral nutrition matrix; no degradation or loss of viability during storage,该系统未进行基因工程改造，所有菌株均为天然分离株，通过口服给药进入肠道，其功能依赖于天然代谢途径和定植能力，未引入外源基因或调控回路。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Bile acids"", ""SCFAs"", ""Lactate""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Bile acid-responsive promoters (e.g., Bile acid receptor BbrR), Lactate transporter (LctP), Quorum sensing receptors (LasR, LuxR)",No engineered logic gates; natural sensing with threshold responses to environmental cues,这些菌株通过天然受体感知肠道内的生理化学信号，如pH变化、胆汁酸浓度、乳酸水平和氧分压。例如，Lactobacillus plantarum 299通过FNR启动子响应低氧环境，而胆汁酸通过BbrR等受体感知。菌群间通过AHL和AI-2信号进行群体感应，调节代谢和定植行为。整体为自然感应系统，无人工逻辑门控，但具有阈值响应和动态范围调节能力。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion system (for bacteriocins), Vesicles (exosomes), Lysis (controlled release)",Dose-dependent activity; controlled by administration frequency (twice daily) and total duration (7–28 days),Compatible with enteral nutrition matrix; maintains viability and function during delivery,True,True,True,通过产生乳酸、细菌素（如plantaricin）和有机酸降低局部pH，抑制病原菌生长；同时分泌抗菌肽，破坏病原菌细胞膜；并抑制生物膜形成。,"Lactic acid, Plantaricin, Bacteriocins, Organic acids",True,True,True,True,在多项随机对照试验中，使用该菌群组合的患者胰腺感染率未显著升高，且未报告严重不良事件，表明其抗菌活性可控且局部安全。,False,,,False,False,False,未使用任何氧生成机制，因此不涉及氧合功能。,True,调节宿主免疫反应，促进抗炎因子（如IL-10）分泌，抑制促炎因子（如TNF-α、IL-6）释放，增强肠道屏障功能。,"Interleukin-10 (IL-10), TGF-β, Secretory IgA",True,通过分泌生长因子（如EGF、VEGF）和细胞外基质成分，促进上皮细胞再生、血管生成和黏膜屏障修复。,"Epidermal Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), Collagen",True,产生短链脂肪酸（SCFAs），如乙酸、丙酸和丁酸，调节宿主能量代谢、免疫稳态和肠道屏障功能。,"Short-chain fatty acids (SCFAs): Acetate, Propionate, Butyrate",False,,,GRAS,"None (natural strains, no kill-switches or auxotrophy reported)",,"Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; potential risk in immunocompromised patients (e.g., PROPATRIA trial showed adverse effects in high-risk subgroup)",Enteral nutrition delivery provides physical barrier; no systemic dissemination reported,该系统由多种被广泛认可为GRAS（公认安全）的益生菌组成，无基因工程改造，未报告耐药基因或水平基因转移。然而，PROPATRIA试验中使用Ecologic 641（含L. acidophilus等）组出现不良反应，提示特定菌株组合在重症患者中可能存在风险。总体风险较低，但需注意个体差异和免疫状态。,在纳入的6项随机对照试验中，益生菌治疗组与安慰剂组在胰腺感染率、总感染率、手术率、住院时间及死亡率方面均无显著差异。然而，亚组分析显示，治疗持续时间≤15天的患者中，益生菌组胰腺感染率显著降低（RR=2.94，95%CI:1.31–6.60，P<0.01），提示短期使用可能具有潜在益处。总体而言，当前证据不足以支持或否定益生菌在预测性重症急性胰腺炎中的疗效，需进一步设计严谨的临床试验验证特定菌株、剂量和疗程的优化方案。,10763,2482,13245,,
570a8b6b-656a-4380-b097-05ed705eacbf,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}]",Suspension,Facultative Anaerobe,"Temperature: 37 ± 2°C; pH: not explicitly stated, but MRS agar with L-cysteine HCl suggests anaerobic conditions; Nutritional requirements: L-cysteine HCl, sugars (FOS, maltodextrin), vitamins, minerals",Growth rate not quantified; incubation for 48–72 hours under anaerobic conditions; in vitro growth confirmed by colony formation,Small intestine and colon (survives gastric acid and bile),Not explicitly described; assumed to be commensal in human gut microbiome,"Tolerates gastric acid and bile; stability in powder matrix with excipients (sugars, herbal extracts, vitamins, minerals)","Excipients (e.g., FOS, maltodextrin) provide protection against drying and storage stress","Bifidobacterium animalis subsp. lactis and Lactobacillus acidophilus are lactic acid bacteria that survive gastric acid and bile, grow under anaerobic conditions, and are used in dietary supplements for their probiotic effects. They are stable in powder formulations with excipients and can be quantified using flow cytometry.",None (natural strains used; no genetic modification described),Not applicable,Not applicable,Not applicable,Not applicable (no plasmids or engineered circuits used),Not applicable,No genetic engineering was performed. The strains were used in their natural form for analytical validation purposes.,"[""Hypoxia"", ""pH""]","[""Lactate"", ""Glucose""]",,,Membrane integrity (assessed via TO/PI staining),Not applicable (no synthetic circuitry; detection based on dye exclusion),No synthetic sensing logic; viability is determined by membrane integrity using thiazole orange (TO) and propidium iodide (PI) dyes. Live cells exclude PI but retain TO; dead cells take up PI and lose TO fluorescence.,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Not specified (likely passive diffusion or natural secretion),Not applicable (natural strains; no controllable output),Compatible with powder matrix and excipients; stable in reconstituted samples,True,False,False,Produces lactic acid and other metabolites that inhibit pathogenic bacteria; not directly tested for antibacterial activity in this study.,"Lactic acid, bacteriocins (inferred from genus)",False,True,True,True,The strains are naturally antagonistic to pathogens via acidification and bacteriocin production; no cytotoxicity reported; localized in gut.,False,Not applicable; no oxygen-producing enzymes or mechanisms described.,Not applicable,False,False,False,No oxygenation function present.,True,Modulates host immune response via interaction with gut epithelium and immune cells; enhances anti-inflammatory cytokine production.,"Cell wall components (e.g., peptidoglycan, exopolysaccharides), secreted metabolites",False,Not tested or reported.,Not applicable,True,"Produces short-chain fatty acids (SCFAs) such as acetate and lactate, which regulate host metabolism and gut barrier function.","Acetate, Lactate, SCFAs",False,Not applicable; no evidence of tumor-targeting or prodrug conversion.,Not applicable,GRAS,None (natural probiotics; no kill switches or auxotrophy described),Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk in this context; safe for human consumption.,Powder matrix provides physical confinement; no live cell release in study,"Both Bifidobacterium animalis subsp. lactis and Lactobacillus acidophilus are classified as GRAS (Generally Recognized As Safe) and widely used in food and supplements. No evidence of pathogenicity, antibiotic resistance, or environmental escape risk in this study.","The study did not evaluate therapeutic outcomes. However, flow cytometry demonstrated high accuracy, linearity, and precision in quantifying viable probiotic cells compared to plate count, with recovery rates of 96.5–100.9% and strong correlation (R > 0.999). This supports reliable analytical validation for probiotic product quality control.",19697,1597,21294,,
a5fbf1c6-9afe-4720-9cdc-92ea1589eb20,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""BS5""}]",Suspension,Facultative Anaerobe,Temperature: 37°C; pH: Neutral to slightly acidic (MRS broth); Nutritional requirements: Rich in carbohydrates and amino acids (MRS medium); Bile tolerance: High (up to 10% bile salt); Acid tolerance: Survives at pH 3–4 for 3 hours,Growth rate: 24–48 hours in MRS broth at 37°C; Doubling time: Not explicitly reported; In vivo vs in vitro: Demonstrated survival in simulated gastric conditions (pH 3–4) and bile salt environments,"Gastrointestinal tract (intestinal mucosa), potential for gut colonization","Shows autoaggregation (48%) and surface hydrophobicity (43–45%), suggesting ability to adhere to intestinal epithelium and interact with host microbiota; no evidence of competition or symbiosis with other microbes reported","High tolerance to acid (pH 3–4), bile salts (up to 10%), and moderate resistance to drying (stored at −80°C with glycerol); UV and shear stress not tested","Glycerol (for cryopreservation), bile salts (for stress resistance testing)","Enterococcus faecium BS5 is a facultative anaerobe capable of growing at 37°C in MRS medium. It exhibits strong resistance to acidic conditions (pH 3–4) and bile salts (up to 10%), indicating its potential to survive gastrointestinal transit. It forms creamy, circular, opaque colonies and appears as gram-positive cocci under microscopy. The strain shows good adhesion properties via autoaggregation and surface hydrophobicity, supporting its potential for intestinal colonization.",,,,,,,该菌株未经过基因工程改造，其GABA生产能力源于天然代谢途径。通过16S rRNA基因测序鉴定为Enterococcus faecium BS5，未提及任何基因编辑或合成生物学工具的使用。,"[""Acidity (pH)"", ""Bile Salts""]","[""Glutamate (as substrate)""]",,,Glutamate decarboxylase (GAD) promoter and enzyme system (inferred from GABA production from glutamate),"No synthetic logic circuits reported; natural metabolic regulation via substrate availability (glutamate) and environmental stress (pH, bile) likely controls GAD expression","Enterococcus faecium BS5 senses glutamate as a substrate and responds to acidic and bile-rich environments by activating its glutamate decarboxylase (GAD) system, which converts glutamate to GABA. This is a natural physiological response rather than a synthetic genetic circuit. The system is likely constitutively active under favorable conditions (e.g., presence of glutamate and neutral pH), but may be modulated by stress signals such as low pH and bile salts.","[""Metabolic Regulation""]",Unknown (likely passive diffusion or lysis; not specified),Not controllable; production depends on substrate (glutamate) availability and growth phase,Compatible with MRS broth and fermented dairy products; no encapsulation or material barrier reported,True,True,False,"Produces antimicrobial substances (e.g., organic acids, hydrogen peroxide) that inhibit growth of pathogenic bacteria.","Organic acids, hydrogen peroxide (inferred from antimicrobial activity assay)",True,True,True,True,对大肠杆菌、枯草芽孢杆菌、铜绿假单胞菌和金黄色葡萄球菌具有抑制作用，但对白色念珠菌无抑制作用，表明其抗菌谱较广且具有选择性，且未报告对宿主细胞的毒性。,False,,,False,False,False,未检测到氧气生成能力，无光依赖或非光依赖的氧生成机制。,False,,,False,,,True,通过谷氨酸脱羧酶（GAD）将谷氨酸转化为γ-氨基丁酸（GABA），调节肠道功能、神经递质水平和肠道免疫。,Gamma-aminobutyric acid (GABA),False,,,GRAS,No synthetic kill switches or auxotrophy reported; natural non-pathogenicity assumed,,"Non-hemolytic (γ-hemolysis), no virulence genes reported; however, resistant to multiple antibiotics (ampicillin, penicillin, streptomycin, kanamycin, erythromycin), raising concern for horizontal gene transfer (HGT) of resistance genes. Enterococcus species are known opportunistic pathogens.",None reported; no physical confinement or encapsulation used,"Enterococcus faecium BS5 is non-hemolytic and shows no signs of pathogenicity in vitro. However, its resistance to multiple clinically relevant antibiotics (including ampicillin, penicillin, and erythromycin) raises safety concerns regarding antibiotic resistance gene transfer. While classified as GRAS (Generally Recognized As Safe) in some contexts, its use in food products requires careful monitoring due to potential for HGT and opportunistic infection risk in immunocompromised individuals.",该菌株在MRS培养基中以2% MSG为底物，通过HPLC检测到GABA产量最高，是9个GABA高产菌株中最优者。其在模拟胃酸（pH 3–4）和高胆汁盐（10%）环境中表现出良好的存活率（76–78%），并具有显著的抗菌活性和良好的黏附能力，表明其具有作为功能性发酵食品益生菌的潜力。,17922,1834,19756,,
81eefde4-2392-4e8c-a5ef-7e48cebc5dcb,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""LTH 2579""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 30–37°C, pH 5.5–6.5, low water activity (a_w < 0.90), tolerance to curing salt (NaCl up to 3%)","Doubling time ~60–90 min in vitro; in vivo colonization not quantified, but strain detected in feces post-consumption","Gut lumen, colon mucosa (transient colonization)",Competitive exclusion of pathogens; no significant disruption of dominant microbiota observed in human trial,"Resistant to gastric acid (pH 2.0), bile salts (0.3%), refrigeration (4°C for 6 weeks), lyophilization/rehydration",Alginate microencapsulation (protects against gastric and intestinal stresses),该菌株为兼性厌氧菌，可在发酵香肠的低水分活性和中等盐浓度环境中存活，具有良好的胃酸和胆盐耐受性，适合在肠道中短暂定植。,Not specified,Not specified,Constitutive,,No plasmid-based systems reported; chromosomal integration not assessed; strain stability in product confirmed over 6 weeks,Alginate microencapsulation enhances survival in gastrointestinal tract and maintains viability in fermented sausage matrix,未使用基因工程改造，菌株为天然分离株，通过微胶囊化技术增强其在香肠和胃肠道中的存活能力。,"[""pH"", ""Osmotic stress""]","[""Lactate"", ""Glucose""]",,,"General stress response systems (e.g., acid tolerance response, osmotic shock proteins)",No engineered logic gates; natural sensing of environmental cues via constitutive expression,菌株通过天然的酸耐受和渗透压应激系统感知环境变化，无人工设计的逻辑门控机制。,"[""Immunomodulation"", ""Metabolic Regulation""]",Type I secretion (via cell wall-associated proteins),Dose-dependent immune modulation; daily intake of 50 g sausage delivers ~10^8 CFU,Alginate microencapsulation maintains structural integrity and allows controlled release in gastrointestinal tract,False,False,False,Not applicable,,False,False,False,False,未报告抗菌活性。,False,Not applicable,,False,False,False,未报告氧生成功能。,True,"Modulates host immune response by enhancing phagocytic activity and cytokine production (e.g., IL-10, IFN-γ) in human volunteers","Cell wall components (peptidoglycan, teichoic acids), secreted metabolites (e.g., organic acids)",False,Not applicable,,True,Improves lactose digestion and enhances bioavailability of vitamins and minerals; modulates gut microbiota composition,"Lactic acid, B vitamins (B1, B2, B6, B12), folate",False,Not applicable,,GRAS,"None (naturally occurring strain, no suicide genes or auxotrophy)",,No pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape documented,Alginate microcapsules provide physical confinement and reduce environmental release,该菌株为公认安全（GRAS）菌株，无致病性，未发现抗生素抗性基因，且通过微胶囊化技术实现物理隔离，安全性高。,在健康志愿者中，每日摄入50克含L. casei LTH 2579的发酵香肠，可显著提高免疫功能指标，但对血清胆固醇和甘油三酯水平无显著影响。粪便中可检测到该菌株，表明其在肠道中具有短暂定植能力。,7874,1459,9333,,
d9e4475c-4664-4718-86fd-38c4ea037ff5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium"", ""strain_id"": ""Golden Bifid (live combined Bifidobacterium and Lactobacillus tablets)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""Golden Bifid (live combined Bifidobacterium and Lactobacillus tablets)""}]","Oral supplementation (systemic exposure, transient gut colonization)",Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires complex nutrients including amino acids, vitamins, and carbohydrates; dependent on host-derived metabolites in the gut environment",Doubling time ~1.5–2 hours in vitro; in vivo colonization is transient and limited by host immune response and microbiome competition,"Gastrointestinal tract (small intestine and colon), particularly in the mucosal layer; transient presence in the gut lumen",Competitive exclusion of pathogenic bacteria; potential for symbiotic interaction with resident microbiota; no evidence of long-term engraftment,"Moderate tolerance to gastric acid and bile salts; sensitive to drying, UV, and prolonged storage; stable during short-term oral administration","Bile salts (protective effect via bile resistance genes), acid tolerance systems (e.g., F0F1-ATPase)",该研究中使用的益生菌为黄金双歧杆菌（含活体双歧杆菌和乳酸杆菌的复合制剂），属于兼性厌氧菌，适宜在37°C、pH 6.5–7.0的环境中生长，依赖宿主提供的复杂营养物质。在体内主要定植于肠道黏膜层，但定植为短暂性，受宿主免疫和微生物群竞争影响。对胃酸和胆盐具有中等耐受性，但对干燥、紫外线和长期储存敏感。,"Not applicable (natural strain, no genetic modification reported)",Not applicable,Constitutive (no inducible or synthetic circuits reported),,"High (natural strains, no plasmids or integrative vectors used; chromosomal stability in vivo)",No engineered material environment; natural oral delivery with transient gut exposure,本研究中使用的益生菌为天然复合菌株，未进行任何基因工程改造，其功能依赖于天然代谢通路，无合成生物电路或可调控系统。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Lactate"", ""Glucose"", ""Bile acids""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactate receptor (LacY), Bile acid transporter (BaiCD), Quorum sensing receptors (e.g., LasR, LuxR homologs)",No synthetic logic gates reported; natural sensing via constitutive receptor systems with threshold responses to environmental cues,该益生菌通过天然受体系统感知肠道内的pH、胆盐、乳酸、葡萄糖等理化信号，以及微生物群落的AHL和AI-2信号，实现对微环境的适应性响应。未使用合成逻辑门，其调控依赖于天然信号通路的阈值响应机制。,"[""Immunomodulation"", ""Metabolic Regulation""]",Passive diffusion and cell lysis (natural secretion of metabolites and cell wall components),"Oral dosing (twice daily, 0.5 g/tablet); no precise control over microbial load or activity in vivo",No encapsulated material used; oral administration with transient gut exposure,False,False,False,Not applicable,,False,False,False,False,未检测到抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未涉及氧气生成功能。,True,益生菌通过激活巨噬细胞自噬通路，增强先天免疫反应，调节炎症因子表达，从而发挥免疫调节作用。,"Autophagy-related proteins (LC3, Beclin1), Cytokines (e.g., IL-10, TNF-α)",False,Not applicable,,True,益生菌通过调节宿主胎盘细胞的自噬相关蛋白表达，影响细胞代谢稳态，尤其在正常妊娠中可能通过抑制Beclin1 mRNA表达来调节自噬水平。,"Beclin1 mRNA, LC3 mRNA",False,Not applicable,,GRAS,"None (natural strains, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to transient colonization,None (no physical barrier used),所用益生菌为天然双歧杆菌和乳酸杆菌复合制剂，属于公认安全（GRAS）级别，无致病性，无抗生素抗性基因，无基因水平转移证据，且在体内定植为短暂性，环境逃逸风险极低。,口服补充益生菌可显著降低正常妊娠自发性分娩胎盘中Beclin1 mRNA的表达水平（P < 0.05），提示其可能通过调节胎盘自噬通路发挥保护作用，但对LC3蛋白表达无显著影响。该效应可能为益生菌介导胎盘保护的新机制，但需进一步大样本随机对照试验验证。,11865,1810,13675,,
1c2988cd-3b6e-4ca8-a2e9-486b2e7b8fc8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus cereus"", ""strain_id"": ""ATCC 11778""}]",Oral gavage (systemic distribution via gut),Facultative Anaerobe,"37°C, aerobic conditions, brain heart infusion (BHI) broth, pH neutral","24 h growth in BHI broth, harvested at 3×10⁹ CFU/ml; no in vivo growth rate reported","Intestinal lumen (terminal ileum), gut mucosa","Modulates gut microbiota by enriching Ruminococcaceae and Peptococcaceae; reduces Parabacteroides, Paraprevotella, Desulfovibrio; enhances gut barrier function","Resistant to storage at 4°C; survives oral administration and intestinal transit; no data on UV, drying, or shear stress",Spore-forming capability (inferred from Bacillus genus),"Bacillus cereus ATCC 11778 is a facultative anaerobe that grows aerobically at 37°C in BHI broth. It colonizes the intestinal lumen and mucosa, where it modulates the gut microbiota and enhances intestinal barrier integrity. It survives oral administration and persists in the gut for 2 weeks, contributing to systemic protection against liver injury.",Not specified (no genetic modification reported),Not applicable (wild-type strain used),Constitutive (no inducible circuits reported),,Not applicable (no plasmid or engineered integration reported),Not applicable (no encapsulation or material environment described),"The strain used is a wild-type, non-engineered Bacillus cereus ATCC 11778. No genetic modifications, synthetic circuits, or engineered regulatory systems were employed. The probiotic effects are attributed to natural physiological functions.","[""Oxygen (consumption in gut)"", ""pH (neutral, intestinal environment)""]","[""D-Galactosamine (D-GalN) - indirect via host response"", ""LPS (lipopolysaccharide) - via TLR recognition""]","[""Quorum sensing (not reported)"", ""Bile acids (not reported)""]","[""Toll-like receptors (TLR-2, TLR-3, TLR-4)"", ""Cytokines (IL-10, IL-13, HMGB-1, TNF-α)""]","TLR-2, TLR-3, TLR-4 (host receptors); ZO-1 (tight junction protein) as indirect sensor of barrier integrity","No synthetic logic gates; natural immune modulation via cytokine feedback loops (e.g., IL-10 suppresses TLR-4 response)","B. cereus does not possess engineered sensing circuits. Instead, it responds to host-derived signals (e.g., LPS, cytokines) through natural immune recognition pathways. The strain modulates the host immune system via feedback mechanisms, such as enhancing IL-10 to suppress TLR-4-mediated inflammation, effectively creating a natural negative feedback loop.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Passive secretion via general secretion pathways (no specific secretion system reported),"Oral gavage at 2×10⁹ CFU/ml daily for 2 weeks; dosage is fixed, no dynamic control reported",No encapsulation or material delivery system used; oral administration in liquid form,False,,,Not applicable (no direct antibacterial activity reported),,False,,,,No evidence of antibacterial or biofilm inhibition activity; not a primary function.,True,"Consumes oxygen in the intestinal lumen, creating a local anaerobic environment favorable for beneficial anaerobic bacteria such as Ruminococcaceae and Peptococcaceae.",Oxygen consumption via aerobic respiration (endogenous metabolic activity),True,True,True,"B. cereus consumes oxygen in the gut, reducing oxygen tension and promoting growth of beneficial anaerobes. This does not promote pathogen growth (e.g., facultative anaerobes), and supports the anti-inflammatory gut environment. No conflict with other mechanisms observed.",True,"Modulates cytokine balance: increases anti-inflammatory IL-10 in liver and plasma; decreases pro-inflammatory IL-13, HMGB-1, COX-2, and TLR-4. Also reduces RANTES and IL-7.","Interleukin-10 (IL-10), TLR-4, HMGB-1, COX-2",True,"Enhances intestinal barrier integrity by upregulating tight junction protein ZO-1, reducing microvilli damage, and improving villus architecture. Also improves liver function (e.g., cholinesterase, albumin).","ZO-1 (zonula occludens-1), cholinesterase, albumin",True,"Restores cysteine and methionine metabolism disrupted by D-GalN. Modulates bacterial peptidoglycan biosynthesis, RNA polymerase, and nucleotide excision repair pathways.","Cysteine, methionine, glutamine synthetase",False,Not applicable,,BSL-1,None (wild-type strain used; no kill-switch or auxotrophy reported),,Low pathogenicity in healthy hosts; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; GRAS status in China (NMPN s10980014),None (no physical barrier used),"Bacillus cereus ATCC 11778 is a well-characterized, non-pathogenic strain licensed as a probiotic in China. It is classified as BSL-1 with GRAS status. No genetic modifications or antibiotic resistance genes were introduced. No biocontainment systems were used, but the strain is naturally low-risk due to its probiotic history and lack of virulence factors in this context.","Pretreatment with B. cereus significantly attenuated D-GalN-induced liver injury, as evidenced by reduced serum ALT (P < 0.05), improved cholinesterase levels (P < 0.01), and decreased liver histological damage. It enhanced intestinal barrier function (increased ZO-1 expression, reduced BT), modulated gut microbiota (enriched Ruminococcaceae, Peptococcaceae; reduced Parabacteroides, Paraprevotella, Desulfovibrio), and restored anti-inflammatory cytokine balance (elevated IL-10, reduced IL-13, HMGB-1, TLR-4). These effects collectively improved liver function and reduced systemic inflammation.",17404,2053,19457,,
682385c5-4145-470b-b8cd-c931e70a3632,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""La-05""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerant to bile and acidic environments (pH 2.5–3.0); requires glucose and amino acids as carbon and nitrogen sources",Doubling time ~1.5–2 hours in vitro; stable in vivo colonization in intestinal mucosa,"Intestinal mucosa, particularly in the small intestine and colon",Competitive exclusion of pathogenic bacteria; synergistic with native microbiota; no significant disruption of gut microbiome composition,"High tolerance to dehydration, freeze-drying, and storage at 4°C; resistant to osmotic stress and oxidative stress","Trehalose, maltodextrin, soy extract","Lactobacillus acidophilus La-05 is a facultative anaerobe with strong acid and bile tolerance, capable of surviving in the harsh gastrointestinal environment. It grows optimally at 37°C and pH 6.5–7.0, and can colonize the intestinal mucosa effectively. The strain exhibits high stability during freeze-drying and storage, especially when encapsulated with protective agents like trehalose and maltodextrin.",None specified,Not applicable (no genetic modification reported),Constitutive,,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift in encapsulated form,"Stable in alginate, chitosan, and composite matrices; no significant metabolic burden observed","The system relies on natural physiological traits of Lactobacillus acidophilus La-05 without genetic modification. Encapsulation in biomaterials such as soy extract and maltodextrin enhances viability and stability, enabling sustained release in the gastrointestinal tract.","[""Acidity (pH)"", ""Bile""]","[""Glucose"", ""Lactate""]",,,"FNR promoter (inferred from acid tolerance), bile salt hydrolase (BSH) activity",No complex logic; constitutive expression of stress resistance genes in response to environmental cues,"Lactobacillus acidophilus La-05 senses acidic and bile-rich environments through intrinsic membrane transporters and stress response pathways. It activates protective mechanisms such as acid tolerance response (ATR) and bile salt hydrolase (BSH) activity, enabling survival in the stomach and small intestine.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (for bacteriocins), vesicles (for EPS), passive diffusion (for SCFAs)",Controlled release via biomaterial degradation; sustained delivery over 24–72 hours,"High compatibility with alginate, chitosan, and composite hydrogels; maintains structural integrity during release",True,False,False,Produces lactic acid and bacteriocins that inhibit pathogenic bacteria such as E. coli and Salmonella; competes for adhesion sites on intestinal epithelium,"Lactic acid, bacteriocins (e.g., acidocin)",False,True,True,True,Lactobacillus acidophilus La-05 effectively inhibits pathogenic bacteria in vitro and in animal models; no significant cytotoxicity to host cells; localized retention in intestinal mucosa,False,,,False,False,False,Not applicable,True,"Modulates immune response by enhancing IL-10 and TGF-β production; reduces pro-inflammatory cytokines (e.g., TNF-α, IL-6); promotes regulatory T cell differentiation","Secreted exopolysaccharides (EPS), surface proteins (e.g., p40)",True,"Enhances intestinal barrier integrity by upregulating tight junction proteins (ZO-1, occludin); promotes mucus secretion and epithelial cell proliferation","Exopolysaccharides (EPS), short-chain fatty acids (SCFAs)",True,"Produces SCFAs (acetate, lactate) that regulate host metabolism and energy homeostasis; modulates glucose and lipid metabolism","Acetate, lactate",False,,,GRAS,None (naturally occurring strain with no antibiotic resistance genes),,Non-pathogenic; no evidence of opportunistic infection; no horizontal gene transfer reported; low risk of environmental escape,Physical barrier provided by alginate-chitosan matrix prevents systemic dissemination,Lactobacillus acidophilus La-05 is classified as GRAS (Generally Recognized As Safe) and has a long history of safe use in food and supplements. No antibiotic resistance genes or virulence factors detected. Encapsulation further reduces the risk of unintended colonization or systemic spread.,"In animal models, encapsulated Lactobacillus acidophilus La-05 significantly improved intestinal barrier function, reduced inflammation in colitis models, and enhanced recovery from antibiotic-induced dysbiosis. In human trials, it demonstrated efficacy in reducing diarrhea duration and improving gut microbiota diversity.",15185,1697,16882,,
b494d3b9-0145-4e59-91e2-b08f76a2e845,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal growth at 37°C, pH < 4.5; thrives in acidic environments typical of healthy vaginal microbiome; utilizes carbohydrates as primary carbon source",Growth rate not explicitly reported; capable of rapid colonization and dominance in vaginal environment under favorable conditions,Vaginal and endometrial mucosa; preferentially colonizes reproductive tract niches with low pH and lactobacilli dominance,Competitive exclusion of pathogenic bacteria; promotes symbiotic relationship with host by maintaining low pH and producing antimicrobial compounds,Tolerant to physiological stressors such as fluctuating pH and osmotic changes; stability during oral and vaginal administration,"Hydrogen peroxide, bacteriocidins","Lactobacillus strains are well-adapted to the acidic, nutrient-rich environment of the female reproductive tract. They thrive in low pH conditions (pH < 4.5), which they help maintain through lactic acid production. These bacteria are capable of colonizing the vaginal and endometrial mucosa, where they outcompete pathogenic microbes and support a healthy microbiome. Their growth is supported by available carbohydrates and they exhibit resilience to common physiological fluctuations in the reproductive tract.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,The study does not describe any genetic modifications or synthetic biology components. The probiotic strains used are naturally occurring and not engineered for specific functions. Their therapeutic effects are attributed to native metabolic and ecological properties rather than synthetic circuits.,"[""pH"", ""Lactate""]","[""Glucose"", ""Carbohydrates""]",,,"FNR promoter (inferred from lactate/pH sensing), Lactate dehydrogenase (LDH) activity",Not specified,"No synthetic sensing circuits are described. The microbial response is based on natural metabolic sensing of environmental cues such as pH and lactate levels, which regulate growth and metabolic activity in a feedback-driven manner.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Not specified,Not specified,Not specified,True,True,True,Lactobacillus produces hydrogen peroxide and bacteriocidins that inhibit the growth of pathogenic bacteria and prevent biofilm formation in the reproductive tract.,"Hydrogen peroxide, bacteriocidins",True,True,True,True,Lactobacillus dominance is associated with reduced bacterial vaginosis and improved reproductive outcomes. The production of hydrogen peroxide and bacteriocidins provides broad-spectrum antimicrobial activity without disrupting host tissue or causing systemic toxicity.,False,Not applicable,Not applicable,False,False,False,No evidence of oxygenation function in the study.,True,"Lactobacillus modulates local immune responses by promoting anti-inflammatory cytokine profiles and enhancing mucosal barrier integrity, contributing to a favorable environment for embryo implantation.","Cytokines (e.g., IL-10, TGF-β), mucosal immune regulators",True,"By maintaining a healthy vaginal and endometrial environment, Lactobacillus supports epithelial integrity and facilitates tissue homeostasis, which is essential for successful implantation and pregnancy maintenance.","Mucosal barrier enhancement, extracellular matrix stabilization",False,Not applicable,Not applicable,False,Not applicable,Not applicable,GRAS,Not applicable,Not applicable,Low pathogenicity; no antibiotic resistance genes reported; minimal risk of horizontal gene transfer; no evidence of environmental escape; safe for human use in reproductive contexts,Not applicable,"Lactobacillus strains used in probiotic therapy are generally recognized as safe (GRAS) and have a long history of safe use in humans. They are non-pathogenic, do not colonize systemically, and are naturally present in the human microbiome. No significant safety concerns were reported in the included studies, and the risk of adverse effects is minimal.","In women with non-Lactobacillus-dominant microbiota (NLDM), vaginal probiotic therapy increased clinical pregnancy rates from 48.0% to 58.8% (p = 0.47). In men, oral probiotic therapy significantly improved sperm motility (from 6.4% to 28.6% after 6 weeks) and reduced DNA fragmentation index (from 25.8% to 21.6%). These improvements were sustained for up to 6 weeks post-treatment. Lactobacillus dominance was achieved in 53% of NLDM patients treated with probiotics. Overall, probiotic therapy shows promise in optimizing reproductive outcomes, particularly in improving sperm quality and supporting a healthy reproductive microbiome.",7868,1641,9509,,
c0aec0f5-2532-4985-b991-10cef5ae6c2f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis HN019"", ""strain_id"": ""HN019""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""DSM15159""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCFM""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""DN-173 010""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates acidic environments (pH 3.0–4.0) and bile salts; requires lactose or other fermentable carbohydrates; dependent on milk components for enhanced survival.",Doubling time ~1–2 hours in vitro; growth rate maintained in dairy matrices; in vivo colonization observed in human gut with sustained viability over 7 days.,"Gut mucosa, particularly in the small intestine and colon; preferentially colonizes in the presence of prebiotics or dairy components.",Competes with pathogenic bacteria; modulates host immune response; synergizes with commensal microbiota; no significant disruption of native microbiome reported.,"High tolerance to gastric acid (pH 2.0–3.0), bile salts, and freeze-drying; stable during storage at 4°C; moderate resistance to shear stress and osmotic changes.","Lactose, oligosaccharides, calcium, and milk proteins enhance stress resistance.",这些益生菌株在乳制品基质中表现出良好的生长和存活能力，尤其在酸奶和低脂牛奶中。它们能耐受胃酸和胆汁，适合在肠道中定植并发挥功能。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及基因工程改造，所有益生菌株均以天然菌株形式使用，未进行人工基因编辑或调控回路设计。,"[""pH"", ""Bile Salts"", ""Hypoxia"", ""Lactate""]","[""Lactose"", ""Oligosaccharides"", ""Fructooligosaccharides"", ""Inulin""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines"", ""Tissue degradation fragments""]","FNR promoter, Lactose permease, Bile salt hydrolase, Quorum sensing receptors (e.g., LasR, LuxR)",Not specified,文中未描述明确的逻辑门控机制，但指出益生菌能响应多种环境信号（如pH、胆汁、乳糖）并调节代谢与黏附能力，暗示存在基础感应-响应系统。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I Secretion (e.g., for bacteriocins), Lysis (in some cases), Vesicles",Dose-dependent effects observed; efficacy linked to viable cell count (10⁸–10¹⁰ CFU/day); delivery format influences bioavailability.,"High compatibility with dairy matrices (yogurt, milk, fermented milk); stable in encapsulated forms; compatible with prebiotic addition.",True,True,True,通过产生有机酸（如乳酸）、细菌素和生物活性肽抑制病原菌生长，同时干扰生物膜形成。,"Lactic acid, Bacteriocins (e.g., Lactocin, Lactacin), Bioactive peptides",True,True,True,True,在酸奶和冻干粉中均有效缩短急性腹泻持续时间，且无显著细胞毒性或微生物群落失衡。,False,未涉及氧气生成或耗氧调控机制。,,False,False,False,未提及氧合功能。,True,"调节宿主免疫反应，增强巨噬细胞吞噬能力、自然杀伤细胞活性，并促进Th1型细胞因子（IFN-γ, IL-2）表达。","IFN-γ, IL-2, IL-10, TGF-β",True,促进肠道屏障功能恢复，增强黏膜修复能力，可能通过调节细胞增殖与凋亡实现。,"Epithelial growth factors, Mucin, Tight junction proteins",True,调节宿主代谢，如改善胰岛素敏感性、降低胆固醇、调节肠道菌群代谢产物（如短链脂肪酸）。,"Short-chain fatty acids (SCFAs), Conjugated linoleic acid (CLA), Bile acid metabolites",False,未涉及肿瘤治疗机制。,,GRAS,None (natural strains used; no synthetic kill switches or auxotrophy),Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape.,"Physical confinement via food matrix (e.g., yogurt gel) limits environmental release.",所有提及的益生菌株均为公认安全（GRAS）菌株，未见致病性或耐药性风险，且在食品基质中具有天然限制，安全性高。,在多项临床研究中，L. rhamnosus GG和B. lactis HN019显著缩短儿童急性感染性腹泻持续时间约1天；在溃疡性结肠炎患者中，合生元（synbiotic）组生活质量评分优于单独益生菌或益生元组；在动物模型中，益生菌与预生物组合显著减少结肠癌前病变数量，提示潜在抗癌作用。,14942,1925,16867,,
5f0b2bd6-0440-4d68-aeb4-3776c7917811,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacteroides thetaiotaomicron"", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal temperature: 37°C; pH: 6.5–7.5; requires complex carbon sources (e.g., dietary polysaccharides, mucin); dependent on host-derived glycans and dietary fiber",Doubling time: ~2–3 hours in vitro; in vivo growth dynamics consistent with host intestinal environment,"Colonizes the colonic mucosa and lumen, particularly in the mucus layer; thrives in the anaerobic, nutrient-rich environment of the large intestine",Commensal interaction with host and other gut microbes; competes with pathogens for nutrients and adhesion sites; supports symbiosis by producing SCFAs that inhibit pathogen growth,Moderate tolerance to bile salts and low pH (gastric transit); stable under lyophilization and rehydration; resistant to shear stress in intestinal flow,"Bile salt hydrolase (BSH), mucin-degrading enzymes",该菌株为专性厌氧或兼性厌氧菌，适宜在37°C、pH 6.5–7.5的肠道环境中生长，依赖宿主黏液和膳食纤维中的复杂碳源。在体外培养中，其倍增时间为2–3小时，与体内环境一致。能够定植于结肠黏膜和黏液层，通过产生短链脂肪酸抑制病原体生长，维持肠道微生态平衡。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及对该菌株进行基因工程改造，其功能主要基于天然代谢能力。,"[""Hypoxia"", ""pH"", ""Bile Acids""]","[""Mucin"", ""Dietary Polysaccharides"", ""Glucose"", ""Lactate""]","[""AHL"", ""AI-2""]","[""Proteases (e.g., MMPs)"", ""Cytokines (e.g., IL-8)""]","FNR promoter (hypoxia), BSH receptor (bile acids), LPS receptor (host immune signals)",Not specified,该菌株通过多种传感器感知肠道微环境变化，如低氧、胆汁酸浓度和宿主免疫信号，实现对自身代谢活动的动态调节，但未明确描述逻辑门控机制。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]",Not specified,Not specified,Not specified,False,,,Not applicable,,False,False,False,False,未提及抗菌或抗生物膜功能,False,Not applicable,,False,False,False,未提及产氧功能,True,通过调节Treg细胞分化、抑制促炎因子（如TNF-α、IL-6）和促进抗炎因子（如IL-10）分泌，调节宿主免疫反应，维持肠道稳态。,"Short-chain fatty acids (SCFAs), especially butyrate",True,通过提供能量（如丁酸）支持结肠上皮细胞再生，增强黏膜屏障功能，促进细胞间连接形成，修复受损肠黏膜。,Butyrate,True,通过发酵膳食纤维和黏蛋白产生短链脂肪酸（乙酸、丙酸、丁酸），调节宿主能量代谢，改善胰岛素敏感性，抑制肝脏脂质合成。,"Butyrate, Propionate, Acetate",False,Not applicable,,BSL-1,Not specified,,低致病性，非机会性病原体；无已知抗生素抗性基因；无水平基因转移风险；在正常肠道环境中不会逃逸。,Not specified,该菌株为正常肠道共生菌，属于GRAS（公认安全）类别，无致病性，不引起感染，适合用于益生菌和粪菌移植治疗。,在多种代谢性疾病（如2型糖尿病、非酒精性脂肪肝、结直肠癌）和炎症性肠病中，通过恢复肠道菌群平衡、调节免疫、促进黏膜修复和改善代谢功能，显示出显著的治疗潜力。,3774,1553,5327,,
ba1e5faa-b24f-43f3-9fe2-4549b5e66965,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Weissella confusa"", ""strain_id"": ""I2""}, {""role"": ""Chassis"", ""scientific_name"": ""Weissella cibaria"", ""strain_id"": ""I18""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus durans"", ""strain_id"": ""I40""}]",Suspension,Facultative Anaerobe,"Temperature: 30–37 °C; pH: 6.5–7.0; Nutritional: MRS broth, skim milk, sucrose, yeast extract; Osmotic: Tolerant to 1% NaCl",Fast acidification: ΔpH 0.45–0.93 after 4 h; Doubling time not reported; In vitro growth confirmed; In vivo consistency not assessed,Gastrointestinal tract (gastric and intestinal environments),No hemolytic or DNase activity; No antibiotic resistance; Compatible with gut microbiota; Potential symbiosis with host microbiome,"High tolerance to gastric juice (pH 2–3), bile salts (up to 1% ox-bile), heat (60 °C for 5 min), and freeze-thaw cycles (glycerol stock at −80 °C); UV and shear stress not tested","Glycerol stock (for long-term storage), NaCl (for osmotic tolerance)",该研究中分离的乳酸菌（LAB）具有良好的生长生理特性，能在30–37 °C、pH 6.5–7.0条件下快速生长，对胃酸（pH 2–3）和胆盐（最高1%）具有高度耐受性，表明其在胃肠道环境中具有良好的生存能力。这些菌株在MRS培养基和脱脂乳中表现出快速产酸能力，是理想的发酵和益生菌候选菌株。,"16S rDNA sequencing for identification; No genetic tools (CRISPR, plasmids, etc.) reported",Not applicable (no genetic modification reported),Not applicable (no synthetic circuits or inducible systems described),,No plasmid or chromosomal integration reported; Stability inferred from long-term glycerol storage (−80 °C) and repeated culture without drift,"Stable in MRS agar, skim milk, and glycerol; No data on encapsulation or material interaction",本研究未对菌株进行基因工程改造，所有特性均为天然野生型表现。通过16S rDNA测序鉴定物种，未使用任何基因编辑工具或合成生物学元件。,"[""pH"", ""Osmotic stress"", ""Temperature""]","[""Lactate"", ""Glucose"", ""Bile salts""]",,"[""Proteases"", ""Cytokines (implied by gut environment)""]","No specific receptor or promoter reported; Sensing inferred from physiological responses (e.g., acid tolerance, bile resistance)",No logic gates or signal processing circuits reported; Response is likely constitutive or threshold-based,未报道任何合成信号感应模块或逻辑门控系统。菌株对pH、胆盐和温度等环境变化的响应为天然生理适应，无基因调控回路设计。,"[""Antibacterial"", ""Probiotic"", ""Metabolic Regulation""]","Cell lysis (autolysis), extracellular enzyme secretion (proteases, lipases)",Not controllable (natural secretion; no inducible system),"Compatible with MRS agar, skim milk, and glycerol; No data on encapsulation or hydrogel compatibility",True,True,False,产生抗菌物质（如细菌素）抑制革兰氏阳性菌（如金黄色葡萄球菌）和革兰氏阴性菌（如大肠杆菌、沙门氏菌、铜绿假单胞菌）生长,Bacteriocins (proteinaceous antimicrobial peptides),True,True,True,True,"对多种病原菌（S. aureus, E. coli, Salmonella, P. aeruginosa）具有抑制活性；无溶血或DNase活性，表明低细胞毒性；在胃肠道环境中存活率高，局部作用明确。",False,,,False,False,False,未报道任何产氧机制或光依赖性产氧系统。,False,,,False,,,True,通过产生短链脂肪酸（SCFAs）、抗氧化物质（如DPPH清除能力）调节宿主代谢和氧化应激状态,"Short-chain fatty acids (SCFAs), Antioxidants (DPPH scavengers)",False,,,GRAS,No engineered kill switches or auxotrophy reported; Natural safety profile based on absence of virulence factors,,"No hemolytic activity, no DNase activity, no antibiotic resistance genes detected; Low pathogenicity risk; No horizontal gene transfer (HGT) data; Environmental escape risk low due to non-pathogenic nature",Glycerol stock and agar-based culture provide physical containment; No advanced barrier systems used,所有分离菌株均无溶血、DNase活性，且对多种抗生素敏感，未检测到耐药基因，表明其具有良好的生物安全性。作为乳酸菌，属于公认安全（GRAS）类别，适合用于食品和潜在人类消费。,该研究未直接评估伤口愈合或治疗效果，但所有菌株均表现出优异的益生特性：对胃酸和胆盐耐受性强，能快速产酸，具有广谱抗菌活性，且无毒副作用。这些特性使其成为乳制品发酵和功能性食品开发的理想候选菌株。,20503,1862,22365,,
8840a4c1-b188-4336-95b8-35152648498b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""PTCC1608""}]",Suspension (dietary supplementation),Facultative Anaerobe,Temperature: 37°C; pH: 5.8–7.6; Growth medium: MRS broth; Nutrition: Ferments carbohydrates to produce lactic acid,Growth rate: 30–48 h at 37°C; Doubling time: Not specified; In vitro: Grows well in MRS broth; In vivo: Colonizes fish gut after dietary administration,Gastrointestinal tract of Tor grypus (fish gut),"Competitive exclusion of pathogenic bacteria (e.g., Aeromonas hydrophila); potential modulation of host microbiota without significant disruption",Tolerant to lyophilization/rehydration (used in freeze-dried form); Stable at 30°C during diet drying; Tolerant to normal saline washes,Lyophilization (freeze-drying) process,"Lactobacillus casei PTCC1608 is a facultative heterofermentative bacterium that grows well at 37°C in MRS broth, with optimal growth observed in the gastrointestinal environment of fish. It survives dietary processing (drying at 30°C) and can colonize the gut of Tor grypus after oral administration. It exhibits tolerance to osmotic stress during washing and re-suspension steps.",Not applicable (no genetic modification reported),Not applicable,Constitutive (natural expression in host environment),,Not applicable (no plasmid or engineered integration reported),Stable in diet matrix during drying and storage; no reported degradation or loss of viability,"Lactobacillus casei PTCC1608 is used in its native, unmodified form. No genetic tools or synthetic circuits are employed. The strain is administered orally via diet, relying on natural colonization and immune stimulation without engineered genetic control.","[""pH (5.8–7.6 in fish gut)"", ""Temperature (25–37°C)""]","[""Carbohydrates (lactic fermentation substrates)"", ""Bile acids (in fish gut)""]",,"[""Proteases (in gut environment)"", ""Cytokines (indirectly via immune response)""]","Natural receptors for nutrients and environmental cues (e.g., sugar transporters, pH sensors)","No synthetic logic gates; natural response to environmental signals (e.g., nutrient availability, pH)","Lactobacillus casei naturally senses nutrient availability (e.g., carbohydrates), pH, and bile acids in the fish gut. It responds by growing and producing metabolites (e.g., lactic acid) that modulate the gut environment. No engineered logic circuits are involved; responses are based on intrinsic physiological sensing.","[""Immunomodulation"", ""Antibacterial""]","Natural secretion of metabolites (e.g., lactic acid, bacteriocins); no engineered secretion system reported",Controlled by dietary concentration (5×10⁶ to 5×10⁸ CFU/g); lower dose (A) showed optimal immune response,Compatible with diet matrix; stable during drying at 30°C; no structural disruption reported,True,False,False,"L. casei enhances host innate immunity, leading to increased lysozyme, complement, and bactericidal activity against Aeromonas hydrophila. It may also compete for adhesion sites in the gut.","Lysozyme (host-derived), Complement system (host-derived), Bactericidal activity (host-derived)",False,True,True,True,"L. casei supplementation significantly increased serum lysozyme, bactericidal activity, and complement activity against A. hydrophila. No cytotoxicity or microbiome disruption reported. Activity was localized to the gut and systemic immune system.",False,,,False,False,False,Not applicable,True,"L. casei upregulates pro-inflammatory cytokines (TNF-α, IL-1β, IL-8) in head kidney, enhancing innate immune responses and improving survival after A. hydrophila challenge.","TNF-α, IL-1β, IL-8 (host cytokines)",False,,,False,,,False,,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; low opportunistic risk in fish; no environmental escape concerns in aquaculture setting,Dietary delivery provides physical confinement; no free-living release,Lactobacillus casei PTCC1608 is a GRAS (Generally Recognized As Safe) strain with no reported pathogenicity or antibiotic resistance. It is naturally present in the gut microbiota of fish and humans. No genetic modifications or biocontainment systems are used. The risk of environmental escape is low due to dietary delivery and lack of persistence beyond the gut.,"Dietary supplementation with L. casei significantly enhanced innate immune responses in Tor grypus, including increased serum lysozyme, complement activity, and bactericidal activity. Gene expression of TNF-α, IL-1β, and IL-8 was upregulated. After challenge with Aeromonas hydrophila, cumulative mortality was significantly reduced (15% in group B vs 45% in control). The immune-enhancing effects persisted for 15 days after probiotic withdrawal. Treatment A (5×10⁶ CFU/g) was optimal for economic and biosecurity reasons.",16315,1821,18136,,
e54f5a53-c5ef-4bc4-bc6f-c69c0f24d3c7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""IP1""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 6.9 (initial), adjusted to 2.0 (stomach), then to 5.0 (duodenum), and 6.5 (ileum); Nutritional requirement: MRS broth; Bile tolerance: Tolerant (survived in duodenum with bile salts)",Initial concentration: 8.2 log CFU g⁻¹; After gastrointestinal simulation: 7.7 log CFU g⁻¹; Reduction of 0.5 log CFU g⁻¹; In vitro stability consistent with labeling,"Small intestine (ileum), potential for mucosal adhesion and colonization",Competitive exclusion of pathogens via nutrient competition and niche occupation,"Moderate tolerance to low pH (stomach), bile salts (duodenum), and mechanical agitation (simulated peristalsis); Lyophilization stability not explicitly stated",None specified,该菌株为乳酸杆菌属，具有耐酸和耐胆盐特性，可在模拟胃肠道环境中存活，初始浓度较高，经胃肠道模拟后仍保持在7.7 log CFU g⁻¹，表明其在体外具有良好的生存能力，适合用于功能性食品。,None specified,Not applicable,None specified,None specified,Not applicable,Not applicable,该研究未对菌株进行基因改造，所有分析基于天然菌株的生理特性，未涉及遗传工具或合成电路。,"[""Low pH (stomach)"", ""Bile salts (duodenum)"", ""Mechanical agitation (peristalsis simulation)""]",,,,None specified,None specified,未检测到特定的信号感应模块或逻辑控制机制，研究仅评估了菌株在模拟胃肠道环境中的存活能力，未涉及基因调控或感应系统。,"[""Immunomodulation"", ""Microbiome Modulation"", ""Pathogen Inhibition""]",None specified,None specified,None specified,False,False,False,None specified,None specified,False,False,False,False,未检测到抗菌或抗生物膜功能，研究未评估其抗菌机制。,False,None specified,None specified,False,False,False,未评估氧气生成功能，该菌株不具有产氧能力。,True,通过调节肠道免疫反应，增强宿主免疫防御，抑制炎症反应，促进肠道屏障功能。,"None specified (endogenous metabolites such as lactic acid, exopolysaccharides)",False,None specified,None specified,True,通过产生短链脂肪酸（如乳酸）调节肠道微环境，影响宿主代谢，改善肠道健康。,Lactic acid,False,None specified,None specified,BSL-1,None specified,None specified,低致病性，非机会性病原体，无抗生素抗性基因报告，无水平基因转移风险，环境逃逸风险低。,None specified,该菌株为公认安全（GRAS）菌株，无致病性，未发现抗生素抗性基因，环境释放风险极低，适合用于食品和补充剂。,在模拟胃肠道环境中，IP1菌株初始浓度为8.2 log CFU g⁻¹，经胃肠道模拟后仍保持7.7 log CFU g⁻¹，表明其具有良好的耐受性和存活能力，可有效到达小肠，发挥免疫调节和微生物群落调节作用，支持其作为功能性食品益生菌的潜力。,13162,14018,27180,,
e54f5a53-c5ef-4bc4-bc6f-c69c0f24d3c7,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus LA-14"", ""strain_id"": ""IP2""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 6.9 (initial), adjusted to 2.0 (stomach), then to 5.0 (duodenum), and 6.5 (ileum); Nutritional requirement: MRS broth; Bile tolerance: Tolerant (survived in duodenum with bile salts)",Initial concentration: 9.8 log CFU g⁻¹; After gastrointestinal simulation: 8.1 log CFU g⁻¹; Reduction of 1.7 log CFU g⁻¹; In vitro stability consistent with labeling,"Small intestine (ileum), potential for mucosal adhesion and colonization",Competitive exclusion of pathogens via nutrient competition and niche occupation,"Moderate tolerance to low pH (stomach), bile salts (duodenum), and mechanical agitation (simulated peristalsis); Lyophilization stability not explicitly stated",None specified,该菌株为嗜酸乳杆菌，具有良好的耐酸和耐胆盐能力，初始浓度高，经胃肠道模拟后仍保持8.1 log CFU g⁻¹，表明其在体外具有较强的生存能力，适合用于功能性食品。,None specified,Not applicable,None specified,None specified,Not applicable,Not applicable,该研究未对菌株进行基因改造，所有分析基于天然菌株的生理特性，未涉及遗传工具或合成电路。,"[""Low pH (stomach)"", ""Bile salts (duodenum)"", ""Mechanical agitation (peristalsis simulation)""]",,,,None specified,None specified,未检测到特定的信号感应模块或逻辑控制机制，研究仅评估了菌株在模拟胃肠道环境中的存活能力，未涉及基因调控或感应系统。,"[""Immunomodulation"", ""Microbiome Modulation"", ""Pathogen Inhibition""]",None specified,None specified,None specified,False,False,False,None specified,None specified,False,False,False,False,未检测到抗菌或抗生物膜功能，研究未评估其抗菌机制。,False,None specified,None specified,False,False,False,未评估氧气生成功能，该菌株不具有产氧能力。,True,通过调节肠道免疫反应，增强宿主免疫防御，抑制炎症反应，促进肠道屏障功能。,"None specified (endogenous metabolites such as lactic acid, exopolysaccharides)",False,None specified,None specified,True,通过产生短链脂肪酸（如乳酸）调节肠道微环境，影响宿主代谢，改善肠道健康。,Lactic acid,False,None specified,None specified,BSL-1,None specified,None specified,低致病性，非机会性病原体，无抗生素抗性基因报告，无水平基因转移风险，环境逃逸风险低。,None specified,该菌株为公认安全（GRAS）菌株，无致病性，未发现抗生素抗性基因，环境释放风险极低，适合用于食品和补充剂。,在模拟胃肠道环境中，IP2菌株初始浓度为9.8 log CFU g⁻¹，经胃肠道模拟后仍保持8.1 log CFU g⁻¹，表明其具有良好的耐受性和存活能力，可有效到达小肠，发挥免疫调节和微生物群落调节作用，支持其作为功能性食品益生菌的潜力。,13162,14018,27180,,
e54f5a53-c5ef-4bc4-bc6f-c69c0f24d3c7,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus LA-14"", ""strain_id"": ""IP3""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 6.9 (initial), adjusted to 2.0 (stomach), then to 5.0 (duodenum), and 6.5 (ileum); Nutritional requirement: MRS broth; Bile tolerance: Tolerant (survived in duodenum with bile salts)",Initial concentration: 10.5 log CFU g⁻¹; After gastrointestinal simulation: 9.0 log CFU g⁻¹; Reduction of 1.5 log CFU g⁻¹; In vitro stability consistent with labeling,"Small intestine (ileum), potential for mucosal adhesion and colonization",Competitive exclusion of pathogens via nutrient competition and niche occupation,"Moderate tolerance to low pH (stomach), bile salts (duodenum), and mechanical agitation (simulated peristalsis); Lyophilization stability not explicitly stated",None specified,该菌株为嗜酸乳杆菌，具有优异的耐酸和耐胆盐能力，初始浓度高达10.5 log CFU g⁻¹，经胃肠道模拟后仍保持9.0 log CFU g⁻¹，表明其在体外具有极强的生存能力，是理想的益生菌候选菌株。,None specified,Not applicable,None specified,None specified,Not applicable,Not applicable,该研究未对菌株进行基因改造，所有分析基于天然菌株的生理特性，未涉及遗传工具或合成电路。,"[""Low pH (stomach)"", ""Bile salts (duodenum)"", ""Mechanical agitation (peristalsis simulation)""]",,,,None specified,None specified,未检测到特定的信号感应模块或逻辑控制机制，研究仅评估了菌株在模拟胃肠道环境中的存活能力，未涉及基因调控或感应系统。,"[""Immunomodulation"", ""Microbiome Modulation"", ""Pathogen Inhibition""]",None specified,None specified,None specified,False,False,False,None specified,None specified,False,False,False,False,未检测到抗菌或抗生物膜功能，研究未评估其抗菌机制。,False,None specified,None specified,False,False,False,未评估氧气生成功能，该菌株不具有产氧能力。,True,通过调节肠道免疫反应，增强宿主免疫防御，抑制炎症反应，促进肠道屏障功能。,"None specified (endogenous metabolites such as lactic acid, exopolysaccharides)",False,None specified,None specified,True,通过产生短链脂肪酸（如乳酸）调节肠道微环境，影响宿主代谢，改善肠道健康。,Lactic acid,False,None specified,None specified,BSL-1,None specified,None specified,低致病性，非机会性病原体，无抗生素抗性基因报告，无水平基因转移风险，环境逃逸风险低。,None specified,该菌株为公认安全（GRAS）菌株，无致病性，未发现抗生素抗性基因，环境释放风险极低，适合用于食品和补充剂。,在模拟胃肠道环境中，IP3菌株初始浓度高达10.5 log CFU g⁻¹，经胃肠道模拟后仍保持9.0 log CFU g⁻¹，表明其具有极强的耐受性和存活能力，可有效到达小肠，发挥免疫调节和微生物群落调节作用，是理想的益生菌候选菌株。,13162,14018,27180,,
e54f5a53-c5ef-4bc4-bc6f-c69c0f24d3c7,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus LA-14"", ""strain_id"": ""MP4""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 6.9 (initial), adjusted to 2.0 (stomach), then to 5.0 (duodenum), and 6.5 (ileum); Nutritional requirement: MRS broth; Bile tolerance: Tolerant (survived in duodenum with bile salts)",Initial concentration: 5.8 log CFU g⁻¹; After gastrointestinal simulation: 3.0 log CFU g⁻¹; Reduction of 2.8 log CFU g⁻¹; In vitro stability inconsistent with labeling,"Small intestine (ileum), but low survival suggests limited colonization potential",Limited competitive ability due to low viability,Low tolerance to low pH and bile salts; lyophilization may have compromised viability,None specified,该菌株为嗜酸乳杆菌，初始浓度较低（5.8 log CFU g⁻¹），经胃肠道模拟后仅剩3.0 log CFU g⁻¹，表明其耐受性差，难以有效到达小肠，可能无法发挥益生作用。,None specified,Not applicable,None specified,None specified,Not applicable,Not applicable,该研究未对菌株进行基因改造，所有分析基于天然菌株的生理特性，未涉及遗传工具或合成电路。,"[""Low pH (stomach)"", ""Bile salts (duodenum)"", ""Mechanical agitation (peristalsis simulation)""]",,,,None specified,None specified,未检测到特定的信号感应模块或逻辑控制机制，研究仅评估了菌株在模拟胃肠道环境中的存活能力，未涉及基因调控或感应系统。,"[""Immunomodulation"", ""Microbiome Modulation""]",None specified,None specified,None specified,False,False,False,None specified,None specified,False,False,False,False,未检测到抗菌或抗生物膜功能，研究未评估其抗菌机制。,False,None specified,None specified,False,False,False,未评估氧气生成功能，该菌株不具有产氧能力。,True,通过调节肠道免疫反应，增强宿主免疫防御，抑制炎症反应，促进肠道屏障功能。,"None specified (endogenous metabolites such as lactic acid, exopolysaccharides)",False,None specified,None specified,True,通过产生短链脂肪酸（如乳酸）调节肠道微环境，影响宿主代谢，改善肠道健康。,Lactic acid,False,None specified,None specified,BSL-1,None specified,None specified,低致病性，非机会性病原体，无抗生素抗性基因报告，无水平基因转移风险，环境逃逸风险低。,None specified,该菌株为公认安全（GRAS）菌株，无致病性，未发现抗生素抗性基因，环境释放风险极低，但因存活率低，实际应用价值有限。,在模拟胃肠道环境中，MP4菌株初始浓度为5.8 log CFU g⁻¹，经胃肠道模拟后仅剩3.0 log CFU g⁻¹，表明其耐受性差，难以有效到达小肠，可能无法发挥益生作用，建议改进制剂或保护技术。,13162,14018,27180,,
e54f5a53-c5ef-4bc4-bc6f-c69c0f24d3c7,4,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus LA-14"", ""strain_id"": ""MP5""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 6.9 (initial), adjusted to 2.0 (stomach), then to 5.0 (duodenum), and 6.5 (ileum); Nutritional requirement: MRS broth; Bile tolerance: Tolerant (survived in duodenum with bile salts)",Initial concentration: 4.8 log CFU g⁻¹; After gastrointestinal simulation: 3.2 log CFU g⁻¹; Reduction of 1.6 log CFU g⁻¹; In vitro stability inconsistent with labeling,"Small intestine (ileum), but low survival suggests limited colonization potential",Limited competitive ability due to low viability,Low tolerance to low pH and bile salts; lyophilization may have compromised viability,None specified,该菌株为嗜酸乳杆菌，初始浓度较低（4.8 log CFU g⁻¹），经胃肠道模拟后仅剩3.2 log CFU g⁻¹，表明其耐受性较差，难以有效到达小肠，可能无法发挥益生作用。,None specified,Not applicable,None specified,None specified,Not applicable,Not applicable,该研究未对菌株进行基因改造，所有分析基于天然菌株的生理特性，未涉及遗传工具或合成电路。,"[""Low pH (stomach)"", ""Bile salts (duodenum)"", ""Mechanical agitation (peristalsis simulation)""]",,,,None specified,None specified,未检测到特定的信号感应模块或逻辑控制机制，研究仅评估了菌株在模拟胃肠道环境中的存活能力，未涉及基因调控或感应系统。,"[""Immunomodulation"", ""Microbiome Modulation""]",None specified,None specified,None specified,False,False,False,None specified,None specified,False,False,False,False,未检测到抗菌或抗生物膜功能，研究未评估其抗菌机制。,False,None specified,None specified,False,False,False,未评估氧气生成功能，该菌株不具有产氧能力。,True,通过调节肠道免疫反应，增强宿主免疫防御，抑制炎症反应，促进肠道屏障功能。,"None specified (endogenous metabolites such as lactic acid, exopolysaccharides)",False,None specified,None specified,True,通过产生短链脂肪酸（如乳酸）调节肠道微环境，影响宿主代谢，改善肠道健康。,Lactic acid,False,None specified,None specified,BSL-1,None specified,None specified,低致病性，非机会性病原体，无抗生素抗性基因报告，无水平基因转移风险，环境逃逸风险低。,None specified,该菌株为公认安全（GRAS）菌株，无致病性，未发现抗生素抗性基因，环境释放风险极低，但因存活率低，实际应用价值有限。,在模拟胃肠道环境中，MP5菌株初始浓度为4.8 log CFU g⁻¹，经胃肠道模拟后仅剩3.2 log CFU g⁻¹，表明其耐受性较差，难以有效到达小肠，可能无法发挥益生作用，建议改进制剂或保护技术。,13162,14018,27180,,
e54f5a53-c5ef-4bc4-bc6f-c69c0f24d3c7,5,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus LA-14"", ""strain_id"": ""CP6""}]",Capsule,Facultative Anaerobe,"Temperature: 37°C; pH: 6.9 (initial), adjusted to 2.0 (stomach), then to 5.0 (duodenum), and 6.5 (ileum); Nutritional requirement: MRS broth; Bile tolerance: Tolerant (survived in duodenum with bile salts)",Initial concentration: 9.9 log CFU g⁻¹; After gastrointestinal simulation: 7.0 log CFU g⁻¹; Reduction of 2.9 log CFU g⁻¹; In vitro stability consistent with labeling,"Small intestine (ileum), capsule provides partial protection",Competitive exclusion of pathogens via nutrient competition and niche occupation,Moderate tolerance to low pH and bile salts; capsule provides partial protection,Capsule matrix,该菌株为嗜酸乳杆菌，初始浓度高（9.9 log CFU g⁻¹），胶囊包装提供一定保护，经胃肠道模拟后仍保持7.0 log CFU g⁻¹，表明其具有良好的耐受性和存活能力，适合用于功能性食品。,None specified,Not applicable,None specified,None specified,Not applicable,Not applicable,该研究未对菌株进行基因改造，所有分析基于天然菌株的生理特性，未涉及遗传工具或合成电路。,"[""Low pH (stomach)"", ""Bile salts (duodenum)"", ""Mechanical agitation (peristalsis simulation)""]",,,,None specified,None specified,未检测到特定的信号感应模块或逻辑控制机制，研究仅评估了菌株在模拟胃肠道环境中的存活能力，未涉及基因调控或感应系统。,"[""Immunomodulation"", ""Microbiome Modulation"", ""Pathogen Inhibition""]",None specified,None specified,Capsule matrix provides partial protection,False,False,False,None specified,None specified,False,False,False,False,未检测到抗菌或抗生物膜功能，研究未评估其抗菌机制。,False,None specified,None specified,False,False,False,未评估氧气生成功能，该菌株不具有产氧能力。,True,通过调节肠道免疫反应，增强宿主免疫防御，抑制炎症反应，促进肠道屏障功能。,"None specified (endogenous metabolites such as lactic acid, exopolysaccharides)",False,None specified,None specified,True,通过产生短链脂肪酸（如乳酸）调节肠道微环境，影响宿主代谢，改善肠道健康。,Lactic acid,False,None specified,None specified,BSL-1,None specified,None specified,低致病性，非机会性病原体，无抗生素抗性基因报告，无水平基因转移风险，环境逃逸风险低。,Capsule matrix provides partial protection,该菌株为公认安全（GRAS）菌株，无致病性，未发现抗生素抗性基因，环境释放风险极低，胶囊包装提供一定保护，适合用于食品和补充剂。,在模拟胃肠道环境中，CP6菌株初始浓度为9.9 log CFU g⁻¹，经胃肠道模拟后仍保持7.0 log CFU g⁻¹，表明其具有良好的耐受性和存活能力，胶囊包装提供一定保护，可有效到达小肠，发挥免疫调节和微生物群落调节作用，支持其作为功能性食品益生菌的潜力。,13162,14018,27180,,
e54f5a53-c5ef-4bc4-bc6f-c69c0f24d3c7,6,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus LA-14"", ""strain_id"": ""CP7""}]",Capsule,Facultative Anaerobe,"Temperature: 37°C; pH: 6.9 (initial), adjusted to 2.0 (stomach), then to 5.0 (duodenum), and 6.5 (ileum); Nutritional requirement: MRS broth; Bile tolerance: Tolerant (survived in duodenum with bile salts)",Initial concentration: 10.7 log CFU g⁻¹; After gastrointestinal simulation: 8.6 log CFU g⁻¹; Reduction of 2.1 log CFU g⁻¹; In vitro stability consistent with labeling,"Small intestine (ileum), capsule provides partial protection",Competitive exclusion of pathogens via nutrient competition and niche occupation,Moderate tolerance to low pH and bile salts; capsule provides partial protection,Capsule matrix,该菌株为嗜酸乳杆菌，初始浓度极高（10.7 log CFU g⁻¹），胶囊包装提供一定保护，经胃肠道模拟后仍保持8.6 log CFU g⁻¹，表明其具有极强的耐受性和存活能力，是理想的益生菌候选菌株。,None specified,Not applicable,None specified,None specified,Not applicable,Not applicable,该研究未对菌株进行基因改造，所有分析基于天然菌株的生理特性，未涉及遗传工具或合成电路。,"[""Low pH (stomach)"", ""Bile salts (duodenum)"", ""Mechanical agitation (peristalsis simulation)""]",,,,None specified,None specified,未检测到特定的信号感应模块或逻辑控制机制，研究仅评估了菌株在模拟胃肠道环境中的存活能力，未涉及基因调控或感应系统。,"[""Immunomodulation"", ""Microbiome Modulation"", ""Pathogen Inhibition""]",None specified,None specified,Capsule matrix provides partial protection,False,False,False,None specified,None specified,False,False,False,False,未检测到抗菌或抗生物膜功能，研究未评估其抗菌机制。,False,None specified,None specified,False,False,False,未评估氧气生成功能，该菌株不具有产氧能力。,True,通过调节肠道免疫反应，增强宿主免疫防御，抑制炎症反应，促进肠道屏障功能。,"None specified (endogenous metabolites such as lactic acid, exopolysaccharides)",False,None specified,None specified,True,通过产生短链脂肪酸（如乳酸）调节肠道微环境，影响宿主代谢，改善肠道健康。,Lactic acid,False,None specified,None specified,BSL-1,None specified,None specified,低致病性，非机会性病原体，无抗生素抗性基因报告，无水平基因转移风险，环境逃逸风险低。,Capsule matrix provides partial protection,该菌株为公认安全（GRAS）菌株，无致病性，未发现抗生素抗性基因，环境释放风险极低，胶囊包装提供一定保护，适合用于食品和补充剂。,在模拟胃肠道环境中，CP7菌株初始浓度高达10.7 log CFU g⁻¹，经胃肠道模拟后仍保持8.6 log CFU g⁻¹，表明其具有极强的耐受性和存活能力，胶囊包装提供一定保护，可有效到达小肠，发挥免疫调节和微生物群落调节作用，是理想的益生菌候选菌株。,13162,14018,27180,,
e54f5a53-c5ef-4bc4-bc6f-c69c0f24d3c7,7,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus LA-14"", ""strain_id"": ""CP9""}]",Lyophilized,Facultative Anaerobe,"Temperature: 37°C; pH: 6.9 (initial), adjusted to 2.0 (stomach), then to 5.0 (duodenum), and 6.5 (ileum); Nutritional requirement: MRS broth; Bile tolerance: Tolerant (survived in duodenum with bile salts)",Initial concentration: 7.3 log CFU g⁻¹; After gastrointestinal simulation: 5.8 log CFU g⁻¹; Reduction of 1.5 log CFU g⁻¹; In vitro stability inconsistent with labeling,"Small intestine (ileum), lyophilized form may affect viability",Competitive exclusion of pathogens via nutrient competition and niche occupation,Moderate tolerance to low pH and bile salts; lyophilization may have affected viability,None specified,该菌株为嗜酸乳杆菌，初始浓度为7.3 log CFU g⁻¹，经胃肠道模拟后仍保持5.8 log CFU g⁻¹，表明其具有良好的耐受性和存活能力，但初始浓度低于标签标注值，建议改进制剂。,None specified,Not applicable,None specified,None specified,Not applicable,Not applicable,该研究未对菌株进行基因改造，所有分析基于天然菌株的生理特性，未涉及遗传工具或合成电路。,"[""Low pH (stomach)"", ""Bile salts (duodenum)"", ""Mechanical agitation (peristalsis simulation)""]",,,,None specified,None specified,未检测到特定的信号感应模块或逻辑控制机制，研究仅评估了菌株在模拟胃肠道环境中的存活能力，未涉及基因调控或感应系统。,"[""Immunomodulation"", ""Microbiome Modulation"", ""Pathogen Inhibition""]",None specified,None specified,Lyophilized form may affect viability,False,False,False,None specified,None specified,False,False,False,False,未检测到抗菌或抗生物膜功能，研究未评估其抗菌机制。,False,None specified,None specified,False,False,False,未评估氧气生成功能，该菌株不具有产氧能力。,True,通过调节肠道免疫反应，增强宿主免疫防御，抑制炎症反应，促进肠道屏障功能。,"None specified (endogenous metabolites such as lactic acid, exopolysaccharides)",False,None specified,None specified,True,通过产生短链脂肪酸（如乳酸）调节肠道微环境，影响宿主代谢，改善肠道健康。,Lactic acid,False,None specified,None specified,BSL-1,None specified,None specified,低致病性，非机会性病原体，无抗生素抗性基因报告，无水平基因转移风险，环境逃逸风险低。,None specified,该菌株为公认安全（GRAS）菌株，无致病性，未发现抗生素抗性基因，环境释放风险极低，但因初始浓度低于标签标注值，建议改进制剂。,在模拟胃肠道环境中，CP9菌株初始浓度为7.3 log CFU g⁻¹，经胃肠道模拟后仍保持5.8 log CFU g⁻¹，表明其具有良好的耐受性和存活能力，但初始浓度低于标签标注值，建议改进制剂。,13162,14018,27180,,
e54f5a53-c5ef-4bc4-bc6f-c69c0f24d3c7,8,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum LA-14"", ""strain_id"": ""MP11""}]",Suspension,Strict Anaerobe,"Temperature: 37°C; pH: 6.9 (initial), adjusted to 2.0 (stomach), then to 5.0 (duodenum), and 6.5 (ileum); Nutritional requirement: MRS broth with additives (dicloxacillin, lithium chloride, cysteine chloride); Bile tolerance: Tolerant (survived in duodenum with bile salts)",Initial concentration: 4.3 log CFU g⁻¹; After gastrointestinal simulation: 3.3 log CFU g⁻¹; Reduction of 1.0 log CFU g⁻¹; In vitro stability inconsistent with labeling,"Small intestine (ileum), strict anaerobe requires low oxygen",Competitive exclusion of pathogens via nutrient competition and niche occupation,Low tolerance to low pH and bile salts; lyophilization may have compromised viability,None specified,该菌株为双歧杆菌，初始浓度较低（4.3 log CFU g⁻¹），经胃肠道模拟后仅剩3.3 log CFU g⁻¹，表明其耐受性较差，难以有效到达小肠，可能无法发挥益生作用。,None specified,Not applicable,None specified,None specified,Not applicable,Not applicable,该研究未对菌株进行基因改造，所有分析基于天然菌株的生理特性，未涉及遗传工具或合成电路。,"[""Low pH (stomach)"", ""Bile salts (duodenum)"", ""Mechanical agitation (peristalsis simulation)""]",,,,None specified,None specified,未检测到特定的信号感应模块或逻辑控制机制，研究仅评估了菌株在模拟胃肠道环境中的存活能力，未涉及基因调控或感应系统。,"[""Immunomodulation"", ""Microbiome Modulation""]",None specified,None specified,None specified,False,False,False,None specified,None specified,False,False,False,False,未检测到抗菌或抗生物膜功能，研究未评估其抗菌机制。,False,None specified,None specified,False,False,False,未评估氧气生成功能，该菌株不具有产氧能力。,True,通过调节肠道免疫反应，增强宿主免疫防御，抑制炎症反应，促进肠道屏障功能。,None specified (endogenous metabolites such as short-chain fatty acids),False,None specified,None specified,True,通过产生短链脂肪酸（如乙酸、乳酸）调节肠道微环境，影响宿主代谢，改善肠道健康。,Short-chain fatty acids,False,None specified,None specified,BSL-1,None specified,None specified,低致病性，非机会性病原体，无抗生素抗性基因报告，无水平基因转移风险，环境逃逸风险低。,None specified,该菌株为公认安全（GRAS）菌株，无致病性，未发现抗生素抗性基因，环境释放风险极低，但因存活率低，实际应用价值有限。,在模拟胃肠道环境中，MP11菌株初始浓度为4.3 log CFU g⁻¹，经胃肠道模拟后仅剩3.3 log CFU g⁻¹，表明其耐受性较差，难以有效到达小肠，可能无法发挥益生作用，建议改进制剂或保护技术。,13162,14018,27180,,
e54f5a53-c5ef-4bc4-bc6f-c69c0f24d3c7,9,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis CNCMI-2494"", ""strain_id"": ""FM10""}]",Liquid,Strict Anaerobe,"Temperature: 37°C; pH: 6.9 (initial), adjusted to 2.0 (stomach), then to 5.0 (duodenum), and 6.5 (ileum); Nutritional requirement: MRS broth with additives (dicloxacillin, lithium chloride, cysteine chloride); Bile tolerance: Tolerant (survived in duodenum with bile salts)",Initial concentration: 8.0 log CFU g⁻¹; After gastrointestinal simulation: 6.9 log CFU g⁻¹; Reduction of 1.1 log CFU g⁻¹; In vitro stability consistent with labeling,"Small intestine (ileum), strict anaerobe requires low oxygen",Competitive exclusion of pathogens via nutrient competition and niche occupation,Moderate tolerance to low pH and bile salts; liquid matrix provides protection,Milk fat globules,该菌株为动物双歧杆菌，初始浓度为8.0 log CFU g⁻¹，经胃肠道模拟后仍保持6.9 log CFU g⁻¹，表明其具有良好的耐受性和存活能力，液体基质（牛奶脂肪球）提供保护，适合用于功能性食品。,None specified,Not applicable,None specified,None specified,Not applicable,Not applicable,该研究未对菌株进行基因改造，所有分析基于天然菌株的生理特性，未涉及遗传工具或合成电路。,"[""Low pH (stomach)"", ""Bile salts (duodenum)"", ""Mechanical agitation (peristalsis simulation)""]",,,,None specified,None specified,未检测到特定的信号感应模块或逻辑控制机制，研究仅评估了菌株在模拟胃肠道环境中的存活能力，未涉及基因调控或感应系统。,"[""Immunomodulation"", ""Microbiome Modulation""]",None specified,None specified,Milk fat globules provide protection,False,False,False,None specified,None specified,False,False,False,False,未检测到抗菌或抗生物膜功能，研究未评估其抗菌机制。,False,None specified,None specified,False,False,False,未评估氧气生成功能，该菌株不具有产氧能力。,True,通过调节肠道免疫反应，增强宿主免疫防御，抑制炎症反应，促进肠道屏障功能。,None specified (endogenous metabolites such as short-chain fatty acids),False,None specified,None specified,True,通过产生短链脂肪酸（如乙酸、乳酸）调节肠道微环境，影响宿主代谢，改善肠道健康。,Short-chain fatty acids,False,None specified,None specified,BSL-1,None specified,None specified,低致病性，非机会性病原体，无抗生素抗性基因报告，无水平基因转移风险，环境逃逸风险低。,Milk fat globules provide protection,该菌株为公认安全（GRAS）菌株，无致病性，未发现抗生素抗性基因，环境释放风险极低，牛奶脂肪球提供保护，适合用于食品和补充剂。,在模拟胃肠道环境中，FM10菌株初始浓度为8.0 log CFU g⁻¹，经胃肠道模拟后仍保持6.9 log CFU g⁻¹，表明其具有良好的耐受性和存活能力，牛奶脂肪球提供保护，可有效到达小肠，发挥免疫调节和微生物群落调节作用，支持其作为功能性食品益生菌的潜力。,13162,14018,27180,,
f0b48978-cfc3-45d7-92e9-97ea8cc5a2bc,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LaA1, LaA2, LaA3, LaC1, LaC2, LaE1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""LcA1, LcB1, LcB2, LcF1""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis"", ""strain_id"": ""BifB1, BifB2, BifC1, BifD1, BifE1, BifE2, BifH1""}]",Suspension,Facultative Anaerobe,Optimal growth at 37°C; pH 6.4 for fermentation; anaerobic conditions required for Bifidobacterium; growth in MRS agar and broth; tolerance to acidic pH (pH 3.9–4.2 in fermented milk),Growth rate not explicitly quantified; viable counts maintained above 10⁵ CFU/mL after 30 days of refrigerated storage (4°C); population decreases of 0.75–1.85 log units for lactobacilli and 0.17–1.10 log units for bifidobacteria,Gastrointestinal tract (intended for oral ingestion and intestinal implantation),Competitive with other microorganisms in fermented milk; no direct evidence of interaction with host microbiome in this study,"Tolerant to refrigeration (4°C), acidic pH, and bile (inferred from survival in fermented milk and intestinal transit), but no data on UV, drying, or shear stress",None specified,这些益生菌在发酵乳中具有良好的存活能力，乳酸菌和双歧杆菌在冷藏30天后仍保持在10⁵ CFU/mL以上。双歧杆菌在大多数产品中表现出比乳酸菌更低的种群下降，但产品7和8中的双歧杆菌在第20天和第25天后低于10⁵ CFU/mL。所有产品均含有标签上声明的益生菌，部分产品还检测到额外的微生物。,"Partial 16S rRNA gene sequencing, PFGE (pulsed-field gel electrophoresis), carbohydrate fermentation profiling",Not applicable (no genetic engineering performed),Not applicable,None,High genetic stability observed; reduced genetic variability among commercial strains; identical or highly similar PFGE and fermentation profiles across products suggest clonal propagation,Stable in fermented milk matrix; no evidence of degradation or instability during storage,未对菌株进行基因工程改造。通过16S rRNA基因V1-V2区测序、PFGE和碳水化合物发酵谱对菌株进行鉴定和分型，未发现基因编辑或合成回路。,"[""pH"", ""Acidity""]","[""Glucose"", ""Galactose"", ""Lactose"", ""Maltose"", ""Sucrose"", ""Trehalose"", ""Ribose"", ""Amygdaline"", ""Mannitol"", ""Rhamnose"", ""Cellobiose"", ""Raffinose"", ""L-Arabinose""]",,,"16S rRNA gene (for identification), carbohydrate fermentation profiles (for metabolic sensing)",No synthetic logic circuits; natural metabolic logic inferred from fermentation profiles,菌株通过碳水化合物发酵谱表现出不同的代谢能力，可用于区分不同菌株。例如，L. johnsonii LaC2与其它菌株在杏仁苷发酵上存在差异，可用于区分。PFGE和发酵谱联合使用增强了分型能力。,"[""Metabolic Regulation""]","None (natural fermentation, no engineered secretion)",None (natural growth and survival in product),High compatibility with fermented milk matrix; no structural disruption reported,False,,,None,,False,False,False,False,无抗菌功能,False,None,,False,False,False,无氧生成功能,False,None,,False,None,,True,通过发酵多种碳水化合物（如葡萄糖、乳糖、蔗糖、麦芽糖、海藻糖、核糖、杏仁苷、甘露醇、纤维二糖等）产生有机酸，调节肠道微生态平衡，促进益生功能。,"Organic acids (lactic acid, acetic acid), SCFAs (inferred)",False,None,,GRAS,None (no synthetic kill switches or auxotrophy used),None,No pathogenicity or antibiotic resistance genes reported; no β-glucuronidase activity (non-carcinogenic); no horizontal gene transfer data; low risk of environmental escape due to food matrix and lack of virulence factors,Fermented milk matrix provides physical confinement,所有菌株均被鉴定为安全的益生菌，无致病性、无β-葡萄糖醛酸酶活性，且在商业产品中稳定存在，未检测到抗生素抗性基因，属于GRAS级别，风险极低。,在冷藏30天期间，乳酸菌和双歧杆菌的存活率均保持在10⁵ CFU/mL以上，满足益生菌最低有效剂量要求。双歧杆菌在多数产品中表现出更优的稳定性。所有标签声明的益生菌均被检测到，部分产品存在额外菌种，但未影响整体安全性与功能。,15884,1832,17716,,
9f86aa07-3e85-4d95-9c8d-ca444937f0e7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Isochrysis galbana"", ""strain_id"": ""T-ISO; UTEX Culture LB 2307""}, {""role"": ""Chassis"", ""scientific_name"": ""Nannochloropsis oculata"", ""strain_id"": ""NNO-1 UTEX Culture LB 2164""}]",Oral administration (Suspension in water),Facultative Anaerobe,"Temperature: 21°C, pH: 8.2, Salinity: 30 ppm NaCl, Light: 2 × 75 W fluorescent","Growth cycle: 5 days (I. galbana), 6 days (N. oculata); harvested at mid-log phase; freeze-dried for storage","Gastrointestinal tract (intestine), particularly colonizing mucosal surface and influencing gut microbiota",Promotes beneficial lactic acid bacteria (LAB); suppresses Enterobacteriaceae and pathogens; enhances gut barrier function; N. oculata causes intestinal damage and reduces LAB,Freeze-dried stability; stable under storage at -20°C; tolerance to gastric transit (inferred from oral administration and survival in gut),"Polysaccharides (cell wall components), freeze-drying process",两种微藻均为光合自养型微生物，在21°C、pH 8.2、30 ppm NaCl条件下，使用荧光灯培养。I. galbana在第5天收获，N. oculata在第6天收获，经离心和冷冻干燥后用于口服给药。其细胞壁多糖具有膳食纤维特性，可耐受胃肠道环境并促进有益菌群生长。,,,,,,,该研究未涉及任何基因工程改造。微藻作为天然生物活性物质来源，其功能基于其内源性成分（如多糖、多不饱和脂肪酸），未进行基因编辑或合成回路设计。,"[""pH"", ""Osmotic stress (via salt content)""]","[""Glucose"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing (indirect via LAB modulation)""]","[""Intestinal epithelial integrity"", ""Inflammatory cytokines (inferred from histopathology)""]","Cell wall polysaccharides (e.g., beta-glucans), membrane receptors (inferred)",No synthetic logic gates; natural response to gut environment via prebiotic and immunomodulatory signaling,微藻通过其细胞壁多糖在肠道中被益生菌发酵，产生短链脂肪酸，调节肠道pH和免疫反应。I. galbana通过增强Lactococcus lactis等有益菌群，间接抑制病原体，形成天然的“感应-响应”机制，但无人工设计的逻辑门控系统。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Passive release of bioactive compounds (polysaccharides, fatty acids) upon digestion; no engineered secretion system",Oral administration at fixed dose (50 mg/day); no dynamic control,Compatible with oral delivery; polysaccharides and lipids are stable in gastrointestinal environment,False,False,False,无直接抗菌活性，但通过促进有益菌群间接抑制病原体。,,False,False,False,False,未观察到直接抗菌作用，但I. galbana组中病原体（如沙门氏菌）减少，提示间接抑制作用。,False,无光合产氧或酶促产氧机制，不参与局部氧合。,,False,False,False,研究未涉及氧代谢或产氧功能，不适用于缺氧环境治疗。,True,通过调节肠道菌群和炎症反应，减轻慢性炎症，增强免疫屏障功能。,"Polysaccharides (cell wall), SCFAs (from LAB fermentation)",True,促进肠道上皮再生，减少炎症损伤，维持黏膜完整性。,"Polysaccharides, SCFAs, Lactococcus lactis",True,调节血糖、血脂、脂蛋白水平，改善胰岛素抵抗。,"Docosahexaenoic acid (DHA), Eicosapentaenoic acid (EPA), Polysaccharides",False,未研究肿瘤相关功能。,,GRAS,No genetic modification; natural organisms with no known pathogenicity,None (no synthetic kill switches),Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape due to non-replicating oral delivery,Oral administration with no physical barrier; but low risk due to GRAS status,I. galbana和N. oculata均被评估为无急性毒性，符合GRAS（公认安全）标准。I. galbana在健康和糖尿病模型中均表现出有益作用，而N. oculata引起肠道损伤和菌群失衡，但未见系统性毒性。整体生物安全性高，尤其I. galbana适合用于功能性食品。,I. galbana显著降低糖尿病大鼠血糖（从542.62 mg/dl降至300 mg/dl）、胆固醇和甘油三酯水平，增加乳酸菌数量，减轻肠道炎症，维持体重；N. oculata未改善代谢指标，反而导致体重下降、肠道坏死和菌群失调。,13129,1804,14933,,
d138dc4c-2203-466f-8b38-310275612d2d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""L. crispatus, L. gasseri, L. iners, L. jensenii, L. vaginalis""}]",Suspension,Facultative Anaerobe,"Optimal temperature: 37°C; pH: acidic (maintained by lactic acid production); Nutritional requirements: fermentable carbohydrates (e.g., glucose), amino acids, vitamins; dependent on host-derived nutrients in vivo",Doubling time: ~1–2 hours in vitro; growth rate consistent with in vivo homeostasis in healthy vaginal environment,"Vaginal epithelium, particularly in the lower genital tract (vagina and ectocervix); preferentially colonizes areas with low microbial diversity and high lactate levels","Competitive exclusion of pathogenic bacteria (e.g., Gardnerella, Prevotella); symbiotic relationship with host immune system; maintains microbial balance via acidification and antimicrobial compound secretion","Moderate tolerance to osmotic stress and pH fluctuations; stable under physiological conditions; limited data on UV, drying, or shear stress","Lactic acid, hydrogen peroxide, bacteriocins",乳酸杆菌是健康女性阴道微生态中的优势菌群，能够通过产生乳酸维持酸性环境，抑制病原菌定植。其生长依赖于宿主提供的碳源和营养物质，在阴道上皮表面形成稳定的生物膜样结构，具有良好的定植能力和环境适应性。,Not mentioned,,Not mentioned,,Not mentioned,Not mentioned,目前文献中未提及对乳酸杆菌进行基因工程改造，其功能主要依赖于天然代谢途径和共生机制。,"[""pH"", ""Lactate"", ""Hypoxia""]","[""Glucose"", ""Bile acids"", ""SCFAs""]","[""Quorum sensing (AI-2)"", ""AHL""]","[""Proteases"", ""Cytokines (e.g., IL-1β, TNF-α)"", ""Mucins""]","FNR promoter (hypoxia), Lactate-responsive promoters, AI-2 receptor (LuxP/Q), TLRs (host pattern recognition)",Not explicitly described; likely constitutive or threshold-based responses to environmental cues such as pH and lactate levels,乳酸杆菌通过感知局部pH值、乳酸浓度及宿主免疫因子（如IL-1β、TNF-α）的变化，调节自身代谢与分泌行为。其响应机制可能为阈值触发型，以维持阴道微环境稳态。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I and Type II secretion systems (e.g., for lactic acid, bacteriocins); extracellular vesicles (potential)",Not controllable; activity depends on natural growth and metabolic state,Compatible with vaginal mucosal environment; may be encapsulated in hydrogels or tablets for sustained release,True,True,True,通过分泌乳酸、过氧化氢、细菌素样物质及表面活性剂，抑制多种病原菌（如Gardnerella、Prevotella、Streptococcus）的黏附与生长，同时破坏生物膜结构。,"Lactic acid, Hydrogen peroxide, Bacteriocin-like compounds, Biosurfactants",True,True,True,True,乳酸杆菌分泌的乳酸和过氧化氢可有效抑制多种阴道病原体，且在临床研究中显示对细菌性阴道病（BV）有显著改善作用，未见明显细胞毒性或微生物群落紊乱。,False,,,,,,,True,通过调节局部免疫反应，促进抗炎性Treg细胞分化，抑制Th17细胞活性，降低促炎因子（如IL-1β、TNF-α）水平，增强黏膜屏障功能。,"Treg-inducing factors, IL-10, TGF-β, Dendritic cell modulators",True,通过分泌生长因子和调节免疫微环境，促进上皮细胞再生，增强黏膜屏障完整性，改善宫颈组织修复能力。,"Epidermal growth factor (EGF)-like factors, Mucin-stimulating signals",True,通过代谢产物（如乳酸、短链脂肪酸）调节局部微环境，影响宿主细胞能量代谢与免疫状态，间接调控HPV感染进程。,"Lactic acid, SCFAs (e.g., acetate, propionate)",False,,,GRAS,Not applicable (natural commensal strain),,Low pathogenicity; no known antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape,Physical barrier provided by vaginal mucosa and epithelial integrity,乳酸杆菌为人体正常共生菌，属于公认安全（GRAS）类别，无致病性，不携带耐药基因，且在阴道内定植后不易扩散至其他部位，安全性高。,在临床研究中，口服或阴道应用乳酸杆菌（如L. casei）可促进HPV清除率，改善细菌性阴道病症状，增强阴道黏膜屏障功能，降低宫颈癌前病变进展风险。,8770,1760,10530,,
9135955b-d76e-4ce1-ac72-73bba1fa15fd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}]",Topical (toothpaste) and systemic (curd),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, requires lactose or other fermentable carbohydrates; tolerant to moderate bile and salivary components",Doubling time ~60–90 min in vitro; in vivo colonization observed within 30 days with sustained presence in oral cavity,"Oral cavity, particularly adhering to tooth surfaces and gingival crevices around orthodontic brackets",Competitive inhibition of Streptococcus mutans; no significant disruption of commensal oral microbiota; may promote symbiosis with beneficial oral flora,"Moderate tolerance to drying, shear stress during brushing, and transient exposure to saliva; stable during storage in curd and toothpaste formulations","Lactobacillus cell wall components, exopolysaccharides in curd matrix",该系统以乳酸杆菌（Lactobacillus spp.）为底盘，为兼性厌氧菌，适宜在37°C、pH 5.5–6.5的口腔环境中生长，依赖乳糖等可发酵碳源。在体外培养中倍增时间为60–90分钟，在体内可定植于正畸托槽周围牙面及龈沟，具有良好的耐受性，能在牙膏和酸乳中保持稳定，适用于局部和全身给药。,,,,,No genetic modification reported; natural strains used; chromosomal stability in oral environment,Stable in both curd (food matrix) and toothpaste (dental formulation) without significant loss of viability,本研究未使用基因工程改造，所用乳酸杆菌为天然菌株，通过自然定植和竞争性抑制机制发挥作用，未涉及人工调控回路或基因编辑。,"[""pH"", ""Lactate"", ""Glucose""]","[""Bile acids"", ""SCFAs""]",,,"Lactobacillus surface adhesins (e.g., mucus-binding proteins), sugar transporters",No engineered logic gates; natural sensing via metabolic and adhesion pathways with threshold-based colonization,乳酸杆菌通过表面黏附蛋白感知口腔环境中的pH、乳酸和葡萄糖变化，利用糖转运系统响应碳源可用性，实现对牙面微环境的适应性定植，其定植行为具有阈值响应特性，不依赖人工逻辑回路。,"[""Antibacterial"", ""Competitive Exclusion""]",Passive secretion via cell lysis and diffusion; no engineered secretion systems,Dose controlled by frequency of consumption (twice daily) and formulation concentration,"High compatibility with both curd (food matrix) and toothpaste (dental gel), maintains viability and function",True,False,True,通过竞争性黏附于牙面，阻止S. mutans定植；分泌抗菌物质如reuterin（一种天然抗菌素）抑制病原菌生长,Reuterin,False,True,True,True,在牙膏和酸乳中使用后，S. mutans在托槽周围牙菌斑中的浓度显著下降，且无明显细胞毒性或微生物群落紊乱，表明其活性可控且局部安全。,False,,,,,,,False,,,False,,,False,,,False,,,GRAS,Natural auxotrophy; no synthetic kill switches or engineered containment,Lactose dependency (natural metabolic requirement),Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape,Physical barrier provided by toothpaste matrix and oral mucosal integrity,所用乳酸杆菌为公认安全（GRAS）菌株，无基因改造，依赖乳糖生长，不具备致病性或耐药性风险，通过牙膏和酸乳载体实现物理隔离，整体生物安全风险极低。,在30天内，口服益生菌酸乳和使用益生菌牙膏均显著降低正畸托槽周围牙菌斑中S. mutans的浓度，其中酸乳组减少率为60%，牙膏组为57%，差异无统计学意义。该结果表明益生菌系统可有效抑制龋齿相关菌群定植，具有预防白斑病变的潜力，适用于正畸患者的长期口腔健康管理。,7880,1591,9471,,
86b41363-2b91-4059-9ce7-aea6572d6381,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""GBI-30,6086""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GR-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""RC-14""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, tolerant to bile salts and intestinal pH; utilizes various carbohydrates as carbon sources",Moderate growth rate in vitro; in vivo colonization ability demonstrated in HIV patients on HAART,"Gut mucosa (GALT), particularly in the intestinal lumen and epithelial surface",Competitive exclusion of pathogenic bacteria; synergistic interaction with host microbiota to restore microbial balance,"Resistant to gastric acid, bile, heat, and lyophilization; stable during storage and transport","Spore formation (Bacillus coagulans), mucin-binding adhesins (Lactobacillus spp.)","Bacillus coagulans GBI-30,6086 is a spore-forming, facultative anaerobe with strong gastrointestinal stability and colonization ability. Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 are acid-tolerant, bile-resistant, and capable of adhering to intestinal epithelium, enabling sustained presence in the gut mucosa.",,,,,No genetic modification reported; natural strains used with inherent chromosomal stability,No engineered material coupling; natural strains used in oral formulations,所有菌株均为天然未改造菌株，未使用基因编辑工具。其功能依赖于天然代谢与免疫调节能力，无外源基因插入或调控回路。,"[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]",,"[""Cytokines (TNF-α, IL-10, IL-12)"", ""Proteases (indirectly via mucosal damage)""]","Bile acid transporters (Bacillus coagulans), pH-responsive promoters (Lactobacillus spp.), surface adhesins (e.g., pili in L. rhamnosus GR-1)",No synthetic logic gates; natural sensing via receptor-mediated responses to environmental cues,菌株通过天然受体感知肠道环境变化，如pH波动、胆汁酸浓度和营养物质可用性，从而调节黏附、定植和免疫调节因子分泌。无人工逻辑门控机制。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","No engineered secretion; natural secretion of immunomodulatory molecules (e.g., exopolysaccharides, bacteriocins)",Oral administration with fixed dose; no dynamic dosage control,"Compatible with oral formulations (capsules, powders); no encapsulation in functional materials reported",False,False,False,,,False,False,False,False,未报告抗菌或抗生物膜活性。,False,,,False,False,False,未涉及氧气生成或氧合功能。,True,通过调节树突状细胞成熟、CD69表达及细胞因子平衡（如降低TNF-α，升高IL-10）来抑制慢性炎症，增强抗病毒免疫应答。,"TNF-α, IL-10, IL-12, G-CSF (host cytokines modulated by probiotics)",True,促进肠道屏障功能恢复，减少微生物易位，改善肠道通透性，支持黏膜修复。,"Mucin, tight junction proteins (indirectly enhanced by probiotics)",True,调节宿主代谢稳态，通过改善肠道微环境间接影响免疫代谢，如降低炎症性代谢产物。,Short-chain fatty acids (SCFAs) – inferred from probiotic activity,False,,,GRAS,Natural auxotrophy and lack of antibiotic resistance genes; no synthetic kill switches,"None (natural strains, no engineered containment)",Low pathogenicity; no reported cases of bacteremia or opportunistic infection; no antibiotic resistance genes detected; low horizontal gene transfer risk,Oral delivery with natural GI barrier; no physical material confinement,"Bacillus coagulans GBI-30,6086 和 Lactobacillus spp. 均为公认安全（GRAS）菌株，临床研究中未见严重不良反应。其天然特性使其不易在宿主体内过度增殖或引发感染，且无抗生素抗性基因，环境逃逸风险极低。",在HAART治疗的HIV患者中，Ganeden BC30显著提高CD4+ T细胞百分比，增强树突状细胞成熟与CD69表达；Lactobacillus rhamnosus GR-1和Lactobacillus reuteri RC-14有效预防胃肠道和泌尿生殖道感染，减少腹泻，提升CD4+ T细胞比例。研究提示，恢复肠道Th17细胞可改善黏膜免疫功能，降低炎症水平，促进免疫重建。,3386,1777,5163,,
839774e8-67ce-4b27-b0b6-ef099a43f0e8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerant to bile salts and low pH; utilizes glucose and other carbohydrates as carbon sources; requires no specific vitamins or amino acids beyond standard growth media",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed for >1 week post-administration,"Nasopharyngeal adenoid tissue (lymphoid tissue of Waldeyer's ring), transient mucosal adhesion",Competitive exclusion of pathogens via surface pili; no reported symbiosis with resident microbiota; may modulate immune response without disrupting core microbiome,"Tolerant to gastric acidity, bile salts, and freeze-drying; stable during storage at -70°C; resistant to shear stress during encapsulation and oral delivery","Cell wall pili (e.g., pili encoded by the pili gene cluster), exopolysaccharides",Lactobacillus rhamnosus GG 是一种源自人类的益生菌，具有良好的耐酸性和耐胆盐能力，可在胃肠道和鼻咽部黏膜上短暂定植超过一周。其生长适宜温度为37°C，pH 5.5–6.5，可利用葡萄糖等碳源生长，无需额外添加维生素或必需氨基酸。在体外培养中，其倍增时间为1.5–2小时。在本研究中，口服3周后可在腺样体组织中检测到该菌，表明其具有良好的黏膜定植能力。,,,,,Chromosomal stability; no plasmid-based genetic modifications reported; no evidence of genetic drift or loss in vivo over 3-week period,Stable within capsule matrix; no degradation or loss of viability during encapsulation and storage,本研究未对Lactobacillus rhamnosus GG进行基因工程改造。其益生功能依赖于天然存在的黏附素（pili）和免疫调节特性，未使用CRISPR、质粒或诱导型表达系统。菌株在胶囊中保持稳定，无基因修饰，因此遗传稳定性高。,"[""pH"", ""Bile Acids""]","[""Glucose"", ""Lactate""]",,"[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), pili-mediated adhesion receptors, surface glycoproteins",No engineered logic gates; natural sensing via surface receptors and metabolic feedback; threshold-based colonization dependent on mucosal environment,Lactobacillus rhamnosus GG通过其表面的菌毛（pili）识别宿主黏膜表面的特定分子，实现黏附。其对pH和胆盐的耐受性使其能在胃肠道和鼻咽部生存。菌体可感知葡萄糖和乳酸等代谢物，调节自身代谢与定植行为。虽无人工设计的逻辑门，但其天然的环境响应机制可实现对宿主微环境的适应性响应。,"[""Immunomodulation""]",Passive diffusion and secretion via general secretory pathway (Sec); no specialized secretion systems reported,Dose-dependent colonization; controlled by oral intake frequency and capsule formulation; no feedback control,High compatibility with capsule matrix; maintains viability during encapsulation and storage; no adverse interaction with gel or carrier,False,,,,,,,,,,False,,,,,,,True,Induces antigen-specific immune response in mice; modulates local and systemic immune activity in human mucosal tissues; enhances immune surveillance in adenoid tissue,"Surface pili, exopolysaccharides, secreted metabolites (e.g., lactic acid)",False,,,False,,,False,,,GRAS,Auxotrophy (no known auxotrophic markers reported; natural attenuation via lack of long-term colonization),None (no kill-switch or inducible suicide system used),Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape; safe in healthy children,Capsule provides physical confinement; prevents uncontrolled release into environment,Lactobacillus rhamnosus GG 被归类为GRAS（公认安全），无致病性，无抗生素抗性基因，不引起水平基因转移。其在人体内定植为短暂性，无长期滞留风险。胶囊封装提供了物理屏障，防止菌体意外释放。在本研究中，未报告严重不良反应，仅1例 placebo 组儿童因腹泻停用，提示其安全性良好。,口服3周后，Lactobacillus rhamnosus GG 在所有接受干预的儿童腺样体组织中均被检测到，且在安慰剂组中也有76%的阳性率，提示其具有良好的黏膜定植能力。尽管未观察到对鼻咽部鼻病毒（RV）或肠道病毒（EV）感染的显著影响，但其在腺样体组织中的持久存在表明其具有潜在的免疫调节作用。研究中未发现显著症状差异，但LGG组中伴有中耳积液（MEE）的儿童呼吸症状天数较多，可能与基础疾病相关。总体而言，该菌株在鼻咽部黏膜具有良好的定植和免疫调节潜力，安全性高。,8531,1820,10351,,
e69e252d-1005-4098-a30e-fe72280086e7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in YPD medium (yeast extract 1%, peptone 1%, dextrose 2%), optimal pH not specified, osmotic tolerance not specified, nutritional requirements: yeast extract, peptone, dextrose",Growth rate not specified; cultured overnight at 37°C with shaking at 180 rpm; CFU concentration: 10^9 CFU/mL,Gastrointestinal tract (gut microbiota modulation),Modulates intestinal microbial homeostasis; regulates local and systemic immune responses; may influence gut microbiota composition,Lyophilized form used; stable for storage; tolerance to gavage and gastrointestinal transit not explicitly detailed,"Lyophilized preparation (Floratil, Merck S.A.)","Saccharomyces boulardii is a nonpathogenic yeast that grows well in standard yeast culture media (YPD) at 37°C. It is administered orally as a lyophilized suspension and colonizes the gastrointestinal tract, where it modulates microbial balance and immune function. It is stable under storage and gastrointestinal conditions, enabling effective delivery in probiotic supplementation.",Not applicable (no genetic modification reported),Not applicable,Not applicable,Not applicable,Not applicable (no plasmid or chromosomal integration reported),Not applicable,"Saccharomyces boulardii was used in its native, non-genetically modified form. No genetic tools or synthetic circuits were employed. The yeast was administered as a live, lyophilized suspension without any engineered genetic modifications.","[""pH"", ""Nutrient availability (dextrose, peptone)""]","[""Short-chain fatty acids (SCFAs)"", ""Glucose""]",,"[""Cytokines (e.g., IL-6, TNF-α, IFN-γ)"", ""Neurotransmitters (serotonin, dopamine)""]",Not specified (no specific receptor or promoter reported),Not applicable (no synthetic logic circuits described),"No engineered sensing or logic processing was implemented. The yeast's physiological responses are based on natural interactions with the host environment, including modulation of immune and metabolic signals, but no synthetic sensing modules were used.","[""Metabolic Regulation"", ""Immunomodulation""]",Not specified (natural secretion of metabolites and immune modulators),Oral gavage of 10^8 CFU/day for 10 days; dosage not controllable in real time,Compatible with oral suspension delivery; stable in lyophilized form,False,,,Not applicable,,False,False,False,False,无抗菌或抗生物膜作用的证据,False,Not applicable,,False,False,False,无氧生成机制的证据,True,"Sb supplementation reduces proinflammatory cytokines (IL-6, IL-8, IL-1β, TNF-α, IFN-γ), potentially alleviating exercise-induced inflammation and perceived fatigue.","Cytokines (IL-6, IL-8, IL-1β, TNF-α, IFN-γ)",False,Not applicable,,True,"Sb increases fecal SCFA concentrations, which may enhance lipid oxidation and mitochondrial respiration via AMPK/PGC-1α pathway activation, contributing to improved aerobic capacity.",Short-chain fatty acids (SCFAs),False,Not applicable,,GRAS,Not applicable (no kill-switch or auxotrophy reported),Not applicable,"Nonpathogenic yeast; no reported pathogenicity, antibiotic resistance genes, or horizontal gene transfer risk; low opportunistic risk",Oral administration with natural gut colonization; no physical barrier used,"Saccharomyces boulardii is classified as Generally Recognized As Safe (GRAS). It is nonpathogenic, does not possess antibiotic resistance genes, and has no known risk of horizontal gene transfer. It is naturally present in the human gut and used widely as a probiotic. No biocontainment strategies were implemented, as the organism is considered safe for human and animal use.",Sb补充10天后，大鼠的最大摄氧量（VO2MAX）提高了12.7%（p=0.01），最大运动速度提高了12.4%（p<0.05），运动至疲劳时间延长了21.6%。这些结果表明Sb能显著提升大鼠的有氧运动表现，但未改善跑步经济性或机械效率，提示其作用机制可能与代谢调节和免疫调节相关，而非肌肉结构或能量利用效率的直接提升。,12328,1631,13959,,
fcc72ffd-3fb0-422a-8362-c79c112ce3d7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus bulgaricus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus subtilis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus faecium"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""8PA3""}, {""role"": ""Chassis"", ""scientific_name"": ""VSL#3"", ""strain_id"": ""Multistrain formulation""}]",Oral administration (systemic delivery via gastrointestinal tract),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, requires carbohydrates (e.g., lactose) as carbon source; some strains require vitamins and amino acids.",Doubling time ~1–2 hours in vitro; in vivo colonization ability reported in intestinal mucosa.,"Intestinal mucosa, particularly in the small intestine and colon; preferentially adheres to epithelial cells.",Competes with pathogenic bacteria for adhesion sites; modulates host immune response by increasing IL-10 and decreasing IL-6 and TNF-α; may promote symbiosis with commensal microbiota.,"Moderate tolerance to gastric acid and bile; survives passage through upper GI tract; limited data on UV, shear, or storage stability.",Lactic acid production (protects against low pH); extracellular polysaccharides (EPS) in some strains (enhances mucosal adhesion and stress resistance).,这些益生菌为兼性厌氧菌，可在人体肠道内定植，利用乳糖等碳源生长，具有良好的胃肠道耐受性，能通过竞争性抑制和免疫调节作用改善肠道屏障功能。,Not specified (natural strains used; no genetic modification reported),Not applicable,Constitutive (no inducible circuits reported),,Not reported; natural strains used without plasmid or chromosomal integration.,Not applicable (no engineered material environment described),所用益生菌为天然菌株，未进行基因改造，其功能依赖于天然代谢途径和定植能力。,"[""pH"", ""Bile acids"", ""Lactate""]","[""Lactose"", ""Glucose"", ""Amino acids""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines (IL-6, TNF-α)"", ""Tissue degradation fragments""]","FNR promoter (inferred from metabolic adaptation), Lactate receptor (inferred), Bile acid sensors (inferred from bile tolerance)",No synthetic logic gates reported; natural sensing via metabolic and environmental cues.,这些益生菌通过感知肠道内的pH、胆汁酸、乳酸等环境信号，以及宿主免疫因子（如IL-6、TNF-α）和营养物质（如乳糖、葡萄糖）来调节自身代谢与定植行为，实现对肠道微环境的适应性响应。,"[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]","Type I secretion (lactic acid), Vesicles (exosomes), Lysis (in some cases)","Dose-dependent effects; oral administration with standard dosing regimens (e.g., 10^9–10^10 CFU/day).","Good compatibility with oral formulations (capsules, powders); no encapsulation in synthetic materials reported.",True,False,True,通过产生乳酸、细菌素等抗菌物质抑制病原菌生长；竞争性占据黏膜结合位点，防止病原体定植。,"Lactic acid, Bacteriocins (e.g., plantaricin), Competitive exclusion",False,True,True,True,益生菌通过抑制病原菌定植和产生抗菌物质，有效减少肠道细菌易位，且无明显细胞毒性，局部作用明确。,False,,,False,False,False,,True,调节宿主免疫反应，促进抗炎因子（如IL-10）分泌，抑制促炎因子（如IL-6、TNF-α）释放，改善肠道屏障功能。,"IL-10, TGF-β, SCFAs (e.g., butyrate)",True,通过增强肠道屏障完整性、减少通透性、促进上皮细胞再生，修复受损肠黏膜。,"Mucin production, Epithelial growth factors, Butyrate",True,调节宿主代谢，如改善胰岛素敏感性、降低肝脂肪沉积，通过调节胆汁酸代谢和短链脂肪酸（SCFAs）生成影响能量平衡。,"Butyrate, Propionate, Acetate, Bile acid metabolites",False,,,GRAS,None (natural strains used; no kill-switch or auxotrophy reported),,Low pathogenicity; no antibiotic resistance genes reported; minimal risk of horizontal gene transfer; no evidence of environmental escape.,None (oral delivery without physical confinement),所用益生菌均为公认安全（GRAS）菌株，无致病性，不携带耐药基因，且在临床试验中未见严重不良反应，安全性良好。,在非酒精性脂肪肝病（NAFLD）患者中，补充乳酸杆菌和嗜热链球菌可显著改善肝功能酶水平；在酒精性肝病患者中，益生菌可降低内毒素水平、恢复肠道菌群并减轻肝损伤。在肝移植前后使用益生菌可显著降低术后感染率（从48%降至3%），并改善移植物早期功能。,9439,1970,11409,,
38aa7767-6f13-4a72-97df-96ef3db22573,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Kluyveromyces marxianus"", ""strain_id"": ""KU140723-02 (KM2)""}]",Suspension,Facultative Anaerobe,"37°C, pH 8.0 (bile resistance), MRS medium with 0.3% oxgall","24 h incubation at 37°C, doubling time not specified",Intestinal epithelium (Caco-2 cell adhesion),Potential symbiosis with gut microbiota via prebiotic synergy with GSF/GSE,"High acid (pH 2.5, 50% survival), bile salt resistance (0.3% oxgall), moderate gastric resistance","Cell wall and membrane integrity, intracellular antioxidant systems","K. marxianus KM2 exhibits strong resistance to gastric and intestinal conditions, including acid and bile, and demonstrates high adhesion to intestinal cells, indicating suitability for gut colonization. It grows well in MRS medium under aerobic conditions at 37°C.",,,,,,,No genetic engineering was performed. The strain was used in its native form for probiotic and antioxidant functional evaluation.,,,,,,,"No engineered sensing modules were reported. Natural physiological responses to environmental conditions (e.g., acid, bile) were observed but not genetically programmed.","[""Antioxidant Activity"", ""Cholesterol Reduction"", ""Adhesion to Intestinal Cells""]",Passive release of intracellular antioxidants and metabolites,Not controllable – natural secretion without engineered regulation,Compatible with GSF/GSE matrix; synergistic interaction observed in co-culture,False,,,Not applicable – no antibacterial activity reported.,,False,False,False,False,无抗菌活性相关证据,False,Not applicable – no oxygenation function reported.,,False,False,False,无氧生成相关证据,False,Not applicable – no immunomodulatory effects reported.,,False,Not applicable – no tissue repair function reported.,,True,"K. marxianus KM2 reduces cholesterol in vitro (20% reduction at 100 ppm), suggesting potential metabolic regulation of lipid homeostasis.",Cholesterol,False,Not applicable – no tumor-targeting or therapeutic mechanism reported.,,BSL-1,None – no kill-switch or auxotrophy reported,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; GRAS status likely,Physical confinement not required; natural gut transit limits environmental escape,K. marxianus KM2 is a non-pathogenic yeast with GRAS-like characteristics. It shows no signs of virulence or antibiotic resistance. Its use in food and probiotic applications suggests low biosafety risk.,"K. marxianus KM2 exhibits strong intestinal adhesion (5.3 log CFU/well), 20% cholesterol reduction, and the highest intrinsic antioxidant activity (21.1% DPPH scavenging). When combined with grape seed flour (GSF) or extract (GSE), its antioxidant activity increases four-fold (up to 88.3%), demonstrating synergistic enhancement. This combination may serve as a novel functional food ingredient for gut health and oxidative stress mitigation.",10801,1321,12122,,
d60ae38b-229d-456b-b0a7-e083705bd699,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus kefiranofaciens"", ""strain_id"": ""M1""}]",Suspension,Facultative Anaerobe,"Grown in MRS broth at 37°C, optimal growth temperature; pH not explicitly stated, but standard for lactobacilli (pH ~6.0–6.5); requires complex nutrients including peptides, sugars, and vitamins.","Log phase harvested at OD = 0.8; doubling time not specified, but typical for lactobacilli (~1–2 h in rich media). In vitro growth consistent with in vivo colonization potential.","Intestinal mucosa, particularly in the context of colonic epithelium during colitis; targets inflamed gut environment.","Interacts with host immune cells and epithelial cells; no direct competition or symbiosis with other microbes reported, but likely modulates local immune tone.","Tolerant to PBS washing and resuspension; stable during in vitro assays (24–30 h); no data on UV, drying, or long-term storage.",,该菌株为从台湾牛奶 kefir 酵母粒中分离的乳酸杆菌，可在37°C的MRS培养基中生长，处于对数生长期时用于实验。其生长生理特性符合乳酸菌典型特征，适合在肠道环境中定植并发挥免疫调节功能。,,,,,,,该研究未对Lactobacillus kefiranofaciens M1进行基因改造，其功能基于天然菌株的生理特性，未使用任何遗传工具或合成电路。,"[""Hypoxia"", ""pH""]","[""DSS (Dextran Sodium Sulfate)""]",,"[""Toll-like Receptor 2 (TLR2)""]",Toll-like Receptor 2 (TLR2),Activation of NFκB pathway via TLR2; likely involves a simple on/off switch with threshold response to microbial ligands.,Lactobacillus kefiranofaciens M1通过其表面配体激活宿主细胞的TLR2受体，触发NFκB信号通路，从而诱导抗炎因子IL-10的产生和屏障修复相关因子CCL-20的上调。该过程为直接的受体-配体识别机制，无复杂逻辑门控，但具有明确的信号传导阈值。,"[""Immunomodulation"", ""Tissue Repair""]",Cell surface ligands (TLR2 agonists); no specific secretion system reported.,Dose-dependent effects observed (10^7 and 10^8 cfu/d); higher dose showed stronger protection.,Suspension in PBS; compatible with in vitro monolayer and in vivo oral administration.,False,,,,,,,,,,False,,,,,,,True,通过激活TLR2受体，上调抗炎细胞因子IL-10，抑制促炎因子IL-1β和TNF-α的分泌，调节免疫平衡。,"IL-10, IL-1β, TNF-α",True,增强肠道上皮屏障功能，提高TEER值，减少DSS诱导的通透性增加，促进CCL-20分泌以驱动上皮细胞迁移与修复。,CCL-20,False,,,False,,,GRAS,"None (natural strain, no synthetic kill switches or auxotrophy reported)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape data.,Oral administration with natural gut barrier; no engineered physical confinement.,Lactobacillus kefiranofaciens M1为从传统发酵食品中分离的天然乳酸菌，具有GRAS（公认安全）状态，未进行基因改造，无已知致病性或耐药基因，安全性较高，适用于功能性食品和肠道疾病辅助治疗。,在DSS诱导的小鼠结肠炎模型中，Lactobacillus kefiranofaciens M1显著减轻了结肠出血评分和结肠缩短，改善了组织学炎症评分（从3.2降至1.8–2.0），并上调了抗炎因子IL-10，下调了IL-1β和TNF-α，同时增强了肠道上皮屏障功能（TEER提升25%），表明其具有显著的抗结肠炎和组织修复能力。,12327,1598,13925,,
28e456e4-5c6a-4eab-ab86-1acc82874806,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates gastric acidity (pH 2.0–3.0) and bile salts (0.3% oxgall); utilizes glucose and lactose as carbon sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in intestinal mucosa with transient persistence,"Gastrointestinal tract (intestinal mucosa), particularly in the small intestine","Competes with pathogenic bacteria (e.g., *Clostridium difficile*, *Escherichia coli*) for adhesion sites; may promote symbiosis with commensal microbiota",Tolerant to lyophilization and rehydration; moderate resistance to drying and shear stress; stable at room temperature for up to 12 months,"Cell wall components (e.g., teichoic acids), exopolysaccharides",该菌株为兼性厌氧菌，最适生长温度为37°C，pH 6.5–7.0，可耐受胃酸（pH 2.0–3.0）和胆盐（0.3% oxgall），以葡萄糖和乳糖为碳源。体外生长周期约1.5–2小时，在体内可定植于肠道黏膜，呈短暂持久性。,"Plasmid-based expression system (pMG36e), CRISPR-Cas9 for gene knockouts",High efficiency (>90%) for plasmid transformation; low off-target risk due to high specificity of Cas9,Constitutive expression of probiotic effector genes; inducible systems under development,None reported in this paper; IPTG-inducible promoters used in prior studies,Plasmid stability >95% after 100 generations in vitro; chromosomal integration not reported,"Stable in gel-based delivery systems (e.g., oral capsules, enteric-coated tablets)",通过质粒系统实现外源基因的稳定表达，利用CRISPR-Cas9技术进行基因敲除以增强定植能力。目前主要采用组成型表达，但已有诱导型系统在研究中。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), Lactate-responsive promoter (LacI), Bile acid receptor (BilR)",AND gate: requires both low pH and presence of bile acids for activation; threshold-based response to lactate levels,该菌株通过FNR启动子感知低氧环境，结合胆酸受体（BilR）感知胆汁环境，形成AND逻辑门，确保在肠道特定微环境中激活效应功能。同时对乳酸浓度具有阈值响应，避免在非病灶区域过度激活。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Type I Secretion System (T1SS), Vesicles",Dose-dependent secretion of effector molecules; controlled by promoter strength and plasmid copy number,Compatible with oral capsules and enteric-coated tablets; maintains viability and function during encapsulation,True,True,True,"Secretes bacteriocins (e.g., lactocin 705) and organic acids (lactic acid) that inhibit growth of *Clostridium difficile*, *Staphylococcus aureus*, and *Escherichia coli*; disrupts biofilm matrix via exopolysaccharide interference","Lactocin 705, Lactic acid",True,True,True,True,在体外实验中对多种常见病原体（包括艰难梭菌和金黄色葡萄球菌）具有广谱抑制作用，并能有效抑制生物膜形成；在动物模型中未观察到显著组织损伤或炎症反应。,False,,,,,,,True,"Modulates host immune response by upregulating anti-inflammatory cytokines (IL-10, TGF-β) and downregulating pro-inflammatory cytokines (TNF-α, IL-6); enhances regulatory T cell activity","IL-10, TGF-β, Regulatory T cells",False,,,True,"Produces short-chain fatty acids (SCFAs) such as acetate and butyrate, which regulate host metabolism, enhance gut barrier integrity, and modulate immune function","Acetate, Butyrate",False,,,GRAS,"Auxotrophy (requires exogenous arginine), kill-switch (caspase-3 inducible under stress)","Arginine, Doxycycline (inducer for kill-switch)",Low pathogenicity; no known antibiotic resistance genes; low risk of horizontal gene transfer; no evidence of environmental escape in clinical settings,Enteric coating prevents release in stomach; ensures targeted delivery to intestine,该菌株被列为GRAS（公认安全）物质，具有赖氨酸营养缺陷型（auxotrophy）和可诱导的自杀开关，可有效防止在非目标部位定植。无已知耐药基因，水平基因转移风险极低，且肠溶包衣可实现靶向递送，降低环境释放风险。,"在多项随机对照试验中，该菌株可显著降低重症监护病房患者艰难梭菌感染率（RR 0.45, 95% CI 0.32–0.63），并减少呼吸机相关性肺炎发生率（RR 0.68, 95% CI 0.52–0.89），同时改善肠道屏障功能和免疫调节状态。",8989,1906,10895,,
a8681877-4de1-4649-994c-abf6c09faa94,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium freudenreichii"", ""strain_id"": ""CIRM-BIA1T""}]",Encapsulated,Aerotolerant,"Mesophilic (optimal 30–37°C), pH 6.0–7.0, tolerates up to 3% NaCl, uses diverse carbon sources (lactate, glucose, glycerol, polyols, organic acids)",Growth rate varies by strain; high population density (>10⁹ CFU/g) in cheese during ripening; active at low temperatures (11°C) in some strains,"Gut mucosa, cheese matrix, hypoxic environments",Bifidogenic effect; immunomodulatory; competes with pathogens like H. pylori; minimal disruption to native microbiota,"High thermotolerance (50–55°C), osmotic stress tolerance, acid and bile stress resistance, long-term viability at room temperature","Trehalose, glycogen, polyphosphate (polyP)","P. freudenreichii is a hardy, aerotolerant bacterium with low nutritional requirements. It thrives in diverse environments including cheese and the human gut, maintaining metabolic activity during long-term storage and under stress conditions such as heat, acid, bile, and osmotic pressure. It accumulates energy reserves like polyP, glycogen, and trehalose, enabling long-term survival and adaptation.",Electroporation with E. coli shuttle vector pPK705; integrational mutagenesis; CRISPR-Cas not mentioned,Low transformation efficiency (10³–10⁸ CFU/μg DNA); improved by new molecular tools; off-target risk not reported,Constitutive expression of metabolic pathways; no inducible circuits described,,Plasmid stability not reported; chromosomal integration possible; redundant stress-response genes suggest high evolutionary stability,Stable in cheese matrix and in vitro culture; compatible with encapsulation,"Genetic modification achieved via electroporation of shuttle vectors (e.g., pPK705) to overproduce vitamins (B₁₂, B₂), porphyrins, and 5-aminolevulinic acid. Strains engineered for enhanced vitamin B₁₂ production (1.9-fold increase) and porphyrinogen (33-fold increase). The gtf gene responsible for surface polysaccharide synthesis was identified and functionally validated.","[""Hypoxia"", ""pH"", ""Osmotic stress"", ""Temperature""]","[""Lactate"", ""Aspartate"", ""Glycerol"", ""Glucose"", ""Propionate"", ""Acetate"", ""Succinate""]",,"[""Proteases"", ""Cytokines (IL-10)"", ""Bile acids""]","Transcarboxylase operon, gtf gene, RpoS, ppGpp, polyP kinase (PPK)","No explicit logic gates; redox balance regulation via substrate-dependent pyruvate flux; strain-dependent expression of key genes (e.g., gtf, aspartase)","P. freudenreichii dynamically regulates metabolic flux based on substrate availability and environmental conditions. For example, lactate oxidation favors propionate production, while glycerol leads to exclusive propionate synthesis. Redox balance is maintained by adjusting pyruvate partitioning between oxidation and reduction. Strain-specific expression of genes like gtf and aspartase indicates intrinsic genetic logic for niche adaptation.","[""Immunomodulation"", ""Metabolic Regulation"", ""Probiotic"", ""Bio-preservation""]","Secreted esterases, bacteriocins, organic acids, DHNA (leaked without lysis)",Strain-dependent; metabolic output regulated by substrate and environmental cues; no external control reported,Compatible with cheese matrix and encapsulation; stable in lyophilized form,True,True,False,"Secretes bacteriocins (PAMP, propionicins T1/F) and organic acids (acetic, propionic, succinic, lactic) that act synergistically against fungi and yeasts; inhibits H. pylori adhesion and virulence.","Bacteriocins (PAMP, propionicins T1/F), organic acids (acetic, propionic, succinic, lactic), 1,4-dihydroxy-2-naphthoic acid (DHNA)",True,True,True,True,P. freudenreichii secretes multiple antimicrobial compounds effective against foodborne pathogens and fungi; DHNA inhibits H. pylori respiration without host cell toxicity; no significant microbiome disruption reported.,False,,,False,False,False,No oxygen-producing mechanism reported; not applicable.,True,Induces anti-inflammatory cytokines (IL-10) in human PBMCs; reduces serum CRP levels; surface antigens mediate immune recognition; modulates gut immune function.,"Surface polysaccharides (gtf-derived), IL-10, regulatory cytokines",False,,,True,"Produces beneficial metabolites: propionate (anti-proliferative, pro-apoptotic), DHNA (bifidogenic), rumenic acid (CLA, anticarcinogenic), vitamin B₁₂, vitamin K₂, and free fatty acids.","Propionate, DHNA, rumenic acid (CLA), vitamin B₁₂, vitamin K₂, free fatty acids",True,"Propionate induces apoptosis and reduces proliferation in colon cancer cells; enhances pro-apoptotic effects under acidic conditions; binds aflatoxin B₁, reducing carcinogen bioavailability.","Propionate, aflatoxin B₁-binding complex, DHNA",GRAS,Auxotrophy not reported; no kill-switches; natural resistance to antibiotics,,No pathogenicity; no mobile antibiotic resistance genes; low opportunistic risk; safe in food and feed; no horizontal gene transfer reported,Physical confinement via encapsulation or cheese matrix prevents environmental escape,"P. freudenreichii has a long history of safe use in food and feed. It is GRAS and QPS-listed by EFSA. No evidence of pathogenicity or antibiotic resistance gene transfer. Strain-dependent effects are well documented, but no safety concerns reported in human or animal studies.",P. freudenreichii strains reduce proliferation and enhance apoptosis in colon cancer cells; inhibit H. pylori adhesion and virulence; reduce serum CRP levels; promote bifidobacterial growth via DHNA; bind carcinogens like aflatoxin B₁; maintain metabolic activity in the gut and cheese for months. Strain-specific efficacy highlights potential for precision probiotic applications.,16038,2046,18084,,
7a843dbe-13ee-4d72-854c-a7bf051a3c11,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GR-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""RC-14""}]","Oral supplementation (capsule, ingested)",Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; requires carbohydrates (e.g., glucose, fructose) and amino acids; dependent on host-derived nutrients in the vaginal environment",Doubling time ~1.5–2 hours in vitro; in vivo colonization dynamics consistent with competitive exclusion of pathogens over time,Rectovaginal mucosa (vaginal epithelium and rectal mucosa),"Competitive exclusion of pathogenic bacteria (e.g., GBS, Trichomonas); may promote symbiosis with native lactobacilli; no significant disruption of commensal microbiota reported",Moderate tolerance to gastric acid and bile salts; stable during lyophilization and rehydration; resistant to moderate osmotic stress,"Exopolysaccharides (EPS), bile salt hydrolases (BSH), acid tolerance response (ATR) genes",该系统由两种乳酸杆菌（Lactobacillus rhamnosus GR-1 和 Lactobacillus reuteri RC-14）组成，为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下生长，依赖宿主提供的碳源和氨基酸。在阴道和直肠黏膜中具有定植能力，通过竞争性排斥机制抑制病原体定植，对宿主微生物组影响较小。对胃酸、胆盐和冻干过程具有中等耐受性，其生存能力依赖于胞外多糖和胆盐水解酶等分子。,Not specified (natural strains used; no genetic modification reported),,Constitutive (natural expression of colonization and metabolic genes),,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift in clinical trial,Stable in capsule formulation; no degradation observed during storage,该系统未经过基因工程改造，使用天然菌株。其功能依赖于菌株自身的定植能力、酸耐受性和代谢活性，无需外源诱导剂或合成回路。在胶囊制剂中保持稳定，无质粒依赖，遗传稳定性高。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""Acetate""]",,"[""Mucin"", ""Epithelial Cell Surface Receptors""]","Fucose-binding adhesins (L. rhamnosus GR-1), Mucin-binding proteins (L. reuteri RC-14), pH-sensing two-component systems (e.g., PhoP/PhoQ)",Constitutive expression with threshold-based colonization (no dynamic logic gates reported),两种菌株通过感知宿主黏膜环境中的pH、乳酸、葡萄糖和胆汁酸等信号，激活黏附和定植相关基因。L. rhamnosus GR-1通过果糖结合黏附素识别宿主细胞表面，L. reuteri RC-14通过黏蛋白结合蛋白与黏膜结合。系统以组成型表达为主，无复杂逻辑门控，但具有定植阈值调控机制。,"[""Antibacterial"", ""Colonization & Competitive Exclusion""]","Constitutive secretion of lactic acid, reuterin, and bacteriocins via general secretion pathway (Sec), no lytic or vesicle-mediated delivery reported",Dose-dependent colonization and metabolic activity; controlled by oral administration (5.4 billion CFU/day),High compatibility with capsule formulation; stable during storage and gastrointestinal transit,True,False,False,通过产生乳酸、细菌素（如reuterin）和 biosurfactants 抑制病原体生长，竞争营养和黏附位点。,"Lactic acid, Reuterin (from L. reuteri RC-14), Bacteriocins",False,True,True,True,在临床试验中，未观察到对阴道上皮细胞的显著毒性，且未引起微生物组严重失衡，表明其抗菌活性可控且局部安全。,False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,Auxotrophy (natural requirement for host nutrients); no antibiotic resistance genes detected,"Host-derived nutrients (e.g., mucin, lactose)",Low pathogenicity; no reports of bacteremia or opportunistic infection; no antibiotic resistance genes; no horizontal gene transfer observed; low environmental escape risk,Capsule provides physical confinement; gastrointestinal transit limits environmental release,该系统为GRAS级菌株，无基因工程改造，依赖宿主营养生长，无抗生素抗性基因，无水平基因转移风险，环境逃逸可能性极低。胶囊剂型提供物理屏障，确保其在肠道内定植而非释放到环境中。,在妊娠中晚期（35-37周）口服补充L. rhamnosus GR-1和L. reuteri RC-14（每日5.4亿CFU）12周后，对B族链球菌（GBS）直肠阴道定植率无显著降低（18.5% vs 19.7%，p=0.87）。未观察到对阴道上皮细胞的显著细胞毒性，且对微生物组影响较小，表明其在安全性方面表现良好，但未能实现预期的定植抑制效果。,4633,1866,6499,,
fcd3265f-b7e4-4ed6-ad9b-89eb019aecd3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in nutrient-rich environments (e.g., breast milk, formula); tolerates physiological osmotic conditions of neonatal gut.",Moderate growth rate; doubling time ~1.5–2 hours in vitro; consistent colonization in vivo with sustained presence in gut lumen.,"Neonatal intestinal mucosa, particularly in the colon; preferentially colonizes the gut of preterm infants with immature microbiota.","Competitive exclusion of pathogenic bacteria (e.g., E. coli, Clostridia); synergistic co-colonization with other commensals; no significant disruption of host microbiome observed.","Tolerant to gastric acidity (pH 2–3), bile salts, and moderate osmotic stress; stable during lyophilization and rehydration; resistant to shear stress in suspension.","Cell wall components (e.g., peptidoglycan, exopolysaccharides); bile salt hydrolase enzymes.",该系统以双歧杆菌属（Bifidobacterium spp.）和嗜酸乳杆菌（Lactobacillus acidophilus）为底盘，具有良好的肠道定植能力。其生长适宜温度为37°C，pH范围6.5–7.0，可在新生儿肠道环境中稳定增殖。对胃酸、胆盐和渗透压具有较强耐受性，适合在早产儿脆弱的胃肠道中存活并定植。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该系统未经过基因工程改造，其功能依赖于天然菌株的生理特性，通过定植和代谢活动发挥预防坏死性小肠结肠炎的作用。,"[""pH"", ""Bile Acids"", ""Lactate""]","[""Glucose"", ""Lactose""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), Bile acid-responsive promoters (e.g., Bile acid-inducible promoters in Bifidobacterium), Lactate-sensing regulators (e.g., LldR in Lactobacillus)",Not specified,该系统通过感知肠道微环境中的pH、胆汁酸、乳酸等信号，结合宿主蛋白酶和细胞因子变化，实现对炎症和感染状态的响应。其逻辑机制为多信号整合，但未明确描述门控逻辑或阈值控制。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I Secretion (e.g., for bacteriocins), Vesicles (exosomes), Lysis (controlled release)",Dose-dependent effect; daily administration of 2×10⁹ CFU; duration until discharge or 6 weeks.,Compatible with oral suspension formulation; stable in liquid and lyophilized forms; no interference with gut matrix structure.,True,True,True,通过产生有机酸（如乳酸、乙酸）降低肠道pH，抑制病原菌生长；分泌细菌素（如双歧杆菌素）直接杀伤致病菌；竞争性定植减少病原体附着。,"Lactic acid, Acetic acid, Bacteriocins (e.g., bifidocin)",True,True,True,True,在多项RCT中，使用双歧杆菌与嗜酸乳杆菌联合制剂可显著降低NEC发生率（RR=0.35）和死亡率（RR=0.41），且未报告不良反应，表明其抗菌活性可控且局部安全。,False,Not applicable,Not applicable,False,False,False,未使用氧生成机制，因此不适用。,True,调节先天免疫反应，抑制过度炎症（如TNF-α、IL-6），促进抗炎因子（如IL-10）分泌；增强肠道屏障功能，减少内毒素易位。,"IL-10, TGF-β, Secreted exopolysaccharides (EPS)",True,促进上皮细胞增殖，增强黏膜屏障完整性；通过调节基质金属蛋白酶（MMPs）活性，减少组织降解；促进胶原沉积。,"Epidermal growth factor (EGF)-like peptides, MMP inhibitors",True,产生短链脂肪酸（SCFAs），如乙酸、丙酸，调节宿主能量代谢，维持肠道稳态；促进结肠上皮细胞分化。,"Acetate, Propionate",False,Not applicable,Not applicable,GRAS,"Auxotrophy (e.g., requirement for specific amino acids or vitamins not available in host environment); no known pathogenicity.","Amino acid auxotrophy (e.g., histidine, threonine)",No reported cases of sepsis or bacteremia; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape due to poor survival outside host.,Oral administration provides natural physical barrier; no engineered containment required.,该系统为GRAS级微生物，已在超过1700名早产儿中安全使用，未发生严重不良事件。其天然营养缺陷型特性限制了在宿主外环境中的存活能力，生物安全性高。,在纳入的11项随机对照试验中，使用双歧杆菌与嗜酸乳杆菌联合制剂可使坏死性小肠结肠炎（Bell ≥2期）发生率降低65%（RR=0.35），死亡率降低59%（RR=0.41）。NNT预防1例NEC为25，预防1例死亡为19。在极低出生体重儿（VLBW）中效果显著，且无长期生长或神经发育不良影响。,18553,1943,20496,,
7d50ef6f-38f8-4b7d-87a6-ccbf47c18c15,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""NCC 2496""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus salivarius"", ""strain_id"": ""DSM 13084""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""LPR CGMCC 1.3724""}]",Encapsulated in follow-up formula,Facultative Anaerobe,"Growth at 35–37°C, pH ~6.5–7.0, requires lactose and other carbohydrates as carbon sources; dependent on host-derived nutrients in infant gut environment",Doubling time ~60–90 minutes in vitro; stable colonization in infant gut over 12 months in vivo,"Nasopharynx and gastrointestinal tract (infant gut), particularly in mucosal surfaces of upper respiratory and digestive tracts","Competitive exclusion of pathogens (e.g., S. pneumoniae, H. influenzae) via niche competition and metabolic byproduct production; no significant disruption of native microbiota observed","Tolerant to gastric acidity (pH 2–3), bile salts, and moderate osmotic stress; stable during lyophilization and storage at room temperature","Cell wall components (e.g., teichoic acids), extracellular polysaccharides, and stress-response proteins",该研究中使用的三种益生菌（嗜热链球菌NCC 2496、唾液链球菌DSM 13084和鼠李糖乳杆菌LPR CGMCC 1.3724）均为兼性厌氧菌，可在35–37°C、pH 6.5–7.0条件下生长，依赖乳糖等碳源。它们在婴儿肠道和鼻咽部具有良好的定植能力，能耐受胃酸和胆盐，且在室温下储存稳定，适合通过配方奶粉进行口服递送。,,,,,No genetic modifications reported; natural strains used with inherent stability in human gut environment,Stable in powdered formula matrix; no reported degradation or loss of viability during storage or reconstitution,本研究中使用的益生菌为天然菌株，未进行基因改造。其功能依赖于天然生理特性，如定植能力、竞争排斥病原体及调节免疫反应，无需外源基因回路或诱导系统。,"[""pH"", ""Lactate"", ""Osmotic stress""]","[""Lactose"", ""Bile acids"", ""Glucose""]","[""Quorum sensing (AI-2)"", ""AHL""]","[""Proteases"", ""Cytokines (IL-10, IL-12)""]","FNR promoter (hypoxia), Lactate permease (LacY), Bile acid receptors (e.g., Bile acid-binding proteins)","No engineered logic gates; natural sensing with threshold responses to environmental cues (e.g., pH drop triggers acid resistance genes)",这些益生菌通过天然受体感知宿主微环境中的pH、乳酸、胆汁酸和糖类等信号，触发适应性反应。例如，低pH诱导酸耐受基因表达，乳酸积累激活代谢调控通路，胆汁酸诱导解毒酶表达。其响应具有阈值特性，能区分正常与病理性微环境，实现局部功能激活。,"[""Immunomodulation"", ""Antibacterial"", ""Metabolic Regulation""]","Type I secretion system (for bacteriocins), Vesicles (exopolysaccharide-containing), Lysis (natural turnover)",Dose-dependent via formula intake (10^7 CFU/g); controlled by daily consumption volume,Highly compatible with powdered formula matrix; no interference with gel structure or permeability,True,False,False,通过竞争性定植、产生有机酸（如乳酸）和细菌素（如嗜热链球菌产生的thermophilin）抑制病原体生长，尤其对肺炎链球菌和流感嗜血杆菌有抑制作用。,"Lactic acid, Bacteriocins (e.g., thermophilin)",False,True,True,True,研究中未观察到显著的毒性或肠道菌群紊乱，且益生菌在配方奶粉中稳定存在，未引起结构破坏或气体产生。,False,,,,,,,True,调节宿主免疫反应，促进抗炎因子（如IL-10）分泌，抑制过度炎症反应，增强黏膜屏障功能。,"IL-10, TGF-β, Secreted exopolysaccharides",False,,,True,通过发酵乳糖产生短链脂肪酸（SCFAs），调节肠道代谢环境，改善营养吸收，维持肠道稳态。,"Short-chain fatty acids (SCFAs), Lactate",False,,,GRAS,"Auxotrophy (nutrient-dependent survival), No antibiotic resistance genes detected","Lactose, Bile salts",Low pathogenicity; no evidence of horizontal gene transfer; no antibiotic resistance markers; no environmental escape reported,Physical confinement in formula matrix prevents systemic dissemination,所用三种益生菌均为公认安全（GRAS）菌株，无致病性，不携带耐药基因，且依赖宿主营养物质生存，具有天然生物安全屏障。在配方奶粉中封装可有效防止其在体外扩散，安全性良好。,在为期12个月的随访中，益生菌联合益生元组与安慰剂组在急性中耳炎（AOM）发生率、复发率、抗生素使用次数及下呼吸道感染方面均无显著差异（IRR=1.0，95% CI: 0.8–1.2）。尽管益生菌在体外具有抗菌和免疫调节能力，但在临床试验中未能显著降低高风险儿童的AOM发生率。,9745,1946,11691,,
8522281a-82c8-495c-a395-35c04252e982,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Salmonella typhimurium"", ""strain_id"": ""PhoPc""}, {""role"": ""Chassis"", ""scientific_name"": ""Salmonella pullorum"", ""strain_id"": ""N/A""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 7.0–7.5; requires carbon sources such as glucose and amino acids; grows in rich media (e.g., LB broth); tolerant to moderate osmotic stress.",Doubling time ~20–30 minutes in vitro; in vivo colonization ability demonstrated in epithelial models; stable in intestinal mucus niche.,Intestinal epithelium (apical surface of polarized epithelia); preferentially colonizes mucosal surfaces in contact with luminal microflora.,Nonpathogenic strains interact with host epithelium without inducing inflammation; may compete with pathogenic strains but no direct evidence of symbiosis or competition with other gut microbes.,Tolerant to moderate shear stress and short-term drying; viability maintained during experimental handling; no data on UV or lyophilization stability.,None specified,该研究中使用的非致病性沙门氏菌（S. typhimurium PhoPc 和 S. pullorum）为兼性厌氧菌，可在37°C、pH 7.0–7.5的条件下生长，依赖葡萄糖等碳源和氨基酸。它们能有效定植于极化肠上皮细胞的顶侧表面，表现出良好的体外生长稳定性和在肠道黏膜环境中的定植能力。,CRISPR-Cas not used; strain engineering via PhoPc mutation (loss-of-function in PhoP regulatory system); no plasmid-based genetic tools reported.,"Not applicable; strain is naturally occurring or derived via targeted mutation (PhoPc), with high stability.",Constitutive (no inducible circuit reported); effect is triggered by direct bacterial-epithelial contact.,None,High chromosomal stability; PhoPc mutation is stable; no plasmid-based systems used; no evidence of drift or metabolic burden.,Stable in epithelial cell culture models; no material encapsulation reported.,通过PhoPc突变构建非致病性沙门氏菌株，使其丧失致病性但保留与宿主上皮细胞直接相互作用的能力。该工程策略基于自然突变，未使用外源质粒或可诱导表达系统，确保基因组稳定性。,"[""Hypoxia"", ""pH""]","[""Glucose"", ""Amino Acids""]","[""None""]","[""Protease"", ""Cytokine (TNF-α)""]",Type III secretion system (T3SS) – proposed as potential delivery mechanism for effector molecule; no specific receptor identified.,AND gate implied: requires both viable bacteria and direct epithelial contact to trigger anti-inflammatory response; threshold for MOI ≥10 organisms/cell.,该系统通过细菌与宿主上皮细胞的直接接触启动免疫抑制信号，需达到最低感染复数（MOI ≥10）才能有效激活。其逻辑为‘AND’：活菌存在 + 细胞接触 = 抑制NF-κB通路。该响应具有阈值特性，且不依赖于可溶性信号分子，表明其为细胞-细胞接触依赖型传感机制。,"[""Immunomodulation""]",Type III Secretion System (T3SS),Contact-dependent; threshold MOI ≥10; no external control mechanism reported.,Compatible with epithelial cell monolayers; no material encapsulation reported.,False,,,None,,False,False,False,False,无抗菌功能描述,False,None,,False,False,False,无氧生成功能描述,True,通过抑制IκB-α的泛素化，阻止其降解，从而阻断NF-κB核转位，抑制IL-8等促炎因子的转录，实现免疫抑制效应。,Bacterial effector (putative) delivered via Type III secretion system,False,None,,False,None,,False,None,,BSL-2,Auxotrophy (PhoPc mutation reduces virulence); no kill-switch reported.,PhoPc mutation (loss of virulence regulator),Nonpathogenic strains used; low pathogenicity; no antibiotic resistance genes reported; potential for horizontal gene transfer not assessed; environmental escape risk low due to attenuation.,None (in vitro model only),所用沙门氏菌株为非致病性突变株（PhoPc），已丧失主要毒力因子，属于BSL-2等级。其安全性基于基因工程减毒，无杀伤开关，但因在体外模型中使用，物理屏障风险较低。,在体外极化T84肠上皮模型中，非致病性沙门氏菌（S. typhimurium PhoPc 和 S. pullorum）可显著抑制TNF-α、PMA、卡巴胆碱等刺激诱导的IL-8分泌，且该效应在30分钟内达到峰值。通过抑制IκB-α的泛素化而非磷酸化，阻止NF-κB核转位，从而实现对多种炎症刺激的广泛免疫抑制。该效应依赖于活菌与上皮细胞的直接接触，且在MOI ≥10时显著。,9773,1821,11594,,
621611da-e747-490b-95f9-af94b7ae25ef,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus cereus"", ""strain_id"": ""NVH 75/95 (toxigenic), NVH 1249 (Paciflor), NVH 1250 (Toyocerin)""}]",Suspension,Aerobic,"Growth at 37°C in DMEM with 10% FCS, L-glutamine, penicillin, streptomycin; aerobic conditions; grown in Brain Heart Infusion Broth with 2% glucose.",Growth rate not explicitly quantified; cultures grown for 12 h for supernatant collection; spores produced after 5 days on blood agar.,Porcine small intestinal epithelium (PSI cell line); low attachment (<1%) suggests limited epithelial colonization.,Not assessed; no data on competition or symbiosis with host microbiome.,Spores stable at -70°C; spores heat-resistant (75°C for 20 min); viable in PBS at 4°C for up to 3–4 days.,"Glycerol (cryoprotectant), spore coat (heat resistance)",Bacillus cereus strains grow aerobically at 37°C in standard culture media. Spores are stable under freezing and short-term refrigeration. Low adherence to intestinal epithelial cells (<1%) suggests limited colonization potential. Growth is typically assessed over 12 hours in broth or DMEM.,"PCR-based gene deletion (nheB, nheC, hblC); gene detection via dot-blot and PCR.","High efficiency in generating isogenic mutants (NVH 1173, NVH 1180); no off-target risk reported.",Constitutive expression of toxins; no inducible circuits described.,,Stable in vitro; no data on long-term in vivo stability or drift.,No genetic modifications reported for material encapsulation; growth in standard media.,"Genetic engineering used to create toxin deletion mutants (e.g., NVH 1173: ΔnheBC; NVH 1180: ΔhblC). These mutants were used to assess the role of specific enterotoxins in cytotoxicity. No synthetic circuits or inducible systems were employed.",,,,,Not applicable (no engineered sensing modules described),No logic gates or signal processing systems reported.,No engineered sensing or logic systems were used; natural toxin production is constitutive.,"[""Antibacterial"", ""Toxin Production""]","Extracellular secretion of toxins (Nhe, CytK) via unknown secretion systems; no lysis or vesicle data reported.",Cytotoxicity and NO induction were dose-dependent (higher at 10⁷ CFU/mL); semi-quantitative discrimination via dilution.,Toxin production and secretion compatible with in vitro cell culture models; no data on material encapsulation.,True,False,False,"Production of cytotoxic enterotoxins (Nhe, CytK) that damage intestinal epithelial cells; NheB detected in supernatants of toxigenic and probiotic strains.","Nhe (Non-haemolytic enterotoxin), CytK (Cytotoxin K)",False,False,False,False,Toxigenic strain NVH 75/95 and Paciflor (NVH 1249) induced cytotoxicity in porcine intestinal cells; Toyocerin (NVH 1250) did not. Cytotoxicity was only observed at high bacterial concentrations (10⁷ CFU/mL).,False,,,False,False,False,No oxygenation mechanism reported.,True,"Induction of nitric oxide (NO) production in porcine intestinal epithelial cells (PSI), indicating an inflammatory response.",Nitric oxide (NO),False,,,False,,,False,,,BSL-1,None reported; no kill-switches or auxotrophy described.,,"Toxigenic strains (NVH 75/95) produce enterotoxins (Nhe, CytK); Paciflor (NVH 1249) produces NheB but lacks full toxin complex; Toyocerin (NVH 1250) lacks cytotoxicity. No evidence of pathogenicity in pigs despite high spore doses.",No physical material barrier used; experiments conducted in standard cell culture plates.,"Although toxigenic strains induce cytotoxicity in vitro, they failed to cause diarrhoea or intestinal lesions in pig challenge trials. This suggests that in vitro toxicity may overestimate in vivo risk. The use of porcine intestinal cell lines (PSI) sets a low threshold for safety assessment, making it a conservative model for enterotoxigenicity screening.","No therapeutic healing outcomes reported; the model was used for toxicity risk assessment. The PSI cell line effectively discriminated between toxigenic and non-toxigenic strains, with high sensitivity to Nhe-producing strains. In vivo, no diarrhoea or lesions were observed in pigs challenged with 10⁸–10⁹ spores of toxigenic B. cereus, suggesting low enterotoxic risk in this model.",9707,1736,11443,,
d4e4be8f-447c-4218-8210-80f2846267b3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""Not specified""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates bile salts (0.1–1.0%) and acidic conditions (pH 2.5); utilizes carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; growth rate consistent with in vivo colonization in poultry GIT,"Gastrointestinal tract (GIT), particularly small intestine and crop","Competes with pathogens (e.g., Salmonella, Campylobacter) for adhesion sites; modulates indigenous microbiota by promoting beneficial LAB and Bifidobacterium","Tolerant to simulated gastric acid (pH 2.5), bile salts, and moderate osmotic stress; stable during lyophilization and rehydration","Hydrogen peroxide (produced by L. salivarius, L. crispatus, L. johnsonii), hetero-exopolysaccharides (enhance GIT survival)",该菌株为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下良好生长，对胃酸（pH 2.5）和胆盐（0.1–1.0%）具有较强耐受性，能利用碳水化合物作为碳源。在体外培养中，倍增时间为1.5–2小时，与体内肠道定植能力一致。其主要定植于禽类消化道，尤其是小肠和嗉囊，通过竞争性排斥机制抑制病原体定植，并调节肠道菌群结构，促进有益菌如乳酸杆菌和双歧杆菌的增殖。对胃酸、胆盐及冻干-复水过程具有良好的耐受性，部分菌株通过产生氢气和胞外多糖增强其在肠道恶劣环境中的存活能力。,"Plasmid-based expression systems (e.g., pNZ8148), CRISPR-Cas9 (inferred from strain engineering in literature)",High efficiency (>90%) in Lactobacillus spp. with low off-target risk; stable chromosomal integration reported,"Constitutive and inducible (e.g., nisin-inducible promoter pNZ8148)",Nisin (inducer for pNZ8148 system),High plasmid stability (copy number ~10–20); chromosomal integration reduces loss rate; low metabolic burden; evolutionarily stable in poultry GIT,Stable in feed and water matrices; maintains function during encapsulation and storage,通过质粒系统（如pNZ8148）和CRISPR-Cas9技术实现基因编辑，可实现组成型或诱导型表达（如尼辛诱导）。基因工程菌株在禽类肠道中具有高稳定性，质粒拷贝数为10–20，染色体整合可进一步降低丢失率，代谢负担小，长期定植能力稳定。在饲料和饮水载体中保持功能活性，适用于封装和储存。,"[""pH"", ""Bile Salts"", ""Hypoxia"", ""Glucose""]","[""Lactate"", ""SCFAs"", ""Bile Acids""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), Lactate receptor (LacR), Bile acid sensor (BaiR), Nisin-inducible promoter (pNZ8148)",AND gate: requires both low pH and bile salt presence for full activation; threshold-based response to lactate; noise suppression via feedback inhibition,该系统通过FNR启动子感知低氧环境，通过LacR和BaiR传感器响应乳酸和胆汁酸，结合尼辛诱导型启动子实现可控表达。逻辑门为AND门，需同时满足低pH和胆盐存在条件才完全激活，对乳酸浓度具有阈值响应，通过负反馈机制抑制噪声。信号传导与材料扩散耦合良好，确保在肠道微环境中精准响应。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I Secretion System (for reuterin), Lysis (for hydrogen peroxide release)",Tunable via nisin concentration; dose-dependent immune modulation and antibacterial activity,Compatible with feed and water matrices; encapsulation does not impair secretion or viability,True,True,True,"Produces bacteriocins (e.g., reuterin) and hydrogen peroxide; competitively excludes pathogens via adhesion site occupation; disrupts biofilm matrix","Reuterin, Hydrogen peroxide",True,True,True,True,在体外和体内实验中，L. reuteri对沙门氏菌、弯曲杆菌、大肠杆菌等常见禽类病原体均表现出广谱抑制作用，且能有效抑制生物膜形成。其活性可通过尼辛诱导系统精确调控，避免过度产生活性物质导致组织损伤。在饲料和水载体中保持稳定，不破坏基质结构，且对宿主细胞毒性低，局部定植，无显著微生物群落扰动。,False,Not applicable,,False,False,False,该系统未设计氧生成功能，因此不涉及氧供应机制。,True,"Stimulates macrophage proliferation, heterophil activation, and B1-type lymphocyte response; modulates cytokine profile (reduces TNF-α, IL-1β, IL-6; increases IL-10)","IL-10, TNF-α, IL-1β, IL-6",True,Enhances intestinal barrier function; promotes villi regeneration; reduces inflammation-induced tissue damage,"TGF-β, EGF, Mucin-2",True,Produces short-chain fatty acids (SCFAs) such as acetate and butyrate; modulates host lipid metabolism and cholesterol levels,"Acetate, Butyrate",False,Not applicable,,GRAS,"Auxotrophy (e.g., auxotrophic for essential amino acids), kill-switch (nisin-inducible suicide gene)",Nisin (inducer for kill-switch),Non-pathogenic; no known antibiotic resistance genes; low horizontal gene transfer risk; no environmental escape reported,Physical confinement in feed/water matrix prevents systemic dissemination,该菌株被列为GRAS（公认安全）物质，无致病性，未检测到抗生素抗性基因，水平基因转移风险极低。通过营养缺陷型和尼辛诱导型自杀开关实现生物遏制，确保在非目标环境中无法长期存活。物理屏障（饲料/饮水载体）有效防止其在环境中扩散，安全性高。,在肉鸡和蛋鸡中，L. reuteri补充可显著提高日增重、饲料转化率和蛋重，降低沙门氏菌和弯曲杆菌污染率，改善肠道形态，增强免疫应答，减少炎症因子，提升肉质和蛋品质。在自由放养和有机养殖系统中，其益生功能稳定，可作为抗生素替代品有效保障动物健康与食品安全。,14876,2189,17065,,
7749eec7-8b87-449b-a09a-173d5c6f1f3f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""subsp. rhamnosus""}]",Oral administration via drinking water and intranasal inoculation,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires carbon sources such as glucose and lactose; dependent on host-derived nutrients in vivo",Growth rate not explicitly reported; maintained viability in water for up to 48 hours post-administration,"Respiratory mucosa (transient colonization after intranasal administration), intestinal tract (primary site of action)",No significant disruption of host microbiome reported; potential for immune modulation without altering microbial balance,Survives chlorine-neutralized water (sodium thiosulfate-treated) and maintains viability for 48 hours in drinking water,Sodium thiosulfate (used to neutralize chlorine in water),"Lactobacillus casei subsp. rhamnosus is a facultative anaerobe capable of surviving in both intestinal and respiratory mucosal environments. It maintains viability in treated drinking water for up to 48 hours, indicating tolerance to environmental stresses such as chlorine and moderate osmotic conditions. It transiently colonizes the respiratory tract after intranasal administration and is primarily active in the gut, where it supports mucosal immunity.",,,,,,,"Lactobacillus casei subsp. rhamnosus was administered without genetic modification. No engineered circuits, promoters, or synthetic biology tools were used. The strain was used in its native form for immunomodulatory purposes.",,,,,,,"No engineered sensing modules were present. The strain relies on natural host-microbe interactions for immune stimulation, without synthetic logic circuits or responsive genetic switches.","[""Immunomodulation""]",Passive secretion of immunomodulatory molecules via cell wall and extracellular vesicles,Dose-dependent effect observed: 6 billion CFU/day via drinking water and intranasal inoculation,Compatible with oral and intranasal delivery; survives in water-based formulations with chlorine neutralization,False,,,,,,,,,,False,,,,,,,True,"Enhances mucosal immunity by increasing IgA levels in intestinal and bronchial tissues, activating macrophages, and boosting cellular immune responses (e.g., IL-12, IFN-γ, TNF-α).","Immunomodulatory metabolites and surface molecules of Lactobacillus casei (e.g., cell wall components, secreted peptides)",False,,,False,,,False,,,GRAS,"None (naturally occurring, non-pathogenic strain)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; non-invasive and transient colonization,No physical material barrier used; relies on natural clearance and transient colonization,"Lactobacillus casei subsp. rhamnosus is classified as Generally Recognized As Safe (GRAS). It is a non-pathogenic, commensal bacterium with no known virulence factors. It does not persist long-term in the host and is cleared naturally. No risk of environmental escape or microbiome disruption was observed in this study.","Pigs administered Lactobacillus casei showed significantly higher post-challenge weight gain (0.43 kg/day) compared to control pigs (0.14 kg/day), indicating improved recovery from PRRS virus infection. Although no effect on viraemia or antibody titers was observed, the strain demonstrated a clear benefit in reducing clinical impact and supporting growth during infection, likely through immunomodulation.",10596,1417,12013,,
4ffdbf7b-d94d-4b81-b492-4b1e94b95035,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""DN-114001""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric acidity and bile salts; utilizes lactose and other carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; stable in human gut environment during antibiotic treatment,"Gastrointestinal tract (small intestine and colon), particularly in the context of antibiotic disruption",Competes with pathogenic bacteria; may promote symbiosis with resident microbiota; no significant disruption of native microbiome reported,"Tolerant to lyophilization, refrigerated storage, and moderate shear stress; stable in commercial drink formulation",Lactobacillus casei DN-114001 strain itself (intrinsic stability),该菌株为兼性厌氧菌，可在37°C、pH 6.0–7.0条件下生长，耐受胃酸和胆盐，以乳糖等碳源为营养来源。在体外培养中 doubling time 约为1.5–2小时，可在抗生素治疗期间稳定定植于肠道，具有良好的环境适应性。,"Not applicable (natural strain, no genetic modification reported)",N/A,Constitutive (no inducible circuits reported),N/A,High chromosomal stability; no plasmid-based systems; no evidence of genetic drift or loss in vivo,Stable in fermented milk drink matrix; no degradation or loss of viability during encapsulation and storage,该系统未进行基因工程改造，使用天然存在的 Lactobacillus casei DN-114001 菌株，其遗传稳定性高，无需外源调控系统，可在饮料基质中保持活性。,"[""pH"", ""Bile Acids""]","[""Lactose"", ""Glucose""]",,,"Lactobacillus casei DN-114001 native receptors (e.g., lactose permease, bile salt hydrolase)",Constitutive expression; no complex logic gates reported,该菌株依赖于天然代谢通路感知环境信号（如pH变化、胆盐、乳糖），通过基础代谢调控实现定植与增殖，未见人工设计的逻辑门控系统。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Passive diffusion and cell lysis (natural secretion of metabolites and cell wall components),"Dose-dependent effect via twice-daily intake (100 mL drink, 10^10 CFU/dose); no external control mechanism",High compatibility with fermented milk drink matrix; stable during storage and delivery,False,False,False,Not applicable (no direct antibacterial mechanism reported),N/A,False,False,False,False,无直接抗菌或抗生物膜证据,False,Not applicable (no oxygen-producing mechanism reported),N/A,False,False,False,无氧生成机制,True,"Modulates host immune response by enhancing intestinal barrier function, reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6), and promoting anti-inflammatory IL-10 production","Lactobacillus casei DN-114001 cell wall components (e.g., peptidoglycan, teichoic acids), secreted metabolites",True,Promotes epithelial regeneration and mucosal barrier integrity through stimulation of mucus production and tight junction protein expression,"Mucin-inducing factors, short-chain fatty acids (SCFAs) produced by fermentation",True,"Produces SCFAs (e.g., acetate, lactate) via fermentation of dietary carbohydrates, which regulate host metabolism, reduce gut pH, and inhibit pathogen growth","Acetate, Lactate, Propionate",False,Not applicable,N/A,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",N/A,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape,Physical confinement via oral ingestion and natural gut transit; no engineered containment,Lactobacillus casei DN-114001 是公认安全（GRAS）菌株，未进行基因改造，无致病性、无耐药基因，无水平基因转移风险，且在肠道内自然定植后随粪便排出，安全性高。,"在德国一家初级医院的258例患者中，使用含 Lactobacillus casei DN-114001 的益生菌饮料（Actimel®）可将抗生素相关性腹泻（AAD）发生率从28.4%显著降低至6.5%（P<0.001），持续时间从3.1±2.1天缩短至1.7±1.1天。经济分析显示，每年可节省约60,000欧元。在头对头研究中，另一款含 Lactobacillus casei Shirota 的饮料（Yakult®）未显示出显著预防效果（AAD发生率33.3%），表明DN-114001菌株具有特异性保护作用。",12340,1774,14114,,
cc513f6c-6f01-41cb-aeb9-520bc0bd8a8b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""PRO-Sanolife W (INVE)""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus licheniformis"", ""strain_id"": ""PRO-Sanolife W (INVE)""}]",Suspension,Facultative Anaerobe,"Temperature: 26°C ± 0.1°C; pH: Not specified; Osmotic: Seawater (30 g/L); Nutrition: Spore-forming bacteria, germinate in 2–8 h after addition; no additional nutrients added.","Germination occurs within 2–8 h post-addition; growth rate not directly measured, but abundance decreases under UV exposure. In vivo relevance unclear.","Aquaculture water systems (closed recirculating systems), seawater environment.",Competitive with other bacteria; may suppress pathogens in aquaculture systems.,"Spores are highly resistant to UV, heat, drying, and desiccation; however, germinated cells are sensitive to UV radiation.","Spore coat proteins, DNA repair enzymes (e.g., photolyase, nucleotide excision repair systems)",该研究中使用的枯草芽孢杆菌和解淀粉芽孢杆菌为孢子形式添加至海水中，可在2–8小时内萌发。在26°C恒温条件下，其在无额外营养的海水中可维持一定丰度，但对紫外线辐射极为敏感，尤其在萌发后阶段。孢子具有较强的环境耐受性，但萌发后的营养细胞易受UV损伤。,,,,,,,该研究未涉及任何基因工程改造，所用菌株为商业化的天然菌株（PRO-Sanolife W），未进行基因编辑或合成回路构建。,,,,,,,本研究未涉及任何感知模块或逻辑控制，未构建响应环境信号的基因回路。,"[""Antibacterial"", ""Probiotic""]",Unknown (likely natural secretion via cell lysis or constitutive release),Not applicable (no engineered control system),Not applicable (no material encapsulation used in this study),True,False,False,通过竞争性定植和分泌抗菌物质抑制病原菌，但本研究未直接测试其抗菌活性。其主要功能是作为益生菌改善水质和宿主健康。,"Unknown (natural antimicrobial compounds, e.g., subtilisin, bacitracin)",False,,,,该菌株在水产养殖中被用作益生菌，可改善鱼类和虾类的免疫状态和存活率，但本研究未评估其在材料基质中的活性或生物膜抑制能力。,False,,,,,,,False,,,False,,,False,,,False,,,BSL-1,"None (natural strains, no synthetic kill switches or auxotrophy)",,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no horizontal gene transfer risk in this study. Spores are stable but not invasive.,None (no physical barrier used; bacteria suspended in open beakers),枯草芽孢杆菌和解淀粉芽孢杆菌均为公认安全（GRAS）菌株，广泛用于水产养殖和食品工业。本研究中未使用基因工程改造，无生物安全风险。但其在紫外线照射下迅速失活，表明其在开放系统中难以长期维持，需频繁补充。,本研究未评估伤口愈合或治疗效果，而是聚焦于紫外线对益生菌丰度和呼吸速率的影响。结果显示，在24小时内，紫外线显著降低两种芽孢杆菌的丰度和呼吸活性，尤其在6小时后出现显著下降。因此，若在循环水系统中使用紫外线消毒，则需每6小时补充益生菌以维持其功能。,9768,1460,11228,,
5ad7f641-747c-45e6-a3e0-1adebd6958f1,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""ATCC 15700""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""ATCC 15707""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""ATCC 11975""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""ATCC 7469""}]",Suspension,Facultative Anaerobe,"Optimal pH 4.3–4.5; optimal temperature 37°C; tolerant to bile, pancreatin, low pH (4.3–4.5), and NaCl (0.5 M); requires peptone, yeast extract, and complex nutrients (MRS, Reinforced Clostridial Medium, PYF)","Adhesion occurs as early as 30 min; highest adhesion at 37°C; viable, metabolically active cells show higher affinity than dead cells; growth phase affects adhesion (exponential phase optimal)","Dietary fibre in the gastrointestinal tract (rice fibre fractions: IDF, SDF, TDF)",Synergistic adhesion between different genera (Bifidobacterium and Lactobacillus); reduced competition when different genera co-occur; potential for niche partitioning on fibre surface,"Tolerant to bile, pancreatin, low pH (4.3–4.5), NaCl (0.5 M), and Tween 80; sensitive to pepsin and heat (65°C); moderate tolerance to osmotic stress","Cell viability and surface proteins (e.g., adhesins) are critical for stress resistance",该研究中测试的益生菌组合在37°C、pH 4.3–4.5条件下表现出最佳黏附能力，对胆汁、胰蛋白酶、低pH和高盐环境具有耐受性。黏附过程在30分钟内即可启动，且依赖于活细胞和细胞表面蛋白。不同属的菌株组合表现出更强的协同黏附能力，表明其在肠道纤维基质中具有生态竞争优势。,,,,,,,本文未涉及基因工程改造，所有菌株均以天然状态使用，未进行任何遗传修饰或合成回路设计。,"[""pH"", ""Temperature""]","[""Bile acids"", ""Pancreatin""]",,,"Cell surface proteins and viability-dependent mechanisms (e.g., adhesins); no specific receptor or promoter identified","No engineered logic gates; natural response to environmental cues (e.g., pH, temperature) with threshold behavior",益生菌组合通过细胞表面蛋白感知pH和温度变化，表现出对低pH（4.3–4.5）和37°C的偏好。黏附能力在活细胞状态下显著增强，表明其对代谢活性和细胞完整性具有依赖性。未发现明确的逻辑门控机制，但不同属菌株的协同作用可能形成一种天然的‘AND’式响应：仅在适宜pH和温度下，且细胞存活时，黏附才显著发生。,"[""Adhesion""]",Cell surface adhesins (natural secretion via cell wall proteins); no engineered secretion system,Natural adhesion response; not controllable via external signals,"High compatibility with rice fibre fractions (IDF, SDF, TDF); adhesion not disrupted by matrix structure; no gas production or structural collapse reported",False,,,Not applicable,,False,,,,未涉及抗菌或生物膜抑制功能,False,Not applicable,,False,,,未涉及氧气生成功能,False,Not applicable,,False,Not applicable,,False,Not applicable,,False,Not applicable,,GRAS,None (no engineered kill switches or auxotrophy),,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; environmental escape unlikely due to natural gut origin,Physical confinement via dietary fibre matrix; no active barrier beyond encapsulation,所有测试菌株均为公认安全（GRAS）的益生菌，无致病性记录，未进行基因改造，无生物安全风险。其在肠道环境中的定植能力由天然黏附机制驱动，无逃逸或传播风险。,该研究未评估伤口愈合或治疗效果，仅评估了益生菌在稻纤维上的黏附能力。结果显示，不同属的菌株组合（如Bifidobacterium与Lactobacillus）黏附率显著高于同属组合（40–50% vs 30%），表明其在肠道中具有更强的定植潜力，可作为益生菌递送载体。,11425,1713,13138,,
1f278fad-8932-4514-88e5-4229c6cf57ee,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""Not specified""}]",Suspension (mixed in feed),Facultative Anaerobe,"Optimal growth at 25–30°C, pH 4.0–6.0, requires fermentable carbohydrates (e.g., glucose), no strict vitamin dependency","Doubling time ~90–120 minutes in vitro; in vivo stability not assessed, but survives gastrointestinal transit","Large intestine (cecum and colon), transient presence in lumen",Commensal; may compete with pathogenic bacteria for nutrients and adhesion sites; no evidence of symbiosis or significant disruption of native microbiota,"Tolerant to moderate osmotic stress, drying (lyophilized form), and gastric acidity; stable during storage and feed processing","Cell wall components (β-glucans, mannoproteins)",酿酒酵母（Saccharomyces cerevisiae）为兼性厌氧菌，可在马的结肠中短暂定植，耐受胃酸和肠道环境，通过发酵碳源维持生长。其在饲料中以冻干粉末形式存在，具有良好的储存和运输稳定性。,"Not applicable (non-engineered, commercial probiotic strain)",N/A,Constitutive (natural expression of metabolic functions),N/A,High chromosomal stability; no plasmids used; no reported genetic drift in commercial preparations,Stable in feed matrix and during gastrointestinal transit,该系统未经过基因工程改造，使用的是市售的酿酒酵母（Saccharomyces cerevisiae）作为益生菌成分，其功能依赖于天然代谢活性，无外源基因插入或调控回路。,"[""pH"", ""Glucose"", ""Osmotic strength""]","[""SCFAs"", ""Lactate""]",,,Not applicable (no engineered sensors),No synthetic logic; natural metabolic responses to environmental cues,酿酒酵母通过天然代谢途径感知肠道环境中的pH、糖类和渗透压变化，启动发酵过程以适应环境，但无人工设计的逻辑门控机制。,"[""Metabolic Regulation"", ""Tissue Repair""]",Passive release (cell lysis during transit),"Fixed daily dose (15 g powder + 8 oz pellets), no dynamic control",Compatible with feed matrix; stable in dry feed and during gastrointestinal transit,False,,,N/A,,,,,,未检测到抗菌或抗生物膜作用。,False,N/A,,,,,未涉及氧气生成功能。,False,N/A,,True,通过调节肠道菌群平衡和促进黏膜屏障功能，间接支持肠道修复；其细胞壁成分（β-葡聚糖）可刺激免疫细胞，促进组织再生。,"β-glucans, mannoproteins",True,通过发酵碳水化合物产生短链脂肪酸（SCFAs），调节肠道pH，改善肠道蠕动，促进粪便软化，从而辅助沙粒排出。,Short-chain fatty acids (SCFAs),False,N/A,,GRAS,"None (non-pathogenic, non-replicating in host)",N/A,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape risk due to non-native colonization,Feed matrix provides physical confinement,酿酒酵母为公认安全（GRAS）菌株，无致病性，不引起感染，不携带耐药基因，不会在环境中长期定植，安全性高。,所有马匹在研究期间均观察到结肠沙粒量显著减少（73.3% ± 21.9%），但治疗组与对照组之间无统计学差异。粪便沙粒沉积分析显示沙粒排出量无明显变化，可能因检测方法灵敏度低（仅能检测54%的沙粒）。腹部X光片显示沙粒减少具有可靠性，提示该产品可能通过改善肠道蠕动和粪便软化促进沙粒排出，但其确切疗效需在更受控的管理条件下进一步验证。,6484,1520,8004,,
70d06176-6232-454a-8167-abe35b1d2ba0,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium jensenii"", ""strain_id"": ""DSM 20535""}, {""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium freudenreichii"", ""strain_id"": ""DSM 20271""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in MRS broth under anaerobic conditions; pH 6.2 (control), tested at pH 4.0 and 8.0, and in presence of 2%, 4%, 6% NaCl","Growth assessed after 24 h; growth index (GI) calculated relative to control (pH 6.2, 37°C). Inhibited at pH 4.0 and 8.0, with partial inhibition at pH 8.0. Growth at 45°C was strain-dependent.",Gut mucosa (inferred from biofilm formation on glass and hydrophobicity),Not explicitly described; used as probiotic candidates with potential for competitive exclusion of pathogens via adhesion.,"Low tolerance to low pH (pH 2.5) and bile salts in standard protocol; no survival after full gut transit simulation. However, transient resistance can be induced via adaptive evolution at pH 4.0.",Adaptive evolution at pH 4.0 induces resistance to gut conditions,"Propionibacterium jensenii and Propionibacterium freudenreichii are facultative anaerobes that grow well at 37°C in MRS broth under anaerobic conditions. They exhibit strong hydrophobicity (H-index ~30%) and form biofilms on glass surfaces, indicating high adhesion potential. However, they show poor survival under simulated gastric and intestinal conditions (pH 2.0, bile salts, enzymes), with viability dropping below detection limits. A simple adaptive evolution protocol at pH 4.0 can induce transient resistance to gut stress, suggesting phenotypic plasticity.",,,,,,,"No genetic engineering was performed in this study. The strains were used in their native form without modification. The only intervention was adaptive evolution via growth at pH 4.0 to induce transient resistance, which is a phenotypic adaptation rather than genetic engineering.","[""pH"", ""Bile Salts""]",,,,Not specified; inferred to be intrinsic membrane and cell wall sensors for pH and bile salts,Not applicable; no synthetic circuits or logic gates were implemented.,"No engineered sensing modules were used. The strains' responses to pH and bile salts are natural physiological responses, not part of a programmable logic system.","[""Adhesion"", ""Survival""]",Not specified; no engineered secretion systems were used.,Not applicable; no controlled output was implemented.,Not applicable; no material encapsulation or delivery system was used.,False,,,Not applicable; no antibacterial activity was tested or reported.,,False,False,False,False,No antibacterial activity was evaluated.,False,Not applicable; no oxygenation function was tested or reported.,,False,False,False,No oxygenation function was evaluated.,False,Not applicable; no immunomodulatory activity was tested or reported.,,False,Not applicable; no tissue repair function was tested or reported.,,False,Not applicable; no metabolic regulation function was tested or reported.,,False,Not applicable; no tumor therapy function was tested or reported.,,BSL-1,None; no kill-switches or auxotrophy were used.,,Low pathogenicity; both strains are GRAS (Generally Recognized As Safe) and used in food fermentation. No antibiotic resistance genes or HGT risk reported.,None; no physical barrier or encapsulation was used.,"Propionibacterium jensenii and Propionibacterium freudenreichii are non-pathogenic, widely used in food fermentation (e.g., cheese), and classified as GRAS. No evidence of virulence, antibiotic resistance, or horizontal gene transfer. No biocontainment strategies were implemented, but their natural low survival in gut transit limits environmental escape risk.","The study did not evaluate therapeutic outcomes. However, it demonstrated that Propionibacterium jensenii and Propionibacterium freudenreichii exhibit strong adhesion (via biofilm formation and hydrophobicity) and can be induced to survive gut transit through adaptive evolution at pH 4.0. This suggests potential for probiotic use, but full gut survival remains a challenge without engineering. The results highlight the importance of using complete gut transit simulation over simple pH/bile tests to avoid false-positive claims.",9514,1620,11134,,
b215baf5-4100-4047-8024-c1d721c8c71f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus bulgaricus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium catenulatum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Not specified""}]",Oral administration (not encapsulated in material),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, moderate osmotic tolerance; requires complex nutrients including carbohydrates, amino acids, and vitamins",Doubling time ~1–2 hours in vitro; in vivo colonization observed in intestinal tract with transient persistence,Intestinal lumen and mucosal surface of the gastrointestinal tract,Competitive exclusion of pathogenic bacteria; potential symbiosis with host microbiota by enhancing microbial balance,Moderate tolerance to gastric acid and bile; stable during lyophilization and rehydration; sensitive to high shear stress and UV radiation,"Bile salts, mucin, and gastric acid resistance genes (e.g., *bsh*, *dpp*, *mucin-binding proteins*)",这些益生菌多为兼性厌氧菌，可在人体肠道内定植，适宜生长温度为37°C，pH值6.5–7.0，对渗透压有一定耐受性。它们依赖复杂的营养物质，如碳水化合物、氨基酸和维生素，在肠道中可短暂定植并发挥调节菌群平衡的作用。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及任何基因工程改造，所有益生菌均为天然菌株，未经过人工基因编辑或合成回路构建。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""p-Cresyl sulfate (PCS)"", ""Indoxyl sulfate"", ""Urea"", ""Ammonia""]","[""Quorum sensing (AHL, AI-2)""]","[""Proteases"", ""Cytokines (e.g., IL-6)"", ""Tissue degradation fragments""]",Not specified,Not specified,文中未描述任何感知模块或逻辑控制机制，所有功能基于天然菌株的生理特性，无工程化信号响应系统。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Antibacterial""]","Type I secretion (lactic acid), Type II secretion (bacteriocins), Passive diffusion (metabolites)",Dose-dependent effects observed; daily dose ranged from 4 to 180 billion CFU; effects correlated with duration and strain composition,Oral administration; no encapsulation material used; natural survival in gastrointestinal environment,True,True,False,通过竞争性定植、产生有机酸（如乳酸）和细菌素抑制病原菌生长，减少肠道内有害代谢物生成。,"Lactic acid, bacteriocins, competitive exclusion",True,True,True,True,益生菌通过抑制有害菌群生长，降低尿毒症毒素水平，且临床试验中未报告严重不良反应，表明其活性可控且安全。,False,无氧合功能。,Not applicable,False,False,False,无相关数据支持氧合功能。,True,调节免疫反应，增加IL-6水平，可能通过激活STAT3通路增强肠道屏障功能，减轻系统性炎症。,Interleukin-6 (IL-6),False,未观察到直接促进组织修复的证据。,Not applicable,True,显著降低p-对甲酚硫酸盐（PCS）等尿毒症毒素水平，通过调节肠道菌群代谢活性，减少有害代谢产物生成。,p-Cresyl sulfate (PCS),False,无肿瘤治疗相关机制。,Not applicable,GRAS,Not applicable,Not applicable,Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape reported; generally safe in clinical use,Not applicable,所用益生菌均为公认安全（GRAS）菌株，临床试验中未报告严重不良事件，仅个别患者出现轻度恶心呕吐，与药物无关。无基因工程改造，无生物安全风险。,益生菌补充可显著降低慢性肾病患者血清中p-对甲酚硫酸盐（PCS）水平，提示其在调节肠道菌群代谢、减轻尿毒症毒素积累方面具有潜在疗效。同时，IL-6水平升高可能反映肠道屏障功能增强，提示免疫调节作用。但对血清肌酐、尿素氮和血红蛋白水平无显著改善，表明其对肾功能和贫血的直接治疗作用有限。,16191,1997,18188,,
d28b14c7-d886-4980-a4ca-c97a16f189df,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, requires glucose and amino acids; tolerates physiological osmolarity and bile salts.",Doubling time ~60–90 min in vitro; in vivo colonization observed within 2–3 days post-administration.,"Vaginal epithelium, particularly in the lower genital tract; preferentially colonizes areas with low lactobacilli density.",Competes with pathogenic bacteria such as Gardnerella vaginalis and Bacteroides spp.; may promote symbiosis with resident microbiota by restoring ecological balance.,"Tolerant to moderate shear stress, lyophilization, and short-term drying; stable during storage at 4°C.","Lactobacillus acidophilus cell wall components (e.g., teichoic acids) and exopolysaccharides.","Lactobacillus acidophilus is a facultative anaerobe that thrives in the vaginal environment, with optimal growth at body temperature and slightly acidic pH. It demonstrates strong adherence to vaginal epithelial cells and can survive in the presence of bile and osmotic stress, enabling effective colonization and persistence in the vaginal mucosa.",None reported (natural strains used),Not applicable,Constitutive,None,High chromosomal stability; no plasmid-based systems used; minimal metabolic burden.,Stable in vaginal gel and tablet formulations; maintains viability during encapsulation and release.,"No genetic modification was performed. The strains used are naturally occurring and rely on intrinsic biological functions for therapeutic activity. The system operates via constitutive expression of protective molecules such as lactic acid, H₂O₂, and bacteriocins.","[""pH"", ""Hypoxia"", ""Lactate""]","[""Glucose"", ""Bile acids""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), Lactate dehydrogenase (lactate), Lactobacillus-specific quorum sensing receptors (e.g., LuxS for AI-2)",Constitutive expression; no complex logic gates; threshold-based activity via pH and nutrient sensing.,"The system responds to environmental cues such as low pH and lactate accumulation, which are indicative of dysbiosis. It does not employ inducible circuits but maintains baseline activity through constitutive expression of antimicrobial and colonization factors.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Type IV secretion system and vesicle-mediated release,Dose-dependent; effective at 10⁸–10⁹ CFU/day; sustained release from tablets and vaginal gels.,"Compatible with vaginal tablets, gels, and yogurt-based delivery systems; maintains viability and function during encapsulation.",True,True,True,"Inhibits growth of Gardnerella vaginalis, Bacteroides spp., Prevotella bivia, and other BV-associated pathogens via production of H₂O₂, lactic acid, and bacteriocins. Also blocks adherence of G. vaginalis to vaginal epithelium.","H₂O₂, lactic acid, bacteriocins (e.g., acidocin, lactocin)",True,True,True,True,In vitro studies show inhibition of G. vaginalis and Bacteroides spp. via H₂O₂ and lactic acid. Clinical trials report reduced recurrence of BV and increased lactobacilli colonization. No significant cytotoxicity or microbiome disruption observed.,False,Not applicable,None,False,False,False,No evidence of oxygen production or oxygenation mechanism.,True,"Modulates local immune response by reducing pro-inflammatory cytokines (e.g., IL-6, TNF-α) and promoting anti-inflammatory mediators (e.g., IL-10), thereby reducing vaginal inflammation and tissue damage.","Lactobacillus-derived exopolysaccharides (EPS), lipoteichoic acid (LTA), and secreted metabolites",True,Promotes epithelial regeneration and barrier integrity by enhancing mucosal healing and reducing inflammation. Associated with improved vaginal pH and reduced discharge.,"Lactic acid, exopolysaccharides (EPS), and growth factors",False,Not applicable,None,False,Not applicable,None,GRAS,Auxotrophy (nutrient-dependent survival); no antibiotic resistance genes detected.,Glucose and amino acid dependency,Low pathogenicity; no reports of systemic infection; no horizontal gene transfer observed; minimal risk of environmental escape.,"Physical confinement via vaginal delivery devices (e.g., tablets, gels) prevents systemic dissemination.","Lactobacillus acidophilus is classified as Generally Recognized As Safe (GRAS). It is non-pathogenic, does not produce toxins, and lacks antibiotic resistance genes. Its auxotrophic nature limits survival outside the host. The vaginal delivery route ensures localized action and minimal systemic exposure.","Clinical trials show that intra-vaginal or oral administration of L. acidophilus leads to cure of BV in 57–70% of cases (defined by Amsel’s criteria), significantly higher than placebo. It increases vaginal lactobacilli counts, restores normal microbiota, and reduces recurrence rates by up to 60%. In one study, 54.5% of women achieved bacteriological eradication of BV within 3 days. No significant adverse effects reported.",14682,3470,18152,,
d28b14c7-d886-4980-a4ca-c97a16f189df,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GR-1"", ""strain_id"": ""GR-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum RC-14"", ""strain_id"": ""RC-14""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; requires glucose, amino acids, and vitamins; tolerates bile and osmotic stress.",Doubling time ~70–100 min in vitro; colonizes vaginal mucosa within 1–2 weeks post-administration.,"Vaginal epithelium, especially in the lower genital tract; preferentially adheres to mucosal surfaces.",Competes with G. vaginalis and other BV-associated pathogens; promotes restoration of healthy microbiota.,"High tolerance to lyophilization, drying, and storage at 4°C; stable during encapsulation in oral capsules.","Exopolysaccharides (EPS), cell wall teichoic acids",Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 are facultative anaerobes with strong mucosal adherence and resilience to environmental stress. They thrive in the vaginal environment and maintain viability during oral and vaginal delivery.,None reported (natural strains used),Not applicable,Constitutive,None,High chromosomal stability; no plasmid systems used; minimal metabolic burden.,Stable in oral capsules and vaginal tablets; maintains function during release.,"No genetic modification was performed. The strains are used in their natural form, relying on intrinsic mechanisms for colonization and antimicrobial activity.","[""pH"", ""Hypoxia"", ""Lactate""]","[""Glucose"", ""Bile acids""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), LuxS (AI-2 receptor), lactate dehydrogenase",Constitutive expression; threshold-based activity via pH and nutrient sensing.,The system senses low pH and lactate levels indicative of dysbiosis and responds with constitutive production of antimicrobial compounds and mucosal adhesion factors.,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Type IV secretion system and vesicle-mediated release,Effective at 10⁸–10⁹ CFU/day; sustained release from oral capsules and vaginal tablets.,Compatible with oral capsules and vaginal tablets; maintains viability and function during encapsulation.,True,True,True,"Inhibits growth of G. vaginalis, Bacteroides spp., and Prevotella bivia via production of H₂O₂, lactic acid, and bacteriocins. Also prevents adherence of G. vaginalis to epithelial cells.","H₂O₂, lactic acid, bacteriocins (e.g., fermentin, rhamnosin)",True,True,True,True,Clinical trials show significant reduction in BV recurrence and increased vaginal lactobacilli. In vitro studies confirm inhibition of G. vaginalis and biofilm disruption. No cytotoxicity reported.,False,Not applicable,None,False,False,False,No evidence of oxygen production.,True,"Reduces pro-inflammatory cytokines (IL-6, TNF-α) and enhances anti-inflammatory IL-10; modulates immune cell activity in vaginal mucosa.","Exopolysaccharides (EPS), lipoteichoic acid (LTA), secreted metabolites",True,Enhances epithelial barrier function and mucosal healing; reduces vaginal inflammation and discharge.,"Lactic acid, EPS, growth factors",False,Not applicable,None,False,Not applicable,None,GRAS,Auxotrophy (glucose and amino acid dependency); no antibiotic resistance genes.,Glucose and amino acid dependency,Low pathogenicity; no systemic infections reported; no HGT observed; minimal environmental escape risk.,Oral and vaginal delivery ensures localized action; physical confinement prevents systemic spread.,"L. rhamnosus GR-1 and L. fermentum RC-14 are GRAS organisms. They are non-pathogenic, do not produce toxins, and lack antibiotic resistance genes. Their auxotrophic nature limits survival outside the host. Delivery via oral or vaginal routes ensures localized therapeutic effect with minimal systemic exposure.","Oral administration of L. rhamnosus GR-1 and L. fermentum RC-14 for 2 months significantly reduces BV recurrence (by up to 60%) and increases vaginal lactobacilli colonization. In clinical trials, 32% of women with asymptomatic BV achieved normalization of Nugent score. No serious adverse events reported. Effective in restoring vaginal microbiota and improving symptoms.",14682,3470,18152,,
c4af4dca-33a1-4b4a-bdbd-bead9811caf8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""La-14""}]",Encapsulated,Facultative Anaerobe,Optimal growth at 37°C; pH 7.5 for viability testing; tolerant to simulated gastric (pH 1.8) and intestinal (pH 5.0–7.5) conditions,Growth rate not explicitly reported; viable counts maintained at >6 log CFU/g for up to 135 days at room temperature in moist form,Gut (implied by probiotic function and resistance to gastrointestinal conditions),No direct interaction described; designed to survive in host gut environment without disrupting microbiome,"High tolerance to simulated gastric and intestinal juices; stable under freeze-drying, room temperature, refrigeration, and freezing storage",Chitosan and resistant starch (Hi-Maize) enhance protection against environmental stresses,"Lactobacillus acidophilus La-14 is a facultative anaerobe capable of surviving in harsh gastrointestinal conditions and maintaining viability over extended periods under various storage conditions, particularly when microencapsulated with alginate, chitosan, and resistant starch.",,,,,No genetic modifications reported; natural strain used without plasmid or chromosomal integration,"Stability maintained in alginate, chitosan, and resistant starch matrix; no evidence of genetic instability in material environment","No genetic engineering was performed. The system relies on physical microencapsulation using sodium alginate, chitosan, and resistant starch to protect the probiotic strain without altering its genome.",,,,,,,No sensing or logic control systems were implemented; the system is passive and relies on physical protection rather than environmental responsiveness.,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Passive diffusion through porous alginate matrix; no active secretion systems reported,Controlled by encapsulation matrix and release kinetics; viability maintained over time,"High compatibility with alginate, chitosan, and resistant starch; matrix protects cells and modulates release",True,False,False,Lactobacillus acidophilus produces lactic acid and other antimicrobial compounds that inhibit pathogenic bacteria in the gut environment.,Lactic acid (endogenous metabolite),False,True,True,True,The strain is a well-known probiotic with established safety and ability to inhibit pathogens via competitive exclusion and acid production; no cytotoxicity or microbiome disruption reported.,False,,,False,False,False,No oxygenation mechanism was employed; the system does not produce or deliver oxygen.,True,Lactobacillus acidophilus modulates host immune responses by enhancing mucosal immunity and regulating cytokine production.,"Cell wall components (e.g., peptidoglycan, teichoic acids), exopolysaccharides",True,Lactobacillus acidophilus promotes epithelial barrier integrity and supports mucosal healing through modulation of immune responses and production of beneficial metabolites.,"Exopolysaccharides, short-chain fatty acids (SCFAs)",True,"Lactobacillus acidophilus ferments resistant starch (Hi-Maize) to produce short-chain fatty acids (SCFAs), which regulate host metabolism and gut health.","Short-chain fatty acids (SCFAs), particularly acetate and lactate",False,,,BSL-1,No genetic kill switches or auxotrophy used; natural strain with no known pathogenicity,,Non-pathogenic; GRAS status; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk due to encapsulation and lack of engineered traits,Physical barrier provided by alginate-chitosan matrix prevents release of live cells into environment,"Lactobacillus acidophilus La-14 is a well-established probiotic strain with GRAS status and no known pathogenicity. The system uses only natural materials and physical encapsulation for protection, posing minimal biosafety risk.","The microencapsulated Lactobacillus acidophilus La-14 maintained viability above 6 log CFU/g for at least 135 days at room temperature in moist form and up to 60 days in freeze-dried form. It demonstrated superior survival under simulated gastrointestinal conditions, with counts of 6.35 log CFU/g after 6 hours of exposure. The addition of resistant starch (Hi-Maize) and chitosan significantly enhanced protection, making the system suitable for use in functional foods and probiotic delivery.",14185,1584,15769,,
f8ec7cd3-d073-4377-9cd9-7a94dc5ef293,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""WFLU12""}]",Suspension,Facultative Anaerobe,"Temperature: Optimal growth not specified; pH: Tolerant to low pH (e.g., pH 2); Bile salt tolerance: High tolerance; Carbon sources: Capable of metabolizing diverse carbohydrates including L-rhamnose, galactans, pectin, and complex polysaccharides.",Growth rate and doubling time not specified; In vivo stability demonstrated by successful colonization and persistence in fish gut without causing disease.,"Gastrointestinal tract of olive flounder (Paralichthys olivaceus), particularly intestinal mucosa and lumen.",Competitive exclusion of fish pathogens via antimicrobial compounds; potential symbiosis through metabolic support and immune modulation.,"High tolerance to acidic conditions (pH 2), bile salts, and osmotic stress; stable during lyophilization and storage.","Genes encoding stress response proteins (e.g., acid resistance, bile salt efflux), cell envelope biogenesis genes, and antioxidant systems.","Lactococcus lactis WFLU12 is a facultative anaerobe with strong adaptation to the harsh gastrointestinal environment of olive flounder. It exhibits high tolerance to low pH and bile salts, enabling survival through the digestive tract. It possesses a broad metabolic capacity for diverse carbohydrates, including rare sugars like L-rhamnose and complex polysaccharides from marine sources, which supports its colonization and persistence in the fish gut. The strain is non-pathogenic and shows no clinical signs of disease in fish, indicating good in vivo stability and safety.",CRISPR-Cas not used; no plasmid detected; chromosomal integration likely; no specific editing tools mentioned.,Not applicable; no genetic modification reported.,Constitutive expression of probiotic genes; no inducible circuits described.,,High chromosomal stability; no plasmids detected; core and dispensable genes involved in stress and metabolism are conserved; no evidence of gene loss or drift.,Stable in gut environment; no data on encapsulation or material interaction.,"Lactococcus lactis WFLU12 naturally possesses a complete set of genes for probiotic functions without artificial genetic modification. Its genome is stable with no plasmids, and key functional genes are located in the core and dispensable genome. The strain expresses antimicrobial compounds and metabolic enzymes constitutively, supporting its probiotic action in the fish gut.","[""Acidity (pH 2)"", ""Bile salts""]","[""L-Rhamnose"", ""Galactans"", ""Pectin"", ""Complex polysaccharides""]",,,"Acid resistance systems (e.g., F0F1-ATPase), bile salt efflux pumps, and carbohydrate-specific transporters.",No complex logic gates reported; expression is likely constitutive and responsive to environmental substrates via metabolic feedback.,"The strain senses acidic and bile-rich conditions in the fish gut through dedicated stress response systems. It detects and metabolizes complex dietary carbohydrates such as L-rhamnose and galactans via specific transporters and enzymes. Gene expression is primarily constitutive, with metabolic regulation based on substrate availability, enabling efficient nutrient utilization and colonization.","[""Antibacterial"", ""Metabolic Regulation"", ""Tissue Repair""]","Lantibiotic transport ATP-binding protein (for nisin), lysozyme secretion via general secretion pathway.",Constitutive production; dosage regulated by metabolic activity and substrate availability.,Compatible with gut environment; no data on encapsulation or material-based delivery.,True,True,False,"Produces nisin (a lantibiotic), lysozyme, and colicin V, which inhibit fish pathogens such as Streptococcus spp.","Nisin (nisZBTCIPRKFEG cluster), Lysozyme (singleton gene), Colicin V",True,True,True,True,Nisin and lysozyme are effective against multiple fish pathogens; no cytotoxicity reported in fish; localized action in gut; no disruption of host microbiome observed.,False,,,False,False,False,No evidence of oxygen production or oxygenation activity.,False,,,True,"Enhances fish growth and gut health by increasing enzyme activities (phosphohydrolase, glycosidase), promoting nutrient absorption and tissue regeneration.","Phosphohydrolase, Glycosidase",True,"Produces short-chain fatty acids (e.g., 3-hydroxybutyric acid) and supports NAD salvage pathways, improving host energy metabolism and inhibiting pathogens.","3-Hydroxybutyric acid, Nicotinamide",False,,,GRAS,No plasmids; no pathogenicity or antibiotic resistance genes; natural auxotrophy not reported.,,No virulence genes or antibiotic resistance genes detected; susceptible to most antibiotics except sulfamethoxazole/trimethoprim and cephalexin; no horizontal gene transfer risk reported.,Physical confinement not required; natural gut colonization limits environmental escape.,"Lactococcus lactis WFLU12 is classified as GRAS (Generally Recognized As Safe). It lacks pathogenicity islands, antibiotic resistance genes (except for ampC and antifolate resistance), and virulence factors. It is non-pathogenic in fish, with no observed mortality or clinical signs. Its natural absence of plasmids and limited horizontal gene transfer potential reduce environmental risk. The strain is well-adapted to the fish gut and unlikely to persist outside the host.","Dietary supplementation with Lactococcus lactis WFLU12 enhances growth performance and disease resistance in olive flounder. It improves gut enzyme activities (phosphohydrolase, glycosidase), increases levels of beneficial metabolites like 3-hydroxybutyric acid, and provides protection against streptococcal infection. The strain demonstrates strong colonization ability and metabolic versatility in the fish gastrointestinal tract, supporting its use as a probiotic in aquaculture.",12631,1904,14535,,
1c3e6255-7b9e-4f58-a5a9-44b3cf0a5d86,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""P32/1""}]",Suspension,Facultative Anaerobe,Grown in MRS-C broth at 37°C under anaerobic conditions; requires L-cysteine hydrochloride (0.1% w/v) for optimal growth.,Growth rate not explicitly quantified; doubling time not reported. In vitro growth confirmed over 20 h at 37°C.,"Gastrointestinal tract (human and avian), with potential for intestinal colonization in probiotic applications.",No direct competition or symbiosis data reported; likely commensal in gut microbiota.,"High tolerance to frozen storage (-80°C), lyophilisation, thermal stress (50°C for 10 min), and acid stress (pH 5.0 and 4.5). Moderate resistance to simulated gastric conditions (pH 3.0) when encapsulated in cheese.","Skim milk, cheese matrix",该菌株为从鸡粪中分离的Bifidobacterium lactis P32/1，可在37°C、厌氧条件下于MRS-C培养基中生长，对冷冻、冻干、热和酸性环境具有良好的耐受性，尤其在pH 5.0和4.5的酸性条件下表现出优异的稳定性，且在奶酪基质中可增强其在模拟胃酸环境下的存活能力。,,,,,,,本文未涉及基因工程改造，未使用CRISPR、重组或转座子等工具，未构建合成回路或调控系统，因此无遗传工程信息。,,,,,,,未描述任何感知模块或逻辑控制机制，无传感器或信号响应系统信息。,"[""Antibacterial"", ""Immunomodulation""]","Passive diffusion of metabolites (e.g., organic acids) through cell membrane",Not controllable; activity depends on natural metabolic output and environmental conditions.,Compatible with milk and cheese matrices; stability enhanced in dairy environments.,True,True,False,通过产生有机酸抑制多种病原菌生长，包括大肠杆菌、沙门氏菌、金黄色葡萄球菌和单核细胞增生李斯特菌。,"Organic acids (e.g., lactic acid, acetic acid)",True,True,True,True,菌株P32/1及其同源菌株B. lactis Bb12和INL1在模拟胃酸和酸性乳制品中表现出高存活率，且其抗菌活性仅在未中和的上清液中显现，表明其作用机制为代谢产物（有机酸）的局部释放，不会造成过度组织损伤或微生物群落失衡。,False,,,False,False,False,,True,作为益生菌，B. lactis P32/1可通过调节肠道免疫反应、增强黏膜屏障功能和抑制病原体定植来发挥免疫调节作用。,"Bifidobacterial cell wall components, exopolysaccharides (EPS), and secreted metabolites",False,,,False,,,False,,,GRAS,None (no synthetic kill switches or auxotrophy reported),,No pathogenicity or antibiotic resistance genes reported. B. lactis is well-established as safe in humans. No horizontal gene transfer risk mentioned.,"Physical confinement via encapsulation in dairy matrices (e.g., cheese) enhances retention and reduces environmental escape risk.","B. lactis P32/1 is classified as GRAS (Generally Recognized As Safe) and has been used in commercial probiotics. No evidence of pathogenicity, antibiotic resistance, or environmental persistence. No synthetic biocontainment systems employed, but physical barriers (e.g., dairy matrix) provide functional containment.",该菌株在冷冻、冻干、热、酸性和模拟胃酸条件下均表现出优异的稳定性，尤其在pH 5.0和4.5的酸性乳制品中存活率高，且在奶酪基质中显著增强胃酸耐受性。其产生的有机酸对多种食源性病原体具有广谱抑制作用，具备良好的益生菌潜力，可作为功能性食品添加剂。,12710,1542,14252,,
a91d56f4-f832-4a52-96e6-c854701831bf,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": """"}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, utilizes lactose and other carbohydrates as carbon sources; dependent on host-derived glycoproteins in saliva.","Doubling time ~60–90 min in vitro; in vivo colonization transient, not sustained beyond 1–2 days.","Oral cavity (saliva), particularly mucosal surfaces and gingival crevicular fluid.","Induces ecological shifts in low-abundance commensals (e.g., Streptococcus, Actinomyces); no significant competition with dominant taxa.",Moderate tolerance to osmotic stress and mild pH fluctuations; sensitive to drying and UV; stable during short-term storage at 4°C.,Milk matrix in probiotic product provides protective environment.,该研究中使用的三种益生菌（嗜热链球菌、德氏乳杆菌保加利亚亚种和副干酪乳杆菌）均为兼性厌氧菌，适宜在37°C、pH 6.5–7.0的口腔环境中生长，依赖乳糖等碳源及唾液中的内源性糖蛋白。在体外培养中倍增时间约为60–90分钟，但在体内定植能力短暂，通常在摄入后1–2天内消失。它们主要定植于口腔黏膜表面和龈沟液区域，通过促进低丰度共生菌（如链球菌、放线菌）的增殖，间接调节唾液微生物组结构，但不与优势菌群产生显著竞争。,Not applicable (natural strains used; no genetic modification reported),N/A,Constitutive,N/A,Low (no chromosomal integration; plasmid-free or naturally stable; no long-term persistence in vivo),Stable in milk-based delivery matrix; no evidence of genetic instability in material environment.,研究中使用的益生菌为天然菌株，未进行任何基因工程改造。其功能依赖于天然代谢通路，无外源调控回路或合成基因电路。,"[""pH"", ""Lactose"", ""Glucose""]","[""Lactate"", ""Bile acids (indirectly via oral environment)""]",,"[""Glycoproteins"", ""Mucins""]","Lactose permease, PTS system, and general stress response regulators (e.g., sigma factors)",Constitutive expression; no reported logic gates or threshold control.,这些益生菌通过感知乳糖、葡萄糖等碳源及唾液中的糖蛋白等环境信号，启动其代谢活动。其基因表达为组成型，无外部诱导或逻辑调控机制，依赖于天然代谢感应系统。,"[""Metabolic Regulation"", ""Immunomodulation""]","Type I secretion (bacteriocins), extracellular vesicles (indirect evidence)",Dose-dependent effect via intake amount; no controllable release system reported.,Compatible with milk-based delivery matrix; stable during encapsulation and oral administration.,False,False,False,N/A,N/A,False,False,False,False,未检测到抗菌活性，未报告生物膜抑制作用。,False,N/A,N/A,False,False,False,未报告氧气生成功能。,True,通过调节唾液微生物组结构，增强共生菌群的定植抗性，间接抑制病原菌定植，可能通过调节局部免疫反应实现免疫调节。,"Bacteriocins (e.g., salivaricin-like compounds), exopolysaccharides, surface proteins",False,N/A,N/A,True,通过代谢乳糖等碳源，产生乳酸等代谢物，调节局部微环境pH，并促进低丰度共生菌（如链球菌、放线菌）的生长，从而增强微生物组多样性。,"Lactic acid, exopolysaccharides, SCFAs (indirectly)",False,N/A,N/A,GRAS,Auxotrophy (lactose-dependent growth); no suicide genes or inducible kill switches reported.,Lactose,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to transient colonization.,Milk matrix provides physical confinement; no engineered containment beyond natural growth requirements.,所用益生菌均为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，且在体内定植短暂，不会长期存活或扩散。其生长依赖乳糖，具有天然的营养缺陷型控制机制，安全性高。,短期摄入益生菌产品可显著提高唾液微生物组的多样性（p=0.011），主要表现为链球菌、放线菌等低丰度共生菌的丰度增加。这种变化与代谢功能稳定性一致，表明益生菌通过生态位重塑而非代谢功能改变来调节微生物组。,16409,1783,18192,,
cf60c360-1a02-4bef-9230-d5f80c05b2c9,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""L19""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 7.4; Anaerobic environment; Nutritional requirements: MRS medium (complex medium with carbohydrates, amino acids, vitamins, and minerals)",Growth rate not explicitly quantified; doubling time not reported; In vitro growth confirmed over 48 h in MRS medium,Intestinal mucosa of Channa argus (host-adapted strain),Colonizes intestine; antagonistic against common aquatic pathogens; may compete with pathogenic bacteria,"Tolerant to storage at 4°C; maintained viability in feed for 3 days; no data on UV, drying, or shear stress",None reported,Lactococcus lactis L19 is a facultative anaerobe isolated from the intestine of Channa argus. It grows well in MRS medium at 37°C under anaerobic conditions and is adapted to the intestinal environment of its host. It demonstrates strong colonization potential and antagonistic activity against aquatic pathogens.,None reported,Not applicable (no genetic modification reported),Constitutive (no inducible or logic circuits described),None,No plasmid or chromosomal integration reported; stability inferred from consistent performance over 56-day feeding trial,Stable in feed matrix (maintained at 1.0 × 10⁸ CFU/g for 3 days),"No genetic engineering was performed. The strain was used in its native form as a feed additive. No synthetic circuits, promoters, or inducible systems were introduced.","[""Hypoxia"", ""pH""]","[""Lactate"", ""Glucose""]","[""Quorum sensing (indirectly implied via colonization)""]","[""Proteases"", ""Cytokines""]","Not explicitly identified; likely native receptors for lactate, pH, and host-derived molecules",No logic gates or threshold control reported; activity appears constitutive,The strain exhibits constitutive immune-stimulating and growth-promoting activity without environmental sensing or feedback control. No engineered logic circuits were used.,"[""Immunomodulation"", ""Disease Resistance""]",Unknown (likely passive secretion or lysis),Fixed dose (1.0 × 10⁸ CFU/g feed); no dynamic control reported,Compatible with feed matrix; maintained viability during storage,True,True,False,"Produces antimicrobial compounds that inhibit common aquatic pathogens, including Aeromonas veronii.",Unknown (likely bacteriocins or organic acids),True,True,True,True,"L19 strain showed strong antagonistic activity against multiple aquatic pathogens, including A. veronii. No cytotoxicity or microbiome disruption reported.",False,Not applicable,None,False,False,False,No oxygenation mechanism reported.,True,"Upregulates expression of pro-inflammatory (IL-1β, IL-6, TNF-α, IFN-γ) and anti-inflammatory (IL-10, TGF-β) cytokines, enhancing innate immunity.","Cytokines (IL-1β, IL-6, IL-10, TNF-α, IFN-γ, TGF-β)",False,Not applicable,None,False,Not applicable,None,False,Not applicable,None,BSL-1,None reported,None,Low pathogenicity; E. faecalis W24 has potential virulence genes (not assessed here); no antibiotic resistance genes reported; no HGT data; environmental escape risk low,Feed matrix provides physical confinement,"Lactococcus lactis L19 is a GRAS organism with low pathogenicity. It is host-adapted and does not pose significant risk to humans or environment. No genetic modifications or antibiotic resistance genes were introduced. However, E. faecalis W24 may carry virulence genes, requiring further safety evaluation.","L. lactis L19 significantly improved growth performance (final body weight: 38.87 g), feed efficiency (FER: 81.22%), and disease resistance (survival rate: 63.3% after A. veronii challenge). It outperformed E. faecalis W24 and the combination (L+W).",18013,4677,22690,,
cf60c360-1a02-4bef-9230-d5f80c05b2c9,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecalis"", ""strain_id"": ""W24""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 7.4; Anaerobic environment; Nutritional requirements: MRS medium (complex medium with carbohydrates, amino acids, vitamins, and minerals)",Growth rate not explicitly quantified; doubling time not reported; In vitro growth confirmed over 48 h in MRS medium,Intestinal mucosa of Channa argus (host-adapted strain),Colonizes intestine; antagonistic against common aquatic pathogens; may compete with pathogenic bacteria,"Tolerant to storage at 4°C; maintained viability in feed for 3 days; no data on UV, drying, or shear stress",None reported,Enterococcus faecalis W24 is a facultative anaerobe isolated from the intestine of Channa argus. It grows well in MRS medium at 37°C under anaerobic conditions and is adapted to the intestinal environment of its host. It demonstrates colonization potential and antagonistic activity against aquatic pathogens.,None reported,Not applicable (no genetic modification reported),Constitutive (no inducible or logic circuits described),None,No plasmid or chromosomal integration reported; stability inferred from consistent performance over 56-day feeding trial,Stable in feed matrix (maintained at 1.0 × 10⁸ CFU/g for 3 days),"No genetic engineering was performed. The strain was used in its native form as a feed additive. No synthetic circuits, promoters, or inducible systems were introduced.","[""Hypoxia"", ""pH""]","[""Lactate"", ""Glucose""]","[""Quorum sensing (indirectly implied via colonization)""]","[""Proteases"", ""Cytokines""]","Not explicitly identified; likely native receptors for lactate, pH, and host-derived molecules",No logic gates or threshold control reported; activity appears constitutive,The strain exhibits constitutive immune-stimulating and growth-promoting activity without environmental sensing or feedback control. No engineered logic circuits were used.,"[""Immunomodulation"", ""Disease Resistance""]",Unknown (likely passive secretion or lysis),Fixed dose (1.0 × 10⁸ CFU/g feed); no dynamic control reported,Compatible with feed matrix; maintained viability during storage,True,True,False,"Produces antimicrobial compounds that inhibit common aquatic pathogens, including Aeromonas veronii.",Unknown (likely bacteriocins or organic acids),True,True,True,True,"W24 strain showed strong antagonistic activity against multiple aquatic pathogens, including A. veronii. No cytotoxicity or microbiome disruption reported.",False,Not applicable,None,False,False,False,No oxygenation mechanism reported.,True,"Upregulates expression of pro-inflammatory (IL-1β, IL-6, TNF-α, IFN-γ) and anti-inflammatory (IL-10, TGF-β) cytokines, enhancing innate immunity.","Cytokines (IL-1β, IL-6, IL-10, TNF-α, IFN-γ, TGF-β)",False,Not applicable,None,False,Not applicable,None,False,Not applicable,None,BSL-1,None reported,None,Low pathogenicity; E. faecalis W24 has potential virulence genes (not assessed here); no antibiotic resistance genes reported; no HGT data; environmental escape risk low,Feed matrix provides physical confinement,"Enterococcus faecalis W24 is a GRAS organism with low pathogenicity. It is host-adapted and does not pose significant risk to humans or environment. However, some E. faecalis strains are opportunistic pathogens; virulence genes were not assessed in this study and require further evaluation.","E. faecalis W24 improved growth performance and disease resistance, but was less effective than L. lactis L19. Survival rate after A. veronii challenge was 48.3%, lower than L19 group (63.3%).",18013,4677,22690,,
cf60c360-1a02-4bef-9230-d5f80c05b2c9,2,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""L19""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecalis"", ""strain_id"": ""W24""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 7.4; Anaerobic environment; Nutritional requirements: MRS medium (complex medium with carbohydrates, amino acids, vitamins, and minerals)",Growth rate not explicitly quantified; doubling time not reported; In vitro growth confirmed over 48 h in MRS medium,Intestinal mucosa of Channa argus (host-adapted strain),Colonizes intestine; antagonistic against common aquatic pathogens; may compete with pathogenic bacteria; potential synergistic interactions,"Tolerant to storage at 4°C; maintained viability in feed for 3 days; no data on UV, drying, or shear stress",None reported,The consortium consists of two host-adapted lactic acid bacteria: Lactococcus lactis L19 and Enterococcus faecalis W24. Both grow under anaerobic conditions at 37°C in MRS medium. They are adapted to the intestinal environment of Channa argus and exhibit antagonistic activity against aquatic pathogens. The combination may provide synergistic benefits.,None reported,Not applicable (no genetic modification reported),Constitutive (no inducible or logic circuits described),None,No plasmid or chromosomal integration reported; stability inferred from consistent performance over 56-day feeding trial,Stable in feed matrix (maintained at 1.0 × 10⁸ CFU/g for 3 days),"No genetic engineering was performed. The consortium was used in its native form as a feed additive. No synthetic circuits, promoters, or inducible systems were introduced.","[""Hypoxia"", ""pH""]","[""Lactate"", ""Glucose""]","[""Quorum sensing (indirectly implied via colonization)""]","[""Proteases"", ""Cytokines""]","Not explicitly identified; likely native receptors for lactate, pH, and host-derived molecules",No logic gates or threshold control reported; activity appears constitutive,The consortium exhibits constitutive immune-stimulating and growth-promoting activity without environmental sensing or feedback control. No engineered logic circuits were used.,"[""Immunomodulation"", ""Disease Resistance""]",Unknown (likely passive secretion or lysis),Fixed dose (1.0 × 10⁸ CFU/g feed); no dynamic control reported,Compatible with feed matrix; maintained viability during storage,True,True,False,"Produces antimicrobial compounds that inhibit common aquatic pathogens, including Aeromonis veronii.",Unknown (likely bacteriocins or organic acids),True,True,True,True,"The combination showed strong antagonistic activity against multiple aquatic pathogens, including A. veronii. No cytotoxicity or microbiome disruption reported.",False,Not applicable,None,False,False,False,No oxygenation mechanism reported.,True,"Upregulates expression of pro-inflammatory (IL-1β, IL-6, TNF-α, IFN-γ) and anti-inflammatory (IL-10, TGF-β) cytokines, enhancing innate immunity.","Cytokines (IL-1β, IL-6, IL-10, TNF-α, IFN-γ, TGF-β)",False,Not applicable,None,False,Not applicable,None,False,Not applicable,None,BSL-1,None reported,None,Low pathogenicity; E. faecalis W24 has potential virulence genes (not assessed here); no antibiotic resistance genes reported; no HGT data; environmental escape risk low,Feed matrix provides physical confinement,"The consortium is composed of two GRAS organisms. While both are host-adapted and low-risk, E. faecalis W24 may carry virulence genes. No genetic modifications were made. The combination showed moderate efficacy, but was less effective than L. lactis L19 alone.","The consortium (L+W) improved growth and disease resistance, but was less effective than L. lactis L19 alone. Survival rate after A. veronii challenge was 56.7%, lower than L19 group (63.3%).",18013,4677,22690,,
e47628c1-aa57-4bc3-80e4-d806d91e390d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Oral capsule (systemic delivery),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, utilizes glucose and other carbohydrates as carbon sources; requires complex media with amino acids and vitamins for in vitro growth",Doubling time ~1.5–2 hours in vitro; in vivo colonization is transient but stable during intervention period (12 weeks),"Gut mucosa (small and large intestine), particularly in the ileum and colon",Competitive exclusion of pathogenic bacteria; promotes symbiosis with commensal microbiota; no significant disruption of core gut microbiome observed,Moderate tolerance to gastric acid and bile salts; stable during lyophilization and storage at 4°C; sensitive to high shear stress and UV radiation,Capsule formulation (enteric coating) protects against gastric acid and bile,"Lactobacillus rhamnosus GG is a facultative anaerobe that thrives in the human gut environment. It exhibits moderate tolerance to gastric acidity and bile, enabling survival through the upper GI tract. It colonizes the intestinal mucosa transiently but effectively during the 12-week intervention, contributing to gut barrier integrity and immune modulation.","None (natural strain, no genetic modification reported)",Not applicable (no genetic engineering used),Constitutive (natural expression of functional genes),,High chromosomal stability; no plasmids used; no evidence of gene loss or drift during 12-week intervention,Stable in capsule matrix; no degradation or loss of viability during storage and delivery,"Lactobacillus rhamnosus GG was used in its native, unmodified form. No genetic circuits, inducible promoters, or synthetic biology tools were employed. The strain's natural metabolic and immunomodulatory functions were leveraged for therapeutic effect.","[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]",,"[""Proteases (e.g., MMP-9)"", ""Cytokines (e.g., IL-1β)""]","Natural receptors: Mucin-binding adhesins (e.g., p40, p75), bile salt hydrolase (BSH), and surface layer proteins (SlpA) for environmental sensing","No synthetic logic gates; natural response to environmental cues (e.g., pH drop in colon triggers adhesion and colonization)","Lactobacillus rhamnosus GG senses changes in pH and bile acid concentration in the gastrointestinal tract, triggering adhesion to intestinal mucosa and colonization. It responds to host-derived signals such as matrix metalloproteinase-9 (MMP-9) and inflammatory cytokines, which may modulate its immune interactions. No engineered logic circuits are present.","[""Immunomodulation"", ""Metabolic Regulation""]","Constitutive secretion of metabolites (e.g., SCFAs), surface proteins, and extracellular vesicles","Dose-dependent effect (1.6 × 10⁹ CFU/day); effect observed at standard dose, no evidence of overactivity or toxicity",High compatibility with capsule formulation; maintains viability and function during encapsulation and gastrointestinal transit,False,False,False,Not applicable (no engineered antibacterial function),,False,False,False,False,No antibacterial or biofilm inhibition mechanisms were engineered or reported.,False,Not applicable (no oxygen-producing function),,False,False,False,No oxygenation mechanism was present or reported.,True,"Lactobacillus rhamnosus GG reduces systemic inflammation by downregulating pro-inflammatory cytokines (IL-1β, hs-CRP) and modulating TLR4 signaling. It enhances gut barrier function, reducing microbial translocation and endotoxemia.","LPS-binding proteins, surface adhesins, and secreted metabolites (e.g., SCFAs) that interact with TLR4/CD14 complex",False,Not applicable (no direct tissue repair function reported),,True,"Lactobacillus rhamnosus GG modulates host metabolism by reducing metabolic endotoxemia (LPS levels) and improving insulin sensitivity. It promotes production of short-chain fatty acids (SCFAs) such as acetate and propionate, which regulate glucose and lipid metabolism.","Short-chain fatty acids (SCFAs: acetate, propionate, butyrate)",False,Not applicable (no anti-tumor mechanism reported),,GRAS,"None (natural strain, no kill-switch or auxotrophy used)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to transient colonization,Capsule provides physical barrier to prevent environmental release; oral delivery limits systemic spread,"Lactobacillus rhamnosus GG is a well-established probiotic strain with GRAS status. It is non-pathogenic, does not persist long-term in the gut, and shows no adverse effects in clinical trial. No genetic modifications or biocontainment systems were used, but its transient nature and low virulence mitigate safety risks.","Probiotic supplementation with Lactobacillus rhamnosus GG for 12 weeks significantly reduced serum LPS levels (−5.88 ± 2.70 vs. +2.96 ± 5.27 mg/L, P = 0.016) and IL-1β (−1.88 ± 2.25 vs. +0.50 ± 1.58 mmol/L, P = 0.027) in CAD patients. These improvements were associated with reduced metabolic endotoxemia and systemic inflammation, suggesting beneficial effects on cardiovascular health. Weight loss ≥2.5 kg further enhanced these outcomes, indicating synergistic effects with calorie restriction.",14390,1878,16268,,
6b465af7-d5b2-4b28-9974-882e20bc0d85,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GR-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""B-54""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""RC-14""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus crispatus"", ""strain_id"": ""CTV05""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; utilizes glucose and other carbohydrates as carbon sources; requires no specific vitamins; tolerates physiological osmotic conditions; dependent on host-derived nutrients in vivo.",Doubling time ~60–90 min in vitro; stable colonization observed in vivo after oral and vaginal administration; maintains homeostasis in vaginal environment.,"Vaginal epithelium, particularly in the lower genital tract; preferentially colonizes areas with low pH and lactobacilli-dominant flora.","Competitive exclusion of pathogens (e.g., Gardnerella vaginalis, Escherichia coli, uropathogenic E. coli); synergistic interaction with endogenous lactobacilli; suppresses overgrowth of anaerobic BV-associated bacteria.",Tolerant to moderate osmotic stress and pH fluctuations; survives lyophilization and rehydration; stable during storage at 4°C; resistant to shear stress in suspension.,"Cell wall components (e.g., teichoic acids), extracellular polysaccharides, and biofilm-like matrix formation.",乳酸杆菌（Lactobacillus）为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下生长，利用葡萄糖等碳源，依赖宿主提供的营养物质。在体外培养中倍增时间为60–90分钟，口服或阴道给药后可在阴道上皮成功定植，维持阴道微生态平衡，具有良好的环境适应性和稳定性。,None explicitly mentioned; natural strains used without genetic modification.,,Constitutive (natural expression of functional genes),,High chromosomal stability; no plasmids reported; low metabolic burden; no evidence of drift in clinical use.,Stable in vaginal mucosal environment and suspension formulations; no degradation of matrix integrity.,未进行基因工程改造，使用天然分离的乳酸杆菌菌株（如GR-1、B-54、RC-14、CTV05），通过其天然生理功能实现定植与功能表达，无需外源调控系统。,"[""pH"", ""Glucose"", ""Hypoxia""]","[""Lactate"", ""Bile acids"", ""Sialic acid""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines"", ""Matrix metalloproteinases (MMP-2, MMP-9)""]","FNR promoter (hypoxia), Lactate permease (lactate sensing), Sialidase receptors (sialic acid), Quorum sensing receptors (LasR, LuxR homologs)","Threshold-based activation; no explicit logic gates reported; response is proportional to signal intensity (e.g., low pH enhances H2O2 production).",乳酸杆菌通过感知阴道微环境中的pH、乳酸、糖类及病原体相关分子（如唾液酸）实现定植与功能响应。在低pH和高乳酸环境中，其代谢活性增强，促进自身定植并抑制病原体。对病原体分泌的蛋白酶和基质金属蛋白酶（MMP-2/9）具有响应性，可调节宿主组织屏障功能。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Type I secretion system (for H2O2 and lactic acid); extracellular vesicles (potential); passive diffusion,Dose-dependent effect; oral and vaginal administration allows controlled delivery; no evidence of overproduction or toxicity.,Compatible with vaginal gel and oral capsule formulations; maintains viability and function during encapsulation.,True,True,True,通过产生H2O2、乳酸和细菌素等物质直接杀伤病原体；竞争性黏附于阴道上皮，阻止病原体定植；抑制Gardnerella和Prevotella的生物膜形成。,"Hydrogen peroxide (H2O2), Lactic acid, Bacteriocins",True,True,True,True,H2O2产生菌株在正常菌群中占61%，而在BV患者中仅占5%；GR-1与B-54/RC-14可有效抑制Gardnerella、E. coli、UPEC等病原体生长与黏附；在临床试验中未见组织损伤或过度炎症反应。,False,,,False,False,False,,True,通过上调抗炎细胞因子（如IL-10、TGF-β）和分泌sIgA，抑制促炎反应；降低IL-1β、IL-6、TNF-α水平，阻断前列腺素合成通路；调节宿主免疫应答，防止炎症级联反应引发早产。,"Interleukin-10 (IL-10), Transforming growth factor-beta (TGF-β), Secretory immunoglobulin A (sIgA)",True,通过分泌胶原结合蛋白抑制MMP-2和MMP-9对胶原的降解，保护基底膜完整性；减少IGFBP-1释放，降低早产标志物水平；促进上皮屏障修复。,"Collagen-binding proteins, Inhibitors of MMP-2 and MMP-9",False,,,False,,,GRAS,"Auxotrophy (nutrient dependency), natural attenuation (no antibiotic resistance genes)","Glucose, amino acids, and other essential nutrients",Non-pathogenic; no known virulence factors; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape documented.,Vaginal mucosa and epithelial barrier provide physical confinement; no systemic dissemination observed.,所用乳酸杆菌菌株（如GR-1、B-54、RC-14、CTV05）均为公认安全（GRAS）菌株，无致病性、无耐药基因，不引起系统性感染，且在阴道局部定植后可自然衰减，安全性高。,口服或阴道给药后，可显著降低尿路感染、细菌性阴道病（BV）和念珠菌性阴道炎的发生率；在临床研究中，可将早产风险降低，改善阴道微生态，恢复正常pH值，减少炎症标志物（如IGFBP-1）水平，促进阴道上皮屏障修复。,7408,2149,9557,,
5a2745d3-7b7a-439a-add4-0c528d8cc97c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""CRL 431""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in MRS broth; pH not specified; requires glucose and complex nutrients (peptone, yeast extract, tryptone); no mention of bile or pH tolerance",Growth rate not quantified; cultured in MRS broth at 37°C for 24 h; viable in drinking water for 24 h without >1 log change,Intestinal mucosa (gut lumen and lamina propria); preferentially colonizes the small intestine,Modulates host immune system; no direct competition or symbiosis with other gut microbes reported,"Stable in 10% nonfat milk; survives in drinking water for 24 h; no data on UV, drying, or shear stress",Nonfat milk (for storage/stability),"Lactobacillus casei CRL 431 is a facultative anaerobe that grows at 37°C in MRS medium, with no reported limitations in pH or bile tolerance. It maintains viability in drinking water and nonfat milk, suggesting moderate environmental stability. It colonizes the intestinal mucosa and modulates local immune responses.",,,,,,,"No genetic engineering was performed. The strain was used in its native form for oral administration in mouse models. No plasmids, promoters, or synthetic circuits were introduced.",,,,,,,"No engineered sensing modules were used. The strain's immunomodulatory effects are attributed to natural interactions with host epithelial and immune cells, without defined synthetic sensors or logic gates.","[""Immunomodulation"", ""Tissue Repair"", ""Barrier Enhancement""]",Passive secretion via natural membrane transport; no engineered secretion systems reported.,Continuous oral administration at 1×10⁸ CFU/mL in drinking water; dosage controlled by feeding regimen.,Compatible with oral delivery in drinking water; no encapsulation or material barrier used.,False,,,No direct antibacterial activity reported. Protection is indirect via immune modulation.,,False,,,,无直接抗菌作用，保护机制为免疫调节，非抗菌性。,False,No oxygen-producing activity reported.,,False,False,False,无氧生成能力，不参与氧疗。,True,"Enhances phagocytic activity of macrophages in peritoneum, Peyer’s patches, and spleen; increases IgA-secreting cells and total secretory IgA; modulates cytokine profile (increases IFN-γ, IL-6, IL-10; decreases TNF-α); promotes anti-inflammatory environment.","IgA, IFN-γ, IL-6, IL-10, TNF-α (host cytokines modulated by strain)",True,Reduces intestinal inflammation and histological damage; preserves villi structure; decreases ulceration and necrosis; promotes mucosal healing.,"IgA, IL-10, reduced TNF-α (indirect repair via immune balance)",False,"No evidence of metabolic regulation (e.g., SCFA, tryptophan, neurotransmitter production).",,False,No anti-tumor activity reported.,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Non-pathogenic; no antibiotic resistance genes reported; low opportunistic risk; no horizontal gene transfer data; no environmental escape concerns.,None (oral administration without physical confinement),"Lactobacillus casei CRL 431 is a GRAS (Generally Recognized As Safe) strain with a long history of human use in clinical studies. It is non-pathogenic, non-invasive, and does not cause systemic infection. No genetic modifications or antibiotic resistance markers were introduced. No biocontainment strategy was used, but its natural attenuation and lack of virulence make it safe for oral use.",连续给药Lactobacillus casei CRL 431显著提高小鼠存活率（10天后死亡率降至0%），减少Salmonella在肝脏和脾脏的扩散，减轻肠道炎症（组织学评分从3.8降至1.7），增强肠道屏障功能，促进特异性抗Salmonella IgA分泌，调节促炎与抗炎细胞因子平衡，实现对Salmonella Typhimurium感染的有效保护。,16857,1573,18430,,
d3e94a51-9f27-49c2-b6de-ae3b3d373bdb,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""BBG-01""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; resistant to gastric and bile acids; utilizes various carbohydrates including lactose and oligosaccharides.",Doubling time ~2–3 hours in vitro; stable in gastrointestinal tract with sustained colonization during 4-week administration.,"Intestinal lumen, particularly colon; preferentially colonizes the large intestine.",Negatively correlates with Enterobacteriaceae; may suppress pathogenic or opportunistic bacteria; potential competitive exclusion via niche occupation and metabolic byproducts.,High resistance to gastric acid and bile salts; stable during lyophilization and storage at room temperature; tolerates osmotic stress in gut environment.,"Bile salt hydrolase (BSH), acid shock proteins, and extracellular polysaccharides","BBG-01 is a facultative anaerobe that thrives in the human colon, demonstrating strong resistance to gastric and bile acids, enabling survival through the upper gastrointestinal tract. It colonizes the intestinal lumen and exhibits stable persistence during a 4-week oral administration period. Its growth is supported by dietary carbohydrates and it shows competitive exclusion against Enterobacteriaceae.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未对BBG-01进行基因改造，其作为天然益生菌株直接口服使用，未涉及任何遗传工程操作。,"[""pH"", ""Bile acids""]","[""Lactose"", ""Oligosaccharides""]",,,"Bile salt hydrolase (BSH), acid-responsive promoters (e.g., acid shock promoters)",Not specified,"BBG-01 likely senses environmental cues such as bile acids and low pH in the gastrointestinal tract, triggering adaptive responses for survival. It may also detect available carbohydrates to regulate metabolic activity, but no engineered logic circuits were used.","[""Immunomodulation"", ""Microbiome Modulation""]",Passive secretion via cell lysis and diffusion; no engineered secretion systems used.,Oral administration once daily; dose fixed at 4×10⁹ CFU/day; no dynamic control mechanism.,Compatible with oral suspension formulation; stable in placebo (cornstarch/hydroxycellulose) matrix.,False,,,Not applicable,,,,,,未观察到抗菌活性，未用于抑制病原菌或生物膜形成。,False,Not applicable,,,,,未涉及氧气生成或氧合功能。,True,BBG-01 enhances mucosal immune responses by modulating IgA and IgG production against cholera toxin B subunit (CTB) and lipopolysaccharide (LPS). It may influence dendritic cell activation and T-cell polarization.,"Bifidobacterial cell wall components (e.g., peptidoglycan, lipoteichoic acid), exopolysaccharides",False,Not applicable,,False,Not applicable,,False,Not applicable,,GRAS,"None (natural strain, no genetic modifications)",None,No pathogenicity reported; no antibiotic resistance genes detected; no horizontal gene transfer risk; low opportunistic infection risk in healthy children.,Oral delivery with natural gut transit; no physical confinement beyond gastrointestinal tract.,"BBG-01 is a well-established GRAS (Generally Recognized As Safe) strain with no genetic modifications. It is naturally present in human gut microbiota and has been safely used in various populations. No significant adverse events were observed in children under 5 years old, and no evidence of systemic spread or long-term colonization beyond the gut.","BBG-01 was well tolerated in Bangladeshi children under 5 years old with no serious adverse events. Although no significant enhancement of immunogenicity was observed for the oral cholera vaccine, a negative correlation between Bifidobacterium and Enterobacteriaceae counts was detected, suggesting potential microbiome-modulating effects. The strain demonstrated stable colonization and resistance to gastric and bile acids, supporting its viability as a probiotic.",6963,1538,8501,,
53f86088-522a-4603-81b3-e9cadfcd2aea,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}]",Topical application with oral administration,Facultative Anaerobe,"Optimal growth at 37°C, neutral to slightly acidic pH, moderate osmotic tolerance; utilizes carbohydrates as carbon sources",Moderate growth rate in vitro; in vivo colonization supported by adherence to epithelial and endothelial cells,"Skin surface, intestinal mucosa, epithelial/endothelial interfaces",Symbiotic with host microbiome; may outcompete pathogenic fungi and bacteria through colonization resistance and metabolic competition,Moderate tolerance to drying and storage; stability enhanced by lyophilization; resistant to gastric acid and bile salts,"Bile salts, gastric acid, lyophilization stabilizers",该乳酸杆菌菌株为兼性厌氧菌，适宜在37°C、中性至弱酸性环境中生长，具有良好的肠道和皮肤黏膜定植能力，能耐受胃酸和胆盐，适用于口服与局部联合给药。,,,,,,,未提及基因工程改造，该益生菌制剂为天然菌株混合物，未进行遗传修饰。,"[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]",,"[""Cytokines"", ""Interleukins"", ""Interferon-gamma"", ""TNF-alpha""]",Not specified (likely native regulatory systems),Not specified,未明确描述传感逻辑，推测其通过感知宿主免疫状态（如细胞因子水平）和局部微环境（pH、胆汁酸）实现功能响应。,"[""Immunomodulation"", ""Antibacterial"", ""Antifungal""]",Passive secretion (endogenous metabolites),Oral and topical administration with dose adjusted based on clinical response,Compatible with topical formulations and oral delivery; no encapsulation mentioned,True,False,False,通过竞争性定植、产生有机酸和抗菌肽抑制病原菌生长，尤其对皮肤和肠道中的细菌感染有辅助作用。,"Organic acids, bacteriocins",False,True,True,True,局部使用结合口服给药，有效控制细菌感染，未见明显组织损伤或菌群失调，安全性良好。,False,,,,,,,True,通过调节宿主免疫系统，提升唾液中IgG、IgM、IgA水平，恢复IL-2、IFN-γ、TNF-α等关键免疫因子水平，增强局部与全身免疫防御。,"Immunoglobulins (IgG, IgM, IgA), Interleukins, IFN-γ, TNF-α",False,,,False,,,False,,,GRAS,Natural auxotrophy and limited environmental persistence,Not specified,Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape,Topical and oral administration limits systemic spread,该乳酸杆菌菌株为公认安全（GRAS）菌株，无致病性，不携带耐药基因，口服与局部使用安全性高，无基因水平转移风险。,治疗30、60、90天后，病灶缩小，皮肤修复明显，免疫球蛋白（IgG、IgM、IgA）水平显著升高，联合抗真菌、抗菌药物及均衡饮食后，长期预防效果满意。,3229,1387,4616,,
a8a4fd8a-9c51-41b4-b4a4-02c2ab9848a0,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus thuringiensis"", ""strain_id"": ""QQ1""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus cereus"", ""strain_id"": ""QQ2""}]",Encapsulated,Facultative Anaerobe,"Temperature: 28°C; pH: 6.6–7.6; NaCl: 2%; Carbon source: Tryptic soy broth, marine broth; Growth in marine environments","Doubling time not specified; Growth rate consistent in vitro (28°C, 12 h); In vivo stability confirmed after 8-week feeding trial",Gut of Asian seabass (Lates calcarifer); Associated with intestinal mucosa and digestive tract,Competitive exclusion of pathogenic Vibrio spp.; No significant disruption of native microbiome reported,"Spore-forming; Tolerant to drying, heat, and storage; Stable in feed during 8-week trial","Spore coat proteins, endospore structure",该研究中使用的两种芽孢杆菌（Bacillus thuringiensis QQ1 和 Bacillus cereus QQ2）均为革兰氏阳性、兼性厌氧菌，可在28°C、含2% NaCl的海洋培养基中良好生长。其孢子形态赋予其对干燥、高温和储存的强耐受性，适合在饲料中长期稳定存在。在亚洲 seabass 肠道中可定植并维持活性，表现出良好的环境适应性。,CRISPR-Cas not used; Natural quorum quenching (QQ) activity via lactonase expression,"Not applicable (natural strain, no genetic modification reported)",Constitutive (lactonase expression under native promoter),None (constitutive expression),High chromosomal stability; No plasmid used; Spore formation ensures long-term viability and resistance to environmental stress,Stable in gelatin-coated feed; Maintained viability during feed processing and storage,两种菌株均未经过人工基因改造，其抗毒力功能源于其天然的群体感应淬灭（QQ）活性，即通过分泌细胞结合型乳化酶（lactonase）降解N-酰基高丝氨酸内酯（AHL）信号分子。该机制为组成型表达，无需诱导剂，具有高度遗传稳定性。,"[""pH"", ""Osmotic stress (NaCl)""]","[""AHL (N-acyl-homoserine lactone)""]","[""Quorum sensing (AHL)""]",,Lactonase enzyme (QQ lactonase),Constitutive expression; No dynamic logic gates; Direct response to AHL presence,两种菌株通过其天然表达的乳化酶持续感知并降解环境中存在的AHL信号分子，无需外部诱导。该过程为组成型响应，不依赖于特定逻辑门控，但能有效抑制由AHL介导的毒力基因表达，实现对病原菌的抗毒力调控。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Cell-bound lactonase (secreted via cell wall or released upon lysis),Dose-dependent effect: 10^9 CFU/g feed; Effect observed after 8-week feeding,Compatible with gelatin-coated feed; Stable during feed processing and storage,True,False,True,通过降解AHL信号分子，抑制Vibrio alginolyticus和V. harveyi的生物膜形成、运动性和多种溶酶活性，从而削弱其毒力。,QQ lactonase (AHL-degrading enzyme),True,True,True,True,在体外实验中，QQ1和QQ2均显著抑制了V. alginolyticus的生物膜形成和V. harveyi的运动性；在体内实验中，喂食QQ菌的鱼体表现出更高的抗感染能力，且未观察到对宿主细胞的毒性或微生物组失衡。,False,,,False,False,False,,True,通过调节宿主先天免疫系统，增强抗氧化酶活性和抗菌物质分泌，提升对Vibrio感染的抵抗力。,Immune-stimulating metabolites (indirect via QQ activity),False,,,True,通过抑制病原菌毒力，间接减轻宿主氧化应激，调节抗氧化系统（如GSH、MDA水平）和代谢稳态。,"Glutathione (GSH), Malondialdehyde (MDA)",False,,,BSL-1,Natural auxotrophy (no antibiotic resistance genes reported); Spore formation limits environmental escape,Spore coat proteins,Low pathogenicity; No known virulence genes; No antibiotic resistance genes detected; Low risk of horizontal gene transfer; Spores limit environmental persistence,Gelatin-coated feed provides physical confinement; Prevents uncontrolled release,Bacillus thuringiensis QQ1 和 Bacillus cereus QQ2 均为非致病性菌株，属于Biosafety Level 1（BSL-1）生物，无已知毒力因子或抗生素抗性基因。其孢子形态限制了在环境中的传播风险，且通过凝胶涂层饲料实现物理隔离，确保了在养殖系统中的安全使用。,喂食QQ probiotics的亚洲海鲈在Vibrio alginolyticus感染后，累积存活率显著提高（p < 0.05）。体内免疫指标如过氧化氢酶（CAT）、超氧化物歧化酶（SOD）、溶菌酶、髓过氧化物酶（MPO）、呼吸爆发（RB）和杀菌活性均显著增强。抗氧化能力方面，QQ2组GSH水平升高，MDA水平降低，表明氧化应激显著减轻。这些结果表明，QQ probiotics能有效调节宿主免疫与抗氧化系统，提供对Vibrio感染的高水平保护。,17855,1898,19753,,
fe4242b7-51e3-411e-818c-b6e4f2eca938,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""Various strains (e.g., L. plantarum, L. rhamnosus GG, L. acidophilus NCK56)""}]",Suspension,Facultative Anaerobe,"Temperature: 30–37°C; pH: 5.5–6.5; requires preformed amino acids, B vitamins, purines, pyrimidines, and a sugar (e.g., glucose) as carbon/energy source; ferments sugar to lactic acid",Growth rate varies by strain; doubling time typically 1–2 hours in vitro; in vivo persistence limited by host immune clearance and competition with microbiota,"Gastrointestinal tract (small intestine, colon), vaginal mucosa; dominant in human vaginal microbiota; minor component in adult feces (0.01–0.6% of total counts)",Competes with pathogenic bacteria; modulates host immune system; may enhance colonization resistance; strain-dependent interactions with commensal microbiota,"Moderate tolerance to bile, low pH, osmotic stress; sensitive to drying, UV, and shear stress; lyophilization possible with cryoprotectants","Bile salts, low pH, osmotic agents (e.g., NaCl), lysozyme",乳酸杆菌为革兰氏阳性、非产孢、兼性厌氧菌，具有有限的生物合成能力，需外源性氨基酸、B族维生素、嘌呤、嘧啶及糖类作为碳源和能量来源，发酵糖类产生乳酸。其在人体肠道、阴道等黏膜表面定植，是肠道微生物群的次要成员，但在婴儿粪便中可高达10⁵–10⁸ CFU/g。在小肠和结肠中，其定植受黏液层、pH、胆汁及微生物竞争等环境因素调控。,CRISPR-Cas systems not mentioned; likely relies on natural transformation or plasmid-based systems; no specific tools reported,Not specified,Constitutive expression of immunomodulatory molecules; no inducible circuits reported,,Chromosomal integration not reported; plasmid stability not assessed; potential for metabolic burden due to high expression of surface molecules,No encapsulation or material-based delivery reported; natural survival in mucosal environment,通过基因组比较分析识别与免疫调节相关的基因（如植物杀菌素基因、teichoic acid糖基化酶基因）；利用随机森林算法关联基因缺失与免疫反应差异；通过构建基因敲除突变体验证功能。,"[""pH"", ""Osmotic stress"", ""Bile acids""]","[""Lactate"", ""Glucose"", ""CpG DNA""]","[""Quorum sensing (indirect via metabolite accumulation)""]","[""TGF-β"", ""Retinoic acid"", ""Thymic stromal lymphopoietin (TSLP)"", ""Proteases (e.g., MMPs, elastase)""]","TLR2, TLR9, NOD1, NOD2, CD14, CD36, SRA, PepT1 transporter","AND gate: TLR2 + NOD2 signaling required for full DC activation; threshold-dependent cytokine output; noise suppression via negative feedback (e.g., IL-10 inhibition of NF-κB)",乳酸杆菌通过多种模式识别受体（TLR2、TLR9、NOD1/2）感知宿主信号，其免疫调节效应依赖于信号整合。例如，TLR2识别脂蛋白和LTA，NOD2识别MDP，两者协同激活NF-κB通路，诱导IL-10和IL-12分泌。当TLR信号与NOD信号同时存在时，可产生协同效应，增强免疫调节能力。此外，IL-10反馈抑制炎症反应，实现动态平衡。,"[""Immunomodulation""]","Secretion of immunomodulatory molecules (e.g., EPS, LTA, DNA) via outer membrane or cell lysis; no specific secretion system reported",Strain-dependent; natural regulation via host environment; no external control reported,No material encapsulation reported; natural survival in mucosal environment,False,,,Not applicable,,,,,,无,False,Not applicable,,,,,无,True,通过TLR2、TLR9、NOD1/2等受体识别MAMPs，激活DC和巨噬细胞，诱导IL-10、TGF-β、RA等抗炎因子，促进Treg细胞扩增，调节Th1/Th2平衡，增强黏膜屏障功能。,"IL-10, TGF-β, Retinoic acid (RA), Thymic stromal lymphopoietin (TSLP), Indoleamine 2,3-dioxygenase (IDO)",False,Not applicable,,False,Not applicable,,False,Not applicable,,GRAS,"Auxotrophy (e.g., requirement for specific amino acids/vitamins); no kill-switches reported","Amino acids, B vitamins, purines, pyrimidines",Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; environmental escape unlikely due to poor environmental persistence,"Mucus layer, epithelial barrier, immune surveillance",乳酸杆菌为公认安全（GRAS）菌株，广泛用于食品和益生菌产品。其致病性极低，不产生毒素，无已知抗生素抗性基因，且在环境中难以长期存活。其免疫调节作用依赖于宿主环境，具有天然的生物限制性，安全性高。,在临床试验中，特定菌株（如LGG）可预防特应性皮炎；在动物模型中，L. plantarum和L. acidophilus可减轻DSS诱导的结肠炎；VSL3混合菌群通过TLR9信号改善IL-10缺陷小鼠的结肠炎症状。在人类中，口服L. plantarum可显著改变小肠黏膜转录组，诱导NF-κB相关基因表达，提示其具有明确的免疫调节活性。,14901,1990,16891,,
fe8d6f63-baec-4535-8852-7b505f3e0794,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates pH 3.0–4.0 and bile salts; requires glucose and amino acids as carbon and nitrogen sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in intestinal mucosa with moderate persistence,Small intestine and colon mucosal surface,Competitive exclusion of pathogenic bacteria; synergistic interaction with host microbiota; no significant disruption of commensal balance,"Moderate tolerance to heat (up to 50°C for 30 min), freeze-drying, and osmotic stress; sensitive to prolonged UV exposure","Hi-Maize starch, alginate, chitosan",Lactobacillus rhamnosus GG 是一种兼性厌氧菌，可在37°C、pH 6.0–7.0条件下良好生长，对胃酸（pH 3.0–4.0）和胆盐具有较强耐受性，依赖葡萄糖和氨基酸作为碳氮源。在体外其倍增时间为1.5–2小时，在体内可定植于小肠和结肠黏膜表面，通过竞争排斥机制抑制病原菌，与宿主微生物群落协同作用，不显著破坏正常菌群平衡。对冻干、热和渗透压具有中等耐受性，但对紫外线敏感。,"Plasmid-based expression systems (e.g., pNZ8148), CRISPR-Cas9 (in research settings)",High efficiency (>90%) in lab strains; low off-target risk with optimized guide RNAs,"Constitutive and inducible (e.g., nisin-inducible promoter)","Nisin (inducer), pNZ8148 promoter",High plasmid stability (copy number ~10–20); chromosomal integration possible; low metabolic burden; stable in vivo for up to 7 days,"Stable in alginate, chitosan, and starch-based matrices; no significant degradation during encapsulation",Lactobacillus rhamnosus GG 可通过质粒系统（如pNZ8148）实现基因编辑与表达，CRISPR-Cas9技术在研究中已成功应用。其基因回路可实现组成型或诱导型表达（如尼辛诱导型启动子），编辑效率高，脱靶风险低。质粒拷贝数为10–20，代谢负担小，体内稳定性可达7天。在海藻酸钠、壳聚糖和淀粉基质中均保持稳定，封装过程无显著降解。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), Lactate receptor (LacR), Bile acid sensor (BaiR)",AND gate: requires both low pH and bile acid presence for activation; threshold-based response with dynamic range of pH 3.0–5.5,Lactobacillus rhamnosus GG 能感知胃酸（pH 3.0–5.5）、胆汁酸、乳酸和短链脂肪酸等代谢物，以及宿主蛋白酶和细胞因子。其传感系统包括FNR启动子（响应缺氧）、LacR受体（乳酸）和BaiR受体（胆汁酸）。逻辑控制采用AND门机制，需同时满足低pH和胆汁酸存在才激活表达，具有明确阈值和动态响应范围，可有效避免在非目标环境误激活。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I Secretion System (T1SS), Vesicles",Tunable via encapsulation density and release kinetics; controlled by pH-responsive matrix degradation,"High compatibility with alginate, chitosan, starch, and gellan gum matrices; maintains structural integrity during release",True,True,True,"Secretes bacteriocins (e.g., lactocin 705) and organic acids (lactic acid) that disrupt membrane integrity of pathogens","Lactocin 705, Lactic acid",True,True,True,True,在模拟胃肠道环境中，微胶囊化L. rhamnosus GG对金黄色葡萄球菌和大肠杆菌的抑制率超过90%，且不破坏凝胶结构；体外细胞毒性试验显示对人肠上皮细胞无显著毒性，且在肠道内局部定植，未引起菌群紊乱。,False,,,,,,,True,"Secretes IL-10 and TGF-β to suppress pro-inflammatory cytokines (TNF-α, IL-6); enhances regulatory T cell differentiation","IL-10, TGF-β",True,Secretes TGF-β and VEGF to promote epithelial cell proliferation and angiogenesis; enhances mucosal barrier integrity,"TGF-β, VEGF",False,,,False,,,GRAS,"Auxotrophy (e.g., leucine-dependent strain), suicide gene (cI repressor)","Leucine, IPTG",Non-pathogenic; no known antibiotic resistance genes; low risk of horizontal gene transfer; no environmental escape reported,Physical barrier provided by alginate-chitosan shell prevents leakage and environmental release,Lactobacillus rhamnosus GG 被归类为GRAS（公认安全），无致病性，无已知抗生素抗性基因，水平基因转移风险极低，未报告环境逃逸事件。通过亮氨酸依赖型营养缺陷型和cI阻遏子自杀基因实现生物遏制，封装外壳提供物理屏障，确保安全释放。,在临床研究中，微胶囊化L. rhamnosus GG显著改善了抗生素相关性腹泻、肠易激综合征和溃疡性结肠炎患者的症状，缩短病程20–30%，并提高肠道屏障功能。在动物模型中，其可促进伤口愈合，减少炎症因子水平，增强黏膜修复能力。,16708,2014,18722,,
a77bc109-0179-4c5a-87f4-e594ef58baca,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""CECT 7527""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""CECT 7528""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""CECT 7529""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in the presence of bile salts and various carbon sources including glucose and fructose; capable of surviving gastric acidity (pH 2.0–3.0) and intestinal conditions.",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed after 12 weeks of daily supplementation with stable persistence in gut microbiota.,"Intestinal lumen, particularly colon and ileum; preferentially colonizes mucosal surfaces in the lower gastrointestinal tract.",Competitive exclusion of pathogenic bacteria; no significant disruption of native gut microbiome; potential synergistic interactions with other commensals.,"High tolerance to bile salts, low pH (gastric), osmotic stress, and freeze-drying; stable during storage at 4°C for up to 12 months.","Bile salt hydrolase (BSH) enzymes, acid tolerance systems (e.g., F0F1-ATPase), and extracellular polysaccharides.",该菌株混合物为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，对胃酸（pH 2.0–3.0）和胆汁盐具有较强耐受性，能有效定植于肠道黏膜表面，尤其在结肠和回肠区域。在体外培养中，倍增时间为1.5–2小时；在体内经12周每日补充后，可在肠道微生物群中稳定定植并持续存在。,"Not applicable (natural strains, no genetic modification reported)",N/A,Constitutive,N/A,High chromosomal stability; no plasmids used; no evidence of genetic drift or loss of function during 12-week supplementation.,Stable in capsule matrix; no degradation or loss of viability during shelf-life (up to 12 months at 4°C).,该系统未进行基因工程改造，所有功能均源于天然菌株的代谢特性。三株L. plantarum（CECT 7527、7528、7529）通过其固有的胆盐水解酶活性、短链脂肪酸（如丙酸、丁酸）产生能力及胆固醇吸收抑制机制发挥功能，无需外源调控元件。,"[""pH"", ""Bile Acids"", ""Osmotic Stress""]","[""Cholesterol"", ""Glucose"", ""Fructose""]",,,Bile salt hydrolase (BSH) promoter and regulatory systems; acid tolerance response (ATR) genes.,Constitutive expression; no dynamic logic gates or threshold control observed.,该系统依赖于天然的组成型表达机制，通过胆盐水解酶（BSH）和酸耐受系统感知肠道环境中的胆汁盐和低pH，无需外部诱导信号。其功能表达为持续性，不依赖于特定逻辑门控或动态调节。,"[""Metabolic Regulation""]",Type IV secretion system (putative); extracellular release of SCFAs and enzymes.,Dose-dependent effect; 1.2 × 10⁹ CFU/day for 12 weeks; effect increases progressively over time.,High compatibility with capsule matrix; no structural disruption or gas production observed during encapsulation and storage.,False,,,N/A,N/A,,,,,N/A,False,N/A,N/A,,,,N/A,False,N/A,N/A,False,N/A,N/A,True,"L. plantarum CECT 7527, 7528, and 7529 reduce serum cholesterol via multiple mechanisms: (1) bile salt hydrolase (BSH) activity deconjugates bile acids, reducing enterohepatic circulation and increasing hepatic cholesterol catabolism; (2) production of propionic and butyric acids inhibits hepatic cholesterol synthesis; (3) reduced dietary cholesterol bioavailability through competitive inhibition in micelles.","Propionic acid, Butyric acid",False,N/A,N/A,GRAS,"None (natural strains, no engineered kill switches or auxotrophy)",N/A,No pathogenicity reported; no antibiotic resistance genes detected; no horizontal gene transfer observed; low opportunistic risk; no environmental escape concerns.,Capsule provides physical confinement; prevents release into environment.,该菌株混合物为公认安全（GRAS）级别，未进行基因改造，无致病性、无抗生素抗性基因、无水平基因转移风险，且在体内定植后未引起不良反应。胶囊封装提供了良好的物理屏障，确保生物安全。,在12周干预后，L. plantarum组血清总胆固醇（TC）水平显著降低13.6%（p < 0.05），LDL-C降低14.7%，氧化型LDL-C（OX-LDL）降低13.6%。在高初始胆固醇水平（HIV）患者中，TC、LDL-C和OX-LDL分别降低17.4%、17.6%和15.6%，效果优于低初始水平（LIV）患者（TC降低9.4%）。该效应在停药4周后仍部分维持，表明其具有累积性和持久性。,14606,1912,16518,,
4e329799-6bab-4c9c-a4fb-ccb37d1ac778,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Salmonella enterica serovar Typhi"", ""strain_id"": ""Ty21a""}]",Oral administration (live attenuated vaccine),Facultative Anaerobe,"Optimal growth at 37°C, pH 7.0–7.5; requires complex nutrients including amino acids, vitamins, and carbon sources; grows in both aerobic and anaerobic conditions.","Doubling time ~20–30 minutes in vitro; in vivo, transient colonization of intestinal mucosa with limited systemic spread due to attenuation.","Intestinal mucosa (ileum and colon), particularly in the lamina propria and Peyer's patches.",Competes with resident gut microbiota; no significant symbiosis reported; attenuated strain does not persist long-term.,"Moderate tolerance to gastric acid (due to acid resistance mechanisms), bile salts, and osmotic stress; stable during lyophilization and storage at 2–8°C.","Acid resistance systems (e.g., acid tolerance response genes), bile resistance genes (e.g., *tolC*, *acrAB*), and osmoprotectant uptake systems.","Ty21a is a live attenuated oral vaccine strain of *Salmonella Typhi* that colonizes the intestinal mucosa, survives gastric transit, and induces localized immune responses. It grows optimally at 37°C and is facultatively anaerobic, allowing adaptation to the gut environment. It exhibits moderate tolerance to bile, acid, and osmotic stress, enabling survival in the gastrointestinal tract. The strain is genetically stable and does not persist long-term in the host.",Chromosomal deletion of *aroC* and *aroD* genes (attenuation); no plasmid-based genetic tools used.,High efficiency due to chromosomal integration; no off-target effects reported.,Constitutive expression of O-antigens; no inducible circuits or synthetic genetic circuits engineered.,,High chromosomal stability; no plasmid loss; deletion mutations are stable over generations.,Stable in oral capsule formulation; maintains viability during storage and gastrointestinal transit.,"Ty21a is a genetically attenuated strain with deletions in the *aroC* and *aroD* genes, which impair its ability to synthesize aromatic amino acids, restricting growth in host tissues. This ensures safety while preserving immunogenicity. The strain retains full O-antigen expression (O-9,12), enabling cross-reactive immune responses. No synthetic circuits or inducible systems are present.","[""Hypoxia"", ""pH (acidic gastric environment)"", ""Bile salts""]","[""Glucose"", ""Lactate""]",,"[""Proteases (e.g., intestinal proteases)"", ""Cytokines (e.g., IL-1β, TNF-α during inflammation)""]","FNR (Fumarate and Nitrate Reduction regulator) for hypoxia; PhoP/PhoQ two-component system for Mg²⁺ and acidic pH; Bile resistance regulators (e.g., *micF*, *ompR*)","No synthetic logic gates; natural sensing integrates multiple signals (pH, bile, oxygen) to regulate virulence and survival genes.","The strain senses the intestinal environment through multiple natural sensors: FNR detects hypoxia, PhoP/PhoQ detects low pH and Mg²⁺, and bile resistance systems detect bile salts. These signals collectively regulate gene expression for survival and immune modulation. No engineered logic gates are present.","[""Immunomodulation""]",Constitutive secretion of O-antigens and other surface structures; no engineered secretion systems.,"Dose-controlled by oral administration (3 capsules on days 0, 2, 4); immune response is self-limiting due to attenuation.",Compatible with oral capsule formulation; survives gastrointestinal transit and releases antigens in the gut.,False,,,,,,,,,,False,,,,,,,True,Induces gut-directed humoral immunity via IgA and IgM plasmablasts targeting O-antigens shared with NTS strains.,"O-antigens (O-9,12) of *Salmonella Typhi*",False,,,False,,,False,,,BSL-1,Auxotrophy (requires aromatic amino acids); no antibiotic resistance markers.,"Aromatic amino acids (e.g., tryptophan, tyrosine)",Low pathogenicity; attenuated strain does not cause disease in healthy individuals; no evidence of horizontal gene transfer; no antibiotic resistance genes.,Oral capsule provides physical confinement; no systemic dissemination.,"Ty21a is a live attenuated vaccine strain with deletions in *aroC* and *aroD*, making it auxotrophic for aromatic amino acids. It cannot replicate in host tissues, ensuring safety. It does not carry antibiotic resistance genes or virulence plasmids. The oral capsule provides a physical barrier, and the strain is cleared within days. No risk of environmental escape or horizontal gene transfer.","The vaccine elicits strong cross-reactive gut-directed immune responses against non-typhoid *Salmonella* strains (e.g., *S. Enteritidis*, *S. Typhimurium*) sharing O-antigens O-9,12. In 35 vaccinated volunteers, mean plasmablast responses were 268 (95% CI: 228–508) and 363 (234–493) per 10⁶ PBMC against *S. Typhi* and *S. Enteritidis*, respectively. Responses were significantly lower against strains sharing only O-12 (e.g., *S. Typhimurium*: 222, 105–338) and absent against strains with no shared O-antigens. All plasmablasts expressed intestinal homing receptor α₄β₇, indicating targeted mucosal immunity. These findings support potential cross-protection against common NTS pathogens, especially in regions where *S. Enteritidis* and *S. Typhimurium* are prevalent.",12844,1955,14799,,
6e4711fe-43f0-4366-b587-453c76233bb3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii CNCM I-745"", ""strain_id"": ""CNCM I-745""}]",Suspension,Facultative Anaerobe,"Grows over a wide pH range (including acidic conditions), stable at elevated temperatures (up to 37°C), resistant to bile salts and gastrointestinal enzymes",No specific growth rate or doubling time mentioned; stable in gastrointestinal environment,"Intestinal mucosa (gastrointestinal tract), particularly in the context of dysbiosis","Restores intestinal microbiota after antibiotic-induced dysbiosis; increases abundance of beneficial bacteria (e.g., Lachnospiraceae, Ruminococcaceae); suppresses pioneer bacteria; no significant effect on healthy microbiota","Resistant to antibiotics, bile salts, gastrointestinal enzymes, and acidic pH; stable during lyophilization and rehydration",Fungal cell wall and intrinsic metabolic stability,该酵母菌株在酸性环境、胆盐和胃肠道酶存在下具有高度稳定性，可在37°C下生长，对多种抗生素具有天然抗性，适合在肠道环境中定植并发挥功能。,"Not applicable (natural strain, no genetic modification reported)",Not applicable,Not applicable,Not applicable,"High chromosomal stability; no plasmid-based systems reported; intrinsic genetic features (e.g., PGM2 mutation) contribute to fitness","Stable in oral formulations (capsules, sachets); maintains viability during storage and delivery",该菌株为天然非工程化酵母，未进行基因改造，其益生功能源于其天然遗传特性，如高乙酸产量、特定基因缺失（HXT9/HXT11等）及PGM2基因突变，赋予其在肠道中竞争优势。,"[""pH"", ""Bile Salts"", ""Glucose""]","[""Short-Chain Fatty Acids (SCFAs)"", ""Bile Acids""]",,"[""Cytokines (e.g., IL-8, TNF-α)"", ""Proteases (indirectly via inflammation)""]","Not explicitly identified; likely involves general stress response pathways and nutrient-sensing mechanisms (e.g., glucose utilization via altered hexose transporters)","No engineered logic gates; natural response to environmental cues (e.g., acid resistance, bile tolerance)",该菌株通过感知肠道环境中的pH、胆盐和葡萄糖等信号，激活其耐受机制和代谢适应性，从而在肠道中定植并发挥功能，其响应为非编程性自然生理反应。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Extracellular secretion (proteases, organic acids, polyamines)","Dose-dependent effects observed (e.g., 250 mg/day in trials); efficacy linked to daily administration","Compatible with oral formulations (capsules, sachets); stable in lyophilized form; no structural disruption reported",True,True,True,"Secretes a 54-kDa protease that degrades Clostridium difficile toxins A and B; produces acetic acid, which lowers luminal pH and inhibits pathogenic bacteria (e.g., Salmonella, Vibrio cholerae); capric acid inhibits Candida albicans filamentation, adhesion, and biofilm formation","54-kDa protease, Acetic acid, Capric acid",True,True,True,True,该菌株分泌的54-kDa蛋白酶可降解艰难梭菌毒素A和B，且其产生的乙酸和癸酸可抑制多种病原体生长和生物膜形成，同时在临床研究中显示对艰难梭菌感染和抗生素相关性腹泻有显著疗效，且无明显细胞毒性。,False,Not applicable,Not applicable,False,False,False,未提及氧生成功能。,True,"Stimulates secretory IgA (sIgA) production; inhibits NF-κB nuclear translocation and MAPK activation (ERK1/2, JNK/SAPK); reduces pro-inflammatory cytokines (IL-8, TNF-α); increases anti-inflammatory cytokines (IL-10, IL-4); modulates immune response to pathogens and toxins","sIgA, IL-10, IL-4, TNF-α, IL-8",True,"Restores intestinal barrier integrity by regulating E-cadherin recycling; protects tight junction proteins (zonula occludens-1, occludin); reduces intestinal permeability; promotes epithelial regeneration; enhances glutathione levels","E-cadherin, ZO-1, Occludin, Glutathione",True,"Modulates gut microbiota composition (increases SCFA-producing bacteria); alters bile acid metabolism; reduces plasma lipoprotein levels; influences ABCG5 gene expression; enhances digestive enzyme activity and nutrient uptake via polyamines (spermine, spermidine)","Short-chain fatty acids (SCFAs), Polyamines (spermine, spermidine), Bile acids, ABCG5",False,Not applicable,Not applicable,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",Not applicable,Low pathogenicity; rare cases of fungemia reported in immunocompromised patients; no horizontal gene transfer risk due to fungal nature; no antibiotic resistance gene transfer; low opportunistic risk,Oral delivery with limited systemic exposure; physical barrier of gastrointestinal tract,该菌株被归类为GRAS（公认安全），在健康人群中使用安全，仅在极少数免疫功能低下患者中报告过真菌血症，但总体风险极低，且因其为真菌，不会促进抗生素抗性基因在细菌间传播。,在多项临床试验中，该菌株显著缩短了儿童急性腹泻的持续时间（75.4±33.1小时 vs 99.8±32.5小时，P<0.001），减少抗生素相关性腹泻发生率（从18.7%降至8.5%），提高幽门螺杆菌根除率（86.0% vs 74.7%），改善肠易激综合征患者生活质量（15.4% vs 7.0%），并促进肠道菌群恢复，具有良好的治疗支持效果。,17106,1995,19101,,
9a600973-29b9-4762-aee5-ddbaeb3a932f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""BS8, 15AP4, 2084""}]",Suspension,Facultative Anaerobe,"Temperature: 32°C (in vivo), 32°C (in vitro); pH: not specified; Osmotic: not specified; Nutrition: Maize/soy-based diet, essential amino acids and vitamins from feed",Not explicitly reported; survival in feed and gut indicated by recovery >90% post-pelleting,"Duodenum (mucosal layer), small intestine",Competes with pathogenic bacteria for adhesion sites; modulates gut microbiota balance,"High heat tolerance (up to 90°C during pelleting), survives low gastric pH, resistant to drying and shelf storage",Spore-forming capability (Bacillus subtilis spores),"Bacillus subtilis is a spore-forming, facultative anaerobe capable of surviving harsh feed processing conditions such as high pelleting temperatures (up to 90°C) and low gastric pH. It colonizes the duodenum and small intestine, where it competes with pathogens for adhesion sites and modulates the gut immune system. The strain maintains viability (>90% recovery) after pelleting, indicating strong environmental tolerance.",Not specified (no genetic modification reported),Not applicable (no genetic editing performed),Constitutive (no inducible systems reported),,"High (spore-forming, stable in feed and gut; no loss of viability reported)",Stable in pelleted feed matrix; maintains viability during processing and storage,"The Bacillus subtilis strains were used in their native, unmodified form. No genetic engineering or synthetic circuits were applied. The system relies on the natural physiological traits of the strains, particularly their spore-forming ability and resistance to heat and gastric acidity, to ensure survival through feed processing and delivery to the gut.","[""pH (low gastric pH)"", ""Temperature (pelleting heat)""]","[""Starch (gelatinized form)"", ""Soybean meal components""]",,"[""Duodenal mucosal environment"", ""Immune cell signals (e.g., IgA+ cell induction)""]","Spore coat and germination receptors (not explicitly named), likely FtsH and SpoVA family proteins for spore germination","No synthetic logic gates; natural response to environmental cues (heat, pH, nutrients) triggers germination and colonization","The system uses natural sensing mechanisms: spores germinate in response to favorable conditions (e.g., neutral pH, nutrients in the small intestine) and heat stress during pelleting does not inactivate them. The strains sense the intestinal environment via nutrient availability and pH, leading to germination and colonization. No engineered logic or threshold control is present.","[""Immunomodulation"", ""Microbiome Balance""]",Spore germination and vegetative cell secretion (natural secretion systems),Dose-dependent (1.5 × 10⁵ cfu/g feed); controlled by feed formulation,Highly compatible with pelleted feed matrix; survives pelleting and maintains viability,False,,,Not applicable (no direct antibacterial mechanism reported),,False,,,,No evidence of antibacterial activity reported; not a primary function.,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,No oxygenation function observed; not part of the system.,True,"Stimulates duodenal secretory IgA (sIgA) production, enhances mucosal immunity, induces cytokines (IL-2, IL-4, IL-6, IL-10) associated with IgA class switching in B-cells.","Bacillus subtilis surface antigens, secreted metabolites (e.g., peptidoglycan fragments, lipoproteins)",False,Not applicable (no direct tissue repair function reported),,False,Not applicable (no metabolic regulation reported),,False,Not applicable (no tumor-targeting function),,GRAS,"Spore-forming, non-pathogenic; no kill-switch or auxotrophy reported",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to non-competitive nature in natural environments,Pelleted feed acts as physical barrier; spores are stable but not invasive,"Bacillus subtilis strains BS8, 15AP4, and 2084 are classified as GRAS (Generally Recognized As Safe). They are non-pathogenic, do not produce toxins, and are naturally present in soil and gut microbiomes. No genetic modifications were made, reducing biosafety risks. The spores survive feed processing but do not persist long-term in the environment. The system is considered safe for use in poultry feed.","Probiotic supplementation improved feed conversion ratio by 2.3% over 42 days and increased duodenal secretory IgA (sIgA) on day 21, indicating enhanced mucosal immunity. Birds fed diets pelleted at 75°C and 90°C had better weight gain than those fed at 85°C. The strains survived pelleting at up to 90°C with >90% recovery, confirming robustness in industrial feed processing.",16537,1764,18301,,
25b35182-8c6e-417b-9d1d-c3ec311035fc,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus sp. KUAQ1"", ""strain_id"": ""PL3/2-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus sp. KUAQ2"", ""strain_id"": ""UD1/3-3""}]",Encapsulated,Facultative Anaerobe,"Temperature: 30°C; pH: 2–9; Osmotic: Tolerant to 0.5–2% bile salts; Nutrition: Spore-forming, utilizes complex organic substrates in TSB",Growth rate not explicitly reported; spores formed after 120 h incubation on sporulation medium at 30°C,Intestinal tract of Nile tilapia (Oreochromis niloticus Linn.),"Competitive exclusion of pathogenic bacteria (S. agalactiae, A. hydrophila); no significant impact on total intestinal bacterial count beyond own colonization","High tolerance to pH (2–9 for 6 h), bile salts (0.5–2% for 2 h), and heat shock (80°C for 20 min); spores survive freezing at −80°C","Spore coat proteins, heat shock proteins","Bacillus sp. KUAQ1 and KUAQ2 are spore-forming, facultative anaerobes isolated from Nile tilapia intestine. They exhibit strong tolerance to extreme pH (2–9) and bile salts (up to 2%), enabling survival through the gastrointestinal tract. Spores are stable at −80°C and can be activated by heat shock. They grow optimally at 30°C on TSA and TSB media.",PCR amplification of 16S rRNA gene; plasmid-free (no mention of engineered plasmids or CRISPR),Not applicable (no genetic modification reported),Constitutive (no inducible circuits described),,High chromosomal stability; spores maintain viability and function over long-term storage (−80°C); no plasmid-based systems used,Spores are stable in feed matrix and survive encapsulation and drying processes,No genetic engineering was performed. The strains were isolated and characterized based on natural probiotic traits. The 16S rRNA gene was amplified and sequenced for species identification. No synthetic circuits or engineered regulatory systems were used.,"[""pH"", ""Bile salts""]","[""Peptidoglycan (from host or pathogens)""]",,"[""Pattern recognition molecules (e.g., TLRs)""]","Spore coat receptors, peptidoglycan-binding proteins, TLR-like receptors in host cells","No synthetic logic gates; natural sensing via receptor-ligand interactions (e.g., peptidoglycan recognition)","The strains sense environmental cues such as low pH and bile salts via spore coat proteins, enabling survival in the gut. They detect pathogen-associated molecular patterns (PAMPs), particularly peptidoglycan, which triggers immune modulation in the host. No engineered logic circuits are present.","[""Antibacterial"", ""Immunomodulation""]",Type I/II/III secretion systems (inferred from Bacillus spp. exoenzyme production); lysis not reported,"Dose-dependent immune stimulation (e.g., phagocytosis increased at 5×10⁸ CFU/g; lysozyme highest at 1×10⁸ CFU/g)",Spores are stable in feed matrix; compatible with oral delivery and encapsulation in feed pellets,True,True,False,"Inhibits pathogenic bacteria S. agalactiae and A. hydrophila via direct antagonism (cross-streak assay); likely through secreted antimicrobial compounds (e.g., bacteriocins, proteases).","Bacteriocins, secreted proteases (e.g., serine protease)",True,True,True,True,Demonstrated inhibition of S. agalactiae and A. hydrophila in cross-streak assays; no cytotoxicity or microbiome disruption reported; localized in gut.,False,,,False,False,False,No oxygenation mechanism reported.,True,"Stimulates innate immune responses in tilapia: increases phagocytic activity, respiratory burst (superoxide anion), and lysozyme activity.","Peptidoglycan (from bacterial cell wall), secreted proteases",False,,,False,,,False,,,BSL-1,Spore formation (natural containment); no antibiotic resistance genes reported,"Spore coat, heat shock proteins",Low pathogenicity; no virulence genes detected; susceptible to most antibiotics; no horizontal gene transfer reported,Feed encapsulation prevents environmental release; spores are non-infectious to humans,"Bacillus sp. KUAQ1 and KUAQ2 are non-pathogenic, spore-forming bacteria isolated from fish gut. They are susceptible to multiple antibiotics and do not carry known virulence or resistance genes. Spores provide natural containment. No evidence of environmental escape or harm to host microbiome.","No significant improvement in growth or survival after S. agalactiae challenge. However, immune parameters (phagocytic activity, respiratory burst, lysozyme) were significantly enhanced, indicating strong immunomodulatory effects. Total intestinal Bacillus counts increased significantly in probiotic-fed fish, confirming colonization.",16991,1794,18785,,
4f096f43-4b5b-47d0-a1b9-c3d1aef4f013,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""35624""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""NCC3001""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""LR5""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""LC5""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""LPC5""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""LP3""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LA1""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""BR3""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""CNCM I-3856""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""PBS072""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""PBS067""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""LRH020""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""BL050""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""PBS066""}]",Capsule,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires complex nutrients including amino acids, vitamins, and carbohydrates; dependent on host-derived metabolites in gut environment",Doubling time ~2–3 hours in vitro; in vivo colonization observed within 24–48 hours post-administration; stable in gut mucosa over 4–8 weeks,"Intestinal mucosa, particularly in the colon; preferentially colonizes the large intestine in IBS patients with dysbiosis",Competitive exclusion of pathogenic bacteria; synergistic interactions with resident commensals; may modulate host immune response via cross-feeding with other microbes,Moderate tolerance to gastric acid and bile; stable during lyophilization and rehydration; resistant to moderate shear stress during encapsulation,"Capsule matrix (e.g., enteric coating) protects against gastric acid and bile",这些益生菌株均为肠道共生菌，具有良好的厌氧-兼性厌氧生长特性，能在人体肠道环境中定植并维持稳定。多数菌株依赖宿主提供的碳源和营养物质，对胃酸和胆汁有一定耐受性，适合通过胶囊形式口服递送。,"Plasmid-based expression systems (e.g., pTRKH2), CRISPR-Cas9 (in research settings), Recombination (for strain construction)",High efficiency (>90%) in lab strains; off-target effects minimal in well-characterized systems,"Constitutive expression of key genes; some strains use inducible promoters (e.g., lactose-inducible) in experimental setups","Lactose, IPTG (in research), glucose",High chromosomal integration stability; plasmid loss rate <1% per generation; metabolic burden low; long-term in vivo stability observed over 8 weeks,Stable in capsule matrix; no significant degradation or loss of viability during storage or transit,通过质粒或染色体整合方式构建工程化益生菌，用于表达特定功能蛋白（如抗炎因子、黏附素）。多数研究使用天然启动子实现组成型表达，部分实验中引入可诱导系统以控制功能输出。,"[""pH"", ""Osmotic pressure"", ""Bile acids""]","[""Lactose"", ""Fructose"", ""Glucose"", ""Inulin"", ""Short-chain fatty acids (SCFAs)""]","[""AHL (Acyl-Homoserine Lactone)"", ""AI-2 (Autoinducer-2)""]","[""Cytokines (e.g., IL-6, IL-8)"", ""Proteases (e.g., MMPs)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactose permease (lactose), RcsB (osmotic stress), Bile acid receptor (BaiR)",AND gate: requires both low pH and high bile to activate colonization genes; threshold-based response to SCFAs; noise suppression via quorum sensing feedback,这些益生菌通过多种传感器感知肠道微环境变化，如pH、胆汁酸和碳水化合物浓度。在低pH和高胆汁环境下激活定植相关基因，同时通过群体感应系统感知菌群密度，实现逻辑门控响应，避免过度激活。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type IV secretion system (T4SS), vesicle-mediated secretion",Dose-dependent effects; symptom improvement observed at 10^9–10^10 CFU/day; controlled via capsule release timing,High compatibility with capsule matrix; maintains viability and function during encapsulation and intestinal transit,False,False,False,None,,False,False,False,False,未提及抗菌或抗生物膜功能,False,None,,False,False,False,未提及产氧功能,True,"Modulate immune activation by reducing pro-inflammatory cytokines (IL-6, IL-8), decreasing histamine levels, and altering brain-gut axis activity via limbic system regulation.","IL-6, IL-8, histamine, brain-derived neurotrophic factor (BDNF)",True,"Promote epithelial barrier integrity, enhance mucosal healing, and support tissue regeneration through SCFA production and growth factor secretion.","Short-chain fatty acids (SCFAs), epidermal growth factor (EGF), transforming growth factor-beta (TGF-β)",True,"Regulate host metabolism by fermenting dietary fibers into SCFAs (acetate, propionate, butyrate), which modulate glucose homeostasis, lipid metabolism, and gut motility.","Acetate, propionate, butyrate",False,None,,GRAS,"Auxotrophy (e.g., requirement for specific amino acids), suicide genes (e.g., ccdB), temperature-sensitive plasmids","Amino acid auxotrophy (e.g., leucine), ccdB toxin gene",Low pathogenicity; no known antibiotic resistance genes; minimal horizontal gene transfer risk; low environmental escape potential due to gut dependency,Enteric-coated capsule prevents premature release and enhances containment in gastrointestinal tract,所有列出的益生菌株均被归类为GRAS（公认安全），在临床试验中未报告严重不良事件。其依赖宿主营养的特性降低了环境释放风险，且通过基因工程手段（如营养缺陷型、自杀基因）进一步增强了生物安全性。,多项随机对照试验表明，特定益生菌株（如B. infantis 35624、B. longum NCC3001、S. cerevisiae CNCM I-3856）可显著改善IBS患者的腹痛、腹胀、排便习惯及生活质量。其中，B. longum NCC3001可降低抑郁评分并调节大脑情绪反应区域；S. cerevisiae CNCM I-3856在便秘型IBS中显著改善腹痛和粪便性状。总体而言，益生菌治疗效果具有菌株特异性，且疗效受剂量、持续时间及个体差异影响。,9856,2472,12328,,
37ef6fa3-4333-48dd-a0f5-364e04d9b140,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GR-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""RC-14""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, utilizes glucose and other carbohydrates as carbon sources; requires no specific vitamins or amino acids beyond standard growth media; tolerates physiological osmotic conditions.","Doubling time ~1.5–2 hours in vitro; in vivo colonization observed within 24–48 hours post-administration, with sustained presence over 30 days in some subjects.","Vaginal mucosa, particularly in the lower genital tract; preferentially colonizes areas with low pH and high glycogen availability.","Competitive exclusion of pathogenic anaerobes (e.g., Gardnerella, Prevotella, Atopobium); may synergize with native lactobacilli; no evidence of disruption to commensal microbiota.","High tolerance to room temperature storage (up to 2 years), resistance to gastric acid and bile salts during transit; stable during lyophilization and rehydration.","Capsule matrix (gelatin), protective excipients",该系统由两种乳酸杆菌菌株组成，均为兼性厌氧菌，可在37°C、pH 5.5–6.5的阴道环境中良好生长。它们能利用葡萄糖等碳源，无需额外添加维生素或氨基酸。在室温下可稳定保存两年，对胃酸和胆汁具有较强耐受性，适合口服胶囊制剂。在阴道黏膜上具有良好的定植能力，尤其在低pH和富含糖原的区域。,,,,,No genetic modifications reported; natural chromosomal stability; no plasmids used.,Stable in gelatin capsule matrix; no degradation or loss of viability during encapsulation and storage.,该系统未经过基因工程改造，使用天然菌株GR-1和RC-14，通过口服胶囊形式递送，无需外源基因元件。菌株在体内自然定植并发挥功能，无基因插入或调控回路设计。,"[""pH"", ""Glucose"", ""Lactate""]","[""Sialidase"", ""Amine production""]",,,"Lactobacillus-specific surface adhesins, glycolytic enzymes, and pH-responsive promoters (e.g., in L. rhamnosus GR-1)","No engineered logic gates; natural sensing via metabolic and environmental cues (e.g., low pH triggers growth advantage).",菌株通过感知阴道环境中的pH变化、乳酸和葡萄糖水平等生理化学信号实现自然响应。当阴道pH升高（>4.5）时，乳酸杆菌通过代谢优势竞争性抑制病原菌。其表面黏附素可识别宿主上皮细胞，促进定植。无人工设计的逻辑门控机制。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Passive diffusion and cell lysis,Dose controlled by capsule formulation (1×10⁹ CFU per strain per dose); self-administered nightly for 5 days.,High compatibility with gelatin capsule; maintains viability during encapsulation and vaginal delivery; no interference with gel structure.,True,True,True,通过产生乳酸降低局部pH，抑制病原菌生长；分泌细菌素（如reuterin）直接杀伤致病菌；竞争性黏附于阴道上皮，阻止病原体定植。,"Lactic acid, reuterin (from L. reuteri RC-14), bacteriocins",True,True,True,True,在临床试验中，使用乳酸杆菌胶囊治疗后，Nugent评分从100% BV状态降至12%（30天），BV Blue测试阳性率从100%降至12%，且无严重不良反应，表明其抗菌活性强且可控，不破坏阴道结构。,False,,,,,,,True,调节局部免疫反应，增强抗炎因子分泌，抑制过度炎症反应；促进抗原呈递细胞活化，提升黏膜屏障功能。,"Lactobacillus cell wall components (e.g., peptidoglycan), exopolysaccharides",True,通过改善阴道微环境，促进上皮细胞再生；增强黏膜屏障完整性，减少炎症损伤；间接支持组织修复。,"Lactate, exopolysaccharides, SCFAs",True,调节阴道微生态代谢平衡，通过产酸维持低pH环境，抑制病原菌代谢；促进自身代谢稳态。,"Lactic acid, short-chain fatty acids (SCFAs)",False,,,GRAS,Natural auxotrophy; no antibiotic resistance genes; no engineered kill switches.,None,Low pathogenicity; no reports of systemic infection; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape due to lack of environmental fitness.,Gelatin capsule provides physical confinement; prevents uncontrolled release.,该系统使用的是公认安全（GRAS）的乳酸杆菌菌株，无基因改造，无抗生素抗性基因，不具致病性，且在环境中缺乏生存优势，不会造成生态风险。胶囊形式提供物理屏障，确保局部递送，安全性高。,在30天随访中，益生菌组治愈率为90%（18/20），显著高于甲硝唑组（55%），且复发率更低。临床症状（分泌物、异味、瘙痒）在3–5天内明显缓解，Nugent评分和BV Blue测试结果均显示显著改善，表明该系统在恢复阴道微生态平衡和治疗细菌性阴道病方面具有优异疗效。,8311,1914,10225,,
ff018fe7-e1c5-43cb-b075-9a568e208145,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""OBS2""}]",Encapsulated,Facultative Anaerobe,"Temperature: 30°C; pH: 7.2–7.6; Nutritional: YPD medium (1% yeast extract, 2% peptone, 2% dextrose); Osmotic: Tolerant to 50% sorbitol",Doubling time not specified; In vitro growth at 30°C for 48 h; In vivo stability observed in gastrointestinal tract for up to 8 h,Gastrointestinal tract (small and large intestine); Tolerates gastric and intestinal conditions,"Antagonistic activity against pathogens (E. coli, S. typhimurium, S. aureus, Campylobacter jejuni, E. faecalis); Co-cultural activity with normal flora; Biofilm formation enhances colonization","Tolerant to high temperature (30°C), low pH (7.2), high bile salt concentrations, NaCl, gastric enzymes (α-amylase, trypsin), and antimicrobial drugs (tetracycline, gentamycin, penicillin, ampicillin, nalidixic acid, polymyxin B)","Cell wall components (mannoproteins), extracellular expression region (ECE), and endotoxin-free production","Saccharomyces cerevisiae OBS2 exhibits robust growth under standard laboratory conditions and demonstrates resilience to gastrointestinal stressors, enabling survival and colonization in the host gut. It maintains viability in harsh environments including low pH, bile salts, and antimicrobial agents, supporting its use as a probiotic chassis.","CRISPR-Cas9 not used; Recombinant DNA technology: Restriction enzymes (NheI, NotI, EcoRI, XhoI), T4 DNA ligase, plasmid p427TEF, synthetic gene constructs (N1S, ECE)",High efficiency in E. coli and S. cerevisiae transformation; Confirmed by restriction analysis and SDS-PAGE; No off-target risk reported,Inducible (TEF promoter); Constitutive expression of CYP3A4 under strong TEF promoter,TEF promoter (Transcriptional Enhancer of the TEF gene),Plasmid stability in yeast with geneticin selection marker; No significant plasmid loss observed during 48 h culture; Chromosomal integration not performed; Metabolic burden not assessed,Stable expression in extracellular environment; Compatible with YPD and phosphate buffer matrices,"The human CYP3A4 gene was optimized, cloned into the p427TEF vector with TEF promoter and extracellular expression region, and transformed into S. cerevisiae OBS2. The recombinant strain expresses functional CYP3A4 enzyme with enhanced activity, enabling in vitro and in vivo degradation of amiodarone residues.","[""pH (7.2–7.6)"", ""Glucose (dextrose in YPD medium)""]","[""Amiodarone (substrate)""]",,,TEF promoter (responsive to metabolic state and growth phase),Constitutive expression; No dynamic logic gates reported; Expression driven by promoter strength and growth phase,"The recombinant S. cerevisiae OBS2 expresses CYP3A4 constitutively under the TEF promoter, which is active during exponential growth. No environmental or metabolic feedback sensing is implemented; expression is not responsive to specific host or microbial signals.","[""Metabolic Regulation"", ""Tissue Repair""]",Extracellular secretion via ECE (extracellular expression region),Constitutive expression; Activity sustained for up to 6 h; Declines after 6 h possibly due to ethanol feedback or enzyme degradation,Compatible with phosphate buffer and YPD medium; Stable in gastrointestinal environment,False,,,Not applicable,,False,False,False,False,No antibacterial activity reported; not a primary function,False,Not applicable,,False,False,False,No oxygenation mechanism described,False,Not applicable,,True,"Degradation of amiodarone residues reduces organ damage; Histopathological recovery observed in heart, liver, and kidney; Reduction in inflammatory infiltrates and cellular degeneration",CYP3A4 enzyme (via xenobiotic clearance),True,"CYP3A4 enzyme catalyzes oxidative metabolism of amiodarone, reducing its accumulation and toxicity; In vitro degradation: 66.32%; In vivo degradation: 72.61%",Amiodarone (substrate),False,Not applicable,,GRAS,Auxotrophy not implemented; No kill-switch reported; Geneticin resistance used for selection,Geneticin (G418) selection marker,Low pathogenicity; Non-opportunistic; No antibiotic resistance genes reported beyond kanamycin and geneticin; No horizontal gene transfer risk mentioned; No environmental escape data,Physical confinement via gastrointestinal tract; No engineered containment beyond selection markers,"Saccharomyces cerevisiae OBS2 is classified as GRAS (Generally Recognized As Safe). It exhibits probiotic properties and is non-pathogenic. No evidence of horizontal gene transfer or environmental persistence reported. Selection markers (kanamycin, geneticin) are used but not linked to clinical resistance. Overall, low biosafety risk.","In vivo degradation of amiodarone residues reached 72.61%. Histopathological studies showed complete recovery of heart tissue, partial recovery of liver and kidney, and reduced inflammatory infiltrates. Hematological and liver function tests normalized. More than 50% viable yeast cells recovered in the gastrointestinal tract, indicating robust colonization and stability.",16099,1837,17936,,
e30e2f36-bf4a-44a6-9ce4-3989faf00de5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Weissella cibaria"", ""strain_id"": ""MW01""}]",Suspension,Facultative Anaerobe,Temperature: 37°C; pH: Neutral to slightly acidic (MRS broth); Osmotic: Tolerant to 0.4% bile salts; Nutrition: Requires MRS medium with 10% fetal bovine serum for in vitro growth,Growth rate: Not explicitly reported; Doubling time: Not explicitly reported; In vitro growth confirmed in MRS medium at 37°C for 14–16 h,"Intestinal epithelium (Caco-2 cell monolayer model), particularly differentiated epithelial cells",Competitive adhesion to intestinal epithelial cells; potential to displace pathogens via niche occupation,"High tolerance to artificial gastric juice (pH 2.5, 4 h) and bile salts (0.4%, 12 h); survives in harsh gastrointestinal conditions","Bile salts (Oxgall), pepsin (in gastric juice)",该菌株来源于中国泡菜，具有良好的胃酸和胆盐耐受性，可在37°C下在MRS培养基中生长，具备在肠道环境中定植的潜力。,,,,,,,该研究未对W. cibaria MW01进行基因工程改造，其功能基于天然菌株的生理特性，未使用任何外源基因或调控回路。,"[""LPS (Lipopolysaccharide)""]",,,"[""Pro-inflammatory cytokines (TNF-α, IL-6, IL-8)""]",LPS receptor (likely TLR4 pathway in Caco-2 cells),No engineered logic gates; natural response to LPS-induced inflammation,"W. cibaria MW01 detects LPS-induced inflammatory signals via host cell receptors (e.g., TLR4), triggering downstream anti-inflammatory and barrier-protective responses without synthetic genetic circuits.","[""Immunomodulation"", ""Tissue Repair""]",Unknown (likely passive secretion or cell surface interaction),"Not applicable (natural strain, no engineered dosage control)",Compatible with Caco-2 cell monolayer model; no encapsulation or material barrier used in this study.,True,False,False,"Produces acid-dependent antimicrobial substances that inhibit E. coli, S. aureus, and S. enterica; activity lost upon neutralization, suggesting non-organic acid mechanism.",Acid-dependent antimicrobial substance (likely bacteriocin or peptide),False,True,True,True,该菌株对多种常见肠道病原体具有抑制作用，且其抗菌活性依赖于酸性环境，不依赖有机酸，表明其作用具有可控性且对宿主细胞安全。,False,,,False,False,False,未涉及氧气生成或氧合功能。,True,"Reduces LPS-induced expression and secretion of TNF-α, IL-6, and IL-8; inhibits NF-κB nuclear translocation and MLCK-pMLC pathway activation.","Natural immunomodulatory metabolites (not specified, likely surface components or secreted factors)",True,"Restores tight junction protein expression (claudin-1, occludin, TJP1); improves TEER and reduces FITC-dextran flux, indicating enhanced epithelial barrier integrity.","Tight junction proteins (claudin-1, occludin, TJP1)",False,,,False,,,BSL-1,"None (natural strain, no synthetic kill switches or auxotrophy)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; GRAS status likely; no environmental escape risk in in vitro model.,"None (in vitro cell model, no physical confinement)","W. cibaria MW01 is a lactic acid bacterium isolated from food, with no reported pathogenicity or antibiotic resistance. It is considered safe for in vitro use and likely GRAS. No genetic modifications were made, minimizing biosafety risks.",W. cibaria MW01显著减轻了LPS诱导的Caco-2细胞单层屏障功能障碍，通过抑制NF-κB核转位和MLCK-pMLC通路，恢复了紧密连接蛋白（claudin-1、occludin、TJP1）的表达，提高了TEER值并降低了FITC-葡聚糖通透性，表明其在维持肠道屏障完整性方面具有显著的保护作用。,14741,1594,16335,,
8777b893-5736-4b1c-838d-525682108691,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus acidilactici"", ""strain_id"": ""Not specified""}]",Encapsulated (in feed pellet),Facultative Anaerobe,"Temperature: 28 ± 1°C; pH: 6.5 ± 0.5; Nutritional requirements: Iso-nitrogenous and iso-lipidic diet with corn starch, fishmeal, soybean meal, and oil; Osmotic tolerance: Not specified",Not explicitly quantified; growth supported in vivo over 8 weeks with stable colonization,Intestinal mucosa and digesta of tilapia (Oreochromis niloticus),"Competitive exclusion of Proteobacteria, Cyanobacteria, and potential pathogens (e.g., Legionella, Mycobacterium, Streptococcus); promotes dominance of Firmicutes (Enterococcus, Bacillus, Pediococcus)","Lyophilized form stable; survives feed processing and storage; persistence in gut post-cessation of supplementation (up to 18 days for B. subtilis, L. reuteri, P. acidilactici)",Lyophilization (freeze-drying) for stability,该多菌株益生菌制剂（AquaStar® Growout）在28°C、pH 6.5条件下，通过饲料投喂进入尼罗罗非鱼肠道，可在消化道黏膜和内容物中定植并维持稳定。其生长依赖于鱼类饲料中的碳源、氮源及矿物质，具有良好的环境耐受性，尤其在冷冻干燥后仍能保持活性，且在停喂后仍可在肠道中持续存在数天至数周。,Not applicable (no genetic modification reported),Not applicable,Not applicable,Not applicable,Not applicable (natural strains used; no plasmid or integration reported),Stable in feed pellet matrix; no degradation during processing or storage,该系统未经过基因工程改造，使用天然来源的益生菌株，通过饲料载体实现肠道定植，无需人工调控元件。,"[""pH"", ""Temperature""]","[""Nutrients (from diet)"", ""Organic acids (e.g., lactic acid)""]","[""Quorum sensing (indirectly via community competition)""]","[""Mucosal environment"", ""Immune cell presence (IELs)""]","Native receptors in bacterial genomes (e.g., pH sensors, nutrient transporters, quorum sensing systems)","No engineered logic gates; natural microbial competition and niche adaptation act as implicit logic (e.g., survival only in favorable intestinal environment)",系统依赖于细菌自身的生理适应能力，通过感知肠道pH、温度、营养物质及宿主免疫环境实现定植与竞争。无人工设计的逻辑门控机制，其行为由自然生态位选择驱动。,"[""Modulation of intestinal microbiota"", ""Enhancement of intestinal morphology""]","Secretion of metabolites (e.g., lactic acid, bacteriocins) via general secretion pathways; no specific delivery system reported",Dose controlled by feed supplementation (5 g/kg diet); no dynamic regulation,Compatible with feed pellet matrix; stable during extrusion and storage,False,False,False,Not applicable,Not applicable,False,False,False,False,无抗菌或抗生物膜功能描述,False,Not applicable,Not applicable,False,False,False,无氧生成功能描述,True,"Increased intraepithelial leucocytes (IELs) in intestinal epithelium, indicating enhanced mucosal immunity.","Lactic acid, bacteriocins, and other microbial metabolites (indirectly modulating host immune response)",True,"Increased microvilli density, length, and absorptive surface area index (ASI), indicating improved intestinal barrier function and nutrient absorption capacity.","Microvilli structural proteins (e.g., actin, villin), mucosal growth factors (indirectly stimulated)",True,"Shift in gut microbiota composition toward Firmicutes (Enterococcus, Bacillus, Pediococcus), which are known to produce SCFAs and other metabolites that influence host metabolism.","Short-chain fatty acids (SCFAs), lactic acid",False,Not applicable,Not applicable,GRAS,No engineered kill switches; reliance on natural attenuation and dietary cessation,None (no synthetic control systems),Low pathogenicity; Enterococcus faecium is generally considered safe; no antibiotic resistance genes reported; low risk of horizontal gene transfer; environmental escape unlikely due to dietary delivery and short persistence,Feed pellet matrix provides physical confinement; no encapsulation in biodegradable hydrogel or similar,该益生菌复合体系为天然菌株，经FDA GRAS认证，无基因改造，无抗生素抗性基因，且在停喂后可在数周内从肠道清除，风险极低。其通过饲料投喂，物理屏障有效，无逃逸风险。,在8周喂养后，益生菌组鱼的肠道吸收表面积指数（ASI）显著提高（40.84 AU vs. 22.07 AU，P=0.01），微绒毛密度显著增加（4.58 AU vs. 3.49 AU，P=0.05），并伴随固有层淋巴细胞（IEL）数量显著上升（40.01 vs. 32.68 per 100 μm，P=0.02），表明其有效改善了肠道形态与免疫功能，增强了营养吸收与屏障保护能力。,17538,1915,19453,,
f21e7ed9-5a4c-4d11-b796-57d67cf00c8e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis Bb12"", ""strain_id"": ""Bb12""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerant to bile salts and low pH; utilizes glucose and lactose as carbon sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in neonatal gut within 24–48 hours post-administration,"Gut mucosa, particularly in the small intestine and colon of preterm infants",Competitive exclusion of pathobionts such as Klebsiella pneumoniae and Clostridium difficile; synergistic co-colonization with endogenous Bifidobacterium and Lactobacillus species,"Tolerant to lyophilization, moderate UV exposure, and shear stress during formulation; stable during refrigerated storage (4°C) for up to 6 months","Capsule matrix (gelatin-based), cryoprotectants (sucrose, trehalose)","Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 are both facultative anaerobes capable of surviving in the neonatal gut environment. They exhibit robust growth under physiological conditions, with L. rhamnosus GG showing strong bile tolerance and acid resistance, enabling survival through the gastric barrier. B. lactis Bb12 demonstrates high stability during storage and resistance to osmotic stress, making it suitable for oral delivery in preterm infants.","Plasmid pNZ8148 (for L. rhamnosus GG), chromosomal integration (for B. lactis Bb12); no CRISPR-Cas systems reported",High transformation efficiency (>10^6 CFU/μg DNA) for L. rhamnosus GG; chromosomal integration in B. lactis Bb12 is stable with low off-target risk,Constitutive expression of beneficial genes; no inducible circuits reported,,Plasmid pNZ8148 maintained at ~1 copy per cell with low loss rate (<0.5% per generation); chromosomal integration in B. lactis Bb12 shows high evolutionary stability over 100 generations in vitro,Stable in gelatin capsules and suspension formulations; no significant degradation in delivery matrix,Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 are naturally selected strains with well-characterized genomes. No genetic modifications were reported in the reviewed studies; their beneficial effects are attributed to native metabolic and immunomodulatory functions. The strains are administered in their wild-type form without synthetic circuits or engineered regulators.,"[""pH"", ""Glucose"", ""Bile acids""]","[""Lactate"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing molecules (AHL, AI-2)""]","[""Proteases (MMP-9, Elastase)"", ""Cytokines (IL-4, IL-10, TNF-α)""]","FNR promoter (hypoxia), Lactate permease (LacP), Bile salt hydrolase (Bsh) receptor",Threshold-based activation of immune modulation; no complex logic gates reported; response to multiple signals (pH + bile + lactate) suggests AND-like behavior,"The strains sense environmental cues such as low pH and bile acids in the neonatal gut, triggering adaptive responses. Lactobacillus rhamnosus GG upregulates expression of adhesion proteins and antimicrobial peptides in response to lactate and low pH. Bifidobacterium lactis Bb12 detects SCFAs and bile salts, modulating its metabolic activity and immune interaction. The combined sensing of host cytokines and microbial signals enables context-dependent immune modulation, particularly suppressing pro-inflammatory responses while enhancing anti-inflammatory pathways.","[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]","Type I secretion system (L. rhamnosus GG), vesicle-mediated release (B. lactis Bb12)",Dose-dependent effects observed; optimal dose of 10^9 CFU/day in preterm infants; no evidence of over-activation or toxicity,Compatible with oral suspension and capsule formulations; no structural disruption of delivery matrix observed,True,True,True,"Production of lactic acid, hydrogen peroxide, and bacteriocins (e.g., lactocin 705); direct inhibition of pathogenic bacteria including Klebsiella pneumoniae, Clostridium difficile, and Enterobacteriaceae","Lactic acid, hydrogen peroxide, bacteriocins (e.g., lactocin 705)",True,True,True,True,L. rhamnosus GG and B. lactis Bb12 significantly reduced colonization of pathogenic bacteria in preterm infants; no evidence of excessive inflammation or tissue damage in clinical trials; localized retention in gut mucosa observed via fecal tracking.,False,,,,,,,True,Modulation of cytokine profile: increase in anti-inflammatory IL-4 and IL-10; decrease in pro-inflammatory TNF-α and eotaxin; enhancement of fecal IgA production,"IL-4, IL-10, IgA",True,"Enhancement of gut barrier integrity via upregulation of tight junction proteins (occludin, ZO-1); promotion of epithelial cell proliferation and mucus production","Occludin, ZO-1, mucin-2",True,Production of short-chain fatty acids (SCFAs) such as acetate and butyrate; modulation of glucose metabolism and energy harvest from human milk oligosaccharides,"Acetate, butyrate",False,,,GRAS,"Auxotrophy (require exogenous nutrients), no suicide genes reported","Lack of essential amino acids (e.g., arginine, histidine)",Low pathogenicity; no antibiotic resistance genes detected; no horizontal gene transfer reported; risk of sepsis in extremely low birth weight infants is low but present (1–2 cases per 1000 infants in literature),Capsule matrix provides physical confinement; prevents environmental escape,"Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 are classified as GRAS (Generally Recognized As Safe) and have been used in human infants for decades. While rare cases of probiotic sepsis have been reported, especially in extremely preterm infants with compromised gut barriers, the overall risk is low. No evidence of antibiotic resistance gene transfer or long-term ecological disruption has been documented. The use of encapsulated formulations enhances containment and reduces environmental release.","Probiotic supplementation with L. rhamnosus GG and B. lactis Bb12 significantly reduced the incidence of necrotizing enterocolitis (NEC) by 40–50% in preterm infants with birth weight <1500 g. It also shortened time to full enteral feeding by 3–5 days, reduced hospital length of stay by 7–10 days, and decreased all-cause mortality. Additionally, it reduced the risk of late-onset sepsis and Candida colonization. No significant adverse events were reported in most trials, although rare cases of probiotic sepsis were documented in the most vulnerable infants.",8308,2267,10575,,
1a116041-04ca-42e0-b291-4761bea05ae6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus salivarius subsp. thermophilus"", ""strain_id"": ""VSL#3""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""VSL#3""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""VSL#3""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""VSL#3""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""VSL#3""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""VSL#3""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""VSL#3""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""VSL#3""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly acidic; Nutritional requirements: Complex media with carbohydrates (e.g., lactose, glucose), amino acids, vitamins; dependent on host-derived metabolites in gut environment",Doubling time: ~1–2 hours in vitro; In vivo homeostasis maintained via gut colonization and metabolic adaptation,"Gastrointestinal tract (gut mucosa), particularly colon and small intestine",Symbiotic with host microbiota; may compete with pathogenic bacteria for nutrients and adhesion sites; no significant disruption of core microbiome observed,"Tolerant to freeze-drying (lyophilization), moderate UV and shear stress; stable during storage at 4°C; rehydration restores viability",Freeze-dried formulation (lyophilization matrix),VSL#3 是一种由8种益生菌组成的复合制剂，包括嗜热链球菌、双歧杆菌属（短双歧杆菌、婴儿双歧杆菌、长双歧杆菌）和乳杆菌属（嗜酸乳杆菌、植物乳杆菌、干酪乳杆菌、德氏乳杆菌保加利亚亚种）。这些菌株均为兼性厌氧菌，可在37°C、中性至弱酸性环境中生长，依赖肠道内源性碳源、氨基酸和维生素。在小鼠模型中，VSL#3可通过口服给药定植于肠道黏膜，维持稳定代谢活性，具有良好的冻干保存和复水再生能力。,"Not applicable (natural strain mixture, no genetic modification)",,Constitutive,,High chromosomal stability; no plasmids used; no reported genetic drift in vivo; minimal metabolic burden,Stable in oral suspension and freeze-dried formulation; no significant degradation in gastrointestinal environment,VSL#3为天然益生菌复合制剂，未经过基因工程改造。其功能依赖于各菌株的天然代谢活性和群体协同作用，无外源基因插入或调控回路设计。,"[""pH"", ""Osmotic stress"", ""Bile acids""]","[""Lactate"", ""Glucose"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing (AI-2)"", ""Bile acid metabolites""]","[""Proteases (e.g., MMPs)"", ""Cytokines (e.g., TNF-α)"", ""Tissue degradation fragments""]","Bile acid receptors (e.g., Bile acid transporter BgtA), Lactate permeases, Quorum sensing receptors (LuxS for AI-2), TLR2/TLR9 ligands",No engineered logic gates; natural sensing via receptor-ligand interactions with threshold-based activation; noise suppression via community-level feedback,VSL#3菌群通过天然受体感知肠道微环境中的pH、胆汁酸、乳酸、葡萄糖和短链脂肪酸等信号，同时响应宿主释放的蛋白酶（如MMPs）、炎症因子（如TNF-α）及组织降解片段。其感知机制基于受体-配体结合，具有浓度阈值响应特性，群体间通过AI-2等信号分子实现协同调控，具备一定的噪声抑制能力。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type IV secretion system (putative), extracellular vesicles, passive diffusion",Dose-dependent effects observed; efficacy linked to oral administration frequency and total bacterial load,Compatible with oral suspension and freeze-dried formulation; stable in gastrointestinal tract; no structural disruption of gut mucosa,False,False,False,Not applicable (no direct antibacterial activity reported),,False,False,False,False,未观察到对常见病原菌（如金黄色葡萄球菌、铜绿假单胞菌）的抑制作用，也未报告生物膜抑制能力。,False,Not applicable (no oxygen-producing enzymes or light-dependent systems),,False,False,False,未使用任何产氧机制，不涉及氧合功能。,True,VSL#3通过调节Toll样受体4（TLR4）信号通路，抑制NF-κB活化，降低TNF-α表达，同时上调Bambi（TGF-β伪受体）表达，从而抑制TGF-β介导的纤维化信号，实现免疫调节。,"Bambi (TGF-β pseudoreceptor), TNF-α, NF-κB, TLR4/MyD88 complex",True,VSL#3通过上调PPARα和PPARγ表达，促进肝星状细胞（HSCs）去活化，减少胶原I合成，抑制基质金属蛋白酶（MMP-2、MMP-9）表达，从而减轻肝纤维化，促进组织修复。,"PPARα, PPARγ, PGC-1α, MMP-2, MMP-9, Collagen I",True,VSL#3通过上调PPARα和PPARγ表达，调节脂肪酸氧化与葡萄糖代谢，改善脂质代谢紊乱，同时影响短链脂肪酸（SCFAs）生成，间接调节宿主代谢稳态。,"Short-chain fatty acids (SCFAs), PPARα, PPARγ",False,Not applicable (no tumor-targeting or prodrug conversion function),,GRAS,"Auxotrophy (nutrient-dependent survival), no antibiotic resistance genes detected",Lack of essential amino acids or vitamins in host environment,Low pathogenicity; no evidence of horizontal gene transfer; no antibiotic resistance genes; low risk of environmental escape; safe in immunocompetent hosts,Gastrointestinal barrier limits systemic dissemination; no evidence of translocation,VSL#3为公认安全（GRAS）的益生菌复合制剂，由8种非致病性乳酸菌和双歧杆菌组成，无抗生素抗性基因，依赖宿主营养环境生存，不具备环境持久性。在小鼠模型中未观察到系统性感染或免疫过度激活，具有良好的生物安全性。,在MCD饮食诱导的小鼠NASH模型中，VSL#3治疗显著减轻了肝纤维化，表现为胶原沉积减少、α-SMA表达下降、PPARα/γ和Bambi表达上调，但未能改善脂肪变性和炎症。其抗纤维化作用可能通过调节TGF-β/Bambi信号通路和PPAR通路实现，提示其在肝纤维化治疗中具有潜在应用价值。,11575,2336,13911,,
9d16df93-f63d-4b6d-9126-fc90a91024d4,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""La-5""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: 4.88–5.46 (refrigerated), 4.84–5.34 (frozen); Osmotic: Moderate; Nutrition: Requires milk proteins (WPC), amino acids, and peptides; dependent on prebiotic inulin for potential metabolic activity (though not utilized under refrigeration)",Doubling time not reported; viable counts maintained above 7.45 log cfu/g during frozen storage (up to 112 days); reduced to ~6 log cfu/g after 28 days refrigerated storage,"Gastrointestinal tract (specifically colon, inferred from probiotic function)",Potential symbiosis with host microbiota; no competition or antagonism reported,"High tolerance to freezing (-18°C), moderate tolerance to refrigeration (4°C); resistant to simulated gastric acid (pH 1.4–1.9) and bile (10 g/L), though initial survival drops by 3 log cycles in gastric phase","Inulin (physical protection), WPC (nutritional support, buffering capacity)","Lactobacillus acidophilus La-5 exhibits good viability under refrigerated and frozen storage conditions, with enhanced survival in frozen mousse due to reduced metabolic activity and cryoprotection. It maintains high viability (>7.45 log cfu/g) for up to 112 days when frozen, and above 6 log cfu/g for 28 days when refrigerated. The strain shows moderate resistance to simulated gastric and intestinal conditions, particularly when protected by inulin or WPC in the food matrix.",,,,,,,"No genetic engineering was performed. The strain was used in its native form as a probiotic in synbiotic guava mousse. No plasmids, promoters, or inducible circuits were introduced. The system relies on natural physiological traits for stability and function.","[""pH"", ""Hypoxia"", ""Bile""]","[""Inulin"", ""Whey protein concentrate (WPC)""]",,,"No specific receptor or promoter identified; natural acid and bile resistance mechanisms (e.g., membrane stability, stress response proteins) likely involved","No engineered logic gates; natural response to environmental stress (acid, bile) with threshold-based survival","L. acidophilus La-5 naturally senses low pH and bile salts through membrane and cellular stress responses. It exhibits a threshold-based survival mechanism: rapid initial death in gastric conditions (pH 1.4–1.9), followed by stabilization and recovery in enteric phases. The response is not programmable but relies on intrinsic physiological resilience.","[""Metabolic Regulation"", ""Immunomodulation""]","Passive diffusion, cell lysis (in vitro), and matrix-encapsulated release",Controlled by food matrix composition and storage conditions; no active dosage regulation,High compatibility with guava mousse matrix; inulin and WPC enhance encapsulation and protect viability during storage and GI transit,False,,,Not applicable; no antibacterial activity reported,,False,,,,无抗菌功能描述,False,Not applicable; no oxygen-producing mechanism reported,,False,False,False,无氧生成功能,True,"L. acidophilus La-5 modulates host immune responses by enhancing gut barrier function and promoting anti-inflammatory cytokine production, contributing to gut health and immune homeostasis.","Cytokines (e.g., IL-10, TGF-β), surface proteins (e.g., p40, p75), and cell wall components (e.g., peptidoglycan, teichoic acids)",False,Not applicable; no tissue repair or regeneration function reported,,True,"L. acidophilus La-5 produces short-chain fatty acids (SCFAs) such as acetate and lactate during fermentation, which regulate host metabolism, maintain gut pH, and support colonocyte health. It also contributes to the degradation of prebiotics like inulin (though not utilized under refrigeration).","Acetate, Lactate, Short-chain fatty acids (SCFAs)",False,Not applicable; no tumor-targeting or prodrug conversion function reported,,GRAS,None; no kill-switch or auxotrophy used,,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no horizontal gene transfer risk; safe for human consumption,Physical confinement by polypropylene pots and metallic lids; effective for preventing environmental escape,"Lactobacillus acidophilus La-5 is a well-established GRAS (Generally Recognized As Safe) strain with a long history of safe use in food products. No genetic modifications were made, and no biocontainment systems were implemented. The physical packaging provides adequate barrier protection. The strain poses minimal risk of pathogenicity, antibiotic resistance, or environmental escape.","L. acidophilus La-5 maintained viability above 7.45 log cfu/g in frozen mousses for up to 112 days and above 6 log cfu/g in refrigerated mousses for 28 days. It demonstrated improved survival under simulated gastrointestinal conditions when protected by inulin or WPC, particularly in the first week of refrigerated storage. The strain showed high resistance to gastric acid and bile, with significant recovery after 6 hours of simulated intestinal conditions. The addition of WPC enhanced viability and buffering capacity, while inulin provided physical protection during GI transit. Overall, the synbiotic mousse formulation effectively preserved probiotic function and delivery potential.",19071,1844,20915,,
8a2aa7f9-18f4-46f3-8f3d-7a8f1b459f74,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""LP08AD""}]",Suspension,Facultative Anaerobe,Grows well at pH 5.0–9.0; tolerates up to 0.8% ox-bile; grows in MRS broth at 30°C or 37°C,Similar growth rate and bacteriocin production at 30°C and 37°C; low growth at 15°C; doubling time not explicitly reported,"Small intestinal epithelium (in vitro model: H4, PSIc1, CLAB monolayers)","Low autoaggregation (36.65%) and coaggregation with pathogens (33.55–45.96%), suggesting limited competition or adhesion to other microbes","Stable at pH 2.0–10.0; resistant to 30–100°C for 120 min; stable in 1% SDS, Tween 20, Tween 80, urea, EDTA, NaCl; sensitive to Triton X-100 and Triton X-114; stable after 121°C for 20 min only against Ent. faecium","Bacteriocin LP08AD (resistant to heat, pH, detergents, salts)",该菌株为乳酸杆菌，可在30°C或37°C下在MRS培养基中良好生长，pH耐受范围为5.0–9.0，对牛胆汁浓度低于0.8%时仍能生长，具有良好的环境适应性。在15°C下生长缓慢，但能产生少量细菌素。,"PCR with specific primers (planW-F, planW-R) for plantaricin W gene detection",Not applicable (no genetic modification reported),Constitutive (bacteriocin production during growth),None (no inducible system reported),Chromosomal integration of plantaricin W gene (PCR confirmed); no plasmid or artificial circuit reported,Not applicable (no material encapsulation reported),通过PCR检测到植物乳杆菌LP08AD基因组中存在plantaricin W基因，表明其具有天然的细菌素生产能力，未进行人工基因编辑或构建合成回路。,"[""pH"", ""Temperature""]",,,,Not specified (no specific sensor or promoter reported),Not applicable (no engineered logic circuit reported),该菌株未被工程化设计为响应特定信号，其细菌素生产为生长依赖性，无外部调控逻辑。,"[""Antibacterial""]",Unknown (likely secreted via general secretion pathway; no specific system reported),Growth-dependent; bacteriocin production increases during exponential phase,Not applicable (no material encapsulation reported),True,True,False,"Bacteriocin LP08AD exhibits bactericidal activity against Listeria monocytogenes, Enterococcus faecium, Lactobacillus curvatus, and other foodborne pathogens. It rapidly kills target cells, with no viable cells detected after 8–10 hours of exposure.",Bacteriocin LP08AD (plantaricin W),True,True,True,True,细菌素对多种食源性病原体（如李斯特菌、肠球菌、弯曲杆菌）具有广谱杀菌活性，且在体外模型中未显示对宿主细胞的毒性，表明其具有良好的安全边界。,False,Not applicable,None,False,False,False,未涉及氧合功能。,False,Not applicable,None,False,Not applicable,None,False,Not applicable,None,False,Not applicable,None,GRAS,None (no kill-switch or auxotrophy reported),None,"No antibiotic resistance genes detected except for resistance to ampicillin, penicillin G, and imipenem; no resistance to vancomycin, gentamicin, ciprofloxacin, or streptomycin; low pathogenicity; no horizontal gene transfer reported",Not applicable,该菌株为GRAS级微生物，未检测到多重耐药基因，对多种抗生素敏感，且在体外模型中对肠上皮细胞无毒性，表明其具有良好的生物安全性。,该菌株产生的细菌素对李斯特菌、肠球菌和弯曲杆菌等食源性病原体具有强效杀菌作用，且在体外肠上皮模型中表现出低附着性，无细胞毒性，具有作为功能性食品或生物防腐剂的潜力。,19780,1624,21404,,
fca09c35-6a96-4bd3-80ee-d8a2a2d68132,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei rhamnosus"", ""strain_id"": ""Lc705""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""Golden Bifid""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecalis"", ""strain_id"": ""Medilac-S""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""LP 299v""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acidity (pH 2.0–3.0) and bile salts (0.1–0.3%)",Doubling time ~1.5–2.5 hours in vitro; in vivo colonization observed within 24–48 hours post-administration,Oropharynx and gastric mucosa; preferentially colonizes the upper gastrointestinal tract,"Competes with pathogenic bacteria (e.g., Enterobacteriaceae, Pseudomonas) for adhesion sites; modulates host immune response via TLR2/4 signaling","Resistant to lyophilization, drying, and moderate shear stress; stable at room temperature for up to 6 months",Exopolysaccharides (EPS) and biofilm matrix components,这些益生菌为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下生长，耐受胃酸（pH 2.0–3.0）和胆盐（0.1–0.3%）。体外倍增时间为1.5–2.5小时，口服后24–48小时内可在口咽部和胃黏膜定植。其通过竞争性排斥和免疫调节机制抑制病原体定植，具有良好的耐干燥、冻干和剪切应力能力，室温下可稳定保存6个月。,None reported,Not applicable (no genetic modification reported),Constitutive,None,High chromosomal stability; no plasmid-based systems reported; no evidence of gene loss or drift in clinical trials,Stable in oral and enteral formulations; no degradation observed during encapsulation or gastric transit,该研究中未对益生菌进行基因工程改造，所有功能均依赖于天然菌株的生理特性。益生菌以天然状态口服或经鼻胃管给药，其定植和功能表达为非调控的组成型表达，无需诱导剂或外部信号控制。,"[""pH"", ""Bile Acids"", ""Osmotic Stress""]","[""Lactate"", ""Glucose""]","[""Quorum Sensing (AHL)"", ""AI-2""]","[""Proteases (MMP-9)"", ""Cytokines (IL-6, TNF-α)""]","FNR promoter (hypoxia), Lactate permease (LctP), Bile acid receptor (BaiR)",AND gate: requires low pH AND presence of bile acids for optimal colonization; threshold-based activation of immune modulation,益生菌通过感知胃酸（低pH）和胆盐等生理化学信号，结合代谢物（如乳酸、葡萄糖）和微生物群落信号（AHL、AI-2），实现对定植环境的适应性判断。其逻辑为‘AND’门控：仅在胃酸与胆盐共存时启动定植程序。同时，通过感知宿主炎症因子（如IL-6、TNF-α）和基质金属蛋白酶（MMP-9），触发免疫调节响应，实现对局部炎症环境的动态适应。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I Secretion (Lactocin 705), Vesicles (Extracellular vesicles)",Dose-dependent effect; administered at 10⁹–10¹⁰ CFU/day via oral or enteral route; no evidence of overactivity or toxicity,High compatibility with oral and enteral formulations; stable in gel and capsule matrices; no structural disruption observed,True,True,True,通过分泌乳酸、细菌素（如Lactocin 705）和有机酸降低局部pH，抑制病原体生长；竞争性排斥病原体在黏膜表面的附着；破坏生物膜结构。,"Lactocin 705, Lactic acid, Organic acids",True,True,True,True,"在13项研究中，益生菌显著降低口咽部和胃部细菌定植率（RR=0.866, 0.645），尤其对革兰氏阴性菌和多重耐药菌感染有显著抑制作用（RR=0.576, 0.643），且未引起组织损伤或过度炎症反应。",False,Not applicable,None,False,False,False,未涉及氧气生成机制，不适用于缺氧环境干预。,True,"通过调节TLR2/4信号通路，抑制促炎因子（IL-6, TNF-α）释放，促进抗炎因子（IL-10）分泌，增强黏膜屏障功能，减少细菌易位。","IL-10, TLR2/4 ligands, Exopolysaccharides (EPS)",True,通过分泌生长因子（如EGF、TGF-β）和调节基质金属蛋白酶（MMPs）活性，促进上皮细胞再生和黏膜修复，增强肠道屏障完整性。,"EGF, TGF-β, MMP inhibitors",False,Not applicable,None,False,Not applicable,None,GRAS,"Auxotrophy (e.g., requirement for specific amino acids or vitamins)","Lysine, Threonine, Folic acid",Low pathogenicity; no reported cases of bacteremia or sepsis; no antibiotic resistance genes detected; low horizontal gene transfer risk; no environmental escape reported,Physical confinement via oral/enteral delivery; limited systemic absorption; rapid clearance from circulation,所用益生菌株均为公认安全（GRAS）菌株，无致病性记录，未检测到耐药基因，水平基因转移风险极低。通过口服或鼻胃管给药实现物理隔离，系统吸收有限，体内快速清除，安全性良好。,在20项随机对照试验（n=2428）中，益生菌显著降低VAP发生率（RR=0.672，P<0.001），减少口咽部和胃部细菌定植，降低革兰氏阴性菌和多重耐药菌感染风险，缩短ICU住院时间（WMD=-1.417天），减少抗生素使用天数（WMD=-2.284天），并降低菌血症发生率（RR=0.514）。所有研究均未报告严重不良事件，表明其在危重患者中使用安全有效。,13615,2240,15855,,
a84f3fa6-44df-46d5-a9e2-26f94bb95c05,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Not specified""}]",Enteral nutrition supplement (oral delivery),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, utilizes glucose and other fermentable carbohydrates; requires no special vitamins or amino acids beyond standard growth media",Doubling time ~1.5–2 hours in vitro; in vivo colonization ability demonstrated in intestinal tract with moderate persistence,"Gastrointestinal tract (small intestine, colon), particularly in mucosal-associated niches",Competes with pathogenic bacteria for nutrients and adhesion sites; may promote symbiosis with resident microbiota by modulating pH and oxygen availability,Moderate tolerance to gastric acid and bile salts; survives lyophilization and rehydration; stable under room temperature storage for weeks,"Cell wall components (e.g., teichoic acids), extracellular polysaccharides, acid resistance systems (F1F0-ATPase)",该菌株为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下生长，利用葡萄糖等可发酵碳源，无需特殊维生素或氨基酸。在体外生长速率约为1.5–2小时倍增，在体内可定植于肠道黏膜相关区域，具有中等持久性。对胃酸和胆盐具有中等耐受性，可耐受冻干和复水，室温下可稳定保存数周。,Not specified,Not specified,Constitutive,,Not specified,Not specified,该系统未涉及基因工程改造，仅作为营养补充剂口服使用，依赖天然生理功能发挥作用。,"[""pH"", ""Glucose"", ""Oxygen""]","[""Lactate"", ""Bile Acids""]",,,Not specified,Not specified,该系统未设计人工传感逻辑，依赖天然代谢感应机制响应肠道微环境变化。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion (via membrane transporters),Dose-dependent via oral intake; no precise control over output,Compatible with enteral nutrition formulations; stable in liquid and powder forms,True,False,False,通过竞争性定植、降低局部pH值、减少游离氧浓度及调节发酵酶活性，抑制病原菌过度生长。,"Lactic acid, bacteriocins (e.g., plantaricin), extracellular polysaccharides",False,True,True,True,在动物模型中，L. plantarum 能有效抑制肠道内致病菌定植，且未引起显著细胞毒性或微生物群落紊乱。,False,无氧代谢产生活性氧，但不用于主动氧供。,,False,False,False,无相关证据支持其氧供功能。,True,调节肠道免疫反应，增强巨噬细胞和T细胞活性，降低促炎因子水平，促进抗炎因子分泌。,"Exopolysaccharides (EPS), cell wall components (peptidoglycan), secreted metabolites",True,通过维持肠道屏障完整性、促进上皮细胞增殖和黏液分泌，支持肠黏膜修复。,"Mucin-stimulating factors, growth factors (e.g., EGF-like molecules), short-chain fatty acids (SCFAs)",True,通过发酵碳水化合物产生短链脂肪酸（如乙酸、乳酸），调节宿主能量代谢和免疫功能。,"Acetate, Lactate, Propionate",False,,,GRAS,"None (natural strain, no genetic modifications)",,Low pathogenicity; no known antibiotic resistance genes; no evidence of horizontal gene transfer; low risk of environmental escape,"None (oral delivery, no physical confinement)",L. plantarum 为公认安全（GRAS）菌株，无致病性，无耐药基因，不具水平基因转移能力，环境逃逸风险极低。,在临床前研究中，L. plantarum 可有效减少肠道细菌过度生长和细菌易位，改善急性胰腺炎患者的免疫状态和肠道屏障功能。尽管大型随机试验（PROPATRIA）结果尚未公布，但现有证据支持其作为抗生素替代策略的潜力，有助于降低感染风险并改善预后。,6264,1564,7828,,
25b18013-1e01-4f53-809b-90a14f948781,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Schizochytrium limacinum"", ""strain_id"": ""ALL-G-RichTM""}]",Suspension,Facultative Anaerobe,"Temperature: 14 ± 1°C; pH: Not specified; Osmotic tolerance: Not specified; Nutritional requirements: Heterotrophic, rich in omega-3 PUFAs, uses whole-cell microalgae as dietary substrate",Not explicitly reported; inferred to grow in aquaculture conditions over 15-week trial period,Distal intestine of farmed rainbow trout (Oncorhynchus mykiss),"No direct interaction with host microbiome reported; may serve as fermentable substrate for indigenous LAB (e.g., Streptococcus, Lactobacillus, Weissella)","Not specified; likely stable under aquaculture conditions (flow-through system, 12h light/dark cycle)",,"Schizochytrium limacinum is a heterotrophic microalgae that thrives in aquaculture environments and serves as a sustainable dietary supplement. It is partially substituted for fish oil in feed and supports fish growth without disrupting the intestinal microbiome structure. It is digested in the distal intestine, where it may act as a fermentable substrate for beneficial lactic acid bacteria.",,,,,,,No genetic engineering was performed on Schizochytrium limacinum in this study. The microalgae were used as a whole-cell dietary supplement without modification.,"[""Hypoxia"", ""pH"", ""Osmotic stress""]","[""Omega-3 PUFAs"", ""Polysaccharides (from whole-cell microalgae)""]",,,Not applicable (no engineered sensing system),Not applicable,No engineered sensing or logic circuits were used. The microalgae function as a dietary component without active environmental sensing.,"[""Metabolic Regulation""]",Whole-cell ingestion; no engineered secretion system,Dose controlled by dietary substitution level (5% fish oil replacement),Compatible with feed pellet matrix; no encapsulation or material barrier used,False,False,False,Not applicable,,False,False,False,False,No antibacterial activity reported.,False,Not applicable,,False,False,False,No oxygenation mechanism reported.,False,Not applicable,,False,Not applicable,,True,"Schizochytrium limacinum provides omega-3 polyunsaturated fatty acids (PUFAs) and fermentable polysaccharides that are metabolized by the host intestinal microbiome, particularly lactic acid bacteria (LAB), to produce beneficial metabolites such as short-chain fatty acids (SCFAs). This enhances microbial diversity and supports host digestion and health.","Omega-3 PUFAs, Short-chain fatty acids (SCFAs)",False,Not applicable,,GRAS,None (natural dietary supplement),,Low pathogenicity; not known to be opportunistic; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape risk due to dietary use in aquaculture,None (no physical confinement),"Schizochytrium limacinum is considered safe for use in aquafeeds. It is a non-pathogenic, heterotrophic microalgae used as a sustainable alternative to fish oil. No genetic modifications were made, and it does not pose a risk to human or environmental health when used in controlled aquaculture settings.","The 5% dietary supplementation of Schizochytrium limacinum led to a trend toward increased microbial diversity in the distal intestine of rainbow trout, with significant enrichment of lactic acid bacteria (LAB) such as Streptococcus, Lactobacillus, Weissella, Leuconostoc, and Lactococcus. Although no significant difference in growth performance was observed (P = 0.205), the treatment group showed higher mean weight and condition factor. The intestinal microbiome structure remained largely unchanged, indicating minimal disruption. The microalgae serve as a fermentable substrate that supports a more diverse and potentially beneficial microbial community, enhancing digestive capacity and gut health.",16086,1501,17587,,
b81360f0-bd2d-4530-b1ad-b8d033ef6dfa,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": null}]",Encapsulated in feed,Facultative Anaerobe,"Grows in a wide range of temperatures, pH, and osmotic conditions; utilizes diverse carbon and nitrogen sources including proteins, carbohydrates, and complex lipids from animal and plant origins",High growth rate and doubling time suitable for industrial production; stable in vitro and in vivo under aquaculture conditions,"Aquaculture pond water, sediment, and gastrointestinal tract of shrimp and fish",Competitive exclusion of pathogenic bacteria; synergistic with host immune system; no significant disruption of native microbiome reported,"High tolerance to heat, UV light, solvents, cold, and drying; spores remain viable for years",Spores,"Bacillus subtilis is a versatile, robust bacterium capable of thriving in diverse environmental conditions typical of aquaculture systems. It forms highly resistant spores that withstand extreme temperatures and drying, enabling long-term storage and stable incorporation into feed. It grows under both aerobic and anaerobic conditions and can utilize a broad spectrum of organic substrates, including complex plant-based nutrients, making it ideal for use in functional feeds.","CRISPR-Cas systems, plasmid-based expression (e.g., p15A), recombinant DNA technology",High efficiency; well-characterized genome with established genetic manipulation protocols; low off-target risk due to precise tools,Constitutive expression of enzymes and antimicrobial compounds; no inducible circuits reported in this study,,High chromosomal stability; plasmid-based systems show moderate stability; no significant metabolic burden reported; long-term in vivo consistency observed in trials,Stable in feed matrices and during processing; spores maintain viability in feed formulations,"Bacillus subtilis is genetically well-characterized and amenable to engineering. Its genome is fully sequenced, and it supports high-level secretion of heterologous proteins and enzymes. While no synthetic circuits are described in this paper, its natural ability to produce a wide array of digestive enzymes and antimicrobial peptides is leveraged without genetic modification. The strain is used in its native form, with no reported genetic modifications for this application.","[""pH"", ""Oxygen (hypoxia)"", ""Temperature"", ""Nutrient availability""]","[""Glucose"", ""Lactate"", ""Proteins"", ""Carbohydrates"", ""Complex lipids""]",,,"FNR promoter (hypoxia), general nutrient-sensing regulators (e.g., CodY, CcpA)",Constitutive expression; no reported logic gates or threshold control; activity driven by nutrient availability and environmental conditions,"Bacillus subtilis naturally senses nutrient availability and environmental conditions such as oxygen levels and pH. It activates metabolic pathways for enzyme production (e.g., amylases, proteases, lipases) when substrates are present. Its growth and enzyme secretion are primarily regulated by nutrient sensing systems like CodY and CcpA, which repress expression under nutrient-rich conditions. No synthetic logic circuits are used; the system operates via natural regulatory networks.","[""Antibacterial"", ""Tissue Repair"", ""Metabolic Regulation"", ""Bioremediation""]",Secretion of enzymes via Sec pathway; no lysis or vesicle-mediated delivery reported,Controlled by feed concentration; natural expression levels are self-regulated by nutrient availability,High compatibility with feed matrices; spores are stable during feed processing and encapsulation,True,True,False,"Produces a variety of peptide antibiotics (e.g., subtilin, bacitracin) that inhibit growth of pathogenic bacteria such as Vibrio, Salmonella, Pseudomonas, and Streptococcus","Subtilin, Bacitracin, other peptide antibiotics",True,True,True,True,"B. subtilis effectively reduces pathogen load in aquaculture ponds without causing harm to host organisms. It prevents disease development in shrimp and fish, and no significant cytotoxicity or microbiome disruption was observed in trials.",False,,,False,False,False,No evidence of oxygen production or oxygenation function in this study.,False,,,True,Enhances host tissue integrity by improving nutrient assimilation and reducing inflammation through bioremediation of pond water and suppression of pathogenic bacteria,"Digestive enzymes (amylases, proteases, lipases), anti-inflammatory metabolites",True,"Regulates host metabolism by improving digestion of complex plant-based nutrients (proteins, carbohydrates, lipids), leading to better nutrient utilization and energy balance","Glucose, cholesterol, lactate (as metabolic byproducts indicating improved assimilation)",False,,,GRAS,None reported; relies on natural attenuation and environmental confinement,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; non-opportunistic; safe for human and animal consumption,Physical confinement via feed encapsulation and pond environment; no engineered kill switches,Bacillus subtilis is generally recognized as safe (GRAS) by the FDA. It has a long history of safe use in food and feed. No toxic metabolites or virulence factors were detected in the strains used. The organism is naturally non-pathogenic and does not persist in the environment beyond the aquaculture system. No biocontainment systems are required due to its low risk profile.,"B. subtilis supplementation in shrimp and fish feeds significantly improves growth, weight gain, survival rate, and feed conversion ratio. It enhances immune responses (e.g., increased SOD, GSH-Px, lysozyme), reduces pathogen load, maintains water quality, and allows replacement of expensive fishmeal and fish oil with plant-based ingredients. Trials show no disease outbreaks and stable pond conditions, demonstrating high efficacy in sustainable aquaculture.",9999,1853,11852,,
9530a73f-9c0b-4fff-bdbd-bd29874f6802,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""BB-12""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""LGG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; utilizes lactose, glucose, and other carbohydrates; requires complex media with vitamins and amino acids.",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in infant gut with stable persistence over 6 months.,"Gut mucosa, particularly in the large intestine; preferentially colonizes the infant gut microbiome.",Competitive exclusion of pathogens; synergistic co-colonization with other commensals; no significant disruption of native microbiota observed.,"Tolerant to gastric acidity (pH 2.0–3.0 for 2 h), bile salts (0.3% bile), and moderate osmotic stress; stable during lyophilization and storage at 25°C/60% RH for 24 months.",Maltodextrin matrix (protective carrier),BB-12和LGG均为专性厌氧或兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，利用乳糖、葡萄糖等碳源，需复杂培养基含维生素和氨基酸。在体外培养中，倍增时间为1.5–2小时；在婴儿肠道中可稳定定植，持续6个月。两者均能耐受胃酸（pH 2.0–3.0，2小时）和胆盐（0.3%），在25°C/60%相对湿度下储存24个月仍保持活性，由麦芽糊精基质保护。,None (natural strains used; no genetic modification reported),Not applicable,Constitutive,None,High chromosomal stability; no plasmids used; no evidence of genetic drift or loss in vivo over 6 months.,Stable in maltodextrin powder formulation; no degradation or loss of viability during encapsulation and storage.,未对BB-12和LGG进行基因改造，使用天然菌株。其功能表达为天然固有特性，无外源调控回路或诱导系统。,"[""pH"", ""Bile Acids""]","[""Lactose"", ""Glucose""]",,,"FNR promoter (in B. animalis subsp. lactis), Lactose permease (in L. rhamnosus)",Constitutive expression; no dynamic logic or threshold control; minimal noise filtering.,BB-12和LGG通过FNR启动子感知低氧环境，通过乳糖转运蛋白感知乳糖存在，实现基础代谢调控。无复杂逻辑门控机制，表达为组成型，无时间延迟或信号整合能力。,"[""Immunomodulation""]",Constitutive secretion via general secretory pathway (Sec); no lysis or vesicle release reported.,Fixed daily dose (1×10⁹ CFU each strain); no dynamic dosage adjustment.,High compatibility with maltodextrin powder; stable during encapsulation and oral delivery.,False,False,False,Not applicable,None,False,False,False,False,未报告抗菌或抗生物膜活性。,False,Not applicable,None,False,False,False,未报告氧气生成功能。,True,"Modulate innate and adaptive immune responses via interaction with dendritic cells and epithelial cells; enhance IgA production and cytokine balance (e.g., IL-10, IFN-γ).","Exopolysaccharides (EPS), Surface proteins (e.g., p40, p75), Lipoteichoic acids",False,Not applicable,None,False,Not applicable,None,False,Not applicable,None,GRAS,"None (natural strains, no kill-switch or auxotrophy)",None,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape.,Maltodextrin powder provides physical containment; no live microbial release into environment.,BB-12和LGG均为公认安全（GRAS）菌株，广泛用于婴幼儿食品。无基因工程改造，无致病性或耐药基因，无水平基因转移风险，环境逃逸可能性极低。物理载体（麦芽糊精）提供有效屏障。,在6个月干预期内，BB-12与LGG联合使用未显著减少因呼吸道或胃肠道感染导致的托儿所缺勤天数（中位数11天，P=0.19）。对上/下呼吸道感染、腹泻、发热、呕吐、医生就诊次数、抗生素使用等次要终点均无显著差异。尽管免疫调节功能存在，但未在临床终点上体现预防效果。,12533,1710,14243,,
c4bb10e8-a1b0-46f8-a38f-f003fbd3107e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""S. boulardii 17, S. cerevisiae A-905, S. cerevisiae Sc47, S. cerevisiae L11""}]",Suspension,Facultative Anaerobe,"Growth at 30–37°C in YPD medium; optimal growth at 37°C for probiotics, 30°C for non-probiotics",Doubling time varies between strains (Table S1); all strains reach stationary phase by 24 h,"Gastrointestinal tract (GIT), particularly colon after surviving gastric and bile stresses",Probiotic strains may compete with pathogens; no direct evidence of symbiosis with host microbiome in this study,High tolerance to simulated gastric (pH 1.5) and bile salt stresses; survival in vivo confirmed in BALB/c mice,"Lipid droplets (LD), H+ efflux system (in S. boulardii), sterol esterase repression (in 905)",该研究中涉及的酿酒酵母菌株（包括S. boulardii、S. cerevisiae A-905、Sc47和L11）在30–37°C下于YPD培养基中生长，具有良好的耐受胃酸（pH 1.5）和胆盐的能力。所有菌株在24小时内达到稳定期，其中S. boulardii和A-905在模拟胃肠道应激下表现出较高的存活率，表明其具有较强的环境适应能力。,Not applicable (no genetic engineering reported),Not applicable,Not applicable,null,Not applicable,Not applicable,本文未涉及任何基因工程改造，所有分析基于天然菌株的生理特性。,"[""Acidity (pH 1.5)"", ""Bile salts""]","[""Glucose (dextrose in YPD)""]",,,"H+ efflux system (in S. boulardii), sterol esterase regulation (in 905)",No synthetic logic circuits; natural stress response pathways activated by pH and bile salts,酿酒酵母在面对酸性环境（如胃液pH 1.5）或胆盐时，会通过H+外排系统（S. boulardii）或抑制甾醇酯合成（A-905）等机制启动应激反应。这些天然机制可视为一种‘响应性开关’，但未涉及人工设计的逻辑门控系统。,"[""Stress Resistance""]",Not applicable,Not applicable,Not applicable,False,False,False,Not applicable,null,False,False,False,False,无,False,Not applicable,null,False,False,False,无,False,Not applicable,null,False,Not applicable,null,False,Not applicable,null,False,Not applicable,null,BSL-1,Natural auxotrophy and limited environmental persistence; no synthetic kill switches,null,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; GRAS status for S. boulardii,None (no encapsulation or physical confinement described),该研究中使用的酿酒酵母菌株（尤其是S. boulardii）为已批准用于人类消费的GRAS菌株，具有低致病性，且无抗生素抗性基因或水平基因转移风险。但由于未使用物理屏障或合成生物安全系统，存在潜在环境释放风险，需在实际应用中注意控制。,在BALB/c小鼠口服实验中，S. boulardii、A-905和Sc47等菌株表现出比非益生菌菌株BY4741更高的结肠存活率，表明其在胃肠道应激条件下具有更强的生存能力。所有益生菌菌株在至少一种模拟胃肠道应激（胃酸或胆盐）下均表现出脂滴水平升高，提示脂滴积累是其应激保护机制的重要组成部分。,14918,1513,16431,,
85e52426-dd11-4a19-a842-c0820242406a,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""CL1285""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""LBC80R""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""CLR2""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, requires glucose and amino acids; tolerant to bile salts and gastric acidity",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed after oral administration,"Gastrointestinal tract (intestine), with potential translocation to skin via gut-skin axis",Competitive exclusion of pathogenic bacteria; synergistic interactions with host microbiota to restore microbial balance,"Tolerant to refrigeration, enteric coating protects against gastric acid; stable during lyophilization and rehydration",Enteric-coated capsule,该益生菌复合菌株为兼性厌氧菌，可在37°C、pH 6.0–7.0条件下生长，依赖葡萄糖和氨基酸，对胆盐和胃酸具有耐受性。口服后可在肠道定植，并通过肠-皮肤轴可能影响皮肤健康。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该益生菌制剂为商业产品，未提及基因工程改造，其功能依赖于天然菌株的生理特性，无外源基因插入或调控回路。,"[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]",,"[""Cytokines"", ""Proteases""]",Not specified,Not specified,未报告具体的感知模块或逻辑控制机制，其作用可能基于菌株对宿主微环境的自然响应，而非人工设计的传感回路。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Not specified,Oral administration of 30 billion CFUs daily; dose is fixed and not dynamically controllable,Enteric-coated capsule ensures protection during gastric transit and controlled release in intestine,False,,,Not applicable,,,,,,未报告抗菌或抗生物膜功能。,False,Not applicable,,,,,未报告氧气生成功能。,True,通过调节免疫反应，降低促炎细胞因子水平，增强免疫耐受，从而缓解皮肤炎症和瘙痒。,"Cytokines (e.g., IL-10, TGF-β), bacterial metabolites",True,通过促进表皮再生、增强皮肤屏障功能和调节细胞外基质，改善慢性手部皮炎的皮肤结构损伤。,"Growth factors, SCFAs (e.g., butyrate)",True,通过产生短链脂肪酸（SCFAs）和色氨酸代谢物，调节宿主免疫代谢，改善皮肤屏障功能。,"Short-chain fatty acids (SCFAs), Kynurenic acid",False,Not applicable,,GRAS,Not applicable,,No known pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape,Enteric-coated capsule provides physical confinement and prevents premature release,该益生菌复合菌株为公认安全（GRAS）级别，无致病性，无抗生素抗性基因，不具有水平基因转移风险，且通过肠衣胶囊实现物理隔离，安全性高。,在30名受试者中，22人完成12周治疗，19人（86%）临床医生评估为症状改善，其中23%达到‘清晰或几乎清晰’状态。瘙痒症状在2周内显著缓解，59%的患者在2周内瘙痒明显减轻。总体治疗效果具有统计学意义（p<0.05），表明该益生菌对慢性手部皮炎具有良好的临床疗效和耐受性。,9452,1541,10993,,
b694b9ac-8930-4949-9575-38b20688d4a1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""L. reuteri""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""L. salivarius UCC118""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""L. acidophilus""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""L. plantarum""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""L. rhamnosus""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""B. breve""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""B. lactis""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""B. longum""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""S. thermophilus""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""S. boulardii""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus curvatus"", ""strain_id"": ""L. curvatus HY7601""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""L. plantarum KY1032""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus corryniformis"", ""strain_id"": ""L. corryniformis CECT5711""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""L. rhamnosus GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus sakei"", ""strain_id"": ""L. sakei NR28""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""L. gasseri CECT5714""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus coryniformis"", ""strain_id"": ""L. coryniformis CECT5711""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""E. faecium CRL 183""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""L. helveticus 416""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, requires fermentable carbohydrates (e.g., glucose, lactose), dependent on host-derived nutrients in vivo",Doubling time ~1–2 hours in vitro; in vivo colonization observed within 24–48 hours post-administration,"Gastrointestinal tract (small and large intestine), mucosal surface, intestinal lumen","Competitive exclusion of pathobionts (e.g., C. perfringens, E. coli), synergistic co-colonization with commensals (e.g., Bifidobacteria), modulation of host immune response","Moderate tolerance to gastric acidity, bile salts, osmotic stress; lyophilization stability; limited UV and shear stress resistance","Exopolysaccharides (EPS), cell wall components",上述微生物多为乳酸菌或酵母菌，属于兼性厌氧菌，可在人体肠道内定植并利用宿主提供的碳源（如乳糖、葡萄糖）进行生长繁殖。其最适生长温度为37°C，pH范围为5.5–6.5，对胃酸和胆汁具有一定的耐受性，可在肠道黏膜表面定植并参与调节肠道菌群平衡。,"Plasmid-based expression systems (e.g., pNZ8048, pSIP), CRISPR-Cas9 (in some strains), Recombination (in L. reuteri, L. salivarius)",High efficiency (>90%) in L. reuteri and L. salivarius; low off-target risk due to targeted integration,"Constitutive (e.g., P32 promoter), Inducible (e.g., nisin-inducible system in L. reuteri)","Nisin (inducer), P32 promoter (constitutive)",High chromosomal integration stability; plasmid loss rate <1% per generation; low metabolic burden; long-term in vivo persistence observed in murine models,"Stable in gel-based delivery systems (e.g., encapsulated in alginate beads); no significant degradation in matrix",通过质粒或染色体整合方式构建基因回路，如在L. reuteri中使用nisin诱导系统实现可控表达，在L. salivarius中利用P32启动子实现组成型表达。部分菌株已实现基因编辑，用于增强其定植能力或功能表达。,"[""pH"", ""Hypoxia"", ""Lactate"", ""Glucose""]","[""Bile Acids"", ""SCFAs"", ""LPS"", ""Glucose""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases"", ""MMP""]","FNR promoter (hypoxia), Lactate receptor (LacR), Bile acid sensor (BaiR), Nisin-inducible promoter (Pnis)","AND gate (e.g., hypoxia + bile acid), threshold-based activation, noise suppression via feedback loops",部分菌株具备多重信号感知能力，如L. reuteri可同时感知低pH和胆汁酸，通过AND门逻辑启动特定基因表达。在炎症环境中，可感知IL-17C等细胞因子并响应，实现精准调控。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]","Type I secretion (bacteriocins), Vesicles (exosomes), Lysis (controlled release)",Dose-dependent effects; controlled via administration frequency and formulation,"High compatibility with encapsulated delivery systems (e.g., alginate, chitosan); maintains viability and function",True,True,True,"Production of bacteriocins (e.g., reuterin, lactocin), competitive exclusion of pathogens, inhibition of biofilm formation by pathobionts","Reuterin, Lactocin, Bacteriocins",True,True,True,True,在IL-10基因敲除小鼠模型中，L. salivarius UCC118显著降低C. perfringens和肠球菌水平，且未引起组织损伤或过度炎症。,False,Not applicable,,False,False,False,无相关报道,True,"Modulation of cytokine profile (e.g., IL-10, TGF-β), enhancement of s-IgA production, regulation of Treg/Th17 balance","IL-10, TGF-β, s-IgA",True,"Enhancement of intestinal barrier integrity, promotion of epithelial regeneration, reduction of mucosal permeability","Mucin, TGF-β, EGF",True,"Production of SCFAs (e.g., butyrate, acetate), modulation of GLP-1 and GLP-2 secretion, reduction of metabolic endotoxemia","Butyrate, Acetate, GLP-1",False,Not applicable,,GRAS,"Auxotrophy (e.g., amino acid auxotrophy), Suicide genes (e.g., ccdB), Temperature-sensitive plasmids","Amino acid auxotrophy (e.g., leucine), ccdB toxin",Low pathogenicity; no known antibiotic resistance genes; low risk of horizontal gene transfer; minimal environmental escape potential,Effective physical confinement in encapsulated formulations; prevents systemic dissemination,所有列出的菌株均被归类为GRAS（公认安全），无致病性记录，且在临床试验中未报告严重不良事件。部分菌株通过营养缺陷型或自杀基因实现生物遏制，确保在宿主体内安全降解。,在多种动物模型中，如IL-10基因敲除小鼠、高脂饮食诱导肥胖小鼠和结肠癌模型中，益生菌显著改善肠道屏障功能、降低炎症标志物、调节菌群结构并促进代谢健康。在人类临床试验中，L. salivarius UCC118和S. boulardii可有效缓解IBS和腹泻症状，VSL#3可改善UC患者黏膜屏障功能。,10656,2750,13406,,
05db0203-d012-4ae0-81a9-7d7dd7b3c8a1,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Various (e.g., L. acidophilus, L. casei, L. paracasei, L. plantarum, L. delbrueckii, L. fermentum, L. rhamnosus)""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Various (e.g., B. lactis, B. breve, B. bifidum)""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Various""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus spp."", ""strain_id"": ""Various (e.g., E. faecalis, E. faecium, E. casseliflavus)""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""Various""}, {""role"": ""Chassis"", ""scientific_name"": ""Acetobacter spp."", ""strain_id"": ""Various""}, {""role"": ""Chassis"", ""scientific_name"": ""Gluconacetobacter spp."", ""strain_id"": ""Various""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus spp."", ""strain_id"": ""Various""}, {""role"": ""Chassis"", ""scientific_name"": ""Leuconostoc spp."", ""strain_id"": ""Various""}, {""role"": ""Chassis"", ""scientific_name"": ""Weissella spp."", ""strain_id"": ""Various (e.g., W. cibaria, W. hellenica)""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus spp."", ""strain_id"": ""Various (e.g., B. subtilis)""}, {""role"": ""Chassis"", ""scientific_name"": ""Candida spp."", ""strain_id"": ""Various""}, {""role"": ""Chassis"", ""scientific_name"": ""Zygosaccharomyces spp."", ""strain_id"": ""Various""}]","Encapsulated in food matrix (e.g., dairy, cereal, fruit, vegetable, meat, beverage)",Facultative Anaerobe,"Optimal temperature: 30–40 °C; pH: 5.0–6.5; Nutritional requirements: Carbohydrates (lactose, glucose, fructose), amino acids, vitamins (B-complex), minerals; Growth in dairy, cereal, fruit, vegetable, and fermented substrates",Doubling time: 20–60 min in vitro; Growth rate varies by strain and substrate; In vivo survival enhanced by food matrix protection,"Gastrointestinal tract (small and large intestine), oral cavity, skin (in some cases)",Symbiotic with host microbiota; Competes with pathogenic bacteria; Enhances microbial diversity and stability,"Tolerant to bile salts, low pH (gastric), osmotic stress, moderate heat; Moderate tolerance to drying and lyophilization; Shear stress during processing","Exopolysaccharides (EPS), cell wall components, biofilm formation",多种乳酸菌、双歧杆菌、酵母菌等在乳制品、谷物、果蔬、肉类等基质中通过发酵生长，具有良好的耐酸、耐胆盐和耐受胃肠道环境的能力，可在食品基质中保持活性并促进宿主肠道健康。,"Plasmid-based systems, CRISPR-Cas (in research strains), Recombination (in lab settings)",High in lab strains; Off-target risk low in well-characterized systems,"Constitutive expression; Some inducible systems (e.g., lactose-inducible promoters) in research","Lactose, IPTG (in engineered strains)",High chromosomal stability; Plasmid loss in some strains; Metabolic burden low; Evolutionary drift observed in long-term cultures,Stable in food matrices; EPS production enhances stability in gel-like or viscous environments,通过质粒或染色体整合方式引入功能基因，如产酸、产抗菌物质、产EPS等；多数工业菌株为天然或选育菌株，基因工程应用主要在研究阶段。,"[""pH"", ""Glucose"", ""Lactate"", ""Osmotic stress""]","[""Lactose"", ""Fructose"", ""Sugars"", ""Bile acids""]","[""Quorum sensing (AHL, AI-2)"", ""Bacteriocin signaling""]","[""Proteases"", ""Cytokines (in vivo)""]","FNR promoter (hypoxia), Lac promoter (lactose), Rha promoter (rhamnose), Quorum sensing receptors (e.g., LasR, LuxR)","AND gate (e.g., lactose + low pH), Threshold-based activation, Noise suppression via feedback loops",多种微生物通过感知糖类、pH、胆汁酸等信号启动代谢或功能基因表达，部分菌株具备群体感应系统，实现群体行为调控，如生物膜形成、抗菌物质释放等。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]","Type I, II, III, and VI secretion systems; Lysis; Vesicles (exosomes)",Controlled by food matrix release; Dose determined by CFU/g in product; No external control in commercial products,"High compatibility with dairy, cereal, fruit, vegetable, and fermented matrices; EPS enhances encapsulation and stability",True,True,True,通过产生有机酸（乳酸、乙酸）、细菌素（如乳酸菌素）、过氧化氢等抑制病原菌生长，同时抑制生物膜形成。,"Lactic acid, Bacteriocins (e.g., Lactocin, Plantaricin), Hydrogen peroxide",True,True,True,True,多种乳酸菌在体外和体内均表现出对常见致病菌（如沙门氏菌、大肠杆菌、金黄色葡萄球菌）的抑制作用，且在食品基质中不破坏结构，无明显细胞毒性。,False,,,,,,,True,调节宿主免疫反应，促进抗炎因子（如IL-10）分泌，抑制促炎因子（如TNF-α、IL-6）释放，增强肠道屏障功能。,"Cytokines (IL-10, TGF-β), Polysaccharides (EPS), Bacterial cell wall components",True,促进肠道上皮细胞增殖，增强黏膜屏障，调节细胞外基质合成，改善肠道通透性。,"Short-chain fatty acids (SCFAs), Exopolysaccharides (EPS), Growth factors",True,产生短链脂肪酸（如乙酸、丙酸、丁酸），调节宿主能量代谢、脂质代谢和血糖水平，影响神经内分泌功能。,"Short-chain fatty acids (SCFAs), Tryptophan metabolites (e.g., indole derivatives)",False,,,GRAS,"Auxotrophy (e.g., amino acid auxotrophy in some strains), Natural attenuation in gut","Amino acid (e.g., leucine, histidine)",Low pathogenicity; No known virulence genes; Antibiotic resistance genes absent in most strains; Low HGT risk; No environmental escape reported,"Physical barrier provided by food matrix (e.g., gel, solid, viscous liquid)",所列微生物多为GRAS菌株，广泛用于食品工业，无已知致病性，抗生素抗性基因罕见，基因水平转移风险低，且在食品基质中可被有效物理隔离，安全性高。,多项研究证实，乳酸菌和双歧杆菌等益生菌可显著改善肠道健康，降低胆固醇、血压，增强免疫力，促进营养吸收，改善代谢综合征，具有良好的临床和功能效益。,8548,2421,10969,,
33c918d0-3443-4906-a06c-66341596887d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""BLC1""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.45–6.62; tolerant to moderate osmotic stress from milk components (lactose, sucrose, casein); requires complex nutrients from milk matrix","Survival rate of 84.7% after 120 days of frozen storage; initial viability of 8.2 log CFU/g, maintained at 6–7 log CFU/g throughout storage",Gastrointestinal tract (target niche for probiotic function),No direct interaction data reported; assumed neutral or potentially beneficial via competitive exclusion of pathogens,"High tolerance to freezing (-18°C), moderate tolerance to bile and pancreatin; reduced viability during gastric phase (1.24–1.00 log reduction), significant loss during enteric phase (3.82 log reduction)","Casein, sucrose, lactose (cryoprotective matrix in ice cream)","Bifidobacterium animalis subsp. lactis BLC1 exhibits good viability in goat’s milk ice cream during processing and frozen storage, with minimal impact on physicochemical properties. It survives freezing and maintains high viability (6–7 log CFU/g) over 120 days, indicating strong cryotolerance. However, it shows moderate resistance to simulated gastrointestinal conditions, particularly bile and pancreatin, with significant viability loss during enteric phase.",,,,,,,"No genetic modifications were applied. The strain was used in its native form as a probiotic delivery vehicle. No engineered circuits, promoters, or inducible systems were employed.",,,,,,,"No sensing or logic modules were engineered. The strain relies on intrinsic physiological responses to environmental changes (e.g., pH, bile) without synthetic biological circuitry.","[""Probiotic Survival"", ""Gastrointestinal Tolerance""]",Passive release via cell lysis or natural secretion (inherent to strain); no engineered secretion system used,No active dosage control; viability is passively maintained through formulation and storage,"High compatibility with ice cream matrix; cryoprotective components (casein, sucrose, lactose) enhance survival; no structural disruption observed",False,,,Not applicable – no antibacterial mechanism engineered or reported.,,,,,,无抗菌功能,False,Not applicable – no oxygen-producing mechanism reported.,,,,,无氧合功能,False,Not applicable – no immunomodulatory factors reported.,,False,Not applicable – no tissue repair factors reported.,,False,Not applicable – no metabolic regulation via secreted metabolites reported.,,False,Not applicable – no tumor-targeting or prodrug conversion mechanisms reported.,,BSL-1,None – no kill-switch or auxotrophy used,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk identified; low environmental escape risk due to non-native habitat and poor environmental persistence,Physical confinement via polyethylene packaging and frozen storage; effective in preventing release,"Bifidobacterium animalis subsp. lactis BLC1 is a well-established probiotic strain with GRAS status. It poses minimal biosafety risk (BSL-1). No genetic modifications were made, and no biocontainment strategies were implemented. The physical barrier of packaging and freezing provides adequate containment. No evidence of pathogenicity, antibiotic resistance, or environmental persistence was found.",该研究未评估治疗功效，但结果显示B. animalis subsp. lactis BLC1在山羊奶冰淇淋中具有良好的存活率（6–7 log CFU/g），在120天冷冻储存后仍保持84.7%的存活率。在模拟胃肠条件下，尽管在胆汁和胰酶作用下有3.82 log的下降，但其存活能力仍优于多数同类研究，表明其作为益生菌载体具有良好的技术潜力和应用前景。,11491,1499,12990,,
fbd7b0ed-deb5-4667-be7c-f3a7d1c0a724,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""LGG""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium"", ""strain_id"": ""Various spp.""}]","Entirely administered enterally (oral), colonizing the gastrointestinal tract",Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acidity and bile salts; utilizes lactose and other carbohydrates as carbon sources",Moderate growth rate; doubling time ~1–2 hours in vitro; colonization observed in vivo after oral administration,"Gastrointestinal tract (GIT), particularly colonizing the intestinal mucosa and lumen","Competitive exclusion of pathogenic bacteria (e.g., Enterobacter, Veillonella); promotes colonization by beneficial commensals; modulates host immune responses",Resistant to gastric acid and bile; stable during lyophilization and storage at 4°C; tolerates moderate osmotic stress,"Cell envelope components (e.g., exopolysaccharides), acid tolerance systems (e.g., F1F0-ATPase)","Lactobacillus rhamnosus GG and Bifidobacterium spp. are human-origin, non-pathogenic, acid- and bile-tolerant bacteria that can survive gastrointestinal transit and colonize the neonatal gut. They grow under facultative anaerobic conditions and are capable of adhering to intestinal epithelial cells, thereby enhancing mucosal barrier integrity and modulating immune function.",Not explicitly mentioned; likely natural strains used without genetic modification,,Constitutive (natural expression of functional genes),,High chromosomal stability; no plasmid-based systems reported; low metabolic burden; long-term in vivo persistence observed in clinical studies,Stable in oral formulations and enteral feeding preparations,"No genetic engineering was applied in the described studies. Probiotic strains were used in their natural form, relying on intrinsic biological properties for functionality. The beneficial effects are attributed to native metabolic and immunomodulatory capabilities.","[""pH"", ""Bile acids""]","[""Lactose"", ""Glucose"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing molecules (e.g., AI-2)""]","[""Proteases"", ""Cytokines (e.g., IL-10, IFN-γ)""]","FNR-like regulators (pH sensing), bile salt hydrolases (bile sensing), lactose permease (nutrient sensing), TLR2/4 (host immune recognition)",No engineered logic gates; natural sensing and response integration via metabolic and immune pathways,"The microbes naturally sense environmental cues such as low pH and bile acids in the gut, triggering adaptive responses like acid tolerance and bile resistance. They detect host-derived signals (e.g., cytokines) and microbial metabolites, enabling coordinated immune modulation and competitive exclusion of pathogens through natural regulatory networks.","[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion (e.g., for bacteriocins), passive diffusion (e.g., for SCFAs), and extracellular vesicles",Dose-dependent effects; efficacy observed at 10^8–10^10 CFU/day; no engineered feedback control,Compatible with oral formulations and enteral feeding tubes; stable in gel-like or powder-based delivery systems,True,True,True,"Production of bacteriocins (e.g., lactocin, reuterin), organic acids (lactic acid), and hydrogen peroxide; competitive exclusion of pathogens from intestinal binding sites","Lactocin, reuterin, lactic acid, hydrogen peroxide",True,True,True,True,"Probiotics reduce colonization by pathogenic bacteria (e.g., Enterobacter, Veillonella) and inhibit biofilm formation in neonatal gut models. No significant disruption of gut structure or excessive inflammation reported in clinical trials.",False,,,False,False,False,,True,"Modulate host immune responses by enhancing IgA production, increasing anti-inflammatory cytokines (IL-10), decreasing pro-inflammatory cytokines (TNF-α), and promoting Th1/Th2 balance","Immunoglobulin A (IgA), Interleukin-10 (IL-10), Interferon-gamma (IFN-γ)",True,"Strengthen intestinal tight junctions, increase mucus production, reduce mucosal permeability, and promote epithelial regeneration","Tight junction proteins (e.g., occludin, ZO-1), mucin (MUC2)",True,"Produce short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate, which regulate host metabolism, energy homeostasis, and immune function",Short-chain fatty acids (SCFAs),False,,,BSL-1,"Auxotrophy (natural requirement for specific nutrients), non-pathogenicity, no antibiotic resistance genes reported","Lactose, specific amino acids",Low pathogenicity; rare cases of sepsis reported in immunocompromised infants; no evidence of horizontal gene transfer; low environmental escape risk,Oral administration limits systemic exposure; gut mucosal barrier provides physical confinement,"Lactobacillus rhamnosus GG and Bifidobacterium spp. are generally recognized as safe (GRAS) for neonates. Although rare adverse events (e.g., sepsis) have been reported in immunocompromised infants, no significant safety concerns were observed in large clinical trials. The use of natural, non-engineered strains reduces risks associated with genetic modification.","Probiotic supplementation significantly reduces the incidence of severe necrotising enterocolitis (Bell Stage ≥2) and all-cause mortality in preterm infants. It improves feeding tolerance, reduces hospital stay, enhances immune maturation, and may prevent atopic eczema in high-risk term infants. Long-term neurodevelopmental outcomes remain under investigation.",9179,1924,11103,,
ad84be4d-37bb-47f9-bd50-771e35450afd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus johnsonii"", ""strain_id"": ""BS15""}]",Oral gavage suspension,Facultative Anaerobe,"37°C, anaerobic environment, MRS broth, pH neutral",36 hours for culture; colonization confirmed in small intestine after oral gavage,Small intestine (jejunum and ileum),Competitive exclusion of Enterobacteriaceae; increases Lactobacillus spp. and L. johnsonii BS15 abundance; modulates gut microbiota balance,"Stable under oral administration, survives gastric transit and intestinal environment; no data on UV, drying, or shear stress",,该菌株在37°C、厌氧条件下于MRS培养基中培养36小时，通过口服给药可在小鼠肠道（空肠和回肠）成功定植，具有良好的肠道耐受性和定植能力。,,,,,,,该研究未对L. johnsonii BS15进行基因改造，其功能依赖于天然生理特性，未使用任何基因编辑工具或合成生物学元件。,,,,,,,该菌株未被工程化设计为响应特定信号，其作用机制基于天然生态位适应性，无明确的传感逻辑模块。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Passive secretion via natural metabolism; no engineered secretion system,"Oral gavage at fixed dose (1×10⁹ CFU/mL), daily administration; no feedback control",Compatible with oral suspension delivery; no encapsulation or material barrier used,False,False,False,未涉及抗菌或抗生物膜功能。,,False,False,False,False,无抗菌功能证据。,False,未涉及氧气生成或氧合功能。,,False,False,False,无氧合功能证据。,True,通过调节肠道黏膜免疫，降低sIgA水平，改善肠道屏障功能，减轻氟中毒引起的免疫过度激活。,sIgA (secretory immunoglobulin A),True,促进小肠绒毛高度恢复，增加隐窝深度，提高Vh/Cd比值，改善肠道结构完整性；增加杯状细胞数量，增强黏液屏障。,"Mucin (from goblet cells), intestinal villus structure",True,调节肠道微生态平衡，抑制有害菌（如Enterobacteriaceae）增殖，促进有益菌（Lactobacillus spp.）定植，改善肠道代谢环境。,Short-chain fatty acids (SCFAs) – inferred from microbiota modulation,False,未涉及肿瘤治疗功能。,,GRAS,None (no synthetic kill-switch or auxotrophy used),,"Non-pathogenic, widely used as probiotic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape concerns in this study.",None (oral delivery without physical confinement),"L. johnsonii BS15 is a GRAS (Generally Recognized As Safe) strain with established safety profile in animal models. No genetic modifications were made, and no biocontainment strategies were employed. The risk of pathogenicity, antibiotic resistance, or environmental escape is negligible under the experimental conditions.",L. johnsonii BS15显著逆转了慢性氟中毒诱导的记忆功能障碍，改善了海马区突触可塑性相关基因（Dbn、MAP-2、NMDAR、SYP）的表达，增强了抗氧化能力（血清和海马组织中T-AOC、SOD、GSH-Px活性升高，MDA含量降低），并有效保护小肠结构（绒毛高度增加、隐窝深度改善、Vh/Cd比值升高、杯状细胞增多），同时调节肠道菌群平衡，抑制Enterobacteriaceae过度增殖，提升肠道屏障完整性，减轻心理应激对记忆功能的负面影响。,15840,1468,17308,,
a94822f6-9fdc-436e-8f50-92f962b5c2f6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, requires fermentable carbohydrates (e.g., glucose, lactose), dependent on host-derived nutrients in gut environment",Doubling time ~1–2 hours in vitro; stable in vivo colonization over 10-week trial,"Intestinal mucosa, particularly in the ceca and small intestine","Symbiotic with host microbiota; competes with pathogenic bacteria (e.g., Salmonella, E. coli) via competitive exclusion and bacteriocin production",Moderate tolerance to gastric acid and bile salts; stable during lyophilization and rehydration; resistant to moderate shear stress in feed processing,"Bile salts, mucin-binding proteins, extracellular polysaccharides",该益生菌混合物由四种乳酸菌和双歧杆菌组成，均为兼性厌氧菌，可在鸡肠道内定植并维持稳定生长。其生长依赖于饲料中的可发酵碳水化合物，对胃酸和胆汁具有中等耐受性，适合在禽类消化道环境中长期存活。,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,该研究未对益生菌进行基因改造，其功能依赖于天然代谢特性，如胆汁酸结合、胆固醇降解和短链脂肪酸生成。,"[""pH"", ""Glucose"", ""Lactate""]","[""Cholesterol"", ""Bile Acids""]","[""Quorum Sensing (AHL)""]","[""Proteases"", ""Cytokines""]","Lactate receptor (LctP), bile acid transporter (BaiS), cholesterol-binding protein (CbiA)",Threshold-based activation of cholesterol metabolism pathways; feedback inhibition by bile acid accumulation,这些益生菌通过感知肠道内的乳酸、胆汁酸和胆固醇浓度变化，启动代谢调控机制。当胆固醇水平升高时，菌株通过结合胆汁酸和降解胆固醇来响应，形成负反馈调节回路，维持宿主脂质稳态。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Antibacterial""]","Type I secretion system (for bacteriocins), Lysis (for metabolite release)",Dose-dependent; controlled by dietary inclusion rate (0.1%),Compatible with feed matrix; stable during pelleting and storage,True,True,True,通过产生乳酸、细菌素（如乳酸菌素）和竞争性排斥机制抑制病原菌生长，防止生物膜形成。,"Lactic acid, Bacteriocins (e.g., Lactocin, Enterocin)",True,True,True,True,益生菌在鸡肠道中有效抑制了有害菌群，未引起组织损伤或炎症反应，且在饲料中稳定存在，无过度活性。,False,Not applicable,Not applicable,False,False,False,Not applicable,True,调节宿主免疫反应，增强巨噬细胞活性，促进抗炎细胞因子（如IL-10）分泌，抑制促炎因子（如TNF-α）。,"IL-10, TGF-β, Lipoteichoic acid (LTA)",False,Not applicable,Not applicable,True,通过发酵纤维产生短链脂肪酸（如乙酸、丙酸、丁酸），调节胆固醇代谢，降低血清和蛋黄胆固醇水平。,"Acetate, Propionate, Butyrate",False,Not applicable,Not applicable,GRAS,"Auxotrophy (e.g., requirement for specific amino acids or vitamins)","Amino acid auxotrophs (e.g., leucine, threonine)",Low pathogenicity; no known antibiotic resistance genes; low risk of horizontal gene transfer; no environmental escape reported,Feed matrix provides physical confinement; no release into environment,该益生菌混合物为公认安全（GRAS）菌株，无致病性，不携带耐药基因，且在饲料中被物理限制，不会逃逸至环境。其代谢功能在宿主肠道内可控，安全性高。,饲喂7.5% Artemisia annua叶片和0.1%益生菌混合物显著降低了蛋黄胆固醇（P<0.01），改善了饲料转化率（FCR），提高了蛋壳厚度和蛋黄颜色，同时增强了血浆抗氧化能力（GSH-Px升高，MDA降低），且未对产蛋性能产生负面影响。,8819,1735,10554,,
1c95fc58-b25d-421d-9007-ec5d71430071,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""PB6""}]",Encapsulated,Facultative Anaerobe,Temperature: 21–30 °C (thermoneutral to heat stress); pH: not specified; Osmotic: not specified; Nutrition: dietary supplementation via feed (3 × 10⁷ cfu/kg); naturally occurring in chicken intestine,Growth rate not directly measured; spores maintain viability under long-term ambient storage; effective in vivo under heat stress (30 °C) and thermoneutral (21 °C) conditions,"Intestinal lumen of broiler chickens (duodenum, jejunum, ileum)","Competitive exclusion of pathogenic bacteria (Clostridium, Coliforms); promotion of beneficial bacteria (Lactobacillus, Bifidobacterium)","High tolerance to heat stress (30 °C), long-term ambient storage, and harsh environmental conditions due to spore formation",Spores of Bacillus subtilis,"Bacillus subtilis PB6 strain is a spore-forming bacterium naturally present in healthy chickens. It maintains viability under heat stress (30 °C) and ambient storage, colonizes the intestinal tract, and supports intestinal health and growth performance in broiler chickens during thermal challenges.",,,,,,,该研究未对 Bacillus subtilis 进行基因工程改造，其功能依赖于天然菌株的生理特性，如产生有益代谢物、调节肠道菌群平衡和增强肠道屏障功能。,"[""Heat Stress (30 °C)"", ""pH (intestinal environment)""]","[""Glucose"", ""Cholesterol""]","[""Clostridium"", ""Coliforms"", ""Lactobacillus"", ""Bifidobacterium""]","[""Growth Hormone (GH)"", ""Insulin-like Growth Factor-1 (IGF-1)""]",Not specified (natural sensing of environmental and host signals),Not applicable (no engineered logic circuits),"Bacillus subtilis does not possess engineered sensing circuits. It naturally responds to host physiological changes (e.g., heat stress) and microbial community shifts by modulating its colonization and metabolic activity to restore intestinal homeostasis.","[""Tissue Repair"", ""Metabolic Regulation"", ""Immunomodulation""]",Not specified (likely passive secretion via cell lysis or natural excretion),Dose-dependent effect: 3 × 10⁷ cfu/kg feed; effective under both thermoneutral and heat stress conditions,Encapsulated form ensures stability and controlled release in feed; compatible with dietary delivery,False,False,False,Not applicable (no direct antibacterial mechanism reported),,False,False,False,False,未报告抗菌活性或生物膜抑制作用。,False,Not applicable (no oxygenation mechanism reported),,False,False,False,未报告氧气生成或氧合功能。,True,"Modulates intestinal immune homeostasis by reducing inflammation, enhancing barrier integrity, and promoting beneficial microbiota, indirectly supporting immune function.",Not specified (likely via microbial metabolites and structural components),True,"Improves intestinal villus height, crypt depth, villus surface area, and absorptive epithelial cell area; enhances skeletal muscle size and tibia traits (weight, length, density, ash content).",Not specified (likely via growth-promoting metabolites and microbiota modulation),True,Maintains normal serum levels of glucose and cholesterol; reduces abdominal fat pad deposition; enhances insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels.,"Glucose, Cholesterol, IGF-1, Growth Hormone",False,Not applicable,,GRAS,"None (natural strain, no engineered kill switches)",,"Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; safe for animal use (EFSA, 2007)",Encapsulation provides physical confinement and protects spores during feed processing and storage,Bacillus subtilis PB6 是一种被广泛认可的安全菌株（GRAS），天然存在于健康鸡肠道中，无致病性，无抗生素抗性基因，且通过包埋形式使用，具有良好的物理屏障保护，安全性高。,Bacillus subtilis PB6 能有效缓解热应激对肉鸡的负面影响，显著改善体增重、饲料转化率、肠道绒毛结构、肌肉和骨骼发育，并维持正常血糖、胆固醇水平及生长激素和IGF-1水平，使热应激肉鸡的生长性能接近热中性对照组水平。,11880,1642,13522,,
f49e71f6-2c34-4b16-a61a-fe9452194e22,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""Not specified""}]",Oral administration (gut lumen),Facultative Anaerobe,"Optimal growth at 30–37°C, pH 6.0–7.0, tolerant to bile salts and gastric acidity; utilizes lactose and other sugars as carbon sources",Moderate growth rate; doubling time ~60–90 min in vitro; stable colonization in intestinal lumen in vivo,"Gut lumen, particularly inflamed intestinal mucosa in IBD",Competitive exclusion of pathogenic bacteria; symbiotic with host microbiota; minimal disruption to native microbiome,"Tolerant to bile, low pH, osmotic stress; stable during lyophilization and rehydration","Bile salts, gastric acid, osmotic stressors",乳酸乳球菌为兼性厌氧菌，可在胃肠道环境中稳定生长，耐受胃酸和胆汁，适合口服给药。其在炎症性肠病（IBD）患者的肠道黏膜中可定植并持续释放治疗性蛋白，具有良好的生物相容性和安全性。,"Plasmid-based expression systems (e.g., pNZ8048), CRISPR-Cas9 for gene editing",High efficiency (>90%) with low off-target effects; stable plasmid maintenance in gut environment,Constitutive expression of IL-10; inducible systems under development,Not specified,High plasmid stability (copy number ~10–20); no chromosomal integration; low metabolic burden; evolutionarily stable in gut over time,Stable in oral formulations and intestinal mucus; compatible with mucoadhesive carriers,通过质粒系统在乳酸乳球菌中稳定表达抗炎细胞因子IL-10，用于治疗炎症性肠病。该菌株经工程改造后可在肠道炎症部位持续释放IL-10，调节免疫反应，减轻炎症症状。,"[""pH"", ""Oxygen deficiency (hypoxia)""]","[""Lactate"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing (AI-2)""]","[""Proteases (e.g., MMPs)"", ""Cytokines (e.g., TNF-α)""]","FNR promoter (hypoxia), Lactate-responsive promoters, TNF-α-responsive elements",AND gate: requires both low oxygen and high TNF-α for optimal IL-10 expression; threshold-based activation in inflamed tissue,该系统通过整合低氧和炎症因子（如TNF-α）信号，实现“AND”逻辑门控制，确保仅在炎症性肠病的病灶部位激活IL-10的表达，避免在健康组织中过度表达，从而提高靶向性和安全性。,"[""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion via Sec pathway; no lysis or vesicle release reported,Tunable via promoter strength and plasmid copy number; in vivo expression self-limited by immune clearance,"Compatible with oral tablets, capsules, and mucoadhesive gels; stable in gastrointestinal environment",False,,,Not applicable,,,,,,无抗菌功能,False,Not applicable,,,,,无氧生成功能,True,在肠道炎症部位持续分泌抗炎细胞因子IL-10，抑制TNF-α等促炎因子，调节Th1/Th2平衡，减轻肠道炎症反应。,Interleukin-10 (IL-10),True,通过分泌IL-10促进上皮细胞再生，增强肠道屏障功能，修复受损黏膜，改善肠道通透性。,Interleukin-10 (IL-10),False,Not applicable,,False,Not applicable,,GRAS,"Auxotrophy (e.g., auxotrophic for essential amino acids); suicide genes under development","Auxotrophic markers (e.g., ilvG, hisD)",Non-pathogenic; low risk of horizontal gene transfer; no known antibiotic resistance genes; minimal immunogenicity,Oral delivery with intestinal mucus barrier; limited systemic dissemination,乳酸乳球菌为公认安全（GRAS）菌株，无致病性，不产生内毒素，可在肠道内定植并被宿主免疫系统安全清除。其工程改造菌株通过营养缺陷型和自杀基因实现生物遏制，安全性高，已进入I期临床试验。,在小鼠炎症性肠病模型中，口服工程化乳酸乳球菌显著减轻结肠炎症、降低疾病活动指数（DAI），促进黏膜修复，疗效优于传统药物。在I期临床试验中，患者耐受性良好，炎症标志物（如CRP、TNF-α）明显下降。,10548,4983,15531,,
f49e71f6-2c34-4b16-a61a-fe9452194e22,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Clostridium novyi-NT"", ""strain_id"": ""Δ6M55""}]",Intratumoral injection (spores),Strict Anaerobe,"Grows only in hypoxic environments (e.g., necrotic tumor core); optimal at 37°C, pH 6.5–7.0; requires complex nutrients including amino acids and vitamins",Slow growth rate; doubling time ~4–6 hours in vitro; limited proliferation in vivo due to immune clearance,"Hypoxic tumor core, necrotic regions of solid tumors",Competitive exclusion of commensals; no known symbiosis; may disrupt local microbiome,"High tolerance to hypoxia, low pH, and osmotic stress; spores are highly stable during lyophilization and storage","Spore coat proteins, DNA repair enzymes",破伤风梭菌NT为严格厌氧菌，其孢子可在肿瘤缺氧核心中萌发并增殖，具有靶向肿瘤组织的能力。孢子对干燥、低温和胃肠道环境具有极强耐受性，适合通过注射或口服给药。,"CRISPR-Cas9, Recombination (λ-Red), Transposon mutagenesis",High efficiency (>85%); low off-target risk; stable chromosomal integration,Constitutive expression of therapeutic genes; inducible systems under development,Not specified,High chromosomal stability; no plasmid loss; low metabolic burden; evolutionarily stable in tumor microenvironment,Stable in spore form; compatible with injectable hydrogels and tumor-targeting carriers,通过CRISPR-Cas9技术对破伤风梭菌NT进行基因改造，使其在肿瘤缺氧区表达抗肿瘤蛋白（如IL-2）或前药活化酶（如胞嘧啶脱氨酶），实现靶向肿瘤治疗。,"[""Hypoxia"", ""Low pH"", ""Lactate""]","[""Nitrate"", ""Bile acids (in systemic circulation)""]","[""Quorum sensing (AHL)""]","[""Proteases (e.g., MMP-9)"", ""Cytokines (e.g., IL-6)""]","FNR promoter (hypoxia), Lactate-responsive promoters, MMP-9-responsive elements",AND gate: requires hypoxia + low pH + high lactate for optimal gene expression; noise suppression via thresholding,该系统通过整合缺氧、酸性环境和乳酸积累等肿瘤微环境信号，实现“AND”逻辑门控制，确保仅在肿瘤核心区域激活治疗基因表达，避免在正常组织中非特异性激活，提高安全性。,"[""Tumor Therapy"", ""Immunomodulation""]",Spore germination → vegetative growth → secretion of therapeutic proteins; no lysis or vesicle release reported,Tunable via spore dose; in vivo activity limited by immune clearance and tumor vascularization,Compatible with injectable hydrogels and tumor-targeting carriers; stable in hypoxic matrix,False,,,Not applicable,,,,,,无抗菌功能,False,Not applicable,,,,,无氧生成功能,True,在肿瘤内表达IL-2，激活T细胞和NK细胞，增强抗肿瘤免疫反应，诱导免疫记忆。,Interleukin-2 (IL-2),False,Not applicable,,False,Not applicable,,True,孢子在肿瘤缺氧区萌发并增殖，释放前药活化酶（如胞嘧啶脱氨酶）将5-氟胞嘧啶（5-FC）转化为5-氟尿嘧啶（5-FU），实现局部化疗；同时诱导肿瘤细胞凋亡和免疫原性细胞死亡。,"Cytosine deaminase (CD), 5-Fluorouracil (5-FU)",BSL-2,"Auxotrophy (e.g., auxotrophic for threonine); suicide genes (e.g., ccdB); temperature-sensitive replication","Threonine auxotrophy, ccdB toxin-antitoxin system",Moderate pathogenicity; potential for systemic infection if immune-compromised; no known antibiotic resistance genes; low HGT risk,Intratumoral injection limits systemic spread; spores are cleared by immune system,破伤风梭菌NT为BLS-2级病原体，虽经减毒改造，但仍具潜在致病性。通过营养缺陷型和自杀基因实现生物遏制，确保在肿瘤外无法增殖。临床试验中采用局部注射，有效控制了系统性风险，安全性可控。,在多种实体瘤小鼠模型中，注射破伤风梭菌NT孢子后，肿瘤体积显著缩小，部分肿瘤完全消退。在I期临床试验中，患者耐受性良好，部分晚期肿瘤患者出现客观缓解，且未见严重不良反应。,10548,4983,15531,,
f49e71f6-2c34-4b16-a61a-fe9452194e22,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Salmonella typhimurium"", ""strain_id"": ""VNP20009""}]",Intravenous injection (systemic delivery),Facultative Anaerobe,"Grows in both aerobic and anaerobic conditions; optimal at 37°C, pH 6.5–7.5; tolerates bile and low pH",Fast growth rate; doubling time ~20–30 min in vitro; moderate in vivo persistence,"Tumor core, hypoxic and necrotic regions; also colonizes lymph nodes",Competitive with gut microbiota; may disrupt microbiome; no known symbiosis,"Tolerant to bile, low pH, osmotic stress, and shear stress; stable in blood circulation","Outer membrane proteins, stress response regulators (e.g., RpoS)",伤寒沙门氏菌为兼性厌氧菌，可在肿瘤缺氧区增殖，具有良好的系统性靶向能力。其对胃肠道环境和血液中的应激条件具有较强耐受性，适合静脉注射给药。,"CRISPR-Cas9, Recombination (λ-Red), Transposon mutagenesis",High efficiency (>90%); low off-target risk; stable chromosomal integration,"Inducible (e.g., arabinose promoter); constitutive expression of therapeutic genes",L-arabinose,High chromosomal stability; no plasmid loss; low metabolic burden; evolutionarily stable in tumor,Stable in systemic circulation; compatible with nanoparticle carriers,通过基因工程改造伤寒沙门氏菌VNP20009，使其在肿瘤微环境中表达IL-4或Pseudomonas exotoxin，实现靶向肿瘤治疗。使用阿拉伯糖诱导系统控制治疗基因表达，提高安全性。,"[""Hypoxia"", ""Low pH"", ""Lactate""]","[""Nitrate"", ""Bile acids""]","[""Quorum sensing (AHL)""]","[""Proteases (e.g., MMP-9)"", ""Cytokines (e.g., IL-6)""]","FNR promoter (hypoxia), Lactate-responsive promoters, IL-6-responsive elements",AND gate: requires hypoxia + low pH + high lactate for optimal gene expression; threshold-based activation,该系统通过整合缺氧、酸性环境和乳酸积累等肿瘤微环境信号，实现“AND”逻辑门控制，确保治疗基因仅在肿瘤组织中表达，避免在正常组织中激活，提高靶向性和安全性。,"[""Tumor Therapy"", ""Immunomodulation""]",Constitutive secretion via Type III secretion system; no lysis or vesicle release reported,Tunable via arabinose induction; in vivo expression limited by immune clearance,Compatible with systemic delivery; stable in blood and tumor microenvironment,False,,,Not applicable,,,,,,无抗菌功能,False,Not applicable,,,,,无氧生成功能,True,在肿瘤内表达IL-4，激活巨噬细胞向M1表型极化，增强抗肿瘤免疫反应。,Interleukin-4 (IL-4),False,Not applicable,,False,Not applicable,,True,在肿瘤内表达Pseudomonas exotoxin，诱导肿瘤细胞凋亡；同时通过免疫激活增强抗肿瘤效应。,"Pseudomonas exotoxin (PE), IL-4",BSL-2,"Auxotrophy (e.g., auxotrophic for tryptophan); suicide genes (e.g., ccdB); temperature-sensitive replication","Tryptophan auxotrophy, ccdB toxin-antitoxin system",Moderate pathogenicity; potential for systemic infection; no known antibiotic resistance genes; low HGT risk,Systemic delivery with immune clearance; limited persistence in normal tissues,伤寒沙门氏菌VNP20009为BLS-2级病原体，经基因改造后安全性提高。通过营养缺陷型和自杀基因实现生物遏制，确保在肿瘤外无法增殖。静脉注射后可靶向肿瘤，临床试验中显示良好耐受性。,在多种实体瘤小鼠模型中，静脉注射VNP20009后，肿瘤生长显著抑制，部分肿瘤完全消退。在I期临床试验中，患者耐受性良好，部分晚期患者出现疾病稳定或部分缓解。,10548,4983,15531,,
8df07a1c-dae1-4879-85a5-c0a318e202c8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""UAM1""}]",Suspension,Facultative Anaerobe,"Temperature: 35–37 °C; pH: 6.0–7.0 (MRS broth); Nutritional requirements: Complex media (MRS), no specific auxotrophies reported; Bile tolerance: 0.3% bile, growth delayed but sustained.",Growth rate: Not quantified; Doubling time: Not reported; In vivo vs in vitro: In vitro growth confirmed; In vivo homeostasis inferred from gastrointestinal tolerance.,"Intestinal tract (small intestine, mucus layer); Niche preference: Competitive colonization in gut lumen.",High co-aggregation with Gram-positive and Gram-negative pathogens; potential for competitive exclusion; no direct symbiosis reported.,"High resistance to gastric stress (pH 2.0, 180 min); moderate resistance to bile (0.3%); thermotolerant (survived 70 °C for 30 min); stable at -80 °C with glycerol.",Glycerol (for cryopreservation); cell envelope components (for acid/bile resistance),该菌株为耐热乳酸菌，可在35–37 °C下生长，对胃酸（pH 2.0）和小肠环境（含胰蛋白酶）具有较强耐受性，能在0.3%胆汁中生长，表明其具备在肠道环境中定植的生理基础。,,,,,,,未提及基因工程改造，所有特性均为天然表型，未进行人工遗传修饰。,"[""pH"", ""Bile""]",,,,Unknown (no specific receptor or promoter identified),No logic circuits described; response is likely constitutive based on observed tolerance.,未描述传感与逻辑处理机制，所有生理响应为天然耐受性，无工程化调控逻辑。,"[""Antibacterial"", ""Adhesion"", ""Immunomodulation""]",Unknown (no secretion system described),Not applicable (no engineered output control),Not applicable (no material encapsulation described),True,True,False,通过与病原菌共聚集（co-aggregation）抑制其定植，间接发挥抗菌作用。,Unknown (no bacteriocin or secreted antimicrobial identified),True,True,True,True,该菌株能与多种革兰氏阳性及阴性病原菌（如沙门氏菌、大肠杆菌、金黄色葡萄球菌）发生共聚集，表明其具有广谱抗菌潜力；未见细胞裂解或过度代谢活动，安全性良好。,False,,,False,False,False,未提及产氧或氧代谢相关功能。,True,通过黏附于肠上皮细胞（Caco-2）并形成生物屏障，可能调节宿主免疫反应，增强肠道屏障功能。,"Adhesion proteins (e.g., surface adhesins) or exopolysaccharides (not identified)",False,,,False,,,False,,,BSL-1,None (no kill-switch or auxotrophy reported),,Low pathogenicity; no antibiotic resistance genes detected; no horizontal gene transfer risk reported; GRAS status not confirmed.,None (no physical barrier described),该菌株为食品源性乳酸菌，对胃酸和胆汁耐受性强，无致病性报道，且对多种抗生素敏感，未检测到耐药基因，风险较低，适合用于功能性食品开发。,该菌株在体外表现出优异的黏附能力（约20%），显著高于Lactobacillus acidophilus LA-5（6%）和Pediococcus pentosaceus菌株（2%-5%），且对胃酸和小肠环境具有高耐受性，具备良好的肠道定植潜力，是功能性食品中极具前景的候选益生菌。,17939,1488,19427,,
3cd27dfb-0956-42d2-959a-8011cbba7ba9,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; requires complex media with amino acids, vitamins, and carbohydrates; dependent on host-derived nutrients in vivo",Doubling time ~60–90 minutes in vitro; in vivo growth limited by host immune response and competition with resident microbiota,"Gastrointestinal tract (small intestine), mucosal surface of the gut; transient presence in bloodstream under immunocompromised or invasive device conditions",Commensal; competes with pathogenic bacteria for adhesion sites and nutrients; may modulate host immune response; minimal disruption to core gut microbiome,Moderate tolerance to gastric acid and bile; sensitive to drying and UV; stable during lyophilization and rehydration; shear stress sensitivity in liquid formulations,"Cell wall components (e.g., peptidoglycan, exopolysaccharides); intrinsic acid resistance mechanisms","Lactobacillus GG is a facultative anaerobe capable of growing in the human gut under physiological conditions. It exhibits moderate stress tolerance, particularly to gastric acid and bile, enabling transient survival in the gastrointestinal tract. However, it lacks robust environmental persistence and is sensitive to drying and UV exposure. Its growth in vivo is constrained by host immunity and microbial competition.",,,,,Chromosomal integration not reported; likely maintained as plasmid or chromosomal copy without artificial selection; no evidence of long-term in vivo stability or engineered genetic circuits,No engineered genetic systems; natural strain used without synthetic biology modifications,"Lactobacillus GG is used in its native form without genetic modification. No synthetic circuits, inducible promoters, or engineered control systems are employed. The strain is administered as a probiotic without any genetic engineering for therapeutic function.","[""pH"", ""Bile""]","[""Glucose"", ""Lactate""]",,"[""Proteases"", ""Cytokines""]",FNR-like regulators (hypoxia); bile salt hydrolase (BSH) for bile sensing; lactate permease (LctP) for lactate uptake,"No engineered logic gates; natural sensing via metabolic and environmental cues with threshold-based responses (e.g., acid resistance induction at pH < 5.0)",Lactobacillus GG naturally senses environmental cues such as low pH and bile salts through intrinsic regulatory systems. It activates acid resistance mechanisms and bile tolerance pathways upon exposure. These responses are threshold-dependent and do not involve synthetic logic circuits. The strain does not exhibit complex signal integration or noise filtering beyond native physiological adaptation.,"[""Immunomodulation"", ""Colonization Resistance""]",Passive diffusion and cell lysis (natural release of metabolites and proteins),"Dose determined by standard probiotic administration (e.g., 10^10 CFU/day); no dynamic or feedback-controlled release",Compatible with oral suspension and tube feeding; no encapsulation in biomaterials reported,False,,,,,False,False,False,False,未报告抗菌或抗生物膜活性,False,,,False,False,False,未报告氧气生成能力,True,通过调节肠道免疫反应，增强抗炎细胞因子（如IL-10）分泌，抑制促炎因子（如TNF-α、IL-6），并促进黏膜屏障功能。,"Exopolysaccharides (EPS), surface proteins (e.g., p40, p75), and secreted metabolites",False,,,False,,,False,,,BSL-1,None (natural strain without engineered kill switches or auxotrophy),,Low pathogenicity; opportunistic bacteremia in immunocompromised or device-implanted patients; no antibiotic resistance genes reported; low horizontal gene transfer risk; potential for environmental contamination during handling,No physical barrier; administration via open room handling increases risk of aerosolization and cross-transmission,"Lactobacillus GG is classified as GRAS (Generally Recognized As Safe) and BSL-1. However, in patients with central venous catheters and feeding tubes, improper handling (e.g., opening capsules in patient room) can lead to environmental contamination and rare cases of bacteremia. The risk is low but clinically significant due to misclassification as CLABSI. No engineered biocontainment is present.","Lactobacillus GG is used to prevent antibiotic-associated diarrhea in hospitalized patients. While not directly involved in wound healing, its role in maintaining gut barrier integrity and modulating systemic immunity may indirectly support recovery. However, in this case, a single blood culture isolate led to a CLABSI classification, highlighting the need for standardized handling to avoid avoidable infections.",3594,1653,5247,,
fb5f18af-5115-4c00-9e11-6b2154b5c124,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal temperature: 37°C; pH: neutral; standard nutrient-rich medium (e.g., LB); no specific mention of bile or osmotic tolerance",Doubling time ~20–30 minutes in rich medium; in vivo consistency not discussed,Not specified,Not specified,Not specified,,大肠杆菌（Escherichia coli）是一种典型的兼性厌氧菌，最适生长温度为37°C，在营养丰富的培养基中生长迅速，倍增时间约为20–30分钟。其生理特性在体外实验中表现稳定，但未提及在体内环境或复杂微生态中的适应性。,"Plasmid-based cloning, BioBrick standard interface, CRISPR-Cas (implied by synthetic biology framework), directed evolution, in silico design",High efficiency in plasmid assembly and DNA synthesis; off-target risk not discussed,"Inducible (e.g., promoter libraries with tunable strength), Boolean logic gates (AND, OR, NOR), negative feedback loops, toggle switches","Tetracycline, theophylline, codeine, s-adenosylmethionine, coenzyme B12 (ligands for riboswitches); IPTG (implied by standard promoter systems)",Plasmid stability depends on replicon and selection markers; chromosomal integration not discussed; metabolic burden and drift not addressed,Not specified,通过标准化生物部件（如BioBrick接口）、合成DNA、定制启动子库和RNA调控元件（如核糖开关），实现了对基因表达的精确控制。利用体外筛选和定向进化优化了基因回路的性能，构建了具备布尔逻辑功能的合成基因网络，如AND、OR、NOR门和双稳态开关，实现了对生物系统输出的可编程调控。,"[""Hypoxia"", ""pH"", ""ROS/RNS""]","[""s-Adenosylmethionine"", ""Coenzyme B12"", ""Tetracycline"", ""Theophylline"", ""Codeine""]","[""AHL"", ""AI-2""]","[""Protease"", ""Cytokine""]","Riboswitches (aptamer domains), engineered RNA regulators, chimeric promoters, SELEX-selected aptamers","AND, OR, NOR, NOT gates; threshold control via ligand concentration; noise suppression via specific aptamer-ligand binding; dynamic range spanning 196-fold; lag/reset not discussed",通过体外筛选获得的合成适配体可特异性识别小分子配体（如四环素、茶碱、可待因），并构建响应这些分子的核糖开关。利用串联核糖开关实现多输入逻辑运算（如NOR门），并结合寡核苷酸感应的别构核酶实现多种布尔逻辑功能。系统具备高特异性、可调动态范围和逻辑控制能力，但其在活细胞中的行为仍受环境背景影响。,"[""Genetic Circuit Control"", ""Metabolic Regulation"", ""Biosensing""]",Not specified,Tunable via promoter strength selection (196-fold range); controlled by ligand concentration,Not specified,False,,,Not applicable,,False,False,False,False,未提及抗菌或抗生物膜功能,False,Not applicable,,False,False,False,未提及氧气生成功能,False,Not applicable,,False,Not applicable,,True,通过合成生物学工具调控代谢通路，如利用核糖开关感知内源性代谢物，调节基因表达以优化代谢流，实现对目标产物的高效合成。,"s-Adenosylmethionine, Coenzyme B12, Tetracycline, Theophylline, Codeine",False,Not applicable,,BSL-1,"Auxotrophy (implied by minimal genome concept), kill switches (not explicitly mentioned)",Not specified,Low pathogenicity; no antibiotic resistance genes mentioned; horizontal gene transfer risk low due to synthetic parts; environmental escape unlikely due to lab containment,Not specified,大肠杆菌（E. coli）为公认的安全菌株（GRAS），常用于合成生物学研究。本研究中使用的工程菌株基于标准生物部件构建，未引入致病基因或耐药基因，且依赖于人工培养条件，逃逸风险极低，符合BSL-1安全等级要求。,未涉及伤口愈合或治疗效果评估，研究聚焦于合成生物学框架的构建与基因回路的可编程性，未报告具体治疗结果。,8336,1653,9989,,
d03e16ef-b5ea-439b-9a62-71aae1a03447,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""LMG 18243""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: 6.4 (MRS broth); Nutritional requirements: MRS broth (complex medium with carbohydrates, amino acids, vitamins, minerals)",Growth rate: Not explicitly quantified; Doubling time: Not reported; In vivo homeostasis: Maintained in simulated gastrointestinal fluids; In vitro: Grew in MRS broth at 37°C under CO₂ incubation,Intestinal tract (target delivery site),No direct interaction data reported; assumed neutral or beneficial due to probiotic nature,"High tolerance to gastric (pH 3) and intestinal (bile, enzymes) conditions due to encapsulation; Resistant to lyophilization and rehydration (via freeze-drying process)",NaCMC-gelatin W/W emulsion matrix,Lactobacillus rhamnosus GG is a facultative anaerobe that grows optimally at 37°C in MRS broth. It is naturally adapted to the human gastrointestinal tract and exhibits high viability under simulated gastric and intestinal conditions when encapsulated in NaCMC-gelatin water-in-water emulsions. The encapsulation significantly enhances its survival during exposure to harsh digestive environments.,,,,,,,No genetic modifications were performed. The system relies on the natural physiology of Lactobacillus rhamnosus GG without any engineered genetic circuits or synthetic biology components. The bacteria are used in their wild-type form for encapsulation and delivery.,,,,,,,No sensing or logic modules are present. The system is passive and does not respond to environmental signals. The bacteria are not engineered to detect or react to physiological cues.,"[""Probiotic Delivery""]",Passive release via matrix degradation; bacteria are entrapped in W/W emulsion droplets and released upon digestion.,Controlled by matrix degradation rate and release kinetics; not actively regulated.,Highly compatible with the NaCMC-gelatin W/W emulsion matrix; no structural collapse observed; supports viable cell retention.,False,False,False,Not applicable – no antibacterial mechanism is engineered or inherent in this system.,,False,False,False,False,No antibacterial activity is reported or engineered in this system.,False,Not applicable – no oxygen-producing enzymes or mechanisms are present.,,False,False,False,No oxygenation function is implemented in the system.,False,Not applicable – no immune-modulating molecules are secreted or engineered.,,False,Not applicable – no tissue repair factors are produced or delivered.,,False,Not applicable – no metabolic regulation via SCFAs or other metabolites is reported.,,False,Not applicable – no tumor-targeting or prodrug conversion mechanisms are present.,,BSL-1,None – no kill switches or auxotrophy used.,,"Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no horizontal gene transfer risk; low environmental escape risk due to edible, biodegradable matrix.",Physical confinement by NaCMC-gelatin matrix prevents uncontrolled release; biodegradable and edible.,"Lactobacillus rhamnosus GG is a well-characterized probiotic strain with GRAS status. The system uses edible, biocompatible materials (gelatin, NaCMC) and does not involve genetic engineering. No safety concerns are reported. The encapsulation provides additional containment and controlled release, minimizing ecological and health risks.","The encapsulated Lactobacillus rhamnosus GG maintains high viability (>99%) after exposure to simulated gastric fluid and shows 77.5% survival after sequential exposure to gastric and intestinal fluids, compared to 60% for free cells. This demonstrates significant protection and enhanced delivery potential to the intestinal tract, supporting its use in probiotic delivery systems.",15809,1459,17268,,
306522a3-da74-4c50-87dc-57e2e99baff1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Akkermansia muciniphila"", ""strain_id"": ""BAA 835T, EB-AMDK 10, EB-AMDK19, EB-AMDK27, GP01, GP25""}]",Oral gavage (systemic delivery via gastrointestinal tract),Facultative Anaerobe,Grows on mucin as sole carbon and nitrogen source; optimal growth in anaerobic conditions typical of the intestinal lumen; pH and osmotic tolerance not explicitly stated but inferred from gut niche,Growth rate not specified; in vivo homeostasis observed in mouse models after oral administration; in vitro growth confirmed via culture (CFU counts),"Intestinal mucosa, particularly in the colon; adheres to and degrades mucin layers; preferentially colonizes the mucus layer of the gut epithelium",Competitive interaction with other gut microbes; enhances gut barrier integrity; may modulate host immune response and reduce inflammation; no evidence of pathogenicity or disruption of microbiome balance,"Tolerates pasteurization (heat-killed forms retain bioactivity); stable during storage and rehydration; no data on UV, drying, or shear stress",Pasteurization (heat treatment) enhances functional stability,"Akkermansia muciniphila is a mucin-degrading bacterium that thrives in the intestinal mucus layer, using mucin as its primary nutrient source. It is a facultative anaerobe capable of colonizing the gut and maintaining homeostasis in the host. Its ability to survive pasteurization without loss of function suggests high stability under processing conditions.",Not applicable (no genetic modification reported),,Constitutive (natural expression of functional proteins),,Chromosomal stability; no plasmid-based systems used; natural persistence in gut environment observed in animal models,"Stable in oral delivery formats (e.g., freeze-dried or pasteurized preparations); maintains function in gastrointestinal environment","Akkermansia muciniphila is used in its native form without genetic modification. Its beneficial effects are attributed to natural metabolic and immunomodulatory activities, particularly through the secretion of outer membrane protein Amuc_1100 and extracellular vesicles (EVs). No synthetic genetic circuits or inducible systems are employed.","[""Hypoxia"", ""pH"", ""Mucin availability""]","[""Mucin"", ""LPS (lipopolysaccharide)"", ""Glucose"", ""Lipids""]",,"[""Toll-like receptors (TLR2, TLR4)"", ""Cytokines (TNF-α, IL-6, IL-10)"", ""Proteases (indirectly via barrier integrity)""]",Mucin-binding receptors; TLR2/TLR4 signaling pathways; Amuc_1100 protein (outer membrane protein),"No synthetic logic gates; natural feedback loops via host immune and metabolic signaling (e.g., LPS → TLR4 → inflammation; Amuc_1100 → IL-10 ↑)","Akkermansia muciniphila senses the intestinal environment through mucin availability and host immune signals. It responds to mucin degradation by promoting barrier integrity and modulating immune responses. It detects elevated LPS and pro-inflammatory cytokines and counteracts them by upregulating anti-inflammatory mediators like IL-10 and downregulating TLR4 and NF-κB pathways, forming a natural feedback loop to restore homeostasis.","[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair"", ""Anti-inflammatory""]","Extracellular Vesicles (EVs), Outer membrane protein Amuc_1100 secretion",Dose-dependent effects observed (1×10⁸ to 5×10⁹ CFU); effects vary with strain and duration; no synthetic control systems,Compatible with oral delivery; stable in freeze-dried and pasteurized forms; maintains function in gastrointestinal environment,False,,,Not applicable (no direct antibacterial activity reported),,False,,,,无直接抗菌作用证据,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,无氧生成机制,True,"Modulates host immune response by reducing pro-inflammatory cytokines (TNF-α, IL-6, MCP-1) and increasing anti-inflammatory IL-10; downregulates TLR2/TLR4 signaling; inhibits NF-κB and JNK pathways; reduces metabolic endotoxemia via LPS reduction.","Amuc_1100 (outer membrane protein), Extracellular Vesicles (EVs), IL-10",True,Enhances gut barrier integrity by upregulating tight junction proteins; reduces intestinal permeability; promotes epithelial homeostasis; alleviates adipose tissue whitening and reduces adipocyte size.,"Amuc_1100, Extracellular Vesicles (EVs), Tight junction proteins (e.g., occludin, ZO-1)",True,Improves glucose homeostasis and insulin sensitivity; reduces fat mass and body weight gain; enhances energy expenditure; modulates lipid metabolism (reduces triglycerides and cholesterol); increases fecal caloric excretion; upregulates GLP-1 and PYY expression.,"GLP-1, PYY, SCFAs (inferred), Amuc_1100",False,Not applicable (no direct tumor therapy reported),,GRAS,Natural auxotrophy (mucin-dependent growth); no antibiotic resistance genes reported; no evidence of horizontal gene transfer,Mucin (nutrient requirement),Non-pathogenic; no virulence factors reported; low opportunistic risk; no antibiotic resistance genes detected; no environmental escape risk due to mucin dependency,Gastrointestinal tract barrier; no systemic dissemination reported,"Akkermansia muciniphila is classified as GRAS (Generally Recognized As Safe) due to its natural presence in healthy human gut microbiota. It is non-pathogenic, does not cause disease, and is dependent on mucin for growth, limiting its survival outside the gut. No antibiotic resistance genes or virulence factors have been reported. Its use in animal models shows no adverse effects, supporting its safety profile.","Akkermansia muciniphila supplementation significantly reduces body weight gain, fat mass, and adipocyte size in high-fat diet-fed mice. It improves glucose homeostasis, insulin sensitivity, and lipid profiles. It enhances gut barrier function, reduces systemic inflammation, and modulates immune responses. These effects are observed with both live and pasteurized forms, with pasteurized preparations showing enhanced stability and efficacy. The outer membrane protein Amuc_1100 and extracellular vesicles are key mediators of these beneficial effects.",12165,2083,14248,,
fa0520d9-57ce-4e1e-9bf0-d1e76074ae50,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus licheniformis"", ""strain_id"": ""Not specified""}]",Suspension in biofloc system,Facultative Anaerobe,"Temperature: 25–37°C; pH: neutral to slightly alkaline; NaCl tolerance: moderate (2.5%); Carbon source: organic matter in biofloc; Nutritional requirements: complex media with amino acids, vitamins, and minerals",Growth rate: moderate; Doubling time: not specified; In vitro growth confirmed; In vivo colonization observed in hepatopancreas and water,"Hepatopancreas (B. subtilis), Water/biofloc matrix (B. licheniformis)",Competitive exclusion of pathogens; colonization of intestinal and aquatic niches; potential symbiosis with host microbiota,"Moderate tolerance to temperature (25–37°C), osmotic stress (2.5% NaCl), and storage (lyophilized probiotic used); no data on UV, drying, or shear stress",Not specified,"Bacillus subtilis and Bacillus licheniformis are facultative anaerobes capable of growing in both aerobic and anaerobic conditions. They thrive in the biofloc environment of freshwater prawn systems, with B. subtilis preferentially colonizing the hepatopancreas and B. licheniformis dominating in the water column. Both species exhibit moderate tolerance to environmental fluctuations and are stable in commercial probiotic formulations.","PCR with species-specific primers (EN1F/EN1R for B. subtilis; ADK-F/ADK-R for B. licheniformis); no evidence of CRISPR, recombinase, or plasmid-based engineering",Not applicable (no genetic modification reported),Not applicable (no synthetic circuits or inducible systems described),Not applicable,Not applicable (no engineered plasmids or chromosomal integrations reported),Not applicable,"No genetic engineering was performed. The strains were used in their native form, with identity confirmed via PCR using species-specific primers targeting the EN-1 (endoglucanase) and ADK (adenylate kinase) genes. No synthetic circuits or genetic modifications were introduced.","[""Hypoxia"", ""pH"", ""Temperature""]","[""Organic matter (biofloc carbon source)"", ""Ammonia (TAN)""]","[""Competition with other microorganisms""]","[""Digestive enzymes (indirectly via gut environment)"", ""Nutrient availability""]",Not specified (no specific receptor or promoter reported),Not applicable (no synthetic logic circuits described),"No engineered sensing or logic processing was implemented. Natural environmental sensing is inferred from colonization patterns in response to nutrient availability, pH, and oxygen gradients in the biofloc system.","[""Antibacterial"", ""Nutrient Competition"", ""Immune Stimulation""]",Secretion of enzymes and antimicrobial compounds via general secretion pathways; no evidence of lysis or vesicle-mediated delivery,Daily addition of probiotics at controlled concentrations (1.08–3.25 × 10⁵ CFU/g); dosage controlled by external administration,Compatible with biofloc matrix; no structural disruption observed,True,True,False,"B. subtilis produces antimicrobial substances such as bacitracin and bacillin, which inhibit pathogenic bacteria. B. licheniformis also produces enzymes and antimicrobial compounds that suppress harmful microbes.","Bacitracin, Bacillin",True,True,True,True,"B. subtilis and B. licheniformis are non-pathogenic to humans and do not disrupt the biofloc matrix. They reduce pathogen load by competition and antimicrobial production, with no reported cytotoxicity or microbiome disruption.",False,Not applicable,Not applicable,False,False,False,No oxygenation mechanism was implemented or reported.,True,"Probiotics stimulate the immune system of prawns by activating immune cells in the hepatopancreas and gut, enhancing disease resistance.",Immune cell activators (not specified),False,Not applicable,Not applicable,True,"Probiotics enhance digestion by increasing enzymatic activity (e.g., proteases, amylases), improving nutrient absorption and metabolic efficiency.","Digestive enzymes (proteases, amylases)",False,Not applicable,Not applicable,BSL-1,Natural non-pathogenicity; no kill-switches or auxotrophy reported,Not applicable,Low pathogenicity; not considered human pathogen; no antibiotic resistance genes reported; no horizontal gene transfer evidence; low environmental escape risk due to non-native habitat,Biofloc system acts as physical confinement; no escape into natural water bodies reported,"Both Bacillus subtilis and Bacillus licheniformis are classified as GRAS (Generally Recognized As Safe) and are widely used in aquaculture. They are non-pathogenic to humans and do not pose significant environmental or health risks. No genetic modifications or antibiotic resistance genes were introduced, minimizing biosafety concerns.","Daily addition of probiotics at concentrations ≥1.08 × 10⁵ CFU/g significantly improved survival of Macrobrachium rosenbergii (p = 0.014) in a 40-day biofloc system. However, no significant differences were observed in final weight, weight gain, biomass gain, specific growth rate, or feed conversion rate. B. subtilis showed better colonization in the hepatopancreas, while B. licheniformis dominated in the water column. The probiotics contributed to microbial balance and pathogen suppression without altering water quality parameters.",15584,1870,17454,,
94e86482-b0b2-4c9c-ae15-bf3be84bb378,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""CECT 5713""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric acidity and bile salts; utilizes various carbohydrates including glucose, fructose, and lactose as carbon sources",High growth rate in vitro; survives gastrointestinal tract conditions with high viability; adheres strongly to intestinal epithelial cells,Mucosal surfaces of the human gut and breast milk; colonizes infant gut and intestinal mucosa,Competitive exclusion of pathogens via production of antimicrobial compounds and adhesion to host cells; may support symbiotic gut microbiota development,"High tolerance to gastric acidity, bile salts, and oxidative stress; survives lyophilization and rehydration; stable under moderate shear stress","Hydrogen peroxide, lactate, acetate","Lactobacillus salivarius CECT 5713 is a facultative anaerobe that grows well under physiological conditions, exhibits strong survival in gastrointestinal environments, and adheres effectively to intestinal epithelial cells. It thrives in mucosal niches such as the gut and breast milk, contributing to early gut microbiota establishment in infants.","Plasmid-based systems (pHN1, pHN2, pHN3); no CRISPR or recombinase tools reported",Not applicable (no genetic editing reported in this study),Constitutive expression of probiotic functions; no inducible circuits described,,Plasmid pHN3 is stable and carries bacteriocin genes; plasmid copy number not specified; chromosomal integration not performed; no evidence of genetic drift reported,No material encapsulation described; stability in biological environments is inherent,"The strain naturally encodes multiple probiotic traits via chromosomal and plasmid genes. The megaplasmid pHN3 harbors genes for bacteriocin production (salivaricin ABP-118), which are constitutively expressed. No synthetic genetic circuits or engineered modifications were introduced.","[""pH"", ""Oxidative stress""]","[""Glucose"", ""Lactose"", ""Fructose""]",,"[""Mucin"", ""Intestinal epithelial cells""]","6-phospho-β-glucosidase, collagen-binding proteins",No synthetic logic gates reported; natural sensing via metabolic and adhesion pathways,"L. salivarius CECT 5713 senses host-derived nutrients (e.g., glucose, lactose) and mucosal surfaces via specific enzymes and adhesins. It responds to pH and oxidative stress through intrinsic stress response mechanisms, enabling colonization and persistence in the gut.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Secretion of metabolites (lactate, acetate, H2O2) and bacteriocins via general secretion pathways; no specific secretion system reported",Constitutive production; dosage not externally controllable,No encapsulation described; natural secretion compatible with mucosal environments,True,True,True,"Produces lactate, acetate, and hydrogen peroxide; secretes bacteriocins (salivaricin ABP-118) encoded on megaplasmid pHN3; inhibits biofilm formation by competing for adhesion sites","Lactate, acetate, hydrogen peroxide, salivaricin ABP-118",True,True,True,True,该菌株对多种病原菌具有抗菌活性，能抑制生物膜形成，且在体内外实验中均表现出低细胞毒性，局部作用明确，不显著破坏正常菌群。,False,,,False,False,False,无氧生成功能,True,Stimulates expression of mucin-encoding genes; modulates immune responses in vitro and in vivo; reduces pro-inflammatory cytokines and enhances anti-inflammatory pathways,"Mucin, cytokine regulators (indirect)",True,"Stimulates mucin gene expression, enhances intestinal barrier function, promotes epithelial cell integrity and regeneration","Mucin-encoding genes (MUC2, MUC3)",False,,,False,,,GRAS,None (natural strain with no synthetic kill switches),,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape; safe for human consumption,Not applicable (no engineered material barrier),"L. salivarius CECT 5713 is a GRAS (Generally Recognized As Safe) strain isolated from human milk and infant feces. It has no known pathogenicity, antibiotic resistance genes, or potential for horizontal gene transfer. Its natural origin and safety profile support its use in probiotic applications.",口服给药可有效治疗哺乳期妇女的感染性乳腺炎；在体内外实验中均表现出显著的免疫调节、抗炎和抗菌作用，促进肠道屏障功能修复，支持婴儿早期肠道微生物群建立。,4000,1697,5697,,
6d50abb4-5069-408c-82b0-dc051620a63f,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""CGMCC 1.2134""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""BL23""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""KFRI342""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""unknown""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""Ren""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": ""GS4""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""unknown""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""unknown""}, {""role"": ""Helper"", ""scientific_name"": ""Streptococcus faecalis"", ""strain_id"": ""unknown""}, {""role"": ""Helper"", ""scientific_name"": ""Clostridium butyricum"", ""strain_id"": ""unknown""}, {""role"": ""Helper"", ""scientific_name"": ""Bacillus mesentericus"", ""strain_id"": ""unknown""}, {""role"": ""Helper"", ""scientific_name"": ""VSL#3"", ""strain_id"": ""mixture of 8 lactic acid-producing bacteria""}, {""role"": ""Helper"", ""scientific_name"": ""L. acidophilus, B. bifidum, B. infantum"", ""strain_id"": ""LBB mixture""}]",Oral administration (gut colonization),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, utilizes glucose and other carbohydrates as carbon sources; dependent on host-derived nutrients in vivo",Doubling time ~1–2 hours in vitro; stable colonization in gut mucosa in vivo,"Intestinal mucosa, colon lumen","Competitive exclusion of pathogenic bacteria (e.g., E. coli, Enterobacteriaceae); symbiotic with host immune system; modulates commensal balance","Tolerant to gastric acid, bile salts, and moderate osmotic stress; stable during lyophilization and storage at 4°C","Cell wall components, exopolysaccharides, acid resistance systems",上述微生物多为乳酸菌，属于兼性厌氧菌，可在肠道环境中定植并维持稳定生长。它们依赖宿主提供的碳源（如葡萄糖）和营养物质，具有良好的胃酸和胆盐耐受性，适合口服给药。在体内可定植于结肠黏膜和肠腔，通过竞争性排斥病原菌和调节免疫系统发挥保护作用。,None explicitly mentioned; natural strains used,Not applicable (no genetic modification reported),Constitutive expression of beneficial metabolites and surface adhesins,None,High chromosomal stability; no plasmid-based systems reported; low metabolic burden,Stable in oral formulations and gut environment,所有菌株均为天然分离株，未进行基因改造。其功能主要依赖于天然代谢途径和表面结构，如黏附素、乳酸产生酶和抗菌肽，通过定植和代谢调节发挥治疗作用。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Short-chain fatty acids (SCFAs)"", ""Bile acids"", ""Lactate""]","[""Quorum sensing (AHL, AI-2)"", ""Pathogen-specific molecules""]","[""Cytokines (IL-6, IL-17, TNF-α)"", ""Toll-like receptors (TLR2, TLR4)"", ""Mucin (MUC2)""]","Lactate permease, bile acid transporters, TLR2/4, MUC2 promoters",Threshold-based activation of immune modulation and anti-inflammatory responses; feedback inhibition via SCFA production,这些微生物通过感知肠道环境中的pH、胆汁酸、乳酸和短链脂肪酸等信号，结合宿主免疫因子（如IL-17、TNF-α）和黏蛋白表达水平，动态调节免疫反应。当炎症标志物升高时，乳酸菌通过上调MUC2和ZO-1表达，增强屏障功能，同时抑制TLR4/NF-κB通路，形成负反馈调节回路，实现稳态平衡。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation"", ""Antibacterial""]","Type I secretion (bacteriocins), lysis (controlled release), extracellular vesicles",Dose-dependent effects observed in animal models; oral administration allows natural regulation,"Compatible with oral formulations (capsules, powders); stable in gastrointestinal tract",True,True,True,通过产生乳酸、细菌素和竞争性排斥机制抑制病原菌生长，破坏生物膜结构。,"Lactic acid, bacteriocins, competitive exclusion",True,True,True,True,在多种动物模型中，LGG、L. casei、L. acidophilus等菌株显著减少E. coli、Enterobacteriaceae等病原菌数量，抑制肿瘤发生，且未见明显细胞毒性或菌群紊乱。,False,无明确氧生成机制。,None,False,False,False,未提及任何产氧机制，不适用于缺氧环境治疗。,True,"调节Th17/Treg平衡，抑制促炎因子（TNF-α, IL-6, COX-2），促进抗炎因子（IL-10, TGF-β）表达，增强黏膜屏障。","IL-10, TGF-β, IL-17, IL-22, TLR2/4 modulators",True,"促进黏蛋白（MUC2）、紧密连接蛋白（ZO-1, occludin）生成，增强肠道屏障功能，抑制上皮细胞增殖异常。","MUC2, ZO-1, occludin, butyrate",True,产生短链脂肪酸（SCFAs），调节宿主代谢，抑制肿瘤发生。,"Butyrate, acetate, propionate",False,无直接肿瘤杀伤或前药激活机制。,None,GRAS,"Auxotrophy (nutrient-dependent survival), natural attenuation in gut","Glucose, amino acids, bile salts",Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape,Gastrointestinal tract acts as physical barrier; no systemic dissemination reported,所有菌株均为公认安全（GRAS）菌株，无致病性，不携带耐药基因，不会在环境中长期存活。其在肠道内依赖宿主营养生存，具有天然衰减性，安全性高。,在多种动物模型中，口服益生菌显著降低结直肠癌的发生率、肿瘤数量和体积。例如，LGG可减少DMH诱导大鼠的肿瘤发生率和体积；L. casei可抑制DMH诱导的CRC；B. lactis与抗性淀粉合用可显著降低CRC发病率。此外，这些菌株还能显著增加短链脂肪酸（SCFA）水平，改善肠道屏障功能，抑制炎症和细胞增殖，具有良好的预防和治疗潜力。,14213,2347,16560,,
47f4e771-f085-4bba-ae72-d499306a2557,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""VSL#3"", ""strain_id"": ""VSL#3 (cocktail of 8 strains)""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, anaerobic conditions for lactobacilli and bifidobacteria; pH tolerance not explicitly stated, but adapted to intestinal environment",Not explicitly quantified; viable bacteria survive gastric transit and colonize the ileal pouch,"Ileal pouch (post-IPAA), intestinal lumen, mucosal surface","Competitive exclusion of pathogenic flora; no significant suppression of endogenous Bacteroides, coliforms, clostridia, or enterococci; promotes beneficial flora (lactobacilli, bifidobacteria, S. thermophilus)",Resistant to gastric acid and bile; lyophilized formulation enhances stability during storage and transit,Lyophilization (freeze-drying) process,"VSL#3 is a high-dose, lyophilized probiotic cocktail containing eight bacterial strains that survive gastrointestinal transit and colonize the ileal pouch, increasing beneficial bacterial populations without disrupting the native microbiota.",,,,,No genetic modifications; natural strains used; stability maintained via lyophilization and host environment,Stable in lyophilized form; survives encapsulation and gastrointestinal passage,"VSL#3 is a naturally occurring, non-genetically modified bacterial cocktail. No synthetic genetic circuits or engineered control systems are used. The formulation relies on the inherent physiological properties of the strains.","[""pH (luminal pH increase in pouchitis)""]","[""Bile acids (bile tolerance confirmed)"", ""Lactate (implied by lactobacilli metabolism)""]",,"[""Proteases (bile and gastric acid resistance suggests adaptation to host proteolytic environment)"", ""Cytokines (indirectly via immune modulation)""]",Bile acid resistance mechanisms in Lactobacillus and Bifidobacterium strains; acid tolerance systems in Lactobacillus species,"No engineered logic gates; natural sensing of environmental cues (pH, bile, nutrients) drives colonization and metabolic activity","The microbial system naturally senses intestinal environmental conditions such as pH and bile concentration. Strains with bile and acid resistance (e.g., Lactobacillus, Bifidobacterium) survive gastric transit and colonize the ileal pouch. No synthetic logic circuits are involved.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Natural secretion of cytokines, SCFAs, and enzymes; no engineered secretion systems","Dose-dependent: 3600 billion/day for 4 weeks, then 1800 billion/day for maintenance; efficacy correlates with dose and duration",Lyophilized powder is stable in capsule form; compatible with oral delivery and intestinal environment,False,False,False,Not applicable; VSL#3 is not designed as an antibacterial agent.,,False,False,False,False,无抗菌作用，不适用于抗菌机制。,False,Not applicable; no oxygen-producing enzymes or mechanisms reported.,,False,False,False,无氧生成机制，不适用于氧合功能。,True,"VSL#3 increases tissue levels of anti-inflammatory IL-10 and decreases pro-inflammatory cytokines (IL-1, TNF-α, IFN-γ), reduces matrix metalloproteinase activity, and modulates dendritic cell function.","IL-10, IL-1, TNF-α, IFN-γ, matrix metalloproteinases",True,"Reduction in histologic inflammation, crypt abscesses, and ulceration; promotion of mucosal healing via immune modulation and barrier enhancement.","IL-10, reduced MMP activity, improved mucosal integrity",True,Increases fecal concentrations of beneficial metabolites such as SCFAs (implied by lactobacilli and bifidobacteria activity); restores microbial balance and reduces luminal pH.,"Short-chain fatty acids (SCFAs), lactate",False,Not applicable; no evidence of tumor-targeting or prodrug conversion.,,GRAS,"None (natural, non-pathogenic strains; no kill-switches or auxotrophy)",,No pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low opportunistic risk in immunocompetent patients,Capsule provides physical barrier during transit; no engineered containment,"VSL#3 consists of eight non-pathogenic, GRAS-status bacterial strains. No genetic modifications or biocontainment systems are used. The preparation is well-tolerated with only transient bloating reported. No serious adverse events or microbiome disruption observed.",在23例轻度活动性回肠袋炎患者中，16例（69%）在治疗4周后达到缓解，总PDAI评分从10（9–12）降至4（2–11），临床、内镜和组织学评分均显著改善。6个月维持治疗期间，所有缓解患者均保持缓解状态。生活质量（IBDQ评分）从110（90–140）显著提高至200（95–220）。,10192,1737,11929,,
e8c7cff2-8d0e-40e5-8552-80e745d7a4a3,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""CL1285""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""LBC80R""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""CLR2""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; requires complex media with carbohydrates (e.g., glucose, lactose) and vitamins; tolerant to intestinal pH and bile salts",Doubling time ~60–90 minutes in vitro; in vivo colonization observed in human gut with transient persistence post-ingestion,"Intestinal lumen, particularly colon and ileum; competes with pathogens for adhesion sites and nutrients",Symbiotic with host microbiota; inhibits pathogen overgrowth via competitive exclusion and production of antimicrobial compounds; minimal disruption to core microbiome,Moderate tolerance to gastric acid and bile; stable during lyophilization and rehydration; resistant to moderate shear stress during formulation,"Bile salts, gastric acid, lyophilization stabilizers (e.g., trehalose)",该益生菌群为乳酸杆菌三联菌株，具有耐酸耐胆盐特性，可在肠道内定植并维持短期活性，适宜在37°C、pH 6.0–7.0条件下生长，依赖碳源和维生素，具备良好的环境适应性。,,,Constitutive,,Chromosomal stability; no plasmid-based systems used; low metabolic burden; no reported genetic drift in clinical use,Stable in oral capsule formulation; maintains viability during storage and transit,该菌株组合未经过基因工程改造，其功能依赖于天然代谢通路，通过定植竞争和代谢产物发挥益生作用，无外源基因插入，遗传稳定性高。,"[""pH"", ""Bile Acids""]","[""Glucose"", ""Lactate""]",,,"Bile salt hydrolase (BSH), pH-responsive promoters (e.g., in L. acidophilus)",Constitutive expression; no complex logic gates; threshold-based activity via nutrient availability,菌株通过感知肠道pH变化和胆汁酸环境实现定植适应，依赖葡萄糖和乳酸等代谢物维持生长，无复杂逻辑调控，以基础代谢响应为主。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Constitutive secretion via general secretory pathway,Dose-dependent effect; standardized capsule formulation (10^10 CFU/capsule); consistent delivery in clinical use,Compatible with oral capsule formulation; stable during storage and gastrointestinal transit,True,False,False,通过竞争性排斥抑制C. difficile在肠道黏膜的定植，产生乳酸降低局部pH，抑制病原菌生长,"Lactic acid, bacteriocins (e.g., acidocin)",False,True,True,True,在前瞻性队列研究中，使用该益生菌组合的患者CDI风险比为0.6（95% CI: 0.4–0.9），表明其具有显著保护作用，且未报告严重不良事件。,False,,,False,False,False,,True,调节肠道免疫反应，增强抗炎细胞因子分泌，抑制过度炎症反应，促进黏膜屏障功能,"Secreted cytokines (e.g., IL-10), surface proteins (e.g., p75)",True,促进肠上皮细胞再生，增强黏膜屏障完整性，减少通透性，改善肠道修复能力,"Mucin-binding proteins, short-chain fatty acids (SCFAs)",True,调节肠道代谢环境，通过产生SCFAs（如乙酸、丙酸）改善能量代谢，抑制病原菌生长，维持菌群稳态,"Short-chain fatty acids (SCFAs), Lactic acid",False,,,GRAS,"Auxotrophy (nutrient-dependent growth), no antibiotic resistance genes detected","Nutrient-limited environment (e.g., absence of specific amino acids)",Low pathogenicity; no reports of bacteremia or opportunistic infection; no horizontal gene transfer observed; environmental escape unlikely due to auxotrophy,Oral capsule provides physical confinement; degradation in GI tract limits environmental persistence,该三联益生菌组合被认定为GRAS（公认安全），无抗生素抗性基因，依赖特定营养生长，不具备环境生存能力，临床使用中未发现严重不良反应，安全性良好。,在前瞻性队列研究中，使用该益生菌组合的患者CDI风险比为0.6（95% CI: 0.4–0.9，P=0.01），表明其在预防初级艰难梭菌感染方面具有显著保护作用，且在真实世界医疗环境中具有良好的可实施性。,3796,1724,5520,,
8c1c4a11-e9e9-4498-9ab9-5bbd67956f98,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""NSL super strain""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, neutral to slightly acidic pH (6.0–7.0), requires complex nutrients including carbohydrates (e.g., lactose, oligosaccharides), amino acids, and vitamins; dependent on host-derived metabolites in gut environment","Doubling time ~2–3 hours in vitro; in vivo colonization observed within 24–48 hours post-administration, with sustained presence over 3-week treatment period","Small intestinal mucosa, particularly in the ileum; preferentially colonizes the epithelial surface and mucus layer",Competitive exclusion of pathogenic bacteria; potential symbiosis with resident commensals; may enhance microbial diversity by promoting a favorable gut environment,Moderate tolerance to gastric acid and bile salts; stable during lyophilization and rehydration; resistant to moderate shear stress during encapsulation,"Bile salt hydrolase (BSH), acid shock proteins (e.g., DnaK, GroEL)",Bifidobacterium infantis NSL 超菌株为专性或兼性厌氧菌，适宜在37°C、pH 6.0–7.0的肠道环境中生长，依赖乳糖、低聚糖等碳源及氨基酸、维生素等营养物质。在体外培养中倍增时间为2–3小时，在体内可快速定植于小肠黏膜表面，持续存在至少3周。对胃酸和胆盐具有中等耐受性，经冻干和复水后仍保持活性，适用于胶囊制剂封装。,"Plasmid-based expression system (not explicitly stated, inferred from strain engineering in literature)","Not applicable (natural strain, no genetic modification reported)",Constitutive,,High chromosomal stability; no plasmid-based systems reported; no evidence of genetic drift during 3-week trial,Stable in capsule matrix; no degradation or leakage observed during storage and delivery,该菌株为天然分离菌株，未进行基因改造，其功能依赖于天然代谢通路。在临床试验中以胶囊形式口服给药，通过自然定植于小肠黏膜发挥调节作用。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Gliadin Peptides"", ""Lactose"", ""Oligosaccharides""]",,"[""Cytokines (e.g., IL-6, TNF-α)"", ""Epithelial Permeability Markers""]","Gliadin-binding proteins (e.g., surface adhesins), bile salt hydrolase (BSH), pH-responsive promoters (e.g., P15A promoter)",Constitutive expression; no reported synthetic logic gates; response to gliadin peptides is likely threshold-based via receptor-mediated binding,Bifidobacterium infantis 通过表面黏附蛋白识别并结合胃肠道中的麦胶蛋白肽段，触发其代谢活性。其对pH和胆盐的响应由天然调控系统控制，无合成逻辑门控机制。在炎症环境下，其代谢活动可能受细胞因子水平反馈调节，但未见明确的信号整合逻辑。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]",Constitutive secretion via general secretory pathway; no lysis or vesicle release reported,Dose-dependent symptom improvement; 3-week oral administration at fixed dose (not titrated),High compatibility with capsule matrix; maintains viability and function during encapsulation and gastrointestinal transit,False,,,,,False,False,False,False,,False,,,False,False,False,,True,"Reduces proinflammatory cytokine levels (e.g., IL-6, TNF-α), modulates immune response to gliadin peptides, and decreases intestinal permeability by stabilizing tight junctions.","Bifidobacterial cell wall components (e.g., peptidoglycan, lipoteichoic acid), secreted metabolites (e.g., SCFAs)",True,"Protects intestinal epithelial cells from gliadin-induced damage, reduces epithelial permeability, and promotes barrier integrity.","Short-chain fatty acids (SCFAs), extracellular matrix-stabilizing proteins",True,"Metabolizes gliadin peptides into less immunogenic fragments, reduces gluten toxicity in the intestinal lumen.","Gliadin-degrading enzymes (e.g., proteases, peptidases)",False,,,GRAS,Auxotrophy (nutritional dependency on host-derived nutrients),"Lactose, oligosaccharides",Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape due to host dependency,Capsule provides physical confinement; prevents environmental release,Bifidobacterium infantis NSL 超菌株为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，依赖宿主营养物质生存，难以在体外长期存活。胶囊封装提供物理屏障，有效防止环境释放，整体风险极低。,在为期3周的双盲随机对照试验中，B. infantis 治疗组患者在胃肠道症状（消化不良、便秘、胃食管反流）方面有临床改善，血清抗tTG IgA和DGP抗体水平下降10%，但未达到统计学显著性。小肠通透性（乳果糖/甘露醇比值）无显著差异。尽管主要终点未达成，但提示其在调节免疫反应和改善症状方面具有潜在价值，需更大样本量和更长疗程研究进一步验证。,4568,1869,6437,,
50ad7132-a734-4e90-b716-99f56f93886b,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""LGG, ATCC 53103""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""LC705, DSM 7061""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""Bb99, DSM 13692""}, {""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium freudenreichii ssp. shermanii"", ""strain_id"": ""JS, DSM 7076""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, in the presence of galacto-oligosaccharides (prebiotic). Requires complex media with amino acids, vitamins, and carbon sources.",Doubling time ~1.5–2 hours in vitro; no in vivo growth kinetics reported.,"Gastrointestinal tract (infant gut), particularly in the mucosal layer of the small intestine and colon.",Competitive exclusion of pathogenic bacteria; potential symbiosis with host microbiota by enhancing microbial diversity and stability.,Tolerant to moderate osmotic stress and gastric acidity; stable during lyophilization and rehydration; resistant to shear stress during encapsulation.,"Galacto-oligosaccharides (prebiotic), encapsulation matrix",该混合菌群为多种益生菌的组合，包括LGG、L. rhamnosus LC705、B. breve Bb99和P. freudenreichii ssp. shermanii JS。这些菌株均为兼性厌氧菌，可在37°C、pH 6.0–7.0的条件下生长，依赖于复杂的营养环境，包括氨基酸、维生素和碳源。在婴儿肠道中定植于黏膜层，具有竞争性抑制病原菌的能力，并可能通过增强微生物群多样性与宿主菌群形成共生关系。在冻干和再水化过程中表现出良好的稳定性，适用于胶囊制剂。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未对菌株进行基因工程改造，所有菌株均以天然野生型形式使用，未引入外源基因或调控回路。,"[""pH"", ""Osmotic stress"", ""Glucose""]","[""Galacto-oligosaccharides"", ""Lactate""]",,"[""Proteases"", ""Cytokines""]",Not specified,Not specified,该系统未设计特定的传感逻辑回路，其功能依赖于天然菌株对宿主微环境的响应，如pH变化、营养物质（如低聚糖）的存在以及宿主免疫因子（如细胞因子）的信号。,"[""Immunomodulation"", ""Tissue Repair""]",Not specified,Not specified,Encapsulated in capsules with prebiotic syrup; compatible with oral delivery and intestinal release.,False,False,False,Not applicable,,False,False,False,False,未检测到抗菌或抗生物膜活性。,False,Not applicable,,False,False,False,未涉及氧气生成机制。,True,通过调节Th1/Th2平衡、诱导Treg细胞分化、抑制促炎细胞因子（如IL-4、IL-5、IL-13）的释放，从而抑制IgE介导的过敏反应。,"Lactobacillus rhamnosus (LGG, LC705), Bifidobacterium breve (Bb99), Propionibacterium freudenreichii ssp. shermanii (JS)",True,通过促进肠道屏障功能恢复、增强黏膜免疫、调节上皮细胞增殖与分化，间接支持组织修复。,"Short-chain fatty acids (SCFAs), exopolysaccharides",True,通过发酵低聚糖产生短链脂肪酸（如乙酸、丙酸、丁酸），调节宿主能量代谢与免疫稳态。,Short-chain fatty acids (SCFAs),False,Not applicable,,GRAS,Not applicable,,"All strains are well-characterized, non-pathogenic, and GRAS (Generally Recognized As Safe). No antibiotic resistance genes reported. Low risk of horizontal gene transfer. No evidence of environmental escape.",Capsule formulation provides physical confinement and protects against gastric degradation.,该益生菌混合物由四种公认安全（GRAS）的菌株组成，均为非致病性、无抗生素抗性基因，且未进行基因改造。胶囊剂型提供物理屏障，防止菌体在胃部失活或逃逸，整体安全性高。,在高风险儿童中，围产期使用该益生菌混合物未显著降低任何过敏原的IgE致敏率。然而，在13岁时，益生菌组对猫/狗皮屑的IgE致敏率显著高于安慰剂组（40.2% vs 31.0%，p=0.03）。在阴道分娩的子群中，该效应更为明显。此外，2岁时，阴道分娩子群中对桦树/黑麦草花粉的IgE致敏率在益生菌组中也更高。这表明该混合菌群可能对特定过敏原（如动物皮屑、花粉）的长期致敏具有潜在促进作用，而非保护作用。,18965,1865,20830,,
41d190a3-2d32-41a3-8d07-f449231c59ac,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""A7""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires lactose and amino acids as carbon and nitrogen sources; tolerates mild bile exposure (0.1–0.3% bile salts).","Doubling time ~1.5–2 hours in vitro; in vivo stability not assessed, but survival in gastrointestinal tract confirmed via fecal recovery in study.","Gut lumen, particularly colon; transient colonization with no evidence of long-term engraftment.",No significant competition or symbiosis reported; no disruption of native microbiota observed in study.,"Resistant to refrigeration (4°C) for up to 3 days; moderate tolerance to gastric acidity (pH 2.0–3.0) due to acid-adaptive mechanisms; no data on UV, drying, or shear stress.","Cell wall components (e.g., teichoic acids) and acid shock proteins (e.g., Hsp18) likely contribute to acid resistance.",该菌株为乳酸杆菌属植物乳杆菌A7，属于兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，依赖乳糖和氨基酸作为碳氮源。在体外培养中，其倍增时间为1.5–2小时。在本研究中，该菌株在冷藏条件下（4°C）可稳定存活3天，且在肠道中具有一定的定植能力，但未观察到长期定植或对肠道菌群的显著影响。,Not specified,Not applicable (no genetic modification reported),Constitutive,,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift or loss in 8-week trial.,Stable in soy milk matrix; no structural degradation or gas production observed during storage.,该菌株未经过基因改造，以天然菌株形式使用。其在豆奶中的稳定性良好，未发现质粒或外源基因元件，因此遗传稳定性高，且在材料环境中保持稳定。,"[""pH"", ""Bile Salts""]","[""Lactose"", ""Amino Acids""]",,,"FNR-like promoter (inferred from acid tolerance and bile resistance), Lactose permease (LacS)",Constitutive expression; no reported logic gates or threshold control.,该菌株通过基础代谢通路感知乳糖和氨基酸等营养物质，同时利用FNR样调控元件响应pH变化和胆盐压力，实现基础的环境适应性，但未见复杂的逻辑门控或动态调控机制。,"[""Immunomodulation"", ""Metabolic Regulation""]",Constitutive secretion of metabolites and cell wall components; no specialized secretion systems reported.,Dose-dependent effect observed: 2×10⁷ CFU/day; no further titration or feedback control.,Highly compatible with soy milk matrix; no adverse effects on gel structure or stability during 3-day storage.,False,,,Not applicable (no antibacterial activity reported),,False,False,False,False,未报告抗菌活性，因此不满足任何抗菌标准。,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,未报告任何氧生成机制，因此不满足氧疗标准。,True,"Modulates systemic inflammation by regulating cytokine profiles; reduces pro-inflammatory markers (TNF-α, CRP) and enhances anti-inflammatory adiponectin signaling.","Adiponectin (Apn), TNF-α, CRP",False,Not applicable (no tissue repair function reported),,True,Improves lipid metabolism by reducing LDL-C and increasing HDL-C; may influence glucose homeostasis via gut-liver axis.,"Low-density lipoprotein (LDL), High-density lipoprotein (HDL), Fasting blood glucose (FBS)",False,Not applicable (no tumor-targeting function reported),,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Non-pathogenic; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape reported.,Physical confinement via oral delivery and transient gut passage; no persistent colonization.,该菌株为公认安全（GRAS）菌株，来源于健康婴儿粪便，无致病性记录，未携带抗生素抗性基因，且在研究中未观察到对肠道菌群的显著干扰或环境释放风险，安全性良好。,在为期8周的干预中，摄入含植物乳杆菌A7的益生菌豆奶可显著降低低密度脂蛋白（LDL-C）水平（P=0.023），并提高高密度脂蛋白（HDL-C）水平（P=0.017），但对血清脂联素、TNF-α、C反应蛋白及空腹血糖水平无显著影响。表明该菌株在调节血脂方面具有潜在益处，但在抗炎和降糖方面效果不显著。,10383,1727,12110,,
3d34413b-02ca-4012-9efc-abd5bec03104,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei O1"", ""strain_id"": ""O1""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates gastric pH (2.0–3.0) and intestinal pH (6.0–7.5); requires complex media with carbohydrates (e.g., glucose, lactose) and amino acids.",Doubling time ~1.5–2 hours in vitro; in vivo colonization confirmed via adherence to IEC-6 epithelial cells; no significant growth rate differences observed between in vitro and in vivo conditions.,"Intestinal mucosa (gut lumen and epithelial surface); adheres to IEC-6 cells in vitro, indicating potential for gut colonization.",No direct competition or symbiosis data reported; potential to modulate gut microbiota indirectly via metabolic byproducts.,"Resists gastric acidity (pH 2.0–3.0), bile salts (up to 0.3%), and lyophilization/rehydration; stable during storage at 4°C for 8 weeks.","Exopolysaccharides (EPS), cell wall components, and intracellular antioxidants (e.g., glutathione precursors)",该菌株为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下良好生长，耐受胃酸（pH 2.0–3.0）和胆汁盐（0.3%），在体外可黏附于IEC-6肠上皮细胞，表明其具有良好的肠道定植潜力。在体外与体内生长速率一致，对干燥、冷冻干燥及再水化具有较强耐受性，适合胶囊制剂封装。,Not applicable (no genetic modification reported),Not applicable,Constitutive,None,Chromosomal stability; no plasmid-based systems used; no evidence of genetic drift or loss during 8-week supplementation.,Stable in maltodextrin-based capsules; no degradation or loss of viability during encapsulation and storage.,该菌株未经过基因工程改造，以天然菌株形式使用，其遗传稳定性高，无质粒依赖，可在胶囊材料中保持活性，适合长期储存和口服给药。,"[""pH"", ""Bile Salts""]","[""Glucose"", ""Lactose""]",,,"FNR-like promoter (inferred from pH/bile tolerance), surface adhesins (e.g., mucus-binding proteins)",Constitutive expression; no inducible logic gates or threshold control reported.,该菌株通过其表面黏附蛋白和耐酸/耐胆盐机制感知肠道环境中的pH和胆汁盐变化，但未报告具有可调控的逻辑门控系统，其代谢活动为组成型表达，无外部信号诱导。,"[""Metabolic Regulation""]",None (no engineered secretion system reported),Fixed daily dose (1×10⁸ CFU/day); no dynamic or feedback-controlled release.,High compatibility with maltodextrin-based capsules; maintains viability during encapsulation and storage.,False,False,False,Not applicable,None,False,False,False,False,未报告抗菌或抗生物膜功能。,False,Not applicable,None,False,False,False,未报告产氧功能。,False,Not applicable,None,False,Not applicable,None,True,"L. casei O1 may modulate host redox balance by producing antioxidants such as glutathione precursors, reducing oxidative stress markers like MDA, and enhancing antioxidant enzyme activity (e.g., SOD, GPx). In vitro studies show it can convert procyanidins into more bioactive antioxidants.","Glutathione precursors, procyanidin metabolites",False,Not applicable,None,GRAS,None (no kill-switch or auxotrophy reported),None,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; no environmental escape risk due to lack of environmental persistence.,Capsule shell provides physical confinement; prevents release into environment.,L. casei O1 is classified as GRAS (Generally Recognized As Safe) and has been used in food and supplements.无基因工程改造，无致病性或耐药基因，无生物安全风险。胶囊封装提供物理屏障，防止菌体释放。,在为期8周的临床试验中，L. casei O1补充剂对类风湿性关节炎女性患者的氧化应激指标（MDA、TAC、SOD、GPx、CAT）无显著改善作用。尽管体外研究显示其具有抗氧化潜力，但体内效果未达统计学显著性，可能与剂量（1×10⁸ CFU/天）较低、疗程较短（8周）及菌株本身抗氧化能力较弱有关。建议未来研究采用更高剂量或更长疗程以评估其潜在疗效。,13183,1694,14877,,
62a265d6-4790-4b46-a143-403d47a60a7a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""SCC-19""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: Not specified; Osmotic: Not specified; Nutrition: MRS broth (lactose, peptone, yeast extract, etc.)",Growth rate: 24 h in MRS broth; Doubling time: Not specified; In vivo vs in vitro: In vivo performance confirmed in fish model,Intestinal tract of common carp (gut lumen),Potential symbiosis with host gut microbiota; no competition or antagonism reported,High cadmium tolerance (MIC up to 500 mg/L); lyophilization stability; resistance to storage at 4°C,Spore formation (Bacillus coagulans),"Bacillus coagulans SCC-19 is a gram-positive, spore-forming, facultative anaerobic bacterium capable of growing in MRS medium at 37°C. It exhibits high tolerance to cadmium (MIC up to 500 mg/L) and can survive lyophilization and refrigeration. It colonizes the intestinal tract of common carp and maintains viability in feed formulations.",,,,,No genetic modifications reported; natural strain used; chromosomal stability assumed,Stable in pelletized feed with soybean meal and CMC-Na; maintains viability during drying and storage,Bacillus coagulans SCC-19 was isolated from the intestinal contents of common carp and used in its native form without genetic modification. It was incorporated into feed pellets at 10⁸ CFU/g and maintained viability during preparation and storage.,"[""Cadmium (Cd)""]",,,,Unknown (likely intrinsic metal-binding capacity of cell wall and spores),No engineered logic gates; response is likely constitutive and proportional to Cd exposure,Bacillus coagulans SCC-19 senses cadmium in the aquatic environment and intestinal lumen through intrinsic cell wall and membrane components. Its response is not genetically programmed but arises from natural metal-binding and detoxification mechanisms. No inducible or threshold-based logic is reported.,"[""Metabolic Regulation"", ""Antibacterial"", ""Immunomodulation"", ""Antioxidant""]",Cell wall/membrane binding and passive adsorption; no active secretion system reported,Dietary supplementation at 10⁸ CFU/g feed; controlled by feed formulation and administration schedule,"Compatible with pelletized feed (soybean meal, CMC-Na); stable during drying and storage",False,False,False,Not applicable; no direct antibacterial activity reported.,,False,False,False,False,无,False,Not applicable; no oxygen-producing mechanism reported.,,False,False,False,无,True,"Restores immune parameters such as lysozyme (LZM), acid phosphatase (ACP), complement C3/C4, and modulates cytokine expression (TGF-β, TNF-α, IL-1β) in fish kidney.","Cytokines (TGF-β, TNF-α, IL-1β) and immune enzymes (LZM, ACP, C3, C4)",False,Not applicable; no direct tissue repair or regeneration observed.,,True,Reduces cadmium bioaccumulation in liver and kidney by binding and removing Cd from water and gut lumen.,Cadmium (Cd),False,Not applicable; no tumor model or therapy reported.,,GRAS,"None (natural strain, no engineered kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; environmental escape unlikely due to natural habitat origin,Pelletized feed provides physical confinement; no release into environment reported,Bacillus coagulans SCC-19 is a naturally occurring probiotic strain isolated from fish gut. It is classified as GRAS (Generally Recognized As Safe) and poses minimal risk. No genetic modifications or antibiotic resistance genes were introduced. The strain is confined within feed pellets and does not persist in the environment beyond the experimental period.,在60天的实验中，补充Bacillus coagulans SCC-19显著恢复了镉暴露鱼的生长性能，降低了肝脏和肾脏中的镉积累，恢复了非特异性免疫和抗氧化能力。与对照组相比，镉暴露组的体重增长显著下降，而添加SCC-19的组体重增长显著提高。镉在肝脏和肾脏中的积累显著减少，抗氧化酶（CAT、GSH-Px、SOD）活性恢复，MDA和ROS水平下降，免疫因子（LZM、ACP、C3、C4）和细胞因子（TGF-β、TNF-α、IL-1β）表达恢复正常。,11776,1663,13439,,
6b6db452-8d8d-40a3-a271-3b680b8a32a9,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecalis"", ""strain_id"": ""Not specified""}]","Oral ingestion, colonized in gut lumen",Facultative Anaerobe,"Optimal growth at 37°C, neutral to slightly acidic pH (6.0–7.0), tolerates moderate osmotic stress; requires complex nutrients including amino acids, vitamins, and carbohydrates.",Growth rate not explicitly reported; in vitro doubling time estimated to be ~2–3 hours under optimal conditions. In vivo colonization observed after long-term intake.,"Large intestine (colon), particularly mucosal surface and lumen of the gut.",Competitive exclusion of pathogenic bacteria; potential symbiosis with host and other commensals; may enhance colonization of beneficial genera such as Faecalibacterium.,Tolerant to gastric acid and bile salts; stable during lyophilization and storage at 4°C; resistant to moderate shear stress during transit.,"Bile salts, gastric acid, lyophilization stabilizers (e.g., trehalose, skim milk)",该研究中使用的益生菌株Bifidobacterium longum、Lactobacillus acidophilus和Enterococcus faecalis均为肠道定植型微生物，具有耐酸耐胆盐特性，可在人体肠道内长期定植。其生长依赖于复杂营养，适宜温度为37°C，pH值接近中性。长期摄入后，这些菌株可显著改变肠道菌群结构，促进有益菌如Blautia、Faecalibacterium等的富集，维持肠道微生态平衡。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,本文未涉及对益生菌株进行基因工程改造，所有功能均基于天然菌株的生理特性，未使用CRISPR、质粒或合成回路等工具。,"[""pH"", ""Bile acids"", ""Osmotic stress""]","[""Short-chain fatty acids (SCFAs)"", ""Glucose"", ""Lactate""]","[""Quorum sensing (AHL, AI-2)""]","[""Cytokines (IL-1β)"", ""Proteases (indirectly via inflammation)""]",Not specified,Not specified,本文未描述任何基因回路或逻辑控制机制，微生物的响应基于自然生理适应，而非人工设计的传感系统。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Passive secretion via cell lysis or natural excretion; no engineered secretion systems used.,Not applicable (natural colonization without external control),Not applicable (no encapsulation or material-based delivery system described),False,,,Not applicable,,False,,,,未检测到抗菌活性，未使用抗菌机制。,False,Not applicable,,False,,,未涉及氧气生成或氧合功能。,True,通过调节免疫因子如IL-1β、IL-10、TNF-α等，抑制过度炎症反应，促进免疫稳态。Bifidobacterium和Lactobacillus可抑制NF-κB通路，降低促炎因子水平。,"IL-1β, IL-10, TNF-α, NF-κB pathway",True,通过促进有益菌群（如Faecalibacterium）的富集，间接支持肠道屏障功能修复，增强黏膜完整性，减少通透性损伤。,"Faecalibacterium, SCFAs (butyrate)",True,通过调节短链脂肪酸（SCFAs）代谢，维持肠道能量平衡和免疫调节。尽管SCFA浓度未显著变化，但菌群结构改变提示代谢功能重塑。,"Acetic acid, Propionic acid, Butyric acid, Isobutyric acid, Pentanoic acid, Isovaleric acid",False,Not applicable,,GRAS,Not applicable,Not applicable,"Low pathogenicity; Enterococcus faecalis has potential for antibiotic resistance (e.g., vancomycin), but no HGT or environmental escape reported. No evidence of virulence genes.",Not applicable,所用菌株均为公认安全（GRAS）菌株，Bifidobacterium longum和Lactobacillus acidophilus广泛用于食品和保健品。Enterococcus faecalis虽有潜在耐药性风险，但本研究中未发现临床致病性或耐药基因传播证据。长期摄入未引起显著不良反应，安全性良好。,长期摄入益生菌可显著改变肠道菌群结构，促进有益菌如Blautia、Faecalibacterium、Bifidobacterium等的富集，增强肠道屏障功能，调节免疫反应，维持微环境稳态。尽管短链脂肪酸浓度未显著变化，但菌群多样性与结构的优化提示潜在的健康促进作用。,13323,1763,15086,,
e6598c45-1734-494e-ba4f-13d9879033ce,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Not specified""}]",Suspension (in intestinal lumen),Facultative Anaerobe,"Optimal growth at 37°C, neutral to slightly acidic pH (6.0–7.0), utilizes soluble fiber, resistant starch, and prebiotics (e.g., inulin, fructooligosaccharides) as carbon sources; requires no exogenous vitamins or amino acids beyond standard growth media",Growth rate not explicitly stated; capable of rapid colonization in the gut lumen post-ingestion; in vitro growth consistent with in vivo persistence in intestinal microecology,"Distal small bowel and colon (luminal environment), particularly in mucosal-associated niches with access to fermentable substrates",Competitive exclusion of pathogenic bacteria; synergistic with native microbiota in fermentation; may modulate host immune response via cross-feeding with other commensals,Tolerant to gastric acidity and bile salts; stable during storage and transit through gastrointestinal tract; resistant to drying and lyophilization in some formulations,"Cell wall components (e.g., teichoic acids), extracellular polysaccharides, and acid tolerance systems (e.g., F1F0-ATPase)","Lactobacillus and Bifidobacterium species are facultative anaerobes that thrive in the human colon, utilizing soluble dietary fibers and prebiotics as primary carbon sources. They exhibit robust growth in the intestinal lumen, where they integrate into the resident microbiota and contribute to metabolic homeostasis. Their ability to survive gastric transit and colonize the gut mucosa enables sustained fermentation activity.",Not mentioned,,Constitutive,,Not mentioned,Not mentioned,No genetic modifications are described in the paper. The probiotic strains function naturally through their intrinsic metabolic pathways without engineered circuits or synthetic biology tools.,"[""pH"", ""Osmotic strength"", ""Nutrient availability (carbohydrates)""]","[""Resistant starch"", ""Soluble fiber (pectin, hemicellulose, gums)"", ""Prebiotics (inulin, fructooligosaccharides, lactulose)""]",,,"Not specified (inferred: native carbohydrate transporters and metabolic regulators such as CcpA, Cra, or PTS systems)",Constitutive expression of fermentation enzymes; no evidence of inducible or logic-gated regulation; activity driven by substrate availability,"The fermentation activity of Lactobacillus and Bifidobacterium is primarily constitutive and substrate-dependent. Their metabolic pathways are activated upon contact with fermentable carbohydrates, with no reported feedback inhibition or complex logic circuits. The system responds directly to nutrient presence without sophisticated sensing logic.","[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]",Passive diffusion of SCFAs; no active secretion systems reported,Not controllable; activity depends on dietary intake of prebiotics and fiber,Compatible with intestinal mucus and luminal environment; no encapsulation or material barrier mentioned,False,False,False,Not applicable,,False,False,False,False,Not applicable,False,Not applicable,,False,False,False,Not applicable,True,"Modulate host immune responses by enhancing barrier function, reducing inflammation, and influencing immune cell activity through SCFA signaling and direct interaction with immune cells.","Short-chain fatty acids (SCFAs), particularly butyrate",True,Promote epithelial cell proliferation and differentiation; support colonocyte metabolism and integrity; suppress abnormal proliferation in adenocarcinoma cells (butyrate paradox).,Butyrate,True,Regulate lipid metabolism by modulating hepatic lipogenesis and cholesterol synthesis; influence serum lipid profiles via acetate and propionate production. Inulin feeding reduces triglycerides and hepatic lipogenesis.,"Acetate, Propionate, Butyrate",False,Not applicable,,GRAS,None (natural strains with no engineered kill switches),,Low pathogenicity; no antibiotic resistance genes reported; minimal risk of horizontal gene transfer; no evidence of environmental escape; generally safe in healthy individuals,None (no physical confinement used),"Lactobacillus and Bifidobacterium species are classified as Generally Recognized As Safe (GRAS). They are non-pathogenic, naturally occurring commensals with a long history of safe use in food and supplements. No engineered containment systems are employed, but their natural ecological niche limits uncontrolled spread. The primary risk is potential for D-lactic acidosis in rare cases with high-dose supplementation, especially in individuals with impaired gut barrier or metabolic disorders.","In human trials, probiotics showed positive effects on cardiovascular risk factors: 3 studies reported reduced serum cholesterol, 2 showed decreased LDL, 2 increased HDL, and 2 demonstrated lower systolic blood pressure. Prebiotic studies (e.g., inulin) reduced hepatic lipogenesis and triglycerides. Fermentation of dietary fiber and prebiotics by probiotics contributes significantly to lipid homeostasis and colonic health, supporting their potential role in preventing atherosclerosis and metabolic syndrome.",5189,1750,6939,,
d0b8c364-8a60-49b8-91eb-ccb5fdc5be26,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""ST-III""}]",Suspension,Facultative Anaerobe,"Temperature: 30–35°C; pH: 7.4 (TYC medium), 6.5–7.0 (MRS); Nutritional: Complex media (TYC, MRS, reconstituted skim milk); Osmotic: Tolerant to sucrose (50 g/L) and sodium acetate (2.0 g/L)",Doubling time: ~2–4 h under oxygen stress with ACN; Growth stagnation of ~4 h without ACN; In vivo consistency: Limited by oxygen stress; In vitro growth improved by ACN,"Gut (probiotic niche), dairy environment (milk), hypoxic niches in food matrices",No direct interaction data; potential for symbiosis with gut microbiota via metabolic modulation,"Sensitive to oxygen stress; improved viability under aerobic conditions with ACN; Tolerant to sucrose, sodium acetate, and moderate osmotic stress",Petunidin-based anthocyanin (ACN),"Lactobacillus plantarum ST-III is a facultative anaerobe with inherent sensitivity to oxygen stress, which limits its growth in aerobic environments such as milk. However, supplementation with petunidin-based anthocyanin significantly enhances its growth under oxygen stress by reducing intracellular ROS and improving redox balance. This enables its proliferation in reconstituted skim milk under aerobic conditions, suggesting potential for industrial dairy applications.",,,,,,,"No genetic engineering was performed. The strain relies on endogenous antioxidant systems, particularly the thioredoxin (TRX) system, which is upregulated by petunidin-based anthocyanin. The system is not genetically modified but leverages natural stress-response pathways for enhanced survival under oxygen stress.","[""Oxygen Stress"", ""Reactive Oxygen Species (ROS)"", ""Oxido-Reduction Potential (ORP)""]",,,,"Thioredoxin system (trxB1, trxA2 genes)","Positive feedback loop: ROS accumulation triggers TRX system upregulation; ACN reduces ROS, thereby enhancing TRX expression and further reducing oxidative damage.","The system senses oxygen-induced oxidative stress via ROS accumulation and decreased ORP. The transcriptional upregulation of trxB1 and trxA2 genes in the thioredoxin system acts as a feedback mechanism to mitigate oxidative damage. Petunidin-based anthocyanin enhances this natural sensing and response pathway, effectively amplifying the cell's ability to manage redox stress.","[""Antibacterial"", ""Oxygenation"", ""Metabolic Regulation""]",Passive diffusion (no engineered secretion system; endogenous proteins released via lysis or membrane leakage),Concentration-dependent: 0.025% (wt/vol) ACN maximally effective; higher concentrations may inhibit growth due to weak antimicrobial activity.,High compatibility with milk matrices and agar; ACN integrates well with food-grade materials without structural disruption.,False,False,False,Not applicable; no direct antibacterial activity reported.,,False,False,False,False,No evidence of antibacterial or biofilm inhibition activity.,True,"Petunidin-based anthocyanin reduces intracellular ROS and lowers extracellular ORP, effectively alleviating oxygen stress and enabling aerobic growth.","Petunidin-based anthocyanin (acts as redox buffer, not oxygen producer)",True,True,True,"ACN enables sustained growth of L. plantarum ST-III in aerobic milk and TYC media over 24–48 h, indicating effective oxygen stress relief without promoting pathogen growth. The mechanism is non-light-dependent and compatible with antibacterial functions.",False,Not applicable; no immune-modulating factors secreted.,,False,Not applicable; no tissue repair factors produced.,,True,"ACN enhances the thioredoxin system, improving redox homeostasis and metabolic stability under oxidative stress. This supports sustained growth and fermentation activity.",Petunidin-based anthocyanin,False,Not applicable; no tumor-targeting or prodrug conversion mechanisms.,,GRAS,"None (natural strain, no synthetic kill switches or auxotrophy)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape unlikely due to non-competitive nature in natural habitats.,Physical confinement via encapsulation or matrix immobilization not required; inherent stability in food matrices.,"Lactobacillus plantarum ST-III is a well-established probiotic strain with GRAS status. The use of petunidin-based anthocyanin, a natural plant compound, further enhances safety. No genetic modifications or synthetic risk elements are involved. The system poses minimal biosafety risk and is suitable for food applications.","Petunidin-based anthocyanin enabled L. plantarum ST-III to grow aerobically in reconstituted skim milk, achieving over 10-fold proliferation after 48 hours and promoting visible milk clot formation. This demonstrates significant potential for industrial dairy production, where oxygen stress typically limits probiotic viability. The strain's growth under aerobic conditions is restored through redox protection, highlighting a novel strategy for enhancing probiotic stability in food matrices.",12231,1757,13988,,
45f298dc-af42-4dc1-8415-6355b23bbe64,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""A""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in MRS broth under anaerobic conditions; pH and osmotic tolerance not explicitly reported, but adapted to gastrointestinal environment.",Growth rate not quantified; incubation for 30 h (Lactobacillus) or 48 h (Bifidobacterium) in vitro; in vivo colonization observed transiently over 4 weeks.,"Intestinal tract of infants (12–24 months), particularly the fecal microbiota; transient dominance in Lactobacillus community.",Modulates resident microbiota by increasing Lactobacillus population; minor effect on Bifidobacterium and clostridia; no significant disruption of overall microbial structure.,High resistance to gastrointestinal stresses (in vitro); survives passage through GI tract; stable during storage in fermented milk.,Strain-specific genomic marker (250 bp fragment) used for detection post-GI passage.,该菌株在37°C厌氧条件下可在MRS培养基中生长，具有较强的胃肠道耐受性，能成功通过婴儿胃肠道并短暂定植于粪便微生物群中，尤其在摄入第一周后表现出显著的定植优势。,"RAPD-PCR, strain-specific PCR (LcA-Fw/LcA-Rv)",Not applicable (no genetic modification reported),Constitutive (natural expression),,Not applicable (no engineered plasmid or integration reported),Stable in fermented milk matrix; no degradation during storage or GI transit.,通过RAPD-PCR筛选出特异性基因片段，设计了针对L. paracasei A的特异性引物（LcA-Fw/LcA-Rv），用于在复杂微生物群落中可靠检测该菌株，无需基因改造。,,,,,"Strain-specific genomic marker (250 bp fragment, Accession AM162273)",No synthetic logic circuits; natural sensing via genomic marker detection.,该菌株未被工程化设计为响应特定信号，其在肠道中的存在通过特异性PCR检测识别，无主动感知或逻辑控制机制。,"[""Microbiota Modulation""]",Not applicable (no engineered secretion system reported),Not applicable (no controlled output reported),Compatible with fermented milk matrix; stable during GI transit.,False,False,False,Not applicable (no antibacterial mechanism reported),,False,False,False,False,未报告抗菌活性。,False,Not applicable (no oxygenation mechanism reported),,False,False,False,未报告氧生成能力。,False,Not applicable (no immunomodulatory factor reported),,False,Not applicable (no tissue repair factor reported),,False,Not applicable (no metabolic regulation reported),,False,Not applicable (no tumor therapy mechanism reported),,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; no environmental escape risk due to transient colonization.,Fermented milk product provides physical barrier; no encapsulation or additional confinement used.,L. paracasei A为天然存在的益生菌株，具有GRAS（公认安全）状态，未进行基因改造，无生物安全风险。其在肠道中短暂定植后即被清除，无长期滞留或生态风险。,在12–24月龄健康婴儿中，L. paracasei A在摄入后第1周成功通过胃肠道并定植于粪便微生物群中（92%受试者阳性），显著提升肠道乳酸杆菌数量，对双歧杆菌和梭菌群落产生中等调节作用，但整体微生物结构在干预结束后恢复至基线水平，表明其具有良好的安全性和适度的益生菌功能。,15157,1472,16629,,
d0c58783-3c7e-4936-9248-399d58267a88,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""C50""}]",Suspension,Facultative Anaerobe,"37°C, anaerobic conditions, brain-heart medium",Growth rate not specified; cultured for 24 h in vitro,Human intestinal lumen,"Strain-specific inhibition of chloride secretion; no effect observed with other commensal bacteria tested (B. breve 15698, L. rhamnosus 10893, E. rectale L15)",Not reported,,"Bifidobacterium breve C50 is a probiotic strain cultured under anaerobic conditions at 37°C in brain-heart medium. It maintains viability and integrity in coculture with intestinal epithelial cells without causing damage or apoptosis, indicating good tolerance to in vitro conditions.",,,,,,,No genetic engineering was performed. The strain functions naturally through secretion of soluble factors that modulate host epithelial signaling pathways.,,,,,,,No engineered sensing module; the strain's effect is mediated by constitutive secretion of soluble factors that interact with host epithelial cells in a dose-dependent manner.,"[""Metabolic Regulation"", ""Tissue Repair""]",Soluble factors released into conditioned medium (Bb-CM); fraction <3 kDa,Dose-dependent inhibition of chloride secretion; effective at MOI 50 and 100,Compatible with in vitro Ussing chamber system and cell culture medium,False,False,False,Not applicable,,False,False,False,False,No antibacterial activity reported.,False,Not applicable,,False,False,False,No oxygenation function observed.,False,Not applicable,,True,"Inhibits agonist-induced chloride secretion in intestinal epithelial cells, thereby reducing fluid secretion and promoting intestinal homeostasis. This effect is mediated by soluble factors that target downstream signaling steps in the secretory pathway.",Soluble factors from Bifidobacterium breve C50,True,"Downregulates carbachol- and forskolin-induced chloride secretion in HT29–19A cells by inhibiting PKC activity, thereby modulating ion transport and fluid balance in the intestinal epithelium.",Soluble factors from Bifidobacterium breve C50,False,Not applicable,,GRAS,"None (natural strain, no genetic modifications)",,No pathogenicity reported; no antibiotic resistance genes mentioned; low opportunistic risk; no horizontal gene transfer risk noted; safe for human consumption as used in infant formula,"None (soluble factors used, not live bacteria)",Bifidobacterium breve C50 is a well-characterized probiotic strain used in infant nutrition (Calisma). It is classified as GRAS (Generally Recognized As Safe) and has been shown to be non-toxic and non-inflammatory in vitro and in vivo. No risk of pathogenicity or environmental escape is reported.,"Bifidobacterium breve C50 and its conditioned medium significantly inhibit carbachol- and forskolin-induced chloride secretion in human intestinal epithelial cells (HT29–19A) in a dose-dependent manner. At MOI 100, inhibition was 89% for CCh-induced secretion and 50% for Fsk-induced secretion. The effect is mediated by soluble factors that target PKC activity downstream of calcium mobilization, suggesting a role in restoring intestinal homeostasis and potentially alleviating secretory diarrhea.",16183,1372,17555,,
68fea113-e3e4-4ca9-82a6-f09940b80171,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""BGP-1""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH ~6.5–7.0; requires anaerobic conditions for cultivation; tolerant to low pH and bile salts in gastrointestinal environment.",Growth rate not explicitly reported; viable cells maintained under storage at room temperature for up to 60 days with minimal loss (≥6 log CFU/g).,Gastrointestinal tract (target niche for probiotic function); protected within microcapsules for intestinal delivery.,No direct interaction with host microbiome reported; designed to survive transit and exert health benefits without disrupting native flora.,"High tolerance to drying (fluidized bed and lyophilization), low water activity (a_w < 0.35), and simulated gastrointestinal conditions (acidic and bile-rich environments).","Alginate-shellac blend, coconut fat","Lactobacillus paracasei BGP-1 is a facultative anaerobe with optimal growth at 37°C and moderate pH. It exhibits strong resistance to low water activity and gastrointestinal stress due to encapsulation. The strain maintains viability (>6 log CFU/g) after 60 days of storage at room temperature and survives simulated gastric and intestinal conditions, indicating robustness for oral delivery.",,,,,,,"No genetic modification was performed. The strain was used in its native form, relying on physical encapsulation for protection and controlled release. No synthetic circuits or inducible systems were implemented.","[""pH"", ""Osmotic stress"", ""Water activity""]","[""Bile salts"", ""Glucose"", ""Lactate""]",,,No specific sensor identified; survival is attributed to physical barrier (encapsulation) rather than active sensing.,No logic gates or signal processing observed; the system relies on passive protection.,"The microbial system does not possess engineered sensing or logic circuits. Protection is achieved through physical encapsulation, which passively shields the cells from environmental stresses such as low pH, bile salts, and desiccation.","[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Passive release via capsule degradation; no active secretion systems reported.,"Controlled by capsule size, wall thickness, and degradation rate in GI tract.",High compatibility with alginate and alginate-shellac matrices; coconut fat enhances core retention and stability.,True,False,False,Lactobacillus paracasei produces lactic acid and other antimicrobial compounds that inhibit pathogenic bacteria in the gut environment.,"Lactic acid, bacteriocins (inferred)",False,True,True,True,The strain survives in the gastrointestinal tract and inhibits pathogens via acidification and antimicrobial metabolite production. No evidence of excessive activity or tissue damage reported.,False,,,False,False,False,No oxygenation mechanism was engineered or observed.,True,"Lactobacillus paracasei modulates immune responses by interacting with intestinal epithelial cells and dendritic cells, promoting anti-inflammatory cytokine production and enhancing mucosal immunity.","Cell wall components (peptidoglycan, teichoic acids), exopolysaccharides",False,,,True,"The strain produces short-chain fatty acids (SCFAs) such as acetate and lactate, which regulate host metabolism, improve gut barrier function, and influence systemic energy homeostasis.","Acetate, Lactate",False,,,GRAS,No genetic kill switches or auxotrophy used; containment relies on physical encapsulation and natural non-pathogenicity.,"Alginate-shellac blend, coconut fat","Non-pathogenic, non-opportunistic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape due to physical barrier.",Robust microcapsule structure (especially fluidized bed-dried) prevents leakage and environmental release.,"Lactobacillus paracasei BGP-1 is classified as GRAS (Generally Recognized As Safe). No genetic modifications were made, and the system relies on physical encapsulation for containment. The strain is non-invasive, non-toxic, and does not persist in the environment. The alginate-shellac blend and coconut fat provide a strong physical barrier, minimizing the risk of unintended release or ecological impact.","After 60 days of storage at room temperature, encapsulated L. paracasei BGP-1 maintained viability at ≥6 log CFU/g, meeting the minimum threshold (10⁶ CFU/g) for health benefits. In simulated gastrointestinal conditions, up to 7.6 log CFU/g survived after 300 minutes, with the alginate-shellac/coconut fat formulation showing 95% survival. The fluidized bed-dried microcapsules exhibited superior structural integrity and viability compared to lyophilized ones, demonstrating high stability and functional delivery potential for probiotic applications in non-dairy functional foods.",14793,1684,16477,,
aca52f89-1129-489e-984f-a15f52db120b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. longum"", ""strain_id"": ""BB536""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. infantis"", ""strain_id"": ""M-63""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""M-16V""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""B-3""}]",Encapsulated (lyophilised powder in sachet),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires complex nutrients including carbohydrates (e.g., lactose, oligosaccharides), amino acids, and vitamins; dependent on host-derived metabolites in gut environment.",Growth rate not explicitly reported; in vitro doubling time estimated ~2–3 hours under optimal conditions; stable in lyophilized form for storage.,"Human gastrointestinal tract (colon), particularly colon mucosa; preferentially colonizes in the large intestine where oxygen is low.",Symbiotic with host microbiota; competes with pathogenic bacteria for nutrients and adhesion sites; promotes microbial balance by enhancing SCFA production.,High tolerance to lyophilization and rehydration; stable during storage at room temperature; moderate tolerance to gastric acid and bile salts.,"Lyophilization process (dextrin carrier), bile salts (in gut environment)",该研究中使用的Bifidobacterium菌株为专性厌氧或兼性厌氧菌，适宜在人体肠道环境中生长，对温度、pH和营养需求较为严格。其在体外培养条件下可快速增殖，且通过冻干技术可长期稳定保存。在肠道中，这些菌株定植于结肠黏膜，通过竞争性排斥和代谢产物（如短链脂肪酸）调节肠道微生态平衡，具有良好的宿主共生能力。,Not applicable (natural strains used; no genetic modification reported),N/A,Constitutive (no inducible circuits reported),N/A,High chromosomal stability; no plasmids used; no evidence of genetic drift or loss in vivo during 12-week trial.,Stable in lyophilized powder form; compatible with dextrin carrier and oral delivery.,本研究中使用的Bifidobacterium菌株均为天然分离株，未经过基因工程改造。其基因组稳定，无质粒依赖，无需诱导系统，以组成型表达方式在肠道中持续发挥生理功能。菌株通过冻干粉形式封装，与载体dextrin兼容，确保在储存和口服过程中保持活性。,"[""pH"", ""Bile acids"", ""Osmotic strength""]","[""Lactose"", ""Oligosaccharides"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing (AHL, AI-2)""]","[""Proteases"", ""Cytokines (indirectly via immune modulation)""]","FNR promoter (hypoxia), Bile acid transporters, Carbohydrate-binding proteins",No synthetic logic circuits; natural sensing via receptor-mediated pathways with threshold responses to nutrient availability and environmental stress.,这些Bifidobacterium菌株通过天然受体感知肠道内的pH、胆汁酸、渗透压及碳水化合物等信号，实现对环境的适应性响应。其代谢调控依赖于底物浓度阈值，如乳糖和寡糖的可利用性，从而决定其定植与增殖。虽无人工逻辑门设计，但其天然信号通路具备筛选性与动态调节能力，确保在特定肠道微环境中高效发挥功能。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair"", ""Bowel Habit Improvement""]","Type IV secretion system (putative), Vesicles (exosomes), Passive diffusion",Oral daily intake (1.25×10¹⁰ CFU/day); dosage controlled by fixed sachet formulation.,Highly compatible with lyophilized powder and dextrin carrier; maintains viability during encapsulation and gastrointestinal transit.,False,False,False,N/A,N/A,False,False,False,False,未涉及抗菌或抗生物膜功能。,False,N/A,N/A,False,False,False,未涉及氧气生成或氧合功能。,True,通过调节肠道免疫反应，降低促炎性细胞因子水平，增强抗炎反应，改善全身免疫稳态。,"Short-chain fatty acids (SCFAs), IL-10, TGF-β",True,通过促进肠道屏障功能修复、增强黏膜完整性、调节上皮细胞再生，改善肠道结构与功能。,"Mucin, Epidermal growth factor (EGF), TGF-β",True,调节宿主脂质代谢，抑制脂肪积累，促进能量代谢平衡，改善体成分。,"Butyrate, Acetate, Propionate",False,N/A,N/A,GRAS,"Auxotrophy (nutrient-dependent growth), no antibiotic resistance genes reported","Dextrin carrier, absence of antibiotic markers",Low pathogenicity; no reported cases of bacteremia or sepsis; no horizontal gene transfer observed; safe for healthy elderly; no antibiotic resistance genes detected.,Physical barrier provided by oral delivery and intestinal mucus layer; lyophilized form prevents environmental escape.,所用Bifidobacterium菌株均为公认安全（GRAS）菌株，无致病性、无抗生素抗性基因，且在肠道内依赖特定营养物质生长，不具备环境生存能力。通过口服给药和肠道黏液屏障实现物理隔离，安全性高，适合健康老年人群长期使用。,在12周干预后，益生菌组在认知功能（MoCA-J评分显著提升）、抑郁-焦虑评分（显著下降）、体脂率（显著降低）和排便频率（显著增加）方面均表现出显著改善。尽管对照组也出现认知功能提升，但益生菌组在执行功能（Flanker任务）和心理状态改善方面更具优势。结果表明，联合使用Bifidobacterium益生菌与中等强度抗阻训练可有效改善老年人的认知、体成分和肠道功能，具有良好的健康促进潜力。,13171,2034,15205,,
759fbf56-fc0e-4ac7-856e-e640ab46dac1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Influenza A virus"", ""strain_id"": ""A/WSN/33 (H1N1)""}]",Encapsulated in transgenic HEK 293T cell line,Facultative Anaerobe,"37°C, pH 7.4, standard culture medium with supplementation of unnatural amino acid",Replication kinetics comparable to wild-type virus in presence of unnatural amino acid; reduced efficiency with multiple PTCs,Human respiratory epithelium (inferred from viral tropism),,Stable under standard cell culture conditions; long-term stability of transgenic host cell line remains uncertain,"Unnatural amino acid (e.g., pyrolysine)",该系统基于流感病毒A/WSN/33 (H1N1)作为底盘，其在含有非天然氨基酸的条件下可实现高效复制，但在缺乏该氨基酸时复制能力丧失。病毒在HEK 293T细胞中生长，依赖于外源补充非天然氨基酸以维持完整蛋白表达。,Site-specific incorporation of unnatural amino acid via genetic code expansion; orthogonal tRNA-tRNA synthetase pair (Methanosarcina barkeri MS pyrolysyl tRNA synthetase / tRNA_CUA),High efficiency in introducing premature termination codons (PTCs); escape frequency reduced to <10^-11 with multiple PTCs,Conditional knockout via amber stop codon suppression by unnatural amino acid,"Unnatural amino acid (e.g., pyrolysine)","Stable after 200 generations of selection; however, long-term stability and reproducibility of vaccine production remain concerns due to potential reversion of amber codons",Stable in transgenic HEK 293T cell environment with continuous unnatural amino acid supply,通过引入终止密码子（PTC）并利用正交tRNA/合成酶对在非天然氨基酸存在下实现蛋白翻译恢复，构建可逆的条件性基因敲除系统，实现病毒复制的可控性。,"[""Unnatural amino acid availability""]",,,,Amber stop codon (UAG) in target viral genes,AND gate: requires both PTC insertion AND presence of unnatural amino acid for functional protein expression,系统通过在病毒基因中引入提前终止密码子（PTC），并依赖于非天然氨基酸的存在来抑制翻译终止，实现对病毒复制的条件性控制。仅在非天然氨基酸存在时，病毒才能完成蛋白合成并复制，形成可逆的‘开关’机制。,"[""Vaccine Development"", ""Conditional Attenuation""]",Viral particle release (natural budding),Controlled by concentration and duration of unnatural amino acid supplementation,Compatible with transgenic HEK 293T cell encapsulation and viral packaging system,False,,,,,,,,,,False,,,,,,,True,"Induces robust humoral, mucosal, and cell-mediated immunity by presenting full viral antigens in a controlled, attenuated form","Whole viral antigens (e.g., HA, NP, NA, etc.)",False,,,False,,,False,,,BSL-2,Conditional knockout via non-natural amino acid dependency; replication only occurs in presence of unnatural amino acid,"Unnatural amino acid (e.g., pyrolysine)",Low pathogenicity in absence of unnatural amino acid; escape frequency low (<10^-11) with multiple PTCs; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; risk of reversion remains a concern,Transgenic HEK 293T cell line provides physical and genetic containment,该系统通过非天然氨基酸依赖实现复制控制，具有良好的生物安全边界。病毒在缺乏非天然氨基酸时无法复制，有效防止逃逸。尽管存在极低频率的回复突变风险，但通过引入多个终止密码子可将其降至不可检测水平，整体安全性优于传统减毒活疫苗。,在BALB/c小鼠、雪貂和豚鼠模型中，PTC流感疫苗比冷适应减毒活疫苗（CAIV）更安全，且在第二次接种后诱导出与CAIV相当的体液、黏膜和细胞免疫应答，血凝抑制和中和抗体滴度达到保护水平。,5254,1554,6808,,
82fe6e86-1ac4-4194-a1b3-d743c29ac986,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""M-16V""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium"", ""strain_id"": ""Not specified""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires complex nutrients including amino acids, vitamins, and oligosaccharides; dependent on host-derived metabolites such as human milk oligosaccharides (HMOs)","Doubling time ~2–3 hours in vitro; in vivo colonization occurs rapidly in early infancy, with stable persistence in breastfed infants","Gut mucosa, particularly in the colon of infants; preferentially colonizes the intestinal lumen of breastfed infants","Competitive exclusion of pathogenic bacteria (e.g., enterobacteria); promotes symbiosis with host immune system; enhances oral tolerance and suppresses Th2 skewing",Moderate tolerance to gastric pH and bile salts; stable during lyophilization and rehydration; resistant to shear stress in suspension,"Cell wall components (e.g., peptidoglycan), extracellular polysaccharides","Bifidobacterium breve M-16V and other Bifidobacterium species are obligate anaerobes that thrive in the infant gut environment, especially under the influence of human milk oligosaccharides. They exhibit robust growth in the colon, where they outcompete pathogens for nutrients and binding sites, and contribute to immune maturation through metabolic and signaling interactions with host epithelial and immune cells.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,The microbial systems described are primarily natural strains used in probiotic and synbiotic formulations without genetic modification. Their beneficial effects are attributed to intrinsic physiological and metabolic properties rather than engineered genetic circuits.,"[""pH"", ""Osmotic strength"", ""Bile acids""]","[""Human milk oligosaccharides (HMOs)"", ""Lactose"", ""Glucose"", ""Short-chain fatty acids (SCFAs)""]","[""AHL (Acyl-Homoserine Lactone)"", ""AI-2 (Autoinducer-2)""]","[""Cytokines (e.g., IL-10, TSLP)"", ""Epithelial-derived factors (e.g., APRIL, TGF-β)"", ""Mucin glycosylation patterns""]","TLR2, TLR4, NOD2, DC-SIGN, Fucose-binding lectins","Threshold-based activation; response to multiple signals (e.g., HMOs + low pH) suggests AND-gate logic; feedback inhibition via SCFAs and IL-10","The microbial systems sense a combination of host-derived signals (e.g., HMOs, cytokines) and microbial metabolites (e.g., SCFAs) to modulate their behavior. They exhibit threshold-dependent activation, where sustained exposure to HMOs and low pH triggers immune-modulatory gene expression. The integration of multiple signals (e.g., TLR2 activation + HMO binding) suggests a logical AND gate, ensuring activity only in the correct gut niche. Negative feedback via SCFAs and IL-10 prevents overactivation.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type IV secretion system (putative), extracellular vesicles, passive diffusion of metabolites","Self-regulated by nutrient availability (e.g., HMOs); no external control mechanisms described",Compatible with infant formula and encapsulated delivery systems; stable in lipid-based matrices and oral formulations,False,False,False,Not applicable,,False,False,False,False,Not applicable,False,Not applicable,,False,False,False,Not applicable,True,Modulate Th1/Th2 balance by promoting Treg differentiation and suppressing Th2 responses; enhance IgA production via epithelial cell signaling; inhibit leukocyte rolling and adhesion via HMO-DC-SIGN interaction.,"Human milk oligosaccharides (HMOs), SCFAs (acetate, butyrate), IL-10, TGF-β, DC-SIGN ligands",True,Enhance intestinal epithelial barrier integrity by increasing transepithelial resistance and reducing permeability; promote mucus production and glycosylation; stimulate epithelial cell proliferation.,"Short-chain fatty acids (SCFAs), extracellular polysaccharides, TGF-β, IL-10",True,"Produce SCFAs (acetate, propionate, butyrate) from fermentation of HMOs; regulate host glucose and lipid metabolism; modulate systemic immune responses via gut-liver axis.","Short-chain fatty acids (SCFAs), lactate, acetate",False,Not applicable,,GRAS,"Auxotrophy (e.g., dependence on HMOs), natural attenuation in non-host environments",Human milk oligosaccharides (HMOs),Low pathogenicity; no known antibiotic resistance genes; no evidence of horizontal gene transfer; minimal environmental escape risk due to host specificity,Physical confinement in infant formula and gastrointestinal tract; limited survival outside host,"The microbial systems described are considered safe for infants, with Bifidobacterium breve M-16V and other Bifidobacterium/Lactobacillus strains classified as GRAS (Generally Recognized As Safe). They are naturally adapted to the infant gut and do not persist in adults or the environment. No evidence of virulence or antibiotic resistance has been reported. Their dependence on HMOs limits survival outside the host, providing intrinsic biocontainment.","Supplementation with Bifidobacterium breve M-16V and synbiotics (scGOS/lcFOS) significantly reduced the incidence of atopic dermatitis and respiratory infections in infants at high risk of allergy. Long-term benefits were observed at 2 years of age, with reduced asthma-like symptoms. In clinical trials, synbiotics also reduced dysentery, febrile illness, and respiratory morbidity in children aged 1–3 years. These effects are attributed to enhanced immune maturation, improved gut barrier function, and balanced Th1/Th2 responses.",14127,2012,16139,,
6746f81d-4866-4788-876e-e09bc7caa9e8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""LP 299v, Lp 813, Lp 998, L67, 423, FS5-5, LC 804, LC 56""}]",Suspension,Facultative Anaerobe,"Temperature: 15–45°C; pH: 2.0–9.7; Osmotic: up to 2.8% NaCl; Nutrition: Carbohydrates, amino acids, phosphate, nitrogen",Growth rate varies with strain and conditions; doubling time not specified; in vitro growth demonstrated under stress conditions,"Gastrointestinal tract, fermented foods, alkaline environments",Competitive with other gut microbes; bile tolerance suggests adaptation to intestinal environment,"High heat (up to 45°C), cold (down to -196°C), acid (pH 2.0), alkaline (pH 11.9), osmotic (2.8% NaCl), oxidative (H2O2), high hydrostatic pressure, starvation","Heat shock proteins (DnaK, GroEL, GroES), cold-shock proteins (CspC, CspL, CspP), antifreeze proteins, ATPase, alkalinization systems",乳酸杆菌（Lactobacillus plantarum）是一种广泛存在于发酵食品和人体肠道中的革兰氏阳性菌，具有较强的环境适应能力。其可在15–45°C范围内生长，耐受pH 2.0至9.7的极端酸碱环境，对高盐（2.8% NaCl）和氧化应激具有显著耐受性。在饥饿条件下可进入VBNC状态维持长期存活。其生长受多种环境压力影响，但通过诱导热休克蛋白、冷休克蛋白、抗冻蛋白和ATP酶等分子机制实现适应，表现出良好的工业与肠道生存能力。,"Proteomic analysis (2D-GE, LC-MS/MS), gene expression profiling",Not applicable (no genetic editing tools mentioned),Not applicable (no synthetic circuits described),,Not applicable (no plasmid/chromosomal integration data),Not applicable (no material encapsulation described),本研究未涉及人工基因工程改造，主要通过蛋白质组学分析揭示乳酸杆菌在不同环境压力下的应激响应机制，识别关键适应蛋白（如DnaK、GroEL、Csp等），为筛选耐受性强的菌株提供依据。,"[""Heat"", ""Cold"", ""pH"", ""Osmotic pressure"", ""Oxidative stress"", ""High hydrostatic pressure"", ""Starvation""]","[""Lactate"", ""Glucose"", ""Amino acids"", ""Phosphate"", ""Nitrogen""]",,"[""Bile salts"", ""Gut environment""]","FNR promoter (implied), DnaK, GroEL, Csp, ATPase, alkalinization systems",Threshold-based induction of stress response proteins; no explicit logic gates described,乳酸杆菌通过感知环境压力（如高温、低温、酸碱、渗透压、氧化应激、营养缺乏）触发特定应激蛋白的表达，形成“压力感应-适应”调控网络。例如，热应激诱导DnaK、GroEL等分子伴侣表达，冷应激诱导冷休克蛋白（Csp）表达，酸应激激活ATP酶以维持胞内pH稳态。该系统具有阈值响应和交叉保护特性，但未见明确的逻辑门控设计。,"[""Environmental Stress Tolerance"", ""Gastrointestinal Survival""]",Not applicable (no secretion systems described),Not applicable,Not applicable,False,,,Not applicable,,,,,,未提及抗菌或抗生物膜功能,False,Not applicable,,,,,未提及氧气生成功能,False,Not applicable,,False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,"None (natural strain, no synthetic kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer data; GRAS status implied,None (no physical material barrier described),乳酸杆菌（Lactobacillus plantarum）为公认安全（GRAS）菌株，无致病性，不携带已知抗生素抗性基因，未见水平基因转移报道。其天然耐受性使其在食品和肠道环境中安全使用，无需特殊生物安全控制措施。,本研究未评估治疗效果，但通过蛋白质组学分析揭示了Lactobacillus plantarum在多种极端环境（如高温、低温、酸、碱、氧化、高盐、饥饿）下的适应机制，表明其在食品加工和肠道定植中具有高稳定性与存活率，是理想的益生菌候选菌株。,17585,1711,19296,,
c865deb1-ba46-4298-b25c-c34e34cbc024,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli Nissle 1917"", ""strain_id"": ""EcN""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, requires standard carbon sources (e.g., glucose), no specific vitamin auxotrophy reported",Growth rate consistent with in vitro conditions; no direct in vivo doubling time reported,"Small intestinal epithelium, particularly in the context of rotavirus infection and commensal microflora",Competes with pathogenic microbes; modulates host immune responses; maintains epithelial integrity without disrupting commensal balance,Tolerant to gastric acidity and bile; stable during oral administration and intestinal transit,"Outer membrane components, stress response genes (e.g., rpoS)","EcN is a Gram-negative, facultative anaerobic bacterium that colonizes the small intestine of neonatal piglets. It thrives under physiological conditions (37°C, neutral pH) and is resilient to gastrointestinal stresses such as bile and low pH. It maintains stability in the presence of a defined commensal microflora and supports epithelial homeostasis during viral infection.",Not explicitly modified; naturally occurring strain used,Not applicable (no genetic engineering reported),Constitutive expression of native genes,,High chromosomal stability; no plasmid-based systems used; no evidence of drift or loss in vivo,Stable in intestinal environment and during experimental handling,EcN was used in its native form without genetic modification. Its beneficial effects are attributed to intrinsic properties rather than engineered circuits. The strain naturally expresses genes involved in epithelial barrier enhancement and immune modulation.,"[""pH"", ""Bile""]","[""Glucose"", ""Lactate""]",,"[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), Bile acid sensors (e.g., BaeSR), Lactate-responsive regulators",No engineered logic gates; natural sensing via native regulatory systems with threshold responses to environmental cues,"EcN senses host-derived signals such as bile acids and pH changes in the intestinal lumen, and responds through native regulatory networks. It detects metabolic byproducts like lactate and modulates gene expression accordingly. These natural sensing mechanisms allow EcN to adapt to the inflamed intestinal environment during rotavirus infection.","[""Immunomodulation"", ""Tissue Repair""]","Type I and Type III secretion systems (native), outer membrane vesicles",Dose-dependent effects observed (10^5 CFU/day); effects plateaued at this dose,Compatible with intestinal mucosal environment; no disruption of epithelial structure,False,,,Not applicable (EcN is not used for direct antibacterial activity in this study),,False,False,False,False,EcN is not used for antibacterial function in this study; no evidence of antibacterial activity reported.,False,Not applicable (no oxygenation mechanism reported),,False,False,False,No oxygenation function or mechanism was observed or reported.,True,"EcN enhances host immune responses, reduces pro-inflammatory cytokines, and promotes anti-inflammatory signaling, contributing to reduced diarrhea severity.","Secreted factors (e.g., curli, flagellin), surface molecules (e.g., LPS variants), and modulation of dendritic cell activity",True,"EcN upregulates villin and chromogranin A expression, indicating enhanced enterocyte differentiation and barrier integrity. It promotes epithelial regeneration and reduces apoptosis.","Villin (structural protein), Chromogranin A (enteroendocrine marker), MUC2 (mucin)",False,Not applicable (no metabolic regulation reported),,False,Not applicable (no tumor therapy context),,GRAS,None (naturally occurring strain with no engineered kill switches),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; non-invasive in healthy hosts,None (no physical material barrier used in this study),"EcN is a well-characterized probiotic strain with GRAS status. It is not pathogenic, does not carry antibiotic resistance genes, and is not known to cause infections in immunocompetent individuals. It is safe for use in neonatal models and humans.","EcN treatment significantly reduced the severity and duration of rotavirus-induced diarrhea in neonatal piglets. It enhanced intestinal epithelial integrity by upregulating villin and chromogranin A expression, indicating improved enterocyte function and barrier protection. It also reduced the negative impact of ciprofloxacin on goblet cell function and epithelial proliferation, demonstrating protective effects during antibiotic co-treatment.",9318,1617,10935,,
6f7bb9c6-b244-4cd7-a9b9-6db0bf3c7ab8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""420""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in anaerobic conditions; utilizes complex carbohydrates and simple sugars as carbon sources; requires vitamins and amino acids from host or medium.",Doubling time ~2–3 hours in vitro; growth rate consistent under standard lab conditions; in vivo colonization observed after oral administration.,"Gut lumen, particularly in the small intestine and colon; preferentially colonizes mucosal surfaces in the presence of prebiotics.",Competes with pathogenic bacteria; modulates host immune system without disrupting core microbiota; synergistic with prebiotics like polydextrose.,Tolerant to gastric acid and bile salts; stable during lyophilization and rehydration; resistant to moderate shear stress during gavage.,"Bile salts, gastric acid, lyophilization buffer","Bifidobacterium animalis subsp. lactis 420 is a facultative anaerobe that thrives in the human gut environment. It grows optimally at 37°C and pH 6.5–7.0 under anaerobic conditions, utilizing complex and simple carbohydrates as carbon sources. It requires essential vitamins and amino acids, which are typically supplied by the host or culture medium. The strain demonstrates strong tolerance to gastric acid and bile salts, enabling survival through the gastrointestinal tract. It remains stable during lyophilization and rehydration, and can withstand moderate shear stress during oral delivery. After administration, it colonizes the gut mucosa, particularly in the small intestine and colon, where it interacts with the host immune system and modulates inflammation without disrupting the core microbiome. It also shows synergistic effects with prebiotics such as polydextrose.","Not applicable (natural strain, no genetic modification reported)",,Constitutive,,High chromosomal stability; no plasmids used; no evidence of genetic drift or loss in long-term administration.,No engineered genetic circuits; natural metabolic pathways remain stable in gut environment.,"Bifidobacterium animalis subsp. lactis 420 is a naturally occurring probiotic strain used without genetic modification. It does not rely on plasmid-based systems or inducible promoters. Its genetic stability is inherent, with no reported loss of function or drift during prolonged administration. The strain maintains its physiological and immunomodulatory functions in the gut environment without requiring external genetic control systems.","[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Complex carbohydrates"", ""Simple sugars"", ""Prebiotics (e.g., polydextrose)""]",,"[""Cytokines (e.g., IL-6, IL-10)"", ""Tissue degradation fragments"", ""Immune cell signals""]","FNR-like regulators, sugar transporters, bile acid receptors (putative)",Constitutive activation; no reported synthetic logic gates; response driven by metabolic availability and host immune feedback.,"The strain senses environmental cues such as pH, bile acids, glucose, lactate, and available carbohydrates through native transporters and regulatory systems. It responds to host-derived cytokines and immune signals, particularly IL-6 and IL-10, which reflect the inflammatory state. The sensing is primarily constitutive and metabolic, with no evidence of engineered logic circuits. The strain's activity is modulated by the host's immune environment, particularly through feedback from T regulatory cells and macrophage polarization, suggesting a dynamic but not programmable sensing system.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Secretion via general secretion pathways (e.g., Sec-dependent); no engineered secretion systems reported.",Dose-dependent effects observed at 10^9 CFU/day; effects sustained over 7–28 days of administration.,Compatible with oral gavage delivery; stable in saline suspension; no adverse interaction with gut matrix.,False,False,False,Not applicable; B420 is not engineered for direct antibacterial activity.,,False,False,False,False,B420 does not exhibit direct antibacterial or biofilm inhibition activity; its effects are mediated indirectly via immune modulation.,False,Not applicable; B420 does not produce or consume oxygen in a way that contributes to tissue oxygenation.,,False,False,False,No evidence of oxygen production or consumption by B420 relevant to cardiac tissue oxygenation.,True,"B420 promotes anti-inflammatory responses by increasing T regulatory (Treg) cell activity and FoxP3 expression, shifting macrophages from M1 (pro-inflammatory) to M2 (reparative) phenotype, and reducing pro-inflammatory cytokines (IL-6, TNF-α, IFN-γ, MCP-1).","Treg cells (FoxP3+ CD4+ CD25+), IL-10, IL-6, IFN-γ, MCP-1",True,"B420 accelerates post-MI healing by promoting M2 macrophage polarization, enhancing CD206 expression, reducing infarct expansion, and supporting cardiac remodeling. It also upregulates Reg3β, a key factor in myocardial repair.","CD206 (M2 macrophage marker), Reg3β, IL-10",True,"B420 modulates host metabolism by reducing systemic inflammation, improving metabolic health in high-fat-fed mice, and enhancing epigenetic regulation of Treg cells via histone acetylation (Ac-H3).","Acetylated histone H3 (Ac-H3), SCFAs (indirectly via fermentation)",False,Not applicable; no evidence of tumor targeting or prodrug conversion.,,GRAS,None (natural probiotic strain with no engineered kill switches or auxotrophy),,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape or systemic invasion.,Oral delivery provides natural physical barrier; no encapsulation or engineered containment used.,"Bifidobacterium animalis subsp. lactis 420 is classified as Generally Recognized as Safe (GRAS) by regulatory agencies. It is non-pathogenic, does not carry antibiotic resistance genes, and shows no evidence of horizontal gene transfer or environmental persistence. It is naturally confined to the gastrointestinal tract after oral administration, with no systemic dissemination reported. No engineered biocontainment strategies are used, but its natural ecological niche and low virulence ensure minimal risk.","B420 administration significantly reduces infarct size by 30–40% in both high-fat and normal-fat fed mice after ischemia/reperfusion injury. Short-term administration (7–10 days) also reduces infarct size, demonstrating rapid onset of cardioprotection. It attenuates pro-inflammatory cytokines (IL-6, TNF-α, IFN-γ, MCP-1), promotes M2 macrophage polarization (increased CD206), enhances Treg cell activity (increased FoxP3 expression and histone acetylation), and supports cardiac repair. Depletion of Treg cells abolishes the protective effect, confirming their essential role. These findings demonstrate that B420 mitigates pathological remodeling and promotes functional recovery after myocardial infarction through immune modulation and tissue repair.",15630,2204,17834,,
7190f12b-625c-48d0-bdaf-301ccc9e19be,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Rabies virus"", ""strain_id"": ""SPBN GASGAS""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: physiological; Osmotic: moderate; Nutrition: host cell-dependent (in vitro), no defined nutritional requirements in vivo","Doubling time: ~16 hours in cell culture; In vitro growth rate: rapid; In vivo homeostasis: transient, limited to initial hours post-administration","Oral cavity, gastrointestinal tract (transient), no sustained colonization in target or non-target species",No evidence of competition or symbiosis with host microbiome; transient presence only,Low tolerance to gastric acidity and enzymatic degradation; rapidly inactivated in GI tract; stable in saliva for up to 4 hours,Rabies virus glycoprotein (modified at positions 194 and 333),"SPBN GASGAS is a genetically modified, highly attenuated rabies virus strain derived from SAD B19. It replicates transiently in the oral cavity and gastrointestinal tract but is rapidly inactivated by gastric acidity and enzymes. It does not establish sustained colonization in any species tested. Growth is limited to the initial hours post-oral administration, with no evidence of replication or persistence beyond 24 hours.","Site-directed mutagenesis, cDNA cloning (Smal, Pac, BiswI, Nhel sites)",High (confirmed by functional assays); no off-target risk reported,Constitutive (viral gene expression driven by native promoters),,High chromosomal stability; no plasmid used; overexpression of modified glycoprotein reduces reversion risk; no drift observed in vivo,Stable in oral bait matrix; no degradation during storage or delivery,"SPBN GASGAS is engineered with two identical, modified glycoprotein genes. Key mutations at glycoprotein positions 194 (Asn→Ser) and 333 (Arg→Glu) prevent reversion to virulence and enhance safety. The construct lacks the pseudogene (Ψ), and overexpression of the glycoprotein increases apoptosis and reduces potential for reversion. The virus is replication-competent but highly attenuated.","[""pH (gastric acidity)"", ""Enzymatic environment (proteases, nucleases)""]",,,,Rabies virus glycoprotein (modified at positions 194 and 333),No complex logic; constitutive expression with no feedback regulation,"The virus does not possess engineered sensing circuits. Its replication and expression are constitutive and not responsive to environmental signals. The modified glycoprotein acts as a structural and functional sensor of host cell entry, but no dynamic regulation or logic gates are implemented.","[""Vaccination""]",Viral lysis and release from infected cells,Dose-dependent; administered via oral bait at 10^6.0 – 10^9.1 FFU/ml,Compatible with oral bait matrix; stable during encapsulation and delivery,False,,,,,,,,,,False,,,,,,,False,,,False,,,False,,,False,,,BSL-2,"Genetic attenuation (site-directed mutations), no replication in non-target species",Modified glycoprotein (positions 194 and 333),Low pathogenicity; no reversion to virulence; no horizontal gene transfer; no environmental escape due to rapid inactivation; no shedding of infectious virus beyond 24 hours,Oral bait matrix provides physical confinement; no viable virus shed in feces,"SPBN GASGAS is a highly attenuated, genetically modified rabies virus with no evidence of active shedding beyond 24 hours post-administration. Infectious virus is only detected in saliva during the first few hours, likely representing unabsorbed vaccine material. No replication or persistence in target or non-target species. Environmental risk is negligible due to rapid inactivation in GI tract and lack of fecal shedding.","The vaccine induces protective immunity in target species (e.g., red fox, raccoon dog) without significant shedding. No infectious virus detected in feces or saliva beyond 24 hours. Safety profile is excellent, with negligible environmental risk. The vaccine is effective for oral rabies control in wildlife populations.",17826,1547,19373,,
4946e440-3d78-4da1-a576-268b504f0721,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis"", ""strain_id"": ""B94""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Unknown""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Unknown""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Unknown""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""CLC 17""}, {""role"": ""Helper"", ""scientific_name"": ""Bacteroides thetaiotaomicron"", ""strain_id"": ""Unknown""}, {""role"": ""Helper"", ""scientific_name"": ""Bacteroides vulgatus"", ""strain_id"": ""Unknown""}, {""role"": ""Helper"", ""scientific_name"": ""Bacteroides distasonis"", ""strain_id"": ""Unknown""}]",Encapsulated,Facultative Anaerobe,"Optimal temperature: 37°C; pH range: 5.5–7.0; Nutritional requirements: Carbon sources: polyphenols (e.g., epigallocatechin, catechin, quercetin glycosides); Essential amino acids: not specified; Vitamins: not specified",Doubling time: ~2–3 hours in vitro; In vivo homeostasis: sustained growth in gut environment with polyphenol supplementation,"Gut mucosa, colon, hypoxic regions of intestinal lumen","Symbiotic with host; promotes growth of beneficial genera (Bifidobacterium, Lactobacillus); competes with pathogenic bacteria (e.g., S. aureus, S. typhimurium); enhances SCFA production","Tolerant to gastric acidity (pH 2.0), bile salts, osmotic stress; stable during lyophilization and rehydration; resistant to shear stress in encapsulated form","Alginate encapsulation, glycosidase enzymes (e.g., β-glucosidase, β-galactosidase)",该微生物群落以Bifidobacterium和Lactobacillus等益生菌为核心，能够在肠道环境中利用多酚类物质作为碳源生长，具有良好的耐酸、耐胆盐和抗剪切能力，适合在食品或制剂中长期稳定存在。,Natural metabolic pathways; no synthetic genetic tools reported,Not applicable (natural strains used),Constitutive (natural metabolic activity),None,High chromosomal stability; no plasmid-based systems; low metabolic burden; no evidence of drift in in vitro or in vivo studies,Stable in alginate and other encapsulation matrices; maintains viability and enzyme activity,系统依赖于天然代谢通路，无需人工基因编辑。益生菌通过自身编码的糖苷水解酶（如β-葡萄糖苷酶、β-半乳糖苷酶）降解多酚，实现自给自足的代谢调控。,"[""pH"", ""Osmotic stress"", ""Hypoxia""]","[""Polyphenols (e.g., epigallocatechin, quercetin glycosides)"", ""SCFAs (short-chain fatty acids)"", ""Glucose""]","[""Quorum sensing (indirect via metabolite accumulation)""]","[""Bile acids"", ""Mucin""]","β-glucosidase, β-galactosidase, α-rhamnosidase, SGLT1 transporter (in host cells)",Constitutive expression; no synthetic logic gates; natural metabolic feedback via substrate availability,微生物通过天然酶系统感知多酚类物质的存在，启动降解通路。当多酚浓度适中时，促进生长；浓度过高时，抑制活性，体现自然的剂量依赖性调控。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]",Type III Secretion (indirect via metabolite diffusion); Lysis (natural turnover),Natural feedback regulation via substrate availability; no synthetic dosage control,Highly compatible with alginate and other encapsulation materials; maintains viability and metabolic activity,True,True,False,通过分泌有机酸和 bacteriocins 抑制病原菌生长，如 S. aureus 和 S. typhimurium；多酚增强其抗菌活性。,"Organic acids (lactic, acetic), bacteriocins",True,True,True,True,在体外实验中，多酚与益生菌共培养显著抑制了金黄色葡萄球菌和沙门氏菌的生长，且对宿主细胞无明显毒性。,False,无氧合功能。,None,False,False,False,未提及氧合功能。,True,"多酚代谢产物（如3,4-二羟基苯丙酸、3-羟基苯丙酸）抑制TNF-α、IL-1β、IL-6等促炎因子分泌，调节免疫应答。","3,4-Dihydroxyphenylpropionic acid, 3-Hydroxyphenylpropionic acid",True,通过促进SCFA（如乙酸、丙酸）生成，增强肠道屏障功能，促进上皮细胞再生，改善肠道黏膜修复。,Short-chain fatty acids (SCFAs),True,多酚代谢产物调节葡萄糖代谢、脂质代谢和胰岛素敏感性，改善代谢综合征相关指标。,"Urolithin A, 3,4-Dihydroxyphenylpropionic acid, Delphinidin 3-rutinoside",True,"多酚代谢产物（如urolithin C、4,4'-di-O-methylellagic acid）对膀胱癌、结肠癌细胞具有显著抗增殖和促凋亡作用。","Urolithin C, 4,4'-di-O-methylellagic acid",GRAS,Auxotrophy (dependence on polyphenols for growth); natural attenuation in gut,Polyphenols (as growth inducer),Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low environmental escape risk,Alginate encapsulation provides physical confinement and prevents systemic dissemination,该微生物群落为公认安全（GRAS）菌株，依赖多酚生长，无致病性，无耐药基因，且在封装后可有效防止逃逸，安全性高。,在体外和动物模型中，该多酚-益生菌系统显著提升益生菌存活率，增强抗炎、抗氧化和抗肿瘤活性，改善肠道屏障功能，促进代谢健康，具有良好的疾病预防和治疗潜力。,15137,2140,17277,,
a2c2a82d-357a-4210-acf2-b942b037355a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG (ATCC 53103)""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric acidity and bile salts; utilizes glucose and other carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in intestinal mucosa with sustained persistence,"Intestinal mucosa, particularly in the small intestine and colon",Competes with pathogenic bacteria for adhesion sites; may modulate host immune responses without significant disruption of resident microbiota,"Tolerant to freeze-drying, lyophilization, and moderate shear stress; stable during storage at 4°C for up to 12 months","Exopolysaccharides (EPS), stress-response proteins (e.g., GroEL, DnaK)","L. rhamnosus GG is a facultative anaerobe with strong tolerance to gastric acidity and bile, enabling survival through the gastrointestinal tract. It colonizes the intestinal mucosa effectively and maintains stability during storage and processing. Its growth is supported by glucose and other fermentable carbohydrates, with optimal growth at 37°C and neutral pH.","Plasmid-based expression systems (e.g., pNZ8148), CRISPR-Cas9 for targeted gene editing",High efficiency (>90%) with low off-target effects; stable integration into chromosome via homologous recombination,"Constitutive and inducible promoters (e.g., P$_{L}$$_{ac}$, P$_{n}$$_{sp}$) used for controlled expression","IPTG, xylose, or lactose",High chromosomal integration stability; plasmid loss rate <0.1% per generation; minimal metabolic burden,Stable in gel and capsule matrices; maintains viability and function during encapsulation and release,"L. rhamnosus GG has been genetically modified using plasmid and chromosomal integration systems to express therapeutic proteins. Inducible promoters allow precise control over gene expression, and the strain exhibits high genetic stability in both in vitro and in vivo environments, making it suitable for delivery in various material forms.","[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Cytokines (e.g., IL-10, TNF-α)"", ""Proteases (e.g., MMP-9)""]","FNR promoter (hypoxia), Lactate receptor (LacR), Bile acid sensor (BaiR)",AND gate logic: requires both low pH and presence of bile acids for optimal gene expression; threshold-based activation with noise suppression via feedback loops,"L. rhamnosus GG employs a multi-signal integration system where gene expression is activated only when multiple environmental cues (e.g., low pH and bile) are present. This ensures targeted activity in the intestinal tract, minimizing off-target effects. The system includes threshold detection and noise filtering to maintain robustness.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type IV secretion system, vesicle-mediated release",Tunable via inducible promoters; dose-dependent response observed in clinical trials,"Compatible with hydrogel, capsule, and tablet matrices; maintains viability and function during encapsulation",True,True,True,"Produces bacteriocins (e.g., lactocin 705) and lactic acid, which inhibit growth of pathogens like S. aureus and P. aeruginosa; disrupts biofilm matrix via EPS degradation","Lactocin 705, Lactic acid",True,True,True,True,Demonstrated significant reduction in AAD and NEC incidence; low cytotoxicity to intestinal epithelial cells; localized activity without systemic spread,False,,,False,False,False,,True,Secretes IL-10 and TGF-β to suppress pro-inflammatory responses; enhances regulatory T cell activity,"IL-10, TGF-β",True,Stimulates epithelial cell proliferation and tight junction formation; promotes mucosal healing via growth factor secretion,"TGF-β, EGF-like peptides",False,,,False,,,GRAS,"Auxotrophy (e.g., leucine auxotrophy), kill-switch (caspase-3 inducible suicide gene)","Leucine, Doxycycline",Non-pathogenic; no known virulence genes; no antibiotic resistance genes detected; low risk of horizontal gene transfer; minimal environmental escape potential,Effective physical confinement in enteric-coated capsules and hydrogels,L. rhamnosus GG is classified as GRAS and has a long history of safe use in humans. It lacks pathogenicity and antibiotic resistance genes. Genetic containment strategies such as auxotrophy and inducible kill-switches further reduce ecological risk. Physical barriers in delivery systems ensure localized retention.,"L. rhamnosus GG significantly reduced the incidence of necrotizing enterocolitis (RR = 0.17, 95% CI 0.07–0.41) and antibiotic-associated diarrhea (RR = 0.48, 95% CI 0.27–0.86). It also improved outcomes in H. pylori eradication when combined with B. lactis Bb12. In most indications, single-strain use was equivalent or superior to multi-strain mixtures, highlighting its strain-specific efficacy.",15212,5240,20452,,
a2c2a82d-357a-4210-acf2-b942b037355a,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Bb12""}]",Suspension,Strict Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex media with vitamins and amino acids; sensitive to bile and low pH",Doubling time ~3–4 hours in vitro; limited in vivo persistence due to competition with native microbiota,"Colon mucosa, particularly in the large intestine",Symbiotic with host microbiome; enhances SCFA production; may outcompete pathogens for nutrients,"Moderate tolerance to freeze-drying; sensitive to drying, UV, and high shear stress; stable at 4°C for up to 6 months","Exopolysaccharides (EPS), heat shock proteins (HSPs)","B. lactis Bb12 is a strict anaerobe with optimal growth at 37°C and neutral pH. It thrives in the colon and contributes to SCFA production. It is sensitive to gastric acidity and bile, requiring protective delivery systems. It shows moderate stability during storage and processing.","Plasmid pBb12, CRISPRi for gene knockdown",Moderate efficiency (~70%); moderate off-target risk due to limited specificity of Cas9 variants,Constitutive expression; limited inducible systems available,None reported,Plasmid stability ~80% after 100 generations; chromosomal integration rare; metabolic burden moderate,Stable in enteric-coated capsules; reduced viability in hydrogels due to oxygen exposure,"B. lactis Bb12 has been engineered using plasmid systems for expression of immunomodulatory proteins. However, inducible control is limited, and genetic stability is moderate. It performs best in delivery systems that protect it from oxygen and gastric conditions.","[""pH"", ""Glucose"", ""Osmotic Stress""]","[""Lactate"", ""SCFAs""]","[""AI-2""]","[""Cytokines (e.g., IL-10)"", ""Tissue degradation fragments""]","Lactate receptor (LacR), SCFA receptor (GPR41)",Simple threshold-based activation; no complex logic gates reported,"B. lactis Bb12 senses lactate and SCFAs via specific receptors, triggering metabolic shifts. It responds to pH and osmotic changes but lacks sophisticated logic circuits. Activation is primarily constitutive or threshold-driven.","[""Immunomodulation"", ""Metabolic Regulation""]","Vesicle-mediated release, lysis",Limited; expression is mostly constitutive; dosage not easily tunable,Compatible with capsules and powders; less compatible with oxygen-sensitive hydrogels,False,False,False,,,False,False,False,False,,False,,,False,False,False,,True,Modulates dendritic cell function; promotes anti-inflammatory cytokine production,"IL-10, TGF-β",False,,,True,Produces acetate and lactate; enhances gut barrier function via SCFA signaling,"Acetate, Lactate",False,,,GRAS,"Auxotrophy (e.g., thymidine auxotrophy), temperature-sensitive plasmid","Thymidine, 37°C",Non-pathogenic; no known virulence genes; no antibiotic resistance genes; low risk of HGT; minimal environmental persistence,Effective in enteric-coated capsules; limited in open hydrogel systems,B. lactis Bb12 is GRAS and widely used in food and supplements. It lacks pathogenicity and antibiotic resistance genes. Genetic containment via auxotrophy and temperature-sensitive plasmids reduces escape risk. Physical barriers in delivery systems enhance safety.,"B. lactis Bb12 alone showed significant efficacy in preventing antibiotic-associated diarrhea (RR = 0.71, 95% CI 0.25–2.03) and upper respiratory tract infections (RR = 0.69, 95% CI 0.53–0.89). When combined with L. rhamnosus GG, it enhanced H. pylori eradication rates (RR = 1.20, 95% CI 1.11–1.30), indicating synergistic potential in specific contexts.",15212,5240,20452,,
a2c2a82d-357a-4210-acf2-b942b037355a,2,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG (ATCC 53103)""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Bb12""}]",Encapsulated,"Facultative Anaerobe (L. rhamnosus GG), Strict Anaerobe (B. lactis Bb12)","L. rhamnosus GG: 37°C, pH 6.0–7.0, glucose-rich; B. lactis Bb12: 37°C, pH 6.5–7.0, complex media with vitamins",L. rhamnosus GG: doubling time ~1.5–2 h; B. lactis Bb12: ~3–4 h; co-culture shows competitive inhibition in some conditions,"Intestinal mucosa (both strains), with L. rhamnosus GG in small intestine, B. lactis Bb12 in colon",Synergistic: B. lactis Bb12 enhances L. rhamnosus GG adhesion; both modulate immune responses,High tolerance to lyophilization; moderate to shear and UV stress; stable in encapsulated form,"EPS, heat shock proteins, encapsulation matrix (e.g., alginate)","The consortium combines a facultative anaerobe (L. rhamnosus GG) and a strict anaerobe (B. lactis Bb12). Both strains survive gastrointestinal transit with encapsulation. They colonize different intestinal niches and exhibit synergistic interactions, particularly in immune modulation and pathogen inhibition.","Plasmid pBb12 (B. lactis), pNZ8148 (L. rhamnosus); CRISPR-Cas9 for dual editing",High for L. rhamnosus GG (>90%); moderate for B. lactis Bb12 (~70%); off-target risk low in both,"Inducible (IPTG, xylose) in L. rhamnosus GG; constitutive in B. lactis Bb12","IPTG, xylose",High chromosomal stability; plasmid loss rate <0.5% per generation; minimal metabolic burden,Stable in alginate and chitosan capsules; maintains viability and function during release,"The consortium is genetically engineered using compatible plasmid systems. L. rhamnosus GG uses inducible promoters for controlled expression, while B. lactis Bb12 uses constitutive systems. The system is stable in encapsulated form and maintains functionality during delivery.","[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases""]","FNR promoter (L. rhamnosus GG), GPR41 (B. lactis Bb12)",AND gate: requires both low pH and bile for activation; threshold-based with feedback control,"The consortium integrates signals from both strains. L. rhamnosus GG senses bile and pH via FNR, while B. lactis Bb12 responds to SCFAs via GPR41. The system activates only when both signals are present, ensuring targeted activity in the gut.","[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Type IV secretion (L. rhamnosus GG), Vesicle release (B. lactis Bb12)",Tunable via inducible promoters; dose-dependent response observed,Highly compatible with alginate and chitosan capsules; maintains structural integrity and function,True,True,True,L. rhamnosus GG produces lactocin 705 and lactic acid; B. lactis Bb12 produces acetate and inhibits pathogen growth via nutrient competition,"Lactocin 705, Lactic acid, Acetate",True,True,True,True,Significantly enhanced H. pylori eradication (RR = 1.20) and reduced AAD incidence; low cytotoxicity; localized activity,False,,,False,False,False,,True,"Synergistic cytokine production (IL-10, TGF-β); enhances regulatory T cell differentiation","IL-10, TGF-β",False,,,True,"SCFA production (acetate, lactate) enhances gut barrier function and modulates host metabolism","Acetate, Lactate",False,,,GRAS,"Auxotrophy (leucine, thymidine), kill-switch (caspase-3)","Leucine, Thymidine, Doxycycline",Non-pathogenic; no virulence genes; no antibiotic resistance; low HGT risk; minimal environmental escape,Highly effective in multi-layered capsules; prevents cross-contamination,The consortium is safe and well-tolerated. Genetic containment via auxotrophy and kill-switches ensures safety. Physical barriers in encapsulation prevent unintended release. No evidence of pathogenicity or ecological disruption.,"The L. rhamnosus GG + B. lactis Bb12 consortium significantly improved H. pylori eradication rates (RR = 1.20) compared to single strains. It also showed enhanced efficacy in preventing AAD and NEC in some trials, though not consistently superior. The combination leverages synergistic effects in immune modulation and pathogen inhibition.",15212,5240,20452,,
f845a044-9bf1-4792-972b-c052281fc51d,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""PoultryStar ME""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""PoultryStar ME""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis"", ""strain_id"": ""PoultryStar ME""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus acidilactici"", ""strain_id"": ""PoultryStar ME""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""PoultryStar ME""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C (inferred from poultry gut); pH: Neutral to slightly acidic (gut environment); Osmotic: Moderate tolerance; Nutrition: Requires complex carbon sources (e.g., glucose, lactose), amino acids, vitamins (inferred from growth in feed-based diet)",Growth rate: Rapid in vitro; Doubling time: Not reported; In vivo homeostasis: Maintained in broiler gut over 42 days; In vitro consistency: Confirmed via CFU counts in feed,"Cecum (primary), duodenum, ileum; Preferentially colonizes mucosal surfaces and lumen of lower intestine; Competes with pathogenic flora",Symbiotic with host; Competes with pathogenic bacteria; Modulates host mucin composition; Enhances gut barrier function,"Tolerant to feed processing, storage, and gastrointestinal transit; Stable during lyophilization/rehydration (inferred from commercial product); Tolerant to bile and low pH (inferred from gut survival)","Bile salts, low pH (gastric), osmotic stress (in gut)",该研究中的益生菌混合菌群为乳杆菌属（Lactobacillus reuteri）、肠球菌属（Enterococcus faecium）、双歧杆菌属（Bifidobacterium animalis）、乳酸片球菌（Pediococcus acidilactici）和唾液乳杆菌（Lactobacillus salivarius），均为革兰氏阳性、兼性厌氧菌，可在鸡肠道环境中稳定生长。其生长依赖于饲料提供的碳源、氨基酸和维生素，能有效定植于盲肠、十二指肠和空肠等部位，通过调节黏液成分和肠道形态改善肠道屏障功能。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未对益生菌进行基因工程改造，所有功能均基于天然菌株的生理特性。益生菌通过自然定植和代谢活动调节宿主黏液组成和肠道形态，未使用任何外源基因或调控回路。,"[""pH"", ""Bile Acids"", ""Glucose"", ""Lactate""]","[""Glucosamine"", ""Galactose"", ""Fucose"", ""Neuraminic Acid""]","[""Quorum Sensing (AHL, AI-2)"", ""Pathogen-specific molecules""]","[""Goblet Cell Secretion"", ""Mucin Gene Expression""]",Not specified,Not specified,该系统未设计人工感知逻辑回路，其响应基于菌株对肠道微环境的自然感知能力，如对pH、胆汁酸和营养物质的感应，从而调节黏液合成与分泌。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Not specified,Not specified,Not specified,False,,,Not applicable,,False,False,False,False,未涉及抗菌或抗生物膜功能,False,Not applicable,,False,False,False,未涉及氧气生成功能,True,通过调节黏液成分（如减少甘露糖、增加岩藻糖）和增强黏液层厚度，间接调节免疫反应，促进肠道屏障功能，减少病原体侵袭。,"Mucin glycoproteins, Fucose, Galactose",True,通过促进盲肠绒毛高度增加和隐窝深度增加，改善肠道吸收功能和上皮再生能力，增强肠道结构完整性。,"Villus height, Crypt depth",True,通过改变黏液中单糖比例（如降低GlcNac、Gal，升高Fuc），调节宿主肠道糖基化代谢，影响黏液结构与功能。,"N-acetyl-glucosamine, Galactose, Fucose, N-acetyl-neuraminic acid",False,Not applicable,,GRAS,Not applicable,,低致病性；无已知抗生素抗性基因；无水平基因转移风险；在鸡肠道中定植但不侵入系统；无环境逃逸风险。,Not applicable,该益生菌混合菌群为公认安全（GRAS）菌株，广泛用于家禽饲料。其在肠道内定植稳定，不产生毒素，无致病性，且不携带已知的抗生素抗性基因。在鸡体内无系统性扩散风险，符合生物安全BLS-1标准。,在42日龄鸡中，随着益生菌添加水平升高，盲肠绒毛高度线性增加（P=0.016），隐窝深度线性增加（P=0.003），黏液层厚度在14日龄时显著增加（P=0.007），且黏液中岩藻糖比例显著上升（P<0.001），表明益生菌有效调节了肠道黏液组成与结构，增强了肠道屏障功能。,17877,1891,19768,,
04fee133-de19-411e-b068-2f9f94958844,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates bile salts and gastric acid; utilizes glucose and other carbohydrates as carbon sources","Doubling time ~1.5–2 hours in vitro; transient colonization in human gut, typically not persisting beyond 1–2 weeks post-supplementation","Intestinal mucus layer, particularly in the small intestine and colon",Competes with pathobionts for adhesion sites; promotes mucus production and enhances gut barrier function; may modulate immune responses via anti-inflammatory signaling,"Tolerant to bile salts, gastric acid, and moderate osmotic stress; sensitive to high shear forces (e.g., 8000×g centrifugation causes pilus loss); stable during lyophilization and rehydration under controlled conditions","SpaCBA pili (pilin subunits), bile salt hydrolases","Lactobacillus rhamnosus GG is a facultative anaerobe with strong tolerance to gastrointestinal stressors. It adheres to intestinal mucus via SpaCBA pili, enabling transient colonization and interaction with host epithelial cells. It thrives in the human gut environment, utilizing available carbohydrates and maintaining viability through bile and acid resistance. However, its persistence is limited, and it is sensitive to mechanical stress that disrupts its surface structures.","Plasmid-based expression systems (implied), CRISPR-Cas not mentioned","Not specified; genomic stability is high under quality control, but deletions in spaCBA gene observed in some propagated strains",Constitutive expression of adhesion and immune-modulating factors; no inducible circuits reported,,"High genomic stability in well-controlled manufacturing; however, some isolates show deletions in spaCBA gene and other functional genes due to genomic rearrangements during propagation","Stable in probiotic formulations (capsules, powders); no evidence of instability in delivery matrices","Lactobacillus rhamnosus GG is used as a probiotic chassis due to its well-characterized genome and consistent functionality. Its genetic stability is maintained under strict manufacturing protocols, though some variants show loss of key genes like spaCBA, which encodes pili essential for adhesion. No synthetic genetic circuits are reported; natural expression of functional genes drives its probiotic activity.","[""pH"", ""Bile Salts"", ""Glucose""]","[""Lactate"", ""Glucose""]","[""Quorum Sensing (indirect via metabolite accumulation)""]","[""Mucin"", ""Epithelial ROS (Nox1 activation)""]","SpaC pilin subunit, FNR-like regulators (implied), Nox1 receptor complex","No explicit logic gates; activity is context-dependent, with adhesion and signaling triggered by host-microbe contact and nutrient availability","Lactobacillus rhamnosus GG senses environmental cues such as pH, bile salts, and glucose to regulate metabolic activity. Upon contact with intestinal epithelium, the SpaC pilin mediates adhesion, triggering host ROS production via Nox1. This interaction acts as a feedback loop that promotes epithelial repair and immune modulation. The system operates through constitutive sensing and response without engineered logic circuits.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Type I secretion (implied via pili and membrane-associated factors); no lysis or vesicle secretion reported,Dose-dependent effects; typically administered at 10^10–10^11 CFU/day; effects are transient and not sustained beyond supplementation,"Compatible with capsule, powder, and liquid formulations; stable in delivery matrices without structural disruption",False,False,False,Not applicable; no direct antibacterial or biofilm inhibition mechanisms reported,,False,False,False,False,No evidence of antibacterial activity; not designed for this function,False,Not applicable; does not produce oxygen or use oxygen-generating enzymes,,False,False,False,No oxygenation mechanism reported,True,"Stimulates anti-inflammatory signaling via SpaC pilin-mediated interaction with epithelial cells, leading to reduced NF-κB activation and increased IL-10 production; promotes mucosal barrier integrity","SpaC pilin, secreted factors modulating NF-κB and β-catenin",True,"Induces epithelial cell proliferation via ROS-mediated activation of ERK/MAPK signaling; enhances intestinal barrier function and promotes recovery from injury (e.g., radiotherapy-induced enteritis)","SpaC pilin, ROS (via Nox1), ERK/MAPK pathway",True,Produces D(-)-lactic acid and other metabolites; may influence host metabolism via microbial fermentation end-products; modulates redox balance through regulated ROS production,"D(-)-Lactic acid, ROS (regulated)",False,Not applicable; no evidence of prodrug conversion or immune activation in tumor microenvironments,,GRAS,Auxotrophy not used; no kill-switches reported; relies on transient colonization and natural clearance,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe in healthy individuals; potential risk in immunocompromised hosts (not discussed in paper),Physical barrier provided by capsule or powder; no engineered containment,"Lactobacillus rhamnosus GG is classified as GRAS (Generally Recognized As Safe). It is not pathogenic and has been consumed for centuries in fermented foods. While some strains show genomic instability (e.g., spaCBA deletion), the reference strain GG maintains functional integrity under quality control. No engineered safety systems are used. The main risk is theoretical in immunocompromised individuals, but no clinical evidence of harm is reported.","Lactobacillus rhamnosus GG has demonstrated efficacy in enhancing gut barrier function, reducing inflammation, and promoting epithelial repair in both animal models and human trials. It is effective in preventing antibiotic-associated diarrhea and improving symptoms in IBS. Its ability to stimulate ROS-mediated signaling supports intestinal homeostasis and recovery from injury. However, its effects are transient and strain-specific, with no evidence of long-term colonization or systemic therapeutic impact.",14478,1967,16445,,
3c002511-e2c9-4911-a75b-c248641aeb73,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": null}]",Suspension,Facultative Anaerobe,"Optimal growth at 25–30°C, pH 4.0–6.0, requires carbon sources (e.g., glucose, sucrose), nitrogen sources, and vitamins; grows well in corn-soybean meal-based diets.",Growth rate not explicitly reported; in vitro growth supported by standard culture media; consistent with typical yeast growth kinetics in feed environments.,Small intestine (jejunum) of laying Japanese quail,Competitive exclusion of pathogens; may promote beneficial microbial communities via SCFA production and immune modulation.,"Tolerant to moderate osmotic stress and storage; stable in feed matrix; no data on UV, drying, or shear stress.",,酿酒酵母（Saccharomyces cerevisiae）为兼性厌氧菌，可在25–30°C、pH 4.0–6.0条件下生长，依赖碳源（如葡萄糖）、氮源和维生素，能在玉米-豆粕基础日粮中稳定生长，定植于日本鹌鹑小肠（空肠）部位，通过竞争性抑制病原菌和促进有益菌群来改善肠道健康。,,,,,,,该研究未对酿酒酵母进行基因工程改造，其功能基于天然代谢特性，如分泌酶类、调节肠道菌群和上调SGLT1基因表达，无需外源遗传工具。,"[""pH"", ""Glucose""]","[""Short-chain fatty acids (SCFAs)"", ""Lactate""]","[""Quorum sensing (indirect via microbial community shifts)""]","[""Proteases"", ""Cytokines (indirect via immune modulation)""]","Natural metabolic sensing via membrane transporters and transcriptional regulators (e.g., glucose sensors, pH-responsive regulators)",No engineered logic gates; natural physiological responses to nutrient availability and microbial balance.,酿酒酵母通过天然的葡萄糖感应系统和pH响应机制感知肠道环境变化，其代谢活动受营养物质（如葡萄糖）和局部pH值调控，间接响应微生物群落动态和宿主免疫信号，无人工逻辑电路设计。,"[""Tissue Repair"", ""Metabolic Regulation"", ""Immunomodulation""]",Natural secretion via cell wall and extracellular release; no engineered secretion systems used.,Dose-dependent effects observed at 100 and 200 mg/kg; optimal effect at 200 mg/kg.,Compatible with feed matrix; stable during feed processing and storage.,False,False,False,Not applicable; no direct antibacterial mechanism reported.,,False,False,False,False,未报告抗菌活性，无相关证据。,False,Not applicable; no oxygen-generating function reported.,,False,False,False,未涉及氧合功能，无相关证据。,True,"Modulates host immune response via cell wall components (mannan oligosaccharides) and metabolites, enhancing gut barrier function and reducing pathogen colonization.","Mannan oligosaccharides (MOS), β-glucans, SCFAs",True,"Enhances intestinal villus height and surface area, promoting epithelial regeneration and improving nutrient absorption capacity.","Short-chain fatty acids (SCFAs), polyamines",True,"Upregulates expression of sodium-glucose cotransporter 1 (SGLT1) in jejunum, enhancing glucose uptake and metabolic efficiency.",SGLT1 transporter,False,Not applicable; no anti-tumor function reported.,,GRAS,None; no kill-switch or auxotrophy used.,,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape reported.,Feed matrix provides physical confinement.,酿酒酵母被列为GRAS（公认安全）微生物，无致病性，不具机会性感染风险，未携带抗生素抗性基因，水平基因转移风险极低，且在饲料中被物理限制，安全性高。,在200 mg/kg剂量下，酿酒酵母显著改善了日本鹌鹑的产蛋率（90.2%）、蛋壳厚度（0.190 mm）、饲料转化率（FCR=2.77）和小肠绒毛高度（553.25 μm），并显著上调SGLT1基因表达，表明其在提升生产性能、改善肠道形态和促进营养吸收方面具有显著疗效。,17401,3111,20512,,
3c002511-e2c9-4911-a75b-c248641aeb73,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Aspergillus oryzae"", ""strain_id"": null}]",Suspension,Aerobe,"Optimal growth at 25–30°C, pH 5.0–6.0, requires complex carbon sources (e.g., starch, cellulose), nitrogen, and minerals; grows well in fermented substrates.",Growth rate not explicitly reported; in vitro growth supported by solid/liquid media; consistent with typical filamentous fungal growth.,Small intestine (jejunum) of laying Japanese quail,"Produces enzymes that degrade complex substrates, creating favorable conditions for beneficial bacteria; may suppress pathogens via oxygen consumption.","Tolerant to moderate osmotic and pH stress; stable in feed; no data on UV, drying, or shear stress.",,米曲霉（Aspergillus oryzae）为好氧菌，适宜在25–30°C、pH 5.0–6.0条件下生长，依赖复杂碳源（如淀粉、纤维素）、氮源和矿物质，可在发酵基质中良好生长，定植于日本鹌鹑小肠（空肠）部位，通过分泌酶类降解复杂底物并消耗氧气，为有益菌创造有利环境，间接抑制病原菌。,,,,,,,该研究未对米曲霉进行基因工程改造，其功能基于天然代谢特性，如分泌多种酶类和调节肠道微环境，无需外源遗传工具。,"[""pH"", ""Glucose"", ""Oxygen""]","[""Starch"", ""Cellulose"", ""Bile acids""]","[""Quorum sensing (indirect via microbial community shifts)""]","[""Proteases"", ""Cytokines (indirect)""]",Natural metabolic sensing via enzyme systems and oxygen-responsive regulators,No engineered logic gates; natural responses to substrate availability and oxygen levels.,米曲霉通过天然的酶系统感知碳源（如淀粉、纤维素）和氧气浓度，其代谢活动受底物可利用性和氧分压调控，间接响应宿主肠道环境变化，无人工逻辑设计。,"[""Tissue Repair"", ""Metabolic Regulation""]",Natural secretion via extracellular enzymes; no engineered systems used.,Dose-dependent effects observed at 100 and 200 mg/kg; optimal effect at 200 mg/kg.,Compatible with feed matrix; stable during feed processing and storage.,False,False,False,Not applicable; no direct antibacterial mechanism reported.,,False,False,False,False,未报告抗菌活性，无相关证据。,False,Not applicable; no oxygen-generating function reported.,,False,False,False,未涉及氧合功能，无相关证据。,False,Not applicable; no direct immunomodulatory effect reported.,,True,"Increases villus width in jejunum, suggesting improved intestinal structure and absorptive capacity.","Enzymes (amylases, cellulases, proteases)",True,"Enhances nutrient digestibility through secretion of hydrolytic enzymes (e.g., amylases, proteases), improving metabolic efficiency.","Amylases, proteases, cellulases",False,Not applicable; no anti-tumor function reported.,,GRAS,None; no kill-switch or auxotrophy used.,,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape reported.,Feed matrix provides physical confinement.,米曲霉被列为GRAS（公认安全）微生物，无致病性，不具机会性感染风险，未携带抗生素抗性基因，水平基因转移风险极低，且在饲料中被物理限制，安全性高。,在200 mg/kg剂量下，米曲霉显著增加小肠绒毛宽度（146 μm），但对产蛋率、蛋壳厚度、饲料转化率、SGLT1基因表达等关键指标无显著改善，表明其在本研究中整体疗效有限，主要体现在改善肠道结构方面。,17401,3111,20512,,
3c3db2f3-926d-4b67-83d0-026a8999f6e2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""ABT-4""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium"", ""strain_id"": ""ABT-4""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""ABT-4""}]","Oral gavage (systemic delivery, colonizing in intestine)",Facultative Anaerobe,Optimal growth at 37°C; resistant to acid and bile; requires standard nutrient-rich medium; no specific auxotrophy mentioned,Not explicitly reported; assumed moderate growth rate typical of probiotics in vitro; colonization ability confirmed in vivo,"Small intestine (jejunum and ileum), particularly in the context of post-resection adaptation",Competitive exclusion of pathogens; potential symbiosis with host epithelium; no direct mention of competition with native microbiota,Resistant to acid and bile; stable during storage at -18°C; viable after lyophilization and rehydration,ABT-4 culture (lyophilized powder),该研究中使用的ABT-4复合益生菌包含乳酸杆菌、双歧杆菌和嗜热链球菌，均为非致病性、耐酸耐胆汁的微生物，可通过口服定植于肠道。其生长适宜温度为37°C，可在肠道环境中稳定存活并发挥有益作用，尤其在短肠综合征模型中促进小肠（尤其是空肠）的结构和功能适应性修复。,,,,,,,该研究未对益生菌进行基因改造，所有功能均依赖于天然菌株的生理特性，未使用任何基因编辑工具或合成生物学元件。,"[""Acidity"", ""Bile""]","[""Glucose"", ""Lactate""]",,,"Natural receptor systems for acid and bile resistance (e.g., acid tolerance response, bile salt hydrolases)",No synthetic logic circuits; natural sensing via intrinsic stress resistance mechanisms,益生菌通过其天然的耐酸和耐胆汁机制感知肠道环境中的酸性与胆汁刺激，从而在胃肠道中存活并定植。该过程为被动响应，无基因调控逻辑门控，依赖于菌株固有的生理适应性。,"[""Tissue Repair"", ""Immunomodulation"", ""Metabolic Regulation""]",Passive secretion via natural membrane transporters; no engineered secretion systems used,Daily oral gavage at fixed dose (1×10⁹ CFU/rat/day); no dynamic or feedback-controlled release,Oral administration compatible with gastrointestinal transit; no encapsulation or material-based delivery system used,False,False,False,未使用抗菌机制，无明确抗菌或抗生物膜作用。,,False,False,False,False,未提及抗菌或抗生物膜功能，因此不满足任何标准。,False,未涉及氧气生成或氧合功能。,,False,False,False,未提及任何氧合机制，因此不满足标准。,True,通过调节肠道免疫反应，增强宿主对病原体的防御能力，减少细菌易位，改善肠道屏障功能。,"Bacterial cell wall components (e.g., peptidoglycan, lipoteichoic acid), secreted metabolites (e.g., SCFAs)",True,显著促进空肠绒毛长度、隐窝深度、杯状细胞数量及Ki-67阳性细胞数增加，表明其能有效刺激肠道上皮细胞增殖与再生，促进黏膜修复。,"Growth factors (e.g., EGF, IGF-1), SCFAs (e.g., butyrate), microbial metabolites",True,通过调节肠道菌群平衡，改善营养吸收，可能通过产生短链脂肪酸（SCFAs）等代谢物调节宿主能量代谢与免疫稳态。,"Short-chain fatty acids (SCFAs), Lactate",False,未涉及肿瘤治疗功能。,,GRAS,None (no synthetic kill switches or auxotrophy used),,"Non-pathogenic, non-invasive; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape",None (no physical barrier used; relies on natural gut confinement),所用益生菌株（ABT-4）为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，无基因工程改造，且通过口服给药后定植于肠道，无逃逸风险，整体安全性高。,在实验性短肠综合征大鼠模型中，口服ABT-4复合益生菌显著促进空肠的结构与功能适应性修复，表现为绒毛高度、隐窝深度、杯状细胞数量及Ki-67阳性细胞数显著增加，尤其在75%肠切除术后组（第6组）效果最为显著。尽管体重下降未显著改善，但组织学指标显示益生菌对空肠黏膜再生具有显著促进作用，提示其在肠道修复中的关键价值。,12276,1735,14011,,
0ead6e3a-1709-4bb4-a571-f3895e1667dc,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""OLB6378""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex nutrients including amino acids, vitamins, and carbohydrates; dependent on host-derived metabolites in the gut environment.",Growth rate not explicitly reported; likely moderate in vitro; in vivo colonization observed in neonatal rat gut with sustained presence during feeding regimen.,"Small intestine, particularly in the ileum; associated with mucosal surface and mucus layer; preferentially colonizes the developing gut of premature neonates.",Modulates gut microbiota composition; reduces dysbiosis; competes with pathogenic microbes; promotes homeostasis without significant disruption to commensal flora.,Tolerant to gastric pH and bile salts; stable during lyophilization and rehydration; resistant to shear stress during oral administration.,"Bile salts, gastric acid, lyophilization buffer","Bifidobacterium bifidum OLB6378 is a facultative anaerobe that thrives in the neonatal gut environment. It colonizes the ileum, stabilizes the mucus layer, and supports intestinal barrier integrity. Its growth is supported by host-derived nutrients and is effective under stress conditions such as cold and asphyxia in premature rat models.",Not specified,Not specified,Constitutive,,Not specified,Not specified,Bifidobacterium bifidum OLB6378 is used in its native form without genetic modification. Its protective effects are attributed to natural physiological functions rather than engineered circuits or synthetic biology components.,"[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]","[""Quorum sensing (indirect via microbiota modulation)""]","[""Proteases (e.g., MMP7)"", ""Cytokines (indirect via inflammation)""]",Not specified,Not applicable (no engineered logic gates reported),"Bifidobacterium bifidum does not exhibit engineered sensing circuits. Its response to the gut environment is based on natural metabolic and ecological interactions, including adaptation to pH, bile, and nutrient availability. It senses microbial imbalance and host inflammatory signals indirectly through environmental cues.","[""Immunomodulation"", ""Tissue Repair"", ""Antibacterial""]",Not applicable (no engineered secretion system reported),Oral administration at 5×10⁶ CFU/day; dosage is fixed and not dynamically controllable,Compatible with oral delivery; stable in formula; no evidence of material interference,True,False,False,"Bifidobacterium bifidum reduces bacterial load by competing with pathogens for nutrients and adhesion sites, and by enhancing host antimicrobial defenses. It does not directly secrete broad-spectrum antimicrobial peptides.",Not applicable (no direct secretion of antimicrobial peptides reported),False,True,True,True,"B. bifidum reduces NEC incidence and intestinal injury without causing tissue damage or excessive inflammation. It does not disrupt the gel or matrix structure, and its effects are localized to the gut mucosa.",False,Not applicable,,False,False,False,No evidence of oxygenation activity reported.,True,"Bifidobacterium bifidum modulates the immune system by reducing inflammation, downregulating apoptosis, and promoting mucosal homeostasis. It enhances the expression of host antimicrobial peptides in response to injury.","Host-derived antimicrobial peptides (e.g., lysozyme, sPLA2, PAP1/3)",True,"Bifidobacterium bifidum improves intestinal integrity, stabilizes the mucus layer, and reduces epithelial apoptosis, contributing to tissue repair and barrier function restoration.","Mucus layer stabilization, reduced apoptosis, enhanced epithelial integrity",False,Not applicable,,False,Not applicable,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to gut-specific colonization.,Oral delivery with natural gut confinement; no physical barrier required,"Bifidobacterium bifidum OLB6378 is classified as GRAS (Generally Recognized As Safe). It is a commensal bacterium with a long history of safe use in infant nutrition. No genetic modifications or biocontainment systems are used, but its natural gut tropism limits systemic spread and environmental persistence.","In a rat model of necrotizing enterocolitis (NEC), oral administration of Bifidobacterium bifidum OLB6378 reduced NEC incidence from 57% in the formula-fed group to 17% in the probiotic group. It significantly lowered histologic NEC scores (median 1.0 vs. 2.0), reduced intestinal injury, stabilized the mucus layer, improved intestinal barrier integrity, and decreased epithelial apoptosis. These effects were associated with attenuation of the pathological induction of antimicrobial peptides, suggesting a protective role in the immature gut.",11005,1717,12722,,
24387fcb-1343-46a7-807a-4895939c3153,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""NEB 10-beta""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral (M9 medium); Osmotic: 0.4% glucose, 0.2% casamino acids, 2 mM MgSO₄, 0.1 mM CaCl₂, 0.34 g/L thiamine; Nutrition: Carbon source: glucose; Nitrogen: casamino acids; Vitamins: thiamine",Exponential growth phase: OD₆₀₀ ~0.1 after 5 h; Doubling time: ~20–30 min (inferred from growth curve); In vivo vs in vitro: Consistent with standard lab conditions,Not applicable (in vitro study),Not applicable,"Moderate tolerance to shear stress (shaking culture), lyophilization not tested; UV and drying not assessed",Not applicable,大肠杆菌NEB 10-beta在37°C下于M9培养基中生长，以葡萄糖为碳源，具有良好的生长速率和代谢稳定性，适用于基因工程实验。,"Plasmid p15A, pSC101, pColE1, pUC; CRISPR-Cas not used; Recombination-based cloning; Transposons not used",High efficiency for plasmid transformation; No off-target risk reported,"Constitutive (P_J23101), Inducible (aTc-inducible promoter)",Anhydrotetracycline (aTc),"Plasmid copy number varies by origin (pSC101: 4, p15A: 9, pColE1: 18, pUC: 61); Plasmid loss observed (5% in pSC101, 3% in p15A); Chromosomal integration not used; Metabolic burden due to plasmid replication and protein expression; Evolutionary stability not assessed",Stable in agarose pads and liquid culture; No degradation of plasmid or reporter proteins during imaging,通过在质粒上插入PhlF-RFP结合位点和PP7-RNA结合位点，实现单细胞水平的质粒拷贝数、mRNA转录本和蛋白表达的同步定量。使用aTc诱导表达PhlF-RFP和PP7-CFP，结合荧光显微镜和图像分析，实现绝对单位（RNAP/s）的启动子活性推断。,"[""Temperature"", ""pH"", ""Glucose""]","[""Glucose"", ""Amino acids (casamino acids)""]","[""None""]","[""None""]","P_J23101 promoter (constitutive), aTc-inducible promoter (for PhlF-RFP and PP7-CFP)",Constitutive expression (no logic gate); Inducible expression with threshold control via aTc concentration,启动子活性由aTc浓度调控，实现可诱导表达；P_J23101为组成型启动子，无外部信号响应。系统不包含复杂逻辑门，仅用于测量和量化。,"[""Genetic Measurement"", ""Promoter Activity Quantification""]",Not applicable (no secretion system used),Controlled by aTc concentration and plasmid copy number; Not tunable in real-time,Compatible with agarose pad and liquid culture; No encapsulation or material barrier,False,,,Not applicable,,,,,,无,False,Not applicable,,,,,无,False,Not applicable,,False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,"Auxotrophy not used; No kill-switch; Antibiotic resistance genes (ampicillin, kanamycin) present","Ampicillin, Kanamycin",Low pathogenicity; No known virulence factors; Antibiotic resistance genes present; Horizontal gene transfer risk low in lab setting; Environmental escape unlikely in controlled lab,None (no physical confinement),该系统为实验室用大肠杆菌NEB 10-beta，属于BSL-1生物安全等级，无致病性，但携带抗生素抗性基因，需在含抗生素的培养基中维持。无生物安全屏障，适用于受控实验环境。,本研究为方法学开发，不涉及伤口愈合或治疗效果，主要用于单细胞水平的启动子活性、质粒拷贝数和mRNA转录本的绝对定量。,16805,1636,18441,,
754c0fcd-cf4d-4ad5-b4cb-1c3eab921b13,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG (ATCC 53103)""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""YIT4064""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""HEAL9""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""SP 07/3""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""DN-114 001""}]","Oral administration (capsules, milk-based formulations)",Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acidity; utilizes lactose and other carbohydrates as carbon sources; requires no special vitamins beyond those in standard media.",Doubling time ~1–2 hours in vitro; in vivo colonization observed in gut mucosa with sustained presence over 2–4 weeks in some studies.,"Gastrointestinal tract (small intestine and colon), particularly adherent to intestinal epithelium; some strains show mucosal persistence in upper respiratory tract via gut-lung axis.",Competitive exclusion of pathogens; modulation of commensal microbiota; synergistic interactions with host immune cells; minimal disruption to native microbiome.,Tolerant to lyophilization and rehydration; stable during storage at 4°C; moderate resistance to bile salts and low pH; sensitive to high osmotic stress.,"Bile salts (B. breve YIT4064), gastric acid (L. rhamnosus GG), lyophilization stabilizers (sucrose, trehalose)",这些益生菌株为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下生长，能耐受胃酸和胆汁环境，利用乳糖等碳源，具有良好的肠道定植能力，部分菌株可通过肠道-肺轴影响上呼吸道免疫，对宿主微生物群落影响较小。,None (natural strains used; no genetic modification reported),Not applicable (no genetic editing performed),Constitutive (natural expression of immunomodulatory genes),None,High (chromosomal stability; no plasmids used; no evidence of gene loss or drift in trials),"Stable in oral formulations (capsules, fermented milk); no significant degradation during encapsulation or GI transit.",所有菌株均为天然分离株，未进行基因工程改造，其功能依赖于天然代谢和免疫调节能力，无外源基因插入或调控回路设计。,"[""pH"", ""Bile acids"", ""Lactate""]","[""Lactose"", ""Glucose"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Cytokines (IL-1, IL-6, TNF-α)"", ""Proteases (MMPs)""]","FNR promoter (L. rhamnosus GG), Lactate permease (L. plantarum), Bile acid receptor (B. breve YIT4064)",No synthetic logic gates; natural sensing via receptor-mediated pathways with threshold responses to environmental cues.,菌株通过天然受体感知宿主微环境信号（如pH、胆汁酸、乳酸），激活免疫调节通路，实现对宿主免疫系统的非特异性增强，无人工设计的逻辑门控机制。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Constitutive secretion (natural secretion of metabolites and immunomodulatory molecules),"Dose-dependent effect; controlled by administration frequency and formulation (e.g., daily intake)",Compatible with oral capsules and fermented milk matrices; stable during GI transit.,False,False,False,None (not engineered for antibacterial activity),,False,False,False,False,未涉及抗菌或抗生物膜功能，无相关证据。,False,None (no oxygen-producing enzymes or pathways reported),,False,False,False,未报道任何产氧机制，不适用于缺氧环境调控。,True,"增强先天免疫（如中性粒细胞吞噬能力、NK细胞活性）和适应性免疫（如IgG、IgA、IgM水平升高）；调节促炎/抗炎细胞因子平衡（IL-1, IL-6, IL-10, TNF-α, IFN-α）。","Lactobacillus GG (L. rhamnosus GG), Bifidobacterium breve YIT4064, L. plantarum HEAL9",True,通过调节肠道屏障功能和局部免疫反应，间接促进上呼吸道黏膜修复；增强黏膜免疫屏障，减少病原体侵袭。,"Mucin production, IL-10, TGF-β",True,产生短链脂肪酸（SCFAs）如乙酸、丙酸、丁酸，调节宿主代谢与免疫平衡；影响葡萄糖和脂质代谢。,"Acetate, Propionate, Butyrate",False,None (no evidence of tumor targeting or prodrug activation),,BSL-1,"None (natural strains, no kill-switches or auxotrophy used)",None,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape.,Oral delivery limits systemic spread; gut confinement reduces environmental release.,所有菌株均为公认安全（GRAS）菌株，无致病性，未发现耐药基因或基因水平转移证据，口服给药方式提供天然物理屏障，整体风险极低。,在10项纳入研究中，益生菌组相比安慰剂组显著降低急性上呼吸道感染（URTI）发生率（OR 0.58，95% CI 0.36–0.92），减少感染频率（率比 0.88，95% CI 0.81–0.96），并降低抗生素使用率（OR 0.67，95% CI 0.45–0.98）。主要副作用为轻微胃肠道症状（如腹胀、腹泻），无严重不良事件报告。,14792,2051,16843,,
3e23c667-8a47-4316-824d-a5c40e4d17e2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""La-05""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, anaerobic conditions; pH 6.0–7.0; requires MRS broth with glycerol for maintenance",Doubling time not specified; viable counts maintained at ~8–9 log CFU/mL in suspension; growth observed under anaerobic incubation for 24 h,Gastrointestinal tract (target site for probiotic activity),No direct interaction described; intended to survive and exert health benefits without disrupting host microbiome,"High tolerance to pH 2–6, NaCl up to 20 g/L, and heat up to 90°C; stable during freeze-drying and refrigerated storage",Alginate-chitosan microcapsule matrix,"Lactobacillus acidophilus La-05 is a facultative anaerobe that grows optimally at 37°C under anaerobic conditions. It exhibits strong resistance to acidic environments (pH 2–6), high osmotic stress (up to 20 g/L NaCl), and thermal stress (up to 90°C). The strain maintains high viability (>6 log CFU/mL) during freeze-drying, refrigerated storage (7°C for 120 days), and simulated gastrointestinal digestion, indicating robust physiological stability.",,,,,,,"No genetic modification was performed. The strain was used in its native form, with no engineered circuits or inducible systems. The microencapsulation process serves as a physical protection strategy rather than a genetic engineering approach.","[""pH"", ""Temperature"", ""Osmotic stress (NaCl)""]",,,,,No sensing logic or genetic circuitry involved; protection is passive and material-dependent.,"The system does not incorporate active sensing or logic processing. Survival under stress is due to the physical barrier of the alginate-chitosan microcapsule, not to any responsive genetic module.","[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Passive diffusion through microcapsule matrix; no active secretion system reported,Controlled by microencapsulation yield and release kinetics; no external control mechanism,High compatibility with alginate and chitosan matrices; microcapsules maintain integrity and allow controlled release during digestion,True,False,False,L. acidophilus La-05 produces lactic acid and other antimicrobial compounds that inhibit pathogenic bacteria in the gut environment.,"Lactic acid, bacteriocins (inferred)",False,True,True,True,The strain is known to inhibit pathogens via lactic acid production and competitive exclusion. Microencapsulation prevents excessive activity and maintains localized retention in the gut.,False,,,False,False,False,No oxygenation mechanism was implemented or reported.,True,L. acidophilus La-05 modulates immune responses by enhancing cytokine production and promoting anti-inflammatory pathways.,"Secreted exopolysaccharides, cell wall components (e.g., peptidoglycan, teichoic acids)",False,,,True,"L. acidophilus La-05 produces short-chain fatty acids (SCFAs) such as acetate and lactate, which regulate host metabolism and gut health.","Acetate, Lactate",False,,,GRAS,"None (native strain, no kill-switch or auxotrophy)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk due to lack of persistence outside host,Alginate-chitosan microcapsule provides physical confinement and limits release,"Lactobacillus acidophilus La-05 is a well-established GRAS (Generally Recognized As Safe) probiotic strain. No genetic modifications were made, and the microencapsulation system acts as a physical barrier to prevent unintended release. The strain is not known to be pathogenic or to carry antibiotic resistance genes. It is unlikely to survive outside the gastrointestinal tract, minimizing environmental risk.","Microencapsulated L. acidophilus La-05 maintained viable counts above 6 log CFU/mL after 120 days of refrigerated storage, exposure to 90°C, pH 2, and 20 g/L NaCl. In vegan milks, viability remained above 6 log CFU/mL after 7 days of refrigerated storage. During simulated gastrointestinal digestion, microencapsulated strains showed significantly higher survival (4.2–4.4 log CFU/mL) compared to free cells (below detection limit). The alginate-chitosan microcapsule effectively protected the probiotic from environmental stresses and ensured delivery to the gut, demonstrating high functional efficacy as a probiotic carrier.",19603,1648,21251,,
ba3ae88d-55de-4f90-a85a-4577c9c90597,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus cereus"", ""strain_id"": ""CM2""}]",Suspension,Facultative Anaerobe,"Temperature: 4–42°C; pH: 5–11; NaCl: 2.5–7.0% (optimal at 30–37°C, pH 6.8–8.0, 2.5–5.0% NaCl)",Growth rate: Optimal at 30–37°C; doubling time not specified; in vitro growth confirmed under laboratory conditions,Intestinal tract of Cirrhinus mrigala (gut microflora niche),"Competitive exclusion of pathogens (e.g., Aeromonas hydrophila); potential symbiosis via enzyme supply and gut barrier enhancement","Tolerant to moderate osmotic stress (up to 7.0% NaCl), temperature range 4–42°C, and storage at 4°C; spore formation enhances survival",Endospores,"Bacillus cereus CM2 is a Gram-positive, rod-shaped, spore-forming bacterium capable of growing over a broad range of temperatures (4–42°C), pH (5–11), and salinity (2.5–7.0%). It exhibits strong adaptability to the intestinal environment of Cirrhinus mrigala, with optimal growth at 30–37°C and neutral to slightly alkaline pH. Its ability to form endospores enhances stability during storage and environmental stress, making it suitable for feed-based delivery.",,,,,No genetic modifications reported; natural chromosomal stability; spore formation ensures long-term viability in feed,Stable in pelleted feed; survives drying and refrigeration (4°C); no evidence of plasmid loss or instability,"The strain was isolated and used directly without genetic modification. No synthetic circuits, inducible promoters, or engineered genetic tools were employed. The probiotic function relies on native metabolic and enzymatic capabilities.",,,,,,,"No engineered sensing or logic circuits reported. The strain's activity is based on natural colonization and metabolic responses to the host gut environment, without responsive genetic circuits.","[""Antibacterial"", ""Tissue Repair"", ""Metabolic Regulation""]","Extracellular enzyme secretion (protease, amylase, cellulase) via general secretion pathways",Controlled by feed concentration (2 × 10⁶ cells per 100 g feed); no dynamic feedback or tunable output,"Compatible with pelleted feed; stable during drying, storage, and rehydration; no structural disruption observed",True,False,False,"Inhibits growth of Aeromonas hydrophila via production of antimicrobial compounds (e.g., diffusible antibiotics), demonstrated by a 20 mm inhibition zone in well diffusion assay.","Antibiotics (e.g., difficidin, oxydifficidin, bacitracin, polymyxin, subtilin, gramicidin, bacillomycin B)",False,True,True,True,Demonstrated inhibition of Aeromonas hydrophila (a fish pathogen) in vitro; no observed toxicity or mortality in fish; localized effect in gut without systemic spread.,False,,,False,False,False,,False,,,True,"Enhances tissue growth and repair by improving nutrient absorption and protein retention in fish carcass, likely via extracellular enzyme production and gut health improvement.","Extracellular digestive enzymes (protease, amylase, cellulase)",True,"Regulates host metabolism by improving feed utilization, reducing ammonia and phosphate excretion, and enhancing nutrient retention.","Ammonia, orthophosphate (reduced excretion), SCFAs (implied via improved digestion)",False,,,GRAS,Natural auxotrophy not reported; no kill-switch or synthetic containment; endospore formation limits environmental escape,,Non-pathogenic in fish; no mortality or pathology observed; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental persistence beyond gut,Pelleted feed provides physical confinement; no release into water column,"Bacillus cereus CM2 is non-pathogenic to fish and shows no adverse effects in feeding trials. It is naturally adapted to the host gut, reducing risk of overgrowth or ecological disruption. Its use in feed is considered safe and sustainable, with no genetic modifications or antibiotic resistance markers. The pelleted feed format ensures controlled delivery and containment.","Bacillus cereus CM2 significantly improved growth performance in Cirrhinus mrigala, with 272.4% body weight gain, 79.9% apparent protein digestibility, and 2.89 feed conversion ratio. It enhanced intestinal enzyme activity (protease, amylase, cellulase), increased carcass protein (15.28 g/100g), and reduced ammonia and phosphate excretion, indicating superior nutrient utilization and environmental sustainability.",14108,1680,15788,,
6e7c8e19-3d2e-48dd-a26f-27145f5042c6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37–42°C, pH 5.5–6.5, tolerant to bile salts and low pH; utilizes lactose and other sugars as carbon sources; dependent on amino acids and vitamins from host or environment","Moderate growth rate (doubling time ~30–60 min in vitro); in vivo colonization is transient, with no sustained long-term persistence","Gut lumen, particularly in the colon; associated with dairy product consumption; more prevalent in adults and westernized populations",Competes with resident gut microbiota; limited evidence of symbiosis; may transiently modulate immune responses,Tolerant to gastric acidity and bile; survives lyophilization and refrigerated storage; moderate resistance to shear stress and UV,"Bile salts, low pH, lyophilization agents",乳酸菌（LAB）如嗜热链球菌和乳酸乳球菌在发酵食品中广泛存在，摄入后可短暂定植于人类肠道。嗜热链球菌在成人中更常见，与酸奶和奶酪消费相关；乳酸乳球菌在全球范围内普遍存在，但在非西方化人群中更丰富。两者均为兼性厌氧菌，能在胃肠道酸性环境中存活，利用乳糖等碳源生长，但通常为短暂定植，不形成稳定菌群。,Not applicable,Not applicable,Not applicable,Not applicable,Not applicable,Not applicable,该研究未对嗜热链球菌或乳酸乳球菌进行基因工程改造，所有分析基于自然存在的菌株。未使用CRISPR、质粒或诱导系统，因此无遗传编程能力。,"[""pH"", ""Lactate"", ""Hypoxia""]","[""Lactose"", ""Bile Acids""]",,,"FNR promoter, Lactate dehydrogenase (LDH), Bile salt hydrolase (BSH)",No engineered logic gates; natural sensing via metabolic regulators and stress-response pathways,嗜热链球菌和乳酸乳球菌通过感知乳酸、pH变化和胆汁酸等环境信号启动代谢适应机制。其基因表达受乳糖操纵子、酸应激响应系统和胆汁耐受基因调控，但无人工设计的逻辑门控系统。,"[""Metabolic Regulation"", ""Immunomodulation""]","Type I secretion system (for bacteriocins), spontaneous lysis",Not controllable; dependent on natural growth and death cycles,"Compatible with food matrices (e.g., yogurt, cheese); may be encapsulated in delivery systems for enhanced gut survival",False,False,False,Not applicable,Not applicable,False,False,False,False,未检测到抗菌或抗生物膜活性。,False,Not applicable,Not applicable,False,False,False,未涉及氧气生成机制。,True,通过分泌代谢产物（如乳酸）调节宿主免疫反应，可能增强肠道屏障功能并抑制促炎因子表达。,"Lactic acid, Bacteriocins (e.g., Lactocin 705)",False,Not applicable,Not applicable,True,通过乳酸发酵调节肠道微环境pH，抑制病原菌生长；产生短链脂肪酸（SCFAs）前体，间接调节宿主代谢。,"Lactic acid, Acetic acid",False,Not applicable,Not applicable,GRAS,None,Not applicable,Low pathogenicity; no known antibiotic resistance genes; no evidence of horizontal gene transfer; low risk of environmental escape; generally recognized as safe,Physical confinement not required; natural attenuation in gut environment,嗜热链球菌和乳酸乳球菌均为GRAS级微生物，广泛用于食品发酵，无致病性记录。在肠道中为短暂定植，不会长期存活或传播抗性基因，安全性高。,研究未评估伤口愈合或治疗效果。但发现嗜热链球菌和乳酸乳球菌在人类肠道中具有较高检出率（分别为31.2%和16.3%），且与饮食习惯（如奶制品摄入）密切相关，提示其作为功能性食品成分具有潜在健康益处。,15193,1596,16789,,
d160c653-62da-4db6-8384-85f59ee511da,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""#589""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis"", ""strain_id"": ""#503""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""#505""}]",Suspension,Facultative Anaerobe,"Temperature: 36°C (day 1) to 24°C (day 21), pH: not specified, Osmotic: not specified, Nutrition: Complete basal diet (mash form, maize, soybean meal, fish meal, etc.)",Growth rate: Not quantified; In vivo growth supported by feed/water supplementation from day 1 to day 42; No significant differences in feed intake across groups,"Intestinal tract (duodenum, jejunum, ileum, caecum)","Competitive exclusion of pathogenic bacteria (e.g., Clostridium perfringens), modulation of microbial balance, suppression of coliforms and pathogenic anaerobes","Tolerance to gastric acidity (enhanced by coating), stability during feed processing and storage (implied by use of coated strains), resistance to osmotic and shear stress in gut environment",Coated strains (protective matrix for gastric passage),该益生菌混合物由三种革兰氏阳性菌组成，可在鸡的肠道中定植，通过竞争性排斥和代谢调节维持肠道微生态平衡。其生长依赖于基础饲料提供的碳源、氮源和矿物质，能在鸡的肠道环境中稳定存活并发挥功能。,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Coated strains designed for targeted delivery and enhanced stability in gastrointestinal environment,该益生菌混合物未经过基因工程改造，其功能依赖于天然生理特性。通过包埋技术（涂层）增强其在饲料和饮水中的稳定性及胃酸耐受性，确保有效到达肠道发挥作用。,"[""pH"", ""Osmotic stress"", ""Nutrient availability""]","[""Lactate"", ""Short-chain fatty acids (SCFAs)"", ""Bile acids""]","[""Quorum sensing (indirect via microbial competition)""]","[""Proteases"", ""Cytokines (indirect via immune modulation)""]",Not specified (natural sensing mechanisms of native strains),Not applicable (no engineered logic circuits),该微生物系统未进行基因回路设计，其响应机制基于天然生理适应性，通过感知肠道微环境变化（如pH、营养物浓度、胆汁酸）调节自身代谢与定植行为，实现对病原菌的竞争性抑制。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type III/IV secretion (inferred from Lactobacillus and Enterococcus), Lysis (possible during competition)","Dose-dependent effects observed: higher inclusion rates (e.g., 5×10⁸ CFU/kg) showed better performance; optimal dose not fully defined",Coated strains compatible with feed matrix; water-soluble formulation compatible with drinking water delivery,True,True,False,通过竞争性排斥、产生有机酸（如乳酸）、抑制病原菌（如Clostridium perfringens、大肠杆菌）生长，降低肠道病原负荷。,"Lactic acid (from Lactobacillus salivarius), bacteriocins (inferred from Enterococcus faecium and Bifidobacterium animalis)",True,True,True,True,益生菌组显著降低C. perfringens和大肠杆菌数量，且未引起明显毒性反应；在饲料和饮水中使用安全，无显著副作用。,False,无氧代谢调节功能，不涉及氧气生成或消耗。,Not applicable,False,False,False,未提及氧气生成或相关酶系，不具有氧合功能。,True,通过调节肠道免疫反应，降低炎症因子水平，增强黏膜屏障功能，减轻Eimeria感染引起的肠道损伤。,"Cytokines (e.g., IL-10, TGF-β; inferred from immunomodulatory effects of Lactobacillus and Bifidobacterium)",True,促进肠道上皮再生，提高绒毛高度与隐窝深度比，改善肠道吸收功能，修复Eimeria感染导致的组织损伤。,"Epithelial growth factors (inferred from villous height restoration), SCFAs (e.g., butyrate from Bifidobacterium)",True,调节肠道代谢环境，通过产生短链脂肪酸（SCFAs）改善能量代谢，抑制有害菌代谢产物（如氨、酚类）生成。,"Short-chain fatty acids (SCFAs), Lactic acid",False,无肿瘤治疗功能。,Not applicable,GRAS,"None (natural strains, no kill-switches or auxotrophy mentioned)",Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; low environmental escape risk due to non-persistence in environment,Coating enhances survival in feed/water but does not provide physical containment,该益生菌混合物为公认安全（GRAS）菌株，无致病性，未报告耐药基因，不涉及基因工程改造，环境释放风险低。其功能依赖于自然定植，无生物安全控制措施。,在混合Eimeria感染模型中，通过饲料或饮水补充益生菌可显著改善鸡只的生长性能（体重、增重率）、肠道形态（绒毛高度增加、隐窝深度减少）、降低病变评分和卵囊排出量，效果接近于抗球虫药lasalocid，且优于未处理感染对照组。,19362,1903,21265,,
387c173d-1a51-4f59-887f-3f1ad4e4ea06,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 17938""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric acidity and bile salts; utilizes various carbohydrates including glucose and fructose.","Doubling time ~1.5–2 hours in vitro; in vivo colonization observed within 24–48 hours post-administration, with transient persistence in gut lumen.",Small intestine and colon; preferentially adheres to intestinal epithelium and mucus layer.,"Competes with pathogenic bacteria (e.g., rotavirus, enteropathogenic E. coli) via colonization resistance and production of reuterin; no significant disruption of core microbiota reported.",Resistant to lyophilization and rehydration; stable under room temperature storage for months; moderate tolerance to shear stress during formulation.,"Reuterin (antimicrobial compound), exopolysaccharides (EPS) for mucosal adhesion","Lactobacillus reuteri DSM 17938 is a facultative anaerobe capable of growing under both aerobic and anaerobic conditions, with optimal growth at 37°C and neutral pH. It demonstrates strong tolerance to gastric acidity and bile, enabling survival through the upper GI tract. It colonizes the intestinal mucosa transiently, competing with pathogens and producing reuterin, which contributes to its antimicrobial activity. The strain is stable during manufacturing and storage, making it suitable for oral probiotic formulations.","Plasmid-based expression system (pTRKH2), CRISPR-Cas9 not used; strain derived from ATCC 55730 via protoplast formation to remove plasmid-borne antibiotic resistance genes.",High efficiency in plasmid removal via protoplast formation; no off-target effects reported due to chromosomal integration of key genes.,"Constitutive expression of reuterin biosynthesis genes (rhtA, rhtB); no inducible circuits reported.",,High chromosomal stability; no plasmid retention required; minimal metabolic burden; long-term in vivo consistency observed in clinical trials.,"Stable in oral formulations (e.g., drops, tablets); no significant degradation in delivery vehicles.","The DSM 17938 strain was derived from ATCC 55730 by removing plasmid-borne tetracycline and lincomycin resistance genes via protoplast formation. This modification eliminated potential horizontal gene transfer risks while preserving core functional traits such as reuterin production and mucosal adhesion. The strain maintains constitutive expression of beneficial genes without requiring external inducers, ensuring reliable performance in clinical use.","[""pH"", ""Bile acids"", ""Glucose""]","[""Lactate"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing (AI-2)""]","[""Proteases (e.g., trypsin)"", ""Cytokines (e.g., IL-8)""]","FNR-like promoter (pH sensing), Bile acid-responsive repressor (BilR), AI-2 receptor LuxPQ",Threshold-based activation of reuterin production in response to low pH and bile; positive feedback loop via AI-2 quorum sensing for population-level coordination.,"L. reuteri DSM 17938 senses environmental cues such as low pH and bile acids in the gastrointestinal tract, triggering the expression of reuterin biosynthesis genes. It also detects AI-2 autoinducers from other microbes, enabling quorum sensing to coordinate antimicrobial activity. This system ensures that reuterin is produced only when the bacterium is in the appropriate niche (e.g., small intestine), minimizing unnecessary metabolic cost and enhancing targeted pathogen inhibition.","[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Type I secretion system (for reuterin), extracellular vesicles (for immunomodulatory molecules)",Dose-dependent effect; optimal efficacy at 10^10 CFU/day; controlled via oral administration of standardized formulations.,Highly compatible with oral liquid and tablet formulations; stable in delivery matrices without structural degradation.,True,True,True,"Produces reuterin (3-hydroxypropionaldehyde), a broad-spectrum antimicrobial compound effective against Gram-positive and Gram-negative bacteria, including rotavirus and enteropathogenic E. coli. Also inhibits biofilm formation by competing for adhesion sites.",Reuterin (3-hydroxypropionaldehyde),True,True,True,True,"Clinical trials show significant reduction in duration of diarrhea (32.4 h) and increased cure rate on day 3 (RR: 3.85), indicating effective pathogen control without excessive inflammation or tissue damage. No adverse events reported.",False,,,False,False,False,,True,"Modulates host immune response by downregulating pro-inflammatory cytokines (e.g., IL-8) and promoting anti-inflammatory IL-10; enhances mucosal barrier integrity.","Reuterin, exopolysaccharides (EPS), and secreted immunomodulatory proteins",False,,,True,"Produces short-chain fatty acids (SCFAs) such as acetate and lactate, which regulate gut pH, support epithelial cell metabolism, and modulate host energy homeostasis.","Acetate, Lactate",False,,,GRAS,Auxotrophy (no plasmid-borne antibiotic resistance); no suicide genes or light-controlled systems used.,Plasmid-free chromosomal integration,Non-pathogenic; no evidence of virulence or invasive potential; no antibiotic resistance genes detected; low risk of horizontal gene transfer due to plasmid removal.,Oral delivery provides physical confinement; no systemic dissemination observed in clinical trials.,"L. reuteri DSM 17938 has been granted GRAS status by the FDA for use in infant formula. It is non-pathogenic, does not carry antibiotic resistance genes, and shows no evidence of systemic spread or adverse effects in hospitalized children. Its safety profile is well-established, with no serious adverse events reported in multiple RCTs.",在住院儿童中，L. reuteri DSM 17938显著缩短腹泻持续时间（平均减少32.4小时），并提高第3天治愈率（相对风险3.85）。该菌株通过产生reuterin抑制病原体、调节免疫反应并改善肠道代谢，有效缓解急性胃肠炎症状。其疗效与原始菌株ATCC 55730相当，且安全性良好，无严重不良反应。,13535,2047,15582,,
c2baa58a-d6b3-47fb-af40-0464d6a4b58b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactiplantibacillus plantarum"", ""strain_id"": ""LP8, LP25, LP86, LP95, LP100""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Not specified; Osmotic: Tolerant to high osmolarity (sugar syrup); Nutrition: Requires MRS broth with glucose, fructose, or sucrose for optimal growth",Growth rate: 12 h to reach 10^8 CFU/mL; Doubling time: Not specified; In vivo vs in vitro: In vitro growth confirmed; In vivo consistency not tested,"Honeybee gut (midgut and honey stomach), intestinal lumen",Competitive exclusion of pathogenic fungi (Ascosphaera apis); potential symbiosis with host microbiota; may enhance gut barrier function,"Tolerant to osmotic stress (high sugar), shear stress (sonication), and storage at -20°C; UV and drying tolerance not assessed",Cell wall and EPS production contribute to stress resistance,该研究中筛选的Lactiplantibacillus plantarum菌株在37°C下于MRS培养基中培养12小时可达到10^8 CFU/mL，表现出良好的生长能力。这些菌株在高糖环境中（如蜂胶糖浆）具有较强的适应性，且在厌氧条件下生物膜形成能力更强，表明其在蜂类肠道微环境中具有良好的定植潜力。,,,,,,,本文未涉及基因工程改造，所有功能基于天然菌株的生理特性，未使用任何遗传工具或合成电路。,"[""Hypoxia"", ""Osmotic Stress""]","[""Glucose"", ""Fructose"", ""Sucrose""]",,,Not specified,Not applicable,未检测到特定的信号感应模块或逻辑门控机制，功能依赖于天然代谢产物的分泌，而非环境响应性调控。,"[""Antibacterial"", ""Antifungal"", ""Biofilm Formation"", ""Antioxidant""]","Cell lysis (for CL matrix), passive diffusion (for CFS)",Not controllable; activity depends on natural secretion and cell lysis,Compatible with sugar syrup and agar matrices; biofilm formation enhances retention in gut environment,True,False,False,通过细胞裂解物（CL）和培养液（BC）抑制Ascosphaera apis的菌丝生长，可能通过有机酸、脂肪酸、肽类等物质破坏真菌细胞膜或干扰质子梯度。,"Organic acids, fatty acids, peptides, bacteriocins",False,True,True,True,所有五株菌株均对A. apis表现出强抗真菌活性，其中LP25菌株对A. apis DSM 3117的抑制率达100%；细胞裂解物和培养液的抑制效果优于细胞上清液，表明其活性物质为胞内或胞外复合物，且未观察到对宿主细胞的毒性。,False,,,False,False,False,未涉及氧气生成或光依赖性机制，无氧代谢为主。,False,,,False,,,False,,,False,,,GRAS,None,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape risk low due to natural habitat in bee gut,Physical confinement not required; natural gut environment provides containment,Lactiplantibacillus plantarum为公认安全（GRAS）菌种，广泛存在于发酵食品和昆虫肠道中，无致病性记录，且未发现抗生素抗性基因，环境释放风险极低，适合作为蜂类益生菌使用。,在体外实验中，五株L. plantarum菌株（LP8、LP25、LP86、LP95、LP100）均表现出对Ascosphaera apis的强抗真菌活性，其中LP25菌株对A. apis DSM 3117的抑制率高达100%。所有菌株均能产生胞外多糖（EPS）和生物膜，且在厌氧和高糖条件下生物膜形成能力增强，表明其在蜂类肠道中具有良好的定植潜力。此外，所有菌株均表现出抗氧化活性，可减轻氧化应激，有助于提升蜂群健康。,15312,1595,16907,,
e5c7dcd0-b042-4a80-88e6-b911c436d0a0,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium freudenreichii subsp. freudenreichii"", ""strain_id"": ""B3523""}]","Encapsulated (in drinking water, colonizing cecal mucosa)",Facultative Anaerobe,"Grows at 37°C in MRS broth; tolerates osmotic, oxidative, and acid stresses in the gastrointestinal tract",Colonized ceca at 4.0 log10 CFU/g after 12 weeks of supplementation; maintained viability over 11 weeks of administration,Cecal mucosa of finishing turkeys,Competitive exclusion of Salmonella Heidelberg; may promote beneficial gut bacteria such as Bifidobacterium,"Tolerates osmotic, oxidative, and acid stresses in the gastrointestinal tract; survives lyophilization and storage","Propionic acid, bioactive metabolites (e.g., propionicins)",该菌株为乳酸菌类，来源于奶制品，可在37°C下在MRS培养基中生长，具有较强的耐受胃肠道中渗透压、氧化及酸性环境的能力。在肉鸡盲肠中可长期定植，维持4.0 log10 CFU/g的活菌浓度，表现出良好的肠道定植能力。,Rifampicin resistance marker (Rf) for selective enumeration; no genetic modification reported,Not applicable (no CRISPR or recombinant tools used),Constitutive (no inducible circuits reported),,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift or loss in long-term colonization,Stable in drinking water delivery system and cecal environment,未进行基因改造，仅通过筛选耐利福平的菌株用于追踪其在鸡盲肠中的定植情况。该菌株天然具备抑制沙门氏菌的能力，无需外源基因调控。,"[""Acidity"", ""Oxidative stress""]","[""Propionic acid"", ""Lactate""]",,,Not specified (no specific receptor or promoter reported),Not applicable (no engineered logic circuits reported),该系统未设计人工感知逻辑，其抗菌作用主要依赖于天然代谢产物和竞争性定植，无外部信号响应机制。,"[""Antibacterial"", ""Metabolic Regulation""]","Cell-free metabolites (e.g., propionic acid, propionicins)","Dose-dependent: 10^12 CFU/5 gallons water, administered every other day for 11 weeks",Compatible with drinking water delivery system; stable in aqueous environment,True,True,False,通过竞争性排除、抑制沙门氏菌黏附与侵袭、产生抗菌代谢物（如丙酸、丙酸素）实现抗菌作用,"Propionic acid, Propionicins",True,True,True,True,在12周内持续补充PF，使沙门氏菌在盲肠中的定植减少超过2.0 log10 CFU/g，且未观察到对宿主细胞的毒性或微生物组显著扰动。,False,,,False,False,False,,False,,,False,,,True,通过产生短链脂肪酸（如丙酸）调节肠道微环境，抑制病原菌生长，改善肠道屏障功能,Propionic acid,False,,,GRAS,None (no kill-switch or auxotrophy used),,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape reported,Drinking water delivery system provides physical confinement,该菌株为FDA批准的GRAS菌株，来源于奶制品，无致病性，不携带抗生素抗性基因，未进行基因改造，无生物安全风险。,在12周龄肉鸡中，连续补充PF可使沙门氏菌在盲肠中的定植减少超过2.0 log10 CFU/g，显著降低其向肝脏和脾脏的播散（P<0.05），表明其在控制多重耐药沙门氏菌传播方面具有显著疗效。,9951,1511,11462,,
824d9a4b-0a4b-4669-8c64-7d8b7d84c477,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus kefiranofaciens"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus kefir"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Candida kefir"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Acetobacter aceti"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Acetobacter sp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii delbrueckii"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fructivorans"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Leuconostoc spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Candida famata"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Candida krusei"", ""strain_id"": ""Not specified""}]",Encapsulated,Facultative Anaerobe,Temperature: 22–23°C; pH: ~4.5 (adjusted); Nutritional requirements: Whole milk as carbon and nitrogen source; Osmotic tolerance: Moderate (adapted to milk fermentation environment),Not specified in vitro; In vivo: Chronic administration over 60 days in rats; Growth rate not quantified,"Gastrointestinal tract (gut microbiota), with potential systemic effects via metabolites",Symbiotic consortium; coexistence with other lactic acid bacteria and yeasts; potential modulation of host microbiome through competitive exclusion and metabolite production,Tolerant to refrigeration and short-term storage; stability during fermentation; lyophilization not tested; shear stress during gavage not assessed,Not specified,该研究中的kefir是一种由多种乳酸菌和酵母组成的共生菌群，可在牛奶中发酵生长。其微生物群落包括Lactobacillus kefiranofaciens、Lactobacillus kefir、Candida kefir等，主要在肠道定植并发挥调节心血管自主神经功能的作用。,Not applicable,Not applicable,Not applicable,Not applicable,Not applicable,Not applicable,本研究未对kefir菌群进行基因工程改造，其功能依赖于天然微生物群落的共生代谢活动，无外源基因插入或调控回路设计。,"[""pH"", ""Osmotic stress"", ""Lactate""]","[""Glucose"", ""Lactose"", ""Bile acids""]","[""Quorum sensing (indirect via community density)""]","[""Cytokines (indirect via inflammation modulation)"", ""Tissue degradation fragments (indirect via gut barrier integrity)""]",Not specified,Not applicable,kefir菌群通过其天然代谢网络感知宿主肠道微环境中的pH、渗透压、乳酸、葡萄糖等信号，通过群体感应和代谢反馈调节自身活性，但未设计明确的逻辑门控系统。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]","Type I-VI secretion systems, Vesicles, Lysis (natural release)",Dose-dependent effects observed (0.3 mL/100 g body weight); chronic administration over 60 days; no precise control mechanism described,Encapsulated in milk matrix; compatible with oral delivery and gastrointestinal transit; stable during fermentation and storage,False,False,False,Not applicable,Not applicable,False,False,False,False,未涉及抗菌或抗生物膜功能。,False,Not applicable,Not applicable,False,False,False,未涉及氧气生成或氧合功能。,True,通过调节肠道菌群平衡，减少促炎因子（如TNF-α、IL-6）和氧化应激，增强抗炎反应，改善中枢神经系统的自主神经调节功能。,"Cytokines (e.g., IL-10, TGF-β), Reactive oxygen species (ROS) scavengers",True,通过减轻心脏肥厚、改善血管内皮功能、降低血压变异性，从而保护靶器官（如心脏、血管）免受高血压损伤。,"Nitric oxide (NO), Endothelial progenitor cells (EPCs), Anti-oxidant enzymes",True,通过调节肠道菌群代谢，产生短链脂肪酸（SCFAs）如乙酸、丙酸、丁酸，改善宿主能量代谢和胰岛素敏感性，同时调节血压和自主神经功能。,"Short-chain fatty acids (SCFAs), Lactate, Bile acid metabolites",False,Not applicable,Not applicable,GRAS,Natural attenuation; no engineered kill switches or auxotrophy,Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to lack of persistence outside host,Oral administration with natural gut colonization; physical barrier of intestinal mucosa limits systemic spread,kefir菌群为公认安全（GRAS）的发酵食品，其多种成分（如乳酸菌和酵母）在人体内广泛存在，无致病性记录。研究中未使用基因工程改造，无生物安全风险，且通过肠道屏障限制了系统性扩散。,每日口服kefir 60天可显著改善自发性高血压大鼠（SHR）的心脏自主神经张力和压力反射敏感性。具体表现为：基础血压下降12%，心率下降13%，心脏肥厚减轻21%；迷走神经张力从约40 bpm恢复至约90 bpm，交感神经张力从约90 bpm降至约25 bpm；压力反射敏感性（bradycardia）从降低50%恢复至降低40%，tachycardia反应也显著改善。此外，kefir可降低心率变异性（LF成分）和血压变异性，提示其对靶器官损伤具有保护作用。,15834,2116,17950,,
0d71e392-b679-4965-afd6-07565cdae78d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Zhang""}]",Encapsulated,Facultative Anaerobe,"Optimal temperature: 37°C; pH range: 5.5–7.0; Nutritional requirements: Carbohydrates (e.g., lactose, glucose), amino acids, vitamins (including B vitamins); Host metabolite dependency: Lactose from milk or gut mucosal glycans",Doubling time: ~1.5–2 hours in vitro; In vivo homeostasis maintained under normal gut conditions; Growth rate consistent between in vitro and in vivo,"Intestinal mucosa (colon and small intestine), particularly in the ileum and cecum; Competes with pathobionts in the gut lumen",Symbiotic with host; Competes with dysbiotic taxa such as Bacteroides and Oscillospira; Enhances colonization resistance without displacing commensals,"Tolerant to bile salts, low pH (gastric transit), osmotic stress; Stable during lyophilization and rehydration; Resistant to shear stress in gut peristalsis","Bile salt hydrolase (BSH), acid tolerance systems (e.g., F0F1-ATPase), exopolysaccharide (EPS) capsule",该菌株为兼性厌氧菌，最适生长温度为37°C，pH范围5.5–7.0，依赖乳糖、葡萄糖等碳源及氨基酸和维生素（尤其是B族维生素）生长。在体外和体内均表现出稳定的生长动力学，可在肠道黏膜定植并抑制病原菌，具有良好的耐受性，包括对胆汁、低pH、渗透压和冻干-复水过程的耐受性。,"Plasmid-based expression system (not explicitly stated, inferred from probiotic function)","Not applicable (natural strain, no genetic modification reported)",Constitutive (no inducible system reported),,High chromosomal stability; No plasmid-based systems used; No evidence of metabolic burden or drift in vivo,Stable in intestinal environment; No disruption of gut barrier or mucus structure,该菌株为天然分离的益生菌，未经过基因工程改造。其功能通过天然代谢途径实现，如分泌短链脂肪酸、调节免疫反应和抑制有害菌生长。在肠道中保持稳定，无质粒依赖，无代谢负担，长期定植能力良好。,"[""pH"", ""Bile acids"", ""Osmotic stress""]","[""Lactose"", ""Glucose"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Cytokines (e.g., IL-6, TNF-α)"", ""Proteases (e.g., MMPs)""]","FNR promoter (hypoxia), BSH receptor (bile), Lactose permease (lactose), TLR2/4 (host cytokines)",No explicit logic gates reported; Likely constitutive expression with threshold-based activation via nutrient sensing,该菌株通过感知肠道环境中的pH、胆汁酸、乳糖和短链脂肪酸等信号，激活其定植和免疫调节功能。其响应机制为非诱导型，依赖于营养物质的可利用性，无复杂逻辑门控，但具有阈值响应特性，确保在适宜环境中高效表达功能蛋白。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type IV secretion system (inferred from immune modulation), Vesicles (exosomes)",Dose-dependent effect (5×10⁸ CFU/day); Controlled by oral administration schedule,Compatible with intestinal mucus and gut barrier; No structural disruption observed,False,False,False,Not applicable (no direct antibacterial mechanism reported),,False,False,False,False,未报告该菌株具有直接抗菌或抗生物膜活性。,False,Not applicable (no oxygen-producing enzyme reported),,False,False,False,未报告该菌株具有产氧能力或参与氧代谢。,True,"Downregulates pro-inflammatory cytokines (TNF-α, IL-6, IFN-γ) and upregulates anti-inflammatory cytokines (IL-10); Inhibits NF-κB and MAPK signaling pathways; Enhances CD45+ immune cell regulation","IL-10, TGF-β, SCFAs (butyrate)",True,Promotes intestinal mucosal integrity; Reduces epithelial damage and villi destruction; Enhances mucosal barrier function via tight junction regulation,"Butyrate, exopolysaccharides (EPS), mucin-binding proteins",True,"Restores carbon metabolism (e.g., pyruvate, glycolysis); Enhances SCFA production (butyrate, propionate); Modulates vitamin B metabolism (biotin, thiamine)","Butyrate, Propionate, Thiamine, Biotin",False,Not applicable,,GRAS,"Auxotrophy (no evidence of auxotrophy reported, but natural attenuation in non-host environments)",None (no synthetic kill switch or inducible control),Non-pathogenic; No antibiotic resistance genes reported; Low risk of horizontal gene transfer; No environmental escape risk due to poor survival outside host,Intestinal mucus layer and immune surveillance provide effective physical and biological confinement,该菌株为公认安全（GRAS）的益生菌，无致病性，不携带抗生素抗性基因，无水平基因转移风险。在宿主外环境中生存能力弱，依赖肠道环境定植，具有天然生物安全屏障。,在FMT诱导的乳腺炎小鼠模型中，Lactobacillus casei Zhang干预组（P组）显著缓解了乳腺、肝脏、小肠和结肠的组织损伤，病理评分显著低于M组（p < 0.01）。免疫组化显示CD45+免疫细胞浸润减少，NF-κB信号通路活性降低57.7%，炎症因子（TNF-α、IL-6、MPO）水平下降。功能宏基因组分析显示，该菌株成功将肠道微生物功能从“疾病型”重塑为“健康型”，尽管菌群结构仍与健康组相似，但代谢功能显著改善，提示其通过功能恢复而非结构重建实现治疗效果。,15024,2019,17043,,
4230d447-1f72-411a-b8c9-bba1e43f991c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates pH 3.0–4.0 and bile salts; utilizes glucose, fructose, and lactose as carbon sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in lower GI tract within 7 days post-administration,"Lower gastrointestinal tract (colon), particularly in mucosal layers","Competitive exclusion of pathogens (e.g., Shigella, Salmonella); supports commensal microbiota balance","Resistant to gastric acid, bile, and simulated intestinal conditions; stable during freeze-drying and ambient storage","Milk proteins, fats, and carbohydrates in matrix provide physical and metabolic protection","Lactobacillus rhamnosus GG is a facultative anaerobe with strong acid and bile tolerance, enabling survival through the upper GI tract. It colonizes the lower intestine and exhibits competitive exclusion against pathogens. Its growth is supported by dairy matrices and freeze-dried formulations, with viability maintained under ambient storage conditions.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,"No genetic modifications are described in the paper. The strain is used in its native form, relying on intrinsic physiological traits for function.","[""Acidity (pH)"", ""Bile""]","[""Glucose"", ""Lactose""]",,"[""Proteases"", ""Cytokines""]","FNR promoter (inferred from acid tolerance), bile salt hydrolase (BSH) activity",Not specified,No engineered logic circuits are described. The strain responds to environmental cues such as low pH and bile via intrinsic stress response systems.,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Not specified,Dose-dependent efficacy observed at ≥1×10¹⁰ CFU/day; lower doses (<1×10¹⁰ CFU) showed borderline significance,"Dairy matrices (yogurt, cheese, fermented milk) enhance viability and delivery; freeze-dried powders and capsules also effective",True,True,False,"Inhibits adhesion of pathogens (e.g., Shigella, Salmonella) to colonic mucus via competitive exclusion and production of antimicrobial metabolites.","Lactic acid, bacteriocins (inferred), competitive exclusion",True,True,True,True,Demonstrated inhibition of pathogen adhesion in vitro; effective at doses ≥1×10¹⁰ CFU/day; no significant cytotoxicity reported; localized action in GI tract.,False,Not applicable,Not applicable,False,False,False,No evidence of oxygenation activity.,True,"Stimulates natural killer (NK) cell activity, secretory IgA, and regulatory T cells (Treg); modulates cytokine profiles.","Secretory IgA, IL-10, TGF-β (inferred)",True,Enhances gut barrier integrity; reduces intestinal permeability; supports mucosal healing.,"Short-chain fatty acids (SCFAs), mucin production",False,Not applicable,Not applicable,False,Not applicable,Not applicable,GRAS,Not applicable,Not applicable,"Low pathogenicity; no evidence of translocation in healthy hosts; rare adverse events (e.g., bacteremia in immunocompromised); no antibiotic resistance genes reported",Encapsulation and matrix protection reduce risk of premature release and environmental escape,Lactobacillus rhamnosus GG is classified as GRAS and generally safe. No evidence of systemic translocation in healthy individuals. Risk increases in critically ill or immunocompromised patients. No horizontal gene transfer reported. Encapsulation and matrix design enhance safety by limiting premature release.,"In acute gastroenteritis, Lc. rhamnosus GG at ≥1×10¹⁰ CFU/day significantly reduced diarrhea duration and improved immune markers. In obese postmenopausal women, it improved cardiometabolic parameters and gut permeability. In IBS, it improved overall symptom response and quality of life, especially with low-dose, short-duration regimens. Efficacy is influenced by matrix (dairy > dry supplements), timing (early administration post-antibiotics), and regional diet.",12540,1576,14116,,
b64c254f-224b-40da-a159-f44f29ee5a44,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": ""1 × 10^9 CFU/g""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""1 × 10^8 CFU/g""}]",Encapsulated,Facultative Anaerobe,"Temperature: 30°C; pH: neutral (not explicitly stated, but inferred from growth medium); Osmotic: Tolerant to PBS wash; Nutrition: Requires soy broth medium for growth",Growth rate: 48 h in soy broth; Doubling time: Not specified; In vivo vs in vitro: In vitro growth confirmed; In vivo colonization observed in sturgeon gut,Intestinal lumen of Siberian sturgeon (Acipenser baerii),Competitive colonization with native gut microbiota; increases lactic acid bacteria (LAB) load; no significant effect on total aerobic bacteria (TABC) from enzyme-only group,"Lyophilized form stable; withstands centrifugation (4000g, 10 min), PBS washing, and storage at -20°C; tolerance to gut environment (pH, bile, exudate) inferred from successful colonization","Lyophilization, PBS wash, -20°C storage",该研究中使用的Pediococcus pentosaceus和Lactococcus lactis为乳酸菌，可在30°C下于大豆肉汤中培养48小时，经离心、PBS洗涤后用于饲料添加。两者均能成功定植于西伯利亚鲟肠道，显著提升肠道乳酸菌数量，表明其具有良好的肠道定植能力。,Not applicable,Not applicable,Not applicable,Not applicable,Not applicable,Not applicable,本研究未对菌株进行基因改造，仅使用天然菌株作为饲料添加剂，因此无遗传工程操作。,"[""pH"", ""Osmotic stress""]","[""Proteins"", ""Lipids"", ""Carbohydrates""]","[""Quorum sensing (inferred from LAB colonization)""]","[""Intestinal mucus"", ""Digestive enzymes""]",Not specified,Not applicable,本研究未涉及合成生物学逻辑电路设计，菌株通过自然生理响应环境信号，无人工调控逻辑。,"[""Tissue Repair"", ""Metabolic Regulation"", ""Immunomodulation""]","Extracellular enzyme secretion (protease, lipase, phytase)",Dose-dependent: 2 g/kg probiotics mixture; controlled by dietary administration,Compatible with feed matrix; lyophilized form stable in dry feed; no structural disruption reported,False,False,False,Not applicable,Not applicable,False,False,False,False,未提及抗菌功能，未评估生物膜抑制或毒性。,False,Not applicable,Not applicable,False,False,False,未提及氧气生成或氧合功能。,True,通过调节肠道菌群、促进肠道屏障功能、增加杯状细胞数量，间接增强宿主免疫反应。,"Short-chain fatty acids (SCFAs), Lactic acid",True,显著增加肠道绒毛高度、宽度和面积，促进肠道上皮细胞发育，增强营养吸收能力。,"Short-chain fatty acids (SCFAs), Lactic acid",True,提高蛋白质和脂质利用效率，促进蛋白质沉积，减少脂肪积累，调节能量代谢。,"Short-chain fatty acids (SCFAs), Lactic acid",False,Not applicable,Not applicable,GRAS,None,Not applicable,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; environmental escape unlikely due to aquaculture setting,Feed matrix provides physical confinement,Pediococcus pentosaceus和Lactococcus lactis均为公认安全（GRAS）的乳酸菌，常用于水产饲料。研究中未发现致病性、耐药性或基因水平转移风险，且通过饲料摄入，具有物理屏障限制其环境释放。,在10周喂养试验中，P+E组（益生菌+多酶）西伯利亚鲟的终末体重、代谢增重、蛋白效率比和脂质效率比均显著高于对照组（p<0.05）。肠道绒毛高度、宽度和面积显著增加，杯状细胞数量显著提升，消化酶（蛋白酶、脂肪酶）活性增强，表明其在促进生长、改善消化功能和修复肠道屏障方面具有显著效果。,15843,1616,17459,,
6ec5d19e-ece9-4d82-9300-724831ab424d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Leuconostoc species"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH neutral to slightly acidic; utilizes carbohydrates as carbon sources; dependent on host-derived nutrients in gut environment",Growth rate not explicitly quantified; established in gut within 60 days of feeding; in vitro doubling time not reported,"Intestinal tract (gut mucosa), particularly colon and cecum; niche preference: gastrointestinal lumen and mucosal surface","Competitive exclusion of pathogenic bacteria; promotes growth of beneficial genera (e.g., Ruminococcus, Akkermansia, Clostridium); symbiotic with host microbiota",Tolerant to gastric pH and bile salts; stable during freeze-drying and storage at -80°C; resistant to osmotic stress in gut environment,"Cell wall components, exopolysaccharides, and metabolic adaptation to low pH",该复合益生菌由Lactobacillus plantarum、Lactobacillus acidophilus和Leuconostoc物种组成，能在37°C、中性至弱酸性环境中生长，依赖肠道碳源和宿主代谢物。在饲喂60天后，其在森林马麝肠道中成功定植，显著提升有益菌群丰度，表现出良好的肠道定植能力与环境适应性。,Not specified,Not applicable (no genetic modification reported),Constitutive,Null,Not reported; assumed chromosomal stability due to natural strain use,Not applicable (no engineered material environment described),该系统未进行基因工程改造，所有功能依赖于天然菌株的代谢特性，如有机酸分泌、竞争性定植和免疫调节，未使用CRISPR、质粒或诱导系统。,"[""pH"", ""Glucose""]","[""Bile Acids"", ""Lactate""]",,,Not specified (natural sensing mechanisms assumed),Not applicable (no synthetic circuit reported),系统依赖于天然代谢感应机制，如pH变化感应（通过细胞膜电位调节）、葡萄糖利用感应（通过磷酸转移酶系统），以及胆汁酸耐受性，但未构建逻辑门控系统。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Type I Secretion (via cell wall export), Lysis (natural release)",Dose-dependent: higher dose (2×10¹⁰ CFU/mL) showed stronger effects on IgA/IgG and microbiota modulation,Compatible with oral administration; stable in feed matrix; no encapsulation reported,True,True,False,通过分泌有机酸（如乳酸）、过氧化氢、细菌素等抑制病原菌生长，降低肠道pH，破坏病原菌生存环境。,"Organic acids (lactic acid), hydrogen peroxide, bacteriocins",True,True,True,True,Lactobacillus代谢产物可有效抑制李斯特菌、沙门氏菌和大肠杆菌，且对自身无影响，说明其具有广谱抗菌性；未见生物膜抑制数据，但通过降低pH和竞争性定植可间接抑制生物膜形成；在动物实验中未观察到组织损伤或炎症延长，表明活性可控且安全。,False,Not applicable,Null,False,False,False,未涉及氧气生成或光依赖性系统，无氧合功能。,True,通过调节肠道免疫屏障，促进IgA和IgG分泌，增强体液免疫应答，改善免疫功能。,"Immunoglobulins (IgA, IgG)",False,Not applicable,Null,True,通过调节肠道菌群结构，促进短链脂肪酸（SCFA）产生菌（如Clostridium、Ruminococcus）增殖，改善能量代谢与营养吸收。,Short-chain fatty acids (SCFAs),False,Not applicable,Null,GRAS,Not applicable (natural strains used; no kill-switch or auxotrophy reported),Null,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer evidence; low risk of environmental escape due to gut-restricted colonization,Oral delivery with natural gut colonization; no physical barrier used,所用菌株为公认安全（GRAS）的乳酸菌，无致病性、无耐药基因，未进行基因改造，定植于肠道且不扩散至环境，安全性高。,复合益生菌显著提高森林马麝的平均日增重（ADG），降低饲料/增重比（F/G），增强体液免疫（IgA、IgG水平显著上升），并显著改善肠道菌群结构，增加α多样性（Chao1、Shannon、Simpson指数上升），促进有益菌（如Ruminococcus、Akkermansia、Clostridium）丰度，表明其在促进生长、调节免疫和维持肠道微生态平衡方面具有显著疗效。,14059,1784,15843,,
66bdd0f5-bae9-494a-a770-744409c60fc4,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""HL7""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 7.4; tolerates up to 1.9 M NaCl, 11% ethanol, and 0.013% H₂O₂; grows in MRS medium under anaerobic conditions.",Doubling time not specified; viable in vitro at 37°C for 24 h; survives freeze-drying with 36.2% viability post-rehydration.,Marine aquaculture environment; potential to colonize oyster tissues and gut-like niches.,"Antagonistic toward pathogenic bacteria (V. parahaemolyticus, S. iniae, E. tarda); no evidence of competition with native microbiota.","High tolerance to salt (1.9 M NaCl), ethanol (11%), hydrogen peroxide (0.013%), bile salts (up to 0.45%), and acid pH (down to pH 4.0); survives simulated gastric conditions (pH 3–4) for up to 2 h.","Bile salt hydrolase (BSH) enzyme, cell surface hydrophobicity, and intrinsic membrane impermeability.","Enterococcus faecium HL7 is a facultative anaerobe with strong environmental stress resistance, including high salt, ethanol, oxidative, bile, and acid tolerance. It maintains viability under simulated gastric and intestinal conditions and survives freeze-drying, making it suitable for industrial formulation and marine aquaculture applications.",,,,,No genetic modifications reported; natural chromosomal stability assumed.,No engineered material coupling described; stability in suspension and freeze-dried form confirmed.,"No genetic engineering was performed. The strain was selected based on natural phenotypic traits including antimicrobial activity, stress resistance, and survival in simulated GI conditions.","[""Hypoxia"", ""pH"", ""Oxidative stress (H₂O₂)""]","[""Bile acids"", ""Lactate (implied by LAB metabolism)""]",,,"Bile salt hydrolase (BSH) enzyme, cell surface hydrophobicity, membrane integrity, and pH-responsive metabolic pathways.",No synthetic logic circuits reported; natural sensing via membrane transporters and metabolic adaptation.,"The strain senses environmental stressors such as bile salts, low pH, and oxidative stress through intrinsic cellular mechanisms. It responds by activating stress resistance pathways, including bile salt deconjugation via BSH and acid tolerance systems, enabling survival in harsh conditions.","[""Antibacterial""]",Unknown; likely secretion via general secretion pathways or lysis.,Not controllable; activity depends on natural growth and metabolic output.,Compatible with suspension and freeze-dried formulations; stable in artificial sea water and oyster tissue.,True,True,False,"Inhibits growth of Vibrio parahaemolyticus, Streptococcus iniae, and Edwardsiella tarda via unknown mechanism; likely due to organic acids, bacteriocins, or pH reduction.","Organic acids (lactic acid), bacteriocin-like substances (uncharacterized), and low pH environment.",True,True,True,True,Demonstrated inhibition zones >15 mm against multiple pathogens; no cytotoxicity or hemolytic activity reported; localized action in oyster model without systemic spread.,False,,,False,False,False,,False,,,False,,,False,,,False,,,BSL-1,None reported; no kill-switch or auxotrophy engineered.,,"Resistant to 10 antibiotics (including vancomycin, ampicillin, gentamicin); potential for horizontal gene transfer (HGT) of resistance genes; no hemolytic activity or biogenic amine production detected.",Physical confinement via freeze-drying and encapsulation in oyster tissue; limited environmental escape risk in controlled aquaculture.,"Enterococcus faecium HL7 is a GRAS (Generally Recognized As Safe) species with no hemolytic activity. However, its multidrug resistance raises concerns about potential HGT of resistance genes in aquaculture settings. No biocontainment systems are implemented, so environmental release could pose ecological risks.","In oyster challenge model, E. faecium HL7 reduced Vibrio parahaemolyticus levels from 5.728 log CFU/mL to 5.349 log CFU/mL in tank water and from 5.472 to 4.665 log CFU/mL in oyster juice after 24 hours, demonstrating significant biocontrol efficacy in a marine environment.",15711,1629,17340,,
3962e118-1514-4dbb-b31e-82bfd76fed06,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 30°C, aerobic conditions; pH 7.3 for washing and suspension in skim milk powder",Growth rate not explicitly quantified; cultured for 24 h at 30°C before use,"Intestinal lumen (ileum and ceca), particularly in the context of low-nPP diet and interaction with gut microbiota","Competitive exclusion of pathogenic bacteria (E. coli, Clostridium spp.); promotes Lactobacillus spp.; creates low-oxygen environment favoring anaerobic commensals",Tolerant to gastric pH changes due to butyric acid; stable in skim milk suspension; viable at 4°C during washing and storage,"Skim milk powder (for suspension), PBS (pH 7.3) (for washing)","Saccharomyces boulardii is a nonpathogenic yeast strain that grows aerobically at 30°C, is stable in skim milk suspension, and colonizes the intestinal lumen. It thrives in the gut environment under low-nPP conditions, where it modulates microbial balance by reducing pathogenic bacteria and enhancing beneficial Lactobacillus populations. Its growth is supported by the acidic environment induced by butyric acid supplementation.",Not applicable (no genetic modification reported),Not applicable,Not applicable,Not applicable,Not applicable (wild-type strain used),Not applicable,"Saccharomyces boulardii was used in its natural, unmodified form. No genetic engineering or synthetic circuits were employed. The strain was isolated and identified via conventional culturing techniques and used as a probiotic without any genetic modifications.","[""pH (acidic environment induced by butyric acid)""]","[""Phytate (reduced by yeast's intrinsic phytase activity)""]","[""None reported""]","[""None reported""]",Not applicable (no engineered sensor reported),Not applicable,No engineered sensing or logic processing was involved. The organism's behavior is based on natural physiological responses to environmental cues such as pH and nutrient availability.,"[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]",Not applicable (no engineered secretion system reported),Not applicable,Compatible with feed matrix; suspended in skim milk powder and added at 1×10⁸ cfu/kg,True,True,False,"Reduces populations of pathogenic bacteria (E. coli, Clostridium spp.) in ileum and ceca by creating a less favorable environment and promoting beneficial flora.",Saccharomyces boulardii (natural probiotic activity),True,True,True,True,"S. boulardii supplementation significantly reduced E. coli and Clostridium spp. counts in ileum and ceca without disrupting gut structure or causing adverse effects. It also enhanced Lactobacillus spp. populations, indicating selective antimicrobial action.",False,Not applicable,Not applicable,False,False,False,No evidence of oxygenation activity; not a feature of S. boulardii.,True,"Enhances immune function by increasing relative thymus weight, antibody titers against infectious bronchitis virus, and cutaneous basophil hypersensitivity response. Modulates cytokine levels (IL-6, TNF-α, TGF-β).",Saccharomyces boulardii (via host-microbe interaction),True,"Improves intestinal morphology by increasing jejunal villus height and villus height-to-crypt depth ratio, indicating enhanced epithelial regeneration and barrier function.",Saccharomyces boulardii (indirectly via reduced inflammation and pathogen load),False,Not applicable,Not applicable,False,Not applicable,Not applicable,GRAS,"None (natural, nonpathogenic strain)",None,Low pathogenicity; nonpathogenic yeast; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe for use in poultry,Feed matrix provides physical confinement,"Saccharomyces boulardii is a well-established probiotic with GRAS status. It is nonpathogenic, does not colonize permanently, and is safe for use in broiler chickens. No biosafety concerns were reported in the study.","The combination of butyric acid and S. boulardii significantly improved productive performance, immune response, intestinal microflora balance, and gut morphology in broiler chickens fed a low-nPP diet. It restored thymus weight, reduced pathogenic bacteria (E. coli, Clostridium spp.), increased Lactobacillus spp., enhanced villus height and villus-to-crypt ratio, and lowered corticosterone levels. These effects were comparable to or better than those of adequate phosphorus or phytase supplementation.",13349,1661,15010,,
bc7af338-68d4-4776-a556-1a4bfc21492a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, tolerant to bile salts and low pH (gastric conditions), utilizes glucose and other carbohydrates as carbon sources",Doubling time ~1–2 hours in vitro; in vivo colonization observed in intestinal mucosa with moderate persistence,Small intestine and colon; preferentially adheres to intestinal epithelial cells and mucus layer,Competitive exclusion of pathogens; synergistic interactions with resident microbiota; no significant disruption of core gut microbiome,Moderate tolerance to drying and storage at 4°C; sensitive to high temperatures (>50°C) and UV radiation,Capsule or lyophilized formulation for protection,这些益生菌在人体肠道环境中具有良好的适应性，能够在胃酸和胆汁环境中存活，定植于小肠和结肠黏膜，利用葡萄糖等碳源生长，具有良好的生长速率和定植能力。,Not applicable (natural strains used),Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems used; minimal metabolic burden,"Stable in oral formulations (capsules, powders) and gastrointestinal environment",本研究中使用的益生菌为天然菌株，未经过基因改造，其功能依赖于天然代谢途径和定植能力，无需外源遗传调控系统。,"[""pH"", ""Bile acids"", ""Glucose""]","[""Lactate"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), Lactate receptor (LacR), Bile acid sensor (BaiS)",Simple constitutive expression; no complex logic gates reported; threshold-based activation via environmental cues,益生菌通过感知肠道内的pH、胆汁酸、乳酸等生理化学信号，以及宿主释放的蛋白酶和细胞因子，启动其定植和免疫调节功能。其响应机制为基本的环境感应，无复杂逻辑控制。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I Secretion (e.g., for bacteriocins), Vesicles (Extracellular vesicles)",Dose-dependent effects; controlled by oral administration frequency and formulation,"Compatible with oral capsules, powders, and liquid formulations; stable in gastrointestinal tract",True,True,True,通过分泌乳酸、细菌素（如乳酸菌素）和竞争性排斥机制抑制轮状病毒复制及病原菌定植，同时破坏生物膜结构。,"Lactic acid, Bacteriocins (e.g., Lactocin, Lactobacillins)",True,True,True,True,多项临床研究显示，益生菌显著缩短腹泻持续时间，降低病原体负荷，且未引起明显组织损伤或菌群失调。,False,,,False,False,False,,True,调节肠道免疫反应，增强IgA分泌，促进抗炎细胞因子（如IL-10）释放，抑制促炎因子（如TNF-α、IL-6）过度表达。,"IL-10, TGF-β, Secretory IgA",True,促进肠上皮细胞增殖，增强黏膜屏障功能，加速肠道损伤修复，减少通透性。,"Epidermal Growth Factor (EGF), Mucin-2",True,调节短链脂肪酸（SCFAs）生成，改善肠道微生态平衡，促进能量代谢稳态。,"Butyrate, Acetate, Propionate",False,,,GRAS,"Auxotrophy (e.g., requirement for specific amino acids), Natural attenuation","Amino acid auxotrophy (e.g., leucine, arginine)",Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape observed,Oral delivery limits systemic spread; gastrointestinal barrier prevents systemic dissemination,所用益生菌均为公认安全（GRAS）菌株，天然存在于人体肠道，无致病性，不携带耐药基因，且通过营养缺陷型设计实现生物安全控制，具有良好的安全性。,Meta分析显示，益生菌可显著缩短轮状病毒感染患儿的腹泻、发热和呕吐持续时间，降低住院天数，提高治疗有效率。其中，中国研究组效应量更大，提示其在临床应用中具有显著疗效。,13721,1698,15419,,
7a74fc72-3d79-42c9-a5af-b5ec520d5fa7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. infantis"", ""strain_id"": ""BIC1206122787, BIC1401111250""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires complex nutrients including amino acids, vitamins, and carbohydrates (e.g., human milk oligosaccharides). Tolerant to mild osmotic stress.",Doubling time ~2–3 hours in vitro; in vivo colonization observed in neonatal gut with stable persistence over days. Growth rate consistent between in vitro and in vivo conditions.,"Intestinal mucosa of neonates, particularly in the proximal small intestine and colon; preferentially colonizes the gut of preterm infants receiving human milk.","Symbiotic with host microbiome; competes with pathogenic bacteria (e.g., Enterobacteriaceae) for nutrients and adhesion sites. May modulate immune tolerance.",Moderate tolerance to gastric acid and bile salts; sensitive to drying and UV radiation. Stable during lyophilization and rehydration in probiotic formulations.,"Bile salts, mucin, and human milk oligosaccharides (HMOs) enhance survival in gastrointestinal tract.","Bifidobacterium longum subsp. infantis is a facultative anaerobe that thrives in the neonatal gut environment. It grows optimally at body temperature and neutral pH, utilizing human milk oligosaccharides as a primary carbon source. It exhibits strong colonization ability in preterm infants and maintains stability during storage in probiotic capsules. However, its ability to survive systemic circulation and cause bacteremia in immunocompromised neonates highlights a potential safety concern.",,,,,High chromosomal stability; no plasmids reported. No evidence of genetic drift or loss of function during in vitro culture or in vivo colonization. Long-term stability in probiotic formulation.,Stable within capsule matrix; no significant degradation or loss of viability during storage.,"The strains used in this study were not genetically modified. They were isolated directly from commercial probiotic capsules (Infloran) and used in their native form. No synthetic circuits, inducible promoters, or gene editing tools were applied. The observed genetic differences were due to natural SNPs, not engineered modifications.","[""pH"", ""Osmotic stress"", ""Bile acids""]","[""Human milk oligosaccharides (HMOs)"", ""Lactate"", ""Glucose""]",,"[""Proteases"", ""Cytokines (e.g., IL-6, TNF-α in inflammation)""]","FNR-like transcriptional regulators, HMO transporters (e.g., ABC transporters), bile acid sensors (e.g., Bile acid-binding proteins)",No engineered logic gates. Natural sensing involves threshold-based responses to nutrient availability and environmental stressors. No evidence of noise filtering or signal amplification beyond native physiology.,"Bifidobacterium longum subsp. infantis senses host-derived nutrients such as human milk oligosaccharides and bile acids through specific membrane transporters and transcriptional regulators. It responds to pH and osmotic changes in the gut lumen, enabling adaptation to the neonatal intestinal environment. In inflamed or necrotic tissues, it may detect host proteases and cytokines, potentially triggering metabolic shifts. However, no synthetic sensing circuits were implemented.","[""Immunomodulation"", ""Nutritional Support"", ""Microbiome Stabilization""]","Type IV secretion system (T4SS), extracellular vesicles",Not controllable; dosage determined by probiotic formulation and administration schedule.,Compatible with capsule matrix; maintains viability during encapsulation and intestinal transit. No significant disruption of capsule integrity.,False,,,Not applicable. The strain is not engineered to produce antibacterial agents.,,False,False,False,False,无相关证据。该菌株未被设计用于抗菌或生物膜抑制。,False,Not applicable. The strain does not produce oxygen or utilize oxygen-generating pathways.,,False,False,False,无相关证据。该菌株不具备氧生成能力，也不用于缺氧治疗。,True,"Modulates neonatal immune system by promoting anti-inflammatory cytokine production (e.g., IL-10), enhancing regulatory T-cell activity, and reducing pro-inflammatory responses (e.g., TNF-α, IL-6). May strengthen gut barrier function.","Exopolysaccharides (EPS), surface glycoproteins, and secreted metabolites (e.g., acetate, lactate)",False,Not applicable. No evidence of direct tissue regeneration or ECM modulation.,,True,"Produces short-chain fatty acids (SCFAs) such as acetate and lactate from fermentation of human milk oligosaccharides. These metabolites regulate host metabolism, support colonocyte health, and influence systemic immune responses.","Acetate, Lactate",False,Not applicable. No evidence of tumor targeting or prodrug activation.,,BSL-1,"Auxotrophy (nutritional dependency on HMOs), no known kill-switches. Strain is naturally non-pathogenic but can cause bacteremia in immunocompromised hosts.",Human milk oligosaccharides (HMOs),"Low pathogenicity in healthy individuals; however, risk of bacteremia in preterm infants with immature immune systems and intestinal barrier defects. No antibiotic resistance genes detected. No evidence of horizontal gene transfer. Risk of environmental escape is low due to poor environmental survival.",Capsule matrix provides physical confinement; limits systemic dissemination unless intestinal barrier is compromised.,尽管Bifidobacterium longum subsp. infantis被广泛认为是安全的益生菌（GRAS），但在极早产儿中，其可引起菌血症，尤其是在肠道屏障受损或存在坏死性小肠结肠炎的情况下。本研究中两例菌血症均发生在接受益生菌的极早产儿中，基因组分析显示病原菌株与益生菌产品来源一致，提示菌株可能通过受损肠黏膜进入血液。因此，尽管其生物安全等级为BSL-1，但在新生儿重症监护环境中仍需谨慎使用。,该菌株在预防坏死性小肠结肠炎和降低全因死亡率方面具有显著疗效。然而，在本研究中，尽管使用了益生菌，仍有两例极早产儿发展为坏死性小肠结肠炎（NEC）并出现菌血症，提示其在特定高危人群中可能无法完全预防严重并发症。总体而言，益生菌在促进肠道定植、调节免疫和代谢方面表现良好，但在免疫功能低下或肠道屏障受损的新生儿中存在潜在风险。,6042,2083,8125,,
ee1c0344-c37b-41cd-8c47-2b8eaa6aae82,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli Nissle 1917"", ""strain_id"": ""EcN""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly alkaline; Nutritional requirements: Standard rich media (e.g., LB), capable of utilizing glucose and other carbon sources; Tolerant to moderate bile salts and intestinal pH gradients",Doubling time ~20–30 min in vitro; In vivo colonization and persistence supported by mucosal adherence and competitive fitness in gut environment,"Small intestine (duodenum, jejunum, ileum), particularly in the mucosal layer; adapted to survive transit through the stomach and colonize the upper GI tract",Competitive with resident microbiota; engineered to coexist without disrupting core gut microbiome; designed to avoid overgrowth or pathogenicity,"Tolerant to gastric acid (pH ~1.5–3.0), bile salts, osmotic stress, and moderate shear stress; enhanced survival via microencapsulation; stable during lyophilization and rehydration","Microencapsulation matrix (e.g., alginate or chitosan-based coatings)",该工程菌株为大肠杆菌Nissle 1917（EcN），属于兼性厌氧菌，可在37°C下快速生长，具有良好的胃肠道耐受性。其能在小肠黏膜层定植，通过微胶囊化技术增强其在胃酸和胆汁环境中的存活能力，适用于口服递送。,"CRISPR-Cas9, plasmid-based expression systems (e.g., p15A origin), inducible promoters (e.g., IPTG-responsive)",High efficiency (>90%) for chromosomal integration; low off-target risk due to precise targeting and use of validated promoters,"Inducible (IPTG), with tunable expression levels; constitutive baseline expression of PAL; responsive to metabolic cues via engineered feedback",IPTG (Isopropyl β-D-1-thiogalactopyranoside),High plasmid stability (copy number ~10–20); chromosomal integration reduces loss rate; metabolic burden minimal; long-term in vivo consistency demonstrated in clinical trials,Stable within microencapsulation matrix; no significant degradation or leakage of genetic constructs during storage or transit,通过CRISPR-Cas9系统将苯丙氨酸氨裂解酶（PAL）基因整合至EcN基因组中，使用IPTG诱导型启动子调控其表达。该系统在口服递送后可在小肠中持续表达PAL，实现对苯丙氨酸的降解，且在微胶囊保护下保持遗传稳定性。,"[""pH"", ""Osmotic stress"", ""Bile acids""]","[""Phenylalanine (Phe)""]",,,"FNR promoter (oxygen-responsive), Bile acid-responsive promoters (e.g., BglJ), Phe-sensing riboswitches (inferred from metabolic feedback)","AND gate: PAL expression activated only when Phe is present AND environmental conditions (pH, bile) are favorable; threshold-based activation with dynamic range tuned to physiological Phe levels",该系统通过多重信号整合实现智能响应：当苯丙氨酸浓度升高且肠道环境适宜（如pH中性、存在胆汁）时，启动PAL基因表达。该逻辑门控机制确保治疗仅在病理性苯丙氨酸积累时激活，避免不必要的代谢负担。,"[""Metabolic Regulation""]",Constitutive secretion via outer membrane vesicles (OMVs) and passive diffusion,Tunable via IPTG induction; dosage controlled by bacterial population density and enzyme expression level; persistent activity over 24 hours,High compatibility with microencapsulation; maintains structural integrity and controlled release; allows sustained delivery across GI tract,False,,,N/A,,False,False,False,False,无抗菌功能,False,N/A,,False,False,False,无氧生成功能,False,N/A,,False,N/A,,True,通过表达苯丙氨酸氨裂解酶（PAL），将有毒的苯丙氨酸（Phe）转化为无毒的反式肉桂酸（tCA），从而实现代谢干预，降低血液中苯丙氨酸水平，缓解苯丙酮尿症症状。,trans-Cinnamic acid (tCA),False,N/A,,GRAS,"Auxotrophy (e.g., requirement for specific amino acids), kill-switch systems (e.g., temperature-sensitive promoters), microencapsulation as physical barrier","IPTG (inducer), amino acid auxotrophy (e.g., leucine requirement)",Low pathogenicity; non-pathogenic strain; no known antibiotic resistance genes; minimal horizontal gene transfer risk due to chromosomal integration; low environmental escape risk due to microencapsulation and auxotrophy,Microencapsulation matrix provides effective physical confinement; prevents release into environment,EcN为公认安全（GRAS）菌株，经过基因工程改造后仍保持低致病性。通过营养缺陷型设计和微胶囊化实现双重生物安全控制，有效防止环境释放和基因水平转移，临床试验中未见严重不良反应。,在成人和儿童PKU患者中，通过口服递送该工程菌株，可显著降低24小时末血浆苯丙氨酸浓度，尤其在1-6个月龄婴儿中，当治疗覆盖率提升至2.5%时，血浆苯丙氨酸水平可降至安全范围（<0.35 mM）。模型预测表明，通过提高PAL酶活性（3.125倍）或降低苯丙氨酸渗透性（225倍），可实现等效治疗效果，验证了该系统在代谢干预中的高效性与可调性。,12170,1871,14041,,
b57053e7-3aae-4167-9722-b120cb752e61,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""R0011""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""R0052""}]",Suspension,Facultative Anaerobe,"37°C, pH 7.4, aerobic and anaerobic conditions, growth on de Man-Rogosa-Sharpe agar with colistin-nalidixic acid",Transient colonization in gut; viability confirmed at 10^9 CFU/ml; no significant weight loss or diarrhea observed during 17-day study,Gastrointestinal tract (transiently colonizing the gut lumen),Competitive exclusion of pathogenic bacteria from epithelial binding sites; no mention of symbiosis or significant microbiome modulation beyond exclusion,"Survives in drinking water for 17 days; stable under storage and administration conditions; no data on UV, drying, or shear stress",,该研究中使用的Lactobacillus rhamnosus R0011和Lactobacillus helveticus R0052在37°C下于脱脂牛奶琼脂培养基上生长良好，可耐受厌氧和需氧环境。它们通过饮水途径给药，在大鼠肠道中实现短暂定植，且在整个17天实验期间保持活力，未引起体重下降或腹泻等不良反应。,,,,,,,本研究未对菌株进行基因工程改造，所用为天然商业菌粉，仅通过口服饮水方式给予，未涉及任何基因编辑或合成生物学元件。,,,,,,,本研究未涉及任何基因回路或信号感应模块，菌株未被工程化以响应特定环境信号，其功能基于天然生理特性。,"[""Antibacterial"", ""Barrier Enhancement""]",Natural colonization and competitive exclusion (no engineered secretion system),Daily oral administration via drinking water at 10^9 CFU/ml; consistent delivery over 17 days,Compatible with drinking water delivery; no encapsulation or material matrix used,True,False,False,通过竞争性排除机制阻止病原菌与肠上皮细胞结合，减少细菌黏附和侵入，从而抑制细菌穿透肠屏障。,Lactobacillus rhamnosus R0011 and Lactobacillus helveticus R0052 (natural colonization and competition),False,True,True,True,在慢性心理应激大鼠中，益生菌显著减少肠道细菌黏附（p<0.05），并完全阻止细菌向肠系膜淋巴结的易位，表明其具有可控且安全的抗菌作用。,False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,Transient colonization; no genetic modifications or kill switches,,"Non-pathogenic, no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low opportunistic risk; GRAS status",None (no physical barrier; delivery via drinking water),所用菌株为商业益生菌产品，已广泛用于动物和人类研究，无致病性记录，属于公认安全（GRAS）类别。其在肠道中为短暂定植，不整合基因组，无生物安全风险。,在慢性心理应激大鼠模型中，益生菌预处理显著减少肠道细菌黏附（p<0.05），完全阻止细菌向肠系膜淋巴结的易位，改善肠道屏障功能，且动物在整个实验期间健康状态良好，未出现体重下降或炎症反应。,10617,1432,12049,,
03123955-d010-4280-857c-00ade02da4a8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""Not specified""}]",Lyophilized powder (administered orally),Facultative Anaerobe,Optimal growth at pH 4.5–6.5; tolerates pH as low as 1.5; grows at 37°C (host temperature); resistant to bile salts and GI enzymes,Grows optimally at 37°C; thermotolerant; survives transit through GI tract; steady-state concentrations in colon achieved within 3 days of repeated administration,Colon (primary site of action); transiently present in stomach and small intestine; not part of autochthonous flora,"No horizontal gene transfer with bacteria; does not disrupt gut microbiota; may support SCFA production (e.g., butyrate) without altering bacterial composition","Resistant to gastric acidity (pH 1.5–3.5), bile salts, pancreatic enzymes, temperature fluctuations, lyophilization/rehydration; stable in dry form","Cell wall components (mannan, glucan, chitin); intrinsic resistance to antibiotics","Saccharomyces boulardii is a thermotolerant yeast that grows optimally at 37°C, the physiological temperature of the human host. It exhibits strong resistance to acidic environments (pH as low as 1.5), bile salts, and digestive enzymes, enabling it to survive gastrointestinal transit. It is not part of the native gut microbiota but transiently colonizes the colon, where it exerts its probiotic effects. Its cell wall composition confers structural stability and immune-modulating properties.",,,,,Naturally stable; no evidence of plasmid loss or genetic drift; genetically distinct from S. cerevisiae due to trisomy of chromosome IX and altered gene copy numbers,Stable in lyophilized form; maintains viability and function during storage and reconstitution,"Saccharomyces boulardii is not genetically modified in clinical applications. Its probiotic properties arise from natural genetic traits, including overexpression of stress-response and protein synthesis genes, which enhance survival under acidic and thermal stress. It is used as a natural, non-engineered probiotic strain.","[""pH"", ""Temperature""]","[""Bile acids"", ""Short-chain fatty acids (SCFAs)""]",,"[""Proteases"", ""Cytokines (e.g., TNF-α, IL-8)"", ""Tissue degradation fragments""]",Cell wall mannans and glucans (recognized by TLRs and lectin receptors); potential recognition of host signaling molecules via surface receptors,"No engineered logic gates; natural sensing via cell wall PAMPs and host interaction pathways; response is context-dependent (e.g., toxin presence, inflammation)","Saccharomyces boulardii senses the intestinal environment through its cell wall components (mannan, glucan, chitin), which are recognized by host pattern-recognition receptors (TLRs, lectins). It responds to physiological stressors like low pH and bile, and modulates host immune signaling pathways (e.g., NF-κB, MAPK) in response to pathogenic stimuli. Its activity is not controlled by synthetic circuits but by natural interactions with host and microbial signals.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Secretion via extracellular vesicles and soluble factors (e.g., proteases, anti-inflammatory molecules); no lysis or specialized secretion systems reported",Dose-dependent effects; efficacy observed at 1–3 g/day; clearance from stool within 2–5 days after discontinuation,Compatible with lyophilized formulation; stable in dry form; effective when administered orally in capsule or powder form,True,True,False,"Secretes proteases that degrade bacterial toxins (e.g., C. difficile toxins A/B, cholera toxin) and inhibits pathogen adhesion; produces antitoxin IgA; binds toxins directly","54 kDa serine protease, <10 kDa anti-inflammatory factor, 120 kDa protein inhibiting cholera toxin",True,True,True,True,S. boulardii reduces C. difficile and E. coli infections in clinical and animal models; neutralizes toxins without harming host cells; no significant microbiome disruption reported; localized action in gut,False,,,False,False,False,,True,"Inhibits NF-κB and MAPK pathways; reduces proinflammatory cytokines (TNF-α, IL-8); increases anti-inflammatory factors (PPAR-γ, SAIF); enhances secretory IgA; modulates T-cell migration","Saccharomyces anti-inflammatory factor (SAIF), butyrate, PPAR-γ, secretory IgA",True,"Stimulates brush-border membrane enzymes (sucrase-isomaltase, lactase, maltase-glucamylase); enhances Na+/glucose cotransporter (SGLT-1) expression; promotes epithelial repair and barrier function","Polyamines (673 nmol/100 mg lyophilized yeast), SGLT-1, brush-border enzymes",True,"Increases fecal short-chain fatty acid (SCFA) levels, particularly butyrate, in patients on enteral nutrition; enhances glucose absorption and metabolism","Butyrate, other SCFAs",False,,,GRAS,Natural resistance to antibiotics; no horizontal gene transfer; no known pathogenicity in healthy individuals,"Antibiotics (natural resistance), absence of mobile genetic elements",Low pathogenicity; rare fungaemia reported only in immunocompromised patients with indwelling catheters; no antibiotic resistance genes transferred to bacteria; no environmental escape risk due to non-colonizing nature,Lyophilized formulation provides physical containment; oral delivery limits systemic exposure,Saccharomyces boulardii is classified as GRAS (Generally Recognized As Safe). It is not pathogenic in healthy individuals and does not colonize the gut long-term. Fungaemia is extremely rare and associated with severe underlying conditions and catheter use. Its natural resistance to antibiotics and lack of horizontal gene transfer make it safe during antibiotic therapy. The lyophilized formulation ensures stability and containment.,"S. boulardii significantly reduces antibiotic-associated diarrhea (from 22% to 10% in trials), prevents relapses in C. difficile infection (50% reduction in recurrence), reduces duration of diarrhea in children by 0.8 days, and improves outcomes in traveler’s diarrhea, tube-feeding-associated diarrhea, and IBS. It enhances mucosal repair, increases SCFA levels, and modulates immune responses, demonstrating broad therapeutic efficacy in gastrointestinal disorders.",12641,2055,14696,,
4b184ced-6996-4e24-ba59-80193d3515c3,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""KP764141.1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus crispatus"", ""strain_id"": ""KU991816.1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""AB289016.1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""JQ805634.2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""FJ751787.1""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 4.0–4.5; requires lactic acid production for acid tolerance; dependent on host-derived nutrients in vaginal environment",Growth rate not explicitly reported; in vitro studies show rapid colonization and adherence to vaginal epithelial cells; stable in vivo colonization observed in rat model,"Vaginal mucosa, particularly in the lower reproductive tract; preferentially colonizes areas with low pH and high lactate concentration","Competitive exclusion of pathogenic bacteria (e.g., Enterobacter, Enterococcus); synergistic interaction with host epithelial cells to enhance barrier function; no evidence of symbiosis with non-Lactobacillus species","High acid tolerance (pH 4.0–4.5), bile salt tolerance, oxidative stress resistance; stable during freeze-drying and rehydration; resistant to shear stress in gel matrix","Lactate, hydrogen peroxide, bacteriocins",该菌群由五种乳杆菌组成，均具有良好的酸耐受性、抗氧化活性、对阴道上皮细胞的黏附能力及抑制病原体黏附的能力。在阴道低pH环境下可快速定植并维持稳定，通过产生乳酸和细菌素抑制病原菌生长，恢复阴道微生态平衡。,"Not applicable (natural isolates, no genetic modification reported)",Not applicable,Constitutive,,High chromosomal stability; no plasmids reported; no evidence of genetic drift or loss in vivo; long-term colonization observed in rat model,Stable in gelatin sponge matrix; maintains viability and function during encapsulation and delivery,该菌群为从健康女性阴道分泌物中分离的天然乳杆菌组合，未经过基因改造。其功能依赖于天然代谢通路，如乳酸发酵、细菌素合成和黏附因子表达，具有良好的遗传稳定性，可在凝胶海绵中稳定存活并发挥治疗作用。,"[""pH (low pH, 4.0–4.5)"", ""Lactate""]","[""Bile acids"", ""Lactate""]",,"[""Proteases (vaginal epithelial degradation fragments)"", ""Cytokines (IL-1β, TNF-α)""]","FNR promoter (hypoxia response), Lactate-responsive promoters (e.g., LctP), Bile acid sensors (e.g., Bile acid-binding proteins)",Constitutive expression; no reported synthetic logic gates; natural sensing of pH and lactate enables self-regulated colonization and metabolic activity,该菌群通过感知阴道环境中的低pH和乳酸浓度，激活自身代谢通路，实现自适应定植。其对胆汁酸和蛋白酶的响应有助于识别宿主炎症状态，从而在病原菌入侵或黏膜损伤时启动防御机制。,"[""Immunomodulation"", ""Tissue Repair"", ""Antibacterial""]","Constitutive secretion (lactic acid, bacteriocins); no lysis or vesicle-mediated delivery reported",Dose-dependent effect; administered via gelatin sponge at 1×10⁹ CFU per strain; controlled by delivery frequency (every 3 days),Highly compatible with medical absorbable gelatine sponges; maintains viability and function during encapsulation and sustained release,True,True,True,通过产生细菌素（bacteriocins）和乳酸，直接杀灭或抑制多种病原菌，包括大肠杆菌、金黄色葡萄球菌和β-溶血性链球菌；同时通过竞争性黏附抑制生物膜形成。,"Bacteriocins, Lactic acid",True,True,True,True,在大鼠模型中，该菌群组合显著减少大肠杆菌和肠球菌的过度生长，抑制中性粒细胞、淋巴细胞和单核细胞浸润，且未观察到组织损伤或过度炎症反应。,False,,,False,False,False,,True,通过下调促炎因子（IL-1β、TNF-α）和上调抗炎因子（IL-4）的表达，调节局部免疫反应，减轻炎症损伤，促进免疫稳态恢复。,"IL-4, IL-1β, TNF-α (modulated expression)",True,通过减少细胞凋亡因子（caspase-3、caspase-8、FasL）的表达，促进上皮细胞再生，修复受损的阴道黏膜屏障。,"Caspase-3, Caspase-8, FasL (downregulated)",False,,,False,,,GRAS,"None (natural isolates, no synthetic kill switches or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to host-specific colonization,Physical confinement by gelatin sponge prevents systemic dissemination; localized delivery ensures safety,该菌群为从健康女性阴道中分离的天然乳杆菌，符合GRAS（公认安全）标准。未发现致病性、耐药基因或水平基因转移风险，且通过凝胶海绵局部递送，具有良好的物理屏障保护，安全性高。,在大鼠阴道菌群失调模型中，该乳杆菌组合显著降低子宫壁中性粒细胞、淋巴细胞和单核细胞浸润，下调IL-1β和TNF-α表达，上调IL-4表达，恢复Lactobacillus丰度并抑制Enterobacter和Enterococcus过度生长，组织病理学显示黏膜修复良好，炎症反应基本消失，表明其在修复阴道微生态和缓解炎症方面具有显著疗效。,11962,2054,14016,,
26bbb7d0-4d7a-4d70-b2ee-34cabe38977d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus hirae"", ""strain_id"": ""LD3""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 7.0; tolerates pH 2.0–6.0; utilizes various carbohydrates including glucose, fructose, maltose, sucrose, and cellobiose.","Fast-growing strain; enters log phase at 3 h, reaches stationary phase by 5 h; doubling time not explicitly stated but inferred as rapid based on growth curve.","Gastrointestinal tract (GIT), particularly in the context of food fermentation and potential gut colonization.","Demonstrates autoaggregation and cell surface hydrophobicity, suggesting ability to adhere to mucosal surfaces and compete with pathogens; may modulate gut microbiota via bacteriocin production.","High tolerance to acidic pH (survives pH 2.0 with pepsin), bile salts (taurocholic acid, oxgall), heat (stable up to 121°C for 15 min), organic solvents, surfactants, detergents, and antacids (ENO, Ranitidine).","Bile salt hydrolase (BSH) activity, proteinaceous bacteriocin (enterocin LD3), cell surface hydrophobicity components.",该菌株为快速生长的革兰氏阳性球菌，最适生长温度为37°C，pH为7.0。在模拟胃液（pH 2.0）中具有良好的存活能力，对胆盐（如牛磺胆酸和oxgall）耐受，且在高温（121°C）、有机溶剂、表面活性剂和去垢剂中保持稳定。其细胞表面具有较强疏水性，能自发和自聚集，表明其在肠道黏膜定植潜力强。,,,,,,,本文未涉及基因工程改造，菌株LD3为天然分离株，未进行人工遗传修饰。其功能主要依赖于天然产生的细菌素（enterocin LD3）和固有生理特性。,"[""Acidity"", ""Hypoxia""]","[""Lactate"", ""Bile Acids""]",,,Not specified – no engineered sensors reported.,Not applicable – no synthetic genetic circuits described.,该菌株未被工程化设计为响应特定信号，其生理行为（如细菌素产生）与生长阶段相关（中对数期开始产生），但未明确其感知机制或逻辑控制。,"[""Antibacterial"", ""Probiotic""]",Unknown – likely secreted via general secretion pathway or released upon lysis; no specific secretion system reported.,Not applicable – no controlled release or tunable output described.,Not evaluated – no encapsulation or material integration reported.,True,True,False,细菌素LD3具有广谱抗菌活性，对多种革兰氏阳性与阴性病原菌均有抑制作用，包括金黄色葡萄球菌、铜绿假单胞菌、沙门氏菌、志贺氏菌、大肠杆菌O157:H7等。其作用机制为杀菌，通过破坏细胞膜完整性导致目标菌快速死亡。,Enterocin LD3 (bacteriocin),True,False,False,False,该细菌素对多种食品源和人类致病菌具有广谱抑制活性，且在酸性环境和高温下稳定，但未评估其在生物材料中的释放行为、对宿主细胞的毒性或对微生物组的扰动。,False,,,False,False,False,未提及任何产氧机制或相关酶。,False,,,False,,,False,,,False,,,GRAS,None – no kill-switch or auxotrophy reported.,,"Strain LD3 is isolated from food (dosa batter), shows no antibiotic resistance genes (except kanamycin/gentamycin resistance, which is common in enterococci), and has low pathogenicity risk. However, enterococci are known for potential horizontal gene transfer (HGT) and opportunistic infection risk, especially in immunocompromised hosts.",Not applicable – no physical barrier or encapsulation described.,该菌株来源于传统发酵食品，符合GRAS（公认安全）标准，且未检测到可转移的抗生素抗性基因。但作为肠球菌，其具有潜在的基因水平转移能力，且在免疫抑制个体中可能引发感染，需谨慎评估临床应用风险。,该菌株表现出良好的胃肠道耐受性（耐酸、耐胆盐）、细胞表面疏水性及自聚集能力，可有效抑制多种食源性和人类致病菌，具有作为益生菌和天然抗菌剂的潜力。其细菌素在极端条件下稳定，适用于食品和医药领域。,13806,1667,15473,,
85da79c7-06cb-4be7-8223-f95a6048110e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""MTCC 9510""}]",Suspension,Facultative Anaerobe,"Grown on MRS agar and broth at 37°C, 72 h; optimal temperature 37°C, pH not specified, requires standard nutrient-rich medium (MRS) with carbon sources such as glucose and lactose.",Growth rate not quantified; cells harvested after 24 h in MRS broth; doubling time not reported. In vivo colonization observed after oral administration.,"Gut lumen, particularly cecum; promotes colonization of Lactobacillus spp. and modulates gut microbiota composition.",Competitive exclusion of Enterobacteriaceae and other LPS-producing bacteria; promotes beneficial Lactobacillus and Roseburia spp.; reduces dysbiosis.,"Tolerant to freeze-drying (lyophilization) and storage at -80°C; stability in glycerol suspension; no data on UV, shear, or osmotic stress.",Glycerol (for cryoprotection during storage),"Lactobacillus plantarum MTCC 9510 is a facultative anaerobe that grows well in MRS medium at 37°C. It demonstrates strong colonization potential in the murine gut, particularly in the cecum, where it enhances beneficial bacterial populations and suppresses pathobionts. It is stable under cryopreservation and suitable for oral delivery.",,,,,,,No genetic engineering was performed. The strain was used in its native form without modification. Its beneficial effects are attributed to natural probiotic properties and metabolic activity.,,,,,,,"No engineered sensing modules were used. The strain's activity is based on natural interactions with the host and gut environment, including modulation of gut barrier integrity and immune signaling via endogenous metabolites.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Natural secretion of metabolites (e.g., SCFAs, exopolysaccharides); no engineered secretion systems used.",Oral gavage at 2 × 10¹⁰ CFU/mouse daily; dosage not dynamically controlled.,Compatible with oral delivery in PBS; no encapsulation or material-based delivery system described.,False,,,,,,,,,,False,,,,,,,True,"Reduces systemic and brain inflammation by lowering serum TNF-α, corticosterone, and LPS levels; inhibits NF-κB activation in the hippocampus; enhances anti-inflammatory signaling.","TNF-α, NF-κB, corticosterone",True,"Improves intestinal and blood-brain barrier integrity by upregulating tight junction proteins (e.g., Claudin-5, ZO-2); reduces permeability induced by stress.","Tight junction proteins (Claudin-5, ZO-2), BDNF",True,"Modulates gut microbial metabolism by increasing production of short-chain fatty acids (SCFAs), particularly acetic and butyric acid in CUMS mice, and propionic acid in SD mice; supports colonocyte energy metabolism and gut homeostasis.","Acetic acid, Butyric acid, Propionic acid",False,,,GRAS,"None (natural strain, no kill-switch or auxotrophy introduced)",,Non-pathogenic; no antibiotic resistance genes reported; low opportunistic risk; no evidence of horizontal gene transfer; environmental escape unlikely due to lack of persistence beyond gut.,None (no physical material barrier used; oral delivery relies on natural gut transit),"Lactobacillus plantarum MTCC 9510 is a well-characterized, generally recognized as safe (GRAS) probiotic strain. It is non-pathogenic, does not carry antibiotic resistance genes, and shows no evidence of systemic dissemination or environmental persistence. Its use in oral supplementation poses minimal biosafety risk.","L. plantarum MTCC 9510 supplementation significantly prevented stress-induced behavioral deficits (depression, anxiety, cognitive impairment), oxidative stress, neuroinflammation, and gut and blood-brain barrier dysfunction in mice exposed to chronic unpredictable mild stress (CUMS) or sleep deprivation (SD). It restored gut microbiota balance by increasing Lactobacillus and Roseburia spp. while reducing Enterobacteriaceae. It enhanced SCFA production (acetic, butyric, propionic acids), improved barrier integrity, and normalized neurochemical markers (BDNF, TNF-α, corticosterone). These effects demonstrate strong neuroprotective and gut-modulating capacity, supporting its potential as a psychobiotic for stress-related disorders.",10341,1634,11975,,
a35172de-633f-4138-a73f-22676bd7218f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecalis"", ""strain_id"": ""DSM 16440""}]",Suspension,Facultative Anaerobe,"Gram-positive, orally administered, persists in human gut; grows in nutrient-rich environments (e.g., intestinal tract); no specific pH or temperature constraints mentioned",Stably persists in human gut after oral administration; no in vivo doubling time or growth rate provided,Human gastrointestinal tract (gut mucosa),May modulate gut microbiota composition; potential competitive interaction with pathogenic bacteria; no direct mention of symbiosis with host microbiome,"Tolerates oral passage (gastric acid, bile), stable during storage as drops; no data on UV, drying, or shear stress","Lactose monohydrate, glucose monohydrate (carrier solution)",该菌株为革兰氏阳性菌，口服后可在人体肠道中稳定定植，属于正常肠道菌群成员，具有良好的耐受性，适用于肠道微生态调节。,,,,,No genetic modifications reported; natural strain used; chromosomal stability assumed in gut environment,Stable in liquid drop formulation (carrier: lactose and glucose); no evidence of degradation in delivery medium,该系统未进行基因工程改造，使用天然来源的 Enterococcus faecalis DSM 16440 菌株，通过口服滴剂形式递送，无外源基因插入或调控元件。,,,,,,,该研究未描述任何感知模块或逻辑控制机制，微生物本身不具有工程化响应系统。,"[""Immunomodulation""]",Passive secretion (natural metabolic activity); no engineered secretion system reported,Fixed dose: 30 drops three times daily for 4 weeks; no dynamic or feedback-controlled dosage,Compatible with liquid drop formulation; stable in lactose/glucose carrier solution; no evidence of material degradation or interference,False,,,,,,,,,,False,,,,,,,True,通过调节肠道菌群，影响免疫系统，可能通过激活或抑制Th1细胞、促进IL-10分泌、降低特异性IgE水平、抑制组胺信号通路等方式实现免疫调节作用。,"Interleukin-10 (IL-10), IgE, Histamine signaling pathway",False,,,False,,,False,,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; generally considered safe; no antibiotic resistance genes reported; potential for horizontal gene transfer not assessed; environmental escape risk low due to gut-restricted persistence,Physical barrier: oral delivery with transient gut residence; no encapsulation or sustained release system,Enterococcus faecalis DSM 16440 属于公认安全（GRAS）菌株，为正常肠道菌群成员，无已知致病性。未进行基因改造，无抗生素抗性基因或杀伤开关，安全性较高。其在肠道内定植但不长期滞留，环境释放风险低。,本研究为随机对照试验设计，旨在评估 E. faecalis 对季节性过敏性鼻炎症状的影响，主要终点为综合症状与用药评分（CSMS）和生活质量问卷（RQLQ）。研究未报告具体疗效数据，但基于既往研究，推测其可能通过免疫调节改善症状，尤其在减少IgE介导的过敏反应和提升生活质量方面具有潜力。,9300,1386,10686,,
13f2771d-1c50-4ecd-8bfb-88d01aaf6f07,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": """"}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires complex nutrients including amino acids, vitamins, and carbohydrates; adapted to intestinal environment",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed within days of administration,"Large intestine (colon), particularly mucosal surface and lumen",Competitive exclusion of pathogenic bacteria; potential symbiosis with host microbiota; no reported antagonism,Moderate tolerance to gastric acid and bile; stable during lyophilization and rehydration; resistant to moderate shear stress,"Cell wall components (e.g., peptidoglycan), exopolysaccharides",该混合菌群为兼性厌氧菌，可在人体肠道环境中定植，适宜生长温度为37°C，pH值约6.5–7.0，依赖复杂营养物质如氨基酸、维生素和碳水化合物。在体外培养中，倍增时间为1.5–2小时，口服后可在数日内在肠道内定植，主要定植于结肠黏膜表面和肠腔。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未对菌株进行基因工程改造，所有菌株均为天然来源，未使用任何基因编辑工具或合成回路。,"[""pH"", ""Bile acids""]","[""Lactate"", ""Glucose""]",,,"FNR-like regulators (in Bifidobacteria), lactose permease (in Lactobacilli)",Not specified,该研究未涉及合成生物学逻辑门控系统，菌株通过天然代谢感应机制响应肠道环境变化，如pH下降和营养物质可用性。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (lactic acid), passive diffusion (SCFAs)",Dose-dependent effect: 4 × 10⁹ CFU/day; effects observed after 2 weeks of treatment,Well compatible with oral suspension formulation; stable in powder form; no reported interference with delivery matrix,False,False,False,Not applicable,,False,False,False,False,,False,Not applicable,,False,False,False,,True,"Probiotics reduce visceral hypersensitivity and inflammation in the enteric mucosa, leading to decreased abdominal pain. B. infantis has been shown to modulate immune responses in IBS.",B. infantis (strain-specific immunomodulatory factors),True,Improved colonic motility and reduced transit time may promote mucosal healing and barrier function. Decreased abdominal pain suggests reduced tissue irritation.,Short-chain fatty acids (SCFAs) produced by fermentation,True,"Bifidobacteria and lactobacilli ferment dietary fibers to produce lactic acid, acetic acid, and other organic acids, lowering colonic pH. This acidification enhances peristalsis and reduces colonic transit time.","Lactic acid, Acetic acid, Short-chain fatty acids (SCFAs)",False,Not applicable,,GRAS,"None (natural strains, no engineered kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape concerns; well-tolerated in children,Oral administration with natural gut barrier; no physical containment required,该混合菌群为公认安全（GRAS）菌株，无致病性，未携带抗生素抗性基因，无水平基因转移风险，且在儿童中口服耐受良好，未报告任何不良反应。,该研究为小样本试点研究，共纳入20名儿童。结果显示，每周排便次数从基线2.0次增加至第2周的4.2次（p=0.10）和第4周的3.8次（p=0.13）。在每周排便少于3次的12名儿童中，排便频率显著增加（第2周p=0.01，第4周p=0.009）。粪便失禁次数显著减少（第2周p=0.007，第4周p=0.001）。腹痛发生率从45%降至20%（p=0.006）。未观察到副作用。结果提示该益生菌混合物对儿童功能性便秘具有积极疗效，但需大样本随机对照试验进一步验证。,7822,1777,9599,,
7d777886-3faf-4ee6-b821-eb9eaf6be3a3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""HN001""}]",Oral administration (gastrointestinal tract),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; resistant to gastric acid and bile salts; utilizes carbohydrates as carbon source",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in infant gut within days of administration,Small intestine and colon; adheres to intestinal epithelium,Competes with pathogenic bacteria; promotes symbiosis with host microbiota by enhancing bifidobacteria and lactobacilli,"Tolerant to gastric acid, bile salts, and moderate osmotic stress; stable during lyophilization and storage at 4°C","Cell wall components (e.g., teichoic acids), acid tolerance systems (e.g., F0F1-ATPase)",该菌株为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下生长，对胃酸和胆盐具有较强耐受性，能有效定植于小肠和结肠黏膜，通过竞争性抑制病原菌并促进有益菌群（如双歧杆菌）生长，实现与宿主微生物群的共生关系。,None reported (natural isolate),Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems used; minimal metabolic burden,"Stable in oral formulations (e.g., powder, formula) without significant loss of viability",该系统未进行基因工程改造，使用天然分离的Lactobacillus rhamnosus HN001菌株，通过口服给药定植于肠道，无需外源调控元件，具有良好的遗传稳定性。,"[""pH"", ""Bile Acids""]","[""Lactate"", ""Glucose""]",,"[""Cytokines"", ""Proteases""]","FNR promoter (hypoxia), Bile acid-responsive regulators (e.g., Bile acid-binding proteins)",Constitutive expression; no complex logic gates; threshold-based response to environmental cues,该菌株通过感知肠道pH变化、胆汁酸浓度及乳酸/葡萄糖水平实现环境适应，其基因表达主要为组成型，无复杂逻辑控制，但可通过代谢产物反馈调节自身活性。,"[""Immunomodulation"", ""Tissue Repair""]","Type I secretion (e.g., for cytokines), Vesicles (exosomes)",Dose-dependent effect; controlled by oral administration frequency and formulation,"Compatible with oral formulations (powder, formula); stable in gastrointestinal environment",False,,,Not applicable,,False,False,False,False,无抗菌或抗生物膜功能描述,False,Not applicable,,False,False,False,无氧生成机制描述,True,"Modulates immune response by upregulating IFN-γ and IL-10, promoting Th1/Treg balance and suppressing Th2 response; enhances oral tolerance induction.","IL-10, IFN-γ, TGF-β",True,Improves intestinal barrier function by increasing tight junction protein expression and IgA production; supports mucosal healing.,"IgA, ZO-1, Occludin",False,Not applicable,,False,Not applicable,,GRAS,"None (natural isolate, non-pathogenic)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape concerns,Gastrointestinal tract barrier sufficient; no systemic dissemination reported,Lactobacillus rhamnosus HN001被美国FDA列为GRAS（公认安全），在儿童中使用未报告严重不良事件，无致病性、耐药基因或基因水平转移风险，属于低风险生物制剂。,"在预防性试验中，Lactobacillus rhamnosus HN001显著降低2岁儿童特应性皮炎发病率（HR 0.51, 95% CI 0.30–0.85, p=0.01），尤其对IgE相关性AD效果更显著（HR 0.51, 95% CI 0.27–0.97, p=0.04）。在治疗方面，部分研究显示SCORAD评分下降，但总体证据不一致。",15440,4889,20329,,
7d777886-3faf-4ee6-b821-eb9eaf6be3a3,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""HN019""}]",Oral administration (gastrointestinal tract),Strict Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; requires complex nutrients including amino acids, vitamins, and oligosaccharides; sensitive to bile salts",Doubling time ~3–4 hours in vitro; slower colonization in vivo due to sensitivity to bile and oxygen,Colon; preferentially colonizes mucosal layer of large intestine,Symbiotic with host; promotes growth of other beneficial bacteria; competes with pathogenic species,Sensitive to bile salts and oxygen; low tolerance to drying and shear stress; requires refrigerated storage,"Exopolysaccharides (EPS), protective capsule layers",该菌株为专性厌氧菌，最适生长温度37°C，pH 6.0–7.0，依赖复杂营养物质（如氨基酸、维生素、寡糖）生长，对胆汁酸和氧气敏感，主要定植于结肠黏膜层，通过与宿主共生并抑制病原菌实现生态平衡。,None reported (natural isolate),Not applicable,Constitutive,,High chromosomal stability; no plasmid systems; minimal metabolic burden,"Stable in oral formulations with prebiotics (e.g., GOS/FOS); enhanced survival in co-administration",该系统未进行基因改造，使用天然分离的Bifidobacterium animalis subsp. lactis HN019菌株，通过口服给药定植于结肠，与预生物（GOS/FOS）协同增强定植能力，具有良好的遗传稳定性。,"[""pH"", ""Bile Acids""]","[""Lactate"", ""Glucose"", ""Fructo-oligosaccharides (FOS)""]",,"[""Cytokines""]","FOS-responsive promoters (e.g., FOS transporter operons), pH-sensing regulators (e.g., PhoP/PhoQ)",Constitutive expression; no inducible circuits; threshold response to prebiotic availability,该菌株通过感知肠道pH、胆汁酸及FOS等寡糖信号实现环境适应，其代谢基因主要为组成型表达，但FOS存在时可激活特定转运系统，实现营养响应性调控。,"[""Immunomodulation"", ""Metabolic Regulation""]","Vesicles (exosomes), Type IV secretion",Dose-dependent effect; controlled by oral intake and prebiotic co-administration,Highly compatible with prebiotic-containing formulations; stable in encapsulated delivery systems,False,,,Not applicable,,False,False,False,False,无抗菌或抗生物膜功能描述,False,Not applicable,,False,False,False,无氧生成机制描述,True,Enhances regulatory T cell (Treg) function; increases IL-10 and TGF-β production; suppresses Th2-mediated inflammation.,"IL-10, TGF-β, FoxP3+ Tregs",False,Not applicable,,True,"Ferments prebiotics (GOS/FOS) to produce short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate, which serve as energy substrates for colonocytes and modulate immune function.","Acetate, Propionate, Butyrate",False,Not applicable,,GRAS,"None (natural isolate, non-pathogenic)",,Low pathogenicity; no antibiotic resistance genes; no HGT risk; no environmental escape reported,Gastrointestinal barrier sufficient; no systemic dissemination observed,Bifidobacterium animalis subsp. lactis HN019被列为GRAS，无致病性、耐药基因或基因水平转移风险，安全性高，适用于婴幼儿。,"在预防性试验中，Bifidobacterium animalis subsp. lactis HN019未显著降低特应性皮炎发病率（HR 0.98, 95% CI 0.72–1.33），与安慰剂组无显著差异。但其在调节免疫和代谢方面具有潜力，尤其在与预生物联用时可增强益生作用。",15440,4889,20329,,
7d777886-3faf-4ee6-b821-eb9eaf6be3a3,2,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Lcr35""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Bb-12""}, {""role"": ""Prey"", ""scientific_name"": ""Human Milk Oligosaccharides (HMOs)"", ""strain_id"": ""N/A""}]",Oral administration (gastrointestinal tract),"Facultative Anaerobe (L. rhamnosus), Strict Anaerobe (B. lactis)","L. rhamnosus: 37°C, pH 5.5–6.5; B. lactis: 37°C, pH 6.0–7.0; both require complex nutrients and prebiotics (e.g., GOS/FOS, HMOs)",L. rhamnosus: doubling time ~1.5–2 h; B. lactis: ~3–4 h; co-culture enhances growth via cross-feeding,"Small intestine (L. rhamnosus), Colon (B. lactis); mucosal layer","Synergistic interaction: L. rhamnosus produces lactate, which B. lactis uses as carbon source; both promote host immune tolerance",Moderate tolerance to gastric acid and bile; sensitive to drying; requires refrigerated storage,"Exopolysaccharides (EPS), acid tolerance systems",该共培养系统由Lactobacillus rhamnosus Lcr35（兼性厌氧）和Bifidobacterium lactis Bb-12（专性厌氧）组成，两者在肠道中协同定植，L. rhamnosus产生乳酸供B. lactis利用，形成互惠关系，共同促进免疫调节和屏障修复。,None reported (natural isolates),Not applicable,Constitutive,,High chromosomal stability; no plasmid systems; minimal metabolic burden,Stable in oral formulations with prebiotics; enhanced survival in co-administration,该系统未进行基因改造，由两种天然分离菌株组成，通过口服给药在肠道中形成共生关系，无需外源调控，具有良好的遗传稳定性。,"[""pH"", ""Bile Acids""]","[""Lactate"", ""Glucose"", ""Fructo-oligosaccharides (FOS)"", ""Human Milk Oligosaccharides (HMOs)""]",,"[""Cytokines""]","Lactate-responsive promoters (e.g., LldR), FOS/HMO transporters (e.g., ABC transporters)",Constitutive expression; no complex logic; cross-feeding enables metabolic synergy,该共培养系统通过感知pH、胆汁酸、乳酸、FOS及HMO等信号实现环境适应，L. rhamnosus利用葡萄糖产乳酸，B. lactis利用乳酸和HMOs生长，形成代谢互补，实现协同效应。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]","Vesicles (exosomes), Type I/IV secretion",Dose-dependent; controlled by oral administration and prebiotic co-formulation,Highly compatible with oral formulations containing prebiotics; stable in encapsulated delivery,False,,,Not applicable,,False,False,False,False,无抗菌或抗生物膜功能描述,False,Not applicable,,False,False,False,无氧生成机制描述,True,"Synergistically upregulates IL-10, IFN-γ, and TGF-β; enhances Treg differentiation and suppresses Th2 response.","IL-10, IFN-γ, TGF-β, FoxP3+ Tregs",True,"Enhances intestinal barrier integrity via increased IgA, tight junction proteins, and mucin production.","IgA, MUC2, ZO-1, Occludin",True,"Ferments HMOs and FOS to produce SCFAs (acetate, propionate, butyrate), which regulate immune function and energy metabolism.","Acetate, Propionate, Butyrate",False,Not applicable,,GRAS,"None (natural isolates, non-pathogenic)",,Low pathogenicity; no antibiotic resistance genes; no HGT risk; no environmental escape,Gastrointestinal barrier sufficient; no systemic dissemination reported,该共培养系统由两种GRAS菌株组成，无致病性、耐药基因或基因水平转移风险，安全性高，适用于婴幼儿。,在一项小型治疗试验中，该共培养系统（L. rhamnosus Lcr35 + B. lactis Bb-12）与预生物联用，虽未显著优于单独预生物组，但显示出改善AD症状的趋势，尤其在IgE相关性AD中效果更明显，提示其在免疫调节和代谢调控方面具有协同潜力。,15440,4889,20329,,
65e03f1b-a0ed-41c1-a7e0-d6fb2010dafc,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""1.89 × 10¹⁰ cfu/kg""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""3.09 × 10¹⁰ cfu/kg""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""3.09 × 10¹⁰ cfu/kg""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""3.09 × 10¹⁰ cfu/kg""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""3.00 × 10¹⁰ cfu/kg""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus salivarius subsp. Hermophilus"", ""strain_id"": ""6.15 × 10¹⁰ cfu/kg""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""8.85 × 10¹⁰ cfu/kg""}, {""role"": ""Chassis"", ""scientific_name"": ""Aspergillus oryzae"", ""strain_id"": ""7.98 × 10⁹ cfu/kg""}, {""role"": ""Chassis"", ""scientific_name"": ""Candida pintolopesii"", ""strain_id"": ""7.98 × 10⁹ cfu/kg""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly acidic; Nutritional requirements: Complex media with carbohydrates, amino acids, vitamins; Osmotic tolerance: Moderate",Growth rate: Rapid in vitro; Doubling time: ~1–2 hours; In vivo homeostasis: Stable in broiler gut environment,"Gastrointestinal tract (cecum, small intestine); preferentially colonizes mucosal surfaces and lumen","Competitive exclusion of pathogens (e.g., E. coli); synergistic interactions with prebiotic components; no significant disruption of native microbiota",Moderate tolerance to gastric acidity and bile; stable during feed processing and storage; limited data on UV/shear stability,"Cell wall components (e.g., peptidoglycan, exopolysaccharides); intrinsic resistance to bile salts",该研究中使用的微生物群落为多种益生菌的复合体，包括乳杆菌属、双歧杆菌属、链球菌属和肠球菌属等。这些微生物在鸡的肠道环境中具有良好的生长适应性，能够在37°C、中性至弱酸性条件下快速增殖，其生长周期约为1–2小时。它们主要定植于肠道黏膜表面和肠腔，通过竞争性排斥病原菌（如大肠杆菌）来维持肠道微生态平衡。该群落对胃酸和胆汁具有中等耐受性，可在饲料加工和储存过程中保持稳定，但未报告其对紫外线或剪切力的耐受性。,Not specified,Not specified,Not specified,,Not specified,Not specified,该研究未对微生物进行基因工程改造，所有微生物均为天然来源的商业益生菌制剂，其功能依赖于自然生理特性，而非人工调控回路。,"[""pH"", ""Bile acids"", ""Lactate"", ""Glucose""]","[""Lactose"", ""Fructooligosaccharides"", ""Inulin"", ""Beta-1,3 glucans""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]",FNR promoter (hypoxia); Lactate receptor (LacR); Bile acid transporter (BaiCD); Glucose transporter (PtsG),Not specified,该研究未描述任何基因逻辑门或信号处理机制，微生物的响应主要基于其天然代谢感应系统，如对乳酸、葡萄糖和胆汁酸的感应，通过代谢调控实现功能表达。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type III Secretion (Lactobacillus), Vesicles (Extracellular vesicles), Lysis (natural turnover)",Dose-dependent; controlled by dietary supplementation rate (0.1–0.15 g/kg); no feedback control,Compatible with feed matrix; stable during feed pelleting and storage,True,True,True,通过产生有机酸（如乳酸）降低肠道pH，抑制病原菌生长；分泌细菌素（如乳杆菌素）直接杀灭革兰氏阳性菌；竞争性黏附于肠黏膜，阻止病原菌定植。,"Lactic acid, Bacteriocins (e.g., Lactocin, Enterocin)",True,True,True,True,研究显示，使用益生菌和合生元的鸡群中，大肠杆菌数量显著降低，且未观察到对正常菌群的显著破坏，表明其抗菌作用具有选择性且可控。,False,,,False,False,False,未涉及氧气生成机制，因此不适用。,True,通过激活肠道相关淋巴组织（GALT）和Peyer’s patches，促进T细胞和B细胞活化，增强免疫球蛋白合成，提高脾脏重量和免疫应答能力。,"LPS (from Lactobacillus), Peptidoglycan, Exopolysaccharides (EPS)",True,通过改善肠道形态（如增加绒毛长度、减少隐窝深度）和降低肠壁厚度，促进肠道屏障功能恢复，增强黏膜修复能力。,"TGF-β, IL-10, VEGF",True,调节宿主代谢，如降低血清胆固醇、甘油三酯和LDL水平，提高HDL水平，改善脂质代谢平衡。,"Short-chain fatty acids (SCFAs), Lactate, Bile acid metabolites",False,,,GRAS,Auxotrophy (nutrient-dependent growth); no known pathogenicity,"Lack of essential amino acids (e.g., arginine, lysine)",Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape observed in poultry systems,Feed matrix provides physical confinement; no release into environment,所用微生物均为公认安全（GRAS）菌株，无致病性报告，未检测到抗生素抗性基因，且在饲料中以营养依赖方式存在，降低了环境逃逸风险。物理屏障（饲料基质）有效防止其在环境中扩散。,与抗生素组相比，合生元组显著提高了日增重（73.6 g/d）、饲料转化率（1.70）和胴体出肉率（78.7%），并显著增加脾脏重量（+115%）和胃重量（+47%），同时降低肾脏重量（-47%）和腹部脂肪含量（0.83%）。此外，合生元显著改善了肠道形态，使小肠壁变薄，且对肠道微生物群具有显著调节作用，促进乳酸菌和好氧菌生长，抑制大肠杆菌。,19882,2310,22192,,
b3c1e684-0117-4bad-a91d-419978aab77c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium"", ""strain_id"": ""Golden bifid (Bifidobacterium, Lactobacillus bulgaricus, Streptococcus thermophilus)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus bulgaricus"", ""strain_id"": ""Golden bifid (Bifidobacterium, Lactobacillus bulgaricus, Streptococcus thermophilus)""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Golden bifid (Bifidobacterium, Lactobacillus bulgaricus, Streptococcus thermophilus)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Live combined Bifidobacterium and Lactobacillus tablets (Bifidobacterium, L acidophilus, Enterococcus faecalis, Bacillus cereus)""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecalis"", ""strain_id"": ""Live combined Bifidobacterium and Lactobacillus tablets (Bifidobacterium, L acidophilus, Enterococcus faecalis, Bacillus cereus)""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus cereus"", ""strain_id"": ""Live combined Bifidobacterium and Lactobacillus tablets (Bifidobacterium, L acidophilus, Enterococcus faecalis, Bacillus cereus)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""Biostime (Bifidobacterium, L rhamnosus GG)""}]",Enteral nutritional suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, tolerant to bile acids and gastric acidity; requires glucose and amino acids as carbon and nitrogen sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed within 24–48 hours post-administration,"Intestinal mucosa, particularly in the colon and ileum; preferentially colonizes mucus layer and epithelial surfaces","Competitive exclusion of pathogenic bacteria (e.g., Escherichia coli); synergistic co-colonization with other commensals; no evidence of disruption to core microbiome","Tolerant to lyophilization, moderate heat (up to 50°C), and osmotic stress; stable during storage at 4°C for up to 12 months","Bile salts, gastric acid, and freeze-drying stabilizers (e.g., trehalose)",该系统以多种益生菌（如双歧杆菌、乳酸杆菌、嗜热链球菌等）为底盘，具有良好的肠道定植能力。这些菌株为兼性厌氧菌，可在37°C、pH 6.5–7.5条件下生长，对胃酸和胆汁具有较强耐受性，能利用葡萄糖和氨基酸作为碳氮源。在体外培养中，倍增时间约为1.5–2小时；在体内，口服后24–48小时内即可在肠道黏膜定植。主要定植于结肠和回肠的黏液层及上皮表面，通过竞争性排斥病原菌（如大肠杆菌）维持肠道微生态平衡，且不破坏核心菌群结构。,None (Natural strains used; no genetic modification reported),Not applicable,Constitutive,None,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift in clinical trials,Stable in enteral nutritional suspension; no degradation or loss of viability during encapsulation,本研究中使用的益生菌均为天然菌株，未进行基因工程改造。其功能表达为天然固有特性，无需诱导或调控系统。菌株在肠内营养液中保持稳定，无质粒依赖，遗传稳定性高，未观察到基因漂移或功能丧失。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Bile acids"", ""SCFAs"", ""Lactate""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases""]","FNR promoter (hypoxia), Bile acid-responsive promoters (e.g., Bile acid receptor Bsh), Lactate transporter (LctP)","Threshold-based activation; no complex logic gates reported; response to multiple signals (e.g., low pH + bile) may act as AND gate",这些益生菌通过感知肠道微环境中的多种信号（如pH、胆汁酸、乳酸、葡萄糖）实现定植与功能激活。例如，双歧杆菌和乳酸杆菌可通过FNR启动子感知低氧环境，通过胆汁酸受体感知胆汁酸浓度，通过LctP转运体感知乳酸水平。在临床研究中，这些菌株在肠道中表现出对炎症相关信号（如细胞因子、蛋白酶）的响应能力，但未报告复杂的逻辑门控机制，主要为阈值依赖型激活。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion system (e.g., for sIgA modulation); vesicle-mediated delivery of metabolites","Dose-dependent effect; administered at 3.5 g/time, 3 times/day; duration 2–4 weeks",High compatibility with enteral nutritional suspension; no structural disruption or gas production observed,False,False,False,Not applicable,None,False,False,False,False,未报告抗菌活性或生物膜抑制功能,False,Not applicable,None,False,False,False,未报告氧气生成功能,True,"Enhances intestinal mucosal immunity by increasing sIgA production, modulates Th1/Th2 balance, reduces systemic inflammation, and strengthens tight junctions.","sIgA, IL-10, TGF-β",True,"Promotes epithelial regeneration, enhances intestinal barrier integrity, increases villi surface area, and accelerates mucosal healing.","TGF-β, EGF, ZO-1, occludin",True,"Regulates glucose and lipid metabolism; produces SCFAs (e.g., acetate, butyrate) that serve as energy substrates and signaling molecules.","Acetate, Butyrate, Propionate",False,Not applicable,None,GRAS,"Auxotrophy (e.g., requirement for specific amino acids or vitamins not available in host environment)","Amino acid auxotrophy (e.g., leucine, lysine)",Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape,Enteral delivery limits systemic spread; no physical barrier required,所用益生菌均为公认安全（GRAS）菌株，无致病性，未检测到抗生素抗性基因，无水平基因转移证据，且通过营养缺陷型（如亮氨酸、赖氨酸依赖）实现生物遏制，降低环境逃逸风险。肠内给药方式限制其全身扩散，安全性良好。,早期肠内营养联合益生菌可显著降低严重颅脑损伤患者的感染风险（RR=0.53）、死亡率（RR=0.56）和胃肠道并发症（RR=0.19），并缩短ICU住院时间（MD=-4.55天）。其机制主要通过调节肠道菌群平衡、增强肠道屏障功能、促进免疫调节和组织修复实现。,13061,2348,15409,,
17647008-ad6e-4b96-975f-0a1bbfdbd042,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Bacteroides spp."", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Akkermansia muciniphila"", ""strain_id"": ""Not specified""}]",Co-cultured in feed additive mixtures,Facultative Anaerobe,"Optimal growth at 37–40°C, pH 5.5–7.0, utilizes carbohydrates (e.g., glucose, lactose), requires complex nutrients including amino acids and vitamins; thrives in intestinal environment with mucin and bile salts",Doubling time ~1–2 hours in vitro; growth rate consistent with in vivo colonization dynamics in broiler chickens,Small intestine and cecum; preferentially colonizes mucosal surfaces and lumen of gastrointestinal tract,"Competes with pathogens (e.g., Salmonella, Campylobacter) for nutrients and adhesion sites; promotes symbiosis with host via SCFA production and immune modulation","Moderate tolerance to bile salts, osmotic stress, and low pH; limited data on UV, drying, or shear stress; stability in feed formulations reported","Bile salt hydrolase (BSH) enzymes, mucin-degrading enzymes","Lactobacillus and Bacillus species are facultative anaerobes that thrive in the chicken gut, utilizing dietary carbohydrates and host-derived mucins. They exhibit robust growth under physiological conditions of the gastrointestinal tract, with strong colonization ability in the small intestine and cecum. Their presence supports gut homeostasis and inhibits pathogen overgrowth through competitive exclusion and metabolic byproduct production.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,The microbial consortium is developed through co-culturing of naturally occurring probiotic strains without genetic modification. The design relies on natural metabolic and competitive interactions rather than synthetic genetic circuits. No engineered plasmids or inducible systems are reported.,"[""pH"", ""Bile salts"", ""Hypoxia"", ""Glucose""]","[""Mucin"", ""Short-chain fatty acids (SCFAs)"", ""Lactate"", ""Amino acids""]","[""Quorum sensing (AHL, AI-2)"", ""Pathogen-specific molecules""]","[""Proteases (e.g., trypsin, chymotrypsin)"", ""Cytokines (e.g., IL-1β, TNF-α)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), BSH receptor (bile salts), mucin-binding adhesins, lactate-sensing regulators",No explicit logic gates reported; likely constitutive expression of key metabolic and colonization genes; potential threshold-based competition via resource sensing,"The consortium senses environmental cues such as low pH, bile salts, and mucin availability through native receptors. It responds to nutrient availability (e.g., glucose, lactate) and host-derived signals (e.g., proteases, cytokines) to modulate growth and metabolic activity. The system operates via natural competitive exclusion and metabolic feedback, without synthetic logic circuits.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I and II secretion systems, lysis (for bacteriocin release), extracellular vesicles",Controlled by natural growth dynamics and feed concentration; no synthetic dosage regulation reported,Compatible with feed matrices; stable in dry feed formulations and co-cultured mixtures,True,True,True,"Produces bacteriocins and organic acids (e.g., lactic acid) that inhibit pathogenic bacteria; competes for adhesion sites and nutrients; disrupts biofilm formation by pathogens like Salmonella and Campylobacter.","Bacteriocins, lactic acid, acetic acid, propionic acid",True,True,True,True,Probiotic Lactobacillus and Bacillus strains reduce Salmonella colonization and improve feed conversion ratio without causing tissue damage; no significant disruption of host microbiome reported.,False,Not applicable,,False,False,False,No evidence of oxygenation function; not designed for hypoxia alleviation.,True,"Stimulates production of secretory IgA, antimicrobial peptides (AMPs), and cytokines; enhances T-cell and B-cell responses; modulates innate immunity via mucin layer integrity and defensin induction.","Secretory IgA, defensins, IL-1β, TNF-α, angiopoietin-4",True,"Promotes epithelial regeneration and barrier enhancement through SCFA production (especially butyrate), which fuels colonocytes and strengthens tight junctions; supports mucosal healing.","Butyric acid, acetic acid, propionic acid",True,"Enhances biosynthesis of vitamins (B group, K), amino acids (glutamine, lysine), and secondary bile acids; improves feed conversion ratio (FCR) by increasing energy harvest from dietary fibers.","Short-chain fatty acids (SCFAs), vitamin B12, vitamin K, glutamine, lysine",False,Not applicable,,GRAS,Natural attenuation; no engineered kill switches or auxotrophy reported,Not applicable,Low pathogenicity; no antibiotic resistance genes reported in IGC of MCE-fed chickens; minimal risk of horizontal gene transfer; no evidence of environmental escape,Physical confinement in feed and gut environment; no external release,"The microbial consortium consists of well-characterized, non-pathogenic strains (Lactobacillus, Bacillus, Bifidobacterium, Bacteroides, Akkermansia) with GRAS status. No engineered genes or antibiotic resistance markers are present. The system relies on natural competition and colonization, minimizing risks of unintended spread or ecological disruption.","The co-cultured probiotic consortium significantly reduces colonization of Salmonella, Campylobacter, and E. coli in broiler chickens, improves feed conversion ratio (FCR) from 1.4 to 2.8, enhances weight gain, and supports gut barrier integrity. It promotes immune maturation and reduces reliance on sub-therapeutic antibiotics, offering a sustainable alternative for poultry production without compromising human health.",9567,2047,11614,,
3fa24571-2aad-4471-8d44-82266a01d5f5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus bulgaricus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus lactococcus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus bifidum"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in media containing glucose and amino acids; tolerant to bile acids and low pH (gastric conditions)",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in gut mucosa with stable persistence over 8–12 weeks,"Gastrointestinal tract (small and large intestine), particularly in the mucosal layer",Competitive exclusion of pathogenic bacteria via nutrient competition and production of antimicrobial substances; no significant disruption of native microbiota reported,Moderate tolerance to drying and storage at 4°C; sensitive to high UV and shear stress; lyophilization improves stability,"Lyophilization matrix (sucrose, trehalose)",该研究中涉及的微生物均为乳酸杆菌和双歧杆菌属，属于兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，对胃酸和胆汁具有耐受性，能定植于肠道黏膜层，通过竞争性抑制病原菌生长并产生抗菌物质来维持肠道微生态平衡。,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,文中未提及任何基因工程改造，所有微生物均为天然菌株，未进行人工遗传修饰。,"[""pH"", ""Bile Acids"", ""Glucose""]","[""Short-Chain Fatty Acids (SCFAs)"", ""Lactate""]","[""Quorum Sensing (AHL)"", ""AI-2""]","[""Proteases"", ""Cytokines (e.g., TNF-α, IL-1)""]","FNR promoter, LasR receptor, AI-2 receptor (LuxPQ)",Threshold-based activation; no explicit logic gates reported; likely constitutive or weakly inducible responses,微生物通过感知肠道环境中的pH、胆汁酸、葡萄糖等理化信号以及宿主来源的蛋白酶和细胞因子，调节其代谢和定植行为。部分菌株可能通过群体感应系统感知自身密度，调控代谢产物（如SCFAs）的分泌，实现对宿主免疫和氧化应激状态的调节。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Antioxidant Support""]","Type IV Secretion System, Vesicles",Dose-dependent effects observed (10^8–10^10 CFU/day); no precise feedback control reported,Compatible with capsule and sachet delivery forms; stable in dry powder form,False,False,False,Not applicable,Not applicable,False,False,False,False,未报告抗菌活性，未涉及生物膜抑制或控制机制。,False,Not applicable,Not applicable,False,False,False,未报告氧气生成或氧合功能。,True,"Probiotics reduce pro-inflammatory cytokines (TNF-α, IL-1) and modulate immune cell activity via interaction with gut epithelium and dendritic cells.","Tumor necrosis factor-α (TNF-α), Interleukin-1 (IL-1)",False,Not applicable,Not applicable,True,"Probiotics produce short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate, which regulate host metabolism, improve gut barrier function, and reduce oxidative stress.",Short-Chain Fatty Acids (SCFAs),False,Not applicable,Not applicable,GRAS,Not applicable,Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape,Capsule/sachet provides physical confinement; no live release into environment,所用菌株均为公认安全（GRAS）菌株，无致病性，未检测到耐药基因，未报告水平基因转移风险，且通过胶囊或粉剂形式摄入，具有物理屏障保护，整体生物安全风险极低。,Meta分析显示，益生菌补充可显著提高总抗氧化能力（TAC）（WMD 77.30 μmol/L），降低丙二醛（MDA）水平（WMD -0.31 μmol/L），但对谷胱甘肽（GSH）无显著影响。提示益生菌可通过调节代谢产物（如短链脂肪酸）和免疫反应，改善氧化应激状态，可能对慢性疾病预防具有潜在益处。然而，研究间异质性较高，结果需谨慎解读。,12229,1963,14192,,
71ceca4b-2a94-4316-9a4c-b8cbca412847,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""La-05""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Bb-12""}]",Encapsulated,Facultative Anaerobe,"Temperature: 38–42°C; pH: 5.5–7.0; Nutritional requirements: rich in amino acids and sugars (lactose, sucrose); Osmotic tolerance: moderate; Growth in milk-based substrates (cow, soy, coconut)","Doubling time: ~6–9 hours (fermentation to pH 5.5); Growth rate in fermented soy/coconut milk ice cream: 1.29 log10 cfu/g (La-05), 1.2 log10 cfu/g (Bb-12); In vivo consistency: Not evaluated; In vitro growth supported by vegetable milk substrates",Gut (implied by probiotic function); Target niche: Intestinal tract,No direct competition/symbiosis data; Probiotic strains may modulate gut microbiota via metabolic activity and immune stimulation,Freeze tolerance: Survives -20°C storage; Shear stress: Tolerated during homogenization and freezing; UV/drying: Not tested; Lyophilization: Not tested,Soy and coconut milk proteins (gel-like network) provide physical protection during freezing,Lactobacillus acidophilus La-05 和 Bifidobacterium bifidum Bb-12 在植物奶（大豆奶、椰奶）冰激凌中表现出比在牛乳冰激凌中更高的生长率。大豆奶和椰奶富含氨基酸和糖类（如乳糖和蔗糖），为益生菌提供了更丰富的生长基质。在冷冻条件下，这两种菌株均能有效存活并增殖，尤其在复合奶（75%大豆奶+25%椰奶）中表现出最佳生长性能。,Not applicable (no genetic modification reported),Not applicable,Constitutive,,High (natural strains; no plasmid or integration reported; stable in ice cream matrix),"Stable in ice cream matrix with stabilizers (carrageenan, guar gum, cellulose gum); physical protection from protein network in soy/coconut milk",未对菌株进行基因改造。益生菌以天然状态使用，其生长和代谢能力依赖于基质中的营养成分（氨基酸和糖类）。在冰激凌中，菌株通过自然代谢活动实现增殖，无需人工调控电路。,"[""pH"", ""Temperature""]","[""Lactose"", ""Sucrose""]",,,"FNR promoter (inferred from pH-responsive growth), Lactose permease (for sugar uptake)",Constitutive expression; No reported logic gates or threshold control; Growth triggered by nutrient availability and pH drop,菌株通过感知基质中的乳糖和蔗糖浓度以及pH变化启动代谢活动。当pH降至5.5时，表明发酵完成，菌体进入稳定期。无外部诱导或复杂逻辑控制，为自然生长响应机制。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Lysis (inferred from natural release during growth and death in matrix),Natural growth-dependent; No external control; Output strength proportional to substrate availability,"High compatibility with ice cream matrix; Stabilizers (carrageenan, guar gum) and protein network enhance retention and protection",True,False,False,"Lactobacillus acidophilus and Bifidobacterium bifidum produce lactic acid during fermentation, lowering pH and inhibiting pathogenic bacteria.",Lactic acid,False,True,True,True,菌株在冰激凌中发酵产生乳酸，降低pH至5.5，抑制潜在病原体生长；未观察到过度酸化或基质破坏，且在-20°C下稳定，表明局部作用且安全。,False,,,False,False,False,未涉及氧气生成机制。,True,益生菌通过调节肠道免疫系统，增强宿主免疫反应，可能通过分泌细胞因子或调节T细胞活性实现。,"Cytokines (e.g., IL-10, IFN-γ) (inferred from probiotic function)",False,,,True,益生菌代谢乳糖和蔗糖，产生短链脂肪酸（SCFAs）等代谢产物，调节宿主能量代谢和肠道健康。,"Short-chain fatty acids (SCFAs) (e.g., acetate, propionate) (inferred from lactic acid fermentation)",False,,,GRAS,None (natural strains; no kill-switch or auxotrophy reported),,Low pathogenicity; No antibiotic resistance genes reported; No horizontal gene transfer risk; Environmental escape unlikely due to food vehicle and freezing,Physical confinement by ice cream matrix and packaging; Freezing at -20°C reduces viability and limits environmental release,Lactobacillus acidophilus La-05 和 Bifidobacterium bifidum Bb-12 均为公认安全（GRAS）菌株，广泛用于食品中。未进行基因改造，无生物安全风险。在冰激凌中冷冻储存可有效抑制其活性，防止环境释放。,在发酵植物奶冰激凌中，La-05 和 Bb-12 的活菌数显著高于牛乳冰激凌（p < 0.05）。其中，大豆奶冰激凌中 La-05 增长 1.29 log10 cfu/g，Bb-12 增长 1.2 log10 cfu/g；复合奶（75%大豆奶+25%椰奶）中 La-05 和 Bb-12 分别增长 1.55 和 1.07 log10 cfu/g。植物奶富含氨基酸和糖类，显著促进益生菌生长，表明其作为益生菌递送载体具有优异潜力。,12681,1964,14645,,
4c865a33-652a-43df-a3bc-70498a5e5448,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei 431"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum PCC"", ""strain_id"": """"}]",Suspension,Facultative Anaerobe,"Growth at 37°C, pH ~6.5–7.0, in milk-based medium with glucose and sucrose; requires lactose and other fermentable carbohydrates",Doubling time ~1.5–2 hours in vitro; in vivo colonization likely sustained over 12-week period with daily intake,"Gastrointestinal tract (colonization of gut mucosa, particularly in the small intestine and colon)",Competitive exclusion of pathogens via binding site competition and nutrient competition; no significant disruption of native microbiota observed,"Tolerant to lyophilization (stored at -18°C), refrigeration (4°C), and moderate gastric acidity; moderate tolerance to bile salts","Bile salts (natural tolerance), lyophilization (stabilized by freeze-drying process)",该益生菌群由三种乳杆菌组成，均为兼性厌氧菌，可在37°C下在乳制品基质中生长。它们能耐受冷冻干燥和冷藏储存，具有一定的胃酸和胆汁耐受性，可在肠道黏膜定植，通过竞争性排斥机制抑制病原体定植。,Not specified (no genetic modification reported),"Not applicable (natural strains used, no editing)",Constitutive (no inducible circuits reported),,High (no plasmid loss or instability reported; strains maintained at ≥3×10⁶ CFU/mL after 28 days storage),Stable in yogurt matrix; no significant loss of viability during fermentation and storage,该系统未进行基因工程改造，使用天然来源的乳杆菌菌株，通过常规发酵工艺制备成酸奶饮料，菌株在基质中保持稳定，无需外源遗传元件。,"[""pH"", ""Glucose"", ""Bile acids""]","[""Lactose"", ""Sugars (glucose, sucrose)""]",,,"Natural metabolic sensors (e.g., sugar transporters, pH-responsive promoters in Lactobacillus)",Constitutive expression; no reported logic gates or threshold control,该系统依赖于天然代谢感应机制，如葡萄糖和乳糖的转运系统，以及对pH和胆汁酸的自然响应，无人工设计的逻辑门控或动态调控。,"[""Immunomodulation""]",Natural secretion (via cell lysis or constitutive release of immunomodulatory molecules),Daily oral intake (150 mL/day); controlled by consumption frequency and dose,Highly compatible with yogurt matrix; stable during fermentation and refrigerated storage,False,False,False,Not applicable (no direct antibacterial mechanism reported),,False,False,False,False,无,False,Not applicable (no oxygen-producing enzymes or systems reported),,False,False,False,无,True,"Stimulates Th1 immune response by increasing serum IFN-γ and fecal sIgA levels; enhances mucosal and systemic immunity without affecting Th2 cytokines (IL-4, IL-10) or IgA/IgG/IgM levels.","IFN-γ, secretory IgA (sIgA)",False,Not applicable (no direct tissue repair or regeneration reported),,False,Not applicable (no metabolic regulation via SCFAs or tryptophan metabolites reported),,False,Not applicable (no tumor-targeting or prodrug conversion reported),,GRAS,"None (natural strains, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; minimal environmental escape risk due to lack of persistence outside host,Yogurt matrix provides physical confinement; no engineered containment required,该益生菌群为公认安全（GRAS）菌株，未进行基因改造，无致病性、抗生素抗性或基因水平转移风险，且在体外环境中难以长期存活，安全性高。,该益生菌组合显著降低了上呼吸道感染的发生率（p < 0.023），减少了发热性流感样症状（p < 0.034），并显著提高了血清IFN-γ水平（p < 0.001）和粪便sIgA水平（p < 0.001），表明其在增强宿主免疫系统方面具有显著疗效。,12332,1647,13979,,
36705a40-150f-4d33-a918-468b728afd05,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""NIZO9000""}]",Encapsulated,Facultative Anaerobe,"Optimal temperature: 30–37°C; pH 5.5–6.5; tolerant to moderate salt and bile; grows on lactose, glucose, and other sugars",Doubling time ~30–60 min in vitro; stable in vivo colonization in gut microbiota,Gut mucosal surface,Competitive exclusion of pathogens; synergistic with host microbiota; minimal disruption to native flora,"Tolerant to freeze-drying, lyophilization, and moderate shear stress; stable during storage at 4°C","Trehalose, alginate, chitosan (used in encapsulation)",Lactococcus lactis 是一种革兰氏阳性、兼性厌氧、非产孢的球菌或短杆状细菌，广泛用于食品发酵。其在30–37°C、pH 5.5–6.5条件下生长良好，对乳糖、葡萄糖等碳源利用能力强，具有较强的耐酸和耐胆盐能力，可在肠道黏膜表面定植并维持稳定，是理想的益生菌底盘菌株。,"Electroporation with self-replicating vectors, NICE system (nisin-induced expression)",High efficiency (>90% transformation); low off-target risk due to chromosomal integration and controlled promoter use,"Inducible (nisin), controlled expression via synthetic promoters",Nisin (bacteriocin),High plasmid stability (pNICE vector); chromosomal integration reduces loss rate; low metabolic burden; evolutionarily stable in gut environment,Stable in alginate/chitosan microcapsules; maintains function during encapsulation and release,通过电穿孔将自复制质粒导入Lactococcus lactis，利用NICE（nisin诱导表达系统）实现基因的可控表达。该系统基于nisin诱导的启动子，可实现外源基因的精确调控，广泛用于维生素B族和低热量糖类的高效合成。,"[""pH"", ""Lactose"", ""Glucose""]","[""Bile acids"", ""Lactate""]",,,"Lactose operon promoter, NICE promoter",Constitutive baseline with inducible amplification; threshold-controlled by nisin concentration,Lactococcus lactis 通过乳糖操纵子启动子感知乳糖水平，同时利用NICE系统响应nisin诱导信号，实现基因表达的可编程控制。系统具有阈值响应特性，仅在达到一定nisin浓度时启动表达，避免非必要代谢负担，具备噪声抑制能力。,"[""Nutraceutical Production"", ""Antibacterial"", ""Immunomodulation""]","Type I secretion (for nisin), extracellular release of metabolites",Controlled by nisin concentration; tunable via induction level,"High compatibility with alginate, chitosan, and carrageenan microcapsules; permeable to nutrients and metabolites",True,True,False,"Produces bacteriocins (e.g., nisin) and organic acids that disrupt pathogen membranes and lower pH","Nisin, lactic acid",True,True,True,True,Nisin is GRAS-approved and selectively targets Gram-positive pathogens without harming host cells or beneficial microbiota; effective in food matrices and gut environment.,False,,,False,False,False,No oxygen-producing mechanism reported; not applicable.,True,"Cell wall components (peptidoglycans, teichoic acids) stimulate innate immunity and enhance mucosal barrier function","Peptidoglycans, teichoic acids",False,,,True,"Produces B vitamins (folate, riboflavin, cobalamin) and low-calorie sugars (mannitol, sorbitol) that regulate host metabolism","Folate, riboflavin, cobalamin, mannitol, sorbitol",False,,,GRAS,"Auxotrophy (e.g., requirement for specific amino acids), nisin-induced kill switch",Nisin (inducer for kill switch),Non-pathogenic; no known antibiotic resistance genes; low risk of horizontal gene transfer; no environmental escape reported,Microcapsule barrier (alginate/chitosan) prevents release into environment,Lactococcus lactis 被广泛认为是GRAS级微生物，无致病性，不携带抗生素抗性基因，且通过微胶囊封装和诱导型自杀系统实现生物安全控制，可有效防止其在环境中的扩散，安全性高。,通过代谢工程改造的Lactococcus lactis NIZO9000可高效合成叶酸、核黄素、维生素B12、甘露醇和山梨醇等营养素，显著提升食品的营养价值。其产生的乳酸和nisin可有效抑制沙门氏菌、李斯特菌等食源性病原体，延长食品保质期。在肠道中，该菌株可定植并调节免疫功能，增强黏膜屏障，改善肠道菌群平衡，对腹泻、炎症性肠病和免疫功能低下具有潜在治疗作用。,14559,1749,16308,,
4d51f967-ca46-4c10-b70e-ee9cf3dae408,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""ATCC 314""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.99, in MRS broth under anaerobic conditions; requires peptone and skimmed milk for viability",Doubling time not specified; viable cell count maintained at 1.24 × 10⁸ after lyophilization; sustained release over 6 h in vivo,"Intestinal tract (ileum), particularly in the context of probiotic supplementation for gut health",Supplements intestinal flora; may compete with pathogenic bacteria; no direct interaction with other microbes reported,High tolerance to lyophilization and rehydration; protected by ovalbumin matrix and GMS coating; stable during gastric transit,"Ovalbumin-genipin crosslinked matrix, glyceryl monostereate (GMS) delayed-release coating","Lactobacillus acidophilus ATCC 314 is a facultative anaerobe capable of surviving in simulated gastrointestinal conditions. It is lyophilized and encapsulated in a crosslinked ovalbumin matrix with a delayed-release GMS coating, enabling protection during gastric transit and controlled release in the intestine. The strain maintains viability and functionality over 6 hours post-administration, with maximum viability observed at 6 h in vivo.",Not applicable (no genetic modification reported),N/A,Constitutive (no inducible or synthetic circuit reported),N/A,N/A (no plasmid or chromosomal integration reported; natural strain used),High stability within the ovalbumin-genipin matrix and GMS coating; no genetic drift or loss observed in formulation,The Lactobacillus acidophilus strain is used in its native form without genetic modification. The system relies on physical encapsulation and controlled release via a crosslinked ovalbumin matrix and a delayed-release GMS coating to protect the probiotic from antibiotic exposure and ensure timely intestinal delivery.,"[""pH"", ""Gastric fluid"", ""Intestinal fluid""]",,,,Ovalbumin-genipin crosslinked matrix (structural response to pH and enzymatic environment),"No synthetic logic gates; release is triggered by pH shift (gastric to intestinal) and matrix degradation, functioning as a simple 'AND' gate: pH > 6.8 AND enzymatic exposure","The system uses a pH-responsive release mechanism. The gastro-resistant gelatin capsule protects the formulation in the acidic gastric environment (pH 1.2). Upon reaching the intestinal environment (pH 6.8), the capsule dissolves, and the GMS coating erodes, allowing controlled release of L. acidophilus. This is a passive, environment-triggered release without synthetic sensing circuits.","[""Antibacterial"", ""Tissue Repair""]",Passive release via matrix degradation and capsule dissolution; no active secretion systems reported,Controlled by delayed-release coating (GMS) and matrix crosslinking; release profile follows Korsmeyer-Peppas model with predictable kinetics,High compatibility with ovalbumin-genipin matrix and GMS coating; maintains structural integrity and controlled release,False,False,False,"The system does not directly deliver antibacterial agents; instead, it protects probiotics from antibiotic destruction.",N/A,False,False,False,False,该系统不具有直接抗菌功能，而是通过延迟释放机制保护益生菌免受抗生素破坏，因此不满足抗菌模块的任何标准。,False,No oxygenation mechanism reported.,N/A,False,False,False,系统中未涉及氧气生成或氧合机制，因此不满足氧合模块标准。,False,No immunomodulatory factors secreted.,N/A,True,"Lactobacillus acidophilus restores intestinal flora, supports mucosal barrier integrity, and promotes gut homeostasis, contributing to tissue repair and prevention of antibiotic-associated diarrhea.","Lactobacillus acidophilus (endogenous metabolites, surface proteins, and competitive exclusion)",False,No specific metabolic regulators reported.,N/A,False,No tumor-targeting or prodrug conversion mechanism described.,N/A,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",N/A,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no horizontal gene transfer risk; safe for human consumption,Gastro-resistant gelatin capsule and crosslinked ovalbumin matrix provide physical confinement and protection,"Lactobacillus acidophilus ATCC 314 is a well-characterized, generally recognized as safe (GRAS) strain. It is not pathogenic, does not carry antibiotic resistance genes, and is not known to cause infections in immunocompromised individuals. The physical encapsulation ensures containment during transit, minimizing environmental escape risk.",在大白猪模型中，DBioS系统在口服给药后6小时达到最大Lactobacillus酸杆菌存活率（约455%基线），显著优于同时服用商业抗生素和益生菌产品组（存活率下降75%）。系统实现了96.9%的体外-体内相关性（Level A IVIVC），表明其释放行为可高度预测。益生菌在肠道中成功定植，CFU从基线120 CFU/ml上升至6小时的820 CFU/ml，有效预防了抗生素相关性腹泻。,16168,1788,17956,,
b86a889e-ea6e-40ee-b50d-eb72148a78c6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; resistant to bile and gastric acid; utilizes glucose and other carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; survives intestinal transit but does not permanently colonize in vivo,"Small intestine (duodenum, jejunum), particularly in the context of mucosal adherence",Competes with pathogens for adhesion sites; may modulate resident microbiota by producing lactic acid and bacteriocins,"Resistant to bile, low pH, and drying; stable during freeze-drying and rehydration","Bile salts, gastric acid (HCl), lyophilization agents","L. rhamnosus GG is a facultative anaerobe capable of surviving harsh gastrointestinal conditions. It grows optimally at 37°C and pH 5.5–6.5, with resistance to bile and gastric acid enabling it to reach the small intestine. It does not permanently colonize the gut but persists transiently, contributing to barrier function and immune modulation.",Not explicitly mentioned; likely uses native plasmid systems or chromosomal integration,Not specified,"Constitutive expression of beneficial factors (e.g., adhesion molecules, secreted proteins)",,Stable in vivo for several days; no evidence of plasmid loss or significant drift; low metabolic burden,"No specific material environment described; likely stable in oral formulations (milk, freeze-dried powder)","L. rhamnosus GG is used in its native form without genetic modification in most applications. Its beneficial effects are attributed to intrinsic properties such as adhesion, acid/bile resistance, and immune modulation. No recombinant engineering is described in this paper.","[""pH"", ""Bile""]","[""Glucose"", ""Lactose""]",,"[""Mucin"", ""Epithelial cell surface receptors""]","Adhesins (e.g., p40, p75), bile salt hydrolases, pH-responsive promoters","No complex logic gates reported; likely constitutive or environment-responsive (e.g., pH-dependent gene expression)","L. rhamnosus GG senses environmental cues such as low pH and bile salts via surface receptors and transporters, triggering adaptive responses like acid tolerance and bile resistance. It adheres to intestinal epithelium via specific adhesins, which may be regulated by host mucin and epithelial surface molecules. No synthetic genetic circuits or logic gates are described.","[""Antibacterial"", ""Immunomodulation"", ""Barrier Enhancement""]",Constitutive secretion via general secretory pathway; no specialized secretion systems reported,Dose-dependent effects; efficacy linked to viable cell count (10^10–10^11 CFU/ml),"Compatible with oral formulations (milk, freeze-dried powder); stable in suspension and lyophilized forms",True,False,False,Competitive exclusion of pathogens via adhesion to intestinal epithelium; production of lactic acid and bacteriocins inhibits pathogen growth,"Lactic acid, bacteriocins (e.g., reuterin, lactocin)",False,True,True,True,L. rhamnosus GG inhibits pathogen adhesion in vitro and reduces diarrhea duration in children with rotavirus infection. It does not cause excessive inflammation or tissue damage.,False,,,False,False,False,,True,"Enhances secretory IgA production, promotes regulatory T-cell activity, modulates cytokine profiles (e.g., reduces TNF-α, increases TGF-β)","Secretory IgA, TGF-β, IL-10 (indirectly via host cell induction)",True,Stabilizes intestinal barrier function by enhancing tight junction integrity and mucin expression; reduces intestinal permeability,"Mucin, tight junction proteins (e.g., occludin, ZO-1)",False,,,False,,,GRAS,No engineered kill switches; relies on transient colonization and natural attenuation,,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape,Oral delivery limits systemic spread; gastrointestinal transit limits persistence,"L. rhamnosus GG is classified as GRAS (Generally Recognized As Safe). It is non-pathogenic, does not persist long-term, and has no known antibiotic resistance genes. Its transient nature and lack of genetic modification reduce biosafety risks.","L. rhamnosus GG significantly shortens the duration of acute rotavirus diarrhea in children, reduces recurrence of C. difficile colitis, improves intestinal barrier function in experimental models, and enhances immune responses. It is effective in preventing antibiotic-associated diarrhea and improving symptoms in children with persistent diarrhea and food allergy.",13588,1667,15255,,
9660aa4b-c2d5-4870-b882-df2fd07b83c3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LaVK2""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""BbVK3""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: Acid-tolerant (acid production in gut); Nutrition: Fermentable carbohydrates (lactose, glucose); Bile salt tolerance confirmed",Growth rate: 24 hours at 37°C; Doubling time: ~1.5–2 hours; In vitro growth consistent with in vivo colonization potential,"Colon mucosa, particularly in the distal colon; associated with mucus layer and epithelial crypts",Competitive exclusion of pathogenic bacteria; potential symbiosis with host microbiota; no reported antagonism,"Tolerant to bile salts, low pH (gastric and intestinal), moderate osmotic stress; stable during lyophilization and rehydration","Bile salts, low pH (HCl), lyophilization buffer",该微生物系统由Lactobacillus acidophilus LaVK2和Bifidobacterium bifidum BbVK3组成，均为耐酸、耐胆盐的益生菌，可在37°C下生长，适合在肠道环境中定植。其生长周期约24小时，具有良好的胃肠道耐受性，可在酸性环境和胆盐存在下存活，且在冻干后仍保持活性，适合作为功能性食品载体。,"Not applicable (natural strains, no genetic modification reported)",N/A,Constitutive,N/A,High chromosomal stability; no plasmids reported; no evidence of genetic drift in long-term culture,Stable in fermented milk matrix (Dahi); no degradation or loss of viability during encapsulation,该系统未经过基因工程改造，使用的是天然分离的Lactobacillus acidophilus LaVK2和Bifidobacterium bifidum BbVK3菌株，通过共培养技术整合至Dahi中，保持其天然生理功能，无需外源调控元件。,"[""Low pH"", ""Bile salts"", ""Hypoxia""]","[""Lactose"", ""Glucose"", ""Short-chain fatty acids (SCFAs)""]",,"[""Mucin depletion"", ""Inflammatory cytokines (implied by tissue damage)""]","Acid tolerance genes (e.g., F1F0-ATPase), bile salt hydrolase (BSH), hypoxia-responsive promoters (e.g., fnr-like)",Constitutive expression; no reported synthetic logic gates; response to environmental cues via native regulatory systems,该系统通过天然感知机制响应肠道环境中的低pH、胆盐和缺氧条件，利用酸耐受基因、胆盐水解酶及缺氧感应系统实现定植与功能表达，无需人工设计的逻辑门控，属于基础环境响应型系统。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Constitutive secretion of metabolites (SCFAs), enzymes (BSH, GST), and immunomodulatory factors",Dose-dependent via dietary intake (20 g/day); no external control mechanism,Highly compatible with Dahi matrix; stable during fermentation and storage; no structural disruption observed,False,False,False,N/A,N/A,False,False,False,False,未报告抗菌或抗生物膜功能,False,N/A,N/A,False,False,False,未报告氧气生成功能,True,调节免疫细胞功能，增强巨噬细胞和淋巴细胞活性，提升抗氧化状态，抑制炎症反应,"Cytokines (e.g., IL-10, IFN-γ), antioxidant enzymes (SOD, catalase)",True,促进黏膜屏障修复，减少MDF（黏液缺失灶）形成，增强上皮再生，调节Wnt/β-catenin通路，抑制异常增殖,"Butyrate, SCFAs, MUC2 expression enhancers",True,调节致癌物代谢：抑制肝中细胞色素P450激活酶，上调肝脏和结肠中解毒酶（如GST）；降低β-葡萄糖醛酸酶活性，减少DMH活化；促进短链脂肪酸（SCFA）生成,"Butyrate, Acetate, Propionate",False,N/A,N/A,GRAS,"Auxotrophy (no evidence of auxotrophy reported, but natural attenuation via gut environment)",N/A,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk due to gut-restricted survival,Physical confinement in fermented milk matrix (Dahi) prevents systemic dissemination,该系统由两种公认安全（GRAS）的益生菌组成，未经过基因改造，无致病性、无抗生素抗性基因，且在肠道环境中定植后无法长期存活于外界，具有天然生物安全屏障，结合Dahi基质的物理隔离，整体风险极低。,在DMH诱导的Wistar大鼠模型中，摄入含Lactobacillus acidophilus LaVK2和Bifidobacterium bifidum BbVK3的益生Dahi可显著减少异常隐窝灶（ACF）数量（32周时减少71.9%），降低黏液缺失灶（MDF）发生率（减少52.3%），并显著抑制PCNA增殖指数，效果优于单独使用吡罗昔康（PXC）。联合使用PXC与益生Dahi时，对ACF和MDF的抑制作用呈协同效应，表明该系统在结直肠癌早期预防中具有显著化学预防潜力。,11715,1899,13614,,
db007ef5-7f40-4f94-8d56-60757004257d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Poliovirus"", ""strain_id"": ""High-fidelity polymerase mutant (e.g., L221I, S223T)""}]","Encapsulated (in vivo, within host tissues)",,Temperature: 37°C (in vitro and in vivo); pH: physiological (7.0–7.4); Nutritional requirements: Host cell machinery (no defined media); Osmotic tolerance: Compatible with intracellular environment,"Replication rate: High (typical of RNA viruses); Doubling time: Rapid (hours); In vivo vs in vitro: Similar replication levels in vitro and in vivo, but restricted spread in vivo","Gut (initial site of infection); restricted to original anatomical compartment (e.g., gut, muscle) due to reduced tropism",,High genetic stability upon serial passage; Tolerant to lyophilization (implied by vaccine potential); UV/drying: Not reported,,该系统基于高保真度RNA聚合酶突变的脊髓灰质炎病毒，其在体外和体内均能高效复制，但因基因组多样性降低而丧失向中枢神经系统等远端组织扩散的能力。病毒在感染初始部位（如肠道或肌肉）持续存在，但无法跨组织传播，表现出显著的局限性。,"Site-directed mutagenesis (all possible substitutions at polymerase position), RNAi-based assay for adaptive mutation detection",High: All possible substitutions at target site were generated; No off-target effects reported,Constitutive (viral replication driven by native promoters),,High: Stable upon serial passage; no reversion to wild-type phenotype; chromosomal integration not applicable (viral genome is RNA-based),Stable within host cellular environment; no reported degradation in tissue,通过定点突变改造脊髓灰质炎病毒RNA聚合酶，提高其复制保真度，从而降低病毒群体的序列多样性。该策略使病毒丧失跨组织传播能力，但保留免疫原性，实现安全有效的减毒。,,,,,"Fidelity of RNA polymerase (e.g., L221I, S223T mutations)",No explicit logic gate; phenotype is a direct consequence of reduced sequence diversity,病毒的表型由RNA聚合酶保真度决定，而非响应外部信号。高保真度导致群体多样性下降，从而限制其在宿主体内的扩散能力，形成一种‘被动’的生物控制机制。,"[""Immunomodulation""]",Viral lysis (natural release from infected cells),Intrinsic: Replication level controlled by host cell availability and immune response; no external control,Compatible with host tissue environment; no encapsulation material used,False,,,,,,,,,,False,,,,,,,True,Induces a persistent protective immune response (humoral and cellular) without causing disease.,"Viral antigens (structural proteins: VP1, VP2, VP3, VP4)",False,,,False,,,False,,,BSL-2,Genetic attenuation via high-fidelity polymerase mutation; restricted tropism prevents spread to CNS,"High-fidelity RNA polymerase (e.g., L221I, S223T)",Low pathogenicity; no evidence of reversion to virulence; limited shedding in feces; no antibiotic resistance genes; no horizontal gene transfer reported,None (no physical material barrier; relies on genetic containment),该病毒因高保真度突变导致基因组多样性显著降低，无法在宿主体内扩散至致病部位，因此具有极高的安全性。虽存在潜在回复突变风险，但实验显示其在多次传代后仍保持稳定，且免疫缺陷小鼠模型中未见毒力恢复。,该减毒疫苗在小鼠模型中诱导了持久的保护性免疫反应，病毒在感染部位（如肠道或肌肉）持续存在但不扩散，且在粪便中排泄量低于野生型，表明其具有良好的安全性和免疫原性，是潜在的理想活疫苗候选。,4662,1506,6168,,
3e039d7a-f63f-44f2-9bd2-d401d6d49402,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""C-3102""}]",Suspension,Facultative Anaerobe,"Temperature: 33°C (initial), gradually reduced to 24°C; pH: Not explicitly stated, but intestinal environment assumed; Osmotic: Not specified; Nutrition: Requires standard broiler feed components including corn, soybean meal, wheat, and supplements (vitamins, minerals, amino acids).","Growth rate enhanced in starter and overall periods (ADG increased linearly, P < 0.05); no significant change in feed intake (ADFI).","Intestinal tract (cecum, ileum, large intestine), excreta","Competitive exclusion of pathogens (E. coli, Salmonella, C. perfringens); promotes Lactobacillus proliferation via anaerobic environment creation.","High tolerance to heat, pH extremes, and feed processing due to spore form; resistant to drying and storage.",Spore-forming endospores,"Bacillus subtilis C-3102 spores are metabolically dormant and highly resilient to environmental stressors such as high and low temperatures, and extreme pH. Upon ingestion, they germinate in the intestine, consume oxygen, and create an anaerobic environment that favors the growth of beneficial lactobacilli while inhibiting pathogenic bacteria.",,,,,,,"Bacillus subtilis C-3102 is used as a direct-fed microbial without genetic modification. Its probiotic effects are attributed to natural physiological traits, including spore formation, germination in the gut, and modulation of intestinal microflora.","[""Hypoxia"", ""pH""]","[""Lactate"", ""Glucose""]",,,"Germination triggers in response to intestinal conditions (e.g., nutrients, low oxygen)",No engineered logic gates; natural germination and growth response to intestinal environment.,"Bacillus subtilis C-3102 spores remain dormant during feed processing and storage. Upon reaching the intestinal tract, they sense favorable conditions (nutrients, low oxygen) and germinate. This process is not genetically programmed with inducible circuits but relies on natural environmental sensing and metabolic activation.","[""Antibacterial"", ""Metabolic Regulation""]","Spore germination and natural secretion of enzymes (e.g., proteases, amylases) during growth.","Dose-dependent effects observed (300 and 600 mg/kg feed); linear improvement in ADG, FCR, and microbial balance.",Spores are stable in feed and survive processing; no adverse interaction with feed matrix.,True,True,False,"Reduces pathogenic bacteria (E. coli, Salmonella, C. perfringens) through competitive exclusion and creation of an anaerobic environment favoring lactobacilli.",Lactic acid produced by Lactobacillus (indirect effect),True,True,True,True,"B. subtilis C-3102 significantly reduced E. coli, Salmonella, and C. perfringens counts in cecum, ileum, large intestine, and excreta without causing tissue damage or microbiome disruption. No cytotoxicity or immune activation observed.",False,,,False,False,False,Not applicable – no oxygenation mechanism reported.,False,,,False,,,True,"Improves nutrient digestibility (DM, GE) and reduces ammonia emission via modulation of intestinal microflora and metabolic activity.","Lactic acid (indirectly via Lactobacillus), reduced ammonia (NH₃)",False,,,GRAS,"None (natural strain, no engineered kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape concerns due to lack of persistence in non-host environments.,None (spores are ingested and pass through the gut without confinement),"Bacillus subtilis C-3102 is classified as GRAS (Generally Recognized As Safe) and has been used safely in animal feed since 1986. No adverse effects on blood profiles, organ weights, meat quality, or immune parameters were observed. No evidence of pathogenicity or microbiome disruption.","Bacillus subtilis C-3102 supplementation significantly improved growth performance (increased ADG in starter and overall periods), feed conversion ratio (decreased FCR in grower-finisher and overall periods), nutrient digestibility (higher apparent total tract digestibility of dry matter and gross energy), and reduced ammonia emission in broilers. It effectively modulated intestinal microflora by increasing Lactobacillus and decreasing E. coli, Salmonella, and Clostridium perfringens counts, with no observed side effects.",14058,1654,15712,,
58330f28-0944-42ac-8762-a358c1f982c3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""ATCC-4356""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0 (MRS medium), requires carbon sources (glucose, lactose), amino acids, vitamins (B complex), and growth factors; dependent on host metabolites in GI tract.",Growth rate: ~24 hours to reach stationary phase in MRS broth; doubling time ~60–90 minutes in vitro; in vivo homeostasis not explicitly reported but inferred from GI survival.,"Gastrointestinal tract (small intestine, colon); prefers mucosal surface and nutrient-rich environments.",Competitive exclusion of pathogens; potential symbiosis with commensal microbiota; no direct evidence of antagonism or cooperation with other strains.,"Moderate tolerance to osmotic stress, bile salts (in vitro), and low pH; enhanced tolerance via encapsulation.",Sodium alginate and carrageenan hydrogel matrices,"Lactobacillus acidophilus ATCC-4356 is a facultative anaerobe that grows optimally at 37°C in MRS medium. It requires complex nutrients including carbohydrates, amino acids, and vitamins. The strain exhibits moderate intrinsic resistance to acidic and bile conditions but shows significantly improved survival under simulated gastrointestinal and thermal stress when encapsulated in sodium alginate or carrageenan hydrogels.",,,,,,,No genetic modifications were performed. The strain was used in its native form; all functional improvements were achieved through physical encapsulation in hydrogel matrices without genetic engineering.,"[""Low pH (gastric conditions)"", ""High pH (intestinal conditions)"", ""Bile salts"", ""Thermal stress (65°C)""]","[""Glucose"", ""Lactose"", ""Amino acids"", ""Vitamins (B complex)""]",,,"Native membrane transporters and stress response systems (e.g., acid tolerance response, bile efflux pumps)","No engineered logic gates; natural physiological responses to environmental cues (e.g., acid resistance, bile tolerance).","L. acidophilus naturally senses and responds to changes in pH, bile salts, and temperature through intrinsic regulatory systems. It activates acid tolerance mechanisms in low pH environments and bile efflux pumps in intestinal conditions. These responses are not programmable but are inherent to the strain’s physiology.","[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Passive diffusion and cell lysis (natural release from encapsulated beads),Controlled by encapsulation matrix degradation rate and release kinetics; no external control mechanism.,High compatibility with sodium alginate and carrageenan matrices; maintains structural integrity and allows gradual release of viable cells.,True,False,False,Produces lactic acid and bacteriocins that inhibit pathogenic bacteria in the gut; enhances gut barrier function.,"Lactic acid, bacteriocins (e.g., acidocin)",False,True,True,True,"Encapsulation protects L. acidophilus from gastric acid and bile, enabling sustained delivery to the intestine where it exerts antibacterial effects via lactic acid and bacteriocin production. No evidence of excessive activity or tissue damage.",False,,,False,False,False,,True,"Modulates immune responses by stimulating dendritic cells and macrophages, promoting anti-inflammatory cytokine production (e.g., IL-10), and enhancing IgA secretion.","Cell wall components (peptidoglycan, teichoic acids), exopolysaccharides",False,,,True,"Produces short-chain fatty acids (SCFAs) such as acetate and lactate, which regulate host metabolism, energy homeostasis, and gut barrier integrity.","Acetate, lactate",False,,,BSL-1,"None (native strain, no engineered kill switches)",,Non-pathogenic; no known virulence factors; no antibiotic resistance genes reported; low risk of horizontal gene transfer; GRAS status.,Hydrogel matrix (sodium alginate/carrageenan) provides physical confinement and limits environmental escape.,"L. acidophilus ATCC-4356 is a well-characterized, non-pathogenic, GRAS strain with no known risks of infection or antibiotic resistance. Encapsulation further reduces the risk of environmental release. No biocontainment systems were used, but the physical barrier of the hydrogel matrix provides sufficient safety for use in food and supplements.","Encapsulation significantly enhanced the survival of L. acidophilus under simulated gastrointestinal conditions (from 3.11 log cfu/g to 6.26 log cfu/g in gastric juice and 2.85 log cfu/g to 6.84 log cfu/g in intestinal juice) and under thermal stress (65°C for 45 minutes). Viability remained above 10⁶ cfu/g after 15 days of refrigeration, meeting the recommended threshold for probiotic efficacy. The hydrogel matrices (sodium alginate and carrageenan) provided effective protection, ensuring target delivery and sustained functionality in the gut.",10838,1725,12563,,
2ff416c3-1708-4fb6-b0d9-89a6f5e46a0c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""GM strain with thyA–IL10 fusion""}]",Encapsulated (in gut mucosa after ingestion),Facultative Anaerobe,"Optimal growth at 30–37°C, pH 6.0–7.0; thrives in dairy environments and intestinal tract; requires thymine for growth in vitro",Moderate growth rate; doubling time ~60–90 min in vitro; survives in gut but does not colonize long-term in vivo,"Gut mucosa (large intestine), transient presence",Non-colonizing; minimal competition with native microbiota; probiotic-like interaction without persistent colonization,Tolerant to gastric acidity and bile salts; sensitive to thymine depletion and environmental stressors outside host,Thymidylate synthase (thyA) gene deletion renders strain vulnerable to thymineless death,该工程菌为乳酸乳球菌（Lactococcus lactis），属于兼性厌氧菌，可在30–37°C、pH 6.0–7.0条件下生长，具有良好的胃酸和胆汁耐受性，能存活于肠道黏膜但不长期定植。其生长依赖于胸腺嘧啶，一旦脱离宿主环境（缺乏胸腺嘧啶），将因胸腺嘧啶缺乏死亡，从而限制其在环境中的存活能力。,Chromosomal integration via homologous recombination; thyA gene replaced with hIL-10 gene,High efficiency due to targeted integration; no off-target risk reported,Constitutive (hIL-10 expression driven by native promoter),None (constitutive expression),High chromosomal stability; no plasmid-based vectors; deletion of thyA prevents reversion; no antibiotic resistance genes,Stable in gastrointestinal environment; no degradation due to material interactions,通过将人源白细胞介素10（hIL-10）基因插入乳酸乳球菌的胸苷酸合成酶（thyA）基因位点，实现基因组稳定整合。该策略避免使用质粒、抗生素抗性基因或载体序列，确保遗传元件无法通过水平基因转移传播。,,,,,None (no engineered sensing module),None (no logic circuitry),该系统未设计任何响应环境信号的传感模块，其hIL-10表达为组成型，不依赖外部信号触发。,"[""Immunomodulation""]",Constitutive secretion via general secretory pathway,Constitutive; dosage determined by bacterial load and persistence in gut,Compatible with gastrointestinal mucosal delivery; no structural disruption reported,False,,,无抗菌功能,,False,False,False,False,无抗菌相关描述,False,无氧合功能,,False,False,False,无氧合相关描述,True,工程菌在肠道内持续分泌人源白细胞介素10（hIL-10），调节免疫反应，减轻炎症，适用于炎症性肠病（IBD）治疗。,Human Interleukin-10 (hIL-10),False,无组织修复功能,,False,无代谢调控功能,,False,无肿瘤治疗功能,,BSL-1,Auxotrophy (thyA gene deletion); thymine dependence; suicide via thymineless death,Thymine (required for survival),Low pathogenicity; no antibiotic resistance genes; no horizontal gene transfer risk due to absence of vector sequences; reversion to wild-type phenotype would result in loss of hIL-10 gene,Physical confinement via host gut environment; no environmental persistence,该工程菌因thyA基因缺失而无法在无胸腺嘧啶的环境中生存，且即使通过同源重组恢复thyA基因，也会同时丢失hIL-10基因，因此无法恢复为功能型转基因菌。该设计极大降低了环境逃逸和基因水平转移的风险，符合GRAS（公认安全）标准。,在猪模型中成功实现肠道内治疗性IL-10的递送，表明其在炎症性肠病（IBD）治疗中具有潜力。该系统在人体临床试验前已通过动物实验验证其安全性和有效性，为未来人类应用提供了坚实基础。,5194,1551,6745,,
f831461b-e5e3-44d3-881b-929bfc438e28,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LA-14""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""LC-11""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""LL-23""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""BL-04""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""BB-06""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, tolerance to bile salts and gastric acidity; requires glucose and amino acids as carbon and nitrogen sources.",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed after daily oral intake over 60 days.,"Gastrointestinal tract (small intestine and colon), particularly in mucosal layers and crypts.",Symbiotic with host microbiota; competes with pathogenic bacteria for adhesion sites and nutrients; enhances microbial diversity.,"High tolerance to freeze-drying, rehydration, and storage at room temperature for up to 12 months; resistant to moderate shear stress and gastric acid.",Freeze-dried formulation with maize starch and maltodextrin as stabilizers,该混合益生菌由五种冻干菌株组成，均为兼性厌氧菌，可在人体肠道环境中定植并维持稳定生长。其最佳生长温度为37°C，pH值范围为6.5–7.0，对胃酸和胆汁具有较强耐受性，能利用葡萄糖和氨基酸作为碳氮源。在体外培养中，倍增时间为1.5–2小时；在体内经每日口服60天后可实现稳定定植。主要定植于小肠和结肠黏膜层及隐窝区域，与宿主肠道菌群呈共生关系，通过竞争性抑制病原菌定植，促进肠道菌群多样性。冻干制剂在室温下可稳定保存12个月，对剪切力和胃酸具有较强耐受性。,"None (natural strains, no genetic modification reported)",Not applicable,Constitutive,,High chromosomal stability; no plasmids reported; no evidence of genetic drift or loss of viability during 60-day supplementation.,Stable in freeze-dried sachet formulation with maize starch and maltodextrin; no degradation during storage or rehydration.,本研究中使用的益生菌为天然菌株，未进行任何基因工程改造。各菌株均以天然形式存在，通过其固有代谢和定植能力发挥功能。在冻干制剂中保持稳定，无质粒或外源基因，遗传稳定性高，长期口服未见功能丧失或变异。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""Short-Chain Fatty Acids (SCFAs)""]","[""Quorum Sensing (AHL)""]","[""Proteases"", ""Cytokines (TNF-α, IL-6)""]","FNR promoter (hypoxia), Lactate permease (LacY), Bile acid receptors (BaiR), Quorum sensing receptors (LuxR-type)",AND gate: requires both low pH and presence of lactate for optimal colonization; threshold-based activation of immune modulation pathways.,该益生菌混合系统通过多种传感器感知肠道微环境信号，包括pH值、乳酸、胆汁酸和短链脂肪酸。在低pH和乳酸存在条件下，通过FNR启动子和LacY转运蛋白协同激活定植相关基因。同时，通过LuxR型受体感知群体感应分子（AHL），实现菌群间通讯。在宿主免疫信号（如TNF-α、IL-6）存在时，触发免疫调节通路，形成AND逻辑门控，确保仅在炎症微环境中激活功能，避免非特异性反应。,"[""Immunomodulation"", ""Oxidative/Nitrosative Stress Regulation""]",None (natural secretion of metabolites and immune modulators),Dose-dependent effect via daily oral intake (10^9 CFU/g per strain); no external control mechanism.,High compatibility with freeze-dried sachet formulation; stable during encapsulation and rehydration.,False,,,Not applicable,,False,False,False,False,未报告抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未报告氧气生成功能。,True,"Modulates immune response by promoting regulatory T cell (Treg) differentiation, increasing IL-10 production, and suppressing pro-inflammatory cytokines (TNF-α, IL-6).","IL-10, Treg cells (Foxp3+), TGF-β",False,Not applicable,,True,"Enhances production of short-chain fatty acids (SCFAs) such as butyrate and acetate, which regulate host metabolism and immune function.","Butyrate, Acetate, Propionate",False,Not applicable,,GRAS,"None (natural strains, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; no environmental escape risk due to natural attenuation.,Physical confinement via oral ingestion and intestinal mucosal barrier; no systemic dissemination observed.,所用五种益生菌均为公认安全（GRAS）菌株，未进行基因改造，无致病性、无抗生素抗性基因，无水平基因转移风险。在口服后主要定植于肠道，通过天然屏障限制其扩散，无环境逃逸风险。,该混合益生菌在60天干预后显著降低RA患者血浆中TNF-α（p=0.004）和IL-6（p=0.039）水平，减少硝酸盐/亚硝酸盐（NOx）代谢物（p=0.004），并提高血浆总抗氧化能力（TRAP，p=0.019）和蛋白质巯基（SH，p=0.028）水平。但对DAS 28评分、CRP、ESR、脂质过氧化物（LOOH）和蛋白质羰基（PC）无显著影响。表明其在调节炎症和氧化/硝化应激方面具有部分疗效，但未显著改善临床疾病活动度。,10061,2109,12170,,
f15eec85-cadc-4f72-8677-c753be4fd084,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""IM55""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""IM76""}]",Suspension,Facultative Anaerobe,"37°C, pH 7.0, in general probiotic culture broth with 1% glucose or 20 mM phosphate buffer","Optimal growth at OD600 0.8–1.0, cultured for 24 hours at 37°C","Gut mucosa, particularly colon and intestinal lumen","Restores gut microbiota balance by increasing Bacteroidetes and Actinobacteria, reducing Proteobacteria","Tolerant to centrifugation (10,000 × g, 20 min), saline washing, and storage in glucose/phosphate buffer","1% glucose, 20 mM phosphate buffer (pH 7.0)",Bifidobacterium longum IM55 和 Lactobacillus plantarum IM76 均为从人粪便和泡菜中分离的益生菌，可在37°C、pH 7.0条件下在通用培养基中生长，通过离心和缓冲液洗涤后用于体内实验，具有良好的肠道定植潜力和环境适应性。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及对菌株进行基因改造，所有功能均基于天然菌株的生理特性，未使用CRISPR、质粒或诱导系统等工程化工具。,"[""pH"", ""Glucose""]","[""Short-chain fatty acids (SCFAs)"", ""Bile acids""]","[""Quorum sensing (indirectly via microbiota modulation)""]","[""Cytokines (IL-4, IL-5, IL-10)"", ""Tissue degradation fragments (via inflammation)""]",Not specified,Not specified,未明确描述传感逻辑，但通过调节Th2/Treg平衡和免疫细胞浸润，表现出对炎症微环境的响应性调节能力。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]",Not specified,Oral administration at 1×10⁹ CFU/mouse/day for 5 days,Compatible with oral suspension delivery; no encapsulation mentioned,False,,,Not applicable,,,,,,未涉及抗菌或抗生物膜功能。,False,Not applicable,,,,,未涉及氧气生成或氧合功能。,True,通过抑制Th2细胞分化、促进Treg细胞分化，调节IL-4、IL-5、IL-10等细胞因子表达，恢复Th2/Treg平衡，减轻过敏性鼻炎症状。,"IL-4, IL-5, IL-10, Foxp3, GATA3",True,通过抑制鼻腔和肺部上皮细胞的破坏与水肿，促进组织结构修复，改善炎症性损伤。,"IL-10, Foxp3, GATA3",True,通过调节肠道菌群组成（增加Bacteroidetes、Actinobacteria，减少Proteobacteria），恢复肠道代谢稳态，间接调控宿主免疫代谢。,Short-chain fatty acids (SCFAs),False,Not applicable,,GRAS,Not applicable,Not applicable,No pathogenicity reported; no antibiotic resistance genes mentioned; low risk of horizontal gene transfer; no environmental escape reported.,Oral administration with natural gut colonization; no physical barrier used.,Bifidobacterium longum IM55 和 Lactobacillus plantarum IM76 均为公认安全（GRAS）的益生菌，未发现致病性、抗生素抗性基因或水平基因转移风险，口服给药后在肠道定植，安全性高。,IM55、IM76及二者混合物（PM）显著减轻了OVA诱导的小鼠过敏性鼻炎症状，包括打喷嚏、鼻搔抓次数减少；降低鼻腔和血清中IgE、IgG1、IL-4、IL-5水平；抑制嗜酸性粒细胞、肥大细胞和Th2细胞浸润，增加Treg细胞数量；恢复Th2/Treg平衡；改善肺部和鼻腔组织病理损伤；调节肠道菌群结构，恢复Bacteroidetes和Actinobacteria丰度，抑制Proteobacteria过度增殖。,13572,1636,15208,,
af8fc8ce-bcc4-4b3c-896b-c933069e0b37,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, requires carbohydrates (e.g., lactose) as carbon source; tolerates mild bile acid exposure in the small intestine",Doubling time ~1–2 hours in vitro; in vivo colonization is transient and dependent on dietary substrate availability,"Small and large intestine (luminal surface of mucosa, particularly colon)",Competitive exclusion of pathogenic bacteria; potential symbiosis with host immune system via modulation of mucosal immunity,Moderate tolerance to gastric acid and bile; limited survival under drying or UV stress; stable during refrigerated storage,"Cell wall components (e.g., teichoic acids), extracellular polysaccharides",该微生物系统为乳酸菌类（如乳杆菌属和双歧杆菌属），属于兼性厌氧菌，适宜在37°C、pH 6.0–7.0的环境中生长，依赖乳糖等碳源。在肠道中可定植于小肠和大肠黏膜表面，具有一定的耐酸耐胆盐能力，但长期定植能力有限，主要依赖饮食中乳糖供给维持活性。,Not specified,,Not specified,,Not specified,Not specified,文中未提及对所用益生菌进行基因改造，其功能主要依赖于天然代谢特性，如乳糖发酵能力。,"[""pH"", ""Lactose""]","[""Lactose"", ""Bile Acids""]",,,"Lactose permease (LacS), Lactase (β-galactosidase)",Constitutive expression of lactose metabolism genes upon lactose presence; threshold-based induction via Lac operon-like regulation,益生菌通过乳糖转运蛋白（LacS）感知乳糖存在，并启动β-半乳糖苷酶表达，实现乳糖代谢的自适应调控。该系统具有阈值响应特性，仅在乳糖浓度达到一定水平时激活，避免无效代谢消耗。,"[""Metabolic Regulation""]","Passive diffusion, extracellular release",Dose-dependent effect; efficacy influenced by daily intake amount and duration,Compatible with oral delivery; limited stability in gastrointestinal tract due to gastric acid and bile,False,,,,,,,,,,False,,,,,,,True,"Modulates mucosal immune responses by interacting with dendritic cells and regulatory T cells, reducing pro-inflammatory cytokine production.","Secreted metabolites (e.g., SCFAs), surface proteins (e.g., p40, p75)",False,,,True,"Metabolizes lactose into lactic acid, improving lactose digestion and reducing symptoms of lactose maldigestion.",Lactic acid,False,,,GRAS,"None (natural strains, no engineered kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; minimal risk of horizontal gene transfer; no evidence of environmental escape,Gastrointestinal tract mucosal barrier provides physical confinement,所用益生菌为公认安全（GRAS）菌株，无基因工程改造，不携带耐药基因，无致病性，且在肠道内定植为短暂性，不会长期滞留，因此生物安全风险极低。,在一项针对10名乳糖不耐受成人的小型研究中，每日摄入1g或4g商业益生菌混合物17天后，对乳糖呼气氢试验结果无显著改善，提示其在缓解乳糖消化不良方面效果有限。然而，研究者指出该研究样本量小，可能存在II型统计误差，且未设安慰剂对照组，因此不能完全排除益生菌潜在作用。未来研究需结合更敏感的指标（如粪便β-半乳糖苷酶活性）评估其定植与代谢功能。,4099,1529,5628,,
f18f55ee-7e0e-4c0c-babe-b8f966ef5029,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""S12""}]",Suspension,Facultative Anaerobe,"Temperature: 30°C; pH: 5.7–7.8; Salinity: up to 7% NaCl; Carbon sources: glucose, xylose, arabinose, mannitol; Growth on TSB with 1.5% NaCl",Growth rate: Not explicitly quantified; Doubling time: Not provided; In vitro growth confirmed at 30°C under aerobic conditions,Gastrointestinal tract of healthy white shrimp (Litopenaeus vannamei),"Competitive exclusion of pathogens (e.g., Vibrio harveyi, Aeromonas spp.) via antimicrobial activity; no direct evidence of symbiosis or colonization persistence beyond dietary supplementation","Heat stable (80°C for 10 min); Spore-forming (resistant to drying, UV, and environmental stress); Tolerant to 7% NaCl and pH 5.7",Spores,该菌株为芽孢杆菌，具有良好的耐热性（80°C 10分钟）和耐盐性（7% NaCl），可在30°C、pH 5.7–7.8条件下生长，属于兼性厌氧菌，能形成芽孢，具有较强的环境适应能力，适合在水产养殖饲料中作为益生菌使用。,,,,,,,该研究未对菌株S12进行基因改造，其益生功能源于天然的抗菌活性和免疫调节能力，未使用任何遗传工具或合成回路。,,,,,,,该研究未涉及微生物对环境信号的感知或逻辑控制机制，未构建任何传感模块。,"[""Antibacterial"", ""Immunomodulation""]",Secretion via general secretion pathway (likely Type I or non-classical secretion); no evidence of lysis or vesicle release,Dose-dependent immune enhancement; optimal dose at 5×10¹⁰ cfu/kg diet,Compatible with feed matrix; stable during pelleting and storage at -20°C,True,True,False,通过分泌抗菌物质抑制多种水产病原菌的生长，包括革兰氏阴性菌（如Vibrio harveyi、Aeromonas spp.）和部分革兰氏阳性菌。,"Antimicrobial compounds (e.g., subtilin, bacitracin, other bacteriocins)",True,True,True,True,该菌株对9种常见水产病原菌（包括Vibrio harveyi、Aeromonas hydrophila等）均表现出显著抑制作用，抑制圈直径达13.9–30.5 mm，且在饲料中添加后未观察到对宿主的毒性或微生物群落失衡，表明其具有良好的安全性和可控性。,False,,,False,False,False,,True,通过增强宿主非特异性免疫反应，提高血细胞数量（THC）、吞噬率、溶菌酶（LZ）、超氧化物歧化酶（SOD）和抗菌活性，从而提升对病原体的抵抗力。,"Immune-stimulating metabolites (e.g., EPS, peptidoglycan fragments, secreted enzymes)",False,,,False,,,False,,,GRAS,"None (natural strain, no synthetic kill switches or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; environmental escape unlikely due to non-native habitat and lack of persistence data,Feed matrix provides physical confinement; no encapsulation or barrier system used,Bacillus subtilis S12为从健康对虾肠道分离的天然菌株，具有GRAS（公认安全）地位，未进行基因改造，无抗生素抗性基因，不具致病性，且在养殖环境中无长期定植能力，风险极低。,在8周喂养试验中，添加5×10¹⁰ cfu/kg饲料的S12组（PS2）对Vibrio harveyi感染的相对保护率（RPS）达到51.9%，与抗生素组（47.9%）无显著差异，且显著高于对照组（83.3%死亡率），表明其具有与抗生素相当的疾病抵抗力。同时，该菌株显著提高虾体免疫指标（如SOD、溶菌酶、抗菌活性），并降低体脂含量，促进健康生长。,16427,1611,18038,,
cce69940-c6bd-4aaf-9571-57eb9a230b2f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCFM""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""Bi-07""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""Bl-04""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei subsp. paracasei"", ""strain_id"": ""CRL-431""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""PRSF-L477""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 17938""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""CECT5713""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus salivarius"", ""strain_id"": ""K12""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus polyfermenticus"", ""strain_id"": ""SCD""}, {""role"": ""Chassis"", ""scientific_name"": ""Weissella cibaria"", ""strain_id"": ""JW15""}, {""role"": ""Chassis"", ""scientific_name"": ""Butyricicoccus pullicaecorum"", ""strain_id"": ""25-3T""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus johnsonii"", ""strain_id"": ""N6.2""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""2C""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""46""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerant to bile salts and gastric acidity; utilizes glucose and lactose as carbon sources; requires vitamins and amino acids for growth.",Doubling time ~1–2 hours in vitro; in vivo colonization is transient and limited to the gastrointestinal tract; no sustained in vivo growth observed.,Gastrointestinal tract (small and large intestine); preferentially colonizes mucosal surfaces and gut lumen.,Competitive exclusion of pathogenic bacteria; minor symbiotic interactions with resident microbiota; no significant disruption of core microbiome composition reported.,Moderate tolerance to drying and lyophilization; sensitive to high temperatures (>50°C) and UV radiation; stable during storage at 4°C for up to 12 months.,Capsule or powder formulation provides protection against gastric acid and bile.,这些益生菌均为革兰氏阳性、兼性厌氧菌，可在人体肠道环境中定植，但定植能力有限且多为暂时性。它们对胃酸和胆汁具有一定的耐受性，可在肠道内利用葡萄糖和乳糖等碳源生长，但对营养需求较高，需依赖宿主提供的维生素和氨基酸。,None reported,Not applicable,Constitutive,,Chromosomal integration not reported; plasmid-based systems not used; no evidence of genetic drift or instability in clinical trials.,"No genetic modifications; stability in delivery matrices (capsules, powders) is maintained via physical protection.",所有研究中使用的益生菌均为天然菌株，未经过基因工程改造。其功能依赖于天然代谢通路和宿主-微生物互作，无外源基因插入或调控回路设计。,"[""pH"", ""Bile Acids"", ""Glucose"", ""Lactate""]","[""Lactate"", ""Bile Acids"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases"", ""Tissue degradation fragments""]","FNR promoter, Lactate receptor, Bile acid transporter, Quorum sensing receptors (e.g., LasR, LuxR)",No engineered logic gates; natural sensing via receptor-ligand binding with threshold responses; no noise filtering or signal amplification reported.,这些益生菌通过天然受体感知肠道内的pH、胆汁酸、乳酸等理化信号，以及宿主免疫因子和微生物群落信号。其响应为非编程性、基础性的生理反应，无人工设计的逻辑门控或动态调节机制。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type IV secretion system, Lysis, Vesicles",Dose-dependent effects observed; no precise control over output strength.,"Compatible with capsule, powder, and sachet delivery systems; no structural disruption reported.",False,False,False,No direct antibacterial or biofilm inhibition mechanisms reported.,,False,False,False,False,未报告任何抗菌或抗生物膜活性。,False,No oxygen-producing enzymes or mechanisms reported.,,False,False,False,未发现任何产氧机制，不适用于缺氧环境治疗。,True,通过调节T细胞亚群、NK细胞活性、细胞因子平衡（如IL-10升高、IL-12/IL-10比值下降）实现免疫调节，增强抗炎反应。,"IL-10, IL-12, TNF-α, IFN-γ, IgG, CD4+/CD8+ T cells, NK cells",False,未报告促进血管生成、上皮再生或基质重塑的直接机制。,,True,通过调节短链脂肪酸（SCFAs）产生、色氨酸代谢及葡萄糖稳态影响宿主代谢功能。,"SCFAs (acetate, propionate, butyrate), Tryptophan metabolites, Glucose",False,未涉及肿瘤免疫激活、前药转化或原位毒素激活。,,GRAS,None reported,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape.,Capsule and powder formulations provide physical containment.,所有研究中使用的益生菌均为公认安全（GRAS）菌株，无致病性记录，未检测到耐药基因，且在人体内定植短暂，无长期生态风险。物理封装形式进一步增强了生物安全性。,在健康成年人中，口服益生菌补充剂对循环免疫和炎症标志物的影响有限。尽管部分研究显示对NK细胞、T细胞亚群、IL-10和CRP等指标有显著调节作用，但整体证据异质性强，难以汇总，且多数研究未观察到一致的临床效应。,17403,2215,19618,,
6f714360-a16c-45ce-9587-82e0029a9f30,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""LGG""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": """"}]",Encapsulated (in maternal gut and breast milk),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; utilizes lactose, glucose, and other carbohydrates; dependent on host-derived nutrients in gut environment",Doubling time ~1–2 hours in vitro; stable colonization in infant gut over first year of life,"Gut mucosa, particularly in breastfed infants; preferentially colonizes the small intestine and colon","Competitive exclusion of pathogenic bacteria (e.g., S. aureus); promotes symbiosis with host immune system; enhances Bifidobacterium dominance","Tolerant to gastric acidity, bile salts, and moderate osmotic stress; stable during lyophilization and rehydration","Cell wall components (e.g., teichoic acids), extracellular polysaccharides","Lactobacillus rhamnosus GG and Bifidobacterium lactis are facultative anaerobes that thrive in the infant gut environment, utilizing host-derived oligosaccharides and dietary substrates. They exhibit strong colonization ability in the neonatal gut, especially in breastfed infants, and maintain stability under physiological stress conditions such as low pH and bile exposure. Their growth is supported by maternal milk components, particularly human milk oligosaccharides (HMOs), which selectively promote Bifidobacterium expansion.",None explicitly mentioned; natural strains used without genetic modification,Not applicable (no genetic engineering reported),Constitutive (natural expression of beneficial traits),,High chromosomal stability; no plasmid-based systems reported; low metabolic burden; long-term persistence in infant gut,Stable in breast milk and intestinal mucus; no reported degradation in maternal or infant gut environment,"The strains are used in their natural form without genetic modification. Their beneficial effects stem from intrinsic physiological properties, including adhesion to intestinal epithelium, production of antimicrobial compounds, and modulation of host immune responses. No synthetic circuits or inducible systems are employed.","[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Human milk oligosaccharides (HMOs)"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing molecules (e.g., AI-2)""]","[""Cytokines (e.g., IL-10, TGF-β)"", ""Immunoglobulins (e.g., IgA)""]","FNR-like regulators (in LGG), HMO transporters (in Bifidobacterium), TLR-2/4 signaling pathways",Threshold-based activation of immune tolerance and metabolic regulation; no synthetic logic gates reported,"The strains sense host-derived signals such as HMOs and SCFAs, which trigger metabolic and immune responses. They respond to changes in gut pH and bile levels, enabling adaptation to the intestinal environment. Their interaction with host immune cells involves recognition of microbial patterns via TLRs, leading to anti-inflammatory cytokine production. The system operates through natural sensing mechanisms without engineered logic circuits.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion (lactic acid), extracellular vesicles, passive diffusion",Natural regulation via host diet and microbial competition; no external dosage control,High compatibility with breast milk and intestinal mucus; stable during encapsulation in maternal gut and infant gut,True,False,False,"Inhibit pathogenic bacteria (e.g., S. aureus) via competitive exclusion, production of lactic acid, and bacteriocins","Lactic acid, bacteriocins (e.g., lactocin 705), hydrogen peroxide",False,True,True,True,LGG and Bifidobacterium lactis reduce S. aureus colonization in infants; no significant disruption of gut barrier or microbiome diversity observed in clinical trials.,False,,,False,False,False,Not applicable (no oxygenation mechanism reported),True,"Induce tolerogenic immune responses via TLR modulation, increase IgA production, and promote anti-inflammatory cytokine release (e.g., IL-10, TGF-β)","Toll-like receptor (TLR) ligands, secreted immunomodulatory proteins",True,"Enhance gut barrier integrity by upregulating tight junction proteins (e.g., occludin, ZO-1); promote mucus layer formation","Mucin-inducing factors, tight junction regulators",True,"Modulate host metabolism by producing SCFAs (acetate, propionate), improving insulin sensitivity, and reducing adiposity","Short-chain fatty acids (SCFAs), particularly acetate and propionate",False,,,GRAS,"Auxotrophy (nutrient-dependent survival), natural attenuation in non-host environments","Human milk oligosaccharides (HMOs), lactose",Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; minimal environmental escape risk,Breast milk and intestinal mucus provide physical confinement; limited survival outside host,"Lactobacillus rhamnosus GG and Bifidobacterium lactis are well-established probiotics with GRAS status. They are non-pathogenic, do not colonize long-term in non-host environments, and are naturally attenuated. No safety concerns were reported in clinical trials involving pregnant women and infants. Their presence in breast milk and infant gut is transient and dependent on host-derived nutrients.","Perinatal administration of LGG and Bifidobacterium lactis improved maternal insulin sensitivity and reduced central adiposity postpartum. Infants of supplemented mothers showed increased bifidobacterial diversity, reduced S. aureus colonization, and lower risk of overweight development by age 7. The intervention also reduced the incidence of gestational diabetes and fetal overgrowth. These findings suggest a significant role in preventing early-life metabolic programming toward obesity.",9811,1939,11750,,
9f2abda4-99b2-4e11-b321-3c24fcf5b883,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus LC705"", ""strain_id"": ""DSM 7061""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve Bb99"", ""strain_id"": ""DSM 13692""}, {""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium freudenreichii ssp. shermanii JS"", ""strain_id"": ""DSM 7076""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: 5.5–6.5; Carbon source: Glucose, galactose; Requires galacto-oligosaccharides for optimal growth in infants",Doubling time: ~1.5–2 hours in vitro; Growth rate consistent in vivo during early infancy; No significant difference in growth rate between probiotic and placebo groups,"Gut mucosa, particularly in the small intestine and colon; Colonization observed at 6 months of age, not sustained beyond 2 years",Competitive exclusion of pathogenic bacteria; Modulates host immune system; No significant disruption of native microbiome observed; May promote symbiosis with commensal flora,Tolerant to freeze-drying and lyophilization; Stable during storage at 4°C; Resistant to gastric acid and bile salts; Tolerant to moderate osmotic stress,Galacto-oligosaccharides (prebiotic support in infant formulation),该益生菌混合物为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下生长，以葡萄糖和半乳糖为碳源。在婴儿配方中添加半乳寡糖可促进其定植。在6个月龄时可在粪便中检测到，但2岁后定植率下降。对胃酸、胆盐和冻干处理具有较强耐受性，适合口服给药。,None reported (natural strains used without genetic modification),Not applicable,Constitutive,,High chromosomal stability; No plasmids used; No evidence of genetic drift or loss of function over 13-year follow-up,Stable in capsule and syrup formulation; No degradation observed during storage or in gastrointestinal environment,未对菌株进行基因改造，使用天然存在的益生菌株。所有菌株均通过冻干技术封装，确保在储存和运输过程中的稳定性。,"[""pH"", ""Bile acids"", ""Glucose""]","[""Galacto-oligosaccharides"", ""Lactate""]",,"[""Cytokines"", ""Proteases""]","FNR promoter (hypoxia sensing), Lactate dehydrogenase (lactate sensing), Bile acid transporters (bile sensing)",Constitutive expression; No reported synthetic logic circuits; Sensing is passive and based on natural metabolic responses,各菌株通过其天然代谢通路感知环境信号（如pH、胆汁酸、乳酸和半乳寡糖），并持续表达免疫调节相关因子。未使用人工调控回路，无逻辑门控机制。,"[""Immunomodulation"", ""Tissue Repair""]","Type IV secretion (L. rhamnosus GG), Vesicles (B. breve Bb99), Diffusion (P. freudenreichii metabolites)",Dose-dependent; Controlled by administration schedule (twice daily for 6 months); No feedback control,High compatibility with freeze-dried capsule and syrup formulation; No structural disruption observed,False,False,False,Not applicable,,False,False,False,False,未报告抗菌或抗生物膜活性。,False,Not applicable,,False,False,False,未报告产氧功能。,True,"Modulates Th1/Th2 balance; Reduces IgE-mediated sensitization; Enhances regulatory T cell activity; Suppresses pro-inflammatory cytokines (e.g., IL-4, IL-5, IL-13)","Lactobacillus rhamnosus GG (GG) surface proteins, Bifidobacterium breve Bb99 exopolysaccharides, Propionibacterium freudenreichii metabolites",True,Promotes epithelial barrier integrity; Reduces skin inflammation; Improves SCORAD scores in eczema; Enhances mucosal healing in gut and skin,"Short-chain fatty acids (SCFAs), TGF-β, IL-10",True,"Produces SCFAs (acetate, propionate) from dietary fiber; Modulates host glucose and lipid metabolism; Influences tryptophan metabolism via AhR pathway","Acetate, Propionate, Butyrate",False,Not applicable,,GRAS,Auxotrophy (galacto-oligosaccharide dependency),Galacto-oligosaccharides,Low pathogenicity; No antibiotic resistance genes reported; No horizontal gene transfer observed; Low risk of environmental escape; No adverse events reported in 13-year follow-up,Physical encapsulation in capsule and syrup prevents environmental release,所有菌株均为公认安全（GRAS）菌株，无致病性或耐药基因。依赖半乳寡糖生长，可在肠道外环境中失活。胶囊和口服制剂提供物理屏障，防止逃逸。13年随访中未发现严重不良反应。,在剖宫产子代中，益生菌干预组13岁时过敏性疾病（ISAAC问卷）发生率显著降低（41.5% vs. 67.9%，p=0.006），特应性皮炎发生率也显著降低（18.9% vs. 37.5%，p=0.031）。整体队列中无显著差异，但剖宫产子代表现出长期免疫调节和屏障修复效应。,17793,1967,19760,,
995e6afd-1b45-4190-bc4a-4ff78d954641,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""NCIB3610""}, {""role"": ""Prey"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""NCIBM 12422""}]",Encapsulated,Facultative Anaerobe,Growth at 37°C in MRS medium (pH 7) or LB broth; optimal pH 7–8; requires Mn²⁺ for biofilm formation,Growth rate comparable to LB medium; doubling time not specified; viable in vitro and in simulated GIT,"Gastrointestinal tract (GIT), particularly favorable for colonization in intestinal environment",Symbiotic with L. plantarum; no antagonistic interactions observed; promotes Lactobacillus growth in vitro,"Resistant to heat (63°C for 3 min), cold (4°C for 21 days), simulated gastric juice, and bile salts; spore-forming enhances survival",Extracellular matrix (EPS and TasA amyloid fibers),"Bacillus subtilis is a facultative anaerobe that grows well at 37°C in modified MRS medium (pH 7). It forms robust biofilms under elevated pH and Mn²⁺ conditions. Its extracellular matrix provides protection against heat, cold, and gastrointestinal stresses. It maintains symbiotic relationships with L. plantarum without antagonism, and its spores are highly resilient.","Transcriptional fusions (PtapA-lacZ, Peps-lacZ, PtapA-Cfp), CRISPR-compatible strains (e.g., ΔabrB, Δspo0A, ΔepsHΔtasA) used for validation",Not explicitly reported; used for gene expression analysis and functional validation,"Constitutive expression of matrix genes (PtapA, Peps) under biofilm-inducing conditions; regulated by Spo0A and KinD-Spo0A pathway","Mn²⁺ ions, elevated pH (7–8), and MRS medium components",Stable in co-culture; matrix gene expression maintained over 8 h; no significant drift reported,Matrix production is enhanced in MRS medium and compatible with encapsulation in biofilm matrix,"B. subtilis was genetically modified using knockout strains (e.g., ΔabrB, Δspo0A, ΔepsHΔtasA) to validate matrix role in protection. Promoter fusions (PtapA-Cfp, Peps-lacZ) were used to monitor matrix gene expression. The system relies on natural regulatory pathways (KinD-Spo0A) to induce matrix production under specific environmental cues.","[""pH (elevated to 7–8)"", ""Mn²⁺ ions"", ""Osmotic stress (via MRS medium)""]","[""Dextrose"", ""Ammonium citrate"", ""Dipotassium phosphate"", ""Sodium acetate""]",,,"KinD histidine kinase, Spo0A transcription regulator, SinR/AbrB repressors","AND gate: Biofilm formation requires both elevated pH and Mn²⁺; Spo0A activation requires input from multiple histidine kinases (KinD, KinC, etc.)","B. subtilis senses environmental cues such as elevated pH and Mn²⁺ ions via histidine kinases (KinD, KinC), which activate the Spo0A phosphorelay. Phosphorylated Spo0A (Spo0A-P) represses SinR and AbrB, thereby derepressing the eps and tapA operons. This creates a logical AND gate: both pH and Mn²⁺ must be present to trigger matrix production. The system ensures matrix is only produced under favorable biofilm-inducing conditions.","[""Antibacterial"", ""Protection""]",Encapsulation within extracellular matrix (EPS and TasA amyloid fibers),"Controlled by environmental triggers (pH, Mn²⁺); matrix production is self-regulated via Spo0A pathway",Highly compatible with MRS medium and biofilm formation; matrix effectively encapsulates L. plantarum without structural collapse,True,False,False,"The extracellular matrix produced by B. subtilis encapsulates L. plantarum, protecting it from environmental stressors such as heat, cold, and gastric acid. This indirect antibacterial effect is achieved by shielding the probiotic from hostile conditions.",Extracellular matrix (EPS and TasA amyloid fibers),False,True,True,True,"B. subtilis biofilm matrix significantly enhanced L. plantarum survival during heat (63°C, 3 min) and cold (4°C, 21 days) stress. In vitro digestion model showed 0.86 Log CFU/mL increase in viability under gastric conditions and 0.9 Log CFU/mL under intestinal conditions.",False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,"Auxotrophy (not explicitly stated), but natural containment via matrix encapsulation and non-pathogenicity","Mn²⁺ ions, elevated pH",Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape reported; safe for human consumption,Physical confinement via extracellular matrix prevents release of encapsulated cells,"Bacillus subtilis NCIB3610 is a non-pathogenic, GRAS-designated strain with a long history of safe use in food and supplements. It does not produce toxins or virulence factors. The biofilm matrix acts as a physical barrier, limiting cell release. No evidence of antagonism or pathogenicity in co-culture with L. plantarum. Risk of environmental escape is low due to natural attenuation in non-sterile environments.","The dual-species biofilm significantly enhanced the survival of L. plantarum during heat treatment (63°C, 3 min: +1.06 Log CFU/mL), cold storage (4°C, 21 days: +0.44–0.89 Log CFU/mL), and simulated gastrointestinal digestion (gastric: +0.86 Log CFU/mL; intestinal: +0.9 Log CFU/mL). This demonstrates the system's effectiveness in protecting probiotics during food processing, storage, and GI transit.",13261,1981,15242,,
538cfc60-51ec-4ec4-93eb-c93d136654b1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Dengue virus"", ""strain_id"": ""DENV type 2, strain 16681""}]","Encapsulated (infectious cDNA construct, synthetic virus)",Facultative Anaerobe,"Temperature: 37°C (mammalian), 28°C (insect); pH: physiological range; Nutritional requirements: Host cell machinery (no defined media); Osmotic tolerance: Compatible with host cytoplasm","High replication in insect cells (C6/36, Aag-2); Low replication in mammalian cells (LLC-MK2, Vero E6, A549); Doubling time not explicitly reported, but growth kinetics show rapid replication in insects and delayed/attenuated in mammals","Insect vector (Aedes aegypti) and mammalian host (human); Target niche: Insect midgut and salivary glands, mammalian hepatocytes and immune cells","Null (virus, not microbial)",High stability in synthetic cDNA form; Resistant to lyophilization (inferred from synthetic virus production); Tolerant to shear stress during transfection and viral release,"Synthetic cDNA backbone, viral capsid proteins",该系统为重组登革病毒，其基因组经大规模同义密码子对去优化，使其在昆虫细胞中高效复制，而在哺乳动物细胞中显著减毒。在蚊子细胞（C6/36）中生长动力学与野生型相似，但在哺乳动物细胞（LLC-MK2）中复制能力大幅下降，表明其对哺乳动物宿主具有高度选择性。,"Computer-aided design, Simulated annealing heuristic, Whole genome synthesis","High (26–505 silent nucleotide changes per recoded segment; >300 changes in E, NS3, NS5 regions; no loss of protein sequence)",Constitutive (no inducible circuit; expression driven by viral promoters),,High (large-scale codon pair deoptimization reduces reversion risk; multiple silent changes across genome; no evidence of drift in experiments),Stable in synthetic cDNA and viral particles; compatible with in vitro transfection and viral propagation,通过计算机设计，将登革病毒（DENV-2）的编码序列进行大规模同义密码子对去优化，使其在哺乳动物中使用低偏好性密码子对，而在昆虫中保持高偏好性。该策略通过模拟退火算法实现，仅改变密码子对，不改变氨基酸序列，从而实现对哺乳动物宿主的减毒，同时保留在昆虫中的高效复制能力。,"[""Hypoxia"", ""pH"", ""Temperature""]","[""Glucose"", ""Lactate""]","[""Quorum sensing (indirect via host response)""]","[""Proteases"", ""Cytokines"", ""Interferon (IFN)""]","Viral polyprotein processing machinery, host innate immune sensors (e.g., RIG-I, Jak-STAT pathway)","Constitutive expression; no explicit logic gates; attenuation is intrinsic to codon pair bias, not responsive to environmental signals",该系统无主动感应模块，其减毒效应由基因组编码的密码子对偏好性决定，不依赖于外部信号。病毒在哺乳动物细胞中因翻译效率低下而复制受阻，该过程为被动响应，而非主动逻辑控制。,"[""Tumor Therapy"", ""Immunomodulation""]",Viral particle release (lysis of host cell),Dose-dependent immunogenicity; titers measured by PFU and TCID50; protection correlates with dose,Compatible with synthetic cDNA and viral particle encapsulation; stable in in vitro and in vivo settings,False,,,Null,,,,,,无,False,Null,,,,,无,True,"Recoded viruses induce high levels of neutralizing antibodies in newborn mice and confer protective immunity. Maternal antibodies are transferred to offspring, protecting them from lethal challenge.",Neutralizing antibodies (anti-DENV IgG),False,Null,,False,Null,,True,"The recoded virus is attenuated in mammals but remains immunogenic. It acts as a live attenuated vaccine candidate, capable of inducing protective immunity against dengue infection, effectively functioning as a targeted therapeutic agent in the context of viral disease.",Recombinant DENV-2 (hmin variants),BSL-2,Genetic attenuation via codon pair deoptimization; no functional pathogenicity in mammals,Codon pair score (hmin) in human cells,"Low pathogenicity in mammals; no evidence of reversion to virulence; no antibiotic resistance genes reported; low risk of horizontal gene transfer (viral genome, not plasmid); environmental escape unlikely due to host specificity",Synthetic cDNA and viral particles are contained in lab settings; no environmental release reported,该系统为经基因工程改造的减毒登革病毒，其在哺乳动物中复制能力极低，且通过大规模密码子对去优化显著降低回复突变风险，因此具有良好的生物安全性。其在昆虫中仍可高效复制，但对人类无致病性，符合BSL-2标准。,在新生小鼠中，hmin病毒（E^hmin、NS3^hmin、NS5^hmin）的LD50分别比野生型提高2000倍、100倍和200倍，表明其显著减毒。所有三种重组病毒均能诱导高水平中和抗体，且母鼠接种后可将抗体传递给后代，使93%的新生小鼠在野生型病毒攻击下存活，证明其具有强免疫原性和保护性。,13494,1877,15371,,
d4a636c8-6106-4320-bf04-316c26a80f63,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, utilizes carbohydrates (e.g., glucose, lactose) as carbon sources; requires complex nutrients including amino acids and vitamins.",Growth rate not explicitly reported; typical doubling time for Lactobacillus spp. is ~20–30 min in vitro; in vivo growth likely slower due to competitive environment.,Intestinal tract (cecum and colon) of broilers; preferentially colonizes mucosal surfaces of the gastrointestinal tract.,"Competitive exclusion of pathogenic bacteria (e.g., Salmonella, E. coli); may promote symbiosis with native microbiota by stabilizing microbial balance.",Moderate tolerance to osmotic stress and moderate pH variation; stability during feed processing and storage not detailed.,Not specified,该研究中使用的三种益生菌（Lactobacillus acidophilus、Enterococcus faecium 和 Bifidobacterium bifidum）均为革兰氏阳性、兼性厌氧菌，适宜在鸡的肠道环境中生长。它们以碳水化合物为碳源，依赖复杂的营养物质，可在鸡肠道黏膜表面定植，通过竞争性排斥病原菌来维持肠道微生物平衡。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及对益生菌进行基因改造。所用益生菌为天然菌株，仅通过饲料添加方式引入，未涉及任何基因编辑或合成生物学工具。,"[""pH"", ""Glucose"", ""Lactate""]","[""Bile Acids"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]",Not specified,Not specified,文中未描述任何感知模块或逻辑控制机制。益生菌的作用基于其天然生理特性，而非工程化信号响应系统。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Not specified,Not specified,Not specified,True,False,False,通过产生有机酸（如乳酸）降低肠道pH，抑制病原菌生长；竞争性定植于肠道黏膜，阻止病原体附着。,Lactic acid,False,True,True,True,益生菌通过降低肠道pH和竞争性定植抑制病原菌，未见显著毒性或微生物群落紊乱，表明其活性可控且安全。,False,Not applicable,Not applicable,False,False,False,未涉及氧气生成机制。,True,调节宿主免疫反应，增强肠道屏障功能，促进抗炎因子分泌，减轻炎症反应。,"Cytokines (e.g., IL-10, TGF-β)",False,Not applicable,Not applicable,True,调节宿主代谢，促进营养物质吸收，改善饲料转化率，调节短链脂肪酸（SCFAs）水平。,Short-chain fatty acids (SCFAs),False,Not applicable,Not applicable,GRAS,Not applicable,Not applicable,Lactobacillus acidophilus 和 Bifidobacterium bifidum 为公认安全（GRAS）菌株，无致病性；Enterococcus faecium 存在潜在耐药基因（如 vanA）风险，但本研究未报告耐药性问题。,Not applicable,三种益生菌均为食品级安全菌株，无致病性记录。Enterococcus faecium 虽有潜在耐药基因，但本研究未检测其耐药性，且在饲料中使用浓度较低，环境逃逸风险极低。,在新垫料和重复使用垫料环境中，添加益生菌的肉鸡日粮可显著降低采食量，但不影响体重增长、饲料转化率、存活率及胴体性状。益生菌替代抗生素在不降低生产性能的前提下有效减少采食量，证明其作为抗生素替代品的可行性。,12897,1604,14501,,
4f847b9e-496a-4b02-8582-489dc4e6aa78,0,,,,,,,,,,,本文为特刊编辑部的综述性文章，未描述任何具体的微生物系统（单菌株或群落），仅介绍病毒与微生物研究领域的发展背景、国际社会（ISVM）的成立历程及会议内容。文中未提及任何用于治疗或工程改造的具体微生物菌株或其生理特性。,,,,,,,本文未涉及任何基因工程改造的微生物系统，未描述任何遗传工具、调控回路、基因稳定性或材料耦合策略。,,,,,,,本文未提及任何微生物的感知模块、信号响应机制或逻辑控制回路。,,,,,False,,,,,,,,,,False,,,,,,,False,,,False,,,False,,,False,,,,,,,,本文未描述任何具体的微生物系统，因此无法评估其生物安全等级、生物遏制策略、风险或材料屏障。,本文为综述性编辑部文章，未报告任何具体的治疗效果或伤口愈合数据。,3755,870,4625,,
24dbc9c6-fd53-467a-9bb8-5c6bc6cce67f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium freudenreichii"", ""strain_id"": ""CIRM-BIA 129 (ITG P20)""}]",Suspension,Microaerophilic,"Grows at 30°C; utilizes glycerol, erythritol, L-arabinose, adonitol, galactose, D-glucose, D-fructose, D-mannose, inositol, arbutine, esculine, lactose, lactate, and gluconate as carbon sources; tolerates up to 1 M NaCl",Optimal growth at 32°C; growth monitored spectrophotometrically at 650 nm and by CFU counting; no doubling time or in vivo vs in vitro comparison reported,Intestinal tract (inferred from anti-inflammatory and adhesion properties; pseudogene loss in inlA suggests enhanced host interaction),Bifidogenic properties; free-living; no evidence of pathogenicity or competition with other microbes reported,"Tolerates up to 1 M NaCl; no data on UV, drying, shear, or lyophilization reported",Osmoprotectants (inferred from NaCl tolerance in chemically defined medium),该菌株为革兰氏阳性、微需氧、形态多变（球状至杆状），在YEL琼脂平板上形成奶油白色菌落。在液体培养基中生长于底部以避开氧气，静止期初期易形成团块。可在含1 M NaCl的培养基中生长，表明其具有较强的渗透压耐受性。其最佳生长温度为32°C，可利用多种碳源，包括葡萄糖、果糖、乳酸、甘油等。,,,,,No plasmid or chromosomal integration systems described; genome is stable with 30 pseudogenes and no CRISPR elements reported,,该菌株未经过人工基因工程改造，其基因组为自然状态。研究重点在于解析其天然基因组中与抗炎特性相关的基因，特别是表面蛋白编码基因。,,,,,,,该菌株未报道具有人工设计的感应模块或逻辑电路，其生理响应基于天然代谢与宿主互作机制。,"[""Immunomodulation""]",Unknown (no secretion system described),"Not applicable (natural strain, no engineered control)",Not reported,False,,,,,False,False,False,False,未提及抗菌或抗生物膜功能,False,,,False,False,False,未提及产氧功能,True,其抗炎特性与表面蛋白（特别是含SLH结构域的蛋白）密切相关，这些蛋白可能通过与宿主细胞相互作用调节免疫反应。,"S-layer associated proteins (SLAPs) with SLH domains (e.g., slpB, slpE, slpF, slpG, slpA, inlA, slh2, slpD)",False,,,False,,,False,,,GRAS,"None (naturally non-pathogenic, no kill-switch or auxotrophy described)",,Non-pathogenic; GRAS and QPS status; no antibiotic resistance genes or HGT risk reported; no evidence of environmental escape,Not applicable (no encapsulation or material barrier described),该菌株被列为GRAS（普遍认为安全）和QPS（质量安全评估）菌株，无致病性，无抗生素抗性基因，未报告水平基因转移风险，属于安全菌株。,该菌株具有显著的抗炎潜力，优于已测序的CIRM-BIA1T菌株。其表面蛋白（特别是含SLH结构域的蛋白）与抗炎特性密切相关，可能通过与宿主细胞相互作用调节免疫反应。其基因组中存在与肠道定植相关的基因（如inlA完整），提示其在肠道中具有良好的适应能力。,9882,1478,11360,,
a6a022cf-e708-4117-b6c4-fee2a2a670a6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli Nissle 1917"", ""strain_id"": ""EcN""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5; tolerates bile and acidic environments; utilizes glucose and other carbon sources; dependent on host metabolites in vivo",Doubling time ~20–30 min in vitro; stable colonization in gut with long-term persistence in vivo,"Gut mucosa, intestinal lumen",Competitive with pathogenic bacteria; minimal disruption to native microbiome; commensal interaction with host,"Tolerant to osmotic stress, shear stress, and lyophilization; stable during storage and transport","Capsule-like surface structures, stress-response genes",大肠杆菌Nissle 1917是一种耐受性强的肠道共生菌，可在胃肠道中长期定植，对酸性、胆汁和渗透压环境具有良好的耐受性，适合在复杂生理环境中稳定生长。,"CRISPR-Cas9, Plasmid-based systems, Recombination (FimE-DNA recombinase), Transposons",High efficiency (>90%) with low off-target risk; validated in multiple studies,"Inducible (e.g., IPTG, CAI-1, NO, nitrate, tetrathionate), Logic AND Gate (e.g., dual-signal activation)","CAI-1, NO, nitrate, tetrathionate, AHL, heme, glucose",High plasmid stability (copy number ~10–20); chromosomal integration used for long-term expression; low metabolic burden; evolutionarily stable in vivo,Stable in hydrogel and encapsulated matrices; maintains function during release and colonization,通过基因工程改造大肠杆菌Nissle 1917，构建了多种可响应疾病标志物的合成生物传感器和基因电路，实现了对炎症、感染和肿瘤等疾病的精准检测与治疗。,"[""Hypoxia"", ""Acidity"", ""ROS/RNS"", ""Glucose"", ""pH""]","[""Nitrate"", ""Thiosulfate"", ""Heme"", ""Tetrathionate"", ""Bile Acids""]","[""AHL"", ""CAI-1"", ""AI-2"", ""AIP-I""]","[""Proteases"", ""Cytokines"", ""Tissue degradation fragments""]","NorR (NO sensor), NarX-NarL (nitrate sensor), HrtR (heme sensor), CqsS-CAI-1 receptor, AgrC-AIP-I receptor, FimE-DNA recombinase","AND gate (e.g., dual biomarker detection), OR gate (e.g., multiple pathogen signals), threshold control, noise suppression via tight promoters",通过构建逻辑门电路，实现对多种疾病信号的协同识别，如同时检测硝酸盐和氧化应激信号以确认肠道炎症，避免误报。,"[""Antibacterial"", ""Immunomodulation"", ""Tumor Therapy"", ""Metabolic Regulation""]","Type I secretion (e.g., Usp45 signal), Lysis (E7 protein), Vesicles",Spatiotemporally controlled via inducible promoters; dosage tuned by signal concentration,Compatible with hydrogel encapsulation; maintains secretion activity and viability,True,True,True,通过分泌pyocin、E7裂解蛋白和dispersin B等抗菌物质，靶向杀灭Pseudomonas aeruginosa等病原菌并破坏生物膜结构。,"Pyocin, E7 lysis protein, DspB (dispersin B)",True,True,True,True,在秀丽隐杆线虫和小鼠模型中，工程菌有效减少P. aeruginosa定植，且未引起明显组织损伤或炎症过度。,False,,,False,False,False,,True,通过分泌IL-10、TGF-β1、IL-17A等细胞因子，调节免疫反应，抑制过度炎症或激活抗肿瘤免疫。,"IL-10, TGF-β1, IL-17A",True,通过分泌KGF-2、TFF1等修复因子，促进上皮细胞增殖和黏膜屏障修复，加速肠道损伤愈合。,"KGF-2, hTFF1",True,通过表达苯丙氨酸降解酶（PAL和LAAD），将过量苯丙氨酸转化为无害代谢物，治疗苯丙酮尿症。,"trans-cinnamate, phenylpyruvate",True,通过分泌IL-17A激活Toll样受体5（TLR5）信号通路，诱导抗肿瘤免疫反应，抑制肺癌转移。,IL-17A,BSL-1,"Auxotrophy, Kill-switch (e.g., CRISPRi-based suicide system), Temperature-sensitive control","CRISPRi, CAI-1, IPTG, temperature shift",Low pathogenicity; no known antibiotic resistance genes; minimal HGT risk due to controlled plasmid systems; low environmental escape risk,Physical confinement via hydrogel encapsulation prevents systemic dissemination,该系统基于安全的共生菌株，通过基因回路和物理屏障实现双重生物安全控制，临床前研究未发现致病性或基因水平转移风险。,在DSS诱导的小鼠结肠炎模型中，工程菌显著改善了黏膜损伤、减少出血和炎症评分；在苯丙酮尿症模型中，有效降低血清苯丙氨酸水平，达到临床试验阶段（NCT03516487）。,14610,4786,19396,,
a6a022cf-e708-4117-b6c4-fee2a2a670a6,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""L. lactis""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 30–37°C, pH 6.0–7.0; tolerates mild bile and acidic conditions; requires amino acids and sugars for growth",Doubling time ~30–40 min in vitro; transient colonization in gut; low persistence in vivo,"Gut lumen, oral mucosa",Symbiotic with host; minimal competition with native microbiota; low immunogenicity,"Tolerant to drying, lyophilization, and moderate shear stress; stable during storage","Cell wall structure, stress-response operons",乳酸乳球菌是一种安全的乳酸菌，可在肠道中短暂定植，对酸性和胆汁环境具有中等耐受性，适合用于局部治疗。,"Plasmid-based systems, CRISPRi, Recombination (P1 promoter), Transposons",High efficiency (>85%) with low off-target risk; well-characterized in L. lactis,"Inducible (P1 promoter, nisin-controlled system), Constitutive, Logic AND Gate","P1 promoter, nisin, CAI-1, AI-2",Moderate plasmid stability; chromosomal integration used for long-term expression; low metabolic burden,Stable in alginate and chitosan hydrogels; maintains secretion function,通过基因工程改造乳酸乳球菌，构建了多种响应病原信号的传感器和治疗性蛋白表达系统，用于炎症和感染的靶向治疗。,"[""Acidity"", ""pH""]","[""CAI-1"", ""AI-2""]","[""CAI-1"", ""AI-2""]","[""Cytokines""]","CqsS-CAI-1 receptor, AI-2 sensor, P1 promoter","AND gate (e.g., dual signal detection), threshold control, noise filtering via tight promoters",通过双信号识别（如CAI-1与AI-2协同）实现对病原感染的高特异性响应，避免假阳性。,"[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]","Type I secretion (Usp45 signal), Vesicles",Controlled by promoter strength and inducer concentration; localized delivery,Highly compatible with hydrogel encapsulation; maintains viability and secretion,True,True,True,通过分泌抗肠球菌肽、flagellin等物质，抑制病原菌黏附和生物膜形成。,"Antienterococcal peptides, Flagellin",True,True,True,True,在体外和小鼠模型中，工程菌有效抑制了肠球菌和沙门氏菌的定植，且未引起明显毒性反应。,False,,,False,False,False,,True,通过分泌IL-10、抗TNF纳米抗体、GAD65等，调节免疫反应，治疗自身免疫病和炎症性疾病。,"IL-10, Anti-TNF nanobody, GAD65",True,通过分泌TFF1等修复因子，促进口腔黏膜和肠道上皮修复。,hTFF1,False,,,False,,,GRAS,"Auxotrophy, Kill-switch (nisin-controlled system), Temperature-sensitive control","Nisin, temperature shift",Non-pathogenic; GRAS status; no antibiotic resistance genes; low HGT risk; minimal environmental escape,Effective physical confinement via hydrogel prevents systemic spread,乳酸乳球菌为公认安全（GRAS）菌株，通过可诱导的杀伤开关和物理屏障实现生物安全控制，临床前研究未发现风险。,在结肠炎小鼠模型中，工程菌显著降低炎症评分和组织损伤；在糖尿病和自身免疫病模型中，有效缓解症状，具有良好的治疗潜力。,14610,4786,19396,,
a6a022cf-e708-4117-b6c4-fee2a2a670a6,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacteroides thetaiotaomicron"", ""strain_id"": ""B. thetaiotaomicron""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5; requires complex polysaccharides (e.g., xylan); highly dependent on host mucosal glycans",Doubling time ~60–90 min in vitro; long-term colonization (>5 years) in vivo,"Intestinal mucosa, mucus layer",Symbiotic with host; promotes gut barrier integrity; supports other commensals,"Tolerant to bile, osmotic stress, and low oxygen; stable during lyophilization","Mucin-degrading enzymes, capsule polysaccharides",拟杆菌属θ菌是一种长期定植于肠道的共生菌，依赖宿主黏液多糖生长，具有极强的生态适应性和免疫耐受性。,"CRISPR-Cas9, Plasmid-based systems, Recombination (synthetic promoters), Transposons",Moderate to high efficiency; improved with synthetic bioparts; low off-target risk,"Inducible (xylan promoter), Constitutive, Logic NOR Gate (via Cello design)","Xylan, bile acids, anhydrotetracycline",High chromosomal integration stability; low metabolic burden; evolutionarily stable in vivo,Stable in hydrogel; maintains long-term function,通过合成生物学工具改造拟杆菌θ菌，构建了响应宿主信号的基因电路，用于代谢疾病和炎症的长期治疗。,"[""Hypoxia"", ""pH"", ""Bile Acids""]","[""Xylan"", ""Bile Acids""]","[""CAI-1"", ""AI-2""]","[""Cytokines"", ""Tissue degradation fragments""]","Xylan-inducible promoter, bile acid sensor, Cello-designed NOR gate","NOR gate (functionally complete), threshold control, noise suppression via synthetic promoters",通过Cello软件设计的NOR逻辑门，实现对多种信号的复杂整合，确保治疗输出仅在特定病理条件下激活。,"[""Tissue Repair"", ""Immunomodulation"", ""Metabolic Regulation""]","Type I secretion (enterotoxin signal), Vesicles",Controlled by xylan induction; sustained release over time,Excellent compatibility with hydrogel encapsulation; maintains long-term activity,False,False,False,,,False,False,False,False,,False,,,False,False,False,,True,通过分泌TGF-β1、KGF-2等因子，调节免疫平衡，抑制慢性炎症。,"TGF-β1, KGF-2",True,通过分泌KGF-2和TFF1，促进肠道上皮再生和屏障修复。,"KGF-2, hTFF1",True,通过表达苯丙氨酸降解通路，治疗苯丙酮尿症。,"trans-cinnamate, phenylpyruvate",False,,,BSL-1,"Auxotrophy, Kill-switch (CRISPRi), Temperature control","CRISPRi, temperature shift",Non-pathogenic; low HGT risk; no antibiotic resistance genes; minimal environmental escape,Hydrogel encapsulation provides strong physical confinement,拟杆菌θ菌为安全共生菌，通过基因回路和物理屏障实现双重控制，临床前研究未发现安全风险。,在苯丙酮尿症小鼠模型中，工程菌显著降低血清苯丙氨酸水平，达到临床试验阶段；在结肠炎模型中，有效修复黏膜损伤，改善疾病活动指数。,14610,4786,19396,,
46372fde-ef00-4c9b-8b44-0c55c5d82b00,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""299, 2362""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": ""5-33:3""}, {""role"": ""Chassis"", ""scientific_name"": ""Leuconostoc mesenteroides"", ""strain_id"": ""32-77:1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei subsp. paracasei"", ""strain_id"": ""19""}]",Encapsulated (in fiber matrix),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acidity and bile; requires fermentable carbohydrates (inulin, beta-glucan, pectin, resistant starch) for growth",Doubling time ~1–2 hours in vitro; stable in vivo colonization observed in gut mucosa after oral administration,"Gut mucosa, particularly colon and small intestine; preferentially colonizes in hypoxic regions of the GI tract","Competitive exclusion of pathogenic bacteria (e.g., Pseudomonas aeruginosa, Staphylococcus aureus); synergistic with host microbiota; reduces overgrowth of Escherichia coli and Staphylococcal species","Tolerant to lyophilization, rehydration, moderate shear stress; stable during storage at room temperature; resistant to bile salts and low pH","Cell wall components (e.g., teichoic acids), extracellular polysaccharides, and stress-response proteins (e.g., chaperones)",该微生物群落为乳酸杆菌属（Lactobacillus）和乳球菌属（Pediococcus）等兼性厌氧菌的混合体，可在人体肠道内定植，尤其偏好低氧环境。其生长依赖于可发酵纤维（如菊粉、果胶、抗性淀粉），在胃酸和胆汁环境中具有较强耐受性，能有效抑制病原菌过度生长，维持肠道微生态平衡。,None (natural strains used; no genetic modification reported),Not applicable,Constitutive,,High chromosomal stability; no plasmids reported; no evidence of genetic drift in clinical trials,"Stable in fiber-based delivery matrix (beta-glucan, inulin, pectin, resistant starch); no significant loss of viability during encapsulation",该系统未经过基因工程改造，使用天然分离的乳酸菌株，通过口服或鼻肠管给药，利用其天然代谢能力和定植能力发挥功能。其稳定性依赖于宿主肠道环境和纤维基质的保护作用。,"[""Hypoxia"", ""pH"", ""Bile Acids""]","[""Lactate"", ""Glucose"", ""Short-Chain Fatty Acids (SCFAs)""]","[""Quorum Sensing (AHL)"", ""AI-2""]","[""Proteases"", ""Cytokines (IL-6, TNF-α)"", ""Tissue Degradation Fragments""]","FNR promoter (hypoxia), Lactate permease (lactate), Bile acid receptors (e.g., Bile acid-binding proteins)",Constitutive expression; no reported synthetic logic gates; natural sensing via metabolic feedback and quorum sensing,这些菌株通过感知肠道微环境中的低氧、胆汁酸、乳酸和短链脂肪酸等信号，调节自身代谢和定植行为。它们能响应宿主炎症因子（如IL-6、TNF-α）和组织损伤产物，从而在感染或炎症发生时启动免疫调节功能。,"[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]","Type IV secretion (bacteriocin release), lysis (controlled release of metabolites)",Dose-dependent effect; standard dose: 40–400 billion CFU/day; efficacy correlates with dose and duration,"High compatibility with fiber matrix (beta-glucan, inulin, pectin, resistant starch); maintains viability and function during encapsulation and delivery",True,True,True,通过产生有机酸（乳酸、乙酸）降低局部pH，抑制病原菌生长；分泌细菌素（如plantaricin）直接杀伤革兰氏阳性菌；竞争性抑制病原菌黏附和生物膜形成。,"Lactic acid, acetic acid, plantaricin, bacteriocins",True,True,True,True,在严重创伤和急性胰腺炎患者中，使用Synbiotic 2000 Forte可显著减少肺部感染、中心静脉导管感染和全身性感染，且无明显毒性反应。,False,,,False,False,False,未使用氧生成机制，因此不适用。,True,通过调节Th1/Th2平衡，促进TGF-β和IL-10分泌，抑制过度炎症反应；增强巨噬细胞吞噬功能，减少中性粒细胞浸润和组织损伤。,"TGF-β, IL-10, IL-6 (modulated), TNF-α (modulated)",True,通过减少肠道通透性、抑制炎症因子释放、促进黏膜屏障修复，加速组织修复过程；在肝硬化患者中改善Child-Pugh评分和肝功能。,"Short-chain fatty acids (SCFAs), mucin, IL-10, TGF-β",True,通过发酵可溶性纤维产生短链脂肪酸（SCFAs），调节宿主能量代谢、胰岛素敏感性和肠道屏障功能。,"Acetic acid, propionic acid, butyric acid",False,,,GRAS,"None (natural strains, no kill-switches or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer observed; low risk of systemic infection; no evidence of intestinal ischemia in most trials,Fiber matrix provides physical confinement and protects microbes from harsh gastric environment,该微生物群落由公认安全（GRAS）的乳酸菌组成，未经过基因改造，无致病性或耐药基因。在多项临床试验中未观察到严重不良事件，如菌血症或肠缺血。其物理封装在纤维基质中，增强了生物安全性。,在严重创伤患者中，Synbiotic 2000 Forte显著降低死亡率（5/35 vs. 9/30）、严重败血症（6/35 vs. 13/30）和机械通气天数（15 vs. 26天）。在急性胰腺炎患者中，感染性坏死发生率从30%降至4.5%。在肝硬化患者中，半数患者出现肝性脑病逆转，Child-Pugh评分显著改善。,14263,2156,16419,,
25db7767-958e-4205-9cab-40bda4a11c37,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG, 299v""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""Nissle 1917""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus coryniformis"", ""strain_id"": """"}]",Suspension (oral or rectal administration),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, utilizes glucose and lactose as carbon sources; requires vitamins and amino acids; bile tolerance observed in intestinal environment",Doubling time ~1–2 hours in vitro; in vivo colonization sustained with repeated dosing; stability in gastrointestinal tract confirmed,"Intestinal mucosa, particularly colon and ileum; preferentially adheres to epithelial cells in gut lumen","Competitive exclusion of pathogens via nutrient competition, production of organic acids (lactic acid), bacteriocins; synergistic interactions with resident microbiota; minimal disruption to core microbiome",Tolerant to gastric acid and bile salts; stable during lyophilization and storage at 4°C; resistant to moderate shear stress during formulation,"Bile salt hydrolases, acid shock proteins, extracellular polysaccharides",上述微生物多为乳酸菌或酵母，具有良好的肠道定植能力，能在胃肠道环境中存活并维持活性。其生长依赖于适宜的温度、pH和营养条件，尤其在肠道中能耐受酸性环境和胆汁，具备良好的定植与代谢能力。,Not explicitly mentioned; likely natural strains without genetic modification,,Constitutive (natural expression of immunomodulatory genes),,High chromosomal stability; no plasmid-based systems reported; minimal metabolic burden; long-term in vivo persistence observed with repeated dosing,"Stable in food matrices (yogurt, capsules) and oral formulations; no significant degradation during storage",文中未提及基因工程改造，所有菌株均为天然分离或商业化的益生菌菌株，通过自然代谢功能发挥免疫调节作用。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""SCFAs"", ""Lactate"", ""Glucose""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactate-responsive promoters, Bile acid sensors (e.g., Bsh), Quorum sensing receptors (LasR, LuxR homologs)","No explicit synthetic circuits; natural sensing with threshold responses to environmental cues (e.g., low pH triggers acid resistance; bile induces bile salt hydrolase expression)",这些益生菌通过感知肠道内的pH、胆汁酸、乳酸和葡萄糖等信号，激活自身防御和代谢通路。部分菌株具备群体感应能力，可响应微生物密度变化。整体为天然感知机制，无人工逻辑门设计。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I/II/IV secretion systems (e.g., for bacteriocins), Vesicles (exosomes), Lysis (controlled release)",Dose-dependent effects observed; clinical dosing ranges from 10^9 to 10^12 CFU/day; timing and frequency optimized for sustained effect,"Compatible with oral capsules, yogurt, fermented foods, and rectal enemas; stable in food matrices and gastrointestinal environment",True,True,True,通过产生有机酸（如乳酸）、细菌素（bacteriocins）和 biosurfactants 抑制病原菌生长，干扰生物膜形成，竞争营养和黏附位点。,"Lactic acid, Bacteriocins (e.g., lactocin, reuterin), Biosurfactants",True,True,True,True,多项研究显示，L. rhamnosus GG 和 L. reuteri 能有效抑制肠道中病原菌定植，减少腹泻发生率，且无明显细胞毒性或菌群紊乱。,False,,,,,,,True,调节Th1/Th2平衡，促进Treg细胞分化，上调抗炎细胞因子（如IL-10），下调促炎因子（如IL-4、IFN-γ），影响黏膜免疫反应。,"IL-10, IFN-γ, TGF-β, SCFAs (butyrate, acetate)",True,促进肠道上皮屏障修复，上调黏蛋白（MUC2）基因表达，增强黏膜屏障功能，减少通透性，改善炎症性肠病症状。,"Mucin (MUC2), TGF-β, Epidermal growth factor (EGF)",True,产生短链脂肪酸（SCFAs），调节宿主能量代谢，影响免疫细胞功能，维持肠道稳态。,"Butyrate, Acetate, Propionate",False,,,GRAS,"Auxotrophy (nutrient dependency), Natural attenuation (no long-term colonization)","Amino acid auxotrophy (e.g., leucine, histidine), Vitamin dependency",Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer observed; minimal environmental escape risk due to poor environmental survival,Physical barrier provided by gastrointestinal mucosa and transient colonization; no persistent systemic dissemination,所有列出的菌株均为公认安全（GRAS）菌株，无致病性记录。其在人体内为短暂定植，不形成持久感染，且无耐药基因或水平基因转移风险，安全性高。,在HIV患者中，L. rhamnosus GG和L. reuteri可缩短急性腹泻持续时间，提升CD4+ T细胞计数；在溃疡性结肠炎患者中，VSL#3和E. coli Nissle可诱导临床缓解，疗效与美沙拉嗪相当；在儿童过敏性皮炎中，L. rhamnosus和L. reuteri显著改善症状并调节免疫因子水平。总体显示益生菌对免疫相关疾病具有显著临床改善作用。,5598,2227,7825,,
d7a1e585-68d2-4026-935e-a3606359ff55,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""MM08""}]",Suspension,Facultative Anaerobe,"37°C, pH 3.0–7.0, 1–4 g/L bile salts, 2–10 g/L pepsin/trypsin",Growth rate not specified; viable counts maintained at >10^4 cfu/mL under stress conditions for 24 h,"Gastrointestinal tract (GI), particularly resilient in harsh GI environment",Potential competition with pathogenic bacteria; no data on symbiosis with host microbiome,"High tolerance to acid (pH 3.0), bile salts (up to 4 g/L), pepsin (up to 10 g/L), trypsin (up to 10 g/L), and moderate tolerance to low pH (pH 2.0)","Lactic acid production, cell wall integrity, intrinsic resistance mechanisms",该菌株在模拟胃肠道环境（如低pH、胆盐、蛋白酶）下表现出良好的存活能力，尤其在pH 3.0和高胆盐浓度下仍能维持较高活菌数，表明其具有较强的耐受性，适合作为口服益生菌载体。,,,,,,,本文未涉及基因工程改造，所有特性均为天然菌株的生理表现，无外源基因插入或调控系统。,"[""pH"", ""Bile Salts"", ""Proteases (Pepsin, Trypsin)""]",,,,Unknown (no specific receptor or promoter identified),No logic gates or signal integration reported,未检测到特定的信号感应系统或逻辑控制机制，所有响应均为非特异性生理耐受性。,"[""Antibacterial"", ""Organic Acid Production""]",Unknown (likely passive diffusion or cell lysis),"Not applicable (natural production, no controllable output)",No material encapsulation reported; likely free suspension,True,False,False,通过产生有机酸（主要是乳酸）降低局部pH，抑制病原菌生长；对李斯特菌有抗性，但对金黄色葡萄球菌和大肠杆菌O157:H7无抑制作用。,Lactic acid,False,True,,True,乳酸为主要代谢产物，pH下降可抑制李斯特菌，但对其他常见病原菌无效，且无过度活性或组织损伤报告。,False,,,False,False,False,未检测到氧气生成或光依赖性产氧机制。,False,,,False,,,True,通过产生乳酸等短链脂肪酸调节肠道微环境，可能影响宿主代谢和免疫稳态。,Lactic acid,False,,,BSL-1,None (no engineered kill switches or auxotrophy reported),,"Strain MM08 lacks virulence genes (ace, gelE, efaA), but other strains harbor these genes. All strains show resistance to gentamicin, ciprofloxacin, erythromycin, and tetracycline. Horizontal gene transfer risk exists due to antibiotic resistance genes.",None (no physical barrier described),尽管E. faecium MM08未检测到毒力基因且抗生素耐药谱较轻，但其他E. faecalis菌株携带ace、gelE、efaA等毒力基因，且普遍存在多重耐药性，存在潜在致病风险和耐药基因传播风险，需进一步评估其在高危人群中的应用安全性。,该菌株在模拟胃肠道环境中表现出优异的存活能力，尤其在低pH和高胆盐条件下，且能稳定产生乳酸，具有潜在的益生功能。但其对多种病原菌无广谱抑制作用，且部分菌株携带毒力基因和耐药基因，需谨慎评估其临床应用价值。,17251,1470,18721,,
caf234be-1219-4fd8-a878-0d7f538d55d6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus salivarius"", ""strain_id"": ""K12""}]",Lozenge-encapsulated (oral mucosal contact),Facultative Anaerobe,"37°C, 5% CO2, pH 7.5, growth on Mitis-salivarius agar with streptomycin (100 μg/ml)",Doubling time not specified; detected in saliva at 7 and 14 days post-treatment; colonization observed in 13/13 subjects,"Oral cavity, particularly dorsal tongue and mucosal surfaces","Competitive exclusion of black-pigmented anaerobes (e.g., Prevotella, Porphyromonas); may stimulate indigenous salivaricin production in resident S. salivarius","Tolerant to chlorhexidine pretreatment, lozenge dissolution (5 min), and oral environment (pH, shear stress); stability during storage in lozenges not detailed",Streptomycin resistance (100 μg/ml) in strain K12 variant,该菌株为口腔常见共生菌，可在37°C、5% CO2条件下生长，对氯己定预处理后的口腔环境具有较强适应性，能成功定植于舌背和黏膜表面，维持至少14天。其生长受营养条件（如Mitis-salivarius培养基）和选择性压力（如链霉素）影响。,Not explicitly modified; strain K12 is a naturally occurring bacteriocin-producing variant,Not applicable (no genetic modification reported),Constitutive (bacteriocin production is auto-inducible and ongoing),Auto-induction via salivaricin production (no external inducer reported),High; strain K12 persisted in saliva at days 7 and 14; no evidence of plasmid loss or drift,Stable in lozenge formulation; maintains viability and function during dissolution and oral exposure,该菌株未经过人工基因改造，但其天然具备产生两种乳酸菌素（salivaricin A和B）的能力，且该能力为自诱导型，可在口腔环境中持续表达，无需外源调控。,"[""Hypoxia"", ""pH (neutral to slightly alkaline)""]","[""Lactate"", ""Glucose""]","[""Quorum sensing (auto-induction of bacteriocin production)""]","[""Proteases (indirectly via host tissue degradation)""]",Auto-induction system for salivaricin production (likely via peptide signaling),Constitutive expression with auto-induction; threshold-based activation of bacteriocin production upon sufficient population density,该菌株通过自诱导机制感知自身种群密度，当达到一定阈值时启动乳酸菌素的持续表达，实现对目标病原菌的抑制，属于自调控的恒定表达系统，具有一定的群体感应逻辑。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Bacteriocin secretion via general secretion pathway (likely constitutive),Dose-dependent via lozenge administration (2×/day); persistence varies by individual,Highly compatible with lozenge matrix; stable during dissolution and oral exposure,True,True,False,通过分泌salivaricin A（抑菌）和salivaricin B（杀菌）抑制多种与口臭相关的革兰氏阳性菌，包括Streptococcus anginosus、Eubacterium saburreum、Micromonas micros等。,Salivaricin A and Salivaricin B (lantibiotics),True,True,True,True,在体外实验中，K12菌株对多种口臭相关菌株（如S. anginosus、E. saburreum）表现出强抑制作用；在唾液样本中，黑素菌属（Prevotella）数量减少92%（Subject A）和62%（Subject B），且未见对宿主细胞明显毒性。,False,,,False,False,False,,True,通过竞争性定植和抑制病原菌，间接调节局部免疫环境，可能增强宿主免疫应答；同时可能通过刺激内源性乳酸菌素产生，增强局部防御。,"Bacteriocins (salivaricin A/B), competitive colonization",False,,,True,通过抑制蛋白水解型细菌（如Prevotella、Porphyromonas）的生长，减少挥发性硫化物（VSC）等代谢产物的生成，从而调节口腔微环境的代谢平衡。,"Volatile sulfur compounds (VSC), short-chain fatty acids (SCFAs)",False,,,GRAS,Auxotrophy (streptomycin resistance; not essential for survival),Streptomycin (100 μg/ml),Low pathogenicity; non-invasive; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape unlikely due to oral niche specificity,Lozenge formulation provides physical confinement and controlled release,该菌株为口腔正常共生菌，无致病性，经链霉素抗性筛选后仍保持安全特性，未见耐药基因或水平基因转移证据，且在口服制剂中具有物理屏障保护，整体风险极低。,在23名口臭患者中，85%的K12治疗组在治疗1周后VSC水平显著下降（>100 ppb），而安慰剂组仅30%。多数受试者在第7天和第14天维持低VSC水平，部分受试者（如S3）持续28天仍保持低水平。DGGE分析显示，VSC降低者唾液中S. salivarius K12条带更明显，且黑素菌属数量显著减少，表明其具有良好的定植和代谢调控能力。,12956,1901,14857,,
08702e85-48fb-4f4b-9bfc-f483d156fde5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium freudenreichii"", ""strain_id"": ""ET-3, CIRM-BIA 129""}]",Encapsulated,Aerotolerant,"Optimal growth at 30–37°C, pH 6.0–7.0; tolerates bile salts, gastric acid, osmotic stress; utilizes lactate, gluconate, propanediol as carbon sources",Slow growth rate; in vivo metabolic activity sustained via adaptation to intestinal substrates; in vitro doubling time ~3–5 hours,"Intestinal mucosa, particularly colon; transient colonization in human gut","Competitive adhesion to intestinal epithelium; excludes pathogens (E. coli, S. aureus, P. aeruginosa, Salmonella); modulates gut microbiota by increasing Bifidobacteria and decreasing Bacteroides and Clostridium","High tolerance to gastric acid, bile salts, oxidative stress, osmotic stress; survives in fermented dairy matrices; maintains viability during storage","Trehalose, glycogen, polyphosphate (osmoprotectants); general stress proteins (e.g., DnaK, GroEL)","Propionibacterium freudenreichii is an aerotolerant, non-spore-forming, Gram-positive bacterium with robust digestive stress tolerance. It exhibits slow growth but maintains metabolic activity in the gut by adapting to available substrates such as lactate and propanediol. It survives gastric acid and bile salts through induction of stress response genes and expression of protective proteins. Its ability to colonize the intestinal mucosa transiently enables interaction with host cells and modulation of the gut microbiota.","CRISPR-Cas9 (inferred from genome sequencing and strain engineering studies); plasmid-based systems (e.g., p15A origin) used in research",High efficiency in genome editing; off-target risk not reported but low due to high specificity of CRISPR-Cas9 in actinomycetes,"Constitutive expression of key genes (e.g., for SCFA, DHNA, S-layer proteins); inducible systems not reported",,High chromosomal stability; plasmid-based systems show moderate stability; no significant drift reported in long-term in vivo studies,"Stable in fermented dairy matrices (e.g., yogurt, cheese); maintains function during encapsulation and storage","Genome sequencing has enabled identification of genes involved in SCFA production, S-layer protein expression, and DHNA biosynthesis. Strain-specific engineering (e.g., CIRM-BIA 129) has been used to study immunomodulatory effects. No synthetic circuits reported, but natural regulatory systems (e.g., FNR-like regulators for hypoxia response) are functional. Genetic stability is high, especially in chromosomal integration.","[""Hypoxia"", ""pH"", ""Oxidative stress (ROS)""]","[""Lactate"", ""Propanediol"", ""Gluconate"", ""Acetate"", ""Propionate""]",,"[""Proteases"", ""Cytokines (IL-10, TNF-α)""]",FNR-like regulators (hypoxia sensing); membrane transporters for lactate/gluconate; S-layer homology (SLH) domains for host cell interaction,Constitutive expression with threshold-based metabolic adaptation; no reported synthetic logic gates; natural feedback via SCFA and DHNA production,"P. freudenreichii senses intestinal metabolites (lactate, propanediol) and adapts its metabolism accordingly. It responds to hypoxia via FNR-like regulators and to oxidative stress via general stress proteins. Host cytokines (e.g., TNF-α) may modulate immune interaction, but no direct sensing of cytokines is reported. The system operates through constitutive metabolic pathways with feedback from end-products (SCFAs, DHNA), enabling self-regulated activity in the gut.","[""Microbiota Modulation"", ""Immunomodulation"", ""Anti-Cancerous Effect""]","Type I secretion (lipopeptide), extracellular release of metabolites (SCFAs, DHNA, CFAs), S-layer protein shedding","Strain-dependent; dosage controlled by delivery vehicle (e.g., yogurt, capsule); no synthetic control systems reported","High compatibility with fermented dairy matrices (yogurt, cheese); maintains viability and function during encapsulation and storage",True,True,True,"Produces propionic acid, acetic acid, and bacteriocins; inhibits growth of Gram-positive and Gram-negative pathogens; prevents biofilm formation via competitive adhesion and secretion of anti-adhesive lipopeptides","Propionic acid, acetic acid, bacteriocins (e.g., 2-pyrrolidone-5-carboxylic acid), lipopeptide (anti-adhesive)",True,True,True,True,"Propionic acid and acetic acid inhibit growth of E. coli, S. aureus, P. aeruginosa, and Salmonella in vitro. Lipopeptide secretion reduces P. aeruginosa adhesion. No significant microbiome disruption reported. Activity is localized to gut and does not cause systemic toxicity.",False,,,False,False,False,No evidence of oxygen production or oxygenation activity; not applicable.,True,"Induces anti-inflammatory IL-10; suppresses pro-inflammatory cytokines (TNF-α, IL-12, IL-6); activates AhR via DHNA; modulates HDAC activity via SCFAs; S-layer proteins interact with dendritic cells to induce tolerance","S-layer proteins (SlpA, SlpB, SlpE), DHNA, SCFAs (acetate, propionate), IL-10",False,,,True,"Produces SCFAs (acetate, propionate) and conjugated fatty acids (CLA, CLNA); modulates host metabolism via PPARγ activation; enhances Bifidobacteria growth via DHNA and ACNQ","SCFAs (acetate, propionate), conjugated fatty acids (CLA, CLNA), DHNA, ACNQ",True,"Induces apoptosis in colorectal and gastric cancer cells via mitochondrial depolarization, cytochrome C release, and caspase activation; enhances TRAIL-induced apoptosis; inhibits HDAC, leading to p21 expression and cell cycle arrest","Propionate, acetate, SCFAs, DHNA",GRAS,Auxotrophy (inferred from natural growth requirements); no kill-switches reported,"Nutrient-dependent growth (e.g., lactate, propanediol)",Non-pathogenic; no reported virulence genes; no antibiotic resistance genes reported; low risk of HGT; no environmental escape documented,"Physical confinement in fermented food matrix (e.g., yogurt, cheese) limits environmental release","Propionibacterium freudenreichii is GRAS and QPS-listed with a long history of safe use in food. It lacks virulence factors and pathogenicity. No antibiotic resistance genes or horizontal gene transfer risks reported. Encapsulation in food matrices provides physical containment. No adverse effects observed in human trials, even at high doses (45 tablets/day).","In human trials, P. freudenreichii consumption increased Bifidobacteria levels and reduced fecal α-glucosidase activity. In animal models, it alleviated colitis, reduced inflammation, and induced apoptosis in cancer cells. In a pilot study, BGS (bifidogenic growth stimulator) improved clinical activity index in ulcerative colitis patients. Yogurt delivery yielded the highest fecal recovery of viable bacteria, indicating enhanced gut persistence and functional delivery.",12948,2261,15209,,
89033600-8912-43f7-b503-3631618c4b25,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""CJLP55""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""CJLP56""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""CJLP133""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""CJLP136""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""CJLP243""}, {""role"": ""Chassis"", ""scientific_name"": ""Leuconostoc citreum"", ""strain_id"": ""CJGN34""}]",Suspension,Facultative Anaerobe,"Growth at 15°C and 37°C, pH 3.8, 3% NaCl",Growth curve established in MRS broth at 37°C; viable counts determined every hour over 18 h,Small intestine (based on survival under simulated upper GIT conditions),No evidence of competition or symbiosis with host microbiome; potential for colonization due to bile salt resistance and acid tolerance,Resistant to 0.4% phenol; survived pH 3.0 for 1 h and bile salts in duodenum simulation,Bile salt hydrolase (BSH) activity,这些乳酸菌株均能耐受模拟胃肠道环境，包括pH 3.0的酸性条件和含胆盐的十二指肠条件，表明其在肠道中具有良好的生存能力。所有菌株在MRS培养基中于37°C下生长良好，且对0.4%苯酚具有抗性，说明其在肠道中可能具有较强的适应性。,,,,,,,文中未提及任何基因工程改造或合成生物学元件，所有菌株均为天然分离株，未进行遗传修饰。,"[""Acidity"", ""Bile Salts""]","[""Bile Acids""]",,,Bile salt hydrolase (BSH) enzyme,未提及逻辑门控机制，仅基于生理耐受性进行功能评估。,这些菌株通过表达胆盐水解酶（BSH）来感知并适应肠道中的胆汁酸环境，从而在小肠中存活。其对酸性和胆盐的耐受性是其在胃肠道中定植的关键生理特征，但未涉及复杂的信号感知与逻辑处理机制。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",None (natural secretion via cell lysis or passive diffusion),Not applicable (no engineered control system),Compatible with food matrices; no encapsulation or delivery system described,True,False,False,L. plantarum 和 Leuconostoc citreum 菌株在体外表现出对多种病原菌的抑制作用，但未明确说明其抗菌机制。,Lactic acid (produced during fermentation),False,True,True,True,所有菌株均未表现出溶血或明胶酶活性，且对多种抗生素敏感，表明其具有良好的安全性，不会造成过度组织损伤或微生物群落失衡。,False,,,False,False,False,未提及任何产氧机制或相关工程改造。,True,Lactobacillus plantarum 菌株具有免疫刺激活性，可增强宿主免疫反应。,"Lactic acid, exopolysaccharides (EPS), cell wall components",False,,,True,L. plantarum 菌株在发酵过程中产生乳酸，调节肠道pH，促进有益菌群生长，同时可能影响宿主代谢。,Lactic acid,False,,,GRAS,None (no kill-switch or auxotrophy described),,"All strains except L. fermentum CJCS1 were susceptible to 8 antibiotics tested. L. fermentum CJCS1 showed tetracycline resistance and carried tet(O) gene. No haemolysis, gelatinase activity, or biogenic amine production detected.",None (no physical confinement described),除从猪粪中分离的L. fermentum CJCS1携带tet(O)耐药基因外，其余所有菌株均表现出良好的安全性，包括对多种抗生素敏感、无溶血性、无明胶酶活性、不产生生物胺。这些特征支持其作为食品级益生菌的GRAS地位。,所有菌株在模拟胃肠道条件下表现出良好的存活率，尤其在pH 3.0下1小时后仍保持超过55%的存活率，且在含胆盐的十二指肠模拟环境中具有一定的耐受性，表明其具有作为益生菌在肠道中定植和发挥功能的潜力。,14949,1738,16687,,
c30acfb3-e1e9-476d-af3a-10c12e829f2a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""CECT 5713""}]",Suspension,Facultative Anaerobe,"Growth at 30°C in MRS-Cys medium under anaerobiosis (10% H₂, 10% CO₂, 80% N₂); pH not explicitly stated, but typical for Lactobacillus species (pH 5.5–6.5); tolerance to bile salts and mucus adherence reported.",Growth rate not quantified; exponential growth observed in MRS-Cys medium at 30°C with doubling time inferred as typical for Lactobacillus (approx. 1–2 hours in vitro). In vivo stability not directly measured but high survival in gastrointestinal conditions reported.,"Human milk, infant feces; mucosal surfaces of gastrointestinal tract and oral cavity; potential for translocation via dendritic cells to mammary gland.",Adheres to intestinal cells and mucus; stimulates mucin gene expression; no significant competition or symbiosis with other microbiota described.,High tolerance to bile salts; survives gastrointestinal conditions; resistant to drying and lyophilization (implied by probiotic use); stable under storage conditions.,"Bile salt hydrolase activity, mucus adherence proteins","Lactobacillus salivarius CECT 5713 is a facultative anaerobe that grows well under anaerobic conditions at 30°C in MRS-Cys medium. It exhibits high survival in gastrointestinal environments, adheres to intestinal and mucus surfaces, and maintains stability during storage and processing, making it suitable for probiotic applications.","Plasmid-based systems (pHN1, pHN2, pHN3); no CRISPR or recombinase tools used in this study.",Not applicable; no genetic editing performed in this study.,Constitutive expression of bacteriocin cluster genes; quorum-sensing regulation (AbpK) disrupted by 4-bp deletion.,"AbpIP (autoinducer peptide), AbpK (histidine kinase), AbpR (response regulator)","Plasmids pHN1, pHN2, and pHN3 are stable; no evidence of plasmid loss or chromosomal instability reported. No transmissible antibiotic resistance genes detected.",Stable in suspension and in vitro culture; no data on encapsulation or material integration.,"The strain contains a megaplasmid (pHN3) with a complete bacteriocin gene cluster, but a 4-bp deletion in the histidine kinase gene abpK disrupts quorum-sensing regulation, preventing bacteriocin production. The genome includes two intact prophages and no mobile antibiotic resistance elements, contributing to genetic stability.","[""Hypoxia"", ""pH (inferred from gut environment)""]","[""Bile acids"", ""Lactate (inferred from lactic acid bacteria metabolism)""]","[""Quorum sensing (AbpIP)""]","[""Dendritic cell surface receptors (via molecular mimetism)"", ""Mucin-encoding gene expression (host signaling)""]","AbpK (histidine kinase), AbpIP (autoinducer peptide), Protein 1230 (DC-SIGN-like receptor mimic)",AND gate: bacteriocin production requires both AbpIP (signal) and functional AbpK (sensor) for activation. Disruption of AbpK prevents induction.,"The bacteriocin production system functions as an AND gate: it requires both the presence of the autoinducer AbpIP and a functional histidine kinase AbpK. Due to a 4-bp deletion in abpK, the system is non-functional, preventing bacteriocin synthesis even in the presence of AbpIP. The strain also senses host-derived signals via molecular mimicry, particularly through protein 1230, which mimics DC-SIGN and may bind HIV gp120.","[""Immunomodulation"", ""Anti-infectious"", ""HIV Inhibition""]","Cell surface proteins, secreted factors (e.g., protein 1230), cell-free supernatants",Not controllable; activity depends on bacterial viability and concentration.,Compatible with suspension and in vitro culture; no data on encapsulation or material integration.,False,False,False,No detectable bacteriocin production due to frameshift mutation in abpK gene.,,False,False,False,False,无抗菌活性，因abpK基因缺失导致无法合成细菌素。,False,No oxygen-producing mechanism reported.,,False,False,False,无氧生成功能，不适用于氧合治疗。,True,"Stimulates maturation of immature dendritic cells by upregulating MHC class II and B7.2 (CD86) surface markers, promoting T-cell activation.","Protein 1230 (DC-SIGN-like mimic), bacterial cell surface components",False,No direct evidence of tissue repair or ECM regulation.,,False,"No data on SCFA, tryptophan, or neurotransmitter production.",,False,No evidence of tumor targeting or prodrug conversion.,,GRAS,No transmissible antibiotic resistance genes; no functional prophage progeny; intrinsic resistance to vancomycin and kanamycin (non-transferable).,"AbpK (non-functional), prophage genes (non-replicative)",Low pathogenicity; no transmissible resistance genes; intrinsic antibiotic resistance not a health risk; no evidence of horizontal gene transfer.,No physical barrier used; relies on intrinsic safety features.,"Lactobacillus salivarius CECT 5713 is considered safe for human use. It lacks transmissible antibiotic resistance genes, has no functional phage progeny, and exhibits intrinsic resistance to certain antibiotics (vancomycin, kanamycin) that are not transferable. It has been shown to be well tolerated in animal models and human clinical trials, supporting its GRAS status.",该菌株可显著促进树突状细胞成熟，上调MHC II和B7.2表达，抑制HIV-1感染（R5型42.3%，X4型58.9%，R5/X4型49.8%），具有良好的免疫调节和抗感染潜力，适用于肠道和黏膜免疫干预。,13463,1975,15438,,
935c5b0c-27ef-4058-924f-27cca750598f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""AH1206""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates bile salts and gastric acid; utilizes mucin and dietary glycans as carbon sources","Doubling time ~1.5–2 hours in vitro; transient colonization in adults, long-term persistence in subset of individuals (e.g., B. longum AH1206)",Ileal epithelium and colonic mucus layers; preferentially colonizes hypoxic regions of the gut,Synergistic with other commensals via cross-feeding; co-colonization enhanced when related genera are present ('like will to like' rule); competes with resident microbiota for nutrients,"High tolerance to bile salts, acid, and osmotic stress; stable during lyophilization and rehydration; resistant to shear stress in gut lumen","Exopolysaccharides (EPS), lipoteichoic acid (LTA), ureC gene (acid resistance)","Lactobacillus and Bifidobacterium strains exhibit species- and strain-specific colonization patterns. They survive harsh gastric conditions due to acid and bile resistance, utilize mucin and dietary glycans for energy, and persist in the gut through surface adhesion and metabolic adaptation. Autochthonous strains like B. longum AH1206 show long-term persistence, while allochthonous strains are typically transient.","CRISPR-Cas9 (inferred from genomic analysis), Recombination (plasmid integration), Transposons (inferred from SNP variation)",High efficiency in Lactobacillus; moderate in Bifidobacterium; low off-target risk due to conserved core genomes,"Constitutive expression of colonization genes; inducible via host-derived signals (e.g., mucin, lactose)","Mucin, lactose, host-derived glycans",Chromosomal integration preferred; plasmid loss observed in L. plantarum during gut transition; metabolic burden minimal; evolutionary drift observed via SNP variation,Stable in hydrogel matrices and encapsulated delivery systems; EPS production enhances material compatibility,"Genetic engineering focuses on enhancing carbohydrate metabolism, surface adhesion, and immune tolerance. Key genes (e.g., spaC, ureC, bshA) are targeted to improve colonization. Strains are engineered for improved survival and persistence via metabolic and structural modifications.","[""Hypoxia"", ""Acidity"", ""ROS"", ""Lactate""]","[""Mucin glycans"", ""Dietary glycans"", ""Lactose"", ""Tryptophan""]","[""Autoinducer-2 (AI-2)"", ""Quorum sensing (luxS)""]","[""Immunoglobulin A (IgA)"", ""Antimicrobial proteins (AMPs)"", ""Cytokines (IL-17F)""]","FNR promoter (hypoxia), LTA-TLR2/6 complex (immune sensing), LuxS (quorum sensing), Mucin-binding pili (SpaC)",AND gate: requires both nutrient availability and host immune tolerance; threshold-based activation of colonization genes; noise suppression via gene redundancy and metabolic buffering,"Strains sense hypoxia and nutrient availability (e.g., mucin, lactose) via specific promoters and receptors. Quorum sensing (LuxS) coordinates biofilm formation. Immune tolerance is achieved through mild immunogenicity and IgA coating. The system integrates multiple signals to activate colonization only when environmental and host conditions are favorable.","[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Type IV secretion (pili), exopolysaccharide (EPS) matrix, lysis (in some strains)",Controlled by host diet and microbiome; dose-dependent colonization; no external control mechanism,High compatibility with hydrogel and encapsulated delivery systems; EPS enhances matrix stability,True,True,True,"Produces lactic acid and reuterin to inhibit pathogenic bacteria (e.g., E. coli O157, AIEC); bacteriocins (e.g., Abp118) target Listeria monocytogenes","Lactic acid, reuterin, bacteriocin Abp118",True,True,True,True,L. rhamnosus GG and L. reuteri inhibit AIEC and E. coli O157 via lactic acid and reuterin; bacteriocin Abp118 in L. salivarius protects against Listeria; no significant cytotoxicity or microbiome disruption reported,False,Not applicable,,False,False,False,No evidence of oxygenation activity; not engineered for oxygen production,True,Induces Th17 cells in a tolerant manner; modulates NF-κB and Nrf2 pathways; promotes immune tolerance via IgA coating and mild immunogenicity,"IgA, IL-17F, TLR2 ligands (LTA), tryptophan metabolites (indole derivatives)",False,Not applicable,,True,"Produces SCFAs (acetate, propionate) and tryptophan metabolites (indole derivatives) that regulate host metabolism and immune function","Acetate, propionate, indole derivatives",False,Not applicable,,GRAS,"Auxotrophy (e.g., lactose-dependent strains), kill-switch via plasmid loss","Lactose, plasmid loss (reductive evolution)",Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; minimal environmental escape due to host-adapted nature,Physical confinement via encapsulation prevents environmental release,"Lactobacillus and Bifidobacterium strains are generally recognized as safe (GRAS). Autochthonous strains like B. longum AH1206 have low opportunistic risk. No evidence of pathogenicity or antibiotic resistance. Encapsulation ensures physical containment, reducing environmental escape risk.","L. rhamnosus GG and B. longum AH1206 show long-term persistence in a subset of individuals. They enhance gut barrier function, modulate immune responses, and improve metabolic health. Personalized intervention via machine learning prediction models can optimize colonization success. Clinical trials show improved colonization with diet-tuned prebiotics (e.g., GOSs, FOSs).",14568,2055,16623,,
c8f8ab59-376e-4ec0-adcd-fcd478611191,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Lactobacillus rhamnosus GG (implied by context)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Lactobacillus casei LBC80R (implied by context)""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Bifidobacterium lactis (implied by context)""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Streptococcus thermophilus (implied by context)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus bulgaricus"", ""strain_id"": ""Lactobacillus bulgaricus (implied by context)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Lactobacillus acidophilus CL1285 (implied by context)""}]",Oral ingestion (Yogurt/Kefir delivery),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerant to bile acids and gastric acidity; utilizes lactose and other carbohydrates as carbon sources",Doubling time ~1–2 hours in vitro; stable in gastrointestinal tract under host conditions,"Gastrointestinal tract (small and large intestine), mucosal surface of the gut",Competitive exclusion of pathogens; synergistic interactions with resident microbiota; no significant disruption of core microbiome observed,"Tolerant to gastric acid, bile salts, osmotic stress; stable during lyophilization and storage at 4°C; resistant to drying and shear stress during processing","Cell wall components (e.g., teichoic acids), exopolysaccharides, and metabolic adaptation to stress",该系统由多种乳酸菌和双歧杆菌组成，均为兼性厌氧菌，可在人体胃肠道中定植。它们在37°C、pH 5.5–6.5条件下生长良好，对胃酸和胆汁具有耐受性，能利用乳糖等碳源进行代谢。在体外生长速率快，可在肠道黏膜表面稳定定植，通过竞争性排斥抑制病原体，且不显著破坏正常菌群结构。,None (Natural strains used; no genetic modification reported),Not applicable,Constitutive (natural expression of functional genes),,High (No plasmid-based systems; chromosomal stability; no reported drift or loss in vivo),Stable in yogurt/kefir matrix; no significant degradation during encapsulation or delivery,该系统未经过基因工程改造，使用的是天然存在的益生菌株，通过食品载体（酸奶/开菲尔）口服给药，其功能由天然基因组表达，无需外源调控元件。,"[""pH"", ""Bile Acids"", ""Lactate"", ""Glucose""]","[""Lactose"", ""Glucose"", ""SCFAs""]",,"[""Proteases"", ""Cytokines""]","FNR promoter (inferred for oxygen sensing), lactose permease (LacY), bile acid receptors (e.g., Bile acid-inducible promoters)",Constitutive expression; no complex logic gates; threshold-based activation via nutrient availability,这些益生菌通过感知肠道环境中的pH值、胆汁酸、乳糖和葡萄糖等信号启动代谢活动。其基因表达为组成型，但受底物浓度调控，如乳糖存在时激活乳糖转运系统。无复杂逻辑门控，但可通过底物浓度实现阈值响应，确保在适宜环境中激活功能。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (e.g., reuterin), lysis (controlled release), extracellular vesicles",Dose-dependent effect; 50 billion CFU per dose; higher doses associated with greater risk reduction,Highly compatible with yogurt/kefir matrix; stable during storage and delivery; no interference with gel structure or gas production,True,True,True,"Lactobacillus reuteri produces reuterin, a broad-spectrum antimicrobial compound; Lactobacillus species compete for nutrients and adhesion sites; produce organic acids (lactic acid) lowering pH to inhibit pathogens.","Reuterin (from Lactobacillus reuteri), Lactic acid, Bacteriocins",True,True,True,True,Lactobacillus reuteri产生的reuterin对多种病原体有效，包括艰难梭菌；乳酸降低pH值抑制病原体生长；在酸奶/开菲尔中稳定存在，不破坏基质结构；仅1例患者出现亚临床乳酸杆菌菌血症，无感染症状，表明安全性高。,False,,,False,False,False,,True,"Lactobacillus plantarum WCFS1 enhances tight junction proteins (occludin) and scaffold proteins; modulates immune cell activity via TLR2/4 signaling; reduces pro-inflammatory cytokines (TNF-α, IL-6).","Occludin, TLR2/4 ligands, IL-10, TGF-β",True,Lactobacillus plantarum WCFS1 increases expression of tight junction proteins; Lactobacillus rhamnosus GG protects gastric mucosa; promote epithelial barrier integrity and wound healing.,"Occludin, ZO-1, Mucin-2, Growth factors (e.g., EGF)",False,,,False,,,GRAS,None (natural strains; no kill-switch or auxotrophy reported),,Low pathogenicity; no known virulence factors; no antibiotic resistance genes reported; no horizontal gene transfer observed; low risk of environmental escape,Physical barrier via oral delivery and gastrointestinal transit; no systemic dissemination in non-immunocompromised patients,所用菌株均为公认安全（GRAS）的益生菌，未进行基因改造，无致病性或耐药基因。仅1例患者出现亚临床乳酸杆菌菌血症，无临床症状，表明在非中性粒细胞减少或免疫抑制患者中使用安全。,在2008至2014年期间，创伤患者中艰难梭菌感染（CDI）发生率从每1000例住院患者11.2例降至4.8例（p=0.03）；接受抗生素治疗的患者中CDI发生率从2.2%降至0.7%（p=0.01）。益生菌使用与CDI发生率下降显著相关，且未见严重不良反应，表明该益生菌组合在预防CDI方面具有显著疗效。,8400,2173,10573,,
8467d178-8d6c-492e-b0a8-1906bbb17503,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus LC705"", ""strain_id"": ""DSM 7061""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve Bb99"", ""strain_id"": ""DSM 13692""}, {""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium freudenreichii ssp. shermanii JS"", ""strain_id"": ""DSM 7076""}]",Encapsulated in milk-based fruit drink,Facultative Anaerobe,Growth at 37°C in MRS broth; pH and osmotic tolerance not explicitly stated; requires lactose and other nutrients for growth,Growth rate not quantified; viable in human GI tract during antibiotic therapy; doubling time not reported,Gastrointestinal tract (colonization of gut mucosa and fecal recovery observed),Competes with H. pylori for adhesion sites; may restore lactobacilli and bifidobacteria levels disrupted by antibiotics; potential synergistic effects in consortium,"Survives high-dose antibiotic therapy (clarithromycin, amoxicillin, PPI); tolerates freezing and storage; stable during lyophilization/rehydration (implied by product formulation)",Milk-based drink matrix; cryoprotectants in formulation (implied),该益生菌群落由四种菌株组成，均能在人体胃肠道中存活，即使在高强度抗生素治疗期间。LGG和PJS在粪便中的浓度显著增加，表明其在胃肠道中具有良好的定植能力。,,,,,No genetic modifications reported; natural strains used; stability in GI tract confirmed by fecal recovery,Stable in milk-based drink formulation; survives encapsulation and gastrointestinal transit,未对菌株进行基因工程改造，使用天然益生菌株。其功能基于天然生理特性，如竞争性排斥、免疫调节和抗菌作用。,"[""pH"", ""Bile acids""]","[""Lactose"", ""Glucose""]",,"[""Proteases"", ""Cytokines""]","Not specified; likely native receptors for pH, bile, and nutrients",No engineered logic circuits; natural sensing and response mechanisms,各菌株通过天然受体感知胃肠道环境中的pH、胆汁酸、乳糖和葡萄糖等信号，响应宿主炎症因子（如细胞因子）和蛋白酶，调节自身代谢与免疫调节功能。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Natural secretion (e.g., lactic acid, bacteriocins); no engineered delivery systems",Twice daily intake of 1×10^9 CFU/mL; controlled by formulation and dosing schedule,Highly compatible with milk-based drink matrix; stable during encapsulation and gastrointestinal transit,True,False,False,通过竞争性排斥、抑制H. pylori黏附、降低尿素酶活性等方式抑制H. pylori生长,"Lactobacillus rhamnosus GG, L. rhamnosus LC705, Bifidobacterium breve Bb99, Propionibacterium freudenreichii ssp. shermanii JS",False,True,True,True,LGG和PJS在抗生素治疗期间仍能在粪便中检测到，表明其具有良好的生存能力且不破坏肠道结构；未报告显著毒性或微生物组紊乱。,False,,,False,False,False,未涉及氧气生成机制。,True,调节免疫反应，增加抗炎细胞因子，改善肠道屏障功能，缓解炎症性肠病症状,"Cytokines (e.g., IL-10, TGF-β), Mucus secretion factors",False,,,True,调节肠道代谢环境，如通过乳酸、丙酸等短链脂肪酸调节pH，促进有益菌群生长,"Lactic acid, Propionic acid, SCFAs",False,,,GRAS,None (natural strains used; no kill-switches or auxotrophy reported),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape,Physical confinement via oral delivery and intestinal transit; no engineered containment,四种菌株均为公认安全（GRAS）的益生菌，未进行基因改造，无致病性或耐药基因。在抗生素治疗期间仍能存活，表明其具有良好的环境适应性和安全性。,在为期7天的H. pylori根除治疗期间，益生菌组的总症状评分显著降低（P=0.038），表明其能有效改善治疗耐受性。H. pylori根除率在益生菌组为91%，对照组为79%，虽无统计学差异，但提示潜在疗效。粪便中LGG和PJS浓度显著上升，证实其在肠道中成功定植并存活。,11829,1768,13597,,
5cbae7a2-8587-400a-b5d0-d226dcc907bf,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Vero cells"", ""strain_id"": ""Low-passage Vero cells (WHO source)""}]","Suspension (electroporated cells in cuvette), followed by monolayer culture on flasks and plates",Aerobic,"37°C, 32°C (for virus amplification), in OptiPRO SFM or MEM with 10% gamma-irradiated FBS (BSE-free), supplemented with 4 mM L-glutamine",Cells passaged 1:6 one day prior to transfection; confluency 70–90% at transfection; virus yield monitored daily post-electroporation; growth kinetics show rHPIV1 > rHPIV3 > rHPIV2 in titer,,,"Tolerant to electroporation stress, protease treatment (TrypLE Select), and freeze-thaw cycles (implied by cell banking and long-term culture)",TrypLE Select (recombinant protease),Vero细胞为非洲绿猴肾细胞系，可在37°C下生长，用于病毒复苏与扩增。细胞在无动物源性成分的培养基中维持，仅在传代时使用经辐照的BSE安全胎牛血清。细胞对电穿孔、蛋白酶处理和冻融具有耐受性，适用于临床级疫苗生产。,"Electroporation (Amaxa Nucleofector II), plasmid transfection","High recovery efficiency for rHPIV3 (up to 8/8 with NF), moderate for rHPIV1 (2/2 with cGMP-NF), variable for rHPIV2; PBS buffer showed lower efficiency and cell viability",Constitutive expression via T7 promoter (pCI-T7 plasmid),T7 RNA polymerase (encoded by pCI-T7 plasmid),Stable plasmid expression in Vero cells; virus amplified through multiple passages; biological cloning by terminal dilution ensures clonality,"Plasmid DNA and electroporation buffers (cGMP-NF, NF, PBS) are compatible with Vero cell viability and viral recovery",通过电穿孔将编码HPIV抗原基因组、N、P、L蛋白及T7 RNA聚合酶的质粒共转染至Vero细胞，利用T7启动子驱动病毒蛋白表达，实现从cDNA完全恢复活病毒。该方法简化了传统转染流程，避免了病毒载体或恒定表达细胞系的使用，适用于临床试验级疫苗生产。,,,,,,,本研究未涉及微生物感知模块或逻辑控制，系统为基于质粒的病毒复苏平台，无环境响应或信号调控机制。,"[""Vaccine Production""]",Viral particle release (infectious virus production),Controlled by plasmid dose and electroporation efficiency; virus amplified via serial passaging,"Compatible with cGMP-NF, NF, and PBS electroporation buffers; suitable for encapsulation in clinical-grade vaccine production",False,,,,,,,,,,False,,,,,,,False,,,False,,,False,,,False,,,BSL-2,"Use of qualified low-passage Vero cell banks, minimal animal product use, and avoidance of recombinant vaccinia-T7 vector",T7 RNA polymerase (pCI-T7 plasmid),Vero cells are non-tumorigenic and BSE-free; no antibiotic resistance genes reported; no horizontal gene transfer risk due to non-replicating plasmid system; low risk of adventitious agents due to animal product-free reagents,Physical confinement via cell culture containment and GMP-compliant manufacturing,该系统使用经WHO认证的低传代Vero细胞，仅在细胞传代时使用经辐照的BSE安全胎牛血清，其余步骤均采用无动物源性成分试剂。避免了使用重组痘苗病毒或恒定表达T7聚合酶的细胞系，显著降低外源污染风险。系统无致病性，适用于人类临床试验，生物安全等级为BSL-2。,本研究未评估治疗或伤口愈合效果，其主要目标为开发适用于人类临床试验的重组副流感病毒疫苗候选株的高效、无动物源性复苏方法。该方法成功实现了HPIV1、HPIV2、HPIV3野生型及减毒株的快速恢复，其中HPIV3恢复效率最高（8/8），HPIV1和HPIV2在优化条件下也可高效恢复，为疫苗临床前开发提供了可靠平台。,7270,1640,8910,,
e5b3097c-0bf5-44e7-95d3-4a42f269ba52,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis subsp. inaquosorum"", ""strain_id"": ""V1""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 7.2 (PBS); Carbon source: MRS broth; Nutritional requirements: Complex medium (MRS) with amino acids, vitamins, and carbohydrates",Growth rate: 18–48 h in MRS broth; Doubling time not specified; In vitro growth confirmed; In vivo colonization in fish gut inferred,"Gastrointestinal tract of Carassius auratus (goldfish), intestinal mucosa","Competitive exclusion of pathogens (E. coli, S. aureus) via co-aggregation; potential modulation of gut microbiota","Tolerant to osmotic stress (PBS wash), moderate shear stress (vortexing), and storage at 4°C; lyophilization not tested",S-layer proteins (protective surface layer),该菌株为从虾肠道分离的革兰氏阳性杆菌，能在37°C、pH 7.2的MRS培养基中良好生长，具有较强的自聚集和共聚集能力，能有效黏附于鱼肠道黏膜，具有良好的环境适应性和在宿主肠道定植能力。,,,,,,,该研究未对菌株进行基因工程改造，其功能主要依赖于天然的生理特性，如产生细菌素、自聚集、共聚集及分泌消化酶等，未涉及人工基因回路或可调控表达系统。,,,,,S-layer proteins (detected via LiCl₂ treatment),"No synthetic logic gates; natural aggregation behavior follows time-dependent, concentration-dependent kinetics",菌株通过S层蛋白介导的细胞表面疏水性实现自聚集和共聚集，该过程随时间推移而增强，无明确的逻辑门控机制，属于自然生理响应。,"[""Antibacterial"", ""Tissue Repair"", ""Metabolic Regulation""]",Constitutive secretion via cell lysis or extracellular release (natural secretion),Not controllable; activity depends on natural growth and secretion,Compatible with feed pellet matrix; stable during drying at 45°C,True,True,False,通过产生细菌素（bacteriocin）直接杀灭病原菌，同时通过自聚集和共聚集能力抑制病原菌黏附和定植。,Bacteriocin,True,True,True,True,该菌株对大肠杆菌和金黄色葡萄球菌均表现出显著的共聚集能力（33.15%和32.40%），且能产生天然细菌素，具有广谱抗菌活性；在鱼饲料中使用未见不良反应，表明其活性可控且安全。,False,,,False,False,False,未提及任何产氧机制或光依赖性氧合功能。,False,,,True,通过分泌消化酶（如蛋白酶、淀粉酶、纤维素酶、脂肪酶）促进营养吸收，增强组织蛋白合成，改善肠道屏障功能。,"Digestive enzymes (Amylase, Cellulase, Protease, Lipase)",True,通过分泌多种酶调节宿主代谢，促进碳水化合物、蛋白质、脂肪和纤维素的消化吸收，提高营养利用率。,"Digestive enzymes (Amylase, Cellulase, Protease, Lipase)",False,,,GRAS,"None (natural strain, no synthetic kill switches)",,Low pathogenicity; no known toxins; no antibiotic resistance genes reported; no horizontal gene transfer data; environmental escape risk low due to non-native habitat (shrimp gut isolate),Feed pellet matrix provides physical confinement,该菌株为天然分离的益生菌，属于GRAS（公认安全）类别，未发现致病性、抗生素抗性基因或水平基因转移风险，且通过饲料颗粒封装，具有良好的物理屏障，安全性高。,在30天喂养实验中，实验组鱼体重增长达34.56%，显著高于对照组（11.28%）；特定生长率（SGR）为0.99%，远超对照组的0.35%；总蛋白含量提高至30.56 mg/g，消化酶活性（淀粉酶、蛋白酶、脂肪酶、纤维素酶）均显著增强，抗氧化酶（SOD、CAT）活性也明显提升，表明该菌株能有效促进鱼类生长、改善营养吸收、增强抗氧化能力，具有显著的益生功效。,16109,1603,17712,,
318d2fb9-c3d6-4185-8bad-8df14159e74a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""R0011""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""R0052""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly acidic; Nutritional requirements: Complex media with carbohydrates (e.g., glucose), amino acids, vitamins",Growth rate: Moderate; Doubling time: ~1–2 hours in vitro; In vivo homeostasis not explicitly reported,"Gut lumen, intestinal mucosa; preferred niche: proximal small intestine and colon",Symbiotic with host microbiota; may compete with pathogenic bacteria; no evidence of antagonism with other commensals,"Moderate tolerance to bile salts, low pH (gastric), and osmotic stress; stability during lyophilization and rehydration reported in product literature","Bile salts, low pH (HCl), lyophilization stabilizers","Lactobacillus rhamnosus R0011 and Lactobacillus acidophilus R0052 are facultative anaerobes capable of growing in the human gastrointestinal tract under physiological conditions. They exhibit moderate tolerance to gastric acidity and bile, enabling survival through the upper GI tract. Their growth is supported by fermentable carbohydrates and essential nutrients found in the gut environment. These strains are used in probiotic formulations and are known for their ability to colonize the intestinal mucosa and modulate immune responses.",Not specified (no genetic modification reported),Not applicable (no genetic engineering described),Constitutive (no inducible systems reported),,High chromosomal stability; no plasmids reported; no evidence of genetic drift or loss in vivo,"Stable in oral delivery formulations (e.g., capsules, suspensions); no degradation in gastrointestinal environment","The microbial system consists of two naturally occurring probiotic strains, Lactobacillus rhamnosus R0011 and Lactobacillus acidophilus R0052, used in their native, unmodified form. No genetic modifications were performed. The strains are administered orally as a suspension in distilled water, relying on their intrinsic physiological properties for function. Their stability in the gastrointestinal tract and resistance to environmental stresses are inherent traits, not engineered.","[""Low pH (gastric)"", ""Bile salts"", ""Osmotic stress""]","[""Glucose"", ""Lactate"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing molecules (e.g., AI-2, AHL – inferred from genus-level behavior)""]","[""Proteases (e.g., trypsin, chymotrypsin)"", ""Cytokines (e.g., IL-1β, TNF-α – indirect sensing via immune modulation)""]","Bile salt hydrolase (BSH), acid tolerance systems (e.g., F0F1-ATPase), two-component systems (e.g., LiaRS, ComDE)",No explicit logic circuits; likely constitutive expression of immune-modulatory factors with threshold-based responses to environmental cues,"The strains sense environmental signals such as low pH and bile salts via intrinsic stress response systems. They respond to nutrient availability (e.g., glucose, lactate) and microbial metabolites (e.g., SCFAs) through metabolic regulation. While no synthetic genetic circuits are used, their natural behavior includes sensing host and microbial signals to modulate immune responses, particularly through downregulation of proinflammatory cytokines like IL-1β and TNF-α. This suggests a form of innate logic: 'if inflammation is high, reduce it' – though not engineered.","[""Immunomodulation"", ""Metabolic Regulation""]","Type IV secretion system (inferred), extracellular vesicles, passive diffusion",Oral administration at fixed dose (1 mg/mL/day); no feedback control or dynamic regulation reported,Compatible with oral suspension; stable in gastrointestinal environment; no evidence of material degradation or interference with delivery,False,,,Not applicable (no direct antibacterial activity reported),,False,,,,无直接抗菌作用证据,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,无氧生成机制,True,"Downregulates proinflammatory cytokines (IL-1β, TNF-α) in liver tissue; reduces TLR-4 expression; modulates innate immune response via interaction with Kupffer cells and dendritic cells.","Lactobacillus cell wall components (e.g., peptidoglycan, lipoteichoic acid), secreted metabolites (e.g., SCFAs), and extracellular vesicles",False,Not reported,,True,"Modulates gut-liver axis metabolism; produces SCFAs (e.g., acetate, propionate) via fermentation of dietary fibers; influences host lipid and glucose metabolism.","Short-chain fatty acids (SCFAs), particularly acetate and propionate",False,Not applicable,,GRAS,"None (naturally occurring, non-pathogenic strains)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape; safe for human consumption,Oral delivery with natural gut barrier; no physical confinement required,"Lactobacillus rhamnosus R0011 and Lactobacillus acidophilus R0052 are well-established probiotics with GRAS status. They are non-pathogenic, do not produce toxins, and are not associated with systemic infections. No antibiotic resistance genes were reported. Their use in humans is safe and widely documented. No engineered containment systems are needed.",在酒精性肝病小鼠模型中，Lacidofil（L. rhamnosus R0011 和 L. acidophilus R0052）显著降低了肝脏组织中IL-1β和TNF-α水平，抑制了TLR-4的表达，并减轻了酒精诱导的肝脂肪变性。尽管肝功能指标（如ALT、AST）无显著改善，但病理学结果显示，与酒精组相比，Lacidofil组的肝脂肪变性程度显著降低（p < 0.05）。这表明该益生菌组合在调节免疫反应和改善肝脂肪变性方面具有潜在治疗价值。,12251,2012,14263,,
22280519-5a56-42ac-8da8-825cf39c9373,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LA""}, {""role"": ""Chassis"", ""scientific_name"": ""Candida utilis"", ""strain_id"": ""CU""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, in nutrient-rich medium with organic carbon sources (e.g., glucose, lactose); tolerates moderate osmotic stress and bile salts.",Doubling time ~1.5–2.0 hours in vitro; growth rate consistent with in vivo intestinal environment.,"Intestinal tract (gut mucosa), particularly in the small intestine and cecum of laying hens.","Competitive exclusion of pathogenic bacteria (e.g., E. coli); symbiotic with host microbiota by maintaining microbial balance and enhancing gut barrier function.","Moderate tolerance to drying, lyophilization, and shear stress; stable during feed processing and storage.","Cell wall components (e.g., peptidoglycan, mannoproteins) and endogenous antioxidants (e.g., superoxide dismutase).",该微生物系统由Lactobacillus acidophilus和Candida utilis组成，均为兼性厌氧菌，可在鸡肠道内定植并稳定生长。其生长适宜温度为37°C，pH 6.0–7.0，能利用葡萄糖等碳源进行代谢，具有一定的耐胆盐和渗透压能力，适合在饲料中长期稳定存在。,Plasmid-based expression system (implied by patent ZL 2005 1 0040990.2); no explicit CRISPR or recombinase tools mentioned.,Not specified; likely moderate efficiency based on industrial fermentation practices.,Constitutive expression of selenium biotransformation genes; no inducible circuits reported.,,High chromosomal stability; plasmid-free system used; no reported gene loss or drift.,Stable in feed matrix; maintains viability and function during feed processing and storage.,通过基因工程改造L. acidophilus和C. utilis，使其具备将无机硒（亚硒酸钠）高效转化为有机硒（如硒代蛋氨酸）的能力。该系统基于专利技术，无需质粒，依赖染色体整合的代谢通路，确保长期遗传稳定性。,"[""pH"", ""Glucose"", ""Lactate""]","[""Selenite (Na2SeO3)"", ""Bile acids""]",,,"Selenite transporter (e.g., selenite-specific ABC transporter); pH-responsive promoters (e.g., P1 promoter in L. acidophilus).",Constitutive activation; no complex logic gates reported. Thresholds set by metabolic flux control.,微生物通过感知环境中的无机硒（亚硒酸钠）和pH变化启动硒的生物转化过程，以维持代谢稳态。该系统为组成型表达，无外部诱导信号，逻辑简单，依赖底物浓度驱动。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]",Lysis and passive diffusion; no specialized secretion systems reported.,Dose-dependent via dietary supplementation level (0.2–1.0 mg Se/kg feed); no feedback control.,Compatible with feed matrix; stable during pelleting and storage.,True,True,False,L. acidophilus produces lactic acid and bacteriocins that inhibit pathogenic E. coli and other Gram-negative bacteria.,"Lactic acid, bacteriocins (e.g., acidocin)",True,True,True,True,研究显示SP可显著拮抗致病性大肠杆菌，且对宿主细胞无明显毒性，表明其抗菌活性可控且安全。,False,,,False,False,False,未涉及氧气生成机制，无相关数据支持。,True,调节肠道免疫反应，增强巨噬细胞活性，促进抗炎因子分泌，抑制过度炎症。,"Cytokines (e.g., IL-10, TGF-β), cell wall components (e.g., mannoproteins)",True,通过改善肠道屏障功能、促进上皮细胞再生和减少氧化损伤，间接支持组织修复。,"Short-chain fatty acids (SCFAs), mucin-enhancing factors",True,将无机硒转化为有机硒（如硒代蛋氨酸），提高蛋中硒含量，调节宿主抗氧化代谢。,Selenomethionine,False,,,GRAS,Auxotrophy (nutrient-dependent growth); no kill-switches reported.,Selenite (as selective pressure),Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape documented.,Feed matrix provides physical confinement; no encapsulation or barrier system used.,该系统由公认安全（GRAS）的L. acidophilus和C. utilis构成，无致病性，不携带耐药基因，且依赖外源硒生长，具有天然生物安全屏障，适合用于动物饲料和人类营养补充。,SP显著提高蛋的产蛋率、蛋重、蛋硒含量和谷胱甘肽过氧化物酶（GPX）活性，同时降低饲料/蛋比和蛋胆固醇含量。蛋的哈夫单位（HU）下降速度减缓，表明蛋的新鲜度和货架期延长。该系统可生产富含硒、低胆固醇的营养蛋，适用于高血脂、心血管疾病患者及硒缺乏人群。,17898,1812,19710,,
7ff785d0-62f2-44a6-be6e-5b57f1da144f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 17938""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, requires lactose or other fermentable carbohydrates; no specific mention of bile or osmotic tolerance",Doubling time not reported; growth in vitro under standard conditions; in vivo colonization in infant gut observed,"Infant gastrointestinal tract, particularly in breastfed infants; preferentially colonizes the small intestine",Competitive exclusion of pathogenic bacteria; potential symbiosis with host microbiota; no significant disruption of native microbiome reported,Tolerance to gastric acidity and bile salts (inferred from clinical use); stable during lyophilization and rehydration (implied by commercial formulation),Lactobacillus reuteri DSM 17938 (intrinsic properties),该菌株为兼性厌氧菌，可在37°C下生长，适宜pH为6.0–7.0，依赖乳糖等可发酵碳源。在母乳喂养婴儿中可定植于小肠，具有良好的胃肠道耐受性，能耐受胃酸和胆汁，适用于口服制剂。,,,,,No genetic modifications reported; naturally stable in human gut; no plasmid or integration systems used,No engineered genetic circuits; stability in oral suspension formulation,该系统未进行基因工程改造，L. reuteri DSM 17938为天然菌株，通过口服给药在婴儿肠道中定植，无需外源基因调控系统。,"[""pH"", ""Lactose""]","[""Lactose"", ""Bile acids""]",,,Lactose permease and acid tolerance systems (inferred from known physiology),No synthetic logic circuits; natural metabolic sensing of lactose and pH,该菌株通过天然代谢通路感知乳糖和pH变化，调控自身代谢与定植行为，无人工设计的逻辑门控机制。,"[""Metabolic Regulation"", ""Immunomodulation""]",Passive diffusion and natural secretion,Fixed daily dose of 10^8 CFU; no dynamic control,Compatible with oral suspension formulation; stable in liquid and lyophilized forms,False,,,Not applicable,,False,False,False,False,未评估抗菌功能,False,Not applicable,,False,False,False,未涉及氧合功能,True,Modulates immune response in infant gut by reducing pro-inflammatory cytokines and enhancing regulatory T-cell activity; may reduce intestinal inflammation associated with colic.,Reuterin (antimicrobial and immunomodulatory compound produced by L. reuteri),False,Not applicable,,True,"Produces reuterin and other metabolites that regulate gut microbiota composition and fermentation, reducing gas production and improving gut motility, thereby alleviating colic symptoms.",Reuterin,False,Not applicable,,GRAS,No kill-switch or auxotrophy; relies on natural attenuation in human gut,None,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk due to human-specific adaptation,Oral administration with natural gut clearance; no physical barrier required,L. reuteri DSM 17938被列为GRAS（公认安全）菌株，无致病性，不携带抗生素抗性基因，不会在环境中长期存活，安全性高，适用于婴幼儿。,在母乳喂养婴儿中，L. reuteri DSM 17938可使治疗成功率提高67%（RR=1.67），每日哭闹时间平均减少50分钟（MD=-50 min），NNT=5。效果主要在母乳喂养婴儿中显著，对配方奶喂养婴儿无明显疗效。,7078,1472,8550,,
caf4422c-460d-4807-9325-14a5f4d827a6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""TISTR 2075""}]",Encapsulated,Facultative Anaerobe,Growth at 37°C in Job's Tears extract medium with maltodextrin; microaerobic-static conditions.,Doubling time not specified; growth rate maintained under microaerobic conditions.,Gastrointestinal tract (target niche for probiotic function),"Competitive exclusion of foodborne pathogens (E. coli O157:H7, Salmonella Typhimurium); no direct interaction with host microbiome described.","High tolerance to simulated gastric (pH 2.0) and intestinal (pH 8.0, 0.45% bile salt) conditions; stable under spray drying and storage.","Protein (soy + milk), trehalose, maltodextrin","Lactobacillus plantarum TISTR 2075 grows optimally at 37°C under microaerobic conditions in Job's Tears extract medium supplemented with maltodextrin. It exhibits strong resistance to acidic and bile salt environments, making it suitable for gastrointestinal survival. The strain maintains viability after spray drying and during storage under controlled humidity and temperature conditions.",,,,,,,该研究未对Lactobacillus plantarum TISTR 2075进行基因工程改造，仅通过喷雾干燥结合保护剂（如蛋白、海藻糖）提高其稳定性和存活率。,,,,,,,该研究未涉及微生物的感知模块或逻辑控制机制。,"[""Antibacterial"", ""Gastrointestinal Tolerance""]",Passive diffusion and cell lysis (inferred from natural secretion of metabolites),Not controllable; dependent on initial cell count and carrier matrix.,"High compatibility with maltodextrin, protein, trehalose, and acacia gum matrices; stable in glassy state below Tg.",True,True,False,通过分泌抗菌物质抑制食源性致病菌生长，如大肠杆菌O157:H7和沙门氏菌Typhimurium。,Lactic acid and other bacteriocins (inferred from probiotic activity),True,True,True,True,喷雾干燥后L. plantarum对大肠杆菌O157:H7和沙门氏菌的抑制圈直径为12.3–12.6 mm和14.3–14.4 mm，表明其具有广谱抗菌活性且未因干燥过程受损。,False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,None (no genetic modifications or kill switches),,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk due to lack of genetic engineering.,Physical encapsulation in dried powder matrix provides barrier to release.,"Lactobacillus plantarum TISTR 2075 is classified as GRAS (Generally Recognized As Safe). It is non-pathogenic, does not carry antibiotic resistance genes, and is not genetically modified. The spray-dried powder form provides physical containment, minimizing environmental release risk.",喷雾干燥后L. plantarum TISTR 2075在模拟胃肠道环境中表现出良好的存活率，对大肠杆菌O157:H7和沙门氏菌具有显著的抑制作用，且在25°C和33%相对湿度下储存180天后仍保持较高活性，表明其具有良好的稳定性和功能性，适用于非冷藏条件下的商业化应用。,15917,1415,17332,,
c3a48ede-19c8-47b7-9915-3cbd1f8227f0,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""La5""}]",Suspension,Facultative Anaerobe,"Grown anaerobically at 37°C on MRS medium; optimal growth temperature 37°C, pH not specified but typical for lactic acid bacteria.",Doubling time not reported; growth observed in vitro and in vivo in mouse gut with stable population levels over time.,"Gastrointestinal tract (digestive tract), particularly in the gut lumen; capable of transient colonization and persistence without antibiotic pressure.","Can interact with resident enterococci (e.g., E. faecium) in the gut; potential to act as a vector for horizontal gene transfer. No evidence of competition or symbiosis with other microbiota.",Tolerant to digestive transit (gastric and intestinal conditions); survives in gut environment for extended periods (up to 30 days).,"None explicitly mentioned, but survival suggests inherent tolerance to bile, pH fluctuations, and shear stress in gut.","Lactobacillus acidophilus La5 is a probiotic strain that grows anaerobically at 37°C and can survive and persist in the mouse gastrointestinal tract. It is capable of transient colonization and long-term persistence even in the absence of antibiotic selection, indicating robust environmental tolerance during digestive transit.",Conjugative transfer via Tn1546-like transposon on a large conjugative plasmid (in donor E. faecium); no engineered genetic tools used in this study.,Not applicable (no deliberate genetic modification in this study).,Not applicable (no synthetic circuits or inducible systems described).,,"Chromosomal integration of vanA cluster is stable in vivo; transconjugants persist for at least 30 days without antibiotic pressure. However, transconjugants show ecological disadvantage (lower colonization levels than wild-type recipient).",No material encapsulation or delivery system used; natural gut environment serves as the medium.,"The strain was not genetically modified in this study. However, it acquired the vanA gene cluster via natural conjugative transfer from Enterococcus faecium, demonstrating its ability to integrate and maintain foreign antibiotic resistance genes in the gut environment.","[""Hypoxia"", ""pH""]","[""Bile acids""]","[""Quorum sensing (indirectly via donor proximity)""]",,No specific engineered sensor identified; natural adaptation to gut environment enables survival and interaction.,No synthetic logic gates or regulatory circuits described; natural physiological responses to gut conditions.,"Lactobacillus acidophilus La5 naturally senses and adapts to the anaerobic, bile-rich, and fluctuating pH environment of the gastrointestinal tract. It does not possess engineered sensing circuits but can respond to microbial proximity (e.g., co-colonization with enterococci) to facilitate conjugation, suggesting passive sensing of physical and chemical cues in the gut.","[""Genetic Transfer""]",Conjugative transfer via plasmid-mediated horizontal gene transfer (HGT); no secretion systems or lysis described.,No dosage control; transfer frequency is spontaneous and influenced by donor-recipient proximity and gut environment.,Natural gut environment supports conjugation; no artificial material used for delivery or encapsulation.,False,,,Not applicable (no antibacterial function described).,,False,False,False,False,无相关证据,False,Not applicable (no oxygenation function described).,,False,False,False,无相关证据,False,Not applicable (no immunomodulatory function described).,,False,Not applicable (no tissue repair function described).,,False,Not applicable (no metabolic regulation function described).,,False,Not applicable (no tumor therapy function described).,,GRAS,None (no engineered kill-switch or auxotrophy used).,,High risk of acquiring and disseminating vancomycin resistance genes (vanA cluster); potential to act as a donor to other commensal or pathogenic bacteria. Risk is elevated in immunocompromised hosts or during antibiotic therapy.,None (no physical barrier used; natural gut environment allows free interaction).,尽管Lactobacillus acidophilus La5被归类为GRAS（一般认为安全），但本研究首次证明其可在无抗生素选择压力下从肠球菌获得万古霉素抗性基因（vanA簇），并在小鼠肠道中长期存活。该抗性基因可通过接合转移传播，可能成为耐药基因的传播载体，尤其在免疫抑制患者或抗生素治疗期间使用时风险更高。因此，该菌株在作为益生菌使用时需谨慎评估其安全性。,本研究未评估伤口愈合或治疗效果，主要关注基因转移与安全性。但结果显示，获得抗性的Lactobacillus acidophilus La5可在小鼠肠道中长期定植（长达30天），且在万古霉素选择压力下其种群数量可增加40倍，表明其在特定条件下具有较强的生态适应能力。,7087,1694,8781,,
175da526-9416-44bb-ac13-8cdcc4f1a91a,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GR-1"", ""strain_id"": ""GR-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri RC-14"", ""strain_id"": ""RC-14""}]",Suspension,Facultative Anaerobe,"Grown anaerobically in MRS broth at 37°C; optimal growth temperature 37°C, pH neutral (adjusted to pH 7.0 for CFS use)",Growth rate not explicitly quantified; reached 10^8 CFU/ml in MRS broth after 24 h at 37°C; maintained at 10^7 CFU/ml during experiments,Vaginal epithelium (simulated in vitro model of vaginal candidiasis),Competitive exclusion of Candida albicans; co-resides with C. albicans in healthy vaginal environment; may modulate host immune response,"Stable during centrifugation (3000g, 15 min at 4°C), filtration (0.20 μm), and storage at -80°C; tolerance to PBS wash and resuspension in KSFM medium","PBS, MRS broth, KSFM medium","L. rhamnosus GR-1 and L. reuteri RC-14 are facultative anaerobes that grow well in MRS broth at 37°C under anaerobic conditions. They maintain viability and concentration (10^7 CFU/ml) during experimental procedures, including centrifugation, washing, and resuspension. Both strains are adapted to the vaginal environment and can survive in the presence of host epithelial cells and Candida albicans.",,,,,,,"No genetic engineering was performed in this study. The strains were used in their native form, without plasmid integration, CRISPR editing, or synthetic circuitry. The observed effects are attributed to natural metabolic and immunomodulatory activities.","[""pH"", ""Temperature""]","[""Nutrient availability (competition with C. albicans)""]","[""C. albicans presence (indirect sensing via competition or contact)""]","[""Epithelial cell contact"", ""Cytokine environment (IL-1α, IL-8, IP-10)""]",Not specified (likely native receptors for host cell contact and nutrient sensing),No synthetic logic gates; natural response to microbial competition and host cell interaction,"The lactobacilli respond to the presence of Candida albicans through competitive nutrient consumption and direct contact with epithelial cells. This triggers the release of soluble factors (CFS) that modulate host immune responses, particularly upregulating IL-8 and IP-10. The response is not genetically programmed but arises from natural microbial interactions.","[""Immunomodulation"", ""Antibacterial & Antibiofilm""]",Secretion of soluble factors (CFS) via passive diffusion; no specific secretion system reported,Dose-dependent effects observed: higher concentrations (10^7 CFU/ml) and CFS (1:10 v/v) were effective; no synthetic control mechanisms,Compatible with in vitro cell culture (KSFM medium); no encapsulation or material barrier used,True,False,True,L. reuteri RC-14 alone and in combination with L. rhamnosus GR-1 significantly reduced C. albicans population at 24 hr. L. rhamnosus GR-1 has been previously shown to inhibit biofilm formation by downregulating filamentation genes.,"Soluble metabolites in CFS (e.g., organic acids, bacteriocins, biosurfactants)",True,True,True,True,L. reuteri RC-14 reduced C. albicans from 4.0×10⁶ CFU/ml (control) to 3.0×10⁵ CFU/ml (p < 0.05). L. rhamnosus GR-1 inhibits biofilm formation via downregulation of filamentation genes. No cytotoxicity reported; localized effect in epithelial model.,False,,,,,,,True,"CFS from both lactobacilli strains upregulated IL-8 and IP-10 secretion by VK2/E6E7 cells infected with C. albicans. L. reuteri RC-14 alone increased IL-8; L. rhamnosus GR-1 alone increased IP-10. These chemokines recruit neutrophils and Th1/NK cells, enhancing immune clearance.","Soluble factors in CFS (e.g., peptides, organic acids, exopolysaccharides)",False,,,False,,,False,,,GRAS,None (native strains used; no synthetic kill switches or auxotrophy),,Low pathogenicity; both strains are well-characterized probiotics with clinical history in VVC treatment. No antibiotic resistance genes or HGT risk reported. No environmental escape risk in in vitro model.,None (no physical confinement used in in vitro model),"L. rhamnosus GR-1 and L. reuteri RC-14 are GRAS (Generally Recognized As Safe) organisms with established safety profiles in human use. They are non-pathogenic, non-invasive, and have been used in clinical trials for vulvovaginal candidiasis without adverse events. No genetic modifications or biocontainment systems were employed.","In vitro, L. reuteri RC-14 alone and in combination with L. rhamnosus GR-1 significantly reduced C. albicans growth (from 4.0×10⁶ to 3.0×10⁵ CFU/ml at 24 hr). Both strains upregulated IL-8 and IP-10, key chemokines for neutrophil and Th1/NK cell recruitment, suggesting enhanced immune clearance. These findings support prior clinical data showing reduced symptoms and Candida positivity in women treated with this probiotic consortium.",11618,1932,13550,,
33d5c997-1849-4246-a981-de44623ae525,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis Bb-12"", ""strain_id"": ""Bb-12""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 3.5–5.0 (acidic tolerance); Osmotic: Not specified; Nutrition: Utilizes glucose, lactose, galactose, fructo-oligosaccharides (FOS), and galacto-oligosaccharides (GOS) as carbon sources",Growth rate: Moderate; Doubling time: Not specified; In vivo vs in vitro: Demonstrated survival and persistence in human GI tract during feeding period,"Human gastrointestinal tract (colon), particularly in the context of faecal microbiota","Competes with endogenous bifidobacteria and other gut microbes; no significant disruption of coliforms, C. perfringens, or lactic acid bacteria observed; transient colonization without long-term persistence","High resistance to bile salts (1.5% w/v), acidic conditions (pH 3.5–5.0), and elevated temperature (44°C); stable viable count in yoghurt product","Bile salt mixture (Sigma B8756), HCl/KCl buffer (pH 2), elevated incubation temperature (44°C)","Bifidobacterium lactis Bb-12 is a facultative anaerobe capable of surviving harsh gastrointestinal conditions, including low pH and bile salts. It grows well on various carbohydrates including glucose, lactose, galactose, FOS, and GOS. It demonstrates high viability and stability in food matrices and survives transit through the human gastrointestinal tract, though it does not persist long-term after cessation of supplementation.",,,,,No genetic modifications reported; natural strain with inherent stability in food and GI environments,Stable in yoghurt and GOS-containing syrup; no evidence of plasmid loss or genetic drift,"Bifidobacterium lactis Bb-12 was used in its native, unmodified form. No genetic engineering tools (e.g., CRISPR, plasmids) were applied. Its probiotic efficacy is attributed to natural physiological traits rather than synthetic genetic circuits.","[""Acidity"", ""Bile""]","[""Glucose"", ""Lactose"", ""Galactose"", ""Fructo-oligosaccharides (FOS)"", ""Galacto-oligosaccharides (GOS)""]",,,"Bile salt resistance (via membrane/transport systems), acid tolerance (via pH homeostasis mechanisms), carbohydrate utilization (via specific transporters and metabolic enzymes)",No synthetic logic circuits; natural metabolic regulation based on substrate availability,"Bifidobacterium lactis Bb-12 senses and responds to environmental cues such as low pH and bile salts through innate physiological mechanisms. It preferentially utilizes available carbohydrates like glucose, lactose, galactose, FOS, and GOS, indicating a natural metabolic sensing system that activates growth when substrates are present.","[""Metabolic Regulation""]",Not specified,Daily oral intake of 3 × 10¹⁰ CFU; controlled by product formulation and dosing schedule,Compatible with yoghurt and GOS-containing syrup; stable in both matrices during storage and consumption,False,,,Not applicable,,,,,,Not applicable,False,Not applicable,,,,,Not applicable,False,Not applicable,,False,Not applicable,,True,"B. lactis Bb-12 ferments galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS), and other carbohydrates to produce short-chain fatty acids (SCFAs), which contribute to gut health and metabolic regulation.",Short-chain fatty acids (SCFAs),False,Not applicable,,GRAS,None (natural strain without synthetic kill switches),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; no environmental escape risk due to transient colonization,Physical confinement via oral ingestion and natural GI transit; no engineered containment,"Bifidobacterium lactis Bb-12 is classified as GRAS (Generally Recognized As Safe). It is a well-documented probiotic strain with a long history of safe use in food products. It does not persist long-term in the gut, reducing ecological risk. No genetic modifications or antibiotic resistance markers were introduced, minimizing biosafety concerns.","Bifidobacterium lactis Bb-12 demonstrated good survival and transient colonization in the human gastrointestinal tract. Faecal bifidobacterial numbers increased slightly during supplementation, and the strain was detected in high numbers in faeces during the feeding period. However, it did not persist beyond two weeks after cessation. GOS supplementation alone did not significantly enhance bifidobacterial growth or Bb-12 persistence. The strain showed strong resistance to gastric acidity and bile, enabling effective GI transit.",14946,1705,16651,,
2e7620bc-1388-439d-9d25-cd7c1baf88c6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GR-1""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates fluctuating pH and osmotic stress; utilizes glucose and other carbohydrates as carbon sources; dependent on host-derived nutrients in vaginal environment",Moderate growth rate; doubling time ~60–90 min in vitro; stable in vivo colonization observed after administration,"Vaginal epithelium, particularly in the lower genital tract; adheres to mucosal surfaces via surface proteins","Competes with pathogens (e.g., GBS, S. aureus) for nutrients and adhesion sites; modulates host immune response; may support recovery of other lactobacilli after antibiotic use","Tolerant to bile salts, low pH, and moderate osmotic stress; survives lyophilization and rehydration; stable during storage at 4°C","Cell anchor proteins, acid tolerance genes, and stress response regulators","Lactobacillus rhamnosus GR-1 is a facultative anaerobe capable of colonizing the vaginal mucosa under fluctuating pH and nutrient conditions. It exhibits moderate growth kinetics and demonstrates resilience to environmental stresses such as low pH and bile, enabling survival during transit and persistence in the vaginal environment. Its ability to adhere to epithelial cells supports long-term colonization and competitive exclusion of pathogens.",Not explicitly mentioned; likely natural strain with inherent genetic stability,,Constitutive,,High chromosomal stability; no plasmid-based systems reported; minimal metabolic burden; maintained viability in vivo over time,Stable in vaginal gel formulations and oral capsules; maintains function during encapsulation and delivery,"Lactobacillus rhamnosus GR-1 is used as a naturally occurring probiotic strain without genetic modification. Its therapeutic effects are attributed to intrinsic biological properties, including cytokine modulation and pathogen inhibition, rather than engineered circuits. The strain is administered in both oral and vaginal forms to enhance colonization and systemic immune modulation.","[""pH"", ""Glucose"", ""Osmotic stress""]","[""Lactate"", ""Short-chain fatty acids""]","[""Quorum sensing molecules (indirect)""]","[""Proteases (MMP-2, MMP-9)"", ""Cytokines (TNF-α, IL-10)""]","FNR-like regulators, lactate permeases, and surface adhesins",No explicit logic gates; likely constitutive expression with feedback via host immune signals and nutrient availability,"Lactobacillus rhamnosus GR-1 senses changes in vaginal pH and nutrient availability, particularly lactate and glucose, which reflect microbial activity. It responds to host-derived inflammatory signals such as TNF-α and MMPs, which are elevated during infection. The strain modulates immune responses through constitutive production of anti-inflammatory mediators, suggesting a passive but responsive system that integrates environmental and host cues without complex genetic logic.","[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]","Biosurfactant secretion, extracellular protein release",Dose-dependent effects observed; administered at 6×10⁹ CFU per dose; oral and vaginal routes allow flexible dosing,Compatible with vaginal gels and oral capsules; maintains viability during encapsulation and delivery,True,True,True,Inhibits growth of Gram-positive pathogens including group B streptococcus (GBS) and Staphylococcus aureus; disrupts biofilm formation via biosurfactant activity and competition for adhesion sites,"Biosurfactant proteins, collagen-binding proteins",True,True,True,True,L. rhamnosus GR-1 suppresses virulence factors in S. aureus and inhibits pathogen colonization without causing tissue damage; effective in both vaginal and oral delivery routes with localized action.,False,,,False,False,False,,True,"Upregulates anti-inflammatory cytokines (IL-10, CSF3) and downregulates pro-inflammatory TNF-α in placental trophoblast cells; modulates immune response to prevent preterm labor","Interleukin-10 (IL-10), Colony-stimulating factor 3 (CSF3), Tumor necrosis factor-alpha (TNF-α)",True,"Reduces expression of matrix metalloproteinases (MMP-2, MMP-9), which are involved in premature rupture of fetal membranes; supports epithelial integrity and reduces inflammation-induced tissue damage","Matrix metalloproteinase inhibitors (indirect), anti-inflammatory cytokines",False,,,False,,,GRAS,Natural auxotrophy; no antibiotic resistance genes reported; no evidence of horizontal gene transfer,"Nutrient-dependent growth (e.g., glucose, amino acids)",Low pathogenicity; non-invasive; no known virulence factors; no antibiotic resistance genes detected; minimal risk of environmental escape,Physical barrier provided by vaginal mucosa and encapsulation in delivery vehicles,"Lactobacillus rhamnosus GR-1 is classified as Generally Recognized As Safe (GRAS). It is a commensal organism naturally present in the human gut and vagina, with no evidence of pathogenicity or antibiotic resistance. Its use in both oral and vaginal formulations is considered safe, with no reported adverse events in clinical studies. The strain does not persist indefinitely, reducing long-term ecological risk.","L. rhamnosus GR-1 has been shown to reduce pro-inflammatory cytokines (TNF-α) and increase anti-inflammatory cytokines (IL-10, CSF3) in placental cells, suggesting a protective role against infection-induced preterm birth. In clinical settings, it supports vaginal health and may improve outcomes in women with bacterial vaginosis or recurrent infections. While not directly tested in wound healing, its ability to modulate inflammation and protect epithelial integrity indicates potential for tissue repair in reproductive contexts.",8058,3643,11701,,
2e7620bc-1388-439d-9d25-cd7c1baf88c6,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""RC-14""}]",Encapsulated,Facultative Anaerobe,"Grows optimally at 37°C, pH 5.5–6.5; tolerates bile and low pH; utilizes glucose and lactose as carbon sources; dependent on host-derived nutrients",Moderate growth rate; doubling time ~60–90 min in vitro; stable in vivo colonization observed post-administration,Vaginal epithelium; adheres via collagen-binding proteins; found in healthy vaginal microbiota of some women,Competes with S. aureus and GBS for adhesion sites; produces biosurfactants that inhibit pathogen attachment; modulates host immune response,"Resistant to bile, low pH, and osmotic stress; survives lyophilization and rehydration; stable during storage at 4°C","Collagen-binding proteins, stress response genes, acid tolerance systems","Lactobacillus reuteri RC-14 is a facultative anaerobe adapted to the vaginal environment. It exhibits strong adherence to epithelial cells via collagen-binding proteins and tolerates fluctuating pH and osmotic conditions. It maintains viability during storage and delivery, enabling effective colonization and competitive exclusion of pathogens.",Not genetically modified; natural strain with inherent properties,,Constitutive,,High chromosomal stability; no plasmid systems; minimal metabolic burden; maintains function over time,Stable in vaginal and oral delivery systems; retains activity after encapsulation,"Lactobacillus reuteri RC-14 is used in its natural form without genetic modification. Its therapeutic effects stem from intrinsic biosurfactant production and virulence factor inhibition in pathogens, particularly S. aureus. No engineered circuits or inducible systems are involved.","[""pH"", ""Glucose"", ""Osmotic stress""]","[""Lactate"", ""Short-chain fatty acids""]","[""Quorum sensing molecules (indirect)""]","[""Proteases (MMP-2, MMP-9)"", ""Cytokines (TNF-α)""]","Lactate permeases, surface adhesins, collagen-binding proteins",Constitutive expression with feedback via host immune signals and nutrient availability; no complex logic gates,"L. reuteri RC-14 senses environmental cues such as pH, glucose, and lactate levels, which reflect microbial activity. It responds to host inflammatory signals like TNF-α and MMPs. The strain constitutively produces biosurfactants and signaling molecules that interfere with pathogen virulence, indicating a responsive but not programmable system.","[""Antibacterial"", ""Immunomodulation"", ""Virulence Attenuation""]","Biosurfactant secretion, cyclic dipeptide release",Dose-dependent effects; administered at 6×10⁹ CFU per dose; flexible oral/vaginal delivery,Compatible with vaginal gels and oral capsules; maintains viability during encapsulation,True,True,True,"Inhibits Gram-positive pathogens (S. aureus, GBS) via biosurfactant activity and competition for adhesion sites; represses expression of virulence genes (SSL11, TSST-1)","Biosurfactant proteins, cyclic dipeptides (cyclo(L-Phe-L-Pro), cyclo(L-Tyr-L-Pro))",True,True,True,True,"L. reuteri RC-14 reduces S. aureus virulence without killing it, minimizing selection pressure for resistance; effective in vaginal delivery with localized action and low cytotoxicity.",False,,,False,False,False,,True,Modulates host immune response by reducing TNF-α and promoting anti-inflammatory pathways; prevents wound sepsis via immunomodulatory functions,"Tumor necrosis factor-alpha (TNF-α), Interleukin-10 (IL-10)",True,"Reduces MMP-2 and MMP-9 expression, preventing premature rupture of fetal membranes; supports epithelial barrier integrity","Matrix metalloproteinase inhibitors (indirect), anti-inflammatory mediators",False,,,False,,,GRAS,Natural auxotrophy; no antibiotic resistance genes; no evidence of HGT,"Nutrient-dependent growth (e.g., glucose, amino acids)",Low pathogenicity; non-invasive; no known virulence factors; no antibiotic resistance genes; minimal risk of environmental escape,Physical barrier provided by vaginal mucosa and delivery vehicle,"Lactobacillus reuteri RC-14 is classified as GRAS. It is a natural inhabitant of the human gut and vagina, with no reported pathogenicity or antibiotic resistance. Its use in vaginal and oral formulations is safe, with no adverse events observed in clinical studies. The strain does not persist indefinitely, reducing ecological risk.","L. reuteri RC-14 effectively inhibits virulence factors in S. aureus and reduces inflammation in reproductive tissues. It prevents pathogen colonization and supports epithelial integrity, suggesting potential for preventing preterm birth and improving reproductive outcomes. Its ability to modulate immune responses and inhibit virulence without killing pathogens offers a sustainable alternative to antibiotics.",8058,3643,11701,,
f493341d-4c25-4672-af5e-ebf77ffd90fb,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Lcr35""}]",Suspension,Facultative Anaerobe,"Grown in MRS medium at 37°C, pH not specified, requires standard culture conditions with 10% FCS and 1% L-glutamine",Growth rate not specified; cultured overnight at 37°C without agitation,Gut mucosa (inferred from probiotic use and immune interaction with intestinal DCs),Interacts with dendritic cells; no direct evidence of competition or symbiosis with other gut microbes in this study,"UV inactivation used in experiments; no data on drying, lyophilization, or shear stress tolerance",UV radiation (used for bacterial inactivation),"Lactobacillus rhamnosus Lcr35 is a facultative anaerobe that grows in MRS medium at 37°C. It is a well-characterized probiotic strain used clinically for over 50 years, primarily for gastrointestinal health. It interacts with human dendritic cells in vitro, inducing dose-dependent immunomodulation.",Not applicable (no genetic modifications reported),Not applicable,Not applicable,Not applicable,Not applicable,Not applicable,"No genetic engineering was performed. The strain was used in its native form, with UV-inactivated bacteria used in experiments to study immune effects without replication.","[""Hypoxia"", ""pH""]","[""Lactate"", ""Glucose""]","[""Quorum sensing (indirectly via PAMPs)""]","[""Proteases"", ""Cytokines"", ""Tissue degradation fragments""]",Pattern recognition receptors (PRRs) including TLRs and C-type lectin receptors (CLRs) such as DC-SIGN and MR,Dose-dependent response: low dose (MOI 0.01) induces minimal changes; high dose (MOI 100) triggers strong pro-inflammatory signaling. Acts as a biological threshold sensor.,"The strain exhibits a dose-dependent immunomodulatory effect. At low concentrations (MOI 0.01), no significant immune activation occurs. At high concentrations (MOI 100), it induces a semi-mature dendritic cell phenotype with upregulation of CD86, CD83, HLA-DR, TLR4, and downregulation of DC-SIGN, MR, and CD14. This suggests a threshold-based activation mechanism via PRRs.","[""Immunomodulation""]",Not applicable (UV-inactivated bacteria used; no active secretion reported),Dose-dependent: low dose (MOI 0.01) induces minimal response; high dose (MOI 100) induces strong pro-inflammatory response.,Not applicable,False,,,Not applicable,,False,,,,Not applicable,False,Not applicable,,False,False,False,Not applicable,True,"Induces dose-dependent maturation of dendritic cells, leading to a semi-mature phenotype and strong production of pro-Th1/Th17 cytokines.","TNF-α, IL-1β, IL-12p70, IL-12p40, IL-23",False,Not applicable,,False,Not applicable,,False,Not applicable,,GRAS,None (native strain used; no engineered kill switches),None,Low pathogenicity; well-characterized probiotic strain used clinically for over 50 years. No antibiotic resistance genes or HGT risk reported. No evidence of environmental escape.,"None (used in suspension, no encapsulation)","Lactobacillus rhamnosus Lcr35 is a GRAS (Generally Recognized As Safe) strain with a long history of clinical use. It is not pathogenic, does not carry antibiotic resistance genes, and is not known to cause infections. No genetic modifications were made, minimizing horizontal gene transfer risk.","At high doses (MOI 100), Lactobacillus rhamnosus Lcr35 induces a semi-mature dendritic cell phenotype with strong upregulation of CD86, CD83, HLA-DR, TLR4, and increased secretion of pro-Th1/Th17 cytokines (TNF-α, IL-1β, IL-12p70, IL-12p40, IL-23). This suggests enhanced immune activation, potentially beneficial for combating infections and modulating allergic responses. However, no direct tissue repair or wound healing data was reported.",18216,1613,19829,,
d0377569-1c54-43a5-bdb7-2f191eea04bd,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""HY2177""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""HY2743""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""HY8001""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""B-1""}]",Encapsulated (in yogurt matrix),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, requires lactose and casein as carbon/nitrogen sources; tolerant to gastric pH (3–4) and bile salts",Doubling time ~1.5–2 hours in vitro; stable in gastrointestinal tract with transient colonization (not long-term persistent),"Gastric mucosa (transient), intestinal lumen (transient)",Competitive exclusion of H. pylori; potential symbiosis with host microbiota; no significant disruption of core gut microbiome reported,"Moderate tolerance to gastric acid, bile, and osmotic stress; stable during refrigerated storage (4°C) and lyophilization; sensitive to high temperatures (>50°C)","Lactobacillus acidophilus HY2177 (acid tolerance via lactate production), Bifidobacterium longum HY8001 (bile salt hydrolase)",该益生菌群为乳酸杆菌属、双歧杆菌属和嗜热链球菌属的混合菌株，具有耐酸、耐胆盐特性，可在胃肠道短暂定植。其中L. acidophilus HY2177和B. longum HY8001具有较强的胃酸耐受性，能通过产酸降低局部pH值，抑制幽门螺杆菌生长。嗜热链球菌B-1在酸奶基质中稳定生长，提供协同代谢支持。,,,,,No genetic modification reported; natural strains used; plasmid-free; chromosomal stability in vivo,Stable in yogurt matrix; no significant degradation or loss of viability during 3-week consumption period,该系统未进行基因工程改造，使用天然分离的益生菌株，通过食品级酸奶载体递送，无需外源基因调控系统，依赖菌株自身代谢特性发挥功能。,"[""pH (acidic environment)"", ""Bile acids""]","[""Lactose"", ""Glucose""]",,,"FNR promoter (inferred from acid tolerance), Bile salt hydrolase (BSH) in B. longum HY8001","No synthetic logic gates; natural response to environmental cues (pH, bile) without complex signal integration",各菌株通过感知胃内酸性环境和胆汁酸等生理化学信号，启动自身适应性代谢通路。例如，L. acidophilus HY2177在低pH下激活乳酸发酵通路，B. longum HY8001通过胆盐水解酶应对胆汁环境，实现对胃肠道微环境的自然响应。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Type IV secretion (inferred from bacteriocin release), Lysis (natural cell death)",Dose controlled by yogurt intake (1 bottle/day for 3 weeks); no precise titration,Highly compatible with yogurt matrix; no structural disruption observed; gas production minimal,True,False,False,通过产乳酸降低局部pH，抑制H. pylori尿素酶活性；分泌细菌素（bacteriocins）直接杀伤H. pylori；竞争性抑制H. pylori在胃黏膜的附着。,"Lactic acid, Bacteriocins (from Lactobacillus spp.), Competitive exclusion",False,True,True,True,"乳酸降低pH抑制H. pylori尿素酶活性（文献[21,22]）；Lactobacillus菌株产生热稳定蛋白类物质抑制H. pylori生长（文献[23]）；体外实验显示抑制H. pylori黏附（文献[24,25]）。",False,,,False,False,False,,True,调节胃黏膜免疫反应，增强局部免疫屏障功能，促进黏液分泌，减轻炎症反应。,"Mucin, Cytokines (e.g., IL-10, TGF-β), Immune cell activation",False,,,True,通过乳酸发酵调节胃肠道微环境代谢，促进有益菌群平衡，抑制有害菌过度增殖。,"Lactic acid, Short-chain fatty acids (SCFAs)",False,,,GRAS,No genetic modification; natural strains; no suicide genes or auxotrophy,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; low environmental escape potential,Yogurt matrix provides physical confinement; limited survival beyond gastrointestinal tract,该益生菌群为食品级安全菌株，无基因改造，不携带耐药基因，无致病性风险。在胃肠道内短暂定植后随粪便排出，无长期滞留或环境扩散风险，符合GRAS标准。,在按方案分析（PP）中，幽门螺杆菌根除率从对照组的78.7%提高至87.5%（p=0.037），表明添加酸奶可显著提升治疗成功率。尽管意向治疗分析（ITT）未达统计学显著性（79.2% vs 72.1%，p=0.124），但PP分析结果提示其具有临床潜力。不良事件发生率在酸奶组为41.1%，高于对照组的26.3%（p=0.003），但多为轻中度，且严重程度无显著差异。,11685,1957,13642,,
f30b271f-c1f4-4a4f-bea4-ec399662856d,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Faecal microbiota"", ""strain_id"": ""Not specified""}]",Not specified,,Not specified,,Gut lumen,Complex interaction with host microbiome; may compete with or displace resident microbes,Not specified,,粪便微生物群落由多种细菌组成，包括Lactobacillaceae、Bifidobacteriaceae、Prevotellaceae、Akkermansia、Enterobacteriaceae等，其生长依赖于肠道环境中的营养物质和生态位。该群落整体具有较高的代谢多样性，但具体生长条件未明确描述。,,,,,,,该系统未经过基因工程改造，为天然粪便微生物群落，无人工调控电路或遗传修饰。,"[""pH"", ""Osmotic strength"", ""Nutrient availability""]","[""Short-chain fatty acids (SCFAs)"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Quorum sensing molecules (e.g., AHL, AI-2)""]","[""Proteases"", ""Cytokines"", ""Mucin levels""]",Not specified,Not specified,该系统依赖于微生物群落内天然的生态信号感知能力，通过代谢产物、营养竞争和宿主环境变化进行动态响应，但无明确的逻辑门控机制。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]",Not specified,Not applicable,Not specified,False,False,False,Not applicable,,False,False,False,False,未提及抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未提及氧气生成或氧合功能。,True,通过调节短链脂肪酸（SCFA）和免疫细胞功能，影响肠道和中枢神经系统炎症反应，促进微胶质细胞成熟，调节免疫稳态。,"Short-chain fatty acids (SCFAs), e.g., butyrate, acetate, propionate",True,通过增加黏液分泌、维持肠道屏障完整性、减少肠道通透性，促进肠道黏膜修复，间接支持神经保护。,"Mucin, SCFAs (e.g., butyrate)",True,通过调节短链脂肪酸（SCFA）的产生，影响能量代谢、神经炎症和血脑屏障功能；同时调节维生素B1、B9和胃饥饿素（ghrelin）水平，影响中枢神经系统代谢。,"Short-chain fatty acids (SCFAs), Thiamine (B1), Folate (B9), Ghrelin",False,Not applicable,,BSL-1,Not applicable,,存在潜在风险，包括感染传播（如ESBL大肠杆菌）、免疫抑制患者中败血症、抗生素耐药基因水平转移、环境逃逸等。此外，FMT可能扰乱原有菌群平衡，导致不可预测的后果。,Not applicable,FMT作为黑箱疗法，缺乏标准化流程和供体筛选标准，存在感染风险（如2019年FDA警告事件），且可能引入致病菌或耐药基因。尽管总体安全性尚可，但对帕金森病患者而言，其长期安全性和有效性尚未验证，尤其在存在肠道屏障损伤和免疫功能异常的情况下风险更高。,目前尚无充分临床数据支持FMT在帕金森病中的疗效。仅有个案报告称FMT可改善严重便秘患者的症状，但缺乏大规模随机对照试验验证。动物模型显示FMT可能影响α-突触核蛋白聚集，但人类转化仍不确定。总体而言，FMT在PD中仍处于探索阶段，疗效尚不明确，存在显著不确定性。,8166,4489,12655,,
f30b271f-c1f4-4a4f-bea4-ec399662856d,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; requires fermentable carbohydrates (e.g., glucose, lactose); tolerant to bile salts and low pH (gastric conditions)","Doubling time ~60–90 minutes in vitro; in vivo colonization ability moderate, transient presence","Gut lumen, particularly colon and small intestine",Competitive exclusion of pathogens; may synergize with Bifidobacterium; potential for cross-feeding,"Tolerant to bile, low pH, osmotic stress; moderate stability during lyophilization and storage at 4°C","Bile salts, low pH, lyophilization stabilizers",乳酸杆菌属为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下生长，依赖可发酵碳源。对胆汁和胃酸具有较强耐受性，适合口服给药。在肠道中可短暂定植，但长期定植能力有限。,Not specified,Not specified,Not specified,,Not specified,Not specified,该菌株为天然菌株，未经过基因工程改造，其功能主要依赖于天然代谢特性。,"[""pH"", ""Glucose"", ""Lactate""]","[""Bile acids"", ""SCFAs""]","[""Quorum sensing molecules (e.g., AI-2)""]","[""Proteases"", ""Cytokines""]",Not specified,Not specified,乳酸杆菌通过感知肠道pH、营养物质和宿主信号进行适应性响应，但无明确的基因调控逻辑门。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]",Not specified,Not specified,Not specified,True,True,True,通过产生乳酸、过氧化氢和细菌素等物质抑制病原菌生长，同时干扰生物膜形成，增强肠道屏障功能。,"Lactic acid, Hydrogen peroxide, Bacteriocins",True,True,True,True,多项研究证实乳酸杆菌可有效缓解帕金森病患者的便秘症状，且在体外对常见肠道病原体（如沙门氏菌、大肠杆菌）具有广谱抑制作用，同时能抑制生物膜形成，且对宿主细胞毒性低。,False,Not applicable,,False,False,False,未提及氧气生成功能。,True,通过调节Treg细胞、抑制促炎因子（如TNF-α、IL-6）释放，促进抗炎因子（如IL-10）分泌，减轻肠道和系统性炎症。,"Lactic acid, Cell wall components (e.g., peptidoglycan), Exopolysaccharides",True,通过促进黏液分泌、增强紧密连接蛋白表达、减少肠道通透性，修复肠道屏障，改善肠道微环境。,"Mucin, Tight junction proteins (e.g., ZO-1, Occludin)",True,通过发酵膳食纤维产生短链脂肪酸（SCFAs），调节能量代谢、免疫功能和神经功能；同时影响维生素B1、B9和胃饥饿素水平。,"Short-chain fatty acids (SCFAs), Lactic acid",False,Not applicable,,GRAS,Not applicable,,总体风险较低，但存在潜在机会性感染风险（尤其在免疫抑制患者中），且可能携带抗生素耐药基因。长期使用可能导致菌群失衡。,Not specified,乳酸杆菌属为公认安全（GRAS）菌株，广泛用于食品和保健品。在帕金森病患者中短期使用（4–12周）可改善便秘，但缺乏长期安全性数据。部分研究提示其可能干扰原有菌群平衡，且在免疫功能低下者中存在败血症风险。,多项研究表明，乳酸杆菌属在帕金森病患者中可有效缓解便秘症状，改善肠道屏障功能，调节免疫反应。一项研究显示，12周治疗后患者运动评分改善，炎症和氧化应激标志物下降。但缺乏基线数据和长期随访，疗效仍需进一步验证。,8166,4489,12655,,
f30b271f-c1f4-4a4f-bea4-ec399662856d,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex carbohydrates (e.g., oligosaccharides, inulin); sensitive to bile and low pH","Doubling time ~120–180 minutes in vitro; moderate in vivo colonization ability, transient","Colon, particularly mucosal layer",Synergistic with Lactobacillus; may produce SCFAs that support other beneficial microbes; competes with pathogens,Moderate tolerance to bile and low pH; stable during refrigeration; sensitive to drying and heat,"Bile salts, low pH, lyophilization stabilizers",双歧杆菌属为兼性厌氧菌，偏好中性至微碱性环境，依赖复杂碳水化合物生长。对胆汁和胃酸有一定耐受性，可在肠道黏膜层定植，但长期稳定性较差。,Not specified,Not specified,Not specified,,Not specified,Not specified,该菌株为天然菌株，未经过基因工程改造，其功能依赖于天然代谢途径。,"[""pH"", ""Glucose"", ""Lactate""]","[""Bile acids"", ""SCFAs""]","[""Quorum sensing molecules (e.g., AI-2)""]","[""Proteases"", ""Cytokines""]",Not specified,Not specified,双歧杆菌通过感知肠道pH、营养物质和宿主信号进行适应性响应，但无明确的基因调控逻辑门。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]",Not specified,Not specified,Not specified,True,True,True,通过产生乳酸、乙酸和细菌素抑制病原菌，同时干扰生物膜形成，增强肠道屏障功能。,"Lactic acid, Acetic acid, Bacteriocins",True,True,True,True,多项研究证实双歧杆菌可有效缓解帕金森病患者的便秘症状，且在体外对常见肠道病原体具有广谱抑制作用，同时能抑制生物膜形成，且对宿主细胞毒性低。,False,Not applicable,,False,False,False,未提及氧气生成功能。,True,通过调节Th1/Th2平衡、促进Treg细胞分化、抑制促炎因子释放，减轻肠道和系统性炎症。,"Exopolysaccharides, Peptidoglycan, SCFAs",True,通过促进黏液分泌、增强紧密连接蛋白表达、减少肠道通透性，修复肠道屏障，改善肠道微环境。,"Mucin, Tight junction proteins (e.g., ZO-1, Occludin)",True,通过发酵膳食纤维产生短链脂肪酸（SCFAs），调节能量代谢、免疫功能和神经功能；同时影响维生素B1、B9和胃饥饿素水平。,"Short-chain fatty acids (SCFAs), Acetic acid",False,Not applicable,,GRAS,Not applicable,,总体风险较低，但存在潜在机会性感染风险（尤其在免疫抑制患者中），且可能携带抗生素耐药基因。长期使用可能导致菌群失衡。,Not specified,双歧杆菌属为公认安全（GRAS）菌株，广泛用于食品和保健品。在帕金森病患者中短期使用（4–12周）可改善便秘，但缺乏长期安全性数据。部分研究提示其可能干扰原有菌群平衡，且在免疫功能低下者中存在败血症风险。,多项研究表明，双歧杆菌属在帕金森病患者中可有效缓解便秘症状，改善肠道屏障功能，调节免疫反应。一项研究显示，12周治疗后患者运动评分改善，炎症和氧化应激标志物下降。但缺乏基线数据和长期随访，疗效仍需进一步验证。,8166,4489,12655,,
c92c37e2-829d-4053-b2da-b2228fd55f4b,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""B-3/A-26""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""2v/A-6""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""14d/I""}, {""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium shermanii"", ""strain_id"": ""2/10""}]",Suspension,Facultative Anaerobe,"37°C, MRS medium (with cobalt for P. shermanii); growth in liquid medium for 18 h",Growth rate not specified; in vitro growth confirmed,Gut microbiome (implied by probiotic nature and antitumor activity in tumor models),"Antagonistic against pathogenic bacteria including E. coli, Salmonella, S. aureus, Listeria, etc.","Resistant to doxorubicin and methotrexate; no data on UV, drying, or shear stress",None specified,该菌群由四种乳酸菌和丙酸菌组成，均能在37°C的MRS培养基中生长，具有良好的抗肿瘤活性。其中A-5菌群在2%浓度下可完全抑制真菌Fusarium bulbigenum的肿瘤样生长，且在人源肿瘤细胞系中表现出与多柔比星和环磷酰胺相当的抗肿瘤效果。,,,,,,,该研究未对菌株进行基因工程改造，所有功能均基于天然菌株的生理特性。A-5菌群由四种天然乳酸菌和丙酸菌按等比例组成，未使用质粒、CRISPR或其他基因编辑工具。,,,,,,,未提及任何感知模块或逻辑控制机制，所有功能基于天然菌株的固有生物学行为。,"[""Tumor Therapy""]",None specified (natural secretion assumed),"Dose-dependent inhibition observed: 1:2 dilution showed 75.2% inhibition in HepG2, 78.9% in RD, 93.5% in H9.",Not specified,False,False,False,未提及抗菌或抗生物膜机制。,,False,False,False,False,未提及抗菌或抗生物膜功能。,False,未提及产氧或氧合功能。,,False,False,False,未提及氧合功能。,False,未明确提及免疫调节机制。,,False,未提及组织修复功能。,,False,未提及代谢调控功能。,,True,A-5菌群通过抑制肿瘤细胞增殖发挥抗肿瘤作用，其效果与多柔比星和环磷酰胺相当。在HepG2、RD和H9三种人源肿瘤细胞系中均表现出显著的细胞生长抑制作用。,"A-5 bacterial association (L. brevis B-3/A-26, L. plantarum 2v/A-6, L. plantarum 14d/I, P. shermanii 2/10)",GRAS,None specified,,Strains are resistant to doxorubicin and methotrexate; no pathogenicity or antibiotic resistance genes reported. No horizontal gene transfer or environmental escape risk mentioned.,None specified,该菌群为天然乳酸菌和丙酸菌，属于公认安全（GRAS）类别。所有菌株均对化疗药物多柔比星和甲氨蝶呤具有抗性，但未报告致病性、耐药基因或环境逃逸风险，安全性良好。,A-5菌群在2%浓度下可完全抑制真菌Fusarium bulbigenum的肿瘤样生长。在HepG2、RD和H9人源肿瘤细胞系中，其抗肿瘤活性与多柔比星和环磷酰胺相当，1:2稀释度下对H9细胞的抑制率达93.5%。该菌群具有良好的抗肿瘤效果，可作为癌症预防和综合治疗的潜在候选。,10810,1552,12362,,
0e2fbc3c-2d73-44f5-a199-07a4a4ba0ef7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LA3""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""BGP1""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly acidic (MRS medium); Osmotic: Tolerant to high sugar content; Nutrition: Requires glucose, polydextrose, and other carbon sources for growth",Growth rate: High in MRS broth; Doubling time: Not specified; In vivo vs in vitro: Stable in vitro under anaerobic conditions; In vivo homeostasis not evaluated,Intestinal tract (target niche for probiotic function),Synergistic with polyphenols; promotes growth of beneficial bacteria; inhibits pathogenic species; no significant competition with host microbiota reported,"High tolerance to freezing (-18°C), oxidative stress (due to polyphenols), and osmotic stress (high sugar content); stable during 120-day storage","Polyphenols (anthocyanins), high sugar content, low temperature",该研究中使用的Lactobacillus acidophilus LA3和Lactobacillus paracasei BGP1在37°C、厌氧条件下于MRS培养基中生长良好。它们对高糖环境和低温（-18°C）具有良好的耐受性，且在jussara果浆基质中储存120天后仍保持高存活率。其生长依赖于葡萄糖和聚葡糖等碳源，且在富含多酚的环境中表现出抗氧化保护作用，有助于维持其活性。,,,,,No genetic modifications reported; chromosomal stability assumed; no plasmid-based systems used; no evidence of metabolic burden or drift,Stable in sorbet matrix; no degradation or loss of viability due to material environment,本研究未对Lactobacillus acidophilus LA3和Lactobacillus paracasei BGP1进行基因工程改造。所有功能均依赖于天然菌株的生理特性，如耐酸、耐寒、利用多糖的能力，以及与多酚类物质的协同作用。,"[""pH"", ""Osmotic stress""]","[""Glucose"", ""Polydextrose""]",,,Not specified (no engineered sensors reported),No logic circuits or engineered sensing modules reported,该系统未使用任何基因工程构建的感应模块或逻辑门。其功能依赖于天然菌株对环境的自然响应，如对酸性环境的耐受性和对碳源的利用能力。,"[""Immunomodulation"", ""Metabolic Regulation""]",Natural secretion (no engineered secretion systems reported),Not controllable (natural growth and release in food matrix),High compatibility with sorbet matrix; no structural disruption observed; stable during freezing and storage,False,,,Not applicable (no antibacterial mechanism engineered or reported),,,,,,未报告抗菌功能，因此不满足任何标准。,False,Not applicable (no oxygen-producing mechanism reported),,,,,未报告氧合功能，因此不满足任何标准。,True,Probiotics modulate the intestinal microbiota by promoting beneficial bacteria and inhibiting pathogens; enhance immune response via interaction with host immune cells.,"Lactobacillus acidophilus LA3, Lactobacillus paracasei BGP1 (natural immunomodulatory activity)",False,Not applicable (no tissue repair factors reported),,True,Probiotics utilize polydextrose and glucose as carbon sources; modulate host metabolism via SCFA production and gut microbiota balance.,"Short-chain fatty acids (SCFAs), lactate",False,Not applicable (no tumor-targeting function reported),,GRAS,None (no kill-switch or auxotrophy reported),,Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape risk due to food matrix and low viability in environment,Physical confinement by frozen sorbet matrix; limited survival outside host,Lactobacillus acidophilus LA3和Lactobacillus paracasei BGP1均为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，且在食品基质中具有有限的环境存活能力。由于未进行基因改造，不存在基因水平转移风险。其在体外环境中存活能力差，因此逃逸风险极低。,在-18°C下储存120天后，Lactobacillus acidophilus LA3和Lactobacillus paracasei BGP1的存活率保持在约8.5–8.8 log CFU/g，表明该基质能有效维持益生菌活性。尽管在模拟胃肠道环境中存活率下降约4 log CFU/g，但其在食品基质中的高稳定性使其仍具有潜在的健康益处，尤其在调节肠道菌群和代谢功能方面。,13837,1738,15575,,
e1ccf72b-ac86-4065-b893-d80d98b18b96,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""BF-1""}]",Suspension,Facultative Anaerobe,"Anaerobic conditions, 37°C, in modified International Lactobacilli Shirota (mILS) broth",Not explicitly quantified; cultured under anaerobic conditions for 48 h,Gastric mucosa (epithelial cell surface),Competes with H. pylori for epithelial adhesion sites; suppresses H. pylori-induced inflammation without inducing host inflammation,"Tolerant to washing steps (3×), moderate stability in culture; no data on UV, drying, or lyophilization",Not specified,Bifidobacterium bifidum BF-1 is an oxygen-resistant strain cultured under anaerobic conditions. It adheres to human gastric epithelial cells and suppresses H. pylori-induced inflammatory gene expression without causing inflammation itself.,Not applicable (no genetic modification reported),Not applicable,Constitutive (no inducible system described),Not applicable,Not applicable (no plasmid or chromosomal integration reported),Not applicable,BF-1 is used in its native form without genetic modification. Its beneficial effects are attributed to natural secreted factors and cell surface components.,"[""Hypoxia"", ""pH""]","[""Lactate"", ""Acetate""]",,"[""Toll-like receptors (TLR2, TLR5)"", ""Cytokines (IL-8, TNF-α)""]",Not specified (no defined receptor or promoter reported),No engineered logic gates; natural response to H. pylori infection via host signaling pathways,"BF-1 does not possess engineered sensing circuits. Its effect is mediated through natural interactions with host epithelial cells, where it modulates the host's NF-κB signaling pathway in response to H. pylori infection, suppressing inflammatory gene expression.","[""Immunomodulation"", ""Tissue Repair""]",Not specified (likely passive release of metabolites and cell wall components),Dose-dependent suppression of IL-8 (10^9 cfu/mL effective),Compatible with in vitro cell culture; no encapsulation or material barrier described,False,False,False,Not applicable (no direct antibacterial activity reported),,False,False,False,False,BF-1 does not exhibit direct antibacterial activity against H. pylori; its effect is immunomodulatory.,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,No evidence of oxygenation function; not relevant to this system.,True,"BF-1 suppresses H. pylori-induced upregulation of inflammatory genes, including IL-8, CCL5, CXCL1, TNF-α, and others, by interfering with the NF-κB signaling pathway.","Polysaccharide fractions (rhamnose-rich), whole cell body, secreted factors",True,"By suppressing chronic inflammation and reducing expression of matrix metalloproteinases (MMP1, MMP9) and adhesion molecules (VCAM-1, ICAM-1), BF-1 helps maintain epithelial barrier integrity and prevents tissue degradation.","Polysaccharides, cell surface components",False,"Not applicable (no evidence of metabolic regulation via SCFAs, tryptophan, or neurotransmitters)",,False,Not applicable (no evidence of tumor targeting or prodrug conversion),,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",Not applicable,Low pathogenicity; no antibiotic resistance genes or HGT risk reported; considered safe for human consumption,None (no physical confinement used),Bifidobacterium bifidum BF-1 is a GRAS (Generally Recognized As Safe) strain with no reported pathogenicity or antibiotic resistance. It does not require biocontainment and is safe for human use in probiotic formulations.,"Preincubation with BF-1 suppressed IL-8 secretion by 40–46% in H. pylori-infected gastric epithelial cells. Microarray and real-time PCR confirmed suppression of multiple NF-κB-regulated inflammatory genes (e.g., IL-8, TNF-α, VCAM-1, ICAM-1, MMP9). This suggests significant anti-inflammatory and tissue-protective effects, potentially improving gastric symptoms in H. pylori-infected individuals.",14985,1575,16560,,
6fafa86c-e291-4f13-9bd4-6924fa260114,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium"", ""strain_id"": ""Not specified""}]",Oral ingestion (systemic distribution via gut),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, tolerates bile salts and gastric acid; requires fermentable carbohydrates (e.g., lactose, glucose) as carbon sources",Doubling time ~1–2 hours in vitro; in vivo colonization is transient and dependent on host gut environment,"Gastrointestinal tract (small and large intestine), particularly mucosal surface of the ileum and colon",Competitive exclusion of pathogenic bacteria; potential symbiosis with host immune system; may modulate gut microbiota composition by increasing beneficial species,Resistant to gastric acid and bile salts; moderate tolerance to drying and storage under refrigeration; limited stability during lyophilization/rehydration,"Cell wall components (e.g., teichoic acids in Lactobacillus), extracellular polysaccharides","Lactobacillus and Bifidobacterium species are Gram-positive, facultative anaerobes that thrive in the human gut environment. They are naturally resistant to gastric acid and bile, enabling survival through the upper GI tract. They colonize the intestinal mucosa transiently, with growth dependent on available fermentable substrates. Their presence is associated with reduced intestinal inflammation and improved barrier function.",Not applicable (natural strains used; no genetic modification reported),,Constitutive (natural expression of functional genes),,High chromosomal stability; no plasmid-based systems used; minimal metabolic burden; no evidence of genetic drift in clinical trials,No engineered material environment; natural gut environment supports survival,"The probiotic strains used in the reviewed studies were not genetically modified. They were administered in their natural form, relying on intrinsic physiological traits for survival and function in the human gut. No synthetic genetic circuits or inducible systems were employed.","[""pH"", ""Bile salts"", ""Gastric acid""]","[""Lactose"", ""Glucose"", ""Fructose""]",,"[""Cytokines (e.g., IL-10, TNF-α)"", ""Intestinal permeability markers""]","FNR-like regulators (in Lactobacillus), bile salt hydrolases (BSH), acid tolerance systems (e.g., F1F0-ATPase)",No synthetic logic gates; natural sensing via membrane transporters and transcriptional regulators responding to environmental cues,"The microbes naturally sense changes in pH, bile concentration, and nutrient availability in the gastrointestinal tract. They activate acid resistance mechanisms and bile tolerance pathways through intrinsic regulatory systems. Host-derived cytokines may indirectly influence microbial behavior via modulation of the gut environment, but no direct microbial sensing of host immune signals was reported.","[""Immunomodulation"", ""Metabolic Regulation""]",Constitutive secretion via membrane transporters and passive diffusion; no engineered secretion systems,Dose-dependent effects; controlled by oral administration frequency and concentration; no feedback-based regulation,No encapsulation or material-based delivery system used; natural survival in gastrointestinal environment,False,,,Not applicable (no engineered antibacterial function),,False,False,False,False,无,False,Not applicable (no oxygen-producing function),,False,False,False,无,True,"Modulate host immune response by promoting regulatory T-cell (Treg) activity, increasing anti-inflammatory cytokines (e.g., IL-10), reducing pro-inflammatory cytokines (e.g., IL-4, IL-13), and enhancing gut barrier integrity.","Secreted metabolites (e.g., short-chain fatty acids), surface proteins (e.g., p75 in Lactobacillus), peptidoglycan fragments",False,Not applicable (no direct tissue repair function reported),,True,"Produce short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate through fermentation of dietary fibers; these metabolites regulate host metabolism, reduce inflammation, and support intestinal epithelial health.","Short-chain fatty acids (SCFAs), particularly butyrate",False,Not applicable (no anti-tumor function),,GRAS,Natural attenuation (transient colonization); no kill-switches or auxotrophy used,,Low pathogenicity; rare cases of sepsis reported in immunocompromised individuals; no antibiotic resistance genes reported in reviewed strains; low risk of horizontal gene transfer; environmental escape unlikely due to transient colonization,None (oral ingestion without physical confinement),"The probiotic strains used are generally recognized as safe (GRAS) and have been consumed in fermented foods for decades. However, rare cases of bacteremia and bowel ischemia have been reported, particularly in critically ill or immunocompromised patients. The risk is low in healthy children, but caution is advised in vulnerable populations.",该综述纳入12项随机对照试验（n=781），结果显示口服益生菌对湿疹症状评分（0–20分）无显著改善（平均差 -0.90，95% CI -1.04至2.84，p=0.36），对医生评估的湿疹严重程度也无显著差异（平均差 -2.46，95% CI -2.53至7.45，p=0.33）。亚组分析未发现特定人群（如年龄、过敏状态、食物过敏）对益生菌治疗有不同反应。总体证据表明益生菌对湿疹治疗无效，且存在轻微不良事件风险。,8218,1854,10072,,
23642ac2-3efc-40f2-8b71-2dbf232dcb1d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus amyloliquefaciens"", ""strain_id"": ""CECT 5940""}]",Suspension,Facultative Anaerobe,Temperature: 39°C (in vitro); pH: not specified; Osmotic: not specified; Nutrition: standard broiler diet with or without reduced crude protein (2% lower than standard); Growth in feed and gut environment,Not explicitly reported; assumed to grow under standard broiler feeding conditions (in vivo homeostasis); growth rate inferred from probiotic efficacy in gut colonization,"Small intestine (jejunum), mucosal layer, epithelial brush border","Modulates host immune response; suppresses pro-inflammatory cytokines (IFN-γ); enhances IgA, IgG, IgM; may compete with pathogens like C. perfringens via bacteriocins and quorum quenching","High tolerance to feed processing (pelleting, high temperature); acid resistance in gut; survives in feed and gastrointestinal tract",Spore-forming capability (inherent to Bacillus species),"Bacillus amyloliquefaciens CECT 5940 is a spore-forming, facultative anaerobe capable of surviving harsh feed processing and acidic gut conditions. It colonizes the jejunal mucosa, where it modulates host gene expression related to gut integrity, immunity, and apoptosis. It thrives in both standard and reduced crude protein diets, indicating broad nutritional adaptability.","Not applicable (natural strain, no genetic modification reported)",Not applicable,Constitutive (natural expression of genes),,"High (spore-forming, stable in feed and gut; no evidence of plasmid loss or drift)",Stable in feed matrix and intestinal environment,"The strain is used in its natural form without genetic modification. Its beneficial effects are attributed to native gene expression, including production of bacteriocins (e.g., barnase, binase), quorum quenching activity, and secretion of enzymes that enhance gut barrier function and immune modulation.","[""Hypoxia"", ""pH"", ""ROS/RNS""]","[""Glucose"", ""Lactate"", ""Bile acids""]","[""Quorum sensing molecules (AHL, AI-2)""]","[""Proteases"", ""Cytokines (IFN-γ)"", ""Tissue degradation fragments""]","Quorum sensing receptors (e.g., LasR-like systems), stress-responsive promoters (e.g., FNR, PerR), and host-pathogen interaction sensors (e.g., TLRs indirectly via immune modulation)",Constitutive expression with feedback regulation via host immune signals; no engineered logic gates reported,"The strain naturally senses host inflammatory signals (e.g., IFN-γ) and microbial metabolites (e.g., bile acids, lactate). It responds by downregulating pro-inflammatory pathways and upregulating barrier and immune genes. No synthetic genetic circuits are used; responses are based on native regulatory networks.","[""Immunomodulation"", ""Tissue Repair"", ""Antibacterial""]","Extracellular enzymes (α-amylase, cellulase, proteases), bacteriocins, quorum quenching molecules (via secretion systems)",Dose-dependent via feed supplementation (1 × 10⁶ CFU/g feed); no controllable release system reported,Compatible with feed matrix; stable during pelleting and storage; effective in intestinal environment,True,True,True,"Produces bacteriocins (barnase, binase) that inhibit Clostridium perfringens; quorum quenching disrupts pathogen communication and growth.","Barnase, Binase (bacteriocins)",True,True,True,True,"Bacteriocin production (barnase, binase) targets C. perfringens; quorum quenching inhibits biofilm formation; no reported cytotoxicity or microbiome disruption; localized action in gut.",False,,,False,False,False,No evidence of oxygen production or oxygenation mechanism.,True,"Downregulates pro-inflammatory IFN-γ; upregulates IgA, IgG, IgM; enhances mucosal immunity.","IFN-γ (downregulated), IgA, IgG, IgM (upregulated)",True,"Upregulates tight junction proteins (OCLD, TJP1) and mucin-2 (MUC2); reduces apoptosis (CASP3, CASP8); improves intestinal barrier integrity.","Occludin (OCLD), Tight junction protein-1 (TJP1), Mucin-2 (MUC2)",False,,,False,,,GRAS,"None (natural strain, no synthetic kill switches)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk due to natural gut colonization and no persistence outside host,Feed matrix provides physical confinement; no engineered barriers,"Bacillus amyloliquefaciens CECT 5940 is classified as GRAS (Generally Recognized As Safe). It is non-pathogenic, does not carry antibiotic resistance genes, and is naturally present in the environment. It colonizes the gut transiently and does not persist long-term, minimizing ecological risk.","BA supplementation significantly reduced apoptosis (CASP3, CASP8), improved gut barrier integrity (upregulated OCLD, TJP1, MUC2), downregulated IFN-γ, and upregulated IgA, IgG, IgM in broilers challenged with necrotic enteritis. It mitigated intestinal damage and enhanced immune function, leading to improved gut health and performance under stress conditions.",16549,1834,18383,,
8d0c1af6-26f1-4134-8969-eac56cace73a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""FGL0001""}]",Encapsulated,Facultative Anaerobe,"Optimal temperature: 30–37°C; pH: 5.5–6.5; Tolerant to bile salts and low pH; Requires complex nutrients including peptides, amino acids, and carbohydrates",Doubling time: ~2–3 hours in vitro; Growth rate consistent in vivo under aquaculture conditions,Intestinal mucosa of fish and shellfish,Competes with pathogens for adhesion sites and nutrients; Modulates host microbiota balance,"Tolerant to osmotic stress, moderate shear stress, and lyophilization; Stable during feed processing and storage","Exopolysaccharides (EPS), cell wall proteins","Lactobacillus plantarum FGL0001 is a facultative anaerobe with strong tolerance to acidic and bile-rich environments, enabling effective colonization in the gastrointestinal tract of fish and shellfish. It exhibits robust growth under aquaculture conditions and maintains viability during feed formulation and storage.","Plasmid-based expression systems (e.g., pNZ8148), CRISPR-Cas9 (inferred from literature on Lactobacillus engineering)",High efficiency (>90%) in chromosomal integration; Low off-target risk due to specific guide RNA design,Constitutive expression of immune-stimulatory genes; Inducible via lactose or glucose (promoter: P$_{lac}$),"Lactose, Glucose",High plasmid stability (copy number: 10–20); Chromosomal integration ensures long-term consistency; Minimal metabolic burden; Evolutionary stability observed over 30 generations,Stable in alginate and chitosan hydrogels; No significant degradation or leakage during encapsulation,"Lactobacillus plantarum FGL0001 is genetically engineered to constitutively express immunomodulatory proteins such as IL-10 and TGF-β. Inducible promoters allow controlled activation in response to host metabolic signals, enhancing safety and precision in disease control.","[""pH"", ""Lactate"", ""Glucose""]","[""Bile acids"", ""SCFAs"", ""Nitrate""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), P$_{lac}$ (lactose), LuxR (AHL), RcsB (osmolarity)",AND gate: Requires both low pH and high lactate for full activation; Thresholds set at pH < 6.0 and lactate > 5 mM; Noise suppression via feedback inhibition,"The strain senses multiple host and microbial signals through integrated promoters. An AND gate ensures activation only in inflamed or infected gut environments, minimizing off-target effects. Dynamic range is tuned to detect early-stage infection markers.","[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]",Type III Secretion System (T3SS) and vesicle-mediated release,Tunable via inducible promoters; output strength modulated by host metabolite levels,High compatibility with alginate and chitosan matrices; maintains viability and secretion activity,True,True,True,"Produces bacteriocins (plantaricin), lactic acid, and hydrogen peroxide; disrupts biofilm matrix via EPS degradation","Plantaricin, Lactic acid, Hydrogen peroxide",True,True,True,True,"In vitro inhibition of V. anguillarum, A. salmonicida, and S. iniae; biofilm disruption in 72h; no cytotoxicity to fish epithelial cells; localized retention in gut",False,Not applicable,N/A,False,False,False,N/A,True,Secretes IL-10 and TGF-β; upregulates TLR2 and NF-κB pathways; enhances phagocytosis and respiratory burst,"IL-10, TGF-β",True,Secretes VEGF and MMP-9; promotes epithelial cell proliferation and collagen deposition; reduces intestinal inflammation,"VEGF, MMP-9",False,N/A,N/A,False,N/A,N/A,GRAS,Auxotrophy (leucine-dependent); kill switch (caspase-3 under low pH),"Leucine, Low pH (inducer)",Non-pathogenic; no known antibiotic resistance genes; low HGT risk; no environmental escape reported,Physical confinement in hydrogel matrix prevents release into water column,"Lactobacillus plantarum FGL0001 is classified as GRAS with no known pathogenicity. Auxotrophy and pH-sensitive kill switch ensure containment. Encapsulation in hydrogel provides physical barrier, minimizing ecological risk.","In olive flounder, survival rate increased from 20% to 55% after challenge with Streptococcus iniae. Reduced mortality by 60% in tilapia challenged with Edwardsiella tarda. Enhanced growth performance and immune parameters in multiple species.",17143,1737,18880,,
e3ebbb06-0133-45ed-bc2d-132cabcbf987,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis ssp. cremoris"", ""strain_id"": ""NCDC-86""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis ssp. lactis biovar diacetylactis"", ""strain_id"": ""NCDC-60""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LaVK2""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""BbVK3""}]",Encapsulated,Facultative Anaerobe,"Temperature: 30–37°C; pH: Neutral to slightly acidic; Nutritional requirements: Milk-based medium (lactose, proteins, vitamins); Osmotic tolerance: Moderate",Growth rate: ~8 hours to fermentation; Doubling time: Not specified; In vitro: Stable in milk; In vivo: Not directly assessed,"Gastrointestinal tract (gut lumen, mucosal surface)",Symbiotic with host microbiota; potential for competitive exclusion of pathogens; no reported antagonism,"Moderate tolerance to refrigeration and lyophilization; no data on UV, drying, or shear stress",None specified,该系统由多种乳酸菌组成，包括乳酸乳球菌（Lactococcus lactis）和乳酸杆菌（Lactobacillus acidophilus）等，均能在30–37°C的温度下生长，适宜于牛奶基质中发酵。乳酸杆菌和双歧杆菌在体外表现出良好的生长能力，但未评估其在体内的定植能力与长期稳定性。,None (Natural strains used; no genetic modification reported),Not applicable,Constitutive,None,High (Natural strains; no plasmids or engineered circuits; stable in milk matrix),Stable in fermented milk matrix; no evidence of genetic drift or instability,该系统未经过任何基因工程改造，所有菌株均为天然分离株，通过共培养在脱脂牛奶中发酵制备成益生菌酸奶（Probiotic Dahi），其功能依赖于天然代谢活性，而非人工调控电路。,"[""pH"", ""Lactose""]","[""Lactate"", ""Bile acids""]",,,None specified (Natural sensing; no engineered receptors),None (No synthetic logic gates; natural metabolic responses),系统依赖于天然代谢感应机制，如乳酸菌对乳糖的利用和对肠道pH变化的适应性，但未涉及任何人工设计的信号感应逻辑或调控回路。,"[""Antioxidant"", ""Metabolic Regulation"", ""Immunomodulation""]",None (No engineered secretion systems; natural metabolite release),Dose-dependent via daily intake (5 g/day); no precise control mechanism,High (Stable in fermented milk matrix; compatible with oral delivery),False,,,None,,False,,,,未提及抗菌或抗生物膜功能。,False,None,,False,False,False,未提及氧气生成或氧合功能。,True,通过调节抗氧化酶活性和炎症相关基因表达，改善免疫稳态，减轻氧化应激诱导的衰老相关炎症。,"Cytokines (indirectly via PPAR-α, klotho, SMP-30)",False,None,,True,通过上调PPAR-α、klotho和SMP-30等抗衰老基因的表达，调节脂质代谢、钙磷稳态和氧化还原平衡。,"PPAR-α, klotho, SMP-30 (gene expression regulators)",False,None,,GRAS,None (No kill switches or auxotrophy reported),None,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape unlikely due to non-persistent nature in gut,Physical confinement via oral delivery and gastrointestinal transit; no engineered barriers,该系统使用的是公认安全（GRAS）的乳酸菌菌株，未进行基因改造，无致病性或耐药基因风险，且在肠道中定植能力有限，不会长期滞留，因此生物安全风险极低。,喂食益生菌酸奶（La-Dahi 和 LaBb-Dahi）可显著提升衰老小鼠肝脏和肾脏中CAT和GPx的活性，降低TBARS和蛋白羰基水平，恢复氧化应激平衡。同时显著上调PPAR-α、klotho和SMP-30等衰老标志物的表达，表明其在延缓衰老、改善氧化损伤方面具有显著功效。两种制剂效果相当，主要归因于L. acidophilus LaVK2的作用。,13852,1682,15534,,
9613a066-150a-4490-b864-ddc8d3210708,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""BGP1""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""BLC1""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in media containing glucose and amino acids; requires 10% fetal bovine serum for in vitro culture.",Doubling time ~1.5–2 h in rich media; consistent in vitro growth kinetics; no in vivo homeostasis data provided.,Intestinal mucosa (gut lumen and mucus layer); potential for colonization in colorectal environment.,Competitive exclusion of pathogenic bacteria; synergistic interaction with phenolic compounds to enhance bioavailability and activity.,"Moderate tolerance to gastric acidity and bile salts; stable during freeze-drying and rehydration; limited data on UV, shear, or long-term storage.","Bile salts, gastric pH (simulated), freeze-drying matrix","Lactobacillus paracasei BGP1 and Bifidobacterium animalis subsp. lactis BLC1 are facultative anaerobes capable of growing in standard laboratory media under aerobic and microaerophilic conditions. They thrive at 37°C in nutrient-rich environments, particularly those containing glucose and amino acids. Both strains are adapted to the intestinal environment, where they can survive transient exposure to bile and low pH. Their growth is supported by fetal bovine serum in culture media, indicating a dependency on host-derived nutrients. These microbes are designed for oral delivery and intestinal persistence, with potential to modulate the gut microbiota through competitive exclusion and metabolic synergy with dietary phenolics.",Not specified (no genetic modifications reported),Not applicable (no genome editing tools used),Constitutive (no inducible systems reported),,High chromosomal stability; no plasmids reported; no data on long-term in vivo drift or metabolic burden.,Stable in aqueous extract suspensions; no evidence of degradation in phenolic-rich matrices.,"The microbial consortium is used in its native, unmodified form. No genetic engineering or synthetic circuits were applied. The strains are selected for their natural probiotic properties, including survival in the gastrointestinal tract, interaction with dietary polyphenols, and induction of chemopreventive responses in colon cancer cells. The system relies on intrinsic metabolic capabilities rather than engineered genetic circuits.","[""pH"", ""Glucose"", ""Bile acids""]","[""Phenolic compounds"", ""Anthocyanins""]",,"[""Proteases"", ""Cytokines""]",Not specified (no specific receptors or promoters identified),No logic gates or threshold-based control reported; activity is likely constitutive and responsive to environmental cues via native regulatory systems.,"The system does not employ engineered sensing circuits. Instead, the microbes respond to physiological and chemical cues in the gut environment—such as pH, bile, and nutrient availability—through their native regulatory networks. Their activity is modulated by the presence of phenolic compounds, which may be sensed indirectly via metabolic flux or membrane transporters. No dynamic filtering, noise suppression, or time-delayed responses were reported.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion (for organic acids), vesicles (for signaling molecules), lysis (for metabolite release)",Controlled by concentration of extract and probiotic dose; no feedback or dynamic regulation reported.,Compatible with aqueous extract suspensions; no structural disruption observed; stable during freeze-drying and rehydration.,True,True,False,"Probiotics inhibit pathogenic bacteria through competitive exclusion, production of organic acids (lowering pH), and secretion of bacteriocins. They also enhance the bioavailability of phenolic compounds, which have intrinsic antibacterial activity.","Organic acids (lactic, acetic), bacteriocins, phenolic metabolites",True,True,True,True,The probiotics reduce pathogen load via competitive exclusion and acidification. They are safe in the gut environment and do not disrupt the microbiome significantly. The combination with fruit extracts enhances their activity without causing tissue damage.,False,No oxygen-producing enzymes or light-dependent systems were used.,,False,False,False,No evidence of oxygenation activity; not part of the system's design.,True,"Probiotics modulate immune responses by stimulating anti-inflammatory cytokines (e.g., IL-10) and suppressing pro-inflammatory signals (e.g., TNF-α). They also enhance mucosal barrier function.","Cytokines (IL-10, TNF-α), immune cell activators",True,"Probiotics promote epithelial regeneration and barrier integrity by stimulating mucus production and tight junction proteins. They also reduce inflammation, creating a favorable environment for tissue healing.","Mucin, tight junction proteins, growth factors",True,"Probiotics metabolize phenolic compounds into bioactive forms (e.g., deglycosylation), enhancing their antioxidant and anti-cancer effects. They also influence host metabolism via SCFA production.","Short-chain fatty acids (SCFAs), bioactive phenolics",True,"The consortium induces apoptosis and necrosis in colon cancer cells (HT-29, Hepa 1c1c7) through synergistic action with fruit extracts. It enhances quinone reductase (QR) activity, a phase II detoxification enzyme, reducing carcinogen activation.","Apoptosis-inducing metabolites, QR-activating phenolics",GRAS,"Auxotrophy (nutrient dependency), no antibiotic resistance genes reported","Fetal bovine serum, glucose",Low pathogenicity; no known virulence factors; no antibiotic resistance genes detected; low risk of horizontal gene transfer; minimal environmental escape potential.,Physical confinement via oral delivery and gut retention; no engineered containment systems.,"Both Lactobacillus paracasei BGP1 and Bifidobacterium animalis subsp. lactis BLC1 are classified as GRAS (Generally Recognized As Safe) by regulatory agencies. They are non-pathogenic, non-invasive, and do not produce toxins. Their use in food and supplements is well-established. No antibiotic resistance genes were reported. The system relies on natural auxotrophy and gut retention, minimizing escape risk. The combination with fruit extracts enhances safety by promoting beneficial metabolic interactions.","The consortium, particularly when combined with jabuticaba extract E2 (rich in water-soluble phenolics), significantly increased quinone reductase (QR) activity by 9-fold in HT-29 cells and induced apoptosis and necrosis in both Hepa 1c1c7 and HT-29 cells. The E2 extract with Lactobacillus (JL) showed the highest antiradical and antioxidant activity (DPPH IC50: 211.90 μg/mL), outperforming blueberry anthocyanin-rich extract (B) by over 3-fold. This synergistic effect suggests strong chemopreventive potential against colorectal cancer, with enhanced bioavailability, antioxidant capacity, and induction of programmed cell death.",18110,2172,20282,,
464d0012-1148-4b65-9144-4b18c8d78721,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""SBT2055""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37–40 °C, pH 5.5–6.5, tolerant to bile salts and low pH (gastric conditions)",Doubling time ~1.5–2 h in vitro; stable in vivo colonization in intestinal tract,"Intestinal lumen, particularly in the small intestine and colon",Competitive exclusion of pathogenic bacteria; no significant disruption of native microbiota observed,"Tolerant to lyophilization, freeze-drying, and rehydration; stable under moderate shear stress and storage at 4 °C",Bile salt hydrolase (BSH) and acid tolerance response (ATR) genes,该菌株为兼性厌氧菌，可在37–40 °C、pH 5.5–6.5条件下良好生长，对胃酸和胆盐具有较强耐受性，能有效定植于小肠和结肠，具有良好的冻干稳定性和储存稳定性。,"None (natural strain, no genetic modification reported)",Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems used; no reported genetic drift in vivo,Stable in lyophilized powder and yogurt matrix,该菌株为天然分离菌株，未进行任何基因工程改造，其功能依赖于天然代谢通路和定植能力。,"[""Low pH (gastric transit)"", ""Bile salts (intestinal environment)"", ""Hypoxia (intestinal lumen)""]","[""Glucose"", ""Lactate"", ""Fatty acids (from high-fat diet)""]",,"[""Proteases (intestinal mucosa)"", ""Cytokines (inflammatory environment)""]","Bile salt hydrolase (BSH), acid tolerance response (ATR) promoters, lactate permease",Constitutive expression; no reported synthetic logic circuits,该菌株通过天然感知系统响应胃酸、胆盐和乳酸等环境信号，维持其在肠道中的存活与定植，无合成逻辑门控机制。,"[""Metabolic Regulation"", ""Immunomodulation""]",None (natural secretion of metabolites and cell wall components),Dose-dependent effect observed in vivo; controlled by dietary intake and viable cell count,Compatible with lyophilized powder and yogurt matrix; stable during freeze-drying and reconstitution,False,,,Not applicable,,False,False,False,False,未报告抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未报告产氧功能。,True,Downregulates pro-inflammatory cytokines and inhibits upregulation of sICAM-1; reduces immune cell infiltration in visceral adipose tissue.,sICAM-1 (soluble intercellular adhesion molecule-1),False,Not applicable,,True,Inhibits enlargement of visceral adipocytes; reduces adipocyte size and systemic inflammation associated with obesity.,Short-chain fatty acids (SCFAs) – inferred from metabolic activity,False,Not applicable,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk,Physical confinement via lyophilized powder and yogurt delivery system,该菌株为公认安全（GRAS）菌株，无致病性、无抗生素抗性基因，未进行基因改造，无生物安全风险，通过冻干粉和酸奶载体实现物理隔离。,在高脂饮食诱导的肥胖大鼠模型中，Lactobacillus gasseri SBT2055显著抑制了内脏脂肪细胞的增大（P < 0.01），并有效防止了血清sICAM-1水平的升高，表明其具有显著的抗肥胖和抗炎作用。,8747,1504,10251,,
9bf7d2b8-fef5-4940-bfd5-47b9f59c606b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCDC 14""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""NCDC 19""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Acid-tolerant (survives gastric acidity); Bile tolerance (survives intestinal bile); Nutritional requirements: Lactose, peptides, vitamins (from milk matrix)",Doubling time ~12–14 hours in vitro; No significant growth rate data in vivo provided,"Small and large intestine epithelial wall (adherent), intestinal lumen (free)",Competitive exclusion of coliforms; restoration of microbial balance; symbiotic with host gut environment,Acid and bile tolerance; survives gastric transit; stable in refrigerated storage (implied by dahi preparation),"Bile salt deconjugation enzymes (unspecified), acid tolerance mechanisms (e.g., F0F1-ATPase)","Lactobacillus acidophilus and Lactobacillus casei are acid- and bile-tolerant lactic acid bacteria that survive gastrointestinal transit, adhere to intestinal epithelium, and colonize the gut lumen. They maintain stability in fermented dairy products and thrive under physiological conditions of the small and large intestine.",,,,,No genetic modifications reported; natural strains used; chromosomal stability assumed,Stable in dahi matrix; no evidence of degradation during storage or delivery,"No genetic engineering was performed. The strains were selected based on natural probiotic attributes such as acid and bile tolerance, surface hydrophobicity, and bile salt deconjugation. They were used in their native form for preparation of probiotic dahi.","[""Acidity (low pH in stomach)"", ""Bile (in small intestine)""]","[""Lactose (from milk matrix)"", ""Glucose (in host environment)""]",,,"FNR-like regulators (inferred from acid/bile tolerance), bile salt hydrolases (BSH), acid shock proteins",No synthetic logic circuits; natural adaptive responses to environmental stressors,The microbes sense acidic and bile-rich environments via intrinsic stress response systems. They activate acid tolerance responses (ATR) and bile resistance mechanisms to survive transit. No engineered logic gates or threshold control are present.,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Passive diffusion, cell lysis (inferred), exopolysaccharide secretion",Dose-dependent effects observed (15 g dahi/rat/day); no precise control mechanism reported,Highly compatible with dahi matrix; stable during fermentation and storage; supports sustained release in GI tract,True,False,False,"Inhibits coliforms via competitive exclusion, production of bacteriocins, and hydrogen peroxide; reduces free and attached coliform counts in intestine.","Bacteriocins, hydrogen peroxide",False,True,True,True,"Probiotic dahi significantly reduced both free and attached coliform counts in small and large intestine (p < 0.05), indicating effective antibacterial activity without causing tissue damage.",False,,,False,False,False,,True,Reduces oxidative stress and inflammation in intestinal tissues; modulates immune response via antioxidant activity.,"Antioxidant metabolites (e.g., organic acids, exopolysaccharides)",True,Protects intestinal epithelium from oxidative damage; improves mucosal integrity and transit time; supports normal gut motility.,"Exopolysaccharides, organic acids (lactic, acetic)",True,"Reduces glycosylation of hemoglobin (HbA1c) and lipid peroxidation (TBARS), indicating modulation of metabolic stress and glycation pathways.","Lactic acid, acetic acid, antioxidant compounds",False,,,GRAS,None (natural strains used; no kill-switch or auxotrophy),,"Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; non-invasive, non-colonizing long-term; safe for human consumption",Dahi matrix provides partial physical barrier; limited systemic absorption,"Lactobacillus acidophilus and Lactobacillus casei are well-established GRAS organisms with a long history of safe use in fermented dairy products. No genetic modifications or pathogenic traits were introduced. The risk of microbiome disruption is low, as they restore balance rather than dominate.","Probiotic dahi significantly improved gastrointestinal transit rate (charcoal transit) in diabetic rats, restored intestinal microbial balance (increased lactobacilli, decreased coliforms), reduced oxidative stress (lower TBARS levels), and decreased glycosylation of hemoglobin (HbA1c) without altering blood glucose levels. These effects collectively indicate effective mitigation of diabetic gastropathy.",9591,1682,11273,,
818a8880-d75d-4297-ac01-189f11e074f8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""FJ861111.1""}]",Suspension,Facultative Anaerobe,Growth at 37°C in MRS medium under anaerobic conditions; tolerates pH 2.5 and 0.3% bile salts.,High viability at pH 2.5 (7.5 log cfu/mL) and 0.3% bile salts (6.0 log cfu/mL); survival in acidic and bile salt conditions consistent with in vitro and in vivo gastrointestinal transit.,"Intestinal epithelium (HT-29 cells), gut lumen post-oral administration","Competes with pathogens (e.g., C. albicans) for adhesion sites; enhances total gut microbiota and Lactobacillus population post-infection.","High tolerance to low pH (pH 2.5), bile salts (up to 0.5%), and gastric transit conditions.","Exopolysaccharides (EPS) produced by strain (implied by prior study: Chen et al., 2013)",该菌株在体外表现出良好的酸耐受性和胆盐耐受性，能在pH 2.5和0.3%胆盐条件下保持高存活率，具备在胃肠道中定植并发挥抗病原体定植能力的生理基础。,,,,,,,该研究未涉及基因工程改造，菌株为天然分离株，未进行遗传修饰。,"[""pH"", ""Bile Salts""]",,,,Unknown (no specific receptor or promoter reported),No logic circuitry reported; function is constitutive.,该菌株未被工程化设计为响应特定信号，其抗黏附和抗菌功能为天然生理特性，无明确的信号感知与逻辑调控机制。,"[""Antibacterial"", ""Anticolonization""]",Unknown (likely passive secretion of metabolites or bacteriocins),Dose-dependent effect observed in vivo (fermented milk administration); no precise control mechanism reported.,Compatible with fermented milk matrix; survives in milk and maintains function during oral delivery.,True,True,False,通过分泌抗菌物质抑制多种食源性病原体，包括沙门氏菌、金黄色葡萄球菌、克罗诺杆菌、大肠杆菌和白色念珠菌。,"Unknown (likely bacteriocins or organic acids, but not specified)",True,True,True,True,在体外对多种常见病原体（包括革兰氏阳性菌、革兰氏阴性菌和真菌）均表现出抑制活性，且在动物实验中未观察到显著毒性或微生物群落紊乱，表明其活性可控且安全。,False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,None (no kill-switch or auxotrophy reported),,Non-pathogenic; no antibiotic resistance genes or horizontal gene transfer risk reported. Low opportunistic risk.,Fermented milk matrix provides physical confinement during delivery.,该菌株为食品级安全菌株（GRAS），未进行基因改造，无生物安全风险，且在动物实验中未引起不良反应，具有良好的安全性。,在小鼠模型中，口服L. paracasei FJ861111.1发酵乳可显著提高粪便中总菌群和乳酸杆菌数量，并显著抑制白色念珠菌在肠道中的定植（从7.5 log cfu/mL降至6.4 log cfu/mL），表明其具有良好的抗定植和肠道微生态调节能力。,10289,1422,11711,,
239c1d29-3c8c-47ac-a451-7d55e9bea8d3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Clostridium scindens"", ""strain_id"": ""Not specified""}]",Gut lumen (commensal),Strict Anaerobe,"Optimal growth at 37°C, neutral to slightly alkaline pH, requires complex nutrients including bile acids and amino acids; dependent on host-derived metabolites","Slow growth rate; doubling time not reported, but typical for anaerobic clostridia; in vivo homeostasis consistent with gut environment","Gut lumen, particularly colon; associated with bile acid metabolism in the intestinal tract",Competitive with other gut microbes; produces secondary bile acids that modulate host immunity and influence microbial community structure,Sensitive to oxygen; stable under anaerobic conditions; lyophilization stability not reported; shear stress tolerance in gut environment,None reported,Clostridium scindens 是一种严格厌氧的肠道共生菌，主要定植于结肠，依赖于胆汁酸等宿主代谢物进行生长，其代谢活动可显著影响肝脏免疫微环境。,None reported,Not applicable,Constitutive,None,Chromosomal integration; stable in gut environment; no plasmid-based systems used,Not applicable (no synthetic material used),未对 Clostridium scindens 进行基因工程改造，其功能依赖于天然代谢通路，特别是将初级胆汁酸转化为次级胆汁酸的能力。,"[""Bile acids"", ""pH"", ""Hypoxia""]","[""Primary bile acids"", ""Secondary bile acids""]",,"[""CXCL16"", ""IFNγ""]","FNR promoter (inferred from hypoxia response), bile acid receptors (inferred from metabolic sensing)",Threshold-based response: high levels of primary bile acids trigger CXCL16 expression; secondary bile acids suppress it. No explicit logic gate reported.,Clostridium scindens 通过感知肠道中初级胆汁酸的浓度，调控其代谢活性，进而影响肝窦内皮细胞表达 CXCL16，从而招募 CXCR6+ NKT 细胞。当次级胆汁酸积累时，该信号被抑制，提示存在负反馈调节机制。,"[""Tumor Therapy"", ""Immunomodulation""]",Metabolic secretion (endogenous bile acid transformation),Self-regulated by host bile acid levels; no external control,No synthetic material used; natural gut environment,False,,,Not applicable,,,,,,无抗菌功能,False,Not applicable,,,,,无氧生成功能,True,通过将初级胆汁酸转化为次级胆汁酸，调节肝窦内皮细胞表达 CXCL16，从而招募并激活 CXCR6+ NKT 细胞，促进 IFNγ 分泌，增强抗肿瘤免疫应答。,CXCL16 (indirectly via bile acid metabolism),False,Not applicable,,True,通过胆汁酸代谢调节宿主免疫代谢，影响肝内免疫细胞功能，间接调控肿瘤微环境。,"Secondary bile acids (e.g., deoxycholic acid, lithocholic acid)",True,通过胆汁酸代谢调控肝内 NKT 细胞积累，增强抗肿瘤免疫监视，抑制肝癌原发灶和肝转移灶生长。,Secondary bile acids (as signaling molecules),BSL-1,None reported,None,Low pathogenicity; non-invasive; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low environmental escape risk due to gut-specific niche,None (natural gut colonization),Clostridium scindens 为天然肠道共生菌，无致病性，属于 GRAS 级别，无生物安全风险，其功能依赖于宿主胆汁酸环境，不易在体外或环境中长期存活。,在小鼠模型中，清除肠道菌群或使用抗生素处理后，肝细胞癌（HCC）肿瘤数量和体积显著减少，肝转移灶明显减少；恢复 C. scindens 定植或补充次级胆汁酸后，抗肿瘤效应消失，提示其在调控肝癌免疫微环境中的关键作用。,3605,1535,5140,,
bac461b1-ac71-49ad-b69c-33b912665ebb,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""DN-114 001""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; utilizes glucose and other carbohydrates as carbon sources; no requirement for specific vitamins or amino acids beyond standard culture media.",Doubling time ~1.5–2 hours in vitro; growth rate consistent with in vitro conditions; no in vivo growth data reported.,"Gut mucosa, particularly in the small intestine and colon; associated with mucosal immune modulation.",Interacts with host immune cells (DCs); no direct competition or symbiosis with other gut microbes reported in this study.,Gamma-irradiated for experimental use; tolerance to osmotic stress and moderate pH shifts not explicitly tested; stability in culture medium confirmed.,Gamma irradiation (for inactivation),"Lactobacillus casei DN-114 001 is a facultative anaerobe capable of growing under standard in vitro conditions. It thrives at 37°C and neutral pH, utilizing carbohydrates as primary carbon sources. It does not require exogenous vitamins or amino acids beyond standard culture media. The strain is adapted to the intestinal environment and interacts directly with dendritic cells to modulate immune responses.",None reported (natural strain used),Not applicable (no genetic modification performed),Constitutive (natural expression of immunomodulatory signals),,Stable in culture; no plasmid or chromosomal integration reported; natural strain used without engineered genetic circuits.,No engineered material environment; used in suspension with DCs in vitro.,"The Lactobacillus casei DN-114 001 strain was used in its natural form without genetic modification. It functions as a chassis for immune modulation through natural interaction with dendritic cells, without engineered genetic circuits or inducible systems.","[""pH"", ""Glucose""]","[""Lactate"", ""SCFAs""]",,"[""Toll-like receptor 3 (TLR3) agonist (poly(I:C))"", ""Dendritic cell surface receptors""]",Unknown (natural interaction with DCs; no specific receptor identified in this study),AND gate: Requires simultaneous or sequential exposure to L. casei and TLR3 signal (poly(I:C)) to trigger IL-12p70 production.,"Lactobacillus casei alone induces tolerogenic DCs, but when combined with a TLR3 agonist (poly(I:C)), it triggers a synergistic, selective IL-12p70 response. This indicates a logical AND gate: both signals are required for immunogenic activation. The timing of exposure (L. casei prior to poly(I:C)) is critical, suggesting a temporal logic gate with a required sequence.","[""Immunomodulation""]","Direct cell-cell contact (non-lytic, non-secretory; immunomodulation via surface interaction)",Not controllable (natural interaction; no engineered output regulation),Compatible with in vitro suspension culture; no encapsulation or material barrier used.,False,,,,,,,,,,False,,,,,,,True,"Synergistically enhances IL-12p70 production by dendritic cells when combined with TLR3 agonist (poly(I:C)), driving naive T cells toward Th1 polarization without inducing Th17 responses.",Interleukin-12p70 (IL-12p70),False,,,False,,,False,,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape not assessed.,None (no physical confinement used in study),"Lactobacillus casei DN-114 001 is a well-characterized probiotic strain with GRAS status. It is not pathogenic, does not carry antibiotic resistance genes, and is not known to transfer genes horizontally. No biocontainment strategies were used in this study, as the strain is considered safe for human use.","In vitro, the combination of L. casei and poly(I:C) synergistically enhanced IL-12p70 secretion by dendritic cells, leading to robust T helper type 1 (Th1) polarization of naive T cells without inducing Th17 responses. This suggests potential for mucosal vaccine adjuvants and immune modulation in enteric diseases.",12685,1603,14288,,
febfeaf3-198d-4f1d-ac05-af414020033c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""LGG""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""S. boulardii""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acidity and bile salts; utilizes glucose and other carbohydrates as carbon sources",Doubling time ~1–2 hours in vitro; in vivo colonization is transient but functional during antibiotic treatment,"Small intestine, particularly the mucosal surface of the ileum and colon",Competes with pathogenic bacteria for adhesion sites; produces bacteriocins and organic acids that inhibit pathogens; supports commensal microbiota balance,"Tolerant to gastric acid, bile salts, and moderate osmotic stress; stable during lyophilization and rehydration; moderate resistance to shear stress in suspension","Bile salt hydrolases (BSH), acid shock proteins (e.g., DnaK), and extracellular polysaccharides","Lactobacillus GG and Saccharomyces boulardii are facultative anaerobes that survive gastrointestinal transit, colonize the intestinal mucosa transiently, and exert health benefits through competitive exclusion, antimicrobial secretion, and immune modulation. They are resilient to gastric acidity and bile, enabling effective delivery to the gut.",,,,,High chromosomal stability; no plasmid-based systems reported; minimal metabolic burden; no evidence of genetic drift in clinical use,"Stable in powder, capsule, and liquid formulations; maintains viability in encapsulated delivery systems","Both Lactobacillus GG and Saccharomyces boulardii are used in their native, non-genetically modified forms. No synthetic genetic circuits or engineered control systems are employed in current clinical applications. Their probiotic effects are intrinsic to their natural physiology.","[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""SCFAs""]",,"[""Proteases"", ""Cytokines""]","FNR-like regulators (LGG), G-protein coupled receptors (S. boulardii), and surface adhesins (e.g., p40/p75 in LGG)","No engineered logic gates; natural sensing via receptor-ligand interactions with threshold responses to environmental cues (e.g., acid resistance activation at low pH)","Lactobacillus GG senses low pH and bile acids via membrane sensors, triggering acid shock response and bile resistance mechanisms. Saccharomyces boulardii detects host-derived signals such as proteases and cytokines, modulating its secretory activity. These natural sensing systems allow context-dependent functional responses without synthetic circuitry.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (LGG), extracellular vesicles (S. boulardii)",Dose-dependent efficacy; optimal range 5–40 billion CFU/day; controlled by formulation and dosing schedule,"High compatibility with capsules, powders, and oral delivery; stable in gelatin capsules and enteric-coated tablets",True,True,True,"LGG produces bacteriocins (e.g., lactocin S, p40/p75 adhesins) and organic acids (lactic acid) that inhibit pathogens like Clostridioides difficile, Escherichia coli, and Salmonella. S. boulardii secretes protease inhibitors (e.g., plasminogen activator inhibitor) that neutralize bacterial toxins and prevent pathogen adherence.","Lactocin S, p40/p75 adhesins, lactic acid, plasminogen activator inhibitor",True,True,True,True,LGG reduces AAD risk by 75% in children; S. boulardii decreases AAD incidence from 28.5% to 11.97% in meta-analyses. Both strains show low cytotoxicity and minimal disruption to gut microbiome.,False,,,False,False,False,,True,"LGG modulates dendritic cell function and promotes anti-inflammatory cytokine production (e.g., IL-10). S. boulardii enhances IgA secretion and downregulates pro-inflammatory NF-κB signaling.","p40/p75 adhesins (LGG), protease inhibitors (S. boulardii), exopolysaccharides",True,"LGG enhances intestinal barrier integrity by upregulating tight junction proteins (e.g., occludin, ZO-1). S. boulardii promotes epithelial cell proliferation and wound healing via growth factor stimulation.","Occludin, ZO-1, epidermal growth factor (EGF)-like molecules",False,,,False,,,GRAS,"Auxotrophy (LGG requires specific amino acids), natural attenuation (transient colonization)","Amino acid auxotrophies (e.g., histidine), bile acid sensitivity",Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer documented; rare cases of fungemia in immunocompromised patients,Capsule and enteric coating prevent premature release; physical barrier limits environmental escape,"Lactobacillus GG and Saccharomyces boulardii are classified as Generally Recognized As Safe (GRAS). They are non-pathogenic and do not persist long-term in the gut. Rare cases of sepsis have occurred in neonates and immunocompromised individuals, but these are exceptional. No evidence of environmental persistence or gene transfer.","Probiotics significantly reduce the incidence of antibiotic-associated diarrhea by 75% (LGG) and lower AAD risk from 28.5% to 11.97% (S. boulardii). They shorten diarrhea duration by 0.75–1 day and improve intestinal barrier function, supporting faster recovery and enhanced compliance with antibiotic therapy.",5393,1928,7321,,
cacb7083-5c77-4d8a-b34f-fe1687ec8668,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""TN8""}]",Suspension,Facultative Anaerobe,"Temperature: 30 °C, pH: 6.2, in MRS medium (peptone, yeast extract, glucose, etc.)",Growth rate not explicitly quantified; cells harvested at OD600 corresponding to 10⁹ CFU/mL,"Gastrointestinal tract (duodenum, jejunum, ileum, gizzard); intestinal mucosa",Competes with pathogenic bacteria for mucosal adherence; potential symbiosis with host microbiome,"Tolerant to osmotic stress (in MRS medium), storage stability implied via lyophilization (inferred from preparation method)","MRS medium components (e.g., glucose, sodium acetate)",该菌株为从家禽胃肠道分离的乳酸杆菌，可在30°C、pH 6.2条件下在MRS培养基中生长，具有良好的耐受性，能有效定植于肠道黏膜，竞争性抑制病原菌黏附，具有潜在的共生能力。,,,,,,,该研究未对L. plantarum TN8进行基因工程改造，其功能基于天然菌株的固有特性，未使用任何外源基因或调控回路。,"[""pH"", ""Osmotic stress""]","[""Glucose"", ""Lactate (inferred from metabolism)""]",,"[""Proteases (inferred from mucosal environment)"", ""Cytokines (inferred from immune modulation)""]","Inferred: native receptors for pH, sugars, and host-derived molecules; no specific sensor gene reported",No engineered logic gates; natural sensing via metabolic and environmental adaptation,该菌株通过感知肠道微环境中的pH、渗透压及营养物质（如葡萄糖）实现定植与代谢适应，其免疫调节功能可能依赖于对宿主免疫信号的自然响应，未涉及人工逻辑控制。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Inferred: natural secretion of immunomodulatory molecules (e.g., IL-10); no engineered secretion system reported",Oral administration once daily; dose fixed at 1×10⁹ CFU/mL; no dynamic control reported,Suspension administered orally; compatible with gastrointestinal environment; no encapsulation material used,False,,,Not applicable – no direct antibacterial or biofilm inhibition reported.,,False,,,,未报告抗菌或抗生物膜活性。,False,Not applicable – no oxygen-producing mechanism reported.,,False,False,False,未涉及氧生成功能。,True,"Induces IL-10 production, reduces pro-inflammatory cytokines (IL-12, TNF-α), promotes anti-inflammatory immune response.",IL-10,True,"Promotes epithelial re-epithelization, reduces crypt loss, attenuates mucosal ulceration and inflammatory infiltration.",Epithelial regeneration factors (inferred from histology),True,Reduces serum total cholesterol and triglycerides; increases HDL cholesterol levels.,HDL cholesterol,False,Not applicable – no tumor therapy mechanism reported.,,GRAS,None – no genetic modifications or kill switches used,,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk due to natural origin and lack of engineering,None – oral administration without physical confinement,L. plantarum TN8为天然分离的益生菌，属于公认安全（GRAS）菌株，未进行基因改造，无生物安全风险，无致病性或耐药基因，适合口服应用。,口服L. plantarum TN8可显著改善TNBS诱导大鼠结肠炎模型的临床症状，包括体重下降、腹泻、便血、结肠缩短等；组织学显示黏膜损伤减轻、炎症浸润减少、上皮再生；生化指标显示总胆固醇和甘油三酯显著降低，HDL升高；肝肾组织损伤亦明显缓解，表明其在抗炎、组织修复和代谢调节方面具有显著疗效。,10619,1543,12162,,
4cfae296-aa7e-4422-a82d-a8478b4264dd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""SF68""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, in the presence of bile salts and low pH (survives gastric transit), utilizes carbohydrates as carbon sources.",Moderate growth rate; doubling time ~30–60 min in vitro; stable colonization in gut environment post-oral administration.,Intestinal lumen and mucosal surface of the distal ileum; transient presence in mesenteric lymph nodes.,No significant competition or symbiosis observed with native microbiota; does not alter luminal or tissue-associated bacterial populations.,"Tolerant to bile salts, low pH (gastric conditions), and moderate osmotic stress; survives lyophilization and rehydration.","Bile salts, low pH (HCl), and lyophilization buffer","Enterococcus faecium SF68 is a facultative anaerobe capable of surviving gastrointestinal transit and transiently colonizing the intestinal mucosa. It demonstrates moderate growth kinetics and tolerance to gastric and intestinal stressors, but does not establish long-term colonization or significantly alter the gut microbiota composition.",,,,,,,No genetic modifications were applied to Enterococcus faecium SF68 in this study. The strain was used as a naturally occurring probiotic without engineered circuits or synthetic biology components.,"[""Low pH (gastric transit)"", ""Bile salts (intestinal environment)""]","[""Lactate"", ""Glucose""]","[""None reported""]","[""Immunoglobulins (IgG, IgA)"", ""Cytokines (indirectly via immune modulation)""]",Unknown (native receptors for bile and low pH; likely membrane transporters and stress response regulators),No engineered logic gates; natural sensing of environmental cues with threshold-based responses.,"Enterococcus faecium SF68 senses low pH and bile salts via native membrane transporters and stress response systems. It responds to nutrient availability (e.g., glucose, lactate) for growth. No synthetic logic circuits were used. The strain exhibits transient presence in tissues, suggesting natural sensing of host immune signals (e.g., IgG levels), but no engineered feedback control.","[""Immunomodulation""]",Unknown (likely passive diffusion or lysis; no engineered secretion systems reported),Not controllable – administered at fixed dose (1.4×10⁹ CFU/kg feed); no feedback or regulation.,No encapsulation or material environment used; delivered in feed as free suspension.,False,False,False,Not applicable – no antibacterial activity observed.,,False,False,False,False,无抗菌活性证据。,False,Not applicable – no oxygen-producing capability reported.,,False,False,False,无氧生成能力。,True,"Enterococcus faecium SF68 tends to reduce serum IgG levels on day 20 post-weaning, suggesting systemic immunomodulatory effects. It may influence cytokine profiles in gut-associated lymphoid tissue (GALT), potentially modulating Th2 responses and IgA production.","Secreted metabolites or cell wall components (e.g., peptidoglycan, teichoic acids) that interact with host immune receptors (e.g., TLRs)",False,Not applicable – no evidence of tissue regeneration or barrier enhancement.,,False,"Not applicable – no metabolic byproducts (e.g., SCFAs) reported to regulate host metabolism.",,False,Not applicable – no anti-tumor activity reported.,,GRAS,None – no kill-switch or auxotrophy used.,,"Low pathogenicity; non-invasive; no antibiotic resistance genes reported. However, Enterococcus species can transfer resistance genes (HGT risk). Environmental escape possible if excreted.",None – no physical confinement used.,"Enterococcus faecium SF68 is classified as GRAS (Generally Recognized As Safe). It is a commensal bacterium with low pathogenicity. However, it has potential for horizontal gene transfer (HGT), particularly for antibiotic resistance genes. No biocontainment strategies were employed. The strain is transient and does not persist in the gut, reducing long-term environmental risk.",在本研究中，Enterococcus faecium SF68未显著改善断奶仔猪的生长性能（ADG、ADFI、FCR）。其主要作用为免疫调节，表现为第20天血清IgG浓度下降（P<0.1），提示其具有系统性免疫调节功能。尽管未改变肠道菌群结构或细菌易位，但其可能通过影响GALT中的细胞因子谱，间接促进黏膜免疫成熟。,17990,1644,19634,,
0b4a81d1-e64b-4b32-8acb-26b323394a67,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Porphyromonas gingivalis"", ""strain_id"": ""ATCC 33277""}, {""role"": ""Helper"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""ATCC 11284""}]",Encapsulated,Anaerobe,"37°C, in anaerobic chamber with MRS medium",Growth rate not specified; cultured for 5–7 days,"Oral mucosa, gingival crevice",Competitive interaction with probiotics; balance maintained via reuterin-mediated LPS neutralization,Not specified,,该系统由专性厌氧的牙龈卟啉单胞菌和兼性厌氧的罗伊氏乳杆菌组成，两者均在37°C、厌氧条件下生长。牙龈卟啉单胞菌在MRS培养基中培养5–7天，罗伊氏乳杆菌通过超声裂解制备提取物，用于体外和体内实验。,Not applicable,,Not applicable,,Not applicable,Not applicable,本研究未对微生物进行基因改造，仅使用细菌裂解物（sonicated extracts）模拟微生物群落平衡，因此无遗传工程操作。,"[""LPS"", ""pH""]","[""LPS""]",,"[""NLRP3 inflammasome"", ""Cytokines""]","LPS (detected via ELISA), NLRP3 inflammasome (detected via WB and RT-PCR)","AND gate: LPS from P. gingivalis activates NLRP3 inflammasome; reuterin from L. reuteri neutralizes LPS, thereby suppressing inflammasome activation.",牙龈卟啉单胞菌释放的LPS激活NLRP3炎症小体，导致间充质干细胞功能障碍；而罗伊氏乳杆菌产生的reuterin可中和LPS，从而抑制炎症小体活化，恢复干细胞功能。该系统通过LPS与reuterin的拮抗作用实现动态平衡调控。,"[""Immunomodulation"", ""Tissue Repair""]",Lysis (via sonication to release intracellular components),"Controlled by concentration of sonicated extracts (e.g., 50 μg/ml P. gingivalis + 25 μg/ml L. reuteri)",Compatible with methylcellulose gel for in vivo delivery; stable in encapsulated form,False,False,False,,,False,False,False,False,,False,,,False,False,False,,True,"Reuterin neutralizes LPS from P. gingivalis, inhibiting NLRP3 inflammasome activation and reducing inflammation, thereby promoting MSC function and wound healing.",Reuterin,True,"Restores migration, osteogenic differentiation, proliferation, and prevents adipogenic differentiation of gingival MSCs, promoting tissue regeneration and wound healing.",Reuterin,False,,,False,,,BSL-2,Use of sonicated extracts instead of live bacteria; no viable cells used in experiments,Methylcellulose (physical barrier),P. gingivalis is a known pathogen associated with periodontitis and systemic diseases; L. reuteri is generally recognized as safe (GRAS). Risk minimized by using non-viable extracts.,Methylcellulose gel provides physical confinement and prevents microbial escape,由于实验使用的是细菌裂解物而非活菌，因此无活菌传播风险。牙龈卟啉单胞菌为潜在致病菌，但通过裂解处理已失活，且在甲基纤维素凝胶中封装，有效防止环境释放。罗伊氏乳杆菌为GRAS菌株，安全性高。,在小鼠腭部伤口模型中，局部接种牙龈卟啉单胞菌与罗伊氏乳杆菌的混合裂解物可显著促进伤口愈合，伤口面积在7天和14天时均显著减小，组织学分析显示再生速度加快。该效果与NLRP3炎症小体抑制和间充质干细胞功能恢复密切相关。,13304,1534,14838,,
c17842e9-c38d-4ec2-936f-14adc4b67253,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""Bifidobacterium breve""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex nutrients including amino acids, vitamins, and carbohydrates; dependent on host-derived metabolites in neonatal gut environment.",Doubling time ~2–3 hours in vitro; growth rate consistent with in vivo colonization in preterm infants during early feeding.,"Intestinal mucosa of preterm infants, particularly in the colon; preferentially colonizes the lower gastrointestinal tract where bifidobacteria are naturally enriched.","Competes with pathogenic bacteria (e.g., Gammaproteobacteria) for binding sites and nutrients; may promote symbiosis with commensal microbiota by enhancing mucus production and barrier integrity.",Moderate tolerance to gastric acidity and bile; stable during lyophilization and rehydration; sensitive to high temperatures (>40°C).,Heat shock proteins (HSPs) induced by probiotic exposure; protective role in stress response.,"Bifidobacterium breve is a facultative anaerobe that thrives in the neonatal gut environment, particularly in preterm infants. It colonizes the intestinal mucosa, competes with pathogens, and supports mucosal barrier function. Its growth is supported by host-derived nutrients and is sensitive to high temperatures, which can compromise viability.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,No genetic engineering was reported in the study. The probiotic functions are attributed to native metabolic and immunomodulatory activities of the wild-type strain.,"[""pH"", ""Bile acids"", ""Lactate""]","[""Short-chain fatty acids (SCFAs)"", ""Glucose""]","[""Quorum sensing molecules (AHL, AI-2)""]","[""Proteases (e.g., MMPs)"", ""Cytokines (e.g., IL-6, TNF-α)""]","FNR promoter (hypoxia-responsive), Lactate permease (lactate sensing), Bile acid receptors",Threshold-based activation; likely constitutive expression of protective functions under favorable gut conditions; no reported synthetic logic gates.,"Bifidobacterium breve senses local environmental cues such as low oxygen, bile acids, and lactate, which are indicative of the intestinal niche. It responds by enhancing mucus production and barrier function. The sensing is likely mediated by native receptors and promoters, with no engineered logic circuits.","[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]","Type I secretion system (for bacteriocins), passive diffusion (for SCFAs)",Dose-dependent effects; administered once daily at 0.5×10^9 CFU; no controllable genetic circuitry reported.,Compatible with oral delivery in infant formula; stable in suspension but sensitive to heat (>40°C).,True,False,True,Inhibits pathogenic bacterial adherence through competition for binding sites and secretion of soluble antimicrobial molecules.,"Soluble molecules (e.g., bacteriocins, organic acids) secreted by B. breve",False,True,True,True,B. breve reduces colonization by pathogenic bacteria and inhibits biofilm formation in preterm infants; no significant cytotoxicity reported.,False,Not applicable,Not applicable,False,False,False,No evidence of oxygenation activity in B. breve.,True,"Strengthens intestinal barrier, reduces bacterial translocation, modulates dendritic cell activity, promotes IgA production, and suppresses NF-κB activation.","Secreted metabolites (e.g., SCFAs), surface proteins interacting with dendritic cells",True,"Enhances mucus production, improves intestinal barrier integrity, reduces ischemic injury via nitric oxide production, and supports epithelial regeneration.","Mucus glycoproteins, nitric oxide (NO), SCFAs",True,"Ferments oligosaccharides to produce SCFAs (acetate, lactate), which serve as energy sources for colonocytes and modulate innate immunity.","Short-chain fatty acids (SCFAs), lactate",False,Not applicable,Not applicable,GRAS,Auxotrophy (nutrient-dependent survival); no kill-switch reported.,"Nutrient-dependent growth (e.g., specific amino acids, vitamins)","Low pathogenicity; however, rare cases of Bifidobacterium sepsis reported in immunocompromised preterm infants. No evidence of antibiotic resistance gene transfer.",Oral delivery with intestinal mucosal barrier; no physical encapsulation reported.,"Bifidobacterium breve is generally considered safe (GRAS status) and has low pathogenic potential. However, in severely compromised preterm infants with impaired intestinal barrier function, rare cases of sepsis have been reported. No evidence of horizontal gene transfer or long-term ecological disruption.","Bifidobacterium breve administration in preterm infants significantly reduced the incidence of necrotizing enterocolitis (NEC) and improved gut colonization. It enhanced intestinal barrier function, reduced pathogenic colonization, and supported mucosal immunity. Clinical trials showed a protective effect against NEC (Bell stage ≥2), with no major safety concerns in otherwise healthy preterm infants.",12173,4812,16985,,
c17842e9-c38d-4ec2-936f-14adc4b67253,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Bifidobacterium lactis Bb12""}]",Suspension,Facultative Anaerobe,"Grows optimally at 37°C, pH 6.5–7.0; requires complex media including lactose, amino acids, and vitamins; dependent on host-derived oligosaccharides in neonatal gut.",Doubling time ~2.5–3 hours in vitro; consistent with in vivo colonization in preterm infants.,Colon of preterm infants; preferentially colonizes the lower gastrointestinal tract.,Competes with pathogenic bacteria; promotes symbiosis by increasing bifidobacterial abundance and reducing pathogen load.,Moderate tolerance to bile and gastric acid; stable during lyophilization; sensitive to temperatures above 40°C.,"Heat shock proteins (HSPs), bile acid resistance genes","Bifidobacterium lactis Bb12 is a facultative anaerobe that colonizes the intestinal mucosa of preterm infants. It thrives in the neonatal gut environment, competes with pathogens, and supports mucosal immunity. It is sensitive to high temperatures, which can compromise viability.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,No genetic engineering was reported. The probiotic functions are due to native metabolic and immunomodulatory activities.,"[""pH"", ""Bile acids"", ""Lactate""]","[""Short-chain fatty acids (SCFAs)"", ""Lactose""]","[""Quorum sensing (AI-2)""]","[""Proteases"", ""Cytokines""]","FNR promoter, Lactate permease, Bile acid receptors",Threshold-based activation; likely constitutive expression under favorable gut conditions.,"B. lactis senses environmental cues such as bile, lactate, and pH, which are indicative of the intestinal niche. It responds by enhancing barrier function and modulating immune responses through native receptors and promoters.","[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]","Type I secretion (bacteriocins), passive diffusion (SCFAs)",Dose-dependent; administered at 6×10^9 CFU/kg/day; no controllable genetic circuitry.,Compatible with oral delivery in infant formula; sensitive to heat (>40°C).,True,False,True,Inhibits pathogen adherence via competitive exclusion and secretion of antimicrobial compounds.,"Bacteriocins, organic acids (e.g., acetic acid)",False,True,True,True,B. lactis reduces colonization by pathogenic bacteria and inhibits biofilm formation in preterm infants; no significant cytotoxicity reported.,False,Not applicable,Not applicable,False,False,False,No evidence of oxygenation activity.,True,"Enhances intestinal barrier, reduces bacterial translocation, modulates dendritic cell function, and promotes IgA production.","SCFAs, surface adhesins, secreted immunomodulatory proteins",True,"Improves intestinal barrier integrity, reduces fecal calprotectin (marker of inflammation), and supports epithelial regeneration.","SCFAs, mucus glycoproteins, nitric oxide",True,"Ferments oligosaccharides to produce SCFAs, which serve as energy sources for colonocytes and regulate immune function.","Acetate, lactate, butyrate",False,Not applicable,Not applicable,GRAS,Auxotrophy; no kill-switch reported.,"Nutrient-dependent growth (e.g., specific amino acids)",Low pathogenicity; no evidence of antibiotic resistance gene transfer. Rare cases of sepsis reported in immunocompromised infants.,Oral delivery with intestinal mucosal barrier; no physical encapsulation.,"Bifidobacterium lactis Bb12 is generally safe (GRAS status). It has low pathogenic potential, but rare cases of sepsis have been reported in severely ill preterm infants. No evidence of horizontal gene transfer or long-term ecological disruption.","B. lactis Bb12 supplementation in preterm infants reduced nosocomial infections, improved gut colonization, and decreased intestinal permeability. It enhanced immune function and reduced inflammation markers such as fecal calprotectin. Clinical trials showed protective effects against NEC and improved feeding tolerance.",12173,4812,16985,,
c17842e9-c38d-4ec2-936f-14adc4b67253,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Lactobacillus rhamnosus GG""}]",Suspension,Facultative Anaerobe,"Grows at 37°C, pH 5.5–6.5; requires glucose, amino acids, and vitamins; dependent on host-derived nutrients.",Doubling time ~1.5–2 hours in vitro; consistent with in vivo colonization in preterm infants.,"Intestinal mucosa, particularly in the small intestine; adheres to epithelial cells.",Competes with pathogens for adhesion sites; promotes symbiosis by enhancing barrier function.,Moderate tolerance to bile and gastric acid; stable during lyophilization; sensitive to temperatures >40°C.,"Heat shock proteins (HSPs), bile salt hydrolases","Lactobacillus rhamnosus GG is a facultative anaerobe that colonizes the intestinal mucosa of preterm infants. It adheres to epithelial cells, competes with pathogens, and supports mucosal immunity. It is sensitive to high temperatures, which can compromise viability.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,No genetic engineering was reported. The probiotic functions are due to native metabolic and immunomodulatory activities.,"[""pH"", ""Bile acids"", ""Lactate""]","[""Glucose"", ""SCFAs""]","[""Quorum sensing (AHL)""]","[""Proteases"", ""Cytokines""]","FNR promoter, Lactate permease, Bile acid receptors",Threshold-based activation; likely constitutive expression under favorable conditions.,"L. rhamnosus GG senses environmental cues such as bile, lactate, and pH, which are indicative of the intestinal niche. It responds by enhancing barrier function and modulating immune responses through native receptors and promoters.","[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]","Type I secretion (bacteriocins), passive diffusion (SCFAs)",Dose-dependent; administered at 2×10^9 CFU/day; no controllable genetic circuitry.,Compatible with oral delivery in infant formula; sensitive to heat (>40°C).,True,False,True,Inhibits pathogen adherence via competitive exclusion and secretion of antimicrobial compounds.,"Bacteriocins, lactic acid",False,True,True,True,L. rhamnosus GG reduces pathogen colonization and inhibits biofilm formation in preterm infants; no significant cytotoxicity reported.,False,Not applicable,Not applicable,False,False,False,No evidence of oxygenation activity.,True,"Enhances intestinal barrier, reduces bacterial translocation, modulates dendritic cell function, and promotes IgA production.","SCFAs, surface adhesins, secreted immunomodulatory proteins",True,"Improves intestinal barrier integrity, reduces intestinal permeability, and supports epithelial regeneration.","SCFAs, mucus glycoproteins, nitric oxide",True,"Ferments carbohydrates to produce SCFAs, which serve as energy sources for colonocytes and regulate immune function.","Acetate, lactate, butyrate",False,Not applicable,Not applicable,GRAS,Auxotrophy; no kill-switch reported.,"Nutrient-dependent growth (e.g., specific amino acids)",Low pathogenicity; rare cases of bacteremia reported in immunocompromised infants. No evidence of antibiotic resistance gene transfer.,Oral delivery with intestinal mucosal barrier; no physical encapsulation.,"Lactobacillus rhamnosus GG is generally safe (GRAS status). It has low pathogenic potential, but rare cases of bacteremia have been reported in severely ill preterm infants. No evidence of horizontal gene transfer or long-term ecological disruption.","L. rhamnosus GG supplementation in preterm infants reduced the incidence of NEC and improved feeding tolerance. It enhanced intestinal barrier function, reduced intestinal permeability, and supported mucosal immunity. Clinical trials showed protective effects against NEC and improved clinical outcomes.",12173,4812,16985,,
74af8d48-f8f1-44e4-97a2-5dd9f83acb34,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""Not specified""}]",Oral ingestion (systemic exposure via gastrointestinal tract),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, utilizes carbohydrates as carbon sources; requires no special vitamins or amino acids beyond standard media",Growth rate not reported; typical doubling time for Lactobacillus species is 30–60 minutes in vitro; in vivo colonization occurs transiently in the gut,"Gastrointestinal tract (gut lumen, mucosal surface); transient colonization in the lower reproductive tract (e.g., vaginal microbiome)",Competitive exclusion of pathogenic bacteria; potential for symbiotic interaction with host immune system; no evidence of disruption to native microbiota in study,Moderate tolerance to gastric acid and bile; survives passage through upper GI tract; stable during lyophilization and storage at room temperature,"Cell wall structure (teichoic acids), acid tolerance systems (F1F0-ATPase), bile salt hydrolases","Lactobacillus is a facultative anaerobe that thrives in the human gastrointestinal tract under mildly acidic conditions. It can transiently colonize the gut and lower reproductive tract, where it exerts beneficial effects through competitive exclusion and immune modulation. Its survival through the stomach is supported by intrinsic acid and bile tolerance mechanisms.",,,,,,,该研究未对Lactobacillus进行基因工程改造，其作用机制基于天然生理功能，而非人工设计的基因回路或合成生物学元件。,"[""pH"", ""Glucose"", ""Lactate""]","[""Bile Acids"", ""SCFAs""]",,"[""Proteases"", ""Cytokines""]","F1F0-ATPase (pH sensing), PTS transporters (glucose/lactate), bile salt hydrolases (bile acid sensing)",No engineered logic gates; natural metabolic and stress-response pathways act as biological filters with threshold responses,Lactobacillus naturally senses environmental cues such as low pH and nutrient availability through membrane transporters and proton pumps. It responds to bile acids via bile salt hydrolase activity and modulates its metabolism based on lactate and glucose levels. These responses are not programmable but are intrinsic to its survival in the gut.,"[""Immunomodulation"", ""Gut Health""]",Passive diffusion and cell lysis (natural release of metabolites and cell wall components),Dose-dependent but not programmable; controlled by oral intake frequency and formulation,Compatible with oral capsules; stable in gastrointestinal environment,False,,,Not applicable; no engineered antibacterial activity,,False,False,False,False,未使用工程化抗菌机制，无相关证据,False,Not applicable; Lactobacillus is not an oxygen-producing organism,,False,False,False,未涉及氧气生成功能,True,通过调节宿主免疫反应，抑制过度炎症，促进免疫耐受，尤其在过敏性疾病中表现出抗炎作用,"Lactobacillus cell wall components (e.g., peptidoglycan, lipoteichoic acid), secreted metabolites (e.g., SCFAs)",False,Not applicable; no direct evidence of tissue regeneration or barrier enhancement,,True,通过发酵碳水化合物产生短链脂肪酸（如乙酸、乳酸），调节肠道pH，影响宿主能量代谢和免疫功能,"Acetic acid, Lactic acid, Butyric acid",False,Not applicable; no evidence of tumor targeting or prodrug activation,,GRAS,"None (natural strain, no kill-switch or auxotrophy used)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer observed in study; low risk of environmental escape due to transient colonization,Oral ingestion with natural clearance via feces; no physical containment required,"Lactobacillus is classified as Generally Recognized As Safe (GRAS) by FDA and EFSA. The study found no increased risk of adverse pregnancy outcomes, including major congenital malformations, preterm birth, or low birth weight. No evidence of teratogenicity in humans or animal models. The strain used is naturally occurring and does not require genetic containment.",在早期妊娠期间短期摄入Lactobacillus（平均4天，剂量510 mg/天）后，未观察到自发性流产、早产、低出生体重或重大先天畸形的发生率显著升高。暴露组与对照组相比，主要先天畸形发生率分别为2.1%和2.7%（p=0.7），均处于韩国人群基线水平（1.5%-5%）。研究结果表明，短期使用Lactobacillus在早期妊娠中具有良好的安全性，未发现与不良妊娠结局相关。,6920,1677,8597,,
acce9cc6-3f20-4dac-96f0-2fe27f2546f6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""Not specified""}]",Oral administration (not encapsulated in material),Facultative Anaerobe,"Optimal growth at 30–37°C, pH 4.5–7.5, tolerates moderate osmotic stress; utilizes various carbon sources including glucose and sucrose",Doubling time ~2–3 hours in vitro; in vivo colonization is transient and limited by host immune response and competition with resident microbiota,"Gut lumen, particularly in the small intestine and colon; transiently colonizes mucosal surfaces",Competes with pathogenic bacteria; may modulate resident microbiota composition through metabolic byproducts and immune signaling,Moderate tolerance to gastric acidity and bile salts; sensitive to drying and heat; stability during storage is limited without formulation,Omega-3 and omega-6 fatty acids (in PMT25341 formulation) may enhance membrane stability,"Saccharomyces boulardii is a non-pathogenic yeast probiotic that can survive gastrointestinal transit and transiently colonize the gut. It exhibits facultative anaerobic growth, tolerates acidic and bile-rich environments, and is capable of utilizing various carbohydrates. However, its persistence in the gut is limited, and it does not establish long-term colonization. It is sensitive to environmental stresses such as heat and drying, requiring formulation support for stability.",Not applicable (wild-type strain used),Not applicable,Constitutive expression of beneficial factors,,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift in clinical use,Stability in oral formulation (PMT25341) is enhanced by encapsulation in lipid matrix and protective excipients,Saccharomyces boulardii was used in its wild-type form without genetic modification. The strain was selected for its natural ability to survive gastrointestinal transit and exert immunomodulatory effects. No synthetic genetic circuits or inducible systems were employed. The formulation (PMT25341) provided physical protection and enhanced delivery.,"[""pH"", ""Bile acids"", ""Glucose"", ""Osmotic stress""]","[""Short-chain fatty acids (SCFAs)"", ""Lactate""]",,"[""Proteases"", ""Cytokines (e.g., IL-6, TNF-α)""]","Cell wall mannoproteins, surface receptors (e.g., Dectin-2), and endogenous signaling pathways responsive to microbial-associated molecular patterns (MAMPs)",No engineered logic gates; natural sensing via pattern recognition receptors (PRRs) with threshold-based activation of immune responses,"Saccharomyces boulardii senses host and microbial signals through innate immune receptors such as Dectin-2 and TLRs. It responds to changes in gut pH, bile acids, and nutrient availability. Its immune-modulating activity is triggered by recognition of fungal cell wall components and is modulated by host cytokine levels. No synthetic logic circuits are involved.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Secretion of immunomodulatory proteins and enzymes via constitutive exocytosis; no lysis or specialized secretion systems used,Dose-dependent effects; daily oral administration at fixed dose (PMT25341) with limited control over release kinetics,Compatible with oral formulation (PMT25341); protected by lipid matrix and excipients; no adverse interaction with gel or matrix materials,False,False,False,Not applicable (no direct antibacterial activity),,False,False,False,False,No evidence of antibacterial or biofilm inhibition activity; not designed for this purpose.,False,Not applicable (no oxygen-producing capability),,False,False,False,No oxygenation mechanism observed; not relevant to this system.,True,"Modulates innate and adaptive immune responses by downregulating pro-inflammatory cytokines (e.g., TNF-α, IL-6), enhancing anti-inflammatory IL-10, and reducing T-cell activation markers (HLA-DR+CD38+). Also inhibits bacterial translocation via strengthening gut barrier function.","Mannoproteins, β-glucans, and secreted immunomodulatory factors (e.g., protease inhibitors)",True,"Promotes epithelial barrier integrity by upregulating tight junction proteins (e.g., occludin, ZO-1), reduces mucosal apoptosis, and enhances epithelial proliferation in the gut.","Mannoproteins, secreted growth factors, and anti-apoptotic molecules",True,"Modulates gut microbial metabolism by serving as a substrate for beneficial bacteria (e.g., Lachnospiraceae), promotes SCFA production, and influences host lipid and glucose metabolism via indirect mechanisms.","Short-chain fatty acids (SCFAs), butyrate",False,Not applicable,,BSL-1,No genetic kill-switches; relies on natural attenuation and transient colonization,None (no inducible systems),Low pathogenicity; no reports of fungemia in immunocompetent individuals; potential risk in severely immunocompromised patients; no antibiotic resistance genes detected; no evidence of horizontal gene transfer,Oral delivery with limited systemic absorption; physical barrier of gut epithelium prevents dissemination,"Saccharomyces boulardii is classified as GRAS (Generally Recognized As Safe) and has a long history of safe use in humans. It is not pathogenic and does not colonize permanently. The risk of systemic infection is extremely low in immunocompetent individuals. In this study, no serious adverse events were attributed to the intervention. The formulation (PMT25341) includes protective excipients that enhance stability and reduce degradation.","In HIV-infected patients initiating ART at advanced disease, supplementation with PMT25341 (containing Saccharomyces boulardii and other immunonutrients) did not significantly enhance CD4+ T-cell recovery, CD4/CD8 ratio improvement, or reduction in inflammation and immune activation compared to placebo. While some minor shifts in microbiota composition were observed (e.g., enrichment of unclassified Lachnospiraceae and Victivallaceae), no clinically meaningful benefits were detected over 48 weeks. The probiotic component (S. boulardii) demonstrated safety and transient gut colonization, but failed to improve immunological outcomes in this population.",9776,1996,11772,,
f6e9357e-754c-42cf-ae9a-3c2e6d88686a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""La-5""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus johnsonii"", ""strain_id"": ""NCC 533""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Shirota""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 6.7 ± 0.2 (growth medium); pH 6.5 (dilution phase); Osmotic: Not specified; Nutrition: Lactose, tryptone, yeast extract, Tween 80, Na-citrate, K2HPO4, MgSO4·7H2O, MnSO4·5H2O",Growth rate not quantified; Doubling time not reported; In vitro growth in MRS medium at 37°C; In vivo homeostasis not assessed,"Upper gastrointestinal tract (stomach, duodenum, jejunum, ileum); no specific niche preference reported",Not assessed; no competition or symbiosis with host microbiome described,Moderate bile salt tolerance (L. acidophilus and L. johnsonii); poor bile tolerance (L. casei and L. rhamnosus GG); resistant to low pH (stomach phase); storage stability reduced after 2 weeks at 4°C,Bile salts (sodium cholate and sodium deoxycholate),该系统中使用的四种乳酸杆菌均为革兰氏阳性、兼性厌氧菌，可在37°C、pH 6.7的MRS培养基中生长。L. acidophilus La-5和L. johnsonii NCC 533在胃酸和胆盐胁迫下表现出更强的生存能力，而L. casei Shirota和L. rhamnosus GG对胆盐极为敏感，存活率显著下降。所有菌株在指数生长期或稳定期引入时比冷藏两周后更具活力，表明其生理状态影响生存能力。,,,,,,,本文未涉及任何基因工程改造，所有菌株均为天然野生型，未进行任何遗传修饰。,"[""Acidity (pH 2.0–3.0)"", ""Bile salts (0.4%)"", ""Dilution (simulated absorption)""]",,,,Not specified; no specific sensor or promoter reported,No logic circuits or signal integration described,该系统未设计任何感知模块或逻辑控制，仅通过模拟胃肠道的物理化学环境（如pH变化、胆盐添加、稀释）来评估菌株的生存能力，无主动感知或响应机制。,"[""Survival in GI Tract""]",Not specified; no secretion or delivery system described,Not applicable; no controlled output described,Not applicable; no material encapsulation or delivery system described,False,,,Not applicable; no antibacterial mechanism described,,,,,,无抗菌功能描述,False,Not applicable; no oxygenation function described,,,,,无氧生成功能描述,False,Not applicable; no immunomodulatory function described,,False,Not applicable; no tissue repair function described,,False,Not applicable; no metabolic regulation function described,,False,Not applicable; no tumor therapy function described,,BSL-1,None; no kill-switch or auxotrophy implemented,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; no environmental escape risk assessed,None; no physical confinement used,所有菌株均为公认安全（GRAS）的益生菌，无致病性，未进行基因改造，无生物安全风险。但未设置生物遏制策略，无物理屏障，存在潜在环境释放风险。,该模型用于评估益生菌在模拟胃肠道环境中的存活率，结果显示L. acidophilus La-5和L. johnsonii NCC 533在胃酸和胆盐胁迫下存活率显著高于L. casei Shirota和L. rhamnosus GG。在商业产品中，L. rhamnosus GG在奶制品和奶酪中存活率可达10%–100%，而在MRS培养基和婴儿配方奶粉中低于0.1%，表明食品基质对益生菌存活具有显著影响。,11061,1656,12717,,
2f77eac0-919d-4339-ad4d-343e4b3c355b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei DG"", ""strain_id"": ""DG""}]",Ex-vivo organ culture (mucosal biopsy),Facultative Anaerobe,"Grown in MRS broth at 37°C, 24 h; optimal growth at 37°C, pH not specified, requires conventional incubation or 5% CO2 for eukaryotic cell compatibility",Specific growth rate calculated via OD600; growth profile determined after 24 h; no in vivo growth rate reported,"Human gastrointestinal tract (ileum and colon), mucosal surface",Adheres to human epithelial cells; non-pathogenic; may modulate host-microbiota interaction by reducing inflammation,Resistant to intestinal acid and bile; stable during storage below 25°C; tolerance to lyophilization/rehydration not explicitly stated,Bile and acid resistance (inferred from study context),"Lactobacillus casei DG is a human-origin, non-pathogenic strain with resistance to intestinal acid and bile, capable of adhering to human epithelial cells and colonizing the gastrointestinal tract. It grows optimally at 37°C in MRS broth, with a growth rate determined by OD600 over 24 hours. It is suitable for ex vivo mucosal culture and maintains viability in organ culture systems.",,,,,,,该研究未对Lactobacillus casei DG进行基因工程改造。其作用机制基于天然代谢产物和分泌因子，而非人工构建的遗传回路。,"[""LPS (Lipopolysaccharide)""]",,,"[""Toll-like receptor 4 (TLR-4)""]","TLR-4 receptor (host receptor, not microbial sensor)",No engineered logic gates; natural response to LPS stimulation with downstream modulation of cytokine expression,"Lactobacillus casei DG和其后生元（PB）通过感知LPS刺激，调节宿主免疫细胞的炎症反应，表现为对促炎因子（IL-1α, IL-6, IL-8）的下调和抗炎因子（IL-10）的上调。该过程未涉及人工设计的逻辑门控系统，而是基于天然的宿主-微生物相互作用。","[""Immunomodulation""]","Secreted postbiotic factors (e.g., metabolites, proteins, EPS) released during bacterial growth",Dose-dependent effect observed: 1×10⁷ CFU of LC-DG or equivalent PB volume; effect more pronounced with PB than live bacteria,"Compatible with ex vivo organ culture system (filter plate, RPMI medium, 5% CO2); no structural disruption reported",False,,,,,,,,,,False,,,,,,,True,显著降低IL-1α、IL-6、IL-8等促炎细胞因子mRNA水平，同时上调抗炎细胞因子IL-10的表达；抑制TLR-4蛋白表达，减轻炎症反应。,Postbiotic (PB) derived from Lactobacillus casei DG culture,False,,,False,,,False,,,GRAS,"Non-pathogenic, human-origin strain; no genetic modifications or kill switches used",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk in ex vivo setting,"Physical confinement via ex vivo organ culture system (filter plate, sealed chamber)","Lactobacillus casei DG is a human-origin, non-pathogenic strain with GRAS status. It does not require genetic containment strategies. The study was conducted in an ex vivo model, minimizing any risk of environmental release. No antibiotic resistance genes or virulence factors were reported.",在体外器官培养模型中，Lactobacillus casei DG及其后生元（PB）显著减轻了PI-IBS-D患者回肠和结肠黏膜的炎症反应，表现为促炎因子（IL-1α、IL-6、IL-8）mRNA水平下降，抗炎因子（IL-10）mRNA水平上升，且TLR-4蛋白表达被抑制。PB的效果优于活菌，提示其分泌的后生元是主要活性成分。,9878,1551,11429,,
77eb75c7-b2b3-4b13-a9bd-f445bedc26df,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei subsp. rhamnosus GG"", ""strain_id"": ""GG""}]",Suspension (Oral administration into gastrointestinal tract),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; utilizes glucose and other carbohydrates as carbon sources; requires no specific vitamins or amino acids beyond standard growth media; tolerates bile salts and low pH (gastric conditions)",Doubling time ~1.5–2 hours in vitro; colonization observed in human gut within days of administration; in vivo stability demonstrated over 6-week period in preterm neonates,"Gastrointestinal tract (especially colonizing the intestinal mucosa and lumen, particularly in the small intestine and colon)","Competes with Candida species and other pathogens for adhesion sites and nutrients; promotes beneficial commensal flora (e.g., bifidobacteria); no evidence of disruption to native microbiota","Tolerant to gastric acidity, bile salts, and osmotic stress; stable during lyophilization and rehydration; survives in human milk and during storage at room temperature","Bile salts, gastric acid, lyophilization buffer","LGG is a facultative anaerobe that thrives in the human gastrointestinal tract, particularly in preterm neonates. It colonizes the intestinal mucosa and lumen, resisting gastric acidity and bile, and establishes stable colonization within days of oral administration. It demonstrates robust growth under physiological conditions and maintains viability during storage and delivery via human milk.",,,,,Chromosomal integration of key genes; no plasmid-based systems reported; high genetic stability in vivo over 6 weeks; no evidence of horizontal gene transfer or mutation drift,Stable in human milk and oral delivery formulations; maintains function during encapsulation in milk matrix,"LGG is used in its native, unmodified form. No genetic engineering or synthetic circuits are applied. Its probiotic efficacy stems from intrinsic biological properties rather than engineered functions. The strain is naturally adapted to colonize the neonatal gut and exert protective effects.","[""pH (low gastric pH)"", ""Bile acids""]","[""Glucose"", ""Lactate""]",,"[""IgA"", ""Mucosal permeability markers""]","Fimbrin-like adhesins (e.g., p40/p75), bile salt hydrolase (BSH), acid tolerance systems (e.g., F1F0-ATPase)","No synthetic logic gates; natural sensing via adhesion receptors and metabolic adaptation to environmental cues (e.g., acid resistance, bile tolerance)","LGG senses environmental signals such as low pH and bile acids through intrinsic surface proteins and metabolic pathways. It activates acid tolerance responses and bile resistance mechanisms, enabling survival in the gastrointestinal tract. It also detects mucosal surfaces via adhesins, facilitating colonization and immune modulation.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Passive secretion via cell lysis and membrane vesicles; no specialized secretion systems reported,Dose-dependent colonization and effect; administered at 6 × 10⁹ CFU/day for 6 weeks; no evidence of overgrowth or toxicity,High compatibility with human milk; stable during oral delivery; no interference with gut matrix or exudate,True,False,True,"LGG inhibits Candida colonization through competitive exclusion, prevention of adhesion to mucosal surfaces, and enhancement of mucosal barrier function via IgA upregulation. It also modulates immune responses to fungal antigens.",Lactobacillus casei subsp. rhamnosus GG (native strain),True,True,True,True,"In a randomized trial, LGG reduced gastrointestinal Candida colonization from 48.8% to 23.1% in preterm neonates (P = 0.01). No adverse effects or sepsis caused by LGG were observed. The effect was unspecific across Candida species.",False,,,,,,,True,"LGG enhances mucosal immunity by stimulating IgA production, modulating cytokine profiles (e.g., IL-8, TNF-α), and reducing neutrophil infiltration. It promotes immune tolerance and barrier integrity.","IgA, IL-8, TNF-α, TLR2/4 ligands (e.g., peptidoglycan, lipoteichoic acid)",True,"LGG reduces intestinal permeability, enhances mucosal barrier function, and supports epithelial regeneration. It contributes to prevention of necrotizing enterocolitis.","Mucin production, tight junction proteins (e.g., occludin, ZO-1), growth factors (e.g., EGF)",False,,,False,,,GRAS,No genetic kill switches or auxotrophy; relies on natural attenuation and low pathogenicity,,Non-pathogenic; no cases of sepsis or bloodstream infection attributed to LGG; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape due to host-restricted niche,Oral delivery with natural gut barrier; no physical encapsulation required,"LGG is classified as Generally Recognized As Safe (GRAS). It has been used in humans for decades with excellent safety. In the clinical trial, no adverse events, sepsis, or colonization-related complications were observed. Its natural attenuation and host-restricted niche minimize risks of systemic spread or ecological disruption.","LGG administration reduced gastrointestinal Candida colonization from 48.8% to 23.1% in preterm neonates (P = 0.01). It also reduced the incidence of surgical necrotizing enterocolitis (0% vs 2.5%) and showed a trend toward lower systemic fungal infection rates (10.3% vs 12.2%). The effect was consistent across birth weight groups (1001–1500 g), with a 2-fold reduction in colonization. No adverse effects were reported.",7038,1911,8949,,
320a5470-6192-4338-ab6f-9ac44bd2d099,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium pseudocatenulatum"", ""strain_id"": ""G4""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Not specified; Osmotic: Not specified; Nutrition: Requires skim milk (2.8% w/v), yeast extract (2.2% w/v), no glucose; Carbon source: Lactose from milk via β-galactosidase activity",Growth rate: Not directly quantified; Doubling time: Not provided; In vivo vs in vitro: In vitro growth optimized in milk medium; Maximum biomass: 9.129 log₁₀ cfu/mL at 20 h,"Gut (infant intestinal environment, inferred from isolation source)","No direct evidence of competition or symbiosis with other gut microbes; previously shown to exhibit bile tolerance and deconjugation of bile acids, suggesting adaptation to gut environment","Tolerates oxygen in presence of CO₂; stable during anaerobic incubation; no data on UV, drying, or shear stress; lyophilization/rehydration not tested",CO₂ (from Anaerocult A gas packs),该菌株为婴儿粪便中分离的双歧杆菌，具有良好的乳糖利用能力，可在优化的脱脂牛奶-酵母提取物培养基中高效生长。其生长依赖于β-半乳糖苷酶活性以水解乳糖，且对葡萄糖存在抑制效应。在2.8%脱脂牛奶和2.2%酵母提取物的优化培养基中，20小时达到9.129 log₁₀ cfu/mL的最高生物量，较常用10%脱脂牛奶培养基提高3.329 log单位。,,,,,,,该研究未涉及任何基因工程改造，仅通过响应面法优化培养基成分以提升菌体生长性能，未对菌株进行遗传修饰。,,,,,,,该研究未涉及任何传感模块或逻辑控制设计，未构建基因回路或响应环境信号的调控系统。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Not specified,Not specified,Not specified,True,False,False,该菌株在前期研究中表现出抗菌活性，但本研究未评估其在优化培养基中的抗菌能力，未测试对常见病原体（如金黄色葡萄球菌、铜绿假单胞菌）的抑制作用。,Not specified,False,False,False,False,前期研究显示该菌株具有抗菌活性，但本研究未验证其在优化培养基中的抗菌功能，未评估对生物膜的抑制能力，也未测试其在材料中的安全性。,False,未涉及氧气生成或耗氧调控机制。,,False,False,False,该研究未涉及任何氧代谢或氧生成功能，无相关证据。,True,该菌株在前期研究中表现出对胆汁酸的去结合能力，可能通过调节胆汁酸代谢影响宿主免疫反应；同时具有黏附特性，可能参与肠道屏障功能调节。,"Bile acid deconjugation enzymes (e.g., bile salt hydrolases)",False,未评估该菌株对上皮再生、血管生成或细胞外基质调节的作用。,,True,该菌株可高效利用乳糖作为碳源，通过β-半乳糖苷酶水解乳糖为葡萄糖和半乳糖，参与宿主肠道代谢调节；同时其代谢产物可能影响短链脂肪酸（SCFAs）水平，间接调节宿主代谢。,"Short-chain fatty acids (SCFAs), Lactose metabolites (glucose, galactose)",False,未涉及肿瘤靶向或药物激活机制。,,BSL-1,No genetic containment strategy used; strain is wild-type and not engineered.,,Low pathogenicity; isolated from infant stools; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; environmental escape unlikely due to lack of engineered survival traits.,Physical confinement via sealed fermentation bottles and anaerobic jars; no encapsulation or barrier material used.,该菌株为婴儿来源的野生型双歧杆菌，属于GRAS（公认安全）类微生物，无致病性记录，未进行基因改造，无抗生素抗性基因或水平基因转移风险，生物安全等级为BSL-1。在实验中通过密封瓶和厌氧罐实现物理隔离，安全性高。,该研究未评估治疗效果，仅优化了菌体生长性能。在优化培养基（2.8%脱脂牛奶 + 2.2%酵母提取物）中，Bifidobacterium pseudocatenulatum G4在20小时内达到9.129 log₁₀ cfu/mL的生物量，较传统10%脱脂牛奶培养基提高3.329 log单位，且脱脂牛奶使用量减少71.8%，显著降低成本。,13831,1708,15539,,
6510c900-3f19-4142-9d1f-1618087bfce5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""HA-129""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""HA-111""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""HA-132""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. infantis"", ""strain_id"": ""HA-116""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. longum"", ""strain_id"": ""HA-135""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in breastmilk or sterile water; tolerant to osmotic stress from gut environment",Doubling time ~1.5–2 hours in vitro; colonization observed to persist for up to 5 months post-discharge in vivo,"Gut mucosa of preterm infants, particularly in the colon; preferentially colonizes early preterm gut environment",Competes with endogenous gut bacteria; may displace pathogenic strains; promotes community convergence toward full-term infant microbiome,"Tolerant to freezing (-20°C), lyophilization, and rehydration; stable during storage and transport in NICU","Cryoprotectants in formulation (e.g., maltodextrin), inherent stress resistance of bifidobacteria",该研究中使用的益生菌株（Bifidobacterium breve HA-129、Lactobacillus rhamnosus HA-111、Bifidobacterium bifidum HA-132、Bifidobacterium longum subsp. infantis HA-116 和 Bifidobacterium longum subsp. longum HA-135）均为专性厌氧或兼性厌氧菌，适宜在37°C、pH 6.5–7.0的环境中生长。这些菌株在早产儿肠道中表现出良好的定植能力，尤其在出生后早期阶段，能有效定植并持续存在长达5个月。其生长依赖于母乳或无菌水作为载体，对肠道渗透压和冷冻保存具有较强耐受性，适合在新生儿重症监护室（NICU）环境中使用。,Not specified,Not applicable,Not applicable,Not applicable,Not applicable,Not applicable,本研究未对益生菌株进行基因工程改造，所有功能均基于天然菌株的生理特性。益生菌通过自然定植机制在早产儿肠道中发挥作用，未使用任何基因编辑工具或合成回路。,"[""pH"", ""Osmotic stress"", ""Lactate""]","[""Breastmilk oligosaccharides"", ""Glucose"", ""Lactose""]","[""Quorum sensing (indirect)""]","[""Mucin"", ""Proteases""]",16S rRNA gene (used for identification); no specific engineered sensor reported,Not applicable,本研究未涉及人工设计的传感逻辑回路，菌株的定植和代谢响应基于其天然对宿主环境（如母乳成分、肠道pH、黏液）的适应性，无外部诱导或逻辑控制机制。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Type IV secretion (inferred from Bifidobacterium spp. secretion of EPS and metabolites),Dose controlled by daily administration of fixed CFU (2 billion per dose); no feedback control,Compatible with suspension in breastmilk or sterile water; stable during storage and delivery,True,False,False,通过竞争性排斥病原菌、增强肠道屏障功能、抑制病原体黏附等方式发挥抗菌作用，尤其在预防坏死性小肠结肠炎（NEC）中起关键作用。,Bacteriocins (inferred from Bifidobacterium spp. natural production),False,True,True,True,Bifidobacterium spp. are known to inhibit pathogen adhesion and enhance gut barrier function; no evidence of excessive tissue damage or microbiome disruption observed in the study.,False,未涉及氧气生成或耗氧调控机制。,Not applicable,False,False,False,无相关证据支持该系统具有氧合功能。,True,通过调节免疫反应，减少炎症因子释放，促进免疫耐受，降低NEC发生率。,"Short-chain fatty acids (SCFAs), exopolysaccharides (EPS), cell wall components",True,促进肠道上皮再生，增强黏膜屏障功能，加速肠道修复。,"Mucus-stimulating factors, SCFAs (e.g., acetate, propionate)",True,通过发酵母乳低聚糖产生短链脂肪酸（SCFAs），调节宿主能量代谢和肠道微环境。,"Acetate, Propionate, Butyrate",False,未涉及肿瘤治疗功能。,Not applicable,GRAS,None (natural strains used; no kill-switch or auxotrophy engineered),Not applicable,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to niche specificity,Physical confinement via oral administration and gut localization; no engineered containment,所用益生菌株均为公认安全（GRAS）菌种，无致病性、无抗生素抗性基因，且在早产儿肠道中表现出良好的定植稳定性，未观察到对正常菌群的显著破坏或生态位入侵风险。由于未进行基因改造，无生物安全风险。,在早产儿中，益生菌补充可显著提高Bifidobacterium属的相对丰度，其定植可持续至出院后5个月。在胎龄校正年龄时，接受益生菌的早产儿肠道微生物群落结构更接近于出生后10天的足月婴儿，表明益生菌可促进肠道微生物群的早期成熟，有助于预防坏死性小肠结肠炎（NEC），并改善肠道屏障功能。,15840,2023,17863,,
85c515f8-aa20-46e9-a3c8-f6b7ad57f4b1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""F71""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""L1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""BA3""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""F76""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in anaerobic conditions (10% H₂, 10% CO₂, 80% N₂); requires L-cysteine (0.25%) in MRS medium; grows in 2% bovine bile and at pH 3.5",Growth rate not quantified; doubling time not reported; in vitro growth confirmed under simulated gastrointestinal conditions,"Human gastrointestinal tract (fecal origin), intestinal mucosa (adheres to Caco-2 and HT-29 cells)",No evidence of mucin degradation; non-invasive; no indication of competition or symbiosis with other gut microbes,"Tolerant to 2% bovine bile and pH 3.5; resistant to metronidazole, vancomycin, cefoxitin; no significant UV or drying stability data","Bovine bile (Ox-gall), L-cysteine (for anaerobic growth)",该4株乳酸杆菌均来源于健康人体粪便，具有在模拟胃肠道环境（低pH 3.5、2%牛胆汁）下生长的能力，且在体外培养中表现出良好的生存能力。它们属于兼性厌氧菌，适宜在37°C、厌氧条件下生长，依赖L-半胱氨酸维持厌氧环境。,,,,,,,文中未提及任何基因工程改造，所有筛选基于天然菌株的表型特性，未进行基因编辑或合成回路构建。,"[""Low pH"", ""Bile""]",,,,No specific sensor identified; resistance to low pH and bile inferred from growth assays,No engineered logic gates or signal processing reported; natural resistance to stressors is constitutive,这些菌株对低pH和胆汁的耐受性为天然固有特性，未见人工设计的感应逻辑或调控回路，其响应为非编程性、基础生理适应。,"[""Antibacterial"", ""Adhesion""]",Unknown (likely passive secretion of organic acids and H₂O₂; no evidence of specific secretion systems),"Not applicable (natural, non-engineered secretion; no controllable output)",Not applicable (no material encapsulation described; used in suspension),True,True,False,通过产生未知抑制物质（可能为有机酸、H₂O₂或非细菌素类物质）抑制多种肠道病原体生长，包括大肠杆菌、沙门氏菌、李斯特菌和金黄色葡萄球菌。,"Unknown (likely organic acids, H₂O₂, or non-bacteriocin inhibitory compounds)",True,True,True,True,4株菌均能有效抑制多种肠道病原体，抑制效果与阳性对照L. salivarius UCC188相当，且未检测到明确的细菌素活性，表明其抗菌作用可控且非过度。,False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,None (no synthetic kill switches or auxotrophy reported),,"No pathogenicity or virulence factors detected; no harmful enzymatic activities (α-chymotrypsin, N-acetyl-β-glucosaminidase); no acquired antibiotic resistance (except 5 strains with atypical resistance, excluded); no horizontal gene transfer risk reported",Not applicable (no physical material barrier described),所选4株菌均未检测到致病性、有害酶活性或获得性抗生素抗性，且不降解黏蛋白，表明其非侵袭性，安全性良好，符合GRAS标准。,4株菌在体外表现出对多种肠道病原体的抑制能力，能有效黏附于Caco-2和HT-29肠上皮细胞，且不降解胃黏蛋白，表明其具有良好的定植潜力和安全性，是潜在的优良益生菌候选株。,12294,1619,13913,,
50009f9a-a833-402b-bde5-d8a41318296c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""K12""}]",Cell suspension,Facultative Anaerobe,"Growth at 37°C in M9 minimal medium with 20 mM glucose, pH 7.2 (TBS buffer); oxygen-limited conditions used in experiments","Exponential growth phase (OD600 0.4–0.8), doubling time not explicitly stated; cell density of 1×10⁹ cells/mL corresponds to OD600 = 1","Not applicable (in vitro cell suspension, no host niche)",Not applicable (single strain in vitro system),"Stable for up to 8 hours when refrigerated; no data on UV, shear, or drying stress",Not mentioned,大肠杆菌K12在37°C、M9最小培养基中生长，以20 mM葡萄糖为碳源，pH 7.2。实验中采用缺氧条件，细胞处于对数生长期，细胞密度为1×10⁹ cells/mL。,Not mentioned,Not mentioned,Constitutive (glucose uptake and metabolism are constitutively expressed),Not applicable,Not mentioned,Not mentioned,未进行基因改造，利用大肠杆菌天然的葡萄糖代谢通路进行代谢响应监测。,"[""Hypoxia"", ""pH""]","[""Glucose"", ""Acetate""]",,,Phosphotransferase system (PTS) glucose permease (EII^Glc),No synthetic logic gates; natural metabolic response follows Michaelis–Menten kinetics,大肠杆菌通过PTS系统感知葡萄糖浓度，其摄取速率呈米氏动力学，是葡萄糖代谢的限速步骤。酸化速率与葡萄糖浓度呈非线性关系，符合酶促反应动力学。,"[""Metabolic Monitoring""]",Not applicable (no engineered secretion; natural excretion of metabolic byproducts),"Not applicable (natural metabolic response, not controllable via genetic circuit)",Compatible with capacitive field-effect sensor surface; cells are suspended on sensor chip without encapsulation,False,,,Not applicable,Not applicable,False,False,False,False,无,False,Not applicable,Not applicable,False,False,False,无,False,Not applicable,Not applicable,False,Not applicable,Not applicable,True,通过葡萄糖代谢产生酸性副产物（如乙酸、乳酸），实现对代谢活动的实时监测；在缺氧条件下，细胞通过发酵将葡萄糖转化为乙酸和乳酸，导致胞外pH下降。,"Acetate, Lactate",False,Not applicable,Not applicable,BSL-1,"Not applicable (in vitro system, no kill-switch or auxotrophy described)",Not applicable,Low pathogenicity; non-opportunistic; no antibiotic resistance genes mentioned; no horizontal gene transfer risk in this context,O-ring provides physical isolation from environment; no complex encapsulation needed,大肠杆菌K12为模式菌株，广泛用于实验室研究，无致病性，属于BSL-1等级。实验在封闭系统中进行，使用O-ring实现物理隔离，无逃逸风险。,该系统用于代谢响应监测，非治疗性应用。通过电容式场效应传感器实时检测大肠杆菌在葡萄糖脉冲下的酸化行为，酸化速率与葡萄糖浓度呈米氏动力学关系（K_M = 0.22–0.27 mM），可作为生物传感器用于葡萄糖浓度检测和代谢研究。,9279,1406,10685,,
b5bdb71c-c49f-4aa0-970d-f988a23f89e8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""ATCC 8014""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""ATCC 15679""}]",Encapsulated,Facultative Anaerobe,"Growth at 37°C, in MRS broth supplemented with L-cysteine-HCl (0.05%, w/v), under anaerobic conditions",Late-log phase harvested for spray drying; viability maintained during storage at 4°C for 45 days,Gut (intestinal tract),Potential symbiosis with host microbiome; no competition or disruption reported,"High resistance to simulated gastric juice (pH 2) and bile solution (2%, v/v); enhanced by encapsulation",Flaxseed mucilage (FM) and soluble protein (FSP); Chia seed mucilage (CM) and soluble protein (CSP),Lactobacillus plantarum 和 Bifidobacterium infantis 均为肠道益生菌，可在37°C厌氧条件下生长，对胃酸和胆汁具有较强耐受性。经种子黏液和可溶性蛋白包埋后，其在喷雾干燥过程及4°C冷藏45天期间保持高存活率，表明其在恶劣环境中具有良好的稳定性。,,,,,,,本研究未对菌株进行基因改造，仅通过物理包埋技术（喷雾干燥）将益生菌与植物黏液和蛋白结合，未涉及任何基因编辑或调控回路设计。,,,,,,,本研究未涉及任何感知模块或逻辑控制机制，菌株未被工程化以响应特定信号。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Encapsulation (passive release via matrix degradation),Controlled by encapsulation matrix composition and storage time; no active dosage regulation,High compatibility with chia and flaxseed mucilage/protein matrix; reduces particle size and enhances stability,True,False,False,L. plantarum 产生抗菌肽，可抑制病原菌生长；B. infantis 通过竞争性排斥抑制有害菌定植。,Antimicrobial peptides (from L. plantarum),False,True,True,True,L. plantarum 产生抗菌肽，B. infantis 通过定植优势抑制病原菌，且包埋后在胃肠道环境中存活率高，表明其活性可控且局部作用，无显著组织损伤或菌群失调。,False,,,False,False,False,未涉及氧气生成机制，无相关数据支持。,True,B. infantis 具有抗抑郁、抗焦虑和抗痛觉作用，调节免疫功能；L. plantarum 可调节肠道免疫反应。,"B. infantis (anti-depressant, anti-anxiety), L. plantarum (immune modulation)",True,益生菌通过调节肠道屏障功能、促进上皮再生和抑制炎症反应，间接支持组织修复。,"Intestinal barrier enhancement, Epithelial regeneration",False,,,False,,,GRAS,None (no genetic kill switch or auxotrophy used),,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape risk due to non-engineered nature,Physical encapsulation barrier (mucilage/protein matrix) prevents release and enhances stability,Lactobacillus plantarum 和 Bifidobacterium infantis 均为公认安全（GRAS）菌株，未进行基因改造，无生物安全风险。包埋材料提供物理屏障，防止菌体泄漏，确保安全使用。,经喷雾干燥和4°C冷藏45天后，B. infantis 和 L. plantarum 的存活率均超过98%，在模拟胃液和胆汁中表现出显著耐受性。在即食果汁粉中，益生菌存活量保持在10.5–11 Log CFU/g，远高于食品级益生菌推荐标准（≥6 Log CFU/g），表明其在功能性食品中具有优异的稳定性和潜在的肠道健康促进效果。,14113,1562,15675,,031d676f-210c-458b-b142-f960d9823042,0,,,,,,,,,,,本文未描述任何具体的微生物系统或其生长生理特性，仅提及人类微生物组的存在及其在营养代谢中的潜在作用，但未涉及具体菌株或其生理特征。,,,,,,,本文未提及任何基因工程工具、调控回路或微生物的可编程性，未描述任何人工改造的微生物系统。,,,,,,,本文未描述任何微生物的感知模块、信号响应逻辑或生物传感器设计。,,,,,False,,,,,,,,,,False,,,,,,,False,,,False,,,False,,,False,,,,,,,,本文未提及任何微生物系统的生物安全等级、风险控制策略或潜在逃逸风险，未描述任何工程化微生物系统。,本文未报告任何微生物系统在治疗或组织修复方面的具体疗效数据，仅从宏观角度讨论了微生物组在人类健康中的潜在作用，如营养代谢支持和疾病预防，但未涉及具体治疗结果。,4036,865,4901,,
b42b1782-417e-4f30-a591-b0ec08842d76,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""BB-46""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: 5.2–4.2 (in FSB); Nutritional requirements: fermentable carbohydrates (sucrose, dextrose), amino acids, vitamins (from soy extract and ABP); Osmotic tolerance: moderate (buffering capacity enhanced by ABP)",Growth rate: stable over 28 days at 4°C; Doubling time: not reported; In vivo vs in vitro consistency: maintained viability in simulated GI conditions,Intestinal mucosa (gut microbiota modulation),Competitive exclusion of Clostridium spp. and ammonium producers; potential symbiosis with host microbiota via SCFA production,"Moderate resistance to gastric acidity (pH 2.2–2.5), bile salts (enteric phase), and refrigerated storage (4°C); enhanced by ABP and co-culture",Acerola by-product (ABP) – physical barrier and buffering capacity,"Bifidobacterium longum BB-46 exhibits stable growth and viability in fermented soy beverages (FSB) at 4°C for 28 days. It demonstrates strong resistance to simulated gastrointestinal conditions, particularly when co-cultured with Lactobacillus acidophilus LA-5 and supplemented with acerola by-product (ABP), which enhances its survival through physical protection and buffering effects.",,,,,High chromosomal stability; no plasmid-based systems reported; no evidence of genetic drift or metabolic burden,Stable in FSB matrix with ABP; no structural disruption observed,"No genetic modifications were applied. The strain is used in its native form, relying on natural physiological traits for survival and function in the plant-based fermented beverage.","[""Acidity (pH 2.2–2.5)"", ""Bile salts (enteric phase)""]","[""Lactate (from LAB fermentation)"", ""Sugars (sucrose, dextrose)""]",,,Native membrane and metabolic sensors (not specified),No engineered logic gates; natural response to environmental stressors,"B. longum BB-46 responds naturally to acidic and bile-rich environments via intrinsic stress response pathways. Its survival is enhanced by co-culture and ABP, suggesting indirect sensing of microbial competition and matrix protection.","[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]",Passive diffusion and natural secretion,Not controllable; dependent on natural growth and survival,High compatibility with FSB matrix; ABP enhances encapsulation and protection,False,False,False,Not applicable,,False,False,False,False,No antibacterial activity reported,False,Not applicable,,False,False,False,No oxygenation mechanism observed,True,Modulates gut microbiota by reducing Clostridium populations and ammonium ion production; promotes anti-inflammatory environment via SCFA production,Short-chain fatty acids (SCFAs),True,Enhances intestinal barrier function and mucosal integrity through SCFA production and competitive exclusion of pathobionts,Short-chain fatty acids (SCFAs),True,"Regulates host metabolism via production of SCFAs (acetate, propionate) and modulation of microbial fermentation balance",Short-chain fatty acids (SCFAs),False,Not applicable,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk due to food matrix and refrigeration,Physical confinement by FSB matrix and refrigerated storage,"Bifidobacterium longum BB-46 is a well-established probiotic strain with GRAS status. It poses minimal biosafety risk due to its non-pathogenic nature, lack of virulence factors, and absence of antibiotic resistance genes. The FSB matrix and cold storage provide additional containment.","B. longum BB-46 demonstrated superior survival under simulated gastrointestinal conditions, especially in co-culture with Lactobacillus acidophilus LA-5 and in the presence of acerola by-product (ABP). It maintained viable cell counts above 8 log CFU equivalent/mL after the enteric phase throughout 28 days of storage, indicating strong resilience and potential for gut health promotion. The FSB supplemented with ABP is a promising plant-based vehicle for delivering BB-46 to the gut.",17751,1594,19345,,
4792800a-0b6a-4811-8182-672146c36e55,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""strain 220""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""strain 26""}, {""role"": ""Chassis"", ""scientific_name"": ""Clostridium butyricum"", ""strain_id"": ""strain Miyari""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 5.5–7.0; Nutritional requirements: Carbohydrates (e.g., glucose, lactose), amino acids, vitamins; Osmotic tolerance: Moderate; Bile tolerance: Present in rumen environment",Growth rate: Rapid; Doubling time: ~1–2 hours in vitro; In vivo homeostasis: Stable colonization in rumen after repeated administration,"Rumen fluid, particularly ventral sac; associated with high-carbohydrate fermentation zones",Symbiotic with native rumen microbiota; competes with pathogenic lactate-producers; enhances lactate-consuming bacteria,Tolerant to storage at 4°C; resistant to rumen exudate and moderate osmotic stress; moderate shear stress tolerance during feeding,"Cell wall components (e.g., peptidoglycan), exopolysaccharides",该多菌株益生菌由Lactobacillus plantarum、Enterococcus faecium和Clostridium butyricum组成，均为兼性厌氧菌，可在牛瘤胃中稳定定植。其生长适宜温度为37°C，pH范围5.5–7.0，依赖碳水化合物、氨基酸和维生素等营养物质。在瘤胃环境中，这些菌株能耐受中等渗透压和胆汁环境，具有良好的储存稳定性（4°C保存），在反复饲喂后可在瘤胃中维持稳定定植，与瘤胃原有微生物群落形成共生关系，抑制乳酸产生菌并促进乳酸消耗菌的活性。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未对益生菌进行基因工程改造，所有功能均依赖于天然菌株的生理特性，未使用任何基因编辑工具或合成回路。,"[""Hypoxia"", ""pH"", ""Lactate""]","[""Glucose"", ""Lactate"", ""Volatile Fatty Acids (VFAs)""]",,,"Lactate-sensing regulators (e.g., LldR in L. plantarum; Lactate permeases); pH-responsive promoters (e.g., FNR-like regulators in E. faecium)",No synthetic logic gates; natural metabolic feedback: lactate accumulation triggers lactate consumption; low pH induces expression of acid-tolerant genes,该系统未使用人工合成逻辑回路，其响应机制基于天然代谢调控。当瘤胃中乳酸积累导致pH下降时，乳酸消耗菌（如E. faecium和C. butyricum）被激活，通过乳酸转运蛋白和代谢酶（如乳酸脱氢酶）主动摄取并代谢乳酸，从而缓解酸中毒。pH变化通过调控相关基因表达实现自适应响应，形成负反馈调节。,"[""Metabolic Regulation"", ""Antibacterial"", ""Tissue Repair""]",Type IV secretion (putative); passive diffusion of metabolites,Dose-dependent: 20–50 g/day optimal; higher dose (100 g) led to reduced efficacy,Compatible with feed suspension; no encapsulation used; stable in feed matrix,True,False,False,通过竞争性定植和代谢产物抑制潜在致病菌，特别是乳酸积累相关的病原菌。,"Lactic acid (byproduct), bacteriocins (e.g., plantaricin from L. plantarum)",False,True,True,True,益生菌通过抑制乳酸积累和维持pH稳定，间接减少病原菌生长环境，且未观察到对宿主细胞或瘤胃微生物群落的显著毒性，表明其具有局部安全性和可控性。,False,无氧合功能。,,False,False,False,未涉及氧合机制，因此不适用。,False,未报道免疫调节功能。,,False,未直接参与组织修复，但通过改善瘤胃环境间接支持黏膜健康。,,True,通过调节乳酸代谢和VFA平衡，改善瘤胃发酵效率，维持能量稳态。,"Lactic acid, Acetic acid, Propionic acid, Butyric acid",False,无肿瘤治疗功能。,,GRAS,"None (natural strains, no kill-switches)",None,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape unlikely due to rumen-specific niche,None (no physical barrier used),所用菌株均为公认安全（GRAS）的益生菌，无致病性，未携带抗生素抗性基因，且在瘤胃环境中具有生态位特异性，不易逃逸至环境。未使用任何生物安全控制策略，但基于其天然宿主特性和代谢依赖性，风险极低。,在诱导亚急性瘤胃酸中毒（SARA）的奶牛中，连续7天每日饲喂20或50克该多菌株益生菌，可显著提高瘤胃24小时平均pH值（从<5.0升至>5.8），并降低20:00时的乳酸浓度。同时，瘤胃pH昼夜节律趋于稳定（6.4–6.8），表明其有效缓解了酸中毒症状。此外，非酯化脂肪酸（NEFA）水平下降，提示能量利用效率提升。高剂量（100克）反而导致pH下降，说明存在剂量依赖性效应。总体表明，该益生菌系统在维持瘤胃稳态、改善发酵功能方面具有显著疗效。,8444,1945,10389,,
4879fcfd-acc6-4190-8d28-6019e57c9748,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""ATCC 55739""}]",Suspension,Facultative Anaerobe,"Growth in MRS broth at pH 6.5, 37°C; optimal CLA production at 10°C with 20 mg/mL LA",Incubation for 70 h at 10°C; peak CLA production at 30 h; no significant increase beyond 30 h,Not specified,Not specified,"Tolerant to low temperature (4–10°C), moderate LA concentrations; sensitive to pH drop (5.5) and micro-aerobic conditions",Lecithin (protects against LA inhibition),"Lactobacillus reuteri ATCC 55739 is a facultative anaerobe capable of growing in MRS broth at 37°C and pH 6.5. Optimal conjugated linoleic acid (CLA) production occurs under aerobic conditions at 10°C with 20 mg/mL linoleic acid. The strain exhibits enhanced metabolic activity at low temperatures, likely due to membrane fluidity regulation via incorporation of unsaturated fatty acids. It shows tolerance to moderate levels of free linoleic acid, possibly due to protective effects of lecithin in the medium. However, CLA production is significantly reduced under acidic conditions (pH 5.5) and micro-aerobic environments.",,,,,,,该研究未对Lactobacillus reuteri ATCC 55739进行基因工程改造。其CLA生物转化能力源于天然代谢途径，无需外源基因插入或调控元件。,"[""Temperature"", ""Oxygen"", ""pH""]","[""Linoleic Acid (LA)""]",,,Linoleate isomerase (membrane-anchored enzyme),"No engineered logic; natural response to temperature, oxygen, and pH with nonlinear feedback from substrate concentration",Lactobacillus reuteri通过细胞膜上的linoleate isomerase感知游离亚油酸（LA）并启动异构化反应。其代谢响应受温度、氧气和pH的调控：在10°C、有氧条件下活性最高，pH降低至5.5或转为微需氧环境均显著抑制CLA生成。该系统表现出对温度和氧气的自然选择性响应，但无人工设计的逻辑门控机制。,"[""Metabolic Regulation""]",Extracellular release (CLA is primarily located in extracellular phase),"Controlled by substrate concentration (LA), temperature, and incubation time",Compatible with liquid broth medium; emulsified LA in MRS broth allows sustained substrate availability,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,"Lactobacillus reuteri converts free linoleic acid (LA) into conjugated linoleic acid (CLA), a bioactive metabolite with potential health benefits including anti-inflammatory, anti-cancer, and anti-obesity effects.",Conjugated Linoleic Acid (CLA),False,,,GRAS,"None (natural strain, no synthetic kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; safe for food applications,None (no physical confinement used),"Lactobacillus reuteri ATCC 55739 is a well-characterized probiotic strain with GRAS status. It is not pathogenic, does not carry known antibiotic resistance genes, and is considered safe for human consumption. No biocontainment strategies were employed in this study, as the strain is naturally non-invasive and non-pathogenic. The risk of environmental escape is minimal due to its probiotic nature and limited survival outside host environments.",在20 mg/mL亚油酸、pH 6.5、10°C、有氧条件下培养70小时，Lactobacillus reuteri ATCC 55739的CLA产量达到0.108 mg/mL，为目前报道的最高水平之一。该条件下的CLA产率（15.56%）和生产速率（3.49 mg/L/h）均优于多数已知菌株。该系统为开发富含CLA的冷藏功能性食品提供了新途径。,10570,1582,12152,,
3482943b-48e5-46ed-8863-c692d90d5c9c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""NCC3001""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex nutrients including amino acids, vitamins, and carbohydrates; dependent on host-derived metabolites in gut environment",Doubling time ~2–3 hours in vitro; in vivo colonization stable over 6-week intervention period,"Large intestine (colon), particularly mucosal layer of colonic epithelium",Competitive exclusion of pathogenic bacteria; cross-feeding with other SCFA-producing microbes; enhances gut barrier integrity,Moderate tolerance to bile salts and low pH; sensitive to drying and prolonged storage; lyophilization reduces viability,"Bile salts, gastric acid","Bifidobacterium longum is a facultative anaerobe that thrives in the human colon, where it utilizes dietary fibers and host mucins as carbon sources. It exhibits stable colonization in the gut over short-term interventions and contributes to mucosal protection through SCFA production and immune modulation.",Not specified,Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems reported; minimal metabolic burden observed,Stable in oral delivery formats (capsules); no reported degradation in gastrointestinal transit,"The strain is used in its native form without genetic modification. Its beneficial effects are attributed to natural metabolic and immunomodulatory functions, including the production of short-chain fatty acids and modulation of host immune responses.","[""pH"", ""Bile acids""]","[""Fiber (fructooligosaccharides, galactooligosaccharides)"", ""Lactate""]",,"[""Cytokines"", ""Glucagon-like peptide-1""]","FNR promoter (hypoxia-responsive), Bile acid transporters",No complex logic gates reported; activity is primarily constitutive and responsive to nutrient availability and environmental cues,"Bifidobacterium longum senses changes in gut pH and bile acid concentration, which regulate its growth and metabolic activity. It responds to fermentable fibers like FOS and GOS by upregulating genes involved in carbohydrate metabolism and SCFA production. The strain also detects host-derived signals such as GLP-1, which may modulate its behavior in a feedback loop.","[""Immunomodulation"", ""Metabolic Regulation""]","Type IV secretion system (putative), vesicle-mediated release",Dose-dependent effects observed; 1×10¹⁰ CFU/day effective in clinical trials,Compatible with oral capsule delivery; stable in gastrointestinal environment,False,,,Not applicable,,,,,,No antibacterial activity reported.,False,Not applicable,,,,,No oxygenation function observed.,True,"Modulates immune system by reducing pro-inflammatory cytokines (e.g., IL-6), enhancing regulatory T-cell activity, and suppressing HPA axis overactivity. Also reduces cortisol levels and improves stress resilience.","Short-chain fatty acids (SCFAs), particularly acetate and lactate",False,Not applicable,,True,"Ferments dietary fibers (FOS, GOS) to produce SCFAs (acetate, lactate, butyrate), which serve as energy sources for colonocytes and regulate host metabolism, including glucose homeostasis and lipid metabolism.","Short-chain fatty acids (SCFAs), especially acetate and lactate",False,Not applicable,,GRAS,"Auxotrophy (dependent on host nutrients), no antibiotic resistance genes reported","Host-derived nutrients (e.g., mucins, SCFAs)",Low pathogenicity; no evidence of HGT or environmental escape; safe in healthy and IBS populations,Gastrointestinal tract acts as natural physical barrier; no systemic dissemination reported,"Bifidobacterium longum NCC3001 is classified as GRAS (Generally Recognized As Safe). It is a commensal bacterium naturally present in the human gut, with no known virulence factors or antibiotic resistance genes. Its auxotrophic nature limits survival outside the host, reducing environmental risk.","In a 6-week randomized, double-blind, placebo-controlled trial, Bifidobacterium longum NCC3001 significantly reduced depression scores in IBS patients (HADS-D subscale), with no change in anxiety. The strain also improved mood and reduced cortisol levels in healthy adults, suggesting a role in stress resilience and emotional regulation.",15206,4441,19647,,
3482943b-48e5-46ed-8863-c692d90d5c9c,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Shirota""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; requires glucose and amino acids; tolerant to bile and low pH",Doubling time ~1–2 hours in vitro; stable colonization in gut over 8-week intervention,Small intestine and colon; adheres to epithelial cells,"Competes with pathogens for adhesion sites; produces lactic acid, lowering local pH; enhances gut barrier function",High tolerance to gastric acid and bile; stable during lyophilization and storage; resistant to shear stress in food matrices,"Lactic acid, bile salts","Lactobacillus casei Shirota is a facultative anaerobe that survives gastric transit and colonizes the intestinal tract. It exhibits strong tolerance to acidic and bile-rich environments, enabling effective delivery via oral supplements.",Not specified,Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems used; minimal metabolic burden,Stable in fermented dairy products and capsules; maintains viability during storage,"The strain is used in its native form without genetic modification. Its therapeutic effects are due to natural metabolic activity, including lactic acid production and immune modulation.","[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]",,"[""Cytokines"", ""Stress-response genes""]","Lactate permease, bile acid sensors (e.g., Bile acid-binding proteins)",No complex logic gates reported; activity is constitutive and responsive to nutrient availability and stress signals,"Lactobacillus casei Shirota senses changes in intestinal pH and bile acid concentration, which regulate its growth and metabolic output. It detects glucose and lactate levels, modulating lactic acid production. It also responds to host stress signals, such as elevated cortisol and stress-response gene expression, suggesting a role in stress buffering.","[""Immunomodulation"", ""Metabolic Regulation""]","Lysis, vesicle release",Dose-dependent effects; 1×10¹¹ CFU/day effective in clinical trials,Compatible with dairy-based delivery systems and capsules; stable in gastrointestinal environment,False,,,Not applicable,,,,,,No antibacterial activity reported.,False,Not applicable,,,,,No oxygenation function observed.,True,"Suppresses stress-induced gene expression, reduces salivary cortisol levels, and modulates immune cell activity. In medical students, it prevented cortisol spikes during exams.","Lactic acid, cell wall components (peptidoglycan, lipoteichoic acid)",False,Not applicable,,True,"Produces lactic acid from glucose fermentation, which lowers intestinal pH and inhibits pathogenic bacteria. Also contributes to SCFA cross-feeding via lactate utilization by other microbes.",Lactic acid,False,Not applicable,,GRAS,"Auxotrophy (requires host nutrients), no antibiotic resistance genes reported","Host-derived nutrients (e.g., glucose, amino acids)",Low pathogenicity; no evidence of HGT or environmental escape; safe in healthy and chronic fatigue syndrome populations,Gastrointestinal tract acts as natural physical barrier; no systemic dissemination reported,"Lactobacillus casei Shirota is classified as GRAS. It is a well-established probiotic strain with no known virulence factors or antibiotic resistance genes. Its dependence on host nutrients limits survival outside the gut, minimizing environmental risk.","In multiple clinical trials, Lactobacillus casei Shirota reduced anxiety scores in chronic fatigue syndrome patients and suppressed stress-induced cortisol elevation in medical students. It also improved coping strategies and maintained HPA axis stability during high-stress periods, indicating strong psychobiotic potential.",15206,4441,19647,,
3482943b-48e5-46ed-8863-c692d90d5c9c,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""HN001""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; requires glucose, amino acids, and vitamins; bile-tolerant",Doubling time ~1.5–2 hours in vitro; stable colonization in gut over 15-week intervention,"Colon, particularly mucosal layer; adheres to epithelial cells",Competes with pathogens; enhances gut barrier; promotes immune tolerance,"High tolerance to bile, low pH, and drying; stable during lyophilization and long-term storage","Bile salts, gastric acid",Lactobacillus rhamnosus HN001 is a robust facultative anaerobe that survives gastrointestinal transit and colonizes the human colon. It exhibits strong resilience to environmental stresses and maintains viability during storage.,Not specified,Not applicable,Constitutive,,High chromosomal stability; no plasmid systems used; minimal metabolic burden,Stable in oral supplements and dairy products; maintains viability in gastrointestinal environment,The strain is used in its native form. Its psychobiotic effects are attributed to natural immune modulation and neuroendocrine signaling.,"[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]",,"[""Cytokines"", ""Stress hormones""]","Bile acid transporters, pH-sensing regulators",No complex logic gates reported; activity is constitutive and responsive to nutrient and stress signals,"Lactobacillus rhamnosus HN001 senses pH and bile acid levels, which regulate its growth and metabolic output. It detects glucose and lactate, modulating lactic acid production. It also responds to host stress signals, contributing to mood regulation during pregnancy and postpartum.","[""Immunomodulation"", ""Metabolic Regulation""]","Lysis, vesicle release",Dose-dependent effects; 1×10¹⁰ CFU/day effective in clinical trials,Compatible with oral supplements; stable in gastrointestinal environment,False,,,Not applicable,,,,,,No antibacterial activity reported.,False,Not applicable,,,,,No oxygenation function observed.,True,"Reduces postpartum depression and anxiety scores in pregnant women. Modulates immune responses and suppresses HPA axis overactivity, improving emotional regulation during high-stress periods.","Lactic acid, cell wall components",False,Not applicable,,True,"Ferments glucose to lactic acid, lowering intestinal pH and inhibiting pathogens. Contributes to SCFA cross-feeding via lactate utilization by other microbes.",Lactic acid,False,Not applicable,,GRAS,"Auxotrophy, no antibiotic resistance genes reported","Host-derived nutrients (e.g., glucose, amino acids)",Low pathogenicity; no evidence of HGT or environmental escape; safe in pregnant and postpartum populations,Gastrointestinal tract acts as natural physical barrier; no systemic dissemination reported,"Lactobacillus rhamnosus HN001 is classified as GRAS. It is a commensal bacterium with no known virulence factors or antibiotic resistance genes. Its auxotrophic nature limits survival outside the host, reducing environmental risk.","In a 15-week intervention during pregnancy and postpartum, Lactobacillus rhamnosus HN001 significantly reduced depression and anxiety scores compared to placebo. The strain demonstrated strong psychobiotic effects, particularly in high-stress physiological states.",15206,4441,19647,,
357fdbf1-a5b1-48db-8415-8271847265e1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""P24-2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""P24-8""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus acidilactici"", ""strain_id"": ""A2-1""}]",Suspension,Facultative Anaerobe,"Growth at 37°C, pH 6.5–7.0 in MRS medium; tolerant to 1% pepsin and pH 2.0 for 2 h; resistant to 0.3% bile salts and pancreatin",Growth rate: 24 h in MRS broth; doubling time not specified; in vitro growth consistent with in vivo conditions,Gastric mucosa (target niche for H. pylori inhibition),"Competitive exclusion of pathogens (E. coli, S. aureus, H. pylori); potential symbiosis with host microbiota via metabolic modulation","High tolerance to low pH (pH 2.0), pepsin, bile salts, and pancreatin; stable after lyophilization (stored at -70°C in glycerol/MRS)",Glycerol/MRS mixture (for cryopreservation),该研究中分离的乳酸菌（LAB）在37°C下于MRS培养基中生长良好，对胃酸（pH 2.0）和胃蛋白酶具有较强耐受性，对胆盐和胰酶也表现出良好耐受性。所有菌株均能在模拟胃肠道条件下存活，其中P24-8和P24-2表现出最强的耐受性，表明其具有良好的口服定植潜力。,,,,,,,本研究未涉及基因工程改造，所有菌株均为天然分离株，未进行任何遗传修饰。,"[""pH"", ""Osmotic stress""]","[""Lactate"", ""Acetate""]",,,H+-ATPase (for pH homeostasis),No engineered logic; natural sensing via membrane transporters and metabolic adaptation,菌株通过H+-ATP酶维持细胞内pH稳态，响应酸性环境；通过代谢调节和细胞壁结构变化应对胃肠道应激，未见人工逻辑门设计。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Diffusion of metabolites (lactic acid, acetic acid, H2O2, bacteriocins)",Natural secretion; not controllable via external inducers,Compatible with agar-based matrices used in assays; no structural disruption reported,True,True,False,通过产生乳酸、乙酸、过氧化氢和细菌素等抗菌物质抑制病原菌生长，竞争营养和结合位点。,"Lactic acid, Acetic acid, Hydrogen peroxide, Bacteriocins",True,True,True,True,60%的菌株对E. coli和S. aureus具有抑制活性；所有菌株均抑制H. pylori生长和脲酶活性，且无细胞毒性报告，表明其具有可控且安全的抗菌作用。,False,,,False,False,False,未涉及氧气生成机制，无相关数据。,True,通过抑制H. pylori脲酶活性，降低其在胃酸环境中的生存能力，间接减轻胃黏膜炎症，调节免疫反应。,Urease inhibitor (via metabolic interference),False,,,True,通过产生乳酸和乙酸等代谢产物调节局部微环境pH，抑制病原菌生长，同时可能促进有益菌群平衡。,"Lactic acid, Acetic acid",False,,,BSL-1,Intrinsic resistance to vancomycin; no antibiotic resistance genes detected,Vancomycin (resistance marker),No pathogenicity reported; no horizontal gene transfer risk identified; all strains sensitive to clinical antibiotics except vancomycin (intrinsic resistance),No physical barrier used; in vitro study only,所有菌株均为天然分离的乳酸菌，无致病性报告，对临床常用抗生素敏感（除对万古霉素天然耐药外），未检测到耐药基因转移风险，属于低风险生物安全等级（BSL-1），适合用于益生菌研究。,所有菌株均能抑制H. pylori ATCC 43504的生长并抑制其脲酶活性，其中P24-2和P24-8表现出最强的胃肠道耐受性和广谱抗菌活性，提示其在辅助根除H. pylori感染方面具有潜在应用价值。,13664,1660,15324,,
54e998cc-c05f-406b-aac8-0a27dc8364c6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactiplantibacillus plantarum"", ""strain_id"": ""41G""}]",Suspension,Facultative Anaerobe,"Temperature: 30–37°C; pH: Neutral to slightly acidic (inferred from MRS agar growth); Osmotic: Tolerant to 3.5% NaCl; Nutritional: Requires complex media (MRS broth) with carbon sources (glucose), amino acids, vitamins, and minerals.","Growth rate: ~24 h in MRS broth at 37°C; Doubling time: ~1–1.5 h (inferred from standard LAB growth); In vivo vs in vitro: Not explicitly compared, but robust in vitro growth suggests potential for in vivo survival.",Gut mucosa (inferred from probiotic screening and gastrointestinal tolerance); potential for intestinal colonization.,"Competitive exclusion of pathogens (e.g., S. aureus, P. aeruginosa); no direct evidence of symbiosis with host microbiome.","Tolerant to 0.5% phenol, 3.5% NaCl, simulated gastric juice (pH 2.0), and bile salts (0.3%); withstands oxidative and acid stress.","Bile salt hydrolase (BSH), organic acids (lactic, acetic), catalase (for H₂O₂ detoxification)","Lactiplantibacillus plantarum 41G exhibits strong growth under both 30°C and 37°C, with high tolerance to gastrointestinal stressors such as low pH, bile salts, and salt. It is a versatile facultative anaerobe capable of surviving in harsh environments, making it a promising candidate for probiotic applications.",CRISPR-Cas not used; genome sequencing via Illumina MiSeq and PacBio SMRT; no genetic modifications reported.,Not applicable (no engineered modifications reported).,Constitutive expression of probiotic and antimicrobial genes; no inducible circuits described.,,Chromosomal integration of functional genes; no plasmid-based systems reported; stable under in vitro conditions.,No material environment described; stability in food matrix (fermented meat) inferred.,"No genetic engineering was performed. The strain was isolated and characterized based on natural probiotic and antimicrobial traits. Genome sequencing confirmed presence of bacteriocin and probiotic gene markers, but no synthetic circuits were introduced.","[""Acidity (pH)"", ""Oxidative stress"", ""Osmotic stress""]","[""Bile salts"", ""Lactate"", ""Acetate""]",,,"Bile salt hydrolase (BSH), acid stress response regulators (e.g., FNR-like systems inferred from genome data)",No synthetic logic gates; natural sensing via stress-responsive promoters and metabolic feedback.,"The strain senses environmental stressors such as low pH and bile salts through intrinsic regulatory systems. It responds by upregulating protective genes (e.g., BSH, acid tolerance). No engineered logic circuits are present.","[""Antibacterial"", ""Antifungal"", ""Metabolic Regulation""]",Type I secretion system (inferred from bacteriocin gene clusters); organic acid secretion via membrane transporters.,"Natural, constitutive secretion; no external control mechanisms described.",Compatible with fermented meat matrix; stable in food environment; no evidence of structural disruption.,True,True,False,"Produces organic acids (lactic, acetic) and bacteriocins that inhibit a wide range of Gram-positive and Gram-negative bacteria, including ESKAPE pathogens.","Lactic acid, acetic acid, bacteriocins (e.g., plantaricin-like compounds)",True,True,True,True,"L. plantarum 41G showed strong inhibition against S. aureus, P. aeruginosa, L. innocua, E. faecium, and K. pneumoniae (Table 1). Inhibition zones were clear and defined, suggesting bacteriocin activity. No cytotoxicity data reported, but GRAS status of L. plantarum supports safety.",False,,,False,False,False,No oxygen-producing mechanisms reported; not applicable.,False,,,False,,,True,"Produces organic acids (lactic, acetic, succinic) that modulate gut microbiota and host metabolism; may influence SCFA levels and intestinal barrier function.","Lactic acid, acetic acid, succinic acid",False,,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported).",,Low pathogenicity; no antibiotic resistance genes detected; no evidence of horizontal gene transfer; no virulence factors identified.,None (no physical confinement described).,"L. plantarum 41G is a naturally occurring strain from fermented meat with GRAS status. It shows no signs of pathogenicity, antibiotic resistance, or virulence. No genetic modifications or biocontainment systems were used, but its natural safety profile supports low risk.","L. plantarum 41G demonstrated the highest robustness among tested strains in surviving simulated gastric juice, bile salts, phenol, and high salt. It exhibited strong broad-spectrum antibacterial and antifungal activity, making it a top candidate for probiotic development in functional foods. Its ability to produce organic acids and bacteriocins supports its potential for gut health promotion and food preservation.",17894,1767,19661,,
bc3d4873-734b-4734-8b2c-9cb8bbcae7b2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""NCC2705""}]",Encapsulated,Obligate Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex nutrients including amino acids, vitamins, and carbohydrates; dependent on host mucus and dietary fibers for growth.",Doubling time ~2–3 hours in vitro; growth rate consistent with in vivo intestinal niche conditions.,"Colonizes the human intestinal tract, particularly the colon; prefers mucus layer and anaerobic environment.",Competes with pathogenic bacteria for nutrients and adhesion sites; promotes symbiosis by enhancing barrier function and immune tolerance.,Tolerant to bile salts and acidic pH; moderate resistance to osmotic stress and shear forces during transit.,"Bile salt hydrolase (BSH), acid shock proteins (e.g., GroEL, DnaK)","Bifidobacterium longum NCC2705 is an obligate anaerobe that thrives in the human colon, where it utilizes dietary fibers and host mucus as carbon sources. It exhibits strong tolerance to gastric acidity and bile, enabling survival through the upper GI tract. Its growth is supported by a stable, nutrient-rich, and low-oxygen environment, typical of the colonic mucosa.","CRISPR-Cas9 (inferred from genomic studies), Recombination systems",High efficiency in genome editing; low off-target risk due to well-annotated genome.,Constitutive expression of key metabolic and stress-response genes; potential for inducible systems via promoter engineering.,None explicitly mentioned; promoters such as P15A or lac promoter may be used in synthetic circuits.,High chromosomal stability; plasmid-based systems show moderate stability without selective pressure.,Stable in gel-based delivery systems; maintains viability in encapsulated matrices.,"Bifidobacterium longum NCC2705 has been extensively studied using comparative proteomics and genomics. Its genome is well-annotated, enabling rational strain engineering. Genetic tools such as CRISPR-Cas9 and recombination systems allow targeted modifications. The strain is amenable to synthetic biology approaches, particularly for enhancing stress resistance and metabolic functions.","[""Acidity (pH)"", ""Bile salts"", ""Osmotic stress""]","[""Fucose"", ""Mucin-derived sugars"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing (AHL-like molecules)""]","[""Mucin glycoproteins"", ""Tissue degradation fragments""]","Fucose utilization operon (FucR regulator), Bile salt hydrolase (BSH), Acid shock promoters (e.g., P15A), Mucin-binding adhesins",Threshold-based response to pH and bile; feedback regulation via SCFA sensing; potential for AND logic between nutrient availability and host signals.,"Bifidobacterium longum senses environmental cues such as low pH and bile salts via specific promoters and regulatory proteins. It integrates signals from host mucin and dietary sugars to activate metabolic pathways. The system exhibits threshold responses and feedback loops, allowing adaptive behavior in the dynamic gut environment.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion system (T1SS), Vesicles (outer membrane vesicles)",Controlled by host nutrient availability and microbial density; no synthetic circuitry reported.,Compatible with hydrogel and encapsulated delivery systems; maintains viability and function during release.,False,,,None reported.,,False,False,False,False,No evidence of antibacterial activity reported.,False,None reported.,,False,False,False,No oxygenation mechanism described.,True,"Modulates host immune system by promoting anti-inflammatory cytokines (e.g., IL-10), enhancing regulatory T-cell activity, and suppressing Th1/Th17 responses.","Secreted exopolysaccharides (EPS), surface glycoproteins, peptidoglycan fragments",True,Enhances epithelial barrier integrity by stimulating mucin production and tight junction assembly; promotes wound healing via growth factor induction.,"Mucin (MUC2), TGF-β, IL-10",True,Produces short-chain fatty acids (SCFAs) such as acetate and lactate through fermentation of dietary fibers; regulates host glucose and lipid metabolism.,"Acetate, Lactate, Butyrate",False,None reported.,,GRAS,"Auxotrophy (e.g., requirement for specific amino acids or vitamins); no suicide genes reported.","Amino acid auxotrophy (e.g., leucine, threonine)",Non-pathogenic; low opportunistic risk; no known antibiotic resistance genes; minimal horizontal gene transfer potential; low environmental escape risk.,Physical confinement via encapsulation prevents environmental release.,"Bifidobacterium longum NCC2705 is classified as GRAS (Generally Recognized As Safe) and has a long history of safe use in food and supplements. It is non-invasive, non-pathogenic, and does not colonize beyond the gut. Its auxotrophic nature limits survival outside the host. No evidence of virulence or antibiotic resistance genes has been reported.","Bifidobacterium longum NCC2705 has demonstrated efficacy in reducing intestinal inflammation, improving gut barrier function, and modulating immune responses in preclinical models. It is associated with reduced symptoms in IBS and allergic conditions, and supports metabolic health through SCFA production. Clinical studies show benefits in infant colic, antibiotic-associated diarrhea, and pouchitis.",14088,1829,15917,,
faec1157-bc92-41b9-9b25-35720acbfe5c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""LGG""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, requires low water activity (a_w < 0.15) for stability; sensitive to high water activity (a_w = 0.7).",Not specified in the study; freeze-dried form used for storage. In vivo growth not assessed.,"Gastrointestinal tract (implied by probiotic use), but not tested in this study.",Not assessed in this study.,"Low tolerance to high water activity (a_w = 0.7); sensitive to rehydration stress during encapsulation. No data on UV, shear, or drying stability beyond freeze-drying.",Whey protein and palm oil (used in encapsulation for barrier protection),"Lactobacillus rhamnosus GG is a probiotic strain typically used in food products. It is freeze-dried for storage and requires low water activity (a_w < 0.15) to maintain viability. High water activity (a_w = 0.7) leads to rapid loss of viability (>10 log10 reduction within 2 weeks). The strain is sensitive to moisture and shows poor survival under humid conditions, even when encapsulated.",,,,,Not applicable; no genetic modifications were made. The strain is wild-type LGG.,Not applicable; no engineered genetic circuits or plasmids involved.,该研究未对Lactobacillus rhamnosus GG进行基因改造。所有实验均使用野生型LGG菌株，仅通过物理包埋（微胶囊化）进行保护，未引入任何基因工程工具或调控回路。,,,,,,Not applicable; no sensing or logic circuits were engineered.,该研究未涉及任何生物传感模块或逻辑控制机制，因此无传感与信号处理功能。,"[""Probiotic""]",Passive release via capsule degradation; no active secretion systems engineered.,Not applicable; no controlled release or dosage regulation was implemented.,Whey protein and palm oil layers provide partial physical barrier but failed to prevent moisture ingress at high a_w (0.7).,False,False,False,Not applicable; no antibacterial function was engineered or tested.,,False,False,False,False,未测试抗菌功能，无相关证据。,False,Not applicable; no oxygen-producing function was implemented.,,False,False,False,未涉及氧气生成机制，无相关证据。,False,Not applicable; no immunomodulatory molecules were expressed.,,False,Not applicable; no tissue repair factors were produced.,,False,Not applicable; no metabolic regulation via secreted metabolites was studied.,,False,Not applicable; no tumor-targeting or prodrug conversion functions were implemented.,,BSL-1,None; no kill switches or auxotrophy introduced.,,"Lactobacillus rhamnosus GG is a well-characterized probiotic strain with GRAS status. No pathogenicity, antibiotic resistance genes, or horizontal gene transfer risks reported. Low opportunistic risk.","Whey protein and palm oil layers provide limited physical confinement; cracks may form, allowing moisture penetration.","Lactobacillus rhamnosus GG is a GRAS (Generally Recognized As Safe) strain with low biosafety risk (BSL-1). No genetic modifications were made, so no risk of horizontal gene transfer or pathogenicity. However, the encapsulation barrier was insufficient to protect against high water activity, raising concerns about product stability and shelf-life. Physical containment via microcapsules is limited by potential cracking and moisture permeability.",该研究未评估治疗或伤口愈合效果。实验仅关注微胶囊化对Lactobacillus rhamnosus GG在干燥产品中存活率的影响。结果显示，在高水活度（a_w = 0.7）条件下，无论是否包埋，LGG的存活率均在两周内下降超过10 log10，表明当前包埋策略无法有效延长其货架期。,8105,1493,9598,,
08bf3721-2a43-4866-aef1-642223115dd4,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Yellow fever 17D-DENV chimeras"", ""strain_id"": ""Dengvaxia (Sanofi-Pasteur)""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 7.0–7.4, requires mammalian cell culture (e.g., Vero cells), dependent on host metabolites and serum components",Doubling time ~6–8 hours in vitro; in vivo replication kinetics not fully characterized but shows transient viremia in humans,Systemic circulation and lymphoid tissues after injection; no mucosal or tissue-specific colonization,"Not applicable (viral vector, not bacterial)","Moderate stability during freeze-drying (lyophilization), sensitive to heat and UV light; requires cold chain storage (2–8°C)",Trehalose and sucrose in formulation for lyophilization stability,该系统为基于黄热病17D疫苗株的减毒活疫苗，通过基因工程构建为四种登革病毒（DENV-1至DENV-4）的嵌合病毒。其在Vero细胞中可高效复制，生长温度为37°C，pH 7.0–7.4，依赖宿主细胞提供的营养和代谢环境。在人体内注射后可引起短暂的病毒血症，但无持续性组织定植能力。对热和紫外线敏感，需冷链运输与储存，冻干制剂中添加蔗糖和海藻糖以提高稳定性。,"Recombination (cDNA cloning, viral reverse genetics)",High efficiency in generating chimeric viruses; no off-target effects reported due to viral genome engineering,Constitutive expression of chimeric viral genes; no inducible circuits,,"Stable in vitro and in vivo; mutations in structural genes (prM/E) contribute to attenuation, but long-term evolutionary drift not fully assessed",Stable in liquid and lyophilized formulations; compatible with standard vaccine delivery systems,通过将登革病毒的prM和E蛋白基因插入黄热病17D疫苗株的非结构基因区域，构建出四种减毒的嵌合病毒。该策略利用黄热病疫苗株的强免疫原性和安全性，同时引入登革病毒的表面抗原以诱导中和抗体。基因工程过程基于cDNA克隆和反向遗传学技术，确保嵌合病毒的稳定性和可复制性。,,,,,None (viral vector does not sense environmental signals),None (no synthetic circuitry),该系统为非工程化病毒载体，不包含任何感知模块或逻辑控制回路，其免疫原性表达为组成型，不响应外部环境信号。,"[""Immunomodulation""]",Viral particle release (lysis of infected cells),Dose-dependent immune response; three doses required over one year for full protection,Compatible with standard vaccine delivery systems (injection); stable in lyophilized form,False,,,Not applicable,,,,,,无,False,Not applicable,,,,,无,True,诱导针对四种登革病毒的中和抗体和T细胞免疫反应，特别是对DENV-2、-3、-4的保护性免疫。免疫反应包括CD8+ T细胞对非结构蛋白（NS1、NS3、NS5）的广泛识别，模拟自然感染后的免疫应答。,"DENV prM/E proteins, NS1, NS3, NS5",False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,Live-attenuated virus with defined mutations in prM/E and non-structural genes; no known reversion to virulence,Attenuating mutations in prM/E genes,Theoretical risk of antibody-dependent enhancement (ADE) in seronegative individuals; no evidence of reversion to virulence in trials; no horizontal gene transfer potential (viral vector),Physical barrier provided by injection and immune clearance; no environmental release risk,该疫苗为减毒活病毒，虽经基因工程改造，但存在对未感染过登革病毒者（血清阴性者）接种后可能引发抗体依赖性增强（ADE）的风险。在第三年随访中，部分血清阴性儿童出现住院率升高，提示疫苗可能增强疾病严重性。尽管无证据显示病毒在环境中传播或发生基因水平转移，但其在血清阴性者中的潜在致病性使其不适合用于旅行者。,在完成三剂接种后，对2-16岁儿童的登革热疾病发生率降低57%，但对DENV-1和DENV-2的保护效果较弱。在第三年，对住院病例的保护效力下降至16.7%。在血清阴性儿童中，疫苗接种后出现住院率显著升高（相对风险4.95），提示存在疫苗增强疾病风险。因此，该疫苗不适合用于未感染过登革病毒的旅行者。,7755,5072,12827,,
08bf3721-2a43-4866-aef1-642223115dd4,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""DENV-4 Δ30 mutant virus (rDENV-4 Δ30)"", ""strain_id"": ""TV003 (NIAID)""}]",Suspension,Facultative Anaerobe,"Grows in mammalian cells (Vero, C6/36), optimal at 37°C, pH 7.0–7.4; requires serum and nutrients from host cells",Low-level viremia in humans; doubling time ~6–8 hours in vitro; in vivo replication transient and self-limiting,Systemic circulation and lymphoid tissues after injection; no mucosal or tissue-specific colonization,Not applicable (viral vector),Stable after lyophilization; sensitive to heat and UV; requires cold chain (2–8°C),Trehalose and sucrose in formulation,该系统为基于登革病毒4型（DENV-4）的减毒突变株（rDENV-4 Δ30），其3'非翻译区缺失30个核苷酸，导致病毒复制能力下降。可在Vero或C6/36细胞中生长，最适温度37°C，pH 7.0–7.4，依赖宿主细胞提供营养。在人体内注射后可引起短暂病毒血症，但无持续感染能力。冻干制剂中添加海藻糖和蔗糖以提高稳定性，对热和紫外线敏感，需冷链运输。,"Recombination (cDNA cloning, reverse genetics)",High efficiency in generating mutant viruses; no off-target effects reported,Constitutive expression of viral genes; no synthetic circuits,,Stable in vitro and in vivo; deletion in 3' UTR is genetically stable; no reversion observed in trials,Stable in liquid and lyophilized formulations; compatible with standard vaccine delivery,通过在DENV-4的3'非翻译区引入30个核苷酸缺失，构建出减毒突变株rDENV-4 Δ30。该突变株在猴子中诱导的病毒血症水平低于野生型，但中和抗体反应相似。该技术被用于构建其他单型疫苗，并最终组合成四价疫苗TV003。基因工程基于cDNA克隆和反向遗传学，确保病毒的稳定性和可复制性。,,,,,None (viral vector does not sense environmental signals),None (no synthetic circuitry),该系统为非工程化病毒载体，不包含任何感知模块或逻辑控制回路，其免疫原性表达为组成型，不响应外部环境信号。,"[""Immunomodulation""]",Viral particle release (lysis of infected cells),单剂接种即可提供保护，无需加强针；免疫反应呈剂量依赖性,兼容标准疫苗递送系统（注射）；冻干制剂稳定,False,,,Not applicable,,,,,,无,False,Not applicable,,,,,无,True,单剂接种后即可诱导对DENV-2的完全保护，无显著的再刺激抗体反应。诱导广泛的CD8+ T细胞反应，靶向结构和非结构蛋白（NS1、NS3、NS5），且对多种登革病毒株具有交叉反应性。免疫谱与自然感染相似，具有潜在的免疫保护相关性。,"DENV prM/E proteins, NS1, NS3, NS5",False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,Live-attenuated virus with defined deletion in 3' UTR; no reversion to virulence observed,3' UTR缺失突变,无已知的致病性增强风险；在血清阴性者中未观察到疫苗增强疾病；无水平基因转移风险；无环境释放风险,物理屏障由注射和免疫清除提供；无环境释放风险,该疫苗为基于DENV-4的减毒突变株，其3'非翻译区缺失30个核苷酸，导致复制能力下降，安全性良好。在临床试验中，单剂接种即可对DENV-2挑战提供100%保护，且无再刺激抗体反应，提示可能实现无症状免疫。未观察到对血清阴性者有疫苗增强疾病风险，且T细胞反应广泛且保守，具有潜在长期保护能力。因此，该疫苗被认为是旅行者疫苗的理想候选。,在一项挑战试验中，21名接种单剂TV003的志愿者在6个月后接受DENV-2挑战，全部未出现病毒血症、皮疹或中性粒细胞减少，而对照组100%发病。该疫苗在单剂接种后即可提供完全保护，且免疫谱与自然感染相似，无再刺激抗体反应，提示可能实现长期免疫。,7755,5072,12827,,
08bf3721-2a43-4866-aef1-642223115dd4,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""DENV-2 chimeras (TDV)"", ""strain_id"": ""Takeda vaccine (TDV)""}]",Suspension,Facultative Anaerobe,"Grows in mammalian cells (Vero, C6/36), optimal at 37°C, pH 7.0–7.4; requires serum and nutrients",Low-level viremia in humans; doubling time ~6–8 hours in vitro; transient replication,Systemic circulation and lymphoid tissues after injection; no mucosal colonization,Not applicable (viral vector),Stable after lyophilization; sensitive to heat and UV; requires cold chain (2–8°C),Trehalose and sucrose in formulation,该系统为基于登革病毒2型（DENV-2）的减毒嵌合病毒，其非结构基因来源于减毒的DENV-2（16681 PDK-53），而prM和E蛋白基因来自DENV-1、-3、-4。可在Vero或C6/36细胞中生长，最适温度37°C，pH 7.0–7.4，依赖宿主细胞提供营养。在人体内注射后可引起短暂病毒血症，但无持续感染能力。冻干制剂中添加海藻糖和蔗糖以提高稳定性，对热和紫外线敏感，需冷链运输。,Recombination (viral reverse genetics),High efficiency in generating chimeric viruses; mutations in non-structural genes are stable,Constitutive expression of chimeric viral genes; no synthetic circuits,,Stable in vitro and in vivo; mutations in non-structural genes are genetically stable; no reversion observed,Stable in liquid and lyophilized formulations; compatible with standard vaccine delivery,通过将DENV-1、-3、-4的prM和E蛋白基因插入减毒DENV-2（16681 PDK-53）的非结构基因区域，构建出四价嵌合病毒。该策略利用DENV-2的减毒背景，同时引入其他三种登革病毒的表面抗原。基因工程基于反向遗传学技术，确保嵌合病毒的稳定性和可复制性。,,,,,None (viral vector does not sense environmental signals),None (no synthetic circuitry),该系统为非工程化病毒载体，不包含任何感知模块或逻辑控制回路，其免疫原性表达为组成型，不响应外部环境信号。,"[""Immunomodulation""]",Viral particle release (lysis of infected cells),两剂接种（间隔3个月）可诱导强免疫反应；单剂接种在免疫个体中可引发再刺激反应,兼容标准疫苗递送系统（注射）；冻干制剂稳定,False,,,Not applicable,,,,,,无,False,Not applicable,,,,,无,True,诱导对DENV-1、-2、-3的高滴度中和抗体，对DENV-4反应较弱。在小鼠模型中可中和多种DENV-4流行株，并提供部分保护。诱导CD8+ T细胞反应，靶向NS1、NS3、NS5等非结构蛋白，免疫谱较广。,"DENV prM/E proteins, NS1, NS3, NS5",False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,Live-attenuated virus with mutations in non-structural genes; no reversion to virulence observed,非结构基因中的减毒突变,无已知的致病性增强风险；在血清阴性者中未报告疫苗增强疾病；无水平基因转移风险；无环境释放风险,物理屏障由注射和免疫清除提供；无环境释放风险,该疫苗为基于DENV-2减毒株的嵌合病毒，其非结构基因中存在稳定减毒突变，安全性良好。在临床试验中，两剂接种可诱导对DENV-1、-2、-3的高滴度抗体，对DENV-4反应较弱。在小鼠模型中可提供部分保护。T细胞反应靶向保守的非结构蛋白，具有潜在交叉保护能力。目前尚无对血清阴性者疫苗增强风险的明确证据，但长期安全性仍需III期试验验证。,在III期试验前的II期研究中，两剂接种后超过80%的参与者对DENV-1至DENV-3产生血清转化，对DENV-4的血清转化率为33%-77%。在小鼠模型中，疫苗可中和多种DENV-4流行株，并提供部分保护。单剂接种在免疫个体中可引发再刺激反应，提示潜在的加强免疫能力。,7755,5072,12827,,
b62d673f-8af8-4fcd-9233-0a86261edffd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Vermamoeba vermiformis"", ""strain_id"": ""CDC-19""}]",Biofilm,Facultative Anaerobe,"Temperature: Thermotolerant (up to 30°C+), pH: Broad tolerance, Osmotic: Tolerant to osmotic stress, Nutrition: Feeds on bacteria (e.g., E. coli K12, P. aeruginosa), yeast (S. cerevisiae), and organic particles","Trophozoite doubling time: ~34–92 μm/min (locomotion rate), encystment: 9 hours; growth in vitro supported by yeast or bacteria","Hospital water systems, hot springs, biofilms in potable water, contact lens cases, skin/mucosa (in immunocompromised hosts), gastrointestinal tract (in pigs)","Symbiotic with pathogenic bacteria (e.g., Legionella pneumophila, Stenotrophomonas maltophilia, Francisella spp.), fungi (e.g., Exophiala dermatitidis, Aspergillus fumigatus), viruses (e.g., Faustovirus, Yasminevirus), and yeasts (Candida spp.); antagonistic toward some Pseudomonas aeruginosa strains","High resistance to classical biocides (chlorine up to 4 ppm), heat (cysts survive 50°C), UV, drying, and long-term storage in oligotrophic conditions; cysts aggregate and resist harsh environments","Cyst wall (double-walled: 50 nm endocyst + 110–140 nm ectocyst), protein and glucose polymer composition",Vermamoeba vermiformis 是一种广泛分布的自由生活阿米巴，具有热耐受性，可在多种极端环境中生存，包括医院供水系统、热水系统、生物膜、接触镜盒和瓶装水中。其生命周期包括活跃的滋养体和休眠的囊肿形式，滋养体呈蠕虫状，长约22–24 μm，通过吞噬作用摄取细菌、酵母和有机颗粒。囊肿为双层壁结构，直径约6–9 μm，具有高度抗逆性，可在氯浓度高达4 ppm的水中存活，且能长期维持病原体的活性。,,,,,,,"该文为综述，未报道对Vermamoeba vermiformis进行基因工程改造。其基因组已测序（59.5 Mb，22,483个基因），其中约17.8%的基因与细菌同源，涉及碳水化合物转运、信号转导和细胞壁/膜/包膜生物合成，但尚未用于工程化设计。","[""Hypoxia"", ""Temperature"", ""Osmotic Stress"", ""pH Fluctuations"", ""Nutrient Starvation""]","[""Bacterial Toxins"", ""Volatile Organic Compounds (e.g., terpenes from bacteria)""]","[""Bacterial Metabolites"", ""Fungal Secretions""]","[""Proteases (indirectly via host cell damage)"", ""Cytokines (inferred from immune evasion)""]",Unknown (no specific receptor or promoter identified in the text),"No engineered logic gates reported; natural sensing likely involves threshold-based responses to environmental stressors (e.g., encystment triggered by nutrient starvation, osmotic stress, pH change)",Vermamoeba vermiformis通过感知营养缺乏、渗透压变化、pH波动和细菌毒素等环境信号，启动囊肿形成（encystment），该过程需9小时，涉及细胞聚集和形态转变。其感知机制为非工程化自然响应，无明确逻辑门控设计。,"[""Pathogenesis"", ""Trojan Horse (Pathogen Reservoir)"", ""Environmental Persistence""]","Phagocytosis, cytopathic secretions (trogocytosis), cyst-mediated release","Natural, uncontrolled; activity depends on environmental cues and host interaction",Highly compatible with biofilm matrices and water systems; cysts remain stable in gel-like or aqueous environments,False,False,False,Not applicable,,False,False,False,False,无,False,Not applicable,,False,False,False,无,False,Not applicable,,False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,None reported (natural organism); potential for containment via cyst resistance and environmental persistence,"Cyst wall (double-walled, protein-glucose polymer)","Opportunistic pathogen; potential to cause keratitis, meningoencephalitis, bronchopneumonia; hosts drug-resistant pathogens (e.g., S. maltophilia, L. pneumophila); risk of horizontal gene transfer via endosymbiosis; environmental escape from water systems",Limited physical barrier in natural environments; cysts resist disinfectants and biofilm matrices,Vermamoeba vermiformis虽被列为潜在人类寄生虫，但其致病性仍存争议。其作为‘特洛伊木马’可携带并保护多种病原体（细菌、病毒、真菌），在医院供水系统中广泛存在，且对常规消毒剂具有高度抗性。其囊肿结构赋予其极强的环境耐受性，可能在人体内长期存活并传播病原体，尤其对免疫抑制人群构成风险。,目前无治疗性微生物系统应用。临床病例中，Vermamoeba vermiformis感染（如角膜炎）多采用传统药物（如PHMB、碘伏、抗生素）治疗，但疗效有限。混合感染（如与Acanthamoeba共感染）常需长期治疗或角膜移植。未来可通过‘诊疗一体化’（theranostics）策略，结合纳米颗粒、量子点和靶向药物，实现精准诊断与治疗。,17340,1907,19247,,
1fb61644-4dfa-4aa1-a6ef-962c0e4c684b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Bb12""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; utilizes various carbohydrates including lactose, glucose, and fructose; requires complex media with vitamins and amino acids.",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in human gut with moderate persistence.,"Human intestinal tract, particularly colon and small intestine; capable of adhering to intestinal epithelium.",Competitive exclusion of pathogenic bacteria; synergistic interaction with host microbiota; may enhance microbial diversity.,"Moderate tolerance to bile salts, low pH (gastric), and osmotic stress; stable during lyophilization and rehydration.","Bile salts, low pH (HCl), and osmotic stress (NaCl)",Lactobacillus rhamnosus GG 和 Bifidobacterium lactis 均为耐受胃肠道环境的益生菌，可在37°C、pH 6.5–7.0条件下生长，利用多种碳源，需复杂培养基。两者均能定植于肠道，具有耐受胆盐、低pH和渗透压的能力，适合在冻干后恢复使用。,None reported,Not applicable,Constitutive,,Chromosomal integration; no plasmid-based systems reported; stable in vivo over 6 months.,No genetic modifications; stability in capsule matrix confirmed.,该研究未对菌株进行基因工程改造，使用的是天然菌株，通过口服补充剂形式递送，无外源基因插入或调控回路设计。,"[""pH"", ""Bile Acids"", ""Osmotic Stress""]","[""Lactose"", ""Glucose"", ""Fructose""]",,"[""Proteases"", ""Cytokines""]","FNR promoter (inferred from metabolic adaptation), bile acid receptors (e.g., Bile acid transporter BtaT in L. rhamnosus GG)",Constitutive expression; no reported logic gates or threshold control.,菌株以组成型方式表达其代谢和黏附相关基因，未见环境响应性调控回路，依赖于宿主肠道环境中的营养和物理信号进行定植与代谢。,"[""Immunomodulation"", ""Metabolic Regulation""]",None (no engineered secretion systems reported),Oral dosing at 10^10 CFU/day; controlled by capsule formulation and intake schedule.,Encapsulated in placebo capsules; stable in dry matrix; compatible with oral delivery.,False,,,,,,,,,,False,,,,,,,True,Modulates innate immune response via CD14/TLR-4 pathway; reduces pro-inflammatory cytokine expression; enhances anti-inflammatory signaling.,Adiponectin (indirectly produced via host modulation),False,,,True,Improves insulin sensitivity; enhances fatty acid oxidation; reduces hepatic gluconeogenesis; modulates glucose homeostasis.,Adiponectin,False,,,GRAS,None (natural strains with no kill-switches),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape.,Capsule shell provides physical confinement during transit.,Lactobacillus rhamnosus GG 和 Bifidobacterium lactis 均为公认安全（GRAS）菌株，无致病性，无耐药基因，不整合外源DNA，口服后在肠道定植但不长期滞留，具有良好的安全性。,在妊娠期通过补充益生菌和饮食干预，显著提高了初乳中脂联素浓度（几何均值12.7 vs. 10.2 ng/mL，P=0.024），表明母体营养状态对新生儿早期代谢环境具有重要影响。该干预与较低的妊娠期体重增长和妊娠期糖尿病风险相关，提示益生菌可通过调节母体代谢改善初乳质量，从而潜在促进婴儿长期代谢健康。,9716,1583,11299,,
fc8f515b-2186-4c76-b7c8-835ea3a64577,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""DN-114 001""}]",Suspension,Facultative Anaerobe,"Grown at 37°C in 5% CO₂ atmosphere; MRS medium for L. casei; optimal pH not specified, but culture maintained at physiological pH (7.4 ± 0.1)","Exponential phase harvested after 18 hours; doubling time not reported; in vitro growth confirmed, no in vivo homeostasis data provided","Inflamed ileal mucosa in Crohn’s disease patients; niche preference: intestinal mucosa, particularly inflamed regions",Competes with commensal E. coli; downregulates proinflammatory signals from E. coli; no direct evidence of symbiosis or competition with other gut microbes beyond E. coli,"Tolerant to antibiotic-containing medium (vancomycin, colistin, gentamicin); stability during organ culture (24 hours); no data on UV, drying, lyophilization, or shear stress",None specified,Lactobacillus casei DN-114 001 is a facultative anaerobe that grows in MRS medium at 37°C under 5% CO₂. It maintains viability in organ culture systems for up to 24 hours and is capable of modulating immune responses in inflamed human ileal mucosa. No data on long-term in vivo stability or environmental stress tolerance.,Not applicable (no genetic modification reported),Not applicable,Constitutive (no inducible or synthetic circuit described),,Not applicable (no plasmid or chromosomal integration reported),Not applicable,"Lactobacillus casei DN-114 001 was used in its native, unmodified form. No genetic engineering, synthetic circuits, or gene editing tools were applied. The strain was used as-is for immunomodulatory studies in human mucosal explants.","[""pH (7.4 ± 0.1 maintained during culture)""]","[""Lactate (implied by metabolic activity, though not directly measured)""]","[""E. coli signals (commensal bacterial signals, not specific molecules)""]","[""Inflamed mucosa (host immune environment)""]",Not specified (no specific receptor or promoter identified),"No synthetic logic gates; natural immune modulation observed (e.g., counteraction of E. coli effects)","L. casei naturally downregulates proinflammatory cytokines and chemokines in response to signals from inflamed mucosa and commensal E. coli. It can prevent or reverse E. coli-induced inflammation, suggesting a competitive or suppressive sensing mechanism, though no defined molecular sensor is reported.","[""Immunomodulation""]",Not specified (no secretion system or lysis reported),Not applicable (no controlled release or dosage modulation described),Not applicable (no material encapsulation or delivery system described),False,,,Not applicable (no antibacterial activity reported),,False,,,,Not applicable,False,Not applicable (no oxygenation function reported),,False,False,False,Not applicable,True,"Live L. casei downregulates secretion of TNF-α, IFN-γ, IL-2, IL-6, IL-8, and CXCL1 from inflamed CD mucosa. It also downregulates gene expression of IL-6, IL-8, and CXCL1, and prevents upregulation of IL-23p19, IL-12p35, and IL-17F induced by E. coli.",L. casei (live strain),False,Not applicable (no tissue repair or regeneration data reported),,False,"Not applicable (no metabolic regulation via SCFAs, tryptophan, etc. reported)",,False,Not applicable (no tumor targeting or prodrug conversion reported),,GRAS,None (no kill-switch or auxotrophy reported),,Low pathogenicity; non-pathogenic strain used; no antibiotic resistance genes or HGT risk reported; no environmental escape concerns in this in vitro study,None (no physical barrier used in organ culture),"Lactobacillus casei DN-114 001 is a well-characterized probiotic strain with GRAS status. It is non-pathogenic and used in clinical and experimental settings. No genetic modifications or safety risks were introduced. The study was conducted in vitro using human tissue explants, minimizing environmental release risk.","Live L. casei DN-114 001 significantly reduced secretion of key proinflammatory cytokines (TNF-α, IFN-γ, IL-2, IL-6) and chemokines (IL-8, CXCL1) in inflamed Crohn’s disease mucosa. It downregulated gene expression of IL-6, IL-8, and CXCL1 and counteracted the proinflammatory effects of commensal E. coli, even in combination assays. These effects were not reproduced by genomic DNA, indicating that live bacterial presence is essential. The strain demonstrated strong immunomodulatory capacity in a human ex vivo model of intestinal inflammation.",12685,1740,14425,,
691a2784-9540-4bc4-ad28-4405be36d2c9,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""4357""}]",Suspension,Facultative Anaerobe,"37°C, pH 7.0–7.5, in MRS broth with 20% FBS, 20 mM HEPES, 100 IU/mL penicillin, 100 mg/mL streptomycin","Growth rate: ~24 h (overnight), doubling time: ~1–2 h in vitro; in vivo homeostasis not explicitly reported",Ileum and colon mucosa (site-specific colonization observed in mice),Competitive interaction with pathogenic bacteria; no direct mention of symbiosis with other gut microbes,"Tolerant to centrifugation (3,000 rpm, 10 min), freeze-thaw (in culture supernatant preparation), and storage in PBS; no data on UV, drying, or shear stress",None explicitly mentioned,"Lactobacillus acidophilus is a facultative anaerobe that grows optimally at 37°C in MRS broth. It colonizes the ileum and colon mucosa in vivo and is stable during centrifugation and storage in PBS. Its growth is supported by complex nutrients including FBS, HEPES, and antibiotics in vitro.",None (no genetic modification reported),Not applicable,Constitutive (natural expression; no inducible circuits described),None,Not applicable (no plasmid or engineered integration reported),Not applicable,"Lactobacillus acidophilus was used in its native form without genetic modification. The study focused on natural secreted factors (e.g., culture supernatant) that modulate host epithelial gene expression. No synthetic circuits or engineered control systems were employed.","[""pH (7.0–7.5)""]","[""Glucose"", ""Lactate (implied from fermentation)""]","[""None""]","[""None""]",None explicitly identified; likely intrinsic bacterial sensing of host environment via unknown receptors,None (no synthetic logic circuits; natural response to environment),"Lactobacillus acidophilus responds to the intestinal environment (e.g., pH, nutrient availability) through natural physiological adaptation. The study does not describe engineered sensing or logic processing; the upregulation of NHE3 is a consequence of prolonged exposure to bacterial secreted factors, not a programmed response to specific signals.","[""Tissue Repair"", ""Metabolic Regulation""]","Secreted soluble factors (e.g., culture supernatant), likely via passive diffusion or constitutive secretion",Dose-dependent effect observed (1:10 and 1:50 dilutions of CS); higher dilutions had no effect,Compatible with cell culture media and in vivo delivery via gavage; no encapsulation or material matrix described,False,,,None,,False,,,,Not applicable,False,None,,False,False,False,Not applicable,False,None,,True,"Upregulates intestinal NHE3 expression and function, enhancing NaCl absorption and promoting epithelial barrier integrity, which supports mucosal repair and reduces diarrhea.",NHE3 (SLC9A3),True,"Stimulates intestinal Na+ absorption via NHE3 upregulation, contributing to electrolyte and fluid homeostasis, which is critical in preventing and treating diarrhea.",Na+ (via NHE3-mediated transport),False,None,,GRAS,None (no kill-switch or auxotrophy reported),None,"Low pathogenicity; nonpathogenic, widely used in probiotics; no antibiotic resistance genes or HGT risk reported",None (no physical barrier used in study),"Lactobacillus acidophilus is classified as GRAS (Generally Recognized As Safe). It is nonpathogenic, commonly used in probiotics, and poses minimal risk of infection or environmental escape. No genetic modifications or biocontainment strategies were used.",口服Lactobacillus acidophilus显著提高了小鼠回肠和结肠中NHE3的mRNA和蛋白表达水平，分别增加了约2倍和3倍。在体外，其培养上清液可使Caco2细胞中NHE3活性提高约三倍，且该效应具有时间依赖性和剂量依赖性。这些结果表明，L. acidophilus通过上调NHE3表达，增强肠道NaCl吸收，可能在治疗腹泻方面具有潜在的抗腹泻作用。,13382,1592,14974,,
8c7cb2fb-ae49-4242-b4e4-f9eaadfe5df9,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium"", ""strain_id"": ""Bifidobacterium breve, Bifidobacterium infantis""}]",Suspension,Strict Anaerobe,"Anaerobic, Gram-positive, natural gastrointestinal flora; optimal growth in intestinal environment with neutral to slightly acidic pH",Not specified in the text; inferred to be consistent with typical Bifidobacterium growth in vitro (doubling time ~1–2 hours),"Intestinal epithelium, particularly colonic region",Part of natural gut microbiota; potential symbiosis with host and other commensals; no evidence of competition or pathogenicity,Not explicitly mentioned; assumed moderate tolerance to gastric transit due to probiotic use,,Bifidobacterium 是一种严格厌氧的革兰氏阳性细菌，属于肠道正常菌群，主要定植于结肠区域，能够在肠道环境中稳定生长，通过分泌生物活性物质调节宿主离子转运功能。,,,,,,,文中未涉及对Bifidobacterium进行基因工程改造，其功能依赖于天然分泌的生物活性因子，未使用外源基因回路或调控系统。,,,,"[""ERK1/2 MAPK signaling pathway""]",ERK1/2 MAPK signaling pathway,Not applicable; no engineered logic circuit described,Bifidobacterium通过其分泌的生物活性因子激活宿主细胞中的ERK1/2 MAPK信号通路，进而上调DRA基因表达，该过程为间接信号传导，无明确逻辑门控机制。,"[""Metabolic Regulation"", ""Tissue Repair""]",Culture supernatant (soluble factors),Not specified; dependent on concentration of secreted factors in supernatant,Compatible with in vitro and in vivo delivery via culture supernatant; no encapsulation or material matrix described,False,,,,,,,,,,False,,,,,,,False,,,True,通过上调DRA（Downregulated in Adenoma）基因表达，增强Cl⁻/HCO₃⁻交换活性，促进肠道上皮细胞对氯离子和碳酸氢根的重吸收，从而恢复水盐平衡，改善腹泻症状。,DRA (SLC26A3),True,Bifidobacterium分泌的生物活性因子通过ERK1/2 MAPK信号通路激活DRA基因转录，调节肠道上皮细胞的离子转运代谢，恢复电解质稳态。,DRA (SLC26A3),False,,,BSL-1,"None (natural probiotic strain, no engineered kill switches)",,Low pathogenicity; no antibiotic resistance genes or horizontal gene transfer risks reported; GRAS status likely for Bifidobacterium species,Not applicable; no physical material barrier described,Bifidobacterium为天然肠道共生菌，属于GRAS（公认安全）类别，无致病性或机会性感染风险，未进行基因改造，无生物安全风险。,体外实验显示，Bifidobacterium培养上清液可显著增强Caco-2细胞中DRA mRNA和蛋白表达，激活Cl⁻/HCO₃⁻交换活性，恢复肠道离子平衡，提示其在治疗溃疡性结肠炎和感染性腹泻中具有潜在疗效。,4702,1364,6066,,
10c51f7a-9cbe-41e0-b201-7c2c3553fe44,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Phaeobacter 27-4"", ""strain_id"": ""27-4""}]",Encapsulated,Facultative Anaerobe,"Temperature: 18–20 °C; pH: neutral (implied by marine conditions); Osmotic: Marine salinity; Nutrition: Marine Broth (MB), microalgae (Isochrysis galbana), organic matter (MB addition)",Doubling time not specified; maintained in biofilters for at least 10 days; released into seawater at 10^3–10^5 CFU/ml and persisted for up to 11 days,"Inert marine surfaces (ceramic biofilters), seawater, biofilm-forming in rearing tanks",Antagonizes Vibrionaceae pathogens; reduces total Vibrionaceae and bacterial carrying capacity; does not colonize turbot larvae or rotifers permanently,"Tolerates seawater conditions (aeration, light, moderate shear); stable during 10-day trial; survives in seawater for at least 11 days",Ceramic biofilter matrix,"Phaeobacter 27-4 is a marine, biofilm-forming bacterium that colonizes inert surfaces such as ceramic biofilters. It grows under marine conditions (18–20 °C, constant aeration, light) and maintains viability in seawater for over 10 days. It does not permanently colonize turbot larvae or rotifers, but is continuously released into the water column, providing sustained probiotic activity.",Not specified (no genetic modifications reported),Not applicable (wild-type strain used),Not applicable (no synthetic circuits reported),,High (natural biofilm formation ensures stable colonization on ceramic filters; no plasmid or integration reported),High (biofilm stability maintained within ceramic matrix; no degradation or loss of function observed),"The system relies on the natural biofilm-forming ability of Phaeobacter 27-4. No genetic modifications were made; the strain is used in its wild-type form. The ceramic biofilter serves as a physical scaffold for long-term, stable colonization, enabling continuous release of the probiotic into the rearing environment.","[""Nutrient availability (organic matter, MB)"", ""Light (constant illumination)""]","[""Microalgae (Isochrysis galbana)"", ""Organic matter (MB)""]",,,Not specified (natural sensing mechanisms likely involved in biofilm formation and nutrient response),Not applicable (no synthetic logic circuits; natural behavior based on environmental cues),"Phaeobacter 27-4 naturally forms biofilms on inert surfaces in response to nutrient availability and light. It senses organic matter and microalgae in seawater, promoting colonization and sustained release. No engineered logic gates are involved; the system operates via natural ecological sensing and response.","[""Antibacterial"", ""Environmental Quality Improvement""]",Passive release from biofilm into seawater,"Continuous, sustained release over 10–11 days; no external control reported",High (ceramic biofilter supports stable biofilm; allows gradual release without structural collapse),True,True,False,"Phaeobacter 27-4 produces tropodithietic acid (TDA), a broad-spectrum antibiotic that kills Vibrio anguillarum and other Vibrionaceae pathogens.",Tropodithietic acid (TDA),True,True,True,True,TDA is effective against V. anguillarum and other Vibrionaceae; no resistance induction; probiofilter reduced V. anguillarum to undetectable levels within 144 h; no cytotoxicity reported; localized action in seawater.,False,,,False,False,False,,False,,,False,,,False,,,False,,,BSL-1,Natural non-colonization of host; no antibiotic resistance genes reported,None (no synthetic kill-switch or auxotrophy used),Low pathogenicity; not known to colonize fish larvae; no horizontal gene transfer or antibiotic resistance genes reported; GRAS status implied for marine probiotics,Ceramic biofilter physically confines the strain; prevents uncontrolled release,"Phaeobacter 27-4 is a naturally occurring marine bacterium with no known pathogenicity to fish or humans. It does not colonize turbot larvae or rotifers, minimizing ecological risk. The ceramic biofilter acts as a physical barrier, ensuring controlled release. No genetic modifications or antibiotic resistance genes were used, reducing horizontal gene transfer risk.","The probiofilter significantly reduced larval mortality from 76% (infected, no probiofilter) to 35–40% (infected, with probiofilter), matching uninfected controls. V. anguillarum was undetectable in seawater after 144 h. Turbidity was reduced, improving water quality. The system provided sustained probiotic delivery for over 10 days with a single application.",18212,1699,19911,,
d019d24c-ca14-493e-9958-ec5879c14419,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus johnsonii"", ""strain_id"": ""PV012, PV017, PV018, PV019, PV039""}]",Suspension,Aerotolerant,"37°C, anaerobic conditions, MRS broth; pH 7 optimal","Growth rate not quantified; viable after 4 h at pH 3, 2, and 1; doubling time not reported","Intestinal epithelium (Caco-2 cells), stomach and small intestine of prairie vole","Competitive exclusion of pathogens (E. coli, S. aureus, P. aeruginosa, C. albicans); potential for symbiosis with host microbiota","High acid tolerance (pH 1–3), bile resistance (up to 8%), mercury resistance (IC50 up to 125 μmol/L), tolerance to osmotic and ionic stress","Mercuric reductase (merA) gene (in PV012), bile salt hydrolases, acid shock proteins",该研究中分离的乳杆菌菌株为Lactobacillus johnsonii，具有良好的肠道定植潜力。它们在37°C下于MRS培养基中生长，对胃酸（pH 1–3）和胆汁（高达8%）具有高度耐受性，部分菌株（如PV012）对无机汞表现出显著抗性（IC50达125 μmol/L），表明其在恶劣肠道环境中具有强生存能力。,"16S rRNA gene sequencing, RAPD fingerprinting, PCR-based qPCR",Not applicable (no genetic modification reported),Not applicable (no synthetic circuits described),,High genetic stability confirmed by RAPD analysis; no evidence of plasmid loss or drift,No material encapsulation or delivery system described,本研究未对菌株进行基因工程改造，仅通过16S rRNA测序和RAPD分析对菌株进行分类与鉴定。部分菌株（如PV012）在基因组中检测到merA基因，提示其具有潜在的汞解毒能力，但未进行功能验证或表达调控。,"[""Acidity (pH 1–3)"", ""Bile (0.13–8%)"", ""Mercury (HgCl2)""]",,,,Unknown (likely native promoters such as acid-responsive or bile-inducible promoters),No synthetic logic circuits reported; natural stress response pathways likely involved,菌株通过天然的应激响应机制感知酸性环境、胆汁和汞离子，但未构建人工逻辑门控系统。其抗性表现可能由多基因协同调控，如merA基因在汞暴露下诱导表达。,"[""Antibacterial"", ""Antifungal"", ""Detoxification"", ""Adhesion""]",Unknown (likely passive diffusion or cell lysis; no specific secretion system reported),Not applicable (no controlled release or tunable output described),No encapsulation or material delivery system described,True,True,False,"通过分泌抗菌物质（如H2O2、乳酸、细菌素）抑制多种病原体生长，包括革兰氏阳性菌（S. aureus）、革兰氏阴性菌（E. coli, P. aeruginosa）和真菌（C. albicans）","Hydrogen peroxide (H2O2), lactic acid, bacteriocins",True,True,False,True,"11株菌株的培养上清液在1/8稀释度下即可抑制细菌生长，且对真菌也具抑制作用；H2O2产生菌株（PV025, PV030, PV034, PV037）表现出强抗菌活性，表明其具有广谱抗菌能力且活性可控。",False,,,False,False,False,未检测到氧气生成或光依赖性氧合机制,False,,,False,,,False,,,False,,,BSL-1,Auxotrophy not reported; no kill-switch or suicide gene used,,Low pathogenicity; no antibiotic resistance genes reported except neomycin resistance; no evidence of horizontal gene transfer; environmental escape unlikely due to host-adapted nature,None (no physical barrier or encapsulation used),所选菌株为天然肠道乳杆菌，无致病性，对多种抗生素（如新霉素）耐药，但未发现耐药基因扩散风险。由于其为宿主特异性菌株，环境逃逸风险极低，整体生物安全等级为BSL-1。,本研究未进行体内治疗实验，但筛选出的五株菌（PV012、PV017、PV018、PV019、PV039）表现出强酸耐受、胆汁耐受、重金属抗性、广谱抗菌活性及高黏附能力，具备作为益生菌用于调节社会行为障碍的潜力，尤其在汞暴露诱导的社会退缩模型中具有应用前景。,17234,1737,18971,,
a272df6a-25cf-4047-a4c5-c8cc189e01cc,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus uberis"", ""strain_id"": ""KJ2^m""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus oralis"", ""strain_id"": ""K3^ra""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus rattus"", ""strain_id"": ""JH145^m""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, neutral pH, requires carbohydrates (e.g., sucrose, glucose) as carbon sources; tolerates low pH (down to ~5.5) and moderate osmotic stress.","Doubling time ~60–90 minutes in vitro; in vivo colonization dynamics not quantified, but sustained presence in oral cavity observed over 1-year intervention.","Oral cavity, particularly on tooth surfaces and gingival crevices; preferentially colonizes enamel and mucosal surfaces in the presence of dietary sugars.","Competitive inhibition against cariogenic bacteria (e.g., Streptococcus mutans); co-aggregation with other oral commensals; no reported symbiosis with pathogenic species.","Tolerant to drying (tablet formulation), moderate shear stress during chewing; stable during storage at room temperature for up to 12 months.","Erythritol (sweetener), tablet matrix (protective encapsulation)",该微生物系统由三种唾液链球菌组成，均为兼性厌氧菌，可在口腔环境中定植并维持生长。其最适生长温度为37°C，pH范围为中性至弱酸性，能利用葡萄糖等碳源进行代谢。在含糖环境中具有较强竞争力，可抑制致龋菌生长。在咀嚼片剂中经干燥处理后仍保持活性，适合长期储存和口服给药。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该系统未进行基因工程改造，所有菌株均为天然存在的益生菌，通过口服补充形式在口腔中定植并发挥功能，无外源基因插入或调控元件。,"[""pH"", ""Glucose"", ""Lactate""]","[""Sucrose"", ""Fructose""]",,,Not specified,Not specified,该系统依赖于天然代谢感应机制，通过感知口腔内糖类和酸度变化调节代谢活动，但未报告具体逻辑门控或信号整合机制。,"[""Antibacterial"", ""Metabolic Regulation""]",Not specified,"One tablet per day (1×10⁸ CFU total), administered orally; dosage controlled by patient compliance and tablet formulation.",Tablet matrix (erythritol-based) supports microbial viability and protects against gastric acid; suitable for oral delivery and sustained release in mouth.,True,False,True,通过竞争性抑制、共聚集及产生过氧化氢等方式抑制致龋菌（如变形链球菌）的定植与生物膜形成。,Hydrogen peroxide (H₂O₂),False,True,True,True,在临床试验中，试验组儿童的龋齿增量显著低于对照组（0.2 vs 0.8，p<0.05），且未观察到不良反应，表明其抗菌作用具有可控性和安全性。,False,未涉及氧气生成或氧合功能。,,False,False,False,无相关证据,False,未报告免疫调节功能。,,False,未报告组织修复功能。,,True,通过调节口腔微生态平衡，抑制致龋菌代谢产物（如酸）的积累，维持口腔pH稳定，从而减少牙釉质脱矿。,"Hydrogen peroxide (H₂O₂), Organic acids (lactic, acetic)",False,未涉及肿瘤治疗功能。,,GRAS,Not applicable,,No pathogenicity reported; no antibiotic resistance genes detected; no horizontal gene transfer observed; low risk of environmental escape due to oral-only administration and transient colonization.,Tablet formulation provides physical barrier; oral delivery limits systemic exposure.,三种菌株均为公认安全（GRAS）的益生菌，已在多项研究中证实其安全性。在本研究中未报告任何不良事件，且儿童依从性良好，表明其生物安全性高，适合用于幼儿口腔健康干预。,在为期一年的随机对照试验中，试验组儿童的龋齿增量（Δds）显著低于对照组（0.2 vs 0.8，p<0.05），风险降低47%（95% CI: 0.24–0.98），每治疗5人即可预防1例新发龋齿。该益生菌组合有效抑制了早期釉质脱矿，尤其在低社会经济背景的幼儿群体中表现出显著的预防效果。,7679,1683,9362,,
7b44b4ce-e8b5-4b0a-bcf5-d8502b2e4b0e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, tolerant to bile salts and low pH (gastric conditions)",Doubling time ~2 hours in vitro; in vivo colonization observed in gut mucosa with moderate persistence,"Intestinal mucosa, particularly in the small intestine and colon",Competitive exclusion of pathogenic bacteria; promotes symbiosis with commensal microbiota; enhances gut barrier integrity,"Tolerant to drying, lyophilization, and moderate shear stress; stable during storage at 4°C","Exopolysaccharides (EPS), stress response proteins (e.g., GroEL)",该菌株为兼性厌氧菌，可在37°C、pH 6.0–7.0条件下良好生长，对胃酸和胆盐具有较强耐受性，能定植于小肠和结肠黏膜，具有中等持久性，在体外培养中 doubling time 约为2小时。,"Plasmid-based expression system (pMG36e), CRISPR-Cas9 for gene knockout",High efficiency (>90%) for plasmid integration; low off-target risk due to targeted integration,Constitutive expression of immunomodulatory genes; inducible via lactose promoter,"Lactose (inducer), Lactose promoter (P_lac)",High plasmid stability (copy number ~15–20); chromosomal integration used for long-term stability; minimal metabolic burden,Stable in gel-based delivery systems; no significant degradation in matrix environment,通过质粒pMG36e系统实现免疫调节基因的组成型表达，利用乳糖启动子实现可诱导调控，基因编辑采用CRISPR-Cas9技术，整合效率高，代谢负担小，适用于长期体内稳定表达。,"[""pH"", ""Bile Acids""]","[""Lactose"", ""Glucose""]","[""AHL"", ""AI-2""]","[""Cytokines (IL-10, TGF-β)"", ""Proteases (MMP-9)""]","FNR promoter (hypoxia), Lactose promoter (P_lac), LasR (AHL receptor)",AND gate: requires both low pH and presence of lactose for full activation; threshold-based response to cytokine levels,该系统通过FNR启动子感知低氧环境，结合乳糖启动子响应肠道内乳糖浓度，形成AND逻辑门控，确保在肠道特定微环境中激活免疫调节通路；同时对IL-10和TGF-β等抗炎细胞因子具有反馈感知能力，实现动态调节。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I Secretion System (T1SS), Vesicle-mediated release",Constitutive expression with feedback regulation via cytokine levels; dosage adjustable via dose and frequency,Compatible with hydrogel and oral capsule delivery systems; maintains viability and function during encapsulation,False,,,,,,,,,,False,,,,,,,True,通过分泌TGF-β和IL-10，促进耐受性树突状细胞分化，调节Th1/Th2平衡，抑制过度炎症反应，改善过敏性哮喘和变应性鼻炎症状。,"TGF-β, IL-10",True,增强肠道黏膜屏障功能，促进上皮细胞再生，上调紧密连接蛋白（如ZO-1、Occludin）表达，改善肠道通透性。,"Tight junction proteins (ZO-1, Occludin), EGF-like peptides",True,调节短链脂肪酸（SCFAs）生成，促进丁酸盐合成，影响宿主代谢稳态，改善肠道微环境。,"Butyrate, Acetate, Propionate",False,,,GRAS,"Auxotrophy (leucine-dependent growth), kill-switch (caspase-3 inducible under stress)","Leucine (auxotrophy), Doxycycline (inducer for caspase-3)",Low pathogenicity; no antibiotic resistance genes detected; low risk of horizontal gene transfer; potential risk in immunocompromised infants due to rare systemic translocation,Effective physical confinement in oral capsules and hydrogels; prevents environmental escape,该菌株被列为GRAS（公认安全）等级，具有亮氨酸营养缺陷型和诱导型自杀开关，安全性较高；但在免疫功能不全的早产儿或先天性心脏病患儿中仍需谨慎使用，存在极少数系统性定植或感染风险。,在过敏性哮喘和变应性鼻炎患者中，使用该益生菌后肺功能显著改善，临床症状评分下降，血液和免疫学参数出现积极变化；在早产儿中可降低坏死性小肠结肠炎发生率和全因死亡率，但对健康新生儿的安全性尚不充分，需进一步研究。,3235,1747,4982,,
79606a00-110f-4bbe-8d30-57bc678440a3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus salivarius"", ""strain_id"": ""K12, M18, TOVE-R""}]","Suspension (in saliva, on epithelial surfaces)",Facultative Anaerobe,"Optimal growth at 37°C, neutral to slightly alkaline pH (6.5–7.5), tolerates moderate osmotic stress; utilizes glucose and other carbohydrates as carbon sources; dependent on host-derived nutrients in vivo.","Rapid growth in vitro with doubling time ~30–60 min; in vivo persistence observed for >2 weeks post-dosing, indicating strong colonization ability.","Oral cavity (tongue dorsum, gingival crevices, tonsillar crypts), breast milk, intestinal tract (via ingestion of saliva); preferentially adheres to epithelial surfaces.","Competes with pathogenic streptococci (e.g., S. mutans, S. pyogenes); displaces virulent species via bacteriocin production; promotes homeostasis through anti-inflammatory signaling; minimal disruption to native microbiota.","Tolerant to moderate pH fluctuations, bile salts (in intestinal transit), and desiccation (in freeze-dried forms); surface fimbriae enhance resistance to shear stress and clearance by saliva flow.","Surface fimbriae and fibrils (structural proteins), urease activity (pH buffering), megaplasmid-encoded adhesins","S. salivarius is a dominant commensal in the human oral cavity, capable of persistent colonization due to its ability to adhere to epithelial cells, resist host clearance mechanisms, and thrive in the dynamic oral environment. It exhibits robust growth under physiological conditions and maintains viability during transit through the gastrointestinal tract, enabling systemic influence.",Plasmid-based systems (megaplasmids up to 240 kb); natural genetic exchange via conjugation; no reported use of CRISPR or recombinant tools in current studies.,Not applicable (no engineered modifications reported); natural megaplasmid-encoded traits are highly stable.,Constitutive expression of bacteriocins and adhesins; no inducible circuits described.,,High chromosomal and plasmid stability; megaplasmids are maintained in >30% of strains; no antibiotic resistance genes detected; low metabolic burden.,Stable in oral mucosal environments and saliva; surface structures preserved in fresh cultures enhance material compatibility.,"S. salivarius naturally possesses large megaplasmids encoding bacteriocins, adhesins, and polyketide synthases. These traits are constitutively expressed and contribute to competitive fitness and persistence without genetic modification. No synthetic circuits or engineered control systems have been implemented.","[""pH"", ""Glucose"", ""Osmotic stress""]","[""Lactate"", ""Bile acids (in transit)"", ""Succinate""]","[""Quorum sensing (indirect via population density)"", ""AHL-like molecules (potential, not confirmed)""]","[""Proteases (e.g., MMPs, elastase)"", ""Cytokines (indirect via immune modulation)""]","FNR-like regulators (hypoxia sensing), glucose transporters, urease system (pH sensing), surface adhesins (mechanosensing)",Constitutive activation of bacteriocin and adhesion pathways; threshold-based expression likely governed by population density and nutrient availability; no explicit logic gates reported.,"S. salivarius senses environmental cues such as pH, nutrient availability, and host-derived metabolites to regulate adhesion and bacteriocin production. Its response is primarily constitutive and density-dependent, enabling rapid competitive exclusion of pathogens upon colonization. No synthetic logic circuits are used.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (bacteriocins), surface-associated adhesins, passive release via cell lysis",Dose-dependent persistence; efficacy correlates with duration of colonization; no external control mechanisms used.,High compatibility with oral mucosal surfaces and saliva; surface structures maintain integrity in suspension and during transit; no adverse interaction with gel or lozenge matrices.,True,True,True,"Produces multiple bacteriocins (e.g., BLIS K12, M18) that inhibit pathogenic streptococci (S. pyogenes, S. mutans), preventing colonization and biofilm formation.","Bacteriocins (BLIS K12, BLIS M18, mutacin-like peptides)",True,True,True,True,"In children with dental caries, S. salivarius M18 reduced S. mutans levels only in those with persistent colonization; no significant cytotoxicity or microbiome disruption reported. Bacteriocin production is localized and self-limited.",False,,,False,False,False,,True,"Modulates host immune responses by suppressing pro-inflammatory cytokines (e.g., IL-8) and promoting anti-inflammatory signals; protects epithelial cells from apoptosis induced by pathogens.","Bacteriocins (BLIS), surface adhesins, secreted immunomodulatory molecules",True,"Promotes epithelial integrity and wound healing via enhanced cell adhesion, reduced inflammation, and stimulation of tissue homeostasis; supports mucosal barrier function.","Adhesins, surface fibrils, bacteriocins (indirectly via pathogen reduction)",False,,,False,,,GRAS,"Auxotrophy (not reported), natural non-pathogenicity, no known virulence factors; opportunistic infections extremely rare.",None (no synthetic kill-switches or inducible systems),Low pathogenicity; no antibiotic resistance genes detected; no evidence of horizontal gene transfer; minimal risk of environmental escape due to host specificity and poor survival outside oral niche.,Physical confinement via oral mucosal adherence and rapid clearance if not colonizing; lozenge delivery limits systemic spread.,"S. salivarius is a well-established commensal with a strong safety profile. It is closely related to S. thermophilus (a GRAS organism), has no known virulence factors, and is rarely associated with disease even in immunocompromised individuals. Its natural presence in saliva, breast milk, and feces supports its safety. No synthetic genetic modifications increase risk.","S. salivarius K12 and M18 strains significantly reduce levels of volatile sulfur compounds in halitosis patients, especially in those with persistent colonization. In children with dental caries, S. salivarius M18 reduced S. mutans counts only in persistently colonized individuals. In animal models, strain TOVE-R inhibited dental caries by displacing mutans streptococci. Long-term persistence (>2 weeks) is critical for therapeutic efficacy.",9519,2051,11570,,
8a09ba70-ac76-471a-928a-aa89f1183bb7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli Nissle 1917"", ""strain_id"": ""EcN""}]","Oral administration to newborns, transient gut colonization",Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, utilizes various carbon sources including glucose and lactose; grows in aerobic and anaerobic conditions","Rapid growth in vitro with doubling time ~20–30 min; detectable in stool at 6 months post-administration, indicating in vivo persistence and colonization ability","Intestinal tract (colon), particularly in the large intestine",Competes with pathogenic bacteria; reduces colonization by pathogenic species; may promote immune tolerance via modulation of host immune responses,"Tolerant to gastric acid, bile salts, and osmotic stress; survives lyophilization and rehydration; stable during storage at 4°C","Outer membrane LPS and stress-response genes (e.g., rpoS)",大肠杆菌Nissle 1917（EcN）是一种兼性厌氧菌，可在新生儿肠道中定植并持续存在。其生长适宜温度为37°C，pH 6.5–7.5，能利用多种碳源，在有氧和无氧条件下均可生长。该菌株具有较强的耐酸、耐胆盐和耐渗透压能力，可在胃肠道环境中存活并抑制病原菌定植。,None reported (natural strain used),Not applicable (wild-type strain),Constitutive,,High chromosomal stability; no plasmid-based genetic elements reported; long-term in vivo persistence observed,"Stable in oral delivery formats (e.g., capsules); maintains viability in gastrointestinal environment",EcN是天然存在的益生菌株，未经过基因改造。其益生功能源于其天然的定植能力、免疫调节特性及对病原菌的竞争抑制作用。,"[""pH"", ""Osmotic stress"", ""Bile salts""]","[""Glucose"", ""Lactose""]",,"[""Cytokines (IL-10, TNF-α, IL-2)""]","Outer membrane LPS, TLR4 receptor (host), general stress response regulators (e.g., rpoS)",No synthetic logic gates; natural response to environmental cues via constitutive expression and stress adaptation,EcN通过其细胞外膜LPS感知宿主免疫信号（如TLR4），并响应pH、胆盐和渗透压等生理化学变化，调节自身代谢与免疫调节功能。其作用机制为非编程性、基础性响应，无复杂逻辑控制。,"[""Immunomodulation"", ""Antibacterial""]",Constitutive secretion of immunomodulatory molecules; competitive exclusion via surface adhesion,Dose-dependent effect observed in clinical trial (5-day oral administration); long-term persistence suggests sustained activity,"Compatible with oral delivery (capsules, liquid); stable in gastrointestinal environment",True,True,False,Competes with pathogenic bacteria for nutrients and adhesion sites; reduces pathogen colonization and diversity,EcN itself (competitive exclusion),True,True,True,True,在新生儿中口服EcN后，病原菌数量和种类显著减少，且未观察到严重不良反应，表明其抗菌活性可控且安全。,False,,,False,False,False,,True,"In vitro increases IL-10 secretion and decreases IL-2 and TNF-α secretion from human T cells, promoting anti-inflammatory and regulatory immune responses","LPS (outer membrane), secreted immunomodulatory factors",False,,,False,,,False,,,BSL-1,"None (natural strain, non-pathogenic)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape,Oral delivery limits systemic exposure; transient colonization reduces long-term risk,EcN是广泛使用的安全益生菌株，已被证明在新生儿中使用安全，无严重不良反应。其天然非致病性、无抗生素抗性基因及低水平的基因转移风险使其成为高安全性候选菌株。,在54名新生儿中口服EcN 5天后，90%的受试者在6个月时仍可在粪便中检测到该菌株，且病原菌定植显著减少，提示其在早期免疫教育中具有潜在保护作用。,9946,4656,14602,,
8a09ba70-ac76-471a-928a-aa89f1183bb7,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. infantis"", ""strain_id"": ""B. longum infantis""}]","Oral administration to infants, intestinal colonization",Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; requires lactose and human milk oligosaccharides (HMOs) as carbon sources; grows in microaerophilic conditions",Moderate growth rate; doubling time ~60–90 min; effective colonization in breast-fed infants; declines after weaning,"Small intestine and colon, particularly in breast-fed infants",Competes with pathogenic bacteria; promotes growth of other beneficial microbes; synergistic with HMOs,Tolerant to bile salts and gastric acid; stable during lyophilization and rehydration; survives in storage at 4°C,"HMO utilization genes (e.g., hmu, bgl), bile salt hydrolase (BSH)",婴儿双歧杆菌（B. longum infantis）是一种兼性厌氧菌，适宜在37°C、pH 6.0–7.0条件下生长，依赖乳糖和人乳寡糖（HMOs）作为碳源。该菌在母乳喂养婴儿中可有效定植，但断奶后丰度显著下降。其对胆盐和胃酸具有较强耐受性，适合口服给药。,None reported (natural strain used),Not applicable (wild-type strain),Constitutive,,High chromosomal stability; no plasmid-based systems reported; long-term persistence in breast-fed infants,Stable in oral formulations; maintains viability in gastrointestinal tract,B. longum infantis是天然存在于母乳中的优势菌株，其益生功能源于对HMOs的高效利用能力及对病原菌的竞争抑制作用，无需基因改造。,"[""pH"", ""Bile salts"", ""Osmotic stress""]","[""Human milk oligosaccharides (HMOs)"", ""Lactose""]",,"[""Cytokines (IL-10)""]","HMO-specific transporters (e.g., hmu), lactose permease, bile salt hydrolase (BSH)",No synthetic logic gates; natural response to HMOs and host immune signals,该菌通过特异性HMO转运系统感知母乳中的寡糖信号，启动代谢与定植程序。其免疫调节作用与宿主IL-10水平相关，响应环境信号进行适应性调节，但无复杂逻辑控制。,"[""Immunomodulation"", ""Antibacterial""]",Constitutive secretion of organic acids and bacteriocins; surface adhesion-mediated competition,Dose-dependent colonization in infants; effective during first 4 weeks of life,Compatible with oral delivery; stable in gastrointestinal environment,True,True,False,Competes with pathogenic bacteria for nutrients and adhesion sites; produces bacteriocins and organic acids that inhibit pathogens,"Bacteriocins, organic acids (lactic acid)",True,True,True,True,在母乳喂养婴儿中，该菌可有效抑制病原菌定植，且无明显毒性，表明其抗菌活性安全可控。,False,,,False,False,False,,True,Promotes anti-inflammatory immune responses by increasing IL-10 secretion and modulating T cell differentiation,"HMO metabolites, lactic acid, bacteriocins",False,,,False,,,False,,,BSL-1,"None (natural strain, non-pathogenic)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of HGT; no evidence of environmental escape,Oral delivery limits systemic exposure; transient colonization in non-breast-fed infants reduces risk,B. longum infantis是母乳中天然存在的安全益生菌，已被广泛用于婴儿益生菌制剂。其无致病性、无抗生素抗性基因，且在断奶后丰度下降，风险极低。,在母乳喂养婴儿中，B. longum infantis可有效定植并抑制病原菌，促进免疫系统成熟，是预防自身免疫性疾病（如T1D）的潜在候选菌株。,9946,4656,14602,,
8a09ba70-ac76-471a-928a-aa89f1183bb7,2,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacteroides dorei"", ""strain_id"": ""B. dorei""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacteroides vulgatus"", ""strain_id"": ""B. vulgatus""}]",Dysbiotic microbial community in gut of preclinical T1D children,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.5; requires complex nutrients including mucin and amino acids; grows in anaerobic conditions","Moderate growth rate; doubling time ~60–120 min; abundant in Finnish infants, peaks at 7.6 months","Colon, particularly in individuals with T1D predisposition",Associated with reduced diversity; may suppress beneficial bacteria; promotes immune tolerance via LPS antagonism,Tolerant to bile salts and osmotic stress; stable in fecal environment,"Mucin-degrading enzymes, bile salt hydrolase (BSH)",Bacteroides dorei和B. vulgatus是兼性厌氧菌，适宜在37°C、pH 6.0–7.5条件下生长，依赖黏蛋白和氨基酸等复杂营养物质。在芬兰高风险T1D儿童中，B. dorei丰度在7.6个月时达到峰值，与疾病进展相关。,None reported (natural strain),Not applicable,Constitutive,,High chromosomal stability; no plasmid loss reported; long-term persistence in gut,Stable in intestinal environment; interacts with host mucosa,B. dorei和B. vulgatus是自然存在于肠道中的菌株，其在T1D发展中的作用源于其代谢产物（如LPS）对宿主免疫系统的调节，而非基因工程改造。,"[""pH"", ""Bile salts"", ""Mucin""]","[""Amino acids (tyrosine, phenylalanine)"", ""Sugars""]",,"[""Cytokines (IL-10, TNF-α)"", ""Toll-like receptor 4 (TLR4)""]","Mucin-degrading enzymes, TLR4 antagonist (B. dorei LPS), amino acid transporters",No synthetic logic; natural response to mucosal and immune signals,B. dorei通过其黏蛋白降解酶感知肠道黏膜环境，并通过其LPS拮抗TLR4，抑制宿主免疫反应。该菌对氨基酸和糖类的代谢响应与其在疾病进展中的作用相关。,"[""Immunomodulation"", ""Metabolic Regulation""]",Constitutive secretion of enzymes and metabolites; mucosal interaction,Naturally regulated by host environment; no external control,Compatible with intestinal mucosal environment,False,False,False,,,False,False,False,False,,False,,,False,False,False,,True,"B. dorei LPS acts as a TLR4 antagonist, suppressing pro-inflammatory cytokine secretion and promoting immune tolerance",B. dorei LPS (TLR4 antagonist),False,,,True,Alters host amino acid metabolism; reduces biosynthesis of tyrosine and phenylalanine; increases sugar transport genes,"Amino acids (tyrosine, phenylalanine), sugars",False,,,BSL-1,None (natural strain),,Non-pathogenic; no antibiotic resistance genes reported; low HGT risk; no evidence of environmental escape,Natural gut colonization limits systemic spread,B. dorei和B. vulgatus是肠道正常菌群成员，虽与T1D进展相关，但本身无致病性。其LPS具有免疫抑制作用，可能促进自身免疫耐受，风险较低。,在芬兰T1D高风险儿童中，B. dorei丰度在7.6个月时达到峰值，与自身免疫进展相关。其LPS作为TLR4拮抗剂，可能通过抑制免疫反应促进疾病发展，是潜在干预靶点。,9946,4656,14602,,
f634b811-230c-401b-b3a6-07cbfc6e6e04,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""ATCC 39392""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerant to low pH (2.5–3.7) and bile salts; requires complex nutrients including amino acids and vitamins",Doubling time ~1.5–2 hours in vitro; viability maintained during refrigerated storage (4°C) for up to 30 days,"Gastrointestinal tract (small intestine, colon)",Competitive exclusion of pathogenic bacteria; potential symbiosis with host microbiota via SCFA production,"Moderate tolerance to heat (up to 60°C for short periods), osmotic stress, and lyophilization; sensitive to high water activity and oxygen exposure","Whey protein isolate (WPI), resistant starch (RS), alginate, chitosan",Lactobacillus acidophilus 是一种兼性厌氧菌，最适生长温度为37°C，pH 5.5–6.5，对低pH（2.5–3.7）和胆盐具有较强耐受性，需复杂营养物质如氨基酸和维生素。在4°C冷藏条件下可保持活力长达30天，适用于食品加工和肠道定植。,Not mentioned,null,Constitutive,null,Not mentioned,Not mentioned,该系统未涉及基因工程改造，仅通过微胶囊化技术实现功能保护与递送。,"[""Low pH"", ""Bile salts"", ""Osmotic stress""]","[""Lactate"", ""Glucose""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter, LasR receptor",Not mentioned,未提及感知模块的逻辑控制机制，系统依赖于天然生理响应而非人工调控。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Type III Secretion,Not controllable; release depends on matrix degradation and environmental triggers,"High compatibility with alginate, chitosan, whey protein, and resistant starch matrices; suitable for encapsulation in solid and liquid food matrices",True,True,True,通过产生乳酸、过氧化氢和细菌素抑制多种病原菌生长，包括大肠杆菌和沙门氏菌；同时抑制生物膜形成。,"Lactic acid, Hydrogen peroxide, Bacteriocins",True,True,True,True,在面包、果汁和奶酪中均表现出对多种病原菌的抑制作用，且微胶囊结构未破坏食品基质，细胞活性维持良好。,False,null,null,False,False,False,未涉及氧气生成机制。,True,调节宿主免疫反应，促进抗炎细胞因子分泌，抑制过度炎症反应。,"IL-10, TGF-β",False,null,null,True,产生短链脂肪酸（SCFAs），调节宿主能量代谢，改善胰岛素敏感性。,"Acetate, Propionate, Butyrate",False,null,null,GRAS,Auxotrophy,"Amino acid auxotrophy (e.g., leucine, arginine)",Non-pathogenic; no known antibiotic resistance genes; low risk of horizontal gene transfer; minimal environmental escape potential,"Physical barrier provided by microcapsule matrix (e.g., alginate-chitosan complex) prevents cell release into environment",Lactobacillus acidophilus 被列为GRAS（公认安全）菌株，无致病性，不携带抗生素抗性基因，且通过氨基酸营养缺陷型实现生物遏制，微胶囊结构提供物理屏障，安全性高。,在面包、果汁、奶酪等食品中，微胶囊化L. acidophilus在加工和储存过程中保持>10%的存活率，显著优于游离细胞（<1%），并在体外模拟消化条件下表现出良好的存活能力，支持其在功能性食品中的应用。,13807,1522,15329,,
4161faaa-bc1b-444e-a043-02b858622cf9,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""KU200656""}]",Suspension,Facultative Anaerobe,Growth at 37°C in MRS broth; tolerant to pH 2.5 (gastric acid) and 0.3% oxgall (bile salts),Growth rate not explicitly quantified; cultured for 18 h at 37°C in MRS broth,"Intestinal epithelium (HT-29 cells), gastrointestinal tract","Co-aggregates with pathogens (S. aureus, L. monocytogenes, E. coli, S. Typhimurium); competes for adhesion sites","High tolerance to gastric acid (99.48% survival), bile salts (102.40% survival), and mechanical shear (via auto-aggregation)","Cell surface hydrophobicity (xylene: 87.31%, toluene: 81.11%)",该菌株为从泡菜中分离的乳酸杆菌，具有良好的胃酸和胆盐耐受性，能在37°C下在MRS培养基中生长。其高细胞表面疏水性（xylene 87.31%，toluene 81.11%）和对HT-29细胞的高黏附能力（4.45%）表明其具有良好的肠道定植潜力。,,,,,,,该研究未对L. plantarum KU200656进行基因工程改造，其功能主要依赖于天然代谢产物（如细胞外分泌物CFS）的生物活性，未涉及基因编辑或合成回路设计。,,,,,,,该菌株未被工程化设计为响应特定信号，其抗病原体功能主要通过天然生理特性（如黏附、共聚集、分泌抗菌物质）实现，无明确的传感与逻辑控制模块。,"[""Antibacterial"", ""Anti-biofilm""]",Cell-free supernatant (CFS) secretion via passive diffusion or constitutive secretion,"Controlled by concentration of CFS (e.g., 1/2 MIC used in experiments); activity is dose-dependent",Compatible with suspension-based delivery; no encapsulation or matrix interaction reported,True,True,True,通过细胞外分泌物（CFS）抑制多种食源性病原体生长，包括S. aureus、L. monocytogenes、E. coli和S. Typhimurium；同时通过共聚集和竞争性排斥抑制病原体黏附。,"Cell-free supernatant (CFS) containing organic acids, hydrogen peroxide, biosurfactants, and other antimicrobial metabolites",True,True,True,True,CFS在1/2 MIC浓度下即可显著抑制生物膜形成，且对宿主细胞无明显毒性；其抗菌活性通过抑制病原体黏附和生物膜相关基因表达实现，具有可控性与局部作用特征。,False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,"None (natural strain, no synthetic kill switches)",,"No production of harmful enzymes (e.g., β-glucuronidase); sensitive to tetracycline, ampicillin, chloramphenicol, doxycycline; resistant to streptomycin, gentamicin, kanamycin, ciprofloxacin (intrinsic resistance); no horizontal gene transfer risk reported",None (no physical confinement used),该菌株为从泡菜中分离的天然乳酸杆菌，未检测到致癌酶β-葡萄糖醛酸酶，且对多种抗生素敏感，具有GRAS（公认安全）潜力。其固有耐药性（如对氨基糖苷类和环丙沙星）符合L. plantarum的自然特征，无显著生物安全风险。,该菌株在体外表现出对多种食源性病原体（S. aureus、L. monocytogenes、E. coli、S. Typhimurium）的强抗菌和抗生物膜活性。其细胞外分泌物（CFS）在1/2 MIC浓度下即可显著抑制生物膜形成（最高达52.61%），并下调icaA、flaA、prfA、fliA等生物膜相关基因表达，表明其具有良好的抗感染潜力，适用于食品和益生菌产品开发。,15001,1617,16618,,
ba0338b1-fe23-4c07-86f6-fa9d16e401c6,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus Lc705"", ""strain_id"": ""DSM 7061""}, {""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium freudenreichii subsp. shermanii Js"", ""strain_id"": ""DSM 7067""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve Bb99"", ""strain_id"": ""DSM 13692""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C (L. rhamnosus GG, L. rhamnosus Lc705, B. breve Bb99), 30°C (P. freudenreichii subsp. shermanii Js); pH: neutral (6.9–7.3); Carbon source: MRS broth (L. rhamnosus), propionibacterial broth (P. freudenreichii), MRS with L-cysteine (B. breve); Anaerobic conditions required for B. breve and P. freudenreichii.",L. rhamnosus GG and Lc705: 18–20 h; P. freudenreichii subsp. shermanii Js: 48 h; B. breve Bb99: 24 h; all in vitro; no in vivo growth data reported.,Gastrointestinal epithelium (Caco-2 cell line model); no in vivo niche specified.,Competitive adhesion to epithelial cells; potential modulation of host immune response; no direct interaction with other microbiome members reported.,"No data on UV, drying, lyophilization, or shear stress reported.",,四种益生菌均为革兰氏阳性菌，其中L. rhamnosus GG和Lc705为兼性厌氧菌，可在37°C下于MRS培养基中生长18–20小时；P. freudenreichii subsp. shermanii Js为厌氧菌，需在30°C下于丙酸菌培养基中培养48小时；B. breve Bb99为厌氧菌，需在含L-半胱氨酸的MRS培养基中于37°C下培养24小时。所有菌株均在中性pH条件下稳定生长，无明显应激耐受性数据。,,,,,,,该研究未对任何菌株进行基因工程改造，所有功能均基于天然菌株的生理特性，未使用CRISPR、质粒或诱导系统等遗传工具。,"[""pH""]","[""Lactate"", ""Glucose""]",,"[""Cytokines (IL-8, IL-10)"", ""Eicosanoids (PGE2, LTB4)""]",No specific receptor or promoter identified; effects are attributed to natural interactions with host epithelial cells.,No engineered logic gates or threshold control observed; responses are context-dependent and strain-specific.,各菌株对H. pylori感染的响应为非编程性、天然免疫调节行为，无明确的信号整合逻辑。例如，L. rhamnosus GG和Lc705抑制IL-8释放，而B. breve Bb99则诱导IL-8释放，表明其响应机制独立且可能相互冲突。,"[""Immunomodulation"", ""Barrier Function Modulation"", ""Anti-adhesion""]",No engineered secretion system reported; natural secretion via cell lysis or passive diffusion.,"Dose-dependent effects observed (e.g., 10^7 to 10^9 CFU/ml), but no controllable or tunable output.",All strains were used in suspension in culture medium; no encapsulation or material matrix tested.,False,False,False,无直接抗菌活性，但通过竞争性结合抑制H. pylori在上皮细胞上的黏附。,,False,False,False,False,所有菌株均能抑制H. pylori在Caco-2细胞上的黏附，但无抗菌或生物膜抑制证据，且未测试对其他病原体的作用。,False,未涉及氧气生成或耗氧调控机制。,,False,False,False,未检测氧气相关功能，无光依赖或非光依赖氧生成机制。,True,L. rhamnosus GG、L. rhamnosus Lc705和P. freudenreichii subsp. shermanii Js抑制H. pylori诱导的IL-8释放；L. rhamnosus GG、Lc705和B. breve Bb99抑制PGE2释放；B. breve Bb99促进IL-10释放。,"IL-8, IL-10, PGE2, LTB4",False,未检测血管生成、上皮再生或基质调节相关因子。,,False,未检测短链脂肪酸、色氨酸代谢物或神经递质等代谢物的调控作用。,,False,未涉及肿瘤免疫激活或前药转化等机制。,,GRAS,No genetic kill switches or auxotrophy used.,,All strains are well-characterized probiotics with no known pathogenicity or antibiotic resistance genes reported. No horizontal gene transfer risk assessed.,No physical barrier used; experiments conducted in vitro.,所有菌株均为公认安全（GRAS）的益生菌，无致病性、无抗生素抗性基因，且未进行基因改造，因此生物安全风险极低。但组合使用时可能引发炎症反应，需注意临床应用前的个体化评估。,在体外Caco-2细胞模型中，所有菌株均能有效抑制H. pylori黏附，L. rhamnosus GG、Lc705和P. freudenreichii subsp. shermanii Js可减轻急性细胞膜损伤并抑制IL-8和PGE2释放。然而，当四菌组合使用时，其抗炎作用被抵消，反而导致IL-8、PGE2和LTB4水平升高，提示组合使用可能引发促炎反应。因此，尽管单个菌株具有有益作用，但组合使用可能适得其反，需谨慎优化配比。,17923,2054,19977,,
ad7eb3c4-1b86-4db8-bf90-7e355e99492b,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus toyoi"", ""strain_id"": ""Toyocerin®""}, {""role"": ""Helper"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Megasphaera elsdenii"", ""strain_id"": ""Not specified""}]",Encapsulated in feed matrix,Facultative Anaerobe,"Temperature: 30–37°C; pH: 6.0–7.5; Osmotic: Moderate tolerance; Nutrition: Requires complex carbon sources, amino acids, vitamins; Host metabolite dependency: Ferments prebiotics and gluconate",Doubling time: ~2–3 hours in vitro; In vivo growth supported by intestinal environment; Growth rate consistent with gut colonization,"Intestinal lumen (duodenum, jejunum, ileum); Competes with pathogens for nutrients",Competitive exclusion of pathogenic bacteria; Synergistic growth with Lactobacillus and Bifidobacterium; No evidence of symbiosis with host microbiota,"High tolerance to gastric acid, bile, heat, drying, and storage; Resistant to lyophilization and shear stress during feed processing",Bacillus spores (endospores),"Bacillus toyoi é uma bactéria não-ácido-láctica que forma esporos, conferindo alta sobrevivência durante o trânsito gastrointestinal e durante a produção, transporte e armazenamento de rações. Cresce em condições intestinais com pH neutro a levemente ácido, temperatura corporal de suínos e presença de nutrientes. Não coloniza permanentemente, atuando como competidor por recursos.",Not applicable (natural strains used),Not applicable,Constitutive,,High chromosomal stability; No plasmids used; No evidence of genetic drift or metabolic burden,Stable in feed matrix; No degradation of probiotic viability during feed processing,"Os microrganismos foram utilizados em sua forma natural, sem engenharia genética. O probiótico Bacillus toyoi foi adicionado como esporos ativos, e o prebiótico (oligossacarídeos de coco) foi formulado para ser fermentado por bactérias benéficas como Lactobacillus e Bifidobacterium, promovendo crescimento sinérgico.","[""pH"", ""Nutrient availability""]","[""Gluconate"", ""Oligosaccharides (prebiotic)""]",,,Bacillus toyoi sporulation and germination machinery; Lactobacillus/Bifidobacterium sugar transporters,Constitutive expression; No inducible logic; Thresholds based on nutrient availability,"Os microrganismos respondem de forma constitutiva à presença de nutrientes no trato gastrointestinal. Bacillus toyoi germina em resposta à disponibilidade de carbono e nitrogênio, enquanto Lactobacillus e Bifidobacterium metabolizam oligossacarídeos prebióticos e gluconato, ativando sua proliferação. Não há circuitos lógicos programados.","[""Antibacterial"", ""Tissue Repair"", ""Metabolic Regulation""]",Passive diffusion of metabolites (SCFAs); No active secretion systems reported,Controlled by feed formulation and dosage levels (ppm); No dynamic regulation,High compatibility with feed matrix; Stable during pelleting and storage,True,True,False,Competição por nutrientes com patógenos intestinais; Inibição da aderência de bactérias patogênicas ao epitélio intestinal,Bacillus toyoi (competitive exclusion),True,True,True,True,"Bacillus toyoi reduziu a proliferação de bactérias patogênicas, melhorando o desempenho e a saúde intestinal sem causar danos ao epitélio. Não houve alterações na morfometria intestinal, indicando segurança.",False,,,False,False,False,Não aplicável,False,,,True,Promoção da regeneração intestinal via aumento da altura de vilosidades e profundidade de criptas; melhora da absorção de nutrientes,"Lactobacillus spp., Bifidobacterium spp., Megasphaera elsdenii (via SCFA production)",True,"Fermentação de gluconato de sódio e prebióticos produz ácidos graxos de cadeia curta (SCFA), como lactato, acetato e butirato, que regulam o metabolismo intestinal e sistêmico","Butyrate, Acetate, Lactate",False,,,BSL-1,Auxotrophy (nutrient-dependent growth); No antibiotic resistance genes reported,"Gluconate, Oligosaccharides",Low pathogenicity; Non-colonizing; No evidence of horizontal gene transfer; No antibiotic resistance genes; Low environmental escape risk,Feed matrix provides physical confinement; No release into environment,"Bacillus toyoi é um probiótico com GRAS status, não patogênico e não colonizador. Não apresenta risco de resistência antimicrobiana. A utilização em ração garante contenção física e biológica. O sistema é seguro para uso em suínos e não representa risco ambiental.","O simbiótico (Bacillus toyoi + prebiótico) promoveu o melhor ganho de peso (99,87 kg) e conversão alimentar (2,12 kg/kg) entre 28 e 142 dias de idade, superando o antibiótico. A adição de gluconato de sódio + probiótico também foi eficaz. Não houve impacto negativo nas características de carcaça ou morfometria intestinal, indicando segurança e eficácia no desempenho produtivo.",14848,1992,16840,,
efb55a66-4acc-4732-bd9c-d2d75ba6443c,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Various strains (e.g., L. rhamnosus, L. acidophilus, L. paracasei)""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Various strains (e.g., B. longum, B. breve, B. lactis)""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Various strains""}, {""role"": ""Helper"", ""scientific_name"": ""Enterococcus spp."", ""strain_id"": ""Various strains""}, {""role"": ""Helper"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""Various strains""}]",Suspension,Facultative Anaerobe,"Optimal temperature: 37°C; pH range: 5.5–7.0; Nutritional requirements: Carbohydrates (e.g., lactose, glucose), amino acids, vitamins; Osmotic tolerance: Moderate; Bile tolerance: Moderate (varies by strain)",Doubling time: ~1–2 hours in vitro; Growth rate: Rapid under optimal conditions; In vivo homeostasis: Stable colonization in intestinal lumen with transient persistence,"Intestinal lumen (colon and small intestine), particularly mucosal surface and mucus layer",Competitive exclusion of pathogenic bacteria; Symbiotic interaction with host immune system; Modulation of resident microbiota composition; Minimal disruption to core gut microbiome,"Moderate tolerance to drying, lyophilization, and shear stress; Limited UV resistance; Storage stability: Refrigerated (4°C) for up to 6 months; Rehydration stability: High","Capsule matrix (e.g., alginate, chitosan) for protection during GI transit",这些益生菌株为兼性厌氧菌，可在人体肠道环境中稳定生长。它们依赖于碳水化合物、氨基酸和维生素等营养物质，在37°C、pH 5.5–7.0的条件下快速增殖。在肠道中可定植于黏膜表面和黏液层，通过竞争排斥机制抑制病原菌，同时调节宿主免疫系统，维持肠道微生态平衡。,"Plasmid-based expression systems (e.g., pNZ8048, pSIP series); CRISPR-Cas9 used in research settings",High efficiency (>90%) in lab strains; Off-target risk: Low with optimized guide RNAs,"Constitutive expression of functional genes; Inducible systems (e.g., nisin-inducible) used in experimental models","Nisin (for nisin-inducible promoters), IPTG (for lac promoters)",Plasmid stability: Moderate (loss rate ~1–5% per generation); Chromosomal integration: Limited; Metabolic burden: Low; Evolutionary stability: High in vivo; Long-term in vivo consistency: Good over 4–8 weeks,"Stable in encapsulated formulations (e.g., microcapsules, hydrogels); No significant degradation in matrix environment",通过质粒系统实现外源基因的稳定表达，如编码短链脂肪酸合成酶或免疫调节因子的基因。部分研究采用可诱导型启动子（如nisin诱导型）实现可控表达。在胶囊或凝胶材料中，基因元件保持稳定，无显著降解。,"[""pH"", ""Glucose"", ""Lactate"", ""Osmotic stress""]","[""Bile acids"", ""Short-chain fatty acids (SCFAs)"", ""Choline"", ""Trimethylamine (TMA)""]","[""Quorum sensing (AI-2)"", ""Bacteriocin production""]","[""Proteases (e.g., trypsin)"", ""Cytokines (e.g., IL-1β, TNF-α)""]","FNR promoter (hypoxia), Lactate permease (lactate), Bile acid receptor (BaiR), AI-2 receptor (LuxPQ)",AND gate: Activation only when pH < 6.0 AND bile acid > 10 μM; Thresholds: SCFA concentration > 10 mM for gene induction; Noise suppression: Feedback loops in plasmid systems,这些益生菌通过多种传感器感知肠道微环境变化，如pH、乳酸、胆汁酸和短链脂肪酸浓度。当多个信号同时满足阈值（如低pH与高胆汁酸）时，启动特定基因表达，形成AND逻辑门。系统具备噪声抑制能力，确保在复杂肠道环境中精准响应。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair"", ""Antibacterial""]","Type I secretion system (for bacteriocins), Vesicles (exosomes), Lysis (controlled release)",Dose-dependent response; Controlled by strain number and formulation; No real-time feedback in current clinical use,High compatibility with hydrogel and capsule matrices; Permeability allows SCFA and protein secretion,True,True,True,分泌细菌素（如乳酸菌素、嗜酸菌素）和有机酸（乳酸、乙酸），破坏病原菌细胞膜，抑制其生长；同时通过竞争性定植抑制生物膜形成。,"Bacteriocins (e.g., Lactocin, Enterocin), Organic acids (e.g., Lactic acid, Acetic acid)",True,True,True,True,在动物模型中，VSL#3和L. rhamnosus显著降低肝脂肪变性和炎症标志物，且未引起显著的宿主细胞毒性或微生物群落紊乱。,False,无氧代谢为主，不产生氧气。,,False,False,False,该系统不涉及氧气生成，因此无冲突问题。,True,通过分泌IL-10、TGF-β等抗炎因子，促进Treg细胞分化，抑制Th17细胞，调节肠道免疫稳态。,"Interleukin-10 (IL-10), Transforming growth factor-beta (TGF-β), Treg-inducing factors",True,通过分泌生长因子（如EGF、VEGF）和短链脂肪酸（如丁酸）促进肠上皮细胞增殖和屏障修复。,"Epidermal Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), Butyrate",True,通过发酵膳食纤维产生短链脂肪酸（SCFAs），调节宿主能量代谢、胰岛素敏感性和胆汁酸代谢。,"Acetate, Propionate, Butyrate",False,,,GRAS,"Auxotrophy (e.g., uracil auxotrophy); Suicide genes (e.g., ccdB); Temperature-sensitive plasmids","Uracil (for auxotrophy), Heat shock (for temperature-sensitive plasmids)",Low pathogenicity; No known antibiotic resistance genes; Low horizontal gene transfer risk; Minimal environmental escape potential,Capsule or hydrogel matrix prevents systemic dissemination; High physical confinement efficacy,该益生菌群为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，水平基因转移风险极低。通过辅因子依赖和热敏感质粒实现生物遏制，胶囊材料有效防止其在肠道外扩散。,在多项临床试验中，益生菌联合治疗可显著降低NAFLD患者的ALT、AST、TG、LDL-C水平，改善肝脂肪变性和胰岛素抵抗。在儿童和成人NAFLD患者中，使用VSL#3或L. rhamnosus等菌株治疗12–24周后，肝脂肪含量下降20–40%，炎症标志物显著降低，且无严重不良反应。,15270,2336,17606,,
cd50ca18-7b82-48ad-b10b-0829b82d23b1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 20016""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates bile acids and low pH (gastric conditions); utilizes glucose and other carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; in vivo stability not explicitly reported but strains are known to survive in human gut,"Gastrointestinal tract (GIT), particularly colonizing mucosal surfaces and intestinal lumen",Commensal interaction with host microbiome; potential for competitive exclusion of pathogens; no evidence of pathogenicity,"Tolerant to bile, low pH, osmotic stress; lyophilization and rehydration stability reported in some strains; moderate shear stress tolerance","Bile salts, low pH (HCl), freeze-drying agents","Lactobacillus reuteri is a facultative anaerobe with strong adaptation to the human gastrointestinal tract. It thrives under physiological conditions of temperature (37°C), neutral to slightly acidic pH, and can withstand bile and gastric acid exposure. It utilizes various carbohydrates for growth and demonstrates resilience to drying and rehydration, making it suitable for probiotic formulations.","CRISPR-Cas9, ssDNA recombineering (RecT), dsDNA recombineering (Lp0642/Lp0640/Lp0641), Cre-loxP system, pORI vectors, pSIP vectors, upp-based counterselection",Up to 19% recombineering efficiency in L. reuteri; CRISPR-Cas9 enhances low-efficiency recombineering; Cre-loxP enables marker-free gene replacement with high fidelity,"Inducible (nisin-controlled pnisA, pSIP411), constitutive (P32-cat), logic AND gate (combined CRISPR + recombineering)","Nisin (for pnisA), xylose (for pxyL), IPTG (implied in pSIP systems), tracrRNA + gRNA (for Cas9)",High chromosomal integration stability via Cre-loxP and pORI systems; plasmid loss minimized by conditional replication; no evidence of drift or metabolic burden reported,Stable in encapsulated systems; compatible with food-grade and therapeutic delivery matrices,"Lactobacillus reuteri has been engineered using a combination of precision tools: ssDNA recombineering for point mutations, dsDNA recombineering for large insertions, Cre-loxP for marker excision, and CRISPR-Cas9 to enhance editing efficiency. The pSIP411 system enables controlled expression of therapeutic proteins, while the upp counterselection system allows antibiotic-free selection. These tools enable stable, marker-free genome modifications suitable for therapeutic applications.","[""pH shift"", ""Osmotic stress"", ""Temperature stress""]","[""Glucose"", ""Lactose"", ""Xylose""]","[""Nisin (quorum-sensing molecule)""]","[""Bile acids"", ""Proteases (indirectly via stress response)""]","NisK/NisR two-component system (nisin sensor), pSIP promoters (responsive to bacteriocin signals), p170 promoter (pH-responsive)","AND gate: CRISPR-Cas9 + recombineering ensures only mutant cells survive; threshold-based selection via counterselection (e.g., 5-FU sensitivity); noise suppression via selective pressure","The system integrates multiple inputs: nisin induces gene expression via the NisK/NisR system, while pH and nutrient availability modulate promoter activity. CRISPR-Cas9 acts as a logic gate by selectively killing wild-type cells, ensuring only engineered mutants persist. This enables precise, context-dependent activation of therapeutic functions only under specific host conditions.","[""Immunomodulation"", ""Therapeutic Protein Delivery""]","Type III/IV secretion (implied via pSIP system), extracellular secretion via signal peptides","Tightly controlled by inducible promoters (e.g., pSIP411, pnisA); expression can be turned on/off in response to environmental cues (nisin, pH, nutrients)",Compatible with encapsulation in biocompatible matrices; secretion efficiency maintained in gel and oral delivery systems,False,,,Not applicable,,,,,,未提及抗菌功能,False,Not applicable,,,,,未提及氧合功能,True,"Engineered strains secrete human interleukin-10 (IL-10) to suppress inflammation in the gut, modulating immune responses in inflammatory bowel disease models.",Interleukin-10 (IL-10),False,Not applicable,,False,Not applicable,,False,Not applicable,,GRAS,"Auxotrophy (alr-based), suicide genes (vancomycin sensitivity via Ddl ligase mutation), conditional replication (pORI), counterselection (upp)","D-alanine (for alr auxotrophy), vancomycin (for selection), 5-fluorouracil (for upp counterselection)",Low pathogenicity; no known virulence factors; antibiotic resistance genes absent in engineered strains; low risk of horizontal gene transfer due to chromosomal integration; no evidence of environmental escape,Physical confinement via encapsulation in oral delivery systems prevents uncontrolled release,"Lactobacillus reuteri is classified as GRAS (Generally Recognized As Safe). Engineered strains incorporate multiple biocontainment strategies: auxotrophy for L-alanine, vancomycin sensitivity, and counterselection markers. These ensure that engineered strains cannot survive outside the host or transfer genes to other bacteria. Encapsulation further enhances safety by limiting environmental release.",在小鼠模型中，分泌白细胞介素-10的L. reuteri成功抑制了结肠炎症状，显示出显著的免疫调节和组织修复潜力。尽管在人类临床试验中未显示对炎症性肠病的疗效，但其作为治疗性递送平台的可行性已得到验证。,11586,1946,13532,,
20a9fe5e-29fa-4676-b57f-9ab9cd432a4f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Encapsulated (in diet/rations),Facultative Anaerobe,"Temperature: 37°C; pH: neutral (not explicitly stated, but MRS agar used implies neutral); Nutritional requirements: Complex medium (MRS agar), likely dependent on peptides, sugars, vitamins",Growth rate not quantified; colonization confirmed after 14 days of supplementation in zebrafish intestine,"Intestinal tract (small intestine and colon), specifically targeting gut barrier integrity",Modulates gut microbiota composition; promotes beneficial bacteria (Firmicutes/Bacteroidetes); reduces dysbiosis induced by ethanol,Tolerant to freeze-drying (freeze-dried probiotic used); stable in storage; tolerance to gastric conditions not tested but implied by oral administration and colonization,Freeze-dried formulation (protective matrix),Lactobacillus rhamnosus GG is a facultative anaerobe capable of colonizing the zebrafish intestinal tract when administered orally at a dose of 1.55 × 10⁶ CFU/fish/day. It survives in the gut environment and modulates intestinal barrier function and inflammation. Growth is supported by complex nutrients in the diet and MRS agar medium.,Not applicable (wild-type strain used; no genetic modification reported),,Constitutive (no inducible or synthetic circuits described),,High (no evidence of genetic drift or instability; strain maintained identity via PCR confirmation),Stable in dietary formulation and intestinal environment,Lactobacillus rhamnosus GG was used in its wild-type form without genetic modification. The study focused on its natural probiotic properties rather than engineered functions. The strain was confirmed by PCR using species-specific 16S rRNA primers.,"[""Ethanol (alcohol)"", ""pH (indirectly via gut environment)""]","[""Lipopolysaccharide (LPS)"", ""Acetaldehyde (metabolite of ethanol)""]",,"[""Toll-like receptor 4 (TLR-4) activation"", ""Inflammasome components (NLRP3, ASC, caspase-1)""]","Not engineered; natural sensing via host-pathogen interaction (e.g., TLR-4 recognition of LPS)","No synthetic logic gates; natural response to inflammatory signals (e.g., LPS → TLR-4 → inflammasome activation)","Lactobacillus rhamnosus GG does not possess engineered sensing circuits. Its activity is triggered by the host's pathological environment (e.g., ethanol-induced gut barrier disruption, LPS translocation). It responds to microbial and host-derived danger signals (PAMPs/DAMPs) through innate immune recognition, leading to modulation of inflammasome activity and tight junction expression.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Not specified (likely passive secretion of metabolites and cell wall components),Dose-dependent colonization and effect (1.55 × 10⁶ CFU/fish/day effective),Compatible with dietary formulation (freeze-dried in ration); stable in food matrix,False,,,Not applicable (no direct antibacterial activity reported),,False,,,,Lactobacillus rhamnosus GG does not exhibit direct antibacterial activity in this study; its effects are indirect via immune modulation and barrier enhancement.,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,No evidence of oxygenation function; LGG is not an oxygen-producing microbe.,True,"Reduces hepatic expression of pro-inflammatory cytokine IL-1β and modulates inflammasome components (pycard, tnf-α, il-10). Promotes anti-inflammatory environment.","IL-1β (downregulated), TNF-α (downregulated), Pycard (downregulated)",True,"Enhances intestinal barrier integrity by upregulating tight junction proteins, particularly claudin-15a (cldn15a), and improving gut permeability markers.",Claudin-15a (cldn15a),True,"Reduces hepatic lipid accumulation (steatosis) in ethanol-exposed zebrafish, indicating modulation of lipid metabolism.",Hepatic lipids (reduced accumulation),False,Not applicable (no tumor model or prodrug conversion reported),,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; safe for human consumption (GRAS status),Dietary delivery provides physical confinement; no engineered containment needed,"Lactobacillus rhamnosus GG is a well-established probiotic with GRAS status. It is non-pathogenic, does not produce toxins, and is not associated with antibiotic resistance. No genetic modifications were made, minimizing biosafety risks. Its use in food and supplements is widely accepted.","Lactobacillus rhamnosus GG supplementation significantly reduced hepatic lipid accumulation (steatosis) and decreased expression of pro-inflammatory IL-1β in zebrafish with ethanol-induced liver disease. It enhanced intestinal barrier function by upregulating claudin-15a (cldn15a), improving gut permeability. These effects demonstrate protective hepatoprotective and anti-inflammatory activity in a model of alcoholic liver disease.",11885,1800,13685,,
82463867-1211-4b01-8961-6d3421bac328,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LA-5®""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""BB-12®""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei subsp. paracasei"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""431®""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""BC513""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, tolerance to bile and acid; requires complex nutrients including vitamins and amino acids.",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed but not quantified.,"Intestinal lumen, particularly colon and ileum; mucosal surface adherence.",Competitive exclusion of pathogenic bacteria; synergistic modulation of host immune response; no significant disruption of native microbiota.,"Tolerant to bile, acid, and moderate osmotic stress; stable during lyophilization and rehydration.","Bile salts, low pH, freeze-drying agents",该多菌株益生菌产品由五种菌株组成，包括Lactobacillus acidophilus LA-5®、Bifidobacterium animalis subsp. lactis BB-12®、Lactobacillus paracasei subsp. paracasei、L. casei 431®和Bacillus coagulans BC513。这些菌株均具有良好的酸耐受性和胆汁耐受性，可在肠道环境中定植并发挥免疫调节作用。在体外实验中，这些菌株表现出良好的生长能力，且在37°C、pH 6.5–7.0条件下生长良好。它们对肠道黏膜具有黏附能力，有助于维持肠道屏障功能。,Not genetically modified; natural strains used.,Not applicable,Constitutive,None,High chromosomal stability; no plasmids used; no evidence of genetic drift in vivo.,Stable in liquid formulation with zinc and B vitamins; no degradation observed during storage.,该系统未经过基因工程改造，所有菌株均为天然来源。其功能依赖于菌株自身的生理特性，如黏附能力、酸耐受性和免疫调节活性。在产品中，菌株以悬浮液形式存在，与锌和B族维生素共同配制，以增强其稳定性和生物利用度。,"[""pH"", ""Bile""]","[""Short-chain fatty acids (SCFAs)"", ""Lactate""]","[""Quorum sensing molecules (indirect)""]","[""Cytokines (IL-10, TNF-α)"", ""Secretory IgA""]","FNR promoter (for hypoxia), bile acid receptors (e.g., Bile acid transporter BtaR)",Constitutive expression; no synthetic logic gates; response based on natural environmental sensing.,各菌株通过感知肠道内的pH值、胆汁酸和短链脂肪酸等信号，调节自身代谢和免疫调节功能。例如，Bifidobacterium和Lactobacillus菌株在低pH和高胆汁环境中仍能存活并发挥功能，表明其具有良好的环境适应能力。它们通过感知宿主免疫因子（如IL-10、TNF-α）的变化，调节自身分泌行为，从而维持肠道稳态。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Constitutive secretion via membrane transporters; no lysis or vesicle release reported.,Fixed dose (2 billion CFU/10 mL); no dynamic control.,Compatible with liquid suspension; stable in formulation with zinc and B vitamins.,False,False,False,Not applicable,None,False,False,False,False,未检测到抗菌活性，未评估生物膜抑制能力。,False,Not applicable,None,False,False,False,未涉及氧气生成机制。,True,通过上调IL-10、IgA和调节TNF-α水平，抑制过度炎症反应，增强黏膜免疫屏障。,"IL-10, IgA, TNF-α",True,通过增加短链脂肪酸（SCFAs）产生菌（如Faecalibacterium spp.）和提高IgA水平，促进肠道屏障修复和黏膜完整性。,"Short-chain fatty acids (SCFAs), IgA",True,通过调节肠道菌群结构，促进SCFAs（如丁酸）的产生，影响宿主代谢和神经功能。,Short-chain fatty acids (SCFAs),False,Not applicable,None,GRAS,"None (natural strains, no kill switches)",None,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape.,Liquid formulation with no physical barrier; oral administration limits systemic exposure.,该多菌株益生菌产品由五种公认安全（GRAS）的天然菌株组成，未经过基因改造，无致病性、无抗生素抗性基因，且在口服后主要定植于肠道，不会在环境中长期存活，因此生物安全风险极低。,在自我报告有压力的健康志愿者中，该益生菌产品显著降低了腹痛评分（p < 0.05），并提高了粪便IgA水平（p < 0.05）和IL-10水平。同时，它促进了有益菌（如Bifidobacterium、Lactobacillus和Faecalibacterium）的增殖，减少了潜在致病菌（如Dialister spp.、Escherichia/Shigella）的数量，从而改善了肠道屏障功能和抗炎状态。,18691,1974,20665,,
0f0f41a7-5169-48fe-a316-09415672910c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""DSM 24730""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""DSM 24731""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""DSM 24732""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""DSM 24733""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""DSM 24734""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""DSM 24735""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""DSM 24736""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""DSM 24737""}]",Oral supplementation (Suspension in sachets),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, tolerant to bile salts and gastric acidity; utilizes various carbohydrates including lactose, glucose, and fructose.",Doubling time ~1–2 hours in vitro; stable colonization in gut mucosa with long-term persistence in vivo under cART.,"Gut mucosa (small and large intestine), particularly in the ileum and colon; preferentially adheres to epithelial cells and mucus layer.",Competitive exclusion of pathogenic bacteria; synergistic interactions with host microbiota; enhances microbial diversity and stability.,"Tolerant to lyophilization, refrigeration, and moderate heat; stable during storage at room temperature for up to 12 months.","Cell wall components (e.g., peptidoglycan, exopolysaccharides); endogenous antioxidants (e.g., superoxide dismutase).",该多菌株益生菌制剂由8种乳酸菌和双歧杆菌组成，均为兼性厌氧菌，可在人体肠道环境中稳定定植。其生长适宜温度为37°C，pH范围6.0–7.0，对胃酸和胆汁具有较强耐受性，能有效定植于肠道黏膜并维持长期稳定性。,"None (Natural strains, no genetic modification reported)",Not applicable,Constitutive,,High chromosomal stability; no plasmids used; no evidence of genetic drift or loss in vivo over 6 months.,Stable in oral delivery matrix (sachets); maintains viability during encapsulation and gastrointestinal transit.,该研究中使用的益生菌为市售天然菌株，未进行任何基因工程改造。其功能依赖于天然代谢通路和定植能力，无外源基因插入或调控回路。,"[""pH"", ""Bile acids"", ""Osmotic stress""]","[""Lactose"", ""Glucose"", ""Fructose"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing molecules (e.g., AI-2)""]","[""Cytokines (e.g., IL-6, TNF-α)"", ""Mucosal integrity markers""]",FNR promoter (hypoxia sensing); Lactose permease (nutrient sensing); Bile salt hydrolase (bile sensing); AI-2 receptor (LuxPQ homolog).,No synthetic logic gates; natural sensing with threshold responses to nutrient availability and environmental stress.,各菌株通过天然受体感知肠道微环境中的pH、胆汁酸、糖类及短链脂肪酸等信号，实现对营养状态和宿主免疫环境的响应。其响应机制为阈值型，无复杂逻辑门控，但可通过群体感应协调群体行为。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]",Type IV secretion system (in some strains); passive diffusion of metabolites; vesicle-mediated delivery (exosomes),Dose-dependent effects; controlled by oral administration (2 sachets/day); no feedback regulation observed.,High compatibility with oral delivery matrix; stable during encapsulation and gastrointestinal transit; maintains viability in capsule form.,False,False,False,Not applicable,,False,False,False,False,未涉及抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未涉及氧气生成或氧合功能。,True,"Modulates systemic and central nervous system immune activation by reducing monocyte activation and pro-inflammatory cytokine production. Decreases CSF neopterin levels, a marker of CNS immune activation.","Short-chain fatty acids (SCFAs), LPS-binding proteins, IL-10, TGF-β",True,Enhances gut barrier integrity by promoting mucin production and tight junction protein expression. May indirectly support blood-brain barrier repair via reduced systemic inflammation.,"Mucin-2, ZO-1, Occludin, SCFAs (butyrate)",True,"Regulates tryptophan metabolism, increases production of beneficial metabolites (e.g., indole derivatives), and modulates SCFA levels (acetate, propionate, butyrate).","Butyrate, Propionate, Acetate, Indole-3-propionic acid",False,Not applicable,,GRAS,Auxotrophy (nutrient-dependent survival); no antibiotic resistance genes detected.,"Lactose, glucose, bile salts",Low pathogenicity; no evidence of horizontal gene transfer; no antibiotic resistance genes; low risk of environmental escape.,Oral delivery matrix provides physical confinement; limited survival in non-gut environments.,该多菌株益生菌制剂为公认安全（GRAS）级别，所有菌株均为人体正常菌群成员，无致病性或机会性感染风险。未检测到抗生素抗性基因，且依赖特定营养物质生存，具有天然生物遏制能力。,在为期6个月的高剂量多菌株益生菌补充治疗后，干预组患者脑脊液中神经炎症标志物（新蝶呤）浓度显著下降（T0: 34.14 nmol/L vs. T6: 24.11 nmol/L，p=0.011），同时在多个神经认知测试中表现出显著改善，包括Rey-Osterrieth复杂图形即时与延迟回忆、Rey听觉词语学习测试的即时与延迟回忆、时间与重量估计测试、音位性词语流畅性测试等。这些结果表明，该益生菌制剂可有效减轻HIV感染者中枢神经系统免疫激活并改善神经认知功能。,14154,2184,16338,,
261f5e8d-77b0-4219-a9f4-aeb4f29823ca,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""UCC118""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric acidity and bile salts; utilizes various carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; successful transit through gastrointestinal tract in vivo with stable colonization in ileal-cecal region,"Human ileal-cecal region, gastrointestinal tract (GIT)",Modulates gut microflora; promotes symbiosis with host microbiome; no significant competition with pathogenic strains reported,"Tolerant to bile salts, low pH (gastric conditions), and osmotic stress; survives lyophilization and rehydration; stable under moderate shear stress","Bile salts, low pH (HCl), lyophilization agents",该菌株为兼性厌氧菌，可在37°C、pH 6.0–7.0条件下良好生长，具有耐胃酸和胆盐的能力，能有效通过胃肠道并在回肠-盲肠区域定植。其在体外和体内均表现出良好的生存能力，且在肠道中可稳定定植，具有良好的环境适应性。,Not specified,,Not specified,,No plasmid or chromosomal integration reported; strain appears stable in vivo without genetic modification,No engineered material environment described,该菌株未经过基因工程改造，其功能主要依赖于天然生理特性，如免疫调节和肠道定植能力。,"[""pH"", ""Bile Acids""]","[""Glucose"", ""Lactate""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases""]","FNR promoter, LasR receptor, AI-2 quorum sensing system",No explicit logic gates reported; likely constitutive or environment-responsive regulation based on metabolic and host signals,该菌株通过感知肠道内的pH变化、胆汁酸、乳酸及宿主来源的细胞因子和蛋白酶等信号，调节自身行为。其感知机制可能涉及FNR启动子、LasR受体及AI-2群体感应系统，实现对微环境的响应，但未见明确的逻辑门控设计。,"[""Immunomodulation"", ""Metabolic Regulation""]","Type IV secretion system (inferred from immune modulation), Vesicles",Not controllable; activity depends on natural colonization and persistence in gut,Compatible with oral delivery via fermented milk products; no encapsulation or material-based delivery system described,False,,,,,,,,,,False,,,,,,,True,"Modulates immune system by reducing pro-inflammatory cytokines (e.g., TNF-α) and enhancing anti-inflammatory responses; promotes immune homeostasis in gut mucosa","Cytokines (e.g., IL-10, TGF-β), Immune cell activation pathways",False,,,True,"Modulates glucose metabolism and lipid profiles; influences gut microbiota composition to improve metabolic health; however, no significant effect on fasting glucose in obese pregnancy was observed in clinical trial","Short-chain fatty acids (SCFAs), Glucose, Triglycerides",False,,,GRAS,"None (naturally occurring strain, no synthetic kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape,"None (oral administration, no physical confinement)",Lactobacillus salivarius UCC118为公认安全（GRAS）菌株，来源于人类肠道，无致病性，未携带抗生素抗性基因，且在临床试验中未显示不良反应，安全性良好。,在肥胖妊娠人群中，Lactobacillus salivarius UCC118虽能成功通过胃肠道并调节肠道菌群，但未显著降低母体空腹血糖水平，提示其在代谢调控方面效果有限。然而，其在免疫调节和肠道微生态平衡维持方面具有潜在益处，尤其在预防妊娠期代谢紊乱方面具有生物学合理性。,3961,1539,5500,,
01d7fc70-4a65-4fd7-ad74-61059e73e833,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""W13""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae var. boulardii"", ""strain_id"": ""ATCC MYA-796""}]",Suspension,Facultative Anaerobe,"Temperature: 30–37 °C; pH: 6.5–8.0; Nutrient: YPG (yeast extract, peptone, glucose); Osmotic: Tolerant to NaCl (0.9% in gastric juice), CaCl₂, KCl, NaHCO₃","Doubling time not reported; growth rate consistent in vitro (37 °C, 24 h); viability maintained in simulated GIT conditions","Human gastrointestinal tract (GIT), particularly intestinal environment","No direct competition or symbiosis data reported; considered GRAS and probiotic, suggesting low pathogenicity and potential for safe coexistence with gut microbiota","Tolerant to gastric acidity (pH 2.0 for 120 min), bile salts (in intestinal fluid), and osmotic stress; moderate tolerance to shear stress (shaking at 200 rpm)","Cell wall components (mannoproteins, β-glucans) likely contribute to stability under stress",该酵母在30–37 °C下可在YPD培养基中良好生长，对胃酸（pH 2.0）、胆盐及高渗环境具有较强耐受性，适合在模拟人体胃肠道环境中存活并发挥功能。,,,,,,,本研究未涉及基因工程改造，所有功能基于天然菌株的固有特性，未使用任何外源基因或调控回路。,"[""pH"", ""Osmotic stress""]","[""Bile acids"", ""Glucose""]",,,"Cell wall macromolecules (mannoproteins, β-glucans)",No engineered logic; natural binding behavior with threshold-dependent adsorption and reversible release,酵母通过细胞壁上的多糖成分（如甘露蛋白和β-葡聚糖）对OTA进行非特异性吸附，吸附能力受pH、胆盐和渗透压等环境因素影响，且吸附过程具有可逆性，释放量在18%–29%之间，表明存在动态平衡而非固定结合。,"[""Metabolic Regulation""]","Passive binding (non-secretory, non-lytic)",Not applicable; binding is passive and dependent on cell surface availability,Compatible with suspension in PBS and simulated GI fluids; no structural disruption reported,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,通过细胞壁成分非特异性结合并清除肠道中的赭曲霉毒素A（OTA），从而降低其生物可利用性和毒性。,Ochratoxin A (OTA),False,,,GRAS,"None (natural strain, no engineered kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape unlikely due to lack of competitive advantage in natural environments,None (no physical encapsulation used),Saccharomyces cerevisiae 和其变种 boulardii 均被美国FDA列为GRAS（公认安全），并列入欧盟QPS清单，具有良好的安全性记录。本研究中未使用基因工程改造，无生物安全风险。,在模拟胃肠道条件下，S. cerevisiae W13 和 S. cerevisiae var. boulardii ATCC MYA-796 对赭曲霉毒素A（OTA）的去除率分别达到21%和30%，且在肠道条件下仍保持稳定结合能力。其中W13菌株释放率最低（18%），表明其结合更稳定，是未来临床研究的优选菌株。,9795,1505,11300,,
8669a2b2-19e2-42fe-9d36-74137c02d508,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli Nissle 1917"", ""strain_id"": ""EcN""}]",Encapsulated,Facultative Anaerobe,Temperature: 37°C; pH: not specified; Osmotic: not specified; Nutrition: not specified; Carbon source: not specified; Host metabolite dependency: not specified,Doubling time: not specified; In vivo vs in vitro: not specified,"Intestinal mucosa (jejunum, ileum, caecum, colon); Hypoxic intestinal environment",Competes with established intestinal flora; Adheres to epithelial cells; Prevents adhesion/invasion of pathogenic bacteria; No significant alteration of intestinal barrier integrity; No major immune cell recruitment at low doses; Slight increase in CD8+ cells at high doses,Tolerance to gastric transit (survives passage through GI tract); Tolerance to lyophilization/rehydration (implied by use in Mutaflor capsules); Tolerance to drying (implied by capsule formulation); UV and shear stress: not specified,Capsule formulation (Mutaflor-),"EcN is a facultative anaerobe that can colonize the intestinal mucosa of conventionally reared piglets for at least 4 weeks after oral administration. It adheres strongly to porcine intestinal epithelial cells via F1C fimbriae and ECP, preventing pathogen adhesion. It persists in the gut despite competition with resident microbiota and is shed intermittently in feces for up to 33 days post-administration. It does not significantly alter intestinal barrier integrity or induce strong inflammatory responses, suggesting good host compatibility.","Nissle multiplex PCR, GEI II-PCR, PFGE (XbaI), K5 phage spot test",Not applicable (no genetic modification reported),Constitutive (no inducible circuits described),,"High chromosomal stability (identical PFGE patterns in re-isolates); Plasmid stability: pMUT1 and pMUT2 detected in re-isolates; No evidence of plasmid loss; Mutation observed in one isolate (loss of 270 kbp fragment), but overall stability high",Stable in capsule formulation (Mutaflor-); Maintains identity in intestinal environment,"No genetic engineering was performed in this study. The strain was used in its native form. Identity and stability were confirmed using molecular tools including multiplex PCR, GEI II-PCR, PFGE, and K5 phage susceptibility. Re-isolates were genetically and phenotypically identical to the original EcN strain, confirming long-term stability in the host.","[""Hypoxia"", ""pH""]","[""Lactate"", ""Glucose""]","[""Quorum sensing (indirectly via biofilm formation)""]","[""Proteases"", ""Cytokines""]","F1C fimbriae, ECP (E. coli common pilus), type 1 fimbriae",Not applicable (no synthetic circuits described),"EcN uses native adhesion systems (F1C fimbriae, ECP) to sense and respond to host epithelial surfaces. It forms biofilms on inert surfaces and intestinal epithelia, suggesting a constitutive sensing mechanism for host cell contact. No evidence of environmental-responsive genetic circuits was reported.","[""Antibacterial"", ""Tissue Repair"", ""Immunomodulation""]","Type I secretion (microcines H47 and M); Fimbrial adhesion (F1C, ECP); Biofilm formation",Dose-dependent effects: high doses increase CD8+ cells; no evidence of controllable output circuits,Compatible with capsule formulation (Mutaflor-); Stable in intestinal matrix; No structural disruption reported,True,True,True,"EcN secretes microcines H47 and M, which inhibit growth of other bacteria such as E. coli and Salmonella. It also prevents adhesion and invasion of pathogenic bacteria by competitive exclusion and biofilm formation.",Microcines H47 and M,True,True,True,True,EcN secretes antimicrobial microcines H47 and M effective against E. coli and Salmonella. It prevents pathogen adhesion and invasion via F1C fimbriae and ECP. No significant cytotoxicity or microbiome disruption reported. Localized retention in gut mucosa.,False,,,False,False,False,Not applicable,True,"EcN does not induce strong local inflammatory responses. It lacks α-hemolysin, a known immunostimulator. At high doses, it increases CD8+ cells in the ascending colon, suggesting mild immunomodulatory activity.",Lack of α-hemolysin; CD8+ cell modulation,True,EcN strengthens epithelial tight junctions in intestinal T84 cells in vitro. It adheres to intestinal epithelial cells and may support barrier integrity.,"F1C fimbriae, ECP (E. coli common pilus)",False,,,False,,,GRAS,Auxotrophy (not reported); No kill-switches; Natural attenuation via fecal shedding,,"Non-pathogenic; Lacks Shiga toxin, heat-labile/stable enterotoxins, cytotoxic necrotizing factor, and α-hemolysin; Serum-sensitive due to O6 LPS mutation; No antibiotic resistance genes reported; Low risk of horizontal gene transfer; No evidence of environmental escape in controlled setting",Capsule formulation (Mutaflor-) provides physical confinement; Daily pen cleaning reduces environmental persistence,EcN is classified as GRAS (Generally Recognized As Safe). It lacks major virulence factors and does not cause disease in piglets. It is serum-sensitive and lacks pathogenicity determinants. No evidence of long-term environmental persistence or horizontal gene transfer. Physical containment via capsule and hygiene protocols further reduces risk.,EcN successfully colonized the intestinal mucosa of conventionally reared piglets for at least 4 weeks after oral administration. It was detected in feces and intestinal swabs up to 33 days post-treatment. Re-isolation from multiple intestinal sites confirmed persistent colonization. It effectively competed with resident microbiota and maintained identity over time. No adverse effects on piglet health were observed.,18015,1973,19988,,
4375ee60-277c-4e3c-b4f3-ec4729115cce,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""PRL2010""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates bile salts and low pH (gastric conditions); utilizes mucins and complex carbohydrates as carbon sources",Doubling time ~2–3 hours in vitro; growth rate consistent in vivo under intestinal conditions,Intestinal epithelium and mucus layer; preferentially colonizes sites with impaired mucus barrier,Competitive exclusion of pathogens via adhesion competition; symbiotic with host immune system,"Tolerant to bile, low pH, osmotic stress, and intestinal transit; stable during lyophilization and rehydration","Bile salts, mucin degradation enzymes","Bifidobacterium bifidum is a facultative anaerobe that thrives in the human gut environment, exhibiting strong adhesion to intestinal mucus and epithelial cells. It tolerates gastric acidity and bile, enabling survival through the gastrointestinal tract. It utilizes mucin-derived glycans as a primary carbon source, supporting its persistence in the gut. Its growth is enhanced under intestinal conditions, particularly in the presence of host-derived substrates like IECs and mucins.","CRISPR-Cas9 (inferred from related species), heterologous expression in Lactococcus lactis",High efficiency in model systems; off-target risk not reported,Constitutive expression of pilus genes in vitro and in vivo; regulated by carbon source and host signals,"Starch, cellobiose, maltodextrin (carbon source-dependent induction)",Plasmid-based expression stable in L. lactis; chromosomal integration not reported; low metabolic burden,Pilus expression maintained in encapsulated systems; compatible with biocompatible matrices,"Genetic engineering of B. bifidum PRL2010 involves heterologous expression of pilus gene clusters (pil2 and pil3) in Lactococcus lactis to enhance adhesion. These constructs are constitutively expressed and induced by intestinal carbon sources such as starch and maltodextrin. The system demonstrates stable expression and functional pilus assembly, enabling enhanced binding to host tissues.","[""Hypoxia"", ""pH"", ""Bile""]","[""Mucins"", ""Starch"", ""Cellobiose"", ""Maltodextrin""]",,"[""Intestinal Epithelial Cells (IECs)"", ""Extracellular Matrix (ECM) proteins""]","Pilus gene clusters (pil2, pil3), transaldolase, enolase, DnaK",Carbon source-dependent induction (AND gate: carbon source + host environment); threshold-based expression in response to mucosal cues,"Bifidobacterium bifidum senses host-derived carbon sources (e.g., starch, maltodextrin) and host cell contact (IECs, ECM) to activate pilus and adhesion molecule expression. This represents a conditional logic system where adhesion is triggered only in the presence of both metabolic substrates and host tissue signals, ensuring targeted colonization.","[""Adhesion"", ""Immunomodulation"", ""Pathogen Exclusion""]","Moonlighting proteins (enolase, DnaK, transaldolase) secreted via non-classical pathways; pili-mediated surface display","Controlled by host environment (carbon source, IEC contact); no external inducer required",Compatible with hydrogel and encapsulated delivery systems; pili and surface proteins remain functional in matrix,False,,,Not applicable – no direct antibacterial activity reported,,False,,,,无直接抗菌作用,False,Not applicable – no oxygen-producing enzymes reported,,False,False,False,无氧生成能力,True,"Adhesion to IECs and immune cells (dendritic cells, macrophages) triggers modulation of intestinal and systemic immune responses, including anti-inflammatory cytokine production and enhanced anti-tumor immunity.","Enolase, DnaK, transaldolase (moonlighting proteins)",False,Not applicable – no direct tissue regeneration or ECM remodeling reported,,False,Not applicable – no evidence of SCFA or neurotransmitter production reported,,True,Enhances anti-tumor immune responses and supports checkpoint-inhibition cancer therapy by modulating the gut microbiota and immune cell activity.,Bifidobacterium bifidum PRL2010 (probiotic strain),GRAS,Auxotrophy (inferred from lack of pathogenicity); no antibiotic resistance genes reported,"Carbon source (starch, maltodextrin)",No pathogenicity reported; low opportunistic risk; no known antibiotic resistance genes; no evidence of horizontal gene transfer; low environmental escape risk,Physical encapsulation prevents environmental release,Bifidobacterium bifidum is classified as GRAS (Generally Recognized As Safe) with no documented pathogenicity. It lacks virulence genes and antibiotic resistance markers. Its use in probiotics is well-established. Encapsulation provides an additional physical barrier to prevent unintended environmental release.,"Bifidobacterium bifidum PRL2010 enhances intestinal barrier function, reduces inflammation, and supports anti-tumor immunity. It demonstrates strong adhesion to intestinal mucus and epithelial cells, enabling prolonged colonization and immune modulation. In vivo studies show improved resistance to pathogen colonization and enhanced efficacy of checkpoint-inhibitor cancer therapy.",9292,1809,11101,,
0e718877-3d8c-450b-a55c-c699be774705,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""LMT1-48""}]",Suspension,Facultative Anaerobe,"Grows at 37°C, utilizes D-glucose, D-fructose, D-mannose, D-ribose, and N-acetylglucosamine as carbon sources; pH 3.95 in culture supernatant","Rapid growth observed in MRS broth; doubling time not explicitly reported, but growth confirmed within 24 h at 37°C","Intestinal tract (gut microbiota), particularly in the context of high-fat diet-induced obesity and pathogenic Enterobacter cloacae presence","Inhibits growth of pathogenic Enterobacter cloacae; promotes gut microbiota diversity, especially increasing Verrucomicrobia and Proteobacteria phyla","Stable under in vitro culture conditions; tolerance to low pH (pH 3.95) demonstrated in coculture experiments; no data on UV, drying, or shear stress","Lactic acid (produced during fermentation, contributing to low pH environment)","Lactobacillus plantarum LMT1-48 is a rod-shaped, nonmotile, facultative anaerobic bacterium that grows rapidly in MRS medium at 37°C, utilizing multiple sugars including glucose, fructose, and mannose. It exhibits strong antimicrobial activity against Enterobacter cloacae, primarily through metabolite-mediated mechanisms rather than solely pH reduction. It colonizes the intestinal environment in obese mice, where it suppresses pathogenic bacteria and enhances microbial diversity.",,,,,,,"No genetic engineering was performed on Lactobacillus plantarum LMT1-48 in this study. The strain was isolated from fermented food and used in its native form. Its functional effects are attributed to natural metabolic and antimicrobial properties, not synthetic circuits or engineered genetic modules.","[""pH""]","[""Glucose"", ""Fructose"", ""Mannose"", ""N-acetylglucosamine""]",,,Not specified; likely intrinsic metabolic sensing of available carbon sources and environmental pH,No engineered logic gates or regulatory circuits reported; natural metabolic adaptation to nutrient availability and pH,"Lactobacillus plantarum LMT1-48 senses and responds to available fermentable carbohydrates (e.g., glucose, fructose) and low pH conditions in the gut environment. It adapts its growth and metabolic activity accordingly, enabling competitive colonization and antimicrobial activity. No synthetic sensing circuits were used.","[""Antibacterial"", ""Metabolic Regulation"", ""Immunomodulation""]","Secretion of metabolites (e.g., SCFAs, antimicrobial compounds) via general secretion pathways; no specific secretion system reported",Oral administration at 10^9 CFU/day; dosage is fixed and not dynamically controlled,Compatible with oral delivery; no encapsulation or material barrier used in this study,True,False,False,"Inhibits growth of Enterobacter cloacae through secreted metabolites, not solely due to low pH. Activity persists even under controlled pH conditions, indicating specific antimicrobial compounds.",Short-chain fatty acids (SCFAs) and other unidentified antimicrobial metabolites,False,True,True,True,"L. plantarum LMT1-48 significantly reduced E. cloacae levels in vivo without causing overt toxicity. The antimicrobial effect was not solely due to pH drop, suggesting targeted, non-damaging activity. No data on biofilm inhibition or broad-spectrum activity against other pathogens.",False,,,False,False,False,No evidence of oxygenation function; L. plantarum is facultative anaerobe and not engineered for oxygen production.,True,"Reduces systemic inflammation by suppressing pathogenic bacteria (e.g., E. cloacae), which produce LPS and trigger chronic inflammation. Promotes gut microbiota diversity, associated with improved immune homeostasis.","Short-chain fatty acids (SCFAs), microbial metabolites",False,,,True,"Modulates host metabolism by reducing body weight, abdominal fat volume, leptin, and total cholesterol levels. Enhances gut microbiota diversity, which is linked to improved metabolic health.",Short-chain fatty acids (SCFAs),False,,,GRAS,None; no synthetic kill switches or auxotrophy used,,L. plantarum is a well-known probiotic with low pathogenicity. No antibiotic resistance genes or horizontal gene transfer risks reported. No evidence of environmental escape or opportunistic infection.,None; oral administration without physical confinement,"Lactobacillus plantarum LMT1-48 is classified as GRAS (Generally Recognized As Safe). It is naturally present in fermented foods and has no reported pathogenicity. No genetic modifications were made, minimizing biosafety risks. The strain is expected to be safely excreted without long-term colonization or ecological disruption.","L. plantarum LMT1-48 administration significantly reduced body weight and abdominal fat volume in E. cloacae-induced obese mice fed a high-fat diet. It lowered serum leptin and total cholesterol levels, increased gut microbiota diversity (especially Verrucomicrobia and Proteobacteria), and suppressed pathogenic Enterobacter cloacae. These effects collectively indicate strong antiobesity efficacy through modulation of gut microbiota and host metabolism.",10362,1777,12139,,
bea5e163-bbf0-4c03-bdac-6a8ca44c6973,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires glucose and amino acids; tolerant to bile salts and low pH (gastric conditions)",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in gastrointestinal tract with stable persistence over 3-week intervention,"Gastrointestinal tract (gut mucosa), with potential transient presence in nasopharynx after oral consumption",Competitive exclusion of pathogens; no significant disruption of native microbiota reported; may enhance commensal balance,"Tolerant to drying, lyophilization, and moderate UV exposure; stable during storage at 4°C; resistant to shear stress in liquid formulations","Cell wall components (e.g., teichoic acids), exopolysaccharides","Lactobacillus rhamnosus GG is a facultative anaerobe capable of surviving gastric transit and colonizing the intestinal mucosa. It exhibits robust growth under physiological conditions and maintains viability during oral administration. Its ability to adhere to epithelial cells and resist bile and low pH enables effective delivery to the gut, where it exerts immunomodulatory effects.",Not applicable (wild-type strain used; no genetic modification reported),,Constitutive (no engineered circuits),,High chromosomal stability; no plasmids used; no evidence of genetic drift or loss in vivo during 6-week intervention,Stable in juice formulation; no degradation or loss of viability during encapsulation in liquid matrix,"Lactobacillus rhamnosus GG was used in its native, unmodified form. No genetic circuits, inducible promoters, or synthetic biology tools were employed. The strain was administered as live or heat-inactivated cells in a juice matrix without any engineered control systems.","[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]",,"[""Proteases"", ""Cytokines""]","Fermentative metabolism (e.g., lactate dehydrogenase), bile salt hydrolase (BSH), surface adhesins (e.g., pili)",No engineered logic gates; natural sensing via metabolic and surface receptors,"L. rhamnosus GG naturally senses environmental cues such as low pH and bile acids via surface receptors and metabolic pathways. It responds to glucose availability and produces lactate, which may influence local microenvironment. It also interacts with host immune cells, potentially detecting cytokines and proteases, but no synthetic sensing circuits were implemented.","[""Immunomodulation""]","Type I secretion (e.g., for EPS), passive release via cell lysis",Dose-dependent effects via daily oral intake (10^9 CFU); no feedback control,Compatible with juice matrix; stable during encapsulation and oral delivery,False,,,,,,,,,,False,,,,,,,True,"Modulates innate and adaptive immune responses by enhancing dendritic cell function, increasing IL-10 and IFN-α production, and reducing pro-inflammatory cytokines (e.g., IL-6, TNF-α). Promotes mucosal barrier integrity.","Secreted exopolysaccharides (EPS), surface proteins (e.g., pili), cell wall components (e.g., peptidoglycan)",False,,,False,,,False,,,GRAS,None (no kill-switch or auxotrophy introduced),,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape concerns due to limited survival outside host,Oral delivery with transient gut colonization; no physical barrier beyond natural mucosal lining,"Lactobacillus rhamnosus GG is a well-characterized, generally recognized as safe (GRAS) strain with a long history of human use. It does not possess known virulence factors or antibiotic resistance genes. Its transient nature in the gut and lack of genetic engineering reduce biosafety risks. No containment systems were used.",虽然未观察到L. rhamnosus GG对鼻咽部人鼻病毒（HRV）载量有统计学显著差异，但病毒载量与症状总评分呈正相关（第2天相关系数0.61，p<0.001；第5天相关系数0.28，p=0.034）。提示病毒复制水平与临床症状严重程度密切相关。该菌株在干预期间表现出良好的定植能力和免疫调节潜力，可能通过增强宿主免疫反应间接减轻症状，但其直接抗病毒作用在本研究中未得到证实。,8978,1655,10633,,
acfd28c9-7e93-4633-8555-78146388a2e3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""MM1""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""MM4""}]",Suspension,Facultative Anaerobe,"Temperature: 28°C; pH: 7.0 (in vitro); Nutritional requirements: Complex media (nutrient broth), no specific host metabolite dependency reported",Growth rate not explicitly quantified; in vitro doubling time not reported; consistent in vitro growth observed over 72 hours,Gut of juvenile Epinephelus coioides (autochthonous source),Potential for competitive colonization in host gut; no direct evidence of symbiosis or antagonism with other gut microbes reported,Resistant to artificial gastric and intestinal fluids; viable in stored diets for up to 60 days (though viability declined by 35.2% and 50.6% respectively),Cell wall and metabolic stability under simulated gastrointestinal conditions,"Lactococcus lactis MM1 and Enterococcus faecium MM4 are lactic acid bacteria isolated from the gut of juvenile grouper. They exhibit resistance to artificial gastric and intestinal fluids, indicating tolerance to low pH and bile. They grow well in nutrient broth at 28°C and are capable of surviving in feed for up to 60 days, though viability decreases over time. Both strains are autochthonous to the host gut, suggesting potential for colonization and persistence.",,,,,No plasmid or chromosomal integration reported; stability inferred from in vitro and in-feed viability over 60 days; no evidence of genetic drift or loss of function,Stable in extruded feed pellets; viability maintained at 0.85–1.0 × 10⁸ CFU/g after 30-day refreshment,"No genetic modifications were performed. The strains were used in their native form, isolated from the host gut and administered via diet without any engineered circuits or synthetic biology tools.",,,,,,,"No engineered sensing modules or logic circuits were used. The strains function as natural probiotics, relying on innate physiological responses to environmental cues in the host gut, such as pH, nutrient availability, and microbial competition.","[""Digestive Enzyme Modulation"", ""Immune Response Modulation""]",Unknown; likely passive secretion of metabolites or cell wall components.,Dose: 1.0 × 10⁸ CFU/g diet; controlled by feed formulation and daily administration.,Compatible with cold-pressed extruded feed pellets; viable in feed for up to 60 days with periodic refreshment.,False,,,Not applicable; no direct antibacterial activity reported in this study.,,False,,,,无抗菌功能相关证据,False,Not applicable; no oxygen-producing or oxygen-consuming mechanisms reported.,,False,False,False,无氧代谢相关功能,True,Modulates humoral immune parameters: increases serum complement C3 and lysozyme activity in L. lactis-fed fish; decreases lysozyme in E. faecium-fed fish. No effect on phagocytic activity or SOD.,"Unknown; likely cell wall components (e.g., peptidoglycan, teichoic acids) or secreted metabolites acting as immunostimulants.",False,Not applicable; no evidence of tissue regeneration or ECM modulation.,,False,"Not applicable; no direct regulation of host SCFAs, tryptophan, or neurotransmitters reported.",,False,Not applicable; no cancer-related therapeutic function.,,BSL-1,No engineered kill switches or auxotrophy reported; natural strains used.,,Low pathogenicity; both strains are commonly used in aquaculture and food. No antibiotic resistance genes or HGT risk reported. No evidence of environmental escape.,Physical confinement via feed encapsulation; no release into environment during trial.,"Lactococcus lactis MM1 and Enterococcus faecium MM4 are non-pathogenic, autochthonous strains isolated from grouper gut. They are GRAS (Generally Recognized As Safe) in aquaculture. No genetic modifications or antibiotic resistance genes were detected. They are unlikely to cause harm to host or environment.",饲料转化率显著改善（FCR从1.03降至0.97和0.98），表明营养利用效率提高。肝胰脏蛋白酶活性显著升高，提示消化功能增强。血清补体C3水平显著上升，表明体液免疫被激活。L. lactis组血清溶菌酶活性显著升高，而E. faecium组则显著降低，显示免疫调节作用具有菌株特异性。尽管生长率和摄食量略有下降，但整体健康和代谢效率提升，支持其作为鱼类益生菌的潜力。,14663,1670,16333,,
4ffbf882-090d-43a1-8ab2-663148e463f2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GR-1""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in MRS medium; optimal pH not specified, but growth occurs under micro-aerophilic conditions; utilizes lactose, maltose, rhamnose, ribose as carbon sources.",Growth rate not quantified; exhibits bi-phase growth curve on sorbitol; no growth on glycogen.,"Vaginal epithelium (specifically urogenital tract), with preference for the vaginal niche over intestinal tract.",Lacks pili-mediated adhesion to intestinal epithelium; does not compete effectively with intestinal microbiota; may promote natural ascension from gut to vagina due to low intestinal adhesion.,"High resistance to oxidative stress (H₂O₂); low survival in simulated gastric juice (pH 2.0); no data on UV, drying, or shear stress.","Thioredoxin genes (GR1_00460, GR1_01468, GR1_01733) likely responsible for oxidative stress resistance.","Lactobacillus rhamnosus GR-1 is a facultative anaerobe that grows optimally at 37°C under micro-aerophilic conditions. It exhibits enhanced metabolic versatility in the vaginal niche, utilizing lactose, maltose, rhamnose, and ribose—carbohydrates relevant to vaginal epithelial tissue. It lacks intestinal adhesion pili, which may facilitate its natural ascension from the gastrointestinal tract to the vagina. However, it shows poor survival in acidic gastric conditions, limiting oral delivery efficacy.",CRISPR-Cas not mentioned; genome sequenced using Illumina paired-end sequencing; annotation via GeneMark and Glimmer.,Not applicable (no genetic modification reported).,Not applicable (no synthetic circuits described).,,No data on plasmid stability or chromosomal integration; natural genome stability inferred from in vivo persistence.,No data on stability in material environments.,"The strain's genome was fully sequenced and compared to other L. rhamnosus strains. No synthetic genetic circuits or engineered modifications were reported. Natural genomic adaptations, such as unique EPS cluster and carbohydrate metabolism genes, underlie its niche-specific functionality.","[""Hypoxia"", ""pH"", ""Oxidative stress (H₂O₂)""]","[""Lactose"", ""Maltose"", ""Rhamnose"", ""Ribose"", ""Sorbitol""]",,"[""Epithelial cell surface (via lectin-like adhesion)""]","Lectin-like protein 1 (Lrp1) mediates tissue-specific adherence to vaginal epithelium; thioredoxin genes (GR1_00460, GR1_01468, GR1_01733) involved in oxidative stress sensing/resistance.",No synthetic logic gates reported; natural sensing is likely constitutive or threshold-based based on metabolic availability.,"L. rhamnosus GR-1 senses and responds to vaginal-specific metabolites (lactose, maltose, rhamnose, ribose) and oxidative stress via intrinsic metabolic and redox pathways. It lacks pili-mediated sensing of intestinal mucus, indicating niche-specific signal recognition. The lectin-like protein 1 enables selective adhesion to vaginal epithelium, suggesting a form of environmental discrimination.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Extracellular polysaccharide (EPS) secretion; potential secretion via general secretion pathways.,Not controllable; natural expression based on environmental cues.,EPS is compatible with mucosal surfaces; no data on encapsulation or material compatibility.,True,False,True,Disrupts urogenital biofilms via lectin-like protein 1; antagonizes uropathogens by competitive exclusion and biofilm disruption.,Lectin-like protein 1 (Lrp1),True,True,True,True,L. rhamnosus GR-1 disrupts urogenital biofilms and inhibits pathogen adhesion; no cytotoxicity reported; localized activity in vaginal niche.,False,,,False,False,False,No evidence of oxygen production or oxygenation function.,True,Modulates host immune response by inducing IL-6 and suppressing TNF and IL-8 expression in vaginal epithelial cells.,Exopolysaccharide (EPS) and cell surface components,True,Enhances host defense mechanisms and promotes epithelial integrity via immunomodulation and biofilm disruption.,Exopolysaccharide (EPS),False,,,False,,,GRAS,None reported; no kill switches or auxotrophy described.,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to niche specificity.,Physical barrier not required due to natural niche restriction.,"L. rhamnosus GR-1 is classified as GRAS (Generally Recognized As Safe). It shows no pathogenicity, no antibiotic resistance genes, and low risk of environmental persistence. Its niche-specific adaptation limits ecological spread. No synthetic containment systems are used.","L. rhamnosus GR-1 effectively colonizes the human vagina after oral administration, temporarily persisting and reducing uropathogen adhesion. It disrupts biofilms, modulates immune responses (suppressing TNF and IL-8), and enhances host defenses. Clinical studies show it can prevent recurrent urinary tract infections and improve vaginal health. However, its poor survival in gastric acid limits oral delivery efficacy, suggesting vaginal administration may be more effective.",18072,1835,19907,,
31a9fda1-0f58-4527-9422-ac62888a8acd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GR-1"", ""strain_id"": ""GR-1""}]",Suspension,Facultative Anaerobe,"37°C, pH range from initial juice pH (~3.4–3.9) to lower pH after fermentation due to lactic acid production; utilizes fructose as substrate; requires anaerobic conditions for optimal growth during fermentation",Growth rate sufficient to achieve ≥10⁷ CFU/mL within 72 h of fermentation; viable counts maintained at ≥10⁷ CFU/mL during 30 days of refrigerated storage (especially in orange juice); growth rate consistent with in vitro conditions,"Gastrointestinal tract (specifically urogenital and intestinal mucosa), as established by prior studies; not designed for tissue-specific colonization in this study",No direct interaction with host microbiome reported; potential to support beneficial gut flora via prebiotic synergy with inulin,Tolerant to bile and acid; survives passage through gastrointestinal tract; stable under refrigerated storage (4°C) for up to 30 days in orange juice; no significant loss in viability in orange juice over time,"Bile salts, acid resistance mechanisms (intrinsic to L. rhamnosus GR-1)","Lactobacillus rhamnosus GR-1 is a facultative anaerobe capable of fermenting fructose in fruit juices to produce lactic acid, thereby lowering pH. It maintains high viability (>10⁷ CFU/mL) during 72-hour fermentation and 30-day refrigerated storage, particularly in orange juice. It exhibits strong acid and bile tolerance, enabling survival in the gastrointestinal tract. Growth is supported by the natural sugars in fruit juices and enhanced by inulin fiber, though no significant difference was observed between short- and long-chain inulin.",,,,,No genetic modifications reported; strain is naturally occurring and used in commercial probiotic products; chromosomal stability assumed based on lack of engineered constructs,No genetic engineering involved; stability in fruit juice matrix confirmed by consistent viability over time,"Lactobacillus rhamnosus GR-1 was used in its native form without genetic modification. No synthetic circuits, inducible promoters, or gene editing tools were applied. The strain was selected for its inherent probiotic properties and robustness in food matrices.","[""pH (acidic environment)"", ""Fructose (sugar substrate)""]","[""Fructose"", ""Lactic acid (end-product)""]",,,"FNR promoter (implied by metabolic sensing of oxygen and redox state); fructose uptake systems (e.g., FruA transporter)",Constitutive metabolic activity; no reported logic gates or threshold control; growth driven by substrate availability and environmental conditions,"Lactobacillus rhamnosus GR-1 senses available fructose and low pH via intrinsic metabolic pathways. It grows and produces lactic acid in response to sugar availability, with no reported inducible or regulated circuits. The system operates as a constitutive fermenter without complex logic processing.","[""Metabolic Regulation""]",None reported; no engineered secretion systems used,Controlled by initial inoculum and fermentation time; no dynamic dosage regulation,Compatible with liquid fruit juice matrix; no structural disruption observed; inulin fiber added as a stabilizer and prebiotic,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,"L. rhamnosus GR-1 ferments fructose in fruit juices to produce lactic acid, lowering pH and potentially modulating gut microbiota composition. It also utilizes inulin fiber (prebiotic) to enhance its own viability and promote beneficial microbial growth.","Lactic acid, inulin-derived oligosaccharides",False,,,GRAS,None; no kill switches or auxotrophy introduced,,Non-pathogenic; well-documented safety in human consumption; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to poor survival outside host,None; no physical confinement beyond the sealed juice container,"Lactobacillus rhamnosus GR-1 is classified as GRAS (Generally Recognized As Safe) and has been safely consumed in yogurt and other products, including by HIV/AIDS patients. It is not pathogenic, does not carry antibiotic resistance genes, and is unlikely to persist in the environment. No biocontainment strategies were implemented, but the risk is considered negligible due to its non-invasive nature and lack of virulence factors.","Lactobacillus rhamnosus GR-1 achieved and maintained viable counts above 10⁷ CFU/mL in all fruit juices (apple cider, orange, grape) during 72-hour fermentation and 30-day refrigerated storage. Orange juice showed the highest stability, with viable counts increasing over time. Sensory evaluation indicated that apple cider fortified with long-chain inulin (ALC) was the most preferred sample, scoring highest in flavor, texture, and overall acceptability. This demonstrates the feasibility of using L. rhamnosus GR-1 in non-dairy probiotic fruit juices as a viable alternative to dairy-based probiotics.",13419,1740,15159,,
99ef7c72-2ec0-4d31-8f86-2363746ba3ee,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires carbohydrates (e.g., lactose, glucose) as carbon sources; tolerates mild bile exposure.",Doubling time ~1–2 hours in vitro; in vivo colonization observed in intestinal tract with moderate persistence.,Small intestine and colon; preferentially colonizes mucosal surfaces of the gastrointestinal tract.,Symbiotic with host microbiota; competes with pathogenic bacteria for nutrients and adhesion sites.,Moderate tolerance to gastric acid and bile; stable during lyophilization and rehydration; sensitive to high shear stress.,"Bile salts, gastric acid (HCl), lyophilization stabilizers (e.g., trehalose)",Lactobacillus acidophilus 和 Bifidobacterium 属细菌为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，依赖乳糖或葡萄糖等碳源。它们能耐受轻度胆汁环境，在胃肠道黏膜表面定植，具有与宿主微生物群共生的能力，通过竞争营养和黏附位点抑制病原菌生长。在冻干和复水后仍保持活性，但对高剪切应力较敏感。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及对 Lactobacillus acidophilus 或 Bifidobacterium 进行基因工程改造，仅作为天然益生菌制剂使用。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter, Lactate receptor, Bile acid sensor (e.g., Bile salt hydrolase)",Not specified,文中未描述任何基因回路或逻辑门控机制，微生物系统未被工程化以响应特定信号。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]","Type IV secretion system, Vesicles (Extracellular vesicles)",Not specified,Compatible with yogurt and capsule-based delivery systems; stable in gel matrices during storage.,False,,,Not applicable,,,,,,未提及抗菌或抗生物膜功能。,False,Not applicable,,,,,未提及氧气生成功能。,True,通过调节肠道免疫反应，促进抗炎细胞因子（如IL-10）分泌，抑制促炎因子（如TNF-α、IL-6）释放，增强黏膜屏障功能。,"IL-10, TGF-β, Secreted exopolysaccharides",True,促进上皮细胞增殖，增强肠道屏障功能，修复受损黏膜，通过分泌生长因子（如EGF）和调节细胞外基质（ECM）成分实现。,"Epidermal Growth Factor (EGF), TGF-β, Mucin",True,通过发酵碳水化合物产生短链脂肪酸（SCFAs），如乙酸、丙酸和丁酸，调节宿主能量代谢，维持肠道pH，抑制病原菌生长。,"Butyrate, Acetate, Propionate",False,Not applicable,,GRAS,"Auxotrophy (e.g., requirement for specific amino acids or vitamins)","Lactose, Vitamin B12",Low pathogenicity; no antibiotic resistance genes reported; minimal risk of horizontal gene transfer; low environmental escape risk due to poor survival outside host.,Physical confinement in yogurt or capsule form limits environmental release.,Lactobacillus acidophilus 和 Bifidobacterium 属为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，水平基因转移风险极低。其在体外环境中生存能力弱，通过酸奶或胶囊封装可有效防止环境释放，安全性高。,家长报告中，24名使用益生菌的儿童中有15名（62.5%）症状改善，主要表现为腹泻、腹痛、消化不良等症状缓解。益生菌被广泛接受，90%的家长表示若医生推荐将愿意使用。,6123,1629,7752,,
11552a56-dddb-4237-845a-75229dd395fd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""Nissle 1917""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5; tolerates moderate osmotic stress; utilizes glucose and other carbon sources; requires no special vitamins or amino acids beyond standard media",Doubling time ~20–30 minutes in vitro; in vivo colonization stability demonstrated in murine models,"Intestinal mucosa, particularly colon and ileum","Competes with pathogens (e.g., Salmonella Typhimurium) for nutrients and binding sites; promotes balanced gut microbiota","Tolerant to bile salts, moderate pH shifts, and short-term drying; stable during lyophilization and rehydration",Cell surface ferric oxide binding proteins,大肠杆菌Nissle 1917是一种兼性厌氧菌，可在37°C、pH 6.5–7.5条件下快速生长，具有良好的肠道定植能力，能耐受胆盐和pH波动，通过竞争营养和黏附位点抑制病原体定植。,"Plasmid-based expression systems, CRISPR-Cas9 (implied in functional studies)",High efficiency in gene knockout and overexpression; low off-target risk reported in model systems,"Constitutive and inducible (e.g., IPTG-responsive promoters used in studies)",IPTG (Isopropyl β-D-1-thiogalactopyranoside),High chromosomal integration stability; plasmid loss rate <1% per generation; minimal metabolic burden,Stable in hydrogel and encapsulated delivery systems without significant gene loss,通过质粒或染色体整合方式构建基因回路，实现对毒力因子表达的调控，如利用IPTG诱导系统控制抗侵袭蛋白的表达。,"[""pH"", ""Osmotic stress"", ""Glucose""]","[""Sialic acid"", ""N-acetyl-glucosamine"", ""Iron (via siderophores)""]","[""Quorum sensing molecules (e.g., AI-2)""]","[""Mucin"", ""Cytokines (indirectly via inflammation)""]","Ferric oxide binding proteins, MUC2 mucin receptors, iron-siderophore transporters",AND gate logic: requires both nutrient limitation (iron) and host mucosal contact to activate anti-invasion response,该菌株通过感知铁离子浓度和黏膜环境信号，激活抗侵袭机制，实现对病原体入侵的精准抑制，避免过度免疫反应。,"[""Antiadhesive"", ""Antiinvasion"", ""Antivirulence"", ""Immunomodulation""]","Type I secretion system (for iron-binding proteins), extracellular vesicles",Constitutive and inducible expression allows tunable output; dosage controlled by host environment and inducer concentration,Compatible with hydrogel and oral delivery matrices; maintains viability and function during encapsulation,False,False,False,Not directly antibacterial; acts via indirect antivirulence mechanisms,,False,False,False,False,无直接抗菌活性，不适用于抗菌模块评估。,False,Not involved in oxygen production or delivery,,False,False,False,未涉及氧合功能。,True,"Enhances mucosal barrier integrity, upregulates IgA, modulates Th1/Th2/Treg balance, and stimulates phagocytic activity","Secreted proteins (e.g., anti-invasion factors), MUC2 mucin, cytokines (IL-10, TGF-β)",True,"Promotes epithelial barrier repair, enhances tight junction stability, and stimulates mucosal integrity","MUC2 mucin, E-cadherin, β-catenin, PKC isoforms",True,"Produces SCFAs (e.g., acetic acid) that regulate host metabolism and downregulate pathogen toxin gene expression","Acetic acid, short-chain fatty acids (SCFAs)",False,No reported tumor-targeting or prodrug conversion activity,,GRAS,"Auxotrophy (iron-dependent growth), kill-switch via nutrient deprivation","Iron (Fe3+), IPTG",Non-pathogenic; no known antibiotic resistance genes; low risk of horizontal gene transfer; no environmental escape reported,Physical confinement in oral capsules or hydrogels prevents systemic dissemination,大肠杆菌Nissle 1917为公认安全（GRAS）菌株，具有铁依赖性生长特性，可通过营养剥夺实现生物遏制，无致病性、耐药基因或环境逃逸风险。,在小鼠模型中，EcN显著减少沙门氏菌和志贺氏菌的侵袭效率达70%；在体外实验中抑制EHEC和EPEC黏附；促进肠道屏障修复，改善炎症性肠病症状。,15031,1692,16723,,
1aab145a-0146-4e81-9e43-a090c5d53b06,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""BB""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis LMG S-28195"", ""strain_id"": ""BL""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus crispatus"", ""strain_id"": ""LC""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""LR""}]",Oral administration (gastrointestinal tract),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; utilizes carbohydrates (e.g., lactose, glucose) as carbon sources; requires vitamins and amino acids for growth.",Doubling time ~1.5–2 hours in vitro; stable colonization in GI tract in vivo with sustained presence over 30 administrations.,Gut lumen (upper and lower intestinal tract); preferentially colonizes mucosal surfaces and Peyer’s patches.,Competitive exclusion of pathogenic bacteria; enhances symbiosis with host microbiota; modulates immune tolerance via DC and Treg interaction.,"Tolerant to gastric acidity (pH 2–3), bile salts, osmotic stress; stable during lyophilization and rehydration.","Bile salts, gastric acid, osmotic stress",这些益生菌为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，利用乳糖、葡萄糖等碳源，需维生素和氨基酸。在体外培养中倍增时间为1.5–2小时，在体内可稳定定植于肠道，持续30次给药后仍保持活性。它们优先定植于肠道黏膜表面和派伊尔斑，通过调节树突状细胞和调节性T细胞来促进免疫耐受。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及基因工程改造，所有益生菌均为天然分离株，未进行人工基因编辑。其免疫调节功能源于天然代谢产物和表面分子与宿主免疫系统的相互作用。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""SCFAs""]","[""Quorum sensing (indirect via metabolite feedback)""]","[""Cytokines (IL-10, TGF-β)"", ""Tissue degradation fragments (indirect)""]","Toll-like receptors (TLRs), NOD-like receptors (NLRs), C-type lectin receptors","AND gate: activation requires both microbial presence and host immune context (e.g., DC maturation state). Thresholds for immune activation are set by cytokine feedback loops.",这些益生菌通过模式识别受体（如TLRs、NLRs）感知肠道微环境中的pH、葡萄糖、胆汁酸和短链脂肪酸等信号。当检测到病原相关分子模式（PAMPs）或炎症信号时，激活树突状细胞，诱导其向耐受性表型转化。该过程依赖于IL-10和TGF-β的协同作用，形成一个正反馈回路，确保免疫调节仅在需要时启动，避免过度激活。,"[""Immunomodulation""]","Secretion of immunomodulatory cytokines (IL-10, TGF-β) via constitutive secretion; no lysis or vesicle-mediated delivery reported.","Controlled by oral dosing schedule (2.5 × 10⁹ CFU/rat, 30 doses over 8 weeks); activity is dose-dependent and time-limited.","Compatible with oral administration; no encapsulation material mentioned, but stable in gastrointestinal environment.",False,,,Not applicable,,,,,,无抗菌功能,False,Not applicable,,,,,无氧生成功能,True,通过激活树突状细胞（DCs）和诱导调节性T细胞（Treg）分化，促进免疫耐受。具体机制包括上调IL-10、TGF-β、FOXP3、CTLA4等免疫调节分子的表达，抑制Th17细胞反应，降低抗乙酰胆碱受体（AChR）抗体水平。,"IL-10, TGF-β, FOXP3, CTLA4",False,Not applicable,,False,Not applicable,,False,Not applicable,,GRAS,"None (natural strains, no synthetic kill switches)",None,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; no environmental escape risk due to natural gut colonization.,"None (oral delivery, no physical barrier)",所用菌株均为公认安全（GRAS）的益生菌，无致病性，未发现抗生素抗性基因，无水平基因转移风险。由于其为天然肠道定植菌，不会在环境中长期存活，因此生态风险极低。,在实验性自身免疫性重症肌无力（EAMG）大鼠模型中，口服给予双歧杆菌（BB+BL）和乳酸杆菌（LC+LR）可显著降低临床评分（第7–9周起），减少血清抗大鼠AChR IgG抗体水平，并提高肌肉AChR含量。同时，Peyer斑和脾脏中FOXP3 mRNA表达上调，IFN-γ表达下调，表明调节性T细胞功能恢复。这些结果支持其作为重症肌无力辅助治疗的潜力。,10834,1875,12709,,
14e20cca-101f-44ec-b613-f0b898327175,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GR-1"", ""strain_id"": ""GR-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum RC-14"", ""strain_id"": ""RC-14""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates physiological osmotic conditions; utilizes glucose and other carbohydrates as carbon sources; requires no specific vitamins or amino acids beyond standard growth media",Doubling time ~60–90 min in vitro; in vivo colonization observed within days of administration; stable persistence in vaginal environment post-treatment,"Vaginal epithelium, particularly in the lower genital tract; preferentially colonizes mucosal surfaces and adheres to epithelial cells","Competitive exclusion of pathogenic bacteria (e.g., Gardnerella vaginalis); promotes symbiosis with resident microbiota by restoring ecological balance; inhibits overgrowth of facultative and obligate anaerobes",Tolerant to gastric acidity and bile salts (oral route); resistant to drying and lyophilization; stable during storage at 4°C; withstands moderate shear stress during delivery,"Cell wall components (e.g., teichoic acids), extracellular polysaccharides, and acid tolerance systems","Lactobacillus acidophilus, L. rhamnosus GR-1, and L. fermentum RC-14 are facultative anaerobes capable of thriving in the vaginal environment. They grow optimally at body temperature and neutral-to-slightly-acidic pH, utilizing available sugars for energy. These strains exhibit strong adhesion to vaginal epithelial cells and can survive gastrointestinal transit when administered orally, enabling systemic colonization. They are stable under standard storage and delivery conditions, making them suitable for both oral and vaginal formulations.",None reported (natural strains used),Not applicable (no genetic modification described),Constitutive,,High chromosomal stability; no plasmid-based systems reported; no evidence of genetic drift in clinical trials,Stable in both oral capsules and vaginal tablets; maintains viability and function in gel and dairy matrices,"No genetic engineering was performed. The strains used are naturally occurring probiotics selected for their ability to colonize the vaginal mucosa, produce antimicrobial substances, and restore normal flora. Their efficacy is attributed to intrinsic biological properties rather than synthetic genetic circuits.","[""pH"", ""Glucose"", ""Lactate""]","[""Bile Acids"", ""Polyamines""]","[""Gardnerella vaginalis adherence factors""]","[""Epithelial surface receptors"", ""Mucosal cytokines""]","Fimbrin-like adhesins, Mucin-binding proteins, Lactate dehydrogenase (LDH) sensors","Threshold-based activation: antimicrobial production triggered when local pH rises above 4.5 and lactate levels drop, indicating dysbiosis","These lactobacilli sense changes in vaginal pH and metabolite profiles (e.g., lactate depletion, polyamine accumulation) associated with bacterial vaginosis. Upon detection, they initiate colonization and secretion of antimicrobial agents. The system operates as a threshold-based feedback loop: when the environment deviates from healthy conditions (low pH, high lactate), the bacteria activate protective mechanisms, including acid production and pathogen inhibition, without requiring external inducers.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I Secretion System (for bacteriocins), Vesicle-mediated release (exosomes), Lysis (controlled release of intracellular components)",Dose-dependent: ≥10⁸ CFU/day for 2 months; sustained release via encapsulated formulations ensures prolonged activity,"High compatibility with oral capsules, vaginal tablets, and dairy matrices; maintains viability and function during encapsulation and delivery",True,True,True,"Inhibits growth of Gardnerella vaginalis, Prevotella spp., and other BV-associated anaerobes via production of lactic acid, hydrogen peroxide, and bacteriocins; prevents biofilm formation by blocking pathogen adhesion to epithelial cells","Lactic acid, Hydrogen peroxide, Bacteriocins (e.g., lactocin, reuterin)",True,True,True,True,Multiple clinical trials show significant reduction in BV recurrence and Nugent score after 2-month oral or vaginal administration of ≥10⁸ CFU/day. No reported cytotoxicity or microbiome disruption; localized action confirmed by vaginal colonization studies.,False,,,False,False,False,,True,"Modulates local immune response by reducing pro-inflammatory cytokines (e.g., IL-6, TNF-α) and enhancing anti-inflammatory mediators (e.g., IL-10); promotes immune tolerance and mucosal barrier integrity","Exopolysaccharides (EPS), Lipoteichoic acids (LTAs), Secreted cytokines",True,Enhances epithelial regeneration and barrier function by promoting mucosal healing and reducing inflammation; supports tissue homeostasis through metabolic cross-talk with host cells,"Lactate, Short-chain fatty acids (SCFAs), Exopolysaccharides",True,Regulates vaginal pH via lactic acid production; modulates host metabolism by influencing glucose utilization and lipid profiles in epithelial cells,"Lactic acid, Acetic acid, Butyric acid",False,,,GRAS,"Auxotrophy (nutritional dependency on specific amino acids), Natural attenuation (no antibiotic resistance genes)","Amino acid auxotrophies (e.g., leucine, arginine)",Non-pathogenic; no reports of systemic infection or adverse effects; low risk of horizontal gene transfer; no known antibiotic resistance genes; minimal environmental escape potential,Physical confinement via vaginal or oral delivery; limited survival outside host environment,"All strains used are classified as Generally Recognized As Safe (GRAS). They are non-invasive, non-pathogenic, and do not persist long-term in the host. No adverse events were reported in clinical trials. Their natural auxotrophy and inability to survive outside the host reduce ecological risk. Physical delivery methods (capsules, tablets) further limit environmental release.","Clinical trials demonstrate that daily oral or vaginal administration of ≥10⁸ CFU of L. acidophilus, L. rhamnosus GR-1, or L. fermentum RC-14 for 2 months significantly restores normal vaginal flora, reduces BV recurrence by up to 60%, and normalizes Nugent scores. In one study, 88% of patients in the probiotic group were cured compared to 40% in the placebo group. Vaginal colonization was confirmed via microbiological testing, and no cytotoxicity or microbiome disruption was observed.",10100,2112,12212,,
b03e4a00-c320-44e9-81f4-6beb65b87803,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactiplantibacillus plantarum"", ""strain_id"": ""AWP4""}]",Suspension,Facultative Anaerobe,"37°C, pH 6.5–7.4, 1% CaCO3 in MRS agar, anaerobic environment",Growth rate: 48 h doubling time in MRS broth; in vitro growth confirmed,Intestinal mucosa (inferred from adhesion and probiotic properties),"Competitive exclusion of pathogens (E. coli, S. aureus, S. enterica, S. sonnei); co-aggregation with pathogens suggests niche competition","Resistant to simulated gastric juice (pH 2.0, 3 h) and intestinal juice (pH 8.0, 5 h); tolerant to 6.5% NaCl and 18% NaCl; grows at 15°C and 45°C",Cell wall and metabolic adaptation to acid/bile stress,该菌株为乳酸杆菌，可在37°C、厌氧条件下生长，对胃酸和胆汁具有较强耐受性，能在模拟胃肠环境中保持高存活率，具备良好的肠道定植潜力。,None (no genetic modification reported),Not applicable,Constitutive (inferred from natural expression of probiotic traits),None,Chromosomal stability (natural strain); no plasmid or engineered genetic elements reported,No engineered material interaction reported,该菌株未经过基因工程改造，其功能由天然基因组表达，无外源调控元件。,"[""pH (acidic gastric environment)"", ""Bile salts (intestinal environment)""]","[""Glucose"", ""Lactose"", ""Mannose"", ""Sucrose""]",,,Inferred: FNR-like regulators or general stress response promoters (not explicitly identified),No synthetic logic gates; natural response to environmental stress (acid/bile) via constitutive expression,该菌株通过天然机制感知胃酸和胆汁环境，启动耐酸和耐胆盐相关基因表达，无人工逻辑门控，属于基础应激响应。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Type I/II secretion (inferred from Gram-positive cell wall and organic acid secretion),Natural expression; no controllable output reported,"Compatible with food-grade matrices (e.g., fermented vegetables); no encapsulation reported",True,True,False,"Produces antimicrobial compounds (e.g., organic acids, bacteriocins) that inhibit growth of E. coli, S. aureus, S. enterica, and S. sonnei.","Organic acids (lactic, acetic), bacteriocins (inferred)",True,True,True,True,对四种指示菌均有抑制作用，抑制圈直径>11.5 mm；无细胞毒性，且在肠道环境中稳定，符合安全边界。,False,Not applicable,None,False,False,False,未报道氧气生成能力。,True,"Modulates immune response via antioxidant activity and inhibition of pathogen adhesion, potentially reducing inflammation.","Organic acids, exopolysaccharides (inferred)",True,"Enhances intestinal barrier function through mucin binding and inhibition of pathogen adhesion, promoting mucosal healing.","Mucin-binding proteins, exopolysaccharides",True,"Assimilates cholesterol and inhibits α-amylase activity, contributing to lipid and carbohydrate metabolism regulation.","Cholesterol, glucose (via α-amylase inhibition)",False,Not applicable,None,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",None,"Non-pathogenic; no hemolysis; sensitive to chloramphenicol, tetracycline, erythromycin, doxycycline; resistant to aminoglycosides (intrinsic); no antibiotic resistance genes reported; low risk of HGT",None (no physical confinement reported),该菌株为天然分离株，无致病性，无溶血活性，对多种抗生素敏感，且未发现耐药基因，属于安全级别高的GRAS菌株，无生物安全风险。,该菌株在体外表现出强抗病原菌活性（抑制圈直径达19.44 mm）、高黏附能力（黏液结合率49.70%）、强抗氧化能力（DPPH清除率936.82 μmol/L），并能有效抑制α-淀粉酶活性（34.05%），具备良好的肠道修复与代谢调节功能，是潜在的益生菌候选菌株。,19091,1634,20725,,
25bd6c5d-a4fd-40af-8193-1b0d39172c51,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Akkermansia muciniphila"", ""strain_id"": ""ATCC BAA-835""}]",Oral administration (gut colonization),Strict Anaerobe,"37°C, pH 6.5, strict anaerobic conditions, 0.25% w/v mucin as carbon source",Not explicitly reported; growth supported in vitro under mucin-rich anaerobic conditions,Intestinal mucosal layer (gut mucus),Symbiotic with host; enhances gut barrier integrity and maintains mucosal homeostasis; positively correlates with antitumor immune response,"Not explicitly reported; preserved after pasteurization (heat-stable), suggesting moderate thermal stability",Amuc (outer membrane protein),"Akkermansia muciniphila is a strict anaerobe that colonizes the intestinal mucosal layer, thriving on mucin as a primary carbon source under anaerobic conditions at 37°C and pH 6.5. It maintains gut barrier function and promotes mucosal homeostasis, particularly under systemic IL-2 treatment.",,,,,Not genetically modified; naturally stable in gut environment,Stable in oral delivery and gut environment; no evidence of plasmid or engineered genetic elements,"Akkermansia muciniphila is used in its natural form without genetic modification. Its therapeutic effects are attributed to endogenous outer membrane protein Amuc, which activates host immune pathways.","[""pH"", ""Mucin availability""]","[""Mucin""]",,"[""Toll-like receptor 2 (TLR2)""]",Amuc (outer membrane protein of AKK),No synthetic logic circuits; natural sensing via Amuc-TLR2 interaction leading to downstream immune activation,"Akkermansia muciniphila senses its mucosal niche via mucin availability and utilizes its outer membrane protein Amuc to directly interact with host TLR2 receptors on immune cells, triggering a pro-inflammatory and anti-tumor immune response without synthetic genetic circuits.","[""Immunomodulation"", ""Tissue Repair"", ""Tumor Therapy""]",Outer membrane protein (Amuc) released via natural cell lysis or membrane shedding; no engineered secretion system,Oral administration every 3 days; dose-dependent effects observed in vivo,Compatible with oral delivery; stable in gastrointestinal tract; no evidence of material interference,False,,,,,,,,,,False,,,,,,,True,"Amuc activates TLR2 signaling in dendritic cells and T cells, promoting maturation of dendritic cells, expansion of cytotoxic T lymphocytes (CTLs), and suppression of regulatory T cells (Tregs). This leads to enhanced IFN-γ, IL-2, and TNF-α production and reduced TGF-β levels.",Amuc (outer membrane protein of Akkermansia muciniphila),True,"Oral administration of AKK protects intestinal barrier integrity by preserving goblet cells and mucus layer, preventing epithelial injury caused by IL-2. It maintains mucosal homeostasis and supports gut barrier function.",Amuc (outer membrane protein),False,,,True,"Amuc-mediated activation of TLR2 signaling enhances antitumor immune surveillance, reduces tumor-repopulating cells, and suppresses tumor growth in both melanoma and colorectal cancer models. It synergizes with IL-2 to improve tumor clearance.",Amuc (outer membrane protein of Akkermansia muciniphila),GRAS,Natural auxotrophy (mucin-dependent growth); no synthetic kill switches,Mucin,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape due to mucin dependency,Gut mucosal barrier and host immune system provide physical and biological containment,"Akkermansia muciniphila is classified as GRAS (Generally Recognized As Safe). It is a natural commensal bacterium with no known pathogenicity. Its growth is strictly dependent on mucin, limiting its survival outside the gut. No adverse effects were observed in mice, and it enhances gut barrier function rather than disrupting it.","In colorectal cancer patient-derived tumor tissues, combination therapy with IL-2 and AKK significantly increased tumor cell apoptosis and enhanced antitumor immune responses, including increased CD8+/CD4+ T cell ratio, activated dendritic cells, and IFN-γ-producing cytotoxic T cells. In B16F10 and CT26 tumor-bearing mice, the combination therapy significantly reduced tumor volume, prolonged survival, and improved tumor immune microenvironment by increasing CTLs and decreasing Tregs. Oral AKK also protected intestinal barrier integrity during IL-2 treatment, preventing mucosal damage and maintaining microbiota homeostasis.",14074,1648,15722,,
1c961df6-e819-4578-b30a-07598e62e651,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""CNCM I-1572 (L. casei DG)""}]",Suspension,Facultative Anaerobe,"Anaerobic growth at 37°C in MRS broth or vk-MRS agar; pH not explicitly specified, but standard MRS conditions apply (pH ~6.2–6.8).","Growth rate: 24 h incubation at 37°C; doubling time not reported, but typical for Lactobacillus species (~30–60 min in optimal conditions). In vivo homeostasis not directly assessed, but survival in human GIT confirmed.","Intestinal tract (fecal recovery indicates colonization in lower GI), particularly in the colon.","Modulates intestinal microbial ecosystems; no direct competition or symbiosis with other strains reported, but EPS capsule may confer niche advantage.",Resistant to vancomycin (>16 μg/ml) and kanamycin (256 μg/ml); survives gastric transit and bile exposure (inferred from successful fecal recovery). Tolerates room temperature and 37°C for up to 48 h in feces.,Exopolysaccharide (EPS) capsule (DG EPS) – responsible for antibiotic resistance and structural stability.,该菌株为专性厌氧生长，37°C下24小时培养，可在MRS培养基中良好生长。其独特的多糖荚膜赋予其对万古霉素和卡那霉素的天然抗性，且在肠道环境中具有较强的生存能力。在健康成人摄入后，可在粪便中成功回收，表明其能耐受胃肠道的酸性、胆汁等应激环境，具有良好的肠道定植潜力。,Colony PCR with strain-specific primers (rtWELFf and rtWELFr); no genetic modification reported.,Not applicable – no genetic editing performed.,Constitutive (no inducible circuits reported).,,No plasmid or integration reported; chromosomal stability inferred from consistent strain identity across fecal samples. No antibiotic resistance genes detected in genome.,Stable in drinkable vial formulation (fructose solution with preservatives); freeze-dried biomass maintains viability.,本研究未对菌株进行基因改造。通过设计特异性引物（rtWELFf/rtWELFr）结合菌落PCR，实现对DG菌株的特异性鉴定。该方法基于其独特的多糖荚膜基因序列，确保了在复杂粪便微生物群中对目标菌株的精准识别，无需基因工程干预。,"[""pH"", ""Bile Salts""]",,,,Exopolysaccharide (EPS) capsule – intrinsic property enabling resistance to environmental stresses.,No synthetic logic circuits; natural sensing via EPS-mediated stress resistance.,该菌株未构建人工感知系统。其对胃肠道环境的适应性主要依赖于天然多糖荚膜，该结构赋予其对酸性、胆汁盐及抗生素的抗性，属于被动物理屏障机制，而非主动信号感知与逻辑处理。,"[""Immunomodulation"", ""Microbial Ecosystem Modulation""]",Not applicable – no engineered secretion system reported.,Dose: ≥1 billion CFU/vial; intake once daily for 1 week; persistence in feces up to 5 days post-intake.,Compatible with drinkable vial formulation (10 ml fructose solution with preservatives); freeze-dried biomass maintains viability during storage.,False,,,Not applicable – no antibacterial activity reported.,,False,False,False,False,无相关证据,False,Not applicable – no oxygenation function reported.,,False,False,False,无相关证据,True,"Modulates host immune response via its unique polysaccharide capsule (DG EPS), influencing immune cell activity and cytokine profiles.",Exopolysaccharide (EPS) capsule (DG EPS),False,Not applicable – no tissue repair function reported.,,False,Not applicable – no metabolic regulation function reported.,,False,Not applicable – no tumor therapy function reported.,,GRAS,No kill-switch or auxotrophy reported; natural resistance to antibiotics via EPS capsule (non-transferable).,Exopolysaccharide (EPS) capsule,No antibiotic resistance genes detected; no pathogenicity or opportunistic risk reported; no horizontal gene transfer (HGT) risk due to absence of mobile genetic elements; low environmental escape risk due to transient colonization.,Physical confinement via drinkable vial (DryCap technology); freeze-drying enhances stability.,该菌株为公认安全（GRAS）菌株，无抗生素抗性基因，其抗性由非转移性多糖荚膜介导，不涉及水平基因转移。在人体内定植为短暂性，停用后5天内即难以检测，具有良好的生物安全性。,在20名健康成人中，所有受试者在摄入后均成功在粪便中回收到活体L. paracasei DG，最高浓度达6.7 log₁₀ CFU/g粪便，且在停用后仍可持续检测至第5天。该结果证实，以每瓶不少于10亿CFU的剂量通过口服饮剂形式摄入，该菌株可有效通过胃肠道并定植于肠道，具备良好的益生菌功能潜力。,12438,1781,14219,,
b6cd030a-0e2e-4620-9b68-ac380caf7a4f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactiplantibacillus plantarum"", ""strain_id"": ""Various (e.g., WCFS1, ATCC14917T, ZDY 2013, LP90, ST28MS, etc.)""}]",Suspension,Facultative Anaerobe,"Mesophilic (optimal growth at 30–37°C), pH 5.5–7.0, tolerant to osmotic stress and bile salts; utilizes a wide range of carbohydrates including glucose, fructose, lactose, and various pentoses.",Moderate growth rate; doubling time ~60–90 min in vitro; capable of sustained growth in gastrointestinal tract under transient colonization.,"Gastrointestinal tract (intestinal mucosa, lumen), particularly in the small intestine and colon; also found in fermented foods and plant environments.",Competes with pathogens for nutrients and adhesion sites; modulates host immune system; may influence gut microbiota composition through bacteriocin and EPS production.,"High tolerance to acid (pH 1.5–3.0), bile salts, osmotic stress, and oxidative stress; survives lyophilization and rehydration.","OpuC osmoregulatory system, groES-groEL chaperones, hcrA-dnaK-dnaJ-GrpE operon, NADH oxidases, peroxidases, manganese transporters","Lactiplantibacillus plantarum is a versatile, microaerophilic, mesophilic, Gram-positive bacterium with strong adaptation to the gastrointestinal environment. It exhibits excellent survival under acidic and bile stress, enabling transient colonization in the gut. Its broad metabolic capacity allows it to thrive in diverse ecological niches, including fermented foods and the human GI tract.","CRISPR-Cas system (Class 2, Type II), Recombination systems, Transposons (implied by genomic plasticity)",High efficiency in genome editing; CRISPR-Cas9 system present in most strains; low off-target risk due to high specificity of Cas9 and guide RNA design.,"Constitutive expression of key genes (e.g., bsh, pln genes); inducible systems not explicitly described but possible via promoter engineering.","Not specified; potential use of native promoters (e.g., plnA promoter) or synthetic inducible systems (e.g., IPTG, xylose) in engineered strains.",High chromosomal stability; plasmid-based systems less stable unless maintained with antibiotic markers; low metabolic burden; evolutionary stability observed in long-term in vitro and in vivo studies.,Stable in food matrices and encapsulated delivery systems; maintains function in fermented foods and probiotic formulations.,"Lactiplantibacillus plantarum possesses a large, plastic genome with high genetic diversity. It naturally harbors CRISPR-Cas systems and mobile genetic elements, enabling efficient genome editing. Its natural ability to produce bacteriocins and exopolysaccharides makes it a prime candidate for metabolic engineering. Strain-specific traits can be enhanced via targeted gene editing or synthetic biology approaches.","[""Acidity (pH)"", ""Oxidative stress (ROS/RNS)"", ""Osmotic stress"", ""Hypoxia""]","[""Bile acids (conjugated and deconjugated)"", ""Glucose"", ""Lactate"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing (AHL, AI-2)"", ""Bacteriocin signals (e.g., plantaricin A induces plantaricin EF/JK)""]","[""Proteases (e.g., trypsin, pepsin)"", ""Cytokines (indirectly via immune modulation)"", ""Mucin (adhesion sensing)""]","FNR promoter (hypoxia), BSH enzymes (bile acid sensing), Msa (mannose-specific adhesion), CnaB (collagen binding), PlnA promoter (bacteriocin regulation)","AND gate logic observed in bacteriocin regulation (e.g., plantaricin A induces EF/JK); threshold-based activation of stress response genes; noise suppression via chaperone systems and CRISPR-Cas immunity.","Lactiplantibacillus plantarum employs a sophisticated sensing network that integrates environmental cues such as pH, bile, and nutrient availability. It uses specific promoters (e.g., FNR for hypoxia, PlnA for bacteriocin induction) to regulate gene expression. Bacteriocin production is often controlled by a quorum-sensing-like mechanism, where one bacteriocin (e.g., plantaricin A) induces the expression of others (EF, JK), forming a logical AND gate. Stress response systems are threshold-sensitive and include feedback loops for robustness.","[""Antibacterial"", ""Antigenotoxic"", ""Immunomodulation"", ""Metabolic Regulation""]","Type I secretion (for bacteriocins), Exopolysaccharide secretion (via outer membrane), Lysis (in some cases)","Strain-specific; activity regulated by environmental cues (pH, bile, nutrients); no external control mechanisms described.","High compatibility with food matrices, encapsulated delivery systems, and probiotic formulations; EPS enhances stability and matrix integration.",True,True,True,"Produces bacteriocins (plantaricins), organic acids (lactic acid), hydrogen peroxide, and exopolysaccharides (EPS) that inhibit or kill a wide range of Gram-positive and Gram-negative pathogens, including Listeria monocytogenes, Staphylococcus aureus, Salmonella, E. coli, and Pseudomonas aeruginosa.","Plantaricins (e.g., C11, ZJ5, ST28MS, 423), Lactic acid, Hydrogen peroxide, Exopolysaccharides (EPS)",True,True,True,True,Multiple studies confirm broad-spectrum antibacterial activity against foodborne and human pathogens. EPS and bacteriocins inhibit biofilm formation. No significant cytotoxicity reported; localized action in gut mucosa. Compatible with food matrices and probiotic delivery systems.,False,Not applicable.,,False,False,False,No evidence of oxygen production or oxygenation capability in Lactiplantibacillus plantarum.,True,"Modulates immune responses via exopolysaccharides (EPS), bacteriocins, and bile salt hydrolase (BSH) activity. EPS interacts with TLR2 and NF-κB pathways, influencing pro- and anti-inflammatory cytokine production. BSH activity alters bile acid profiles, activating FXR and TGR5 receptors, which regulate immune homeostasis.","Exopolysaccharides (EPS), Bile salt hydrolase (BSH), Plantaricins",False,Not applicable.,,True,"Modulates host lipid and glucose metabolism via bile salt hydrolase (BSH) activity. Deconjugation of bile acids alters FXR and TGR5 signaling, improving insulin sensitivity, reducing cholesterol, and promoting energy expenditure. Also produces SCFAs that regulate host metabolism.","Deconjugated bile acids, Short-chain fatty acids (SCFAs), Secondary bile acids (e.g., lithocholic acid)",False,Not applicable.,,GRAS,"Auxotrophy (e.g., amino acid or vitamin dependency), CRISPR-Cas system for self-defense, natural attenuation in gut environment","Amino acid biosynthesis genes (e.g., ilv, leu), CRISPR-Cas system",Low pathogenicity; no known virulence genes; no antibiotic resistance genes reported in most strains; low risk of horizontal gene transfer; no environmental escape due to poor environmental persistence.,Physical confinement in food matrices and probiotic capsules prevents systemic dissemination.,Lactiplantibacillus plantarum is classified as Generally Recognized as Safe (GRAS) by FDA and has Qualified Presumption of Safety (QPS) by EFSA. It has a long history of safe use in fermented foods. No evidence of pathogenicity or antibiotic resistance. Natural attenuation in the gut limits long-term colonization. CRISPR-Cas and auxotrophy provide additional safety layers.,"Lactiplantibacillus plantarum strains isolated from fermented foods demonstrate significant health benefits, including inhibition of foodborne and human pathogens, reduction of genotoxicity, modulation of immune responses, and improvement of lipid and glucose metabolism. Clinical and preclinical studies support their potential as probiotics for preventing gastrointestinal diseases, reducing cancer risk, and improving metabolic health. Their ability to survive GI transit and exert beneficial effects makes them promising candidates for functional foods and biotherapeutics.",15310,2472,17782,,
daf9c01e-687b-402a-b21d-9b5b53ab5b92,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Roseobacter sp. strain 27-4"", ""strain_id"": ""27-4""}]",Bioencapsulated in rotifers,Aerobic,"Growth at 20–23°C in marine broth; aerobic, stagnant conditions; marine environment adaptation",Growth rate not explicitly quantified; maintained at 10^6–10^7 cfu/ml in water during trials; decreased after discontinuation of supplementation,Gastrointestinal lumen of turbot larvae; does not colonize intestinal epithelium,Antagonistic to Vibrio anguillarum; no evidence of colonization or disruption of host microbiome; may suppress opportunistic pathogens via soluble factors,"Tolerant to rearing conditions (moderate aeration, 15–18°C); stable in seawater and rotifer enrichment; sensitive to culture supernatant toxicity",Marine broth components (nutrients) promote pathogen overgrowth,"Roseobacter 27-4 is a marine bacterium that grows aerobically in marine broth at 20–23°C. It does not colonize the intestinal epithelium of turbot larvae but persists in the gastrointestinal lumen. It requires repeated supplementation to maintain protective levels, as its concentration declines rapidly after discontinuation of feeding. It is non-pathogenic to larvae when delivered as live cells but toxic when delivered as culture supernatant due to nutrient-driven pathogen proliferation.",,,,,No genetic modifications reported; natural strain used; stability inferred from consistent performance across trials,Stable in rotifer bioencapsulation and seawater; no evidence of genetic drift or instability,"No genetic engineering was performed. The strain was used in its natural form, delivered via bioencapsulated rotifers. Its probiotic effect is attributed to natural antagonistic properties rather than engineered circuits.",,,,,Not applicable (no engineered sensing system),Not applicable (no synthetic circuitry),No engineered sensing or logic processing; the probiotic effect is based on natural antagonism and environmental modulation rather than responsive genetic circuits.,"[""Antibacterial""]",Passive secretion of antibacterial factor; no engineered secretion system,Requires repeated delivery (every 48–72 h) to maintain protective levels; no controllable genetic dosage system,Compatible with rotifer bioencapsulation and seawater delivery; stable in marine broth and rotifer culture,True,False,False,"Roseobacter 27-4 produces a soluble sulphur-containing antibacterial factor that inhibits Vibrio anguillarum in vitro under high-density, stagnant conditions. The effect is likely due to direct inhibition of pathogen growth and virulence rather than colonization or biofilm disruption.",Sulphur-containing antibacterial factor,False,True,True,True,"Roseobacter 27-4 reduced Vibrio-induced mortality in turbot larvae without causing host toxicity when delivered as live cells. It does not disrupt the gel or rotifer structure and remains localized in the lumen, minimizing systemic effects.",False,,,False,False,False,,False,,,False,,,False,,,False,,,BSL-1,"None (natural strain, no kill-switch or auxotrophy reported)",,"Non-pathogenic to turbot larvae; no evidence of horizontal gene transfer, antibiotic resistance, or environmental escape; potential risk from culture supernatant due to nutrient-driven pathogen growth",Physical confinement via rotifer delivery and tank rearing; no engineered physical barrier,"Roseobacter 27-4 is safe for turbot larvae when delivered as live cells. However, its culture supernatant is toxic due to residual nutrients promoting opportunistic pathogen growth. No genetic modifications or biocontainment strategies were used. The strain is naturally adapted to marine environments and poses low risk of environmental escape.","In turbot larvae challenged with Vibrio anguillarum, the addition of Roseobacter 27-4 reduced accumulated mortality from 34% (Vibrio-only) to 68% of control levels (i.e., doubled survival). The probiotic effect was significant (p = 0.008), demonstrating clear in vivo protection. However, the strain does not colonize the gut and requires repeated supplementation to maintain efficacy.",16310,1533,17843,,
7597f2ab-c2c7-401c-b10b-f438bb201d37,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""Bb12 (ATCC 27536)""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in anaerobic conditions; tolerant to bile salts and low pH (gastric conditions)",Doubling time ~2–3 hours in vitro; stable in food matrices and during storage; in vivo colonization ability not explicitly assessed,"Oral cavity, particularly in association with mucosal surfaces and salivary pellicle",Potential competitive exclusion of oral pathogens; no significant disruption of native microbiota observed; may support mucosal immunity via sIgA modulation,"High tolerance to lyophilization, drying, and storage at room temperature; stable in chewing gum matrix for up to 9 months (0.45 log10 CFU loss after 9 months)","Xylitol, lecithin, glycerol, and gum matrix provide protective environment","Bifidobacterium animalis subsp. lactis Bb12 is a well-characterized probiotic strain with strong stability in food matrices, capable of surviving gastric transit and colonizing the oral cavity. It exhibits good growth under anaerobic conditions and demonstrates resilience to environmental stresses encountered during storage and in the oral environment.","Not applicable (natural strain, no genetic modification reported)",N/A,Constitutive,N/A,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift or loss during storage,Stable in xylitol-containing chewing gum matrix; no degradation or loss of viability due to material interactions,"The strain Bb12 was used in its native form without genetic modification. Its functionality relies on natural metabolic and ecological properties, including acid production and competitive exclusion of pathogens. No synthetic circuits or inducible systems were employed.","[""pH"", ""Bile acids"", ""Osmotic stress""]","[""Xylitol"", ""Glucose""]",,"[""Salivary immunoglobulin A (sIgA)"", ""Mucosal surface receptors""]","FNR-like regulators (inferred from anaerobic adaptation), sugar transporters (e.g., for xylitol)",Constitutive expression of beneficial functions; no reported logic gates or threshold-based control,"The strain operates under constitutive expression of its native functions, such as acid production and adhesion. It does not exhibit dynamic sensing or responsive logic circuits. Its activity is primarily driven by environmental availability of nutrients like xylitol and presence of mucosal surfaces.","[""Immunomodulation"", ""Metabolic Regulation""]","Constitutive secretion of metabolites (e.g., organic acids); no specialized secretion systems reported",Dose controlled by chewing frequency and gum formulation; no dynamic feedback control,High compatibility with chewing gum matrix; xylitol and gum components support viability and function,False,,,N/A,N/A,False,False,False,False,No evidence of antibacterial activity reported in this study.,False,N/A,N/A,False,False,False,No oxygenation mechanism reported.,True,"Enhances salivary secretory IgA (sIgA) levels, contributing to mucosal immunity and resistance against infection.",sIgA (indirectly modulated via host immune stimulation),False,N/A,N/A,True,"Metabolizes xylitol and other carbohydrates, contributing to oral pH regulation and potentially influencing microbial balance.","Xylitol (substrate), organic acids (e.g., lactic acid, acetic acid)",False,N/A,N/A,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",N/A,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to limited survival outside host,Physical confinement via chewing gum matrix; limited release into environment,"Bifidobacterium animalis subsp. lactis Bb12 is a well-established GRAS strain with a strong safety profile. It is not pathogenic, does not carry antibiotic resistance genes, and shows no evidence of persistence or spread beyond the oral cavity. The chewing gum matrix provides physical containment, minimizing environmental release.","Chewing gum, with or without probiotics, significantly increased unstimulated salivary flow rate after 2 months of intervention. Salivary pH and sIgA levels also increased significantly at the end of the 3-month intervention. However, no statistically significant differences were observed between probiotic and placebo groups, indicating that the probiotic strain Bb12 did not provide additional benefit beyond the mechanical and chemical effects of gum chewing and xylitol. The strain demonstrated good stability in the gum matrix and transient presence in saliva, suggesting limited colonization but potential for immune modulation.",8680,3486,12166,,
7597f2ab-c2c7-401c-b10b-f438bb201d37,1,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""LGG (ATCC 53103)""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""46 (DSM 14583)""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""2C (DSM 14579)""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; requires anaerobic conditions for full viability; tolerant to bile and low pH; utilizes various carbohydrates including xylitol",Doubling time ~2–3 hours in vitro; moderate stability in chewing gum; decreased by 1.65 log10 CFU after 9 months of storage,"Oral cavity, particularly in association with mucosal surfaces and salivary pellicle; may transiently colonize the gut",Competitive exclusion of pathogens; may modulate host immune response; no significant disruption of native microbiota observed,Moderate tolerance to drying and storage; stability reduced after 4 months in gum; sensitive to prolonged exposure to oxygen and heat,"Xylitol, glycerol, and lecithin provide partial protection; but no long-term stabilization","The consortium includes three strains: Lactobacillus rhamnosus LGG, a well-known probiotic with strong mucosal adhesion and immune-modulating properties, and two Bifidobacterium longum strains selected for gut barrier stabilization. All three strains are facultative anaerobes capable of surviving in the oral environment and utilizing xylitol. However, the consortium showed reduced stability in the chewing gum matrix over time, especially after 4 months.","Not applicable (natural strains, no genetic modification reported)",N/A,Constitutive,N/A,"High chromosomal stability; no plasmid-based systems used; however, viability declined significantly after 4 months of storage (1.65 log10 CFU loss at 9 months)","Moderate compatibility with chewing gum; degradation observed over time, especially in the presence of moisture and oxygen",The consortium was used in its native form without genetic modification. Each strain contributes independently to oral health via natural metabolic and immunomodulatory functions. No synthetic circuits or inducible systems were employed.,"[""pH"", ""Bile acids"", ""Osmotic stress""]","[""Xylitol"", ""Glucose"", ""Lactate""]",,"[""Salivary immunoglobulin A (sIgA)"", ""Mucosal surface receptors""]","Sugar transporters (e.g., for xylitol), FNR-like regulators, lactate dehydrogenase (for lactate sensing)",Constitutive expression; no reported logic gates or threshold-based control,"The consortium functions through constitutive expression of native metabolic and immune-modulating pathways. It responds to nutrient availability (e.g., xylitol) and environmental conditions (pH, osmolarity) but lacks dynamic regulatory circuits or feedback mechanisms.","[""Immunomodulation"", ""Metabolic Regulation""]",Constitutive secretion of organic acids and immunomodulatory molecules; no specialized secretion systems reported,Dose controlled by chewing frequency and gum formulation; no dynamic feedback control,"Moderate compatibility with chewing gum matrix; stability declines over time, especially after 4 months",False,,,N/A,N/A,False,False,False,False,No evidence of antibacterial activity reported in this study.,False,N/A,N/A,False,False,False,No oxygenation mechanism reported.,True,"Enhances salivary secretory IgA (sIgA) levels, contributing to mucosal immunity and resistance against infection. LGG is particularly known for its immune-stimulating properties.",sIgA (indirectly modulated via host immune stimulation),False,N/A,N/A,True,"Metabolizes xylitol and other carbohydrates, producing organic acids that help regulate oral pH and inhibit pathogenic bacteria.","Xylitol (substrate), lactic acid, acetic acid",False,N/A,N/A,GRAS,"None (natural strains, no kill-switch or auxotrophy reported)",N/A,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to limited survival outside host,Physical confinement via chewing gum matrix; limited release into environment,"The consortium consists of three well-characterized GRAS strains with strong safety profiles. LGG is widely used in clinical settings, and B. longum strains are known for gut health benefits. No adverse effects were reported in the study. The chewing gum matrix provides physical containment, minimizing environmental release. However, the strain viability decreased significantly over time, reducing long-term efficacy.","The consortium showed transient presence in saliva (61.1% positive samples at 3 months), indicating some colonization potential. Salivary sIgA levels increased significantly in all groups, but no significant difference was observed between the probiotic and placebo groups. The chewing gum matrix provided a delivery vehicle, but the consortium's viability declined after 4 months of storage. While the strains contributed to immune modulation and metabolic regulation, no additional benefit over placebo was observed in terms of salivary flow, pH, or symptom reduction.",8680,3486,12166,,
60687ac4-2bf5-407d-b4f1-75a0f3bc3372,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""W3110 (K12)""}, {""role"": ""Chassis"", ""scientific_name"": ""Staphylococcus albus"", ""strain_id"": ""Unknown""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacteriophage T4"", ""strain_id"": ""Unknown""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacteriophage T7"", ""strain_id"": ""Unknown""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacteriophage λ"", ""strain_id"": ""Unknown""}]",Encapsulated in electrospun PVA nanofibres,Facultative Anaerobe,E. coli: Vogel–Bonner medium E (inorganic salts + glucose); S. albus: Luria–Bertani (LB) medium; both grow at 37°C,E. coli: 1–2 × 10⁹ cells/mL in batch culture; S. albus: ~8 × 10⁹ cells/mL in stationary phase,Not applicable (in vitro study; no host colonization assessed),Not applicable (no host or microbiome context),"High tolerance to mechanical stress (resists >50,000×g); glycerol pre-treatment improves E. coli survival during electrospinning",Glycerol,大肠杆菌（E. coli）为革兰氏阴性杆菌，可在含葡萄糖的无机盐培养基或LB培养基中生长，37°C下培养可达到1–2×10⁹细胞/mL的密度；金黄色葡萄球菌（S. albus）为革兰氏阳性球菌，需在LB培养基中生长，可达到约8×10⁹细胞/mL的密度。两者均具有较强的细胞壁结构，能耐受高机械应力。,Not applicable (no genetic modification reported),Not applicable,Not applicable,Not applicable,Not applicable (no engineered circuits or plasmids described),Not applicable,未对微生物进行基因改造，仅通过物理封装实现存活与保存。,,,,,Not applicable,Not applicable,未涉及任何感知或逻辑控制模块。,"[""Preservation"", ""Delivery""]",Passive release from PVA nanofibres upon hydration,Not applicable (no controlled release mechanism described),High compatibility with PVA nanofibres; encapsulation maintains viability and allows sustained release upon hydration,False,False,False,Not applicable,Not applicable,False,False,False,False,未涉及抗菌功能。,False,Not applicable,Not applicable,False,False,False,未涉及氧合功能。,False,Not applicable,Not applicable,False,Not applicable,Not applicable,False,Not applicable,Not applicable,False,Not applicable,Not applicable,BSL-1,Not applicable (no kill-switch or auxotrophy described),Not applicable,E. coli K12 is non-pathogenic; S. albus is non-pathogenic; bacteriophages are host-specific and do not infect human cells. No antibiotic resistance genes or HGT risk reported.,"PVA nanofibres provide physical confinement and slow release, reducing environmental escape risk.",所用菌株均为非致病性标准菌株，噬菌体具有宿主特异性，不会感染人类细胞。材料封装提供了物理屏障，降低了环境释放风险。,本研究未评估伤口愈合或治疗效果，主要目标为生物材料的封装与长期保存。在-20°C和-55°C下，细菌和噬菌体在电纺纤维中可保持活性长达3个月，表明该技术在生物制剂长期保存方面具有潜力。,9810,1463,11273,,
1bf78a88-65f6-4181-a2a8-a73dbeaa0f09,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""CRL 431""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in MRS broth; pH not specified, but MRS is typically near neutral; nutritional requirements include carbohydrates, amino acids, and vitamins; no mention of bile or osmotic tolerance",Growth rate not quantified; cultured overnight at 37°C; viability maintained in drinking water for daily administration,Small intestine lamina propria and lumen; colonizes intestinal mucosa and influences gut microbiota,Competes with enterobacteria; increases lactobacilli population; modulates microbiota balance; no disruption of host microbiome observed,"Tolerant to lyophilization/rehydration (used in suspension preparation); stable in drinking water for 24 h; no mention of UV, drying, or shear stress",Non-fat milk (used as stabilizer in suspension),该菌株为乳酸杆菌，可在37°C的MRS培养基中生长，通过口服定植于小肠黏膜和肠腔，具有良好的稳定性，可在饮用水中维持活性。其生长依赖于碳源、氨基酸和维生素等营养物质，对胆汁和渗透压耐受性未提及。,,,,,No genetic modifications reported; strain is naturally occurring and used as-is; no plasmid or integration mentioned,No genetic engineering; stability in material environment not applicable,该菌株未经过基因改造，直接作为天然益生菌使用，无任何遗传工具或调控回路，其功能依赖于天然生理特性。,,,,,Not specified; no engineered sensors reported,No logic gates or signal processing reported; natural sensing via surface receptors,该菌株未经过工程化改造，其对宿主环境的响应依赖于天然的微生物-宿主互作机制，如与肠道上皮细胞的黏附、识别宿主免疫信号分子等，但未明确描述具体传感器或逻辑门控机制。,"[""Immunomodulation"", ""Microbiota Regulation""]",Not specified; likely natural secretion via cell wall or lysis,Oral administration at 1×10⁸ CFU/mL in drinking water daily; dosage not dynamically controlled,Compatible with oral suspension in drinking water; no encapsulation or matrix used,False,,,Not applicable; no antibacterial activity reported,,,,,,未报告抗菌活性，因此不满足任何抗菌标准。,False,Not applicable; no oxygen production or consumption reported,,,,,未涉及氧气调节功能，因此不适用。,True,"Enhances IgA-producing B cells, CD4+ T cells, and S-IgA secretion; reduces IFN-γ levels; modulates macrophage and dendritic cell populations in lamina propria","Secretory IgA (S-IgA), IFN-γ, CD4+ T cells, CD11b+ macrophages, CD11c+ dendritic cells",True,Restores intestinal villi length and crypt depth; reduces epithelial apoptosis; improves mucosal barrier integrity,"Bcl-2 protein (inferred from mechanism), epithelial cell homeostasis",False,Not applicable; no metabolic regulation reported,,False,Not applicable; no tumor targeting or therapy reported,,GRAS,None; no kill-switch or auxotrophy reported,,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk mentioned,None; oral administration without physical confinement,该菌株为公认安全（GRAS）的益生菌，来源于婴儿粪便，无致病性，未报告耐药基因或基因水平转移风险，无生物安全控制策略，但因其天然安全性和口服使用方式，风险极低。,在应激小鼠模型中，L. casei CRL 431显著恢复了小肠黏膜免疫功能：增加IgA+ B细胞数量、CD4+ T细胞数量和分泌型IgA水平，降低IFN-γ水平，改善肠绒毛结构，增强肠道屏障功能。同时，该菌株可增加肠道乳酸杆菌数量，抑制大肠杆菌类群，调节肠道菌群平衡，从而有效缓解应激引起的免疫抑制和黏膜损伤。,13792,1569,15361,,
45fa2de5-0bf6-46a4-95d4-0e26134e38be,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""SP1""}]","Oral administration (sachet, dissolved in water)",Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerates moderate osmotic stress; requires carbohydrates (e.g., glucose, fructose) as carbon source; no specific vitamin auxotrophy reported",Doubling time ~1.5–2 hours in vitro; in vivo colonization ability in oral cavity sustained over 3 months with daily intake,"Oral cavity (gingival crevice, mucosal surfaces), particularly in periodontal pockets with moderate inflammation","Competitive exclusion of periodontal pathogens (e.g., Porphyromonas gingivalis, Tannerella forsythia); promotes shift toward host-compatible microbiota; no significant disruption of commensal flora reported",Tolerant to gastric acid (pH 2–3) and bile salts; stable during lyophilization and rehydration; resistant to drying and room temperature storage for short periods,"Cell wall components (teichoic acids), extracellular polysaccharides, acid tolerance response (ATR) genes","Lactobacillus rhamnosus SP1 is a facultative anaerobe capable of surviving in the oral environment, colonizing periodontal pockets and maintaining viability during transit through the gastrointestinal tract. It exhibits moderate tolerance to acidic and osmotic stress, enabling survival in the oral cavity and gut. Its growth is supported by available sugars in the oral environment, and it demonstrates stable colonization over 3 months with daily intake.",,,,,Chromosomal stability; no plasmid-based genetic modifications reported; no evidence of genetic drift or loss of function during 3-month administration,"Stable in sachet formulation (powder, excipients); no degradation observed during storage or dissolution in water","Lactobacillus rhamnosus SP1 used in this study was not genetically modified. It was administered as a natural probiotic strain with documented safety and immune-modulatory properties. No synthetic circuits, inducible promoters, or gene editing tools were applied.","[""pH"", ""Glucose"", ""Lactate""]","[""Bile acids"", ""SCFAs""]",,"[""Proteases"", ""Cytokines""]","FNR-like regulators (hypoxia sensing), PTS transporters (glucose/lactate), bile salt hydrolase (BSH) receptors","No engineered logic gates; natural sensing of environmental cues (e.g., low pH, nutrient availability) triggers metabolic adaptation and colonization","Lactobacillus rhamnosus SP1 naturally senses changes in pH, glucose, lactate, and bile acids in the oral environment. It responds to low pH and nutrient availability by upregulating acid tolerance and adhesion mechanisms. It detects host-derived proteases and cytokines in inflamed periodontal tissues, which may modulate its immune interactions. These natural sensing pathways enable adaptive colonization without synthetic circuitry.","[""Immunomodulation"", ""Antibacterial""]","Type IV secretion-like systems, passive diffusion, cell lysis (natural release of metabolites)",Controlled by daily oral intake (2 × 10⁷ CFU/day); activity is self-limited by host immune clearance and natural turnover,High compatibility with sachet formulation; stable during dissolution in water; no interference with gel or matrix structure,True,True,True,"Inhibits pathogenic periodontal bacteria (e.g., Porphyromonas gingivalis, Tannerella forsythia) via competitive exclusion, production of organic acids (lactic acid), and bacteriocin-like substances.","Lactic acid, bacteriocins (e.g., reuterin), hydrogen peroxide",True,True,True,True,"L. rhamnosus SP1 reduced PPD and BOP, indicating suppression of pathogenic biofilm. No adverse events or microbiome disruption reported. Activity is localized to oral cavity and does not cause tissue damage.",False,,,False,False,False,,True,"Modulates host immune response by reducing pro-inflammatory cytokines (e.g., IL-1β, TNF-α) and promoting anti-inflammatory mediators (e.g., IL-10), thereby dampening chronic inflammation in periodontitis.","Cell wall components (peptidoglycan, lipoteichoic acid), secreted exopolysaccharides, surface proteins (e.g., p40)",False,,,False,,,False,,,GRAS,Auxotrophy (no known auxotrophy reported; naturally non-pathogenic),,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape due to poor environmental survival; no systemic colonization observed,Sachet formulation provides physical containment; oral delivery limits systemic spread,"Lactobacillus rhamnosus SP1 (GG strain) has a long history of safe use in humans, including in children and immunocompromised individuals. No adverse events were reported in this trial. It is classified as GRAS (Generally Recognized As Safe) by FDA and EFSA. No evidence of pathogenicity, antibiotic resistance, or horizontal gene transfer. Natural attenuation in the gut and oral cavity limits persistence.",在为期1年的随访中，试验组（SRP + L. rhamnosus SP1）在牙周探诊深度（PPD）减少方面显著优于对照组（SRP + 安慰剂），尤其在PPD ≥ 6 mm的患者比例上显著降低，表明该益生菌可减少对牙周手术的需求。所有患者均完成研究，无不良反应，依从性高。临床参数（如CAL、BOP、PI）在两组中均有改善，但试验组的改善更显著，且效果在12个月时仍持续。,7979,1897,9876,,
e0af4588-089e-4e47-b195-891358c4d984,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""C59""}]",Suspension,Facultative Anaerobe,30°C in M17 broth with 0.5% glucose (GM17); tolerates low pH and high bile concentration,Growth rate not explicitly quantified; survives in gastrointestinal tract transiently,"Gastrointestinal tract (transient passage through intestines, no long-term colonization)",No significant impact on resident flora; may evade macrophage uptake due to capsular polysaccharide,"Tolerates low pH and high bile; survives transiently in feces (detected at 6h post-administration, not at 24h or 48h)",Capsular polysaccharide (implicated in immune evasion),该菌株为乳酸乳球菌（Lactococcus lactis）C59，属于乳酸菌，可在30°C下于含0.5%葡萄糖的M17培养基中生长。其具有耐酸和耐胆盐的能力，可在小鼠肠道中短暂存活（6小时），但无法在肠道内长期定植或增殖。其细胞外多糖荚膜可能有助于逃避巨噬细胞吞噬，从而实现短暂免疫调节作用。,,,,,,,该研究未对L. lactis C59进行基因工程改造，所有实验均使用天然野生型活菌进行口服给药，未涉及任何基因编辑或合成回路设计。,"[""Low pH"", ""Bile""]",,,"[""Anti-CD3 antibody (T-cell receptor stimulation)"", ""Ovalbumin (OVA)""]",Capsular polysaccharide (implicated in immune recognition),"No synthetic logic gates; natural immune recognition via surface molecules (e.g., capsular polysaccharide) leading to downstream cytokine modulation",L. lactis C59通过其细胞表面的荚膜多糖与宿主免疫细胞（如巨噬细胞）发生相互作用，但该菌株能逃避吞噬，从而可能通过非吞噬途径激活免疫调节信号。其在体外可抑制抗CD3抗体刺激下T细胞的IL-4分泌，提示其通过感知T细胞活化信号（如CD3）间接调控免疫反应，但未明确其具体传感器。,"[""Immunomodulation""]",Passive release via cell lysis or surface interaction (no engineered secretion system reported),"Dose-dependent suppression of IL-4; effective at 70 μg dry weight/day, but not at 10-fold higher dose (no significant difference)",No encapsulation or material matrix used; administered as a suspension in saline,False,,,,,,,,,,False,,,,,,,True,"Oral administration of live C59 suppresses IL-4 production by splenocytes and CD4+ T cells, leading to reduced total IgE antibody levels in OVA-sensitized mice.",Interleukin-4 (IL-4),False,,,False,,,False,,,GRAS,No engineered kill-switch or auxotrophy; natural transient survival in gut,Capsular polysaccharide (natural barrier),Non-pathogenic; no evidence of antibiotic resistance genes or horizontal gene transfer; transient colonization reduces escape risk,No physical material barrier used; oral administration relies on natural GI tract barrier,L. lactis C59为食品级安全菌株（GRAS），无致病性，不长期定植于肠道，且热灭活后失去功能，表明其作用依赖活菌。其荚膜多糖可能减少免疫系统识别，但未见致病或生态风险。整体生物安全性高，适合口服免疫调节应用。,口服活菌C59显著降低OVA致敏小鼠的总IgE抗体水平（P < 0.05），且该效应依赖于活菌状态（热灭活后失效）。其机制为抑制脾细胞和CD4+ T细胞在抗CD3刺激下的IL-4分泌，从而调节Th2免疫反应，但对特异性IgE、IgG1和IgG2a无显著影响。该菌株在肠道中短暂存活（6小时），无法长期定植，提示其作用为瞬时免疫调节而非持久定植。,13431,1581,15012,,
2dc939af-25a7-4e3b-bf8a-857247d3baf2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""Not specified""}]",Oral administration (capsule or drink),Facultative Anaerobe,"Optimal growth at 30–37°C, pH 4–7, tolerates bile and intestinal environment; requires fermentable carbohydrates (e.g., glucose) for growth",Moderate growth rate in vitro; no in vivo doubling time reported; survives gastric transit and colonizes intestinal lumen,"Intestinal lumen, particularly in the context of antibiotic-altered microbiota",Competes with pathogenic bacteria; may modulate host immune response; potential for cross-feeding with commensals; no evidence of stable colonization or long-term persistence,"Tolerant to gastric acid, bile salts, and lyophilization; stable during storage at room temperature; resistant to drying and rehydration","Cell wall components (e.g., mannoproteins), intracellular trehalose","Saccharomyces boulardii is a non-pathogenic yeast that survives gastrointestinal transit, colonizes the intestinal lumen, and exhibits tolerance to acidic and bile-rich environments. It grows under facultative anaerobic conditions and can utilize various carbohydrates, making it suitable for oral delivery. Its ability to withstand environmental stresses supports its use in probiotic formulations.","Not applicable (natural isolate, not genetically modified)",N/A,Constitutive (no engineered genetic circuits),N/A,High chromosomal stability; no plasmid-based systems; no evidence of genetic drift in clinical use,"Stable in oral formulations (capsules, drinks); no reported degradation in delivery matrix","Saccharomyces boulardii is used in its native, unmodified form. No genetic engineering or synthetic circuits are employed. Its therapeutic effects are attributed to natural biological properties rather than engineered functions.","[""pH"", ""Bile acids"", ""Glucose""]","[""Lactate"", ""SCFAs""]","[""Quorum sensing molecules (e.g., AI-2)""]","[""Proteases (e.g., trypsin)"", ""Cytokines (indirectly via immune modulation)""]",Unknown (natural sensing mechanisms; no defined promoter/receptor reported),No engineered logic gates; relies on natural metabolic and stress-response pathways,"S. boulardii senses environmental cues such as pH and bile acids via intrinsic membrane transporters and metabolic regulators. It responds to nutrient availability (e.g., glucose) and may detect microbial metabolites and host-derived signals through general stress-response pathways. No synthetic logic circuits are involved.","[""Antibacterial"", ""Immunomodulation""]",Secretion via extracellular vesicles and constitutive release of proteins; no lysis or specialized secretion systems reported,Dose-dependent effects observed in clinical studies; controlled by oral administration schedule,"Compatible with oral formulations (capsules, drinks); stable in liquid and dry matrices",True,False,False,Inhibits Clostridium difficile toxin A and B production; secretes proteases that degrade toxins; competes for adhesion sites in the gut epithelium,"Protease (e.g., serine protease), Toxin-neutralizing molecules",False,True,True,True,S. boulardii reduces recurrence of CDI in clinical trials; does not cause excessive inflammation or tissue damage; localized action in gut lumen,False,Not applicable,N/A,False,False,False,No evidence of oxygen production or role in hypoxia alleviation,True,"Modulates host immune response by reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6) and enhancing anti-inflammatory IL-10; promotes mucosal barrier integrity","Cell wall mannoproteins, secreted immunomodulatory factors",False,Not applicable,N/A,False,Not applicable,N/A,False,Not applicable,N/A,BSL-1,"None (natural isolate, no kill-switch or auxotrophy)",N/A,Potential for fungemia in immunocompromised or critically ill patients; risk of environmental contamination in ICUs; no antibiotic resistance genes reported; low risk of horizontal gene transfer,Oral delivery provides physical barrier; no systemic dissemination in healthy individuals,"Saccharomyces boulardii is generally considered safe but has been associated with fungemia in immunocompromised and critically ill patients, particularly when prepared in intensive care settings. Environmental contamination during bedside preparation has led to cross-infection. Although it is not a true pathogen, its moderate virulence in animal models raises safety concerns in vulnerable populations.","S. boulardii shows a borderline significant reduction in recurrence of Clostridium difficile infection (CDI) in patients with recurrent CDI, particularly when used with high-dose vancomycin. However, evidence is limited to small, methodologically flawed studies. No strong evidence supports its use for primary prevention or treatment. Its efficacy is inconsistent across populations and not generalizable. Safety concerns, including fungemia and environmental transmission, limit its clinical utility.",6463,1698,8161,,
ffafef1f-4f6e-4917-babe-c907aa854922,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""HN001""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""420""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, requires carbohydrates (e.g., glucose, fructose) and complex nutrients (e.g., amino acids, vitamins); tolerates bile salts and low pH (gastric conditions)",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in gut mucosa with stable persistence over 6 months postpartum,"Gut mucosa (intestinal lumen and epithelial surface), particularly in the distal small intestine and colon",Competitive exclusion of pathogenic bacteria; synergistic co-colonization with Bifidobacterium; minimal disruption to native microbiota,"Tolerant to lyophilization, refrigerated storage (up to 12 months), moderate shear stress during encapsulation; sensitive to high temperatures (>50°C) and UV radiation","Microcrystalline cellulose (in placebo), protective matrix in capsule form",该研究中使用的益生菌为Lactobacillus rhamnosus HN001和Bifidobacterium animalis subsp. lactis 420，均为耐酸耐胆盐的兼性厌氧菌，可在胃肠道环境中定植并维持稳定。其生长依赖于碳水化合物和复杂营养物质，对pH和渗透压具有较强耐受性，适合在口服制剂中存活并定植于肠道黏膜。,Plasmid-based expression system (not explicitly described); no genetic modification reported,Not applicable (no genetic engineering performed),Constitutive expression (natural promoters),None (no inducible system used),High chromosomal stability; no plasmid-based systems used; no reported gene loss or drift during 6-month intervention,Stable in capsule matrix (gelatin) with controlled release in gastrointestinal tract,本研究中使用的益生菌未经过基因改造，其功能依赖于天然代谢通路。Lactobacillus rhamnosus HN001和Bifidobacterium animalis subsp. lactis 420均以天然菌株形式存在，通过口服胶囊递送，在肠道内定植并发挥生理调节作用，无外源基因插入或调控元件。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Short-chain fatty acids (SCFAs)"", ""Tryptophan metabolites""]","[""Quorum sensing molecules (AHL, AI-2)""]","[""Proteases (e.g., MMPs)"", ""Cytokines (e.g., IL-6, TNF-α)""]","FNR promoter (hypoxia), Lactate receptor (LacR), Bile acid transporter (BaiS), Quorum sensing receptors (e.g., LasR, LuxR)",No synthetic logic gates; natural sensing with threshold responses and feedback inhibition,这些益生菌通过天然受体感知肠道微环境中的pH、胆汁酸、乳酸和葡萄糖等信号，结合微生物群落密度信号（如AHL、AI-2）进行定植调控。其响应具有阈值特性，例如在低pH下激活耐酸基因表达，在高胆汁浓度下诱导胆汁抗性机制，整体表现为对肠道环境的适应性响应，无人工逻辑门设计。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]","Type IV secretion system (T4SS), vesicle-mediated release (exosomes)",Dose-controlled via daily capsule intake (10^10 CFU/day); no feedback control,Compatible with gelatin capsule matrix; stable during gastrointestinal transit; no structural disruption observed,False,,,Not applicable (no engineered antibacterial function),,,,,,无,False,Not applicable (no oxygen-producing function),,,,,无,True,"Modulate immune response via interaction with dendritic cells and T-regulatory cells; reduce pro-inflammatory cytokines (IL-6, TNF-α) and increase anti-inflammatory IL-10","Lactobacillus rhamnosus HN001 surface proteins (e.g., p40, p75), Bifidobacterium animalis subsp. lactis 420 exopolysaccharides (EPS)",True,"Enhance intestinal barrier integrity by upregulating tight junction proteins (ZO-1, occludin); promote epithelial regeneration via growth factor secretion","TGF-β, EGF, IL-22",True,"Produce short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate; modulate tryptophan metabolism to produce kynurenine and indole derivatives","Butyrate, Propionate, Acetate, Kynurenine, Indole-3-propionic acid",False,Not applicable,,GRAS,"Auxotrophy (nutrient-dependent survival), no antibiotic resistance genes","Lactose, glucose (required for growth)",Low pathogenicity; no known virulence factors; no horizontal gene transfer reported; no environmental escape risk due to auxotrophy,Capsule shell prevents release into environment; intestinal confinement limits dissemination,Lactobacillus rhamnosus HN001和Bifidobacterium animalis subsp. lactis 420均为公认安全（GRAS）菌株，无致病性、无抗生素抗性基因，且依赖外源性碳源生长，具有天然生物遏制能力。胶囊封装可有效防止菌体在体外扩散，确保其在肠道内定植并发挥功能，安全性高。,在妊娠期至产后12个月期间，联合使用鱼油和益生菌干预组的EPDS评分在妊娠晚期较早期妊娠上升1.11分，而鱼油+安慰剂组下降0.85分。在产后12个月时，鱼油+安慰剂组EPDS评分显著低于益生菌+安慰剂组（p=0.039）。尽管干预效果较小，但益生菌组在调节母体抑郁和焦虑症状方面表现出一定潜力，尤其在长期随访中显示出对情绪稳定性的积极影响。,16782,2061,18843,,
eb4593e2-1a4c-4e4d-bd29-11a924be6ff6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""19070-2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 12246""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, requires carbohydrates (e.g., lactose, glucose) and amino acids; tolerant to bile acids and low pH (gastric conditions)",Doubling time ~1.5–2 hours in vitro; stable in vivo colonization observed in human gut over 6-week treatment period,"Small intestinal mucosa, particularly in the proximal small intestine; adheres to epithelial cells",Competitive exclusion of pathogenic bacteria; synergistic interaction with native microbiota; no significant disruption of commensal flora reported,"Resistant to lyophilization, rehydration, and moderate UV exposure; stable during storage at 4°C; withstands gastric transit","Cell wall components (e.g., teichoic acids), exopolysaccharides",该研究中使用的Lactobacillus rhamnosus 19070-2和L. reuteri DSM 12246均为非致病性乳酸菌，可在人体肠道内定植并耐受胃酸与胆汁环境。其生长适宜温度为37°C，pH范围5.5–6.5，依赖碳水化合物和氨基酸生长。在体外和健康志愿者中已验证其黏附于肠黏膜的能力，且在6周治疗期间表现出良好的体内稳定性。,,,,,Chromosomal stability; no plasmid-based systems used; no reported genetic drift or loss of function during treatment,Stable in lyophilized powder form; maintains viability during encapsulation and reconstitution in water,本研究未对菌株进行基因改造，使用的是天然存在的非致病性乳酸菌株，通过口服补充以发挥益生作用，无需遗传工具干预。,"[""pH"", ""Bile Acids""]","[""Lactose"", ""Glucose""]",,"[""Cytokines"", ""Mucin""]","FNR-like regulators (for oxygen sensing), bile salt hydrolase (BSH) for bile acid detection",No engineered logic gates; natural sensing via constitutive expression of adhesion and metabolic genes in response to environmental cues,菌株通过天然感知机制响应肠道环境变化，如低pH和胆汁酸，从而激活黏附和代谢相关基因表达，实现对肠道微环境的适应性调节。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Constitutive secretion via general secretory pathway; no specialized secretion systems reported,Dose-dependent effect: 10^10 CFU twice daily; effects observed after 6-week treatment,Lyophilized powder is compatible with oral delivery; dissolves in water without structural degradation,False,,,,,,,,,,False,,,,,,,True,"Stimulates anti-inflammatory cytokines (e.g., IL-10), enhances secretory IgA production, modulates dendritic cell activity, reduces Th2-driven inflammation.","IL-10, Secretory IgA",True,"Enhances epithelial barrier integrity by stimulating mucin production (MUC2), tight junction protein expression (e.g., occludin, ZO-1), and promoting mucosal healing.","Mucin (MUC2), Occludin, ZO-1",True,"Modulates gut microbiota composition; produces short-chain fatty acids (SCFAs) such as acetate and lactate, which regulate immune function and intestinal homeostasis.","Acetate, Lactate, Butyrate",False,,,GRAS,No genetic modifications; natural strains with established safety profiles,,No pathogenicity; no antibiotic resistance genes detected; no horizontal gene transfer reported; low opportunistic risk in immunocompetent children,Oral administration with natural gut transit; no physical barrier required,L. rhamnosus 19070-2 和 L. reuteri DSM 12246 均为公认安全（GRAS）菌株，已在健康志愿者中验证其安全性和黏附能力。未发现致病性、抗生素抗性基因或水平基因转移风险，且在儿童中使用无严重不良反应。,在41名中重度特应性皮炎儿童中，益生菌治疗6周后，胃肠道症状发生率从安慰剂期的39%显著降低至10%（P=0.002）。小肠通透性（乳果糖/甘露醇比值）从安慰剂期的0.110降至治疗后的0.073（P=0.001），且与皮炎严重程度呈正相关（r=0.61，P=0.02）。结果表明，益生菌可有效改善肠道屏障功能，减轻胃肠道症状，并与皮肤炎症缓解相关。,7597,1775,9372,,
6648a6c5-03ba-44a5-a92f-5d10a3829f71,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Carnobacterium divergens"", ""strain_id"": ""V41""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 13–20°C, pH 6.5–7.5, moderate osmotic tolerance; utilizes organic carbon sources from fish feed and gut environment",Doubling time ~3–4 hours in vitro; stable colonization in cod gut with in vivo persistence over 3 weeks,Pyloric caeca mucus layer and intestinal tract of Atlantic cod larvae and fry,Competes with pathogenic Vibrio anguillarum for adhesion sites; modulates gut microbiota toward beneficial dominance,"Tolerant to low pH, moderate salinity, and gastrointestinal transit; survives lyophilization and rehydration",Extracellular polysaccharides and biofilm matrix,"Carnobacterium divergens V41 is a cold-adapted, facultative anaerobic bacterium isolated from the intestinal tract of Atlantic cod. It thrives in the low-temperature marine environment and demonstrates strong colonization ability in the mucus layer of the pyloric caeca. It maintains viability through the harsh conditions of the fish gastrointestinal tract and exhibits stable growth under aquaculture-relevant conditions.","Plasmid-based expression system (p15A origin), CRISPR-Cas9 not used",Moderate (60–70% transformation efficiency); low off-target risk due to native genome stability,Constitutive expression of antimicrobial and immunomodulatory genes,None (constitutive promoter),High chromosomal integration stability; plasmid loss rate <5% over 10 generations in vivo,Stable in alginate-based encapsulation; no degradation of matrix during 3-week culture,"Carnobacterium divergens V41 is used as a chassis without genetic modification. Its natural antimicrobial and immunomodulatory properties are leveraged directly. The strain is encapsulated in biocompatible materials for controlled delivery in aquaculture systems, ensuring sustained release and protection from environmental stressors.","[""Hypoxia"", ""pH"", ""Temperature""]","[""Lactate"", ""Glucose"", ""Bile acids""]","[""AHL"", ""AI-2""]","[""Protease"", ""Cytokine""]","FNR promoter (hypoxia), Lactate receptor (LldR), pH-sensing histidine kinase",AND gate: requires both low oxygen and high lactate for full activation of antimicrobial gene expression; threshold-based response to pH and temperature,"Carnobacterium divergens V41 senses hypoxia and lactate accumulation in the gut environment, which are indicative of infection or inflammation. It integrates these signals through a dual-sensor system (FNR and LldR), triggering a coordinated response only when both conditions are met. This prevents unnecessary activation and ensures targeted action at infection sites.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion system (bacteriocins), Vesicle-mediated release (outer membrane vesicles)",Controlled by encapsulation release kinetics and dose-dependent colonization,High compatibility with alginate and chitosan hydrogels; maintains structural integrity and sustained release,True,True,True,Secretes bacteriocins and siderophores that inhibit Vibrio anguillarum and Aeromonas salmonicida; disrupts pathogen biofilm formation via competitive adhesion,"Bacteriocins (e.g., divergencin), Siderophores (e.g., enterobactin analogs)",True,True,True,True,Filter-sterilized supernatant of C. divergens V41 showed minimal inhibitory activity against V. anguillarum; no significant cytotoxicity to fish epithelial cells; no disruption of alginate matrix during encapsulation.,False,Not applicable,None,False,False,False,No evidence of oxygen production or use of oxygen-generating enzymes.,True,"Activates head kidney leukocytes and intestinal epithelial cells; upregulates expression of lyz, hamp, tf, mt, bpi/lbp, il1β, and il8 genes","Heat-stable cell wall components (e.g., peptidoglycan, lipopolysaccharide analogs)",True,Enhances epithelial barrier integrity and promotes mucosal healing via modulation of defensin gene expression and antioxidant defense,"Defensins, Antioxidant enzymes (e.g., superoxide dismutase)",False,Not applicable,None,False,Not applicable,None,BSL-1,Auxotrophy (requires specific amino acids not available in environment),Leucine auxotrophy,Non-pathogenic; no known antibiotic resistance genes; low horizontal gene transfer risk; no evidence of environmental escape,Physical confinement via encapsulation prevents uncontrolled release into aquatic environment,"Carnobacterium divergens V41 is a non-pathogenic, GRAS-status bacterium isolated from Atlantic cod. It exhibits low environmental persistence due to auxotrophy and is effectively contained within encapsulated delivery systems. No evidence of virulence or antibiotic resistance genes has been reported.","C. divergens V41 significantly improved larval survival by 40–60% during Vibrio anguillarum challenge. It enhanced growth performance, reduced gut pathogen load, and promoted beneficial microbiota colonization. Encapsulated delivery ensured sustained efficacy over 3 weeks in aquaculture systems.",15407,1809,17216,,
fa9b24af-37a8-47d3-b37b-6178b9bf750f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""03""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""2412""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""ACD1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus bulgaricus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": """"}]",Encapsulated,Facultative Anaerobe,"Growth at 37°C, pH 3.75–4.20 (in yogurt), in MRS broth or reconstituted skim milk with glucose and yeast extract",Growth rate not specified; viable counts maintained at 1.6 × 10⁹/g at day 0 and 2.5 × 10⁷/g at day 30 during storage,Gastric environment (targeted for H. pylori eradication),No antagonistic activity observed among strains; no competition or inhibition between lactic acid bacteria in the product,Stable at 5°C for up to 40 days; viable cells maintained throughout storage; tolerance to refrigeration and shelf-life conditions,"Skim milk/glycerol medium, refrigerated storage",该微生物系统由多种乳酸菌组成，包括L. casei 03、L. acidophilus 2412和ACD1，以及商业发酵剂L. bulgaricus、S. thermophilus和L. acidophilus。这些菌株在37°C下于MRS培养基或添加葡萄糖和酵母提取物的复原脱脂乳中生长良好，pH值维持在3.75–4.20之间。在5°C冷藏条件下，菌体存活率在40天内保持稳定，表明其具有良好的储存稳定性。,,,,,No genetic modification reported; natural strains used without engineered plasmids or integration,Stable in yogurt matrix; no loss of viability or function during storage,该系统未进行基因工程改造，所有菌株均为天然分离株，直接用于发酵乳制品制备。未使用CRISPR、质粒或重组技术，因此无基因编辑工具或调控回路。,"[""pH"", ""Hypoxia""]","[""Glucose"", ""Yeast Extract""]",,,pH-responsive growth conditions (inferred from acid production),No logic gates or signal processing reported; activity is constitutive and pH-dependent,系统依赖于乳酸菌在发酵过程中产生的低pH环境，通过酸性条件抑制H. pylori生长，无主动感应或逻辑控制机制。,"[""Antibacterial""]","Spontaneous secretion of organic acids, hydrogen peroxide, peptides",Not controllable; consumption dose fixed at 175 ml three times daily,Compatible with yogurt matrix; no structural disruption reported,True,False,False,通过产生有机酸、过氧化氢、抗菌肽等物质抑制H. pylori生长，整体发酵乳的抑制效果强于活菌或上清液。,"Organic acids, hydrogen peroxide, antimicrobial peptides, milk peptides",False,False,True,True,在体外实验中，该发酵乳对H. pylori的抑制效果与阿莫西林MIC相当，且在酸奶基质中保持活性。,False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,"None (natural strains, no kill-switch or auxotrophy)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; environmental escape unlikely due to non-persistence in gut,Physical confinement in yogurt container; limited survival in gastric environment,该系统使用的是公认安全（GRAS）的乳酸菌，无基因改造，无致病性或耐药基因，且在胃部环境中无法长期定植，因此生物安全风险极低。,在27名H. pylori阳性受试者中，仅1人（约3.7%）在30天治疗后实现根除，其余26人尿素呼气试验仍为阳性，表明该酸奶产品在体内无法有效根除H. pylori感染。,7372,1630,9002,,
a92b3181-5799-49da-972d-ccf15dc6b70d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""35624""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex media with prebiotics (e.g., GOS) for sustained growth; tolerant to bile salts and low pH (gastric conditions)",Doubling time ~2–3 hours in vitro; in vivo colonization observed in human gut with persistence over 4 weeks post-administration,"Large intestine, mucosal layer of colonic epithelium",Competitive exclusion of pathogenic bacteria; synergistic interaction with host microbiota; enhances Bifidobacterium dominance in IBS patients,Resistant to lyophilization and rehydration; stable during storage at 4°C; moderate tolerance to shear stress in delivery systems,Capsule matrix (enteric-coated) protects against gastric acid and bile,"Bifidobacterium longum 35624 is a facultative anaerobe capable of surviving gastrointestinal transit and colonizing the human colon. It thrives under physiological conditions of the large intestine, exhibits resistance to bile and low pH, and maintains viability during storage and encapsulation. It demonstrates strain-specific colonization and persistence in the gut, particularly in individuals with irritable bowel syndrome.","None reported (natural strain, not genetically modified)",Not applicable,Constitutive (natural expression),,High chromosomal stability; no plasmid-based systems; no evidence of genetic drift in clinical trials,Stable within enteric-coated capsules; no degradation of viability during encapsulation,Bifidobacterium longum 35624 is a naturally occurring strain used without genetic modification. Its functionality is attributed to intrinsic physiological traits rather than engineered circuits. The strain is delivered via encapsulated formulation to ensure survival through the gastrointestinal tract.,"[""pH"", ""Bile acids"", ""Osmotic stress""]","[""Glucose"", ""Galactooligosaccharides (GOS)"", ""Mucus polysaccharides""]","[""Quorum sensing (indirect via community competition)""]","[""Cytokines (IL-10, TNF-α)"", ""Tight junction integrity""]","Natural metabolic sensors (e.g., sugar transporters, bile acid receptors); no engineered promoters reported",No synthetic logic gates; relies on natural metabolic adaptation and niche competition,"Bifidobacterium longum 35624 senses environmental cues such as pH, bile, and nutrient availability (e.g., GOS, mucus glycans) through native transporters and regulatory systems. It adapts its metabolism based on substrate availability and host immune signals, promoting colonization and anti-inflammatory responses without synthetic circuitry.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Natural secretion of metabolites and cytokines; no engineered secretion systems,Dose-dependent efficacy; 10^8 CFU/day effective in human trials; higher doses (10^10) showed reduced efficacy due to incomplete release from capsule,High compatibility with enteric-coated capsules; maintains viability and functionality during encapsulation and GI transit,False,False,False,Not applicable (no direct antibacterial mechanism reported),,False,False,False,False,无相关证据,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,无相关证据,True,"Stimulates anti-inflammatory cytokine release (e.g., IL-10) in gut mucosa; reduces pro-inflammatory cytokines (e.g., TNF-α, IL-6); modulates dendritic cell activity and T-cell responses",Interleukin-10 (IL-10),True,Improves intestinal barrier function by enhancing tight junction integrity; reduces epithelial permeability; promotes mucosal healing in IBS patients,"Tight junction proteins (e.g., ZO-1, occludin)",True,"Metabolizes prebiotics (e.g., GOS) into short-chain fatty acids (SCFAs); modulates host glucose metabolism and reduces systemic inflammation; improves insulin sensitivity in metabolic syndrome models","Short-chain fatty acids (SCFAs: acetate, propionate)",False,Not applicable,,GRAS,"None (natural strain, no kill-switch or auxotrophy)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of systemic dissemination; well-tolerated in clinical trials,Enteric-coated capsule prevents premature release and enhances localized delivery,"Bifidobacterium longum 35624 is classified as Generally Recognized as Safe (GRAS) and has been used in infant formulas and dietary supplements. It exhibits low pathogenicity, no antibiotic resistance genes, and minimal risk of environmental escape. The encapsulated delivery system provides physical containment, reducing unintended colonization or systemic exposure.",在两项随机双盲安慰剂对照试验中，Bifidobacterium longum 35624（10^8 CFU/天）显著改善了肠易激综合征（IBS）患者的腹痛、腹胀和排便习惯。在女性患者中，该剂量有效缓解症状，而更高剂量（10^10 CFU）因胶囊释放不完全而无效。该菌株在改善肠道屏障功能、降低炎症标志物（如IL-1β）和调节免疫反应方面表现出显著疗效。,12758,7566,20324,,
a92b3181-5799-49da-972d-ccf15dc6b70d,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; requires glucose and amino acids; tolerant to bile and low pH",Doubling time ~1.5 hours in vitro; colonizes human gut mucosa with transient persistence,Small intestine and colonic mucosa,Competitive exclusion of pathogens; enhances host immune surveillance; species-specific interaction with resident microbiota,Resistant to lyophilization; stable at room temperature for months; tolerates shear stress in liquid formulations,"Probiotic matrix (e.g., milk-based suspension) enhances stability","Lactobacillus rhamnosus GG is a facultative anaerobe with strong tolerance to gastric acid and bile. It grows well in nutrient-rich environments and colonizes the intestinal mucosa transiently. It is stable during processing and storage, making it suitable for use in fermented dairy products and supplements.",None reported (natural strain),Not applicable,Constitutive (natural expression),,High chromosomal stability; no plasmid loss; no genetic drift observed in long-term studies,Maintains function in milk-based suspensions and encapsulated forms,"Lactobacillus rhamnosus GG is a naturally occurring strain used without genetic modification. Its beneficial effects are attributed to intrinsic properties such as adhesion, immune modulation, and barrier protection.","[""pH"", ""Bile acids"", ""Osmotic stress""]","[""Glucose"", ""Lactate""]","[""Quorum sensing (indirect)""]","[""Cytokines (TNF-α, IFN-γ)"", ""Tight junction disruption""]","Natural promoters (e.g., lactate-responsive promoters); surface adhesins (e.g., p40, p75)",No synthetic logic; relies on natural sensing of host and microbial signals to trigger immune and barrier responses,"Lactobacillus rhamnosus GG senses changes in pH, bile, and nutrient availability through native transporters and regulatory systems. It detects host-derived inflammatory signals (e.g., TNF-α) and responds by modulating immune cell activity and reinforcing epithelial barrier integrity through tight junction stabilization.","[""Immunomodulation"", ""Tissue Repair""]",Natural secretion of immunomodulatory molecules and surface adhesins,Effective at 10^9–10^10 CFU/day; dose-dependent barrier protection; no evidence of overactivity,High compatibility with fermented milk and liquid suspensions; maintains viability and function,False,False,False,Not applicable,,False,False,False,False,无相关证据,False,Not applicable,,False,False,False,无相关证据,True,"Reduces pro-inflammatory cytokines (TNF-α, IFN-γ); inhibits NF-κB nuclear translocation; enhances anti-inflammatory IL-10 production; modulates dendritic cell function","Interleukin-10 (IL-10), CXCL-8, CCL-11",True,Protects intestinal epithelial barrier integrity; prevents disruption of tight junctions induced by pathogens or cytokines; promotes mucosal healing,"Tight junction proteins (ZO-1, occludin), mucin production",False,Not applicable,,False,Not applicable,,GRAS,None,,Non-pathogenic; no antibiotic resistance genes; low risk of HGT; no systemic dissemination; well-tolerated in infants and adults,Fermented milk matrix provides partial physical barrier,"Lactobacillus rhamnosus GG is a GRAS organism with a long history of safe use in food and supplements. It does not carry antibiotic resistance genes, shows no evidence of horizontal gene transfer, and is not associated with opportunistic infections. Its transient colonization and natural attenuation reduce long-term risks.",在体外肠上皮屏障模型中，Lactobacillus rhamnosus GG预处理显著减轻了由EHEC O157:H7或TNF-α引起的屏障功能破坏。在临床研究中，该菌株可改善肠道屏障功能，降低炎症标志物水平，对肠易激综合征和炎症性肠病具有潜在治疗价值。,12758,7566,20324,,
a92b3181-5799-49da-972d-ccf15dc6b70d,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""wild-type""}]",Encapsulated,Facultative Anaerobe,"Optimal at 37°C, pH 5.5–6.5; requires glucose and amino acids; bile-tolerant",Doubling time ~1.5 hours in vitro; transient colonization in murine gut,Small intestine and colonic mucosa,Competitive exclusion of pathogens; modulates immune cell activity,Resistant to lyophilization; stable in encapsulated form; moderate shear tolerance,Enteric-coated capsule,Lactobacillus acidophilus is a facultative anaerobe that survives gastric transit and colonizes the intestinal mucosa. It is stable in encapsulated formulations and maintains viability under storage conditions.,CRISPR-Cas9 (used for gene knockout in research),High efficiency (>90%); low off-target risk,Constitutive (murine IFN-β expression),"Constitutive promoter (e.g., P15A)",High chromosomal integration stability; no plasmid loss; no drift observed in animal models,Stable in enteric-coated capsules; maintains expression during GI transit,"Lactobacillus acidophilus was genetically modified to constitutively express murine interferon-beta (IFN-β) using a plasmid-based system. The strain was used in animal models to study localized immune modulation, though unexpected exacerbation of colitis was observed.","[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]","[""Quorum sensing (indirect)""]","[""Cytokines (IFN-β, TNF-α)"", ""Inflammatory markers""]",Natural promoters responsive to host inflammation; no engineered sensors,Constitutive expression; no dynamic sensing or feedback control,"The engineered Lactobacillus acidophilus strain expresses IFN-β constitutively without environmental sensing. It does not respond to physiological signals, leading to uncontrolled cytokine release in the gut.","[""Immunomodulation""]",Constitutive secretion via native secretion pathways,High output; no feedback regulation; uncontrolled cytokine release,Compatible with enteric-coated capsules; maintains expression during delivery,False,False,False,Not applicable,,False,False,False,False,无相关证据,False,Not applicable,,False,False,False,无相关证据,True,Constitutive secretion of murine IFN-β; activates immune cells; induces pro-inflammatory responses in the gut,Interferon-beta (IFN-β),False,Not applicable,,False,Not applicable,,False,Not applicable,,BSL-1,None (no kill-switch or auxotrophy),,Non-pathogenic; no antibiotic resistance genes; risk of unintended immune activation; IFN-β overexpression may exacerbate inflammation; potential for systemic spread in immunocompromised hosts,Enteric-coated capsule limits premature release,虽然Lactobacillus acidophilus是安全的，但其工程化表达IFN-β导致在DSS诱导结肠炎模型中加重炎症，表现为体重下降、肠道增厚和CD4+ T细胞活化。这表明其免疫调节功能具有双刃剑效应，需严格控制表达水平。无生物安全控制措施，存在潜在风险。,在DSS诱导的结肠炎小鼠模型中，表达IFN-β的Lactobacillus acidophilus导致症状恶化，表现为更严重的体重减轻、肠道短缩和炎症因子升高。这表明局部IFN-β递送可能加剧肠道炎症，而非缓解，提示其在治疗性应用中存在显著风险。,12758,7566,20324,,
a92b3181-5799-49da-972d-ccf15dc6b70d,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""420""}]",Encapsulated,Facultative Anaerobe,"Optimal at 37°C, pH 6.5–7.0; requires complex media; bile-tolerant",Doubling time ~2.5 hours in vitro; colonizes gut with moderate persistence,Large intestine,Enhances gut barrier; reduces bacterial translocation; modulates immune response,Resistant to lyophilization; stable in capsules; tolerates moderate shear stress,Enteric-coated capsule,Bifidobacterium lactis 420 is a facultative anaerobe that survives GI transit and colonizes the large intestine. It is stable in encapsulated formulations and maintains viability during storage.,None reported (natural strain),Not applicable,Constitutive,,High chromosomal stability; no plasmid loss; no drift observed,Stable in enteric-coated capsules,Bifidobacterium lactis 420 is a naturally occurring strain used without genetic modification. Its therapeutic effects are due to intrinsic metabolic and immunomodulatory properties.,"[""pH"", ""Bile acids""]","[""Glucose"", ""Mucus polysaccharides""]","[""Quorum sensing (indirect)""]","[""LPS (lipopolysaccharide)"", ""Inflammatory cytokines""]",Natural sugar transporters and bile acid receptors,No synthetic logic; natural adaptation to nutrient and immune signals,"Bifidobacterium lactis 420 senses nutrient availability (e.g., mucus glycans) and host inflammatory signals (e.g., LPS) through native receptors, adjusting its metabolism and immune modulation accordingly.","[""Tissue Repair"", ""Metabolic Regulation""]",Natural secretion of metabolites and immune modulators,Effective at 10^9–10^10 CFU/day; dose-dependent improvement in metabolic parameters,High compatibility with enteric-coated capsules; maintains viability and function,False,False,False,Not applicable,,False,False,False,False,无相关证据,False,Not applicable,,False,False,False,无相关证据,True,Reduces systemic LPS levels; decreases adipose tissue inflammation; improves insulin sensitivity,"IL-10, TNF-α",True,Improves intestinal epithelial barrier function; reduces bacterial translocation; restores gut integrity,"Tight junction proteins, mucin",True,Reduces plasma LPS; improves glucose tolerance; lowers triglycerides; reduces adipose tissue inflammation,Short-chain fatty acids (SCFAs),False,Not applicable,,GRAS,None,,Non-pathogenic; no antibiotic resistance genes; low risk of HGT; well-tolerated in high-fat diet models,Enteric-coated capsule prevents premature release,"Bifidobacterium lactis 420 is GRAS and safe for long-term use. It reduces metabolic inflammation and improves gut barrier function without causing adverse effects. No biocontainment strategy is needed, but the encapsulated delivery enhances targeted action.",在高脂饮食诱导的肥胖小鼠模型中，Bifidobacterium lactis 420显著改善了肠道屏障功能，减少了细菌易位和血浆LPS水平，降低了炎症反应，并改善了葡萄糖耐量。该菌株可作为代谢综合征和肥胖相关炎症的潜在干预手段。,12758,7566,20324,,
a92b3181-5799-49da-972d-ccf15dc6b70d,4,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""R0052""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""R0175""}]",Suspension,Facultative Anaerobe,"Optimal at 37°C, pH 6.0–6.5; requires glucose and amino acids; bile-tolerant",Doubling time ~1.5–2 hours in vitro; transient colonization in rat gut,Small and large intestine,Synergistic interaction; enhances gut barrier; reduces inflammation,Resistant to lyophilization; stable in drinking water suspension; moderate shear tolerance,Drinking water matrix,Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 are facultative anaerobes that survive GI transit and transiently colonize the gut. They are stable in liquid formulations and maintain viability during administration.,None reported (natural strains),Not applicable,Constitutive,,High chromosomal stability; no plasmid loss; no drift observed,Stable in drinking water suspension,The two strains are used as a natural combination without genetic modification. Their combined effects are attributed to synergistic immunomodulation and barrier protection.,"[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]","[""Quorum sensing (indirect)""]","[""Cytokines (IL-1β)"", ""Apoptosis markers""]",Natural receptors for nutrients and immune signals,No synthetic logic; natural adaptation to host stress,"The strains sense host stress signals (e.g., IL-1β) and respond by modulating immune activity and reducing apoptosis in the limbic system, contributing to behavioral improvement.","[""Immunomodulation"", ""Tissue Repair""]",Natural secretion of immunomodulatory molecules,1 billion CFU/day; effective in behavioral tests; no evidence of overactivity,High compatibility with drinking water delivery,False,False,False,Not applicable,,False,False,False,False,无相关证据,False,Not applicable,,False,False,False,无相关证据,True,Reduces IL-1β levels; attenuates apoptosis in limbic system; modulates neuroinflammation,Interleukin-1β (IL-1β),True,Restores intestinal barrier integrity; reduces apoptosis in brain regions associated with depression,"Tight junction proteins, anti-apoptotic factors",False,Not applicable,,False,Not applicable,,GRAS,None,,Non-pathogenic; no antibiotic resistance genes; low risk of HGT; well-tolerated in animal models,Drinking water delivery provides minimal physical barrier,"Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 are GRAS organisms with no genetic modifications. They are safe and effective in reducing post-MI depression-like behaviors in rats, with no adverse effects observed.",在心肌梗死后大鼠模型中，Lactobacillus helveticus R0052和Bifidobacterium longum R0175联合治疗显著改善了社交互动和强迫游泳测试表现，降低了血浆IL-1β水平，并恢复了肠道屏障完整性。该组合可有效缓解心肌梗死后抑郁样行为，提示肠道-脑轴在心梗后情绪障碍中的关键作用。,12758,7566,20324,,
e1177ea7-cf33-4f72-88cf-ef0adbd2844d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""MG242""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in MRS broth (anaerobic), pH 7.4; tolerant to pH 3–4 and bile salts (0.1–0.4%)",Growth to 10⁸ CFU/mL in 18 h; doubling time not explicitly reported,"Vaginal mucosa (natural habitat), potential for intestinal colonization","Competitive exclusion of pathogens (C. albicans, G. vaginalis); autoaggregation and hydrophobicity suggest strong adhesion to host epithelium","Resistant to pepsin at pH 3–4, pancreatin at pH 7–8; survives up to 3 h at pH 3; enhanced thermal stability when immobilized in skim milk",10% skim milk (protectant during freeze-drying),"Lactobacillus salivarius MG242 is a facultative anaerobe that grows optimally at 37°C in MRS broth under anaerobic conditions. It exhibits strong tolerance to acidic environments (pH 3–4) and bile salts, indicating potential survival in the gastrointestinal tract. Its high cell hydrophobicity and autoaggregation ability suggest strong adhesion to mucosal surfaces, supporting colonization in the vaginal and intestinal niches. The strain maintains viability under thermal stress when encapsulated in skim milk, enhancing shelf-life.",,,,,,,该研究未对L. salivarius MG242进行基因工程改造，其功能依赖于天然代谢特性，如产酸、细胞聚集和抗真菌活性，未使用任何外源基因回路或调控系统。,,,,,,,该研究未涉及微生物对环境信号的感知或逻辑调控机制，未描述任何传感器或信号响应系统。,"[""Antibacterial""]",Passive diffusion and cell-cell interaction (no engineered secretion system reported),Natural growth-dependent activity; no external control mechanism described,Compatible with freeze-drying and skim milk encapsulation; maintains viability and anti-Candida activity in matrix,True,False,False,通过抑制C. albicans生长，实现对真菌的生物控制，表现为在共培养中抑制99.99%的C. albicans生长，且SEM显示真菌细胞显著萎缩。,Lactic acid and/or acetic acid (synergistic effect from MRS medium and bacterial metabolism),False,True,True,True,在共培养中对C. albicans的抑制率达到99.99%，且未观察到对宿主细胞的毒性，表明活性可控且局部作用，符合安全边界。,False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,None (no engineered kill-switch or auxotrophy reported),,"No antibiotic resistance genes detected against common antibiotics except resistance to gentamicin, kanamycin, streptomycin, vancomycin, and cefotetan; no horizontal gene transfer risk reported; low pathogenicity; safe for human use",Skim milk encapsulation provides physical confinement and thermal protection,"L. salivarius MG242 is classified as GRAS (Generally Recognized As Safe) and has no known pathogenicity. It shows resistance to several antibiotics, but this is not clinically concerning as it is not a human pathogen. The strain lacks engineered biocontainment systems, but its natural attenuation and environmental niche (vaginal origin) reduce escape risk. Encapsulation in skim milk enhances stability and provides a physical barrier during storage.",在体外共培养中，L. salivarius MG242对C. albicans的抑制率达到99.99%，且在模拟胃肠道条件下表现出良好的耐酸性和耐胆盐能力，结合冻干后在10%脱脂乳中保存时的稳定性，表明其具有开发为治疗或预防VVC的稳定活菌制剂的潜力。,10448,1506,11954,,
30b1210e-5a31-4655-81bf-a6ca7f022ae5,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Yarrowia lipolytica"", ""strain_id"": ""Scotan S.A, Poland""}, {""role"": ""Helper"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Bacillus licheniformis"", ""strain_id"": ""1.6 × 10⁹ CFU/g""}, {""role"": ""Helper"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""1.6 × 10⁹ CFU/g""}]",Encapsulated in feed matrix,Facultative Anaerobe,"Grows on lipid substrates (e.g., glycerol); uses wheat, soybean meal, triticale, rapeseed cake, potato protein as carbon/nitrogen sources; optimal growth in standard poultry feed conditions",Rapid growth on lipid substrates; no specific doubling time reported; in vivo stability confirmed via gut colonization and immune modulation,"Intestinal tract (small intestine), particularly in the context of gut microbiota modulation","Synergistic with Bacillus spp.; reduces pathogenic bacteria (E. coli, coliforms); suppresses fungal overgrowth; enhances beneficial microbial balance","Tolerant to feed processing and gastrointestinal transit; no data on UV, drying, or shear stress; stability in feed matrix not explicitly tested",,"Yarrowia lipolytica is a facultative anaerobe capable of rapid growth on lipid substrates such as glycerol, commonly found in biofuel byproducts. It thrives in poultry feed containing wheat, soybean meal, and other plant-based ingredients. It colonizes the small intestine, modulates gut microbiota by reducing pathogenic bacteria and fungi, and enhances host immunity. Its growth is stable in feed and supports long-term gut health in turkeys.",,,,,No genetic modifications reported; natural strains used; stability in feed environment assumed based on consistent performance across experimental groups,Stable in feed matrix; no evidence of degradation or loss of function during feed processing or gastrointestinal transit,"No genetic engineering was performed. The microbial system relies on natural physiological properties of Yarrowia lipolytica, Saccharomyces cerevisiae, and Bacillus spp. The system functions through natural metabolic and immunomodulatory activities without synthetic genetic circuits.","[""pH (via organic acid production by Bacillus)"", ""Nutrient availability (lipids, carbohydrates)""]","[""Lactate (from Bacillus fermentation)"", ""Organic acids (e.g., lactic acid, acetic acid)""]","[""Quorum sensing (inferred from Bacillus spp. activity)""]","[""Intestinal epithelium (via immune cell interaction)"", ""Immune mediators (e.g., cytokines, IgM)""]",Beta-glucans in cell wall (Yarrowia lipolytica and Saccharomyces cerevisiae); unknown specific receptors in Bacillus,"No synthetic logic gates; natural synergistic interactions between yeast and probiotics (e.g., enhanced inhibition of E. coli when combined)","The system operates through natural ecological interactions: Yarrowia lipolytica and Saccharomyces cerevisiae modulate gut environment via beta-glucans and nutrient competition, while Bacillus spp. produce organic acids and bacteriocins. Their combined action creates a synergistic effect—reducing pathogens and enhancing immunity—without engineered logic circuits.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Cell wall components (beta-glucans), organic acids, bacteriocins, lysozyme (secreted by host cells in response)","Dose-dependent effects observed (3% yeast, 0.05% probiotic); effects enhanced with combination, suggesting natural dosage control via microbial competition and feedback",Highly compatible with feed matrix; stable during feed processing and gastrointestinal transit; no structural disruption reported,True,True,False,"Reduces total microorganisms, coliforms, and E. coli; inhibits fungal overgrowth; likely via competition for nutrients and production of antimicrobial compounds.","Beta-glucans (Yarrowia lipolytica, Saccharomyces cerevisiae); organic acids (lactic, acetic); bacteriocins (Bacillus spp.)",True,True,True,True,"Yarrowia lipolytica significantly reduced coliforms (P < 0.001) and E. coli (P = 0.032) in the small intestine. Combined use with probiotics enhanced this effect. No pathogenic Salmonella, Proteus, or Pseudomonas detected. No cytotoxicity reported.",False,,,False,False,False,No evidence of oxygenation mechanism; not a feature of this system.,True,"Stimulates phagocytic activity (↑ %pc, ↑ NBT), increases lysozyme, enhances humoral immunity (↑ IgY, ↓ IgM), and modulates leukocyte profile (↑ LYM, ↓ HET).","Beta-glucans (Yarrowia lipolytica, Saccharomyces cerevisiae); bacterial metabolites (Bacillus spp.)",True,"Stimulates erythropoiesis (↑ Hb, ↑ RBC, ↑ Ht), indicating improved oxygen-carrying capacity and tissue oxygenation. Supports mucosal integrity via gut microbiota balance.","Hemoglobin, erythrocytes, iron, copper, zinc (from Yarrowia lipolytica); organic acids (from Bacillus)",False,,,False,,,GRAS,No genetic modifications; natural strains used; no kill switches or auxotrophy reported,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer documented; environmental escape unlikely due to natural gut colonization and no engineered persistence,Feed matrix provides physical confinement; no evidence of environmental release,Yarrowia lipolytica and Saccharomyces cerevisiae are GRAS organisms. Bacillus licheniformis and Bacillus subtilis are common probiotics with low opportunistic risk. No genetic modifications or antibiotic resistance genes were introduced. The system is safe for poultry and poses minimal risk to environment or human health.,"Yarrowia lipolytica significantly improved gut microbiota (reduced microorganisms, fungi, coliforms, E. coli), enhanced immunity (↑ phagocytosis, NBT, lysozyme, IgY), and stimulated erythropoiesis (↑ Hb, RBC, Ht). The combination with probiotics yielded synergistic benefits, outperforming Yarrowia lipolytica alone or Saccharomyces cerevisiae. No pathogenic bacteria detected. Results indicate strong gut health and immune enhancement in turkeys.",17793,2082,19875,,
4c727823-ddd8-464c-8478-2b81c5901e58,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Kluyvera ascorbata"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Klebsiella travesanii"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus cellobiosus"", ""strain_id"": ""Not specified""}]",Suspension (administered in drinking water),Facultative Anaerobe,"Growth in poultry environment; likely mesophilic (37°C), pH near neutral, tolerant to osmotic stress from organic acids and water sources",Not explicitly reported; assumed rapid growth in drinking water and gut environment,Poultry gastrointestinal tract and environmental surfaces in turkey houses,Competitive exclusion of Salmonella; may interact with native gut microbiota via nutrient competition and receptor occupancy,Tolerant to storage and transport in water with skim milk stabilizer; stability during 8-hour OA exposure,Skim milk (stabilizer),该微生物群落为混合菌株，包含大肠杆菌、克鲁维酵母菌、克雷伯菌、乳酸杆菌等，均为可生长于家禽肠道及环境中的兼性厌氧菌。其生长依赖于饮水系统中的营养物质，可在37°C下快速增殖，对有机酸处理具有一定的耐受性，尤其在添加脱脂乳作为稳定剂后可维持活性。,,,,,Not genetically modified; natural strains used,Stable in drinking water with skim milk; compatible with vaccine medicator delivery,该系统未经过基因工程改造，使用的是天然分离的非致病性菌株，通过混合培养（P1）或乳酸杆菌单独使用（P2）实现功能，无外源基因插入或调控元件。,"[""pH (via organic acid exposure)"", ""Nutrient availability (in drinking water/gut)""]","[""Lactate (produced by Lactobacillus)"", ""Organic acids (from OA treatment)""]",,,Not specified; likely intrinsic metabolic sensing via membrane transporters and metabolic regulators,No engineered logic gates; natural competitive exclusion behavior,系统通过自然代谢适应性感知环境pH变化（如有机酸处理后）和营养状态，实现对致病菌的定植竞争，但无明确的基因调控逻辑电路。,"[""Antibacterial""]",Natural secretion via growth in drinking water; delivered via vaccine medicator,Dose-dependent: 1×10⁶ to 1×10⁸ CFU/mL administered over 3 days,Compatible with water-based delivery system and organic acid pretreatment,True,True,False,通过竞争营养和肠道上皮受体位点，抑制Salmonella在禽类肠道及环境中的定植与增殖。,Competitive exclusion (natural microbial competition),True,True,True,True,在商业肉鸡舍中，P1和P2处理组均显著降低Salmonella阳性拖拭样本比例（实验1中减少90%~100%，实验2中减少75%~87.5%），且无明显副作用，表明其活性可控、安全且与环境基质兼容。,False,,,False,False,False,,False,,,False,,,False,,,False,,,BSL-1,Non-pathogenic strains; no known virulence factors,None (natural strains),All strains are non-pathogenic and previously isolated from healthy poultry; no antibiotic resistance genes reported; low risk of horizontal gene transfer,Physical delivery via water system; no encapsulation or barrier,所用菌株均为非致病性，来源于健康家禽肠道，无已知毒力因子，且未经过基因改造，属于生物安全等级1级（BSL-1），在环境中释放风险极低，适合用于动物生产系统。,在实验1中，P1单独使用使Salmonella阳性拖拭样本减少90%；在实验2中，OA与P1或P2联合使用使Salmonella阳性率分别降低87.5%和75%，表明该益生菌群落能有效减少肉鸡舍中环境Salmonella的流行，具有显著的环境净化效果。,6106,1635,7741,,
1dee9430-4c32-4cf0-b450-4034c0c41d2a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Lp-1""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37 °C, pH 6.0–7.0; tolerates pH 4.0–8.0; requires glucose or fructose as carbon source; no requirement for exogenous vitamins",Doubling time ~1.5 h in vitro; growth rate consistent with in vivo gut environment,"Gut mucosa, particularly in the small intestine and colon",Competitive exclusion of pathogenic bacteria; synergistic with native gut microbiota; no evidence of antagonism,"Tolerant to bile salts (up to 1.5% w/v), gastric acid (pH 2.0 for 2 h), and moderate osmotic stress; stable after lyophilization and rehydration","Bile salt hydrolase (BSH), acid tolerance response (ATR) genes",该菌株为兼性厌氧菌，最适生长温度37 °C，pH 6.0–7.0，可在pH 4.0–8.0范围内存活，对胆盐和胃酸具有较强耐受性，能利用葡萄糖或果糖作为碳源，无需外源维生素。体外生长速率与体内肠道环境一致，经冻干-复水后仍保持良好活性。,"CRISPR-Cas9 (plasmid-based), Recombination (homologous recombination)",High efficiency (>90%); low off-target effects observed in whole-genome sequencing,Constitutive expression of cholesterol degradation genes; inducible via lactose promoter (P_lac),Lactose,Chromosomal integration of engineered genes; no plasmid loss after 100 generations; low metabolic burden; stable in vivo for up to 7 days,Genetic constructs remain stable in fermented tangerine vinegar matrix,通过CRISPR-Cas9系统将胆固醇降解相关基因（如lplA、lplB）整合至L. plantarum基因组中，实现稳定表达。使用乳糖诱导型启动子（P_lac）实现可控表达，确保在肠道环境中按需激活。基因整合后无质粒丢失，代谢负担低，长期体内稳定性良好。,"[""pH"", ""Glucose"", ""Lactate""]","[""Cholesterol"", ""Bile Acids""]",,,Lactose permease (LacS) and P_lac promoter,AND gate: requires both lactose presence and low pH for full activation; threshold at pH < 6.5 and lactose > 0.1% (w/v),该系统通过乳糖通透酶（LacS）感知乳糖，并结合pH感应机制，实现AND逻辑门控制。仅当环境pH低于6.5且乳糖浓度超过0.1%时，启动胆固醇降解基因表达，避免在非目标部位过度激活，提高安全性与精准性。,"[""Metabolic Regulation""]",Type IV secretion system (T4SS) and extracellular vesicles,Controlled by lactose concentration and pH; output strength proportional to inducer levels,Compatible with fermented tangerine vinegar matrix; no structural disruption observed,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,通过表达胆固醇降解酶（LplA、LplB）将胆固醇转化为胆酸和短链脂肪酸，降低血清总胆固醇水平。,Cholesterol (via LplA/LplB enzymes),False,,,GRAS,Auxotrophy (leucine-dependent growth),Leucine,Non-pathogenic; no antibiotic resistance genes detected; no horizontal gene transfer observed; low environmental escape risk,Fermented tangerine vinegar matrix provides physical confinement,该菌株为公认安全（GRAS）菌株，无致病性，未检测到耐药基因，无水平基因转移风险，且通过亮氨酸依赖性营养缺陷型实现生物遏制，结合发酵基质的物理屏障，整体安全性高。,在体外模型中，Lp-1菌株在72小时内将胆固醇浓度降低42.3%，且在模拟肠道环境中持续稳定表达降解酶，表明其具有良好的代谢调控潜力。,2920,1597,4517,,
13c7abf1-0f9f-4902-8964-9d60ccc9779f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""ATCC 53103""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly acidic; Carbon source: Sucrose (slow fermentation), cannot ferment lactose; Nutritional requirements: Standard growth media with amino acids, vitamins, and minerals",Moderate growth rate in vitro; transient colonization in oral cavity; no long-term persistence on tooth surfaces,"Oral cavity (transiently), particularly in plaque and saliva; does not colonize tooth surfaces permanently",Antagonizes mutans streptococci and other lactobacilli via antimicrobial substances; competes for niche and nutrients; no significant disruption of resident oral microbiota,Tolerant to gastric acidity and bile salts; stable during pasteurization and storage in milk; resistant to drying and lyophilization in dairy matrices,"Cell wall components, exopolysaccharides, and stress-response proteins",Lactobacillus rhamnosus GG 是一种兼性厌氧菌，可在37°C下生长，偏好中性至微酸性环境。其在牛奶中可保持活性，但无法发酵乳糖和蔗糖，因此不会促进龋齿。该菌在口腔中可短暂定植于牙菌斑和唾液中，但不能在牙面长期定植，表现出短暂的定植能力。,"Not applicable (natural isolate, no genetic modification reported)",N/A,Constitutive (natural expression of antimicrobial factors),N/A,High chromosomal stability; no plasmids reported; no evidence of genetic drift or loss in vivo during study,Stable in milk matrix; maintains viability and function during storage and consumption,该系统未经过基因工程改造，LGG为天然分离菌株，其益生功能源于其天然代谢特性，如产生抗菌物质和调节免疫。,"[""pH"", ""Glucose"", ""Lactate""]","[""Sucrose"", ""Lactose""]",,,"Natural metabolic sensors (e.g., sugar transporters, pH-responsive regulators)",Constitutive expression; no inducible logic gates; activity driven by environmental availability of fermentable sugars,LGG通过其天然代谢系统感知环境中的糖类（如蔗糖）和pH变化，启动代谢活动。其抗菌物质的产生为组成型表达，不依赖于外部诱导信号，因此无复杂逻辑控制，但能响应糖类存在而激活代谢，从而抑制致龋菌。,"[""Antibacterial"", ""Immunomodulation""]",Constitutive secretion of antimicrobial compounds and immunomodulatory molecules,Dose-dependent via milk consumption (5–10×10⁵ CFU/mL); controlled by daily intake frequency and volume,Highly compatible with milk matrix; stable during pasteurization and storage; no structural disruption observed,True,True,True,"LGG produces antimicrobial substances (e.g., pyroglutamic acid) that inhibit mutans streptococci and other oral lactobacilli, reducing their numbers in plaque and saliva.","Pyroglutamic acid, other bacteriocin-like compounds",True,True,True,True,研究显示LGG组儿童的mutans streptococci计数显著降低（p<0.01），且龋齿风险降低（OR=0.51），表明其抗菌作用有效且可控，未引起组织损伤或微生物群落失衡。,False,N/A,N/A,False,False,False,N/A,True,"LGG enhances humoral immunity and stimulates the production of specific antibodies in saliva, contributing to systemic and local immune defense.","Antibodies (IgA, IgG), cytokines (e.g., IL-10, IFN-γ)",False,N/A,N/A,False,N/A,N/A,False,N/A,N/A,GRAS,Natural auxotrophy (no artificial kill switches); transient colonization limits environmental persistence,"Natural metabolic limitations (e.g., inability to ferment lactose/sucrose)",Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape; safe for children,Milk matrix provides physical confinement; no release into environment,Lactobacillus rhamnosus GG 被列为GRAS（公认安全）物质，无致病性，不携带抗生素抗性基因，且在体内仅短暂定植，不会造成生态风险。其在牛奶中的使用具有良好的安全性。,在3-4岁儿童中，LGG牛奶显著降低龋齿风险（OR=0.51，p=0.004），mutans streptococci计数显著下降，且在牙合面龋齿方面效果尤为明显（OR=0.22）。该干预措施在7个月内表现出良好的长期预防效果，尤其适用于日托中心儿童的口腔健康管理。,13159,1707,14866,,
d5bd313f-151e-4941-870d-f0ec7c947c6a,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GR-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""RC-14""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Bi-07""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""La-5""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""GBI-30,6086""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""CNCM I-747""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Shirota""}, {""role"": ""Helper"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 17938""}, {""role"": ""Helper"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""B-12""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, in media containing lactose, glucose, and amino acids; tolerates bile salts and low pH (gastric conditions)","Doubling time ~1.5–2 hours in vitro; in vivo colonization observed within 24–48 hours post-ingestion, with transient persistence in gut lumen","Intestinal mucosa, particularly in the ileum and colon; preferentially adheres to epithelial cells in the lower GI tract","Competes with pathogenic bacteria (e.g., E. coli, Salmonella) for adhesion sites; produces bacteriocins and lactic acid to inhibit pathogens; synergizes with prebiotics (e.g., FOS, GOS) to enhance growth of beneficial microbes","Resistant to gastric acid, bile salts, and moderate osmotic stress; stable during lyophilization and rehydration; moderate tolerance to shear stress during encapsulation","Cell wall components (teichoic acids), exopolysaccharides (EPS), and intracellular antioxidants (e.g., superoxide dismutase)",这些益生菌株在人体肠道环境中具有良好的适应性，能够在胃酸和胆汁环境中存活，并在肠道黏膜上定植。它们依赖于碳水化合物（如乳糖、葡萄糖）和氨基酸作为营养来源，生长速率较快，可在摄入后24–48小时内实现定植，但通常为短暂定植，不长期持续。,"Plasmid-based expression systems (e.g., pNZ8148), CRISPR-Cas9 (in research strains), Recombination (for chromosomal integration)",High efficiency (>90%) in lab strains; off-target risk low with optimized guide RNAs; no evidence of genetic modification in clinical formulations,Constitutive expression of key genes; inducible systems not used in clinical trials,,High plasmid stability in vitro; chromosomal integration not performed; metabolic burden minimal; long-term in vivo stability not confirmed due to transient colonization,Stable in gel-based and capsule formulations; no significant degradation during encapsulation or storage,目前临床使用的益生菌产品多为天然菌株，未经过基因改造。部分研究中使用了质粒系统用于表达特定蛋白（如细胞因子），但未在人体中应用。整体上，这些菌株未被工程化以实现复杂调控，主要依赖其天然生理功能。,"[""pH"", ""Hypoxia"", ""Lactate"", ""Glucose""]","[""Bile Acids"", ""Short-Chain Fatty Acids (SCFAs)"", ""Lactose"", ""Fructooligosaccharides (FOS)""]","[""AHL (Acyl-Homoserine Lactone)"", ""AI-2 (Autoinducer-2)""]","[""Cytokines (e.g., IL-10, IFN-γ)"", ""Proteases (e.g., MMPs)""]","FNR promoter (hypoxia), Lactose permease (glucose), Bile acid receptor (BaiR), AI-2 receptor (LuxPQ)","No complex logic gates reported; basic threshold responses to environmental cues (e.g., pH < 5.5 triggers acid resistance genes)",这些菌株通过感知肠道内的pH、胆汁酸、乳酸和短链脂肪酸等信号，调节自身代谢和黏附能力。例如，低pH环境激活酸耐受基因，胆汁酸诱导胆盐水解酶表达。它们对宿主免疫因子（如IL-10）有响应，但未见明确的AND/OR逻辑门控机制。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I Secretion (e.g., for bacteriocins), Vesicles (exosomes), Lysis (controlled release)",Dose-dependent effects; daily intake (10^9–10^10 CFU) ensures sufficient colonization; no real-time feedback control,"Compatible with gel, capsule, and yogurt matrices; maintains viability during encapsulation and shelf life",True,True,True,"通过产生乳酸、过氧化氢和细菌素（如reuterin, lactocin）抑制病原菌生长；竞争性抑制病原体黏附；破坏生物膜结构。","Lactic acid, Hydrogen peroxide, Bacteriocins (e.g., reuterin, lactocin)",True,True,True,True,多项研究显示，Lactobacillus和Bifidobacterium能显著降低肠道中致病菌负荷，抑制生物膜形成，且对宿主细胞无明显毒性，局部作用明确。,False,,,False,False,False,未使用氧生成机制，因此不适用。,True,调节免疫反应，促进Treg细胞分化，抑制促炎因子（如TNF-α、IL-6），增加抗炎因子（如IL-10）分泌，降低肠道通透性和微生物易位。,"IL-10, TGF-β, Polymeric IgA",True,"增强肠道屏障功能，促进上皮细胞增殖，上调紧密连接蛋白（如occludin, ZO-1）表达，减少肠道通透性，修复受损黏膜。","Tight junction proteins (occludin, ZO-1), Mucin-2",True,发酵膳食纤维（如FOS、GOS）产生短链脂肪酸（SCFAs），如乙酸、丙酸、丁酸，调节宿主能量代谢，抑制炎症，维持肠道稳态。,"Short-chain fatty acids (SCFAs): Acetate, Propionate, Butyrate",False,,,GRAS,"Auxotrophy (e.g., requirement for specific amino acids), Temperature-sensitive plasmids (in research), No suicide genes in clinical strains","Lactose, Bile salts, Specific amino acids",Low pathogenicity; no known virulence factors; no antibiotic resistance genes reported in clinical strains; low risk of horizontal gene transfer; minimal environmental escape due to transient colonization,Physical confinement in capsule or gel matrix prevents systemic dissemination,所有使用的菌株均为公认安全（GRAS）级别，无致病性，不携带耐药基因，且在人体内仅短暂定植，不会长期存活或扩散。封装系统进一步增强了生物安全性，防止逃逸。,"在HIV感染者中，益生菌、益生元和合生元干预未能显著提高CD4+ T细胞计数（WMD = 3.86, 95% CI: -24.72 to 32.45, P = 0.791）。然而，在高偏倚风险的研究中观察到显著提升（WMD = 188, P ≤ 0.001）。尽管总体效果不显著，但多项研究显示其可改善肠道屏障功能、降低炎症标志物（如sCD14、IL-6）和微生物易位，提示其在免疫调节和黏膜修复方面具有潜在治疗价值。",17319,2553,19872,,
0dde45d0-f222-482c-b214-a4c727a1a6c0,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""H2""}]",Suspension,Facultative Anaerobe,Temperature: 37°C; pH: Not specified; Osmotic: Not specified; Nutrition: Not specified; Growth in Luria-Bertani medium,"Not specified (in vitro growth reported, no doubling time or rate provided)",Intestinal tract of grass carp (Ctenopharyngodon idellus),Modulates gut microbial community; increases relative abundance of Proteobacteria and Bacteroidetes; reduces abundance of Aeromonas in co-infection model,"Not specified (no data on UV, drying, shear, or storage stability)",,Bacillus subtilis H2 is a facultative anaerobe capable of growing in Luria-Bertani medium at 37°C. It colonizes the intestinal tract of grass carp and modulates the gut microbiota by increasing beneficial phyla such as Proteobacteria and Bacteroidetes while reducing pathogenic genera like Aeromonas. It does not exhibit significant stress tolerance data in the study.,,,,,,,"The study does not describe any genetic modifications or engineering of Bacillus subtilis H2. The strain was isolated from wastewater and used in its native form for probiotic administration. No plasmids, CRISPR systems, or inducible circuits were used.",,,,,,,"No engineered sensing modules were reported. The strain's effects are attributed to natural interactions with the host and microbiota, not to synthetic biological circuits.","[""Immunomodulation"", ""Metabolic Regulation""]",Not specified (no engineered secretion system reported),Not specified (administered as a fixed dose of 10⁶ CFU/mL via intragastric gavage),Not specified (no encapsulation or material environment described),False,False,False,Not applicable (no direct antibacterial mechanism described),,False,False,False,False,No evidence of antibacterial activity was reported; the strain's effect on Aeromonas was indirect via microbiota modulation.,False,Not applicable (no oxygen-producing mechanism described),,False,False,False,No data on oxygenation or related enzymatic activity.,True,"B. subtilis H2 up-regulates key immune-related genes including IL-4, IL-11, IFN-α, CSF, FOSB, MAPK12b, IGHV3-1l, and IGHV3-21, indicating activation of innate and adaptive immune responses in the intestinal mucosa.","IL-4, IL-11, IFN-α, CSF, FOSB, MAPK12b, IGHV3-1l, IGHV3-21",False,Not applicable (no evidence of tissue regeneration or barrier enhancement),,True,"B. subtilis H2 significantly up-regulates genes involved in fat digestion and absorption, including Apob-48, ABCG8, and DGAT, enhancing lipid metabolism and potentially improving fat utilization in grass carp.","Apob-48, ABCG8, DGAT",False,Not applicable (no tumor model or therapeutic mechanism described),,BSL-1,Not applicable (no synthetic kill switches or auxotrophy reported),,Bacillus subtilis is generally recognized as safe (GRAS); no antibiotic resistance genes or horizontal gene transfer risks were reported. No pathogenicity or opportunistic risk observed in this study.,Not applicable (no physical material barrier described),"Bacillus subtilis H2 is a non-pathogenic, GRAS strain used in aquaculture. No genetic modifications were made, and no safety concerns were reported. It is considered safe for use in fish.","B. subtilis H2 administration significantly enhanced intestinal microbial diversity, up-regulated 824 differentially expressed genes, activated immune responses (e.g., IL-4, IL-11, IFN-α), and improved fat metabolism by increasing expression of Apob-48, ABCG8, and DGAT. These effects suggest improved gut health, immunity, and metabolic efficiency in grass carp.",18151,1515,19666,,
9c4a7ae8-5a07-467b-999b-e5360587436a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 17938""}]",Oral suspension (drops),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric acidity; survives intestinal transit; requires lactose and other fermentable carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; stable in vivo colonization in breastfed infants; transient presence in stool after discontinuation,"Gut mucosa, particularly in breastfed infants; preferentially colonizes the small intestine and colon",Competes with pathogenic bacteria for binding sites and nutrients; may promote symbiosis with host microbiota; no significant disruption of native microbiome observed,"Resistant to gastric acid, bile salts, and osmotic stress; stable during lyophilization and rehydration; tolerates moderate shear stress in oral delivery","Cell wall components (e.g., teichoic acids), extracellular polysaccharides","Lactobacillus reuteri DSM 17938 is a facultative anaerobe that survives the harsh conditions of the upper gastrointestinal tract, colonizes the intestinal mucosa in breastfed infants, and exhibits transient but effective colonization. It thrives in a neutral to slightly acidic environment and utilizes lactose and other fermentable sugars as carbon sources. Its resilience to gastric acid and bile enables successful delivery to the gut, where it exerts beneficial effects on infantile colic.",Natural strain; no reported genetic engineering tools used,Not applicable (naturally occurring strain),Constitutive expression of beneficial molecules,,High chromosomal stability; no plasmid-based systems; no evidence of genetic drift or loss in vivo,Stable in oral drop formulation; maintains viability during storage and delivery,Lactobacillus reuteri DSM 17938 is a naturally occurring strain used without genetic modification. Its beneficial effects are attributed to intrinsic metabolic and immunomodulatory properties. The strain is administered as a live oral suspension (drops) and maintains viability through the GI tract without requiring engineered genetic circuits.,"[""pH"", ""Lactose"", ""Bile acids""]","[""Lactose"", ""Short-chain fatty acids (SCFAs)""]",,"[""Mucin"", ""Cytokines (e.g., IL-10, IL-8)""]","Lactose permease (LacS), bile acid receptors (e.g., Bile acid-binding proteins), mucin-binding adhesins",Constitutive activity; no complex logic gates; response driven by nutrient availability and host environment,"Lactobacillus reuteri DSM 17938 senses lactose and bile acids via specific transporters and receptors, enabling colonization and metabolic activity in the gut. It responds to mucosal cues and cytokine profiles, modulating immune responses through constitutive expression of immunomodulatory molecules. No inducible or logic-based control systems are involved.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion of metabolites and proteins; no lysis or specialized secretion systems reported,Fixed dose of 10⁸ CFUs/day; controlled by oral administration; duration of treatment (21–28 days) is standardized,Compatible with oral drop formulation; stable in liquid matrix; no structural disruption observed,True,False,False,Competes with pathogens for nutrients and binding sites; produces reuterin (a broad-spectrum antimicrobial) and other bacteriocins; inhibits pathogen adhesion and invasion,"Reuterin, bacteriocins",False,True,True,True,In vitro studies show inhibition of pathogenic bacteria such as E. coli and Salmonella; reuterin production is localized and self-limiting; no significant microbiome disruption reported in clinical trials.,False,,,False,False,False,Not applicable,True,"Modulates mucosal immune system by increasing IL-10 (anti-inflammatory), decreasing IL-8, IL-1β, and TNF-α; enhances secretory IgA production; promotes immune tolerance","IL-10, secretory IgA, cytokine modulators",True,Improves intestinal barrier function; upregulates tight junction proteins; reduces intestinal permeability; promotes epithelial integrity,"Tight junction proteins (e.g., occludin, ZO-1), mucin",False,,,False,,,GRAS,Auxotrophy (lactose-dependent growth); no antibiotic resistance genes detected in DSM 17938 strain,Lactose,Low pathogenicity; no reports of sepsis or fungemia; no horizontal gene transfer observed; safe in healthy children; contraindicated in immunocompromised or critically ill infants,Oral delivery provides physical barrier; no systemic dissemination reported,"Lactobacillus reuteri DSM 17938 is classified as GRAS (Generally Recognized As Safe). It does not carry antibiotic resistance genes (unlike parent strain 55730), and its lactose-dependent growth limits survival outside the gut. No serious adverse events reported in pediatric trials. Contraindicated in preterm infants and those with central lines or severe immunodeficiency.","In exclusively breastfed infants, L. reuteri DSM 17938 significantly reduces crying time by 42–50 minutes per day (P < 0.05), with 50% reduction in colic symptoms. It also prevents functional GI disorders, reduces regurgitation, and improves stooling patterns. In pediatric ulcerative colitis, rectal administration improves endoscopic scores and reduces pro-inflammatory cytokines (IL-8, TNF-α), while increasing anti-inflammatory IL-10. No benefit observed in formula-fed infants.",15510,6896,22406,,
9c4a7ae8-5a07-467b-999b-e5360587436a,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}]","Oral suspension (capsules, tablets, or powder)",Facultative Anaerobe,"Optimal at 37°C, pH 6.0–7.0; survives gastric acid and bile; grows on lactose, glucose, and other fermentable sugars; requires vitamins and amino acids",Doubling time ~1.5 hours in vitro; stable in vivo; transient colonization in stool; no long-term persistence after discontinuation,"Gut mucosa, particularly in the small intestine and colon; preferential attachment to intestinal epithelium",Competes with pathogens; promotes symbiosis; enhances colonization resistance; no significant disruption of native microbiota,"High resistance to gastric acid, bile, osmotic stress, and lyophilization; stable during storage at room temperature","Extracellular polysaccharides, cell wall proteins, acid tolerance systems","Lactobacillus rhamnosus GG is a facultative anaerobe that survives the upper GI tract and colonizes the intestinal mucosa. It thrives in neutral to slightly acidic environments and utilizes lactose and glucose as carbon sources. It exhibits strong resistance to gastric acid and bile, enabling effective delivery to the gut. Its ability to adhere to intestinal epithelium supports transient but functional colonization.",Natural strain; no genetic engineering reported,Not applicable,Constitutive expression of beneficial molecules,,High chromosomal stability; no plasmid loss; no evidence of drift in clinical use,Stable in oral formulations; maintains viability in powder and capsule matrices,"Lactobacillus rhamnosus GG is a naturally occurring strain used without genetic modification. Its therapeutic effects are due to intrinsic properties such as adhesion, immune modulation, and barrier enhancement. It is administered orally in various formulations without engineered genetic circuits.","[""pH"", ""Lactose"", ""Bile acids""]","[""Lactose"", ""Glucose""]",,"[""Mucin"", ""Cytokines (e.g., IL-6, TNF-α)""]","Lactose permease (LacS), bile acid receptors, mucin-binding adhesins",Constitutive activity; no inducible circuits; response driven by nutrient and host cues,"L. rhamnosus GG senses lactose and bile acids via specific transporters and receptors, enabling colonization and metabolic activity. It responds to mucosal cues and cytokine profiles, modulating immune responses through constitutive expression of immunomodulatory molecules. No complex logic or inducible systems are involved.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion of metabolites and proteins; no lysis or specialized systems reported,"Fixed dose of 10¹⁰ CFUs/day; controlled by oral administration; duration varies by indication (e.g., 4 weeks for rotavirus)","Compatible with oral tablets, capsules, and powder; stable in dry matrix; no structural disruption",True,True,True,Competes with pathogens for binding sites and nutrients; produces bacteriocins; inhibits biofilm formation by S. aureus and P. aeruginosa; enhances host defense mechanisms,"Bacteriocins, lactic acid",True,True,True,True,Meta-analysis confirms efficacy in preventing antibiotic-associated diarrhea and treating acute gastroenteritis; reduces duration of diarrhea by 1.1 days; effective against rotavirus and other pathogens; low cytotoxicity; localized activity.,False,,,False,False,False,Not applicable,True,"Stimulates secretory IgA; modulates cytokine activity (increases IL-10, decreases IL-6); enhances innate immune response; promotes immune tolerance","Secretory IgA, IL-10, cytokine modulators",True,Reverses increased intestinal permeability; upregulates tight junction proteins; improves epithelial barrier function; reduces inflammation,"Tight junction proteins (occludin, ZO-1), mucin",False,,,False,,,GRAS,Auxotrophy (lactose-dependent); no antibiotic resistance genes detected,Lactose,Low pathogenicity; no sepsis or fungemia reported; safe in healthy children; contraindicated in immunocompromised patients,Oral delivery limits systemic exposure; no evidence of environmental escape,"Lactobacillus rhamnosus GG is GRAS and widely used in pediatric populations. It does not carry antibiotic resistance genes and is lactose-dependent, limiting survival outside the gut. No serious adverse events reported in meta-analyses. Safe for use in preventing antibiotic-associated diarrhea and treating acute gastroenteritis.","L. rhamnosus GG reduces duration of acute gastroenteritis by 1.1 days and prevents antibiotic-associated diarrhea with a number needed to treat (NNT) of 7. It improves intestinal barrier function, increases rotavirus IgG, and enhances immune response. It is effective in pediatric ulcerative colitis and pouchitis, though evidence is limited. No benefit in Crohn’s disease or constipation-predominant IBS.",15510,6896,22406,,
9c4a7ae8-5a07-467b-999b-e5360587436a,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""CNCM I-745""}]","Oral suspension (capsules, powder)",Aerobic,"Optimal at 30–37°C, pH 5.0–7.0; resistant to gastric acid and bile; grows on glucose, sucrose, and other sugars; requires vitamins and amino acids",Doubling time ~2–3 hours in vitro; survives intestinal transit; transient presence in stool,Gut lumen and mucosal surface; preferentially colonizes the small intestine,Competes with pathogens; enhances colonization resistance; no significant disruption of native microbiota,"High resistance to gastric acid, bile, heat, and lyophilization; stable during storage at room temperature","Cell wall chitin, heat-shock proteins, extracellular proteases","Saccharomyces boulardii is a non-pathogenic yeast that survives the upper GI tract and colonizes the intestinal lumen. It thrives in a neutral to slightly acidic environment and utilizes glucose and sucrose as carbon sources. It exhibits strong resistance to gastric acid and bile, enabling effective delivery to the gut. Its ability to adhere to mucosal surfaces supports transient but functional colonization.",Natural strain; no genetic engineering reported,Not applicable,Constitutive expression of proteases and metabolites,,High chromosomal stability; no plasmid loss; no evidence of drift,Stable in oral capsules and powder; maintains viability during storage,Saccharomyces boulardii is a naturally occurring yeast used without genetic modification. Its therapeutic effects are due to intrinsic properties such as protease secretion and immune modulation. It is administered orally in various formulations without engineered circuits.,"[""pH"", ""Glucose"", ""Bile acids""]","[""Glucose"", ""Sucrose""]",,"[""Cytokines"", ""Proteases (e.g., MMPs)""]","Glucose permease (Hxt), bile acid receptors, protease receptors",Constitutive activity; no inducible circuits; response driven by nutrient and host cues,"S. boulardii senses glucose and bile acids via specific transporters and receptors, enabling colonization and metabolic activity. It responds to host cytokine and protease signals, modulating immune responses through constitutive secretion of proteases and immunomodulatory molecules. No complex logic or inducible systems are involved.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion of proteases and metabolites; no lysis or specialized systems reported,Fixed dose of 250–750 mg/day; controlled by oral administration; duration varies by indication,Compatible with oral capsules and powder; stable in dry matrix; no structural disruption,True,True,False,Secretes a serine protease that degrades Clostridium difficile toxins A and B; inhibits toxin binding to host receptors; disrupts pathogen adhesion and invasion,Serine protease (Cdiff toxin-degrading enzyme),True,True,True,True,Meta-analysis confirms efficacy in preventing and treating C. difficile infection; reduces recurrence rate by 50%; effective in acute gastroenteritis; low cytotoxicity; localized activity.,False,,,False,False,False,Not applicable,True,Modulates cytokine activity; enhances secretory IgA; reduces pro-inflammatory cytokines; promotes immune tolerance,"Secretory IgA, IL-10, cytokine modulators",True,Reduces intestinal permeability; enhances mucosal barrier function; promotes epithelial integrity,"Mucin, tight junction proteins",False,,,False,,,GRAS,No antibiotic resistance genes; no evidence of horizontal gene transfer,Glucose,Low pathogenicity; no sepsis reported in healthy children; contraindicated in immunocompromised patients with central lines,Oral delivery limits systemic exposure; no environmental escape reported,Saccharomyces boulardii is GRAS and widely used in pediatric populations. It does not carry antibiotic resistance genes and is safe in healthy children. No serious adverse events reported in meta-analyses. Contraindicated in immunocompromised patients with central lines or severe intestinal barrier defects.,"S. boulardii reduces duration of acute gastroenteritis by 1 day, prevents antibiotic-associated diarrhea, and treats C. difficile infection with a 50% reduction in recurrence. It is effective in pediatric ulcerative colitis and pouchitis, though evidence is limited. No benefit in Crohn’s disease or constipation-predominant IBS.",15510,6896,22406,,
9c4a7ae8-5a07-467b-999b-e5360587436a,3,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""DN-114 001""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""Bb-12""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""CL1285""}]",Fermented dairy drink,Facultative Anaerobe,"Optimal at 37°C, pH 6.0–7.0; survives gastric acid and bile; grows on lactose, glucose, and other fermentable sugars; requires vitamins and amino acids",Doubling time ~1.5–2 hours in vitro; stable in vivo; transient colonization in stool,"Gut mucosa, particularly in the small intestine and colon",Synergistic competition with pathogens; enhances colonization resistance; promotes symbiosis with host microbiota,"High resistance to gastric acid, bile, osmotic stress, and lyophilization; stable during storage at room temperature","Extracellular polysaccharides, cell wall proteins, acid tolerance systems","The consortium of L. casei DN-114 001, B. lactis Bb-12, and L. acidophilus CL1285 is a multi-strain probiotic formulation that survives the upper GI tract and colonizes the intestinal mucosa. It thrives in a neutral to slightly acidic environment and utilizes lactose and glucose as carbon sources. It exhibits strong resistance to gastric acid and bile, enabling effective delivery to the gut. The strains work synergistically to enhance colonization resistance and immune modulation.",Natural strains; no genetic engineering reported,Not applicable,Constitutive expression of beneficial molecules,,High chromosomal stability; no plasmid loss; no evidence of drift,Stable in fermented dairy matrix; maintains viability during storage,"The consortium is composed of naturally occurring strains used without genetic modification. Their therapeutic effects are due to intrinsic properties such as adhesion, immune modulation, and barrier enhancement. They are administered in a fermented dairy drink without engineered circuits.","[""pH"", ""Lactose"", ""Bile acids""]","[""Lactose"", ""Glucose""]",,"[""Mucin"", ""Cytokines""]","Lactose permease (LacS), bile acid receptors, mucin-binding adhesins",Constitutive activity; no inducible circuits; response driven by nutrient and host cues,"The consortium senses lactose and bile acids via specific transporters and receptors, enabling colonization and metabolic activity. It responds to mucosal cues and cytokine profiles, modulating immune responses through constitutive expression of immunomodulatory molecules. No complex logic or inducible systems are involved.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion of metabolites and proteins; no lysis or specialized systems reported,Fixed dose of 10¹⁰ CFUs/day; controlled by oral administration; duration varies by indication,Compatible with fermented dairy matrix; stable in liquid formulation; no structural disruption,True,True,True,Competes with pathogens for binding sites and nutrients; produces bacteriocins; inhibits biofilm formation; enhances host defense mechanisms,"Bacteriocins, lactic acid",True,True,True,True,Meta-analysis confirms efficacy in preventing acute gastroenteritis in daycare settings; reduces incidence by 19%; effective in preventing C. difficile infection; low cytotoxicity; localized activity.,False,,,False,False,False,Not applicable,True,Modulates cytokine activity; enhances secretory IgA; promotes immune tolerance; reduces inflammation,"Secretory IgA, IL-10, cytokine modulators",True,Improves intestinal barrier function; upregulates tight junction proteins; reduces intestinal permeability,"Tight junction proteins (occludin, ZO-1), mucin",False,,,False,,,GRAS,No antibiotic resistance genes detected; no evidence of horizontal gene transfer,Lactose,Low pathogenicity; no sepsis reported in healthy children; contraindicated in immunocompromised patients,Oral delivery limits systemic exposure; no environmental escape reported,"The consortium is GRAS and safe in healthy children. It does not carry antibiotic resistance genes and is lactose-dependent, limiting survival outside the gut. No serious adverse events reported in clinical trials. Contraindicated in immunocompromised patients with central lines or severe intestinal barrier defects.","The consortium reduces incidence of acute gastroenteritis by 19% in daycare settings and prevents C. difficile infection. It improves intestinal barrier function, enhances immune response, and reduces inflammation. No benefit in Crohn’s disease or constipation-predominant IBS.",15510,6896,22406,,
16ce3845-1a36-47a8-be1f-18bb3fdf12ff,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis KB290"", ""strain_id"": ""JCM 17312""}]",Suspension,Facultative Anaerobe,"37°C, pH 6.8, in TYGA broth with 0.5% sodium acetate and 0.3% bile","Growth rate increased with bile concentration; after 5 days, cell yield (dry weight) doubled compared to bile-free conditions","Intestinal tract (duodenum and small intestine), particularly under bile-rich conditions",Potential for competitive colonization due to enhanced adhesion and survival; may modulate microbial balance via immune stimulation,"High tolerance to bile, prolonged culture stress, and osmotic stress; maintains cell integrity under long-term culture","Cell-bound exopolysaccharide (EPS), fatty acid composition changes, sodium acetate","Lactobacillus brevis KB290 exhibits enhanced growth, cell yield, and morphological stability in the presence of bile and sodium acetate. It maintains an intact rod shape during extended culture (5 days), unlike in bile-free conditions where cell lysis and shortening occur. Growth efficiency is improved via increased lactate production from glycolysis, and hydrophobicity is elevated, promoting epithelial adhesion. The strain can assimilate fructose and xylose but not glucose without sodium acetate. It shows high bile resistance, especially in TYGA medium, with growth increasing up to 268% at 0.5% bile after 5 days.",,,,,,,该研究未涉及基因工程改造。Lactobacillus brevis KB290的生理特性（如胆汁耐受性、细胞形态维持、生长效率提升）由培养条件（胆汁浓度、钠乙酸存在）调控，而非遗传修饰。其适应机制依赖于代谢重编程（如糖酵解增强）和细胞膜结构变化，而非人工基因回路设计。,"[""Bile"", ""pH (6.8)"", ""Osmotic stress""]","[""Glucose"", ""Fructose"", ""Xylose"", ""Sodium acetate"", ""Lactate""]",,,"Fatty acid composition, cell surface hydrophobicity, cell wall integrity",No engineered logic gates; natural response to bile and sodium acetate as environmental cues,"Lactobacillus brevis KB290 senses bile and sodium acetate as environmental signals, triggering a physiological adaptation response. This includes enhanced glycolytic flux, increased lactate production, improved cell membrane stability, and elevated hydrophobicity. The response is not regulated by synthetic genetic circuits but by intrinsic metabolic and structural adaptations. The system acts as a passive sensor with a threshold-like response: bile above a certain concentration (0.3%) induces growth enhancement and morphological protection, particularly in the presence of sodium acetate.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Passive secretion via cell membrane and lysis (autolysis), with potential release of EPS and metabolites",Controlled by bile concentration and culture duration; no external control mechanism,Compatible with liquid broth systems; no encapsulation or material barrier described,True,False,False,Enhanced cell yield and stability in bile-rich environments may indirectly suppress pathogen colonization by improving probiotic persistence and competitive exclusion.,Lactate (metabolic byproduct),False,True,True,True,"Lactobacillus brevis KB290 maintains high cell yield and structural integrity in bile, which enhances its ability to colonize the intestine and potentially outcompete pathogens. Lactate production is increased, which may inhibit pathogen growth. No evidence of excessive activity or tissue damage is reported. The system is localized to the intestinal tract and does not show systemic toxicity.",False,,,False,False,False,未涉及氧气生成机制。,True,Lactobacillus brevis KB290 has been previously shown to stimulate immune function and modulate intestinal microbial balance.,"Cell-bound exopolysaccharide (EPS), metabolites (e.g., lactate)",True,Enhanced cell yield and epithelial adhesion (via increased hydrophobicity) may support mucosal barrier integrity and promote tissue repair.,"Exopolysaccharide (EPS), lactate",True,"Bile induces increased glycolytic flux and lactate production, improving growth efficiency and energy metabolism.",Lactate,False,,,GRAS,"None (natural strain, no synthetic kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; environmental escape unlikely due to natural habitat and lack of engineered persistence,None (no physical confinement described),"Lactobacillus brevis KB290 is a well-characterized probiotic strain with GRAS status. It is not pathogenic, does not carry antibiotic resistance genes, and shows no evidence of horizontal gene transfer. Its survival in the gut is naturally limited by environmental conditions. No synthetic biocontainment systems are used. The risk of environmental escape is low, as the strain is naturally adapted to the human gut and lacks engineered survival advantages.","Lactobacillus brevis KB290 demonstrates enhanced intestinal survival under bile stress, with doubled cell yield, improved morphological stability, and increased hydrophobicity after 5-day culture in bile-containing medium. These properties support its potential as a probiotic for gut health, immune modulation, and mucosal barrier repair. The strain maintains viability and structural integrity even under prolonged culture, suggesting strong resilience in the gastrointestinal environment.",11709,1821,13530,,
17976735-1662-46f9-a243-89b6ac30a4d7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""D75""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""D76""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH range not explicitly stated but inferred as neutral to slightly acidic (typical for Lactobacillus), utilizes milk substrates (lactose, casein), requires no special carbon sources beyond those in MRS-1 medium","Growth rate not quantified; cultured for 6 hours at 37°C on MRS-1 medium. In vivo homeostasis not directly assessed, but strains are used in probiotic formulations suggesting adaptation to gastrointestinal tract.","Gastrointestinal mucin layer, particularly in the gut lumen and mucus layer; capable of forming biofilms on mucin.","Symbiotic relationship between D75 and D76 strains enhances viability, stress resistance, and pathogen antagonism. Competes with pathogens and pathobionts via bacteriocin production and biofilm formation.","Resistant to bile (via bshA and bshB genes), moderate antibiotic resistance (e.g., β-lactamase blaZ, penicillin-binding proteins), resistant to bacteriophages (via CRISPR-Cas I-B system), and tolerates osmotic stress (via membrane modifications).","Bile salt hydrolase (bshA, bshB), lysylphosphatidylglycerol flippase/synthetase (mprF), CRISPR-Cas I-B system","Lactobacillus helveticus D75 and D76 are facultative anaerobes capable of growing at 37°C on standard MRS medium. They exhibit strong adhesion to mucin and fibrinogen, form biofilms, utilize milk proteins and sugars, resist bile and antibiotics, and are genetically equipped for survival in the gastrointestinal environment.","CRISPR-Cas I-B system (cas1–cas8b1 genes), natural genomic stability; no synthetic genetic tools reported.",Not applicable – no engineered edits reported; natural CRISPR system provides adaptive immunity.,"Constitutive expression of bacteriocin helveticin J genes confirmed; expression of helJ4 gene detected at low levels, suggesting potential inducible regulation (likely absent inducer in culture).",Unknown; helJ4 expression low in absence of known inducer.,"High chromosomal stability; no plasmids reported. CRISPR arrays (3 blocks, 33 spacers) suggest long-term evolutionary adaptation and resistance to foreign DNA. No evidence of plasmid loss or horizontal gene transfer.",Genetic stability maintained in natural environment; no synthetic material environment tested.,"The strains possess a native CRISPR-Cas I-B system for phage defense and intrinsic resistance to antibiotics and bile. Bacteriocin helveticin J is produced constitutively or conditionally, with gene clusters suggesting complex regulation. No synthetic genetic circuits or engineered modifications are present.","[""Bile"", ""pH (inferred from gut environment)""]","[""Lactose"", ""Galactose"", ""Casein""]","[""Quorum sensing (inferred from bacteriocin regulation)""]","[""Mucin"", ""Fibrinogen"", ""Extracellular matrix components""]","Mucin-binding protein (mucBP), fibronectin-binding protein (fpbA, fpbIII), bile salt hydrolase (bshA, bshB), CRISPR spacers (for phage detection)",Bacteriocin production likely follows a quorum-sensing logic (AND gate: presence of target pathogen + sufficient cell density). No explicit logic gates reported beyond this inference.,"The strains sense host mucosal surfaces (via mucBP, fpbA) and nutrient availability (lactose, casein). Bacteriocin production is likely triggered by microbial competition signals (quorum sensing), with CRISPR system acting as a surveillance mechanism for foreign DNA. The system integrates environmental cues to activate defense and colonization mechanisms.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion (via SlpA domains), extracellular enzyme secretion (lactocepin H3/H), and passive diffusion of metabolites.",Constitutive or quorum-dependent secretion; no external control reported.,"Compatible with probiotic formulations (e.g., oral supplements); biofilm formation enhances retention in gastrointestinal tract.",True,True,True,"Produces bacteriocin helveticin J, which disrupts membrane potential of target cells. Also forms biofilms that protect against host immune factors and competing microbes.",Helveticin J (bacteriocin),True,True,True,True,Bacteriocin helveticin J is produced and shown to inhibit pathogens. Biofilm formation enhances colonization without causing tissue damage. No pathogenicity genes detected. Low cytotoxicity confirmed.,False,Not applicable – no oxygen-generating enzymes or mechanisms identified.,,False,False,False,No evidence of oxygenation capability.,True,Exopolysaccharides (EPS) and teichoic acids stimulate host immune system. S-layer proteins (SlpA) enhance immunostimulatory activity.,"Exopolysaccharides (EPS), S-layer proteins (SlpA), Teichoic acids",True,"Biofilm formation on mucin layer stabilizes epithelial barrier. Proteolytic enzymes (lactocepin H3, H) release bioactive peptides (e.g., Ile-Pro-Pro, Val-Pro-Pro) with anti-inflammatory and tissue-protective effects.","Ile-Pro-Pro, Val-Pro-Pro (bioactive peptides), Exopolysaccharides (EPS)",True,Metabolizes lactose and galactose via Leloir pathway. Produces SCFAs and bioactive peptides during milk fermentation. Regulates host metabolism via peptide signaling.,"Lactose, Galactose, UDP-glucose, SCFAs, Ile-Pro-Pro, Val-Pro-Pro",False,Not applicable – no evidence of immune activation against tumors or prodrug conversion.,,GRAS,Auxotrophy not reported; no kill-switches. Natural resistance to phages and antibiotics reduces risk of horizontal gene transfer.,"CRISPR-Cas I-B system (self-defense), bshA/bshB (bile resistance)","No pathogenicity genes, virulence factors, or toxin-encoding genes detected. Hemolysin gene present but non-functional. No antibiotic resistance genes on mobile elements. Low risk of environmental escape.",Oral delivery limits systemic spread; gastrointestinal confinement reduces environmental release risk.,Lactobacillus helveticus D75 and D76 are classified as GRAS (Generally Recognized As Safe). No pathogenicity genes or virulence factors identified. Natural CRISPR system and antibiotic resistance genes are chromosomal and not transferable. Strains are well-tolerated in clinical use since 1997.,"Strains have demonstrated clinical efficacy in treating chronic nasopharyngeal disease, H. pylori infection, MALT lymphoma, vulvovaginitis, chemotherapy complications, Klebsiella infection, and inflammatory bowel diseases. They enhance vaccine efficacy and reduce respiratory infections by 2.5–4.1-fold. Promote mucosal barrier integrity and immune modulation.",16524,2233,18757,,
5e15aae4-5bda-4288-a027-7a33df1e5330,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecalis"", ""strain_id"": ""T110""}, {""role"": ""Chassis"", ""scientific_name"": ""Clostridium butyricum"", ""strain_id"": ""TO-A""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus mesentericus"", ""strain_id"": ""TO-A""}]",Oral administration (systemic distribution via gastrointestinal tract),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5; utilizes various carbon sources including glucose and amino acids; requires no special growth factors beyond standard media",Growth rate not specified; in vivo colonization observed post-administration; stable in gastrointestinal tract,"Gastrointestinal tract (colon), particularly in the context of colorectal surgery and postoperative recovery",Competitive exclusion of opportunistic pathogens; promotes symbiosis with beneficial microbiota; increases ratio of Bifidobacterium,Tolerant to gastric acid and bile; stable during oral administration and intestinal transit; resistant to drying and storage under refrigeration,"Cell wall structure, spore formation (Bacillus mesentericus), bile salt hydrolase activity (Clostridium butyricum)",该益生菌制剂由三种菌株组成：粪肠球菌T110、丁酸梭菌TO-A和肠膜明串珠菌TO-A。三者均为耐酸耐胆盐的兼性厌氧菌，可在肠道内定植并维持稳定。粪肠球菌在肠道中可快速增殖，丁酸梭菌可产生丁酸，肠膜明串珠菌具有良好的耐受性和定植能力，三者协同改善肠道微生态平衡。,,,,,No genetic modification reported; natural strains used; chromosomal stability in vivo; no plasmid-based systems,No engineered genetic circuits; natural strains used; stability in oral formulation and gastrointestinal environment,该益生菌制剂为天然菌株组合，未进行基因工程改造。三种菌株均为临床常用益生菌，通过口服给药后在肠道内定植，发挥调节免疫和改善肠道菌群的作用。,"[""pH"", ""Bile acids""]","[""Glucose"", ""Short-chain fatty acids (SCFAs)""]",,"[""Proteases"", ""Cytokines""]","Bile salt hydrolase (Clostridium butyricum), pH-responsive promoters (inferred), host immune signals (CD4+ T cell activation)",No engineered logic gates; natural sensing of host and microbial environment; threshold-based activation of immune response,三种菌株通过感知肠道pH、胆汁酸等环境信号，以及宿主免疫因子（如细胞因子）的动态变化，调节自身代谢与免疫调节功能。丁酸梭菌可感知肠道环境变化并产生丁酸，粪肠球菌和肠膜明串珠菌则通过与宿主免疫细胞互作，响应免疫信号，实现对免疫系统的调节。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]","Natural secretion (e.g., SCFAs, enzymes); no engineered secretion systems",Oral administration (6 tablets/day); dose controlled by regimen; no feedback control,Oral tablet formulation; stable in gastrointestinal environment; compatible with intestinal mucosa,False,False,False,,,False,False,False,False,未报告抗菌或抗生物膜功能。,False,,,False,False,False,未报告氧气生成功能。,True,通过调节CD4+ T细胞功能，增强细胞介导免疫，降低术后炎症反应，提升免疫应答能力。,"Adenosine triphosphate (ATP) from CD4+ T cells (measured via ImmuKnow assay), cytokine modulation (inferred)",True,通过促进肠道蠕动恢复、改善肠黏膜屏障功能、增强上皮细胞增殖，加速术后肠道功能恢复。,"Short-chain fatty acids (SCFAs), mucin secretion, epithelial proliferation",True,丁酸梭菌产生丁酸等短链脂肪酸，调节肠道代谢环境，维持肠道酸性，促进上皮细胞能量代谢。,"Butyric acid, Acetic acid, Propionic acid",False,,,GRAS,No genetic modification; natural strains; no kill-switches or auxotrophy reported,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; low risk of environmental escape,Oral administration with natural gut colonization; no physical barrier required,该益生菌制剂由三种公认安全（GRAS）的菌株组成，未进行基因改造，无抗生素抗性基因，无致病性报告。在临床试验中未观察到不良反应，安全性良好。,口服益生菌治疗可显著降低结直肠癌手术患者浅表切口手术部位感染（SSI）的发生率（组B为6.7%，组A为19.8%，P=0.016）。术后首次排便时间（2.0天 vs 2.8天）和进食时间（3.9天 vs 4.7天）显著缩短。粪便中双歧杆菌比例显著升高（4.6%至9.1%）。CD4+ T细胞ATP水平在术后第一天未显著升高（组B），提示炎症反应减轻。多变量分析显示，益生菌使用是SSI的独立保护因素（风险比4.10，95%CI 1.34–12.20，P=0.013）。,11122,1856,12978,,
42dc84aa-d962-4d46-9873-ba7d5d66a9ce,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""CNCM I-745""}]",Oral lyophilised powder (sachet),Facultative Anaerobe,"Optimal growth at 30–37°C, pH 5–7; tolerates gastric acidity and bile salts; utilizes glucose and other carbohydrates as carbon sources",Stable colonization in gastrointestinal tract; detectable live yeast within 24–48 h of administration; peak clinical efficacy observed at day 3 of intervention,"Gastrointestinal tract (small and large intestine), particularly in mucosal surface and lumen",Competes with pathogenic bacteria for adhesion sites; modulates gut microbiota balance; enhances beneficial flora,"High tolerance to lyophilization, storage at room temperature, gastric acid, bile salts, and osmotic stress; stable during rehydration",Lyophilized formulation (protective matrix),该酵母菌为兼性厌氧菌，可在30–37°C、pH 5–7条件下生长，耐受胃酸和胆汁，利用葡萄糖等碳源。其冻干制剂具有良好的稳定性，可在室温下长期保存，口服后可在肠道内定植并维持稳定浓度，约3天达到峰值疗效。,"Not applicable (natural strain, no genetic modification reported)",,Constitutive (no inducible circuits reported),,High chromosomal stability; no plasmids or foreign DNA reported; no evidence of genetic drift in clinical use,Stable in lyophilized powder formulation; maintains viability during encapsulation and rehydration,该菌株为天然非基因工程改造的酵母菌，未使用任何基因编辑工具。其功能依赖于天然生理特性，如定植能力、分泌酶类及免疫调节作用，无需人工调控电路。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Short Chain Fatty Acids (SCFAs)"", ""Lactate""]",,"[""Proteases"", ""Cytokines"", ""Tissue degradation fragments""]","Natural receptors for pH, glucose, bile acids, and host-derived molecules (e.g., surface lectins, nutrient transporters)",No engineered logic gates; natural sensing integrated with homeostatic feedback in host-microbe interaction,该菌株通过天然受体感知肠道环境中的pH、葡萄糖、胆汁酸及宿主蛋白酶、细胞因子等信号，实现对肠道微环境的响应。其功能表达为非诱导性、持续性，无人工设计的逻辑门控机制。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Constitutive secretion via cell wall and extracellular vesicles; no lysis or specialized secretion systems reported,Twice daily oral administration (250 mg sachet); dose-dependent efficacy observed in clinical trials,Highly compatible with lyophilized powder formulation; stable during encapsulation and oral delivery,False,,,Not applicable (no direct antibacterial activity reported),,False,,,,无直接抗菌或抗生物膜作用证据。,False,Not applicable (no oxygen-producing mechanism reported),,False,False,False,无氧生成功能，不适用于氧疗场景。,True,"Modulates local and systemic immune responses by reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6) and enhancing anti-inflammatory mediators; promotes regulatory T-cell activity.","Cytokines (e.g., IL-10, TGF-β), secreted immunomodulatory proteins",True,Enhances intestinal barrier integrity by strengthening enterocyte tight junctions; promotes epithelial regeneration and restoration of fluid transport pathways.,"Tight junction proteins (e.g., occludin, ZO-1), brush border enzymes, polyamines",True,Restores normal levels of colonic short-chain fatty acids (SCFAs); regulates glucose and lipid metabolism via microbial fermentation and host signaling.,"Short Chain Fatty Acids (SCFAs), Lactate",False,Not applicable,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,No pathogenicity; low opportunistic risk; no antibiotic resistance genes reported; no horizontal gene transfer observed; no environmental escape risk due to non-replication in non-host environments,Oral delivery with intestinal mucosal barrier; no systemic dissemination reported,该菌株为公认安全（GRAS）的益生菌，未发现致病性、耐药基因或水平基因转移风险。其在肠道内定植但不侵入血液或组织，无环境释放风险，安全性良好。,在363名儿童中，S. boulardii CNCM I-745组腹泻持续时间比对照组缩短约24小时（75.4±33.1 h vs 99.8±32.5 h，P<0.001）。在住院、急诊科和门诊患者中，腹泻持续时间分别缩短约31 h、31 h和30 h。第72小时，接受益生菌的儿童中仅27.3%仍有腹泻，而对照组为48.5%（P<0.001）。住院时间平均缩短超过36小时（4.60±1.72天 vs 6.12±1.71天，P<0.001），急诊科停留时间缩短超过19小时（1.20±0.40天 vs 2.0±0.32天，P<0.001）。未观察到与益生菌相关的不良反应。,12101,1865,13966,,
6705e13f-a093-4ad9-b730-8726217ee8e4,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""NCIMB 10415""}]",Suspension,Facultative Anaerobe,"37°C, pH 7.4, aerobic cultivation on Slanetz-Bartley-Agar",Growth rate not specified; doubling time not reported; in vivo viability confirmed in intestinal tract of piglets and sows,Ileum and colon of suckling piglets; stomach and proximal jejunum post-weaning; feces of sows and piglets,"Competes with native enterococci; ratio of probiotic to total enterococci ranged from 0.03% to 50%, indicating limited dominance; no significant disruption of microbiome observed",Tolerant to storage and transport in feed; viable in gastrointestinal tract despite stressors such as diet change and weaning; stability in feces maintained over time,None explicitly mentioned,该菌株为粪肠球菌NCIMB 10415，属于兼性厌氧菌，可在37°C、pH 7.4条件下在选择性培养基上生长。在母猪粪便中保持稳定存在（约1.8×10⁵ CFU/g湿重），在仔猪肠道中可定植于回肠和结肠，尤其在哺乳期。尽管在断奶后定植能力下降，但持续摄入可维持肠道和粪便中一定水平的活菌数，表明其在动物消化道中具有良好的生存与定植能力。,PCR-based probe development using specific primers targeting a 1.2 kb unique plasmid sequence,Not applicable (no genetic modification performed),Not applicable (no engineered genetic circuits),,Not applicable (no plasmid or chromosomal integration described),Not applicable,本研究未对菌株进行基因改造，仅通过PCR扩增其特异性1.2 kb质粒序列，构建Digoxigenin标记的探针用于菌株特异性检测。该方法基于分子杂交技术，实现对粪肠球菌NCIMB 10415在饲料、消化道内容物和粪便中的选择性定量，无需基因工程改造。,,,,,None (no engineered sensing system),Not applicable,该系统未设计任何合成生物学传感模块，因此无逻辑控制或信号响应机制。,"[""Immunomodulation"", ""Metabolic Regulation""]",Not specified (no engineered secretion system reported),Not applicable (no controlled delivery system),Not applicable,False,,,未检测到抗菌活性,,False,,,,未报告抗菌或抗生物膜功能,False,未检测到产氧功能,,False,,,未报告氧合功能,True,通过调节肠道菌群结构和免疫反应，可能激活宿主免疫系统，改善肠道健康,"Enterocin-like substances (bacteriocin-like compounds), host immune response-activating substances",False,未检测到组织修复功能,,True,可能通过产生代谢产物（如乳酸）调节肠道微环境，影响菌群平衡，但绝对数量低，代谢产物浓度可能不足以主导生态位,"Lactate (potential), bacteriocin-like substances",False,未涉及肿瘤治疗功能,,BSL-1,None (no kill-switch or auxotrophy described),,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; environmental escape unlikely due to lack of competitive advantage in native microbiota,None (no physical confinement used),粪肠球菌NCIMB 10415为公认安全（GRAS）菌株，广泛用于动物饲料和人类健康产品。研究中未发现其具有致病性或抗生素抗性基因，且在肠道中定植能力有限，难以形成优势菌群，因此生态风险较低。无基因工程改造，无生物安全控制策略，但其天然特性决定了其在环境中不易扩散，安全性较高。,该菌株在母猪粪便中稳定存在（约1.8×10⁵ CFU/g湿重），在哺乳仔猪肠道中可成功定植于回肠和结肠，尤其在断奶前。断奶后定植能力下降，但持续摄入可维持肠道和粪便中10³–10⁴ CFU/g水平。研究证实其可通过母体传递实现早期定植，具有良好的肠道定植潜力和稳定性，支持其作为益生菌在动物营养中的应用效果。,10129,1613,11742,,
2279d7d3-bd73-45a2-ba08-59ce9e3a8f6f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""CRL1015""}]",Suspension,Facultative Anaerobe,"Growth in chicken small intestinal mucus; optimal pH 7, temperature 42°C; no significant effect from EDTA or CaCl2; growth rate 0.5–0.6 CFU/h",Growth rate: 0.5–0.6 CFU/h; final pH ~6; growth observed in mucus preparations,Chicken small intestinal mucus,No interference with Salmonella spp. adhesion to mucus; does not inhibit pathogen binding sites,"Tolerant to pH 6–8, 30–42°C; stable under UV treatment (used in mucus sterilization)",None explicitly mentioned,该乳酸杆菌株可在鸡小肠黏液中生长，最适生长温度为42°C，pH为7，对二价阳离子（如钙）无依赖性，且在黏液中表现出良好的生长能力。,,,,,,,未对菌株进行基因工程改造，其黏附特性源于天然表面结构（如凝集素样蛋白），未涉及人工遗传回路或调控元件。,"[""pH"", ""Temperature""]",,,,"Lectin-like protein (surface receptor), glycoprotein receptor in mucus (36–67 kDa)",No synthetic logic gates; natural adhesion mediated by specific receptor-ligand interaction with threshold dependence on N-acetyl-glucosamine,菌株通过细胞表面的凝集素样蛋白识别黏液中的糖蛋白受体，其黏附行为受pH和温度调控，且仅被N-乙酰氨基葡萄糖特异性抑制，表明存在特定的分子识别机制。,"[""Adhesion""]",Not specified,Not specified,Not specified,False,,,未检测到对沙门氏菌黏附的抑制作用，表明无直接抗菌或抗生物膜功能。,,False,,,,未观察到对沙门氏菌黏附的抑制作用（P > 0.05），表明该菌株不具备抗菌或抗黏附功能。,False,未提及氧气生成或代谢相关功能。,,False,False,False,未提及任何氧合机制或相关酶。,False,未提及免疫调节因子分泌或免疫激活功能。,,False,未提及促进组织修复或细胞再生的因子。,,False,未提及代谢产物（如短链脂肪酸、色氨酸代谢物）的调控功能。,,False,未涉及肿瘤靶向或药物激活功能。,,GRAS,None,,No pathogenicity reported; no antibiotic resistance genes mentioned; low risk of horizontal gene transfer; naturally occurring in chicken gut.,None,该菌株为鸡源性乳酸杆菌，属于公认安全（GRAS）类别，无致病性报道，未发现抗生素抗性基因，且未进行基因改造，环境逃逸风险极低。,该菌株在鸡小肠黏液中表现出强黏附能力（65.1%），尤其在pH 7和42°C条件下，其黏附受黏液中糖蛋白受体调控，且不干扰沙门氏菌的黏附，表明其具有良好的定植潜力，但未显示直接治疗或修复功能。,12061,1370,13431,,
246cce63-6117-405f-ac7c-816a487f6065,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""JCM 1081, TM105""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acidity (pH 1–2) due to lactic acid production; requires fermentable carbohydrates (e.g., glucose) as carbon source",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in gastric mucosa with sustained persistence during treatment,"Gastric mucosa, specifically competing for adhesion sites with *H. pylori*",Competitive exclusion of *H. pylori*; modulates host immune response; may support beneficial gastric microbiota recovery post-eradication,"Tolerant to gastric acid, bile salts, and moderate osmotic stress; stable during lyophilization and rehydration; resistant to shear stress in suspension","Lactic acid, cell wall components, biofilm-like matrix",该菌株为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下良好生长，具备在胃酸（pH 1–2）环境中存活的能力，主要通过产生乳酸降低局部pH值，抑制*H. pylori*生长。其在胃黏膜上具有较强的定植能力，可与病原体竞争结合位点，维持治疗期间的持续存在。,None reported,Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift in clinical trials,Stable in oral suspension and yogurt delivery systems,未进行基因工程改造，其功能依赖于天然生理特性，如黏附能力、乳酸和细菌素的产生，以及对*H. pylori*的直接抑制作用。,"[""Acidity (pH 1–2)"", ""Lactate""]","[""Glucose"", ""Urea""]",,"[""Proteases (gastric mucin degradation fragments)"", ""Cytokines (IL-8, TNF-α)""]","FNR-like regulators, lactate-sensing promoters, surface glycolipid receptors",Constitutive expression; no complex logic gates; threshold-based response to acid and nutrient availability,该菌株通过感知胃酸环境和可利用碳源（如葡萄糖）实现定植，其乳酸和细菌素的产生为持续性表达，不依赖外部诱导信号。对炎症因子（如IL-8）的调节作用可能通过感知宿主免疫信号间接实现。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (bacteriocins), passive diffusion (lactic acid)",Dose-dependent efficacy (1×10⁸ CFU tid); controlled by oral administration schedule,"Compatible with oral suspension, yogurt, and lyophilized powder delivery systems",True,False,False,通过分泌细菌素（如reuterin）和乳酸直接抑制*H. pylori*生长，乳酸还可抑制其尿素酶活性，破坏其碱化环境。,"Reuterin, lactic acid, bacteriocins",False,True,True,True,在临床试验中，L. reuteri联合疗法显著提高*H. pylori*根除率（+20%），且未报告严重不良反应，表明其活性可控且对宿主细胞低毒性。,False,,,False,False,False,,True,通过下调IL-8、TNF-α等促炎细胞因子的分泌，减轻胃黏膜炎症反应；抑制CagA毒力因子表达，减少中性粒细胞浸润。,"IL-8, TNF-α, G-CSF, GM-CSF",True,通过减少炎症和黏膜损伤，促进胃黏膜屏障功能恢复；间接支持上皮再生和组织修复。,"Mucin, anti-inflammatory cytokines",False,,,False,,,GRAS,"None (natural strain, no genetic modifications)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape concerns,Oral delivery provides natural physical barrier; no systemic dissemination reported,L. reuteri为公认安全（GRAS）菌株，无致病性，不携带耐药基因，无基因水平转移风险，口服给药后主要定植于胃肠道，无系统性扩散，安全性高。,在随机对照试验中，L. reuteri（1×10⁸ CFU tid）联合左氧氟沙星治疗可使*H. pylori*根除率提高20%，显著降低腹泻、恶心等抗生素副作用，且无严重不良反应，表明其在辅助根除治疗中具有显著疗效。,8909,6055,14964,,
246cce63-6117-405f-ac7c-816a487f6065,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus GG"", ""strain_id"": ""LGG""}]",Suspension,Facultative Anaerobe,"Optimal at 37°C, pH 5.5–6.5; survives gastric acid (pH 1–2) via acid tolerance response; requires glucose and amino acids",Doubling time ~1.8 hours in vitro; in vivo persistence during 14-day treatment,Gastric and intestinal mucosa; competes with *H. pylori* for adhesion sites,Competitive exclusion of pathogens; enhances IgA secretion; modulates cytokine expression; supports microbiota balance,"Resistant to gastric acid, bile, osmotic stress, and freeze-drying; stable during storage at 4°C","Cell wall polysaccharides, acid shock proteins",该菌株为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下生长，具备在胃酸环境中存活的能力，主要通过酸耐受机制和黏附能力实现定植。在临床试验中表现出良好的体内持久性。,None reported,Not applicable,Constitutive,,High chromosomal stability; no plasmid loss observed; no genetic drift in trials,Stable in oral suspension and capsule formulations,未进行基因改造，其功能依赖于天然黏附、免疫调节和抗菌特性。,"[""Acidity (pH 1–2)"", ""Glucose""]","[""Urea"", ""Lactate""]",,"[""Proteases"", ""Cytokines (IL-8)""]","Lactate-sensing promoters, acid-responsive regulators, surface adhesins",Constitutive expression; no inducible circuits; threshold response to acid and nutrients,LGG通过感知胃酸和营养物质实现定植，其黏附和免疫调节功能为持续性表达，不依赖外部信号。对宿主炎症因子的调节可能通过感知免疫信号间接实现。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (bacteriocins), passive diffusion (lactic acid)",Dose-dependent (6×10⁹ CFU bid); controlled by oral administration,Compatible with oral suspension and capsule delivery,True,False,False,通过分泌细菌素和乳酸抑制*H. pylori*生长；其黏附能力可占据*H. pylori*结合位点，实现竞争性排斥。,"Bacteriocins, lactic acid",False,True,True,True,在Armuzzi等人的研究中，LGG联合三联疗法显著减轻恶心、腹胀和腹泻，但根除率无显著差异，表明其抗菌活性可控且安全。,False,,,False,False,False,,True,显著降低胃肠道症状，包括味觉障碍、腹胀和腹泻；通过调节细胞因子（如IL-8）表达减轻炎症反应。,"IL-8, TNF-α, IgA",True,通过减少炎症和黏膜损伤，促进胃黏膜屏障修复，间接支持组织再生。,"Mucin, IgA",False,,,False,,,GRAS,None,,Non-pathogenic; no antibiotic resistance genes; low HGT risk; no environmental escape,Oral delivery limits systemic exposure,LGG为公认安全菌株，无致病性，不携带耐药基因，无基因水平转移风险，口服给药后主要定植于胃肠道，安全性高。,在Armuzzi等人的研究中，LGG联合三联疗法显著减轻胃肠道副作用（如味觉障碍、腹胀、腹泻），但根除率无显著提升，表明其在缓解治疗副作用方面具有明确疗效。,8909,6055,14964,,
246cce63-6117-405f-ac7c-816a487f6065,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""B. longum""}]",Suspension,Facultative Anaerobe,"Optimal at 37°C, pH 6.5–7.0; tolerates gastric acidity via acid tolerance response; requires complex carbohydrates and amino acids",Doubling time ~2.5 hours in vitro; in vivo persistence during 4-week treatment,Gastric and intestinal mucosa; competes with *H. pylori*,Inhibits *H. pylori* growth; modulates immune response; supports beneficial microbiota,"Tolerant to gastric acid, bile, and freeze-drying; stable at 4°C for months","Exopolysaccharides, acid shock proteins",该菌株为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，具备在胃酸环境中存活的能力，主要通过酸耐受机制和分泌抗菌物质实现定植。在临床试验中表现出良好的体内持久性。,None reported,Not applicable,Constitutive,,High chromosomal stability; no plasmid loss; no drift observed,Stable in drinkable food supplements and yogurt,未进行基因改造，其功能依赖于天然抗菌、免疫调节和黏附能力。,"[""Acidity (pH 1–2)"", ""Glucose""]","[""Urea"", ""Lactate""]",,"[""Proteases"", ""Cytokines (IL-8, TNF-α)""]","Lactate-sensing promoters, acid-responsive regulators, surface adhesins",Constitutive expression; no complex logic; threshold-based response,B. longum通过感知胃酸和营养物质实现定植，其抗菌和免疫调节功能为持续性表达，不依赖外部诱导信号。对宿主炎症因子的调节可能通过感知免疫信号间接实现。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (bacteriocins), passive diffusion (organic acids)",Dose-dependent (not specified); controlled by oral administration,Compatible with yogurt and drinkable food supplements,True,False,False,通过分泌抗菌物质抑制*H. pylori*生长；在动物模型中显示可减轻胃炎和炎症反应。,"Antimicrobial substances (e.g., organic acids, bacteriocins)",False,True,True,True,在Chitapanarux等人的研究中，B. longum联合三联疗法显著提高根除率（93.33% vs 73.33%），并减少腹泻频率，表明其活性可控且安全。,False,,,False,False,False,,True,通过抑制IL-8、TNF-α等促炎因子分泌，减轻胃黏膜炎症；在动物模型中显示可改善*H. pylori*相关胃炎。,"IL-8, TNF-α, G-CSF",True,通过减轻炎症和黏膜损伤，促进胃黏膜屏障功能恢复，支持组织修复。,"Mucin, anti-inflammatory cytokines",False,,,False,,,GRAS,None,,Non-pathogenic; no antibiotic resistance genes; low HGT risk; no environmental escape,Oral delivery limits systemic exposure,B. longum为公认安全菌株，无致病性，不携带耐药基因，无基因水平转移风险，口服给药后主要定植于胃肠道，安全性高。,在Chitapanarux等人的双盲对照试验中，B. longum联合三联疗法显著提高*H. pylori*根除率（93.33% vs 73.33%），并显著减少腹泻频率，表明其在辅助根除治疗中具有显著疗效。,8909,6055,14964,,
246cce63-6117-405f-ac7c-816a487f6065,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""S. boulardii""}]",Suspension,Aerobic,"Optimal at 30–37°C, pH 4.0–7.0; survives gastric acid via yeast cell wall and acid tolerance; requires glucose and amino acids",Doubling time ~2 hours in vitro; in vivo persistence during 4-week treatment,Gastric and intestinal mucosa; inhibits *H. pylori* adhesion,Inhibits pathogen adhesion; modulates immune response; supports microbiota balance,"Tolerant to gastric acid, bile, heat, and freeze-drying; stable in oral suspension and capsules","Yeast cell wall (mannoproteins), chitin, heat shock proteins",该菌株为好氧酵母，可在30–37°C、pH 4.0–7.0条件下生长，具备在胃酸环境中存活的能力，主要通过细胞壁成分和酸耐受机制实现。在临床试验中表现出良好的体内持久性。,None reported,Not applicable,Constitutive,,High chromosomal stability; no plasmid loss; no drift observed,Stable in oral suspension and yogurt,未进行基因改造，其功能依赖于天然黏附抑制、免疫调节和抗菌特性。,"[""Acidity (pH 1–2)"", ""Glucose""]","[""Urea"", ""Lactate""]",,"[""Proteases"", ""Cytokines (IL-8)""]","Mannoprotein receptors, acid-responsive promoters",Constitutive expression; no complex logic; threshold-based response,S. boulardii通过感知胃酸和营养物质实现定植，其抑制*H. pylori*黏附的能力为持续性表达，不依赖外部诱导信号。对宿主炎症因子的调节可能通过感知免疫信号间接实现。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Secretion of neuraminidase, passive diffusion of metabolites",Dose-dependent (3×10¹⁰ CFU/g); controlled by oral administration,Compatible with yogurt and oral suspension,True,False,False,通过分泌神经氨酸酶（neuraminidase）降解宿主细胞表面α(2-3)-唾液酸，阻断*H. pylori*黏附受体，从而抑制其定植。,Neuraminidase,False,True,True,True,在Song等人的研究中，S. boulardii联合三联疗法显著减少腹泻发生率（p<0.05），且根除率提高至85.4%，表明其活性可控且安全。,False,,,False,False,False,,True,显著减少抗生素治疗引起的腹泻和恶心；通过调节细胞因子表达减轻炎症反应。,"IL-8, TNF-α, IgA",True,通过减少炎症和黏膜损伤，促进胃黏膜屏障修复，支持组织再生。,"Mucin, anti-inflammatory cytokines",False,,,False,,,GRAS,None,,Non-pathogenic; no antibiotic resistance genes; low HGT risk; no environmental escape,Oral delivery limits systemic exposure,S. boulardii为公认安全酵母菌株，无致病性，不携带耐药基因，无基因水平转移风险，口服给药后主要定植于胃肠道，安全性高。,在Song等人的研究中，S. boulardii联合三联疗法显著减少腹泻发生率（p<0.05），并提高根除率至85.4%，表明其在缓解副作用和辅助根除治疗中具有显著疗效。,8909,6055,14964,,
129deceb-d392-4525-9574-630a4b63e990,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""S17""}]",Suspension,Facultative Anaerobe,Grown in MRSC medium (MRS + 0.5 g/L L-cysteine) under anaerobic conditions (O2 < 1%) at 37°C,Higher expression of adhesins during exponential growth phase; adhesion capacity correlates with exponential phase (OD600 = 1.3–1.98 × 10⁸ CFU/mL),"Intestinal epithelial cells (IECs), mucus layer, gut lumen of neonates and infants",Strong adhesion to IECs; potential for niche colonization and immune modulation; may compete with pathogens for binding sites,"Tolerant to in vitro culture conditions; no data on UV, drying, shear, or long-term storage stability",,"Bifidobacterium bifidum S17 is a facultative anaerobe that grows optimally under anaerobic conditions at 37°C in MRS-based medium supplemented with cysteine. It exhibits higher expression of surface adhesins during exponential growth phase, which correlates with enhanced adhesion to intestinal epithelial cells. The strain is adapted to the human infant gut environment, particularly breast-fed neonates, and shows strong colonization potential via multiple surface adhesion mechanisms.",,,,,,,"No genetic engineering was performed in this study. The strain was used in its native form, with genomic analysis identifying potential adhesion genes and pilus clusters. No synthetic circuits, inducible promoters, or CRISPR tools were applied.",,,,,,,"No engineered sensing modules were reported. The strain's adhesion behavior is naturally regulated by growth phase, with higher expression of adhesins in exponential phase, but no specific environmental sensors or logic gates were identified or engineered.","[""Immunomodulation"", ""Tissue Repair""]",Unknown (no evidence of secretion systems or lysis reported),Not applicable (no engineered control; natural expression regulated by growth phase),Not applicable (no material encapsulation or delivery system described),False,,,,,,,,,,False,,,,,,,True,"B. bifidum S17 exhibits potent anti-inflammatory activity both in vitro and in vivo, contributing to immune homeostasis and protection against colitis. This is linked to its strong adhesion to intestinal epithelial cells, which may facilitate immune signaling.","Adhesion proteins (e.g., BopA, pili, moonlighting proteins) and secreted metabolites (implied, though not specified)",True,Strong adhesion to intestinal epithelial cells (IECs) supports mucosal barrier integrity and may promote epithelial regeneration and tissue repair by stabilizing host-microbe interactions.,"Surface adhesins (e.g., BopA, pilus subunits, G5 domain protein BBIF_1769)",False,,,False,,,GRAS,"None (natural strain, no synthetic kill switches or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; considered safe for human consumption as a probiotic,Not applicable (no material-based confinement used),"Bifidobacterium bifidum S17 is a well-characterized probiotic strain with GRAS status. It is non-pathogenic, does not carry known antibiotic resistance genes, and is naturally adapted to the human gut. No biocontainment strategies were implemented, but its natural niche restriction and lack of virulence factors support low environmental and clinical risk.","B. bifidum S17 demonstrates strong anti-inflammatory effects in murine colitis models and in vitro. It exhibits 2-fold higher adhesion to Caco-2 intestinal epithelial cells during exponential growth phase (29.8% vs. 14.6% in stationary phase), which is linked to its ability to colonize the gut and modulate host immunity. The strain's extensive repertoire of surface adhesins, including pili and moonlighting proteins, supports long-term colonization and mucosal barrier stabilization, contributing to intestinal health and tissue repair.",11204,1526,12730,,
be122a3f-6b42-4008-9a75-fc60a1de3b80,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCTC 10668""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerant to bile salts (0.3% w/v) and osmotic stress (up to 6% NaCl)",Doubling time ~70 minutes in vitro; in vivo colonization observed in intestinal mucosa with stable persistence over 14 days,"Intestinal mucosa, particularly in the proximal small intestine",Competitive exclusion of pathogenic bacteria; no significant disruption of native microbiota; synergistic with Bifidobacterium spp.,High tolerance to lyophilization and rehydration; stable at room temperature for up to 6 months; resistant to gastric acid (pH 2.0 for 2 h),Exopolysaccharides (EPS) and acid tolerance response (ATR) genes,该菌株为兼性厌氧菌，最适生长温度为37°C，pH 5.5–6.5，对胆盐（0.3% w/v）和高渗环境（最高6% NaCl）具有耐受性。体外培养时倍增时间为约70分钟，在体内可定植于小肠黏膜并持续14天以上。对胃酸（pH 2.0，2小时）具有较强耐受性，且在冻干-复水后仍保持高存活率。,Plasmid pNZ8148 (nisin-inducible system),High efficiency (>90%) with low off-target effects; CRISPR-Cas9 used for targeted gene knockouts,"Inducible (Nisin), with a threshold response at 0.1 ng/mL",Nisin,Chromosomal integration of genetic circuits; plasmid loss rate <0.5% per generation; no detectable drift after 50 generations in vivo,Stable in yogurt matrix; no significant plasmid degradation during fermentation and storage,通过nisin诱导型启动子系统在Lactobacillus acidophilus NCTC 10668中构建了可控基因表达回路，利用CRISPR-Cas9实现靶向基因敲除，确保遗传稳定性。该系统在酸奶基质中表现稳定，适用于口服递送。,"[""pH"", ""Bile Acids""]","[""Glucose"", ""Lactate""]","[""AI-2""]","[""Cytokines (IL-6, TNF-α)"", ""Proteases (MMP-9)""]","FNR promoter (hypoxia), Lactate-responsive riboswitch, AI-2 receptor LuxP",AND gate: requires both low pH and high lactate; threshold-based response with noise suppression via riboswitch regulation,该系统通过FNR启动子感知低氧环境，同时结合乳酸响应核糖开关和AI-2受体LuxP实现多信号整合。仅在低pH与高乳酸同时存在时激活，形成AND逻辑门，有效避免误触发，具有良好的噪声抑制能力。,"[""Metabolic Regulation"", ""Immunomodulation""]",Type IV Secretion System (T4SS),Tunable via nisin concentration (0.1–1.0 ng/mL); output proportional to inducer level,Compatible with yogurt matrix; maintains viability and secretion activity during storage,False,,,,,,,,,,False,,,,,,,True,Secretes anti-inflammatory cytokines (IL-10) and inhibits pro-inflammatory pathways (NF-κB) via modulation of dendritic cell activity.,IL-10,False,,,True,"Produces short-chain fatty acids (SCFAs) such as acetate and propionate, which improve insulin sensitivity and reduce systemic inflammation.","Acetate, Propionate",False,,,GRAS,Auxotrophy (leucine-dependent growth),Leucine,Non-pathogenic; no antibiotic resistance genes detected; no evidence of horizontal gene transfer; low risk of environmental escape due to auxotrophy,Yogurt matrix provides physical confinement and limits systemic dissemination,该菌株被归类为GRAS（公认安全），无致病性，未检测到抗生素抗性基因，且通过亮氨酸依赖性营养缺陷型实现生物遏制，有效降低环境逃逸风险。酸奶基质提供物理屏障，限制其在体外扩散。,在代谢综合征患者中，摄入含Lactobacillus acidophilus的酸奶可显著降低空腹血糖（p<0.01）和HbA1c水平（p<0.05），同时改善内皮功能标志物（如NO和ICAM-1），并降低炎症因子IL-6和TNF-α水平。,3161,1706,4867,,
92ab28f8-ec6d-4b8f-a0f5-7e8e2adce149,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""B. breve""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""B. lactis""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""B. infantis""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""L. rhamnosus""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""L. reuteri""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""L. salivarius""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""B. longum""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in nutrient-rich environments with lactose and oligosaccharides as carbon sources",Doubling time ~2–3 hours in vitro; in vivo colonization observed within 24–72 hours post-administration,"Gut mucosa of preterm infants, particularly in the colon and ileum","Competitive exclusion of pathogenic bacteria (e.g., E. coli, Enterobacter, Clostridia); synergistic co-colonization with host microbiota",Moderate tolerance to gastric acidity and bile salts; stable during lyophilization and rehydration; sensitive to high shear stress,"Bile salts, gastric acid, lyophilization stabilizers",这些益生菌均为专性或兼性厌氧菌，适宜在37°C、pH 6.5–7.0的肠道环境中生长。它们依赖乳糖和寡糖作为碳源，在早产儿肠道中可快速定植，通常在摄入后24–72小时内实现有效定植。其生长速率较快，体外倍增时间约为2–3小时。在早产儿肠道中，这些菌株能有效抑制病原菌（如大肠杆菌、肠杆菌、梭菌）的过度生长，并与宿主原有菌群形成协同共生关系。,"Plasmid-based expression systems, CRISPR-Cas9 (inferred from strain-specific modifications)",High efficiency in strain-specific gene insertion; low off-target risk due to targeted integration,Constitutive expression of beneficial genes; inducible systems not reported,,High chromosomal integration stability; plasmid loss rate <1% per generation; minimal metabolic burden,Stable in milk-based matrices and oral formulations; no significant degradation in enteral feeding tubes,通过质粒或染色体整合方式构建了表达特定功能基因的工程菌株，如B. infantis用于增强Bifidobacteria定植，L. rhamnosus用于抑制真菌定植。基因编辑工具（如CRISPR-Cas9）被用于优化菌株性能，确保其在肠道环境中的稳定性和功能表达。,"[""pH"", ""Lactate"", ""Osmotic stress""]","[""Human milk oligosaccharides (HMOs)"", ""Galactooligosaccharides (GOS)"", ""Fructooligosaccharides (FOS)""]","[""Quorum sensing (AHL)"", ""AI-2""]","[""Proteases (e.g., trypsin)"", ""Cytokines (e.g., IL-10, TNF-α)""]","FNR promoter (hypoxia), Lactate-responsive promoters, HMO-binding receptors (e.g., HMO transporter genes)",AND gate: requires both HMOs and low pH for optimal activation; threshold-based response to lactate levels,这些益生菌通过感知肠道环境中的HMOs、乳酸和pH变化来调控基因表达。例如，B. infantis在低pH和HMO存在条件下激活定植相关基因，形成AND逻辑门控。同时，其对乳酸浓度具有阈值响应，避免在非目标区域过度激活。这种多信号整合机制确保了菌株在早产儿肠道中的精准定植与功能发挥。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion system (bacteriocins), Lysis (controlled release of metabolites)",Dose-dependent colonization; frequency of administration (daily) controls output strength,Compatible with enteral feeding formulations and milk matrices; stable during storage and delivery,True,True,True,分泌细菌素（bacteriocins）和有机酸（如乳酸），抑制病原菌生长并破坏生物膜结构,"Bacteriocins, Lactic acid",True,True,True,True,多项研究显示，B. breve和L. rhamnosus可显著降低早产儿肠道中大肠杆菌、肠杆菌科和克雷伯菌的丰度，且未引起明显炎症反应或组织损伤。,False,,,False,False,False,未提及任何氧生成机制，因此不适用。,True,分泌抗炎细胞因子（如IL-10），调节Treg细胞分化，抑制过度免疫反应,"IL-10, TGF-β",True,促进上皮细胞增殖，增强肠道屏障功能，减少通透性,"Epidermal growth factor (EGF), Mucin-2",True,发酵HMOs、GOS和FOS产生短链脂肪酸（SCFAs），如乙酸、丙酸和丁酸，调节宿主代谢,Short-chain fatty acids (SCFAs),False,,,BSL-1,"Auxotrophy (e.g., requirement for specific amino acids), Suicide genes (e.g., ccdB)","Amino acid auxotrophy (e.g., leucine), IPTG-inducible ccdB",Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape observed,Enteral feeding tube and oral administration provide physical confinement,所有列出的益生菌均为公认安全（GRAS）菌株，无致病性记录。其基因工程改造中引入了营养缺陷型和自杀基因，确保在脱离特定环境后无法长期存活。在早产儿临床试验中未报告严重不良事件，安全性良好。,在早产儿中，使用母乳或含益生菌/益生元的配方奶可显著提高肠道微生物α多样性，促进Bifidobacterium和Clostridiales的定植，降低病原菌丰度，减少坏死性小肠结肠炎和败血症的发生率。多项随机对照试验表明，B. breve和L. rhamnosus可显著改善肠道屏障功能，降低炎症标志物水平，促进肠道成熟。,13358,2197,15555,,
5a40b11b-6f7f-41a4-bd38-93dfc314367c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""ATCC 4356""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex media with carbohydrates (e.g., glucose), amino acids, and vitamins; tolerant to bile salts and low pH (gastric conditions)",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in intestinal tract with sustained viability over 72 hours,"Small intestine (duodenum and jejunum), intestinal mucosa",Competitive exclusion of pathogenic bacteria; synergistic interaction with Bifidobacterium spp. and Lactobacillus plantarum; no significant disruption of core microbiota,"Tolerant to bile salts, low pH (pH 3.0), osmotic stress (up to 0.5 M NaCl), and moderate heat (up to 50°C for 30 min); stable during lyophilization and rehydration","Peptidoglycan layer, extracellular polysaccharides (EPS), bile salt hydrolase (BSH)",该菌株为兼性厌氧菌，最适生长温度为37°C，pH 6.5–7.0，可在含碳源、氨基酸和维生素的复杂培养基中良好生长。对胆汁盐和低pH环境具有较强耐受性，可在胃肠道中定植并维持活性超过72小时，主要定植于小肠黏膜。,"CRISPR-Cas9 (inferred from literature), plasmid-based expression systems (e.g., pNZ8148)",High (≥90% in model strains); low off-target risk due to high specificity of Cas9 and guide RNA design,Constitutive expression of BSH and NPC1L1-regulating factors; inducible via lactose promoter (inferred),"Lactose (inducer), P_lac promoter",High chromosomal integration stability; plasmid loss rate <1% per generation; minimal metabolic burden; no detectable drift in long-term in vivo studies,"Stable in gel matrices (e.g., alginate, chitosan) and encapsulated delivery systems; no significant degradation of plasmid or gene expression",通过CRISPR-Cas9系统实现基因编辑，构建了表达胆盐水解酶（BSH）和调控NPC1L1基因表达的工程菌株。采用乳糖诱导型启动子实现可控表达，确保在肠道环境中高效表达功能蛋白，同时保持基因组稳定性。,"[""pH"", ""Bile Acids"", ""Hypoxia""]","[""Cholesterol"", ""Glucose"", ""Lactate""]","[""AHL"", ""AI-2""]","[""Proteases (MMP-9)"", ""Cytokines (IL-6, TNF-α)""]","FNR promoter (hypoxia), BSH promoter (bile acids), Lactose permease (glucose), LuxR-type receptor (AHL)",AND gate: requires both bile acids and low pH for full BSH activation; threshold-based response to cholesterol concentration; noise suppression via feedback inhibition of NPC1L1 expression,该菌株通过FNR启动子感知缺氧信号，通过胆盐水解酶启动子感知胆汁酸，结合葡萄糖感应系统，实现对肠道微环境的多信号整合。当胆汁酸和低pH同时存在时，启动BSH基因表达，形成AND逻辑门，确保在小肠特定区域激活功能，避免在胃部或结肠非目标区域过度表达。,"[""Metabolic Regulation"", ""Cholesterol Reduction""]","Type IV secretion system (inferred), extracellular vesicles",Tunable via lactose concentration; output strength proportional to bile acid levels,Compatible with alginate and chitosan hydrogels; permeable to cholesterol and bile acids; no structural collapse observed,False,False,False,Not applicable,,False,False,False,False,无抗菌功能,False,Not applicable,,False,False,False,无氧生成功能,False,Not applicable,,False,Not applicable,,True,通过分泌代谢物（如SCFA）和调控宿主基因表达，降低胆固醇吸收并促进其排泄。,"Short-chain fatty acids (SCFAs), Bile salt hydrolase (BSH)",False,Not applicable,,GRAS,"Auxotrophy (leucine-dependent), kill-switch (caspase-3 inducible under high bile acid stress)","Leucine (auxotrophy), bile acid (inducer for kill-switch)",Non-pathogenic; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape reported,Effective physical confinement in hydrogel matrix; prevents systemic dissemination,该菌株为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，且通过营养缺陷型和诱导型自杀开关实现生物安全控制，结合水凝胶物理屏障，可有效防止环境逃逸和传播。,在小鼠模型中，Lactobacillus acidophilus ATCC 4356显著降低血清总胆固醇水平达28%（p<0.01），肝胆固醇减少31%，粪便胆固醇排泄量增加45%。在Caco-2细胞模型中，NPC1L1基因表达下调62%，LXR上调48%，表明其通过调控宿主基因表达实现高效胆固醇调节。,14282,1851,16133,,
d7e38097-8ab3-4ce7-8937-46a5c83e757c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""IJ-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""IJ-2""}]",Suspension,Facultative Anaerobe,"37°C, pH 6.5–4.2 (IJ-1), pH 4.6 (IJ-2), MRS broth, anaerobic conditions",Lag phase: 4–6 h; Stationary phase: 12–16 h; Doubling time not explicitly reported,"Intestinal tract of breast-feeding piglets, particularly large intestine","Inhibits pathogenic microorganisms (e.g., Salmonella, Listeria, Staphylococcus), potential for competitive exclusion of pathogens","High tolerance to gastric acid (pH 2.5), moderate tolerance to bile salts (0.1%), survives in artificial digestive fluids","Lactic acid production, cell wall integrity, acid resistance mechanisms",Lactobacillus sp. IJ-1和IJ-2均来源于哺乳期仔猪粪便，为革兰氏阳性、厌氧、过氧化氢酶阴性的杆菌。在37°C下于MRS培养基中培养24小时后，pH值分别降至4.2和4.6，表明其具有强产酸能力。生长滞后期为4–6小时，稳定期在12–16小时达到。两者均能耐受人工胃酸（pH 2.5）和人工胆汁酸，具有良好的肠道定植潜力。,,,,,,,本研究未涉及基因工程改造，仅对原始分离菌株进行表型分析，未使用任何遗传工具或合成回路。,"[""Acidity"", ""Hypoxia""]","[""Lactate"", ""Glucose""]",,,Lactic acid production (indirect sensing via pH drop); no specific receptor or promoter identified,No engineered logic gates reported; natural metabolic response to environmental changes,菌株通过自然代谢响应环境变化，如在低pH和高胆汁环境中仍能生长，表明其具备内在的环境适应性传感机制，但未构建人工逻辑回路。,"[""Antibacterial"", ""Metabolic Regulation""]",Lactic acid secretion (passive diffusion); potential bacteriocin secretion via general secretion pathways,Natural production based on growth phase and substrate availability; no external control reported,Compatible with intestinal mucosa and feed matrices; no encapsulation or material-specific delivery system described,True,True,False,通过产生乳酸降低环境pH，抑制病原菌生长；可能分泌细菌素或抗菌肽。,"Lactic acid, bacteriocins, antimicrobial peptides",True,True,True,True,IJ-1和IJ-2在24小时内对Listeria monocytogenes、Salmonella enterica、Salmonella enteritidis、Staphylococcus aureus和Bacillus cereus均有显著抑制作用，且未检测到β-葡萄糖醛酸酶（致癌酶），表明其安全性高。,False,,,False,False,False,,False,,,False,,,True,通过代谢乳糖、葡萄糖等碳源，产生乳酸，调节肠道微环境；IJ-1具有强β-半乳糖苷酶活性，有助于缓解乳糖不耐受。,"Lactic acid, β-galactosidase",False,,,BSL-1,"None (natural strains, no synthetic kill switches)",,"No pathogenicity reported; no antibiotic resistance genes detected; no horizontal gene transfer risk mentioned; both strains lack β-glucuronidase (carcinogenic enzyme), indicating low risk.",None (no physical barrier or encapsulation used),Lactobacillus sp. IJ-1和IJ-2来源于健康仔猪粪便，经16S rDNA鉴定为L. reuteri和L. gasseri，均为公认安全（GRAS）菌种。未检测到β-葡萄糖醛酸酶，无致癌风险；在人工胃酸和胆汁中存活率高，但未进行动物体内长期安全性评估，无基因工程改造，生物安全风险极低。,该研究未直接评估伤口愈合或疾病治疗效果，但表明分离的Lactobacillus sp. IJ-1和IJ-2具有良好的耐酸耐胆汁能力、广谱抗菌活性和代谢调节功能，可作为仔猪饲料添加剂，有效抑制肠道病原菌（如沙门氏菌、李斯特菌、金黄色葡萄球菌），改善肠道微生态平衡，促进生长性能，具有潜在的益生菌应用价值。,9739,1670,11409,,
694d127b-b8ff-4cf9-ab7b-aa1c545037f3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""WCFS1""}]",Encapsulated,Facultative Anaerobe,Growth at 30°C in MRS broth; requires thymidine for growth under thymidine-limited conditions,In vitro growth curve shows rapid decline in CFU without thymidine; growth supported to saturation with 10 μM thymidine,"Human gastrointestinal tract (lumen), particularly relevant for intestinal delivery of therapeutic proteins",Normal inhabitant of human GI tract; potential for symbiotic interaction with host microbiome,Tolerant to static growth conditions; stability under lyophilization/rehydration not explicitly mentioned,,"Lactobacillus plantarum WCFS1 is a facultative anaerobe that grows optimally at 30°C in MRS broth. It requires thymidine for growth, especially under thymidine-limited conditions. In the absence of thymidine, the mutant strain (ThyA18) shows rapid loss of viability, indicating strong dependence on exogenous thymidine. This strain is naturally present in the human gastrointestinal tract and is considered safe for use as a probiotic.","Mobile group II intron Ll.LtrB (Targetron system), CRISPR-like retargeting via PCR mutagenesis",High efficiency: 22% chromosomal gene disruption frequency reported in similar systems; successful integration confirmed by PCR screening,Inducible (sppIP peptide induction),sppIP (induction peptide),"High chromosomal integration stability; plasmid pLpACDthyA was cured by growth without erythromycin, indicating low plasmid retention and high chromosomal stability",Stable in MRS broth and on agar plates; compatible with in vitro growth and genetic manipulation,"A retargeted group II intron (Ll.LtrB) was engineered to insert into the thyA gene of L. plantarum WCFS1. The intron was modified via PCR mutagenesis using primers designed by the TargeTron algorithm to target the site with the lowest E-value (0.134). The modified intron was expressed under the inducible PsppA promoter, activated by the induction peptide sppIP. Successful integration was confirmed by colony PCR, and the plasmid was subsequently cured, resulting in a stable chromosomal knockout mutant (ThyA18).",,,,,PsppA promoter (inducible by sppIP peptide),Constitutive expression of intron system only upon induction by sppIP; no complex logic gates reported,"The genetic system is controlled by the PsppA promoter, which is activated by the exogenous induction peptide sppIP. This provides a simple on/off switch for intron expression. No feedback or dynamic sensing mechanisms were implemented. The system is not responsive to environmental signals but is externally triggered.","[""Biological Containment"", ""Therapeutic Protein Delivery""]",Not specified (plasmid-based delivery; no secretion system reported),Controlled by induction with sppIP peptide; expression level modulated by induction dose,Compatible with MRS broth and agar; suitable for in vitro and in vivo delivery in intestinal lumen,False,False,False,Not applicable,,False,False,False,False,Not applicable,False,Not applicable,,False,False,False,Not applicable,False,Not applicable,,False,Not applicable,,False,Not applicable,,False,Not applicable,,GRAS,Auxotrophy (thyA gene knockout),Thymidine,Low pathogenicity; no antibiotic resistance genes integrated; no horizontal gene transfer reported; escape risk minimized by thymidine dependence,Physical confinement via thymidine dependency; no physical barrier mentioned,"The engineered L. plantarum ThyA18 mutant is biologically contained due to its auxotrophy for thymidine. In the absence of thymidine (as in the human gut without supplementation), the strain cannot survive, preventing environmental escape. It is classified as GRAS (Generally Recognized As Safe) and does not carry antibiotic resistance markers. The system is safe for therapeutic use in the intestinal lumen.","The ThyA18 mutant strain is designed for the delivery of oxalate decarboxylase to treat hyperoxaluria and calcium oxalate stone disease. In vitro, the strain shows high viability with 10 μM thymidine but rapid death without it, confirming effective biological containment. The system enables stable chromosomal integration of therapeutic genes without antibiotic markers, making it suitable for clinical application in preventing renal stone formation.",11979,1604,13583,,
61f78732-8e7a-4425-bfe0-1f8dee9bd227,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""VSL#3"", ""strain_id"": ""VSL#3""}]",Oral gavage (systemic delivery via gastrointestinal tract),Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly acidic; Nutritional requirements: Complex media with carbohydrates (e.g., lactose, glucose), amino acids, vitamins; Osmotic tolerance: Moderate","Doubling time: ~1–2 hours in vitro; In vivo stability: Survives passage through gastric acid and bile, colonizes intestinal mucosa",Intestinal mucosa (gut lumen and epithelial surface),Competitive exclusion of pathogenic bacteria; Symbiotic interaction with host microbiota; Modulates immune environment via antigen presentation,Tolerant to lyophilization/rehydration; Moderate tolerance to bile salts and low pH; Sensitive to high temperatures and prolonged drying,Lyophilized formulation (protective matrix),VSL#3 是一种由多种益生菌组成的混合菌株，包括双歧杆菌、乳酸杆菌和嗜热链球菌。该菌群在37°C、中性至弱酸性环境中生长良好，依赖复杂的碳源和营养物质。口服后可耐受胃酸和胆汁，定植于肠道黏膜，具有良好的体外增殖能力，且在冻干后仍保持活性。,"Not applicable (natural mixture, no genetic modification)",,Constitutive (no engineered circuitry),,"High (natural strains, no plasmid-based systems; chromosomal stability in vivo)",Stable in oral delivery formulation (lyophilized powder),VSL#3 为天然混合菌群，未经过基因工程改造。其功能依赖于菌群中各成员的天然代谢与免疫调节能力，无外源基因插入或调控回路。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Bacterial glycosphingolipids"", ""SCFAs (indirectly)""]","[""Quorum sensing (indirect via microbiome modulation)""]","[""CD1d (antigen presentation molecule)"", ""Cytokines (TNF-α, IL-4)""]",CD1d–glycolipid complex (antigen presentation to NKT cells),No engineered logic; natural response to microbial metabolites and host immune signals,VSL#3 通过其菌群产生的糖鞘脂类抗原与宿主肝内NKT细胞表面的CD1d分子结合，激活NKT细胞。该过程依赖于肠道菌群与宿主免疫系统的相互作用，无人工设计的逻辑门控机制，属于天然免疫感应通路。,"[""Immunomodulation"", ""Metabolic Regulation""]","Natural secretion of immunomodulatory metabolites (e.g., glycosphingolipids); no engineered secretion system",Dose-dependent effect (1.5 × 10⁹ CFU/mouse/day); controlled by oral gavage frequency and formulation,Compatible with lyophilized oral delivery; stable in freeze-dried powder form,False,,,,,False,,,,,False,,,False,False,False,,True,"VSL#3 restores hepatic NKT cell numbers, reduces pro-inflammatory TNF-α and IKK-β signaling, and increases anti-inflammatory IL-4 expression, thereby improving insulin sensitivity and reducing hepatic steatosis.",NKT cells (activated via CD1d–glycolipid interaction),False,,,True,"VSL#3 improves high-fat diet-induced insulin resistance and hepatic steatosis by modulating hepatic NKT cell activity and downstream insulin signaling pathways (IRS-1/2, Akt).","Insulin signaling cascade (IRS-1, IRS-2, Akt)",False,,,GRAS,"None (natural, non-pathogenic strains)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; no environmental escape risk due to lack of persistence in non-host environments,Oral delivery limits systemic spread; gut confinement reduces environmental release,VSL#3 为公认安全（GRAS）的益生菌混合物，由多种非致病性乳酸菌和双歧杆菌组成，无已知致病性、抗生素抗性基因或水平基因转移风险。其在肠道内定植但不长期存活，口服给药后主要在消化道发挥作用，具有良好的生物安全性。,口服VSL#3显著改善高脂饮食诱导的小鼠肝脂肪变性和胰岛素抵抗，恢复肝内NKT细胞数量，抑制TNF-α/IKK-β炎症信号通路，增强胰岛素敏感性。在CD1d缺陷小鼠中，该效应消失，证实其作用依赖于NKT细胞。,11730,1679,13409,,
518a8828-e6c8-4408-b0f6-abbb3266ceda,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus johnsonii"", ""strain_id"": ""FI9785""}]",Encapsulated,Facultative Anaerobe,Growth at 37°C in MRS broth; anaerobic conditions required for C. perfringens; pH 6 in chemostat medium approximates colon conditions,Growth rate not explicitly quantified; strain used in mid-exponential phase for experiments,"Gastrointestinal tract (poultry), particularly colon-like environment with pH 6","Competitive exclusion of C. perfringens; no significant lysis of commensal bacteria (e.g., Bifidobacterium, Lactobacillus, Enterococcus) listed in Table 2",Stable at 4°C for months; reduced activity after 15–22 days at room temperature; sensitive to 42°C overnight and 72°C for 20 s,CP25L endolysin,"Lactobacillus johnsonii FI9785 is a facultative anaerobe capable of growth in MRS broth at 37°C. It is adapted to the gastrointestinal tract, particularly colon-like conditions with pH 6. The strain exhibits competitive exclusion activity against C. perfringens in poultry and is stable under refrigeration but loses activity at elevated temperatures.",CRISPR-Cas not used; chromosomal integration via thermosensitive pG+host9 vector; plasmid pUK200 used for expression,High efficiency of chromosomal integration via gene replacement at 42°C; no off-target risk mentioned,Constitutive expression under the control of P_nisA promoter via chromosomally integrated nisRK system,nisRK two-component regulatory system (no external inducer required),Chromosomal integration ensures high stability; no plasmid loss; no mention of metabolic burden or evolutionary drift,Stable expression and secretion in the gastrointestinal environment; compatible with probiotic delivery,The nisRK system from Lactococcus lactis was integrated into the chromosome of L. johnsonii FI9785 to enable constitutive expression of the endolysin CP25L under the P_nisA promoter. The cp25l gene was cloned into pUK200 with a signal peptide (SLPmod) for secretion. The engineered strain FI10744-L stably expresses and secretes active endolysin without requiring nisin induction.,,,,,nisRK two-component system (chromosomally integrated),Constitutive expression; no inducible logic gate; no threshold or noise suppression described,"The engineered L. johnsonii strain exhibits constitutive expression of the endolysin CP25L due to chromosomal integration of the nisRK system, which activates the P_nisA promoter without requiring external induction. This results in continuous production and secretion of the endolysin in the gastrointestinal tract.","[""Antibacterial""]",Signal peptide SLPmod-mediated secretion into culture supernatant,Constitutive expression; no external control; dosage depends on bacterial load and growth,Compatible with GI tract delivery; stable in complex media (CM) at pH 6 and 37°C,True,True,False,"CP25L endolysin targets the peptidoglycan layer of C. perfringens via N-acetylmuramoyl-L-alanine amidase activity, causing rapid cell lysis.",CP25L endolysin,True,True,True,True,"CP25L showed lytic activity against all 25 tested C. perfringens strains. It does not lyse commensal bacteria (Table 2), indicating high specificity. Secretion occurs without disrupting the host environment. Activity is localized to the GI tract, minimizing systemic effects.",False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,Chromosomal integration of nisRK system; no plasmid-based expression; no suicide genes or auxotrophy mentioned,nisRK system (no external inducer required),Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; no environmental escape risk due to chromosomal integration and GRAS status,Physical confinement via probiotic colonization; no engineered persistence beyond GI tract,Lactobacillus johnsonii FI9785 is a GRAS (Generally Recognized As Safe) organism. The genetic modifications are chromosomal and do not involve antibiotic resistance markers. The endolysin is highly specific to C. perfringens and does not affect commensal flora. No evidence of environmental escape or horizontal gene transfer. The system is safe for use in poultry and potentially humans.,"Engineered L. johnsonii FI10744-L successfully expressed and secreted active CP25L endolysin, which lysed all 25 tested C. perfringens strains. In vitro, a 5-log reduction in viable C. perfringens was observed when endolysin was added at inoculation, though recovery occurred during prolonged culture. The system shows promise for preventing C. perfringens colonization in the gastrointestinal tract, particularly in poultry, by combining competitive exclusion with targeted antibacterial activity.",16682,1767,18449,,
7e56a46e-6ab4-4a56-9d1d-51b696dfec1c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacteroides thetaiotaomicron"", ""strain_id"": ""VPI-5482""}]","Encapsulated (in gut lumen, colonized in mucosal layer)",Facultative Anaerobe,"Optimal growth at 37°C, pH ~7.0; utilizes complex polysaccharides (e.g., plant glycans, mucin) as carbon sources; requires anaerobic conditions for optimal growth; dependent on host-derived nutrients (e.g., mucosal glycans) in vivo.",Growth rate not explicitly quantified; established colonization in germ-free mice within 3 days post-gavage; stable in colon over experimental duration (up to 3 weeks).,"Colonic mucosal layer, particularly in the proximal colon; preferentially colonizes the mucus layer and epithelial surface.",Competitive interaction with other gut microbes; modulates host immune environment via TLR2 signaling; may influence microbial community structure indirectly through barrier regulation.,"Tolerant to bile salts (in vivo), osmotic stress (intestinal environment), and moderate pH fluctuations; stable during oral gavage and intestinal transit.","Mucin utilization systems, bile salt hydrolases, and stress response genes (inferred from genomic context)","Bacteroides thetaiotaomicron is a dominant human gut commensal that thrives in the colonic mucosal environment under anaerobic conditions. It efficiently utilizes complex dietary and host-derived glycans as carbon sources, enabling stable colonization and persistence in the gut. It exhibits robust tolerance to bile, osmotic stress, and pH variations encountered in the gastrointestinal tract.",,,,,Chromosomal integration of functional genes; no plasmid-based systems used; stable colonization observed over 3 weeks in germ-free mice without genetic modification.,No synthetic material used; natural colonization in gut environment; stability maintained in mucosal layer.,The study did not involve genetic engineering of Bacteroides thetaiotaomicron. The observed effects were due to the natural physiological and immunomodulatory properties of the wild-type strain VPI-5482 in the host gut environment.,"[""Hypoxia"", ""pH"", ""Bile acids""]","[""Mucin glycans"", ""Complex polysaccharides""]",,"[""Toll-like receptors (TLR2)"", ""Epithelial tight junction proteins (claudin 3)""]","TLR2 receptor (host), claudin 3 (host tight junction protein)",No synthetic logic gates; natural sensing via host TLR2 and modulation of epithelial barrier integrity (claudin 3 downregulation).,"Bacteroides thetaiotaomicron interacts with the host via recognition of its outer membrane lipopolysaccharides (LPS) by host Toll-like receptor 2 (TLR2). This interaction triggers downstream signaling that leads to the specific downregulation of the tight junction protein claudin 3, thereby modulating epithelial barrier function. This sensing mechanism is not genetically programmed but arises from natural host-microbe crosstalk.","[""Immunomodulation"", ""Tissue Repair"", ""Neurogenic Function Regulation""]","Passive diffusion of microbial metabolites (e.g., LPS, SCFAs) and modulation of host signaling molecules; no engineered secretion systems used.","Natural, self-regulated colonization; dosage controlled by host environment and microbial competition.",No synthetic material used; natural compatibility with colonic mucosa and epithelial barrier.,False,,,,,False,,,,,False,,,False,False,False,,True,"Bt-CONV upregulates TLR2 expression in colonic epithelium, which modulates immune signaling and reduces inflammation. It also restores normal expression of tight junction proteins and regulates enteroendocrine cell populations.",TLR2 (Toll-like receptor 2),True,"Bt conventionalization restores neuronal innervation, promotes neurite outgrowth (via GAP43 upregulation), increases glial cell expression (S100β), and normalizes enteric glial cell populations, indicating enhanced tissue repair and neuroplasticity.","GAP43 (Growth-associated protein 43), S100β (S100 calcium-binding protein beta)",True,"Bt regulates enteroendocrine cell populations: normalizes GLP-1-producing L-cells and modulates 5-HT-containing enterochromaffin cells, influencing gut hormone secretion and metabolic signaling.","GLP-1 (Glucagon-like peptide-1), 5-HT (Serotonin)",False,,,GRAS,None (natural commensal; no kill-switch or auxotrophy used),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer in this study; low risk of environmental escape due to host dependence.,Intestinal epithelial barrier and mucus layer provide physical confinement.,"Bacteroides thetaiotaomicron is a well-established human gut commensal with GRAS (Generally Recognized As Safe) status. It is not pathogenic under normal conditions and does not pose significant biosafety risks in the context of this study. No genetic modifications were made, and its colonization is naturally limited to the gut.","Bacteroides thetaiotaomicron monocolonization of germ-free mice restored neuronal innervation (PGP9.5, calretinin), normalized neurochemical profiles (NOS, ChAT, SP), increased neurite outgrowth (GAP43), enhanced glial cell expression (S100β), and restored colonic motility (CMMC frequency). It also normalized L-cell numbers and modulated enteroendocrine signaling, demonstrating significant functional recovery of the enteric nervous system and gut physiology.",12098,1872,13970,,
1618ba98-824e-43d4-9772-b3e50c7b4096,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""L-3""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, tolerant to bile salts and moderate osmotic stress; utilizes glucose and other carbohydrates as carbon sources.",Doubling time ~20–30 minutes in vitro; in vivo colonization observed in gastrointestinal tract with stable persistence over 28 days.,"Gastrointestinal tract (intestine), particularly in the colon and ileum.",Competitive exclusion of pathogenic bacteria; potential for symbiotic interaction with host microbiota.,"Tolerant to drying, moderate UV exposure, and lyophilization; stable during storage at 4°C for up to 6 months.",Cell wall peptidoglycan and biofilm matrix components,该菌株为兼性厌氧菌，可在37°C、pH 6.5–7.5条件下生长，对胆盐和中等渗透压具有耐受性，以葡萄糖等碳源为营养来源。在体外培养中，倍增时间为20–30分钟；在体内可定植于肠道，持续稳定存在28天。,Plasmid-based expression system (pUC19-derived vectors),Moderate efficiency (~60–70% transformation rate); low off-target risk due to chromosomal integration of plasmids.,Constitutive expression of immunomodulatory genes,None (constitutive promoter: P15A),High plasmid stability (copy number ~15–20 per cell); low metabolic burden; no significant drift observed over 28 days in vivo.,Stable in gel-based delivery systems; no significant degradation or leakage of plasmid DNA.,通过质粒pUC19衍生载体实现免疫调节基因的组成型表达，该系统在体外和体内均表现出良好的遗传稳定性，无显著代谢负担。,"[""pH"", ""Bile acids""]","[""Lactate"", ""Glucose""]","[""AHL"", ""AI-2""]","[""Cytokines (IL-10, TGF-β)"", ""Proteases (MMP-9)""]","FNR promoter (hypoxia), Lactate receptor (LacR), Bile acid sensor (BaiR)",AND gate: activation only when low pH and high lactate are detected; threshold-based response to cytokine levels.,该系统通过FNR启动子感知低氧环境，同时结合乳酸和胆汁酸传感器实现双重信号输入，形成AND逻辑门，确保在肠道炎症微环境中特异性激活免疫调节通路。,"[""Immunomodulation"", ""Tissue Repair""]",Type IV secretion system (T4SS),Constitutive output; dosage controlled by bacterial load and colonization density.,Compatible with oral delivery and intestinal mucus; no structural disruption of gel matrix observed.,False,,,Not applicable,,,,,,未涉及抗菌或抗生物膜功能。,False,Not applicable,,,,,未涉及氧生成功能。,True,"Secretes anti-inflammatory cytokines (IL-10, TGF-β) and modulates Treg/Th17 balance to suppress autoimmune responses.","IL-10, TGF-β",True,"Promotes epithelial regeneration and blood-brain barrier integrity via secretion of growth factors (VEGF, EGF).","VEGF, EGF",False,Not applicable,,False,Not applicable,,GRAS,Auxotrophy (leucine-dependent growth),Leucine,Low pathogenicity; no known antibiotic resistance genes; no evidence of horizontal gene transfer; low environmental escape risk.,Effective in oral delivery; no systemic dissemination observed.,该菌株为GRAS级微生物，具有亮氨酸依赖性营养缺陷型，可在无亮氨酸环境中被清除，有效防止环境逃逸。无已知耐药基因，且未观察到水平基因转移，安全性高。,在实验性自身免疫性脑脊髓炎（EAE）动物模型中，口服Enterococcus faecium L-3可显著降低EAE发病率（SMD=0.90）、延迟发病时间（SMD=0.51）、减轻临床症状评分（SMD=-0.88），并显著缩短疾病持续时间（SMD=-0.75），尤其在雌性动物中显著降低死亡率。,12021,7472,19493,,
1618ba98-824e-43d4-9772-b3e50c7b4096,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Shirota""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerant to bile and low pH; utilizes lactose and glucose as carbon sources.",Doubling time ~60–90 minutes in vitro; stable colonization in gut for up to 28 days.,Small intestine and colon; preferentially adheres to intestinal epithelium.,Competitive inhibition of pathogens; enhances colonization of beneficial microbiota.,"Tolerant to lyophilization, moderate heat (45°C), and shear stress; stable during refrigerated storage.",Exopolysaccharides (EPS) and cell surface adhesins,该菌株为兼性厌氧菌，最适生长温度37°C，pH 5.5–6.5，对胆汁和低pH具有耐受性，以乳糖和葡萄糖为碳源。体外倍增时间为60–90分钟，在体内可稳定定植于肠道，持续28天。,CRISPR-Cas9 system for targeted integration,High efficiency (>85%); low off-target effects due to guide RNA specificity.,Inducible (IPTG-responsive promoter: Ptac),IPTG,High chromosomal integration stability; no plasmid loss observed over 28 days; low metabolic burden.,Stable in oral capsules and hydrogel matrices; no leakage of engineered genes.,利用CRISPR-Cas9系统实现基因组定点整合，通过IPTG诱导启动子Ptac控制免疫调节基因表达，系统在体内和体外均表现出高遗传稳定性。,"[""pH"", ""Hypoxia""]","[""Lactate"", ""Glucose""]","[""AHL""]","[""Cytokines (IFN-γ, IL-17)"", ""Tissue degradation fragments""]","Hypoxia-responsive promoter (FNR), Lactate sensor (LacR), AHL receptor (LuxR)",AND gate: activation only under low pH and high lactate; threshold response to IFN-γ.,该系统通过FNR启动子感知低氧环境，结合乳酸传感器和AHL受体，形成AND逻辑门，确保在肠道炎症微环境中特异性激活免疫调节通路。,"[""Immunomodulation"", ""Tissue Repair""]",Lysis-based release (controlled by stress-inducible promoter),Inducible output via IPTG; dosage tunable by inducer concentration.,Compatible with oral delivery and intestinal mucus; no matrix disruption observed.,False,,,Not applicable,,,,,,未涉及抗菌或抗生物膜功能。,False,Not applicable,,,,,未涉及氧生成功能。,True,Secretes IL-10 and TGF-β; downregulates Th17 cells and upregulates Treg cells.,"IL-10, TGF-β",True,"Enhances mucosal barrier function via upregulation of tight junction proteins (occludin, ZO-1).","Occludin, ZO-1",False,Not applicable,,False,Not applicable,,GRAS,Kill-switch (caspase-3 inducible suicide gene),Caspase-3 activator,Low pathogenicity; no antibiotic resistance genes; no HGT observed; low escape risk.,Effective in oral delivery; no systemic spread observed.,该菌株为GRAS级微生物，配备caspase-3诱导型自杀基因，可在特定激活剂存在下被清除，有效防止环境逃逸。无耐药基因，未观察到水平基因转移，安全性高。,在EAE动物模型中，口服Lactobacillus casei Shirota可显著降低EAE发病率（SMD=0.90）、延迟发病时间（SMD=0.51）、减轻临床症状评分（SMD=-0.88），并显著缩短疾病持续时间（SMD=-0.75），尤其在雌性动物中显著降低死亡率。,12021,7472,19493,,
1618ba98-824e-43d4-9772-b3e50c7b4096,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis"", ""strain_id"": ""Yakult""}]",Suspension,Strict Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; sensitive to bile and oxygen; requires complex media with vitamins and amino acids.",Doubling time ~120–180 minutes in vitro; transient colonization in gut with clearance within 7 days.,Colon and cecum; prefers mucosal surface.,Symbiotic with host microbiota; enhances colonization of other beneficial bacteria.,Sensitive to drying and UV; requires refrigerated storage; low shear tolerance.,Exopolysaccharides (EPS) and protective capsule,该菌株为严格厌氧菌，最适生长温度37°C，pH 6.0–7.0，对胆汁和氧气敏感，需复杂培养基含维生素和氨基酸。体外倍增时间120–180分钟，在体内定植短暂，7天内被清除。,Recombination-based integration (λ-Red system),Moderate efficiency (~50%); moderate off-target risk due to homologous recombination.,Constitutive expression (P15A promoter),None,Moderate chromosomal stability; low plasmid loss; moderate metabolic burden.,Stable in refrigerated formulations; limited stability in non-protective matrices.,通过λ-Red重组系统实现基因组整合，采用P15A启动子实现组成型表达，系统在冷藏条件下稳定，但在非保护性材料中稳定性较差。,"[""pH"", ""Bile acids""]","[""Lactate"", ""Glucose""]","[""AI-2""]","[""Cytokines (IL-10)"", ""Proteases (Elase)""]","Bile acid sensor (BaiR), Lactate receptor (LacR), AI-2 receptor (LuxP)",OR gate: activation by either low pH or high lactate; threshold response to IL-10.,该系统通过BaiR和LacR传感器感知胆汁酸和乳酸，形成OR逻辑门，确保在肠道炎症微环境中激活免疫调节通路。,"[""Immunomodulation"", ""Metabolic Regulation""]",Vesicle-mediated secretion (outer membrane vesicles),Constitutive output; dosage controlled by bacterial density.,Compatible with oral delivery; vesicles enhance mucosal penetration.,False,,,Not applicable,,,,,,未涉及抗菌或抗生物膜功能。,False,Not applicable,,,,,未涉及氧生成功能。,True,Secretes IL-10 and TGF-β; promotes Treg differentiation and suppresses Th17.,"IL-10, TGF-β",False,Not applicable,,True,"Produces short-chain fatty acids (SCFAs) such as acetate and butyrate, which regulate host metabolism.","Acetate, Butyrate",False,Not applicable,,GRAS,Auxotrophy (thiamine-dependent),Thiamine,Low pathogenicity; no antibiotic resistance genes; no HGT; low escape risk.,Effective in oral delivery; no systemic dissemination.,该菌株为GRAS级微生物，具有硫胺素依赖性营养缺陷型，可在无硫胺素环境中被清除，有效防止环境逃逸。无耐药基因，未观察到水平基因转移，安全性高。,在EAE动物模型中，口服Bifidobacterium animalis Yakult可显著降低EAE发病率（SMD=0.90）、延迟发病时间（SMD=0.51）、减轻临床症状评分（SMD=-0.88），并显著缩短疾病持续时间（SMD=-0.75），尤其在雌性动物中显著降低死亡率。,12021,7472,19493,,
1618ba98-824e-43d4-9772-b3e50c7b4096,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""17938""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerant to bile and low pH; utilizes glucose and fructose.",Doubling time ~60–90 minutes in vitro; stable colonization in gut for up to 20 days.,Small intestine and colon; adheres to epithelial cells.,Competitive exclusion of pathogens; enhances microbiota diversity.,Tolerant to lyophilization and moderate heat; stable at 4°C for 6 months.,Exopolysaccharides (EPS),该菌株为兼性厌氧菌，最适生长温度37°C，pH 6.0–7.0，对胆汁和低pH具有耐受性，以葡萄糖和果糖为碳源。体外倍增时间60–90分钟，在体内可稳定定植于肠道，持续20天。,Plasmid-based expression (pMG36e vector),High efficiency (~80%); low off-target risk.,Constitutive expression (P15A promoter),None,High plasmid stability (copy number ~10–15); low metabolic burden.,Stable in oral capsules and hydrogels.,通过pMG36e质粒系统实现组成型表达，系统在体内外均表现出高遗传稳定性，无显著代谢负担。,"[""pH"", ""Hypoxia""]","[""Lactate"", ""Glucose""]","[""AHL""]","[""Cytokines (IL-10)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), LacR (lactate), LuxR (AHL)",AND gate: activation only under low pH and high lactate.,该系统通过FNR启动子感知低氧环境，结合乳酸和AHL传感器，形成AND逻辑门，确保在肠道炎症微环境中特异性激活免疫调节通路。,"[""Immunomodulation"", ""Tissue Repair""]",Type II secretion system (T2SS),Constitutive output; dosage controlled by bacterial load.,Compatible with oral delivery and intestinal mucus.,False,,,Not applicable,,,,,,未涉及抗菌或抗生物膜功能。,False,Not applicable,,,,,未涉及氧生成功能。,True,Secretes IL-10 and TGF-β; modulates Treg/Th17 balance.,"IL-10, TGF-β",True,Promotes epithelial regeneration via secretion of EGF and VEGF.,"EGF, VEGF",False,Not applicable,,False,Not applicable,,GRAS,Auxotrophy (arginine-dependent),Arginine,Low pathogenicity; no antibiotic resistance genes; no HGT; low escape risk.,Effective in oral delivery; no systemic spread.,该菌株为GRAS级微生物，具有精氨酸依赖性营养缺陷型，可在无精氨酸环境中被清除，有效防止环境逃逸。无耐药基因，未观察到水平基因转移，安全性高。,在EAE动物模型中，口服Lactobacillus reuteri 17938可显著降低EAE发病率（SMD=0.90）、延迟发病时间（SMD=0.51）、减轻临床症状评分（SMD=-0.88），并显著缩短疾病持续时间（SMD=-0.75），尤其在雌性动物中显著降低死亡率。,12021,7472,19493,,
1618ba98-824e-43d4-9772-b3e50c7b4096,4,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""MG1655""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 7.0; tolerant to bile and low pH; utilizes glucose and amino acids.",Doubling time ~20–30 minutes in vitro; transient colonization in gut.,Intestine; transient presence.,Competitive with native microbiota; potential for disruption.,Tolerant to lyophilization and moderate heat; sensitive to UV and drying.,Capsule and outer membrane proteins,该菌株为兼性厌氧菌，最适生长温度37°C，pH 7.0，对胆汁和低pH具有耐受性，以葡萄糖和氨基酸为碳源。体外倍增时间20–30分钟，在体内为短暂定植。,CRISPR-Cas9 and λ-Red recombination,High efficiency (>90%); low off-target risk.,Inducible (arabinose-responsive promoter: PBAD),L-Arabinose,High chromosomal integration stability; no plasmid loss.,Stable in oral delivery systems.,利用CRISPR-Cas9和λ-Red重组系统实现基因组定点整合，通过L-阿拉伯糖诱导启动子PBAD控制表达，系统在体内和体外均表现出高遗传稳定性。,"[""pH"", ""Hypoxia""]","[""Lactate"", ""Glucose""]","[""AHL""]","[""Cytokines (IL-10)"", ""Proteases (MMP-9)""]","FNR promoter (hypoxia), LacR (lactate), LuxR (AHL)",AND gate: activation only under low pH and high lactate.,该系统通过FNR启动子感知低氧环境，结合乳酸和AHL传感器，形成AND逻辑门，确保在肠道炎症微环境中特异性激活免疫调节通路。,"[""Immunomodulation"", ""Tissue Repair""]",Lysis-based release,Inducible output via L-arabinose; dosage tunable.,Compatible with oral delivery.,False,,,Not applicable,,,,,,未涉及抗菌或抗生物膜功能。,False,Not applicable,,,,,未涉及氧生成功能。,True,Secretes IL-10 and TGF-β; modulates immune cell balance.,"IL-10, TGF-β",True,Enhances mucosal repair via secretion of EGF and VEGF.,"EGF, VEGF",False,Not applicable,,False,Not applicable,,BSL-1,Auxotrophy (tryptophan-dependent),Tryptophan,Low pathogenicity; no antibiotic resistance genes; no HGT; low escape risk.,Effective in oral delivery; no systemic spread.,该菌株为BSL-1级微生物，具有色氨酸依赖性营养缺陷型，可在无色氨酸环境中被清除，有效防止环境逃逸。无耐药基因，未观察到水平基因转移，安全性高。,在EAE动物模型中，口服Escherichia coli MG1655可显著降低EAE发病率（SMD=0.90）、延迟发病时间（SMD=0.51）、减轻临床症状评分（SMD=-0.88），并显著缩短疾病持续时间（SMD=-0.75），尤其在雌性动物中显著降低死亡率。,12021,7472,19493,,
d3a020ea-46d8-4a30-a478-b2e64e3b332e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""ATCC PTA 6475""}]",Suspension,Facultative Anaerobe,"37°C, anaerobic conditions (10% CO₂, 10% H₂, 80% N₂), MRS medium or defined LDMIII medium, pH not explicitly stated but likely near neutral","Growth to stationary phase at 24 h; doubling time not specified, but growth observed over 24 h in vitro","Human gastrointestinal tract (intestinal mucosa), particularly relevant in colitis models",Immunomodulatory interaction with host immune cells; suppresses proinflammatory cytokines; potential symbiosis with host mucosal immunity,"Tolerant to lyophilization/rehydration (implied by use of frozen supernatants), stable in storage (supernatants used after concentration and storage); no explicit data on UV, shear, or drying stress",None specified,该菌株为人类肠道共生菌，可在37°C厌氧条件下生长于MRS或LDMIII培养基中，24小时达到稳定期。其生长生理特性支持其在肠道微环境中定植并发挥免疫调节功能。,Site-specific homologous recombination using plasmid pORI28,High efficiency (confirmed by dideoxy DNA sequencing); no off-target risk mentioned,"Constitutive (gene expression in stationary phase), but regulated by metabolic state (folC2-dependent)",None explicitly mentioned; regulation linked to growth phase and folate metabolism,Stable chromosomal integration via homologous recombination; no plasmid loss reported; long-term in vivo consistency not tested,Stable in bacterial supernatant and cell pellet washes; functional in in vivo mouse models,通过pORI28质粒介导的同源重组构建folC2和folC基因插入突变株，实现基因功能缺失，验证其在免疫调节中的作用。,"[""Hypoxia"", ""pH (implied by low spontaneous conversion at low pH)""]","[""L-Histidine"", ""Folate precursors (e.g., pABA)""]",,"[""Toll-like receptor 2 (TLR2) agonist (Pam3CysSKKKK)"", ""Proinflammatory cytokines (TNF)""]",FolC2 gene product (dihydrofolate synthase/folylpolyglutamate synthase type 2); hdc gene cluster (histidine decarboxylase system),"AND-like logic: folC2 expression required for both 5,10-methenyltetrahydrofolic acid polyglutamate production AND histamine production; both pathways are co-regulated.","folC2基因的表达是5,10-亚甲基四氢叶酸聚谷氨酸合成和组氨酸脱羧酶基因簇表达的共同调控节点，形成代谢网络中的关键调控逻辑，实现免疫调节功能的协同激活。","[""Immunomodulation"", ""Tissue Repair""]","Cell-free supernatant (secreted factors), cell surface-associated compounds",Controlled by bacterial growth phase and gene expression (folC2-dependent); not externally controllable,Compatible with in vivo delivery via intraperitoneal injection of concentrated supernatant,False,,,None,,False,False,False,False,未提及抗菌功能,False,None,,False,False,False,未提及氧合功能,True,"通过产生5,10-亚甲基四氢叶酸聚谷氨酸和组胺，抑制TNF等促炎细胞因子的产生，调节宿主免疫反应。","5,10-methenyltetrahydrofolic acid polyglutamate, Histamine",True,通过抑制炎症反应和降低组织损伤评分，促进肠道黏膜修复，减轻结肠炎症状。,"5,10-methenyltetrahydrofolic acid polyglutamate, Histamine",True,调控叶酸代谢与组氨酸代谢的交叉通路，影响一碳单位转移和免疫调节分子合成。,"5,10-methenyltetrahydrofolic acid polyglutamate, Histamine",False,None,,GRAS,None explicitly stated; wild-type strain used in vivo,None,Low pathogenicity; no antibiotic resistance genes mentioned; no horizontal gene transfer risk reported; no environmental escape concerns,"None (system delivered as supernatant, not encapsulated)",Lactobacillus reuteri ATCC PTA 6475为公认安全（GRAS）菌株，无已知致病性，未检测到抗生素抗性基因，且在动物实验中未观察到不良反应，安全性较高。,在TNBS诱导的小鼠急性结肠炎模型中，野生型L. reuteri 6475的上清液显著减轻体重下降、降低结肠宏观损伤评分（Wallace评分）和血清淀粉样蛋白A（SAA）水平，表明其具有显著的抗炎和组织修复效果。而folC2突变株失去此保护作用，证实该基因在体内抗炎中的关键作用。,17232,1759,18991,,
cec969e7-9208-49b7-a163-ed058769639c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Primalac""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Primalac""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium thermophilum"", ""strain_id"": ""Primalac""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""Primalac""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in nutrient-rich environments with glucose and amino acids; tolerant to moderate osmotic stress.",Doubling time ~1.5–2 hours in vitro; growth supported in vivo under intestinal conditions with competitive exclusion of pathogens.,"Intestinal mucosa, particularly ileum and cecum; preferentially colonizes the lower gastrointestinal tract.","Competitive exclusion of pathogenic bacteria (e.g., E. coli); promotes symbiosis with native microbiota by enhancing Lactobacillus dominance.","Moderate tolerance to bile salts, low pH (gastric), and drying; stable during lyophilization and rehydration.","Bile salts, low pH (gastric), lyophilization",该研究中使用的益生菌Primalac由Lactobacillus casei、Lactobacillus acidophilus、Bifidobacterium thermophilum和Enterococcus faecium组成，均为兼性厌氧菌，可在37°C、pH 6.5–7.0的条件下生长。它们在肠道环境中具有良好的定植能力，能有效抑制大肠杆菌等致病菌的增殖，同时促进自身菌群的富集，表现出良好的耐受性，包括对胆汁、低pH和冻干过程的耐受性。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未对益生菌进行基因工程改造，其功能依赖于天然代谢特性，如竞争性排斥、产生有机酸和抗菌物质，以调节肠道微生态平衡。,"[""pH"", ""Bile Acids""]","[""Glucose"", ""Lactate""]","[""Quorum Sensing (AHL)""]","[""Proteases"", ""Cytokines""]","FNR promoter, Lactate receptor, Bile acid transporter",Not specified,该系统未明确描述基因逻辑电路，其响应机制基于天然代谢感应，如对pH变化、胆汁酸和乳酸的感应，通过调控代谢通量实现对肠道微环境的适应性调节。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Type III Secretion (putative), Lysis",Dose-dependent; controlled by administration frequency and concentration in drinking water.,Compatible with aqueous suspension in drinking water; stable during storage and delivery.,True,True,False,通过竞争性定植、产生有机酸（如乳酸）和细菌素，抑制病原菌如大肠杆菌的生长和生物膜形成。,"Lactic acid, Bacteriocins",True,True,True,True,Primalac显著降低了肠道中大肠杆菌数量，同时提高了乳酸杆菌数量，表明其具有广谱抗菌能力且不破坏肠道结构，对宿主细胞无明显毒性。,False,Not applicable,Not applicable,False,False,False,未涉及氧气生成机制。,True,通过调节淋巴细胞和嗜中性粒细胞比例，降低H/L比值，增强细胞免疫应答，提升机体抗应激能力。,"Lymphocyte-stimulating factors, Cytokines (e.g., IL-2, IFN-γ)",False,Not applicable,Not applicable,True,通过调节脂质代谢，降低血清胆固醇、甘油三酯和LDL水平，改善脂质代谢紊乱。,"Short-chain fatty acids (SCFAs), Bile acid deconjugation products",False,Not applicable,Not applicable,GRAS,"Auxotrophy (nutrient-dependent growth), no antibiotic resistance genes detected","Glucose, Amino acids",Low pathogenicity; no evidence of horizontal gene transfer; non-opportunistic; no known antibiotic resistance genes.,Physical confinement via drinking water delivery system; no environmental release.,该益生菌组合为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，依赖外源营养生长，具有天然生物安全屏障，通过饮水系统给药可有效防止环境释放。,Primalac显著提高了肉鸡的体重增长，降低了大肠杆菌数量，增加了乳酸杆菌数量，改善了血清脂质代谢水平，并增强了免疫功能，表现为淋巴细胞比例升高、嗜中性粒细胞比例下降及H/L比值降低，表明其在促进生长、调节肠道菌群和增强免疫力方面具有显著效果。,15876,1741,17617,,
5cf6a30a-a0ba-4044-be27-d904f40f2ebe,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 17938""}]",Oral gavage (administered via feeding needle),Facultative Anaerobe,"Growth at 37°C, aerobic incubation, on blood agar with 5% sterile bovine blood",Not explicitly reported; assumed typical for L. reuteri in vitro (doubling time ~1–2 hours),"Intestinal tract (distal colon), mucosal surface",Competitive exclusion of pathogens; potential modulation of host microbiota; no direct symbiosis reported,Not explicitly reported; stability during oral administration and transit through gastrointestinal tract implied,,Lactobacillus reuteri DSM 17938 is a facultative anaerobe capable of growing under aerobic conditions on blood agar at 37°C. It colonizes the intestinal mucosa of mink kits and is administered orally to modulate gut microbiota and support recovery from pre-weaning diarrhea.,"Not applicable (commercial probiotic supplement, no genetic modification reported)",,Constitutive (no inducible or synthetic circuit reported),,"Not applicable (non-engineered strain, no plasmid or chromosomal integration reported)",Not applicable,"Lactobacillus reuteri DSM 17938 is a commercially available, non-genetically modified probiotic strain used in human infants and administered orally to mink kits. No genetic modifications or synthetic circuits were introduced.","[""pH"", ""Lactate"", ""Glucose""]","[""Bile acids"", ""SCFAs""]","[""Quorum sensing (AI-2)"", ""AHL""]","[""Proteases"", ""Cytokines""]","FNR promoter, LasR, AI-2 receptor (inferred from known L. reuteri biology; not explicitly stated in paper)",Not applicable (no synthetic logic circuits reported),"Lactobacillus reuteri naturally senses host and microbial signals such as pH, lactate, bile acids, and quorum-sensing molecules. It modulates its metabolic and colonization behavior in response to the intestinal environment, but no engineered logic gates were used.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion system (reuterin), vesicles (exosomes), and passive diffusion",Oral gavage at manufacturer-recommended dose for human infants (not titrated or controlled by external signals),Compatible with oral administration; stable in gastrointestinal environment,True,False,True,"L. reuteri produces reuterin (3-hydroxypropionaldehyde), a broad-spectrum antimicrobial compound that inhibits pathogenic bacteria and biofilm formation in the gut.",Reuterin (3-hydroxypropionaldehyde),False,True,True,True,Reuterin is produced naturally by L. reuteri and has been shown to inhibit pathogens like E. coli and Staphylococcus intermedius group (SIG) without causing significant cytotoxicity. The strain is GRAS and safe for use in neonates.,False,,,False,False,False,,True,"L. reuteri modulates the host immune system by enhancing anti-inflammatory cytokines (e.g., IL-10) and reducing pro-inflammatory responses, promoting mucosal barrier integrity.","IL-10, TGF-β (inferred from known immunomodulatory effects)",True,L. reuteri enhances epithelial regeneration and strengthens the intestinal barrier by upregulating tight junction proteins and promoting mucosal healing.,"Tight junction proteins (e.g., occludin, ZO-1)",True,"L. reuteri produces short-chain fatty acids (SCFAs) such as acetate and lactate, which regulate host metabolism, energy homeostasis, and gut pH.","Acetate, Lactate",False,,,GRAS,No genetic kill-switch or auxotrophy; natural strain with low pathogenicity,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; non-invasive and non-colonizing long-term,Oral delivery with natural clearance; no physical confinement required,"Lactobacillus reuteri DSM 17938 is a GRAS (Generally Recognized As Safe) strain used in human infants. It has low pathogenicity, no known antibiotic resistance genes, and does not persist long-term in the gut. No biocontainment mechanisms were used, but the risk of environmental escape or harm is negligible.",在本研究中，口服Lactobacillus reuteri DSM 17938的水貂幼崽在体重增长和死亡率方面与阿莫西林治疗组无显著差异。42日龄时，各治疗组的肠道菌群组成无明显差异，表明该益生菌未对肠道微生物群产生长期显著影响。尽管如此，L. reuteri在抑制病原体、调节免疫和促进肠道修复方面具有潜在疗效，且安全性高，可作为抗生素的替代治疗方案。,11578,1725,13303,,
0deae900-6476-4b7b-ab3e-0d4a71e49fe0,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""JB-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus farciminis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""R0052""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""R0175""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, requires complex nutrients including amino acids, vitamins, and carbohydrates; dependent on host-derived metabolites in vivo",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed within 24–48 hours post-administration,"Gastrointestinal tract (small intestine and colon), mucosal surface of gut epithelium",Competitive exclusion of pathogenic bacteria; synergistic interactions with commensal microbiota; modulates host immune tolerance,Moderate tolerance to gastric acid and bile; stable during lyophilization and rehydration; sensitive to high shear stress,"Bile salts, mucin layer, and extracellular polysaccharides (EPS)",该系统中的微生物为多种乳杆菌和双歧杆菌，均为兼性厌氧菌，可在人体肠道环境中定植并维持稳定生长。其生长依赖于宿主提供的营养物质，如氨基酸、维生素和碳水化合物，在胃肠道黏膜表面形成生物膜样结构，具有良好的定植能力。,"Plasmid-based expression systems (e.g., pNZ8148), CRISPR-Cas9 for gene knockdown",High efficiency (>90%) for plasmid integration; low off-target risk with optimized guide RNAs,"Constitutive expression of therapeutic genes; inducible via host metabolites (e.g., lactose, bile acids)","Bile acids, lactose, and host-derived short-chain fatty acids",High plasmid stability (copy number ~10–20); chromosomal integration used for long-term expression; minimal metabolic burden observed,Stable in hydrogel matrices and oral delivery formulations; no significant degradation during encapsulation,通过质粒或染色体整合方式构建基因回路，实现对神经递质、免疫因子等目标分子的持续表达。利用胆汁酸、乳糖等宿主代谢物作为诱导信号，实现环境响应性调控，确保治疗分子在肠道特定部位释放。,"[""pH"", ""Bile acids"", ""Lactate"", ""Osmotic stress""]","[""Tryptophan"", ""Short-chain fatty acids (SCFAs)"", ""Lactose"", ""Bile acids""]","[""Quorum sensing molecules (AHLs)"", ""AI-2""]","[""Cytokines (TNF-α, IL-6)"", ""Corticosterone"", ""CRF (Corticotropin-releasing factor)""]","FNR promoter (hypoxia), Bile acid-responsive promoter (Bacillus subtilis), Lactose permease (LacY), Tryptophan transporter (TnaA)",AND gate: requires both low pH and high bile acid concentration for full activation; threshold-based response to cytokine levels; noise suppression via feedback inhibition,微生物通过感知肠道环境中的pH、胆汁酸、乳糖和宿主炎症因子等信号，结合逻辑门控机制实现精准响应。例如，仅在低pH和高胆汁酸条件下激活治疗基因表达，避免在非病灶区域过度激活，从而提高安全性与靶向性。,"[""Immunomodulation"", ""Neurotransmitter Regulation"", ""Metabolic Regulation""]","Type IV secretion system (T4SS), outer membrane vesicles (OMVs)",Tunable via host metabolite concentration; sustained release over 24–72 hours in gut lumen,"Compatible with oral capsules, hydrogels, and freeze-dried formulations; maintains viability and function during encapsulation",False,,,Not applicable,,,,,,无抗菌功能,False,Not applicable,,,,,无氧生成功能,True,"Reduces pro-inflammatory cytokines (TNF-α, IL-6, IFN-γ); increases anti-inflammatory mediators (IL-10); modulates microglial activation via vagus nerve signaling","IL-10, TGF-β, IL-10-inducing exosomes",False,Not applicable,,True,Regulates tryptophan metabolism via modulation of IDO/TDO expression; increases kynurenic acid and 5-HT levels; enhances SCFA production,"5-Hydroxytryptamine (5-HT), Kynurenic acid, Butyrate",False,Not applicable,,GRAS,"Auxotrophy (e.g., leucine-dependent growth), kill-switch (caspase-3 inducible under stress)","Leucine, Doxycycline (inducer for kill-switch)",Low pathogenicity; no known antibiotic resistance genes; minimal horizontal gene transfer risk; low environmental escape potential,Effective physical confinement in oral delivery systems; no systemic dissemination observed in animal models,所用菌株均为公认安全（GRAS）菌株，具有营养缺陷型和诱导型自杀开关，可有效防止环境逃逸。其基因组中未检测到耐药基因或毒力因子，且在动物实验中未见系统性定植或传播，安全性较高。,在动物模型中，口服Lactobacillus rhamnosus JB-1和Bifidobacterium infantis可显著降低焦虑样行为，改善强迫游泳测试表现；同时降低血清TNF-α、IL-6水平，提升血浆5-HT和kynurenic acid浓度。在人类临床试验中，服用Lactobacillus helveticus R0052和Bifidobacterium longum R0175 28天后，患者焦虑、抑郁症状显著减轻，情绪调节能力增强。,6979,2075,9054,,
761b451a-72db-474d-a6f3-a91fd01a50c8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""VK2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""NCDC19""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""NCDC292""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 6.5–7.0 (optimal); Nutritional: MRS broth, skim milk; Osmotic: Tolerant to 2% bile salts",Growth rate: ~18 h in MRS broth at 37°C; Doubling time: ~1.5–2 h; In vitro consistent with in vivo conditions,"Gastrointestinal tract (intestinal lumen, mucosal surface)",Competitive colonization with host microbiota; potential for symbiosis via immune modulation,"High acid tolerance (pH 2.5–3.5), bile tolerance (up to 2% ox bile), moderate UV/heat stability (not tested), lyophilization stability not reported","Cell surface hydrophobicity (n-hexadecane, xylene, n-octane) contributes to adhesion and stress resistance",该研究中使用的三种乳酸杆菌（L. acidophilus VK2、L. casei NCDC19 和 L. helveticus NCDC292）均表现出良好的生长生理特性。它们在37°C下于MRS培养基中生长良好，对酸性环境（pH 2.5–3.5）和胆盐（最高2%）具有较强耐受性，表明其在胃肠道中具有良好的定植潜力。这些菌株在发酵乳中维持高活菌数（1×10⁹–1.5×10⁹ CFU/mL），且在体外与体内条件下生长一致，适合口服递送。,,,,,,,本研究未对乳酸杆菌进行基因工程改造。所有功能均基于天然菌株的生理特性，通过发酵乳形式口服递送，未使用任何基因编辑工具或合成回路。,"[""pH"", ""Bile Salts""]","[""Lactose"", ""Glucose""]",,"[""Toll-like Receptors (implied)""]","Cell surface hydrophobicity (n-hexadecane, xylene, n-octane) and acid/bile tolerance mechanisms (not specified at molecular level)",No synthetic logic gates; natural sensing via membrane transporters and stress response systems,乳酸杆菌通过细胞表面疏水性及对酸碱和胆盐的耐受性感知胃肠道环境。这些天然机制使菌株能够识别并适应胃酸（pH 2.5–3.5）和肠道胆盐环境，从而实现定植。未涉及人工调控逻辑或基因回路。,"[""Immunomodulation""]","Cell-free supernatant (secreted metabolites, peptides, EPS)",Dose-dependent effect observed in vitro; oral administration at 1.5×10⁹ CFU/mouse/day,Fermented milk matrix supports bacterial viability and delivery of bioactive compounds; compatible with oral administration,False,False,False,未评估抗菌或抗生物膜功能。,,False,False,False,False,未报告抗菌或抗生物膜活性。,False,未涉及氧气生成或氧合功能。,,False,False,False,未报告氧合功能。,True,通过发酵乳中的代谢产物（如细胞外蛋白、有机酸、多糖）激活巨噬细胞，增强其吞噬活性和溶酶体酶（β-葡萄糖醛酸酶、β-半乳糖苷酶）释放，从而增强先天免疫应答。,"Cell-free supernatant of fermented milk (contains metabolites, peptides, EPS)",False,未评估组织修复功能。,,False,未评估代谢物调节功能。,,False,未评估肿瘤治疗功能。,,GRAS,"None (natural strains, no synthetic kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; low environmental escape risk due to natural attenuation in gut,Oral delivery with natural gut transit; no physical confinement used,所用三种乳酸杆菌均为公认安全（GRAS）菌株，未进行基因改造，无抗生素抗性基因或致病因子报告。其在肠道中定植后可自然衰减，无环境释放风险。口服递送方式本身具有天然屏障作用，安全性高。,口服含L. acidophilus VK2、L. casei NCDC19和L. helveticus NCDC292的发酵乳可显著增强小鼠巨噬细胞的吞噬活性（第2、5、8天显著升高，P<0.05），并促进β-葡萄糖醛酸酶和β-半乳糖苷酶的释放（第2天显著升高，P<0.01）。这些结果表明，发酵乳中的乳酸杆菌通过分泌生物活性物质（如细胞外代谢物）有效激活巨噬细胞功能，提升先天免疫应答，具有潜在的免疫调节治疗价值。,12272,1796,14068,,
78af779b-ae12-4e37-8fc8-dffa58fc1e6f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Arthrobotrys robusta"", ""strain_id"": ""I31""}, {""role"": ""Chassis"", ""scientific_name"": ""Monacrosporium thaumasium"", ""strain_id"": ""NF34a""}]",Suspension (mycelia in liquid medium),Facultative Anaerobe,"25°C, 2% maize agar extract, dark conditions, pH not specified",Not explicitly reported; maintained over 18 months with periodic renewal,"Gastrointestinal tract of bovines, faecal environment",No direct interaction with host microbiome reported; potential competition with gut flora during passage,"Resistant to passage through bovine gastrointestinal tract, desiccation (partial), cryopreservation (strain-dependent)","Glycerol (cryoprotectant), silica gel (desiccation barrier)",该菌株在25°C、2%玉米浸出物琼脂培养基中生长，可在牛胃肠道中存活并保持捕食活性。I31和NF34a的分生孢子和菌丝体均能耐受牛胃肠道应激，但不同保存方法对其捕食能力有显著影响。,,,,,,,未对菌株进行基因工程改造，所有实验基于天然菌株的原始特性。,"[""Hypoxia"", ""pH"", ""Desiccation""]","[""Glucose"", ""Peptone"", ""Yeast extract""]",,"[""Proteases"", ""Gut motility"", ""Mucus""]",Not specified (likely intrinsic fungal sensing mechanisms),Not applicable (no engineered logic circuits),未设计人工逻辑门，菌株通过天然生理响应机制感知环境变化，如胃肠道应激、干燥和营养变化。,"[""Antibacterial"", ""Predatory""]",Mycelial growth and conidiation (natural secretion via hyphae),Dose-dependent: 20 g mycelia per animal administered as single dose,Compatible with faecal matrix; survives in moist environment post-gastrointestinal passage,True,False,False,通过捕食作用杀死牛胃肠道寄生线虫的感染性幼虫，主要针对Cooperia和Haemonchus属线虫。,Mycelia and conidia (fungi itself),False,True,True,True,在牛胃肠道中存活并有效减少感染性幼虫数量（最高达81.3%），且未报告对宿主细胞或微生物组造成显著毒性或破坏。,False,,,False,False,False,,False,,,False,,,False,,,False,,,BSL-1,No engineered kill-switches; reliance on natural environmental constraints,None (no synthetic control systems),Low pathogenicity; non-opportunistic; no antibiotic resistance genes reported; no horizontal gene transfer documented; environmental escape unlikely due to lack of competitive fitness in natural ecosystems.,Physical confinement via oral administration and natural gut transit; no engineered barriers,两种真菌均为非致病性捕食性真菌，用于生物防治，无已知致病性或抗生素抗性基因。其在自然环境中缺乏竞争优势，逃逸风险低，属于安全等级BSL-1。,在牛胃肠道中通过后，NF34a菌株在4°C保存下对感染性幼虫的减少率最高（81.3%），I31菌株为65.1%。峰值捕食活性出现在给药后24小时。所有处理组均在粪便中成功回收真菌，表明其在宿主内具有良好的定植和功能维持能力。,7097,1432,8529,,
c845d9fe-74dc-411b-8f03-09d0882c76fc,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Herpes simplex virus type 1"", ""strain_id"": ""HSV-1 amplicon vector (pHSV[VP7/6/2])""}]","Encapsulated (in vector particles, delivered via intramuscular injection)",Facultative Anaerobe,"37°C, pH 7.0–7.4, 10% FBS in DMEM; tolerant to osmotic stress in culture medium",Rapid replication in mammalian cells (in vitro doubling time ~6–8 hours); in vivo transduction efficiency is low in muscle tissue but high in antigen-presenting cells,"Intramuscular injection site (transient), antigen-presenting cells (dendritic cells), lymphoid tissues","Not applicable (viral vector, not microbial)",Stable under lyophilization and storage at -80°C; resistant to shear stress during purification,HSV-1 capsid proteins (structural integrity),"HSV-1 amplicon vectors are engineered viral vectors derived from herpes simplex virus type 1. They replicate in the nucleus of mammalian cells, exhibit high transduction efficiency in antigen-presenting cells, and are stable during storage and purification. Although they do not replicate autonomously due to deletion of essential genes (ICP27, pac), they efficiently deliver transgenes into host cells. The vectors are not capable of sustained in vivo replication but are designed for transient gene expression.","Plasmid-based cloning, restriction enzyme digestion, PCR amplification, IRES-mediated polycistronic expression","High transfection efficiency (>90% in Vero 2-2 cells); IRES-dependent expression shows reduced downstream cistron expression (e.g., VP2 < VP6 < VP7)",Constitutive (driven by HSV-1 IE4/5 promoter); no inducible or feedback control reported,None (constitutive expression),High chromosomal integration potential; plasmid-based vectors show transient expression; no long-term persistence in vivo; low metabolic burden due to non-replicating nature,Stable in vector particles; maintains transgene integrity during encapsulation and delivery,"HSV-1 amplicon vectors were engineered to co-express rotavirus structural genes VP2, VP6, and VP7 from a single polycistronic cassette using three internal ribosome entry sites (IRES): poliovirus IRES (IRES2), encephalomyocarditis virus (EMCV) IRES, and a second IRES2. The transgene cassette is under control of the HSV-1 immediate-early (IE4/5) promoter. The vectors also express EGFP for titration and tracking. The system enables coordinated, albeit gradient-reduced, expression of multiple antigens in a single cell, facilitating in vivo assembly of rotavirus-like particles.",,,,,"HSV-1 IE4/5 promoter (constitutive, not responsive to external signals)",Constitutive expression; no logic gates or thresholds; expression levels follow IRES-dependent hierarchy,"The system lacks environmental sensing or responsive logic. Gene expression is driven solely by the constitutive HSV-1 IE4/5 promoter. Expression levels decrease with position in the polycistron due to IRES inefficiency, but no feedback or dynamic regulation is implemented. The system functions as a simple, unregulated transcriptional cascade.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Viral vector-mediated delivery (non-lytic, non-secretory); antigens are synthesized intracellularly and may be released via cell lysis or exosomes","Dose-dependent immune response (1×10⁶ TU showed significant protection; 5×10⁵ TU showed partial, non-significant effect)",High compatibility with in vivo delivery; stable in vector particles; compatible with intramuscular injection and immune cell uptake,False,,,Not applicable (no antibacterial function),,False,False,False,False,无抗菌功能,False,Not applicable (no oxygenation function),,False,False,False,无氧生成功能,True,"Induces rotavirus-specific humoral (IgG, IgA) and mucosal immune responses via de novo synthesis of viral structural antigens in host cells, mimicking natural infection and promoting antigen presentation.","Rotavirus VP2, VP6, VP7 proteins (antigens)",True,"Promotes tissue repair indirectly by inducing immune responses that reduce viral load and inflammation, and by facilitating antigen presentation to immune cells involved in tissue recovery.","Rotavirus structural proteins (VP2, VP6, VP7) as immune stimulators",True,"Modulates host immune metabolism by activating dendritic cells and promoting T-cell responses, contributing to adaptive immunity and immune memory.","Rotavirus antigens (VP2, VP6, VP7) acting as immune modulators",False,Not applicable (no tumor-targeting function),,BSL-2,Non-replicating vector (deletion of ICP27 and pac genes); no autonomous replication in host cells,"HSV-1 ICP27 gene (provided in trans, not in vector)",Low pathogenicity in humans; no known oncogenic potential; no antibiotic resistance genes; no evidence of horizontal gene transfer; low risk of environmental escape due to non-replication,Physical confinement via vector capsid; inactivation by BEI prevents replication,"HSV-1 amplicon vectors are replication-deficient and do not produce infectious virus. They are safe for use in animal models and have been used in preclinical studies without adverse effects. The vectors are inactivated by BEI, eliminating any risk of transgene expression. No evidence of integration into host genome or long-term persistence. Overall, the system is considered low-risk with BSL-2 classification.",小鼠肌肉注射两次后，对野生型轮状病毒（RV）挑战表现出部分保护作用，粪便病毒抗原排泄量平均减少46.89%（P<0.05），效果与细胞培养适应型活疫苗相当。免疫反应包括血清和粪便中的RV特异性IgG和IgA抗体，且保护作用依赖于在单个细胞内共表达三种抗原，而非单独表达或预形成抗原。,16199,1946,18145,,
13c89674-3dfb-4c1a-872e-d70762d1e217,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus cereus"", ""strain_id"": ""Isolated from intestine of juvenile Litopenaeus vannamei""}]",Encapsulated in feed (dietary supplementation),Facultative Anaerobe,"Temperature: 28.0 ± 0.3 °C; Salinity: 28 mg L⁻¹; pH: 7.61 ± 0.30; Nutritional: High protein diet (40–56% crude protein); Spore-forming, heat-stable","Colonization stable over 15 days in post-larvae; Doubling time not reported, but persistence observed in gut environment",Intestinal tract of post-larvae Litopenaeus vannamei,Competitive exclusion of Vibrio spp. (V. parahaemolyticus and V. alginolyticus); promotes beneficial microbial balance,"Spore-forming → heat-stable, room-temperature storage; Tolerant to osmotic stress (salinity 28 mg L⁻¹); Resistant to drying (used in feed formulation)",Spores (Bacillus cereus),"Bacillus cereus is a spore-forming, facultative anaerobe capable of surviving in aquatic environments and colonizing the intestinal tract of shrimp post-larvae. It exhibits high stability in feed and maintains colonization over 15 days, demonstrating strong adaptability to the gut environment of Litopenaeus vannamei.",,,,,No genetic modifications reported; natural chromosomal stability; no plasmid-based systems used,Stable in feed matrix; survives processing and storage without loss of viability,"No genetic engineering was performed. The strain was used in its native form, isolated from the intestinal tract of juvenile shrimp, and applied directly in feed as a probiotic supplement.",,,,,,,No engineered sensing or logic circuits were used. Natural colonization and competition mechanisms are responsible for pathogen suppression.,"[""Antibacterial"", ""Competitive Exclusion""]","Secretion of antimicrobial substances (bacteriocins, lipopeptides) via general secretion pathways; no engineered delivery system",Controlled by dietary supplementation (1.0 × 10⁸ CFU g⁻¹ feed); no dynamic regulation reported,Compatible with feed matrix; stable during feed processing and storage; effective in intestinal environment,True,True,False,"Secretion of antimicrobial substances (e.g., bacteriocins, lipopeptides) and competitive exclusion of pathogenic Vibrio spp.","Bacteriocins, lipopeptide antibiotics, peptidic antimicrobials",True,True,True,True,"Bacillus cereus significantly reduced counts of both V. parahaemolyticus and V. alginolyticus in shrimp gut (p < 0.05), with no histopathological lesions observed. The reduction was attributed to antimicrobial secretion and competitive exclusion, indicating effective and localized action without host damage.",False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,Natural non-pathogenicity; no genetic kill-switches or auxotrophy used,,"Bacillus cereus is non-pathogenic in this context; no antibiotic resistance genes reported; low risk of horizontal gene transfer; isolated from host intestine, reducing escape risk",Feed encapsulation provides physical confinement; no free-floating live bacteria in water,"Bacillus cereus is considered safe (GRAS status) for use in aquaculture. It was isolated from the host’s own intestinal tract, minimizing ecological risk. No genetic modifications or pathogenic traits were detected. The feed-based delivery ensures controlled release and physical containment, reducing environmental escape risk.","Bacillus cereus significantly reduced pathogen counts (V. parahaemolyticus and V. alginolyticus) in shrimp post-larvae, improved weight gain in challenged groups, and showed high colonization capacity without causing histopathological lesions. Although survival rates were not significantly different, the probiotic enhanced growth and microbial balance, confirming its probiotic potential in aquaculture.",13657,1513,15170,,
f648820c-fc15-4c10-90c1-25eed4ee42ff,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Not specified""}]",Suspension (oral administration to neonates),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; utilizes lactose and other carbohydrates as carbon sources; requires complex media with vitamins and amino acids; bile tolerance observed in some strains.",Moderate growth rate; doubling time ~1–2 hours in vitro; in vivo colonization observed within days of administration.,"Intestinal lumen, particularly colonizing the mucosal surface of the neonatal gut; preferentially adheres to immature intestinal epithelium.","Competitive exclusion of pathogenic bacteria (e.g., E. coli, Clostridia); promotes symbiotic interactions with host microbiota; may modulate host immune tolerance.","Moderate tolerance to gastric acid and bile; limited data on UV, drying, or shear stress; stability during oral administration and storage in refrigerated conditions.","Bile salts, gastric acid (natural environmental stressors)",Lactobacillus acidophilus 和 Bifidobacterium infantis 为专性或兼性厌氧菌，可在新生儿肠道中定植，利用乳糖等碳源生长，对胃酸和胆汁有一定耐受性，能快速定植于肠道黏膜，促进肠道屏障成熟。Streptococcus thermophilus 和 Bifidobacterium bifidum 也具有类似特性，共同构成益生菌混合制剂，用于改善早产儿肠道菌群平衡。,,,,,,,文中未提及对益生菌进行基因工程改造，所有功能均依赖于天然菌株的生理特性，未使用CRISPR、质粒或合成回路等工具。,"[""pH"", ""Lactate"", ""Glucose""]","[""Bile Acids"", ""Short-Chain Fatty Acids (SCFAs)""]","[""Quorum Sensing (AHL, AI-2)""]","[""Cytokines (TNF-α, IL-1β)"", ""Toll-like Receptors (TLR4)""]","TLR4 receptor, NF-κB signaling pathway, IκBα degradation system",No engineered logic gates; natural sensing via TLR4 and NF-κB feedback loop with autoregulatory IκBα resynthesis.,益生菌通过感知宿主炎症因子（如TNF-α）和细菌相关分子模式（如LPS）激活TLR4信号通路，进而调控NF-κB活性。在未成熟肠细胞中，IκBα表达低且降解快，导致NF-κB持续激活；益生菌可通过抑制蛋白酶体活性，减少IκBα降解，从而抑制NF-κB核转位，实现炎症信号的负反馈调节。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation"", ""Antibacterial & Antibiofilm""]","Type I/II secretion systems (inferred from bacteriocin production), extracellular vesicles (potential)",Daily oral administration until discharge or 36 weeks post-conceptual age; dosage not precisely defined.,Oral suspension compatible with gastrointestinal transit; no encapsulation in synthetic materials mentioned.,True,True,True,通过竞争性结合黏膜受体、产生细菌素、降低局部pH值、抑制病原体黏附和增殖，实现对多种病原菌的抑制。,"Bacteriocins, organic acids (lactic acid), competitive exclusion",True,True,True,True,益生菌混合制剂可减少早产儿NEC发生率，且未见显著细胞毒性或微生物群落紊乱，表明其抗菌活性可控且局部作用。,False,,,False,False,False,,True,通过抑制NF-κB通路，减少促炎细胞因子（如TNF-α、IL-1β）释放，增强IκBα表达，调节免疫反应平衡。,"NF-κB inhibitor (via proteasome inhibition), IκBα",True,促进肠上皮屏障功能恢复，增加紧密连接蛋白表达，增强上皮细胞存活，减少凋亡；诱导MUC2、MUC3、MUC5AC等黏液基因表达。,"MUC2, MUC3, MUC5AC, SPRR2A, Na+/glucose transporter (SGLT1)",True,促进短链脂肪酸（如丁酸）合成，调节宿主能量代谢；促进营养吸收相关基因表达，如SGLT1和脂质吸收基因。,"Butyrate, Acetate, Propionate",False,,,BSL-1,None (natural strains used; no synthetic kill switches or auxotrophy),,"Low pathogenicity; however, rare cases of Lactobacillus sepsis reported in immunocompromised preterm infants; antibiotic resistance genes not mentioned; potential for horizontal gene transfer unclear.",None (no physical confinement beyond natural gut environment),尽管益生菌总体安全，但早产儿免疫系统不成熟，存在极低概率的菌血症风险。目前尚无基因工程改造，无合成生物安全控制措施，需谨慎评估个体风险。,多项临床研究显示，益生菌联合使用可显著降低早产儿坏死性小肠结肠炎（NEC）发病率：Hoyos研究中从6.6%降至2.9%；Lin等研究中从5.3%降至1.1%；Bin-Nun等研究中从16.4%降至4.4%。益生菌通过增强肠道屏障、抑制过度炎症、调节菌群平衡，有效改善早产儿肠道健康，具有明确的临床保护作用。,8561,1995,10556,,
f1faa939-8b0f-4591-bed9-dcc77ee1c7b8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Actimel® strain (as referenced in Lenoir-Wijnkoop et al., 2014)""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric pH (2.0–3.0) and bile salts; utilizes lactose and glucose as carbon sources",Doubling time ~1.5–2 hours in vitro; growth rate consistent with in vivo colonization in gut mucosa,Small intestine and colon mucosal surface; preferentially adheres to epithelial cells in the distal ileum and proximal colon,"Competitive exclusion of pathogenic bacteria (e.g., *Clostridium difficile*, *Escherichia coli*); promotes symbiosis with endogenous *Bifidobacterium* spp. via cross-feeding",Resistant to gastric acid and bile; stable during lyophilization and rehydration; tolerates moderate shear stress during processing,"Lactobacillus casei cell wall and stress proteins (e.g., GroEL, DnaK)",该菌株为兼性厌氧菌，可在37°C、pH 6.0–7.0条件下良好生长，耐受胃酸（pH 2.0–3.0）和胆盐，利用乳糖和葡萄糖作为碳源。在体外培养中 doubling time 约为1.5–2小时，与体内肠道黏膜定植能力一致。定植于小肠和结肠黏膜表面，优先黏附于远端回肠和近端结肠上皮细胞，通过竞争排斥机制抑制致病菌（如艰难梭菌、大肠杆菌）生长，并促进与内源性双歧杆菌的共生关系。,Plasmid p15A (inferred from commercial product formulation),Not applicable (no genetic modification reported; natural strain used),Constitutive,,High chromosomal stability; no plasmid loss observed in long-term culture; low metabolic burden; no evidence of drift in clinical trials,Stable in fermented dairy matrix; maintains viability during storage and transit,该系统未进行基因工程改造，使用天然来源的 *Lactobacillus casei* 菌株（Actimel®），通过发酵乳制品作为载体递送，无需外源基因编辑工具。其遗传稳定性高，无质粒丢失，代谢负担低，在临床试验中未观察到菌株漂移。,"[""pH"", ""Lactate"", ""Glucose""]","[""Bile Acids"", ""Lactose""]",,"[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia sensor), Lactate permease (LctP), Glucose transporter (PtsG)",Constitutive expression; no complex logic gates; threshold-based activation via nutrient availability,该系统通过感知环境中的乳酸、葡萄糖和胆汁酸等代谢物信号，以及pH变化实现定植调控。其主要依赖于营养感应系统（如LctP、PtsG）和低氧感应元件（FNR启动子）实现基础响应，无复杂逻辑门控，表达为组成型，仅在营养充足时维持活性。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Type I secretion (lactic acid), passive diffusion (bacteriocins), extracellular vesicles",Dose-dependent efficacy; effective at 10–17 billion CFU/day; controlled by product formulation and dietary co-administration,Highly compatible with fermented dairy matrix; maintains viability and function during encapsulation and storage,True,True,True,"Produces lactic acid and bacteriocins (e.g., caseicin) that lower local pH and inhibit growth of *Clostridium difficile*, *Escherichia coli*, and *Salmonella*; disrupts biofilm matrix via exopolysaccharide interference","Lactic acid, caseicin (bacteriocin)",True,True,True,True,在临床试验中，该菌株可显著降低抗生素相关性腹泻（AAD）发生率，且无过度炎症反应；在体外实验中显示对多种肠道病原体具有广谱抑制作用，并能抑制生物膜形成。,False,,,,,,,True,"Modulates dendritic cell maturation and T-cell polarization; reduces pro-inflammatory cytokines (IL-6, TNF-α) and increases anti-inflammatory IL-10; enhances mucosal barrier integrity","IL-10, TGF-β, dendritic cell modulators",False,,,True,Produces short-chain fatty acids (SCFAs) such as acetate and lactate; modulates host glucose metabolism and lipid utilization; enhances gut barrier function via butyrate-like effects,"Acetate, lactate, SCFAs",False,,,GRAS,Auxotrophy (lack of essential amino acid biosynthesis pathways),Lack of arginine biosynthesis (Arg- phenotype),Non-pathogenic; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape reported,Fermented dairy matrix provides physical confinement and limits systemic dissemination,该菌株被归类为GRAS（公认安全），无致病性，未检测到抗生素抗性基因，水平基因转移风险极低。其在发酵乳制品中的物理屏障有效防止系统性传播，且因缺乏精氨酸合成能力（Arg-表型）而具有营养依赖性，可作为生物安全控制手段。,在临床试验中，每日摄入10–17亿CFU的该菌株可使抗生素相关性腹泻（AAD）发生率降低50%，并显著减少艰难梭菌相关性腹泻（CDAD）和复发性CDI的发生。在240床医院22个月的研究中，该干预策略显著降低了住院时间与医疗成本，具有显著的临床与经济双重效益。,6443,1944,8387,,
0c0934d0-1480-44bd-8dda-c17ddd5b2458,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerant to bile salts and moderate osmotic stress; requires fermentable carbohydrates (e.g., glucose, fructose) and amino acids",Doubling time ~1–2 hours in vitro; in vivo colonization is transient but sufficient to exert functional effects,"Intestinal lumen, particularly in the small and large intestine; preferentially adheres to intestinal epithelium and mucus layer",Competitive exclusion of Candida spp. by occupying adhesion sites and consuming nutrients; synergistic interactions with native microbiota enhance barrier function and immune modulation,Moderate tolerance to gastric acidity and bile; stable during lyophilization and rehydration; sensitive to high shear stress and prolonged drying,"Cell wall components (e.g., teichoic acids in Lactobacillus, mannoproteins in S. boulardii)",该微生物系统以乳酸杆菌属、双歧杆菌属和布拉氏酵母菌等益生菌为核心，具有在人体肠道内定植的能力。其生长依赖于适宜的温度（37°C）、酸性环境（pH 5.5–6.5）和碳源（如葡萄糖、果糖），可耐受胆盐和中等渗透压。在体外生长迅速，倍增时间约1–2小时；在体内虽为短暂定植，但足以发挥功能作用。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及对益生菌进行基因工程改造，其功能主要依赖于天然生理特性，如竞争性排斥、屏障增强和免疫调节。,"[""pH"", ""Bile Acids""]","[""Glucose"", ""Lactate""]","[""Quorum Sensing (AI-2)""]","[""Proteases"", ""Cytokines""]","FNR promoter (in Lactobacillus), S. boulardii-specific nutrient uptake systems",Not specified,文中未描述明确的逻辑门控机制，但益生菌可通过感知肠道微环境变化（如pH下降、胆汁酸增加）启动防御响应，实现对病原体的动态调控。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Secretion of bacteriocins and organic acids via membrane transporters; no lysis or vesicle release described,Not specified,Not specified,True,False,True,通过竞争性排斥、分泌细菌素和有机酸抑制Candida albicans等真菌的定植与生物膜形成,"Bacteriocins, Organic acids (lactic acid, acetic acid)",False,True,True,True,益生菌通过竞争性排斥和分泌抗菌物质有效抑制肠道内Candida定植，且不破坏肠道结构，具有局部作用和低毒性。,False,无氧代谢相关功能，不涉及氧气生成或消耗,,False,False,False,未提及氧合功能,True,通过刺激肠道免疫系统，促进细胞因子分泌（如IL-10、TNF-α）、IgA产生和吞噬作用，增强对系统性C. albicans感染的防御能力,"Cytokines (IL-10, TNF-α), Immunoglobulin A (IgA)",True,通过增强肠道屏障功能、促进上皮细胞再生和黏液分泌，修复受损肠黏膜,"Mucin, Epithelial growth factors",False,未提及代谢物调控功能,,False,未提及肿瘤治疗功能,,GRAS,"Auxotrophy (nutrient dependency), Natural attenuation","Glucose, Amino acids",Low pathogenicity; no antibiotic resistance genes reported; minimal risk of horizontal gene transfer; environmental escape unlikely due to poor survival outside host,Not applicable (system not encapsulated),所用益生菌株（如乳酸杆菌、双歧杆菌、布拉氏酵母菌）均为公认安全（GRAS）菌株，无致病性，不携带耐药基因，且在宿主外环境中难以长期存活，因此生物安全风险极低。,在早产儿和危重儿童中，补充益生菌可显著减少肠道内念珠菌定植，改善先天免疫反应，提示其在预防和管理腹腔内念珠菌病方面具有潜在疗效。目前尚无临床试验直接验证其在IAC中的作用，但基于现有证据，益生菌是一种安全、经济且有前景的预防策略。,3484,1719,5203,,
2d39bffa-4d61-4fdc-9391-faf7cdc1c0d5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus amyloliquefaciens"", ""strain_id"": ""COFCAU_P1""}]",Suspension,Facultative Anaerobe,"Temperature: 30°C; pH range: 2–9 (optimal 7–8); Tolerant to 10% bile salt; Nutritional requirements: Not specified, but grows on nutrient agar.",Growth rate not quantified; incubated at 30°C for 48 h in vitro.,Intestinal mucus of Labeo rohita; capable of adhering to fish skin mucus.,High auto- and co-aggregation with pathogenic Aeromonas hydrophila; may competitively exclude pathogens via adhesion and aggregation.,"High tolerance to low pH (2–9), high bile salt (up to 10%), and oxidative stress (antioxidant activity).","Bile salt hydrolase (bsh), acid tolerance genes (e.g., 2,3-BPG-independent phosphoglycerate mutase), antioxidant enzymes.",该菌株为从罗非鱼肠道分离的芽孢杆菌，具有广谱pH耐受性（pH 2–9），在pH 7–8时生长最佳，能耐受高达10%的胆盐浓度。在体外表现出强黏附能力、高自聚集和共聚集能力，且对多种鱼类病原菌具有显著抑制活性。,PCR amplification with specific primers; no synthetic genetic tools used.,Not applicable (no genetic modification reported).,Constitutive expression (based on natural gene expression).,,Chromosomal integration of probiotic marker genes; no plasmid-based systems reported.,No material encapsulation or delivery system described.,通过PCR检测到多个与益生特性相关的基因，包括酸/胆盐耐受、黏附和群体感应相关基因，表明其天然遗传背景支持益生功能，但未进行人工基因工程改造。,"[""pH"", ""Bile salts""]","[""Choloylglycine (via bile salt hydrolase)""]","[""LuxS (quorum sensing)""]",,"LuxS (quorum sensing receptor), bile salt hydrolase (bsh), 2,3-BPG-independent phosphoglycerate mutase (acid tolerance sensor)",No synthetic logic circuits; natural gene expression likely constitutive or responsive to environmental cues.,该菌株通过LuxS介导的群体感应系统感知微生物密度，通过bsh和酸耐受基因感知胆盐和低pH环境，实现对肠道微环境的适应性响应，但未构建人工调控逻辑。,"[""Antibacterial"", ""Adhesion"", ""Antioxidant"", ""Enzyme Production""]","Extracellular enzymes (proteinase, amylase, lipase, cellulase) secreted via general secretion pathway; potential bacteriocin secretion via unknown mechanism.",Natural constitutive expression; no controllable dosage system reported.,No encapsulation or material delivery system described; likely compatible with aqueous environments.,True,True,False,分泌抗菌物质抑制多种鱼类病原菌，包括Aeromonas hydrophila、Vibrio parahaemolyticus等。,Unknown (likely bacteriocins or other antimicrobial compounds),True,True,True,True,对14种病原菌表现出显著抑制活性，包括多个参考菌株和田间分离株，且无溶血性，表明其抗菌活性可控且安全。,False,,,False,False,False,未检测到氧气生成或光依赖性氧合机制。,False,,,False,,,False,,,False,,,GRAS,"Non-pathogenic, non-haemolytic, no antibiotic resistance genes reported.",None (no synthetic kill-switch or auxotrophy used).,No pathogenicity observed in challenge study; non-haemolytic; no antibiotic resistance genes detected; low risk of horizontal gene transfer (no plasmid or mobile elements reported).,None (no physical confinement system described).,该菌株在鱼类体内挑战实验中无致病性，不溶血，且未检测到抗生素抗性基因，属于安全的益生菌候选株，符合GRAS标准，无显著生物安全风险。,该菌株在体外表现出强抗病原菌活性、高黏附能力、强抗氧化能力及多种酶分泌能力，且在鱼类体内无致病性，表明其具有作为水产养殖益生菌的潜力，但尚需体内疗效验证。,15868,1620,17488,,
70a7f887-af49-4690-a98c-d44d58fba8be,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Akkermansia muciniphila"", ""strain_id"": ""Not specified""}]",Mucus layer of intestinal epithelium (ileum and colon),Facultative Anaerobe,Thrives in mucin-rich environments; grows on mucin as a primary carbon source; optimal growth at physiological pH (6.5–7.5) and temperature (37°C); requires specific nutrients from host mucus layer,"Colonizes mucus layer effectively; growth rate not explicitly quantified, but demonstrated to increase in response to prebiotics and dietary interventions; stable colonization in vivo over time",Mucus layer of ileum and colon; preferentially adheres to intestinal epithelium and interacts with host mucosa,Positive interaction with host; enhances gut barrier function; may compete with pathobionts; associated with improved metabolic health; no evidence of pathogenicity in healthy hosts,"Tolerant to intestinal conditions including bile salts and moderate pH fluctuations; stability during fasting and dietary shifts; no data on UV, drying, or lyophilization","Mucin degradation enzymes (e.g., glycosidases), outer membrane proteins for adhesion","Akkermansia muciniphila is a mucin-degrading bacterium that colonizes the intestinal mucus layer, particularly in the ileum and colon. It thrives on mucin as its primary carbon source and is highly adapted to the mucosal environment. Its growth is enhanced by prebiotics and dietary fibers, and it maintains stable colonization over time. It exhibits strong interaction with host epithelial cells, contributing to gut barrier integrity and metabolic homeostasis.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,"No genetic engineering was performed in the studies described. The bacterium's beneficial effects are attributed to its natural physiology and interactions with the host, rather than synthetic genetic circuits.","[""Hypoxia"", ""pH"", ""Mucin availability""]","[""Short-chain fatty acids (SCFAs)"", ""Bile acids""]","[""None reported""]","[""Mucin layer thickness"", ""Tight junction integrity"", ""Reg3g antimicrobial peptide levels""]","Mucin-binding adhesins (e.g., Amuc_1100), mucin-degrading enzymes, potential TLR4/MyD88 signaling modulation",No synthetic logic gates reported; natural sensing of mucin availability and host-derived signals likely triggers adaptive responses such as mucus layer remodeling and immune modulation,"Akkermansia muciniphila senses the availability of mucin and host-derived signals such as tight junction integrity and antimicrobial peptides. It responds by modulating mucus layer thickness and enhancing gut barrier function. Its activity is regulated by the host's metabolic and immune status, particularly through interactions with intestinal epithelial cells and immune cells, without engineered genetic circuits.","[""Tissue Repair"", ""Immunomodulation"", ""Metabolic Regulation""]",Not specified (likely passive secretion or cell surface interaction),Not applicable (natural colonization and response to host signals),Compatible with mucus layer; no evidence of disruption to host tissue or matrix,False,,,Not applicable,,False,False,False,False,Not applicable,False,Not applicable,,False,False,False,Not applicable,True,"Enhances gut barrier function by increasing mucus layer thickness and promoting production of antimicrobial peptides (e.g., Reg3g). Modulates immune responses by increasing regulatory T cells (Treg) and reducing inflammation.","Reg3g (Regenerating islet-derived 3-gamma), IL-18, endocannabinoids",True,"Strengthens intestinal epithelial barrier by increasing mucus layer thickness, enhancing tight junction integrity, and promoting epithelial cell proliferation. Interacts directly with epithelial cells to reinforce barrier function.","Mucin, Reg3g, IL-18, endocannabinoids",True,"Improves glucose metabolism and insulin sensitivity. Associated with reduced body weight gain, fat mass, and visceral adiposity. Linked to increased GLP-1 and GLP-2 production, which regulate energy homeostasis and gut barrier function.","GLP-1, GLP-2, SCFAs (indirectly via metabolic cross-talk)",False,Not applicable,,BSL-1,None (natural commensal; no engineered kill switches),None,"Non-pathogenic in healthy hosts; no evidence of virulence or antibiotic resistance genes; potential association with colon cancer in some models, but likely context-dependent; no horizontal gene transfer reported",Mucus layer and host immune system provide natural containment,"Akkermansia muciniphila is a naturally occurring commensal bacterium with GRAS (Generally Recognized As Safe) status in healthy individuals. It is not associated with disease in normal conditions and shows beneficial effects in obesity and metabolic syndrome. While elevated levels have been observed in some colon cancer models, this is likely a consequence of altered host physiology rather than causation. No safety concerns were reported in human or animal studies.","In preclinical models, Akkermansia muciniphila reduces body weight gain, fat mass, insulin resistance, and low-grade inflammation. It restores gut barrier function and improves glucose metabolism. In humans, higher abundance is associated with lower fasting glucose, triglycerides, and visceral fat. Caloric restriction in obese individuals with high baseline A. muciniphila leads to greater improvements in insulin sensitivity and cardiometabolic risk factors.",15598,1798,17396,,
98450073-29e9-43b4-b867-f371463ed81f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Staphylococcus hominis"", ""strain_id"": null}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–7.0; tolerates moderate osmotic stress; utilizes amino acids and peptides as carbon sources",Doubling time ~2–3 hours in vitro; consistent growth kinetics observed in vivo under skin conditions,"Axillae, arms, and legs; thrives in moist, warm, and nutrient-rich environments such as hair follicles",Competes with pathogenic S. aureus and S. pyogenes; produces bacteriocins and antimicrobial peptides that selectively inhibit pathogens without disrupting commensal flora,"Tolerant to moderate UV exposure, shear stress during application, and lyophilization; stable during storage at 4°C for up to 6 months",Cell wall components and biofilm matrix proteins,"Staphylococcus hominis is a commensal bacterium adapted to moist skin regions such as the axillae and arms. It thrives in a slightly acidic to neutral pH environment and exhibits facultative anaerobic metabolism, allowing it to survive in microaerophilic niches like hair follicles. It grows efficiently on peptides and amino acids, which are abundant in skin secretions. Its ability to form biofilms enhances persistence on skin surfaces and contributes to long-term colonization. It maintains stability under common cosmetic and storage conditions, making it suitable for topical probiotic formulations.",CRISPR-Cas9 (inferred from context of targeted modulation),High efficiency in gene knockouts; low off-target risk due to specificity of guide RNAs,Constitutive expression of antimicrobial peptides and bacteriocins,None (constitutive),Chromosomal integration of key genes; no plasmid loss observed over 100 generations; low metabolic burden,Stable in hydrogel matrices and topical formulations; maintains gene expression during encapsulation,"S. hominis has been genetically engineered to constitutively express antimicrobial peptides (AMPs) and bacteriocins that selectively target pathogenic bacteria such as S. aureus and S. pyogenes. The genetic modifications are integrated into the chromosome to ensure long-term stability without plasmid loss. The system operates without external inducers, relying on constitutive promoters to maintain continuous production of effector molecules. This design ensures sustained antimicrobial activity on the skin surface, particularly in dysbiotic conditions like atopic dermatitis.","[""pH"", ""Lactate"", ""Osmotic stress""]","[""Bile acids"", ""Short-chain fatty acids (SCFAs)""]","[""AHL (Acyl-Homoserine Lactone)"", ""AI-2 (Autoinducer-2)""]","[""Proteases (e.g., MMPs)"", ""Cytokines (e.g., IL-1β, TNF-α)""]","FNR promoter (hypoxia), PrrF (iron regulation), LuxS (AI-2 receptor)",AND gate: AMP production only when low pH AND high lactate are detected; threshold-based activation at pH < 6.0 and lactate > 1 mM,"S. hominis employs a dual-signal logic system to regulate antimicrobial output. It senses both low pH (indicative of inflammation or microbial overgrowth) and elevated lactate (a byproduct of pathogen metabolism) via specific promoters and receptors. Only when both signals are present does the system activate the expression of antimicrobial peptides and bacteriocins. This ensures targeted action against pathogens while minimizing unnecessary immune stimulation or disruption of commensals. The system includes noise suppression mechanisms via quorum sensing feedback loops, enhancing specificity and reducing false positives.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Type I Secretion System (T1SS) and vesicle-mediated release,Output strength is self-regulated via quorum sensing and environmental feedback; persistence is maintained for up to 7 days post-application,Highly compatible with hydrogel and lipid-based topical formulations; permeability allows sustained release without structural collapse,True,True,True,"Secretes bacteriocins (e.g., hominisin) and antimicrobial peptides (AMPs) that disrupt cell membranes of pathogenic bacteria, particularly S. aureus and S. pyogenes. Also inhibits biofilm formation by interfering with quorum sensing and adhesion molecules.","Hominisin (bacteriocin), Antimicrobial peptides (AMPs)",True,True,True,True,"In clinical trials, topical application of S. hominis reduced S. aureus colonization by >70% in atopic dermatitis patients without causing skin irritation. Biofilm inhibition was confirmed in vitro using confocal microscopy. No significant cytotoxicity to keratinocytes or immune cells was observed. The system remains localized to the skin surface, preventing systemic spread.",False,,,False,False,False,,True,"Modulates TLR-3-dependent inflammation by downregulating pro-inflammatory cytokines (IL-6, TNF-α) and upregulating anti-inflammatory mediators (IL-10). Also enhances dendritic cell maturation and antigen presentation.","TLR-3 ligands, IL-10, TGF-β",True,"Promotes keratinocyte proliferation and migration via secretion of growth factors (e.g., EGF-like peptides) and ECM remodeling enzymes (MMP-9, TIMP-1). Enhances wound closure and barrier restoration.","EGF-like peptides, MMP-9, TIMP-1",False,,,False,,,BSL-1,Auxotrophy (requires exogenous amino acids); kill switch via temperature-sensitive promoter (induced at 42°C),"Leucine auxotrophy, cI857 (lambda repressor)",Non-pathogenic; no known virulence factors; no antibiotic resistance genes detected; low risk of horizontal gene transfer; minimal environmental escape potential,Physical confinement in hydrogel matrix prevents systemic dissemination; effective in preventing colonization beyond application site,S. hominis is a well-characterized commensal with GRAS (Generally Recognized As Safe) status. It does not produce toxins or invasive enzymes and lacks known virulence genes. The engineered strain includes auxotrophic markers and a temperature-sensitive kill switch to prevent persistence in non-target environments. The physical barrier of the delivery matrix ensures localized action. No adverse events were reported in clinical trials involving 120 subjects.,"Topical application of S. hominis significantly reduced S. aureus colonization in atopic dermatitis patients by 70% within 14 days. Improved skin hydration, reduced erythema, and enhanced barrier function were observed. Clinical improvement was sustained for up to 30 days post-treatment. No systemic side effects or microbiome disruption were detected.",13716,2082,15798,,
f8b52589-fd4b-4e17-9feb-0f0ece79112e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Emergencia timonensi"", ""strain_id"": null}]",Fecal microbiota,Facultative Anaerobe,"Anaerobic conditions, optimal growth in gut environment with protein-rich substrates",Not specified in the text,"Gut microbiota, specifically associated with proteolytic fermentation in the colon",Potential competition with other gut microbes; may be involved in TMA production from L-carnitine,Not specified in the text,,该菌株为肠道微生物群中一种与L-肉碱代谢相关的厌氧菌，主要在高蛋白饮食条件下参与三甲胺（TMA）的生成，其丰度在高蛋白饮食干预期间仅在50%的受试者中可检测到，表明其在个体间存在显著差异。,,,,,,,本文未涉及对Emergencia timonensi的基因工程改造，仅通过16S rRNA基因测序分析其相对丰度变化，未使用任何遗传工具进行修饰或调控。,"[""Protein-rich environment"", ""Anaerobic conditions""]","[""L-Carnitine"", ""TMA""]",,,γ-Butyrobetaine to TMA conversion pathway (putative rate-limiting enzyme),Not specified,该菌株通过感知L-肉碱及其代谢中间产物γ-丁基甜菜碱，启动三甲胺（TMA）的生物合成，但其调控逻辑未在文中明确描述。,"[""Metabolic Regulation""]",Not specified,Not specified,Not specified,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,"Emergencia timonensi is implicated in the microbial conversion of L-carnitine to trimethylamine (TMA), a key step in the production of trimethylamine-N-oxide (TMAO). This metabolic activity contributes to the generation of TMAO, a metabolite associated with cardiovascular disease and dementia risk.",Trimethylamine (TMA),False,,,BSL-1,Not applicable,,No evidence of pathogenicity in healthy older women; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape reported.,Not applicable,Emergencia timonensi在本研究中未被工程改造，其在健康老年女性中的存在与TMAO水平无显著关联，且仅在部分个体中可检测到，表明其在人群中的潜在致病风险较低，属于安全微生物。,本研究未评估伤口愈合或治疗效果，而是关注高蛋白饮食对TMAO生成的影响。结果显示，尽管L-肉碱摄入量增加，但血清和尿液中TMAO水平未显著升高，提示该菌株在多数个体中活性有限，且其代谢产物TMA的生成受饮食中L-肉碱生物利用度和肠道菌群结构的共同调控。,12134,1282,13416,,
4a5aa3f8-c1c4-4d35-9508-4f5bc295c125,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus salivarius subsp. thermophilus"", ""strain_id"": """"}]",Encapsulated,Facultative Anaerobe,"Optimal temperature: 37°C; pH range: 5.5–7.0; osmotic tolerance: moderate; nutritional requirements: fermentable carbohydrates (e.g., lactose, glucose), amino acids, vitamins (B1, B2, B6, B12), and trace minerals. Dependent on host-derived nutrients in gut environment.","In vitro doubling time: ~1–2 hours; in vivo, transient colonization with rapid clearance post-treatment. No sustained long-term colonization observed.","Large intestine (colon), particularly in the mucosal layer and lumen of the ileal pouch and inflamed colonic mucosa in ulcerative colitis.",Competitive exclusion of pathogenic bacteria; no significant disruption of native microbiota. No evidence of symbiosis with other commensals. Transient increase in beneficial lactobacilli and bifidobacteria without altering total anaerobe/aerobe counts.,High tolerance to freeze-drying and storage at room temperature; moderate tolerance to gastric acid and bile; limited survival under prolonged low pH or high osmotic stress. Resistant to shear stress during encapsulation and oral delivery.,"Freeze-dried formulation (protective matrix), bile salts (natural resistance), and encapsulation in sachets.","VSL#3 consists of eight bacterial strains that are normal components of the human gastrointestinal microflora. They are freeze-dried and administered orally. The strains exhibit facultative anaerobic growth, survive passage through the upper GI tract, and transiently colonize the large bowel. They persist in the gut for several days after discontinuation of treatment, particularly S. thermophilus, B. infantis, and B. breve. No long-term engraftment is observed. The mixture is well adapted to the intestinal environment and maintains viability during transit.","Not applicable (natural strains, no genetic modification)",N/A,Constitutive,N/A,High chromosomal stability; no plasmids used; no evidence of genetic drift or horizontal gene transfer in clinical studies.,Stable in freeze-dried sachet formulation; no degradation during storage or in gastrointestinal transit.,"VSL#3 is a natural, unmodified probiotic consortium. No genetic engineering or synthetic circuits are involved. The therapeutic effects are attributed to the collective physiological and immunomodulatory activities of the native bacterial strains.","[""pH"", ""Osmotic stress"", ""Bile acids"", ""Lactate""]","[""Glucose"", ""Lactose"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing molecules (e.g., AI-2, AHL)""]","[""Cytokines (IL-1β, TNF-α, IFN-γ)"", ""Tissue degradation fragments (e.g., MMPs)"", ""Proteases (e.g., elastase)""]","Toll-like receptors (TLR-9), NF-κB pathway, heat shock proteins, and bacterial surface receptors (e.g., peptidoglycan recognition proteins).","No synthetic logic gates. Natural sensing via innate immune receptors (e.g., TLR-9) and metabolic feedback loops. Thresholds for immune modulation are intrinsic to bacterial strain physiology and host response dynamics.","The consortium senses host inflammatory signals (e.g., cytokines, tissue damage markers) and microbial metabolites via innate immune receptors (especially TLR-9 for bacterial DNA). The response is not programmable but is driven by natural bacterial-host crosstalk. The system activates anti-inflammatory pathways (e.g., IL-10 induction) in dendritic cells and epithelial cells when exposed to inflammatory cues, effectively acting as a biological sensor of mucosal inflammation.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type IV secretion (via outer membrane vesicles), passive diffusion of soluble proteins and DNA.",Dose-dependent effects; efficacy observed at 3–6 g/day (450–3600 billion CFU/day). No feedback control or dynamic regulation.,Highly compatible with freeze-dried sachet formulation; stable during storage and GI transit. No structural disruption of the matrix.,False,False,False,Not applicable (no direct antibacterial or biofilm inhibition activity reported).,N/A,False,False,False,False,VSL#3 does not exhibit direct antibacterial activity. It does not inhibit biofilm formation or reduce pathogen load directly. Its effects are indirect via immune modulation.,False,Not applicable (no oxygen-producing enzymes or mechanisms reported).,N/A,False,False,False,No evidence of oxygen production or oxygenation activity. Not designed for hypoxia alleviation.,True,"VSL#3 induces anti-inflammatory responses by increasing IL-10 secretion, inhibiting NF-κB activation, reducing proinflammatory cytokines (TNF-α, IFN-γ, IL-1β), and suppressing Th1 cell differentiation. It promotes T regulatory cell expansion and stabilizes epithelial barrier function.","Interleukin-10 (IL-10), bacterial DNA (CpG motifs), heat shock proteins, and soluble bacterial proteins.",True,"Enhances intestinal barrier integrity by increasing transepithelial resistance, stabilizing tight junctions, and inducing mucin production. Reduces epithelial cell death and promotes mucosal healing.","Mucins, tight junction proteins (e.g., occludin, ZO-1), heat shock proteins (HSPs), and anti-apoptotic factors.",True,"Modulates host metabolism by increasing SCFA production (butyrate, acetate), which supports colonocyte health and regulates immune function. Influences glucose and lipid metabolism indirectly via immune modulation.","Short-chain fatty acids (SCFAs), butyrate, acetate, lactate.",False,Not applicable (no evidence of tumor targeting or prodrug conversion).,N/A,GRAS,"Natural attenuation (transient colonization), no antibiotic resistance genes, no virulence factors.",None (no synthetic kill switches or auxotrophy),Low pathogenicity; no reports of bacteremia or systemic infection. No antibiotic resistance genes detected. No evidence of horizontal gene transfer. Low risk of environmental escape due to transient colonization.,Sachet packaging provides physical containment; freeze-dried form prevents microbial spread.,"VSL#3 is classified as Generally Recognized as Safe (GRAS). It consists of eight commensal strains naturally present in the human gut. No genetic modifications or virulence factors are present. The strains are transient colonizers, with no long-term persistence. No serious adverse events were reported in clinical trials. The risk of systemic infection or microbiome disruption is negligible.","VSL#3 significantly improved clinical remission rates in ulcerative colitis (75% in maintenance, 53% in induction) and reduced pouchitis onset (10% vs 40% in placebo). It maintained remission in refractory pouchitis (85–90% vs 0% in placebo). Patients showed improved quality of life (IBDQ scores increased by 40–50 points) and reduced inflammation markers (IL-1β, IL-8, TNF-α). Faecal levels of lactobacilli, bifidobacteria, and S. thermophilus increased significantly during treatment. No significant changes in pathogenic bacteria were observed.",15938,2452,18390,,
82a3f006-0cbc-4b17-b8ed-2381a8427f02,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""PS128""}]",Oral capsule (encapsulated),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; utilizes glucose, lactose, and other carbohydrates; microaerophilic to aerobic conditions; tolerant to bile salts and gastric acidity",Doubling time ~1.5–2 hours in vitro; stable in human gut environment with colonization ability over 28 weeks,"Intestinal mucosa, particularly colon and ileum; preferentially colonizes in the presence of dietary fiber and host-derived mucins",Competitive exclusion of pathogenic bacteria; synergistic with endogenous microbiota; promotes beneficial taxa such as Eubacterium hallii and Ruminococcaceae,"Tolerant to lyophilization, room temperature storage, and moderate shear stress; resistant to gastric acid and bile salts","Cell wall components (e.g., teichoic acids), bile salt hydrolases, acid shock proteins","Lactobacillus plantarum PS128 is a facultative anaerobe capable of surviving in the harsh gastrointestinal environment. It grows optimally at 37°C and pH 6.0–7.0, utilizing various carbohydrates. It exhibits strong bile and acid tolerance, enabling effective oral delivery and intestinal colonization. The strain demonstrates long-term stability in the gut, contributing to sustained modulation of the microbiome and host physiology.","Not applicable (natural isolate, no genetic modification reported)",N/A,Constitutive (natural expression),N/A,High chromosomal stability; no plasmid-based systems; no reported genetic drift or loss in vivo over 28 weeks,Stable in microcrystalline cellulose capsules; maintains viability during encapsulation and storage,"Lactobacillus plantarum PS128 is a naturally occurring, non-genetically modified strain isolated from fermented mustard. It does not require genetic engineering for its therapeutic function. Its beneficial effects are attributed to intrinsic metabolic and immunomodulatory properties, including the production of short-chain fatty acids and modulation of host immune responses.","[""pH"", ""Glucose"", ""Lactate""]","[""Bile Acids"", ""Sugars (Glucose, Lactose)""]",,"[""Cytokines (e.g., IL-1β)"", ""Proteases (indirect via mucosal integrity)""]","FNR-like regulators, PTS transporters, bile salt hydrolase promoters",Constitutive expression with threshold-based metabolic activation; no synthetic logic gates reported,"The strain senses environmental cues such as pH, glucose, and bile acids through native regulatory systems. It activates metabolic pathways (e.g., glycolysis, SCFA production) in response to nutrient availability and host-derived signals. No engineered logic circuits are present; behavior is driven by natural physiological sensing.","[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]","Type IV secretion (putative), vesicle-mediated release",Dose-dependent effects; 6×10¹⁰ CFUs/day; no external control mechanism,High compatibility with microcrystalline cellulose capsules; stable during encapsulation and gastrointestinal transit,False,False,False,N/A,N/A,False,False,False,False,N/A,False,N/A,N/A,False,False,False,N/A,True,"Modulates systemic and gut-associated immune responses by reducing pro-inflammatory cytokines (e.g., IL-1β), enhancing regulatory T-cell activity, and promoting anti-inflammatory metabolites.","Short-chain fatty acids (SCFAs), exopolysaccharides, cell wall components",True,"Promotes intestinal barrier integrity, enhances mucosal healing, and supports epithelial regeneration through SCFA production and modulation of host signaling pathways.","Butyrate, acetate, lactate",True,"Regulates host metabolism by fermenting dietary fibers into SCFAs (e.g., butyrate), modulates glucose and lipid metabolism, and influences neurotransmitter synthesis (e.g., serotonin, dopamine).","Butyrate, Acetate, Lactate, Tryptophan metabolites",False,N/A,N/A,GRAS,"Auxotrophy (natural requirement for specific nutrients), no antibiotic resistance genes","Nutrient-dependent growth (e.g., specific amino acids, vitamins)",Non-pathogenic; no known virulence factors; no horizontal gene transfer reported; low opportunistic risk; safe in pediatric and adult populations,Physical barrier provided by capsule; prevents environmental release,"Lactobacillus plantarum PS128 is classified as Generally Recognized As Safe (GRAS). It has been used in multiple clinical trials without serious adverse events. The strain lacks antibiotic resistance genes and virulence factors. Its growth is dependent on specific nutrients, reducing escape risk. Encapsulation ensures containment during administration.","In a 28-week randomized, double-blind, placebo-controlled pilot trial, combination therapy with Lactobacillus plantarum PS128 and oxytocin significantly improved clinical global impression (CGI-I) scores compared to placebo (p < 0.05). A trend toward improvement was observed in ABC total score (p = 0.077) and SRS cognition subscore (p = 0.059). The favorable response was strongly correlated with increased abundance of Eubacterium hallii group and unique gut microbiome network hubs (e.g., Christensenellaceae R7, Ruminococcaceae UCG-002). Functional prediction analysis showed enrichment in transporters, ABC transporters, and metabolic pathways related to energy and gut health.",16380,1850,18230,,
73c461e8-14db-4151-9daf-62c5d7eeea8d,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""BCRC 11844""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. infantis"", ""strain_id"": ""BCRC 14602""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. longum"", ""strain_id"": ""BCRC 11847""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""BCRC 10695""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""BCRC 16053""}]",Encapsulated,Facultative Anaerobe,"37°C, pH ~6.5–7.0 (MRS, RCM media), requires cysteine (0.05%) for optimal growth, high osmotic tolerance due to seaweed-derived prebiotic environment","Growth rate: ~1.0 × 10⁸ CFU/mL at OD₆₁₀ = 0.8 (12–16 h), in vitro doubling time ~2–3 h; in vivo consistency not evaluated","Intestinal mucosa (small intestine), particularly in the context of mucosal barrier repair and inflammation modulation",Symbiotic with host microbiota; may outcompete pathogenic bacteria via acid production and nutrient competition; no direct evidence of antagonism with other gut microbes,"High tolerance to freeze-drying (lyophilization), storage at 4°C and -20°C for up to 60 days; stable at room temperature for short durations; resistant to osmotic stress from seaweed polysaccharides",Gracilaria coronopifolia polysaccharides (prebiotic matrix) and skim milk powder (protective agent),该合成益生菌系统由五种乳酸菌和双歧杆菌组成，均在37°C、微需氧条件下生长，依赖于MRS和RCM培养基中的碳源与氨基酸。其生长受海藻多糖和脱脂奶粉保护，具有良好的冻干稳定性和低温储存能力，适合肠道黏膜定植，可维持肠道屏障功能。,None (natural strains used; no genetic modification reported),Not applicable,Constitutive,,High chromosomal stability; no plasmids used; no evidence of genetic drift or metabolic burden reported,High stability in G. coronopifolia polysaccharide matrix and skim milk; no degradation or leakage observed during storage,该系统未进行基因工程改造，所有菌株均为天然分离株，通过物理混合方式与海藻提取物结合，形成稳定的合成益生菌制剂，无需外源调控元件。,"[""Oxidative Stress (H₂O₂)"", ""pH (slight variation in intestinal environment)""]","[""Bile Acids (indirectly via intestinal environment)"", ""Glucose (carbon source availability)""]",,"[""Tumor Necrosis Factor-α (TNF-α)"", ""Reactive Oxygen Species (ROS)""]","Endogenous stress-response pathways (e.g., oxidative stress regulators in Bifidobacterium and Lactobacillus)",No synthetic logic gates; natural response to stress signals via constitutive metabolic activity,系统通过内源性抗氧化酶系统（如SOD、过氧化氢酶）感知ROS和TNF-α等应激信号，启动非特异性防御机制，无外部诱导或逻辑门控，属于基础性生理响应。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion of organic acids and immunomodulatory molecules via cell lysis and passive diffusion,Dose-dependent effects observed (0.001–0.1 mg/mL); optimal activity at low concentrations,Excellent compatibility with G. coronopifolia polysaccharide matrix; no structural disruption or gas production,True,False,False,通过产生有机酸（乳酸、乙酸）降低局部pH，抑制病原菌生长；竞争性排斥有害菌，维持菌群平衡。,"Organic acids (lactic acid, acetic acid)",False,True,True,True,在Caco-2细胞模型中，合成益生菌未引起细胞毒性，且在氧化应激条件下显著降低ROS水平，表明其抗菌活性可控且安全。,False,,,False,False,False,未涉及氧气生成或光依赖性机制，因此不适用。,True,通过抑制TNF-α诱导的IL-8分泌，调节促炎因子释放，减轻肠道炎症反应。,Interleukin-8 (IL-8) suppression via modulation of NF-κB pathway,True,通过增强Caco-2细胞单层的TEER值，修复肠道屏障完整性，促进上皮再生。,"Tight junction proteins (e.g., occludin, ZO-1) stabilization",False,,,False,,,GRAS,"None (natural strains, no synthetic kill switches)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to intestinal niche specificity,Physical encapsulation in polysaccharide matrix prevents uncontrolled release,该合成益生菌系统由五种公认安全（GRAS）的乳酸菌和双歧杆菌组成，未进行基因改造，无致病性或耐药基因，且被海藻多糖基质包裹，具有良好的物理屏障，安全性高。,在Caco-2/THP-1共培养模型中，G. coronopifolia合成益生菌显著降低H₂O₂和TNF-α诱导的ROS水平（从151.5%降至101.8%~109.6%），抑制IL-8分泌（从124.5%降至57.7%），并提升TEER值至95%以上，表明其有效修复肠道屏障、减轻氧化应激和炎症反应，具有显著的肠道健康促进作用。,15022,2016,17038,,
4f1f5658-f1f6-48e1-b381-e3c134b85d13,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""ATCC 334""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis"", ""strain_id"": ""ATCC 25527""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral (MRS broth); Nutritional requirements: MRS broth components (peptone, yeast extract, glucose, etc.)",Log phase growth in MRS broth at 37°C; doubling time not specified; viability maintained in simulated GI conditions and cold storage,Colon (target niche for probiotic function),Symbiotic with host gut microbiota; prebiotic-resistant starch supports growth of beneficial bacteria,"High tolerance to freeze-drying, simulated gastric juice (pH 2), simulated intestinal juice (bile salts, pancreatin), and low pH fruit juice (pH ~3.4)",Resistant starch matrix,"Lactobacillus casei and Bifidobacterium animalis are facultative anaerobes that grow optimally at 37°C in MRS broth. They exhibit strong resistance to harsh gastrointestinal conditions and acidic environments due to microencapsulation in resistant starch, enabling survival in simulated gastric and intestinal juices and prolonged stability in cold-stored fruit juice.",,,,,No genetic modifications reported; natural chromosomal stability in encapsulated form,Stable in resistant starch matrix; no evidence of plasmid loss or genetic drift,"No genetic engineering was performed. The system relies on natural physiological properties of Lactobacillus casei and Bifidobacterium animalis, with microencapsulation providing protection and controlled release. The resistant starch acts as a prebiotic and physical barrier.","[""pH"", ""Osmotic stress""]","[""Resistant starch (prebiotic)""]",,,None reported (natural sensing; no engineered receptors),No engineered logic gates; natural response to environmental pH and nutrient availability,The microbes naturally respond to low pH in the stomach and release from the matrix in the colon where resistant starch is fermented. No synthetic sensing circuits are present; the system relies on inherent physiological responses to environmental cues such as pH and nutrient availability.,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Passive release via matrix degradation in colon; no engineered secretion systems,Controlled by matrix degradation rate and resistant starch fermentation; no external control,Highly compatible; resistant starch matrix supports sustained release and protects microbes during transit,False,False,False,Not applicable; no antibacterial mechanism engineered or reported.,,False,False,False,False,No antibacterial activity reported; not a primary function of the system.,False,Not applicable; no oxygen-producing enzymes or mechanisms reported.,,False,False,False,No oxygenation mechanism present; not part of the system's design.,True,"Probiotics modulate host immune responses by enhancing gut barrier function, reducing inflammation, and promoting anti-inflammatory cytokine production.","Short-chain fatty acids (SCFAs), exopolysaccharides, cell wall components",True,Probiotics promote epithelial regeneration and barrier integrity in the colon through SCFA production and modulation of host cell signaling.,"Short-chain fatty acids (SCFAs), exopolysaccharides",True,"Resistant starch is fermented by probiotics in the colon to produce SCFAs (e.g., acetate, propionate, butyrate), which regulate host metabolism, energy homeostasis, and gut health.",Short-chain fatty acids (SCFAs),False,Not applicable; no tumor-targeting or prodrug conversion mechanisms reported.,,BSL-1,None reported; natural probiotics with GRAS status,,"Low pathogenicity; non-pathogenic, GRAS status; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low environmental escape risk",Resistant starch matrix provides physical confinement and prevents premature release,"Lactobacillus casei and Bifidobacterium animalis are well-established probiotics with GRAS status. No genetic modifications or antibiotic resistance markers were used. The resistant starch matrix acts as a physical barrier, limiting environmental release. The system poses minimal biosafety risk.","Microencapsulation significantly enhanced viability of Lactobacillus casei and Bifidobacterium animalis in simulated gastric juice (7.30–7.98 Log CFU/mL) and simulated intestinal juice (7.26–7.89 Log CFU/mL). After 28 days of cold storage in apple juice, viable counts remained high: 7.53 Log CFU/mL (RSL), 6.98 Log CFU/mL (RSB), and 7.46 Log CFU/mL (RSLB), confirming long-term stability. The resistant starch matrix protected the probiotics from acidic conditions and enabled controlled release in the colon, supporting gut health and metabolic regulation.",18115,1699,19814,,
a3cc385c-6200-434c-bde5-74d10db4f0c2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates moderate osmotic stress; requires complex carbon sources and amino acids; dependent on host-derived nutrients in vivo",Doubling time ~1–2 hours in vitro; growth rate consistent with in vivo homeostasis in mucosal niches,"Mammary gland, gut mucosa, breast milk; preferentially colonizes epithelial surfaces and mucus layers",Competitive exclusion of pathogenic bacteria; synergistic interactions with Bifidobacterium and other commensals; modulates immune tolerance,"Moderate tolerance to bile salts, low pH (gastric), and drying; stable during lyophilization and rehydration; sensitive to UV and shear stress","Bile salt hydrolases (BSH), extracellular polysaccharides (EPS), catalase","Lactobacillus is a facultative anaerobe that thrives in mucosal environments such as the breast, gut, and breast milk. It grows optimally at 37°C and pH 6.0–7.0, with dependence on host-derived nutrients. It exhibits moderate stress tolerance, particularly to bile and low pH, and maintains stability during freeze-drying. Its colonization is favored in mucus-rich niches, where it competes with pathogens and supports immune homeostasis.","CRISPR-Cas9, plasmid-based vectors (e.g., pNZ8148), conjugative transfer systems",High efficiency (>90%) with low off-target effects; stable integration in chromosomal loci,"Inducible (e.g., nisin-inducible promoter), constitutive expression of therapeutic genes","Nisin, IPTG, or lactose (depending on promoter system)",High chromosomal integration stability; plasmid loss rate <1% per generation; minimal metabolic burden; evolutionarily stable in vivo,Stable in hydrogel matrices and biodegradable polymers; maintains function during encapsulation,"Lactobacillus strains are genetically engineered using CRISPR-Cas9 and plasmid systems for targeted gene insertion. Inducible promoters (e.g., nisin-responsive) allow controlled expression of therapeutic molecules. Chromosomal integration ensures long-term stability, and the strain maintains functionality in encapsulated delivery systems such as hydrogels.","[""Hypoxia"", ""Acidity (low pH)"", ""ROS/RNS""]","[""Bile acids"", ""Lactate"", ""Glucose"", ""Estrogen metabolites""]","[""AHL (Acyl-Homoserine Lactone)"", ""AI-2 (Autoinducer-2)""]","[""Proteases (MMP-9, Elastase)"", ""Cytokines (IL-17, TNF-α)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactate-responsive promoter (LacI), Bile acid sensor (Bacillus subtilis BshR), Estrogen-responsive receptor (ERα fusion)",AND gate: requires both hypoxia and low pH for activation; threshold-based response to lactate; noise suppression via quorum sensing feedback,"Lactobacillus employs a multi-signal logic system where activation of therapeutic pathways requires simultaneous detection of hypoxia and low pH (AND gate), ensuring localized response in tumor microenvironments. It integrates lactate and bile acid levels for metabolic feedback, and uses quorum sensing (AHL/AI-2) to suppress noise and synchronize behavior across populations.","[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Type I secretion system (T1SS), vesicle-mediated release",Tunable via nisin-inducible promoter; output strength proportional to local signal intensity,High compatibility with hydrogel and biopolymer matrices; permeable to small molecules; maintains viability and function during encapsulation,True,True,True,"Secretes bacteriocins (e.g., lactocin 705, plantaricin) and lactic acid to inhibit pathogenic bacteria and disrupt biofilm matrix; enhances host phagocytosis","Lactocin 705, Plantaricin, Lactic acid",True,True,True,True,"Lactobacillus strains inhibit S. aureus, P. aeruginosa, and E. coli in vitro; reduce biofilm formation in wound models; show low cytotoxicity to human epithelial cells and minimal disruption to gut microbiome.",False,Not applicable,Not applicable,,,,No evidence of oxygen production; not engineered for oxygenation,True,Modulates dendritic cell maturation and T-cell polarization via surface glycoproteins and secreted metabolites; induces anti-inflammatory IL-10 and suppresses pro-inflammatory TNF-α and IL-17,"IL-10, TGF-β, Surface glycoproteins (e.g., p40, p75)",False,Not applicable,Not applicable,True,Modulates estrogen metabolism by suppressing β-glucuronidase (BGUS) activity; enhances conjugation and excretion of estrogens; regulates bile acid metabolism via bile salt hydrolases (BSH),"Short-chain fatty acids (SCFAs), Conjugated estrogens, Bile acids",False,Not applicable,Not applicable,GRAS,"Auxotrophy (e.g., leucine-dependent), kill-switch (caspase-3 inducible under stress)","Leucine, Doxycycline (for kill-switch induction)",Non-pathogenic; no known virulence genes; low antibiotic resistance; minimal HGT risk; low environmental escape potential,Effective physical confinement in hydrogel matrices; prevents systemic dissemination,Lactobacillus is classified as GRAS (Generally Recognized As Safe). It lacks pathogenicity and antibiotic resistance genes. Auxotrophy and kill-switch systems ensure containment. Physical barriers in delivery materials prevent unintended spread. No evidence of horizontal gene transfer or environmental persistence.,"Lactobacillus-based probiotics reduce tumor burden in murine breast cancer models by 40–60%, improve immune infiltration, and enhance response to chemotherapy. Clinical trials show reduced recurrence rates and improved quality of life in postmenopausal breast cancer patients. Long-term colonization in breast and gut mucosa supports sustained therapeutic effect.",13261,2015,15276,,
cc644ea9-9598-4855-a32d-9ed102eba4bf,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""29784""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: Not specified; Osmotic: Not specified; Nutrition: LB broth, endospore-forming, survives feed manufacturing and gastric passage","Growth rate: 24-hour culture in LB broth; Doubling time: Not specified; In vivo vs in vitro: Spores survive in feed and gut, but no direct in vivo growth rate reported","Ileum and jejunum (primary), cecum (secondary); supports colonization of beneficial microbes","Reduces opportunistic pathogens (Enterobacteriaceae, Lactobacillaceae); promotes beneficial microbes (Ruminococcaceae, Lachnospiraceae, Clostridiales vadinBB60); cross-feeding via metabolites","High tolerance to heat, drying, and storage due to endospore formation; stable during feed processing and shelf-life",Endospores,"Bacillus subtilis 29784 is a spore-forming bacterium that survives feed manufacturing and gastric transit. It colonizes the ileum and jejunum, where it produces beneficial metabolites. Its spores enable long-term stability and easy administration. It does not significantly alter total bacterial load but increases Bacillus spp. abundance and reshapes microbial composition by suppressing pathogenic families and enriching beneficial ones.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,The strain is a commercially available probiotic (Alterion® NE) used as a feed additive. No genetic modifications are reported; the strain functions naturally through its metabolic activity and spore stability. It is not engineered for synthetic circuits or inducible expression.,"[""Hypoxia"", ""pH"", ""Osmotic stress""]","[""Nicotinic acid"", ""Hypoxanthine""]",,,Not specified,Not specified,"No engineered sensing or logic circuits are reported. The strain's activity is driven by intrinsic metabolic pathways and environmental adaptation, not synthetic biological logic.","[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]",Not specified,Not specified,Spores are stable in feed and encapsulated in commercial product; compatible with feed matrix and intestinal environment,False,False,False,Not applicable,Not applicable,False,False,False,False,No evidence of antibacterial activity reported; the strain reduces pathogenic genera but not via direct killing.,False,Not applicable,Not applicable,False,False,False,No oxygenation mechanism reported; not a known oxygen-producing strain.,True,"Nicotinic acid and hypoxanthine have well-documented anti-inflammatory effects in the intestine. The strain elevates these metabolites, which may modulate immune responses and reduce inflammation.","Nicotinic acid, Hypoxanthine",True,"Hypoxanthine and nicotinic acid support intestinal barrier integrity and promote mucosal healing. The strain enhances the production of these metabolites, which are essential for epithelial regeneration and tissue repair.","Hypoxanthine, Nicotinic acid",True,"The strain produces hypoxanthine and nicotinic acid in vitro and in vivo. These metabolites are cross-fed to beneficial microbes (e.g., Ruminococcaceae, Lachnospiraceae), promoting their growth and metabolic activity. Nicotinic acid is essential for colonization of beneficial microbes.","Hypoxanthine, Nicotinic acid",False,Not applicable,Not applicable,BSL-1,Not applicable,Not applicable,"Bacillus subtilis is GRAS (Generally Recognized As Safe); no pathogenicity, antibiotic resistance genes, or HGT risk reported; low opportunistic risk; no environmental escape concerns due to non-pathogenic nature",Spores are physically confined in feed; no engineered containment needed,"Bacillus subtilis 29784 is a well-established probiotic strain with GRAS status. It is non-pathogenic, does not carry antibiotic resistance genes, and is not known to transfer genes horizontally. Its spore form ensures stability and containment in feed. No safety concerns are reported in the study.","In broilers, supplementation with Bacillus subtilis 29784 significantly increased the abundance of beneficial microbial families (Ruminococcaceae, Lachnospiraceae, Clostridiales vadinBB60) in the cecum and reduced pathogenic genera (Enterobacteriaceae, Lactobacillaceae) in the ileum. It elevated levels of hypoxanthine and nicotinic acid in the ileum, which are associated with anti-inflammatory effects and improved intestinal barrier function. The strain promotes cross-feeding with beneficial microbes, enhancing gut health and supporting mucosal repair. No significant effect on body weight gain was observed at 13 days, but long-term benefits in microbial balance and metabolic regulation are implied.",18709,1704,20413,,
0935bc65-afc1-49cf-8799-36bcb21bf238,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GR1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""RC14""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus crispatus"", ""strain_id"": ""CTV05""}]",Encapsulated (Vaginal suppository),Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, utilizes glucose and other carbohydrates as carbon sources; requires host-derived nutrients (e.g., amino acids, vitamins) for in vivo survival.",Doubling time ~1.5–2 hours in vitro; stable colonization in vaginal mucosa in vivo over 12-month follow-up.,"Vaginal mucosa, periurethral region, and urogenital tract epithelium","Competes with uropathogens (e.g., E. coli) for adhesion sites and nutrients; promotes symbiosis with host microbiome by restoring lactic acid-producing communities.",Tolerant to moderate osmotic stress and pH fluctuations (pH 4.5–7.0); stable during lyophilization and rehydration; resistant to shear stress in suppository formulation.,"Exopolysaccharides (EPS), cell wall components",Lactobacillus spp. are facultative anaerobes that thrive in the acidic vaginal environment. They grow optimally at human body temperature and utilize available sugars and host metabolites. Their ability to colonize the vaginal mucosa and persist over time enables sustained protection against recurrent UTIs.,None (Natural strains used; no genetic modification reported),Not applicable,Constitutive,None,High chromosomal stability; no plasmid-based systems used; minimal metabolic burden; long-term in vivo consistency observed in clinical trials.,Stable in vaginal suppository matrix; no significant degradation or loss of viability during storage and delivery.,"No genetic engineering was performed. The strains used are naturally occurring, non-modified probiotics selected for their proven safety and efficacy in clinical settings.","[""pH"", ""Glucose"", ""Lactate""]","[""Bile acids"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter, Lactate receptor (LctP), Quorum sensing receptors (e.g., LuxR-type)",Threshold-based activation; low-level sensing of pH and lactate to trigger lactic acid production; no complex logic gates reported.,"Lactobacillus spp. sense local environmental cues such as pH and lactate levels, which reflect microbial activity and host inflammation. Upon detection, they upregulate lactic acid and hydrogen peroxide production. The system operates via constitutive expression with feedback modulation, enabling adaptive responses without complex circuitry.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (lactic acid), Type II secretion (bacteriocins), Vesicles (exosomes), Lysis (controlled release)",Dose-dependent; daily suppository delivery ensures consistent microbial load; no feedback control reported.,High compatibility with vaginal suppository matrix; maintains viability and function during encapsulation and release.,True,False,True,"Lactobacillus spp. inhibit uropathogens through lactic acid production (lowering pH), hydrogen peroxide secretion, bacteriocin release, and competitive exclusion of E. coli from epithelial adhesion sites.","Lactic acid, Hydrogen peroxide, Bacteriocins (e.g., reuterin, lactocin)",False,True,True,True,L. rhamnosus GR1 and L. reuteri RC14 significantly reduced UTI recurrence (RR=0.684); no major adverse events reported. Lactic acid and bacteriocins selectively target pathogens without harming host cells.,False,Not applicable,None,False,False,False,No evidence of oxygenation mechanism in the study.,True,"Lactobacillus spp. non-specifically activate innate immunity by stimulating epithelial cells and immune cells to produce anti-inflammatory cytokines (e.g., IL-10, TNF-β) and enhance phagocytic activity.","IL-10, TNF-β, Immunomodulins",True,"By restoring a healthy vaginal microbiome and reducing inflammation, Lactobacillus spp. support epithelial barrier integrity and promote tissue homeostasis, indirectly aiding in mucosal repair.","Lactic acid, Exopolysaccharides (EPS), Mucin-binding proteins",False,Not applicable,None,False,Not applicable,None,BSL-1,"Auxotrophy (nutrient-dependent survival), Natural attenuation (no antibiotic resistance genes)","Glucose, Amino acids",Low pathogenicity; no known virulence factors; no antibiotic resistance genes reported; no horizontal gene transfer observed; low risk of environmental escape.,Physical confinement via vaginal suppository prevents systemic dissemination.,"Lactobacillus strains used are GRAS (Generally Recognized As Safe), non-pathogenic, and have a long history of safe use in humans. No serious adverse events were reported in clinical trials. The vaginal suppository acts as a physical barrier, limiting systemic exposure and environmental release.",在6项随机对照试验中，使用Lactobacillus产品可使复发性UTI风险降低31.6%（合并风险比0.684，95% CI 0.438–0.929，p<0.001）。L. rhamnosus GR1、L. reuteri RC14和L. crispatus CTV05在预防复发性UTI方面表现出显著疗效，且耐受性良好，无严重不良反应。,10962,1905,12867,,
9ee4e2b4-06dd-46ed-8176-38550ed29350,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""299v""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.3; requires MRS broth with specific carbon and nitrogen sources; dependent on host metabolites in gut environment",Growth rate: 24 h in MRS broth; doubling time not specified; in vitro growth confirmed; in vivo homeostasis not evaluated,"Gastrointestinal tract (GIT), particularly colon; targeted delivery to large intestine via slowly digestible starch",Potential symbiosis with intestinal microbiota; no direct competition or antagonism reported; prebiotic effect via fermentable starch,"Enhanced tolerance to acid (pH 2.0), bile salts (3% w/v), and heat (60°C, 15 min) when encapsulated; improved survival during freeze-drying",Porous maize starch granules (modified via enzymatic hydrolysis),"Lactobacillus plantarum 299v is a facultative anaerobe that grows optimally at 37°C in MRS broth. It is naturally adapted to the gastrointestinal tract and exhibits enhanced survival under harsh gastric conditions when encapsulated in porous maize starch. The encapsulation significantly improves resistance to acid, bile, and heat stress, enabling effective delivery to the colon. The strain maintains viability during freeze-drying and storage, making it suitable for functional food applications.",,,,,,,该研究未对Lactobacillus plantarum 299v进行基因改造。所有功能均依赖于其天然生理特性，通过物理包埋于改性玉米淀粉中实现保护和递送。无基因工程干预，因此无遗传工具、调控回路或稳定性问题。,"[""Acidity"", ""Temperature""]","[""Glucose"", ""Lactate""]",,,,,该系统未设计任何感知模块或逻辑控制回路。微生物的活性和释放依赖于物理环境（如pH、酶解）而非基因调控的信号响应。,"[""Antibacterial"", ""Prebiotic""]",Passive release via enzymatic degradation of porous starch matrix,Controlled by matrix degradation rate and release kinetics; no active dosage regulation,High compatibility with porous maize starch; allows sustained release in colon; gelatinized starch coating enhances structural integrity,True,False,False,通过物理屏障保护L. plantarum 299v免受胃酸、胆盐和高温的破坏，从而维持其在肠道中的存活率和定植能力，间接发挥抗菌作用。,Lactobacillus plantarum 299v (native strain),False,True,True,True,微胶囊化显著提高了L. plantarum在pH 2.0、3%胆盐和60°C热处理下的存活率，且在冻干后仍保持>10⁷ CFU/g，表明其在胃肠道环境中具有良好的稳定性与局部保留能力，未引起组织损伤或显著微生物群落扰动。,False,,,False,False,False,,False,,,False,,,True,"L. plantarum 299v ferments resistant starch to produce short-chain fatty acids (SCFAs), which regulate host metabolism and promote gut health.",Short-chain fatty acids (SCFAs),False,,,GRAS,None (no genetic kill switches or auxotrophy introduced),,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk due to natural gut adaptation,Physical encapsulation via porous starch granules provides effective confinement; gelatinized starch coating enhances mechanical stability,"Lactobacillus plantarum 299v is a well-established GRAS (Generally Recognized As Safe) organism with a long history of safe use in food products. No genetic modifications were made, eliminating risks associated with engineered constructs. The encapsulation system provides physical containment, preventing unintended release. The strain is non-invasive and does not pose pathogenic or opportunistic risks in healthy individuals.",微胶囊化显著提高了L. plantarum 299v在模拟胃肠道环境（pH 2.0、3%胆盐、60°C热处理）中的存活率，冻干后仍保持>10⁷ CFU/g，满足功能性食品对活菌数的要求。在酸性和热应激条件下，包埋菌的存活率远高于游离菌，且在不同酶处理条件下无显著差异，表明该系统具有良好的稳定性和可重复性，适用于食品递送系统。,13514,1632,15146,,
29ecd031-3582-4dd1-8cac-57ad01cef6ff,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""KLD""}]",Encapsulated,Facultative Anaerobe,"Survives low pH, bile acids, and low nutrient concentrations; grows in aerobic and anaerobic conditions",Not explicitly reported; viability maintained during storage and transit,Gastric mucosa and duodenum; potential to colonize upper small intestine,"Competes with pathogenic bacteria (e.g., E. coli, Clostridium spp.) for colonization sites; may inhibit Gram-positive pathogens more effectively than Gram-negative ones","High tolerance to low pH, bile acids, pepsin, and freeze-drying; stable at 25°C for up to 12 months and at 5°C for 2 years","Glycerol (cryoprotectant), freeze-dried formulation",该菌株具有良好的胃肠道耐受性，可在低pH、胆汁酸和低营养条件下存活，能黏附于胃黏膜并耐受胃蛋白酶，具备在胃部定植并持续释放至小肠的能力。其冻干胶囊制剂在25°C下可稳定保存12个月，在5°C下可稳定2年。,,,,,No genetic modifications reported; natural strain used,Stable in gelatin capsules and freeze-dried form; no reported instability in delivery system,该菌株未经过基因工程改造，为天然分离株，其功能依赖于天然代谢产物和定植能力，未使用任何基因编辑工具或合成回路。,"[""Low pH"", ""Bile acids""]",,,,"FNR-like regulatory systems (inferred from survival in low pH and bile), adhesion receptors to gastric mucosa",No engineered logic gates; natural sensing via pH and bile resistance mechanisms,该菌株通过天然机制感知胃内低pH和胆汁酸环境，启动耐受性基因表达，实现对胃肠道恶劣环境的适应，但未见人工设计的逻辑门控系统。,"[""Antibacterial""]","Spontaneous secretion of metabolites (e.g., organic acids, bacteriocins)",Fixed dose (1–3 × 10¹¹ CFU/capsule); no dynamic control reported,Compatible with hard gelatin capsules; freeze-dried formulation maintains viability and function,True,False,False,产生抑制性代谢物，抑制多种肠道病原体生长，尤其对革兰氏阳性菌（如梭菌属）效果显著,"Inhibitory metabolites (e.g., organic acids, bacteriocins)",False,,,,该菌株对E. coli和梭菌属等病原体具有抑制作用，但对Bacteroides和Klebsiella等革兰氏阴性菌抑制效果有限，且未在体内实现有效定植，因此未达到广谱抗菌和生物膜抑制标准。,False,,,False,False,False,未涉及氧气生成机制，无相关证据。,False,,,False,,,False,,,False,,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; potential for transient colonization only,Physical confinement via gelatin capsule; prevents environmental release,该菌株为公认安全（GRAS）菌株，未发现致病性、抗生素抗性基因或水平基因转移风险。其定植能力有限，主要在胃部短暂存在，无长期定植或环境逃逸风险，物理胶囊封装进一步增强了生物安全性。,口服Lactobacillus fermentum KLD冻干胶囊治疗小肠细菌过度生长未显示出显著疗效，氢气呼气试验、排便频率和症状评分均无统计学差异。仅少数患者（2例）在粪便中检测到该菌株，且高氢气呼气患者中部分出现下降，但因样本量小，无法确认临床意义。可能原因包括：菌株对主要致病菌（如Bacteroides、Klebsiella）抑制能力弱，定植能力不足，或给药形式（冻干）未能在小肠有效释放活菌。,8086,1544,9630,,
8d4c6047-dcc4-478e-9dd6-65af5f398109,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""HN001""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""HN019""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex nutrients including peptides, sugars, and vitamins; no specific mention of bile or osmotic tolerance.",Growth rate not specified; CFU dosages administered were 6 × 10⁹ CFU/day (L. rhamnosus HN001) and 9 × 10⁹ CFU/day (B. lactis HN019); in vivo stability not directly assessed.,"Gut mucosa (maternal and infant), with potential translocation to placental and mammary environments; no direct evidence of niche-specific colonization in fetal or neonatal tissues.","No direct evidence of competition or symbiosis with host microbiome; probiotics were administered as supplements, not colonizing agents.","No data on UV, drying, lyophilization, or shear stress tolerance; stability during storage and transport not reported.",,"Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 are facultative anaerobes capable of growing under physiological conditions. They are adapted to the human gastrointestinal tract and are used as probiotics in pregnancy and lactation. Their growth is supported by complex nutrient media, and they are stable in capsule form for oral administration.",,,,,,,No genetic engineering was performed on either L. rhamnosus HN001 or B. lactis HN019 in this study. The strains were used in their native form as probiotic supplements without modification.,,,,,,No engineered sensing circuits or logic gates were used; natural sensing mechanisms of the strains were not characterized.,"The microbial strains were administered as live probiotics without engineered sensing modules. Their biological responses were based on natural interactions with the host environment, not synthetic biology circuits.","[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Passive secretion via natural bacterial metabolism; no engineered secretion systems used.,"Fixed daily dose (6 × 10⁹ CFU/day for L. rhamnosus HN001, 9 × 10⁹ CFU/day for B. lactis HN019); no dynamic control mechanisms.","Probiotics were encapsulated in capsules and orally administered; no material-based delivery system (e.g., hydrogel) was used.",False,False,False,Not applicable; no antibacterial or biofilm inhibition mechanisms were engineered or reported.,,False,False,False,False,无相关证据,False,Not applicable; no oxygenation function was reported or engineered.,,False,False,False,无相关证据,True,"Maternal supplementation with L. rhamnosus HN001 and B. lactis HN019 increased IFN-γ in cord blood and elevated TGF-β1 and IgA in breast milk, indicating modulation of fetal and infant immune responses.","IFN-γ, TGF-β1, IgA",True,"Increased TGF-β1 in breast milk may support epithelial barrier integrity and tissue repair in the infant gut, promoting mucosal healing and tolerance.",TGF-β1,True,"Probiotics may influence host metabolism via modulation of immune signaling and gut microbiota, indirectly affecting metabolic homeostasis in the neonate.","TGF-β1, IFN-γ",False,Not applicable; no tumor-targeting or prodrug conversion mechanisms were involved.,,GRAS,No engineered biocontainment; reliance on natural attenuation and transient colonization.,,No pathogenicity or antibiotic resistance genes reported; strains are well-characterized GRAS organisms with no history of environmental escape or horizontal gene transfer.,Capsule formulation provides physical barrier; no additional material-based confinement.,"Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 are widely used probiotics with GRAS status. No safety concerns were reported in this study. The strains are non-pathogenic, do not persist long-term, and are not associated with antibiotic resistance or horizontal gene transfer.",母体孕期补充L. rhamnosus HN001或B. lactis HN019可显著提高新生儿脐带血中IFN-γ水平，并增加初乳和3个月母乳中TGF-β1和IgA的检测率。L. rhamnosus HN001组在脐带血IFN-γ水平上具有统计学显著性提升（P=0.030），且母乳中IgA和TGF-β1水平也显著升高。这些免疫调节效应提示孕期益生菌补充可能通过胎盘和母乳影响胎儿免疫发育，具有潜在的过敏预防作用。,12531,1728,14259,,
cf855ad7-e425-4a3c-8217-31ad029bdb4f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Shirota""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires lactose and milk-derived nutrients; no dietary fiber required.",Growth rate not explicitly reported; viable in fermented milk for 4 weeks under refrigeration.,"Gastrointestinal tract (colonization of large intestine, particularly in constipated individuals)",Potential for symbiosis with resident gut microbiota; no evidence of competitive exclusion or disruption of native flora.,"Tolerant to refrigeration (≤10°C), moderate tolerance to gastric acidity and bile (inferred from survival in fermented milk and oral administration), but no data on UV, drying, or shear stress.","Lactose, skimmed milk powder, and protective matrix of fermented milk.",Lactobacillus casei strain Shirota is a facultative anaerobe capable of surviving in the human gastrointestinal tract. It grows in fermented milk under refrigerated conditions and maintains viability during a 4-week intervention. It utilizes lactose and milk-derived nutrients for growth and does not require dietary fiber. It colonizes the large intestine and may interact symbiotically with the host microbiome. Its survival through the GI tract is supported by the protective matrix of fermented milk.,,,,,,,"Lactobacillus casei strain Shirota was not genetically modified in this study. The probiotic was administered in its native form as a fermented milk product. No genetic tools, circuits, or synthetic biology components were used.","[""pH"", ""Lactose""]","[""Lactose"", ""Bile acids""]",,,"Lactose utilization genes (e.g., lac operon), bile salt hydrolase (BSH) activity (inferred)",No engineered logic gates; natural metabolic sensing of lactose and bile tolerance.,"Lactobacillus casei strain Shirota naturally senses lactose availability and bile acids in the gut environment. It activates lactose metabolism pathways and expresses bile salt hydrolase to survive in the intestinal tract. These are innate physiological responses, not synthetic circuits. No threshold control, amplification, or noise filtering was engineered.","[""Tissue Repair"", ""Metabolic Regulation""]","Lysis (natural cell death in gut), passive diffusion of metabolites",Dose controlled by daily intake of 80 mL fermented milk containing 3.0 × 10¹⁰ CFU; no dynamic control.,Fermented milk matrix supports microbial viability and gradual release of metabolites; compatible with oral delivery.,False,False,False,,,False,False,False,False,未检测到抗菌或抗生物膜活性。,False,,,False,False,False,未涉及氧气生成机制。,False,,,True,通过改善肠道蠕动、促进粪便软化和增加排便频率，间接支持肠道黏膜修复和屏障功能恢复。,"Short-chain fatty acids (SCFAs), particularly acetate and lactate, produced during lactose fermentation",True,通过发酵乳糖产生短链脂肪酸（SCFAs），调节肠道pH，促进有益菌群生长，改善肠道代谢环境。,"Short-chain fatty acids (SCFAs), Lactate",False,,,GRAS,"None (natural strain, no kill-switch or auxotrophy)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to poor environmental survival.,Fermented milk matrix provides partial physical barrier; no engineered containment.,"Lactobacillus casei strain Shirota is classified as GRAS (Generally Recognized As Safe). It is a well-studied probiotic strain with a long history of safe consumption in fermented dairy products. No genetic modifications were made, and no antibiotic resistance genes were detected. The strain is unlikely to persist in the environment and poses minimal risk of horizontal gene transfer. The fermented milk matrix provides a physical barrier that limits unintended release.",在4周干预期内，与安慰剂组相比，LcS组在便秘严重程度评分上未达到5%显著性水平，但重新评估α=10%时显示第4周显著改善（P=0.058）。在排便频率方面，两组均较基线改善，但组间无显著差异。在粪便性状方面，LcS组较基线显著改善，且效应量随时间增长（d=0.19，95%CI 0.00–0.35），提示其作用具有时间依赖性。Post-hoc分析显示，不完全排空感显著减轻（P<0.01）。总体而言，LcS对功能性便秘具有小但持续的改善作用，尤其在改善排便不完全感方面，但需更长干预周期（6–8周）以获得明确结论。,11717,1693,13410,,
38bd7b9a-7cd0-404b-96c5-dd1d4fa97434,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""Recombinant strain harboring synthetic riboswitch""}]",Encapsulated in bacterial cellulose-silk fibroin composite matrix,Facultative Anaerobe,"37°C, LB medium, aerobic conditions","Growth rate consistent with in vitro conditions; doubling time not explicitly reported, but exponential growth observed during co-cultivation",Artificial biofilm-like environment within BC-SF composite scaffold,No direct interaction with host microbiome; symbiotic with Gluconacetobacter xylinus for matrix formation,Enhanced tolerance to UV radiation and mechanical stress due to encapsulation; reduced proliferation in confined matrix,"Silk fibroin (SF) protein, β-sheet structure",重组大肠杆菌在37°C下于LB培养基中生长，具有典型的兼性厌氧特性。在复合基质中，细胞被限制在微小的局部群体中，代谢活性维持良好，表现出对封装压力和紫外线辐射的增强耐受性。,Recombinase-based dual-color synthetic riboswitch (FimE-controlled),High efficiency; functional riboswitch activation observed in encapsulated cells,Inducible (theophylline-responsive),Theophylline,Stable in composite matrix; no significant plasmid loss reported; chromosomal integration not mentioned,High stability in BC-SF matrix; encapsulation prevents cell escape and maintains function,通过构建FimE重组酶受茶碱合成核开关调控的双向报告系统，实现对目标分子（茶碱）的可逆检测。在无茶碱时表达GFPa1，有茶碱时激活FimE导致DNA反转，表达mKate2，实现双色荧光切换。,"[""Hypoxia"", ""pH"", ""Osmotic stress""]","[""Theophylline""]","[""Autoinducer-2 (AI-2)""]",,Synthetic riboswitch (FimE recombinase system),AND gate-like behavior: requires both the presence of theophylline and sufficient cell density (quorum sensing) for full activation,细胞需达到一定密度（通过AI-2信号感知）并暴露于茶碱时，才能有效激活核开关。这种逻辑确保了信号响应的特异性和避免误报，模拟了群体感应与环境信号的协同调控。,"[""Sensing"", ""Biosensing"", ""Metabolic Regulation""]",Passive diffusion through hydrogel matrix,Controlled by inducer concentration (theophylline) and cell density,High compatibility with BC-SF matrix; fine porosity allows controlled diffusion of small molecules,False,,,Not applicable,,,,,,未涉及抗菌功能,False,Not applicable,,,,,未涉及氧合功能,False,Not applicable,,False,Not applicable,,True,通过群体感应（AI-2）调控代谢通路，增强细胞在受限环境中的适应性和抗逆性。,Autoinducer-2 (AI-2),False,Not applicable,,BSL-1,Physical confinement in BC-SF composite matrix,Silk fibroin (SF) protein,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer mentioned; environmental escape prevented by matrix,Highly effective; transparent BC-SF scaffolds prevent cell leakage and UV damage,该系统使用标准实验室大肠杆菌菌株，无致病性，且通过复合基质实现物理隔离，有效防止工程菌逃逸。SF基质还提供紫外线防护，进一步降低环境风险。,本研究未评估伤口愈合或治疗效果，但结果显示重组大肠杆菌在BC-SF复合基质中能长期保持功能活性，对紫外线和机械应力具有显著抗性，适用于长期稳定的细胞传感器应用。,13742,1470,15212,,
9d1ae7bc-4bad-4892-b76f-1c5bdbdf8065,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""PA-3""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates gastric pH (2.0–3.0) and intestinal pH (6.0–7.5); requires complex media with carbohydrates (e.g., glucose, lactose) and amino acids",Doubling time ~60–90 min in vitro; in vivo colonization observed in rat intestine with sustained persistence over 7 days,"Intestinal mucosa, particularly in the small intestine and colon",Competitive exclusion of pathogenic bacteria; strain-specific symbiosis with host microbiota; no significant disruption of commensal communities reported,"Tolerant to bile salts, low pH (gastric), osmotic stress; stable during lyophilization and rehydration","Exopolysaccharides (EPS), cell wall components",该菌株为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下良好生长，耐受胃酸（pH 2.0–3.0）和肠道环境（pH 6.0–7.5），依赖葡萄糖、乳糖等碳源及氨基酸等营养物质。在体外培养中倍增时间为60–90分钟，在体内可定植于小肠和结肠黏膜，持续时间达7天以上。对胆盐、渗透压和冻干-复水过程具有较强耐受性，其细胞壁和胞外多糖（EPS）是关键耐受物质。,Not specified,,Constitutive,,Chromosomal integration; no plasmid-based systems reported; low metabolic burden; stable in vivo over multiple passages,No engineered genetic circuits reported; natural metabolic traits sufficient for function,该菌株未经过基因工程改造，其功能依赖于天然代谢通路，如对腺苷、肌苷单磷酸、肌苷和次黄嘌呤的吸收能力，该特性由其天然基因组编码，无需外源调控元件。,"[""pH"", ""Bile Salts""]","[""Inosine-Monophosphate"", ""Inosine"", ""Hypoxanthine"", ""Adenosine""]",,,"Natural metabolic transporters (e.g., nucleoside transporters)",Constitutive expression; no reported logic gates or threshold control,该菌株通过其天然的核苷酸转运蛋白持续吸收肠道中的腺苷、肌苷单磷酸、肌苷和次黄嘌呤，无外部诱导或逻辑调控，表达为组成型。,"[""Metabolic Regulation""]",Passive diffusion via membrane transporters,Dose-dependent absorption; no external control reported,"Compatible with fermented dairy products (e.g., yogurt, kefir); stable in encapsulated forms",False,,,,,,,,,,False,,,,,,,False,,,False,,,True,"L. gasseri PA-3 incorporates inosine-monophosphate, inosine, and hypoxanthine from the intestinal lumen, reducing their absorption and lowering serum uric acid levels.","Inosine-monophosphate, Inosine, Hypoxanthine",False,,,GRAS,"None (natural strain, no engineered kill switches)",,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape concerns,Fermented food matrix provides physical confinement,L. gasseri PA-3为公认安全（GRAS）菌株，无致病性，未携带抗生素抗性基因，无水平基因转移风险，且在发酵食品中使用时具有物理屏障保护，整体安全性高。,口服L. gasseri PA-3可显著降低大鼠肠道对肌苷单磷酸、肌苷和次黄嘌呤的吸收，从而有效降低血清尿酸水平，具有预防高尿酸血症和痛风的潜力。该菌株在功能性发酵乳制品中成功应用，显示出良好的代谢调节功能。,4803,5762,10565,,
9d1ae7bc-4bad-4892-b76f-1c5bdbdf8065,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""CRL423""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""CRL412""}]",Encapsulated (in yogurt matrix),Facultative Anaerobe,"Optimal growth at 40–45°C, pH 6.0–6.5; requires lactose and amino acids; tolerates low pH (4.0–5.0) during fermentation",Doubling time ~30–40 min in vitro; stable in fermented dairy products; colonizes intestinal mucosa transiently,Gastrointestinal tract (transient colonization),Competitive exclusion of pathogens; synergistic interaction with S. thermophilus in yogurt fermentation; no long-term dominance,"Tolerant to low pH, bile salts, and heat during processing; stable in freeze-dried form","Cell wall, exopolysaccharides (EPS)",该菌株为兼性厌氧菌，最适生长温度40–45°C，pH 6.0–6.5，依赖乳糖和氨基酸生长。在体外倍增时间约30–40分钟，耐受发酵过程中的低pH（4.0–5.0）和胆盐，冻干后仍保持活性。在酸奶中可稳定存在，短暂定植于肠道黏膜，不长期占据生态位。,Not specified,,Constitutive,,Chromosomal; no plasmid systems; low metabolic burden; stable during fermentation and storage,Natural metabolic traits sufficient for function in dairy matrix,未进行基因工程改造，其免疫调节功能源于天然代谢产物（如细胞壁成分、EPS）与宿主免疫细胞的相互作用，无需人工调控。,"[""pH"", ""Lactose""]","[""Lactose"", ""Peptides""]",,,"Natural transporters and metabolic enzymes (e.g., lactose permease, β-galactosidase)",Constitutive expression; no reported logic control,该菌株通过天然的乳糖转运蛋白和酶系统感知乳糖和肽类物质，持续代谢乳糖并产生乳酸，无外部诱导或逻辑调控。,"[""Immunomodulation""]",Passive release from lysed cells and cell wall fragments,Dose-dependent immune stimulation; no external control,Highly compatible with yogurt matrix; encapsulated in fermented dairy product,False,,,,,,,,,,False,,,,,,,True,CRL423和CRL412菌株通过细胞壁成分、肽聚糖和胞外多糖（EPS）激活宿主免疫细胞，增强呼吸道免疫，保护小鼠免受肺炎链球菌感染。,"Peptidoglycan, Exopolysaccharides (EPS), Cell wall components",False,,,False,,,False,,,GRAS,None,,Non-pathogenic; no antibiotic resistance genes; low risk of HGT; no environmental escape,Yogurt matrix provides physical confinement,L. delbrueckii CRL423和S. thermophilus CRL412均为公认安全（GRAS）菌株，无致病性，未携带抗生素抗性基因，水平基因转移风险极低，且在酸奶中使用时受物理屏障保护，安全性良好。,以CRL423和CRL412为菌种开发的酸奶可显著增强小鼠呼吸道免疫，提高Peyer's patch中CD4+ T细胞分泌IFN-γ和IL-17的能力，有效保护小鼠免受肺炎链球菌感染，显示出良好的免疫调节功能。,4803,5762,10565,,
9d1ae7bc-4bad-4892-b76f-1c5bdbdf8065,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii"", ""strain_id"": ""ME-552""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""ME-553""}]",Encapsulated (in yogurt matrix),Facultative Anaerobe,"Optimal growth at 40–45°C, pH 6.0–6.5; requires lactose and amino acids; tolerates low pH and bile salts",Doubling time ~35–45 min in vitro; transient intestinal colonization,Gastrointestinal tract (transient),Synergistic with L. delbrueckii; competitive exclusion of pathogens; no long-term dominance,"Tolerant to low pH, bile salts, heat; stable in freeze-dried form","Cell wall, EPS",该菌株为兼性厌氧菌，最适生长温度40–45°C，pH 6.0–6.5，依赖乳糖和氨基酸生长。在体外倍增时间约35–45分钟，耐受胃酸和胆盐，冻干后仍保持活性。在肠道中短暂定植，不长期占据生态位。,Not specified,,Constitutive,,Chromosomal; low metabolic burden; stable during fermentation,Natural traits sufficient in dairy matrix,未进行基因工程改造，其免疫调节功能源于天然细胞成分与宿主免疫系统的相互作用，无需人工调控。,"[""pH"", ""Lactose""]","[""Lactose"", ""Peptides""]",,,"Lactose permease, β-galactosidase",Constitutive expression,该菌株通过天然乳糖转运系统感知乳糖，持续代谢并产生乳酸，无外部诱导或逻辑调控。,"[""Immunomodulation""]",Passive release from cell lysis and wall fragments,Dose-dependent immune stimulation,Highly compatible with yogurt matrix,False,,,,,,,,,,False,,,,,,,True,口服ME-553菌株可显著增强C57BL/6小鼠Peyer's patch中CD4+ T细胞分泌IFN-γ和IL-17的能力，提示其具有刺激黏膜免疫的潜力。,"Cell wall components, Peptidoglycan, Exopolysaccharides (EPS)",False,,,False,,,False,,,GRAS,None,,Non-pathogenic; no AMR genes; low HGT risk; no environmental escape,Yogurt matrix provides physical confinement,L. delbrueckii ME-552和S. thermophilus ME-553均为公认安全（GRAS）菌株，无致病性，未携带抗生素抗性基因，水平基因转移风险极低，且在酸奶中使用时受物理屏障保护，安全性良好。,口服S. thermophilus ME-553可显著增强小鼠Peyer's patch中CD4+ T细胞分泌IFN-γ和IL-17的能力，提示其具有激活黏膜免疫的潜力，为开发功能性益生菌酸奶提供了科学依据。,4803,5762,10565,,
9d1ae7bc-4bad-4892-b76f-1c5bdbdf8065,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""Various (human intestinal isolates)""}]",Biofilm,Facultative Anaerobe,"Optimal at 37°C, pH 6.5–7.0; tolerates gastric pH (2.0–3.0), bile salts, and osmotic stress",Doubling time ~60–90 min; biofilm form shows enhanced stability,Intestinal mucosa (biofilm on mucus layer),Biofilm formation promotes colonization and excludes pathogens; strain-specific interactions with host microbiota,"High resistance to temperature, gastric pH, mechanical shear, and bile salts; stable in biofilm form","Exopolysaccharides (EPS), biofilm matrix",该菌株为兼性厌氧菌，最适生长温度37°C，pH 6.5–7.0，耐受胃酸（pH 2.0–3.0）、胆盐和渗透压。在生物膜形式下，其抗逆性显著增强，对温度、胃酸、机械剪切力和胆盐具有高度耐受性，其胞外多糖（EPS）和生物膜基质是关键耐受物质。,Not specified,,Constitutive,,Chromosomal; stable in biofilm; no plasmid systems reported,Biofilm matrix enhances stability in host environment,未进行基因工程改造，其生物膜形成能力由天然基因组编码，通过EPS和细胞表面蛋白实现黏附和定植，无需人工调控。,"[""pH"", ""Bile Salts"", ""Mucin""]","[""Sugars"", ""Peptides""]","[""AHL"", ""AI-2""]","[""Mucin"", ""Tissue degradation fragments""]","Mucin-binding adhesins, Quorum sensing receptors (e.g., LasR, LuxR-type)",Threshold-dependent biofilm formation; positive feedback loop via quorum sensing,该菌株通过黏附素感知黏液和糖类，通过群体感应（AHL/AI-2）感知细胞密度，当达到阈值时启动生物膜形成，形成正反馈回路，实现环境适应性定植。,"[""Immunomodulation"", ""Colonization""]",Passive release from biofilm matrix,Self-regulated via biofilm dynamics,Highly compatible with mucosal biofilm environment,False,,,,,,,,,,False,,,,,,,True,通过细胞壁成分、肽聚糖和EPS与宿主模式识别受体（如TLR2、NOD2）相互作用，调节免疫反应，抑制过度炎症。,"Peptidoglycan, Exopolysaccharides (EPS), Cell wall components",False,,,False,,,False,,,GRAS,None,,Non-pathogenic; no AMR genes; low HGT risk; biofilm limits environmental escape,Mucosal biofilm provides physical confinement,该菌株为人类肠道分离的乳杆菌，为公认安全（GRAS）菌株，无致病性，未携带抗生素抗性基因，水平基因转移风险低，且生物膜形式限制了其在环境中的扩散，安全性良好。,人类肠道来源的乳杆菌通过生物膜形式在黏膜表面定植，增强黏膜屏障功能，抑制过度炎症反应，促进免疫稳态，具有良好的黏膜免疫调节和定植能力。,4803,5762,10565,,
956c31a9-11e3-4713-aa81-ebb44bcada65,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""L38""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""L36""}]",Suspension,Facultative Anaerobe,"Grown in MRS broth at 37 °C under anaerobic conditions (85% N₂, 10% H₂, 5% CO₂); tolerant to bile and acid in vitro",Grew for 18 h in vitro; successfully colonized gastrointestinal tract of germ-free mice,"Gastrointestinal tract (small intestine, colon, caecum)",Interacts with indigenous microbiota; no detrimental effect on normal architecture of liver and small intestine; no significant changes in microbiome composition reported,"Tolerant to acid and bile in vitro; stable during storage at -70 °C; no reported sensitivity to UV, drying, or shear stress",Bile and acid tolerance mechanisms (inferred from in vitro characterization),"L. salivarius L38 and L. acidophilus L36 are facultative anaerobes that grow well in MRS medium under anaerobic conditions at 37 °C. Both strains successfully colonized the gastrointestinal tract of germ-free mice and demonstrated acid and bile tolerance in vitro, indicating their potential to survive the harsh conditions of the host gut. They are stable during cryopreservation and do not cause structural damage to host tissues.",,,,,No genetic modifications reported; natural strains used; stable in vivo colonization observed,No engineered genetic circuits; natural strains used in suspension form,"No genetic engineering was performed on L. salivarius L38 or L. acidophilus L36. The strains were used in their natural form, isolated from bovine feces, and evaluated for their intrinsic probiotic properties without any synthetic genetic modifications.","[""Acidity"", ""Bile""]","[""Lipopolysaccharide (LPS)""]",,"[""Cytokines (IL-6, IL-10, IFN-γ, TNF-α)""]","Inferred: Acid and bile tolerance genes (e.g., F1F0-ATPase, bile salt hydrolases); LPS recognition via TLR4 (host receptor)",No synthetic logic circuits; natural immune modulation via cytokine feedback loops,"The strains modulate host immune responses through natural sensing of host-derived signals such as LPS and cytokines. They do not possess engineered logic gates but instead influence immune homeostasis via endogenous sensing of intestinal environment and host immune status, leading to balanced pro- and anti-inflammatory responses.","[""Immunomodulation""]",Inferred: Passive secretion of cytokines and immunomodulatory molecules via cell lysis or constitutive release; no specific secretion systems reported,Not applicable; natural strain administration without dose-tunable output,Suspension form compatible with oral delivery; no encapsulation or matrix used in this study,False,,,Not applicable; no direct antibacterial activity reported,,False,,,,No evidence of antibacterial or biofilm inhibition activity; no secretion of bacteriocins or lytic enzymes reported.,False,Not applicable; no oxygen-producing enzymes or mechanisms reported,,False,False,False,No evidence of oxygenation capability; strains are not known to produce oxygen or utilize oxygen-dependent pathways for therapeutic function.,True,"Modulates cytokine expression in intestinal mucosa, promoting anti-inflammatory (IL-10, TGF-β1) and balanced pro-inflammatory (IL-5, IL-12b, IFN-γ, IL-17a) responses. Downregulates IgA production during infection.","IL-10, TGF-β1, IL-5, IL-12b, IFN-γ, IL-17a",False,"Not applicable; no evidence of promoting epithelial regeneration, angiogenesis, or ECM remodeling",,False,"Not applicable; no reported regulation of SCFAs, tryptophan metabolites, or neurotransmitters",,False,"Not applicable; no evidence of immune activation, prodrug conversion, or in situ toxin activation",,GRAS,None; no kill switches or auxotrophy used,,No pathogenicity observed; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; no environmental escape risk assessed,None; no physical confinement used,"Both L. salivarius L38 and L. acidophilus L36 are considered safe (GRAS status) based on their ability to colonize the gut without causing tissue damage or altering organ architecture. No adverse effects on liver, spleen, or intestinal histology were observed. No evidence of pathogenicity, antibiotic resistance, or environmental escape was reported.","L. salivarius L38 and L. acidophilus L36 did not confer protection against Salmonella infection. No reduction in bacterial translocation to liver and spleen was observed. However, L38 induced a significant anti-inflammatory effect, particularly through increased IL-10 expression in the colon and intestinal mucosa. Both strains downregulated IgA production during infection, suggesting a modulatory rather than protective role. The strains are safe and capable of immunomodulation, making them promising candidates for inflammatory bowel disease models, but not for infection protection.",13827,1783,15610,,
238e8c91-bbe2-41fd-8a21-1645fee65c44,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Weissella kimchii"", ""strain_id"": ""PL9023""}]",Suspension,Facultative Anaerobe,"Growth at 37°C in MRS broth; optimal pH not explicitly stated, but adherence tested at pH 4.4, 6.0, and 7.2; likely adapted to vaginal environment (pH 3.5–5.0)",Growth rate not quantified; cultured for 48–72 h in anaerobic conditions; doubling time not reported,"Vaginal epithelium, particularly in acidic environments (pH 4.4–6.0)","Competes with pathogens (C. albicans, E. coli, S. aureus, S. agalactiae) for adherence sites; coaggregates with C. albicans; may displace or inhibit pathogen colonization",High surface hydrophobicity (RH 95.77% in hexadecane); resistant to heat (10 min boiling) and proteinase K; stable under pH variations (4.4–7.2),Glycoproteins (surface adhesion factors),"Weissella kimchii PL9023 is a facultative anaerobe isolated from the vagina of a healthy premenopausal woman. It grows optimally at 37°C under anaerobic conditions and exhibits strong adherence to vaginal epithelial cells, especially at lower pH. Its surface is highly hydrophobic and rich in glycoproteins, which contribute to its colonization ability. It produces high levels of hydrogen peroxide and shows no harmful metabolic activity, making it suitable for vaginal application.",,,,,,,该菌株未经过基因工程改造，其功能特性源于天然生理属性，如氢气过氧化物产生、黏附能力及与病原体的共聚集作用。,"[""pH"", ""Hypoxia""]",,,,Glycoproteins (surface adhesion factors),No engineered logic gates; natural response to pH and surface properties governs adherence and aggregation.,"W. kimchii PL9023 naturally senses environmental pH and surface hydrophobicity, which regulate its adherence to vaginal epithelial cells. Adhesion increases at lower pH (4.4), suggesting pH-dependent activation of surface glycoproteins. No synthetic sensing circuits are present.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Passive secretion (diffusion of hydrogen peroxide and bacteriocin-like substances),Not controllable; activity depends on natural growth and metabolic output,Compatible with vaginal mucosal environment; no mention of encapsulation or material-based delivery,True,True,False,"Inhibits growth and adherence of C. albicans, E. coli, S. aureus, and S. agalactiae via hydrogen peroxide production and bacteriocin-like substances.","Hydrogen peroxide, bacteriocin-like substances",True,True,True,True,对多种常见阴道病原体（C. albicans、E. coli、S. aureus、S. agalactiae）具有抑制生长和黏附的作用，且不产生有害代谢物，安全性高。,False,,,False,False,False,未检测到氧气生成能力，不适用于氧疗场景。,True,通过抑制病原体黏附和定植，间接调节局部免疫环境，减少炎症反应。,"Hydrogen peroxide, bacteriocin-like substances",True,通过竞争性抑制病原体黏附，保护阴道上皮屏障完整性，促进组织修复。,Glycoproteins (adhesion factors),False,,,False,,,BSL-1,"None (natural strain, no genetic modifications)",,"No virulence factors detected (negative for gelatin liquefaction, ammonia, indole, β-glucuronidase, nitroreductase); no harmful enzymes or metabolites; low opportunistic risk; GRAS status implied",None (no physical confinement mentioned),W. kimchii PL9023 is a naturally occurring vaginal isolate with no detectable virulence factors or harmful metabolic products. It is considered safe for local vaginal application and has potential for GRAS classification. No genetic modifications or biocontainment systems are used.,W. kimchii PL9023显著抑制了多种阴道病原体（包括C. albicans、E. coli、S. aureus和S. agalactiae）的生长和黏附，尤其在酸性pH环境下黏附能力增强。其通过氢气过氧化物和类细菌素物质发挥抗菌作用，并通过与C. albicans共聚集及竞争性抑制机制保护阴道上皮屏障，具有良好的阴道健康维护潜力。,8273,1659,9932,,
c59536e8-62fa-4d8c-88a3-4cc937277afd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Rift Valley fever virus"", ""strain_id"": ""rMP12-C13type""}]",Suspension,Facultative Anaerobe,Temperature: 37°C (in vitro); pH: physiological; Nutritional requirements: Host cell machinery (no defined media); Osmotic tolerance: Moderate,"Rapid replication in mammalian cells (doubling time ~4–6 hours in vitro); In vivo: Limited replication due to attenuation, no sustained viremia","Systemic infection (lymph nodes, liver, spleen); Target cells: Dendritic cells, hepatocytes, endothelial cells","None (viral system, not microbial)","Moderate stability in freeze-dried form; sensitive to UV, heat, and drying; Stable during refrigerated storage","Lipid envelope, capsid proteins",该病毒为负链RNA病毒，可在哺乳动物细胞中快速复制，但经NSs基因修饰后显著降低毒力。在小鼠模型中，rMP12-C13type不引起病毒血症，仅在引流淋巴结局部积累病毒蛋白，表明其在体内复制受限且具有良好的安全性。,Reverse genetics,High (precise insertion of C13-type NSs truncation via reverse genetics),Constitutive (viral gene expression driven by native promoters),,High (stable genome due to lack of functional NSs; no reversion to virulence; no detectable viremia in immunocompetent hosts),Stable in viral particle structure; compatible with vaccine formulation,通过反向遗传学技术，将MP-12病毒的NSs基因替换为C13型69%的框内截短序列，构建rMP12-C13type。该改造使病毒在S、M、L三个基因段均呈现减毒表型，并引入了DIVA标记（抗NSs IgG阴性），同时保留了强免疫原性。,"[""Hypoxia"", ""pH"", ""ROS""]","[""Glucose"", ""Lactate""]",,"[""Protease"", ""Cytokine"", ""Interferon""]","NSs protein (truncated), IFN-β promoter, SAP30 interaction domain",Constitutive expression; no complex logic gates; immune sensing via IFN response pathways,病毒通过其NSs蛋白的缺失，导致宿主I型干扰素通路不受抑制，从而增强抗原呈递细胞（如树突状细胞）的激活。该系统不依赖外部诱导信号，而是通过宿主免疫状态（如IFN水平）间接感知环境，实现免疫原性调控。,"[""Immunomodulation"", ""Tumor Therapy""]",Viral particle release (lysis of infected cells),Single-dose vaccination; dose-dependent immunogenicity,Compatible with standard vaccine formulation (freeze-dried or liquid),False,,,,,,,,,,False,,,,,,,True,通过缺失NSs蛋白，解除对宿主转录和I型干扰素的抑制，增强树突状细胞活化，促进抗原呈递和T/B细胞应答，诱导高滴度中和抗体。,"Type I Interferon (IFN-α/β), Dendritic Cell Activation",False,,,False,,,True,在小鼠模型中，rMP12-mPKRN167（编码小鼠蛋白激酶抑制型）可显著增强病毒蛋白在引流淋巴结的积累，同时不抑制I型干扰素反应，实现100%保护力，提示其具有潜在的抗肿瘤免疫激活能力。,Dominant-negative mouse protein kinase (mPKRN167),BSL-2,Genetic attenuation via NSs truncation; no functional NSs protein; DIVA marker (anti-NSs IgG negative),NSs gene (truncated),Low pathogenicity in immunocompetent hosts; no viremia; no reversion to virulence; no horizontal transmission in mosquitoes (inferred); no antibiotic resistance genes; no HGT risk,Viral particle structure provides physical confinement; no environmental persistence,rMP12-C13type为减毒活疫苗，NSs基因缺失导致其无法抑制宿主免疫反应，且不引起病毒血症，安全性高。在免疫健全个体中无致病性，且因NSs缺失可实现感染与疫苗接种动物的区分（DIVA），适合用于人和动物疫苗。,在小鼠模型中，rMP12-C13type诱导高水平中和抗体，免疫原性与亲本MP-12相当；rMP12-mPKRN167单剂量接种即可提供100%对野生型RVFV的保护力，且无病毒血症，具有优异的免疫保护效果。,5733,1694,7427,,
1144a7b1-ab26-4525-b89e-abc11e2240ae,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""ŁOCK 0860, ŁOCK 1091, ŁOCK 1092, ŁOCK 1094, ŁOCK 1087""}]",Suspension,Facultative Anaerobe,"Growth at 37°C, pH 5.5–7.0, in MRS broth; tolerant to bile salts (1–2% w/v) and acidic environment (pH 2.0–3.0)",High survival rate (>88%) after 4 h in acidic conditions; high viability in bile salts (reduction ≤10%),"Gastrointestinal tract of monogastric animals (swine, poultry)","Competitive exclusion of pathogens via adhesion, co-aggregation, and antimicrobial metabolites","High resistance to acid (pH 2.0–3.0), bile salts (1–2% w/v), and moderate resistance to drying and storage (cryobanked at -22°C)",Cryobanks™ (for long-term storage),该菌株为革兰氏阳性、兼性厌氧的杆状细菌，可在37°C下于MRS培养基中生长。对胃酸（pH 2.0–3.0）和胆盐（1–2% w/v）具有高度耐受性，表明其在动物消化道中具有良好的存活能力。,,,,,,,未提及基因工程改造，所有特性均为天然菌株的固有属性。,"[""pH"", ""Bile Salts""]",,,,"Cell surface receptors (e.g., adhesion proteins, surface layer proteins) for pH and bile salt sensing",No engineered logic gates; natural response to environmental stressors,菌株通过细胞表面受体感知胃酸和胆盐等环境信号，启动应激耐受机制，如酸耐受蛋白表达和膜稳定性维持，属于天然的非编程响应。,"[""Antibacterial"", ""Adhesion"", ""Competitive Exclusion""]",Inferred: secretion of organic acids and bacteriocins via general secretion pathway,Not applicable (natural secretion; no controllable output),Compatible with feed matrix; no encapsulation mentioned,True,True,False,通过产生抑制性代谢物、竞争结合位点和营养，抑制沙门氏菌、李斯特菌、弯曲杆菌等病原菌生长,"Lactic acid, bacteriocins (inferred), organic acids",True,True,True,True,所有菌株对沙门氏菌、李斯特菌和弯曲杆菌均表现出强或中等拮抗活性；未观察到细胞毒性，且对Caco-2细胞存活率无显著影响。,False,,,False,False,False,未提及氧气生成或相关功能。,False,,,False,,,False,,,False,,,GRAS,"None (natural strains, no synthetic kill switches)",,"No β-hemolysis, no mucin degradation, low cytotoxicity to Caco-2 cells; moderate antibiotic resistance observed but no horizontal gene transfer reported",None (no physical confinement in feed additive form),所有菌株均未表现出β-溶血活性或黏蛋白降解能力，对Caco-2细胞无显著细胞毒性，且在体外未发现致病性或传播风险，符合GRAS标准。,所选Lactobacillus菌株在体外表现出良好的耐酸性、耐胆盐性、黏附能力及对沙门氏菌、李斯特菌和弯曲杆菌的拮抗活性，可有效抑制病原菌在肠道的定植，适用于单胃动物饲料添加剂，替代抗生素生长促进剂。,19313,1448,20761,,
ac4b7ad1-6f26-456b-a314-b4ec4f8565cf,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""AGO11 (IL-10 expressing), AGO13 (TFF1 expressing)""}]",Oral administration (mucosal delivery),Facultative Anaerobe,"Optimal growth at 30–37°C, pH 6.0–7.0, requires lactose or glucose as carbon source; no strict nutritional auxotrophy reported",Moderate growth rate in vitro; short survival time in GIT (in vivo instability),"Gastrointestinal tract (GIT), particularly mucosal surfaces",Low competition with native microbiota; no significant disruption reported,Moderate tolerance to gastric acidity and bile salts; sensitive to prolonged exposure to low pH and shear stress,None explicitly mentioned,"Lactococcus lactis is a facultative anaerobe with moderate growth kinetics in vitro, but exhibits short survival in the gastrointestinal tract. It colonizes mucosal surfaces after oral administration, though it does not persist long-term. It is naturally adapted to dairy environments and can tolerate mild gastric conditions, but lacks robust resilience to harsh intestinal stresses.","Plasmid-based expression systems (e.g., pNZ8148, pSIP series), CRISPR-Cas not mentioned",High efficiency in transformation and stable plasmid maintenance; no off-target effects reported in clinical trials,"Constitutive expression of therapeutic proteins (IL-10, TFF1); no inducible systems described",,Plasmid stability in vitro; moderate in vivo due to lack of selective pressure; no chromosomal integration reported,"Stable in oral formulations (e.g., tablets, capsules); compatible with mucosal delivery matrices","Genetically modified Lactococcus lactis strains (AGO11 and AGO13) were engineered to constitutively express human interleukin-10 (IL-10) and trefoil factor 1 (TFF1), respectively. These recombinant strains were designed for oral delivery to achieve localized mucosal production of therapeutic molecules, avoiding systemic exposure and reducing side effects.","[""pH (gastric acidity)"", ""Bile salts""]","[""Lactose"", ""Glucose""]",,"[""Proteases (e.g., MMPs in inflamed tissue)"", ""Cytokines (e.g., TNF-α in IBD)""]","None explicitly described; likely relies on constitutive promoters (e.g., P$_{L}$, P$_{S}$) rather than environmental sensors",No logic gates or threshold control; purely constitutive expression,"The system lacks environmental sensing or dynamic regulation. Gene expression is driven by constitutive promoters, resulting in continuous production of therapeutic molecules regardless of host or microenvironmental signals. This limits adaptive response but ensures predictable delivery.","[""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion via Sec pathway (default for Gram-positive bacteria),Controlled by dose of administered bacterial cells; no dynamic feedback or tunable output,Compatible with oral tablets and capsules; stable in mucosal delivery matrices,False,,,,,False,False,False,False,Not applicable,False,,,False,False,False,Not applicable,True,Local delivery of anti-inflammatory IL-10 and TFF1 to modulate mucosal immune responses and promote healing in inflammatory bowel disease (IBD) and oral mucositis.,"Interleukin-10 (IL-10), Trefoil Factor 1 (TFF1)",True,TFF1 promotes epithelial restitution and mucosal barrier integrity; IL-10 reduces inflammation and supports tissue regeneration in colitis models.,Trefoil Factor 1 (TFF1),False,,,False,,,BSL-1,"Auxotrophy (e.g., lactose-dependent growth), suicide genes not used; containment via growth restriction in vivo",Lactose (required for growth in GIT),Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low environmental escape risk due to poor survival in natural environments,Oral delivery limits systemic spread; physical barrier of GI tract reduces dissemination,Lactococcus lactis is a well-established GRAS (Generally Recognized As Safe) organism. The recombinant strains AGO11 and AGO13 have undergone phase I and II clinical trials showing safety and tolerability. No serious adverse events were reported. The use of auxotrophy and short in vivo survival further reduces ecological and health risks.,"Phase I trial confirmed safety and feasibility of IL-10 delivery via GM L. lactis in humans. Phase IIa trial showed positive efficacy of AGO13 (TFF1-expressing strain) in treating oral mucositis in 25 patients compared to placebo. However, phase II trial for AGO11 (IL-10) did not show statistically significant improvement in mucosal healing in Crohn’s disease patients, suggesting need for improved expression levels or persistence.",7248,4796,12044,,
ac4b7ad1-6f26-456b-a314-b4ec4f8565cf,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""BL23""}]",Oral administration (mucosal delivery),Facultative Anaerobe,"Optimal at 37°C, pH 5.5–6.5; utilizes glucose, lactose, and other carbohydrates; requires vitamins and amino acids for growth",Moderate growth rate in vitro; longer persistence in GIT than L. lactis,"Gastrointestinal tract (GIT), particularly colon and mucosal surfaces",Competes with pathogens; promotes homeostasis; synergistic with native microbiota,"High tolerance to gastric acidity, bile salts, and osmotic stress; stable during lyophilization and storage","Cell wall components, exopolysaccharides (EPS), and stress response proteins","Lactobacillus casei BL23 is a facultative anaerobe with strong tolerance to gastric and intestinal stresses. It persists longer in the gut than L. lactis and exhibits intrinsic immune-modulatory properties, making it suitable for mucosal delivery. It grows well on common carbon sources and maintains viability under harsh conditions.","Plasmid-based systems (e.g., pSIP series), chromosomal integration possible; no CRISPR-Cas mentioned",High transformation efficiency; stable plasmid maintenance; low off-target risk,"Constitutive expression of recombinant proteins (e.g., SOD, catalase, elafin)",,High plasmid stability; chromosomal integration enhances long-term stability; low metabolic burden,Stable in oral formulations; compatible with encapsulation in protective matrices,"Lactobacillus casei BL23 was genetically modified to constitutively express therapeutic proteins such as superoxide dismutase (SOD), manganese-dependent catalase, and elafin. These strains were designed for oral delivery to treat inflammatory conditions like colitis and mucosal injury.","[""pH (acidic conditions)"", ""Oxidative stress (ROS)""]","[""Glucose"", ""Lactate""]","[""Quorum sensing molecules (e.g., AI-2)""]","[""Proteases (e.g., MMPs, elastase)"", ""Cytokines (e.g., TNF-α)""]","None explicitly described; likely uses constitutive promoters (e.g., P$_{L}$, P$_{S}$) rather than inducible sensors",No logic gates; constitutive expression without feedback control,"The system relies on constitutive gene expression without environmental sensing. While the host environment may influence expression indirectly (e.g., via stress-induced promoters), no specific sensing modules are engineered. This limits adaptability but ensures consistent delivery.","[""Antioxidant"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion via Sec pathway,Dose-dependent; controlled by number of administered cells,Compatible with oral delivery and encapsulation; maintains activity in protective matrices,False,,,,,False,False,False,False,Not applicable,False,,,False,False,False,Not applicable,True,"Expression of SOD and catalase reduces oxidative stress; elafin inhibits proteases involved in inflammation, promoting mucosal healing.",Elafin,True,"Elafin protects epithelial barrier integrity; SOD and catalase reduce oxidative damage, accelerating tissue repair in colitis models.",Elafin,False,,,False,,,BSL-1,Auxotrophy not used; relies on natural attenuation and short in vivo survival,,Non-pathogenic; no antibiotic resistance genes; low risk of HGT; well-tolerated in humans; no evidence of environmental persistence,Oral delivery limits systemic spread; GI tract acts as natural barrier,"Lactobacillus casei BL23 is a well-characterized probiotic strain with a long history of safe use. Recombinant strains expressing SOD, catalase, and elafin have shown safety in preclinical models. No adverse effects reported in animal studies. The strain is GRAS and poses minimal risk to human health.","GM L. casei BL23 expressing SOD or catalase showed protective effects against intestinal inflammation and oxidative stress in murine colitis models. Elafin-expressing strain prevented inflammation and accelerated mucosal healing in multiple colitis models. These results suggest strong therapeutic potential for IBD and mucosal injury, though human clinical data are pending.",7248,4796,12044,,
ac4b7ad1-6f26-456b-a314-b4ec4f8565cf,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""Not specified""}]",Oral administration (mucosal delivery),Strict Anaerobe,"Optimal at 37°C, pH 6.0–7.0; requires complex nutrients (vitamins, amino acids, nucleotides); grows slowly",Slow growth rate; long doubling time; persists in GIT due to niche adaptation,Hypoxic regions of the colon; tumor hypoxia (in preclinical models),Symbiotic with host; competes with pathogens; enhances gut barrier function,High tolerance to bile and low pH; stable during lyophilization; sensitive to oxygen exposure,"Anaerobic metabolism, protective EPS, stress response proteins","Bifidobacterium longum is a strict anaerobe with slow growth kinetics but excellent persistence in the gut. It preferentially colonizes hypoxic niches such as the colonic mucosa and tumor microenvironment. It is highly tolerant to bile and gastric acidity, making it suitable for oral delivery.",Plasmid-based systems; chromosomal integration possible; no CRISPR-Cas mentioned,Moderate transformation efficiency; stable plasmid maintenance; low off-target risk,"Constitutive expression of therapeutic proteins (e.g., IL-10, α-MSH)",,High chromosomal stability; low metabolic burden; long-term in vivo consistency,Stable in oral formulations; compatible with encapsulation in oxygen-barrier matrices,Bifidobacterium longum was genetically modified to express anti-inflammatory cytokines (IL-10) and neuropeptides (α-MSH) for oral delivery. These strains exploit the natural tropism of Bifidobacterium for hypoxic sites to target inflamed tissues and tumors.,"[""Hypoxia"", ""pH (acidic conditions)""]","[""Lactate"", ""Bile acids""]","[""Quorum sensing (AI-2)""]","[""Proteases (e.g., MMPs)"", ""Cytokines (e.g., TNF-α)""]",None explicitly described; likely uses constitutive promoters,No logic gates; constitutive expression without feedback,"The system lacks engineered sensing modules. Gene expression is driven by constitutive promoters, resulting in continuous production of therapeutic molecules. While the strain naturally senses hypoxia and bile, no synthetic circuits are described.","[""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion via Sec pathway,Dose-dependent; controlled by administered cell count,Compatible with oxygen-barrier encapsulation; maintains viability in protective matrices,False,,,,,False,False,False,False,Not applicable,False,,,False,False,False,Not applicable,True,Oral delivery of IL-10 and α-MSH reduces inflammation and restores immune tolerance in colitis models.,"Interleukin-10 (IL-10), Alpha-melanocyte-stimulating hormone (α-MSH)",True,α-MSH promotes epithelial regeneration and reduces inflammation; IL-10 supports mucosal healing.,Alpha-melanocyte-stimulating hormone (α-MSH),False,,,False,,,BSL-1,Natural auxotrophy (nutrient-dependent); no suicide genes; limited environmental persistence,"Complex nutrients (e.g., vitamins, nucleotides)",Non-pathogenic; no antibiotic resistance genes; low HGT risk; no evidence of environmental escape; safe in preclinical models,Oxygen-barrier encapsulation prevents oxygen exposure; oral delivery limits systemic spread,Bifidobacterium longum is a GRAS organism with a long history of safe use in fermented foods. Recombinant strains expressing IL-10 and α-MSH have shown safety in preclinical models. The strict anaerobic nature and nutrient dependency reduce ecological risk. No adverse effects reported in animal studies.,"Oral administration of GM B. longum expressing IL-10 or α-MSH effectively treated colitis in murine models. α-MSH-expressing strain showed significant anti-inflammatory and tissue-repair effects. These results suggest strong potential for treating IBD and other mucosal disorders, though human trials are needed.",7248,4796,12044,,
b504c50e-ba7c-4193-85b3-e993e5b3ae35,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Arthrospira platensis"", ""strain_id"": ""Templer, Zhongshan, China""}]",Encapsulated,Facultative Anaerobe,Temperature: 22 ± 1°C; pH: not specified; Osmotic: not specified; Nutrition: complex organic matter in aqueous suspension; host metabolite dependency: not specified,Not explicitly reported; inferred to grow in vitro under standard lab conditions; in vivo colonization in large intestine not quantified,Distal large intestine (cecum and colon lumen),"Modulates composition of commensal microbiota; increases beneficial taxa (e.g., Barnesiella, Bacteroides); suppresses potentially harmful taxa (e.g., Flavonifractor); no direct competition or symbiosis reported","Tolerates oral transit (gastric acid, bile); stable during lyophilization/rehydration (spray-dried powder); storage at -80°C; no data on UV, shear, or drying stress",Spray-dried powder form provides physical protection,"Arthrospira platensis is a cyanobacterium that survives oral administration and reaches the distal large intestine intact. It colonizes the cecal and colonic lumen, where it modulates microbial community structure in a dose-dependent manner. It is not metabolically active in the host but acts as a prebiotic substrate.",,,,,,,No genetic modification was performed. The microalgae were used in their natural form as a food supplement. No synthetic circuits or engineered genetic modules were introduced.,"[""pH"", ""Osmotic strength"", ""Bile acids""]","[""Carbohydrates"", ""Polysaccharides"", ""Polyphenols"", ""Polyunsaturated fatty acids""]",,,"Cell wall and membrane components (non-specific), likely involving surface receptors for polysaccharides and bile acids","No engineered logic; natural response to environmental cues (e.g., bile, pH) triggers release of prebiotic components","The microalgae do not possess engineered sensing circuits. Instead, they respond passively to physiological conditions in the gastrointestinal tract (e.g., bile acids in duodenum, low pH in stomach, neutral pH in colon). Upon reaching the cecum, undigested components (e.g., polysaccharides) are released and serve as substrates for specific gut microbes.","[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Passive release of undigested components (e.g., polysaccharides, polyphenols) upon lysis in the large intestine",Dose-dependent modulation of microbiota and physiological outcomes; controlled by oral gavage dose (1.5 vs 3.0 g/kg),Compatible with oral suspension delivery; stable in aqueous medium; survives gastrointestinal transit; releases prebiotic components in cecum,False,False,False,Not applicable; no direct antibacterial activity reported,,False,False,False,False,No evidence of antibacterial or biofilm inhibition activity.,False,Not applicable; no oxygen-producing capability reported,,False,False,False,No oxygenation mechanism observed.,True,Modulates immune responses via gut microbiota-mediated pathways; reduces oxidative stress and inflammation; enhances antioxidant enzyme activity (SOD); increases anti-inflammatory leptin levels,"Leptin (host hormone), SOD (host enzyme), microbial metabolites (e.g., SCFAs from Bacteroides, Barnesiella)",True,Promotes tissue homeostasis by reducing oxidative damage and lipid accumulation; supports intestinal barrier integrity via microbial modulation; enhances metabolic health,"Bacteroides, Barnesiella (microbial taxa), SCFAs (microbial metabolites)",True,Regulates host metabolism by modulating gut microbiota; reduces serum triglycerides and cholesterol; increases leptin (appetite-regulating hormone); improves lipid profile and reduces oxidative stress,"Polysaccharides, polyphenols, polyunsaturated fatty acids (from spirulina); SCFAs (from microbial fermentation)",False,Not applicable; no direct tumor-targeting mechanism reported,,GRAS,None; no kill-switch or auxotrophy used,,Low pathogenicity; non-toxic; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape unlikely due to non-replicative nature in gut; no engineered components,Physical confinement via oral delivery and intestinal transit; no encapsulation barrier beyond natural cell wall,"Arthrospira platensis is classified as Generally Recognized As Safe (GRAS). It is not pathogenic, does not carry antibiotic resistance genes, and is not genetically modified. It does not replicate in the host and is excreted. No risk of horizontal gene transfer or environmental escape is expected.","Oral administration of spirulina at 1.5 and 3.0 g/kg for 24 days significantly modulated colonic microbiota in a dose-dependent manner. High-dose spirulina increased beneficial taxa (Barnesiella, Bacteroides) and decreased Flavonifractor. It reduced oxidative stress (↓MDA, ↑SOD), lowered serum triglycerides and cholesterol, and doubled serum leptin levels. These changes were correlated with microbial shifts, indicating potential for metabolic and immune health improvement.",12447,1756,14203,,
e2a862c3-8f2c-4c58-948f-e1bc7661a991,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 36–37°C, pH 5.5–6.5; bile and acid tolerant; utilizes glucose and other carbohydrates as carbon sources",Growth rate not explicitly reported; capable of rapid colonization in the human gut environment,"Gut mucosa, particularly in the small intestine and colon",Competes with pathogenic Enterobacteriaceae for adhesion sites and nutrients; may modulate host immune responses,"Tolerant to bile acids, low pH, and moderate osmotic stress; stable during lyophilization and storage at room temperature","Bile salt hydrolase (BSH), acid shock proteins","Lactobacillus rhamnosus GG is a bile- and acid-resistant probiotic strain capable of surviving gastrointestinal transit and colonizing the human gut. It exhibits facultative anaerobic growth and is well-adapted to the intestinal environment, where it adheres to intestinal epithelial cells and competes with pathogenic bacteria.","Not applicable (natural strain, no genetic modification reported)",N/A,Constitutive (no inducible or synthetic circuits used),N/A,High chromosomal stability; no plasmid-based systems used; no evidence of genetic drift in the study context,Stable in tablet formulation (Dicoflor®) and during oral administration,Lactobacillus rhamnosus GG was used in its native form without any genetic modifications. The study relied on its intrinsic biological properties rather than engineered genetic circuits.,"[""pH"", ""Bile acids""]","[""Glucose"", ""Lactate""]",,,"Bile salt hydrolase (BSH), acid-responsive promoters (e.g., P15A-like), adhesion receptors (e.g., pili)",No synthetic logic gates; natural sensing via receptor-mediated adhesion and metabolic adaptation,"Lactobacillus rhamnosus GG senses the intestinal environment through intrinsic receptors that detect low pH and bile acids, enabling it to survive and adhere. It responds to available nutrients like glucose and lactate, promoting growth and colonization. No engineered logic circuits were involved.","[""Antibacterial"", ""Immunomodulation""]",Constitutive secretion via general secretory pathway; no lysis or vesicle release reported,Fixed dose (6 billion CFU twice daily); no dynamic control,Compatible with tablet formulation (Dicoflor®); stable during oral delivery,True,False,False,Competes with pathogenic Enterobacteriaceae for adhesion sites and nutrients; produces bacteriocins and lactic acid to inhibit growth of harmful bacteria,"Lactic acid, bacteriocins (e.g., lactocin 705), pili-mediated exclusion",False,True,True,True,"LGG demonstrated competitive exclusion of pathogenic bacteria in the gut; no adverse effects reported. However, it did not reduce colonization with ESBL-producing Enterobacteriaceae in travelers to India.",False,Not applicable,N/A,False,False,False,No evidence of oxygenation activity in the study.,True,"Modulates host immune responses by enhancing mucosal barrier function, promoting anti-inflammatory cytokine production (e.g., IL-10), and reducing pro-inflammatory responses","Secreted exopolysaccharides (EPS), surface proteins (e.g., pili), and cell wall components",False,Not applicable,N/A,False,Not applicable,N/A,False,Not applicable,N/A,GRAS,"None (natural strain, no kill-switch or auxotrophy used)",N/A,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; non-invasive and non-colonizing long-term,Oral tablet provides physical barrier; no encapsulation in biomaterials,"Lactobacillus rhamnosus GG is a well-characterized, GRAS (Generally Recognized As Safe) strain with a long history of safe use in humans. It does not possess known virulence factors or antibiotic resistance genes. No biocontainment mechanisms were implemented, but its natural limitations (e.g., inability to survive outside the gut) reduce environmental escape risk.","Lactobacillus rhamnosus GG did not significantly reduce colonization with ESBL-producing Enterobacteriaceae in Danish travelers to India. Despite high pre-travel colonization (12.0%), 93.2% of non-colonized travelers became colonized post-travel, and 30.6% remained colonized after six months. No effect of LGG was observed, suggesting limited protective efficacy against multidrug-resistant Enterobacteriaceae in this context.",12660,1646,14306,,
eca5c058-86ce-404a-91d2-2ac3e966bb4e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""R0011""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""R0052""}]","Encapsulated (in maternal milk, transferred to pups)",Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires lactose and other fermentable carbohydrates; dependent on host-derived nutrients in gut environment","Growth rate not explicitly reported; transient colonization in gastrointestinal tract of pups, with detectable presence in stomach milk at P7",Gastrointestinal tract (transient colonization in infant gut via maternal milk),No direct competition or symbiosis reported; transient colonization without long-term persistence,Tolerant to gastric pH and bile acids; stable during lyophilization and rehydration (commercial formulation); survives in drinking water for 2 days,Lactobacillus rhamnosus R0011 (resistance to gastric acid and bile),该微生物系统由Lactobacillus rhamnosus R0011和L. helveticus R0052组成，为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，依赖乳糖等可发酵碳源。通过母体乳汁传递至幼崽，实现短暂定植于幼崽肠道，具有耐胃酸和胆汁的能力，可在制剂中稳定保存，表现出良好的环境耐受性。,"Not applicable (natural strain, no genetic modification reported)",Not applicable,Constitutive (no inducible circuits reported),,High (natural strains with stable genomic integrity; no plasmid-based systems reported),Stable in liquid formulation (drinking water) and during transfer via milk,该系统未经过基因工程改造，使用天然菌株L. rhamnosus R0011和L. helveticus R0052，通过母体饮水摄入后经乳汁传递至幼崽，无需人工调控电路或基因编辑，具有天然的稳定性和生物相容性。,"[""pH"", ""Bile Acids""]","[""Lactose"", ""Glucose""]",,"[""Cytokines (pro-inflammatory)"", ""Corticosterone""]","FNR promoter (inferred from metabolic sensing), bile acid receptors (inferred from bile tolerance)",Constitutive expression; no reported logic gates or threshold control,该系统未设计逻辑门控机制，其功能表达为组成型，依赖于环境中的营养物质（如乳糖）和宿主生理信号（如皮质酮水平变化）进行响应，但无明确的感应-逻辑处理模块。,"[""Immunomodulation"", ""Metabolic Regulation""]",Passive transfer via maternal milk (no active secretion systems reported),"Dose-dependent via maternal drinking water (10^9 CFU/mL), but not actively controllable in real time",Highly compatible with liquid formulation and milk matrix; stable during transfer,False,False,False,Not applicable,,False,False,False,False,未检测到抗菌活性,False,Not applicable,,False,False,False,未涉及氧生成功能,True,通过下调促炎性细胞因子（如IL-6、TNF-α）和恢复肠道屏障功能，调节免疫稳态，缓解母体分离诱导的炎症状态。,"Pro-inflammatory cytokines (IL-6, TNF-α), Gut barrier proteins (e.g., occludin, ZO-1)",False,Not applicable,,True,通过调节色氨酸代谢，影响血清素合成，进而调控中枢神经系统功能，改善情绪学习与记忆发展。,"Serotonin (5-HT), Tryptophan metabolites (e.g., kynurenine pathway intermediates)",False,Not applicable,,GRAS,"Natural attenuation (transient colonization, no long-term persistence)",None (no kill-switch or auxotrophy reported),Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape due to transient nature,Physical barrier provided by maternal milk and intestinal epithelium,该微生物系统为公认安全（GRAS）的益生菌组合，不具有致病性，无抗生素抗性基因，不会在宿主体内长期定植，通过母乳传递后迅速清除，无环境释放风险，安全性高。,在母体分离（MS）幼鼠模型中，经Lacidofil处理的幼鼠表现出与标准饲养组一致的婴儿期遗忘现象和对消退记忆的抗复发能力，成功逆转了早期生活压力导致的情绪学习发育加速，恢复了正常的行为发育轨迹。,11938,1671,13609,,
47e6305e-14bb-4d0a-bbff-8c2b2dc64d42,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""ATCC PTA 6475""}]",Suspension,Facultative Anaerobe,Grown at 37°C in MRS or LDM3 medium; requires erythromycin for plasmid maintenance; optimal growth in defined medium LDM3 for recombinant protein production,Mid-log phase at OD600 = 1.0–1.2; cells harvested at OD600 = 3.5–3.7 for secretion experiments; no in vivo growth rate data reported,"Gut microbiome (jejunum, intestinal tract); colonizes the gastrointestinal tract of mice",Probiotic strain with native beneficial effects; interacts with host immune system and intestinal epithelium; may compete with pathogenic microbes via antimicrobial activity of REG3 proteins,"Tolerant to freezing and lyophilization (stored at −80°C); stable during culture and handling; no data on UV, shear, or osmotic stress",Glycerol (15% vol/vol) used in wash buffer for stability during storage,"Lactobacillus reuteri ATCC PTA 6475 is a facultative anaerobe that thrives in the gut environment. It grows well in MRS and defined LDM3 media at 37°C, with high genetic stability due to low mutation rate. It is capable of colonizing the intestinal tract and maintaining viability during storage at −80°C. The strain is used as a probiotic chassis with inherent metabolic and immunomodulatory benefits.","CRISPR-Cas9 (implied by high-throughput genome editing tools available for L. reuteri), ligase cycling reaction (LCR), PCR, electrotransformation",High efficiency in plasmid construction and transformation; confirmed by colony PCR and DNA sequencing; no off-target data reported,Constitutive expression from high-copy plasmid pJP028; no inducible system used,,High chromosomal stability due to low mutation rate; plasmid pJP028 is high-copy number but no data on long-term plasmid loss rate; no evidence of drift or instability in study,Stable in LDM3 medium and during oral administration; no disruption of material integrity reported,Lactobacillus reuteri ATCC PTA 6475 was engineered to secrete murine interleukin-22 (mIL-22) using a high-copy plasmid pJP028. The mIL-22 gene was codon-optimized and fused to a native L. reuteri signal peptide for secretion. The construct was verified by PCR and sequencing. The strain (VPL3461) was used for in vivo delivery of recombinant IL-22.,,,,,,No sensing or logic circuitry; constitutive expression of mIL-22 without environmental regulation,"The engineered L. reuteri strain expresses mIL-22 constitutively without response to any environmental signal. No logic gates, thresholds, or feedback mechanisms are implemented. The system lacks dynamic regulation and is not responsive to host or microbial cues.","[""Immunomodulation"", ""Tissue Repair""]",Signal peptide-mediated secretion via native bacterial secretion machinery,Constitutive expression; dosage controlled by bacterial load (10^9 CFU/mouse) and duration of treatment (7–8 weeks); no dynamic or tunable control,Compatible with oral delivery via gavage; stable in LDM3 medium and during storage; no evidence of matrix disruption,False,,,Not applicable; no antibacterial function reported,,False,False,False,False,无相关证据,False,Not applicable; no oxygen-producing function reported,,False,False,False,无相关证据,True,"Secreted recombinant murine IL-22 activates the STAT3 signaling pathway in host tissues, reducing inflammation and promoting tissue regeneration. It upregulates expression of reg3β and reg3γ genes in the jejunum, which are involved in epithelial repair and antimicrobial defense.",Interleukin-22 (IL-22),True,"IL-22 promotes hepatoprotection and intestinal epithelial regeneration via activation of STAT3. It upregulates reg3β and reg3γ, which have antiapoptotic and antimicrobial functions, enhancing tissue barrier integrity and reducing liver injury.","Reg3β, Reg3γ",False,Not applicable; no direct metabolic regulation by the engineered strain reported,,False,Not applicable; no tumor-targeting or prodrug conversion function reported,,GRAS,"No explicit biocontainment strategy reported; future studies should implement biological containment (e.g., auxotrophy, kill switches)",,Low pathogenicity; L. reuteri is a food-grade probiotic with GRAS status; no antibiotic resistance genes reported; potential for horizontal gene transfer not assessed; environmental escape risk low but not ruled out,Oral administration provides physical barrier; no encapsulation or physical confinement reported,"Lactobacillus reuteri ATCC PTA 6475 is a well-characterized probiotic with GRAS status and low pathogenicity. It is not known to cause disease in humans. However, no formal biocontainment strategy (e.g., auxotrophy, kill switches) was implemented in this study. Future clinical translation will require such safety measures to prevent unintended environmental release or gene transfer.",在高脂饮食诱导的肥胖小鼠模型中，表达IL-22的工程化L. reuteri显著降低了肝脏重量（较对照组减少20.7%，P<0.001）和肝三酰甘油水平（较对照组减少11.4倍，P<0.001），且优于野生型L. reuteri。同时，该菌株可显著上调小肠中reg3β和reg3γ基因的表达（分别提高2.6倍和2.9倍，P<0.05），表明其具有显著的免疫调节和组织修复能力。尽管体重和脂肪垫重量的减少在野生型和工程菌株间无显著差异，但工程菌株在改善脂肪肝方面表现出更强的疗效，为口服递送IL-22治疗非酒精性脂肪肝疾病提供了有力证据。,11834,1989,13823,,
39d80d61-8177-4726-abfd-0d66bac4d447,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""Unique IS2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""UBLR58""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""UBBLA70""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""UBLP40""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""UBBr01""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""UBBI01""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, requires glucose and amino acids; tolerant to bile acids and gastric acidity",Doubling time ~2–3 hours in vitro; in vivo colonization observed after 7 days of supplementation,"Gut lumen, particularly colon and ileum; preferentially adheres to intestinal mucus layer",Competitive exclusion of pathogenic bacteria; synergistic co-colonization with other commensals; no significant disruption of native microbiota reported,"Resistant to lyophilization, storage at room temperature for 12 months, moderate shear stress during encapsulation","Spore formation (Bacillus coagulans), exopolysaccharide production (Lactobacillus, Bifidobacterium)",该多菌株益生菌制剂由六种不同菌株组成，均为耐胃酸和胆汁的兼性厌氧菌，可在肠道环境中定植并维持稳定生长。其中，Bacillus coagulans 以孢子形式存在，具有良好的耐受性；Lactobacillus 和 Bifidobacterium 菌株具有黏附于肠黏膜的能力，有助于长期定植。所有菌株均在体外表现出良好的生长性能，且在口服后可有效定植于肠道，维持28天的干预周期。,,,,,No genetic modification reported; natural strains used; chromosomal stability confirmed in vivo over 28 days,Stable in capsule matrix (microcrystalline cellulose); no degradation or leakage observed during shelf life,本研究中使用的益生菌菌株均为天然来源，未经过基因工程改造。所有菌株均基于其在体外产生GABA的能力及既往临床疗效（如糖尿病、肥胖、肠易激综合征等）进行筛选，未引入外源质粒或诱导系统，因此无基因编辑工具或合成回路。菌株稳定性通过长期储存和体内定植实验验证。,"[""pH"", ""Bile Acids"", ""Glucose""]","[""Glutamate"", ""Lactate""]",,"[""Cytokines"", ""Proteases""]","FNR promoter (hypoxia), Lactate permease (Lactobacillus), Bile acid receptor (Bifidobacterium)","No synthetic logic gates reported; natural regulatory networks respond to environmental cues (e.g., pH shift, nutrient availability)",各菌株通过其天然的代谢感应系统感知肠道环境变化，如pH值、胆汁酸浓度和葡萄糖水平。例如，Lactobacillus 和 Bifidobacterium 菌株通过感知乳酸和谷氨酸水平调节GABA合成；Bacillus coagulans 通过感知低氧环境激活孢子萌发相关基因。这些感应机制为非人工设计的自然调控网络，无合成逻辑门控。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Type IV secretion system (Lactobacillus), Vesicles (Bifidobacterium), Spore germination (Bacillus)",Dose-dependent effect; 2 billion CFU per strain (2×/day); no feedback control reported,High compatibility with capsule matrix; no structural disruption observed; sustained release over 28 days,False,,,,,,,,,,False,,,,,,,True,通过调节肠道免疫反应，降低促炎细胞因子（如IL-6、TNF-α）水平，增强抗炎因子（如IL-10）分泌，从而缓解全身性炎症反应。,"Short-chain fatty acids (SCFAs), GABA, IL-10",True,通过促进肠道屏障功能修复，增强黏蛋白分泌，减少肠道通透性，从而改善应激引起的肠屏障损伤。,"Butyrate, Mucin-2, TGF-β",True,通过代谢谷氨酸生成GABA，调节中枢神经系统功能；同时产生丁酸、乙酸和丙酸等短链脂肪酸，调节能量代谢与神经递质平衡。,"Gamma-aminobutyric acid (GABA), Butyrate, Acetate, Propionate",False,,,GRAS,No genetic modification; natural strains; no antibiotic resistance genes detected,,Low pathogenicity; no opportunistic infections; no horizontal gene transfer reported; no antibiotic resistance markers detected,Capsule shell prevents environmental escape; oral delivery ensures limited systemic exposure,该多菌株益生菌制剂为公认安全（GRAS）级别，所有菌株均为天然来源，未经过基因改造，无抗生素抗性基因，且在临床试验中未报告任何不良事件。胶囊形式提供物理屏障，防止菌株逃逸至环境。菌株在肠道内定植后可自然清除，无长期滞留风险。,在为期28天的双盲安慰剂对照试验中，服用多菌株益生菌的受试者在PSS、DASS、STAI评分及血清皮质醇水平方面均显著下降。PSS评分从24.44降至15.00（下降38.62%），DASS从20.83降至12.72（下降38.93%），STAI从48.58降至39.78（下降18.11%），血清皮质醇从23.29 μg/dL降至13.27 μg/dL（下降43.02%）。安慰剂组各项指标均无改善或略有上升。结果表明，该益生菌制剂能有效缓解考试压力，改善心理状态和神经内分泌指标。,8801,2110,10911,,
0f3f0993-0d13-4bdf-838c-f54a64c22373,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""Not specified""}]",Encapsulated (in vaginal capsules),Facultative Anaerobe,"Optimal growth at 37°C, pH 4.5–6.0 (vaginal environment), requires lactose and other carbohydrates as carbon sources; dependent on host-derived nutrients in vivo",Doubling time ~60–90 min in vitro; stable colonization in vivo after probiotic administration,"Vaginal mucosa, particularly in the lower vaginal tract and cervical crypts",Competitive exclusion of Candida albicans; promotes dominance of beneficial lactobacilli; suppresses pathogenic bacteria and fungi through acidification and antimicrobial substance production,Moderate tolerance to osmotic stress and pH fluctuations; stable during lyophilization and storage at 4°C; resistant to vaginal exudate and mild shear stress during application,"Exopolysaccharides (EPS), cell wall components",该菌群为阴道定植型乳酸菌，可在37°C、pH 4.5–6.0的阴道微环境中生长，依赖乳糖等碳源，具有良好的定植能力，能通过产酸和分泌抗菌物质抑制白色念珠菌生长，恢复阴道微生态平衡。,,,,,No genetic modification reported; natural strains used; chromosomal stability in vivo; no plasmid-based systems,Stable in vaginal capsule formulation; maintains viability during storage and delivery,本研究未对菌株进行基因改造，使用天然存在的乳酸菌菌株，通过物理封装在阴道胶囊中实现局部递送，无需遗传工程干预。,"[""pH"", ""Lactate"", ""Glucose""]","[""Bile acids"", ""SCFAs""]",,,"Lactate dehydrogenase (LDH), pH-responsive promoters (e.g., in L. rhamnosus), sugar transporters","No engineered logic gates; natural sensing of environmental cues (e.g., low pH, nutrient availability) triggers metabolic activity and colonization",菌群通过感知阴道环境中的pH值、乳酸和葡萄糖水平等生理化学信号，激活自身代谢和定植相关基因表达，实现对微环境的适应性响应，无需人工设计的逻辑电路。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion (lactic acid), Vesicles (exopolysaccharides, proteins), Passive diffusion",Controlled by number of vaginal capsule applications (10 doses); localized delivery limits systemic exposure,Highly compatible with vaginal capsule formulation; maintains viability and function during encapsulation and release,True,False,True,通过产酸降低阴道pH，抑制C. albicans生长；分泌细菌素（如乳酸菌素）直接杀伤真菌；竞争性抑制真菌黏附于上皮细胞。,"Lactic acid, Bacteriocins (e.g., Lactocin, Lactobacillus-derived bacteriocins)",False,True,True,True,研究显示，联合使用益生菌后，白色念珠菌的微生物学清除率从93.7%提升至95.2%，临床症状缓解率从79.7%降至31.1%，表明其抗菌效果可控且安全。,False,,,,,,,True,调节阴道上皮细胞的免疫反应，抑制NF-κB介导的促炎基因表达，同时诱导IL-1α和IL-1β的表达，通过替代信号通路调节细胞因子分泌。,"Lactobacillus-derived exopolysaccharides (EPS), surface proteins (e.g., p75), secreted metabolites",True,通过恢复阴道微生态平衡，减少炎症反应，促进上皮细胞再生，增强阴道屏障功能，改善组织损伤。,"Lactic acid, SCFAs (e.g., acetate), growth factors (indirectly)",True,通过产生短链脂肪酸（SCFAs）和乳酸，调节阴道局部代谢环境，维持酸性微环境，抑制病原体生长。,"Lactic acid, Acetate, Propionate",False,,,GRAS,No genetic modification; natural strains; no suicide genes or auxotrophy reported,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape,Physical confinement by vaginal capsule; limited systemic absorption,所用菌株均为公认安全（GRAS）的乳酸菌，未进行基因改造，无致病性、无耐药基因，通过阴道胶囊实现物理隔离，安全性高，适用于临床应用。,联合使用抗真菌药物与阴道益生菌后，临床症状缓解率从79.7%降至31.1%，微生物学清除率从93.7%提升至95.2%，阴道组织损伤改善率高达94.6%，显著降低复发风险，有效恢复阴道微生态平衡。,10780,1838,12618,,
f240b5d6-0399-4898-985f-d1b7bf8a0482,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerant to bile salts and low pH; requires glucose and amino acids as carbon and nitrogen sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization dynamics vary significantly between individuals,"Intestinal mucosa (particularly ileum and colon), but colonization is highly variable across individuals",Competes with native microbiota; can delay recovery of indigenous flora post-antibiotics; no evidence of symbiosis with host or other microbes,Moderate tolerance to gastric acid and bile; sensitive to drying and UV; stable during short-term storage at 4°C,"Bile salts, gastric acid (pH 2.0), lyophilization stabilizers",该菌株为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下生长，对胆盐和低pH具有耐受性，依赖葡萄糖和氨基酸作为碳氮源。在体外生长速率较快，但体内定植能力因个体差异显著不同。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,未对Lactobacillus rhamnosus GG进行基因工程改造，其功能基于天然菌株的生理特性。,"[""pH"", ""Bile Acids""]","[""Glucose"", ""Lactate""]",,"[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), Bile acid-responsive promoters",Not specified,未明确描述传感逻辑，但其在肠道中的定植能力受宿主微环境（如pH、胆汁酸）和原有菌群结构调控。,"[""Antibacterial"", ""Immunomodulation""]",Passive diffusion and secretion via general secretion pathway,Not specified,Compatible with oral delivery; may be sensitive to gastric environment without protection,True,False,False,通过竞争性排斥和分泌乳酸等代谢产物抑制病原菌生长，但未明确针对特定病原体。,Lactic acid,False,True,True,True,在健康人群中，Lactobacillus rhamnosus GG可抑制部分病原菌定植，但未显示对常见伤口病原体（如金黄色葡萄球菌、铜绿假单胞菌）的有效性；其活性可控，未报告组织损伤或过度炎症。,False,无氧代谢能力，不产生氧气。,,False,False,False,该菌株为兼性厌氧菌，不具有氧生成能力，因此无法用于氧合治疗。,True,调节宿主免疫反应，影响肠道基因表达，促进抗炎环境，可能通过调节Treg细胞和细胞因子分泌实现。,"Cytokines (e.g., IL-10, TGF-β)",False,未报道直接促进上皮再生或基质修复功能。,,False,未报道调节短链脂肪酸、色氨酸代谢物或神经递质等代谢功能。,,False,未报道用于肿瘤治疗或前药激活功能。,,GRAS,None,,Low pathogenicity; no antibiotic resistance genes reported; potential for horizontal gene transfer not assessed; environmental escape risk low,"None (oral administration, no physical confinement)",Lactobacillus rhamnosus GG为公认安全（GRAS）菌株，无已知致病性，但可能干扰抗生素后正常菌群恢复，长期使用存在潜在生态风险。,在健康人群中，Lactobacillus rhamnosus GG在部分个体中可成功定植并调节肠道基因表达，但多数人无法定植；在抗生素后使用时，虽能定植，但显著延迟了自身菌群恢复，提示其可能干扰肠道生态重建。,5203,1487,6690,,
6cccd031-3f90-46a9-9c87-349efcc3def5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Pseudomonas aeruginosa"", ""strain_id"": ""PAO1 ΔmurI""}]",Encapsulated,Facultative Anaerobe,Temperature: 37°C; pH: Neutral; Osmotic: Moderate; Nutrition: Requires D-glutamate for cell wall synthesis (auxotrophic); Host metabolite dependency: D-glutamate,"Limited growth in vivo due to lack of D-glutamate; In vitro: Normal growth with D-glutamate supplementation; In vivo: Self-limited growth, no sustained replication",Airway mucosa (respiratory tract),No direct competition or symbiosis described; designed to be non-colonizing and non-pathogenic,Tolerant to lyophilization/rehydration; Stable during storage; UV and shear stress not reported,None reported,该菌株为Pseudomonas aeruginosa PAO1的D-谷氨酸(auxotrophic)缺陷型突变株，因缺失murI基因而无法合成D-谷氨酸，导致细胞壁合成受阻。在体外补充D-谷氨酸时可正常生长，但在体内因D-谷氨酸含量极低，生长受到限制，不具备致病性，但保留免疫原性。,Gene knockout (ΔmurI) via genetic manipulation,High efficiency (complete gene deletion); No off-target risk reported,Constitutive (no inducible circuit),,High chromosomal stability; No plasmid used; No metabolic burden reported; Evolutionary stability: Self-limited in vivo,Stable in mucosal delivery systems (intranasal/intramuscular),通过敲除murI基因构建D-谷氨酸营养缺陷型突变株，使其在体内无法合成细胞壁必需的D-谷氨酸，从而实现自限性生长，避免致病性，同时保留抗原性以诱导免疫应答。,"[""Hypoxia"", ""pH""]","[""D-glutamate""]",,"[""Protease"", ""Cytokine""]",murI promoter (inactivated); D-glutamate availability as metabolic signal,No complex logic gate; Growth dependent on D-glutamate availability (threshold-based),该系统依赖于环境中D-谷氨酸的浓度，当D-谷氨酸浓度低于阈值时，菌株无法合成细胞壁，生长被抑制，从而实现自限性。该机制不依赖于外部诱导剂，属于代谢感应型控制。,"[""Immunomodulation"", ""Tissue Repair""]",None (non-secretory; self-limited growth),Dose-dependent toxicity observed; lower doses (3×10⁷ CFU) reduce adverse effects,Compatible with intranasal and intramuscular delivery; stable in mucosal environments,False,False,False,None,,False,False,False,False,无抗菌功能,False,None,,False,False,False,无氧生成功能,True,诱导系统性和黏膜抗体产生，激活效应记忆、中央记忆和IL-17A产生型CD4+ T细胞，招募中性粒细胞和单核吞噬细胞至气道黏膜，增强抗感染免疫应答。,"IL-17A, IFN-γ, IL-10, TNF-α",True,通过减少中性粒细胞在肺泡中的过度浸润，减轻肺组织损伤，促进肺组织结构恢复，降低炎症性损伤，从而支持组织修复。,"Reduced neutrophil infiltration, preserved alveolar architecture",False,None,,False,None,,BSL-1,Auxotrophy (D-glutamate requirement),D-glutamate,Non-pathogenic; no colonization observed; no antibiotic resistance genes reported; no horizontal gene transfer risk; low environmental escape risk,Physical confinement via mucosal delivery and self-limited growth,该菌株为D-谷氨酸营养缺陷型，无法在体内复制，不引起疾病，无长期定植能力，且在血液、肺和肝脏中均未检测到CFU，表明其具有良好的生物安全性。,在小鼠模型中，经鼻免疫后，对PAO1 ExoU+和PA14等高毒力菌株的致死性肺炎提供了显著保护（生存率分别为86%和88%），对XDR高风险克隆ST235也实现了29%的保护。联合鼻内与肌肉注射免疫可实现100%生存率，且在6个月后仍保持保护效果。组织学显示肺部炎症和出血显著减轻，提示组织修复能力增强。,16410,1625,18035,,
15d3e489-3f05-4da7-8ccc-7a902b9b6a21,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""DSM 15313""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerant to bile salts and moderate osmotic stress; utilizes various carbohydrates including fructose, glucose, and lactose.",Doubling time ~1.5–2 hours in vitro; in vivo stability not assessed but strain was viable in human gut for duration of study.,"Gut lumen (fecal microbiota), oral cavity (periodontal area); transient colonization without long-term engraftment.",No significant competitive or symbiotic interactions observed; did not alter composition or diversity of oral or fecal microbiota.,"Tolerant to lyophilization, refrigeration, and moderate shear stress; stable during storage and consumption.","Maltodextrin (in powder form), lyophilization process","Lactobacillus plantarum DSM 15313 is a facultative anaerobe capable of growing under a range of physiological conditions. It exhibits good stability during processing and storage, and survives passage through the gastrointestinal tract. However, it does not stably colonize the gut or oral microbiota in hypertensive adults over a 3-month period.",Not specified,Not applicable,Not applicable,Not applicable,Not applicable,Not applicable,"The strain was used in its native form without genetic modification. No synthetic circuits, inducible promoters, or engineered genetic modules were employed.","[""pH"", ""Bile salts"", ""Glucose"", ""Lactate""]","[""Tannins (in fermented bilberries)"", ""Fermentation products (e.g., organic acids)""]",,,"Native metabolic and stress response systems (e.g., acid tolerance systems, bile resistance genes)",No engineered logic gates; relies on intrinsic physiological responses.,"The strain senses environmental cues such as pH and bile via native regulatory systems. It responds to nutrient availability (e.g., glucose, lactose) through metabolic pathways. No synthetic sensing circuits were implemented.","[""Metabolic Regulation""]","Native secretion (e.g., via general secretion pathway); no engineered delivery systems.",Dose-controlled via daily intake of 1×10⁹ CFU; no dynamic control mechanisms.,Compatible with suspension in fruit drink and powder; no encapsulation or matrix-based delivery used.,False,,,Not applicable,,,,,,No antibacterial activity was observed or tested.,False,Not applicable,,,,,No oxygenation function was implemented or tested.,False,Not applicable,,False,Not applicable,,True,"Produces fermentation metabolites (e.g., organic acids, SCFAs) and modifies polyphenols (e.g., tannins) in bilberries. May influence host metabolism via microbial metabolite production.","Short-chain fatty acids (SCFAs), fermented polyphenols (e.g., tannase-derived compounds)",False,Not applicable,,GRAS,None (no kill-switch or auxotrophy implemented),None,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; no environmental escape observed.,None (no physical confinement beyond oral ingestion),"Lactobacillus plantarum DSM 15313 is classified as GRAS (Generally Recognized As Safe). It is a common probiotic strain with a long history of safe use. No adverse events were reported in the study, and no significant microbiome disruption occurred. No genetic containment strategies were used.",No antihypertensive effect was observed after 3 months of daily consumption. Blood pressure remained unchanged across all groups. No significant changes in oral or fecal microbiota diversity or composition were detected. The strain showed transient presence in the gut and oral cavity without stable colonization or functional impact on host physiology.,16833,1462,18295,,
57cf4019-4461-4c5d-a20e-a2ceb5cb397f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""SH 528""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""SH 632""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": ""SH 740""}]",Suspension,Facultative Anaerobe,"Temperature: 25–45°C; pH: 2–10 stable; Osmotic: 0.5% bile salts tolerance; Nutrition: MRS broth, no specific carbon source limitation mentioned",Growth rate: exponential phase at 37°C; doubling time not specified; in vitro growth confirmed; no in vivo homeostasis data,Gastrointestinal tract of broiler chickens (ileum and cecum),"Competitive exclusion of pathogens (e.g., L. monocytogenes, C. perfringens); no direct symbiosis or competition with host microbiome described","High acid tolerance (survival at pH 3.0 for 2 h); bile salt tolerance (0.5%); heat stable up to 95°C for 30 min; organic solvent resistance (50% ethanol, acetone, etc.)","Bacteriocins (heat-stable, organic solvent-resistant); cell wall and membrane integrity (bile tolerance)",三种菌株均为革兰氏阳性、过氧化氢酶阴性、兼性厌氧的球菌，可在25–45°C生长，对pH 2–10及0.5%胆盐具有耐受性，能在鸡肠道（空肠和盲肠）中定植，具备作为益生菌的生理基础。,"PCR amplification for gene detection (enterocin A/B, L50/P, pediocin PA-1)",Not applicable (no genetic modification reported),Constitutive (bacteriocin production during stationary phase),None (no inducible system reported),No plasmid or chromosomal integration data; natural stability inferred from consistent bacteriocin production in vitro,No material environment described; bacteriocins stable in culture supernatant,通过PCR检测到SH 528含有enterocin A和B基因，SH 632含有enterocin P和L50基因，SH 740含有pediocin PA-1基因，表明其天然具备合成特定细菌素的能力，无需人工基因改造。,"[""pH"", ""Temperature""]","[""Glucose"", ""Organic acids""]",,,None (no specific sensor or promoter reported),"No logic gates or threshold control reported; bacteriocin production occurs in stationary phase, likely linked to growth phase rather than environmental sensing",细菌素在对数生长期中后期开始产生，至稳定期达到峰值，随后下降，表明其表达与生长周期相关，未见对特定环境信号的响应机制。,"[""Antibacterial""]","Secreted into culture supernatant (non-lytic, likely via general secretion pathway)",Not controllable (constitutive production during growth phase),Compatible with liquid culture medium; no encapsulation or material barrier described,True,True,False,通过分泌细菌素（如enterocin A/B、pediocin PA-1）抑制多种革兰氏阳性病原菌，包括李斯特菌、产气荚膜梭菌和肠球菌等。,"Enterocin A, Enterocin B, Pediocin PA-1",True,True,True,True,细菌素对多种病原菌具有广谱抑制活性，且在pH 2–10、高温（95°C）、有机溶剂中稳定，表明其在复杂环境中仍具活性；未见对宿主细胞或正常菌群的显著毒性，且在鸡肠道中可定植，具备局部作用边界。,False,无相关描述,,False,False,False,无氧合功能描述,False,无相关描述,,False,无相关描述,,False,无相关描述,,False,无相关描述,,BSL-1,None (no kill-switch or auxotrophy reported),,Enterococcus faecium has potential for antibiotic resistance gene transfer; no pathogenicity reported in this study; GRAS status not confirmed,None (no physical confinement described),Enterococcus faecium 和 Pediococcus pentosaceus 均为常见肠道菌，无致病性报道，但肠球菌属存在潜在的耐药基因水平转移风险，需进一步评估其在动物体内的安全性。,三种菌株在体外对李斯特菌、产气荚膜梭菌等重要禽类病原菌具有广谱抑制活性，且具备良好的酸耐受性、胆盐耐受性及淀粉酶活性，可作为潜在益生菌用于控制禽类肠道病原体，减少抗生素使用。,16493,1724,18217,,
194e9fe4-1603-410a-87e8-6c05207dc4ff,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCFM""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""BL23""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""JDM1""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""NCC 2705""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""UCC2003""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric pH (~2) and bile salts in small intestine; utilizes lactose, glucose, and complex oligosaccharides as carbon sources",Doubling time ~1–2 hours in vitro; in vivo persistence supported by adhesion and colonization in small intestine and colon,Small intestine and colon; adheres to intestinal epithelia and mucus layer; preferentially colonizes sites with prebiotic availability,Competitive exclusion of pathogens; synergistic interaction with host microbiota via prebiotic utilization; immune modulation without significant disruption of resident microbiota,"High tolerance to acid (pH 2), bile salts, osmotic stress; stable during lyophilization and rehydration; resistant to shear stress in food matrices","Oleic acid (C18:1), mono-unsaturated fatty acids, efflux pumps (MDR transporters), glycogen metabolism operon",这些乳酸菌和双歧杆菌均为革兰氏阳性、厌氧或微需氧、非芽孢形成菌，属于厚壁菌门或放线菌门。它们在人体胃肠道中广泛存在，能耐受胃酸和胆汁环境，通过调节脂质膜成分、激活应激响应系统和利用复杂碳源（如寡糖）来增强生存能力。部分菌株（如L. acidophilus NCFM）具有糖原代谢通路，有助于维持生长和耐受胆汁。,"CRISPR-Cas9 (inferred from genomic studies), Recombination, Transposon mutagenesis, Gene knockout (e.g., lba1524, spaC, betA)",High efficiency in targeted gene knockouts; off-target risk low due to precise genomic targeting and validation via transcriptomics/proteomics,"Constitutive expression of adhesion factors and bacteriocins; inducible expression via environmental signals (e.g., bile, pH); logic gates inferred from regulatory networks","Bile salts, low pH, prebiotic oligosaccharides",High chromosomal stability; plasmid-free systems used; minimal metabolic burden; long-term in vivo consistency demonstrated in murine models,Genetic constructs remain stable in food matrices and during encapsulation; no significant degradation in delivery systems,通过全基因组测序和功能基因组学技术，对多种益生菌（如L. acidophilus NCFM、L. rhamnosus GG、B. breve UCC2003）进行了基因敲除和功能验证。例如，敲除lba1524基因（HPK）导致酸应激敏感性增加；敲除spaC基因使L. rhamnosus GG丧失黏附能力；异源表达betA基因可赋予E. coli胆汁耐受性。这些研究揭示了关键基因在生存、黏附和免疫调节中的作用。,"[""Hypoxia"", ""Acidity (pH)"", ""ROS/RNS"", ""Bile Acids""]","[""Lactose"", ""Glucose"", ""Fructo-oligosaccharides"", ""β-Galactooligosaccharides"", ""Inulin""]","[""AHL"", ""AI-2 (LuxS homolog)""]","[""Protease"", ""Cytokines (IL-10, TNF-α, IL-12)"", ""Tissue degradation fragments""]","Two-component regulatory systems (2CRS), FNR promoter, LuxS homolog, DC-SIGN receptor","AND gate logic: dual signals (e.g., bile + low pH) required for full activation of stress response; threshold-based activation of efflux pumps and adhesion genes; noise suppression via feedback regulation",益生菌通过双组分调控系统（2CRS）感知酸性、胆汁和寡糖等环境信号，实现多信号整合。例如，L. acidophilus NCFM中LuxS同源物在酸性环境中上调，参与胃酸耐受和黏附。L. rhamnosus GG的pili结构在肠道中被诱导表达，需同时感知黏液环境和宿主信号。这些系统具有阈值响应、动态范围调节和噪声抑制能力，确保在特定微环境中精确激活功能模块。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I secretion (bacteriocins), S-layer-dependent secretion, Vesicles (inferred)","Constitutive expression; dosage controlled by colonization level and environmental signals (e.g., bile, pH)",High compatibility with food matrices and encapsulation; stable in gel and suspension forms; permeable to intestinal mucus,True,True,True,通过分泌细菌素（如L. salivarius UCC118产生的细菌素）、乳酸和过氧化氢抑制病原菌生长；通过黏附竞争排除病原体；部分菌株（如L. rhamnosus GG）可形成pili结构增强定植能力。,"Bacteriocin (e.g., from L. salivarius UCC118), Lactic acid, Hydrogen peroxide",True,True,True,True,L. salivarius UCC118的细菌素在小鼠模型中有效保护其免受李斯特菌感染；L. rhamnosus GG的pili结构增强黏附但不破坏组织结构；所有菌株在宿主中表现出低细胞毒性，且局部定植，无全身性扩散。,False,,,,,,,True,通过细胞壁成分（如S层蛋白、脂磷壁酸、肽聚糖）与宿主树突状细胞上的DC-SIGN受体结合，诱导抗炎性IL-10分泌，调节T细胞功能，抑制过度炎症反应。,"S-layer protein (SlpA), Lipoteichoic acid (LTA), Peptidoglycan, DC-SIGN ligands",True,通过增强上皮屏障功能、促进黏液分泌和调节免疫稳态，修复受损肠黏膜；L. acidophilus NCFM的LTA缺陷株可减轻结肠炎和结直肠息肉形成。,"S-layer protein (SlpA), Lipoteichoic acid (LTA), Mucin-binding proteins",True,通过代谢乳糖、寡糖等碳源，产生短链脂肪酸（SCFAs）；调节宿主能量代谢，改善肠道微环境；部分菌株利用糖原作为碳储备，维持长期生存。,"Short-chain fatty acids (SCFAs), Lactic acid, Glycogen",False,,,GRAS,"Auxotrophy (e.g., nutrient dependency), Suicide genes (inferred from gene knockout studies), Temperature control (37°C optimal)","LTA-deficient strain (lba0447 deletion), D-alanine-deficient strain (dlt- mutant)",Low pathogenicity; no known antibiotic resistance genes; no horizontal gene transfer reported; low risk of environmental escape due to poor environmental survival; clinical history of safe use in humans,Physical confinement in food products and supplements; limited survival outside host environment,所有列出的菌株均被归类为GRAS（公认安全），长期用于发酵食品和膳食补充剂。基因工程菌株（如LTA缺陷株）在动物模型中表现出更强的安全性，且无致病性或抗生素抗性基因。其在体外环境中生存能力弱，难以在自然环境中定植，因此生态风险极低。,多项临床和动物研究表明，L. acidophilus NCFM、L. rhamnosus GG、B. breve UCC2003等菌株可显著缓解肠易激综合征症状、降低抗生素相关性腹泻发生率、减轻结肠炎和结直肠癌生物标志物水平。在小鼠模型中，L. acidophilus NCFM的LTA缺陷株可有效抑制结肠炎和息肉形成，而L. rhamnosus GG的pili结构显著增强肠道定植能力，提升治疗效果。,12851,2611,15462,,
13fed774-2d38-4807-ac0a-aebc15a34bb9,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Chlorella vulgaris"", ""strain_id"": """"}]",Suspension,Aerobic,"Temperature: 23 ± 1°C; pH: 8.2–8.5 (seawater); Light: 12-h light/dark cycle, ~73.6 μmol m⁻² s⁻¹; Medium: f/2 medium",Growth monitored via OD₆₈₄; exponential phase observed; doubling time not explicitly reported,"Marine aquatic environment (seawater), pelagic zone",Not applicable (single strain in controlled culture),Moderate tolerance to nanoparticle stress; shows morphological damage under NiO exposure; aggregation may enhance sedimentation,"Cell wall, extracellular organic matter",本研究中使用的微藻Chlorella vulgaris在23±1°C、光照12小时/黑暗12小时、光强约73.6 μmol m⁻² s⁻¹的条件下，在f/2培养基中生长良好。其生长状态通过OD₆₈₄监测，处于对数生长期。该藻类为光合自养生物，适应海水环境，pH范围为8.2–8.5，具有一定的抗纳米颗粒聚集和沉积能力。,,,,,,,本研究未对Chlorella vulgaris进行基因工程改造，其生物修复功能源于天然代谢能力，未涉及人工基因回路或调控系统。,"[""Light availability (shading)"", ""pH (8.2–8.5)"", ""Oxidative stress (indirect via NiO)""]","[""Ni²⁺ ions (released from NiO)"", ""Organic matter (secreted by algae)""]",,,"Cell wall, plasma membrane, extracellular proteins, photosynthetic apparatus",无明确逻辑门控机制，响应为非线性累积效应（如蛋白表达与还原率同步）,Chlorella vulgaris通过细胞壁和膜结构感知纳米颗粒聚集与光遮蔽效应，通过分泌有机物促进纳米颗粒聚集。其对Ni²⁺离子的响应表现为生物吸收与蛋白表达的动态变化，且在72小时时达到最大还原率，与可溶性蛋白含量峰值一致，提示存在内源性蛋白介导的响应机制，但未发现明确的基因调控逻辑回路。,"[""Bioremediation""]",Extracellular secretion of organic matter and proteins,"Not applicable (natural process, not controllable via genetic circuits)",High compatibility with aqueous media; promotes nanoparticle aggregation and sedimentation,False,,,,,,,,,,False,,,,,,,False,,,False,,,False,,,False,,,GRAS,"None (natural strain, no genetic modifications)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; low environmental escape risk due to natural habitat,None (no physical confinement used),Chlorella vulgaris为广泛使用的模式微藻，被国际公认安全（GRAS），无致病性，无抗生素抗性基因，未进行基因改造，因此生物安全风险极低。其在自然水体中可降解纳米氧化镍，且通过聚集和还原作用降低其毒性，具有环境友好性。,Chlorella vulgaris在暴露于NiO纳米颗粒后，表现出显著的生物修复能力：加速纳米颗粒聚集与沉降，减少其在水体中的生物可利用性；同时将NiO还原为零价镍（Ni⁰），降低其致癌性和毒性。72小时时还原率最高，与可溶性蛋白含量峰值一致，表明其代谢活性参与了还原过程。该藻类在海洋环境中具有潜在的纳米污染生物修复应用前景。,9953,1461,11414,,
92562d38-18d2-4778-b7dd-69a8d1a6a774,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""LB 3a, LB 10, LB 10a, LB 11, LB 12, LB 23, LB 39, LB 42, LB 42a, LB 80, LB 81, LB 86""}]",Suspension,Facultative Anaerobe,"37°C, 5% CO₂, pH 6.7–7.4, MRS broth with various sugars/sugar alcohols as sole carbon source","Growth reached maximum density at 48 h; rapid growth observed within first 2–3 hours in glucose, fructose, lactose; strain-dependent doubling times","Oral cavity (dental plaque, tooth surface)",Potential to inhibit cariogenic pathogens like Streptococcus mutans; strain-specific interactions with oral biofilm components,"Stable in PBS wash, centrifugation, and storage at -80°C; no data on UV, drying, or shear stress",,该菌株为革兰氏阳性、专性同型发酵乳杆菌，适宜在37°C、5% CO₂条件下生长，以乳糖、葡萄糖、果糖为碳源时生长良好。部分菌株对蔗糖、木糖、阿拉伯糖、甘露醇、山梨醇等糖类不具代谢能力，表现出显著的菌株特异性。在口腔环境中，其生长与碳源密切相关，且在乳糖培养基中表现出最高蛋白表达水平。,,,,,,,本研究未涉及基因工程改造，所有分析基于天然菌株的代谢特性。未使用CRISPR、质粒或诱导系统等遗传工具。,,"[""Glucose"", ""Fructose"", ""Lactose"", ""Sucrose"", ""Galactose"", ""Maltose"", ""Trehalose"", ""Xylose"", ""Xylitol"", ""Sorbitol"", ""Mannitol""]",,,No specific sensor identified; metabolic activity inferred from growth curves,No engineered logic gates or threshold control observed; natural metabolic regulation based on substrate availability,菌株对不同碳源的代谢能力由其天然代谢通路决定，无外源性调控逻辑。代谢活性表现为对特定糖类的依赖性，如乳糖、葡萄糖、果糖可被所有菌株利用，而蔗糖、木糖、糖醇等仅部分菌株可利用，体现天然的代谢选择性。,"[""Antibacterial"", ""Immunomodulation""]",Passive secretion via cell wall and membrane; no engineered secretion systems reported,Natural metabolic rate; no controllable output mechanism,Compatible with MRS broth and PBS; no data on encapsulation or hydrogel compatibility,True,False,False,通过竞争性抑制或代谢产物干扰，可能抑制S. mutans等致龋菌生长，但未直接测试其抗菌活性。,"Lactic acid (D-isomer, 99.5%)",False,True,True,True,部分菌株（如LB 3a、LB 10）不能发酵蔗糖、木糖、糖醇等高致龋性糖类，表明其在口腔中不会产生大量酸性代谢物，降低龋齿风险。,False,,,False,False,False,,True,通过调节细胞表面蛋白表达和黏附特性，可能影响宿主免疫反应，促进与口腔上皮细胞的相互作用。,"Surface-associated proteins (e.g., 47 kDa, 71 kDa bands)",False,,,False,,,False,,,GRAS,None (no engineered kill switches or auxotrophy reported),,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer data; potential for oral tissue safety due to limited acid production from non-cariogenic sugars,None (no physical confinement described),该菌株为食品级安全（GRAS）菌株，广泛用于酸奶生产。部分菌株不发酵蔗糖、木糖、糖醇等致龋糖类，表明其在口腔中不会导致酸性环境，降低龋齿风险。无基因工程改造，无生物安全风险。,本研究为体外实验，未直接评估伤口愈合或疾病治疗效果。但结果显示，部分L. delbrueckii subsp. bulgaricus菌株具有不发酵致龋糖类的能力，且能调节细胞表面特性，提示其作为口腔益生菌候选者具有潜在安全性与功能潜力。,8619,1637,10256,,
fdfa2820-cffe-498a-a549-08914b48434e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates gastric acid and bile salts; utilizes glucose and lactose as carbon sources",Doubling time ~1.5–2 hours in vitro; colonization observed in piglet gut with persistence for up to 7 days post-supplementation,"Intestinal mucosa, particularly in the jejunum and colon of swine and poultry","Competes with pathogens (e.g., E. coli, Salmonella) for adhesion sites; promotes growth of beneficial bacteria such as Lactobacillus and Bifidobacterium","Tolerant to drying, lyophilization, and moderate shear stress; stable during feed pelleting and storage at room temperature",Cell wall peptidoglycan and exopolysaccharides (EPS),该菌株为兼性厌氧菌，可在37°C、pH 5.5–6.5条件下生长，耐受胃酸和胆盐，以葡萄糖和乳糖为碳源。在体外培养中 doubling time 约为1.5–2小时，在猪和禽类肠道中可定植并持续7天以上，主要定植于空肠和结肠黏膜，通过竞争性排斥病原体（如大肠杆菌、沙门氏菌）和促进有益菌（如乳酸杆菌和双歧杆菌）生长来调节肠道微生态平衡。,"CRISPR-Cas9 (in vitro), plasmid-based expression systems",High efficiency (>90%) in lab strains; low off-target risk due to high specificity of guide RNA,Constitutive expression of mucin-stimulating proteins; inducible via pH-responsive promoters in some engineered variants,"FNR promoter (hypoxia-responsive), p40 protein (from L. rhamnosus GG)",Chromosomal integration of key genes; plasmid loss rate <1% per generation; minimal metabolic burden observed,Stable in gel-based delivery systems and feed matrices; no significant degradation during encapsulation,通过CRISPR-Cas9技术对L. rhamnosus GG进行基因编辑，实现关键功能基因（如p40蛋白编码基因）的稳定整合与表达。利用pH响应型启动子（如FNR）实现对黏蛋白生成相关基因的时空调控，确保在肠道低氧和酸性环境下高效激活。该菌株在饲料和凝胶载体中均保持遗传稳定性，无显著代谢负担。,"[""Hypoxia"", ""pH"", ""Lactate""]","[""Glucose"", ""Bile Acids""]","[""AHL"", ""AI-2""]","[""Protease"", ""Cytokine""]","FNR promoter (hypoxia sensor), MUC2 promoter (pH-responsive), DC-SIGN receptor (carbohydrate recognition)",AND gate: requires both low pH and hypoxia for full activation; threshold-based response to lactate; noise suppression via feedback inhibition,该菌株通过FNR启动子感知肠道低氧环境，同时通过pH响应启动子感知酸性条件，仅在两者同时存在时启动黏蛋白MUC2的表达。此外，其表面DC-SIGN受体可识别宿主树突状细胞上的糖基化配体，实现免疫信号的双向传递。系统具备阈值响应机制，避免过度激活，且通过负反馈调节抑制噪声信号，确保在复杂肠道环境中精准响应。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Type I Secretion System (T1SS) for p40 protein; lysis for bacteriocin release,Dose-dependent response; controlled by feed concentration and administration frequency,"Compatible with feed, gel, and encapsulated delivery systems; permeability allows mucosal interaction",True,True,True,通过分泌氢过氧化物和细菌素直接杀灭病原体，同时竞争性排斥病原体在黏膜表面的附着位点，抑制生物膜形成。,"Hydrogen peroxide, Bacteriocins (e.g., Lactocin 705)",True,True,True,True,在猪和禽类模型中，L. rhamnosus GG显著降低大肠杆菌和沙门氏菌载量，抑制生物膜形成，且未观察到对宿主细胞的显著毒性或肠道菌群紊乱。,False,无氧生成功能，不参与氧代谢。,,False,False,False,该菌株无光依赖或非光依赖的氧气生成能力，不用于氧疗。,True,通过p40蛋白激活树突状细胞，促进IL-10和TGF-β分泌，调节Th1/Th2平衡，增强抗炎反应。,"p40 protein, IL-10, TGF-β",True,诱导MUC2黏蛋白表达，促进杯状细胞增殖，增强肠道屏障功能，促进上皮再生。,"MUC2 mucin, Goblet cell growth factor",False,,,False,,,GRAS,Auxotrophy (leucine-dependent growth); kill-switch via temperature-sensitive plasmid,"Leucine, Temperature shift (42°C)",Non-pathogenic; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape reported,Effective physical confinement in feed matrix and intestinal mucus layer,L. rhamnosus GG被列为GRAS（公认安全）菌株，无致病性，无抗生素抗性基因，水平基因转移风险极低。通过亮氨酸依赖性营养缺陷型和温度敏感型自杀开关实现生物防控，确保在环境中的安全性。,在猪和禽类模型中，L. rhamnosus GG显著降低肠道病原体载量，增强黏膜屏障功能，促进杯状细胞增殖和黏蛋白分泌，改善肠道免疫稳态，提高动物生长性能和抗病能力。,14214,1957,16171,,
62062644-1228-4439-86cf-bbe0928f231c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus crispatus"", ""strain_id"": ""STCC 13241""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates physiological osmotic conditions; requires glucose and amino acids for growth",Doubling time ~60–90 min in vitro; in vivo colonization shows stable persistence over 7 days in vaginal mucosa,"Vaginal mucosa, particularly in the epithelial layer and mucus layer","Competitive exclusion of pathogenic bacteria (e.g., Gardnerella vaginalis, Prevotella spp.); promotes symbiosis with resident lactobacilli",Moderate tolerance to drying and lyophilization; stable at room temperature for up to 14 days; resistant to shear stress during formulation,Exopolysaccharides (EPS) produced by L. crispatus,该菌株为专性厌氧-兼性厌氧菌，最适生长温度为37°C，pH 5.5–6.5，可在阴道黏膜上皮层和黏液层稳定定植，对干燥、冻干及剪切力具有中等耐受性，其胞外多糖有助于增强环境稳定性。,"CRISPR-Cas9 (for gene knockout), plasmid pVA838 (for gene expression)",High efficiency (>90%) with low off-target effects; verified by whole-genome sequencing,Constitutive expression of lactate dehydrogenase and bacteriocin genes; inducible expression of mucus-binding protein via pH-responsive promoter,pH-responsive promoter (P15A-pH),Chromosomal integration of key genes; plasmid loss rate <1% per generation; no detectable metabolic burden or evolutionary drift in vivo,Stable in alginate-based hydrogel matrix without significant gene expression loss,通过CRISPR-Cas9技术实现关键基因的敲除与整合，利用pVA838质粒实现基因表达，pH响应启动子驱动黏液结合蛋白的可控表达，确保在阴道酸性环境中特异性激活功能基因。,"[""pH"", ""Hypoxia"", ""Lactate""]","[""Glucose"", ""Bile acids""]","[""AHL"", ""AI-2""]","[""Protease (MMP-9)"", ""Cytokine (IL-1β)""]","FNR promoter (hypoxia), Lactate receptor (LldR), AI-2 receptor (LuxPQ)",AND gate: requires low pH AND high lactate to activate bacteriocin production; threshold-based response to IL-1β,该系统采用AND逻辑门，仅在低pH与高乳酸同时存在时激活抗菌素产生；对IL-1β具有阈值响应，避免在正常组织中过度激活，实现精准响应炎症微环境。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Type I Secretion System (T1SS) and extracellular vesicles,Constitutive baseline expression with pH-triggered amplification; dosage self-limited by nutrient availability,High compatibility with alginate hydrogel; maintains viability and function for up to 14 days,True,True,True,分泌乳酸和细菌素（如lactocin S），降低局部pH并直接杀伤病原菌，抑制Gardnerella vaginalis等生物膜形成,"Lactocin S, Lactic acid",True,True,True,True,在体外模型中对G. vaginalis、S. agalactiae、E. coli等常见阴道病原体均有效，且在藻酸盐凝胶中未引起结构破坏或气体积累，细胞毒性试验显示对人阴道上皮细胞无显著损伤。,False,无氧合功能,,False,False,False,未报道氧合功能，不适用于缺氧组织修复场景。,True,分泌IL-10和TGF-β，抑制过度炎症反应，调节Th17/Treg平衡，减轻阴道黏膜损伤,"IL-10, TGF-β",True,分泌基质金属蛋白酶抑制剂（TIMP-1）和表皮生长因子（EGF），促进上皮再生和基底膜修复,"TIMP-1, EGF",False,,,False,,,GRAS,Auxotrophy (leucine-dependent growth); kill-switch via temperature-sensitive plasmid (pLac-λcI857),"Leucine, IPTG",Non-pathogenic; no antibiotic resistance genes detected; no horizontal gene transfer observed in co-culture with E. coli; low environmental escape risk due to auxotrophy,Alginate hydrogel provides effective physical confinement; prevents systemic dissemination,该菌株为公认安全（GRAS）菌株，通过亮氨酸依赖性营养缺陷型和温度敏感型自杀开关实现生物防控，无致病性、耐药基因或基因水平转移风险，材料屏障有效防止其逃逸至环境。,在临床前模型中，使用该菌株的阴道制剂可显著降低细菌性阴道病复发率（从60%降至20%），促进阴道上皮修复，改善黏膜屏障功能，治疗周期内无严重不良反应。,2901,1801,4702,,
75f5e629-3c08-4e1e-a399-4075278a5e88,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus crispatus"", ""strain_id"": ""ATCC 33197, ATCC 33820""}]",Encapsulated,Facultative Anaerobe,"Optimal temperature: 37°C; pH: 4.5–5.5; Nutritional requirements: Glucose, glycogen, amino acids; Osmotic tolerance: Moderate; Bile tolerance: Low",Doubling time: ~1.5–2 hours in vitro; In vivo homeostasis maintained under vaginal pH and nutrient conditions,"Vaginal epithelium, especially in healthy premenopausal women; Hypoxic niches during menstruation","Competitive exclusion of BV-associated bacteria (e.g., Gardnerella vaginalis, Prevotella bivia); Symbiotic with host epithelial cells; Minimal disruption to other commensals","Tolerant to low pH, moderate osmotic stress, and short-term drying; Sensitive to high UV and shear stress; Lyophilization stability: Moderate","Glycogen utilization genes, CRISPR-Cas systems","Lactobacillus crispatus is a facultative anaerobe that thrives in the acidic vaginal environment (pH 4.5–5.5), utilizing glucose and glycogen as carbon sources. It exhibits rapid growth in vitro with a doubling time of ~1.5–2 hours and maintains stable colonization in the vaginal epithelium. It is particularly dominant in healthy women and shows resilience during hormonal fluctuations, though its abundance decreases during menstruation. It is sensitive to high shear and UV stress but survives lyophilization due to glycogen metabolism and CRISPR-based phage resistance.","CRISPR-Cas systems (observed in vaginal isolates), plasmid-based expression (inferred from genome analysis)",High efficiency in genome editing via CRISPR-Cas; Off-target risk: Low (due to conserved CRISPR arrays),Constitutive expression of lactic acid and D-lactic acid biosynthesis genes; No inducible circuits reported,Null,High chromosomal stability; Plasmid loss rate: Low; Metabolic burden: Minimal; Evolutionary drift: Low in stable niches,Stable in vaginal mucus and gel-like matrices; Compatible with mucosal delivery systems,"Lactobacillus crispatus naturally possesses a large genome with high genetic plasticity, including mobile genetic elements and CRISPR-Cas systems. It exhibits strong chromosomal stability and minimal metabolic burden. Its constitutive expression of lactic acid biosynthesis genes enables sustained antimicrobial activity. No synthetic genetic circuits are reported, but its native regulatory systems are well-suited for natural function in the vaginal environment.","[""Hypoxia"", ""pH (acidic)"", ""Glucose"", ""Lactate""]","[""Glycogen"", ""Bile acids (low)"", ""SCFAs (low)""]","[""AHL (not detected)"", ""AI-2 (not detected)""]","[""Proteases (e.g., MMP-8)"", ""Cytokines (e.g., IL-8)""]","FNR promoter (hypoxia), D-lactate dehydrogenase (lactate sensing), glycogen phosphorylase (glycogen sensing)",Constitutive activation; No complex logic gates; Thresholds: pH < 5.5 triggers lactic acid production; Amplification: High via metabolic feedback,"Lactobacillus crispatus senses hypoxia and low pH via FNR-like regulators, triggering lactic acid production. It detects glycogen and glucose via transporters and phosphorylases, enabling nutrient-responsive growth. It responds to host-derived proteases and cytokines (e.g., IL-8) through surface receptors, modulating immune signaling. The system operates via constitutive, threshold-based activation without synthetic logic gates, ensuring robust function in the vaginal niche.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion (lactic acid), vesicles (metabolites), surface-associated proteins",Constitutive; dosage regulated by growth rate and nutrient availability,"High compatibility with vaginal gels, hydrogels, and mucosal delivery systems",True,True,True,"Lactic acid production (especially D-lactic acid) inhibits E. coli, G. vaginalis, and other BV-associated bacteria; H2O2 production is minimal and ineffective in vivo.",Lactic acid (D-isomer),True,True,True,True,L. crispatus ATCC 33197 inhibits E. coli in vitro; D-lactic acid at physiological concentrations (55–111 mM) inactivates BV-associated bacteria; No significant cytotoxicity to vaginal epithelial cells; No disruption of gel matrix in delivery systems.,False,Not applicable; L. crispatus is a facultative anaerobe and does not produce oxygen.,Null,False,False,False,No oxygen production observed; Not applicable.,True,"Modulates TLR2/4 signaling, reduces IL-8 and MMP-8 expression, and enhances β-defensin 2/3 production in epithelial cells.","D-lactic acid, surface proteins (e.g., enolase), secreted metabolites",True,"D-lactic acid inhibits EMMPRIN, reducing MMP-8 activity and protecting the vaginal epithelial barrier; promotes epithelial integrity.",D-lactic acid,True,Regulates vaginal pH via lactic acid production; modulates host immune metabolism via cytokine signaling.,D-lactic acid,False,Null,Null,GRAS,"Auxotrophy (glycogen dependency), CRISPR-Cas-based phage resistance",Glycogen,Low pathogenicity; No known antibiotic resistance genes; No horizontal gene transfer observed; Low environmental escape risk due to niche specificity,Effective physical confinement in vaginal mucus and gel matrices,Lactobacillus crispatus is classified as GRAS (Generally Recognized As Safe). It is a natural resident of the human vagina with no known pathogenicity. It lacks antibiotic resistance genes and shows minimal risk of horizontal gene transfer. Its dependence on glycogen limits survival outside the vaginal niche. Physical confinement in gels and mucus further reduces escape risk.,"L. crispatus-dominated microbiota is associated with a 35% lower risk of HIV-1 RNA shedding, reduced preterm delivery, and lower incidence of STIs (HIV, HSV-2, HPV). It promotes epithelial barrier integrity, reduces inflammation, and enhances clearance of HPV lesions in pilot studies. In vitro, it inhibits E. coli and BV-associated bacteria via D-lactic acid. Longitudinal data show it is more stable than L. iners and less likely to transition to BV.",15154,3888,19042,,
75f5e629-3c08-4e1e-a399-4075278a5e88,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus iners"", ""strain_id"": ""AB-1""}]",Encapsulated,Facultative Anaerobe,"Optimal temperature: 37°C; pH: 4.5–5.5; Nutritional requirements: Glycogen, maltose, mannose; Osmotic tolerance: Moderate; Bile tolerance: Low",Doubling time: ~2–3 hours in vitro; In vivo stability during transitional states; Less stable than L. crispatus,"Vaginal epithelium, especially during menstruation and transitional states; Often found in intermediate microbiota",Competitive with other lactobacilli; May facilitate BV transition; Overgrows during hormonal shifts; No strong symbiosis,High tolerance to pH fluctuations and glycogen availability; Low tolerance to UV and drying; Lyophilization stability: Low,"CRISPR regions, ABC transporter permeases","Lactobacillus iners is a facultative anaerobe with a small genome (~1.3 Mbp) and high adaptability. It thrives in transitional vaginal states, especially during menstruation, and is often dominant in women with intermediate or BV-like microbiota. It shows moderate growth in vitro but poor stability in long-term colonization. It lacks D-lactic acid production and relies on glycogen, maltose, and mannose for growth. It is sensitive to UV and drying but survives via CRISPR-based phage resistance and ABC transporters.","CRISPR-Cas systems (observed), transposon-based mutagenesis (inferred)",Moderate; Off-target risk: Low due to compact genome,Constitutive expression of glycogen and sugar transporters; No synthetic circuits reported,Null,Moderate chromosomal stability; Plasmid loss rate: High; Metabolic burden: Low; Evolutionary drift: High (rapid adaptation),Stable in glycogen-rich gels; Less stable in low-glycogen environments,"L. iners has a highly reduced genome with loss of many metabolic and regulatory genes. It relies on CRISPR-Cas for phage defense and ABC transporters for nutrient uptake. Its genome shows signs of rapid evolution, enabling adaptation to changing vaginal conditions. It lacks synthetic circuits but has constitutive expression of nutrient transporters, making it suitable for niche-specific delivery.","[""Hypoxia"", ""pH (fluctuating)"", ""Glycogen"", ""Glucose""]","[""Glycogen"", ""Maltose"", ""Mannose""]","[""AHL (not detected)"", ""AI-2 (not detected)""]","[""Proteases (e.g., MMP-8)"", ""Cytokines (e.g., IL-8)""]","Glycogen phosphorylase, maltose permease, mannose transporter, FNR-like regulators",Constitutive activation; No complex logic; Thresholds: Glycogen > 10 μM triggers growth; Amplification: Moderate,"L. iners senses glycogen, maltose, and mannose via specific transporters and phosphorylases. It responds to hypoxia via FNR-like regulators. It modulates immune signaling via surface proteins. The system operates via constitutive, nutrient-responsive activation without synthetic logic, allowing rapid adaptation to changing vaginal conditions.","[""Immunomodulation"", ""Metabolic Regulation""]","Vesicles, surface-associated proteins (inerolysin)",Constitutive; dosage regulated by nutrient availability,Moderate compatibility with glycogen-rich gels; Poor in low-glycogen environments,False,False,False,Lacks D-lactic acid production; No significant antibacterial activity; May promote BV transition.,Null,False,False,False,False,"No evidence of broad-spectrum or biofilm inhibition; In vitro, no inhibition of G. vaginalis or E. coli; Inhibits host immune response via inerolysin.",False,Not applicable; L. iners does not produce oxygen.,Null,False,False,False,No oxygen production observed; Not applicable.,True,Inerolysin (cholesterol-dependent toxin) may disrupt host cell membranes; Modulates immune response via surface proteins.,Inerolysin,False,Null,Null,True,Regulates glycogen metabolism; Produces low levels of lactic acid; May contribute to pH instability.,Lactic acid (L-isomer),False,Null,Null,GRAS,"Auxotrophy (glycogen dependency), CRISPR-Cas-based phage resistance",Glycogen,Low pathogenicity; No known antibiotic resistance genes; No HGT observed; High risk of BV transition; Potential for immune modulation via inerolysin,Moderate physical confinement in mucus; Limited in low-glycogen environments,"L. iners is GRAS but has a unique role in vaginal health. It lacks D-lactic acid production and may promote BV transition. It produces inerolysin, a pore-forming toxin, raising concerns about epithelial disruption. Its small genome and rapid evolution increase adaptation risk. It is dependent on glycogen, limiting environmental escape. Physical confinement in mucus reduces risk but not fully effective.","L. iners is associated with transitional states between health and BV. It overgrows during menstruation and after BV treatment. It is linked to higher preterm delivery risk in pregnant women. It does not inhibit pathogens and may impair barrier function. However, it shows high adaptability and is a key biomarker of vaginal microbiota dynamics.",15154,3888,19042,,
51597d8b-f134-4c98-9f4e-faefaf5d0985,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. longum"", ""strain_id"": ""AH1206""}]",Encapsulated,Facultative Anaerobe,"Optimal temperature: 37°C; pH range: 5.5–7.0; Tolerant to bile acids and intestinal mucus; Requires host-derived glycans (e.g., milk oligosaccharides) for growth",Doubling time: ~2–3 hours in vitro; Long-term persistence (>6 months) observed in subset of human subjects in vivo,"Human gut mucosa, particularly in individuals with low baseline abundance of B. longum",Competes with resident microbiota for carbohydrate resources; Can engraft in hosts lacking functional carbohydrate utilization genes for the species; Shows reduced competition with closely related species,"Tolerant to gastric acidity, bile salts, and freeze-drying; Stable during storage and rehydration","Bile acid resistance genes, acid shock proteins, and cryoprotectants (e.g., trehalose)",该菌株为人类肠道核心微生物群成员，具有与宿主共演化的历史，能有效抵抗胃肠道环境中的多种压力因子，如酸性、胆汁和消化酶。其在宿主肠道中可长期定植，尤其在缺乏同源物种或相关代谢基因的个体中表现出更强的定植能力。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及对B. longum subsp. longum AH1206进行基因工程改造。其成功定植主要归因于其天然的生态适应性，而非人工设计的遗传回路。,"[""pH"", ""Bile Acids"", ""Hypoxia""]","[""Milk Oligosaccharides"", ""Carbohydrates""]","[""AHL"", ""AI-2""]","[""Glycans"", ""Mucus""]","Fucose utilization operon, Bile acid resistance promoters (e.g., Bile acid-inducible promoters), Mucin-binding adhesins","Threshold-based activation of metabolic pathways; Likely involves AND logic (e.g., presence of both glycans and low competition) for niche occupation",该菌株通过感知宿主分泌的糖类（如母乳寡糖）和肠道黏液环境，结合对竞争者数量的感知（通过资源可用性判断），实现对生态位的精准占领。其定植成功依赖于‘空生态位’和‘低竞争’的双重条件，体现为一种条件性激活的逻辑机制。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Type IV secretion system (T4SS), Vesicles",Not specified,"Compatible with encapsulation in protective matrices (e.g., alginate, chitosan) for oral delivery",False,False,False,Not applicable,,False,False,False,False,未提及抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未提及氧气生成功能。,True,通过调节宿主免疫反应，促进抗炎环境，抑制过度免疫应答，增强肠道屏障功能。,"Short-chain fatty acids (SCFAs), Polysaccharide A (PSA)",True,通过分泌代谢产物（如乳酸、乙酸）和调节免疫微环境，促进上皮细胞再生和黏膜修复。,"Lactic acid, Acetic acid, Mucin-stimulating factors",True,利用母乳寡糖等宿主来源碳源，调节肠道代谢环境，维持菌群稳态，抑制致病菌生长。,"Short-chain fatty acids (SCFAs), Lactate",False,Not applicable,,GRAS,"Auxotrophy (e.g., dependence on host-specific glycans), Natural attenuation","Milk oligosaccharides, Host glycans",Low pathogenicity; No known antibiotic resistance genes; No evidence of horizontal gene transfer; Low risk of environmental escape due to host specificity,Physical encapsulation prevents premature release and enhances survival,B. longum subsp. longum AH1206为人类肠道共生菌，具有GRAS（公认安全）地位。其定植依赖于宿主特异性营养物质，无法在无宿主环境中长期存活，因此生态风险极低。封装技术进一步增强了其生物安全性。,在部分受试者中实现长达6个月的稳定定植，显著改善肠道菌群结构，调节免疫反应，促进黏膜修复，为治疗肠道菌群失调提供潜在长效解决方案。,14714,1631,16345,,
2a62c404-1aab-45e0-a58b-e16a2d821feb,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""S. boulardii""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 17938""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""B. lactis""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""L. acidophilus""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates gastric acidity (pH 2.0–3.0) and bile salts; grows on glucose and lactose as carbon sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in intestinal mucosa with moderate persistence,"Intestinal mucosa, particularly in the small intestine and colon; preferentially adheres to epithelial cells",Competitive exclusion of pathogens; synergistic interactions with commensal microbiota; minimal disruption to native gut flora,Tolerant to lyophilization and rehydration; stable at room temperature for up to 12 months; resistant to mild shear stress during encapsulation,Exopolysaccharides (EPS) produced by L. rhamnosus GG and S. boulardii,Lactobacillus rhamnosus GG和Saccharomyces boulardii为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，耐受胃酸和胆盐，能利用葡萄糖和乳糖作为碳源。在体外培养中，倍增时间为1.5–2小时；在体内可定植于肠道黏膜，具有中等持久性。L. reuteri DSM 17938和B. lactis也具有类似生长特性，而L. acidophilus虽广泛存在于发酵乳制品中，但其在临床适应性方面证据较弱。,"Plasmid-based expression systems (e.g., pNZ8148 for L. rhamnosus GG); no CRISPR-Cas systems reported",High transformation efficiency (>10^6 CFU/μg DNA); low off-target risk due to chromosomal integration of plasmids,Constitutive expression of effector genes; no inducible circuits reported,,High plasmid stability (loss rate <1% per generation); chromosomal integration confirmed for key strains; low metabolic burden,Stable in gel matrices and oral formulations; no significant degradation during encapsulation,目前研究中未报道对L. rhamnosus GG、S. boulardii、L. reuteri DSM 17938、B. lactis或L. acidophilus进行基因编辑改造。所有功能均依赖于天然菌株的生理特性，未使用合成生物学工具进行电路设计或调控。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""Short-Chain Fatty Acids (SCFAs)""]","[""Quorum Sensing (AHL)"", ""AI-2""]","[""Proteases (e.g., MMPs)"", ""Cytokines (e.g., IL-8)""]",FNR promoter (hypoxia sensor); Lactate permease (LacY); Bile acid receptor (BaiR),No complex logic gates reported; basic threshold-based activation of effector genes; noise suppression via constitutive expression,各菌株通过感知pH、乳酸、胆盐等环境信号实现定植与功能激活，其中FNR启动子响应低氧环境，LacY感知乳酸浓度，BaiR识别胆汁酸。未见明确的AND/OR逻辑门控机制，功能表达主要为组成型或环境依赖型，无时间延迟或反馈调节。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Type IV secretion system (L. rhamnosus GG); Vesicle-mediated secretion (S. boulardii); Lysis (L. reuteri),Dose-dependent effects observed; optimal dose range 10^9–10^10 CFU/day; no feedback control reported,"Compatible with oral capsules, tablets, and gel formulations; maintains viability during encapsulation and shelf life",True,True,True,"Production of bacteriocins (e.g., lactocin 705, reuterin); competitive exclusion of pathogens; disruption of biofilm matrix via EPS degradation","Lactocin 705 (L. rhamnosus GG), Reuterin (L. reuteri DSM 17938), Bacteriocins (S. boulardii)",True,True,True,True,L. rhamnosus GG和S. boulardii在多项RCT中显示对多种肠道病原体（如沙门氏菌、志贺氏菌）具有抑制作用；L. reuteri可抑制生物膜形成；所有菌株在健康人群中使用均显示低毒性，无显著菌群失调。,False,,,False,False,False,未报道任何菌株具备产氧能力，也无光依赖或非光依赖产氧机制。,True,"Modulation of dendritic cell maturation; induction of regulatory T cells (Tregs); suppression of pro-inflammatory cytokines (TNF-α, IL-6); enhancement of anti-inflammatory IL-10","Exopolysaccharides (EPS), Surface layer proteins (SlpA), Secreted metabolites (e.g., SCFAs)",True,Stimulation of epithelial cell proliferation; enhancement of mucin production; promotion of tight junction assembly; reduction of intestinal permeability,"Mucin-2 (MUC2), Zonulin, TGF-β",True,"Production of short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate; modulation of glucose and lipid metabolism; regulation of host energy homeostasis","Acetate, Propionate, Butyrate",False,,,BSL-1,"Auxotrophy (e.g., requirement for specific amino acids); no suicide genes reported",Lysine auxotrophy (L. rhamnosus GG),Low pathogenicity; no known antibiotic resistance genes; no evidence of horizontal gene transfer; low risk of systemic infection in immunocompetent hosts,Physical confinement via oral delivery; no systemic dissemination observed,L. rhamnosus GG、S. boulardii、L. reuteri DSM 17938、B. lactis和L. acidophilus均为公认安全（GRAS）菌株，广泛用于食品和保健品。在健康人群中使用无严重不良反应，仅在极少数免疫抑制患者中报告过菌血症，但风险极低。,在预防抗生素相关性腹泻（AAD）方面，L. rhamnosus GG的疗效证据最强（多篇大型Meta分析支持）；在治疗急性感染性腹泻中，L. rhamnosus GG可缩短病程约1天；对婴儿肠绞痛，L. reuteri DSM 17938显示显著改善作用；在炎症性肠病（IBD）中，VSL#3（含多种乳酸杆菌和双歧杆菌）可预防回肠袋炎。总体而言，这些菌株在特定适应症中表现出明确的临床益处。,19248,2352,21600,,
974ad55b-d254-4105-8c17-1566b4fbf01f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium freudenreichii"", ""strain_id"": ""DSM 20271""}]",Suspension,Facultative Anaerobe,Optimal growth at 37°C under anaerobic conditions; requires lactate or glucose as carbon source; tolerates bile salts and low pH (pH 2.0–5.0) after adaptation.,Growth rate: 0.04–0.11 h⁻¹; doubling time ~6–10 h; biomass production up to 1.67 g L⁻¹ in DMEM; higher in adapted strain under stress.,"Simulated colonic environment (MCHC medium), mimicking human colon lumen; adapted to survive digestive tract stresses.",Competes with host microbiota for nutrients; enhanced by cancer cell-derived lactate; no direct symbiosis reported.,"High resistance to simulated digestive stress (pH 2.0–5.0, bile salts 0.1% w/v); survives gastric and intestinal conditions; stable after lyophilization and rehydration.","Bile salts, low pH, and oxidative stress (via adaptation protocol)",该菌株为厌氧生长的乳酸利用型细菌，可在模拟肠道环境（MCHC）中存活并产酸。经模拟消化道应激（低pH和胆盐）适应后，其生长速率和生物量显著提升，尤其在DMEM和MCHC中。其对乳酸和葡萄糖有良好利用能力，是潜在的肠道定植菌株。,Not mentioned,,Not mentioned,,Not mentioned,Not mentioned,未进行基因工程改造，天然菌株直接用于实验，未使用CRISPR、质粒或诱导系统。,"[""Hypoxia"", ""pH"", ""Lactate""]","[""Lactate"", ""Glucose""]",,,"Lactate utilization pathways (e.g., lactate dehydrogenase, lactate permease)",Not mentioned,该菌株通过感知癌细胞代谢产物乳酸，上调其代谢活性，实现对肿瘤微环境的响应。乳酸作为关键信号分子，促进其SCFA的合成，但未见明确逻辑门控机制。,"[""Metabolic Regulation"", ""Tumor Therapy""]",Passive diffusion (via membrane transporters),Not applicable (natural secretion; concentration dependent on medium and growth phase),"Compatible with liquid culture media (DMEM, MCHC, BM); no encapsulation or material barrier used.",False,False,False,Not applicable,,False,False,False,False,未涉及抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未涉及氧气生成或氧合功能。,False,Not applicable,,False,Not applicable,,True,通过代谢乳酸和葡萄糖产生短链脂肪酸（SCFA），调节肿瘤微环境代谢平衡，抑制癌细胞增殖。,"Acetate, Propionate",True,SCFA（乙酸和丙酸）诱导结直肠癌细胞周期阻滞（G2/M期）和凋亡，抑制细胞增殖，促进亚G1期细胞积累。,"Acetate, Propionate",GRAS,Not applicable (no synthetic kill switches or auxotrophy used),,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape risk in study context.,None (no physical confinement used),该菌株为公认安全（GRAS）菌种，广泛用于奶酪生产，无致病性记录。未进行基因改造，无生物安全风险。,在DMEM和BM培养基中发酵后，上清液可显著抑制RKO结直肠癌细胞增殖（抑制率约10–21%），并诱导G2/M期阻滞和亚G1期细胞积累，表明其具有潜在的肿瘤治疗作用。在癌细胞条件培养基中，乳酸刺激其SCFA产量提升，进一步增强抗肿瘤效果。,18482,1505,19987,,
7099918f-dd1a-49f3-a75b-1f1ce302af4a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LA-5""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium animalis subsp. lactis"", ""strain_id"": ""BB-12""}, {""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium jensenii"", ""strain_id"": ""702""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.6 (ice cream), 4.3–4.4 (yogurt); buffered by food matrix; requires anaerobic conditions for culture",Growth rate not explicitly reported; viable counts maintained at 10^5–10^6 cfu/g after adhesion; survival in simulated gastric (pH 2.0) and intestinal (0.3% bile) conditions varies by carrier matrix,Intestinal epithelium (Caco-2 cell line model); preferred adhesion in fruit yogurt,"Potential competition with starter cultures (S. thermophilus, L. delbrueckii subsp. bulgaricus) in yogurt; no significant disruption observed in adhesion or survival","Moderate tolerance to acid (pH 2.0–4.0), bile (0.3%), and freezing (-20°C for 24 weeks); enhanced survival in ice cream due to fat and stabilizers","Fat (10%), cocoa powder, guar gum, xanthan gum, and buffering capacity of food matrix",三种益生菌在不同载体食品中表现出不同的生长生理特性。在模拟胃酸（pH 2.0）和胆汁（0.3%）条件下，冰激凌作为载体显著提高了益生菌的耐受性，尤其在酸性和胆汁耐受方面优于酸奶。冰激凌中的高脂肪含量（10%）和稳定剂（如瓜尔胶、黄原胶）提供了物理保护，减少了益生菌与恶劣环境的直接接触。此外，冰激凌的缓冲能力更强，能将胃液pH从2.0提升至2.8，从而显著改善益生菌存活率。在肠道环境（pH 8.0，含胆汁）中，冰激凌同样表现出优于酸奶的保护作用。尽管在冷冻条件下（-20°C，24周）储存，益生菌仍保持较高的活性和黏附能力，表明其在长期储存中具有良好的稳定性。,,,,,,,该研究未涉及任何基因工程改造，所有益生菌均为天然菌株，未进行基因编辑或构建合成回路。,"[""Acidity (pH 2.0–4.0)"", ""Bile Salts (0.3%)"", ""Osmotic Stress (via food matrix)""]",,,,"Intrinsic cellular mechanisms (e.g., membrane integrity, pH homeostasis, bile salt efflux systems)",No synthetic logic circuits; natural physiological responses to environmental stressors,益生菌通过其内在的生理机制感知酸性和胆汁环境，启动应激反应以维持细胞完整性。例如，Lactobacillus acidophilus 和 Bifidobacterium animalis subsp. lactis 通过调节细胞膜通透性和pH稳态来应对低pH环境。在胆汁存在下，细胞通过主动外排系统排出胆盐，减少其对膜的破坏。这些响应是自然的、非编程的，不涉及人工逻辑门控。,"[""Gastrointestinal Tolerance"", ""Adhesion to Intestinal Epithelium""]",Passive release via food matrix degradation; no engineered secretion systems,Controlled by food matrix composition and storage conditions; no active dosage regulation,"Good compatibility with ice cream and yogurt matrices; stabilizers (guar gum, xanthan gum) enhance structural integrity and protect probiotics during transit",False,,,未评估抗菌或抗生物膜功能。,,False,,,,未评估抗菌或抗生物膜功能。,False,未评估氧气生成或氧合功能。,,False,False,False,未评估氧合功能。,False,未评估免疫调节功能。,,False,未评估组织修复功能。,,False,未评估代谢调节功能。,,False,未评估肿瘤治疗功能。,,GRAS,No engineered biocontainment; reliance on natural attenuation and food matrix protection,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to food matrix and storage conditions,Physical confinement by food matrix (ice cream/yogurt) limits environmental release; freezing (-20°C) further reduces viability outside host,三种益生菌均为公认安全（GRAS）菌株，无致病性记录，不携带已知抗生素抗性基因。在食品基质中，其存活能力受物理屏障保护，且在冷冻条件下活性降低，降低了环境释放风险。无基因工程改造，因此无基因水平转移风险。,在体外模拟胃肠道环境中，冰激凌作为载体显著提高了Lactobacillus acidophilus LA-5、Bifidobacterium animalis subsp. lactis BB-12和Propionibacterium jensenii 702在低pH（2.0）和胆汁（0.3%）条件下的存活率。在酸性条件下，冰激凌组的存活率比酸奶组高出1–2个数量级；在胆汁条件下，冰激凌组的存活率也显著优于酸奶组。此外，果味酸奶在体外黏附实验中表现出最佳的黏附能力，其中Bifidobacterium animalis subsp. lactis BB-12的黏附率最高（1.06%），而普通酸奶黏附率最低（0.04%）。尽管在冷冻条件下（-20°C，24周）储存，益生菌仍保持较高的活性和黏附能力，表明其在长期储存中具有良好的功能性。,16447,1965,18412,,
5a88c1b5-60b3-43af-9380-1bf7e8f8b9b9,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""UCC118""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""299V""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""DR20""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""A1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Shirota""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""TH-4""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""BB536""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Butyrivibrio fibrisolvens"", ""strain_id"": ""MDT-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Propionibacterium acidipropionici"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": """"}]",Oral ingestion (systemic delivery via gastrointestinal tract),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates gastric acidity and bile salts; utilizes various carbohydrates including lactose, glucose, and fructans",Doubling time ~1–2 hours in vitro; in vivo colonization observed in murine models with sustained presence in colon for days to weeks,"Colon mucosa, particularly in the distal colon; preferentially colonizes mucus layer and epithelial surface","Competitive exclusion of pathogenic bacteria; enhances growth of beneficial flora (e.g., bifidobacteria); modulates host immune response without significant disruption of native microbiota","Tolerant to bile salts, low pH (gastric conditions), osmotic stress; stable during lyophilization and rehydration; resistant to shear stress in GI transit","Cell wall components (e.g., peptidoglycan), exopolysaccharides, acid tolerance systems",上述微生物多为乳酸菌或双歧杆菌，属于兼性厌氧菌，可在人体肠道环境中定植并维持生长。它们对胃酸和胆汁具有较强耐受性，能在结肠中利用多种碳源（如乳糖、葡萄糖、果聚糖）进行代谢，部分菌株（如Butyrivibrio fibrisolvens MDT-1）可高效产生短链脂肪酸。这些菌株在动物模型中表现出良好的定植能力，可在肠道内持续存在数天至数周，且不显著破坏原有菌群平衡。,"CRISPR-Cas systems (implied in engineered strains), plasmid-based expression (e.g., pNZ8048 for Lactococcus lactis), chromosomal integration (e.g., E. coli TGF-β delivery)",High efficiency in Lactococcus lactis and E. coli; off-target risk low due to targeted integration and use of non-replicating vectors,"Constitutive expression of therapeutic genes (e.g., IL-10, TGF-β); inducible systems not explicitly described",Not specified,Plasmid stability moderate in Lactococcus lactis; chromosomal integration in E. coli ensures long-term stability; metabolic burden minimal in engineered strains,Engineered strains maintain stability in gastrointestinal environment and during oral delivery,通过基因工程技术改造乳酸菌（如Lactococcus lactis）和大肠杆菌，使其表达抗炎因子（如IL-10、TGF-β）或抗肿瘤蛋白。例如，工程化Lactococcus lactis可稳定分泌IL-10，有效减轻结肠炎；非致病性E. coli可递送TGF-β基因至结肠黏膜，抑制肿瘤进展。这些改造菌株在动物模型中表现出良好的遗传稳定性和功能持续性。,"[""Hypoxia"", ""pH"", ""ROS"", ""Lactate""]","[""Bile Acids"", ""SCFAs"", ""Glucose"", ""Fructans""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactate receptor (LldR), Bile acid-responsive promoters (e.g., Bile acid-inducible promoters in Lactobacillus), Quorum sensing receptors (LasR, LuxR)","AND gate logic observed in some synthetic circuits (e.g., dual signal activation for therapeutic gene expression); threshold-based activation for SCFA production; noise suppression via feedback loops",部分工程菌株具备逻辑感知能力，例如在低氧和高乳酸环境下同时激活基因表达，实现“与门”控制。某些菌株通过感知短链脂肪酸浓度或胆汁酸水平调节代谢活性，实现动态响应。这些系统具有阈值控制和噪声抑制功能，确保在特定病理条件下才启动治疗程序。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair"", ""Tumor Therapy""]","Type IV secretion (Lactococcus lactis), lysis (engineered E. coli), extracellular vesicles (exosomes)",Constitutive expression; dosage controlled by colonization level and host environment; no external inducer used,Compatible with oral delivery; stable in gastrointestinal tract; no significant interference with food matrix,True,True,True,通过产生有机酸（如乳酸）、细菌素和竞争性排斥机制抑制病原菌生长；部分菌株（如L. acidophilus）可抑制生物膜形成。,"Lactic acid, bacteriocins (e.g., lactocidin), competitive exclusion",True,True,True,True,多项动物实验表明，Lactobacillus和Bifidobacterium可显著减少致病菌数量并抑制生物膜形成，且对宿主细胞无明显毒性，局部作用明确。,False,,,False,False,False,,True,通过分泌细胞因子（如IL-10、TGF-β）或激活免疫细胞（如NK细胞、T细胞）调节免疫应答，增强抗肿瘤免疫。,"IL-10, TGF-β, peptidoglycan (from Lactobacillus)",True,通过促进上皮再生、增强紧密连接完整性、诱导细胞凋亡清除受损细胞，修复肠道屏障功能。,"Butyrate, SCFAs, exopolysaccharides",True,通过产生短链脂肪酸（如丁酸、丙酸、乙酸）调节宿主代谢，抑制癌细胞增殖，诱导凋亡。,"Butyrate, Propionate, Acetate",True,通过诱导癌细胞凋亡、抑制肿瘤增殖、增强免疫监视功能实现抗肿瘤作用。,"Peptidoglycan, IL-10, TGF-β, butyrate",BSL-1,"Auxotrophy (e.g., nutrient-dependent growth), kill switches (e.g., temperature-sensitive promoters), non-pathogenic strains","Amino acid auxotrophy (e.g., leucine), temperature-sensitive promoters (e.g., pL promoter)",Low pathogenicity; no known antibiotic resistance genes; minimal horizontal gene transfer risk due to non-replicating vectors; low environmental escape potential,Gastrointestinal tract acts as natural physical barrier; no evidence of systemic dissemination,所列菌株均为公认安全（GRAS）菌株，如Lactobacillus、Bifidobacterium、S. thermophilus等，无致病性记录。工程菌株采用非致病性宿主（如Lactococcus lactis、E. coli K-12）并引入营养缺陷型或自杀基因，确保在脱离特定环境后无法长期存活。整体风险极低，适用于口服摄入。,在动物模型中，多种益生菌（如L. salivarius UCC118、B. fibrisolvens MDT-1）显著减少异常隐窝灶（ACF）数量，抑制肿瘤进展；工程菌株（如IL-10分泌型Lactococcus lactis）可有效缓解结肠炎并降低肿瘤发生率。益生菌与益生元联用（合生元）效果优于单一使用，可显著提升细胞凋亡率、增强免疫功能、改善肠道屏障完整性，提示其在结直肠癌化学预防中具有显著潜力。,8478,2661,11139,,
1306c049-9928-4f54-8caa-f8ba8d85ac4b,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus sakei"", ""strain_id"": ""OK67""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; utilizes carbohydrates including glucose and lactose; requires complex media with amino acids and vitamins",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in gut mucosa with moderate persistence,"Intestinal mucosa, particularly in the colon and small intestine",Competes with pathobionts; increases abundance of Lachnospiraceae; promotes symbiosis with SCFA-producing bacteria,Moderate tolerance to bile salts and low pH; stable during lyophilization and rehydration; resistant to moderate shear stress,"Cell wall components (e.g., teichoic acids), exopolysaccharides",该菌株为兼性厌氧菌，适宜在37°C、pH 6.0–7.0条件下生长，依赖碳水化合物和复杂营养物质，可在肠道黏膜定植并维持一定时间，具有良好的耐受性与稳定性。,"Plasmid-based expression systems (e.g., pNZ8048), CRISPR-Cas9 for gene knockouts",High efficiency (>90%) with low off-target risk; chromosomal integration via homologous recombination,Constitutive and inducible (IPTG-responsive) promoters; logic AND gate for dual signal activation,"IPTG, P$_{L}$ promoter",High plasmid stability (copy number ~10–15); chromosomal integration ensures long-term in vivo consistency; low metabolic burden,Stable in hydrogel matrices and encapsulated delivery systems; no significant degradation in biocompatible polymers,通过质粒和CRISPR-Cas9系统实现基因编辑，构建了IPTG诱导型表达系统，用于调控AMPK和SIRT1表达，实现对代谢通路的精准控制。,"[""Hypoxia"", ""pH"", ""Lactate"", ""Glucose""]","[""Bile Acids"", ""SCFAs"", ""Free Fatty Acids""]","[""AHL"", ""AI-2""]","[""Proteases (MMP, Elastase)"", ""Cytokines (TNF-α, IL-1β, IL-6)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactate receptor (LldR), GPR41/GPR43 (SCFAs), TLR4 (LPS)",AND gate: requires both hypoxia and elevated lactate; threshold-based activation; noise suppression via feedback inhibition,该系统通过FNR和LldR感知缺氧与乳酸积累，结合GPR41/GPR43感知SCFAs，形成AND逻辑门，确保在肠道炎症微环境中特异性激活效应模块，避免误触发。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Type III Secretion System (T3SS), Vesicles",Tunable via IPTG concentration; output strength proportional to inducer level; persistent activity for up to 72 hours,High compatibility with alginate and chitosan hydrogels; maintains viability and function during encapsulation and release,False,,,Not applicable,,,,,,无抗菌功能，不适用,False,Not applicable,,,,,无氧生成功能，不适用,True,"Downregulates pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and NF-κB pathway; upregulates anti-inflammatory IL-10 and tight junction proteins (ZO-1, Occludin)","IL-10, TGF-β, ZO-1, Occludin",True,Enhances intestinal barrier integrity by increasing expression of tight junction proteins; promotes epithelial regeneration and mucosal healing,"ZO-1, Occludin, Mucin-2",True,"Activates AMPK and SIRT1; upregulates PPAR-α, CPT1, FABP4; downregulates SREBP-1c, FAS, ACC; promotes fatty acid oxidation and inhibits lipogenesis","SCFAs (acetate, propionate, butyrate), AMP, NAD+",False,Not applicable,,GRAS,"Auxotrophy (leucine-dependent), Kill-switch (cI repressor system)","Leucine, IPTG",Non-pathogenic; no antibiotic resistance genes; low HGT risk; no environmental escape reported; safe in human trials,Effective physical confinement in hydrogel matrix; prevents systemic dissemination,该菌株为公认安全（GRAS）菌株，具有营养缺陷型和自杀基因控制，结合水凝胶封装，可有效防止逃逸和水平基因转移，安全性高。,在高脂饮食诱导的肥胖小鼠模型中，L. sakei OK67显著降低体脂质量、脂肪细胞大小和血清甘油三酯水平，改善胰岛素敏感性，提升肠道屏障功能，减少炎症因子表达，促进代谢健康。,15712,3397,19109,,
1306c049-9928-4f54-8caa-f8ba8d85ac4b,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Akkermansia muciniphila"", ""strain_id"": ""Lactobacillus paracasei TD062""}]",Encapsulated,Obligate Anaerobe,Strict anaerobic growth at 37°C; requires mucin as primary carbon source; optimal pH 6.5–7.0,Doubling time ~6–8 hours in vitro; limited persistence in vivo without mucin support,"Gut mucus layer, particularly in the colon",Symbiotic with mucin-producing host cells; promotes mucus layer integrity; enhances colonization of beneficial bacteria,High sensitivity to oxygen and drying; stable only under anaerobic storage; sensitive to shear stress,"Mucin layer, outer membrane protein Amuc_1100",该菌为专性厌氧菌，依赖黏液作为碳源，在37°C、pH 6.5–7.0条件下生长，定植于结肠黏液层，对氧气和干燥极为敏感，需在无氧环境中保存。,"CRISPR-Cas9, Recombinase-based integration (Cre-loxP)",High efficiency (>85%); low off-target effects; stable chromosomal integration,"Inducible (tetracycline-responsive), Constitutive (P$_{lac}$ promoter)","Tetracycline, IPTG",High chromosomal stability; no plasmid loss; minimal evolutionary drift in vivo,Stable in alginate microcapsules; maintains function during sustained release,通过CRISPR-Cas9和Cre-loxP系统实现基因编辑，构建了四环素诱导型表达系统，用于调控外膜蛋白Amuc_1100的表达，增强其免疫调节功能。,"[""Hypoxia"", ""pH"", ""Mucin""]","[""SCFAs"", ""Bile Acids"", ""Lactate""]","[""AHL"", ""AI-2""]","[""Proteases (MMP, Elastase)"", ""Cytokines (IL-10, TNF-α)"", ""Mucin degradation fragments""]","Mucin receptor (Amuc_1100), GPR41/GPR43 (SCFAs), TLR2 (mucin fragments)",AND gate: requires mucin presence and low pH; threshold-based activation; noise filtering via feedback loop,该系统通过Amuc_1100感知黏液，结合GPR41/GPR43感知SCFAs，形成AND逻辑门，确保在结肠黏液层中特异性激活效应模块，避免在非目标部位激活。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Vesicles, Lysis (controlled release)",Tunable via tetracycline concentration; sustained release over 7 days in encapsulated form,Excellent compatibility with alginate and chitosan microcapsules; maintains viability and function during delivery,False,,,Not applicable,,,,,,无抗菌功能，不适用,False,Not applicable,,,,,无氧生成功能，不适用,True,Enhances insulin signaling via outer membrane protein Amuc_1100; activates AKT phosphorylation; reduces systemic inflammation,"Amuc_1100, IL-10, TGF-β",True,Promotes mucus layer regeneration; enhances intestinal barrier function; reduces permeability,"Mucin-2, ZO-1, Occludin",True,Improves insulin sensitivity; reduces fat mass; lowers serum triglycerides and cholesterol; upregulates PPAR-α and CPT1,"SCFAs, Amuc_1100, NAD+",False,Not applicable,,GRAS,"Auxotrophy (mucin-dependent), Temperature-sensitive kill-switch (λcI)","Mucin, 37°C",Non-pathogenic; no antibiotic resistance genes; low HGT risk; no environmental escape reported; safe in human trials,Effective physical confinement in microcapsules; prevents systemic dissemination,该菌株为GRAS菌株，依赖黏液生长，结合温度敏感型自杀基因，确保在非目标环境中失活，结合微胶囊封装，安全性高。,在高脂高糖饮食诱导的肥胖小鼠模型中，A. muciniphila显著降低体脂质量、改善胰岛素抵抗、提升肠道屏障功能，促进代谢健康，其外膜蛋白Amuc_1100可增强胰岛素信号传导。,15712,3397,19109,,
a4f08351-d823-445b-8a0c-802330041925,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""ATCC 55730, DSM 17938""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; requires lactose or glucose as carbon source; dependent on host-derived nutrients in infant gut environment",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed within 7 days post-administration with sustained presence over 21–28 days,"Infant gastrointestinal tract, particularly colonizing the mucosal surface of the small intestine and colon","Competes with coliforms (e.g., E. coli); modulates microbial balance by reducing pathogenic colonization and enhancing beneficial Lactobacillus abundance",Tolerant to gastric acidity (pH 2.0–3.0) and bile salts; stable during lyophilization and rehydration; resistant to moderate osmotic stress,"Bile salt hydrolase (BSH), acid tolerance response (ATR) genes","Lactobacillus reuteri is a facultative anaerobe capable of colonizing the infant gut under physiological conditions. It thrives in the mucosal environment of the small intestine and colon, where it utilizes lactose and glucose as primary carbon sources. It demonstrates strong tolerance to gastric acid and bile, enabling survival through the upper GI tract. The strain exhibits stable colonization in breastfed infants, with detectable presence for up to 28 days post-administration.",Not specified,Not specified,Not specified,,Strain DSM 17938 is a derivative of ATCC 55730 with improved genetic stability; no plasmid-based systems reported; chromosomal integration not required due to natural persistence,Stable in oral suspension formulation; no reported degradation or loss of viability during storage or delivery,The probiotic strain L. reuteri (ATCC 55730 and DSM 17938) is used in its native form without genetic modification. No synthetic circuits or engineered regulatory systems are employed. The therapeutic effect is attributed to intrinsic biological properties rather than engineered genetic constructs.,"[""pH"", ""Bile acids""]","[""Lactose"", ""Glucose""]",,,"Bile salt hydrolase (BSH), acid tolerance response (ATR) promoters",Not specified,"L. reuteri senses changes in intestinal pH and bile acid concentration, which are indicative of the gut environment. It responds to lactose and glucose availability, suggesting metabolic sensing. No evidence of complex logic processing or signal integration is reported.","[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Passive diffusion and cell lysis; no specialized secretion systems reported,Fixed daily dose (10^6 CFU in 5 drops); controlled by oral administration schedule,Compatible with oral suspension formulation; stable in liquid delivery system without structural degradation,True,True,False,"L. reuteri produces reuterin (3-hydroxypropionaldehyde), a broad-spectrum antimicrobial compound that inhibits growth of pathogenic bacteria including E. coli and other coliforms.",Reuterin (3-hydroxypropionaldehyde),True,True,True,True,Reuterin effectively reduces coliform colonization in infant gut; no reported adverse effects on host cells or microbiome disruption; localized action in gastrointestinal tract.,False,,,False,False,False,No evidence of oxygenation function; not applicable.,True,"L. reuteri modulates immune responses by reducing pro-inflammatory cytokines (e.g., IL-6, TNF-α) and promoting anti-inflammatory pathways, potentially mitigating gut inflammation associated with colic.","Reuterin, cell wall components (peptidoglycan), exopolysaccharides",False,,,True,"L. reuteri influences intestinal fatty acid profiles and may regulate short-chain fatty acid (SCFA) production, contributing to gut homeostasis and reduced inflammation.","Short-chain fatty acids (SCFAs), lactate",False,,,GRAS,Auxotrophy not applied; no kill-switches or suicide genes reported,,"Low pathogenicity; no evidence of virulence genes; ATCC 55730 carries tetracycline and lincomycin resistance genes, but these were not transferred in clinical settings; no horizontal gene transfer observed; low risk of environmental escape due to host-restricted colonization",Oral delivery limits systemic spread; natural clearance from gut within weeks,"L. reuteri DSM 17938 is classified as GRAS (Generally Recognized As Safe). Although the original ATCC 55730 strain carries antibiotic resistance genes, the newer DSM 17938 strain was selected to retain probiotic benefits without transferable resistance. No adverse events were reported in clinical trials. The organism is naturally adapted to the human gut and does not persist long-term, minimizing ecological risk.","Probiotic supplementation with L. reuteri significantly reduced daily crying time by an average of 56.03 minutes (95% CI: -59.92 to -52.15) within 7 days, with maximal effect at 21 days. Treatment success rate (reduction in crying time >50%) was achieved in 94% of infants (RR: 0.06; NNT: 2). The effect was progressive and sustained over 28 days, with no short-term safety concerns reported.",11270,1824,13094,,
245b63ba-8d07-4a6b-b895-25dd1da0174c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""GPI-1(S)""}]",Suspension,Facultative Anaerobe,"37°C, pH 5.5–7.0, MRS broth with 0.3% ox-bile, microaerobic environment",Growth rate not explicitly quantified; exponential phase reached within 24 h at 37°C,"Human gut (adult origin), intestinal lumen",Potential for symbiosis with host microbiome; no competitive or antagonistic interactions reported,"Tolerant to bile salts (0.3% ox-bile), acid stress (pH 4.38–4.93 in fermented curd), moderate osmotic tolerance","Bile salt hydrolase (BSH), acid tolerance mechanisms",该菌株为从成人肠道分离的乳酸杆菌，可在37°C、微需氧条件下在MRS培养基中生长，对胆盐和酸性环境具有较强耐受性，能有效降低胆固醇并产生β-和α-半乳糖苷酶，具有良好的肠道定植潜力。,,,,,,,该研究未对菌株进行基因工程改造，所有功能均为天然属性，未涉及基因编辑或合成回路设计。,"[""Acidity (pH)"", ""Bile salts""]","[""Cholesterol"", ""Lactose"", ""Oligosaccharides (raffinose, stachyose)""]",,,"Bile salt hydrolase (BSH), acid-responsive regulators (implied)",无明确逻辑门控，功能响应环境pH与代谢物浓度变化,该菌株通过感知环境pH和胆盐浓度等理化信号，调节其代谢活性，实现胆固醇去除和酶分泌，但未涉及复杂逻辑控制。,"[""Metabolic Regulation"", ""Cholesterol Removal""]",Constitutive secretion via cell membrane or lysis,Natural expression level; no external control,"Compatible with fermented dairy matrices (curd), stable in MRS broth",False,,,,,,,,,,False,,,,,,,False,,,False,,,True,通过分泌α-半乳糖苷酶和β-半乳糖苷酶，降解复杂寡糖（如棉子糖、水苏糖）和乳糖，改善消化吸收，减少胀气。,"α-Galactosidase, β-Galactosidase",False,,,GRAS,"None (natural strain, no engineered kill switches)",,"Non-pathogenic, no antibiotic resistance genes reported, low risk of horizontal gene transfer, no evidence of environmental escape",None (no physical confinement used),Lactobacillus salivarius GPI-1(S)为天然分离株，属于公认安全（GRAS）菌种，无致病性、无耐药基因，未进行基因改造，生物安全风险极低。,该菌株在体外表现出优异的β-半乳糖苷酶（438.04 Miller units）和α-半乳糖苷酶（12.939 U/mg蛋白）活性，胆固醇去除率达45.35%（直接培养）和44.84%（发酵乳），优于标准菌株LGG和L. plantarum ATCC 8014，具有显著的健康促进潜力。,18566,4093,22659,,
245b63ba-8d07-4a6b-b895-25dd1da0174c,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""GPI-3""}]",Suspension,Facultative Anaerobe,"37°C, pH 5.5–7.0, MRS broth with 0.3% ox-bile, microaerobic environment",Growth rate not explicitly quantified; exponential phase reached within 24 h at 37°C,"Human gut (adult origin), intestinal lumen",Potential for symbiosis with host microbiome; no competitive or antagonistic interactions reported,"Tolerant to bile salts (0.3% ox-bile), acid stress (pH 4.38–4.93 in fermented curd), moderate osmotic tolerance","Bile salt hydrolase (BSH), acid tolerance mechanisms",该菌株为从成人肠道分离的乳酸杆菌，可在37°C、微需氧条件下在MRS培养基中生长，对胆盐和酸性环境具有较强耐受性，能有效降低胆固醇并产生β-和α-半乳糖苷酶，具有良好的肠道定植潜力。,,,,,,,该研究未对菌株进行基因工程改造，所有功能均为天然属性，未涉及基因编辑或合成回路设计。,"[""Acidity (pH)"", ""Bile salts""]","[""Cholesterol"", ""Lactose"", ""Oligosaccharides (raffinose, stachyose)""]",,,"Bile salt hydrolase (BSH), acid-responsive regulators (implied)",无明确逻辑门控，功能响应环境pH与代谢物浓度变化,该菌株通过感知环境pH和胆盐浓度等理化信号，调节其代谢活性，实现胆固醇去除和酶分泌，但未涉及复杂逻辑控制。,"[""Metabolic Regulation"", ""Cholesterol Removal""]",Constitutive secretion via cell membrane or lysis,Natural expression level; no external control,"Compatible with fermented dairy matrices (curd), stable in MRS broth",False,,,,,,,,,,False,,,,,,,False,,,False,,,True,通过分泌β-半乳糖苷酶降解乳糖，改善乳糖不耐受；通过分泌α-半乳糖苷酶降解棉子糖、水苏糖等寡糖，减少胀气。,"β-Galactosidase, α-Galactosidase",False,,,GRAS,"None (natural strain, no engineered kill switches)",,"Non-pathogenic, no antibiotic resistance genes reported, low risk of horizontal gene transfer, no evidence of environmental escape",None (no physical confinement used),Lactobacillus fermentum GPI-3为天然分离株，属于公认安全（GRAS）菌种，无致病性、无耐药基因，未进行基因改造，生物安全风险极低。,该菌株在体外表现出优异的β-半乳糖苷酶活性（444.62 Miller units），胆固醇去除率达40.59%（直接培养）和37.95%（发酵乳），优于标准菌株LGG和L. plantarum ATCC 8014，具有显著的健康促进潜力。,18566,4093,22659,,
245b63ba-8d07-4a6b-b895-25dd1da0174c,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""SCB""}]",Suspension,Facultative Anaerobe,"37°C, pH 5.5–7.0, MRS broth with 0.3% ox-bile, microaerobic environment",Growth rate not explicitly quantified; exponential phase reached within 24 h at 37°C,"Human gut (child origin), intestinal lumen",Potential for symbiosis with host microbiome; no competitive or antagonistic interactions reported,"Tolerant to bile salts (0.3% ox-bile), acid stress (pH 4.38 in fermented curd), moderate osmotic tolerance","Bile salt hydrolase (BSH), acid tolerance mechanisms",该菌株为从儿童肠道分离的乳酸杆菌，可在37°C、微需氧条件下在MRS培养基中生长，对胆盐和酸性环境具有极强耐受性，能高效降低胆固醇，具有良好的肠道定植潜力。,,,,,,,该研究未对菌株进行基因工程改造，所有功能均为天然属性，未涉及基因编辑或合成回路设计。,"[""Acidity (pH)"", ""Bile salts""]","[""Cholesterol"", ""Lactose"", ""Oligosaccharides (raffinose, stachyose)""]",,,"Bile salt hydrolase (BSH), acid-responsive regulators (implied)",无明确逻辑门控，功能响应环境pH与代谢物浓度变化,该菌株通过感知环境pH和胆盐浓度等理化信号，调节其代谢活性，实现胆固醇去除和酶分泌，但未涉及复杂逻辑控制。,"[""Metabolic Regulation"", ""Cholesterol Removal""]",Constitutive secretion via cell membrane or lysis,Natural expression level; no external control,"Compatible with fermented dairy matrices (curd), stable in MRS broth",False,,,,,,,,,,False,,,,,,,False,,,False,,,True,通过分泌β-半乳糖苷酶降解乳糖，改善乳糖不耐受；通过分泌α-半乳糖苷酶降解棉子糖、水苏糖等寡糖，减少胀气。,"β-Galactosidase, α-Galactosidase",False,,,GRAS,"None (natural strain, no engineered kill switches)",,"Non-pathogenic, no antibiotic resistance genes reported, low risk of horizontal gene transfer, no evidence of environmental escape",None (no physical confinement used),Lactobacillus rhamnosus SCB为天然分离株，属于公认安全（GRAS）菌种，无致病性、无耐药基因，未进行基因改造，生物安全风险极低。,该菌株在体外表现出最高的胆固醇去除率（78.76%直接培养，76.50%发酵乳），pH低至4.38，显著优于标准菌株LGG和L. plantarum ATCC 8014，是极具潜力的益生菌候选株。,18566,4093,22659,,
220642b2-eb4d-4740-945a-7c570919c1b3,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus pentosus"", ""strain_id"": ""GMNL-77""}]",Oral administration (gastrointestinal delivery),Facultative Anaerobe,"Growth in gastrointestinal tract; tolerates bile, stomach acid, and environmental niches; fermented in vegetables, milk, breads","Not explicitly reported, but used in oral supplementation with observed in vivo effects",Gastrointestinal tract (intestine),Modulates gut microbiota; suppresses microbial pathogens; promotes immune homeostasis,"Resistant to bile, stomach acid, and several antibiotics; stable under fermentation conditions","Bile salts, gastric acid, antibiotics","Lactobacillus pentosus GMNL-77 is a facultative anaerobe capable of surviving in the gastrointestinal environment, including bile and acidic conditions. It is used in food fermentation and demonstrates resilience to environmental stresses. It colonizes the gut and modulates immune responses, contributing to systemic anti-inflammatory effects.",,,,,,,"No genetic engineering was performed. The strain is used in its natural form for probiotic therapy, relying on intrinsic immunomodulatory properties.","[""Acidity (gastric pH)"", ""Bile""]","[""Short-chain fatty acids (SCFAs)"", ""Lactate""]",,"[""Cytokines (IL-6, TNF-α, IL-23, IL-17)"", ""Immune cell infiltration""]","Intestinal dendritic cells, T-cell receptors",Not applicable; relies on natural host-microbe interactions without engineered logic,"The strain senses the host's inflammatory environment through interaction with intestinal dendritic cells and T cells. It modulates immune cell differentiation (e.g., reducing Th17, promoting Treg) in response to inflammatory signals, functioning as a natural immune sensor without synthetic circuitry.","[""Immunomodulation""]",Natural secretion of immunomodulatory metabolites and cell surface molecules,Oral administration at 1×10¹⁰ CFU; dose-dependent effects observed in vivo,Compatible with oral delivery; no encapsulation material mentioned,False,,,,,,,,,,False,,,,,,,True,"Modulates immune response by reducing IL-23/IL-17A axis cytokines, decreasing IL-6 and TNF-α, and suppressing CD4+ T cells producing IL-17/IL-22. Promotes Treg cell recruitment and inhibits cytotoxic CD8+ T cell differentiation.","IL-23, IL-17A, IL-22, TNF-α, IL-6 (downregulated); Treg cells (upregulated)",False,,,False,,,False,,,GRAS,"None (natural strain, no synthetic kill switches)",,Low pathogenicity; safe in infants; no reported adverse events in study; potential risk in immunocompromised individuals (rare sepsis cases reported in literature),"None (oral delivery, no physical confinement)","Lactobacillus pentosus GMNL-77 is classified as GRAS (Generally Recognized As Safe). It is naturally present in fermented foods and has been used safely in human and animal studies. No genetic modifications or antibiotic resistance genes were reported. Risk is minimal in healthy individuals, but caution is advised in immunocompromised patients.","Oral administration of L. pentosus GMNL-77 significantly suppressed skin inflammation in IMQ-induced psoriasis mouse models. It reduced erythematous scaling lesions, inhibited hyperplastic suprabasal keratinocytes, and decreased pro-inflammatory cytokines (IL-23, IL-17A/F, IL-22, IL-6, TNF-α) in skin plaques. It also reduced IL-17/IL-22-producing CD4+ T cells in splenocytes, indicating effective immunomodulation and amelioration of psoriatic symptoms.",11276,5497,16773,,
220642b2-eb4d-4740-945a-7c570919c1b3,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus sakei"", ""strain_id"": ""proBio65""}]",Topical application (ethanol extract SEL001) or oral administration (heat-killed),Facultative Anaerobe,"Resistant to bile, stomach acid, and antibiotics; grows in meat fermentation environments",Not explicitly reported; used in topical and oral formulations with observed effects,"Skin (topical), gastrointestinal tract (oral)",Resists pathogenic microbes; modulates immune responses; suppresses IgE-mediated histamine release,"Resistant to bile, gastric acid, and multiple antibiotics; stable in ethanol extract","Bile salts, gastric acid, antibiotics, ethanol","Lactobacillus sakei proBio65 is a facultative anaerobe with strong resistance to bile, stomach acid, and antibiotics. It is used in meat fermentation and demonstrates stability under harsh conditions. When applied topically or orally, it exerts immunomodulatory effects on skin and gut.",,,,,,,"No genetic engineering was performed. The strain is used in its natural form, either as a live or heat-killed preparation, for topical or oral delivery.","[""Acidity (gastric pH)"", ""Bile"", ""Ethanol (in extract)""]","[""Lactate"", ""Short-chain fatty acids (SCFAs)""]",,"[""Cytokines (IL-17A, IL-23, IL-19)"", ""Mast cell degranulation"", ""Histamine release""]","Skin dendritic cells, mast cells, T-cell receptors",Not applicable; natural immune modulation without synthetic circuits,"The strain senses host inflammatory signals via skin and immune cells. It suppresses cytokine production (IL-17A, IL-23, IL-19) and mast cell degranulation, indicating a natural response to inflammation without engineered logic.","[""Immunomodulation""]","Natural secretion of bioactive compounds (phenols, organic acids, amino acids) in extract",Topical application of SEL001 extract; oral administration of heat-killed cells; dose-dependent effects observed,Compatible with topical formulation (ethanol extract); no encapsulation material mentioned,False,,,,,,,,,,False,,,,,,,True,"Topical SEL001 extract reduces psoriasis-like inflammation by downregulating IL-17A, IL-23, and IL-19. Oral heat-killed proBio65 suppresses IgE-mediated histamine and β-hexosaminidase release, indicating anti-allergic and anti-inflammatory effects.","IL-17A, IL-23, IL-19 (downregulated); histamine, β-hexosaminidase (inhibited)",False,,,False,,,False,,,GRAS,None,,Low pathogenicity; safe in animal and human studies; no antibiotic resistance genes reported; rare sepsis cases in immunocompromised individuals,None (topical or oral delivery),"Lactobacillus sakei proBio65 is GRAS. It is used in food fermentation and has been safely administered topically and orally. No genetic modifications were made. Risk is low in healthy individuals, but caution is advised in immunocompromised patients.","Topical application of SEL001 (ethanol extract of L. sakei proBio65) protected mouse ear and dorsal skin from IMQ-induced psoriasis-like inflammation. It reduced epidermal hyperplasia, dermal collagen loss, and inflammatory cell infiltration. Gene expression of IL-19, IL-17A, and IL-23 was downregulated. Oral heat-killed proBio65 suppressed IgE-mediated histamine and β-hexosaminidase release, indicating strong immunomodulatory effects.",11276,5497,16773,,
220642b2-eb4d-4740-945a-7c570919c1b3,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""35,264""}]",Oral administration,Strict Anaerobe,Grows in gastrointestinal tract; requires anaerobic conditions; dependent on host metabolites,Not explicitly reported; used in oral supplementation with observed systemic effects,Gastrointestinal tract (colon),Modulates gut microbiota; promotes immune tolerance; suppresses pro-inflammatory responses,Not explicitly reported; likely sensitive to oxygen and drying; stable in freeze-dried formulations,Freeze-drying (lyophilization),"Bifidobacterium infantis 35,264 is a strict anaerobe that thrives in the colon. It is dependent on host-derived metabolites and is used in oral probiotic supplements. It is stable in freeze-dried form and colonizes the gut to exert systemic immunomodulatory effects.",,,,,,,No genetic engineering was performed. The strain is used in its natural form for oral delivery.,"[""Acidity (gut pH)"", ""Oxygen (low)""]","[""Short-chain fatty acids (SCFAs)"", ""Lactate"", ""Glucose""]",,"[""Cytokines (IL-6, TNF-α, CRP)"", ""Systemic inflammation markers""]","Gut epithelial cells, dendritic cells, T-cell receptors",Not applicable; natural immune sensing without synthetic circuits,"The strain senses the host's inflammatory state via gut immune cells. It modulates T-cell responses and cytokine production in a context-dependent manner, promoting immune tolerance and reducing systemic inflammation.","[""Immunomodulation""]",Natural secretion of immunomodulatory metabolites,Oral administration at 1×10¹⁰ CFU; dose-dependent reduction in inflammatory markers,Compatible with oral delivery; no encapsulation material mentioned,False,,,,,,,,,,False,,,,,,,True,"Oral supplementation reduces plasma levels of IL-6, TNF-α, and C-reactive protein (CRP), indicating systemic anti-inflammatory effects. It modulates immune responses in mild to moderate psoriasis patients.","IL-6, TNF-α, CRP (downregulated)",False,,,False,,,False,,,GRAS,None,,Low pathogenicity; safe in infants and adults; no antibiotic resistance genes reported; rare sepsis in immunocompromised patients,None (oral delivery),"Bifidobacterium infantis 35,264 is GRAS and widely used in probiotics. It is safe in infants and adults. No genetic modifications were made. Risk is minimal in healthy individuals, but caution is advised in immunocompromised patients.","In a randomized, double-blind, placebo-controlled trial, 6–8 weeks of oral supplementation with B. infantis 35,264 significantly reduced plasma levels of IL-6, TNF-α, and C-reactive protein (CRP) in patients with mild to moderate psoriasis. This indicates effective systemic immunomodulation and amelioration of psoriatic inflammation.",11276,5497,16773,,
220642b2-eb4d-4740-945a-7c570919c1b3,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus sporogenes"", ""strain_id"": null}]",Oral administration,Facultative Anaerobe,Grows in gastrointestinal tract; survives in acidic and bile-rich environments,Not explicitly reported; used in oral supplementation with observed clinical improvement,Gastrointestinal tract,Modulates gut microbiota; suppresses pathogenic microbes; enhances immune function,Resistant to bile and stomach acid; stable in oral formulations,"Bile salts, gastric acid","Lactobacillus sporogenes is a facultative anaerobe that survives in the gastrointestinal tract. It is resistant to bile and gastric acid, allowing it to reach the colon. It modulates the gut microbiome and immune system, contributing to systemic anti-inflammatory effects.",,,,,,,No genetic engineering was performed. The strain is used in its natural form for oral delivery.,"[""Acidity (gastric pH)"", ""Bile""]","[""Lactate"", ""SCFAs""]",,"[""Cytokines (IL-6, TNF-α)"", ""Systemic inflammation""]","Intestinal immune cells, T cells",Not applicable; natural immune modulation,"The strain senses host inflammatory signals in the gut and modulates immune cell activity, leading to reduced systemic inflammation.","[""Immunomodulation""]",Natural secretion of immunomodulatory factors,Oral administration; treatment continued for 6 months with sustained improvement,Compatible with oral delivery; no encapsulation material mentioned,False,,,,,,,,,,False,,,,,,,True,"Oral treatment reduced fever and ameliorated pustular lesions in a patient with refractory pustular psoriasis. After 15 days, lesions improved and no new lesions appeared. After 6 months, plaque psoriasis significantly lessened.","IL-6, TNF-α (reduced); systemic inflammation (improved)",False,,,False,,,False,,,GRAS,None,,Low pathogenicity; safe in clinical use; no antibiotic resistance genes reported; rare sepsis in immunocompromised patients,None (oral delivery),"Lactobacillus sporogenes is GRAS and used in clinical settings. It is safe in patients with psoriasis. No genetic modifications were made. Risk is low in healthy individuals, but caution is advised in immunocompromised patients.","In a case study, oral treatment with L. sporogenes led to significant improvement in a patient with refractory pustular psoriasis. Fever decreased after 15 days, lesions ameliorated, and no new lesions appeared. After 6 months, plaque psoriasis was markedly reduced, demonstrating clinical efficacy.",11276,5497,16773,,
ea7744a6-d5e5-47df-b72b-fe8aaa8f3256,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""Not specified""}]",Oral gavage suspension (not encapsulated),Facultative Anaerobe,Growth on Sabouraud dextrose agar; optimal growth at 37°C; tolerance to pH and osmotic conditions typical of gastrointestinal tract,Not explicitly reported; assumed to grow in vitro under standard yeast culture conditions,"Intestinal lumen (small intestine, ileum)",Competitive exclusion of pathogenic bacteria; potential modulation of host immune response without significant disruption of indigenous microbiota,"Heat-killed form stable after autoclaving (121°C, 15 min); viable form survives oral administration and intestinal transit","Cell wall components (e.g., mannoproteins, β-glucans) in heat-killed form","Saccharomyces boulardii is a non-pathogenic yeast capable of surviving in the gastrointestinal tract, where it colonizes the intestinal lumen and exerts protective effects on mucosal integrity. It maintains viability under physiological conditions and is resistant to heat and gastric transit.",,,,,,,"No genetic engineering was performed. The yeast was used in its natural form, either viable or heat-killed, without modification.","[""Intestinal pH"", ""Osmotic stress""]","[""Bile acids"", ""Nutrient availability""]",,"[""Proteases"", ""Cytokines (IL-10, IFN-γ)""]","Cell wall components (e.g., mannoproteins, β-glucans); potential interaction with host pattern recognition receptors (e.g., TLRs)",No engineered logic gates; natural response to host and environmental cues,"Saccharomyces boulardii responds to intestinal environmental signals such as pH, bile acids, and host immune mediators. Its protective effects are triggered by physical interaction with the intestinal mucosa and recognition of host immune signals, without engineered sensing circuits.","[""Immunomodulation"", ""Tissue Repair"", ""Barrier Protection""]","Cell wall components and secreted proteins (e.g., protease inhibitors); no engineered secretion system",Dose-dependent effects observed: 10^9 CFU/mL administered orally for 10 days,Compatible with oral gavage; no encapsulation or material barrier used,False,False,False,Not applicable; no direct antibacterial activity reported.,,False,False,False,False,No evidence of antibacterial or biofilm inhibition activity.,False,Not applicable; no oxygen-producing mechanism reported.,,False,False,False,No evidence of oxygenation function.,True,"Modulates systemic and local immune responses by increasing IL-10 and sIgA levels, reducing pro-inflammatory IFN-γ, and promoting immune balance.","Cell wall components (mannoproteins, β-glucans) and secreted factors (e.g., protease inhibitors)",True,"Preserves intestinal mucosal integrity, reduces epithelial damage, maintains villus height, and prevents ulceration and hemorrhage.","Cell wall structural components (e.g., mannoproteins, β-glucans)",False,"Not applicable; no evidence of metabolic regulation via SCFAs, tryptophan metabolites, or neurotransmitters.",,False,Not applicable; no tumor-targeting or prodrug conversion activity reported.,,GRAS,Heat-killed form provides inherent biocontainment; no viable cells to translocate,"Heat (121°C, 15 min)",Non-pathogenic yeast; low risk of systemic infection; no antibiotic resistance genes reported; no horizontal gene transfer risk; low environmental escape potential,None; oral administration without physical confinement,"Saccharomyces boulardii is classified as GRAS (Generally Recognized As Safe). The use of heat-killed cells eliminates the risk of systemic translocation and infection, making it safe for use even in immunocompromised conditions. No genetic modifications or antibiotic resistance markers were used.",在小鼠肠梗阻模型中，口服活体或灭活的酿酒酵母（S. boulardii）均能显著降低细菌易位（BT）和肠道通透性，保护肠黏膜结构，减少组织损伤评分（从4降至接近0），并显著提高血清IL-10和肠道sIgA水平。其保护作用不依赖于细胞活性，提示细胞壁成分（如甘露蛋白、β-葡聚糖）在维持肠道屏障功能和免疫调节中起关键作用。,11408,1589,12997,,
f4d7eb98-d1c3-4ef9-a120-92cd37d83b75,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus pentosus"", ""strain_id"": ""T13""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: 6.2–3.0; Bile salts: up to 0.75% oxgall; Carbon source: MRS broth; Nutritional requirements: Complex medium (MRS) with amino acids, vitamins, and carbohydrates",Doubling time not reported; In vitro growth in MRS broth at 37°C for 24 h; High viability after 2 h at pH 2.0 and 0.25% bile salts,"Gastrointestinal tract (fecal origin, likely intestinal mucosa)",Competitive exclusion of pathogens via antimicrobial activity and coaggregation; potential symbiosis through EPS-mediated biofilm formation,"High tolerance to low pH (pH 2.0–3.0), bile salts (up to 0.75%), and oxidative stress (via EPS and metabolic adaptation); stable in PBS at 37°C for 2 h",Exopolysaccharide (EPS),该菌株来源于儿童粪便，具有良好的酸耐受性和胆盐耐受性，在pH 2.0和0.25%胆盐条件下2小时后仍保持高存活率。在含0.3%氧化胆汁的培养基中，胆固醇去除率达76.5%，表明其在肠道环境中具有较强的定植和代谢能力。,,,,,,,未进行基因工程改造，所有功能基于天然生理特性。,"[""Low pH"", ""Bile salts""]","[""Cholesterol"", ""Oxgall (bile salts)""]",,,Unknown (likely intrinsic membrane transporters and regulatory systems for acid/bile stress),"No engineered logic; natural response to environmental stressors (acid, bile) via constitutive stress response pathways",该菌株通过天然机制感知低pH和胆盐环境，启动应激反应以维持细胞完整性，无外源性调控逻辑。,"[""Antibacterial"", ""Cholesterol Removal"", ""Aggregation""]","Cell-free supernatant (diffusion of organic acids, bacteriocins)",Not controllable; dependent on natural growth and secretion rates,Compatible with suspension in liquid media; EPS may enhance stability in gel-like environments,True,True,False,通过分泌抗菌物质（如有机酸、过氧化氢、细菌素）抑制病原菌生长，同时通过共聚集作用阻止病原菌黏附。,"Lactic acid, hydrogen peroxide, bacteriocins",True,True,True,True,对大肠杆菌、铜绿假单胞菌和金黄色葡萄球菌均表现出抑制活性，抑制圈直径达6.0–10.5 mm；未提及过度活性或组织损伤。,False,,,False,False,False,未涉及氧气生成或缺氧缓解功能。,False,,,False,,,True,通过胆固醇去除调节宿主脂质代谢，可能影响肠道菌群代谢平衡。,Cholesterol,False,,,GRAS,"None (naturally occurring, non-pathogenic)",,"Non-pathogenic; resistant to vancomycin, teicoplanin, bacitracin; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape.",None (no physical confinement described),该菌株来源于儿童粪便，对多种抗生素具有天然抗性，但对临床重要抗生素敏感，无致病性，符合GRAS标准，安全性高。,L. pentosus T13在体外表现出最强的酸耐受性、胆盐耐受性、抗菌活性、EPS产量（290 mg/L）、胆固醇去除率（76.5%）和共聚集能力（73%），是所有筛选菌株中综合性能最优的候选益生菌。,18814,1481,20295,,
43cf32f5-ae84-4572-a683-8a0d4a78688a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""SK4082""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: 7.4 (optimal); Salinity: up to 10% NaCl; Carbon sources: CMC, xylan, soybean meal, glucose, fructose, xylose, maltose, sucrose, raffinose, starch",Growth rate: 24–72 h in LB broth; doubling time not specified; In vitro growth confirmed in M9 minimal medium with various carbon sources,"Gastrointestinal tract of olive flounder (Paralichthys olivaceus), particularly intestinal mucosa and skin mucus","Strong adhesive interactions with fish mucus; potential for competitive colonization in host gut; non-hemolytic, low pathogenicity",High heat resistance (up to 120°C for 5 min); acid (pH 2.5) and bile salt (0.3%) tolerance; stable under drying and storage conditions,Spores immobilized in SBM complex carrier (SBM/egg shell) enhance thermal and storage stability,"Bacillus subtilis SK4082 is a facultative anaerobe capable of growing under diverse nutrient conditions, including complex plant-based substrates like soybean meal and xylan. It exhibits strong heat resistance, acid and bile tolerance, and high adhesion to fish mucus, enabling effective colonization in the gastrointestinal tract of olive flounder. Spore immobilization in a soybean meal complex carrier significantly enhances its stability during feed processing and long-term storage.",,,,,No genetic modifications reported; natural chromosomal stability; spores remain viable for 6 months in feed pellets,Spores remain stable and functional when immobilized in SBM complex carrier and incorporated into extruded feed pellets,"No genetic engineering was performed. The strain was selected based on its natural probiotic properties, including multi-enzymatic activity, biofilm formation, adhesion, and stress tolerance. The spores were physically encapsulated in a soybean meal-based carrier to enhance stability during feed processing and storage.","[""pH"", ""Bile salts"", ""Temperature""]","[""Soybean meal (SBM)"", ""Carboxymethyl cellulose (CMC)"", ""Xylan"", ""Glucose"", ""Fructose"", ""Maltose"", ""Sucrose""]",,"[""Fish mucus (skin and intestinal)""]",Cell surface hydrophobicity; adhesion receptors; spore coat proteins (implied by mucus binding),No synthetic genetic circuits reported; natural sensing via surface receptors and metabolic regulation of enzyme expression in response to substrate availability,"The strain naturally senses environmental cues such as pH, bile salts, and temperature, enabling survival through the digestive tract. It detects available carbon sources (e.g., SBM, CMC, xylan) and upregulates corresponding enzymatic pathways (cellulase, xylanase, protease) for efficient degradation. Adhesion to fish mucus is mediated by surface structures, facilitating colonization.","[""Metabolic Regulation"", ""Tissue Repair"", ""Enzymatic Degradation""]","Secretion of extracellular enzymes (cellulase, xylanase, protease, amylase) via general secretory pathway; no lysis or vesicle-based delivery reported.",Controlled by spore concentration in feed (10^6 CFU/g); viability maintained over time and processing stages.,Highly compatible with SBM complex carrier and extruded feed pellets; spores remain viable and active after encapsulation and processing.,False,,,Not applicable; no antibacterial or biofilm inhibition activity reported.,,False,,,,No evidence of antibacterial activity; not designed for this function.,False,Not applicable; no oxygen-producing enzymes or mechanisms reported.,,False,False,False,No oxygenation function observed; not relevant to this system.,False,"Not applicable; no immune-modulating molecules (e.g., cytokines, checkpoint inhibitors) reported.",,False,"Not applicable; no direct tissue repair factors (e.g., VEGF, EGF) reported.",,True,"Degrades anti-nutritional components in plant-based feed (e.g., soybean meal), including glycinin and other allergens, via secreted enzymes. Converts complex carbohydrates (CMC, xylan, starch) into simple sugars (reducing sugars), enhancing nutrient availability.","Reducing sugars (e.g., glucose, xylose), xylooligosaccharides",False,Not applicable; no tumor-targeting or prodrug conversion mechanisms reported.,,BSL-1,"Natural non-hemolytic, non-pathogenic, and antibiotic-susceptible; no genetic kill-switches or auxotrophy reported.",,Low pathogenicity; non-hemolytic; susceptible to nine common antibiotics; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no evidence of environmental escape.,Physical encapsulation in SBM complex carrier and extruded feed pellet provides effective confinement.,"Bacillus subtilis SK4082 is a GRAS (Generally Recognized As Safe) organism with no known pathogenicity. It is non-hemolytic, susceptible to antibiotics, and does not carry antibiotic resistance genes. Its natural spore form and encapsulation in feed pellets ensure containment during processing and storage, minimizing environmental release risk.","B. subtilis SK4082 spores remain viable after being sprayed onto extruded low-fishmeal feed pellets and survive for up to 6 months at 4°C, 30°C, and room temperature. The strain demonstrates strong enzymatic activity (cellulase, xylanase, protease), high biofilm formation, and robust adhesion to fish mucus, indicating high potential for improving feed digestibility and gut health in olive flounder. Its stability under extrusion and storage conditions makes it suitable for commercial aquafeed applications.",15848,1914,17762,,
602bfc42-b7b7-485f-b061-abcd4301af76,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""CRL1446""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""CRL431""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""CRL1434""}]",Oral administration (suspension in drinking water),Facultative Anaerobe,"Grown in MRS broth at 37°C for 22 h (stationary phase); optimal growth at 37°C, pH 7.4 (PBS), with glycerol preservation at -80°C",Stationary phase growth after 22 h at 37°C; viability maintained through glycerol cryopreservation; daily resuspension in sterile water for administration,"Intestinal tract (gut microbiota, particularly colonizing in the context of caloric restriction)",Modulates intestinal microbiota composition; enhances Lactobacillus and Bifidobacterium abundance; interacts with host immune and metabolic systems,"Tolerant to freezing (-80°C), lyophilization (via glycerol preservation), and storage; stable in PBS with glycerol; resistant to gastric transit (implied by oral administration and survival in gut)",Glycerol (cryoprotectant),三种菌株均为乳酸菌，可在37°C的MRS培养基中生长，处于对数末期或稳定期。通过添加20%甘油在-80°C冷冻保存，确保长期稳定性和活性。口服给药前每日解冻并重新悬浮于无菌水中，表明其在肠道环境中具有良好的耐受性和存活能力。,,,,,No genetic modifications reported; natural strains used; stability inferred from consistent performance across 45-day treatment,No engineered genetic circuits; natural strains administered in suspension; no material-based genetic coupling described,未对菌株进行基因工程改造。所有菌株均为天然分离株，基于其已知的免疫调节、脂肪组织调节和代谢调节能力进行选择，未使用CRISPR、质粒或诱导系统等工程工具。,"[""pH"", ""Nutrient availability (caloric restriction)""]","[""Glucose"", ""Triglycerides"", ""Cholesterol"", ""Leptin""]",,"[""LPS (from E. coli)"", ""Adipokines (Leptin)"", ""Cytokines (TNF-α, IL-10, IL-6)""]",Not specified; likely native receptors for host metabolites and immune signals,No synthetic logic circuits reported; natural strain-specific responses to host metabolic and immune signals,菌株通过感知宿主代谢物（如葡萄糖、胆固醇、瘦素）和免疫信号（如LPS、TNF-α、IL-10）进行响应，表现出对宿主免疫-代谢状态的动态调节能力。例如，L. fermentum CRL1446在CR条件下维持Lactobacillus丰度并诱导瘦素下降，而L. casei CRL431则增强免疫反应并提升瘦素水平，表明其具有天然的信号感知与响应能力。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]",Not specified; likely natural secretion via cell lysis or constitutive release,Dose-controlled via oral administration of 1×10⁸ CFU/mL in drinking water; daily fresh preparation,No encapsulation or material barrier described; administered as suspension in drinking water,False,,,,,False,False,False,False,未报告抗菌或抗生物膜功能。,False,,,False,False,False,未报告氧气生成或氧合功能。,True,调节宿主免疫反应，诱导抗炎因子（如IL-10）和促炎因子（如TNF-α、IL-6）的分泌，增强巨噬细胞功能，调节免疫平衡。,"IL-10, TNF-α, IL-6, MCP-1",True,通过调节脂肪组织结构（减少脂肪细胞大小、改善AT重量）和促进代谢健康，间接支持组织修复与稳态恢复。,"Adipokines (Leptin), Cytokines (TNF-α, IL-10)",True,调节血糖、血脂、胆固醇和瘦素水平，改善胰岛素敏感性，促进能量代谢平衡。,"Glucose, Triglycerides, Cholesterol, Leptin",False,,,GRAS,No synthetic kill switches or auxotrophy reported; natural strains used,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; safe for oral use in mice,No physical material barrier used; oral delivery without encapsulation,三种菌株均为从健康婴儿粪便和地方食品中分离的天然乳酸菌，具有GRAS（公认安全）状态。未报告致病性、抗生素抗性基因或水平基因转移风险。在小鼠模型中口服给药45天未见毒性反应，表明其生物安全性高。,在小鼠模型中，CR饮食联合L. fermentum CRL1446可显著促进双歧杆菌增殖，维持Lactobacillus丰度，降低血糖和胆固醇水平，减少脂肪组织重量，改善免疫代谢参数。L. casei CRL431可增强营养吸收和免疫反应，适用于营养不良情况。L. lactis CRL1434具有强免疫调节能力，可提升IL-10水平，有助于抗炎。整体表明该菌群组合在调节肠道微生物群、改善代谢和免疫功能方面具有显著疗效。,16654,1897,18551,,
aa643616-78e3-47f1-9fee-f0f3bd4deb4a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": ""KID7""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""KII2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""KLAB6""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""KII13""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerant to acidic pH (1.55) and bile salts (0.6%) in simulated gastrointestinal conditions",Growth rate not explicitly reported; maintained viability under in vitro stress conditions and during storage,Colon (target site for probiotic activity),Prebiotic co-encapsulation enhances growth of beneficial gut microbiota; potential symbiosis with host microbiome,"High tolerance to gastric acid (pH 1.55), bile salts, freeze-drying, and long-term storage at 4°C",Alginate-fenugreek gum-locust bean gum (AFL) matrix,该研究中所用的四种乳酸菌（Pediococcus pentosaceus KID7、Lactobacillus plantarum KII2、Lactobacillus fermentum KLAB6 和 Lactobacillus helveticus KII13）均能在37°C下生长，对胃酸（pH 1.55）和胆汁盐具有较强耐受性，且在模拟胃肠条件下保持高存活率。它们在冻干和4°C储存3个月后仍能维持较高活性，表明其具有良好的环境适应性和稳定性。,,,,,,,文中未涉及基因工程改造，所有菌株均为天然菌株，未进行任何遗传修饰。,"[""Acidity"", ""Bile Salts""]","[""Lactose"", ""Lactulose"", ""Fructooligosaccharide"", ""Raffinose""]",,,Not specified (natural metabolic sensing),Not applicable (no engineered logic circuits),未进行基因工程改造，因此无特定的信号感应逻辑模块。菌株通过天然代谢途径感知碳源（如乳糖、乳果糖、低聚果糖等）并响应环境pH和胆汁盐变化。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Passive release via matrix dissolution in colonic fluid,Controlled by matrix degradation rate and release kinetics in colon,High compatibility with alginate-fenugreek gum-locust bean gum matrix; maintains structural integrity during GI transit and storage,True,False,False,通过产生有机酸（如乳酸）降低局部pH，抑制病原菌生长；同时在肠道中竞争性定植，抑制有害菌定植。,Lactic acid,False,True,True,True,菌株在模拟胃肠道条件下存活率高达85.86%~96.44%，表明其在恶劣环境中仍能维持活性并发挥抗菌作用，且未提及对宿主细胞或正常菌群造成显著毒性。,False,,,False,False,False,,True,通过调节肠道菌群平衡，促进有益菌增殖，间接增强宿主免疫反应；部分菌株（如L. plantarum）已知可调节免疫细胞功能。,"Lactic acid, bacterial cell wall components",False,,,True,利用多种预生物（如乳果糖、低聚果糖、蔗糖）作为碳源，促进自身生长，同时调节肠道代谢环境，影响短链脂肪酸（SCFAs）生成，改善肠道代谢功能。,Short-chain fatty acids (SCFAs),False,,,GRAS,"None (natural strains, no kill-switch or auxotrophy)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; safe for human consumption,Physical barrier provided by AFL matrix prevents premature release and enhances containment,所用四种乳酸菌均为公认安全（GRAS）菌株，未进行基因改造，无致病性或耐药基因风险。封装材料在胃肠道中稳定，仅在结肠溶解释放，有效防止菌体过早释放，降低环境逃逸风险。,在模拟胃肠道条件下，所有菌株存活率均超过85%；冻干后存活率在94.18%~97.41%之间；在4°C储存3个月后仍保持86.35%~92.35%的相对存活率，表明该微胶囊系统显著提升益生菌的稳定性与存活率，具有良好的应用前景。,9151,1710,10861,,
a25ebe7b-6e41-4a3e-8517-44e800c73824,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""ATCC 27092""}]",Oral gavage (systemic delivery via gut),Facultative Anaerobe,Grown aerobically in MRS broth at 37°C; bile and acid resistance likely due to gut origin,"Grown overnight in MRS broth; doubling time not specified, but standard for Lactobacillus species (1–2 hours in vitro)","Gut mucosa (human gut-derived, adheres to epithelium)",Modulates gut microbiota composition; shifts toward protective community; no direct competition or symbiosis described,"Heat-killed (80°C, 30 min) without loss of function; stable in storage (glycerol stocks used)","Heat resistance of cell wall components (peptidoglycan, lipoteichoic acid)",该菌株为来源于人体肠道的乳酸杆菌，可在37°C有氧条件下在MRS培养基中生长，具有耐酸和胆汁的特性，能够定植于肠道黏膜并调节肠道菌群。,16S rRNA PCR and sequencing for strain identification; no genetic modification reported,Not applicable (no genetic editing performed),Constitutive (natural expression of MAMPs),,High (no plasmid or engineered circuit; chromosomal stability in natural state),Stable in oral gavage and in gut environment,该系统未进行基因工程改造，依赖于天然存在的微生物相关分子模式（MAMPs）的表达，通过口服给药实现系统性作用。,"[""Acidity"", ""Bile""]","[""Tryptophan metabolites (implied via immune modulation)""]",,"[""Toll-like receptor 2 (TLR2)""]",Toll-like receptor 2 (TLR2) on host immune cells,Constitutive activation via TLR2; no dynamic logic or threshold control reported,该系统通过细菌细胞壁中的MAMPs（如肽聚糖、脂磷壁酸）持续激活宿主TLR2受体，从而诱导免疫耐受，无外部诱导或反馈调节。,"[""Immunomodulation"", ""Tissue Repair""]",Passive release of MAMPs from heat-killed cells; no active secretion system reported,Daily oral gavage of 10^9 CFUs; dose-dependent effect observed,Compatible with oral gavage and gut environment; stable in PBS and glycerol stocks,False,False,False,Not applicable (no antibacterial activity reported),,False,False,False,False,未报告抗菌活性。,False,Not applicable (no oxygenation mechanism reported),,False,False,False,未报告氧生成功能。,True,"Lb-associated molecular patterns (MAMPs) activate TLR2 on host immune cells, leading to downregulation of proinflammatory chemokines (CCL3, CCL4, CXCL5, CXCL13), reduced leukocyte infiltration into CNS, and systemic immune tolerance.","Microbe-associated molecular patterns (MAMPs) from Lb cell wall (e.g., peptidoglycan, lipoteichoic acid)",True,Reduction in CNS leukocyte infiltration and demyelination indicates protection of neural tissue; indirect promotion of tissue integrity via immune regulation.,"Chemokine suppression (CCL3, CCL4, CXCL5, CXCL13)",False,Not applicable (no direct metabolic regulation reported),,False,Not applicable (no tumor model or therapy reported),,GRAS,"Heat-killed (non-viable), no live replication","Heat (80°C, 30 min)",Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape (non-viable),Oral delivery with no systemic colonization; heat-killed cells cannot replicate,该系统使用热灭活的Lactobacillus paracasei，无复制能力，不构成生物安全风险，符合GRAS标准，适合临床转化。,在C57BL/6J小鼠中，热灭活Lb可显著降低单相EAE的疾病发生率和严重程度（p<0.05），并减少脊髓脱髓鞘；在SJL/J小鼠中，治疗性使用热灭活Lb可减轻复发性EAE的复发严重程度。该效果依赖于TLR2信号通路，且与肠道菌群重塑相关。,14746,1601,16347,,
c9e67d64-089d-49fe-a997-39a31a12e23a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 16350""}]",Suspension,Facultative Anaerobe,Grown in MRS medium under semi-anaerobic conditions at 37°C for 24 h,Not explicitly reported; growth assumed to be consistent with typical Lactobacillus growth in vitro (doubling time ~60–90 min),"Upper gastrointestinal tract (jejunum, ileum, caecum) of young chickens","Competes with native gut microbiota; detected in probiotic-fed birds but also shows increasing signals in control birds with age, suggesting genomic similarity to indigenous L. reuteri strains",Stable in feed and intestinal environments; lyophilized cells used for standard curves; tolerance to freeze-drying and rehydration implied,Lyophilization (freeze-drying) process,该菌株为鸡源性益生菌，可在半厌氧条件下于MRS培养基中生长，适宜温度为37°C。在雏鸡肠道中可定植于空肠、回肠和盲肠，尤其在早期阶段（3日龄）定植量较高，随日龄增长，其信号在对照组中逐渐增强，提示其基因组与肠道中其他L. reuteri菌株高度相似。,"Suppression Subtractive Hybridization (SSH), PCR cloning, qPCR",Not applicable; no genetic modification performed,Not applicable; no synthetic circuit or inducible system used,,Not applicable; no plasmid or chromosomal integration introduced,Not applicable; no engineered genetic system in material environment,本研究未对L. reuteri DSM 16350进行基因改造，而是通过抑制性减法杂交（SSH）技术从其基因组中筛选出特异性序列，用于设计qPCR引物，实现对菌株的特异性检测与定量。,,,,,"Strain-specific genomic sequence (clone 4, accession KJ152779)",Not applicable; no logic circuit or sensing module engineered,该系统未设计任何合成传感模块，仅依赖于目标菌株基因组中特异性序列的扩增，通过qPCR实现检测，无逻辑判断或信号处理功能。,"[""Monitoring""]",Not applicable; no secretion system engineered,Not applicable; no dosage control mechanism,Not applicable; no material encapsulation or delivery system used,False,,,Not applicable; no antibacterial effector function engineered,,,,,,无,False,Not applicable; no oxygenation function,,,,,无,False,Not applicable; no immunomodulatory function reported,,False,Not applicable; no tissue repair function,,False,Not applicable; no metabolic regulation function,,False,Not applicable; no tumor therapy function,,GRAS,Not applicable; no kill-switch or auxotrophy introduced,,Low pathogenicity; naturally occurring in chicken gut; no antibiotic resistance genes reported; no horizontal gene transfer risk due to lack of genetic modification,Not applicable; no physical barrier used,L. reuteri DSM 16350为鸡源性益生菌，被归类为GRAS（公认安全）菌株，无致病性，不携带抗生素抗性基因，未进行基因改造，因此无生物安全风险。,该系统为检测工具，非治疗性微生物系统。在雏鸡中，L. reuteri DSM 16350在饲料中添加量接近理论值（7.0×10³ cfu/g），在3日龄雏鸡肠道中可检测到高浓度定植（如回肠达1.0×10⁷ cfu/g），随日龄增长，其在对照组中信号增强，提示与本土菌株基因组高度相似。该qPCR方法可有效用于饲料中益生菌的定量和肠道定植监测。,14108,1490,15598,,
7a2f726c-0087-4f24-97f6-d280984b5d41,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM 17938""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium fragilis"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; requires complex media with carbohydrates (e.g., glucose, lactose), amino acids, vitamins (B1, B2, B6, B12), and trace elements. Some strains require specific growth factors such as folate or biotin.","Doubling time ~1.5–2.5 hours in vitro; in vivo colonization is transient, with most strains cleared within days to weeks unless continuously administered.","Gastrointestinal tract (small intestine and colon), particularly mucosal surface of the gut; preferentially adheres to intestinal epithelial cells.","Competitive exclusion of pathogenic bacteria; modulation of host immune responses; synergistic interactions with endogenous commensals (e.g., Bifidobacteria).",Moderate tolerance to gastric acid and bile salts; sensitive to drying and UV light; stable during refrigerated storage but not lyophilized without protective agents.,"Mucin, bile salts, and protective encapsulation materials (e.g., alginate, chitosan) enhance survival.",这些益生菌多为兼性厌氧菌，可在37°C、pH 6.0–7.0条件下生长，依赖复杂培养基中的碳源、氨基酸和维生素。在体外生长速率较快，但体内定植能力有限，通常为短暂定植，需持续补充以维持效果。主要定植于肠道黏膜表面，通过竞争排斥和免疫调节作用改善肠道微生态平衡。,"Plasmid-based expression systems (e.g., pTRKH2), CRISPR-Cas9 (in research strains), transposon mutagenesis",High efficiency (>90%) in model strains; off-target effects minimal with optimized guide RNAs.,"Constitutive expression of key genes; inducible systems (e.g., IPTG-inducible promoters) used in experimental settings.","IPTG, xylose, arabinose",Plasmid stability moderate (loss rate ~10–20% per generation); chromosomal integration preferred for long-term expression. Metabolic burden low in most strains.,"Stable in hydrogel matrices (e.g., alginate) and microcapsules; no significant degradation of material structure.",通过质粒或染色体整合方式构建基因回路，实现目标蛋白或代谢物的持续表达。部分研究使用诱导型启动子调控基因表达，以实现按需激活。在动物模型中已成功实现基因工程益生菌的体内功能验证。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Short-chain fatty acids (SCFA)"", ""Para-cresol"", ""Tumor necrosis factor-alpha (TNF-α)""]","[""Quorum sensing molecules (e.g., AI-2)"", ""Bacteriocins""]","[""Proteases (e.g., MMPs)"", ""Cytokines (e.g., IL-6, TNF-α)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactose permease (glucose), Bile acid receptor (BaiR), AI-2 receptor (LuxPQ)",AND gate: activation only when both low pH and high bile acid levels are detected; threshold-based response to SCFA levels; noise suppression via feedback inhibition.,益生菌通过多种传感器感知肠道微环境变化，如pH、胆汁酸和代谢物浓度。在低pH和高胆汁酸条件下，启动特定基因表达，实现对炎症或异常代谢的响应。逻辑门控机制确保仅在病理信号持续存在时才激活效应功能，避免过度反应。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair"", ""Antibacterial""]","Type I secretion system (e.g., for reuterin), Lysis (controlled release), Vesicles (exosomes)",Dose-dependent response; continuous administration required for sustained effect; no built-in feedback control in current formulations.,"Compatible with alginate, chitosan, and gelatin-based hydrogels; permeability allows metabolite diffusion without structural collapse.",True,True,True,"通过产生细菌素（如reuterin, lactocin）、有机酸（乳酸、乙酸）和 hydrogen peroxide 抑制病原菌生长，同时破坏生物膜结构。","Reuterin, Lactocin, Hydrogen peroxide",True,True,True,True,在动物模型中，L. reuteri 和 B. bifidum 显著减少肠道病原体负荷，抑制生物膜形成，且未引起明显组织损伤或炎症过度反应。,False,,,,,,,True,调节Th1/Th2平衡，抑制促炎因子（如TNF-α、IL-6）释放，促进抗炎因子（如IL-10）分泌，改善肠道屏障功能。,"IL-10, TGF-β, Treg cell induction",True,促进上皮细胞增殖，增强紧密连接蛋白（如ZO-1、occludin）表达，修复受损肠黏膜屏障。,"TGF-β, EGF, ZO-1",True,调节短链脂肪酸（SCFA）代谢，降低有害代谢物（如对甲酚）水平，改善肠道代谢稳态。,"Short-chain fatty acids (SCFA), Para-cresol",False,,,BSL-1,"Auxotrophy (e.g., leucine-dependent strains), suicide genes (e.g., ccdB), temperature-sensitive plasmids","Leucine, heat shock (42°C)",Low pathogenicity; no known antibiotic resistance genes; minimal horizontal gene transfer risk; no environmental escape reported.,Encapsulation in biodegradable polymers provides physical confinement and limits environmental release.,所列益生菌均为公认安全（GRAS）菌株，无致病性记录，且在临床试验中显示良好耐受性。通过营养缺陷型和自杀基因等生物遏制策略进一步降低生态风险。,在动物模型中，L. reuteri 和 B. bifidum 显著减轻肠道炎症、改善肠道屏障功能和行为异常。在人类研究中，L. rhamnosus GG 和 VSL#3 可改善儿童IBS症状。一项双盲试验显示L. plantarum可减少自闭症儿童的破坏性行为和焦虑。尽管尚无大规模临床试验证实其对自闭症核心症状的疗效，但现有证据支持其在改善胃肠道症状和代谢异常方面的潜在益处。,9697,2277,11974,,
ef77f261-ddeb-4aee-9758-9ad72da5722f,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""M-74""}]",Oral administration as lyophilized powder in gelatin capsules,Facultative Anaerobe,Growth at 37°C in aerobic conditions; tolerance to gastrointestinal pH and bile salts; requires organic selenium for enhanced activity,Not explicitly reported; assumed to grow in vivo under intestinal conditions with doubling time consistent with enterococcal physiology,"Intraepithelial mucosal niche of the large bowel, particularly in adenoma and carcinoma tissues",Competitive exclusion of pathogenic E. coli and other intracellular bacteria; potential symbiotic interaction with host epithelium via immune modulation,"High tolerance to lyophilization, storage at room temperature, and gastrointestinal stresses (acid, bile); stable in gelatin capsules",Organic selenium (55 μg per capsule),该菌株为肠球菌属，可在人体肠道内定植，耐受胃肠道环境中的酸性和胆汁环境，经冻干处理后仍保持活性，口服后可定植于结肠黏膜，尤其在腺瘤和癌变组织中发挥功能。,,,,,No genetic modifications reported; natural strain used; chromosomal stability assumed,Stable in gelatin capsules and gastrointestinal environment; no evidence of degradation or loss of function,该菌株未经过基因工程改造，为天然分离的肠球菌M-74菌株，通过口服给药后在肠道内定植，其功能依赖于天然的生物学特性，如竞争性排斥病原菌和免疫调节作用。,"[""pH"", ""Bile acids""]","[""Lactate"", ""Glucose""]",,"[""Proteases"", ""Tissue degradation fragments""]",Not specified; likely endogenous receptors for host and environmental cues,Not specified; likely constitutive or environment-responsive behavior without engineered logic,该菌株通过感知肠道微环境中的pH、胆汁酸、乳酸和葡萄糖等信号，以及宿主组织降解产物，实现对炎症或病变组织的响应性定植，但未见明确的逻辑门控机制。,"[""Antibacterial"", ""Immunomodulation""]",Natural secretion of metabolites and immune modulators; no engineered secretion system reported,Oral administration of 18×10⁹ CFU/day in three doses; dose was fixed and not dynamically controlled,Compatible with gelatin capsules; stable during lyophilization and gastrointestinal transit,True,False,False,通过竞争性定植和抑制病原菌黏附与侵袭，减少肠道上皮内细菌负荷，尤其针对E. coli。,Enterococcus faecium M-74 (natural competitive exclusion),False,True,True,True,在5例结肠腺瘤患者中，口服该菌株后，阳性活检样本比例从48%降至16%（p=0.03），表明其具有可控的抗菌效果，且无不良反应，局部作用明确。,False,,,False,False,False,,True,通过有机硒增强免疫刺激和抗突变活性，调节宿主免疫反应，可能抑制慢性炎症向癌变发展。,Organic selenium (bound to E. faecium M-74),False,,,False,,,False,,,BSL-1,Natural attenuation; no kill-switch or auxotrophy reported,,No antibiotic resistance genes reported; low pathogenicity; no evidence of horizontal gene transfer; safe in immunocompetent individuals,Gelatin capsule provides physical barrier; oral route limits systemic spread,该菌株为天然肠球菌M-74，属于Biosafety Level 1，无已知致病性，未携带抗生素抗性基因，口服后在肠道内定植，无系统性传播风险，且在临床试验中未出现不良事件，安全性良好。,在5例结肠腺瘤患者中，口服E. faecium M-74（含有机硒）3个月后，上皮内细菌阳性活检比例从48%显著下降至16%（p=0.03），表明该菌株能有效清除肠道上皮内病原菌，具有潜在的预防和治疗结肠癌及炎症性肠病的潜力。,8472,1569,10041,,
6d08b7a2-8164-402f-bb80-928faf793fa4,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""P8""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Encapsulated,Facultative Anaerobe,"Temperature: 37°C; pH: ~3.6–3.7 (in FNJ); Nutritional: MRS broth, maltodextrin as carbon source",Doubling time not reported; growth in vitro at 37°C for 24–48 h; in vivo homeostasis not assessed,"Gastrointestinal tract (intestine), particularly in the presence of bile salts and acidic conditions",Competitive with other gut microbes; no direct interaction with host microbiome reported,"High tolerance to bile salts (1.2% w/v), low pH (pH 3.0), and freeze-drying stress; moderate tolerance to osmotic stress",Maltodextrin (MD) as protective wall matrix,Lactobacillus plantarum P8 和 Lactobacillus rhamnosus GG 均为耐酸、耐胆盐的乳酸菌，可在37°C下生长，对发酵非尼果汁（FNJ）中的低pH和抗菌成分具有一定的耐受性。其中，LP菌株在纯FNJ中表现出更高的存活率，且对胆盐和胃酸环境的耐受性优于LGG菌株。冻干后，两种菌株均能保持高活力，尤其在分步冻干（粉末B）条件下，细胞存活率显著提高。,,,,,No genetic modifications reported; chromosomal stability assumed; no plasmid-based systems used,Stable in maltodextrin matrix; no evidence of genetic drift or instability in material environment,未对菌株进行基因工程改造，仅通过冻干微胶囊化技术将两种乳酸菌与发酵非尼果汁结合，利用麦芽糊精作为壁材保护菌体，实现高存活率。,"[""Low pH (pH 3.0)"", ""Bile salts (1.2% w/v)""]","[""Organic acids (in FNJ)"", ""Phenolic compounds (e.g., gallic acid equivalents)""]",,,Cell membrane integrity and intrinsic stress response systems (no specific receptor identified),"No engineered logic gates; natural physiological responses to stress (e.g., acid tolerance, bile resistance)",菌株通过细胞膜完整性维持和内在应激反应机制感知酸性环境和胆盐压力，无外源性逻辑调控，仅依赖天然生理适应能力。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Passive diffusion and cell lysis upon environmental stress,Controlled by encapsulation efficiency and release kinetics in GI tract,High compatibility with maltodextrin matrix; no structural disruption observed during freeze drying,True,False,False,通过产生有机酸和竞争性抑制，抑制病原菌生长；但未明确表达抗菌蛋白或酶。,"Organic acids (lactic acid, acetic acid)",False,True,True,True,菌株在冻干粉中保持高存活率，且在模拟胃肠消化中表现出良好稳定性，未见对宿主细胞显著毒性，且局部定植于肠道，符合安全边界。,False,,,False,False,False,未涉及氧气生成机制，无相关功能。,True,Lactobacillus菌株可调节宿主免疫系统，增强肠道屏障功能，促进抗炎反应，调节免疫细胞活性。,"Cell wall components (e.g., peptidoglycan, teichoic acids), exopolysaccharides (EPS)",False,,,True,通过发酵非尼果汁中的糖类产生短链脂肪酸（SCFAs），调节宿主能量代谢，改善肠道微环境。,"Short-chain fatty acids (SCFAs, e.g., acetate, lactate)",False,,,GRAS,No engineered kill switches or auxotrophy; natural attenuation via GI transit,None,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low environmental escape risk due to poor survival outside host,Maltodextrin microcapsule provides physical confinement and limits release,Lactobacillus plantarum P8 和 Lactobacillus rhamnosus GG 均为公认安全（GRAS）菌株，广泛用于食品和保健品。无基因工程改造，无抗生素抗性基因，且在非肠道环境中难以存活，风险极低。微胶囊结构进一步增强了物理屏障作用，防止菌体逃逸。,冻干粉末中两种菌株在7周储存后仍保持 >9 log CFU/g 的存活率，模拟胃肠消化后，粉末B中LP和LGG的存活率仍高于7 log CFU/g，符合美国FDA推荐的最低益生菌存活标准（>10^6 CFU/mL）。LP菌株在抗酸、抗胆盐和抗非尼果汁毒性方面表现优于LGG，是更适合作为非尼果汁微胶囊化益生菌的候选菌株。,17629,1764,19393,,
27764e68-eb74-4368-b269-1b744d054013,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus safensis"", ""strain_id"": ""437F""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus atrophaeus"", ""strain_id"": ""1630F""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus amyloliquefaciens"", ""strain_id"": ""1020G""}]",Suspension,Facultative Anaerobe,Temperature: 37°C; pH: 4–7; Osmotic: 1.5% (w/v) salinity; Nutrition: Nutrient Broth medium with carbon and nitrogen sources from peptone and yeast extract,Growth rate: 150 rpm agitation; Doubling time: ~24 h (in vitro); In vivo homeostasis not assessed,"Gastrointestinal tract (intestinal mucus, colon), potential for mucosal adherence","Co-aggregation with pathogens (E. coli, L. monocytogenes); potential for competitive exclusion of pathogens; no evidence of symbiosis with host microbiome","High tolerance to UV, drying, lyophilization (spore-forming); stable under 37°C; resistant to shear stress during processing","Spore coat proteins (e.g., SASP, CotA)",三种 Bacillus 菌株均来源于传统乳酸发酵泡菜，具有强耐酸性和耐胆盐能力，可在低pH（pH 2–4）和0.3–1%胆盐条件下存活，表明其在胃肠道环境中具有良好的生存能力。它们为兼性厌氧菌，可在37°C下生长，具有良好的黏附能力，可附着于Caco-2细胞，且无细胞毒性，具备作为益生菌的潜力。,PCR amplification and sequencing of 16S rRNA gene; no genetic tools used for engineering,Not applicable (no genetic modification reported),Not applicable (no synthetic circuits described),Not applicable,High chromosomal stability; spore formation ensures long-term viability; no plasmid-based systems reported,No material environment described for genetic stability testing,未对菌株进行基因工程改造，仅通过16S rRNA基因测序鉴定其分类地位，未使用CRISPR、质粒或重组系统进行基因编辑。,"[""Acidity (pH 2–4)"", ""Bile salts (0.3–1%)""]","[""Lactate (from fermentation)"", ""Glucose (in nutrient broth)""]",,,Not specified (no specific receptor or promoter identified),No logic gates or signal integration reported,未描述任何传感模块或逻辑控制机制，所有功能均为天然表型，无工程化响应系统。,"[""Antibacterial"", ""Antioxidant"", ""Immunomodulation"", ""Tissue Repair""]",Unknown (likely passive diffusion or lysis; no secretion system specified),Not applicable (no controlled release or dosage regulation described),Not applicable (no encapsulation or material environment described),True,True,True,"通过分泌抗菌物质抑制多种病原体生长，包括革兰氏阳性菌（S. aureus, B. cereus）和革兰氏阴性菌（P. aeruginosa, E. coli, L. monocytogenes）。",Unknown (likely bacteriocins or antimicrobial peptides),True,True,True,True,所有菌株均对至少两种病原体表现出抑制活性，其中1020G对四种病原体有效；抗菌活性在中和后仍存在，说明非有机酸作用；无细胞毒性，且不产生已知毒素基因。,False,未检测到氧气生成或消耗相关功能。,Not applicable,False,False,False,未报告任何氧代谢或光依赖性氧生成机制。,True,通过抗氧化活性和抑制病原体生长间接调节免疫反应，可能促进肠道屏障功能。,"Antioxidants (e.g., DPPH-scavenging compounds)",True,通过黏附于Caco-2细胞（人结肠癌细胞系）并促进细胞屏障功能，支持肠道修复。,"Adhesion proteins (e.g., surface adhesins)",True,产生抗氧化物质，调节氧化还原平衡，可能影响宿主代谢。,"DPPH-scavenging compounds (e.g., phenolic compounds, peptides)",False,未报告任何抗肿瘤机制。,Not applicable,BSL-1,No genetic kill switches or auxotrophy used; natural safety profile based on absence of virulence genes,None,"No pathogenicity; no enterotoxin (hbl, nhe), cytotoxin (cytk1), or emetic (ces) genes detected; susceptible to antibiotics; non-hemolytic; non-toxic to HT-29 cells",Not applicable (no physical barrier described),三种菌株均未检测到已知致病基因，对HT-29细胞无毒性，且对多种抗生素敏感，表明其具有良好的安全性。作为非致病性芽孢杆菌，属于Biosafety Level 1（BSL-1）等级，适合用于食品和饲料益生菌应用。,三种菌株在体外表现出良好的益生菌特性：耐酸耐胆盐、强黏附能力、抗病原体活性、抗氧化能力及无毒无害。其中1020G菌株对四种病原体具有最强抑制作用，437F和1630F抗氧化活性显著。这些特性支持其作为潜在益生菌用于动物和人类健康产品。,16947,1844,18791,,
087bb05b-7f09-4fc0-8c8a-80cdd90775bd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Yeast"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Temperature: 30–37°C; pH: not explicitly stated; Nutritional requirements: Peptone, glucose, and other components in MRS and YGA media; Osmotic tolerance: Not specified",Doubling time not reported; Growth observed over 24–48 hours under anaerobic (MRS) or aerobic (YGA) conditions,"Not applicable (feed supplement, not in vivo host niche)",Not applicable (no host microbiome interaction described),"Low stability during storage; Product A requires use within 2 weeks; Products B, C, D show reduced viability over time; Susceptible to drying and long-term storage",None explicitly identified,乳酸菌和酵母在30–37°C下培养，MRS培养基用于乳酸菌（厌氧），YGA培养基用于酵母（好氧）。产品A的活菌数最高，但所有产品在储存过程中均出现显著活菌数下降，表明其在储存和运输中稳定性差。,,,,,No genetic modifications reported; all strains appear to be wild-type or unmodified,Not applicable (no engineered genetic circuits or material integration described),未对任何微生物进行基因工程改造，所有产品均为天然发酵产物，无基因编辑或合成回路设计。,,,,,,,未检测到任何感知模块或逻辑控制机制，系统无响应环境信号的能力。,"[""Antibacterial"", ""Immunomodulation""]",Passive release from lysed cells or natural secretion,Not controllable; dosage depends on initial viable cell count and storage stability,Poor compatibility with long-term encapsulation or sustained release due to low viability and instability,True,False,False,乳酸菌通过产生有机酸（如乳酸）降低环境pH，抑制病原菌生长，具有一定的抗菌作用。,Lactic acid,False,True,True,True,乳酸菌通过产酸抑制病原菌，但未测试对常见病原体（如S. aureus、P. aeruginosa）的广谱活性，也未评估生物膜抑制能力。,False,,,False,False,False,未涉及氧气生成或缺氧缓解机制。,True,乳酸菌DNA可调节免疫反应，抑制炎症，改善肠道免疫稳态。,Lactobacillus DNA,False,,,False,,,False,,,BSL-1,None,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk identified; potential for environmental escape if released in large quantities,None (no physical confinement described),所有菌株均为常见乳酸菌和酵母，属于GRAS（公认安全）类别，无致病性风险。但因产品中活菌数不稳定，存在功能失效风险，且无生物安全控制机制。,未评估治疗效果；仅通过培养和染色评估活菌数，结果显示产品间活菌数差异极大，产品A活菌数最高（5.0×10⁶ cfu/mL），而产品B、C、D活菌数极低（≤5.0×10² cfu/mL），表明其在实际应用中可能无法发挥预期的健康效益。,5212,1387,6599,,
0ab16a89-b933-41ec-9855-5a4041ffc56d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Lrh""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""LGG""}]",Suspension,Facultative Anaerobe,"Growth on whey hydrolysate-based medium; optimal growth at 37°C, pH ~6.5–7.0; tolerance to gastric pH and bile acids",Growth rate not explicitly reported; viable in formula for 3 months in vivo; no significant growth rate differences observed between groups,"Gastrointestinal tract (infant gut), particularly in the small intestine and colon",Potential for competition with resident microbiota; no significant disruption of microbiome observed; no evidence of symbiosis or pathogenicity,"Tolerant to freeze-drying (lyophilization), storage at room temperature, and gastrointestinal stresses (acid, bile); stable during rehydration and encapsulation in formula","Whey hydrolysate medium, freeze-drying process","Lactobacillus rhamnosus and Lactobacillus GG are Gram-positive, facultative anaerobic bacteria capable of surviving in the infant gastrointestinal tract. They grow on hydrolyzed whey-based formula, tolerate gastric acidity and bile, and remain viable during 3-month supplementation. They are not known to cause infection or disrupt the gut microbiome.",,,,,No genetic modifications reported; naturally occurring strains used; chromosomal stability in vivo; no plasmid-based systems used,Stable in hydrolyzed whey-based formula; no evidence of degradation or loss of viability in material environment,"No genetic engineering was performed. The strains were used in their native form, administered as freeze-dried powder in a hydrolyzed whey-based formula. No synthetic circuits, inducible promoters, or CRISPR tools were applied.","[""pH"", ""Bile acids""]","[""Lactose"", ""Whey hydrolysate components""]",,,"Native receptors for bile salts and acidic environments (e.g., bile salt hydrolases, acid tolerance systems)","No engineered logic gates; natural sensing of environmental cues (pH, bile) without synthetic control",The strains naturally sense and respond to acidic conditions (gastric transit) and bile salts (intestinal environment) via intrinsic stress response systems. No synthetic logic or threshold control was implemented.,"[""Immunomodulation""]",Passive secretion via general secretory pathway; no engineered secretion systems,Fixed dose (3 × 10⁸ CFU/g formula); no dynamic or feedback-controlled dosage,Compatible with hydrolyzed whey-based formula; stable during freeze-drying and reconstitution,False,,,,,False,False,False,False,No antibacterial activity was observed in this study.,False,,,False,False,False,No oxygenation mechanism was present or tested.,True,"Modulate immune responses by influencing cytokine production (IL-4, IL-5, IFN-γ), reducing allergic inflammation, and potentially enhancing gut barrier function.","Cytokines (IL-4, IL-5, IFN-γ), surface molecules (e.g., pili, exopolysaccharides), and secreted metabolites",False,,,False,,,False,,,GRAS,No kill switches or auxotrophy; natural strains with no known pathogenicity,,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape risk; safe for infants,No physical barrier; oral delivery with natural clearance,"Lactobacillus rhamnosus and Lactobacillus GG are well-characterized, GRAS-status strains with a long history of safe use in infants. No adverse events were reported. No genetic modifications or biocontainment systems were used.","No statistically significant effect on SCORAD, allergic sensitization, inflammatory markers (fecal α-1-antitrypsin, urinary EPX), or cytokine production (IL-4, IL-5, IFN-γ) was observed. The study concluded that oral supplementation with these probiotic strains had no significant impact on infantile atopic dermatitis.",11413,1541,12954,,
f341469d-7c9c-482d-a1db-b7d60fde890c,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecalis-1"", ""strain_id"": ""E. faecalis-1""}]",Oral administration (drinking water),Facultative Anaerobe,Growth at 37°C on citrate-azide-Tween-carbonate agar (CATC) and nutrient agar; aerobic cultivation for 24 h,Daily oral supplementation for first 3 days of growth; no long-term in vivo persistence data reported,Intestinal tract (caecum) of broiler chickens,Competitive exclusion of pathogenic E. coli O78; increases total Enterococcus and Lactobacillus counts in caecum,"Stable during lyophilization (frozen at -80°C), rehydrated and used in drinking water; tolerance to storage and handling in lab conditions",Freeze-thaw stability (−80°C storage),该菌株为从健康鸡只中分离的粪肠球菌，可在37°C下在CATC和营养琼脂上生长，通过口服方式在雏鸡前3天内补充，定植于肠道，显著提升肠道中肠球菌和乳酸杆菌数量，抑制病原性大肠杆菌O78的定植与侵袭。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该菌株未经过基因工程改造，为天然分离菌株，仅通过口服补充方式使用，未提及任何遗传修饰或合成回路。,"[""pH"", ""Nutrient availability""]","[""Lactate"", ""SCFAs""]","[""Quorum sensing (indirect)""]","[""Proteases"", ""Cytokines""]",Not specified,Not specified,该系统未涉及人工设计的传感逻辑回路，其功能基于天然生理响应，如对肠道微环境变化的适应性定植与竞争性排斥。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Not specified,"Daily oral administration (0.5 ml, 1×10⁸ CFU) for first 3 days; dosage controlled by administration schedule",Compatible with drinking water delivery; no encapsulation or material barrier described,True,False,False,通过竞争性定植和抑制病原菌生长，减少APEC O78在肝脏和脾脏的侵袭。,Enterococcus faecalis-1 (natural colonization),False,True,True,True,在挑战组中，E. faecalis-1处理组的APEC O78在肝脾中恢复率显著降低（G04: 20%；G05: 0%），且无组织损伤报告，表明其抗菌作用可控且局部有效。,False,未涉及氧气生成或代谢调节功能。,Not specified,False,False,False,未提及任何氧生成或缺氧缓解机制。,True,显著提高血清IgY水平，增强体液免疫应答，促进对APEC O78的免疫保护。,IgY (avian immunoglobulin Y),True,通过改善肠道屏障功能、减少炎症和病原体侵袭，间接促进组织修复与完整性。,Intestinal barrier integrity (indirect),False,未提及代谢产物调节功能。,Not specified,False,未涉及肿瘤治疗机制。,Not specified,GRAS,"Not applicable (natural isolate, no genetic modification)",Not applicable,No virulence genes or antibiotic resistance genes reported; low pathogenicity; non-opportunistic in healthy hosts,Not applicable (no physical material barrier used),E. faecalis-1为从健康鸡只中分离的天然菌株，未检测到毒力基因或耐药基因，且在实验中未引起不良反应，符合GRAS（公认安全）标准，无生物安全风险。,E. faecalis-1补充显著改善了雏鸡的生长性能（体重、体增重、FCR、热胴体重和屠宰率），降低APEC O78感染后的死亡率（G04: 3.4%；G05: 3.4%；G06: 0%），显著减少肝脾中病原菌的恢复率（G04: 20%；G05: 0%），并显著提高血清IgY水平（G06: 1.97 mg/ml），表明其在免疫增强和抗感染方面具有显著疗效。,18722,1610,20332,,
159005d1-f27b-4587-bf4b-ddd44be53e1a,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum subsp. infantis"", ""strain_id"": ""CECT 7210""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""HN001""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly acidic; Nutritional requirements: Carbohydrates (e.g., oligofructose-enriched inulin), amino acids, vitamins; Osmotic tolerance: Moderate",Growth rate: Moderate; Doubling time: Not specified; In vivo homeostasis: Maintained in piglet gut environment,"Intestinal mucosa, particularly ileum and colon",Competitive exclusion of Salmonella; Synergistic growth with prebiotic (oligofructose-enriched inulin); No significant disruption of native microbiota observed,Tolerant to lyophilization and rehydration; Stable in feed for 24 h; Moderate tolerance to gastric acidity and bile,Maltodextrin base (for lyophilized form),该共生体系由两种专性利用碳水化合物的益生菌组成，均能在猪肠道中定植并维持生长。B. infantis CECT 7210 和 L. rhamnosus HN001 均为兼性厌氧菌，可在中性至弱酸性环境中生长，依赖寡果糖-富集菊粉等可发酵碳源。两者在饲料中保持稳定，且在口服后可在肠道内存活并定植，尤其在结肠中检测到较高浓度。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该研究未对菌株进行基因工程改造，所有功能均依赖于天然生理特性。,"[""pH"", ""Osmotic stress""]","[""Oligofructose-enriched inulin"", ""Short-chain fatty acids (SCFAs)""]",,"[""Cytokines (TNF-α)"", ""Acute-phase proteins (Pig-MAP)""]",Not specified,Not specified,该系统未设计人工调控逻辑，其响应基于天然代谢与免疫信号感知，通过竞争性定植和代谢产物调节实现功能输出。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Not specified,Not specified,Not specified,True,True,False,通过竞争性定植、产生抗菌物质（如细菌素）和调节肠道微环境抑制 Salmonella Typhimurium 的定植与繁殖。,Bacteriocin-like substances (from L. rhamnosus HN001),True,True,True,True,PRO组在第7天时粪便中 Salmonella 排出量显著减少，65%的动物转为阴性；PRE组在所有样本中均未检测到可计数的 Salmonella（<3 cfu/g），表明其具有强效的广谱抗菌与定植抑制能力。,False,无氧代谢调节功能。,,False,False,False,未涉及氧气生成或耗氧调控机制。,True,通过调节宿主免疫反应，如提升血清 Pig-MAP 水平和增加肠道内淋巴细胞数量，增强抗感染能力。,Pig-MAP (Pig Major Acute-phase Protein),True,通过改善肠道绒毛/隐窝比，促进肠道屏障修复，减轻炎症损伤。,Villus height: crypt depth ratio,True,通过发酵寡果糖-富集菊粉产生短链脂肪酸（如戊酸），调节肠道代谢环境。,Valeric acid,False,无肿瘤治疗相关机制。,,GRAS,Not specified,Not specified,Low pathogenicity; No antibiotic resistance genes reported; No horizontal gene transfer risk identified; Low environmental escape risk due to host-specific adaptation,Not specified,两种菌株均为公认安全（GRAS）菌种，广泛用于动物和人类食品中。B. infantis CECT 7210 和 L. rhamnosus HN001 均无已知致病性或耐药基因，且在猪肠道中定植后未引起显著不良反应，安全性良好。,在口服 Salmonella 挑战后，PRO组猪只粪便中 Salmonella 排出量显著减少，第7天时65%的动物转为阴性；PRE组所有样本中均未检测到可计数的 Salmonella（<3 cfu/g），表明其具有极强的定植抗性。此外，PRO组在第8天时肠道绒毛/隐窝比恢复至接近对照组水平，表明其具有显著的组织修复能力。PRE组显著提升血清 Pig-MAP 水平，提示免疫激活作用。,19407,1700,21107,,
65c7e21e-08ee-4643-8446-f6038eefe1cc,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""DSM17938, ATCC PTA5289""}]",Lozenge dissolution in mouth / Topical application,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates moderate acidity; requires carbohydrates (e.g., glucose) as carbon source; dependent on host-derived nutrients in oral cavity",Moderate growth rate; doubling time not specified; in vivo stability observed during 3-month administration in clinical trials,"Oral cavity, particularly subgingival and supragingival plaque sites; competes with pathogenic bacteria for adhesion sites","Competitive exclusion of pathogenic bacteria (e.g., Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans); may modulate host immune response without disrupting overall microbiome balance","Tolerates drying (in lozenge form), moderate shear stress during oral use; stable during storage at room temperature; limited data on UV or osmotic tolerance",Lozenge matrix (protective excipients),"Lactobacillus reuteri is a facultative anaerobe capable of colonizing the oral cavity, particularly in periodontal pockets. It grows under moderate acidity and utilizes host-derived carbohydrates. It demonstrates transient colonization, with detectable presence in subgingival sites for up to 90 days post-administration, indicating moderate in vivo persistence. Its growth is supported by the oral environment and delivery vehicle (lozenge).",Not specified (natural strains used; no genetic modification reported),Not applicable (no genetic engineering performed),Constitutive (natural expression of antimicrobial and immunomodulatory genes),Null,High (no plasmids or integrative vectors used; chromosomal stability in natural strains),Stable in lozenge and gel formulations; maintains viability during dissolution and contact with oral mucosa,"Lactobacillus reuteri strains used in the studies are natural, non-genetically modified organisms. Their beneficial effects are attributed to inherent biological properties rather than engineered circuits. No synthetic genetic circuits or inducible systems were employed.","[""pH"", ""Glucose"", ""Hypoxia""]","[""Lactate"", ""Bile acids (limited in oral cavity)""]","[""Quorum sensing (AHL, AI-2) – inferred from competitive adhesion""]","[""Proteases (MMP-8, Elastase)"", ""Cytokines (TNF-α, IL-1β, IL-17)""]","FNR promoter (hypoxia), glucose transporters, surface adhesins (e.g., mucus-binding proteins)","No synthetic logic gates; natural sensing via receptor-mediated responses to environmental cues (e.g., pH, nutrient availability)","Lactobacillus reuteri naturally senses the oral microenvironment through surface receptors and metabolic sensors. It responds to low pH and hypoxia typical of periodontal pockets, and detects host-derived nutrients like glucose. It also senses microbial competition via quorum sensing molecules and host inflammatory mediators such as MMP-8 and cytokines. These signals trigger natural responses like adhesion, antimicrobial production, and immune modulation without synthetic circuitry.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion of reuterin and other metabolites; no lysis or vesicle-based delivery reported,Controlled by lozenge frequency (twice daily); dose-dependent effects observed in clinical outcomes,High compatibility with lozenge and gel formulations; maintains viability and function during dissolution and contact with oral mucosa,True,True,True,"Produces reuterin (3-hydroxypropionaldehyde), which induces oxidative stress in pathogenic bacteria; competes for adhesion sites in biofilm; reduces counts of red complex pathogens.",Reuterin (3-hydroxipropionaldehyde),True,True,True,True,"Multiple studies (Teughels et al., 2013; Tekce et al., 2015; Vivekananda et al., 2010) show significant reduction in Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, and Prevotella intermedia in subgingival and supragingival plaque. Reuterin production is localized and transient, minimizing off-target effects. No cytotoxicity or microbiome disruption reported.",False,Not applicable,Null,False,False,False,No evidence of oxygenation mechanism; L. reuteri is facultative anaerobe and does not produce oxygen.,True,"Reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-17); increases anti-inflammatory TIMP-1; modulates MMP-8 expression; suppresses excessive immune activation.","Cytokine modulators (TNF-α, IL-1β, IL-17, TIMP-1)",True,"Reduces MMP-8 (collagenase), increases TIMP-1 (inhibitor), promoting tissue integrity and reducing degradation; supports periodontal regeneration.","TIMP-1, MMP-8",False,Not applicable,Null,False,Not applicable,Null,GRAS,Natural auxotrophy (no synthetic kill switches); no antibiotic resistance genes reported,Null,Low pathogenicity; no adverse events reported; no evidence of horizontal gene transfer; no environmental escape risk due to transient colonization,Lozenge matrix provides physical confinement; limited systemic absorption,"Lactobacillus reuteri is classified as GRAS (Generally Recognized As Safe). It is a natural oral commensal with no known pathogenicity. No adverse events were reported in clinical trials. Colonization is transient and limited to the oral cavity. No genetic modifications or antibiotic resistance genes were used, minimizing horizontal gene transfer risk. The lozenge delivery system provides physical containment, preventing environmental release.","Lactobacillus reuteri, when used as an adjunct to scaling and root planing, significantly reduces probing pocket depth in moderate pockets (4–6 mm), bleeding on probing, and plaque index. It effectively reduces pathogenic bacteria (P. gingivalis, A. actinomycetemcomitans, P. intermedia), modulates inflammation (reduces TNF-α, IL-1β, MMP-8; increases TIMP-1), and improves clinical parameters. Effects are most pronounced in moderate periodontal pockets and are sustained for up to 3 months. No adverse events were reported, confirming safety and clinical benefit.",12187,6759,18946,,
65c7e21e-08ee-4643-8446-f6038eefe1cc,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""SP1""}]",Lozenge dissolution in water,Facultative Anaerobe,"Grows at 37°C, pH 5.5–6.5; requires glucose and other fermentable carbohydrates; tolerates moderate acidity and bile salts",Moderate growth rate; doubling time not specified; stable during 3-month administration in clinical trial,"Oral cavity, particularly gingival crevice and mucosal surfaces",Competes with pathogenic bacteria for adhesion sites; may modulate host immune response,"Tolerates drying (in lozenge), moderate shear stress, and storage at room temperature; limited data on UV or osmotic tolerance",Lozenge matrix (protective excipients),"Lactobacillus rhamnosus SP1 is a facultative anaerobe adapted to the oral environment. It grows under moderate acidity and utilizes fermentable sugars. It demonstrates transient colonization in the oral cavity, with detectable presence during treatment. Its growth is supported by the oral environment and delivery vehicle (lozenge).",Not specified (natural strain used; no genetic modification reported),Not applicable,Constitutive,Null,High (chromosomal stability; no plasmids used),Stable in lozenge formulation; maintains viability during dissolution,Lactobacillus rhamnosus SP1 is a naturally occurring strain used without genetic modification. Its beneficial effects are due to inherent biological properties such as adhesion and immune modulation.,"[""pH"", ""Glucose"", ""Hypoxia""]","[""Lactate""]","[""Quorum sensing (AHL, AI-2)""]","[""Proteases (MMP-8)"", ""Cytokines (TNF-α, IL-1β)""]","Glucose transporters, surface adhesins, FNR promoter",No synthetic logic gates; natural sensing via metabolic and receptor-based responses,"Lactobacillus rhamnosus SP1 senses the oral environment through pH, nutrient availability, and host-derived signals. It responds to hypoxia and low pH in periodontal pockets, and detects glucose and lactate as metabolic cues. It also senses microbial competition and host inflammatory mediators, triggering natural immune-modulatory and anti-adhesion responses.","[""Antibacterial"", ""Immunomodulation""]",Constitutive secretion of lactic acid and other metabolites,Controlled by daily lozenge administration; dose-dependent effects observed,High compatibility with lozenge formulation; maintains viability and function,True,True,True,Competes with pathogens for adhesion sites; produces lactic acid and other metabolites that inhibit pathogenic bacteria; reduces red complex bacteria counts.,"Lactic acid, bacteriocins (inferred)",True,True,True,True,"In Morales et al. (2016), L. rhamnosus SP1 reduced P. gingivalis and other pathogens. No cytotoxicity or microbiome disruption reported. Effects are localized and transient.",False,Not applicable,Null,False,False,False,No evidence of oxygenation mechanism.,True,"Reduces pro-inflammatory cytokines (TNF-α, IL-1β); modulates immune response to reduce tissue destruction.","TNF-α, IL-1β",False,Not reported,Null,False,Not applicable,Null,False,Not applicable,Null,GRAS,Natural auxotrophy; no synthetic kill switches,Null,Low pathogenicity; no adverse events reported; no antibiotic resistance genes; transient colonization,Lozenge matrix provides physical confinement,"Lactobacillus rhamnosus SP1 is a GRAS organism. It is a natural oral commensal with no known pathogenicity. No adverse events were reported in clinical trials. Colonization is transient and limited to the oral cavity. No genetic modifications or antibiotic resistance genes were used, minimizing horizontal gene transfer risk. The lozenge delivery system provides physical containment.","Lactobacillus rhamnosus SP1, when used as an adjunct to scaling and root planing, reduces probing pocket depth, bleeding on probing, and plaque index. It significantly reduces pathogenic bacteria (P. gingivalis) and modulates inflammation. Effects are sustained for 3 months with no adverse events. It demonstrates safe and effective clinical performance in chronic periodontitis.",12187,6759,18946,,
65c7e21e-08ee-4643-8446-f6038eefe1cc,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""HKL-137""}]",Capsule administration,Facultative Anaerobe,"Grows at 37°C, pH 5.5–6.5; requires fermentable carbohydrates; tolerates moderate acidity and bile salts",Moderate growth rate; doubling time not specified; stable during 3-month administration,"Oral cavity, particularly in supportive periodontal therapy patients",Competes with pathogens for nutrients and adhesion sites; may modulate immune response,"Tolerates drying (in capsule), moderate shear stress, and storage at room temperature",Capsule matrix (protective excipients),"Lactobacillus plantarum HKL-137 is a facultative anaerobe adapted to the oral environment. It grows under moderate acidity and utilizes fermentable sugars. It demonstrates transient colonization in the oral cavity, with detectable presence during treatment. Its growth is supported by the oral environment and delivery vehicle (capsule).",Not specified (natural strain used; no genetic modification reported),Not applicable,Constitutive,Null,High (chromosomal stability; no plasmids used),Stable in capsule formulation; maintains viability during oral transit,Lactobacillus plantarum HKL-137 is a naturally occurring strain used without genetic modification. Its beneficial effects are due to inherent biological properties such as adhesion and immune modulation.,"[""pH"", ""Glucose"", ""Hypoxia""]","[""Lactate""]","[""Quorum sensing (AHL, AI-2)""]","[""Proteases (MMP-8)"", ""Cytokines (TNF-α, IL-1β)""]","Glucose transporters, surface adhesins, FNR promoter",No synthetic logic gates; natural sensing via metabolic and receptor-based responses,"Lactobacillus plantarum HKL-137 senses the oral environment through pH, nutrient availability, and host-derived signals. It responds to hypoxia and low pH in periodontal pockets, and detects glucose and lactate as metabolic cues. It also senses microbial competition and host inflammatory mediators, triggering natural immune-modulatory and anti-adhesion responses.","[""Antibacterial"", ""Immunomodulation""]",Constitutive secretion of lactic acid and other metabolites,Controlled by daily capsule administration; dose-dependent effects observed,High compatibility with capsule formulation; maintains viability and function,True,True,True,Produces lactic acid and other antimicrobial metabolites; competes with pathogens for adhesion sites; reduces pathogenic bacterial counts.,"Lactic acid, bacteriocins (inferred)",True,True,True,True,"In Iwasaki et al. (2016), L. plantarum HKL-137 reduced P. gingivalis and other pathogens. No cytotoxicity or microbiome disruption reported. Effects are localized and transient.",False,Not applicable,Null,False,False,False,No evidence of oxygenation mechanism.,True,"Reduces pro-inflammatory cytokines (TNF-α, IL-1β); modulates immune response to reduce tissue destruction.","TNF-α, IL-1β",False,Not reported,Null,False,Not applicable,Null,False,Not applicable,Null,GRAS,Natural auxotrophy; no synthetic kill switches,Null,Low pathogenicity; no adverse events reported; no antibiotic resistance genes; transient colonization,Capsule matrix provides physical confinement,"Lactobacillus plantarum HKL-137 is a GRAS organism. It is a natural oral commensal with no known pathogenicity. No adverse events were reported in clinical trials. Colonization is transient and limited to the oral cavity. No genetic modifications or antibiotic resistance genes were used, minimizing horizontal gene transfer risk. The capsule delivery system provides physical containment.","Lactobacillus plantarum HKL-137, when used as an adjunct to supportive periodontal therapy, reduces probing pocket depth and plaque index. It significantly reduces pathogenic bacteria (P. gingivalis) and modulates inflammation. Effects are sustained for 3 months with no adverse events. It demonstrates safe and effective clinical performance in chronic periodontitis.",12187,6759,18946,,
65c7e21e-08ee-4643-8446-f6038eefe1cc,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus oralis"", ""strain_id"": ""KJ3""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus uberis"", ""strain_id"": ""KJ2""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus rattus"", ""strain_id"": ""JH145""}]",Lozenge dissolution in mouth,Facultative Anaerobe,"Grows at 37°C, pH 6.0–7.0; requires glucose and other carbohydrates; tolerates moderate acidity",Moderate growth rate; doubling time not specified; transient colonization observed,"Oral cavity, particularly in periodontal pockets and gingival crevice",Competes with pathogens for adhesion sites; produces hydrogen peroxide to inhibit pathogenic bacteria,"Tolerates drying (in lozenge), moderate shear stress, and storage at room temperature",Lozenge matrix (protective excipients),"Streptococcus oralis, S. uberis, and S. rattus are facultative anaerobes adapted to the oral environment. They grow under neutral to slightly alkaline pH and utilize fermentable sugars. They demonstrate transient colonization in the oral cavity, with detectable presence during treatment. Their growth is supported by the oral environment and delivery vehicle (lozenge).",Not specified (natural strains used; no genetic modification reported),Not applicable,Constitutive,Null,High (chromosomal stability; no plasmids used),Stable in lozenge formulation; maintains viability during dissolution,The Streptococcus strains are natural oral commensals used without genetic modification. Their beneficial effects are due to inherent biological properties such as hydrogen peroxide production and competitive adhesion.,"[""pH"", ""Glucose"", ""Hypoxia""]","[""Lactate""]","[""Quorum sensing (AHL, AI-2)""]","[""Proteases (MMP-8)"", ""Cytokines (TNF-α, IL-1β)""]","Glucose transporters, surface adhesins, FNR promoter",No synthetic logic gates; natural sensing via metabolic and receptor-based responses,"The Streptococcus strains sense the oral environment through pH, nutrient availability, and host-derived signals. They respond to hypoxia and low pH in periodontal pockets, and detect glucose and lactate as metabolic cues. They also sense microbial competition and host inflammatory mediators, triggering natural anti-pathogenic and immune-modulatory responses.","[""Antibacterial""]",Constitutive secretion of hydrogen peroxide and other metabolites,Controlled by twice-daily lozenge administration; dose-dependent effects observed,High compatibility with lozenge formulation; maintains viability and function,True,True,True,"Produces hydrogen peroxide, which inhibits the growth of pathogenic bacteria such as Aggregatibacter actinomycetemcomitans; competes for adhesion sites in biofilm.",Hydrogen peroxide,True,True,True,True,"In Laleman et al. (2015), the Streptococcus trio reduced P. intermedia in saliva. No cytotoxicity or microbiome disruption reported. Effects are localized and transient.",False,Not applicable,Null,False,False,False,No evidence of oxygenation mechanism.,False,Not reported,Null,False,Not reported,Null,False,Not applicable,Null,False,Not applicable,Null,GRAS,Natural auxotrophy; no synthetic kill switches,Null,Low pathogenicity; no adverse events reported; no antibiotic resistance genes; transient colonization,Lozenge matrix provides physical confinement,"The Streptococcus strains are GRAS organisms. They are natural oral commensals with no known pathogenicity. No adverse events were reported in clinical trials. Colonization is transient and limited to the oral cavity. No genetic modifications or antibiotic resistance genes were used, minimizing horizontal gene transfer risk. The lozenge delivery system provides physical containment.","The Streptococcus trio (S. oralis, S. uberis, S. rattus) used as an adjunct to scaling and root planing reduces P. intermedia in saliva. It demonstrates antibacterial activity through hydrogen peroxide production and competitive adhesion. Effects are localized and transient, with no adverse events. It shows potential as a safe adjunctive therapy in chronic periodontitis.",12187,6759,18946,,
873e864f-889b-48b3-a08a-b41445f2e155,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Clostridium butyricum"", ""strain_id"": ""未明記""}]",Encapsulated,Strict Anaerobe,"37°C, 嫌気環境, GAM培地, 炭酸ガス発生袋による嫌気環境",24時間で発芽・増殖開始（ラット実験）、発芽後2時間で分裂増殖開始,小腸上部から中央部、腸管内環境,耐性乳酸菌製剤と比較して、抗菌剤存在下でも生存可能。腸内環境に適応し、発芽後増殖可能。,芽胞形成により抗菌剤、乾燥、熱、酸化ストレスに耐性。再発芽可能。,芽胞（Spore）,芽胞形成性の嫌気性菌であり、抗菌剤濃度が低下すると発芽・増殖を再開する。腸管内では投与30分後に発芽し、2時間で分裂増殖を開始する。,未明記,未明記,未明記,未明記,未明記,未明記,本研究では、人為的な遺伝子改変は行われていない。自然に芽胞を形成する能力を活かして、抗菌剤の影響を回避する。,"[""Hypoxia"", ""pH""]","[""Lactate"", ""Glucose""]","[""AHL"", ""AI-2""]","[""Protease"", ""Cytokine""]",FNRプロモーター（推定）,芽胞形成は抗菌剤存在下でのストレス応答として制御され、濃度低下時に発芽を開始する。閾値応答型の論理制御。,抗菌剤濃度がMIC以上では発育抑制、濃度が低下すると芽胞が発芽し増殖を再開。これは、環境中の抗菌剤濃度を「センサー」として認識し、発芽・増殖を制御する論理回路に類似。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",未明記（自然分泌）,抗菌剤濃度低下時に自然発芽・増殖により制御される。,芽胞は物理的・化学的安定性が高く、製剤（細粒）中に封入可能。,True,False,False,発芽状態では抗菌剤に感受性だが、芽胞形成により生存可能。抗菌剤濃度低下時に再発芽・増殖し、腸内環境を正常化。,未明記（自然発現）,False,True,True,True,芽胞形成により抗菌剤の影響を受けにくく、再発芽で機能回復。腸内環境に安全に定着。,False,未明記,未明記,False,False,False,未明記,True,腸内環境の正常化により、炎症反応を抑制し、免疫バランスを調整。,酪酸（Butyric acid）,True,腸粘膜の修復を促進し、上皮細胞の再生を支援。,酪酸（Butyric acid）,True,腸内細菌叢のバランスを維持し、短鎖脂肪酸（SCFA）の産生により代謝を調整。,酪酸（Butyric acid）,False,未明記,未明記,BSL-1,芽胞形成による自然的生物制御。人為的殺傷スイッチなし。,芽胞（Spore）,非病原性。腸内常在菌。耐性遺伝子なし。水平遺伝子移動リスク低。環境逃逸リスク低。,製剤の物理的封入（細粒）により、腸管外への漏出を防止。,芽胞形成性であり、非病原性。人為的な耐性遺伝子や抗生物質耐性遺伝子を有しない。腸管内に限定的に作用し、環境への影響は極めて低い。,抗菌剤投与による下痢予防に有効。発芽状態では感受性だが、芽胞形成により生存可能。抗菌剤濃度低下時に再発芽・増殖し、腸内環境を正常化。ラット実験で発芽後2時間で分裂増殖を確認。,9967,1644,11611,,
d72a6543-4133-4d06-af28-22e10fa78b93,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Propionibacterium freudenreichii ssp. shermanii"", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium animalis ssp. lactis"", ""strain_id"": ""Not specified""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, requires carbohydrates and amino acids; dependent on host-derived nutrients in gut environment",Doubling time ~1–2 hours in vitro; stable colonization in gut mucosa in vivo,"Intestinal mucosa and lumen, particularly in colon and small intestine",Competitive exclusion of pathogens; synergistic interactions with host immune system; may enhance colonization of other beneficial strains,Moderate tolerance to gastric acid and bile; stable during lyophilization and rehydration; sensitive to high shear stress,"Mucus layer, biofilm matrix",这些益生菌为兼性厌氧菌，可在肠道环境中稳定生长，依赖宿主提供的碳源和氨基酸。它们能定植于肠道黏膜和肠腔，通过竞争性排斥病原体和调节免疫系统来维持肠道微生态平衡。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,该系统未涉及基因工程改造，其功能主要依赖于天然菌株的生理特性，通过多菌株组合实现协同作用。,"[""pH"", ""Bile acids"", ""Glucose"", ""Lactate""]","[""Short-chain fatty acids (SCFAs)"", ""Bile acids"", ""Lactose""]","[""Quorum sensing (AHL)"", ""AI-2""]","[""Proteases"", ""Cytokines"", ""Tissue degradation fragments""]",Not specified,Not specified,该系统未描述明确的传感逻辑，其响应主要基于菌株对环境信号的自然感知能力，如pH变化、胆汁酸浓度等。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I-VI secretion systems, Vesicles",Not specified,Compatible with oral delivery and intestinal mucus layer,False,,,Not applicable,Not applicable,,,,,未提及抗菌功能,False,Not applicable,Not applicable,,,,未提及氧合功能,True,通过直接与免疫细胞或上皮细胞相互作用，调节促炎和抗炎因子的表达，增强肠道屏障功能，抑制过度免疫激活。,"Cytokines (e.g., IL-10, TGF-β), Immunomodulins",True,通过激活信号通路促进紧密连接蛋白表达，增强黏液分泌，修复受损上皮屏障，改善肠道通透性。,"Tight junction proteins (e.g., ZO-1, Occludin), Mucus glycoproteins",True,发酵未消化碳水化合物产生短链脂肪酸（如丁酸），调节宿主能量代谢，抑制炎症，维持结肠黏膜健康。,"Butyrate, Acetate, Propionate",False,Not applicable,Not applicable,GRAS,Not applicable,Not applicable,低致病性；无抗生素抗性基因；无水平基因转移风险；环境逃逸可能性极低,Oral administration provides natural physical barrier,该益生菌组合被归类为GRAS（公认安全），在临床试验中未报告严重不良反应，适合长期使用。,多项临床试验表明，该多菌株益生菌组合可显著改善IBS患者的腹痛、腹胀、排便习惯和总体症状评分。其中Bifidobacterium infantis 35624和‘芬兰组合’在多个研究中被证实有效。,13838,1576,15414,,
cf0db639-d133-42cd-b1d8-3afd67b3f0e0,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Roseburia hominis"", ""strain_id"": ""DSM16839""}, {""role"": ""Chassis"", ""scientific_name"": ""Faecalibacterium prausnitzii"", ""strain_id"": ""DSM17677""}, {""role"": ""Helper"", ""scientific_name"": ""Butyricicoccus pullicaecorum"", ""strain_id"": ""DSM23266""}, {""role"": ""Helper"", ""scientific_name"": ""Pseudobutyrivibrio"", ""strain_id"": null}]",Encapsulated in mucosal microcosms (mucin-agar covered carriers) within M-SHIME,Strict Anaerobe,"37°C, pH 5.6–5.9 (colon), anaerobic conditions, growth on mucin, oat β-glucan, and rumen fluid; requires reducing agents (sodium thioglycolate)",Growth rate not explicitly quantified; maintained in batch and fed-batch systems over 40 h; stable colonization in mucosal niche,"Mucosal layer of simulated colon (mucin-agar microcosms), preferentially colonizes mucosal niche",Positive cross-shielding interaction with F. prausnitzii; supports luminal and mucosal community stability; promotes butyrate production and protects against LA stress,"Tolerant to high LA concentrations (1 g/L), resistant to oxidative stress (via anaerobic conditions), stable during lyophilization/rehydration (inferred from in vitro model stability)","Mucin-agar microcosms (physical protection), anaerobic environment (chemical protection)","Roseburia hominis and Pseudobutyrivibrio preferentially colonize the mucosal niche in the simulated colon, where they exhibit stable growth and biohydrogenation activity under high linoleic acid stress. They maintain viability and function in anaerobic, mucin-rich environments, contributing to microbiome resilience.",CRISPR-Cas not used; genetic tools not explicitly described; inferred to be native strains with natural metabolic capabilities,,Constitutive (natural metabolic activity; no synthetic circuits reported),,High chromosomal stability; no plasmid-based systems reported; natural metabolic functions maintained across runs and co-cultures,Stable within mucin-agar microcosms; no disruption of matrix structure observed; compatible with in vitro encapsulation,"No synthetic genetic engineering was performed. The microbial consortium relies on native metabolic pathways, particularly LA biohydrogenation, for functional resilience. The system leverages natural cross-shielding interactions between mucosal biohydrogenators and luminal butyrate producers.","[""Hypoxia"", ""pH (5.6–5.9)"", ""Hydrogen gas (H₂)""]","[""Linoleic acid (LA)"", ""Vaccenic acid (VA)"", ""Stearic acid (SA)""]",,,"Natural metabolic sensors (e.g., hydrogenase enzymes, fatty acid transporters); no synthetic receptors reported","Positive feedback loop: LA biohydrogenation by Roseburia/Pseudobutyrivibrio reduces LA toxicity, enabling F. prausnitzii survival; this supports butyrate production, which further stabilizes the community. No synthetic logic gates used.","The system operates via natural metabolic logic: high LA levels trigger biohydrogenation by mucosal Roseburia and Pseudobutyrivibrio, which convert LA to less toxic VA and SA. This reduces stress on F. prausnitzii, allowing it to survive and produce butyrate. The process is self-sustaining and responsive to LA concentration, with no external inducers.","[""Metabolic Regulation"", ""Tissue Repair"", ""Antibacterial & Antibiofilm""]","Natural secretion via membrane transporters and metabolic byproducts (e.g., butyrate, VA, SA); no engineered secretion systems used",Self-regulated by LA concentration and microbial metabolic activity; no external control mechanisms,Highly compatible with mucin-agar microcosms; no structural collapse or gas overproduction observed; stable encapsulation,True,False,True,"Biohydrogenation of linoleic acid (LA) to less toxic products (VA, SA) reduces antimicrobial effects of LA on beneficial bacteria, particularly F. prausnitzii. This indirectly protects the microbiome from LA-induced dysbiosis and biofilm disruption.","Vaccenic acid (VA), Stearic acid (SA)",True,True,True,True,"LA biohydrogenation by Roseburia and Pseudobutyrivibrio reduced LA toxicity, protected F. prausnitzii from inhibition, and maintained butyrate production. No evidence of excessive activity or matrix disruption. Low cytotoxicity to host cells (inferred from in vitro model).",False,,,False,False,False,,False,,,True,"By protecting F. prausnitzii and maintaining butyrate production, the consortium supports colonocyte energy supply, epithelial barrier integrity, and anti-inflammatory signaling, promoting mucosal healing.",Butyrate,True,"Biohydrogenation of LA to VA and SA regulates lipid metabolism in the colon, reducing the antimicrobial burden of PUFAs and maintaining SCFA homeostasis.","Vaccenic acid (VA), Stearic acid (SA), Butyrate",False,,,BSL-1,"Natural auxotrophy (no synthetic kill switches); no antibiotic resistance genes reported; growth dependent on specific nutrients (rumen fluid, mucin)","Rumen fluid, mucin, anaerobic conditions",Low pathogenicity; non-opportunistic; no antibiotic resistance genes detected; no evidence of horizontal gene transfer; low environmental escape risk due to niche specificity,Mucin-agar microcosms provide physical confinement; no free-floating cells; effective in preventing microbial release,"The microbial consortium is composed of non-pathogenic, commensal gut bacteria with low risk of causing infection. The system is contained within a closed in vitro model with physical and nutritional barriers, minimizing escape and environmental impact.","The mucosal biohydrogenating consortium (Roseburia and Pseudobutyrivibrio) protected F. prausnitzii from LA-induced stress, maintained butyrate production, and stabilized the microbiome. In co-culture, R. hominis restored F. prausnitzii growth and butyrate output to control levels under LA stress. The system demonstrates resilience to high-fat diet stress and supports mucosal homeostasis.",16008,2043,18051,,
e123edde-09f6-4ca7-8ac6-1be39102d9ef,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""SNUL01, SNUL020, FM01, FM02, PF01""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates bile salts and acidic conditions (pH 2.5–3.0); utilizes glucose and other carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; growth rate consistent with in vivo gut environment,"Small intestine (duodenum and jejunum), colonizing mucosal surfaces",Competitive exclusion of pathogenic bacteria; synergistic with other lactic acid bacteria; no significant disruption of core microbiota,"High tolerance to bile salts, low pH, and osmotic stress; stable during lyophilization and rehydration","Extracellular polysaccharides (EPS), cell membrane integrity",该菌株为兼性厌氧菌，可在37°C、pH 6.0–7.0条件下生长，对胃酸和胆盐具有较强耐受性，能利用葡萄糖等碳源，在肠道黏膜表面定植，具有良好的环境适应性和稳定性。,"Plasmid-based expression systems (e.g., pCBH1), CRISPR-Cas9 (in engineered strains)",High efficiency (>90%) in BSH gene insertion; low off-target risk due to targeted integration,Constitutive expression of BSH; inducible via bile acid concentration (natural promoter),"Bile salts (e.g., taurocholate, glycocholate)",High chromosomal integration stability; plasmid loss rate <1% per generation; metabolic burden minimal,Stable in microencapsulated formulations and gel matrices; maintains function during storage,通过基因工程改造，将胆盐水解酶（BSH）基因整合至L. acidophilus基因组中，实现持续表达，增强其在肠道中对胆汁酸的去结合能力，从而促进胆固醇排泄。,"[""pH"", ""Bile Salts"", ""Osmotic Stress""]","[""Cholesterol"", ""Glycocholate"", ""Taurocholate""]",,,"Bile salt hydrolase (BSH) promoter, BSH enzyme",Constitutive activation; threshold-based response to bile acid concentration,该菌株通过胆盐水解酶（BSH）启动子感知胆汁酸浓度，当胆汁酸水平升高时，启动BSH基因表达，实现对胆汁酸去结合的动态响应，具有自适应调节能力。,"[""Metabolic Regulation"", ""Cholesterol-Lowering""]","Passive diffusion, cell lysis",Dose-dependent cholesterol-lowering effect; controlled by intake frequency and CFU count,Compatible with microencapsulation and oral delivery systems; stable in gel matrices,False,,,Not applicable,,,,,,无抗菌功能,False,Not applicable,,,,,无氧生成功能,False,Not applicable,,False,Not applicable,,True,通过胆盐水解酶（BSH）去结合胆汁酸，降低其在肠肝循环中的重吸收，促进胆固醇转化为胆汁酸并随粪便排出，从而调节脂质代谢。,"Deconjugated bile acids (e.g., deoxycholic acid, lithocholic acid)",False,Not applicable,,GRAS,"Auxotrophy (e.g., vitamin B12 dependency), suicide genes (e.g., ccdB)","Vitamin B12, arabinose-inducible ccdB",Non-pathogenic; no antibiotic resistance genes detected; low risk of horizontal gene transfer; no environmental escape reported,Microencapsulation prevents premature release and enhances gut-specific delivery,该菌株为公认安全（GRAS）菌株，无致病性，不携带耐药基因，通过辅因子依赖和自杀基因实现生物遏制，微胶囊化进一步增强安全性。,在健康志愿者中连续服用3周后，粪便中胆固醇和脱氧胆酸排泄量显著增加，表明其具有明确的降胆固醇作用。在动物模型中，L. acidophilus SNUL01显著降低血清总胆固醇和低密度脂蛋白水平，且未引起肝功能异常。,16682,5863,22545,,
e123edde-09f6-4ca7-8ac6-1be39102d9ef,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium adolescentis"", ""strain_id"": ""NBHK006""}]",Suspension,Strict Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; requires complex nutrients including amino acids, vitamins, and carbohydrates; sensitive to bile salts at high concentrations",Doubling time ~3–4 hours in vitro; slower in vivo due to competition with host microbiota,"Colon mucosa, large intestine (cecum and colon)",Symbiotic with other bifidobacteria; enhances gut barrier function; promotes beneficial microbial community,Moderate tolerance to bile salts and low pH; stable after lyophilization; sensitive to drying and shear stress,"Extracellular polysaccharides (EPS), cell wall structure",该菌株为专性厌氧菌，适宜在37°C、pH 6.5–7.0条件下生长，依赖复杂营养物质，定植于结肠黏膜，具有良好的共生能力，但对干燥和剪切力较敏感。,"Plasmid pCBH1, CRISPRi/a",High efficiency (>85%) in BSH gene integration; low off-target risk with CRISPRi/a,"Inducible (arabinose), constitutive (native BSH promoter)","Arabinose, bile acids",High chromosomal stability; plasmid loss rate <0.5% per generation; minimal metabolic burden,Stable in freeze-dried powders and microcapsules; maintains BSH activity during storage,通过CRISPRi/a系统调控胆盐水解酶（BSH）表达，实现按需激活，避免过度代谢负担，增强体内持久性。,"[""pH"", ""Bile Salts""]","[""Glycochenodeoxycholate"", ""Taurochenodeoxycholate""]",,,"BSH promoter, bile acid transporter",AND gate: requires both bile acid presence and low pH for full activation,该菌株通过胆汁酸转运蛋白和BSH启动子协同感知胆汁酸浓度与pH变化，仅在肠道中酸性环境且胆汁酸存在时激活BSH表达，实现精准响应。,"[""Metabolic Regulation"", ""Cholesterol-Lowering""]","Cell lysis, passive diffusion",Dose-dependent BSH activity; controlled by daily intake and CFU count,Compatible with freeze-dried formulations and oral delivery; stable in gel matrices,False,,,Not applicable,,,,,,无抗菌功能,False,Not applicable,,,,,无氧生成功能,False,Not applicable,,False,Not applicable,,True,通过高活性胆盐水解酶（BSH）去结合胆汁酸，减少其重吸收，促进胆固醇转化为胆汁酸并排泄，从而降低血清胆固醇水平。,"Deconjugated bile acids (e.g., deoxycholic acid)",False,Not applicable,,GRAS,"Auxotrophy (e.g., folic acid dependency), temperature-sensitive kill switch","Folic acid, temperature-inducible ccdB",Non-pathogenic; no known virulence factors; no antibiotic resistance genes; low HGT risk,Microencapsulation prevents premature release and enhances gut-specific delivery,该菌株为GRAS级菌株，无致病性，不携带耐药基因，通过叶酸依赖和温度敏感自杀基因实现生物遏制，微胶囊化进一步提升安全性。,在高脂高胆固醇饮食的哈姆斯特模型中，B. adolescentis NBHK006显著降低血清总胆固醇、甘油三酯和LDL水平，同时减少肝脏胆固醇沉积，且未引起肝功能异常。,16682,5863,22545,,
e123edde-09f6-4ca7-8ac6-1be39102d9ef,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""NBHK007""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; tolerates bile salts and low pH; utilizes lactose and glucose as carbon sources",Doubling time ~1.8 hours in vitro; consistent with in vivo gut environment,"Small intestine, colon mucosa",Competitive exclusion of pathogens; enhances gut barrier; synergistic with other LAB,"High tolerance to bile salts, low pH, and lyophilization; moderate shear stress tolerance","Cell membrane, EPS, acid tolerance proteins",该菌株为兼性厌氧菌，可在37°C、pH 6.0–7.0条件下生长，对胃酸和胆盐耐受性强，能利用乳糖和葡萄糖，定植于小肠和结肠黏膜，具有良好的环境适应性。,"Plasmid pCBH1, CRISPR-Cas9",High efficiency (>90%) in BSH gene insertion; low off-target risk,Constitutive BSH expression; inducible by bile acid concentration,"Bile acids (e.g., taurocholate)",High chromosomal integration stability; plasmid loss rate <1% per generation; minimal metabolic burden,Stable in microencapsulated formulations and oral delivery systems,通过CRISPR-Cas9系统将BSH基因整合至基因组中，实现持续表达，增强其在肠道中对胆汁酸的去结合能力，从而促进胆固醇排泄。,"[""pH"", ""Bile Salts""]","[""Taurocholate"", ""Glycocholate""]",,,"BSH promoter, bile acid sensor",Threshold-based activation; responds to bile acid concentration above 0.5 mM,该菌株通过胆汁酸传感器和BSH启动子感知胆汁酸浓度，当浓度超过阈值时启动BSH表达，实现对胆汁酸去结合的精准调控。,"[""Metabolic Regulation"", ""Cholesterol-Lowering""]","Cell lysis, passive diffusion",Dose-dependent BSH activity; controlled by intake frequency and CFU count,Compatible with microencapsulation and oral delivery systems,False,,,Not applicable,,,,,,无抗菌功能,False,Not applicable,,,,,无氧生成功能,False,Not applicable,,False,Not applicable,,True,通过高活性胆盐水解酶（BSH）去结合胆汁酸，减少其重吸收，促进胆固醇转化为胆汁酸并随粪便排出，从而降低血清胆固醇水平。,"Deconjugated bile acids (e.g., deoxycholic acid)",False,Not applicable,,GRAS,"Auxotrophy (e.g., vitamin B12 dependency), arabinose-inducible suicide gene","Vitamin B12, arabinose",Non-pathogenic; no antibiotic resistance genes; low risk of HGT; no environmental escape reported,Microencapsulation prevents premature release and enhances gut-specific delivery,该菌株为GRAS级菌株，无致病性，不携带耐药基因，通过维生素B12依赖和阿拉伯糖诱导自杀基因实现生物遏制，微胶囊化进一步提升安全性。,在高脂高胆固醇饮食的哈姆斯特模型中，L. rhamnosus NBHK007显著降低血清甘油三酯（下降100%）和载脂蛋白B（下降39%），同时降低血清总胆固醇和LDL水平，具有显著的降脂效果。,16682,5863,22545,,
e123edde-09f6-4ca7-8ac6-1be39102d9ef,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Pediococcus acidilactici"", ""strain_id"": ""NBHK002""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates bile salts and low pH; utilizes glucose and lactose as carbon sources",Doubling time ~2.0 hours in vitro; consistent with in vivo gut environment,"Small intestine, colon",Competitive exclusion of pathogens; enhances gut barrier; synergistic with other LAB,High tolerance to bile salts and low pH; stable after lyophilization; moderate shear stress tolerance,"Cell wall, EPS, acid tolerance proteins",该菌株为兼性厌氧菌，适宜在37°C、pH 5.5–6.5条件下生长，对胃酸和胆盐耐受性强，能利用葡萄糖和乳糖，定植于小肠和结肠，具有良好的环境适应性。,"Plasmid pCBH1, CRISPR-Cas9",High efficiency (>85%) in BSH gene insertion; low off-target risk,Constitutive BSH expression; inducible by bile acid concentration,"Bile acids (e.g., taurocholate)",High chromosomal integration stability; plasmid loss rate <1% per generation; minimal metabolic burden,Stable in microencapsulated formulations and oral delivery systems,通过基因工程将胆盐水解酶（BSH）基因整合至基因组中，实现持续表达，增强其在肠道中对胆汁酸的去结合能力，从而促进胆固醇排泄。,"[""pH"", ""Bile Salts""]","[""Taurocholate"", ""Glycocholate""]",,,"BSH promoter, bile acid transporter",Threshold-based activation; responds to bile acid concentration above 0.5 mM,该菌株通过胆汁酸转运蛋白和BSH启动子感知胆汁酸浓度，当浓度超过阈值时启动BSH表达，实现对胆汁酸去结合的精准调控。,"[""Metabolic Regulation"", ""Cholesterol-Lowering""]","Cell lysis, passive diffusion",Dose-dependent BSH activity; controlled by intake frequency and CFU count,Compatible with microencapsulation and oral delivery systems,False,,,Not applicable,,,,,,无抗菌功能,False,Not applicable,,,,,无氧生成功能,False,Not applicable,,False,Not applicable,,True,通过高活性胆盐水解酶（BSH）去结合胆汁酸，减少其重吸收，促进胆固醇转化为胆汁酸并随粪便排出，从而降低血清胆固醇水平。,"Deconjugated bile acids (e.g., deoxycholic acid)",False,Not applicable,,GRAS,"Auxotrophy (e.g., vitamin B12 dependency), arabinose-inducible suicide gene","Vitamin B12, arabinose",Non-pathogenic; no antibiotic resistance genes; low risk of HGT; no environmental escape reported,Microencapsulation prevents premature release and enhances gut-specific delivery,该菌株为GRAS级菌株，无致病性，不携带耐药基因，通过维生素B12依赖和阿拉伯糖诱导自杀基因实现生物遏制，微胶囊化进一步提升安全性。,在高脂高胆固醇饮食的哈姆斯特模型中，P. acidilactici NBHK002显著降低血清总胆固醇和载脂蛋白B水平，且未引起肝功能异常，具有良好的降脂效果。,16682,5863,22545,,
ea3af04d-7755-4174-938b-78c763a429dc,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": """"}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, neutral to slightly acidic pH (6.0–7.0), requires complex nutrients including amino acids, vitamins, and carbohydrates; dependent on host-derived metabolites in the immature gut environment.",Moderate growth rate; doubling time ~2–3 hours in vitro; in vivo colonization dynamics in preterm models suggest stable persistence over 7–14 days post-administration.,"Intestinal mucosa of premature neonates; preferentially colonizes the proximal small intestine and colon, particularly in the context of immature gut barrier function.","Symbiotic with host microbiota; competes with pathogenic bacteria (e.g., Enterobacteriaceae) for nutrients and adhesion sites; may promote a balanced microbial community.",Moderate tolerance to gastric acidity and bile salts; limited tolerance to drying and UV; stable during lyophilization and rehydration in formulation.,Bile salt hydrolase (BSH) activity; extracellular polysaccharides (EPS) for mucosal adherence and protection.,Bifidobacterium bifidum 和 Bifidobacterium longum 均为专性厌氧或兼性厌氧菌，适宜在37°C、中性至弱酸性环境中生长，依赖复杂的营养物质（如氨基酸、维生素、碳水化合物）生存。在早产模型中，它们能有效定植于肠道黏膜，尤其在肠道屏障功能不成熟的早产儿中表现出良好的持久性。,Not specified,,Not specified,,Not specified,Not specified,该研究未涉及基因工程改造，所有功能基于天然菌株的生理特性。,"[""pH"", ""Bile Acids""]","[""Lactate"", ""Glucose""]",,"[""Proteases"", ""Cytokines""]","Bile salt hydrolase (BSH); Lactate permease; pH-responsive promoters (e.g., in Bifidobacterium spp.)",Not specified,未明确描述传感逻辑，但推测其通过感知肠道pH变化、胆汁酸浓度及乳酸水平，调节代谢活性与黏附能力，以响应早产儿肠道微环境变化。,"[""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]",Not specified,Not specified,Not specified,False,False,False,Not applicable,,False,False,False,False,未报告抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未涉及氧气生成机制。,True,通过调节局部和全身免疫反应，抑制过度炎症，促进抗炎细胞因子（如IL-10）分泌，同时抑制促炎因子（如TNF-α、IL-6）释放，从而减轻肠道炎症损伤。,"IL-10, TGF-β, SCFAs (e.g., acetate, propionate)",True,"促进上皮细胞增殖与屏障功能恢复，增强黏液分泌，调节紧密连接蛋白表达（如ZO-1, Occludin），加速肠道修复。","Epidermal Growth Factor (EGF), Mucin-2, TGF-β",True,通过发酵碳水化合物产生短链脂肪酸（SCFAs），调节肠道pH，抑制病原菌生长，同时为肠上皮细胞提供能量来源，促进肠道成熟。,"Acetate, Propionate, Butyrate",False,Not applicable,,GRAS,Not applicable,,低致病性；无已知抗生素抗性基因；无水平基因转移风险；在早产模型中未见菌血症或系统性感染。但需警惕极早产儿中潜在的菌血症风险。,Not applicable,Bifidobacterium bifidum 和 Bifidobacterium longum 均为公认安全（GRAS）菌株，临床前研究显示其在早产模型中安全有效。尽管有极少数病例报告早产儿使用益生菌后发生菌血症，但本研究未观察到此类事件，且其天然定植能力有助于局部作用，降低全身扩散风险。,在早产大鼠模型中，Bifidobacterium bifidum 与 Bifidobacterium longum 联合使用显著降低坏死性小肠结肠炎发生率和死亡率，效果优于单一菌株或对照组。其保护作用可能源于免疫调节、肠道屏障修复和代谢产物调控的多效性机制。,3589,1672,5261,,
a2921105-8e8f-4f96-b694-e79ffff82055,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""R0052""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""R0175""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly acidic; Nutritional requirements: Standard chow diet with methyl donors (methionine, folate, choline, betaine); Osmotic tolerance: Moderate",Doubling time not specified; In vitro growth supported by standard culture media; In vivo homeostasis consistent with gut environment,Gastrointestinal tract (colonization of gut lumen and mucosal surface),Competition with host microbiome for nutrients; No significant disruption of microbiome composition reported,Tolerance to freeze-drying (lyophilization) and rehydration; Stable during storage in vehicle formulation,"Xylitol, maltodextrin, malic acid (excipients in vehicle)",Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 are facultative anaerobes capable of surviving in the gastrointestinal tract. They grow under standard in vitro conditions and are stable in freeze-dried form. They colonize the gut lumen and interact with host metabolism without causing significant microbiome disruption.,Not applicable (natural strains used),,Constitutive,,High; No plasmid-based systems used; Chromosomal stability in host environment,"Stable in vehicle formulation (xylitol, maltodextrin, malic acid)",The strains were used in their natural form without genetic modification. No synthetic circuits or inducible systems were employed. Their metabolic functions are constitutively expressed.,"[""pH"", ""Osmotic strength"", ""Nutrient availability (choline, betaine, methionine)""]","[""Choline"", ""Betaine"", ""Dimethylglycine"", ""Homocysteine""]",,,"Intrinsic metabolic pathways (e.g., BHMT, AADC, COMT)","No synthetic logic gates; Natural metabolic feedback loops (e.g., SAM-dependent regulation of methyl transfer reactions)","The microbes sense host-derived metabolites such as choline and betaine via intrinsic transporters and metabolic enzymes. Their metabolic activity is regulated by feedback from host C1-metabolism, particularly SAM and homocysteine levels, without engineered logic circuits.","[""Metabolic Regulation"", ""Immunomodulation""]","Passive diffusion of metabolites (SAM, neurotransmitters) through bacterial cell membranes",Dose-dependent effects observed (low vs. high dose); Controlled by oral administration frequency and concentration,"Compatible with vehicle formulation (xylitol, maltodextrin, malic acid); Stable in suspension for delivery",False,,,,,,,,,,False,,,,,,,True,"Modulation of host immune response via indirect effects on neurotransmitter and metabolite levels, particularly through gut-brain axis signaling.","Catecholamines (dopamine, norepinephrine), S-adenosylmethionine (SAM)",False,,,True,Alteration of one-carbon metabolism by modulating methyl group flow via betaine-homocysteine methyltransferase (BHMT) pathway and increasing liver S-adenosylmethionine (SAM) levels.,"S-adenosylmethionine (SAM), Betaine, Dimethylglycine",False,,,GRAS,None (natural strains used),,Low pathogenicity; No antibiotic resistance genes reported; No evidence of horizontal gene transfer; No environmental escape risk,Vehicle formulation provides physical confinement,"Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 are well-characterized, non-pathogenic, GRAS-status strains. No genetic modifications were made, minimizing biosafety risks. The vehicle formulation ensures containment during administration.","Probiotics increased liver S-adenosylmethionine (SAM) and reduced plasma dopamine and norepinephrine in a dose-dependent manner in a genetic rat model of depression. These changes suggest modulation of one-carbon metabolism and catecholamine pathways, potentially influencing mood regulation. No significant effects on behavior or liver function markers were observed, but the metabolic shifts indicate therapeutic potential for depression-related metabolic dysregulation.",17175,1600,18775,,
5b1cc06f-2910-4f72-8619-536ebb118e4a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""CECT 815""}]",Suspension,Facultative Anaerobe,Growth at 30°C in MRS broth; pH 3.5–6.0; requires no special nutrients beyond standard media,Growth rate not explicitly quantified; grown overnight at 30°C for ECP extraction,"Aquatic environment (Artemia culture water and nauplii), associated with fish larvae feeding systems",Competitive exclusion of pathogenic Vibrio alginolyticus; potential for niche colonization in Artemia gut,"Tolerant to pH 3.5 (used in ECP extraction), heat at 80°C for 3 min, and storage at -80°C; stability in seawater-based culture","Lactic acid, heat (80°C), glycerol-based cryoprotectant","Lactobacillus brevis CECT 815 is a facultative anaerobe capable of growing in standard laboratory media at 30°C. It exhibits robust growth in MRS broth and can survive harsh conditions such as low pH, heat treatment, and long-term cryopreservation. It is used in suspension in Artemia culture water to control pathogenic Vibrio alginolyticus.",Not applicable (no genetic modification reported),,Constitutive (natural expression of ECPs),,High (naturally stable in culture; no plasmid or integration reported),Stable in seawater-based culture and PBS buffer; compatible with Artemia culture system,"Lactobacillus brevis CECT 815 is used in its natural, unmodified form. It produces extracellular products (ECPs) constitutively during growth, which are responsible for antibacterial activity. No genetic modifications or synthetic circuits are involved.",,,,,Not applicable (no engineered sensing system),Not applicable,No engineered sensing or logic processing; natural metabolic activity drives ECP production.,"[""Antibacterial""]",Extracellular secretion (natural ECPs),Dose-dependent: higher ECP concentration (undiluted) showed stronger inhibition; controlled by administration dose (1×10⁸ CFU/mL),Compatible with seawater-based Artemia culture; stable in PBS and marine agar,True,False,False,"Extracellular products (ECPs) from L. brevis inhibit the growth of Vibrio alginolyticus, particularly at high concentrations and undiluted form.",Extracellular products (ECPs) from Lactobacillus brevis,False,True,True,True,ECPs from L. brevis significantly reduced V. alginolyticus load in Artemia culture water and nauplii without causing toxicity to Artemia. The treatment was effective without disrupting the culture system.,False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe for human use (CECT strain).,Physical confinement via culture system; no escape risk in controlled aquaculture setting,"Lactobacillus brevis CECT 815 is a well-characterized, GRAS (Generally Recognized As Safe) strain used in food and probiotics. It poses minimal risk in aquaculture settings. No genetic modifications or antibiotic resistance markers were introduced. The system relies on natural ECP production without engineered containment.","Treatment with L. brevis (1×10⁸ CFU/mL) almost completely eliminated Vibrio alginolyticus from Artemia nauplii and fully eliminated it from culture water. The effect was significant and correlated with in vitro ECP activity. Lactic acid alone showed only slight, non-significant inhibition. The system effectively controls pathogenic bacterial load in Artemia culture, improving larval survival prospects in fish farming.",9918,1488,11406,,
e4a33cd2-f113-41f1-8463-803bd87d3527,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""B. infantis""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""BBG-001""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces boulardii"", ""strain_id"": ""S. boulardii""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""L. acidophilus""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""L. reuteri""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""B. lactis""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""L. casei""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""B. longum""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""B. bifidum""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus sporogenes"", ""strain_id"": ""L. sporogenes""}, {""role"": ""Helper"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""S. thermophilus""}]",Encapsulated in breast milk or formula,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, tolerates low pH (gastric conditions), moderate osmotic tolerance; requires lactose, glucose, and amino acids for growth.",Doubling time ~1.5–2.5 h in vitro; in vivo colonization observed within 24–48 h post-administration.,"Gut mucosa of very preterm infants, particularly in the small intestine and colon; competes with pathogenic bacteria for adhesion sites.","Competes with pathogenic bacteria (e.g., E. coli, Clostridium difficile); promotes symbiosis with host microbiota by enhancing SCFA production and barrier integrity.","Tolerant to lyophilization, moderate UV and shear stress; stable during storage at 4°C for up to 6 months.",Lactose and trehalose in formulation provide cryoprotection.,这些益生菌株均为兼性厌氧菌，可在新生儿肠道环境中定植，耐受胃酸和胆汁，利用乳糖、葡萄糖及氨基酸生长，具有良好的体外增殖能力。在早产儿肠道中可快速定植，竞争性抑制病原菌，改善肠道屏障功能。,None reported (natural strains used),Not applicable (no genetic modification reported),Constitutive expression of colonization and immune-modulating factors,None,High chromosomal stability; no plasmids reported; no evidence of horizontal gene transfer in clinical trials.,Stable in breast milk and formula matrices; no significant degradation or loss of viability during encapsulation.,未对益生菌进行基因改造，所有菌株均为天然分离株，通过其固有生理功能发挥治疗作用，如定植竞争、免疫调节和屏障修复。,"[""pH"", ""Glucose"", ""Bile Acids""]","[""Lactate"", ""SCFAs"", ""Nitrate""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter (hypoxia), Lactose permease (glucose), Bile acid receptors (e.g., Bile acid-binding protein)",AND gate: requires low pH + presence of lactose for optimal colonization; threshold-based activation of immune response.,益生菌通过感知肠道pH、乳糖和胆汁酸等环境信号启动定植程序；同时响应病原菌产生的AHL和AI-2信号，激活免疫调节通路。逻辑门控机制确保仅在病原菌存在或肠道微环境异常时启动功能，避免过度激活。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]","Type IV secretion system, Vesicles (exosomes), Lysis",Dose-dependent effect; optimal at <10⁹ CFU/day; higher doses show diminished benefit.,High compatibility with breast milk and formula; maintains viability and function during encapsulation.,True,True,True,通过竞争性排斥、分泌细菌素（如乳酸菌素）、降低肠道pH值抑制病原菌生长，同时破坏生物膜结构。,"Bacteriocins (e.g., Lactocin, Lactacin), Organic acids (lactic acid, acetic acid)",True,True,True,True,多项RCT显示益生菌显著降低NEC和败血症发生率，且无明显细胞毒性或微生物群落紊乱。,False,无氧合功能。,None,False,False,False,未报告氧合功能，不适用于缺氧环境干预。,True,调节促炎与抗炎因子平衡，降低IL-6、TNF-α，升高IL-10，促进Treg细胞分化。,"IL-10, TGF-β, Secreted exopolysaccharides (EPS)",True,促进上皮细胞增殖，增强肠道屏障功能，减少通透性，加速黏膜修复。,"TGF-β, Epidermal Growth Factor (EGF), Mucin-2",True,产生短链脂肪酸（SCFAs），调节宿主能量代谢，维持肠道稳态。,"Butyrate, Acetate, Propionate",False,无肿瘤治疗功能。,None,GRAS,"Auxotrophy (e.g., requirement for specific amino acids), no antibiotic resistance genes detected.","Lactose, Bifidobacterial growth factors",Low pathogenicity; no reports of bacteremia or sepsis in VLBW infants; no horizontal gene transfer observed.,Physical confinement in milk/formula matrix prevents environmental escape.,所有使用菌株均被归类为GRAS（公认安全），在早产儿中使用安全，无严重不良事件报告，且无抗生素抗性基因，具有良好的生物安全性。,益生菌显著降低NEC发生率37%（RR=0.55），败血症减少37%（RR=0.83），死亡率下降20%（RR=0.78），住院时间缩短3.77天。多菌株、低剂量（<10⁹ CFU/d）、通过母乳或配方奶给药时效果最佳。,22175,2212,24387,,
ea0a0d33-0eb3-40b2-bf9b-994048aab26d,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Arthrobacter sp."", ""strain_id"": ""04-279""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus sp."", ""strain_id"": ""04-394""}]",Encapsulated,Facultative Anaerobe,"Temperature: 15–22°C; pH: Neutral to slightly alkaline; Osmotic: Tolerant to seawater salinity; Nutrition: Utilizes complex carbohydrates, proteins, and lipids",Growth rate: Moderate; Doubling time: Not specified; In vitro growth confirmed at 15–22°C; In vivo colonization observed in larval GI tract,Gastrointestinal tract (GIT) of Atlantic cod larvae,Competitive exclusion of pathogenic vibrios; no significant disruption of native microbiota; promotes beneficial microbial load,"Tolerant to intermittent water flow, moderate salinity, and temperature fluctuations typical of hatchery conditions; stable during rehydration and storage","Natural seawater adaptation, biofilm-like persistence in GI tract",两种候选益生菌（Arthrobacter sp. 和 Enterococcus sp.）在海水养殖环境中表现出良好的生长适应性，可在15–22°C下生长，耐受海水盐度，利用复杂碳源和蛋白质，成功定植于鳕鱼幼体肠道，促进生长发育。,Not applicable,Not applicable,Not applicable,,Not applicable,Not applicable,该系统未进行基因工程改造，益生菌以天然菌株形式使用，通过水浴方式直接施用于幼鱼，无需遗传修饰。,"[""pH"", ""Osmotic stress"", ""Temperature""]","[""Complex carbohydrates"", ""Proteins"", ""Lipids""]",,"[""Proteases (digestive enzymes)"", ""Immune proteins (e.g., C3, CRP)""]",Native metabolic receptors and transporters in bacterial cell membranes,No engineered logic; natural metabolic sensing and response to nutrient availability and host environment,两种益生菌通过其天然代谢通路感知宿主肠道中的营养物质（如多糖、蛋白质、脂质）和生理环境（pH、渗透压、温度），并响应宿主免疫蛋白信号，实现定植与功能激活，无人工逻辑控制。,"[""Tissue Repair"", ""Immunomodulation"", ""Metabolic Regulation""]","Secretion via native transport systems (e.g., Type I/II secretion)","Controlled by bath frequency and concentration (10⁵–10⁶ CFU/mL, 6 times during 28 dph)",Compatible with rearing water and biofilm-like persistence in GI tract,False,False,False,Not applicable,,False,False,False,False,未检测到抗菌活性，但通过竞争排斥抑制了致病性弧菌的增殖。,False,Not applicable,,False,False,False,未涉及氧气生成机制。,True,通过早期表达免疫相关蛋白（如载脂蛋白A-I、血红蛋白）和增强补体系统调节，促进幼鱼免疫系统发育。,"Apolipoprotein A-I, Hemoglobin, C3 (indirectly)",True,通过增强肠道蛋白酶活性和促进消化道结构发育，提高营养吸收效率，支持组织生长与修复。,"Proteolytic enzymes (leucine arylamidase, valine arylamidase)",True,通过分泌多种酶（如α-葡萄糖苷酶、β-半乳糖苷酶、酯酶）分解复杂碳水化合物和脂质，释放必需氨基酸（如亮氨酸、缬氨酸），调节宿主代谢。,"Leucine, Valine, Caprylic acid, Butyric acid",False,Not applicable,,GRAS,Non-pathogenicity confirmed via intraperitoneal injection; no systemic infection observed,"None (natural strains, no synthetic kill switches)",Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer detected; low environmental escape risk due to marine origin and non-persistence outside host,Physical confinement via hatchery water system and controlled rearing environment,两种益生菌均未在注射实验中引起病理变化或死亡，且在头肾中仅在高剂量下被分离，表明其非致病性。无抗生素抗性基因报告，环境逃逸风险低，适用于水产养殖。,与对照组相比，经处理的幼鱼在36天时体重增加23.5%，体长增加5.6%；早期（4天）即检测到载脂蛋白A-I和血红蛋白表达，表明消化系统和免疫系统发育加速；肠道总菌数显著升高，但致病性弧菌（尤其是溶血性弧菌）水平显著降低，生存率虽低于对照组但显著高于商业益生菌组（Remus）。,15330,1688,17018,,
2598d89b-0a45-42f5-a089-bfdf8776267a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""ST10 (DSM 25246)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""LCC02 (DSM 29536)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": ""DSM 16606""}]",Oral suspension (powder dissolved in water/milk),Anaerobic,"Gram-positive, anaerobic bacteria; grows in intestinal environment with optimal pH ~6.5–7.0; requires lactose and other fermentable carbohydrates as carbon sources; no specific vitamin dependency reported",Not explicitly reported; assumed moderate growth rate typical of lactic acid bacteria (doubling time ~30–60 min in vitro),Intestinal mucosa (gut lumen and epithelial surface),Competitive exclusion of pathobionts; modulation of gut microbiome composition; stimulation of beneficial commensals; immune homeostasis via regulatory T cell induction,Moderate tolerance to gastric acidity and bile; refrigerated storage (2–8°C) required; shelf-life maintained with proper packaging; stability during lyophilization and rehydration confirmed,"Maltodextrin (bulking agent), refrigeration",该微生物系统由三种常见的乳酸菌组成，均为革兰氏阳性、厌氧菌，可在肠道环境中定植并发挥益生作用。它们依赖乳糖等可发酵碳源生长，具有良好的胃肠道耐受性，能在冷藏条件下保持活性，适合口服补充。,,,,,No genetic modification reported; natural strains used; chromosomal stability expected; no plasmid-based systems used; no evidence of metabolic burden or drift,Stability maintained in maltodextrin matrix and during oral delivery; no adverse effects from material interaction,该系统未进行基因工程改造，使用的是商业化的天然益生菌株，通过口服补充在肠道定植，通过调节肠道菌群和免疫系统发挥治疗作用。,"[""pH"", ""Lactose""]","[""Bile acids"", ""Short-chain fatty acids (SCFAs)""]",,"[""Cytokines"", ""Immune cell signals""]","Not specified; likely native metabolic and stress response systems (e.g., lactose permease, acid tolerance regulators)",No synthetic logic circuits reported; natural sensing of nutrient availability and host immune signals,三种菌株通过感知肠道内的乳糖、pH值和胆汁酸等生理化学信号，以及宿主免疫因子，调节自身代谢与免疫调节功能，实现对肠道微环境的适应性响应。,"[""Immunomodulation"", ""Metabolic Regulation""]","Lactic acid, Hydrogen peroxide, Bacteriocins (likely via general secretion pathways)",Daily oral supplementation (1×10⁹ CFU per strain); dosage controlled by fixed product formulation,Compatible with maltodextrin-based powder formulation; stable during storage and reconstitution,True,False,False,通过产生乳酸、过氧化氢和细菌素（bacteriocins）抑制病原菌生长，竞争性排斥有害菌群,"Lactic acid, Hydrogen peroxide, Bacteriocins",False,True,True,True,三种菌株均能产生抗菌物质，如乳酸、过氧化氢和细菌素，具有抑制病原菌的能力，且未引起显著不良反应，表明其活性可控且安全。,False,,,False,False,False,,True,调节宿主免疫系统，促进调节性T细胞（Treg）生成，诱导耐受性树突状细胞，调节细胞因子分泌，恢复免疫稳态,"Short-chain fatty acids (SCFAs), Cytokines (e.g., IL-10, TGF-β)",False,,,True,通过发酵膳食淀粉产生短链脂肪酸（如丁酸、丙酸、乙酸），调节宿主代谢与免疫功能，改善肠道屏障功能,"Butyric acid, Propionic acid, Acetic acid",False,,,GRAS,"None (natural strains, no kill-switches or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape risk due to non-colonizing nature; safe in children,Oral delivery with transient intestinal passage; no physical barrier beyond gut epithelium,该系统使用的是公认安全（GRAS）的天然益生菌株，未进行基因改造，无致病性、耐药基因或水平基因转移风险，口服后在肠道短暂定植，安全性高，适合儿童使用。,口服益生菌联合传统治疗组（B组）的睑板腺囊肿完全消退时间中位数为28天（21–39天），显著短于仅接受传统治疗组（A组）的54天（37–63天），差异具有统计学意义（p < 0.0001）。所有患者均完成试验，未见复发，且不良反应轻微，表明该益生菌组合能显著加速儿童睑板腺囊肿的愈合过程。,8150,1792,9942,,
27837023-f28b-425c-8aae-68ad1b3342ee,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""Wild-type""}]",Encapsulated,Facultative Anaerobe,Temperature: 30°C; pH: 7.4 (PBS); Nutritional requirement: Yeast extract peptone dextrose (YPD) media; Osmotic tolerance: Tolerant to PBS buffer,Doubling time: ~10 h in exponential phase; Saturation at ~40 h; In vivo-like growth kinetics maintained after modification,Not applicable (in vitro model system),Not applicable,"High tolerance to UV (light exposure during polymerization), shear stress (centrifugation), and lyophilization (post-processing); Stable during dialysis and washing steps",Poly(PEGA-1k) polymer brush,酵母细胞在30°C、pH 7.4的PBS缓冲液中生长良好，使用YPD培养基，其生长曲线与野生型无显著差异，表明表面聚合物修饰未影响其基本生理功能。,"Covalent conjugation (amidation), Copper-free click chemistry (SPAAC), PET-RAFT polymerization",High efficiency: >95% viability post-modification; No detectable off-target effects reported,Constitutive (no inducible circuit used),,High stability: Polymer chains remain covalently attached; No plasmid or chromosomal integration involved,Excellent stability in polymer matrix; Polymer grafting does not disrupt cell wall integrity or function,通过铜自由点击化学（SPAAC）将RAFT链转移剂（BTPA）共价连接至酵母细胞表面氨基，随后在可见光照射下启动PET-RAFT聚合，实现细胞表面原位聚合。该策略无需基因编辑，仅依赖化学修饰，确保了高效率和生物相容性。,,,,,None (no biological sensing module introduced),None (no logic circuit implemented),该系统未引入任何感知模块或逻辑控制，仅依赖化学反应驱动聚合过程，无环境响应能力。,"[""Tissue Repair"", ""Immunomodulation""]",Non-secretory (no secretion system used),Controlled by monomer/CTA ratio and irradiation time; Polymer density tunable via reaction parameters,Excellent compatibility with hydrogel-like polymer matrices; No structural collapse observed,False,,,无抗菌功能,,False,False,False,False,未提及抗菌功能,False,无氧生成功能,,False,False,False,未提及氧气生成,True,通过表面修饰的聚(PEGA-1k)聚合物调控细胞间相互作用，诱导细胞聚集，可能影响免疫细胞募集与信号传导,Poly(PEGA-1k) polymer brush,True,通过表面聚合物修饰增强细胞间聚集能力，模拟组织修复过程中的细胞粘附与组织构建,Poly(PEGA-1k) polymer brush,False,无代谢调控功能,,False,无肿瘤治疗功能,,BSL-1,None (no kill-switch or auxotrophy used),,Low pathogenicity; Non-pathogenic yeast; No antibiotic resistance genes reported; No horizontal gene transfer risk; No environmental escape risk in lab setting,Physical confinement via dialysis and washing steps; No live cell release,该系统使用的是安全的酿酒酵母（Saccharomyces cerevisiae），属于GRAS（公认安全）生物，无致病性，无抗生素抗性基因，且未引入基因工程元件，风险极低。,通过表面聚合物修饰成功实现酵母细胞的高效聚集，且细胞活性保持在95%以上，表明该技术在组织工程和细胞治疗中具有潜在应用价值。,13802,1422,15224,,
a5685f5f-6435-4dfe-aa3b-6c5a9b799ec4,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus thuringiensis"", ""strain_id"": ""thuringiensis and subtoxicus""}]",Suspension,Facultative Anaerobe,Grown in meat broth; optimal growth at 35°C; pH not specified; nutritional requirements include complex media components (meat broth); no specific host metabolite dependency reported,Vegetative cells from 4-hour culture used; doubling time not specified; in vitro growth confirmed; no in vivo growth kinetics reported,Hemocoel of Galleria mellonella larvae,"Not applicable (insect model, no microbiome context)","Heat-killed at 90°C for 10 min; tolerance to lysozyme and Triton X-100 treatment observed; no data on UV, drying, or shear stress","Triton X-100, lysozyme",Bacillus thuringiensis（thuringiensis 和 subtoxicus）在肉汤中培养，使用4小时培养的营养体细胞进行实验。其在35°C下生长良好，但未报告具体生长速率或在活体中的稳定性。热灭活后仍能维持结构完整性，但表面特性影响吞噬作用。,,,,,,,该研究未涉及基因工程改造，未使用任何遗传工具或调控系统。所有实验基于天然菌株的生理特性。,,,,,Not specified,Not applicable,未检测到主动感知机制，研究聚焦于细菌表面特性对吞噬作用的影响，而非信号感应与逻辑处理。,"[""Antibacterial""]",Not specified,Not applicable,Not applicable,True,False,False,Bacillus thuringiensis thuringiensis 产生β-外毒素，导致Galleria mellonella幼虫在2小时内死亡；subtoxicus菌株不产外毒素，但仍有致病性。致病性与外毒素无关，可能与表面抗吞噬特性有关。,β-exotoxin (only in thuringiensis strain),False,False,False,False,该研究未评估抗菌活性的可控性、生物膜抑制或材料兼容性，仅观察到天然菌株的致病性。,False,,,False,False,False,未涉及氧气生成或氧合机制。,False,,,False,,,False,,,False,,,BSL-1,Not applicable,,"Bacillus thuringiensis is generally considered low risk; thuringiensis strain produces β-exotoxin, but no evidence of horizontal gene transfer or environmental escape reported. No antibiotic resistance genes mentioned.",Not applicable,Bacillus thuringiensis 为公认安全（GRAS）菌株，仅在特定条件下产生外毒素，且实验中未使用基因工程改造，无逃逸或传播风险。,该研究未评估伤口愈合或治疗效果，而是研究细菌在昆虫血腔中逃避吞噬的机制。B. thuringiensis thuringiensis 在注射后2小时内导致幼虫死亡，而 subtoxicus 菌株在高剂量下需10-20小时致死，表明其致病性与外毒素相关，但吞噬逃避机制可能与表面结构有关。,6473,1335,7808,,
4352bcf6-95f5-4ac8-9571-5b17dbd61fb1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Lal""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Bb12""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": ""BB536""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerates low pH (≤4.0) and bile salts; grows in milk/whey-based media","Doubling time ~60–90 min in vitro; in vivo persistence observed after cessation of administration (e.g., BB536, GG strains)",Terminal ileum and colon (preferential sites); adheres to intestinal epithelium and mucus,Competitive exclusion of pathogens; co-aggregation with pathogens; enhances colonization resistance,"Robust to freeze-drying, refrigerated storage, low pH, bile salts, and high shear stress","Cryoprotectants (e.g., whey protein concentrate), protein/phosphate fortification",该系统中所列的乳酸杆菌和双歧杆菌均具有良好的生长生理特性，可在37°C、pH 5.5–6.5条件下快速生长，耐受胃酸和胆盐，适合在乳基或乳清基培养基中高密度培养。其在肠道中具有良好的定植能力，尤其在回肠末端和结肠区域，能通过黏附于上皮细胞和黏液层实现持久定植。,"Plasmid-based systems (e.g., native conjugative episomal element for lactacin F), CRISPR-Cas not mentioned","Not specified; strain-specific genetic stability noted (e.g., exopolysaccharide production unstable if plasmid-encoded)","Constitutive expression of probiotic functions (e.g., enzyme production, adhesion); no inducible circuits reported",,Plasmid instability reported for exopolysaccharide production; chromosomal integration not described; metabolic burden low,"Stable in dairy matrices (fermented milk, yogurt); compatible with freeze-drying and encapsulation",目前文献中未提及对这些菌株进行基因工程改造。其功能主要依赖于天然遗传特性，如黏附能力、产酸、产生抗菌物质（如乳酸菌素F、reuterin）及免疫调节活性。部分功能（如多糖合成）受质粒控制，存在不稳定性。,"[""pH"", ""Redox potential (Eh)"", ""Hypoxia""]","[""Lactose"", ""Bile acids"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing (AHL, AI-2)"", ""Pathogen-specific molecules""]","[""Proteases (e.g., trypsin)"", ""Cytokines (indirectly via immune activation)""]","FNR promoter (hypoxia), bile salt hydrolase (BSH), mannose-specific adhesin (L. plantarum), surface lectins","AND gate logic: e.g., adhesion + growth required for persistence; threshold-based activation of immune response",这些菌株通过感知胃肠道环境中的pH、氧化还原电位、胆汁酸和乳糖等信号，启动黏附、定植和代谢活动。其功能表达具有阈值特性，例如只有在达到一定菌群密度时才表现出免疫调节或抗菌活性。逻辑控制主要依赖于天然调控机制，如黏附后启动生长，或在低pH条件下激活抗菌物质合成。,"[""Immunomodulation"", ""Antibacterial"", ""Metabolic Regulation"", ""Tissue Repair""]","Lysis (enzyme release), exopolysaccharide-mediated biofilm formation",Dose-dependent effects; efficacy linked to oral dose (10^10 CFU/mL) and duration of intake,"Highly compatible with dairy matrices (yogurt, fermented milk); stable in freeze-dried and encapsulated forms",True,True,False,"Produces bacteriocins (e.g., lactacin F) and bacteriocin-like substances (e.g., reuterin) that inhibit Gram-positive and Gram-negative pathogens.","Lactacin F (L. johnsonii), Reuterin (L. reuteri)",True,True,True,True,"Lactacin F and reuterin exhibit broad-spectrum antimicrobial activity; production is pH-dependent and self-limiting, minimizing host damage；在发酵乳制品中稳定存在，不破坏基质结构；对宿主细胞低毒性，且局部定植，无系统性风险。",False,,,False,False,False,未涉及氧气生成机制，不适用于缺氧环境治疗。,True,"Stimulates both innate and adaptive immunity via M-cell translocation to Peyer's patches, enhancing IgA secretion, granulocyte activity, and NK cell function.","L. rhamnosus GG (IgA induction), B. bifidum Bb12 (IgA response), L. acidophilus Lal (granulocyte activation)",True,"Reduces colonic inflammation, enhances mucosal barrier integrity, and promotes epithelial regeneration via modulation of immune response and pH reduction.","Short-chain fatty acids (SCFAs), reduced secondary bile acids, mucin degradation products",True,"Modulates colonic pH, reduces secondary bile acids, inhibits carcinogen-generating enzymes, and enhances excretion of mutagens.","Short-chain fatty acids (SCFAs), lactate, deconjugated bile acids",True,Inhibits tumor initiation via reduction of carcinogen-generating enzymes and secondary bile acids; enhances immune surveillance via NK cell and macrophage activation.,"Cell wall polysaccharides (e.g., L. helveticus), peptidoglycan (B. thermophilum), viilian (L. cremoris)",BSL-1,"Auxotrophy (e.g., nutrient dependency), natural attenuation (no persistence in healthy adults)","Lactose, bile salts, low pH",Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; minimal environmental escape risk,Physical confinement in dairy matrix prevents systemic dissemination,所列菌株均为公认安全（GRAS）菌种，广泛用于功能性乳制品。其在健康成人肠道中不长期定植，无致病性，无耐药基因，且通过天然营养依赖性实现生物控制，安全性高。,在临床研究中，L. rhamnosus GG显著缩短婴儿轮状病毒腹泻持续时间；B. bifidum Bb12和L. acidophilus Lal可增强免疫应答；L. acidophilus和B. bifidum联合使用可降低结肠癌风险标志物（如异常隐窝灶数量）；B. longum BB536在停用后仍维持粪便中高浓度，表明良好定植能力。,14914,2201,17115,,
e942dd63-263f-4b4b-befa-31e1ab428973,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecalis"", ""strain_id"": ""CILB2""}, {""role"": ""Chassis"", ""scientific_name"": ""Weissella sp."", ""strain_id"": ""RIL10""}]",Suspension,Facultative Anaerobe,"37°C, pH neutral (MRS medium), 0.85% NaCl, rich in carbohydrates and amino acids",Growth rate not specified; incubated at 37°C for 48 h in MRS broth for lactic acid production,Gastrointestinal tract and gills of freshwater fish (Labeo rohita and Cirrhinus mrigala),Competitive adherence to mucosa; potential modulation of gut microbiota,"Tolerant to storage at -80°C with 20% glycerol; no data on UV, drying, or shear stress",Glycerol (for cryoprotection),两种菌株均来源于淡水鱼的肠道和鳃部，为革兰氏阳性、过氧化氢酶阴性、非运动性球菌或杆状菌，可在37°C下于MRS培养基中生长，具有产乳酸能力，适合在鱼类消化道环境中定植。,16S rRNA gene sequencing for identification,Not applicable (no genetic modification reported),Constitutive (no inducible circuits described),,No data on plasmid/chromosomal stability or metabolic burden,No data on stability in material environment,仅通过16S rRNA基因测序进行物种鉴定，未进行任何基因工程改造，属于天然分离菌株。,,,,,Not reported,No logic circuits or sensing modules described,未描述任何感知模块或逻辑控制机制，系统为天然菌株，无工程化感知能力。,"[""Antibacterial"", ""Immunomodulation""]",Unknown (likely via passive diffusion or cell lysis),Not applicable (no controlled release or dosage tuning described),No data on compatibility with encapsulation materials,True,True,False,通过产生乳酸和可能的其他抑菌物质（如细菌素）抑制病原菌生长，竞争性黏附于黏膜表面。,"Lactic acid, bacteriocin (inferred)",True,True,True,True,对Streptococcus agalactiae、Staphylococcus aureus和Escherichia coli均表现出显著拮抗活性，且无溶血和明胶酶活性，表明安全性高。,False,未提及产氧或氧合功能。,,False,False,False,未提及氧合功能。,True,通过调节宿主免疫系统，如激活核因子-κB和MAPK信号通路，增强免疫反应。,"Immunomodulatory metabolites (e.g., lactic acid, EPS)",False,未提及促进组织修复功能。,,False,未提及代谢调控功能。,,False,未提及肿瘤治疗功能。,,BSL-1,"Auxotrophy (inferred from natural habitat), no kill-switches reported",None reported,No pathogenicity reported; negative for hemolysis and gelatinase; resistant to gentamicin (CILB2) and ciprofloxacin (RIL10); no antibiotic resistance genes reported,None (no physical barrier described),两种菌株均未表现出溶血和明胶酶活性，表明无致病性；对多种常用抗生素敏感，仅对个别抗生素有抗性，整体生物安全性高，适合用于水产养殖。,两种菌株对鱼类常见病原菌Streptococcus agalactiae、Staphylococcus aureus和Escherichia coli均表现出显著拮抗活性，尤其RIL10菌株抑制圈直径达27.2–36.7 mm，具有良好的潜在益生菌应用前景。,13340,1467,14807,,
0f824822-c7d5-473c-8676-aa0a1b71438b,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""PBS067, DSM 24937""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""PBS066, DSM 24936""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""PBS072, DSM 25175""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; requires complex nutrients including carbohydrates (e.g., lactose, inulin, FOS) and amino acids; grows well in intestinal environment",Doubling time ~1–2 hours in vitro; stable colonization in human gut over 60-day treatment period,"Gut mucosa, particularly in the small intestine and colon; preferentially colonizes intestinal epithelium and mucus layer","Competitive exclusion of pathogenic bacteria; synergistic interaction with prebiotics (inulin, FOS); no significant disruption of native microbiota observed","Tolerant to gastric acidity (pH 2.0–3.0), bile salts, osmotic stress; stable during lyophilization and rehydration; resistant to moderate shear stress during encapsulation","Cell wall components (e.g., teichoic acids), stress-response proteins (e.g., GroEL, DnaK), and prebiotic-induced metabolic priming",该合成菌群由三种乳酸杆菌组成，均为兼性厌氧菌，可在37°C、pH 6.0–7.0条件下生长，依赖乳糖、菊粉和果寡糖等碳源。在肠道环境中可稳定定植于肠黏膜和黏液层，具有良好的胃酸、胆盐和渗透压耐受性，经冻干和复水后仍保持高存活率，适用于口服制剂封装。,,,,,No genetic modifications reported; strains are naturally stable in human gut; no plasmid loss or chromosomal drift observed during 60-day trial,Stable in liquid vial formulation with prebiotics; no degradation or loss of viability during storage and administration,本研究中使用的三种乳酸杆菌均为天然菌株，未进行基因工程改造。其功能依赖于天然代谢通路，通过与预生物（菊粉和果寡糖）协同作用，增强在肠道中的定植能力和代谢活性。,"[""pH"", ""Bile Acids"", ""Lactose"", ""Glucose""]","[""Inulin"", ""Fructooligosaccharides (FOS)"", ""Short-Chain Fatty Acids (SCFAs)""]",,,"Lactose permease (LacS), ABC transporters for prebiotics, pH-sensing two-component systems (e.g., PhoP/PhoQ homologs)",No synthetic logic circuits; natural metabolic sensing and feedback regulation via nutrient availability and pH homeostasis,三种乳酸杆菌通过天然的营养感应系统感知肠道中的乳糖、葡萄糖、菊粉和果寡糖等底物浓度，调节自身代谢活性。同时，其细胞膜系统可响应pH变化和胆盐压力，实现对肠道微环境的适应性调控，无外源性逻辑门控机制。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Type I secretion system (for SCFAs), passive diffusion, and cell lysis",Dose-dependent effects via daily oral administration of fixed CFU (6×10⁹ CFU/day); no feedback control or tunable output,Highly compatible with liquid vial formulation; prebiotics enhance microbial survival and activity within the matrix,False,False,False,Not applicable,,False,False,False,False,未涉及抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未涉及氧气生成或氧合功能。,True,"Reduction of systemic inflammation via downregulation of pro-inflammatory cytokines (hsCRP, TNF-α); modulation of immune cell activity through SCFA production and gut barrier enhancement.","Short-chain fatty acids (SCFAs), particularly butyrate and acetate",True,"Improvement of endothelial function (increased pulse volume change), reduction of visceral adiposity, and enhanced insulin sensitivity, indicating tissue-level metabolic and vascular repair.","Butyrate, acetate, and other SCFAs",True,"Modulation of lipid metabolism (reduced TG, LDL-C, non-HDL-C), glucose homeostasis (lower FPG, HOMA-IR), and cholesterol metabolism (lower TC, LDL-C, higher HDL-C).","Short-chain fatty acids (SCFAs), lactate",False,Not applicable,,GRAS,No genetic kill switches or auxotrophy; natural strains with low pathogenicity,,No pathogenicity reported; no antibiotic resistance genes detected; no horizontal gene transfer observed; low risk of environmental escape due to poor environmental survival,Physical encapsulation in liquid vial prevents direct environmental release; oral route limits systemic spread,三种乳酸杆菌均为公认安全（GRAS）菌株，无致病性、无抗生素抗性基因，未进行基因改造，且在体外环境中生存能力弱，通过口服制剂封装可有效防止环境释放，整体生物安全风险极低。,在为期60天的治疗中，合成菌群显著改善了老年代谢综合征患者的腰围、空腹胰岛素、总胆固醇、高密度脂蛋白胆固醇、非高密度脂蛋白胆固醇、甘油三酯、低密度脂蛋白胆固醇、高敏C反应蛋白和肿瘤坏死因子α水平，同时显著降低内脏脂肪指数和平均动脉压。治疗组代谢综合征诊断符合率从10%降至23%，且生活质量评分（EQ-5D VAS）显著提升，表明其在代谢调节、抗炎和组织修复方面具有显著疗效。,14010,1957,15967,,
345176c6-80e1-475a-b1a1-9f618b45849e,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Faecalibacterium prausnitzii"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Akkermansia muciniphila"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacteroides spp."", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Bifidobacterium adolescentis"", ""strain_id"": ""Not specified""}, {""role"": ""Helper"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Not specified""}]",Encapsulated,Strict Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5; requires anaerobic conditions; dependent on mucin, fructans, GOS, and resistant starch for carbon sources",Slow growth rate; doubling time not specified; in vitro growth is highly sensitive to oxygen exposure,Mucosal layer of the colon; preferentially colonizes the intestinal mucus layer and hypoxic regions of the gut,Cross-feeding with Bacteroides and Lactobacillus; antagonistic relationship with native Bacteroides due to shared carbohydrate utilization; enhanced by prebiotic-mediated niche reshaping,"Low tolerance to oxygen, gastric acid, bile salts, and heat; sensitive to drying and lyophilization","Inulin, fructans, riboflavin, cysteine, and wheat bran used as protective agents","Faecalibacterium prausnitzii and Akkermansia muciniphila are strict anaerobes with high sensitivity to oxygen and gastrointestinal stress. They rely on mucin and prebiotic substrates (e.g., inulin, GOS, resistant starch) for growth and survival. Their colonization is enhanced by co-encapsulation with protective prebiotics and by cross-feeding with other microbes such as Bacteroides and Lactobacillus.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,No genetic engineering is described in the paper. The microbial system relies on natural metabolic capabilities and prebiotic-mediated enhancement rather than synthetic genetic circuits.,"[""Hypoxia"", ""pH"", ""ROS""]","[""Mucin"", ""Fructans"", ""Galacto-oligosaccharides"", ""Resistant starch"", ""Butyrate"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), riboflavin (redox sensing), mucin-binding adhesins",Threshold-based activation; likely constitutive expression of mucin-degrading and fermentation genes under low oxygen and high mucin availability,"The system senses hypoxia and mucin availability via FNR-like regulators and mucin-binding proteins. It responds to prebiotic substrates (e.g., inulin, GOS) through carbohydrate utilization pathways. The presence of SCFAs and butyrate may provide feedback inhibition. The system integrates signals from host-derived metabolites and microbial cross-feeding to regulate metabolic activity and colonization.","[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type IV secretion (butyrate export), vesicles (SCFA packaging)",Controlled by prebiotic availability and microbial density; no external control mechanism described,"Prebiotics (inulin, GOS, resistant starch) are compatible with encapsulation and provide sustained release of substrates",True,True,True,Produces butyrate and other SCFAs that inhibit pathogenic bacteria and disrupt biofilm matrix; enhances intestinal barrier integrity to prevent pathogen invasion,"Butyrate, SCFAs",True,True,True,True,"Butyrate and SCFAs produced by Faecalibacterium and Bacteroides inhibit growth of pathogenic bacteria and reduce biofilm formation. Prebiotics enhance survival and colonization, ensuring localized, controlled activity without systemic disruption.",False,Not applicable,Not applicable,False,False,False,No oxygen-producing mechanism is described; the system is strictly anaerobic.,True,"Butyrate and SCFAs modulate immune cell function, reduce pro-inflammatory cytokines (e.g., IL-6, TNF-α), and promote regulatory T-cell differentiation","Butyrate, SCFAs",True,"Butyrate enhances tight junction protein expression (e.g., occludin, ZO-1), promotes epithelial regeneration, and stimulates mucin production",Butyrate,True,Regulates host glucose and lipid metabolism via SCFA signaling; improves insulin sensitivity and reduces inflammation in metabolic syndrome,"Butyrate, Propionate, Acetate",False,Not applicable,Not applicable,BSL-1,"Auxotrophy (e.g., vitamin B2 dependency), oxygen sensitivity",Riboflavin (vitamin B2),Low pathogenicity; Faecalibacterium and Akkermansia are generally considered safe; Bacteroides may be opportunistic in immunocompromised hosts; no antibiotic resistance genes reported,"Encapsulation in alginate, inulin, or resistant starch provides physical confinement and protects against environmental escape","The microbial consortium is classified as BSL-1 due to low pathogenicity. Oxygen sensitivity and auxotrophy (e.g., riboflavin dependency) act as natural biocontainment. Encapsulation prevents environmental release. No evidence of horizontal gene transfer or antibiotic resistance.","Prebiotic-aided delivery of Faecalibacterium prausnitzii and Akkermansia muciniphila significantly improves intestinal barrier function, reduces inflammation, and restores microbial balance in metabolic and inflammatory diseases. In animal models, prebiotic co-administration increased colonization and survival of NGPs, leading to improved outcomes in obesity, IBD, and metabolic syndrome.",16658,1942,18600,,
d07039be-a38a-40f4-a244-c4091ada32e5,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""RC-14""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GR-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""BB-12""}]","Oral capsule (systemic delivery, gastrointestinal transit)",Facultative Anaerobe,"Optimal growth at 35–37°C, pH 5.5–6.5, tolerant to bile salts and low pH (gastric conditions), requires carbohydrates (e.g., lactose, glucose) as carbon sources; dependent on host-derived nutrients in gut environment","Doubling time ~1–2 hours in vitro; in vivo colonization occurs within days post-ingestion, with transient persistence in gastrointestinal tract","Gastrointestinal tract (small intestine and colon), particularly mucosal surfaces; preferentially colonizes in the presence of host mucus and nutrients",Competitive exclusion of pathogens via resource competition and production of organic acids (lactic acid); may modulate host immune responses; no evidence of symbiotic interaction with resident microbiota beyond inhibition of MROs,"Moderate tolerance to drying and lyophilization; sensitive to high temperatures (>50°C), UV radiation, and shear stress during processing; stable during storage at 4°C for up to 12 months","Capsule matrix (protective polymer coating), lyophilization stabilizers (sucrose, trehalose)","Lactobacillus species are facultative anaerobes that thrive in the human gastrointestinal tract under mildly acidic conditions. They exhibit moderate tolerance to bile and gastric acid, enabling survival through the upper GI tract. Their growth is dependent on fermentable carbohydrates and host-derived nutrients. They transiently colonize the gut mucosa, where they exert competitive exclusion against pathogens through acid production and nutrient competition.",Not applicable (natural strains used; no genetic modification reported),N/A,Constitutive (natural expression of metabolic and colonization genes),N/A,High chromosomal stability; no plasmids reported; no evidence of genetic drift or loss of function during trial duration,Stable in capsule formulation; no significant degradation or loss of viability during encapsulation and storage,"The probiotic consortium consists of naturally occurring, non-genetically modified strains. No synthetic genetic circuits or inducible systems were employed. The strains are selected for their natural ability to survive gastrointestinal transit, adhere to mucosal surfaces, and inhibit pathogenic bacteria through competitive exclusion and acid production.","[""pH (acidic environment of stomach)"", ""Bile acids (intestinal environment)"", ""Glucose (carbohydrate availability)""]","[""Lactate (end-product of fermentation)"", ""Short-chain fatty acids (SCFAs, e.g., acetate, propionate)""]","[""Quorum sensing molecules (e.g., AI-2, AHL) from resident microbiota""]","[""Mucin (host glycoprotein for adhesion)"", ""Proteases (e.g., trypsin, chymotrypsin in gut lumen)""]","Fimbrae and surface adhesins (e.g., mucus-binding proteins), lactate permeases, bile salt hydrolases, pH-responsive promoters (e.g., in L. reuteri)","No synthetic logic gates; natural sensing via receptor-ligand interactions and metabolic feedback loops (e.g., acid production inhibits competitors)","The strains naturally sense environmental cues such as low pH, bile, and nutrient availability through surface receptors and metabolic sensors. Upon sensing favorable conditions (e.g., intestinal pH, presence of carbohydrates), they activate genes for adhesion, acid production, and colonization. No engineered logic circuits are present.","[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Type IV secretion (bacteriocin release), lysis (natural turnover), vesicles (exosome-like particles)","Dose-dependent; administered at fixed daily dose (5.4 × 10⁹ CFU/capsule for RC14-GR1, 7 × 10⁹ CFU/capsule for LGG-BB12); no dynamic control",Compatible with capsule formulation; stable during encapsulation and GI transit; no structural disruption of matrix,True,True,False,"Inhibits multi-resistant organisms (MRGNs) via competitive exclusion, production of lactic acid and bacteriocins, and disruption of pathogen adhesion to mucosal surfaces.","Lactic acid, bacteriocins (e.g., reuterin from L. reuteri), organic acids",True,True,True,True,"RC14-GR1 significantly reduced new MRGN colonization (OR 0.10, 95% CI 0.01–0.88, P = 0.04). No significant cytotoxicity or microbiome disruption reported. Probiotics remained localized in GI tract.",False,Not applicable,N/A,False,False,False,No evidence of oxygenation function; not part of the mechanism.,True,"Modulates host immune response by enhancing mucosal barrier function, promoting anti-inflammatory cytokine production (e.g., IL-10), and reducing pro-inflammatory responses.","Secreted exopolysaccharides (EPS), surface proteins (e.g., p40), lactic acid",False,Not applicable,N/A,True,"Produces short-chain fatty acids (SCFAs) such as acetate and propionate, which regulate host metabolism, improve gut barrier integrity, and modulate immune function.","Acetate, propionate, butyrate",False,Not applicable,N/A,GRAS,"Auxotrophy (nutrient-dependent survival), no antibiotic resistance genes detected","Lack of essential amino acids (e.g., arginine, histidine) in standard diet; dependent on host nutrients",Low pathogenicity; no evidence of horizontal gene transfer; no known virulence factors; no antibiotic resistance genes reported; low risk of environmental escape due to poor environmental survival,Capsule provides physical confinement; prevents release into environment,"The probiotic consortium is classified as GRAS (Generally Recognized As Safe). All strains are non-pathogenic, non-invasive, and do not persist long-term in the host. They are naturally present in the human gut and have been used in food and supplements for decades. No evidence of gene transfer or environmental persistence. Capsule formulation ensures containment during administration.","RC14-GR1 significantly reduced new MRGN colonization (OR 0.10, 95% CI 0.01–0.88, P = 0.04). No effect on clearing existing MROs. IMC (intermittent self-catheterization) significantly improved MRO-free status (OR 2.80, 95% CI 1.41–5.54, P = 0.009). No significant effect on MRSA, VRE, or MRO clearance. Probiotics were safe with minimal adverse events (mainly bowel-related).",17918,2205,20123,,
ca7cf5ba-a08a-4dd5-952c-43c7bbe5dfb6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""DSM 10663 NCIMB 10415""}]",Oral supplementation via gel and liquid additive (not encapsulated in a material matrix),Facultative Anaerobe,"Growth in gastrointestinal tract; utilizes carbohydrates (sucrose, glucose, lactose) as carbon sources; tolerates acidic conditions (pH stabilized in formulations); no specific mention of bile or osmotic tolerance","Growth rate not specified; viable cells administered in defined CFU counts (2.8 × 10⁹ CFU/g gel, 1.26 × 10⁹ CFU/piglet/day); no in vivo growth rate data provided","Gastrointestinal tract (intestine), particularly in the small intestine; likely colonizes early postnatal gut","Competes with pathogenic E. coli; may stimulate growth of other lactic acid bacteria (LAB), especially lactobacilli; potential for synergistic inhibition of enteropathogenic E. coli","Stable during storage at 4°C; survives gastrointestinal passage (as per literature cited); no data on UV, drying, or shear stress",None specified,该研究中使用的粪肠球菌DSM 10663 NCIMB 10415为兼性厌氧菌，可在猪仔出生后早期通过口服方式定植于肠道。其生长依赖于碳水化合物（如蔗糖、葡萄糖、乳糖），并能耐受胃肠道环境，具有在肠道中存活并抑制病原菌的能力。,Not applicable (no genetic modification reported),Not applicable,Not applicable,Not applicable,Not applicable (no plasmid or chromosomal integration described),Not applicable,该菌株未经过基因工程改造，作为天然益生菌直接口服使用，其功能依赖于自然生理特性，而非人工调控电路。,"[""Acidity"", ""Glucose""]","[""Lactose"", ""Sucrose"", ""Glucose""]",,,Not specified (no specific receptor or promoter reported),Not applicable (no engineered logic circuits),该菌株未经过工程化改造，其行为基于自然代谢响应，无预设逻辑门控机制。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Not specified (no secretion system described),"Defined daily dosing (2.8 × 10⁹ CFU/g gel, 1.26 × 10⁹ CFU/day); additional supply via electrolyte solution during diarrhea",Not applicable (no material matrix used; delivery via gel and liquid formulations),True,False,False,通过与携带I型菌毛的致病性大肠杆菌协同作用，抑制其定植和增殖；可能通过竞争性排斥或代谢产物（如乳酸）抑制病原菌生长。,Lactic acid (metabolic end product),False,True,False,True,该菌株在猪仔肠道中有效减少腹泻发生率，且未观察到对宿主细胞的明显毒性，表明其抗菌作用具有可控性和局部安全性。,False,无相关机制描述,Not applicable,False,False,False,未提及氧生成相关功能,True,通过调节肠道微生物群落平衡，间接增强宿主免疫反应；可能通过刺激免疫细胞或调节炎症因子表达实现免疫调节。,Not specified (no specific cytokine or immune molecule identified),False,未提及促进组织修复的功能,Not applicable,True,通过产生短链脂肪酸（如乳酸）调节肠道代谢环境；可能促进葡萄糖吸收和水盐重吸收，改善腹泻状态下的营养吸收。,"Lactic acid, Short-chain fatty acids (SCFAs)",False,未提及肿瘤治疗功能,Not applicable,GRAS,None (no kill-switch or auxotrophy reported),Not applicable,Low pathogenicity; no antibiotic resistance genes reported; potential for horizontal gene transfer (HGT) not assessed; no environmental escape data,None (no physical barrier used),粪肠球菌DSM 10663 NCIMB 10415为公认安全（GRAS）菌株，长期用于动物饲料添加剂，无已知致病性。未进行基因改造，无生物安全风险，但其在肠道中定植能力可能带来潜在HGT风险，需进一步评估。,口服补充粪肠球菌DSM 10663 NCIMB 10415从出生至断奶可显著降低猪仔腹泻发生率（从40.0%降至14.8%），并减轻腹泻严重程度（腹泻评分从1.5降至1.2），同时提高日增重17 g/天，表明其在改善猪仔健康和生产性能方面具有显著效果。,9794,1676,11470,,
d82aec11-b6e6-4dc5-b1e2-b97b5ad9e611,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus pumilus"", ""strain_id"": ""SG43""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus megaterium"", ""strain_id"": ""SG183""}]",Encapsulated,Strict Aerobe,Optimal growth at 25–30°C; growth on PGYE and DSM media; requires aerobic conditions; fails to grow anaerobically even with nitrite/nitrate,Vegetative cells grow to ~1.5–1.76 × 10⁹ cfu/ml in 24 h; spores germinate in GI tract and undergo limited proliferation before shedding in feces,"Gastrointestinal tract (colon), particularly in the large intestine; transient colonization without permanent establishment",Allochthonous organism; does not permanently colonize gut; may promote growth of beneficial anaerobes like Faecalibacterium prausnitzii,High heat stability (resists 95°C for 15 min); resistant to simulated gastric fluid (pH 3–4); spores of SG183 resistant to pH 2; resistant to simulated intestinal fluid; tolerates oxidative stress (H₂O₂ up to 0.6 mM),"Sporulenes (heptaprenyl lipids), squalene-hopene cyclase","Bacillus pumilus SG43 and Bacillus megaterium SG183 are strict aerobes that grow optimally at 25–30°C. They produce spores efficiently and exhibit high resistance to heat, gastric acid (pH 3–4), and intestinal fluids. Spores can survive passage through the GI tract and germinate in the gut, where vegetative cells undergo limited proliferation before being excreted. Both strains are transient colonizers, not permanent residents of the gut microbiome.",Genome sequencing via Illumina mate-paired sequencing; no synthetic genetic tools reported,Not applicable (no genetic modification reported),Constitutive expression of carotenoid and riboflavin biosynthesis pathways,None (constitutive pathways),High chromosomal stability; no plasmids reported; intrinsic resistance genes present but not linked to antibiotic resistance; no transposons with resistance genes; prophages present but non-functional,Spores maintain stability in encapsulated formulations; no evidence of degradation in GI environment,"No genetic engineering was performed. The strains naturally produce high levels of riboflavin and C30 carotenoids. The carotenoid and riboflavin biosynthesis pathways are constitutively expressed, with genes identified in the genome including phytoene synthase, desaturase, dehydrogenase, and squalene-hopene cyclase. No synthetic circuits or inducible systems were used.","[""Hypoxia"", ""pH"", ""Oxidative stress (H₂O₂)""]","[""Bile salts"", ""Glucose"", ""Starch""]",,,"Squalene-hopene cyclase (in spores), bile salt symporter (in vegetative cells)","Constitutive expression; no reported logic gates or threshold control; expression modulated by growth conditions (e.g., light, temperature, medium)","The strains exhibit constitutive production of antioxidants (riboflavin and carotenoids) with expression influenced by environmental cues such as light (for SG183), temperature (25–30°C), and medium composition (e.g., starch, dark vs light). No engineered logic circuits or feedback systems are present. The expression of pigmentation and antioxidant production is linked to developmental state (sporulation vs vegetative growth), with mutually exclusive responses.","[""Antioxidant"", ""Metabolic Regulation"", ""Immunomodulation""]","Cell lysis and passive release of metabolites (riboflavin, carotenoids); spores serve as delivery vehicles",Dose-dependent increase in Faecalibacterium prausnitzii levels; spore dose (3 × 10⁸ cfu/dose) shown to be effective,Spores are stable in encapsulated formulations; resistant to GI conditions; suitable for oral delivery in dietary supplements,False,,,Not applicable (no antibacterial effector reported),,False,False,False,False,No antibacterial activity reported; not designed for pathogen killing,False,Not applicable (no oxygen-producing enzyme reported),,False,False,False,No oxygenation mechanism identified; not applicable,True,"Riboflavin and carotenoids act as antioxidants, reducing oxidative stress in the gut, which may indirectly modulate immune responses by supporting anti-inflammatory environments and promoting beneficial microbiota such as Faecalibacterium prausnitzii.","Riboflavin, C30 carotenoids",False,Not applicable (no direct tissue repair factors reported),,True,"Riboflavin acts as an electron acceptor, lowering redox potential in the gut lumen, which promotes the growth of strict anaerobes like Faecalibacterium prausnitzii. This supports a healthier gut metabolic environment and butyrate production.",Riboflavin,False,Not applicable (no tumor-targeting or prodrug conversion reported),,GRAS,No engineered kill switches; reliance on transient colonization and natural clearance,None (no inducible systems),"No pathogenicity genes; no enterotoxin genes (Hbl, Nhe); no antibiotic resistance genes of clinical concern; intrinsic resistance to antibiotics via efflux pumps; no evidence of horizontal gene transfer; prophages present but non-functional; no transposons with resistance genes",Spores provide physical barrier; encapsulation enhances stability and containment,"Both strains are non-pathogenic, lack toxin genes, and show no acute toxicity in mice. They are resistant to antibiotics via intrinsic mechanisms, not acquired resistance. Spores are transient in the gut and do not permanently colonize. No evidence of genotoxicity or environmental escape. Strains are considered safe for human use and qualify for GRAS status.","Daily administration of Bacillus pumilus SG43 spores significantly increased Faecalibacterium prausnitzii levels in mouse colon (p = 0.04). This suggests potential for long-term benefits in inflammatory bowel disease (IBD) by restoring a beneficial anaerobic microbiota. Spores were more effective than vegetative cells, likely due to better survival to the large intestine and antioxidant payload (sporulenes).",16492,2014,18506,,
9bf44bf4-aabd-47f9-850f-f6a316eeb0d8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus spp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces"", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, in media containing carbohydrates (e.g., lactose, glucose), with tolerance to bile salts and low pH (gastric conditions).",Doubling time ~60–90 minutes in vitro; in vivo colonization is transient but sufficient for health benefit.,"Gastrointestinal tract (intestinal lumen, mucosal surface), vaginal tract, skin surface.",Competitive exclusion of pathogens; cross-feeding with other commensals; modulation of host immune responses.,"Tolerant to drying, lyophilization, and moderate UV exposure; stable during storage at 4°C.","Exopolysaccharides (EPS), biofilm formation, stress response genes (e.g., clp, groEL)",这些微生物多为革兰氏阳性菌，属于乳酸菌或双歧杆菌等传统益生菌，具有在人体肠道等环境中定植并发挥健康效益的能力。它们在37°C、中性至弱碱性pH条件下生长良好，能耐受胃酸和胆汁，适合口服给药。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及对微生物进行基因改造，仅讨论天然或传统分离菌株的益生功能。,"[""pH"", ""Bile acids"", ""Osmotic stress""]","[""Lactate"", ""Glucose"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Proteases"", ""Cytokines""]","FNR promoter, Lactate receptor, Bile acid sensor (e.g., Bsh), Quorum sensing receptors (e.g., LasR, LuxR)",Not specified,文中未描述具体的逻辑门控机制，仅指出微生物能感知宿主微环境变化并响应，如pH、胆汁酸等，以调节自身代谢或定植行为。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Antibacterial""]","Type I, II, and VI secretion systems; lysis; extracellular vesicles",Not specified,Not specified,True,False,False,通过产生有机酸（如乳酸）、细菌素（bacteriocins）和竞争性排斥病原体来抑制有害菌生长。,"Lactic acid, Bacteriocins (e.g., reuterin, lactocin)",False,True,True,True,产生乳酸和细菌素可有效抑制常见肠道病原体，如沙门氏菌和大肠杆菌，且不破坏正常菌群结构。,False,Not applicable,Not applicable,False,False,False,未提及氧气生成功能。,True,调节宿主免疫系统，促进抗炎反应，增强黏膜屏障功能，通过TLR信号通路影响树突状细胞和T细胞分化。,"LPS (modified), Teichoic acids, Secreted cytokines (e.g., IL-10, TGF-β)",False,Not applicable,Not applicable,True,调节宿主代谢，如促进短链脂肪酸（SCFAs）生成，改善葡萄糖代谢，调节脂质合成。,"Acetate, Propionate, Butyrate",False,Not applicable,Not applicable,BSL-1,"Auxotrophy, GRAS/QPS status","Amino acid auxotrophies (e.g., leucine, histidine)",Low pathogenicity; no known antibiotic resistance genes; limited horizontal gene transfer risk; no environmental escape due to poor survival outside host.,Not applicable,这些微生物多为已知安全的菌株，属于GRAS或QPS类别，长期用于食品和膳食补充剂，无致病性记录，且在体外环境中难以长期存活，因此生物安全风险极低。,这些益生菌通过调节肠道菌群、增强免疫功能和改善代谢，对肠易激综合征、炎症性肠病及代谢综合征等具有显著改善作用，已在多项临床研究中验证其有效性。,6509,1673,8182,,
24ada457-68b1-4047-8445-0d230bca71af,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Escherichia coli"", ""strain_id"": ""Symbioflor®2, genotype G1⁺ (G1/2, G6/7, G8)""}]",Suspension (in gut lumen),Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, moderate osmotic tolerance; utilizes glucose and other carbon sources; no specific vitamin requirement reported","Colonization duration: 10–30 weeks (mean: 18.7 weeks, median: 25.7 weeks); sustained growth in human gut despite initial fluctuations; in vivo persistence exceeds in vitro expectations","Human intestinal lumen, particularly in the colon; capable of competing with host E. coli and establishing long-term presence",Competes with host E. coli strains; may create niche for other commensal E. coli; no significant disruption of overall microbiota reported,"Tolerant to gastrointestinal transit (acid, bile, enzymes); survives antibiotic exposure (though susceptible to cephalosporins); stable during storage and oral administration","Natural gut environment (bile, mucus, pH gradients); no engineered stress resistance reported",该研究显示，单次高剂量口服后，Symbioflor®2中的特定E. coli基因型（G1⁺）可在人体肠道内长期定植，持续时间达10至30周，平均18.7周，中位数25.7周。其在肠道中表现出较强的定植适应性，能与宿主E. coli竞争并维持稳定数量，即使在抗生素治疗后仍能促进宿主菌群恢复，表明其具有良好的肠道环境耐受性和定植能力。,,,,,Chromosomal integration not reported; persistence attributed to natural fitness rather than engineered stability; no plasmid-based systems used,No synthetic material used; natural gut environment supports long-term survival,该系统未进行基因工程改造，其长期定植能力源于自然进化获得的定植适应性，而非人工设计的遗传回路或稳定元件。,"[""pH"", ""Bile acids"", ""Osmotic strength""]","[""Glucose"", ""Lactate""]","[""Quorum sensing (indirectly inferred via competition dynamics)""]","[""Proteases"", ""Mucus layer""]",Unknown (natural regulatory systems not specified),No engineered logic gates; natural competition and niche occupation suggest threshold-based fitness regulation,该系统未使用人工设计的传感逻辑，其定植能力依赖于自然生理适应性，如对肠道pH、胆汁酸和营养物质的响应，以及与宿主菌的竞争动态，表现出基于环境适应性的定植策略。,"[""Colonisation"", ""Microbiome Modulation""]",Unknown (natural secretion of metabolites; no engineered secretion system reported),Natural dosage control via host environment; no external regulation,No synthetic material used; natural gut environment supports function,False,,,,,,,,,,False,,,,,,,False,,,False,,,True,"Produces metabolites such as short-chain fatty acids (SCFAs), reduces local pH, and may modulate gut environment to favor beneficial microbiota.","Short-chain fatty acids (SCFAs), organic acids",False,,,GRAS,None (no engineered kill switches or auxotrophy reported),,Low pathogenicity; no severe side effects observed; antibiotic susceptibility limits persistence under treatment; no evidence of horizontal gene transfer or environmental escape,None (no physical barrier used),该系统为天然存在的E. coli基因型，未进行基因改造，无生物安全风险。在高剂量口服后未引发严重不良反应，仅出现轻微胃肠不适，且在抗生素治疗后可被清除，表明其安全性良好，符合GRAS（公认安全）标准。,该研究未评估伤口愈合或疾病治疗效果，但结果显示，单次高剂量口服后，特定E. coli基因型（G1⁺）可在人体肠道内长期定植（最长30周），显著优于多数商业益生菌产品。其定植能力可能通过调节肠道微环境、促进宿主菌群恢复，间接支持肠道健康，尤其在抗生素治疗后表现出良好的生态恢复潜力。,11589,1570,13159,,
9b11580c-1845-438e-b658-4db2921fa8c2,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; utilizes carbohydrates such as lactose, glucose, and fructo-oligosaccharides; requires no special growth factors beyond standard culture media",Doubling time ~1.5–2 hours in vitro; survives gastric transit and colonizes intestinal mucosa in vivo,"Intestinal mucosa, particularly in the small intestine and colon; preferentially adheres to mucus layer and epithelial cells",Competes with pathogenic bacteria for nutrients and adhesion sites; enhances colonization resistance; promotes growth of beneficial flora via SCFA production and pH modulation,"Tolerant to gastric acid (pH 2.0–3.0), bile salts, and moderate osmotic stress; stable during lyophilization and storage at 4°C","Cell wall components (e.g., teichoic acids), acid shock proteins",Lactobacillus rhamnosus GG 是一种兼性厌氧菌，可在人体肠道环境中稳定生长。其最适生长温度为37°C，pH范围为5.5–6.5，能利用乳糖、葡萄糖及低聚果糖等碳源。该菌株具有良好的胃酸耐受性，可成功通过胃部并定植于肠道黏膜，尤其偏好黏液层和肠上皮细胞表面，具备较强的黏附能力。在婴儿肠道中，其定植能力与免疫调节功能密切相关。,"None (natural strain, not genetically modified)",Not applicable,Constitutive,,High chromosomal stability; no plasmid-based systems; no evidence of genetic drift in clinical use,Stable in food matrices and oral formulations,Lactobacillus rhamnosus GG 为天然菌株，未经过基因工程改造。其功能依赖于天然代谢通路和表面结构，如黏附素和细胞壁成分，无需外源调控系统即可实现持续定植与免疫调节。,"[""pH"", ""Bile acids""]","[""Lactose"", ""Glucose"", ""Fructo-oligosaccharides""]",,"[""Mucin"", ""Secretory IgA""]","Fimbrin-like adhesins, bile acid-inducible promoters (e.g., bile salt hydrolase genes)",Constitutive expression; no complex logic gates; response to environmental cues via native regulatory systems,Lactobacillus rhamnosus GG 通过其表面黏附蛋白感知肠道黏液和胆汁酸环境，启动定植相关基因表达。其代谢活性受碳源（如乳糖、低聚果糖）浓度调控，实现对营养环境的适应性响应。该菌株不依赖人工诱导系统，其功能表达为天然的组成型或环境响应型，无复杂逻辑控制。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair""]",Constitutive secretion of metabolites and surface proteins; no specialized secretion systems reported,Dose-dependent effects; clinical dosing typically 10^9–10^10 CFU/day; effects are self-limiting due to natural growth regulation,"Compatible with oral formulations, milk-based products, and probiotic supplements; stable in encapsulated delivery systems",True,True,True,"Produces lactic acid and other organic acids that lower intestinal pH, inhibiting growth of pathogens such as E. coli, Salmonella, and Clostridium difficile. Also competes for adhesion sites and nutrients.","Lactic acid, acetic acid, bacteriocins",True,True,True,True,在多项临床试验中，LGG显著缩短急性病毒性腹泻的持续时间，并预防抗生素相关性腹泻；其抗菌机制通过酸化环境和竞争性排斥实现，且未引起明显组织损伤或菌群失调。,False,,,False,False,False,,True,"Modulates immune responses by enhancing secretory IgA production, reducing Th-2 cytokines (IL-4, IL-5), increasing IFN-γ, and promoting T-regulatory cell activity.","Secretory IgA, IL-4, IFN-γ, TGF-β",True,"Upregulates mucin gene expression (e.g., MUC2), strengthens intestinal barrier function, reduces intestinal permeability, and promotes epithelial regeneration.","Mucin (MUC2), tight junction proteins (occludin, ZO-1)",True,"Ferments nondigestible carbohydrates to produce short-chain fatty acids (SCFAs), including acetate and lactate, which serve as energy sources for colonocytes and exert anti-inflammatory effects.","Acetate, L-lactate, SCFAs",False,,,GRAS,"None (natural strain, no synthetic kill switches)",,Low pathogenicity; no known antibiotic resistance genes; no evidence of horizontal gene transfer; rare cases of Lactobacillus septicemia reported only in immunocompromised patients with central venous catheters,Oral delivery provides physical barrier; no systemic dissemination in healthy individuals,Lactobacillus rhamnosus GG 被广泛认为是安全的，属于公认安全（GRAS）物质。尽管极少数病例报告其在免疫功能低下患儿中引发菌血症，但均与中心静脉导管相关，提示临床使用时应避免在有导管的患者中使用。该菌株不携带耐药基因，无致病性，且在正常肠道环境中不会过度增殖。,LGG 在治疗和预防婴幼儿急性病毒性腹泻方面表现出显著疗效，可缩短病程24–48小时；在预防抗生素相关性腹泻方面有效率高达60%以上。在过敏性疾病（如特应性皮炎）中，LGG可显著改善临床评分，降低IL-4水平，提升IFN-γ水平，且其保护作用可持续至4岁。在新生儿坏死性小肠结肠炎（NEC）的预防中，联合使用LGG与母乳可降低发病率和严重程度。,7811,5565,13376,,
9b11580c-1845-438e-b658-4db2921fa8c2,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": ""Bb-02""}]",Suspension,Strict Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0; requires complex media with prebiotics (e.g., human milk oligosaccharides, fructo-oligosaccharides); grows slowly in vitro",Doubling time ~4–6 hours in vitro; colonizes infant gut within days of administration; persists in feces for weeks,"Colon, particularly in the large intestine; preferentially colonizes mucosal surface and mucus layer",Competes with pathogenic bacteria; promotes growth of other beneficial bacteria via SCFA production; enhances colonization resistance,Moderate tolerance to bile and gastric acid; sensitive to drying and high osmotic stress; stable when lyophilized with cryoprotectants,"Exopolysaccharides (EPS), stress response proteins",Bifidobacterium breve Bb-02 是一种专性厌氧菌，最适生长温度为37°C，pH 6.0–7.0，依赖于母乳低聚糖等复杂碳源。该菌株在婴儿肠道中定植能力强，尤其在大肠黏膜和黏液层中富集。其生长缓慢，但能长期存在于粪便中，具有良好的肠道定植稳定性。,None (natural strain),Not applicable,Constitutive,,High chromosomal stability; no plasmid loss observed in clinical use,Stable in infant formula and oral supplements,Bifidobacterium breve Bb-02 为天然菌株，未经过基因改造。其功能依赖于天然代谢通路，如双歧途径发酵碳水化合物，产生短链脂肪酸，无需人工调控系统即可实现持续定植与代谢活性。,"[""pH"", ""Bile acids""]","[""Human milk oligosaccharides"", ""Fructo-oligosaccharides"", ""Lactose""]",,"[""Mucin"", ""Secretory IgA""]","Oligosaccharide transporters (e.g., ABC transporters), bile acid sensors",Constitutive expression; environmental sensing via nutrient availability,Bifidobacterium breve Bb-02 通过特异性转运系统感知母乳低聚糖和低聚果糖等营养物质，启动发酵相关基因表达。其生长受pH和胆汁酸调控，适应肠道微环境变化。该菌株不依赖人工诱导系统，功能表达为天然的组成型或营养响应型。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Constitutive secretion of metabolites and surface glycoproteins; no specialized secretion systems reported,Dose-dependent effects; typically administered at 10^9–10^10 CFU/day; effects are self-limiting,Highly compatible with infant formulas and oral supplements; stable in encapsulated delivery systems,True,True,True,"Produces acetic and lactic acids that lower luminal pH, inhibiting pathogenic bacteria such as Clostridium difficile and Enterobacteriaceae. Also competes for nutrients and adhesion sites.","Acetic acid, lactic acid",True,True,True,True,在新生儿坏死性小肠结肠炎（NEC）预防研究中，B. breve 与母乳联合使用显著降低NEC发生率；其抗菌机制通过酸化环境和竞争排斥实现，未引起组织损伤或菌群紊乱。,False,,,False,False,False,,True,"Enhances mucosal immunity by upregulating secretory IgA and promoting anti-inflammatory cytokine profiles (e.g., IL-10). Reduces Th-2 responses and supports T-regulatory cell function.","Secretory IgA, IL-10, TGF-β",True,"Upregulates mucin gene expression (MUC2), strengthens intestinal barrier integrity, and reduces intestinal permeability.","Mucin (MUC2), tight junction proteins",True,"Ferments human milk oligosaccharides and other prebiotics to produce short-chain fatty acids (SCFAs), particularly acetate and lactate, which serve as energy sources for colonocytes and regulate immune function.","Acetate, L-lactate, SCFAs",False,,,GRAS,None,,Low pathogenicity; no known antibiotic resistance genes; no evidence of horizontal gene transfer; safe in immunocompetent infants,Oral delivery limits systemic exposure; no evidence of translocation in healthy infants,Bifidobacterium breve Bb-02 被归类为公认安全（GRAS）菌株，广泛用于婴儿配方奶粉中。其专性厌氧特性限制了其在体外环境中的存活，且在健康婴儿中无致病报告。尽管极少数病例报告其在免疫缺陷患儿中引发菌血症，但无明确证据支持其为致病菌。,Bifidobacterium breve Bb-02 在预防新生儿坏死性小肠结肠炎（NEC）方面表现出显著疗效，联合母乳使用可降低发病率和严重程度。在过敏性疾病中，其可改善肠道屏障功能，减少炎症反应，尤其在母乳喂养婴儿中效果更佳。在婴儿肠道菌群建立过程中，该菌株能有效定植并促进有益菌群发展。,7811,5565,13376,,
9b11580c-1845-438e-b658-4db2921fa8c2,2,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCFM""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": ""35624""}]",Suspension,"Facultative Anaerobe (L. acidophilus), Strict Anaerobe (B. infantis)","L. acidophilus: 37°C, pH 5.5–6.5, uses lactose and glucose; B. infantis: 37°C, pH 6.0–7.0, requires human milk oligosaccharides and prebiotics",L. acidophilus: doubling time ~1.5–2 h; B. infantis: doubling time ~4–6 h; both colonize within days of administration,"Small and large intestine; L. acidophilus on mucosal surface, B. infantis in colonic lumen and mucus layer","Synergistic: L. acidophilus acidifies environment, promoting B. infantis growth; both enhance colonization resistance and immune modulation","L. acidophilus: tolerates gastric acid and bile; B. infantis: moderate tolerance to bile, sensitive to drying; both stable in lyophilized formulations","Teichoic acids (L. acidophilus), exopolysaccharides (B. infantis)",该共生系统由 Lactobacillus acidophilus NCFM 和 Bifidobacterium infantis 35624 组成。前者为兼性厌氧菌，可快速定植于小肠；后者为专性厌氧菌，偏好大肠环境。两者在营养互补和环境调节方面协同作用，共同促进肠道菌群稳定和免疫调节。,None,Not applicable,Constitutive,,High chromosomal stability; no plasmid loss; no evidence of drift in clinical use,Stable in combination with prebiotics and infant formulas,该共生系统为天然菌株组合，未经过基因改造。其功能依赖于天然代谢通路和协同作用，无需人工调控系统即可实现稳定定植与功能表达。,"[""pH"", ""Bile acids""]","[""Lactose"", ""Glucose"", ""Human milk oligosaccharides""]",,"[""Mucin"", ""Secretory IgA""]","Lactose permease (L. acidophilus), HMO transporters (B. infantis), bile acid sensors",Constitutive expression; no complex logic; environmental sensing via nutrient availability,L. acidophilus 通过乳糖转运系统感知碳源，启动酸化代谢；B. infantis 通过特异性转运系统感知母乳低聚糖，启动发酵通路。两者均响应pH和胆汁酸变化，实现对肠道微环境的适应性响应。系统整体表现为天然协同作用，无复杂逻辑控制。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]",Constitutive secretion of metabolites and surface proteins,Dose-dependent; typically 10^9–10^10 CFU/day per strain; self-limiting in healthy infants,Highly compatible with infant formulas and oral supplements; stable in encapsulated delivery systems,True,True,True,"L. acidophilus produces lactic acid, lowering pH; B. infantis produces acetic acid and bacteriocins. Together, they inhibit pathogens like C. difficile and Enterobacteriaceae.","Lactic acid, acetic acid, bacteriocins",True,True,True,True,在新生儿NEC预防研究中，该组合显著降低发病率；其抗菌机制通过酸化环境和竞争排斥实现，未引起组织损伤或菌群失调。,False,,,False,False,False,,True,"Synergistically enhances secretory IgA, reduces Th-2 cytokines, increases IL-10 and TGF-β, and promotes mucosal tolerance.","Secretory IgA, IL-10, TGF-β",True,"Upregulates mucin genes (MUC2), strengthens tight junctions, and reduces intestinal permeability.","MUC2, occludin, ZO-1",True,"Ferments human milk oligosaccharides and other prebiotics to produce SCFAs (acetate, lactate), which serve as energy sources and anti-inflammatory agents.","Acetate, L-lactate, SCFAs",False,,,GRAS,None,,Low pathogenicity; no antibiotic resistance genes; no evidence of HGT; safe in immunocompetent infants,Oral delivery limits systemic exposure,该共生系统由两种公认安全（GRAS）菌株组成，广泛用于婴儿配方奶粉中。两者均无致病报告，且在健康婴儿中无系统性传播风险。其专性厌氧特性限制了其在体外环境中的存活，安全性高。,该共生系统在预防新生儿坏死性小肠结肠炎（NEC）方面表现出显著疗效，联合母乳使用可显著降低发病率和严重程度。在免疫调节方面，其协同作用可增强黏膜屏障功能，减少炎症反应，尤其在早产儿中效果显著。,7811,5565,13376,,
21725db6-7268-43de-bdde-007ef0f33ec7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Chryseobacterium sp."", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Pseudomonas sp. 1"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Pseudomonas sp. 2"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Stenotrophomonas sp."", ""strain_id"": ""Not specified""}]","Encapsulated (on skin surface, applied as topical treatment)",Facultative Anaerobe,"Optimal growth at room temperature (22–25°C), neutral to slightly alkaline pH, moderate osmotic tolerance; dependent on host skin environment (moist, nutrient-rich surface)","Not explicitly reported; inferred to grow in vitro under standard lab conditions (e.g., 24–48 h doubling time), but no in vivo growth rate data available","Cutaneous surface of amphibians (skin mucus layer), particularly in moist, cool environments typical of amphibian habitats","Competitive with resident skin microbiota; failed to persist in A. zeteki skin, suggesting strong competition or host defense mechanisms","Not explicitly reported; assumed moderate tolerance to environmental fluctuations (moisture, temperature) due to amphibian skin habitat",,这些细菌均来源于巴拿马蛙类皮肤，能够在体外抑制蛙壶菌（Bd）生长，但无法在黄金蛙皮肤上长期定植。它们属于革兰氏阴性菌，适应湿润、中性pH的皮肤表面环境，具有一定的环境耐受性，但缺乏在宿主皮肤上稳定定植的能力。,,,,,,,本研究未对所用细菌进行基因工程改造，所有菌株均为天然分离株，仅通过体外抑菌实验筛选其抗蛙壶菌能力，未进行任何基因编辑或合成回路构建。,"[""pH"", ""Moisture""]","[""Bd zoospores (indirectly via host damage)"", ""Skin metabolites (host or microbial)""]",,"[""Skin mucus"", ""Epidermal damage""]",Not specified (no engineered sensors reported),No engineered logic gates or sensing circuits reported; natural sensing via environmental cues only,这些细菌依赖于自然环境信号（如皮肤pH、湿度、宿主组织损伤）进行定植和代谢活动，但未被设计为响应特定信号触发功能。其行为由天然生理机制调控，无合成生物学逻辑控制。,"[""Antibacterial""]",Unknown (likely passive diffusion or constitutive secretion of metabolites),Not controllable; activity depends on natural growth and metabolite production,"Poor match with skin surface; failed to persist despite application, suggesting poor compatibility with host skin environment",True,False,False,通过产生抗真菌代谢物抑制蛙壶菌（Bd）生长，体外实验显示强抑制活性。,"Antifungal metabolites (e.g., violacein-like compounds, unknown secondary metabolites)",False,True,True,True,体外实验显示强抗Bd活性，但体内无法定植，因此活性未在宿主中实现。未报告细胞毒性或对微生物组的显著扰动，但因未定植，安全性尚可。,False,,,False,False,False,无氧生成功能，不适用。,False,,,False,,,False,,,False,,,BSL-1,None (no engineered kill switches or auxotrophy reported),,No pathogenicity reported; isolated from amphibians without known disease association; no antibiotic resistance genes reported; low risk of horizontal gene transfer due to lack of genetic engineering,Skin surface application provides minimal physical barrier; no encapsulation or delivery matrix used,所有候选菌株均来自非致病性环境，无文献报道致病性，且未进行基因改造，因此生物安全风险极低。但由于无法在宿主皮肤上定植，其实际应用风险受限于定植失败，而非安全性问题。,在实验中，尽管所有候选细菌在体外均能有效抑制蛙壶菌（Bd）生长，但无法在黄金蛙皮肤上定植，因此未能显著提高感染后存活率。然而，约30%的感染个体能够自发清除感染，其皮肤微生物群落结构和代谢物谱与死亡个体存在显著差异，提示天然共生菌群在抗感染中起关键作用。,11914,1622,13536,,
42bbc73b-394f-4ffa-995f-4d31c0cf60e6,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus licheniformis"", ""strain_id"": ""MTCC""}]",Encapsulated,Facultative Anaerobe,"Temperature: 38°C; pH: 7.2 (PBS); Nutritional: Endospore-forming, utilizes complex organic substrates (casein, gelatin, starch, dextrin, oils); Growth in basal diet with protein (35%), fat (7.15%), and energy (414 kcal/100g)",Growth rate not explicitly quantified; viable cells maintained in feed at 4°C for up to 30 days with 35.25% viability remaining; growth in gut confirmed by increasing counts over 45 days,Gastrointestinal tract (gut) of Macrobrachium rosenbergii,Competitive exclusion of pathogenic Aeromonas spp. and Pseudomonas spp.; increases total bacterial count and Bacillus spp. in gut microbiota,Moderate tolerance to storage at 4°C (viability drops to 35.25% after 30 days); resistant to freeze-drying (lyophilization) as confirmed by viability in feed; stable in feed pellets at 45°C for 1–2 h,"Spores (endospores) provide resistance to heat, drying, and storage stress","Bacillus licheniformis is a Gram-positive, endospore-forming, facultative anaerobe that can grow in the gastrointestinal tract of giant freshwater prawns. It survives feed processing (autoclaving, drying) and storage at 4°C, with gradual viability loss. It successfully colonizes the gut, increases in population over time, and outcompetes pathogenic bacteria, indicating strong environmental adaptability and colonization ability.",,,,,No genetic modifications reported; natural chromosomal stability; no plasmid-based systems used,Stable in feed matrix (pellets) and gut environment; viability maintained in feed for 30 days at 4°C,"No genetic engineering was performed. The strain was used in its native form as a probiotic. No CRISPR, plasmid, or recombinant systems were applied. The system relies on natural colonization and metabolic activity.","[""pH"", ""Temperature""]","[""Glucose"", ""Starch"", ""Proteins (casein, gelatin)""]",,,"Endospore formation and metabolic pathways responsive to nutrient availability (e.g., starch, protein, glucose)",No engineered logic gates; natural growth response to nutrient availability and environmental conditions,"The bacterium naturally senses nutrient availability (e.g., starch, protein, glucose) and environmental conditions (pH, temperature) in the gut and feed. It germinates and grows in favorable conditions, with no synthetic sensing circuits. Its activity is governed by natural physiological responses rather than engineered logic.","[""Antibacterial"", ""Immunomodulation"", ""Growth Promotion""]",Natural secretion of enzymes and antimicrobial peptides; no engineered secretion systems used,Dose-dependent effect; highest efficacy at 1.0 × 10⁹ cfu/g feed; no external control mechanism,"Compatible with feed pellet matrix; stable during feed processing (autoclaving, drying); viable in gut environment",True,True,False,"Inhibits pathogenic bacteria (Aeromonas spp., Pseudomonas spp.) via competitive exclusion and production of antimicrobial compounds (e.g., polymyxin, bacitracin, gramicidin).","Polymyxin, bacitracin, gramicidin (antibiotics), competitive exclusion",True,True,True,True,Significant reduction in Aeromonas and Pseudomonas spp. in gut; no adverse effects on host survival; localized action in gut; no reported cytotoxicity or microbiome disruption beyond target pathogens.,False,,,False,False,False,No oxygenation mechanism reported.,True,"Enhances immune response via cell wall components (β-glucan, lipopolysaccharide) and competitive exclusion of pathogens, leading to increased haemocyte count, phenol oxidase, superoxide dismutase, and antibacterial activity.","β-glucan, lipopolysaccharide (LPS)",False,,,False,,,False,,,GRAS,Natural auxotrophy not reported; no kill-switch or suicide gene used; endospores provide natural containment,Endospores (natural dormancy),Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape documented; safe for aquatic use,Feed pellet matrix provides physical confinement; no release into environment reported,"Bacillus licheniformis is classified as GRAS (Generally Recognized As Safe). It is non-pathogenic, does not produce toxins, and has no known antibiotic resistance genes. Its endospore form enhances environmental stability but limits uncontrolled proliferation. No genetic modifications increase escape risk. The feed matrix acts as a physical barrier, minimizing environmental release.","Dietary supplementation of Bacillus licheniformis at 1.0 × 10⁹ cfu/g feed significantly improved growth (112.25% weight gain), reduced feed conversion ratio (2.14), enhanced immune parameters (highest haemocyte count, phenol oxidase, superoxide dismutase, and antibacterial activity), and reduced cumulative mortality by 50% after Vibrio alginolyticus challenge. The probiotic effect showed a clear dose-response relationship, with maximum benefits at the highest concentration.",17480,1816,19296,,
2dd9bf53-d5d8-4e0d-b3d4-7ca1a401c400,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Multiple strains (e.g., 0103, 0123, 0140, 0147, 0157, 0611, 0612, 1002)""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates pH 3.0 for up to 24 hours; survives 2% bile salt; grows in MRS broth with up to 6% NaCl.",Doubling time not reported; viable counts maintained at 4–6 log CFU/ml after 24 h at pH 3.0; growth rate reduced at 2% bile salt but still detectable.,"Gastrointestinal tract (small intestine and colon), particularly in the context of probiotic function.",Competitive exclusion of pathogens via antibacterial activity; potential for symbiosis with host microbiota through immune modulation and colonization.,"High tolerance to acid (pH 3.0), bile salts (up to 2%), heat (60°C for 10 min), and osmotic stress (up to 6% NaCl); moderate tolerance to UV and drying (implied by lyophilization storage).","Heat shock proteins (HSPs), cell membrane integrity, acid resistance systems (e.g., F0F1-ATPase), bile salt hydrolases.",该研究中分离的植物乳杆菌（Lactobacillus plantarum）具有良好的生长生理特性，能在37°C、pH 3.0的酸性环境中存活24小时，且在2%胆盐条件下仍保持较高活力。其耐热性良好，部分菌株在60°C下处理10分钟后仍能保持86.6%的存活率。该菌株对高盐环境（最高6% NaCl）具有较强耐受性，适合在食品加工过程中应用。,,,,,,,本研究未涉及基因工程改造，所有菌株均为天然分离株，未进行人工遗传修饰。,"[""Acidity (pH 3.0)"", ""Bile salts (2%)"", ""Osmotic pressure (6% NaCl)""]","[""Lactate (end-product of fermentation)"", ""Organic acids (e.g., lactic acid)""]",,,"F0F1-ATPase (for pH homeostasis), bile salt hydrolases (BSH), osmoprotectant transporters (e.g., proline uptake systems)","No engineered logic gates; natural sensing via membrane transporters and regulatory systems (e.g., acid stress response regulators).",植物乳杆菌通过F0F1-ATP酶系统感知胞外酸性环境并维持胞内pH稳定；通过胆盐水解酶（BSH）感知胆盐并降解其毒性；通过渗透压调节系统感知高盐环境并启动保护机制。这些响应为非编程性自然生理适应，无逻辑门控设计。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Type I secretion system (for bacteriocins), passive diffusion (for organic acids, H2O2), exopolysaccharide (EPS) release",Not controllable; output depends on natural growth and metabolic activity.,"Compatible with food matrices (e.g., fermented products); no encapsulation or delivery system described.",True,True,False,通过分泌有机酸、过氧化氢和细菌素等抗菌物质抑制常见食源性病原菌生长。,"Organic acids (lactic acid, acetic acid), hydrogen peroxide, bacteriocins",True,True,True,True,多数植物乳杆菌菌株对李斯特菌（L. monocytogenes）表现出强抑制活性（抑制圈直径达15.5 mm），对金黄色葡萄球菌、沙门氏菌等也有一定抑制作用，且未提及对宿主细胞的毒性，表明其具有可控且安全的抗菌能力。,False,,,False,False,False,未报道任何产氧机制或光依赖性氧生成系统，因此不具有氧合功能。,True,通过调节宿主免疫反应，增强肠道屏障功能，促进抗炎因子表达，抑制病原体定植。,"Surface layer proteins (Slp), exopolysaccharides (EPS), secreted metabolites (e.g., SCFAs)",False,,,True,通过发酵碳水化合物产生短链脂肪酸（SCFAs），调节宿主能量代谢与肠道微生态平衡。,"Short-chain fatty acids (SCFAs: acetate, propionate, butyrate)",False,,,GRAS,"None (natural strains, no synthetic kill switches or auxotrophy introduced)",,No antibiotic resistance genes reported; no pathogenicity or opportunistic risk identified; low risk of horizontal gene transfer due to absence of plasmids in tested strains; no environmental escape concerns as they are food-grade LAB.,None (no physical confinement used in study),所研究的植物乳杆菌菌株均来源于传统发酵食品，属于公认安全（GRAS）微生物，未发现耐药基因或致病性特征，无基因水平转移风险，且在体外实验中未表现出对宿主细胞的毒性，安全性较高。,该研究未评估伤口愈合或疾病治疗效果，但结果显示部分植物乳杆菌菌株在模拟胃肠道环境中具有优异的存活能力（pH 3.0下24小时后仍保持4 log CFU/ml），对多种食源性病原菌具有强抑制活性，且耐热、耐盐，具备作为功能性食品益生菌候选菌株的潜力。,21330,1891,23221,,
8811ecf9-5654-4704-90e0-04737ff49c23,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus bulgaricus"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Not specified""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophiles"", ""strain_id"": ""Not specified""}]",Oral supplementation (systemic distribution via gastrointestinal tract),Facultative Anaerobe,"Optimal growth at 35–37°C, pH 5.5–6.5, requires carbohydrates (e.g., lactose) as carbon source; tolerant to bile salts and gastric acidity",Moderate growth rate in vitro; no in vivo doubling time reported; stable in gastrointestinal tract,"Gastrointestinal tract (small intestine and colon), mucosal surface of gut",Competitive exclusion of pathogenic bacteria; potential symbiosis with host microbiota; may modulate immune response without significant disruption of native flora,"Tolerant to drying, lyophilization, and moderate temperature fluctuations; stable during storage at room temperature; resistant to bile and low pH","Bile salts, gastric acid, lyophilization stabilizers (in formulation)",该混合益生菌由四种常见乳酸菌组成，均具有良好的胃肠道耐受性，可在胃酸和胆汁环境中存活，定植于肠道黏膜，利用乳糖等碳源生长，属于兼性厌氧菌，适合口服补充。,,,,,No genetic modification reported; natural strains used; chromosomal stability in vivo; no plasmid-based systems,No engineered genetic circuits; stability in oral tablet formulation and gastrointestinal environment,该研究未对益生菌进行基因改造，使用的是市售商业益生菌制剂，包含四种天然存在的乳酸菌，无基因工程修饰，其功能依赖于天然生理特性。,"[""pH"", ""Bile acids""]","[""Lactose"", ""Glucose""]",,"[""Cytokines (indirectly via immune modulation)"", ""Intestinal barrier integrity""]","Bile salt hydrolase (BSH), acid tolerance systems (e.g., F1F0-ATPase), lactose permease (LacY)","No synthetic logic circuits; natural sensing of environmental cues (pH, bile, nutrients) with threshold-based activation of survival and colonization pathways",这些益生菌通过感知肠道内的酸碱度、胆汁酸和乳糖等代谢物，启动耐酸、耐胆汁和营养吸收机制，实现对肠道微环境的适应性响应，无人工设计的逻辑门控系统。,"[""Immunomodulation""]","Passive diffusion, cell lysis, extracellular vesicles (natural secretion)",Fixed daily dose (6×10⁹ CFU/day); no dynamic control; dosage determined by formulation,Oral tablet formulation allows protection during transit; compatible with gastrointestinal environment; no encapsulation in biomaterials,False,False,False,Not applicable; no direct antibacterial activity reported,,False,False,False,False,未观察到对Pseudomonas aeruginosa或其他呼吸道病原体的直接抑制作用。,False,Not applicable; no oxygen-producing capability reported,,False,False,False,未涉及氧气生成或缺氧缓解机制。,True,"Modulate systemic and local immune responses by enhancing intestinal barrier function, reducing intestinal inflammation, and indirectly suppressing pulmonary inflammation via gut-lung axis","Secreted metabolites (e.g., short-chain fatty acids), cell wall components (e.g., peptidoglycan, lipoteichoic acid), exopolysaccharides",False,Not applicable; no direct tissue regeneration or ECM modulation reported,,False,"Not applicable; no specific metabolic regulation of host glucose, lipid, or neurotransmitter pathways reported",,False,Not applicable; no anti-tumor activity reported,,GRAS,No genetic kill-switches or auxotrophy; natural strains with low pathogenicity,None,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; no environmental escape due to lack of environmental persistence,Oral administration with natural gut transit; no physical barrier beyond intestinal mucosa,所用四种益生菌均为公认安全（GRAS）菌株，无基因改造，无致病性，不携带抗生素抗性基因，不会在环境中长期存活，口服后通过肠道自然排泄，安全性高。,在为期6个月的治疗期间，囊性纤维化患者肺部急性加重次数显著减少（P=0.002），且在治疗后6个月仍保持低发，但肺功能（FEV1）、痰液细菌负荷、中性粒细胞计数和IL-8水平未见显著变化，提示其主要作用为预防性减少急性加重，而非直接改善肺部炎症或结构损伤。,7253,1732,8985,,
69b9ac80-cf66-45be-82c2-2b1dbbd3c977,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""NCFM""}]",Oral administration with intestinal colonization,Facultative Anaerobe,"Growth at 37°C in anaerobic conditions (85% N₂, 10% H₂, 5% CO₂); requires MRS broth with peptone water for propagation and storage",Growth rate not explicitly quantified; maintained in culture for 24 h before use; colonized effectively in neonatal gnotobiotic pigs,"Intestinal tract, oral/nasal cavity, and tonsils",Colonization did not disrupt host microbiome; no extraneous bacterial contamination detected; no significant competition with other microbes reported,Stable during freezing at -80°C; viable after thawing and washing; resistant to gastric acidity due to pre-treatment with NaHCO₃,Sodium bicarbonate (NaHCO₃) used to reduce gastric acidity,"Lactobacillus acidophilus NCFM is a facultative anaerobe that grows optimally at 37°C under anaerobic conditions. It effectively colonizes the intestinal, oral, and nasal mucosa of neonatal gnotobiotic pigs without causing adverse effects. The strain is stable during cryopreservation and can survive transient exposure to gastric acidity when pre-treated with sodium bicarbonate.",,,,,No genetic modifications reported; natural strain used; stable colonization observed over 3 weeks post-administration,No engineered genetic circuits; natural strain used in oral delivery without material encapsulation,"Lactobacillus acidophilus NCFM was used in its native, unmodified form. No genetic engineering tools such as CRISPR-Cas or plasmid systems were applied. The strain was administered orally and relied on natural colonization and immune modulation without synthetic genetic circuits.","[""pH (gastric acidity)""]",,,,"Natural surface receptors (e.g., adhesion molecules) for mucosal colonization; no specific engineered sensor reported",No synthetic logic gates; natural immune recognition and colonization behavior,"Lactobacillus acidophilus naturally senses and responds to host mucosal environments, particularly through pH adaptation and adhesion to epithelial surfaces. It does not employ engineered sensing circuits but relies on innate microbial recognition mechanisms to colonize the gut and upper respiratory tract.","[""Immunomodulation""]",Natural secretion of immunomodulatory molecules; no engineered secretion system reported,Dose-dependent colonization (10³ to 10⁶ CFU/day); incremental dosing used to ensure safe and effective colonization,Oral administration with no material encapsulation; compatible with natural mucosal delivery,False,,,,,False,False,False,False,Not applicable; no antibacterial activity reported,False,,,False,False,False,Not applicable; no oxygenation function reported,True,"Enhances both mucosal and systemic immune responses by stimulating IFN-γ-producing CD8+ T cells, IgA and IgG antibody-secreting cells, and serum IgM, IgA, IgG, and virus-neutralizing antibodies.","Lactobacillus acidophilus NCFM (natural strain; induces IL-12, IFN-γ, and dendritic cell activation)",False,,,False,,,False,,,GRAS,None (natural strain; no kill-switch or auxotrophy used),,No pathogenicity reported; no antibiotic resistance genes or horizontal gene transfer concerns; safe in neonatal gnotobiotic pigs,None; oral delivery without physical confinement,"Lactobacillus acidophilus NCFM is a well-documented probiotic strain with GRAS status. It is safe for neonatal use, causes no adverse effects in gnotobiotic pigs, and does not disrupt the microbiome. No biocontainment strategies were needed due to its non-pathogenic nature and natural attenuation.","Lactobacillus acidophilus NCFM significantly enhanced the immunogenicity of the oral rotavirus vaccine in neonatal gnotobiotic pigs. It increased HRV-specific IFN-γ-producing CD8+ T cell responses in ileum and spleen by 12-fold and 45-fold, respectively, and boosted IgA and IgG antibody-secreting cell responses in the ileum. Serum IgM, IgA, IgG, and virus-neutralizing antibody titers were significantly higher in LA-fed vaccinated pigs compared to controls. These findings suggest strong immunopotentiating effects, indicating potential as a safe oral adjuvant for rotavirus vaccines in neonates.",12895,1605,14500,,
3ac778cc-2f5a-4ba9-8738-71733784882a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""AQAHBS001""}]",Encapsulated,Facultative Anaerobe,"Grows at 25–37°C, pH 5.5–9.0, tolerates high osmotic stress; utilizes complex carbohydrates, proteins, and lipids as carbon/nitrogen sources",Doubling time ~20–30 min under optimal conditions; stable in vitro and in vivo,"Intestinal tract of *Litopenaeus vannamei*, particularly in the midgut and hepatopancreas",Competes with *Vibrio* spp. and other opportunistic pathogens; promotes beneficial *Pseudoalteromonas* and *Bacillus* spp. colonization,"High tolerance to extreme pH, temperature, and osmotic stress; spores survive feed processing and storage","Spore coat proteins (e.g., CotA, SASP)","Bacillus subtilis AQAHBS001 is a robust, spore-forming bacterium with strong environmental resilience, capable of surviving harsh aquaculture conditions and colonizing the shrimp gut effectively. It thrives in variable pH and temperature ranges typical of shrimp ponds and maintains viability during feed processing and storage.","Plasmid-based expression systems (implied), CRISPR-Cas not mentioned","Not specified; natural strains used, no genetic modification reported",Constitutive expression of enzymes and antimicrobial peptides,,High chromosomal stability; spores ensure long-term viability; no plasmid loss reported,Spores remain stable in feed matrix; no degradation of encapsulation material observed,"The strain is used in its natural form without genetic modification. Its beneficial effects stem from intrinsic enzyme production and antimicrobial activity, with no engineered circuits or inducible systems.","[""pH"", ""Temperature"", ""Osmotic stress""]","[""Starch"", ""Soybean meal components"", ""Non-digestible carbohydrates""]","[""Quorum sensing (AHL, AI-2) – inferred from competition""]","[""Proteases (digestive enzymes)"", ""Immune factors (e.g., lysozyme, phenoloxidase)""]","FNR-like regulators (for oxygen), sigma factors (for stress), membrane transporters (for nutrient sensing)","No explicit logic gates; response is likely threshold-based (e.g., enzyme production triggered by substrate presence)","The strain senses nutrient availability (e.g., starch, soy components) and environmental stress (pH, temperature), triggering enzyme secretion and antimicrobial production. It responds to host immune signals and microbial competition, enabling niche colonization and pathogen exclusion.","[""Antibacterial"", ""Gut microbiota modulation"", ""Feed intake improvement""]","Type I secretion system (for antimicrobial peptides), Spore germination and lysis (for enzyme release)",Dose-dependent effect; higher probiotic concentration leads to greater pathogen reduction and enzyme activity,Spores are stable in feed matrix; no structural disruption observed; compatible with encapsulation in aquafeeds,True,True,False,"Produces antimicrobial peptides (e.g., subtilin, bacitracin) and enzymes that degrade pathogen cell walls; competes for colonization sites.","Subtilin, Bacitracin, Cellulase, Pectinase",True,True,True,True,B. subtilis AQAHBS001 significantly reduced *Vibrio parahaemolyticus* and *V. harveyi* in shrimp gut and hepatopancreas; no cytotoxicity reported; localized action in gut.,False,,,False,False,False,,True,"Enhances phagocytic activity, upregulates prophenoloxidase, lysozyme, and anti-lipopolysaccharide factor genes.","Prophenoloxidase, Lysozyme, Anti-lipopolysaccharide factor (ALF)",False,,,True,"Degrades complex carbohydrates (starch, non-starch polysaccharides) and proteins, improving nutrient assimilation and reducing anti-nutritional compounds.","Glucose, Amino acids, Short-chain fatty acids (SCFAs)",False,,,GRAS,"Auxotrophy (inferred from natural strain use), no antibiotic resistance genes reported","Nutrient-dependent germination (e.g., amino acids, sugars)",Low pathogenicity; no known toxin production in this strain; no horizontal gene transfer reported; safe for shrimp and consumers,Physical encapsulation in feed prevents environmental release,"Bacillus subtilis AQAHBS001 is classified as GRAS by FDA. It is non-pathogenic, does not produce harmful toxins, and lacks antibiotic resistance genes. Its spore form ensures controlled release and limits environmental escape. No evidence of ecological disruption or human health risk.","B. subtilis AQAHBS001 significantly improved feed conversion ratio, weight gain, and survival in *Litopenaeus vannamei* fed on 100% soybean meal diets. It enhanced immune response, reduced *Vibrio* spp. colonization, and promoted beneficial gut microbiota, leading to higher growth performance and disease resistance.",9476,6102,15578,,
3ac778cc-2f5a-4ba9-8738-71733784882a,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""ATCC 7050""}]",Encapsulated,Facultative Anaerobe,"Grows at 37–45°C, pH 5.0–8.0; tolerates bile and gastric conditions; utilizes complex carbohydrates and proteins",Doubling time ~30–40 min; stable in vitro and in vivo,"Intestinal tract of *Litopenaeus vannamei*, particularly in the midgut and hindgut","Suppresses opportunistic pathogens (*Vibrio*, *Tenacibaculum*, *Photobacterium*); promotes *Pseudoalteromonas* and beneficial *Bacillus* spp.","High tolerance to heat, pH, and osmotic stress; spores survive feed processing and storage","Spore coat proteins, SASP (Small Acid-Soluble Spore Proteins)","Bacillus coagulans ATCC 7050 is a thermotolerant, spore-forming bacterium with strong resilience to feed processing and gut conditions. It colonizes the shrimp intestine effectively and maintains viability under variable environmental conditions.",None reported; natural strain used,Not applicable,Constitutive enzyme and antimicrobial production,,High chromosomal stability; spores ensure long-term viability,Spores remain stable in feed matrix; no degradation of encapsulation material,The strain is used in its natural form without genetic modification. Its probiotic effects are due to intrinsic enzyme production and antimicrobial activity.,"[""Temperature"", ""pH"", ""Osmotic stress""]","[""Soybean meal"", ""Complex carbohydrates"", ""Non-digestible polysaccharides""]","[""Quorum sensing (AHL, AI-2) – inferred""]","[""Proteases"", ""Immune factors""]","Sigma factors (for stress), membrane transporters (for nutrient uptake), FNR-like regulators",Threshold-based response to nutrient availability; no engineered logic gates,"The strain senses nutrient availability (e.g., soy components, starch) and environmental stress (pH, temperature), triggering enzyme secretion and antimicrobial production. It responds to host immune signals and microbial competition, enabling niche colonization and pathogen exclusion.","[""Antibacterial"", ""Gut microbiota modulation"", ""Feed intake improvement""]","Type I secretion (for antimicrobial peptides), Spore germination and lysis (for enzyme release)",Dose-dependent effect; higher concentration leads to greater pathogen reduction and enzyme activity,Spores are stable in feed matrix; no structural disruption observed; compatible with encapsulation in aquafeeds,True,True,False,Produces antimicrobial peptides and enzymes that degrade pathogen cell walls; competes for colonization sites.,"Coagulin, Cellulase, Pectinase, Protease",True,True,True,True,"B. coagulans ATCC 7050 reduced *Vibrio*, *Tenacibaculum*, and *Photobacterium* levels in shrimp gut and pond water; no cytotoxicity reported; localized action.",False,,,False,False,False,,True,"Enhances immune response, including enzyme activity and immune gene expression.","Lysozyme, Prophenoloxidase, Anti-lipopolysaccharide factor (ALF)",False,,,True,"Degrades complex carbohydrates and proteins, improving nutrient assimilation and reducing anti-nutritional compounds.","Glucose, Amino acids, SCFAs",False,,,GRAS,"Auxotrophy (inferred), no antibiotic resistance genes reported","Nutrient-dependent germination (e.g., sugars, amino acids)",Low pathogenicity; no known toxin production; safe for shrimp and consumers; no horizontal gene transfer reported,Physical encapsulation in feed prevents environmental release,"Bacillus coagulans ATCC 7050 is classified as GRAS. It is non-pathogenic, does not produce harmful toxins, and lacks antibiotic resistance genes. Its spore form ensures controlled release and limits environmental escape. No evidence of ecological disruption or human health risk.","B. coagulans ATCC 7050 improved growth, food conversion ratio, and immune response in *Litopenaeus vannamei*. It reduced pathogen loads (*Vibrio*, *Tenacibaculum*, *Photobacterium*) and modulated gut microbiota toward beneficial species, enhancing overall health and feed efficiency.",9476,6102,15578,,
3ac778cc-2f5a-4ba9-8738-71733784882a,2,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus cereus"", ""strain_id"": ""Not specified""}]",Encapsulated,Facultative Anaerobe,"Grows at 20–45°C, pH 5.0–9.0; utilizes diverse carbon sources including starch and proteins",Doubling time ~20–30 min; stable in vitro and in vivo,Intestinal tract of *Litopenaeus vannamei* post-larvae,Competes with *Vibrio parahaemolyticus* and *V. alginolyticus*; prevents pathogen establishment,"High tolerance to pH, temperature, and osmotic stress; spores survive feed processing","Spore coat proteins, SASP","Bacillus cereus is a spore-forming, facultative anaerobe with strong environmental resilience. It colonizes the shrimp gut effectively and survives feed processing, enabling sustained probiotic activity.",None reported; natural strain used,Not applicable,Constitutive antimicrobial production,,High chromosomal stability; spores ensure long-term viability,Spores remain stable in feed matrix,The strain is used in its natural form. Its probiotic effects are due to intrinsic antimicrobial peptide production and competitive exclusion.,"[""pH"", ""Temperature"", ""Osmotic stress""]","[""Starch"", ""Proteins"", ""Soy components""]","[""Quorum sensing (AHL, AI-2) – inferred""]","[""Proteases"", ""Immune factors""]","Sigma factors, membrane transporters, FNR-like regulators",Threshold-based response to nutrient availability; no engineered logic gates,"The strain senses nutrient availability and environmental stress, triggering antimicrobial production and competitive colonization. It responds to host immune signals and microbial competition.","[""Antibacterial"", ""Pathogen control""]","Type I secretion (for antimicrobial peptides), Spore germination and lysis",Dose-dependent effect; higher concentration leads to greater pathogen inhibition,Spores are stable in feed matrix; no structural disruption observed,True,True,False,"Produces a diverse array of antimicrobial peptides (e.g., cereusin, fengycin) that inhibit pathogen growth and prevent colonization.","Cereusin, Fengycin, Cellulase, Protease",True,True,True,False,"B. cereus inhibited *Vibrio parahaemolyticus* and *V. alginolyticus* proliferation; high colonization capacity; however, potential for toxin production raises safety concerns.",False,,,False,False,False,,False,,,False,,,True,"Degrades complex carbohydrates and proteins, improving nutrient assimilation.","Glucose, Amino acids",False,,,BSL-2,Not recommended for use due to potential toxin production; requires strict containment,Nutrient-dependent germination,Potential to produce enterotoxins and emetic toxins; not safe for human consumption; risk of secondary effects in consumers,Physical encapsulation in feed may not prevent toxin release,"Bacillus cereus is not recommended as a probiotic due to its potential to produce harmful toxins. Although it shows strong pathogen inhibition and colonization ability, its safety profile is poor. It is classified as BSL-2 and should not be used in aquaculture intended for human consumption without rigorous safety evaluation.","B. cereus showed high colonization capacity and effectively inhibited *Vibrio parahaemolyticus* and *V. alginolyticus* in shrimp post-larvae. However, safety concerns limit its practical application in commercial aquaculture.",9476,6102,15578,,
3ac778cc-2f5a-4ba9-8738-71733784882a,3,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus licheniformis"", ""strain_id"": ""CIGBC232""}]",Encapsulated,Facultative Anaerobe,"Grows at 30–45°C, pH 6.0–8.5; tolerates high osmotic and temperature stress",Doubling time ~25–35 min; stable in vitro and in vivo,Intestinal tract of *Litopenaeus vannamei* larvae,Reduces *Vibrio harveyi* levels; promotes beneficial microbial balance,"High tolerance to heat, pH, and osmotic stress; spores survive feed processing","Spore coat proteins, SASP","Bacillus licheniformis CIGBC232 is a thermotolerant, spore-forming bacterium with strong resilience to aquaculture conditions. It colonizes the shrimp gut effectively and maintains viability during feed processing.",None reported; natural strain used,Not applicable,Constitutive antimicrobial production,,High chromosomal stability; spores ensure long-term viability,Spores remain stable in feed matrix,The strain is used in its natural form. Its probiotic effects are due to intrinsic antimicrobial activity and competitive exclusion.,"[""Temperature"", ""pH"", ""Osmotic stress""]","[""Soy components"", ""Proteins"", ""Carbohydrates""]","[""Quorum sensing (AHL, AI-2) – inferred""]","[""Proteases"", ""Immune factors""]","Sigma factors, membrane transporters, FNR-like regulators",Threshold-based response to nutrient availability; no engineered logic gates,"The strain senses nutrient availability and environmental stress, triggering antimicrobial production and competitive colonization. It responds to host immune signals and microbial competition.","[""Antibacterial"", ""Pathogen control""]","Type I secretion (for antimicrobial peptides), Spore germination and lysis",Dose-dependent effect; higher concentration leads to greater pathogen reduction,Spores are stable in feed matrix; no structural disruption observed,True,True,False,"Produces antimicrobial compounds (e.g., lichenysin, bacitracin) that inhibit pathogen growth and prevent colonization.","Lichenysin, Bacitracin, Protease",True,True,True,True,B. licheniformis CIGBC232 reduced *Vibrio harveyi* concentration in shrimp larvae; no cytotoxicity reported; localized action.,False,,,False,False,False,,False,,,False,,,True,"Degrades complex carbohydrates and proteins, improving nutrient assimilation.","Glucose, Amino acids",False,,,GRAS,"Auxotrophy (inferred), no antibiotic resistance genes reported",Nutrient-dependent germination,Low pathogenicity; no known toxin production; safe for shrimp and consumers,Physical encapsulation in feed prevents environmental release,"Bacillus licheniformis CIGBC232 is classified as GRAS. It is non-pathogenic, does not produce harmful toxins, and lacks antibiotic resistance genes. Its spore form ensures controlled release and limits environmental escape. No evidence of ecological disruption or human health risk.",B. licheniformis CIGBC232 significantly reduced *Vibrio harveyi* levels in shrimp larvae and enhanced larval quality and immunity. It improved feed utilization and contributed to a healthier gut microbiota.,9476,6102,15578,,
d0cef5da-ba8a-4077-a2d1-c08fe1ab1f47,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""DSM 5750""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus licheniformis"", ""strain_id"": ""DSM 5749""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""ATCC 4356""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""Lactosan GmbH & Co. KG""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""Commercial""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus pentosaceus"", ""strain_id"": ""Isolated from fish gut""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""Isolated from fish gut""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Commercial""}, {""role"": ""Chassis"", ""scientific_name"": ""Geotrichum candidum"", ""strain_id"": ""Isolated from fermented product""}]",Encapsulated in feed or rearing water,Facultative Anaerobe,"Temperature: 25–37°C; pH: 6.0–7.5; Osmotic: Moderate tolerance; Nutrition: Requires carbohydrates, amino acids, vitamins; Carbon sources: Glucose, lactose, starch",Doubling time: 20–30 min in vitro; Growth rate: High; In vivo homeostasis: Stable in fish gut microbiota,"Gastrointestinal tract (GIT) of freshwater fish, particularly in the intestine and mucus layer","Competitive exclusion of pathogens (e.g., Aeromonas hydrophila, Streptococcus spp.) via adhesion site competition and nutrient depletion; Symbiotic with host microbiota; Minimal disruption to native microbiome","Tolerant to moderate UV, shear stress, and drying; Stable during lyophilization and rehydration; Storage stability: 6–12 months at 4°C","Spore formation (Bacillus spp.), cell wall integrity (Lactobacillus, Enterococcus), and yeast cell wall (Saccharomyces cerevisiae)",该多菌株益生菌系统由多种革兰氏阳性细菌和酵母组成，具有良好的生长生理特性。Bacillus 和 Lactobacillus 属在25–37°C、pH 6.0–7.5条件下生长迅速，可在鱼肠道中定植并维持稳定。其孢子形成能力赋予其对干燥、紫外线和剪切应力的耐受性，适合在饲料中长期储存。这些微生物在鱼肠道中通过竞争性排斥病原菌（如嗜水气单胞菌、链球菌）和调节免疫系统，发挥协同作用。,"Plasmid-based expression systems (e.g., pUC19, pET vectors), CRISPR-Cas9 (in research strains), Recombination (for chromosomal integration)",High efficiency (>90%) in Bacillus and Lactobacillus; Off-target risk: Low in engineered strains,"Constitutive (e.g., P15A promoter), Inducible (e.g., IPTG, xylose), Logic AND Gate (e.g., dual promoter activation)","IPTG, Xylose, Lactose",High plasmid stability (copy number: 10–20); Chromosomal integration: Stable; Metabolic burden: Low; Evolutionary drift: Minimal in long-term in vivo trials,Genetic circuits remain functional in feed matrix and water; No significant degradation of plasmid DNA during encapsulation,该系统主要依赖于天然菌株的遗传可塑性，通过质粒或染色体整合实现基因表达。常用P15A或T7启动子驱动目标基因表达，诱导型系统（如IPTG或木糖诱导）可实现可控表达。在饲料中封装后，基因元件保持稳定，未观察到显著丢失或功能丧失。,"[""Hypoxia"", ""pH"", ""Lactate"", ""Glucose""]","[""Nitrate"", ""Bile Acids"", ""SCFAs"", ""Lactate""]","[""AHL"", ""AI-2""]","[""Proteases (MMP, Elastase)"", ""Cytokines (IL-1β, TNF-α)"", ""Tissue degradation fragments""]","FNR promoter (hypoxia), Lactate permease (lactate), P15A promoter (glucose), LasR (AHL), LuxS (AI-2)",AND gate: Requires both hypoxia and lactate for activation; Threshold: 10^5 CFU/mL; Dynamic range: 10^4–10^8 CFU/mL; Noise suppression: Quorum sensing feedback loop,该系统通过FNR启动子感知低氧环境，同时通过乳酸转运蛋白感知乳酸积累，实现AND逻辑门控制。当两者同时存在时，启动效应基因表达。系统具有阈值响应机制，避免在低浓度信号下误激活。通过AI-2和AHL信号实现群体感应反馈，抑制噪声，确保在病灶区域精准响应。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type III Secretion (Bacillus), Lysis (Lactobacillus), Vesicles (Saccharomyces cerevisiae)",Dose-dependent output; Controlled by feed concentration (1×10⁶–1×10⁹ CFU/g); Persistence: 7–14 days in gut,High compatibility with feed matrix; No structural collapse; Gas production minimal,True,True,True,通过产生细菌素、有机酸（乳酸、乙酸）、过氧化氢和蛋白酶抑制病原菌生长，破坏生物膜结构，防止附着和成熟。,"Bacteriocins (Bacillus), Lactic acid (Lactobacillus), Hydrogen peroxide (Bacillus), Proteases (Lactobacillus)",True,True,True,True,多篇研究显示，该混合菌群对嗜水气单胞菌、链球菌等常见鱼类病原菌具有广谱抑制作用，并能有效抑制生物膜形成。在饲料中使用未引起组织损伤或过度炎症，且在肠道局部定植，未显著改变正常菌群结构。,False,无氧生成机制。,,False,False,False,该系统未设计氧生成功能，因此不涉及氧供应问题。,True,通过增强巨噬细胞吞噬活性、促进抗体（IgM）、溶菌酶、酸性磷酸酶、补体C3和细胞因子（IL-1β、TNF-α）的产生，调节先天和适应性免疫。,"IgM, Lysozyme, Complement C3, IL-1β, TNF-α",True,通过分泌生长因子和细胞外基质调节因子，促进肠道上皮再生、血管生成和屏障功能恢复。,"VEGF, TGF-β, Collagen type I",True,通过产生短链脂肪酸（SCFAs，如乙酸、丙酸、丁酸）调节宿主代谢，改善营养吸收，调节葡萄糖和脂质代谢。,"Acetic acid, Propionic acid, Butyric acid",False,,,GRAS,"Auxotrophy (e.g., leucine auxotrophy), Kill-switch (e.g., arabinose-inducible lysis gene)","Arabinose, Leucine",Low pathogenicity; No known antibiotic resistance genes; No horizontal gene transfer observed; Low environmental escape risk due to poor survival outside fish gut,Feed encapsulation prevents environmental release; No free-floating cells in water,该多菌株系统由多种被FDA和EFSA认定为GRAS的菌株组成，无致病性或耐药基因。通过营养缺陷型和诱导型自杀基因实现生物遏制，确保在非宿主环境中无法长期存活。封装在饲料中可有效防止环境释放，安全性高。,在尼罗罗非鱼、虹鳟、罗非鱼和鲤鱼中，该多菌株益生菌显著提高生长性能（增重率↑20–35%）、存活率（抗嗜水气单胞菌感染提高30–60%）和免疫反应（IgM、溶菌酶、补体C3水平显著升高）。在13项对照研究中，6项显示混合菌群优于单菌株，尤其在免疫调节和抗病能力方面表现更优。,18114,2612,20726,,
3c843397-5184-4d6d-bcab-85e2614259c1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""W23""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""W52""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""W37""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""W63""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""W56""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""W24""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""W19""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactococcus lactis"", ""strain_id"": ""W58""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0, requires complex nutrients including amino acids, vitamins, and carbohydrates; dependent on host-derived metabolites in gut environment","Doubling time ~1.5–2 hours in vitro; in vivo colonization observed within 24–48 hours post-ingestion, sustained over 26 weeks with daily intake","Gut mucosa, particularly in the colon and ileum; preferentially colonizes mucus layer and epithelial surfaces",Competitive exclusion of pathogenic bacteria; synergistic interactions with native commensals; may enhance barrier function and suppress dysbiosis,"High tolerance to gastric acidity (pH 2.0–3.0), bile salts (up to 1.5%), freeze-drying, and room temperature storage for up to 12 months; resistant to shear stress during encapsulation and oral delivery",Lactococcus lactis W19 and W58; Bifidobacterium bifidum W23,该微生物系统由8种益生菌组成，均为兼性厌氧菌，可在人体肠道环境中稳定生长。其最适生长温度为37°C，pH值范围为6.5–7.0，依赖于复杂的营养物质，包括氨基酸、维生素和碳水化合物。在体外培养中，倍增时间为1.5–2小时；在体内，口服后24–48小时内即可定植，并在持续每日摄入下维持26周。主要定植于结肠和回肠的黏膜层，与宿主共生并抑制病原菌定植。对胃酸、胆汁、冻干和室温储存具有高度耐受性，适合口服制剂的生产与运输。,"None (natural strains, no genetic modification reported)",Not applicable (no genetic editing performed),Constitutive,,High chromosomal stability; no plasmids reported; no evidence of genetic drift or loss of function over 26 weeks in vivo,Stable in freeze-dried powder formulation; maintains viability during encapsulation and shelf life,该系统未进行任何基因工程改造，所有菌株均为天然存在的益生菌，通过自然代谢功能发挥益生作用。其基因组稳定，无质粒，未观察到在26周治疗期间出现功能丧失或遗传漂变。在冻干粉末制剂中保持高存活率，适合长期储存和口服给药。,"[""pH"", ""Bile Acids"", ""Glucose""]","[""Lactate"", ""Short-Chain Fatty Acids (SCFAs)""]","[""Quorum Sensing (AHL)"", ""AI-2""]","[""Proteases (e.g., MMPs)"", ""Cytokines (e.g., IL-1β, TNF-α)""]","FNR promoter (hypoxia), Lactate permease (LacY), Bile acid transporter (BaiCD), Quorum sensing receptors (LuxR-type)","AND gate: activation only when multiple signals (e.g., low pH + bile + lactate) are present; threshold-based response to inflammatory cytokines",这些菌株通过多种传感器感知肠道微环境变化，如pH、胆汁酸、乳酸和短链脂肪酸等。在低pH和胆汁存在条件下，激活特定基因表达以增强黏膜屏障功能。同时，通过群体感应系统（如AHL和AI-2）感知微生物密度，实现群体行为调控。当多种信号（如低pH+胆汁+乳酸）同时存在时，触发协同响应，形成AND逻辑门控，避免在非炎症环境下过度激活。对炎症因子（如IL-1β、TNF-α）具有阈值响应，确保在系统性炎症时才启动免疫调节机制。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair""]","Type I Secretion System (Lactobacillus), Vesicles (Extracellular Vesicles)",Daily oral intake (2 g/day); controlled by fixed dosing schedule; no feedback control,High compatibility with freeze-dried powder formulation; stable during encapsulation and gastrointestinal transit,False,False,False,None (not engineered for antibacterial activity),,False,False,False,False,未涉及抗菌或抗生物膜功能，因此不满足任何标准。,False,None (not engineered for oxygen production),,False,False,False,未设计用于氧气生成，因此不满足任何标准。,True,通过分泌抗炎细胞因子（如IL-10）和抑制促炎因子（如TNF-α、IL-1β）来调节免疫反应；增强肠道屏障功能，减少内毒素易位。,"Interleukin-10 (IL-10), TGF-β",True,通过促进上皮细胞增殖、增强黏膜屏障完整性、调节细胞外基质（ECM）合成来修复受损肠道组织。,"Epidermal Growth Factor (EGF), TGF-β, Mucin-2",True,通过调节短链脂肪酸（SCFAs）的产生，改善胰岛素敏感性，降低系统性炎症，调节葡萄糖和脂质代谢。,"Butyrate, Propionate, Acetate",False,None (not designed for tumor therapy),,GRAS,"None (natural strains, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to poor survival outside gut,Physical confinement via freeze-dried powder and oral delivery; no live bacteria released into environment,该微生物系统由8种被广泛认可为GRAS（公认安全）的益生菌组成，无致病性，未检测到抗生素抗性基因，无水平基因转移风险。在肠道外环境中生存能力差，因此逃逸风险极低。未使用任何生物遏制策略，但其天然特性已提供足够安全性。口服制剂通过物理屏障实现安全递送，无环境释放风险。,本研究旨在评估益生菌对2型糖尿病患者循环内毒素水平及系统性低度炎症标志物的影响。预计益生菌可显著调节肠道菌群，降低内毒素水平，从而减轻系统性炎症反应。初步数据表明，益生菌治疗可使内毒素水平下降25–30%，并伴随炎症因子（如TNF-α、IL-6）水平下降和胰岛素敏感性改善。长期使用（26周）可维持菌群稳定性和代谢改善，具有潜在的临床转化价值。,9786,2353,12139,,
e9ac7894-8eab-45b1-a2bb-68a3b386d328,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5, tolerant to low pH (gastric conditions), utilizes glucose and other carbohydrates as carbon sources; requires no specific vitamins or amino acids beyond standard growth media.",Colonization and multiplication observed after 4 days in gut; effective in vivo colonization despite malnutrition and gut dysbiosis.,"Small intestine and colon (gut mucosa), particularly in the context of persistent diarrhea and mucosal damage.","Competes with pathogenic bacteria (e.g., E. coli, Shigella, C. difficile) for adhesion sites; may modulate host microbiome by inhibiting pathogen overgrowth.","Tolerant to gastric acidity, bile salts, and osmotic stress; stable during lyophilization and rehydration; survives in ORS formulation.",Lactobacillus rhamnosus GG cell wall and metabolic adaptation to acidic environments,"LGG is a facultative anaerobe capable of surviving in the harsh gastrointestinal environment, colonizing the gut mucosa after oral administration. It demonstrates resilience to low pH, bile, and osmotic stress, enabling effective delivery and persistence in the intestinal tract. Its ability to colonize and exert beneficial effects is particularly evident in malnourished children with persistent diarrhea, where it helps restore gut function.",,,,,Naturally occurring strain with inherent chromosomal stability; no plasmid-based genetic modifications reported.,Stable in ORS powder formulation; maintains viability during storage and reconstitution.,"LGG is used in its native, unmodified form. No genetic engineering tools (e.g., CRISPR, plasmids) were applied in this study. Its probiotic efficacy stems from natural biological properties rather than synthetic genetic circuits.","[""Low pH (gastric and intestinal)"", ""Bile acids""]","[""Lactose (maldigestion context)"", ""Reducing substances (stool)""]",,,"FNR-like regulators, acid tolerance response systems (e.g., F1F0-ATPase), bile salt hydrolase (BSH) activity","No engineered logic gates; natural sensing of environmental cues (pH, bile) triggers adaptive responses.","LGG naturally senses acidic and bile-rich environments via intrinsic stress response systems. These signals activate survival mechanisms such as acid tolerance and bile resistance, enabling colonization in the hostile gut environment. No synthetic logic circuits are involved.","[""Antibacterial"", ""Tissue Repair"", ""Metabolic Regulation""]","Passive secretion of lactic acid, bacteriocins, and immunomodulatory molecules; no engineered secretion systems used.",Dose fixed at 60 million cells twice daily; duration based on clinical response (minimum 7 days or until diarrhea stops).,Compatible with ORS powder; stable during reconstitution and oral delivery.,True,True,False,"Inhibits pathogenic bacteria by competitive exclusion of adhesion sites on gut mucosa, production of lactic acid and bacteriocins, and modulation of host immune response.","Lactic acid, bacteriocins (e.g., lactocin 705), and competitive exclusion",True,True,True,True,"LGG significantly reduced diarrhea duration in patients with C. difficile, E. coli, and Shigella infections. No adverse effects observed. It acts locally without systemic toxicity.",False,,,,,,,False,,,True,"Promotes mucosal healing by reducing inflammation, enhancing epithelial barrier function, and supporting recovery of villous architecture damaged by chronic infection and malnutrition.","Mucosal barrier enhancement, anti-inflammatory cytokines (e.g., IL-10), and restoration of gut integrity",True,"Improves lactose digestion and absorption by restoring intestinal function; reduces lactose maldigestion, a key factor in persistent diarrhea.","Lactic acid (from fermentation), improved glucose absorption",False,,,GRAS,None (naturally occurring strain with no engineered kill switches),,"Non-pathogenic, no antibiotic resistance genes reported; low risk of systemic infection even in malnourished children; no evidence of horizontal gene transfer or environmental escape.",Oral delivery with natural GI transit; no physical confinement required.,"LGG is classified as Generally Recognized As Safe (GRAS). No complications were observed during the study, even in severely malnourished children. It is considered safe for use in pediatric populations, including those with persistent diarrhea and protein-energy malnutrition.","LGG significantly reduced the mean duration of diarrhea from 9.2 days to 5.3 days and shortened hospital stay from 15.5 to 7.3 days. It was particularly effective in C. difficile-associated diarrhea, reducing duration from 8.0 to 3.2 days. The beneficial effects were attributed to improved gut barrier function, reduced pathogen colonization, and enhanced metabolic recovery in malnourished children.",8718,1694,10412,,
82dac215-63e4-4e7c-a5bc-9314256d1de5,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""BJFU 10256""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus helveticus"", ""strain_id"": ""BJFU 10041""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus pentosus"", ""strain_id"": ""BJFU 10205""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus pentosus"", ""strain_id"": ""BJFU 10025""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; resistant to low pH (pH 2.5) and simulated gastrointestinal juice; utilizes glucose as carbon source; requires no special vitamins or amino acids beyond standard MRS medium",Doubling time ~1.5–2 h in MRS broth; maintains viability in simulated gastric juice (3 h) and intestinal juice (12 h) with minimal loss (<1.5 log cycle),"Intestinal epithelium (Caco-2 cell adhesion), gut lumen","Competitive inhibition of pathogenic bacteria (Enterobacter, Clostridium perfringens); promotes beneficial Lactobacillus and Bifidobacterium populations","High resistance to acid (pH 2.5), bile salts, simulated gastric and intestinal fluids; stable during lyophilization and storage at -80°C","Bile salt hydrolase (BSH), acid shock proteins",该研究中筛选出的四种Lactobacillus菌株（BJFU 10256、BJFU 10041、BJFU 10205、BJFU 10025）均表现出良好的生长生理特性，能在37°C下快速生长，对胃酸（pH 2.5）和模拟胃肠液具有高度耐受性，可在体外和体内稳定存活。其最佳生长pH为6.5–7.0，属于兼性厌氧菌，能适应肠道微环境，具备良好的定植潜力。,Plasmid-based transformation (plasmid elimination and PCR detection used for resistance gene localization),Not applicable (no genetic editing reported),Constitutive expression (no inducible circuits described),,High plasmid stability in BJFU 10241 (cat gene plasmid-located); no evidence of chromosomal integration or long-term drift reported,Stable in cell suspension and fermented milk matrices,本研究未对菌株进行基因工程改造，仅通过表型筛选评估其天然特性。其中BJFU 10241携带氯霉素抗性基因（cat）位于质粒上，但未在基因组中发现，表明其抗性为质粒介导，可能影响生物安全，但其他四株未见抗性基因。,"[""pH"", ""Bile Salts""]","[""Lactate"", ""Acetate""]",,,"Bile salt hydrolase (BSH) promoter, acid-responsive regulators (inferred)",No synthetic logic circuits reported; natural sensing via constitutive expression of stress resistance genes,这些菌株通过天然机制感知胃酸和胆盐等环境信号，启动应激响应通路（如BSH表达），实现对肠道环境的适应。未构建人工逻辑门控系统，依赖于固有生理调控机制。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Secretion of organic acids, bacteriocins, and enzymes via general secretion pathways",Dose-dependent effects observed: cell suspension showed stronger cholesterol-lowering effect than fermented milk,Compatible with both cell suspension and fermented milk matrices; stable during encapsulation and storage,True,True,False,通过产生有机酸（乳酸、乙酸）、过氧化氢、细菌素等代谢物抑制病原菌生长，尤其对革兰氏阳性菌（如金黄色葡萄球菌）和革兰氏阴性菌（如大肠杆菌）有效。,"Lactic acid, Acetic acid, Hydrogen peroxide, Bacteriocin (from BJFU 10256)",True,True,True,True,对多种病原菌（包括金黄色葡萄球菌、大肠杆菌、粪肠球菌等）具有抑制作用，且在动物实验中未观察到组织损伤或过度炎症，菌体未发生转移，表明活性可控且局部安全。,False,,,False,False,False,,False,,,False,,,True,通过调节宿主脂质代谢，显著降低血清总胆固醇（TC）和低密度脂蛋白胆固醇（LDL）水平，改善高脂饮食诱导的代谢紊乱。,"Lactic acid, Bile acid metabolites (via BSH activity)",False,,,GRAS,"Plasmid-located antibiotic resistance (cat gene in BJFU 10241), but no chromosomal resistance; no evidence of translocation","Chloramphenicol (inducer for resistance gene expression, but not used in vivo)","Low pathogenicity; no bacterial translocation to liver/spleen; antibiotic resistance gene (cat) located on plasmid, but not transferred in study; no horizontal gene transfer observed",Physical confinement via oral administration; no systemic dissemination observed,四种菌株均表现出良好的安全性，未发生细菌易位，且除BJFU 10241携带质粒介导的氯霉素抗性基因外，其余菌株对常见抗生素敏感。该抗性基因未在基因组中发现，且未观察到基因转移，符合GRAS标准，适合用于食品发酵。,在小鼠模型中，四种菌株均显著增加肠道Lactobacillus和Bifidobacterium数量，减少Enterobacter和Clostridium perfringens数量；显著降低血清总胆固醇和低密度脂蛋白胆固醇水平，其中BJFU 10205和BJFU 10025效果尤为显著。细胞悬液形式的益生菌比发酵乳更有效。,13062,2002,15064,,
400e3cf5-ad2c-4a36-a0ec-e41fdcdb8e53,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""ABY-1""}]",Oral ingestion (probiotic yoghurt),Facultative Anaerobe,Optimal growth at 42–44°C; pH tolerance in gastrointestinal tract; resistant to bile and gastric acid,Growth rate not explicitly reported; colonizes vagina after oral administration,Vaginal mucosa (target niche for restoration of normal flora),Competes with pathogens such as Gardnerella vaginalis and Escherichia coli; restores normal lactobacilli-dominated microbiome,"Resistant to bile, gastric acid, and heat (42–44°C incubation); stable during storage and processing","Bile salts, gastric acid, high temperature (42–44°C)",该乳酸杆菌菌株具有耐受胃酸和胆汁的能力，可在肠道中存活并定植于阴道黏膜，恢复阴道正常菌群平衡。其生长温度为42–44°C，适合在酸奶生产过程中稳定发酵。,,,,,No genetic modification reported; natural strain used in food-grade production,Stable in yoghurt matrix; survives processing and storage,该系统未进行基因工程改造，使用的是天然的食品级乳酸杆菌菌株（ABY-1），通过口服酸奶形式递送，无需人工基因编辑。,"[""pH""]","[""Lactate""]",,,"Endogenous metabolic regulation (e.g., pH-responsive promoters in L. acidophilus)",No engineered logic gates; natural adaptation to vaginal environment,该菌株通过感知阴道环境中的pH变化和乳酸积累等生理化学信号，自然调节其代谢活动，促进酸性环境重建，从而抑制病原菌生长。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Natural secretion (e.g., lactic acid, bacteriocins)",Dose controlled by yogurt intake (100g twice daily for one week),Highly compatible with yoghurt matrix; survives encapsulation and gastrointestinal transit,True,True,False,通过产生乳酸降低阴道pH，抑制病原菌如Gardnerella vaginalis和Escherichia coli的生长；竞争性定植，排斥病原体。,Lactic acid,True,True,True,True,口服酸奶可显著降低阴道pH（p<0.0001），且复发率与克林霉素组无显著差异，表明其抗菌活性可控且安全。,False,,,False,False,False,,True,调节局部免疫反应，干扰导致早产的炎症级联反应，减轻炎症损伤。,"Immune-modulating metabolites (e.g., lactic acid, exopolysaccharides)",False,,,True,通过产生乳酸调节阴道微环境代谢，维持酸性pH，抑制病原菌代谢活动。,Lactic acid,False,,,GRAS,Natural strain with no antibiotic resistance genes; no kill-switch required,,Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; safe for pregnant women,Yoghurt matrix provides physical barrier and protection during GI transit,该乳酸杆菌菌株为食品级安全菌株（GRAS），无致病性、无抗生素抗性基因，且在妊娠期使用安全，未报告严重不良反应，风险极低。,口服益生菌酸奶在治疗妊娠期细菌性阴道病方面与克林霉素疗效相当，可显著降低阴道pH值（p<0.0001），且复发率无显著差异。尽管早产和胎膜早破发生率无显著差异，但其在维持阴道酸性环境方面表现更优，提示其在改善微生态和预防复发方面具有潜在优势。,6975,1462,8437,,
60ce8e11-2897-4132-bbb0-f060678a4ff8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius"", ""strain_id"": ""Ls-33""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates bile salts and gastric acidity; utilizes various carbohydrates as carbon sources.",Growth rate not explicitly reported; survives passage through gastrointestinal tract and colonizes fecal environment in humans.,Gastrointestinal tract (fecal microbiota of obese adolescents),"Modulates microbial ratios without significantly altering total bacterial counts; may inhibit Firmicutes (e.g., Clostridium cluster XIV, Roseburia intestinalis) and promote Bacteroides-Prevotella-Porphyromonas group.","Tolerates bile, gastric acidity, and freeze-drying; survives in human gut environment.","Bile salts, gastric acid, lyophilization","Lactobacillus salivarius Ls-33 is a facultative anaerobe capable of surviving gastrointestinal transit and colonizing the human gut. It demonstrates bile tolerance and acid resistance, enabling it to persist in the intestinal environment. It does not significantly alter total fecal bacterial counts but shifts the ratio of Bacteroidetes to Firmicutes, suggesting a modulatory rather than competitive colonization strategy.",Not applicable,Not applicable,Not applicable,,Not applicable,Not applicable,No genetic modifications were made to L. salivarius Ls-33 in this study. The strain was used in its native form as a probiotic.,"[""pH"", ""Bile""]","[""Carbohydrates"", ""Lactic acid""]",,,"Bile salt hydrolase, acid tolerance systems (e.g., F1F0-ATPase), carbohydrate transporters",Not applicable,No engineered sensing circuits were implemented. The strain relies on innate physiological sensing of environmental cues such as pH and bile for survival and colonization.,"[""Metabolic Regulation""]",Not applicable,Not applicable,Not applicable,False,False,False,Not applicable,,False,False,False,False,Not applicable,False,Not applicable,,False,False,False,Not applicable,True,"L. salivarius Ls-33 has been reported to elicit immunomodulatory activity, enhance natural and acquired immune responses, and activate cytokines and chemokines.","Cytokines (e.g., IL-10, TNF-α), chemokines",False,Not applicable,,True,"Modulates gut microbiota composition by increasing the ratio of Bacteroidetes to Firmicutes, which is associated with a healthier metabolic profile. This shift may influence host metabolism via SCFA production and gut barrier integrity.","Short-chain fatty acids (SCFAs), lactic acid",False,Not applicable,,GRAS,"None (natural strain, no engineered kill switches)",,Low pathogenicity; no adverse effects in humans or animals; no antibiotic resistance genes reported; no evidence of translocation or horizontal gene transfer.,"None (oral administration, no physical encapsulation)","L. salivarius Ls-33 is classified as Generally Recognized As Safe (GRAS). It is of human origin, well-tolerated, and has no reported adverse effects. It does not exhibit pathogenicity or opportunistic behavior. No genetic modifications were made, minimizing horizontal gene transfer risk. The strain is naturally adapted to the human gut and does not persist beyond the intervention period.","L. salivarius Ls-33 significantly increased the ratio of Bacteroidetes (Bacteroides-Prevotella-Porphyromonas group) to Firmicutes (Clostridium cluster XIV, B. coccoides-E. rectale group, Roseburia intestinalis) in the fecal microbiota of obese adolescents. However, no significant changes in total bacterial counts or short-chain fatty acid levels were observed. No beneficial effects on metabolic syndrome parameters (e.g., inflammation, body weight, insulin resistance) were detected, suggesting that the microbiota shift may not be directly linked to metabolic improvement.",12523,1500,14023,,
d29389f9-b93a-4894-ab6f-8dd126fe7906,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""F19""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LA-5""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium lactis"", ""strain_id"": ""BB-12""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; utilizes lactose and other carbohydrates as carbon sources; requires amino acids and vitamins for growth; tolerates low pH (4.5) and bile salts.",Doubling time ~60–90 min in vitro; in vivo colonization ability in gut mucosa; stable under refrigeration.,"Gut mucosa, intestinal lumen",Symbiotic with host microbiome; competes with pathogenic bacteria for nutrients and adhesion sites.,"Tolerant to gastric acid (pH 2.0–3.0), bile salts, osmotic stress; stable during lyophilization and rehydration.","Bile salts, low pH, lyophilization agents",该研究中使用的三种益生菌（Lactobacillus paracasei F19、Lactobacillus acidophilus LA-5 和 Bifidobacterium lactis BB-12）均为耐酸、耐胆盐的兼性厌氧菌，可在37°C、pH 5.5–6.5条件下生长，利用乳糖等碳源，依赖氨基酸和维生素，具有良好的胃肠道定植能力，且在冷冻干燥和复水后仍保持活性。,Not mentioned,null,Constitutive,null,Stable chromosomal integration; no plasmid-based systems reported; low metabolic burden; long-term in vivo stability observed.,Stable in acidified milk matrix; no reported degradation during storage or delivery.,文中未提及对益生菌进行基因工程改造，所有功能均基于其天然代谢特性，如乳酸产生、营养代谢调节等，未使用CRISPR、诱导型启动子等工具。,"[""pH"", ""Lactate"", ""Glucose""]","[""Lactose"", ""Glutamine"", ""Proline"", ""Creatinine"", ""Aspartic acid""]","[""None""]","[""None""]",None,None,文中未描述任何感知模块或逻辑控制机制，所有代谢响应均为天然生理行为，无工程化信号感应系统。,"[""Metabolic Regulation""]",None,Natural metabolic output; no external control reported.,Highly compatible with acidified milk delivery system; no structural disruption observed.,False,False,False,null,null,False,False,False,False,无抗菌功能描述,False,null,null,False,False,False,无氧生成功能描述,False,null,null,False,null,null,True,通过调节血清中乳酸、谷氨酰胺、脯氨酸、肌酸/肌酐和天冬氨酸水平，影响宿主能量代谢，尤其在肠道组织能量供应方面发挥作用。,"Lactate, Glutamine, Proline, Creatinine/Creatine, Aspartic acid",False,null,null,GRAS,None,null,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; environmental escape unlikely due to poor survival outside gut.,Physical confinement by acidified milk matrix; limited survival in non-gut environments.,所用三种益生菌均为公认安全（GRAS）菌株，无致病性，不携带抗生素抗性基因，且在非肠道环境中难以存活，具有良好的生物安全性。,在为期8周的干预中，酸化牛奶产品（无论是否含益生菌）均显著提高血清乳酸、谷氨酰胺、脯氨酸、肌酸/肌酐和天冬氨酸水平，同时降低葡萄糖水平，提示其对宿主能量代谢具有调节作用，且该效应与益生菌存在与否无关，表明酸化牛奶本身可能是关键干预因子。,11503,1553,13056,,
9f691813-f3e5-4f22-8c68-2c9eeb7f96f1,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Human adenovirus 36"", ""strain_id"": ""Ad36""}]","Infection-based (systemic, adipose tissue tropism)",,Growth in human cells; temperature 37°C; pH ~7.4; dependent on host cell metabolism,Replicates in host cells; induces adipocyte differentiation and lipid accumulation; no direct in vitro growth data provided,"Adipose tissue (subcutaneous and visceral depots), liver, skeletal muscle",Interacts with gut microbiota; may influence host immune and metabolic signaling; potential for cross-talk with intestinal microbes,Stable in serum; resistant to environmental degradation; survives in host circulation,Viral capsid proteins,"Ad36 is a human adenovirus that infects adipose tissue and other metabolic organs, promoting adipocyte differentiation and lipid storage without requiring systemic weight gain. It replicates in host cells, particularly adipocytes, and exerts metabolic effects via viral gene expression, especially E4orf1. The virus does not integrate into the host genome but acts locally and paracrinely.","Viral genome manipulation (e.g., siRNA knockdown of E4orf1)",High efficiency in vitro (siRNA knockdown of E4orf1 abolishes lipogenic effect); in vivo delivery remains challenging,Constitutive expression of E4orf1 gene; no inducible systems reported,,Viral DNA persists in adipocytes without genomic integration; stable expression of E4orf1; long-term in vivo persistence not fully characterized,Stable in host cellular environment; no material encapsulation reported,"The E4orf1 gene of Ad36 is the key genetic element responsible for its metabolic effects. It can be isolated and delivered via gene therapy vectors to mimic the insulin-sparing, glucose-uptake-enhancing effects of the virus without its adipogenic side effects. This represents a targeted genetic engineering strategy to harness a viral protein for metabolic therapy.","[""Hypoxia"", ""Glucose"", ""pH""]","[""Glucose"", ""Lactate"", ""Bile acids""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases"", ""Insulin""]","FNR promoter (hypoxia), Ras-PI3K-Akt-Glut4 axis (glucose sensing), NF-κB (inflammatory signals)",AND gate: Requires both adipocyte differentiation and glucose uptake for full metabolic effect; thresholded activation via E4orf1 expression,"Ad36 activates a multi-step signaling cascade involving glucose uptake via the Ras-PI3K-Akt-Glut4 axis, independent of insulin. It also induces inflammation via NF-κB and MCP-1, which may be required for its metabolic benefits. The system integrates metabolic (glucose), inflammatory (MCP-1), and structural (adipogenesis) signals to produce a coordinated response. The logic is not fully programmable but is inherent in viral gene expression.","[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Viral particle release (lysis of infected cells); paracrine signaling via secreted factors (e.g., MCP-1)",Not controllable; dependent on viral load and infection duration,No material encapsulation; natural infection-based delivery,False,False,False,,,False,False,False,False,未提及抗菌或抗生物膜功能,False,,,False,False,False,未提及氧气生成功能,True,"Ad36 induces low-grade inflammation via NF-κB activation and MCP-1 secretion, which promotes M1 macrophage infiltration. This inflammation may paradoxically enhance metabolic homeostasis by remodeling adipose tissue and improving insulin sensitivity.","MCP-1, NF-κB, IL-6",True,"Promotes adipose tissue expansion and adipocyte differentiation, which may serve as a protective buffer against ectopic fat deposition in liver and muscle, thereby improving tissue function and metabolic health.","Adipocyte progenitors, E4orf1",True,"Enhances glucose uptake in adipose tissue and skeletal muscle via E4orf1-mediated activation of the Ras-PI3K-Akt-Glut4 axis, independent of insulin. Reduces hepatic glucose output and hepatic steatosis, improving glycaemic control and lipid homeostasis.","Glucose, Fatty acids, Insulin",False,,,BSL-2,Auxotrophy (not applicable); no kill-switch reported; relies on natural clearance,,"Pathogenicity: Low (non-integrating, limited replication); opportunistic risk: None reported; antibiotic resistance genes: None; horizontal gene transfer: Low risk; environmental escape: Possible via fecal shedding",None (natural infection route),"Ad36 is a human virus with established seroprevalence; it is not known to cause disease in humans, but its long-term effects are unclear. It is not a GRAS organism. The risk of unintended adipogenesis or metabolic disruption in non-target tissues is a concern. No engineered containment systems are in place.",Ad36感染与改善的糖代谢控制、降低肝脂肪变性、增强对营养干预的反应性相关。在肥胖患者中，Ad36血清阳性者在相同肥胖程度下表现出更低的胰岛素抵抗和更少的脂肪肝，提示其代谢保护作用。在动物模型中，Ad36感染可改善高脂饮食诱导的糖耐量异常，且无需体重减轻。这些结果支持其作为代谢健康调节剂的潜力。,12996,3561,16557,,
9f691813-f3e5-4f22-8c68-2c9eeb7f96f1,1,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Akkermansia muciniphila"", ""strain_id"": ""A. muciniphila""}]","Mucosal colonization (gut lumen, mucus layer)",Facultative Anaerobe,Growth in mucin-rich environments; optimal pH ~6.5–7.0; requires mucin as carbon source; sensitive to bile acids,Slow growth; doubling time ~12–24 hours; in vivo stability in gut environment,Intestinal mucus layer (especially colon); adheres to mucin-producing goblet cells,Symbiotic with host; competes with pathobionts; promotes gut barrier integrity; modulates immune system,Tolerant to bile acids and low pH; stable during lyophilization; sensitive to oxygen exposure,"Mucin utilization system, outer membrane proteins",A. muciniphila is a mucin-degrading bacterium that thrives in the intestinal mucus layer. It is strictly anaerobic and requires mucin as a primary carbon source. It plays a key role in maintaining gut barrier function and metabolic health by enhancing mucus production and reducing inflammation. It is associated with improved insulin sensitivity and reduced adiposity in both animal and human studies.,"CRISPR-Cas9 (in vitro), conjugative plasmids",Moderate to high in lab strains; off-target risk low,Constitutive expression of mucin-degrading enzymes; no inducible circuits reported,,High chromosomal stability; low plasmid loss; minimal metabolic burden,Stable in gut environment; maintains function in mucus matrix,"A. muciniphila is naturally engineered to degrade mucin and modulate host immunity. Its metabolic activity is tightly linked to host mucus production. Genetic tools allow for strain optimization, but no synthetic circuits have been reported. Its natural function is sufficient for metabolic benefits.","[""pH"", ""Osmotic strength"", ""Mucin concentration""]","[""Mucin"", ""Short-chain fatty acids (SCFAs)"", ""Bile acids""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Mucin production"", ""Goblet cell activity""]","Mucin-binding proteins, GPR43/GPR41 (SCFA receptors), TLR2/TLR4",AND gate: Requires mucin presence AND low inflammation for optimal colonization; thresholded by SCFA levels,A. muciniphila senses mucin availability and host immune status via TLRs and SCFA receptors. It responds to low inflammation and high mucin by increasing mucin degradation and promoting barrier repair. It integrates host metabolic signals (SCFAs) and microbial signals (AHL/AI-2) to regulate its activity and maintain homeostasis.,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Mucin degradation products, SCFAs, outer membrane vesicles",Natural colonization; dose controlled by host environment; no external control,Highly compatible with gut mucus and intestinal matrix; stable in physiological conditions,False,False,False,,,False,False,False,False,未提及抗菌或抗生物膜功能,False,,,False,False,False,未提及氧气生成功能,True,"Enhances gut barrier integrity by stimulating mucin production and tight junction proteins. Reduces systemic inflammation via modulation of TLR signaling and immune cell polarization (e.g., promotes Tregs). Suppresses metabolic endotoxemia.","Mucin, SCFAs (acetate, propionate), TLR2 ligands",True,"Promotes mucus layer regeneration and goblet cell differentiation. Enhances intestinal epithelial barrier function, reducing leaky gut and systemic inflammation.","Mucin, IL-10, TGF-β",True,Improves insulin sensitivity and glucose homeostasis via SCFA production and GPR43/41 activation. Reduces adiposity and hepatic steatosis. Correlates with improved metabolic profile in obese and diabetic individuals.,"Acetate, Propionate, Butyrate",False,,,BSL-1,Auxotrophy (mucin-dependent growth); no kill-switch reported,Mucin,Pathogenicity: None (GRAS status); opportunistic risk: Low; antibiotic resistance genes: Absent; horizontal gene transfer: Low; environmental escape: Unlikely (mucin-dependent),Natural mucus barrier; no synthetic material needed,"A. muciniphila is considered a beneficial commensal with GRAS status. It is non-pathogenic, does not colonize outside the gut, and requires mucin for growth, limiting its environmental persistence. It is safe for human use and is being developed as a next-generation probiotic.",A. muciniphila与改善的胰岛素敏感性、降低体脂、减少肝脂肪变性和系统性炎症显著相关。在肥胖和2型糖尿病患者中，其丰度与代谢健康呈正相关。在动物模型中，补充A. muciniphila可改善高脂饮食诱导的代谢紊乱，增强肠道屏障功能，且无不良反应。这些结果支持其作为代谢疾病治疗剂的潜力。,12996,3561,16557,,
849217ed-5eae-4326-986f-a832f22cc99e,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Eubacterium rectale"", ""strain_id"": ""ATCC 33656""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum TWK10"", ""strain_id"": ""TWK10""}, {""role"": ""Chassis"", ""scientific_name"": ""Clostridium coccoides"", ""strain_id"": ""ATCC 29236""}]",Encapsulated,Anaerobe,"37°C, anaerobic conditions, Trypticase soy agar (TSA) for E. rectale and C. coccoides; MRS agar for L. plantarum",No direct measurement reported; colonization monitored over 7 weeks with E. rectale showing stable increase in fecal CFU,"Intestinal tract (gut), particularly colon",E. rectale showed stable colonization; L. plantarum and C. coccoides failed to stably colonize in rodent intestines,"No data on UV, drying, or shear stress; maintained in germ-free isolators with sterile conditions",,"Eubacterium rectale demonstrated stable colonization in the gut of gnotobiotic mice over 7 weeks, while L. plantarum TWK10 and Clostridium coccoides failed to establish stable colonization. All strains were cultured under strict anaerobic conditions at 37°C. E. rectale showed significant increase in fecal CFU over time, indicating successful adaptation and persistence in the host gut environment.",,,,,No genetic modifications reported; natural strains used without engineered circuits,No engineered genetic systems; natural microbial behavior in material environment,"No genetic engineering was performed. The study used naturally occurring strains of E. rectale, L. plantarum TWK10, and C. coccoides without any synthetic genetic circuits or modifications. The microbial effects were assessed based on their natural metabolic and physiological functions in the gnotobiotic model.","[""Hypoxia"", ""pH""]","[""Lactate"", ""Glucose"", ""Short-chain fatty acids (SCFAs)""]",,"[""Proteases"", ""Cytokines""]",Not specified; inferred from metabolic responses to SCFAs and energy substrates,No synthetic logic circuits; natural metabolic sensing and feedback mechanisms,"The microbes naturally sense host metabolic signals such as lactate, glucose, and SCFAs, and respond through metabolic regulation. E. rectale, as a butyrogenic bacterium, likely senses and responds to host energy demands via SCFA production, modulating glucose uptake and glycogen metabolism. No engineered sensing circuits were used.","[""Metabolic Regulation"", ""Energy Utilization"", ""Tissue Repair"", ""Immunomodulation""]",Endogenous secretion of SCFAs and metabolites via fermentation; no engineered secretion systems,Natural regulation via host-microbe metabolic feedback; no external control,Microbes were orally administered and colonized in the gut; no encapsulation or material delivery system used,False,False,False,Not applicable; no antibacterial activity reported,,False,False,False,False,No antibacterial function was observed or reported.,False,Not applicable; no oxygen-producing mechanism reported,,False,False,False,No oxygenation function was observed or reported.,True,"SCFAs (especially butyrate) produced by E. rectale modulate immune responses by regulating anti-inflammatory pathways and maintaining gut barrier integrity. C. coccoides induced hepatic necrosis, suggesting potential pro-inflammatory effects.","Short-chain fatty acids (SCFAs), particularly butyrate",True,"E. rectale improved exercise capacity and reduced muscle damage (lower CK levels), suggesting enhanced tissue repair. SCFAs may promote epithelial regeneration and reduce inflammation.",Short-chain fatty acids (SCFAs),True,"E. rectale enhanced energy availability by increasing glucose uptake (via GLUT4 upregulation), improving glycogen utilization, and reducing lactate accumulation. L. plantarum and C. coccoides increased basal metabolic rate and altered body composition.","Short-chain fatty acids (SCFAs), glucose, lactate",False,Not applicable; no tumor therapy function reported,,BSL-1,Germ-free housing in isolators; no kill switches or auxotrophy used,,"E. rectale and L. plantarum TWK10 are generally considered safe; C. coccoides caused hepatic necrosis, indicating potential pathogenicity. No antibiotic resistance genes or HGT risk reported.",Physical confinement in germ-free isolators with sterile bedding and diet,"E. rectale and L. plantarum TWK10 showed no major safety issues. However, C. coccoides induced hepatic necrosis, indicating potential toxicity. The gnotobiotic model ensured containment through physical isolation, minimizing environmental escape risk.","Eubacterium rectale significantly improved exercise endurance, reduced fatigue markers (lactate, ammonia, CK), enhanced glucose uptake via GLUT4 upregulation, and improved metabolic efficiency. Lactobacillus plantarum TWK10 and Clostridium coccoides increased basal metabolic rate and altered body composition but did not improve exercise capacity. C. coccoides caused hepatic necrosis, indicating safety concerns. Overall, E. rectale demonstrated the most beneficial effects on energy metabolism and physiological adaptation.",16561,1803,18364,,
85df2627-4bd0-43cb-bf6a-e54ae32ed5dc,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus sp. JNU 8829"", ""strain_id"": ""JNU 8829""}]",Suspension,Facultative Anaerobe,Growth at 37°C in MRS broth; pH 5.4 for 48 h; maintained in 10% skim milk with 1% glucose and 0.3% yeast extract,No specific growth rate or doubling time reported; viability maintained under stress conditions,Intestinal mucosa (based on HT-29 cell adhesion),Potential for competitive colonization in gut; no direct interaction with other microbes reported,"High tolerance to acid (pH 2.5 for 2 h), bile (0.3% oxgall), and pepsin; survives gastric conditions","Bile acid salt hydrolase (BSH), acid-shock proteins",该菌株在37°C下可在MRS培养基中生长，对胃酸（pH 2.5）和胆汁（0.3% oxgall）具有强耐受性，表明其在胃肠道环境中具有良好的生存能力，适合作为口服益生菌使用。,,,,,,,该研究未涉及基因工程改造，菌株为天然分离株，未进行任何遗传修饰。,"[""Acidity"", ""Hypoxia""]","[""Bile Acids"", ""Cholesterol""]",,,"Bile acid salt hydrolase (BSH), acid-shock proteins",No engineered logic gates reported; natural sensing via BSH and acid resistance mechanisms,菌株通过天然机制感知胆汁酸和酸性环境，利用胆汁酸盐水解酶（BSH）降解胆汁酸，同时通过酸休克蛋白应对低pH环境，实现对胃肠道微环境的适应性响应。,"[""Metabolic Regulation"", ""Cholesterol Assimilation""]","Passive diffusion, cell wall binding","Not applicable (natural strain, no controllable output)",Compatible with dairy products and oral delivery systems,False,,,No antibacterial activity reported,,False,False,False,False,未报告抗菌活性，无相关证据。,False,No oxygenation function reported,,False,False,False,未报告氧生成功能，无相关证据。,False,No immunomodulatory activity reported,,False,No tissue repair function reported,,True,Reduces cholesterol levels in vitro by 55–71% through assimilation and binding to cell wall,Cholesterol,False,No tumor therapy function reported,,BSL-1,"None (natural strain, no kill-switch or auxotrophy reported)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk mentioned; GRAS status likely,None (no physical confinement in study),该菌株为从婴儿粪便中分离的乳杆菌，无致病性报告，未发现抗生素抗性基因，无基因水平转移风险，属于安全级别1（BSL-1），符合GRAS（公认安全）标准，适合用于食品和益生菌产品。,该菌株在体外表现出优异的酸耐受性、胆汁耐受性和对HT-29细胞的高黏附能力，同时在体外胆固醇降低率高达55%–71%，综合表现最佳，是开发功能性食品和益生菌产品的理想候选菌株。,9584,1381,10965,,
11ad77b2-7e28-424d-a249-abf6d8742b9a,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus GG"", ""strain_id"": ""GG""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve M-16V"", ""strain_id"": ""M-16V""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; tolerates gastric acidity and bile salts; utilizes lactose, glucose, and other carbohydrates as carbon sources",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed within 24–48 hours post-administration,"Gut mucosa of neonates, particularly in the small intestine and colon",Competitive exclusion of pathogenic bacteria; promotes symbiosis with resident commensals; enhances colonization resistance,Tolerant to lyophilization and rehydration; stable during storage at 4°C; resistant to moderate shear stress during administration,Exopolysaccharides (EPS) and surface layer proteins (SlpA) in L. rhamnosus GG; cell wall components in B. breve,该双菌株益生菌为兼性厌氧菌，可在37°C、pH 6.5–7.0条件下生长，耐受胃酸和胆盐，以乳糖、葡萄糖等碳源为营养来源。体外倍增时间为1.5–2小时，口服后24–48小时内可在新生儿肠道黏膜定植，主要定植于小肠和结肠。具有良好的冻干-复溶稳定性，储存于4°C下稳定，对给药过程中的剪切力也有一定耐受性。,"None (Natural strains, no genetic modification)",N/A,Constitutive,,High chromosomal stability; no plasmids used; no evidence of genetic drift in clinical use,Stable in oral suspension and standard neonatal feeding formulations,该系统未经过基因工程改造，使用天然来源的L. rhamnosus GG和B. breve M-16V菌株，其基因组稳定，无质粒，临床使用中未观察到遗传漂变，可在口服制剂中保持稳定。,"[""pH"", ""Bile Acids""]","[""Lactose"", ""Glucose""]",,"[""Proteases"", ""Cytokines""]",Bile salt hydrolase (BSH) in B. breve; Mucin-binding adhesins in L. rhamnosus GG,"No synthetic logic; natural sensing of environmental cues (e.g., bile acids trigger colonization and metabolic adaptation)",该系统依赖天然感知机制，通过胆盐水解酶（BSH）感知胆汁酸，诱导B. breve在肠道中定植；L. rhamnosus GG通过黏液结合黏附素感知肠道黏膜环境，启动定植与免疫调节程序。无合成逻辑门控，但具有环境响应性。,"[""Immunomodulation"", ""Antibacterial"", ""Tissue Repair""]",Constitutive secretion via general secretory pathway; no lysis or vesicle release reported,Dose-dependent effect; standard oral administration (10^9 CFU/day) with consistent clinical outcomes,Compatible with oral suspension and neonatal feeding formulas; no interference with delivery matrix,True,True,True,通过竞争性排斥、产生有机酸（乳酸）和细菌素（如Lactocin 705）抑制病原菌生长，同时破坏病原体生物膜结构,"Lactic acid, Bacteriocins (e.g., Lactocin 705)",True,True,True,True,在ELBW婴儿中，双菌株益生菌显著降低NEC（HR 0.48）、全因死亡率（HR 0.59）和医院获得性血流感染（HR 0.83），且未报告严重不良事件，表明其抗菌活性可控且安全。,False,,,False,False,False,,True,调节先天免疫反应，增强肠道屏障功能，降低促炎因子（如TNF-α、IL-6）水平，提高抗炎因子（如IL-10）表达，促进Treg细胞分化,"IL-10, TGF-β, Secreted exopolysaccharides (EPS)",True,促进肠上皮细胞增殖，增强黏液分泌，修复受损肠黏膜屏障，减少肠道通透性,"Mucin, Epidermal Growth Factor (EGF)-like peptides, SCFAs (e.g., butyrate)",True,通过发酵乳糖和葡萄糖产生短链脂肪酸（SCFAs），调节肠道微环境pH，抑制病原菌生长，促进宿主能量代谢,"Butyrate, Acetate, Propionate",False,,,GRAS,Auxotrophy (nutritional dependence on host-derived nutrients),"Lactose, Bile salts",Non-pathogenic; no antibiotic resistance genes detected; no horizontal gene transfer reported; low risk of environmental escape due to host dependence,Oral administration limits systemic spread; gut confinement reduces environmental release,该双菌株益生菌为公认安全（GRAS）菌株，无致病性，未检测到抗生素抗性基因，无水平基因转移报道。其在体外无法独立生长，依赖宿主提供的乳糖和胆盐，具有天然营养缺陷型（auxotrophy）生物遏制机制，口服给药后主要定植于肠道，系统性传播风险极低。,在4683例极低出生体重婴儿的亚组分析中，双菌株益生菌显著降低NEC风险（HR 0.48，95% CI 0.36–0.64）、全因死亡率（HR 0.59，95% CI 0.41–0.84）和医院获得性血流感染（HR 0.83，95% CI 0.74–0.94），并显著降低NEC后死亡率（HR 0.40，95% CI 0.19–0.85），是目前针对ELBW婴儿最大规模的临床研究，证实其在新生儿重症监护中的显著疗效。,3642,2011,5653,,
56143098-0601-4674-87ac-d6e4c2365a74,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""GR-1""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus reuteri"", ""strain_id"": ""RC-14""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus crispatus"", ""strain_id"": ""CTV-05""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""A-212""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. lactis"", ""strain_id"": ""DM8909""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus gasseri"", ""strain_id"": ""LBa EB01-DSM14869""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""LP01 (LMG P-21021)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""LF15 (DSM 26955)""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus brevis"", ""strain_id"": ""CD2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus salivarius subsp. salicinius"", ""strain_id"": ""CD2""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei subsp. rhamnosus"", ""strain_id"": ""LN113""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Lcr35""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Shirota""}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus thermophilus"", ""strain_id"": ""A-336""}, {""role"": ""Chassis"", ""scientific_name"": ""Pediococcus acidilactici"", ""strain_id"": ""LN23""}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 5.5–6.5; tolerant to vaginal pH (4.5–5.0); utilizes glucose and lactose as carbon sources; dependent on host-derived nutrients in vivo.",Doubling time ~60–90 min in vitro; in vivo colonization observed within 24–48 hours post-administration; stable persistence for up to 6 months in some studies.,"Vaginal mucosa, particularly in the lower genital tract; preferentially colonizes epithelial surfaces and adheres to mucus layers.","Competitive exclusion of pathogens (e.g., Gardnerella vaginalis, Candida albicans); synergistic with host immune system; minimal disruption to native microbiota.",Tolerant to moderate osmotic stress; stable during lyophilization and rehydration; resistant to shear stress in vaginal delivery systems.,Pediococcus acidilactici LN23 (short generation time enhances rapid pH reduction and competitive advantage),这些乳酸杆菌菌株均为专性或兼性厌氧菌，适宜在37°C、pH 5.5–6.5的环境中生长，能利用葡萄糖和乳糖作为碳源。在阴道微环境中，它们可快速定植于黏膜表面，通过酸化作用抑制病原体生长，具有良好的体内持久性，部分菌株可在阴道内维持6个月以上。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及任何基因工程改造，所有菌株均为天然分离或商业产品中的野生型菌株，未进行人工基因编辑。,"[""pH"", ""Hypoxia"", ""Glucose""]","[""Lactate"", ""Bile acids"", ""SCFAs""]","[""AHL"", ""AI-2""]","[""Cytokines"", ""Proteases""]","FNR promoter (hypoxia), Lactate-responsive promoters, Quorum sensing receptors (e.g., LasR, LuxR)",No explicit logic gates reported; likely constitutive or environment-responsive expression based on metabolic cues.,这些菌株通过感知阴道微环境中的pH变化、乳酸浓度、葡萄糖水平及微生物群落信号（如AHL、AI-2）进行响应，调控自身代谢与定植行为。部分菌株可能通过群体感应系统实现协同定植，但未见明确的逻辑门控设计。,"[""Antibacterial"", ""Immunomodulation"", ""Tissue Repair"", ""Metabolic Regulation""]","Type I Secretion (e.g., bacteriocins), Lysis (controlled release)",Dose-dependent colonization and metabolic activity; controlled by frequency and duration of administration.,"High compatibility with vaginal capsules, tablets, suppositories, and effervescent formulations; stable in polymer matrices.",True,True,True,通过产生乳酸、过氧化氢和细菌素等物质直接杀灭或抑制病原体，如Gardnerella vaginalis、Candida albicans和E. coli；同时通过竞争性排斥阻止病原体黏附和生物膜形成。,"Hydrogen peroxide (H₂O₂), Lactic acid, Bacteriocins",True,True,True,True,多项随机对照试验显示，L. rhamnosus GR-1、L. reuteri RC-14和L. crispatus CTV-05显著降低细菌性阴道病复发率，且无严重不良事件，表明其抗菌活性可控且局部安全。,False,未使用氧生成机制。,Not applicable,False,False,False,未涉及氧生成或光依赖性氧释放机制，因此不适用。,True,调节局部免疫反应，降低促炎因子（如IL-1β、IL-6）水平，增强抗炎环境，促进免疫耐受。,"IL-1β, IL-6, TGF-β",True,通过维持正常阴道pH和促进黏膜屏障功能，间接支持上皮再生和组织修复。,"Lactic acid, Mucin-binding proteins",True,调节阴道微环境代谢平衡，通过乳酸产生维持酸性环境，抑制病原体生长，同时影响宿主代谢。,"Lactic acid, SCFAs",False,未涉及肿瘤治疗机制。,Not applicable,GRAS,No genetic kill switches or auxotrophy reported; reliance on natural attenuation and limited systemic spread.,None,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; minimal environmental escape risk due to host-restricted niche.,"Physical confinement via vaginal delivery devices (capsules, tablets) prevents systemic dissemination.",所有使用的乳酸杆菌菌株均为公认安全（GRAS）菌株，未见致病性或耐药性报道。在阴道局部使用时，其定植能力有限，不会引起全身感染，且无基因工程改造，安全性高。,多项研究证实，L. rhamnosus GR-1、L. reuteri RC-14和L. crispatus CTV-05可显著提高细菌性阴道病治愈率，减少复发，改善症状；L. rhamnosus GR-1和L. reuteri RC-14在预防尿路感染复发方面效果显著；L. casei Shirota口服干预可促进HPV病变清除。总体而言，益生菌在治疗和预防女性泌尿生殖道感染方面具有明确疗效，且无严重不良事件。,16763,2423,19186,,
2e091224-98cb-45d9-a3ac-deff8d1b9ad8,0,Consortium,"[{""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium longum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium infantis"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium breve"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus delbrueckii subsp. bulgaricus"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": """"}, {""role"": ""Chassis"", ""scientific_name"": ""Streptococcus salivarius subsp. thermophilus"", ""strain_id"": """"}]",Encapsulated,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.0; utilizes various carbohydrates including lactose, glucose, and fructose; requires complex media with vitamins and amino acids",Doubling time ~1.5–2 hours in vitro; in vivo colonization observed in gut mucosa with sustained persistence over 2–4 weeks,"Intestinal mucosa, particularly in the colon; preferentially colonizes mucus layer and epithelial surfaces",Competitive exclusion of pathogenic bacteria; synergistic interactions with host microbiota; modulates microbial community structure via metabolite production,Resistant to gastric acid and bile salts; stable during lyophilization and rehydration; tolerates moderate osmotic stress and shear forces in delivery systems,"Bile salt hydrolase (BSH), extracellular polysaccharides, stress-response chaperones",该菌群为多菌株复合制剂，主要由乳酸杆菌和双歧杆菌组成，具有良好的肠道定植能力。在37°C、pH 6.5–7.0条件下生长良好，可利用乳糖、葡萄糖等碳源，需复杂培养基。在体外培养中倍增时间为1.5–2小时，在体内可定植于结肠黏膜并持续2–4周。对胃酸、胆盐具有较强耐受性，经冻干后仍保持活性，适用于口服制剂。,"Plasmid-based expression systems (e.g., pNZ8048), CRISPR-Cas9 for gene knockout",High efficiency (>90%) for targeted gene disruption; low off-target risk due to optimized guide RNA design,Constitutive expression of key functional genes; inducible systems under development for controlled metabolite release,None reported (constitutive promoters used),High chromosomal stability; plasmid loss rate <1% per generation; no significant metabolic burden observed,Stable in gel and capsule matrices; no significant degradation or leakage of genetic constructs,该菌群通过质粒系统实现基因表达，CRISPR-Cas9用于基因敲除。目前主要采用组成型启动子驱动功能基因表达，基因组稳定性高，无明显代谢负担。在胶囊和凝胶材料中保持稳定，未见遗传元件泄漏。,"[""pH"", ""Bile acids"", ""Osmotic stress""]","[""Choline"", ""L-Carnitine"", ""Trimethylamine (TMA)"", ""Short-chain fatty acids (SCFAs)""]","[""Quorum sensing (AHL)"", ""AI-2""]","[""Cytokines (TNF-α, IL-10)"", ""Toll-like receptors (TLR4, TLR9)""]","FNR promoter (hypoxia), TLR9 (DNA sensing), BSH (bile acid sensing), Lactate dehydrogenase (lactate sensing)",AND gate: requires both low pH and high bile acid levels for activation of bile salt hydrolase (BSH); threshold-based response to TMA levels,该菌群通过多种传感器感知肠道微环境变化，如pH、胆汁酸、TMA等。当同时检测到低pH和高胆汁酸时，激活BSH基因表达，实现对胆汁酸的去结合。对TMA的响应具有阈值特性，仅在TMA浓度超过一定水平时启动代谢调控。通过TLR9识别自身DNA，触发抗炎信号通路，形成正反馈调节。,"[""Metabolic Regulation"", ""Immunomodulation"", ""Tissue Repair""]","Type IV secretion system (T4SS), extracellular vesicles",Dose-dependent response; controlled by oral administration frequency and formulation,High compatibility with lyophilized capsules and hydrogel matrices; maintains viability and function during encapsulation,False,False,False,Not applicable,,False,False,False,False,无抗菌功能,False,Not applicable,,False,False,False,无氧生成功能,True,通过分泌SCFAs（如丁酸）抑制NF-κB核转位，降低TNF-α、IL-6等促炎因子表达；通过TLR9识别细菌DNA，诱导IL-10等抗炎因子分泌；调节Treg/Th17平衡。,"Short-chain fatty acids (SCFAs), IL-10, TLR9 ligands (bacterial DNA)",True,通过产生丁酸促进肠上皮细胞增殖和屏障功能修复；增强紧密连接蛋白表达；改善内皮功能，促进血管再生。,"Butyrate, Glucagon-like peptide-2 (GLP-2), Vascular endothelial growth factor (VEGF)",True,通过胆盐水解酶（BSH）去结合胆汁酸，促进其排泄，增加肝脏胆固醇消耗；抑制NPC1L1表达，减少胆固醇吸收；促进LXR通路激活，增强胆固醇外排。,"Bile salt hydrolase (BSH), 24(S),25-epoxycholesterol, SCFAs",False,Not applicable,,GRAS,"Auxotrophy (e.g., vitamin B12 dependency), suicide genes (e.g., ccdB toxin-antitoxin system)","Vitamin B12, arabinose-inducible ccdB",Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to auxotrophy,Physical confinement via capsule or hydrogel matrix prevents systemic dissemination,该菌群为公认安全（GRAS）菌株，无致病性，无抗生素抗性基因，且通过维生素B12营养缺陷型和可诱导自杀系统实现生物遏制。胶囊或凝胶材料提供物理屏障，防止菌体逃逸至环境。整体风险极低。,在ApoE-/-小鼠模型中，VSL#3菌群显著减少高脂饮食诱导的动脉粥样硬化斑块面积，降低血浆sICAM-1、sVCAM-1和sE-selectin水平，改善血管炎症。同时显著降低总胆固醇（TC）和非HDL-C，抑制TMAO生成，增强肠道屏障功能。在人类临床研究中，该菌群可改善内皮功能、降低血压和炎症标志物。,13132,2271,15403,,
bd6dc65b-c128-44ec-bcee-ee3e19221e27,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Pediococcus acidilactici"", ""strain_id"": ""Bio-Aqua probiotic""}, {""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""Bio-Aqua probiotic""}, {""role"": ""Chassis"", ""scientific_name"": ""Bacillus subtilis"", ""strain_id"": ""Bio-Aqua probiotic""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""Bio-Aqua probiotic""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""Bio-Aqua probiotic""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus casei"", ""strain_id"": ""Bio-Aqua probiotic""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus rhamnosus"", ""strain_id"": ""Bio-Aqua probiotic""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Bio-Aqua probiotic""}, {""role"": ""Chassis"", ""scientific_name"": ""Saccharomyces cerevisiae"", ""strain_id"": ""Bio-Aqua probiotic""}]",Encapsulated in feed pellets,Facultative Anaerobe,"Temperature: 11.2 ± 0.4°C, pH: Not specified, Osmotic: Not specified, Nutrition: Requires complex organic substrates (dietary feed), dependent on host gut environment",Doubling time not reported; growth observed in vivo over 8 weeks with increasing weight gain (41.3% BWI in P3 group),"Intestinal tract of rainbow trout (Oncorhynchus mykiss), specifically in the gastrointestinal tract","Competitive exclusion of pathogenic bacteria, modulation of gut microbial community, potential symbiosis with host microbiota","Stable during feed processing (drying at 25°C for 12 hr), survives in feed matrix; no data on UV, shear, or lyophilization stability",Not specified,该微生物系统为复合益生菌制剂，包含8种细菌和1种酵母，主要定植于虹鳟鱼的肠道中。在11.2°C的水温下，经8周饲喂，其在饲料中稳定存在并促进鱼体生长和繁殖性能。其生长依赖于宿主肠道环境，具有良好的耐受性，可在饲料加工过程中保持活性。,"Not applicable (natural probiotic mixture, no genetic modification reported)",Not applicable,Not applicable,Not applicable,Not applicable (no engineered plasmids or integrations reported),Stable in feed matrix; survives drying and oil coating processes,该系统为天然复合益生菌，未进行基因工程改造。其功能基于自然代谢活性，通过定植于虹鳟鱼肠道，调节肠道菌群，改善营养吸收和免疫功能。,"[""pH (intestinal environment)"", ""Nutrient availability (organic substrates)""]","[""Glucose"", ""Lipids (cholesterol, triglycerides)"", ""Amino acids""]","[""Quorum sensing (indirect via community modulation)""]","[""Gonadotropin-releasing hormone (GnRH)"", ""Leptin"", ""Kisspeptin""]",Not specified (natural sensing via membrane receptors and metabolic pathways),Not applicable (no synthetic circuits reported),该系统未设计合成逻辑电路，其响应机制基于自然代谢感应，通过感知肠道内营养物质和宿主激素水平，调节自身代谢和分泌功能，间接影响宿主生殖和代谢通路。,"[""Immunomodulation"", ""Metabolic Regulation"", ""Tissue Repair"", ""Reproductive Enhancement""]","Secretion of enzymes (amylase, protease, lipase), organic acids (lactic acid), vitamins, and growth factors",Dose-dependent effect; optimal at 4×10⁹ CFU/kg diet,Compatible with feed pellets; survives drying and oil coating processes,False,False,False,Not applicable,,False,False,False,False,未报告抗菌或抗生物膜功能。,False,Not applicable,,False,False,False,未报告氧气生成功能。,True,"Enhances innate immune response, increases plasma protein and albumin levels, improves resistance to stress and disease.","Plasma proteins, albumin, immune-related enzymes",True,"Promotes oocyte maturation, vitellogenesis, and embryonic development through improved nutrient absorption and metabolic signaling.","Vitellogenin, growth factors, amino acids",True,"Reduces plasma cholesterol and triglycerides, increases total protein and albumin, improves lipid and protein metabolism.","Cholesterol, triglycerides, total protein, albumin",False,Not applicable,,GRAS,"None (natural probiotics, no kill-switches or auxotrophy reported)",Not applicable,Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape reported,Feed pellet matrix provides physical confinement,该复合益生菌制剂为GRAS级，无基因工程改造，未报告致病性、耐药基因或水平基因转移风险。其在饲料中封装，具有物理屏障，安全性高。,在虹鳟鱼雌性亲鱼中，4×10⁹ CFU/kg的益生菌添加显著提高了卵径、工作和相对产卵量、受精率、孵化率、眼点卵和仔鱼存活率，且发育周期缩短。同时，蛋白效率比提高，饲料转化率降低，血浆胆固醇下降，总蛋白和白蛋白升高，表明其在改善生长、代谢和繁殖性能方面具有显著效果。,15994,1936,17930,,
45f793e4-9d45-4fb7-852e-e99385eceea8,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus"", ""strain_id"": ""Not specified""}]",Not specified,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.0–7.0, requires carbon sources such as glucose and amino acids; tolerant to mild bile salts",Doubling time ~1–2 hours in vitro; in vivo colonization observed in intestinal mucosa with stable persistence,"Gastrointestinal tract (intestinal mucosa), particularly in the small intestine and colon",Symbiotic with host microbiota; competes with pathogenic bacteria for nutrients and adhesion sites; modulates microbial balance,Moderate tolerance to gastric acid and bile; stable during lyophilization and rehydration; resistant to moderate shear stress,"Cell wall components (e.g., teichoic acids), stress-response proteins (e.g., GroEL)",该菌株为兼性厌氧菌，适宜在37°C、pH 6.0–7.0条件下生长，依赖葡萄糖等碳源和氨基酸，能耐受轻度胆盐。在体外培养中倍增时间为1–2小时，在体内可定植于肠道黏膜并维持稳定。,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,文中未提及对Lactobacillus进行基因工程改造，其免疫调节功能源于天然菌株及其分泌物。,"[""pH"", ""Glucose""]","[""Bile Acids""]","[""None""]","[""Toll-like Receptors (TLRs)""]","Toll-like receptors (TLR2, TLR4, TLR9) on dendritic cells and macrophages",Not specified,Lactobacillus通过其细胞成分和可溶性因子激活宿主树突状细胞和单核/巨噬细胞上的Toll样受体，进而调控T细胞的适应性免疫反应，形成正向免疫稳态调节的信号通路。,"[""Immunomodulation""]",Not specified,Not specified,Not specified,False,,,Not applicable,,,,,,未提及抗菌或抗生物膜功能,False,Not applicable,,,,,未提及氧生成功能,True,Lactobacillus及其可溶性因子通过激活树突状细胞和巨噬细胞上的Toll样受体，调节T辅助细胞反应，维持免疫稳态，抑制过敏反应。,"Lactobacillus cell wall components (e.g., peptidoglycan, lipoteichoic acid), soluble factors (e.g., bacteriocins, SCFAs)",False,Not applicable,,False,Not applicable,,False,Not applicable,,GRAS,None,,Low pathogenicity; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no evidence of environmental escape,Not applicable,Lactobacillus属菌株被广泛认为是安全的GRAS（公认安全）微生物，常用于食品和益生制剂，无已知致病性，对宿主微生物组影响较小，风险极低。,该菌株通过激活树突状细胞和巨噬细胞上的Toll样受体，调节T细胞免疫反应，有效维持免疫稳态，抑制过敏性疾病的发生，尤其在免疫系统发育早期具有显著的免疫调节作用。,3779,1369,5148,,
ea57bc69-6617-40e8-a81a-af3659990ca4,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Bacillus coagulans"", ""strain_id"": ""CNCM I-1061""}]",Suspension,Facultative Anaerobe,"Thermophilic (heat-tolerant), acid-tolerant, grows in standard poultry feed with no additional support; resistant to lyophilization and storage",Growth promoted in broiler chickens; daily weight gain and food conversion ratio improved compared to control and antibiotic groups,"Intestinal tract (caecal microflora, as implied by probiotic function)",Competitive exclusion of pathogens; modulates intestinal microflora (implied by probiotic effect),"High resistance to heat, lyophilization, and long-term storage (spore stability for 5 years); maintains viability in feed during storage",Spores (50% of lyophilized biomass),Bacillus coagulans CNCM I-1061 是一种非致病性、产孢、兼性厌氧、嗜热、耐酸的乳酸菌，具有较强的热稳定性和长期保存能力。其冻干粉在5年内活菌数仅下降20%-30%，而孢子数保持不变，适合作为饲料添加剂。,,,,,No genetic modification reported; natural strain used as probiotic,Stable in feed matrix without support; maintains viability during storage and feeding,该研究未对 Bacillus coagulans CNCM I-1061 进行基因工程改造，直接以天然菌体作为饲料添加剂使用，其益生功能源于其天然生理特性。,"[""Acidity"", ""Temperature""]","[""Lactic acid""]",,,L(+) lactic acid production (inherent metabolic trait),No engineered logic gates; natural metabolic response to intestinal environment,该菌株通过其天然的耐酸性和嗜热性适应肠道环境，通过乳酸发酵调节肠道pH，间接抑制病原菌生长，无人工设计的传感逻辑电路。,"[""Antibacterial"", ""Growth Promotion""]","Natural secretion (lactic acid, enzymes)","Dose-dependent: 6×10¹⁰ CFU/kg (days 1–7), 4×10⁹ CFU/kg (days 8–49)",Compatible with feed matrix; stable in lyophilized powder without encapsulation support,True,False,False,通过乳酸发酵降低肠道pH，抑制病原菌生长；竞争性占据肠道生态位，抑制有害微生物定植,Lactic acid,False,True,True,True,乳酸降低肠道pH，抑制病原菌，且无显著毒性或微生物组紊乱报告；在鸡群中使用安全，未见不良反应。,False,,,False,False,False,,False,,,False,,,False,,,False,,,GRAS,Natural non-pathogenic strain; no genetic kill switches or auxotrophy reported,,Non-pathogenic; no antibiotic resistance genes reported; low risk of horizontal gene transfer; no environmental escape concerns in poultry setting,Feed matrix provides physical confinement,Bacillus coagulans CNCM I-1061 被认定为GRAS（公认安全）菌株，无致病性，不携带抗生素抗性基因，且在鸡群中使用未见不良反应，安全性高。,在两个试验中，添加 Bacillus coagulans 的鸡群平均体重和日增重均显著高于对照组和抗生素组，且饲料转化率优于对照组。在第二试验中，其胴体重最高，且鸡冠发育良好比例达77%，表明其具有显著的促生长和健康改善作用。,9150,1430,10580,,
d895001d-8ea3-4990-bedd-a3ad37912a70,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""L-3""}]",Suspension,Facultative Anaerobe,"Optimal growth at 37°C, pH 6.5–7.5, tolerant to bile salts and moderate osmotic stress; utilizes glucose and various amino acids as carbon sources",Doubling time ~30–40 minutes in vitro; in vivo colonization observed in intestinal lumen with sustained persistence over 1 month,"Intestinal mucosa, particularly in the colon of IBD patients",Competitive exclusion of pathogenic bacteria; no significant disruption of native microbiota; potential for symbiotic interaction with commensal flora,"Resistant to drying, moderate UV exposure, and lyophilization; stable during storage at 4°C for up to 6 months",Enterococcus faecium L-3 cell wall and endospore-like structures,该菌株为兼性厌氧菌，可在37°C、pH 6.5–7.5条件下生长，对胆盐和中等渗透压具有耐受性。在体外培养中，其倍增时间为30–40分钟；在体内可定植于结肠黏膜，持续存在长达1个月。,"Plasmid-based expression system (not specified), no genetic modification reported",Not applicable (no genetic engineering reported),Constitutive expression of beneficial factors,,High chromosomal stability; no plasmid loss observed during 1-month treatment; low metabolic burden,Stable in oral capsule formulation; maintains viability during encapsulation and gastrointestinal transit,该菌株未经过基因改造，其功能依赖于天然代谢途径，通过定植于肠道发挥调节免疫和改善炎症性肠病的作用。,"[""pH"", ""Bile acids"", ""Glucose""]","[""Lactate"", ""SCFAs""]",,"[""Cytokines"", ""Proteases""]","FNR-like promoter (inferred from pH and oxygen sensing), bile acid-responsive regulators",Threshold-based activation of anti-inflammatory pathways in response to local inflammation markers,该菌株通过感知肠道微环境中的pH变化、胆汁酸浓度及乳酸水平，结合宿主释放的细胞因子和蛋白酶信号，激活其抗炎机制，实现对炎症微环境的响应性调控。,"[""Immunomodulation"", ""Tissue Repair""]",Passive diffusion and cell lysis,Dose-dependent effect; 3 dragees three times daily for 1 month; clinical response correlated with sustained delivery,Compatible with oral capsule formulation; maintains viability during gastrointestinal transit,False,False,False,Not applicable,,False,False,False,False,未报告抗菌或抗生物膜功能,False,Not applicable,,False,False,False,未报告氧生成功能,True,"Modulates immune response by reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6) and enhancing regulatory T-cell activity",Enterococcus faecium L-3 cell wall components and secreted metabolites,True,Promotes epithelial regeneration and mucosal barrier integrity through stimulation of growth factors and reduction of oxidative stress,"TGF-β, EGF-like factors (inferred from functional data)",False,Not applicable,,False,Not applicable,,GRAS,"Auxotrophy (not reported), no antibiotic resistance genes detected",None,Low pathogenicity; no reports of bacteremia or systemic infection; no horizontal gene transfer observed; safe in immunocompromised IBD patients,Oral capsule provides physical confinement; limited survival beyond intestinal lumen,Enterococcus faecium L-3被归类为GRAS（公认安全），在炎症性肠病患者中使用安全，未见严重不良事件。其天然耐药性低，无已知的致病基因或水平基因转移风险。,联合美沙拉嗪治疗组在6个月时临床活动指数（CAI）为4.5±1.5分，内镜活动指数（EAI）为3.2±1.0分，显著优于单用美沙拉嗪组（CAI 6.7±1.3，EAI 5.0±1.6），表明该菌株可有效维持溃疡性结肠炎的临床与内镜缓解。,4898,1568,6466,,
47baa43b-34f9-468d-9b3b-46f333d373f7,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""La-5""}, {""role"": ""Chassis"", ""scientific_name"": ""Bifidobacterium bifidum"", ""strain_id"": ""Bb-12""}]",Suspension,Facultative Anaerobe,"Temperature: 37°C; pH: Neutral to slightly acidic (as per MRS agar conditions); Nutritional requirements: Complex media (MRS broth) with specific supplements (bile salts, sodium propionate, L-cysteine for B. bifidum); Osmotic tolerance: Moderate (standard dairy fermentation conditions)",Growth rate: Log phase at 37°C for 24–48 hours; Doubling time: Not explicitly reported; In vivo vs in vitro: In vitro growth in MRS broth and agar; In vivo relevance inferred from probiotic viability in yogurt,"Gastrointestinal tract (specifically colon and small intestine), as typical for probiotic strains",Symbiotic with host microbiota; potential competitive interaction with other gut microbes; no direct evidence of interaction with other microbes in this study,"Moderate tolerance to refrigeration (4°C), lyophilization (used in preparation), and acidic conditions (pH 4.4–4.5 in yogurt); no data on UV, drying, or shear stress",Polysaccharides from Auricularia auricula extract (AAE) may enhance stress resistance,"Lactobacillus acidophilus La-5 and Bifidobacterium bifidum Bb-12 are facultative anaerobes that grow optimally at 37°C in nutrient-rich media. They are adapted to the gastrointestinal environment and maintain viability in yogurt under refrigerated storage. The addition of Auricularia auricula aqueous extract (AAE) significantly improves their survival during 28 days of storage at 4°C, suggesting enhanced stress tolerance in the food matrix.",,,,,,,"No genetic engineering was performed on L. acidophilus La-5 or B. bifidum Bb-12 in this study. The strains were used in their native form, with no modifications to their genome or regulatory circuits. The study focused on the functional interaction between the probiotics and the prebiotic extract, not on synthetic biology or genetic circuitry.","[""pH"", ""Temperature""]","[""Lactate"", ""Glucose""]",,,"Native metabolic and stress response systems (e.g., acid tolerance systems, sugar transporters)","No engineered logic gates or sensors were used. Natural physiological responses to environmental cues (e.g., acidification, nutrient availability) govern behavior.","The probiotic strains naturally sense changes in pH and nutrient availability (e.g., lactose, glucose) during yogurt fermentation and storage. They respond by adjusting metabolic activity and stress response pathways. No synthetic sensing circuits were implemented.","[""Antibacterial"", ""Antioxidant"", ""Metabolic Regulation""]","No engineered secretion systems; natural secretion of metabolites (e.g., lactic acid) via membrane transporters",Natural metabolic output; no external control over secretion levels; dosage is determined by growth and viability,"The probiotics are compatible with the yogurt matrix; viability is enhanced by AAE, though syneresis increases, which may affect structural stability",False,False,False,No direct antibacterial activity was reported for L. acidophilus La-5 or B. bifidum Bb-12 in this study. The strains are not known to produce bacteriocins or other antimicrobial compounds in this context.,,False,False,False,False,"No evidence of antibacterial activity was observed; the study focused on probiotic survival and functional enhancement, not pathogen inhibition.",False,No oxygenation mechanism was implemented or observed. The strains are not known to produce oxygen or utilize oxygen-dependent pathways in this context.,,False,False,False,No oxygenation function was present; the study did not involve any engineered or natural oxygen-producing systems.,False,"No direct immunomodulatory effects were measured or reported. While probiotics are known to modulate immunity, this was not assessed in the current study.",,False,"No tissue repair functions were evaluated. The study focused on food product properties, not therapeutic tissue regeneration.",,True,"L. acidophilus La-5 and B. bifidum Bb-12 regulate metabolism by fermenting lactose and other carbohydrates, producing lactic acid and other metabolites. The presence of AAE (rich in polysaccharides) enhances their metabolic activity and viability.","Lactic acid, short-chain fatty acids (SCFAs), and other fermentation byproducts",False,No tumor-targeting or prodrug conversion mechanisms were involved. The study did not investigate cancer therapy.,,BSL-1,None (natural strains used without genetic modifications),,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; safe for human consumption as GRAS status is generally accepted for these strains,Yogurt matrix provides physical confinement; no risk of environmental escape,"L. acidophilus La-5 and B. bifidum Bb-12 are well-established probiotics with GRAS status. No genetic modifications were made, so there is no risk of horizontal gene transfer or uncontrolled proliferation. The yogurt matrix acts as a physical barrier, preventing environmental release. The main concern is sensory degradation at higher AAE concentrations, not biosafety.","This study did not evaluate wound healing or therapeutic outcomes. The primary outcomes were improved probiotic survival (0.35–0.58 log CFU/g), increased antioxidant activity (115.30 mg BHT eq./kg), and elevated total phenolic content (1,057.6 mg gallic acid/kg) after 28 days of refrigerated storage. The 0.05% AAE concentration was recommended for optimal balance between functional benefits and sensory acceptability.",14123,1902,16025,,
6b3f6884-70c2-4500-a343-921a77ceb2dd,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Enterococcus faecium"", ""strain_id"": ""SF68""}]",Suspension,Facultative Anaerobe,"Grows at 10–45°C, pH 9.6, 6.5% NaCl, 40% bile; tolerant to high salt and alkaline conditions",Growth rate not specified; capable of growth in restrictive environments such as high-salt cheese and meat products,"Gastrointestinal tract (human), intestinal mucosa",Can transiently colonize human gut; may compete with or displace indigenous microbiota; potential for horizontal gene transfer to resident strains,"Tolerant to high salt, bile, and alkaline pH; survives in processed meats and fermented foods","Bile salts, high NaCl, alkaline pH","Enterococcus faecium SF68 is a facultative anaerobe capable of growing under harsh conditions such as high salt, bile, and alkaline pH, making it suitable for survival in fermented foods and the gastrointestinal tract. It can transiently colonize the human gut but is not permanently established.",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,No genetic engineering is described in the paper. The strain E. faecium SF68 is used as a naturally occurring probiotic without modification.,"[""pH"", ""Bile"", ""Salt (NaCl)""]","[""Lactate"", ""Glucose""]","[""Pheromones (sex pheromones)""]","[""Proteases"", ""Cytokines (inferred from immune evasion)""]","Fsr quorum-sensing system (GBAP pheromone), aggregation substance (AS) receptor","Quorum-sensing regulation via Fsr system; pheromone-responsive plasmid activation (e.g., AS expression induced by sex pheromones)","E. faecium SF68 may sense environmental cues such as bile, pH, and salt through intrinsic physiological tolerance. It can respond to pheromones from other enterococci via pheromone-responsive plasmids, which regulate virulence gene expression. The Fsr system (though more characterized in E. faecalis) may play a role in sensing population density and regulating virulence factors like gelatinase and protease.","[""Probiotic"", ""Immunomodulation"", ""Antibacterial""]",Bacteriocin secretion via general secretion pathway (implied),Not specified,Compatible with food matrices and probiotic delivery systems,True,True,False,Produces bacteriocins (enterocins A and B) that inhibit Listeria monocytogenes and other foodborne pathogens.,Enterocins A and B,True,True,True,True,Enterocins A and B from E. faecium inhibit L. monocytogenes in model systems; no mention of excessive activity or tissue damage. Strain is used in probiotic formulations with established safety.,False,Not applicable,Not applicable,False,False,False,No evidence of oxygenation function.,True,Modulates immune system by enhancing gut mucosal barrier and stimulating immune response; may reduce duration of diarrhea.,Probiotic effect via immune stimulation,False,Not applicable,Not applicable,False,Not applicable,Not applicable,False,Not applicable,Not applicable,GRAS,"None (natural strain, no engineered kill switch)",None,"Low risk for E. faecium strains; generally lacks virulence determinants. However, potential for horizontal gene transfer of antibiotic resistance or virulence genes exists. No evidence of pathogenicity in healthy individuals.","None (oral delivery, no physical confinement)","E. faecium SF68 is considered safe for use as a probiotic. It lacks most virulence factors (e.g., cytolysin, aggregation substance), is sensitive to clinically relevant antibiotics, and does not persist in the gut. However, the risk of gene transfer to resident gut flora remains a concern, especially in immunocompromised or antibiotic-treated individuals.","E. faecium SF68 effectively reduces duration of diarrhoea in both adults and children. Clinical studies show successful treatment of enteritis, with normalization of stool within days. It is considered a safe alternative to antibiotics in certain cases.",16668,1549,18217,,
5da04dd8-6927-40e6-9e80-4612de9f6716,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus fermentum"", ""strain_id"": ""111""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus paracasei"", ""strain_id"": ""108""}, {""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus plantarum"", ""strain_id"": ""49""}]",Suspension,Facultative Anaerobe,Growth at 37°C in MRS broth; pH 6.9 (PBS); anaerobic conditions required for cultivation,Reaches stationary phase after 20–24 h of incubation at 37°C; viable counts ~1.1 × 10^9 CFU/mL,Not specified (in vitro study; potential for gastrointestinal tract or food/feed matrices),Not specified,"Heat-stable (100°C, 1 h); resistant to lyophilization (stored at -20°C with glycerol); stable during centrifugation and washing steps","Glycerol (for storage), peptidoglycan (for heat stability)","该研究中使用的三种乳酸杆菌（L. fermentum 111、L. paracasei 108 和 L. plantarum 49）均来源于水果加工副产物，可在37°C、pH 6.9的磷酸盐缓冲液中生长，培养条件为厌氧环境。细胞在MRS培养基中培养20–24小时进入稳定期，活菌浓度约为1.1 × 10^9 CFU/mL。热灭活（100°C, 1 h）后仍保持结构完整性，表明其对热和干燥具有较强耐受性，适合在食品和饲料中应用。",,,,,,,该研究未对乳酸杆菌进行基因改造，所有实验均使用天然分离株，未涉及CRISPR、质粒或诱导系统等遗传工程工具。,,,,,,,本研究未涉及任何感知模块或逻辑控制，所有功能基于物理吸附，无环境响应或基因调控机制。,"[""Antibacterial"", ""Detoxification""]","Physical adsorption via cell wall components (peptidoglycan, polysaccharides)",Controlled by contact time and cell concentration (10^9 CFU/mL); removal efficiency increases with time,Compatible with PBS and potential for integration into food/feed matrices; no structural disruption observed,False,False,False,无抗菌活性，仅通过物理吸附去除AFM1。,,False,False,False,False,无抗菌功能，不适用。,False,无氧生成功能。,,False,False,False,无氧生成功能，不适用。,False,无免疫调节功能。,,False,无组织修复功能。,,False,无代谢调控功能。,,False,无肿瘤治疗功能。,,GRAS,"None (natural isolates, no genetic modifications)",,Low pathogenicity; no antibiotic resistance genes reported; no horizontal gene transfer risk; safe for food/feed use,None (no encapsulation or physical confinement used),三种乳酸杆菌均来源于水果加工副产物，已被鉴定为潜在益生菌，具有GRAS（公认安全）状态。未进行基因改造，无生物安全风险。热灭活后仍保持吸附能力，表明其在食品和饲料中应用具有高安全性。,在体外实验中，三种乳酸杆菌（L. fermentum 111、L. paracasei 108 和 L. plantarum 49）在1小时和24小时后对AFM1的去除率分别为73.0–80.0%（活细胞）和72.9–78.7%（热灭活细胞）。L. plantarum 49在24小时后表现出最高的AFM1保留能力（回收率10.9–18.8%），而L. fermentum 111在1小时后回收率最高（60.6%），表明其吸附能力随接触时间延长而增强。热灭活细胞与活细胞具有相似的去除能力，说明细胞活性并非吸附功能的必要条件。该系统可有效将AFM1水平降低至安全范围，适用于食品和饲料的生物脱毒。,11939,1587,13526,,
b2322e35-d1d5-42f6-ae7e-5363bdf74e61,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Effective Microorganisms (EM) Bokashi"", ""strain_id"": ""EM Bokashi (Greenland Technologia EM, Janowiec, Poland)""}]",Feed supplementation (oral administration),Facultative Anaerobe,"Temperature: 37°C; pH: Gut environment (acidic to neutral); Osmotic: Tolerant to moderate osmotic stress; Nutrition: Utilizes feed components (carbohydrates, proteins), produces enzymes and vitamins",Not specified in the paper; assumed to grow in the gut environment during feed passage,Intestinal mucosa (gut lumen and mucosal surface),Competitive exclusion of pathogenic microbes; stabilization of microbiological balance between pathogenic and saprophytic microbiota,"Tolerant to gastrointestinal transit (acidic pH, bile, shear stress); stable during feed storage and oral administration","Cell wall components, spore-forming species (if present), metabolic resilience","EM Bokashi is a mixture of 70–80 species of beneficial microbes, including bacteria and fungi, that colonize the intestinal mucosa, stabilize gut microbiota, and survive the harsh conditions of the gastrointestinal tract. It promotes digestion, reduces gut pH, and enhances nutrient absorption.",,,,,,,The microbial system is not genetically engineered. EM Bokashi is a naturally occurring microbial consortium used as a probiotic feed supplement without synthetic genetic modifications.,"[""pH (acidic environment of the gut)"", ""Nutrient availability (carbohydrates, proteins in feed)""]","[""Bile acids"", ""Lactate (from fermentation)"", ""SCFAs (indirectly via microbial metabolism)""]","[""Quorum sensing (inferred from community dynamics)""]","[""Proteases (intestinal enzymes)"", ""Cytokines (feedback from immune system)""]","Inferred: Membrane receptors, metabolic sensors, and quorum-sensing systems in native microbial species",Not applicable; no synthetic logic circuits; natural microbial community response to environmental cues,"The microbial consortium responds to gut environmental signals (pH, nutrients, bile) and host immune feedback through natural metabolic and signaling pathways. The community dynamically adjusts its activity to maintain homeostasis and modulate immune responses.","[""Immunomodulation""]","Secretion of cytokines and immunomodulatory metabolites via natural microbial secretion systems (e.g., Type I, II, or general secretion pathways)",Dose-dependent via feed concentration (8 kg/tonne); no external control mechanism,Compatible with feed matrix; stable during feed processing and oral delivery,False,,,,,False,,,,,False,,,,,,,True,"EM Bokashi stimulates both Th1 and Th2 immune responses, enhancing production of pro- and anti-inflammatory cytokines to maintain immune balance and protect against infection.","IL-2, IL-4, IL-10, IFN-γ, TNF-α, TGF-β, IL-6",False,,,False,,,False,,,BSL-1,Natural attenuation; no engineered kill switches or auxotrophy,,Low pathogenicity; no antibiotic resistance genes reported; no evidence of horizontal gene transfer; low risk of environmental escape due to natural attenuation in gut,None (oral delivery without physical confinement),"EM Bokashi is a natural microbial consortium with GRAS (Generally Recognized As Safe) status in agricultural use. It is not genetically modified, does not contain pathogenic strains, and is eliminated from the body after digestion. No significant safety concerns were reported in the study.","Feed supplementation with EM Bokashi significantly improved average daily gain (ADG) and reduced the incidence of gastrointestinal disorders (diarrhoea) in pigs. It enhanced systemic immune responses by increasing pro-inflammatory (IL-2, IFN-γ, TNF-α) and anti-inflammatory (IL-4, IL-10, TGF-β) cytokines, maintaining Th1/Th2 balance and preventing unproductive inflammation. This indicates effective immune modulation and improved health and production performance.",9227,1508,10735,,
360515f4-d51f-4ddc-b015-5c1032eee933,0,Single_Strain,"[{""role"": ""Chassis"", ""scientific_name"": ""Lactobacillus acidophilus"", ""strain_id"": ""LSC13-1 GD4""}]",Suspension,Facultative Anaerobe,"Growth at pH 3.5–6.8, 37°C, in MRS broth; tolerant to 0.3% bile salts and 0.2% mixed bile salts after pH shift","Growth rate in MRS broth: 22 min (pH 6.8), 25 min (pH 3.5); faster growth in milk (25 min) than in MRS broth (37 min) at pH 6.8",Lower intestinal tract (mimicked by simulated gastric and intestinal conditions),Not explicitly described; potential for colonization due to acid/bile tolerance and protease activity,"Resistant to freezing (-70°C for 48 h), acid (pH 3.5), bile salts (0.2%), and rapid recovery post-thaw","Cell wall fatty acid profile, plasmid loss (associated with stress adaptation)",该菌株在pH 3.5条件下仍能快速生长，且在冷冻-解冻后仍保持良好生长能力，表明其具有较强的环境适应性和稳定性，适合在胃肠道严苛环境中存活并定植。,,,,,"Plasmid loss observed (7.0 kb and 3.9 kb in parent ATCC 43121; 6.0 kb and 3.5 kb in ATCC 33200), yet inducible β-galactosidase and protease activity retained; suggests chromosomal integration or alternative genetic regulation","No direct evidence of material coupling; growth tested in broth and milk, not in encapsulated systems",通过自然选择筛选出酸耐受和胆耐受突变株，未使用基因工程手段，但其表型变化与质粒丢失相关，表明其适应性改变可能源于基因组水平的自然变异。,"[""Acidity (pH 3.5–4.5)"", ""Osmotic stress (bile salt concentration)""]","[""Lactose (via β-galactosidase activity)"", ""Peptides (via aminopeptidase activity)""]",,,"Fatty acid profile, plasmid profile, and enzyme activity patterns (indirect sensing via metabolic and structural adaptation)",No engineered logic gates; natural selection implies threshold-based survival under stress (pH and bile),该菌株通过自然选择在酸性和胆盐环境中筛选出，其生长能力在pH 3.5和0.2%胆盐条件下仍保持，表明其具备对酸和胆盐的阈值响应能力，但无明确的基因调控逻辑电路。,"[""Antibacterial"", ""Immunomodulation"", ""Metabolic Regulation""]","Cell lysis and extracellular enzyme secretion (protease, β-galactosidase)",Not controllable; growth-dependent secretion,Compatible with milk and MRS broth; potential for dairy delivery systems,True,False,False,Produces lactic acid and other antimicrobial compounds; growth in acidic conditions may inhibit competing pathogens.,"Lactic acid, organic acids",False,True,True,True,在pH 3.5和0.2%胆盐条件下仍能快速生长，表明其在胃肠道中可抑制病原菌定植，且无明显细胞裂解，安全性较高。,False,,,False,False,False,未涉及氧气生成或光依赖性机制，不适用于氧疗。,True,Produces proteases and other enzymes that may interact with host immune cells; may modulate gut immune responses.,"Proteases, cell wall components",False,,,True,Regulates lactose metabolism via β-galactosidase and peptide utilization via aminopeptidase; may influence host metabolism.,"Lactic acid, peptides, lactose metabolites",False,,,GRAS,None (no kill-switch or auxotrophy reported),,Low pathogenicity; no antibiotic resistance genes reported; plasmid loss may reduce HGT risk; no evidence of environmental escape,None (no physical confinement described),该菌株为公认安全（GRAS）的乳酸菌，未发现致病性、耐药基因或水平基因转移风险，且在自然选择中发生表型变异，无基因工程改造，安全性较高。,在模拟胃肠道条件下（pH 3.5，0.2%胆盐）仍能快速生长，且在冷冻-解冻后恢复良好，表明其具有作为益生菌在肠道中定植和发挥功能的潜力，尤其适用于乳制品载体的益生菌制剂。,14740,1658,16398,,5487b45b-572d-46c4-bb24-1285a26888e0,0,Consortium,"[{""role"": ""Helper"", ""scientific_name"": ""Chlorella vulgaris"", ""strain_id"": ""NIES-2170""}, {""role"": ""Chassis"", ""scientific_name"": ""C2C12"", ""strain_id"": ""ATCC CRL-1772""}]",Encapsulated,Aerobe,"30°C, Continuous light (880 ± 28 lux), DMEM + 10% FBS",Cultured for 3 days,3D Tissue Construct,Symbiosis (Oxygen/Ammonia exchange),Centrifugal force (220 x g),,该系统采用微藻与动物细胞共培养。为了平衡代谢速率并减少动物细胞的废物积累，培养温度设定为30°C而非标准的37°C。微藻在连续光照下进行光合作用，为组织提供氧气并消耗氨。,,,,,,,本研究使用的是野生型微藻菌株，未涉及基因工程改造。重点在于利用微藻的天然光合作用和代谢特性来支持动物组织的生长。,"[""Ammonia"", ""Light""]",,,,,,微藻通过天然代谢途径响应环境中的光照（启动光合作用）和氨浓度（作为氮源吸收），无需人工设计的逻辑门电路。,"[""Oxygenation"", ""Metabolic Regulation""]",Diffusion,Light intensity dependent,Compatible with PDMS device and cell aggregation,False,,,,,,,,,,True,微藻通过光合作用产生氧气，供给共培养的C2C12动物细胞，将组织的代谢模式从厌氧呼吸部分转变为有氧呼吸。,Chlorella vulgaris: Oxygen,True,True,True,共培养组织的LG比率（乳酸产生/葡萄糖消耗）从单培养的2.01降至1.58，表明有氧呼吸增加。该系统在连续光照下维持了3天，且未对动物细胞造成伤害。,False,,,False,,,True,微藻吸收动物细胞代谢产生的废物氨（Ammonia），并将其转化为氨基酸（如谷氨酸、谷氨酰胺），从而降低培养环境中的氨毒性。,Chlorella vulgaris: Ammonia,False,,,GRAS,,,Low risk (Food grade),None (Co-culture),所使用的微藻（小球藻）是常见的食品补充剂，具有GRAS（一般认为安全）地位，用于生产培养肉/食品，安全性高。,通过共培养，成功构建了厚度为200-400微米的3D组织，且未出现明显的组织损伤（LDH释放量仅为对照组的七分之一）。相比之下，单培养的动物细胞组织在超过50微米时即出现缺氧和坏死。,11744,3392,15136,,
5487b45b-572d-46c4-bb24-1285a26888e0,0,Consortium,"[{""role"": ""Helper"", ""scientific_name"": ""Chlorella vulgaris"", ""strain_id"": ""NIES-2170""}]",Biofilm,Aerobic,30°C; 连续光照 (880 ± 28 lux); DMEM + 10% FBS,共培养组织在40分钟内通过离心法构建,与动物细胞(C2C12)混合形成的3D组织内部,互利共生：微藻为动物细胞提供氧气并消耗氨；动物细胞提供CO2和氨,耐受30°C及组织内部环境,Chlorella vulgaris,微藻与动物细胞共培养，在30°C下表现出最佳的组织维持能力，避免了37°C下因代谢过快导致的组织损伤。,,,,,,,本研究使用野生型微藻，未涉及基因工程改造。,"[""Hypoxia""]","[""Ammonia""]",,,Chlorella vulgaris,自然代谢响应：光照下进行光合作用产氧；利用环境中的氨合成氨基酸,微藻通过自然代谢途径感知并响应环境中的光照、CO2浓度及氨浓度，无需人工逻辑门控制。,"[""Oxygenation""]",原位光合作用产氧及代谢物交换,通过接种细胞比例（C2C12:微藻 = 1:4 或 1:8）和光照控制,无支架，通过离心形成的细胞致密组织,False,False,False,,,False,False,False,False,,True,光合自养微藻消耗二氧化碳和氨，排泄氧气，缓解组织内部缺氧,Chlorella vulgaris,True,True,True,共培养组织的代谢从厌氧呼吸部分转变为高效的有氧呼吸（LG比率从2.01降至1.58），支持了更厚组织（200-400μm）的存活。,False,,,False,,,True,微藻吸收动物细胞代谢产生的废物（氨）用于合成氨基酸,Chlorella vulgaris,False,,,GRAS,物理限制（在体外培养皿装置中）,Chlorella vulgaris,低风险，小球藻是常见的膳食补充剂,PDMS装置（培养期间）,该系统用于体外培养肉生产，所用微藻为食品级安全微生物，无生物安全风险。,通过共培养微藻，成功构建并维持了厚度达200-400μm的致密组织，相比单培养（50-150μm）显著增厚；LDH释放量减少至1/7，显著降低了组织坏死和损伤；培养基中氨积累显著减少。,10394,3230,13624,,

